<SEC-DOCUMENT>0001140361-23-034222.txt : 20230712
<SEC-HEADER>0001140361-23-034222.hdr.sgml : 20230712
<ACCEPTANCE-DATETIME>20230712163035
ACCESSION NUMBER:		0001140361-23-034222
CONFORMED SUBMISSION TYPE:	PRER14A
PUBLIC DOCUMENT COUNT:		17
FILED AS OF DATE:		20230712
DATE AS OF CHANGE:		20230712

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATALYST BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562020050
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PRER14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		231084543

	BUSINESS ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-871-0761

	MAIL ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>PRER14A
<SEQUENCE>1
<FILENAME>ny20006478x8_prer14a.htm
<DESCRIPTION>PRER14A
<TEXT>
<html><head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head><body style="color: #000000;" bgcolor="#ffffff">
<!--Begin Page 1-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="ny20006478x8_prer14a_100-regcov_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div><div class="page-content"><div class="block-main" style="width: 540pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 9.5pt; text-align: center;">UNITED STATES <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;">SECURITIES AND EXCHANGE COMMISSION <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 12pt;">Washington, D.C. 20549</font></div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 13.25pt;"> </div></div> <div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">SCHEDULE 14A<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Amendment No. 3) <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 12pt;">Proxy Statement Pursuant to Section 14(a) of the </font><br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 12pt;">Securities Exchange Act of 1934</font></div> <div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 13.25pt;"> </div></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Filed by the Registrant &#x2612;</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Filed by a Party other than the Registrant <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Check the appropriate box:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 540pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 2.22%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#x2612;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 95.56%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preliminary Proxy Statement</div></td></tr><tr><td style="width: 2.22%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 10pt;">&#x2610;</font><font style="font-size: 10pt;"> </font></div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 95.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))<font style="font-weight: normal;"> </font></div></td></tr><tr><td style="width: 2.22%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 10pt;">&#x2610;</font></div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 95.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Definitive Proxy Statement </div></td></tr><tr><td style="width: 2.22%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 10pt;">&#x2610;</font></div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 95.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Definitive Additional Materials </div></td></tr><tr><td style="width: 2.22%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 10pt;">&#x2610;</font></div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 95.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Soliciting Material Pursuant to &#167;240.14a-12</div></td></tr></table><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 20pt; font-weight: bold; margin-top: 18.5pt; text-align: center;">Catalyst Biosciences, Inc. <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 20pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 10pt;">(Name of the Registrant as Specified In Its Charter) </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.5pt; text-align: center;">N/A <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)<font style="font-weight: normal;"> </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Payment of Filing Fee (Check the appropriate box): </div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 540pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 2.22%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 10pt;">&#x2610;</font></div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 95.56%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">No fee required. </div></td></tr><tr><td style="width: 2.22%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#x2612;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 95.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fee paid previously with preliminary materials.</div></td></tr><tr><td style="width: 2.22%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 10pt;">&#x2610;</font></div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 95.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.</div></td></tr></table></div></div><div class="block-frill" style="width: 540pt; margin-top: 12pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div></div>
<!--End Page 1-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 2-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_101-letter_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"> <div class="h1" style="color: #FC0014; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">PRELIMINARY PROXY STATEMENT <br></div><div class="h1" style="color: #FC0014; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">SUBJECT TO COMPLETION, DATED JULY 12, 2023</div> <div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">PROPOSED BUSINESS COMBINATION<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">YOUR VOTE IS VERY IMPORTANT</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">To the Stockholders of Catalyst Biosciences, Inc.:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">You are cordially invited to attend a virtual special meeting of stockholders of Catalyst Biosciences, Inc., a Delaware corporation (&#8220;Catalyst&#8221;), which will be held on &#8195;&#8195;&#8195; , 2023, at &#8195;&#8195;&#8195; Pacific Time, unless postponed or adjourned to a later date. The Catalyst special meeting will be held entirely online. You will be able to attend and participate in the Catalyst special meeting online by visiting http://www.virtualshareholdermeeting.com/CBIO2023SM, where you will be able to listen to the meeting live, submit questions and vote. On December&#160;26, 2022, Catalyst acquired the F351 Assets (as defined below) from GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (&#8220;GNI Japan&#8221;), and GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability (&#8220;GNI Hong Kong&#8221; and, together with GNI Japan, the &#8220;Sellers&#8221;), pursuant to that certain Asset Purchase Agreement, dated December&#160;26, 2022, as amended on March 29, 2023 (the &#8220;F351 Agreement&#8221;), by and among Catalyst and the Sellers. Pursuant to the F351 Agreement, Catalyst acquired all of the assets and intellectual property rights primarily related to the Sellers&#8217; proprietary Hydronidone compound (collectively, the &#8220;F351 Assets&#8221;), other than related assets and intellectual property rights located in the People&#8217;s Republic of China (the &#8220;PRC&#8221;). The F351 Assets include 15&#160;issued or pending patents and patent applications outside of the PRC, with the last acquired issued patent expected to expire in August 2037.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under the terms of the F351 Agreement and upon the effective time of the transactions contemplated by the F351&#160;Agreement, Catalyst issued to the Sellers equity interests with an aggregate value of $35,000,000 in the form of: 6,266,521 shares of Catalyst&#8217;s common stock, par value $0.001 per share (the &#8220;Catalyst Common Stock&#8221;); and 12,340 shares of Catalyst Series X Convertible Preferred Stock, par value $0.001 per share (the &#8220;Catalyst Convertible Preferred Stock&#8221;), which Catalyst Convertible Preferred Stock is convertible, upon the approval of the stockholders of Catalyst (as further described herein) into shares of Catalyst Common Stock at a ratio of one (1) share of Catalyst Convertible Preferred Stock to 10,000 shares of Catalyst Common Stock.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, Catalyst, GNI USA, Inc., a Delaware corporation (&#8220;GNI USA&#8221;), GNI Japan, GNI Hong Kong, Shanghai Genomics, Inc., a company organized under the laws of the PRC (&#8220;SG&#8221; and collectively with GNI USA, GNI Japan and GNI HK, &#8220;Contributors,&#8221; and each a &#8220;Contributor&#8221;), the individuals (each, a &#8220;Minority Holder&#8221; and collectively, the &#8220;Minority Holders&#8221;) listed on an annex thereto, and Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares (&#8220;CPI&#8221;), entered into the Business Combination Agreement on December&#160;26, 2022, as amended on March 29, 2023 (the &#8220;Business Combination Agreement&#8221;). The Business Combination Agreement contains the terms and conditions of the proposed business combination pursuant to which Catalyst will acquire an indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the PRC (&#8220;BC&#8221;).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Business Combination Agreement, (a) GNI USA will contribute all of its ordinary shares in the capital of CPI, par value $0.0001 per share (each a &#8220;CPI Ordinary Share&#8221;), to Catalyst in exchange for 688,850,101 shares of Catalyst Common Stock (the &#8220;CPI Contribution&#8221;), (b) GNI USA will contribute its interest in Further Challenger International Limited, a company incorporated and existing under the laws of the British Virgin Islands with company number 1982271 (&#8220;Further Challenger&#8221;), to Catalyst in exchange for 264,971,695 shares of Catalyst Common Stock (the &#8220;FC Contribution&#8221;) and (c) each Minority Holder will contribute 100% of the interest he or she holds in his or her respective Entity (as defined in the Business Combination Agreement) to Catalyst in exchange for an aggregate of 156,954,428 shares of Catalyst Common Stock to be issued to such Minority Holders (the &#8220;Minority Holder Contributions&#8221; and together with the CPI Contribution and the FC Contribution, the &#8220;Contributions&#8221;). At the election of GNI USA or any Minority Holder, GNI USA or such Minority Holder may be issued shares of Catalyst Convertible Preferred Stock in lieu of some or all of the shares of Catalyst Common Stock GNI USA or any such Minority Holder is entitled to receive. Catalyst stockholders immediately before the Contributions are expected to own approximately 2.5% of the outstanding shares of the combined company, GNI USA is expected to own approximately 85.2% of the outstanding shares of the combined company and the Minority Holders are expected to own approximately 12.3% of the outstanding shares of the combined company, in each case, assuming conversion of the Catalyst Convertible </div></div></div></div>
<!--End Page 2-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 3-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_101-letter_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Preferred Stock and subject to certain assumptions, including, but not limited to, a valuation for Catalyst equal to $8.5 million and a valuation for the percentage of BC acquired in the business combination equal to $299.8 million. The combined company following the Contributions is referred to herein as the combined company.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, at the Effective Time (as defined in the Business Combination Agreement), BC will terminate its 2021 Stock Incentive Plan (the &#8220;2021 Plan&#8221;) and each option (a &#8220;BC Option&#8221;) to purchase common shares (the &#8220;BC Common Shares&#8221;) of BC outstanding under the 2021 Plan will be terminated and replaced with options granted pursuant to a sub-plan for PRC participants under the Gyre Therapeutics, Inc. 2023 Omnibus Incentive Plan (the &#8220;2023 Omnibus Incentive Plan&#8221;) that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Prior to the closing of the Contributions, Catalyst will conduct a reverse stock split of the Catalyst Common Stock, at a ratio of not less than 1-for- &#8195;&#8195;&#8195; and not more than 1-for- &#8195;&#8195;&#8195; and thereafter, each share of Catalyst Common Stock and option to purchase Catalyst Common Stock that is issued and outstanding at the Effective Time will remain issued and outstanding and such shares will be unaffected by the Contributions. Immediately before the Contributions, the Catalyst stockholders as of immediately prior to the Contributions hold approximately 83.4% of the outstanding shares of capital stock of Catalyst, GNI Japan owns approximately 2.4% of the outstanding shares of capital stock of Catalyst and GNI Hong Kong owns approximately 14.2% of the outstanding shares of capital stock of Catalyst. Immediately after the Contributions, the Catalyst stockholders as of immediately prior to the Contributions are expected to own approximately 2.5% of the outstanding shares of capital stock of the combined company, GNI USA is expected to own approximately 85.2% of the outstanding shares of capital stock of the combined company and the Minority Holders are expected to own approximately 12.3% of the outstanding shares of capital stock of the combined company, in each case, assuming conversion of the Catalyst Convertible Preferred Stock. Immediately after the Contributions, the Catalyst stockholders as of immediately prior to the Contributions are expected to own approximately 2.0% of the outstanding shares of the combined company, GNI USA is expected to own approximately 70.6% of the outstanding shares of the combined company, the Minority Holders are expected to own approximately 10.2% of the outstanding shares of the combined company, the holders of options granted under the 2023 Omnibus Incentive Plan (&#8220;Gyre Options&#8221;) are expected to own approximately 16.6% of the outstanding shares of the combined company and the holders of outstanding options of Catalyst are expected to own approximately 0.6% of the outstanding shares of the combined company, in each case, on a fully diluted basis assuming conversion of the Catalyst Convertible Preferred Stock and including the outstanding options of Catalyst and the Gyre Options to be granted in respect of the BC Options.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC faces various risks and uncertainties related to doing business in the PRC. BC&#8217;s business operations are primarily conducted in the PRC, and BC is subject to complex and evolving PRC laws and regulations. For a detailed description of risks related to doing business in the PRC, please refer to the risks disclosed under &#8220;<font style="font-style: italic;">Risk </font><font style="font-style: italic;">Factors&#8212;Risks Related to BC&#8212;Risks Related to BC&#8217;s Business Operations in the PRC</font>.&#8221;</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The PRC government&#8217;s significant authority in regulating the combined company&#8217;s operations and its oversight and control over offerings conducted overseas by, and foreign investment in, PRC-based issuers could significantly limit or completely hinder the combined company&#8217;s ability to offer or continue to offer securities to investors and cause the value of the combined company&#8217;s securities to significantly decline or be worthless if the Contributions are consummated. Implementation of industry-wide regulations, including data security or anti-monopoly related regulations, in this nature could result in a material change in the combined company&#8217;s operations and may cause the value of the combined company&#8217;s securities to significantly decline or become worthless if the Contributions are consummated. Risks and uncertainties arising from the legal system in China, including risks and uncertainties regarding the enforcement of laws and quickly evolving rules and regulations in China could result in a material adverse change in the combined company&#8217;s operations and the value of the combined company&#8217;s common stock if the Contributions are consummated. For example, in recent years, the PRC government has made statements and taken regulatory actions to regulate certain market players or to improve its supervision of the market in general, such as those related to data security or anti-monopoly concerns. There is no assurance that any new rules or regulations promulgated in the future will not impose additional requirements on the combined company. If any such rules or regulations are adopted, the combined company may be subject to more stringent regulatory scrutiny for its operation and financing efforts, which may in turn result in more compliance costs and expenses for the combined company, delay the combined company&#8217;s investment and financing activities, or otherwise impact the combined company&#8217;s ability to conduct its business, accept foreign investments, or list on a U.S. or other foreign exchange following the </div></div></div></div>
<!--End Page 3-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 4-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_101-letter_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Contributions. For more details, see &#8220;<font style="font-style: italic;">Risk Factors Risks Related to BC</font><font style="font-style: italic;">&#8212;</font><font style="font-style: italic;">Risks Related to BC&#8217;s Business Operations </font><font style="font-style: italic;">in the PRC&#8212;The PRC government may intervene in or influence BC&#8217;s operations at any time, which could result in </font><font style="font-style: italic;">a change in BC&#8217;s operations and There are uncertainties regarding the interpretation and enforcement of PRC laws, </font><font style="font-style: italic;">rules and regulations</font>.&#8221;</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Cybersecurity Review Measures published by the Cybersecurity Administration of China, which became effective on February 15, 2022, critical information infrastructure operators purchasing network products and services which affect or may affect national security, or online platform operators possessing personal information of more than one million users, seeking to be listed on foreign stock markets must apply for a cybersecurity review by the Cybersecurity Review Office. For a detailed description, please refer to risks disclosed under &#8220;<font style="font-style: italic;">Risk </font><font style="font-style: italic;">Factors&#8212;Risks Related to BC&#8212;Risks Related to BC&#8217;s Business Operations in the PRC&#8212;Risks Relating to BC&#8217;s </font><font style="font-style: italic;">Financial Position and Need for Additional Capital-Compliance with the PRC&#8217;s new Data Security Law, Cyber </font><font style="font-style: italic;">Security Law, Cybersecurity Review Measures, Personal Information Protection Law, regulations and guidelines </font><font style="font-style: italic;">relating to the multi-level protection scheme on cyber security and any other future laws and regulations may entail </font><font style="font-style: italic;">significant expenses and could affect BC&#8217;s business</font>.&#8221;</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to Special Administrative Measure (Negative List) for Access of Foreign Investments (2021 Edition) which became effective on January 1, 2022 (the &#8220;Negative List&#8221;), if a PRC company, which engages in any business where foreign investment is prohibited under the Negative List, or prohibited businesses, seeks an overseas offering or listing, it must obtain the approval from competent governmental authorities. For a detailed description, please refer to &#8220;<font style="font-style: italic;">BC&#8217;s Business&#8212;Regulations on M&amp;A and Overseas Listings</font>.&#8221;</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">However, applicable PRC laws and regulations may be tightened, and new laws or regulations may be introduced to impose additional government approval, license, and permit requirements. If BC or its subsidiaries fail to obtain and maintain such approvals, licenses, or permits required for its business, inadvertently conclude that such approval is not required, or respond to changes in the regulatory environment, BC or its subsidiaries could be subject to liabilities, penalties, and operational disruption, which may materially and adversely affect its business, operating results, financial condition and the value of our ordinary shares, significantly limit or completely hinder our ability to offer or continue to offer securities to investors, or cause such securities to significantly decline in value or become worthless.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Generally, cash is transferred through BC&#8217;s organization in the following manner: (i) funds are transferred to BC from CPI as needed through BJContinent Pharmaceuticals Limited, a company incorporated under the laws of Hong Kong with limited liability (&#8220;BJC Limited&#8221;), or from other domestic shareholders, in the form of capital contributions or shareholder loans; and (ii) dividends or other distributions may be paid by BC to CPI through BJC Limited, or to other domestic shareholders.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In September 2020, BC paid a cash dividend of $1.9 million to BJC Limited. As required under the PRC Enterprise Income Tax Law, the dividends paid by BC were subject to a withholding tax rate of 10%. Such amount was settled in full net of withholding PRC tax through multiple payments by August 2020.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Since BC&#8217;s inception to the date of this proxy statement, there were no transfers, dividends, or distributions between BJC Limited, BC, BC&#8217;s wholly-owned subsidiary (Beijing Continent Biomedical Technology Co., Ltd., a company organized under the laws of the PRC (&#8220;BC Biomedical&#8221;)), or to investors (except as disclosed above and excluding shareholder capital contributions). BC intends to retain all available funds and any future earnings for use in the operation of its business and does not anticipate paying any cash dividends on its capital stock in the foreseeable future. Notwithstanding the foregoing, any determination to pay cash dividends subsequent to the Contributions will be at the discretion of the combined company&#8217;s board of directors and will depend upon a number of factors, including the combined company&#8217;s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors the combined company&#8217;s board of directors deems relevant. For more details, see &#8220;<font style="font-style: italic;">BC&#8217;s Business&#8212;Regulatory Requirements in the PRC&#8212;Dividends, </font><font style="font-style: italic;">Distributions and Other Transfers</font><font style="font-style: italic;">&#8221;,</font><font style="font-style: italic;"> </font><font style="font-style: italic;">Audited Financial Statements of Beijing Continent Pharmaceuticals Co., Ltd. </font>and<font style="font-style: italic;"> &#8220;Selected Historical and Unaudited Pro Forma Condensed Combined Financial Information&#8212;Unaudited Pro </font><font style="font-style: italic;">Forma Condensed Combined Financial Information&#8221;</font><font style="font-style: italic;"> </font>included elsewhere in this proxy statement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under the Holding Foreign Companies Accountable Act (the &#8220;HFCAA&#8221;), the SEC is required to identify issuers that retain an auditor that has a branch or office that is located in a foreign jurisdiction and that the Public Company Accounting Oversight Board (the &#8220;PCAOB&#8221;) determines it is unable to inspect or investigate completely because of a position taken by an authority in that foreign jurisdiction. On December 16, 2021, the PCAOB issued a report on </div></div></div></div>
<!--End Page 4-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 5-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_101-letter_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">its determination that it is unable to inspect or investigate completely PCAOB-registered accounting firms headquartered in the PRC and in Hong Kong. On December 15, 2022, the PCAOB announced that it was able to conduct inspections and investigations of PCAOB-registered public accounting firms headquartered in mainland PRC and Hong Kong in 2022, and as a result, the PCAOB vacated its December 2021 determinations. While vacating those determinations, the PCAOB noted that, should it encounter any impediment to conducting an inspection or investigation of auditors in mainland PRC or Hong Kong as a result of a position taken by any authority there, the PCAOB would act to immediately reconsider the need to issue new determinations consistent with the HFCAA and PCAOB Rule 6100.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If (i) the combined company&#8217;s operations require that it retain an auditor that is headquartered in mainland PRC to act as a principal auditor in order to comply with the standards of the PCAOB and (ii) the PCAOB retakes a position that is similar to its December 2021 determinations, then the combined company would be identified by the SEC as a Commission-Identified Issuer. In accordance with the HFCAA, the combined company&#8217;s securities would be prohibited from being traded on a national securities exchange or in the over-the-counter trading market in the United States if the SEC identifies the combined company as a Commission-Identified Issuer for two consecutive years in the future. The combined company&#8217;s operations will likely require such an auditor to act as its principal auditor. For a detailed description of risks of and impacts on the combined company relating to the HFCAA and related regulations, please refer to risks disclosed under &#8220;<font style="font-style: italic;">Risk Factors&#8212;Risks Related to the Combined Company&#8212;The </font><font style="font-style: italic;">PRC-operations portion of the combined company&#8217;s audit may be conducted by an independent registered public </font><font style="font-style: italic;">accounting firm that is not subject to inspection by the PCAOB, which may negatively impact investor sentiment </font><font style="font-style: italic;">towards the combined company or its PRC operations, which could adversely affect the market price of the combined </font><font style="font-style: italic;">company&#8217;s common stock</font>.&#8221; </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Shares of Catalyst Common Stock are currently listed on The Nasdaq Capital Market under the symbol &#8220;CBIO.&#8221; Catalyst has filed a listing application for the combined company with The Nasdaq Stock Market Inc. (&#8220;Nasdaq&#8221;). After completion of the Contributions, the combined company will be renamed &#8220;Gyre Therapeutics, Inc.&#8221; and it is expected that the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol &#8220;GYRE.&#8221; On &#8195;&#8195;&#8195; , the last trading day before the date of this proxy statement, the closing sale price of Catalyst Common Stock was $ &#8195;&#8195;&#8195; per share.</div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst stockholders are cordially invited to attend the special meeting of Catalyst stockholders. Catalyst is holding its special meeting of stockholders, or the Catalyst special meeting, on &#8195;&#8195;&#8195; , 2023, at &#8195;&#8195;&#8195; Pacific Time, unless postponed or adjourned to a later date, in order to obtain the stockholder approvals necessary to complete the Contributions and related matters. The Catalyst special meeting will be held entirely online. Catalyst stockholders will be able to attend and participate in the Catalyst special meeting online by visiting http://www.virtualshareholdermeeting.com/CBIO2023SM, where they will be able to listen to the meeting live, submit questions and vote. At the Catalyst special meeting, Catalyst will ask its stockholders: </div> <table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To approve, for purposes of Nasdaq Listing Rules 5635(a) and (b), the issuance of shares of Catalyst Common Stock and Catalyst Convertible Preferred Stock, each pursuant to the terms of the Business Combination Agreement (as it may be amended from time to time), a copy of which is attached as Annex&#160;A to this proxy statement;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To approve, for purposes of Nasdaq Listing Rules 5635(a) and (b), the conversion of Catalyst Convertible Preferred Stock into shares of Catalyst Common Stock pursuant to the F351 Agreement, a copy of which is attached as Annex&#160;B to this proxy statement;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To adopt and approve an amendment to the restated certificate of incorporation of Catalyst to increase the number of authorized shares of Catalyst Common Stock from 100,000,000 shares to &#8195;&#8195;&#8195; shares;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To adopt and approve an amendment to the restated certificate of incorporation of Catalyst to effect a reverse stock split of Catalyst Common Stock, by a ratio of not less than 1-for- &#8195;&#8195;&#8195;and not more than 1-for- &#8195;&#8195;&#8195;, such ratio and the implementation and timing of the reverse stock split to be determined in the discretion of Catalyst&#8217;s board of directors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To adopt and approve an amendment to the restated certificate of incorporation of Catalyst to create a new class of non-voting common stock of Catalyst;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To approve the Gyre Therapeutics, Inc. 2023 Omnibus Incentive Plan;</div></td></tr></table></div></div></div>
<!--End Page 5-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 6-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_101-letter_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To adopt and approve an amendment to the restated certificate of incorporation of Catalyst to allow for stockholder action by written consent in certain circumstances; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To elect as director the two nominees named in the proxy statement to serve until the 2026 annual meeting of stockholders and until his or her successor is duly elected and qualified;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To approve, by non-binding advisory vote, the compensation of Catalyst&#8217;s named executive officers;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To conduct an advisory vote on the frequency of future advisory votes on executive compensation;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To ratify the selection of EisnerAmper LLP as Catalyst&#8217;s independent registered public accounting firm; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To consider and vote upon an adjournment of the Catalyst special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1, 2, 3, 4, 5 and 6.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">After careful consideration, the Catalyst board of directors has approved the Business Combination Agreement and has determined that it is advisable to consummate the Contributions and the other transactions contemplated by the Business Combination Agreement. Catalyst&#8217;s board of directors has approved the proposals described in this proxy statement and recommends that its stockholders vote &#8220;FOR&#8221; Proposal Nos. 1, 2, 3, 4, 5, 6, 7, 9, 11 and 12, &#8220;FOR&#8221; the election of the director nominees named in Proposal No. 8 and &#8220;ONE YEAR&#8221; on Proposal No. 10, as described in this proxy statement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">More information about Catalyst, BC, the Business Combination Agreement and the transactions contemplated thereby, and the foregoing proposals is contained in this proxy statement. Catalyst urges you to read this proxy statement carefully and in its entirety. IN PARTICULAR, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED UNDER &#8220;<u>RISK FACTORS</u>&#8221; BEGINNING ON PAGE <a href="#tRF">34</a> OF THIS PROXY STATEMENT.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst is excited about the opportunities the Contributions bring to Catalyst&#8217;s stockholders and thanks you for your consideration and continued support. Sincerely,</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 35.9%; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 32.05%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 32.05%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 0%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 32.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 32.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 0%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Nassim Usman, Ph.D.</div></td><td class="gutter" style="width: 32.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 32.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 0%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">President and Chief Executive Officer</div></td><td class="gutter" style="width: 32.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 32.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 0%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.</div></td><td class="gutter" style="width: 32.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 32.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 0%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the transactions in this proxy statement, passed upon the merits or fairness of the Business Combination Agreement or the Contributions, or passed upon the adequacy or accuracy of this proxy statement. Any representation to the contrary is a criminal offense.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">This proxy statement is dated &#8195;&#8195; , 2023 and is first being mailed to Catalyst stockholders on or about &#8195;&#8195; , 2023.</div></div></div></div>
<!--End Page 6-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 7-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_102-notice_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Catalyst Biosciences, Inc.<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">611 Gateway Blvd<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Suite 120<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">South San Francisco, CA 94080<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(650) 871-0761<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">NOTICE OF SPECIAL MEETING OF STOCKHOLDERS </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">To the stockholders of Catalyst Biosciences, Inc.:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">NOTICE IS HEREBY GIVEN <font style="font-weight: normal;">that a virtual special meeting of stockholders, or the Catalyst special meeting, will </font><font style="font-weight: normal;">be held on &#8195;&#8195;&#8195; 2023, &#8195;&#8195;&#8195; at Pacific Time, unless postponed or adjourned to a later date. The Catalyst special </font><font style="font-weight: normal;">meeting will be held entirely online. You will be able to attend and participate in the Catalyst special meeting online </font><font style="font-weight: normal;">by visiting http://www.</font><font style="font-weight: normal;">virtualshareholdermeeting</font><font style="font-weight: normal;">.com</font><font style="font-weight: normal;">/CBIO2023SM</font><font style="font-weight: normal;">, where you will be able to listen to the meeting </font><font style="font-weight: normal;">live, submit questions and vote.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The Catalyst special meeting will be held for the following purposes: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To approve, for purposes of Nasdaq Listing Rule 5635(a) and (b), the issuance of shares of common stock of Catalyst Biosciences, Inc. (&#8220;Catalyst&#8221;), par value $0.001 per share (&#8220;Catalyst Common Stock&#8221;) and shares of Catalyst Series X Convertible Preferred Stock, par value $0.001 per share (the &#8220;Catalyst Convertible Preferred Stock&#8221;), each pursuant to the terms of the Business Combination Agreement and the F351 Agreement (as they may be amended from time to time), copies of which are attached as Annex&#160;A and Annex&#160;B, respectively, to this proxy statement;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To approve, for purposes of Nasdaq Listing Rules 5635(a) and (b), the conversion of Catalyst Convertible Preferred Stock into shares of Catalyst Common Stock pursuant to the Asset Purchase Agreement, dated December&#160;26, 2022, by and among Catalyst, GNI Japan and GNI Hong Kong (the &#8220;F351 Agreement&#8221;), a copy of which is attached as Annex&#160;B to this proxy statement;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To adopt and approve an amendment to the restated certificate of incorporation of Catalyst to increase the number of authorized shares of Catalyst Common Stock from 100,000,000 shares to &#8195;&#8195;&#8195; shares;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To adopt and approve an amendment to the restated certificate of incorporation of Catalyst to effect a reverse stock split of Catalyst Common Stock, by a ratio of not less than 1-for- &#8195;&#8195;&#8195; and not more than 1-for- &#8195;&#8195;&#8195;, such ratio and the implementation and timing of the reverse stock split to be determined in the discretion of Catalyst&#8217;s board of directors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To adopt and approve an amendment to the restated certificate of incorporation of Catalyst to create a new class of non-voting common stock of Catalyst;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To approve the Gyre Therapeutics, Inc. 2023 Omnibus Incentive Plan;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To adopt and approve an amendment to the restated certificate of incorporation of Catalyst to allow for stockholder action by written consent in certain circumstances; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To elect as director the two nominees named in the proxy statement to serve until the 2026 annual meeting of stockholders and until his or her successor is duly elected and qualified;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To approve, by non-binding advisory vote, the compensation of Catalyst&#8217;s named executive officers;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To conduct an advisory vote on the frequency of future advisory votes on executive compensation; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To ratify the selection of EisnerAmper LLP as Catalyst&#8217;s independent registered public accounting firm; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To consider and vote upon an adjournment of the Catalyst special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1, 2, 3, 4, 5 and 6.</div></td></tr></table><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 15.38%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Record Date<font style="font-weight: normal;">:</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Catalyst&#8217;s board of directors has fixed the close of business on &#8195;&#8195;&#8195; , 2023 as the record date for the determination of stockholders entitled to notice of and to vote at, the Catalyst special meeting and any adjournment or postponement thereof. Only stockholders of record of Catalyst at the close of business on the record date are entitled to notice of and to vote at </div></td></tr></table></div></div></div>
<!--End Page 7-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 8-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_102-notice_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">the Catalyst special meeting. Notwithstanding the foregoing, holders of outstanding shares of Catalyst Series Y Preferred Stock, par value $0.001 per share (&#8220;Catalyst Series Y Preferred Stock&#8221;) will only be entitled to vote such shares on Proposal No. 4 and will only be able to vote to the extent that such shares have not been automatically redeemed in the Initial Redemption, as described in this proxy statement. At the close of business on the record date, &#8195;&#8195;&#8195; shares of Catalyst Common Stock were issued and outstanding and &#8195;&#8195;&#8195; shares of Catalyst Series Y Preferred Stock were issued and outstanding.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Your vote is important. Assuming a quorum is present, (i)&#160;the affirmative vote of the holders of a majority of all of the shares of Catalyst Common Stock present in person or represented by proxy at the Catalyst special meeting and entitled to vote on such matter is required for approval of Proposal Nos. 1, 2, 6, 9, 11 and 12 and for approval of one of the options set forth under Proposal No. 10, (ii)&#160;the affirmative vote of the holders of a majority of the outstanding shares of Catalyst Common Stock entitled to vote thereon is required for approval of Proposal Nos. 3 and 5, (iii) the affirmative vote of the holders of a majority of the outstanding shares of Catalyst Common Stock and Catalyst Series Y Preferred Stock entitled to vote thereon is required for approval of Proposal No. 4, (iv)&#160;the affirmative vote of the holders of two-thirds of the outstanding shares of Catalyst Common Stock entitled to vote thereon is required for approval of Proposal No. 7 and (v)&#160;the two nominees receiving the highest number of affirmative &#8220;FOR&#8221; votes shall be elected as Class&#160;II directors pursuant to Proposal No. 8.<font style="font-weight: normal;"> </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Approval of Proposal Nos. 1, 2, 3, 4 and 6 is a condition to the completion of the Contributions. Therefore, the Contributions cannot be consummated without the approval of Proposal Nos. 1, 2, 3, 4 and 6.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Even if you plan to virtually attend the Catalyst special meeting, Catalyst requests that you sign and return the enclosed proxy or submit a proxy to vote by mail or online to ensure that your shares will be represented at the Catalyst special meeting if you are unable to virtually attend. You may change or revoke your proxy at any time before it is voted at the Catalyst special meeting. As a result of the dividend of shares of Catalyst Series Y Preferred Stock to stockholders of record as of the close of business on June 30, 2023, each holder of shares of Catalyst Common Stock will also hold a number of one one-thousandths of a share of Catalyst Series Y Preferred Stock equal to the whole number of shares of Catalyst Common Stock held by such holder. Because any one one-thousandths of a share of Catalyst Series Y Preferred Stock that is not present in person or by proxy at the Catalyst special meeting as of immediately prior to the opening of the polls at the Catalyst special meeting will be automatically redeemed, if you fail to attend the Catalyst special meeting or fail to submit a proxy to vote your shares, your shares of Catalyst Series Y Preferred Stock will be redeemed immediately prior to the opening of the polls at the Catalyst special meeting and you will not be entitled to vote those shares at the Catalyst special meeting.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">CATALYST&#8217;S BOARD OF DIRECTORS HAS DETERMINED AND BELIEVES THAT EACH OF THE PROPOSALS OUTLINED ABOVE IS FAIR TO, IN THE BEST INTERESTS OF AND ADVISABLE TO CATALYST AND ITS STOCKHOLDERS AND HAS APPROVED EACH SUCH PROPOSAL. CATALYST&#8217;S BOARD OF DIRECTORS RECOMMENDS THAT CATALYST STOCKHOLDERS VOTE &#8220;FOR&#8221; EACH SUCH PROPOSAL.<font style="font-weight: normal;"> </font></div><div style="padding: 6pt; border: 0.5pt solid #000000; margin-left: 0.5pt; margin-top: 4.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 461.5pt; text-align: justify; margin-left: 0pt;"><font style="font-weight: bold;">Important Notice Regarding the Availability of Proxy Materials for the Stockholders&#8217; Meeting to Be Held </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 461.5pt; margin-top: 0pt; text-align: center;"><font style="font-weight: bold;">on &#8195;&#8195;&#8195;</font><font style="font-weight: bold;">, 2023, at </font><font style="font-weight: bold;">&#8195;&#8195;&#8195; </font><font style="font-weight: bold;">Pacific Time via the internet</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 461.5pt; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 461.5pt; margin-top: 0pt; text-align: justify; margin-left: 0pt;">This notice of special meeting of stockholders and the related proxy statement and annual report to stockholders </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">re available at http://www.virtualshareholdermeeting.com/CBIO2023SM</div></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">By Order of Catalyst&#8217;s Board of Directors,<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195; <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic;">Nassim Usman, Ph.D.</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic;">President and Chief Executive Officer </font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic;">South San Francisco </font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic;">&#8195;&#8195;&#8195; , 2023</font></div></div></div></div>
<!--End Page 8-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 9-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_102-notice_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">REFERENCES TO ADDITIONAL INFORMATION </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This proxy statement incorporates important business and financial information about Catalyst that is not included in or delivered with this document. You may obtain this information without charge through the Securities and Exchange Commission website (<font style="font-style: italic;">www.sec.gov</font>) or upon your written or oral request by contacting Catalyst Biosciences, Inc. at 611 Gateway Blvd. Suite 120, South San Francisco, California 94080.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">To ensure timely delivery of these documents, any request should be made no later than &#8195;&#8195;&#8195; , 2023 to receive them before the Catalyst special meeting.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For additional details about where you can find information about Catalyst, please see the section entitled &#8220;<font style="font-style: italic;">Where </font><font style="font-style: italic;">You Can Find More Information</font>&#8221; beginning on page <a href="#tWYC">343</a> of this proxy statement.</div></div></div></div>
<!--End Page 9-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 10-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_103-toc_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">TABLE OF CONTENTS</div><a name="TOC"><!--Anchor--></a><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tQAA">QUESTIONS AND ANSWERS ABOUT THE CONTRIBUTIONS<font style="padding-left: 3.48pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tQAA"><font style="padding-left: 10pt;">1</font></a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSOT">SUMMARY OF THE PROXY STATEMENT<font style="padding-left: 0.37pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tSOT"><font style="padding-left: 5.37pt;">11</font></a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tMPA">MARKET PRICE AND DIVIDEND INFORMATION<font style="padding-left: 4.98pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tMPA"><font style="padding-left: 5pt;">31</font></a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRF">RISK FACTORS<font style="padding-left: 2.32pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tRF"><font style="padding-left: 5pt;">34</font></a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tCSC">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS AND MARKET AND INDUSTRY DATA<font style="padding-left: 3.89pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tCSC"><font style="padding-left: 0.37pt;">115</font></a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tTSM">THE SPECIAL MEETING OF CATALYST STOCKHOLDERS<font style="padding-left: 0.64pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tTSM"><font style="padding-left: 0.37pt;">118</font></a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tTC">THE CONTRIBUTIONS<font style="padding-left: 4.2pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tTC">123</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tTBC">THE BUSINESS COMBINATION AGREEMENT<font style="padding-left: 4.77pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tTBC">144</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tART">AGREEMENTS RELATED TO THE CONTRIBUTIONS<font style="padding-left: 4.76pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tART">157</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCEA">CATALYST EXECUTIVE AND DIRECTOR COMPENSATION<font style="padding-left: 0.83pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tCEA">162</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tBCE">BC EXECUTIVE COMPENSATION<font style="padding-left: 4.2pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tBCE">173</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tMBS">MATTERS BEING SUBMITTED TO A VOTE OF CATALYST STOCKHOLDERS<font style="padding-left: 1.38pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tMBS">177</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tPROP1">PROPOSAL NO. 1: APPROVAL OF THE ISSUANCE OF SHARES OF CATALYST COMMON STOCK AND CATALYST PREFERRED STOCK PURSUANT TO THE TERMS OF THE BUSINESS COMBINATION AGREEMENT FOR PURPOSES OF NASDAQ LISTING RULES 5635(A) AND (B)<font style="padding-left: 2.53pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tPROP1">177</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tPROP2">PROPOSAL NO. 2: APPROVAL OF CONVERSION OF CATALYST CONVERTIBLE PREFERRED STOCK INTO SHARES OF CATALYST COMMON STOCK PURSUANT TO THE TERMS OF THE F351 AGREEMENT FOR PURPOSES OF NASDAQ LISTING RULES 5635(A) AND (B)<font style="padding-left: 2.53pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tPROP2">178</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tPROP3">PROPOSAL NO. 3: ADOPTION AND APPROVAL OF AN AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF CATALYST TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF CATALYST COMMON STOCK<font style="padding-left: 2.51pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tPROP3">180</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tPROP4">PROPOSAL NO. 4: ADOPTION AND APPROVAL OF AN AMENDMENT TO CATALYST&#8217;S RESTATED CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF CATALYST COMMON STOCK BY A RATIO OF NOT LESS THAN 1-FOR-&#8195; AND NOT MORE THAN 1-FOR-&#8195;, SUCH RATIO AND THE IMPLEMENTATION AND TIMING OF THE REVERSE STOCK SPLIT TO BE DETERMINED IN THE DISCRETION OF CATALYST&#8217;S BOARD OF DIRECTORS<font style="padding-left: 2.7pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tPROP4">182</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tPROP5">PROPOSAL NO. 5: ADOPTION AND APPROVAL OF AN AMENDMENT TO CATALYST&#8217;S RESTATED CERTIFICATE OF INCORPORATION TO CREATE A NEW CLASS OF NON-VOTING COMMON STOCK OF CATALYST<font style="padding-left: 0.09pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tPROP5">189</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tPROP6">PROPOSAL NO. 6 APPROVAL OF THE GYRE THERAPEUTICS, INC. 2023 OMNIBUS INCENTIVE PLAN<font style="padding-left: 4.75pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tPROP6">191</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tPROP7">PROPOSAL NO. 7 ADOPTION AND APPROVAL OF AN AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATE OF CATALYST TO ADOPT ACTION BY WRITTEN CONSENT OF THE STOCKHOLDERS<font style="padding-left: 0.86pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tPROP7">197</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPROP8">PROPOSAL NO. 8 ELECTION OF DIRECTORS<font style="padding-left: 1.16pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tPROP8">198</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPROP9">PROPOSAL NO. 9 ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION<font style="padding-left: 0.26pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tPROP9">201</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tPROP10">PROPOSAL NO. 10 ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION<font style="padding-left: 3.1pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tPROP10">202</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tPROP11">PROPOSAL NO. 11 RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM<font style="padding-left: 0.31pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tPROP11">203</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPROP12">PROPOSAL NO. 12 APPROVAL OF POSSIBLE ADJOURNMENT OF THE SPECIAL MEETING<font style="padding-left: 0.64pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tPROP12">204</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCG">CORPORATE GOVERNANCE<font style="padding-left: 1.97pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tCG">205</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCB">CATALYST&#8217;S BUSINESS<font style="padding-left: 3.76pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tCB">212</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tBCB">BC&#8217;S BUSINESS<font style="padding-left: 4.73pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tBCB">231</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tCMD">CATALYST MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS<font style="padding-left: 4.57pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tCMD">275</a></div></td></tr></table></div></div></div>
<!--End Page 10-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 11-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_103-toc_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tBCM">BC MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS<font style="padding-left: 4.55pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tBCM">285</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tMFT">MANAGEMENT FOLLOWING THE CONTRIBUTIONS<font style="padding-left: 1.27pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tMFT">303</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tCRA">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS OF THE COMBINED COMPANY<font style="padding-left: 3.43pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tCRA">312</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tSHA">SELECTED HISTORICAL AND UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION<font style="padding-left: 1.8pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tSHA">314</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tNTU">NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION<font style="padding-left: 3.63pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tNTU">325</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDOC">DESCRIPTION OF CATALYST CAPITAL STOCK<font style="padding-left: 3.65pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tDOC">330</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPSOC">PRINCIPAL STOCKHOLDERS OF CATALYST<font style="padding-left: 1.36pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tPSOC">336</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPSOBC">PRINCIPAL STOCKHOLDERS OF BC<font style="padding-left: 2.34pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tPSOBC">337</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPSOT">PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY<font style="padding-left: 2.36pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tPSOT">339</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tHI">HOUSEHOLDING INFORMATION<font style="padding-left: 1.45pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tHI">341</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tWYC">WHERE YOU CAN FIND MORE INFORMATION<font style="padding-left: 1.84pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tWYC">343</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tTN">TRADEMARK NOTICE<font style="padding-left: 4.2pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tTN">344</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tOM">OTHER MATTERS<font style="padding-left: 0.29pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tOM">344</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tFSS">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA INDEX TO FINANCIAL STATEMENTS<font style="padding-left: 4.41pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><a href="#tFSS"><font style="padding-left: 1.11pt;">F-</font>1</a></div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXA">Annex&#160;A<font style="font-weight: normal;">&#8212;Business Combination Agreement and Amendment to Business Combination Agreement</font><font style="font-weight: normal; padding-left: 3.7pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.22pt; text-align: left;"><a href="#tANXA">A-1</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tANXB">Annex&#160;B&#8212;<font style="font-weight: normal;">F351 Asset Purchase Agreement and Agreement and Amendment to F351 Asset Purchase </font><font style="font-weight: normal;">Agreement</font><font style="font-weight: normal; padding-left: 3.07pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.22pt; text-align: left;"><a href="#tANXB"><font style="padding-left: 0.55pt;">B-</font>1</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXC">Annex&#160;C<font style="font-weight: normal;">&#8212;Opinion of Catalyst&#8217;s Financial Advisor</font><font style="font-weight: normal; padding-left: 1.44pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.22pt; text-align: left;"><a href="#tANXC"><font style="padding-left: 0.55pt;">C-</font>1</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tANXD">Annex&#160;D<font style="font-weight: normal;">&#8212;Contingent Value Rights Agreement and Amendment to Contingent Value Rights </font><font style="font-weight: normal;">Agreement</font><font style="font-weight: normal; padding-left: 3.07pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.22pt; text-align: left;"><a href="#tANXD">D-1</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tANXE">Annex&#160;E<font style="font-weight: normal;">&#8212;Form of Certificate of Amendment for the Authorized Share Increase, the Reverse Stock </font><font style="font-weight: normal;">Split, the creation of the Non-Voting Common Stock and the Stockholder Action by Written </font><font style="font-weight: normal;">Consent</font><font style="font-weight: normal; padding-left: 4.73pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.22pt; text-align: left;"><a href="#tANXE"><font style="padding-left: 1.11pt;">E-</font>1</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXF">Annex&#160;F<font style="font-weight: normal;">&#8212;Gyre Therapeutics, Inc. 2023 Omnibus Incentive Plan</font><font style="font-weight: normal; padding-left: 4.44pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.22pt; text-align: left;"><a href="#tANXF"><font style="padding-left: 1.66pt;">F-</font>1</a></div></td></tr></table></div></div></div>
<!--End Page 11-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 12-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_104-qa_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tQAA"><!--Anchor--></a>&#8199;QUESTIONS AND ANSWERS ABOUT THE CONTRIBUTIONS</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Except where specifically noted, the following information and all other information contained in this proxy statement does not give effect to the proposed reverse stock split described in Proposal No. 4 of this proxy statement<font style="font-style: normal;">.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following section provides answers to frequently asked questions about the Contributions. This section, however, provides only summary information. For a more complete response to these questions and for additional information, please refer to the cross-referenced sections. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What are the Contributions? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">Catalyst Biosciences, Inc. (&#8220;Catalyst&#8221;), GNI USA, Inc., a Delaware corporation (&#8220;GNI USA&#8221;), GNI Group </font><font style="font-weight: normal;">Ltd., a company incorporated under the laws of Japan with limited liability (&#8220;GNI Japan&#8221;), GNI Hong Kong </font><font style="font-weight: normal;">Limited, a company incorporated under the laws of Hong Kong with limited liability (&#8220;GNI Hong Kong&#8221;), </font><font style="font-weight: normal;">Shanghai Genomics, Inc., a company organized under the laws of the PRC (&#8220;SG&#8221; and collectively with GNI </font><font style="font-weight: normal;">USA, GNI Japan and GNI HK, &#8220;Contributors,&#8221; and each a &#8220;Contributor&#8221;), the individuals (each, a &#8220;Minority </font><font style="font-weight: normal;">Holder&#8221; and collectively, the &#8220;Minority Holders&#8221;) listed on an annex thereto and Continent Pharmaceuticals </font><font style="font-weight: normal;">Inc., a Cayman Islands company limited by shares (&#8220;CPI&#8221;), entered into the Business Combination Agreement </font><font style="font-weight: normal;">on December&#160;26, 2022, a copy of which is attached as Annex&#160;A to this proxy statement, and amended such </font><font style="font-weight: normal;">Business Combination Agreement on March</font><font style="font-weight: normal;"> </font><font style="font-weight: normal;">29</font><font style="font-weight: normal;">, 2023, a copy of which is attached as Annex&#160;A (the &#8220;Business </font><font style="font-weight: normal;">Combination Agreement&#8221;)</font><font style="font-style: italic; font-weight: normal;">. </font><font style="font-weight: normal;">The Business Combination Agreement contains the terms and conditions of the </font><font style="font-weight: normal;">proposed business combination pursuant to which Catalyst will acquire an indirect controlling interest in Beijing </font><font style="font-weight: normal;">Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the PRC (&#8220;BC&#8221;). </font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Pursuant to the Business Combination Agreement, (a) GNI USA will contribute all of its ordinary shares in the capital of CPI, par value $0.0001 per share (each a &#8220;CPI Ordinary Share&#8221;) to Catalyst in exchange for 688,850,101 shares of Catalyst Common Stock, par value $0.001 per share (the &#8220;Catalyst Common Stock&#8221;) (the &#8220;CPI Contribution&#8221;), (b) GNI USA will contribute its interest in Further Challenger International Limited, a company incorporated and existing under the laws of the British Virgin Islands with company number 1982271 (&#8220;Further Challenger&#8221;), to Catalyst in exchange for 264,971,695 shares of Catalyst Common Stock (the &#8220;FC Contribution&#8221;) and (c) each Minority Holder will contribute 100% of the interest he or she holds in his or her respective Entity (as defined in the Business Combination Agreement) to Catalyst in exchange for an aggregate of 156,954,428 shares of Catalyst Common Stock to be issued to such Minority Holders (the &#8220;Minority Holder Contributions&#8221; and together with the CPI Contribution and the FC Contribution, the &#8220;Contributions&#8221;). At the election of GNI USA or any Minority Holder, GNI USA or such Minority Holder shall be issued shares of Catalyst Convertible Preferred Stock in lieu of some or all of the shares of Catalyst Common Stock GNI USA or such Minority Holder is entitled to receive. References to the &#8220;combined company&#8221; are to Gyre Therapeutics, Inc. following the consummation of the transactions contemplated by the Business Combination Agreement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In addition, at the Effective Time (as defined in the Business Combination Agreement), BC will terminate its 2021 Stock Incentive Plan (the &#8220;2021 Plan&#8221;) and each option (a &#8220;BC Option&#8221;) to purchase common shares (the &#8220;BC Common Shares&#8221;) of BC outstanding under the 2021 Plan will be terminated and replaced with options granted pursuant to a sub-plan for PRC participants under the Gyre Therapeutics, Inc. 2023 Omnibus Incentive Plan (the &#8220;2023 Omnibus Incentive Plan&#8221;) that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Prior to the closing of the Contributions, Catalyst will conduct a reverse stock split of the Catalyst Common Stock, at a ratio of not less than 1-for-&#8195;&#8195;&#8195;&#8195; and not more than 1-for-&#8195;&#8195;&#8195;&#8195; and thereafter, each share of Catalyst Common Stock and option to purchase Catalyst Common Stock that is issued and outstanding at the Effective Time will remain issued and outstanding and such shares will be unaffected by the Contributions. Otherwise, each share of Catalyst Common Stock and option to purchase Catalyst Common Stock that is issued and outstanding at the Effective Time will remain issued and outstanding and such shares and options will be unaffected by the Contributions. Immediately after the Contributions, Catalyst stockholders as of immediately prior to the Contributions are expected to own approximately 2.5% of the outstanding shares of the combined company, GNI USA is expected to own approximately 85.2% of the outstanding shares of the combined company and the Minority Holders are expected to own approximately 12.3% of the outstanding shares of the combined company, in each case, assuming conversion of the Catalyst Convertible Preferred Stock. Immediately after the Contributions, the holders of the capital stock of Catalyst as of immediately prior to the Contributions are expected to own approximately 2.0% of the outstanding shares of the combined company, GNI USA is </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">1<br></div></div></div>
<!--End Page 12-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 13-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_104-qa_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">expected to own approximately 70.6% of the outstanding shares of the combined company, the Minority Holders are expected to own approximately 10.2% of the outstanding shares of the combined company, the holders of options granted under the 2023 Omnibus Incentive Plan (&#8220;Gyre Options&#8221;) are expected to own approximately 16.6% of the outstanding shares of the combined company and the holders of outstanding options of Catalyst are expected to own approximately 0.6% of the outstanding shares of the combined company, in each case, on a fully diluted basis assuming conversion of the Catalyst Convertible Preferred Stock and including the outstanding options of Catalyst and the Gyre Options to be granted in respect of the BC Options. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Why are the two companies proposing to complete the transactions contemplated by the Business Combination Agreement?</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">Catalyst and BC&#8217;s management believe that the transactions contemplated by the Business Combination </font><font style="font-weight: normal;">Agreement will result in a commercial-stage organ fibrosis and inflammatory disease company, with the drug </font><font style="font-weight: normal;">ETUARY approved for the treatment of pulmonary fibrosis in the PRC and a robust pipeline of product </font><font style="font-weight: normal;">candidates in various stages of development, including a </font><font style="font-weight: normal;">P</font><font style="font-weight: normal;">hase 3 study of Hydronidone in HBV associated </font><font style="font-weight: normal;">fibrosis in the PRC and a </font><font style="font-weight: normal;">P</font><font style="font-weight: normal;">hase 2 study of Hydronidone in the United States in non-alcoholic steatohepatitis </font><font style="font-weight: normal;">(&#8220;NASH&#8221;) fibrosis that is planned to begin in 2023. For a more complete description of the reasons for the </font><font style="font-weight: normal;">Contributions, please see the sections titled &#8220;</font><font style="font-style: italic; font-weight: normal;">The Contributions&#8212;Catalyst Reasons for the Contributions</font><font style="font-weight: normal;">&#8221; and </font><font style="font-weight: normal;">&#8220;</font><font style="font-style: italic; font-weight: normal;">The Contributions&#8212;GNI Parties Reasons for the Contributions</font><font style="font-weight: normal;">&#8221; beginning on pages </font><font style="font-weight: normal;"><a href="#tCRF">125</a></font><font style="font-weight: normal;"> and </font><font style="font-weight: normal;"><a href="#tGNI">126</a></font><font style="font-weight: normal;">, respectively, </font><font style="font-weight: normal;">of this proxy statement.</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Why am I receiving this proxy statement? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">You are receiving this proxy statement because you have been identified as a stockholder of Catalyst as of the record </font><font style="font-weight: normal;">date and you are entitled to vote at the Catalyst special meeting to approve the matters set forth herein. This proxy </font><font style="font-weight: normal;">statement is used to solicit proxies for the Catalyst special meeting to vote on the matters set forth herein. </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What proposals will be voted on at the Catalyst special meeting the approval of which are conditions to the closing of the Contributions? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">Pursuant to the terms of the Business Combination Agreement, the following proposals must be approved by the </font><font style="font-weight: normal;">requisite stockholder vote at the Catalyst special meeting in order for the Contributions to close:</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Proposal No.&#160;1: To approve, for purposes of Nasdaq Listing Rule 5635(a) and (b), the issuance of shares of Catalyst Common Stock and shares of Catalyst Convertible Preferred Stock, each pursuant to the terms of the Business Combination Agreement (as it may be amended from time to time), a copy of which is attached as Annex&#160;A to this proxy statement.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Proposal No.&#160;2: To approve, for purposes of Nasdaq Listing Rules 5635(a) and (b), the conversion of Catalyst Convertible Preferred Stock into shares of Catalyst Common Stock pursuant to the F351 Agreement, dated as of December&#160;26, 2022, by and among Catalyst, GNI Japan and GNI Hong Kong, as amended on March&#160;29, 2023 (the &#8220;F351 Agreement&#8221;), a copy of which is attached as Annex&#160;B to this proxy statement.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Proposal No.&#160;3: To adopt and approve an amendment to the restated certificate of incorporation of Catalyst to increase the number of authorized shares of Catalyst Common Stock from 100,000,000 shares to &#8195;&#8195;&#8195; shares.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Proposal No.&#160;4: To adopt and approve an amendment to the restated certificate of incorporation of Catalyst to effect a reverse stock split of Catalyst Common Stock, by a ratio of not less than 1-for-&#8195;&#8195;&#8195;&#8195; and not more than 1-for-&#8195;&#8195;&#8195;&#8195;, such ratio and the implementation and timing of the reverse stock split to be determined in the discretion of Catalyst&#8217;s board of directors. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Proposal No.&#160;5: To adopt and approve an amendment to the restated certificate of incorporation of Catalyst to create a new class of non-voting common stock of Catalyst.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Proposal No.&#160;6: To approve an amendment and restatement of 2023 Omnibus Incentive Plan.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Proposal No. 12: To consider and vote upon an adjournment of the Catalyst special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1, 2, 3, 4, 5 and 6.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">2<br></div></div></div>
<!--End Page 13-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 14-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_104-qa_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">Approval of Proposal Nos. 1, 2, 3, 4 and 6 is a condition to the completion of the Contributions. Therefore, the Contributions cannot be consummated without the approval of Proposal Nos. 1, 2, 3, 4 and 6.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In addition to the requirement of obtaining Catalyst stockholder approval, each of the other closing conditions set forth in the Business Combination Agreement must be satisfied or waived. For a more complete description of the closing conditions under the Business Combination Agreement, please see the section entitled &#8220;<font style="font-style: italic;">The </font><font style="font-style: italic;">Business Combination Agreement&#8212;Conditions to the Completion of the Contributions</font>&#8221; beginning on page <a href="#tCTT">152</a> of this proxy statement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The presence at the Catalyst special meeting, in person or being represented by proxy, of the holders of one-third of the outstanding shares of Catalyst Common Stock entitled to vote at the Catalyst special meeting, shall constitute a quorum at the meeting for the purpose of approving the proposals.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What stockholder votes are required to approve the proposals at the Catalyst special meeting? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">Assuming a quorum is present, the affirmative vote of the holders of a majority of all of the shares of Catalyst </font><font style="font-weight: normal;">Common Stock present in person or represented by proxy at the Catalyst special meeting and entitled to vote </font><font style="font-weight: normal;">on such matter is required for approval of Proposal Nos. 1, 2, 6, 9, 11 and 12. On Proposal Nos. 1, 2, 6, 9, 11 </font><font style="font-weight: normal;">and 12, abstentions will have the same effect as &#8220;AGAINST&#8221; votes and broker non-votes, if any, will have no </font><font style="font-weight: normal;">effect.</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Assuming a quorum is present, the affirmative vote of the holders of a majority of all of the shares of Catalyst Common Stock present in person or represented by proxy at the Catalyst special meeting and entitled to vote on such matter is required for approval of Proposal No. 10. Abstentions on Proposal No. 10 will have the same effect as a vote against each option, and broker non-votes, if any, will have no effect. Because Proposal No. 10 has multiple options, if none of the options receives the affirmative vote of the holders of a majority of all of the shares of Catalyst Common Stock present in person or represented by proxy at the Catalyst special meeting and entitled to vote on the matter, then we will consider the stockholders to have approved the option selected by the holders of a plurality of the shares of Catalyst Common Stock present in person or represented by proxy at the Catalyst special meeting and entitled to vote on the matter.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Assuming a quorum is present, the affirmative vote of the holders of a majority of the outstanding shares of Catalyst Common Stock entitled to vote at the Catalyst special meeting is required for approval of Proposal&#160;Nos.&#160;3 and 5. Abstentions and broker non-votes, if any, will have the same effect as &#8220;AGAINST&#8221; votes on Proposal Nos. 3 and 5. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Assuming a quorum is present, the affirmative vote of the holders of a majority of the outstanding shares of Catalyst Common Stock and Catalyst Series Y Preferred Stock (defined below) entitled to vote at the Catalyst special meeting is required for approval of Proposal No.&#160;4. Please refer to the discussion below under &#8220;How many votes do I have?&#8221; for a description of the Catalyst Series&#160;Y Preferred Stock, which is entitled to be voted together with the Catalyst Common Stock as a single class on Proposal No.&#160;4. Shares of Catalyst Series&#160;Y Preferred Stock that are not present in person or by proxy as of immediately prior to the opening of the polls at the Catalyst special meeting will be automatically redeemed in the Initial Redemption (defined below) and, therefore, will not be outstanding or entitled to vote on Proposal No.&#160;4 and will be excluded from the calculation as to whether Proposal No.&#160;4, respectively, passes at the Catalyst special meeting. Due to the voting power of the shares of Catalyst Series&#160;Y Preferred Stock that are redeemed pursuant to the Initial Redemption, the holders of Catalyst Common Stock that submit a proxy to vote their shares at the Catalyst special meeting or vote at the Catalyst special meeting will effectively have enhanced voting power on Proposal No.&#160;4 over holders of Catalyst Common Stock that are not represented in person or by proxy at the Catalyst special meeting. This means that Proposal No. 4 could be approved by the affirmative vote of the holders of less than a majority of the outstanding shares of Catalyst Common Stock. Abstentions and broker non-votes, if any, will have the same effect as &#8220;AGAINST&#8221; votes on Proposal No.&#160;4.</div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Delaware General Assembly has passed amendments to the DGCL that would change the stockholder vote required to effect a reverse split of stock that is listed on a national securities exchange and meets certain other requirements. The Catalyst Common Stock is listed on the Nasdaq Capital Market, a national securities exchange. The DGCL amendments are anticipated to become effective on August&#160;1, 2023, if they are signed into law by the Governor of Delaware, or otherwise enacted pursuant to Delaware law, on or before that date. If the amendments to the DGCL become effective before Catalyst files the amendment to the restated certificate of </div> </div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">3<br></div></div></div>
<!--End Page 14-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 15-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_104-qa_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">incorporation of Catalyst with the Delaware Secretary of State to effect the Reverse Stock Split, the Catalyst board of directors reserves the right to rely upon the new stockholder vote requirements authorized by the DGCL amendments to determine if Proposal No.&#160;4 has been adopted. The DGCL amendments would permit Catalyst to effect the Reverse Stock Split if the votes cast &#8220;FOR&#8221; Proposal No.&#160;4 exceed the votes cast &#8220;AGAINST&#8221; Proposal No.&#160;4, assuming the presence of a quorum and if the shares of Catalyst Common Stock meet the listing requirement of the Nasdaq Capital Market relating to the minimum number of holders immediately after the amendment to the restated certificate of incorporation effecting the Reverse Stock Split becomes effective. Under this voting standard, abstentions and broker non-votes (if any), and shares of Catalyst Common Stock that are not present in person or by proxy at the Catalyst special meeting, will have no effect on the outcome of the vote on Proposal No.&#160;4.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Assuming a quorum is present, the affirmative vote of the holders of two-thirds of the outstanding shares of Catalyst Common Stock entitled to vote at the Catalyst special meeting is required for approval of Proposal&#160;No.&#160;7. Abstentions and broker non-votes, if any, will have the same effect as &#8220;AGAINST&#8221; votes on Proposal No. 7.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Assuming a quorum is present, the two nominees receiving the highest number of affirmative &#8220;FOR&#8221; votes shall be elected as Class&#160;II directors pursuant to Proposal No. 8. Shares withheld and broker non-votes, if any, will have no effect.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">As of May&#160;15, 2023, GNI Japan and GNI HK owned or controlled approximately 16.6% of the outstanding shares of Catalyst Common Stock entitled to vote at the Catalyst special meeting. Pursuant to the Business Combination Agreement, these stockholders have agreed to vote all shares of Catalyst Common Stock owned by them as of the record date in favor of Proposal Nos. 1-6.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What will BC shareholders, the Minority Holders and BC option holders receive in the Contributions? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">BC shareholders and the Minority Holders will receive shares of Catalyst Common Stock. Catalyst stockholders immediately before the Contributions are expected to own approximately 2.5% of the outstanding shares of the combined company, GNI USA is expected to own approximately 85.2% of the outstanding shares of the combined company and the Minority Holders are expected to own approximately 12.3% of the outstanding shares of the combined company, in each case, assuming conversion of the Catalyst Convertible Preferred Stock and subject to certain assumptions, including, but not limited to, a valuation for Catalyst equal to $8.5&#160;million and a valuation for the percentage of BC acquired in the business combination equal to $299.8&#160;million. Immediately after the Contributions, the holders of the capital stock of Catalyst as of immediately prior to the Contributions are expected to own approximately 2.0% of the outstanding shares of the combined company, GNI USA is expected to own approximately 70.6% of the outstanding shares of the combined company, the Minority Holders are expected to own approximately 10.2% of the outstanding shares of the combined company, the holders of Gyre Options to be granted in respect of BC Options are expected to own approximately 16.6% of the outstanding shares of the combined company and the holders of outstanding options of Catalyst are expected to own approximately 0.6% of the outstanding shares of the combined company, in each case, on a fully diluted basis assuming conversion of the Catalyst Convertible Preferred Stock and including the outstanding options of Catalyst and the Gyre Options to be granted in respect of the BC Options. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">At the Effective Time of the Contributions, BC will terminate the 2021 Plan and BC Options outstanding thereunder will be terminated and replaced with Gyre Options. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">For a more complete description of what BC shareholders and option holders will receive in the Contributions, please see the sections titled &#8220;<font style="font-style: italic;">The Contributions&#8212;Consideration</font>&#8221;<font style="font-style: italic;"> </font>beginning on page <a href="#tCON">139</a> of this proxy statement. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Will the common stock of the combined company trade on an exchange<font style="font-weight: normal;">? </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">Shares of Catalyst Common Stock are currently listed on The Nasdaq Capital Market under the symbol </font><font style="font-weight: normal;">&#8220;CBIO.&#8221; Catalyst </font><font style="font-weight: normal;">has filed</font><font style="font-weight: normal;"> a listing application for the combined company with The Nasdaq Stock Market </font><font style="font-weight: normal;">(&#8220;Nasdaq&#8221;). After completion of the Contributions, the combined company will be renamed &#8220;Gyre </font><font style="font-weight: normal;">Therapeutics, Inc.&#8221; and it is expected that the common stock of the combined company will trade on Nasdaq </font><font style="font-weight: normal;">under the symbol &#8220;GYRE.&#8221; On &#8195;&#8195;&#8195;&#8195;, 2023, the last trading day before the date of this proxy statement, </font><font style="font-weight: normal;">the closing sale price of Catalyst Common Stock was $&#8195;&#8195;&#8195;&#8195; per share.</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">4<br></div></div></div>
<!--End Page 15-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 16-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_104-qa_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Who will be the directors of the combined company following the Contributions? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">Immediately following the Contributions, the combined company&#8217;s board of directors will be composed of </font><font style="font-weight: normal;">eight&#160;(8) members, consisting of Gordon G. Carmichael, Thomas Eastling, Ying Luo, Ph.D., Songjiang Ma, </font><font style="font-weight: normal;">Renate Parry, Nassim Usman, Ph.D., Charles Wu, Ph.D. and Han Ying, Ph.D.</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Who will be the executive officers of the combined company immediately following the Contributions? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">Immediately following the Contributions, the executive management team of the combined company is expected </font><font style="font-weight: normal;">to consist of: </font></div></td></tr></table><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 20.51%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title Immediately Following Contributions<br></div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title Immediately Prior to Contributions</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Charles Wu, Ph.D.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Executive Officer and Director</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director of BC</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Songjiang Ma</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">President and Director</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Honorary Chairman, Director of BC</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ruoyu Chen</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interim Chief Financial Officer</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Senior Vice President of Finance of GNI USA; Director of BC</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weiguo Ye</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Operating Officer</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director, President of BC</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Suzana Corritori,<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">M.D., Ph.D., MSc.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vice President of Clinical Development and Regulatory Affairs</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">President &amp; Owner of Corritori Consulting, Inc.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">As a Catalyst stockholder, how does Catalyst&#8217;s board of directors recommend that I vote? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">After careful consideration, Catalyst&#8217;s board of directors recommends that Catalyst stockholders vote &#8220;FOR&#8221; </font><font style="font-weight: normal;">Proposal Nos. 1, 2, 3, 4, 5, 6, 7, 9, 11 and 12, &#8220;FOR&#8221; the election of the director nominees named in </font><font style="font-weight: normal;">Proposal&#160;No. 8 and &#8220;ONE YEAR&#8221; on Proposal No. 10.</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What risks should I consider in deciding whether to vote in favor of the Contributions? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">You should carefully review the section entitled &#8220;</font><font style="font-style: italic; font-weight: normal;">Risk Factors</font><font style="font-weight: normal;">&#8221; beginning on page </font><font style="font-weight: normal;"><a href="#tRF">34</a></font><font style="font-weight: normal;"> of this proxy statement </font><font style="font-weight: normal;">and the annexes attached hereto and documents incorporated by reference herein, which set forth certain risks </font><font style="font-weight: normal;">and uncertainties related to the Contributions, risks and uncertainties to which the combined company&#8217;s business </font><font style="font-weight: normal;">will be subject and risks and uncertainties to which each of Catalyst and BC, as independent companies, are </font><font style="font-weight: normal;">subject.</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">When do you expect the Contributions to be consummated? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">The Contributions are anticipated to close promptly after the Catalyst special meeting scheduled to be held on </font><font style="font-weight: normal;">&#8195;&#8195;&#8195;&#8195;, 2023, but the exact timing cannot be predicted. For more information, please see the section entitled </font><font style="font-weight: normal;">&#8220;</font><font style="font-style: italic; font-weight: normal;">The Business Combination Agreement&#8212;Conditions to the Completion of the Contributions</font><font style="font-weight: normal;">&#8221; beginning on page </font><font style="font-weight: normal;"><a href="#tCTT">152</a></font><font style="font-weight: normal;"> of this proxy statement.</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What do I need to do now? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">Catalyst urges you to read this proxy statement carefully, including the annexes attached hereto and the </font><font style="font-weight: normal;">documents incorporated by reference and to consider how the Contributions affect you.</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">If you are a Catalyst stockholder of record, you may vote or provide your proxy instructions in one of four different ways: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">You can attend the Catalyst special meeting online and vote online during the special meeting.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">You can mail your signed proxy card in the enclosed return envelope.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">You can provide your proxy instructions via telephone by following the instructions on your proxy card.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">You can provide your proxy instructions via the internet by following the instructions on your proxy card.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Your signed proxy card, telephonic proxy instructions or internet proxy instructions must be received by to be counted.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">5<br></div></div></div>
<!--End Page 16-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 17-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_104-qa_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">If you hold your shares in &#8220;street name&#8221; (as described below), you may provide your proxy instructions via telephone or the internet by following the instructions on your vote instruction form. Please provide your proxy instructions only once, unless you are revoking a previously delivered proxy instruction and as soon as possible so that your shares can be voted at the Catalyst special meeting.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What happens if I do not return a proxy card or otherwise vote or provide proxy instructions, as applicable? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">If you are a Catalyst stockholder, the failure to return your proxy card or otherwise vote or provide proxy </font><font style="font-weight: normal;">instructions may reduce the aggregate number of votes required to approve Proposal Nos. 1, 2, 6, 9, 11 and 12 </font><font style="font-weight: normal;">and to approve one of the options under Proposal No. 10. Also, your shares will not be counted for purposes of </font><font style="font-weight: normal;">determining whether a quorum is present at the Catalyst special meeting unless your broker has and exercises, </font><font style="font-weight: normal;">discretionary authority to vote on certain matters.</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">May I attend the Catalyst special meeting and vote in person? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">The Catalyst special meeting will be held entirely online. Stockholders of record as of the close of business on </font><font style="font-weight: normal;">will be able to attend and participate in the Catalyst special meeting online by accessing </font><font style="font-weight: normal;">www.</font><font style="font-weight: normal;">virtualshareholdermeeting.com/CBIO2023SM</font><font style="font-weight: normal;">. To join the Catalyst special meeting, you will need to have </font><font style="font-weight: normal;">your 16-digit control number which is included on your Notice of Internet Availability of Proxy Materials and </font><font style="font-weight: normal;">your proxy card. If your shares are held in &#8220;street name,&#8221; you should contact your bank, broker or other nominee </font><font style="font-weight: normal;">to obtain your 16-digit control number or otherwise vote through your bank, broker or other nominee.</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Who can vote?</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">Only stockholders of record at the close of business on &#8195;&#8195;&#8195;, 2023 (the &#8220;Record Date&#8221;) are entitled to notice </font><font style="font-weight: normal;">of the Catalyst special meeting and to vote on the proposals described in this proxy statement. At the close of </font><font style="font-weight: normal;">business on the Record Date, &#8195;&#8195;&#8195;&#160;shares of Catalyst Common Stock were issued and outstanding, and </font><font style="font-weight: normal;">&#8195;&#8195;&#8195;&#160;shares of Catalyst Series Y Preferred Stock, par value $0.001&#160;per share (&#8220;Catalyst Series&#160;Y Preferred </font><font style="font-weight: normal;">Stock&#8221;), were issued and outstanding. Holders of outstanding shares of Catalyst Series&#160;Y Preferred Stock will </font><font style="font-weight: normal;">only be entitled to vote such shares on Proposal No.&#160;4 and will only be able to vote to the extent that such shares </font><font style="font-weight: normal;">have not been automatically redeemed in the Initial Redemption (defined below).</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Of the shares of Catalyst Common Stock issued and outstanding and entitled to vote, 6,266,521&#160;shares of Catalyst Common Stock were issued in the F351&#160;Acquisition (as described in &#8220;Proposal No.&#160;2 &#8211; General&#8221; below) and are not entitled to vote on Proposal No.&#160;2 for purposes of the listing rules of Nasdaq. Catalyst anticipates that these 6,266,521&#160;shares of Catalyst Common Stock will be voted in favor of Proposal No.&#160;2 for purposes of adopting the proposal under Delaware law. However, to comply with Nasdaq rules, Catalyst will instruct the inspector of elections to conduct a separate tabulation that subtracts 6,266,521&#160;shares from the total number of shares voted in favor of Proposal No.&#160;2 to determine whether that proposal has been adopted in accordance with applicable Nasdaq rules.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Why did the Catalyst board of directors decide to issue shares of Catalyst Series&#160;Y Preferred Stock?</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">Over the past several years, several large brokerage firms (particularly firms with heavily retail stockholders) </font><font style="font-weight: normal;">have changed their voting policies and now no longer return broker votes at stockholder meetings. As a result </font><font style="font-weight: normal;">of these changes, numerous peer companies have had difficulty obtaining the requisite level of approval for </font><font style="font-weight: normal;">proposals, such as the reverse stock split proposal, even where the votes cast were overwhelmingly in favor of </font><font style="font-weight: normal;">the proposal. In such situations, the will of the voting stockholders is effectively ignored due to an overall low </font><font style="font-weight: normal;">level of voting turnout. In the case of the matters to be voted on at the Catalyst special meeting, the Catalyst </font><font style="font-weight: normal;">board of directors was concerned that a low level of voter turnout would frustrate the will of the voting </font><font style="font-weight: normal;">stockholders and potentially endanger both Catalyst&#8217;s continued listing on Nasdaq and its ability to issue </font><font style="font-weight: normal;">additional shares of common stock to fund ongoing operations. In light of these concerns, the Catalyst board of </font><font style="font-weight: normal;">directors determined that it was in the best interests of Catalyst and its stockholders to issue shares of Catalyst </font><font style="font-weight: normal;">Series&#160;Y Preferred Stock to help mitigate execution risk in connection with the Catalyst special meeting and </font><font style="font-weight: normal;">reverse stock split. In approving the issuance of the Catalyst Series&#160;Y Preferred Stock, the Catalyst board of </font><font style="font-weight: normal;">directors noted in particular that the Catalyst Series&#160;Y Preferred Stock votes would simply mirror the votes cast </font><font style="font-weight: normal;">by the common stock, thereby preserving the relative &#8220;for&#8221; and &#8220;against&#8221; voting ratios.</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">6<br></div></div></div>
<!--End Page 17-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 18-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_104-qa_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">How many votes do I have?</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">Each share of Catalyst Common Stock is entitled to one vote on each proposal to be voted on at the Catalyst </font><font style="font-weight: normal;">special meeting.</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">As announced on June&#160;20, 2023, the Catalyst board of directors declared a dividend of one one-thousandth (1/1,000th) of a share of Catalyst Series&#160;Y Preferred Stock for each outstanding share of Catalyst Common Stock to stockholders of record of Catalyst Common Stock as of the close of business on June&#160;30, 2023. The holders of Catalyst Series Y Preferred Stock have 250,000 votes per whole share of Catalyst Series Y Preferred Stock (<font style="font-style: italic;">i.e.</font>, 250 votes per one one-thousandth of a share of Catalyst Series&#160;Y Preferred Stock) and are entitled to vote with the Catalyst Common Stock, together as a single class, on Proposal No.&#160;4, but are not otherwise entitled to vote on any other proposal to be presented at the Catalyst special meeting. Notwithstanding the foregoing, each share of Catalyst Series&#160;Y Preferred Stock redeemed pursuant to the Initial Redemption (defined below) will have no voting power with respect to Proposal No.&#160;4 (or any other matter). When a holder of Catalyst Common Stock submits a vote on Proposal No.&#160;4, the corresponding number of fractional shares of Catalyst Series&#160;Y Preferred Stock held by such holder will be automatically voted in a mirrored fashion unless otherwise indicated. For example, if a stockholder holds 10 shares of Catalyst Common Stock (entitled to one vote per share) and votes in favor of Proposal No.&#160;4, then 2,510 votes will be recorded in favor of Proposal No.&#160;4, because the stockholder&#8217;s shares of Catalyst Series&#160;Y Preferred Stock will automatically be voted in favor of Proposal No.&#160;4 alongside such stockholder&#8217;s shares of Catalyst Common Stock.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">All shares of Catalyst Series&#160;Y Preferred Stock that are not present in person or by proxy at the Catalyst special meeting as of immediately prior to the opening of the polls at the Catalyst special meeting will be automatically redeemed (the &#8220;Initial Redemption&#8221;). Any outstanding shares of Catalyst Series&#160;Y Preferred Stock that have not been redeemed pursuant to the Initial Redemption will be redeemed in whole, but not in part, (i)&#160;if and when ordered by the Catalyst board of directors or (ii)&#160;automatically upon the effectiveness of the amendment to the restated certificate of incorporation of Catalyst effecting the reverse stock split.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Who counts the votes? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">Broadridge Financial Solutions, Inc. (&#8220;Broadridge&#8221;) will be engaged as Catalyst&#8217;s independent agent to tabulate </font><font style="font-weight: normal;">stockholder votes, which Catalyst refers to as the inspector of election. If you are a stockholder of record, your </font><font style="font-weight: normal;">executed proxy card is returned directly to Broadridge for tabulation.</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">If my shares of Catalyst Common Stock are held in &#8220;street name&#8221; by my broker, will my broker vote my shares for me? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">Unless your broker has discretionary authority to vote on certain matters, your broker will not be able to vote </font><font style="font-weight: normal;">your shares of Catalyst Common Stock on matters requiring discretionary authority without instructions from </font><font style="font-weight: normal;">you. If you hold shares beneficially in &#8220;street name&#8221; and do not provide your broker or other agent with voting </font><font style="font-weight: normal;">instructions, your shares may constitute &#8220;broker non-votes.&#8221; A &#8220;broker non-vote&#8221; occurs when shares held by </font><font style="font-weight: normal;">a broker are not voted with respect to a particular proposal because the broker does not have or did not exercise </font><font style="font-weight: normal;">discretionary authority to vote on the matter and has not received voting instructions from its clients. These </font><font style="font-weight: normal;">matters are referred to as &#8220;non-routine&#8221; matters. On non-routine items for which you do not give your broker </font><font style="font-weight: normal;">instructions, shares of Catalyst Common Stock will be treated as broker non-votes. Whether a proposal is </font><font style="font-weight: normal;">considered routine or non-routine is subject to stock exchange rules and final determination by the stock </font><font style="font-weight: normal;">exchange. To make sure that your vote is counted, you should instruct your broker to vote your shares, following </font><font style="font-weight: normal;">the procedures provided by your broker.</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What are broker non-votes and do they count for determining a quorum? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">Generally, broker non-votes occur when there is at least one discretionary and one non-discretionary proposal </font><font style="font-weight: normal;">to be voted on at the meeting and shares held by a broker in &#8220;street name&#8221; for a beneficial owner are voted on </font><font style="font-weight: normal;">at least one &#8220;routine&#8221; proposal but not voted with respect to a particular proposal because the broker (i)&#160;has not </font><font style="font-weight: normal;">received voting instructions from the beneficial owner for that proposal or (ii)&#160;lacks discretionary voting power </font><font style="font-weight: normal;">to vote those shares for that proposal. A broker is entitled to vote shares held for a beneficial owner on routine </font><font style="font-weight: normal;">matters without instructions from the beneficial owner of those shares. On the other hand, absent instructions </font><font style="font-weight: normal;">from the beneficial owner of such shares, a broker is not entitled to vote shares held for a beneficial owner on </font><font style="font-weight: normal;">non-routine matters.</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">7<br></div></div></div>
<!--End Page 18-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 19-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_104-qa_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">Broker non-votes, if any, will be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the Catalyst special meeting. Broker non-votes will not be treated as votes entitled to vote on a proposal. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What if I sign and return a proxy card or otherwise vote but do not indicate specific choices?</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-style: italic; font-weight: normal;">Registered Stockholder: Shares Registered in Your Name</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The shares represented by each signed and returned proxy will be voted at the Catalyst special meeting by the persons named as proxies in the proxy card in accordance with the instructions indicated on the proxy card. However, if you are the registered stockholder and sign and return your proxy card without giving specific instructions, the persons named as proxies in the proxy card will vote your shares of Catalyst Common Stock and, with respect to Proposal No.&#160;4, your shares of Catalyst Series&#160;Y Preferred Stock, in accordance with the recommendations of the Catalyst board of directors. Your shares will be counted toward the quorum requirement.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 20pt; text-align: left;">Beneficial Owner: Shares Registered in the Name of a Broker, Fiduciary or Custodian</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">If you are the beneficial owner and sign and return your voting instruction form without giving specific instructions, your broker, fiduciary or custodian will only be able to vote your shares of Catalyst Common Stock and, with respect to Proposal No.&#160;4, your shares of Catalyst Series&#160;Y Preferred Stock, with respect to proposals considered to be &#8220;routine.&#8221; Your broker, fiduciary or custodian is not entitled to vote your shares with respect to &#8220;non-routine&#8221; proposals, resulting in a broker non-vote with respect to such proposals.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">May I change my vote after I have submitted a proxy or provided proxy instructions? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">Catalyst stockholders of record, unless such stockholder&#8217;s vote is subject to a support agreement, may change </font><font style="font-weight: normal;">their vote at any time before their proxy is voted at the Catalyst special meeting in one of four ways: </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">You may submit another properly completed proxy with a later date by mail or via the internet.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">You can provide your proxy instructions via telephone at a later date.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">You may send a written notice that you are revoking your proxy to Catalyst&#8217;s Corporate Secretary at investors@catbio.com.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">You may attend the Catalyst special meeting online and vote by following the instructions at www.virtualshareholdermeeting.com/CBIO2023SM.com. Simply attending the Catalyst special meeting will not, by itself, revoke your proxy.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Your signed proxy card, telephonic proxy instructions, internet proxy instructions or written notice must be received by to be counted.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">If a Catalyst stockholder who owns shares of Catalyst Common Stock in &#8220;street name&#8221; has instructed a broker to vote its shares of Catalyst Common Stock, the stockholder must follow directions received from its broker to change those instructions.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Who is paying for this proxy solicitation? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">Catalyst and the GNI Parties will share equally the cost of printing and filing of this proxy statement and the </font><font style="font-weight: normal;">proxy card. Arrangements will also be made with brokerage firms and other custodians, nominees and </font><font style="font-weight: normal;">fiduciaries who are record holders of Catalyst Common Stock for the forwarding of solicitation materials to the </font><font style="font-weight: normal;">beneficial owners of Catalyst Common Stock. Catalyst and the GNI Parties will reimburse these brokers, </font><font style="font-weight: normal;">custodians, nominees and fiduciaries for the reasonable out-of-pocket expenses they incur in connection with the </font><font style="font-weight: normal;">forwarding of solicitation materials. Catalyst will retain Broadridge to assist it in soliciting proxies using the </font><font style="font-weight: normal;">means referred to above. Catalyst and the GNI Parties will pay the fees of Broadridge, which are expected to </font><font style="font-weight: normal;">be approximately $</font><font style="font-weight: normal;">&#8195;&#8195;</font><font style="font-weight: normal;">, plus reimbursement of out-of-pocket expenses.</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Catalyst is also retaining Morrow Sodali LLC (&#8220;Morrow Sodali&#8221;) as a solicitation agent. The services Morrow Sodali will perform include the consultation and preparation in connection with the proxy solicitation services relating to the Catalyst special meeting, including any adjournment or postponement thereof, the identification of significant holders, on a best effort basis, of street accounts owning common shares and units, acting as </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">8<br></div></div></div>
<!--End Page 19-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 20-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_104-qa_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">solicitor and, if requested, telephoning individual holders of record, as well as Non- Objecting Beneficial Owners (&#8220;NOBOs&#8221;), to a level to be determined. For such services, Catalyst is paying Morrow Sodali a fixed fee of $15,500, plus associated reasonable and documented out-of-pocket disbursements, and a performance fee at Catalyst&#8217;s discretion based on Morrow Sodali&#8217;s service.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What are the material U.S. federal income tax consequences of the Contributions to Catalyst stockholders? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">Catalyst stockholders will not sell, exchange or dispose of any shares of Catalyst Common Stock in the </font><font style="font-weight: normal;">Contributions. Thus, there generally will be no material U.S. federal income tax consequences to Catalyst </font><font style="font-weight: normal;">stockholders upon consummation of the Contributions.</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What are the material U.S. federal income tax consequences of the Contributions to GNI USA? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">(i) Catalyst, (ii)&#160;GNI USA, GNI Japan, GNI Hong Kong, SG, Further Challenger, CPI and BC (together, the </font><font style="font-weight: normal;">&#8220;GNI Parties&#8221;) and (iii)&#160;the Minority Holders, intend for the Contributions, taken together, to qualify as a </font><font style="font-weight: normal;">transaction governed by Section 351(a) of the Internal Revenue Code of 1986 (as amended, the &#8220;Code&#8221;). </font><font style="font-weight: normal;">Assuming the Contributions qualify for the intended tax treatment, subject to the limitations and qualifications </font><font style="font-weight: normal;">described in the section entitled &#8220;</font><font style="font-style: italic; font-weight: normal;">The Contributions&#8212;Material U.S. Federal Income Tax Consequences of the </font><font style="font-style: italic; font-weight: normal;">Contributions</font><font style="font-weight: normal;">,&#8221; GNI USA will not recognize gain or loss for U.S. federal income tax purposes upon the receipt </font><font style="font-weight: normal;">of shares of Catalyst Common Stock in exchange for shares of CPI common stock and/or ordinary shares of </font><font style="font-weight: normal;">Further Challenger in the Contributions. For a more detailed discussion of the material U.S. federal income tax </font><font style="font-weight: normal;">consequences of the Contributions, see &#8220;</font><font style="font-style: italic; font-weight: normal;">The Contributions&#8212;Material U.S. Federal Income Tax Consequences </font><font style="font-style: italic; font-weight: normal;">of the Contributions</font><font style="font-weight: normal;">&#8221; beginning on page </font><font style="font-weight: normal;"><a href="#tMUF1">141</a></font><font style="font-weight: normal;"> of this proxy statement.</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What are the material U.S. federal income tax consequences of the receipt of contingent value rights (&#8220;CVRs&#8221;) to Catalyst stockholders? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">The U.S. federal income tax treatment of Catalyst stockholders&#8217; receipt of the CVRs is unclear. Catalyst will </font><font style="font-weight: normal;">report the issuance of the CVRs to Catalyst stockholders as a distribution of property with respect to Catalyst </font><font style="font-weight: normal;">Common Stock. If the issuance of the CVRs is treated as a distribution of property, each Catalyst stockholder </font><font style="font-weight: normal;">will be treated as receiving a distribution in an amount equal to the fair market value of the CVRs issued to such </font><font style="font-weight: normal;">Catalyst stockholder on the date of the issuance. This distribution generally should be treated first as a taxable </font><font style="font-weight: normal;">dividend to the extent of the Catalyst stockholder&#8217;s pro rata share of Catalyst&#8217;s current or accumulated earnings </font><font style="font-weight: normal;">and profits for the year of issuance (as determined for U.S. federal income tax purposes), then as a non-taxable </font><font style="font-weight: normal;">return of capital to the extent of the Catalyst stockholder&#8217;s basis in its Catalyst Common Stock and finally as </font><font style="font-weight: normal;">capital gain from the sale or exchange of Catalyst Common Stock with respect to any remaining value. </font><font style="font-weight: normal;">Catalyst </font><font style="font-weight: normal;">is in the process of performing an analysis of the its earnings and profits and some or all of the issuance of CVRs </font><font style="font-weight: normal;">could be treated as a dividend for U.S. federal income tax purposes if Catalyst determines that it has current or </font><font style="font-weight: normal;">accumulated earnings and profits.</font><font style="font-weight: normal;"> See the section entitled &#8220;</font><font style="font-style: italic; font-weight: normal;">Agreements Related to the Contributions&#8212;CVR </font><font style="font-style: italic; font-weight: normal;">Agreement&#8212;Material U.S. Federal Income Tax Consequences of the Receipt of CVRs</font><font style="font-weight: normal;">&#8221; beginning on page </font><font style="font-weight: normal;"><a href="#tMUF">157</a></font><font style="font-weight: normal;"> </font><font style="font-weight: normal;">of this proxy statement for a more complete description of the material U.S. federal income tax consequences </font><font style="font-weight: normal;">of the receipt of CVRs to Catalyst stockholders, including possible alternative treatments.</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What are the material U.S. federal income tax consequences of the proposed reverse stock split to Catalyst U.S. holders? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">Catalyst intends for the proposed reverse stock split to qualify as a &#8220;recapitalization&#8221; within the meaning of </font><font style="font-weight: normal;">Section 368(a)(1)(E) of the Code. In general and subject to the qualifications and limitations set forth in the </font><font style="font-weight: normal;">section entitled &#8220;</font><font style="font-style: italic; font-weight: normal;">Proposal No. 4&#8212;Material U.S. Federal Income Tax Consequences of the Reverse Stock Split</font><font style="font-weight: normal;">&#8221; </font><font style="font-weight: normal;">beginning on page </font><font style="font-weight: normal;"><a href="#tMUF2">187</a></font><font style="font-weight: normal;"> of this proxy statement, if the proposed reverse stock split qualifies as a </font><font style="font-weight: normal;">&#8220;recapitalization&#8221; within the meaning of Section 368(a)(1)(E) of the Code, a Catalyst U.S. holder (as defined </font><font style="font-weight: normal;">on page </font><font style="font-weight: normal;"><a href="#tRecap">158</a></font><font style="font-weight: normal;">) should not recognize gain or loss upon the proposed reverse stock split. As discussed in more detail </font><font style="font-weight: normal;">in the section entitled &#8220;</font><font style="font-style: italic; font-weight: normal;">Agreements Related to the Contributions&#8212;CVR Agreement&#8212;Material U.S. Federal </font><font style="font-style: italic; font-weight: normal;">Income Tax Consequences of the Receipt of CVRs</font><font style="font-weight: normal;">&#8221; beginning on page </font><font style="font-weight: normal;"><a href="#tMUF">157</a></font><font style="font-weight: normal;"> of this proxy statement, these </font><font style="font-weight: normal;">consequences assume that distribution of the CVRs will be treated for U.S. federal income tax purposes as </font><font style="font-weight: normal;">separate and distinct from the proposed reverse stock split. See the section entitled &#8220;</font><font style="font-style: italic; font-weight: normal;">Proposal No. 4&#8212;Material </font><font style="font-style: italic; font-weight: normal;">U.S. Federal Income Tax Consequences of the Reverse Stock Split</font><font style="font-weight: normal;">&#8221; beginning on page </font><font style="font-weight: normal;"><a href="#tMUF2">187</a></font><font style="font-weight: normal;"> of this proxy </font><font style="font-weight: normal;">statement for a more complete description of the material U.S. federal income tax consequences of the proposed </font><font style="font-weight: normal;">reverse stock split to Catalyst U.S. holders.</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">9<br></div></div></div>
<!--End Page 20-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 21-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_104-qa_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Who can help answer my questions? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: justify;"><font style="font-weight: normal;">If you are a Catalyst stockholder and would like additional copies of this proxy statement without charge or if </font><font style="font-weight: normal;">you have questions about the Contributions, including the procedures for voting your shares, you should contact: </font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">Broadridge Financial Solutions, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">51 Mercedes Way<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Edgewood, New York 11717<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">sendmaterial@proxyvote.com<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Telephone: 1 (800) 579-1639</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">10<br></div></div></div>
<!--End Page 21-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 22-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20006478x8_prer14a_105-sum_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSOT"><!--Anchor--></a>SUMMARY OF THE PROXY STATEMENT</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This summary highlights selected information from this proxy statement and may not contain all of the information that is important to you. To better understand the Contributions and the proposals being considered at the Catalyst special meeting, you should read this entire proxy statement carefully, including the Business Combination Agreement, the F351 Agreement and the other annexes to which you are referred in this proxy statement and the documents incorporated by reference herein. For more information, please see the section entitled &#8220;Where You Can Find More Information&#8221; beginning on page <a href="#tWYC">343</a> of this proxy statement. Except where specifically noted, the following information and all other information contained in this proxy statement does not give effect to the proposed reverse stock split of Catalyst Common Stock described in Proposal No. 4 of this proxy statement.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The Companies </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: normal; font-weight: normal;">611 Gateway Blvd</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: normal; font-weight: normal;">Suite 120</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: normal; font-weight: normal;">South San Francisco, CA 94080</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: normal; font-weight: normal;">Telephone: (650) 871-0761</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst Biosciences, Inc., together with its subsidiary (&#8220;Catalyst&#8221;), is a biopharmaceutical company focused on the development and commercialization of Hydronidone for the treatment of nonalcoholic steatohepatitis (&#8220;NASH&#8221;) in the United States. Hydronidone is being evaluated for the treatment of liver fibrosis associated with a broad spectrum of chronic liver diseases. A Phase 1 clinical trial of Hydronidone has been completed in the United States and generated pharmacokinetics (&#8220;PK&#8221;), safety and tolerability data of single and multiple ascending doses of Hydronidone in U.S. healthy subjects. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This Phase 1 clinical trial of Hydronidone was conducted on the basis of an investigational new drug (&#8220;IND&#8221;) application that was filed in 2016 for Hydronidone as an anti-fibrotic agent with a focus on liver fibrosis. Upon the Federal Drug Administration&#8217;s (&#8220;FDA&#8221;) review of such IND, the Phase 1 clinical trial was initiated and completed. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst anticipates filing an IND application for the treatment of NASH in the United States in late 2023. NASH is a severe form of nonalcoholic fatty liver disease (&#8220;NAFLD&#8221;), characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, hepatocellular carcinoma (&#8220;HCC&#8221;) and death. There are currently no approved products for the treatment of NASH. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst plans to initiate the clinical development of Hydronidone in NASH fibrosis in a randomized, double-blind, placebo-controlled, parallel group, Phase 2a, Proof-of-Concept (&#8220;PoC&#8221;) clinical study evaluating the safety, tolerability, PK, and Pharmacodynamics (&#8220;PD&#8221;) of Hydronidone capsules administered daily at an oral dose of 360&#160;mg (given as 120 mg thrice daily (&#8220;TID&#8221;)) for 24 weeks to adult subjects with advanced liver fibrosis associated with noncirrhotic NASH. The main goal of the proposed Phase 2a study is to obtain early PoC for Hydronidone in subjects with NASH fibrosis as a basis of expansion into a more comprehensive Phase 2/3 clinical program, provided that the drug is successful. The study will include a small sample size (total of 60 evaluable subjects) who will receive in a 2:1 ratio Hydronidone or Placebo. The study will evaluate changes from baseline in a set of noninvasive biochemical and imaging biomarkers relevant to assessment of NASH fibrosis in the context of drug exposure, as well as the mechanism of anti-fibrotic action of Hydronidone. The study will employ PK blood sampling and assessment of the initial population PK and PK/PD relationship to inform Hydronidone treatment in future clinical studies in NASH fibrosis. In addition, this trial will include a disease-specific patient-reported outcomes (&#8220;PROs&#8221;), a validated composite Chronic Liver Disease Questionnaire (&#8220;CLDQ&#8221;) &#8211; NASH, to collect patient-reported data about the impact of Hydronidone treatment on quality of life of subjects with advanced NASH fibrosis. Before the F351 Acquisition, GNI USA engaged in a pre-IND dialogue with the FDA in connection with this Phase 2a clinical study. The FDA&#8217;s written responses to GNI USA commented on the adequacy of the existing data package for filing an IND for the NASH fibrosis indication, including the proposed Phase 2a study design, and provided recommendations and guidance on the requirements for the IND filing. In connection with the F351 Acquisition, GNI initiated the transfer of ownership of the IND to Catalyst. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Prior to Catalyst&#8217;s acquisition from GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (&#8220;GNI Japan&#8221;) and GNI Hong Kong of all of the assets and intellectual property rights primarily related to the proprietary Hydronidone compound (collectively, the &#8220;F351 Assets&#8221;), other than such assets and intellectual property rights located in the People&#8217;s Republic of China (the &#8220;PRC&#8221;) (the &#8220;F351 Acquisition&#8221;), Catalyst was engaged in the research and development of product candidates from Catalyst&#8217;s protease engineering platform. In </div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">11<br></div></div></div>
<!--End Page 22-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 23-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20006478x8_prer14a_105-sum_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">February 2022, Catalyst announced that it engaged Perella Weinberg Partners as a financial advisor to assist Catalyst in exploring strategic alternatives to monetize its assets. In March 2022, Catalyst ceased research and development activities and in May 2022, Catalyst entered into an asset purchase agreement with Vertex Pharmaceuticals Inc., pursuant to which Vertex Pharmaceuticals Inc. (&#8220;Vertex&#8221;) purchased Catalyst&#8217;s complement portfolio, including CB 2782-PEG and CB 4332, as well as its complement-related intellectual property, including the ProTUNE&#8482; and ImmunoTUNE&#8482; platforms, for $60.0&#160;million in cash consideration. $55.0&#160;million was received upfront and the remaining $5.0&#160;million was retained by Vertex as a hold-back until one year after the closing date to satisfy certain post-closing indemnification obligations. Any amounts received from Vertex with respect to this hold-back will be distributed to holders of the contingent value right issued to Catalyst stockholders of record on January&#160;5, 2023 (the &#8220;CVR Holders&#8221;). On February&#160;27, 2023, Catalyst signed an asset purchase agreement with GC Biopharma (&#8220;GCBP&#8221;) pursuant to which GCBP acquired Catalyst&#8217;s legacy rare bleeding disorders programs, including marzeptacog alpha activated(&#8220;MarzAA&#8221;), dalcinonacog alpha (&#8220;DalcA&#8221;) and CB-2679d-GT, for a total of $6&#160;million; $1&#160;million payable on signing and $5&#160;million payable on February&#160;28, 2025, subject to satisfaction of post-closing indemnification obligations. In March 2023, Catalyst distributed net proceeds of approximately $0.2 million to the CVR Holders. Once received, any additional net proceeds from the transaction will be distributed to the CVR Holders. Catalyst is also pursuing certain legal claims against a third party related to payments under a 2016 asset purchase agreement, and any net recoveries related to these claims will be distributed to the CVR Holders.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst had net loss of $8.2&#160;million for the year ended December&#160;31, 2022 and net income of $260,000 for the three months ended March 31, 2023, and an accumulated deficit of $410.9&#160;million as of December&#160;31, 2022 and $410.7 million as of March 31, 2023. As of December&#160;31, 2022, Catalyst had $21.7&#160;million of cash and cash equivalents. As of March 31, 2023, Catalyst had $8.1 million of cash and cash equivalents. Substantially all its operating losses were incurred in its research and development programs and in its general and administrative operations. Catalyst believes that its existing cash and cash equivalents and investments will be sufficient to fund its cash requirements for at least the next 12 months from the date of the filing of this proxy statement, assuming Catalyst stockholders approve the Conversion Proposal.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">Beijing Continent Pharmaceuticals Co., Ltd<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: normal; font-weight: normal;">Room 320507-320509, Building 5, Wangjing SOHO Tower, Yard 1, Futong East Street</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: normal; font-weight: normal;">Chaoyang District, Beijing, PRC</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: normal; font-weight: normal;">Telephone: +86-10-88877935</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the PRC (&#8220;BC&#8221;), is a commercial-stage biopharmaceutical company committed to the research, development, manufacturing and commercialization of innovative drugs for organ fibrosis. BC&#8217;s commercialized product, ETUARY (pirfenidone capsule) and other product candidates were all initially acquired or in-licensed from GNI Japan. BC initially focused on the treatment of idiopathic pulmonary fibrosis (&#8220;IPF&#8221;) and has gradually broadened its therapeutic field and research and development efforts to other areas of organ fibrosis. BC&#8217;s flagship product, ETUARY, was approved in the PRC in 2011 and is among the first three approved drugs for IPF worldwide. Thereafter, BC has developed a pipeline of four additional innovative drug candidates and has had nine-years of successful commercialization.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As the PRC&#8217;s first approved treatment for IPF, ETUARY has been included in the National Reimbursement Drug List (the &#8220;NRDL&#8221;) of the PRC since 2017. Filling an IPF treatment vacuum in the PRC as the first approved IPF treatment, ETUARY has developed rapidly and maintained a dominant market share in the PRC. The prevalence of IPF in the PRC increased from 83,002 patients in 2017 to 131,654 patients in 2022 and it is expected to increase to 214,664 patients by 2027 and 320,677 patients by 2031. The total estimated market size for IPF treatments in the PRC was $127.4&#160;million in 2022 and is expected to grow to $698.6&#160;million by 2031, according to Frost &amp; Sullivan. Moreover, as different organ fibrosis diseases share a similar pathogenic mechanism and fibrosis process, BC is seeking to expand the use of ETUARY to include other pulmonary fibrosis diseases such as systemic sclerosis-related interstitial lung disease (&#8220;SSc-ILD&#8221;), dermatomyositis-related interstitial lung disease (&#8220;DM-ILD&#8221;) and pneumoconiosis, as well as diseases causing renal fibrosis such as diabetic kidney disease (&#8220;DKD&#8221;). Specifically, BC has commenced Phase 3 clinical trials for the treatment of SSc-ILD, DM-ILD and pneumoconiosis and completed Phase 1 clinical trials for the treatment of DKD. The success of ETUARY lays the foundation for BC&#8217;s research and development and registration strategy to further expand the use of such drugs to indications with large patient populations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Through in-house research and development efforts and collaborative arrangements with the GNI Parties, in addition to ETUARY, BC has developed a pipeline of pharmaceutical product candidates at various phases of clinical development, including Hydronidone, F528, F230 and F573. Specifically, liver fibrosis is an area of BC&#8217;s focus and </div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">12<br></div></div></div>
<!--End Page 23-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 24-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20006478x8_prer14a_105-sum_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">BC&#8217;s key product candidate in this area is Hydronidone. Hydronidone is currently in its Phase 3 clinical trial and has the potential to be the world&#8217;s first approved drug to treat liver fibrosis associated with chronic hepatitis B (&#8220;CHB&#8221;). According to Frost &amp; Sullivan, the number of patients with liver fibrosis in the PRC reached 140.3&#160;million in 2022, of which approximately 45.3%, or 63.6&#160;million, were caused by CHB. To date, no specific therapeutic drugs treating HBV-associated liver fibrosis have been approved worldwide and Hydronidone is the most clinically-advanced anti-liver fibrosis drug both in the PRC and globally. BC&#8217;s Phase 2 clinical trials of Hydronidone demonstrated favorable results in reversing the fibrosis process. Hydronidone was granted a Breakthrough Therapy designation by the National Medical Products Administration&#8217;s (&#8220;NMPA&#8221;) Center for Drug Evaluation (&#8220;CDE&#8221;) in March 2021 and the patient enrollment for its Phase 3 clinical trial was commenced in January 2022. As of May 9, 2023, BC has completed the enrollment of 124 subjects, which is 50% of the target enrollment. However, Hydronidone&#8217;s Breakthrough Therapy designation does not increase the likelihood that Hydronidone will ultimately receive approval from the NMPA or other comparable regulatory authorities. BC expects to submit an NMPA application for Hydronidone in the PRC in the first quarter of 2025. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">With a deep understanding in molecular signaling pathway from BC&#8217;s years of research into organ fibrosis, BC has also expanded its research and development to include potential treatments for chronic obstructive pulmonary disease (&#8220;COPD&#8221;), pulmonary arterial hypertension (&#8220;PAH&#8221;) and acute/acute-on-chronic liver failure (&#8220;ALF/ACLF&#8221;):</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><font style="font-style: italic;">F528</font>. BC is evaluating in preclinical studies for the treatment of COPD F528, which is a novel anti-inflammatory agent that targets inhibition of multiple inflammatory cytokines and has the potential to modify the progression of COPD with low toxicity <font style="font-style: italic;">in vivo</font>. According to Frost &amp; Sullivan, the number of COPD patients in the PRC reached 106.4&#160;million in 2022 and is expected to reach 110.1&#160;million by 2031. The current standard of care is primarily used to relieve symptoms, reduce the frequency and severity of disease deterioration and improve cardio endurance. BC believes that F528 could provide a first-line therapy for COPD and adjust the long-term lung function degradation. BC intends to file an IND application in the PRC in the first quarter of 2024.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><font style="font-style: italic;">F230</font>. BC is evaluating in preclinical studies for the treatment of PAH F230, which is a selective endothelin receptor antagonist. PAH is a progressive, life-threatening cardiovascular disease. According to Frost &amp; Sullivan, the number of PAH patients in the PRC reached 57,882 in 2022 and is expected to reach 70,279 by 2031. BC plans to file an IND application in the PRC in the first quarter of 2024.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><font style="font-style: italic;">F573</font>. BC is evaluating F573 in Phase 1 clinical trials for the treatment of ALF/ACLF. According to Frost &amp; Sullivan, the number of patients in the PRC with ALF/ACLF reached 39,247 in 2022. The main treatment options for ALF/ACLF include comprehensive medical therapy, non-biological artificial liver support therapy and liver transplantation. However, there are currently no approved drugs for the treatment of ALF/ACLF. BC enrolled the first subject for the Phase 1 clinical study in January 2022 and initiated its Phase&#160;2 clinical study in March 2023.</div></td></tr></table></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">13<br></div></div></div>
<!--End Page 24-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 25-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20006478x8_prer14a_105-sum_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">The following chart summarizes the development status of our product candidates in the PRC.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.75pt; text-align: center;"><img style="height: 361px; width: 556px;" src="ny20006478x8_graphic01.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC is one of only a few biopharmaceutical companies focusing on organ fibrosis drugs in the PRC with manufacturing and commercialization capabilities. BC owns two production centers in Beijing and Cangzhou. The Beijing production center has an annual production capacity of 200&#160;million capsules with plans to scale to 500&#160;million capsules. The Cangzhou production facility an annual production capacity of 30 tons of active pharmaceutical ingredients (&#8220;APIs&#8221;) in 2021 and was approved to expand annual production capacity to 50 tons of APIs. BC has also established a professional sales team and a comprehensive sales network to commercialize ETUARY. As of March 31, 2023, BC&#8217;s sales and marketing team consisted of 352 members with an average of nine years of experience.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC&#8217;s total revenue and net profit increased from $47.1&#160;million and $10.2&#160;million in 2019, to $64.8&#160;million and $18.5 million in 2020, with a growth rate of 37.6% and 81.4%, respectively. BC&#8217;s total revenue and net profit further increased to $88.5&#160;million and $23.2&#160;million in 2021, growing 36.6% and 25.4%, respectively. This growth was primarily attributable to the increased market demand of ETUARY, which is the first IPF drug marketed in the PRC. BC faces limited competition in the IPF drug market and BC directs its marketing resources to physician adoption of ETUARY. For the years ended December&#160;31, 2021 and December&#160;31, 2022, BC&#8217;s total revenue was $88.5&#160;million and $102.5&#160;million, respectively, and BC&#8217;s net profit was $23.2&#160;million and $22.5&#160;million, respectively. For the three months ended March 31, 2023 and March 31, 2022, BC&#8217;s total revenue was $24.6 million and $25.0 million, respectively, and BC&#8217;s net profit was $5.4 million and $6.2 million, respectively.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Generally, cash is transferred through BC&#8217;s organization in the following manner: (i) funds are transferred to BC from CPI as needed through BJContinent Pharmaceuticals Limited, a company incorporated under the laws of Hong Kong with limited liability (&#8220;BJC Limited&#8221;), or from other domestic shareholders, in the form of capital contributions or shareholder loans; and (ii) dividends or other distributions may be paid by BC to CPI through BJC Limited, or to other domestic shareholders.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In September 2020, BC paid a cash dividend of $1.9 million to BJC Limited. As required under the PRC Enterprise Income Tax Law, the dividends paid by BC were subject to a withholding tax rate of 10%. Such amount was settled in full net of withholding PRC tax through multiple payments by August 2020.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Since BC&#8217;s inception to the date of this proxy statement, there were no transfers, dividends, or distributions between BJC Limited, BC, BC Biomedical, or to investors (except as disclosed above and excluding shareholder capital contributions). BC intends to retain all available funds and any future earnings for use in the operation of its business and does not anticipate paying any cash dividends on its capital stock in the foreseeable future. Notwithstanding the foregoing, any determination to pay cash dividends subsequent to the Contributions will be at the discretion of the </div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">14<br></div></div></div>
<!--End Page 25-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 26-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20006478x8_prer14a_105-sum_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">combined company&#8217;s board of directors and will depend upon a number of factors, including the combined company&#8217;s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors the combined company&#8217;s board of directors deems relevant. For more details, see &#8220;<font style="font-style: italic;">BC&#8217;s Business&#8212;Regulatory Requirements in the PRC&#8212;Dividends, Distributions and Other Transfers&#8221;, Audited </font><font style="font-style: italic;">Financial Statements of Beijing Continent Pharmaceuticals Co., Ltd.</font> and &#8220;<font style="font-style: italic;">Selected Historical and Unaudited Pro </font><font style="font-style: italic;">Forma Condensed Combined Financial Information&#8212;Unaudited Pro Forma Condensed Combined Financial </font><font style="font-style: italic;">Information</font>&#8221; included elsewhere in this proxy statement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under Cayman Islands law, CPI is permitted to provide funding to its subsidiaries through loans or capital contributions without restrictions on the amounts of the funds, provided that such funding is in the best interests of CPI and for proper purpose. Subject to compliance with applicable solvency requirements, there is no further Cayman Islands statutory restriction on the amount of funds that may be distributed by BC by dividend provided that no dividend shall be paid other than out of profits or, subject to certain statutory restrictions, the share premium account of CPI. The Cayman Islands does not impose a withholding tax on payments of dividends to shareholders.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC&#8217;s largest shareholder is BJC Limited. Under Hong Kong law, if BJC Limited were able to declare dividends, such dividends could only be paid by BJC Limited out of its distributable profits (that is, accumulated realized profits, so far as not previously utilized by distribution or capitalization, less accumulated realized losses, so far as not previously written off in a reduction or reorganization of capital), as permitted under Hong Kong law. Dividends cannot be paid out of share capital. There are no restrictions or limitation under the laws of Hong Kong imposed on the conversion of HKD into foreign currencies and the remittance of currencies out of Hong Kong. Under the current practice of the Inland Revenue Department of Hong Kong, no tax is payable in Hong Kong in respect of dividends paid by BC.</div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under PRC laws and regulations, BC is subject to restrictions on foreign exchange and cross-border cash transfers, including to parent companies and U.S. shareholders. The ability to distribute earnings to the parent companies and U.S. shareholders is also limited. Current PRC regulations permit BC to pay dividends to BJC Limited only out of its accumulated profits as determined in accordance with PRC accounting standards and regulations. BC is required to set aside at least 10% of its after-tax profits as the statutory common reserve fund until the cumulative amount of the statutory common reserve fund reaches 50% or more of its registered capital, if any, to fund its statutory common reserves, which are not available for distribution as cash dividends. In addition, the revenue and assets of BC are generally denominated in RMB, which is not freely convertible into other currencies. The PRC government imposes controls on the convertibility of RMB into foreign currencies and, in certain cases, the remittance of currency out of the PRC. As a result, shortages in foreign currencies may limit the ability of BC to remit sufficient foreign currency to offshore entities related to BC for such offshore entities to pay dividends or make other payments or otherwise to satisfy its foreign-currency-denominated obligations. Prior to the Contributions, the offshore shareholders of BC are BJC Limited, CPI (an indirect shareholder of BC), Nepenthe Holdings Limited, a company incorporated under the laws of Hong Kong with limited liability (&#8220;Nepenthe&#8221;), Ratel Holdings Limited, a company incorporated in the British Virgin Islands with limited liability (&#8220;Ratel&#8221;), Aaring Limited, a company incorporated under the laws of Hong Kong with limited liability (&#8220;Aaring&#8221;), and Rosefinch Holdings Limited, a company incorporated in the British Virgin Islands (&#8220;Rosefinch&#8221;). Following the Contributions, Gyre Therapeutics, Inc. will be an indirect shareholder of BC, and Nepenthe, Ratel, Aaring, Rosefinch, CPI and Further Challenger will be wholly-owned by Gyre Therapeutics, Inc. and will remain shareholders of BC. For more details, see &#8220;<font style="font-style: italic;">Regulatory Requirements in the </font><font style="font-style: italic;">PRC&#8212;Dividends, Distributions and Other Transfers</font>&#8221;.</div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC has established stringent controls and procedures for cash flows within BC&#8217;s organization. Each transfer of cash between entities, across borders, and to offshore shareholders is subject to internal approval. To effect a cash transfer, a number of steps are required, including, but not limited to, the issuance of a payment receipt, logging into an online banking system and completing its verification process, inspection of the invoice, and payment execution. Different employees must complete each stage of a cash transfer and only the finance department is authorized to make cash transfers. Within the finance department, the roles of payment approval, payment execution, record keeping, and auditing are segregated to minimize risk. </div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">GNI Group Ltd.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: normal; font-weight: normal;">Nihonbashi-Honcho YS Bldg. 3rd Floor</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: normal; font-weight: normal;">2-2-2 Nihonbashi-Honcho, Chuo-ku,</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: normal; font-weight: normal;">103-0023 Tokyo, Japan</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: normal; font-weight: normal;">Telephone: +81-3-6214-3600</font></div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">15<br></div></div></div>
<!--End Page 26-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 27-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20006478x8_prer14a_105-sum_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">GNI Japan is a vertically-integrated, multinational bio-pharma company, comprised of drug research, clinical development, manufacturing, sales and marketing. GNI Japan&#8217;s primary operations are located in the PRC, enabling GNI Japan to leverage the PRC&#8217;s comparative cost advantage in clinical trials to develop Class 1 &#8220;First to Market&#8221; drug products for the PRC domestic market. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">GNI Hong Kong Limited<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: normal; font-weight: normal;">12/F Elite Centre, 22 Hung TO</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: normal; font-weight: normal;">Kwun Tong KL, Hong Kong</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">GNI Hong Kong manages intellectual property rights for the GNI Parties outside of the PRC.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">GNI USA, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: normal; font-weight: normal;">1</font><font style="font-style: normal; font-weight: normal;">273</font><font style="font-style: normal; font-weight: normal;">0 High Bluff Drive, Suite 250</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: normal; font-weight: normal;">San Diego, CA 92130</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">GNI USA is a holding and investment company with no business operations or assets other than intangible assets, the capital stock of its direct and indirect subsidiaries and intercompany loan payables. Consequently, GNI USA is dependent on loans, dividends, interest and other payments from its subsidiaries to make principal and interest payments on its indebtedness, meet working capital requirements and make capital expenditures. As presently structured, its operating subsidiaries are the sole source of cash for such payments and there is no assurance that the cash for those interest payments will be available. Through its direct and indirect subsidiaries and investments, GNI USA engages in research and development for the treatment of NASH liver disease in the United States.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">Further Challenger International Limited<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: normal; font-weight: normal;">Unit 8, 3/F., Qwomar Trading Complex</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: normal; font-weight: normal;">Blackburne Road, Port Purcell, Road Town</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: normal; font-weight: normal;">Tortola, British Virgin Islands VG1110</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Further Challenger is a holding company with no business operations or assets other than intangible assets, the capital stock of its direct and indirect subsidiaries and intercompany loan payables. Consequently, Further Challenger is dependent on loans, dividends, interest and other payments from its subsidiaries to make principal and interest payments on its indebtedness, meet working capital requirements and make capital expenditures. As presently structured, its operating subsidiaries are the sole source of cash for such payments and there is no assurance that the cash for those interest payments will be available.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">Continent Pharmaceuticals Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: justify;"><font style="font-style: normal; font-weight: normal;">Campbells Corporate Services Limited, which is situated at c/o Campbells Corporate Services Limited, Floor 4, </font><font style="font-style: normal; font-weight: normal;">Willow House, Cricket Square, Grand Cayman KY1-9010, Cayman Islands, provides the registered office for CPI</font><font style="font-style: normal; font-weight: normal;">.</font><font style="font-style: normal; font-weight: normal;"> </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">CPI is a holding company with no business operations or assets other than the capital stock of its direct and indirect subsidiaries and intercompany loan receivables. Consequently, CPI is dependent on loans, dividends, interest and other payments from its subsidiaries to make principal and interest payments on its indebtedness, meet working capital requirements and make capital expenditures. As presently structured, its operating subsidiaries are the sole source of cash for such payments and there is no assurance that the cash for those interest payments will be available.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">The Contributions (see page <a href="#tTC">123</a>) </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Business Combination Agreement, Catalyst will acquire an indirect controlling interest in BC pursuant to the following transactions: (a) the CPI Contribution, (b) the FC Contribution and (c) the Minority Holder Contributions. The Contributions are intended to qualify as exchanges governed by Section 351(a) of the Code for U.S. federal income tax purposes.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Subject to the terms and conditions of the Business Combination Agreement, at the Effective Time, (a) GNI USA will contribute all of the CPI Ordinary Shares it holds immediately prior to the Effective Time to Catalyst in exchange for 688,850,101 shares of Catalyst Common Stock, (b) GNI USA will contribute all of the ordinary shares of Further Challenger it holds immediately prior to the Effective Time to Catalyst in exchange for 264,971,695 shares of Catalyst Common Stock and (c) each Minority Holder will contribute 100% of the interest he or she holds in his or her respective Entity to Catalyst in exchange for an aggregate of 156,954,428 shares of Catalyst Common Stock in the amounts set forth on an annex to the Business Combination Agreement. At the election of GNI USA or any Minority Holder, GNI USA or such Minority Holder shall be issued shares of Catalyst Convertible Preferred Stock in lieu of some or all of the shares of Catalyst Common Stock GNI USA or such Minority Holder is entitled to receive. </div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">16<br></div></div></div>
<!--End Page 27-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 28-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20006478x8_prer14a_105-sum_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">In addition, at the Effective Time, BC will terminate the 2021 Plan and each BC Option under the 2021 Plan will be terminated and replaced with options granted pursuant to a sub-plan for PRC participants under the 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Immediately after the Contributions, the holders of the capital stock of Catalyst as of immediately prior to the Contribution are expected to own approximately 2.5% of the outstanding shares of the combined company, GNI USA is expected to own approximately 85.2% of the outstanding shares of the combined company and the Minority Holders are expected to own approximately 12.3% of the outstanding shares of the combined company, in each case, assuming conversion of the Catalyst Convertible Preferred Stock, and the combined company will own the F351 Assets and an approximately 69.7% indirect controlling interest in BC. Immediately after the Contributions, the holders of the capital stock of Catalyst as of immediately prior to the Contributions are expected to own approximately 2.0% of the outstanding shares of the combined company, GNI USA is expected to own approximately 70.5% of the outstanding shares of the combined company, the Minority Holders are expected to own approximately 10.2% of the outstanding shares of the combined company, the holders of options granted under the 2023 Omnibus Incentive Plan (&#8220;Gyre Options&#8221;) to be granted in respect of BC Options are expected to own approximately 16.6% of the outstanding shares of the combined company and the holders of outstanding options of Catalyst are expected to own approximately 0.6% of the outstanding shares of the combined company, in each case, on a fully diluted basis assuming conversion of the Catalyst Convertible Preferred Stock and including the outstanding options of Catalyst and the Gyre Options to be granted in respect of the BC Options. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Each share of Catalyst Common Stock issued and outstanding at the time of the Contributions will remain issued and outstanding and such shares will be appropriately adjusted to reflect the proposed reverse stock split. In addition, each option to purchase shares of Catalyst Common Stock that is outstanding immediately prior to the Effective Time, whether vested or unvested, will survive the closing and remain outstanding in accordance with its terms. The number of shares of Catalyst Common Stock underlying such options and the exercise prices for such stock options will be appropriately adjusted to reflect the proposed reverse stock split.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For a more complete description of the Contributions please see the section entitled &#8220;<font style="font-style: italic;">The Contributions</font>&#8221; beginning on page <a href="#tTC">123</a> in this proxy statement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Contributions will be completed as promptly as practicable after all of the conditions to completion of the Contributions are satisfied or waived, including the approval by the Catalyst stockholders of the issuance of Catalyst Common Stock pursuant to the terms of the Business Combination Agreement. Catalyst and the GNI Parties are working to complete the Contributions as quickly as practicable. The Contributions are anticipated to close promptly after the Catalyst special meeting scheduled to be held on &#8195;&#8195;&#8195;&#8195;, 2023. However, Catalyst and the GNI Parties cannot predict the exact timing of the completion of the Contributions because they are subject to the satisfaction of various conditions. After completion of the Contributions, assuming that Catalyst receives the required stockholder approval, Catalyst will be renamed &#8220;Gyre Therapeutics, Inc.&#8221; </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Trading in the combined company&#8217;s securities may be prohibited under the Holding Foreign Companies Accountable Act (the &#8220;HFCAA&#8221;) under certain circumstances. Under the HFCAA, the SEC is required to identify issuers that retain an auditor that has a branch or office that is located in a foreign jurisdiction and that the Public Company Accounting Oversight Board (the &#8220;PCAOB&#8221;) determines it is unable to inspect or investigate completely because of a position taken by an authority in that foreign jurisdiction. On December 16, 2021, the PCAOB issued a report on its determination that it is unable to inspect or investigate completely PCAOB-registered accounting firms headquartered in the PRC and in Hong Kong. On December 15, 2022, the PCAOB announced that it was able to conduct inspections and investigations of PCAOB-registered public accounting firms headquartered in mainland PRC and Hong Kong in 2022 and as a result, the PCAOB vacated its December 2021 determinations. While vacating those determinations, the PCAOB noted that, should it encounter any impediment to conducting an inspection or investigation of auditors in mainland PRC or Hong Kong as a result of a position taken by any authority there, the PCAOB would act to immediately reconsider the need to issue new determinations consistent with the HFCAA and PCAOB Rule 6100.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If (i) the combined company&#8217;s operations require that it retain an auditor that is headquartered in mainland PRC to act as a principal auditor in order to comply with the standards of the PCAOB and (ii) the PCAOB retakes a position that is similar to its December 2021 determinations, then the combined company would be identified by the SEC as a Commission-Identified Issuer. In accordance with the HFCAA, the combined company&#8217;s securities would be prohibited from being traded on a national securities exchange or in the over-the-counter trading market in the United </div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">17<br></div></div></div>
<!--End Page 28-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 29-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20006478x8_prer14a_105-sum_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">States if the SEC identifies the combined company as a Commission-Identified Issuer for two consecutive years in the future. The combined company&#8217;s operations will likely require such an auditor to act as its principal auditor. For a detailed description of risks of and impacts on the combined company relating to the HFCAA and related regulations, please refer to risks disclosed under &#8220;<font style="font-style: italic;">Risk Factors&#8212;Risks Related to the Combined Company&#8212;</font><font style="font-style: italic;">The </font><font style="font-style: italic;">PRC-operations portion of the combined company&#8217;s audit may be conducted by an independent registered public </font><font style="font-style: italic;">accounting firm that is not subject to inspection by the PCAOB, which may negatively impact investor sentiment </font><font style="font-style: italic;">towards the combined company or its PRC operations, which could adversely affect the market price of the combined </font><font style="font-style: italic;">company&#8217;s common stock.</font>&#8221; </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Catalyst&#8217;s Reasons for the Contributions <font style="font-weight: normal;">(see page </font><font style="font-weight: normal;"><a href="#tCRF">125</a></font><font style="font-weight: normal;">) </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">During the course of its evaluation of the F351 Agreement, the Business Combination Agreement and the transactions contemplated thereby, Catalyst&#8217;s then-board of directors held numerous meetings, consulted with Catalyst&#8217;s management, legal counsel and financial advisors and reviewed and assessed a significant amount of information. In reaching its decision to approve the F351 Agreement, the Business Combination Agreement and the transactions contemplated thereby, Catalyst&#8217;s then-board of directors considered a number of factors that it viewed as supporting its decision to approve the F351 Agreement, the Business Combination Agreement and the transactions contemplated thereby. Several factors considered by the Catalyst&#8217;s then-board of directors included:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s historical and current business, financial performance and condition, operations, management and competitive position;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s then-board of directors&#8217; belief that no reasonable alternatives to the Contributions were likely to create greater value for Catalyst stockholders after reviewing the various alternatives, including a belief that a dissolution of Catalyst was the likeliest alternative to the Contributions and the likelihood of achieving any such alternative relative to the likelihood of consummating the Contributions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s ability to make a distribution of capital to Catalyst stockholders and still complete the Contributions; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s then-board of directors&#8217; consideration of the financial analyses of Raymond James, including its opinion to Catalyst&#8217;s then-board of directors as to the fairness, from a financial point of view and as of the date of the opinion, to Catalyst of the Transaction Consideration (as defined in the Raymond James&#8217; fairness opinion) to be paid by Catalyst pursuant to the F351 Agreement and the Business Combination Agreement, as more fully described below under the caption &#8220;<font style="font-style: italic;">The Contributions&#8212;Opinion of Catalyst&#8217;s Financial </font><font style="font-style: italic;">Advisor</font>,&#8221; beginning on page <a href="#tOCF">128</a> in this proxy statement.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For additional information, please see the section entitled &#8220;<font style="font-style: italic;">The Contributions&#8212;Catalyst&#8217;s Reasons for the </font><font style="font-style: italic;">Contributions</font>&#8221; beginning on page <a href="#tCRF">125</a> of this proxy statement. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">GNI Parties Reasons for the Contributions<font style="font-weight: normal;"> (see page </font><font style="font-weight: normal;"><a href="#tGNI">126</a></font><font style="font-weight: normal;">) </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The board of directors and executive directors, as applicable, of the GNI Parties have each approved the Business Combination Agreement, the Contributions and the transactions contemplated thereby. The board of directors and executive directors, as applicable, of the GNI Parties each reviewed several factors in reaching their decisions and believe that the Business Combination Agreement, the Contributions and the transactions contemplated thereby are advisable and fair to and in the best interests of, the GNI Parties and their respective shareholders and stockholders, as applicable. Several factors considered by the board of directors and executive directors, as applicable, of the GNI Parties included: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the Contributions will provide the GNI Parties and the Minority Holders with greater liquidity by owning publicly-traded stock and expanding both the access to capital for BC and the range of investors potentially available as a public company, compared to the investors BC could otherwise gain access to if it continued to operate as a privately-held company;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the potential benefits from increased public market awareness of BC and its pipeline;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the belief of the board of directors and executive directors, as applicable, of the GNI Parties that this transaction provides a viable alternate public listing strategy for BC and addresses the risk of the lack of an available market for an initial public offering for BC at a later date; and </div></td></tr></table></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">18<br></div></div></div>
<!--End Page 29-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 30-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20006478x8_prer14a_105-sum_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the projected financial position, operations, management structure, operating plans and anticipated cash burn rate of the combined company, including the ability to support the combined company&#8217;s current and planned clinical trials and operations.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For additional information, please see the section entitled &#8220;<font style="font-style: italic;">The Contributions&#8212;GNI Parties Reasons for the </font><font style="font-style: italic;">Contributions</font>&#8221; beginning on page <a href="#tGNI">126</a> of this proxy statement.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Recommendation of Catalyst&#8217;s Board of Directors <font style="font-weight: normal;">(see page </font><font style="font-weight: normal;"><a href="#tReCBD">118</a></font><font style="font-weight: normal;">) </font></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s board of directors has determined and believes it is fair to, in the best interests of and advisable to, Catalyst and its stockholders to approve the issuance of shares of Catalyst Common Stock and shares of Catalyst Convertible Preferred Stock, each pursuant to the terms of the Business Combination Agreement (as it may be amended from time to time) for purposes of Nasdaq Listing Rules 5635(a) and (b), as described in this proxy statement. Catalyst&#8217;s board of directors recommends that Catalyst stockholders vote &#8220;FOR&#8221; Proposal No. 1.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s board of directors has determined and believes it is fair to, in the best interests of and advisable to, Catalyst and its stockholders to approve, for purposes of Nasdaq Listing Rules 5635(a) and (b), the conversion of Catalyst Convertible Preferred Stock into shares of Catalyst Common Stock pursuant to the F351 Agreement. Catalyst&#8217;s board of directors recommends that Catalyst stockholders vote &#8220;FOR&#8221; Proposal No. 2.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s board of directors has determined and believes it is fair to, in the best interests of and advisable to, Catalyst and its stockholders to adopt and approve an amendment to the restated certificate of incorporation of Catalyst to increase the number of authorized shares of Catalyst Common Stock from 100,000,000 shares to &#8195;&#8195;&#8195; shares. Catalyst&#8217;s board of directors recommends that Catalyst stockholders vote &#8220;FOR&#8221; Proposal No. 3.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s board of directors has determined and believes it is fair to, in the best interests of and advisable to, Catalyst and its stockholders to adopt and approve an amendment to the restated certificate of incorporation of Catalyst to effect a reverse stock split of Catalyst Common Stock, by a ratio of not less than 1-for- &#8195;&#8195;&#8195; and not more than 1-for-&#8195;&#8195;&#8195;, such ratio and the implementation and timing of the reverse stock split to be determined in the discretion of Catalyst&#8217;s board of directors. Catalyst&#8217;s board of directors recommends that Catalyst stockholders vote &#8220;FOR&#8221; Proposal No. 4.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s board of directors has determined and believes it is fair to, in the best interests of and advisable to, Catalyst and its stockholders to adopt and approve an amendment to the restated certificate of incorporation of Catalyst to create a new class of non-voting common stock of Catalyst. Catalyst&#8217;s board of directors recommends that Catalyst stockholders vote &#8220;FOR&#8221; Proposal No. 5.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s board of directors has determined and believes it is fair to, in the best interests of and advisable to, Catalyst and its stockholders to approve the 2023 Omnibus Incentive Plan. Catalyst&#8217;s board of directors recommends that Catalyst stockholders vote &#8220;FOR&#8221; Proposal No. 6.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s board of directors has determined and believes it is fair to, in the best interests of and advisable to, Catalyst and its stockholders to approve the adjournment of the Catalyst special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1, 2, 3, 4, 5 and 6. Catalyst&#8217;s board of directors recommends that Catalyst stockholders vote &#8220;FOR&#8221; Proposal No. 12. </div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Opinion of Catalyst&#8217;s Financial Advisor <font style="font-weight: normal;">(see page </font><font style="font-weight: normal;"><a href="#tOCF">128</a></font><font style="font-weight: normal;">) </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst retained Raymond James &amp; Associates, Inc., or Raymond James, as its financial advisor in connection with the Contributions and other transactions contemplated by the F351 Agreement and the Business Combination Agreement. Catalyst&#8217;s then-board of directors selected Raymond James to act as Catalyst&#8217;s financial advisor based on Raymond James&#8217; qualifications, reputation, experience and expertise in the biopharmaceutical industry, its knowledge of and involvement in recent transactions in the biopharmaceutical industry and its relationship with Catalyst and its business. Raymond James is an internationally-recognized investment banking and financial services company that has substantial experience in transactions similar to the Contributions and other transactions contemplated by the F351 Agreement and the Business Combination Agreement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with this engagement, Catalyst&#8217;s then-board of directors requested that Raymond James evaluate the fairness, from a financial point of view, to Catalyst of the Transaction Consideration (as defined in the Raymond </div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">19<br></div></div></div>
<!--End Page 30-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 31-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20006478x8_prer14a_105-sum_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">James fairness opinion) to be paid by Catalyst. On December&#160;21, 2022, at a meeting of Catalyst&#8217;s then-board of directors, Raymond James rendered to Catalyst&#8217;s then-board of directors its oral opinion, which was subsequently confirmed by delivery of a written opinion dated December&#160;21, 2022, that, as of such date and based upon and subject to the various procedures followed, assumptions made, matters considered and the qualifications and limitations upon the review undertaken by Raymond James in preparing its opinion, the Transaction Consideration to be paid by Catalyst was fair, from a financial point of view, to Catalyst. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The full text of the Raymond James fairness opinion, which describes, among other things, the various procedures followed, assumptions made, matters considered, qualifications and limitations upon the scope of the review undertaken by Raymond James in preparing its opinion, is attached to this proxy statement as Annex&#160;C and is incorporated by reference in its entirety to this proxy statement. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Raymond James&#8217; financial advisory services and opinion were provided for the information and assistance of the members of Catalyst&#8217;s then-board of directors (in their capacity as directors and not in any other capacity) in connection with and for purposes of Catalyst&#8217;s then-board of directors&#8217; consideration of the Contributions and other transactions contemplated by the F351 Agreement and the Business Combination Agreement and the Raymond James fairness opinion addressed only the fairness, from a financial point of view, to Catalyst as of the date thereof of the Transaction Consideration (as defined in the Raymond James fairness opinion) to be paid by Catalyst. The opinion of Raymond James does not address any other term or aspect of the F351 Agreement or the Business Combination Agreement or the Contributions or other transactions contemplated thereby. The Raymond James fairness opinion does not constitute a recommendation to Catalyst&#8217;s board of directors or any stockholder of Catalyst as to whether or how such holder should vote or otherwise act with respect to the Contributions, other transactions contemplated by the F351 Agreement or the Business Combination Agreement or any other matter.<font style="font-style: normal; font-weight: normal;"> </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The full text of the Raymond James fairness opinion should be read carefully in its entirety for a description of the assumptions made and the qualifications and limitations upon the review undertaken by Raymond James in preparing its opinion.<font style="font-style: normal; font-weight: normal;"> </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Overview of the F351 Agreement, the Business Combination Agreement and Agreements Related to the Contributions<font style="font-weight: normal;"> (see page </font><font style="font-weight: normal;"><a href="#tTBC">144</a></font><font style="font-weight: normal;">) </font></div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The F351 Agreement </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On December&#160;26, 2022, Catalyst acquired the F351 Assets (as defined below) from GNI Japan and GNI Hong Kong, pursuant to the F351 Agreement, by and among Catalyst and GNI Japan and GNI Hong Kong. Pursuant to the F351 Agreement, Catalyst acquired the F351 Assets, other than such assets and intellectual property rights located in the PRC. The F351 Assets include 15 issued or pending patents and patent applications outside of the PRC, with the last acquired issued patent expected to expire in August 2037.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under the terms of the F351 Agreement, on January&#160;17, 2023, Catalyst paid GNI Japan and GNI Hong Kong $35,000,000 in the form of: 6,266,521 shares of Catalyst Common Stock; and 12,340 shares of Catalyst Convertible Preferred Stock.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The Contributions<font style="font-style: normal; font-weight: normal;"> </font><font style="font-style: normal; font-weight: normal;">(see page </font><font style="font-style: normal; font-weight: normal;"><a href="#tTC">123</a></font><font style="font-style: normal; font-weight: normal;">)</font><font style="font-style: normal; font-weight: normal;"> </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Subject to the terms and conditions of the Business Combination Agreement, at the Effective Time, (a) GNI USA will contribute all of the CPI Ordinary Shares it holds immediately prior to the Effective Time to Catalyst in exchange for 688,850,101 shares of Catalyst Common Stock, (b) GNI USA will contribute all of the ordinary shares of Further Challenger it holds immediately prior to the Effective Time to Catalyst in exchange for 264,971,695 shares of Catalyst Common Stock and (c) each Minority Holder will contribute 100% of the interest he or she holds in his or her respective Entity to Catalyst in exchange for an aggregate of 156,954,428 shares of Catalyst Common Stock in the amounts set forth on an annex to the Business Combination Agreement. At the election of GNI USA or any Minority Holder, GNI USA or such Minority Holder shall be issued shares of Catalyst Convertible Preferred Stock in lieu of some or all of the shares of Catalyst Common Stock GNI USA or such Minority Holder is entitled to receive. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Immediately after the Contributions, Catalyst stockholders as of immediately prior to the Contributions are expected to own approximately 2.5% of the outstanding shares of common stock of the combined company, GNI USA is expected to own approximately 85.2% of the outstanding shares of the combined company and the Minority Holders are expected to own approximately 12.3% of the outstanding shares of the combined company, in each case, assuming conversion of the Catalyst Convertible Preferred Stock, and the combined company will own the F351 Assets and an approximately 69.7% indirect controlling interest in BC.</div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">20<br></div></div></div>
<!--End Page 31-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 32-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20006478x8_prer14a_105-sum_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Treatment of BC Options<font style="font-style: normal; font-weight: normal;"> </font><font style="font-style: normal; font-weight: normal;">(see page </font><font style="font-style: normal; font-weight: normal;"><a href="#tTBCO">138</a></font><font style="font-style: normal; font-weight: normal;">)</font><font style="font-style: normal; font-weight: normal;"> </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">At the Effective Time of the Contributions, BC will terminate the 2021 Plan and BC Options outstanding thereunder will be terminated and replaced with options granted pursuant to a sub-plan for PRC participants under the 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Treatment of Catalyst Common Stock and Catalyst Options<font style="font-style: normal; font-weight: normal;"> (see page </font><font style="font-style: normal; font-weight: normal;"><a href="#tTBC">144</a></font><font style="font-style: normal; font-weight: normal;">) </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Each share of Catalyst Common Stock issued and outstanding at the time of the Contributions will remain issued and outstanding and such shares will be appropriately adjusted to reflect the proposed reverse stock split. In addition, each option to purchase shares of Catalyst Common Stock that is outstanding immediately prior to the Effective Time, whether vested or unvested, will survive the closing and remain outstanding in accordance with its terms. The number of shares of Catalyst Common Stock underlying such options and the exercise prices for such stock options, will be appropriately adjusted to reflect the proposed reverse stock split.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Conditions to the Completion of the Contributions<font style="font-style: normal; font-weight: normal;"> (see page </font><font style="font-style: normal; font-weight: normal;"><a href="#tCTT">152</a></font><font style="font-style: normal; font-weight: normal;">) </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">To complete the Contributions, Catalyst stockholders must approve Proposals No. 1, 2, 3, 4 and 6. Additionally, each of the other closing conditions set forth in the Business Combination Agreement must be satisfied or waived.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Non-Solicitation<font style="font-style: normal; font-weight: normal;"> (see page </font><font style="font-style: normal; font-weight: normal;"><a href="#tNS">149</a></font><font style="font-style: normal; font-weight: normal;">) </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Business Combination Agreement contains &#8220;non-solicitation&#8221; provisions, pursuant to which, subject to specified exceptions, Catalyst has agreed that it will not and Catalyst will not permit or authorize any of its subsidiaries or any director, officer, employee, investment banker, financial advisor, attorney, accountant or other advisor, agent or representative to, directly or indirectly: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Solicit, initiate, endorse, encourage or facilitate any inquiry, proposal or offer with respect to, or the making or completion of, any Acquisition Proposal (as defined in the section of this proxy statement titled &#8220;<font style="font-style: italic;">The </font><font style="font-style: italic;">Business Combination Agreement&#8212;Non-Solicitation</font>&#8221;), or any inquiry, proposal or offer that is reasonably likely to lead to any Acquisition Proposal;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">enter into, continue or otherwise participate in any discussions or negotiations regarding, or furnish to any person any information or data with respect to, or otherwise cooperate in any way with, any Acquisition Proposal; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">resolve, agree or propose to do any of the foregoing.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Adverse Recommendation Change<font style="font-style: normal; font-weight: normal;"> (see page </font><font style="font-style: normal; font-weight: normal;"><a href="#tBRC">150</a></font><font style="font-style: normal; font-weight: normal;">) </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Subject to specified exceptions described in the Business Combination Agreement, Catalyst has agreed that its board of directors (and any committee thereof) may not take any of the following actions, each of which are referred to in this proxy statement as a Catalyst &#8220;Adverse Recommendation Change&#8221;: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">withdraw (or modify or qualify in any manner adverse to the Contributors) the recommendation or declaration of advisability by the Catalyst board or any such committee of the Business Combination Agreement, the Contributions, Proposal Nos. 1, 2, 3, 4, 5 and 6 or any of the other transactions contemplated by the Business Combination Agreement;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">recommend or otherwise declare advisable the approval by the Catalyst stockholders of any Acquisition Proposal;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">cause or permit Catalyst or any of its subsidiaries to enter into any letter of intent, memorandum of understanding, agreement in principle, acquisition agreement, merger agreement, option agreement, joint venture agreement, partnership agreement or other contract, except for an Acceptable Confidentiality Agreement (as defined in the section of this proxy statement titled &#8220;<font style="font-style: italic;">The Business Combination </font><font style="font-style: italic;">Agreement&#8212;Non-Solicitation</font>&#8221;), in each case constituting or related to, or which is intended to or is reasonably likely to lead to, any Acquisition Proposal; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">resolve, agree or propose to do any of the foregoing.</div></td></tr></table></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">21<br></div></div></div>
<!--End Page 32-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 33-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20006478x8_prer14a_105-sum_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Termination of the Business Combination Agreement<font style="font-style: normal; font-weight: normal;"> (see page </font><font style="font-style: normal; font-weight: normal;"><a href="#tTAT">154</a></font><font style="font-style: normal; font-weight: normal;">) </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Either Catalyst or the Contributors may terminate the Business Combination Agreement under certain circumstances, which would prevent the Contributions from being consummated.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Termination Fee<font style="font-style: normal; font-weight: normal;"> (see page </font><font style="font-style: normal; font-weight: normal;"><a href="#tTF">155</a></font><font style="font-style: normal; font-weight: normal;">) </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Upon termination of the Business Combination Agreement under specified circumstances, Catalyst may be required to pay the Contributors a termination fee of $2.0&#160;million and the Contributors or Catalyst, as the case may be, may be required to reimburse the other parties for reasonable out-of-pocket fees and expenses incurred by such party in connection with the transactions contemplated by the Business Combination Agreement, up to a maximum amount of $2.0&#160;million.</div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">22<br></div></div></div>
<!--End Page 33-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 34-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20006478x8_prer14a_105-sum_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Organizational Structure</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following diagrams illustrate in simplified terms the current organizational structure of Catalyst, BC and the expected structure of the combined company following the Contributions:</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">Catalyst &#8211; Before the Contributions<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.25pt; text-align: center;"><img style="height: 92px; width: 275px;" src="ny20006478x8_graphic08a.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Percentages above reflect the total voting power of each stockholder following the F351 Acquisition and do not reflect conversion of the Catalyst Convertible Preferred Stock issued to GNI Japan and GNI Hong Kong pursuant to the F351 Agreement.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">BC &#8211; Before the Contributions</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.25pt; text-align: center;"><img style="height: 237px; width: 604px;" src="ny20006478x8_graphic08b.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Prior to the Effective Time of the Contributions, GNI Japan and GNI Hong Kong will transfer 100% of their respective interests in CPI to GNI USA.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Prior to the Effective Time of the Contributions, GNI Japan and GNI Hong Kong will transfer all of their respective shares of Catalyst Common Stock and Catalyst Convertible Preferred Stock to GNI USA.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">BJC Limited is a wholly-owned subsidiary of CPI and direct shareholder of BC. The immediate holding company of BC is BJC Limited.</div></td></tr></table></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">23<br></div></div></div>
<!--End Page 34-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 35-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20006478x8_prer14a_105-sum_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">After the Contributions<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.25pt; text-align: center;"><img style="height: 288px; width: 568px;" src="ny20006478x8_graphic08c.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Calculated as a percentage of the total outstanding shares of capital stock of the combined company. Immediately following the Contributions, on a fully diluted basis (including the outstanding options of Catalyst and the Gyre Options to be granted in respect of the BC Options), the holders of the capital stock of Catalyst as of immediately prior to the Contributions are expected to own approximately 2.0% of the combined company, GNI USA is expected to own approximately 70.6% of the combined company, the Entities are expected to own approximately 10.2% of the combined company, the holders of Gyre Options to be granted in respect of BC Options are expected to own approximately 16.6% of the combined company and the holders of outstanding options of Catalyst are expected to own approximately 0.6% of the combined company.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Calculated as a percentage of the total outstanding shares of BC. At the Effective Time of the Contributions, outstanding BC Options will be terminated and replaced with options granted under the 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding. When such options are exercised for Gyre Options, BC is expected to issue a pro rata number of BC Common Shares to BJC Limited to proportionally increase the combined company&#8217;s indirect interest in BC and proportionally decrease the remaining BC shareholders&#8217; interest in BC. When all such options are exercised for Gyre Options, the Entities are expected to own approximately 8% of BC, BJC Limited is expected to own approximately 61.7% of BC, and the PRC Shareholders are expected to own approximately 30.3% of BC.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Management Following the Contributions<font style="font-weight: normal;"> (see page </font><font style="font-weight: normal;"><a href="#tMFT">303</a></font><font style="font-weight: normal;">) </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Effective as of the closing of the Contributions, the combined company&#8217;s executive officers are expected to be the following individuals: </div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 31.62%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title Immediately Following Contributions<br></div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title Immediately Prior to Contributions</div></td></tr><tr><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Charles Wu, Ph.D.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Executive Officer and Director</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director of BC</div></td></tr><tr><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Songjiang Ma</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">President and Director</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Honorary Chairman, Director of BC</div></td></tr><tr><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ruoyu Chen</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interim Chief Financial Officer</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Senior Vice President of Finance of GNI USA; Director of BC </div></td></tr><tr><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weiguo Ye</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Operating Officer</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director, President of BC</div></td></tr><tr><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Suzana Corritori, M.D., Ph.D., MSc.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vice President of Clinical Development and Regulatory Affairs</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">President &amp; Owner of Corritori Consulting, Inc.</div></td></tr></table></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">24<br></div></div></div>
<!--End Page 35-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 36-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20006478x8_prer14a_105-sum_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Interests of Certain Directors, Officers and Affiliates of Catalyst and the Contributors<font style="font-weight: normal;"> (see page </font><font style="font-weight: normal;"><a href="#tICD">136</a></font><font style="font-weight: normal;">) </font></div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Interests of Catalyst</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In considering the recommendation of Catalyst&#8217;s then-board of directors with respect to issuing shares of Catalyst Common Stock in the Contributions and other matters to be acted upon by the Catalyst stockholders at the Catalyst special meeting, Catalyst stockholders should be aware that Catalyst&#8217;s directors and executive officers may have interests in the Contributions that are different from, or in addition to, the interests of Catalyst stockholders generally. Interests of Catalyst&#8217;s directors and executive officers may be different from or in addition to the interests of Catalyst stockholders for the following reasons, among others:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">One of Catalyst&#8217;s directors prior to the execution of the Business Combination Agreement, Nassim Usman, Ph.D., and two additional existing directors, Thomas Eastling and Ying Luo, will continue as directors of the combined company after the Effective Time and, following the closing of the Contributions, will be eligible to be compensated as non-employee directors of Catalyst pursuant to the Catalyst non-employee director compensation policy that is expected to remain in place following the Effective Time.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Under the terms of the F351 Agreement and the Business Combination Agreement, Catalyst&#8217;s directors and executive officers are entitled to continued indemnification, expense advancement and insurance coverage.</div></td></tr></table> <table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The combined company&#8217;s board of directors is expected to approve grants of fully vested awards of stock options under the 2023 Omnibus Incentive Plan to Nassim Usman, Ph.D., Seline Miller, Thomas Eastling and Ruoyu Chen. The approximate grant date fair value of such grants are as follows: Nassim Usman, Ph.D. ($841,820), Seline Miller ($169,423), Thomas Eastling ($841,820) and Ruoyu Chen ($84,711). The combined company&#8217;s board is also expected to approve an additional award of stock options under the 2023 Omnibus Incentive Plan to Ms. Miller, which will vest subject to her completion of a consulting term following the closing of the Contributions.</div></td></tr></table> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">These interests are discussed in more detail in the sections titled &#8220;<font style="font-style: italic;">The Contributions&#8212;Interests of Catalyst&#8217;s </font><font style="font-style: italic;">Directors and Executive Officers in the Contributions</font>,&#8221; &#8220;<font style="font-style: italic;">The Business Combination Agreement&#8212;Indemnification </font><font style="font-style: italic;">and Insurance for Directors and Officers</font>&#8221; and &#8220;<font style="font-style: italic;">Catalyst Executive and Director Compensation</font>&#8221; beginning on pages <a href="#tICD">136</a>, <a href="#tIDA">151</a> and <a href="#tCEA">162</a>, respectively of this proxy statement. The members of Catalyst&#8217;s then-board of directors were aware of and considered these potential interests, among other things, in evaluating and negotiating the Business Combination Agreement, F351 Agreement and the Contributions and in recommending to Catalyst stockholders the proposals being submitted to Catalyst stockholders at the Catalyst special meeting be approved. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Interests of the GNI Parties</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In considering the recommendations of each of the GNI Parties&#8217; board of directors or executive directors, as applicable, with respect to approving the Business Combination Agreement, stockholders should be aware that the Contributors&#8217; directors and executive officers may have interests in the Contributions that are different from, or in addition to, the interests of the Contributors&#8217; stockholders generally. Interests of the directors and executive officers may be different from or in addition to the interests of the stockholders for the following reasons, among others: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">As of May 15, 2023, GNI Japan and GNI Hong Kong beneficially owned, in the aggregate, approximately 16.6% of the shares of Catalyst Common Stock and 80.5% of the shares of Catalyst Common Stock upon conversion of the Catalyst Convertible Preferred Stock upon the approval of Proposal No. 2 and successful application for initial listing with The Nasdaq Capital Market (&#8220;Nasdaq&#8221;). </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Certain of the directors and executive officers of the GNI Parties are expected to continue as or become directors and executive officers of the combined company upon the closing of the Contributions and all such directors and officers, as well as the directors and executive officers of BC and Further Challenger, are entitled to certain indemnification coverage pursuant to the terms of the Business Combination Agreement. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">These interests are discussed in more detail in the sections titled &#8220;<font style="font-style: italic;">The Contributions&#8212;Interests of GNI Parties&#8217; </font><font style="font-style: italic;">Directors and Executive Officers in the Contributions</font>,&#8221; &#8220;<font style="font-style: italic;">The Business Combination Agreement&#8212;Indemnification </font><font style="font-style: italic;">and Insurance for Directors and Officers</font>&#8221; and &#8220;<font style="font-style: italic;">BC Executive Compensation</font>&#8221; beginning on pages <a href="#tIGP">138</a>, <a href="#tIDA">151</a> and <a href="#tBCE">173</a>, respectively, of this proxy statement. The members of each of the Contributors&#8217; board of directors or executive directors, as applicable, were aware of and considered these interests, among other things, in evaluating and negotiating the Business Combination Agreement and the Contributions.</div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">25<br></div></div></div>
<!--End Page 36-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 37-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20006478x8_prer14a_105-sum_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Material U.S. Federal Income Tax Consequences of the Contributions<font style="font-weight: normal;"> (see page </font><font style="font-weight: normal;"><a href="#tMUF1">141</a></font><font style="font-weight: normal;">) </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst and the GNI Parties intend for the Contributions, taken together, to qualify as a transaction governed by Section 351(a) of the Code. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Assuming the Contributions qualify for the intended tax treatment, subject to the limitations and qualifications described in the section entitled &#8220;<font style="font-style: italic;">The Contributions&#8212;Material U.S. Federal Income Tax Consequences of the </font><font style="font-style: italic;">Contributions</font>,&#8221; GNI USA will not recognize gain or loss for U.S. federal income tax purposes upon the receipt of shares of Catalyst Common Stock in exchange for shares of CPI common stock and/or ordinary shares of Further Challenger in the Contributions.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If the Contributions do not qualify for the intended tax treatment, GNI USA generally would be required to recognize gain or loss upon the contribution of CPI common stock and ordinary shares of Further Challenger in the Contributions equal to the difference between the fair market value of the shares of Catalyst Common Stock received in exchange for the CPI common stock and ordinary shares of Further Challenger in the Contributions and GNI USA&#8217;s adjusted tax basis in the shares of fair market value of the shares of CPI common stock and ordinary shares of Further Challenger surrendered. Determining the actual tax consequences of the Contributions to GNI USA and the other Contributors may be complex and will depend on the facts of each Contributor&#8217;s own circumstances. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For a more detailed discussion of the material U.S. federal income tax consequences of the Contributions, see &#8220;<font style="font-style: italic;">The </font><font style="font-style: italic;">Contributions&#8212;Material U.S. Federal Income Tax Consequences of the Contributions</font>&#8221; beginning on page <a href="#tMUF1">141</a> of this proxy statement.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Material U.S. Federal Income Tax Consequences of the Receipt of CVRs <font style="font-weight: normal;">(see page </font><font style="font-weight: normal;"><a href="#tMUF">157</a></font><font style="font-weight: normal;">)</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The U.S. federal income tax treatment of the Catalyst stockholders&#8217; receipt of the CVRs is unclear. Catalyst will report the issuance of the CVRs to Catalyst stockholders as a distribution of property with respect to Catalyst Common Stock. If the issuance of the CVRs is treated as a distribution of property, each Catalyst stockholder will be treated as receiving a distribution in an amount equal to the fair market value of the CVRs issued to such Catalyst stockholder on the date of the issuance. This distribution should be treated first as a taxable dividend to the extent of the Catalyst stockholder&#8217;s pro rata share of Catalyst&#8217;s current or accumulated earnings and profits (as determined for U.S. federal income tax purposes), then as a non-taxable return of capital to the extent of the Catalyst stockholder&#8217;s basis in its Catalyst Common Stock and finally as capital gain from the sale or exchange of Catalyst Common Stock with respect to any remaining value. Catalyst is in the process of performing an analysis of the Company's earnings and profits and some or all of the issuance of the CVRs could be treated as a dividend for U.S. federal income tax purposes if Catalyst determines that it has current or accumulated earnings and profits. Any portion of the issuance of CVRs that is not treated as a dividend may be subject to the 1% Excise Tax under the IRA. As discussed in more detail in the section entitled &#8220;<font style="font-style: italic;">Agreements Related to the Contributions&#8212;CVR </font><font style="font-style: italic;">Agreement&#8212;Material U.S. Federal Income Tax Consequences of the Receipt of CVRs</font>&#8221; beginning on page <a href="#tMUF">157</a> of this proxy statement, these consequences assume that distribution of the CVRs will be treated for U.S. federal income tax purposes as separate and distinct from the proposed reverse stock split. See the section entitled &#8220;<font style="font-style: italic;">Agreements Related </font><font style="font-style: italic;">to the Contributions&#8212;CVR Agreement&#8212;Material U.S. Federal Income Tax Consequences of the Receipt of CVRs</font>&#8221; beginning on page <a href="#tMUF">157</a> of this proxy statement for a more complete description of the material U.S. federal income tax consequences of the receipt of CVRs to Catalyst stockholders, including possible alternative treatments.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Material U.S. Federal Income Tax Consequences of the Reverse Stock Split<font style="font-weight: normal;"> (see page </font><font style="font-weight: normal;"><a href="#tMUF2">187</a></font><font style="font-weight: normal;">) </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst intends the proposed reverse stock split to qualify as a &#8220;recapitalization&#8221; within the meaning of Section&#160;368(a)(1)(E) of the Code. In general and subject to the qualifications and limitations set forth in the section entitled &#8220;<font style="font-style: italic;">Proposal No. 4&#8212;Material U.S. Federal Income</font> <font style="font-style: italic;">Tax Consequences of the Reverse Stock Split</font>&#8221; beginning on page <a href="#tMUF2">187</a> of this proxy statement, if the proposed reverse stock split qualifies as a &#8220;recapitalization&#8221; within the meaning of Section 368(a)(1)(E) of the Code, a Catalyst U.S. holder (as defined on page <a href="#tREC">158</a>) should not recognize gain or loss upon the proposed reverse stock split. See the section entitled &#8220;<font style="font-style: italic;">Proposal No. 4&#8212;Material U.S. Federal </font><font style="font-style: italic;">Income</font> <font style="font-style: italic;">Tax Consequences of the Reverse Stock Split</font>&#8221; beginning on page <a href="#tMUF2">187</a> of this proxy statement for a more complete description of the material U.S. federal income tax consequences of the proposed reverse stock split to Catalyst U.S. holders.</div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">26<br></div></div></div>
<!--End Page 37-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 38-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20006478x8_prer14a_105-sum_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Risk Factor Summary</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Both Catalyst and BC are subject to various risks associated with their businesses and their industries. In addition, the Contributions, including the possibility that the Contributions may not be completed, poses a number of risks to each company and its respective securityholders, including the following risks: </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Risks Related to the Contributions </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst stockholders will experience substantial dilution in the Contributions. Catalyst stockholders may not realize a benefit from the Contributions commensurate with the ownership dilution they will experience in connection with the Contributions.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Failure to complete the Contributions may result in either Catalyst paying a termination fee to the Contributors and reimbursing the Contributors for their fees and expenses, or the Contributors reimbursing Catalyst for its fees and expenses, which could harm the common stock price of Catalyst and future business and operations of each party.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">If the conditions to the Contributions are not satisfied or waived, the Contributions may not occur.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Risks Related to the Proposed Reverse Stock Split </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The reverse stock split may not increase the combined company&#8217;s stock price over the long-term.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Risks Related to Catalyst</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst has incurred significant losses since its inception and is expected to continue to incur significant losses for the foreseeable future.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst has no history of obtaining regulatory approval or commercialization of pharmaceutical products, and it may be unable to do so for any product candidates Catalyst acquires or develops, including Hydronidone, which may make it difficult to evaluate Catalyst&#8217;s prospects.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst is substantially dependent on the success of its lead product candidate, Hydronidone, and its future clinical trials may not be successful.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst expects to seek to establish additional collaborations, and, if Catalyst is not able to establish them on commercially reasonable terms, Catalyst may have to alter its development and commercialization plans.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s future success depends on its ability to retain key executives and to attract, retain and motivate qualified personnel.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If Catalyst is unable to obtain, protect or enforce intellectual property rights related to its product candidates, Catalyst may not be able to compete effectively in its markets.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If Catalyst is not able to obtain, or if there are delays in obtaining, required regulatory approvals, Catalyst will not be able to commercialize its product candidates, including Hydronidone, and its ability to generate revenue will be materially impaired.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst is developing Hydronidone for the treatment of NASH, an indication for which there are no approved products. The requirements for approval of Hydronidone by the FDA and comparable foreign regulatory authorities may be difficult to predict and may change over time, which makes it difficult to predict the timing and costs of the clinical development.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst has recently received a Nasdaq notice for failing to comply with the minimum bid price listing requirement and there is no assurance Catalyst will regain compliance or maintain its Nasdaq listing.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst may not be able to continue as a going concern if the conversion of Catalyst Series X Convertible Preferred Stock, par value $0.001 per share (the &#8220;Catalyst Convertible Preferred Stock&#8221;) is not approved by its stockholders.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Risks Related to BC</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">BC is largely dependent on sales of ETUARY, its commercialized product, within a competitive environment and BC may be unable to maintain or increase the sales volume, pricing levels and profit margins.</div></td></tr></table></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">27<br></div></div></div>
<!--End Page 38-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 39-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20006478x8_prer14a_105-sum_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">BC&#8217;s business and financial prospects depend substantially on the success of its clinical stage and pre-clinical stage drug candidates and BC may be unable to successfully complete their clinical development, obtain relevant regulatory approvals or achieve their commercialization, or may experience significant delays in doing so.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">BC&#8217;s drugs and future approved drug candidates may fail to achieve the degree of market acceptance by physicians, medical institutions, pharmacies, patients, third-party payers and others in the medical community necessary for commercial success.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The actual market size of BC&#8217;s drug candidates may be smaller than it anticipates, which could render some drug candidates ultimately unprofitable even if commercialized and BC&#8217;s growth is limited by existing and newly identified cases of IPF patients in the PRC until the expanded indications of ETUARY and BC&#8217;s other drug candidates are approved and become profitable.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">All material aspects of the research, development, manufacturing and commercialization of BC&#8217;s drugs and drug candidates are heavily regulated.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Even if BC is able to obtain patent protection for our drugs and drug candidates, the term of such protection, if any, is limited and third parties could develop and commercialize products and technologies similar or identical to ours and compete directly against us after the expiration of BC&#8217;s patent rights.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If BC determines its intangible assets to be impaired, BC&#8217;s results of operations and financial condition may be adversely affected.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">BC&#8217;s operations are primarily conducted in China, and BC is subject to complex and evolving PRC laws and regulations, which, if the Contributions are consummated, exposes investors in the combined company to risks.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The PRC government may intervene in or influence BC&#8217;s operations at any time, which could result in a change in BC&#8217;s and, if the Contributions are consummated, the combined company&#8217;s, operations and/or value of its securities.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">There are uncertainties regarding the interpretation and enforcement of PRC laws, rules and regulations, which can evolve quickly with little advance notice, which may materially and adversely affect BC&#8217;s, and if the Contributions are consummated, the combined company&#8217;s, business, financial condition, and results of operations.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Restrictions on currency exchange, including the risks of transferring cash outside of the PRC, may limit BC&#8217;s ability to receive and use effectively financing in foreign currencies.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Since BC is a legal entity registered in Beijing, PRC, it is classified as a PRC tax resident for PRC income tax purposes by default, and such classification results in unfavorable tax consequences to BC and its non-PRC shareholders.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Risks Related to the Combined Company</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The PRC government&#8217;s significant authority in regulating the combined company&#8217;s operations and its oversight and control over offerings conducted overseas by, and foreign investment in, PRC-based issuers could significantly limit or completely hinder the combined company&#8217;s ability to offer or continue to offer securities to investors and cause the value of the combined company&#8217;s securities to significantly decline or be worthless if the Contributions are consummated. For more details regarding the risks related to operations in the PRC, see <font style="font-style: italic;">Risk Factors&#8212;Risks Related to BC&#8212;Risks Related to BC&#8217;s Operations in the </font><font style="font-style: italic;">PRC</font>. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The market price of the combined company&#8217;s common stock following the completion of the Contributions is expected to be volatile and the market price of the common stock may drop following the Contributions.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Following the Contributions, the combined company may be unable to integrate successfully and realize the anticipated benefits of the Contributions.</div></td></tr></table></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">28<br></div></div></div>
<!--End Page 39-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 40-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20006478x8_prer14a_105-sum_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The combined company will need substantial additional funding before it can complete the development of its product candidates. If the combined company is unable to obtain such additional capital on favorable terms, on a timely basis or at all, it would be forced to delay, reduce or eliminate its product development and clinical programs and may not have the capital required to otherwise operate its business.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The combined company will incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The PRC-operations portion of the combined company&#8217;s audit may be conducted by an independent registered public accounting firm that is not subject to inspection by the Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;), which may negatively impact investor sentiment towards the combined company or its PRC operations, which could adversely affect the market price of the combined company&#8217;s common stock. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">These risks and other risks are discussed in greater detail under the section entitled &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; beginning on page&#160;<a href="#tRF">34</a> of this proxy statement. Catalyst and the GNI Parties encourage you to read and consider all of these risks carefully.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Regulatory Approvals<font style="font-weight: normal;"> (see page </font><font style="font-weight: normal;"><a href="#tRA">141</a></font><font style="font-weight: normal;">) </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In the United States, Catalyst must comply with applicable federal and state securities laws and the rules and regulations of Nasdaq in connection with the issuance of shares of Catalyst Common Stock to GNI USA and the Minority Holders in connection with the transactions contemplated by the Business Combination Agreement and the filing of this proxy statement with the SEC. Catalyst does not intend to seek any regulatory approval from antitrust authorities to consummate the transactions.</div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On February 17, 2023, the China Securities Regulatory Commission (&#8220;CSRC&#8221;) issued the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Enterprises (the &#8220;Trial Measures&#8221;), which became effective on March&#160;31, 2023. On the same date, CSRC circulated No. 1 to No. 5 Supporting Guidance Rules, the Notes on the Trial Measures, the Notice on Administration Arrangements for the Filing of Overseas Listings by Domestic Enterprises and the relevant CSRC Answers to Reporter Questions on the official website of CSRC. These new regulations propose to establish a new filing-based regime to regulate overseas offerings and listings by PRC domestic companies. Accordingly, on May 22, 2023, BC submitted the filing documents pursuant to the Trial Measures to the CSRC that must be accepted prior to the anticipated closing of the Contributions. In June 2023, BC received comments from the CSRC on its filing materials, and BC filed its responses and supplemental materials to the CSRC. As of the date of this filing, BC has not received final confirmation from the CSRC regarding the completion of the Trial Measures filing process. </div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC does not believe it falls within any of the circumstances specified in the Trial Measures in which overseas issuance and listing are prohibited. As long as BC complies with all relevant requirements, takes all necessary steps and submits all relevant materials as required, BC expects that there are no significant legal impediments to its completion of the filing process with the CSRC. However, there is still uncertainty as to whether BC will be able to complete the filing, and if it is unable to complete the filing process, BC will have to suspend or terminate the Contributions. Furthermore, pursuant to the Trial Measures, if domestic enterprises fail to fulfill the filing procedures or offer and list in an overseas market against the prohibited circumstances, they would be warned and fined not less than approximately $144,092 but not more than approximately $1.4 million. The controlling shareholder or the actual controller of a domestic enterprise who organizes or instructs to engage in such illegal acts will be fined not less than approximately $144,092 but not more than approximately $1.4 million. If the filing materials of a domestic enterprise contain false records, misleading statements or material omissions, the CSRC will order correction, issue a warning, and impose a fine of not less than approximately $144,092 and not more than approximately $1.4&#160;million. The controlling shareholder or actual controller of a domestic enterprise who organizes or directs to engage in the illegal acts in the preceding paragraph, or conceals the relevant matters leading to the occurrence of the foregoing, shall be subject to a fine of not less than approximately $144,092 and not more than approximately $1.4&#160;million. </div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of May 15, 2023, BC has received all material permissions and approvals required for its business operations. As of May 15, 2023, BC Biomedical has obtained a business license but has no business operations. For a table that sets forth the details of material licenses, permits and approvals, see <font style="font-style: italic;">BC&#8217;s Business&#8212;Permits and Other Approvals</font> in this proxy statement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Except for the filing BC will make with the CSRC as described above, BC does not expect that any other governmental agency is required to approve BC&#8217;s operations, including the Cyberspace Administration of China. </div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">29<br></div></div></div>
<!--End Page 40-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 41-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20006478x8_prer14a_105-sum_pg20"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">However, applicable PRC laws and regulations may be tightened, and new laws or regulations may be introduced to impose additional government approval, license, and permit requirements. If BC or its subsidiaries fail to obtain and maintain such approvals, licenses, or permits required for BC&#8217;s business, inadvertently conclude that such approval is not required, or fail to respond to changes in the regulatory environment, BC or its subsidiaries could be subject to liabilities, penalties, and operational disruption, which may materially and adversely affect its business, operating results, financial condition and the value of the combined company&#8217;s common stock, and if the Contributions are consummated, significantly limit or completely hinder the combined company&#8217;s ability to offer or continue to offer securities to investors, or cause such securities to significantly decline in value or become worthless. For more details on the risks of BC&#8217;s operations in the PRC, see <font style="font-style: italic;">Risk Factors&#8212;Risks Related to BC&#8212; Risks Related to BC&#8217;s Business </font><font style="font-style: italic;">Operations in the PRC</font>.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Nasdaq Stock Market Listing <font style="font-weight: normal;">(see page </font><font style="font-weight: normal;"><a href="#tNSM">143</a></font><font style="font-weight: normal;">) </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst has filed a listing application to cause the shares of Catalyst Common Stock to be issued in connection with the Contributions to be approved for listing on Nasdaq. If such application is accepted, Catalyst and the GNI Parties anticipate that the common stock of the combined company, which will be renamed Gyre Therapeutics, Inc., will be listed on Nasdaq following the closing of the Contributions under the trading symbol &#8220;GYRE.&#8221; </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Anticipated Accounting Treatment<font style="font-weight: normal;"> (see page </font><font style="font-weight: normal;"><a href="#tAAT">142</a></font><font style="font-weight: normal;">) </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For accounting purposes, CPI is considered to be acquiring Catalyst in this transaction. The transaction is expected to be accounted for as a reverse asset acquisition under existing U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;), which is subject to change and interpretation. To determine the accounting for this transaction under U.S. GAAP, a company must assess whether an integrated set of assets and activities should be accounted for as an acquisition of a business or an asset acquisition. The guidance requires an initial screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single asset or group of similar assets. If that screen is met, the operations acquired are not a business. Catalyst is not expected to meet the definition of a business since substantially all of the fair value is included in IPR&amp;D and no substantive processes are being acquired. As such, the Contributions are expected to be treated as an asset acquisition. The accounting treatment is dependent on certain valuations and other studies that have yet to commence or progress to a stage where there is sufficient information for a definitive measurement. A final determination of these estimated fair values, which cannot be made prior to the completion of the transaction, will be based on the actual net tangible and intangible assets of Catalyst that exist as of the completion of the transaction.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">No Appraisal Rights for Catalyst Stockholders <font style="font-weight: normal;">(see page </font><font style="font-weight: normal;"><a href="#tNAR">143</a></font><font style="font-weight: normal;">) </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Appraisal rights are statutory rights under the Delaware General Corporation Law (the &#8220;DGCL&#8221;) that enable stockholders who object to certain extraordinary transactions to demand that the corporation pay such stockholders the fair value of their shares instead of receiving the consideration offered to stockholders in connection with the extraordinary transaction. Holders of Catalyst Common Stock are not entitled to appraisal rights under Delaware law in connection with the Contributions.</div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">30<br></div></div></div>
<!--End Page 41-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 42-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20006478x8_prer14a_105-sum_pg21"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tMPA"><!--Anchor--></a>MARKET PRICE AND DIVIDEND INFORMATION </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Market Price Information </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Catalyst Common Stock is currently listed on The Nasdaq Capital Market under the symbol &#8220;CBIO.&#8221;</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The closing price of Catalyst Common Stock on December&#160;23, 2022, the last trading day prior to the public announcement of the Contributions, was $0.50 per share, and the closing price of Catalyst Common Stock on May 15, 2023, was $0.22 per share, in each case as reported on The Nasdaq Capital Market.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Because the market price of Catalyst Common Stock is subject to fluctuation, the market value of the shares of Catalyst Common Stock that Contributors will receive in connection with the Contributions may increase or decrease.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">BC is a private company and its common shares are not publicly traded.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Assuming approval of Proposal Nos. 1 and 2 and successful application for initial listing with Nasdaq, Catalyst and the GNI Parties anticipate that the common stock of the combined company, which will be renamed Gyre Therapeutics, Inc., will be listed on Nasdaq following the closing of the Contributions under the trading symbol &#8220;GYRE.&#8221;</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of &#8195;&#8195;&#8195;, 2023, the Record Date for the Special Meeting, there were approximately &#8195;&#8195;&#8195; holders of record of Catalyst Common Stock. As of &#8195;&#8195;&#8195;, 2023, BC had 10 holders of record of BC ordinary shares. For detailed information regarding the beneficial ownership of certain Catalyst stockholders, see the sections titled &#8220;<font style="font-style: italic;">Principal </font><font style="font-style: italic;">Stockholders of Catalyst</font>&#8221; and &#8220;<font style="font-style: italic;">Principal S</font><font style="font-style: italic;">tock</font><font style="font-style: italic;">holders of BC</font>&#8221; on pages <a href="#tPSOC">336</a> and <a href="#tPSOBC">337</a>, respectively, of this proxy statement.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Dividends</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On September&#160;20, 2022, Catalyst paid a special cash dividend of $45.0&#160;million (or $1.43 per share) to Catalyst&#8217;s common stockholders of record as of the close of business on September&#160;6, 2022, and on January&#160;12, 2023, Catalyst paid a special cash dividend of $7.6&#160;million (or $0.24 per share) to Catalyst&#8217;s common stockholders of record as of the close of business on January&#160;5, 2023. Catalyst determined, in accordance with the adjustment provision of the Catalyst Biosciences, Inc. 2018 Omnibus Incentive Plan (the &#8220;2018 Plan&#8221;), that the special cash dividends were unusual and non-recurring and that appropriate adjustment to the stock options to purchase shares of Catalyst Common Stock outstanding under the 2018 Plan were required. Catalyst treated these adjustments as a modification to the original stock option grants because the terms of the agreements were modified in order to preserve the value of the option awards after a large non-recurring cash dividend. These options were amended to decrease the exercise price and increase the number of shares subject to the stock option on a proportionate basis. No incremental value was provided to the option holders as a result of the modification and no additional compensation cost was recorded by Catalyst. In 2020, BC paid a cash dividend of $1.9&#160;million to BJContinent Pharmaceuticals Limited, a company incorporated under the laws of Hong Kong with limited liability (&#8220;BJC Limited&#8221;). BC intends to retain all available funds and any future earnings for use in the operation of its business and does not anticipate paying any cash dividends on its capital stock in the foreseeable future. Notwithstanding the foregoing, any determination to pay cash dividends subsequent to the Contributions will be at the discretion of the combined company&#8217;s board of directors and will depend upon a number of factors, including the combined company&#8217;s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors the combined company&#8217;s board of directors deems relevant. For more details, see &#8220;<font style="font-style: italic;">BC&#8217;s Business&#8212;Regulatory Requirements in the </font><font style="font-style: italic;">PRC&#8212;Dividends, Distributions and Other Transfers&#8221;, Audited Financial Statements of Beijing Continent </font><font style="font-style: italic;">Pharmaceuticals Co., Ltd. and &#8220;Selected Historical and Unaudited Pro Forma Condensed Combined Financial </font><font style="font-style: italic;">Information&#8212;Unaudited Pro Forma Condensed Combined Financial Information&#8221;</font> included elsewhere in this proxy statement. </div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">31<br></div></div></div>
<!--End Page 42-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 43-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_105-sum_pg22"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">SUMMARY OF SIGNIFICANT IFRS TO U.S. GAAP DIFFERENCES</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Major GAAP Difference Identified and Adjusted</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">1.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; text-align: left;">Lease amortization</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under U.S. GAAP, for operating leases, the amortization of right-of-use assets and the interest expense element of lease liabilities are recorded together as lease expenses, which results in a straight-line recognition effect in the consolidated statements of operations. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under IFRS, all leases are accounted for like finance leases where right-of-use assets are generally depreciated on a straight-line basis while lease liabilities are measured under the effective interest method, which results in higher expenses at the beginning of the lease term and lower expenses near the end of the lease term. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">2.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; text-align: left;">Share-based compensation</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under U.S. GAAP, compensation cost should be recognized only if it is probable that the performance condition will be achieved. An initial public offering (&#8220;IPO&#8221;) constitutes a performance condition that is not considered probable until the IPO completion date under U.S. GAAP, resulting in later recognition of the cost in comparison to IFRS&#160;Standards. When share-based awards are modified, and the modification is considered a type III modification &#8212; improbable to probable under U.S. GAAP &#8212; an entity will begin recording share-based compensation expense based on the fair value of the modified awards over the remaining vesting period.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under IFRS, share-based compensation expenses are recognized to the extent of the best estimate of the number of equity instruments that will ultimately vest. The best estimate takes into account the likelihood of the service/non-marketing performance conditions being met. An IPO with the requirement of employees&#8217; service is considered as non-marketing performance condition, and the likelihood of IPO is taken into account to determine the vesting period and the number of equity instruments to be vested.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">3.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; text-align: left;">Internally developed intangible assets</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under U.S. GAAP, research and development activities are expensed as incurred. Milestone payment for acquired in-process research and development (&#8220;IPR&amp;D&#8221;) incurred prior to regulatory approval are expensed as incurred.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under IFRS, expenditure incurred on projects to develop new products can be capitalized and deferred when an entity can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the project and the ability to measure reliably the expenditure during the development.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">32<br></div></div></div>
<!--End Page 43-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 44-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_105-sum_pg23"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">IMPORTANT INFORMATION ABOUT EXCHANGE RATES</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Certain information presented in this proxy statement has been converted from Renminbi to U.S. dollars at the rates, as set by the People&#8217;s Bank of China for each of the applicable dates, below: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">for assets and liabilities:</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">RMB 6.8717 to US$1.00 for the three months ended March 31, 2023;</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">RMB 6.3482 to US$1.00 for the three months ended March 31, 2022;</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">RMB 6.9646 to US$1.00 for the year ended December&#160;31, 2022; and</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">RMB 6.3757 to US$1.00 for the year ended December&#160;31, 2021;</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">for profit, loss and cashflow:</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">RMB 6.8476 to US$1.00 for the three months ended March 31, 2023;</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">RMB 6.3504 to US$1.00 for the three months ended March 31, 2022;</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">RMB 6.7208 to US$1.00 for the year ended December&#160;31, 2022; and </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">RMB 6.4512 to US$1.00 for the year ended December&#160;31, 2021; </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">for equity items and all other items:</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">the historical exchange rate of Renminbi to U.S. dollars at the time the figure is reported to occur. </font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Exchange rates fluctuate, and such fluctuation can be significant. No representation is made that any Renminbi amounts referred to in this proxy statement could have been, or could be, converted to U.S. dollars at any particular rate, or at all.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">33<br></div></div></div>
<!--End Page 44-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 45-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tRF"><!--Anchor--></a>RISK FACTORS </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The combined company will be faced with a market environment that cannot be predicted and that involves significant risks, many of which will be beyond its control. In addition to the other information contained or incorporated by reference in this proxy statement, you should carefully consider the material risks described below before deciding how to vote your shares of Catalyst Common Stock. You should also read and consider the other information in this proxy statement and additional information about Catalyst set forth in its Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2022, which is filed with the Securities and Exchange Commission, or the SEC, as such risks may be updated or supplemented in its subsequent Quarterly Reports on Form&#160;10-Q or Current Reports on Form 8-K, each of which is incorporated by reference into this proxy statement. Please see the section entitled &#8220;Where You Can Find More Information&#8221; beginning on page <a href="#tWYC">343</a> of this proxy statement for further information regarding the documents incorporated by reference into this proxy statement.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;"><u>Risks Related to the Strategic Transactions</u></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Risks Related to the Contributions </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Failure to complete the Contributions may result in either Catalyst paying a termination fee to the Contributors and reimbursing the Contributors for their fees and expenses, or the Contributors reimbursing Catalyst for its fees and expenses, which could harm the common stock price of Catalyst and future business and operations of each party.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">If the Contributions are not completed, Catalyst and the Contributors are subject to the following risks: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">if the Business Combination Agreement is terminated under certain specified circumstances, Catalyst will be required to pay the Contributors a termination fee of $2.0&#160;million and reimburse the Contributors for all of their reasonable out-of-pocket fees and expenses incurred by the Contributors up to $2.0&#160;million; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">if the Business Combination Agreement is terminated under certain other specified circumstances, the Contributors will be required to reimburse Catalyst for all of its reasonable out-of-pocket fees and expenses incurred by Catalyst up to $2.0&#160;million; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the price of Catalyst Common Stock may decline and could fluctuate significantly; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">costs related to the Contributions, such as financial advisor, legal and accounting fees, which Catalyst estimates will total approximately $1.75 million in the aggregate, a majority of which must be paid even if the Contributions are not completed.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If the Business Combination Agreement is terminated and the board of directors of Catalyst or equivalent thereof of the Contributors determines to seek another business combination, there can be no assurance that either Catalyst or the Contributors will be able to find a partner with whom a business combination would yield greater benefits than the benefits to be provided under the Business Combination Agreement.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">If the conditions to the Contributions are not satisfied or waived, the Contributions may not occur.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Even if the Business Combination Agreement is adopted by the stockholders of Catalyst, specified conditions must be satisfied or waived to complete the Contributions. These conditions are set forth in the Business Combination Agreement and described in the section entitled &#8220;<font style="font-style: italic;">The Business Combination Agreement&#8212;Conditions to the </font><font style="font-style: italic;">Completion of the Contributions</font>&#8221; beginning on page <a href="#tCTT">152</a> of this proxy statement, which includes a description of which conditions may be waived. Catalyst and the Contributors cannot assure you that all of the conditions to the consummation of the Contributions will be satisfied or waived. If the conditions are not satisfied or waived, the Contributions may not occur or the closing may be delayed, and Catalyst and BC each may lose some or all of the intended benefits of the Contributions.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">The Contributions may be completed even though a material adverse effect may result from the announcement of the Contributions, industry-wide changes or other causes.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In general, neither Catalyst nor the Contributors is obligated to complete the Contributions if there is a material adverse effect affecting the other party between December&#160;26, 2022, the date of the Business Combination Agreement, and the closing of the Contributions. However, certain types of changes are excluded from the concept of a &#8220;material adverse effect.&#8221; Such exclusions include but are not limited to changes in general economic or market conditions, industry wide changes, changes in GAAP and IFRS, changes in laws, rules or regulations of general </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">34<br></div></div></div>
<!--End Page 45-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 46-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">applicability or interpretations thereof, natural disasters, epidemics, pandemics or other disease outbreaks (including the COVID-19 pandemic), outbreaks of major hostilities or acts of terrorism, changes resulting from the announcement or pendency of the Contributions, and failures to meet internal guidance, budgets, plans or forecasts. Therefore, if any of these events were to occur impacting Catalyst, the Contributors or CPI, the other parties would still be obliged to consummate the closing of the Contributions. If any such adverse changes occur and Catalyst and BC consummate the closing of the Contributions, the stock price of the combined company may suffer. This in turn may reduce the value of the Contributions to the stockholders of Catalyst, the shareholders of BC or both. For a more complete discussion of what constitutes a material adverse effect on Catalyst, the Contributors or CPI, see the section entitled &#8220;<font style="font-style: italic;">The Business Combination Agreement&#8212;Conditions to the Completion of the Contributions</font>&#8221; beginning on page <a href="#tCTT">152</a> of this proxy statement.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: justify;">If Catalyst and the Contributors complete the Contributions, the combined company may need to raise additional capital by issuing additional equity securities or through debt financing or licensing arrangements, which may cause significant dilution to the combined company&#8217;s stockholders or restrict the combined company&#8217;s operations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Additional financing may not be available to the combined company when it is needed or may not be available on favorable terms. To the extent that the combined company raises additional capital by issuing equity securities, such financing will cause additional dilution to all securityholders of the combined company, including Catalyst&#8217;s pre-Contributions securityholders and BC&#8217;s former securityholders. It is also possible that the terms of any new equity securities may have preferences over the combined company&#8217;s common stock. Any debt financing the combined company enters into may involve covenants that restrict its operations. These restrictive covenants may include limitations on additional borrowing and specific restrictions on the use of the combined company&#8217;s assets, as well as prohibitions on its ability to create liens, pay dividends, redeem its stock or make investments. In addition, if the combined company raises additional funds through licensing arrangements, it may be necessary to grant licenses on terms that are not favorable to the combined company.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: justify;">Some directors and executive officers of Catalyst, the Contributors, CPI and BC may have interests in the Contributions that are different from yours and that may influence them to support or approve the Contributions without regard to your interests.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Directors and executive officers of Catalyst, the Contributors and CPI may have interests in the Contributions that are different from, or in addition to, the interests of other Catalyst stockholders generally. These interests with respect to Catalyst&#8217;s directors and executive officers may include, among others, that certain of Catalyst&#8217;s executives are entitled to, in connection with a qualifying termination of employment, accelerated vesting of options with respect to Catalyst Common Stock and the payment of severance, that certain of Catalyst&#8217;s executives are entitled to the extension of the applicable executive&#8217;s post-termination exercise period with respect to their options in the event of the executive&#8217;s continued employment through the closing of the Contributions, and that all of Catalyst&#8217;s directors and executive officers are entitled to certain indemnification and liability insurance coverage pursuant to the terms of the Business Combination Agreement. In addition, current members of the Catalyst board of directors, Nassim Usman, Ph.D, Thomas Eastling and Ying Luo, Ph.D., are expected to continue as directors of the combined company after the Effective Time, and, following the closing of the Contributions, will be eligible to be compensated as non-employee directors of the combined company pursuant to the Catalyst non-employee director compensation policy that is expected to remain in place following the Effective Time. These interests with respect to the Contributors&#8217; and CPI&#8217;s directors and executive officers may include, among others, that certain of the Contributors&#8217; and CPI&#8217;s directors and executive officers have options, subject to vesting, to purchase BC ordinary shares which, after the Effective Time, will be converted into and become options to purchase shares of the common stock of the combined company; and all of the Contributors and CPI&#8217;s directors and executive officers are entitled to certain indemnification and liability insurance coverage pursuant to the terms of the Business Combination Agreement. In addition, certain of BC&#8217;s executive officers are expected to continue as executive officers of the combined company after the Effective Time. Further, some of the current members of BC&#8217;s board of directors are expected to continue as directors of the combined company after the Effective Time, and, following the closing of the Contributions, will be eligible to be compensated as non-employee directors of the combined company pursuant to the Catalyst non-employee director compensation policy that is expected to remain in place following the Effective Time. Certain directors and executive officers own options to purchase the shares of their respective companies.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Catalyst board of directors and the equivalent governing bodies of the Contributors and CPI were aware of and considered those interests, among other things, in reaching their decisions to approve and adopt the Business </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">35<br></div></div></div>
<!--End Page 46-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 47-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Combination Agreement, approve the Contributions, and recommend the approval of the Business Combination Agreement and certain related matters to Catalyst and BC stockholders. These interests, among other factors, may have influenced the directors and executive officers of Catalyst, the Contributors and CPI to support or approve the Contributions.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For more information regarding the interests of Catalyst, the Contributors and CPI directors and executive officers in the Contributions, please see the sections titled &#8220;<font style="font-style: italic;">The Contributions&#8212;Interests of Catalyst&#8217;s Directors and </font><font style="font-style: italic;">Executive Officers in the Contributions</font>&#8221; beginning on page <a href="#tICD">136</a> and &#8220;<font style="font-style: italic;">The Contributions&#8212;Interests of GNI Parties&#8217; </font><font style="font-style: italic;">Directors and Executive Officers in the Contributions</font>&#8221; beginning on page <a href="#tIGP">138</a> of this proxy statement.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s CVR was distributed to its stockholders of record on January&#160;5, 2023; other stockholders, including purchasers of Catalyst common stock after January&#160;5, 2023, will not benefit from the distribution under the CVR. CVR Holders may potentially not receive any payment on the CVRs and the CVRs may otherwise expire valueless.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Contingent Value Rights Agreement (the &#8220;CVR Agreement&#8221;) dated December&#160;26, 2022, Catalyst&#8217;s CVR was distributed to its stockholders of record on January&#160;5, 2023 the (&#8220;CVR Holders&#8221;). CVR distributions, if any, will consist of net proceeds from any potential future sale of Catalyst&#8217;s legacy assets or claims, net cash in excess of $1.0&#160;million, as of the closing of the Contributions, net cash received from the transaction with Vertex Pharmaceuticals Incorporated (&#8220;Vertex&#8221;) in May 2022, up to $5.0&#160;million, net proceeds from the payment of the remaining $5.0&#160;million due from the sale of Catalyst&#8217;s legacy hemophilia assets to GC Biopharma (&#8220;GCBP&#8221;), and net proceeds from certain legal claims that Catalyst has against a third party. The amount that can be distributed will depend on a variety of factors, including the value, if any, received for Catalyst&#8217;s legacy assets or claims, the amount of expenses Catalyst incurs before the closing of the Contributions, and the amount, if any, received from Vertex and GCBP. There can be no assurance as to the timing or amount of distributions to Catalyst&#8217;s stockholders pursuant to the CVR Agreement, and such amounts may ultimately be higher or lower than anticipated.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Furthermore, other Catalyst stockholders, including purchasers of Catalyst common stock after January&#160;5, 2023, will not benefit from the distribution under the CVR.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst may not be able to achieve successful results from the disposition of such assets as described above. If this is not achieved for any reason within the time periods specified in the CVR Agreement, or the permitted deductions set forth in the CVR Agreement are greater than any gross proceeds, no payments will be made under the CVRs, and the CVRs will expire valueless. For further information regarding the CVR Agreement, please see the section entitled &#8220;<font style="font-style: italic;">Agreements Related to the Contributions</font>&#8212;<font style="font-style: italic;">CVR Agreement</font>&#8221; beginning on page <a href="#tCVR">157</a> of this proxy statement. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Catalyst stockholders may not realize a benefit from the Contributions commensurate with the ownership dilution they will experience in connection with the Contributions.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst stockholders will experience substantial dilution of their ownership interests in connection with the Contributions. Immediately before the Contributions and without giving effect to the conversion of the Catalyst Convertible Preferred Stock issued pursuant to the F351 Agreement, the Catalyst stockholders as of immediately prior to the Contributions hold approximately 83.4% of the outstanding shares of capital stock of Catalyst, GNI Japan owns approximately 2.4% of the outstanding shares of capital stock of Catalyst and GNI Hong Kong owns approximately 14.2% of the outstanding shares of capital stock of Catalyst. Immediately after the Contributions, Catalyst stockholders as of immediately prior to the Contributions are expected to own approximately 2.5% of the outstanding shares of the combined company, assuming conversion of the Catalyst Convertible Preferred Stock (or approximately 2.0% of the outstanding shares of the combined company on a fully diluted basis, assuming conversion of the Catalyst Convertible Preferred Stock and including the outstanding options of Catalyst and the Gyre Options to be granted in respect of the BC Options). If the combined company is unable to realize the full strategic and financial benefits currently anticipated from the Contributions, Catalyst stockholders will have experienced substantial dilution of their ownership interests without receiving any commensurate benefit, or only received part of the commensurate benefit to the extent the combined company is able to realize only part of the strategic and financial benefits currently anticipated from the Contributions.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">If the Contributions are not completed, Catalyst&#8217;s stock price may fluctuate significantly.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The market price of Catalyst&#8217;s common stock is subject to significant fluctuations. During the 12-month period ended December&#160;31, 2022, the closing sales price of Catalyst&#8217;s common stock on The Nasdaq Capital Market ranged from a high of $1.99 on August&#160;19, 2022 to a low of $0.36 on May&#160;13, 2022. Market prices for securities of pharmaceutical, </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">36<br></div></div></div>
<!--End Page 47-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 48-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">biotechnology and other life science companies have historically been particularly volatile. In addition, the market price of Catalyst Common Stock will likely be volatile based on whether stockholders and other investors believe that Catalyst can complete the Contributions or otherwise raise additional capital to support Catalyst&#8217;s operations if the Contributions are not consummated and another strategic transaction cannot be identified, negotiated and consummated in a timely manner, if at all. Additional factors that may cause the market price of Catalyst Common Stock to fluctuate include: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in the industries in which Catalyst operates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">material and adverse impacts of public health crises on the markets and the broader global economy; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the public&#8217;s reaction to Catalyst&#8217;s press release, its other public announcements and its filings with the SEC; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">additions and departures of key personnel; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in laws and regulations affecting Catalyst&#8217;s business;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">commencement of, or involvement in, litigation;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">changes in Catalyst&#8217;s capital structure, such as future issuances of securities or the issuance of additional debt;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">general economic and political conditions such as recessions, interest rates, fuel prices, foreign currency fluctuations, international tariffs, social, political and economic risks and acts of war or terrorism; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">changes attributable to the public announcement or pendency of the Contributions (including the impact thereof on relationships with employees and any federal, state, or local government entities). </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of Catalyst Common Stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Failure to effectively retain, attract and motivate key employees could diminish the anticipated benefits of the Business Combination.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The success of the Business Combination will depend in part on the attraction, retention and motivation of executive personnel critical to the business and operations of the combined company. Executives may experience uncertainty about their future roles with Catalyst and BC during the pendency of the Business Combination or after its completion. In addition, competitors may recruit BC management. If the combined company following the Business Combination is unable to attract, retain and motivate executive personnel that are critical to the successful operations of the combined company, the combined company could face disruptions in its operations, strategic relationships, key information, expertise or know-how and unanticipated recruitment and onboarding costs. In addition, the loss of key personnel could diminish the anticipated benefits of the Business Combination.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">During the pendency of the Contributions, Catalyst may not be able to enter into a business combination with another party on more favorable terms because of restrictions in the Business Combination Agreement, which could adversely affect its business prospects.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Covenants in the Business Combination Agreement impede the ability of Catalyst to make acquisitions during the pendency of the Contributions, subject to specified exceptions. In addition, while the Business Combination Agreement is in effect, Catalyst is generally prohibited from soliciting, proposing, seeking or knowingly encouraging, facilitating or supporting any inquiries, indications of interest, proposals or offers that constitute or may reasonably be expected to lead to certain transactions involving a third party, including a merger, sale of assets or other business combination, subject to specified exceptions. Any such transactions could be favorable to Catalyst&#8217;s stockholders, but Catalyst may be unable to pursue them. For more information, see the section entitled &#8220;<font style="font-style: italic;">The Business Combination </font><font style="font-style: italic;">Agreement&#8212;Non-Solicitation</font>&#8221; beginning on page <a href="#tNS">149</a> of this proxy statement. In addition, if the Business Combination Agreement is terminated under specified circumstances, Catalyst would be required to pay the Contributors a termination fee of $2.0&#160;million and reimburse the Contributors for all of their reasonable out-of-pocket fees and expenses up to $2.0&#160;million. This termination fee and expense reimbursement may discourage third parties from submitting competing proposals to Catalyst or its stockholders, and may cause the Catalyst board of directors to be less inclined to recommend a competing proposal.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">37<br></div></div></div>
<!--End Page 48-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 49-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Because the lack of a public market for BC&#8217;s common shares makes it difficult to evaluate the fair market value of BC&#8217;s common shares, Catalyst may pay more than the fair market value of the indirect controlling interest in BC and/or GNI USA and the Minority Holders may receive consideration in the Contributions that is less than the fair market value of their indirect ownership of BC.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The outstanding common shares of BC are privately held and are not traded in any public market. The lack of a public market makes it difficult to determine the fair market value of BC&#8217;s common shares. Because the percentage of Catalyst equity to be issued to GNI USA and the Minority Holders was determined based on negotiations between the parties, it is possible that the value of the Catalyst Common Stock to be received by GNI USA and the Minority Holders will be less than the fair market value of their indirect ownership of BC, or Catalyst may pay more than the aggregate fair market value for the indirect controlling interest in BC.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">The Contributions, taken together, may not qualify as a transaction governed by Section 351(a) of the Code for U.S. federal income tax purposes, resulting in recognition of taxable gain or loss by GNI USA.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As described in the section entitled &#8220;<font style="font-style: italic;">The Contributions&#8212;Material U.S. Federal Income Tax Consequences of the </font><font style="font-style: italic;">Contributions</font>&#8221; in this proxy statement, Catalyst, the Contributors and BC intend for the Contributions, taken together, to qualify as a transaction governed by Section 351(a) of the Code. However, the completion of the Contributions is not conditioned on the Contributions qualifying for the intended tax treatment or upon the receipt of an opinion of counsel to that effect. In addition, Catalyst, the Contributors and BC have not sought and do not intend to seek any opinions of counsel or rulings from the U.S. Internal Revenue Service, or IRS, regarding the intended tax treatment and, even if opinions of counsel were sought and obtained, such opinions would not be binding upon the IRS or a court. Consequently, there can be no assurance that the IRS will not challenge the intended tax treatment of the Contributions and, if challenged, that a court would not sustain the IRS&#8217; position. In the event that the Contributions do not so qualify, GNI USA generally would recognize gain or loss upon the contribution of CPI common stock and ordinary shares of Further Challenger in the Contributions equal to the difference between the fair market value of the shares of Catalyst Common Stock received in exchange for the CPI common stock and ordinary shares of Further Challenger in the Contributions and GNI USA&#8217;s adjusted tax basis in the shares of fair market value of the shares of CPI common stock and ordinary shares of Further Challenger surrendered. Determining the actual tax consequences of the Contributions to GNI USA and the other Contributors may be complex and will depend on the facts of each Contributor&#8217;s own circumstances. Each Contributor is urged to consult with his, her or its own tax advisor with respect to the tax consequences of the Contributions.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Foreign subsidiaries may directly become subject to U.S. federal income tax and be subject to a branch profits tax in the United States, which could reduce Catalyst&#8217;s after-tax returns and the value of Catalyst&#8217;s shares.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst currently intends to conduct substantially all of its businesses and operations in a manner such that any foreign subsidiaries, including BC and Further Challenger, will not be treated as engaged in a trade or business in the United States and will not be subject to additional U.S. income tax or branch profits tax. However, it is not entirely clear when a foreign subsidiary is treated as being engaged in a trade or business in the United States for U.S. federal income tax purposes. Accordingly, Catalyst cannot assure you that the IRS will not contend, perhaps successfully, that Catalyst&#8217;s foreign subsidiaries are engaged in a trade or business in the United States or are subject to more U.S. income tax than they currently incur. A foreign corporation deemed to be so engaged would be subject to U.S. federal income tax on its income that is treated as effectively connected with the conduct of that trade or business, as well as to branch profits tax on its &#8220;dividend equivalent amount,&#8221; unless the corporation is entitled to relief under an applicable tax treaty, which is determined on an annual basis.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">The U.S. federal income tax treatment of the CVRs is unclear, and there can be no assurance that the Internal Revenue Service would not assert, or that a court would not sustain, a position that could result in adverse U.S. federal income tax consequences to holders of the CVRs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The U.S. federal income tax treatment of the CVRs is unclear. There is no legal authority directly addressing the U.S. federal income tax treatment of the receipt of, and payments on, the CVRs, and there can be no assurance that the IRS would not assert, or that a court would not sustain, a position that could result in adverse U.S. federal income tax consequences to holders of the CVRs. As discussed in the section entitled &#8220;<font style="font-style: italic;">Agreements Related to the </font><font style="font-style: italic;">Contributions&#8212;CVR Agreement&#8212;Material U.S. Federal Income Tax Consequences of the Receipt of CVRs</font>,&#8221; Catalyst will treat the issuance of the CVRs as a distribution of property with respect to its stock. However, there is no authority directly addressing whether contingent value rights with characteristics similar to the CVRs should be </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">38<br></div></div></div>
<!--End Page 49-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 50-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">treated as a distribution of property with respect to the corporation&#8217;s stock, a distribution of equity, a &#8220;debt instrument&#8221; or an &#8220;open transaction&#8221; for U.S. federal income tax purposes. In addition, although Catalyst will estimate the value of the CVRs for purposes of reporting the distribution on Form 1099 to Catalyst stockholders, the value of the CVRs is uncertain, and the IRS or a court could determine that the value of the CVRs at the time of issuance was higher. In such case, the Catalyst stockholders could be treated as having additional income or gain upon receipt of the CVRs as described further in the section entitled &#8220;<font style="font-style: italic;">Agreements Related to the Contributions&#8212;CVR </font><font style="font-style: italic;">Agreement&#8212;Material U.S. Federal Income Tax Consequences of the Receipt of CVRs</font>&#8221; beginning on page <a href="#tMUF">157</a> of this proxy statement. Further, notwithstanding Catalyst&#8217;s position that the receipt of CVRs and the proposed reverse stock split are appropriately treated as separate transactions, it is possible that the IRS or a court could determine that the Catalyst stockholders&#8217; receipt of the CVRs and the proposed reverse stock split constitute a single &#8220;recapitalization&#8221; for U.S. federal income tax purposes. No assurance can be given that the IRS would not assert, or that a court would not sustain, a position contrary to Catalyst&#8217;s position, which could result in adverse U.S. federal income tax consequences to holders of the CVRs. The tax consequences of such alternative treatments are described below under the section entitled &#8220;<font style="font-style: italic;">Agreements Related to the Contributions&#8212;CVR Agreement&#8212;Material U.S. Federal Income Tax </font><font style="font-style: italic;">Consequences of the Receipt of CVRs</font>,&#8221; beginning on page <a href="#tMUF">157</a> of this proxy statement.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Catalyst may be subject to a new 1% U.S. federal excise tax in connection with the issuance of the CVRs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On August&#160;16, 2022, President Biden signed into law the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;), which, among other things, imposes a 1% excise tax (the &#8220;Excise Tax&#8221;) on certain repurchases of stock by publicly-traded domestic corporations. The Excise Tax will apply to repurchases occurring in 2023 and beyond. The amount of the Excise Tax is generally 1% of the fair market value of the repurchased stock at the time of the repurchase. The U.S. Department of the Treasury has authority to provide regulations and other guidance to carry out, and prevent the abuse or avoidance of, the Excise Tax. On December&#160;27, 2022, the U.S. Department of the Treasury issued Notice 2023-2, which provides interim guidance regarding the application of the Excise Tax pending forthcoming proposed regulations. Catalyst is in the process of performing an analysis of the Company's earnings and profits and some or all of the issuance of the CVRs could be treated as a dividend for U.S. federal income tax purposes if Catalyst determines that it has current or accumulated earnings and profits. Any portion of the issuance of CVRs that is not treated as a dividend may be subject to the 1% Excise Tax under the IRA.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The extent of the Excise Tax that Catalyst may incur would depend on a number of factors, including the extent such issuances could be treated as dividends and not repurchases, fair market value of the Catalyst Common Stock treated as being redeemed (if any), and the content of any regulations and other guidance from the U.S. Department of the Treasury that may be issued and applicable to such issuances. In addition, the amount of Excise Tax imposed with respect to repurchases of stock by a repurchasing corporation may be reduced by the fair market value of stock issued by the repurchasing corporation during the same taxable year. Absent the issuance of applicable guidance to the contrary, Catalyst currently expects that this reduction may be available with respect to the issuance of the Catalyst Common Stock in the Contributions. It is possible, however, that applicable guidance is issued that would prevent or limit the potential application of this rule.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Excise Tax is imposed on the repurchasing corporation itself, not the investors from which shares are repurchased, and the mechanics of any required payment of the Excise Tax have not yet been determined. The imposition of the Excise Tax, if any, with respect to the issuance of the CVRs could reduce the amount of cash available to Catalyst and have a material adverse effect on liquidity and operations.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Risks Related to the Proposed Reverse Stock Split </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">The reverse stock split may not increase the combined company&#8217;s stock price over the long-term.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The principal purpose of the reverse stock split is to increase the per-share market price of Catalyst&#8217;s common stock above the minimum bid price requirement under the Nasdaq rules so that the listing of the combined company and the shares of Catalyst Common Stock being issued in the Contributions on Nasdaq will be approved. It cannot be assured, however, that the reverse stock split will accomplish this objective for any meaningful period of time. While it is expected that the reduction in the number of outstanding shares of common stock will proportionally increase the market price of the combined company&#8217;s common stock, it cannot be assured that the reverse stock split will increase the market price of its common stock by a multiple of the reverse stock split ratio mutually agreed by Catalyst and BC, or result in any permanent or sustained increase in the market price of the combined company&#8217;s common stock, which is dependent upon many factors, including the combined company&#8217;s business and financial </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">39<br></div></div></div>
<!--End Page 50-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 51-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">performance, general market conditions and prospects for future success. Thus, while the stock price of the combined company might meet the listing requirements for Nasdaq initially, it cannot be assured that it will continue to do so.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The reverse stock split may decrease the liquidity of the combined company&#8217;s common stock.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Although Catalyst&#8217;s board of directors believes that the anticipated increase in the market price of the combined company&#8217;s common stock resulting from the proposed reverse stock split could encourage interest in its common stock and possibly promote greater liquidity for its stockholders, such liquidity could also be adversely affected by the reduced number of shares outstanding after the reverse stock split. The reduction in the number of outstanding shares may lead to reduced trading and a smaller number of market makers for the combined company&#8217;s common stock. In addition, the reverse stock split may not result in an increase in the combined company&#8217;s stock price necessary to satisfy Nasdaq&#8217;s initial listing requirements for the combined company.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The reverse stock split may lead to a decrease in the combined company&#8217;s overall market capitalization.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Should the market price of the combined company&#8217;s common stock decline after the reverse stock split, the percentage decline may be greater, due to the smaller number of shares outstanding, than it would have been prior to the reverse stock split. A reverse stock split is often viewed negatively by the market and, consequently, can lead to a decrease in the combined company&#8217;s overall market capitalization. If the per share market price does not increase in proportion to the reverse stock split ratio, then the value of the combined company, as measured by its stock capitalization, will be reduced. In some cases, the per-share stock price of companies that have effected reverse stock splits subsequently declined back to pre-reverse split levels, and accordingly, it cannot be assured that the total market value of the combined company&#8217;s common stock will remain the same after the reverse stock split is effected, or that the reverse stock split will not have an adverse effect on the combined company&#8217;s stock price due to the reduced number of shares outstanding after the reverse stock split.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Risks if the Adjournment Proposal is Not Approved</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If the Adjournment Proposal is not approved, and an insufficient number of votes have been obtained to authorize the consummation of the Contributions, the Catalyst board of directors will not have the ability to adjourn the special meeting of stockholders to a later date in order to solicit further votes, and, therefore, the Contributions will not be approved, and, therefore, the Contributions may not be consummated.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Catalyst board of directors is seeking approval to adjourn the special meeting of stockholders to a later date or dates if, at the special meeting of stockholders, based upon the tabulated votes, there are insufficient votes to approve each of the Condition Precedent Proposals. If the Adjournment Proposal is not approved, the Catalyst board of directors will not have the ability to adjourn the extraordinary general meeting to a later date and, therefore, will not have more time to solicit votes to approve the Condition Precedent Proposals. In such events, the Contributions would not be completed.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><u>Risks Related to Catalyst</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As described below, if the Contributions are not completed, Catalyst will reconsider its strategic alternatives, including dissolving and liquidating its assets, pursuing another strategic transaction, or operating its business. If the Contributions are not completed, Catalyst will face various risks related to its financial condition and need for capital; its ability to execute on alternative strategies; discovery, development and commercialization of its product candidates; its intellectual property; regulatory and compliance matters; and its status as a public company, all as further discussed in the Risk Factors, including this subsection entitled &#8220;&#8212;Risks Related to Catalyst.&#8221;<font style="font-style: normal;"> </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Unless the context otherwise requires, references to &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; in this subsection &#8220;&#8212;Risks Related to Catalyst&#8221; generally refer to Catalyst in the present tense and the post-combination Company from and after the Contributions.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Risks Related to Catalyst&#8217;s Financial Condition and Capital Requirements</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst has incurred significant losses since its inception and is expected to continue to incur significant losses for the foreseeable future.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst is a preclinical-stage biotechnology company and has not yet generated significant revenues. Catalyst has incurred net losses in each year since its inception in August 2002, including net losses of $8.2&#160;million and $87.9&#160;million for the years ended December&#160;31, 2022 and 2021, respectively. As of December&#160;31, 2022 and March&#160;31, 2023, Catalyst had an accumulated deficit of $410.9&#160;million and $410.7 million, respectively.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">40<br></div></div></div>
<!--End Page 51-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 52-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Even after the F351 Acquisition, Catalyst is still in the early stages of development of its product candidates, and has no products approved for commercial sale. To date, Catalyst has financed its operations primarily through issuances of shares of common stock, from private placements of convertible preferred stock, and from payments under collaboration agreements.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst has devoted most of its financial resources to research and development, including its preclinical and clinical development activities. If the Contributions are not consummated, Catalyst expects to continue to incur significant expenses and operating losses over the next several years as it continues the development of its complement product candidates. Catalyst&#8217;s operating losses may fluctuate significantly from quarter to quarter and year to year. Catalyst is expected to continue to incur significant expenses and operating losses for at least the next several years as it:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">continues clinical development of Hydronidone;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">further develops the manufacturing process for its product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">attracts, hires and retains skilled personnel&#894;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">seeks regulatory and marketing approvals for any of its product candidates that successfully complete clinical studies&#894;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">acquires or in-licenses other product candidates and technologies&#894;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">maintains, protects and expands its intellectual property portfolio&#894;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">creates additional infrastructure to support operations as a public company and its product development and planned future commercialization efforts&#894; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">experiences any delays or other issues with any of the above.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">To become and remain profitable, Catalyst must succeed in developing and eventually commercializing products that generate significant revenue. This will require Catalyst to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling any products for which regulatory approval is obtained. Catalyst is only in the preliminary stages of most of these activities. Catalyst may never succeed in these activities and, even if it does, it may never generate revenues that are significant enough to achieve profitability.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, Catalyst is unable to accurately predict the timing or amount of increased expenses or when, or if, Catalyst will be able to achieve profitability. Even if Catalyst does achieve profitability, Catalyst may not be able to sustain or increase profitability on a quarterly or annual basis. Failure to become and remain profitable would depress the value of Catalyst&#8217;s common stock and could impair Catalyst&#8217;s ability to raise capital, expand its business, maintain research and development efforts, diversify product offerings or even continue operations. A decline in the value of Catalyst&#8217;s common stock could also cause you to lose all or part of your investment.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If the Contributions are not completed, Catalyst will reconsider its strategic alternatives, including dissolving and liquidating its assets, pursuing another strategic transaction, or operating its business. Catalyst&#8217;s future capital requirements depend on many factors, and adequate additional financing may not be available to it on acceptable terms, or at all.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst expects to devote significant time and resources to the completion of the Contributions. However, there can be no assurances that such activities will result in the completion of the Contributions. If the Contributions are not completed, Catalyst will reconsider its strategic alternatives. Catalyst considers one of the following courses of action to be the most likely alternatives if the Contributions are not completed:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Dissolve and liquidate its assets<font style="font-style: normal;">. If, for any reason, the Contributions do not close, Catalyst&#8217;s board of directors </font><font style="font-style: normal;">may conclude that it is in the best interest of stockholders to dissolve the company and liquidate its assets. In </font><font style="font-style: normal;">that event, Catalyst would be required to pay all of its debts and contractual obligations, and to set aside certain </font><font style="font-style: normal;">reserves for potential future claims. There would be no assurances as to the amount or timing of available cash </font><font style="font-style: normal;">remaining to distribute to stockholders after paying Catalyst&#8217;s obligations and setting aside funds for reserves.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Pursue another strategic transaction<font style="font-style: normal;">. Catalyst may resume the process of evaluating a potential strategic </font><font style="font-style: normal;">transaction in order to attempt another strategic transaction like the Contributions.</font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">41<br></div></div></div>
<!--End Page 52-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 53-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">Operate its business<font style="font-style: normal;">. Catalyst&#8217;s board of directors may elect to seek new product candidates for development.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Raise additional capital<font style="font-style: normal;">. Catalyst may </font><font style="font-style: normal;">raise additional capital to fund its development of Hydronidone, which </font><font style="font-style: normal;">may be dilutive to Catalyst stockholders. For details regarding the risks related to raising additional capital, see </font><font style="font-style: normal;">the Risk Factor entitled &#8220;&#8212;</font>Catalyst will need additional capital to continue product development and may not be able to do so. If Catalyst is unable to raise sufficient capital, it will be forced to delay, reduce or eliminate product development programs.<font style="font-style: normal;">&#8221;</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If Catalyst&#8217;s board of directors elects to seek new product candidates for development, Catalyst expects that it would incur significant research and development expenses. If Catalyst is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate any such future research and development programs or commercialization efforts and/or Catalyst could be forced to revise or abandon its current business strategy.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Catalyst will need additional capital to continue product development and may not be able to do so. If Catalyst is unable to raise sufficient capital, it will be forced to delay, reduce or eliminate product development programs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. If Catalyst continues with preclinical and clinical development activities, it will continue to incur expenses related to the preclinical and clinical development of its complement product candidates. Catalyst believes that its available cash and cash equivalents will be sufficient to fund its operations for 12 months from the filing of this proxy statement, assuming Catalyst&#8217;s stockholders approve the conversion of Catalyst Convertible Preferred Stock. However, Catalyst expects to need to raise substantial additional capital to continue the clinical development of Hydronidone and depending on the availability of capital, may need to delay or cease development of some or all of its product candidates. Even if Catalyst raises additional capital, it may elect to focus its efforts on one or more development programs and delay or cease other development programs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Until Catalyst can generate sufficient revenue from its product candidates, if ever, it expects to finance future cash needs through public or private equity offerings, debt financings, corporate collaborations and/or licensing arrangements. Additional funds may not be available when Catalyst needs them on terms that are acceptable, or at all. If adequate funds are not available, Catalyst may be required to delay, reduce the scope of or eliminate some or all of its research or development programs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Because successful development of its product candidates is uncertain, Catalyst is unable to estimate the actual funds required to complete research and development and commercialize its products under development. Catalyst&#8217;s future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the costs and results of preclinical studies or clinical trials of Hydronidone or its other complement product candidates, and expenses related to potential clinical development of such candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the number and characteristics of product candidates that it pursues;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the costs it incurs related to the sale of its legacy assets or claims;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the terms and timing of any future collaboration, licensing or other arrangements that Catalyst may establish;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">its headcount and costs associated with hiring or retaining personnel;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the outcome, timing and cost of regulatory approvals;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the cost of obtaining, maintaining, defending and enforcing intellectual property rights, including patent rights;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the effect of competing technological and market developments;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the cost and timing of completing outsourced manufacturing activities;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">market acceptance of any product candidates for which Catalyst may receive regulatory approval;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which Catalyst may receive regulatory approval;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the costs of continuing to operate its business, including costs associated with being a public company; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the extent to which Catalyst acquires, licenses or invests in businesses, products or technologies.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">42<br></div></div></div>
<!--End Page 53-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 54-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">If the Contributions are not consummated, Catalyst will require additional capital to achieve its business objectives. Additional funds may not be available on a timely basis, on favorable terms or at all, and such funds, if raised, may not be sufficient to enable it to continue to implement Catalyst&#8217;s long-term business strategy. Any additional fundraising efforts may divert its management from their day-to-day activities, which may adversely affect its ability to develop and commercialize its product candidates. Further, its ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic or the conflict between Russia and Ukraine. If Catalyst is unable to raise sufficient additional capital, it could be forced to curtail its planned operations and the pursuit of its strategy.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Based on Catalyst&#8217;s public float, as of the date of Catalyst&#8217;s Form 10-K for the year ended December 31, 2022 filed with the SEC on March 30, 2023, Catalyst is only permitted to utilize a &#8220;shelf&#8221; registration statement on Form S-3, including the registration statement under which its Equity Distribution Agreement with Piper Sandler &amp; Co. is operated, subject to Instruction I.B.6 to Form S-3, which is referred to as the &#8220;baby shelf&#8221; rule. For so long as Catalyst&#8217;s public float is less than $75 million, it may not sell more than the equivalent of one-third of its public float during any 12 consecutive months pursuant to the baby shelf rules. Although alternative public and private transaction structures may be available, these may require additional time and cost, may impose operational restrictions on Catalyst, and may not be available on attractive terms.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As discussed above, if the Contributions are not completed, Catalyst will reconsider its strategic alternatives, including dissolving and liquidating its assets, pursuing another strategic transaction, or operating its business. If Catalyst&#8217;s board of directors elects to seek product candidates for development, Catalyst will face the risks related to discovery, development and commercialization of its product candidates set forth in this section, in addition to other risks described in this Risk Factors section.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Raising additional funds by issuing securities or through licensing arrangements may cause dilution to stockholders, restrict Catalyst&#8217;s operations or require Catalyst to relinquish proprietary rights.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">To the extent that Catalyst raises additional capital through the sale of equity or convertible debt securities, stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of common stockholders. Catalyst currently has in place an Equity Distribution Agreement with Piper Sandler &amp; Co. that permits it, subject to applicable SEC regulations, to issue up to $50.0&#160;million worth of shares of its common stock in &#8220;at the market&#8221; transactions at prevailing market prices.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Debt financing, if available at all, may involve agreements that include covenants limiting or restricting its ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If Catalyst raises additional funds through collaborations, strategic alliances or licensing arrangements with third&#160;parties, Catalyst may have to relinquish valuable rights to its technologies, product candidates or future revenue streams or grant licenses on terms that are not favorable to Catalyst. Catalyst may also seek to access the public or private capital markets whenever conditions are favorable, even if it does not have an immediate need for additional capital at that time. There can be no assurance that Catalyst will be able to obtain additional funding if, and when necessary. If Catalyst is unable to obtain adequate financing on a timely basis, Catalyst could be required to delay, curtail or eliminate one or more, or all, of its development programs or grant rights to develop and market product candidates that Catalyst would otherwise prefer to develop and market ourselves.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst currently has an effective registration statement on Form S-3 that allows Catalyst to offer up to $150.0&#160;million of securities in one or more offerings, subject to limitations under applicable SEC rules, including up to $50.0&#160;million of common stock issuable under its Equity Distribution Agreement with Piper Sandler &amp; Co. Any additional sales in the public market of its common stock or other securities under these shelf registration statements could adversely affect prevailing market prices for its common stock.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">SEC regulations limit the amount of funds Catalyst can raise during any 12-month period pursuant to its shelf registration statement on Form S-3.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">SEC regulations limit the amount that companies with a public float of less than $75 million may raise during any 12-month period pursuant to a shelf registration statement on Form S-3, referred to as the &#8220;baby shelf&#8221; rules. Since the filing of Catalyst&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 30, 2023, Catalyst has been subject to such rules. Under these regulations, the amount of funds Catalyst can raise through primary public offerings of securities in any 12-month period using its registration statement on </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">43<br></div></div></div>
<!--End Page 54-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 55-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Form&#160;S-3, including the registration statement under which its Equity Distribution Agreement with Piper Sandler &amp; Co is operated, is limited to one-third of the aggregate market value of the shares of its common stock held by non-affiliates of the company. Therefore, Catalyst will be limited in the amount of proceeds it is able to raise by selling shares of its common stock using its Form S-3 until such time as its public float exceeds $75 million. Furthermore, if Catalyst is required to file a new registration statement on another form, it may incur additional costs and be subject to delays due to review by the SEC staff.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Risks Related to Catalyst&#8217;s Business Operations and Product Candidates</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst has no history of obtaining regulatory approval or commercialization of pharmaceutical products, and it may be unable to do so for any product candidates Catalyst acquires or develops, including Hydronidone, which may make it difficult to evaluate Catalyst&#8217;s prospects.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst began operations in August 2002. Catalyst&#8217;s operations to date have been limited to financing and staffing Catalyst, developing its technology and product candidates, establishing collaborations and conducting Phase 2 clinical trials on small numbers of patients. Catalyst has not yet demonstrated an ability to successfully conduct a Phase 3 clinical trial, obtain marketing approvals, manufacture a product at commercial scale repeatedly, or arrange for a third party to do so on its behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions about Catalyst&#8217;s future product development timelines, clinical trial plans, expenses, success or viability may not be as accurate as they could be if Catalyst had a longer operating history or a history of successfully developing and commercializing pharmaceutical products.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If Catalyst is required to conduct additional preclinical studies or clinical trials of Hydronidone beyond those that Catalyst currently contemplates, if Catalyst is unable to successfully complete clinical trials of Hydronidone or other testing, or if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, Catalyst may:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">be delayed in obtaining regulatory approval from the FDA, EMA or other regulatory authorities for Hydronidone;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">not obtain regulatory approval at all and lose its ability to further develop and commercialize Hydronidone;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">obtain regulatory approval for indications or patient populations that are not as broad as intended or desired;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">continue to be subject to post-marketing testing requirements from the FDA, EMA or other regulatory authorities; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">experience having the product removed from the market after obtaining regulatory approval.</div></td></tr></table><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: justify;">Catalyst is substantially dependent on the success of its lead product candidate, Hydronidone, and its future clinical trials may not be successful.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s future success is substantially dependent on its ability to timely obtain marketing approval for, and then successfully commercialize, Hydronidone, Catalyst&#8217;s lead product candidate. Catalyst expects to invest a majority of its efforts and financial resources into the research and development of Hydronidone. Catalyst is planning to initiate a Phase 2a, Proof-of-Concept (&#8220;PoC&#8221;) clinical trial in late 2023 to evaluate the safety, tolerability, PK, and PD of Hydronidone for patients with advanced liver fibrosis associated with noncirrhotic NASH. The FDA has provided pre-IND advice on the design of the planned Phase 2a trial of Hydronidone and provided clear guidance on the requirements for the IND filing. If Catalyst observes positive trends in the Phase 2a trial of Hydronidone, it expects to initiate a Phase 2 trial of Hydronidone.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Hydronidone will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, marketing approval in multiple jurisdictions, substantial investment and significant marketing efforts before Catalyst generates any revenues from product sales. Catalyst is not permitted to market or promote Hydronidone, or any other product candidates, before Catalyst receives marketing approval from the FDA and comparable foreign regulatory authorities, and Catalyst may never receive such marketing approvals.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The success of Hydronidone will depend on a variety of factors. Catalyst does not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to Catalyst&#8217;s intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any future collaborator. Accordingly, Catalyst cannot assure you that it will ever be able to generate revenue through the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">44<br></div></div></div>
<!--End Page 55-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 56-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">sale of Hydronidone, even if approved. If Catalyst is not successful in commercializing Hydronidone, or is significantly delayed in doing so, Catalyst&#8217;s business will be materially harmed.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">If Catalyst experiences delays or difficulties in the commencement of clinical trials or patient enrollment in clinical trials, its regulatory approvals could be delayed or prevented.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst or its collaborators may not be able to initiate or continue clinical trials for its product candidates if Catalyst is unable to locate, enroll and maintain enrollment of a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. Furthermore, there are inherent difficulties in enrolling NASH patients, which can currently only be definitively diagnosed through a liver biopsy. Specifically, identifying patients most likely to meet NASH enrollment criteria on biopsy is an on-going challenge, with existing clinical indicators lacking both sensitivity and specificity. As a result, NASH trials often suffer from high levels of screen failure following central review of the baseline liver biopsy, which can lead to lower enrollment. As a result of such difficulties and the significant competition for recruiting NASH patients in clinical trials, Catalyst or its future collaborators may be unable to enroll the patients Catalyst needs to complete clinical trials on a timely basis, or at all. In addition, Catalyst&#8217;s competitors, some of whom have significantly greater resources than Catalyst does, are conducting clinical trials for the same indications and seek to enroll patients in their studies that may otherwise be eligible for Catalyst&#8217;s clinical studies or trials. Since the number of qualified clinical investigators is limited, Catalyst expects to conduct some of its clinical trials at the same clinical trial sites that some of Catalyst&#8217;s competitors use, which could further reduce the number of patients who are available for Catalyst&#8217;s clinical trials in these sites. The availability of other approved products and other products in clinical trials have and may limit the number of patients willing to participate in Catalyst&#8217;s clinical trials.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Patient enrollment is affected by other factors including:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the severity of the disease under investigation;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the eligibility criteria for the study in question;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the perceived risks and benefits of the product candidate under study;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the efforts to facilitate timely enrollment in clinical trials;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">clinical trials of other product candidates in the same indication;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">laboratory testing and turnaround time for samples needed for eligibility assessments;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the patient referral practices of physicians;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the ability to monitor patients adequately during and after treatment; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the proximity and availability of clinical trial sites for prospective patients.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s inability to enroll a sufficient number of patients for its clinical trials will result in significant delays and could require Catalyst to abandon one or more clinical trials altogether. Enrollment delays in clinical trials conducted by Catalyst may also result in increased development costs for its product candidates, which would cause the value of Catalyst to decline and limit its ability to obtain additional financing.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Geopolitical events and global economic conditions, public health crises such as COVID-19, and the conflict between Russia and Ukraine may impact Catalyst&#8217;s third-party supply of the raw materials and components needed for its product candidates which increases the risk that Catalyst will not have sufficient quantities of such product candidates or products or such quantities at an acceptable cost, which delay, prevent or impair its development efforts.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If supplies of the raw materials for its product candidates are significantly delayed, or if the third parties that Catalyst engages to supply any materials or to manufacture any products for its preclinical tests and clinical trials should cease to continue to do so for any reason, including due to the effects of global economic conditions, including inflation and rising interest rates, public health crises such as the COVID-19 pandemic, and the conflict between Russia and Ukraine, Catalyst likely would experience delays in advancing these tests and trials while Catalyst identifies and qualifies replacement suppliers or manufacturers and Catalyst may be unable to obtain replacement supplies on terms that are favorable to Catalyst. In addition, if Catalyst is not able to obtain adequate supplies of its product candidates or the substances used to manufacture them, it will be more difficult for Catalyst to develop its product candidates and compete effectively.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">45<br></div></div></div>
<!--End Page 56-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 57-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s current and anticipated dependence upon third-party suppliers may adversely affect its ability to develop product candidates and could delay its clinical trials and development programs, and otherwise harm its operations and financial condition and increase its costs and expenses.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Risks Related to the Discovery, Development and Commercialization of Catalyst&#8217;s Product Candidates</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst may expend its limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Because Catalyst has limited financial and management resources, Catalyst must focus on development programs and product candidates that Catalyst identifies for specific indications. As such, Catalyst is currently primarily focused on the development of Hydronidone. As a result, Catalyst may forego or delay pursuit of opportunities with other product candidates or for other indications for these product candidates that later prove to have greater commercial potential. Catalyst&#8217;s resource allocation decisions may cause Catalyst to fail to capitalize on viable commercial products or profitable market opportunities. Catalyst&#8217;s spending on current and future development programs and product candidates for specific indications may not yield any commercially viable products. If Catalyst does not accurately evaluate the commercial potential or target market for a particular product candidate, Catalyst may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for Catalyst to retain sole development and commercialization rights to such product candidate.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Catalyst may not be successful in its efforts to build a pipeline of additional product candidates.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst may not be able to continue to identify and develop new product candidates in addition to its current pipeline. Even if Catalyst is successful in continuing to build its pipeline, the potential product candidates that Catalyst identifies may not be suitable for clinical development. For example, product candidates may be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be successfully developed, much less receive marketing approval and achieve market acceptance. If Catalyst does not successfully develop and commercialize product candidates based upon its approach, Catalyst will not be able to obtain product revenue in future periods, which likely would result in significant harm to its financial position and adversely affect its stock price. Clinical drug development involves a lengthy and expensive process with an uncertain outcome.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Results from preclinical or early stage clinical trials, including the results of BC&#8217;s preclinical testing and early clinical trials of Hydronidone, may not be confirmed in later trials or be predictive of the success of later clinical trials, including the results of Hydronidone&#8217;s later clinical trials. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The outcome of preclinical studies and early clinical trials may not be predictive of the success of late-stage clinical trials. Trials of Catalyst&#8217;s product candidates in larger numbers of patients may not have similar efficacy results and could result in adverse effects that were not observed in the earlier trials with smaller numbers of patients.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst will be required to demonstrate substantial evidence through well-controlled clinical trials that Catalyst&#8217;s Hydronidone is safe and effective before Catalyst can seek marketing approvals for Hydronidone&#8217;s commercial sale. Demonstrations of efficacy or an acceptable safety profile in BC&#8217;s prior preclinical studies does not mean that future clinical trials will yield the same results. For instance, Catalyst does not know whether Hydronidone will perform in future clinical trials as Hydronidone has performed in preclinical studies and early clinical trials conducted by BC, and, despite Hydronidone&#8217;s Phase 1 trial in the United States demonstrating tolerability and PK and BC&#8217;s Phase 2 clinical trial in the PRC demonstrating results in the reversal of HBV-associated fibrosis, to date, there is no effective clinical therapy for liver fibrosis, and no specific therapeutic drugs have been approved worldwide. Product candidates, including Hydronidone, may fail to demonstrate in later-stage clinical trials sufficient safety and efficacy to the satisfaction of the FDA and other comparable foreign regulatory authorities despite having progressed through preclinical studies and earlier stage clinical trials. Regulatory authorities may also limit the scope of later-stage trials until Catalyst has demonstrated satisfactory safety or efficacy results in earlier-stage trials. In particular, in late 2023, we plan to initiate a Phase 2a PoC clinical trial to evaluate the safety, tolerability, PK, and initial efficacy of Hydronidone in patients with advanced liver fibrosis associated with noncirrhotic NASH. The FDA has reviewed the planned Phase 2a trial of Hydronidone and provided clear guidance on the design and trial assessment as well as requirements for the IND filing. If Catalyst observes positive trends in the Phase 2a trial of Hydronidone, it expects to initiate a larger Phase 2 trial in Hydronidone. Although data from liver fibrosis associated with chronic hepatitis&#160;B (&#8220;CHB&#8221;) patients in BC&#8217;s Phase 2 clinical trial in the PRC demonstrated Hydronidone has the potential to improve </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">46<br></div></div></div>
<!--End Page 57-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 58-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">liver fibrosis, the efficacy of the Hydronidone in prior preclinical studies in a NASH model does not mean that future clinical trials will yield the same results. In addition to the pre-IND guidance provided, at the time of review of the IND application, the FDA may require additional investigations (nonclinical) and analyses (both nonclinical and clinical, including the analysis of the supportive clinical trials conducted in the PRC) before it accepts the IND file to ensure that there is sufficient and adequate information on the risks to human subjects. Such additional requests may delay the timelines for the IND filing and initiation of the planned Phase 2a trial in NASH fibrosis. Furthermore, if the FDA believes that additional data is necessary to supplement Catalyst&#8217;s clinical study data and Phase 2a clinical trial data, then the FDA may require Catalyst to conduct additional trials before expanding into a broader Phase 2 clinical trial. There is no guarantee that the FDA and other comparable foreign regulatory authorities will consider the data that is expected to be obtained in the planned Phase 2a trial in the United States sufficient to allow Catalyst to expand the development of Hydronidone in a larger Phase 2 or confirmatory Phase 3 clinical trial. Even if Catalyst is able to initiate Catalyst&#8217;s planned clinical trials on schedule, there is no guarantee that Catalyst will be able to complete such trials on the timelines Catalyst anticipates or that such trials will produce positive results. Any limitation on Catalyst&#8217;s ability to conduct clinical trials could delay or prevent regulatory approval or limit the size of the patient population to which Catalyst may market Catalyst&#8217;s product candidates, if approved. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage NASH clinical trials after achieving positive results in earlier development, and Catalyst may face similar setbacks. The likelihood of obtaining regulatory approval can only be determined from data obtained in clinical trials and the totality of evidence on the efficacy and safety of a product. Many companies that believed their product candidates performed satisfactorily in preclinical studies and early clinical trials have nonetheless failed to obtain marketing approval for the product candidates. Even if Catalyst believes that the results of clinical trials for its product candidates warrant marketing approval, the FDA or comparable foreign regulatory authorities may disagree and may not grant marketing approval of its product candidates without conducting additional studies.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. Any Phase 2, Phase 3 or other clinical trials that Catalyst may conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market its product candidates.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: justify;">Preliminary, &#8220;top-line&#8221; or interim data from Catalyst&#8217;s clinical trials that it announces or publishes from time to time may change as more patient data become available and are subject to audit and verification procedures.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">From time to time, Catalyst may publicly disclose preliminary or top-line data from Catalyst&#8217;s clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data. Catalyst also makes assumptions, estimations, calculations and conclusions as part of Catalyst&#8217;s analyses of these data without the opportunity to fully and carefully evaluate complete data. As a result, the preliminary or top-line results that Catalyst reports may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated or subsequently made subject to audit and verification procedures.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Any preliminary or top-line data should be viewed with caution until the final data are available. From time to time, Catalyst may also disclose interim data from Catalyst&#8217;s preclinical studies and clinical trials. Interim data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from Catalyst&#8217;s clinical trials continue other treatments. Further, others, including regulatory agencies, may not accept or agree with Catalyst&#8217;s assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate and Catalyst&#8217;s company in general. In addition, the information Catalyst chooses to publicly disclose regarding a particular preclinical study or clinical trial is based on what is typically extensive information, and you or others may not agree with what Catalyst determines is material or otherwise appropriate information to include in Catalyst&#8217;s disclosure. If the preliminary, top-line or interim data that Catalyst reports differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, Catalyst&#8217;s ability to obtain approval for, and commercialize, Catalyst&#8217;s product candidates may be harmed, which could harm Catalyst&#8217;s business, operating results, prospects or financial condition.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">47<br></div></div></div>
<!--End Page 58-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 59-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">A variety of risks associated with marketing Catalyst&#8217;s product candidates internationally may materially adversely affect Catalyst&#8217;s business.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst may also plan to eventually seek regulatory approval of Catalyst&#8217;s Hydronidone outside of the United States and, accordingly, Catalyst expects that it will be subject to additional risks related to operating in foreign countries if Catalyst obtains the necessary approvals, including differing regulatory requirements in foreign countries. Risks associated with international operations may materially adversely affect Catalyst&#8217;s business, financial condition and results of operations.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s product candidates, including Hydronidone, may cause significant adverse events, toxicities or other undesirable side effects that may result in a safety profile that could prevent regulatory approval, marketing approval or market acceptance, or limit their commercial potential.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If Catalyst&#8217;s product candidates, including Hydronidone, are associated with undesirable side effects or have unexpected characteristics in preclinical studies or clinical trials when used alone or in combination with other approved products or INDs, Catalyst may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may prevent Catalyst from achieving or maintaining market acceptance of the affected product candidate and may adversely affect Catalyst&#8217;s business, financial condition and prospects significantly.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In general, the anticipated clinical trials of Hydronidone will include patients with advanced liver fibrosis who are at risk of further progression to cirrhosis and deterioration, but are not critically ill. A certain percentage of patients with HBV-induced liver fibrosis treated with Hydronidone have experienced adverse events, including gastrointestinal diseases, ear and labyrinth diseases, systemic diseases, metabolic and nutritional diseases, skin and subcutaneous tissue diseases, heart organ diseases, and hepatobiliary system diseases. However, the risk/benefit of Hydronidone in NASH may differ from that shown in HBV liver fibrosis patients and there is always a risk that the severity and frequency of the adverse events may worsen. See the section entitled &#8220;<font style="font-style: italic;">Catalyst&#8217;s </font><font style="font-style: italic;">Business&#8212;Hydronidone Overview</font>.&#8221;</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Adverse events or deaths in clinical trials involving Catalyst&#8217;s product candidates, even if not ultimately attributable to Catalyst&#8217;s product or product candidates, could result in increased government regulation, unfavorable public perception and publicity, potential regulatory delays in the testing or licensing of Catalyst&#8217;s product candidates, stricter labeling requirements for those product candidates that are licensed and a decrease in demand for any such product candidates.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Additionally, if one or more of Catalyst&#8217;s product candidates receives marketing approval and Catalyst or others later identify undesirable side effects or adverse events caused by such products, a number of potentially significant negative consequences could result. For example, regulatory authorities may suspend, limit or withdraw approvals of such product or seek an injunction against its manufacture or distribution, require additional warnings on the label, including &#8220;boxed&#8221; warnings, or issue safety alerts, require press releases or other communications containing warnings or other safety information about the product, require Catalyst to change the way the product is administered or conduct additional clinical trials or post-approval studies, require Catalyst to create a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) which could include a medication guide outlining the risks of such side effects for distribution to patients, impose fines, injunctions or criminal penalties. Catalyst could also be sued and held liable for harm caused to patients, and Catalyst&#8217;s reputation may suffer. Any of these events could prevent Catalyst from achieving or maintaining market acceptance of the particular product candidate, if approved, and could seriously harm Catalyst&#8217;s business.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Breakthrough Therapy designation by the FDA for any product candidate may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that the product candidate will receive marketing approval.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Hydronidone was granted a Breakthrough Therapy designation by the PRC&#8217;s National Medical Products Administration&#8217;s (&#8220;NMPA&#8221;) Center for Drug Evaluation (&#8220;CDE&#8221;) in March 2021 and the patient enrollment for its Phase 3 clinical trial was commenced in January 2022. However, Hydronidone&#8217;s Breakthrough Therapy designation does not increase the likelihood that Hydronidone will ultimately receive approval from the NMPA or other comparable regulatory authority. Catalyst may, in the future, apply for Breakthrough Therapy designation in the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">48<br></div></div></div>
<!--End Page 59-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 60-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">United States, or the equivalent thereof in other foreign jurisdictions (where available), for its product candidates, depending on robustness of the clinical benefit in clinical trials. A Breakthrough Therapy is defined as a product candidate that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Product candidates designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the submission of the New Drug Application (&#8220;NDA&#8221;).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if Catalyst believes that one of its product candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. In addition, even if one or more of its product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidate no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Risks Related to Catalyst&#8217;s Reliance on Third Parties</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst expects to seek to establish additional collaborations, and, if Catalyst is not able to establish them on commercially reasonable terms, Catalyst may have to alter its development and commercialization plans.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s drug development programs and the potential commercialization of its product candidates will require substantial additional cash to fund expenses. Catalyst has previously relied on collaborators, such as Biogen, Pfizer and ISU, to contribute to the development of its product candidates. Catalyst may, in the future, form or seek strategic alliances, create joint ventures or collaborations, or enter into licensing arrangements with third parties that it believes will complement or augment Catalyst&#8217;s development and commercialization efforts with respect to Hydronidone and/or Catalyst more broadly. Any of these relationships may require Catalyst to increase its near and long-term expenditures, issue securities that dilute Catalyst&#8217;s existing stockholders or disrupt its management and business.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst faces significant competition in seeking appropriate collaborators. Whether Catalyst can reach a definitive agreement with a collaborator will depend, among other things, upon its assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of preclinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities and the regulatory pathway for any such approval, the potential market for the product candidate, the costs and complexities of manufacturing and delivering the product to patients and the potential of competing products. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available for collaboration and whether such a collaboration could be more attractive than the one with Catalyst. There can also be no assurance that Catalyst will enter into any collaboration agreements, or that any such agreements will be on favorable terms.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Collaborations are complex and time consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Catalyst may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If Catalyst is unable to do so, Catalyst may have to curtail the development of the product candidate for which Catalyst is seeking to collaborate, reduce or delay its development program or one or more of its other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, and increase its expenditures and undertake development or commercialization activities at its own expense. If Catalyst elects to increase its expenditures to fund development or commercialization activities on its own, Catalyst may need to obtain additional capital, which may not be available to Catalyst on acceptable terms or at all. If Catalyst does not have sufficient funds, Catalyst may not be able to further develop its product candidates or bring them to market and generate product revenue.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">49<br></div></div></div>
<!--End Page 60-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 61-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Catalyst contracts with third parties for the manufacture of its product candidates for preclinical testing and expects to continue to do so for clinical testing and commercialization. This reliance on third parties increases the risk that Catalyst will not have sufficient quantities or quality of its product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair its development or commercialization efforts.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst currently has no internal capabilities to manufacture its product candidates for clinical use or for preclinical trials following good manufacturing practices (&#8220;GMP&#8221;), or good laboratory practices (&#8220;GLP&#8221;). Catalyst expects to rely on one or more third-party contractors to manufacture, package, label and distribute clinical supplies and commercial quantities of any product candidate that Catalyst commercializes following approval for marketing by applicable regulatory authorities. Catalyst also expects to rely on one or more third-party contractors to manufacture its product candidates for use in its clinical trials. Reliance on such third-party contractors entails risks, including:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the inability to identify and negotiate manufacturing and supply agreements with suitable manufacturers;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">manufacturing delays if its third-party contractors give greater priority to the supply of other products over its product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between Catalyst and them;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the possible termination or nonrenewal of agreements by third-party contractors at a time that is costly or inconvenient for Catalyst;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the possible breach by the third-party contractors of its agreements with them;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the failure of third-party contractors to comply with applicable regulatory requirements;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the possible mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being properly identified;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the possibility of clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the possible misappropriation of its proprietary information, including its trade secrets and know-how.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst may incur delays in product development resulting from the need to identify or qualify manufacturers for its product candidates. Catalyst&#8217;s current and anticipated future dependence upon others for the manufacture of its product candidates may adversely affect its future profit margins and its ability to commercialize any products that receive marketing approval on a timely and competitive basis.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: justify;">Catalyst is subject to many manufacturing risks, any of which could substantially increase its costs and limit supply of its product candidates and any future products.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">To date, Catalyst&#8217;s product candidates have been manufactured by third-party manufacturers solely for preclinical studies and relatively small clinical trials. The process of manufacturing its complement associated therapeutic product candidates is complex, highly regulated and subject to several risks, including:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the manufacturing facilities in which its products are made could be adversely affected by equipment failures, labor and raw material shortages, financial difficulties of its contract manufacturers, including as a result of the evolving effects of the COVID-19 pandemic, natural disasters, power failures, local political unrest and numerous other factors; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">any adverse developments affecting manufacturing operations or the scale up of manufacturing operations for its products may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the supply of its product candidates. Catalyst may also have to record inventory write-offs and incur other charges and expenses for product candidates or drug substances that fail to meet specifications, undertake costly remediation efforts or seek costlier manufacturing alternatives.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Specifically, Catalyst plans to enter into various development, manufacturing and clinical supply services agreements with third-party manufacturers for drug substance and drug product manufacturing of its product candidate Hydronidone. If Catalyst&#8217;s third-party manufacturers are not able to provide sufficient quantities or quality of its of product candidates on a timely basis, or at all, whether due to production shortages or other supply delays or interruptions resulting from the ongoing COVID-19 pandemic or otherwise, its preclinical trials, clinical trials or regulatory approvals, as applicable, may be delayed. Significant portions of its research and development resources </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">50<br></div></div></div>
<!--End Page 61-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 62-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">are focused on manufacturing. If any of its third-party manufacturers experiences difficulties in scaling production or experiences product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error or improper storage conditions, the potential trials of the affected product candidate would be delayed, perhaps substantially, which could materially and adversely affect its business.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst has minimal process development capabilities and has access only to external manufacturing capabilities. Catalyst does not have, and Catalyst does not currently plan to acquire or develop, the facilities or capabilities to manufacture bulk drug substance or filled drug product for use in clinical trials or commercialization. Any delay or interruption in the supply of clinical trial material or preclinical trial material could delay the completion of clinical trials or preclinical trials, increase the costs associated with maintaining such trial programs and, depending upon the period of delay, require Catalyst to commence new clinical trials or preclinical trials at additional expense or terminate the trials completely.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Catalyst and its contract manufacturers will be subject to significant regulation with respect to manufacturing its products. The manufacturing facilities on which Catalyst will rely may not continue to meet regulatory requirements and have limited capacity.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">All entities involved in the preparation of therapeutics for clinical studies or commercial sale, including any contract manufacturers for its product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical studies must be manufactured in accordance with GMP. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of its product candidates that may not be detectable in final product testing. Catalyst or its contract manufacturers must supply all necessary documentation in support of an NDA on a timely basis and must adhere to the FDA&#8217;s GLP and GMP regulations enforced by the FDA through its facilities inspection program. Catalyst&#8217;s facilities and quality systems and the facilities and quality systems of some or all its third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of its product candidates. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of its product candidates or the associated quality systems for compliance with the regulations applicable to the activities being conducted. If these facilities do not pass a pre-approval plant inspection or do not have a GMP compliance status acceptable for the FDA, FDA approval of the products will not be granted.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The regulatory authorities also may, at any time following approval of a product for sale, audit its manufacturing facilities or those of its third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of its product specifications or applicable regulations occurs independent of such an inspection or audit, Catalyst or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for Catalyst or a third-party to implement and that may include the temporary or permanent suspension of a clinical study or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon Catalyst or third parties with whom Catalyst contracts could materially harm its business.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If Catalyst or any of its third-party manufacturers fails to maintain regulatory compliance, the FDA can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new drug product or biologic product, or revocation of a pre-existing approval. As a result, its business, financial condition and results of operations may be materially harmed.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Additionally, if supply from one approved manufacturer is interrupted, there could be a significant disruption in commercial supply. An alternative manufacturer would need to be qualified through a NDA supplement which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in its desired clinical and commercial timelines.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">These factors could cause the delay of clinical studies, regulatory submissions, required approvals or commercialization of its product candidates, cause Catalyst to incur higher costs and prevent Catalyst from commercializing its products successfully. Furthermore, if its suppliers fail to meet contractual requirements, and Catalyst is unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, its clinical studies may be delayed, or Catalyst could lose potential revenue.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">51<br></div></div></div>
<!--End Page 62-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 63-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Catalyst relies on third parties to conduct certain aspects of its preclinical studies and any clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such tasks or trials.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst relies on third parties such as contract research organizations (&#8220;CROs&#8221;), medical institutions and clinical investigators to conduct certain aspects of preclinical development, including assay development and testing, and to enroll qualified patients and conduct, supervise and monitor clinical trials. Catalyst&#8217;s reliance on these third parties for preclinical and clinical development activities reduces its control over these activities. Catalyst&#8217;s reliance on these third parties, however, will not relieve Catalyst of its regulatory responsibilities, including ensuring that its clinical studies are conducted in accordance with good clinical practices, and the investigational plan and protocols contained in the relevant regulatory application, such as an investigational new drug application (&#8220;IND&#8221;). In addition, the CROs with whom Catalyst contracts may not complete activities on schedule or may not conduct its preclinical studies or clinical studies in accordance with regulatory requirements or its clinical study design. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, its efforts to complete development and obtain regulatory approvals for, and to commercialize, its product candidates may be delayed or prevented.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Risks Related to Employee Matters, Managing Growth and Catalyst&#8217;s Business Operations</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s future success depends on its ability to retain key executives and to attract, retain and motivate qualified personnel.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon its ability to attract and retain highly qualified managerial, scientific and medical personnel. Catalyst is highly dependent on its executive management and scientific personnel. Catalyst does not maintain &#8220;key man&#8221; insurance policies on the lives of these individuals or the lives of any of its other employees. In addition, Catalyst will need to add personnel to achieve its business objectives. The loss of the services of any of its executive officers, other key employees, and its inability to find suitable replacements, or its inability to hire new clinical development and manufacturing personnel, could result in delays in product development and harm its business.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst conducts operations at its facility in the San Francisco Bay Area. This region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in its market is intense and may limit its ability to hire and retain highly qualified personnel on acceptable terms or at all.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">To induce valuable employees to remain at Catalyst, in addition to salary and cash incentives, Catalyst has provided stock options that vest over time. The value to employees of stock options that vest over time may be significantly affected by movements in Catalyst&#8217;s stock price that are beyond its control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite its efforts to retain valuable employees, members of management and scientific and development teams have terminated and may terminate their employment with Catalyst on short notice. Catalyst&#8217;s employees are under at-will employment arrangements, which means that any of its employees can leave employment with Catalyst at any time, with or without notice. Failure to retain, replace or recruit personnel could harm its business.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst is exposed to the risk of fraud or other misconduct by its employees, principal investigators, consultants and collaborators. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA and non-U.S. regulators, to provide accurate information to the FDA and non-U.S. regulators, to comply with healthcare fraud and abuse laws and regulations in the United States and abroad, to report financial information or data accurately or to disclose unauthorized activities to Catalyst. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained during clinical studies that could result in regulatory sanctions and cause serious harm to its reputation. It is not always possible to identify and deter employee misconduct, and the precautions Catalyst takes to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting Catalyst from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">52<br></div></div></div>
<!--End Page 63-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 64-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg20"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">regulations. If any such actions are instituted against Catalyst and Catalyst is not successful in defending itself or asserting its rights, those actions could have a significant impact on its business, including the imposition of significant fines or other sanctions.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Catalyst will continue to incur significant costs as a result of operating as a public company, and its management is required to devote substantial time to compliance initiatives.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As a public company, Catalyst has and will continue to incur significant legal, accounting and other expenses , including costs associated with public company reporting and corporate governance requirements, in order to comply with the rules and regulations imposed by the Sarbanes-Oxley Act and the Dodd-Frank Wall Street Reform and Consumer Protection, as well as rules implemented by the SEC and Nasdaq. Stockholder activism, the political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which Catalyst operates its business in ways that are not currently anticipated. Its management and other personnel need to devote a substantial amount of time to these compliance initiatives. In addition, these rules and regulations make it difficult and expensive for Catalyst to obtain director and officer liability insurance, and Catalyst may be required to incur substantial costs to maintain its current levels of such coverage. Catalyst expects that it will annually incur significant expenses to comply with the requirements imposed on Catalyst as a public company. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Risks Related to Catalyst&#8217;s Intellectual Property</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If Catalyst is unable to obtain, protect or enforce intellectual property rights related to its product candidates, Catalyst may not be able to compete effectively in its markets.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst relies upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to its product candidates. The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. Third parties may challenge the validity, enforceability or scope of its patents, which may result in those patents being narrowed or invalidated. The patent applications that Catalyst owns may fail to result in issued patents with claims that cover its product candidates in the United States or in other foreign countries. Furthermore, even if they are unchallenged, its patents and patent applications may not adequately protect its intellectual property, provide exclusivity for its product candidates or prevent others from designing around its claims. Certain of its patents also cover processes, for which enforcement can be difficult. Any of these outcomes could impair its ability to prevent competition from third parties that may have an adverse impact on its business.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If the patents or patent applications Catalyst holds or has in-licensed for its programs or product candidates are invalidated or fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for its product candidates, it could threaten its ability to commercialize future products. Further, if Catalyst encounters delays in regulatory approvals, the period of time during which Catalyst could market a product candidate under patent protection could be reduced. In addition, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20&#160;years after it is filed. Various extensions may be available; however the life of a patent, and the protection it affords, is limited. Once the patent life has expired for a product, Catalyst may be subject to competition from generic medications.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition to the protection afforded by patents, Catalyst relies on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that Catalyst elects not to patent and other elements of its product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. Catalyst seeks to protect its proprietary technology and processes, in part, by entering into confidentiality agreements with its employees, consultants, scientific advisors and contractors. Catalyst also seeks to preserve the integrity and confidentiality of its data and trade secrets by maintaining the physical security of its premises and physical and electronic security of its information technology systems. While Catalyst has confidence in these individuals, organizations and systems, agreements or security measures may be breached, and Catalyst may not have adequate remedies for any breach. In addition, its trade secrets may otherwise become known or be independently discovered by competitors.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Although Catalyst expects all of its employees and consultants to assign their applicable inventions to Catalyst, and all of its employees, consultants, advisors and any third parties who have access to its proprietary know-how, information or technology to enter into confidentiality agreements, Catalyst cannot provide guarantee that all such </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">53<br></div></div></div>
<!--End Page 64-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 65-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg21"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">agreements have been duly executed or that its trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to its trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of its trade secrets could impair its competitive position and may have a material adverse effect on its business. Additionally, if the steps taken to maintain its trade secrets are deemed inadequate, Catalyst may have insufficient recourse against third parties for misappropriating the trade secret. In addition, others may independently discover its trade secrets and proprietary information.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Further, filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and Catalyst&#8217;s intellectual property rights in some countries outside the United States are less extensive than those in the United States. In addition, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, Catalyst may encounter significant problems in protecting and defending its intellectual property both in the United States and abroad. If Catalyst is unable to prevent material disclosure of the non-patented intellectual property related to its technologies to third parties, and there is no guarantee that Catalyst will have any such enforceable trade secret protection, Catalyst may not be able to establish or maintain a competitive advantage in its market, which could materially adversely affect its business, results of operations and financial condition.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Third-party claims of intellectual property infringement or challenging the inventorship or ownership of its patents may prevent or delay its development and commercialization efforts.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and <font style="font-style: italic;">inter partes</font> reexamination proceedings before the USPTO, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which Catalyst is pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that its product candidates may be subject to claims of infringement of the patent rights of third parties.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Third parties may assert that the manufacture, use or sale of its product candidates infringes patents held by such third parties, or that Catalyst is employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to compositions of matter, materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of its product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that its product candidates or current products may infringe.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, Catalyst has received confidential and proprietary information from third parties, and Catalyst employs individuals who were previously employed at other biotechnology or pharmaceutical companies. Catalyst may be subject to claims that its employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or its employees&#8217; former employers. Litigation may be necessary to defend against these claims.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Parties making claims against Catalyst may obtain injunctive or other equitable relief that could effectively block its ability to further develop and commercialize one or more of its product candidates unless Catalyst redesigned infringing products (which may be impossible) or obtained a license under the applicable patents (which may not be available on commercially reasonable terms or at all), or until such patents expire.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Catalyst may be involved in lawsuits to protect or enforce its patents.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Competitors may infringe Catalyst&#8217;s patents. To counter infringement or unauthorized use, Catalyst or its collaborators may be required to file infringement claims that can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one of Catalyst&#8217;s patents is not valid, is unenforceable and/or is not infringed, or may refuse to stop the other party from using the technology at issue on the grounds that its patents do not cover the technology in question. An adverse result in any litigation or defense proceeding could put one or more of Catalyst&#8217;s patents at risk of being invalidated or interpreted narrowly and could put its patent applications at risk of not issuing.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Interference proceedings provoked by third parties or brought by Catalyst may be necessary to determine the priority of inventions with respect to its patents or patent applications or those of its licensors. An unfavorable outcome could </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">54<br></div></div></div>
<!--End Page 65-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 66-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg22"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">require Catalyst to cease using the related technology or to attempt to license rights from the prevailing party. Catalyst&#8217;s business could be harmed if the prevailing party does not offer Catalyst a license on commercially reasonable terms. Catalyst may not be able to prevent, alone or with its licensors, misappropriation of its intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of its confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of its common stock.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Intellectual property litigation could cause Catalyst to spend substantial resources and distract its personnel from their normal responsibilities.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Even if resolved in Catalyst&#8217;s favor, litigation or other legal proceedings relating to intellectual property claims, regardless of their merit, would cause Catalyst to incur significant expenses, and could distract its technical and management personnel from their normal responsibilities. In the event of a successful claim of infringement against Catalyst, Catalyst may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, in addition to paying royalties, redesign infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of its common stock. Such litigation or proceedings could substantially increase its operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. Catalyst may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of its competitors may be able to sustain the costs of such litigation or proceedings more effectively than Catalyst can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise its ability to compete in the marketplace.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Catalyst may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">A third-party may hold intellectual property, including patent rights, that is important or necessary to the development of its products. It may be necessary for Catalyst to use the patented or proprietary technology of third parties to commercialize its products, in which case Catalyst would be required to obtain a license from these third parties on commercially reasonable terms, or its business could be harmed, possibly materially.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Risks Related to Regulatory Approval of Catalyst&#8217;s Product Candidates and Other Compliance Matters</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If Catalyst is not able to obtain, or if there are delays in obtaining, required regulatory approvals, Catalyst will not be able to commercialize its product candidates, including Hydronidone, and its ability to generate revenue will be materially impaired.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The process of obtaining regulatory approvals, both in the United States and abroad, is unpredictable, expensive and typically takes many years following commencement of clinical trials, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Hydronidone currently has one active IND application with the FDA in the United States for the treatment of liver fibrosis associated with a broad spectrum of chronic liver diseases. In the future, it is expected that an additional IND will be filed for Hydronidone specifically for NASH, and Catalyst may file additional IND applications for future indications or future product candidates. If any such future IND is not accepted by the FDA, Catalyst&#8217;s clinical development timeline may be negatively impacted and any future clinical programs may be delayed or terminated. As a result, Catalyst may be unable to obtain regulatory approvals or successfully commercialize its products. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst cannot guarantee that any preclinical studies and clinical trials will be conducted as planned or completed on schedule, if at all. The clinical development of its product candidates is susceptible to the risk of failure at any stage of drug development, including failure to demonstrate efficacy in a clinical trial or across a suitable population of patients, the occurrence of severe or medically or commercially unacceptable adverse events, failure to comply </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">55<br></div></div></div>
<!--End Page 66-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 67-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg23"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">with protocols or applicable regulatory requirements and determination by the FDA or any comparable foreign regulatory authority that a drug product is not approvable. It is possible that even if one or more of its product candidates has a beneficial effect, that effect will not be detected during clinical evaluation as a result of one or more of a variety of factors, including the size, duration, design, measurements, conduct or analysis of its clinical trials. Conversely, as a result of the same factors, its clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst cannot commercialize product candidates in the United States without first obtaining regulatory approval from the FDA. Similarly, Catalyst cannot commercialize product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of Catalyst&#8217;s product candidates, including Catalyst&#8217;s lead product candidate Hydronidone, Catalyst must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that Catalyst&#8217;s product candidates are both safe and effective for each targeted indication. Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Further, Catalyst&#8217;s product candidates, including Hydronidone, may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude Catalyst&#8217;s obtaining marketing approval. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that Catalyst&#8217;s data are insufficient for approval and require additional preclinical, clinical or other data. Catalyst&#8217;s product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of Catalyst&#8217;s clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; serious and unexpected drug-related side effects may be experienced by participants in Catalyst&#8217;s clinical trials or by individuals using drugs similar to Catalyst&#8217;s product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; the FDA or comparable foreign regulatory authorities may disagree with Catalyst&#8217;s interpretation of data from preclinical studies or clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the data collected from clinical trials of Catalyst&#8217;s product candidates may not be acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and Catalyst may be required to conduct additional clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the FDA or the applicable foreign regulatory authority may disagree regarding the formulation, labeling and/or the specifications of Catalyst&#8217;s product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which Catalyst contracts for clinical and commercial supplies; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering Catalyst&#8217;s clinical data insufficient for approval. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The approval requirements for Catalyst&#8217;s product candidates are likely to vary by jurisdiction such that success in one jurisdiction is not necessarily predicative of success elsewhere.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: justify;">Catalyst may experience delays in completing planned clinical trials for a variety of reasons, including delays related to:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the availability of financial resources to commence and complete the planned trials;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">inability to reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">56<br></div></div></div>
<!--End Page 67-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 68-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg24"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">obtaining approval at each clinical trial site by an independent institutional review board (&#8220;IRB&#8221;);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">recruiting suitable patients to participate in trials;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">having patients complete a trial or return for post-treatment follow-up;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">clinical trial sites deviating from trial protocol or dropping out of a trial;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adding new clinical trial sites&#894; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">manufacturing sufficient quantities of qualified materials under Current Good Manufacturing Practice (&#8220;cGMPs&#8221;) regulations and applying them on a subject-by-subject basis for use in clinical trials.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst could also experience delays in obtaining approval if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of its product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles given the serious nature of the diseases for the core indications for its product candidates. Additionally, a clinical trial may be suspended or terminated by Catalyst, the IRBs for the institutions in which the trials are being conducted, the Data Monitoring Committee for the trial, or by the FDA or other regulatory authorities for a number of reasons, including failure to conduct the clinical trial in accordance with regulatory requirements or its clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues, or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, the FDA review and approval process could be delayed by any future shutdown of the U.S. government, and its development activities could be harmed or delayed as a result. If Catalyst experiences termination of, or delays in the completion of, any clinical trial of its product candidates, its ability to commercialize its product candidates will be harmed and its ability to generate revenue will be materially impaired. Additionally, delays in completing trials will increase costs, delay Catalyst&#8217;s product development and approval process, and impair its ability to commence product sales and generate revenue. Many of the factors that could create or lead to a delay in the commencement or completion of clinical trials may lead to the denial of regulatory approval for its product candidates.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in Catalyst&#8217;s failing to obtain regulatory approval to market Catalyst&#8217;s product candidates, including Hydronidone, which would significantly harm Catalyst&#8217;s business, results of operations and prospects.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If Catalyst were to obtain approval, regulatory authorities may approve any of Catalyst&#8217;s product candidates, including Hydronidone, for fewer or more limited indications than Catalyst requests, including failing to approve the most commercially promising indications, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. If Catalyst is not able to obtain, or if there are delays in obtaining, required regulatory approvals for Catalyst&#8217;s product candidates, including Hydronidone, Catalyst will not be able to commercialize, or will be delayed in commercializing, Catalyst&#8217;s product candidates and Catalyst&#8217;s ability to generate revenue will be materially impaired.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Catalyst is developing Hydronidone for the treatment of NASH, an indication for which there are no approved products. The requirements for approval of Hydronidone by the FDA and comparable foreign regulatory authorities may be difficult to predict and may change over time, which makes it difficult to predict the timing and costs of the clinical development.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst is developing Hydronidone for the treatment of NASH, an indication for which there are no approved products. Although there are guidelines issued by the FDA for the development of drugs for the treatment of NASH, the development of a novel product candidate such as Hydronidone may be more expensive and take longer than for other, better known or extensively studied product candidates. As other companies are in later stages of clinical trials for their potential NASH therapies, Catalyst expects that the path for regulatory approval for NASH therapies may continue to evolve in the near term as these other companies refine their regulatory approval strategies and interact with regulatory authorities. Such evolution may impact Catalyst&#8217;s future clinical trial designs, including trial size and endpoints, in ways that Catalyst cannot predict today. In particular, regulatory authority expectations about liver biopsy data may evolve especially as more information is published about the inherent variability in liver biopsy data. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">57<br></div></div></div>
<!--End Page 68-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 69-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg25"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Certain of Catalyst&#8217;s competitors have experienced regulatory setbacks for NASH therapies following communications from the FDA. Catalyst currently does not know the impact, if any, that these setbacks could have on the path for regulatory approval for NASH therapies generally or for Hydronidone. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s anticipated development costs would likely increase if development of Hydronidone or any future product candidate is delayed because Catalyst is required by the FDA to perform studies or trials in addition to, or different from, those that Catalyst currently anticipates, or make changes to ongoing or future clinical trial designs. In addition, if Catalyst is unable to leverage our safety database for NASH indications, Catalyst may be required to perform additional trials, which would result in increased costs and may affect the timing or outcome of its clinical trials. In addition, Hydronidone may not be developed as a monotherapy, but as a part of a combination therapy, which will add to the complexity of clinical development and may cause further delays in Hydronidone&#8217;s development and affect Catalyst&#8217;s costs and divert management&#8217;s resources.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">If Catalyst is required by the FDA to obtain approval of a companion diagnostic test in connection with approval of any of Catalyst&#8217;s product candidates, including Hydronidone, and Catalyst fails to obtain or face delays in obtaining FDA approval of a diagnostic device, Catalyst will not be able to commercialize such product candidate and Catalyst&#8217;s ability to generate revenue will be materially impaired.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If safe and effective use of any of Catalyst&#8217;s product candidates depends on an <font style="font-style: italic;">in vitro</font> diagnostic that is not otherwise commercially available, then the FDA generally will require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves Catalyst&#8217;s product candidates, if at all. Companion diagnostics are developed in conjunction with clinical programs for the associated product and are subject to regulation as medical devices by the FDA and comparable regulatory authorities.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to FDA guidance, if the FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic is not also approved or cleared for that indication. If a satisfactory companion diagnostic is not commercially available, Catalyst may be required to develop or obtain one that would be subject to regulatory approval requirements. The process of obtaining or creating such diagnostics is time-consuming and costly. If the FDA or a comparable foreign regulatory authority requires approval of a companion diagnostic for any of Catalyst&#8217;s product candidates, including Hydronidone, whether before or after it obtains marketing approval, Catalyst, and/or future collaborators, may encounter difficulties in developing and obtaining approval for such product candidate. Any delay or failure by Catalyst or third-party collaborators to develop or obtain regulatory approval of a companion diagnostic could delay or prevent approval or continued marketing of such product candidate. Catalyst may also experience delays in developing a sustainable, reproducible and scalable manufacturing process for the companion diagnostic or in transferring that process to commercial partners or negotiating insurance reimbursement plans, all of which may prevent Catalyst from completing Catalyst&#8217;s clinical trials or commercializing Catalyst&#8217;s product candidates, if approved, on a timely or profitable basis, if at all.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose Catalyst to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which Catalyst obtains marketing approval. Catalyst&#8217;s future arrangements with third-party payors and customers may expose Catalyst to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which Catalyst would market, sell and distribute its products. As a pharmaceutical company, even though Catalyst does not and may not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are and will be applicable to its business. These regulations include:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the Federal Healthcare Anti-Kickback Statute that prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid, and which will constrain its marketing practices and the marketing practices of its licensees, educational programs, pricing policies, and relationships with healthcare providers or other entities;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">58<br></div></div></div>
<!--End Page 69-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 70-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg26"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the federal physician self-referral prohibition, commonly known as the Stark Law, which prohibits physicians from referring Medicare or Medicaid patients to providers of &#8220;designated health services&#8221; with whom the physician or a member of the physician&#8217;s immediate family has an ownership interest or compensation arrangement, unless a statutory or regulatory exception applies;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">federal false claims laws that prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other government reimbursement programs that are false or fraudulent, and which may expose entities that provide coding and billing advice to customers to potential criminal and civil penalties, including through civil whistleblower or qui tam actions, and including as a result of claims presented in violation of the Federal Healthcare Anti-Kickback Statute, the Stark Law or other healthcare-related laws, including laws enforced by the FDA;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and also created federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services that, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">federal physician sunshine requirements under the ACA, which requires manufacturers of approved drugs, devices, biologics and medical supplies to report annually to the U.S. Department of Health and Human Services, information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the Federal Food, Drug, and Cosmetic Act, which, among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, state laws requiring pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and which may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and state and foreign laws governing the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and often are not preempted by federal laws such as HIPAA, thus complicating compliance efforts.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Efforts to ensure that its business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that its business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If Catalyst&#8217;s operations are found to be in violation of any of these laws or any other governmental regulations that may apply to it, Catalyst may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of its operations. If any physicians or other healthcare providers or entities with whom Catalyst expects to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s results of operations may be adversely affected by current and potential future healthcare legislative and regulatory actions. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">All jurisdictions in which Catalyst conducts its research, development, manufacturing and commercialization activities regulate these activities in great depth and detail. Obtaining regulatory approvals is a lengthy, expensive and uncertain process. Catalyst intends to focus its activities in the major markets of the PRC and the United States. These </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">59<br></div></div></div>
<!--End Page 70-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 71-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg27"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">geopolitical areas all have strict regulation on medical devices, and, in doing so, they employ broadly similar regulatory strategies, including regulation of product development, approval, manufacturing, sales and marketing and distribution of medical devices. However, regulatory regimes vary in different regions, which makes regulatory compliance more complex and costly for companies like Catalyst that plan to operate in each of these regions.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Legislative and regulatory actions affecting government prescription drug procurement and reimbursement programs occur relatively frequently. In the United States, the ACA was enacted in 2010 to expand healthcare coverage. Since then, numerous efforts have been made to repeal, amend or administratively limit the ACA in whole or in part. For example, the Tax Cuts and Jobs Act, signed into law by President Trump in 2017, repealed the individual health insurance mandate, which is considered a key component of the ACA. In December 2018, a Texas federal district court struck down the ACA on the grounds that the individual health insurance mandate is unconstitutional, although this ruling has been stayed pending appeal. The ongoing challenges to the ACA and new legislative proposals have resulted in uncertainty regarding the ACA&#8217;s future viability and destabilization of the health insurance market. The resulting impact on its business is uncertain and could be material.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Efforts to control prescription drug prices could also have a material adverse effect on its business. For example, in 2018, President Trump and the Secretary of the U.S. Department of Health and Human Services released the &#8220;American Patients First Blueprint&#8221; and have begun implementing certain portions. The initiative includes proposals to increase generic drug and biosimilar competition, enable the Medicare program to negotiate drug prices more directly and improve transparency regarding drug prices and ways to lower Catalyst consumers&#8217; out-of-pocket costs. The Trump administration also proposed to establish an &#8220;international pricing index&#8221; that would be used as a benchmark to determine the costs and potentially limit the reimbursement of drugs under Medicare Part B. Among other pharmaceutical manufacturer industry-related proposals, Congress has proposed bills to alter the benefit structure to increase manufacturer contributions in the catastrophic phase. The volume of drug pricing-related bills dramatically increased under the previous Congress, and the resulting impact on its business is uncertain and could be material. The extent to which the 118th Congress will continue this approach is uncertain.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The IRA provides the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) with the ability to directly negotiate prescription drug and biologic prices with manufacturers and to cap out-of-pocket spending for Medicare Part D enrollees. Each year, CMS will select and negotiate a preset number of high-spend drugs and biologics covered under Medicare Parts B and D that lack generic or biosimilar competition. Price negotiations for Part D begin in 2023. Taking effect in 2023, the IRA provides a new &#8220;inflation rebate&#8221; that requires drug manufacturers to pay a rebate to the federal government if the price for a drug or biologic under Medicare Parts B or D increases faster than the rate of inflation. The IRA contains a number of other provisions intended to reduce drug spending and the federal deficit, and the IRA&#8217;s impact on competition and commercialization is uncertain but could be material.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, many states have proposed or enacted legislation that seeks to indirectly or directly regulate pharmaceutical drug pricing, such as by requiring biopharmaceutical manufacturers to publicly report proprietary pricing information or to place a maximum price ceiling on pharmaceutical products purchased by state agencies. For example, in 2017, California&#8217;s governor signed a prescription drug price transparency state bill into law, requiring prescription drug manufacturers to provide advance notice and explanation for price increases of certain drugs that exceed a specified threshold. Both Congress and state legislatures are considering various bills that would reform drug purchasing and price negotiations, allow greater use of utilization management tools to limit Medicare Part D coverage, facilitate the import of low priced drugs from outside the United States and encourage the use of generic drugs. Such initiatives and legislation may cause added pricing pressures on its products.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Changes to the Medicaid program at the federal or state level could also have a material adverse effect on its business. Proposals that could impact coverage and reimbursement of its products, including giving states more flexibility to manage drugs covered under the Medicaid program and permitting the re-importation of prescription medications from Canada or other countries, could have a material adverse effect by limiting its products&#8217; use and coverage. Furthermore, state Medicaid programs could request additional supplemental rebates on its products as a result of an increase in the federal base Medicaid rebate. To the extent that private insurers or managed care programs follow Medicaid coverage and payment developments, they could use the enactment of these increased rebates to exert pricing pressure on its products, and the adverse effects may be magnified by their adoption of lower payment schedules.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">60<br></div></div></div>
<!--End Page 71-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 72-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg28"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Other proposed regulatory actions affecting manufacturers could have a material adverse effect on its business. It is difficult to predict the impact, if any, of any such proposed legislative and regulatory actions or resulting state actions on the use and reimbursement of its products in the United States, but its results of operations may be adversely affected. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: justify;">Catalyst is subject to evolving privacy and data protection laws, including HIPAA and the EU General Data Protection Regulation (EU) 2016/679 (&#8220;GDPR&#8221;). If Catalyst fails to protect personal information or comply with existing or future data protection regulations, its business, financial condition, results of operations and prospects may be materially adversely affected.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Numerous state and federal laws and regulations govern the collection, dissemination, use, privacy, confidentiality, security, availability, integrity, and other processing of personal information. HIPAA establishes a set of national privacy and security standards for the protection of protected health information (as defined in HIPAA) (&#8220;PHI&#8221;) by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the business associates with whom such covered entities contract for services. HIPAA requires covered entities and business associates, such as Catalyst, to develop and maintain policies with respect to the protection of, use and disclosure of electronic PHI, including the adoption of administrative, physical and technical safeguards to protect such information, and certain notification requirements in the event of a data breach.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The collection and use of personal health data and other personal data in the EU is governed by the provisions of the GDPR, which came into force in May 2018, related data protection laws in individual EU Member States as well as implementations of the GDPR in the European Economic Area. The GDPR establishes a number of strict requirements and restrictions applicable to the processing (processing includes collecting, analyzing and transferring) of personal data (<font style="font-style: italic;">i.e.</font>, data which identifies an individual or from which an individual is identifiable) in particular with respect to health data from clinical trials and adverse event reporting. The GDPR includes requirements relating to the legal basis of the processing (such as consent of the individuals to whom the personal data relates), the information provided to the individuals prior to processing their personal data, the notification obligations to the national data protection authorities and or data subjects (in particular in case of a data breach), and the security and confidentiality of the personal data. EU Member States may also impose additional requirements in relation to health, genetic and biometric data through their national legislation. Furthermore, it affords various rights to individuals (<font style="font-style: italic;">e.g.</font>,&#160;the right to access or erasure of personal data), and imposes potential penalties for breaches of up to 4% of the annual worldwide turnover or &#8364;20&#160;million, whichever is greater. In case of a breach of the GDPR, individuals (<font style="font-style: italic;">e.g.</font>, study subjects) may also have a right to compensation for financial or non-financial losses (<font style="font-style: italic;">e.g.</font>, distress). </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">There may be circumstances under which a failure to comply with the GDPR, or the exercise of individual rights under the GDPR, would limit Catalyst&#8217;s ability to utilize clinical trial data collected on study subjects. Furthermore, there is a growing trend towards the required public disclosure of clinical trial data in the EU, which adds to the complexity of obligations relating to processing health data from clinical trials. Such public disclosure obligations are provided in the new EU Clinical Trials Regulation (EU CTR), EMA disclosure initiatives and voluntary commitments by industry. Failing to comply with these obligations could lead to government enforcement actions and significant penalties, harm to reputation, and adversely impact the business and operating results. The uncertainty regarding the interplay between different regulatory frameworks, such as the CTR and the GDPR, further adds to the complexity. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, Catalyst is subject to various U.S. state laws which may require Catalyst to modify its data processing practices and policies and to incur substantial costs and expenses in an effort to comply.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: justify;">If Catalyst fails to comply with environmental, health and safety laws and regulations, Catalyst could become subject to fines or penalties or incur costs that could harm its business.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst is subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, its operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if Catalyst contracts with third parties for the disposal of these materials and waste products, Catalyst cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of its hazardous materials, Catalyst could be held liable for any resulting damages, and any liability could exceed its resources. Catalyst also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">61<br></div></div></div>
<!--End Page 72-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 73-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg29"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Catalyst maintains workers&#8217; compensation insurance to cover Catalyst for costs and expenses Catalyst may incur due to injuries to its employees resulting from the use of hazardous materials, but this insurance may not provide adequate coverage against potential liabilities. However, Catalyst does not maintain insurance for environmental liability or toxic tort claims that may be asserted against Catalyst.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, Catalyst may incur substantial costs to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair its research, development or production efforts that could adversely affect its business, financial condition, results of operations or prospects. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: justify;">Even if Catalyst receives regulatory approval of Catalyst&#8217;s product candidates, including Hydronidone, Catalyst will be subject to extensive ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and Catalyst may be subject to penalties if Catalyst fails to comply with regulatory requirements or experience unanticipated problems with Catalyst&#8217;s product candidates.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Any regulatory approvals that Catalyst may receive for Catalyst&#8217;s product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product candidate, including Hydronidone, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a REMS in order to approve Catalyst&#8217;s product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or comparable foreign regulatory authorities approve Catalyst&#8217;s product candidates, Catalyst&#8217;s product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export will be subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable foreign regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with cGMPs and GCPs for any clinical trials that Catalyst conducts following approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMPs. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: justify;">Catalyst identified a material weakness in its internal control over financial reporting in its consolidated financial statements for the year ended December&#160;31, 2021. If Catalyst fails to maintain effective internal control over financial reporting, Catalyst may not be able to accurately or timely report its financial condition or results of operations, which may adversely affect its business and share price. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the preparation and audit of its consolidated financial statements for the year ended December&#160;31, 2021, a material weakness was identified in Catalyst&#8217;s internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of its consolidated financial statements will not be prevented or detected on a timely basis. Catalyst&#8217;s material weakness related to the following control deficiency: Catalyst did not design and maintain effective controls related to the review of certain contracts, including the proper application of U.S. GAAP. Specifically, Catalyst did not design and maintain controls to properly review the retention bonuses granted to its employees in November 2021 after its reduction in workforce to assess the appropriate accounting treatment under U.S. GAAP.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">While Catalyst took steps to remediate the material weakness, Catalyst cannot assure you that the measures Catalyst has taken to date and may take in the future will prevent or avoid potential future material weakness. The effectiveness of its internal control over financial reporting is subject to various inherent limitations, including cost limitations, judgments used in decision making, assumptions about the likelihood of future events, the possibility of human error and the risk of fraud. If Catalyst is unable to record, process and report financial information accurately, and to prepare financial statements within the time periods specified by the forms of the SEC, Catalyst could be adversely affected which, in turn, may adversely affect its reputation and business and the market price of its common stock. In addition, any such failures could result in litigation or regulatory actions by the SEC or other regulatory authorities, loss of investor confidence, delisting of its securities and harm to its reputation and financial condition, or diversion of financial and management resources from the operation of its business.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">62<br></div></div></div>
<!--End Page 73-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 74-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg30"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Risks Related to Commercialization of Catalyst&#8217;s Product Candidates</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Even if any of its product candidates receives marketing approval, Catalyst may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If any of its product candidates receives marketing approval, Catalyst may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For example, to date, no specific therapeutic drugs treating HBV-associated liver fibrosis have been approved worldwide, and doctors may not accept or use Hydronidone as a treatment for liver fibrosis even if Hydronidone receives marketing approval. If its product candidates do not achieve an adequate level of acceptance, Catalyst may not generate significant product revenues and Catalyst may not become profitable. The degree of market acceptance of its product candidates, if approved for commercial sale, will depend on several factors, including:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The efficacy and safety profile of Hydronidone compared with other competitor anti-fibrosis treatments;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Catalyst&#8217;s ability to offer its products for sale at competitive prices&#894;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the convenience of TID dosing compared with alternative treatments;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">patient understanding of NASH and associated fibrosis and its progressive nature and need for treatment;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">improvement of confirmatory-diagnosis and monitoring of NASH and associated fibrosis;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies&#894;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the strength of marketing and distribution support&#894;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the availability of third-party coverage and adequate reimbursement&#894;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the prevalence and severity of any side effects&#894; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any restrictions on the use of its products together with other medications.</div></td></tr></table><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Catalyst&#8217;s product candidates are years away from regulatory approval.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s development candidates are not expected to be commercially available for several years, if at all. Further, the commercial success of product candidates will depend upon its acceptance by physicians, individuals, third-party payors and other key decision-makers as a therapeutic and cost-effective alternative to products available at the time, which may include competing products currently under development by others. See the risk factor titled &#8220;&#8212;<font style="font-style: italic;">Catalyst </font><font style="font-style: italic;">faces substantial competition that may result in others discovering, developing or commercializing products before </font><font style="font-style: italic;">or more successfully than Catalyst does</font>.&#8221; If Catalyst is unable to successfully develop, obtain regulatory approval in a timely manner (including due to reasons that are beyond its control, such as changes in regulations or a shutdown of the federal government, including the FDA) and commercialize its development candidates, its ability to generate revenue from product sales will be significantly delayed and its business will be materially and adversely affected, and Catalyst may not be able to earn sufficient revenues to continue as a going concern.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The regulatory authorities in the United States and the EU have not approved any products for the treatment of NASH, and while there are guidelines issued by the FDA for the development of drugs for the treatment of NASH and an FDA surrogate endpoint table for drug approval, it is unclear whether the requirements for approval will change in the future or whether the FDA will rely on regulatory precedent for future regulatory approvals. Any such changes may require Catalyst to conduct new trials that could delay its timeframe and increase the costs of our programs related to Hydronidone or any future product candidate for the treatment of NASH. In addition, Catalyst cannot be certain which efficacy endpoints or presentation thereof clinical or regulatory agencies may require in a Phase 3 clinical trial of NASH or for approval of Catalyst&#8217;s product candidates.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Even if the FDA or other regulatory agency approves its product candidates, the approval may impose significant restrictions on the indicated uses, conditions for use, labeling, advertising, promotion, marketing and/or production of such product and may impose ongoing commitments or requirements for post-approval studies, including additional research and development and clinical trials. The FDA and other agencies also may impose various civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">63<br></div></div></div>
<!--End Page 74-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 75-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg31"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Regulatory approval from authorities in foreign countries will be needed to market its product candidates in those countries. Approval by one regulatory authority does not ensure approval by regulatory authorities in other jurisdictions. If Catalyst fails to obtain approvals from foreign jurisdictions, the geographic market for its product candidates would be limited. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Catalyst faces substantial competition that may result in others discovering, developing or commercializing products before or more successfully than Catalyst does.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. Catalyst faces potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies, and public and private research institutions. Any product candidates that Catalyst successfully develops and commercializes will compete with existing therapies and new therapies that may become available in the future.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Although there are no currently approved therapeutic drug treatments for liver fibrosis, several companies are developing product candidates in clinical studies. For details, see &#8220;<font style="font-style: italic;">BC&#8217;s Business&#8212;Competition</font>&#8221; in this proxy statement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst faces competition with respect to Catalyst&#8217;s current product candidates and will face competition with respect to any future product candidates from segments of the pharmaceutical, biotechnology and other related industries that pursue targeted therapies for patients with NASH. If Hydronidone or Catalyst&#8217;s future product candidates do not offer sustainable advantages over competing products, Catalyst may otherwise not be able to successfully compete against current and future competitors.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s competitors may obtain regulatory approval of their products more rapidly than Catalyst may or may obtain patent protection or other intellectual property rights that limit Catalyst&#8217;s ability to develop or commercialize Catalyst&#8217;s product candidates. Catalyst&#8217;s competitors may also develop drugs that are more effective, more convenient, more widely used and less costly or have a better safety profile than Catalyst&#8217;s products and these competitors may also be more successful than Catalyst in manufacturing and marketing their products. In addition, Catalyst will likely need to develop Catalyst&#8217;s product candidates in collaboration with companion diagnostic companies, and Catalyst will face competition from other companies in establishing these future collaborations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s commercial opportunity in different indications could be reduced or eliminated if competitors develop and market products or therapies that are more convenient to use, more effective, less expensive, and safer to use than its products. Furthermore, if competitors gain FDA approval earlier than Catalyst does, Catalyst may be unable to establish a strong market presence or to gain market share. The key competitive factors affecting the success of all its product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the level of generic competition, and the availability of reimbursement from government and other third-party payors. Catalyst&#8217;s product candidates, if any are approved, may compete with these existing drug and other therapies but may not be competitive with them in price. Catalyst expects that if Catalyst&#8217;s product candidates are approved, they will be priced at a significant premium over competitive generic, including branded generic, products. As a result, obtaining market acceptance of, and gaining significant share of the market for, any of Catalyst&#8217;s product candidates that Catalyst successfully introduces to the market will pose challenges.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Many of the companies against which Catalyst is competing or against which Catalyst may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than Catalyst does. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of its competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with Catalyst in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and individual registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, its programs.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Even if Catalyst commercializes any product candidates, the products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives that would harm its business.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">64<br></div></div></div>
<!--End Page 75-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 76-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg32"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, Catalyst may obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay its commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues Catalyst is able to generate from the sale of the product in that country. Adverse pricing limitations may hinder its ability to recoup its investment in one or more product candidates, even if its product candidates obtain marketing approval.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for certain medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that Catalyst or its collaborators commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Reimbursement may affect the demand for, or the price of, any product candidate that receives marketing approval. Obtaining and maintaining adequate reimbursement for its products may be difficult. Catalyst may be required to conduct expensive pharmaco-economic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, Catalyst may not be able to successfully commercialize any product candidate for which Catalyst obtains marketing approval.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside the United States. Moreover, eligibility for reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers its costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover its costs and may not be made permanent.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Catalyst&#8217;s inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that it develops could have a material adverse effect on its operating results, ability to raise capital needed to commercialize products and overall financial condition.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit its ability to market those products and decrease its ability to generate revenue.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford expensive treatments. Sales of Catalyst&#8217;s product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of its product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, Catalyst may not be able to successfully commercialize its product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow Catalyst to establish or maintain pricing sufficient to realize a sufficient return on its investment.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. Moreover, increasing efforts by governmental and third-party payors, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">65<br></div></div></div>
<!--End Page 76-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 77-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg33"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">products approved and, as a result, they may not cover or provide adequate payment for its product candidates. Catalyst expects to experience pricing pressures in connection with the sale of any of its product candidates, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Risks Related to Catalyst&#8217;s Common Stock</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">The market price of Catalyst Common Stock has historically been highly volatile.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The trading price of Catalyst Common Stock has historically been highly volatile and there have been significant periods of time in which the trading volume of its common stock has been low, which can contribute to volatility in price. Additionally, the stock market in general has experienced extreme price and volume fluctuations. The market prices of securities of pharmaceutical, biopharmaceutical and biotechnology companies in particular have been extremely volatile and have experienced fluctuations that have often been unrelated or disproportionate to operating performance. Factors giving rise to this volatility may include:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">disclosure of clinical trial results;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">regulatory or political developments in both the United States and abroad&#894;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">developments concerning proprietary rights, including patents and litigation matters&#894;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">disclosure of new collaborations or other strategic transactions&#894;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">public concern about the safety or efficacy of product candidates or technology, their components, or related technology or new technologies generally&#894;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">public announcements by competitors or others regarding new products or new product candidates&#894; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">general market conditions and comments by securities analysts and investors.</div></td></tr></table><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Fluctuations in operating results could adversely affect the price of Catalyst&#8217;s common stock.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s operating results are likely to fluctuate significantly from quarter to quarter and year to year. These fluctuations could cause its stock price to decline. Some of the factors that may cause operating results to fluctuate on a period-to-period basis include the scope, progress, duration results and costs of preclinical and clinical development programs, as well as non-clinical studies and assessments of product candidates and programs, restructuring costs, implementation or termination of collaboration, licensing, manufacturing or other material agreements with third parties, non-recurring revenue or expenses under any such agreement, the cost, timing and outcomes of regulatory compliance, approvals or other regulatory actions and general and industry-specific economic conditions, particularly as it affects the pharmaceutical, biopharmaceutical or biotechnology industries in the United States. Period-to-period comparisons of its historical and future financial results may not be meaningful, and investors should not rely on them as an indication of future performance. Fluctuating losses may fail to meet the expectations of securities analysts or investors. Failure to meet these expectations may cause the price of its common stock to decline.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Sales of a significant number of shares of Catalyst&#8217;s common stock in the public markets, or the perception that such sales could occur, could depress the market price of its common stock.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s current trading volumes are modest, and sales of a substantial number of shares of its common stock in the public market, or the perception that these sales could occur, could cause the market price to decline. Catalyst has effective registration statements on Form S-3 that enables Catalyst to sell up to $150.0&#160;million of securities in one or more offerings, subject to limitations under applicable SEC rules, including up to $50.0&#160;million of common stock issuable under its Equity Distribution Agreement with Piper Sandler &amp; Co. Any additional sales in the public market of its common stock or other securities under these shelf registration statements could adversely affect prevailing market prices for its common stock. In addition, Catalyst has outstanding options to purchase 8,464,567 shares of common stock at a weighted average exercise price of $1.30 as of March 31, 2023. If such options are exercised and the shares are sold into the open market, such sales also might make it more difficult for Catalyst to sell equity securities in the future at a time and at a price that Catalyst deems appropriate. Conversion or exercise of these securities into shares of its common stock will cause dilution to the other holders of its common stock, and all such stock may be sold in the public market after conversion or exercise, subject to restrictions under the securities laws, which may lead to a decline in the market price of its common stock.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">66<br></div></div></div>
<!--End Page 77-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 78-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg34"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Anti-takeover provisions in its charter documents and provisions of Delaware law may make an acquisition more difficult and could result in the entrenchment of management.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst is incorporated in Delaware. Anti-takeover provisions of Delaware law and its charter documents may make a change in control or efforts to remove management more difficult. Also, under Delaware law, its board of directors may adopt additional anti-takeover measures. The existence of the following provisions of Delaware law and its restated certificate of incorporation and amended and restated bylaws could limit the price that investors might be willing to pay in the future for shares of its common stock.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s restated certificate of incorporation authorizes its board of directors to issue up to 5,000,000 shares of preferred stock and to determine the terms of those shares of stock without any further action by its stockholders. If the board of directors exercises this power to issue preferred stock, it could be more difficult for a third-party to acquire a majority of its outstanding voting stock and vote the stock they acquire to remove management or directors.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s restated certificate also provides staggered terms for the members of its board of directors, and that directors may be removed by stockholders only for cause and only by vote of the holders of 66 2/3% of voting shares then outstanding. In addition, stockholders currently are not permitted to call special meetings of stockholders, or to act by written consent without a meeting. These provisions may prevent stockholders from replacing the entire board in a single proxy contest, making it more difficult for a third party to acquire control without the consent of its board of directors. These provisions could also delay the removal of management by the board of directors with or without cause.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As a Delaware corporation, Catalyst is also subject to certain Delaware anti-takeover provisions. Under Delaware law, a publicly-held corporation may not engage in a business combination with any holder of 15% or more of its voting stock unless the holder has held the stock for three years or, among other things, the board of directors has approved the transaction. Catalyst&#8217;s board of directors could rely on Delaware law to prevent or delay an acquisition.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Catalyst is a smaller reporting company, and Catalyst cannot be certain if the reduced disclosure requirements applicable to smaller reporting companies will make its common stock less attractive to investors.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst has been a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and thus have been allowed to provide simplified executive compensation disclosures in its filings. Catalyst has also had certain other decreased disclosure obligations in its SEC filings. Catalyst cannot predict whether investors find its common stock less attractive because of its reliance on any of these exemptions. If some investors find its common stock less attractive as a result, there may be a less active trading market for its common stock and its stock price may be more volatile.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">General Risk Factors</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Catalyst&#8217;s common stock may be delisted from Nasdaq.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As previously reported, on November&#160;2, 2022, Catalyst received a letter from the Listing Qualifications Department of The Nasdaq Stock Market, LLC informing Catalyst that, because the closing bid price for Catalyst&#8217;s common stock listed on Nasdaq was below $1.00 for 30&#160;consecutive trading days, Catalyst was not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Marketplace Rule 5550(a)(2) (the &#8220;Minimum Bid Price Requirement&#8221;). Catalyst was granted 180 calendar days, or until May&#160;1, 2023, to regain compliance with the Minimum Bid Price Requirement. </div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On May 2, 2023, Catalyst was notified by the Listing Qualifications Staff (the &#8220;Staff&#8221;) of Nasdaq that Catalyst did not meet the Minimum Bid Price Requirement and was not eligible for a second 180-day period. As previously reported, on April 4, 2023, the Staff notified Catalyst that it failed to comply with Nasdaq&#8217;s $2,500,000 minimum stockholders&#8217; equity requirement for continued listing as set forth in Listing Rule 5550(b)(1) (the &#8220;Equity Requirement&#8221;). The deficiency with regards to the Equity Requirement serves as an additional and separate basis for delisting. Catalyst timely submitted a hearing request to Nasdaq&#8217;s Hearings Department. The hearing request stays the suspension of Catalyst&#8217;s common stock pending the panel&#8217;s conclusion of the hearing process. Catalyst believes that completion of the transactions under the Business Combination Agreement and reverse stock split as described in this proxy statement will enable the combined company following the transactions under the Business Combination Agreement to meet the applicable Nasdaq initial listing requirements, providing a basis for suspension of delisting. On June 27, 2023, the panel granted Catalyst a suspension of delisting until October 30, 2023. However, there can be no assurance that the combined company will meet Nasdaq&#8217;s initial listing requirements or, if the Contributions are not consummated, that Catalyst will continue listing on The Nasdaq Capital Market.</div> </div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">67<br></div></div></div>
<!--End Page 78-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 79-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg35"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Delisting of Catalyst&#8217;s common stock from The Nasdaq Capital Market could materially adversely impact the liquidity and value of Catalyst&#8217;s common stock and could prevent the closing of the transactions contemplated by the Business Combination Agreement. Catalyst&#8217;s ability to publicly or privately sell equity securities and the liquidity of its common stock could be adversely affected if it is delisted from The Nasdaq Capital Market or if it is unable to transfer its listing to another stock market. If Catalyst&#8217;s common stock is delisted by Nasdaq, it could lead to a number of negative implications, including an adverse effect on the price of its common stock, increased volatility in its common stock, limited availability of market quotations for its common stock, reduced liquidity in its common stock, the loss of federal preemption of state securities laws and greater difficulty in issuing additional securities and obtaining financing. In addition, delisting of Catalyst&#8217;s common stock could deter broker-dealers from making a market in or otherwise seeking or generating interest in its common stock, could result in a loss of current or future coverage by certain sell-side analysts and might deter certain institutions and persons from investing in its securities at all. Delisting could also cause a loss of confidence of Catalyst&#8217;s customers, collaborators, vendors, suppliers and employees, which could harm its business and future prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Catalyst may not be able to continue as a going concern if the conversion of Catalyst Convertible Preferred Stock is not approved by its stockholders. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As part of the F351 Agreement, Catalyst issued 12,340 shares of Catalyst Convertible Preferred Stock, which upon stockholder approval, will be converted to Catalyst Common Stock, subject to applicable beneficial ownership limitations. The terms of the Catalyst Convertible Preferred Stock include a cash settlement feature which provides that if Catalyst stockholders fail to approve the conversion of the Catalyst Convertible Preferred Stock by September 30, 2023, Catalyst could be required to make cash payments to the holders of Catalyst Convertible Preferred Stock significantly in excess of its current liquidity. Catalyst believes that stockholders who are entitled to vote on the conversion proposal at Catalyst's 2023 Annual Meeting of Stockholders, which is expected to be held in the third quarter of 2023, will vote to approve the proposal. However, the vote of Catalyst's common stockholders is outside of Catalyst's control. Catalyst's independent registered public accounting firm has issued a report that raised substantial doubt about Catalyst's ability to continue as a going concern.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;"><u>Risks Related to BC</u></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Risks Relating to the Research and Development and Sales and Distribution of BC&#8217;s Drugs and Drug Candidates</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC is largely dependent on sales of ETUARY, its commercialized product, within a competitive environment and BC may be unable to maintain or increase ETUARY&#8217;s sales volume, pricing levels and profit margins.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC is largely dependent on sales of ETUARY, but BC may not be able to maintain ETUARY&#8217;s sales volumes, pricing levels or profit margins. Sales of ETUARY accounted for 98.1% and 97.0% of BC&#8217;s total revenue in 2021 and 2022, respectively, and BC expects that sales of ETUARY will continue to comprise a substantial portion of BC&#8217;s total revenue in the near future. As a result, any reduction in sales or profit margins of ETUARY will thus have a material negative impact on BC&#8217;s business and results of operations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, the pharmaceutical industries are characterized by rapid changes in technology, constant enhancement of industrial know-how and frequent emergence of new products, which renders BC&#8217;s targeted markets highly competitive. Notably, the IPF drug market in the PRC is characterized by increasingly fierce competition, with one pirfenidone product and one nintedanib product approved and commercialized as of May 15, 2023, in addition to BC&#8217;s ETUARY. There are also several drug candidates that have entered into Phase 2 or more advanced clinical trial stage. With the increase in the penetration rate of IPF drugs and the expansion of the overall market, more market players will join the IPF market, and, consequently, the sales of BC&#8217;s ETUARY, which accounted for 55.3% of the total market in 2022, may decrease. For details, see &#8220;<font style="font-style: italic;">BC&#8217;s Business&#8212;Our Products and Product Pipeline&#8212;ETUARY: </font><font style="font-style: italic;">National Class 1.1 New Drug for IPF Approved in 2011&#8212;Market Opportunities and Competition</font>&#8221; in this proxy statement. New entrants to the IPF market in the PRC may exert downward pressure on BC&#8217;s average selling price of ETUARY, which may negatively impact sales and/or profit of ETUARY.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Many of BC&#8217;s competitors, including foreign pharmaceutical companies, may have substantially greater clinical, research, regulatory, manufacturing, marketing, financial and human resources compared to BC. Certain of BC&#8217;s competitors may be actively engaged in research and development in areas where BC has products or where BC is developing drug candidates or new indications for BC&#8217;s existing products. Other companies may discover, develop, acquire or commercialize products more quickly or more successfully than BC does. Moreover, there may also be </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">68<br></div></div></div>
<!--End Page 79-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 80-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg36"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">significant consolidation in the pharmaceutical industry among BC&#8217;s competitors or ventures among competitors that may increase their market share. Furthermore, BC&#8217;s competitors may apply for and obtain marketing approvals in the PRC or other countries for products with the same intended use as BC&#8217;s drugs and drug candidates more rapidly than BC does. The capacity of the relevant authorities, such as the NMPA, to concurrently review multiple marketing applications for the same type of innovative drug may be limited. Therefore, such authorities&#8217; review of BC&#8217;s drug candidates may be delayed when there is concurrent review of BC&#8217;s drug candidates with BC&#8217;s competitors&#8217; products, and the registration process of BC&#8217;s products may be prolonged.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition to market competition from generic drugs and other products or therapies indicated for the same disease, many of the factors discussed in this Risk Factors section could adversely affect sales of ETUARY, including but not limited to, pricing pressures caused by government policies and inclusion or removal from the governmental medical insurance coverage, market acceptance among the medical community, disruptions in manufacturing or distribution, issues with product quality or side effects and disputes over intellectual property. Moreover, despite BC&#8217;s efforts, BC may be unable to develop or acquire new products that would diversify BC&#8217;s business and reduce BC&#8217;s dependence on ETUARY.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">BC&#8217;s business and financial prospects depend substantially on the success of BC&#8217;s clinical stage and pre-clinical stage drug candidates, and BC may be unable to successfully complete their clinical development, obtain relevant regulatory approvals or achieve their commercialization, or may experience significant delays in doing so.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC&#8217;s ability to generate revenue and realize profitability depends on the successful completion of the development of BC&#8217;s drug candidates, obtaining necessary regulatory approvals, and manufacturing and commercializing BC&#8217;s drug candidates, which is contingent upon various factors. Such factors include: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">successful enrollment in, and completion of, clinical trials, as well as completion of pre-clinical studies and favorable safety and efficacy data therefrom; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">receipt of regulatory approvals; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">enhancing BC&#8217;s commercial manufacturing capabilities;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the performance by CROs, or other third parties, of their duties to BC in a manner that complies with BC&#8217;s trial protocols and applicable laws and protects the integrity of the resulting data;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">obtaining, maintaining, protecting and enforcing patent, trade secret and other intellectual property and proprietary protection and regulatory exclusivity, and ensuring BC does not infringe, misappropriate or otherwise violate the patent, trade secret or other intellectual property and proprietary rights of third parties; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">successfully launching commercial sales; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">obtaining and/or maintaining favorable governmental and private medical reimbursement; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">efficiently and cost-effectively enhancing BC&#8217;s marketing platform and distribution capabilities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">competition with other drugs and drug candidates; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">continued acceptable safety profile following regulatory approval.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC may not be able to achieve one or more of the foregoing factors in a timely manner or at all. As a result, BC could experience significant delays in or obtaining or not be able to obtain approval for and/or successful commercialization of BC&#8217;s drugs and drug candidates, which would render BC unable to achieve its planned milestones and materially harm BC&#8217;s drug development prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Clinical drug development involves a lengthy and expensive process and outcomes are uncertain, and BC may not successfully complete clinical trials or procedures for drugs under development or demonstrate the safety and efficacy of BC&#8217;s drug candidates to the satisfaction of regulatory authorities.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Before obtaining regulatory approval for the sale of BC&#8217;s drug candidates, BC must conduct extensive clinical trials to demonstrate their safety and efficacy, but there can be no assurance that such trials will be completed in a timely or cost-effective manner, due to the inherently unpredictable nature of clinical drug development. Events that may prevent successful or timely completion of clinical development may include: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">regulators, institutional review boards or ethics committees not authorizing BC or BC&#8217;s investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">69<br></div></div></div>
<!--End Page 80-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 81-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg37"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">BC&#8217;s inability to reach agreements on acceptable terms with prospective CROs, SMOs and hospitals as trial centers; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">manufacturing issues, including problems with manufacturing, supply quality, compliance with GMP, or obtaining sufficient quantities of a drug candidate for use in a clinical trial in a timely manner; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">clinical trials producing negative or inconclusive results, resulting in additional clinical trials or abandoning drug development programs;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes to the clinical trial protocol;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">BC&#8217;s third-party contractors&#8217; failing to comply with regulatory requirements or meet their contractual obligations to BC in a timely manner, or at all; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">BC&#8217;s suspending or terminating clinical trials for various reasons, including negative or inconclusive clinical response or a finding that participants are being exposed to unacceptable health risks or experiencing adverse effects; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the cost of clinical trials being greater than BC anticipates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the supply or quality of BC&#8217;s drug candidates or other materials necessary to conduct clinical trials being insufficient or inadequate; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">delays in having patients complete participation in a trial or return for post-treatment follow-up; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">participants choosing an alternative treatment for the indication for which BC is developing its product candidates, or participating in competing clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">occurrence of adverse effects or serious adverse effects associated with the product candidate that are viewed to outweigh its potential benefits; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the occurrence of serious adverse events in clinical trials of competing products or conducted by competitors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">third-party clinical investigators losing the licenses or permits necessary to perform BC&#8217;s clinical trials, not performing BC&#8217;s clinical trials on its anticipated schedule or consistent with the clinical trial protocol or other regulatory requirements or committing fraud; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the results of pre-clinical studies or early clinical trials not being predictive of the results of later-stage clinical trials, and initial or interim results of a trial not being predicative of final results.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If BC experiences delays in the completion of, or the termination of, a clinical trial of any of BC&#8217;s drug candidates, the commercial prospects of that drug candidate may be harmed. Specifically, BC may: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">be delayed in obtaining regulatory approval; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">be required to conduct additional clinical trials or other testing beyond those that BC currently contemplates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">obtain approval for indications that are not as broad as intended; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">be subject to additional post-marketing testing requirements;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">be subject to restrictions on how the drug is distributed or used; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">be unable to obtain reimbursement for the use of the drug. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Consequentially, any delays in completing BC&#8217;s clinical trials may increase BC&#8217;s costs, delay BC&#8217;s drug candidate development and approval process, and jeopardize BC&#8217;s ability to commercialize BC&#8217;s approved products and generate revenues. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">If BC encounters difficulties or delays in enrolling patients in BC&#8217;s clinical trials, BC&#8217;s clinical development activities could be delayed or otherwise adversely affected.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The timely completion of clinical trials in compliance with BC&#8217;s protocols depends substantially on BC&#8217;s ability to enroll and retain a sufficient number of patients in a trial. However, BC may experience difficulties in patient enrollment for a variety of reasons, including BC&#8217;s drug candidates&#8217; targeting rare diseases, the size and nature of the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">70<br></div></div></div>
<!--End Page 81-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 82-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg38"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">patient population for such rare diseases, the patient eligibility criteria defined in the protocol, the accessibility of trial sites for the patients, and the patients&#8217; perceptions as to the potential advantages and side effects of the drug candidates being studied in relation to other available products, product candidates or therapies. Moreover, BC&#8217;s clinical trials will likely compete with other clinical trials for drug candidates that are in the same therapeutic areas as other drug candidates of BC, which will reduce the number and types of patients available to BC.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Even if BC is able to enroll a sufficient number of patients, delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect BC&#8217;s ability to advance the development of drug candidates.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: justify;">Adverse events or undesirable side effects caused by BC&#8217;s drug candidates could interrupt, delay or halt clinical trials, delay or prevent regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any regulatory approval.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries and discomforts, to their doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. Regulatory authorities may draw different conclusions or require additional testing to confirm these determinations, if they occur. In addition, it is possible that as BC tests its product candidates in larger, longer and more extensive clinical trials with a broader group of patients, or as use of these product candidates becomes more widespread if they receive marketing approval, illnesses, injuries, discomforts and other AEs that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by participants. Many times, side effects are only detectable after investigational product candidates are tested in large-scale, Phase 3 trials or, in some cases, after they are made available to patients on a commercial scale after approval. If additional clinical experience indicates that any of BC&#8217;s current product candidates and any future product candidates has serious or life-threatening side effects or other side effects that outweigh the potential therapeutic benefit, the development of the product candidate may fail or be delayed, or, if the product candidate has received marketing approval, such approval may be revoked, which would harm BC&#8217;s business, prospects, operating results and financial condition.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Any adverse events or serious adverse events reported in BC&#8217;s clinical trials caused by BC&#8217;s drug candidates could give rise to significant negative consequences. Such consequences may include: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">regulatory authorities may order BC to cease further development of, or deny approval of, BC&#8217;s drug candidates for any or all targeted indications;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">regulatory authorities may withdraw approvals or revoke licenses of an approved drug candidate, or BC may determine to do so even if not required; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">regulatory authorities may require additional warnings on the label of an approved drug candidate or impose other limitations on an approved drug candidate; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">BC may be required to develop a risk evaluation mitigation strategy for the drug candidate, or to incorporate additional requirements under the risk evaluation mitigation strategy; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">BC may be required to conduct post-market studies; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">BC could be subject to litigation proceedings and held liable for harm caused to patients; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">patient enrollment may be insufficient or slower than BC anticipates or patients may drop out or fail to return for post-treatment follow-up at a higher rate than anticipated. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In any such events, BC may suspend, delay or alter development or marketing of BC&#8217;s drug candidates, and the subsequent costs thereof may be substantially higher than anticipated.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: justify;">In conducting drug research and development, BC faces potential liabilities; in particular, product liability claims or lawsuits that could cause BC to incur substantial liabilities.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC faces an inherent risk of product liability as a result of clinical trials if BC&#8217;s drug candidates cause, or are perceived to cause, injury, or are found to be otherwise unsuitable during clinical testing. Regardless of the merits or eventual outcome, such liability claims may, among others, result in: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">decreased demand for BC&#8217;s drug candidates after commercialization; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">71<br></div></div></div>
<!--End Page 82-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 83-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg39"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">injury to BC&#8217;s reputation; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">withdrawal of clinical trial participants and inability to continue clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">initiation of investigations by regulators; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">costs to defend the related litigation; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a diversion of management&#8217;s time and BC&#8217;s resources; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">substantial monetary awards to trial participants or patients.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">To cover such liability claims arising from clinical trials, BC has clinical trial insurance for all of its trials, which are necessary for the approval of commercialization of BC&#8217;s pipeline drugs. However, it is possible that BC&#8217;s liabilities could exceed BC&#8217;s insurance coverage or that BC&#8217;s insurance will not cover all situations in which a claim against BC could be made. BC may also not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">BC&#8217;s substantial investment in research and development in order to develop BC&#8217;s drugs and drug candidates and enhance BC&#8217;s technologies may ultimately fail to materialize.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The global pharmaceutical market is constantly evolving, and BC must keep pace with new technologies and methodologies to maintain BC&#8217;s competitive position. BC&#8217;s future success partially depends on BC&#8217;s ability to launch new products that meet evolving market demands, in particular, new drugs, that are effective in treating new diseases and illnesses. However, there can be no assurance that BC will be able to respond to emerging or evolving trends by improving BC&#8217;s product portfolio in a timely manner, or at all. For the years ended December&#160;31, 2021 and 2022, and for the three months ended March 31, 2023, BC incurred substantial expenditure related to the research and development of BC&#8217;s drugs and drug candidates, and BC expects to continue to invest significant amounts of human and capital resources to develop BC&#8217;s drugs and drug candidates while enhancing BC&#8217;s technologies that will allow BC to advance its pipeline drugs. BC also intends to continue to strengthen its technical capabilities in drug discovery, development, and manufacturing, which are capital and time intensive. However, there can be no assurance that BC will be able to develop, improve or adapt to new technologies and methodologies, successfully identify new technological opportunities, or develop and bring new or enhanced products to market.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">BC may allocate its limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may later prove to be more profitable or for which there is a greater likelihood of success.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Due to limited financial and managerial resources, BC focuses its product pipeline on drug candidates that BC identifies for specific indications, and, as a result, BC may forego or delay pursuit of opportunities with other drug candidates or for other indications that may later prove to have greater commercial potential or a greater likelihood of success. If BC does not accurately evaluate the commercial potential or target market for a particular drug candidate, BC may allocate internal resources to a drug candidate in a therapeutic area and fail to allocate similar resources to other drug candidates or in other therapeutic areas for which it would have been more advantageous to pursue.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">BC may be unable to identify, discover, or develop new drug candidates, or to identify additional therapeutic opportunities for BC&#8217;s drug candidates, in order to expand or maintain BC&#8217;s product pipeline.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC cannot guarantee that it will be successful in identifying potentially optimal drug candidates to enrich BC&#8217;s pipeline. Research programs to pursue the development of BC&#8217;s drug candidates for additional indications and to identify new drug candidates and drug targets require substantial technical, financial and human resources. BC&#8217;s research programs may initially show positive results in identifying potential indications and/or drug candidates, yet fail to yield results for clinical development for a number of reasons. Accordingly, there can be no assurance that BC will be able to identify new drug candidates or additional therapeutic opportunities for BC&#8217;s drug candidates or to develop suitable potential drug candidates through internal research programs, which could materially and adversely affect BC&#8217;s future growth and prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">BC&#8217;s products may be excluded or removed from national, provincial or other government-sponsored medical insurance programs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under medical insurance programs in the PRC, patients are entitled to reimbursement of all or a portion of the cost of pharmaceutical products listed in the National Reimbursement Drug List (the &#8220;NRDL&#8221;), the relevant provincial </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">72<br></div></div></div>
<!--End Page 83-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 84-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg40"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">reimbursement drug lists, or other medical insurance reimbursement lists. However, such inclusion is based on a variety of factors, including clinical needs, use frequency, efficacy, safety and price, which may be outside of BC&#8217;s control. Moreover, the relevant PRC government authorities may, from time to time, review and revise, or change the scope of reimbursement for, the products that are included in the medical insurance reimbursement lists.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">While BC&#8217;s ETUARY has been included in the NRDL as a Category B drug for its IPF indication since 2017, there can be no assurance that it will remain so listed, or unimpacted negatively by changes in the scope of reimbursement. To the extent that BC&#8217;s future approved drug candidates are not included in any medical insurance reimbursement list, or if any such insurance schemes are changed or canceled, which results in the removal of such drug candidates from the relevant medical insurance reimbursement lists, patients may choose, and hospitals, pharmacies and other medical institutions may recommend, alternative treatment methods, which may reduce demand for BC&#8217;s products and adversely impact BC&#8217;s sales.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">BC may face pressure to lower the prices of its products in order for such products to qualify for medical insurance reimbursement or due to market competition.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC may face pressure to lower the prices of its future approved drug candidates in order to have such drug candidates included in the medical insurance reimbursement lists, while such low price and reimbursement may not necessarily lead to increased sales. It is difficult to estimate the net effect of decreased prices and the potential of increased sales on BC&#8217;s profitability, and BC&#8217;s profits from the sales of its future products may decrease if BC significantly lowers prices without a greater increase in sales.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, it is typical that the prices of pharmaceutical products will decline over the life of the product as a result of, among other things, increased competition from substitute products, the tender process by the hospitals or the government authorities, pricing policies of the relevant government authorities, or voluntary price adjustments by pharmaceutical companies. Any strategic downward price adjustments of BC&#8217;s existing or future approved products due to market competition could have a materially adverse effect on BC&#8217;s business and results of operations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Moreover, BC&#8217;s marketed ETUARY is subject to the risk of being included in the PRC&#8217;s centralized volume-based procurement scheme. For details, see &#8220;<font style="font-style: italic;">&#8212;The policies of centralized volume-based procurement set by the PRC </font><font style="font-style: italic;">government may cover BC&#8217;s products in the future, and the prices of BC&#8217;s products may decrease, which in turn may </font><font style="font-style: italic;">have a material adverse impact on BC&#8217;s revenue, financial condition and results of operation</font>&#8221; in this Risk Factors section.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">BC&#8217;s drugs and future approved drug candidates may fail to achieve the degree of market acceptance by physicians, medical institutions, pharmacies, patients, third-party payors and others in the medical community necessary for commercial success.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The commercial success of BC&#8217;s existing and future approved products depends upon the degree of market acceptance such products can achieve, particularly among physicians, hospitals, pharmacies and other medical institutions, which is contingent upon a number of factors. Such factors affecting the market acceptance of a current or future approved product may include: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the clinical indications for which the product is approved;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the safety and efficacy of the product;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the potential and perceived advantages and disadvantages of the product, relative to competing or alternative products or treatments;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the affordability of the product; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the cost of treatment in relation to alternative treatments and therapies; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the strength of BC&#8217;s relationships with patient communities;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the ability of third-party coverage and adequate reimbursement;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the willingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement by third-party payors and government authorities; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">73<br></div></div></div>
<!--End Page 84-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 85-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg41"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the strength of marketing and distribution support; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the prevalence and severity of any side effects; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the current diagnostic conditions of the disease for which the product is indicated, which may be influenced by the number of physicians from the relevant department and their respective experiences, available diagnostic methods and equipment therefor; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the effectiveness of BC&#8217;s sales and marketing efforts.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If BC&#8217;s existing and future approved products fail to achieve or maintain widespread market acceptance, or if new products introduced by BC&#8217;s competitors are perceived more favorably by healthcare practitioners and patients, are more cost-effective or otherwise render BC&#8217;s products obsolete, the demand for BC&#8217;s products may decline and BC&#8217;s business and profitability may be materially and adversely affected.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">BC may fail to win bids to sell BC&#8217;s products to PRC public hospitals through the centralized tender process.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Because a considerable portion of pharmaceutical products BC sells to its distributors are sold to public hospitals and other medical institutions in the PRC, BC must submit bids in a centralized tender process to supply BC&#8217;s products to these institutions at specified prices. Each public medical institution in the PRC must generally procure drugs through a provincial centralized drug purchase platform and make substantially all of its purchases of pharmaceutical products through a centralized tender process. BC&#8217;s bids submitted in the centralized tender process are generally considered on the basis of price relative to substitute products and the clinical effectiveness of such substitute products, as well as the quality of BC&#8217;s products and services, among other things. As a result, BC&#8217;s sales volumes and profitability depend on BC&#8217;s ability to successfully differentiate its products and price its bids in a manner that enables BC to succeed in the centralized tender process at profitable levels.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">However, BC may fail to win bids in a centralized tender process due to various factors, including reduced demand for the relevant product, noncompetitive bidding price, failure to meet certain quality requirements, or the relevant product&#8217;s being perceived to be less clinically effective than competing products. If BC&#8217;s products are not selected in the centralized tender process in one or more regions, BC&#8217;s sales of the relevant products to the public hospitals in those regions may encounter difficulties, and BC&#8217;s market share, revenues and profitability could be adversely affected.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: justify;">The policies of centralized volume-based procurement set by the PRC government may cover BC&#8217;s products in the future, and the prices of BC&#8217;s products may decrease, which in turn may have a material adverse impact on BC&#8217;s revenue, financial condition and results of operation.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">PRC government authorities have implemented policies that aim to further increase the affordability of pharmaceutical products, including the centralized volume-based drug procurement system. For further details, see &#8220;<font style="font-style: italic;">BC&#8217;s Business&#8212;Product Pricing&#8212;Centralized Tender Process and Centralized Volume-based Procurement System&#8221; </font>and<font style="font-style: italic;"> &#8220;BC&#8217;s Business&#8212;Regulatory Requirements in the PRC&#8212;PRC Regulations in Relation to the Pharmaceutical </font><font style="font-style: italic;">Industry&#8212;Centralized Drug Procurement and Use</font>&#8221; in this proxy statement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Future procurement will include drugs listed in the NRDL that have great market demand and high purchase price, and future procurement is expected to gradually cover all types of domestically marketed drugs necessary for clinical use and of reliable quality to the extent possible. As a result, all appropriate drugs may be procured thereunder. Appropriate procurement methods for &#8220;orphan drugs&#8221; and drugs in shortage may be actively explored to ensure stable supply.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC&#8217;s marketed ETUARY is currently not subject to the centralized volume-based procurement process. However, it is uncertain whether the centralized volume-based procurement scope would be expanded in the future and result in the inclusion of BC&#8217;s ETUARY or other drug candidates if commercialized, which may cause their retail prices to decrease. Moreover, if any products comparable or similar to BC&#8217;s products or product candidates if commercialized are included in the centralized volume-based procurement, patients&#8217; willingness to use BC&#8217;s products may be materially and adversely affected and BC may need to change its pricing strategy. If any or all of the foregoing were to occur, BC&#8217;s sales revenue may decrease, which in turn would have a material adverse impact on BC&#8217;s financial condition, profitability and results of operation.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">74<br></div></div></div>
<!--End Page 85-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 86-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg42"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The actual market size of BC&#8217;s drug candidates may be smaller than BC anticipates, which could render some drug candidates ultimately unprofitable even if commercialized, and BC&#8217;s growth may be limited by existing and newly identified cases of IPF patients in the PRC until the expanded indications of ETUARY and BC&#8217;s other drug candidates are approved and become profitable.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC&#8217;s spending on current and future research and development programs and drug candidates for specific indications may not yield any commercially viable products, since the market opportunities for BC&#8217;s drug candidates may be smaller than BC anticipates. Similarly, the actual market size of BC&#8217;s ETUARY may not be as large as BC anticipates. The total addressable market opportunity will depend on, among other things, acceptance of the drug by the medical community and patient access, drug pricing and reimbursement. Moreover, the number of patients in the addressable markets may be lower than expected, patients may not be amenable to treatment with BC&#8217;s drugs, or new patients may become increasingly difficult to identify or access. Further, new studies may change the estimated incidence or prevalence of the diseases that BC&#8217;s drug candidates target. Any of the above unfavorable developments could have a material adverse effect on BC&#8217;s business, financial condition and results of operations. In particular, if the existing and newly identified cases of IPF patients in the PRC are fewer than BC expects, BC&#8217;s growth and financial position may be negatively impacted until the expanded indications of ETUARY and BC&#8217;s other drug candidates such as Hydronidone are approved and become profitable.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">There may be a decrease in the prevalence of IPF in the PRC in the future, which in turn may have a negative impact on the market size of ETUARY.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to Frost &amp; Sullivan, the prevalence of IPF in the PRC has increased from 83,002 patients in 2017 to 131,654 patients in 2022, and is expected to increase to 214,664 patients by 2027 and 320,677 patients by 2031. Notwithstanding the short term increase in the prevalence of IPF, with strengthening of the public health system as well as medical and technological advancement in the PRC, the potential risks that cause IPF may be lowered or eliminated in the future which in turn may lead to corresponding decrease in the prevalence of IPF in the PRC. The shrinking prevalence of IPF in the PRC, as a result, may have a negative impact on the market size of ETUARY.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">BC may be unable to conduct effective academic marketing.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Effective marketing and successful sales are crucial for BC to increase the market penetration of BC&#8217;s commercialized products, expand BC&#8217;s coverage of hospitals, pharmacies and other medical institutions and promote new products in the future. In particular, BC places a strong emphasis on academic marketing, through which BC promotes its products to medical professionals, hospitals, pharmacies and other medical institutions. While BC&#8217;s sales and marketing force actively works with medical professionals, hospitals, pharmacies and other medical institutions and BC endeavors to inform them of the distinctive characteristics, advantages, safety and efficacy of BC&#8217;s products as compared to BC&#8217;s competitors&#8217; products, BC may not be able to successfully enhance BC&#8217;s product awareness and receive recognition from them.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">BC may fail to maintain a qualified sales and marketing force.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In order to successfully market and sell BC&#8217;s commercialized products, BC&#8217;s sales and marketing teams possess a relatively high level of technical knowledge, up-to-date understanding of industry trends, necessary expertise in the relevant therapeutic areas and products, as well as sufficient promotion and communication abilities. However, there can be no assurance that there will be a sufficient amount of competent sales professionals with the relevant rare disease knowledge and/or academic key opinion leaders (&#8220;KOLs&#8221;) or doctor networks available for hire. As a result, if BC is unable to effectively train its in-house sales representatives or monitor and evaluate their academic marketing performances, BC&#8217;s sales and marketing may be less successful than desired.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Moreover, BC&#8217;s ability to attract, motivate and retain a sufficient number of qualified sales professionals is especially important because BC primarily relies on its in-house sales force to market BC&#8217;s products. As competition for experienced marketing, promotion and sales personnel is intense, BC may be unable to attract, motivate and retain a sufficient number of marketing, promotion and sales professionals. If BC fails to maintain a qualified sales and marketing force, sales volume of BC&#8217;s products may be adversely affected and BC may be unable to expand BC&#8217;s coverage of hospitals, pharmacies and other medical institutions or increase BC&#8217;s market penetration.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">BC may fail to maintain or expand an effective distribution network for BC&#8217;s products or further expand BC&#8217;s distribution channel.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As BC primarily relies on its network of distributors to distribute BC&#8217;s products and intends to continue engaging distributors to sell BC&#8217;s products in the foreseeable future, BC&#8217;s ability to maintain and grow its business depends </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">75<br></div></div></div>
<!--End Page 86-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 87-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg43"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">on its ability to maintain and manage a sufficient number of distributors with an extensive sales network, which BC could fail to achieve for several reasons. BC&#8217;s distributors may be unable to maintain or expand their sales network, or may encounter difficulties in selling BC&#8217;s products. BC&#8217;s distributors might elect not to renew their agreements with BC or otherwise terminate their business relationships with BC for various reasons, such as price controls or other factors that substantially reduce the margins they can obtain through the resale of BC&#8217;s products. Further, BC may fail to find an appropriate group of distributors suitable for BC&#8217;s products, or the costs of doing so are prohibitively high. Any disruption to BC&#8217;s distribution network, including BC&#8217;s failure to maintain relationships, form new relationships or renew BC&#8217;s existing distribution agreements, could negatively affect BC&#8217;s ability to sell its products and may materially and adversely affect BC&#8217;s business, results of operations, financial condition and prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: justify;">Incidents, or perceived incidents, of severe side effects caused by BC&#8217;s products could materially and adversely affect BC&#8217;s reputation and results of operations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC&#8217;s products may cause undesirable or unintended side effects as a result of a number of factors, many of which are outside BC&#8217;s control. These factors include potential side effects not revealed in clinical testing, unusual but severe side effects in isolated cases, defective products not detected by BC&#8217;s quality management system, and misuse of BC&#8217;s products by end-users.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Further, BC&#8217;s products may be perceived to cause severe side effects if other pharmaceutical companies&#8217; products containing the same or similar active pharmaceutical ingredients, raw materials or delivery technologies as BC&#8217;s products cause or are perceived to have caused severe side effects, or if regulators or international institutions determine that products containing the same or similar pharmaceutical ingredients as BC&#8217;s products&#8217; cause severe side effects. BC&#8217;s products may also be perceived to cause severe side effects when a conclusive determination as to the cause of the severe side effects is not obtained or is unobtainable.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If BC&#8217;s products cause, or are perceived to cause, severe side effects, BC may face a number of consequences, including, but not limited to: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">injury or death of patients;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a decrease in the demand for, and sales of, the relevant products;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">recall or withdrawal of the relevant products;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">revocation of regulatory approvals for the relevant products or the relevant production facilities;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">damage to the brand name of BC&#8217;s products and the reputation of BC&#8217;s company;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">stricter and more frequent regulatory inspections of BC&#8217;s production facilities and products;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">removal of relevant products from any medical insurance reimbursement lists;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">inability to participate in the centralized tender process;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">exposure to lawsuits and regulatory investigation relating to the relevant products that result in liabilities, fines or penalties; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">breach of contract with BC&#8217;s major customers.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Such incidences may cause negative publicity and have material adverse impact on BC&#8217;s business and results of operations.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: justify;">Adverse drug reactions and negative results from off-label use of BC&#8217;s products could materially harm BC&#8217;s business reputation, product brand name, and financial condition and expose BC to liability.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Products distributed or sold in the pharmaceutical market may be subject to off-label drug use, and may be prescribed for an indication, dosage or in a dosage form that is not in accordance with regulatory approved usage and labeling. As such, BC&#8217;s products may be subject to off-label drug use and may be prescribed to a patient population, or in a dosage or dosage form that has not been approved by competent authorities, which may render BC&#8217;s products less effective or entirely ineffective and cause adverse drug reactions. Any of these occurrences can create negative </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">76<br></div></div></div>
<!--End Page 87-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 88-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg44"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">publicity and significantly harm BC&#8217;s business reputation, product brand name, commercial operations and financial condition, including BC&#8217;s share price. These occurrences may also expose BC to liability and cause, or lead to, a delay in the progress of BC&#8217;s clinical trials and may ultimately result in failure to obtain regulatory approval for BC&#8217;s drug candidates.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Risks Relating to Manufacture and Supply of BC&#8217;s Products</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Manufacturing pharmaceutical products on a large commercial scale is highly exacting and complex, and BC may encounter problems during the process.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The manufacturing of pharmaceutical products is highly complex, and problems may arise during manufacturing for a variety of reasons, including, but not limited to: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">equipment malfunction;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to follow specific protocols and procedures;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in product specification;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">low quality or insufficient supply of raw materials;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">delays in the construction of new facilities or the expansion of BC&#8217;s existing manufacturing facilities and limits to manufacturing capacity due to regulatory requirements;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in the types of products produced;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">advances in manufacturing techniques;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">physical limitations that may inhibit continuous supply;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">man-made or natural damages, other disasters and environmental factors; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">shortage of qualified personnel or key contractors. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Despite BC&#8217;s quality control and assurance system and procedures, BC may not be able to eliminate such risks, which may delay or suspend BC&#8217;s manufacturing activities, and BC may not be able to secure temporary, alternative manufacturers for BC&#8217;s drugs with the terms, quality and costs acceptable to BC, or at all. If BC encounters any manufacturing problems, including those listed above, BC&#8217;s clinical trials and/or the availability of BC&#8217;s products for commercial sale may be delayed, and BC may spend significant time and costs in order to rectify such problems and maintain production at BC&#8217;s manufacturing facilities. Moreover, products with quality issues may have to be discarded, resulting in product shortages or additional expenses.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Furthermore, manufacturing methods and formulation are sometimes altered through the development of drug candidates from clinical trials to approval, and further to commercialization, in an effort to optimize manufacturing processes and results. Such changes carry the risk that they will not achieve these intended objectives, and any of these changes could cause the drug candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay the commercialization of drug candidates and require bridging studies or the repetition of one or more clinical trials, which may result in increases in clinical trial costs, delays in drug approvals and jeopardize BC&#8217;s ability to commence product sales and generate revenue.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: justify;">Delays in completing and receiving regulatory approvals for BC&#8217;s manufacturing facilities could delay BC&#8217;s development plans or commercialization efforts.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC&#8217;s existing and planned manufacturing facilities, as well as BC&#8217;s manufacturing process, will be subject to ongoing, periodic inspection by the NMPA or other comparable regulatory agencies to ensure compliance with GMP, which is usually the prerequisite to obtain marketing approval. Moreover, BC must obtain various permits, certificates and other approvals for BC&#8217;s manufacturing facilities and other premises from the relevant administrative authorities at various stages of property development, including, planning permits, construction permits, land use rights certificates, environmental assessments, fire control assessments, construction completion inspections and ownership certificates. Failure to comply with applicable regulations could lead to increased expense and result in sanctions being imposed on BC (including fines, injunctions, civil penalties, requirements to suspend or pause one or more of BC&#8217;s clinical trials); failure to obtain marketing approval of BC&#8217;s drug candidates; delays, suspension or </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">77<br></div></div></div>
<!--End Page 88-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 89-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg45"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">withdrawal of approvals; supply disruptions; license revocation; seizures or recalls of drugs or drug candidates; operating restrictions and criminal prosecutions, any of which could materially and adversely harm BC&#8217;s business.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: justify;">BC may experience substantial disruption to BC&#8217;s production sites and problems in manufacturing BC&#8217;s products.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC is dependent on BC&#8217;s manufacturing facilities in Beijing, PRC and Cangzhou, PRC. The continued operation of BC&#8217;s manufacturing facilities and BC&#8217;s production safety may be substantially interrupted due to a number of factors, many of which are outside of BC&#8217;s control. These factors may include fire, flood, earthquakes, power outages, fuel shortages, mechanical breakdowns, terrorist attacks and wars, or other natural disasters, as well as loss of licenses, certifications and permits, changes in governmental planning for the land underlying these facilities or their vicinity and regulatory changes. Moreover, the production activities on BC&#8217;s manufacturing facilities may be suspended on a temporary basis due to governmental policies or regulations, including that on environmental protection, combating COVID-19 or organizing public events. If the operation of any of BC&#8217;s manufacturing facilities is substantially disrupted, BC may not be able to replace the equipment or inventories at such facilities, or use different sites or a third-party contractor to continue BC&#8217;s production in a legal, timely and cost-effective manner or at all. Although BC maintains property insurance for certain properties, machinery and equipment and other assets owned, operated or deemed important for BC, in line with industry practice in the PRC, BC does not have certain types of insurance, such as business interruption insurance. The amount and nature of BC&#8217;s insurance coverage may not be sufficient to cover any substantial losses in the event of a significant disruption to any of BC&#8217;s manufacturing facilities.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Since September 2021, as a result of the shortage of coal supply combined with high electricity demand from manufacturers, the PRC has experienced widespread power outages. The PRC government has imposed power curbs, including imposing power restrictions on factories in a number of provinces in the PRC to deal with an imbalance in energy supply and demand. As of May 15, 2023, we have not received any notice from relevant government authorities ordering us to temporarily suspend or limit production, and our Beijing and Cangzhou production centers were not subject to any power restrictions. The PRC government imposed power restrictions did not have a material adverse impact on our business operations or financial performance during the years ended December&#160;31, 2021 and 2022 and up to May 15, 2023.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">BC may not be able to meet the increasing demand for BC&#8217;s products, maintain adequate manufacturing capacity or successfully manage BC&#8217;s anticipated growth.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">To produce BC&#8217;s increasing number of drug candidates, if approved, in the quantities that BC believes will be required to meet anticipated market demand, BC may need to increase BC&#8217;s production capacity over the initial level of production by constructing new manufacturing facilities and production lines. However, BC&#8217;s ability to successfully implement BC&#8217;s expansion plan for increasing production capacities is subject to a number of risks and uncertainties, including, but not limited to, the risk of construction delays and delays in equipment procurement, and BC&#8217;s ability to timely recruit sufficient qualified staff to support the increase in BC&#8217;s production capacity. If BC is unable to do so, is delayed, faces costs that are not economically feasible or cannot find a third-party manufacturer, BC may not be able to produce BC&#8217;s future approved drug candidates in sufficient quantities to meet future demand. Moreover, BC&#8217;s plans to increase BC&#8217;s production capacities require significant capital investment and the actual costs of BC&#8217;s expansion plan may exceed BC&#8217;s original estimates, which could adversely affect the return on BC&#8217;s expenditure.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Furthermore, given the size of BC&#8217;s existing and planned manufacturing facilities, BC may not be able to fully utilize within a reasonable period of time after BC commences operation. During the construction and ramp-up period, there may be significant changes in the macroeconomics of the pharmaceutical industry, including, among other things, market demand, product and supply pricing trends and customer preferences. Any adverse trends in this area could result in operational inefficiency and unused capacity in BC&#8217;s facilities.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Fluctuations in prices of BC&#8217;s raw materials and energy supply, as well as other costs associated with BC&#8217;s production processes, may have a material adverse effect on BC if it is not able to pass the cost increases on to BC&#8217;s customers.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In order to manufacture BC&#8217;s products, BC must obtain sufficient quantities of high-quality raw materials and stable supply of energy and power at commercially acceptable prices and in a timely manner, which exposes BC to risks associated with fluctuations in prices of raw materials. The prices of such materials may be affected by a number of factors, including market supply and demand, the PRC or international environmental and regulatory requirements, </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">78<br></div></div></div>
<!--End Page 89-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 90-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg46"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">natural disasters such as the outbreak of COVID-19 and the global and local economic conditions. In addition, BC may be subject to fluctuations in other costs associated with BC&#8217;s production processes, such as costs of waste disposal, which are beyond BC&#8217;s control. BC may have limited capability to increase its revenue in a timely manner, and a significant increase in such costs may increase BC&#8217;s cost of sales and negatively affect BC&#8217;s profit margins.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Failure to maintain optimal inventory levels could increase BC&#8217;s operating costs or lead to unfulfilled customer orders.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC is required to maintain optimal inventory levels in order to satisfy demand coming from BC&#8217;s extensive distribution network and successfully meet BC&#8217;s customers&#8217; demand. However, BC may not be able to maintain proper inventory levels of BC&#8217;s products as a result of rapid changes in product life cycles, changing clinical demands and uncertainty of product developments and launches, as well as the volatile economic environment in the PRC. There can be no assurance that BC can accurately predict these trends and events and avoid over-stocking or under-stocking BC&#8217;s products. Further, demand for products could change significantly between the time when the products are ordered and the time they are ready for delivery.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Inventory levels in excess of demand may result in inventory write-downs, expiration of BC&#8217;s products or an increase in inventory holding costs and a potential negative effect on BC&#8217;s liquidity. On the other hand, if BC underestimates demand, BC may experience inventory shortages which may, in turn, result in unfulfilled customer orders, leading to a negative impact on BC&#8217;s customer relationships.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Risks Relating to BC&#8217;s Reliance on Third Parties</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC has entered into, and may in the future enter into, collaboration agreements and strategic alliances, and BC may not realize any or all benefits of collaboration, alliances or licensing arrangements, and disputes may arise between BC and BC&#8217;s current or future collaboration partners.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC has in the past formed, and may in the future seek and form, strategic alliances, joint ventures or other collaborations, including entering into licensing arrangements with third parties that BC believes will complement or augment BC&#8217;s development and commercialization efforts with respect to BC&#8217;s existing drug candidates and any future drug candidates that BC may develop. BC&#8217;s strategic collaboration with partners involves numerous risks. BC may not achieve the revenue and cost synergies expected from the transactions, as such synergies are inherently uncertain and subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and are beyond BC&#8217;s control. In addition, the synergies from BC&#8217;s collaboration with BC&#8217;s partners may be offset by other costs incurred during the collaboration, including increases in other expenses, operating losses or problems in the business unrelated to BC&#8217;s collaboration. BC may not be able to recover any consideration that BC paid or will pay during past or future collaborations, including upfront payments, if BC fails to successfully realize benefits from the collaboration.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Moreover, disputes may arise between BC and BC&#8217;s current or future collaboration partners. Such disputes or BC&#8217;s partners&#8217; failure to fully perform their obligations may cause delay or termination of the research, development or commercialization of BC&#8217;s drug candidates, or result in costly litigation or arbitration that may divert management attention and resources. In particular, international business relationships subject BC to additional risks that may materially and adversely affect BC&#8217;s ability to attain or sustain profitable operations, including, difficulty of effective enforcement of contractual provisions in local jurisdictions, and third-party collaborators may not properly obtain, maintain, protect or enforce BC&#8217;s patent, trade secret and other intellectual property rights and regulatory exclusivity for BC&#8217;s drug candidates or may use BC&#8217;s intellectual property that exposes BC to potential litigation or other intellectual property-related proceedings that could jeopardize or invalidate BC&#8217;s intellectual property. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">BC&#8217;s rights to develop and commercialize some of BC&#8217;s drug candidates are subject, in part, to the terms and conditions of licenses granted to BC by others.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The success of BC&#8217;s collaborations with BC&#8217;s partners depends on each party&#8217;s performing its respective obligations under the relevant collaboration agreement. Such agreements may impose on BC diligence obligations in product development or commercialization, payment obligations when certain development or regulatory milestones and sales are achieved and other obligations. If BC fails to comply with BC&#8217;s obligations under BC&#8217;s current or future agreements, BC&#8217;s counterparties may have the right to terminate these agreements, in which event BC may not be able to develop, manufacture or market the drug candidate that is covered under the agreements. Termination of the licenses or assignments provided for under these agreements or reduction or elimination of BC&#8217;s rights under these agreements may result in BC having to negotiate new or amended agreements with less favorable terms, or cause BC to lose BC&#8217;s rights under these agreements, including BC&#8217;s rights to important intellectual property or technology.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">79<br></div></div></div>
<!--End Page 90-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 91-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg47"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">In addition, BC may not have the exclusive right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications covering the drug candidates that BC is licensed or assigned from third parties. In the event that these patents and patent applications are not prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent with the best interests of BC&#8217;s business, BC&#8217;s rights to the relevant intellectual property may be reduced or eliminated, and BC&#8217;s right to develop and commercialize the drug candidates covered under the agreement could be adversely affected.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Moreover, the third parties on whom BC relies with respect to licenses to certain patent rights and other intellectual property rights that are important or necessary to the development, manufacture or commercialization of BC&#8217;s drug candidates may themselves rely on upstream licenses from other third parties. Such sub-licenses may not provide exclusive rights to use the covered intellectual property in all relevant fields of use or in all territories in which BC may wish to develop or commercialize BC&#8217;s drug candidates, and add further uncertainties and complications as to the scope of BC&#8217;s rights under the relevant agreement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Further, the license or assignment agreements BC has entered into, or will enter into in the future, are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what BC believes to be the scope of its rights to the relevant intellectual property or technology, or increase what BC believes to be its financial or other obligations under the relevant agreement, either of which could have a material adverse effect on BC&#8217;s advancement through its collaboration relationship with its partners. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Because BC works with various third parties to conduct a certain number of BC&#8217;s pre-clinical studies and clinical trials, BC may not be able to obtain regulatory approval for, or commercialize, BC&#8217;s drug candidates, or may experience delays in doing so, if these third parties do not successfully carry out their contracted duties or meet expected deadlines.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC has worked with, and plans to continue to work with, third-party collaborators, such as CROs, to monitor and manage data for BC&#8217;s ongoing pre-clinical and clinical programs and for the manufacturing of a portion of BC&#8217;s drug candidate supply for use in preclinical and clinical trials. For more details, see &#8220;<font style="font-style: italic;">BC&#8217;s Business&#8212;Our Research and </font><font style="font-style: italic;">Development</font>&#8221; in this proxy statement. BC&#8217;s CROs are not its employees or affiliates, and except for remedies available to BC under its agreements with its CROs, BC cannot control whether or not its CROs devote sufficient time and resources to BC&#8217;s ongoing pre-clinical studies, clinical and non-clinical programs and manufacturing processes. If CROs do not successfully carry out their contractual duties or obligations or meet expected timelines, compromise the quality or accuracy of the clinical data obtained by CROs or BC&#8217;s investigators due to failure to adhere to BC&#8217;s clinical protocols, regulatory requirements or for other reasons, or the quality of the products manufactured fails to comply with GMP, BC&#8217;s clinical trials may be extended, delayed or terminated and BC may fail to obtain regulatory approval for or successfully commercialize BC&#8217;s drug candidates.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If any of BC&#8217;s collaborators breach or terminate their agreements with BC, BC may not be able to enter into arrangements with alternative collaborators or to do so on commercially reasonable terms. Switching or adding collaborators involves additional cost and delays, which can materially affect BC&#8217;s ability to meet its desired clinical development timelines.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Additionally, BC, its CROs for clinical programs and BC&#8217;s investigators are required to comply with GCP for all of BC&#8217;s drug candidates in clinical development. If BC or any of its CROs or investigators fail to comply with applicable GCP, the clinical data generated in BC&#8217;s clinical trials may be deemed unreliable and NMPA or comparable regulatory authorities may require BC to perform additional clinical trials before approving BC&#8217;s marketing applications, which would delay the regulatory approval process.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">If BC&#8217;s distributors act in violation of the relevant agreements, or if sub-distributors with whom BC has not entered into distribution agreements do not comply with policies and measures that BC&#8217;s distributors agree to comply with, BC&#8217;s business, prospects and reputation could be materially and adversely affected.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">While BC relies on the distribution agreements and the policies and measures BC has in place to manage BC&#8217;s distributors, BC cannot guarantee that it will be able to effectively manage BC&#8217;s distributors, or that BC&#8217;s distributors will comply with BC&#8217;s agreements and policies. If BC&#8217;s distributors take one or more of the following actions, BC&#8217;s business, results of operations, prospects and reputation may be adversely affected:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">failing to distribute BC&#8217;s products in the manner BC contemplates, impairing the effectiveness of BC&#8217;s distribution network;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">80<br></div></div></div>
<!--End Page 91-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 92-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg48"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">breaching the distribution agreements or BC&#8217;s policies and measures;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">failing to maintain the requisite licenses, permits or approvals or failure to comply with applicable regulatory requirements; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">violating any applicable anti-corruption, anti-bribery, competition or other laws and regulations. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Any such actual or alleged violation or non-compliance by BC&#8217;s distributors of the distribution agreements, BC&#8217;s policies or any applicable laws and regulations could result in the erosion of BC&#8217;s goodwill, expose BC to liabilities, disrupt BC&#8217;s distribution network and create an unfavorable public perception about the quality of BC&#8217;s products.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Moreover, some of BC&#8217;s distributors engage sub-distributors to distribute BC&#8217;s products, and BC does not engage these sub-distributors directly or maintain contractual relationships with them. Instead, BC mainly relies on BC&#8217;s distributors to manage and control their sub-distributors in accordance with regulatory requirements, the terms of the distribution agreements between BC and its distributors and BC&#8217;s policies for its distributors. Since BC&#8217;s control is limited over these sub-distributors, there is no assurance that the sub-distributors will comply with the geographical restrictions agreed to with BC&#8217;s distributors or other distribution requirements under BC&#8217;s distribution agreements and policies. As a result, there can be no assurance that BC will be able to identify or remediate any practices by any sub-distributors&#8217; that may be detrimental to BC&#8217;s business in a timely manner or at all, which may adversely affect BC&#8217;s results of operations and reputation.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Because BC relies on a limited number of suppliers for certain of its raw materials, BC may experience supply interruptions that could harm its ability to manufacture products.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">During the years ended December&#160;31, 2021 and 2022, and the three months ended March 31, 2023, BC had a small number of suppliers, with whom BC believes it has stable relationships. However, the stability of operations and business strategies of BC&#8217;s suppliers are beyond its control, and there can be no assurance that it will be able to maintain a stable relationship and high-quality outsourced raw materials or services with BC&#8217;s large suppliers. Moreover, BC has single-source suppliers for some principal raw materials. For details, see &#8220;<font style="font-style: italic;">BC&#8217;s Business&#8212;Raw </font><font style="font-style: italic;">Materials and Suppliers</font>&#8221; in this proxy statement. There can be no assurance that BC can timely find a replacement if needed to provide the raw materials of equal quality at a similar price, which could disrupt BC&#8217;s operations. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Risks Relating to Extensive Governmental Regulations</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">All material aspects of the research, development, manufacturing and commercialization of BC&#8217;s drugs and drug candidates are heavily regulated.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">All jurisdictions in which BC intends to conduct BC&#8217;s research, development, manufacturing and commercialization activities regulate these activities in great depth and detail. Obtaining regulatory approvals and maintaining compliance with applicable laws and regulations is a lengthy, expensive and uncertain process which requires the expenditure of substantial time and financial resources. Failure to comply with the applicable requirements at any time during the drug development process or approval process, or after approval, may subject BC to administrative or judicial sanctions. These sanctions could include, but are not limited to, a regulator&#8217;s refusal to approve pending applications, withdrawal of an approval, license revocation, a clinical hold, voluntary or mandatory product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">The regulatory approval processes of the NMPA and other comparable regulatory authorities are lengthy, time-consuming and inherently unpredictable.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Obtaining regulatory approvals for pharmaceutical products is a lengthy, costly and uncertain process. Specifically, BC could fail to receive regulatory approval for BC&#8217;s drug candidates for many reasons, including:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to begin or complete clinical trials due to disagreements with regulatory authorities;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to demonstrate a drug candidate&#8217;s safety and efficacy;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure of clinical trial results to meet the level of statistical significance required for approval;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">data integrity issues related to BC&#8217;s clinical trials;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">government authority&#8217;s disagreement with BC&#8217;s interpretation of data from pre-clinical studies or clinical trials;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">81<br></div></div></div>
<!--End Page 92-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 93-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg49"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">government authority&#8217;s requirement of additional information, including pre-clinical and clinical data, to support approval; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">clinical sites, investigators or other participants in BC&#8217;s clinical trials deviating from a trial protocol, failing to conduct the trial in accordance with regulatory requirements, or withdrawing from a trial. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">All these factors, among others, may delay or prevent approval and BC&#8217;s commercialization plans, or may result in BC ceasing a development program.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Additionally, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking regulatory approvals in various jurisdictions could result in significant delays, difficulties and costs for BC, and there can be no assurance that BC will be able to meet regulatory requirements of different jurisdictions. Also, BC&#8217;s failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">BC&#8217;s drugs and future approved drug candidates will be subject to ongoing or additional regulatory obligations and continued regulatory review.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC&#8217;s drugs and future approved drug candidates are or will be subject to ongoing regulatory requirements with respect to manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-market studies, submission of safety, efficacy and other post-market information, and other requirements of regulatory authorities in the PRC and/or other countries in which BC commercializes its drugs and drug candidates. Following an approval for commercial sale of any drug candidates, certain changes to the product, such as changes in manufacturing processes and additional labeling claims, may be subject to additional review and approval by the NMPA and/or comparable regulatory authorities. Accordingly, BC expects to devote time, resources and management&#8217;s effort in all areas of regulatory compliance. For details of other potential consequences in the event that BC fails to maintain compliance with such ongoing or additional regulatory requirements, see &#8220;<font style="font-style: italic;">&#8212;All material </font><font style="font-style: italic;">aspects of the research, development, manufacturing and commercialization of BC&#8217;s drugs and drug candidates are </font><font style="font-style: italic;">heavily regulated</font>&#8221; in this section.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">BC&#8217;s failure to obtain or renew certain approvals, licenses, permits and certificates required for BC&#8217;s business may materially and adversely affect BC&#8217;s business, financial condition and results of operations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to relevant laws, regulations and relevant regulatory practice by governmental authorities, BC is required to obtain and maintain various approvals, licenses, permits and certificates from relevant authorities to operate BC&#8217;s business. Some of these approvals, permits, licenses and certificates are subject to periodic renewal and/or reassessment by the relevant authorities, and the standards of such renewal and/or reassessment may change from time to time. Any failure to obtain or renew any approvals, licenses, permits and certificates necessary for BC&#8217;s operations may result in enforcement actions thereunder, including orders issued by the relevant regulatory authorities ceasing BC&#8217;s operations, and may include corrective measures requiring capital expenditure or remedial actions. If the interpretation or implementation of existing laws and regulations changes, or new regulations come into effect requiring BC to obtain any additional approvals, permits, licenses or certificates that were previously not required to operate BC&#8217;s existing businesses, there can be no assurance that it will successfully obtain such approvals, permits, licenses or certificates.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">BC may be directly or indirectly subject to applicable anti-kickback, false claims laws, physician payment transparency laws, fraud and abuse laws or similar healthcare and security laws and regulations in the PRC and other jurisdictions, which could, in the event of non-compliance, expose BC to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If BC obtains approval from the NMPA or other comparable regulatory authorities for any of BC&#8217;s drug candidates and begins commercializing those drugs in the PRC and BC&#8217;s other target markets, BC&#8217;s operations may be subject to various fraud and abuse laws of various jurisdictions, including, but not limited to, the PRC Anti-Unfair Competition Law, the PRC Criminal Law and the physician payment sunshine laws and regulations. There are ambiguities as to what is required to comply with any of these requirements, and violations of such fraud and abuse laws may be punishable by criminal and/or civil sanctions, including penalties, fines and/or exclusion or suspension from governmental healthcare programs and debarment from contracting with the relevant jurisdiction. As law enforcement authorities increase their focus on enforcing these laws, efforts to ensure that BC&#8217;s business arrangements with third parties comply with applicable healthcare laws and regulations may involve substantial costs.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">82<br></div></div></div>
<!--End Page 93-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 94-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg50"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">If BC fails to comply with applicable anti-bribery laws, BC&#8217;s reputation may be harmed and BC could be subject to penalties and significant expenses that could have a material adverse effect on BC&#8217;s business, financial condition and results of operations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC is subject to the anti-bribery laws of various jurisdictions. As BC&#8217;s business expands, the applicability of relevant anti-bribery laws to BC&#8217;s operations is expected to increase. BC&#8217;s procedures and controls to monitor anti-bribery compliance may fail to protect BC from reckless or criminal acts committed by BC&#8217;s employees or agents. If BC, due to either BC&#8217;s own deliberate or inadvertent acts or those of third parties, fails to comply with applicable anti-bribery laws, BC&#8217;s reputation could be harmed and BC could incur criminal or civil penalties, other sanctions and/or significant expenses, which could have a material adverse effect on BC&#8217;s business, including BC&#8217;s financial condition, results of operations, cash flows and prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Changes in government regulations or practices related to the healthcare industry, including healthcare reform and compliance with new regulations, may result in additional costs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The policies of the NMPA and other regulatory authorities may change, or additional government regulations may be enacted, that could prevent, limit or delay regulatory approval of BC&#8217;s drug candidates, restrict or regulate post-approval activities and affect BC&#8217;s profitability. BC cannot predict the likelihood, nature or extent of governmental policies or regulations that may arise from future legislation or administrative actions in the PRC or abroad, where the regulatory environment is constantly evolving. For example, if changes to regulatory requirements and guidance require BC to substantially amend clinical trial protocols, BC may experience increased costs or inability to complete clinical trials in a timely manner or at all. Changes in government regulations relating to pharmaceutical product registrations and approvals, such as a relaxation in regulatory requirements, or the introduction of simplified approval procedures, could lower the barriers to entry for potential competitors, or increased regulatory requirements could increase the difficulty to satisfy such requirements.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In recent years, there have been, and will likely continue to be, efforts to enact administrative or legislative measures that include more rigorous coverage criteria and may result in downward pressure on prices on BC&#8217;s products. For details of the risks associated with such downward pricing pressure, see &#8220;<font style="font-style: italic;">&#8212;Risks Relating to the Research and </font><font style="font-style: italic;">Development and Sales and Distribution of BC&#8217;s Drugs and Drug Candidates&#8212;BC may face pressure to lower the </font><font style="font-style: italic;">prices of its products in order for such products to qualify for medical insurance reimbursement or due to market </font><font style="font-style: italic;">competition.</font>&#8221; in this Risk Factors section.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Furthermore, any changes in laws and regulations on collection and transfer of personal data in the PRC, including the Personal Information Protection Law of the PRC and the Administrative Regulations on Human Genetic Resources of the PRC, could affect BC&#8217;s ability to use medical data and subject BC to liability for the use of such data for previously permitted purposes.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The PRC government or other government authorities in countries where BC plans to sell BC&#8217;s products could adopt new or different regulations with respect to sales of pharmaceutical products to address bribery, corruption or other concerns. New or different regulations could result in increased costs incurred by BC, its employees or distributors in selling BC&#8217;s products, or impose restrictions on sales and marketing activities, which could, in turn, increase BC&#8217;s costs.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">BC is subject to stringent privacy laws, information security policies and contractual obligations related to data privacy and security, and BC is exposed to risks related to BC&#8217;s management of patient medical data and other personal or sensitive information.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">When conducting its clinical trials, BC may be subject to relevant local, state, national and international data protection and privacy laws, directives, regulations, standards and contractual obligations that apply to the collection, use, retention, protection, disclosure, transfer and other processing of personal data in the jurisdictions in which BC currently and expects to operate and conduct its clinical trials. If such institutions or personnel release or transfer patient private or medical records without patient consent, they may be held liable for damage caused thereby. Data protection and privacy law regimes may continue to evolve, which may result in increased public scrutiny and stricter levels of enforcement and sanctions, which could result in increased costs of compliance. Failure to comply with any of these laws could result in enforcement action against BC, including fines, imprisonment of company officials and public censure. Although BC&#8217;s access to personal data is limited to trial data, including case report forms, the retention of which is required by applicable laws and regulations, any failure or perceived failure by BC to prevent information security breaches, to comply with applicable privacy policies or privacy-related legal obligations, or </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">83<br></div></div></div>
<!--End Page 94-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 95-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg51"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">secure information that results in the unauthorized release or transfer of personally identifiable information or other patient data, could cause reputational harm to BC and expose BC to legal proceedings. While BC has and expects to continue to have measures to maintain the confidentiality of the medical records and personal data collected of patients enrolled in BC&#8217;s clinical trials, including providing for confidentiality obligations under agreements with BC&#8217;s clinical trial collaborators, these measures may not always be effective.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, BC&#8217;s clinical trials frequently involve professionals from third-party institutions working on site with BC&#8217;s staff and enrolled patients. BC cannot ensure that such persons will always comply with BC&#8217;s data privacy measures. BC cooperates with third parties, including hospitals, CROs and other third-party contractors and consultants for BC&#8217;s clinical trials and operations. If BC&#8217;s third-party partners release or transfer, or are perceived to release or transfer, patient data in an unauthorized manner, or misuse or are perceived to misuse patient data for an unauthorized purpose, patients may perceive such actions as a compromise of BC&#8217;s confidentiality measures.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Risks Relating to BC&#8217;s Intellectual Property Rights</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If BC or BC&#8217;s licensors are unable to obtain and maintain adequate patent and other intellectual property protection for BC&#8217;s drugs and drug candidates worldwide, or if the scope of such intellectual property rights obtained is not sufficiently broad, third parties could compete directly against BC, and BC&#8217;s ability to successfully develop and commercialize any of BC&#8217;s drugs and drug candidates could be materially and adversely affected.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC&#8217;s success depends in large part on BC&#8217;s ability to protect its proprietary technology, drugs and drug candidates from competition by obtaining, maintaining and enforcing BC&#8217;s intellectual property rights, including patent rights. In order to protect the technologies, drugs and drug candidates that BC considers commercially important, BC, among others, filed and continues to file patent applications in the PRC and other countries. However, applying for patent protection is an expensive and time-consuming process, and BC may not be able to successfully file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. BC may not be able to prevent competitors from developing and commercializing competitive products in all such fields and territories.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Patents may be invalidated and patent applications may not be granted for various reasons, including because of known or unknown prior deficiencies in the patent applications or due to the lack of novelty or inventiveness of the underlying invention or technology. For example, there can be no assurance that BC was the first to make the inventions claimed in BC&#8217;s patents or pending patent applications because of the delay between publications of discoveries in scientific or patent literature and actual discoveries and patent applications. Under the &#8220;first-to-file&#8221; system adopted by the PRC, and, recently, the United States, even after reasonable investigation, BC may be unable to determine with certainty whether BC&#8217;s drugs, drug candidates, processes, technologies, improvement and other related matters are or may become unpatentable because a third party filed or may file a patent application earlier than BC has or does for inventions thereunder that are the same or substantially similar to BC&#8217;s inventions.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Therefore, the validity of issued patents, patentability of pending patent applications and applicability of such patent protections to BC&#8217;s programs may be lower in priority than third-party patents issued on a later date if the application for such patents was filed prior to BC&#8217;s and the technologies underlying such patents are the same or substantially similar to BC&#8217;s. In addition, BC may be involved in claims and disputes of intellectual property infringement in other jurisdictions (for example, in the United States), and the defense of these claims or disputes, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from BC&#8217;s business.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Obtaining and maintaining BC&#8217;s patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and BC&#8217;s patent protection could be reduced or eliminated for non-compliance with these requirements.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The China National Intellectual Property Administration (the &#8220;CNIPA&#8221;) and other governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. For example, in several stages over the lifetime of a patent, periodic maintenance fees are due to be paid to the CNIPA and other patent agencies. Although an inadvertent lapse can, in many cases, be cured by payment of a late fee or by other means in accordance with the applicable rules, non-compliance could result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Such non-compliance events may include failure to respond to official actions in a timely manner, non-payment of fees, and failure to properly submit formal documents. In addition, under PRC patent law, </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">84<br></div></div></div>
<!--End Page 95-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 96-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg52"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">any applicant that applies for a patent in a foreign country for an invention or utility model accomplished in the PRC must report to the CNIPA for confidentiality examination. If the applicant fails to report to the CNIPA for confidentiality examination, the patent right may not be granted if an application is later filed in the PRC.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: justify;">The scope of BC&#8217;s patent protection may be uncertain, and BC&#8217;s current or future patents may be challenged and invalidated after issuance.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications BC licenses or owns currently or in the future are to be issued as patents, they may not be issued in a form that will provide BC with any meaningful protection, prevent competitors or other third parties from competing with BC, or otherwise provide BC with any competitive advantage. In addition, the patent position of medical device companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of BC&#8217;s patent rights are highly uncertain.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and BC&#8217;s owned or licensed patents may be challenged in the courts or patent offices in the PRC and other jurisdictions. For example, BC may be subject to a third-party submission of prior art to the CNIPA or other related intellectual property offices, or become involved in post-grant proceedings such as opposition, derivation, revocation, invalidation, re-examination or <font style="font-style: italic;">inter partes</font> review, or interference proceedings or similar proceedings in foreign jurisdictions challenging the priority of BC&#8217;s invention or other features of patentability of BC&#8217;s patents and patent applications. Moreover, any claims that BC asserts against competitors who infringe, or are perceived to infringe, BC&#8217;s patent rights or misappropriate or otherwise violate BC&#8217;s intellectual property rights could, in turn, assert against BC invalidity or unenforceability of BC&#8217;s patents. Third-party submissions, proceedings or litigation may result in substantial costs and require significant time from BC&#8217;s scientists, experts and management, even if the outcome is favorable to BC. An adverse determination or outcome of a third-party submission, proceeding or litigation may result in loss of patent rights or exclusivity, or in patent claims being narrowed, invalidated or held unenforceable, which could limit BC&#8217;s ability to prevent competitors from using or commercializing similar or identical technologies and products, or limit the duration of the patent protection of BC&#8217;s technologies, drugs and drug candidates.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Even if BC is able to obtain patent protection for BC&#8217;s drugs and drug candidates, the term of such protection, if any, may be limited, and third parties could develop and commercialize products and technologies similar or identical to BC&#8217;s and compete directly against BC after the expiration of BC&#8217;s patent rights.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Although various adjustments and extensions may be available, the term of a patent, and the protection it affords, may be limited. Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such drug candidates may expire before or shortly after such drug candidates are commercialized. Even if BC successfully obtains patent protection for a drug candidate, such drug candidate may face competition from generic or biosimilar medications once the patent has expired. Upon the expiration of BC&#8217;s current or future issued patents, BC will not be able to assert such patent rights against potential competitors and BC&#8217;s business and results of operations may be adversely affected.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: justify;">Insufficient patent linkage, patent term extension and data and market exclusivity for NMPA-approved pharmaceutical products could increase the likelihood of early generic competition for BC&#8217;s drug candidates in the PRC.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In the PRC, the recent amendment to the PRC Patent Law, which was promulgated in October 2020 and effective as of June 2021, provides for the general principles of patent term extension and patent linkage, but does not include the revised implementation rules and operational details. Since 2020, several draft measures have been published by the NMPA, CNIPA, and the Supreme People&#8217;s Court for public comment, proposing frameworks for patentees to defend their patent exclusivity and apply for patent term extension. As of May 15, 2023, the final versions of these draft measures have not been published, and it is uncertain how the PRC government will implement the patent term extension or patent linkage system. The patents BC has in-licensed or owns in the PRC may not be eligible to be extended for any patent term lost during the regulatory review process. If BC is unable to obtain patent term extension in the PRC, BC&#8217;s competitors or other third parties may obtain approval for competing products following BC&#8217;s patent expiration.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">85<br></div></div></div>
<!--End Page 96-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 97-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg53"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">BC may initiate lawsuits to protect or enforce its intellectual property rights, or third parties may pursue claims against BC for alleged infringement, misappropriation or violation of such third-party intellectual property rights, which could be expensive and time-consuming.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC&#8217;s commercial success depends, in part, on BC&#8217;s ability to avoid infringing, misappropriating or otherwise violating the intellectual property rights of third parties. However, BC&#8217;s efforts to identify and avoid infringing on third parties&#8217; intellectual property rights may not always be successful. Defending against third parties&#8217; intellectual right infringement allegations, meritorious or not, may be expensive and time consuming, and could be a substantial diversion of BC&#8217;s resources and BC&#8217;s management team&#8217;s attention. Furthermore, because of the substantial amount of discovery that may be required in connection with intellectual property litigation, BC&#8217;s confidential information may be compromised by disclosure made during discovery.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In the event that third parties assert infringement claims against BC, there can be no assurance that the outcome would be in BC&#8217;s favor, as whether a product infringes on third parties&#8217; intellectual property rights involves an analysis of complex legal and factual issues, and the burden of proof required to successfully challenge a third-party intellectual property right may be high. If BC was found by courts or other competent authorities to have infringed on the patent or other intellectual property rights of third parties, BC may be subject to injunctive or other equitable relief, which could prevent BC from developing and commercializing BC&#8217;s drugs and drug candidates, or delay the development or commercialization process. BC may be required to obtain and maintain licenses from third parties in order to continue the development of BC&#8217;s drug candidates or BC&#8217;s general operations, which may have an adverse impact on BC&#8217;s financial position and profitability. Even if litigations or other proceedings are resolved in BC&#8217;s favor, BC&#8217;s involvement in such proceedings may attract publicity and result in a substantial adverse effect on BC&#8217;s reputation and brand name. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC&#8217;s owned or in-licensed patents and other intellectual property may be subject to priority disputes, inventorship disputes or similar proceedings, and BC or BC&#8217;s licensors may be unsuccessful in such proceedings. If BC or BC&#8217;s licensors are unsuccessful in such proceedings, BC may need to obtain licenses from third parties, which may not be available on commercially reasonable terms or at all. If BC is unable to obtain licenses in a timely manner or at all, BC may cease the development, manufacture and commercialization of one or more of BC&#8217;s drugs or drug candidates.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC or BC&#8217;s licensors may be subject to claims from former employees, collaborators or other third parties that allege they have an interest in BC&#8217;s owned or licensed patents or other intellectual property. If BC or BC&#8217;s licensors are unsuccessful in interference proceedings or other priority or validity disputes to which BC&#8217;s owned or licensed intellectual properties are subject, BC may lose valuable intellectual property rights, such as loss of one or more patents or exclusive ownership, or BC&#8217;s patent claims&#8217; being narrowed, invalidated or held unenforceable. BC may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes, in order to continue the development, manufacture and commercialization of one or more of BC&#8217;s drug candidates. However, such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. Even if BC is successful in an interference proceeding or other similar priority or inventorship disputes, it could result in substantial costs and may be a distraction to BC&#8217;s management and other employees.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: justify;">Changes in patent law could diminish the value of patents generally, which may impair BC&#8217;s ability to protect its pipeline products.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Decisions made by the National People&#8217;s Congress of the PRC and the CNIPA could change the laws and regulations governing patents in unpredictable ways that may affect BC&#8217;s ability to obtain new patents or to enforce BC&#8217;s existing patents and/or future patents. The United States has enacted and is currently implementing wide-ranging patent reform legislation. In addition, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. Similar changes in the laws of other jurisdictions may impact the value of BC&#8217;s patent rights or BC&#8217;s other intellectual property rights. In addition to increasing uncertainty with regard to BC&#8217;s ability to obtain patents in the future, there is uncertainty with respect to the value of patents once obtained, if any. As the laws and regulations governing patents evolve in the PRC and other jurisdictions, such changes may have a negative impact on BC&#8217;s intellectual property protection.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">86<br></div></div></div>
<!--End Page 97-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 98-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg54"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">BC may fail to protect the confidentiality of its trade secrets, BC may be subject to claims that BC&#8217;s employees, consultants or advisers have wrongfully used or disclosed alleged trade secrets of their former employers, and third parties may assert ownership of intellectual property that BC regards as its own.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition to BC&#8217;s issued patent and pending patent applications, BC relies on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain BC&#8217;s competitive position and to protect BC&#8217;s drugs and drug candidates. In order to protect these trade secrets, BC implements various measures, including entering into non-disclosure and confidentiality agreements or including non-disclosure and confidentiality provisions in agreements with parties that have access to BC&#8217;s trade secrets. However, non-disclosure agreements with employees, consultants, contractors and other parties may not adequately prevent unauthorized disclosure of BC&#8217;s trade secrets and other proprietary information. Parties may breach such agreements and wrongfully disclose BC&#8217;s proprietary information, and BC may not be able to obtain adequate remedies for such breach. Pursuing a claim that a party illegally disclosed or misappropriated a trade secret could be difficult, expensive and time-consuming, and the outcome of such claim is unpredictable.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Moreover, some of BC&#8217;s employees, including senior management, may have been employed at other pharmaceutical companies, including BC&#8217;s competitors or potential competitors. Such employees may have executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. BC may be subject to claims that it or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. In the event that litigation is necessary to defend against such claims, BC may be subject to monetary damages and lose valuable intellectual property rights or personnel.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: justify;">BC may fail to protect its trademarks and trade names, which may negatively affect its ability to build brand recognition in its markets of interest.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC currently owns issued trademark registrations and has trademark applications pending in order to build name recognition among potential partners and customers in BC&#8217;s markets of interest. However, such trademark registrations and applications subject BC to risks of trademark invalidity, dilution and infringement. BC&#8217;s trademark registrations and applications may be subject to a governmental or third-party objection, and may be challenged, infringed, circumvented or declared generic. If an issued trademark registration or trademark application is successfully challenged, then BC may not be able to register or maintain such trademark registration or application. Moreover, as BC&#8217;s products continue to be marketed, such products&#8217; reliance on BC&#8217;s trademarks to differentiate BC from its competitors may increase. BC may not be able to prevent third parties from adopting, registering or using trademarks and trade dress that infringe, dilute or otherwise violate BC&#8217;s trademark rights, or from engaging in conduct that constitutes unfair competition, defamation or other violations of BC&#8217;s trademark rights. In addition, owners of other registered trademarks or trademarks that incorporate variations of BC&#8217;s registered or unregistered trademarks or trade names may pursue trade name or trademark infringement claims against BC. If BC is unable to establish name recognition based on BC&#8217;s trademarks and trade names, then BC may not be able to compete effectively in its markets of interest, and BC&#8217;s business may be adversely affected.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: justify;">Protecting BC&#8217;s intellectual property rights in all jurisdictions worldwide would be prohibitively expensive, and BC may not be able to adequately enforce its intellectual property rights.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Filing, prosecuting, and defending patents on drug candidates in all jurisdictions worldwide would be prohibitively expensive. Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for BC to prevent patent infringement or marketing of competing products in violation of BC&#8217;s intellectual property and proprietary rights. In jurisdictions where BC has not obtained patent protection, competitors may be able to use BC&#8217;s technologies to develop their own products and sell or import products made using BC&#8217;s inventions in such jurisdictions. These products may compete with BC&#8217;s products, and BC&#8217;s existing patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">87<br></div></div></div>
<!--End Page 98-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 99-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg55"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Intellectual property rights may not address all potential threats to BC&#8217;s business or competitive advantage.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The degree of protection afforded by BC&#8217;s intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect BC&#8217;s business or permit BC to maintain its competitive advantage. The limitations of currently available intellectual property protection regimes include that: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">others may be able to make products that are similar to BC&#8217;s drugs or drug candidates or utilize similar technologies that are not covered by BC&#8217;s owned and licensed patents; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">others may independently develop similar or alternative technologies or duplicate any of BC&#8217;s technologies without infringing, misappropriating or otherwise violating BC&#8217;s intellectual property rights; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the proprietary technologies on which BC relies may not be patentable; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">BC may choose not to file a patent for certain trade secrets or know-how, yet a third party may subsequently file a patent covering such intellectual property. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Should any of these events occur, they could have a material adverse effect on BC&#8217;s business, financial condition, results of operations and prospects.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Risks Relating to BC&#8217;s Financial Position and Need for Additional Capital</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC may need to obtain additional financing to fund its expansion of research and development and operations, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force BC to delay, limit or terminate certain of its productive development programs, commercialization efforts or other operations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The development, commercialization, manufacturing, marketing, sales and distribution of biopharmaceutical products and product candidates is capital-intensive. BC&#8217;s business operations and its implementation of strategies will require significant funding, including: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the costs of research and development programs for enriching and promoting BC&#8217;s product pipeline;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the expenses associated with promoting academic marketing and expanding BC&#8217;s sales and distribution network;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the outcome, costs and timing of seeking and obtaining regulatory approvals;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the number and characteristics of product candidates that BC pursue;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the funding required to consummate value accretive business development and strategic collaborations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the costs and timing associated with manufacturing BC&#8217;s products and product candidates, and establishing commercial supplies and sales, marketing and distribution capabilities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">BC&#8217;s efforts to maintain, expand and defend the scope of its intellectual property portfolio, including the amount and timing of any payments BC may be required to make, or that it may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the capital expenditure required to increase BC&#8217;s production capacity and to expand and upgrade BC&#8217;s facilities; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">BC&#8217;s need and ability to retain key management and hire scientific, technical, business and medical personnel. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, many aspects of BC&#8217;s general business operations have on-going funding requirements that may increase over time. While BC expects that the implementation of its strategies and business plans may require BC to rely in part on external financing sources, BC&#8217;s ability to obtain additional capital on commercially reasonable terms is subject to a variety of factors, many of which are outside of BC&#8217;s control, including BC&#8217;s future financial condition, results of operations and cash flows, the global economic conditions, industry and competitive conditions, interest rates, prevailing conditions in the credit markets and government policies on lending. If BC cannot obtain additional capital on commercially reasonable terms or at all, BC may not be able to execute its strategies and business plans as currently contemplated, which could have a material adverse effect on BC&#8217;s business, financial condition and results of operations.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">88<br></div></div></div>
<!--End Page 99-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 100-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg56"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">BC&#8217;s high gross margin during the years ended December&#160;31, 2021 and 2022 and the three months ended March 31, 2023 may not be sustainable.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">During the years ended December&#160;31, 2021 and 2022, BC maintained a high level of gross margin. BC&#8217;s profit margins were 95.5% and 95.6% for the years ended December&#160;31, 2021 and 2022, respectively, due to our mature technology and significant cost reduction due to the scale effect. For the three months ended March 31, 2023, BC&#8217;s profit margin was 95.5%. However, there can be no assurance that BC will sustain a similarly high gross margin in the future. Various factors may affect BC&#8217;s gross margin, many of which are beyond its control. For example, changes in the competitive landscape of the relevant markets may decrease the average selling prices of BC&#8217;s products, which may have a negative effect on BC&#8217;s gross margin. Moreover, BC&#8217;s gross margin will be influenced by various components of BC&#8217;s costs, such as the cost of raw materials. For details, see &#8220;<font style="font-style: italic;">&#8212;Risks Relating to Manufacture and Supply of BC&#8217;s Products&#8212;Fluctuations in prices </font><font style="font-style: italic;">of BC&#8217;s raw materials and energy supply, as well as other costs associated with BC&#8217;s production processes, may have a </font><font style="font-style: italic;">material adverse effect on BC if BC is not able to transfer the cost increase to BC&#8217;s customers</font>&#8221; in this Risk Factors section.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">BC&#8217;s five largest customers accounted for a substantial amount of BC&#8217;s revenue during the years ended December&#160;31, 2021 and 2022, and three months ended March 31, 2023, which subjects BC to concentration risks.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC&#8217;s five largest customers accounted for a substantial amount of BC&#8217;s revenue for the years ended December&#160;31, 2021 and 2022 and the three months ended March 31, 2023. For details, see &#8220;<font style="font-style: italic;">BC&#8217;s Business&#8212;Customers</font>&#8221; in this proxy statement. As such, BC may be exposed to credit risks, and there can be no assurance that it can properly assess and respond in a timely manner to changes in BC&#8217;s customers&#8217; credit profile. As of December&#160;31, 2021 and 2022, BC had certain concentrations of credit risk of 10% and 10%, respectively. As of March 31, 2023, BC had certain concentrations of credit risk of 10%. In addition, as of December&#160;31, 2021, 53.7% and 85.1%, and as of December&#160;31, 2022, 45.1% and 78.3%, of BC&#8217;s trade receivables were due from BC&#8217;s largest customer and BC&#8217;s five largest customers, respectively. As of March 31, 2023, 49.3% and 83.5% of BC&#8217;s trade receivables were due from BC&#8217;s largest customer and BC&#8217;s five largest customers, respectively. If such customers&#8217; cash flows, working capital, financial condition or results of operations decrease, they may be unable, or they may otherwise be unwilling, to pay trade receivables owed to BC promptly or at all. Any substantial defaults or delays could materially and adversely affect BC&#8217;s cash flows, and if BC terminates its relationships with its customers as a result of such customers&#8217; default or payment delay, then that may adversely and materially affect BC&#8217;s cash flows and operations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If any of BC&#8217;s major customers stops purchasing BC&#8217;s products or substantially reduces order size in the future, whether due to the termination or amendment of BC&#8217;s contractual relationship with such customer, or due to any other reason unrelated to BC, BC may not be able to identify and sell BC&#8217;s products to an alternative customer in a timely manner, or at all. As a result, BC&#8217;s business and financial performance may be materially and adversely affected.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Share-based payments may cause dilution to BC&#8217;s existing shareholders and have a negative effect on BC&#8217;s financial performance.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC adopted employee incentive plans for the benefit of BC&#8217;s employees as remuneration for their services provided to BC to incentivize and reward eligible persons who have contributed to the success of BC. During the year ended December&#160;31, 2021, BC reversed expenses for share-based compensation of $0.28&#160;million. During the year ended December 31, 2022, BC incurred expenses for share-based compensation of $1.28 million and during the three months ended March 31, 2023, BC incurred expenses for share-based compensation of $0.2 million. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Effective upon the consummation of the Contributions, BC intends to terminate the 2021 Plan and all awards outstanding thereunder. Thereafter, a sub-plan to the 2023 Omnibus Incentive Plan (the &#8220;PRC Sub-plan&#8221;) will be used to facilitate grants of stock options to certain BC employees, on terms substantially similar in all material respects to those previously outstanding under the 2021 Plan. Issuance of additional shares pursuant to the PRC Sub-plan may dilute the ownership of the combined company&#8217;s existing stockholders.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">BC may face risk regarding the obsolescence of its inventories.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC&#8217;s inventories consist of raw materials, works in progress, semi-finished goods and finished goods. As of December&#160;31, 2021 and 2022, BC&#8217;s inventories were valued at $5.7&#160;million and $6.1&#160;million, respectively, and as of March 31, 2023, BC&#8217;s inventories were valued at $5.7 million. During the years ended December&#160;31, 2021 and 2022, and the three months ended March 31, 2023, BC did not identify material inventory items requiring impairment provisioning, and BC believes that maintaining appropriate levels of inventory helps BC meet market demands in a timely manner. BC generally purchases supplies based on its estimated demand and manufacturing capacity, and BC&#8217;s </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">89<br></div></div></div>
<!--End Page 100-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 101-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg57"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">management system covers each stage of the warehousing process. The storage and distribution of BC&#8217;s inventories are closely monitored in order to keep BC&#8217;s inventories and logbook consistent. However, as BC&#8217;s business expands, BC&#8217;s inventory levels may increase and the risk of obsolescence may increase accordingly. Furthermore, any unexpected material fluctuations in the supplies or changes in customers&#8217; preferences may lead to decreased demand and overstocking of supplies and increase the risk of obsolescence.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">If BC's intangible assets are impaired, BC's results of operations and financial condition may be adversely affected. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC has intangible assets primarily consisting of product development in progress, patents, technological know-how, and computer software, which accounted for a considerable portion of BC's total assets as of December 31, 2021 and 2022 and March 31, 2023. The value of BC's intangible assets is based on a number of assumptions made by BC's management. If any of these assumptions do not materialize, or if the performance of BC's business is not consistent with such assumptions, BC may have to write off a significant portion of BC's intangible assets and record a significant impairment loss. In addition, BC's determination on whether intangible assets are impaired requires an estimation of the carrying amount and recoverable amount of an intangible asset. If the carrying amount exceeds its recoverable amount, BC's intangible assets may be impaired, which could have a material adverse effect on BC's business, financial condition and results of operations. For details of BC's accounting policies with respect to intangible assets, see &#8220;<font style="font-style: italic;">Audited Financial Statements of Beijing Continent Pharmaceuticals Co., Ltd. &#8212;Summary of </font><font style="font-style: italic;">Significant Accounting Policies</font>&#8221; in this proxy statement. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">If BC is subject to U.S. GAAP reporting requirements, it would be difficult and costly for BC to comply with. If BC decides to convert its accounting standards of its financial statements from IFRS to U.S. GAAP, there may be significant effect on its reported financial results. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The SEC permits foreign private businesses to present financial statements in accordance with IFRS as issued by the IASB. In the future, if BC were required to change its basis of accounting from IFRS to U.S. GAAP, it may be difficult and costly for BC to comply with. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">At any time in the future, BC may decide to convert the accounting standards of its financial statements from IFRS to U.S. GAAP. The application by BC of different accounting standards could have a significant effect on BC's reported financial results. Additionally, U.S. GAAP is subject to interpretation by the Financial Accounting Standards Board, the American Institute of Certified Public Accountants, the SEC, and various bodies formed to promulgate and interpret appropriate accounting principles. A change in these principles or interpretations could have a significant effect on BC's reported financial results.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">BC may be subject to credit risk in collecting trade receivables due from its customers.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of December&#160;31, 2021 and 2022, BC&#8217;s trade receivables amounted to $10.0&#160;million and $15.6&#160;million, respectively, which primarily represented the balances due from BC&#8217;s distributors. As of March 31, 2023, BC&#8217;s trade receivables amounted to $12.5, which primarily represented the balances due from BC&#8217;s distributors. BC&#8217;s liquidity and cash flow are directly affected by its customers&#8217; ability to pay BC in a timely manner, but there can be no assurance that BC&#8217;s customers will not default on BC in the future, despite BC&#8217;s efforts to conduct credit assessments. During the years ended December&#160;31, 2021 and 2022, BC&#8217;s trade receivables turnover days were 37 days and 46 days, respectively. During the three months ended March 31, 2023, BC&#8217;s trade receivables turnover days were 54 days.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If any of BC&#8217;s customers&#8217; business, cash flow, conditions or results of operations decrease, such customers may be unable or unwilling to pay trade receivables owed to BC promptly or at all. Bankruptcy or deterioration of the credit condition of BC&#8217;s major customers could also materially and adversely affect BC&#8217;s collection of trade receivables. For details of the risk associated with concentrations of credit risk that BC is exposed to, see &#8220;&#8212;<font style="font-style: italic;">BC&#8217;s five largest </font><font style="font-style: italic;">customers accounted for a substantial amount of BC&#8217;s revenue during the years ended December&#160;31, 2021 and 2022, </font><font style="font-style: italic;">and three month ended March 31, 2023, </font><font style="font-style: italic;">which subjects BC to concentration risks</font>&#8221; in this Risk Factors section. If significant amounts due to BC is not settled in a timely manner, BC may incur significant write-offs and BC&#8217;s liquidity and cash flow may be adversely affected.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">BC has historically received government grants and has been entitled to preferential tax treatment, but BC may not continue to receive government financial incentives in the future.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC has historically received government grants in connection with certain of its research and development and manufacturing activities, and recognized government grants under other income and gains of $0.1&#160;million and $0.9&#160;million for the years ended December&#160;31, 2021 and 2022, respectively, and $0.1 million for the three months </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">90<br></div></div></div>
<!--End Page 101-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 102-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg58"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">ended March 31, 2023. For details of the amounts of BC&#8217;s other recognized income, see Note 5 to the <font style="font-style: italic;">Audited </font><font style="font-style: italic;">Financial Statements of Beijing Continent Pharmaceuticals Co., Ltd.</font> to this proxy statement. BC was also entitled to a preferential corporate income tax rate of 15% for each of the years ended December&#160;31, 2021 and 2022 as a High and New Technology Enterprise. In addition, BC&#8217;s ETUARY has been entitled to a preferential value-added tax (&#8220;VAT&#8221;) treatment at the tax rate of 3%. However, there can be no assurance of the continued availability of such preferential treatment. BC&#8217;s eligibility for government grants and preferential tax rates depends on a variety of factors, including, but not limited to, the assessment of BC&#8217;s improvement on existing technologies, relevant government policies and the availability of funding at different granting authorities. In addition, the timing, amount and criteria of government financial incentives are determined within the sole discretion of the local PRC government authorities. Government financial incentives are non-recurring in nature, and there can be no guarantee that BC will continue to receive government incentives. In addition, some government financial incentives may be subject to the satisfaction of certain conditions, including compliance with the applicable financial incentive agreements and completion of the specific projects therein, which BC may not satisfy. Any reduction or elimination of the government financial incentives BC currently receives could have an adverse effect on BC&#8217;s financial condition.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Risks Relating to BC&#8217;s General Operations</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC may fail to sufficiently and promptly respond to clinical demand and market changes in the pharmaceutical industry.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Clinical demand and market conditions for pharmaceutical products may change rapidly and significantly, and BC&#8217;s success in part depends on BC&#8217;s ability to anticipate product offering lead-times and demand, identify customer preferences and adapt BC&#8217;s products to these preferences. BC may need to adjust BC&#8217;s research and development plan, production scale and schedule, product portfolio and inventory levels based on customer demand, sales trends and other market conditions. However, there can be no assurance that BC will be able to sufficiently and promptly respond to changes in clinical demand and purchasing patterns in a timely manner or at all.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Business disruptions could seriously harm BC&#8217;s future revenue and financial condition and increase BC&#8217;s costs and expenses.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC&#8217;s operations, and those of BC&#8217;s distributors, suppliers, research institution collaborators and other business partners, could be subject to natural or man-made disasters, health epidemics or business interruptions, for which BC is predominantly self-insured. Damage or extended periods of interruption to BC&#8217;s and BC&#8217;s partners&#8217; administration, development, research, manufacturing or storage facilities due to fire, natural disaster, health epidemic, power loss, communications failure, unauthorized entry or other events could cause BC to cease or delay development or commercialization of some or all of BC&#8217;s drug candidates, seriously harm BC&#8217;s and its partners&#8217; operations and financial condition and increase BC&#8217;s and its partners&#8217; costs and expenses.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">BC is highly dependent on the services of its senior management team and if BC is not able to retain these members of its management team and recruit and retain additional management, clinical and scientific personnel, BC&#8217;s business may be harmed.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC&#8217;s success is highly dependent the services of its directors and senior management to manage BC&#8217;s business and operations, and BC&#8217;s key research and development personnel to develop new products, technologies and applications and to enhance BC&#8217;s existing products. BC&#8217;s ability to attract, hire, retain and motivate qualified scientific, technical, clinical, manufacturing and sales and marketing personnel, as well as other consultants and advisers, is also crucial for BC. Although BC has entered into employment agreements and consulting agreements with each of BC&#8217;s executives, employees, consultants and advisers, they may terminate their agreements with BC at their election. The loss of the services of any of these persons could impede the achievement of BC&#8217;s research, development and commercialization objectives. If BC is not able to retain its management and to attract, on terms acceptable to BC, additional qualified personnel necessary for the continued development of BC&#8217;s business, BC may not be able to sustain its operations or grow. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC competes for qualified personnel with other pharmaceutical and biotechnology companies, universities and research institutions. The pool of suitable candidates is limited, and BC may not be able to hire and retain enough skilled and experienced scientists or other technical personnel at the current level of wages, and may need to offer higher compensation and other benefits, which could materially and adversely affect BC&#8217;s financial condition and results of operations.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">91<br></div></div></div>
<!--End Page 102-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 103-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg59"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">BC&#8217;s future performance will also depend, in part, on its ability to successfully integrate newly hired executive officers into its management team and BC&#8217;s ability to develop an effective working relationship among senior management. BC&#8217;s failure to integrate these individuals and create effective working relationships among them and other members of management could result in inefficiencies in the development and commercialization of BC&#8217;s product candidates, harming future marketing approvals, sales of BC&#8217;s product candidates and BC&#8217;s results of operations. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: justify;">BC&#8217;s business, results of operations and financial position may be adversely affected by the ongoing COVID-19 pandemic.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC&#8217;s business operations have been, and may continue to be, negatively affected by the COVID-19 pandemic. For example, any temporary suspension of production, shortage of labor and raw materials or disruption of local and international travel may affect imports related to BC&#8217;s business. In addition, the completion of technological improvements to BC&#8217;s manufacturing facilities may be delayed. The COVID-19 pandemic may delay the development progress of drug candidates due to a prolonged process of patient enrollment for BC&#8217;s ongoing clinical trials, the removal of enrolled patients and the delay of response from the relevant governmental authorities reviewing BC&#8217;s clinical trial applications.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">COVID-19 has impacted the eligible patients for BC&#8217;s trials, including BC&#8217;s ongoing clinical trials of pirfenidone in CTD-ILD and pneumoconiosis and its Phase 3 trial in Hydronidone and Phase 2 trial in F573, which has resulted in delays in patient recruitment and the clinical results of BC&#8217;s trials. Despite the measures BC has taken to arrange procurement, manufacturing and sales in response to COVID-19, there can be no assurance that BC will not be subject to further negative impact if the outbreak persists or escalates. BC cannot forecast with certainty the future impact of additional outbreaks or government restrictions, including further shelter-in-place or other government restrictions implemented in response to such outbreaks, or the ability of BC&#8217;s suppliers and other business partners to remain in business during the ongoing pandemic or additional outbreaks. With the uncertainties surrounding the COVID-19 outbreak, the risk to BC&#8217;s business and the related financial impact remains uncertain.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: justify;">BC may become a party or subject to litigation, legal disputes, claims, administrative proceedings or other administrative measures, which may divert BC&#8217;s management&#8217;s attention and result in costs and liabilities, and there can be no assurance that the results of such legal proceedings would favor BC.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC may from time to time become subject to various litigation, legal or contractual disputes, investigations or administrative proceedings arising in the ordinary course of BC&#8217;s business, including, but not limited to, various disputes with or claims from BC&#8217;s suppliers, customers, contractors, licensors, business partners and other third parties that BC engages for its business operations. Ongoing or threatened litigation, legal disputes, claims, investigations or administrative proceedings may divert BC&#8217;s management&#8217;s attention and BC&#8217;s time and resources. Furthermore, whether a certain litigation, dispute, investigation or proceeding may have a materially adverse effect on BC is subject to a variety of factors, including, but not limited to, the facts and circumstances of the proceeding, the likelihood of loss, the monetary amount at stake and the parties involved. If any verdict or award is rendered against BC or if BC agrees to settle with an adverse party, BC could be required to pay significant monetary damages, assume other liabilities and/or suspend or terminate the related business projects. Negative publicity arising from litigation, legal disputes, investigations or administrative proceedings may damage BC&#8217;s reputation and adversely affect the image of BC&#8217;s brands and products.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: justify;">If BC or its employees, distributors, agents, suppliers or affiliates engage, or are perceived to engage in misconduct or breach of relevant agreements, including corrupt practices or unauthorized distribution of confidential information, BC could be exposed to regulatory investigations, costs and liabilities.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC is subject to risks related to actions taken by BC, BC&#8217;s employees, distributors, agents, suppliers or affiliates that may or are perceived to constitute violations of anti-corruption and other related laws in jurisdictions where BC conducts business. Allegations of corrupt practices against BC, BC&#8217;s employees, distributors, agents or affiliates or the pharmaceutical industry in general could generate negative publicity and materially and adversely affect BC&#8217;s reputation and business prospects. Despite BC&#8217;s procedures and controls to monitor compliance with applicable anti-corruption laws, BC may be exposed to risks for actions taken by BC, BC&#8217;s employees or distributors, in which case government authorities may seize the products involved in any illegal or improper conduct engaged in by BC, BC&#8217;s employees or distributors. BC may also be subject to claims, fines or suspension of its operations.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">92<br></div></div></div>
<!--End Page 103-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 104-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg60"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BC may be subject to product liability claims that could expose BC to costs and liabilities.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC is exposed to product liability risks as a result of developing, producing, marketing, promoting and selling pharmaceutical products in the PRC and other jurisdictions. Such claims may arise if any of BC&#8217;s products are deemed or proven to be unsafe, ineffective, defective or contaminated, or if BC is alleged to have engaged in practices such as insufficient or improper labeling of products or providing inadequate, insufficient or misleading warnings or disclosures regarding side effects. A product liability claim brought against BC may, regardless of merit or outcome, result in reputational harm and strain on financial resources and may consume the time and attention of BC&#8217;s management. If BC is unable to successfully defend itself against such claims, BC may, among others, be subject to product recalls, civil liability for physical injury, death or other losses caused by BC&#8217;s products, criminal liability and the revocation of BC&#8217;s business licenses. PRC laws and regulations currently do not require BC to, and BC does not, maintain liability insurance to cover product liability claims. As a result, BC may not be able to recover BC&#8217;s losses resulting from future product liability claims.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">BC may grow its business in part through acquisitions, which may increase BC&#8217;s capital requirements, dilute BC&#8217;s shareholders, cause BC to incur debt or assume contingent liabilities and have material adverse effect on BC&#8217;s ability to manage its business, and BC may fail to successfully complete such acquisitions or enhance post-acquisition performances in the future.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">To enhance BC&#8217;s growth and benefit BC&#8217;s product development, technology advancement and distribution network, BC may acquire businesses, products, technologies or know-how or enter into strategic partnerships. Any completed, in-process or potential acquisition or strategic partnership may entail numerous risks, including:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">inability to identify suitable acquisition targets and reach agreement on acceptable terms;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">lack of access to financing for acquisitions on acceptable terms or at all, or otherwise on assumption of additional indebtedness or contingents and issuance of BC&#8217;s equity securities;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">failure to obtain or secure the governmental approvals and third-party consents necessary to consummate any proposed acquisition;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">increased operating expenses, including research and development expenses due to an increased number of drug candidates, administrative expenses and selling expenses;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">diversion of BC&#8217;s management&#8217;s attention from BC&#8217;s existing product programs and initiatives in pursuing such a strategic merger or acquisition;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">difficulty in retention of key employees, the loss of key personnel and uncertainties in BC&#8217;s ability to maintain key business relationships;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products and drug candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">inability to generate revenue from acquired technology and/or products sufficient to meet BC&#8217;s objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs; and/or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">deficiencies in internal controls, data adequacy and integrity, product quality and regulatory compliance and product liabilities in the acquired business BC discovers after such acquisition. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">BC&#8217;s plan to grow its business through such acquisitions may not materialize as expected.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">BC&#8217;s internal risk management and control system may not be adequate or effective to detect potential risks in BC&#8217;s business as intended.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC has an internal control system in place to monitor and control potential risk areas relevant to BC&#8217;s business operations. However, due to the inherent limitations in the design and implementation of BC&#8217;s internal control system, if external circumstances change substantially or extraordinary events take place, BC&#8217;s internal control system may not be sufficiently effective in identifying, managing and preventing all risks. Further, integration of various business operations from future acquisitions may expose BC to additional, unknown internal control risks, despite BC&#8217;s efforts to anticipate such issues. BC&#8217;s risk management and internal controls also depend on effective </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">93<br></div></div></div>
<!--End Page 104-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 105-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg61"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">implementation by BC&#8217;s employees. There can be no assurance that such implementation by BC&#8217;s employees will always function as intended, or such implementation will not be subject to human errors, mistakes or intentional misconduct.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Breach, failure or disruption in or to BC&#8217;s information system could compromise sensitive information related to its business and expose BC to liability or reputational harm, and BC&#8217;s ability to effectively manage BC&#8217;s business operations could be adversely affected.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC&#8217;s information systems may fail and are subject to risks of breakdown, breach, interruption or damage from computer viruses, computer hackers, malicious code, employee error or malfeasance, theft or misuse, denial-of-service attacks, sophisticated nation-state and nation-state-supported actors, unauthorized access, natural disasters, terrorism, war, telecommunication and electrical failures or other compromise. Any system damage or failure that interrupts data input, retrieval or transmission or increases service time could disrupt BC&#8217;s normal operations, including the loss of clinical trial data from completed or future clinical trials. Loss of clinical trial data could result in delays in BC&#8217;s regulatory approval efforts and significantly increase BC&#8217;s costs to recover or reproduce the data. There can be no assurance that BC will be able to effectively handle a failure of BC&#8217;s information systems, or that BC will be able to restore BC&#8217;s operational capacity in a timely manner or at all to avoid disruption to BC&#8217;s business. To the extent that any disruption or security breach were to result in a loss of, or damage to, BC&#8217;s data or applications, or inappropriate use, disclosure of or access to confidential or proprietary information, BC could incur liability, BC&#8217;s competitive position could be harmed and the further development and commercialization of BC&#8217;s drugs and drug candidates could be hindered or delayed.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC may collect and store sensitive personal data in the ordinary course of BC&#8217;s business. For details, see &#8220;<font style="font-style: italic;">&#8212;Risks </font><font style="font-style: italic;">Relating to Extensive Governmental Regulations&#8212;BC is subject to stringent privacy laws, information security </font><font style="font-style: italic;">policies and contractual obligations related to data privacy and security, and BC is exposed to risks related to BC&#8217;s </font><font style="font-style: italic;">management of patient medical data and other personal or sensitive information.</font>&#8221; in this Risk Factors section. If personal data are compromised due to a material breach of BC&#8217;s information, the market perception of the effectiveness of BC&#8217;s security measures could be harmed and BC&#8217;s reputation and credibility could be damaged. BC could be subject to regulatory actions and/or claims made by individuals and groups in private litigation involving privacy issues related to data collection and use practices and other data privacy laws and regulations.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">If BC fails to comply with environmental, health and safety laws and regulations, BC could become subject to fines or penalties or incur costs that could materially and adversely affect BC&#8217;s business.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Because BC&#8217;s operations involve the use of hazardous chemical materials and may produce hazardous waste, BC is subject to numerous environmental, health and safety laws and regulations, including those governing air emissions, discharge of water and the handling, use, storage, treatment and disposal of hazardous materials and wastes. While BC has entered into hazardous waste disposal agreements with third parties for the disposal of these materials and wastes, BC cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from BC&#8217;s use of hazardous materials, BC could be held liable for any resulting damages, and incur significant costs associated with civil or criminal fines and penalties. Further, BC does not maintain insurance for environmental liability or toxic tort claims that may be asserted against BC in connection with BC&#8217;s storage, use or disposal of hazardous materials and waste.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Increased labor costs negatively affect BC&#8217;s operations and have an adverse impact on BC&#8217;s profitability.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC&#8217;s strategies and business growth may require BC to hire additional employees, and BC may also hire additional employees as a result of acquisitions. The average cost of labor in the PRC has been steadily increasing in recent years as a result of inflation, government-mandated wage increases and other changes in PRC labor laws, as well as competition for talent and qualified employees among pharmaceutical companies. As a result, increased labor costs could have negative effects on BC&#8217;s growth and decrease BC&#8217;s profitability.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">BC has limited insurance coverage, and any claims beyond BC&#8217;s insurance coverage may result in substantial costs and a diversion of resources.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC operates in the pharmaceutical industry, which involves numerous operating risks and occupational hazards. The insurance policies BC maintains are required under the applicable laws and regulations as well as based on BC&#8217;s assessment of its operational needs and industry practice. For more details, see &#8220;<font style="font-style: italic;">BC&#8217;s Business&#8212;Insurance</font>&#8221; in this proxy statement. However, there can be no assurance that the existing insurance coverage is sufficient to compensate </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">94<br></div></div></div>
<!--End Page 105-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 106-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg62"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">for actual losses suffered or incurred. In addition, there are certain types of losses, such as losses from war, acts of terrorism, health or public security hazards, earthquakes, typhoons, flooding and other natural disasters, for which BC cannot obtain insurance at a reasonable cost or at all. If an uninsured loss or a loss in excess of insured limits were to occur, BC&#8217;s business, results of operations and financial condition may be materially and adversely affected. For details of the specific risks of inadequate insurance coverage in the event of product liability claims and environmental liabilities, see &#8220;<font style="font-style: italic;">&#8212;BC may be subject to product liability claims that could expose BC to costs and </font><font style="font-style: italic;">liabilities</font>&#8221; and &#8220;<font style="font-style: italic;">&#8212;If BC fails to comply with environmental, health and safety laws and regulations, BC could </font><font style="font-style: italic;">become subject to fines or penalties or incur costs that could materially and adversely affect the success of BC&#8217;s </font><font style="font-style: italic;">business</font>,&#8221; respectively, in this section.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: justify;">Changes in the U.S. and international trade policies, particularly with regards to the PRC, may adversely impact BC&#8217;s business and operating results.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">International market conditions and the international regulatory environment have historically been affected by competition among countries and geopolitical frictions. Changes to trade policies, treaties and tariffs of the jurisdictions in which BC operates, or the perception that these changes could occur, could adversely affect the financial and economic conditions of the jurisdictions in which BC operates, as well as BC&#8217;s overseas expansion, BC&#8217;s financial condition and results of operations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For example, BC purchased raw materials from certain overseas suppliers through procurement agents during the years ended December&#160;31, 2021 and 2022. In the event that the countries from which BC&#8217;s agents import raw materials impose export controls, trade restrictions or other trade barriers affecting the exportation of such components or raw materials, BC may not be able to obtain a steady supply of necessary components or raw materials at competitive prices, and BC&#8217;s business and operations may be materially and adversely affected. In addition, the United States government has recently made significant changes in its trade policy and has taken certain actions that may materially impact international trade, such as announcing import tariffs which have led to other countries, including the PRC and members of the European Union, imposing tariffs against the United States in response. There can be no assurances as to whether and to what extent any such actions would have a significant effect on BC or BC&#8217;s industry.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Risks Related to BC&#8217;s Business Operations in the PRC</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The PRC government may intervene in or influence BC&#8217;s operations at any time, which could result in a change in BC&#8217;s operations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The PRC government has some oversight and discretion over the conduct of BC&#8217;s business and may intervene or influence BC&#8217;s operations as the government deems appropriate to further regulatory, political and societal goals. The PRC government has recently published new policies that significantly affected certain industries such as the education and internet industries, and BC cannot rule out the possibility that it will in the future release regulations or policies regarding BC&#8217;s industry that could require BC to seek permission from the PRC authorities to continue to operate BC&#8217;s business that could potentially affect BC&#8217;s business, financial condition and results of operations. Furthermore, recent statements made by the PRC government, including the Opinions on Strictly Cracking Down Illegal Securities Activities in Accordance with the Law, and new rules published for comments by the PRC government, including the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Enterprises to become effective on March&#160;31, 2023, establish a new filing-based regime to regulate overseas offerings and listings by domestic companies. If BC were to become subject to the direct intervention or influence of the PRC government at any time due to changes in laws or other unforeseeable reasons, it may require a material change in BC&#8217;s operations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, the risks that the PRC government may intervene or influence the combined company&#8217;s operations at any time following the consummation of the Contributions could significantly limit or completely hinder the combined company&#8217;s ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or be worthless. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">95<br></div></div></div>
<!--End Page 106-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 107-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg63"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The pharmaceutical industry in the PRC is highly regulated and such regulations are subject to change, which may affect approval and commercialization of BC&#8217;s drugs and drug candidates.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The pharmaceutical industry in the PRC is subject to comprehensive government regulation and supervision, encompassing the approval, registration, manufacturing, packaging, licensing and marketing of new drugs. For details of a discussion of regulatory requirements that are applicable to BC&#8217;s current and planned business in the PRC, see &#8220;<font style="font-style: italic;">BC&#8217;s Business&#8212;Regulatory Requirements in the PRC</font>&#8221; in this proxy statement. BC believes its strategy and approach are consistent with the PRC government&#8217;s policies, but BC cannot ensure that its strategy and approach will continue to be consistent. In recent years, the regulatory framework for the pharmaceutical industry in the PRC has undergone significant changes, and BC expects that it will continue to undergo significant changes. Any such changes or amendments may result in:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">increased compliance costs on BC&#8217;s business; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">delays in or prevention of successful development or commercialization of BC&#8217;s drug candidates; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reduction of the current benefits BC experiences and believes are available to BC from developing and manufacturing drugs in the PRC. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The PRC authorities have also become increasingly vigilant in enforcing laws in the pharmaceutical industry, and any failure by BC to maintain compliance with applicable laws and regulations may result in the suspension or termination of BC&#8217;s business activities in the PRC.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: justify;">Adverse changes in political, economic and other policies of the PRC government could have a material adverse effect on the overall economic growth of the PRC, which could reduce the demand for BC&#8217;s products, or otherwise materially and adversely affect BC&#8217;s business, operations or competitive position.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC&#8217;s business, results of operations, financial condition and prospects may be influenced to a significant degree by economic, political, legal and social conditions in the PRC. The PRC&#8217;s economy differs from the economies of developed countries in many respects, including with respect to the amount of government involvement, level of development, growth rate, control of foreign exchange, allocation of resources and an evolving regulatory system. The PRC government has implemented various measures to encourage economic development and guide the allocation of resources, but some of these measures may have a negative effect on BC. For example, BC&#8217;s financial condition and results of operations may be adversely affected by government control over capital investments or changes in tax regulations that are currently applicable to BC. Growth of the PRC economy has been uneven across different regions and among various economic sectors of the PRC, and there can be no assurance that future growth will be sustained at similar rates or at all. If the business environment or economic conditions in the PRC deteriorates from the perspective of domestic or international investment, BC&#8217;s business may also be adversely affected.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">There are uncertainties regarding the interpretation and enforcement of PRC laws, rules and regulations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The PRC legal system is a civil law system based on written codes and statutes. Unlike the common law system, prior court decisions may be cited as persuasive authority, but have limited precedential value. Since the late 1970s, the PRC government has promulgated a comprehensive system of laws, rules and regulations governing economic matters in general. However, as these laws and regulations are relatively recent and the number of published decisions is limited, their interpretation and enforcement involve significant and certainties, and can be inconsistent and unpredictable. Since PRC administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection BC may experience compared to developed legal systems. These uncertainties may impede BC&#8217;s ability to enforce the contracts BC has entered into and could materially and adversely affect BC&#8217;s business, financial condition and results of operation.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Furthermore, PRC laws and regulations afford significant protection to state-owned assets. Contributions that may lead to losses of state-owned assets are subject to heightened scrutiny by the competent authorities, and the competent authorities have significant discretion in interpreting and implementing the relevant laws and regulations. In the event BC or its affiliates conduct transactions with state-owned enterprises or their affiliates, BC is exposed to risks and uncertainties involving the potential of loss of state-owned assets, which may subject BC to liabilities and could materially and adversely affect BC&#8217;s business, financial condition and results of operation.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">96<br></div></div></div>
<!--End Page 107-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 108-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg64"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The PRC legal system is based in part on government policies and internal rules, some of which are not published on a timely basis or at all, and which may have a retroactive effect. As a result, BC may not be aware of BC&#8217;s violation of these policies and rules until after the occurrence of the violation.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Litigants may experience difficulties in effecting service of legal process and enforcing judgments against BC and BC&#8217;s management.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC is incorporated under the laws of the PRC with limited liability, and substantially all of BC&#8217;s assets are located in the PRC. In addition, a majority of BC&#8217;s directors and supervisors and all of BC&#8217;s senior management personnel reside within the PRC, and substantially all their assets are located within the PRC. As a result, it may not be possible to effect service of process within the United States or elsewhere outside the PRC upon BC or most of BC&#8217;s directors, supervisors and senior management personnel.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">When it comes to trans-jurisdictional recognition and enforcement of judgments, the PRC does not have treaties providing for the reciprocal recognition and enforcement of judgments of courts with the United States or many other countries. In addition, Hong Kong has no arrangement for the reciprocal enforcement of judgments with the United States. As a result, recognition and enforcement in the PRC or Hong Kong of judgments of a court obtained in the United States and any of the other jurisdictions mentioned above may be difficult or impossible.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On July&#160;14, 2006, Hong Kong and the PRC entered into the Arrangement on Reciprocal Recognition and Enforcement of Judgments in Civil and Commercial Matters by the Courts of the Mainland and of the Hong Kong Special Administrative Region Pursuant to Choice of Court Agreements Between Parties Concerned (the &#8220;Arrangement&#8221;), pursuant to which a party with an enforceable final court judgment rendered by a Hong Kong court requiring payment of money in a civil and commercial case according to a choice of court agreement in writing may apply for recognition and enforcement of the judgment in the PRC. Similarly, a party with an enforceable final judgment rendered by a PRC court requiring payment of money in a civil and commercial case pursuant to a choice of court agreement in writing may apply for recognition and enforcement of such judgment in Hong Kong. A choice of court agreement in writing is defined as any agreement in writing entered into between parties after the effective date of the Arrangement in which a Hong Kong court or a PRC court is expressly designated as the court having sole jurisdiction for the dispute.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On January&#160;18, 2019, the Supreme People&#8217;s Court and the government of the Hong Kong Special Administrative Region entered into the Arrangement on Reciprocal Recognition and Enforcement of Judgments in Civil and Commercial Matters by the Courts of the Mainland and of the Hong Kong Special Administrative Region (the &#8220;New Arrangement&#8221;), which seeks to establish a mechanism with further clarification on and certainty for recognition and enforcement of judgments in a wider range of civil and commercial matters between Hong Kong Special Administrative Region and the PRC. The New Arrangement discontinued the requirements for a choice of court agreement for bilateral recognition and enforcement. The New Arrangement will only take effect after the promulgation of a judicial interpretation by the Supreme People&#8217;s Court and the completion of the relevant legislative procedures in the Hong Kong Special Administrative Region. The New Arrangement will, upon its effectiveness, supersede the Arrangement. Therefore, before the New Arrangement becomes effective it may be difficult or impossible to enforce a judgment rendered by a Hong Kong court in the PRC if the parties in the dispute do not agree to enter into a choice of court agreement in writing. As a result, it may be difficult or impossible for investors to effect service of process against BC&#8217;s assets or management in the PRC in order to seek recognition and enforcement of foreign judgments in the PRC.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Implementation of the labor laws and regulations in the PRC may adversely affect BC&#8217;s business and results of operations, and failure to fully comply with PRC labor-related laws may expose BC to potential liabilities and penalties.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the PRC Labor Contract Law, employers are subject to stricter requirements in terms of signing labor contracts, minimum wages, paying remuneration, determining the term of employees&#8217; probation and unilaterally terminating labor contracts. Due to lack of detailed interpretative rules and broad discretion of the local competent authorities, it is uncertain as to how the labor contract law and its implementation rules will affect BC&#8217;s current employment policies and practices. BC&#8217;s employment policies and practices may violate the labor contract law or its implementation rules, and BC may thus be subject to related penalties, fines or legal fees.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Compliance with the labor contract law and its implementation rules may increase BC&#8217;s operating expenses, in particular, BC&#8217;s personnel expenses. In the event that BC decides to terminate some of BC&#8217;s employees or otherwise </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">97<br></div></div></div>
<!--End Page 108-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 109-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg65"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">change BC&#8217;s employment or labor practices, the labor contract law and its implementation rules may also limit BC&#8217;s ability to effect those changes in a desirable or cost-effective manner, which could adversely affect BC&#8217;s business and results of operations. According to the PRC Social Insurance Law (the &#8220;Social Insurance Law&#8221;), employees must participate in pension insurance, work-related injury insurance, medical insurance, unemployment insurance and maternity insurance, and the employers must, together with their employees or separately, pay the social insurance premiums for such employees. Recently, the PRC government enhanced its measures relating to social insurance collection, which may lead to stricter enforcement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC expects its labor costs to increase due to the implementation of these laws and regulations. Compliance with the Social Insurance Law and its implementation rules may increase BC&#8217;s operating expenses, in particular, BC&#8217;s personnel expenses. As the interpretation and implementation of these laws and regulations are still evolving, there can be no assurance that BC&#8217;s employment practice policy will at all times be deemed to be in full compliance with labor-related laws and regulations in the PRC, which may subject BC to labor disputes or government investigations. If BC is deemed to have violated relevant labor laws and regulations, BC could be required to provide additional compensation to BC&#8217;s employees and BC&#8217;s business, financial condition and results of operations could be materially and adversely affected.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Fluctuations in exchange rates may result in foreign currency exchange losses.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The change in the value of the Renminbi against other currencies may fluctuate and is affected by, among other things, changes in the PRC&#8217;s political and economic conditions and the PRC&#8217;s foreign exchange policies, as well as supply and demand in the local market. BC is exposed to the risks of market forces or government policies and their impact on the exchange rate between Renminbi or other currencies in the future. Substantially all of BC&#8217;s costs are denominated in Renminbi and most of BC&#8217;s financial assets are also denominated in Renminbi. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">BC&#8217;s operations are subject to and may be affected by changes in PRC tax laws and regulations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The PRC government from time to time adjusts or changes its tax laws and regulations, and future adjustments or changes to PRC tax laws and regulations, together with any uncertainty resulting therefrom, could have an adverse effect on BC&#8217;s results of operations. BC&#8217;s ETUARY has been subject to a preferential VAT treatment at the tax rate of 3%, applicable to a number of drugs for rare diseases, since March 2019. However, there can be no assurance that BC&#8217;s applicable VAT rate will stay the same or decrease, and any future changes to the VAT policies may negatively impact the selling price of BC&#8217;s products and future approved drug candidates.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Furthermore, under the amended Individual Income Tax Law, foreign nationals who have no domicile in the PRC, but have resided in the PRC for a total of 183 days or more in a tax year, are subject to PRC individual income tax on their income gained within or outside the PRC. The amended Individual Income Tax Law may materially affect BC&#8217;s ability to attract and retain highly skilled foreign scientists and research technicians to work in the PRC. BC is also subject to periodic examinations on fulfillment of BC&#8217;s tax obligation under the PRC tax laws and regulations by PRC tax authorities, and there can be no assurance that any such examinations by PRC tax authorities would not result in fines, other penalties or actions that could adversely affect BC&#8217;s business, financial condition and results of operations, as well as BC&#8217;s reputation.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">BC may be restricted from transferring BC&#8217;s scientific data abroad or using human genetic resources collected in the PRC.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On March&#160;17, 2018, the General Office of the State Council promulgated the Measures for the Management of Scientific Data (the &#8220;Scientific Data Measures&#8221;), which provides a broad definition of scientific data and relevant rules for the management of scientific data. According to the Scientific Data Measures, enterprises in the PRC must seek governmental approval before any scientific data involving a state secret may be transferred abroad or to foreign parties. Upon approval by the competent authorities, the enterprise shall undergo the required procedures, and enter into the confidentiality agreements with the users of the scientific data. Further, any researcher conducting research funded at least in part by the PRC government is required to submit relevant scientific data for management by the entity to which such researcher is affiliated before such data may be published in any foreign academic journal. Given that the term &#8220;state secret&#8221; is not clearly defined, if and to the extent any data collected or generated in connection with BC&#8217;s R&amp;D of medical drug candidates are subject to the Scientific Data Measures and any subsequent laws as required by the relevant government authorities, there can be no assurance that BC can always obtain relevant approvals for sending scientific data (such as the results of BC&#8217;s pre-clinical studies or clinical trials conducted within the PRC) abroad or to BC&#8217;s foreign partners in the PRC. As a result, BC may be subject to fines and other administrative penalties imposed by those government authorities.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">98<br></div></div></div>
<!--End Page 109-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 110-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg66"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">In addition, pursuant to the Service Guide for Administrative Licensing Items Concerning Examination and Approval of Sampling, Collecting, Trading or Exporting Human Genetic Resources, or Taking Such Resources out of the PRC (the &#8220;Service Guide&#8221;), the sampling, collection or research activities of human genetic resources through clinical trials is required to be filed online with the China Human Genetic Resources Management Office. Furthermore, the Administrative Regulations on Human Genetic Resources of the PRC (the &#8220;Human Genetic Resources Regulation&#8221;) stipulates that collecting human genetic resources of the PRC&#8217;s important genetic families and specific regions, or collecting those human genetic resources in such categories and quantities as prescribed by the administrative department for science and technology under the State Council, preserving the PRC&#8217;s human genetic resources and providing the basic platform for scientific research, utilization of the PRC&#8217;s human genetic resources for international cooperation in scientific research, as well as transporting the PRC&#8217;s materials of human genetic resources abroad shall be subject to the approval of the administrative department for science and technology under the State Council. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If BC is unable to obtain necessary approvals or comply with the regulatory requirements in a timely manner, or at all, BC&#8217;s R&amp;D of drug candidates may be hindered. If the relevant government authorities consider the transmission of BC&#8217;s scientific data or collection and usage of human genetic resources to be in violation of the requirements under applicable PRC laws and regulations, BC may be subject to fines and other administrative penalties imposed by those government authorities. Furthermore, it is possible that the regulation may be interpreted and applied in a manner that is inconsistent with BC&#8217;s clinical trial practices, potentially resulting in the confiscation of human genetic resources samples and associated data and administrative fines.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: justify;">Changes in the political and economic policies of the PRC government or relations between the PRC and the United States may affect BC&#8217;s business, financial condition and results of operations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Due to BCs operations in the PRC, BC&#8217;s business, results of operations and financial condition may be influenced to a certain degree by economic, political, legal and social conditions in the PRC or changes in government relations between the PRC and the United States or other governments. There is significant uncertainty about the future relationship between the United States and the PRC with respect to trade policies, treaties, government regulations and tariffs. the PRC&#8217;s economy differs from the economies of developed countries in many respects, including with respect to the amount of government involvement, level of development, growth rate, control of foreign exchange and allocation of resources. While the PRC&#8217;s economy has experienced significant growth over the past four decades, growth has been uneven across different regions and among various economic sectors. The PRC government has implemented various measures to encourage economic development and guide the allocation of resources. Some of these measures may benefit the overall PRC economy, but may have a negative effect on BC. In addition, in the past, the PRC government implemented certain measures, including interest rate increases, to control the pace of economic growth. These measures may cause a decrease in economic activity in the PRC, which may affect BC&#8217;s business and results of operations. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">During the years ended December&#160;31, 2021 and 2022, BC relied on certain overseas suppliers to obtain raw materials, and BC has relied on collaboration with entities in foreign countries and regions in connection with its business operations. BC may also pursue partnerships with entities in foreign countries and regions in the future. BC&#8217;s business is therefore subject to changing international economic, regulatory, social and political conditions, and local conditions in foreign countries and regions. As a result, the PRC&#8217;s political relationships with those foreign countries and regions may affect development and commercialization of BC&#8217;s drugs and drug candidates.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Additionally, the PRC&#8217;s political relationships with those foreign countries and regions may also affect BC&#8217;s current and future relationships with third parties. There can be no assurance that BC&#8217;s existing or potential collaborators will not alter their perception of BC or their preferences as a result of adverse changes to the state of political relationships between the PRC and the relevant foreign countries or regions, and such alteration may cause a decline in the demand for BC&#8217;s products and adversely affect BC&#8217;s business, financial condition, results of operations, cash flows and prospects.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In July 2021, the PRC government provided new guidance on the PRC-based companies raising capital outside of the PRC, including through arrangements called variable interest entities (&#8220;VIEs&#8221;). In light of such developments, the SEC has imposed enhanced disclosure requirements on the PRC-based companies seeking to register securities with the SEC. Although BC does not have a VIE structure, due to BC&#8217;s operations in the PRC, any future PRC, U.S. or other rules and regulations that place restrictions on capital raising or other activities by companies with operations </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">99<br></div></div></div>
<!--End Page 110-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 111-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg67"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">in the PRC could affect BC&#8217;s business and results of operations. If the business environment in the PRC deteriorates from the perspective of domestic or international investment, or if relations between the PRC and the United States or other governments deteriorate, the PRC government may intervene with BC&#8217;s operations and BC&#8217;s business in the PRC and United States.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Changes in U.S. and PRC regulations may impact BC&#8217;s business, its operating results and its ability to raise capital.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The U.S. government, including the SEC, has made statements and taken certain actions that led to changes to United States and international relations, and will impact companies with connections to the United States or the PRC, including imposing several rounds of tariffs affecting certain products manufactured in the PRC, imposing certain sanctions and restrictions in relation to the PRC and issuing statements indicating enhanced review of companies with certain operations based in the PRC. It is unknown whether and to what extent new legislation, executive orders, tariffs, laws or regulations will be adopted, or the effect that any such actions would have on companies with significant connections to the United States or to the PRC, BC&#8217;s industry or on BC. BC conducts research activities and has business operations both in the United States and the PRC. Any unfavorable government policies on cross-border relations and/or international trade, including increased scrutiny on companies with certain operations based in the PRC, capital controls or tariffs, may affect the competitive position of BC&#8217;s drug products, the hiring of scientists and other research and development personnel, the demand for BC&#8217;s drug products, the import or export of raw materials in relation to drug development or BC&#8217;s ability to raise capital, or prevent BC from selling its drug products in certain countries. Furthermore, the SEC has issued statements primarily focused on companies with certain operations based in the PRC, such as BC. For example, on July&#160;30, 2021, Gary Gensler, Chairman of the SEC, issued a Statement on Investor Protection Related to Recent Developments in the PRC, pursuant to which Chairman Gensler stated that he has asked the SEC staff to engage in targeted additional reviews of filings for companies with certain operations based in the PRC. The statement also addressed risks inherent in companies with VIE structures. BC does not have a VIE structure and is not in an industry that is subject to foreign ownership limitations by the PRC. However, it is possible that the combined company&#8217;s periodic reports and other filings with the SEC may be subject to enhanced review by the SEC and this additional scrutiny could affect BC&#8217;s ability to effectively raise capital in the United States.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In response to the SEC&#8217;s July&#160;30, 2021 statement, the China Securities Regulatory Commission (&#8220;CSRC&#8221;) announced on August&#160;1, 2021 that &#8220;[i]t is our belief that Chinese and U.S. regulators shall continue to enhance communication with the principle of mutual respect and cooperation, and properly address the issues related to the supervision of the PRC-based companies listed in the U.S. so as to form stable policy expectations and create benign rules framework for the market.&#8221; While the CSRC will continue to collaborate &#8220;closely with different stakeholders including investors, companies, and relevant authorities to further promote transparency and certainty of policies and implementing measures,&#8221; it emphasized that it &#8220;has always been open to companies&#8217; choices to list their securities on international or domestic markets in compliance with relevant laws and regulations.&#8221;</div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On February 17, 2023, the CSRC issued the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Enterprises (the &#8220;Trial Measures&#8221;), which became effective on March&#160;31, 2023. On the same date, CSRC circulated No. 1 to No. 5 Supporting Guidance Rules, the Notes on the Trial Measures, the Notice on Administration Arrangements for the Filing of Overseas Listings by Domestic Enterprises and the relevant CSRC Answers to Reporter Questions on the official website of CSRC. These new regulations propose to establish a new filing-based regime to regulate overseas offerings and listings by PRC domestic companies. Accordingly, on May&#160;22, 2023, BC submitted the filing documents pursuant to the Trial Measures to the CSRC that must be accepted prior to the anticipated closing of the Contributions. In June 2023, BC received comments from the CSRC on its filing materials, and BC filed its responses and supplemental materials to the CSRC. As of the date of this filing, BC has not received final confirmation from the CSRC regarding the completion of the Trial Measures filing process. </div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">There is still uncertainty as to whether BC will be able to complete the filing, and if it is unable to complete the filing process, BC will have to suspend or terminate the Contributions. Furthermore, pursuant to the Trial Measures, if domestic enterprises fail to fulfill the filing procedures or offer and list in an overseas market against the prohibited circumstances, they would be warned and fined not less than approximately $144,092 but not more than approximately $1.4 million. The controlling shareholder or the actual controller of a domestic enterprise who organizes or instructs to engage in such illegal acts will be fined not less than approximately $144,092 but not more than approximately $1.4 million. If the filing materials of a domestic enterprise contain false records, misleading statements or material omissions, the CSRC will order correction, issue a warning, and impose a fine of not less than </div> </div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"> <div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">100<br></div> </div></div>
<!--End Page 111-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 112-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg68"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">approximately $144,092 and not more than approximately $1.4&#160;million. The controlling shareholder or actual controller of a domestic enterprise who organizes or directs to engage in the illegal acts in the preceding paragraph, or conceals the relevant matters leading to the occurrence of the foregoing, shall be subject to a fine of not less than approximately $144,092 and not more than approximately $1.4&#160;million. </div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If any new legislation, executive orders, tariffs, laws and/or regulations are implemented, if existing trade agreements are renegotiated, if the U.S. or the PRC governments take retaliatory actions due to the recent U.S.-PRC tension or if the PRC government exerts more oversight and control over securities offerings that are conducted in the United States, such changes could have an adverse effect on BC&#8217;s business, financial condition and results of operations, and BC&#8217;s ability to raise capital.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Compliance with the PRC&#8217;s new Data Security Law, Cyber Security Law, Cybersecurity Review Measures, Personal Information Protection Law, regulations and guidelines relating to the multi-level protection scheme on cyber security and any other future laws and regulations may entail significant expenses and could affect BC&#8217;s business.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The PRC has implemented or will implement rules and is considering a number of additional proposals relating to data protection. The Data Security Law provides that the data processing activities must be conducted based on &#8220;data classification and hierarchical protection system&#8221; for the purpose of data protection and prohibits entities in the PRC from transferring data stored in the PRC to foreign law enforcement agencies or judicial authorities without prior approval by the PRC government.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Additionally, the PRC&#8217;s Cyber Security Law and the Administrative Measures for the Hierarchical Protection of Information Security requires companies to take certain organizational, technical and administrative measures and other necessary measures to ensure the security of their networks and data stored on their networks. Under the multi-level protection scheme (&#8220;MLPS&#8221;), entities operating information systems must have a thorough assessment of the risks and the conditions of their information and network systems to determine the level of the entity&#8217;s information and network systems. These levels range from the lowest Level 1 to the highest Level 5 pursuant to a series of national standards on the grading and implementation of the classified protection of cyber security. The grading result will determine the set of security protection obligations that entities must comply with. Entities classified as Level 2 or above should report the grade to the relevant government authority for examination and approval.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Recently, the Cybersecurity Administration of China (&#8220;CAC&#8221;) has taken action against several PRC internet companies in connection with their initial public offerings on U.S. securities exchanges for alleged national security risks and improper collection and use of the personal information of PRC data subjects. According to the official announcement, the action was initiated based on the National Security Law, the Cyber Security Law and the Cybersecurity Review Measures, which are aimed at &#8220;preventing national data security risks, maintaining national security and safeguarding public interests.&#8221; </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Revised CAC Measures, critical information infrastructure operators procuring network products and services, and online platform operators (as opposed to &#8220;data processors&#8221; in the Revised Draft CAC Measures) carrying out data processing activities which affect or may affect national security, shall conduct a cybersecurity review pursuant to the provisions therein. In addition, online platform operators possessing personal information of more than one million users seeking to be listed on foreign stock markets must apply for a cybersecurity review. On November&#160;14, 2021, the CAC further published the Regulations on Network Data Security Management (Draft for Comment), or the Draft Management Regulations, under which data processors refer to individuals and organizations who determine the data processing activities in terms of the purpose and methods at their discretion. The Draft Management Regulations reiterate that data processors shall be subject to cybersecurity review if&#8201; (i)&#160;they process personal information of more than one million persons and they are aiming to list on foreign stock markets or (ii)&#160;their data processing activities affect or may affect PRC national security. The Draft Management Regulations also request data processors seeking to list on foreign stock markets to annually assess their data security by themselves or through data security service organizations, and submit the assessment reports to relevant competent authorities. As the Draft Management Regulations are released only for public comment, the final version and the effective date thereof is subject to change. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of the date of this proxy statement, BC has not received any notice from any PRC regulatory authority identifying BC as a &#8220;critical information infrastructure operator,&#8221; &#8220;online platform operator&#8221; or &#8220;data processor,&#8221; or requiring BC to go through the cybersecurity review procedures pursuant to the Revised CAC Measures and the Draft </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">101<br></div></div></div>
<!--End Page 112-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 113-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg69"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Management Regulations. Based on BC&#8217;s understanding of the Revised CAC Measures, and the Draft Management Regulations if enacted as currently proposed, BC does not expect to become subject to cybersecurity review by the CAC for issuing securities to foreign investors because: (i)&#160;the clinical and preclinical data BC handles in its business operations, either by its nature or in scale, do not normally trigger significant concerns over PRC national security and (ii)&#160;BC has not processed, and does not anticipate to process in the foreseeable future, personal information for more than one million users or persons. However, there remains uncertainty as to how the Revised CAC Measures, and the Draft Management Regulations, if enacted as currently proposed, will be interpreted or implemented. Furthermore, there remains uncertainty as to whether the PRC regulatory authorities may adopt new laws, regulations, rules, or detailed implementation and interpretation in relation, or in addition, to the Revised CAC Measures and the Draft Management Regulations. While BC intends to closely monitor the evolving laws and regulations in this area and take all reasonable measures to mitigate compliance risks, BC cannot guarantee that its business and operations will not be adversely affected by the potential impact of the Revised CAC Measures, the Draft Management Regulations or other laws and regulations related to privacy, data protection and information security.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Furthermore, the Personal Information Protection Law provides a comprehensive set of data privacy and protection requirements that apply to the processing of personal information and expands data protection compliance obligations to cover the processing of personal information of persons by organizations and individuals in the PRC, and the processing of personal information of persons in the PRC outside of the PRC if such processing is for purposes of providing products and services to, or analyzing and evaluating the behavior of, persons in the PRC. The Personal Information Protection Law also provides that critical information infrastructure operators and personal information processing entities who process personal information meeting a volume threshold to be set by PRC cyberspace regulators are also required to store in the PRC personal information generated or collected in the PRC, and to pass a security assessment administered by PRC cyberspace regulators for any export of such personal information. Lastly, the Personal Information Protection Law contains proposals for significant fines for serious violations of up to approximately $7.2 million or 5% of annual revenues from the prior year and may also be ordered to suspend any related activity by competent authorities. BC does not maintain, nor does BC intend to maintain in the future, personally identifiable health information of patients in the PRC. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Interpretation, application and enforcement of these laws, rules and regulations evolve from time to time and their scope may continually change, through new legislation, amendments to existing legislation or changes in enforcement. Compliance with the PRC&#8217;s new Cyber Security Law and Data Security Law could significantly increase the cost to BC of providing BC&#8217;s service offerings, require significant changes to BC&#8217;s operations or even prevent BC from providing certain service offerings in jurisdictions in which BC currently operates or in which BC may operate in the future. Despite BC&#8217;s efforts to comply with applicable laws, regulations and other obligations relating to privacy, data protection and information security, it is possible that BC&#8217;s practices, offerings or platform could fail to meet all of the requirements imposed on BC by the Cyber Security Law, the Data Security Law and/or related implementing regulations. Any failure on BC&#8217;s part to comply with such law or regulations or any other obligations relating to privacy, data protection or information security, or any compromise of security that results in unauthorized access, use or release of personally identifiable information or other data, or the perception or allegation that any of the foregoing types of failure or compromise has occurred, could damage BC&#8217;s reputation, discourage new and existing counterparties from contracting with BC or result in investigations, fines, suspension or other penalties by PRC government authorities and private claims or litigation, any of which could adversely affect BC&#8217;s business, financial condition and results of operations. Even if BC&#8217;s practices are not subject to legal challenge, the perception of privacy concerns, whether or not valid, may harm BC&#8217;s reputation and brand and adversely affect BC&#8217;s business, financial condition and results of operations. Moreover, the legal uncertainty created by the Data Security Law, the Revised CAC Measures and the recent PRC government actions could adversely affect BC&#8217;s ability, on favorable terms, to raise capital.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">BC may be exposed to liabilities under the U.S. Foreign Corrupt Practices Act, or the FCPA, and similar anti-corruption and anti-bribery laws of the PRC and other countries in which BC operates, as well as U.S. and certain foreign export controls, trade sanctions and import laws and regulations. Compliance with these legal requirements could limit BC&#8217;s ability to compete in foreign markets, and any determination that BC has violated these laws could have a material adverse effect on BC&#8217;s business or BC&#8217;s reputation. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC&#8217;s operations are subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of the PRC and other countries in which BC operates. The FCPA and these other laws generally prohibit BC, BC&#8217;s officers and BC&#8217;s employees and intermediaries from, directly or indirectly, offering, authorizing or making improper </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">102<br></div></div></div>
<!--End Page 113-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 114-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg70"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">payments to non-U.S. government officials for the purpose of obtaining or retaining business or other advantage. BC may engage third parties for clinical trials outside of the United States, to sell BC&#8217;s products abroad and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. BC has direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. As BC&#8217;s business expands, the applicability of the FCPA and other anti-bribery laws to BC&#8217;s operations will increase. If BC&#8217;s procedures and controls to monitor anti-bribery compliance fail to protect BC from reckless or criminal acts committed by BC&#8217;s employees or agents or if BC, or BC&#8217;s employees, agents, contractors or other collaborators, fail to comply with applicable anti-bribery laws, BC&#8217;s reputation could be harmed and BC could incur criminal or civil penalties, other sanctions and/or significant expenses, which could have a material adverse effect on BC&#8217;s business, including BC&#8217;s financial condition, results of operations, cash flows and prospects. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, BC&#8217;s products may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations. Governmental regulation of the import or export of BC&#8217;s products, or BC&#8217;s failure to obtain any required import or export authorization for BC&#8217;s products, when applicable, could harm BC&#8217;s international or domestic sales and adversely affect BC&#8217;s revenue. Compliance with applicable regulatory requirements regarding the export of BC&#8217;s products may create delays in the introduction of BC&#8217;s products in international markets or, in some cases, prevent the export of BC&#8217;s products to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments and persons targeted by U.S. sanctions. If BC fails to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons or products targeted by such regulations, could result in decreased use of BC&#8217;s products by, or in BC&#8217;s decreased ability to export BC&#8217;s products to, existing or potential customers with international operations. Any decreased use of BC&#8217;s products or limitation on BC&#8217;s ability to export or sell BC&#8217;s products would likely adversely affect BC&#8217;s business. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Restrictions on currency exchange, including the risks of transferring cash outside of the PRC, may limit BC&#8217;s ability to receive and use effectively financing in foreign currencies. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC&#8217;s ability to obtain currency exchange is subject to significant foreign exchange controls and, in the case of transactions under the capital account, requires the approval of and/or registration with PRC government authorities, including the State Administration of Foreign Exchange, or SAFE. In particular, if BC finances by means of foreign debt from BJC Limited or other foreign lenders, the amount is not allowed to, among other things, exceed the statutory limits and such loans must be registered with the local branch of SAFE. If BC finances by means of additional capital contributions, these capital contributions are subject to registration with the State Administration for Market Regulation or its local branch, reporting of foreign investment information with the Ministry of Commerce of the PRC (&#8220;MOFCOM&#8221;), or its local branch or registration with other governmental authorities in the PRC. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In light of the various requirements imposed by PRC regulations on loans to, and direct investment in, PRC-based entities by offshore holding companies, there can be no assurance that BC will be able to complete the necessary government requirements or obtain the necessary government approvals on a timely basis, if at all, with respect to future loans or capital contributions by BC. If BC fails to adhere to such requirements or obtain such approval, BC&#8217;s ability to capitalize or otherwise fund BC&#8217;s PRC operations, including BC&#8217;s technology development may be negatively affected, which could materially and adversely affect BC&#8217;s ability to fund and expand BC&#8217;s business.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">PRC regulations relating to the establishment of offshore special purpose companies by residents in the PRC may subject BC&#8217;s PRC resident beneficial owners in the PRC to liability or penalties, or may otherwise adversely affect BC. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&#8217; Offshore Investment and Financing and Roundtrip Investment through Special Purpose Vehicles, or SAFE Circular 37 requires residents of the PRC to register with local branches of SAFE in connection with their direct establishment or indirect control of an offshore entity, for the purpose of overseas investment and financing, with such residents&#8217; legally owned assets or equity interests in domestic enterprises or offshore assets or interests, referred to in SAFE Circular 37 as a &#8220;special purpose vehicle.&#8221; The term &#8220;control&#8221; under SAFE Circular 37 is broadly defined as the operation rights, beneficiary rights or decision-making rights acquired by residents of the PRC in the offshore special purpose vehicles or PRC companies by such means as acquisition, trust, proxy, voting rights, repurchase, convertible bonds or other </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">103<br></div></div></div>
<!--End Page 114-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 115-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg71"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">arrangements. SAFE Circular 37 further requires amendment to the registration in the event of any changes with respect to the basic information of or any significant changes with respect to the special purpose vehicle, such as an increase or decrease of capital contributed by PRC residents, share transfer or exchange, merger, division or other material events. If the shareholders of the offshore holding company who are residents of the PRC do not complete their registration with the local SAFE branches, the PRC subsidiaries may be prohibited from making distributions of profits and proceeds from any reduction in capital, share transfer or liquidation to the offshore parent company and from carrying out subsequent cross-border foreign exchange activities, and the offshore parent company may be restricted in its ability to contribute additional capital into its PRC subsidiaries. Moreover, failure to comply with the SAFE registration and amendment requirements described above could result in liability under PRC law for evasion of applicable foreign exchange restrictions. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Certain residents of the PRC may hold direct or indirect interests in BC&#8217;s company, and BC will request residents of the PRC who BC knows hold direct or indirect interests in BC&#8217;s company, if any, to make the necessary applications, filings and amendments as required under SAFE Circular 37 and other related rules. However, BC may not at all times be fully aware or informed of the identities of BC&#8217;s shareholders or beneficial owners that are required to make such registrations, and BC cannot provide any assurance that these residents will comply with BC&#8217;s requests to make or obtain any applicable registrations or comply with other requirements under SAFE Circular 37 or other related rules. The failure or inability of BC&#8217;s PRC resident shareholders to comply with the registration procedures set forth in these regulations may subject BC to fines or legal sanctions, restrictions on BC&#8217;s cross-border investment activities. Moreover, failure to comply with the various foreign exchange registration requirements described above could result in liability under PRC law for circumventing applicable foreign exchange restrictions. As a result, BC&#8217;s business operations and BC&#8217;s ability to make distributions to you could be materially and adversely affected.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: justify;">Any failure to comply with PRC regulations regarding the registration requirements for BC&#8217;s employee equity incentive plans may subject BC to fines and other legal or administrative sanctions, which could adversely affect BC&#8217;s business, financial condition and results of operations. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Notices on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in Stock Incentive Plans of Overseas Publicly Listed Companies, or the Stock Option Rules and other relevant rules and regulations, PRC citizens or non-PRC citizens residing in the PRC for a continuous period of not less than one year who participate in any stock incentive plan of an overseas publicly listed company, subject to a few exceptions, are required to register with SAFE through a domestic qualified agent, which could be a PRC subsidiary of such overseas listed company, and complete certain procedures. BC&#8217;s employees who are PRC citizens or who reside in the PRC for a continuous period of not less than one year and who participate in Catalyst&#8217;s stock incentive plans will be subject to such regulation. BC plans to assist BC&#8217;s employees to register their equity awards. However, any failure of PRC individual beneficial owners and holders of equity awards under Catalyst&#8217;s stock incentive plans to comply with the SAFE registration requirements may subject them to fines and legal sanctions. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: justify;">Since BC is a legal entity registered in Beijing, PRC, it is classified as a PRC tax resident for PRC income tax purposes by default, and such classification results in unfavorable tax consequences to BC and its non-PRC shareholders.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under Article 2 of the PRC Enterprise Income Tax Law, a resident enterprise is an enterprise that is established within the territory of the PRC or an enterprise established with a &#8220;de facto management body&#8221; within the PRC.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC is a PRC tax resident for PRC tax purposes by default because it is a legal entity registered in Beijing, PRC. Because BC is a PRC tax resident for PRC enterprise income tax purposes, BC is subject to PRC tax at a rate of 25% on its world-wide income, which materially reduces BC&#8217;s net income. In addition, BC is also subject to PRC tax resident income tax reporting obligations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Furthermore, because BC is a PRC tax resident for enterprise income tax purposes, gains realized on the Contributions may be subject to PRC tax, at a rate of 10% in the case of non-PRC enterprises or 20% in the case of non-PRC individuals (in each case, subject to the provisions of any applicable tax treaty), if such gains are deemed to be from PRC sources.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">104<br></div></div></div>
<!--End Page 115-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 116-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg72"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">BC and its shareholders face uncertainties with respect to indirect transfers of equity interests in PRC resident enterprises or other assets attributed to a PRC establishment of a non-PRC company, or other assets attributable to a PRC establishment of a non-PRC company. Enhanced scrutiny over acquisition transactions by the PRC tax authorities may have a negative impact on potential offshore restructuring transactions or sales of the shares of BC&#8217;s offshore holding companies or investments where PRC taxable assets are involved.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The PRC tax authorities have enhanced their scrutiny over the direct or indirect transfer of certain taxable assets, including, in particular, equity interests in a PRC resident enterprise, by a non-resident enterprise by promulgating and implementing Notice of Ministry of Finance and State Administration of Taxation (&#8220;SAT&#8221;) on Several Issues relating to Treatment of Corporate Income Tax Pertaining to Restructured Business Operations of Enterprises (&#8220;Circular 59&#8221;) and the Notice on Strengthening Administration of Enterprise Income Tax for Share Transfers by Non-PRC Resident Enterprises (&#8220;Circular 698&#8221;). Pursuant to the Bulletin on Issues of Enterprise Income Tax and Indirect Transfers of Assets by Non-PRC Resident Enterprises (&#8220;Bulletin 7&#8221;) an &#8220;indirect transfer&#8221; of assets, including equity interests in a PRC resident enterprise, by non-PRC resident enterprises may be recharacterized and treated as a direct transfer of PRC taxable assets, if such arrangement does not have a reasonable commercial purpose and was established for the purpose of avoiding payment of PRC enterprise income tax. As a result, gains derived from such indirect transfer may be subject to PRC enterprise income tax.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to Bulletin 7, &#8220;PRC taxable assets&#8221; include assets attributed to an establishment in the PRC, immoveable properties located in the PRC, and equity investments in PRC resident enterprises, in respect of which gains from their transfer by a direct holder, being a non-PRC resident enterprise, would be subject to PRC enterprise income taxes. When determining whether there is a &#8220;reasonable commercial purpose&#8221; of the transaction arrangement, factors to be taken into consideration include: whether the main value of the equity interest of the relevant offshore enterprise derives from PRC taxable assets; whether the assets of the relevant offshore enterprise mainly consists of direct or indirect investment in the PRC or if its income mainly derives from the PRC; whether the offshore enterprise and its subsidiaries directly or indirectly holding PRC taxable assets have real commercial nature which is evidenced by their actual function and risk exposure; the duration of existence of the business model and organizational structure; the replicability of the transaction by direct transfer of PRC taxable assets; and the tax situation of such indirect transfer and applicable tax treaties or similar arrangements. In respect of an indirect offshore transfer of assets of a PRC establishment, the resulting gain is to be included with the enterprise income tax filing of the PRC establishment or place of business being transferred, and would consequently be subject to PRC enterprise income tax at a rate of 25%. Where the underlying transfer relates to the immoveable properties located in the PRC or to equity investments in a PRC resident enterprise, which is not related to a PRC establishment or place of business of a non-resident enterprise, a PRC enterprise income tax at 10% would apply, subject to available preferential tax treatment under applicable tax treaties or similar arrangements, and the party who is obligated to make the transfer payments has the withholding obligation. Where the payor fails to withhold any or sufficient tax, the transferor shall declare and pay such tax to the tax authority by itself within the statutory time limit. Late payment of applicable tax will subject the transferor to default interest. Bulletin 7 does not apply to transactions of sale of shares by investors through a public stock exchange where such shares were acquired from a transaction through a public stock exchange.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Bulletin 7 may be determined by the tax authorities to be applicable to some of BC&#8217;s offshore restructuring transactions or sales of the shares of BC&#8217;s offshore holding companies or investments where PRC taxable assets are involved. The transferors and the transferees may be subject to tax filing or withholding and tax payment obligations, while BC may be requested to assist in such filings. Furthermore, the transferors or the transferees (as withholding agent) may be required to spend valuable resources to comply with Bulletin 7 or to establish that the transferors should not be taxed under Bulletin 7, for BC&#8217;s previous and future restructuring or disposal of shares of BC&#8217;s offshore subsidiaries. The PRC tax authorities have the discretion under Bulletin 7 to adjust the taxable capital gains based on the difference between the fair value of the taxable assets transferred and the cost of investment. If the PRC tax authorities adjust the taxable income of the transactions under Bulletin 7, income tax costs on the transferor side associated with such potential acquisitions or disposals will increase.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC faces uncertainties on the reporting and consequences on future private equity financing transactions, share exchange or other transactions involving the transfer of shares in BC by investors that are non-PRC resident enterprises. The PRC tax authorities may pursue such non-resident enterprises with respect to a filing or the transferees with respect to withholding obligation, and request BC to assist in the filing. As a result, non-resident </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">105<br></div></div></div>
<!--End Page 116-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 117-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg73"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">enterprises in such transactions may become at risk of being subject to filing obligations or being taxed, under Circular 59 or Bulletin 7 and Bulletin 37, and may be required to expend valuable resources to comply with Circular&#160;59, Bulletin 7 and Bulletin 37 or to establish that its non-resident enterprises should not be taxed under these circulars.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The PRC tax authorities have the discretion under SAT Circular 59, Bulletin 7 and Bulletin 37 to adjust the taxable capital gains based on the difference between the fair value of the taxable assets transferred and the cost of investment. Although BC currently has no plans to pursue any acquisitions in the PRC or elsewhere in the world, BC may pursue acquisitions in the future that may involve complex corporate structures. Because BC is a PRC tax resident by default, and if the PRC tax authorities adjust the taxable income of the transactions under SAT Circular&#160;59 or Bulletin 7 and Bulletin 37, BC&#8217;s income tax costs associated with such potential acquisitions will be increased, which may have an adverse effect on BC&#8217;s financial condition and results of operations.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;"><u>Risks Related to the Combined Company</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In determining whether you should approve the issuance of shares of Catalyst Common Stock, the change of control resulting from the Contributions and other matters related to the Contributions, as applicable, you should carefully read the following risk factors in addition to the risks described above.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">The market price of the combined company&#8217;s common stock is expected to be volatile, and the market price of the common stock may drop following the Contributions.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The market price of the combined company&#8217;s common stock following the Contributions could be subject to significant fluctuations. Some of the factors that may cause the market price of the combined company&#8217;s common stock to fluctuate include: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">timing and results of INDs, preclinical studies and clinical trials of the combined company&#8217;s product candidates, or those of the combined company&#8217;s competitors or the combined company&#8217;s existing or future collaborators; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the success of competitive products or announcements by potential competitors of their product development efforts; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">failure to meet or exceed financial and development projections the combined company may provide to the public; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to meet or exceed the financial and development projections of the investment community; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">if the combined company does not achieve the perceived benefits of the Contributions as rapidly or to the extent anticipated by financial or industry analysts; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by the combined company or its competitors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">actions taken by regulatory agencies with respect to the combined company&#8217;s product candidates, clinical studies, manufacturing process or sales and marketing terms; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">disputes or other developments relating to proprietary rights, including patents, litigation matters and the combined company&#8217;s ability to obtain patent protection for its technologies; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">additions or departures of key personnel; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">lawsuits, including patent or stockholder litigation; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">if securities or industry analysts do not publish research or reports about the combined company&#8217;s business, or if they issue adverse or misleading opinions regarding its business and stock; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in the market valuations of similar companies; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">geo-political developments, general market or macroeconomic conditions including inflation and interest rates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">market conditions in the pharmaceutical and biotechnology sectors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in the structure of healthcare payment systems; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">106<br></div></div></div>
<!--End Page 117-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 118-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg74"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">announcement of expectation of additional financing efforts; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">sales of securities by the combined company or its securityholders in the future; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">if the combined company fails to raise an adequate amount of capital to fund its operations and continued development of its product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">trading volume of the combined company&#8217;s common stock; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">publicity or announcements by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the impact of any natural disasters or public health emergencies, such as the COVID-19 pandemic; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the introduction of technological innovations or new product candidates that compete with the products and services of the combined company; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">period-to-period fluctuations in the combined company&#8217;s financial results.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of the combined company&#8217;s common stock. In addition, macroeconomic conditions, a recession, depression or other sustained adverse market event resulting from the spread of COVID-19 or otherwise could materially and adversely affect the combined company&#8217;s business and the value of its common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies. Furthermore, market volatility may lead to increased shareholder activism if the combined company experiences a market valuation that activists believe is not reflective of its intrinsic value. Activist campaigns that contest or conflict with the combined company&#8217;s strategic direction or seek changes in the composition of its board of directors could have an adverse effect on its operating results and financial condition.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: justify;">Following the Contributions, the combined company may be unable to integrate successfully and realize the anticipated benefits of the Contributions.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Contributions involves the combination of two companies which currently operate as independent companies. The combined company may fail to realize some or all of the anticipated benefits of the Contributions if the integration process takes longer than expected or is more costly than expected.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Potential difficulties the combined company may encounter in the integration process include the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the inability to successfully combine the businesses of Catalyst and BC in a manner that permits the combined company to achieve the anticipated benefits from the Contributions, which would result in the anticipated benefits of the Contributions not being realized partly or wholly in the time frame currently anticipated or at all; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">creation of uniform standards, controls, procedures, policies and information systems; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">potential unknown liabilities and unforeseen increased expenses, delays or regulatory conditions associated with the Contributions.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, Catalyst and BC have operated and, until the completion of the Contributions, will continue to operate, independently. It is possible that the integration process also could result in the diversion of each company&#8217;s management&#8217;s attention, the disruption or interruption of, or the loss of momentum in, each company&#8217;s ongoing businesses or inconsistencies in standards, controls, procedures and policies, any of which could adversely affect the combined company&#8217;s ability to maintain its business relationships or the ability to achieve the anticipated benefits of the Contributions, or could otherwise adversely affect the business and financial results of the combined company.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">107<br></div></div></div>
<!--End Page 118-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 119-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg75"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The combined company could potentially need additional funding before it can complete the development of its product candidates. If the combined company is unable to obtain such additional capital on favorable terms, on a timely basis or at all, it would be forced to delay, reduce or eliminate its product development, clinical programs and ability to partner with third parties or enter into strategic collaborations, and may not have the capital required to otherwise operate its business.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. The combined company has only generated revenues from the commercial sale of ETUARY and will not be able to generate any additional product revenues until the combined company receives approval to sell its other product candidates from the FDA, NMPA or other regulatory authorities. The cash expected from both Catalyst and BC at closing, in addition to the funds generated by the combined company&#8217;s revenue, is expected to fund operations for at least the next twelve months. As the combined company has only generated revenue from commercial sales of ETUARY to date and does not expect to generate any additional revenue from its other drug candidates for at least twelve months through the combined company&#8217;s Phase 2a trial, if ever, the combined company will need to raise substantial additional capital in order to fund its future research and development, including its plans for new clinical trials, product development, partnerships with third parties and strategic collaborations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The combined company may seek to raise additional funds through various potential sources, such as equity and debt financings, or through strategic collaborations and license agreements. There can be no assurance that the combined company will be able to secure such additional sources of funds to support its operations or, if such funds are available, that such additional financing will be sufficient to meet its needs. Moreover, to the extent that the combined company raises additional funds by issuing equity securities, its stockholders may experience additional significant dilution and new investors could gain rights, preferences and privileges senior to the holders of common stock. Debt financing, if available, may involve restrictive covenants. To the extent that the combined company raises additional funds through collaboration and licensing arrangements, it may be necessary to relinquish some rights to its technologies or product candidates, or grant licenses on terms that may not be favorable.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Given the combined company&#8217;s capital constraints, it will need to prioritize spending on its clinical and preclinical programs. If the combined company is unable to raise sufficient funds to support its planned operations, it may elect to discontinue certain of its ongoing activities or programs. The combined company&#8217;s inability to raise additional funds could also prevent it from taking advantage of opportunities to pursue promising new or existing programs in the future.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The combined company&#8217;s forecasts regarding its beliefs in the sufficiency of its financial resources to support its planned operations are forward-looking statements and involve significant risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed elsewhere in this &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; section. These estimates are based on assumptions that may prove to be wrong, and the combined company could utilize its available capital resources sooner than currently expected.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: justify;">The combined company will incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The combined company will incur significant legal, accounting and other expenses as a public company that BC did not incur as a private company, including costs associated with public company reporting obligations under the Exchange Act. Several members of the combined company&#8217;s management team will be executive officers of BC prior to the Contributions, some of whom have not previously managed and operated a public company. These executive officers and other personnel will need to devote substantial time to gaining expertise related to public company reporting requirements and compliance with applicable laws and regulations to ensure that the combined company complies with all of these requirements. Any changes the combined company makes to comply with these obligations may not be sufficient to allow it to satisfy its obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for the combined company to attract and retain qualified persons to serve on the board of directors or on board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">108<br></div></div></div>
<!--End Page 119-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 120-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg76"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The unaudited pro forma condensed combined financial data for Catalyst and BC included in this proxy statement is preliminary, and the combined company&#8217;s actual financial position and operations after the Contributions may differ materially from the unaudited pro forma financial data included in this proxy statement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The unaudited pro forma financial data for Catalyst and BC included in this proxy statement is presented for illustrative purposes only and is not necessarily indicative of the combined company&#8217;s actual financial condition or results of operations of future periods, or the financial condition or results of operations that would have been realized had the entities been combined during the periods presented. The unaudited pro forma financial statements have been derived from the historical financial statements of Catalyst and BC and adjustments and assumptions have been made regarding the combined company after giving effect to the Contributions. The information upon which these adjustments and assumptions have been made is preliminary, and these kinds of adjustments and assumptions are difficult to make with accuracy. Moreover, the unaudited pro forma financial statements do not reflect all costs that are expected to be incurred by the combined company in connection with the transactions or that have been incurred since the date of such unaudited pro forma financial statements. The assumptions used in preparing the unaudited pro forma financial information may not prove to be accurate, and other factors may affect the combined company&#8217;s financial condition following the transaction. The combined company&#8217;s actual results and financial position after the Contributions may differ materially and adversely from the unaudited pro forma financial data included in this proxy statement. For more information see the section entitled &#8220;<font style="font-style: italic;">Selected Historical and Unaudited Pro Forma Condensed </font><font style="font-style: italic;">Combined Financial Information&#8212;Unaudited Pro Forma Condensed Combined Financial Information</font>&#8221; beginning on page <a href="#tUPF">319</a>.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Provisions that will be in the combined company&#8217;s certificate of incorporation and bylaws and provisions under Delaware law could make an acquisition of the combined company, which may be beneficial to its stockholders, more difficult and may prevent attempts by its stockholders to replace or remove its management.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Provisions that will be included in the combined company&#8217;s certificate of incorporation and bylaws may discourage, delay or prevent a merger, acquisition or other change in control of the combined company that stockholders may consider favorable, including transactions in which its common stockholders might otherwise receive a premium price for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of the combined company&#8217;s common stock, thereby depressing the market price of its common stock. In addition, because the combined company&#8217;s board of directors will be responsible for appointing the members of the combined company&#8217;s management team, these provisions may frustrate or prevent any attempts by the combined company&#8217;s stockholders to replace or remove its current management by making it more difficult for stockholders to replace members of the combined company&#8217;s board of directors. Among other things, these provisions will:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">continue the use of a classified board of directors such that not all members of the combined company board of directors are elected at one time; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">allow the authorized number of the combined company&#8217;s directors to be changed only by resolution of its board of directors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">limit the manner in which stockholders can remove directors from the combined company&#8217;s board of directors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">provide for advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and for nominations to the combined company&#8217;s board of directors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">limit who may call stockholder meetings; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">limit actions by the combined company&#8217;s stockholders by written consent; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">authorize the combined company&#8217;s board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by the combined company&#8217;s board of directors; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">require the approval of the holders of at least two-thirds of the votes that all combined company stockholders would be entitled to cast to amend or repeal certain provisions of the combined company&#8217;s certificate of incorporation or bylaws.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Moreover, because the combined company is incorporated in Delaware, it is governed by the provisions of Section&#160;203 of the DGCL, which generally prohibits a person who, together with their affiliates and associates, owns </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">109<br></div></div></div>
<!--End Page 120-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 121-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg77"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">15% or more of the company&#8217;s outstanding voting stock from, among other things, merging or combining with the company for a period of three years after the date of the transaction in which the person acquired ownership of 15% or more of the company&#8217;s outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">The certificate of incorporation and bylaws of the combined company will generally provide that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between the combined company and its stockholders, which could limit its stockholders&#8217; ability to obtain a favorable judicial forum for disputes with the combined company or its directors, officers or other employees.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The certificate of incorporation and bylaws of the combined company will provide that, unless the company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) is the sole and exclusive forum for the following types of proceedings: (1) any derivative action or proceeding brought on the combined company&#8217;s behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of the combined company&#8217;s directors, officers, employees or stockholders to the company or its stockholders, (3) any action asserting a claim arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware or (4) any action asserting a claim arising pursuant to any provision of the combined company&#8217;s restated certificate of incorporation or its bylaws (in each case, as they may be amended from time to time) or governed by the internal affairs doctrine. This choice of forum provision will not apply to suits brought to enforce a duty or liability created by the Securities Act, the Exchange Act or any other claim for which federal courts have exclusive jurisdiction.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This exclusive forum provision may make it more expensive for stockholders to bring a claim than if the stockholders were permitted to select another jurisdiction and may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with the combined company or its directors, officers or other employees or stockholders, which may discourage such lawsuits against the combined company and its directors, officers and other employees and stockholders. Alternatively, if a court were to find the choice of forum provision contained in the combined company&#8217;s certificate of incorporation and bylaws to be inapplicable or unenforceable in an action, the combined company may incur additional costs associated with resolving such action in other jurisdictions, which could materially and adversely affect its business, financial condition and results of operations.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">The combined company&#8217;s ability to utilize its net operating loss carryforwards and tax credit carryforwards may be subject to limitations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of December&#160;31, 2022, Catalyst had approximately $194.1 of federal and $3.6 of state net operating loss carryforwards (&#8220;NOLs&#8221;) available to reduce future taxable income. Under Section 382 and Section 383 of the Code and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; its ability to use its pre-change NOLs and other pre-change tax attributes (such as research tax credits) to offset its post-change income may be limited. A Section 382 &#8220;ownership change&#8221; is generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period. Such limitations may result in expiration of a portion of the NOL carryforwards before utilization. The Company determined that ownership changes occurred December&#160;31, 2007, August&#160;20, 2015, April&#160;13, 2017, February&#160;15, 2018; February&#160;18, 2020, and December&#160;26, 2022. Approximately $156.5&#160;million and $75.2&#160;million of the NOLs will expire unutilized for federal and California purposes, respectively. The Contributions, if completed, may result in an additional ownership change and Catalyst may experience additional ownership changes in the future due to subsequent shifts in its stock ownership (some of which are outside of its control). </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, the combined company&#8217;s ability to use its NOLs to offset potential future taxable income and related income taxes that would otherwise be due is dependent upon the combined company&#8217;s generation of future taxable income, and Catalyst and BC cannot predict with certainty when, or whether, the combined company will generate sufficient taxable income to use all of its NOLs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Even if the combined company achieves profitability, it may not be able to utilize a material portion of Catalyst&#8217;s or the combined company&#8217;s NOLs and other tax attributes, which could have a material adverse effect on cash flow and results of operations. Similar provisions of state tax law may also apply to limit the combined company&#8217;s use of accumulated state tax attributes. There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs, or other unforeseen reasons, the combined company&#8217;s existing NOLs could expire or otherwise be unavailable to offset future income tax liabilities.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">110<br></div></div></div>
<!--End Page 121-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 122-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg78"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Changes in tax laws or in their implementation may adversely affect the combined company&#8217;s business and financial condition.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the IRS and the U.S. Treasury Department. Changes in tax law may adversely affect the combined company&#8217;s business or financial condition or holders of its common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. It cannot be predicted whether, when, in what form or with what effective dates tax laws, regulations and rulings may be enacted, promulgated or issued, which could result in an increase in the combined company&#8217;s or its stockholders&#8217; tax liability or require changes in the manner in which the combined company operates in order to minimize or mitigate any adverse effects of changes in tax law. Prospective investors should consult their tax advisors regarding the potential consequences of changes in tax law on combined company&#8217;s business and on the ownership and disposition of its common stock.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Catalyst and BC do not anticipate that the combined company will pay any cash dividends in the foreseeable future.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The current expectation is that the combined company will retain its future earnings, if any, to fund the growth of the combined company&#8217;s business as opposed to paying dividends. As a result, capital appreciation, if any, of the common stock of the combined company will be your sole source of gain, if any, for the foreseeable future.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">An active trading market for the combined company&#8217;s common stock may not develop and its stockholders may not be able to resell their shares of common stock for a profit, if at all.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Prior to the Contributions, there had been no public market for shares of BC common shares. An active trading market for the combined company&#8217;s common stock may never develop or be sustained following the Effective Time. In the absence of an active trading market for the combined company&#8217;s common stock, investors may be unable to sell their shares. In addition, there can be no assurance that, at the time of the extraordinary general meeting, the combined company will have received confirmation from Nasdaq of the listing of the combined company&#8217;s common stock, or that approval will be obtained prior to the consummation of the Contributions, and it is possible that such condition to the consummation of the Contributions may be waived by the parties to the Business Combination Agreement. As a result, you may be asked to vote to approve the Contributions and the other proposals included in this proxy statement without such confirmation, and, further it is possible that such confirmation may never be received and the Contributions could still be consummated if such condition is waived in writing by the parties to the Business Combination Agreement and therefore the combined company&#8217;s common stock would not be listed on any nationally recognized securities exchange.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Future sales of shares by existing stockholders could cause the combined company&#8217;s stock price to decline.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If existing securityholders of Catalyst and BC sell, or indicate an intention to sell, substantial amounts of the combined company&#8217;s common stock in the public market after legal restrictions on resale discussed in this proxy statement lapse, the trading price of the common stock of the combined company could decline. Based on shares outstanding as of December&#160;31, 2022, and shares expected to be issued upon completion of the Contributions, the combined company is expected to have outstanding a total of approximately 1,148,532,798 shares of common stock immediately following the completion of the Contributions (before adjustment for the reverse stock split). All outstanding shares of common stock, other than shares held by affiliates of the combined company, will be freely tradable, without restriction, in the public market. In addition, shares of common stock that are subject to outstanding options of BC will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements and Rules 144 and 701 under the Securities Act. If these shares are sold, the trading price of the combined company&#8217;s common stock could decline.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">The combined company will be a &#8220;controlled company&#8221; within the meaning of the Nasdaq listing standards and, as a result, will qualify for, and intend to rely on, exemptions from certain corporate governance requirements. The stockholders of the combined company will not have the same protections afforded to stockholders of companies that are subject to such requirements.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">After the consummation of the Contributions, the GNI Parties will control a majority of the voting power of combined company outstanding common stock. As a result, the combined company will qualify as a &#8220;controlled company&#8221; within the meaning of the corporate governance standards of Nasdaq. Under these rules, a listed company of which more than 50% of the voting power with respect to the election of directors is held by an individual, group </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">111<br></div></div></div>
<!--End Page 122-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 123-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg79"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">or another company is a &#8220;controlled company&#8221; and may elect not to comply with certain corporate governance requirements, including the requirement that (i)&#160;a majority of the combined company board of directors consist of independent directors, (ii)&#160;director nominees be selected or recommended to the board entirely by independent directors and (iii)&#160;the compensation committee be composed entirely of independent directors.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Following the consummation of the Contributions, the combined company intends to rely on some or all of these exemptions. As a result, at least initially, the combined company will not have a majority of independent directors, and the combined company&#8217;s compensation committee and nominating committee will not consist entirely of independent directors. Accordingly, you may not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of Nasdaq.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">After completion of the Contributions, the combined company&#8217;s executive officers, directors and principal stockholders will have the ability to control or significantly influence all matters submitted to the combined company&#8217;s stockholders for approval.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Upon the completion of the Contributions, it is anticipated that the combined company&#8217;s executive officers, directors and principal stockholders will, in the aggregate, beneficially own approximately 8.0% of the combined company&#8217;s outstanding shares of common stock. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to the combined company&#8217;s stockholders for approval, as well as the combined company&#8217;s management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of the combined company&#8217;s assets. This concentration of voting power could delay or prevent an acquisition of the combined company on terms that other stockholders may desire.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">The combined company may be exposed to increased litigation, including stockholder litigation, which could have an adverse effect on the combined company&#8217;s business and operations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The combined company may be exposed to increased litigation from stockholders, suppliers and other third parties due to the combination of Catalyst&#8217;s business and BC&#8217;s business following the Contributions. Such litigation may have an adverse impact on the combined company&#8217;s business and results of operations or may cause disruptions to the combined company&#8217;s operations. In addition, in the past, stockholders have initiated class action lawsuits against biotechnology companies following periods of volatility in the market prices of these companies&#8217; stock. Such litigation, if instituted against the combined company, could cause the combined company to incur substantial costs and divert management&#8217;s attention and resources, which could have a material adverse effect on the combined company&#8217;s business, financial condition and results of operations.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about the combined company, its business or its market, its stock price and trading volume could decline.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The trading market for the combined company&#8217;s common stock will be influenced by the research and reports that equity research analysts publish about it and its business. Equity research analysts may elect not to provide research coverage of the combined company&#8217;s common stock after the completion of the Contributions, and such lack of research coverage may adversely affect the market price of its common stock. In the event it does have equity research analyst coverage, the combined company will not have any control over the analysts or the content and opinions included in their reports. The price of the combined company&#8217;s common stock could decline if one or more equity research analysts downgrade its stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of the combined company or fails to publish reports on it regularly, demand for its common stock could decrease, which in turn could cause its stock price or trading volume to decline.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">The combined company&#8217;s internal control over financial reporting may not meet the standards required by Section&#160;404 of the Sarbanes-Oxley Act, and failure to achieve and maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act, could have a material adverse effect on the combined company&#8217;s business and share price.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As a privately held company, BC was not required to evaluate its internal control over financial reporting in a manner that meets the standards of publicly traded companies required by Section 404 of the Sarbanes-Oxley Act, or Section&#160;404. Following the Contributions, the combined company&#8217;s management will be required to report on the effectiveness of the combined company&#8217;s internal control over financial reporting. The rules governing the standards that must be met for the combined company&#8217;s management to assess the combined company&#8217;s internal control over financial reporting are complex and require significant documentation, testing and possible remediation.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">112<br></div></div></div>
<!--End Page 123-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 124-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg80"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Any failure to maintain effective internal control over financial reporting could severely inhibit the combined company&#8217;s ability to accurately report its financial condition, results of operations or cash flows. If the combined company is unable to conclude that its internal control over financial reporting is effective, or if the combined company&#8217;s independent registered public accounting firm determines the combined company has a material weakness or significant deficiency in the combined company&#8217;s internal control over financial reporting once that firm begins its reporting on internal control over financial reporting, investors may lose confidence in the accuracy and completeness of the combined company&#8217;s financial reports, the market price of the combined company&#8217;s common stock could decline and the combined company could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in the combined company&#8217;s internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict the combined company&#8217;s future access to the capital markets.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: justify;">The PRC-operations portion of the combined company&#8217;s audit may be conducted by an independent registered public accounting firm that is not subject to inspection by the Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;), which may negatively impact investor sentiment towards the combined company or its PRC operations, which could adversely affect the market price of the combined company&#8217;s common stock. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On December&#160;18, 2020, the Holding Foreign Companies Accountable Act (the &#8220;HFCAA&#8221;) was signed into law. The HFCAA requires that the SEC identify issuers that retain an auditor that has a branch or office that is located in a foreign jurisdiction and that the PCAOB determines it is unable to inspect or investigate completely because of a position taken by an authority in that foreign jurisdiction. As the combined company may have an auditor that is located in the PRC, a jurisdiction where the PCAOB has been unable to conduct inspections without the approval of the PRC authorities, they would not be subject to inspection. Among other things, the HFCAA requires the SEC to prohibit the securities of any issuer from being traded on any of the U.S. national securities exchanges, such as The Nasdaq Capital Market, or on the U.S. &#8220;over-the-counter&#8221; markets, if the auditor of the issuer&#8217;s financial statements is not subject to PCAOB inspections for three consecutive &#8220;non-inspection&#8221; years after the law became effective. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On December&#160;29, 2022, the Accelerating Holding Foreign Companies Accountable Act (the &#8220;AHFCAA&#8221;) was signed into law as part of a package of bills. The AHFCAA reduces the number of consecutive non-inspection years required for triggering the listing and trading prohibitions under the HFCAA from three years to two years, thus reducing the time period before the combined company&#8217;s securities may be prohibited from trading or delisted.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On December&#160;16, 2021, the PCAOB issued a report on its determination that it is unable to inspect or investigate completely PCAOB-registered accounting firms headquartered in the PRC and in Hong Kong.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On December&#160;2, 2021, the SEC adopted final amendments to its rules implementing the HFCAA and established procedures to identify issuers and prohibit the trading of the securities of certain registrants as required by the HFCAA. This rule stated that only the principal accountant, as defined by Rule 2-05 of Regulation S-X and PCAOB AS 1205, is &#8220;deemed &#8216;retained&#8217; for purposes of Section 104(i)&#160;of the Sarbanes-Oxley Act and the Commission&#8217;s determination of whether the registrant should be a Commission Identified Issuer.&#8221; The HFCAA does not apply to registrants that retain a principal accountant that is headquartered in the U.S. and subject to PCAOB inspection. Accordingly, if the combined company&#8217;s principal accountant is headquartered in the United States, then the HFCAA would not apply. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On December&#160;15, 2022, the PCAOB announced that it was able to conduct inspections and investigations of PCAOB-registered public accounting firms headquartered in mainland PRC and Hong Kong in 2022. The PCAOB vacated its previous 2021 determinations accordingly. While vacating those determinations, the PCAOB noted that, should it encounter any impediment to conducting an inspection or investigation of auditors in mainland PRC or Hong Kong as a result of a position taken by any authority there, the PCAOB would act to immediately reconsider the need to issue new determinations consistent with the HFCAA and PCAOB&#8217;s Rule 6100.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If the combined company&#8217;s operations require its independent registered public accounting firm be located in the PRC or Hong Kong in order to comply with the standards of the PCAOB regarding principal auditor then the HFCAA would apply to the combined company, including the potential delisting from The Nasdaq Capital Market and prohibition from trading in the over-the counter market in the United States. Such a restriction would negatively impact the combined company&#8217;s ability to raise capital. The combined company&#8217;s operations will likely require such an auditor to act as its principal auditor. Additionally, it is possible that in the future Congress could amend the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">113<br></div></div></div>
<!--End Page 124-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 125-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_106-risk_pg81"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">HFCAA or the SEC could modify its regulations to apply the restrictions, including trading prohibitions and delisting, under the HFCAA in situations in which an independent registered public accounting firm in the PRC or Hong Kong performs part of the audit such as in the combined company&#8217;s current situation. There are currently no such proposals.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Inspections of auditors conducted by the PCAOB in territories outside of the PRC have at times identified deficiencies in those auditors&#8217; audit procedures and quality control procedures, which may be addressed as part of the inspection process to improve future audit quality. The lack of PCAOB inspections of audit work undertaken in the PRC prevents the PCAOB from evaluating the effectiveness of such audits and such auditors&#8217; quality control procedures. As a result, investors are deprived of the potential benefits of such PCAOB inspections, which could cause investors and potential investors in the combined company&#8217;s common stock to lose confidence in the audit procedures conducted, which may negatively impact investor sentiment towards the combined company or its PRC operations, which in turn could adversely affect the market price of its common stock.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">You may have difficulty enforcing judgments obtained against the combined company.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Substantially all of the combined assets are located outside of the United States. Most of the combined company&#8217;s operations and administrative and corporate functions will be conducted in the PRC. In addition, several of the combined company&#8217;s directors and officers are nationals and residents of countries other than the United States. A substantial portion of the assets of these persons are located outside the United States. As a result, due to the lack of reciprocity and treaties between the United States and some of these foreign jurisdictions, together with cost and time constraints, it may be difficult for you to effect service of process within the United States upon these persons. In particular, several of the combined company&#8217;s officers and directors are generally located in the PRC, and it will be more difficult to enforce liabilities and enforce judgments on those individuals.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">114<br></div></div></div>
<!--End Page 125-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 126-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_107-caution_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCSC"><!--Anchor--></a>CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS AND MARKET AND INDUSTRY DATA </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This proxy statement contains forward-looking statements relating to Catalyst, BC, the Business Combination and the other proposed transactions contemplated thereby that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this proxy statement, including statements regarding Catalyst&#8217;s, BC&#8217;s or the combined company&#8217;s future results of operations and financial position, business strategy, development plans, planned clinical trials, future results of clinical trials, expected research and development costs, regulatory approvals, commercial strategy, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will&#8221; or &#8220;would&#8221; or the negative of these terms or other similar expressions. Forward-looking statements contained in this proxy statement include, but are not limited to, statements about: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the ability of the combined company&#8217;s clinical trials to demonstrate safety and efficacy of the combined company&#8217;s product candidates and other positive results; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the combined company&#8217;s ability to develop a pipeline of product candidates to address unmet needs in the treatment of organ fibrosis and other inflammatory diseases; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the timing, progress and results of clinical trials for Hydronidone from Catalyst&#8217;s Phase 2a trial, F573 from BC&#8217;s Phase 2 clinical study, ETUARY from BC&#8217;s Phase 2/3 clinical study, and other product candidates the combined company may develop, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the studies or trials will become available and research and development programs;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the timing, scope and likelihood of regulatory filings and approvals, including timing of INDs and final FDA approval of Hydronidone for the treatment of NASH and liver fibrosis associated with CHB, ETUARY for the treatment of dermatomyositis-related interstitial lung disease (&#8220;DM-ILD&#8221;) and sclerosis-related interstitial lung disease (&#8220;SSc-ILD&#8221;), F528 for the treatment of chronic obstructive pulmonary disease (&#8220;COPD&#8221;), F230 for the treatment of pulmonary arterial hypertension (&#8220;PAH&#8221;), and any other future product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the timing, scope or likelihood of foreign regulatory filings and approvals; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s expectations regarding the reconsideration of its strategic alternatives in the event the Business Combination is not completed; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the combined company&#8217;s expectations regarding the future pursuit of product development efforts, including whether it will pursue such efforts, estimates regarding the expenses, future revenue, timing of any future revenue, capital requirements and need for additional financing related to such efforts, the timing of and ability of combined company to pursue such efforts and combined company&#8217;s plans to develop and, if approved, subsequently commercialize any product candidates resulting from such efforts; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s expectations regarding its ability to fund its operating expenses and capital expenditure requirements with its cash, cash equivalents and investments; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the combined company&#8217;s ability to develop and advance current product candidates and programs into, and successfully complete, clinical studies; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the combined company&#8217;s manufacturing, commercialization and marketing capabilities and strategy; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">plans relating to commercializing the combined company&#8217;s product candidates, if approved, including the geographic areas of focus and sales strategy; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the need to hire additional personnel and the combined company&#8217;s ability to attract and retain such personnel; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the size of the market opportunity for the combined company&#8217;s product candidates, including estimates of the number of patients who suffer from the diseases the combined company is targeting; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">115<br></div></div></div>
<!--End Page 126-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 127-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_107-caution_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">expectations regarding the approval and use of the combined company&#8217;s product candidates in combination with other drugs; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expectations regarding potential for accelerated approval or other expedited regulatory designation; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the combined company&#8217;s competitive position and the success of competing therapies that are or may become available; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">estimates of the number of patients that the combined company will enroll in its clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the beneficial characteristics and the potential safety, efficacy and therapeutic effects of the combined company&#8217;s product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the combined company&#8217;s ability to obtain and maintain regulatory approval of its product candidates and its expectations regarding particular lines of therapy; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">plans relating to the further development of the combined company&#8217;s product candidates, including additional indications the combined company may pursue; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">existing regulations and regulatory developments in the United States, Europe, the PRC and other jurisdictions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">expectations regarding the impact of the COVID-19 pandemic on Catalyst&#8217;s, BC&#8217;s or the combined company&#8217;s business; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the intellectual property position of the combined company, including the scope of protection the combined company is able to establish and maintain for intellectual property rights covering ETUARY, Hydronidone, F573 F528, and F230, and other product candidates the combined company may develop, including the extensions of existing patent terms where available, the validity of intellectual property rights held by third&#160;parties and the combined company&#8217;s ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the combined company&#8217;s continued reliance on third parties to conduct additional clinical trials of the combined company&#8217;s product candidates and for the manufacture of its product candidates for clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the combined company&#8217;s relationships with patient advocacy groups, KOLs, regulators, the research community and payors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the combined company&#8217;s ability to obtain and negotiate favorable terms of, any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize the combined company&#8217;s product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the pricing and reimbursement of ETUARY, Hydronidone, F573 F528, and F230, and other product candidates the combined company may develop, if approved; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the rate and degree of market acceptance and clinical utility of ETUARY, Hydronidone, F573 F528, and F230, and other product candidates the combined company may develop; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s, BC&#8217;s or the combined company&#8217;s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Catalyst&#8217;s, BC&#8217;s or the combined company&#8217;s financial performance; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the period over which Catalyst, BC or the combined company estimate their existing cash and cash equivalents will be sufficient to fund their planned operating expenses and capital expenditure requirements; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">statements regarding the approval and closing of the Business Combination; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the timing of the consummation of the Business Combination; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s ability to solicit a sufficient number of proxies to approve the change of control resulting from the Business Combination; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">satisfaction of conditions to the completion of the Business Combination; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">116<br></div></div></div>
<!--End Page 127-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 128-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_107-caution_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the expected benefits of the Business Combination; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Catalyst&#8217;s and BC&#8217;s ability to complete the Business Combination; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expectations about the continued listing of Catalyst Common Stock on The Nasdaq Capital Market; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the impact of laws and regulations; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">expectations regarding the period during which the combined company will qualify as a smaller reporting company under the Exchange Act.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">These forward-looking statements are based largely on the current expectations and projections of Catalyst&#8217;s, BC&#8217;s or the combined company&#8217;s business, the industry in which Catalyst and BC operate and financial trends that Catalyst and BC believe may affect the business, financial condition, results of operations and prospects of Catalyst, BC or the combined company, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this proxy statement and are subject to a number of risks, uncertainties and assumptions described in the section entitled &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; beginning on page&#160;<a href="#tRF">34</a> of this proxy statement. Additional factors that could cause actual results to differ materially from those expressed in the forward-looking statements are discussed in reports filed with the SEC by Catalyst. Please see the section&#160;entitled &#8220;<font style="font-style: italic;">Where You Can Find More Information</font>&#8221; beginning on page <a href="#tWYC">343</a> of this proxy statement. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in these forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, Catalyst and BC do not plan to publicly update or revise any forward-looking statements contained herein until after the distribution this proxy statement, whether as a result of any new information, future events or otherwise.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, statements that say &#8220;Catalyst and/or BC believe(s)&#8221; and similar statements reflect the beliefs and opinions on the relevant subject of Catalyst and BC. These statements are based upon information available to Catalyst and BC as of the date of this proxy statement, and while Catalyst and BC believe such information forms a reasonable basis for such statements, such information may be limited or incomplete and the statements of Catalyst and/or BC should not be read to indicate that Catalyst or BC have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">You should read this proxy statement and the documents that are referenced in this proxy statement with the understanding that the actual future results, levels of activity, performance and events and circumstances of Catalyst, BC or the combined company may be materially different from what Catalyst or BC expects.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, this proxy statement includes statistical and other industry and market data that was obtained from independent industry publications and research, surveys and studies conducted by independent third parties, as well as Catalyst&#8217;s and BC&#8217;s estimates. The market data used in this proxy statement involves a number of assumptions and limitations and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Catalyst&#8217;s and BC&#8217;s estimates include assumptions based on their respective industry knowledge, industry publications, third-party research and other surveys. While Catalyst and BC believe that their respective internal assumptions and estimates are reasonable, no independent source has verified such assumptions or estimates.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">117<br></div></div></div>
<!--End Page 128-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 129-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_108-meeting_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tTSM"><!--Anchor--></a>THE SPECIAL MEETING OF CATALYST STOCKHOLDERS </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Date, Time and Place</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Catalyst special meeting will be held on &#8195;&#8195;&#8195;&#8195;, 2023, commencing at &#8195;&#8195;&#8195;&#8195;Pacific Time, unless postponed or adjourned to a later date. The Catalyst special meeting will be held entirely online. Catalyst is sending this proxy statement to its stockholders in connection with the solicitation of proxies by Catalyst&#8217;s board of directors for use at the Catalyst special meeting and any adjournments or postponements of the Catalyst special meeting. This proxy statement is first being mailed to Catalyst stockholders on or about &#8195;&#8195;&#8195;&#8195;, 2023.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Purposes of the Catalyst Special Meeting </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The purposes of the Catalyst special meeting are:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">to approve the issuance of shares of Catalyst Common Stock and Catalyst Convertible Preferred Stock pursuant to the terms of the Business Combination Agreement (as it may be amended from time to time), a copy of which is attached as Annex A to this proxy statement, for purposes of Nasdaq Listing Rules&#160;5635(a) and (b);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">to approve the conversion of Catalyst Convertible Preferred Stock into shares of Catalyst Common Stock pursuant to the F351 Agreement (as it may be amended from time to time), a copy of which is attached as Annex B to this proxy statement, for purposes of Nasdaq Listing Rules&#160;5635(a) and (b);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">to adopt and approve an amendment to the restated certificate of incorporation of Catalyst to increase the number of authorized shares of Catalyst Common Stock from 100,000,000 shares to &#8195;&#8195;&#8195;&#8195;shares;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">to adopt and approve an amendment to the restated certificate of incorporation of Catalyst to effect a reverse stock split of Catalyst Common Stock, by a ratio of not less than 1-for- &#8195;&#8195;&#8195;&#8195;and not more than 1-for- &#8195;&#8195;&#8195;&#8195;, such ratio and the implementation and timing of the reverse stock split to be determined in the discretion of Catalyst&#8217;s board of directors;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">to adopt and approve an amendment to the restated certificate of incorporation of Catalyst to create a new class of non-voting common stock of Catalyst; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to approve the adoption of the 2023 Omnibus Incentive Plan; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">to adopt and approve an amendment to the restated certificate of incorporation of Catalyst to allow for stockholder action by written consent in certain circumstances; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">to elect as director the two nominees named in the proxy statement to serve until the 2026 annual meeting of stockholders and until his or her successor is duly elected and qualified;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to approve, by non-binding advisory vote, the compensation of Catalyst&#8217;s named executive officers;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to conduct an advisory vote on the frequency of future advisory votes on executive compensation;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">to ratify the selection of EisnerAmper LLP as Catalyst&#8217;s independent registered public accounting firm; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">to consider and vote upon an adjournment of the Catalyst special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1, 2, 3, 4, 5 and 6.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The issuance of shares of common stock of Catalyst in connection with the Contributions pursuant to Proposal&#160;No.&#160;1 and the conversion of Catalyst Convertible Preferred into shares of Catalyst Common Stock pursuant to the F351 Agreement cannot take place unless approved by Catalyst stockholders and the Contributions are consummated. Therefore, the Contributions cannot be consummated without the approval of Proposals No. 1, 2, 3, 4 and 6.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;"><a name="tReCBD"><!--Anchor--></a>Recommendation of Catalyst&#8217;s Board of Directors</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s board of directors has determined and believes it is fair to, in the best interests of and advisable to, Catalyst and its stockholders to approve the issuance of shares of Catalyst Common Stock and shares of Catalyst Convertible Preferred Stock, each pursuant to the terms of the Business Combination Agreement (as it may be amended from time to time) for purposes of Nasdaq Listing Rules 5635(a) and (b), as described in this proxy statement. Catalyst&#8217;s board of directors recommends that Catalyst stockholders vote &#8220;FOR&#8221; Proposal No. 1.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">118<br></div></div></div>
<!--End Page 129-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 130-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_108-meeting_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s board of directors has determined and believes it is fair to, in the best interests of and advisable to Catalyst and its stockholders to approve, for purposes of Nasdaq Listing Rules 5635(a) and (b), the conversion of Catalyst Convertible Preferred Stock into shares of Catalyst Common Stock pursuant to the F351 Agreement. Catalyst&#8217;s board of directors recommends that Catalyst stockholders vote &#8220;FOR&#8221; Proposal No. 2.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s board of directors has determined and believes it is fair to, in the best interests of and advisable to Catalyst and its stockholders to adopt and approve an amendment to the restated certificate of incorporation of Catalyst to increase the number of authorized shares of Catalyst Common Stock from 100,000,000 shares to &#8195;&#8195;&#8195;&#8195;shares. Catalyst&#8217;s board of directors recommends that Catalyst stockholders vote &#8220;FOR&#8221; Proposal No. 3.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s board of directors has determined and believes it is fair to, in the best interests of and advisable to Catalyst and its stockholders to adopt and approve an amendment to the restated certificate of incorporation of Catalyst to effect a reverse stock split of Catalyst Common Stock, by a ratio of not less than 1-for- &#8195;&#8195;&#8195;&#8195; and not more than 1-for- &#8195;&#8195;&#8195;&#8195;, such ratio and the implementation and timing of the reverse stock split to be determined in the discretion of Catalyst&#8217;s then-board of directors. Catalyst&#8217;s board of directors recommends that Catalyst stockholders vote &#8220;FOR&#8221; Proposal No. 4.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s board of directors has determined and believes it is fair to, in the best interests of and advisable to Catalyst and its stockholders to adopt and approve an amendment to the restated certificate of incorporation of Catalyst to create a new class of non-voting common stock of Catalyst. Catalyst&#8217;s board of directors recommends that Catalyst stockholders vote &#8220;FOR&#8221; Proposal No. 5.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s board of directors has determined and believes it is fair to, in the best interests of and advisable to Catalyst and its stockholders to approve the 2023 Omnibus Incentive Plan. Catalyst&#8217;s board of directors recommends that Catalyst stockholders vote &#8220;FOR&#8221; Proposal No. 6.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s board of directors has determined and believes it is fair to, in the best interests of and advisable to, Catalyst and its stockholders to approve an amendment to the restated certificate of incorporation of Catalyst to provide for shareholder action by written consent in certain circumstances. Catalyst&#8217;s board of directors recommends that Catalyst stockholders vote &#8220;FOR&#8221; Proposal No. 7.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s board of directors has determined and believes it is fair to, in the best interests of and advisable to, Catalyst and its stockholders to elect the two director nominees named in Proposal No. 8. Catalyst&#8217;s board of directors recommends that Catalyst stockholders vote &#8220;FOR&#8221; each of the nominees named in Proposal No. 8.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s board of directors has determined and believes it is fair to, in the best interests of and advisable to, Catalyst and its stockholders to approve, by non-binding advisory vote, the compensation of Catalyst&#8217;s named executive officers. Catalyst&#8217;s board of directors recommends that Catalyst stockholders vote &#8220;FOR&#8221; Proposal No. 9.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s board of directors has determined and believes it is fair to, in the best interests of and advisable to, Catalyst and its stockholders to conduct an advisory vote to determine the frequency of future advisory votes on executive compensation every one year. Catalyst&#8217;s board of directors recommends that Catalyst stockholders vote for &#8220;ONE YEAR&#8221; on Proposal No. 10.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s board of directors has determined and believes it is fair to, in the best interests of and advisable to, Catalyst and its stockholders to ratify the selection of EisnerAmper LLP as Catalyst&#8217;s independent auditor for 2023. Catalyst&#8217;s board of directors recommends that Catalyst stockholders vote &#8220;FOR&#8221; Proposal No. 11.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s board of directors has determined and believes it is fair to, in the best interests of and advisable to Catalyst and its stockholders to approve the adjournment of the Catalyst special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1, 2, 3, 4, 5 and 6. Catalyst&#8217;s board of directors recommends that Catalyst stockholders vote &#8220;FOR&#8221; Proposal No. 12. </div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Record Date and Voting Power</div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Only stockholders of record of Catalyst at the close of business on the record date, which is &#8195;&#8195;&#8195;&#8195;, 2023, are entitled to notice of and to vote at the Catalyst special meeting. Notwithstanding the foregoing, holders of outstanding </div> </div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"> <div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">119<br></div> </div></div>
<!--End Page 130-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 131-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_108-meeting_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">shares of Catalyst Series&#160;Y Preferred Stock will only be entitled to vote such shares on Proposal No.&#160;4 and will only be able to vote to the extent that such shares have not been automatically redeemed in the Initial Redemption, as described in this proxy statement. At the close of business on the record date, &#8195;&#8195;&#8195; shares of Catalyst Common Stock were issued and outstanding and &#8195;&#8195;&#8195; shares of Catalyst Series Y Preferred Stock were issued and outstanding. Each share of Catalyst Common Stock entitles the holder thereof to one vote on each matter submitted for stockholder approval. Please refer to the discussion in the Q&amp;A section under &#8220;What stockholder votes are required to approve the proposals at the Catalyst special meeting?&#8221; and &#8220;How many votes do I have?&#8221; for a description of the voting power of the Catalyst Series Y Preferred Stock, which is entitled to be voted together with the Catalyst Common Stock as a single class on Proposal No.&#160;4.</div> <div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Voting and Revocation of Proxies </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: justify;">This proxy statement is solicited on behalf of Catalyst&#8217;s board of directors for use at the Catalyst special meeting.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If, as of the record date referred to above, your shares were registered directly in your name with the transfer agent for Catalyst Common Stock, American Stock Transfer &amp; Trust Company, LLC, then you are a stockholder of record. Whether or not you plan to attend the Catalyst special meeting online, Catalyst urges you to fill out and return the proxy card or submit a proxy to vote over the telephone or on the internet as instructed below to ensure your vote is counted.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The procedures for voting are as follows: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If you are a stockholder of record, you may vote at the Catalyst special meeting. Alternatively, you may submit a proxy to vote by using the accompanying proxy card, over the internet or by telephone. Whether or not you plan to attend the Catalyst special meeting, Catalyst encourages you to submit your proxy to vote to ensure your vote is counted. Even if you have submitted a proxy before the Catalyst special meeting, you may still attend the Catalyst special meeting and vote in person. In such case, your previously-submitted proxy will be disregarded.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To vote at the Catalyst special meeting, attend the Catalyst special meeting online and follow the instructions posted at http://www.virtualshareholdermeeting.com/CBIO2023SM.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To submit your proxy using the proxy card, simply complete, sign and date the accompanying proxy card and return it promptly in the envelope provided. If you return your signed proxy card before the Catalyst special meeting, Catalyst will vote your shares in accordance with the proxy card.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To submit your proxy over the internet, follow the instructions provided on the Notice of Internet Availability.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To submit your proxy by telephone, you may call the toll-free number found on the Notice of Internet Availability.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If you are a beneficial owner of shares registered in the name of your broker, bank or other agent, you should have received a voting instruction card and voting instructions with these proxy materials from that organization rather than from Catalyst. Simply complete and mail the voting instruction card to ensure that your vote is counted. To vote in person at the Catalyst special meeting, you must obtain a valid proxy from your broker, bank or other agent. Follow the instructions from your broker, bank or other agent included with these proxy materials, or contact your broker, bank or other agent to request a proxy form.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst provides internet proxy voting to allow you to submit your proxy to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and telephone companies.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If you hold shares beneficially in &#8220;street name&#8221; and do not provide your broker or other agent with voting instructions, your shares may constitute &#8220;broker non-votes.&#8221; A &#8220;broker non-vote&#8221; occurs when shares held by a broker are not voted with respect to a particular proposal because the broker does not have or did not exercise discretionary authority to vote on the matter and has not received voting instructions from its clients. These matters are referred to as &#8220;non-routine&#8221; matters. On non-routine items for which you do not give your broker instructions, shares of Catalyst Common Stock will be treated as broker non-votes. Whether a proposal is considered routine or non-routine is subject to stock exchange rules and final determination by the stock exchange.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">120<br></div></div></div>
<!--End Page 131-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 132-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_108-meeting_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">All properly-executed proxies that are not revoked will be voted at the Catalyst special meeting and at any adjournments or postponements of the Catalyst special meeting in accordance with the instructions contained in the proxy. <font style="font-weight: bold;">If a holder of Catalyst Common Stock executes and returns a proxy and does not specify otherwise, the </font><font style="font-weight: bold;">shares represented by that proxy will be voted &#8220;FOR&#8221; Proposal Nos. 1, 2, 3, 4, 5, 6, 7, 9, 11 and 12, &#8220;FOR&#8221; </font><font style="font-weight: bold;">the election of each of the director nominees named in Proposal No. 8 and &#8220;ONE YEAR&#8221; on Proposal No. 10 </font><font style="font-weight: bold;">in accordance with the recommendation of Catalyst&#8217;s board of directors.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If you are a stockholder of record of Catalyst, you may change your vote at any time before your proxy is voted at the Catalyst special meeting in any one of the following ways: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">You may submit another properly completed proxy with a later date by mail or via the internet.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">You can provide your proxy instructions via telephone at a later date.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">You may send a written notice that you are revoking your proxy to Catalyst&#8217;s Corporate Secretary at 611&#160;Gateway Blvd. Suite 120, South San Francisco, California 94080.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">You may attend the Catalyst special meeting online and vote by following the instructions at http://www.virtualshareholdermeeting.com/CBIO2023SM.com. Simply attending the Catalyst special meeting will not, by itself, revoke your proxy.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">If your shares are held by your broker, bank or other agent, you should follow the instructions provided by them.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Required Vote </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The presence at the Catalyst special meeting, in person or represented by proxy, of the holders of one-third of the outstanding shares of Catalyst Common Stock entitled to vote at the Catalyst special meeting shall constitute a quorum for the transaction of business. Abstentions and broker non-votes, if any, will be counted towards a quorum.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Votes will be counted by the inspector of election appointed for the meeting, who will separately count &#8220;FOR&#8221; and &#8220;AGAINST&#8221; votes, abstentions and broker non-votes. Assuming a quorum is present, the affirmative vote of the holders of a majority of all of the shares of Catalyst Common Stock present in person or represented by proxy at the Catalyst special meeting and entitled to vote on such matter is required for approval of Proposal Nos. 1, 2, 6, 9, 11 and 12. On Proposal Nos. 1, 2, 6, 9, 11 and 12, abstentions will have the same effect as &#8220;AGAINST&#8221; votes and broker non-votes, if any, will have no effect.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Assuming a quorum is present, the affirmative vote of the holders of a majority of all of the shares of Catalyst Common Stock present in person or represented by proxy at the Catalyst special meeting and entitled to vote on such matter is required for approval of Proposal No. 10. Abstentions on Proposal No. 10 will have the same effect as a vote against each option, and broker non-votes, if any, will have no effect. Because Proposal No. 10 has multiple options, if none of the options receives the affirmative vote of the holders of a majority of all of the shares of Catalyst Common Stock present in person or represented by proxy at the Catalyst special meeting and entitled to vote on the matter, then we will consider the stockholders to have approved the option selected by the holders of a plurality of the shares of Catalyst Common Stock present in person or represented by proxy at the Catalyst special meeting and entitled to vote on the matter. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Assuming a quorum is present, the affirmative vote of the holders of a majority in voting power of the outstanding shares of Catalyst Common Stock entitled to vote thereon is required for approval of Proposal Nos. 3 and 5. Abstentions and broker non-votes, if any, will have the same effect as &#8220;AGAINST&#8221; votes on Proposal Nos. 3 and 5.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Assuming a quorum is present, the affirmative vote of the holders of a majority of the outstanding shares of Catalyst Common Stock and Catalyst Series Y Preferred Stock entitled to vote at the Catalyst special meeting is required for approval of Proposal No. 4. Please refer to the discussion in the Q&amp;A section under &#8220;What stockholder votes are required to approve the proposals at the Catalyst special meeting?&#8221; and &#8220;How many votes do I have?&#8221; for a description of the voting power of the Catalyst Series Y Preferred Stock, which is entitled to be voted together with the Catalyst Common Stock as a single class on Proposal No. 4. Shares of Catalyst Series Y Preferred Stock that are not present in person or by proxy as of immediately prior to the opening of the polls at the Catalyst special meeting will be automatically redeemed in the Initial Redemption and, therefore, will not be outstanding or entitled to vote on Proposal No. 4 and will be excluded from the calculation as to whether Proposal No. 4, respectively, passes at the Catalyst special meeting. Due to the voting power of the shares of Catalyst Series Y Preferred Stock that are redeemed pursuant to the Initial Redemption, the holders of Catalyst Common Stock that submit a proxy to vote their shares </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">121<br></div></div></div>
<!--End Page 132-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 133-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_108-meeting_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">at the Catalyst special meeting or vote at the Catalyst special meeting will effectively have enhanced voting power on Proposal No. 4 over holders of Catalyst Common Stock that are not represented in person or by proxy at the Catalyst special meeting. This means that Proposal No. 4 could be approved by the affirmative vote of the holders of less than a majority of the outstanding shares of Catalyst Common Stock. Abstentions and broker non-votes, if any, will have the same effect as &#8220;AGAINST&#8221; votes on Proposal No. 4.</div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Delaware General Assembly has passed amendments to the DGCL that would change the stockholder vote required to effect a reverse split of stock that is listed on a national securities exchange and meets certain other requirements. The Catalyst Common Stock is listed on the Nasdaq Capital Market, a national securities exchange. The DGCL amendments are anticipated to become effective on August 1, 2023, if they are signed into law by the Governor of Delaware, or otherwise enacted pursuant to Delaware Law, on or before that date. If the amendments to the DGCL become effective before Catalyst files the amendment to the restated certificate of incorporation of Catalyst with the Delaware Secretary of State to effect the Reverse Stock Split, the Catalyst board of directors reserves the right to rely upon the new stockholder vote requirements authorized by the DGCL amendments to determine if Proposal No. 4 has been adopted. The DGCL amendments would permit Catalyst to effect the Reverse Stock Split if the votes cast &#8220;FOR&#8221; Proposal No. 4 exceed the votes cast &#8220;AGAINST&#8221; Proposal No. 4, assuming the presence of a quorum and if the shares of Catalyst Common Stock meet the listing requirement of the Nasdaq Capital Market relating to the minimum number of holders immediately after the amendment to the restated certificate of incorporation effecting the Reverse Stock Split becomes effective. Under this voting standard, abstentions and broker non-votes (if any), and shares of Catalyst Common Stock that are not present in person or by proxy at the Catalyst special meeting, will have no effect on the outcome of the vote on Proposal No. 4.</div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Assuming a quorum is present, the affirmative vote of the holders of two-thirds in voting power of the outstanding shares of Catalyst Common Stock entitled to vote thereon is required for approval of Proposal No. 7. Abstentions and broker non-votes, if any, will have the same effect as &#8220;AGAINST&#8221; votes on Proposal No. 7.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Assuming a quorum is present, the two nominees receiving the highest number of affirmative &#8220;FOR&#8221; votes shall be elected as Class&#160;II directors pursuant to Proposal No. 8. Shares withheld and broker non-votes, if any, will have no effect.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Proposal Nos. 1, 2, 3, 4 and 6 are a condition to the completion of the Contributions. Therefore, the Contributions cannot be consummated without the approval of Proposal Nos. 1, 2, 3, 4 and 6. The issuance of Catalyst Common Stock in connection with the Contributions will not take place unless Proposal Nos. 1, 2, 3, 4 and 6 are approved by Catalyst stockholders and the Contributions are consummated.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of May 15, 2023, the directors and certain executive officers of Catalyst owned or controlled approximately 0.3% of the outstanding shares of Catalyst Common Stock entitled to vote at the Catalyst special meeting. As of May 19, 2023, GNI Japan and GNI Hong Kong owned or controlled approximately 16.6% of the outstanding shares of Catalyst Common Stock entitled to vote at the Catalyst special meeting.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Solicitation of Proxies</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition to solicitation by mail, the directors, officers, employees and agents of Catalyst may solicit proxies from Catalyst stockholders by personal interview, telephone, email, fax or otherwise. Catalyst and the GNI Parties will share equally the costs of printing and filing this proxy statement and proxy card. Arrangements will also be made with brokerage firms and other custodians, nominees and fiduciaries who are record holders of Catalyst Common Stock for the forwarding of solicitation materials to the beneficial owners of Catalyst Common Stock. Catalyst and the GNI Parties will reimburse these brokers, custodians, nominees and fiduciaries for the reasonable out-of-pocket expenses they incur in connection with the forwarding of solicitation materials. Catalyst will retain Broadridge to assist it in soliciting proxies using the means referred to above. Catalyst and the GNI Parties will pay the fees of Broadridge, which are expected to be approximately $ &#8195;&#8195;&#8195;plus reimbursement of out-of-pocket expenses.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Other Matters</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of the date of this proxy statement, Catalyst&#8217;s board of directors does not know of any business to be presented at the Catalyst special meeting other than as set forth in the notice in this proxy statement. If any other matters should properly come before the Catalyst special meeting, it is intended that the shares represented by proxies will be voted with respect to such matters in accordance with the judgment of the persons voting the proxies.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">122<br></div></div></div>
<!--End Page 133-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 134-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_108-meeting_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tTC"><!--Anchor--></a>THE CONTRIBUTIONS </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This section and the section entitled &#8220;The Business Combination Agreement&#8221; beginning on page <a href="#tTBC">144</a> of this proxy statement describe the material aspects of the Contributions and the Business Combination Agreement. While Catalyst and the GNI Parties believe that this description covers the material terms of the Contributions and the Business Combination Agreement, it may not contain all of the information that is important to you. You should read carefully this entire proxy statement for a more complete understanding of the Contributions and the Business Combination Agreement and the other documents to which you are referred in this proxy statement. See the section entitled &#8220;Where You Can Find More Information&#8221; beginning on page <a href="#tWYC">343</a> of this proxy statement.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Catalyst&#8217;s Background of the Contributions</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In November 2021, Catalyst announced the discontinuation of its Phase 3 and Phase 1/2 clinical trials of MarzAA based on a number of factors, including challenges in enrollment resulting from the limited number of potential patients eligible to enroll in these trials, difficulties in identifying and enrolling eligible patients during the pandemic, delays in enrollment resulting from COVID-19, competition from approved therapies, the capital requirements to complete the trials, and other factors. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In February 2022, Catalyst announced that it had engaged Perella Weinberg Partners (&#8220;PWP&#8221;), a leading global independent advisory firm, as a financial advisor to assist Catalyst in exploring strategic alternatives, including a potential sale of Catalyst, a sale of Catalyst&#8217;s assets, or other alternatives to monetize Catalyst&#8217;s assets. In February&#160;2022, Catalyst&#8217;s board of directors also formed a transaction committee to oversee its strategic alternative process (the &#8220;Transaction Committee&#8221;). The members of the Transaction Committee were Augustine Lawlor, Jeanne&#160;Jew and Sharon Tetlow.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Between February and early April 2022, PWP and Catalyst explored Catalyst&#8217;s strategic alternatives related to the licensing or sale of Catalyst&#8217;s complement and hemophilia programs engaged with many potential counterparties. This exploration included outreach to approximately 75 potentially interested parties, the execution of confidentiality agreements with 15 parties (such agreements contained a customary standstill provision that, among other things, permitted interested parties to confidentially request from Catalyst a waiver of the standstill, and that terminated upon Catalyst&#8217;s entry into the Business Combination Agreement), due diligence conducted by 14 parties, process letters sent to 13 parties, two offers received to purchase Catalyst&#8217;s complement-related assets, including an offer from Vertex. Catalyst also received one subsequent verbal offer for the purchase of Catalyst&#8217;s complement-related assets. Throughout this period, the Transaction Committee reviewed these proposals with Catalyst&#8217;s entire board of directors, PWP, Catalyst&#8217;s management, and Catalyst&#8217;s outside legal advisors, and discussed negotiating strategies and plans. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In parallel, between February 2022 and July 2022, Catalyst, PWP and another financial advisor, Raymond James (&#8220;RJ&#8221;), reviewed approximately 40 potential reverse merger transactions. In February 2022, Catalyst received an initial indication of interest to combine with a company (&#8220;Company A&#8221;) in a reverse merger transaction. This proposed transaction was subject to several conditions, including a concurrent $70&#160;million financing by Company A and an assumed Catalyst net cash amount at closing equal to $30&#160;million. Catalyst and Company A and their respective outside legal and financial advisors negotiated the terms and conditions of definitive legal agreements through May 2022, at which time it became apparent that all conditions could not be satisfied. As a result, Catalyst ceased negotiations with Company A.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">During the period between February and July 2022 the Transaction Committee held approximately 21 meetings, often with representatives of PWP and RJ, to evaluate all potential transactions including reverse mergers, out-licensing, and asset sales.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">With respect to reverse merger transactions reviewed during this period, the Transaction Committee elected not to proceed with any of these potential transactions because of, among other reasons: uncertainty about the scientific rationale or business prospects of the proposed counterparties to such transactions; transaction requirements related to Catalyst retaining significant amounts of cash to fund future operations of the resulting entity, thereby reducing the amount of cash that Catalyst could distribute to its stockholders; the capital requirements of the surviving company following any such transaction and the likelihood of raising such capital at reasonable valuations, if at all; dilution to Catalyst stockholders from the initial proposed transaction and likely additional dilution resulting from additional fundraising; and uncertainty of completing any such transaction. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">During April and May 2022, Catalyst and Vertex and their respective outside legal and financial advisors conducted due diligence on Catalyst&#8217;s complement-related assets and certain other assets, and negotiated the final terms and </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">123<br></div></div></div>
<!--End Page 134-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 135-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_108-meeting_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">definitive legal agreements under which Vertex would acquire such assets from Catalyst for up to $60&#160;million in cash, including an initial payment of $55&#160;million at closing and a subsequent payment of up to $5&#160;million payable on the completion of certain obligations. In May 2022, Catalyst&#8217;s board of directors and its outside legal and financial advisors discussed the terms and conditions of such proposed asset sale to Vertex and related matters, following which Catalyst&#8217;s board of directors unanimously approved the Vertex transaction. Among the factors considered by Catalyst&#8217;s board of directors were the non-contingent cash consideration offered by Vertex, the amount, duration, and conditions related to consideration holdback, Catalyst&#8217;s board of directors&#8217; belief that the terms and conditions offered by Vertex were superior to all other offers received as part of Catalyst&#8217;s exploration of strategic alternatives with PWP during this period, the opinion of Potter Anderson &amp; Coroon LLP that a vote of the Catalyst stockholders to approve the Vertex transaction was not required under Delaware law, the fact that the Vertex proposal provided for a simultaneous signing and closing of the transaction, which was viewed favorably by Catalyst&#8217;s board of directors, and Catalyst&#8217;s board of directors&#8217; belief that the Vertex transaction provided certainty of closing. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Following the consummation of the Vertex transaction, Catalyst&#8217;s assets consisted primarily of the discontinued MarzAA and other hemophilia assets and cash on hand. Catalyst also owned certain contractual rights related to the sale of legacy assets from a prior company, Targacept, which were of uncertain value.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In June, July, and August 2022, Catalyst&#8217;s board of directors continued their review of strategic alternatives. In furtherance of the foregoing, Catalyst&#8217;s board of directors, along with its outside legal and financial advisors, continued to discuss potential reverse merger transactions, potential transactions to sell MarzAA and the other hemophilia assets, and alternatives for distributing cash to Catalyst&#8217;s stockholders, including a potential dividend or tender offer. In late August 2022, following the dismissal of certain stockholder litigation and the closing of the Vertex transaction, Catalyst&#8217;s board of directors declared a special cash dividend to its stockholders of approximately $45&#160;million, which was paid in September 2022.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In September 2022, Catalyst&#8217;s board of directors considered two potential reverse merger transactions, one of which Catalyst&#8217;s board of directors did not consider feasible due to financing considerations, and the other of which Catalyst&#8217;s board of directors had uncertainties about due to the nature of the target company&#8217;s business. The Catalyst Board, along with its outside legal advisors, also discussed the potential to dissolve Catalyst, including the requirement to obtain a stockholder vote and the probability of doing so, timing, potential expense, and the amounts and timing of potential distributions to stockholders.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In October 2022, Catalyst received, and Catalyst&#8217;s board of directors discussed, a letter of intent from GNI regarding a proposed transaction (the &#8220;Transaction&#8221;), including the possibility of valuing MarzAA and DalcA assets as part of the Transaction. GNI&#8217;s and Catalyst&#8217;s legal representatives continued to discuss potential transaction structures considering GNI&#8217;s financial reporting obligations and tax considerations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In November 2022, GNI provided a revised letter of intent regarding the Transaction, including the addition of a cash distribution to Catalyst stockholders, the distribution of the CVR to Catalyst&#8217;s current stockholders that would include value received for MarzAA, DalcA, and Catalyst&#8217;s other assets, and provisions related to expense sharing between Catalyst and GNI, with a goal towards maximizing the amount of cash that could be distributed to Catalyst stockholders in connection with the Transaction. Both the original October letter of intent and the revised November letter of intent contemplated that, following the F351 Acquisition and until the completion of the Contributions, the Catalyst board of directors would consist of three legacy Catalyst directors and two new directors designated by GNI. Both letters of intent also contemplated that Nassim Usman, Ph.D. and Seline Miller would continue in their roles as Chief Executive Officer and interim Chief Financial Officer, respectively, during this period. The November letter of intent also contemplated appropriate management retention awards through the closing of the Contributions. These awards were subsequently negotiated as discussed in the section entitled &#8220;<font style="font-style: italic;">Catalyst Executive and Director </font><font style="font-style: italic;">Compensation&#8212;Post-Closing Arrangements</font>&#8221; beginning on page <a href="#tPCA1">164</a> of this proxy statement. Dr. Usman has had discussions with representatives of GNI regarding his role as a board member of the combined company following the Contributions; however, except as expressly described in this proxy statement, there are no written agreements between Catalyst, GNI or BC and Dr. Usman regarding his compensation or role following the completion of the Contributions. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The current President and Chief Executive Officer of Catalyst will serve as a director on the board of directors of the combined company. Nassim Usman, Ph.D. has eight years of experience as a director of a public company, and </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">124<br></div></div></div>
<!--End Page 135-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 136-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_108-meeting_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Catalyst believes that this experience will be valuable for the combined company. In addition, Dr. Usman&#8217;s financial expertise qualifies him to be chair of the audit committee of the combined company. For those reasons, Catalyst negotiated with Dr. Usman for him to remain involved as a director for the combined company. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Seline Miller will cease serving as Catalyst&#8217;s interim Chief Financial Officer at the Effective Time and, following the consummation of the Contributions, will not continue as an executive officer of the combined company.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst reviewed the updated term sheet with members of the Transaction Committee, who unanimously favored moving forward with negotiations for the Transaction. On November&#160;10, 2022, Catalyst&#8217;s board of directors met and discussed the status of discussions with GNI regarding the Transaction, as well as the status of other potential asset sale or acquisition discussions.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In November and December 2022, legal representatives from Catalyst and GNI exchanged and negotiated draft legal documents regarding the Transaction. On November&#160;9, 2022, Catalyst engaged Raymond James to conduct an analysis of the fairness of the Transaction to Catalyst from a financial point of view. On December&#160;20, 2022, Catalyst&#8217;s board of directors reviewed the terms and conditions of the Transaction. At this meeting, representatives or Orrick, Herrington &amp; Sutcliffe LLP, Catalyst&#8217;s legal advisors, discussed Catalyst&#8217;s board of directors&#8217; fiduciary duties with respect to the Transaction, and representatives of Raymond James delivered their opinion that the Transaction Consideration (as defined in the Raymond James Fairness Opinion) to be paid by Catalyst pursuant to the Business Combination Agreement is fair to Catalyst from a financial point of view. <font style="font-style: italic;">See</font> &#8220;&#8212;<font style="font-style: italic;">Opinion of Catalyst&#8217;s </font><font style="font-style: italic;">Financial Advisor</font>&#8221; below. On December&#160;21, 2022, Catalyst&#8217;s board of directors unanimously approved the Transaction and related matters. See &#8220;&#8212;<font style="font-style: italic;">Catalyst&#8217;s Reasons for the Contributions</font>&#8221; below.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a name="tCRF"><!--Anchor--></a>Catalyst&#8217;s Reasons for the Contributions</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">During the course of its evaluation of the F351 Agreement and the Business Combination Agreement and the transactions contemplated thereby, Catalyst&#8217;s then-board of directors held numerous meetings, consulted with Catalyst&#8217;s management, legal counsel and financial advisors and reviewed and assessed a significant amount of information. In reaching its decision to approve the Contributions and the transactions contemplated by the F351 Agreement and the Business Combination Agreement, Catalyst&#8217;s then-board of directors considered a number of supporting factors and risks and countervailing factors related to entering into the F351 Agreement and the Business Combination Agreement and the transactions contemplated thereby, including:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s historical and current business, financial performance and condition, operations, management and competitive position;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the current industry and economic conditions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Catalyst&#8217;s prospects if it were to remain an independent company;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Catalyst&#8217;s inability to regain compliance with Nasdaq listing requirements;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s then-board of directors&#8217; belief that no reasonable alternatives to the Contributions were likely to create greater value for Catalyst stockholders after reviewing the various alternatives, including a belief that a dissolution of Catalyst was the likeliest alternative to the Contributions and the likelihood of achieving any such alternative relative to the likelihood of consummating the Contributions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the anticipated cash resources and potential access to liquidity sources of the combined company following the consummation of the Contributions relative to Catalyst&#8217;s stand-alone, anticipated burn rate;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s ability to make a distribution of capital to Catalyst stockholders and still complete the Contributions; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s then-board of directors&#8217; consideration of the financial analyses of Raymond James, including its opinion to Catalyst&#8217;s then-board of directors as to the fairness, from a financial point of view and as of the date of the opinion, to Catalyst the Transaction Consideration (as defined in the Raymond James fairness opinion) pursuant to the F351 Agreement and the Business Combination Agreement, as more fully described below under the caption &#8220;<font style="font-style: italic;">The Contributions&#8212;Opinion of Catalyst&#8217;s Financial Advisor</font>,&#8221; beginning on page <a href="#tOCF">128</a> in this proxy statement.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">125<br></div></div></div>
<!--End Page 136-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 137-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_108-meeting_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s then-board of directors also reviewed the terms of the F351 Agreement, the Business Combination Agreement and related transaction documents, including those described below and concluded that the terms of the F351 Agreement, the Business Combination Agreement and related transaction documents, in the aggregate, were advisable and reasonable under the circumstances:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the expected dilutive impact resulting from and the relative percentage ownership of GNI and the Catalyst stockholders upon, the consummation of the Contributions (including upon the conversion of the Catalyst Convertible Preferred Stock);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the likelihood of consummating the Contributions given the limited number and nature of the closing conditions under the F351 Agreement and the Business Combination Agreement; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the various deal protection provisions under the Business Combination Agreement, including limitations on Catalyst&#8217;s then-board of directors&#8217; ability to solicit other strategic alternatives and the potential payment by the Catalyst of the Termination Fee (as defined therein);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the transactions contemplated by the F351 Agreement are consummated immediately upon signing, are independent of the transactions contemplated by the Business Combination Agreement and therefore, the potential adverse effects on Catalyst in the event that Catalyst stockholders do not vote to approve the Business Combination or the conversion of the Catalyst Convertible Preferred Stock into shares of Company Common Stock in accordance with Nasdaq Listing Rule 5635;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the potential adverse economic effects to Catalyst under the Certificate of Designation if Catalyst stockholders do not approve the conversion of the Catalyst Convertible Preferred Stock into shares of Company Common Stock and the Catalyst Convertible Preferred Stock is prohibited from converting into shares of Company Common Stock; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the amounts and likelihood of holders of CVRs receiving the payments under the CVR Agreement.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The foregoing information and factors considered by Catalyst&#8217;s then-board of directors are not intended to be exhaustive, but are believed to include all of the material factors considered by Catalyst&#8217;s then-board of directors. In view of the wide variety of factors considered in connection with its evaluation of the Contributions and the complexity of these matters, Catalyst&#8217;s then-board of directors did not find it useful and did not attempt, to quantify, rank or otherwise assign relative weights to these factors. In considering the factors described above, individual members of Catalyst&#8217;s then-board of directors may have given different weight to different factors. Catalyst&#8217;s then-board of directors conducted an overall analysis of the factors described above, including thorough discussions with and questioning of the Catalyst management team and the legal and financial advisors of Catalyst, and considered the factors overall to be favorable to and to support its determination.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;"><a name="tGNI"><!--Anchor--></a>GNI Parties Reasons for the Contributions</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In the course of reaching their decision to approve the Contributions, the board of directors and executive directors, as applicable, of the GNI Parties held numerous meetings, consulted with senior management of the GNI Parties, BC&#8217;s financial advisors and legal counsel and considered a wide variety of factors, including, among others, the following material factors (which factors are not necessarily presented in any order of relative importance): </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the Contributions will provide the GNI parties and the Minority Holders with greater liquidity by owning publicly traded stock and expanding both the access to capital for BC and the range of investors potentially available as a public company, compared to the investors BC could otherwise gain access to if it continued to operate as a privately held company; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the historical and current information concerning BC&#8217;s business, including its financial performance and condition, operations, management and preclinical and clinical data; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the competitive nature of the industry in which BC operates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the belief of the board of directors and executive directors, as applicable, of the GNI Parties that this transaction provides a viable alternate public listing strategy for BC and addresses the risk of the lack of an available market for an initial public offering of BC at a later date; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the projected financial position, operations, management, operating plans and financial projections of the combined company, including the impact of the CVR Agreement; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">126<br></div></div></div>
<!--End Page 137-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 138-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_108-meeting_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the expected cash resources of the combined company (including the ability to support the combined company&#8217;s current and planned clinical trials and operations); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the terms and conditions of the Business Combination Agreement, including the following: </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the determination that the expected relative percentage ownership of Catalyst&#8217;s stockholders and GNI USA in the combined company was appropriate, based on the judgment and assessment of the board of directors and executive directors, as applicable, of the GNI Parties of the approximate valuations of Catalyst and BC; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the expectation that the Contributions, taken together, will qualify as a transaction governed by Section 351(a) of the Code, for U.S. federal income tax purposes, with the result that in the Contributions GNI USA will generally not recognize taxable gain or loss for U.S. federal income tax purposes, as more fully described below under the caption &#8220;<font style="font-style: italic;">The Contributions&#8212;Material U.S. </font><font style="font-style: italic;">Federal Income Tax Consequences of the Contributions</font>,&#8221; beginning on page <a href="#tMUF1">141</a> in this proxy statement; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the limited number and nature of the conditions of the obligation of Catalyst to consummate the Contributions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the conclusion of the board of directors and executive directors, as applicable, of the GNI Parties that the potential termination fees of $2&#160;million payable by Catalyst to the Contributors in certain circumstances and the circumstances when such fees may be payable, were reasonable; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the belief that the other terms of the Business Combination Agreement, including the parties&#8217; representations, warranties and covenants and the conditions to their respective obligations, were reasonable in light of the entire transaction; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the ability to obtain a Nasdaq listing and the change of the combined company&#8217;s name to Gyre Therapeutics, Inc. upon the closing of the Contributions; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the likelihood that the Contributions will be consummated on a timely basis.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The board of directors and executive directors, as applicable, of the GNI Parties also considered a number of uncertainties and risks in its deliberations concerning the Contributions and the other transactions contemplated by the Business Combination Agreement, including the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the possibility that the Contributions might not be completed and the potential adverse effect of the public announcement of the Contributions on the reputation of BC and the ability of BC to obtain financing in the future in the event the Contributions is not completed; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the risk that future sales of common stock by existing Catalyst stockholders may cause the price of Catalyst Common Stock to fall, thus reducing the potential value of Catalyst Common Stock received by GNI USA and the Minority Holders following the Contributions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the possibility that Contributors or Catalyst, as the case may be, may be required to reimburse the other parties for reasonable out-of-pocket fees and expenses incurred by such party in connection with the transactions contemplated by the Business Combination Agreement, up to a maximum amount of $2.0&#160;million;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the potential reduction of Catalyst&#8217;s net cash prior to the closing; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the possibility that Catalyst could, under certain circumstances, consider unsolicited acquisition proposals if superior to the Contributions or change its recommendation to approve the Contributions upon certain events; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the possibility that the Contributions might not be completed in a timely manner or at all, for a variety of reasons, such as the failure of Catalyst to obtain the required stockholder vote and the potential adverse effect on the reputation of BC and the ability of BC to obtain financing in the future in the event the Contributions are not completed; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the costs involved in connection with completing the Contributions, the time and effort of the senior management of the GNI Parties required to complete the Contributions, the related disruptions or potential </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">127<br></div></div></div>
<!--End Page 138-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 139-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_108-meeting_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">disruptions to BC&#8217;s business operations and future prospects, including its relationships with its employees, suppliers and partners and others that do business or may do business in the future with BC and related administrative challenges associated with combining the companies; </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the additional expenses and obligations to which BC&#8217;s business will be subject following the Contributions that BC has not previously been subject to and the operational changes to BC&#8217;s business, in each case, that may result from being a public company; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the fact that the representations and warranties in the Business Combination Agreement do not survive the closing of the Contributions and the potential risk of liabilities that may arise post-closing; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">various other risks associated with the combined company and the Contributions, including the risks described in the section entitled &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; in this proxy statement.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The foregoing information is not intended to be exhaustive, but summarizes the material factors considered by the board of directors and executive directors, as applicable, of the GNI Parties in their consideration of the Business Combination Agreement and the transactions contemplated. The board of directors and executive directors, as applicable, of the GNI Parties concluded that the benefits, advantages and opportunities of a potential transaction outweighed the uncertainties and risks described above. After considering these and other factors, the board of directors and executive directors, as applicable, of the GNI Parties each unanimously approved the Business Combination Agreement, the Contributions and the other transactions contemplated by the Business Combination Agreement.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;"><a name="tOCF"><!--Anchor--></a>Opinion of Catalyst&#8217;s Financial Advisor</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst retained Raymond James &amp; Associates, Inc., or Raymond James, as its financial advisor in connection with the Contributions and other transactions contemplated by the F351 Agreement and the Business Combination Agreement. Catalyst&#8217;s then-board of directors selected Raymond James to act as Catalyst&#8217;s financial advisor based on Raymond James' qualifications, reputation, experience and expertise in the biopharmaceutical industry, its knowledge of and involvement in recent transactions in the biopharmaceutical industry and its relationship with Catalyst and its business. Raymond James is an internationally-recognized investment banking and financial services company that has substantial experience in transactions similar to the Contributions and other transactions contemplated by the F351 Agreement and the Business Combination Agreement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with this engagement, Catalyst&#8217;s then-board of directors requested that Raymond James evaluate the fairness, from a financial point of view, to Catalyst of the Transaction Consideration (as defined in the Raymond James fairness opinion) to be paid by Catalyst. On December&#160;21, 2022, at a meeting of Catalyst&#8217;s then-board of directors, Raymond James rendered to Catalyst&#8217;s then-board of directors its oral opinion, which was subsequently confirmed by delivery of a written opinion dated December&#160;21, 2022, that, as of such date and based upon and subject to the various procedures followed, assumptions made, matters considered and the qualifications and limitations upon the review undertaken by Raymond James in preparing its opinion, the Transaction Consideration to be paid by Catalyst was fair, from a financial point of view, to Catalyst. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The full text of the Raymond James fairness opinion, which describes, among other things, the various procedures followed, assumptions made, matters considered, qualifications and limitations upon the scope of the review undertaken by Raymond James in preparing its opinion, is attached to this proxy statement as Annex&#160;C and is incorporated by reference in its entirety to this proxy statement. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Raymond James&#8217; financial advisory services and opinion were provided for the information and assistance of the members of Catalyst&#8217;s then-board of directors (in their capacity as directors and not in any other capacity) in connection with and for purposes of Catalyst&#8217;s then-board of directors&#8217; consideration of the Contributions and other transactions contemplated by the F351 Agreement and the Business Combination Agreement and the Raymond James fairness opinion addressed only the fairness, from a financial point of view, to Catalyst as of the date thereof, of the Transaction Consideration (as defined in the Raymond James fairness opinion) to be paid by Catalyst. The opinion of Raymond James does not address any other term or aspect of the F351 Agreement or the Business Combination Agreement or the Contributions or other transactions contemplated thereby. The Raymond James fairness opinion does not constitute a recommendation to Catalyst&#8217;s board of directors or any stockholder of Catalyst as to whether or how such holder should vote or otherwise act with respect to the Contributions, other transactions contemplated by the F351 Agreement or the Business Combination Agreement or any other matter.<font style="font-weight: normal;"> </font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">128<br></div></div></div>
<!--End Page 139-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 140-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_108-meeting_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The full text of the Raymond James fairness opinion should be read carefully in its entirety for a description of the assumptions made and the qualifications and limitations upon the review undertaken by Raymond James in preparing its opinion.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with rendering the opinion described above and performing its related financial analyses, Raymond James, among other things:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed the financial terms and conditions of (a) the Asset Purchase as stated in the draft of the F351 Agreement dated as of December&#160;20, 2022, such draft being the last draft of the F351 Agreement provided to Raymond James and not materially different from the final agreement, and (b) the Contributions as stated in the draft of the Business Combination Agreement, dated as of December&#160;20, 2022, such draft being the last draft of the Business Combination Agreement provided to Raymond James and not materially different from the final agreement;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed the financial terms and conditions of the CVRs as stated in the draft of the CVR Agreement, dated as of December&#160;20, 2022, such draft being the last draft of the CVR Agreement provided to Raymond James;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed certain information related to the historical, current and future operations, financial condition and prospects of Catalyst made available to Raymond James by Catalyst;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed certain information related to the historical, current and future operations of BC and the Purchased Assets (as defined in the F351 Agreement) made available to Raymond James by Catalyst, including, but not limited to, financial projections prepared by the management of Catalyst for the period ending 2023 through 2031, as approved for Raymond James' use by Catalyst as of December&#160;19, 2022 (the &#8220;Projections&#8221;);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed Catalyst&#8217;s recent public filings and certain other publicly-available information regarding Catalyst, GNI Japan, the Asset Sellers (as defined in the Raymond James fairness opinion), the Contributors, CPI and BC;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed certain other non-public financial, operating and other information regarding Catalyst, GNI Japan, the Asset Sellers, the Contributors, Continent and BC provided to Raymond James by Catalyst;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed the financial and operating performance of selected public companies that Raymond James deemed to be relevant;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">considered the publicly available financial terms of certain transactions Raymond James deemed to be relevant; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed the current and historical market prices for Catalyst Common Stock and the current market prices of the publicly traded securities of certain other companies that Raymond James deemed to be relevant; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">considered certain discussions and negotiations between representatives of Catalyst, BC, the Asset Sellers and/or the Contributors in which Raymond James participated.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Raymond James also performed a discounted cash flow analysis with respect to BC and the Purchased Assets based upon the Projections, (as defined below), received a certificate addressed to Raymond James from a member of senior management of Catalyst regarding, among other things, the accuracy of the information, data and other materials (financial or otherwise) provided to, or discussed with, Raymond James by or on behalf of Catalyst, conducted such other financial studies, analyses and inquiries and considered such other information and factors as Raymond James deemed appropriate and discussed with members of the senior management of Catalyst certain information relating to the aforementioned and any other matters which Raymond James has deemed relevant to its inquiry.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">With the consent of Catalyst's then-board of directors, Raymond James has assumed and relied upon the accuracy and completeness of all information supplied by or on behalf of Catalyst or otherwise reviewed by or discussed with Raymond James and Raymond James has undertaken no duty or responsibility to, nor did Raymond James, independently verify any of such information. Raymond James has not made or obtained an independent appraisal of the assets or liabilities (contingent or otherwise) of Catalyst or BC. With respect to the Projections and any other forward-looking information and data provided to or otherwise reviewed by or discussed with Raymond James, Raymond James has, with the consent of Catalyst&#8217;s then-board of directors, assumed that the Projections and such other information and data have been reasonably prepared in good faith on bases reflecting the best currently </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">129<br></div></div></div>
<!--End Page 140-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 141-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_108-meeting_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">available estimates and judgments of the management of Catalyst and Raymond James has relied upon Catalyst to advise Raymond James promptly if any information previously provided became inaccurate or was required to be updated during the period of Raymond James review. Raymond James expresses no opinion with respect to the Projections or the assumptions on which they are based. Raymond James has assumed that the final forms of the Transaction Agreements will be substantially similar to the drafts reviewed by Raymond James and that the Contributions and other transactions contemplated by the F351 Agreement and the Business Combination Agreement will be consummated in accordance with the terms of the Transaction Agreements without waiver or amendment of any conditions thereto. Furthermore, Raymond James has assumed, in all respects material to its analysis, that the representations and warranties of each party contained in the Transaction Agreements are true and correct and that each such party will perform all of the covenants and agreements required to be performed by it under the Transaction Agreements without being waived. Raymond James has relied upon and assumed, without independent verification, that (i)&#160;the Contributions and other transactions contemplated by the F351 Agreement and the Business Combination Agreement will be consummated in a manner that complies in all respects with all applicable international, federal and state statutes, rules and regulations and (ii)&#160;all governmental, regulatory and other consents and approvals necessary for the consummation of the Contributions will be obtained and that no delay, limitations, restrictions or conditions will be imposed or amendments, modifications or waivers made that would have an effect on the Contributions or such other transactions contemplated by the F351 Agreement and the Business Combination Agreement, Catalyst or BC that would be material to Raymond James' analyses or the Raymond James fairness opinion. Furthermore, at Catalyst&#8217;s direction, Raymond James has ascribed no value to the CVRs and therefore is not providing any opinion with regard to any aspect of the CVRs, which are further described in the CVR Agreement.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16pt; margin-left: 0pt; text-align: left;">Material Financial Analyses</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following summarizes the material financial analyses reviewed by Raymond James with Catalyst&#8217;s then-board of directors during its meeting on December 21, 2022. Unless the context indicates otherwise, the analyses relied upon the closing price of the common stock of the selected companies listed below as of December 20, 2022. Unless otherwise indicated, for each of the following analyses performed by Raymond James, financial and market data and earnings estimates for the selected companies were based on the companies&#8217; filings with the SEC and certain publicly available research analyst estimates for those companies. The financial analyses summarized below include information presented in tabular format. In order to fully understand the financial analyses performed by Raymond James, the tables must be read together with the text of each summary. The tables alone do not constitute a complete description of the financial analyses performed by Raymond James. Considering the data set forth in the tables below without considering the full narrative description of the financial analyses, including the methodologies and assumptions underlying the analyses, could create a misleading or incomplete view of the financial analyses performed by Raymond James. No company or transaction used in the analyses described below is identical or directly comparable to Catalyst, BC or the Contributions or other transactions contemplated by the F351 Agreement and the Business Combination Agreement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Selected Companies Analysis<font style="font-style: normal;">. Raymond James analyzed the equity values of the following 16 publicly-traded </font><font style="font-style: normal;">biotechnology companies (the &#8220;Selected Companies&#8221;). Selected Companies included clinical- or commercial-stage </font><font style="font-style: normal;">biotechnology companies targeting pulmonary and liver fibrosis indications as well as other similar indications</font><font style="font-style: normal;"> with </font><font style="font-style: normal;">equity values between $100.0 million and $2.0 billion.</font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">($ in millions)<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: normal;">Company </font></div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.81%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 21.46%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Equity Value (as of 12/20/22) </div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">89bio, Inc. <font style="padding-left: 0.29pt;"></font></div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 21.46%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 32.71pt; text-align: left;">$<font style="padding-left: 7.5pt;">525.9 </font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Arbutus Biopharma Corporation <font style="padding-left: 2.54pt;"></font></div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 21.46%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 32.71pt; text-align: left;"><font style="padding-left: 12.5pt;">378.7 </font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">BELLUS Health Inc. <font style="padding-left: 2.81pt;"></font></div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 21.46%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 32.71pt; text-align: left;"><font style="padding-left: 5pt;">1,096.1 </font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CymaBay Therapeutics, Inc. <font style="padding-left: 3.28pt;"></font></div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 21.46%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 32.71pt; text-align: left;"><font style="padding-left: 12.5pt;">391.2 </font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">FibroGen, Inc. <font style="padding-left: 4.75pt;"></font></div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 21.46%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 32.71pt; text-align: left;"><font style="padding-left: 5pt;">1,350.2 </font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Genfit S.A. <font style="padding-left: 2.52pt;"></font></div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 21.46%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 32.71pt; text-align: left;"><font style="padding-left: 12.5pt;">178.8 </font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Intercept Pharmaceuticals, Inc. <font style="padding-left: 3.68pt;"></font></div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 21.46%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 32.71pt; text-align: left;"><font style="padding-left: 12.87pt;">511.1 </font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Inventiva S.A. <font style="padding-left: 0.3pt;"></font></div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 21.46%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 32.71pt; text-align: left;"><font style="padding-left: 12.5pt;">182.8 </font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Mirum Pharmaceuticals, Inc. <font style="padding-left: 1.44pt;"></font></div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 21.46%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 32.71pt; text-align: left;"><font style="padding-left: 12.5pt;">654.8 </font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Oramed Pharmaceuticals Inc. <font style="padding-left: 4.51pt;"></font></div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 21.46%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 32.71pt; text-align: left;"><font style="padding-left: 12.5pt;">323.9 </font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pliant Therapeutics, Inc. <font style="padding-left: 4.94pt;"></font></div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 21.46%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 32.71pt; text-align: left;"><font style="padding-left: 12.5pt;">929.4</font> </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">130<br></div></div></div>
<!--End Page 141-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 142-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_108-meeting_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">($ in millions)<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: normal;">Company </font></div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.81%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 21.46%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Equity Value (as of 12/20/22) </div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">PureTech Health plc <font style="padding-left: 1.02pt;"></font></div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 21.46%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 35.21pt; text-align: left;"><font style="padding-left: 7.5pt;">919.0 </font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Terns Pharmaceuticals, Inc. <font style="padding-left: 2.14pt;"></font></div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 21.46%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 35.21pt; text-align: left;"><font style="padding-left: 7.5pt;">317.8 </font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Theravance Biopharma, Inc. <font style="padding-left: 3.66pt;"></font></div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 21.46%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 35.21pt; text-align: left;"><font style="padding-left: 7.5pt;">725.0 </font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Verona Pharma plc <font style="padding-left: 1.43pt;"></font></div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 21.46%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 35.21pt; text-align: left;">1,405.8 </div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Viking Therapeutics, Inc. <font style="padding-left: 1.1pt;"></font></div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 21.46%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 35.21pt; text-align: left;"><font style="padding-left: 7.5pt;">551.4</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Raymond James calculated the equity values of the Selected Companies. Raymond James reviewed the mean, median, 25<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> percentile and 75<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> percentile of equity values of the Selected Companies to derive a range of potential values for BC. Raymond James compared those equity values to the Transaction Consideration. The results of the Selected Companies analysis are summarized below:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 3.87%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="10" style="width: 56.36%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Selected Companies Equity Value as of 12/20/22<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($ in millions) </div></td></tr><tr class="header"><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 3.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.87%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.7%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">25<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Percentile </div></td><td class="gutter" style="width: 3.87%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 3.87%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Median </div></td><td class="gutter" style="width: 3.87%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 3.87%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Mean </div></td><td class="gutter" style="width: 3.87%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 3.87%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.69%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">75<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Percentile </div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Equity Value <font style="padding-left: 4.58pt;"></font></div></td><td class="gutter" style="width: 3.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.7%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;">$365.0 </div></td><td class="gutter" style="width: 3.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$538.6 </div></td><td class="gutter" style="width: 3.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$652.6 </div></td><td class="gutter" style="width: 3.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.27pt; text-align: left;">$921.6</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Selected Transaction Analysis<font style="font-style: normal;">. Raymond James analyzed publicly available information relating to selected </font><font style="font-style: normal;">acquisition transactions that were announced and consummated between 2021 and December 20, 2022 for which the </font><font style="font-style: normal;">buyer acquired an ownership stake of greater than 50% </font><font style="font-style: normal;">for an implied equity value between $10.0 million and $3.0 </font><font style="font-style: normal;">billion, </font><font style="font-style: normal;">and in which the target was either a late-clinical-stage biotechnology company or commercial-stage </font><font style="font-style: normal;">biotechnology company </font><font style="font-style: normal;">with one or two marketed products with less than $400.0 million in most recent historical </font><font style="font-style: normal;">annual revenue </font><font style="font-style: normal;">(the &#8220;Selected Transactions&#8221;). </font><font style="font-style: normal;">Biotechnology companies specializing in oncology, gene therapy, cell </font><font style="font-style: normal;">therapy, and COVID-19 were omitted due to their dissimilarity to the indications targeted by BC. </font><font style="font-style: normal;">No target of a </font><font style="font-style: normal;">transaction used in this analysis is identical to BC. For each transaction, Raymond James reviewed the implied equity </font><font style="font-style: normal;">value. Implied equity value was estimated excluding the value of any contingent value rights. The Selected </font><font style="font-style: normal;">Transactions used in the analysis included:</font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 470.78pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 10.2%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">($ in millions)<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-style: normal;">Announce</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-style: normal;">Date </font></div></td><td class="gutter" style="width: 0.42%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.42%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 29.73%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Target </div></td><td class="gutter" style="width: 0.42%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.42%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 41.76%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Buyer</div></td><td class="gutter" style="width: 0.42%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.42%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 15.77%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Implied Equity Value <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(excluding CVR) </div></td></tr><tr><td style="width: 10.2%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">08/22/2022 </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 29.73%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Aerie Pharmaceuticals, Inc. </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 41.76%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Alcon Research, Ltd.</div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.77%; text-align: right; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">$753.5 </div></td></tr><tr><td style="width: 10.2%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">07/21/2022 </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 29.73%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ARS Pharmaceuticals, Inc. </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.76%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Silverback Therapeutics, Inc.</div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.77%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">251.8 </div></td></tr><tr><td style="width: 10.2%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">07/11/2022 </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 29.73%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">La Jolla Pharmaceutical Company </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 41.76%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Innoviva, Inc.</div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.77%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">150.5 </div></td></tr><tr><td style="width: 10.2%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">06/23/2022 </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 29.73%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Radius Health, Inc. </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.76%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gurnet Point Capital and Patient Square Capital</div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.77%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">502.6 </div></td></tr><tr><td style="width: 10.2%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">01/19/2022 </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 29.73%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Zogenix, Inc. </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 41.76%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">UCB Biosciences, Inc.</div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.77%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">1,488.0 </div></td></tr><tr><td style="width: 10.2%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">11/22/2021 </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 29.73%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sanifit Therapeutics S.A. </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.76%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vifor Pharma AG</div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.77%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">230.5 </div></td></tr><tr><td style="width: 10.2%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">11/11/2021 </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 29.73%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Forendo Pharma Ltd </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 41.76%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Organon &amp; Co.</div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.77%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">75.0 </div></td></tr><tr><td style="width: 10.2%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">09/29/2021 </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 29.73%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Caelum Biosciences, Inc. </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.76%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Alexion Pharmaceuticals, Inc.</div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.77%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">150.0 </div></td></tr><tr><td style="width: 10.2%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">09/13/2021 </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 29.73%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">First Wave Bio, Inc. </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 41.76%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">AzurRx BioPharma</div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.77%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">24.0 </div></td></tr><tr><td style="width: 10.2%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">09/08/2021 </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 29.73%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Kadmon Holdings, Inc. </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.76%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sanofi</div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.77%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">1,646.7 </div></td></tr><tr><td style="width: 10.2%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">05/24/2021 </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 29.73%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Strongbridge Biopharma plc </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 41.76%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Xeris Biopharma Holdings, Inc.</div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.77%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">184.2 </div></td></tr><tr><td style="width: 10.2%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">05/05/2021 </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 29.73%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chiasma, Inc. </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.76%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amryt Pharma plc</div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.77%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">260.3 </div></td></tr><tr><td style="width: 10.2%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">02/01/2021 </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 29.73%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Viela Bio, Inc. </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 41.76%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Horizon Therapeutics plc</div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.77%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">2,909.9 </div></td></tr><tr><td style="width: 10.2%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">01/04/2021 </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 29.73%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Arvelle Therapeutics GmbH </div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.76%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Angelini Acraf</div></td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.77%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">610.0</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Raymond James calculated the implied equity values of the Selected Transactions. Raymond James reviewed the mean, median, 25th percentile and the 75th percentile of the implied equity values to derive a range of potential values for BC. Raymond James compared those implied equity values to the Transaction Consideration. The results of the Selected Transactions analysis are summarized below:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 3.87%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="10" style="width: 56.36%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Selected Transactions as of 12/20/22<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($ in millions) </div></td></tr><tr class="header"><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 3.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.87%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.7%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">25<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Percentile </div></td><td class="gutter" style="width: 3.87%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 3.87%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Median </div></td><td class="gutter" style="width: 3.87%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 3.87%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Mean </div></td><td class="gutter" style="width: 3.87%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 3.87%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.69%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">75<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Percentile </div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Implied Equity Value (excluding CVR) </div></td><td class="gutter" style="width: 3.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.7%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;">$158.9 </div></td><td class="gutter" style="width: 3.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$256.1 </div></td><td class="gutter" style="width: 3.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$659.8 </div></td><td class="gutter" style="width: 3.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.27pt; text-align: left;">$717.7</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">131<br></div></div></div>
<!--End Page 142-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 143-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_108-meeting_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Discounted Cash Flow Analysis<font style="font-style: normal;">. Raymond James also performed a discounted cash flow analysis with respect to BC </font><font style="font-style: normal;">and the Purchased Assets based upon the Projections and the certificate received from a member of management of </font><font style="font-style: normal;">Catalyst.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Raymond James analyzed the discounted present value of BC&#8217;s unlevered, after-tax, risk-adjusted free cash flows for the years ending December 31, 2023 through 2031 on a standalone basis. Raymond James used after-tax, risk adjusted unlevered free cash flows, defined as earnings before interest, after taxes, plus depreciation, plus amortization, less capital expenditures, less investment in working capital.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The discounted cash flow analysis was based on the Projections. Consistent with the periods included in the Projections, Raymond James used calendar year 2031 as the final year for the analysis and assumed that BC has no terminal value as of December 31, 2031.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The projected after-tax, risk-adjusted unlevered free cash flows were discounted using rates ranging from 10.7% to 12.7%, which reflected the weighted average after-tax cost of debt and equity capital associated with executing BC&#8217;s business plan. Raymond James reviewed the range of risk-adjusted equity values derived in the discounted cash flow analysis and compared them to the Transaction Consideration. The results of the discounted cash flow analysis are summarized below:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 33.35%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">BC Implied Equity Value as of 12/20/22<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($ in millions) </div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.55%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.98%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Minimum </div></td><td class="gutter" style="width: 2.55%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.55%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.26%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Maximum </div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Risk Adjusted Implied Equity Value <font style="padding-left: 4.6pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.98%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.97pt; text-align: left;">$408.4 </div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.63pt; text-align: left;">$447.8</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Summary<font style="font-style: normal;">. Raymond James compared the low and high range of implied values for BC to the $335 million proposed </font><font style="font-style: normal;">purchase price and determined that such amount was less than the range of most of the range of implied values for </font><font style="font-style: normal;">BC.</font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Summary<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">($ in millions) </div></td><td class="gutter" style="width: 6.68%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 6.68%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 6.68%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 6.68%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 6.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 6.68%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">LOW</div></td><td class="gutter" style="width: 6.68%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 6.68%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">HIGH </div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Selected Companies analysis<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup> <font style="padding-left: 0.69pt;"></font></div></td><td class="gutter" style="width: 6.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 6.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$365.0 </div></td><td class="gutter" style="width: 6.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 6.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$921.6 </div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Selected Transactions analysis<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup> <font style="padding-left: 0.12pt;"></font></div></td><td class="gutter" style="width: 6.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 6.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$158.9 </div></td><td class="gutter" style="width: 6.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 6.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$717.7 </div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Discounted cash flow analysis <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup> <font style="padding-left: 1.26pt;"></font></div></td><td class="gutter" style="width: 6.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 6.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$408.4 </div></td><td class="gutter" style="width: 6.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 6.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$447.8</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Selected Companies analysis represents a range of the 25<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> percentile to 75th percentile of the equity values. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Selected Transactions analysis represents a range of the 25<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> percentile to the 75<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> percentile of the implied equity value excluding any value associated with contingent value rights (CVRs). </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Discounted cash flow analysis based on risk adjusted equity value.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Raymond James fairness opinion is based upon market, economic, financial and other circumstances and conditions existing and disclosed to Raymond James as of December&#160;20, 2022 and any material change in such circumstances and conditions would require a reevaluation of the Raymond James fairness opinion, which Raymond James is under no obligation to undertake. Raymond James has relied upon and assumed, without independent verification, that there has been no change in the business, assets, liabilities, financial condition, results of operations, cash flows or prospects of Catalyst, Continent, GNI Japan, BC, any Asset Seller or any Contributor since the respective dates of the most recent financial statements and other information, financial or otherwise, provided to Raymond James that would be material to Raymond James' analyses or the Raymond James fairness opinion and that there is no information or any facts that would make any of the information reviewed by Raymond James incomplete or misleading in any material respect.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Raymond James expresses no opinion as to the underlying business decision to effect the Contributions or other transactions contemplated by the F351 Agreement and the Business Combination Agreement, the structure or tax consequences of the Contributions or other transactions contemplated by the F351 Agreement and the Business Combination Agreement or the availability or advisability of any alternatives to the Contributions. While Raymond James provided advice to Catalyst with respect to the proposed Contributions and other transactions contemplated by the F351 Agreement and the Business Combination Agreement, Raymond James did not recommend any specific amount of consideration or that any specific consideration constituted the only appropriate consideration for the Contributions and other transactions contemplated by the F351 Agreement and the Business Combination Agreement. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">132<br></div></div></div>
<!--End Page 143-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 144-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_108-meeting_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">In addition, Raymond James does not express any opinion as to the likely trading range of Catalyst Common Stock following the Contributions and other transactions contemplated by the F351 Agreement and the Business Combination Agreement, which may vary depending on numerous factors that generally impact the price of securities or on the financial condition of Catalyst at that time.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Raymond James fairness opinion is limited to the fairness, from a financial point of view, to Catalyst of the Transaction Consideration to be paid by Catalyst. Raymond James expresses no opinion with respect to any other reasons, legal, business or otherwise, that may support the decision of the board of directors of Catalyst to approve or consummate the Contributions and other transactions contemplated by the F351 Agreement and the Business Combination Agreement. Furthermore, no opinion, counsel or interpretation is intended by Raymond James on matters that require legal, accounting or tax advice. It is assumed that such opinions, counsel or interpretations have been or will be obtained from the appropriate professional sources. Furthermore, Raymond James has relied, with the consent of Catalyst's then-board of directors, on the fact that Catalyst has been assisted by legal, accounting and tax advisors and Raymond James has, with the consent of Catalyst's then-board of directors, relied upon and assumed the accuracy and completeness of the assessments by Catalyst and its advisors as to all legal, accounting and tax matters with respect to Catalyst and the Contributions and other transactions contemplated by the F351 Agreement and the Business Combination Agreement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In formulating its opinion, Raymond James has considered only what it understands to be the Transaction Consideration to be paid by Catalyst in the Contributions and other transactions contemplated by the F351 Agreement and the Business Combination Agreement as described above and Raymond James did not consider and expresses no opinion on, the fairness of the amount or nature of any compensation to be paid or payable to any of Catalyst&#8217;s, Continent&#8217;s, any Asset Seller&#8217;s or any Contributor&#8217;s officers, directors or employees, or class of such persons, whether relative to the compensation received by any such party or otherwise. Raymond James has not been requested to opine as to and the Raymond James fairness opinion does not express an opinion as to or otherwise address, among other things: (i)&#160;the fairness of the Contributions or other transactions contemplated by the F351 Agreement and the Business Combination Agreement to the holders of any class of securities, creditors or other constituencies of Catalyst, or to any other party, or (ii)&#160;the fairness of the Transaction to any one class or group of Catalyst&#8217;s or any other party&#8217;s security holders or other constituencies vis-&#224;-vis any other class or group of Catalyst&#8217;s or such other party&#8217;s security holders or other constituencies (including, without limitation, the allocation of any consideration to be received in the Contributions and other transactions contemplated by the F351 Agreement and the Business Combination Agreement amongst or within such classes or groups of security holders or other constituencies or parties). Raymond James is not expressing any opinion as to the impact of the Contributions and other transactions contemplated by the F351&#160;Agreement and the Business Combination Agreement on the solvency or viability of Catalyst, Continent, any Asset Seller or any Contributor or the ability of Catalyst, Continent, any Asset Seller or any Contributor to pay their respective obligations when they come due.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The preparation of an opinion regarding fairness is a complex process and is not susceptible to a partial analysis or summary description. Raymond James believes that its analyses must be considered as a whole and that selecting portions of its analyses, without considering the analyses taken as a whole, would create an incomplete view of the process underlying its opinion. In addition, Raymond James considered the results of all its analyses and did not assign relative weights to any of the analyses, but rather made qualitative judgments as to significance and relevance of each analysis and factor, so the ranges of valuations resulting from any particular analysis described above should not be taken to be the view of Raymond James as to the actual value of Catalyst. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In performing its analyses, Raymond James made numerous assumptions with respect to industry performance, general business, economic and regulatory conditions and other matters, many of which are beyond the control of Catalyst. The analyses performed by Raymond James are not necessarily indicative of actual values, trading values or actual future results which might be achieved, all of which may be significantly more or less favorable than suggested by its analyses. Such analyses were provided to the then-Catalyst board of directors (solely in its capacity as such) and were prepared solely as part of the analysis of Raymond James of the fairness, from a financial point of view, to Catalyst of the Transaction Consideration to be paid by Catalyst. The analyses do not purport to be appraisals or to reflect the prices at which companies may actually be sold, and such estimates are inherently subject to uncertainty. The opinion of Raymond James was one of many factors taken into account by the then-board of directors of Catalyst in making its determination to approve the Contributions and other transactions contemplated </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">133<br></div></div></div>
<!--End Page 144-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 145-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_108-meeting_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">by the F351 Agreement and the Business Combination Agreement. Neither Raymond James&#8217; opinion nor the analyses described above should be viewed as determinative of the then-board of directors of Catalyst or Catalyst management&#8217;s views with respect to Catalyst or the Contributions and other transactions contemplated by the F351 Agreement and the Business Combination Agreement. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Raymond James opinion was necessarily based upon market, economic, financial and other circumstances and conditions existing and disclosed to it on December 20, 2022, and any material change in such circumstances and conditions may affect the opinion of Raymond James, but Raymond James does not have any obligation to update, revise or reaffirm that opinion. Raymond James relied upon and assumed, without independent verification, that there had been no change in the business, assets, liabilities, financial condition, results of operations, cash flows or prospects of Catalyst since the respective dates of the most recent financial statements and other information, financial or otherwise, provided to Raymond James that would be material to its analyses or its opinion, and that there was no information or any facts that would make any of the information reviewed by Raymond James incomplete or misleading in any material respect. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">During the two years preceding the date of Raymond James&#8217; written opinion, Raymond James has been engaged by or otherwise performed services for Catalyst for which it was paid fees of approximately $951,000 (separate from any amounts that were paid to Raymond James under the engagement letter described in this proxy statement pursuant to which Raymond James was retained as a financial advisor to Catalyst to assist in reviewing strategic alternatives). Catalyst also reimbursed Raymond James for its expenses incurred in connection with its services. During the two years preceding the date of Raymond James&#8217; written opinion, Raymond James has not been engaged by or otherwise performed services for BC, GNI, or their respective affiliates. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For services rendered in connection with the delivery of its opinion, Catalyst paid Raymond James a cash advisory fee of $750,000 upon delivery of its opinion, which was not contingent upon the successful completion of the Contributions or other transactions contemplated by the F351 Agreement and the Business Combination Agreement or on the conclusion reached in its opinion. Catalyst also agreed to reimburse Raymond James for its expenses incurred in connection with its services, including the fees and expenses of its counsel, and will indemnify Raymond James against certain liabilities arising out of its engagement. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Raymond James is actively involved in the investment banking business and regularly undertakes the valuation of investment securities in connection with public offerings, private placements, business combinations and similar transactions. In the ordinary course of business, Raymond James may trade in the securities of Catalyst for its own account and for the accounts of its customers and, accordingly, may at any time hold a long or short position in such securities. Raymond James may provide investment banking, financial advisory and other financial services to Catalyst or other participants in the Contributions or other transactions contemplated by the F351 Agreement and the Business Combination Agreement in the future, for which Raymond James may receive compensation. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The delivery of the Raymond James fairness opinion was approved by an opinion committee of Raymond James. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Raymond James fairness opinion is for the information of the then-board of directors of Catalyst (solely in each director&#8217;s capacity as such) in evaluating the proposed Contributions and other transactions contemplated by the F351 Agreement and the Business Combination Agreement and does not constitute a recommendation to the board or any stockholder of Catalyst regarding how the board or any such stockholder should vote on the proposed Contributions and other transactions contemplated by the F351 Agreement and the Business Combination Agreement.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Certain BC Unaudited Prospective Financial Information</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As a matter of course, Catalyst does not publicly disclose forecasts or internal projections of future financial results due to, among other reasons, the uncertainties of the new drug development, approval and commercialization processes, and the inherent unpredictability and subjectivity of underlying assumptions and estimates concerning future revenues, expenses and liabilities. However, in connection with Catalyst&#8217;s then-board of directors&#8217; evaluation of the Transaction Consideration, certain internal financial projections (the &#8220;Projections&#8221;) for BC were prepared by the management of Catalyst and provided to Raymond James solely for use by Raymond James in connection with the rendering of its fairness opinion and performing its related financial analyses, as described below. A summary of the Projections is set forth below.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The inclusion of the Projections should not be deemed an admission or representation by Catalyst, Raymond James, BC or any of their respective officers, directors, affiliates, advisors, or other representatives with respect to such Projections. The Projections are not included to influence your views on the Contributions or other transactions </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">134<br></div></div></div>
<!--End Page 145-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 146-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_108-meeting_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">contemplated by the F351 Agreement and the Business Combination Agreement and are summarized in this proxy statement solely to provide stockholders access to certain non-public information considered by Catalyst&#8217;s then-board of directors in connection with its evaluation of the Contributions or other transactions contemplated by the F351 Agreement and the Business Combination Agreement and provided to Catalyst&#8217;s financial advisor, Raymond James, to assist with its financial analyses as described in the section titled &#8220;Opinion of Catalyst&#8217;s Financial Advisor.&#8221; The information from the Projections should be evaluated, if at all, in conjunction with the historical financial statements and other information regarding Catalyst and BC in this proxy statement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Projections were not prepared with a view toward public disclosure, nor were they prepared with a view toward compliance with published guidelines of the SEC, the guidelines established by the American Institute of Certified Public Accountants for preparation and presentation of prospective financial information, or generally accepted accounting principles (&#8220;GAAP&#8221;). Neither Catalyst&#8217;s nor BC&#8217;s independent registered public accounting firm, nor any other independent accountant, has audited, reviewed, compiled, examined or performed any procedures with respect to the unaudited prospective financial information for the purpose of its inclusion herein, and accordingly, neither the independent registered public accounting firm of Catalyst or BC nor any other independent accountant expresses an opinion or provides any other form of assurance with respect thereto for the purpose of this proxy statement. The reports of the independent accountant of Catalyst and BC included in this proxy statement relate to the previously issued financial statements of Catalyst and BC. The reports do not extend to the Projections and should not be read to do so.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Projections are being included in this proxy statement in accordance with subsection (a)(6) of Item 1015 of Regulation M-A because they constitute part of the bases of the analysis conducted by Raymond James as described herein, in connection with delivering its opinion described under the section entitled &#8220;Opinion of Catalyst&#8217;s Financial Advisor.&#8221; The Projections include estimates concerning unlevered, after-tax, risk-adjusted free cash flow, which is a &#8220;non-GAAP financial measure&#8221;. Non-GAAP financial measures should not be viewed as a substitute for GAAP financial measures and may be different from non-GAAP financial measures used by other companies. Furthermore, there are limitations inherent in non-GAAP financial measures because they exclude charges and credits that are required to be included in a GAAP presentation. Accordingly, non-GAAP financial measures should be considered together with, and not as an alternative to, financial measures prepared in accordance with GAAP. The SEC rules, which otherwise would require a reconciliation of a non-GAAP financial measure to a GAAP financial measure, do not apply to non-GAAP financial measures provided to a board of directors or to financial advisors in connection with a proposed business combination transaction such as a merger if the disclosure is included in a document such as this proxy statement to comply with requirements under state laws, including case law. The Projections were provided to Raymond James in order for it to render its opinion and to Catalyst&#8217;s then-board of directors in connection with its consideration of the Contributions and other transactions contemplated by the F351 Agreement and the Business Combination Agreement, and Catalyst believes it has an obligation to disclose such projections under Delaware law, including applicable case law, in order to provide a fair summary of certain of the financial analyses and substantive work of Raymond James. In addition, reconciliations of non-GAAP financial measures to a GAAP financial measure were not provided to nor relied upon by Raymond James in connection with rendering its opinion with respect to the Contributions and other transactions contemplated by the F351 Agreement and the Business Combination Agreement. Accordingly, Catalyst has not provided a reconciliation of the financial measures included in the Projections to the relevant GAAP financial measures.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Projections are subjective in many respects and thus subject to interpretation. While presented with numeric specificity, the Projections reflect numerous estimates and assumptions that are inherently uncertain with respect to general business, economic, market and financial conditions and matters specific to Catalyst or BC that are inherently uncertain and beyond BC&#8217;s or Catalyst&#8217;s control and which may prove not to have been, or to no longer be, accurate, including matters relating to the development of BC&#8217;s product candidates, the likelihood of receiving FDA approval for BC&#8217;s product candidates, the future commercial success of BC&#8217;s products, if developed, approved and commercialized, and the other factors described or referenced under the section entitled &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; and under the section entitled &#8220;Risk Factors,&#8221; all of which are difficult to predict and many of which are beyond Catalyst&#8217;s or BC&#8217;s control. If any of these variables, estimates and assumptions prove to be wrong, the actual results for the combined company&#8217;s business may differ materially from the results reflected in the Projections. In addition, the Projections cover an extended period of time, and this information by its nature becomes subject to greater uncertainty with each successive year. Accordingly, there can be no assurance that the estimates and assumptions made in preparing the Projections will prove accurate or that any of the Projections will be realized. Important factors that may affect actual results and cause these Projections to not be achieved </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">135<br></div></div></div>
<!--End Page 146-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 147-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_108-meeting_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">include, but are not limited to, risks and uncertainties relating to BC&#8217;s business (including the ability to achieve strategic goals, objectives and targets over the applicable periods, and obtain regulatory approval of BC&#8217;s product candidates), the future commercial success of BC&#8217;s current and future products, the successful development of BC&#8217;s product candidates, industry performance, the regulatory environment, general business and economic conditions and other factors.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Projections assume sufficient capital availability for BC. Many of the assumptions reflected in the Projections are subject to change, and none of the Projections reflect revised prospects for BC&#8217;s business, changes in general business or economic conditions or any other transaction or event that has occurred or that may occur and that was not anticipated at the time such financial information was prepared. Except required by law, neither Catalyst nor BC assume any obligation, nor does any of them intend, to update or otherwise revise the Projections to reflect circumstances existing or arising after the date the Projections were generated or to reflect the occurrence of future events, even in the event that any or all of the assumptions or other information underlying the Projections are shown to be in error. There can be no assurance that the results reflected in any of the Projections will be realized or that actual results will not materially vary from the Projections. Therefore, the inclusion of the Projections in this proxy statement should not be relied on as predictive of actual future events nor construed as financial guidance.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Neither Catalyst nor BC has made, in the F351 Agreement and the Business Combination Agreement or otherwise, any representation to the other party, or to any other person, concerning any of the Projections. The inclusion of the Projections herein should not be regarded as an indication that Catalyst, Raymond James, BC or any of their respective affiliates or representatives considered or consider the Projections to be necessarily indicative of actual future events, and the Projections should not be relied upon as such. Furthermore, the Projections do not take into account the effect of any failure of the Contributions or other transactions contemplated by the F351 Agreement and the Business Combination Agreement to be consummated and should not be viewed as accurate or continuing in that context. The summaries of the Projections are not included in this proxy statement in order to induce any Catalyst stockholder to vote in favor of the Contributions or other transactions contemplated by the F351 Agreement and the Business Combination Agreement or any of the other proposals to be voted on at the Catalyst Special Meeting.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">In light of the foregoing factors and the uncertainties inherent in financial projections, stockholders are cautioned not to place undue reliance, if any, on the Projections.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table presents a summary of the estimated BC unlevered after tax risk adjusted free cash flows from the Projections used by Raymond James, and is included below to provide Catalyst stockholders access to specific non-public information that was considered by Raymond James and Catalyst&#8217;s then-board of directors for purposes of evaluating the Transaction Consideration to be paid by Catalyst in the Contributions and other transactions contemplated by the F351 Agreement and the Business Combination Agreement.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 25.64%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023 </div></td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div></td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div></td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026 </div></td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2027 </div></td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2028 </div></td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2029 </div></td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2030 </div></td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2031 </div></td></tr><tr><td style="width: 25.64%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Unlevered After Tax Risk Adjusted Free Cash Flows </div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$5.4 </div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">($5.5) </div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$21.6 </div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$49.5 </div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$70.7 </div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$106.7 </div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$125.7 </div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$149.3 </div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$179.1</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Projections were prepared by Catalyst and included certain assumptions relating to, among other things, Catalyst&#8217;s expectations, which may not prove to be accurate, relating to the business, earnings, cash flow, development and launch of new products, commercial success of future products, and prospects of BC, industry metrics and the regulatory and commercial probability of success. The Projections assumed an annual growth rate between (202%) and 493%. These growth rates were based on BC&#8217;s management&#8217;s estimates of various factors, including previous growth rate, market size, competition, yearly cost of treatment, and marketing capability.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Projections are subject to many risks and uncertainties, and you are urged to review the section titled &#8220;Risk Factors&#8221; for a description of risk factors relating to the Contributions or other transactions contemplated by the F351 Agreement and the Business Combination Agreement and BC&#8217;s business. You should also read the section titled &#8220;Forward-Looking Statements&#8221; for additional information regarding the risks inherent in forward-looking information such as the Projections.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;"><a name="tICD"><!--Anchor--></a>Interests of Catalyst&#8217;s Directors and Executive Officers in the Contributions </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In considering the recommendation of Catalyst&#8217;s then-board of directors with respect to the Contributions, holders of shares of Catalyst Common Stock should be aware that Catalyst&#8217;s executive officers and directors may have interests in the Contributions that may be different from, or in addition to, those of Catalyst stockholders generally. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">136<br></div></div></div>
<!--End Page 147-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 148-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_108-meeting_pg20"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">These interests may create potential conflicts of interest. Catalyst&#8217;s then-board of directors was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Contributions and related transactions and to recommend that Catalyst stockholders vote in favor of the proposals.</div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The combined company&#8217;s board of directors is expected to approve grants of awards of fully vested stock options under the 2023 Omnibus Incentive Plan to Nassim Usman, Ph.D., Seline Miller, Thomas Eastling and Ruoyu Chen. The approximate grant date fair value of such grants are as follows: Nassim Usman, Ph.D. ($841,820), Seline Miller ($169,423), Thomas Eastling ($841,820) and Ruoyu Chen ($84,711). The combined company&#8217;s board is also expected to approve an additional award of stock options under the 2023 Omnibus Incentive Plan to Ms. Miller, which will vest subject to her completion of a consulting term following the closing of the Contributions. </div> <div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Severance Benefits</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the severance agreements between Catalyst and Grant Blouse, in the event that Catalyst consummates the Contributions prior to the expiration of the nine-month period beginning from his separation from Catalyst, Catalyst will pay Mr.&#160;Blouse all then unpaid severance pay in a lump sum within 30 days following the later of (i)&#160;the Effective Time and (ii)&#160;the effective date of his severance agreements. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to his employment agreement with Catalyst, as modified by that certain Waiver Agreement dated January&#160;17, 2023, in connection with the termination of his employment, Dr. Nassim Usman shall be entitled to receive, subject to certain conditions described in Dr. Usman&#8217;s amended and restated employment agreement, the following:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">continued base salary for twelve (12) months after the termination (the &#8220;Usman Severance Period&#8221;);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">accelerated vesting of options that would otherwise have vested during the Usman Severance Period; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">payment by Catalyst of the same portion of his monthly premium under COBRA as it pays for active employees until (i)&#160;the close of the Usman Severance Period if the termination occurs outside of the CIC Protection Period or (ii)&#160;the end of the 18-month period following termination if such termination occurs during the CIC Protection Period. &#8220;CIC Protection Period&#8221; refers to the 6-month period prior to, or the 18-month period following, a change in control (as defined in the employment agreement).</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to her employment agreement with Catalyst, as modified by that certain Waiver Agreement dated January&#160;17, 2023 and as further amended thereafter, if Seline Miller&#8217;s employment is terminated, she shall be entitled to receive, subject to certain conditions described in Mrs.&#160;Miller&#8217;s employment agreement, the following:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">continued base salary (i)&#160;for nine (9) months after the termination if such termination occurs after August&#160;31, 2023, or (ii)&#160;until May&#160;31, 2024, if such termination occurs prior to August&#160;31, 2023 (the &#8220;Miller Severance Period&#8221;);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">accelerated vesting of options that would otherwise have vested during the Miller Severance Period; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">payment by Catalyst of the same portion of her monthly premium under COBRA as it pays for active employees until (i)&#160;the close of the Miller Severance Period if the termination occurs outside of the CIC Protection Period or (ii)&#160;the end of the 12-month period following termination if such termination occurs during the CIC Protection Period.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Ownership Interests</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of May 15, 2023, Catalyst&#8217;s directors and executive officers beneficially owned, in the aggregate, approximately 0.3% of the shares of Catalyst Common Stock, which, for purposes of this subsection, excludes any shares of Catalyst Common Stock issuable upon exercise or settlement of stock options to purchase shares of Catalyst Common Stock or restricted stock units held by such individual. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Management Following the Contributions</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Three of Catalyst&#8217;s existing directors, Thomas Eastling, Ying Luo and Nassim Usman, Ph.D., will continue as directors of the combined company after the Effective Time and, following the closing of the Contributions, will be eligible to be compensated as a non-employee director of Catalyst pursuant to the Catalyst non-employee director compensation policy that is expected to remain in place following the Effective Time.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">137<br></div></div></div>
<!--End Page 148-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 149-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_108-meeting_pg21"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Indemnification of Officers and Directors</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst has entered into indemnification agreements with each of Catalyst&#8217;s directors and executive officers, including the two directors appointed to the board following the signing of the Business Combination Agreement, Ying Luo, Ph.D. and Thomas Eastling. Pursuant to the indemnification agreements, Catalyst has agreed to indemnify and hold harmless these directors and officers to the fullest extent permitted by the DGCL. The agreements generally cover expenses that a director or officer incurs or amounts that a director or officer becomes obligated to pay because of any proceeding to which he or she is made or threatened to be made a party or participant by reason of his or her service as a current or former director, officer, employee or agent of Catalyst. The agreements also provide for the advancement of expenses to the directors and officers subject to specified conditions. There are certain exceptions to Catalyst&#8217;s obligation to indemnify the directors and officers, including any intentional malfeasance or act where the director or officer did not in good faith believe he or she was acting in Catalyst&#8217;s best interests, with respect to &#8220;short-swing&#8221; profit claims under Section 16(b) of the Exchange Act and, with certain exceptions, with respect to proceedings that he or she initiates.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;"><a name="tIGP"><!--Anchor--></a>Interests of GNI Parties&#8217; Directors and Executive Officers in the Contributions </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In considering the recommendation of the board of directors and executive directors, as applicable, of the GNI Parties with respect to approving the Contributions, stockholders should be aware that the board of directors and executive directors, as applicable, of the GNI Parties may have interests in the Contributions that are different from, or in addition to, the interests of BC. These interests may present them with actual or potential conflicts of interest and these interests, to the extent material, are described below.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The board of directors and executive directors, as applicable, of the GNI Parties were aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Business Combination Agreement and the Contributions.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Ownership Interests </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of May 15, 2023, GNI Japan and GNI Hong Kong beneficially owned, in the aggregate, approximately 16.6% of the shares of Catalyst Common Stock and 80.5% of the shares of Catalyst Common Stock upon conversion of the Catalyst Convertible Preferred Stock that is convertible upon the approval of Proposal No. 2 and successful application for initial listing with The Nasdaq Stock Market.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;"><a name="tTBCO"><!--Anchor--></a>Treatment of BC Options </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">At the Effective Time of the Contributions, BC will terminate the 2021 Plan and BC Options outstanding thereunder will be terminated and replaced with options granted pursuant to a sub-plan for PRC participants under the 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The table below sets forth information regarding the BC Options held as of May 15, 2023 granted under any employee or director stock option, stock purchase or equity compensation plan, arrangement or agreement of BC. The number of shares of common stock underlying the Gyre Options granted in respect of the BC Options will be adjusted appropriately to reflect the proposed reverse stock split. In addition, when such Gyre Options are exercised in exchange for shares of the combined company&#8217;s common stock, BC is expected to issue a pro rata number of BC Common Shares to BJC Limited, a wholly-owned subsidiary of CPI and direct shareholder of BC, to proportionally increase the combined company&#8217;s indirect interest in BC. This increase in the combined company&#8217;s indirect interest in BC will maintain the combined company&#8217;s proportionate ownership in BC when such Gyre Options are exercised for the combined company&#8217;s common stock.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div></td><td class="gutter" style="width: 0.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Options <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Held<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td><td class="gutter" style="width: 0.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.45%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercise <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Price of All <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Options<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td><td class="gutter" style="width: 0.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gyre <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Options<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div></td><td class="gutter" style="width: 0.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercise <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Price of Gyre <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Options<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup> </div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Executive Officers of BC<br></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Songjiang Ma <font style="padding-left: 0.96pt;"></font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">2,434,150 </div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 8.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.52pt; text-align: left;">$1.41</div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">67,650,710 </div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 10.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.22pt; text-align: left;">$0.05 </div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lin Han <font style="padding-left: 4.29pt;"></font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 7.5pt;">209,942 </font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.52pt; text-align: left;">$1.41</div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">5,834,778</font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.22pt; text-align: left;">$0.05 </div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Qijia Liu <font style="padding-left: 0.96pt;"></font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 7.5pt;">196,728 </font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 8.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.52pt; text-align: left;">$1.41</div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">5,467,530 </font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 10.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.22pt; text-align: left;">$0.05 </div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weiguo Ye <font style="padding-left: 3.69pt;"></font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 7.5pt;">898,691 </font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.52pt; text-align: left;">$1.41</div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">24,976,721 </div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.22pt; text-align: left;">$0.05 </div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Li Zhang <font style="padding-left: 0.4pt;"></font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 1pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 1pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">13,796 </font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 1pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 1pt;">&#8203;</td><td style="width: 8.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.52pt; text-align: left;">$1.41</div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 1pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 1pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">383,423 </font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 1pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 1pt;">&#8203;</td><td style="width: 10.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.22pt; text-align: left;">$0.05 </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">138<br></div></div></div>
<!--End Page 149-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 150-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_108-meeting_pg22"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div></td><td class="gutter" style="width: 0.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Options <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Held<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td><td class="gutter" style="width: 0.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.45%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercise <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Price of All <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Options<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td><td class="gutter" style="width: 0.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gyre <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Options<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div></td><td class="gutter" style="width: 0.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercise <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Price of Gyre <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Options<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup> </div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Directors of BC<br></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ying Luo <font style="padding-left: 4.28pt;"></font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 8.55%; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: justify;">1,808,537 </div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 8.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.02pt; text-align: left;">$<font style="padding-left: 5pt;">1.</font>41</div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 9.62%; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: justify;">50,263,465 </div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 10.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.72pt; text-align: left;">$<font style="padding-left: 5pt;">0.05</font> </div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Charles Wu <font style="padding-left: 0.43pt;"></font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">91,977 </font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.02pt; text-align: left;">$<font style="padding-left: 5pt;">1.41 </font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">2,556,256 </font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.72pt; text-align: left;">$<font style="padding-left: 5pt;">0.05</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ruoyu Chen <font style="padding-left: 2.07pt;"></font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 7.5pt;">312,248 </font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 8.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.02pt; text-align: left;">$<font style="padding-left: 5pt;">1.</font>41</div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">8,678,101 </font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 10.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.72pt; text-align: left;">$<font style="padding-left: 5pt;">0.05</font> </div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Yuwen Wu <font style="padding-left: 3.21pt;"></font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.02pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.72pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font> </div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Xiaoxing Jiang<font style="padding-left: 4.85pt;"></font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 1pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 1pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font> </div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 1pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 1pt;">&#8203;</td><td style="width: 8.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.02pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 1pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 1pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 1pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 1pt;">&#8203;</td><td style="width: 10.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.72pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Pursuant to the 2021 Plan, the BC Options were granted on February 4, 2021, and vested 20 months after the grant date (the &#8220;Vesting Period&#8221;). 50% of each person&#8217;s BC Options may be exercised from the first day that BC&#8217;s board of directors has certified the conditions to exercise have been met until the last business day of the 12 months following the expiration of the Vesting Period (the &#8220;First Exercisable Period&#8221;). The remaining 50% may be exercised following the expiration of the First Exercisable Period and from the first day that BC&#8217;s board of directors has certified the conditions to exercise have been met until the last business day of the 24 months following the expiration of the Vesting Period. As of the date of this table, BC&#8217;s board of directors has certified that all of the conditions to exercise will have been met when the Contributions have been consummated. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The exercise price is RMB 9.79. The foreign exchange rate reported by the People's Bank of China as of the date of this table was 6.9400.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Each BC Option will be converted into 27.8 Gyre Options, which such ratio is equal to the quotient of 1,110,776,224 shares of Catalyst Common Stock to be issued in the Business Combination divided by 39,967,000 BC shares exchanged by BJC Limited and the Minority Holders for the Catalyst Common Stock in the Contribution.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The exercise price of the Gyre Options is equal to the quotient of the exercise price of each BC option divided by 27.8, and such amount is converted into U.S. dollars.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Management Following the Contributions </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As described elsewhere in this proxy statement, including in the section captioned &#8220;<font style="font-style: italic;">Management Following the </font><font style="font-style: italic;">Contributions</font>,&#8221; certain of BC&#8217;s directors and executive officers are expected to become the directors and executive officers of the combined company upon the closing of the Contributions.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Limitations of Liability and Indemnification </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For a discussion of the indemnification provisions related to the directors and executive officers of BC and Further Challenger are entitled to under the Business Combination Agreement, please see the section entitled &#8220;<font style="font-style: italic;">The Business </font><font style="font-style: italic;">Combination Agreement&#8212;Indemnification and Insurance for Directors and Officers</font>&#8221; beginning on page <a href="#tIDA">151</a> of this proxy statement.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Form of the Contributions</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Business Combination Agreement, Catalyst will acquire an indirect controlling interest in BC pursuant to the following transactions: (a) GNI USA will contribute all of its CPI Ordinary Share to Catalyst, (b) GNI USA will contribute its interest in Further Challenger to Catalyst and (c) each Minority Holder will contribute 100% of the interest he or she holds in his or her respective Entity to Catalyst. The Contributions are intended to qualify as exchanges governed by Section 351 of Code for U.S. federal income tax purposes.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a name="tCON"><!--Anchor--></a>Consideration </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Subject to the terms and conditions of the Business Combination Agreement, at the Effective Time, (a) GNI USA will contribute all of the CPI Ordinary Shares it holds immediately prior to the Effective Time to Catalyst in exchange for 688,850,101 shares of Catalyst Common Stock, (b) GNI USA will contribute all of the ordinary shares of Further Challenger it holds immediately prior to the Effective Time to Catalyst in exchange for 264,971,695 shares of Catalyst Common Stock and (c) each Minority Holder will contribute 100% of the interest he or she holds in his or her respective Entity to Catalyst in exchange for an aggregate of 156,954,428 shares of Catalyst Common Stock in the amounts set forth on an annex to the Business Combination Agreement. At the election of GNI USA or any Minority Holder, GNI USA or such Minority Holder shall be issued shares of Catalyst Convertible Preferred Stock in lieu of some or all of the shares of Catalyst Common Stock GNI USA or such Minority Holder is entitled to receive.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">139<br></div></div></div>
<!--End Page 150-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 151-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_108-meeting_pg23"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Calculation of Catalyst&#8217;s Final Net Cash </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the terms of the Business Combination Agreement, Catalyst&#8217;s &#8220;final net cash&#8221; means, whether positive or negative, without duplication, as of immediately prior to the Effective Time the sum (without duplication) of the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">unrestricted (a) cash and cash equivalents and (b) marketable securities, in each case determined in accordance with GAAP; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">short-term investments; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">accounts receivable, determined, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in the forms, reports, schedules, statements and other documents required to be filed with or furnished to the SEC by Catalyst and he audited balance sheet of Catalyst as of December&#160;31, 2021, included in Catalyst&#8217;s Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8.5pt; margin-left: 0pt; text-align: left;"><u>Minus</u><font style="font-style: normal;"> the sum (without duplication) of the following: </font></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s consolidated short-term and long-term liabilities accrued at the closing of the Contributions under GAAP (including fees and expenses incurred with respect to the Contributions and related transactions and excluding non-cash liabilities (<font style="font-style: italic;">e.g.</font>, deferred revenue));</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any accrued and unpaid tax liabilities of Catalyst and its subsidiaries;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the cash cost of change in control payments, including termination or similar payments to current or former employees or other service provider of such party that have to be paid by a party in connection with, or at the time of, the closing of the Contributions and/or the termination of Catalyst&#8217;s then employees (if any);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the cash costs of any retention payments or other bonuses due to any current or former employee as of the closing of the Contributions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">80% of the sum of estimated cash costs associated with the termination of ongoing contractual obligations relating to Catalyst&#8217;s legacy business operations (including, without limitation, CRO fees, consulting fees with termination provisions and manufacturing obligations);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">to the extent not included in the balance sheet liabilities, other outstanding contractual obligations of Catalyst;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the aggregate costs associated with obtaining a D&amp;O tail policy (if applicable); and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">any amounts paid or payable as bonuses to employees granted prior to the date of the Business Combination Agreement.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8.5pt; margin-left: 0pt; text-align: left;"><u>Plus</u><font style="font-style: normal;">, solely with respect to Catalyst, prepaid expenses.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Two business days prior to the closing of the Contributions, Catalyst will deliver to the Contributors a schedule (the &#8220;Net Cash Schedule&#8221;) setting forth, in reasonable detail, Catalyst&#8217;s good-faith, estimated calculation of Net Cash, including each component thereof as of the close of business on the last Business Day prior to the closing of the Contributions prepared and certified by Catalyst&#8217;s principal financial or accounting officer. Catalyst will make available to the Contributors, as requested by the Contributors, the work papers and back-up materials used or useful in preparing the Net Cash Schedule.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s net cash balance is subject to numerous factors, some of which are outside of Catalyst&#8217;s control. The actual amount of net cash will depend significantly on the timing of the closing of the Contributions.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Effective Time</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Business Combination Agreement requires the parties to consummate the Contributions as promptly as practicable (and, in any event, within two business days unless any conditions remain unsatisfied or unwaived) after all of the conditions to the consummation of the Contributions contained in the Business Combination Agreement are satisfied or waived, including the adoption of the approval by the Catalyst stockholders of the issuance of Catalyst Common Stock and the conversion of Catalyst Convertible Preferred Stock issued pursuant to the F351 Agreement into Catalyst Common Stock and the other transactions proposed under the Business Combination Agreement, other </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">140<br></div></div></div>
<!--End Page 151-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 152-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_108-meeting_pg24"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">than those conditions that by their nature are to be satisfied at the closing of the Contributions. The Contributions will become effective as of 12:01 a.m. on the date on which the closing of the Contributions occur or at such other time as Catalyst, the Contributors and BC shall agree in writing. Neither Catalyst nor BC can predict the exact timing of the consummation of the Contributions.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a name="tRA"><!--Anchor--></a>Regulatory Approvals </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In the United States, Catalyst must comply with applicable federal and state securities laws and the rules and regulations of Nasdaq in connection with the issuance of shares of Catalyst Common Stock to GNI USA and the Minority Holders in connection with the transactions contemplated by the Business Combination Agreement and the filing of this proxy statement with the SEC. Catalyst does not intend to seek any regulatory approval from antitrust authorities to consummate the transactions.</div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On February, 17, 2023, the CSRC issued the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Enterprises (the &#8220;Trial Measures&#8221;), which became effective on March&#160;31, 2023. On the same date, CSRC circulated No. 1 to No. 5 Supporting Guidance Rules, the Notes on the Trial Measures, the Notice on Administration Arrangements for the Filing of Overseas Listings by Domestic Enterprises and the relevant CSRC Answers to Reporter Questions on the official website of CSRC. These new regulations propose to establish a new filing-based regime to regulate overseas offerings and listings by PRC domestic companies. Accordingly, on May 22, 2023, BC submitted the filing documents pursuant to the Trial Measures to the CSRC that must be accepted prior to the anticipated closing of the Contributions. In June 2023, BC received comments from the CSRC on its filing materials, and BC filed its responses and supplemental materials to the CSRC. As of the date of this filing, BC has not received final confirmation from the CSRC regarding the completion of the Trial Measures filing process. </div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC does not believe it falls within any of the circumstances specified in the Trial Measures in which overseas issuance and listing are prohibited. As long as BC complies with all relevant requirements, takes all necessary steps and submits all relevant materials as required, BC expects that there are no significant legal impediments to its completion of the filing process with the CSRC. However, there is still uncertainty as to whether BC will be able to complete the filing, and if it is unable to complete the filing process, BC will have to suspend or terminate the Contributions. Furthermore, pursuant to the Trial Measures, if domestic enterprises fail to fulfill the filing procedures or offer and list in an overseas market against the prohibited circumstances, they would be warned and fined not less than approximately $144,092 but not more than approximately $1.4 million. The controlling shareholder or the actual controller of a domestic enterprise who organizes or instructs to engage in such illegal acts will be fined not less than approximately $144,092 but not more than approximately $1.4 million. If the filing materials of a domestic enterprise contain false records, misleading statements or material omissions, the CSRC will order correction, issue a warning, and impose a fine of not less than approximately $144,092 and not more than approximately $1.4 million. The controlling shareholder or actual controller of a domestic enterprise who organizes or directs to engage in the illegal acts in the preceding paragraph, or conceals the relevant matters leading to the occurrence of the foregoing, shall be subject to a fine of not less than approximately $144,092 and not more than approximately $1.4 million. </div> <div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;"><a name="tMUF1"><!--Anchor--></a>Material U.S. Federal Income Tax Consequences of the Contributions</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following discussion is a summary of the material U.S. federal income tax consequences of the Contributions to GNI USA, but this discussion does not purport to be a complete analysis of all potential tax consequences that may be relevant to GNI USA. The effects of other U.S. federal tax laws (such as estate and gift tax laws, the corporate alternative minimum tax, the Medicare contribution tax on net investment income or the rules related to &#8220;qualified small business stock&#8221; within the meaning of Section 1202 of the Code) and any applicable state, local or non-U.S. tax laws are not discussed. This discussion is based on the Code, Treasury Regulations promulgated thereunder, judicial decisions and published rulings and administrative pronouncements of the IRS, in each case, in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a Catalyst stockholder. Catalyst has not sought and does not intend to seek any opinions of counsel or rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a position contrary to that discussed below regarding the tax consequences of the Contributions.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This discussion is limited to GNI USA and does not address consequences relevant to the other Contributors, Catalyst Stockholders or the Minority Holders.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">141<br></div></div></div>
<!--End Page 152-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 153-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_108-meeting_pg25"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">IT IS RECOMMENDED THAT CATALYST STOCKHOLDERS AND MINORITY HOLDERS CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE CONTRIBUTIONS.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16pt; margin-left: 0pt; text-align: left;">General</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For U.S. federal income tax purposes, it is intended that the Contributions, taken together, qualify as a transaction governed by Section 351(a) of the Code. Catalyst, the Contributors and BC have not sought, nor do they intend to seek, any ruling from the IRS or opinion of counsel with respect to the qualification of the Contributions, taken together, as a transaction governed by Section 351(a) of the Code, and no assurance can be given that the IRS will agree with the views expressed herein, or that a court will not sustain any challenge by the IRS in the event of litigation. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16pt; margin-left: 0pt; text-align: left;">Tax Treatment for GNI USA</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Subject to the limitations and qualifications set forth in this section &#8220;&#8212;<font style="font-style: italic;">Material U.S. Federal Income Tax </font><font style="font-style: italic;">Consequences of the Contributions</font>,&#8221; the following are the anticipated material U.S. federal income tax consequences to GNI USA as a result of the contribution of CPI common stock and ordinary shares of Further Challenger in the Contributions pursuant to a transaction governed by Section 351 of the Code:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">no gain or loss upon will be recognized on the contribution of shares of CPI common stock or ordinary shares of Further Challenger for Catalyst Common Stock in the Contributions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the tax basis in the Catalyst Common Stock received in the Contributions will be equal to the tax basis of the CPI common stock or ordinary shares of Further Challenger surrendered in exchange therefor; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the holding period for shares of Catalyst Common Stock received in the Contributions includes its holding period for its shares of CPI common stock or ordinary shares of Further Challenger surrendered in exchange therefor.</div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Tax Consequences if the Contributions Fail to Qualify as an Exchange Governed by Section 351(a) of the Code</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If the Contributions do not qualify as a transaction governed by Section 351(a) of the Code, GNI USA generally would recognize gain or loss for U.S. federal income tax purposes on each share of common stock of BC or ordinary share of Further Challenger contributed to Catalyst in the Contributions in an amount equal to the difference between the fair market value, at the time of the Contributions, of the Catalyst Common Stock received in the Contributions and GNI USA&#8217;s tax basis in the shares of BC common stock and ordinary shares of Further Challenger surrendered in the Contributions. Gain or loss must be calculated separately for each block of BC common stock or ordinary shares of Further Challenger exchanged by GNI USA if such blocks were acquired at different times or for different prices. Any gain or loss recognized generally would be capital gain or loss and generally would be long-term capital gain or loss if GNI USA&#8217;s holding period in a particular block exceeds one year at the Effective Time. The deductibility of capital losses is subject to limitations. GNI USA&#8217;s tax basis in shares of Catalyst Common Stock received in the Contributions would be equal to the fair market value thereof as of the closing of the Contributions and GNI USA&#8217;s holding period in such shares would begin on the day following the Contributions.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;"><a name="tAAT"><!--Anchor--></a>Anticipated Accounting Treatment </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For accounting purposes, CPI is considered to be acquiring Catalyst in this transaction. The transaction is expected to be accounted for as a reverse asset acquisition under existing U.S. GAAP, which is subject to change and interpretation. To determine the accounting for this transaction under U.S. GAAP, a company must assess whether an integrated set of assets and activities should be accounted for as an acquisition of a business or an asset acquisition. The guidance requires an initial screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single asset or group of similar assets. If that screen is met, the operations acquired are not a business. Catalyst is not expected to meet the definition of a business since substantially all of the fair value is included in IPR&amp;D and no substantive processes are being acquired. As such, the Contributions are expected to be treated as an asset acquisition. The accounting treatment is dependent on certain valuations and other studies that have yet to commence or progress to a stage where there is sufficient information for a definitive measurement. A final determination of these estimated fair values, which cannot be made prior to the completion of the transaction, will be based on the actual net tangible and intangible assets of Catalyst that exist as of the completion of the transaction.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">142<br></div></div></div>
<!--End Page 153-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 154-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_108-meeting_pg26"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><a name="tNSM"><!--Anchor--></a>Nasdaq Stock Market Listing </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Shares of Catalyst Common Stock are currently listed on The Nasdaq Capital Market under the symbol &#8220;CBIO.&#8221; Catalyst has agreed to cause the shares of Catalyst Common Stock being issued in the Contributions to be approved for listing on Nasdaq at or prior to the Effective Time.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, under the Business Combination Agreement, each of Catalyst&#8217;s, the Contributors&#8217; and CPI&#8217;s obligation to complete the Contributions is subject to the satisfaction or waiver by each of the parties, at or prior to the Contributions, of various conditions, including that the shares of Catalyst Common Stock to be issued in the Contributions have been approved for listing on Nasdaq as of the closing of the Contributions.</div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst has filed a listing application for the combined company with Nasdaq. If the Nasdaq listing application is accepted, Catalyst and the GNI Parties anticipate that the common stock of the combined company, which will be renamed Gyre Therapeutics, Inc., will be listed on The Nasdaq Stock Market following the closing of the Contributions under the trading symbol &#8220;GYRE.&#8221; In order for the Nasdaq listing application to be accepted, among other requirements, the combined company must maintain a bid price of $4 or higher. As of &#8195;&#8195;&#8195;&#8195;, 2023, the bid price of Catalyst Common Stock was $&#8195;&#8195;&#8195;.</div> <div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a name="tNAR"><!--Anchor--></a>No Appraisal Rights for Catalyst Stockholders</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Appraisal rights are statutory rights under the DGCL that enable stockholders who object to certain extraordinary transactions to demand that the corporation pay such stockholders the fair value of their shares instead of receiving the consideration offered to stockholders in connection with the extraordinary transaction. However, appraisal rights are not available in all circumstances. Holders of Catalyst Common Stock are not entitled to appraisal rights under Delaware law in connection with the Contributions.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">143<br></div></div></div>
<!--End Page 154-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 155-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_109-agreement_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tTBC"><!--Anchor--></a>THE BUSINESS COMBINATION AGREEMENT</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following is a summary of the material terms of the Business Combination Agreement. A copy of the Business Combination Agreement is attached to this proxy statement as Annex&#160;A and is incorporated by reference into this proxy statement. The Business Combination Agreement has been attached to this proxy statement to provide you with information regarding its terms. It is not intended to provide any other factual information about Catalyst, BC or the GNI Parties. The following description does not purport to be complete and is qualified in its entirety by reference to the Business Combination Agreement. You should refer to the full text of the Business Combination Agreement for details of the Contributions and the terms and conditions of the Business Combination Agreement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Business Combination Agreement contains representations and warranties that Catalyst, on the one hand, and the GNI Parties and the Minority Holders, on the other hand, have made to one another as of specific dates. These representations and warranties have been made for the benefit of the other parties to the Business Combination Agreement and may be intended not as statements of fact but rather as a way of allocating the risk to one of the parties if those statements prove to be incorrect. In addition, the assertions embodied in the representations and warranties are qualified by information in confidential disclosure schedules exchanged by the parties in connection with signing the Business Combination Agreement. While Catalyst and the GNI Parties do not believe that these disclosure schedules contain information required to be publicly disclosed under the applicable securities laws, other than information that has already been so disclosed, the disclosure schedules do contain information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the attached Business Combination Agreement. Accordingly, you should not rely on the representations and warranties as current characterizations of factual information about Catalyst or the GNI Parties because they were made as of specific dates, may be intended merely as a risk allocation mechanism between Catalyst and the GNI Parties and are modified by the disclosure schedules.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Structure </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Subject to the terms and conditions of the Business Combination Agreement and in accordance with applicable law, at the completion of the Combinations, CPI and Further Challenger will become wholly owned subsidiaries of Catalyst. Through CPI and Further Challenger, Catalyst will indirectly own BC. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Completion and Effectiveness of the Contributions</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Contributions will be completed as promptly as practicable after all of the conditions to completion of the Contributions are satisfied or waived, including the approval by the stockholders of Catalyst. Catalyst and the GNI&#160;Parties are working to complete the Contributions as quickly as practicable and expect that the Contributions will be completed soon after the Catalyst special meeting of stockholders scheduled to be held on &#8195;&#8195;, 2023. However, Catalyst and the GNI Parties cannot predict the completion of the Contributions or the exact timing of the completion of the Contributions because it is subject to various conditions.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Treatment of BC Options </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">At the Effective Time of the Contributions, BC will terminate the 2021 Plan and BC Options outstanding thereunder will be terminated and replaced with options granted pursuant to a sub-plan for PRC participants under the 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Treatment of Catalyst Common Stock and Catalyst Options </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Each share of Catalyst Common Stock issued and outstanding at the time of the Contributions will remain issued and outstanding. In addition, each option to purchase shares of Catalyst Common Stock that is outstanding immediately prior to the Effective Time, whether vested or unvested, will survive the closing and remain outstanding in accordance with its terms. The number of shares of Catalyst Common Stock underlying such options and the exercise prices for such stock options will be appropriately adjusted to reflect the proposed reverse stock split.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst and the GNI Parties have agreed that the Contributions constitute or will be deemed to constitute a &#8220;change of control&#8221; or &#8220;change in control&#8221; for purposes of the Catalyst stock plans and any awards issued thereunder and for purposes of any employee benefit plan maintained for current or former employees or directors of or independent contractors to Catalyst, except as expressly set forth in agreements between Catalyst and certain employees, including Dr. Usman and Ms.&#160;Miller. Immediately after the Contributions, Catalyst stockholders as of immediately prior to the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">144<br></div></div></div>
<!--End Page 155-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 156-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_109-agreement_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Contributions are expected to own approximately 2.5% of the outstanding shares of common stock of the combined company (assuming conversion of the Catalyst Convertible Preferred Stock), subject to certain assumptions, including, but not limited to, a valuation for Catalyst equal to $8.5&#160;million and a valuation for the percentage of BC acquired in the business combination equal to $299.8&#160;million. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Directors and Officers of Catalyst Following the Contributions </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Business Combination Agreement, each of the directors and officers of Catalyst who will not continue as directors or officers of the combined company following the consummation of the Contributions will resign effective as of the Effective Time. Effective as of the Effective Time, the combined company board of directors will consist of a total of eight directors, who shall be Gordon G. Carmichael, Ph.D., Thomas Eastling, Ying Luo, Ph.D., Songjiang Ma, Renate Parry, Ph.D., Nassim Usman, Ph.D. Charles Wu, Ph.D. and Han Ying, Ph.D. In addition, upon the Effective Time, Charles Wu, Ph.D. will serve as Chief Executive Officer, Songjiang Ma will serve as President, Ruoyu Chen will serve as Interim Chief Financial Officer, Weiguo Ye will serve as Chief Operating Officer and Suzana Corritori, M.D., Ph.D., MSc. will serve as Vice President of Clinical Development and Regulatory Affairs of the combined company.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Amendment of the Restated Certificate of Incorporation of Catalyst </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s certificate of incorporation shall be identical to its certificate of incorporation prior to the Effective Time (which will include the amendments contemplated by Proposal Nos. 3, 4, 5 and 7, if approved by stockholders) unless the Contributors elect to amend it further prior to the closing.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Representations and Warranties </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Business Combination Agreement contains customary representations and warranties of the CPI and Catalyst for a transaction of this type relating to, among other things: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">corporate organization, standing and power and similar corporate matters; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">capitalization; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">subsidiaries; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">authority to enter into the Business Combination Agreement and the related agreements and the absence of certain conflicts;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">financial statements and, with respect to Catalyst, documents filed with the SEC and the accuracy of information contained in those documents; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">liabilities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">material changes or events; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">litigation; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">permits and compliance with laws; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">healthcare regulatory matters; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">employee benefit plans; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">employee matters; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">environmental matters; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">tax matters; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">contracts; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">insurance; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">real property and leaseholds; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">intellectual property; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">state takeover statutes; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">145<br></div></div></div>
<!--End Page 156-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 157-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_109-agreement_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">with respect to Catalyst, brokers, fees and expenses; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">certain transactions or relationships with affiliates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">with respect to CPI, absence of rights plans; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">certain payments.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Business Combination Agreement contains customary representations and warranties of the Contributors and the Minority Holders for a transaction of this type relating to, among other things:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">with respect to the Contributors, corporate organization, standing and power and similar corporate matters; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">with respect to the Contributors, capitalization and subsidiaries; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">authority to enter into the Business Combination Agreement and the related agreements and the absence of certain conflicts;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">ownership of shares to be contributed to Catalyst; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">with respect to the Contributors, brokers, fees and expenses; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">accredited investor status; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">with respect to the Minority Holders, the organization, standing, power, capitalization and subsidiaries of the entities with respect to which the Minority Holders will contribute their interests to Catalyst. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The representations and warranties are, in many respects, qualified by materiality and knowledge and will not survive the Contributions, but their accuracy forms the basis of one of the conditions to the obligations of Catalyst, CPI and the Contributors to complete the Contributions.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Covenants; Conduct of Business Pending the Contributions </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst has agreed that, except as required by law, during the period commencing on the date of the Business Combination Agreement and continuing until the earlier to occur of the effective time and the termination of the Business Combination Agreement, Catalyst and its subsidiaries will act and carry on its business in the ordinary course of business in all material respects consistent with past practice and use reasonable best efforts to preserve its and each of its subsidiaries&#8217; business organization, assets, rights and properties, keep available the services of its present officers, employees and consultants and preserve its goodwill and its relationships with customers, suppliers, licensors, licensees, distributors and others having business dealings with it. Catalyst has also agreed that, subject to certain limited exceptions, it will not, and will not cause or permit any of its subsidiaries to, during the period commencing on the date of the Business Combination Agreement and continuing until the earlier to occur of the effective time and the termination of the Business Combination Agreement, take any action that would reasonably be expected to materially impeded or delay the Combinations, or take any of the following actions without the consent of the Contributors: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">subject to certain exceptions, (A) declare, set aside or pay any dividends on, or make any other distributions (whether in cash, stock or property) in respect of, any of its capital stock or other equity interests, (B)&#160;purchase, redeem or otherwise acquire shares of its capital stock or its other equity interests or any options, warrants or rights to acquire any such shares or other equity interests or (C) split, combine, reclassify or otherwise amend the terms of any of its capital stock or other equity interests or issue or authorize the issuance of any other securities in respect of, in lieu of or in substitution for shares of its capital stock or other equity interests;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">issue, deliver, sell, grant, pledge or otherwise encumber or subject to any Lien any shares of its capital stock, or grant any person any right to acquire any shares of its capital stock; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">amend or otherwise change, or authorize or propose to amend or otherwise change, its certificate of incorporation or bylaws (or similar organizational documents);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">acquire (i)&#160;by merging or consolidating with, purchasing an equity interest in or a portion of the assets of, making an investment in or loan or capital contribution to or in another manner, any corporation partnership, association or other business organization or division thereof or (ii)&#160;any assets; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">146<br></div></div></div>
<!--End Page 157-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 158-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_109-agreement_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">sell, lease, license, sell and leaseback, abandon, mortgage or otherwise encumber or subject to any lien or otherwise dispose in whole or in part of any material properties, assets or rights or any interest therein of Catalyst or any of its subsidiaries; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">adopt or enter into a plan of complete or partial liquidation, dissolution, restructuring, recapitalization or other reorganization; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">(A) incur, create, assume or otherwise become liable for, or repay or prepay, any indebtedness, or amend, modify or refinance any indebtedness or (B) make any loans, advances or capital contributions to, or investments in, any other person; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">incur or commit to incur any material new capital expenditure or authorization or commitment with respect thereto; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">enter into, materially amend or terminate any material contract;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">commence any legal action (other than an action as a result of any action commenced against Catalyst or any of its subsidiaries), or compromise, settle or agree to settle any legal action (including any action relating to the Business Combination Agreement or the transactions contemplated thereby);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">implement or adopt any change to its financial or tax accounting methods, principles or practices, except as required by a change in accounting standards or law; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">settle or compromise any liability for taxes; file any amended tax return or claim for tax refund; make (outside of the ordinary course of business and other than on a basis consistent with past practice), revoke or modify any tax election; file any tax return other than on a basis consistent with past practice, unless required by applicable law; consent to any extension or waiver of the limitation period applicable to any claim or assessment in respect of taxes (other than an extension for the filing of a tax return in the ordinary course of business); grant any power of attorney with respect to taxes; enter into any tax allocation agreement, tax sharing agreement, tax indemnity agreement, tax holiday or any closing or other similar agreement; or change any method of accounting for tax purposes;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">except to the extent required by applicable law (including Section 409(A) of the Internal Revenue Code), any arrangement in effect as of the date of the Business Combination Agreement, or as consistent with past practice, (A) increase the compensation or benefits of any director or executive officer of Catalyst, (B)&#160;amend or adopt any compensation or benefit plan including any pension, retirement, profit-sharing, bonus or other employee benefit or welfare benefit plan (other than any such adoption or amendment that does not increase the cost to Catalyst or any of its subsidiaries of maintaining the applicable compensation or benefit plan) with or for the benefit or its employees or directors or (C) accelerate the vesting of, or the lapsing of restrictions with respect to, any stock options or other stock-based compensation; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">hire or, subject to certain exceptions, terminate any employees or otherwise cause any employees to resign; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">pay, discharge or satisfy any claim or liability, other than the payment, discharge or satisfaction, in the ordinary course of business, of liabilities reflected or reserved against on the Parent Balance Sheet (as defined in the Business Combination Agreement) or subsequently incurred in the ordinary course of business;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">accelerate the collection of or discount any accounts receivable, delay the payment of accounts payable or defer expenses, reduce inventories or otherwise increase cash on hand; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">fail to keep in force insurance policies or replacement or revised provisions regarding insurance coverage with respect to the assets, operations and activities of Catalyst and its subsidiaries as currently in effect;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">permit the lapse of any right relating to Intellectual Property (as defined in the Business Combination Agreement) or any other intangible asset used in the business of Catalyst or any of its subsidiaries;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">renew or enter into any non-compete, exclusivity, non-solicitation or similar agreement that would restrict or limit the operations of Catalyst or any of its subsidiaries;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">enter into any new line of business outside of its existing business; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">enter into any new lease or amend the terms of any existing lease of real property; or</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">147<br></div></div></div>
<!--End Page 158-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 159-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_109-agreement_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">authorize any of, or commit or agree, in writing or otherwise, to take any of, the foregoing actions or any action that would make any representation or warranty of Catalyst in the Business Combination Agreement untrue or incorrect in any material respect, or would materially impair, delay or prevent the satisfaction of any conditions to obligations of the parties to effect the Contributions.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Contributors have agreed that, except as required by law, during the period commencing on the date of the Business Combination Agreement and continuing until the earlier to occur of the Effective Time and the termination of the Business Combination Agreement, each Contributor and its subsidiaries will act and carry on its business in the ordinary course of business in all material respects consistent with past practice and use reasonable best efforts to preserve its and each of its subsidiaries&#8217; business organization, assets, rights and properties, keep available the services of its present officers, employees and consultants and preserve its goodwill and its relationships with customers, suppliers, licensors, licensees, distributors and others having business dealings with it. Each Contributor has also agreed that, subject to certain limited exceptions, it will not and will not cause or permit any of its subsidiaries to, during the period commencing on the date of the Business Combination Agreement and continuing until the earlier to occur of the effective time and the termination of the Business Combination Agreement, take any action that would reasonably be expected to materially impeded or delay the Combinations, or take any of the following actions without the consent of Catalyst: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">subject to certain exceptions, (A) declare, set aside or pay any dividends on, or make any other distributions (whether in cash, stock or property) in respect of, any of its capital stock or other equity interests, (B)&#160;purchase, redeem or otherwise acquire shares of its capital stock or its other equity interests or any options, warrants, or rights to acquire any such shares or other equity interests or (C) split, combine, reclassify or otherwise amend the terms of any of its capital stock or other equity interests or issue or authorize the issuance of any other securities in respect of, in lieu of or in substitution for shares of its capital stock or other equity interests;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">issue, deliver, sell, grant, pledge or otherwise encumber or subject to any lien any shares of its capital stock, or grant any person any right to acquire any shares of its capital stock; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">amend or otherwise change, or authorize or propose to amend or otherwise change, its certificate of incorporation or bylaws (or similar organizational documents);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">acquire (i)&#160;by merging or consolidating with, purchasing an equity interest in or a portion of the assets of, making an investment in or loan or capital contribution to or in another manner, any corporation partnership, association or other business organization or division thereof or (ii)&#160;any assets; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">sell, lease, license, sell and leaseback, abandon, mortgage or otherwise encumber or subject to any lien or otherwise dispose in whole or in part of any material properties, assets or rights or any interest therein of Catalyst or any of its subsidiaries; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">adopt or enter into a plan of complete or partial liquidation, dissolution, restructuring, recapitalization or other reorganization; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">enter into any new line of business outside of its existing business; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">authorize any of, or commit, resolve or agree to take any of, the foregoing actions.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Contingent Value Rights </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On December&#160;26, 2022, Catalyst declared a dividend to its common stockholders of record of the right to receive one CVR for each outstanding share of Catalyst Common Stock held by such stockholder as of such date, each representing the right to receive contingent payments upon the occurrence of certain events set forth in and subject to and in accordance with the terms and conditions of, the CVR Agreement in the form attached to the Business Combination Agreement, discussed in greater detail under the section entitled &#8220;<font style="font-style: italic;">Agreements Related to the </font><font style="font-style: italic;">Contributions&#8212;CVR Agreement</font>&#8221; beginning on page <a href="#tCVR">157</a> of this proxy statement. The record date for such dividend was January&#160;5, 2023. In connection with such dividend, Catalyst caused the CVR Agreement to be duly authorized, executed and delivered by Catalyst and American Stock Transfer &amp; Trust Company, LLC (the &#8220;Rights Agent&#8221;).</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">148<br></div></div></div>
<!--End Page 159-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 160-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_109-agreement_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><a name="tNS"><!--Anchor--></a>Non-Solicitation </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst has agreed that, except as described below, it will not and will not permit or authorize its subsidiaries or any director, officer, employee, investment banker, financial advisor, attorney, accountant or other advisor, agent or representative to: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">solicit, initiate, endorse, encourage or facilitate any inquiry, proposal or offer with respect to, or the making or completion of, any Acquisition Proposal, or any inquiry, proposal or offer that is reasonably likely to lead to any Acquisition Proposal; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">enter into, continue or otherwise participate in any discussions or negotiations regarding, or furnish to any person information or data with respect to, or otherwise cooperate in any way with, any Acquisition Proposal; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">resolve, agree or propose to do any of the foregoing.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Notwithstanding the foregoing, Catalyst may actively take any and all actions with respect to the sale or license of its legacy assets, technology and intellectual property.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">An &#8220;Acquisition Proposal&#8221; means any proposal or offer with respect to any direct or indirect acquisition or purchase or license, in one transaction or a series of transactions and whether through any merger, reorganization, consolidation, tender offer, self-tender, exchange offer, stock acquisition, asset acquisition, binding share exchange, business combination, recapitalization, liquidation, dissolution, joint venture, licensing or similar transaction, or otherwise, of (A) assets or businesses of Catalyst and its subsidiaries that generate 15% or more of the net revenues or net income (for the 12-month period ending on the last day of Catalyst&#8217;s most recently completed fiscal quarter) or that represent 15% or more of the total assets (based on fair market value) of Catalyst and its subsidiaries, taken as a whole, immediately prior to such transaction or (B) 10% or more of any class of capital stock, other equity securities or voting power of Catalyst, any of its subsidiaries or any resulting parent company of Catalyst, in each case other than the transactions contemplated by the Business Combination Agreement. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Notwithstanding the restrictions described above or anything to the contrary set forth in the Business Combination Agreement, before obtaining Catalyst stockholder approval, Catalyst may (A) furnish non-public information with respect to Catalyst and its subsidiaries to any third party (and the representatives of such third party) or (B) engage in discussions or negotiations with any third party (and the representatives of such third party) regarding any Acquisition Proposal, provided that: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Catalyst&#8217;s board of directors believes in good faith such Acquisition Proposal to be bona fide; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst has not materially breached the non-solicitation provisions of the Business Combination Agreement described above; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s board of directors has determined in good faith, after consultation with outside legal counsel and its financial advisor, that such Acquisition Proposal constitutes or is reasonably likely to lead to a Superior Proposal;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s board of directors has determined in good faith, after consultation with outside legal counsel and its financial advisor, that failure to take the actions referred to in clauses (A) and (B) above would constitute a breach of its fiduciary duties to its stockholders under applicable law; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst receives from the third party an executed confidentiality agreement containing terms substantially similar to and no less favorable to Catalyst than, those contained in the confidentiality agreements between Catalyst and GNI Japan and Catalyst and BC.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">A &#8220;Superior Proposal&#8221; means any unsolicited bona fide binding written Acquisition Proposal that is fully financed or has fully committed financing that the Catalyst board determines in good faith (after consultation with outside counsel and its financial advisor), taking into account all legal, financial, regulatory and other aspects of the proposal and the person making the proposal, is (A) more favorable to the stockholders of Catalyst from a financial point of view than the transactions contemplated by the Business Combination Agreement (including any adjustment to the terms and conditions proposed by the Contributors in response to such proposal) and (B) reasonably likely of being completed on the terms proposed on a timely basis; provided that, for purposes of this definition of &#8220;Superior Proposal,&#8221; references in the term &#8220;Acquisition Proposal&#8221; to &#8220;15%&#8221; shall be deemed to be references to &#8220;50%&#8221;.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">149<br></div></div></div>
<!--End Page 160-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 161-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_109-agreement_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The Business Combination Agreement also provides that Catalyst will as promptly (and, in any event, within 24 hours of receipt) advise the Contributors in writing of (i)&#160;any indication by any person that it is considering making an Acquisition Proposal, (ii)&#160;any inquiry or request for information, discussion or negotiation that is reasonably likely to lead to or that contemplates an Acquisition Proposal or (iii)&#160;any proposal or offer that is or is reasonably likely to lead to an Acquisition Proposal, in each case, together with a description of the material terms and conditions of and facts surrounding any such indication, inquiry, request, proposal or offer, the identity of the person making any such indication, inquiry, request, proposal or offer and a copy of any written proposal, offer or draft agreement provided by such person. Catalyst shall keep the Contributors informed (orally and in writing) with respect to the status and details (including within 24 hours after the occurrence of any amendment, modification, development, discussion or negotiation) of any Acquisition Proposal. Catalyst must provide the Contributors with written notice of the first decision by Catalyst&#8217;s board of directors to consider any Acquisition Proposal, to enter into discussions or negotiations concerning any Acquisition Proposal or to provide non-public information with respect to such to any person and in no event shall begin providing such information or engaging in such discussions or negotiations prior to providing such notice.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a name="tBRC"><!--Anchor--></a>Adverse Recommendation Change </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under the Business Combination Agreement, subject to certain exceptions described below, Catalyst agreed that its board of directors (and any committee thereof) may not take any of the following actions, each of which are referred to in this proxy statement as an &#8220;Adverse Recommendation Change&#8221;: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">withdraw, modify or qualify in any manner adverse to the Contributors the recommendation or declaration of advisability by the Catalyst board of directors of the Business Combination Agreement the transactions contemplated thereby or the proposals to be considered at the Catalyst special meeting;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">recommend or otherwise declare advisable the approval by Catalyst stockholders of any Acquisition Proposal; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">resolve, agree or propose to taken of the foregoing actions. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">However, notwithstanding the foregoing, at any time prior to the approval of the proposals to be considered at the Catalyst special meeting by the necessary vote of Catalyst stockholders, with respect to a Superior Proposal or in response to an Intervening Event, the Catalyst board of directors may (i)&#160;make an Adverse Recommendation Change or (ii)&#160;with respect solely to a Superior Proposal that was unsolicited and did not otherwise breach the non-solicitation provisions of the Business Combination Agreement, terminate the Business Combination Agreement and concurrently enter into a binding alternative acquisition agreement, if: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the Catalyst board of directors determines in good faith, after consultation with outside legal counsel, that the failure to do so would result in a breach of its fiduciary duties to the stockholders of Catalyst under applicable law, taking into account all adjustments to the terms of the Business Combination Agreement that may be offered by the Contributors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst has provided at least five business days&#8217; prior written notice to the Contributors that it intends to effect an Adverse Recommendation Change and specifies the reasons therefor, including the terms and conditions of and the identity of the person making, such Superior Proposal and contemporaneously furnishes written copies of any relevant proposed transactions agreements with any party making a potential Superior Proposal; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst has complied in all material respects with the non-solicitation provisions of the Business Combination Agreement in connection with any potential Superior Proposal or Intervening Event; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">after the Contributors have delivered to Catalyst a written, binding and irrevocable offer to alter the terms or conditions of the Business Combination Agreement during the required five business day notice period, the Catalyst board of directors has determined in good faith after consultation with outside legal counsel and after considering the terms of such offer by the Contributors, that the Superior Proposal continues to be a Superior Proposal and the failure to effect an Adverse Recommendation Change would result in a breach of its fiduciary duties to Catalyst stockholders under applicable law.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">150<br></div></div></div>
<!--End Page 161-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 162-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_109-agreement_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">In addition, the Catalyst board of directors may not make an Adverse Recommendation Change in response to an Intervening Event unless: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst provides the Contributors with written information describing such Intervening Event in reasonable detail as soon as reasonably practicable after becoming aware of it; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst keeps the Contributors reasonably informed of developments with respect to such Intervening Event;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst notifies the Contributors in writing at least five business days before making an Adverse Recommendation Change with respect to such Intervening Event of its intention to do so and specifies the reasons therefor; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">after the Contributors have delivered to Catalyst a written, binding and irrevocable offer to alter the terms or conditions of the Business Combination Agreement during the required five business day notice period, the Catalyst board of directors has determined in good faith after consultation with outside legal counsel and after considering the terms of such offer by the Contributors, that the failure to effect an Adverse Recommendation Change would result in a breach of its fiduciary duties to Catalyst stockholders under applicable law.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">An &#8220;Intervening Event&#8221; means a material event or circumstance that was not known or reasonably foreseeable to the Catalyst board of directors prior to the execution of the Business Combination Agreement (or if known, the consequences of which were not known or reasonably foreseeable), which event or circumstance, or any material consequence thereof, becomes known to the Catalyst board of directors prior to the receipt of approval by Catalyst stockholders of the proposals that does not relate to (A) an Acquisition Proposal, (B) CPI or its Subsidiaries (including any Company Material Adverse Effect), (C) any actions taken pursuant to the Business Combination Agreement or (D) any changes in the price of the Catalyst Common Stock. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Meeting of Catalyst&#8217;s Stockholders </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst is obligated under the Business Combination Agreement to take all action necessary under applicable law, its certificate of incorporation and amended and restated bylaws and Nasdaq rules to duly call, give notice of, convene and hold a meeting of the holders of Catalyst Common Stock for the purpose of considering and voting to approve the proposals set forth herein. The Catalyst special meeting will be held promptly (and, in any event, within five Business Days) following (x)&#160;in the event the preliminary Proxy Statement is not reviewed by the SEC, the expiration of the waiting period in Rule 14a-6(a) under the Exchange Act, or (y) in the event the preliminary Proxy Statement is reviewed by the SEC, receipt of oral or written notification of the completion of the review by the SEC.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><a name="tIDA"><!--Anchor--></a>Indemnification and Insurance for Directors and Officers </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under the Business Combination Agreement, from the Effective Time through the sixth anniversary of the date on which the Effective Time occur, Catalyst and CPI have agreed to indemnify and hold harmless each person who was at the time of the execution of the Business Combination Agreement, or has been at any time prior to the date of the Business Combination Agreement, or who becomes prior to the Effective Time, a director or officer of Catalyst, CPI or Further Challenger, against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements, incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the indemnified officer or director is or was a director or officer of Catalyst or of CPI, whether asserted or claimed prior to, at or after the Effective Time, to the extent permitted under the DGCL. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">From the Effective Time through the sixth anniversary of the date on which the Effective Time occurs, the provisions of the certificate of incorporation and bylaws of Catalyst with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers of Catalyst shall not be amended, modified or repealed in a manner that would adversely affect the rights of the individuals who, at or prior to the Effective Time, were officers or directors of Catalyst, unless such modification is required by applicable law. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">To the extent permitted by applicable law, the memorandum and articles of association of CPI shall contain, and Catalyst shall cause the memorandum and articles of association of CPI to so contain, provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth in the certificate of incorporation and bylaws of Catalyst.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst will secure and purchase a six-year &#8220;tail policy&#8221; on their respective existing directors&#8217; and officers&#8217; liability insurance policies.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">151<br></div></div></div>
<!--End Page 162-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 163-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_109-agreement_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Additional Agreements </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Each of the parties has agreed to use reasonable best efforts to: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">take, or cause to be taken, all actions necessary, proper or advisable to consummate and make effective the transactions contemplated by the Business Combination Agreement; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">use reasonable best efforts to:</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">obtain all required consents, approvals or waivers from, or participation in other discussions or negotiations with, third parties; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">obtain all necessary actions or nonactions, waivers, consents, approvals, orders and authorizations from governmental entities; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">execute and deliver any additional instruments necessary to consummate the transactions contemplated by the Business Combination Agreement and fully carry out its purposes. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Pursuant to the Business Combination Agreement, Catalyst has further agreed that: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst will use reasonable best efforts to remain listed on Nasdaq and cause the shares of Catalyst Common Stock to be issued or reserved for issuance pursuant to the Business Combination Agreement to be approved for listing on Nasdaq and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst will, upon request by the Contributors and subject to the approval of the proposals set forth herein, approve and adopt an increase to the number of shares reserved under the Equity Plan. </div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;"><a name="tCTT"><!--Anchor--></a>Conditions to the Completion of the Contributions </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following contains a description of the material conditions to the completion of the Contributions. Each party&#8217;s obligation to complete the Contributions is subject to the satisfaction or waiver by each of the parties, at or prior to the closing, of various conditions, which include the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Proposal Nos. 1, 2, 3, 4 and 6 having been approved at a meeting of Catalyst&#8217;s stockholders, at which a quorum is present, by the requisite vote of the stockholders of Catalyst under applicable law and stock market regulations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the waiting period (and any extensions thereof) applicable to the consummation of the Contributions under the HSR Act and any other applicable law having expired or been terminated;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">no temporary restraining order, preliminary or permanent injunction or other judgment, order or decree issued by any court of competent jurisdiction or other legal restraint or prohibition shall be in effect and no law shall have been enacted, entered, promulgated, enforced or deemed applicable by any governmental entity that prohibits or makes illegal the consummation of the Contributions; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the shares of Catalyst Common Stock to be issued in the Contributions pursuant to the Business Combination Agreement having been approved for listing on Nasdaq.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, the obligation of Catalyst to complete the Contributions is further subject to the satisfaction or waiver of the following conditions: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the representations and warranties of the Contributors and CPI must be true and correct on the date of the Business Combination Agreement and on the closing date of the Contributions as if made on the date on which the Contributions are to be completed or, if such representations and warranties address matters as of a particular date, then as of that particular date, except for inaccuracies the circumstances giving rise to which, individually or in the aggregate, have not had and would not reasonably be expected to have a CPI Material Adverse Effect; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each of the Contributors and CPI must have performed in all material respects all obligations required to be performed by it under the Business Combination Agreement on or prior to the closing date; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst must have received an officers&#8217; certificate duly executed by an officer of each of the Contributors and CPI to the effect that certain closing conditions have been satisfied; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">GNI USA and each of the Minority Holders shall have delivered to Catalyst an appropriate tax form.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">152<br></div></div></div>
<!--End Page 163-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 164-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_109-agreement_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">&#8220;CPI Material Adverse Effect&#8221; means any event, change, circumstance, occurrence, effect or state of facts that (A)&#160;is or would reasonably be expected to be materially adverse to the business, assets, liabilities, financial condition, results of operations of CPI and its subsidiaries, taken as a whole, or (B) materially impairs the ability of CPI to consummate the Contributions or any of the other transactions contemplated by the Business Combination Agreement; provided, however, that in the case of clause (A) only, CPI Material Adverse Effect shall not include any event, change, circumstance, occurrence, effect or state of facts to the extent resulting from (1) changes or conditions generally affecting the industries in which CPI or any of its subsidiaries operates, or the economy or the financial, debt, banking, capital, credit or securities markets, in the United States, including effects on such industries, economy or markets resulting from any regulatory and political conditions or developments in general, (2) the outbreak or escalation of war or acts of terrorism or any natural disasters, acts of God or comparable events, epidemic, pandemic or disease outbreak (including the COVID-19 virus) or any worsening of the foregoing or any declaration of martial law, quarantine or similar directive, policy or guidance or law or other action by any governmental entity in response thereto, (3) changes in law or International Financial Reporting Standards, or the interpretation or enforcement thereof, (4) the public announcement of the Business Combination Agreement or (5) any specific action taken (or&#160;omitted to be taken) by CPI at or with the express written consent of Catalyst; provided that, with respect to clauses (1), (2) and (3), the impact of such event, change, circumstance, occurrence, effect or state of facts is not disproportionately adverse to CPI as compared to other participants in the industries in which CPI operates.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, the obligation of the Contributors and CPI to complete the Contributions is further subject to the satisfaction or waiver of the following conditions: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the representations and warranties of Catalyst must be true and correct on the date of the Business Combination Agreement and on the closing date of the Contributions as if made on the date on which the Contributions are to be completed or, if such representations and warranties address matters as of a particular date, then as of that particular date, except for inaccuracies the circumstances giving rise to which, individually or in the aggregate, have not had and would not reasonably be expected to have a Catalyst Material Adverse Effect; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst must have performed in all material respects all obligations required to be performed by it under the Business Combination Agreement on or prior to the closing date; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the Contributors must have received an officer&#8217;s certificate duly executed by an executive officer of Catalyst to the effect that certain closing conditions have been satisfied; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the Contributors must have received copies of the resignations, effective as of the Effective Time, of each director and officer of Catalyst and its subsidiaries, other than resignations from the individuals who will continue as directors or officers following the Effective Time; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Catalyst shall have delivered to the Contributors an appropriate tax certificate.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;Catalyst Material Adverse Effect&#8221; means any event, change, circumstance, occurrence, effect or state of facts that (A) is or would reasonably be expected to be materially adverse to the business, assets, liabilities, financial condition or results of operations of Catalyst and its subsidiaries, taken as a whole, or (B) materially impairs the ability of Catalyst to consummate the Contributions or any of the other transactions contemplated by the Business Combination Agreement; provided, however, that, in the case of clause (A) only, Parent Material Adverse Effect shall not include any event, change, circumstance, occurrence, effect or state of facts to the extent resulting from (1) changes or conditions generally affecting the industries in which the Catalyst and its subsidiaries operate, or the economy or the financial, debt, banking, capital, credit or securities markets, in the United States, including effects on such industries, economy or markets resulting from any regulatory and political conditions or developments in general, (2) the outbreak or escalation of war or acts of terrorism or any natural disasters, acts of God or comparable events, epidemic, pandemic or disease outbreak (including the COVID-19 virus) or any worsening of the foregoing or any declaration of martial law, quarantine or similar directive, policy or guidance or law or other action by any governmental entity in response thereto, (3) changes in law or generally accepted accounting principles in the United States, or the interpretation or enforcement thereof, (4) the public announcement of the Business Combination Agreement or (5)&#160;any specific action taken (or omitted to be taken) by Catalyst at or with the express written consent of the Contributors; provided that, with respect to clauses (1), (2) and (3), the impact of such event, change, circumstance, occurrence, effect or state of facts is not disproportionately adverse to Catalyst and its subsidiaries, taken as a whole, as compared to other participants in the industries in which Catalyst and its subsidiaries operate.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">153<br></div></div></div>
<!--End Page 164-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 165-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_109-agreement_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Each of Catalyst, the Contributors and CPI may waive any or all of the conditions to the closing of the Contributions that are for its benefit to the extent permitted by applicable laws. Catalyst, the Contributors and CPI do not believe that applicable laws would permit them to waive (i)&#160;the condition for obtaining approval from Catalyst&#8217;s stockholders of Proposal No. 1 or (ii)&#160;the condition for obtaining approval of the Contributions from the shareholders of each of the Contributors and CPI.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;"><a name="tTAT"><!--Anchor--></a>Termination and Termination Fees </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Termination of the Business Combination Agreement </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Business Combination Agreement may be terminated at any time before the Effective Time, whether before or (subject to the terms of the Business Combination Agreement) after the required Catalyst stockholder approvals to complete the Contributions have been obtained, as set forth below: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by mutual written consent of Catalyst and Contributors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by either Catalyst or the Contributors, if: </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the Contributions have not been consummated by September&#160;30, 2023; provided that the right to terminate the Business Combination Agreement on or after such date will not be available to any party whose action or failure to act has been a principal cause of the failure of the Contributions to occur on or before September&#160;30, 2023; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">any court of competent jurisdiction or other governmental entity has issued a final and nonappealable judgment, order, injunction, rule or decree, or taken any other final and nonappealable action restraining, enjoining or otherwise prohibiting the Contributions; provided, however, that the party seeking to terminate the Business Combination Agreement for this reason shall have used its reasonable best efforts to contest, appeal and remove such judgment, order, injunction, rule, decree, ruling or other action in accordance with the Business Combination Agreement; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">at the Catalyst special meeting (including any adjournment or postponement) at which and Catalyst stockholders have taken a vote on the proposals set forth herein, such proposals have not been approved by the Catalyst stockholders; provided, however, that Catalyst may not terminate the Business Combination Agreement pursuant to this provision if the failure to fulfil any obligation under the Business Combination Agreement has been a principal cause of the failure to obtain the required approval of Catalyst stockholders; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by Catalyst, if any of the following circumstances shall occur: </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the Contributors or CPI have breached or failed to perform any of its representations, warranties, covenants or agreements set forth in the Business Combination Agreement, or if any representation or warranty of the Contributors or CPI have become untrue, which breach or failure to perform or to be true, individually or in the aggregate, if occurring at the Effective Time, would result in the failure of a closing condition and cannot be cured by the earlier of the outside date and 30 days after giving written notice to the Contributors or CPI of such breach or failure; provided that Catalyst may not terminate the Business Combination Agreement pursuant to this provision if Catalyst is then in material breach of any its covenants or agreements set forth in the Business Combination Agreement such that any closing condition would not be satisfied; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">at any time prior to the approval by Catalyst stockholders of the proposals set forth herein, in order to accept a Superior Proposal in accordance with the provisions of the Business Combination Agreement; provided that Catalyst shall have simultaneously entered into the associated alternative acquisition agreement, complied with the non-solicitation provisions of the Business Combination Agreement and paid to the Contributors the termination fee;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by the Contributors, if any of the following circumstances shall occur: </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst has breached or failed to perform certain of its representations, warranties, covenants or agreements set forth in the Business Combination Agreement, or if any representation or warranty of the Contributors or CPI have become untrue, which breach or failure to perform or to be true, individually or in the aggregate, if occurring at the Effective Time, would result in the failure of a closing condition and cannot be cured by the earlier of the outside date and 30 days after giving written </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">154<br></div></div></div>
<!--End Page 165-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 166-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_109-agreement_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 60pt; text-align: justify;">notice to the Contributors or CPI of such breach or failure; provided that Catalyst may not terminate the Business Combination Agreement pursuant to this provision if Catalyst is then in material breach of any its covenants or agreements set forth in the Business Combination Agreement such that any closing condition would not be satisfied; or </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">(A) an Adverse Recommendation Change shall have occurred, (B) Catalyst shall, within 10 business days of a tender offer or exchange offer relating to Catalyst securities having been commenced, fail to publicly recommend against such tender or exchange offer or (C) Catalyst shall have failed to publicly reaffirm its recommendation of the Contributions within five business days after the date any Acquisition Proposal or material modification thereto is first commenced, publicly announced, distributed or disseminated to Catalyst&#8217;s stockholders upon a request to do so by the Contributors.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The party desiring to terminate the Business Combination Agreement will give the other party written notice of such termination.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><a name="tTF"><!--Anchor--></a>Termination Fees Payable by Catalyst </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Catalyst must pay to the Contributors a termination fee of $2&#160;million if: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">(A) an Acquisition Proposal or intention to make an Acquisition proposal is made directly to Catalyst&#8217;s stockholders or is otherwise publicly disclosed or otherwise communicated to senior management of Catalyst or Catalyst&#8217;s board of directors, (B) the Business Combination Agreement is terminated by the Contributors or Catalyst pursuant to (b)(i)&#160;or (b)(iii)&#160;above and (C) within 18 months after the date of such termination, Catalyst enters into an agreement in respect of any Acquisition Proposal or recommends or submits any Acquisition Proposal to its stockholders for adoption (provided, that for purposes of clause (C), each reference to &#8220;15%&#8221; in the definition of &#8220;Acquisition Proposal&#8221; shall be deemed to be a reference to &#8220;50%&#8221;);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Business Combination Agreement is terminated by the Contributors pursuant to (d)(ii)&#160;above; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Business Combination Agreement is terminated by Catalyst pursuant to (c)(ii)&#160;above. </div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Expense Reimbursements </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If Catalyst terminates the Business Combination Agreement pursuant to (c)(i)&#160;above, the Contributors shall reimburse Catalyst for all of its reasonable out-of-pocket fees and expenses incurred by Catalyst in connection with the authorization, preparation, investigation, negotiation, execution and performance of the Business Combination Agreement and the Contributions, up to $2&#160;million. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If the Contributors terminate the Business Combination Agreement pursuant to (d)(i)&#160;above, Catalyst shall reimburse the Contributors for all of their reasonable out-of-pocket fees and expenses incurred by the Contributors in connection with the authorization, preparation, investigation, negotiation, execution and performance of the Business Combination Agreement and the Contributions, up to $2&#160;million.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Amendment </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Business Combination Agreement may be amended, modified or supplemented by Catalyst, the Contributors and CPI. Such amendment may be made at any time prior to the Effective Time and requires the approval of the respective boards of directors or equivalent bodies of CPI, the Contributors and Catalyst, except that after the Business Combination Agreement has been adopted and approved by the Catalyst stockholders, no amendment which by law requires further approval by the Catalyst stockholders, as the case may be, may be made without such further approval. Any amendment to Sections 1.1, 1.4, Article V, Sections 6.3(c), 6.3(d) and 8.4 (to the extent that such amendment to Section 8.4 pertains to the foregoing) must also be approved by the Minority Holders. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Fees and Expenses </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Business Combination Agreement provides all fees and expenses incurred in connection with the Business Combination Agreement and the transactions contemplated thereby shall be paid by the party incurring such expenses, except as described above in the section entitled &#8220;<font style="font-style: italic;">The Business Combination Agreement&#8212;Termination and </font><font style="font-style: italic;">Termination Fees</font>&#8221; beginning on page <a href="#tTAT">154</a> of this proxy statement and except that the Contributors and Catalyst will share equally (i)&#160;the filing and other fees paid to the SEC or under the HSR Act and (ii)&#160;all fees and expenses, other than attorneys&#8217; and accountants&#8217; fees, incurred in relation to the printing, filing and mailing of this proxy statement and any amendments or supplements thereto. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">155<br></div></div></div>
<!--End Page 166-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 167-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_109-agreement_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">In addition, the Contributors shall reimburse Catalyst for ongoing operating expenses in excess of $500,0000 (but not to exceed $1&#160;million) in the aggregate, where such expenses are solely incurred between the date of the Business Combination Agreement and the Effective Time, provided that such expenses shall be set forth on a budget that is approved by Catalyst&#8217;s board of directors after the date of the Business Combination Agreement and delivered to CPI within 30 days of the date of the Business Combination Agreement and the aggregate sum of such reimbursed amounts shall be distributed to the Catalyst stockholders pursuant to the CVR Agreement. Operating expenses in excess of $1&#160;million (if any) incurred by Catalyst, where such expenses are solely incurred between the date of the Business Combination Agreement and the effective date of the Contributions, shall be borne equally by CPI and Catalyst; provided that any such expenses shall be approved by Catalyst&#8217;s board of directors.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">156<br></div></div></div>
<!--End Page 167-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 168-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_109-agreement_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tART"><!--Anchor--></a>AGREEMENTS RELATED TO THE CONTRIBUTIONS</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><a name="tCVR"><!--Anchor--></a>CVR Agreement</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Overview </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Concurrent with the signing of the Business Combination Agreement on December&#160;26, 2022, Catalyst and the Rights Agent entered into the CVR Agreement, pursuant to which each holder of Catalyst Common Stock, excluding the Sellers, as of January&#160;5, 2023 (the &#8220;CVR Record Date&#8221;) received one contractual CVR issued by Catalyst, subject to and in accordance with the terms and conditions of the CVR Agreement, for each share of Catalyst Common Stock held by such holder at the CVR Record Date. Each CVR entitles the holder thereof to receive (i)&#160;certain cash payments from the net proceeds, if any, related to (a) the disposition of Catalyst&#8217;s legacy assets within 90 calendar days after the remainder of the Holdback Amount (as defined in the CVR Agreement) is finally determined and received by Catalyst or (b)&#160;the resolution of certain legal claims; <font style="font-style: italic;">provided, however,</font> such period will be automatically extended for any Claim (as&#160;defined in the CVR Agreement) for an additional one-year period to the extent any Claim is appealed during the initial term, (ii) 100% of the excess cash (net of all current or contingent liabilities, including transaction-related expenses) retained by Catalyst in excess of $1,000,000 as of the Closing and (iii) 100% of the amount actually received (net of indemnity claims, if any) by Catalyst pursuant to the asset purchase agreement, dated as of May&#160;19, 2022, by and between Catalyst and Vertex.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The contingent payments under the CVR Agreement, if they become payable, will become payable to the Rights Agent for subsequent distribution to the CVR Holders. In the event that no such proceeds are received, or the permitted deductions under the CVR Agreement are greater than any such proceeds, CVR Holders will not receive any payment pursuant to the CVR Agreement. There can be no assurance that CVR Holders will receive any amounts with respect thereto. The CVRs are not transferable, except in certain limited circumstances provided in the CVR Agreement, are not certificated or evidenced by any instrument and are not registered with the SEC or listed for trading on any exchange. The CVRs will not have any voting or dividend rights and will not represent any equity or ownership interest in Catalyst or any of its affiliates. No interest will accrue on any amounts payable in respect of the CVRs. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The foregoing description of the CVR Agreement does not purport to be complete and is qualified in its entirety by the full text of the form of CVR Agreement, which is included in Annex&#160;D to this proxy statement.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;"><a name="tMUF"><!--Anchor--></a>Material U.S. Federal Income Tax Consequences of the Receipt of CVRs</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following discussion is a summary of the material U.S. federal income tax consequences of the receipt of CVRs to Catalyst stockholders who receive CVRs with respect to Catalyst Common Stock, but this discussion does not purport to be a complete analysis of all potential tax consequences that may be relevant to a Catalyst stockholder. The effects of other U.S. federal tax laws, such as estate and gift tax laws and any applicable state, local or non-U.S. tax laws are not discussed. This discussion is based on the Code, Treasury Regulations promulgated thereunder, judicial decisions and published rulings and administrative pronouncements of the IRS, in each case, in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a Catalyst stockholder. Catalyst has not sought and does not intend to seek any opinions of counsel or rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a position contrary to that discussed below regarding the tax consequences of the receipt of CVRs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This discussion is limited to Catalyst stockholders that hold Catalyst Common Stock as a &#8220;capital asset&#8221; within the meaning of Section 1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences that may be relevant to a Catalyst stockholder&#8217;s particular circumstances, including the impact of the alternative minimum tax or the Medicare contribution tax on net investment income or the rules related to &#8220;qualified small business stock&#8221; within the meaning of Section 1202 of the Code. In addition, it does not address (1) the tax consequences of transactions effectuated before, after or at the same time as the distribution of the CVRs, whether or not they are in connection with the distribution of the CVRs, including, without limitation, the Contributions and the reverse stock split, except as specifically provided below and (2) consequences relevant to Catalyst stockholders subject to special rules, including, without limitation: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">certain U.S. expatriates and former citizens or long-term residents of the U.S.; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Catalyst U.S. holders whose functional currency is not the U.S. dollar; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">persons holding Catalyst Common Stock as part of a hedge, straddle or other risk-reduction strategy or as part of a conversion transaction or other integrated investment; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">157<br></div></div></div>
<!--End Page 168-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 169-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_109-agreement_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">banks, insurance companies and other financial institutions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">real estate investment trusts or regulated investment companies; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">brokers, dealers or traders in securities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">&#8220;controlled foreign corporations,&#8221; &#8220;passive foreign investment companies,&#8221; and corporations that accumulate earnings to avoid U.S. federal income tax; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">S corporations, partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">tax-exempt organizations or governmental organizations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">persons subject to special tax accounting rules as a result of any item of gross income with respect to Catalyst Common Stock being taken into account in an &#8220;applicable financial statement&#8221; (as defined in the Code); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons deemed to sell Catalyst Common Stock under the constructive sale provisions of the Code; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">persons who hold or received Catalyst Common Stock pursuant to the exercise of any employee stock option or otherwise as compensation; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">tax-qualified retirement plans.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If an entity treated as a partnership for U.S. federal income tax purposes holds Catalyst Common Stock, the tax treatment of a partner in the partnership and such partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding Catalyst Common Stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;"><a name="tREC"><!--Anchor--></a>IT IS RECOMMENDED THAT CATALYST STOCKHOLDERS CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE RECEIPT OF CVRs ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For purposes of this discussion, a &#8220;Catalyst U.S. holder&#8221; is a beneficial owner of Catalyst Common Stock that, for U.S. federal income tax purposes, is or is treated as: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an individual who is a citizen or resident of the U.S.; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">a corporation created or organized under the laws of the U.S., any state thereof or the District of Columbia; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">a trust that (i)&#160;is subject to the primary supervision of a U.S. court and the control of one or more &#8220;United&#160;States persons&#8221; (within the meaning of Section 7701(a)(30) of the Code) over all of its substantial decisions or (ii)&#160;has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For purposes of this discussion, a &#8220;Catalyst non-U.S. holder&#8221; means a beneficial owner of Catalyst Common Stock that is neither a Catalyst U.S. holder nor a partnership (or other entity treated as a partnership) for U.S. federal income tax purposes.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 0pt; text-align: left;"><a name="tRecap"><!--Anchor--></a>Alternative Treatment of the Receipt of CVRs and the Proposed Reverse Stock Split as a Single Recapitalization </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst will treat the proposed reverse stock split as a &#8220;recapitalization&#8221; within the meaning of Section 368(a)(1)(E) of the Code that is separate from Catalyst&#8217;s distribution of the CVRs. Notwithstanding that Catalyst will report the receipt of CVRs and the proposed reverse stock split as separate transactions, it is possible that the IRS or a court could determine that the receipt of the CVRs and the proposed reverse stock split constitute a single &#8220;recapitalization&#8221; for U.S. federal income tax purposes. In such case, the tax consequences of the receipt of CVRs and the proposed reverse stock split could differ from those described below and would depend in part on many of the same considerations described below, including whether the CVRs should be treated as property, equity or debt instruments or should be subject to the &#8220;open transaction&#8221; doctrine. In general, if the CVRs are treated as property and are not subject to the &#8220;open transaction&#8221; doctrine and the receipt of the CVRs and the proposed reverse stock split constitute a single &#8220;recapitalization&#8221; for U.S. federal income tax purposes, then a Catalyst stockholder may </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">158<br></div></div></div>
<!--End Page 169-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 170-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_109-agreement_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">recognize gain (but not loss) equal to the lesser of (i)&#160;the fair market value of the CVRs received and (ii)&#160;the excess (if any) of (A) the sum of (1) the fair market value of the CVRs received and (2) the fair market value of the shares of Catalyst Common Stock received in the proposed reverse stock split (including any cash received in lieu of a fractional share) over (B) the Catalyst stockholder&#8217;s adjusted tax basis in the Catalyst Common Stock surrendered in the proposed reverse stock split.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The remainder of this discussion assumes that the distribution of the CVRs to Catalyst stockholders will be treated for U.S. federal income tax purposes as a transaction that is separate and distinct from the proposed reverse stock split.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 0pt; text-align: left;">Receipt of CVRs by Catalyst U.S. Holders </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">There is substantial uncertainty as to the tax treatment of the CVRs. Specifically, there is no authority directly addressing whether contingent value rights with characteristics similar to the CVRs should be treated as a distribution of property with respect to Catalyst Common Stock, a distribution of equity, a &#8220;debt instrument&#8221; or an &#8220;open transaction&#8221; for U.S. federal income tax purposes and such determinations are inherently factual in nature.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As a result, it is not possible to express a definitive conclusion as to the U.S. federal income tax treatment of receipt of the CVRs or receipt of any payment pursuant to the CVRs. Based on the specific characteristics of the CVRs, Catalyst intends the issuance of the CVRs to be treated and will treat such issuance, as a distribution of property with respect to its stock. No assurance can be given that the IRS would not assert, or that a court would not sustain, a position contrary to any description of the intended tax consequences summarized below. No opinion of counsel or ruling has been or will be sought from the IRS regarding the tax treatment of the CVRs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Treatment as Distribution of Property. <font style="font-style: normal;">As discussed above, Catalyst will report the issuance of the CVRs as a </font><font style="font-style: normal;">distribution of property with respect to its stock. Assuming such treatment is respected by the IRS, each Catalyst </font><font style="font-style: normal;">U.S.&#160;holder should be treated as receiving a distribution in an amount equal to the fair market value of the CVRs </font><font style="font-style: normal;">issued to such Catalyst U.S. holder on the date of the issuance. This distribution should be treated first as a taxable </font><font style="font-style: normal;">dividend to the extent of the Catalyst U.S. holder&#8217;s pro rata share of Catalyst&#8217;s current or accumulated earnings and </font><font style="font-style: normal;">profits for the year of issuance (as determined for U.S. federal income tax purposes), then as a non-taxable return of </font><font style="font-style: normal;">capital to the extent of the Catalyst U.S. holder&#8217;s basis in its Catalyst Common Stock and finally as capital gain from </font><font style="font-style: normal;">the sale or exchange of Catalyst Common Stock with respect to any remaining value. Catalyst has accumulated </font><font style="font-style: normal;">earnings and profits and expects to have current earnings and profits for the relevant taxable year. Thus, Catalyst </font><font style="font-style: normal;">expects the distribution of the CVRs to be treated as a dividend for U.S. federal income tax purposes to the extent </font><font style="font-style: normal;">of Catalyst&#8217;s earnings and profits. Catalyst U.S. holders will receive a Form 1099-DIV notifying them of the portion </font><font style="font-style: normal;">of the CVR value that is treated as a dividend to the extent of Catalyst&#8217;s earnings and profits for U.S. federal income </font><font style="font-style: normal;">tax purposes. Although Catalyst will estimate the value of the CVRs for purposes of reporting on Form 1099-DIV </font><font style="font-style: normal;">to Catalyst U.S. holders, the value of the CVRs is uncertain and the IRS or a court could determine that the value </font><font style="font-style: normal;">of the CVRs at the time of issuance was higher. In such case, the Catalyst U.S. holders could be treated as having </font><font style="font-style: normal;">additional income or gain upon receipt of the CVRs as described above. A Catalyst U.S. holder&#8217;s initial tax basis in </font><font style="font-style: normal;">such holder&#8217;s CVRs should equal the fair market value of such CVRs on the date of their issuance. The holding period </font><font style="font-style: normal;">of such CVRs should begin on the day after the date of issuance.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Future payments received by a Catalyst U.S. holder with respect to a CVR would likely be treated as a non-taxable return of such Catalyst U.S. holder&#8217;s adjusted tax basis in the CVR to the extent thereof and payment in excess of such amount may be treated as ordinary income. However, the treatment of future payments, if any, pursuant to the CVRs is uncertain and alternative treatments are possible.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Alternative Treatment as Equity. <font style="font-style: normal;">It is possible that the issuance of the CVRs could be treated as a distribution of </font><font style="font-style: normal;">equity for U.S. federal income tax purposes, in which case Catalyst U.S. holders generally should not recognize gain </font><font style="font-style: normal;">or loss as a result of the issuance of the CVRs. Each Catalyst U.S. holder&#8217;s tax basis in such holder&#8217;s Catalyst </font><font style="font-style: normal;">Common Stock would be allocated between such holder&#8217;s Catalyst Common Stock and such holder&#8217;s CVRs based </font><font style="font-style: normal;">on the fair market value of the CVRs on the date of their issuance and the fair market value of such holder&#8217;s Catalyst </font><font style="font-style: normal;">Common Stock. The holding period of such CVRs should include the Catalyst U.S. holder&#8217;s holding period of such </font><font style="font-style: normal;">holder&#8217;s Catalyst Common Stock. Future payments, if any, on a CVR received by a Catalyst U.S. holder should be </font><font style="font-style: normal;">treated as a dividend to the extent of the Catalyst U.S. holder&#8217;s pro rata share of Catalyst&#8217;s current or accumulated </font><font style="font-style: normal;">earnings and profits at the time of such payment (as determined for U.S. federal income tax purposes), then as a </font><font style="font-style: normal;">non-taxable return of capital to the extent of the Catalyst U.S. holder&#8217;s basis in the CVR and finally as capital gain </font><font style="font-style: normal;">from the sale or exchange of the CVR with respect to any remaining amount. As discussed above, Catalyst will not </font><font style="font-style: normal;">report the issuance of the CVRs as a distribution of equity for U.S. federal income tax purposes.</font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">159<br></div></div></div>
<!--End Page 170-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 171-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_109-agreement_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Alternative Treatment as Debt Instrument. <font style="font-style: normal;">It is also possible that the CVRs could be treated as one or more &#8220;debt </font><font style="font-style: normal;">instruments.&#8221; If the CVRs are treated as one or more &#8220;debt instruments,&#8221; then payments received with respect to the </font><font style="font-style: normal;">CVRs would likely be treated as payments in retirement of a &#8220;debt instrument,&#8221; except to the extent of interest </font><font style="font-style: normal;">imputed under the Code. If this tax treatment were to apply, interest generally would be imputed under complex rules. </font><font style="font-style: normal;">In such a case, a Catalyst U.S. holder would be required to include any such interest in income on an annual basis, </font><font style="font-style: normal;">whether or not currently paid. As discussed above, Catalyst will not report the issuance of the CVRs as a distribution </font><font style="font-style: normal;">of a &#8220;debt instrument&#8221; for U.S. federal income tax purposes.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Alternative Treatment as &#8220;Open Transaction.&#8221; <font style="font-style: normal;">It is also possible that the issuance of the CVRs could be treated as </font><font style="font-style: normal;">subject to the &#8220;open transaction&#8221; doctrine if the value of the CVRs at closing cannot be &#8220;reasonably ascertained.&#8221; </font><font style="font-style: normal;">If the receipt of CVRs were treated as an &#8220;open transaction&#8221; for U.S. federal income tax purposes, each Catalyst </font><font style="font-style: normal;">U.S.&#160;holder should not immediately take the CVRs into account in determining whether such holder must recognize </font><font style="font-style: normal;">income or gain, if any, on the receipt of the CVRs and such holder would not take any tax basis in the CVRs. Rather, </font><font style="font-style: normal;">the Catalyst U.S. holder&#8217;s U.S. federal income tax consequences would be determined at the time future payments, </font><font style="font-style: normal;">if any, with respect to the CVRs are received or deemed received in accordance with the Catalyst U.S. holder&#8217;s </font><font style="font-style: normal;">regular method of accounting based on whether, as discussed above, the CVRs are treated as a distribution of property </font><font style="font-style: normal;">or of debt or equity. As discussed above, Catalyst will not report the issuance of the CVRs as an open transaction </font><font style="font-style: normal;">for U.S. federal income tax purposes.</font></div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Receipt of CVRs by Catalyst Non-U.S. Holders </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Provided that the issuance of the CVRs is treated as a distribution of property with respect to Catalyst Common Stock, each Catalyst non-U.S. holder should be treated as receiving a distribution in an amount equal to the fair market value of the CVRs issued to such Catalyst non-U.S. holder on the date of the issuance. This distribution should be treated first as a taxable dividend to the extent of the Catalyst non-U.S. holder&#8217;s pro rata share of Catalyst&#8217;s current or accumulated earnings and profits for the year of issuance (as determined for U.S. federal income tax purposes), then as a non-taxable return of capital to the extent of the Catalyst non-U.S. holder&#8217;s basis in its Catalyst Common Stock and finally as capital gain from the sale or exchange of Catalyst Common Stock with respect to any remaining amount. Catalyst is in the process of performing an analysis of its earnings and profits and some or all of the distribution could be treated as a dividend for U.S. federal income tax purposes if Catalyst determines that it has current or accumulated earnings and profits. If Catalyst cannot determine at the time of the distribution of the CVRs whether or not the amount of such distribution will exceed current and accumulated earnings and profits, Catalyst or the applicable withholding agent may withhold (potentially by utilizing other property of such Catalyst non-U.S. holder held in an account with the applicable withholding agent) at the rate applicable to dividends, as described below.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Dividend payments to a Catalyst non-U.S. holder generally will be subject to withholding at a 30% rate. If a Catalyst non-U.S. holder is eligible for a lower treaty rate, withholding will be at such lower treaty rate only if such Catalyst non-U.S. holder provides a duly executed and properly completed version of the appropriate IRS Form W-8 (or&#160;applicable successor form) certifying such Catalyst non-U.S. holder&#8217;s qualification for the reduced rate. If a Catalyst non-U.S. holder holds the stock through a financial institution or other intermediary, the Catalyst non-U.S.&#160;holder will be required to provide appropriate documentation to the intermediary, which then will be required to provide certification to the applicable withholding agent, either directly or through other intermediaries. Catalyst non-U.S. holders who do not timely provide the applicable withholding agent with the required certification, but who qualify for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Subject to the discussions below regarding FATCA (as defined below) and backup withholding, if the issuance of the CVRs is effectively connected with a Catalyst non-U.S. holder&#8217;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the Catalyst non-U.S. holder maintains a permanent establishment in the United States to which the distribution of the CVRs is attributable), the Catalyst non-U.S. holder will be exempt from U.S. federal withholding tax and the distribution of the CVRs generally will be subject to U.S.&#160;federal income tax on a net income basis in the same manner as if such Catalyst non-U.S. holder were a U.S. holder. To claim the exemption, the Catalyst non-U.S. holder must furnish to the applicable withholding agent a duly executed and properly completed version of IRS Form W-8ECI (or applicable successor form), certifying that the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">160<br></div></div></div>
<!--End Page 171-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 172-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_109-agreement_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">distribution is effectively connected with the Catalyst non-U.S. holder&#8217;s conduct of a trade or business within the United States. A Catalyst non-U.S. holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on all or a portion of its effectively connected earnings and profits for the taxable year.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Future payments, if any, to a Catalyst non-U.S. holder with respect to a CVR may also be subject to withholding at a 30% rate unless the holder establishes a reduced treaty rate or that such income is exempt from withholding because it is effectively connected with the holder&#8217;s conduct of a trade or business within the United States.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under the provisions of the Code commonly referred to as the Foreign Account Tax Compliance Act, or FATCA, the issuance of the CVRs and future payments, if any, to a Catalyst non-U.S. holder with respect to the CVRs may be subject to withholding at a rate of 30% if the Catalyst non-U.S. holder fails to satisfy prescribed certification requirements. In general, no such withholding will be required with respect to a Catalyst non-U.S. holder that timely provides certifications that establish an exemption from FATCA withholding on a duly executed and properly completed version of the appropriate IRS Form W-8. If withholding under FATCA is required, Catalyst non-U.S.&#160;holders not otherwise subject to withholding (or that otherwise would be entitled to a reduced rate of withholding) may be required to seek a refund or credit from the IRS.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Any withholding required by Catalyst or other applicable withholding agents may be satisfied by Catalyst or such agent by withholding a portion of the issued CVRs, from future payments, if any, on the CVRs, or from other property of the Catalyst non-U.S. holder held in an account with the applicable withholding agent.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">To the extent that the issuance of the CVRs is treated as capital gain from the sale or exchange of Catalyst Common Stock, such gain generally will not be subject to U.S. federal income tax unless (i)&#160;such gain is effectively connected with the conduct by a Catalyst non-U.S. holder of a trade or business in the United States (and, if an income tax treaty applies, the gain is generally attributable to a U.S. permanent establishment maintained by such Catalyst non-U.S.&#160;holder), (ii)&#160;in the case of gain realized by a Catalyst non-U.S. holder that is an individual, such Catalyst non-U.S. holder is present in the United States for 183 days or more in the taxable year of the sale and certain other conditions are met or (iii)&#160;Catalyst is or has been a United States real property holding corporation, or USRPHC, for U.S. federal income tax purposes and, if the shares are &#8220;regularly traded on an established securities market,&#8221; such Catalyst non-U.S. holder owned, directly or indirectly, at any time during the five-year period ending on the date of the distribution, more than five percent of the shares of Catalyst Common Stock and such Catalyst non-U.S. holder is not eligible for any treaty exemption. Catalyst believes it is not and has not been, a USRPHC for U.S. federal income tax purposes. In addition, although not free from doubt, Catalyst believes that shares of Catalyst Common Stock currently should be considered to be regularly traded.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Due to the legal and factual uncertainty regarding the tax treatment of the CVRs (and any future distributions pursuant to the CVRs), Catalyst non-U.S. holders are urged to consult their tax advisors concerning the recognition of gain and/or loss or withholding that may apply in connection with the CVRs and any future distributions pursuant to the CVRs.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Information Reporting and Backup Withholding </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In general, the issuance of the CVRs to Catalyst U.S. holders will be reported to the IRS unless the holder is an exempt recipient. Backup withholding, currently at a rate of 24%, may apply unless the Catalyst U.S. holder (1) is an exempt recipient or (2) provides a certificate (generally on an IRS Form W-9) containing the Catalyst U.S. holder&#8217;s name, address, correct federal taxpayer identification number and statement that the Catalyst U.S. holder is a U.S.&#160;person and is not subject to backup withholding.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">A Catalyst non-U.S. holder will not be subject to backup withholding with respect to the issuance of the CVRs, provided the Catalyst non-U.S. holder certifies its non-U.S. status, such as by providing a duly executed and properly completed version of the appropriate IRS Form W-8, or otherwise establishes an exemption. However, information returns will be filed with the IRS in connection with the issuance of the CVRs, regardless of whether any tax was actually withheld. Copies of these information returns may also be made available under the provisions of a specific treaty or agreement to the tax authorities of the country in which the Catalyst non-U.S. holder resides or is established.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or credit against a holder&#8217;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">PLEASE CONSULT YOUR TAX ADVISOR WITH RESPECT TO THE PROPER CHARACTERIZATION OF THE RECEIPT OF THE CVRs.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">161<br></div></div></div>
<!--End Page 172-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 173-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_110-executive_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCEA"><!--Anchor--></a>CATALYST EXECUTIVE AND DIRECTOR COMPENSATION </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Executive Compensation </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s named executive officers for 2022, which consist of its principal executive officer and the next two most highly compensated executive officers, are:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Nassim Usman, Ph.D., Catalyst&#8217;s President and Chief Executive Officer;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Grant Blouse, Catalyst&#8217;s Chief Scientific Officer;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Seline Miller, Catalyst&#8217;s Interim Chief Financial Officer.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;"><a name="tSCT"><!--Anchor--></a>Summary Compensation Table </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table shows for the fiscal years ended December&#160;31, 2022 and 2021 compensation awarded to or paid to Catalyst&#8217;s named executive officers. </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 25.64%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name and <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Principal Position</div></td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.27%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year</div></td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.31%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Salary ($)</div></td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.61%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; white-space: nowrap; text-align: center;">Bonus ($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; white-space: nowrap; text-align: center;">Option <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; white-space: nowrap; text-align: center;">Awards ($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Non-Equity <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Incentive Plan <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Compensation <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)</div></td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">All Other <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Compensation <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div></td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total ($)</div></td></tr><tr><td rowspan="2" style="width: 25.64%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Nassim Usman, Ph.D.<font style="font-weight: normal; padding-left: 3.36pt;"></font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-align: left;"><font style="font-weight: normal;">President and Chief </font><font style="font-weight: normal;">Executive Officer</font><br></div></td><td class="gutter" rowspan="2" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.27%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">2022</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: center; vertical-align: top; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.86pt; text-align: left;">595,000</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.16pt; text-align: left;">1,149,000</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.28pt; text-align: left;">640,434</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.63%; text-align: center; vertical-align: top; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: top; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.91pt; text-align: left;"><font style="padding-left: 5pt;">8,348</font></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">2,392,782</div></td></tr><tr><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.27%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">2021</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: center; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.86pt; text-align: left;">595,000</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.16pt; text-align: left;"></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.28pt; text-align: left;">622,642</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.63%; text-align: center; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.89pt; text-align: left;"></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.91pt; text-align: left;">&#8203;<font style="padding-left: 0.37pt;">11,600</font></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">&#8203;1,229,242</div></td></tr><tr><td rowspan="2" style="width: 25.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Grant Blouse<font style="font-weight: normal; padding-left: 4.74pt;"></font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-align: left;"><font style="font-weight: normal;">Chief Scientific Officer</font><br></div></td><td class="gutter" rowspan="2" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.27%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">2022</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: center; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.86pt; text-align: left;">414,000</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.16pt; text-align: left;">&#8203;<font style="padding-left: 7.5pt;">572,249</font></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.28pt; text-align: left;"><font style="padding-left: 5pt;">78,499</font></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.63%; text-align: center; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.89pt; text-align: left;"></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.91pt; text-align: left;">12,200</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">1,076,948</div></td></tr><tr><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.27%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">2021</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: center; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.86pt; text-align: left;">407,333</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.16pt; text-align: left;"><font style="padding-left: 12.5pt;">77,324</font></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.28pt; text-align: left;">252,037</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.63%; text-align: center; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.89pt; text-align: left;"></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.91pt; text-align: left;"><font style="padding-left: 0.37pt;">11,600</font></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">&#8203;<font style="padding-left: 7.5pt;">748,294</font></div></td></tr><tr><td rowspan="2" style="width: 25.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Seline Miller<font style="font-weight: normal; padding-left: 1.96pt;"></font><font style="font-weight: normal;"> </font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-align: left;"><font style="font-weight: normal;">Interim Chief Financial </font><font style="font-weight: normal;">Officer</font><br></div></td><td class="gutter" rowspan="2" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.27%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">2022</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: center; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.86pt; text-align: left;">&#8203;325,000</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.16pt; text-align: left;">&#8203;<font style="padding-left: 7.5pt;">370,351</font></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.28pt; text-align: left;"><font style="padding-left: 5pt;">42,210</font></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.63%; text-align: center; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.89pt; text-align: left;"></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.91pt; text-align: left;">12,200</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 7.5pt;">749,761</font></div></td></tr><tr><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.27%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">2021</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: center; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.86pt; text-align: left;">201,426</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.16pt; text-align: left;"><font style="padding-left: 12.5pt;">53,455</font></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.28pt; text-align: left;"><font style="padding-left: 5pt;">58,458</font></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.63%; text-align: center; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.89pt; text-align: left;"></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.91pt; text-align: left;"><font style="padding-left: 5pt;">6,248</font></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 7.5pt;">31</font>9,587</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 9.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The amounts paid in 2022 reflect special bonuses that were paid in connection with Catalyst&#8217;s sale of its complement-related assets to Vertex for up to $60 million and the subsequent distribution of approximately $45 million to Catalyst&#8217;s stockholders in a special dividend, as well as Catalyst&#8217;s distribution of approximately $7.5 million to its stockholders as a special dividend, along with the distribution to Catalyst&#8217;s stockholders of a CVR.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The amounts in this column reflect the aggregate grant date fair value of options awarded during the year calculated in accordance with Financial Accounting Standards Board Accounting Standards Codification Compensation-Stock Compensation (Topic 718), or ASC 718, disregarding the potential for forfeitures, regardless of the period in which the corresponding compensation expense was recorded in accordance with ASC 718.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The amount in this column for Dr. Usman, Dr. Blouse and Ms. Miller represent Catalyst 401(k) plan matches.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">162<br></div></div></div>
<!--End Page 173-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 174-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_110-executive_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Outstanding Equity Awards at Fiscal Year-End</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table provides information regarding unexercised stock options held by each of the named executive officers as of the end of fiscal year 2022, which reflects adjustments to the exercise price and the number of shares subject to each stock option that were made in connection with certain changes in Catalyst&#8217;s capitalization that occurred on or prior to the end of fiscal year 2022, as required pursuant to the terms of the applicable equity plan. This information does not give effect to the proposed Reverse Stock Split or the payment of the special, one-time cash dividend payment of $1.43 per share to holders of its common stock and on January&#160;31, 2023.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 30.77%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div></td><td class="gutter" style="width: 2.43%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.43%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Grant Date</div></td><td class="gutter" style="width: 2.43%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.43%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.89%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Securities <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Underlying <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unexercised <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Option <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercisable <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(#)</div></td><td class="gutter" style="width: 2.43%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.43%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Securities <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Underlying <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unexercised <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Option <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unexercisable <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(#)</div></td><td class="gutter" style="width: 2.43%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.43%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.36%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Option <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercise <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Price ($)</div></td><td class="gutter" style="width: 2.43%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.43%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.73%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Option <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Expiration <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Date</div></td></tr><tr><td rowspan="9" style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Nassim Usman, Ph.D.<font style="padding-left: 1.25pt;"></font></div></td><td class="gutter" rowspan="9" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">8/20/2015</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)(2)</sup></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.56pt; text-align: left;"><font style="padding-left: 10pt;">5,705</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.91pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.62pt; text-align: left;">45.43</div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">1/3/2023</font></div></td></tr><tr><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10/22/2015<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)(3)</sup></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.56pt; text-align: left;"><font style="padding-left: 5pt;">57,053</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.91pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.62pt; text-align: left;">17.36</div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">10/22/2025</div></td></tr><tr><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5.37pt;">7/11/2017</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.56pt; text-align: left;">988,193</div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.91pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.62pt; text-align: left;"><font style="padding-left: 5pt;">1.22</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5.37pt;">7/11/2027</font></div></td></tr><tr><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">1/12/2018 </font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.56pt; text-align: left;">361,372</div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.91pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.62pt; text-align: left;"><font style="padding-left: 5pt;">3.98</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">1/12/2028</font></div></td></tr><tr><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">7/30/2018</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.56pt; text-align: left;">285,294</div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.91pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.62pt; text-align: left;"><font style="padding-left: 5pt;">2.55</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">7/30/2028</font></div></td></tr><tr><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">1/24/2019</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(7)</sup></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.56pt; text-align: left;">297,972</div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.91pt; text-align: left;"><font style="padding-left: 17.5pt;">6,341</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.62pt; text-align: left;"><font style="padding-left: 5pt;">2.10</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">1/24/2029</font></div></td></tr><tr><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">1/23/2020</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(8)</sup></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.56pt; text-align: left;">318,975</div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.91pt; text-align: left;"><font style="padding-left: 7.87pt;">118,475</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.62pt; text-align: left;"><font style="padding-left: 5pt;">1.81</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">1/23/2030</font></div></td></tr><tr><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">2/8/2021</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(9)</sup></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.56pt; text-align: left;">244,088</div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.91pt; text-align: left;"><font style="padding-left: 7.5pt;">288,460</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.62pt; text-align: left;"><font style="padding-left: 5pt;">1.55</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">2/8/2031</font></div></td></tr><tr><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">6/1/2022</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(10)</sup></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.56pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.91pt; text-align: left;">1,521,568</div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.62pt; text-align: left;"><font style="padding-left: 5pt;">0.32</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">6/1/2032</font></div></td></tr><tr><td rowspan="7" style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Grant Blouse, Ph.D.<font style="padding-left: 4.03pt;"></font></div></td><td class="gutter" rowspan="7" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">7/16/2018</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(11)</sup></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.56pt; text-align: left;"><font style="padding-left: 0.73pt;">114,117</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.91pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.62pt; text-align: left;"><font style="padding-left: 5pt;">3.21</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">7/16/2028</font></div></td></tr><tr><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">7/30/2018</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(12)</sup></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.56pt; text-align: left;"><font style="padding-left: 5pt;">38,038</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.91pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.62pt; text-align: left;"><font style="padding-left: 5pt;">2.55</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">7/30/2028</font></div></td></tr><tr><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">1/24/2019</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(13)</sup></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.56pt; text-align: left;"><font style="padding-left: 5pt;">67,043</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.91pt; text-align: left;"><font style="padding-left: 17.5pt;">1,426</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.62pt; text-align: left;"><font style="padding-left: 5pt;">2.10</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">1/24/2029</font></div></td></tr><tr><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">1/23/2020</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(14)</sup></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.56pt; text-align: left;"><font style="padding-left: 5pt;">97,079</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.91pt; text-align: left;"><font style="padding-left: 12.5pt;">36,057</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.62pt; text-align: left;"><font style="padding-left: 5pt;">1.81</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">1/23/2029</font></div></td></tr><tr><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">2/8/2021</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(9)</sup></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.56pt; text-align: left;"><font style="padding-left: 5pt;">67,122</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.91pt; text-align: left;"><font style="padding-left: 12.5pt;">79,328</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.62pt; text-align: left;"><font style="padding-left: 5pt;">1.55</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">2/8/2031</font></div></td></tr><tr><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">6/16/2021</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(15)</sup></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.56pt; text-align: left;"><font style="padding-left: 5pt;">35,660</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.91pt; text-align: left;"><font style="padding-left: 12.5pt;">59,437</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.62pt; text-align: left;"><font style="padding-left: 5pt;">1.14</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">6/16/2031</font></div></td></tr><tr><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5.37pt;">2/11/2022</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(16)</sup></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.56pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.91pt; text-align: left;"><font style="padding-left: 7.5pt;">760,783</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.62pt; text-align: left;"><font style="padding-left: 5pt;">0.14</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5.37pt;">2/11/2032</font></div></td></tr><tr><td rowspan="2" style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Seline Miller<font style="padding-left: 3.18pt;"></font></div></td><td class="gutter" rowspan="2" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">4/15/2021</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(17)</sup></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.56pt; text-align: left;"><font style="padding-left: 5pt;">26,617</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.91pt; text-align: left;"><font style="padding-left: 12.5pt;">34,245</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.62pt; text-align: left;"><font style="padding-left: 5pt;">1.27</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">4/15/2031</font></div></td></tr><tr><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5.37pt;">2/11/2022</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(16)</sup></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.56pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.91pt; text-align: left;"><font style="padding-left: 7.5pt;">408,921</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.62pt; text-align: left;"><font style="padding-left: 5pt;">0.14</font></div></td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5.37pt;">2/11/2032</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">These stock options were granted by Catalyst&#8217;s board of directors on the grant dates listed, but were assumed by Catalyst upon the closing of the merger on August&#160;20, 2015 and converted into options to purchase common stock of Catalyst as described in the table.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">These options became fully vested on August&#160;20, 2019. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">These options became fully vested on September&#160;1, 2019.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">These options became fully vested on June&#160;15, 2021.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(5)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The options became fully vested on January&#160;12, 2022.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(6)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The options became fully vested on June&#160;13, 2022.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(7)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The remaining portion of these options to purchase common stock vests at the rate of 1/48th of the total number of shares subject to the option on the 24th day of each month, with the final tranche vesting on January&#160;24, 2023.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(8)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The remaining portion of these options to purchase common stock vests at the rate of 1/48th of the total number of shares subject to the option on the 23rd day of each month, with the final tranche vesting on January&#160;23, 2024.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(9)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The remaining portion of these options to purchase common stock vests at the rate of 1/48th of the total number of shares subject to the option on the 8th day of each month, with the final tranche vesting on February&#160;8, 2025.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(10)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">This option grant is subject to vesting upon the attainment of milestones established by the compensation committee of Catalyst&#8217;s board of directors (the &#8220;Compensation Committee&#8221;), none of which milestones has occurred.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(11)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The options became fully vested on July&#160;2, 2022.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(12)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The options became fully vested on July&#160;1, 2022.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(13)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The remaining portion of these options to purchase common stock vests at the rate of 1/48th of the total number of shares subject to the option on the 24th day of each month, with the final tranche vesting on January&#160;24, 2023.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(14)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The remaining portion of these options to purchase common stock vests at the rate of 1/48th of the total number of shares subject to the option on the 23rd day of each month, with the final tranche vesting on January&#160;23, 2024.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(15)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The remaining portion of these options to purchase common stock vests at the rate of 1/48th of the total number of shares subject to the option on the 16th day of each month thereafter, with the final tranche vesting on June&#160;16, 2025.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">163<br></div></div></div>
<!--End Page 174-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 175-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_110-executive_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5.25pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(16)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">These options to purchase common stock vest at the rate of 1/4 of the total number of shares subject to the option on February&#160;11, 2023 and at the rate of 1/48th of the total number of shares subject to the option on the 11th day of each month thereafter, with the final tranche vesting on February&#160;11, 2026.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(17)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The remaining portion of these options to purchase common stock vests at the rate of 1/48th of the total number of shares subject to the option on the 29th day of each month thereafter, with the final tranche vesting on March&#160;29, 2025.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;"><a name="tPCA1"><!--Anchor--></a>Post-Closing Arrangements</div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the Contributions, Catalyst&#8217;s board of directors is expected to adopt the 2023 Omnibus Incentive Plan, subject to stockholder approval, in order to facilitate the grant of equity awards to attract, retain and incentivize employees (including its named executive officers). Please see the section entitled &#8220;<font style="font-style: italic;">Proposal No. 6 &#8211; Approval of the </font><font style="font-style: italic;">2023 Omnibus Incentive Plan</font>&#8221; for a summary of the material terms of the 2023 Omnibus Incentive Plan. Immediately following the consummation of the Contributions, the combined company&#8217;s board of directors is expected to approve grants of awards of fully vested stock options under the 2023 Omnibus Incentive Plan representing the following percentages of the outstanding shares of the combined company, on a fully diluted basis assuming conversion of the Catalyst Convertible Preferred Stock and including the outstanding options of Catalyst, the Gyre Options to be granted in respect of the BC Options and such grants, to Nassim Usman, Ph.D. (0.33%) and Seline Miller (0.07%), as well as to Thomas Eastling (0.33%), Ruoyu Chen (a current GNI consultant who is expected to serve as Interim Chief Financial Officer of the combined company following the Contributions) (0.03%) and one other GNI consultant (0.03%), for contributions to realizing the successful completion of the entire transaction. The approximate grant date fair value of such grants are as follows: Nassim Usman, Ph.D. ($841,820), Seline Miller ($169,423), Thomas Eastling ($841,820), Ruoyu Chen ($84,711) and one other GNI consultant ($84,711).</div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Seline Miller will cease serving as Catalyst&#8217;s interim Chief Financial Officer at the Effective Time and, following the consummation of the Contributions, will not continue as an executive officer of the combined company. Ms. Miller entered into an amendment to her employment agreement with Catalyst providing that, if Ms. Miller experiences a qualifying termination after August 31, 2023, she will continue to receive payment of her base salary for nine months from such termination date, and if Ms. Miller experiences a qualifying termination prior to August 31, 2023, she will receive continued payment of her base salary until May 31, 2024, and in each case, continued vesting of stock options for the duration of the applicable severance period. Additionally, Ms. Miller has entered into a consulting agreement with Catalyst providing that, in her capacity as a consultant and reporting to the Chief Financial Officer or the Interim Chief Financial Officer of the combined company (as applicable), Ms. Miller will provide integration and transition assistance commencing upon the closing of the Contributions until March 31, 2024, at a rate of $350 per hour, provided that, if the amount aggregate of consulting fees paid to Ms. Miller under her consulting agreement is less than $100,000 as of March 31, 2024, Catalyst will, on such date, pay Ms. Miller the an amount equal to the difference between $100,000 and the amount of such aggregate consulting fees previously paid. Upon the closing of the Contributions, Ms.&#160;Miller will also be awarded an additional stock option under the 2023 Omnibus Incentive Plan for 100,000 shares of common stock pursuant to the terms of the consulting agreement, which will become vested, if at all, on March 31, 2024, subject to Ms. Miller&#8217;s continued service to Catalyst pursuant to her consulting agreement through such date. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Limitation of Liability and Indemnification </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst has entered into indemnification agreements with each of its directors and with each executive officer. Pursuant to the indemnification agreements, Catalyst has agreed to indemnify and hold harmless these directors and officers to the fullest extent permitted by the DGCL. The agreements generally cover expenses that a director or officer incurs or amounts that a director or officer becomes obligated to pay because of any proceeding to which he or she is made or threatened to be made a party or participant by reason of his or her service as a current or former director, officer, employee or agent of Catalyst. The agreements also provide for the advancement of expenses to the directors and officers subject to specified conditions. There are certain exceptions to Catalyst&#8217;s obligation to indemnify the directors and officers, including any intentional malfeasance or act where the director or officer did not in good faith believe he or she was acting in Catalyst&#8217;s best interests, with respect to &#8220;short-swing&#8221; profit claims under Section 16(b) of the Exchange Act and, with certain exceptions, with respect to proceedings that he or she initiates.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">164<br></div></div></div>
<!--End Page 175-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 176-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_110-executive_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Director Compensation </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Until 2022, pursuant to Catalyst&#8217;s non-employee directors&#8217; compensation policy (directors who are Catalyst employees do not receive any compensation for their service on Catalyst&#8217;s board of directs), Catalyst&#8217;s non-employee directors were eligible to receive the following:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Initial Equity Grants. Each non-employee director who joins Catalyst&#8217;s board of directors received an option to purchase 28,000 shares of common stock, which will vest over three years, subject to continued service.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Annual Retainers. Each non-employee director received an annual retainer for service on Catalyst&#8217;s board of directors consisting of an option to purchase 14,000 shares of common stock, to be awarded at Catalyst&#8217;s annual stockholders&#8217; meeting and which will vest over one year. However, due to the changes in Catalyst&#8217;s business, no annual option grants were awarded in connection with Catalyst&#8217;s 2022 Annual Meeting of Stockholders. Such awards were in addition to annual cash retainers for service on Catalyst&#8217;s board of directors and committees of Catalyst&#8217;s board of directors, or for service as chair of Catalyst&#8217;s board of directors or such committees (inclusive of retainers for service as a member), which were paid quarterly in the amounts as follows:</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 79.49%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additional annual retainer fees for service as member or chair of</div></td><td class="gutter" style="width: 1.66%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.66%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Member</div></td><td class="gutter" style="width: 1.66%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.66%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Chair</div></td></tr><tr><td style="width: 79.49%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Board of Directors<font style="padding-left: 2.87pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$40,000</div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$75,000</div></td></tr><tr><td style="width: 79.49%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Audit Committee<font style="padding-left: 3.95pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 5pt;">9,000</font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$18,000</div></td></tr><tr><td style="width: 79.49%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Compensation Committee<font style="padding-left: 3.96pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 5pt;">7,000</font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$14,000</div></td></tr><tr><td style="width: 79.49%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Governance and Nominating Committee<font style="padding-left: 4.55pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 5pt;">5,000</font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$10,000</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to a policy approved by the Catalyst&#8217;s then-board of directors, each director may elect to receive some or all of his or her retainer service fees in the form of fully vested shares of Catalyst Common Stock.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Director Compensation for 2022</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table shows for the year ended December&#160;31, 2022 certain information with respect to the compensation of Catalyst&#8217;s non-employee directors serving during 2022. For information regarding compensation paid to Nassim Usman, Ph.D., see the &#8220;<font style="font-style: italic;">Summary Compensation Table</font>&#8221; on page <a href="#tSCT">162</a>.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 51.28%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div></td><td class="gutter" style="width: 1.16%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.16%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.15%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fees Earned or <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Paid in Cash ($)</div></td><td class="gutter" style="width: 1.16%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.16%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.17%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Option Awards <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)(2)</sup></div></td><td class="gutter" style="width: 1.16%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.16%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.78%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stock Grants<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)</div></td><td class="gutter" style="width: 1.16%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.16%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.3%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total ($)</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Augustine Lawlor<font style="padding-left: 4.19pt;"></font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.15%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.69pt; text-align: left;">91,000</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.17%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.15pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.78%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.89pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.98pt; text-align: left;">91,000</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Andrea Hunt<font style="padding-left: 4.74pt;"></font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.15%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.69pt; text-align: left;">50,000</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.17%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.15pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.78%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.89pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.98pt; text-align: left;">50,000</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Eddie Williams<font style="padding-left: 4.76pt;"></font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.15%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.69pt; text-align: left;">45,000</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.17%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.15pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.78%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.89pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.98pt; text-align: left;">45,000</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Errol B. De Souza<font style="padding-left: 1.7pt;"></font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.15%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.69pt; text-align: left;">59,000</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.17%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.15pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.78%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.89pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.98pt; text-align: left;">59,000</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Geoffrey Ling<font style="padding-left: 4.37pt;"></font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.15%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.69pt; text-align: left;">47,000</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.17%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.15pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.78%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.89pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.98pt; text-align: left;">47,000</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jeanne Jew<font style="padding-left: 1.42pt;"></font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.15%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.69pt; text-align: left;">49,000</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.17%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.15pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.78%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.89pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.98pt; text-align: left;">49,000</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sharon Tetlow<font style="padding-left: 3.39pt;"></font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.15%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.69pt; text-align: left;">58,000</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.17%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.15pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.78%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.89pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.98pt; text-align: left;">58,000</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 8.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The amounts in this column reflect the aggregate grant date fair value of stock options granted during the fiscal year ended December&#160;31, 2022 calculated in accordance with ASC 718, disregarding the potential for forfeitures.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The following table sets forth the aggregate number of option awards held by each non-employee director serving in 2022 as of December&#160;31, 2022:</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 428pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 78.5%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div></td><td class="gutter" style="width: 3.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 3.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 15.38%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Aggregate Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Option Awards</div></td></tr><tr><td style="width: 78.5%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Augustine Lawlor<font style="padding-left: 0.36pt;"></font></div></td><td class="gutter" style="width: 3.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 19.91pt; text-align: left;">154,054</div></td></tr><tr><td style="width: 78.5%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Andrea Hunt<font style="padding-left: 1.8pt;"></font></div></td><td class="gutter" style="width: 3.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 19.91pt; text-align: left;">148,350</div></td></tr><tr><td style="width: 78.5%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Eddie Williams<font style="padding-left: 3.8pt;"></font></div></td><td class="gutter" style="width: 3.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 19.91pt; text-align: left;">148,350</div></td></tr><tr><td style="width: 78.5%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Errol B. De Souza<font style="padding-left: 3.37pt;"></font></div></td><td class="gutter" style="width: 3.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 19.91pt; text-align: left;">157,218</div></td></tr><tr><td style="width: 78.5%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Geoffrey Ling<font style="padding-left: 2.51pt;"></font></div></td><td class="gutter" style="width: 3.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 19.91pt; text-align: left;">109,255</div></td></tr><tr><td style="width: 78.5%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jeanne Y. Jew<font style="padding-left: 3.03pt;"></font></div></td><td class="gutter" style="width: 3.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 19.91pt; text-align: left;"><font style="padding-left: 4pt;">44,385</font></div></td></tr><tr><td style="width: 78.5%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sharon Tetlow<font style="padding-left: 1.72pt;"></font></div></td><td class="gutter" style="width: 3.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 19.91pt; text-align: left;">109,255</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Contributions-related Compensation of Named Executive Officer</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table and the related footnotes present information about the compensation payable to Catalyst&#8217;s named executive officers. The compensation shown in the table below is intended to comply with Item 402(t) of </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">165<br></div></div></div>
<!--End Page 176-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 177-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_110-executive_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Regulation S-K, which requires disclosure of information about compensation for each named executive officer that is based on or otherwise relates to the Contributions. The cash and perquisites/benefits disclosure provided by this table is quantified assuming that the following events occur on May&#160;15, 2023, the latest practicable date prior to the filing of this proxy statement: (i)&#160;the consummation of the Contributions and (ii)&#160;each of Dr. Usman and Ms.&#160;Miller experience a &#8220;qualifying termination&#8221; (as defined below) immediately following the consummation of the Contributions. The equity disclosure provided in this table is quantified assuming that the consummation of the Contributions occurs on May&#160;15, 2023, the latest practicable date prior to the filing of this proxy statement. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As used in the discussion below, &#8220;single-trigger&#8221; refers to benefits that arise solely as a result of the consummation of the Contributions (regardless of whether a qualifying termination has occurred) and &#8220;double-trigger&#8221; refers to benefits that require two conditions, which are the consummation of the Contributions, as well as a qualifying termination following the consummation of the Contributions.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s named executive officers are not entitled to any pension or non-qualified deferred compensation benefits enhancements, or any other form of compensation that is based on or otherwise related to the Contributions.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Please note that the amounts indicated below are estimates based on multiple assumptions that may or may not actually occur (including assumptions described in this proxy statement) or may occur at times different than the time assumed. Some of these assumptions are based on information not currently available and, as a result, the actual amounts, if any, to be received by Catalyst&#8217;s named executive officers may differ in material respects from the amounts set forth below. </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div></td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cash <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Equity <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.4%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Perquisites/Benefits <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div></td><td class="gutter" style="width: 1.29%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.29%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Nassim Usman, Ph.D.<font style="padding-left: 1.25pt;"></font></div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">595,000</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.94%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.56pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.4%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.94pt; text-align: left;">96,860</div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">691,860</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Grant Blouse<font style="padding-left: 2.63pt;"></font></div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">257,375</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.94%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.56pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.4%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.94pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">257,375</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Seline Miller<font style="padding-left: 3.18pt;"></font></div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">243,750</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.94%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.56pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.4%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.94pt; text-align: left;">55,018</div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">298,768</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 9.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The amounts in this column for Dr. Usman and Ms.&#160;Miller represent potential cash severance payments that Dr. Usman and Ms.&#160;Miller will be entitled to receive only upon a termination without &#8220;cause&#8221; or as a result of &#8220;constructive termination,&#8221; (as each such terms is defined in their respective employment agreements) (each referred to herein as a &#8220;qualifying termination&#8221;). Dr. Usman&#8217;s amended and restated employment agreement, as modified by that certain Waiver Agreement dated January 17, 2023 (the &#8220;Usman Employment Agreement&#8221;), and Ms.&#160;Miller&#8217;s employment agreement, as modified by that certain Waiver Agreement dated January 17, 2023, and as further amended thereafter (the &#8220;Miller Employment Agreement&#8221;), provide for the following potential cash severance payments upon a qualifying termination: (i)&#160;for Dr. Usman, base salary continuation for the 12 month-period immediately following the termination date (the &#8220;Usman Severance Period&#8221;); and (ii)&#160;for Ms.&#160;Miller, base salary continuation for the Miller Severance Period, in each case, payable in accordance with Catalyst&#8217;s standard payroll practice following the effective date of the release described below. As a condition to receiving the severance benefits set forth in the table above, Dr. Usman and Ms.&#160;Miller must enter into a separation agreement and execute a full and irrevocable waiver and release of all claims in Catalyst&#8217;s favor. Payment of certain of these amounts may also be subject to required six-month delays under Section 409A of the Code. The cash severance payments described above for Dr. Usman and Ms.&#160;Miller would not be considered &#8220;single trigger&#8221; or &#8220;double trigger&#8221; because they are payable upon the occurrence of any qualifying termination, regardless of whether the consummation of the Contributions has also occurred.</div></td></tr></table><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 20pt; text-align: justify;">The amount in this column for Mr.&#160;Blouse represents cash severance payments that will accelerate under Mr.&#160;Blouse&#8217;s separation agreement in connection with the consummation of the Contributions. In connection with Mr.&#160;Blouse&#8217;s termination of employment with Catalyst on January&#160;15, 2023, Mr.&#160;Blouse entered into a separation agreement providing for base salary continuation for the 9-month period following his termination (the &#8220;Blouse Severance Period&#8221;); provided that, if the consummation of the Contributions occurs during the Blouse Severance Period, any then unpaid portion of Mr.&#160;Blouse&#8217;s cash severance will be paid in a lump sum within 30 days following the consummation of the Contributions. As a condition to receiving the severance benefits set forth in the table above, Mr.&#160;Blouse was required to execute a full and irrevocable waiver and release of all claims in Catalyst&#8217;s favor, which was included in Mr.&#160;Blouse&#8217;s separation agreement. The accelerated cash severance payments described above for Mr.&#160;Blouse would not be considered &#8220;single trigger&#8221; or &#8220;double trigger&#8221; because they will be payable to Mr.&#160;Blouse pursuant to the terms of his separation agreement regardless of whether the consummation of the Contributions occurs. Mr.&#160;Blouse&#8217;s separation agreement does not provide for any additional payments or benefits in connection with the consummation of the Contributions.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">These amounts represent the estimated intrinsic value of Dr. Usman&#8217;s and Ms.&#160;Miller&#8217;s unvested stock options that will accelerate upon a qualifying termination. The Usman Employment Agreement and the Miller Employment Agreement each provide that all unvested options that would have vested during the Usman Severance Period or the Miller Severance Period, as applicable, had Dr. Usman and Ms. Miller remained employed during such periods will immediately vest upon a qualifying termination. As a condition to receiving the accelerated vesting described above, Dr. Usman and Ms.&#160;Miller must enter into a separation agreement and execute a full and irrevocable waiver and release of all claims in Catalyst&#8217;s favor. The accelerated vesting benefits described above for Dr. Usman and Ms.&#160;Miller would not be considered &#8220;single trigger&#8221; or &#8220;double trigger&#8221; because the accelerated vesting would occur upon the occurrence of any qualifying termination, regardless of whether the consummation of the Contributions has also occurred.</div></td></tr></table><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 20pt; text-align: justify;">&#8220;Intrinsic value&#8221; with respect to Dr. Usman&#8217;s and Ms.&#160;Miller&#8217;s unvested stock options refers, in accordance with Item 402(t), to the excess of the average closing market price of Catalyst&#8217;s common stock over the first 5 business days following December&#160;27, 2022, the date of the first announcement of the Contributions, over the exercise price of the Catalyst stock options held by Dr. Usman and Ms.&#160;Miller that were unvested as of May&#160;15, 2023. Because the exercise price of each Catalyst stock option held by Dr. Usman and Ms.&#160;Miller that was unvested as of May&#160;15, 2023 exceeded the average closing market price of Catalyst&#8217;s common stock over the first 5 business days following December&#160;27, 2022, the amount reported in the table above for Dr. Usman and Ms.&#160;Miller is $0. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">166<br></div></div></div>
<!--End Page 177-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 178-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_110-executive_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5.25pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The amounts in this column for Dr. Usman and Ms.&#160;Miller represent the value of COBRA benefits Dr. Usman and Ms.&#160;Miller will be entitled to receive only upon a qualifying termination. The Usman Employment Agreement and the Miller Employment Agreement each provide that if the applicable executive experiences a qualifying termination during the 6-month period prior to, or the 18-month period following, a change in control (which includes the consummation of the Contributions), and the executive elects to continue company health insurance coverage under COBRA, Catalyst will pay the same portion of the executive&#8217;s monthly premium under COBRA as it pays for active employees until the earliest of (i)&#160;the date that is 18 months (for Dr. Usman) or 12 months (for Ms.&#160;Miller) following termination, (ii)&#160;the expiration of the executive&#8217;s continuation coverage under COBRA or (iii)&#160;the date when the executive becomes eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment. As a condition to receiving the COBRA benefits described above, Dr. Usman and Ms.&#160;Miller must each enter into a separation agreement and execute a full and irrevocable waiver and release of all claims in Catalyst&#8217;s favor. Certain of these amounts may also be subject to required six-month delays under Section 409A of the Code. The COBRA benefits described above for Dr. Usman and Ms.&#160;Miller are considered &#8220;double trigger&#8221; payments because they will only be paid in connection with the occurrence of a qualifying termination that occurs during the 6-month period prior to, or the 18-month period following, the consummation of the Contributions.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">167<br></div></div></div>
<!--End Page 178-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 179-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_111-pvp_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Hedging and Pledging Policy</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under the terms of Catalyst&#8217;s insider trading policy, no employees, contractors, consultants and members of Catalyst&#8217;s board of directors (and their respective family members and any affiliated entities) may engage in hedging or monetization transactions involving Catalyst&#8217;s securities, such as contingent or forward contracts, collars and other similar or related arrangements. In addition, such persons may not hold Catalyst&#8217;s securities in a margin account or pledge our securities as collateral. This policy covers equity securities that are granted to the employee or director as compensation or held, directly or indirectly, by the employee or director.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Pay Versus Performance</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item&#160;402(v)&#160;of Regulation S-K, we are providing the following information about the relationship between executive compensation actually paid and certain financial performance of Catalyst. Because Catalyst is a smaller reporting company, in accordance with the smaller reporting company rules under Item 402(v)&#160;of Regulation S-K, Catalyst has provided the information required by Item 402(v)&#160;of Regulation S-K for two fiscal years and is not required to provide disclosures under Item 402(v)(2)(iv), (v)(5), (v)(2)(vi)&#160;or (v)(6).</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td rowspan="2" style="width: 30.77%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Year</div></td><td class="gutter" rowspan="2" style="width: 0.78%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 0.78%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 11.05%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Summary <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Compensation <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Table Total for <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">PEO<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup></div></td><td class="gutter" rowspan="2" style="width: 0.78%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 0.78%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 10.54%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Compensation <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Actually Paid <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">to PEO<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup></div></td><td class="gutter" rowspan="2" style="width: 0.78%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 0.78%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 11.05%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Summary <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Compensation <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Table Total for <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Non-PEO <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">NEOs<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup></div></td><td class="gutter" rowspan="2" style="width: 0.78%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 0.78%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 10.54%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Compensation <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Actually Paid <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">to Non-PEO <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">NEOs<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4</sup></div></td><td class="gutter" rowspan="2" style="width: 0.78%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.78%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.12%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Initial Fixed <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">$100 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Investment <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Based On:</div></td><td class="gutter" style="width: 0.78%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 0.78%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 7.57%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Net <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Income <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(millions)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">6</sup></div></td></tr><tr class="header"><td class="gutter" style="width: 0.78%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.12%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shareholder <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Return<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">5</sup></div></td><td class="gutter" style="width: 0.78%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td></tr><tr><td style="width: 30.77%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">(a)<br></div></td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.05%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">(b)</div></td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">(c)</div></td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.05%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">(d)</div></td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">(e)</div></td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.12%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">(f)</div></td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.57%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">(h)</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2022<font style="padding-left: 1.5pt;"></font></div></td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.05%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.35pt; text-align: left;">$2,105,532</div></td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.16pt; text-align: left;">$1,763,799</div></td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.05%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.1pt; text-align: left;">$795,530</div></td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.16pt; text-align: left;">$1,090,213</div></td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.58pt; text-align: left;">$32.24</div></td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.47pt; text-align: left;">($<font style="padding-left: 5pt;">8.2)</font></div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2021<font style="padding-left: 1.5pt;"></font></div></td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.05%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.35pt; text-align: left;">$1,235,751</div></td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.16pt; text-align: left;">$<font style="padding-left: 12.5pt;">88,374</font></div></td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.05%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.1pt; text-align: left;">$579,478</div></td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.16pt; text-align: left;">$<font style="padding-left: 7.5pt;">154,959</font></div></td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.58pt; text-align: left;">$14.48</div></td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.47pt; text-align: left;">($87.9)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">1.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The dollar amounts reported in column (b) are the amounts of total compensation reported for Dr. Usman (Catalyst&#8217;s President and Chief Executive Officer) for each corresponding year in the &#8220;Total&#8221; column of the Summary Compensation Table. Refer to &#8220;Catalyst Executive and Director Compensation &#8211; Executive Compensation &#8211; Summary Compensation Table.&#8221;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">2.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The dollar amounts reported in column (c) represent the amount of &#8220;compensation actually paid&#8221; to Dr. Usman, as computed in accordance with Item 402(v)&#160;of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Dr. Usman during the applicable year. In accordance with the requirements of Item 402(v)&#160;of Regulation S-K, the following adjustments were made to Dr. Usman&#8217;s total compensation for each year to determine the compensation actually paid:</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 42.06%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Year</div></td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.08%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Reported <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Summary <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Compensation <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Table Total for <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">PEO</div></td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.7%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Reported <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value of Equity <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Awards<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(a)</sup></div></td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Equity <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Award <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(b)</sup></div></td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.52%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Compensation <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Actually Paid <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">to PEO</div></td></tr><tr><td style="width: 42.06%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2022<font style="padding-left: 2pt;"></font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.85pt; text-align: left;">$2,105,532 </div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.7%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 12.18pt; text-align: left;">$640,434</div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 10.43pt; text-align: left;">$298,701</div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 6.66pt; text-align: left;">$1,763,799</div></td></tr><tr><td style="width: 42.06%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2021<font style="padding-left: 2pt;"></font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.85pt; text-align: left;">$1,235,751 </div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.7%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 12.18pt; text-align: left;">$622,642</div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 10.43pt; text-align: left;">($524,735)</div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 6.66pt; text-align: left;">$<font style="padding-left: 10pt;">88,374</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The grant date fair value of equity awards represents the total of the amounts reported in the &#8220;Option Awards&#8221; column in the Summary Compensation Table for the applicable year.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">168<br></div></div></div>
<!--End Page 179-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 180-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_111-pvp_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5.25pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(b)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The equity award adjustments for each applicable year include the addition (or subtraction, as applicable) of the following: (i)&#160;the year-end fair value of any equity awards granted in the applicable year that are outstanding and unvested as of the end of the year; (ii)&#160;the amount of change as of the end of the applicable year (from the end of the prior fiscal year) in fair value of any awards granted in prior years that are outstanding and unvested as of the end of the applicable year; (iii)&#160;for awards that are granted and vest in same applicable year, the fair value as of the vesting date; (iv)&#160;for awards granted in prior years that vest in the applicable year, the amount equal to the change as of the vesting date (from the end of the prior fiscal year) in fair value; (v)&#160;for awards granted in prior years that are determined to fail to meet the applicable vesting conditions during the applicable year, a deduction for the amount equal to the fair value at the end of the prior fiscal year; and (vi)&#160;the dollar value of any dividends or other earnings paid on stock or option awards in the applicable year prior to the vesting date that are not otherwise reflected in the fair value of such award or included in any other component of total compensation for the applicable year. The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. The amounts deducted or added in calculating the equity award adjustments are as follows:</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 437.02pt; margin-left: 30pt;"><tr class="header"><td style="width: 19.22%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Year</div></td><td class="gutter" style="width: 0.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.31%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year End <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair Value <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of Equity <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Awards</div></td><td class="gutter" style="width: 0.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.76%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year over <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair Value <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Outstanding <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">and <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unvested <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Equity <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Awards </div></td><td class="gutter" style="width: 0.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value as <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of Vesting <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Date of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Equity <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Awards Granted <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">and <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Vested in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">the Year</div></td><td class="gutter" style="width: 0.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year over <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair Value <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of Equity <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Awards <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Granted in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Prior <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Years that <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Vested in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">the Year</div></td><td class="gutter" style="width: 0.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.35%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair Value <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">at the End <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of the Prior <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Equity <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Awards <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">that Failed <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">to Meet <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Vesting <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Conditions <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in the Year</div></td><td class="gutter" style="width: 0.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.86%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dividends or <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">other Earnings <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Paid on Stock <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">or Option <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Awards not <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Otherwise <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Reflected in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair Value or <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Compensation</div></td><td class="gutter" style="width: 0.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.96%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total Equity <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Award <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments</div></td></tr><tr><td style="width: 19.22%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2022<font style="padding-left: 1pt;"></font></div></td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 5.15pt; text-align: left;">$<font style="padding-left: 14pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 6.33pt; text-align: left;">$<font style="padding-left: 4pt;">72,434</font></div></td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 22.8pt; text-align: left;">$ &#8212;</div></td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;">$226,267</div></td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 14.43pt; text-align: left;">$ &#8212;</div></td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 19.92pt; text-align: left;">$ &#8212;</div></td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 6.76pt; text-align: left;">$298,701</div></td></tr><tr><td style="width: 19.22%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2021<font style="padding-left: 1pt;"></font></div></td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 5.15pt; text-align: left;">$48,280</div></td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 6.33pt; text-align: left;">($404,024)</div></td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 22.8pt; text-align: left;">$ &#8212;</div></td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;">($168,992)</div></td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 14.43pt; text-align: left;">$ &#8212;</div></td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 19.92pt; text-align: left;">$ &#8212;</div></td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 6.76pt; text-align: left;">($524,735)</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">3.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The dollar amounts reported in column (d) represent the average of the amounts reported for Catalyst&#8217;s named executive officers (NEOs) as a group (excluding Dr. Usman, who has served as our CEO since 2015) in the &#8220;Total&#8221; column of the Summary Compensation Table in each applicable year. The names of each of the NEOs (excluding Dr. Usman) included for purposes of calculating the average amounts in each applicable year are as follows: (i)&#160;for 2022, Grant Blouse and Seline Miller; and (ii)&#160;for 2021, Grant Blouse, Seline Miller, Clinton Musil and Howard Levy.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">4.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The dollar amounts reported in column (e) represent the average amount of &#8220;compensation actually paid&#8221; to the NEOs as a group (excluding Dr.&#160;Usman), as computed in accordance with Item 402(v)&#160;of Regulation S-K. The dollar amounts do not reflect the actual average amount of compensation earned by or paid to the NEOs as a group (excluding Dr. Usman) during the applicable year. In accordance with the requirements of Item 402(v)&#160;of Regulation S-K, the following adjustments were made to average total compensation for the NEOs as a group (excluding Dr.&#160;Usman) for each year to determine the compensation actually paid, using the same methodology described above in Note 2:</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 42.05%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Year</div></td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.08%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Reported <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Summary <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Compensation <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Table Total for <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Non-PEO <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">NEOs</div></td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.7%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Reported <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value of Equity <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Awards</div></td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Equity <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Award <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(a)</sup></div></td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.52%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Compensation <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Actually Paid <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">to Non-PEO <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">NEOs</div></td></tr><tr><td style="width: 42.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2022<font style="padding-left: 2.5pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.11pt; text-align: left;">$795,530</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.7%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.43pt; text-align: left;">$<font style="padding-left: 5pt;">60,355</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.51pt; text-align: left;">$355,038</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.16pt; text-align: left;">$1,090,213</div></td></tr><tr><td style="width: 42.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2021<font style="padding-left: 2.5pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.11pt; text-align: left;">$579,478</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.7%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.43pt; text-align: left;">$200,606</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.51pt; text-align: left;">($223,913)</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.16pt; text-align: left;">$<font style="padding-left: 7.5pt;">154,959</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The amounts deducted or added in calculating the total average equity award adjustments are as follows:</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 408pt; margin-left: 30pt;"><tr class="header"><td style="width: 20.59%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Year</div></td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year End <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Equity <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Awards</div></td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.46%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year over <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair Value <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Outstanding <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">and <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unvested <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Equity <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Awards </div></td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.39%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value as <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of Vesting <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Date of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Equity <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Awards <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Granted <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">and <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Vested in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">the Year</div></td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.37%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year over <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair Value <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of Equity <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Awards <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Granted in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Prior <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Years that <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Vested in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">the Year</div></td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.01%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair Value <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">at the End <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of the Prior <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Equity <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Awards <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">that Failed <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">to Meet <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Vesting <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Conditions <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in the Year</div></td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average Value <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of Dividends <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">or other <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Earnings Paid <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">on Stock or <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Option <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Awards not <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Otherwise <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Reflected in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair Value or <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Compensation</div></td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.67%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Equity <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Award <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments</div></td></tr><tr><td style="width: 20.59%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2022<font style="padding-left: 1pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.37pt; text-align: left;">$275,842</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.46%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;">$20,227</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 11.11pt; text-align: left;">$ &#8212;</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.37%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 6.11pt; text-align: left;">$58,969</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 5.43pt; text-align: left;">$<font style="padding-left: 18pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 18.81pt; text-align: left;">$ &#8212;</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 6.76pt; text-align: left;">$355,038</div></td></tr><tr><td style="width: 20.59%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2021<font style="padding-left: 1pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.37pt; text-align: left;">$<font style="padding-left: 8pt;">7,447</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.46%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;">($27,804)</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 11.11pt; text-align: left;">$ &#8212;</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.37%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 6.11pt; text-align: left;">($36,454)</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 5.43pt; text-align: left;">($167,102)</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 18.81pt; text-align: left;">$ &#8212;</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 6.76pt; text-align: left;">($223,913)</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">5.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between Catalyst&#8217;s share price at the end and the beginning of the measurement period by Catalyst&#8217;s share price at the beginning of the measurement period.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">6.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The dollar amounts reported represent the amount of net loss reflected in Catalyst&#8217;s audited financial statements for the applicable year.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">169<br></div></div></div>
<!--End Page 180-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 181-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_111-pvp_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Analysis of the Information Presented in the Pay versus Performance Table</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">While Catalyst generally utilizes many factors to align executive compensation with Catalyst performance, including the qualifications, experience, role and responsibilities of our executives, a review of comparable company data (except Catalyst did not conduct a formal comparability analysis in 2022, when Catalyst anticipated beginning a wind-down process of its operations), assessments of individual performance, and other performance measures, all of those factors are not presented in the Pay versus Performance table. Moreover, Catalyst generally seeks to incentivize long-term performance, and therefore, does not specifically align Catalyst&#8217;s performance measures with compensation that is actually paid (as computed in accordance with Item 402(v)&#160;of Regulation S-K) for a particular year. In accordance with Item 402(v)&#160;of Regulation S-K, Catalyst is providing the following descriptions of the relationships between information presented in the Pay versus Performance table.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">170<br></div></div></div>
<!--End Page 181-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 182-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_111-pvp_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Compensation Actually Paid and Cumulative TSR</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As demonstrated by the following graph, the amount of compensation actually paid to Dr. Usman and the average amount of compensation actually paid to Catalyst&#8217;s NEOs as a group (excluding Dr. Usman) is generally aligned with the upward trend of Catalyst&#8217;s cumulative TSR over the two years presented in the table. Though Catalyst does not use cumulative TSR in its executive compensation program, compensation actually paid is aligned with Catalyst&#8217;s cumulative TSR over the period presented as a significant portion of the compensation actually paid to Dr. Usman and to the other NEOs is comprised of equity awards.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.75pt; text-align: center;"><img style="height: 305px; width: 516px;" src="ny20006478x8_bargraph01.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;"> </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">171<br></div></div></div>
<!--End Page 182-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 183-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_111-pvp_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Compensation Actually Paid and Net Income (Loss)</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst has never been profitable and has incurred significant operating losses in each year since inception. As demonstrated by the following table, while Catalyst experienced challenges with respect to net loss in 2021 and 2022, the amount of compensation actually paid to Dr. Usman and the average amount of compensation actually paid to Catalyst&#8217;s NEOs as a group (excluding Dr. Usman) is generally aligned with Catalyst&#8217;s improvement with respect to net loss over the two years presented in the table. Catalyst does not use net income or loss as a performance measure in its executive compensation program.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 367px; width: 520px;" src="ny20006478x8_bargraph02.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">172<br></div></div></div>
<!--End Page 183-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 184-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_112-comp_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tBCE"><!--Anchor--></a>BC EXECUTIVE COMPENSATION</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Overview </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following section discusses the material components of the executive compensation program for BC&#8217;s named executive officers who are identified in the Summary Compensation Table below. This discussion may contain forward-looking statements that are based on BC&#8217;s current plans, considerations, expectations and determinations regarding future compensation programs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">For 2022, BC&#8217;s named executive officers were: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Songjiang Ma, General Manager;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Lin Han, Vice President and Chief Financial Officer;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Qijia Liu, Vice President;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Weiguo Ye, Executive Vice President and Chief Operating Officer; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Li Zhang, Vice President.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">2022 Compensation of Named Executive Officers </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For the year ended December&#160;31, 2022, the compensation for each named executive officer generally consisted of a base salary, performance-based cash bonus, standard employee benefits and stock options under BC&#8217;s equity plan. These elements (and the amounts of compensation and benefits under each element) were selected because BC believes they are necessary to help attract and retain executive talent which is fundamental to its success. Below is a more detailed summary of the current executive compensation program as it relates to BC&#8217;s named executive officers.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Base Salary </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The named executive officers receive a base salary to compensate them for services rendered to BC. Base salaries are intended to provide a fixed level of compensation sufficient to attract and retain an effective management team, when considered in combination with the other components of BC&#8217;s executive compensation program. The relative levels of base salary for the named executive officers are designed to reflect each executive officer&#8217;s skill set, experience, scope of responsibility and accountability. Please see the &#8220;Salary&#8221; column in the Summary Compensation Table for the base salary amount received by each named executive officer during the year ended December&#160;31, 2022.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">2022 Bonuses</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC maintains a cash-based bonus program in which certain of its employees, including its named executive officers, are eligible to receive discretionary annual cash bonuses based on BC&#8217;s evaluation of the employee&#8217;s individual performance and contributions, as well as BC&#8217;s overall financial condition and performance. Bonus compensation is designed to incentivize the named executive officers with a variable level of compensation, hold executives accountable by rewarding them based on actual business results and help create a &#8220;pay for performance&#8221; culture. Please see the &#8220;Bonus&#8221; column in the Summary Compensation Table for the actual cash bonus amount earned by each named executive officer for the year ended December&#160;31, 2022.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Equity Compensation </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;">Equity Incentive Plan and Outstanding Awards</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC maintains the Stock Incentive Plan, referred to as the 2021 Plan, in order to facilitate the grant of equity-based incentive awards to its employees, including its named executive officers, which are designed to align the interests of BC&#8217;s employees with those of BC&#8217;s stockholders. Stock options are the only form of equity award available for grant under the 2021 Plan, and as of December&#160;31, 2022, stock options were the only type of equity incentives that BC had granted to the named executive officers. BC has historically used stock options as incentives for long-term incentive compensation to the named executive officers as the return on the awards is tied to an increase in BC&#8217;s stock price. 9,197,685 shares of BC stock were reserved for issuance in connection with grants of stock options under the 2021 Plan, collectively representing approximately 15.0% of the aggregate number of shares of BC stock outstanding. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">173<br></div></div></div>
<!--End Page 184-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 185-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_112-comp_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">All stock options under the 2021 Plan have a seven-year term and were granted with an exercise price of approximately $1.41 per share. Stock options granted under the 2021 Plan generally vest over a 20-month period (which may be adjusted to 17-23 months by BC&#8217;s board of directors) subject to the achievement of corporate performance conditions, and may be subject to acceleration of vesting and exercisability upon certain termination events. In the event of a change in control of BC, the 2021 Plan provides that awards outstanding thereunder will generally remain unchanged. Please see &#8220;&#8212;<font style="font-style: italic;">Outstanding Equity Awards at Fiscal 2022 Year-End</font>&#8221; below for additional information regarding outstanding stock options held by each of the named executive officers as of the 2022&#160;year-end.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Effective upon the consummation of the Contributions, BC intends to terminate the 2021 Plan and all awards outstanding thereunder. Thereafter, the PRC Sub-plan will be used to facilitate grants of stock options to certain BC employees, on terms substantially similar in all material respects to those previously outstanding under the 2021 Plan. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12.5pt; margin-left: 20pt; text-align: left;">2023 Omnibus Incentive Plan</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst will adopt and seek stockholder approval of the 2023 Omnibus Incentive Plan. If Catalyst&#8217;s stockholders approve the 2023 Omnibus Incentive Plan and it becomes effective, BC employees will be eligible to receive awards thereunder following the Contributions. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The aggregate number of shares of common stock of Catalyst reserved for issuance pursuant to awards under the 2023 Omnibus Incentive Plan is equal to &#8195;&#8195;&#8195;% of the common stock outstanding, including shares authorized under the 2023 Omnibus Incentive Plan. Any employee, director or consultant of Catalyst (including, after the Contributions, employees of BC) is eligible to receive an award under the 2023 Omnibus Incentive Plan, to the extent that an offer of such award is permitted by applicable law, stock market or exchange rules, and regulations or accounting or tax rules and regulations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The 2023 Omnibus Incentive Plan provides for the grant of stock options (including incentive stock options and non-qualified stock options), restricted stock, restricted stock units, performance-based awards, other stock-based awards, or any combination thereof. No determination has been made as to the types or amounts of awards that will be granted to specific individuals under the 2023 Omnibus Incentive Plan. Each award will be set forth in a separate grant notice or agreement and will indicate the type and terms and conditions of the award. Please see the section entitled &#8220;<font style="font-style: italic;">Proposal No. 6&#8212;Approval of the GYRE Therapeutics, Inc. 2023 Omnibus Incentive Plan</font>&#8221; for a summary of the material terms of the 2023 Omnibus Incentive Plan.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Summary Compensation Table</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table presents all of the compensation awarded to or earned by or paid to BC&#8217;s named executive officers for the year ended December&#160;31, 2022.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 33.33%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name and Principal Position</div></td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.27%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fiscal <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year</div></td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Salary <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Bonus <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Option <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Awards <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div></td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Non-Equity <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Incentive <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Plan <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Compensation <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)</div></td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">All Other <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Compensation <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)</div></td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.69%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total ($)</div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Songjiang Ma <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-align: left;">Executive Director And <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-align: left;">General Manager<font style="padding-left: 1.3pt;"></font></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 1pt; text-align: left;">2022</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 4.5pt;">99,452</font></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 4.5pt;">36,900</font></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">338,950</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20.16pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20.16pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.75pt;">475,302</font></div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lin Han <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-align: left;">Vice President And Chief <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-align: left;">Financial Officer<font style="padding-left: 2.46pt;"></font></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 4.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 1pt; text-align: left;">2022</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 0.33pt;">116,937</font></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 4.5pt;">29,758</font></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.5pt;">29,234</font></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20.16pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20.16pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.75pt;">175,929</font></div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weiguo Ye <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-align: left;">Executive Vice President <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-align: left;">And Chief Operating Officer<font style="padding-left: 3.49pt;"></font></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 1pt; text-align: left;">2022</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">161,574</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">210,689</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">125,141</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20.16pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20.16pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.75pt;">497,404</font></div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Li Zhang <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-align: left;">Vice President<font style="padding-left: 1.82pt;"></font></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 4.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 1pt; text-align: left;">2022</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">129,417</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">164,207</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9pt;">1,921</font></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20.16pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20.16pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.75pt;">295,545 </font></div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Qijia Liu <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-align: left;">Vice President<font style="padding-left: 1.82pt;"></font></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 1pt; text-align: left;">2022</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">105,509</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 4.5pt;">63,534</font></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.5pt;">27,394</font></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20.16pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20.16pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.75pt;">196,437</font></div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="padding-left: 0.39pt;"></font></div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">612,889</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">505,088</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">522,640</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20.16pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20.16pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.06%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1,640,617</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 8.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The amounts disclosed represent the dollar value of base salary earned by the named executive officer during 2022. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The amounts disclosed represent discretionary annual bonuses earned by the named executive officer during 2021 and paid in 2022. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The amounts disclosed represent the aggregate grant date fair value of the stock options awarded in 2022 computed in accordance with IFRS, rather than the amounts paid to or realized by the named individual.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">174<br></div></div></div>
<!--End Page 185-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 186-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_112-comp_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Outstanding Equity Awards at Fiscal 2022 Year-End </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table presents information regarding the outstanding equity awards held by each of BC&#8217;s named executive officers as of December&#160;31, 2022.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 23.08%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="13" style="width: 52.36%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Option Awards</div></td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.28%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stock Awards</div></td></tr><tr class="header"><td style="width: 23.08%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div></td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.93%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Grant Date</div></td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.89%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Securities <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Underlying <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unexercised <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Options <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercisable <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(#)</div></td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Securities <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Underlying <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unexercised <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Options <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unexercisable <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(#)</div></td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.85%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; white-space: nowrap; text-align: center;">Option <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; white-space: nowrap; text-align: center;">Exercise <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; white-space: nowrap; text-align: center;">Price ($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Option <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Expiration <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Date</div></td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.97%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of Shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">or Units <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of Stock <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">That Have <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Not Vested <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(#)</div></td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Market Value <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of Shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">or Units <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of Stock <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">That Have <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Not Vested <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td></tr><tr><td style="width: 23.08%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Songjiang Ma<font style="padding-left: 3.29pt;"></font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2/4/2021<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.8pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.92pt; text-align: left;">2,434,150</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.85%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.12pt; text-align: left;">1.40568</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.88%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.66pt; text-align: left;">2/4/2028</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.66pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.16%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.77pt; text-align: left;">&#8212;</div></td></tr><tr><td style="width: 23.08%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lin Han<font style="padding-left: 1.62pt;"></font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2/4/2021<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.8pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.92pt; text-align: left;"><font style="padding-left: 7.5pt;">209,942</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.85%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.12pt; text-align: left;">1.40568</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.88%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.66pt; text-align: left;">2/4/2028</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.66pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.16%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.77pt; text-align: left;">&#8212;</div></td></tr><tr><td style="width: 23.08%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weiguo Ye<font style="padding-left: 1.02pt;"></font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2/4/2021<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.8pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.92pt; text-align: left;"><font style="padding-left: 7.5pt;">898,691</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.85%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.12pt; text-align: left;">1.40568</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.88%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.66pt; text-align: left;">2/4/2028</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.66pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.16%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.77pt; text-align: left;">&#8212;</div></td></tr><tr><td style="width: 23.08%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Li Zhang<font style="padding-left: 2.73pt;"></font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2/4/2021<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.8pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.92pt; text-align: left;"><font style="padding-left: 12.5pt;">13,796</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.85%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.12pt; text-align: left;">1.40568</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.88%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.66pt; text-align: left;">2/4/2028</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.66pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.16%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.77pt; text-align: left;">&#8212;</div></td></tr><tr><td style="width: 23.08%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Qijia Liu<font style="padding-left: 3.29pt;"></font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2/4/2021<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.8pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.92pt; text-align: left;"><font style="padding-left: 7.5pt;">196,728</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.85%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.12pt; text-align: left;">1.40568</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.88%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.66pt; text-align: left;">2/4/2028</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.66pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.16%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.77pt; text-align: left;">&#8212;</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Pursuant to the 2021 Plan, the BC Options were granted on February 4, 2021, and vested 20 months after the grant date (the &#8220;Vesting Period&#8221;). 50% of each person&#8217;s BC Options may be exercised from the first day that BC&#8217;s board of directors has certified the conditions to exercise have been met until the last business day of the 12 months following the expiration of the Vesting Period (the &#8220;First Exercisable Period&#8221;). The remaining 50% may be exercised following the expiration of the First Exercisable Period and from the first day that BC&#8217;s board of directors has certified the conditions to exercise have been met until the last business day of the 24 months following the expiration of the Vesting Period. As of the date of this table, none of the BC Options are exercisable. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Exercise price of the options held by each named executive officer has been converted from RMB to U.S. dollars at a rate of RMB 6.9646&#160;to $1.00, the exchange rate on December 31, 2022, as reported by the People&#8217;s Bank of China. </div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Executive Compensation Arrangements</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Songjiang Ma</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Mr.&#160;Songjiang Ma currently receives an annual base salary of $99,452 and is eligible for an annual discretionary performance bonus with a target amount of up to 130% of his base salary.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Lin Han</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Mr.&#160;Lin Han currently receives an annual base salary of $116,937 and is eligible for an annual discretionary performance bonus with a target amount of up to 130% of his base salary.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Weiguo Ye</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Mr.&#160;Weiguo Ye currently receives an annual base salary of $161,574 and is eligible for an annual discretionary performance bonus with a target amount of up to 130% of his base salary.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Li Zhang</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Ms.&#160;Li Zhang currently receives an annual base salary of $129,417 and is eligible for an annual discretionary performance bonus with a target amount of up to 130% of her base salary.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Qijia Liu</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Ms.&#160;Qijia Liu currently receives an annual base salary of $105,509 and is eligible for an annual discretionary performance bonus with a target amount of up to 130% of her base salary.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">175<br></div></div></div>
<!--End Page 186-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 187-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_112-comp_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Director Compensation </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">2022 Director Compensation Table </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table sets forth information for the year ended December&#160;31, 2022 regarding the compensation awarded to or earned by certain of BCs non-employee directors.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div></td><td class="gutter" style="width: 1.17%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.17%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.26%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fees <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Earned <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">or <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Paid in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cash ($)</div></td><td class="gutter" style="width: 1.17%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.17%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.57%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stock <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Awards <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)</div></td><td class="gutter" style="width: 1.17%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.17%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Option <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Awards <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)</div></td><td class="gutter" style="width: 1.17%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.17%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.3%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total ($)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ruoyu Chen<font style="padding-left: 3.39pt;"></font></div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.91pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.57%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.03pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">43,480</div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.99pt; text-align: left;">43,480</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Yuwen Wu<font style="padding-left: 4.54pt;"></font></div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.91pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.57%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.03pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.99pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Youming Cheng<font style="padding-left: 3.29pt;"></font></div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.91pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.57%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.03pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.99pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Guowei Zhu<font style="padding-left: 3.4pt;"></font></div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.91pt; text-align: left;">17,855</div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.57%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.03pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.99pt; text-align: left;">17,855</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Bing Chen<font style="padding-left: 0.62pt;"></font></div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.91pt; text-align: left;">17,855</div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.57%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.03pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.99pt; text-align: left;">17,855</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jianyuan Jack Luo<font style="padding-left: 3.42pt;"></font></div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.91pt; text-align: left;">17,855</div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.57%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.03pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.99pt; text-align: left;">17,855</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Hui Xia<font style="padding-left: 1.74pt;"></font></div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.91pt; text-align: left;">14,879</div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.57%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.03pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.17%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.99pt; text-align: left;">14,879</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Non-Employee Director Compensation</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Prior to the Contributions, BC did not have a formal policy to provide any cash or equity compensation to its non-employee directors for their service on its board of directors or committees of its board of directors. In connection with closing of the Contributions, it is expected that the combined company will provide compensation to non-employee directors that is consistent with Catalyst&#8217;s current practices, however, these director compensation policies may be reevaluated by the combined company and the compensation committee following the completion of the Contributions and may be subject to change. Non-employee directors are expected to receive an annual retainer fee and equity compensation in the form of a stock option grant.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the closing of the Contributions and the transition of the board of directors, the combined company expects to evaluate Catalyst&#8217;s director compensation practices and finalize the combined company&#8217;s non-employee director compensation program, pursuant to which non-employee directors will be eligible to receive compensation for service on the board of directors of the combined company and its committees. The board of directors of the combined company expects to review director compensation periodically to ensure that director compensation remains competitive such that the combined company is able to recruit and retain qualified directors.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">176<br></div></div></div>
<!--End Page 187-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 188-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tMBS"><!--Anchor--></a>MATTERS BEING SUBMITTED TO A VOTE OF CATALYST STOCKHOLDERS<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195; <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><a name="tPROP1"><!--Anchor--></a>PROPOSAL NO. 1:<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">APPROVAL OF THE ISSUANCE OF SHARES OF CATALYST COMMON STOCK AND CATALYST PREFERRED STOCK PURSUANT TO THE TERMS OF THE BUSINESS COMBINATION AGREEMENT FOR PURPOSES OF NASDAQ LISTING RULES 5635(A) AND (B)</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">General</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">At the Catalyst special meeting, Catalyst stockholders will be asked to approve the issuance of shares of Catalyst Common Stock and Catalyst Convertible Preferred Stock pursuant to the terms of the Business Combination Agreement (as it may be amended from time to time) in accordance with Nasdaq Listing Rules 5635(a) and (b).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Immediately following the Contributions, it is expected that pre-Contributions Catalyst stockholders will own approximately 2.5% of the outstanding shares of the combined company, GNI USA will own approximately 85.2% of the outstanding shares of the combined company and the Minority Holders will own approximately 12.3% of the outstanding shares of the combined company, in each case, assuming conversion of the Catalyst Convertible Preferred Stock, and the combined company will own an approximately 69.7% indirect controlling interest in BC. Immediately after the Contributions, the holders of the capital stock of Catalyst as of immediately prior to the Contributions are expected to own approximately 2.0% of the outstanding shares of the combined company, GNI USA is expected to own approximately 70.6% of the outstanding shares of the combined company, the Minority Holders are expected to own approximately 10.2% of the outstanding shares of the combined company, the holders of Gyre Options to be granted in respect of BC Options are expected to own approximately 16.6% of the outstanding shares of the combined company and the holders of outstanding options of Catalyst are expected to own approximately 0.6% of the outstanding shares of the combined company, in each case, on a fully diluted basis assuming conversion of the Catalyst Convertible Preferred Stock and including the outstanding options of Catalyst and the Gyre Options to be granted in respect of the BC Options. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The terms of, reasons for and other aspects of the Business Combination Agreement, the Contributions and the issuance of Catalyst Common Stock and Catalyst Preferred Stock in the Contributions are described in detail in the other sections in this proxy statement. Copies of the Business Combination Agreement and the Amendment to the Business Combination Agreement are attached as Annex&#160;A, respectively, to this proxy statement.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Stockholder Approval Requirement for Purposes of Nasdaq Listing Rules 5635(a) and (b)<font style="font-weight: normal;"> </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to Nasdaq Listing Rule 5635(a), stockholder approval is required prior to the issuance of common stock or other securities convertible into or exercisable for common stock, in connection with the acquisition of the stock or assets of another company, if such securities are not issued in a public offering and (i)&#160;the common stock has, or will have upon issuance, voting power equal to or in excess of 20.0% of the voting power outstanding before the issuance of such securities, or (ii)&#160;the number of shares of common stock to be issued is or will be equal to or in excess of 20.0% of the number of shares of common stock outstanding before the issuance of such securities. Because Catalyst expects to issue 953,821,796 shares of Catalyst Common Stock to GNI and an aggregate of 156,954,428 shares of Catalyst Common Stock to the Minority Holders in accordance with the terms and subject to the conditions of the Business Combination Agreement, which number exceeds 20.0% of both the voting power and the number of shares of Catalyst Common Stock outstanding before such issuance, Catalyst is seeking the approval of its stockholders for the issuance of shares of Catalyst Common Stock pursuant to the Business Combination Agreement pursuant to Nasdaq Listing Rule 5635(a).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Additionally, pursuant to Nasdaq Listing Rule 5635(b), stockholder approval is required prior to the issuance of common stock that will result in a change of control of a listed company. Because Catalyst expects that the consummation of the Contributions, including the issuance of shares of Catalyst Common stock to GNI USA and the Minority Holders pursuant to the Business Combination Agreement, will constitute a change of control for purposes of Nasdaq Listing Rule 5635(b), Catalyst is seeking the approval of its stockholders for the issuance of shares of Catalyst Common Stock pursuant to the Business Combination Agreement pursuant to Nasdaq Listing Rule 5635(b).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">CATALYST&#8217;S BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THIS PROPOSAL NO. 1.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;FOR&#8221; the approval of this Proposal No. 1.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">177<br></div></div></div>
<!--End Page 188-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 189-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPROP2"><!--Anchor--></a>PROPOSAL NO. 2:<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">APPROVAL OF CONVERSION OF CATALYST CONVERTIBLE PREFERRED STOCK INTO SHARES OF CATALYST COMMON STOCK PURSUANT TO THE TERMS OF THE F351 AGREEMENT FOR PURPOSES OF NASDAQ LISTING RULES 5635(A) AND (B)</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">General</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">At the Catalyst special meeting, Catalyst stockholders will be asked to approve the issuance of shares of Catalyst Common Stock upon the conversion of Catalyst Convertible Preferred Stock issued pursuant to the terms of the F351 Agreement (as it may be amended from time to time) in accordance with Nasdaq Listing Rules 5635(a) and (b).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the F351 Agreement, on December&#160;26, 2022, Catalyst issued 10,577 shares of Catalyst Convertible Preferred Stock to GNI Hong Kong and 1,763 shares of Catalyst Convertible Preferred Stock to GNI Japan. In addition, pursuant to the Business Combination Agreement, at the election of GNI USA or any Minority Holder, GNI USA or such Minority Holder shall be issued shares of Catalyst Convertible Preferred Stock in lieu of some or all of the shares of Catalyst Common Stock GNI USA or such Minority Holder is entitled to receive in connection with the Contributions. The Catalyst Convertible Preferred Stock is intended to have rights that are generally equivalent to Catalyst Common Stock, provided that the Catalyst Convertible Preferred Stock does not have the right to vote on most matters (including the election of directors). 123,400,000 shares of Catalyst Common Stock are issuable upon conversion of the above-described Catalyst Convertible Preferred Stock, assuming the approval of the Proposal No. 2 and subject to certain beneficial ownership limitations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Subject to stockholder approval, each share of Catalyst Convertible Preferred Stock is convertible into Catalyst Common Stock at a rate equal to $10,000 per share divided by $1.00 (the &#8220;Conversion Ratio&#8221;). This Proposal No.&#160;2 would provide the necessary approval to permit such conversion. If Catalyst&#8217;s stockholders have not approved the conversion of Catalyst Convertible Preferred Stock into Catalyst Common Stock by September&#160;30, 2023, then a holder of Catalyst Convertible Preferred Stock may require Catalyst to settle any conversion demand made thereafter by paying an amount equal to the Fair Value (defined below) of such undelivered shares, with such payment to be made within two Business Days from the date of request by the holder of Catalyst Convertible Preferred Stock, whereupon the Catalyst&#8217;s obligations to deliver such shares underlying the Catalyst Convertible Preferred Stock will be extinguished. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The terms of, reasons for and other aspects of the F351 Agreement, the Business Combination Agreement and the issuance of Catalyst Preferred Stock in connection with the F351 Agreement and Business Combination Agreement are described in detail in the other sections in this proxy statement. A copy of the Business Combination Agreement is attached as Annex&#160;A to this proxy statement and a copy of the F351 Agreement is attached as Annex&#160;B to this proxy statement.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Shares Issuable Upon Conversion </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Shares Issuable Upon Conversion Set forth below is a table summarizing the issued and outstanding Catalyst Convertible Preferred Stock, as well as the number of shares of Catalyst Common Stock that are potentially issuable upon conversion of the Catalyst Convertible Preferred Stock.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 15.28%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Catalyst Convertible <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Preferred Stock <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Issued and <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Outstanding</div></td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.39%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Catalyst <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(as converted)</div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI Hong Kong<font style="padding-left: 2.64pt;"></font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.28%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.02pt; text-align: left;">10,577</div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.65pt; text-align: left;">105,770,000 </div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI Japan<font style="padding-left: 2.64pt;"></font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.28%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.02pt; text-align: left;"><font style="padding-left: 5pt;">1,763</font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.65pt; text-align: left;"><font style="padding-left: 5pt;">17,630,000</font></div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="padding-left: 1.09pt;"></font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.28%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.02pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">12,340</font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.65pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 50pt;">123,400,000</font></div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Stockholder Approval Requirement for Purposes of Nasdaq Listing Rules 5635(a) and (b)</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to Nasdaq Listing Rule 5635(a), stockholder approval is required prior to the issuance of common stock or other securities convertible into or exercisable for common stock, in connection with the acquisition of the stock or assets of another company, if such securities are not issued in a public offering and (i)&#160;the common stock has, or will have upon issuance, voting power equal to or in excess of 20.0% of the voting power outstanding before the issuance </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">178<br></div></div></div>
<!--End Page 189-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 190-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">of such securities, or (ii)&#160;the number of shares of common stock to be issued is or will be equal to or in excess of 20.0% of the number of shares of common stock outstanding before the issuance of such securities. For purposes of Nasdaq Listing Rule 5635(a), the issuance of any Catalyst Common Stock in connection with the F351 Agreement and Business Combination Agreement would be aggregated together. Thus, in order to permit the issuance of Catalyst Common Stock upon conversion of the Catalyst Convertible Preferred Stock, Catalyst must first obtain stockholder approval of this issuance. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Additionally, pursuant to Nasdaq Listing Rule 5635(b), stockholder approval is required prior to the issuance of common stock that will result in a change of control of a listed company. Because Catalyst expects that the conversion of Catalyst Preferred Stock into Catalyst Common Stock upon the approval of Proposal No. 2 will constitute a change of control for purposes of Nasdaq Listing Rule 5635(b), Catalyst is seeking the approval of its stockholders for the issuance of shares of Catalyst Common Stock upon the conversion of Catalyst Convertible Preferred Stock issued pursuant to the terms of the F351 Agreement and Business Combination Agreement pursuant to Nasdaq Listing Rule&#160;5635(b).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">CATALYST&#8217;S BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THIS PROPOSAL NO. 2</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;FOR&#8221; the approval of this Proposal No. 2.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">179<br></div></div></div>
<!--End Page 190-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 191-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">PROPOSAL NO. 3:<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195; <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><a name="tPROP3"><!--Anchor--></a>ADOPTION AND APPROVAL OF AN AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF CATALYST TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF CATALYST COMMON STOCK</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">General </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst is seeking stockholder approval for a proposal to adopt an amendment to its restated certificate of incorporation to increase the number of authorized shares of Catalyst Common Stock from 100,000,000 shares to &#8195;&#8195;&#8195; shares.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s restated certificate of incorporation currently authorizes 100,000,000 shares of common stock, par value $0.001 per share and 5,000,000 shares of preferred stock, par value $0.001 per share, of which &#8195;&#8195;&#8195; shares of common stock and no shares of preferred stock were outstanding as of &#8195;&#8195;&#8195; , 2023, the record date for the Catalyst special meeting. The proposed amendment to Catalyst&#8217;s restated certificate of incorporation would not increase or otherwise affect its authorized preferred stock. Catalyst Common Stock is all of a single class, with equal voting, distribution, liquidation and other rights. The additional Catalyst Common Stock to be authorized by adoption of the amendment would have rights identical to Catalyst&#8217;s currently outstanding common stock.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">A copy of the amendment to Catalyst&#8217;s restated certificate of incorporation is attached as Annex&#160;E to this proxy statement. If Catalyst&#8217;s stockholders approve this proposal, subject to the discretion of Catalyst&#8217;s board of directors, Catalyst intends to file the amendment to its restated certificate of incorporation with the Secretary of State of the State of Delaware prior to the Effective Time. In the event that Catalyst&#8217;s board of directors determines to effect the authorized share increase that is the subject of this Proposal No. 3 and the Reverse Stock Split that is the subject of Proposal No. 4, assuming that each proposal is approved by the Catalyst stockholders, Catalyst&#8217;s board of directors would effect the authorized share increase before effecting the Reverse Stock Split.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Purpose </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As described in greater detail in Proposal No. 1, Catalyst will be required to issue shares of its common stock to GNI USA and the Minority Holders pursuant to the terms of the Business Combination Agreement. In addition, if Proposal No. 6 is approved, Catalyst will reserve additional shares of its common stock for future issuance under the 2023 Omnibus Incentive Plan. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s board of directors believes that as a result of the foregoing, the number of authorized shares of common stock that would be authorized and unissued and not reserved for issuance will not be an adequate number of shares to assure that there will be sufficient shares available for future issuance under the 2023 Omnibus Incentive Plan, taking into account (i)&#160;the cancellation of the BC Options upon the effective time of the Contributions in exchange for Gyre Options and (ii)&#160;the conversion of the Gyre Options into options to purchase shares of the combined company as described in Proposal No. 6. In addition, there will not be sufficient shares available for issuance in connection with possible future acquisitions, equity and equity-based financings, possible future awards under employee benefit plans and other corporate purposes. Therefore, Catalyst&#8217;s board of directors has determined that it is in the best interests of Catalyst and its stockholders to amend its restated certificate of incorporation as described herein.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Except for (i)&#160;the issuance of shares pursuant to the terms of the Business Combination Agreement, which is the subject of Proposal No. 1 and which is described elsewhere in this proxy statement, (ii)&#160;the issuance of Catalyst Common Stock upon the conversion of Catalyst Convertible Preferred Stock, which is the subject of Proposal No.&#160;2 and which is described elsewhere in this proxy statement and (iii)&#160;the issuance of shares that may result from the shares available for issuance under the 2023 Omnibus Incentive Plan, which is the subject of Proposal No. 6, Catalyst does not currently have any plans, proposals or arrangement to issue any of its authorized but unissued shares of common stock.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Possible Effects of the Amendment </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If the amendment to Catalyst&#8217;s restated certificate of incorporation is approved, the additional authorized shares would be available for issuance at the discretion of Catalyst&#8217;s board of directors and without further stockholder approval, except as may be required by law or the rules of The Nasdaq Stock Market on which Catalyst Common </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">180<br></div></div></div>
<!--End Page 191-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 192-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Stock is listed. The additional shares of authorized common stock would have the same rights and privileges as the shares of Catalyst Common Stock currently issued and outstanding. Holders of Catalyst Common Stock have no preemptive rights.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The issuance of additional shares of common stock may, among other things, have a dilutive effect on earnings per&#160;share and on stockholders&#8217; equity and voting rights. Furthermore, future sales of substantial amounts of Catalyst Common Stock, or the perception that these sales might occur, could adversely affect the prevailing market price of Catalyst Common Stock or limit Catalyst&#8217;s ability to raise additional capital. Stockholders should recognize that, as a result of this proposal, they will own a smaller percentage of shares relative to the total authorized shares of the company than they presently own.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">CATALYST&#8217;S BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THIS PROPOSAL NO. 3.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;FOR&#8221; the approval of this Proposal No. 3.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">181<br></div></div></div>
<!--End Page 192-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 193-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">PROPOSAL NO. 4:<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><a name="tPROP4"><!--Anchor--></a>ADOPTION AND APPROVAL OF AN AMENDMENT TO CATALYST&#8217;S RESTATED CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF CATALYST COMMON STOCK BY A &#8195;&#8195;&#8195; RATIO OF NOT LESS THAN 1-FOR- &#8195;&#8195;&#8195; AND NOT MORE THAN 1-FOR- &#8195;&#8195;&#8195;, SUCH RATIO AND THE IMPLEMENTATION AND TIMING OF <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">THE REVERSE STOCK SPLIT TO BE DETERMINED IN THE DISCRETION OF <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">CATALYST&#8217;S BOARD OF DIRECTORS</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">General Information on Reverse Stock Split </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst is seeking stockholder approval for a proposal to adopt an amendment to its restated certificate of incorporation to effect a reverse stock split, which is referred to herein as the Reverse Stock Split, of Catalyst&#8217;s issued common stock by a ratio of not less than 1-for- &#8195;&#8195;&#8195; and not more than 1-for- &#8195;&#8195;&#8195;, such ratio and the implementation and timing of the Reverse Stock Split to be determined in the discretion of Catalyst&#8217;s board of directors as described below.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The form of the amendment to Catalyst&#8217;s restated certificate of incorporation to effect the Reverse Stock Split, which Catalyst&#8217;s board of directors approved and declared advisable on&#8195;&#8195;&#8195; , 2023, is attached as Annex&#160;E to this proxy statement. If this Proposal No. 4 is approved, the Reverse Stock Split would become effective on or around the closing date of the Contributions. Assuming that the Contributions are approved, the exact ratio of the Reverse Stock Split will be determined in the discretion of Catalyst&#8217;s board of directors in consultation and cooperation with the GNI Parties prior to the effective time of the Reverse Stock Split and will be publicly announced by Catalyst prior to such effective time of the Reverse Stock Split. If the Contributions are not approved or consummated, Catalyst&#8217;s board of directors may elect to proceed with the Reverse Stock Split even in the absence of completion of the Contributions and the exact ratio of the Reverse Stock Split will be determined by Catalyst&#8217;s board of directors. Catalyst&#8217;s board of directors may effect only one Reverse Stock Split in connection with this Proposal No. 4. Catalyst believes that enabling the boards of directors of Catalyst to set the ratio of the Reverse Stock Split within the stated range will provide it with the flexibility to implement the Reverse Stock Split in a manner designed to maximize the anticipated benefits for Catalyst&#8217;s stockholders. In determining a ratio of the Reverse Stock Split, if any, following the receipt of stockholder approval, the boards of directors of Catalyst may consider, among other things, factors such as: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the historical trading prices and trading volume of Catalyst Common Stock; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the number of shares of Catalyst Common Stock outstanding;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the then-prevailing trading price and trading volume of Catalyst Common Stock and the anticipated or actual impact of the Reverse Stock Split on the trading price and trading volume for Catalyst Common Stock; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the anticipated impact of a particular ratio on Catalyst&#8217;s ability to reduce administrative and transactional costs; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">prevailing general market and economic conditions.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst reserves the right to elect to abandon the Reverse Stock Split, including any or all proposed ratios for the Reverse Stock Split, if it determines, in its sole discretion, that the Reverse Stock Split is no longer in the best interests of Catalyst and the Catalyst Stockholders. Catalyst&#8217;s board of directors must determine to effect the Reverse Stock Split. In the event that Catalyst&#8217;s board of directors determines to effect the authorized share increase that is the subject of Proposal No. 3 and the reverse stock split that is the subject of this Proposal No. 4, assuming that each proposal is approved by the Catalyst stockholders, Catalyst&#8217;s board of directors would effect the authorized share increase before effecting the Reverse Stock Split. Depending on the ratio for the Reverse Stock Split determined by Catalyst&#8217;s board of directors, no fewer than every &#8195;&#8195;&#8195; and no more than every &#8195;&#8195;&#8195; shares of issued common stock will be reclassified into one share of common stock. As set forth in the form of amendment attached hereto as Annex&#160;E, any whole number of shares ascertainable within such range, together with the remaining provisions of the form of amendment not set forth in brackets, constitutes a separate amendment that is being submitted to the stockholders of Catalyst for their adoption and approval pursuant to this Proposal No. 4 in accordance with Section 242 of the DGCL. The final determination of the Reverse Stock Split ratio will be made by Catalyst&#8217;s board of directors as described herein and will be announced publicly prior to the effective time of the Reverse Stock Split. All amendments other than the amendment filed by Catalyst with the Secretary of State of the State of Delaware will be abandoned upon the filing of such amendment. Such amendment will not change the number of authorized shares of preferred stock of Catalyst, or the par value of Catalyst Common Stock or Preferred Stock.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">182<br></div></div></div>
<!--End Page 193-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 194-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Background and Reasons for the Reverse Stock Split; Potential Consequences of the Reverse Stock Split </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Catalyst&#8217;s board of directors approved the proposal approving the Reverse Stock Split for the following reasons: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s board of directors believes effecting the Reverse Stock Split may be an effective means of ensuring that the combined company can satisfy the initial listing requirements for its common stock on The Nasdaq Stock Market, thereby avoiding a delisting; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s board of directors believes that even if the Contributions are not approved or consummated, effecting the Reverse Stock Split may be an effective means to ensure that Catalyst can satisfy the continued listing requirements for the Nasdaq Capital Market; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Catalyst&#8217;s board of directors believes a higher stock price may help generate investor interest in Catalyst and help Catalyst attract and retain employees.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Nasdaq Listing Requirements </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of the date of this proxy statement, Catalyst Common Stock is listed on The Nasdaq Capital Market under the symbol &#8220;CBIO.&#8221;</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to Nasdaq rules, a Nasdaq-listed issuer must apply for initial inclusion following a transaction whereby the issuer combines with a non-Nasdaq entity, resulting in a change of control of the issuer and potentially allowing the non-Nasdaq entity to obtain a Nasdaq listing. Accordingly, the listing standards of Nasdaq will require the combined company to have, among other things, a $4.00 per share minimum bid price upon the closing of the Contributions. The combined company may not be able to meet the $4.00 per share minimum bid price requirement of the Nasdaq Capital Market unless Catalyst effects the Reverse Stock Split to increase the per share market price of its common stock.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, the standards of the Nasdaq Capital Market require Catalyst to maintain, among other things, a $1.00 per share minimum bid price in order to stay in compliance with specified continued listing requirements that are currently in effect and that would remain in effect if the Contributions are not approved or consummated. Catalyst&#8217;s board of directors expects that the Reverse Stock Split will have the effect of increasing the market price of Catalyst Common Stock so that Catalyst will be better able to maintain compliance with the relevant Nasdaq listing requirements.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Potential Increased Investor Interest and Ability to Attract and Retain Employees </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, Catalyst&#8217;s board of directors believes that a higher stock price may help generate investor interest in Catalyst and help Catalyst attract and retain employees. If the Reverse Stock Split successfully increases the per share price of Catalyst Common Stock, Catalyst&#8217;s board of directors also believes this increase could result in the potential for increased trading volume in Catalyst Common Stock and the potential for future financings by Catalyst.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">While reducing the number of outstanding shares of Catalyst Common Stock through the Reverse Stock Split is intended, absent other factors, to increase the per share market price of Catalyst Common Stock, other factors, such as factors relating to the Contributions and F351 Agreement described elsewhere in this proxy statement, Catalyst&#8217;s financial results, market conditions and the market perception of Catalyst&#8217;s business may adversely affect the market price of Catalyst Common Stock. As a result, there can be no assurance that the Reverse Stock Split, if effected, will result in the intended benefits described above, that the market price of Catalyst Common Stock will increase following the Reverse Stock Split or that the market price of Catalyst Common Stock will not decrease in the future. Additionally, Catalyst cannot assure you that the market price per share of its common stock after the Reverse Stock Split will increase in proportion to the reduction in the number of shares of Catalyst Common Stock outstanding before the Reverse Stock Split. Accordingly, the total market capitalization of Catalyst Common Stock after the Reverse Stock Split may be lower than the total market capitalization before the Reverse Stock Split.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Procedure for Implementing the Reverse Stock Split </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Reverse Stock Split would become effective upon the filing of the certificate of amendment to Catalyst&#8217;s restated certificate of incorporation with the Secretary of State of the State of Delaware. Assuming that the Contributions are approved, the Reverse Stock Split would become effective on or around the closing date of the Contributions. If the Contributions are not approved or consummated, the timing of the Reverse Stock Split will be determined by the board of directors of Catalyst in its sole discretion. In addition, Catalyst&#8217;s board of directors reserves the right, </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">183<br></div></div></div>
<!--End Page 194-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 195-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">notwithstanding stockholder approval of this Proposal No. 4 and without further action by the stockholders, to elect not to proceed with the Reverse Stock Split if, at any time prior to filing the certificate of amendment to Catalyst&#8217;s restated certificate of incorporation to effect the Reverse Stock Split, or, in the event that the amendment is not effective until a later time, such later time, Catalyst&#8217;s board of directors, in its sole discretion, determines that it is no longer in Catalyst&#8217;s best interests and the best interests of its stockholders to proceed with the Reverse Stock Split. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Effect of the Reverse Stock Split on Holders of Outstanding Common Stock </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Depending on the ratio for the Reverse Stock Split determined by the board of directors of Catalyst, a minimum of every &#8195;&#8195;&#8195; and a maximum of every &#8195;&#8195;&#8195; shares of issued common stock will be reclassified into one new share of common stock. Based on 37,759,825 shares of common stock issued and outstanding as of May&#160;15, 2023, immediately following the Reverse Stock Split, Catalyst would have approximately &#8195;&#8195;&#8195; shares of common stock issued and outstanding if the ratio for the Reverse Stock Split is 1-for- &#8195;&#8195;&#8195; and approximately &#8195;&#8195;&#8195; shares of common stock issued and outstanding if the ratio for the Reverse Stock Split is 1-for- &#8195;&#8195;&#8195; . Any other ratio selected within such range would result in a number of shares of common stock issued and outstanding of between approximately and shares. In addition, giving effect to the Contributions and the conversion of the Catalyst Convertible Preferred Stock into Catalyst Common Stock pursuant to the F351 Agreement and based on 37,759,825&#160;shares of common stock issued and outstanding as of May&#160;15, 2023, Catalyst would have approximately &#8195;&#8195;&#8195; million shares of common stock issued and outstanding if the ratio for the Reverse Stock Split is 1-for- &#8195;&#8195;&#8195; and approximately &#8195;&#8195;&#8195; million shares of common stock issued and outstanding if the ratio for the Reverse Stock Split is 1-for- &#8195;&#8195;&#8195; .</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The actual number of shares issued and outstanding after giving effect to the Reverse Stock Split, if implemented, will depend on the ratio for the Reverse Stock Split that is ultimately determined by the board of directors of Catalyst.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Reverse Stock Split will affect all holders of Catalyst Common Stock uniformly and will not affect any stockholder&#8217;s percentage ownership interest in Catalyst, except that, as described below under <font style="font-style: italic;">&#8220;&#8212;Fractional </font><font style="font-style: italic;">Shares</font>,&#8221; record holders of common stock otherwise entitled to a fractional share as a result of the Reverse Stock Split will receive cash in lieu of such fractional share. In addition, the Reverse Stock Split will not affect any stockholder&#8217;s proportionate voting power (subject to the treatment of fractional shares).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Reverse Stock Split may result in some stockholders owning &#8220;odd lots&#8221; of less than 100 shares of common stock. Odd lot shares may be more difficult to sell and brokerage commissions and other costs of transactions in odd lots may be higher than the costs of transactions in &#8220;round lots&#8221; of even multiples of 100 shares.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">After the effective time of the Reverse Stock Split, Catalyst Common Stock will have a new Committee on Uniform Securities Identification Procedures (&#8220;CUSIP&#8221;) number, which is a number used to identify its equity securities and stock certificates with the older CUSIP numbers will need to be exchanged for stock certificates with the new CUSIP numbers by following the procedures described below. After the effectiveness of the Reverse Stock Split, Catalyst will continue to be subject to the periodic reporting and other requirements of the Exchange Act. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">All shares of Catalyst Series Y Preferred Stock that are not present in person or by proxy at the Catalyst special meeting as of immediately prior to the opening of the polls at the Catalyst special meeting will be automatically redeemed in the Initial Redemption. Any outstanding shares of Catalyst Series Y Preferred Stock that are not redeemed pursuant to the Initial Redemption will be redeemed in whole, but not in part, (i) if and when ordered by the Catalyst board of directors or (ii) automatically upon the effectiveness of the amendment to the restated certificate of incorporation of Catalyst effecting the Reverse Stock Split. Please refer to the discussion in the Q&amp;A section under &#8220;What stockholder votes are required to approve the proposals at the Catalyst special meeting?&#8221; and &#8220;How many votes do I have?&#8221; for a description of the voting power of the Catalyst Series Y Preferred Stock.</div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Delaware General Assembly has passed amendments to the DGCL that would change the stockholder vote required to effect a reverse split of stock that is listed on a national securities exchange and meets certain other requirements. The Catalyst Common Stock is listed on the Nasdaq Capital Market, a national securities exchange. The DGCL amendments are anticipated to become effective on August 1, 2023, if they are signed into law by the Governor of Delaware, or otherwise enacted pursuant to Delaware law, on or before that date. If the amendments to the DGCL become effective before Catalyst files the amendment to the restated certificate of incorporation of Catalyst with the Delaware Secretary of State to effect the Reverse Stock Split, the Catalyst board of directors reserves the right to rely upon the new stockholder vote requirements authorized by the DGCL amendments to determine if Proposal No. 4 has been adopted. The DGCL amendments would permit Catalyst to effect the Reverse </div> </div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">184<br></div></div></div>
<!--End Page 195-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 196-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Stock Split if the votes cast &#8220;FOR&#8221; Proposal No. 4 exceed the votes cast &#8220;AGAINST&#8221; Proposal No. 4, assuming the presence of a quorum and if the shares of Catalyst Common Stock meet the listing requirement of the Nasdaq Capital Market relating to the minimum number of holders immediately after the amendment to the restated certificate of incorporation effecting the Reverse Stock Split becomes effective. Under this voting standard, abstentions and broker non-votes (if any), and shares of Catalyst Common Stock that are not present in person or by proxy at the Catalyst special meeting, will have no effect on the outcome of the vote on Proposal No. 4.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Authorized Shares of Common Stock </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Except for (i)&#160;the issuance of shares pursuant to the terms of the Business Combination Agreement, which is the subject of Proposal No. 1 and which is described elsewhere in this proxy statement, (ii)&#160;the issuance of Catalyst Common Stock upon the conversion of Catalyst Convertible Preferred Stock, which is the subject of Proposal No. 2 and which is described elsewhere in this proxy statement and (iii)&#160;the issuance of shares that may result from the shares available for issuance under the 2023 Omnibus Incentive Plan, which is the subject of Proposal No. 6, Catalyst does not currently have any plans, proposals or arrangement to issue any of its authorized but unissued shares of common stock.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Beneficial Holders of Common Stock (i.e., stockholders who hold in &#8220;street name&#8221;) </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For purposes of implementing the Reverse Stock Split, Catalyst intends to treat shares held by stockholders through a bank, broker, custodian or other nominee in the same manner as registered stockholders whose shares are registered in their names. Banks, brokers, custodians or other nominees will be instructed to effect the Reverse Stock Split for their beneficial holders holding Catalyst Common Stock in &#8220;street name.&#8221; However, these banks, brokers, custodians or other nominees may have different procedures than registered stockholders for processing the Reverse Stock Split. Stockholders who hold shares of Catalyst Common Stock with a bank, broker, custodian or other nominee and who have any questions in this regard are encouraged to contact their banks, brokers, custodians or other nominees.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Registered &#8220;Book-Entry&#8221; Holders of Common Stock (i.e., stockholders that are registered on the transfer agent&#8217;s books and records but do not hold stock certificates) </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Certain of Catalyst&#8217;s registered holders of common stock may hold some or all of their shares electronically in book-entry form with the transfer agent. These stockholders do not have stock certificates evidencing their ownership of Catalyst Common Stock. They are, however, provided with a periodic statement reflecting the number of shares registered in their accounts.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Stockholders who hold shares electronically in book-entry form with the transfer agent will not need to take action to receive whole shares of post-split common stock, because the exchange will be automatic.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Exchange of Stock Certificates </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If the Reverse Stock Split is effected, stockholders holding certificated shares (<font style="font-style: italic;">i.e.</font>, shares represented by one or more physical stock certificates) will be requested to exchange their old stock certificate(s) (each an &#8220;Old Certificate&#8221;) for shares held in book-entry form through the Depository Trust Company&#8217;s Direct Registration System representing the appropriate number of whole shares of Catalyst Common Stock resulting from the Reverse Stock Split. Stockholders of record upon the effective time of the Reverse Stock Split will be furnished the necessary materials and instructions for the surrender and exchange of their Old Certificate(s) at the appropriate time by Catalyst&#8217;s transfer agent, American Stock Transfer &amp; Trust Company, LLC. Stockholders will not have to pay any transfer fee or other fee in connection with such exchange. As soon as practicable after the effective time of the Reverse Stock Split, Catalyst&#8217;s transfer agent will send a transmittal letter to each stockholder advising such holder of the procedure for surrendering Old Certificate(s) in exchange for new shares held in book-entry form.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">YOU SHOULD NOT SEND YOUR OLD CERTIFICATES NOW. YOU SHOULD SEND THEM ONLY AFTER YOU RECEIVE THE LETTER OF TRANSMITTAL FROM THE TRANSFER AGENT.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As soon as practicable after the surrender to the transfer agent of any Old Certificate(s), together with a properly completed and duly executed transmittal letter and any other documents the transfer agent may specify, the transfer agent will have its records adjusted to reflect that the number of whole shares of post-split common stock into which the shares represented by such Old Certificate(s) have been reclassified in connection with the Reverse Stock Split are held in book-entry form in the name of such person.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">185<br></div></div></div>
<!--End Page 196-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 197-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Until surrendered as contemplated herein, a stockholder&#8217;s Old Certificate(s) shall be deemed at and after the effective time of the Reverse Stock Split to represent the number of whole shares of Catalyst Common Stock resulting from the Reverse Stock Split as well as the right to receive cash in lieu of any fractional shares.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Any stockholder whose Old Certificate(s) have been lost, destroyed or stolen will be entitled to new shares in book-entry form only after complying with the requirements that Catalyst and its transfer agent customarily apply in connection with lost, stolen or destroyed certificates.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">No service charges, brokerage commissions or transfer taxes shall be payable by any holder of any Old Certificate(s), except that if any book-entry shares are to be issued in a name other than that in which the Old Certificate(s) are registered, it will be a condition of such issuance that (1) the person requesting such issuance must pay to Catalyst any applicable transfer taxes or establish to Catalyst&#8217;s satisfaction that such taxes have been paid or are not payable, (2) the transfer complies with all applicable federal and state securities laws and (3) the surrendered Old Certificate(s) are properly endorsed and otherwise in proper form for transfer. In lieu of holding their shares in book-entry form, any stockholder who holds Old Certificate(s) and wants to continue holding certificated shares may receive new certificates by contacting Catalyst&#8217;s transfer agent and complying with the customary requirements that apply to the issuance of certificated shares.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Fractional Shares </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Fractional shares will not be issued in connection with the Reverse Stock Split. Stockholders who would otherwise hold fractional shares of Catalyst Common Stock as a result of the Reverse Stock Split will be entitled to receive a cash payment (without interest and subject to applicable withholding taxes) in lieu thereof in an amount equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing trading price of the Catalyst Common Stock on The Nasdaq Capital Market during regular trading hours for the five trading days immediately preceding the effective time of the Reverse Stock Split.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Stockholders should be aware that, under the escheat laws of the various jurisdictions where stockholders reside, where Catalyst is domiciled and where the funds will be deposited, sums due for fractional interests resulting from the Reverse Stock Split that are not timely claimed after the effective time in accordance with applicable law may be required to be paid to the designated agent for each such jurisdiction. Thereafter, stockholders otherwise entitled to receive such funds may have to seek to obtain them directly from the state to which they were paid.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Effect of the Reverse Stock Split on Employee Plans and Options </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the various instruments governing Catalyst&#8217;s then outstanding stock option awards, in connection with any Reverse Stock Split, Catalyst&#8217;s board of directors will reduce the number of shares of common stock issuable upon the exercise of the stock options in proportion to the ratio of the Reverse Stock Split and proportionately increase the exercise price of outstanding stock. In connection with such proportionate adjustments, the number of shares of common stock issuable upon exercise, vesting or conversion of outstanding stock options will be rounded down to the nearest whole share and the exercise prices will be rounded up to the nearest cent and no cash payment will be made in respect of such rounding.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Accounting Matters </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The amendment to Catalyst&#8217;s restated certificate of incorporation will not affect the par value of Catalyst Common Stock per share, which will remain $0.001 par value per share. As a result, as of the effective time of the Reverse Stock Split, the par value attributable to Catalyst Common Stock will decrease with the corresponding increase in the additional paid-in capital account on Catalyst&#8217;s balance sheet. Reported per share net income or loss will be higher because there will be fewer shares of Catalyst Common Stock outstanding.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">No Appraisal Rights </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under the DGCL, Catalyst&#8217;s stockholders are not entitled to dissenter&#8217;s rights or appraisal rights with respect to the Reverse Stock Split and Catalyst will not independently provide its stockholders with any such rights.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Interest of Certain Persons in Matters to Be Acted Upon </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">No officer or director of Catalyst has any substantial interest, direct or indirect, by security holdings or otherwise, in the Reverse Stock Split that is not shared by all of Catalyst&#8217;s other stockholders.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">186<br></div></div></div>
<!--End Page 197-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 198-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><a name="tMUF2"><!--Anchor--></a>Material U.S. Federal Income Tax Consequences of the Reverse Stock Split </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following discussion is a summary of the material U.S. federal income tax consequences of the Reverse Stock Split to Catalyst U.S. Holders (which, for purposes of this discussion, has the same meaning as in &#8220;<font style="font-style: italic;">Agreements </font><font style="font-style: italic;">Related to the Business Combination Agreement&#8212;CVR Agreement&#8212;Material U.S. Federal Income Tax </font><font style="font-style: italic;">Consequences of the Receipt of CVRs</font>&#8221;), but does not purport to be a complete analysis of all potential tax consequences that may be relevant to Catalyst U.S. holders. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The effects of other U.S. federal tax laws, such as estate and gift tax laws and any applicable state, local or non-U.S. tax laws are not discussed. This discussion is based on the Code, Treasury Regulations promulgated thereunder, judicial decisions and published rulings and administrative pronouncements of the IRS, in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a Catalyst U.S. holder. Catalyst has not sought and does not intend to seek any opinions of counsel or rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a position contrary to that discussed below regarding the tax consequences of the Reverse Stock Split.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This discussion is limited to Catalyst U.S. holders that hold Catalyst Common Stock as a &#8220;capital asset&#8221; within the meaning of Section 1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences that may be relevant to a Catalyst U.S. holder&#8217;s particular circumstances, including the impact of the alternative minimum tax or the Medicare contribution tax on net investment income or the rules related to &#8220;qualified small business stock&#8221; within the meaning of Section 1202 of the Code. In addition, it does not address consequences relevant to Catalyst U.S. holders subject to special rules, including, without limitation: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">U.S. expatriates and former citizens or long-term residents of the U.S.; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Catalyst U.S. holders whose functional currency is not the U.S. dollar; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">persons holding Catalyst Common Stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated investment; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">banks, insurance companies and other financial institutions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">real estate investment trusts or regulated investment companies; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">brokers, dealers or traders in securities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">S corporations, partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">tax-exempt organizations or governmental organizations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">persons subject to special tax accounting rules as a result of any item of gross income with respect to Catalyst Common Stock being taken into account in an &#8220;applicable financial statement&#8221; (as defined in the Code); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons deemed to sell Catalyst Common Stock under the constructive sale provisions of the Code; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">persons who hold or received Catalyst Common Stock pursuant to the exercise of any employee stock option or otherwise as compensation; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">tax-qualified retirement plans.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If an entity treated as a partnership for U.S. federal income tax purposes holds Catalyst Common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding Catalyst Common Stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">IT IS RECOMMENDED THAT CATALYST STOCKHOLDERS CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">187<br></div></div></div>
<!--End Page 198-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 199-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE REVERSE STOCK SPLIT ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst intends the Reverse Stock Split to qualify as a &#8220;recapitalization&#8221; within the meaning of Section 368(a)(1)(E) of the Code. Assuming such treatment, a Catalyst U.S. holder should not recognize gain or loss upon the Reverse Stock Split. In addition, a Catalyst U.S. holder&#8217;s aggregate tax basis in the shares of Catalyst Common Stock received pursuant to the Reverse Stock Split should equal the aggregate tax basis of the shares of Catalyst Common Stock surrendered, excluding any portion of such basis that is allocated to any fractional share of Catalyst Common Stock and such Catalyst U.S. holder&#8217;s holding period in the shares of Catalyst Common Stock received should include the holding period in the shares of Catalyst Common Stock surrendered. Treasury Regulations provide detailed rules for allocating the tax basis and holding period of the shares of Catalyst Common Stock surrendered to the shares of Catalyst Common Stock received pursuant to the Reverse Stock Split. Holders of shares of Catalyst Common Stock acquired on different dates and at different prices should consult their tax advisors regarding the allocation of the tax basis and holding period of such shares of Catalyst Common Stock.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This discussion assumes that the distribution of CVRs to Catalyst U.S. holders will be treated for U.S. federal income tax purposes as a transaction that is separate and distinct from the Reverse Stock Split. However, it is possible that the IRS or a court could determine that the Reverse Stock Split and the receipt of CVRs constitute a single &#8220;recapitalization&#8221; for U.S. federal income tax purposes. For a discussion of such treatment with respect to the CVRs, see the section entitled &#8220;<font style="font-style: italic;">Agreements Related to the Business Combination Agreement&#8212;CVR Agreement&#8212;Material </font><font style="font-style: italic;">U.S. Federal Income Tax Consequences of the Receipt of CVRs</font>&#8221; beginning on page <a href="#tMUF">157</a> of this proxy statement. If the Reverse Stock Split and receipt of CVRs are treated as a single &#8220;recapitalization&#8221; for U.S. federal income tax purposes, then a Catalyst U.S. holder may be required to recognize gain (but not loss) equal to the lesser of (i)&#160;the fair market value of the CVRs received (assuming the receipt of CVRs is treated as a distribution of property as described in &#8220;<font style="font-style: italic;">Agreements Related to the </font><font style="font-style: italic;">Contributions</font><font style="font-style: italic;">&#8212;CVR Agreement&#8212;Material U.S. Federal Income Tax </font><font style="font-style: italic;">Consequences of the Receipt of CVRs</font>&#8221;) and (ii)&#160;the excess (if any) of (A) the sum of (1) the fair market value of the CVRs received and (2) the fair market value of the shares of Catalyst Common Stock received in the Reverse Stock Split (including any cash in lieu of a fractional share) over (B) the Catalyst U.S. holder&#8217;s adjusted tax basis in the Catalyst Common Stock surrendered in the Reverse Stock Split.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">CATALYST&#8217;S BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THIS PROPOSAL NO. 4.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;FOR&#8221; the approval of this Proposal No. 4.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">188<br></div></div></div>
<!--End Page 199-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 200-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">PROPOSAL NO. 5:<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195; <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><a name="tPROP5"><!--Anchor--></a>ADOPTION AND APPROVAL OF AN AMENDMENT TO CATALYST&#8217;S RESTATED CERTIFICATE OF INCORPORATION TO CREATE A NEW CLASS OF NON-VOTING COMMON STOCK OF CATALYST</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">General </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst is seeking stockholder approval for a proposal to adopt an amendment to its restated certificate of incorporation to authorize up to 20,000,000 shares of non-voting common stock, par value $0.001 per share (&#8220;Catalyst Non-Voting Common Stock&#8221;). </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s restated certificate of incorporation currently authorizes 100,000,000 shares of common stock, par value $0.001 per share and 5,000,000 shares of preferred stock, par value $0.001 per share, of which &#8195;&#8195;&#8195; shares of common stock and no shares of preferred stock were outstanding as of &#8195;&#8195;&#8195; , 2023, the record date for the Catalyst special meeting. The proposed amendment to Catalyst&#8217;s restated certificate of incorporation would not increase or otherwise affect its authorized preferred stock. Catalyst Common Stock is currently all of a single class, with equal voting, distribution, liquidation and other rights. Holders of Catalyst Non-Voting Common Stock to be authorized by adoption of the amendment will have identical rights to holders of Catalyst Common Stock, provided that, (i)&#160;except as otherwise expressly provided in Catalyst&#8217;s restated certificate of incorporation or as required by applicable law, on any matter that is submitted to a vote by Catalyst&#8217;s stockholders, holders of Catalyst Non-Voting Common Stock will not be entitled to any votes per share of Catalyst Non-Voting Common Stock, including for the election of directors and (ii)&#160;holders of Catalyst Non-Voting Common Stock will have the right to convert each share of Catalyst Non-Voting Common Stock into one share of Catalyst Common Stock at such holder&#8217;s election, provided that as a result of such conversion, such holder, together with its affiliates and any members of a Schedule 13(d) group with such holder, would not beneficially own in excess of 9.99% of Catalyst Common Stock immediately prior to and following such conversion (the &#8220;Non-Voting Beneficial Ownership Limitation&#8221;), unless otherwise as expressly provided for in Catalyst&#8217;s restated certificate of incorporation. However, the Non-Voting Beneficial Ownership Limitation may be increased or decreased to any other percentage (not to exceed 19.99%) designated by such holder of Catalyst Non-Voting Common Stock upon 61 days&#8217; notice to Catalyst. The Non-Voting Common Stock will not be listed on any securities exchange.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">A copy of the amendment to Catalyst&#8217;s restated certificate of incorporation is attached as Annex&#160;E to this proxy statement. If Catalyst&#8217;s stockholders approve this proposal, subject to the discretion of Catalyst&#8217;s board of directors, Catalyst intends to file the amendment to its restated certificate of incorporation with the Secretary of State of the State of Delaware prior to the Effective Time. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Purpose </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s board of directors believes that the creation of Catalyst Non-Voting Common Stock will help generate investor interest in Catalyst by allowing potential investors to purchase Catalyst Non-Voting Common Stock in the event that potential investors do not want to purchase in excess of 9.99% of Catalyst Common Stock. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Except for (i)&#160;the issuance of shares pursuant to the terms of the Business Combination Agreement, which is the subject of Proposal No. 1 and which is described elsewhere in this proxy statement, (ii)&#160;the issuance of Catalyst Common Stock upon the conversion of Catalyst Convertible Preferred Stock, which is the subject of Proposal No.&#160;2 and which is described elsewhere in this proxy statement and (iii)&#160;the issuance of shares that may result from the shares available for issuance under the 2023 Omnibus Incentive Plan, which is the subject of Proposal No. 6, Catalyst does not currently have any plans, proposals or arrangement to issue any of its authorized but unissued shares of common stock.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Possible Effects of the Amendment </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst Non-Voting Common Stock will rank pari passu with Catalyst Common Stock with respect to the payment of dividends or distributions. Accordingly, the holders of record of Catalyst Non-Voting Common Stock will be entitled to receive as, when and if declared by the board of directors of Catalyst, dividends in the same per share amount as paid on Catalyst Common Stock and no dividends will be payable on Catalyst Common Stock or any other class or series of Catalyst&#8217;s capital stock ranking with respect to dividends pari passu with Catalyst&#8217;s Common Stock unless a dividend identical to that paid on Catalyst&#8217;s Common Stock is payable at the same time on the Non-Voting Common Stock in an amount per share equal to the product of (i)&#160;the per share dividend declared and paid in respect </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">189<br></div></div></div>
<!--End Page 200-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 201-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">of each share of Catalyst Common Stock and (ii)&#160;the number of shares of Catalyst Common Stock into which such share of Catalyst Non-Voting Common Stock is then convertible (without regard to any limitations on conversion of Catalyst Non-Voting Common Stock); provided, however, that if a stock dividend is declared on Catalyst Common Stock payable solely in Catalyst Common Stock, the holders of Catalyst Non-Voting Common Stock will be entitled to a stock dividend payable solely in shares of Catalyst Non-Voting Common Stock. In the event that the board of directors of Catalyst does not declare or pay any dividends with respect to shares of the Catalyst Common Stock, the holders of Catalyst Non-Voting Common Stock will have no right to receive any dividends. The holders of Catalyst Non-Voting Common Stock will, with respect to rights upon liquidation, winding up and dissolution, rank (i)&#160;subordinate and junior in right of payment to all other securities of Catalyst that, by their respective terms, are senior to Catalyst Non-Voting Common Stock or Catalyst Common Stock and (ii)&#160;pari passu with Catalyst Common Stock.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The holders of Catalyst Non-Voting Common Stock will not have any voting rights, except as may otherwise from time to time be required by law. Catalyst Non-Voting Common Stock will not be redeemable at the option of Catalyst or any holder thereof at any time; provided that Catalyst will not be prohibited from repurchasing or otherwise acquiring the shares of Catalyst Non-Voting Common Stock in voluntary transactions with the holders thereof, subject to compliance with any applicable legal or regulatory requirements. Any shares of Catalyst Non-Voting Common Stock repurchased or otherwise acquired may be reissued as additional shares of Catalyst Non-Voting Common Stock.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Each holder of Catalyst Non-Voting Common Stock will be permitted to convert such holder&#8217;s shares of Non-Voting Common Stock into shares of Catalyst Common Stock at any time or from time to time; provided that upon such conversion, the holder, together with all affiliates of the holder, will not own or control in the aggregate more than 9.9% of Catalyst Common Stock (or of any class of Catalyst&#8217;s voting securities), excluding for the purpose of this calculation any reduction in the ownership resulting from transfers by such holder of voting securities (which does not include Catalyst Non-Voting Common Stock). In any such conversion of Catalyst Non-Voting Common Stock, each share of Catalyst Non-Voting Common Stock will convert into one share of Catalyst Common Stock.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Upon conversion of the shares of Catalyst Non-Voting Common Stock to shares of Catalyst Common Stock, the converted shares of Catalyst Common Stock would have the same rights and privileges as the previously issued and outstanding shares of Catalyst Common Stock, including the right to cast one vote per share and to participate in dividends when and to the extent declared and paid by Catalyst. Any issuance of additional shares of Catalyst Common Stock as a result of the conversion of the shares of Catalyst Non-Voting Common Stock would increase the total number of outstanding shares of Catalyst Common Stock, which would result in dilution to the percentage ownership, voting power and earnings per share of the existing holders of Catalyst Common Stock.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">CATALYST&#8217;S BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THIS PROPOSAL NO. 5.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;FOR&#8221; the approval of this Proposal No. 5.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">190<br></div></div></div>
<!--End Page 201-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 202-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">PROPOSAL NO. 6<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><a name="tPROP6"><!--Anchor--></a>APPROVAL OF THE GYRE THERAPEUTICS, INC. 2023 OMNIBUS INCENTIVE PLAN</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Overview</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Assuming that the Contributions are approved, Catalyst&#8217;s stockholders are also being asked to approve and adopt the 2023 Omnibus Incentive Plan. In designing the 2023 Omnibus Incentive Plan, the anticipated future equity needs were considered, and a total of &#8195;&#8195;&#8195; shares of Catalyst Common Stock will be reserved for issuance under the 2023 Omnibus Incentive Plan (representing &#8195;&#8195;&#8195; % of Catalyst&#8217;s fully diluted common stock as of &#8195;&#8195;&#8195; , 2023). Catalyst&#8217;s board of directors has approved the 2023 Omnibus Incentive Plan, subject to receiving stockholder approval. A summary of the principal features of the 2023 Omnibus Incentive Plan is provided below. This summary does not purport to be complete and is subject to, and qualified in its entirety by, the complete text of the 2023 Omnibus Incentive Plan. If the Contributions are consummated and the 2023 Omnibus Incentive Plan is approved by Catalyst&#8217;s stockholders, the 2023 Omnibus Incentive Plan will be assumed by the combined company and a number of shares of the combined company equal to the number of Catalyst shares reserved under the 2023 Omnibus Incentive Plan will be issuable under the 2023 Omnibus Incentive Plan, and no additional awards will be granted under our 2018 Omnibus Incentive Plan, our current equity compensation plan.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If the Contributions are consummated and the 2023 Omnibus Incentive Plan is not approved by Catalyst&#8217;s stockholders, Catalyst will be unable to make equity grants to its employees, consultants and directors, and therefore Catalyst will be at a significant competitive disadvantage in attracting, retaining and motivating talented individuals who contribute to Catalyst&#8217;s success.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Considerations for the Approval of the Plan</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The 2023 Omnibus Incentive Plan incorporates corporate governance best practices to align Catalyst&#8217;s equity compensation program with the interests of Catalyst&#8217;s stockholders. Certain of the corporate governance best practices included in the 2023 Omnibus Incentive Plan are as follows:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><font style="font-style: italic;">Restricted dividends on awards</font>. The 2023 Omnibus Incentive Plan prohibits the payment of dividends in respect of an award (other than awards of restricted stock) prior to the time such award (or the applicable portion thereof) vests (and, in the case of performance awards, the applicable performance condition is achieved).</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><font style="font-style: italic;">No &#8220;liberal&#8221; change in control definition</font>. The change in control definition under the 2023 Omnibus Incentive Plan is only triggered in those instances where an actual change in control occurs, such as a 50% or greater change in beneficial ownership (see &#8220;Change in Control,&#8221; below).</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><font style="font-style: italic;">Clawback of awards</font>. The 2023 Omnibus Incentive Plan provides that awards granted thereunder are subject to any clawback or recoupment policies that we have in effect from time to time.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Summary of the 2023 Omnibus Incentive Plan</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Purpose</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The purpose of the 2023 Omnibus Incentive Plan is to enable Catalyst to offer its employees, directors and other individual service providers long-term equity-based incentives in Catalyst, thereby attracting, retaining and rewarding such individuals, and strengthening the mutuality of interests between such individuals and Catalyst&#8217;s stockholders.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Eligibility</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s employees, non-employee directors, individual consultants, advisors and other service providers are eligible to receive awards under the 2023 Omnibus Incentive Plan based on the Compensation Committee&#8217;s determination, in its sole discretion, that an award to such individual will further the 2023 Omnibus Incentive Plan&#8217;s stated purpose (as described above). Awards of incentive stock options will be limited to Catalyst&#8217;s employees or certain of Catalyst&#8217;s affiliates. As of &#8195;&#8195;&#8195; , 2023 there are approximately &#8195;&#8195;&#8195; employees and approximately&#8195;&#8195;&#8195; individual consultants, directors, advisers and other service providers eligible to receive awards under the 2023 Omnibus Incentive Plan. Following the consummation of the Contributions, approximately &#8195;&#8195;&#8195; employees and &#8195;&#8195;&#8195; individual consultants, directors, advisers and other service providers of the combined company are expected to be eligible to receive awards under the 2023 Omnibus Incentive Plan.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">191<br></div></div></div>
<!--End Page 202-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 203-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Authorized Shares</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Subject to adjustment (as described below), the number of shares of Catalyst Common Stock that may be subject to awards granted under the 2023 Omnibus Incentive Plan is &#8195;&#8195;&#8195; , and the number of shares of Catalyst Common Stock that may be subject to incentive stock options granted under the 2023 Omnibus Incentive Plan is &#8195;&#8195;&#8195; . The number of shares of Catalyst Common Stock reserved for issuance under the 2023 Omnibus Incentive Plan will automatically increase on the first day of each calendar year during the term of the 2023 Omnibus Incentive Plan, commencing on January&#160;1, 2024 (assuming the 2023 Omnibus Incentive Plan becomes effective in 2023) through January&#160;1, 2033, by the least of (i) &#8195;&#8195;&#8195; % of the total number of shares of all classes of Catalyst Common Stock outstanding on December 31 of the immediately preceding calendar year or (ii)&#160;such smaller number of shares of our common stock as determined by our board of directors. If an award expires or is canceled or forfeited, or is otherwise settled without the issuance of shares, the shares covered by the award will again be available for issuance under the 2023 Omnibus Incentive Plan. Shares tendered or withheld to pay or satisfy the exercise price of a stock option or SAR or to pay taxes in respect of any stock option or SAR, will again be available for issuance under the 2023 Omnibus Incentive Plan. Shares underlying replacement awards (<font style="font-style: italic;">i.e.</font>, awards granted as replacements for awards granted by a company that we acquire or with which we combine) will not reduce the number of shares available for issuance under the plan. The 2023 Omnibus Incentive Plan limits non-employee director compensation, including cash fees and incentive equity awards (based on their grant-date fair value), to a maximum of (i) $750,000 during the initial annual period following a non-employee director&#8217;s appointment or election to our board of directors and (ii) $500,000 per each subsequent calendar year, in each case, in respect of their service as non-employee directors. The limitation on non-employee director compensation applies beginning the first calendar year following the effective date of the 2023 Omnibus Incentive Plan.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Administration</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The 2023 Omnibus Incentive Plan is administered by the Compensation Committee.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The Compensation Committee has authority under the 2023 Omnibus Incentive Plan to:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">designate participants;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">determine the types of awards to grant, the number of shares to be covered by awards, the terms and conditions of awards, the circumstances under which awards may be canceled, forfeited or suspended, and whether awards may be deferred;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">amend the terms of any outstanding awards;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">correct any defect, supply any omission or reconcile any inconsistency in the 2023 Omnibus Incentive Plan or any award agreement, in the manner and to the extent it shall deem desirable to carry the 2023 Omnibus Incentive Plan into effect;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">interpret and administer the 2023 Omnibus Incentive Plan and any instrument or agreement relating to, or award made under, the 2023 Omnibus Incentive Plan; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">make any other determination and take any other action that it deems necessary or desirable to administer the 2023 Omnibus Incentive Plan, in each case, as it deems appropriate for the proper administration of the 2023 Omnibus Incentive Plan and compliance with applicable law, stock market or exchange rules and regulations or accounting or tax rules and regulations.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Compensation Committee may delegate some or all of its authority under the 2023 Omnibus Incentive Plan, to the extent permitted by applicable law, to (i)&#160;one or more of Catalyst&#8217;s officers (except that such delegation will not be applicable to grant awards to a person then covered by Section 16 of the Exchange Act) and (ii)&#160;one or more committees of Catalyst&#8217;s board of directors.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Establishment of Sub-Plans</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s board of directors has the authority to establish one or more sub-plans under the 2023 Omnibus Incentive Plan to facilitate the local administration of the 2023 Omnibus Incentive Plan in any jurisdiction in which Catalyst and Catalyst&#8217;s affiliates operate and to conform the 2023 Omnibus Incentive Plan to the legal requirements of any such jurisdiction or to allow for favorable tax treatment under any applicable provision of tax law. Catalyst&#8217;s board of directors may establish such sub-plans by adopting supplements setting forth (i)&#160;such limitations on the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">192<br></div></div></div>
<!--End Page 203-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 204-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Compensation Committee&#8217;s discretion under the 2023 Omnibus Incentive Plan as the board of directors deems necessary or desirable and (ii)&#160;such additional terms and conditions not otherwise inconsistent with the 2023 Omnibus Incentive Plan as the board of directors deems necessary or desirable. All sub-plans adopted by the board of directors will be deemed to be part of the 2023 Omnibus Incentive Plan, but each such sub-plan will only apply to participants within the affected jurisdiction.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Types of Awards</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The 2023 Omnibus Incentive Plan provides for grants of stock options (both nonqualified and incentive stock options), SARs, restricted stock, restricted stock units, performance awards and other cash-based or stock-based awards. Any award may be granted alone or in tandem with other awards, and may be granted in addition to, or in substitution for, other types of awards.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Stock Options<font style="font-style: normal;">. A stock option is a contractual right to purchase shares at a future date at a specified exercise price. </font><font style="font-style: normal;">The per share exercise price of a stock option will be determined by the Compensation Committee and may not be </font><font style="font-style: normal;">less than the fair market value of a share of Catalyst Common Stock on the grant date. The Compensation Committee </font><font style="font-style: normal;">will determine the date after which each stock option may be exercised, the method and form by which each option </font><font style="font-style: normal;">is to be exercised, and the expiration date of each option, provided that no option will be exercisable more than </font><font style="font-style: normal;">10&#160;years after the grant date. Options intended to be incentive stock options under Section 422 of the Code may not </font><font style="font-style: normal;">be granted to any person who is not an employee of us or any parent or subsidiary, as defined in Section 424 of the </font><font style="font-style: normal;">Code. There have not yet been any options granted under the 2023 Omnibus Incentive Plan, and so there are no </font><font style="font-style: normal;">options outstanding under the 2023 Omnibus Incentive Plan.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Stock Appreciation Rights<font style="font-style: normal;">. Stock appreciation rights (SARs) represent a contractual right to receive, in cash or shares, </font><font style="font-style: normal;">an amount equal to the appreciation of one share from the grant date. The terms and conditions applicable to stock </font><font style="font-style: normal;">options also apply to SARs.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Restricted Stock<font style="font-style: normal;">. Restricted stock is an award of shares that are subject to restrictions on transfer and a substantial </font><font style="font-style: normal;">risk of forfeiture. Recipients of restricted stock generally have the rights and privileges of a stockholder, including </font><font style="font-style: normal;">the right to vote such shares of restricted stock and receive dividends.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Restricted Stock Units<font style="font-style: normal;">. A restricted stock unit award is a right to receive a specified number of shares of Catalyst </font><font style="font-style: normal;">Common Stock (or the fair market value thereof in cash, other property or any combination thereof, as determined </font><font style="font-style: normal;">by the Compensation Committee), subject to the expiration of a specified restriction period and/or the achievement </font><font style="font-style: normal;">of any performance measures selected by the Compensation Committee, consistent with the terms of the 2023 </font><font style="font-style: normal;">Omnibus Incentive Plan. The restricted stock unit award agreement will specify whether the award recipient is </font><font style="font-style: normal;">entitled to receive dividend equivalents with respect to the number of shares of Catalyst Common Stock subject to </font><font style="font-style: normal;">the award. Prior to the settlement of a restricted stock unit award in Catalyst Common Stock, the award recipient will </font><font style="font-style: normal;">have no rights or privileges as a stockholder of Catalyst with respect to Catalyst Common Stock subject to the award.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Performance Awards<font style="font-style: normal;">. Performance awards, which may be denominated in cash, shares or units (including restricted </font><font style="font-style: normal;">stock units), will be earned on the satisfaction of performance goals specified by the Compensation Committee. With </font><font style="font-style: normal;">respect to any performance award that becomes settled in Catalyst Common Stock upon achievement or satisfaction </font><font style="font-style: normal;">of the applicable performance conditions, prior to such settlement the award recipient will have no rights or privileges </font><font style="font-style: normal;">as a stockholder of Catalyst with respect to Catalyst Common Stock subject to the award.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Other Cash-Based and Other Stock-Based Awards<font style="font-style: normal;">. The Compensation Committee is authorized to grant other </font><font style="font-style: normal;">cash-based and other stock-based awards that are payable in cash or Catalyst Common Stock (or a combination </font><font style="font-style: normal;">thereof), and may be granted either independently or as an element of or supplement to any other award under the </font><font style="font-style: normal;">2023 Omnibus Incentive Plan. Other stock-based awards are valued in whole or in part by reference to such stock, </font><font style="font-style: normal;">including restricted stock units, phantom stock and similar units.</font></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Dividends and Dividend Equivalents</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Other than with respect to awards of restricted stock, awards granted under the 2023 Omnibus Incentive Plan may not provide for any dividend to be payable to the participant in respect of such award prior to the time such award (or the applicable portion thereof) vests (and, in the case of performance awards, the applicable performance condition is achieved). The Compensation Committee may, in its discretion, provide for dividend equivalents on awards of restricted stock units.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">193<br></div></div></div>
<!--End Page 204-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 205-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Adjustments</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In the event the Compensation Committee determines that, as a result of any dividend or other distribution (other than an ordinary dividend or distribution), recapitalization, stock split, reverse stock split, reorganization, merger, amalgamation, consolidation, separation, rights offering, split-up, spin-off, combination, repurchase or exchange of shares of our common stock or other securities, or other similar corporate transaction or event affecting our common stock or of changes in applicable laws, regulations or accounting principles, an adjustment is necessary to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the 2023 Omnibus Incentive Plan, the Compensation Committee will adjust equitably any or all of: (i)&#160;the number and type of shares or other securities that thereafter may be made the subject of awards, including the aggregate limit under the 2023 Omnibus Incentive Plan; (ii)&#160;the number and type of shares or other securities subject to outstanding awards; (iii)&#160;the grant, purchase, exercise or hurdle price for any award or, if deemed appropriate, make provision for a cash payment to the holder of an outstanding award; and (iv)&#160;the terms and conditions of any outstanding awards, including the performance criteria of any performance awards.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Change in Control</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In the event of a change in control, except as otherwise provided in the applicable award agreement, the Compensation Committee may provide for:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">continuation or assumption of outstanding awards under the 2023 Omnibus Incentive Plan by Catalyst (if&#160;Catalyst is the surviving corporation) or by the surviving corporation or its parent;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">substitution or replacement or any outstanding award for a cash payment;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">acceleration of the vesting (including the lapse of any restriction) and exercisability of outstanding awards, in each case, either (i)&#160;immediately prior to or as of the date of the change in control, (ii)&#160;upon a participant&#8217;s involuntary termination of service on or within a specified period following the change in control, or (iii)&#160;upon the failure of the successor or surviving corporation (or its parent) to continue or assume such outstanding awards;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">in the case of a performance award, determination of the level of attainment of the applicable performance conditions; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">cancellation of outstanding awards under the 2023 Omnibus Incentive Plan in consideration of a payment, with the form, amount and timing of such payment to be determined by the Compensation Committee in its sole discretion, provided that (i)&#160;such payment is made in cash, securities, rights and/or other property, (ii)&#160;the amount of such payment equals the value of the award, as determined by the Compensation Committee in its sole discretion (provided that the Compensation Committee may cancel out-of-the-money options or SARs for no consideration) and (iii)&#160;such payment will be made promptly following the change in control, in compliance with Section 409A of the Code.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">A change in control generally means (i)&#160;the acquisition of 50% or more of Catalyst Common Stock or combined voting power of voting securities; (ii)&#160;a change in the composition of Catalyst&#8217;s board of directors such that, during any 12-month period, the individuals who as of the beginning of such period constitute Catalyst&#8217;s board of directors cease for any reason to constitute at least 50% of Catalyst&#8217;s board of directors (provided that any individual becoming a member of Catalyst&#8217;s board of directors after the beginning of such 12-month period whose election or nomination for election by Catalyst&#8217;s stockholders was approved by a vote of at least a majority of the directors immediately prior to the date of such appointment or election will be considered as though such individual were a member of Catalyst&#8217;s board of directors at the beginning of such 12-month period); (iii)&#160;Catalyst&#8217;s merger or consolidation with another entity after which Catalyst&#8217;s voting securities outstanding immediately prior to such transaction do not continue to represent 50% or more of the total voting power of Catalyst&#8217;s stock or of the surviving entity or parent entity thereof (if we are not the surviving entity in such merger or consolidation); or (iv)&#160;a disposition of all or substantially all of Catalyst&#8217;s assets.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Amendment and Termination</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s board of directors may amend, modify, suspend, discontinue or terminate the 2023 Omnibus Incentive Plan (or any portion thereof) at any time. However, no such action may, without the consent of the participant, materially adversely affect the rights of such participant under any award previously granted (other than to apply with applicable </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">194<br></div></div></div>
<!--End Page 205-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 206-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">law or to impose any clawback or recoupment provisions on any awards). Additionally, no such action may be made without Catalyst&#8217;s stockholder approval, if such approval is required by applicable law or by the rules of the stock market or exchange on which our common shares are principally quoted or traded. No award may be granted pursuant to the 2023 Omnibus Incentive Plan after the 10th anniversary of the date on which the 2023 Omnibus Incentive Plan was approved by Catalyst&#8217;s stockholders.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Repricing</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Compensation Committee may, through cancellation or re-grant or any other method, reduce, or have the effect of reducing, the exercise or hurdle price of any award established at the time of grant without approval of our stockholders.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Cancellation or &#8220;Clawback&#8221; of Awards</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Compensation Committee may, to the extent permitted by applicable law and stock exchange rules or by any of Catalyst&#8217;s policies (including any recoupment policy Catalyst may adopt from time to time or pursuant to the recoupment provisions in any award agreement), cancel or require reimbursement of any awards granted, shares issued or cash received upon the vesting, exercise or settlement of any awards granted under the 2023 Omnibus Incentive Plan or the sale of shares underlying such awards.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Term</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The 2023 Omnibus Incentive Plan expires 10&#160;years after the date on which the Contributions are consummated, unless earlier terminated (x)&#160;upon the maximum number of shares of common stock available for issuance under the 2023 Omnibus Incentive Plan having been issued or (y) by the board of directors at its discretion (and in accordance with the terms of the 2023 Omnibus Incentive Plan).</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">U.S. Federal Income Tax Consequences of Equity Awards</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following is a general summary under current law of certain United States federal income tax consequences to Catalyst and participants who are citizens or individual residents of the United States relating to awards granted under the 2023 Omnibus Incentive Plan. This summary deals with the general tax principles that apply to such awards and is provided only for general information. Certain kinds of taxes, such as foreign taxes, state and local income taxes, payroll taxes and the alternative minimum tax, are not discussed. This summary is not tax advice and it does not discuss all aspects of federal taxation that may be relevant to Catalyst and participants. Accordingly, Catalyst urges each participant to consult his or her own tax advisor as to the specific tax consequences of participation in the 2023 Omnibus Incentive Plan under federal, state, local and other applicable laws. In addition, Catalyst may be subject to limits on tax deductibility relating to compensation described herein under certain statutory provisions, including Sections 162(m) and 280G of the Code.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Non-Qualified Stock Options</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">A non-qualified stock option is an option that does not meet the requirements of Section 422 of the Code. A&#160;participant generally will not recognize taxable income when granted a non-qualified stock option. When the participant exercises the stock option, he or she generally will recognize taxable ordinary income equal to the excess of the fair market value of the shares received on the exercise date over the aggregate exercise price of the shares. The participant&#8217;s tax basis in the shares acquired on exercise of the option will be increased by the amount of such taxable income. Catalyst generally will be entitled to a corresponding federal income tax deduction. When the participant sells the shares acquired on exercise, the participant generally will realize long-term or short-term capital gain or loss, depending on whether the participant holds the shares for more than one year before selling them.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Incentive Stock Options</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">An incentive stock option (&#8220;ISO&#8221;) is an option that meets the requirements of Section 422 of the Code. A participant will not have taxable income when granted an ISO or when exercising an ISO. If a participant exercises an ISO and does not dispose of the shares until the later of two years after the grant date and one year after the exercise date, the entire gain, if any, realized when the participant sells the shares will be taxable as long-term capital gain. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">195<br></div></div></div>
<!--End Page 206-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 207-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg20"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">However, even though a participant will not have taxable income when exercising an ISO, the exercise of an ISO is taken into account for purposes of determining whether the participant has any alternative minimum tax liability (described below). Catalyst generally will not be entitled to a corresponding federal income tax deduction.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If a participant disposes of the shares received upon exercise of an ISO within the one-year or two-year periods described above, it will be considered a &#8220;disqualifying disposition.&#8221; Under such circumstances, the participant generally will realize ordinary income in the year of the disposition, and Catalyst generally will be entitled to a corresponding federal income tax deduction. The amounts of the participant&#8217;s ordinary income and Catalyst&#8217;s deduction will equal the excess of the lesser of the amount, if any, realized on the disposition and the fair market value of the shares on the exercise date over the aggregate exercise price of the ISO. Any additional gain or loss that the participant realizes on the disposition will be long-term or short-term capital gain or loss, depending on whether the participant holds the shares for more than one year before selling them.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If a participant exercises an ISO more than three months after the participant&#8217;s employment with Catalyst terminates, the option will be treated as a non-qualified stock option for federal income tax purposes. If a participant is disabled and terminates employment because of his or her disability, the three-month period is extended to one year. The three-month period does not apply in the case of a participant&#8217;s death.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Stock Appreciation Rights (SARs)</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">A participant does not recognize income at the time a SAR is granted. A participant will recognize income at the time cash or stock representing the amount of the appreciation is transferred to the participant pursuant to exercise of a SAR. The amount of income will equal the amount of cash or fair market value of shares paid or transferred to the participant and will be ordinary income. Catalyst generally will be entitled to a corresponding federal income tax deduction.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Restricted Stock</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Unless a participant makes an election to accelerate recognition of the income to the date of grant as described below, the participant generally will not recognize income, and Catalyst generally will not be entitled to a corresponding federal income tax deduction at the time restricted stock is granted. When the restrictions lapse, the participant generally will recognize ordinary income equal to the fair market value of the shares as of that date, less any amount paid for the restricted stock, and Catalyst generally will be entitled to a corresponding federal income tax deduction at that time. If the participant files an election under Section 83(b) of the Code within 30 days after the date of grant of the restricted stock, the participant generally will recognize ordinary income as of the date of grant equal to the fair market value of the common shares as of that date, less any amount the participant paid for the restricted stock, and Catalyst generally will be entitled to a corresponding federal income tax deduction at that time. Any future appreciation in the shares generally will be taxable to the participant at capital gains rates. However, if the restricted stock is later forfeited, the participant generally will not be able to recover the tax previously paid pursuant to his Section 83(b) election.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Restricted Stock Units</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">A participant does not recognize taxable income at the time of grant of a restricted stock unit, and Catalyst is not entitled to a tax deduction at that time. The participant will recognize compensation taxable as ordinary income (and subject to income tax withholding), however, at the time of the settlement of the award, equal to the fair market value of any shares delivered and the amount of cash paid by Catalyst. Catalyst will be entitled to a corresponding deduction, except to the extent that the deduction limits of Section 162(m) of the Code apply.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">PRC Sub-plan</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The PRC Sub-plan will govern stock options granted to certain BC employees or service providers. The PRC Sub-plan is generally intended to replace BC&#8217;s 2021 Plan, which will be terminated (along with all options outstanding thereunder) effective as of the closing of the Contributions. The terms and conditions of the PRC Sub-plan and the options granted thereunder will generally be substantially similar in all material respects to the 2021 Plan and the options that were outstanding thereunder immediately prior to the closing of the Contributions.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">CATALYST&#8217;S BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THIS PROPOSAL NO. 6.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;FOR&#8221; the approval of this Proposal No. 6.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">196<br></div></div></div>
<!--End Page 207-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 208-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg21"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">PROPOSAL NO. 7<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195; <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><a name="tPROP7"><!--Anchor--></a>ADOPTION AND APPROVAL OF AN AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF CATALYST TO ADOPT ACTION BY WRITTEN CONSENT OF THE STOCKHOLDERS</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">General </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Assuming that the Contributions are approved, Catalyst is seeking stockholder approval for a proposal to adopt an amendment to its restated certificate of incorporation to allow stockholders to act by written consent, for so long as GNI USA and its affiliates beneficially own 50% or more of the combined voting power of the outstanding shares of Catalyst common stock. The form of the amendment to Catalyst&#8217;s restated certificate of incorporation to allow stockholder action by written consent, which Catalyst&#8217;s board of directors approved and declared advisable on &#8195;&#8195;&#8195; , 2023, is attached as Annex&#160;E to this proxy statement. If this Proposal No. 7 is approved, the amendment to allow stockholder action by written consent would become effective immediately following the closing of the Contributions. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Background and Purpose </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under Section 228 of the DGCL, stockholders may act by written consent to take any action which may be or is required to be taken at any annual or special meeting of stockholders, without prior notice and without a vote, unless otherwise specified in a company's certificate of incorporation. Catalyst&#8217;s restated certificate of incorporation currently requires that such actions only be taken at an annual or special meeting of stockholders. The purpose of the amendment is to streamline and increase the efficiency of the combined company&#8217;s corporate governance processes following the Contributions and eliminate the need to incur the unnecessary time and expense associated with convening special meetings of stockholders. This change would be effective for so long as the combined company is considered a &#8220;controlled company&#8221; under Nasdaq rules and is generally consistent with governance practices among other controlled companies. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, following the amendment, to the extent that the stockholders of Catalyst were to act by written consent, SEC rules generally would require Catalyst to distribute an information statement to stockholders whose consent was not solicited and to disclose on Form 8-K the actions taken by written consent.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Effect of the Amendment </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If this amendment is approved, Catalyst&#8217;s certificate of incorporation will be amended allow to stockholders to act by written consent for so long as GNI USA and its affiliates beneficially own 50% or more of the combined voting power of the outstanding shares of Catalyst common stock.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">CATALYST&#8217;S BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THIS PROPOSAL NO. 7.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;FOR&#8221; the approval of this Proposal No. 7.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">197<br></div></div></div>
<!--End Page 208-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 209-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg22"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">PROPOSAL NO. 8<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195; <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><a name="tPROP8"><!--Anchor--></a>ELECTION OF DIRECTORS</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The total number of authorized directors on Catalyst&#8217;s board of directors is currently fixed at five. Pursuant to Catalyst&#8217;s certificate of incorporation and bylaws, Catalyst&#8217;s board of directors is divided into three classes with staggered three-year terms. At the special meeting (which is being held in lieu of an annual meeting of stockholders for 2023), stockholders will vote to elect each of the two Class&#160;II director nominees named in this proxy statement to serve until the 2026 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified or until his or her earlier resignation or removal (including in connection with the Contributions, as discussed below). Notwithstanding stockholder approval of this proposal, if stockholders approve Proposals 1, 2, 3, 4, 5 and 6, then it is expected that at the Effective Time Andrea Hunt and Augustine Lawlor will resign from the board of directors, the size of the board of directors will be increased to eight (8) directors, and Gordon G. Carmichael, Ph.D., Songjiang Ma, Renate Perry, Ph.D., Charles Wu, Ph.D. and Han Ying, Ph.D. will be appointed to the board of directors, as discussed in more detail in <font style="font-style: italic;">Management of the Combined Company&#8212;Executive Officers and Directors of the </font><font style="font-style: italic;">Combined Company Following the Contributions</font>.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s board of directors has nominated Andrea Hunt and Nassim Usman, Ph.D. as the Class&#160;II director nominees. Ms.&#160;Hunt currently serves as a Class&#160;II director. Dr. Usman currently serves as a Class&#160;III director. Catalyst&#8217;s board of directors has determined that effective as of the special meeting in lieu of an annual meeting of stockholders for 2023, and subject to election by the stockholders, Dr. Usman be moved to Class&#160;II. Ms.&#160;Hunt and Dr. Usman were each most recently elected by stockholders at the 2020 Annual Meeting of Stockholders, and each has indicated that he or she is willing and able to serve as a director. However, if either of the nominees becomes unable or, for good cause, unwilling to serve, proxies may be voted for the election of such other person or persons as shall be designated by Catalyst&#8217;s board of directors, or the board of directors may decrease the size of the board of directors.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Stockholders cannot submit proxies voting for a greater number of persons than the two nominees named in this Proposal No. 8. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">There are no family relationships between any of Catalyst&#8217;s directors, its nominees or its executive officers. Except in connection with the F351 Agreement and Business Combination Agreement, there are also no arrangements or understandings between any director, nominee or executive officer and any other person pursuant to which he or she has been or will be selected as a director and/or executive officer. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Nominees for Class&#160;II Director </div> <table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div></td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 2.85%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Age</div></td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.89%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class</div></td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 38.46%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Position</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Andrea Hunt<font style="padding-left: 0.74pt;"></font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.85%; text-align: center; vertical-align: top; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.67pt; text-align: left;">63</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.89%; text-align: center; vertical-align: top; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.78pt; text-align: left;">II</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 38.46%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Audit Committee Member; Compensation <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Committee Member; Governance and <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Nominating Committee Chair</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Nassim Usman, Ph.D.<font style="padding-left: 3.25pt;"></font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.85%; text-align: center; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.67pt; text-align: left;">64</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.89%; text-align: center; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.78pt; text-align: left;">II</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 38.46%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">President and Chief Executive Officer</div></td></tr></table> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Andrea Hunt<font style="font-weight: normal;"> has served on Catalyst&#8217;s board of directors since October 2017. Ms.&#160;Hunt served as the Vice President </font><font style="font-weight: normal;">of New Product Gene Therapy, Neuroscience, Oncology and Ophthalmology with Shire from June 2016 until June </font><font style="font-weight: normal;">2017, where she developed and integrated disease area strategies for Shire&#8217;s gene therapy platform, Neuroscience, </font><font style="font-weight: normal;">Oncology and Ophthalmology franchises. She previously served as the Vice President - Global Franchise Head for </font><font style="font-weight: normal;">Blood Disorders with Baxalta from June 2015 to June 2016 before it was acquired by Shire. From 1988 to 2015, </font><font style="font-weight: normal;">Ms.&#160;Hunt served in various roles with Baxter Healthcare, most recently as Vice President - Lead BAX855 and Gene </font><font style="font-weight: normal;">Therapy in the Biosciences division from 2014 to June 2015. Ms.&#160;Hunt serves on the board of OX2 Therapeutics, </font><font style="font-weight: normal;">and is an advisor to Cell One Partners. She previously served as a board member of the Alliance for Regenerative </font><font style="font-weight: normal;">Medicine and was an advisor to the Angiogenesis Foundation. She also previously served on the Ryan Banks </font><font style="font-weight: normal;">Academy board. Ms.&#160;Hunt received her M.B.A. from the University of Michigan at Ann Arbor and her B.S. in </font><font style="font-weight: normal;">Hospital Dietetics and B.A. in Foods &amp; Nutrition from the University of Illinois at Urbana-Champaign. </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Ms.&#160;Hunt&#8217;s breadth of experience with pharmaceutical and biotechnology companies, together with her service as a director for another biopharmaceutical company, qualifies her to serve on the board of directors. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Nassim Usman, Ph.D.<font style="font-weight: normal;"> served as Chief Executive Officer and a member of the board of directors of Catalyst Bio from </font><font style="font-weight: normal;">February 2006 until the completion of the merger of Catalyst Bio and Catalyst (formerly known as Targacept, Inc.) </font><font style="font-weight: normal;">in August 2015. Since August 2015, Dr. Usman has served as our President and Chief Executive Officer and a </font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">198<br></div></div></div>
<!--End Page 209-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 210-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg23"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">director. Dr. Usman is currently a Venture Partner at Morgenthaler Ventures. Prior to joining Morgenthaler in 2005, he was Senior Vice President and Chief Operating Officer at Sirna Therapeutics Inc., which was subsequently acquired by Merck, from 2004 to 2005, and held various R&amp;D positions at both Sirna and Ribozyme Pharmaceuticals, including Vice President of R&amp;D and Chief Scientific Officer, from 1992 to 2004. During his industrial career, Dr. Usman has overseen the entry of several drugs into clinical development, completion of multiple licensing deals with pharmaceutical and biotechnology companies and raised capital in both private and public financings. Prior to moving into the private sector in 1992, Dr. Usman was an NIH Fogarty and NSERC Postdoctoral Fellow and Scientist in the Departments of Biology and Chemistry at the Massachusetts Institute of Technology from 1987 to 1992. He has authored more than 70 scientific articles and is the named inventor in 130 issued patents and patent applications. Dr. Usman is a past director of Mosaic Biosciences, Principia Biopharma, Osprey Pharmaceuticals, Archemix Corporation and atugen AG (now Silence Therapeutics) and served on the science advisory boards of RXi Pharmaceuticals and Noxxon Pharma AG. He received his B.Sc. (Honours) and Ph.D. in organic chemistry from McGill University. In his doctoral dissertation, he developed a method for the solid-phase synthesis of RNA that is widely used in science and in two marketed RNA products (Macugen&#8482; and Onpattro&#8482;). </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Dr. Usman&#8217;s role as Catalyst&#8217;s President and Chief Executive Officer and extensive experience and innovations in the field of biotechnology, particularly with companies engaged in clinical drug development, qualifies him to serve on the Board. In addition, Dr. Usman&#8217;s academic expertise and accomplishments provide the board of directors with in-depth product and field knowledge. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Continuing Directors </div> <table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 20.51%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div></td><td class="gutter" style="width: 1.01%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.01%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 2.85%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Age</div></td><td class="gutter" style="width: 1.01%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.01%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.89%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class</div></td><td class="gutter" style="width: 1.01%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.01%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 66.67%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Position</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Augustine Lawlor<font style="padding-left: 0.19pt;"></font></div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.85%; text-align: center; vertical-align: top; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.67pt; text-align: left;">67</div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.89%; text-align: center; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">I</div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 66.67%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Audit Committee Chair; Compensation Committee <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Chair; Governance and Nominating Committee Member</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thomas Eastling<font style="padding-left: 0.18pt;"></font></div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.85%; text-align: center; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.67pt; text-align: left;">63</div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.89%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">III</div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 66.67%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Audit Committee Member; Compensation Committee Member</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ying Luo, Ph.D.<font style="padding-left: 1.01pt;"></font></div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.85%; text-align: center; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.67pt; text-align: left;">57</div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.89%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">I</div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 66.67%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Chairman of the Board; Governance and Nominating Committee Member</div></td></tr></table> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Augustine Lawlor<font style="font-weight: normal;"> has served as a member of Catalyst&#8217;s board of directors since February 2006 and as Chairman </font><font style="font-weight: normal;">of the Board since February 2018. Since January 2016, Mr.&#160;Lawlor has served as Chief Operating Officer of Leap </font><font style="font-weight: normal;">Therapeutics, Inc., an oncology company listed on Nasdaq. He has been a Managing Partner of HealthCare Ventures </font><font style="font-weight: normal;">since 2000. From 1997 to 2000, he served as Chief Operating Officer of LeukoSite, Inc., a biotechnology company </font><font style="font-weight: normal;">acquired by Millennium Pharmaceuticals Inc. in 1999. Mr.&#160;Lawlor was previously a management consultant with </font><font style="font-weight: normal;">KPMG. He is currently a director of Cardiovascular Systems, Inc. and PainReform Ltd, which are listed on Nasdaq, </font><font style="font-weight: normal;">and LayerBio, Inc. Mr.&#160;Lawlor received his Master&#8217;s in Public and Private Management from Yale University. </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Mr.&#160;Lawlor&#8217;s experience as a successful venture capitalist, service on the boards of public and private companies, and roles in commercial and business development in the pharmaceutical and biotechnology industries qualifies him to serve on the board of directors. </div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Thomas Eastling<font style="font-weight: normal;"> has served on Catalyst&#8217;s board of directors since December 2022. Mr.&#160;Eastling has served as a </font><font style="font-weight: normal;">board member and Chief Financial Officer of Cullgen Inc. (&#8220;Cullgen&#8221;), a privately-held biotech firm in San Diego, </font><font style="font-weight: normal;">since February 2018 and as an outside member of GNI Japan since April 2013 and </font><font style="font-weight: normal;">an advisor to the </font><font style="font-weight: normal;">executive </font><font style="font-weight: normal;">committee </font><font style="font-weight: normal;">of GNI Japan since September 2013. He previously served as Chief Financial Officer of GNI Japan, a </font><font style="font-weight: normal;">vertically-integrated, multinational bio-pharma company, focused on drug research, clinical development, </font><font style="font-weight: normal;">manufacturing, sales and marketing, from 2013 to 2021. Mr.&#160;Eastling has more than nine years of experience serving </font><font style="font-weight: normal;">as a public company board member, as well as positions on numerous private company boards. His career covers </font><font style="font-weight: normal;">35&#160;years of experience in executive management, global finance, and mergers and acquisitions, with senior postings </font><font style="font-weight: normal;">in New York, London, Tokyo and Hong Kong. Mr.&#160;Eastling started his career on Wall Street at Nikko Securities Co. </font><font style="font-weight: normal;">International, Inc., where he worked from June 1983 to November 1999, rising to the position of Senior Vice </font><font style="font-weight: normal;">President &amp; General Manager of the Investment Banking and Syndicate Divisions. Mr.&#160;Eastling was the Company </font><font style="font-weight: normal;">Representative in Japan for Duff &amp; Phelps Credit Rating Co., which was acquired by Fitch Ratings, Inc. in 2021, from </font><font style="font-weight: normal;">May 2000 to June 2001 and subsequently worked as Managing Director for Softbank Corp. from July 2001 to July </font><font style="font-weight: normal;">2003. In 2009 he relocated to Hong Kong with American Appraisal where he served as Director of the firm&#8217;s </font><font style="font-weight: normal;">Transaction Advisory Services in Asia from April 2008 to August 2013. He returned to Japan in 2013 to assume the </font><font style="font-weight: normal;">position of Chief Financial Officer and Representative Executive Officer for GNI Japan from 2013 to 2021, </font></div> </div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">199<br></div></div></div>
<!--End Page 210-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 211-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg24"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">relocating in 2021 to Cullgen&#8217;s San Diego headquarters. Mr.&#160;Eastling has a bachelor&#8217;s degree from the University of Southern California and a master&#8217;s degree from the American Graduate School of International Management. He graduated from the Board Director Training Institute of Japan and is a member of the National Association of Corporate Directors. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Mr.&#160;Eastling&#8217;s financial expertise from his extensive experience in investment banking and as a Chief Financial Officer for various companies, as well as his experience as a director of public and private companies in the life sciences industry, qualifies him to serve on the board of directors. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Ying Luo, Ph.D.<font style="font-weight: normal;"> has served on Catalyst&#8217;s board of directors since December 2022. Dr. Luo has served as a director, </font><font style="font-weight: normal;">representative executive officer, president and chief executive officer of GNI Japan since 2007, Chief Executive </font><font style="font-weight: normal;">Officer of SG from 2001 to 2021, chairman of the board of BC since 2011, a director of the board of GNI Hong Kong </font><font style="font-weight: normal;">since 2013, and chairman of the board and Chief Executive Officer of Cullgen, since 2018. Dr. Luo has also served </font><font style="font-weight: normal;">as a director of the board and President of GNI USA since 2015 and a director of Berkeley Advanced Biomaterials </font><font style="font-weight: normal;">LLC since 2017. Dr. Luo had been a postdoctoral fellow at the University of California at San Francisco studying </font><font style="font-weight: normal;">HIV gene regulation from 1991 to 1992, a scientist at Aviron Company from 1992 to 1993, a scientist at Clontech </font><font style="font-weight: normal;">Laboratories from 1993 to 1997 and senior scientist/director/senior director of genomics and target discovery of Rigel </font><font style="font-weight: normal;">Inc. from 1997 to 2000, where he led research in the field of protein-protein interactions in cancer and inflammation </font><font style="font-weight: normal;">signaling pathways. In his career, Dr. Luo has authored more than 37 research publications. Dr. Luo completed his </font><font style="font-weight: normal;">undergraduate education at Peking Union Medical College (Peking University&#8217;s Premedicine) from 1982 to 1986 and </font><font style="font-weight: normal;">received his doctorate in biomedical sciences from the University of Connecticut Health Center in 1991.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Dr. Luo&#8217;s scientific expertise from his extensive experience in R&amp;D at biotechnology companies, as well as his experience as an executive and director of public and private companies in the life sciences industry qualifies him to serve on the board of directors. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Recommendation of Catalyst&#8217;s board of directors:<font style="font-weight: normal;"> </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Catalyst&#8217;s board of directors recommends a vote FOR each of the nominees named in Proposal No. 8.<font style="font-weight: normal;"> </font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">200<br></div></div></div>
<!--End Page 211-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 212-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg25"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">PROPOSAL NO. 9<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195; <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><a name="tPROP9"><!--Anchor--></a>ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In accordance with Section 14A of the Exchange Act, in this proposal Catalyst is providing its stockholders with the opportunity to vote to approve, on a nonbinding, advisory basis, the compensation of Catalyst&#8217;s named executive officers as described in the &#8220;Catalyst&#8217;s Executive and Director Compensation&#8221; section, the tabular disclosure regarding such compensation and the accompanying narrative disclosure, as set forth in this proxy statement. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Prior to casting your vote on this proposal, Catalyst encourages you to read the &#8220;<font style="font-style: italic;">Catalyst Executive and Director </font><font style="font-style: italic;">Compensation</font>&#8221; section of this proxy statement (beginning on page <a href="#tCEA">162</a>) for a detailed discussion of Catalyst&#8217;s policies and practices relating to the compensation of its named executive officers. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Compensation Committee believes that the objectives of Catalyst&#8217;s executive compensation program, as they relate to Catalyst&#8217;s named executive officers, are appropriate for a company in Catalyst&#8217;s position and that Catalyst&#8217;s compensation policies and practices help meet those objectives. In addition, the Compensation Committee believes that Catalyst&#8217;s executive compensation program, as it relates to Catalyst&#8217;s named executive officers, achieves an appropriate balance between fixed compensation and variable incentive compensation, pays for performance and promotes an alignment between the interests of Catalyst&#8217;s named executive officers and Catalyst&#8217;s stockholders. Accordingly, Catalyst is asking its stockholders to approve the compensation of its named executive officers. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This vote is advisory, which means that the vote on executive compensation is not binding on Catalyst, Catalyst&#8217;s board of directors or the Compensation Committee. The vote on this resolution is not intended to address any specific element of compensation, but rather relates to the overall compensation of Catalyst&#8217;s named executive officers, as described in this proxy statement in accordance with the compensation disclosure rules of the SEC. To the extent there is a significant vote against Catalyst&#8217;s named executive officer compensation as disclosed in this proxy statement, the Compensation Committee will evaluate whether any actions are necessary to address Catalyst stockholders&#8217; concerns. Unless the board of directors modifies its policy on the frequency of holding these votes, the next advisory vote to approve executive compensation is expected to occur in 2024.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Recommendation of Catalyst&#8217;s board of directors: </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s board of directors recommends a vote FOR the approval of the compensation of our named executive officers, as disclosed in this proxy statement.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">201<br></div></div></div>
<!--End Page 212-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 213-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg26"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">PROPOSAL NO. 10<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><a name="tPROP10"><!--Anchor--></a>ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In accordance with Section 14(a) of the Exchange Act, in this proposal Catalyst is providing its stockholders with the opportunity to vote, on a non-binding, advisory basis, on the frequency of future advisory votes on executive compensation, such as the one in Proposal No. 9 above. Stockholders may indicate whether they prefer that Catalyst holds future votes once every one, two, or three years. Stockholders may also abstain from casting a vote on this proposal. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In consideration of best practices in corporate governance, Catalyst&#8217;s board of directors has determined that an advisory vote on executive compensation that occurs every year is the most appropriate for Catalyst, and therefore Catalyst&#8217;s board of directors recommends that you vote to hold such votes every one year. Catalyst recognizes that the stockholders may have different views as to the best approach for Catalyst, and therefore Catalyst looks forward to hearing from its stockholders as to their preferences on the frequency of an advisory vote on executive compensation. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This vote is advisory, which means that it is not binding on Catalyst, its board of directors or the Compensation Committee. However, the board of directors and the Compensation Committee will take into account the outcome of the vote when considering the frequency of future advisory votes on executive compensation. The board of directors may decide that it is in the best interests of Catalyst&#8217;s stockholders and Catalyst to hold an advisory vote on executive compensation more or less frequently than the frequency receiving the most votes cast by Catalyst&#8217;s stockholders. The next advisory vote to approve the frequency of future advisory votes on executive compensation is expected to occur in 2029.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Recommendation of Catalyst&#8217;s board of directors: </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s board of directors recommends that stockholders vote to hold an advisory vote on executive compensation every ONE YEAR.<font style="font-weight: normal;"> </font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">202<br></div></div></div>
<!--End Page 213-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 214-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg27"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">PROPOSAL NO. 11<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><a name="tPROP11"><!--Anchor--></a>RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The audit committee of Catalyst&#8217;s board of directors (the &#8220;Audit Committee&#8221;) has selected EisnerAmper LLP (&#8220;EisnerAmper&#8221;) as Catalyst&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2023. EisnerAmper has served as Catalyst&#8217;s independent registered public accounting firm since 2015. Catalyst is soliciting stockholder ratification of the appointment of EisnerAmper, although stockholder ratification is not required by law. If the appointment of EisnerAmper is not ratified at the special meeting, the Audit Committee will consider whether to appoint a different independent registered public accounting firm. Even if the selection is ratified, the Audit Committee, in its discretion, may direct the selection of a different independent registered public accounting firm at any time during the year if it determines that such a change would be in the best interests of Catalyst and its stockholders.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">A representative of EisnerAmper is expected to be present at the special meeting. This representative will have an opportunity to make a statement and will be available to respond to appropriate questions. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Principal Accountant Fees and Services </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table summarizes the audit fees billed and expected to be billed by EisnerAmper for the indicated fiscal years and the fees billed by EisnerAmper for all other services rendered during the indicated fiscal years. All services associated with such fees were pre-approved by the Audit Committee in accordance with the &#8220;<font style="font-style: italic;">Audit Committee </font><font style="font-style: italic;">Pre-Approval Policy</font>&#8221; described below.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.26%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fiscal 2022</div></td><td class="gutter" style="width: 1.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.26%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fiscal 2021</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Audit Fees<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 4.33pt;"></font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.58pt; text-align: left;">$282,990</div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.58pt; text-align: left;">$326,575</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Audit-Related Fees:<font style="padding-left: 1.42pt;"></font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.58pt; text-align: left;"><font style="padding-left: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.58pt; text-align: left;"><font style="padding-left: 27.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tax Fees:<font style="padding-left: 3.22pt;"></font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.58pt; text-align: left;"><font style="padding-left: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.58pt; text-align: left;"><font style="padding-left: 27.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">All Other Fees:<font style="padding-left: 4.2pt;"></font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.58pt; text-align: left;"><font style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; min-width: 37.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.58pt; text-align: left;"><font style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; min-width: 37.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Fees:<font style="padding-left: 2.66pt;"></font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.58pt; text-align: left;">$282,990</div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.58pt; text-align: left;">$326,575</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Audit Fees include fees billed for the applicable year for services in connection with the audit of Catalyst&#8217;s financial statements included in Catalyst&#8217;s Annual Report on Form 10-K, quarterly reports on Form 10-Q, and, for fiscal year 2021, its registration statement on Forms S-3.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Audit Committee Pre-Approval Policy </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Audit Committee has adopted a policy that requires the Audit Committee to approve all audit and permissible non-audit services to be provided by the independent registered public accounting firm prior to its engagement to provide such services. The Audit Committee has established a pre-approval policy for certain audit and non-audit services, up to a specified amount for each identified service that may be provided by the independent registered public accounting firm. In addition, the Chairperson of the Audit Committee, or any member of the Audit Committee designated by the Chairperson, may specifically approve any service that is not a prohibited non-audit service if the fees for such service are not reasonably expected to exceed $10,000. Any such approval by the Chairperson or his designee must be reported to the Audit Committee at its next scheduled meeting. The pre-approved services of the independent registered public accounting firm, and corresponding maximum fees, are reviewed annually by the Audit Committee. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Recommendation of Catalyst&#8217;s board of directors: </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s board of directors recommends a vote FOR ratification of EisnerAmper LLP as Catalyst&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2023.<font style="font-weight: normal;"> </font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">203<br></div></div></div>
<!--End Page 214-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 215-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_113-proposals_pg28"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">PROPOSAL NO. 12<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><a name="tPROP12"><!--Anchor--></a>APPROVAL OF POSSIBLE ADJOURNMENT OF THE SPECIAL MEETING </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If Catalyst fails to receive a sufficient number of votes to approve Proposal Nos. 1, 2, 3, 4, 5 or 6, Catalyst may propose to adjourn the Catalyst special meeting, for a period of not more than 60 days, for the purpose of soliciting additional proxies to approve Proposal Nos. 1, 2, 3, 4, 5 and 6. Catalyst currently does not intend to propose adjournment at the Catalyst special meeting if there are sufficient votes to approve Proposal Nos. 1, 2, 3, 4, 5 and 6. Additionally, pursuant to Article IV, Section 4 of Catalyst&#8217;s amended and restated bylaws, any meeting of stockholders may be adjourned from time to time to reconvene at any other time and to any other place at which a meeting of stockholders may be held under Catalyst&#8217;s amended and restated bylaws by the chairman of the board of directors, the chief executive officer, the president or a majority of the directors then in office.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">CATALYST&#8217;S BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THIS PROPOSAL NO. 12.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;FOR&#8221; the approval of this Proposal No. 12.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">204<br></div></div></div>
<!--End Page 215-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 216-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_114-corp_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCG"><!--Anchor--></a>CORPORATE GOVERNANCE</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Board Leadership Structure </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The roles of Chief Executive Officer and Chairman of the board of directors are held by separate individuals. This separation of roles enables Catalyst&#8217;s Chief Executive Officer to focus on his core responsibility of leading and managing Catalyst&#8217;s operations and day-to-day performance, consistent with strategic direction provided by the board of directors, and Catalyst&#8217;s Chairman of the board of directors to focus on leading the board of directors in its fundamental role of providing guidance to, and independent oversight of, Catalyst&#8217;s management. The board of directors and each of its committees are chaired by directors whom the board of directors has determined are independent in accordance with the applicable listing standards of Nasdaq.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Director Independence </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Nasdaq&#8217;s listing standards and Catalyst&#8217;s Corporate Governance Guidelines require that the board of directors consist of a majority of independent directors, as determined under the applicable Nasdaq listing standard. The board of directors, with the assistance of the Governance and Nominating Committee, has determined that each of Thomas&#160;Eastling, Andrea Hunt, Augustine Lawlor and Ying Luo qualifies as an independent director and that each of Errol B. De Souza, Ph.D., Jeanne Jew, Geoffrey Ling, M.D./Ph.D., Sharon Tetlow and Eddie Williams qualified as an independent director for the period in which they served during 2022. In making this determination, the board of directors has determined that no relationships exist which would preclude the finding of independence under the applicable Nasdaq listing standard, and that no relationships exist which, in the opinion of the board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In making these determinations, Catalyst&#8217;s directors reviewed and discussed information provided by Catalyst&#8217;s directors and Catalyst with regard to each director&#8217;s business and personal activities as they may relate to Catalyst and its management. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Role of the Board of Directors in Risk Oversight </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The board of directors is involved in Catalyst&#8217;s risk oversight in multiple ways. The board of directors oversees Catalyst&#8217;s management of risks related to Catalyst&#8217;s financial condition and risks inherent in drug development and commercialization. In addition, the board of directors routinely receives at its meetings business updates from various members of management. These updates may identify matters that have emerged within that member of management&#8217;s scope of responsibility that involve operational, financial, legal or regulatory risks and, in these cases, the board of director&#8217;s risk oversight role is to provide guidance to management.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The board of directors also exercises a risk oversight role through its Audit Committee, Compensation Committee and Governance and Nominating Committee, each of which is structured to include only independent directors and is separately chaired. Each such committee provides regular reports of its actions to the full board of directors. In particular, the Audit Committee is responsible for discussing Catalyst&#8217;s exposure to material risks and the adequacy of Catalyst&#8217;s risk management activities with management and Catalyst&#8217;s independent registered public accounting firm. The Audit Committee&#8217;s primary emphasis is financial risk, including Catalyst&#8217;s internal control over financial reporting, and it reviews information received from Catalyst&#8217;s independent registered public accounting firm as to the effectiveness of Catalyst&#8217;s internal control over financial reporting and from other third parties in support of management&#8217;s assessment of the effectiveness of Catalyst&#8217;s internal control over financial reporting. The Audit Committee also oversees Catalyst&#8217;s management of exposure to certain financial risks through its periodic review of Catalyst&#8217;s investment policy and the allocation of Catalyst&#8217;s investment portfolio. The Compensation Committee is responsible for considering whether Catalyst&#8217;s compensation programs and practices are reasonably likely to have a material adverse effect on Catalyst. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Contacting the Board of Directors </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The board of directors will receive and review written communications submitted by stockholders to the attention of the board of directors. The Chairperson of the Governance and Nominating Committee is primarily responsible for monitoring communications from stockholders and for providing copies or summaries to the other directors as she considers appropriate. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Stockholders who wish to send communications on any topic to the board of directors should address such communications to the board of directors, c/o Secretary, Catalyst Biosciences, Inc., 611 Gateway Boulevard, </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">205<br></div></div></div>
<!--End Page 216-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 217-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_114-corp_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Suite 120, South San Francisco, California 94080. Catalyst&#8217;s Corporate Secretary will forward all communications addressed to the board of directors to the Chairperson of the Governance and Nominating Committee. You should indicate on your correspondence that you are a Catalyst stockholder. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Corporate Governance Guidelines </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The board of directors has adopted Corporate Governance Guidelines that address a number of matters applicable to directors, including, as examples, independence, qualification standards, compensation, conduct and frequency of meetings, executive sessions and management evaluation and succession. You can find Catalyst&#8217;s Corporate Governance Guidelines on the &#8220;Investors&#8221; page of Catalyst&#8217;s website, <font style="font-style: italic;">www.catalystbiosciences.com</font>, under the &#8220;Corporate Governance&#8221; tab. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Code of Business Conduct and Ethics </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst has adopted a Code of Business Conduct and Ethics that applies to all of Catalyst&#8217;s directors, officers and employees, including Catalyst&#8217;s principal executive, principal financial and principal accounting officers, or persons performing similar functions. Catalyst&#8217;s Code of Business Conduct and Ethics is posted on Catalyst&#8217;s website located at <font style="font-style: italic;">www.catalystbiosciences.com</font>, under &#8220;Governance Highlights.&#8221; Catalyst intends to disclose on its website any amendments to, or waivers from, the code of business conduct and ethics that are required to be disclosed pursuant to the disclosure requirements of Item 5.05 of Form 8-K within four business days following the date of the amendment or waiver.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Catalyst&#8217;s Board of Directors and its Committees </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In 2022, the board of directors met fifteen (15) times. Except Dr. Geoffrey Ling, each of Catalyst&#8217;s directors attended at least 75% of the aggregate number of meetings of the board of directors and the committees on which he or she served, during the period in which he or she served as a director or committee member. Catalyst&#8217;s Corporate Governance Guidelines provide that Catalyst&#8217;s directors are also expected to attend annual meetings of stockholders. All of Catalyst&#8217;s directors attended the 2022 annual meeting of stockholders. The board of directors currently has the following standing committees: an Audit Committee, a Compensation Committee, and a Governance and Nominating Committee. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Audit Committee </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s Audit Committee generally assists the board of directors in its oversight of Catalyst&#8217;s accounting, financial reporting and internal control functions, the audit of Catalyst&#8217;s financial statements and internal control over financial reporting and the review of Catalyst&#8217;s interim financial statements. In 2022, the Audit Committee met five (5) times. The Audit Committee has a written charter approved by the board of directors that is compliant with the standards of Nasdaq. A copy of the Audit Committee charter is available on the investors section of Catalyst&#8217;s website (<font style="font-style: italic;">www.catalystbiosciences.com</font>) under the heading &#8220;Governance Highlights.&#8221; The responsibilities and activities of the Audit Committee are described in greater detail in the &#8220;Report of the Audit Committee&#8221; and include the following:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the appointment, compensation, retention and oversight of any independent registered public accounting firm that Catalyst engages to issue an audit report, or to perform other audit, review or attest services, for its financial statements, and evaluating auditor independence;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">receiving and reviewing reports of management and the independent registered public accounting firm regarding the annual audit process, as well as the review process for its interim financial statements; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewing with management significant accounting issues, policies relating to its financial statements and its cash management program; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">discussing with management and the independent registered public accounting firm its exposure to material risks and the adequacy of its risk management activities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewing management&#8217;s assessment of the effectiveness of, and its independent registered public accounting firm&#8217;s report on, its internal control over financial reporting; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">monitoring the rotation of partners of the independent registered public accounting firm on our engagement team as required by law; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">206<br></div></div></div>
<!--End Page 217-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 218-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_114-corp_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">approving, to the extent required by applicable law or Nasdaq listing standards or by its related person transactions policy, related person transactions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal accounting controls or auditing matters; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">responding to any report of evidence of a material violation of the securities laws or breach of fiduciary duty that it receives; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">preparing the report of the audit committee required by applicable SEC rules to be included in its annual proxy statement. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Audit Committee currently consists of Mr.&#160;Lawlor, who serves as Chair, Mr.&#160;Eastling and Ms.&#160;Hunt. As required by the Nasdaq rules, the members of the Audit Committee each qualify as &#8220;independent&#8221; under special standards established for members of audit committees. To qualify as &#8220;independent&#8221; to serve on the Audit Committee, the Nasdaq rules and the applicable rules of the SEC require that a director does not accept any consulting, advisory, or other compensatory fee from Catalyst, other than for service as a director, or be an affiliated person of Catalyst. In accordance with Nasdaq rules, each member of the Audit Committee must be able to read and understand financial statements with at least one member who has past employment experience or background which results in the individual&#8217;s financial sophistication. Mr.&#160;Eastling and Ms.&#160;Hunt are directors who have been determined by the board of directors to be the audit committee financial experts, as defined by applicable SEC rules, and possess financial sophistication, as defined by the Nasdaq rules. The designation does not impose any duties, obligations or liability that are greater than are generally imposed on them as members of the Audit Committee and the board of directors, and their designation as audit committee financial experts pursuant to this SEC requirement does not affect the duties, obligations or liability of any other member of the Audit Committee or the board of directors. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Compensation Committee </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In 2022, the Compensation Committee met four (4) times. The Compensation Committee has a written charter approved by the board of directors that is compliant with the standards of the Nasdaq. The Compensation Committee reviews and reassesses the adequacy of its charter on an annual basis. A copy of the Compensation Committee charter is available on the investors section of Catalyst&#8217;s website (<font style="font-style: italic;">www.catalystbiosciences.com</font>) under the heading &#8220;Governance Highlights.&#8221; The responsibilities of the Compensation Committee include the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewing periodically Catalyst&#8217;s compensation philosophy and the adequacy of compensation plans and programs for its executive officers and other employees; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the appointment, compensation and oversight of any compensation expert, legal counsel or other adviser that the Compensation Committee determines to engage and the consideration of factors relevant to such expert&#8217;s, counsel&#8217;s or adviser&#8217;s independence; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewing the performance of its Chief Executive Officer and establishing the compensation of all of its executive officers; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">approving employment, severance and change in control agreements, and any amendments, for Catalyst&#8217;s executive officers; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">administering (or overseeing the administration of) Catalyst&#8217;s stock option and other equity-based plans and other employee benefit and incentive plans, to the extent consistent with their respective terms; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">assessing annually any risks associated with its compensation policies and practices; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewing and discussing with management its Compensation Discussion and Analysis disclosure and formally recommending to the board of directors that it be included in its Annual Report on Form 10-K (either directly or by incorporation by reference to its annual proxy statement), to the extent required of Catalyst; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">making a recommendation to the board of directors with respect to the board of directors&#8217; recommendation to its stockholders on any proposal that its stockholders approve the compensation of its Named Executive Officers on an advisory basis; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">207<br></div></div></div>
<!--End Page 218-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 219-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_114-corp_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">making a recommendation to the board of directors, at least once every six years, whether to submit the compensation of its Named Executive Officers to an advisory vote of its stockholders every one, two or three years; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">preparing the report of the Compensation Committee required by applicable SEC rules to be included in its Annual Report on Form 10-K (either directly or by incorporation by reference to its annual proxy statement); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">periodically evaluating and making recommendations to the board of directors concerning the compensation of non-employee directors; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">forming and delegating authority to subcommittees when it considers appropriate. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The Compensation Committee currently consists of Mr.&#160;Lawlor, who serves as Chair, Mr.&#160;Eastling and Ms.&#160;Hunt. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As required by the Nasdaq rules, the members of the Compensation Committee each qualify as &#8220;independent&#8221; under special standards established for members of compensation committees. To qualify as independent to serve on the Compensation Committee, the Nasdaq rules require that the board of directors consider all factors specifically relevant to determining whether a director has a relationship to Catalyst which is material to that director&#8217;s ability to be independent from management in connection with the duties of a Compensation Committee member, including, but not limited to, the source of compensation of such director, and whether such director is affiliated with Catalyst, a subsidiary of Catalyst or an affiliate of a subsidiary of Catalyst. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, the Compensation Committee, from time to time, retains independent compensation consultants to assist it with assessing the competitiveness of executive and board of directors compensation. In 2022, the Compensation Committee retained Radford, an Aon Hewitt company (&#8220;Radford&#8221;), as an independent compensation consultant. The Compensation Committee determined, based on its review of all relevant factors, including those set forth in Rule&#160;10C-1b(4)(i)&#160;through (iv)&#160;under the Exchange Act, that the work of Radford has not created any conflict of interest.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Historically, Catalyst&#8217;s Chief Executive Officer makes recommendations to the Compensation Committee, and is involved in the determination of compensation for the respective executive officers that report to him, except that Catalyst&#8217;s Chief Executive Officer does not make recommendations as to his own compensation. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Compensation Committee Interlocks and Insider Participation </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">None of the directors who served on Catalyst&#8217;s Compensation Committee during the fiscal year ended December&#160;31, 2022 was an officer within the meaning of Rule 3b-2 under the Exchange Act, or an employee of Catalyst during or prior to the fiscal year ended December&#160;31, 2022 nor did any of such directors have any relationship during the past year that would have been required to be disclosed pursuant to Item 404 of Regulation S-K. None of Catalyst&#8217;s executive officers currently serve, or in the past year have served, as a member of the board of directors or compensation committee, or other committee serving an equivalent function, of any other entity that has one or more executive officers serving on Catalyst&#8217;s board of directors or Compensation Committee.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Governance and Nominating Committee </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In 2022, the Governance and Nominating Committee met eleven (11) times. The Governance and Nominating Committee has a written charter approved by the board of directors that is compliant with the standards of Nasdaq. A copy of the Governance and Nominating Committee charter is available on the investors section of Catalyst&#8217;s website (<font style="font-style: italic;">www.catalystbiosciences.com</font>) under the heading &#8220;Governance Highlights.&#8221; The responsibilities of the Governance and Nominating Committee include the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">identifying individuals qualified to serve as directors and committee members, recommending to the board of directors nominees for election at its annual stockholders&#8217; meetings and recommending to the board of directors individuals to fill vacancies on the board of directors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">making recommendations to the board of directors concerning the criteria for membership on the board of directors and the size, composition, chairmanship and compensation of the board of directors and its committees; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">considering whether and how it takes into account diversity in identifying nominees; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">monitoring and making recommendations to the board of directors regarding corporate governance matters; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">208<br></div></div></div>
<!--End Page 219-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 220-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_114-corp_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">advising the board of directors on corporate governance matters generally; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">conducting an annual review of the performance of the board of directors and its committees. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Governance and Nominating Committee currently consists of Ms.&#160;Hunt, who serves as Chair, Mr.&#160;Lawlor and Dr. Luo. As required by the Nasdaq rules, the members of the Governance and Nominating Committee each qualify as &#8220;independent&#8221; directors.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Although Catalyst&#8217;s board of directors does not maintain a specific policy with respect to board diversity, Catalyst&#8217;s board of directors believes that the board of directors should be a diverse body and the Governance and Nominating Committee operates based on the belief that the backgrounds and qualifications of the directors as a group provide a significant breadth and diversity of experience, knowledge and abilities. In considering whether to recommend any particular candidate for inclusion in Catalyst&#8217;s slate of recommended nominees, the Governance and Nominating Committee applies certain criteria set forth in the Corporate Governance Guidelines. In particular, each nominee should possess: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a reputation for integrity, honesty and adherence to high ethical standards; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">sound judgment and a willingness and ability to contribute positively to decision-making processes; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">a commitment to understand Catalyst and its industry and to regularly attend and participate in meetings of the board of directors and, as applicable, its committees; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the interest in and ability to understand sometimes conflicting interests of various constituencies, such as stockholders, employees, governmental or regulatory bodies, creditors and the general public, and to act in the interests of all stockholders; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">no actual or apparent conflict of interest that would impair the ability to represent the interests of all stockholders and to fulfill the responsibilities of a director. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Governance and Nominating Committee does not assign specific weights to particular criteria, and no particular criterion is a prerequisite for a nominee. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Governance and Nominating Committee recommends to the board of directors individuals to be nominated for election as directors. In considering an incumbent director as a nominee, the Governance and Nominating Committee considers his or her prior contributions to the functioning of the board of directors and, as applicable, its committees. The Governance and Nominating Committee may also receive recommendations for nominees from members of the board of directors or management and may from time to time engage a third-party search firm to help identify potential nominees. If a candidate is identified, the Governance and Nominating Committee evaluates his or her qualifications and other biographical information, taking into account the backgrounds and qualifications of the continuing members of the Board and the criteria included in Catalyst&#8217;s Corporate Governance Guidelines. Members of the Governance and Nominating Committee and the Chief Executive Officer then interview the candidate or, if multiple candidates are identified, select candidates for further consideration. Following discussion of the candidates identified and evaluated, the Governance and Nominating Committee recommends to the board of directors a list of nominees for election. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Stockholders may recommend individuals for consideration by the Governance and Nominating Committee as potential nominees for director by submitting their names, together with a comprehensive written resume of each potential nominee&#8217;s business experience and background and a signed consent stating that he or she is willing to be considered as a nominee and, if nominated and elected, will serve as a director, to Governance and Nominating Committee of the board of directors, c/o Secretary, Catalyst Biosciences, Inc., 611 Gateway Boulevard, Suite 120, South San Francisco, California 94080. The submission must also include a statement as to whether the stockholder, or, if the recommendation is being made by a group of stockholders, whether the group of stockholders, beneficially owned Catalyst Common Stock as of the date the recommendation is made. Assuming that the required information has been provided by the deadline that applies for stockholder proposals to be included in the proxy materials for Catalyst&#8217;s 2024 annual meeting of stockholders as specified under &#8220;Stockholder Proposals&#8221; under the &#8220;OTHER MATTERS&#8221; section of this proxy statement, the committee expects to evaluate stockholder-recommended candidates using substantially the same process and applying substantially the same criteria as described above.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">209<br></div></div></div>
<!--End Page 220-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 221-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_114-corp_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">BOARD DIVERSITY MATRIX</div> <table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-top: 1pt solid #000000;"><tr class="header"><td class="gutter" style="width: 0.64%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 4.25pt;">&#8203;</td><td colspan="13" style="width: 98.72%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Board Diversity Matrix (As of July 12, 2023)</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 4.25pt;">&#8203;</td></tr><tr class="header"><td class="gutter" style="width: 0.64%; font-size: 2pt; border-left: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 41.13%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.75pt; text-align: left;">Total Number of Directors</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td colspan="10" style="width: 54.49%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">#</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td></tr><tr class="header"><td class="gutter" style="width: 0.64%; font-size: 2pt; border-left: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 41.13%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Female</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Male</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.8%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; white-space: nowrap; text-align: center;">Non-Binary</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 23.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; white-space: nowrap; text-align: center;">Did Not Disclose Gender</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td></tr><tr><td class="gutter" style="width: 0.64%; font-size: 2pt; border-left: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 41.13%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.75pt; text-align: left;">Part I: Gender Identity</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.65%; text-align: left; vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.63%; text-align: left; vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.8%; text-align: left; vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 23.13%; text-align: left; vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td></tr><tr><td class="gutter" style="width: 0.64%; font-size: 2pt; border-left: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 41.13%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.75pt; text-align: left;">Directors</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">1</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4 </div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.8%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 23.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td></tr><tr><td class="gutter" style="width: 0.64%; font-size: 2pt; border-left: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 41.13%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.75pt; text-align: left;">Part II: Demographic Background</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.8%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 23.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td></tr><tr><td class="gutter" style="width: 0.64%; font-size: 2pt; border-left: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 41.13%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.75pt; text-align: left;">African American or Black</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.8%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 23.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td></tr><tr><td class="gutter" style="width: 0.64%; font-size: 2pt; border-left: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 41.13%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.75pt; text-align: left;">Alaskan Native or Native American</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.8%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 23.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td></tr><tr><td class="gutter" style="width: 0.64%; font-size: 2pt; border-left: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 41.13%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.75pt; text-align: left;">Asian</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">1</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.8%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 23.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td></tr><tr><td class="gutter" style="width: 0.64%; font-size: 2pt; border-left: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 41.13%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.75pt; text-align: left;">Hispanic or Latinx</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.8%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 23.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td></tr><tr><td class="gutter" style="width: 0.64%; font-size: 2pt; border-left: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 41.13%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.75pt; text-align: left;">Native Hawaiian or Pacific Islander</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.8%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 23.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td></tr><tr><td class="gutter" style="width: 0.64%; font-size: 2pt; border-left: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 41.13%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.75pt; text-align: left;">White</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">3</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.8%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 23.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td></tr><tr><td class="gutter" style="width: 0.64%; font-size: 2pt; border-left: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 41.13%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.75pt; text-align: left;">Two or More Races or Ethnicities</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">1 </div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.8%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 23.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td></tr><tr><td class="gutter" style="width: 0.64%; font-size: 2pt; border-left: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 41.13%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.75pt; text-align: left;">LGBTQ+</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td colspan="10" style="width: 54.49%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td></tr><tr><td class="gutter" style="width: 0.64%; font-size: 2pt; border-left: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.13%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.75pt; text-align: left;">Did Not Disclose Demographic Background</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td colspan="10" style="width: 54.49%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td></tr></table> </div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">210<br></div></div></div>
<!--End Page 221-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 222-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_114-corp_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">CATALYST REPORT OF THE AUDIT COMMITTEE</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Catalyst&#8217;s Audit Committee has reviewed and discussed with Catalyst&#8217;s management and EisnerAmper Catalyst&#8217;s audited consolidated financial statements for the fiscal year ended December 31, 2022. Catalyst&#8217;s Audit Committee has also discussed with EisnerAmper the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board, or the PCAOB, and the SEC.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Catalyst&#8217;s Audit Committee has received and reviewed the written disclosures and the letter from EisnerAmper required by applicable requirements of the PCAOB regarding the independent accountant&#8217;s communications with Catalyst&#8217;s audit committee concerning independence, and has discussed with EisnerAmper its independence from Catalyst.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Based on the review and discussions referred to above, Catalyst&#8217;s Audit Committee recommended to Catalyst&#8217;s board of directors that the audited consolidated financial statements be included in Catalyst Annual Report on Form 10-K for the fiscal year ended December 31, 2022 for filing with the SEC.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">Submitted by the Audit Committee</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; text-indent: 20pt; text-align: center;">Augustine Lawlor, Chair <br></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Thomas Eastling <br></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Andrea Hunt</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">211<br></div></div></div>
<!--End Page 222-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 223-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_115-bus01_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCB"><!--Anchor--></a>CATALYST&#8217;S BUSINESS </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In this prospectus, unless the context requires otherwise, references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Catalyst&#8221; or &#8220;the Company&#8221; refer to Catalyst Biosciences, Inc. and its consolidated subsidiary.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Summary </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst Biosciences, Inc., together with its subsidiary (&#8220;Catalyst&#8221;), is a biopharmaceutical company focused on the development and commercialization of Hydronidone for the treatment of NASH in the United States. Hydronidone is being evaluated for the treatment of liver fibrosis associated with a broad spectrum of chronic liver diseases. A Phase 1 clinical trial of Hydronidone has been completed in the United States and generated PK, safety and tolerability data of single and multiple ascending doses of Hydronidone in U.S. healthy subjects. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Overview</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Prior to ceasing research and development activities in March 2022, Catalyst had engineered several protease assets that were designed to address unmet medical needs in disorders of the complement or coagulation systems. Prior to the F351 Agreement, Catalyst had engaged in the research and development of product candidates from Catalyst&#8217;s protein engineering platform. In February 2022, Catalyst announced that it engaged Perella Weinberg Partners as a financial advisor to assist Catalyst in exploring strategic alternatives to monetize its assets. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In March 2022, Catalyst ceased research and development activities and in May 2022, Catalyst entered into an asset purchase agreement with Vertex, pursuant to which Vertex purchased Catalyst&#8217;s complement portfolio, including CB&#160;2782-PEG and CB 4332, as well as its complement-related intellectual property, including the ProTUNETM and ImmunoTUNETM platforms, for $60.0&#160;million in cash consideration. $55.0&#160;million was received upfront and the remaining $5.0&#160;million was retained by Vertex as a hold-back until one year after the closing date to satisfy certain post-closing indemnification obligations. Any amounts received from Vertex with respect to this hold-back will be distributed to the CVR Holders.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On September&#160;20, 2022, Catalyst paid a special, one-time cash dividend payment of $1.43 per share, or approximately $45.0&#160;million, to holders of its common stock.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On December&#160;26, 2022, Catalyst executed the F351 Agreement and the Business Combination Agreement. For further information about the F351 Agreement and the Business Combination Agreement, see the sections entitled &#8220;<font style="font-style: italic;">Questions and Answers About the Contributions</font>&#8221; and &#8220;<font style="font-style: italic;">The Business Combination Agreement</font>&#8221; beginning on pages <a href="#tQAA">1</a> and <a href="#tTBC">144</a>, respectively, elsewhere in this proxy statement. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In accordance with the Business Combination Agreement, on December&#160;26, 2022, Catalyst executed the CVR Agreement. For further information about the CVR Agreement, see the section entitled &#8220;<font style="font-style: italic;">Agreements Related to the </font><font style="font-style: italic;">Contributions&#8212;CVR Agreement</font>&#8221; beginning on page <a href="#tCVR">157</a> elsewhere in this proxy statement. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On February&#160;27, 2023, Catalyst signed an asset purchase agreement with GCBP pursuant to which GCBP acquired Catalyst&#8217;s legacy rare bleeding disorders programs including MarzAA, DalcA and CB-2679d-GT for a total of $6.0&#160;million, $1.0&#160;million payable on signing and $5.0&#160;million payable on February&#160;28, 2025, subject to satisfaction of post-closing indemnification obligations. In March 2023, Catalyst distributed net proceeds of approximately $0.2 million to the CVR Holders. Once received, any additional net proceeds from the transaction will be distributed to the CVR Holders. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst is also pursuing certain legal claims against a third party related to payments under a 2016 asset purchase agreement, and any net recoveries related to these claims will be distributed to the CVR Holders.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Current Product Development Plans </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst anticipates filing an IND application for the treatment of NASH in the United States in late 2023. NASH is a severe form of nonalcoholic fatty liver disease (&#8220;NAFLD&#8221;), characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, HCC and death. There are currently no approved products for the treatment of NASH. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Hydronidone is a structural analogue of the approved anti-fibrotic (pulmonary fibrosis) drug pirfenidone. Hydronidone has been shown to inhibit <font style="font-style: italic;">in vitro</font> both p38&#947; kinase activity and TGF-&#223;1-induced excessive collagen synthesis in hepatic stellate cells (&#8220;HSCs&#8221;),which are recognized as critical events in the development and </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">212<br></div></div></div>
<!--End Page 223-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 224-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_115-bus01_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">progression of fibrosis in the liver. This is further supported by its anti-proliferative effects on the HSCs in the liver. <font style="font-style: italic;">In vitro</font> anti-fibrotic effects of Hydronidone were also confirmed in several established <font style="font-style: italic;">in vivo</font> rodent models of liver fibrosis such as carbon tetrachloride (&#8220;CCl<sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">4</sub>&#8221;)-induced liver fibrosis mouse model, DMN-induced liver fibrosis rat model, and HSA-induced liver fibrosis rat model, as well as mouse model of NASH fibrosis (CCl<sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">4</sub> +Western [High Fat] Diet). In the NASH mouse model, Hydronidone significantly reduced the severity of fibrosis, as well as demonstrated improvements in the functional, biochemical and histopathological attributes of the affected liver tissue, including a significant reduction of hydroxyproline content and liver enzymes (ALT), aspartate (AST), a decrease in liver fat degeneration, and decreases in the levels of several of inflammatory cytokines at doses of 3-10 mg/kg/day, as well as a decrease in the NAS score in the CCl<sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">4</sub> and WD-induced fibrosis and cell ballooning NASH models at doses of 15-50 mg/kg bid (HEDs of 144 &#8211; 480 mg) which are relevant to human exposure. Thus, the key attributes of Hydronidone&#8217;s molecular mechanisms of action in animal models of liver fibrosis, support its efficacy potential in liver fibrosis of various etiologies including those associated with NASH. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst plans to initiate clinical development of Hydronidone in NASH fibrosis in a randomized, double-blind, placebo-controlled, parallel group, Phase 2a, PoC clinical study evaluating the safety, tolerability, PK, and Pharmacodynamics (&#8220;PD&#8221;) of Hydronidone capsules administered daily at an oral dose of 360 mg (given as 120 mg TID) for 24 weeks to adult subjects with advanced liver fibrosis associated with noncirrhotic NASH. The main goal of the proposed Phase 2a study is to obtain early PoC for Hydronidone in subjects with NASH fibrosis as a basis of expansion into a more comprehensive Phase 2/3 clinical program. The study will include a small sample size (total of 60 evaluable subjects) who will receive in a 2:1 ratio Hydronidone or Placebo. A single dose level that was shown to be safe and effective in a 52-week clinical study in PRC subjects with advanced fibrosis associated with chronic Hepatitis B (CHB) infection will be used. The study will evaluate trends of changes from baseline in a set of noninvasive biochemical and imaging biomarkers relevant to assessment of NASH fibrosis in the context of drug exposure, as well as the mechanism of anti-fibrotic action of Hydronidone. The study will include PK blood sampling and assessment of the initial population PK and preliminary PK/PD relationship to inform Hydronidone treatment in future clinical studies in NASH fibrosis. In addition, this trial will include a disease-specific PROs, a validated composite CLDQ &#8211; NASH, to collect patient-reported data about the impact of Hydronidone treatment on quality of life of subjects with advanced NASH fibrosis. Before the F351 Acquisition, GNI USA engaged in a pre-IND dialogue with the FDA in connection with this Phase 2a clinical study. The FDA&#8217;s written responses to GNI USA commented on the adequacy of the existing data package for filing an IND for the NASH fibrosis indication, including the proposed Phase 2a study design, and provided recommendations and guidance on the requirements for the IND filing. In connection with the F351 Acquisition, GNI initiated the transfer of ownership of the IND to Catalyst.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">NASH represents a large and rapidly growing problem in the United States and worldwide. Diagnoses have been on the rise and are expected to increase dramatically in the next decade. The prevalence of NAFLD, which affects approximately 25% of the global population, and NASH, which develops in approximately 20% to 25% of NAFLD patients, is driven primarily by the worldwide obesity epidemic. As a result, the prevalence of NASH has increased significantly in recent decades, paralleling similar trends in the prevalence of obesity, insulin resistance and Type 2 diabetes. The prevalence of these conditions is expected to increase further in view of the unhealthy nutrition habits, such as consumption of a diet high in fructose, sucrose and saturated fats, and sedentary behavior that characterize modern lifestyle.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Hydronidone is a structural analogue of the approved drug pirfenidone. Hydronidone has been shown to inhibit <font style="font-style: italic;">in </font><font style="font-style: italic;">vitro</font> both p38&#947; kinase activity and TGF-&#223;1-induced excessive collagen synthesis in HSCs, which are recognized as critical events in the development and progression of fibrosis in the liver. This is further supported by its anti-proliferative effects on the HSCs in the liver. The key attributes of Hydronidone&#8217;s molecular mechanisms of action in animal models of liver fibrosis included that of NASH, support its efficacy potential in liver fibrosis of various etiologies including that associated with NASH. Hydronidone has exhibited protective effects on CCl<sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">4</sub>+WD induced NASH; the total NAS and fibrosis scores were statistically significantly lower following Hydronidone dosing at 15-50 mg/kg/day. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In preclinical studies, the key attributes of Hydronidone&#8217;s molecular mechanisms of action in animal models of liver fibrosis included that of NASH, support its efficacy potential in liver fibrosis of various etiologies including that associated with NASH. To support the indication of NASH-associated fibrosis, GNI USA evaluated the anti-fibrotic effects of Hydronidone in a murine NASH model which is characterized by a rapid progression of extensive liver fibrosis. The model was induced by feeding male C57BL/6J mice (n=20/group) a high fat diet for 14 weeks. Subcutaneous injections of CCl<sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">4</sub> in weeks 11-14 served as an accelerator of the liver pathology and exacerbated </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">213<br></div></div></div>
<!--End Page 224-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 225-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_115-bus01_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">histological features of NASH and associated fibrosis. The establishment of the NASH model was indicated by statistically significantly higher body weights, lower food intake, and histopathologically observed fatty degeneration, inflammatory infiltrates, and hepatocellular ballooning in NASH mice <font style="font-style: italic;">vs</font> negative control. The NAS total score, ballooning, and steatosis score in the NASH mice (positive control, model) group increased significantly compared to Naive (negative control group). Hydronidone exhibited protective effect on CCl<sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">4</sub>+WD induced NASH; the total NAS and fibrosis score were statistically significantly lower following Hydronidone dosing at 15-50&#160;mg/kg/day. Fibrosis and cell ballooning were significantly inhibited by Hydronidone, but no effects on inflammation and steatosis were observed. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On February&#160;27, 2023, Catalyst signed an asset purchase agreement with GCBP pursuant to which GCBP acquired Catalyst&#8217;s legacy rare bleeding disorders programs including MarzAA, DalcA and CB-2679d-GT for a total of $6&#160;million, $1&#160;million payable on signing and $5&#160;million payable on February&#160;28, 2025, subject to satisfaction of post-closing indemnification obligations. In March 2023, Catalyst distributed net proceeds of approximately $0.2 million to the CVR Holders. Once received, any additional net proceeds from the transaction will be distributed to the CVR Holders. Catalyst is also pursuing certain legal claims against a third party related to payments under a 2016 asset purchase agreement, and any net recoveries related to these claims will be distributed to the CVR Holders.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Catalyst is located in South San Francisco, California and operates in one segment.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Disease Overview &#8211; NASH</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">NASH, a severe form of NAFLD, is characterized histologically by the additional presence of inflammation and hepatocellular injury, such as visible ballooning, and has a significantly worse prognosis, with the potential to progress to liver fibrosis, cirrhosis or HCC.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">NASH represents a large and rapidly growing problem in the United States and worldwide. Diagnoses have been on the rise and are expected to increase dramatically in the next decade. The prevalence of NAFLD, which affects approximately 25% of the global population, and NASH, which develops in approximately 20% to 25% of NAFLD patients, is driven primarily by the worldwide obesity epidemic. As a result, the prevalence of NASH has increased significantly in recent decades, paralleling similar trends in the prevalence of obesity, insulin resistance and Type 2 diabetes. The prevalence of these conditions is expected to increase further due to unhealthy nutrition habits, such as consumption of a diet high in fructose, sucrose and saturated fats, and sedentary behavior.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The critical pathophysiologic mechanisms underlying the development and progression of NASH include reduced ability to metabolize and clear lipids, increased insulin resistance, injury to hepatocytes and liver fibrosis in response to hepatocyte injury. NASH patients have an excessive accumulation of fat in the liver resulting primarily from a caloric intake above and beyond energy needs. A healthy liver contains less than 5% fat, but a liver in someone with NASH can contain more than 20% fat. This abnormal liver fat contributes to the progression to NASH, a liver necro-inflammatory state, that can lead to scarring, also known as fibrosis, and, for some, can progress to cirrhosis and liver failure&#8212;cirrhosis develops in approximately 20% to 45% of patients. In some cases, cirrhosis progresses to decompensated cirrhosis, which results in permanent liver damage that can lead to liver failure. In addition, it is estimated that 8% of patients with advanced fibrosis will develop HCC. NASH is a complex, multifaceted disease that does not just affect the liver. Patients with NASH frequently have other significant metabolic co-morbidities such as obesity, hyperglycemia, dyslipidemia and systemic hypertension (a constellation of which is commonly referred to as metabolic syndrome) and these further contribute to the risk of cardiovascular disease.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Etiology of NASH</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Understanding of the pathophysiologic mechanisms that lead to NASH has evolved in recent years. Excessive caloric overload, metabolic dysregulation, cardio-metabolic co-morbidities and genetic risk factors increase the likelihood of developing NASH, with a multitude of potential mechanistic contributors to pathophysiology. In NASH, the liver&#8217;s capacity to handle the primary metabolic energy substrates, carbohydrates and fatty acids, is overwhelmed. This occurs when there is an excess of free fatty acids deposited in the liver or their disposal from the liver is impaired. The accumulation of surplus free fatty acids leads to the formation of toxic lipid species. These toxic lipids then induce endoplasmic reticulum stress, oxidative stress and an inflammatory response, which can result in hepatocellular injury and death. This may lead to fibrosis and genomic instability, which may worsen over time to cirrhosis and HCC, respectively.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">214<br></div></div></div>
<!--End Page 225-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 226-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_115-bus01_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The critical pathophysiologic mechanisms underlying development and progression of NASH include (1) reduced ability to handle lipids, (2) increased insulin resistance, (3) injury to hepatocytes and (4) development and progression of liver fibrosis in response to hepatocyte injury.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Diagnosis</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Most people with NASH are asymptomatic and their disease is often discovered incidentally following a liver imaging procedure, such as an ultrasound, prescribed for other reasons or as part of an investigation for elevated liver enzymes. Once suspected clinically, a liver biopsy is required to definitively diagnose NASH, which necessitates the joint presence of steatosis, ballooning and lobular inflammation. Once pathologically confirmed, the severity of NAFLD and NASH is determined using the histologically validated NAS, which grades disease activity on a scale of 0 to 8. The NAS is the sum of the individual scores for steatosis (0 to 3), lobular inflammation (0 to 3), and hepatocellular ballooning (0 to 2) but does not include a score for fibrosis. Fibrosis staging (F0-F4) relies on the Kleiner classification (F0 = no fibrosis; F1 = perisinusoidal or periportal fibrosis (not both); F2 = both perisinusoidal and periportal fibrosis; F3 = bridging fibrosis; F4 = cirrhosis).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Histological diagnosis remains the gold standard for assessment of NASH and fibrosis. However, given that liver biopsy is associated with risks of pain, bleeding and other morbidity, as well as significant cost, the procedure is not practical for general patient screening. Additionally, histology diagnosis is confounded by evaluation of a small sliver of a large heterogenous organ that may not represent the full organ, and significant variability in reading of slides including inter- and intra-reader variability. Several non-invasive tools such as clinical risk scores, serum markers and imaging techniques are increasingly used to assess NASH patients. Non-invasive tests (&#8220;NITs&#8221;) such as the Fibroscan-AST score, Fibrosis-4 index, the Enhanced Liver Fibrosis score and vibration-controlled transient elastography, have been validated and are increasingly used. These NITs have an excellent negative predictive value and an acceptable positive predictive value for detection of advanced (&#8805; F3) fibrosis and are increasingly used in clinical settings. Additionally, evidence is emerging that shows a correlation between reduction in steatosis as measured by MRI-proton density fat fraction (MRI-PDFF) and reduction in ALT &#8805;17 U/L and histologic improvement on liver biopsy. In draft guidance, the FDA encouraged sponsors to identify biochemical or noninvasive imaging biomarkers that, once characterized and agreed by the FDA, could replace liver biopsies for patient selection and efficacy assessment in clinical trials.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We expect that the validation and subsequent adoption of these NITs will result in an increase in the diagnosis and treatment rates for NASH in the future.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Hydronidone Overview</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Hydronidone, Catalyst&#8217;s Phase 1 clinical-stage drug, has the potential to treat NASH. To date, there are no approved products for the treatment of NASH. The Phase 1 clinical trial results demonstrated that Hydronidone was well tolerated when administered as a single oral dose of 30 mg or 120 mg and when administered as repeated oral doses of 30 mg or 120 mg TID for 7 consecutive days. Hydronidone may reverse liver fibrosis by inhibiting hepatic stellate cell proliferation and the TGF-&#223;1 signaling pathway, both of which play major roles in the liver fibrosis associated with NASH. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Mechanism of Action </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Hydronidone is a structural analogue of the approved drug pirfenidone. Hydronidone has been shown to inhibit both p38&#947; kinase activity and TGF-&#223;1-induced excessive collagen synthesis <font style="font-style: italic;">in vitro</font> in HSCs, which are recognized as critical events in the development and progression of fibrosis in the liver. This is further supported by its anti-proliferative effects on the HSCs in the liver.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In vitro<font style="font-style: normal;"> anti-fibrotic effects of Hydronidone were also confirmed in several established </font>in vivo<font style="font-style: normal;"> models of liver fibrosis </font><font style="font-style: normal;">such as CCl</font><font style="font-style: normal;"><sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">4</sub></font><font style="font-style: normal;">-induced liver fibrosis mouse model, DMN-induced liver fibrosis rat model, and HSA-induced liver </font><font style="font-style: normal;">fibrosis rat model, as well as mouse model of NASH fibrosis (CCl</font><font style="font-style: normal;"><sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">4</sub></font><font style="font-style: normal;"> +Western [High Fat] Diet). </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In the NASH mouse model, Hydronidone significantly reduced the severity of fibrosis, as well as demonstrated improvements in the functional, biochemical and histopathological attributes of the affected liver tissue, including a significant reduction of hydroxyproline content and liver enzymes (ALT), aspartate (AST), a decrease in liver fat degeneration, and decreases in the levels of several inflammatory cytokines at doses of 3-10 mg/kg/day, as well as a decrease in the NAS score in the CCl<sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">4</sub> and WD-induced fibrosis and cell ballooning NASH models at doses of 15-50 mg/kg bid (HEDs of 144 &#8211; 480 mg) which are relevant to human exposure.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">215<br></div></div></div>
<!--End Page 226-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 227-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_115-bus01_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Thus, the key attributes of Hydronidone&#8217;s molecular mechanisms of action in animal models of liver fibrosis support its efficacy potential in liver fibrosis of various etiologies, including those associated with NASH. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">The diagram below illustrates the mechanism of action of Hydronidone:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;"><img style="height: 275px; width: 509px;" src="ny20006478x8_graphic02.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">216<br></div></div></div>
<!--End Page 227-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 228-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_115-bus01_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Biological Effects of Hydronidone</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Hydronidone is a new chemical entity, structural analogue of an approved anti-fibrotic drug, pirfenidone. The chemical structure and formula of Hydronidone are presented below.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; text-align: center;">N-(4-hydroxyphenyl)-5-methyl-2-pyridone<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"><img style="height: 275px; width: 152px;" src="ny20006478x8_graphic03.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Hydronidone has been shown to inhibit both p38&#947; kinase activity and TGF-&#223;1-induced excessive collagen synthesis in HSCs, which are recognized as critical events in the development and progression of fibrosis in the liver. This is further supported by its anti-proliferative effects on the HSCs in the liver.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In vitro<font style="font-style: normal;"> anti-fibrotic effects of Hydronidone were also confirmed in several established </font>in vivo<font style="font-style: normal;"> models of liver fibrosis </font><font style="font-style: normal;">such as CCl</font><font style="font-style: normal;"><sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">4</sub></font><font style="font-style: normal;">-induced liver fibrosis mouse model, DMN-induced liver fibrosis rat model, and HSA-induced liver </font><font style="font-style: normal;">fibrosis rat model, as well as mouse model of NASH fibrosis (CCl</font><font style="font-style: normal;"><sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">4 </sub></font><font style="font-style: normal;">+Western [High Fat] Diet).</font><font style="font-style: normal;"> </font></div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Clinical Development of Hydronidone in NASH </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Phase 1 in the United States</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The primary objective of this study was to assess the PK of Hydronidone capsules when administered as single and repeated doses to healthy adult volunteers, and the secondary objective was to evaluate the safety and tolerability of Hydronidone capsules following single and multiple dose oral administrations to healthy adult volunteers. This Phase&#160;1 clinical trial of Hydronidone was conducted on the basis of an IND that was filed in 2016 for Hydronidone as an anti-fibrotic agent with focus on liver fibrosis. Upon the FDA&#8217;s review of such IND, the Phase 1 clinical trial was initiated and completed. This was an open-label, two-part study in healthy subjects. Part I was a single escalating dose, sequential cohort study of oral capsules of Hydronidone 30 mg and Hydronidone 120 mg . Part II was a multiple escalating dose, sequential cohort study of oral capsules of Hydronidone 30 mg TID for seven days and Hydronidone 120 mg TID for seven days. In Part II, subjects received an extra dose on the morning of Study Day 8. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Following single oral doses of Hydronidone 30 mg or 120 mg in Part I of the study, Hydronidone was rapidly absorbed showing a linear PK pattern of exposure, with mean elimination half-life of Hydronidone was 5 to 6 hours, and was 5 to 7 hours for M3 and M4 metabolites. Following repeated oral doses of Hydronidone 30 mg or 120 mg TID for seven days in Part II of the study, Hydronidone capsules were rapidly absorbed with similar PK pattern of exposure as seen following single doses of Hydronidone and similar half-life. Modest accumulation (less than 1.5-fold increase) was observed for Hydronidone, M3 and M4 with repeated 30 mg or 120 mg TID. Dose-normalized Hydronidone C<sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">max</sub> and AUC values were similar in males and females.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Overall, Hydronidone was well tolerated when administered as a single oral dose of 30 mg or 120 mg and when administered as repeated oral doses of 30 mg or 120 mg TID for 7 consecutive days. There were no premature discontinuations due to adverse events (&#8220;AEs&#8221;), no serious adverse events (&#8220;SAEs&#8221;) nor deaths reported in this study. Treatment-emergent AEs reported following single dose administration in Part I of the study included a single AE of rhinorrhoea and scattered, isolated, reversible laboratory abnormalities. Treatment-emergent AEs reported </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">217<br></div></div></div>
<!--End Page 228-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 229-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_115-bus01_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">following repeated dose administration in Part II of the study included headache (25.0%), constipation (16.7%) and somnolence (12.5%). Abdominal discomfort and flatulence were also reported as GI AEs in 1 subject each. Scattered, isolated, reversible or stable laboratory abnormalities were reported in 1 or 2 subjects. There were no clinically significant overall changes in safety laboratory tests that were attributable to study drug, including no evidence of any significant drug-induced liver injury, nor clinically significant overall changes in vital signs, ECG parameters or physical examinations that were attributable to study drug.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Phase 2</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">To support the IND filing and initiation of the proposed Phase 2a clinical study, Catalyst plans to cross-reference all nonclinical and clinical data obtained in studies completed under the currently active IND in the United States, as well as those previously completed in the PRC. Specifically, the initiation of this clinical study is supported by comprehensive ICH-compliant package of nonclinical studies, including long-term toxicology studies, the completed Phase 1 study bridging safety, tolerability, and PK in the United States in healthy subjects (single and multiple dosing), and the recently completed 52-week Phase 2 clinical trial of Hydronidone in PRC subjects with liver fibrosis associated with CHB infection conducted by BC. Catalyst believes that the results obtained in these nonclinical and clinical studies provide adequate information on the current clinical risk/benefit profile of the drug and allow for safe initiation of the proposed Phase 2a clinical study of Hydronidone in NASH associated fibrosis. However, if the FDA believes that additional data is necessary to supplement Catalyst&#8217;s clinical study data and Phase 2a clinical trial data, then the FDA may require Catalyst to conduct additional trials before expanding into a broader Phase 2 clinical trial. For more details, see &#8220;<font style="font-style: italic;">Risk Factors&#8212;Risks Related to Catalyst&#8212;Risks Related to the Discovery, Development and </font><font style="font-style: italic;">Commercialization of Catalyst&#8217;s Product Candidates&#8212; Results from preclinical or early stage clinical trials, </font><font style="font-style: italic;">including the results of BC&#8217;s preclinical testing and early clinical trials of Hydronidone, may not be confirmed in later </font><font style="font-style: italic;">trials or be predictive of the success of later clinical trials, including the results of Hydronidone&#8217;s later clinical </font><font style="font-style: italic;">trials</font>&#8221;. Because the FDA will ultimately evaluate the adequacy of the IND file upon review of the data package submitted, which includes both nonclinical and clinical data, there is a risk that the FDA may request additional information or recommendations for monitoring in the planned Phase 2a clinical study, in addition to the previously provided pre-IND advice. Before the F351 Acquisition, GNI USA engaged in a pre-IND dialogue with the FDA in connection with this Phase 2a clinical study. The FDA&#8217;s written responses to GNI USA commented on the adequacy of the existing data package for filing an IND for the NASH fibrosis indication, including the proposed Phase 2a study design, and provided recommendations and guidance on the requirements for the IND filing. In connection with the F351 Acquisition, GNI initiated the transfer of ownership of the IND to Catalyst. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst plans to initiate clinical development of Hydronidone in NASH fibrosis in a randomized, double-blind, placebo-controlled, parallel group, Phase 2a, Proof-of-Concept (&#8220;PoC&#8221;) clinical study evaluating the safety, tolerability, PK, and Pharmacodynamics (&#8220;PD&#8221;) of Hydronidone capsules administered daily at an oral dose of 360 mg (given as 120 mg TID) for 24 weeks to adult subjects with advanced liver fibrosis associated with noncirrhotic NASH. The main goal of the proposed Phase 2a study is to obtain early PoC for Hydronidone in subjects with NASH fibrosis as a basis of expansion into a more comprehensive Phase 2/3 clinical program. The study population will be further characterized by inclusion and exclusion criteria at baseline, which will include, among the others, serum biomarkers (<font style="font-style: italic;">i.e.</font>, NAFLD scoring) and imaging modality, such as LSM via FibroScan. Magnetic Resonance Elastography may be evaluated in a selected number of subjects as an exploratory measure. The cut-offs of both non-invasive biomarkers as well as elastography will be consistent with identifying patients with advanced fibrosis while separating them from those indicative of cirrhosis. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The proposed severity of fibrosis will allow more space for separation from placebo, if any. It has been shown that more severe fibrosis responds favorably to Hydronidone in the clinical trial of Hepatitis B-associated liver fibrosis, without significant safety concerns. In addition, these patients are at high risk for progression to cirrhosis without adequate treatment options, and as such, they are a suitable population for treatment with Hydronidone. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Agreements Relating to the Hydronidone Program</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">F351 Asset Purchase Agreement</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On December&#160;26, 2022, Catalyst acquired the F351 Assets from the GNI Japan and GNI Hong Kong. Pursuant to the F351 Agreement, Catalyst acquired all of the assets and intellectual property rights primarily related to GNI Japan&#8217;s and GNI Hong Kong&#8217;s proprietary Hydronidone compound, other than such assets and intellectual property rights located in the PRC. The F351 Assets include 15 issued or pending patents and patent applications outside of the PRC, with the last acquired issued patent expected to expire in August 2037.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">218<br></div></div></div>
<!--End Page 229-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 230-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_115-bus01_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Under the terms of the F351 Agreement and upon the effective time of the transactions contemplated by the F351 Agreement, Catalyst paid GNI Japan and GNI Hong Kong $35,000,000 in the form of: 6,266,521 shares of Catalyst Common Stock; and 12,340 shares of Catalyst Convertible Preferred Stock.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Competition</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The biopharmaceutical industry is intensely competitive and subject to rapid innovation and significant technological advancements. We believe the key competitive factors that will affect the development and commercial success of Hydronidone and any future product candidates are efficacy, safety and tolerability profile, reliability, convenience of dosing, price, the level of generic competition and reimbursement. Our competitors include multinational pharmaceutical companies, specialized biotechnology companies, universities and other research institutions. A number of biotechnology and pharmaceutical companies are pursuing the development or marketing of pharmaceuticals that target the same diseases that we are targeting. Smaller or earlier-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Given the high incidence of NASH, it is likely that the number of companies seeking to develop products and therapies for the treatment of liver and cardio-metabolic diseases, such as NASH, will increase.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If Hydronidone is approved for the treatment of NASH, future competition could also arise from select products currently in development, including: Firsocostat/GS-0976, an ACC inhibitor, and Cilofexor/GS-9674, an FXR agonist, from Gilead Sciences, Inc.; Clesacostat/PF-05221304, an ACC inhibitor, and PF-06835919, a KHK inhibitor, from Pfizer Inc.; Ocaliva, an FXR agonist from Intercept Pharmaceuticals, Inc.; Resmetirom, a beta-thyroid hormone receptor agonist from Madrigal Pharmaceuticals, Inc.; VK2809, a beta-thyroid hormone receptor agonist from Viking Therapeutics, Inc.; Aldafermin, an FGF19 analog from NGM Biopharmaceuticals, Inc.; MK-3655, an FGFR1c/KLB agonist antibody from Merck &amp; Co., Inc.; Efruxifermin, a FGF21 fusion protein from Akero Therapeutics, Inc.; Pegozafermin, a FGF21 fusion protein from 89bio, Inc.; Belapectin, a Galectin-3 inhibitor from Galectin Therapeutics Inc.; Aramchol, a synthetic conjugate of cholic acid and arachidic acid from Galmed Pharmaceuticals Ltd.; Semaglutide, a GLP-1 receptor agonist from Novo Nordisk A/S; Pemvidutide/ALT-801, a dual GLP-1/glucagon agonist from Altimmune; Tirzepatide, a dual GIP/GLP-1 receptor agonist from Eli Lilly and Company; Lanifibranor, a PPAR alpha/delta/gamma agonist from Inventiva; NNC0194-0499, an FGF21 analog from Novo Nordisk; BOS-580, an FGF21 analog from Boston Pharmaceuticals; and BFKB8488A, an FGFR1/KLB agonist antibody from Genentech; and pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 from 89bio, Inc.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Many of our competitors have substantially greater financial, technical, human and other resources than we do and may be better equipped to develop, manufacture and market technologically superior products. In addition, many of these competitors have significantly longer operating histories and greater experience than we have in undertaking nonclinical studies and human clinical trials of new pharmaceutical products and in obtaining regulatory approvals of human therapeutic products. Many of our competitors have established distribution channels for the commercialization of their products, whereas we have no such channel or capabilities. In addition, many competitors have greater name recognition and more extensive collaborative relationships. As a result, our competitors may obtain regulatory approval of their products more rapidly than we do or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidate or any future product candidates. Our competitors may also develop and succeed in obtaining approval for drugs that are more effective, more convenient, more widely used and less costly or have a better safety profile than our products and these competitors may also be more successful than we are in manufacturing and marketing their products. If we are unable to compete effectively against these companies, then we may not be able to commercialize our product candidate or any future product candidates or achieve a competitive position in the market. This would adversely affect our ability to generate revenue. Our competitors also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and enrolling patients for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Manufacturing and Supply</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Currently, the manufacturing of Hydronidone active pharmaceutical ingredients (&#8220;API&#8221;) and drug product supplies required for supporting the Phase 2a clinical study in NASH is being outsourced to WuXi STA, based in the PRC. The API and drug product will be of cGMP grade quality, and batch release and stability studies will comply with applicable regulatory requirements. Currently, the manufacturing and quality agreements for the Hydronidone API and drug product supplies to support the Phase 2a clinical study in NASH are under negotiation.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">219<br></div></div></div>
<!--End Page 230-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 231-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_115-bus01_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Intellectual Property </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our success depends in part upon our ability to protect our core technology and intellectual property. Our intellectual property is critical to our business and we strive to protect it through a variety of approaches, including by obtaining and maintaining patent protection in the United States and internationally for our product candidates, new targets, indications and applications and other inventions important to our business. For our product candidates, we generally pursue patent protection covering compositions of matter, methods of manufacture and methods of use. As we further develop our product candidates, we plan to identify additional novel candidates for patent protection that may potentially enhance commercial success, including pursuit of claims directed to new therapeutic indications. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Hydronidone Patents</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our Hydronidone patent portfolio currently consists of five (5) patent families, including patents and/or patent applications in the United States, the Patent Cooperation Treaty, the European Patent Convention and Japan.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The first patent family is entitled &#8220;DERIVATIVES OF PYRIDONE AND THE USE OF THEM&#8221;. The patent family provides granted patent protection in six countries, including the Australia (AU Patent Number 2003284808, expiry date November 13, 2023), United States (U.S. Patent Number 7,825,133, expiry date: September 22, 2024; U.S. Patent Numbers 8,022,087 and 8,084,465, expiry dates: November 14, 2023), Japan (JP Patent Number 4614884, expiry date: November 14, 2023), Canada (CA Patent Number 2,545,813, expiry date November 13, 2023), India (IND Patent Number 256615, expiry date November 13, 2023) and EU (EU Patent Number 1683788 B1, expiry date: November 13, 2023). The granted claims protect our lead drug candidate Hydronidone and pharmaceutical compositions thereof, as well as methods for preparing or using Hydronidone to treat fibrosis. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The second patent family is entitled &#8220;USE OF PYRIDONE DERIVATIVES IN PREVENTING AND TREATING RADIATION LUNG INJURY. USE OF PYRIDONE DERIVATIVES IN THE PREVENTION OR TREATMENT OF TISSUE OR ORGAN TOXICITY INDUCED BY CYTOTOXIC AGENTS AND RADIATION&#8221;. The patent family provides granted patent protection in four countries, including the United States (U.S. Patent Number 8,765,726, expiry date: July 17, 2028), Japan (JP Patent Number 5213852, expiry date: September 25, 2026), Canada (CA Patent Number 2,656,017, expiry date September 24, 2026) and EU (EU Patent Number 2036555 B1, expiry date: September 24, 2026). The granted claims relate to methods for using Hydronidone to treat certain cytotoxic- or radiation-induced injuries, such as pneumonitis.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The third patent family is entitled &#8220;METHOD FOR PREPARING HYDRONIDONE&#8221;. The patent family provides granted patent protection in Japan (JP Patent Number 6764998, expiry date: August 3, 2037) for a method of preparing Hydronidone.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The fourth patent family is entitled &#8220;METHOD FOR PREPARING HYDRONIDONE&#8221;. The patent family provides granted patent protection in Japan (JP Patent Number 6764999, expiry date: August 3, 2037) for a method of preparing Hydronidone.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The fifth patent family is entitled &#8220;PHARMACEUTICAL HYDRONIDONE FORMULATIONS FOR DISEASES&#8221;. The patent family comprises a pending Patent Cooperation Treaty application (PCT/CN2021/088104, international filing date: April 19, 2021). The pending claims relate to methods for using Hydronidone to treat liver fibrosis, liver cirrhosis, advanced hepatitis B viral infection, or NASH fibrosis.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We expect to continue to file patent applications to cover methods of treating additional indications, as well as new forms, formulations, and methods of manufacturing Hydronidone.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Government Regulation</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Government authorities in the United States, at the federal, state and local levels, and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, product approval, manufacture, quality control, manufacturing changes, packaging, storage, recordkeeping, labeling, promotion, advertising, sales, distribution, marketing, and import and export of drugs and biologic products. Our current product candidates are expected to be regulated as drugs. The processes for obtaining regulatory approval in the United States and in foreign countries and jurisdictions, along with compliance with applicable statutes and regulations and other regulatory authorities both pre- and post-commercialization, are a significant factor in the production and marketing of our products and our research and development activities and require the expenditure of substantial time and financial resources.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">220<br></div></div></div>
<!--End Page 231-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 232-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_115-bus01_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Review and Approval of Drugs in the United States</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In the United States, the FDA and other government entities regulate drugs under the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;) and the regulations promulgated thereunder, as well as other federal and state statutes and regulations. Failure to comply with applicable legal and regulatory requirements in the United States at any time during the product development process, approval process, or after approval, may subject us to a variety of administrative or judicial sanctions, such as a delay in approving or refusal by the FDA to approve pending applications, withdrawal of approvals, delay or suspension of clinical trials, issuance of warning letters and other types of regulatory letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil monetary penalties, refusals of or debarment from government contracts, exclusion from the federal healthcare programs, restitution, disgorgement of profits, civil or criminal investigations by the FDA, U.S. Department of Justice, State Attorneys General, and/or other agencies, False Claims Act suits and/or other litigation, and/or criminal prosecutions.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">An applicant seeking approval to market and distribute a new drug in the United States must typically undertake the following:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">completion of pre-clinical laboratory tests, animal studies, and formulation studies in compliance with the FDA&#8217;s GLP, regulations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">submission to the FDA of an IND for human clinical testing, which must become effective without FDA objection before human clinical trials may begin;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">approval by an IRB, representing each clinical site before each clinical trial may be initiated;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">performance of adequate and well-controlled human clinical trials in accordance with the FDA&#8217;s good clinical practice (&#8220;GCP&#8221;), regulations, to establish the safety and effectiveness of the proposed drug product for each indication for which approval is sought;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">preparation and submission to the FDA of an NDA;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">review of the NDA by an FDA advisory committee, where applicable;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the drug product, and the active pharmaceutical ingredient or ingredients thereof, are produced to assess compliance with cGMP, regulations and to assure that the facilities, methods, and controls are adequate to ensure the product&#8217;s identity, strength, quality, and purity;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">payment of user fees, as applicable, and securing FDA approval of the NDA; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">compliance with any post-approval requirements, such as any REMS, or post-approval studies required by the FDA.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Preclinical Studies and an IND</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Preclinical studies can include <font style="font-style: italic;">in vitro</font> and animal studies to assess the potential for adverse events and, in some cases, to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. Other studies include laboratory evaluation of the purity, stability and physical form of the manufactured drug substance or API and the physical properties, stability and reproducibility of the formulated drug or drug product. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. Some preclinical testing, such as longer-term toxicity testing, animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to a proposed clinical trial and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Following commencement of a clinical trial under an IND, the FDA may place a clinical hold on that trial. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a specific protocol or part of a protocol is not allowed to proceed, while other protocols may do so. No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">221<br></div></div></div>
<!--End Page 232-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 233-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_115-bus01_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Human Clinical Studies in Support of an NDA</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Information about certain clinical trials must be submitted within specific timeframes to the NIH for public dissemination on its ClinicalTrials.gov website.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Phase 1: The product candidate is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Phase 2: The product candidate is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Phase 3: The product candidate is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Phase 1, Phase 2, and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. The FDA will typically inspect one or more clinical sites in late-stage clinical trials to assure compliance with GCP and the integrity of the clinical data submitted.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Submission of an NDA to the FDA</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Assuming successful completion of required clinical testing and other requirements, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the drug product for one or more indications. Under federal law, the submission of most NDAs is additionally subject to an application user fee, currently $2.876&#160;million for fiscal year 2021, for applications requiring clinical data, and the sponsor of an approved NDA is also subject to an annual program fee, currently $336,432 for fiscal year 2021. These fees are adjusted annually.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under certain circumstances, the FDA will waive the application fee for the first human drug application that a small business, defined as a company with less than 500 employees, including employees of affiliates, submits for review. An affiliate is defined as a business entity that has a relationship with a second business entity if one business entity controls, or has the power to control, the other business entity, or a third-party controls, or has the power to control, both entities. In addition, an application to market a prescription drug product that has received orphan designation </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">222<br></div></div></div>
<!--End Page 233-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 234-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_115-bus01_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">is not subject to a prescription drug user fee unless the application includes an indication for other than the rare disease or condition for which the drug was designated. Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a disease or condition that affects fewer than 200,000 individuals in the United States, or for which there is no reasonable expectation that U.S. sales will be sufficient to recoup the development and production costs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The FDA conducts a preliminary review of an NDA within 60 days of its receipt and informs the sponsor by the 74th day after the FDA&#8217;s receipt of the submission to determine whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance goals in the review process of NDAs. Most such applications are meant to be reviewed within ten months from the date of filing, and most applications for &#8220;priority review&#8221; products are meant to be reviewed within six months of filing. The review process may be extended by the FDA for three additional months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with GMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with cGCP.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The FDA also may require submission of a REMS plan to mitigate any identified or suspected serious risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">The FDA&#8217;s Decision on an NDA</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On the basis of the FDA&#8217;s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information for the FDA to reconsider the application. If those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies be conducted to further assess the drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, which can materially affect the potential market and profitability of the product. After approval, the FDA may seek to prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. Some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">223<br></div></div></div>
<!--End Page 234-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 235-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_115-bus01_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Fast Track Designation, Accelerated Approval, Priority Review, Orphan Drug Designation and Breakthrough Therapy Programs</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Fast Track</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">There are several FDA programs intended to help facilitate the development of new drugs and biologics that meet certain criteria. Specifically, new drugs and biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug or biological product may request the FDA to designate the drug or biological product as a Fast Track product at any time during the clinical development of the product. Under a Fast Track designation, the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable and the sponsor pays any required user fees upon submission of the first section of the application. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Priority Review</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or biological product designated for priority review to facilitate the review.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Accelerated Approval</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">A product that is being studied for safety and effectiveness in treating serious or life-threatening illnesses and provides meaningful therapeutic benefit over existing treatments may receive accelerated approval, which means that it may be approved on the basis of adequate and well-controlled clinical trials establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. As a condition of approval, the FDA may require that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. In addition, the FDA currently requires pre-approval of promotional materials as a condition for accelerated approval, which could adversely impact the timing of the commercial launch of the product. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Orphan Drug Designation</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. If a product that has orphan drug designation subsequently receives FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same disease, except in limited circumstances, for seven years. These circumstances are an inability to supply the drug in sufficient quantities or a situation in which a new formulation of the drug has shown superior safety or efficacy or a major contribution to patient care. This exclusivity, however, could also block the approval of its product for seven years if a competitor obtains earlier approval of the same drug for the same indication.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Rare Pediatric Drug Designation</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">There are FDA programs intended to help facilitate the development of new drugs and biologics that meet certain criteria. Specifically, new drugs and biological products are eligible for rare pediatric disease designation if they treat a serious or life-threatening condition that affects less than 200,000 individuals in the United States per year and who are primarily less than 18&#160;years of age. Under the FDA&#8217;s rare pediatric disease designation program, the FDA may grant a priority review voucher to a sponsor who receives a product approval for a rare pediatric disease. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Breakthrough Therapy Designation</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">A product may also be eligible for receipt of a Breakthrough Therapy designation. The Breakthrough Therapy designation is intended to expedite the FDA&#8217;s review of a potential new drug for serious or life-threatening diseases where &#8220;preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">224<br></div></div></div>
<!--End Page 235-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 236-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_115-bus01_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.&#8221; The designation of a drug as a Breakthrough Therapy provides the same benefits as are available under the Fast Track program, as well as intensive FDA guidance on the product&#8217;s development program. Fast Track designation, priority review, accelerated approval and Breakthrough Therapy designation do not change the standards for approval, but they may expedite the development or approval process.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Post-Approval Requirements</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events or problems with manufacturing processes of unanticipated severity or frequency, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">fines, warning letters or holds on post-approval clinical trials;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">product seizure or detention, or refusal to permit the import or export of products; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">injunctions or the imposition of civil or criminal penalties.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant criminal and civil liability.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, (&#8220;PDMA&#8221;), which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Hatch-Waxman Patent Certification and the 30 Month Stay</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Upon approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&#8217;s product or a method of using the product. Each of the patents listed by the NDA </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">225<br></div></div></div>
<!--End Page 236-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 237-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_115-bus01_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">sponsor is published in the Orange Book. When an Abbreviated New Drug Application (&#8220;ANDA&#8221;) applicant files its application with the FDA, the applicant is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Specifically, the applicant must certify with respect to each patent that:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the required patent information has not been filed;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the listed patent has expired;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the listed patent is invalid, unenforceable or will not be infringed by the new product.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">A certification that the new product will not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. If the applicant does not challenge the listed patents or indicate that it is not seeking approval of a patented method of use, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired. If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit or a decision in the infringement case that is favorable to the ANDA applicant.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">To the extent that a Section 505(b)(2) applicant is relying on studies conducted for an already approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would. As a result, approval of a 505(b)(2) NDA can be stalled until all the listed patents claiming the referenced product have expired, until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the referenced product has expired, and, in the case of a Paragraph IV certification and subsequent patent infringement suit, until the earlier of 30 months, settlement of the lawsuit or a decision in the infringement case that is favorable to the Section 505(b)(2) applicant.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Legislative Developments</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The 21st Century Cures Act (the &#8220;Cures Act&#8221;), which was signed into law in December 2016, includes provisions to accelerate the development and delivery of new treatments. For example, the Cures Act requires the FDA to establish a program to evaluate the potential use of real world evidence to help to support the approval of a new indication for an approved drug and to help to support or satisfy post-approval study requirements, to issue guidance on adaptive and novel clinical trial designs for new drugs, and to establish a process for qualifying drug development tools used to support FDA approval for marketing or investigational use of a drug. The Cures Act also permits the FDA to rely on qualified data summaries to support the approval of a supplemental application for an already approved drug. The FDA is in the process of implementing the Cures Act requirements.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Disclosure of Clinical Trial Information</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Sponsors of clinical trials of FDA-regulated products, are required to register and disclose certain clinical trial information. Information related to the product, patient population, phase of investigation, trial sites and investigators and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed in certain circumstances for up to two years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Other U.S. Healthcare Laws and Compliance Requirements</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In the United States, its activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to CMS, other divisions of the U.S. Department of Health and Human Services (<font style="font-style: italic;">e.g.</font>, the Office of Inspector General), the U.S. Department of Justice, or DOJ and individual U.S. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">226<br></div></div></div>
<!--End Page 237-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 238-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_115-bus01_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Attorney offices within the DOJ and state and local governments. For example, sales, marketing and scientific/educational grant programs must comply with the anti-fraud and abuse provisions of the Social Security Act, the false claims laws, the privacy provisions of the Health Insurance Portability and Accountability Act, or HIPAA and similar state laws, each as amended.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers and formulary managers on the other. There are statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Catalyst&#8217;s practices may not in all cases meet all the criteria for protection under a statutory exception or regulatory safe harbor.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Additionally, the intent standard under the Anti-Kickback Statute was amended by the Affordable Care Act (&#8220;ACA&#8221;) to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it to have committed a violation. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act (discussed below).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The civil monetary penalties statute imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The federal False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the federal government or knowingly making, using, or causing to be made or used, a false record or statement material to a false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. Recently, several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of the product for unapproved and thus non-reimbursable, uses. HIPAA created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of, or payment for healthcare benefits, items or services.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst may be subject to data privacy and security regulations by both the federal government and the states in which Catalyst conducts its business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH and its implementing regulations, imposes requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to business associates, independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">227<br></div></div></div>
<!--End Page 238-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 239-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_115-bus01_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Additionally, the federal Physician Payments Sunshine Act within the ACA and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report information related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians and their immediate family members.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">To distribute products commercially, Catalyst must comply with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing and to prohibit certain other sales and marketing practices. All its activities are potentially subject to federal and state consumer protection and unfair competition laws.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If its operations are found to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that apply to Catalyst, Catalyst may be subject to penalties, including without limitation, civil, criminal and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government, or refusal to allow Catalyst to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings and the curtailment or restructuring of its operations, any of which could adversely affect its ability to operate its business and its results of operations.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Coverage, Pricing and Reimbursement</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which Catalyst obtains regulatory approval. In the United States and markets in other countries, sales of any products for which Catalyst receives regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for such products. In the United States, third-party payors include federal and state healthcare programs, privately managed care providers, health insurers and other organizations. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all the FDA-approved products for a particular indication. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. Catalyst may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost-effectiveness of its products, in addition to the costs required to obtain the FDA approvals. Its product candidates may not be considered medically necessary or cost-effective. A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. This is also true of Medicare reimbursement, where different vendors process payments, so that coverage by one vendor does not assure that all other vendors will provide coverage. Adequate third-party reimbursement may not be available to enable Catalyst to maintain price levels sufficient to realize an appropriate return on its investment in product development. In addition, the United States federal government position on matters related to drug pricing is evolving and uncertain and any changes could have a material impact on drug pricing generally in the United States, including for its product candidates if approved.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">228<br></div></div></div>
<!--End Page 239-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 240-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_115-bus01_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines but monitor and control company profits. The National Institute for Health and Care Excellence (NICE) in the United Kingdom also requires consideration of cost-benefit analysis. The downward pressure on healthcare costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The marketability of any product candidates for which Catalyst receives regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and Catalyst expects will continue to increase the pressure on healthcare pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which Catalyst receives regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">The Foreign Corrupt Practices Act</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries and to devise and maintain an adequate system of internal accounting controls for international operations.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Additional Regulation</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect its business. These and other laws govern the use, handling and disposal of various biological, chemical and radioactive substances used in and wastes generated by, its operations. If its operations result in contamination of the environment or expose individuals to hazardous substances, Catalyst could be liable for damages and governmental fines. Catalyst believes that it is in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on its business. Catalyst cannot predict, however, how changes in these laws may affect its future operations.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Government Regulation Outside of the United States</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition to regulations in the United States, Catalyst will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of its products. Whether or not Catalyst obtains FDA approval of a product, Catalyst must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the EU, for example, a clinical trial application must be submitted to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the clinical trial application is approved in accordance with a country&#8217;s requirements, clinical trial development may proceed. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">To obtain regulatory approval of an investigational drug or biological product under EU regulatory systems, Catalyst must submit a marketing authorization application. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">229<br></div></div></div>
<!--End Page 240-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 241-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_115-bus01_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If Catalyst or its potential collaborators fail to comply with applicable foreign regulatory requirements, Catalyst may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Employees</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We consider our ability to recruit, retain and motivate our employees to be critical to our success. We are an equal opportunity employer and we are fundamentally committed to creating and maintaining a work environment in which employees are treated with respect and dignity. All human resources policies, practices and actions related to hiring, promotion, compensation, benefits and termination are administered in accordance with the principal of equal employment opportunity, meaning that they are made on the basis of individual skills, knowledge, abilities, job performance and other legitimate criteria and without regard to race, color, religion, sex, sexual orientation, gender expression or identity, ethnicity, national origin, ancestry, age, mental or physical disability, genetic information, any veteran status, any military status or application for military service, or membership in any other category protected under applicable law.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of March 31, 2023, we had 4 full-time employees. Of the full-time employees, as of such date, all employees were engaged in finance and general management. Of our employees as of March 31, 2023, 50% were male and 50% were female. We have no collective bargaining agreements with our employees, and we have not experienced any work stoppages. We consider our relations with our employees to be good.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We aim to provide our employees with competitive salary and benefits that enable them to achieve a good quality of life and plan for the future. Our benefits are based on local norms and market preferences, but include all salary and social benefits required by local law (including paid time off for vacation and sick leave) and many additional benefits that go beyond legal requirements.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">To maintain and enhance the safety of our employees, we promote a culture of continuous improvement and individual accountability to provide safe workplaces. The safety of our employees has been a priority throughout our response to the COVID-19 pandemic. Our management team guided our operations in the processes and procedures to comply with applicable government-imposed health and safety-related operating restrictions, and to enhance the safety of our facilities to protect the health of our employees. The management team continues to operate, updating guidance as the pandemic has continued and the medical science and government guidance and orders have evolved. We continue to enforce COVID-19 health and safety protocols and have implemented protocols to address actual and suspected cases of COVID-19 and resulting contact tracing and quarantine requirements. Throughout the pandemic, we have been communicating regularly with our employees and monitoring their views on issues related to COVID-19 and the workplace as well as general levels of engagement. In addition, management has regularly updated our board of directors on our COVID-19 status and response, including with respect to employee safety.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">230<br></div></div></div>
<!--End Page 241-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 242-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tBCB"><!--Anchor--></a>BC&#8217;S BUSINESS </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7.5pt; margin-left: 0pt; text-align: justify;">In this section, references to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and &#8220;our company&#8221; refer to Beijing Continent Pharmaceuticals Co., Ltd.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Overview </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We are a commercial-stage biopharmaceutical company committed to the research, development, manufacturing and commercialization of innovative drugs for organ fibrosis. Our commercialized product ETUARY (pirfenidone capsule) and other product candidates were all initially acquired or in-licensed from GNI Japan. We initially focused on the treatment of idiopathic pulmonary fibrosis (&#8220;IPF&#8221;) and have gradually broadened our therapeutic field and research and development efforts to other areas of organ fibrosis. Our flagship product, ETUARY, was approved in the PRC in 2011 and is among the first three approved drugs for IPF worldwide. Thereafter, we have developed a pipeline of additional innovative drug candidates Hydronidone, F528, F230 and F573 and have had nine years of successful commercialization of ETUARY.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As the PRC&#8217;s first approved treatment for IPF, ETUARY has been included in the National Reimbursement Drug List (the &#8220;NRDL&#8221;) of the PRC since 2017. Filling a vacuum in the PRC as the first approved IPF treatment, ETUARY has developed rapidly and maintained a dominant market share in the PRC. The total estimated market size for IPF treatments in the PRC was $127.4&#160;million in 2022 and is expected to grow to $698.6&#160;million by 2031, according to Frost &amp; Sullivan. Moreover, as different organ fibrosis diseases share a similar pathogenic mechanism and fibrosis process, we are seeking to expand the use of ETUARY to include other pulmonary fibrosis diseases, such as SSc-ILD, DM-ILD and pneumoconiosis, as well as diseases causing renal fibrosis, such as diabetic kidney disease (&#8220;DKD&#8221;). The success of ETUARY in the IPF drug market lays the foundation for our research and development and registration strategy to further expand the use of such drugs to indications with large patient populations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Through in-house research and development efforts and collaborative arrangements with GNI Japan, we have developed, in addition to ETUARY, a pipeline of pharmaceutical product candidates at various phases of clinical development, including Hydronidone, F528, F230 and F573. Specifically, liver fibrosis is an area of our focus and our key product candidate in this area is Hydronidone. Hydronidone is currently in its Phase 3 clinical trial and has the potential to be the world&#8217;s first approved drug to treat liver fibrosis associated with chronic hepatitis B (&#8220;CHB&#8221;). According to Frost &amp; Sullivan, the number of patients with liver fibrosis in the PRC reached 140.3&#160;million in 2022, of which approximately 45.3%, or 63.6&#160;million, were caused by CHB. To date, no specific therapeutic drugs treating HBV-associated liver fibrosis have been approved worldwide. Our Phase 2 clinical trials of Hydronidone demonstrated positive results in reversing the fibrosis process. Hydronidone was granted a Breakthrough Therapy designation by the NMPA&#8217;s Center for Drug Evaluation (&#8220;CDE&#8221;) in March 2021 and we commenced patient enrollment for the Phase 3 clinical trial in January 2022. However, Hydronidone&#8217;s Breakthrough Therapy designation does not increase the likelihood that Hydronidone will ultimately receive approval from the NMPA or other comparable regulatory authorities. As of May 9, 2023, we have completed the enrollment of 124 subjects, which is 50% of the target enrollment. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">With a deep understanding in molecular signaling pathway from our years of research into organ fibrosis, we have also expanded our research and development to include potential treatments for chronic obstructive pulmonary disease (&#8220;COPD&#8221;), pulmonary arterial hypertension (&#8220;PAH&#8221;) and acute/acute-on-chronic liver failure (&#8220;ALF/ACLF&#8221;):</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><font style="font-style: italic;">F528</font>. We are evaluating F528 in preclinical studies for the treatment of COPD. F528 is a novel anti-inflammation agent that targets inhibition of multiple inflammatory cytokines and has the potential to modify the progression of COPD with low toxicity <font style="font-style: italic;">in vivo</font>. According to Frost &amp; Sullivan, the number of COPD patients in the PRC reached 106.4&#160;million in 2022 and is expected to reach 110.1 million by 2031. The current standard of care is primarily used to relieve symptoms, reduce the frequency and severity of disease deterioration and improve cardio endurance. We expect that F528 could provide a first-line therapy for COPD and reduce long-term lung function degradation. We intend to file an IND application in the PRC for F528 first quarter of 2024.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><font style="font-style: italic;">F230</font>. We are evaluating F230, a selective endothelin receptor antagonist, in preclinical studies for the treatment of PAH. PAH is a progressive, life-threatening cardiovascular disease. According to Frost &amp; Sullivan, the number of PAH patients in the PRC reached 57,882 in 2022 and is expected to reach 70,279 by 2031. We plan to file an IND application in the PRC in the first quarter of 2024.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">231<br></div></div></div>
<!--End Page 242-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 243-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><font style="font-style: italic;">F573</font>. We are evaluating F573 in Phase 1 clinical trials for the treatment of ALF/ACLF. According to Frost&#160;&amp; Sullivan, the number of patients in the PRC with ALF/ACLF reached 39,247 in 2022. The main treatment options for ALF/ACLF include comprehensive medical therapy, non-biological artificial liver support therapy and liver transplantation. However, there are currently no approved drugs for the treatment of ALF/ACLF. We enrolled the first subject for the Phase 1 clinical study in January 2022 and initiated our Phase 2 clinical study in March 2023.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">The following chart summarizes the development status of our product candidates in the PRC.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;"><img style="height: 388px; width: 598px;" src="ny20006478x8_graphic01x1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our products and product candidates, including ETUARY, were initially acquired from GNI Japan, GNI USA, GNI Hong Kong, SG, and CPI and have been continually developed by us since their acquisition. Currently, we own all related IP rights to these products, except for the Hydronidone rights outside of the PRC, which are now owned by Catalyst pursuant to the F351 Agreement and the research and development capabilities to expand into new product indications and discover and develop new drug candidates. The continued development and expansion of our pipeline products is provided by our in-house research and development team led by experienced project leaders in the pharmaceutical industry.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">While advancing the research and development of our pipeline products, we are one of only a few of biopharmaceutical companies focusing on organ fibrosis drugs in the PRC with manufacturing and commercialization capabilities and an established track record. For further details about our two manufacturing centers, manufacturing capabilities and processes, see &#8220;&#8212;<font style="font-style: italic;">Land and Properties</font>&#8221; and &#8220;&#8212;<font style="font-style: italic;">Production and Quality </font><font style="font-style: italic;">Control&#8212;In-House Manufacturing Facilities.</font>&#8221; For further details about our professional sales team and a comprehensive sales network, see &#8220;&#8212;<font style="font-style: italic;">Sales, Marketing and Distribution.</font>&#8221; </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We are also one of a limited number of biopharmaceutical companies in the PRC that has grown from a development-stage company to achieving sustained profitability. Our total revenue and net profit increased from $47.1&#160;million and $10.2&#160;million in 2019, to $64.8&#160;million and $18.5&#160;million in 2020, respectively, with respective growth rates of 37.6% and 81.4%. Our total revenue and net profit further increased to $88.5&#160;million and $23.2&#160;million in 2021, with respective growth rates of 36.6% and 25.4%. This growth was primarily attributable to the increased market demand for ETUARY, which is the first IPF drug marketed in the PRC. We face limited competition in the IPF drug market and we direct our marketing resources to encourage physician adoption of ETUARY. For the years ended December&#160;31, 2021 and December&#160;31, 2022, our total revenue was $88.5&#160;million and </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">232<br></div></div></div>
<!--End Page 243-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 244-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">$102.5&#160;million, respectively, and our net profit was $23.2&#160;million and $22.5&#160;million, respectively. For the three months ended March 31, 2022 and March 31, 2023, our total revenue was $25.0 million and $24.6 million, respectively, and our net profit was $6.2 million and $5.4 million, respectively</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Our Products and Product Pipeline </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">ETUARY: National Class 1.1 New Drug for IPF Approved in 2011</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Overview</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">ETUARY (pirfenidone capsule) was approved as a National Class 1.1 New Drug in 2011 for the treatment of IPF, a rare disease. We initially acquired the intellectual property rights of pirfenidone for the treatment of IPF from SG in July 2011 and acquired the remaining rights of pirfenidone in September 2020. Given the absence of an approved IPF treatment in the PRC, ETUARY was included in the NRDL in 2017 and held a dominant market share of over 90% and 70%, of total sales in the PRC in 2020 and 2021, respectively. Clinical studies have shown that ETUARY can effectively slow down the decline in lung function and IPF disease progression. Moreover, given that different organ fibroses have similar pathogenic mechanisms and fibrosis processes, we are currently working to expand the therapeutic indications of ETUARY to other pulmonary fibrosis diseases, such as SSc-ILD, DM-ILD and pneumoconiosis, as well as diseases causing renal fibrosis, such as DKD.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Mechanism of Action</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pulmonary fibrosis is caused by activation of alveolar cells after epithelial damage, which secretes a series of pro-inflammatory cytokines, activating fibroblast proliferation and myofibroblast differentiation and reducing the rate of apoptosis. ETUARY reduces Type I Collagen expression by inhibiting the expression of pro-fibrogenic mediators, including TGF-&#223;1, platelet-derived growth factor (&#8220;PDGF&#8221;) and fibroblast growth factor (&#8220;FGF&#8221;), which ultimately reduces fibroblast proliferation and collagen fiber synthesis and decreases extracellular matrix accumulation. It also inhibits TNF-&#945;, IL-1 and other inflammatory mediators, thus reducing the inflammatory response.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The diagram below illustrates the mechanism of action of pirfenidone.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; text-align: center;"><img style="height: 305px; width: 624px;" src="ny20006478x8_graphic04.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Market Opportunities and Competition</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 12pt; margin-left: 0pt; text-align: left;">IPF</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">IPF is a rare disease, defined as a chronic, progressive fibrotic interstitial pneumonia of unknown cause to the lungs, occurring primarily in the elderly. It is characterized by progressive worsening of dyspnea and lung function and is associated with a poor prognosis. The average five-year survival rate for patients with IPF is 32%, with the average 10-year survival rate dropping to 16%.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">233<br></div></div></div>
<!--End Page 244-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 245-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">According to Frost &amp; Sullivan, the prevalence of IPF in the PRC increased from 83,002 patients in 2017 to 131,654 patients in 2022 at a CAGR of 9.7%, and it is expected to increase to 214,664 patients by 2027 at a CAGR of 10.3% from 2022 to 2027 and to 320,677 patients by 2031 at a CAGR of 10.6% from 2027 to 2031. The total market size of IPF in the PRC increased from $13.6&#160;million in 2017 to $127.4 in 2022 at a CAGR of 56.3%, and is expected to reach $344.9&#160;million by 2027 at a CAGR of 22.0% from 2022 to 2027 and $698.6&#160;million by 2031 at a CAGR of 19.3% from 2027 to 2031.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The scarring of lung tissues is irreversible. However, proper treatment may slow the rate of fibrosis, increase the patient&#8217;s survival rate, alleviate the patient&#8217;s symptoms and improve the patient&#8217;s quality of life. There are currently two types of IPF drugs approved in the PRC: pirfenidone and nintedanib. They are both clinically shown to slow down the formation of scar tissue in the lungs of IPF patients and are the only drugs that are considered effective for the treatment of organ fibrosis in the PRC. According to the latest guideline for the treatment of IPF issued by the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society and Latin American Thoracic Association (&#8220;ATS/ERS/JRS/ALAT&#8221;), pirfenidone and nintedanib are the only two types of IPF drug conditionally recommended with moderate-quality evidence.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pirfenidone has been clinically shown to slow down the development of scar tissues in the lungs of IPF patients. Based on the vast clinical needs for pirfenidone, ETUARY was approved as the PRC&#8217;s first National Class 1.1 New Drug for the treatment of mild to moderate IPF.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Since its commercialization, ETUARY has remained a dominant player in the IPF drug market, with a market share of over 90% in 2020 and over 70% in 2021. Sales of ETUARY have continued to grow rapidly, increasing from $63.3&#160;million in 2020 to $86.8&#160;million in 2021 to $99.3 million in 2022 and we expect our sales growth to continue. In 2021, the market share of ETUARY decreased to 78.8%, primarily due to recent inclusion of competitors&#8217; products into NRDL (such as Ofev by Boehringer Ingelheim) and the related increased sales of such competitors&#8217; products. In 2022, the market share of ETUARY decreased to 55.3%, primarily due to the market share of new drugs rising rapidly as a result of new drugs having different shelf times and targeting different indications. Despite the recent decrease of market share of ETUARY in the IPF market, we continue to expect a strong sales performance due to: (i)&#160;sustained increases in the prevalence of IPF; and (ii)&#160;future indication expansion of ETUARY for the potential treatment of DM-ILD, SSc-ILD, pneumoconiosis, and DKD. In addition, there are various barriers to entry for the potential market entrants. For instance, it is difficult for new entrants to build an experienced and specialized sales and marketing team in the short term given that sales and marketing strategies of organ fibrosis drugs significantly differ from that of etiological treatment drugs and long-term and stable collaboration with KOLs and hospitals is critical to developing and optimizing product portfolio, effectively educating and penetrating the market and recruiting patients for clinical trials.</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 20pt; margin-left: 0pt; text-align: left;">SSc-ILD and DM-ILD</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Connective tissue disease associated with interstitial lung disease (&#8220;CTD-ILD&#8221;) is non-idiopathic interstitial pneumonia. CTD is a type of autoimmune disease that causes damage to various organs throughout the body based on chronic inflammation of blood vessels and connective tissue. ILD is one of the most serious pulmonary complications and can result in significant morbidity and mortality when associated with CTD.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">SSc is a CTD characterized by degenerative microvascular phenomena and immune system activation, leading to fibrosis of the skin and internal organs. ILD is very frequent in patients affected by SSc, reaching about 50% prevalence, representing the leading SSc-related cause of death. DM is characterized by proximal skeletal muscle weakness and muscle inflammation. Among patients with DM, ILD is a major cause of morbidity and mortality. The frequency of ILD in DM has been reported to range between 5% and 45% depending on the diagnostic method.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to Frost &amp; Sullivan, the prevalence of CTD-ILD in the PRC increased from approximately 2.3&#160;million patients in 2017 to 2.4&#160;million patients in 2022, and is expected to reach 2.5&#160;million patients in 2027 and 2.6&#160;million patients in 2031. Among the CTD-ILD patients, approximately 8.4% are SSc-ILD and DM-ILD patients in 2022. The market size of anti-fibrosis drugs for SSc-ILD/DM-ILD patients was $9.1 million in 2022 and is expected to reach $53.1&#160;million by 2027 and $117.6&#160;million by 2031 at a CAGR of 42.4% from 2022 to 2027 and a CAGR of 22.0% from 2027 to 2031.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">SSc-ILD and DM-ILD are induced by known factors, including specific exposure or autoimmune diseases (such as scleroderma and rheumatoid arthritis). Symptoms include chronic cough, expectoration, hemoptysis, progressive dyspnea and intermittent fever. The treatment of CTD-ILD (including SSc-ILD and DM-ILD) is a combination of the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">234<br></div></div></div>
<!--End Page 245-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 246-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">immunosuppressive treatment for CTD and the anti-fibrosis treatment for ILD, which can effectively prevent or even reverse the progression of ILD lesion and protect the pulmonary function of patients. Recommended immunological drugs include cyclophosphamide, mycophenolate mofetil and azathioprine. Anti-fibrosis treatment methods vary with different types of CTD-related ILD in terms of the timing, drug selection, dosage and treatment duration. Recommended anti-fibrosis drugs include pirfenidone and nintedanib.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pirfenidone is an antifibrotic agent with anti-inflammatory properties, including inhibition of proinflammatory cytokines and inhibition of inflammatory cell proliferation. Despite the differences in their clinical presentation, IPF, SSc-ILD and DM-ILD share some overlapping pathogenic mechanisms, including injury to structural cells, fibroblast activation, myofibroblast accumulation, expression of fibrogenic cytokines and growth factors and progressive ILD. Based on the results of pirfenidone&#8217;s preclinical studies, we are evaluating its efficacy on patients with SSc-ILD and DM-ILD in Phase 3 clinical trials. Currently, nintedanib is approved for the treatment of anti-fibrosis in patients with SSc-ILD.</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Pneumoconiosis</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pneumoconiosis refers to a spectrum of pulmonary diseases caused by inhalation of mineral dust, usually as the result of certain occupations. The main pathological features include chronic pulmonary inflammation and progressive pulmonary fibrosis, which can eventually lead to death caused by respiratory and/or heart failure. Pneumoconiosis is widespread globally and a serious global public health concern. Its high incidence and mortality result from improper occupational protection and the lack of early diagnostic methods and effective treatments.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to Frost &amp; Sullivan, in the PRC, the prevalence of pneumoconiosis increased from 850,299 patients in 2017 to 926,769 patients in 2022, and it is expected to increase to 962,562 patients by 2027 and 980,917 patients by 2031. The market size of anti-fibrosis drugs for pneumoconiosis is expected to reach $12.1&#160;million by 2027 and $64.1&#160;million by 2031 a CAGR of 51.7% from 2027 to 2031.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">To date, there are two pirfenidone product candidates for the treatment of pneumoconiosis in various clinical stages in the PRC. We enrolled the first patient in our Phase 3 clinical study of ETUARY for the treatment of pneumoconiosis in June 2022, making ETUARY the most clinically advanced anti-fibrosis drug for the treatment of pneumoconiosis in the PRC. As of May&#160;15, 2023, no anti-fibrosis product for the treatment of pneumoconiosis had been approved in the PRC.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">An experimental study on silica-induced lung fibrosis in rats demonstrated that pirfenidone can slow the transformation from epithelial to mesenchymal cells when administered for 14 days and 28 days. These treatments were associated with a significant down-regulation of vimentine and up-regulation of E-cadherin, suggesting that pirfenidone can exhibit an inhibiting effect on silica-induced epithelial-mesenchymal transition (&#8220;EMT&#8221;) in rats.</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">DKD</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">DKD is a chronic kidney disease (&#8220;CKD&#8221;) caused by diabetes mellitus. DKD is clinically manifested as specific pathological structural and functional changes in the kidney of diabetes patients. In addition, DKD has become the primary cause of progression from CKD to the end-stage renal disease and one of the main diseases causing renal fibrosis. As one of the serious complications of diabetes, DKD in the PRC is characterized by high prevalence, low awareness rate, low treatment rate and low control rate.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to Frost &amp; Sullivan, the prevalence of DKD in the PRC increased from 45.4&#160;million patients in 2017 to 53.2&#160;million patients in 2022, and it is expected to increase to 61.5&#160;million patients by 2031. The DKD market in the PRC increased from $24.2&#160;billion in 2017 to $37.2&#160;billion in 2022 and it is predicted to expand to $51.5&#160;billion by 2027 and $60.3&#160;billion by 2031.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The standard of care (&#8220;SOC&#8221;) for DKD has been blood glucose control, blood pressure control and blood liquid control. However, current therapeutic strategies are far from being completely effective because no available therapy successfully prevents DKD and many patients still progress to end-stage renal disease. The current available drugs for the treatment of DKD include hypoglycemic drugs, antihypertensive drugs and lipid-lowering drugs. There is no specific anti-fibrosis drug approved for the treatment of DKD globally or in the PRC.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pirfenidone has demonstrated positive therapeutic effects on DKD due to its unique mechanism of action. Several growth factors or cytokines that are locally produced in the kidney appear to contribute to the extracellular matrix accumulation, inflammation and scarring in progressive DKD. The TGF-&#223;1 system is activated and plays a pathogenetic role in DKD in </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">235<br></div></div></div>
<!--End Page 246-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 247-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">animal models of type 1 and type 2 diabetes. In addition, several studies in patients with type 1 and type 2 diabetes indicate increased renal production of TGF-&#223;1. The TNF-&#945;&#8217; system has also recently been linked with human DKD on the basis of circulating blood levels and gene expression in kidneys from patients with DKD. Pirfenidone has been found to inhibit TGF-&#223;1 production and consequent matrix deposition in experimental animal models of kidney disease. In animal models and cell culture studies, pirfenidone also reduces TNF-&#945;&#8217; production. Previous studies also showed that oral pirfenidone administered to db/db mice after the onset of established DKD was effective in reducing glomerulosclerosis.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Summary of Clinical Results</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of May&#160;15, 2023, BC or SG conducted over 10 clinical trials to explore the clinical benefits of pirfenidone in the PRC. As the first drug approved for IPF in the PRC, ETUARY was approved upon completion of Phase 2a clinical trials. Summarized below are the results of selected key clinical trials of ETUARY.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;"><u>Registered Phase 2a clinical trial of pirfenidone for IPF</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Trial Design: This study was a randomized, double-blind, multi-dose, parallel-controlled, multicenter Phase 2a clinical trial to investigate the effectiveness of pirfenidone combined with basic treatment for IPF. The objective was to evaluate the safety and efficacy of pirfenidone capsules, as well as to determine the most appropriate clinical treatment dose by observing the therapeutic effects of pirfenidone capsules on pulmonary function (including arterial blood gas analysis), the six-minute walk test (&#8220;6MWT&#8221;), survival, quality of life and high-resolution computed tomography imaging in IPF patients. The treatment group was divided into two dose treatment groups, a 400 mg/tid treatment group and a 600 mg/tid treatment group. 24 patients were enrolled in each treatment group. The placebo group was also divided into two groups, a four capsules/tid group and a six capsules/tid group, with 12 patients in each group. The treatment and placebo groups were assigned in a 2:2:1:1 ratio and patients were stratified and randomized to be assigned to receive pirfenidone or placebo. The primary endpoints were pulmonary function parameters, 6MWT results and survival rate.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">This trial has been completed with a total of 72 patients enrolled.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The efficacy results of the trial were as follows:</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 17.95%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Therapeutic Effect</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 17.95%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Criteria</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 58.97%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Results (FAS, after 12 months treatment)</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pulmonary function</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Diffusing capacity of carbon monoxide % (&#8220;DLco%&#8221;) </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">There was a statistically significant difference among the three groups of the change in DLco% (P=0.0306), with a mean change of -2.79&#177;9.34% in the 600 mg treatment group and a mean change of -14.92&#177;16.40% in the placebo group (P=0.0014 for the two groups).</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Diffusing capacity of carbon monoxide (&#8220;DLco&#8221;)</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">There was a statistically significant difference among the three groups of the change in DLco (P=0.0049), with a mean change of -0.42&#177;3.45% in the 600 mg treatment group and a mean change of -3.14&#177;4.44% in the placebo group (P=0.0016 for the two groups).</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Arterial oxygen saturation (&#8220;SaO2&#8221;)</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">There was a statistically significant difference among the three groups of the change in arterial oxygen saturation (SaO2) (P=0.0145), with a mean change of -3.83&#177;4.02% in the placebo group and -0.30&#177;3.05% in the 400 mg group (P=0.0055 for the two groups).</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6MWT </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pulse oxygen saturation (&#8220;SpO2&#8221;)</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">There was a statistically significant difference among the three groups of the change in SpO2 after 6MWT (P=0.0168), with a mean change of -9.08&#177;10.66% in the placebo group and 0.22&#177;7.30% in the 400 mg treatment group (P=0.0062 for the two groups).</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Survival rate</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">N/A</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The mortality of placebo group, 400 mg treatment group and 600 </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">236<br></div></div></div>
<!--End Page 247-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 248-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 17.95%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Therapeutic Effect</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 17.95%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Criteria</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 58.97%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Results (FAS, after 12 months treatment)</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">mg treatment group was 20.83%, 21.74% and 16.67%, respectively, with no statistical significance.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">17 patients experienced SAEs, but none were drug-related. The incidence of adverse drug reactions (&#8220;ADRs&#8221;) in the placebo group, 400 mg and 600 mg treatment groups was 41.67%, 29.17% and 45.83%, respectively, with no statistical difference between the three groups. The incidence of rash in the treatment groups was statistically different from that in the placebo group and was present in all of the 600 mg treatment groups with an incidence of 20.83%. The common ADRs included nausea (12.5% in each of the 400 mg treatment group and 600&#160;mg treatment group), photosensitivity (4.17% in the 400 mg treatment group and 12.5% in the 600 mg treatment group) and drowsiness (8.33% in the 600 mg treatment group), but these were not statistically significant from the placebo group. The incidence of AEs in the placebo group, 400 mg and 600 mg treatment groups was 70.83%, 66.67% and 66.67%, respectively, with no statistical difference between the three groups. The average incidence of significant adverse events in each of the placebo group and the 400 mg and 600 mg treatment groups was 54.17%, with no statistical difference between the three groups. The incidence of SAEs (including mortality and hospitalization) in each of the placebo group and the 400 mg and 600 mg treatment groups was 29.17%, 20.83% and 20.83%, with no statistical difference between the three groups.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">After 12 months of treatment, pirfenidone was effective in slowing down the decline in DLco%, DLco, SaO2 and SpO2 immediately after 6MWT. No drug-related SAEs were observed and rash and nausea were the most common ADRs. The results show that pirfenidone has potential for the treatment of IPF.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15.5pt; margin-left: 0pt; text-align: left;"><u>Phase 3 clinical trial of pirfenidone for the treatment of SSc-ILD</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We are conducting a randomized, double-blind, placebo-controlled, multicenter Phase 3 clinical trial. The purpose of this registration trial is to evaluate the efficacy and safety of pirfenidone in the treatment of SSc-ILD. The primary endpoint is the change in FVC% at 52 weeks of treatment compared to baseline. 144 patients are planned to be enrolled in the trial, with 108 in the treatment group and 36 in the control group.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This trial enrolled the first patient in June 2018. Due to the outbreak of COVID-19 and the scarcity of eligible patients, this trial is still in the process of recruiting patients and therefore no clinical results are currently available for analysis.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15.5pt; margin-left: 0pt; text-align: left;"><u>Phase 3 clinical trial of pirfenidone for the treatment of DM-ILD</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We are conducting a randomized, double-blind, placebo-controlled, multicenter Phase 3 clinical trial. The purpose of this registration trial is to evaluate the efficacy and safety of pirfenidone for the treatment of DM-ILD. The primary endpoint is the change in FVC% at 52 weeks of treatment compared to baseline. 152 patients will be enrolled in the trial, with 114 in the treatment group and 38 in the control group.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This trial enrolled the first patient in June 2018. Due to the outbreak of COVID-19 and the scarcity of eligible patients, this trial is still in the process of recruiting patients and no clinical results are currently available for analysis.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15.5pt; margin-left: 0pt; text-align: left;"><u>Phase 3 clinical trial of pirfenidone for the treatment of pneumoconiosis</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We are conducting a randomized, double-blind, placebo-controlled, multi-center Phase 3 clinical trial. The purpose of this registration trial is to evaluate the efficacy and safety of pirfenidone in the treatment of pneumoconiosis. The primary endpoint is the change in force vital capacity at 52 weeks of treatment compared to baseline. 272 patients will be enrolled in the trial, with 136 in the treatment group and 136 in the control group.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">We obtained ethics committee approval as of January 2022 and enrolled the first patient in June 2022.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16pt; margin-left: 0pt; text-align: left;"><u>Phase 1 clinical trial of pirfenidone for the treatment of DKD</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We are conducting an open-label, parallel-controlled, single-center clinical trial. The purpose of this registration trial is to evaluate the safety and PK of a single dose of pirfenidone capsules in patients with CKD stages G2 and G3a. 24 subjects were enrolled, consisting of 12 patients with renal insufficiency and 12 healthy volunteers.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Phase 1 clinical trial was completed in March 2022. In this trial, pirfenidone was tolerated when used in patients with chronic kidney disease G2 and G3a, there is no significant change in the main pharmacokinetic parameters compared with healthy controls, and no dose adjustment is required.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">237<br></div></div></div>
<!--End Page 248-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 249-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Our Clinical-Stage Product - Hydronidone: A Drug to Reverse Liver Fibrosis Associated with CHB</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Overview</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Hydronidone, our Phase 3 clinical-stage product candidate, has the potential to become the first approved drug to treat liver fibrosis associated with CHB. According to Frost &amp; Sullivan, CHB is the number one cause of liver fibrosis in the PRC and the number of patients with liver fibrosis in the PRC reached approximately 140.3&#160;million in 2022, of which approximately 45.3% were caused by CHB. To date, there is no effective clinical therapy for liver fibrosis and no specific therapeutic drugs have been approved worldwide. Hydronidone demonstrated positive results the reversal of the fibrosis process in its Phase&#160;2 clinical trial. Hydronidone may reverse liver fibrosis by inhibiting hepatic stellate cell proliferation and the TGF-&#223;1 signaling pathway, both of which play major roles in the liver fibrosis associated with CHB. Due to the results of the Phase 2 clinical trial in CHB-induced liver fibrosis, and as one of the first drugs announced to treat liver fibrosis, Hydronidone was granted a Breakthrough Therapy designation by the CDE in March 2021 and we commenced patient enrollment for the Phase 3 clinical trial in January 2022. As of May 9, 2023, we have completed the enrollment of 124 subjects, which is 50% of the target enrollment. We expect to submit an NMPA application for Hydronidone in the PRC in the first quarter of 2025. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Mechanism of Action</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">When injuries occur and epithelial and/or endothelial cells are damaged, pro- inflammatory cytokines are released by the coagulation cascade for immune cell recruitment, mainly neutrophils and macrophages. These recruited immune cells function as the scavenger to remove tissue debris and dead cells, resulting in acute inflammation. Meanwhile, immune cells themselves release factors like chemokines and cytokines to amplify inflammatory reactions. Next, the released factors, such as TGF-&#223;1, PDGF, interleukin-13 and interleukin-4, induce the limited activation and proliferation of myofibroblasts. Hydronidone is expected to treat and reverse liver fibrosis in chronic viral hepatitis&#160;B by inhibiting the proliferation of HSCs and the TGF-&#223;1 signaling pathway.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">The diagram below illustrates the mechanism of action of Hydronidone:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 275px; width: 509px;" src="ny20006478x8_graphic02.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Market Opportunities and Competition</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">CHB is a major cause of liver morbidity and mortality worldwide. Patients chronically infected with the hepatitis&#160;B&#160;virus tend to experience liver fibrosis and may develop end-stage liver disease, such as decompensated cirrhosis and hepatocellular carcinoma (HCC), without intervention. In the PRC, about 70% of cirrhoses were developed from&#160;HBV infection, which reflects the significant demand for the treatment of liver fibrosis associated with CHB.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to Frost &amp; Sullivan, the prevalence of liver fibrosis associated with CHB globally increased from&#160;221.1&#160;million patients in 2017 to 257.8&#160;million patients in 2022. The prevalence of liver fibrosis associated with </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">238<br></div></div></div>
<!--End Page 249-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 250-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">CHB in the PRC from&#160;2017 to 2022 ranges from 63.6&#160;million to 66.4&#160;million patients and is expected to remain stable in the next 10&#160;years. The anti-liver fibrosis drug market in the PRC has increased from $138.0&#160;million in 2017 to $162.7&#160;million in 2022 and we expect the market to grow to $338.0&#160;million in 2027 and $801.2&#160;million in 2031, at a CAGR of 15.8% and 24.1%, respectively.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Etiological treatment is currently the most common treatment of liver fibrosis. For liver fibrosis associated with CHB, antiviral therapy is only able to suppress the viral infection, but is unable to prevent, slow or reverse the progress of fibrosis. Anti-fibrotic treatment is recommended for the treatment of intermediate and advanced liver fibrosis, as well as early-stage cirrhosis. As of May&#160;15, 2023, no chemical or biological drugs treating liver fibrosis that have been approved globally or in the PRC. The inability of etiological treatment to reverse fibrosis and the lack of treatment for liver fibrosis diseases, including those associated with CHB, suggests a massive unmet need for effective antifibrotic therapy. Globally, there are currently a series of drugs that are in late-stage (Phase 2 or later) clinical trials for the treatment of liver fibrosis. Of these clinical stage drugs, Hydronidone is the most clinically advanced product candidate in the PRC that has the potential to effectively reverse the fibrosis process.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In our clinical trials, Hydronidone showed results in reversing the process of liver fibrosis. Our Phase 2 clinical results in CHB patients with liver fibrosis show that, using the pathological score of Ishak stage as the primary outcome measure, the treatment group showed better results in reversing liver fibrosis than the placebo group after 52 weeks of treatment. In particular, around 56.1% of the patients achieved a fibrosis regression of &gt; 1 in the 270 mg group. We commenced the patient enrollment for the Phase 3 clinical trial in January 2022. As of May 9, 2023, we have completed the enrollment of 124 subjects, which is 50% of the target enrollment.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to Frost &amp; Sullivan, the commercialization of Hydronidone could open the market for HBV-associated anti-liver fibrosis drugs in the PRC in 2025, the year in which the market for the anti-fibrosis drug for the treatment of CHB is expected to reach $25.2&#160;million. Leveraging first-mover advantages, such as better market education, better brand recognition, higher patient adherence and richer sales and marketing experience, we anticipate Hydronidone will have a higher penetration rate among patients with liver fibrosis associated with CHB as compared with other competing drugs.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">Summary of Clinical Results</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of May&#160;15, 2023, more than five clinical trials sponsored by us or SG were carried out to explore the clinical risk/benefit of Hydronidone. Summarized below are the results of selected key clinical trials of Hydronidone.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;"><u>Phase 2 Study of Hydronidone for liver fibrosis associated with CHB in the PRC</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We conducted a randomized, double-blind, placebo-controlled, Entecavir-based treatment (the first-line drug for the treatment of CHB virus infection), multi-center, dose-escalation study assessing the safety and efficacy of Hydronidone for treatment of patients in the PRC with liver fibrosis associated with CHB. The Phase 2 study was designed to be randomized in 240 patients divided into four dose-escalating groups (placebo; 180 mg/day; 270&#160;mg/day; and 360 mg/day) with a primary endpoint of the reduction of the liver fibrosis score (Ishak Scoring System) by greater than or equal to one grade after taking Hydronidone in combination with Entecavir.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The study met its primary endpoint of a statistically-significant improvement in the liver fibrosis score over the 52-week treatment versus placebo (p=0.0245). The percentages of patients who achieved a fibrosis regression of &gt; 1 were 25.58% (placebo), 40.48% (180 mg/day), 56.10% (270 mg/day) and 43.90% (360 mg/day). Accordingly, the 270 mg/day treatment group showed the highest percentage of patients who were able to reach the primary endpoint.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Hydronidone showed better safety results when compared to the placebo in this study. In the placebo group, 180 mg treatment group, 270 mg treatment group and 360 mg treatment group, rates of SAEs were 4.65%, 2.38%, 2.38% and 7.32%, respectively, with no statistical significance. A total of 7 (4.17%) subjects experienced 7 serious adverse events (SAEs) throughout the study: 2 (4.6%) in the placebo group, 1 (2.38%) in the 180 mg group, 1 (2.38%) in the 270 mg group and 3 (7.32%) in 360 mg group, with no statistical significance. The SAEs were laboratory abnormalities, elevation of transaminases, embolic infarction, comminuted fracture, osteoporosis, unplanned pregnancy and hypertension. No deaths occurred.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Hydronidone showed data in improving liver fibrosis associated with CHB after 52&#160;weeks of treatment, with the best efficacy results at 270 mg/day. Hydronidone in combination with Entecavir has promising effects over 52 weeks in the treatment of liver fibrosis associated with CHB.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">239<br></div></div></div>
<!--End Page 250-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 251-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><u>Phase 3 Study of Hydronidone for liver fibrosis associated with CHB in the PRC</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We are conducting a randomized, double-blind, placebo-controlled, Entecavir-based treatment (the&#160;first-line drug for the treatment of CHB), multi-center study assessing the safety and efficacy of Hydronidone for treatment of patients in the PRC with liver fibrosis associated with CHB. The Phase 3 study was designed to be randomized in 248 patients with a primary endpoint of the reduction of the liver fibrosis score (Ishak Scoring System) by at least one grade after taking Hydronidone in combination with Entecavir.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We commenced patient enrollment for the Phase 3 clinical trials of Hydronidone in January 2022. As of May 9, 2023, we have completed the enrollment of 124 subjects, which is 50% of the target enrollment. This trial is actively recruiting additional patients and no clinical results are currently available for analysis.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18pt; margin-left: 0pt; text-align: left;">Licenses, Rights and Obligations</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In September 2020, we entered into an intellectual property transfer agreement with GNI Japan and three of its subsidiaries (SG, GNI Tianjin Limited and GNI-HK) for the transfer of IP rights related to Hydronidone. According to that agreement, we acquired the intellectual property rights of Hydronidone and retain the exclusive rights to use those intellectual property rights in mainland PRC and the right of first offer to the global intellectual property rights of Hydronidone. In connection with the F351 Acquisition, we waived our right of first offer under such agreement. For details, see &#8220;<font style="font-style: italic;">Catalyst&#8217;s Business&#8212;Agreements Relating to the Hydronidone Program&#8212;F351 Asset Purchase </font><font style="font-style: italic;">Agreement.</font>&#8221;</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">F573: Potential Category 1 New Drug for ALF/ACLF</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Overview</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">F573 is a caspase inhibitor and a potential Category 1 new drug for the treatment of ALF/ACLF. We acquired the intellectual property rights of F573 from a subsidiary of GNI in September 2020. According to Frost &amp; Sullivan, the number of patients with ALF/ACLF in 2022 reached 39,247 in the PRC. The main treatment options for ALF/ACLF include comprehensive medical therapy, non-biological artificial liver support therapy and liver transplantation. Currently, there are no drugs specifically for the treatment of ALF/ACLF. We enrolled the first subject for the Phase 1 clinical study in January 2022 and initiated its Phase 2 clinical study in March 2023.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Mechanism of Action</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Inflammatory response and immune dysfunction can lead to massive liver cell death, which causes ALF/ACLF. Therefore, inhibiting the apoptosis process of normal hepatocytes helps to delay the progression of ALF/ACLF. The main mediating pathways of hepatocyte apoptosis include the mitochondrial pathway and the death receptors pathway, where the caspase family plays an important role as the main executive molecules. The main mechanism of F573 is to inhibit the activity of the caspase family, including caspases 3, 6, 7, 8 and 9 and to reduce the cleavage effects on poly-ADP-ribose polymerase, thus blocking the cell apoptosis process mediated by endogenous or exogenous signals. As a result, hepatic failure is expected to be alleviated by F573.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The diagram below illustrates the mechanism of action of F573:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.75pt; text-align: center;"><img style="height: 221px; width: 491px;" src="ny20006478x8_graphic05.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">240<br></div></div></div>
<!--End Page 251-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 252-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Market Opportunities and Competition</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">ALF/ACLF is severe liver damage caused by a variety of factors, resulting in severe impairment or loss of synthesis of detoxification, metabolism and biotransformation functions. ALF/ACLF can follow with syndromes of jaundice, coagulation dysfunction, hepatorenal syndrome, hepatic encephalopathy and ascites. The causes of ALF/ACLF are complex and include the hepatitis viruses (especially HBV) and other viruses, drugs, hepatotoxic substances (<font style="font-style: italic;">e.g.</font>, alcohol and chemical agents), bacteria and parasites. In the PRC, HBV, drugs and hepatotoxic substances are the most common causes of ALF/ACLF.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to Frost &amp; Sullivan, the prevalence of ALF/ACLF in the PRC was 43,123 patients in 2017 and 39,247 patients in 2022 and is expected to be 34,969 patients in 2027 and 31,485 patients in 2031. The market size of ALF/ACLF in the PRC was $278.6&#160;million in 2017 and $253.5&#160;million in 2022 and it is expected to be $225.9&#160;million in 2027 and $203.3&#160;million in 2031.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The main treatment options for liver failure include comprehensive medical therapy, non-biological artificial liver support treatment and liver transplantation. Medical treatment mainly includes general supportive therapy, symptomatic treatment, etiological treatment and treatment for complications.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The efficacy profile of F573 has been demonstrated in four preclinical studies. In <font style="font-style: italic;">in vitro</font> studies, F573 has a significant inhibitory effect on apoptosis in a variety of cells. Specifically, F573 had a protective effect on HeLa cells, human normal hepatocytes L02 and Jurkat cells while inhibiting Caspase-3 enzyme activity and reducing its ability to cleave the substrate AC-DEVD-AMC. F573 improved liver function and alleviated the liver injury caused by D-GalN/LPS-induced fulminant liver failure in rats, which significantly inhibited hepatocyte necrosis and apoptosis and showed a preventive and therapeutic effect on acute and severe liver injury. In a pharmacodynamic acute liver injury experiment on D-Gal/LPS mortality in mice, F573 had a protective effect against acute liver injury caused by D-Gal and LPS in km mice and prolonged the survival time of km mice. F573 has been shown to improve liver function and reduce liver injury in ConA-induced acute liver failure in BALB/c mice. F573 significantly inhibits hepatocyte necrosis and apoptosis and has a preventive and therapeutic effect on acute and severe liver injury.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Clinical Development Plan</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We enrolled the first subject for our Phase 1 clinical trial to assess the tolerance and PK of single and multiple doses of F573 in January 2022. We recruited 100 healthy subjects for this trial and completed the Phase 1 clinical observations of tolerability and PK in July 2022. We initiated our Phase 2 clinical study in March 2023.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Phase 1 Study of F573 for ALF/ACLF</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Cmax of F573 was not dose-dependent at the dose range from 0.5mg/kg to 2.0mg/kg, and AUC0-t and AUC0-&#8734; of F573 showed linear pharmacokinetics. The rate of absorption of F573 showed sex differences. F573 was administered once a day for 7 days without accumulation in the human body.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Phase 2 Study of F573 for ALF/ACLF</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Phase 2 study is designed to be a randomized, double-blind, placebo-controlled clinical trial. The main objective of this study is to assess the efficacy and safety of F573 for injection in the treatment of liver injury/failure. The Phase&#160;2 study is divided into three stages.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">First Stage<font style="font-style: normal;">: 36 patients with 1/2 grade DILI and 12 patients with CHB are expected to enroll. First, DILI patients </font><font style="font-style: normal;">will be treated with the trial drug at either 0.5, 1.0, 2.0 mg/kg or placebo in a 1:1:1:1 ratio. CHB patients will receive </font><font style="font-style: normal;">the trial drug or placebo in a 3:1 ratio.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Second Stage<font style="font-style: normal;">: The 2/3 grade DILI patients and CHB patients are expected to enroll, 12 cases in each group, and are </font><font style="font-style: normal;">expected to be assigned to the experimental group and the control group in a ratio of 3:1. </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">After obtaining subject consent, pharmacokinetic blood samples will be collected for CHB patients in stages 1 and 2 in this trial.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Third Stage<font style="font-style: normal;">: This study is expected to use a randomized, double-blind, placebo-controlled design. The study is </font><font style="font-style: normal;">designed to be divided into screening period (14 days), treatment period (28 days) and follow-up period (90 days).</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">48 screen eligible subjects are expected to receive trial drug or placebo in a ratio of 3:1, once a day for 28 days. Subjects are also expected to receive concurrent drug acetylcysteine injection (NAC). After withdrawal, the subjects will be followed up for 90 days for safety.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">241<br></div></div></div>
<!--End Page 252-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 253-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Licenses, Rights and Obligations</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In September 2020, we entered into an intellectual property assignment agreement with Continent Cayman (a&#160;wholly-owned subsidiary of GNI Japan and indirect holder of our company) whereby we acquired the intellectual property rights to F573. According to the agreement, we own the global rights to develop and commercialize F573. For more details, see &#8220;<font style="font-style: italic;">BC&#8217;s Business&#8212;Our Products and Product Pipeline&#8212;F573: Potential Category 1 New Drug </font><font style="font-style: italic;">for ALF/ACLF.</font>&#8221;</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Our Preclinical-Stage Product Candidates</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">F528: A Potential First-line Therapy for COPD</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">F528 is an anti-inflammatory small molecule drug candidate developed for the treatment of COPD. F528 is a novel anti-inflammation agent that targets inhibition of multiple inflammatory cytokines and could modify the progression of COPD with extreme low toxicity <font style="font-style: italic;">in vivo</font>. In September 2020, we acquired from SG the intellectual property rights to F528, as well as the global rights to develop and commercialize F528. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">COPD is a chronic inflammatory lung disease which causes obstructed air flow from the lungs. It consists of three separate illnesses: emphysema, chronic bronchitis and chronic obstructive asthma. COPD causes the destruction of barriers between alveoli inside the lungs, causing airways to get swollen and clogged with mucus. In most cases, COPD develops very slowly and symptoms may emerge for years before being diagnosed.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to Frost &amp; Sullivan, prevalence of COPD in the PRC increased from 102.7&#160;million patients in 2017 to 106.4&#160;million patients in 2022 and is expected to increase to 108.6&#160;million patients in 2027 and 110.1&#160;million patients in 2031. The COPD market in the PRC was $0.9&#160;billion in 2017 to $1.1&#160;billion in 2022. The market is predicted to expand to $1.3&#160;billion by 2027 and $1.5&#160;billion by 2031.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The drug treatment of COPD is mainly used to relieve symptoms, reduce the frequency and severity of disease deterioration and improve cardio endurance and health. Currently, there is no conclusive clinical trial evidence showing that existing drugs can slow down the long-term decline in lung function. For late-stage COPD patients, currently-available treatment options achieve limited therapeutic effects. As clinical research results from external parties indicated, 2% of patients were reported to gain improvement in exercise capability after 24 months of standard medical treatment and none were reported to gain improved health-related quality of life. Thus, there are significant unmet clinical needs for COPD patients.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We believe F528 could become first-line therapy for COPD. It has exhibited a favorable preclinical profile in the treatment of COPD. In a preclinical study of the effect of F528 in rats with COPD induced by smoke exposure and LPS tracheal injection, the lung index, the alveolar space and the lung injury score were significantly decreased after the treatment of F528. F528 is currently in preclinical studies. Three indexes are statistically significant difference between treatment groups and disease control. We intend to file an IND application in the first quarter of 2024.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">F230: Selective Antagonist of EPA for PAH</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">F230 is a selective-receptor antagonist to treat PAH. In March 2021, we entered into a sublicense agreement with GNI whereby GNI sub-licensed to us the exclusive right to research, develop and commercialize F230 in mainland PRC and such sub-license is authorized under the license agreement between GNI and Eisai Co., Ltd., a Japanese pharmaceutical company. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">PAH is a rare disease and a progressive, life-threatening disorder characterized by increased pressure in the pulmonary arteries that carry blood from the heart to the lungs. PAH occurs when the pulmonary arteries thicken or grow rigid. This restricts blood flow through the lungs, causing pulmonary hypertension and making the heart work harder to pump blood to the lungs. The exact cause of PAH is unknown and there is no known cure for PAH. PAH is a serious disease that has a short life expectancy if left untreated. The prognosis for the treatment of PAH is poor, with a high mortality rate and survival of less than three years in the absence of standard therapy.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to Frost &amp; Sullivan, the prevalence of PAH in the PRC increased from 49,004 patients in 2017 to 57,882 patients in 2022 and it is expected to increase to 67,682 patients by 2027 and 70,279 patients by 2031. The market size of PAH in the PRC increased from $0.29&#160;billion in 2017 to $0.37&#160;billion in 2022 and it is expected to increase to $0.47&#160;billion by 2027 and $0.52&#160;billion by 2031.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For the study of Hypoxia-induced PAH in rats, F230 resulted in significant decreases of, or exhibited a decrease trend based on different dose groups, in mean pulmonary arterial pressure (mPAP), right ventricular systolic pressure </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">242<br></div></div></div>
<!--End Page 253-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 254-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">(RVSP), right ventricular/left ventricular plus septum (RV/LV+S) and pulmonary artery wall thickness (PAWT). Even at minimum effective dosage, the differences of those indexes between treatment group and PAH group are statistically significant. F230 is currently in preclinical studies. We intend to file an IND application in the first quarter of 2024.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Other Drug Candidates</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">To supplement and enrich our product candidate pipeline for the treatment of CLD-associated diseases and multiple sclerosis, we acquired two drugs, the Avatrombopag Maleate Tablets and the Fingolimod Hydrochloride Capsules. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In June 2021, we entered into a transfer agreement with Nanjing Healthnice Pharmaceutical Technology Co., Ltd. (&#8220;Nanjing Healthnice&#8221;), an independent third party, in relation to the Avatrombopag Maleate Tablets, a drug for the treatment of CLD-associated thrombocytopenia. Pursuant to this transfer agreement, Nanjing Healthnice agreed to transfer to us the Avatrombopag Maleate Tablets and all relevant technologies, and it shall complete any research, trial and APIs registration and transfer to us all materials necessary for the application of marketing approval by CDE. Upon the completion of this transfer agreement, we will be approved by NMPA as the marketing authorization holder of the Avatrombopag Maleate Tables. In exchange for our rights, we will pay a total amount of approximately $2.3&#160;million upon certain milestones (<font style="font-style: italic;">e.g.</font>, the completion of bioequivalence study, or the registration application to CDE) being met. We have completed the bioequivalence study and as of May&#160;15, 2023, we have made total payments of approximately $1.8&#160;million.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In December 2019, we entered into a transfer agreement with Oryza Pharmaceuticals Shenzhen Limited (&#8220;Shenzhen Ruihua&#8221;), an independent third party, in relation to the Fingolimod Hydrochloride Capsules, a drug for the treatment of multiple sclerosis. Pursuant to this transfer agreement, Shenzhen Ruihua agreed to transfer to us the Fingolimod Hydrochloride Capsules and all relevant technologies, and it shall assist us in completing any research, trial and other required procedures and transfer to us all materials necessary for the application of marketing approval of CDE. Upon the completion of this transfer agreement, we will be approved by NMPA as the marketing authorization holder of the Fingolimod Hydrochloride Capsules. In exchange for our rights, we will pay a total amount of $0.6&#160;million and the payments will be made by installments conditioned upon certain milestones (<font style="font-style: italic;">e.g.</font>, the completion of bioequivalence study, or the registration application to CDE) being met. We have completed the bioequivalence study and as of May&#160;15, 2023, we have made total payments of approximately $0.6&#160;million.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Our Strategy </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We are committed to bringing hope through innovation to patients with organ fibrosis. We are seeking to implement the following strategies to achieve our mission and goals:</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Solidify our leading position in the treatment of fibrosis diseases, enrich our product portfolio and explore indication expansion</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We have successfully commercialized ETUARY for the treatment of IPF and we expect to continue to research and develop the application of ETUARY to other indications to solidify our market position. Specifically, Phase 3 clinical trials for the treatment of SSc-ILD and DM-ILD are underway . We enrolled the first patient in June 2022 in the Phase&#160;3 clinical study of ETUARY for the treatment of pneumoconiosis. We are conducting a Phase 1 clinical trial in ETUARY for the treatment of DKD. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Currently, we have only one commercialized product for the treatment of IPF in a relatively small market. To expand our market, we are actively exploring additional indications for ETUARY and developing other drug candidates for the treatment of various fibrosis diseases. Our Hydronidone is being developed to treat liver fibrosis associated with CHB, the prevalence of which reached 63.6&#160;million patients in 2022 in the PRC according to Frost &amp; Sullivan. We commenced patient enrollment for our Phase 3 clinical trial in January 2022 and plan to enroll 248 patients in total. As of May 9, 2023, we have completed the enrollment of 124 subjects, which is 50% of the target enrollment. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our early clinical-stage product pipeline includes F573 for ALF/ACLF treatment. F573 has entered into Phase 1 clinical trials. We completed our Phase 1 clinical observations of tolerability and PK in July 2022 and initiated our Phase 2 clinical study of F573 in March 2023. We have also established a tiered preclinical product pipeline. For instance, we are researching and developing F528 for the treatment of COPD, and we intend to file an IND application in the first quarter of 2024. In addition, our F230 is currently in its preclinical phase and has demonstrated the potential to significantly alleviate PAH in animal studies, and we anticipate filing an IND application in the first quarter of 2024.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">243<br></div></div></div>
<!--End Page 254-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 255-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Further enhance our academic promotion and expand our sales network</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Enhancing academic promotion is one of our key sales approaches. We work to maintain close and long-term collaboration with academic organizations, promote expert consensus, attend international and domestic academic conferences, closely communicate with KOLs and improve our brand recognition. We will actively participate in online and offline academic activities and host academic conferences, to promote the market education, raise our brand recognition and increase the clinical use of our products.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We have established a comprehensive sales network and accumulated rich sales experience, which enables us to quickly realize sales a product candidate is approved. We provide on-the-job training to our sales team to educate them on the latest research and clinical practice and gain an in-depth understanding on the clinical benefits of our product portfolio. To expand the geographic coverage of product sales, precisely target the clinical needs and improve our market penetration, we deploy our sales teams and resources to hospitals and expand our reach to additional small and medium-sized cities across the PRC.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Prudently enrich our product portfolio through value accretive business development and strategic collaborations</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Complementary to our in-house research and development efforts, stay abreast of cutting-edge technology and product developments in the industry by bringing in products and technology that are in line with our development strategies and research and development principle through acquisition, in-licensing or collaboration. We intend to build a dedicated and seasoned business development team to seek value accretive opportunities to support our growing business development needs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We proactively yet prudently source, identify, and execute promising in-licensing or acquisition opportunities. We have acquired or in-licensed the intellectual property rights of certain drug candidates from GNI Japan, particularly the intellectual property rights to Hydronidone in mainland PRC. This contract was assigned to Catalyst in connection with that certain F351 Agreement. For more details, see &#8220;<font style="font-style: italic;">Catalyst&#8217;s Business&#8212;Agreements Relating to the </font><font style="font-style: italic;">Hydronidone Program&#8212;F351 Asset Purchase Agreement.</font>&#8221; Leveraging our well established medical and pharmaceutical network, we will continue to collaborate with domestic and multinational industry leaders to optimize our pipeline structure and maximize the clinical and commercial value of our product portfolio.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We continue to focus on high-quality products that are synergistic with our existing product pipeline. For instance, to enrich our hepatic product pipeline, we have acquired promising products for the treatment of thrombocytopenia in patients with chronic liver disease. Meanwhile, leveraging our extensive research and development and commercial experience, we are also exploring other disease areas such as multiple sclerosis.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Expand and upgrade our facilities to increase production capacity and control production costs</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">To facilitate research and development of our product pipelines, meet growing market demands, and realize our plan of sales expansion, we commenced the construction of an innovative drug research, development and production center in Shunyi, Beijing in June 2022. We plan to add additional production capacity of 500&#160;million capsules by 2024 and continue to scale up our production capacity in accordance with our sales and the market demand for our products and product candidates.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, we expect to ramp up our production capacity in line with the development and commercialization progress of our products. To secure stable and sufficient supply of APIs of high quality at reasonable costs, we have built our API production center in Cangzhou, PRC and plan to expand our production capacity through technology upgrades. When we complete the upgrade of our facilities, we plan to increase our annual production capacity to 50&#160;tons of APIs after our Cangzhou facility is put into full operation. Our API production capability reduces our reliance on the upper-stream suppliers of raw materials, improves our cost management and renders us pricing advantages.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Continuously attract, develop and retain high-quality talent</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As a profitable and innovative pharmaceutical company, maintaining a streamlined talent team tailored to the features of our product pipeline and our development needs is crucial for our efficiency. To attract and retain talent, we are committed to the consistent development of a cohesive and vibrant corporate culture and attach great importance to the training and development of each of our employees.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">244<br></div></div></div>
<!--End Page 255-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 256-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Our experienced sales and marketing team is crucial to our continuous growth. To expand our national network and penetrate into small and medium-sized cities across the PRC, we intend to further strengthen our sales and marketing capabilities by gradually increasing our headcount in this area. As an innovative company, we recruit experienced and skilled production technicians and research and development talent in related fields in the PRC and globally. We also plan to build our business development team to coordinate and implement our strategic collaboration plans. Relying on our strong branding, competitive salaries and equity incentives, we expect to attract talented people to join our team.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Our Strengths </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Long-term commitment to the treatment of organ fibrosis given ETUARY being one of the first three drugs for IPF globally</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our rich pipeline and our revenue of $86.8&#160;million and $99.3 million for ETUARY in 2021 and 2022, respectively, has laid a solid foundation for us in organ fibrosis treatment. ETUARY (pirfenidone capsule) is the first drug in the PRC and among the first three drugs in the world approved to treat IPF.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">IPF is a chronic condition in which scar tissues build up in lungs from unknown causes, which primarily occurs in the elderly. IPF patients have an average survival time of two to three years, or three to five years if receiving early diagnosis, and five-year survival rate of 20% to 40%. For more details, see &#8220;<font style="font-style: italic;">BC&#8217;s Business</font>&#8212;<font style="font-style: italic;">Our Products and </font><font style="font-style: italic;">Product Pipeline</font>&#8212;<font style="font-style: italic;">ETUARY: National Class 1.1 New Drug for IPF Approved in 2011&#8212;Market Opportunities and </font><font style="font-style: italic;">Competition</font>&#8212;<font style="font-style: italic;">IPF.</font>&#8221; </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, we have an extensive pipeline of drug candidates focusing on fibrosis of various organs, including lung, liver and kidney. Among them, Hydronidone is being developed for the treatment of the liver fibrosis disease. We are also expanding the indication of our ETUARY to DKD, the renal disease that causes renal fibrosis.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Hydronidone, potentially the first approved drug for liver fibrosis associated with CHB</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">With nearly 20&#160;years of dedicated research in pulmonary fibrosis diseases, deep know-how accumulated in organ fibrosis treatment, coupled with the fact that fibrosis occurs in different organs with the similar pathogenic mechanism, we have expanded from pulmonary fibrosis to the treatment of liver fibrosis which addresses unmet clinical needs and a growing market. Our innovative small molecule drug, Hydronidone, presents a favorable profile for liver fibrosis associated with CHB. It reverses liver fibrosis by inhibiting hepatic stellate cell proliferation while simultaneously blocking the TGF-&#223;1 signaling pathway, both of which play important roles in the liver fibrosis associated with CHB. Due to the severity of the disease and the clinical trial progress of Hydronidone comparing with the currently available treatments, in March 2021, the CDE granted Hydronidone a Breakthrough Therapy designation, which helps to accelerate the review of drugs that have early evidence to suggest that the drug may demonstrate a substantial improvement over currently available therapies. We commenced the patient enrollment for our Phase 3 clinical trial in January 2022. As of May 9, 2023, we have completed the enrollment of 124 subjects, which is 50% of the target enrollment. We expect to submit an NMPA application for Hydronidone in China in the first quarter of 2025.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Professional sales and marketing team and nationwide sales network</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">There is an extremely high barrier for commercializing orphan drugs due to the scarcity of patients. We have established a professional sales and marketing team and a comprehensive sales network during the commercialization of ETUARY, which are evidenced by its strong sales track record and dominant market position. Currently, our sales network covers 30 provinces, autonomous regions and municipalities in the PRC. Our sales network grew rapidly, covering 2,763 and 2,901 hospitals and pharmacies in 2021 and 2022, respectively. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of March 31, 2023, our sales and marketing team had 352 employees with an average of nine years of experience. Among them, our vice president in charge of sales has more than 25&#160;years of experience in multinational pharmaceutical companies and PRC innovative pharmaceutical companies and our core regional managers have an average of 17&#160;years of industry experience and 11&#160;years of management experience. One-third of the other members of our sales team worked for international pharmaceutical companies and one-fourth have a bachelor&#8217;s degree or above in biology, medicine or pharmacy. We believe that our comprehensive integrated sales network and accumulated management and sales experience will allow us to continue to be a dominant player in the IPF market in the PRC and to achieve rapid sales of new products once they are launched.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">245<br></div></div></div>
<!--End Page 256-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 257-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Comprehensive manufacturing facilities and strict quality control</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our ability to produce both APIs and drug products internally provides us with stringent control over the supply chain, which enables us to maintain cost-effective production and lower our exposure to unforeseen supply chain disruptions. For more details about our two manufacturing centers, manufacturing capabilities and processes, see &#8220;&#8212;<font style="font-style: italic;">Land and Properties</font>&#8221; and &#8220;&#8212;<font style="font-style: italic;">Production and Quality Control&#8212;In-House Manufacturing Facilities.</font>&#8221; </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Experienced senior management team with strong execution capability</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We have an experienced management team with strong execution capability and an average of more than 20&#160;years of industry experience. See &#8220;<font style="font-style: italic;">Management Following the Contributions</font>&#8221; for more detail about BC&#8217;s management team. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Background on Organ Fibrosis</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Overview</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Organ damage and inflammation trigger a complex series of cellular and molecular responses that ultimately lead to tissue fibrosis. Although this fibrogenic response may have adaptive features in the short term, it will progress over time and ultimately result in cellular dysfunction and organ failure. Tissue fibrosis can affect virtually every organ system, including skin, lungs, liver and kidney. Organ fibrosis as a reactive progress to organ damage and inflammation, in certain cases, is associated with and/or is a result of no effective treatment of other diseases (<font style="font-style: italic;">e.g.</font>, CTD, DKD and CHB). Organ fibrosis constitutes a major challenge to global health owing to the large number of affected individuals, the incomplete knowledge of fibrosis pathogenesis and limited effective therapeutic treatments. Organ fibrosis and resultant organ failure account for at least one-third of deaths worldwide. Organ fibrosis is a leading cause of morbidity and mortality worldwide. In 2021, the patients suffering from major organ fibrosis amounted to 171.9&#160;million in the PRC. Organ fibrosis includes pulmonary fibrosis, liver fibrosis, renal fibrosis and myocardial fibrosis.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The prevalence of diseases causing pulmonary fibrosis, liver fibrosis, renal fibrosis and myocardial fibrosis increased from 186.0&#160;million patients in 2017 to 198.7&#160;million patients in 2022 at a CAGR of 1.3%. It is expected to increase to 211.8&#160;million patients by 2027 and 221.3&#160;million patients by 2031 at a CAGR of 1.3% from 2022 to 2027 and a CAGR of 1.1% from 2027 to 2031. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; text-align: center;">Prevalence of Major Organ Fibrosis Diseases in China, 2017-2031E</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"><img style="height: 319px; width: 625px;" src="ny20006478x8_graphic06.jpg">&#8201;<br></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; margin-top: 24pt; margin-left: 0pt; text-align: justify;">Source: Weiskirchen R, Weiskirchen S, Tacke F. Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications. Mol Aspects Med. 2019 Feb;65:2-15; Wang J, Zhang L, Tang SC, et al. Disease burden and challenges of chronic kidney disease in North and East Asia. Kidney Int. 2018;94(1):22-25; Estimation of Prevalence of Kidney Disease Treated With Dialysis in China: A Study of Insurance Claims </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">246<br></div></div></div>
<!--End Page 257-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 258-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; margin-top: 5.25pt; margin-left: 0pt; text-align: justify;">Data; Global, regional and national burden of chronic kidney disease, 1990&#8211;2017: a systematic analysis for the Global Burden of Disease Study 2017; Zhao X, Kwan JYY, Yip K, Liu PP, Liu FF. Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov. 2020 Jan;19(1):57-75; Richeldi L, Rubin AS, Avdeev S, Udwadia ZF, Xu ZJ. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India and China. BMC Med. 2015 Sep 24;13:237; Frost &amp; Sullivan Analysis.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Therapies for fibrosis mainly consist of drug treatment, non-drug treatment and general treatment. Drug treatment can be further divided into (i)&#160;anti-fibrosis treatment which focuses on relief or reversal of organ fibrosis and (ii)&#160;etiological treatment which focuses on treating the causal diseases that lead to fibrosis. Currently there are two commercialized anti-pulmonary fibrosis drugs in the PRC, pirfenidone and nintedanib. Non-drug treatment mainly includes organ transplantation and oxygen therapy. General treatment includes dietary adjustment and lifestyle modification.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Land and Properties </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Owned Properties</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of May 15, 2023, we had land use right certificates for two parcels of land in Shunyi District, Beijing and Cangzhou, Hebei province, with an aggregate site area of 66,559 square meters and building ownership certificates for six properties with an aggregate gross floor area of 12,206 square meters. Our two production centers are in Beijing and Cangzhou. For more details regarding our manufacturing capabilities and processes, see &#8220;&#8212;<font style="font-style: italic;">Production </font><font style="font-style: italic;">and Quality Control.</font>&#8221;</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Leased Properties</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of May&#160;15, 2023, we leased 19 properties in the PRC. Among our 19 leased properties, seven are used as offices, eleven are used as employee dormitories and one is operated as a laboratory.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Occupational, Health, Safety and Environmental Matters </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We are subject to various health, safety, social and environmental laws and regulations and our operations are regularly inspected by local government authorities. We are committed to social responsibilities and consider environmental, social and governance essential to our continuous development and we believe we have adequate policies ensuring compliance with all health, safety, social and environmental protection regulations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under the oversight of the senior management, we actively identify and monitor the actual and potential impact of environmental, social and climate-related risks on our business, strategy and financial performance and incorporate considerations for these issues into our business, strategic and financial planning with a particular focus on areas such as employee responsibility, environment responsibility and public responsibility. Corporate social responsibility is viewed as part of our core growth philosophy and pivotal to our ability to create sustainable value for our stockholders.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, we monitor and enforce the compliance of our operations with environment, health and safety laws and regulations. This responsibility is executed through training, formulation and implementation of strategies, policies, standards and metrics, communication of environmental, health and safety policies and procedures through a team of coordinators, environmental, health and safety audits and incident response planning and implementation. With the oversight of our management, our quality control team assesses the likelihood of such risks occurring and the estimated magnitude of any potential impact.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Permits and Other Approvals </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of May&#160;15, 2023, we have received all material permissions and approvals required for our business operations. As of May 15, 2023, our wholly-owned subsidiary (Beijing Continent Biomedical Technology Co., Ltd., a company organized under the laws of the PRC (&#8220;BC Biomedical&#8221;)) has obtained a business license but has no business operations. The following table sets forth the details of material licenses, permits and approvals:</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 31.62%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">License/Permit</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 31.62%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Validity Period</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 31.62%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Authority</div></td></tr><tr><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Drug Production License</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">January 2022 &#8211; September 2025</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Beijing Medical Products Administration </div></td></tr><tr><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Information Service Qualification Certificate</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">January 2021 &#8211; January 2026</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Beijing Medical Products Administration</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">247<br></div></div></div>
<!--End Page 258-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 259-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 31.62%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">License/Permit</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 31.62%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Validity Period</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 31.62%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Authority</div></td></tr><tr><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Zhongguancun High- tech Enterprise</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 2022 &#8211; December 2024</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Administrative Commission of Zhongguancun Science Park</div></td></tr><tr><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">High-tech Enterprise Certificate</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">November 2022 &#8211; November 2025</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Beijing Municipal Science &amp; Technology Commission,<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Beijing Municipal Finance Bureau, Beijing Municipal Administration of Taxation</div></td></tr><tr><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Drug Registration Approval (pirfenidone)</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Valid until December 2023</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">NMPA</div></td></tr><tr><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Drug Registration Approval (pirfenidone capsule)</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Valid until December 2023</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">NMPA</div></td></tr><tr><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">GMP Certificate for Pharmaceutical Products (Pirfenidone APIs)</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">July 2019 &#8211; July 2024</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Beijing Medical Products Administration</div></td></tr><tr><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Foreign Trade Operators Registration Form</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">From February 2022</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.62%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Beijing Municipal Commission of Commerce</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Cybersecurity Review Measures published by the CAC, which became effective on February 15, 2022, critical information infrastructure operators purchasing network products and services which affect or may affect national security, or online platform operators possessing personal information of more than one million users, seeking to be listed on foreign stock markets must apply for a cybersecurity review by the Cybersecurity Review Office. We did not apply for a cybersecurity review and do not expect to be subject to cybersecurity review, given that: (i) the clinical and preclinical data we handle in our business operations, either by its nature or in scale, do not normally trigger significant concerns over PRC national security and (ii) we have not processed, and do not anticipate processing in the foreseeable future, personal information for more than one million users or persons. For a detailed description, please refer to risks disclosed under &#8220;<font style="font-style: italic;">Risk Factors&#8212;Risks Related to BC&#8212;Risks Related to BC&#8217;s Business </font><font style="font-style: italic;">Operations in the PRC&#8212;Risks Relating to BC&#8217;s Financial Position and Need for Additional Capital-Compliance with </font><font style="font-style: italic;">the PRC&#8217;s new Data Security Law, Cyber Security Law, Cybersecurity Review Measures, Personal Information </font><font style="font-style: italic;">Protection Law, regulations and guidelines relating to the multi-level protection scheme on cyber security and any </font><font style="font-style: italic;">other future laws and regulations may entail significant expenses and could affect BC&#8217;s business</font>.&#8221;</div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to Special Administrative Measure (Negative List) for Access of Foreign Investments (2021 Edition) which became effective on January 1, 2022 (the &#8220;Negative List&#8221;), if a PRC company, which engages in any business where foreign investment is prohibited under the Negative List, or prohibited businesses, seeks an overseas offering or listing, it must obtain the approval from competent governmental authorities. We, as a commercial-stage biopharmaceutical company, are not operating in an industry that prohibits or limits foreign investment under Negative List. As a result, other than filing with the CSRC, we believe that we are not required to obtain any regulatory approval from any PRC authorities prior to the closing of the Contributions. See &#8220;<font style="font-style: italic;">Regulations on M&amp;A </font><font style="font-style: italic;">and Overseas Listings</font>&#8221; in this section.</div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">However, applicable PRC laws and regulations may be tightened, and new laws or regulations may be introduced to impose additional government approval, license, and permit requirements. If we or our subsidiaries fail to obtain and maintain such approvals, licenses, or permits required for our business, inadvertently conclude that such approval is not required, or respond to changes in the regulatory environment, we or our subsidiaries could be subject to liabilities, penalties, and operational disruption, which may materially and adversely affect our business, operating results, financial condition and the value of our ordinary shares, significantly limit or completely hinder our ability to offer or continue to offer securities to investors, or cause such securities to significantly decline in value or become worthless.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Our Research and Development</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We consistently devote resources to research and development to achieve long-term growth. We believe the diversification and expansion of our product pipeline through both in-house research and development and through external collaboration are critical to our long-term competitiveness and success. Our research and development expenses charged to profit or loss were $8.5 million and $7.2 million in 2021 and 2022, respectively, and the capitalized expenditures were $4.9 million and $6.1 million in 2021 and 2022, respectively, representing 15.2% and 13.0% of our revenue for each of the respective years. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">248<br></div></div></div>
<!--End Page 259-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 260-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">We have a dedicated in-house research and development team of 79 employees as of March 31, 2023. Our research and development department is comprised of the following departments: drug discovery, CMC (chemistry, manufacturing and control), clinical development, medical affairs and regulatory affairs. Our research and development employees possess significant expertise in molecular biology, chemistry regulatory affairs and clinical development. Through cross-functional collaboration, our research and development organization has enabled us to develop new drug products to address unmet clinical needs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We employ a clinical-demand-oriented and market-driven approach to our research and development efforts. We first identify suitable drug development targets and carry out project evaluation and overall project design based on our development strategies and then explore and establish experimental methodology by coordinating across different experimental platforms. We carefully select drug development programs by balancing the commercial potential of each drug candidate and its likelihood of successful development, its potential competition, and the ultimate market size.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Drug Discovery</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our molecule screening and design capabilities increase the possibility of success of advancing molecules from preclinical studies to market, enable innovative therapeutic approaches and support rich pipeline assets built around key pathways and targets. We have built an efficient system to conduct target identification and validation, compound design and screen and lead compound optimization. During the discovery stage, drug candidates are tested for their absorption, distribution, metabolism, excretion and toxicological (ADME/Tox) properties, and promising compounds are optimized through structure modification to achieve maximum efficacy and minimum toxicity. Our research and development centers support a targeted drug discovery and screening platform, which can efficiently complete target identification and validation, compound design and lead optimization.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">During the drug discovery stage, we explore new research and development opportunities, conduct feasibility research and provide evaluation for the opportunities. We also design and prepare new chemical compounds, conduct systematic research related to the manufacturing process and quality management of the new drugs and develop technology platforms to support, manage and supervise the related technologies.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Chemistry, Manufacture &amp; Controls (&#8220;CMC&#8221;)</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">CMC Group</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The CMC Group is a critical link between discovery and clinical study. It is responsible for developing chemical and pharmaceutical processes, so that drug substances can be made with the desired physical and chemical properties and formulated to achieve maximum bio availability and stability. During the CMC stage, the synthesis of each API molecule is investigated thoroughly to ensure that the drug substance can reach pre-determined quality standards, the manufacturing processes are safe, robust, economical and environmentally friendly and the drug products have good stability and suitable storage conditions and shelf life.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Clinical Development Group</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our clinical development team oversees clinical trials for drug development, sets up the procedural standard of clinical affairs and handles clinical medicine matters. Our clinical development team also focuses on clinical development strategy, clinical trial protocol design, clinical trial operation coordination, pharmacovigilance and clinical trial quality control. Our clinical development team members specialize in management of all stages of our clinical trials, including clinical trial design, implementation, drug supply and the collection and analysis of trial data. We collaborate with top clinical experts in various areas as our principal investigators, leverage the operational capabilities of industry leading CROs and rely on well-known academic medical institutions and clinical trial centers in the PRC and abroad to promote the high quality and efficient implementation of our clinical trials in the PRC.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Clinical Trial Design and Implementation</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our clinical development group manages all stages of clinical trials, including protocol design, operation and the collection and analysis of clinical data. Our rapid trial advancements are driven by (i)&#160;our strategic decision to initiate clinical phase trials with our outstanding preclinical results, (ii)&#160;rigorous trial design, (iii)&#160;long-term partnership with numerous hospitals and principal investigators from different regions and (iv)&#160;seamless execution. Leveraging our extensive knowledge and experience in clinical trials, our clinical development experts identify unique therapeutic opportunities for our drug candidates based on the differentiating properties observed in clinical trials and improve clinical plans accordingly. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">249<br></div></div></div>
<!--End Page 260-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 261-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg20"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Competition </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The organ fibrosis market is subject to rapid change. While we believe that our robust pipeline of innovative products and drug candidates, strong sales and marketing capability and experienced leadership team provide us with competitive advantages, we face potential competition from many different sources working to develop therapies targeting the same indications which our marketed drug or our drug candidates target. These include major pharmaceutical companies, specialty pharmaceutical and biotechnology companies of various sizes, academic institutions, government agencies and research institutions. Any drug candidates that we successfully develop and commercialize will compete both with existing drugs and with any new drugs that may become available in the future. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our products primarily compete with products that are indicated for similar conditions as our products on the basis of efficacy, price and general market acceptance by medical professionals and hospitals. The identities of our key competitors vary by product or drug candidate, while in certain cases, our competitors may have greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We believe our continued success will primarily depend on our ability to develop innovative products and advanced technologies, apply technologies to all production lines, continuously develop an extensive product portfolio and pipeline, effectively commercialize and market our existing and future products, expand our distribution network and maintain customer relationships, attract and retain seasoned and talented technology development personnel, maintain high quality standards, maintain a highly efficient operational model and obtain and maintain regulatory approvals.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Production and Quality Control</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">In-House Manufacturing Facilities</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our manufacturing facilities are situated in Beijing and Cangzhou, Hebei province, in the PRC. During the years ended December&#160;31, 2021 and 2022, 100% of pirfenidone we sold was manufactured at our Beijing and Cangzhou facilities. Our manufacturing facilities are designed and operated in compliance with GMP regulations.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Quality Management</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We believe that the product quality is fundamental to ensure the safety of patients and achieve our long-term development. Our quality management team monitors every stage of our operations in accordance with NMPA&#8217;s regulations. We implement quality management measures throughout our production process, including supplier examination, raw material inspection and testing and process control, and all products are thoroughly inspected and tested before release. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Procurement Quality Control</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We have established internal procedures governing the selection for raw material suppliers and quality control to meet the requirements of relevant GMP and pharmaceutical registration regulations. We select our raw material suppliers based on a variety of factors, including their economic status, capital, reputation, quality control management, production scale and technological strengths and evaluate them based on their qualification, feedback to our questionnaire and our on-site examination. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Logistics and Delivery Management</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We have entered into logistics service agreements with third parties. Pursuant to the arrangement, logistics service providers provide delivery services in a safe and timely manner pursuant to our requirements, while we are responsible for the quality of goods. Our logistics service providers are responsible for any loss caused by their negligence during their provision of the logistics service, including transfer, loading, unloading, transportation and delivery. Our logistics service providers also liaise and handle the insurance aspects, while we arrange the payment of insurance premiums together with the freight charges.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Inventory Management</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our inventory principally consists of raw materials, work-in-progress, semi-finished goods (representing APIs) and finished products. We endeavor to maintain our inventory at a reasonable level that is sufficient to sustain our production without interruption. We enter into supply agreements with reference to our annual sales plan, manufacturing plan and procurement plan. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">250<br></div></div></div>
<!--End Page 261-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 262-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg21"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Sales, Marketing and Distribution </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Our In-House Sales and Marketing Team</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of May&#160;15, 2023, our in-house sales and marketing team had market coverage of 30 provinces, autonomous regions and municipalities in the PRC. Our sales and marketing team is primarily responsible for establishing and maintaining relationships with outlets in their covered regions. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We believe the relatively high level of medical knowledge and skill of our sales and marketing team are important to the implementation of our academic marketing approach and maintenance of our reputation as a leading pharmaceuticals company. As of March&#160;31, 2023, our in-house sales and marketing team included 352 employees, with an average of more than nine years of experience in pharmaceutical sales. Our more experienced staff also share their academic promotion networking experience on a regular basis. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For more details regarding the qualifications of our employees, see &#8220;<font style="font-style: italic;">Employees and Human Capital</font>&#8221; in this section of the proxy statement. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Academic Promotion</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We emphasize academic promotion and patient service in our sales and marketing efforts. We strive to promote and strengthen our academic recognition and brand awareness among medical experts by educating doctors and other medical professionals on ETUARY, our other product candidates and their respective indications. We believe that our working relationships with medical experts help to raise our profile, enhance awareness of ETUARY in the medical community and among patients, increase the clinical capabilities of healthcare providers and provide us with valuable clinical data to improve ETUARY, all of which help us more effectively market and sell ETUARY.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Distribution</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Distributors are our direct customers and they resell our products to the outlets including hospitals, other medical institutions and pharmacies. Distributors are primarily responsible for the delivery of products and their payments, while our in-house sales and marketing team is responsible for conducting academic marketing activities and other promotional efforts. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">From time to time, we have terminated or opted to not renew our collaboration relationships with certain distributors due to consolidation of distribution channels and unstable business management of the distributors. At the same time, we add new distributors primarily as a result of the continued expansion and optimization of our sales network. In general, our relationships with our major distributors have remained stable. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Product Pricing </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We take into account a number of factors in determining our prices, which primarily includes our research and development, production and marketing costs and expenses, the perceived value of products, our market share and the competitive landscape. In addition, our pricing strategies are also affected by the regulations and policies imposed on the pharmaceutical industry, including medical insurance reimbursement standards and regulation of medical and pricing practices. Our commercialization team closely monitors new policies affecting the pricing of pharmaceutical products in the PRC and keeps updating our pricing strategies to navigate in the evolving regulatory environment and cope with local policies and competition in different provinces, with the goal of maintaining the price levels of our products and maximizing our overall sales in the PRC. For details, see &#8220;<font style="font-style: italic;">BC&#8217;s Business&#8212;Regulatory Requirements in </font><font style="font-style: italic;">the PRC&#8212;Other PRC Regulations in Relation to the Pharmaceutical Industry&#8212;Price Controls</font>&#8221; in this proxy statement.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">National Reimbursement Drug List</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Participants in the national public medical insurance program are eligible for full or partial reimbursement of the purchase price of drugs included in the NRDL which sets forth the payment standard for drugs under the basic medical insurance, work-related injury insurance and maternity insurance funds. For further details, see &#8220;<font style="font-style: italic;">BC&#8217;s </font><font style="font-style: italic;">Business</font>&#8212;<font style="font-style: italic;">Regulatory Requirements in the PRC</font>&#8212;<font style="font-style: italic;">Other PRC Regulations in Relation to the Pharmaceutical </font><font style="font-style: italic;">Industry</font>&#8212;<font style="font-style: italic;">Coverage of the National Medical Insurance Program</font>&#8221; in this proxy statement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The government started to regularly adjust the NRDL since 2017 and our ETUARY successfully entered into the NRDL within the same year. The latest version of the NRDL has been implemented from March&#160;1, 2023.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">251<br></div></div></div>
<!--End Page 262-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 263-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg22"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Two-Invoice System</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On December&#160;26, 2016, the State Counsel Healthcare Reform Committee, National Health and Family Planning Commission, the National Development and Reform Commission (the &#8220;NDRC&#8221;) and other relevant government authorities jointly issued the Circular on Issuing the Implementing Opinions on Carrying out the Two-Invoice System for Drug Procurement among Public Medical Institutions (for trial implementation) (the &#8220;Circular 4&#8221;), which provides detailed rules regarding the implementation of the Two-Invoice System at a national level. For details, see &#8220;<font style="font-style: italic;">BC&#8217;s Business</font>&#8212;<font style="font-style: italic;">Regulatory Requirements in the PRC</font>&#8212;<font style="font-style: italic;">Other PRC Regulations in Relation to the Pharmaceutical </font><font style="font-style: italic;">Industry &#8212;Drug Distribution and Two-Invoice System</font>&#8221; in this proxy statement. To comply with relevant regulations, we primarily adopt the single-layer distribution model with distributors who directly on-sell our products to hospitals and public medical institutions. Certain distributors may engage sub-distributors for the sales to pharmacies, which were not subject to the regime of the Two-Invoice System. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Centralized Tender Process and Centralized Volume-Based Procurement System</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Prices of most pharmaceutical products in the PRC sold to public hospitals and public medical institutions are determined through a competitive centralized tender process at the provincial or municipal level with varying terms and procedures. In the centralized tender process, the winner pharmaceutical production companies will be allowed to sell their products to public hospitals and other public medical institutions at the bid prices. The centralized tender process can create pricing pressure among substitute products or products that are perceived by the market to be substitute products and resulted in significant change in how drugs are priced and procured in the PRC. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Intellectual Property </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Intellectual property rights are important to the success of our business. Our future commercial success depends, in part, on our ability to obtain and maintain patent and other intellectual property and proprietary protection for commercially important technologies, inventions and know-how related to our business, defend and enforce our patents, preserve the confidentiality of our trade secrets and operate without infringing, misappropriating or otherwise violating the valid, enforceable intellectual property rights of third parties. As of May 15, 2023, we were the owner of all the patents and patent applications which are material to our business. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Patents</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of December&#160;31, 2022, we owned 14 granted patents and eight patent applications in the PRC and three active Patent Cooperation Treaty (&#8220;PCT&#8221;) patent applications. We believe there is no material legal impediment for us to obtain the approvals for these pending patents and trademarks. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The term of individual patents depends on the legal term for patents in the jurisdictions in which they are granted. In most jurisdictions, the patent term for inventions is 20&#160;years from the earliest claimed filing date of a non-provisional patent application in the applicable jurisdiction. The actual protection afforded by a patent varies on a claim-by-claim and country-by-country basis and depends upon many factors, including the type of patent, the scope of its coverage, the availability of any patent term extensions or adjustments, the availability of legal remedies in a particular country and the validity and enforceability of the patent. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Below is a summary of our eight patents, eight patent applications and three PCT applications related to our product pipeline:</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 17.95%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Patent/Application No.</div></td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 28.21%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Description</div></td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.69%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Related <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Product</div></td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Jurisdiction</div></td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Status</div></td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 17.39%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Expiration Date</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ZL200380110691.0</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 28.21%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pyridone derivatives and the application </div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">F351</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">PRC</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Granted</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.39%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">November 14, 2023</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ZL200810201706.9</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 28.21%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A method for preparing hydronidone</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">F351</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">PRC</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Granted</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">October 24, 2028</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ZL202110287773.2</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 28.21%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A method for preparing crystal form of hydronidone and the application </div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">F351</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">PRC</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Granted</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">March 17, 2041</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CN201780048534.3</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 28.21%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A method for preparing hydronidone</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">F351</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">PRC</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Pending</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">---</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">252<br></div></div></div>
<!--End Page 263-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 264-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg23"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 17.95%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Patent/Application No.</div></td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 28.21%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Description</div></td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.69%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Related <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Product</div></td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.74%; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: justify;">Jurisdiction</div></td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Status</div></td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 17.39%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Expiration Date</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CN201780048603.0</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 28.21%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A method for preparing hydronidone</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">F351</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">PRC</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Pending</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.39%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">---</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CN202211364720.7</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 28.21%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A method for preparing hydronidone</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">F351</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">PRC</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Pending</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">---</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CN202310048439.0</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 28.21%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A method for preparing hydronidone</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">F351</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">PRC</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Pending</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">---</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CN202110531848.7 </div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 28.21%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Application of hydronidone in preparation of drugs for treatment or prevention of hepatic fibrosis in chronic viral hepatitis B </div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">F351</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">PRC</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Pending</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">---</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CN202110627506.5</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 28.21%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">a combination of hydronidone and dextromethorphan and their application to the treatment of pulmonary fibrosis</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">F351</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">PRC</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Pending</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">--</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">PCT/CN2022/093039</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 28.21%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Application of hydronidone in preparation of drugs for treatment or prevention of hepatic fibrosis in chronic viral hepatitis B </div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">F351</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">PCT</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Pending</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">--</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">PCT/CN2022/097197</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 28.21%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">a combination of hydronidone and dextromethorphan and their application to the treatment of pulmonary fibrosis</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">F351</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">PCT</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Pending</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">--</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ZL201110025509.8</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 28.21%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">a dipeptide derivatives to improve liver function and the application</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">F573</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">PRC</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Granted</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">January 24, 2031</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ZL201110025516.8 </div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 28.21%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">dipeptide derivatives and the application</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">F573</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">PRC</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Granted</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">January 24, 2031</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CN202210532274.X</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 28.21%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">dipeptide derivative composition, preparation method and application </div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">F573</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">PRC</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Pending</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">---</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ZL200680054930.9</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 28.21%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The use of derviate of pyridone for preventing and treating radioactive injury of lungs</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">F647</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">PRC</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Granted</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">September 25, 2026</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ZL200410018582.2</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 28.21%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The use of pirfenidone for treating hepatic injury and necrosis and acute lung injury</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">F647</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">PRC</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Granted</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">May 24, 2024</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ZL201810246953.4</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 28.21%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">a method for preparing Pirfenidone and its application</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">F647</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">PRC</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Granted</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">March 23, 2038</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">PCT/CN2020/070981</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 28.21%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Macrolide compound and its use of treatment chronic respiratory disease</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">F528</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">PCT</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Pending</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">---</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CN202080078212.5</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 28.21%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Macrolide compound and its use of treatment chronic respiratory disease</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">F528</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">PRC</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Pending</div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.39%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">---</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">253<br></div></div></div>
<!--End Page 264-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 265-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg24"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Trade Secrets</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We may rely, in some circumstances, on trade secret and/or confidential information to protect aspects of our technology. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with consultants, scientific advisers and contractors. We have entered into confidentiality agreements and non-competition agreements with our senior management and key members of our research and development team and other employees who have access to trade secrets or confidential information about our business.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. For details of risks related thereto, see &#8220;<font style="font-style: italic;">Risk Factors</font>&#8212;<font style="font-style: italic;">Risks Related to BC</font>&#8212;<font style="font-style: italic;">Risks Relating to BC&#8217;s Intellectual Property Rights</font>&#8221; in this proxy statement.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Marks</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We conduct our business under the brand name of &#8220;Continent&#8221; or &#8220;<img style="height: 17px; width: 41px; margin-right: -28pt; margin-bottom: -3pt;" src="ny20006478x8_graphic09.jpg"><font style="padding-left: 30pt;">&#8221;. As of </font>March 31, 2023, we owned four registered artwork copyrights, 13 registered software copyrights and 34 registered trademarks in the PRC. We also owned seven registered trademarks in Hong Kong, one international trademark of &#8220;ETUARY&#8221; and the trademark application of &#8220;ETUARY&#8221; in seven countries and regions including the United States, EU and Japan. As of the same date, we are also the registered owner of 13 domain names.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We enter into collaboration agreements and other relationships with pharmaceutical companies and other industry participants to leverage our intellectual property or gain access to the intellectual property of others. For details, see &#8220;<font style="font-style: italic;">BC&#8217;s Business&#8212;Our Products and Product Pipeline</font>&#8221; in this proxy statement. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Raw Materials and Suppliers </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We procure raw materials and equipment for the development and manufacture of our products and drug candidates from highly reputable manufacturers and suppliers. We mainly purchase raw materials, packing materials, third-party contracting services for research and development purposes, machines and equipment. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We have single-source suppliers for some principal raw materials. We believe we will be able to source these raw materials from alternative suppliers at similar terms as our suppliers sell these raw materials through multiple distributors who each stock inventory. In order to mitigate any risks relating to single-sourced suppliers, we have preliminarily selected an additional list of suppliers from which we will purchase these raw materials for our new Cangzhou facility. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Regulatory Requirements in the PRC</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Government authorities in the PRC extensively regulate, among other things, the research, development, testing, product approval, manufacture, quality control, manufacturing changes, packaging, storage, recordkeeping, labeling, promotion, advertising, sales, distribution, marketing, and import and export of drugs and biologic products. Our current product candidates are expected to be regulated as drugs. The processes for obtaining regulatory approval in the PRC, along with compliance with applicable statutes and regulations and other regulatory authorities both pre-&#160;and post-commercialization, are a significant factor in the production and marketing of our products and our research and development activities and require the expenditure of substantial time and financial resources.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Drug Regulatory Regime</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The drug regulatory regime in the PRC consists of the Standing Committee of the National People&#8217;s Congress (the&#160;&#8220;SCNPC&#8221;), the State Council and several ministries and agencies under the State Council&#8217;s authority including, among others, the National Medical Products Administration (&#8220;NMPA&#8221;), the predecessor of which is the China Food and Drug Administration (&#8220;CFDA&#8221;), the National Health Commission (the &#8220;NHC&#8221;), the predecessors of which are the National Health and Family Planning Commission of the PRC and the National Healthcare Security Administration (the &#8220;NHSA&#8221;).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The NMPA, is a regulatory authority responsible for registration and supervision of pharmaceutical products, cosmetics and medical equipment under the supervision of State Administration for Market Regulation (&#8220;SAMR&#8221;).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The NHC is the chief healthcare regulator of the PRC, and is primarily responsible for drafting national healthcare policy, regulating public health, medical services and the health contingency system of the PRC, coordinating healthcare reform in the PRC and overseeing the operation of medical institutions and practicing of medical personnel in the PRC.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">254<br></div></div></div>
<!--End Page 265-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 266-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg25"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The NHSA is responsible for drafting and implementing policies, plans and standards of medical insurance, maternity insurance and medical assistance, administering the PRC&#8217;s healthcare fund, formulating a uniform medical insurance catalogue and payment standards for drugs, regulating medical disposables and healthcare services, and formulating and administering the bidding and tendering policies for drugs and medical disposables.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Laws and regulations in relation to Drugs</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Pharmaceutical Product Development</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In the PRC, the NMPA monitors and supervises the administration of pharmaceutical products, as well as medical devices and equipment. The local provincial medical products administrative authorities in the PRC are responsible for the supervision and administration of drugs within their respective administrative regions. According to the Drug Administration Law of the PRC (the &#8220;Drug Administration Law&#8221;), drugs refer to articles which are used in the prevention, treatment and diagnosis of human diseases and intended for the regulation of the physiological functions of human beings, for which indications or functions, usage and dosage are specified, including traditional PRC drugs, chemical drugs and biological products. The Drug Administration Law and the Implementing Regulations of the Drug Administration Law of the PRC, have established the legal framework for the administration of pharmaceutical products and applies to entities and individuals engaged in the research, production, trade, application, supervision and administration of pharmaceutical products. The Drug Administration Law provides a framework for the administration of pharmaceutical manufactures, pharmaceutical trading companies, medical institutions and the development, research, manufacturing, distribution, packaging, pricing and advertisements of pharmaceutical products. Pursuant to the NMPA, individuals conducting drug trials must submit relevant data, materials and samples, including research and development methods, quality indicators, pharmacological and toxicological test results and other related material, to the NMPA for approval. The drug administrative department of the State Council will approve or reject applications within 60 business days from the receipt of the clinical trial application. In the event the NMPA fails to notify a clinical trial applicant of its approval or rejection within the prescribed 60 business day period, the application will be deemed approved under the NMPA. Upon an applicant&#8217;s completion of clinical trials and satisfaction of the criteria set forth by the NMPA, the NMPA will issue a drug registration certificate. The Implementing Regulations of the Drug Administration Law of the PRC provides detailed implementation regulations for the Drug Administration Law.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15pt; margin-left: 0pt; text-align: left;">Non-Clinical Research and Animal Testing</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The State Administration for Market Regulation requires preclinical data to support registration applications for imported and domestic drugs. Pursuant to the Circular on Administrative Measures for Certification of Good Laboratory Practice for Non-clinical Laboratory Studies<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">,</sup> the NMPA is responsible for the certification of non-clinical research institutions across the PRC and the local provincial medical products administrative authorities are in charge of the daily supervision of non-clinical research institutions in the PRC. The NMPA decides whether an institution is qualified for undertaking pharmaceutical non-clinical research by evaluating such institution&#8217;s organizational administration, research personnel, equipment and facilities and operation and management of non-clinical pharmaceutical projects<font style="font-style: italic;">.</font> A GLP Certification will be issued by the NMPA if all the relevant requirements are satisfied, which will also be published on the NMPA&#8217;s website. When the GLP requirements are met, the State Drug Administration will approve and issue the drug GLP certification which is valid for five years. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Administrative Regulations on Experimental Animals, the Administrative Measures on Good Practice of Experimental Animals and the Administrative Measures on the Certificate for Experimental Animals (for Trial Implementation) regulates the use and breeding of experimental animals and performing experimentation on animals requires a Certificate for Use of Laboratory Animals. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15pt; margin-left: 0pt; text-align: left;">Approval and Reform for Clinical Trials of New Drugs</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under the Administrative Measures for Drug Registration, the PRC Drug Administration Law and Implementing Regulations of the PRC Drug Administration Law, new drug applications are subject to clinical trials. The NMPA has taken a number of steps to increase efficiency for approving clinical trial applications and has also significantly increased monitoring and enforcement of the Good Clinical Practice for Drug Trials (the &#8220;PRC&#8217;s GCP&#8221;), to ensure data integrity.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Administrative Measures for Drug Registration confirms a number of reform actions, including but not limited to: (i)&#160;the full implementation of MAH System and implied approval of the commencement of clinical trials; </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">255<br></div></div></div>
<!--End Page 266-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 267-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg26"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">(ii)&#160;implementing associated review of drugs, excipients and packaging materials; and (iii)&#160;introducing procedures for expedited registration of drugs, including (a) procedures for ground-breaking therapeutic drugs, (b) procedures for conditional approval, (c) procedures for prioritized reviews and approval and (d) procedures for special examination and approval. Upon completion of nonclinical research, clinical trials must be conducted for the application of a new drug registration and applicants must apply for approval of IND from the NMPA, or the CDE before conducting clinical trials.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Opinions of the State Council on the Reform of Evaluation and Approval System for Drugs and Medical Devices, established a framework for reforming the evaluation and approval system for drugs and medical devices.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Announcement of the China Food and Drug Administration on Several Policies on the Appraisal and Approval of Drug Registration, further simplifies the approval process of drugs and provides that the IND of new drugs is subject to one-off umbrella approval and the declaration review or approval by stages will no longer be adopted. According to the Announcement of the State Drug Administration on Adjusting Evaluation and Approval Procedures for Clinical Trials for Drugs, within 60 days after the acceptance of and the fees paid for the IND, the applicant may conduct the clinical trials for the drug in accordance with the clinical trial protocol submitted, if the applicant has not received any negative or questioning opinion from the CDE.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Priority Review and Approval Procedures for Drug Marketing Authorizations (for Trial Implementation) further clarified that a fast track IND or drug registration pathway will be available to the innovative drugs.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Regarding International Multi-Center Clinical Trials</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the International Multi-Center Clinical Trial Guidelines (for Trial Implementation), promulgated by the NMPA, international multi-center clinical trial applicants may simultaneously perform clinical trials in different centers using the same clinical trial protocol. Where the applicants plan to implement the International Multi-center clinical trials in the PRC, the applicants must comply with the Drug Administration Law, the Regulations for the Implementation of the PRC Drug Administration Law and the Measures for the Administration of Drug Registration. Additionally, applicants must execute the GCP, make reference to universal international principles such as the ICH-GCP and comply with the laws and regulations of the countries involved in the International Multi-Center clinical trials. Where the applicants plan to use the data derived from the International Multi-Center clinical trials for approval of a drug registration in the PRC, the application must involve at least two countries, including the PRC, and must satisfy the requirements for clinical trials set forth in the Notice on Issuing the International Multi-Center Clinical Trial Guidelines (for Trial Implementation) and the Administrative Measures for Drug Registration and other related laws and regulations.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Drug Clinical Trial Registration</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Administrative Measures for Drug Registration, upon obtaining the approval of its IND, the applicant must, prior to conducting the clinical trial of drugs, register on the registration and information announcement platform for clinical trials of drugs, information regarding the scheme of the clinical trial.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Announcement on Drug Clinical Trial Information Platform, all clinical trials approved by the NMPA and conducted in the PRC must complete a clinical trial registration and publish trial information through the Drug Clinical Trial Information Platform. The applicant must complete the trial pre-registration within one month after obtaining the approval of the IND in order to obtain the trial&#8217;s unique registration number and complete registration of certain follow-up information before the first subject&#8217;s enrolment in the trial. If the registration is not completed within one year after the approval of the IND, the applicant must submit an explanation and if applicant&#8217;s first submission is not completed within three years, the approval of the IND will automatically expire.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15pt; margin-left: 0pt; text-align: left;">Phases of Clinical Trials and the Communication with the CDE</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Administrative Measures for Drug Registration, a clinical trial consists of Phases 1, 2, 3, 4 and bioequivalence trial. In addition to the characteristics of a drug and the research purpose, the research contents must also include clinical pharmacological research, exploratory clinical trial, confirmatory clinical trial and post-marketing research under the Administrative Measures for Drug Registration.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Circular on Adjusting Evaluation and Approval Procedures for Clinical Trials for Drugs, where the application for clinical trial of new investigational drug has been approved upon the completion of Phases 1 and 2&#160;clinical trials and prior to Phase 3 clinical trial, the applicant must also submit the application for Communication </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">256<br></div></div></div>
<!--End Page 267-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 268-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg27"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Session to CDE. Once the application is submitted for Communication Session to CDE, the applicant must discuss with CDE the key technical questions including the design of Phase 3 clinical trial protocol. Within 60 days after the acceptance of and the fees paid for the IND application, if the applicant has not received any negative or questioning opinion from the CDE, the applicant may conduct the clinical trials for the drug in accordance with the clinical trial protocol submitted.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Administrative Measures for Communication on Drug Research, Development and Technical Reviews, during the research and development periods and in the registration applications of the innovative new drugs (among others), the applicants may propose to conduct communication meetings with the CDE. The communication meetings can be classified into three types. Type 1 meetings are convened to address key safety issues in clinical trials of drugs and key technical issues in the research and development of breakthrough therapeutic drugs. Type II meetings are held during the key research and development periods of drugs, and mainly include meetings before the IND application, meetings upon the completion of Phase 2 trials and before the commencement of Phase&#160;3 trials, meetings before submitting a marketing application for a new drug and meetings for risk evaluation and control. Type III meetings refer to meetings not classified as Type I or Type II.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Sampling and Collecting Human Genetic Resources Filing</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Regulations of the PRC on the Administration of Human Genetic Resources, further stipulates that in order to obtain marketing authorization for relevant drugs and medical devices in the PRC, no approval is required in international clinical trial cooperation using the PRC&#8217;s human genetic resources at clinical institutions without export of human genetic resource materials. However, the two parties must file the type, quantity and usage of the human genetic resource to be used with the administrative department of science and technology under the State Council before clinical trials may commence. According to the Service Guide for Administrative Licensing Items concerning Examination and Approval of Sampling, Collecting, Trading or Exporting Human Genetic Resources, or Taking Such Resources out of the PRC, the sampling, collection or research activities of human genetic resources by a&#160;foreign-invested sponsor falls within the scope of international cooperation and the cooperating organization of the PRC must apply for approval of the China Human Genetic Resources Management Office. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Administrative Regulations of the PRC on Human Genetic Resources, no approval is required in international clinical trial cooperation using the PRC&#8217;s human genetic resources at clinical institutions without export of human genetic resource materials in order to obtain marketing authorization for relevant drugs and medical devices in the PRC. However, the two parties must file the type, quantity and usage of the human genetic resource to be used with the administrative department of science and technology under the State Council before clinical trials commence.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On June 1, 2023, The Ministry of Science and Technology promulgated the Implementation Rules for the Administrative Regulation on Human Genetic Resources (the &#8220;HGR Implementation Rules&#8221;), which will become effective on July 1, 2023. The HGR Implementation Rules have refined the Regulations of the PRC on the Administration of Human Genetic Resources, including, but not limited to, refining the definition of &#8220;human genetic resources information&#8221;, clarifying the identification standard of &#8220;foreign entities&#8221;, adjusting the scope of collection licensing, and adjusting and improving the approval procedures for international cooperative scientific research and administrative supervision rules.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Registration of Drug Marketing</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Administrative Measures for Drug Registration, an applicant must complete studies in pharmacy, pharmacology and toxicology, as well as clinical trials of pharmaceuticals. The applicant must submit an application for drug marketing authorization and the relevant research materials in accordance with the submission requirements after determining quality standards, verifying commercial scale manufacturing process and preparing to undergo examination and inspection for drug registration. Once an application is submitted, the CDE will assemble pharmacists, medical professionals and other technical specialists to analyze the drug&#8217;s safety, effectiveness and quality control. After the comprehensive review, the drug will be approved for marketing and a drug registration certificate shall be issued.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Marketing Authorization Holder System</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Drug Administration Law, the state implements the drug marketing authorization holder system for drug management. The drug marketing authorization holder is an enterprise or a drug development institution that has obtained the drug registration certificate and is responsible for non-clinical research, clinical trials, production </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">257<br></div></div></div>
<!--End Page 268-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 269-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg28"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">and operation, post-marketing research, adverse reaction monitoring, reporting and processing of drugs in accordance with the provisions of the Drug Administration Law. Other units and individuals engaged in drug development, production, operation, storage, transportation, use and other activities shall bear corresponding responsibilities pursuant to the Drug Administration Law.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under the Circular of the China Food and Drug Administration on the Matters Relating to Promotion of the Pilot Program for the Drug Marketing Authorization Holder System (the &#8220;Circular on Drug Marketing Authorization Holder System&#8221;), the drug marketing authorization holder must establish a drug quality assurance system and be equipped with special personnel to take charge of quality management on drugs independently. Additionally, the drug marketing authorization holder must regularly review the quality management system of the drug manufacturer and the drug distributor and supervise its continuous quality assurance and control capabilities. A drug marketing authorization holder who manufactures drugs on its own shall obtain a drug production license in accordance with the Circular on Drug Marketing Authorization Holder System and entrust a qualified drug manufacturer. The drug regulatory authority of the State Council has formulated guidelines for the quality of pharmaceuticals entrusted manufacturing, to guide and supervise the drug marketing authorization holder and the entrusted manufacturer to fulfill their drug quality assurance obligations. Where a drug marketing authorization holder, a drug manufacturer or a drug distributor are entrusted to store or transport drugs, the drug marketing authorization holder shall evaluate the trustee&#8217;s quality assurance capabilities and risk management capabilities, sign a trust agreement with the trustee, agree on drug quality responsibilities and operating procedures and supervise the trustee. The drug marketing authorization holder, drug manufacturers, drug distributors and medical institutions shall establish and implement a drug traceability system in accordance with regulations to ensure that drugs are traceable. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Drugs&#8217; Registration Classification</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under the Measures for the Administration of Drug Registration, drugs are classified into PRC medicine, chemical medicine, biological products and others. According to the Notice of the NMPA about the Issuing of the Reform Plan for the Registration Classification of the Chemical Drugs, the registration classification of the chemical drugs are adjusted to five categories. Category 1 drugs refer to innovative chemical drugs that have not been marketed anywhere in the world. Improved new chemical drugs that are not marketed anywhere in the world fall into Category&#160;2 drugs. Generic chemical drugs that have equivalent quality and efficacy to the originator&#8217;s drugs that have been marketed abroad but not yet in the PRC are classified as Category 3 drugs. Generic drugs that have equivalent quality and efficacy to the originator&#8217;s drugs and have been marketed in the PRC fall into Category 4 drugs. Category&#160;5 drugs are drugs which have already been marketed abroad, but are not yet approved in the PRC. Category&#160;1 and 2 drugs must follow the registration application procedure for new drugs according to the Measures for the Administration of Drug Registration; Category 3 and 4 drugs must follow the procedure for generic drugs; and Category 5 drugs must follow the application and regulation requirements for importing drugs. Where there is a discrepancy between the Notice of the NMPA about the Issuing of the Reform Plan for the Registration Classification of the Chemical Drugs and the Measures for the Administration of Drug Registration, the Notice of the NMPA about the Issuing of the Reform Plan for the Registration Classification of the Chemical Drugs must be complied with.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Chemical Drug Registration Classification and Application Data Requirements, innovative chemical drugs and improved new chemical drugs are categorized as Category 5.1 drugs, while generic chemical drugs, all of which shall have been already marketed abroad but not yet approved in the PRC are categorized as Category&#160;5.2&#160;drugs.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Special Examination and Fast Track Approval for Drugs Targeting Rare Diseases</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Notice on Publishing the Procedures of Developing the Rare Disease List, the following four criteria must be met at the same time for rare disease designation: (i)&#160;the disease has a low incidence or prevalence in PRC and abroad; (ii)&#160;the disease significantly impacts the patient and his or her family; (iii)&#160;there is a clear diagnosis method; and (iv)&#160;the disease can be treated or intervened in an economically feasible way, or it has been included in a national scientific research project if there is no effective treatment or intervention for such disease. In principle, the catalog update time shall not be shorter than 2&#160;years.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">With certain drugs targeting rare diseases being listed in National Rare Disease List, a company may be eligible for the priority review and approval of new drugs for these diseases from the NMPA.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Administrative Provisions on Special Examination and Approval of the Registration of New Drugs, special examination and approval for new drugs registration applications applies when (1) the effective constituent </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">258<br></div></div></div>
<!--End Page 269-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 270-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg29"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">of a drug extracted from plants, animals and minerals, as well as the preparations thereof, have never been marketed in the PRC and the material medicines and the preparations thereof are newly discovered; (2) the chemical raw materials for medicines as well as the preparations thereof and the biological product have not been approved for marketing, either in the PRC or aboard; (3) new drugs with distinctive clinical treatment advantages for diseases such as AIDS, malignant tumor or other rare diseases; or (4) new drugs for diseases that currently lacking effective treatment. Under the circumstances set out in (1) and (2) above, drug registration applicants may make special approval applications in submitting applications for clinical trials of new drugs; under the circumstances set out in&#160;(3) and (4) above, drug registration applicants may make special approval applications only in applying for production.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Opinions of the State Council on the Reform of Evaluation and Approval System of Drugs and Medical Devices, a special evaluation and approval system shall be adopted for innovative drugs to accelerate the evaluation and approval process for innovative drugs for prevention and treatment of AIDS, cancer, major infectious diseases, rare diseases and other diseases.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Announcement of the State Drug Administration and the NHC on Optimizing the Evaluation and Approval of Drug Registration, the CDE will prioritize the allocation of resources for review, inspection, examination and approval of registration applications that have been included in the scope of priority evaluation and approval.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Good Manufacturing Practices</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Good Manufacturing Practice for Drugs, provided guidance for the quality management, organization and staffing, production premises and facilities, equipment, material and products, recognition and inspection, documentation maintenance, manufacture management, quality control and quality assurance, contractual manufacture and contractual inspection for the products, product delivery and recalls of a manufacturer.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Drug Administration Law, one engaged in drug manufacturing activities shall still comply with the GMP and establish a sound GMP management system, to ensure that the entire process of drug manufacturing is maintained to meet the statutory requirements and the GMP requirements enacted by the drug regulatory authority under the State Council in accordance with the Drug Administration Law. The legal representative of and principal person in charge of a drug manufacturer are fully responsible for the drug manufacturing activities of the enterprise.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Drug Production License</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under the Measures for the Supervision and Administration of Drug Production promulgated by SAMR, persons engaging in pharmaceutical manufacturing activities shall be subject to approval by the pharmaceuticals administrative authorities of the province, autonomous region or centrally- administered municipality where the persons engaging in pharmaceutical manufacturing activities are located, obtain a Drug Production License pursuant to the Measures for the Supervision and Administration of Drug Production promulgated by SAMR , comply strictly with the pharmaceutical manufacturing quality control norms and ensure that the manufacturing process complies with statutory requirements at all times. The Drug Production License shall indicate the license number, classification code, enterprise name, unified social credit code, domicile (premises), legal representative, person in charge of the enterprise, person in charge of production, person in charge of quality, qualified person, production address and scope of production, issuing organ, date of issuance and period of validity<font style="font-style: italic;">.</font> The period of validity of Drug Production License is five years. In the event the license holder needs to continue to manufacture pharmaceuticals upon the expiration of the Drug Production License, it shall apply to the original issuing authorities for reissuance of a Drug Production License six months before the expiration date of the Drug Production License. Although the Announcement on Matters Concerning the Implementation of the Drug Administration Law of the PRC no longer requires GMP certificates for drug manufacturing enterprises, the competent drug administrative authorities shall, based on regulatory needs, conduct compliance inspection of drug manufacturing quality control examination before drug marketing procedure.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Drug Business License and Good Supply Practice Requirements</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to Drug Administration Law and the Regulations for the Implementation of the PRC Drug Administration Law, in order to be engaged in the drug wholesale distribution and retailing of drugs, a company must obtain a Drug Business License with an appropriate &#8220;scope of distribution&#8221; from the local drug regulatory authority and comply with the Good Supply Practice for Pharmaceutical Products (the &#8220;GSP&#8221;) promulgated by the CFDA under the State Council. Under the Administrative Measures for Pharmaceutical Trading Licenses, a Pharmaceutical Trading License is valid for five years. Each holder of the Pharmaceutical Trading License must apply for an extension of its permit six months prior to expiration.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">259<br></div></div></div>
<!--End Page 270-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 271-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg30"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Pursuant to the Announcement of the NMPA on Matters Concerning the Implementation of the Drug Administration Law of the PRC, the competent regulatory authorities shall, based on regulatory needs, conduct the supervision and regulation through changing to the inspection of the implementation of the GSP from time to time and supervising the compliance of enterprises.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Other PRC Regulations in relation to the Pharmaceutical Industry</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Drug Recall</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Measures on the Administration of Drug Recalls, the term &#8220;drug recalls&#8221; refers to the activities of a drug marketing authorization holder to recall drugs that have been marketed, but have quality problems or other potential safety hazards under the prescribed procedures and take corresponding measures to timely control risks and eliminate potential hazards. The term &#8220;quality problems or other potential safety hazards&#8221; refers to non-compliance of drugs with statutory requirements, or other unreasonable risks that may endanger human health and life safety caused by drugs due to research and development, production, storage and transportation, labeling and other reasons. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Administrative Protection and Monitoring Periods for New Drugs</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Implementing Regulations for the Drug Administration Law of the PRC, based on the needs for protection of public health, the NMPA may set an observation period of not more than five years for new drugs produced by drug manufacturers; and no approval shall be given to any other manufacturers to produce or import the said drugs during the observation period.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">Packaging of Pharmaceutical Products</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Drug Administration Law, drug packaging must be printed or affixed with a label and include the literature pursuant to the provisions. According to the Measures for The Administration of Pharmaceutical Packaging, pharmaceutical packaging must comply with national and professional standards. If there is no national or professional standard available, an applicant can formulate and implement its own standards after obtaining the approval of the provincial administration or bureau of standards. The applicant must reapply if it needs to change its own packaging standards. Drugs that have not been developed and approved for packaging standards cannot be sold or marketed in the PRC (except for drugs for the military). According to the PRC&#8217;s GCP Administration, the packaging labels of the investigational product must indicate the information on the use only for clinical trial, clinical trial information and information on the drug for clinical trial, but the blinded state may be kept in blind trials.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">Insert Sheet and Labels of Pharmaceutical Products</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to Administrative Provisions on Pharmaceutical Directions and Label, the insert sheets and labels of drugs should be reviewed and approved by the NMPA. A drug insert sheet should include the important scientific data, conclusions and information concerning drug safety and efficacy in order to direct the safe and rational use of drugs. The inner label of a drug should bear such information as the drug&#8217;s name, indication or function, strength, dose and usage, production date, batch number, expiry date and drug manufacturer, and the outer label of a drug should indicate such information as the drug&#8217;s name, ingredients, description, indication or function, strength, dose and usage, adverse reaction, contraindications, precautions, storage, production date, batch number, expiry date, approval number and drug manufacturer.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">Advertising of Pharmaceutical Products</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Interim Administrative Measures for Censorship of Advertisements for Drugs, Medical Devices, Dietary Supplements and Foods for Special Medical Purpose, the contents of a drug advertisement must be based on the drug instructions approved by the drug administrations under the State Council. Where a drug advertisement involves drug name, indications or major functions and pharmacological effects, the drug advertisement not go beyond the scope of instructions and must state contraindications and adverse reactions in a prominent position. Prescription drug advertisements must also state that &#8220;the advertisement is meant to be read only by medical and pharmaceutical professionals&#8221; in a prominent position and OTC drug advertisements must also add the non-prescription drug label (OTC) in a prominent place and state that &#8220;please purchase and use the drugs in accordance with the drug instructions or under the guidance of a pharmacist&#8221; in a prominent position.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">260<br></div></div></div>
<!--End Page 271-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 272-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg31"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Drug Technology Transfer</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Drug technology transfer refers to the transfer of drug production technology by the owner to a drug manufacturer as the transferee and the application for drug registration by the drug manufacturer as the transferee pursuant to the provisions under Technology Transfer Regulations. The NMPA promulgated the Administrative Provisions for Registration of Drug Technology Transfer, to standardize the registration process of drug technology transfer, which includes application for, evaluation, review, approval and supervision of drug technology transfer registration. Drug technology transfer includes new drug technology transfer and drug production technology transfer. An application for drug technology transfer must be submitted to the provincial drug regulatory authority and the SFDA will ultimately make an approval decision based on the comprehensive opinions of the drug review center. Eligible applications will receive a letter of approval and a drug approval number for the supplementary application.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18pt; margin-left: 0pt; text-align: left;">Online Drug Information Services</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Administrative Measures for Online Drug Information Service, the operational internet drug information service refers to the activities of providing medical information (including medical devices) and other services through the internet. Where any website intends to provide internet drug information services, the website must file an application with the local provincial counterparts of NMPA and will be subject to the examination and approval thereof for obtaining the qualifications for providing internet drug information services. The validity term for a Qualification Certificate for Internet Drug Information Services is five years and may be renewed at least six months prior to its expiration date upon a re-examination by the relevant authority. Pursuant to the Measures Regarding the Administration of Drug Information Service over the internet, the internet drug information services are classified into two categories: profit-making services and non-profit- making services. Profit-making services refers to that of providing internet users with drug information in return for service fees whilst non-profit-making services refers to that of providing internet users with drug information which is shared and accessible by the public through the internet free of charge.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18pt; margin-left: 0pt; text-align: left;">Centralized Drug Procurement and Use</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Circular of the General Office of the State Council on Issuing the Pilot Program for Conducting Centralized Drug Procurement and Use by the State and the Opinions of the National Healthcare Security Administration on Supporting Measures Concerning Medical Insurance for the Pilot Program for Conducting Centralized Procurement and Use of Drugs by the State (&#8220;4+7 Centralized Drug Procurement&#8221;), eleven pilot cities including Beijing, Tianjin, Shanghai, Chongqing Shenyang, Dalian, Xiamen, Guangzhou, Shenzhen, Chengdu and Xi&#8217;an, are selected as the pilot cities for the centralized procurement and use of drugs under the organization of the country. The scope of drugs to be procured in a centralized manner includes selected varieties from the generic names corresponding to generic drugs passing consistency evaluation of quality and efficacy. On the basis of the procurement submitted by public medical institutions in the pilot regions, the total procurement is estimated at 60%-70% of total annual drug consumption of all public medical institutions in the pilot regions and the centralized drug purchasing prices will be formed by conducting quantity-specific procurement, pegging procurement to prices and trading procurement for prices. After completing the purchases by the public medical institutions in the pilot regions, the public medical institutions will use the selected drugs as the priority drugs and the quantity of the selected drugs used during the pilot procurement period will be no less than that of the non-selected drugs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Implementation Opinions on Expanding the Regional Scope in the Pilot Program for Conducting Centralized Procurement and Use of Drugs by the State to Wider Areas issued by several authorities including the National Healthcare Security Administration and NMPA, among others, the mode of centralized procurement of drugs with quantity for centralized procurement and use of drugs organized by the country is being promoted throughout the country. Such mode is applicable to 25 designated generic drugs in the pilot program of centralized drug procurement and use of drugs organized by the country.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under 4+7 Centralized Drug Procurement, the healthcare institutions have priority when it comes to procuring the bid-winning drugs and the doctors have to prescribe the bid-winning drugs so as to satisfy the required quantity commitment of the healthcare institutions. As a result, the sales volume of the bid-winning drugs will significantly increase in the short run, which enables the drugs to gain a substantial market share. Despite the erosion of the average selling price, in the medium run, winning bidders are expected to continue obtaining a higher market share. Given that winning bidders are awarded with the guaranteed procurement, such pharmaceutical companies may be able to reduce their sales and marketing expenses.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">261<br></div></div></div>
<!--End Page 272-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 273-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg32"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Coverage of the National Medical Insurance Program</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under the Decision of the State Council on Establishing the Urban Employees&#8217; Basic Medical Insurance System, all employers in urban cities are required to enroll their employees in the basic medical insurance program and employers and employees must jointly contribute to the insurance premiums. Under the Guiding Opinions of the State Council about the Pilot Urban Resident Basic Medical Insurance, urban residents of the pilot district, rather than urban employees, may voluntarily join Urban Resident Basic Medical Insurance. The Opinions of the State Council on Integrating the Basic Medical Insurance Systems for Urban and Rural Residents requires the integration of the urban resident basic medical insurance and the new rural cooperative medical care system. Additionally, the Guiding Opinions of the State Council about the Pilot Urban Resident Basic Medical Insurance established a unified basic medical insurance system, which covers all urban and rural residents other than rural migrant workers and persons in flexible employment arrangements who participate in the basic medical insurance for urban employees. Program participants are eligible for full or partial reimbursement of the cost of medicines included in the medical insurance catalogue.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Notice Regarding the Tentative Measures for the Administration of the Scope of Basic Medical Insurance Coverage for Pharmaceutical Products for Urban Employee, a pharmaceutical product listed in the medical insurance catalogue must be clinically necessary, safe, effective, reasonably priced, easy to use, available in sufficient quantity and must meet one of the following requirements: (1) be set forth in the pharmacopoeia of the PRC, (2)&#160;satisfy the standards promulgated by the NMPA and (3) be approved by the NMPA for imported pharmaceutical products.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Tentative Measures for the Administration of the Scope of Basic Medical Insurance Coverage for Pharmaceutical Products for Urban Employee, the PRC Ministry of Labor and Social Security, together with other government authorities, has the power to determine the medicines included in the National Medical Insurance Catalog, which is divided into two parts, Part A and Part B. Provincial governments are required to include all Part A medicines listed on the National Medical Insurance Catalog in their provincial Medical Insurance Catalog, but have the discretion to adjust upwards or downwards by no more than 15% from the number of Part B medicines listed in the National Medical Insurance Catalog. As a result, the contents of Part B of the provincial Medical Insurance Catalogs may differ from region to region in the PRC. Patients purchasing medicines included in Part A of the Medical Insurance Catalog are entitled to reimbursement in accordance with the regulations in respect of basic medical insurance. Patients purchasing medicines included in Part B of the Medical Insurance Catalog are required to pay a certain percentage of the purchase price and the remainder of the purchase price shall be reimbursed in accordance with the regulations in respect of basic medical insurance. The percentage of reimbursement for Part B medicines is stipulated by local authorities and in result may differs from region to region in the PRC.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15pt; margin-left: 0pt; text-align: left;">National Essential Drug List</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Opinions of the General Office of the State Council on Improving the National Essential Drugs System, Circular on the Issuance the Administrative Measures for the List of National Essential Drugs, and the National Essential Drug List (2018) (the &#8220;National Essential Drug List&#8221;), basic healthcare institutions funded by government (primarily county-level hospitals, county-level PRC medicine hospitals, rural clinics and community clinics), must store and use drugs listed in the National Essential Drug List. The drugs listed in the National Essential Drug List must be purchased by centralized tender process and shall be subject to the price control by NDRC. Remedial drugs in the National Essential Drug List are listed in the Medical Insurance Catalogue and the entire amount of the purchase price of such drugs is entitled to reimbursement.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15pt; margin-left: 0pt; text-align: left;">Medical Insurance Reimbursement Standards</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Decision of the State Council on Establishing the Urban Employees&#8217; Basic Medical Insurance System, Opinions on the Establishment of the New Rural Cooperative Medical System, the Guiding Opinions of the State Council about the Pilot Urban Resident Basic Medical Insurance and the Opinions of the State Council on Integrating the Basic Medical Insurance Systems for Urban and Rural Residents, medical insurance would be available to all employees and residents in both rural and urban areas.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Notice of Opinion on the Diagnosis and Treatment Management, Scope and Payment Standards of Medical Service Facilities Covered by the National Urban Employees Basic Medical Insurance Scheme, the basic medical insurance scheme would cover a portion of the costs of diagnostic and treatment devices, as well as diagnostic testing. The scope and rate of reimbursement are determined by provincial policies.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">262<br></div></div></div>
<!--End Page 273-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 274-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg33"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The major aim of the Guidance on Further Deepening the Reform of the Payment Method of Basic Medical Insurance released by the General Office of the State Council is to develop a diverse reimbursement mechanism that includes diagnosis-related groups, per-capita caps and per-bed-day caps. These new reimbursement systems have been implemented across the country, replacing the previous reimbursement method, which is based on service category and product price.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17pt; margin-left: 0pt; text-align: left;">Price Controls</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For drugs with their prices determined by the market, the Drug Administration Law of the PRC requires that these drugs&#8217; prices are determined by the market and marketing authorization holders, manufacturers and distributors of drugs and medical institutions must conduct pricing under the principles of fairness, rationality, good faith and consistency between quality and prices. Marketing authorization holders, manufacturers and distributors of drugs and medical institutions must comply with the price management rules for drugs of the medicinal product price department of the State Council to determine the prices of drugs and are prohibited from making exorbitant profits, price monopoly and price fraud, among others.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to Price Law of the PRC, drug prices must be set in compliance with the law of value. Prices of most commodities and services are market-adjusted prices and prices of a very small number of commodities and services are government- guided prices or government-set prices. The prices of pharmaceutical products are mainly determined by market competition. Instead of direct governmental price controls, the government primarily regulates prices by establishing a centralized procurement mechanism, revising medical insurance reimbursement standards and strengthening regulation of medical and pricing practices.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Opinions on Effectively Carrying out Drug Price Administration at Present promulgated by National Healthcare Security Administration seek to further improve the drug pricing formation mechanism and emphasizes the market-oriented drug pricing mechanism. Although narcotic drugs and Class&#160;I psychotropic drugs are subject to government pricing, other drugs are priced by drug operators according to the market. Meanwhile, the national and provincial medical security departments may implement or commission price cost investigation on drug suppliers and the results can be used as the basis for determining whether the drugs were sold at unfair prices.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17pt; margin-left: 0pt; text-align: left;">Drug Distribution and Two-Invoice System</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Implementing Opinions on Promoting the &#8220;Two-Invoice System&#8221; for Drug Procurement By Public Medical Institutions (For Trial Implementation) (&#8220;Two-Invoice System Notice&#8221;) is a system that mandates pharmaceutical manufacturers to issue one invoice to pharmaceutical distributors and pharmaceutical distributors to provide another invoice to public medical institutions. The Two-Invoice System excludes the sale of products invoiced from the manufacturer to its wholly owned or controlled distributors, or for imported drugs, to their exclusive distributor, or from a distributor to its wholly owned or controlled subsidiary. Pharmaceutical companies must comply with the Two-Invoice System in order to engage in procurement processes with public hospitals.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Several Opinions of the General Office of the State Council on Further Reform and Improvement in Policies of Drug Production, Circulation and Use, the Two-Invoice System would be promoted in pilot provinces (autonomous regions and municipalities directly under the Central Government) and pilot cities for public hospital reform, with the goal of having it implemented nationwide by 2018 and it has been implemented nationwide by 2018. Pharmaceutical companies must comply with the Two-Invoice System in order to engage in procurement processes with public hospitals.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Regulation in Relation to Intellectual Property Rights</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Patents</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Patent Law of the PRC and the Implementation Rules of the Patent Law of the PRC, an invention-creation shall mean an invention, utility model or design. Inventions and utility models for which patent rights are granted and an invention-creation must possess novelty, creativity and practicality. The Patent Office under the State Intellectual Property Office is responsible for receiving, examining and approving patent applications. The protection period is 20&#160;years for an invention patent, 10&#160;years for a utility model patent and 15&#160;years for a design patent, commencing from such patent&#8217;s application date. Any patentee or interested party may file a lawsuit with a&#160;people&#8217;s court against any individual or entity that utilizes a patent or conducts any other activity that infringes a&#160;patent without the patent holder&#8217;s authorization, and may request regulatory authorities to order the infringer to stop </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">263<br></div></div></div>
<!--End Page 274-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 275-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg34"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">the infringement act forthwith or impose a fine on the infringer. If the patent infringement is found to constitute a crime, the patent infringer shall be held criminally liable in accordance with applicable laws. According to the PRC Patent Law, for public health purposes, the State Intellectual Property Office of the PRC may grant a compulsory license for manufacturing patented drugs and exporting them to countries or regions covered under relevant international treaties to which PRC has acceded. In addition, according to the Patent Law, any organization or individual that applies for a patent in a foreign country for an invention or utility model patent established in the PRC is required to report to the State Intellectual Property Office for confidentiality examination.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16pt; margin-left: 0pt; text-align: left;">Trademarks</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Trademark Law of the PRC and the Regulations on the Implementation of the Trademark Law of the PRC, the validity period of registered trademarks is 10&#160;years, calculated from the date of approval of the registration. A trademark registrant intending to continue to use the registered trademark upon expiry of the period of validity must undergo the renewal formalities within 12 months before expiry according to the relevant provisions. If it fails to do so, the trademark registrant may be granted a six-month grace period. The period of validity of each renewal is 10&#160;years, commencing from the day after the expiry date of the last period of validity. If the renewal formalities are not satisfied within the grace period, the registration of the trademark is canceled. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16pt; margin-left: 0pt; text-align: left;">Copyright</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Copyright in the PRC is protected by the Copyright Law of the PRC and Regulations for the Implementation of the Copyright Law of PRC. These laws and regulations provide provisions on the classification of works and the obtaining and protection of copyright and its related rights.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16pt; margin-left: 0pt; text-align: left;">Domain Names</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Domain names are protected under the Measures for the Administration of Internet Domain Names issued by the Ministry of Industry and Information Technology (the &#8220;MIIT&#8221;) and Implementing Rules on Registration of China Country Code Top-level Domain Names issued by China Internet Network Information Center. The MIIT is the regulatory body responsible for the administration of PRC internet domain names. The China Internet Network Information Center is responsible for the administration of registration of China country code top-level domain names. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16pt; margin-left: 0pt; text-align: left;">Trade Secrets</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Anti-Unfair Competition Law of the PRC and Provisions of the Supreme People&#8217;s Court on Several Issues Concerning the Application of Law in the Trial of Civil Cases Involving Trade Secret Infringement, the term &#8220;trade secrets&#8221; refers to technical and business information that is unknown to the public, has utility, may create business interests or profits for its legal owners or holders and is maintained as a secret by its legal owners or holders. Under the PRC Anti-Unfair Competition Law, business persons are prohibited from infringing others&#8217; trade secrets by: (1) acquiring a trade secret from the right holder by theft, bribery, fraud, coercion, electronic intrusion or any other illicit means; (2) disclosing, using or allowing another person to use a trade secret acquired from the right holder by any means as specified in the preceding subparagraph; (3) disclosing, using or allowing another person to use a trade secret in its possession, in violation of its confidentiality obligation or the requirements of the right holder for keeping the trade secret confidential; and (4) abetting a person, or tempting or aiding a person into or in acquiring, disclosing, using or allowing another person to use the trade secret of the right holder in violation of his or her non-disclosure obligation or the requirements of the right holder for keeping the trade secret confidential. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Regulations on Environmental Protection</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Environmental Protection Law of the PRC, the Regulations on the Administration of Construction Project Environmental Protection and the Environmental Impact Assessment Law of the PRC and Law of the PRC on the Prevention and Control of Environment Pollution Caused by Solid Wastes, an enterprise, which causes environmental pollution and discharges other materials that endanger the public, must implement environmental protection methods and procedures into its business operations. Where effects may be exerted on the environment after the completion of construction projects, the construction enterprise must submit an environmental impact report (form) or environmental impact registration form to the relevant environmental protection department. Any project that is required to prepare the environmental impact report (form) in accordance with the law must obtain the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">264<br></div></div></div>
<!--End Page 275-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 276-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg35"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">approval from the relevant environmental protection department for its environmental impact assessment documents; otherwise, construction on the project may not begin. Pursuant to the Administrative Measures for Pollutant Discharge Licensing (for Trial Implementation) and the Regulations on the Administration of Pollutant Discharge Permits, a pollutant-discharging entity must legally hold a pollutant discharge license and discharge pollutants in compliance with the pollutant discharge license. Any entity must obtain a pollutant discharge license prior to discharging any pollutants. A pollutant discharge license shall be valid from the date on which the decision on the granting of the license is made. A discharge license issued for the first time shall be valid for three years and a renewed license shall be valid for five years. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Notice of the General Office of the State Council on Issuing the Implementation Plan for the Permit System for Controlling the Discharge of Pollutant Emission and the Classification Administration List of Pollutant Discharge Permitting for Fixed Pollution Sources (2019 Version), the state implements a focused management, a simplification management and a registration management of emission permits based on the pollutant discharging enterprises and other manufacturing businesses&#8217; amount of pollutants, emissions and the extent of environmental damage. The manufacturing of drug substance and manufacturing dose for chemical drugs (except for manufacturing of dose for chemical drugs that are simply mixed or repackaged) fall within the industries that are strictly regulated, and must obtain the discharge permit in accordance with the prescribed time limit.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Hazardous Chemicals</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Regulations on Safety Administration of Hazardous Chemicals (the &#8220;Hazardous Chemicals Regulation&#8221;), provides regulatory requirements on the safe production, storage, use, operation and transportation of hazardous chemicals. The PRC government exerts strict control over implementing overall planning and rational layout for the production and storage of hazardous chemicals and exam safety conditions of construction project concerning manufacturing or storing hazardous chemicals. An enterprise that manufactures and stores hazardous chemicals is required to appoint a qualified institution to conduct safety evaluations of its safety production conditions once every three years and to prepare a safety evaluation report. Such report shall set out the rectification measures and plans for problem solution as to the safety production. The safety evaluation report and the implementation of the rectification measure must be filed with the safety supervision regulatory authority.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Administrative Measures for the Registration of Hazardous Chemicals, the state adopts a registration system for hazardous chemicals. The registration of hazardous chemicals are subject to the principles of application by enterprises, two-level review, unified issuance of certificates and hierarchical administration. Where any registering enterprise fails to go through the registration formalities for hazardous chemicals or fails to go through the formalities for altering the registration contents of hazardous chemicals when the type of registration changes or the hazardous chemicals it manufactures or imports have new hazardous characteristics, the registering enterprise must make corrections and may be subject to a fine of not more than 50,000 yuan. If the registering enterprise refuses to make corrections, it shall be given a fine of not less than 50,000 yuan but not more than 100,000 yuan. If the circumstance is serious, the registering enterprise will be ordered to suspend production and business for rectification.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the administrative Regulations on Precursor Chemicals, promulgated by State Council, the state applies the classified administration and licensing system to the production, distribution, purchase, transportation and import and export of precursor chemicals. An entity that is to purchase any precursor chemical in Category II or III must, prior to the purchase, report the type and quantity in demand for record, with the public security authority of the local people&#8217;s government at the county level.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Product Liability</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Product Quality Law of the PRC, manufacturers shall be liable for the quality of products they produce and guarantee that the product quality meets the requirements stipulated by laws and shall not mix impurities or imitations into products, pass fake goods off as genuine ones or shoddy products as good ones or sub-standard products as standard ones. Sellers are required to take measures to ensure the quality of the products sold by them. The manufacturer shall be liable to compensate for any bodily injuries or damage to property other than the defective product itself resulting from the defects in the product, unless the manufacturer is able to prove that: (1) the product has never been circulated; (2) the defects causing injuries or damage did not exist at the time when the product was circulated; or (3) the science and technology at the time when the product was circulated were at a level incapable of detecting the defects. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Civil Code of the PRC, where a defect of a product endangers the personal or property safety of another person, the manufacturer or the seller shall assume civil liabilities in accordance with the law.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">265<br></div></div></div>
<!--End Page 276-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 277-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg36"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Labor Protection</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Labor Law of the PRC, employers must develop and improve their rules and regulations in accordance with the law to ensure that workers enjoy their labor rights and perform their labor obligations. Employers must develop and improve the system of labor safety and sanitation and strictly implement the national protocols and procedures on labor safety. Employers must guard against labor safety accidents and reduce occupational hazards and labor safety and sanitation facilities must meet the relevant national standards. Employers must provide workers with the necessary labor protection equipment that meets the safety and hygiene conditions stipulated under national regulations by the State and conduct regular health checks for workers who engage in operations with occupational hazards. Laborers engaged in special operations must have received specialized training and obtained the pertinent qualifications.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to Labor Contract Law of the PRC and the Implementation Regulations of the Labor Contract Law of the PRC, employers and employees must enter into written labor contracts to establish their employment relationships. With respect to a circumstance where a labor relationship has already been established but no formal contract has been made, a written labor contracts must be entered into within one month from the date when the employee begins to work. In addition, wages shall not be lower than the local minimum wage standard.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to Interim Provisions on Labor Dispatch, employers may employ dispatched workers only for temporary, auxiliary or substitutable positions and must strictly control the number of dispatched workers which may not exceed 10% of the total number of its workers.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Notice of the General Office of the Ministry of Human Resources and Social Security of the PRC on the Proper Handling of Labor Relations During the Prevention and Control of Pneumonia Epidemic Caused by the Novel Coronavirus, in the event that corporate employees who are patients or suspected patients of COVID-19 (as well as their close contacts) cannot provide normal service due to the quarantine or medical observation period, quarantine measures or other emergency measures imposed by the government, the enterprise must pay their employee the salary of that period and may not terminate the labor contract with such employee in accordance with Articles 40 and 41 of the Labor Contract Law of the PRC. For labor contracts which expire during the period described in the prior sentence, the enterprise must extent the employment period to the termination of the medical treatment period, the medical observation period, the quarantine period or the emergency measures of the government due to the COVID-19.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Social Insurance and Housing Fund Regulations</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Social Insurance Law of the PRC, the Interim Regulation on Levying Social Insurance Premiums, the Regulation on Work-Related Injury Insurance, the Regulation on Unemployment Insurance and the Trial Measures for Maternity Insurance of Enterprises Employees, the employer must contribute to social insurance plans covering basic pensions insurance, basic medical insurance, maternity insurance, work injury insurance and unemployment insurance. Basic pension, medical and unemployment insurance contributions shall be paid by both employers and employees, while work-related injury insurance and maternity insurance contributions shall only be paid by employers. Employers who fail to promptly contribute social security premiums in full shall be ordered by the social security premium collection agency to make or supplement contributions within a prescribed time limit and shall be subject to a late payment fine computed from the due date at the rate of 0.05% per day; where payment is not made within prescribed time limit, the relevant administrative authorities shall impose a fine ranging from one to three times the outstanding amount.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Regulation on the Administration of Housing Provident Fund, employers must register with the competent managing center for housing provident funds and upon the examination by such center, these employers shall complete procedures for opening an account at the bank for the deposit of employees&#8217; housing provident funds. Employers are also required to pay and deposit housing funds on behalf of their employees in full and in a timely manner. Employers that violate the Regulation on Housing Provident Fund and fail to open housing provident fund accounts for their employees with the housing fund administration center within a designated period or fail to go through the formalities of opening housing provident fund accounts for their employees shall be subject to a fine ranging from approximately $1,441 to $7,204. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Foreign Investment</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Foreign Investment Law of the PRC and the Implementing Regulation for the Foreign Investment Law, applies to any investment activities directly or indirectly conducted by a foreign natural person, enterprise or other </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">266<br></div></div></div>
<!--End Page 277-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 278-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg37"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">organization and a foreign-invested enterprise established prior to the effective date of the Foreign Investment Law shall adjust its legal form or governance structure to comply with the provisions of the Company Law of the PRC or the Partnership Enterprises Law of the PRC, as applicable and complete amendment registration before January&#160;1, 2025. According to the Foreign Investment Law of the PRC, the state applies the administrative system of pre-establishment national treatment plus negative list to foreign investment and accords national treatment to foreign investment outside of the negative list. Furthermore, the Implementing Regulation for the Foreign Investment Law provides implementing measures and detailed rules to ensure the effective implementation of the Foreign Investment Law.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On December&#160;30, 2019, the MOFCOM and the State Administration for Market Regulation, or the SAMR, jointly promulgated the Measure for Reporting of Information on Foreign Investment, which came into effect on January&#160;1, 2020 and pursuant to which, the establishment of the foreign-invested enterprises, including establishment through purchasing the equities of a domestic non-foreign-invested enterprise or subscribe to the increased capital of a domestic non-foreign funded enterprise and its subsequent changes are required to submit an initial or change report through the Enterprise Registration System.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Provisions for Guiding the Foreign Investment Direction, categorizes all foreign-invested projects into encouraged, permitted, restricted and prohibited projects. Foreign investment projects that are not encouraged, restricted or prohibited are classified as permitted foreign investment projects.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Negative List sets out in a unified manner the special management measures for the access of foreign investments such as requirements for equity and senior management. Any field falling outside the Negative List shall be administered under the principle of equal treatment to domestic and foreign investment. Domestic enterprises engaged in businesses in fields prohibited from investment by the Negative List must be reviewed and approved by the relevant competent authorities of the state before issuing shares abroad and listing for trading. Foreign investors are not allowed to participate in the operation and management of the enterprises and their equity ratio are governed with reference to the relevant regulations on the management of domestic securities investment by overseas investors.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Regulations on Outbound Investment</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Administrative Measures on Outbound Investments, the MOFCOM and the commerce departments at provincial levels shall subject the overseas investment of enterprises to recordation or confirmation management, depending on the actual circumstances of investment. Overseas investment involving any sensitive country or region, or any sensitive industry is subject to confirmation management. Overseas investment under other circumstances is subject to recordation management.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Administrative Measures for the Outbound Investment of Enterprises, an enterprise in the territory of the PRC (the PRC Investor&#8221;) shall, in overseas investment, undergo the formalities for the confirmation or recordation, among others, of an overseas investment project (the &#8220;Investment Project&#8221;), report the relevant information and cooperate in supervisory inspection. Sensitive Investment Projects conducted by PRC Investors directly or through overseas enterprises controlled by them shall be subject to confirmation management. Non-sensitive Investment Project directly conducted by PRC Investors, namely, non-sensitive Investment Projects involving PRC Investors&#8217; direct contribution of assets or rights and interests or provision of financing or security, shall be subject to recordation management. The aforementioned sensitive Investment Project means an Investment Project involving a sensitive country or region or a sensitive industry. The NDRC promulgated the Catalogue of Sensitive Sectors for Outbound Investment (2018 Edition) to list the sensitive industries in detail.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Enterprise Income Tax</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to Law of the PRC on Enterprise Income Tax (the &#8220;EIT Law&#8221;), the income tax rate for resident enterprises is 25% commencing from January&#160;1, 2008 (with certain exceptions for qualified enterprises). The Implementation Rules on the Enterprise Income Tax Law of the PRC (the &#8220;EIT Implementation Rules&#8221;), requires non-resident enterprises which have not established agencies or offices in PRC, or which have established agencies or offices in PRC but whose income has no association with such agencies or offices, to pay enterprise income tax on its income earned from inside PRC. Such income of non-resident enterprises is taxed at the reduced rate of 10% and is withheld at the source of the income, for which the payer thereof shall be the withholding agent.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Non-resident Enterprises Taxation Arrangement</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Arrangement between Mainland PRC and the Hong Kong Special Administrative Region for the Avoidance of Double Taxation and Prevention of Tax Evasion with Respect to Taxes on Incomes, or the Double Tax </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">267<br></div></div></div>
<!--End Page 278-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 279-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg38"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Avoidance Arrangement, the tax rate on dividends declared by a PRC resident enterprise to a Hong Kong resident enterprise will be no more than 5%, if the Hong Kong resident enterprise directly holds at least 25% of the PRC enterprise.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Administrative Measures for Entitlement to Treaty Benefits for Non-resident Taxpayers, non-resident taxpayers claiming treaty benefits shall be handled in accordance with the principles of &#8220;self-assessment, claiming benefits, retention of the relevant materials for future inspection.&#8221; Where a non-resident taxpayer self-assesses and concludes that it satisfies the criteria for claiming treaty benefits, it may (i)&#160;enjoy treaty benefits at the time of tax declaration or at the time of withholding through the withholding agent, (ii)&#160;simultaneously gather and retain the relevant materials pursuant to the provisions of the Administrative Measures on Non-resident Taxpayers Enjoying Treaty Benefits for future inspection and (iii)&#160;accept follow-up administration by the tax authorities.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Announcement of the State Administration of Taxation on Issues Relating to Withholding at Source of Income Tax of Non-resident Enterprises when (i)&#160;the withholding agent enters into a business contract with a non-resident enterprise in relation to income derived from or accruing in the PRC,(ii)&#160;the non-resident enterprise has no office or premises established in the PRC or (iii)&#160;the income derived or accrued has no de facto relationship with the office or premises established, and the contract stipulates that the withholding agent shall bear the tax payable amount, the tax-exclusive income amount derived by the non-resident enterprise will be converted to tax-inclusive income amount and the tax withheld must be turned over to the relevant taxing authority.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Value-added Tax (VAT)</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Interim Regulations of the PRC on Value-Added Tax and the Implementing Rules for the Interim Regulations of the PRC on Value-added Tax, all enterprises and individuals that engage in the sale of goods, the provision of processing, repair and replacement services, sales of service, intangible assets and real estate and the importation of goods within the territory of the PRC must pay VAT at the rate of 17%, except when specified otherwise.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Circular of the Ministry of Finance and the State administration of Taxation on Adjustment to Value-Added Tax Rates, the VAT rates of 17% and 11% applicable to taxpayers engaging in the sale or import of goods shall be adjusted to 16% and 10% respectively. For export goods that originally applied a 17% tax rate and an export tax rebate rate of 17%, the export tax rebate rate is adjusted to 16%. For export goods and cross-border taxable acts that originally applied a 11% tax rate and an export rebate rate of 11%, the export tax rebate rate is adjusted to 10%.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Announcement on Relevant Policies for Deepening Value-Added Tax Reform, for taxpayers engaging in the sale or import of goods that originally applied a 16% tax rate, the export tax rebate rate is adjusted to 13%. According to Circular on the Value-added Tax Policies for Rare Disease Drugs, for the production and sale of drugs for rare diseases, VAT shall be calculated and paid at the rate of 3% under the simplified method.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Foreign Exchange</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Regulation of the PRC on Foreign Exchange Administration, the foreign exchange income and expenditure and foreign exchange business operations of PRC institutions and individuals, as well as the foreign exchange income and expenditure and foreign exchange business operations conducted within the territory of the PRC by overseas institutions and individuals, shall be subject to Foreign Exchange Administration. The Renminbi is freely convertible for payments of current account items such as trade and service-related foreign exchange transactions and dividend payments, but is not freely convertible for capital expenditure items such as direct investments, loans or investments in securities outside of the PRC unless approval from the SAFE or its local counterpart is obtained in advance.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Administrative Regulation regarding Foreign Exchange Settlement, Sales and Payment, foreign exchange receipts under the current account of foreign-invested enterprises may be retained to the fullest extent specified by the foreign exchange bureau. Any portion in excess of such amount shall be sold to a designated foreign exchange bank or through a foreign exchange swap center.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Circular on Further Simplifying and Improving Policies on Foreign Exchange Administration for Direct Investment, banks shall directly examine and handle foreign exchange registration under overseas direct investment. The State Administration of Foreign Exchange and its branches shall indirectly regulate the foreign exchange registration of direct investment through banks.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">268<br></div></div></div>
<!--End Page 279-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 280-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg39"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Pursuant to the Decision of the State Council on Matters relating to Canceling and Adjusting a Group of Administrative Examination and Approval Items, the administrative approval by the SAFE and its branches for matters concerning the repatriation and settlement of foreign exchange of overseas-raised funds through overseas listing was canceled. According to the Notice on Issues Concerning the Foreign Exchange Administration of Overseas Listing, a domestic company shall, within 15 business days from the date of the end of its overseas listing issuance, register the overseas listing with the local branch office of SAFE at the place of its establishment. The proceeds from an overseas listing of a domestic company may be remitted to the domestic account or deposited in an overseas account, but the use of the proceeds shall be consistent with the content of the prospectus and other disclosure documents.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Notice on Revolutionizing and Regulating Capital Account Settlement Management Policies, foreign currency earnings in capital accounts that maintain relevant policies of willingness to exchange settlement and have been clearly implemented on (including the recalling of raised capital by overseas listing) may undertake foreign exchange settlement in the banks according to actual business needs of the domestic institutions. The tentative percentage of foreign exchange settlement for foreign currency earnings in capital account of domestic institutions is 100%, subject to adjust of the SAFE in due time in accordance with international revenue and expenditure situations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&#8217; Offshore Investment and Financing and Roundtrip Investment through Special Purpose Vehicles (the &#8220;Circular 37&#8221;) requires PRC residents to register their legally owned assets or equity interests in domestic enterprises or offshore assets or interests with local branches of SAFE in connection with their direct establishment or indirect control of an offshore entity, for the purpose of overseas investment and financing. Failure to comply with the various SAFE registration requirements described above could result in liability under the PRC law for evasion of foreign exchange controls. The Circular on Further Simplifying and Improving Policies for Foreign Exchange Administration for Direct Investment allows banks to directly examine and handle the initial foreign exchange registration and amendment registration under the Circular 37 on behalf of the SAFE.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Regulations relating to stock incentive plans</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The SAFE promulgated the Notices on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in Stock Incentive Plans of Overseas Publicly Listed Companies, or the Stock Option Rules, which prescribed that PRC citizens or non-PRC citizens residing in the PRC for a continuous period of no less than one year (except for foreign diplomatic personnel in the PRC and representatives of international organizations in the PRC) who participate in any stock incentive plan of an overseas publicly-listed company shall, through the domestic company to which the said company is affiliated, collectively entrust a domestic agency (as such agency may be the PRC affiliate of the overseas publicly listed company which participates in stock incentive plan, or other domestic institutions qualified for asset trust business lawfully designated by such company) to handle foreign exchange registration and entrust an overseas institution to handle issues such as the exercise of options, the purchase and sale of corresponding stocks or equity and transfer of corresponding funds. In addition, the domestic agency is required to amend the SAFE registration with respect to the stock incentive plan if there is any material change to the stock incentive plan. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Regulations on Dividend Distribution</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The principal laws, rules and regulations governing dividend distributions by foreign-invested enterprises in the PRC are the PRC Company Law and the Foreign Investment Law and its Implementation Regulations. Under these requirements, foreign-invested enterprises may only pay dividends out of their accumulated profit, if any, as determined in accordance with PRC accounting standards and regulations. A PRC company is required to allocate at least 10% of its respective accumulated after-tax profits each year, if any, to fund certain capital reserve funds until the aggregate amount of these reserve funds have reached 50% of the registered capital of the enterprises. A PRC company is not permitted to distribute any profits until any losses from prior fiscal years have been offset. Profits retained from prior fiscal years may be distributed together with distributable profits from the current fiscal year.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The EIT Law and the EIT Implementation Rules provide that since January&#160;1, 2008, an enterprise income tax rate of 10% will normally be applicable to dividends declared to non-PRC resident investors that have an establishment or place of business in the PRC, or that have such establishment or place of business but the relevant income is not effectively connected with the establishment or place of business, to the extent such dividends are derived from </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">269<br></div></div></div>
<!--End Page 280-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 281-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg40"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">sources within the PRC, unless any such non-PRC resident investors&#8217; jurisdiction of incorporation has a tax treaty with the PRC that provides for a preferential withholding arrangement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Arrangement Between the Mainland of the PRC and the Hong Kong Special Administrative Region for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Incomes (the &#8220;Double Tax Avoidance Arrangement&#8221;) and other applicable PRC laws, if a Hong Kong resident enterprise is determined by the competent PRC tax authority to have satisfied the relevant conditions and requirements under such Double Tax Avoidance Arrangement and other applicable laws, the 10% withholding tax on the dividends the Hong Kong resident enterprise receives from a PRC resident enterprise may be reduced to 5%. However, based on the Notice of the State Administration of Taxation on Issues Relating to the Implementation of Dividend Clauses in Tax Treaties, issued by SAT in 2009, if the relevant PRC tax authorities determine, in their discretion, that a company benefits from such reduced income tax rate due to a structure or arrangement that is primarily tax-driven, such PRC tax authorities may adjust the preferential tax treatment. According to the Announcement of the State Administration of Taxation on Issues Relating to &#8220;Beneficial Owner&#8221; in Tax Treaties issued by SAT in 2018, if an applicant&#8217;s business activities do not constitute substantive business activities, it could result in the negative determination of the applicant&#8217;s status as a &#8220;beneficial owner&#8221; and consequently, the applicant could be precluded from enjoying the above-mentioned reduced income tax rate of 5% under the Double Tax Avoidance Arrangement.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Dividends, Distributions and Other Transfers </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Generally, cash is transferred through our organization in the following manner: (i) funds are transferred to us from CPI as needed through BJContinent Pharmaceuticals Limited, a company incorporated under the laws of Hong Kong with limited liability (&#8220;BJC Limited&#8221;), or from other domestic shareholders, in the form of capital contributions or shareholder loans; and (ii) dividends or other distributions may be paid by us to CPI through BJC Limited, or to other domestic shareholders.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In September 2020, we paid a cash dividend of $1.9 million to BJC&#160;Limited. As required under the PRC Enterprise Income Tax Law, the dividends paid by us were subject to a withholding tax rate of 10%. Such amount was settled in full net of withholding PRC tax through multiple payments by August 2020. In the future, cash proceeds raised from overseas financing activities, may be transferred to us via capital contribution or shareholder loans, as the case may be.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Since BC&#8217;s inception to the date of this proxy statement, there were no transfers, dividends, or distributions between BJC Limited, BC, BC Biomedical, or to investors (except as disclosed above and excluding shareholder capital contributions). We intend to retain all available funds and any future earnings for use in the operation of its business and does not anticipate paying any cash dividends on its capital stock in the foreseeable future. Notwithstanding the foregoing, any determination to pay cash dividends subsequent to the Contributions will be at the discretion of the combined company&#8217;s board of directors and will depend upon a number of factors, including the combined company&#8217;s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors the combined company&#8217;s board of directors deems relevant. For additional information, see <font style="font-style: italic;">Audited Financial Statements of Beijing Continent Pharmaceuticals Co., Ltd.</font> and &#8220;<font style="font-style: italic;">Selected </font><font style="font-style: italic;">Historical and Unaudited Pro Forma Condensed Combined Financial Information&#8212;Unaudited Pro Forma </font><font style="font-style: italic;">Condensed Combined Financial Information</font>&#8221; included elsewhere in this proxy statement. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under Cayman Islands law, CPI is permitted to provide funding to its subsidiaries through loans or capital contributions without restrictions on the amounts of the funds, provided that such funding is in the best interests of CPI and for proper purpose. Subject to compliance with applicable solvency requirements, there is no further Cayman Islands statutory restriction on the amount of funds that may be distributed by BC by dividend provided that no dividend shall be paid other than out of profits or, subject to certain statutory restrictions, the share premium account of CPI. The Cayman Islands does not impose a withholding tax on payments of dividends to shareholders.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our largest shareholder is BJC Limited. Under Hong Kong law, if BJC Limited were able to declare dividends, such dividends could only be paid by BJC Limited out of its distributable profits (that is, accumulated realized profits, so far as not previously utilized by distribution or capitalization, less accumulated realized losses, so far as not previously written off in a reduction or reorganization of capital), as permitted under Hong Kong law. Dividends cannot be paid out of share capital. There are no restrictions or limitation under the laws of Hong Kong imposed on the conversion of HKD into foreign currencies and the remittance of currencies out of Hong Kong. Under the current practice of the Inland Revenue Department of Hong Kong, no tax is payable in Hong Kong in respect of dividends paid by us.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">270<br></div></div></div>
<!--End Page 281-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 282-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg41"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Under PRC laws and regulations, we are subject to restrictions on foreign exchange and cross-border cash transfers, including to the parent companies and U.S. shareholders. The ability to distribute earnings to the parent companies and U.S. shareholders is also limited. Current PRC regulations permit us to pay dividends to BJC Limited only out of our accumulated profits as determined in accordance with PRC accounting standards and regulations. We are required to set aside at least 10% of our after-tax profits as the statutory common reserve fund until the cumulative amount of the statutory common reserve fund reaches 50% or more of our registered capital, if any, to fund our statutory common reserves, which are not available for distribution as cash dividends. In addition, our revenue and assets are generally denominated in RMB, which is not freely convertible into other currencies. The PRC government imposes controls on the convertibility of RMB into foreign currencies and, in certain cases, the remittance of currency out of the PRC. As a result, shortages in foreign currencies may limit our ability to remit sufficient foreign currency to offshore entities related to us for such offshore entities to pay dividends or make other payments or otherwise to satisfy its foreign-currency-denominated obligations. Prior to the Contributions, our offshore shareholders are BJC Limited, CPI (an indirect shareholder of BC), Nepenthe Holdings Limited, a company incorporated under the laws of Hong Kong with limited liability (&#8220;Nepenthe&#8221;), Ratel Holdings Limited, a company incorporated in the British Virgin Islands with limited liability (&#8220;Ratel&#8221;), Aaring Limited, a company incorporated under the laws of Hong Kong with limited liability (&#8220;Aaring&#8221;), and Rosefinch Holdings Limited, a company incorporated in the British Virgin Islands (&#8220;Rosefinch&#8221;). Following the Contributions, our offshore shareholders will be Gyre Therapeutics, Inc., which will be an indirect shareholder, and Nepenthe, Ratel, Aaring, Rosefinch, CPI and Further Challenger, each of which will be wholly-owned by Gyre Therapeutics, Inc. </div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We have established stringent controls and procedures for cash flows within our organization. Each transfer of cash between entities, across borders, and to U.S. shareholders, is subject to internal approval. To effect a cash transfer, a number of steps are needed, including but not limited to the issuance of payment receipt, logging into the online banking system and completing its verification process, inspection of the invoice, and payment execution. A single employee is not permitted to complete each and every stage of a cash transfer, but rather only portions of the whole procedure. Only the finance department is authorized to make cash transfers. Within the finance department, the roles of payment approval, payment execution, record keeping, and auditing are segregated to minimize risk.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">According to the Foreign Investment Law of the PRC and its implementing rules, which jointly established the legal framework for the administration of foreign-invested companies, a foreign investor may, in accordance with other applicable laws, freely transfer into or out of the PRC its contributions, profits, capital earnings, income from asset disposal, intellectual property, royalties acquired, compensation or indemnity legally obtained, and income from liquidation, made or derived within the territory of the PRC in renminbi, or RMB, or any foreign currency, and any entity or individual shall not illegally restrict such transfer in terms of the currency, amount and frequency. According to the Company Law of the PRC and other PRC laws and regulations, we may pay dividends only out of their respective accumulated profits as determined in accordance with PRC accounting standards and regulations. In&#160;addition, we are required to set aside at least 10% of our accumulated after-tax profits, if any, each year to fund a certain statutory reserve fund, until the aggregate amount of such fund reaches 50% of its registered capital. Where the statutory reserve fund is insufficient to cover any loss we incurred in the previous financial year, our current financial year&#8217;s accumulated after-tax profits shall first be used to cover the loss before any statutory reserve fund is drawn therefrom. At our discretion, we may allocate a portion of our after-tax profits based on PRC accounting standards to a discretionary reserve fund.</div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">RMB is not freely convertible into other currencies. The PRC government imposes controls on the convertibility of RMB into foreign currencies and, in certain cases, the remittance of currency out of the PRC. Shortages in availability of foreign currency may then restrict our ability to remit sufficient foreign currency to offshore entities related to us for such offshore entities to pay dividends or make other payments or otherwise to satisfy our foreign-currency-denominated obligations. Prior to the Contributions, our offshore shareholders are BJC Limited, CPI (an indirect shareholder of BC), Nepenthe Holdings Limited, a company incorporated under the laws of Hong Kong with limited liability (&#8220;Nepenthe&#8221;), Ratel Holdings Limited, a company incorporated in the British Virgin Islands with limited liability (&#8220;Ratel&#8221;), Aaring Limited, a company incorporated under the laws of Hong Kong with limited liability (&#8220;Aaring&#8221;), and Rosefinch Holdings Limited, a company incorporated in the British Virgin Islands (&#8220;Rosefinch&#8221;). Following the Contributions, our offshore shareholders will be Gyre Therapeutics, Inc., which will be an indirect shareholder, and Nepenthe, Ratel, Aaring, Rosefinch, CPI and Further Challenger, each of which will be wholly-owned by Gyre Therapeutics, Inc. The RMB is currently convertible under the &#8220;current account,&#8221; which includes dividends, trade and service-related foreign exchange transactions, but not under the &#8220;capital account,&#8221; which includes foreign direct investment and foreign currency debt, including loans we may secure for our onshore </div> </div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">271<br></div></div></div>
<!--End Page 282-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 283-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg42"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">subsidiaries. Currently, we may purchase foreign currency for settlement of&#8201; &#8220;current account transactions,&#8221; without the approval of the State Administration of Foreign Exchange of the PRC, or SAFE, by complying with certain procedural requirements. However, the relevant PRC governmental authorities may limit or eliminate our ability to purchase foreign currencies in the future for current account transactions. The PRC government may continue to strengthen its capital controls, and additional restrictions and substantial vetting processes may be instituted by SAFE for cross-border transactions falling under both the current account and the capital account. Any existing and future restrictions on currency exchange may limit our ability to utilize revenue generated in RMB to fund our business activities outside of the PRC or pay dividends in foreign currencies to holders of our securities. Foreign exchange transactions under the capital account remain subject to limitations and require approvals from, or registration with, SAFE and other relevant PRC governmental authorities. This could affect our ability to obtain foreign currency through debt or equity financing for BC and its subsidiaries.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Regulations on M&amp;A and Overseas Listings</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">MOFCOM, the CSRC, SAFE and other three other PRC governmental and regulatory agencies jointly promulgated the Provisions on Merger and Acquisition of Domestic Enterprises by Foreign Investors (the &#8220;M&amp;A Rules&#8221;), which became effective in 2006 and was latest amended in 2009. The M&amp;A Rules, among other things, requires that if an overseas company established or controlled by PRC companies or individuals (the &#8220;PRC Citizens&#8221;), intends to acquire interests or assets of any other PRC domestic company affiliated with the PRC Citizens, such acquisition must be submitted to MOFCOM for approval. The M&amp;A Rules also requires that offshore special purpose vehicles formed for overseas listing purposes through acquisitions of PRC domestic companies and controlled by PRC companies or individuals, to obtain the approval of the CSRC prior to the listing and trading of such special purpose vehicles&#8217; securities on an overseas stock exchange.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The M&amp;A Rules also establish procedures and requirements that could make some acquisitions of PRC companies by foreign investors more time-consuming and complex, including requirements in some instances that MOFCOM be notified in advance of any change-of-control transaction in which a foreign investor takes control of a PRC domestic enterprise. In addition, the Rules on Implementation of Security Review System for the Merger and Acquisition of Domestic Enterprises by Foreign Investors issued by MOFCOM in 2011 specify that mergers and acquisitions by foreign investors that raise &#8220;national defense and security&#8221; concerns and mergers and acquisitions through which foreign investors may acquire de facto control over domestic enterprises that raise &#8220;national security&#8221; concerns are subject to strict review by MOFCOM and prohibit any activities attempting to bypass such security review, including by structuring the transaction through a proxy or contractual control arrangement. The NDRC and MOFCOM jointly promulgated the Measures for the Security Review of Foreign Investment to forth provisions concerning the security review mechanism on foreign investment, including the types of investments subject to review, review scopes and procedures, among others. According to the Measures for the Security Review of Foreign Investment, foreign investments in military, national defense-related areas or in locations in proximity to military facilities, or foreign investments that would result in acquiring the actual control of assets in certain key sectors, such as critical agricultural products, energy and resources, equipment manufacturing, infrastructure, transport, cultural products and services, information technology, Internet products and services, financial services and technology sectors, are required to obtain approval from designated government authorities in advance.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Enterprises (the &#8220;Trial Measures&#8221;), together with the No. 1 to No. 5 Supporting Guidance Rules, the Notes on the Trial Measures, the Notice on Administration Arrangements for the Filing of Overseas Listings by Domestic Enterprises and the relevant CSRC Answers to Reporter Questions (the &#8220;Guidance Rules and Notice&#8221;), reiterate the basic supervision principles as reflected in the Administration Provisions and the Measures by providing substantially the same requirements for filings of overseas offering and listing by domestic companies and made the following updates compared to the draft Provisions and Measures: (a) further clarification of the circumstances prohibiting overseas issuance and listing; (b)&#160;further clarification of the standard of indirect overseas listing under the principle of substance over form, and (c) adding more details of filing procedures and requirements by setting different filing requirements for different types of overseas offering and listing. Under the Trial Measures and the Guidance Rules and Notice, domestic companies conducting overseas securities offering and listing activities, either in direct or indirect form, shall complete filing procedures with the CSRC pursuant to the requirements of the Trial Measures within three working days following its submission of initial public offerings or listing application. The domestic companies shall complete the filing procedures with the CSRC if such submission of initial public offerings or listing application with the overseas supervision administrations is made while the approval from overseas supervision administrations or stock </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">272<br></div></div></div>
<!--End Page 283-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 284-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg43"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">exchanges has not been obtained on or prior to the effective date of the Trial Measures, and for us, since we are a domestic enterprise in the PRC, upon completion of the Contributions, the Contributions will constitute an indirect overseas listing under the Trial Measures, and, as a result, we are required to file with the CSRC for the overseas listing application. In accordance with the Trial Measures, since Catalyst filed the preliminary proxy statement in connection with the Contributions with the SEC before the date of effectiveness of the Trial Measures, we reasonably believe that we shall complete the CSRC filing procedure prior to the anticipated closing of the Contributions. On May 22, 2023, we submitted the filing documents pursuant to the Trial Measures to the CSRC. In June 2023, we received comments from the CSRC on our filing materials, and we filed our responses and supplemental materials to the CSRC. As of the date of this filing, we have not received final confirmation from the CSRC regarding the completion of the Trial Measures filing process. </div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We do not believe we fall within any of the circumstances specified in the Trial Measures in which overseas issuance and listing are prohibited. As long as we comply with all relevant requirements, take all necessary steps and submit all relevant materials as required, we expect that there are no significant legal impediments to our completion of the filing process with the CSRC. However, there is still uncertainty as to whether we will be able to complete the filing, and if we are unable to complete the filing process, we will have to suspend or terminate the Contributions. Furthermore, pursuant to the Trial Measures, if domestic enterprises fail to fulfill the above-mentioned filing procedures or offer and list in an overseas market against the prohibited circumstances, they would be warned and fined not less than approximately $144,092 but not more than approximately $1.4&#160;million. The controlling shareholder or the actual controller of a domestic enterprise who organizes or instructs to engage in such illegal acts will be fined not less than approximately $144,092 but not more than approximately $1.4&#160;million. If the filing materials of a domestic enterprise contain false records, misleading statements or material omissions, the CSRC will order correction, issue a warning, and impose a fine of not less than approximately $144,092 and not more than approximately $1.4&#160;million. The&#160;controlling shareholder or actual controller of a domestic enterprise who organizes or directs to engage in the illegal acts in the preceding paragraph, or conceals the relevant matters leading to the occurrence of the foregoing, shall be subject to a fine of not less than approximately $144,092 and not more than approximately $1.4&#160;million.</div> <div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Employees and Human Capital </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of March 31, 2023, we had 540 total employees, including 154 employees in Beijing, 39 employees in Cangzhou and 347 employees in other regions which were primarily our sales and marketing employees located across the nation. We recruit our employees based on a number of factors, including work experience, educational background and the requirements of a relevant vacancy. We provide internal and external training for our management staff and other employees in various areas, such as product knowledge, project development and team building. We provide our employees with regular feedback and assess our employees based on their performance to determine their salary, promotion and career development.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In compliance with the relevant PRC labor laws, we enter into individual employment contracts with our employees covering matters such as terms, wages, bonuses, employee benefits, workplace safety and grounds for termination. The remuneration package of our employees includes salary and bonus, which are generally based on their qualifications, industry experience, position and performance. We consider the remuneration package of our employees to be competitive among our domestic competitors. The social insurance and housing provident funds for our employees have been paid in full during the years ended December&#160;31, 2021 and 2022 and as of May 15, 2023. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We are also subject to safety laws and regulations of the PRC. We have implemented various internal occupational health and safety procedures to maintain a safe work environment, including adopting protective measures at our production centers, inspecting our equipment and facilities regularly to identify and address safety hazards and providing regular training to our employees on safety awareness.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of May 15, 2023, we have formed a labor union to represent our employees. We believe that we have maintained good working relationships with our employees. During the years ended December&#160;31, 2021 and 2022 and up to May 15, 2023, we were not subject to any material claims, lawsuits, penalties or administrative actions relating to non-compliance with occupational health and safety laws or regulations and had not experienced any strikes, labor disputes or industrial actions which have had a material effect on our business. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Legal Proceedings</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We may be subject to legal proceedings, investigations and claims arising from the ordinary course of our business from time to time and we may also initiate legal proceedings in order to protect our intellectual property and other </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">273<br></div></div></div>
<!--End Page 284-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 285-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_116-bus02_pg44"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">rights. We do not consider any claims, lawsuits, or proceedings that are currently pending against BC, individually or in the aggregate, to be material to our business or likely to result in a material adverse effect on our future operating results, financial condition, or cash flows. From time to time, we may be subject to various claims, lawsuits, and other legal and administrative proceedings that may arise in the ordinary course of business. Some of these claims, lawsuits, and other proceedings may range in complexity and result in substantial uncertainty; it is possible that they may result in damages, fines, penalties, non-monetary sanctions or relief.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">PRC Taxation</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under Article 2 of the PRC Enterprise Income Tax Law, a resident enterprise is an enterprise that is established within the territory of the PRC or an enterprise established with a &#8220;de facto management body&#8221; within the PRC. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We are a PRC resident enterprise for PRC tax purposes by default because we are a legal entity registered in Beijing, PRC. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Because we are a PRC resident enterprise for Enterprise Income Tax, or EIT, purposes, we are required to withhold tax at a rate of 10% on dividends we pay to our shareholders that are non-resident enterprises. In addition, non-resident enterprise shareholders are subject to a 10% PRC withholding tax on gains realized on the sale or other disposition of ordinary shares. Furthermore, gains derived by our non-PRC individual shareholders from the sale of our ordinary shares may be subject to a 20% PRC withholding tax. It is unclear whether our non-PRC individual shareholders would be subject to any PRC tax (including withholding tax) on dividends received by such non-PRC individual shareholders since we are a PRC resident enterprise. If any PRC tax were to apply to dividends realized by non-PRC individuals, it will generally apply at a rate of 20%. The PRC tax liability may be reduced under applicable tax treaties. However, it is unclear whether our non-PRC shareholders would be able to claim the benefits of any tax treaty between their country of tax residence and the PRC since we are a PRC resident enterprise. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">See the section entitled &#8220;<font style="font-style: italic;">Risk Factors&#8212;Risks Related to BC</font>&#8212;<font style="font-style: italic;">Risks Related to BC&#8217;s Business Operations in the </font><font style="font-style: italic;">PRC&#8212;Since BC is a legal entity registered in Beijing, PRC, it is classified as a PRC tax resident for PRC income </font><font style="font-style: italic;">tax purposes by default, and such classification results in unfavorable tax consequences to BC and its non-PRC </font><font style="font-style: italic;">shareholders.</font>&#8221; </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">With respect to gains realized from the sale or other disposition of the shares, there is a possibility that a PRC tax authority may impose an income tax under the indirect transfer rules set out under the Announcement of the State Administration of Taxation on Several Issues Concerning the Enterprise Income Tax on Indirect Property Transfer by Non-Resident Enterprises, or SAT Circular 7, except that such transaction could fall under the safe harbor thereunder. See the section entitled &#8220;<font style="font-style: italic;">Risk Factors&#8212;Risks Related to BC</font>&#8212;<font style="font-style: italic;">Risks Related to BC&#8217;s Business Operations </font><font style="font-style: italic;">in the PRC&#8212;BC and its shareholders face uncertainties with respect to indirect transfers of equity interests in PRC </font><font style="font-style: italic;">resident enterprises or other assets attributed to a PRC establishment of a non-PRC company, or other assets </font><font style="font-style: italic;">attributable to a PRC establishment of a non-PRC company. Enhanced scrutiny over acquisition transactions by the </font><font style="font-style: italic;">PRC tax authorities may have a negative impact on potential offshore restructuring transactions or sales of the shares </font><font style="font-style: italic;">of BC&#8217;s offshore holding companies or investments where PRC taxable assets are involved.</font>&#8221;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">274<br></div></div></div>
<!--End Page 285-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 286-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_117-mda01_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCMD"><!--Anchor--></a>CATALYST MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">You should read the following discussion and analysis of Catalyst&#8217;s financial condition and results of operations in conjunction with the financial statements and the related notes, each included elsewhere in this proxy statement. In addition to historical financial information, the following discussion contains forward-looking statements that reflect Catalyst&#8217;s plans, estimates, beliefs and expectations that involve risks and uncertainties. Catalyst&#8217;s actual results and the timing of events could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this proxy statement, particularly in &#8220;Risk Factors&#8221; and &#8220;Cautionary Statement Concerning Forward-Looking Statements and Market and Industry Data.&#8221;</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Overview</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">F351 Asset Acquisition </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On December&#160;26, 2022, Catalyst acquired the F351 Assets from the Sellers pursuant to that certain F351 Agreement, by and among Catalyst and the Sellers. The F351 Assets include 15 issued or pending patents and patent applications outside of the PRC, with the last acquired issued patent expected to expire in August 2037. Under the terms of the F351 Agreement and upon the effective time of the transactions contemplated by the F351 Agreement, Catalyst issued to the Sellers equity interests with an aggregate value of $35.0 million in the form of 6,266,521 shares of Catalyst Common Stock and 12,340 shares of Catalyst Convertible Preferred Stock, which Catalyst Convertible Preferred Stock is convertible, upon the approval of the stockholders of Catalyst (as further described herein) into shares of Catalyst Common Stock at a ratio of one (1) share of Catalyst Convertible Preferred Stock to 10,000 shares of Catalyst Common Stock. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Subject to stockholder approval, each share of Catalyst Convertible Preferred Stock issued under the F351 Agreement is convertible into 10,000 shares of Catalyst Common Stock. Pursuant to the F351 Agreement, Catalyst has agreed to hold a stockholders&#8217; meeting, which is expected to be held in the third quarter of 2023, to submit the following matters to Catalyst&#8217;s stockholders for their consideration: (i)&#160;the approval of the conversion of the Catalyst Convertible Preferred Stock into shares of Catalyst Common Stock in accordance with Nasdaq rules, or the Conversion Proposal, and (ii)&#160;if necessary or appropriate, the approval of an amendment to Catalyst&#8217;s certificate of incorporation to authorize sufficient shares of common stock for the conversion of the Catalyst Convertible Preferred Stock issued pursuant to the F351 Agreement. Following stockholder approval of the Conversion Proposal, each share of Catalyst Convertible Preferred Stock is convertible into shares of Catalyst Common Stock at any time at the option of the holder thereof, into 10,000 shares of Catalyst Common Stock, subject to certain limitations, including that a holder of Catalyst Convertible Preferred Stock is prohibited from converting shares of Catalyst Convertible Preferred Stock into shares of Catalyst Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be initially set at 9.99% and thereafter adjustable by the holder to a number between 4.99% and 19.99%) of the total number of shares of Catalyst Common Stock issued and outstanding immediately after giving effect to such conversion.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Business Combination Agreement</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On December&#160;26, 2022, Catalyst, the Contributors, the Minority Holders and CPI entered into the Business Combination Agreement. The Business Combination Agreement contains the terms and conditions of the proposed business combination pursuant to which Catalyst will acquire an indirect controlling interest in BC. The closing of the Business Combination Agreement will be subject to stockholder approval at a stockholder meeting expected to be held in the third quarter of 2023 and certain customary closing conditions. If the transaction is approved by stockholders, Catalyst would issue at closing a total of up to 1,110,776,224 shares of Catalyst Common Stock for an indirect controlling interest in BC. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Business Combination Agreement contains certain termination rights, including the right for it to terminate the Business Combination Agreement to enter into a definitive agreement for a superior proposal. Upon termination of the Business Combination Agreement under specified circumstances, Catalyst may be required to pay a termination fee of $2.0&#160;million and either party, as the case may be, may be required to reimburse the other party for reasonable out-of-pocket fees and expenses incurred by such party in connection with the Business Combination Agreement, up to a maximum amount of $2.0&#160;million.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">275<br></div></div></div>
<!--End Page 286-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 287-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_117-mda01_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Contingent Value Rights Agreement</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Concurrent with the signing of the Business Combination Agreement, Catalyst entered into the CVR Agreement, pursuant to which each CVR Holder, excluding the Sellers, received one contractual CVR issued by Catalyst, subject to and in accordance with the terms and conditions of the CVR Agreement, for each share of Catalyst Common Stock held by such holder at the CVR Record Date. Each CVR entitles the holder thereof to receive (i)&#160;certain cash payments from the net proceeds, if any, related to (a) the disposition of Catalyst&#8217;s legacy assets within 90 calendar days after the remainder of the Holdback Amount (as defined in the CVR Agreement) is finally determined and received by Catalyst or (b)&#160;the resolution of certain legal claims; <font style="font-style: italic;">provided, however,</font> such period will be automatically extended for any Claim (as defined in the CVR Agreement) for an additional one-year period to the extent any Claim is appealed during the initial term, (ii) 100% of the excess cash (net of all current or contingent liabilities, including transaction-related expenses) retained by Catalyst in excess of $1.0&#160;million as of the closing date of the transactions under the Business Combination Agreement, and (iii) 100% of the amount actually received (net of indemnity claims, if any) by Catalyst pursuant to the Asset Purchase Agreement, dated as of May&#160;19, 2022, by and between Catalyst and Vertex. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The contingent payments under the CVR Agreement, if they become payable, will become payable to the Rights Agent (as defined in the CVR Agreement) for subsequent distribution to the CVR Holders. In the event that no such proceeds are received, or the permitted deductions under the CVR Agreement are greater than any such proceeds, CVR Holders will not receive any payment pursuant to the CVR Agreement. There can be no assurance that CVR Holders will receive any amounts. The CVRs are not transferable, except in certain limited circumstances as provided for in the CVR Agreement, will not be certificated or evidenced by any instrument, and will not be registered with the SEC or listed for trading on any exchange.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Prior to the F351 Acquisition, Catalyst was engaged in the research and development of product candidates from Catalyst&#8217;s protease engineering platform. In February 2022, Catalyst announced that it engaged Perella Weinberg Partners as a financial advisor to assist Catalyst in exploring strategic alternatives to monetize its assets. In March&#160;2022, Catalyst ceased research and development activities and in May 2022, Catalyst entered into an asset purchase agreement with Vertex, pursuant to which Vertex purchased Catalyst&#8217;s complement portfolio, including CB&#160;2782-PEG and CB 4332, as well as its complement-related intellectual property, including the ProTUNE&#8482; and ImmunoTUNE&#8482; platforms, for $60.0&#160;million in cash consideration. $55.0&#160;million was received upfront and the remaining $5.0&#160;million was retained by Vertex as a hold-back until one year after the closing date to satisfy certain post-closing indemnification obligations. Any amounts received from Vertex with respect to this hold-back, net of expenses, are being distributed to the CVR Holders. On February&#160;27, 2023, Catalyst signed an asset purchase agreement with GCBP pursuant to which GCBP acquired Catalyst&#8217;s legacy rare bleeding disorders programs including MarzAA, DalcA and CB-2679d-GT for a total of $6.0&#160;million in cash consideration, $1.0&#160;million payable on signing and $5.0&#160;million payable on February&#160;28, 2025, subject to satisfaction of post-closing indemnification obligations. In March 2023, Catalyst distributed net proceeds of approximately $0.2&#160;million to the CVR Holders. Once received, any additional net proceeds from the transaction will be distributed to the CVR Holders. Catalyst is also pursuing certain legal claims against a third party related to payments under a 2016 asset purchase agreement, and any net recoveries related to these claims will be distributed to the CVR Holders. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Financial Operations Overview</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst has no drug products approved for commercial sale and has not generated any revenue from drug product sales.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">With the exception of the three months ended March 31, 2023 and June 30, 2022, Catalyst has never been profitable and has incurred significant operating losses in each year since inception. Catalyst had net income of $0.3 million and net losses of $14.5 million for the three months ended March 31, 2023 and 2022, respectively, and net losses of $8.2&#160;million and $87.9&#160;million for the years ended December&#160;31, 2022 and 2021, respectively. As of March 31, 2023, Catalyst had an accumulated deficit of $410.7 million and cash and cash equivalents of $8.1 million. Substantially all its operating losses were incurred in its research and development programs and in its general and administrative operations.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Collaboration Revenue </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Collaboration revenue consists of revenue earned for performance obligations satisfied pursuant to the License and Collaboration Agreement with Biogen entered into in December 2019 and terminated in May&#160;2022 (the &#8220;Biogen </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">276<br></div></div></div>
<!--End Page 287-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 288-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_117-mda01_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Agreement&#8221;). Catalyst recognized collaboration revenue for reimbursable third-party vendor, out-of-pocket and personnel costs pertaining to the Biogen Agreement, of $0.8&#160;million and $7.3&#160;million during the years ended December&#160;31, 2022 and 2021, respectively.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst has not generated any revenue from the sale of any drug products and Catalyst does not expect to generate any revenue from the sale of drug products until Catalyst obtains regulatory approval of and commercializes its product candidates.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Cost of Collaboration Revenue</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Cost of collaboration revenue consists of fees for research and development services payable to third-party vendors and personnel costs, corresponding to the recognition of collaboration revenue from Biogen. Cost of collaboration revenue does not include any allocated overhead costs. Catalyst recognized third-party vendor, out-of-pocket and personnel costs, most of which were reimbursable, pertaining to the Biogen Agreement of $0.8&#160;million and $7.4&#160;million during the years ended December&#160;31, 2022 and 2021, respectively, and recorded such costs as cost of collaboration revenue.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Acquired In-process Research and Development Expenses</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Acquired in-process research and development (&#8220;IPR&amp;D&#8221;) expense resulted from the acquisition of the F351 Assets in December 2022. The acquisition costs allocated to acquire IPR&amp;D with no alternative future use was recorded as an expense at the acquisition date.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Research and Development Expenses </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of March 2022, Catalyst ceased the development of certain programs and during the quarter ended June&#160;30, 2022, Catalyst ceased all research and development activities. Research and development expenses represent costs incurred to conduct research, such as the discovery and development of its product candidates. Catalyst recognizes all research and development costs as they are incurred. Nonrefundable advance payments for goods or services used in research and development are deferred and capitalized. The capitalized amounts are then expensed as the related goods are delivered or services are performed, or until it is no longer expected that the goods or services will be delivered.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Research and development expenses have traditionally consisted primarily of the following:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">employee-related expenses, which include salaries, benefits and stock-based compensation;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">laboratory and vendor expenses, including payments to consultants and third parties, related to the execution of preclinical, non-clinical and clinical studies;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the cost of acquiring and manufacturing preclinical and clinical materials and developing manufacturing processes;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">clinical trial expenses, including costs of third-party clinical research organizations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">performing toxicity and other preclinical studies; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">facilities and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation and amortization expense and other supplies.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The table below details its internal and external costs for research and development for the period presented, excluding the acquired IPR&amp;D (<font style="font-style: italic;">in thousands)</font>. </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 17.68%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31,</div></td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 18.33%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 31,</div></td></tr><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.47%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023</div></td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.07%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Personnel and other <font style="padding-left: 2.09pt;"></font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 5pt;">6,135</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$17,198</div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.14pt; text-align: left;">$522</div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.13pt; text-align: left;">$4,140</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stock-based compensation <font style="padding-left: 0.43pt;"></font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">330</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">1,202</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.14pt; text-align: left;"><font style="padding-left: 10pt;">66</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.13pt; text-align: left;"><font style="padding-left: 12.5pt;">128</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Complement<font style="padding-left: 4.84pt;"></font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">4,139</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">24,698</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.14pt; text-align: left;"><font style="padding-left: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.13pt; text-align: left;"><font style="padding-left: 5pt;">3,383</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Hemophilia<font style="padding-left: 4.29pt;"></font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">2,433</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">25,791</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.14pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 20pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.13pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">2,052</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total research and development expenses<font style="padding-left: 2.28pt;"></font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$13,037</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$68,889</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.14pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 20pt;">$588</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.13pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">$9,703</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">277<br></div></div></div>
<!--End Page 288-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 289-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_117-mda01_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The largest component of total operating expenses had historically been Catalyst&#8217;s investment in research and development activities, including the clinical and manufacturing development of its product candidates. Costs listed for its hemophilia and complement programs above consist of clinical trial, manufacturing and research costs. Its internal resources, employees and infrastructure, identified above as personnel and other, are generally not directly tied to individual product candidates or development programs. As such, Catalyst does not maintain information regarding these costs incurred for these research and development programs on a project-specific basis.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst has entered into a Cost Sharing and Agency Agreement with GNI USA, Inc. pursuant to which GNI USA,&#160;Inc. will be responsible for development expenses related to the F351 Assets until the closing of the transactions under the Business Combination Agreement. Accordingly, since Catalyst has ceased its other research and development activities, it does not expect to incur material research and development expenses until the closing of the transactions under the Business Combination Agreement. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">General and Administrative Expenses</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">General and administrative expenses consist of personnel costs, allocated expenses, expenses for outside professional services, including legal, human resources, audit and accounting services, and other general expenses. Personnel costs consist of salaries, bonuses, benefits and stock-based compensation. Catalyst incurs expenses associated with operating as a public company, including expenses related to compliance with the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;), insurance expenses, audit expenses, investor relations activities, Sarbanes-Oxley compliance expenses and other administrative expenses and professional services. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Gain on Disposal of Assets</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Gain on disposal of assets for the three months ended March 31, 2023 resulted from the sale of Catalyst&#8217;s legacy rare bleeding disorder program, including MarzAA, DalcA and CB-2679d-GT to GCBP in February 2023. The gain is presented net of the direct costs incurred in connection with the transaction. The gain on disposal of assets for the year ended December 31, 2022 resulted from the sale of Catalyst&#8217;s complement portfolio and related intellectual property to Vertex in May 2022. The gain is presented net of the direct costs incurred to transact the sale and losses incurred in connection with the sale of Catalyst&#8217;s property and equipment.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Results of Operations</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Comparisons for the Three Months Ended March 31, 2023 and 2022</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The following table summarizes Catalyst&#8217;s results of operations data for the periods presented <font style="font-style: italic;">(in thousands)</font>:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.52%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 17.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Ended March&#160;31, </div></td><td class="gutter" style="width: 1.52%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.16%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.02%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.52%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023 </div></td><td class="gutter" style="width: 1.52%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.52%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022 </div></td><td class="gutter" style="width: 1.52%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.52%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change ($) </div></td><td class="gutter" style="width: 1.52%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.52%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change (%) </div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Revenue: <br></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Collaboration <font style="padding-left: 3.18pt;"></font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 15.83pt;">794 </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;">$<font style="padding-left: 12.5pt;">(794) </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.94pt; text-align: left;">(100)% </div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses (income): <br></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cost of collaboration <font style="padding-left: 2.09pt;"></font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt;">798 </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;"><font style="padding-left: 17.5pt;">(798) </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.94pt; text-align: left;">(100)% </div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development <font style="padding-left: 3.77pt;"></font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.83pt;">588 </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.33pt;">9,703 </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;"><font style="padding-left: 10.37pt;">(9,115) </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.94pt; text-align: left;"><font style="padding-left: 5pt;">(94)% </font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">General and administrative <font style="padding-left: 3.22pt;"></font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">3,970 </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.33pt;">4,994 </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;"><font style="padding-left: 10pt;">(1,024) </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.94pt; text-align: left;"><font style="padding-left: 5pt;">(21)% </font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Gain on disposal of assets, net <font style="padding-left: 2.95pt;"></font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">(4,736</font><font style="min-width: 30.83pt;">) </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(4,736</font><font style="min-width: 35.83pt;">) </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.94pt; text-align: left;"><font style="padding-left: 3.33pt;">100% </font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total operating expenses (income)<font style="padding-left: 1.14pt;"></font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">(178</font><font style="min-width: 30.83pt;">) </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">15,495 </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(15,673</font><font style="min-width: 35.83pt;">) </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.94pt; text-align: left;"><font style="padding-left: 18.33pt;">* </font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income (loss) from operations<font style="padding-left: 3.22pt;"></font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.83pt;">178 </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">(14,701) </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;"><font style="padding-left: 8.33pt;">14,879 </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.94pt; text-align: left;"><font style="padding-left: 18.33pt;">* </font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest and other income, net<font style="padding-left: 4.05pt;"></font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">96 </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">165 </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(69</font><font style="min-width: 35.83pt;">) </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.94pt; text-align: left;"><font style="padding-left: 18.33pt;">* </font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income (loss) before income taxes<font style="padding-left: 0.46pt;"></font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">274 </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(14,536</font><font style="min-width: 35.83pt;">) </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">14,810 </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.94pt; text-align: left;"><font style="padding-left: 5pt;">(42)% </font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income tax expenses <font style="padding-left: 3.21pt;"></font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">14 </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">14 </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.94pt; text-align: left;"><font style="padding-left: 3.33pt;">100% </font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net income (loss)<font style="padding-left: 3.76pt;"></font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 30.83pt;">$</font><font style="padding-left: 10.83pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">260 </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">$(14,536</font><font style="min-width: 35.83pt;">) </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">$</font><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">14,796 </font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.94pt; text-align: left;"><font style="padding-left: 18.33pt;">*</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Not meaningful</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">278<br></div></div></div>
<!--End Page 289-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 290-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_117-mda01_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Collaboration Revenue</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Collaboration revenue for the three months ended March 31, 2022 consisted of reimbursable collaboration expenses from the Biogen Agreement. No collaboration revenue was recognized for the three months ended March 31, 2023.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Cost of Collaboration</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Cost of collaboration revenue for the three months ended March 31, 2022 primarily related to reimbursable third-party vendor and personnel costs incurred pertaining to the Biogen Agreement. No cost of collaboration revenue was recognized for the three months ended March 31, 2023.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Research and Development Expenses</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Research and development expenses were $0.6 million and $9.7 million during the three months ended March 31, 2023 and 2022, respectively, a decrease of $9.1 million, or 94%. The decrease was due primarily to a decrease of $3.6&#160;million in personnel-related costs, a decrease of $3.4 million in complement-related costs, and a decrease of $2.1&#160;million in hemophilia-related costs. Research and development expenses for the three months ended March 31, 2022 include approximately $0.6 million of severance and other costs related to Catalyst&#8217;s reduction-in-force. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">General and Administrative Expenses</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">General and administrative expenses were $4.0 million and $5.0 million during the three months ended March 31, 2023 and 2022, respectively, a decrease of $1.0 million, or 21%. The decrease was due primarily to a decrease of $0.7&#160;million in professional services and a $0.4 million decrease in personnel-related costs, partially offset by an increase of $0.1 million in facilities and overhead costs. General and administrative expenses for the three months ended March 31, 2022 include approximately $0.4 million of severance and other costs related to Catalyst&#8217;s reduction-in-force. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Gain on Disposal of Assets, Net</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Gain on disposal of assets, net was $4.7 million for the three months ended March 31, 2023, which related to the sale of Catalyst&#8217;s legacy rare bleeding disorder program to GCBP in February 2023.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Interest and Other Income, Net</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The $0.1 million decrease in interest and other income, net for the three months ended March 31, 2023 compared to the three months ended March 31, 2022 was primarily due to a gain on extinguishment of $0.2 million recognized in the first quarter of 2022 where there was no comparable activity in the first quarter of 2023, partially offset by an increase in interest income of $0.1 million.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Comparisons for the Years Ended December 31, 2022 and 2021</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The following table summarizes Catalyst&#8217;s results of operations data for the periods presented (in thousands):</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.14%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31,</div></td><td class="gutter" style="width: 1.14%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.16%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.02%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.14%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.14%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.14%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td><td class="gutter" style="width: 1.14%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.14%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change ($)</div></td><td class="gutter" style="width: 1.14%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.14%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change (%)</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Revenue:<br></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Collaboration <font style="padding-left: 3.18pt;"></font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;">$<font style="padding-left: 15.83pt;">794</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;">$<font style="padding-left: 8.33pt;">7,338</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.18pt; text-align: left;">$<font style="padding-left: 5pt;">(6,544)</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.43pt; text-align: left;">(89)%</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses (income):<br></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cost of collaboration <font style="padding-left: 2.09pt;"></font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 20.83pt;">798</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 13.33pt;">7,380</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.18pt; text-align: left;"><font style="padding-left: 10pt;">(6,582)</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.43pt; text-align: left;">(89)%</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development <font style="padding-left: 3.77pt;"></font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 8.33pt;">13,037</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 8.33pt;">68,889</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.18pt; text-align: left;"><font style="padding-left: 5pt;">(55,852)</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.43pt; text-align: left;">(81)%</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">General and administrative <font style="padding-left: 3.22pt;"></font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 8.33pt;">17,366</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 8.33pt;">18,963</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.18pt; text-align: left;"><font style="padding-left: 10pt;">(1,597)</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.43pt; text-align: left;"><font style="padding-left: 5pt;">(8)%</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Acquired in-process research and development <font style="padding-left: 2.15pt;"></font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 8.33pt;">35,390</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.18pt; text-align: left;"><font style="padding-left: 8.33pt;">35,390</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.43pt; text-align: left;"><font style="padding-left: 13.33pt;">*</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Gain on disposal of assets, net <font style="padding-left: 2.95pt;"></font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(57,186</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.18pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(57,186</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.43pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 13.33pt;"></font><font style="min-width: 13.33pt;">*</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total operating expenses <font style="padding-left: 2.24pt;"></font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">9,405</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">95,232</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.18pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(85,827</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.43pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 13.33pt;">(90</font><font style="min-width: 13.33pt;">)%</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from operations <font style="padding-left: 1.54pt;"></font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 10.37pt;">(8,611)</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 5pt;">(87,894)</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.18pt; text-align: left;"><font style="padding-left: 8.33pt;">79,283</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.43pt; text-align: left;">(90)%</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest and other income (expense), net <font style="padding-left: 3.53pt;"></font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">717</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(39</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.18pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">756</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.43pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 13.33pt;"></font><font style="min-width: 13.33pt;">*</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss before income taxes <font style="padding-left: 3.78pt;"></font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(7,894</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(87,933</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.18pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">80,039</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.43pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 13.33pt;">(91</font><font style="min-width: 13.33pt;">)%</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">279<br></div></div></div>
<!--End Page 290-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 291-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_117-mda01_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.14%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31,</div></td><td class="gutter" style="width: 1.14%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.16%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.02%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.14%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.14%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.14%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td><td class="gutter" style="width: 1.14%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.14%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change ($)</div></td><td class="gutter" style="width: 1.14%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.14%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change (%)</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income tax expenses<font style="padding-left: 1.54pt;"></font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.78pt; text-align: left;"><font style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">348</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.84pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">348</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.43pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 13.33pt;"></font><font style="min-width: 13.33pt;">*</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss<font style="padding-left: 3.18pt;"></font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.78pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 30.83pt;">$(8,242</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">$(87,933</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.84pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$79,691</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.43pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 13.33pt;">(91</font><font style="min-width: 13.33pt;">)%</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 20pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Not meaningful</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Collaboration Revenue</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Collaboration revenue for the years ended December&#160;31, 2022 and 2021 consisted of reimbursable collaboration expenses from the Biogen Agreement.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Cost of Collaboration</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Cost of collaboration revenue for the years ended December&#160;31, 2022 and 2021 primarily related to reimbursable third-party vendor and personnel costs incurred pertaining to the Biogen Agreement.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Research and Development Expenses</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Research and development expenses, excluding the acquired IPR&amp;D, were $13.0&#160;million and $68.9&#160;million during the years ended December&#160;31, 2022 and 2021, respectively, a decrease of approximately $55.9&#160;million, or 81%. The decrease was due primarily to a decrease of $23.4&#160;million in hemophilia-related costs, a decrease of $20.5&#160;million in complement-related costs, a decrease of $11.1&#160;million in personnel-related costs, and a decrease of $0.9&#160;million in stock-based compensation costs. Research and development expenses for the year ended December&#160;31, 2022 include approximately $0.6&#160;million of severance and other costs related to Catalyst&#8217;s reduction-in-force.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">General and Administrative Expenses</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">General and administrative expenses were $17.4&#160;million and $19.0&#160;million during the years ended December&#160;31, 2022 and 2021, respectively, a decrease of approximately $1.6&#160;million, or 8%. The decrease was due primarily to a decrease of $2.1&#160;million in professional services, a decrease of $2.1&#160;million in personnel-related costs, partially offset by an increase of $2.2&#160;million in facilities and other administrative costs, which primarily related to transaction costs incurred in connection with the Business Combination Agreement and costs related to Catalyst&#8217;s operating leases, an increase of $0.2&#160;million related to Catalyst&#8217;s allowance for doubtful accounts, and a net increase of $0.2&#160;million related to settlements reached with Biogen and certain contract service vendors. General and administrative expenses for the year ended December&#160;31, 2022 include approximately $0.4&#160;million of severance and other costs related to Catalyst&#8217;s reduction-in-force.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Acquired In-Process Research and Development</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Acquired IPR&amp;D was $35.4&#160;million for the year ended December&#160;31, 2022, which related to the acquisition of the F351 Assets in December 2022. The acquisition cost allocated to acquire IPR&amp;D with no alternative future use was recorded as an expense at the acquisition date. No acquired IPR&amp;D expenses were incurred in 2021.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Gain on Disposal of Assets, Net</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Gain on disposal of assets, net was $57.2&#160;million for the year ended December&#160;31, 2022, which primarily consisted of a $57.4&#160;million gain related to the sale of its complement portfolio to Vertex in May 2022.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Interest and Other Income (Expense), Net</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The $0.8&#160;million increase in interest and other income (expense), net for the year ended December&#160;31, 2022 compared to the year ended December&#160;31, 2021 was primarily due to a $0.2&#160;million gain recognized upon the extinguishment of a liability and an increase in interest income. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Liquidity and Capital Resources</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On March 8, 2023, Catalyst distributed the net cash proceeds received from the GCBP asset sale of $0.2 million, or $0.01 per share, to holders of Catalyst Common Stock, excluding the Sellers.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">280<br></div></div></div>
<!--End Page 291-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 292-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_117-mda01_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">On September&#160;20, 2022, Catalyst paid a special, one-time cash dividend of $1.43 per share, or approximately $45.0&#160;million, to holders of Catalyst Common Stock. On December&#160;27, 2022, Catalyst declared another special cash dividend of $0.24 per share, or approximately $7.6&#160;million, to holders of Catalyst Common Stock, excluding the Sellers, which was paid on January&#160;12, 2023.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of March 31, 2023, Catalyst had $8.1 million of cash and cash equivalents. For the three months ended March 31, 2023, Catalyst had net income of $0.3&#160;million and $6.2 million cash used in operating activities. Catalyst had an accumulated deficit of $410.7 million as of March 31, 2023. Catalyst expects that its existing cash and cash equivalents are sufficient to support its operating expenses through at least the next 12 months from the date of this filing, assuming Catalyst&#8217;s stockholders approve the Conversion Proposal. Catalyst&#8217;s estimate as to how long it expects its cash and cash equivalents to be able to fund its operations is based on assumptions that may prove to be wrong, and it could use Catalyst&#8217;s available capital resources sooner than it currently expects. Further, changing circumstances, some of which may be beyond Catalyst&#8217;s control, could cause it to consume capital significantly faster than currently anticipated, and Catalyst may need to seek additional funds sooner than planned. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the F351 Agreement, Catalyst issued Catalyst Convertible Preferred Stock to the Sellers. Catalyst is obligated to seek stockholder approval for the conversion of the Catalyst Convertible Preferred Stock into common stock. In the event that Catalyst fails to timely hold the stockholders&#8217; meeting or fails to obtain stockholder approval of the Conversion Proposal, then the holders of the Catalyst Convertible Preferred Stock would be entitled to require Catalyst to redeem, in cash, the shares of common stock underlying its Catalyst Convertible Preferred Stock at a price per share equal to the fair value of the common stock. If Catalyst is forced to redeem a significant amount of shares underlying the Catalyst Convertible Preferred Stock, it could, among other things, materially affect Catalyst&#8217;s results of operations and cash usage forecasts, require Catalyst to raise additional capital and impact its ability to raise additional capital. Also, while Catalyst cannot predict the amount with any level of certainty, there is a level of cash settlement at which, if it is exceeded, could require Catalyst to make redemption payments in excess of its current liquidity. Catalyst believes that its stockholders who are entitled to vote on the Conversion Proposal at its 2023 Annual Meeting of Stockholders, which is expected to be held in the third quarter of 2023, will vote to approve the proposal. However, as the vote of Catalyst&#8217;s stockholders is outside of its control, there is substantial doubt about Catalyst&#8217;s ability to continue as a going concern within one year from the filing of this proxy statement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst expects to finance any future cash needs through a combination of divestitures of its product candidates or other assets, equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. There can be no assurance as to the timing, terms or consummation of any divestiture or financing, and the terms of any such financing may adversely affect Catalyst&#8217;s stockholders&#8217; rights. If Catalyst raises funds through collaborations, strategic alliances or licensing arrangements with third parties, it may have to relinquish valuable rights to its technologies, product candidates or to grant licenses on terms that may not be favorable to Catalyst.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The following table summarizes Catalyst&#8217;s cash flows for the periods presented <font style="font-style: italic;">(in thousands):</font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.62%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 18.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31,</div></td><td class="gutter" style="width: 1.62%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.62%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 18.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 31,</div></td></tr><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.62%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.62%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.62%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td><td class="gutter" style="width: 1.62%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash used in operating activities <font style="padding-left: 4.89pt;"></font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$(33,096)</div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$(83,755)</div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 5pt;">(6,216)</font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$(12,050)</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash provided by investing activities <font style="padding-left: 1.55pt;"></font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">55,426</font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">48,189</font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 21.2pt;">411</font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">2,504</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash (used in) provided by financing activities <font style="padding-left: 1.02pt;"></font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5.37pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(45,011</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">49,553</font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(7,762</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">16</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net (decrease) increase in cash and cash equivalents <font style="padding-left: 3.3pt;"></font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">$(22,681</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">$</font><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">13,987</font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">$(13,567</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">$</font><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">(9,530</font><font style="min-width: 35.83pt;">)</font></div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Cash Flows from Operating Activities</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Cash used in operating activities for the three months ended March 31, 2023 was $6.2 million. The most significant component of Catalyst&#8217;s cash used was net loss of $4.4 million excluding the net gain of $4.7 million from the sale of its legacy rare bleeding disorder program. The net loss included non-cash stock-based compensation expense of $0.2 million. In addition, net cash outflow of $2.0 million was attributable to the change in its net operating assets and liabilities primarily as a result of a $2.4 million decrease in accrued compensation and other accrued liabilities and a $0.2 million decrease in accounts payable, partially offset by a $0.6 million decrease in prepaid and other current assets.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Cash used in operating activities for the three months ended March 31, 2022 was $12.1 million. The most significant component of Catalyst&#8217;s cash used was a net loss of $14.5 million. This included non-cash expense related to </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">281<br></div></div></div>
<!--End Page 292-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 293-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_117-mda01_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">stock-based compensation of $0.5 million, bad debt expense of $0.2 million and depreciation and amortization of $0.1 million. In addition, cash inflow of $1.7 million was attributable to the change in its net operating assets and liabilities primarily as a result of a $1.5 million decrease in prepaid and other current assets, a $1.1 million decrease in accounts receivable, and a $1.0 million increase in accrued compensation and other accrued liabilities, partially offset by a $1.7 million decrease in accounts payable and a $0.2 million decrease in deferred revenue related to the Biogen Agreement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Cash used in operating activities for the year ended December&#160;31, 2022 was $33.1&#160;million. The most significant component of Catalyst&#8217;s cash used was a net loss of $8.2&#160;million. The net loss included the net gain of $57.2&#160;million from the sale of its complement portfolio and other assets, offset by non-cash expense primarily related to IPR&amp;D of $35.4&#160;million that resulted from the acquisition of the F351 Assets in December 2022, in exchange for shares of Catalyst&#8217;s stock, stock-based compensation of $1.3&#160;million, bad debt expense of $0.2&#160;million, and depreciation and amortization of $0.2&#160;million. In addition, net cash outflow of $4.9&#160;million was attributable to the change in its net operating assets and liabilities primarily as a result of a $6.2&#160;million decrease in accounts payable, and a $1.9&#160;million decrease in accrued compensation and other accrued liabilities, partially offset by a $1.6&#160;million decrease in accounts and other receivables and a $1.6&#160;million decrease in prepaid and other current assets.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Cash used in operating activities for the year ended December&#160;31, 2021 was $83.8&#160;million. The most significant component of Catalyst&#8217;s cash used was a net loss of $87.9&#160;million. This included non-cash expenses related to stock-based compensation of $3.4&#160;million and depreciation and amortization of $0.3&#160;million. In addition, cash inflow of $0.5&#160;million was attributable to the change in its net operating assets and liabilities primarily as a result of a $3.9&#160;million decrease in prepaid and other assets, a $1.5&#160;million decrease in accounts receivable, and a $0.5&#160;million increase in accounts payable, offset by a $3.7&#160;million decrease in accrued compensation and other accrued liabilities and a $1.8&#160;million decrease in deferred revenue related to the Biogen Agreement.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Cash Flows from Investing Activities</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Cash provided by investing activities for the three months ended March 31, 2023 was $0.4 million, due to $1.0&#160;million in cash proceeds from the sale of the Catalyst&#8217;s legacy rare bleeding disorder program to GCBP, offset by $0.6&#160;million in transaction costs related to the sale of its legacy rare bleeding disorder program to GCBP. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Cash provided by investing activities for the three months ended March 31, 2022 was $2.5 million, due primarily to proceeds from maturities of investments.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Cash provided by investing activities for the year ended December&#160;31, 2022 was $55.4&#160;million, due to $55.0&#160;million in cash proceeds from the sale of its complement portfolio to Vertex, $2.5&#160;million due to proceeds from maturities of investments, and $0.5&#160;million in proceeds from the sale of property and equipment, partially offset by $2.6&#160;million in transaction costs related to the sale of its complement portfolio to Vertex. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Cash provided by investing activities for the year ended December&#160;31, 2021 was $48.2&#160;million, due to $49.0&#160;million in proceeds from maturities of investments, offset by $0.8&#160;million used in purchases of property and equipment.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Cash Flows from Financing Activities</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Cash used in financing activities for the three months ended March 31, 2023 was $7.8 million, due primarily to the special dividend paid in January 2023 and the distribution of net proceeds related to the GCBP Agreement to the CVR Holders.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Cash provided by financing activities for the three months ended March 31, 2022 was due to the issuance of stock grants.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Cash used in financing activities for the year ended December&#160;31, 2022 was $45.0&#160;million, due to the special dividend issued and paid in September 2022, offset by the issuance of a minimal amount of stock grants and option exercises.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Cash provided by financing activities for the year ended December&#160;31, 2021 was $49.6&#160;million, due to $49.3&#160;million in net proceeds from the issuance of common stock related to its public offering in the first quarter of 2021 and $0.3&#160;million in proceeds from ESPP purchases of common stock and stock option exercises.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Critical Accounting Polices and Estimates</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and Catalyst&#8217;s discussion and analysis of its financial condition and operating results require Catalyst&#8217;s management to make judgments, assumptions and estimates that affect the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">282<br></div></div></div>
<!--End Page 293-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 294-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_117-mda01_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">amounts reported in its consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates, and such differences may be material.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Management believes Catalyst&#8217;s critical accounting policies and estimates discussed below are critical to understanding its historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Stock-based Compensation</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst measures the cost of employee, non-employee and director services received in exchange for an award of equity instruments based on the fair value-based measurement of the award on the date of grant and recognize the related expense over the period during which an employee, non-employee or director is required to provide service in exchange for the award on a straight-line basis. The estimated fair value of equity awards that contain performance conditions is expensed over the term of the award once Catalyst has determined that it is probable that performance conditions will be satisfied.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Determining the fair value of stock-based awards at the grant date requires judgment. Catalyst uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the grant date fair value of options using an option-pricing model is affected by Catalyst&#8217;s assumptions regarding a number of variables including the fair value of its common stock, its expected common stock price volatility over the expected life of the options, expected term of the stock option, risk-free interest rates and expected dividends. Catalyst records stock-based compensation as a compensation expense, net of the forfeited awards. Catalyst elected to account for forfeitures when they occur. As such, Catalyst recognizes stock-based compensation expense over their requisite service period based on the vesting provisions of the individual grants. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">F351 Asset Acquisition </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On December&#160;26, 2022, Catalyst completed its acquisition of the F351 Assets in accordance with the terms of the F351 Agreement. Catalyst concluded that the acquisition did not result in the acquisition of a business, as substantially all of the fair value of the assets acquired was concentrated in a single identifiable asset, the intellectual property rights (outside of the PRC) to a clinical stage drug candidate for the treatment of liver fibrosis, or the F351&#160;Assets. Significant judgment was required in evaluating the terms of the F351 Agreement and in valuing and recording the acquired assets at fair value as well as determining whether the acquired IPR&amp;D had an alternative future use. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Catalyst Convertible Preferred Stock </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the F351 Acquisition, Catalyst issued shares of Catalyst Convertible Preferred Stock to the Sellers. Each share of Catalyst Convertible Preferred Stock is convertible into 10,000 shares of Catalyst Common Stock, subject to stockholder approval under Nasdaq rules and subject to a beneficial ownership conversion blocker. Catalyst classified the Catalyst Convertible Preferred Stock as temporary equity on the consolidated balance sheet because if conversion to Catalyst Common Stock is not approved by the stockholders, the Catalyst Convertible Preferred Stock would be redeemable at the option of the holders for cash equal to the closing price of Catalyst Common Stock on last trading day prior to the holder&#8217;s redemption request. Catalyst recorded the Catalyst Convertible Preferred Stock at its relative fair value on the date of issuance (i.e., the closing date of the F351 Acquisition) and did not adjust the carrying value to its redemption value since the Catalyst Convertible Preferred Stock is not currently redeemable, and it is not probable that it will become redeemable in the future at the balance sheet date. Significant judgment was required in evaluating the various rights of the Catalyst Convertible Preferred Stock and in classifying and measuring the Catalyst Convertible Preferred Stock as well as determining whether the Catalyst Convertible Preferred Stock is a participating security upon issuance. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Contingent Value Rights Liability</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On December&#160;26, 2022, Catalyst executed the CVR Agreement, pursuant to which each CVR Holder received one contractual CVR for each share of Catalyst Common Stock held by such holder. Each CVR entitles the holder thereof to receive cash payments in the future. Certain contingent payments under the CVR Agreement qualified as derivatives under ASC 815, <font style="font-style: italic;">Derivatives and Hedging</font>, and were recorded as a liability on the balance sheet as of </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">283<br></div></div></div>
<!--End Page 294-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 295-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_117-mda01_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">March 31, 2023 and December&#160;31, 2022. The CVR liability is considered a Level 3 instrument that is initially measured at its estimated fair value on the transaction date and subsequently remeasured at each reporting date with changes recorded in the consolidated statement of operations. The determination of the initial and subsequent fair value of the CVR liability requires significant judgment by management. Changes in any of the inputs not related to facts and circumstances existing as of the transaction date may result in a significant fair value adjustment, which can impact the results of operations in the period in which the adjustment is made.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">284<br></div></div></div>
<!--End Page 295-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 296-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_118-mda02_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tBCM"><!--Anchor--></a>BC MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">AND RESULTS OF OPERATIONS </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: justify;">In this section, references to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and &#8220;our company&#8221; refer to Beijing Continent Pharmaceuticals Co., Ltd.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing elsewhere in this proxy statement. Some of the information contained in this discussion and analysis or set forth elsewhere in this proxy statement, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks, uncertainties and assumptions. As a result of many factors, including those factors set forth in the section entitled &#8220;Risk Factors,&#8221; our actual results could differ materially from the results described in or implied by these forward-looking statements. You should carefully read the section entitled &#8220;Risk Factors&#8221; to gain an understanding of the factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section entitled &#8220;Cautionary Statement Concerning Forward-Looking Statements and Market and Industry Data.&#8221;</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Overview </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We are a commercial-stage biopharmaceutical company committed to the research, development, manufacturing and commercialization of innovative drugs for organ fibrosis. Our commercialized product, ETUARY and other product candidates were all initially acquired or in-licensed from GNI Japan. We have long been focusing on the treatment of IPF and has gradually broadened its therapeutic field and research and development efforts to other areas of organ fibrosis. Our flagship product ETUARY (pirfenidone capsule) was approved in the PRC in 2011 and is among the first three approved drugs for IPF worldwide. Thereafter, we developed a pipeline of additional innovative drug candidates and has had nine years of successful commercialization. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We are also one of the few innovative biopharmaceutical companies in the PRC that has been able to achieve self-sustainable growth. Our total revenue and net profit increased from approximately $47.1 million and $10.2 million in 2019, to approximately $64.8 million and $18.5 million in 2020, with a growth rate of 37.6% and 81.4%, respectively. Our total revenue and net profit further increased to approximately $88.5 million and $23.2 million in 2021, growing 36.6% and 25.4%, respectively. Such growth was primarily due to the increased market demand of ETUARY, the first IPF drug marketed in the PRC. The significant increase in the sales of ETUARY has been benefited from the relatively limited competition and our dominant position in the IPF drug market in the PRC as we devotes our marketing resources to continuously increase physician adoption of ETUARY. For the year ended December&#160;31, 2022, our total revenue was $102.5&#160;million and our net profit was $22.5&#160;million. Our total revenue and net profit decreased from approximately $25.0 million and $6.2 million, respectively, for the three months ended March 31, 2022, to $24.6 million and $5.4 million, respectively, for the three months ended March 31, 2023, a decrease of 1.6% and 12.9%, respectively. In RMB terms our total revenue increased 5.7% and net profit decreased 5.5%, respectively.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Recent Developments </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">The Contributions</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Subject to the terms and conditions of the Business Combination Agreement, at the Effective Time, (a) GNI USA will contribute all of the CPI Ordinary Shares it holds immediately prior to the Effective Time to Catalyst in exchange for 688,850,101 shares of Catalyst Common Stock, (b) GNI USA will contribute all of the ordinary shares of Further Challenger it holds immediately prior to the Effective Time to Catalyst in exchange for 264,971,695 shares of Catalyst Common Stock and (c) each Minority Holder will contribute 100% of the interest he or she holds in his or her respective Entity to Catalyst in exchange for an aggregate of 156,954,428 shares of Catalyst Common Stock in the amounts set forth on an annex to the Business Combination Agreement. At the election of GNI USA or any Minority Holder, GNI USA or such Minority Holder shall be issued shares of Catalyst Convertible Preferred Stock in lieu of some or all of the shares of Catalyst Common Stock GNI USA or such Minority Holder is entitled to receive. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Immediately after the Contributions, Catalyst stockholders as of immediately prior to the Contributions are expected to own approximately 2.5% of the outstanding shares of common stock of the combined company, GNI USA is expected to own approximately 85.2% of the outstanding shares of the combined company and the Minority Holders are expected to own approximately 12.3% of the outstanding shares of the combined company, in each case, assuming </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">285<br></div></div></div>
<!--End Page 296-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 297-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_118-mda02_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">conversion of the Catalyst Convertible Preferred Stock, and the combined company will own the F351&#160;Assets and an approximately 69.7% indirect controlling interest of the combined company.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Business Impact of the COVID-19 Pandemic </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Since late 2019, the outbreak of a novel strain of coronavirus causing coronavirus disease 2019 (COVID-19) has materially and adversely affected the global economy. During the early phases of COVID-19 outbreak, the governmental restrictive measures resulted in significantly reduced mobility of our employees, causing most to work remotely. We implemented various precautionary measures and adjusted our employees&#8217; work arrangements in accordance with the relevant regulations and policies, which allowed us to maintain a sufficient number of personnel to work on-site and continue our research and development activities. Since February 2020, all of our facilities have resumed normal operations. Nevertheless, the outbreak and continued impact of COVID-19 still caused delays in the research and development of Hydronidone and F573, because the governmental anti-epidemic measures resulted in limitations on our ability to fully devote human resources to our operations, freely travel to clinical trial sites and efficiently test and improve production technologies to facilitate optimization of our chemical, manufacturing and control (including production process, impurity research, quality research and stability research) compared to the pre-COVID-19 era. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Since late July 2021, COVID-19 has recurred in the form of the Delta variant in the PRC and overseas and since November 2021, another variant designated as Omicron has also been discovered in many cases around the globe (the &#8220;Recurrences&#8221;). The Recurrences did not have any material impact on our sales and marketing efforts and research and development activities. For more information regarding the risks related to COVID-19, see the section entitled &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; beginning on page <a href="#tRF">34</a> of this proxy statement.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Components of Our Results of Operations </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Revenue</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our revenues have been generated from the sales of drug products, including ETUARY and generic drugs, and the license of intellectual property related to transferring API technologies on omeprazole sodium enteric-coated, one of our generic drugs.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Drug Product Sales</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We generate revenue through sales of ETUARY and certain generic drugs. We consider our generic drugs as cash flow generating assets until the approval for the respective drug expires, and we do not expect to further expand our R&amp;D or commercialization efforts thereon afterwards. In years ended December 31, 2021 and 2022, our sales from generic drugs were $1.6 million and $1.8 million, respectively, accounting for 1.8% and 1.8% of the total revenue of the corresponding period. For the three months ended March 31, 2023 and 2022, our sales from generic drugs were $0.4 million and $0.3 million, respectively, accounting for 1.6% and 1.2% of the total revenue of the corresponding period. In line with the common practice in the PRC pharmaceutical industry and our sales strategy, our generic drugs are marketed and promoted by third-party distributors. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As we continue to expand in the IPF market, we expect revenue to increase as physicians continue to adopt ETUARY as a method of treatment. As discussed in the &#8220;<font style="font-style: italic;">Selling Expenses</font>&#8221; section below, a significant portion of our efforts and resources are allocated to our sales team and distribution network in order to expand our service to more patients. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our in-house sales and marketing teams market and promote ETUARY to the outlets including hospitals and other medical institutions as well as pharmacies mainly by way of academic promotion activities. From time to time, we also engage third-party promotion service providers to facilitate our marketing activities. We sell our products through third-party distributors, who purchase ETUARY from us and then resell to the outlets, where patients buy ETUARY with physician prescriptions.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">286<br></div></div></div>
<!--End Page 297-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 298-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_118-mda02_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">During the years ended December 31, 2021 and 2022, distributors were our direct customers, and sales to distributors accounted for 100% of our revenue from ETUARY. Our distributors then sell ETUARY to the outlets, including hospitals and other medical institutions as well as pharmacies. ETUARY has been listed as a Category B drug in the NRDL since 2017. The following diagram illustrates our relationship with distributors, hospitals, pharmacies and patients:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 184px; width: 497px;" src="ny20006478x8_graphic07.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In 2021 and 2022, the total revenue generated from our five largest customers on a group basis amounted to approximately $68.8 million and $78.3 million, respectively, representing 77.8% and 76.4%, respectively, of our revenue in each of the corresponding year. Meanwhile, the largest customer group accounted for 47.9% and 47.6%, respectively, of our revenue in 2021 and 2022. For the three months ended March 31, 2023 and 2022, the revenue generated from the largest customer group accounted for 49.7% and 48.4%, respectively, of our total revenue in the corresponding periods. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Many of our distributors are members of large pharmaceutical distributor groups in the PRC. In particular, sales derived from subsidiaries of Sinopharm Group Co. Ltd. (collectively with its subsidiaries, the &#8220;Sinopharm Group&#8221;) accounted for 47.9% and 47.6%, respectively, of our total sales in 2021 and 2022, and 49.7% and 48.4% of our total sales in the three months ended March 31, 2023 and 2022, respectively; see &#8220;<font style="font-style: italic;">Risk Factors&#8212;Risks Related to </font><font style="font-style: italic;">BC&#8212;Risks Relating to BC&#8217;s Financial Position and Need for Additional Capital&#8212;</font><font style="font-style: italic;">BC&#8217;s five largest customers </font><font style="font-style: italic;">accounted for a substantial amount of BC&#8217;s revenue during the years ended December 31, 2021 and 2022, and three </font><font style="font-style: italic;">months ended March 31, 2023, which subjects BC to concentration risks</font>&#8221; in this proxy statement. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">ETUARY has been included in the NRDL as a Part B drug since 2017 and therefore is entitled to partial reimbursement of the purchase price and patients are required to pay the remainder of the purchase price. Our selling price (<font style="font-style: italic;">i.e.</font>, ex-factory price charged to distributors and certain pharmacies) is set at a lower level than the ultimate purchase price. The difference between our selling price and the ultimate purchase price would allow reasonable profit margin of the distributors and retail pharmacies. We also set the selling price range of our products that are charged by our distributors to their end-customers in the distribution agreements, which is equal to the ultimate purchase price (<font style="font-style: italic;">i.e.</font>, approximately $104 or $106 per bottle) and which remained the same level since its launch in 2014 up to March 1, 2023. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">License of Intellectual Property</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We license intellectual property related to API technologies on omeprazole sodium enteric-coated to Fu Fang Chuan Gui Tincture. Revenue from licensing intellectual property is recognized when the control of the right to use of the license is transferred to the customer. Milestone payments, which are included in the transaction price to the extent that it is highly probable that a significant reversal of accumulative revenue recognized will not occur, represent a form of variable consideration when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes milestone payments, we evaluates whether the milestones are considered highly probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the control of the Company, such as regulatory approvals, are not considered highly probable of being achieved until those approvals are received. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">287<br></div></div></div>
<!--End Page 298-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 299-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_118-mda02_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Cost of Sales</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Cost of sales primarily consists of (i)&#160;raw material costs; (ii)&#160;staff costs for production employees; (iii)&#160;depreciation and amortization related to plants and equipment and intangible assets used in production; (iv)&#160;taxes and surcharges; (v)&#160;transportation costs; and (vi)&#160;miscellaneous.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16pt; margin-left: 0pt; text-align: left;">Raw Material Costs and Suppliers</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Raw material costs consist of costs for the purchase of the compounds required to create our drug products and materials related thereto. We expect our raw material costs as a percentage of drug product sales to be stable in the future.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">During the years ended December 31, 2021 and 2022, fluctuations in raw materials costs have not had a material impact on our results of operations or gross profit margin. For 2021 and 2022, purchases from our five largest suppliers in aggregate accounted for 16.5% and 16.3% of our total purchases (including value added tax), respectively and purchases from our largest supplier accounted for 5.6% and 5.0% of our total purchases for the same periods (including value added tax), respectively. During the three months ended March 31, 2022 and 2023, purchases from our five largest suppliers in the aggregate accounted for 24.2% and 17.3% of our total purchases (including value added tax), respectively, and purchases from our largest supplier accounted for 10.8% and 6.5% of our total purchases for the same periods (including value added tax), respectively.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16pt; margin-left: 0pt; text-align: left;">Staff Costs</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Staff costs primarily consist of salaries and benefits for our production staff. Staff costs are impacted by the average social wage and benefits levels, which we expect to increase in the future.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16pt; margin-left: 0pt; text-align: left;">Depreciation and Amortization</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Depreciation and amortization is comprised of machinery, buildings, capitalized development costs and various machinery equipment and intellectual property. We expect expenses particularly related to depreciation to increase moderately as we continue to invest in our production capabilities and accommodate the expected future increase in drug product sales.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Selling, General and Administrative Expenses</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Selling Expenses</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Selling expenses primarily relate to sales of ETUARY and consist of conference expenses incurred from hosting academic conferences, seminars and symposia; promotional expenses associated with market education on ETUARY for its use in hospitals; and staff costs primarily consisting of salaries and benefits for our in-house marketing and promotion staff. The IPF market in China is expanding and we plan to increase investment in doctor education and market awareness, which we expect will result in greater patient market share.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">General and Administrative Expenses</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">General and administrative expenses consist of (i)&#160;accounting, IT, legal, administrative, and other internal service staff costs; (ii)&#160;share-based compensation representing share options granted to our functional employees; (iii)&#160;professional service fees, primarily for legal and accounting services; and (iv)&#160;other miscellaneous expenses.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our general and administrative expenses will decrease in the near future because we incurred one-time professional service fees during our previously contemplated initial public offering process.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Research and Development Expenses (R&amp;D)</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our R&amp;D expenses consist of (i)&#160;R&amp;D department staff costs, (ii)&#160;materials and utilities costs, (iii)&#160;pre-clinical research costs, (iv)&#160;clinical trial costs, (v)&#160;intellectual property costs associated with our acquisition of intellectual property rights, and (vi)&#160;share-based compensation for research and development staff. The R&amp;D expenses represent our development expenses in pre-clinical and clinical research. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our efforts are focused on adding indications for ETUARY and Hydronidone. The number of patients enrolled in clinical trials and the speed of patient enrollment are the key factors that impact our R&amp;D costs. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">288<br></div></div></div>
<!--End Page 299-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 300-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_118-mda02_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">We expect our R&amp;D costs will continue to increase for the foreseeable future as we enroll more patients in our clinical trials and increase R&amp;D activities. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Results of Operations </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">The following table summarizes our results of operations for the periods presented (in millions):</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.26%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 14.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Ended March 31,</div></td><td class="gutter" style="width: 1.26%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.26%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 12.64%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change</div></td><td class="gutter" style="width: 1.26%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.26%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 13.91%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31,</div></td><td class="gutter" style="width: 1.26%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.26%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 13.35%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change</div></td></tr><tr class="header"><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.26%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.86%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023</div></td><td class="gutter" style="width: 1.26%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.26%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.78%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.26%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.26%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.32%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dollars</div></td><td class="gutter" style="width: 1.26%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.26%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">%</div></td><td class="gutter" style="width: 1.26%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.26%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.26%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.26%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td><td class="gutter" style="width: 1.26%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.26%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.32%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dollars</div></td><td class="gutter" style="width: 1.26%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.26%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">%</div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Revenue<font style="padding-left: 0.51pt;"></font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><font style="padding-left: 8.33pt;">24.6</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><font style="padding-left: 7.96pt;">25.0</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt;">(0.4)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 6.67pt;">(1.6)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$102.5</div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 3.33pt;">88.5</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;">$14.0</div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">15.8</font></div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cost of Sales<font style="padding-left: 1.08pt;"></font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><font style="padding-left: 10pt;">(1.1)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><font style="padding-left: 9.63pt;">(1.2)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 8.33pt;">0.1</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 6.67pt;">(8.3)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 11.67pt;">(4.5)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">(4.0)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;"><font style="padding-left: 6.67pt;">(0.5)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">12.5</font></div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gross Profit<font style="padding-left: 1.08pt;"></font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><font style="padding-left: 8.33pt;">23.5</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><font style="padding-left: 7.96pt;">23.8</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt;">(0.3)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 6.67pt;">(1.3)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">98.0</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">84.5</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;"><font style="padding-left: 5pt;">13.5</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">16.0</font></div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other Income and Gains<font style="padding-left: 4.99pt;"></font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><font style="padding-left: 13.33pt;">0.2</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><font style="padding-left: 12.96pt;">0.1</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 8.33pt;">0.1</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">100.0</div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15pt;">1.6</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.33pt;">0.8</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;"><font style="padding-left: 10pt;">0.8</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt;">100.0</font></div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and Development Expenses<font style="padding-left: 2.79pt;"></font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><font style="padding-left: 10pt;">(1.6)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><font style="padding-left: 9.63pt;">(2.1)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 8.33pt;">0.5</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 1.67pt;">(23.8)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 11.67pt;">(8.5)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">(7.2)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;"><font style="padding-left: 6.67pt;">(1.3)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">18.1</font></div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Selling Expenses<font style="padding-left: 1.07pt;"></font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><font style="padding-left: 5pt;">(12.8)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><font style="padding-left: 5pt;">(11.3)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt;">(1.5)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">13.3</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.67pt;">(52.6)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">(44.1)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;"><font style="padding-left: 6.67pt;">(8.5)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">19.3</font></div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and Administrative Expenses<font style="padding-left: 2.22pt;"></font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><font style="padding-left: 10pt;">(1.9)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><font style="padding-left: 9.63pt;">(2.4)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 8.33pt;">0.5</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 1.67pt;">(20.8)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 11.67pt;">(8.9)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">(3.6)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;"><font style="padding-left: 6.67pt;">(5.3)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt;">147.2</font></div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other Expenses<font style="padding-left: 1.64pt;"></font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><font style="padding-left: 10pt;">(0.3)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><font style="padding-left: 9.63pt;">(0.1)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt;">(0.2)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">200.0</div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 11.67pt;">(1.2)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">(1.0)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;"><font style="padding-left: 6.67pt;">(0.2)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">20.0</font></div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Finance Costs<font style="padding-left: 3.3pt;"></font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><font style="padding-left: 15.46pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 10.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">(0.1)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;"><font style="padding-left: 10pt;">0.1</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(100.0)</div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Profit before Tax<font style="padding-left: 0.86pt;"></font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><font style="padding-left: 13.33pt;">7.1</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><font style="padding-left: 12.96pt;">8.0</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt;">(0.9)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 2.04pt;">(1</font>1.3)</div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">28.4</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">29.3</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;"><font style="padding-left: 6.67pt;">(0.9)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">(2.7)</font></div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income Tax Expense<font style="padding-left: 0.3pt;"></font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><font style="padding-left: 10pt;">(1.7)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><font style="padding-left: 9.63pt;">(1.8)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 8.33pt;">0.1</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 6.67pt;">(5.6)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 11.67pt;">(5.9)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">(6.1)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;"><font style="padding-left: 10pt;">0.2</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">(3.3)</font></div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net Profit<font style="padding-left: 4.96pt;"></font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;">$<font style="padding-left: 8.33pt;">5.4</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;">$<font style="padding-left: 7.96pt;">6.2</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;">$ (0.8)</div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 1.67pt;">(12.9)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 5pt;">22.5</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 3.33pt;">23.2</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;">$<font style="padding-left: 1.67pt;">(0.7)</font></div></td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.26%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">(3.0)</font></div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Comparison of the Three Months Ended March 31, 2023 and 2022</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Revenues</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Revenue was $24.6 million for the three months ended March 31, 2023, a decrease of $0.4 million, compared to $25.0&#160;million for the three months ended March 31, 2022. In RMB terms, revenue increased by 5.7% for the three months ended March 31, 2023 as compared to the same period in 2022. Excluding the foreign exchange rate influence, the increase was primarily due to an increase in the sales volume of ETUARY of 13,370 bottles. This reflects the strong market demand in the first quarter of 2023 compared with the same period last year, and our efforts to enhance our sales and marketing capabilities.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The drug products we sell consist of ETUARY and certain generic drugs. We consider our generic drugs as cash flow generating assets until the approval for the respective drug expires, and we do not expect to further expand our R&amp;D or commercialization efforts thereon afterwards. A breakdown of revenue by products is set forth in the following table (in millions):</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.86%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 18.26%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31,</div></td><td class="gutter" style="width: 1.86%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.86%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 12.77%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.86%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.27%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023</div></td><td class="gutter" style="width: 1.86%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.86%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.27%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.86%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.86%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.32%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dollars</div></td><td class="gutter" style="width: 1.86%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.86%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">%</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ETUARY<font style="padding-left: 0.5pt;"></font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.77pt; text-align: left;"><font style="padding-left: 5pt;">24.</font>2</div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.76pt; text-align: left;"><font style="padding-left: 5pt;">24.7</font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt;">(0.</font>5)</div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 1.67pt;">(</font>2.0)</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Generic Drugs<font style="padding-left: 1.09pt;"></font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.77pt; text-align: left;"><font style="padding-left: 10pt;">0.</font>4</div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.76pt; text-align: left;"><font style="padding-left: 10pt;">0.3</font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 8.33pt;">0.1</font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">33.3</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="padding-left: 0.09pt;"></font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.77pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">$24.6</font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.76pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">$25.0</font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 20.83pt;">$(0.4</font><font style="min-width: 20.83pt;">)</font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 3pt double #000000; min-width: 17.5pt;">(1.6</font><font style="min-width: 17.5pt;">)</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table sets forth the average selling price and sales volume of ETUARY in the three months ended March 31, 2023 and 2022:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="10" style="width: 36%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div></td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.93%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.41%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 16.9%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023 </div></td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 16.9%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022 </div></td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.93%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.41%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.95%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">selling <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">price </div></td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.73%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Sales <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">volume </div></td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.95%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">selling <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">price </div></td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.73%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Sales <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">volume </div></td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.93%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">% change <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">selling price </div></td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.41%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">% change <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in sales <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">volume </div></td></tr><tr class="header"><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.95%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">$ </div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.73%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Bottles &#8216;000 </div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.95%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">$ </div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.73%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Bottles &#8216;000 </div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.93%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.41%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ETUARY <font style="padding-left: 1.54pt;"></font></div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;">91.8 </div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.73%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.93pt; text-align: left;">264 </div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;">98.4 </div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.73%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.93pt; text-align: left;">251 </div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.93%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.96pt; text-align: left;">(6.7) </div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.08pt; text-align: left;">5.2</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">289<br></div></div></div>
<!--End Page 300-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 301-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_118-mda02_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Cost of Sales</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table summarizes the period-over-period changes in the cost of sales for the periods presented (in millions): </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 15.91%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Ended March 31,</div></td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 14.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.82%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023</div></td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.82%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.32%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dollars</div></td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.45%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">% </div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Raw Materials<font style="padding-left: 1.09pt;"></font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.88pt; text-align: left;"><font style="padding-left: 5pt;">0.6</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.88pt; text-align: left;"><font style="padding-left: 5pt;">0.6</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 10.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Production Employees<font style="padding-left: 3.85pt;"></font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.88pt; text-align: left;"><font style="padding-left: 5pt;">0.2</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.88pt; text-align: left;"><font style="padding-left: 5pt;">0.2</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 10.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Taxes and Surcharges<font style="padding-left: 1.98pt;"></font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.88pt; text-align: left;"><font style="padding-left: 5pt;">0.1</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.88pt; text-align: left;"><font style="padding-left: 5pt;">0.1</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 10.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Miscellaneous<font style="padding-left: 2.74pt;"></font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.88pt; text-align: left;"><font style="padding-left: 5pt;">0.2</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.88pt; text-align: left;"><font style="padding-left: 5pt;">0.3</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt;">(0.1)</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(33.3)</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Cost of Sales<font style="padding-left: 2.34pt;"></font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.88pt; text-align: left;">$1.1</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.88pt; text-align: left;">$1.2</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;">$(0.1)</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">(8.3)</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Costs of sales were $1.1 million for the three months ended March 31, 2023, a decrease of $0.1 million compared to $1.2 million for the three months ended March 31, 2022. In RMB terms, costs of sales increased by 1.4% for the three months ended March 31, 2023 as compared to the same period in 2022.The increase in RMB terms is materially consistent with the increase in volume of net product sales. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Gross Profit and Gross Profit Margin</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our gross profit represents our revenue less our cost of sales, and our gross profit margin represents our gross profit as a percentage of our revenue. Our gross profit amounted to $23.5 million and $23.8 million for the three months ended March 31, 2023 and 2022, respectively, while our gross profit margin reached 95.5% and 95.2% during the same periods. In RMB terms, our gross profit increased by 6.0% for the three months ended March 31, 2023 as compared to the same period in 2022. Specifically, the following table sets forth the breakdown of gross profit from sales of drug products in absolute amounts and gross profit margin in percentages by product type for the periods indicated:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="10" style="width: 41.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March 31,</div></td></tr><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.85%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023</div></td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.85%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td></tr><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross profit</div></td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross profit<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">margin</div></td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross profit</div></td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross profit<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">margin</div></td></tr><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dollars</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">%</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dollars</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">%</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ETUARY<font style="padding-left: 1.5pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.71pt; text-align: left;"><font style="padding-left: 5pt;">23.4</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.21pt; text-align: left;">96.7</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.71pt; text-align: left;"><font style="padding-left: 5pt;">23.7</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.21pt; text-align: left;">96.0</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Generic Drugs<font style="padding-left: 2.09pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.71pt; text-align: left;"><font style="padding-left: 10pt;">0.1</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.21pt; text-align: left;"><font style="padding-left: 5pt;">3.5</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.71pt; text-align: left;"><font style="padding-left: 10pt;">0.1</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.21pt; text-align: left;"><font style="padding-left: 5pt;">6.7</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">TOTAL<font style="padding-left: 4.71pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.71pt; text-align: left;">$23.5</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.21pt; text-align: left;">95.5</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.71pt; text-align: left;">$23.8</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.21pt; text-align: left;">95.2</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our gross profit margin levels are high due to our mature technology and significant cost reduction due to the scale effect. We believe that our gross margin rate is within a reasonable range.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our gross margins have remained stable over the last two years and we believe they will remain relatively stable in the future. We expect no material favorable or unfavorable impact on revenues or gross profit margins.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The following table summarizes the gross-margin rate changes for the periods presented:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 12.82%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Three Months<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">March 31, </div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Revenue <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(ETUARY) <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(<font style="font-style: italic; font-weight: normal;">'000s</font><font style="font-weight: normal;">) </font></div></td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.3%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cost of sales <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(ETUARY) <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(<font style="font-style: italic; font-weight: normal;">'000s</font><font style="font-weight: normal;">) </font></div></td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.44%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Sales quantity <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(<font style="font-style: italic; font-weight: normal;">Bottles</font><font style="font-weight: normal;">) </font></div></td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.45%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unit selling <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">price </div></td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.82%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unit cost </div></td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.82%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">margin <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">rate </div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2023 <br></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.15pt; text-align: left;">$24,223 </div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.76pt; text-align: left;">$809 </div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.44%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.19pt; text-align: left;">263,940 </div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.52pt; text-align: left;">$91.8 </div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.25pt; text-align: left;">$3.1 </div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.25pt; text-align: left;">96.7% </div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2022 <br></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.15pt; text-align: left;">$24,653 </div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.76pt; text-align: left;">$977 </div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.44%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.19pt; text-align: left;">250,570 </div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.52pt; text-align: left;">$98.4 </div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.25pt; text-align: left;">$3.9 </div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.25pt; text-align: left;">96.0%</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">However, if the scope of the centralized volume-based procurement is expanded in the future to include ETUARY or our other drug candidates, if commercialized, it may cause their retail prices to decrease, which would result in a material negative impact on our revenues and gross margins. For more detail, see &#8220;<font style="font-style: italic;">Risk Factors&#8212;Risks Related to </font><font style="font-style: italic;">BC&#8212;Risks Relating to the Research and Development and Sales and Distribution of BC&#8217;s Drugs and Drug </font><font style="font-style: italic;">Candidates&#8212;The policies of centralized volume-based procurement set by the PRC government may cover BC&#8217;s </font><font style="font-style: italic;">products in the future, and the prices of BC&#8217;s products may decrease, which in turn may have a material adverse </font><font style="font-style: italic;">impact on BC&#8217;s revenue, financial condition and results of operation.</font>&#8221;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">290<br></div></div></div>
<!--End Page 301-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 302-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_118-mda02_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Research and Development Expenses</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table summarizes the period-over-period changes in R&amp;D expenses for the periods presented (in millions):</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 17.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 31,</div></td><td class="gutter" style="width: 1.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 14.11%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.27%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023</div></td><td class="gutter" style="width: 1.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.27%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.32%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dollars</div></td><td class="gutter" style="width: 1.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">%</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">R&amp;D Staff<font style="padding-left: 1.25pt;"></font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.26pt; text-align: left;"><font style="padding-left: 5pt;">0.5</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.27pt; text-align: left;"><font style="padding-left: 5pt;">0.5</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 10.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Materials and Utilities<font style="padding-left: 4.43pt;"></font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.26pt; text-align: left;"><font style="padding-left: 5pt;">0.6</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.27pt; text-align: left;"><font style="padding-left: 5pt;">0.8</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt;">(0.2)</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">(</font>25.0)</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pre-clinical Research<font style="padding-left: 4.43pt;"></font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.26pt; text-align: left;"><font style="padding-left: 5pt;">0.2</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.27pt; text-align: left;"><font style="padding-left: 5pt;">0.2</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 10.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Clinical Trials<font style="padding-left: 2.71pt;"></font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.26pt; text-align: left;"><font style="padding-left: 5pt;">0.1</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.27pt; text-align: left;"><font style="padding-left: 5pt;">0.4</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt;">(0.3)</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">(</font>75.0)</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Intellectual Property<font style="padding-left: 2.75pt;"></font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.26pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.27pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 10.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation and Amortization<font style="padding-left: 4.98pt;"></font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.26pt; text-align: left;"><font style="padding-left: 5pt;">0.1</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.27pt; text-align: left;"><font style="padding-left: 5pt;">0.1</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 10.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share-Based Compensation<font style="padding-left: 3.87pt;"></font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.26pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.27pt; text-align: left;"><font style="padding-left: 5pt;">0.1</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt;">(0.1)</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(100.0)</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Others<font style="padding-left: 3.85pt;"></font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.26pt; text-align: left;"><font style="padding-left: 5pt;">0.1</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.27pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 8.33pt;">0.1</font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">100.0</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total R&amp;D Expenses<font style="padding-left: 4pt;"></font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.26pt; text-align: left;">$1.6</div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.27pt; text-align: left;">$2.1</div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;">$ (0.5)</div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">(23.8)</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">R&amp;D expenses were $1.6 million for the three months ended March 31, 2023, a decrease of $0.5 million compared to $2.1 for the three months ended March 31, 2022. This decrease was primarily due to decrease in clinical trials expense and materials used.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Selling Expenses</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table summarizes the period-over-period changes in selling expenses for the periods presented (in millions):</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.93%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 17.83%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three months ended<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31,</div></td><td class="gutter" style="width: 1.93%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.93%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 12.91%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.93%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023</div></td><td class="gutter" style="width: 1.93%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.93%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.95%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.93%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.93%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.32%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dollars</div></td><td class="gutter" style="width: 1.93%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.93%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">%</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Conferences<font style="padding-left: 0.53pt;"></font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.19pt; text-align: left;"><font style="padding-left: 10pt;">3.1</font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.18pt; text-align: left;"><font style="padding-left: 9.63pt;">2.7</font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.69pt; text-align: left;"><font style="padding-left: 5pt;">0.4</font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">14.8</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Promotional<font style="padding-left: 1.06pt;"></font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.19pt; text-align: left;"><font style="padding-left: 10pt;">5.1</font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.18pt; text-align: left;"><font style="padding-left: 9.63pt;">4.5</font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.69pt; text-align: left;"><font style="padding-left: 5pt;">0.6</font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">13.3</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketing and Sales Staff<font style="padding-left: 4.06pt;"></font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.19pt; text-align: left;"><font style="padding-left: 10pt;">4.1</font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.18pt; text-align: left;"><font style="padding-left: 9.63pt;">3.7</font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.69pt; text-align: left;"><font style="padding-left: 5pt;">0.4</font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10.8</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Travelling<font style="padding-left: 4.19pt;"></font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.19pt; text-align: left;"><font style="padding-left: 10pt;">0.3</font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.18pt; text-align: left;"><font style="padding-left: 9.63pt;">0.2</font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.69pt; text-align: left;"><font style="padding-left: 5pt;">0.1</font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">50.0</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Others<font style="padding-left: 3.85pt;"></font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.19pt; text-align: left;"><font style="padding-left: 10pt;">0.2</font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.18pt; text-align: left;"><font style="padding-left: 9.63pt;">0.2</font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.69pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Selling Expenses<font style="padding-left: 2.34pt;"></font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.19pt; text-align: left;">$12.8</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.18pt; text-align: left;">$11.3</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.69pt; text-align: left;">$1.5</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">13.3</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Selling expenses were $12.8 million for the three months ended March 31, 2023, an increase of $1.5 million compared to $11.3 million for the three months ended March 31, 2022. This increase was primarily due to increases in our staff costs, promotional activities and conferences.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">General and Administrative Expenses</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table summarizes the period-over-period changes in general and administrative expenses for the periods presented (in millions):</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.77%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 18.08%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 31,</div></td><td class="gutter" style="width: 1.77%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.77%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 13.31%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.77%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.27%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023</div></td><td class="gutter" style="width: 1.77%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.77%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.27%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.77%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.77%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.32%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dollars</div></td><td class="gutter" style="width: 1.77%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.77%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.45%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">%</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Staff<font style="padding-left: 1.24pt;"></font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.26pt; text-align: left;"><font style="padding-left: 5pt;">0.4</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.26pt; text-align: left;"><font style="padding-left: 5pt;">0.6</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt;">(0.2)</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(33.3)</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Professional Fees<font style="padding-left: 4.42pt;"></font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.26pt; text-align: left;"><font style="padding-left: 5pt;">1.1</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.26pt; text-align: left;"><font style="padding-left: 5pt;">1.0</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 8.33pt;">0.1</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt;">10.0</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share-Based Compensation<font style="padding-left: 3.87pt;"></font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.26pt; text-align: left;"><font style="padding-left: 5pt;">0.2</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.26pt; text-align: left;"><font style="padding-left: 5pt;">0.5</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt;">(0.3)</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(60.0)</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation and Amortization<font style="padding-left: 4.98pt;"></font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.26pt; text-align: left;"><font style="padding-left: 5pt;">0.1</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.26pt; text-align: left;"><font style="padding-left: 5pt;">0.1</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 10.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Miscellaneous<font style="padding-left: 2.74pt;"></font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.26pt; text-align: left;"><font style="padding-left: 5pt;">0.1</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.26pt; text-align: left;"><font style="padding-left: 5pt;">0.2</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt;">(0.1)</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(50.0)</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total General and Administrative Expenses<font style="padding-left: 3.48pt;"></font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.26pt; text-align: left;">$1.9</div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.26pt; text-align: left;">$2.4</div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;">$ (0.5)</div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(20.8)</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">291<br></div></div></div>
<!--End Page 302-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 303-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_118-mda02_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">General and Administrative Expenses were $1.9 million for the three months ended March 31, 2023, a decrease of $0.5 million compared to $2.4 million for the three months ended March 31, 2022. The decrease was primarily due to the decrease in recognition of share-based compensation expenses in accordance with the applicable IFRS schedule.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Comparison of the Years Ended December 31, 2022 and 2021</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Revenues</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: justify;">The following table summarizes the period-over-period changes in revenue for the periods presented (in millions):</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.37%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31,</div></td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 13.49%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.57%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.5%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.32%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dollars</div></td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">%</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sale of Pharmaceutical Products<font style="padding-left: 3.33pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.64pt; text-align: left;">$101.1</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.64pt; text-align: left;">$88.4</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;">$12.7</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">14.4</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">License of Intellectual Property<font style="padding-left: 1.67pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 9.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.64pt; text-align: left;"><font style="padding-left: 15pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">1.4</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 8.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.64pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">0.1</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">1.3</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">1419.8</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Revenue<font style="padding-left: 1.77pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.64pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">$102.5</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.64pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">$88.5</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">$14.0</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 3pt double #000000; min-width: 27.5pt;">15.8</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Revenue was $102.5&#160;million for the year ended December&#160;31, 2022, an increase of $14&#160;million, compared to $88.5&#160;million for the year ended December&#160;31, 2021. The increase was primarily due to an increase in the sales volume of ETUARY of $12.5&#160;million, despite temporary delays in sales due to the impact of the COVID-19 pandemic in China, beginning with reoccurrences in the first quarter of 2022, and an increase in revenue of $1.3&#160;million as a result of licensing our intellectual property. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The drug products we sold consist of ETUARY and certain generic drugs. We consider our generic drugs as cash flow generating assets until the approval for the respective drug expires, and we do not expect to further expand our R&amp;D or commercialization efforts thereon afterwards. A breakdown of revenue by products is set forth in the following table (in millions):</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.42%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.9%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31,</div></td><td class="gutter" style="width: 1.42%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.42%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 11.89%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.42%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.57%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.42%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.42%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.5%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td><td class="gutter" style="width: 1.42%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.42%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.32%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dollars</div></td><td class="gutter" style="width: 1.42%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.42%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">%</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ETUARY<font style="padding-left: 0.5pt;"></font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.64pt; text-align: left;">$<font style="padding-left: 5pt;">99.3</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.64pt; text-align: left;">$86.8</div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;">$12.5</div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">14.4</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Generic Drugs<font style="padding-left: 1.09pt;"></font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.64pt; text-align: left;"><font style="padding-left: 15pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">1.8</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.64pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">1.6</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">0.2</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 17.5pt;">1</font><font style="border-bottom: 1pt solid #000000; min-width: 17.5pt;">2</font><font style="border-bottom: 1pt solid #000000; min-width: 17.5pt;">.</font><font style="border-bottom: 1pt solid #000000; min-width: 17.5pt;">5</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="padding-left: 0.09pt;"></font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.64pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">$101.1</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.64pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">$88.4</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.19pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">$12.7</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 17.5pt;">14.4</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following table sets forth the average selling price and sales volume of ETUARY in 2021 and 2022:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="10" style="width: 36%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31,</div></td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.93%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.41%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 16.9%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 16.9%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.93%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.41%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.95%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">selling <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">price</div></td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.73%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Sales <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">volume</div></td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.95%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">selling <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">price</div></td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.73%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Sales <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">volume</div></td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.93%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">% change <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">selling price</div></td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.41%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">% change <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in sales <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">volume</div></td></tr><tr class="header"><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.95%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">$</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.73%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Bottles &#8216;000</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.95%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">$</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.73%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Bottles &#8216;000</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.93%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.41%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ETUARY<font style="padding-left: 4.5pt;"></font></div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;">92.6</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.73%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.18pt; text-align: left;">1,073</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;">95.6</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.73%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.93pt; text-align: left;">908</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.93%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.96pt; text-align: left;">(3.1)</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.58pt; text-align: left;">18.2</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Cost of Sales</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table summarizes the period-over-period changes in the cost of sales for the periods presented (in millions):</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.42%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.9%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31,</div></td><td class="gutter" style="width: 1.42%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.42%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 11.89%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.42%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.42%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.42%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td><td class="gutter" style="width: 1.42%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.42%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.32%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dollars</div></td><td class="gutter" style="width: 1.42%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.42%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">%</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Raw Materials<font style="padding-left: 1.09pt;"></font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;">$2.3</div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;">$2.0</div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;">$<font style="padding-left: 3.33pt;">0.3</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">15.0</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Production Employees<font style="padding-left: 3.85pt;"></font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;"><font style="padding-left: 5pt;">0.8</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;"><font style="padding-left: 5pt;">0.7</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 8.33pt;">0.1</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">14.3</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Taxes and Surcharges<font style="padding-left: 1.98pt;"></font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;"><font style="padding-left: 5pt;">0.6</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;"><font style="padding-left: 5pt;">0.5</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 8.33pt;">0.1</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">20.0</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Miscellaneous<font style="padding-left: 2.74pt;"></font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 17.5pt;">0.8</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 17.5pt;">0.8</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 20.83pt;">(0.0</font><font style="min-width: 20.83pt;">)</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 17.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Cost of Sales<font style="padding-left: 2.34pt;"></font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 17.5pt;">$4.5</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 17.5pt;">$4.0</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 20.83pt;">$</font><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 20.83pt;">0.5</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 17.5pt;">12.5</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">292<br></div></div></div>
<!--End Page 303-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 304-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_118-mda02_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Costs of sales were $4.5&#160;million for the year ended December&#160;31, 2022, an increase of $4.0&#160;million, compared to $0.5&#160;million for the year ended December&#160;31, 2021. The increase is materially consistent with the increase in volume of net product sales. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Gross Profit and Gross Profit Margin</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our gross profit represents our revenue less our cost of sales, and our gross profit margin represents our gross profit as a percentage of our revenue. Our gross profit amounted to $98.0&#160;million and $84.5&#160;million for the years ended December&#160;31, 2021 and 2022, respectively, while our gross profit margin reached 95.6% and 95.5% during the same years. Specifically, the following table sets forth the breakdown of gross profit from sales of drug products in absolute amounts and gross profit margin in percentages by product type for the years/periods indicated:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="10" style="width: 41.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31,</div></td></tr><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.85%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.85%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross profit</div></td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross profit <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">margin</div></td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross profit</div></td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross profit <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">margin</div></td></tr><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dollars</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">%</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dollars</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">%</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ETUARY<font style="padding-left: 1.5pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.71pt; text-align: left;"><font style="padding-left: 5pt;">96.3</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.21pt; text-align: left;">96.9</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.71pt; text-align: left;"><font style="padding-left: 5pt;">84.4</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.21pt; text-align: left;">97.2</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Generic Drugs<font style="padding-left: 2.09pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.71pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">0.3</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.21pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 17.5pt;">17.9</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.71pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">0.1</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.21pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 17.5pt;">1</font><font style="border-bottom: 1pt solid #000000; min-width: 17.5pt;">.</font><font style="border-bottom: 1pt solid #000000; min-width: 17.5pt;">9</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.71pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">$96.6</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.21pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 17.5pt;">95.5</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.71pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">$84.5</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.21pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 17.5pt;">95.5</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our gross profit margin levels are high due to our mature technology and significant cost reduction due to the scale effect. We believe that our gross margin rate is within a reasonable range.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our gross margins have remained stable over the last two years and are expected to remain relatively stable in the future. We expect no material favorable or unfavorable impact on revenues or gross profit margins.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The following table summarizes the gross-margin rate changes for the periods presented:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 12.82%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31, </div></td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Revenue <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(ETUARY) <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(<font style="font-style: italic; font-weight: normal;">'000s</font><font style="font-weight: normal;">) </font></div></td><td class="gutter" style="width: 1.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.05%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cost of goods sales <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(ETUARY) <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(<font style="font-style: italic; font-weight: normal;">'000s</font><font style="font-weight: normal;">) </font></div></td><td class="gutter" style="width: 1.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.44%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Sales quantity <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(<font style="font-style: italic; font-weight: normal;">Bottles</font><font style="font-weight: normal;">) </font></div></td><td class="gutter" style="width: 1.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.45%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unit selling <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">price </div></td><td class="gutter" style="width: 1.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.82%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unit cost </div></td><td class="gutter" style="width: 1.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.82%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">margin <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">rate </div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2021 <br></div></td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.15pt; text-align: left;">$86,835 </div></td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.05%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.12pt; text-align: left;">$2,459 </div></td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.44pt; text-align: left;"><font style="padding-left: 7.5pt;">907,858 </font></div></td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.02pt; text-align: left;">$95.6 </div></td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.74pt; text-align: left;">$2.70 </div></td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.25pt; text-align: left;">97.2% </div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2022 <br></div></td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.15pt; text-align: left;">$99,341 </div></td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.05%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.12pt; text-align: left;">$3,015 </div></td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.44pt; text-align: left;">1,072,740 </div></td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.02pt; text-align: left;">$92.60 </div></td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.74pt; text-align: left;">$2.81 </div></td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.25pt; text-align: left;">97.0%</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For the years ended December 31, 2022 and 2021, the unit cost of each bottle of ETUARY was approximately $2.80, of which the cost of raw materials accounts for approximately half, and the proportion of which has remained stable. The other 50% of the cost are labor and overhead, which are also relatively stable.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The market supply of major raw materials is sufficient to maintain stable procurement prices. The historical gross margin rates when ETUARY was first approved and sold are as below:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The gross margin rate has improved since 2014 and has remained stable in the most recent four years.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 208pt; margin-left: 130pt;"><tr class="header"><td style="width: 9.62%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Year</div></td><td class="gutter" style="width: 29.1%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 29.1%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 32.18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross Margin Rate</div></td></tr><tr><td style="width: 9.62%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2014</div></td><td class="gutter" style="width: 29.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 29.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 32.18%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.22pt; text-align: left;">88.35%</div></td></tr><tr><td style="width: 9.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2015</div></td><td class="gutter" style="width: 29.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 29.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 32.18%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.22pt; text-align: left;">92.46%</div></td></tr><tr><td style="width: 9.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2016</div></td><td class="gutter" style="width: 29.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 29.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 32.18%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.22pt; text-align: left;">94.68%</div></td></tr><tr><td style="width: 9.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2017</div></td><td class="gutter" style="width: 29.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 29.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 32.18%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.22pt; text-align: left;">94.74%</div></td></tr><tr><td style="width: 9.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2018</div></td><td class="gutter" style="width: 29.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 29.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 32.18%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.22pt; text-align: left;">94.94%</div></td></tr><tr><td style="width: 9.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2019</div></td><td class="gutter" style="width: 29.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 29.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 32.18%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.22pt; text-align: left;">96.28%</div></td></tr><tr><td style="width: 9.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2020</div></td><td class="gutter" style="width: 29.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 29.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 32.18%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.22pt; text-align: left;">96.04%</div></td></tr><tr><td style="width: 9.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2021</div></td><td class="gutter" style="width: 29.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 29.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 32.18%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.22pt; text-align: left;">97.17%</div></td></tr><tr><td style="width: 9.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2022</div></td><td class="gutter" style="width: 29.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 29.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 32.18%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.22pt; text-align: left;">96.96%</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">However, if the scope of the centralized volume-based procurement is expanded in the future to include ETUARY or our other drug candidates, if commercialized, it may cause their retail prices to decrease, which would result in a material negative impact on our revenues and gross margins. For more detail, see &#8220;<font style="font-style: italic;">Risk Factors&#8212;Risks Related to </font><font style="font-style: italic;">BC&#8212;Risks Relating to the Research and Development and Sales and Distribution of BC&#8217;s Drugs and Drug </font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">293<br></div></div></div>
<!--End Page 304-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 305-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_118-mda02_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Candidates&#8212;The policies of centralized volume-based procurement set by the PRC government may cover BC&#8217;s products in the future, and the prices of BC&#8217;s products may decrease, which in turn may have a material adverse impact on BC&#8217;s revenue, financial condition and results of operation<font style="font-style: normal;">.&#8221;</font></div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Research and Development Expenses</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: justify;">The following table summarizes the period-over-period changes in R&amp;D expenses for the periods presented (in millions):</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.19%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.46%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31,</div></td><td class="gutter" style="width: 1.19%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.19%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 13.23%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.19%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.19%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.19%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td><td class="gutter" style="width: 1.19%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.19%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.32%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dollars</div></td><td class="gutter" style="width: 1.19%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.19%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">%</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">R&amp;D Staff<font style="padding-left: 1.25pt;"></font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;">$2.2</div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;">$2.1</div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;">$<font style="padding-left: 3.33pt;">0.1</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.33pt;">4.8</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Materials and Utilities<font style="padding-left: 4.43pt;"></font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;"><font style="padding-left: 5pt;">2.8</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;"><font style="padding-left: 5pt;">1.9</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 8.33pt;">0.9</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">47.4</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pre-clinical Research<font style="padding-left: 4.43pt;"></font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;"><font style="padding-left: 5pt;">1.1</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;"><font style="padding-left: 5pt;">1.8</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt;">(0.7)</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">(38.9)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Clinical Trials<font style="padding-left: 2.71pt;"></font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;"><font style="padding-left: 5pt;">1.5</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;"><font style="padding-left: 5pt;">0.6</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 8.33pt;">0.9</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt;">150.0</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Intellectual Property<font style="padding-left: 2.75pt;"></font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;"><font style="padding-left: 5pt;">0.1</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt;">(0.1)</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(100.0)</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation and Amortization<font style="padding-left: 4.98pt;"></font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;"><font style="padding-left: 5pt;">0.5</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;"><font style="padding-left: 5pt;">0.5</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 10.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.33pt;">0.0</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share-Based Compensation<font style="padding-left: 3.87pt;"></font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;"><font style="padding-left: 5pt;">0.2</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 8.33pt;">0.2</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt;">100.0</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Others<font style="padding-left: 3.85pt;"></font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 17.5pt;">0.2</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 17.5pt;">0.2</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 10.83pt; border-bottom: 1pt solid #000000; min-width: 20.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">0.0</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total R&amp;D Expenses<font style="padding-left: 4pt;"></font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 17.5pt;">$8.5</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.39pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 17.5pt;">$7.2</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 20.83pt;">$</font><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 20.83pt;">1.3</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">18.1</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">R&amp;D expenses were $8.5&#160;million for the year ended December&#160;31, 2022, an increase of $1.3&#160;million, compared to $7.2&#160;million for the year ended December&#160;31, 2021. The increase was primarily due to an increase in clinical trial costs in line with our continued progress in conducting clinical trials for our drug candidates.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Selling Expenses</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: justify;">The following table summarizes the period-over-period changes in selling expenses for the periods presented (in millions):</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.72%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31,</div></td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 12.43%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.32%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dollars</div></td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.45%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">%</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Conferences<font style="padding-left: 0.53pt;"></font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;">$12.4</div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;">$10.6</div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;">$<font style="padding-left: 3.33pt;">1.8</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">17.0</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Promotional<font style="padding-left: 1.06pt;"></font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="padding-left: 5pt;">23.7</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="padding-left: 5pt;">18.1</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 8.33pt;">5.6</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">30.9</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketing and Sales Staff<font style="padding-left: 4.06pt;"></font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="padding-left: 5pt;">14.9</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="padding-left: 5pt;">13.3</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 8.33pt;">1.6</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">12.0</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Travelling<font style="padding-left: 4.19pt;"></font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="padding-left: 10pt;">0.6</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="padding-left: 10pt;">1.0</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt;">(0.4)</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">(40.0)</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Others<font style="padding-left: 3.85pt;"></font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">1.0</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">1.1</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 20.83pt;">(0.1</font><font style="min-width: 20.83pt;">)</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 20.83pt;">(9.1</font><font style="min-width: 20.83pt;">)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Selling Expenses<font style="padding-left: 2.34pt;"></font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">$52.6</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">$44.1</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 20.83pt;">$</font><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 20.83pt;">8.5</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 20.83pt;">19.3</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Selling expenses were $52.6&#160;million for the year ended December&#160;31, 2022, an increase of $8.5&#160;million, compared to $44.1&#160;million for the year ended December&#160;31, 2021. This increase was primarily due to increases in our staff costs, promotional activities and conferences.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">General and Administrative Expenses</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table summarizes the period-over-period changes in general and administrative expenses for the periods presented (in millions):</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31,</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 12.69%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.68%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.39%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.32%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dollars</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">%</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Staff<font style="padding-left: 1.24pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.55pt; text-align: left;">$2.9</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.55pt; text-align: left;">$<font style="padding-left: 3.33pt;">2.1</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;">$<font style="padding-left: 3.33pt;">0.8</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt;">38.1</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Professional Fees<font style="padding-left: 4.42pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.55pt; text-align: left;"><font style="padding-left: 5pt;">3.8</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.55pt; text-align: left;"><font style="padding-left: 8.33pt;">0.7</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 8.33pt;">3.1</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">442.9</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share-Based Compensation<font style="padding-left: 3.87pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.55pt; text-align: left;"><font style="padding-left: 5pt;">1.1</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.55pt; text-align: left;"><font style="padding-left: 5pt;">(0.2)</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 8.33pt;">1.3</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">100.0</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation and Amortization<font style="padding-left: 4.98pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.55pt; text-align: left;"><font style="padding-left: 5pt;">0.6</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.55pt; text-align: left;"><font style="padding-left: 8.33pt;">0.7</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt;">(0.1)</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 1.67pt;">(14.3)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Miscellaneous<font style="padding-left: 2.74pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.55pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 17.5pt;">0.5</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.55pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 20.83pt;">0.3</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 20.83pt;">0.2</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">66.7</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total General and Administrative Expenses<font style="padding-left: 3.48pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.55pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 17.5pt;">$8.9</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.55pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 20.83pt;">$</font><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 20.83pt;">3.6</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 20.83pt;">$</font><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 20.83pt;">5.3</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">147.2</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">294<br></div></div></div>
<!--End Page 305-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 306-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_118-mda02_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">General and Administrative Expenses were $8.9&#160;million for the year ended December&#160;31, 2022, an increase of $5.3&#160;million, compared to $3.6&#160;million for the year ended December&#160;31, 2021. The increase was primarily due to an increase in our professional service fees incurred in 2022 related to our previously contemplated initial public offering process and share-based compensation expenses.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Other Income (Expense), net</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Other Income was $0.4&#160;million for the year ended December&#160;31, 2022, an increase of $0.7&#160;million, compared to expense, net of $0.3&#160;million for the year ended December&#160;31, 2021. The increase was due to the increase of government grants in 2022. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Liquidity and Capital Resources </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Funding Requirements</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We believe that our available cash and cash equivalents as of the date of this proxy statement will be sufficient to fund our anticipated level of operations for at least the next 12 months. We expect to use cash flows from operations to meet our current and future financial obligations, including funding our operations, and capital expenditures. Our ability to make these payments depends on our future performance, which will be affected by financial, business, economic, regulatory and other factors, many of which we cannot control. Factors that may affect financing requirements include, but are not limited to:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the timing, progress, cost and results of our clinical trials, preclinical studies and other discovery and research and development activities;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the timing and outcome of, and costs involved in, seeking and obtaining marketing approvals for our products, and in maintaining quality systems standards for our products;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the timing of, and costs involved in, commercial activities, including product marketing, sales and distribution;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our ability to successfully commercialize and to obtain regulatory approval for, and successfully commercialize our other or future product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">increases or decreases in revenue from our marketed products, including decreases in revenue resulting from generic entrants or health epidemics or pandemics such as COVID-19;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the number and development requirements of other product candidates that we pursue;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to manufacture sufficient quantities of our products to meet expected demand;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the costs of preparing, filing, prosecuting, maintaining and enforcing any patent claims and other intellectual property rights, litigation costs and the results of litigation;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our ability to enter into collaboration, licensing or distribution arrangements and the terms and timing of these arrangements;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the potential need to expand our business, resulting in additional payroll and other overhead expenses;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the potential in-licensing of other products or technologies;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the emergence of competing technologies or other adverse market or technological developments; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the impacts of inflation and resulting cost increases.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Future capital requirements will also depend on the extent to which we acquire or invest in additional complementary businesses, products and technologies.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Sources of Liquidity</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We have financed our operations primarily through cash generated from our operating activities, and our primary use of cash is to fund our capital expenditures and operating expenses, which primarily consist of purchase of fixed assets and intangible assets, R&amp;D expenses, selling expenses and general and administrative expenses. Going forward, we believe that our liquidity requirements will be satisfied with cash flows generated from our operating activities. As </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">295<br></div></div></div>
<!--End Page 306-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 307-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_118-mda02_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">of December&#160;31, 2022, we had cash and cash equivalents of $23.5&#160;million. As of March 31, 2023, we had cash and cash equivalents of $26.5 million. Taking into account the financial resources available to us, we believe that we have sufficient working capital to meet our present requirements for the next 12&#160;months from the date of this proxy statement.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Cash Flows</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">The following table summarizes our cash flows for the periods set forth below (<font style="font-style: italic;">in millions</font>):</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 15.77%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Ended March 31,</div></td><td class="gutter" style="width: 2.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.06%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 14.45%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31,</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.06%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.96%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023</div></td><td class="gutter" style="width: 2.06%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.06%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.68%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 2.06%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.06%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 2.06%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.06%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash flow from operating activities<font style="padding-left: 0.02pt;"></font></div></td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.89pt; text-align: left;">$11.9</div></td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;">$<font style="padding-left: 3.33pt;">9.0</font></div></td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 3.33pt;">19.2</font></div></td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$20.5</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash flow used in investing activities<font style="padding-left: 1.13pt;"></font></div></td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.89pt; text-align: left;"><font style="padding-left: 6.3pt;">(9.0)</font></div></td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><font style="padding-left: 5pt;">(3.1)</font></div></td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">(19.1)</font></div></td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 6.67pt;">(8.1)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash flow used in financing activities<font style="padding-left: 0.02pt;"></font></div></td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.89pt; text-align: left;"><font style="padding-left: 6.3pt; border-bottom: 1pt solid #000000; min-width: 22.13pt;">(0.1</font><font style="min-width: 22.13pt;">)</font></div></td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 20.83pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 20.83pt;">0</font><font style="border-bottom: 1pt solid #000000; min-width: 20.83pt;">.1</font><font style="min-width: 20.83pt;">)</font></div></td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">(0.5</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">(6.7</font><font style="min-width: 22.5pt;">)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Effect of foreign exchange rate changes on cash and cash equivalents </div></td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.89pt; text-align: left;"><font style="padding-left: 9.63pt; border-bottom: 1pt solid #000000; min-width: 22.13pt;">0.2</font></div></td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 20.83pt;">0.1</font></div></td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">(2.2</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">0.5</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net increase (decrease) in cash and cash equivalents<font style="padding-left: 0.63pt;"></font></div></td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.13pt;">$</font><font style="padding-left: 4.63pt; border-bottom: 3pt double #000000; min-width: 22.13pt;">3.0</font></div></td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 20.83pt;">$</font><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 20.83pt;">5.9</font></div></td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 25.83pt;">$</font><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">(2.6</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.06%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">$</font><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 22.5pt;">6.2</font></div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Operating Activities</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Net cash flow from operating activities for the year ended December&#160;31, 2022 was $19.2&#160;million, and consisted of $28.4&#160;million from profit before tax, offset by $7.9&#160;million from increase of accounts receivable and $6.3&#160;million from income tax paid. The decrease in net cash flows from operating activities was $1.3&#160;million, and was primarily due to $8.4&#160;million in increased selling expenses, $5.3&#160;million in increased general and administrative expenses and $1.3&#160;million in increased research and development expenses offset by $13.9&#160;million increase in sales.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Net cash flow from operating activities for the year ended December&#160;31, 2021 was $20.5&#160;million, and consisted of $29.3&#160;million from profit before tax, offset by $2.4&#160;million from increase of inventory, $1.9&#160;million from increase of accounts receivable and $5.0&#160;million from income tax paid. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Net cash flow from operating activities for the three months ended March 31, 2023 was $11.9 million, and principally consisted of $7.1 million from profit before tax, $4.3 million from decrease of accounts receivable, and $0.5 million from decrease of inventory. The increase in net cash flows from operating activities was $2.9 million, and was primarily due to the impact of the COVID-19 epidemic at the end of 2022, because customers were unable to make timely payments in December 2022, resulting in delayed payments being made in the first quarter of 2023.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Net cash flow from operating activities for the three months ended March 31, 2022 was $9.0 million, and principally consisted of $7.9 million from profit before tax, and $2.3 million from increase in other payable and accruals, offset by $1.3 million from increase in deposits and other receivables. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Investing Activities</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">During the year ended December&#160;31, 2022, the net cash used in investing activities was $19.1&#160;million, and consisted of $5.1&#160;million purchase in property, plant and equipment, $6.5&#160;million purchase in intangible assets and $7.5&#160;million purchase of long-term bank deposits. The increase in net cash used in investing activities was $11.0&#160;million as compared with 2021, primarily as a result of (i)&#160;purchase of long-term bank deposit of $7.5&#160;million and (ii)&#160;increase in purchasing of property, plant and equipment of $4.0&#160;million.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">During the year ended December&#160;31, 2021, the net cash used in investing activities was $8.1&#160;million, and consisted of $1.1&#160;million purchase in property, plant and equipment and $7.2&#160;million purchase in intangible assets. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Net cash flow used in investing activities for the three months ended March 31, 2023 was $9.0 million, and consisted of (i) purchase of long-term bank deposit of $5.8 million, (ii) purchase of property, plant and equipment of $1.8&#160;million, and (iii) purchase of intangible assets of $1.4 million.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Net cash flow used in investing activities for the three months ended March 31, 2022 was $3.1 million, and consisted of $0.6 million purchase in property, plant and equipment and $2.5 million purchase in intangible assets.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">296<br></div></div></div>
<!--End Page 307-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 308-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_118-mda02_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Financing Activities</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">During the year ended December&#160;31, 2022, net cash used in financing activities was $0.5&#160;million. The decrease in net cash used in financing activities was $6.2&#160;million as compared with 2021, and was primarily as a result of repayment of bank loans in 2021.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Net cash flow used in operating activities for the three months ended March 31, 2023 was $0.1 million, and consisted of the payment of the principal portion and interest for lease liabilities.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Net cash flow used in financing activities for the three months ended March 31, 2022 was $0.1 million, and consisted of the payment of the principal portion and interest for lease liabilities.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Contractual Obligations and Commitments</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Operating Lease Obligations</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We lease office space for our corporate headquarters in Beijing, China under a lease that expires in June 2024. As of December&#160;31, 2022, undiscounted future minimum lease payments amounted to $0.7.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Capital commitments <font style="font-style: normal; font-weight: normal;">(in millions)</font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.57%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31,</div></td></tr><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Contracted, but not provided for:<br></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property, plant and equipment<font style="padding-left: 4.57pt;"></font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;">$<font style="padding-left: 5pt;">5.9</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;">$<font style="padding-left: 5pt;">0.2</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development<font style="padding-left: 3.1pt;"></font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">30.7</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">27.1</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="font-weight: normal;"> </font><font style="font-weight: normal; padding-left: 2.31pt;"></font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">$</font><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">36.6</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">$</font><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">27.</font><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">3</font></div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Off-Balance Sheet Arrangements </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Critical Accounting Policies and Significant Judgments and Estimates</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our consolidated financial statements are prepared in accordance with IFRS as issued by the IASB. The significant accounting policies and methods used in preparation of BC&#8217;s consolidated financial statements are described in Note&#160;2.4, <font style="font-style: italic;">Summary of Significant Accounting Policies</font>, in the <font style="font-style: italic;">Audited Financial Statements of Beijing Continent </font><font style="font-style: italic;">Pharmaceuticals Co., Ltd</font> to this proxy statement. The preparation of our consolidated financial statements requires us to make estimates and assumptions that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities at the date of our financial statements, and the reported amount of revenue and expenses during the reported periods. There can be no assurance that actual results will not differ from those estimates. We have identified certain estimates as critical to our business operations and the understanding of our results of operations. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Revenue from Contracts with Customers</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We applied the following judgment that significantly affects the determination of the amount and timing of revenue from contracts with customers. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16pt; margin-left: 0pt; text-align: left;">Determining the Method to Estimate Consideration Payable to a Customer </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Certain contracts for the sale of pharmaceutical products include certain sales rebates, which are incurred after the control rights of products are passed to distributors, and give rise to consideration payable to a customer. Since the exact amounts of the rebates are not finalized at the time of revenue recognition, we apply deductions from revenue based on our historical experience. There may be differences between the deductions and the actual settlements. In estimating consideration payable to a customer, we are required to use either the expected value method or the most likely amount method, depending on which method better predicts the amount of consideration to which it will be entitled.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We have determined that the most likely amount method is the appropriate method to use in estimating consideration payable to a customer.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">297<br></div></div></div>
<!--End Page 308-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 309-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_118-mda02_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Determining the Method to Estimate Variable Consideration and Assessing the Constraint for the Sale of Pharmaceutical Products</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Certain contracts for the sale of pharmaceutical products include the right to return products due to defects, which gives rise to variable consideration. In estimating variable consideration, we are required to use either the expected value method or the most likely amount method based on which method better predicts the amount of consideration to which it will be entitled. We determined that the expected value method is the appropriate method to use in estimating the variable consideration for the sale of pharmaceutical products with rights of return due to defective products given the large number of customer contracts that have similar characteristics.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Before including any amount of variable consideration in the transaction price, we consider whether the amount of variable consideration is constrained. We determined that the estimates of variable consideration are not constrained based on its historical experience, business forecast and the current economic conditions. In addition, the uncertainty on the variable consideration will be resolved within a short time frame.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 0pt; text-align: left;">Development Costs</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Development costs are capitalized at the end of each of the reporting periods in accordance with the accounting policy for research and development expenses. Determining the commencement date of the capitalization period requires our management to make assumptions regarding our intention to complete and our ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the project and the ability to measure reliably the expenditure during the development stage. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 0pt; text-align: left;">Impairment of Non-Financial Assets</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We assess whether there are any indicators of impairment for all non-financial assets at the end of each of the reporting periods. Product development in progress is tested for impairment annually and at other times when such an indicator exists. Other non-financial assets are tested for impairment when there are impairment indicators. An impairment exists when the carrying value of an asset or a cash-generating unit exceeds its recoverable amount, which is the higher of its fair value less costs of disposal and its value in use. The calculation of the fair value less costs of disposal is based on available data from binding sales transactions in an arm&#8217;s length transaction of similar assets or observable market prices less incremental costs for disposing of the asset. When value in use calculations are applied, management must estimate the expected future cash flows from the asset or cash-generating unit and choose a suitable discount rate in order to calculate the present value of those cash flows.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Recently Issued Accounting Pronouncements </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has not applied the following new and revised IFRSs, that have been issued but are not yet effective, in the financial statements.</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendments to IFRS 10 and IAS 28</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sale or Contribution of Assets between an Investor and its Associate or Joint Venture<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup><font style="font-style: normal;"> </font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">IFRS 17</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Insurance Contracts<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup><font style="font-style: normal;"> </font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendments to IFRS 17</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Insurance Contracts<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1, 3</sup><font style="font-style: normal;"> </font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendments to IAS 1</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Classification of Liabilities as Current or Non-current (the &#8220;2020 Amendments&#8221;)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4,5</sup><font style="font-style: normal;"> </font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendments to IAS 1</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-current Liabilities with Covenants (the &#8220;2022 Amendments&#8221;)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4</sup><font style="font-style: normal;"> </font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendments to IAS8</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Definition of Accounting Estimates<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup><font style="font-style: normal;"> </font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendments to IAS 1 and IFRS Practice Statement 2</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Disclosure of Accounting Policies<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup><font style="font-style: normal;"> </font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendments to IAS 12</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred Tax related to Assets and Liabilities arising from a Single Transaction<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup><font style="font-style: normal;"> </font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendments to IFRS 16</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease Liability in a Sale and Leaseback<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4</sup></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">1<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Effective for annual periods beginning on or after January&#160;1, 2023.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">2<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">No mandatory effective date yet determined but available for adoption.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">3<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">As a consequence of the amendments to IFRS 17 issued in June 2020, IFRS 4 was amended to extend the temporary exemption that permits insurers to apply IAS 39 rather than IFRS 9 for annual periods beginning before January&#160;1, 2023.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">298<br></div></div></div>
<!--End Page 309-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 310-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_118-mda02_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5.25pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">4<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Effective for annual periods beginning on or after January&#160;1, 2024.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">5<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">As a consequence of the 2022 Amendments, the effective date of the 2020 Amendments was deferred to annual periods beginning on or after January&#160;1, 2024.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We are in the process of making an assessment of the impact of these new and revised IFRSs upon initial application and has concluded that the adoption of them will not have a material impact on the our financial position and financial performance.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Quantitative and Qualitative Disclosures About Market Risks </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Foreign currency risk</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC mainly operates in Mainland China with transactions primarily settled in RMB. The foreign exchange risk arising from recognized assets and liabilities is considered to be minimal.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18pt; margin-left: 0pt; text-align: left;">Credit risk</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC trades only with recognized and creditworthy third parties. It is BC&#8217;s policy that all customers who wish to trade on credit terms are subject to credit verification procedures. In addition, balances of receivables are monitored on an ongoing basis and BC&#8217;s exposure to bad debts is not significant.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The credit risk of BC&#8217;s other financial assets, which comprise cash and bank balances, bank deposits and other receivables included in BC&#8217;s financial statements, arises from default of counterparty with a maximum exposure equal to the carrying amounts of these instruments.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Since BC trades only with recognized and creditworthy third parties, there is no requirement for collateral. For trade and other receivables, the credit quality of the counterparties is assessed by taking into account their financial position, credit history and other factors. Given the constant repayment history, BC is of the opinion that the risk of default by these counterparties is not significant.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">At the end of each reporting period, BC had certain concentrations of credit risk. As of December&#160;31, 2022 and 2021, $30,858.9 and $26,082.5, respectively, were deposited with various major reputable financial institutions located in the PRC. As of March 31, 2023 and 2022, $39,837.5 and $31,949.4, respectively, were deposited with various major reputable financial institutions located in the PRC. In May 2015, a new Deposit Insurance System (&#8220;DIS&#8221;) managed by the People&#8217;s Bank of China (&#8220;PBOC&#8221;) was implemented by the PRC government. Deposits in the licensed banks in mainland China are protected by DIS, up to a limit of approximately $71.8. In the event of bankruptcy of one of these financial institutions, BC may be unable to claim its deposits back in full. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of December&#160;31, 2022 and 2021, BC had trade receivables arising from product sales of $15,738.9 and $10,117.2, respectively. As of March 31, 2023 and 2022, BC had trade receivables arising from product sales of $12,600.8 and $10,706.2, respectively. BC monitors economic conditions to identify facts or circumstances that may indicate receivables are at risk of collection. As of December&#160;31, 2022 and 2021, BC's three largest customers contributed a total of 69.7% and 77.7% of trade receivables, respectively. As of March 31, 2023 and 2022, BC&#8217;s three largest customers contributed a total of 76.2% and 77.1% of trade receivables, respectively. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For the year ended December&#160;31, 2022, revenue contributed by BC's three largest customers represented 48.3%, 11.4% and 10.9% of pharmaceutical product revenue, respectively. For the three months ended March 31, 2023, revenue contributed by BC&#8217;s three largest customers represented 49.7%, 13.4% and 10.1% of pharmaceutical product revenue, respectively. For the year ended December&#160;31, 2021, revenue contributed by BC's three largest customers represented 48.0%, 12.0% and 10.9% of pharmaceutical product revenue, respectively. For the three months ended March 31, 2022, revenue contributed by BC&#8217;s three largest customers represented 48.4%, 12.5% and 10.8% of pharmaceutical product revenue, respectively. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The tables below show the credit quality and the maximum exposure to credit risk based on BC's credit policy, which is mainly based on past due information unless other information is available without undue cost or effort, and year-end staging classification as of December&#160;31, 2022 and 2021. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The amounts presented are gross carrying amounts for financial assets (in thousands). </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">As at December&#160;31, 2022 </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">299<br></div></div></div>
<!--End Page 310-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 311-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_118-mda02_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">12-month <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ECLs </div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 26.32%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Lifetime ECLs </div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stage 1 </div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stage 2 </div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stage 3 </div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Simplified <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">approach </div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade receivables <font style="padding-left: 3.89pt;"></font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$15,738.9 </div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$15,738.9 </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Debt investments at fair value through other comprehensive income <font style="padding-left: 1.87pt;"></font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">1</font>,521.6 </div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">1</font>,521.6 </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Financial assets included in prepayments, deposits and other receivables <font style="padding-left: 3.55pt;"></font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">976.2</font> </div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">976.2</font> </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and bank balances <font style="padding-left: 1.88pt;"></font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">23,464.4</font> </div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">23,464.4</font> </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Bank deposits <font style="padding-left: 2.96pt;"></font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 40pt;">7,394.5</font><font style="border-bottom: 1pt solid #000000; min-width: 40pt;"> </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 40pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 40pt;">7,394.5</font><font style="border-bottom: 1pt solid #000000; min-width: 40pt;"> </font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">$31,835.1</font><font style="border-bottom: 3pt double #000000; min-width: 40pt;"> </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">$17,260.5</font><font style="border-bottom: 3pt double #000000; min-width: 40pt;"> </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">$49,095.6</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 13.75pt; margin-left: 0pt; text-align: left;">As at December&#160;31, 2021 </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">12-month <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ECLs </div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 26.32%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Lifetime ECLs </div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stage 1 </div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stage 2 </div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stage 3 </div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Simplified <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">approach </div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade receivables <font style="padding-left: 3.89pt;"></font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 0.37pt;">10,117.2</font> </div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 0.37pt;">10,117.2</font> </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Debt investments at fair value through other comprehensive income <font style="padding-left: 1.87pt;"></font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">389.0</font> </div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">389.0</font> </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Financial assets included in prepayments, deposits and other receivables <font style="padding-left: 3.55pt;"></font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">872.8</font> </div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">872.8</font> </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and bank balances <font style="padding-left: 1.88pt;"></font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 40pt;">26,082.5</font><font style="border-bottom: 1pt solid #000000; min-width: 40pt;"> </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 40pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 40pt;">26,082.5</font><font style="border-bottom: 1pt solid #000000; min-width: 40pt;"> </font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">$26,955.3</font><font style="border-bottom: 3pt double #000000; min-width: 40pt;"> </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">$10,506.2</font><font style="border-bottom: 3pt double #000000; min-width: 40pt;"> </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">$37,461.5</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The tables below show the credit quality and the maximum exposure to credit risk based on BC's credit policy, which is mainly based on past due information unless other information is available without undue cost or effort, and periods-end staging classification as of March 31, 2023 and 2022. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">The amounts presented are gross carrying amounts for financial assets (in thousands).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">As at March 31, 2023 </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">12-month<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ECLs</div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 26.32%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Lifetime ECLs</div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stage 1</div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stage 2</div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stage 3</div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Simplified<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">approach</div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade receivables<font style="padding-left: 2.22pt;"></font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$12,600.8</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$12,600.8</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Debt investments at fair value through other comprehensive income<font style="padding-left: 0.2pt;"></font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">608.3</font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">608.3</font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Financial assets included in prepayments, deposits and other receivables<font style="padding-left: 1.88pt;"></font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">1,074.1</font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">1,074.1</font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and bank balances<font style="padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">26,459.2</font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">26,459.2</font> </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Bank deposits<font style="padding-left: 1.29pt;"></font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">13,378.2</font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">13,378.2</font> </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 0.37pt;">40,911.</font>5</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$13,209.1 </div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$54,120.6</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">300<br></div></div></div>
<!--End Page 311-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 312-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_118-mda02_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">As at March 31, 2022 </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">12-month<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ECLs</div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 26.32%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Lifetime ECLs</div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stage 1</div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stage 2</div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stage 3</div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Simplified<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">approach</div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade receivables<font style="padding-left: 2.22pt;"></font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$10,706.2</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$10,706.2</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Debt investments at fair value through other comprehensive income<font style="padding-left: 0.2pt;"></font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">332.7 </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">332.7</font> </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Financial assets included in prepayments, deposits and other receivables<font style="padding-left: 1.88pt;"></font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">937.7</font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">937.7</font> </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and bank balances<font style="padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">31,949.4 </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">31,949.4</font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$32,887.1 </div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 0.37pt;">&#8203;</font>11,038.9 </div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$43,926.0</div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Liquidity risk </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC&#8217;s policies are to maintain sufficient cash and bank balances and to have available funding through bank and other borrowings to meet its working capital requirements. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The maturity profile of BC&#8217;s financial liabilities as at the end of the reporting period, based on the contractual undiscounted payments, is as follows (in thousands): </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">As at December&#160;31, 2022 </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">On demand </div></td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.12%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Less than <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1&#160;year </div></td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1 to 2 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">years </div></td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.27%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2 to 5 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">years </div></td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.48%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade payables<font style="padding-left: 2.21pt;"></font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;">$<font style="padding-left: 7.5pt;">122.0</font> </div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.91pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.27%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.99pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 7.5pt;">122.0</font> </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Financial liabilities included in customers&#8217; deposits, other payables and accruals <font style="padding-left: 2.45pt;"></font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 5pt;">3,225.0</font> </div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.91pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.27%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.99pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">3,225.0</font> </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amounts due to related parties <font style="padding-left: 4.11pt;"></font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 12.87pt;">112.7</font> </div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.91pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.27%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.99pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.87pt;">112.7</font> </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities <font style="padding-left: 1.31pt;"></font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 25pt; border-bottom: 1pt solid #000000; min-width: 35pt;">&#8212; </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.91pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">510.7</font><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;"> </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">232.6</font><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;"> </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.27%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.99pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212; </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 35pt;">743.3</font><font style="border-bottom: 1pt solid #000000; min-width: 35pt;"> </font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35pt;">$3,459.7</font><font style="border-bottom: 3pt double #000000; min-width: 35pt;"> </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.91pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">$510.7</font><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;"> </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">$232.6</font><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;"> </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.27%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.99pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212; </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35pt;">$4,203.0</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As at December&#160;31, 2021 </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.88%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">On demand </div></td><td class="gutter" style="width: 1.88%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.88%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.12%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Less than <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1&#160;year </div></td><td class="gutter" style="width: 1.88%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.88%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1 to 2 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">years </div></td><td class="gutter" style="width: 1.88%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.88%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2 to 5 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">years </div></td><td class="gutter" style="width: 1.88%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.88%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.48%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade payables<font style="padding-left: 2.21pt;"></font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;">$<font style="padding-left: 7.5pt;">251.0</font> </div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.91pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 7.5pt;">251.0</font> </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Financial liabilities included in customers&#8217; deposits, other payables and accruals <font style="padding-left: 2.45pt;"></font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 5pt;">1,574.3</font> </div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.91pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">1</font>,574.3 </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amounts due to related parties <font style="padding-left: 4.11pt;"></font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 12.5pt;">107.1</font> </div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.91pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">107.1</font> </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities <font style="padding-left: 1.31pt;"></font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 25pt; border-bottom: 1pt solid #000000; min-width: 35pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.91pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">538.0</font><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;"> </font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">528.4</font><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;"> </font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">239.5</font><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;"> </font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 35pt;">1,305.9</font><font style="border-bottom: 1pt solid #000000; min-width: 35pt;"> </font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35pt;">$</font><font style="border-bottom: 3pt double #000000; min-width: 35pt;">1,932.4</font><font style="border-bottom: 3pt double #000000; min-width: 35pt;"> </font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.91pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">$</font><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">538.0</font><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;"> </font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">$528.4</font><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;"> </font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">$239.5</font><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;"> </font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35pt;">$3,238.3</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As at March 31, 2023 </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">On demand</div></td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.12%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Less than<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1 year</div></td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1 to 2<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">years</div></td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.27%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2 to 5<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">years</div></td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.48%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade payables<font style="padding-left: 2.21pt;"></font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;">$<font style="padding-left: 7.5pt;">279.6 </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.91pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.27%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.99pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 7.5pt;">279.6</font> </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Financial liabilities included in customers&#8217; deposits, other payables and accruals <font style="padding-left: 2.45pt;"></font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 5pt;">1,332.6 </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.91pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.27%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.99pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">1,332.6</font> </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amounts due to related parties <font style="padding-left: 4.11pt;"></font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 12.87pt;">112.6 </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.91pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.27%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.99pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.87pt;">112.6</font> </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities <font style="padding-left: 1.31pt;"></font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 25pt;">&#8212; </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.91pt; text-align: left;"><font style="padding-left: 5pt;">507.3</font> </div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">122.5</font> </div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.27%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.99pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">629.8</font> </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;">$1,724.8 </div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.91pt; text-align: left;">$507.3 </div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$122.5 </div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.27%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.99pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$2,354.6</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">301<br></div></div></div>
<!--End Page 312-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 313-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_118-mda02_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">As at March 31, 2022 </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">On demand </div></td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.12%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Less than<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1 year </div></td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1 to 2<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">years </div></td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.27%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2 to 5<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">years </div></td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.48%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade payables<font style="padding-left: 2.21pt;"></font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;">$<font style="padding-left: 7.5pt;">198.5 </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.91pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.27%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.99pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 7.5pt;">198.5</font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Financial liabilities included in customers&#8217; deposits, other payables and accruals <font style="padding-left: 2.45pt;"></font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 12.5pt;">913.5 </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.91pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.27%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.99pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">913.5</font> </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amounts due to related parties <font style="padding-left: 4.11pt;"></font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 12.5pt;">125.7 </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.91pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.27%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.99pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">125.7</font> </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities <font style="padding-left: 1.31pt;"></font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 25pt;">&#8212; </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.91pt; text-align: left;"><font style="padding-left: 5pt;">575.9 </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">544.9 </font></div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.27%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.99pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">1,120.8</font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;">$1,237.7 </div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.91pt; text-align: left;">$575.9 </div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$544.9 </div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.27%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.99pt; text-align: left;">&#8212; </div></td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$2,358.5</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0.5pt; margin-left: 0pt; text-align: left;"> </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">302<br></div></div></div>
<!--End Page 313-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 314-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_119-management_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tMFT"><!--Anchor--></a>MANAGEMENT FOLLOWING THE CONTRIBUTIONS</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Executive Officers and Directors of the Combined Company Following the Contributions</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Upon the completion of the Contributions, the business and affairs of the combined company will be managed under the direction of the combined company&#8217;s board of directors, subject to the requirements of Delaware law.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The combined company&#8217;s board of directors will initially be fixed at eight (8) members, consisting of three (3) current Catalyst board members (Thomas Eastling, Ying Luo, Ph.D. and Nassim Usman, Ph.D.), two (2) current BC board members (Songjiang Ma and Charles Wu, Ph.D.) and three (3) other board members (Gordon G. Carmichael, Ph.D., Renate Parry, Ph.D and Han Ying, Ph.D). In conjunction with the completion of the Contributions, current Catalyst board members, Andrea Hunt and Augustine Lawlor, are expected to resign as members of the Catalyst&#8217;s board. The staggered structure of the current Catalyst board of directors will remain in place for the combined company&#8217;s board of directors following the completion of the Contributions, with Class&#160;I directors holding terms expiring at the 2025&#160;Annual Meeting, Class&#160;II directors holding terms expiring at the 2026 Annual Meeting and Class&#160;III directors holding terms expiring at the 2024 Annual Meeting).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The executive officers of the combined company will be appointed by and serve at the discretion of, the combined company&#8217;s board of directors. There are no family relationships among those who will be the combined company&#8217;s directors or executive officers.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table lists the names and ages, as of May&#160;15, 2023 and positions of the individuals who are expected to serve as executive officers and directors of the combined company upon completion of the Contributions: </div> <table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 35.9%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Age</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 56.41%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Position</div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Executive Officers:<br></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 56.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 56.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Charles Wu, Ph.D. <font style="padding-left: 0.83pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7pt; text-align: left;">63</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Executive Officer and Class&#160;III Director</div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Songjiang Ma <font style="padding-left: 4.96pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7pt; text-align: left;">68</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">President and Class&#160;I Director</div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ruoyu Chen<font style="padding-left: 4.39pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7pt; text-align: left;">53</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interim Chief Financial Officer</div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weiguo Ye <font style="padding-left: 2.69pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7pt; text-align: left;">46</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Operating Officer</div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Suzana Corritori, M.D., Ph.D., MSc. <font style="padding-left: 2.22pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7pt; text-align: left;">61</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vice President of Clinical Development and Regulatory Affairs </div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-Employee Directors:<br></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ying Luo, Ph.D. <font style="padding-left: 4.68pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7pt; text-align: left;">57</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chairman of the Board and Class&#160;I Director</div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gordon G. Carmichael, Ph.D. <font style="padding-left: 0.55pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7pt; text-align: left;">75</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Class&#160;II Director</div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Renate Parry, Ph.D. <font style="padding-left: 1.46pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7pt; text-align: left;">60</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Class&#160;III Director</div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Han Ying, Ph.D. <font style="padding-left: 4.5pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7pt; text-align: left;">58</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Class&#160;II Director</div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thomas Eastling <font style="padding-left: 3.85pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7pt; text-align: left;">63</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Class&#160;III Director</div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Nassim Usman, Ph.D. <font style="padding-left: 1.92pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7pt; text-align: left;">64</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Class&#160;II Director</div></td></tr></table> <div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Executive Officers </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Charles Wu, Ph.D.<font style="font-weight: normal;"> will be the Chief Executive Officer and a director of the combined company. </font><font style="font-weight: normal;">Dr. Wu</font><font style="font-weight: normal;"> has served </font><font style="font-weight: normal;">as</font><font style="font-weight: normal;"> a director of BC since April 2023.</font><font style="font-weight: normal;"> </font><font style="font-weight: normal;">Dr. Wu has over 30&#160;years of experience in the field of CMC. He joined BC as </font><font style="font-weight: normal;">the chief technology officer in January 2020,</font><font style="font-weight: normal;"> which position he held until April 2023,</font><font style="font-weight: normal;"> and served as the general </font><font style="font-weight: normal;">manager of BC&#8217;s Cangzhou branch from January 2020 to October 2020. He was further appointed as vice president </font><font style="font-weight: normal;">in December 2020</font><font style="font-weight: normal;">, which position he held until April 2023</font><font style="font-weight: normal;">. Prior to joining </font><font style="font-weight: normal;">BC</font><font style="font-weight: normal;">, Dr. Wu served as a vice president </font><font style="font-weight: normal;">of the Active Pharmaceutical Ingredient (API) division of Zhejiang Huahai Pharmaceutical Co., Ltd. (&#8220;Zhejiang </font><font style="font-weight: normal;">Huahai&#8221;) from February 2019 to September 2019</font><font style="font-weight: normal;">,</font><font style="font-weight: normal;"> as a technical consultant of Shandong Lixin Pharmaceuticals Co., </font><font style="font-weight: normal;">Ltd. from January 2018 to February&#160;2019</font><font style="font-weight: normal;">,</font><font style="font-weight: normal;"> as the general manager of Teva Pharmaceutical &amp; Chemical (Hangzhou) </font><font style="font-weight: normal;">Co., Ltd. from November 2016 to January 2018</font><font style="font-weight: normal;">,</font><font style="font-weight: normal;"> as the general manager of Xellia (Taizhou) Pharmaceutical Co., Ltd. </font><font style="font-weight: normal;">from April 2014 to November 2016</font><font style="font-weight: normal;">,</font><font style="font-weight: normal;"> as the vice president of Lianhe Chemical Technology Co., Ltd. from June 2011 </font><font style="font-weight: normal;">to March 2013</font><font style="font-weight: normal;"> and</font><font style="font-weight: normal;"> as the executive director in API production technology of Zhejiang Huahai from April 2010 to </font><font style="font-weight: normal;">June 2011. Dr. Wu has also had extensive experience in R&amp;D in the pharmaceutical industry, which includes his </font><font style="font-weight: normal;">research experience at Wyeth Holdings Corporation, Honeywell International Inc. (formerly known as AlliedSignal </font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">303<br></div></div></div>
<!--End Page 314-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 315-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_119-management_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Inc.), Rohm and Haas Company and the Virginia Polytechnic Institute and State University. Dr. Wu obtained his bachelor&#8217;s degree in polymer chemistry from University of Science and Technology of China in the PRC in July 1983. He further obtained his doctoral degree in chemistry from University of Maryland, College Park in December 1989. He obtained his MBA certificate from Tulane University in April 2004. He obtained the qualification of professor-level senior engineer from Zhejiang Province Human Resources and Social Security Department in June&#160;2015.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Songjiang Ma<font style="font-weight: normal;"> will be the President and a director of the combined company. </font><font style="font-weight: normal;">Mr. Ma has served as</font><font style="font-weight: normal;"> an executive </font><font style="font-weight: normal;">director </font><font style="font-weight: normal;">of BC since January 2022 and as Honorary Chairman since April 2023. Prior to being</font><font style="font-weight: normal;"> re-designated as an </font><font style="font-weight: normal;">executive director</font><font style="font-weight: normal;">, Mr. Ma served as a director</font><font style="font-weight: normal;"> of BC</font><font style="font-weight: normal;"> from June 2006</font><font style="font-weight: normal;">. Mr.&#160;Ma has over 25&#160;years of experience in </font><font style="font-weight: normal;">the pharmaceutical industry. Mr.&#160;Ma founded Kangdini Factory, one of the founding shareholders of BC, in June </font><font style="font-weight: normal;">1996, and acted as its general manager from June 1996 to March 2006, and then as the supervisor since March 2006. </font><font style="font-weight: normal;">After the incorporation of BC in June 2002, he served as the vice president of BC from June 2002 to July 2011 and </font><font style="font-weight: normal;">then as the general manager since July 2011. Prior to founding Kangdini Factory, Mr.&#160;Ma served as the general </font><font style="font-weight: normal;">manager of Beijing Pan-continental Medical Limited. He also worked at the Beijing Science Institute of Electric </font><font style="font-weight: normal;">Power Research Institute Computer College from September 1983 to December 1987, during which he was also </font><font style="font-weight: normal;">seconded to Beijing Jinxing Computer Engineering Company from June 1985 to October 1986. He worked at </font><font style="font-weight: normal;">Shaanxi Communication Planning and Design Institute Co., Ltd. (formerly known as Shaanxi Provincial Institute of </font><font style="font-weight: normal;">Posts) from September 1978 to September 1980. </font><font style="font-weight: normal;">Mr. Ma was the chairman of Beijing Dalu Automation Control </font><font style="font-weight: normal;">System Co., Ltd., the business license of which was revoked on December 9, 1999. He confirmed that, to the best </font><font style="font-weight: normal;">of his knowledge and belief, as of </font><font style="font-weight: normal;">May&#160;15</font><font style="font-weight: normal;">, 2023, no claims have been made against him and he is not aware of any </font><font style="font-weight: normal;">threatened or potential claims made against him and there are no outstanding claims and/or liabilities as a result of </font><font style="font-weight: normal;">the revocation of the above company. </font><font style="font-weight: normal;">Mr.&#160;Ma </font><font style="font-weight: normal;">graduated from Beijing University of Posts and Telecommunication </font><font style="font-weight: normal;">(formerly known as Beijing College of Posts and Telecommunication) in the PRC in August&#160;1978, majoring in radio </font><font style="font-weight: normal;">technology and short-wave communication. He further obtained his master&#8217;s degree in engineering from China </font><font style="font-weight: normal;">Electric Power Research Institute (formerly known as Electric Power Research Institute) in the PRC in September </font><font style="font-weight: normal;">1983.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Ruoyu Chen<font style="font-weight: normal;"> will be the Interim Chief Financial Officer of the combined company. Ms. Chen has worked as senior </font><font style="font-weight: normal;">vice president of finance of GNI USA since 2021. She is primarily responsible for managing GNI Japan&#8217;s business </font><font style="font-weight: normal;">in the United States. She has also served as a director of BC since 2018. Ms. Chen has over 20 years of management </font><font style="font-weight: normal;">experience working for multinational companies in departments such as global finance, audit, internal control, </font><font style="font-weight: normal;">taxation, administration and mergers and acquisitions. From 2014 to 2021, Ms. Chen served as the director of finance </font><font style="font-weight: normal;">and accounting of GNI Japan and directly reported to the chief financial officer of GNI Japan. In this role, she led </font><font style="font-weight: normal;">investments, financing, financial reporting, </font><font style="font-weight: normal;">and </font><font style="font-weight: normal;">public company disclosure, and was responsible for budget </font><font style="font-weight: normal;">management and financial analysis. From 2012 to 2014, Ms. Chen worked</font><font style="font-weight: normal;"> as </font><font style="font-weight: normal;">a </font><font style="font-weight: normal;">manager of the internal audit division</font><font style="font-weight: normal;"> </font><font style="font-weight: normal;">at Protiviti Japan</font><font style="font-weight: normal;">. From 2007 to 2011, she worked at BDO International Japan as an auditor. From 1999 to 2003, Ms. </font><font style="font-weight: normal;">Chen worked at </font><font style="font-weight: normal;">Arthur</font><font style="font-weight: normal;"> Andersen Japan, where she participated in strategic consulting projects that implemented the </font><font style="font-weight: normal;">enterprise resource planning systems at several Japanese multinational companies. From 1997 to 1999, she worked </font><font style="font-weight: normal;">as a corporate strategy consultant for Mitsubishi UFJ Consulting and Research Japan. Ms. Chen holds a bachelor&#8217;s </font><font style="font-weight: normal;">degree from Nankai University in the PRC and a master&#8217;s degree from the Graduate School of Economics at Kyoto </font><font style="font-weight: normal;">University in Japan. She is a certified public accountant in Washington State and a CFA Level 2 candidate.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Weiguo Ye<font style="font-weight: normal;"> will be the Chief Operating Officer of the combined company. Mr.&#160;Ye</font><font style="font-weight: normal;"> has served as BC&#8217;s director and </font><font style="font-weight: normal;">president since April 2023, and</font><font style="font-weight: normal;"> </font><font style="font-weight: normal;">is primarily responsible for </font><font style="font-weight: normal;">the </font><font style="font-weight: normal;">overall management </font><font style="font-weight: normal;">and</font><font style="font-weight: normal;"> operation of BC. Mr.&#160;Ye has </font><font style="font-weight: normal;">over 20&#160;years of experience in the pharmaceutical industry. </font><font style="font-weight: normal;">Prior to his current position with BC, Mr. Ye held a series </font><font style="font-weight: normal;">of positions at BC of increasing responsibility, including</font><font style="font-weight: normal;"> as a sales director </font><font style="font-weight: normal;">from December 2016 to </font><font style="font-weight: normal;">September</font><font style="font-weight: normal;"> 2017</font><font style="font-weight: normal;">,</font><font style="font-weight: normal;"> </font><font style="font-weight: normal;">vice president from September 2017 to May 2018</font><font style="font-weight: normal;">,</font><font style="font-weight: normal;"> executive vice president </font><font style="font-weight: normal;">from</font><font style="font-weight: normal;"> May&#160;2018</font><font style="font-weight: normal;"> to April 2023</font><font style="font-weight: normal;"> and</font><font style="font-weight: normal;"> chief </font><font style="font-weight: normal;">operating officer </font><font style="font-weight: normal;">from</font><font style="font-weight: normal;"> January 2021</font><font style="font-weight: normal;"> to April 2023</font><font style="font-weight: normal;">. Prior to joining BC, Mr.&#160;Ye </font><font style="font-weight: normal;">had over 18&#160;years of sales </font><font style="font-weight: normal;">management experience. Mr.&#160;Ye served as the marketing vice president of Hubei Monyan Pharmaceuticals Co., Ltd. </font><font style="font-weight: normal;">from March 2015 to November 2016</font><font style="font-weight: normal;"> and</font><font style="font-weight: normal;"> as the grand area manager and then national sales director of Jiangsu </font><font style="font-weight: normal;">Simcere Pharmaceutical Co., Ltd. from November 2011 to February 2015. He worked at Shanghai Roche </font><font style="font-weight: normal;">Pharmaceutical Ltd. from August 1997 to November 2011, with his last position as the regional sales manager. Mr.&#160;Ye </font><font style="font-weight: normal;">obtained his undergraduate diploma in applied pharmacy through online learning from Peking University in the PRC </font><font style="font-weight: normal;">in July 2009. He further obtained his executive master of business administration degree (EMBA) from China Europe </font><font style="font-weight: normal;">International Business School in the PRC in August 2021. </font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">304<br></div></div></div>
<!--End Page 315-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 316-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_119-management_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Suzana Corritori, M.D., Ph.D., MSc.<font style="font-weight: normal;"> will serve as the Vice President of Clinical Development and Regulatory </font><font style="font-weight: normal;">Affairs of the combined company. She has over 30&#160;years of experience in biopharmaceutical and medical device </font><font style="font-weight: normal;">product development. Since 2008, she has served as the President and Founder of Corritori Consulting Inc., a drug </font><font style="font-weight: normal;">development consulting firm providing comprehensive drug development and regulatory expertise in both the </font><font style="font-weight: normal;">domestic and international arenas. Over her career, Dr. Corritori has held a number of high-level positions at various </font><font style="font-weight: normal;">biotechnology companies, including as Director of Biomedical Research at ICN Pharmaceuticals from 1990 to 2002, </font><font style="font-weight: normal;">Director of Drug Development at Avanir Pharmaceuticals from 2002 to 2004, Senior Director of Clinical </font><font style="font-weight: normal;">Development at Allergan from 2004 to 2006, Senior Medical Director at ACADIA Pharmaceuticals from 2006 to </font><font style="font-weight: normal;">2008, Chief Scientific Officer &amp; Head, Drug Development at Nativis, Inc. in 2009, Vice President of Clinical Affairs </font><font style="font-weight: normal;">at ReShape Medical, Inc. from 2010 to 2011, Vice President of Clinical Affairs at Obalon Therapeutics, Inc. from </font><font style="font-weight: normal;">2011 to 2012, and Senior Vice President of Strategic Drug Development Solution at Precision for Medicine and Rare </font><font style="font-weight: normal;">Disease from 2018 to 2019. Dr Corritori received her MSc., Ph.D. and M.D. from the School of Medicine at the </font><font style="font-weight: normal;">University of Belgrade and was a Postdoctoral Fellow at the University of Southern California.</font></div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Non-Employee Directors </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Ying Luo, Ph.D. <font style="font-weight: normal;">has served as a director of Catalyst since December 2022 and as a director, representative executive </font><font style="font-weight: normal;">officer, president and chief executive officer of GNI Japan since 2007, Chief Executive Officer of SG from 2001 to </font><font style="font-weight: normal;">2021, chairman of the board of BC since 2011, a director of the board of GNI Hong Kong since 2013 and chairman </font><font style="font-weight: normal;">of the board and Chief Executive Officer of Cullgen since 2018. Dr. Luo has also served as a director of the board </font><font style="font-weight: normal;">and President of GNI USA since 2015 and a director of Berkeley Advanced Biomaterials LLC since 2017. Dr. Luo </font><font style="font-weight: normal;">had been a postdoctoral fellow at the University of California at San Francisco studying HIV gene regulation from </font><font style="font-weight: normal;">1991 to 1992, a scientist at Aviron Company from 1992 to 1993, a scientist at Clontech Laboratories from 1993 to </font><font style="font-weight: normal;">1997 and senior scientist/director/senior director of genomics and target discovery of Rigel Inc. from 1997 to 2000, </font><font style="font-weight: normal;">where he led research in the field of protein-protein interactions in cancer and inflammation signaling pathways. In </font><font style="font-weight: normal;">his career, Dr. Luo has authored more than 37 research publications. Dr. Luo completed his undergraduate education </font><font style="font-weight: normal;">at Peking Union Medical College (Peking University&#8217;s Premedicine) from 1982 to 1986 and received his doctorate </font><font style="font-weight: normal;">in biomedical sciences from the University of Connecticut Health Center in 1991.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Dr. Luo&#8217;s scientific expertise from his extensive experience in R&amp;D at biotechnology companies, as well as his experience as an executive and director of public and private companies in the life sciences industry, qualifies him to serve on the combined company&#8217;s board of directors.</div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Thomas Eastling<font style="font-weight: normal;"> has served as a director of Catalyst since December 2022 and served as a board member and Chief </font><font style="font-weight: normal;">Financial Officer of Cullgen, since February 2018 and as an outside member of GNI Japan since April 2013 and </font><font style="font-weight: normal;">an </font><font style="font-weight: normal;">advisor to the </font><font style="font-weight: normal;">executive committee </font><font style="font-weight: normal;">of GNI Japan since September 2013. He previously served as Chief Financial </font><font style="font-weight: normal;">Officer of GNI Japan, a vertically-integrated, multinational bio-pharma company, focused on drug research, clinical </font><font style="font-weight: normal;">development, manufacturing, sales and marketing, from 2013 to 2021. Mr.&#160;Eastling has more than nine years of </font><font style="font-weight: normal;">experience serving as a public company board member, as well as positions on numerous private company boards. </font><font style="font-weight: normal;">His career covers 35&#160;years of experience in executive management, global finance and mergers and acquisitions, with </font><font style="font-weight: normal;">senior postings in New York, London, Tokyo and Hong Kong. Mr.&#160;Eastling started his career on Wall Street at Nikko </font><font style="font-weight: normal;">Securities Co. International, Inc., where he worked from June 1983 to November 1999, rising to the position of </font><font style="font-weight: normal;">Senior Vice President &amp; General Manager of the Investment Banking and Syndicate Divisions. Mr.&#160;Eastling was the </font><font style="font-weight: normal;">Company Representative in Japan for Duff &amp; Phelps Credit Rating Co., which was acquired by Fitch Ratings, Inc. </font><font style="font-weight: normal;">in 2021, from May 2000 to June 2001 and subsequently worked as Managing Director for Softbank Corp. from </font><font style="font-weight: normal;">July&#160;2001 to July 2003. In 2009 he relocated to Hong Kong with American Appraisal where he served as Director </font><font style="font-weight: normal;">of the firm&#8217;s Transaction Advisory Services in Asia from April 2008 to August 2013. He returned to Japan in 2013 </font><font style="font-weight: normal;">to assume the position of Chief Financial Officer and Representative Executive Officer for GNI Japan from 2013 to </font><font style="font-weight: normal;">2021, relocating in 2021 to Cullgen&#8217;s San Diego headquarters. Mr.&#160;Eastling has a bachelor&#8217;s degree from the </font><font style="font-weight: normal;">University of Southern California and a master&#8217;s degree from the American Graduate School of International </font><font style="font-weight: normal;">Management. He graduated from the Board Director Training Institute of Japan and is a member of the National </font><font style="font-weight: normal;">Association of Corporate Directors.</font></div> <div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Mr.&#160;Eastling&#8217;s financial expertise from his extensive experience in investment banking and as a Chief Financial Officer for various companies, as well as his experience as a director of public and private companies in the life sciences industry, qualifies him to serve on the combined company&#8217;s board of directors.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Nassim Usman, Ph.D.<font style="font-weight: normal;"> served as Chief Executive Officer and a member of the board of directors of Catalyst Bio from </font><font style="font-weight: normal;">February 2006 until the completion of the merger of Catalyst Bio and Catalyst (formerly known as Targacept, Inc.) </font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">305<br></div></div></div>
<!--End Page 316-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 317-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_119-management_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">in August 2015. Since August 2015, Dr. Usman has served as Catalyst&#8217;s President and Chief Executive Officer and as a director. Dr. Usman is currently a Venture Partner at Morgenthaler Ventures. Prior to joining Morgenthaler in 2005, he was Senior Vice President and Chief Operating Officer at Sirna Therapeutics Inc., which was subsequently acquired by Merck, from 2004 to 2005 and held various research and development positions at both Sirna and Ribozyme Pharmaceuticals, including Vice President of research and development and Chief Scientific Officer, from 1992 to 2004. During his industrial career, Dr. Usman has overseen the entry of several drugs into clinical development, completion of multiple licensing deals with pharmaceutical and biotechnology companies and raised capital in both private and public financings. Prior to moving into the private sector in 1992, Dr. Usman was an NIH Fogarty and NSERC Postdoctoral Fellow and Scientist in the Departments of Biology and Chemistry at the Massachusetts Institute of Technology from 1987 to 1992. He has authored more than 70 scientific articles and is the named inventor in 130 issued patents and patent applications. Dr. Usman is a past director of Mosaic Biosciences, Principia Biopharma, Osprey Pharmaceuticals, Archemix Corporation and atugen AG (now Silence Therapeutics) and served on the science advisory boards of RXi Pharmaceuticals and Noxxon Pharma AG. He received his B.Sc. (Honours) and Ph.D. in organic chemistry from McGill University. In his doctoral dissertation, he developed a method for the solid-phase synthesis of RNA that is widely used in science and in two marketed RNA products (Macugen&#8482; and Onpattro&#8482;).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Dr. Usman is qualified to serve on the combined company&#8217;s board of directors because of his perspective and experience as Catalyst&#8217;s President and Chief Executive Officer and extensive experience, both scientific and business and innovations in the field of biotechnology, particularly with companies engaged in clinical drug development. In addition, Dr. Usman&#8217;s academic expertise and accomplishments provide the combined company&#8217;s board of directors with in-depth product and field knowledge.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Gordon G. Carmichael, Ph.D.<font style="font-weight: normal;"> will be a director of the combined company. Since 2017, he has served as a Director </font><font style="font-weight: normal;">of the Connecticut Cell and Genome Engineering Core Facility. Dr. Carmichael has been a Professor of Genetics and </font><font style="font-weight: normal;">Genome Sciences at the University of Connecticut Health Center in Farmington, Connecticut Health since 2003. His </font><font style="font-weight: normal;">research focuses on the molecular signals which control the expression and function of RNA molecules. In 2018, he </font><font style="font-weight: normal;">was elected to the Connecticut Academy of Science and Engineering. Dr. Carmichael served on National Institutes </font><font style="font-weight: normal;">of Health review panels from 2017 to 2018, and in 2023, as a member of the R35 Review Panel. Since 2017, he has </font><font style="font-weight: normal;">been on the Editorial Board of the journals </font><font style="font-style: italic; font-weight: normal;">Biomolecules</font><font style="font-weight: normal;"> and </font><font style="font-style: italic; font-weight: normal;">Frontiers in Genetics</font><font style="font-weight: normal;"> and was an Associate Editor of </font><font style="font-style: italic; font-weight: normal;">WIREs RNA</font><font style="font-weight: normal;">, a scientific journal, from 2010 to 2018. He was a postdoctoral fellow in virology at the Swiss Institute </font><font style="font-weight: normal;">for Experimental Cancer Research and at Harvard Medical School and was named as a fellow of the Jane Coffin </font><font style="font-weight: normal;">Childs Memorial Fund for Medical Research. Dr. Carmichael was also a research fellow and assistant professor in </font><font style="font-weight: normal;">pathology at Harvard Medical School from 1977 to 1982. He holds a B.S. in physics from Duke University, and a </font><font style="font-weight: normal;">Ph.D. in biophysics from Harvard University. His Ph.D. research was carried out in the lab of Nobel Laureates James </font><font style="font-weight: normal;">Watson and Walter Gilbert.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Dr. Carmichael is qualified to serve on the combined company&#8217;s board of directors because of his extensive and high-level experience with biomolecular research which, along with his academic expertise, provides the combined company&#8217;s board of directors with a valuable perspective and important insight. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Han Ying, Ph.D. <font style="font-weight: normal;">will be a director of the combined company. Dr. Ying currently serves as a director of the Gene </font><font style="font-weight: normal;">Corporation and as a director of Base Therapeutics. Dr. Ying has served as the co-founder and chief operating officer </font><font style="font-weight: normal;">of Base Therapeutics since 2021. From 2020 to 2021, he served as the chief technology officer for Tactiva </font><font style="font-weight: normal;">Therapeutics. From 2017 to 2019, Dr. Ying served as the scientific founding team member for T-Cure Bioscience and </font><font style="font-weight: normal;">as chief scientific officer in the in the biomedical sector of Sanpower Group. From 1999 to 2022, Dr. Ying served </font><font style="font-weight: normal;">as a principal investigator at the Maxine Dunitz Neurosurgical Institute, where he oversaw a clinical laboratory </font><font style="font-weight: normal;">conducting dendritic cell vaccine trials for malignant brain tumors. From 2002 to 2007, he served as a project leader </font><font style="font-weight: normal;">in the Cancer Research Department of Berlex Biosciences. From 2007 to 2009, Dr. Ying was at Monogram </font><font style="font-weight: normal;">Biosciences, a personalized medicine company that developed biomarkers for a selection of patients for novel </font><font style="font-weight: normal;">targeted drugs. In 2012, Dr. Ying co-founded Immunnova, a biotech company focused on dendritic cell vaccines and </font><font style="font-weight: normal;">antigen-specific T cells. He has consulted for several early and late-stage biotech companies in the field of cancer </font><font style="font-weight: normal;">immunotherapy, including HRYZ, Sanpower Group and SinoBioway, and he served as the key technical expert for </font><font style="font-weight: normal;">the international mergers and acquisitions team that completed the acquisition of Dendreon by Sanpower Group in </font><font style="font-weight: normal;">2017. Dr. Ying received his Ph.D. in cancer biology from Stanford University and his B.S. and M.S. in biological </font><font style="font-weight: normal;">studies from Beijing University. He completed his post-doctoral training at the National Cancer Institute. </font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">306<br></div></div></div>
<!--End Page 317-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 318-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_119-management_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Dr. Ying&#8217;s over 20&#160;years of experience in immunology, the pharmaceutical industry, biotech startups, operations, project management and fundraising make him qualified to serve on the combined company&#8217;s board of directors. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Renate Parry, Ph.D.<font style="font-weight: normal;"> will be a director of the combined company. Since 2020, she has served as a consultant in </font><font style="font-weight: normal;">oncology research and development and business strategy. She worked at Varian Medical Systems (&#8220;Varian&#8221;), a </font><font style="font-weight: normal;">medical device company, as Senior Manager from 2008 to 2012, then as Director of Translational Medicine from </font><font style="font-weight: normal;">2012 to 2016, and as Senior Director from 2016 to 2019, where she was responsible for developing and implementing </font><font style="font-weight: normal;">a novel strategy to improve cancer radiation therapy while reducing radiation-induced side effects. Prior to Varian, </font><font style="font-weight: normal;">Dr. Parry served as an oncology scientist for Berlex Biosciences, and as a research scientist at the Institute for </font><font style="font-weight: normal;">Diagnostic Research at Schering AG. She has developed and advanced three novel drugs for oncology and fibrosis </font><font style="font-weight: normal;">indications, advancing these programs from conception to clinical trials. Dr. Parry has authored or co-authored over </font><font style="font-weight: normal;">15 publications and has 15 registered patents. She received her diploma and Ph.D. in biology from the Institute of </font><font style="font-weight: normal;">Toxicology at the Johannes-Gutenberg-University of Mainz, Germany. </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Dr. Parry is qualified to serve on the combined company&#8217;s board of directors because of her over 25&#160;years of experience in management of research and development activities in pharmaceutical, biotechnology and medical device companies, including her experience and expertise in oncology research and development. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Controlled Company Exception</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Following the completion of the Contributions, the GNI Parties will control a majority of the voting power of the combined company&#8217;s outstanding common stock. As a result, the combined company will qualify as a &#8220;controlled company&#8221; within the meaning of the Nasdaq listing standards. Under these rules, the combined company may elect not to comply with certain corporate governance requirements, including the requirement that (i)&#160;a majority of the combined company board of directors consist of independent directors, (ii)&#160;director nominees be selected or recommended to the board entirely by independent directors and (iii)&#160;the compensation committee be composed entirely of independent directors.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Following the completion of the Contributions, the combined company intends to rely on the exemptions described in clauses (i), (ii)&#160;and (iii)&#160;above. Accordingly, the combined company&#8217;s stockholders will not have the same protections afforded to stockholders of companies that are subject to all of the Nasdaq corporate governance requirements. In the event that the combined company ceases to be a &#8220;controlled company&#8221; and its shares continue to be listed on the Nasdaq, it will be required to comply with these provisions within the applicable transition periods.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Family Relationships</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Mr. Eastling, who is a current director of Catalyst and will be a director of the combined company, and Ms. Chen, who will be the Interim Chief Financial Officer of the combined company, are husband and wife. There are no other family relationships among any of the directors or executive officers of the combined company.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Director Independence Following the Contributions</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Prior to the closing of the Contributions, Catalyst&#8217;s board of directors will undertake a review of the independence of each combined company director. Based on information provided by each combined company director concerning her or his background, employment and affiliations, it is expected that Catalyst&#8217;s board of directors will determine that each of Gordon G. Carmichael, Renate Parry, Nassim Usman, Ph.D and Han Ying, Ph.D has no relationships that would interfere with the exercise of independent judgment in carrying out the responsibilities of a combined company director and that each of Gordon G. Carmichael, Renate Parry, Nassim Usman, Ph.D and Han Ying, Ph.D, is &#8220;independent&#8221; as that term is defined under the Nasdaq listing standards. In making these determinations, Catalyst&#8217;s board of directors will consider the current and prior and anticipated relationships of each non-employee combined company director with Catalyst, the GNI Parties and the combined company and all other facts and circumstances Catalyst&#8217;s board of directors deems relevant in determining their independence, including the beneficial ownership of securities of the combined company by each non-employee combined company director and the transactions described in the section &#8220;<font style="font-style: italic;">Certain Relationships and Related Party Transactions of the Combined Company.</font>&#8221;</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Board Leadership Structure Following the Contributions</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Following the completion of the Contributions, Ying Luo, Ph.D. is expected to serve as the combined company&#8217;s Chairman of the Board. The combined company&#8217;s Principles of Corporate Governance will provide its board of </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">307<br></div></div></div>
<!--End Page 318-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 319-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_119-management_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">directors with the flexibility to combine or separate the positions of Chairman of the Board and Chief Executive Officer. Following the completion Contributions, we believe that this structure will enable the Chairman to oversee corporate governance matters and the CEO to focus on leading the combined company&#8217;s business. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Following the completion of the Contributions, we expect the independent directors generally to have the opportunity to meet in executive sessions without management present at every regular meeting of the combined company&#8217;s board of directors. The purpose of these executive sessions is to encourage and enhance communication among non-management and independent directors.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We believe that that the programs for overseeing risk, as described in the &#8220;&#8212;<font style="font-style: italic;">Role of the Combined Company&#8217;s Board </font><font style="font-style: italic;">in Risk Oversight Following the Contributions</font>&#8221; section below, would be effective under a variety of leadership frameworks. Accordingly, the risk oversight function of the combined company&#8217;s board of directors did not significantly impact the selection of the leadership structure.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Role of the Combined Company&#8217;s Board in Risk Oversight Following the Contributions</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Following the completion of the Contributions, one of the key functions of the combined company&#8217;s board of directors will be informed oversight of the risk management process. The combined company&#8217;s board of directors does not anticipate having a standing risk management committee, but rather anticipates administering this oversight function directly through the board of directors as a whole, as well as through various standing committees of the board of directors that address risks inherent in their respective areas of oversight. In particular, the board of directors will be responsible for monitoring and assessing strategic risk exposure and the audit committee of the combined company&#8217;s board of directors will have the responsibility to consider and discuss major financial risk exposures and the steps management will take to monitor and control such exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The audit committee of the combined company&#8217;s board of directors will also monitor compliance with legal and other applicable regulatory requirements. The compensation committee of the combined company&#8217;s board of directors will assess and monitor whether the combined company&#8217;s compensation plans, policies and programs comply with applicable legal and regulatory requirements.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Committees of the Board of Directors of the Combined Company Following the Contributions</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The combined company&#8217;s board of directors will have the following standing committees: audit committee, compensation committee and nominating and corporate governance committee.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Audit Committee </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The audit committee of the combined company&#8217;s board of directors will oversee (a) its accounting and financial reporting processes, including the audits and integrity of its financial statements; (b) its compliance with ethical, legal and regulatory requirements; (c) the outside auditor&#8217;s qualifications and independence and (d) the performance of its outside auditor. As part of this oversight, the audit committee of the combined company&#8217;s board of directors will, among other things:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">be responsible for the appointment, compensation, retention and oversight of the work of the outside auditor;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">approve and oversee policies and procedures with respect to audit and permissible non-audit services to be provided by the outside auditor;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">review and discuss with management and the outside auditor the annual audited and quarterly unaudited financial statements of the combined company and the independent auditor&#8217;s reports related to the financial statements, and recommend to the board of directors whether the annual audited financial statements should be included in the combined company&#8217;s Annual Reports on Form 10-K;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">review and discuss the adequacy and effectiveness of the combined company&#8217;s internal financial controls and disclosure controls and procedures;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">review and discuss earnings press releases and corporate practices with respect to earnings press releases and financial information and earnings guidance provided to analysts and ratings agencies;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">review and discuss the combined company&#8217;s practices with respect to risk assessment and risk management;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">308<br></div></div></div>
<!--End Page 319-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 320-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_119-management_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">oversee the combined company&#8217;s compliance program with respect to legal, regulatory and ethical requirements, and establish and oversee procedures for handling reports of potential misconduct; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">establish and periodically review policies and procedures for the review, approval and ratification of related person transactions, and review and approve such transactions consistent with the policies and procedures.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the completion of the Contributions, the combined company&#8217;s board of directors is expected to ratify the selection of the members of the audit committee of the combined company&#8217;s board of directors. Following the completion of the Contributions, the members of the audit committee of the combined company&#8217;s board of directors are expected to be Nassim Usman, Ph.D., Renate Parry and Han Ying, Ph.D. To qualify as independent to serve on the audit committee of the combined company&#8217;s board of directors, listing standards of Nasdaq and the applicable SEC rules require that a director not accept any consulting, advisory or other compensatory fee from the combined company, other than for service as a director, or be an affiliated person of the combined company. Catalyst and the GNI Parties intend that, following the completion of the Contributions, the composition of the audit committee of the combined company&#8217;s board of directors will comply with the applicable requirements of the rules and regulations of Nasdaq and the SEC.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Compensation Committee </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The compensation committee of the combined company&#8217;s board of directors will assist the board of directors in discharging its responsibilities relating to compensation of the combined company&#8217;s executive officers and directors. In carrying out its duties, the compensation committee of the combined company&#8217;s board of directors will, among other things:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">oversee the combined company&#8217;s overall compensation philosophy, policies and programs;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">oversee and approve, as applicable, the evaluation and compensation of the combined company&#8217;s executive officers, including the chief executive officer, including approving the grant of equity awards to executive officers;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">administer and make recommendations to the board of directors with respect to the combined company&#8217;s incentive compensation and equity-based compensation plans that are subject to the board of directors&#8217; approval;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">review and approve the design of other benefit plans pertaining to executive officers;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">approve, amend or modify the terms of other compensation and benefit plans as appropriate;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">review and recommend to the board of directors employment and severance arrangements for executive officers, including employment agreements and change-in-control provisions, plans or agreements;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">review, discuss with management and approve compensation disclosures, as required by SEC rules;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">review the form and amount of compensation paid to directors for their service on the board of directors and its committees and recommend changes in compensation to the board of directors as appropriate;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">oversee succession planning with respect to executive officers;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">oversee risks related to the combined company&#8217;s compensation policies and programs; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">oversee the work of compensation consultants involved in determining or recommending executive or director compensation.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The compensation committee of the combined company&#8217;s board of directors is expected to retain these duties and responsibilities following completion of the Contributions.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the completion of the Contributions, the combined company&#8217;s board of directors is expected to ratify the selection of the members of the compensation committee of the combined company&#8217;s board of directors. Following the completion of the Contributions, the members of the Compensation Committee are expected to be Nassim Usman, Ph.D., Han Ying, Ph.D., Gordon G. Carmichael and Renate Parry. The combined company intends to take advantage of the exception available for &#8220;controlled companies&#8221; under which it is not required to have a compensation committee comprised entirely of independent directors within the meaning of the independent director guidelines of Nasdaq. Catalyst and the GNI Parties believe that, following the completion of the Contributions, the composition of the compensation committee of the combined company&#8217;s board of directors will comply with the applicable requirements of the rules and regulations of Nasdaq.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">309<br></div></div></div>
<!--End Page 320-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 321-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_119-management_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Nominating and Corporate Governance Committee</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The nominating and corporate governance committee of the combined company&#8217;s board of directors will identify director candidates, recommend director candidates to the board of directors and take the lead in shaping the combined company&#8217;s corporate governance. Among its specific duties and responsibilities, the nominating and corporate governance committee of the combined company&#8217;s board of directors will: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">develop and recommend to the board of directors criteria for identifying and evaluating director candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">evaluate the composition of the board of directors to assess whether the skills, experience, characteristics and other criteria established by the board of directors are currently represented on the board of directors as a whole and with respect to each individual director, and to assess the criteria that may be needed in the future;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">identify, review the qualifications of and recruit director candidates, including recommending candidates to the board of directors as necessary to fill vacancies and newly created directorships;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">assess the qualifications, contributions and independence of incumbent directors in determining whether to recommend them for reelection to the board of directors and recommend to the board of directors nominees for election or reelection;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">discuss succession planning for the board of directors and key leadership roles on the board of directors and its committees;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">develop and review a set of corporate governance principles and recommend changes to the board of directors as appropriate;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">make recommendations to the board of directors concerning the size, structure, composition and functioning of the board of directors and its committees; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">oversee the evaluation of the board of directors and its committees.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the completion of the Contributions, the combined company&#8217;s board of directors is expected to ratify the selection of the members of the nominating and corporate governance committee of the combined company&#8217;s board of directors. Following the completion of the Contributions, the members of the nominating and corporate governance committee of the combined company&#8217;s board of directors are expected to be Ying Luo, Ph.D., Thomas Eastling, and Gordon G. Carmichael. The combined company intends to take advantage of the exception available for &#8220;controlled companies&#8221; under which it is not required to have a nominating committee comprised entirely of independent directors within the meaning of the independent director guidelines of Nasdaq. Catalyst and the GNI Parties believe that, following the completion of the Contributions, the composition of nominating and corporate governance committee of the combined company&#8217;s board of directors will comply with the applicable requirements of the rules and regulations of Nasdaq.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Compensation Committee Interlocks and Insider Participation </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">None of the proposed combined company&#8217;s executive officers serves as a member of the board of directors or compensation committee of any entity that has one or more executive officers who is proposed to serve on the combined company&#8217;s board of directors or the combined company&#8217;s compensation committee following the completion of the Contributions. Dr. Usman, who is proposed to serve on the combined company&#8217;s compensation committee, currently serves as an executive officer of Catalyst. Dr. Usman is not proposed to serve as an executive officer of the combined company following the completion of the Contributions.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Non-Employee Director Compensation </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Prior to the Contributions, BC did not have a formal policy to provide any cash or equity compensation to its non-employee directors for their service on its board of directors or committees of its board of directors. In connection with closing of the Contributions, it is expected that the combined company will provide compensation to non-employee directors that is consistent with Catalyst&#8217;s current practices, however, these director compensation policies may be re-evaluated by the combined company and the compensation committee following the completion of the Contributions and may be subject to change. Non-employee directors are expected to receive an annual retainer fee and equity compensation in the form of a stock option grant.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">310<br></div></div></div>
<!--End Page 321-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 322-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_119-management_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">In connection with the closing of the Contributions and the transition of the board of directors, the combined company expects to evaluate Catalyst&#8217;s director compensation practices and finalize the combined company&#8217;s non-employee director compensation program, pursuant to which non-employee directors will be eligible to receive compensation for service on the board of directors of the combined company and its committees. The board of directors of the combined company expects to review director compensation periodically to ensure that director compensation remains competitive such that the combined company is able to recruit and retain qualified directors.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">311<br></div></div></div>
<!--End Page 322-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 323-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_120-certain_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCRA"><!--Anchor--></a>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS OF THE COMBINED COMPANY </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;"><u>BC Transactions</u> </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">F351 Transfer Agreement</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In September 2020, BC entered into an intellectual property transfer agreement with GNI Japan and three of its subsidiaries (SG, GNI Tianjin Limited and GNI HK) for the transfer of IP rights related to Hydronidone. According to that transfer agreement, BC acquired the intellectual property rights related to Hydronidone and retain (1) the exclusive right to use those intellectual property rights in mainland PRC and (2) the right of first offer to the global intellectual property rights related to Hydronidone. During the year ended December 31, 2021, BC paid GNI Tianjin Limited $2.6 million as part of the consideration under the agreement. Pursuant to the terms and conditions thereof, BC is obligated to pay (i) $4.8 million once the NDA for Hydronidone is submitted to the NMPA in China, (ii) $1.2&#160;million once such NDA has passed the on-site inspection for drug registration by the NMPA and (iii) $7 million once such NDA is approved by the NMPA. Following the F351 Acquisition, BC continues to retain such exclusive right in mainland PRC and right of first offer related to Hydronidone. In connection with the F351 Acquisition, BC waived its right of first offer under such agreement. For details, see &#8220;<font style="font-style: italic;">Catalyst&#8217;s Business&#8212;Agreements Relating to </font><font style="font-style: italic;">the Hydronidone Program&#8212;F351 Asset Purchase Agreement</font>.&#8221;</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Research and Development Services</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">During the year ended December 31, 2022, BC received from SG operations, consulting, advisory and related services in connection with BC&#8217;s research and development efforts relating to Hydronidone and paid SG an aggregate amount of $170,367 for such services. These fees were paid to SG in amounts mutually agreed upon in advance by BC and SG in consideration of certain services and materials provided to BC on an as-needed basis, from time to time and at BC&#8217;s request. Such fees were paid pursuant to invoices submitted to BC by SG from time to time.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Equity Grants to Executive Officers and Directors </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC has granted stock options to its executive officers and certain directors, as more fully described in the sections titled &#8220;<font style="font-style: italic;">BC Executive Compensation</font>&#8221; and &#8220;<font style="font-style: italic;">Management Following the Contributions&#8212;Non-Employee Director </font><font style="font-style: italic;">Compensation,</font>&#8221; respectively, in this proxy statement.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Director and Executive Officer Compensation </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Please see the sections titled &#8220;<font style="font-style: italic;">Management Following the Contributions&#8212;Non-Employee Director Compensation</font>&#8221; and &#8220;<font style="font-style: italic;">BC Executive Compensation</font>&#8221; in this proxy statement for information regarding the compensation of BC&#8217;s directors and executive officers.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Executive Compensation and Employment Arrangements</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst has entered into employment agreements with certain of its executive officers. For more information regarding the agreements with Nassim Usman, Ph.D. and Seline Miller, see &#8220;<font style="font-style: italic;">Catalyst Executive and Director </font><font style="font-style: italic;">Compensation</font>&#8221; in this proxy statement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Thomas Eastling, who is a current director of Catalyst and will be a director of the combined company, and Ruoyu Chen, who will be the Interim Chief Financial Officer of the combined company, are husband and wife. Ms. Chen is expected to receive compensation comparable to similarly situated officers in accordance with the combined company&#8217;s executive compensation policies, practices and committee approval procedures to be established following the Contributions.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Indemnification Agreements</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst has entered into indemnification agreements with each of its directors and with each executive officer. Pursuant to the indemnification agreements, Catalyst has agreed to indemnify and hold harmless these directors and officers to the fullest extent permitted by the DGCL. The agreements generally cover expenses that a director or officer incurs or amounts that a director or officer becomes obligated to pay because of any proceeding to which he or she is made or threatened to be made a party or participant by reason of his or her service as a current or former director, officer, employee or agent of Catalyst. The agreements also provide for the advancement of expenses to the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">312<br></div></div></div>
<!--End Page 323-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 324-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_120-certain_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">directors and officers subject to specified conditions. There are certain exceptions to Catalyst&#8217;s obligation to indemnify the directors and officers, including any intentional malfeasance or act where the director or officer did not in good faith believe he or she was acting in Catalyst&#8217;s best interests, with respect to &#8220;short-swing&#8221; profit claims under Section 16(b) of the Exchange Act and, with certain exceptions, with respect to proceedings that he or she initiates.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Policies and Procedures Regarding Related Party Transactions</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s board of directors has adopted a written policy pursuant to which each actual or proposed financial transaction, arrangement or relationship (including any indebtedness or guarantee of indebtedness) or series of similar financial transactions, arrangements or relationships, other than specified employment and compensatory matters, in which (i)&#160;Catalyst was or would be a participant, (ii)&#160;the amount involved exceeds $120,000 and (iii)&#160;a &#8220;related person&#8221; (as defined under Item 404 of Regulation S-K) has a direct or indirect material interest, is submitted to Catalyst&#8217;s audit committee for its review and approval or, if applicable, ratification. These transactions, arrangements or relationships are known as &#8220;related person transactions.&#8221;</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under the policy, Catalyst&#8217;s chief financial officer and outside counsel consult regarding any proposed transaction, arrangement or relationship that is identified as a possible related person transaction. If they determine Catalyst desires to proceed with the proposed transaction, arrangement or relationship and the outside counsel determines, based on available information, that the proposed transaction may constitute a related person transaction, it is submitted to the Audit Committee for its consideration. The Audit Committee is to consider all available relevant facts and circumstances, including the benefits to Catalyst, the impact on a director&#8217;s independence in the event the related person is a director (or a family member or entity affiliated with a director), the availability of other sources for comparable products or services, the proposed terms and the terms available to or from parties that are not related persons. Absent special circumstances, the Audit Committee may approve only those related person transactions that it determines to be in or not contrary to the best interests of Catalyst and its stockholders. No member of the Audit Committee may participate in any review, consideration or approval of any related person transaction with respect to which the member or any of his or her immediate family members is the related person.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">313<br></div></div></div>
<!--End Page 324-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 325-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_121-selected_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSHA"><!--Anchor--></a>SELECTED HISTORICAL AND UNAUDITED PRO FORMA CONDENSED<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">COMBINED FINANCIAL INFORMATION </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Selected Historical Condensed Consolidated Financial Data of Catalyst </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following tables summarize Catalyst&#8217;s financial data. The statement of operations data for the years ended December&#160;31, 2022 and 2021 and the balance sheet data as of December&#160;31, 2022 and 2021 have been derived from Catalyst&#8217;s audited condensed financial statements included elsewhere in this proxy statement. The selected financial information as of and for the three months ended March&#160;31, 2023 are derived from the unaudited historical condensed statement of operations and unaudited condensed balance sheet of Catalyst included elsewhere in this proxy statement. You should read the following selected financial data together with &#8220;<font style="font-style: italic;">Catalyst Management&#8217;s Discussion </font><font style="font-style: italic;">and Analysis of Financial Condition and Results of Operations</font>&#8221; and Catalyst&#8217;s financial statements and the related notes included elsewhere in this proxy statement. Catalyst&#8217;s historical results are not necessarily indicative of results that should be expected in any future period.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">314<br></div></div></div>
<!--End Page 325-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 326-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_121-selected_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><u>Selected Condensed Consolidated Statement of Operations Data:</u> </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">Catalyst Biosciences, Inc.<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Consolidated Statements of Operations<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(In thousands, except share and per share amounts)</font></div> <table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 57.91%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.75%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 16.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended,</div></td><td class="gutter" style="width: 0.75%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.75%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 22.86%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December 31,</div></td></tr><tr class="header"><td style="width: 57.91%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.75%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 16.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 31, 2023 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 0.75%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.75%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.68%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 0.75%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.75%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.68%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021 </div></td></tr><tr><td style="width: 57.91%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Revenue:<br></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 16.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 57.91%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Collaboration<font style="padding-left: 3.51pt;"></font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 16.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.03pt; text-align: left;">$<font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 30pt;">794</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 22.5pt;">7,338</font></div></td></tr><tr><td style="width: 57.91%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 16.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 57.91%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses (income):<br></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 16.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 57.91%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cost of collaboration<font style="padding-left: 2.41pt;"></font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 16.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.03pt; text-align: left;"><font style="padding-left: 40pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 35pt;">798</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 27.5pt;">7,380</font></div></td></tr><tr><td style="width: 57.91%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development<font style="padding-left: 4.1pt;"></font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 16.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.03pt; text-align: left;"><font style="padding-left: 35pt;">588</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">13,037</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">68,889</font></div></td></tr><tr><td style="width: 57.91%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">General and administrative<font style="padding-left: 3.55pt;"></font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 16.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.03pt; text-align: left;"><font style="padding-left: 27.5pt;">3,970</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">17,366</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">18,963</font></div></td></tr><tr><td style="width: 57.91%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Acquired in-process research and development<font style="padding-left: 2.48pt;"></font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 16.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.03pt; text-align: left;"><font style="padding-left: 40pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">35,390</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 40pt;">&#8212;</font></div></td></tr><tr><td style="width: 57.91%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Gain on disposal of assets, net<font style="padding-left: 3.28pt;"></font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 16.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.03pt; text-align: left;"><font style="padding-left: 24.17pt; border-bottom: 1pt solid #000000; min-width: 50pt;">(4,</font><font style="border-bottom: 1pt solid #000000; min-width: 50pt;">736</font><font style="min-width: 50pt;">)</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 50pt;">(57,186</font><font style="min-width: 50pt;">)</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 40pt; border-bottom: 1pt solid #000000; min-width: 50pt;">&#8212;</font></div></td></tr><tr><td style="width: 57.91%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total operating expenses (income)<font style="padding-left: 3.14pt;"></font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 16.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.03pt; text-align: left;"><font style="padding-left: 31.67pt; border-bottom: 1pt solid #000000; min-width: 50pt;">(178</font><font style="min-width: 50pt;">)</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; min-width: 50pt;">9,405</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 50pt;">95,232</font></div></td></tr><tr><td style="width: 57.91%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income (loss) from operations<font style="padding-left: 0.22pt;"></font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 16.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.03pt; text-align: left;"><font style="padding-left: 35pt;">178</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 24.54pt;">(8,611)</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 19.17pt;">(87,894)</font></div></td></tr><tr><td style="width: 57.91%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest and other income (expense), net<font style="padding-left: 3.86pt;"></font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 16.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.03pt; text-align: left;"><font style="padding-left: 40pt; border-bottom: 1pt solid #000000; min-width: 50pt;">96</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 35pt; border-bottom: 1pt solid #000000; min-width: 50pt;">717</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 36.67pt; border-bottom: 1pt solid #000000; min-width: 50pt;">(39</font><font style="min-width: 50pt;">)</font></div></td></tr><tr><td style="width: 57.91%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income (loss) before income taxes<font style="padding-left: 2.46pt;"></font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 16.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.03pt; text-align: left;"><font style="padding-left: 35pt; border-bottom: 1pt solid #000000; min-width: 50pt;">274</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 24.17pt; border-bottom: 1pt solid #000000; min-width: 50pt;">(7,894</font><font style="min-width: 50pt;">)</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 50pt;">(87,933</font><font style="min-width: 50pt;">)</font></div></td></tr><tr><td style="width: 57.91%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income tax expenses<font style="padding-left: 3.54pt;"></font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 16.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.03pt; text-align: left;"><font style="padding-left: 40pt; border-bottom: 1pt solid #000000; min-width: 50pt;">14</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 35pt; border-bottom: 1pt solid #000000; min-width: 50pt;">348</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 40pt; border-bottom: 1pt solid #000000; min-width: 50pt;">&#8212;</font></div></td></tr><tr><td style="width: 57.91%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net income (loss)<font style="padding-left: 0.76pt;"></font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 16.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.03pt; text-align: left;"><font style="padding-left: 35pt; border-bottom: 1pt solid #000000; min-width: 50pt;">260</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 50pt;">$</font><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 50pt;">(8,242</font><font style="min-width: 50pt;">)</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 50pt;">$</font><font style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; min-width: 50pt;">(87,933</font><font style="min-width: 50pt;">)</font></div></td></tr><tr><td style="width: 57.91%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Net income (loss) per share attributable to common stockholders, basic and diluted<font style="padding-left: 4.08pt;"></font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 16.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.03pt; text-align: left;"><font style="padding-left: 32.5pt; border-bottom: 3pt double #000000; min-width: 50pt;">0.01</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 50pt;">$</font><font style="padding-left: 24.17pt; border-bottom: 3pt double #000000; min-width: 50pt;">(0.26</font><font style="min-width: 50pt;">)</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 50pt;">$</font><font style="padding-left: 24.17pt; border-bottom: 3pt double #000000; min-width: 50pt;">(2.87</font><font style="min-width: 50pt;">)</font></div></td></tr><tr><td style="width: 57.91%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Shares used to compute net loss per share attributable to common stockholders, basic<font style="padding-left: 1.59pt;"></font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 16.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.03pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 50pt;">37,758,416</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 50pt;">31,545,723</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 50pt;">30,640,977</font></div></td></tr><tr><td style="width: 57.91%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Shares used to compute net loss per share attributable to common stockholders, diluted<font style="padding-left: 4.36pt;"></font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 16.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.03pt; text-align: left;"><font style="padding-left: 5pt;">37,984,324</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">31,545,723</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">30,640,977</font></div></td></tr><tr><td style="width: 57.91%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 16.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 57.91%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash dividends paid per common share<font style="padding-left: 1.89pt;"></font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 16.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.03pt; text-align: left;">$<font style="padding-left: 27.5pt;">0.24</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 27.5pt;">1.43</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 35pt;">&#8212;</font></div></td></tr><tr><td style="width: 57.91%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CVR cash dividends paid per common share<font style="padding-left: 0.24pt;"></font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 16.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.03pt; text-align: left;">$<font style="padding-left: 27.5pt;">0.01</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 35pt;">&#8212;</font></div></td></tr><tr><td style="width: 57.91%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash dividends declared, unpaid, per common share<font style="padding-left: 4.69pt;"></font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 16.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.03pt; text-align: left;">$<font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 27.5pt;">0.24 </font></div></td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 35pt;">&#8212;</font></div></td></tr></table> </div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">315<br></div></div></div>
<!--End Page 326-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 327-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_121-selected_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><u>Selected Consolidated Balance Sheet Data:</u> </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 9pt; text-align: center;">Catalyst Biosciences, Inc.<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Consolidated Balance Sheets<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(In thousands, except shares and per share amounts)</font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.12%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.6%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 31, 2023<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 1.12%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.12%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.08%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.12%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.12%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.08%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021 </div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assets<br></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current assets: <br></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 2.77pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;">$<font style="padding-left: 13.33pt;">8,099</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;">$<font style="padding-left: 8.33pt;">21,666</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;">$<font style="padding-left: 8.33pt;">44,347</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Short-term investments<font style="padding-left: 1.08pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 18.33pt;">2,504</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accounts and other receivables<font style="padding-left: 2.78pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 18.33pt;">5,000</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;"><font style="padding-left: 18.33pt;">5,000</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 18.33pt;">1,818</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Prepaid and other current assets<font style="padding-left: 0.01pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">915</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;"><font style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">1,540</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">2,807</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total current assets<font style="padding-left: 1.8pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 13.33pt;">14,014</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;"><font style="padding-left: 13.33pt;">28,206</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 13.33pt;">51,476</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Long-term receivable from GCBP<font style="padding-left: 1.11pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 18.33pt;">4,550</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other assets, noncurrent<font style="padding-left: 1.94pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 25.83pt;">168</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;"><font style="padding-left: 25.83pt;">168</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 25.83pt;">472</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Right-of-use assets<font style="padding-left: 3.31pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 30.83pt;">17</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;"><font style="padding-left: 30.83pt;">66</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 18.33pt;">2,744</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property and equipment, net<font style="padding-left: 4.7pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 35.83pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">1</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;"><font style="padding-left: 35.83pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">4</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">970</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total assets<font style="font-weight: normal; padding-left: 0.88pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40.83pt;">$</font><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 40.83pt;">18,750</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40.83pt;">$</font><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 40.83pt;">28,444</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40.83pt;">$</font><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 40.83pt;">55,662</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Liabilities, redeemable convertible preferred stock and stockholders&#8217; equity (deficit)<br></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current liabilities: <br></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accounts payable<font style="padding-left: 3.31pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;">$<font style="padding-left: 25.83pt;">16</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;">$<font style="padding-left: 20.83pt;">194</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;">$<font style="padding-left: 13.33pt;">6,419</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accrued compensation<font style="padding-left: 2.76pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 18.33pt;">1,085</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;"><font style="padding-left: 18.33pt;">2,582</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 18.33pt;">1,467</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Deferred revenue<font style="padding-left: 4.99pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 25.83pt;">230</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other accrued liabilities<font style="padding-left: 2.77pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 25.83pt;">743</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;"><font style="padding-left: 18.33pt;">1,452</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 18.33pt;">4,072</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Dividends payable<font style="padding-left: 4.97pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;"><font style="padding-left: 18.33pt;">7,558</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">CVR derivative liability<font style="padding-left: 2.19pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 18.33pt;">5,000</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;"><font style="padding-left: 18.33pt;">5,000</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Operating lease liability<font style="padding-left: 2.76pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 30.83pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;"><font style="padding-left: 30.83pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">38</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">1,977</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total current liabilities<font style="padding-left: 2.9pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 18.33pt;">6,844</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;"><font style="padding-left: 13.33pt;">16,824</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 13.33pt;">14,165</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CVR derivative liability, noncurrent<font style="padding-left: 3.69pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 18.33pt;">4,550</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating lease liability, noncurrent<font style="padding-left: 4.26pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 30.83pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;"><font style="padding-left: 30.83pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">408</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities<font style="padding-left: 4.55pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 13.7pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">11,394</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">16,824</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">14,573</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Commitments and Contingencies (Note 8) <br></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Series X redeemable convertible preferred stock, $0.001 par value, 123,418 shares authorized; 12,340 shares issued and outstanding as of December 31, 2022 and no shares issued and outstanding as of December 31, 2021<font style="padding-left: 0.25pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 13.33pt;">33,309</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;"><font style="padding-left: 13.33pt;">33,309</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stockholders&#8217; equity (deficit):<br></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Common stock, $0.001 par value, 100,000,000 shares authorized; 37,759,825, 37,756,574 and 31,409,707 shares issued and outstanding at March 31, 2023, December 31, 2022 and 2021, respectively<font style="padding-left: 2.19pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 30.83pt;">37</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;"><font style="padding-left: 30.83pt;">37</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 30.83pt;">31</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Additional paid-in capital<font style="padding-left: 1.09pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 8.33pt;">384,686</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;"><font style="padding-left: 8.33pt;">389,210</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 8.33pt;">443,752</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accumulated deficit<font style="padding-left: 3.31pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">(410,676</font><font style="min-width: 40.83pt;">)</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">(410,936</font><font style="min-width: 40.83pt;">)</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.75pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">(402,694</font><font style="min-width: 40.83pt;">)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total stockholders&#8217; equity (deficit)<font style="padding-left: 4.77pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">(25,953</font><font style="min-width: 40.83pt;">)</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">(21,689</font><font style="min-width: 40.83pt;">)</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">41,089</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; equity (deficit)<font style="font-weight: normal; padding-left: 2.4pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 3pt double #000000; min-width: 40.83pt;">18,750</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.16pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40.83pt;">$</font><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 40.83pt;">28,444</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40.83pt;">$</font><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 40.83pt;">55,662</font></div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Selected Historical Condensed Financial Data of BC </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify; line-height: 11pt;">The following tables summarize BC&#8217;s financial data under U.S. GAAP. The statement of operations data for the years ended December&#160;31, 2022 and 2021 and the balance sheet data as of December&#160;31, 2022 and 2021 have been converted from BC&#8217;s audited condensed financial statements, and the statement of operations data for the three months ended March&#160;31, 2023 and the balance sheet data as of March&#160;31, 2023 have been converted from BC's unaudited interim condensed financial statements, in each case in conformity with IFRS included elsewhere in this proxy statement, as adjusted for the differences between U.S. GAAP and IFRS. You should read the following selected financial data together with &#8220;<font style="font-style: italic;">BC Management&#8217;s Discussion and Analysis of Financial Condition and Results </font><font style="font-style: italic;">of Operations</font>&#8221; and BC&#8217;s financial statements and the related notes included elsewhere in this proxy statement. BC&#8217;s historical results are not necessarily indicative of results that should be expected in any future period.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">316<br></div></div></div>
<!--End Page 327-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 328-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_121-selected_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><u>Selected Unaudited Statement of Operations Data under U.S. GAAP</u><u>:</u> </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.16%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 15.82%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2023</div></td><td class="gutter" style="width: 1.16%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.16%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 17.99%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Years Ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31,</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.16%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 15.82%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(unaudited)</div></td><td class="gutter" style="width: 1.16%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.16%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.01%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.16%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.16%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 15.82%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in thousands)</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td colspan="4" style="width: 17.99%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in thousands)</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Revenues<font style="padding-left: 1.63pt;"></font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.12pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 35.83pt;">$</font><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">24,560</font><font style="border-bottom: 1pt solid #000000; min-width: 35.83pt;"> </font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 37.5pt;">$102,461</font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 35.83pt;">$</font><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">88,517</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Gross profit<font style="padding-left: 1.63pt;"></font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.12pt; text-align: left;">$<font style="padding-left: 3.33pt;">23,419</font> </div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">97,923</font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">84,493</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses:<br></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Selling and marketing<font style="padding-left: 0.52pt;"></font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.12pt; text-align: left;">$(12,791) </div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 1.67pt;">(52,554)</font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 0.37pt;">(44,117)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">General and administrative<font style="padding-left: 0.55pt;"></font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.12pt; text-align: left;"><font style="padding-left: 10pt;">(2,035)</font> </div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 7.04pt;">(11,305)</font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">(3,991)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development<font style="padding-left: 1.1pt;"></font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.12pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(2,768</font><font style="min-width: 35.83pt;">)</font><font style="min-width: 35.83pt;"> </font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 37.5pt;">(15,245</font><font style="min-width: 37.5pt;">)</font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(14,459</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total operating expenses<font style="padding-left: 4.57pt;"></font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.12pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(17,594</font><font style="min-width: 35.83pt;">)</font><font style="min-width: 35.83pt;"> </font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 37.5pt;">(79,104</font><font style="min-width: 37.5pt;">)</font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(62,567</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total other income, net<font style="padding-left: 0.4pt;"></font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.12pt; text-align: left;"><font style="padding-left: 22.5pt;">(50)</font> </div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">425</font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">(313)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income Before Income Taxes<font style="padding-left: 0.33pt;"></font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.12pt; text-align: left;"><font style="padding-left: 13.33pt;">5,775</font> </div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">19,244</font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">21,613</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income tax expense<font style="padding-left: 4.43pt;"></font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.12pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(1,536</font><font style="min-width: 35.83pt;">)</font><font style="min-width: 35.83pt;"> </font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 11.67pt; border-bottom: 1pt solid #000000; min-width: 37.5pt;">(4,531</font><font style="min-width: 37.5pt;">)</font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(4,947</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net Income<font style="padding-left: 2.74pt;"></font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.12pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">4,239</font><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;"> </font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 37.5pt;">$</font><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 37.5pt;">14,713</font></div></td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">$</font><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">16,666</font></div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;"><u>Selected Unaudited Balance Sheet Data under U.S. GAAP</u><u>:</u> </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.16%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.6%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2023</div></td><td class="gutter" style="width: 2.16%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.16%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 18.21%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31,</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.16%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.6%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(unaudited)</div></td><td class="gutter" style="width: 2.16%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.16%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 2.16%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.16%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.6%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in thousands)</div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td colspan="4" style="width: 18.21%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in thousands)</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assets<br></div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 2.77pt;"></font></div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">$26,459</font><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;"> </font></div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">$23,464</font></div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">$26,083</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Current Assets<font style="padding-left: 2.34pt;"></font></div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">47,080</font><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;"> </font></div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">47,942</font></div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">44,841</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Assets<font style="padding-left: 1.21pt;"></font></div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">89,468</font><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;"> </font></div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">82,243</font></div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">68,621</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Current Liabilities<font style="padding-left: 2.34pt;"></font></div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">12,841</font><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;"> </font></div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5.37pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">11,208</font></div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">10,294</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Liabilities<font style="padding-left: 1.21pt;"></font></div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">13,900</font><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;"> </font></div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">12,221</font></div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5.37pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">11,927</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Shareholders&#8217; Equity<font style="padding-left: 1.97pt;"></font></div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">$75,568</font><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;"> </font></div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">$70,022</font></div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">$56,694</font><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;"> </font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Working Capital<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 4.79pt;"></font></div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 5pt;">34,239</font> </div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">36,734</font></div></td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.16%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">34,547</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Working capital is defined as current assets less current liabilities. </div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Selected Unaudited Pro Forma Condensed Combined Financial Data of Catalyst and BC </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For accounting purposes, CPI is considered to be acquiring Catalyst in this transaction. The transaction is expected to be accounted for as a reverse asset acquisition under existing U.S. GAAP, which is subject to change and interpretation. To determine the accounting for this transaction under U.S. GAAP, a company must assess whether an integrated set of assets and activities should be accounted for as an acquisition of a business or an asset acquisition. The guidance requires an initial screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single asset or group of similar assets. If that screen is met, the operations acquired are not a business. Catalyst is not expected to meet the definition of a business since substantially all of the fair value is included in IPR&amp;D and no substantive processes are being acquired. As such, the Contributions are expected to be treated as an asset acquisition. The accounting treatment is dependent on certain valuations and other studies that have yet to commence or progress to a stage where there is sufficient information for a definitive measurement. A final determination of these estimated fair values, which cannot be made prior to the completion of the transaction, will be based on the actual net tangible and intangible assets of Catalyst that exist as of the completion of the transaction.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">317<br></div></div></div>
<!--End Page 328-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 329-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_121-selected_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The unaudited pro forma condensed combined balance sheet assumes that the Contributions were consummated as of December&#160;31, 2022 and combines the historical balance sheets of Catalyst and BC as of such date. The unaudited pro forma condensed combined statement of operations for the years ended December&#160;31, 2022 and 2021 assumes that the Contributions were consummated as of January&#160;1, 2022 and combines the historical results of Catalyst and BC for the respective periods presented.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The selected unaudited pro forma condensed combined financial data are presented for illustrative purposes only and are not necessarily indicative of the combined financial position or results of operations of future periods or the results that actually would have been realized had the entities been a single entity during these periods. The selected unaudited pro forma condensed combined financial data for the years ended December&#160;31, 2021 and December&#160;31, 2022 are derived from the unaudited pro forma condensed combined financial information and should be read in conjunction with that information. For more information, please see the section entitled &#8220;<font style="font-style: italic;">Unaudited Pro Forma </font><font style="font-style: italic;">Condensed Combined Financial Information</font>&#8221; in this proxy statement.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><u>Selected Unaudited Pro Forma Condensed Combined Statement of Operations:</u> </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.86%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 15.82%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 31, 2023</div></td><td class="gutter" style="width: 0.86%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.86%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.06%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2022</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.86%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 31.61%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in thousands, except per share amounts)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unaudited Pro Forma Combined Statement of Operations:<br></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Revenues<font style="padding-left: 0.63pt;"></font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.53pt; text-align: left;">$<font style="padding-left: 12.5pt;">24,560</font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.41pt; text-align: left;">$<font style="padding-left: 7.5pt;">103,255</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cost of revenue<font style="padding-left: 4.53pt;"></font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.53pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(1,141</font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.41pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(5,336</font><font style="min-width: 45pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Gross profit<font style="padding-left: 0.63pt;"></font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.53pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 45pt;">23,419</font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.41pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 45pt;">97,919</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses (income):<br></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Selling and marketing expenses<font style="padding-left: 0.1pt;"></font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.53pt; text-align: left;"><font style="padding-left: 17.5pt;">12,791</font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.41pt; text-align: left;"><font style="padding-left: 17.5pt;">52,554</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development<font style="padding-left: 0.1pt;"></font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.53pt; text-align: left;"><font style="padding-left: 22.5pt;">3,356</font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.41pt; text-align: left;"><font style="padding-left: 17.5pt;">28,282</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">General and administrative<font style="padding-left: 4.55pt;"></font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.53pt; text-align: left;"><font style="padding-left: 22.5pt;">6,005</font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.41pt; text-align: left;"><font style="padding-left: 17.5pt;">28,721</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Acquired in-process research and development<font style="padding-left: 3.48pt;"></font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.53pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.41pt; text-align: left;"><font style="padding-left: 17.5pt;">71,254</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Gain on disposal of assets, net<font style="padding-left: 4.28pt;"></font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.53pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(4,736</font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.41pt; text-align: left;"><font style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(57,186</font><font style="min-width: 45pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total operating expenses<font style="padding-left: 3.57pt;"></font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.53pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 45pt;">17,416</font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.41pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 45pt;">123,625</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income (loss) from operations<font style="padding-left: 1.22pt;"></font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.53pt; text-align: left;"><font style="padding-left: 22.5pt;">6,003</font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.41pt; text-align: left;"><font style="padding-left: 14.17pt;">(25,706)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest and other income, net<font style="padding-left: 2.05pt;"></font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.53pt; text-align: left;"><font style="padding-left: 35pt; border-bottom: 1pt solid #000000; min-width: 45pt;">46</font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.41pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 45pt;">1,142</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income (loss) before income taxes<font style="padding-left: 3.46pt;"></font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.53pt; text-align: left;"><font style="padding-left: 22.5pt;">6,049</font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.41pt; text-align: left;"><font style="padding-left: 14.17pt;">(24,564)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Income tax expense<font style="padding-left: 3.43pt;"></font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.53pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(1,550</font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.41pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(4,879</font><font style="min-width: 45pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net income (loss)<font style="padding-left: 1.76pt;"></font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.53pt; text-align: left;"><font style="padding-left: 22.5pt;">4,499</font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.41pt; text-align: left;"><font style="padding-left: 14.17pt;">(29,443)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net income attributable to noncontrolling interest <font style="padding-left: 4.01pt;"></font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.53pt; text-align: left;"><font style="padding-left: 22.5pt;">1,476</font> </div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.41pt; text-align: left;"><font style="padding-left: 22.5pt;">5,123</font> </div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net income attributable to Catalyst Convertible Preferred Stock <font style="padding-left: 0.71pt;"></font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.53pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 45pt;">293</font><font style="border-bottom: 1pt solid #000000; min-width: 45pt;"> </font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.41pt; text-align: left;"><font style="padding-left: 35pt; border-bottom: 1pt solid #000000; min-width: 45pt;">&#8212; </font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net income (loss) attributable to common stockholders, basic <font style="padding-left: 4.88pt;"></font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.53pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 45pt;">$</font><font style="padding-left: 17.5pt; border-bottom: 3pt double #000000; min-width: 45pt;">&#8203;</font><font style="border-bottom: 3pt double #000000; min-width: 45pt;">2,730</font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.41pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 45pt;">$</font><font style="padding-left: 9.17pt; border-bottom: 3pt double #000000; min-width: 45pt;">(34,566</font><font style="min-width: 45pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net income (loss) attributable to common stockholders, diluted<font style="padding-left: 0.97pt;"></font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.53pt; text-align: left;"><font style="padding-left: 22.5pt;">2,751 </font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.41pt; text-align: left;"><font style="padding-left: 14.17pt;">(34,566)</font> </div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net income (loss) per share, basic<font style="padding-left: 4.86pt;"></font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.53pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 45pt;">$</font><font style="padding-left: 22.5pt; border-bottom: 3pt double #000000; min-width: 45pt;">0.00</font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.41pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 45pt;">$</font><font style="padding-left: 19.17pt; border-bottom: 3pt double #000000; min-width: 45pt;">(0.03</font><font style="min-width: 45pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net income (loss) per share, diluted<font style="padding-left: 2.63pt;"></font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.53pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 45pt;">$</font><font style="padding-left: 22.5pt; border-bottom: 3pt double #000000; min-width: 45pt;">0.00</font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.41pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 45pt;">$</font><font style="padding-left: 19.17pt; border-bottom: 3pt double #000000; min-width: 45pt;">(0.03</font><font style="min-width: 45pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average shares outstanding, basic<font style="padding-left: 2.32pt;"></font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.53pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 45pt;">1,148,534</font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.41pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 45pt;">1,142,322</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average shares outstanding, diluted<font style="padding-left: 0.09pt;"></font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.53pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 45pt;">1,247,771</font></div></td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.86%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.41pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 45pt;">1,142,322</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">318<br></div></div></div>
<!--End Page 329-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 330-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_121-selected_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><u>Selected Unaudited Pro Forma Condensed Combined Balance Sheet Data</u>: </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.18%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.6%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 31, 2023</div></td></tr><tr class="header"><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.18%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.6%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in thousands)</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unaudited Pro Forma Combined Balance Sheet:<br></div></td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 3.77pt;"></font></div></td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;">$<font style="padding-left: 3.33pt;">27,459</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accounts and other receivables<font style="padding-left: 3.78pt;"></font></div></td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;"><font style="padding-left: 8.33pt;">12,504</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Inventories<font style="padding-left: 1.52pt;"></font></div></td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;"><font style="padding-left: 13.33pt;">5,693</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Working capital<font style="padding-left: 1.76pt;"></font></div></td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;"><font style="padding-left: 8.33pt;">36,050</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Long-term receivable from GCBP <font style="padding-left: 4.15pt;"></font></div></td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;"><font style="padding-left: 13.33pt;">4,550</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Long-term bank deposits<font style="padding-left: 4.86pt;"></font></div></td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;"><font style="padding-left: 8.33pt;">13,378</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total assets<font style="padding-left: 4.44pt;"></font></div></td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;"><font style="padding-left: 8.33pt;">96,015</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accrued expenses and other liabilities<font style="padding-left: 1.01pt;"></font></div></td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;"><font style="padding-left: 13.33pt;">8,735</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CVR derivative liability, noncurrent <font style="padding-left: 1.36pt;"></font></div></td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;"><font style="padding-left: 13.33pt;">4,550</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Catalyst convertible preferred stock<font style="padding-left: 1.01pt;"></font></div></td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;"><font style="padding-left: 8.33pt;">28,382</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accumulated deficit<font style="padding-left: 4.31pt;"></font></div></td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;"><font style="padding-left: 5pt;">(21,995)</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Noncontrolling Interest<font style="padding-left: 2.09pt;"></font></div></td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;"><font style="padding-left: 8.33pt;">26,313</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total stockholders&#8217; equity<font style="padding-left: 1.3pt;"></font></div></td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;"><font style="padding-left: 8.33pt;">22,870</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total equity<font style="padding-left: 2.76pt;"></font></div></td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;"><font style="padding-left: 8.33pt;">49,183</font></div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;"><a name="tUPF"><!--Anchor--></a>Unaudited Pro Forma Condensed Combined Financial Information </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The unaudited pro forma condensed combined information does not give effect to the proposed reverse stock split described in Proposal No. 4 of this proxy statement, as any adjustment for the proposed reverse stock split is not factually supportable given that the terms of the proposed reverse stock split are not yet known. The unaudited pro forma condensed combined information does not give effect to any potential exercises of the Gyre Options to be granted in respect of the BC&#160;Options and conversion of Catalyst Convertible Preferred Stock.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following unaudited pro forma condensed combined financial information gives effect to the Contributions and other related events contemplated by the Business Combination Agreement as described in Note 1 to this unaudited pro forma condensed combined financial information. It was prepared using the acquisition method of accounting under GAAP. For accounting purposes, CPI is considered to be acquiring Catalyst. After completion of the Contributions, the combined company will be renamed &#8220;Gyre Therapeutics, Inc.&#8221;</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">CPI, which holds a 55.97% indirect ownership interest in BC, will be deemed to be the accounting acquirer for financial reporting purposes even though Catalyst will be issuing shares of Catalyst Common Stock and Catalyst Preferred Stock pursuant to the Business Combination Agreement. This determination is based on the expectations that, immediately following the Contributions: (i)&#160;GNI USA (as one of the current stockholders of CPI) will own a substantial majority of the voting power of the combined company; (ii)&#160;CPI, through GNI USA, will have the ability to control the board of directors of the combined company; and (iii)&#160;senior management of BC will hold a majority of the key positions in senior management of the combined company.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Contributions are expected to be accounted for as a reverse asset acquisition as, at the closing of the Contributions, Catalyst is not expected to meet the definition of a business because Catalyst does not have an organized workforce that significantly contributes to its ability to create output, and substantially all of its fair value is concentrated in cash and in-process research and development (&#8220;IPR&amp;D&#8221;). </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of March 31, 2023, CPI had two subsidiaries. Prior to the Contributions, CPI has or will have divested all of its assets other than its 55.97% indirect ownership interest in BC. The unaudited pro forma condensed combined balance sheet data assumes that the Contributions took place on March 31, 2023 and combines the historical balance sheets of Catalyst and BC as of such date. The unaudited pro forma condensed combined statements of operations for the three months ended March&#160;31, 2023 and the year ended December&#160;31, 2022 assume that the Contributions took place as of January&#160;1, 2022 and combine the historical results of Catalyst and BC for the periods presented.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">319<br></div></div></div>
<!--End Page 330-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 331-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_121-selected_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The historical financial statements of Catalyst and the historical financial statements of BC have been adjusted to give pro forma effect to transaction accounting adjustments, including the non-controlling interest in BC not held by CPI. Adjustments are based on information available to management during the preparation of the unaudited pro forma condensed combined financial information and assumptions that management believes are reasonable and supportable.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The unaudited pro forma condensed combined financial information is based on the assumptions and adjustments that are described in the accompanying notes. Accordingly, the pro forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed and have been made solely for the purpose of providing unaudited pro forma condensed combined financial information. Differences between these preliminary estimates and the final accounting, expected to be completed after the closing of the Contributions, will occur and these differences could have a material impact on the accompanying unaudited pro forma condensed combined financial information and the combined company&#8217;s future results of operations and financial position. In addition, differences between the preliminary and final amounts will likely occur as a result of the amount of cash used for Catalyst&#8217;s operations, changes in the fair value of Catalyst Common Stock, and other changes in Catalyst&#8217;s assets and liabilities.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The unaudited pro forma condensed combined financial information is preliminary and has been prepared for illustrative purposes only and is not necessarily indicative of the financial position or results of operations in future periods or the results that actually would have been realized had Catalyst and CPI been a combined company during the specified periods. The actual results reported in periods following the Contributions may differ significantly from those reflected in the unaudited pro forma condensed combined financial information presented herein for a number of reasons, including, but not limited to, differences in the assumptions used to prepare this pro forma financial information.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The unaudited pro forma condensed combined financial information, including the notes thereto, should be read in conjunction with the Catalyst and BC historical audited financial statements for the year ended December&#160;31, 2022 and the unaudited condensed financial statements for the three months ended March 31, 2023 included elsewhere in this proxy statement. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Accounting rules require evaluation of certain assumptions, estimates, or determination of financial statement classifications. The accounting policies of Catalyst may materially vary from those of CPI. During preparation of the unaudited pro forma condensed combined financial information as set forth in this proxy statement, management has performed a preliminary analysis of Catalyst&#8217;s accounting policies and financial statement classifications and is not aware of any material differences in the application of GAAP between the two companies. Following the closing of the Contributions, management will conduct another review of Catalyst&#8217;s accounting policies in order to determine if differences in accounting policies require adjustment or reclassification of Catalyst&#8217;s results of operations or reclassification of assets or liabilities to conform to CPI&#8217;s accounting policies and classifications. As a result of such review, management may identify differences that, when conformed, could have a material impact on these unaudited pro forma condensed combined financial statements.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">320<br></div></div></div>
<!--End Page 331-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 332-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_121-selected_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Unaudited Pro Forma Condensed Combined Balance Sheet <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of March 31, 2023 <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-style: italic;">(in thousands)</font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.99%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.31%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Transaction <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accounting<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments</div></td><td class="gutter" style="width: 2.15%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.13%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.99%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Catalyst</div></td><td class="gutter" style="width: 2.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.31%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beijing <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Continent</div></td><td class="gutter" style="width: 2.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Contributions</div></td><td class="gutter" style="width: 2.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Note 4</div></td><td class="gutter" style="width: 2.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pro Forma <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Combined</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assets<br></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Current assets:<br></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 1.77pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 5pt;">8,099</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;">$26,459</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.98pt; text-align: left;">$<font style="padding-left: 5pt;">(1,740</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">B</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;">$27,459</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.98pt; text-align: left;"><font style="padding-left: 22.5pt;">(50</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">C</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.98pt; text-align: left;"><font style="padding-left: 10pt;">(5,309</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">D</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Notes receivable<font style="padding-left: 1.76pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 17.5pt;">608</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 17.5pt;">608</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Accounts and other receivables<font style="padding-left: 1.78pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">5,000</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 5pt;">12,504</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.98pt; text-align: left;"><font style="padding-left: 10pt;">(5,000</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">A</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 5pt;">12,504</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Prepayments<font style="padding-left: 2.85pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 17.5pt;">877</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 17.5pt;">877</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Inventories<font style="padding-left: 4.52pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 10pt;">5,693</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 10pt;">5,693</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Prepaid and other current assets<font style="padding-left: 4.01pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 32.7pt;">915</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 32.7pt;">939</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.98pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 36.03pt;">(104</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 36.03pt;"></font><font style="min-width: 36.03pt;">)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">B</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.7pt;">1,750</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Total current assets<font style="padding-left: 0.8pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">14,014</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 5pt;">47,080</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.98pt; text-align: left;"><font style="padding-left: 5pt;">(12,203</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 5pt;">48,891</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property, plant and equipment, net<font style="padding-left: 3.52pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 27.5pt;">1</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 5pt;">19,341</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 5pt;">19,342</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Long-term receivable from GCBP<font style="padding-left: 0.11pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">4,550</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 10pt;">4,550</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Intangible assets, net<font style="padding-left: 4.26pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 10pt;">2,506</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 10pt;">2,506</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Right-of-use assets<font style="padding-left: 2.31pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">17</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 10pt;">2,165</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 10pt;">2,182</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Long-term prepayments<font style="padding-left: 2.31pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 17.5pt;">481</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 17.5pt;">481</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred tax assets<font style="padding-left: 1.78pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 10pt;">4,382</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 10pt;">4,382</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Long-term bank deposits<font style="padding-left: 2.86pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 5pt;">13,378</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 5pt;">13,378</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other assets, noncurrent<font style="padding-left: 0.94pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 32.7pt;">168</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 32.7pt;">135</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="border-bottom: 1pt solid #000000; padding-left: 36.03pt; margin-left: 5.98pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 32.7pt;">303</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Total assets<font style="padding-left: 2.44pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.7pt; padding-right: 0.2pt;">$18,750</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.7pt; padding-right: 0.2pt;">$89,468</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.98pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 36.03pt;">$(12,203</font><font style="padding-left: 0.2pt; border-bottom: 3pt double #000000; min-width: 36.03pt;"></font><font style="min-width: 36.03pt;">)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.7pt; padding-right: 0.2pt;">$96,015</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Liabilities, redeemable convertible preferred stock, and stockholders&#8217; equity (deficit)<br></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Current liabilities:<br></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Accounts payable<font style="padding-left: 0.44pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 18.09pt;">16</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;">$<font style="padding-left: 13.28pt;">280</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.98pt; text-align: left;">$<font style="padding-left: 18.28pt;">(16</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">B</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;">$<font style="padding-left: 13.28pt;">280</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Other payable &#8211; related parties<font style="padding-left: 4.53pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.7pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 18.46pt;">113</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 18.46pt;">113</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Accrued compensation<font style="padding-left: 0.68pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10.98pt;">1,085</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 22.7pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.98pt; text-align: left;"><font style="padding-left: 11.18pt;">(1,085</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">B</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 22.7pt;">&#8212;</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Accrued expenses and other liabilities<font style="padding-left: 1.46pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 18.09pt;">743</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 10.98pt;">8,735</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.98pt; text-align: left;"><font style="padding-left: 18.28pt;">(743</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">B</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 10.98pt;">8,735</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">CVR dividend liability<font style="padding-left: 0.49pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10.98pt;">5,000</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 22.7pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.98pt; text-align: left;"><font style="padding-left: 11.18pt;">(5,000</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">A</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 22.7pt;">&#8212;</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Contract liabilities<font style="padding-left: 3.44pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.7pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 22.89pt;">58</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 22.89pt;">58</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Income tax payable<font style="padding-left: 3.06pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.7pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 10.98pt;">3,148</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 10.98pt;">3,148</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Operating lease liability<font style="padding-left: 1.66pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.7pt; border-bottom: 1pt solid #000000; min-width: 32.7pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 18.09pt; border-bottom: 1pt solid #000000; min-width: 32.7pt;">507</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="border-bottom: 1pt solid #000000; padding-left: 36.03pt; margin-left: 5.98pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 18.09pt; border-bottom: 1pt solid #000000; min-width: 32.7pt;">507</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Total current liabilities<font style="padding-left: 1.8pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10.98pt;">6,844</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 6.18pt;">12,841</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.98pt; text-align: left;"><font style="padding-left: 11.18pt;">(6,844</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 6.18pt;">12,841</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating lease liability, noncurrent<font style="padding-left: 0.51pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.7pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 18.09pt;">123</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 18.09pt;">123</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CVR derivative liability, noncurrent<font style="padding-left: 4.75pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10.98pt;">4,550</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 22.7pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 10.98pt;">4,550</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other liabilities, noncurrent<font style="padding-left: 2.72pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.7pt; border-bottom: 1pt solid #000000; min-width: 32.7pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 18.09pt; border-bottom: 1pt solid #000000; min-width: 32.7pt;">936</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="border-bottom: 1pt solid #000000; padding-left: 36.03pt; margin-left: 5.98pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 18.09pt; border-bottom: 1pt solid #000000; min-width: 32.7pt;">936</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Total liabilities<font style="padding-left: 1.88pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.55pt; border-bottom: 1pt solid #000000; min-width: 32.7pt;">11,394</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 6.18pt; border-bottom: 1pt solid #000000; min-width: 32.7pt;">13,900</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.98pt; text-align: left;"><font style="padding-left: 11.18pt; border-bottom: 1pt solid #000000; min-width: 36.03pt;">(6,844</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 36.03pt;"></font><font style="min-width: 36.03pt;">)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 6.18pt; border-bottom: 1pt solid #000000; min-width: 32.7pt;">18,450</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Catalyst Convertible Preferred Stock<font style="padding-left: 1.61pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.18pt;">33,309</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 22.7pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.98pt; text-align: left;"><font style="padding-left: 9.51pt;">28,382</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">F</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 6.18pt;">28,382</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.98pt; text-align: left;"><font style="padding-left: 6.37pt;">(33,309</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">G</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stockholders' equity (deficit):<br></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Common stock<font style="padding-left: 0.19pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.89pt;">37</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 22.7pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.98pt; text-align: left;"><font style="padding-left: 21.42pt;">992</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">F</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 10.98pt;">1,149</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.98pt; text-align: left;"><font style="padding-left: 23.09pt;">(37</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">G</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.98pt; text-align: left;"><font style="padding-left: 21.42pt;">157</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">H</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">321<br></div></div></div>
<!--End Page 332-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 333-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_121-selected_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.99%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.31%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Transaction <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accounting<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments</div></td><td class="gutter" style="width: 2.15%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.13%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.99%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Catalyst</div></td><td class="gutter" style="width: 2.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.31%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beijing <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Continent</div></td><td class="gutter" style="width: 2.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Contributions</div></td><td class="gutter" style="width: 2.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Note 4</div></td><td class="gutter" style="width: 2.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pro Forma <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Combined</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Additional paid-in capital<font style="padding-left: 0.09pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.13pt; text-align: left;"><font style="padding-left: 8.33pt;">384,686</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.85pt; text-align: left;"><font style="padding-left: 5pt;">47,265</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 15pt;">(5,309)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">D</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.12pt; text-align: left;"><font style="padding-left: 8.33pt;">41,910</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 10pt;">(19,627)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">E</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 18.33pt;">8,487</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">F</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 5pt;">(379,377)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">G</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 18.33pt;">5,785</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">H</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Statutory reserve<font style="padding-left: 0.64pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.13pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.85pt; text-align: left;"><font style="padding-left: 10pt;">5,326</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 15pt;">(2,345)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">E</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.12pt; text-align: left;"><font style="padding-left: 13.33pt;">2,981</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Retained earnings (accumulated deficit)<font style="padding-left: 2.35pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.13pt; text-align: justify;"><font style="padding-left: 5pt;">(410,676)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.85pt; text-align: left;"><font style="padding-left: 5pt;">24,779</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 27.5pt;">(50)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">C</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.12pt; text-align: left;"><font style="padding-left: 5pt;">(21,995)</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 10pt;">(10,910)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">E</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 10pt;">(37,861)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">F</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 8.33pt;">412,723</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">G</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accumulated other comprehensive loss<font style="padding-left: 4.56pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.13pt; text-align: left;"><font style="padding-left: 30.83pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.85pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(1,802</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">793</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">E</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.12pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(1,175</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 22.5pt;">(166)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">H</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total stockholders' equity (deficit)<font style="padding-left: 3.03pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.13pt; text-align: justify;"><font style="padding-left: 10pt;">(25,953)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.85pt; text-align: left;"><font style="padding-left: 5pt;">75,568</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 10pt;">(26,745)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.12pt; text-align: left;"><font style="padding-left: 8.33pt;">22,870</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Noncontrolling interest<font style="padding-left: 0.64pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.13pt; text-align: left;"><font style="padding-left: 30.83pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.85pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">32,089</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">E</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.12pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">26,313</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 15pt;">(5,776)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">H</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total equity (deficit)<font style="padding-left: 0.23pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.99%; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.13pt; text-align: justify;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">(25,953</font><font style="min-width: 40.83pt;">)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.85pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">75,568</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">(432</font><font style="min-width: 40.83pt;">)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.12pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">49,183</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Total liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit)<font style="font-weight: normal; padding-left: 1.19pt;"></font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.13pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40.83pt;">$</font><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 40.83pt;">18,750</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.85pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$89,468</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40.83pt;">$</font><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 40.83pt;">(12,203</font><font style="min-width: 40.83pt;">)</font></div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.12pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">$</font><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">96,015</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">322<br></div></div></div>
<!--End Page 333-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 334-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_121-selected_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Unaudited Pro Forma Condensed Combined Statement of Operations <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the Three Months Ended March 31, 2023 <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-style: italic;">(in thousands, except per share data)</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.31%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Transaction <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accounting<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments</div></td><td class="gutter" style="width: 2%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.61%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Catalyst</div></td><td class="gutter" style="width: 2%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.31%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beijing <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Continent</div></td><td class="gutter" style="width: 2%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Contributions</div></td><td class="gutter" style="width: 2%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Note 4</div></td><td class="gutter" style="width: 2%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.61%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pro Forma <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Combined</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Revenues<font style="padding-left: 0.63pt;"></font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.86pt; text-align: left;">$24,560</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.49pt; text-align: left;">$<font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 12.5pt;">24,560</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cost of revenue<font style="padding-left: 4.53pt;"></font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.86pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(1,141</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.49pt; text-align: left;"><font style="padding-left: 35pt; border-bottom: 1pt solid #000000; min-width: 45pt;">&#8212;</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(1,141</font><font style="min-width: 45pt;">)</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Gross profit<font style="padding-left: 0.63pt;"></font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.86pt; text-align: left;"><font style="padding-left: 5pt;">23,419</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.49pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">23,419</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses (income):<br></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Selling and marketing expenses<font style="padding-left: 0.1pt;"></font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.86pt; text-align: left;"><font style="padding-left: 5pt;">12,791</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.49pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">12,791</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development<font style="padding-left: 0.1pt;"></font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">588</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.86pt; text-align: left;"><font style="padding-left: 10pt;">2,768</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.49pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">3,356</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">General and administrative<font style="padding-left: 4.55pt;"></font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">3,970</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.86pt; text-align: left;"><font style="padding-left: 10pt;">2,035</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.49pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">6,005</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Gain on disposal of assets, net<font style="padding-left: 4.28pt;"></font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(4,736</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.86pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.49pt; text-align: left;"><font style="padding-left: 35pt; border-bottom: 1pt solid #000000; min-width: 45pt;">&#8212;</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(4,736</font><font style="min-width: 45pt;">)</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total operating expenses (income)<font style="padding-left: 4.14pt;"></font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(178</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.86pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">17,594</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.49pt; text-align: left;"><font style="padding-left: 35pt; border-bottom: 1pt solid #000000; min-width: 45pt;">&#8212;</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 45pt;">17,416</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income from operations<font style="padding-left: 1.76pt;"></font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">178</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.86pt; text-align: left;"><font style="padding-left: 10pt;">5,825</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.49pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">6,003</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest and other income, net<font style="padding-left: 2.05pt;"></font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">96</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.86pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(50</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.49pt; text-align: left;"><font style="padding-left: 35pt; border-bottom: 1pt solid #000000; min-width: 45pt;">&#8212;</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 35pt; border-bottom: 1pt solid #000000; min-width: 45pt;">46</font><font style="border-bottom: 1pt solid #000000; min-width: 45pt;"> </font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income before income taxes<font style="padding-left: 4pt;"></font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">274</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.86pt; text-align: left;"><font style="padding-left: 10pt;">5,775</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.49pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">6,049</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Income tax expenses<font style="padding-left: 4.54pt;"></font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(14</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.86pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(1,536</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.49pt; text-align: left;"><font style="padding-left: 35pt; border-bottom: 1pt solid #000000; min-width: 45pt;">&#8212;</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(1,550</font><font style="min-width: 45pt;">)</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net income<font style="padding-left: 2.3pt;"></font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">260</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.86pt; text-align: left;"><font style="padding-left: 10pt;">4,239</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.49pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">4,499</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Net income attributable to noncontrolling interest<font style="padding-left: 0.07pt;"></font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.86pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.49pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 45pt;">1,476</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">AA</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 45pt;">1,476</font><font style="border-bottom: 1pt solid #000000; min-width: 45pt;"> </font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net income attributable to stockholders<font style="padding-left: 3.45pt;"></font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">260</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.86pt; text-align: left;"><font style="padding-left: 10pt;">4,239</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.49pt; text-align: left;"><font style="padding-left: 19.17pt;">(1,476)</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">3,023</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Net income attributable to Catalyst Convertible Preferred Stock<font style="padding-left: 0.66pt;"></font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.86pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.49pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 45pt;">293</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">EE</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 45pt;">293</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Net income attributable to common stockholders &#8211; basic <font style="padding-left: 3.43pt;"></font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">$</font><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">260</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.86pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">$</font><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">4,239</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.49pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 45pt;">$</font><font style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(1,769</font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">EE</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 45pt;">$</font><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 45pt;">2,730</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Net income attributable to common stockholders - diluted<font style="padding-left: 1.2pt;"></font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 12.5pt;">260 </font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.86pt; text-align: left;">$<font style="padding-left: 5pt;">4,239 </font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.49pt; text-align: left;">$<font style="padding-left: 14.17pt;">(1,748) </font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">EE </div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 17.5pt;">2,751</font> </div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net income per common share, basic<font style="padding-left: 2.07pt;"></font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$</font><font style="padding-left: 10pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">0.01</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="border-bottom: 3pt double #000000; padding-left: 45pt; margin-left: 1.49pt;"></font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 45pt;">$</font><font style="padding-left: 22.5pt; border-bottom: 3pt double #000000; min-width: 45pt;">0.00</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net income per common share, diluted<font style="padding-left: 4.84pt;"></font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$</font><font style="padding-left: 10pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">0.01</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="border-bottom: 3pt double #000000; padding-left: 45pt; margin-left: 1.49pt;"></font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 45pt;">$</font><font style="padding-left: 22.5pt; border-bottom: 3pt double #000000; min-width: 45pt;">0.00</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Weighted average common share outstanding &#8211; basic<font style="padding-left: 0.63pt;"></font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">37,758</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.49pt; text-align: left;"><font style="padding-left: 5.37pt; border-bottom: 3pt double #000000; min-width: 45pt;">1,110,776</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">DD</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 45pt;">1,148,534</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Weighted average common share outstanding &#8211; diluted<font style="padding-left: 3.39pt;"></font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">37,984</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.49pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 45pt;">1,209,787</font></div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.84%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">DD</div></td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 45pt;">1,247,771</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">323<br></div></div></div>
<!--End Page 334-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 335-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_121-selected_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Unaudited Pro Forma Condensed Combined Statement of Operations <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the Year Ended December&#160;31, 2022<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-style: italic;">(in thousands, except per share data)</font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 28.85%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.89%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.14%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Transaction <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accounting <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments</div></td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.24%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.63%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.21%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.97%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Transaction <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accounting <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments</div></td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.23%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.65%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 28.85%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.89%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Catalyst</div></td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.14%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">GCBP Asset <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Sale</div></td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.24%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Note 4</div></td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Catalyst <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">(As adjusted)</div></td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.21%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beijing <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Continent</div></td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.97%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Contributions</div></td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.23%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Note 4</div></td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pro Forma <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Combined</div></td></tr><tr><td style="width: 28.85%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Revenues<font style="padding-left: 2.76pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 14.24pt;">794</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;">$<font style="padding-left: 14.24pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.08pt; text-align: left;">$<font style="padding-left: 14.24pt;">794</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$102,461</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.91pt; text-align: left;">$<font style="padding-left: 26.67pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.23%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 6.75pt;">103,255</font></div></td></tr><tr><td style="width: 28.85%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cost of revenue<font style="padding-left: 4.29pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.75pt; border-bottom: 1pt solid #000000; min-width: 32.24pt;">(798</font><font style="min-width: 32.24pt;">)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 18.74pt; border-bottom: 1pt solid #000000; min-width: 27.74pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.08pt; text-align: left;"><font style="padding-left: 15.75pt; border-bottom: 1pt solid #000000; min-width: 32.24pt;">(798</font><font style="min-width: 32.24pt;">)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10.51pt; border-bottom: 1pt solid #000000; min-width: 33.75pt;">(4,538</font><font style="min-width: 33.75pt;">)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.91pt; text-align: left;"><font style="padding-left: 31.17pt; border-bottom: 1pt solid #000000; min-width: 40.17pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.23%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.26pt; border-bottom: 1pt solid #000000; min-width: 40.5pt;">(5,336</font><font style="min-width: 40.5pt;">)</font></div></td></tr><tr><td style="width: 28.85%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Gross profit (loss)<font style="padding-left: 0.79pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 24.75pt;">(4)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 18.74pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.08pt; text-align: left;"><font style="padding-left: 24.75pt;">(4)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9pt;">97,923</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.91pt; text-align: left;"><font style="padding-left: 31.17pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.23%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.75pt;">97,919</font></div></td></tr><tr><td style="width: 28.85%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses (income):<br></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.23%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 28.85%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Selling and marketing expenses<font style="padding-left: 1.31pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 23.24pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 18.74pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.08pt; text-align: left;"><font style="padding-left: 23.24pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9pt;">52,554</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.91pt; text-align: left;"><font style="padding-left: 31.17pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.23%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.75pt;">52,554</font></div></td></tr><tr><td style="width: 28.85%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development<font style="padding-left: 4.31pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.49pt;">13,037</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 4.5pt;">(2,433)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.24%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">AA</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.08pt; text-align: left;"><font style="padding-left: 7.49pt;">10,604</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9pt;">15,245</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.91pt; text-align: left;"><font style="padding-left: 31.17pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.23%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.75pt;">21,909</font></div></td></tr><tr><td style="width: 28.85%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">General and administrative<font style="padding-left: 3.82pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.49pt;">17,</font>366</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 18.74pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.24%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.08pt; text-align: left;"><font style="padding-left: 7.49pt;">17,</font>366</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9.33pt;">11,305</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.91pt; text-align: left;"><font style="padding-left: 26.67pt;">350</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.23%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">CC</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.75pt;">32,961</font> </div></td></tr><tr><td style="width: 28.85%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Acquired in-process research and development<font style="padding-left: 1.27pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.49pt;">35,390</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 18.74pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.24%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.08pt; text-align: left;"><font style="padding-left: 7.49pt;">35,390</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 24.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.91pt; text-align: left;"><font style="padding-left: 15.42pt;">31,456</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.23%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">DD</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.75pt;">66,846 </font></div></td></tr><tr><td style="width: 28.85%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Gain on disposal of assets, net<font style="padding-left: 0.07pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.5pt; border-bottom: 1pt solid #000000; min-width: 32.24pt;">(57,186</font><font style="min-width: 32.24pt;">)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 4.5pt; border-bottom: 1pt solid #000000; min-width: 27.74pt;">(5,206</font><font style="min-width: 27.74pt;">)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.24%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">AA</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.08pt; text-align: left;"><font style="padding-left: 4.5pt; border-bottom: 1pt solid #000000; min-width: 32.24pt;">(62,392</font><font style="min-width: 32.24pt;">)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 24.75pt; border-bottom: 1pt solid #000000; min-width: 33.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.91pt; text-align: left;"><font style="padding-left: 31.17pt; border-bottom: 1pt solid #000000; min-width: 40.17pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.23%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.76pt; border-bottom: 1pt solid #000000; min-width: 40.5pt;">(62,392</font><font style="min-width: 40.5pt;">)</font></div></td></tr><tr><td style="width: 28.85%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Total operating expenses<font style="padding-left: 1.93pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 11.99pt; border-bottom: 1pt solid #000000; min-width: 32.24pt;">8,607</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 4.5pt; border-bottom: 1pt solid #000000; min-width: 27.74pt;">(7,639</font><font style="min-width: 27.74pt;">)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.24%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.08pt; text-align: left;"><font style="padding-left: 18.74pt; border-bottom: 1pt solid #000000; min-width: 32.24pt;">968</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9pt; border-bottom: 1pt solid #000000; min-width: 33.75pt;">79,104</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.91pt; text-align: left;"><font style="padding-left: 15.42pt; border-bottom: 1pt solid #000000; min-width: 40.17pt;">31,806</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.23%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 11.91pt; border-bottom: 1pt solid #000000; min-width: 40.5pt;">111,878</font><font style="border-bottom: 1pt solid #000000; min-width: 40.5pt;"> </font></div></td></tr><tr><td style="width: 28.85%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income (loss) from operations<font style="padding-left: 1.82pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9.33pt;">(</font>8,611)</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 7.49pt;">7,639</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.24%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.08pt; text-align: left;"><font style="padding-left: 15.75pt;">(</font>972)</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9pt;">18,819</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.91pt; text-align: left;"><font style="padding-left: 12.42pt;">(</font>31,806)</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.23%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.76pt;">(</font>13,959)</div></td></tr><tr><td style="width: 28.85%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt; text-align: left;">Interest and other income (expense), net<font style="padding-left: 2.76pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 18.74pt; border-bottom: 1pt solid #000000; min-width: 32.24pt;">717</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 18.74pt; border-bottom: 1pt solid #000000; min-width: 27.74pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.24%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.08pt; text-align: left;"><font style="padding-left: 18.74pt; border-bottom: 1pt solid #000000; min-width: 32.24pt;">717</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.25pt; border-bottom: 1pt solid #000000; min-width: 33.75pt;">425</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.91pt; text-align: left;"><font style="padding-left: 31.17pt; border-bottom: 1pt solid #000000; min-width: 40.17pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.23%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.25pt; border-bottom: 1pt solid #000000; min-width: 40.5pt;">1,142 </font></div></td></tr><tr><td style="width: 28.85%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income (loss) before income taxes<font style="padding-left: 0.85pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9pt;">(</font>7,894)</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 7.49pt;">7,639</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.24%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.08pt; text-align: left;"><font style="padding-left: 15.75pt;">(</font>255)</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9pt;">19,244</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.91pt; text-align: left;"><font style="padding-left: 12.42pt;">(31,806)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.23%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.76pt;">(</font>12,817)</div></td></tr><tr><td style="width: 28.85%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Income tax expense<font style="padding-left: 4.8pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.75pt; border-bottom: 1pt solid #000000; min-width: 32.24pt;">(348</font><font style="min-width: 32.24pt;">)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 18.74pt; border-bottom: 1pt solid #000000; min-width: 27.74pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.24%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.08pt; text-align: left;"><font style="padding-left: 15.75pt; border-bottom: 1pt solid #000000; min-width: 32.24pt;">(348</font><font style="min-width: 32.24pt;">)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10.51pt; border-bottom: 1pt solid #000000; min-width: 33.75pt;">(4,531</font><font style="min-width: 33.75pt;">)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.91pt; text-align: left;"><font style="padding-left: 31.17pt; border-bottom: 1pt solid #000000; min-width: 40.17pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.23%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.26pt; border-bottom: 1pt solid #000000; min-width: 40.5pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 40.5pt;">4,879</font><font style="border-bottom: 1pt solid #000000; min-width: 40.5pt;"></font><font style="min-width: 40.5pt;">)</font></div></td></tr><tr><td style="width: 28.85%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net income (loss)<font style="padding-left: 2.29pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9pt;">(</font>8,242)</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 7.49pt;">7,639</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.24%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.08pt; text-align: left;"><font style="padding-left: 15.75pt;">(</font>603)</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9pt;">14,713</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.91pt; text-align: left;"><font style="padding-left: 12.42pt;">(31,806)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.23%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.76pt;">(</font>17,696)</div></td></tr><tr><td style="width: 28.85%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt; text-align: left;">Net income attributable to noncontrolling interest<font style="padding-left: 1.28pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 23.24pt; border-bottom: 1pt solid #000000; min-width: 32.24pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 18.74pt; border-bottom: 1pt solid #000000; min-width: 27.74pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.24%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.08pt; text-align: left;"><font style="padding-left: 23.24pt; border-bottom: 1pt solid #000000; min-width: 32.24pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 24.75pt; border-bottom: 1pt solid #000000; min-width: 33.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.91pt; text-align: left;"><font style="padding-left: 19.92pt; border-bottom: 1pt solid #000000; min-width: 40.17pt;">5,123</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.23%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">BB</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.25pt; border-bottom: 1pt solid #000000; min-width: 40.5pt;">5,123 </font></div></td></tr><tr><td style="width: 28.85%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Net income (loss) attributable to common stockholders<font style="padding-left: 2.78pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.24pt;">$</font><font style="padding-left: 4.5pt; border-bottom: 3pt double #000000; min-width: 32.24pt;">(</font><font style="border-bottom: 3pt double #000000; min-width: 32.24pt;">8,242</font><font style="border-bottom: 3pt double #000000; min-width: 32.24pt;"></font><font style="min-width: 32.24pt;">)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.74pt;">$</font><font style="padding-left: 2.99pt; border-bottom: 3pt double #000000; min-width: 27.74pt;">7,639</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.24%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.08pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.24pt;">$</font><font style="padding-left: 11.25pt; border-bottom: 3pt double #000000; min-width: 32.24pt;">(</font><font style="border-bottom: 3pt double #000000; min-width: 32.24pt;">603</font><font style="border-bottom: 3pt double #000000; min-width: 32.24pt;"></font><font style="min-width: 32.24pt;">)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 33.75pt;">$</font><font style="padding-left: 4.5pt; border-bottom: 3pt double #000000; min-width: 33.75pt;">14,713</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.91pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40.17pt;">$</font><font style="padding-left: 7.92pt; border-bottom: 3pt double #000000; min-width: 40.17pt;">(36,929</font><font style="min-width: 40.17pt;">)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.23%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.76pt; border-bottom: 3pt double #000000; min-width: 40.5pt;">(</font><font style="border-bottom: 3pt double #000000; min-width: 40.5pt;">22,819</font><font style="border-bottom: 3pt double #000000; min-width: 40.5pt;"></font><font style="min-width: 40.5pt;">)</font></div></td></tr><tr><td style="width: 28.85%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt; text-align: left;">Net loss per common share, basic and diluted<font style="padding-left: 2.77pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.24pt;">$</font><font style="padding-left: 9pt; border-bottom: 1pt solid #000000; min-width: 32.24pt;">(0.26</font><font style="min-width: 32.24pt;">)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.24%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.23%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 40.5pt;">$</font><font style="padding-left: 17.26pt; border-bottom: 1pt solid #000000; min-width: 40.5pt;">(0.02</font><font style="min-width: 40.5pt;">)</font></div></td></tr><tr><td style="width: 28.85%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt; text-align: left;">Weighted average common share outstanding &#8211; basic and diluted<font style="padding-left: 3.8pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.49pt; border-bottom: 3pt double #000000; min-width: 32.24pt;">31,546</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.24%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.91pt; text-align: left;"><font style="padding-left: 4.5pt; border-bottom: 3pt double #000000; min-width: 40.17pt;">1,110,776</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.23%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">EE</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.5pt; border-bottom: 3pt double #000000; min-width: 40.5pt;">1,142,322</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">324<br></div></div></div>
<!--End Page 335-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 336-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_122-unaudited_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tNTU"><!--Anchor--></a>NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Description of the Contributions and other related transactions </div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Business Combination Agreement </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On December&#160;26, 2022, Catalyst, CPI, GNI USA, GNI Japan, GNI Hong Kong, SG and the Minority Holders entered into the Business Combination Agreement, as amended on March 29, 2023. Under the Business Combination Agreement, Catalyst will acquire an indirect controlling interest in BC. Subject to the terms and conditions set forth in the Business Combination Agreement, at the Effective Time of the Contributions,</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">GNI USA will contribute all of its CPI Ordinary Shares to Catalyst in exchange for 688,850,101 shares of Catalyst Common Stock (as previously defined in this proxy statement, the &#8220;CPI Contribution&#8221;),</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">b)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">GNI USA will contribute its interest in Further Challenger to Catalyst in exchange for 264,971,695 shares of Catalyst Common Stock (as previously defined in this proxy statement, the &#8220;FC Contribution&#8221;), and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">c)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each Minority Holder will contribute 100% of the interest he or she holds in his or her respective entity to Catalyst in exchange for an aggregate of 156,954,428 shares of Catalyst Common Stock (as previously defined in this proxy statement, the &#8220;Minority Holder Contributions&#8221;).</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As a result of the CPI Contribution and the FC Contribution, Catalyst will directly and indirectly hold 100% of CPI&#8217;s shares. Through Catalyst&#8217;s ownership of CPI, Catalyst will hold a 55.97% indirect interest in BC. Further, after the CPI Contribution and the FC Contribution, CPI will hold no assets other than its 55.97% indirect ownership interest in BC. After the Minority Holder Contributions, Catalyst will obtain additional indirect interests in BC and hold, in aggregate, a&#160;65.18% indirect interest in BC. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Immediately after the closing of the Contributions, assuming there are no conversions of Catalyst Convertible Preferred Stock, current holders of CPI&#8217;s capital stock are expected to own approximately 83.59% of the outstanding shares of Catalyst Common Stock, Catalyst&#8217;s current stockholders are expected to own approximately 2.74% of the outstanding Catalyst Common Stock, and the Minority Holders are expected to own approximately 13.67% of the outstanding shares of Catalyst Common Stock. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">At the Effective Time, BC will terminate the 2021 Plan and the BC Options outstanding under the 2021 Plan will be terminated and replaced with options granted pursuant to a sub-plan for PRC participants under the 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Each share of Catalyst Common Stock and option to purchase Catalyst Common Stock that is issued and outstanding at the Effective Time will remain issued and outstanding and such shares and options will be unaffected by the Contributions. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">To complete the Contributions, Catalyst stockholders must approve Proposals No. 1, 2, 3, 4 and 6. Additionally, each of the other closing conditions set forth in the Business Combination Agreement must be satisfied or waived.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Contingent Value Rights Agreement </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Concurrent with the signing of the Business Combination Agreement on December&#160;26, 2022, Catalyst and the Rights Agent entered into the CVR Agreement as amended on March 29, 2023, pursuant to which each holder of Catalyst Common Stock, excluding the Sellers, as of the CVR Record Date received one contractual CVR issued by Catalyst, subject to and in accordance with the terms and conditions of the CVR Agreement, for each share of Catalyst Common Stock held by such holder at the CVR Record Date. Each CVR entitles the holder thereof to receive (i)&#160;certain cash payments from the net proceeds related to the disposition of Catalyst&#8217;s legacy assets or resolution of certain legal claims within three years following the Closing (as defined in the CVR Agreement), (ii) 100% of the excess cash (net of all current or contingent liabilities, including transaction-related expenses) retained by Catalyst in excess of $1,000,000 as of the Closing and (iii) 100% of the amount actually received (net of indemnity claims, if any) by Catalyst pursuant to the Asset Purchase Agreement, dated as of May&#160;19, 2022, by and between Catalyst and Vertex. The CVRs will not have any voting or dividend rights and will not represent any equity or ownership interest in Catalyst or any of its affiliates. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Basis of Pro Forma Presentation </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The unaudited pro forma condensed combined financial information was prepared in accordance with GAAP and pursuant to the rules and regulations of Article 11 of Regulation S-X. The unaudited pro forma condensed combined </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">325<br></div></div></div>
<!--End Page 336-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 337-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_122-unaudited_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">balance sheet as of March 31, 2023 gives effect to the Contributions as if they had been consummated on March&#160;31, 2023. The unaudited pro forma condensed combined statements of operations for the three months ended March&#160;31, 2023 and the year ended December&#160;31, 2022 give effect to the Contributions as if they had been consummated on January&#160;1, 2022. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Additionally, the unaudited pro forma condensed combined balance sheet and statements of operations reflect the other related transactions that will have occurred at or prior to the completion of the Contributions. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Based on CPI&#8217;s preliminary review of CPI&#8217;s and Catalyst&#8217;s summary of significant accounting policies, the amount of any adjustments to the historical financial statements of Catalyst to conform Catalyst&#8217;s accounting policies to those of CPI are not expected to be material. Upon completion of the Contributions, further review of Catalyst&#8217;s accounting policies may result in additional revisions to Catalyst&#8217;s accounting policies and classifications to conform to those of CPI.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The unaudited pro forma condensed combined financial information has been prepared with the expectation that the Contributions will be treated as an asset acquisition, with CPI treated as the accounting acquirer. Since Catalyst is the legal acquirer, the Contributions will be accounted for as a reverse asset acquisition. To determine the accounting for this transaction under GAAP, a company must assess whether an integrated set of assets and activities should be accounted for as an acquisition of a business or an asset acquisition. The guidance requires an initial screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single asset or group of similar assets. If that screen is met, the operations acquired are not a business. Catalyst is not expected to meet the definition of a business since substantially all of the fair value is included in IPR&amp;D and no substantive processes are being acquired. As such, the Contributions are expected to be treated as an asset acquisition. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The unaudited pro forma condensed combined financial statements also give effect to the other related transactions that are not directly attributable to the Contributions but are deemed relevant to the pro forma financial position and operations of the combined company. Since these transactions will impact the net assets ultimately acquired, the pro forma adjustments reflect the assumed distribution of Catalyst&#8217;s cash in excess of $1.0&#160;million under the CVR Agreement after considering settlement of Catalyst&#8217;s remaining obligations immediately prior to the closing of the Contributions. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The unaudited pro forma condensed combined financial information is based on assumptions and adjustments that are reasonable and supportable. Key assumptions include the estimated fair value of equity consideration as well as assets acquired and liabilities assumed, which will be impacted by changes in the capitalization of CPI and Catalyst, changes in the share price of Catalyst, changes in Catalyst&#8217;s assets and liabilities and actual transaction costs to be incurred. Accordingly, the pro forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed and have been made solely for the purpose of providing unaudited pro forma condensed combined financial information. Differences between these preliminary estimates and the final accounting, expected to be completed after the closing of the Contributions, will occur and these differences could have a material impact on the accompanying unaudited pro forma condensed combined financial information and the combined company&#8217;s future results of operations and financial position. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Preliminary Purchase Price for the CPI Contribution and the FC Contribution</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accompanying unaudited pro forma condensed combined financial statements reflect an estimated purchase price of approximately $37.9 million, which consists of the following (in thousands, except per share amount):</div> <table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Catalyst Common Stock outstanding<font style="padding-left: 3.08pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">37,760</font></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Multiplied by the assumed price per share of Catalyst stock<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 3.86pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">$</font><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8203;</font><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">0.23</font></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fair value of common shares of the combined company to be owned by Catalyst&#8217;s stockholders<font style="padding-left: 4.31pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 5pt;">&#8203;</font>8,685</div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fair value of preferred shares of the combined company to be owned by Catalyst&#8217;s stockholders<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><font style="padding-left: 3.93pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">$</font><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">2</font><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">8</font><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">,382</font></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Estimated acquisition-date fair value of Catalyst<font style="padding-left: 0.36pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$37,067</div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pre-combination Catalyst stock options assumed by CPI<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup><font style="padding-left: 3.82pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">$</font><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8203;</font><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">794</font></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total preliminary estimated purchase price<font style="font-weight: normal; padding-left: 4.96pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$</font><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">37,861</font></div></td></tr></table> <div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 10.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The estimated purchase price was based on the closing price of Catalyst Common Stock on June&#160;14, 2023. The actual purchase price will fluctuate until the Effective Time. Therefore, the estimated consideration expected to be transferred reflected in this unaudited pro forma condensed combined financial information does not purport to represent what the actual transferred consideration will be when the transaction is completed.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">326<br></div></div></div>
<!--End Page 337-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 338-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_122-unaudited_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5.25pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">This amount is calculated, for purposes of this unaudited pro forma condensed combined financial information, based on 12,340 shares of Catalyst Convertible Preferred Stock outstanding as of March&#160;31, 2023. Each share of preferred stock converts into 10,000 shares of common stock. The fair value was estimated using the closing price of Catalyst Common Stock on June&#160;14, 2023 and the number of underlying common shares. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Effective with the Contributions, any option to purchase Catalyst Common Stock that is issued and outstanding at the Effective Time will remain issued and outstanding and such option will be unaffected by the Contributions. In a reverse acquisition, however, from an accounting perspective, the Catalyst employee stock option awards have been exchanged for share-based payment awards of the accounting acquirer. Accordingly, this balance represents the precombination service portion of the estimated fair value of the employee stock option awards issued to Catalyst option holders. In calculating the estimated fair value of the option awards based on the Black-Scholes model, management used the following weighted-average assumptions: </div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr><td style="width: 93.75%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected term (in years)<font style="padding-left: 2.16pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4pt;">5.66</font></div></td></tr><tr><td style="width: 93.75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Volatility<font style="padding-left: 3.36pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">92.58%</div></td></tr><tr><td style="width: 93.75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Risk free interest rate<font style="padding-left: 2.38pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4pt;">3.00%</font></div></td></tr><tr><td style="width: 93.75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dividend yield<font style="padding-left: 4.57pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">&#8212;%</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">A preliminary allocation of the total preliminary estimated purchase price, as shown above, to the acquired assets and assumed liabilities of Catalyst based on the estimated fair values as of March 31, 2023 is as follows (in thousands):</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 2.77pt;"></font></div></td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 5pt;">&#8203;</font>1,000</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prepaid and other current assets <font style="padding-left: 1.68pt;"></font></div></td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.87pt;">811</font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property and equipment, net <font style="padding-left: 1.37pt;"></font></div></td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 27.5pt;">1</font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Right-of-use assets <font style="padding-left: 4.98pt;"></font></div></td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">17</font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Long-term receivable from GCBP<font style="padding-left: 1.11pt;"></font></div></td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">4,550</font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other assets, noncurrent<font style="padding-left: 1.94pt;"></font></div></td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">168</font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">IPR&amp;D<font style="padding-left: 4.95pt;"></font></div></td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">35,864</font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CVR derivative liability, noncurrent<font style="padding-left: 3.69pt;"></font></div></td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(4,550</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net assets acquired <font style="padding-left: 3.33pt;"></font></div></td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$</font><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">37,861</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The allocation of the estimated purchase price is preliminary because the Contributions have not yet been completed. The final determination of the purchase price allocation is anticipated to be completed as soon as practicable after closing of the Contributions and will be based on the fair values of the assets acquired and liabilities assumed as of the closing date of the Contributions. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The pro forma statements of operations for the three months ended March 31, 2023 and for the year ended December&#160;31, 2022 include transaction costs of $0.3 million and $1.0&#160;million, respectively, incurred by Catalyst in connection with the Contributions and recorded as expense in the historical condensed consolidated statement of operations for the respective periods. Such transaction costs are not expected to recur. CPI did not incur any direct transaction costs in connection with the Contributions. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">4.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Pro Forma Adjustments </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The pro forma adjustments included in the unaudited pro forma condensed combined balance sheets as of March&#160;31, 2023 are as follows:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 40pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(A)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To reflect the receipt of the $5.0 million hold-back under the asset purchase agreement with Vertex expected to be received prior to the closing of the Contributions, which will be immediately distributed to the CVR holders subject to the terms and conditions of the CVR Agreement. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 40pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(B)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To reflect Catalyst&#8217;s planned settlement of outstanding receivables and obligations immediately prior to the closing of the Contributions.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 40pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(C)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To reflect the payment of Contributions-related transaction costs consisting of legal fees, advisory fees, accounting and audit fees and other expenses to be incurred by Catalyst between March 31, 2023 and the closing of the Contributions. Such costs are assumed to be paid by Catalyst immediately prior to the closing of the Contributions.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 40pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(D)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To reflect the distribution of cash in excess of $1.0 million, after the settlement of Catalyst&#8217;s outstanding obligations, to the CVR holders under the CVR Agreement immediately prior to the closing of the Contributions. Such amount will change depending on the amounts necessary to cover outstanding obligations upon the closing of the Contributions.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">327<br></div></div></div>
<!--End Page 338-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 339-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_122-unaudited_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 0pt;"><tr><td style="width: 40pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(E)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To reflect the noncontrolling interest ownership of 44.03% in BC not held by CPI immediately after the CPI Contribution and the FC Contribution. After the CPI Contribution and the FC Contribution, CPI will hold no assets other than its 55.97% indirect ownership interest in BC.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 40pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(F)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Represents estimated purchase consideration values based on the Catalyst equity to be acquired, using the Catalyst closing stock price of $0.23 as of June 14, 2023. The net impact to CPI&#8217;s retained earnings resulting from all the pro forma balance sheet adjustments is the immediate expensing of Catalyst&#8217;s IPR&amp;D of $35.9 million.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 40pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(G)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To eliminate Catalyst&#8217;s historical stockholders&#8217; equity and Catalyst Convertible Preferred Stock balances, including accumulated deficit. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 40pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(H)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To reflect the additional ownership interest in BC acquired from the Minority Holders without an accompanying change in control (the Minority Holder Contributions). After the Minority Holder Contributions, the noncontrolling interest ownership in BC not held by Catalyst will be 34.82%. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The pro forma adjustments included in the unaudited pro forma condensed combined statements of operations for the three months ended March 31, 2023 and the year ended December 31, 2022 are as follows:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 40pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(AA)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To reflect net income attributable to noncontrolling interest ownership of 34.82% in BC not held by Catalyst after the Minority Holder Contributions for the three months ended March 31, 2023 and the year ended December 31, 2023.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 40pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(BB)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To reflect Contributions-related transaction costs consisting of legal fees, advisory fees, accounting and audit fees and other expenses to be incurred by Catalyst between March 31, 2023 and the closing of the Contributions. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 40pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(CC)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To reflect an adjustment to immediately expense the value attributed to Catalyst&#8217;s intangible assets consisting of IPR&amp;D related to the F351 Assets. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 40pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(DD)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The weighted average shares outstanding for the period has been calculated as if the Contributions occurred on January 1, 2022, calculated as the sum of 1) historical weighted average shares outstanding for Catalyst, and 2) Catalyst shares issuable upon the closing of the Contributions. The following table presents the calculation of the pro forma weighted average number of common stock outstanding (in thousands).</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 428pt; margin-left: 40pt;"><tr class="header"><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.41%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 17.3%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 31, 2023</div></td><td class="gutter" style="width: 1.41%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.41%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 15.38%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2022 </div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted average Catalyst shares outstanding <font style="padding-left: 1.27pt;"></font></div></td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.03pt; text-align: left;"><font style="padding-left: 12.5pt;">37,758</font></div></td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.91pt; text-align: left;"><font style="padding-left: 12.5pt;">31,546</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Estimated shares of Catalyst Common Stock to be issued to CPI shareholders upon closing of the Contributions<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 2.26pt;"></font></div></td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.03pt; text-align: left;"><font style="padding-left: 0.37pt;">1,110,776</font></div></td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.91pt; text-align: left;"><font style="padding-left: 0.37pt;">1,110,776</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Pro forma combined weighted average number of shares of common stock - basic <font style="padding-left: 3.2pt;"></font></div></td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.03pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">1,148,534</font></div></td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.91pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">1,142,322</font><font style="border-bottom: 3pt double #000000; min-width: 40pt;"> </font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Effect of dilutive stock options - Catalyst<font style="padding-left: 1.74pt;"></font></div></td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.03pt; text-align: left;"><font style="padding-left: 25pt;">226</font></div></td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.91pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Effect of dilutive stock options - BC<font style="padding-left: 1.18pt;"></font></div></td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.03pt; text-align: left;"><font style="padding-left: 12.87pt; border-bottom: 1pt solid #000000; min-width: 40pt;">99,011</font></div></td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.91pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 40pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Pro forma combined weighted average number of shares of common stock - diluted <font style="padding-left: 0.97pt;"></font></div></td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.03pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">1,247,771</font></div></td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.91pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">1,142,322</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 40pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Estimated shares of Catalyst Common Stock to be issued to CPI shareholders upon closing of the Contributions reflect 953,822&#160;shares, in aggregate, to be issued to GNI USA and 156,954 shares to be issued to the Minority Holders.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">328<br></div></div></div>
<!--End Page 339-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 340-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_122-unaudited_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 0pt;"><tr><td style="width: 40pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(EE)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Catalyst Convertible Preferred Stock contractually entitles the holders of such shares to participate in dividends, contingent upon the closing of the Contributions. The following table reconciles the numerators of the pro forma combined basic and diluted net income (loss) per common share calculation (in&#160;thousands).</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 428pt; margin-left: 40pt;"><tr class="header"><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.41%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 17.3%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 31, 2023</div></td><td class="gutter" style="width: 1.41%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.41%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 15.38%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2022 </div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pro forma combined net income (loss) <font style="padding-left: 0.45pt;"></font></div></td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.28pt; text-align: left;">$4,499</div></td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15pt; text-align: left;">$(29,443)</div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Less: Estimated net (income) loss attributable to noncontrolling interest <font style="padding-left: 3.74pt;"></font></div></td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.28pt; text-align: left;"><font style="padding-left: 5pt;">1,476</font></div></td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15pt; text-align: left;"><font style="padding-left: 13.33pt;">5,123</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Less: Estimated net income attributable to Catalyst Convertible Preferred Stock<font style="padding-left: 3.2pt;"></font></div></td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.28pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">293</font></div></td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Pro forma combined net income attributable to common stockholders - basic <font style="padding-left: 2.1pt;"></font></div></td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.28pt; text-align: left;"><font style="padding-left: 5pt;">2,730</font></div></td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15pt; text-align: left;"><font style="padding-left: 5pt;">(34,566)</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Add: Estimated adjustments to undistributed earnings allocated to Catalyst Convertible Preferred Stock<font style="padding-left: 0.45pt;"></font></div></td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.28pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">21</font></div></td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Pro forma combined net income (loss) attributable to common stockholders - diluted <font style="padding-left: 4.87pt;"></font></div></td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.28pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">$</font><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">2,751</font></div></td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.41%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">$(34,566</font><font style="min-width: 35.83pt;">)</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">329<br></div></div></div>
<!--End Page 340-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 341-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_123-desc_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tDOC"><!--Anchor--></a>DESCRIPTION OF CATALYST CAPITAL STOCK</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following summary of certain provisions of the combined company&#8217;s capital stock after giving effect to the Contributions and the approval of Proposals Nos. 3, 4, 5 and 7 by stockholders at the Catalyst special meeting does not purport to be complete and is subject to the provisions of Catalyst&#8217;s restated certificate of incorporation, as amended on August&#160;20, 2015 and February&#160;10, 2017 and to be further amended by the amendment to Catalyst&#8217;s restated certificate of incorporation, a form of which is attached as Annex&#160;E to this proxy statement (the &#8220;Charter Amendment&#8221; and the restated certificate of incorporation as amended by the Charter Amendment, the &#8220;Proposed Charter&#8221;) and Catalyst&#8217;s amended and restated bylaws, as amended on December&#160;22, 2022 (the &#8220;Catalyst Bylaws&#8221;), qualified by reference to such organizational documents and the applicable provisions of the DGCL. Catalyst has filed copies of its organizational documents with the SEC as exhibits to its periodic filings, which you are urged to read carefully. We also urge you to read the Catalyst&#8217;s restated certificate of incorporation, as amended, including the Charter Amendment, a form of which is attached hereto as Annex&#160;E, and is incorporated herein by reference, in its entirety. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">General</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The Proposed Charter will authorize the issuance of up to &#8195;&#8195;&#8195; ordinary shares, consisting of:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8195;&#8195;&#8195;&#8195; shares of Catalyst Common Stock, par value $0.001 per share;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">20,000,000 shares of Catalyst Non-Voting Common Stock, par value $0.001 per share; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">5,000,000 shares of Catalyst Preferred Stock, par value $0.001 per share. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The material terms of each of Catalyst Common Stock, Catalyst Non-Voting Common Stock and Catalyst Preferred Stock are summarized below. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Catalyst Common Stock </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under the Proposed Charter, the combined company has authority to issue&#8195;&#8195;&#8195; shares of Catalyst Common Stock, par value $0.001 per share. As of March&#160;31, 2023, 37,759,825 shares of Catalyst Common Stock were issued and outstanding. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Dividends<font style="font-style: normal; font-weight: normal;">. Subject to preferential dividend rights of any other class or series of stock, the holders of shares of </font><font style="font-style: normal; font-weight: normal;">Catalyst Common Stock are entitled to receive dividends, including dividends of the combined company&#8217;s stock, as </font><font style="font-style: normal; font-weight: normal;">and when declared by the combined company&#8217;s board of directors, subject to any limitations imposed by law and to </font><font style="font-style: normal; font-weight: normal;">the rights of the holders, if any, of Catalyst Preferred Stock. </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Liquidation<font style="font-style: normal; font-weight: normal;">. In the event the combined company is liquidated, dissolved or its affairs are wound up, after the </font><font style="font-style: normal; font-weight: normal;">combined company pays or makes adequate provisions for all of its known debts and liabilities, each holder of </font><font style="font-style: normal; font-weight: normal;">Catalyst Common Stock will be entitled to share ratably in all assets that remain, subject to any rights that are granted </font><font style="font-style: normal; font-weight: normal;">to the holders of any class or series of Catalyst Preferred Stock.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Voting Rights<font style="font-style: normal; font-weight: normal;">. For all matters submitted to a vote of stockholders, each holder of Catalyst Common Stock is entitled </font><font style="font-style: normal; font-weight: normal;">to one vote for each share registered in his or her name. Except as may be required by law and in connection with </font><font style="font-style: normal; font-weight: normal;">some significant actions, such as mergers, consolidations, or amendments to the Proposed Charter that affect the </font><font style="font-style: normal; font-weight: normal;">rights of stockholders, holders of Catalyst Common Stock vote together as a single class. There is no cumulative </font><font style="font-style: normal; font-weight: normal;">voting in the election of the combined company&#8217;s directors, which means that, subject to any rights to elect directors </font><font style="font-style: normal; font-weight: normal;">that are granted to the holders of any class or series of preferred stock, a plurality of the votes cast at a meeting of </font><font style="font-style: normal; font-weight: normal;">stockholders at which a quorum is present is sufficient to elect a director.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Other Rights and Restrictions<font style="font-style: normal; font-weight: normal;">. Subject to the preferential rights of any other class or series of stock, all shares of </font><font style="font-style: normal; font-weight: normal;">Catalyst Common Stock have equal dividend, distribution, liquidation and other rights and have no preference, </font><font style="font-style: normal; font-weight: normal;">appraisal or exchange rights, except for any appraisal rights provided by Delaware law. Furthermore, holders of </font><font style="font-style: normal; font-weight: normal;">Catalyst Common Stock have no conversion, sinking fund or redemption rights, or preemptive rights to subscribe for </font><font style="font-style: normal; font-weight: normal;">any of the combined company&#8217;s securities. The Proposed Charter and the Catalyst Bylaws do not restrict the ability </font><font style="font-style: normal; font-weight: normal;">of a holder of Catalyst Common Stock to transfer his or her shares of Catalyst Common Stock.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The rights, powers, preferences and privileges of holders of Catalyst Common Stock are subject to and may be adversely affected by, the rights of holders of Catalyst Convertible Preferred Stock and holders of shares of any other series of preferred stock which the combined company may designate and issue from time to time in the future.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">330<br></div></div></div>
<!--End Page 341-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 342-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_123-desc_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Listing<font style="font-style: normal; font-weight: normal;">. Catalyst Common Stock is listed on the Nasdaq Capital Market.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Transfer Agent and Registrar<font style="font-style: normal; font-weight: normal;">. The transfer agent for Catalyst Common Stock is American Stock Transfer &amp;Trust </font><font style="font-style: normal; font-weight: normal;">Company, LLC. Its address is 6201 15th Avenue, Brooklyn, NY 11219.</font></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Catalyst Non-Voting Common Stock</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under the Proposed Charter, holders of Catalyst Non-Voting Common Stock have identical rights to holders of Catalyst Common Stock, provided that, (i)&#160;except as otherwise expressly provided in the Proposed Charter or as required by applicable law, on any matter that is submitted to a vote by the combined company&#8217;s stockholders, holders of Catalyst Non-Voting Common Stock will not be entitled to any votes per share of Catalyst Non-Voting Common Stock, including for the election of directors and (ii)&#160;holders of Catalyst Non-Voting Common Stock will have the right to convert each share of Catalyst Non-Voting Common Stock into one share of Catalyst Common Stock at such holder&#8217;s election, provided that as a result of such conversion, such holder, together with its affiliates and any members of a Schedule 13(d) group with such holder, would not beneficially own in excess of the Non-Voting Beneficial Ownership Limitation, unless otherwise as expressly provided for in the Proposed Charter. However, the Non-Voting Beneficial Ownership Limitation may be increased or decreased to any other percentage (not to exceed 19.99%) designated by such holder of Catalyst Non-Voting Common Stock upon 61 days&#8217; notice to the combined company. The Non-Voting Common Stock will not be listed on any securities exchange.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Catalyst Preferred Stock </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under the Proposed Charter, the combined company has authority, subject to any limitations prescribed by law and without further stockholder approval, to issue from time to time up to 5,000,000 shares of Catalyst Preferred Stock, par value $0.001 per share, in one or more series. On December&#160;22, 2022, Catalyst designated 123,418 shares of Catalyst Preferred Stock as &#8220;Series X Convertible Preferred Stock&#8221; (defined as &#8220;Catalyst Convertible Preferred Stock&#8221; in this proxy statement). As of March&#160;31, 2023, Catalyst has 12,340 shares of Catalyst Convertible Preferred Stock issued and outstanding. As announced on June&#160;20, 2023, the Catalyst board of directors declared a dividend of one one-thousandth (1/1,000th) of a share of &#8220;Series Y Preferred Stock&#8221; (as defined as &#8220;Catalyst Series&#160;Y Preferred Stock&#8221; in this proxy statement) for each outstanding share of Catalyst Common Stock to stockholders of record of Catalyst Common Stock as of the close of business on June&#160;30, 2023.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Proposed Charter, the combined company is authorized to issue &#8220;blank check&#8221; preferred stock, which may be issued from time to time in one or more series upon authorization by the combined company&#8217;s board of directors. The combined company&#8217;s board of directors, without further approval of the stockholders, is authorized to fix the designation, powers, preferences, relative, participating optional or other special rights and any qualifications, limitations and restrictions applicable to each series of the preferred stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes could, among other things, adversely affect the voting power or rights of the holders of Catalyst Common Stock and, under certain circumstances, make it more difficult for a third party to gain control of the combined company, discourage bids for Catalyst Common Stock at a premium or otherwise adversely affect the market price of the common stock.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Catalyst Convertible Preferred Stock</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Conversion<font style="font-style: normal; font-weight: normal;">. Under the Proposed Charter, (i)&#160;effective as of 5:00 p.m. (New York City time) on the second business </font><font style="font-style: normal; font-weight: normal;">day after the date on which such stockholder approval is received, each share of Catalyst Convertible Preferred Stock </font><font style="font-style: normal; font-weight: normal;">then outstanding automatically converts into approximately 10,000 of Catalyst Common Stock, and (ii)&#160;at any time </font><font style="font-style: normal; font-weight: normal;">thereafter at the option of the holder thereof, into approximately 10,000 shares of Catalyst Common Stock, in the case </font><font style="font-style: normal; font-weight: normal;">of each of (i)&#160;and (ii)&#160;subject to certain beneficial ownership limitations, including that a holder of Catalyst </font><font style="font-style: normal; font-weight: normal;">Convertible Preferred Stock is prohibited from converting shares of Catalyst Convertible Preferred Stock into shares </font><font style="font-style: normal; font-weight: normal;">of Catalyst Common Stock if, as a result of such conversion, such holder, together with its affiliates, would </font><font style="font-style: normal; font-weight: normal;">beneficially own more than a specified percentage (to be initially set at 9.9% and thereafter adjusted by the holder </font><font style="font-style: normal; font-weight: normal;">between to a number between 4.9% and 19.9%) of the total number of shares of Catalyst Common Stock issued and </font><font style="font-style: normal; font-weight: normal;">outstanding immediately after giving effect to such conversion.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Voting Rights<font style="font-style: normal; font-weight: normal;">. Except as otherwise provided in the Certificate of Designation or as otherwise required by the DGCL, </font><font style="font-style: normal; font-weight: normal;">Catalyst Convertible Preferred Stock does not have voting rights. However, as long as any shares of Catalyst </font><font style="font-style: normal; font-weight: normal;">Convertible Preferred Stock are outstanding, in addition to any other requirement of the DGCL or the Proposed </font><font style="font-style: normal; font-weight: normal;">Charter, Catalyst shall not, without the affirmative vote of the holders of a majority of the then outstanding shares </font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">331<br></div></div></div>
<!--End Page 342-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 343-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_123-desc_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">of Catalyst Convertible Preferred Stock, (i)&#160;alter or change adversely the powers, preferences or rights given to Catalyst Convertible Preferred Stock or alter or amend the Certificate of Designation, amend or repeal any provision of or add any provision to, the Proposed Charter or the Catalyst Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Catalyst Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of Catalyst Convertible Preferred Stock, regardless of whether any of the foregoing actions shall be by means of amendment to the Proposed Charter or by merger, consolidation or otherwise, (ii)&#160;issue further shares of Catalyst Convertible Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Catalyst Convertible Preferred Stock, (iii)&#160;at any time while at least 30% of the originally issued Catalyst Convertible Preferred Stock remains issued and outstanding, consummate either: (A) any Fundamental Transaction (as defined in the Certificate of Designation) or (B) any merger or consolidation of the combined company with or into another entity or any stock sale to, or other business combination in which the combined company&#8217;s stockholders immediately before such transaction do not hold at least a majority of the capital stock of the combined company immediately after such transaction, or (iv)&#160;enter into any agreement with respect to any of the foregoing.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Dividends<font style="font-style: normal; font-weight: normal;">. Holders of Catalyst Convertible Preferred Stock shall be entitled to receive when, as and if dividends are </font><font style="font-style: normal; font-weight: normal;">declared and paid on shares of Catalyst Common Stock, an equivalent dividend (with the same dividend declaration </font><font style="font-style: normal; font-weight: normal;">date and payment date), calculated on an as-converted basis without regard to the Beneficial Ownership Limitation </font><font style="font-style: normal; font-weight: normal;">(as defined in the Certificate of Designation), provided, however, in no event shall holders of Catalyst Convertible </font><font style="font-style: normal; font-weight: normal;">Preferred Stock be entitled to receive (a) the &#8220;rights&#8221; distributed pursuant to the CVR Agreement or any amounts </font><font style="font-style: normal; font-weight: normal;">paid under the CVR Agreement, or (b) cash distributions declared by the combined company on or prior to the closing </font><font style="font-style: normal; font-weight: normal;">of the transactions contemplated by the Business Combination Agreement.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Liquidation<font style="font-style: normal; font-weight: normal;">. Catalyst Convertible Preferred Stock ranks (i)&#160;senior to any class or series of capital stock of the </font><font style="font-style: normal; font-weight: normal;">combined company hereafter created specifically ranking by its terms junior to any Catalyst Convertible Preferred </font><font style="font-style: normal; font-weight: normal;">Stock; (ii)&#160;on parity with Catalyst Common Stock, Catalyst Non-Voting Common Stock and any class or series of </font><font style="font-style: normal; font-weight: normal;">capital stock of the combined company hereafter created specifically ranking by its terms on parity with Catalyst </font><font style="font-style: normal; font-weight: normal;">Convertible Preferred Stock; and (iii)&#160;junior to (A) any class or series of capital stock of the combined company </font><font style="font-style: normal; font-weight: normal;">hereafter created specifically ranking by its terms senior to any Catalyst Convertible Preferred Stock or (B) any </font><font style="font-style: normal; font-weight: normal;">&#8220;rights&#8221; distributed pursuant to the CVR Agreement or any amounts paid under the CVR Agreement, in each case, </font><font style="font-style: normal; font-weight: normal;">as to distributions of assets upon liquidation, dissolution or winding up of the combined company, whether </font><font style="font-style: normal; font-weight: normal;">voluntarily or involuntarily.</font></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Certain Effects of Authorized but Unissued Stock</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst has shares of common stock and preferred stock available for future issuance without stockholder approval, subject to any limitations imposed by the listing requirements of The Nasdaq Capital Market. The combined company may issue these additional shares for a variety of corporate purposes, including future public or private offerings to raise additional capital or to facilitate corporate acquisitions or for payment as a dividend on the combined company&#8217;s capital stock. The existence of unissued and unreserved preferred stock may enable the combined company&#8217;s board of directors to issue shares of preferred stock with terms that could render more difficult or discourage a third-party attempt to obtain control of the combined company by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the continuity of the combined company&#8217;s management. In addition, if the combined company issues preferred stock, the issuance could adversely affect the voting power of holders of Catalyst Common Stock and the likelihood that holders of Catalyst Common Stock will receive dividend payments or payments upon liquidation.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Anti-Takeover Effects of the Proposed Charter and the Catalyst Bylaws </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The DGCL, the Proposed Charter and the Catalyst Bylaws contain provisions that could have the effect of delaying, deferring or discouraging another party from acquiring control of the combined company. These provisions, which are summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of the combined company to first negotiate with the combined company&#8217;s board of directors.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Staggered Board; Removal of Directors.<font style="font-style: normal; font-weight: normal;"> The Proposed Charter provides for the combined company&#8217;s board of </font><font style="font-style: normal; font-weight: normal;">directors to be divided into three classes serving staggered terms. Approximately one-third of the combined </font><font style="font-style: normal; font-weight: normal;">company&#8217;s board of directors will be elected each year. The provision for a classified board could prevent a party who </font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">332<br></div></div></div>
<!--End Page 343-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 344-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_123-desc_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">acquires control of a majority of the outstanding voting stock from obtaining control of the board of directors until the second annual stockholders meeting following the date the acquirer obtains the controlling stock interest. The classified board provision could discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of the combined company and could increase the likelihood that incumbent directors will retain their positions. The Proposed Charter provides that directors may be removed with or without cause only by the affirmative vote of the holders of at least 66 2/3% of the voting power of all outstanding stock entitled to vote in the election of directors, voting together as a single class.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Amendment of the Proposed Charter and the Catalyst Bylaws<font style="font-style: normal; font-weight: normal;">. In addition to any vote of the holders of any class </font><font style="font-style: normal; font-weight: normal;">or series of stock of the combined company required by any applicable law, the Proposed Charter requires that the </font><font style="font-style: normal; font-weight: normal;">Proposed Charter and/or the Catalyst Bylaws may be amended, altered or repealed by the affirmative vote of holders </font><font style="font-style: normal; font-weight: normal;">of at least 66 2/3% of the voting power of the then-outstanding stock entitled to vote generally in the election of </font><font style="font-style: normal; font-weight: normal;">directors, voting together as a single class. These provisions could discourage a potential acquirer from making a </font><font style="font-style: normal; font-weight: normal;">tender offer or otherwise attempting to obtain control of the combined company and could delay changes in </font><font style="font-style: normal; font-weight: normal;">management.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Advance Notice Requirements for Stockholder Proposals.<font style="font-style: normal; font-weight: normal;"> The Catalyst Bylaws establish an advance notice </font><font style="font-style: normal; font-weight: normal;">procedure for stockholder proposals to be brought before an annual stockholders meeting, including proposed </font><font style="font-style: normal; font-weight: normal;">nominations of persons for election to the combined company&#8217;s board of directors. At an annual stockholders </font><font style="font-style: normal; font-weight: normal;">meeting, stockholders may only consider proposals or nominations specified in the notice of meeting or brought </font><font style="font-style: normal; font-weight: normal;">before the meeting by or at the direction of the combined company&#8217;s board of directors. Stockholders may also </font><font style="font-style: normal; font-weight: normal;">consider a proposal or nomination by a person who was a stockholder of record on the record date for the meeting, </font><font style="font-style: normal; font-weight: normal;">who is entitled to vote at the meeting and who has given to the combined company&#8217;s Corporate Secretary timely </font><font style="font-style: normal; font-weight: normal;">written notice, in proper form, of his or her intention to bring that business before the annual stockholders meeting. </font><font style="font-style: normal; font-weight: normal;">The Catalyst Bylaws do not give the combined company&#8217;s board of directors the power to approve or disapprove </font><font style="font-style: normal; font-weight: normal;">stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual </font><font style="font-style: normal; font-weight: normal;">meeting of the stockholders. However, the Catalyst Bylaws may have the effect of precluding the conduct of business </font><font style="font-style: normal; font-weight: normal;">at a meeting if the proper procedures are not followed. These provisions may also discourage or deter a potential </font><font style="font-style: normal; font-weight: normal;">acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise </font><font style="font-style: normal; font-weight: normal;">attempting to obtain control of the combined company.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Special Meetings.<font style="font-style: normal; font-weight: normal;"> The Catalyst Bylaws provide that only the combined company&#8217;s board of directors, the chairperson </font><font style="font-style: normal; font-weight: normal;">of the combined company&#8217;s board of directors, the president of the combined company or the chief executive officer </font><font style="font-style: normal; font-weight: normal;">of the combined company may call a special meeting of stockholders. Because the combined company&#8217;s stockholders </font><font style="font-style: normal; font-weight: normal;">do not have the right to call a special meeting, a stockholder could not force stockholder consideration of a proposal </font><font style="font-style: normal; font-weight: normal;">over the opposition of the combined company&#8217;s board of directors by calling a special meeting of stockholders prior </font><font style="font-style: normal; font-weight: normal;">to such time as a majority of the combined company&#8217;s board of directors, the chairperson of the combined company&#8217;s </font><font style="font-style: normal; font-weight: normal;">board of directors, the president of the combined company or the chief executive officer of the combined company </font><font style="font-style: normal; font-weight: normal;">believed the matter should be considered or until the next annual meeting provided that the requestor met the notice </font><font style="font-style: normal; font-weight: normal;">requirements. The restriction on the ability of stockholders to call a special meeting means that a proposal to replace </font><font style="font-style: normal; font-weight: normal;">the board also could be delayed until the next annual stockholders meeting.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Stockholder Action by Written Consent.<font style="font-style: normal; font-weight: normal;"> Under Section 228 of the DGCL, stockholders may act by written consent </font><font style="font-style: normal; font-weight: normal;">to take any action which may be or is required to be taken at any annual or special meeting of stockholders, without </font><font style="font-style: normal; font-weight: normal;">prior notice and without a vote, unless otherwise specified in a company&#8217;s certificate of incorporation. The Proposed </font><font style="font-style: normal; font-weight: normal;">Charter permits stockholder action by written consent until such time as the combined company is no longer </font><font style="font-style: normal; font-weight: normal;">considered a &#8220;controlled company&#8221; under Nasdaq rules.</font></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Anti-Takeover Effects of Provisions of Delaware Law</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under Section 203 of the DGCL, the combined company would generally be prohibited from engaging in any business combination with any interested stockholder for a period of three years following the time that this stockholder became an interested stockholder unless:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">prior to this time, the combined company&#8217;s board of directors approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">333<br></div></div></div>
<!--End Page 344-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 345-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_123-desc_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">transaction commenced, excluding shares owned by persons who are directors and also officers and by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">at or subsequent to such time, the business combination is approved by the combined company&#8217;s board of directors and authorized at a special or annual stockholders meeting, by the affirmative vote of at least 66&#160;2/3% of the outstanding voting stock that is not owned by the interested stockholder.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Under Section 203 of the DGCL, a &#8220;business combination&#8221; includes:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any merger or consolidation involving the corporation and the interested stockholder;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder, subject to limited exceptions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In general, Section 203 of the DGCL defines an interested stockholder as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by such entity or person.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Limitation of Liability and Indemnification</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Proposed Charter provides that the combined company&#8217;s directors shall not be personally liable to the combined company or the combined company&#8217;s stockholders for monetary damages for any breach of fiduciary duty as a director, except for liability for breach of the director&#8217;s duty of loyalty to the combined company or the combined company&#8217;s stockholders, for acts or omissions not in good faith or involving intentional misconduct or a knowing violation of law, for payment of dividends or approval of stock purchases or redemptions that are prohibited by the DGCL, or for any transaction from which the director derived an improper personal benefit. Under the DGCL, the combined company&#8217;s directors have a fiduciary duty to the combined company that is not eliminated by this provision of the Proposed Charter and, in appropriate circumstances, equitable remedies such as injunctive or other forms of non-monetary relief will remain available. This provision also does not affect the combined company&#8217;s directors&#8217; responsibilities under any other laws, such as federal securities laws or state or federal environmental laws.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Section 145 of the DGCL empowers a corporation to indemnify its directors and officers against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by them in connection with any action, suit or proceeding brought by third parties by reason of the fact that they were or are directors or officers of the corporation, if they acted in good faith, in a manner they reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe that their conduct was unlawful. The DGCL provides further that the indemnification permitted thereunder shall not be deemed exclusive of any other rights to which the directors and officers may be entitled under the corporation&#8217;s bylaws, any agreement, a vote of stockholders or otherwise. The Proposed Charter provides that, to the fullest extent permitted by Section 145 of the DGCL, the combined company shall indemnify any person who is or was a director or officer of the combined company, or is or was serving at the combined company&#8217;s request as a director, officer or trustee of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, against the expenses, liabilities or other matters referred to in or covered by Section&#160;145 of the DGCL. The Catalyst Bylaws provide that the combined company will indemnify any person who was or is a party or threatened to be made a party to any proceeding by reason of the fact that such person is or was a director or officer of the combined company or is or was serving at the combined company&#8217;s request as a director, officer or trustee of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise to the fullest extent permitted by the DGCL.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, the combined company has entered into indemnification agreements with each of the combined company&#8217;s directors and with certain of the combined company&#8217;s executive officers. Pursuant to the indemnification </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">334<br></div></div></div>
<!--End Page 345-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 346-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_123-desc_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">agreements, the combined company has agreed to indemnify and hold harmless these directors and officers to the fullest extent permitted by the DGCL. The agreements generally cover expenses that a director or officer incurs or amounts that a director or officer becomes obligated to pay because of any proceeding to which he or she is made or threatened to be made a party or participant by reason of his or her service as a current or former director, officer, employee or agent of the combined company. The agreements also provide for the advancement of expenses to the directors and officers subject to specified conditions. There are certain exceptions to the combined company&#8217;s obligation to indemnify the directors and officers, including any intentional malfeasance or act where the director or officer did not in good faith believe he or she was acting in the combined company&#8217;s best interests, with respect to &#8220;short-swing&#8221; profit claims under Section 16(b) of the 1934 Act and, with certain exceptions, with respect to proceedings that he or she initiates.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Section 145 of the DGCL also empowers a corporation to purchase insurance for its officers and directors for such liabilities. The combined company maintains liability insurance for its officers and directors.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">335<br></div></div></div>
<!--End Page 346-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 347-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_124-principal_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPSOC"><!--Anchor--></a>PRINCIPAL STOCKHOLDERS OF CATALYST</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Except where specifically noted, the following information and all other information contained in this proxy statement does not give effect to the proposed Reverse Stock Split.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 3pt; margin-left: 0pt; text-align: justify;">The following table sets forth information regarding the beneficial ownership of Catalyst Common Stock as of May&#160;15, 2023 by:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each of its directors;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each of its named executive officers;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each person known by Catalyst to beneficially own 5% or more of its common stock; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">all of its directors and executive officers as a group.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 3pt; margin-left: 0pt; text-align: justify;">Applicable percentage ownership is based on 37,759,825 shares of common stock outstanding on May&#160;15, 2023. The number of shares of common stock beneficially owned by each stockholder is determined under rules issued by the SEC and includes voting or investment power with respect to securities. Under these rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power and includes any shares that an individual or entity has the right to acquire beneficial ownership of within 60 days of May&#160;15, 2023 through the exercise of any warrant, stock option or other right. For purposes of calculating each person&#8217;s or group&#8217;s percentage ownership, stock options and warrants exercisable and notes convertible, within 60&#160;days after May&#160;15, 2023 are included for that person or group, but not the stock options of any other person or group. Unless otherwise indicated, the address of all listed stockholders is c/o Catalyst Biosciences, Inc., 611&#160;Gateway Blvd, Suite 120, South San Francisco, CA 94080. Each of the stockholders listed has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name of Beneficial Owner</div></td><td class="gutter" style="width: 1.5%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.5%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of Shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Owned</div></td><td class="gutter" style="width: 1.5%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.5%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percentage <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of Shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Owned</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Greater than 5% Stockholders<br></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities affiliated with GNI Japan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 0.66pt;"></font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6,266,521</div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.74pt; text-align: left;">16.60%</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Laurence W. Lytton<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><font style="padding-left: 2.93pt;"></font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2,667,333</div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.74pt; text-align: left;"><font style="padding-left: 5pt;">7.06%</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Named Executive Officers and Directors<br></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Grant Blouse<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup><font style="padding-left: 4.89pt;"></font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">807,072</font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.74pt; text-align: left;"><font style="padding-left: 5pt;">2.09%</font> </div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thomas Eastling<font style="padding-left: 4.18pt;"></font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.74pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Andrea Hunt<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup><font style="padding-left: 1pt;"></font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">267,869</font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: right; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">*%</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Augustine Lawlor<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup><font style="padding-left: 0.45pt;"></font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">297,641</font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 8.54%; text-align: right; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">*%</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ying Luo, Ph.D.<font style="padding-left: 0.01pt;"></font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.74pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Seline Miller<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup><font style="padding-left: 0.44pt;"></font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">61,786</font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 8.54%; text-align: right; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">*%</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Nassim Usman, Ph.D.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(7)</sup><font style="padding-left: 3.51pt;"></font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4,382,175</div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.74pt; text-align: left;">10.41%</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">All current executive officers and directors as a group (7 persons)<font style="padding-left: 1.72pt;"></font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5,816,543</div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.74pt; text-align: left;">13.39%</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 9.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents beneficial ownership of less than one percent (1%) of the outstanding shares of Catalyst Common Stock. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Consists of (1) 895,217 shares held directly by GNI Japan and (2) 5,371,303 shares held by GNI Hong Kong. GNI Hong Kong, through GNI Japan-affiliated entities, is a wholly-owned subsidiary of GNI Japan. By virtue of such relationship, GNI Japan may be deemed to have voting and investment power with respect to the shares held by GNI Hong Kong. The principal business address of GNI Group Ltd. is Nihonbashi-Honcho YS Bldg. 3rd Floor, 2-2-2 Nihonbashi-Honcho, Chuo-ku, 103-0023 Tokyo, Japan. The principal business address of GNI Hong Kong is 12/F Elite Centre, 22 Hung TO, Kwun Tong KL, Hong Kong.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The information reported is based on a Schedule 13G filed with the SEC on February&#160;13, 2023. The shares are held directly by Laurence W. Lytton. The principal business address of Mr.&#160;Lytton is 467 Central Park West, New York, NY 10025.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes 797,695 shares underlying options that are exercisable as of the date of this table or will become exercisable within 60 days after such date. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes 239,641 shares underlying options that are exercisable as of the date of this table or will become exercisable within 60 days after such date.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(5)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes (1) 24,215 shares owned by the Lawlor Family Trust UAD 4-17-00, for which Augustine Lawlor&#8217;s spouse serves as a Trustee, and (2)&#160;248,853 shares underlying options that are exercisable as of the date of this table or will become exercisable within 60 days after such date.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(6)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes 55,286 shares underlying options that are exercisable as of the date of this table or will become exercisable within 60 days after such date.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(7)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes (1) 8,456 shares owned by the Usman Family Trust, for which Nassim Usman, Ph.D. serves as Trustee, (2) 1,168 shares owned by the Nassim Usman IRA, for which Dr. Usman is a Trustee and (3) 4,348,010 shares underlying options that are exercisable as of the date of this table or will become exercisable within 60 days after such date.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">336<br></div></div></div>
<!--End Page 347-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 348-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_124-principal_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPSOBC"><!--Anchor--></a>PRINCIPAL STOCKHOLDERS OF BC</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">The following table sets forth the beneficial ownership of BC&#8217;s ordinary shares as of May&#160;15, 2023 by: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each person, or group of affiliated persons, who is known by BC to beneficially own more than 5% of its ordinary shares; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each of BC&#8217;s named executive officers; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each of BC&#8217;s directors; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">all of BC&#8217;s current executive officers and directors as a group.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC has determined beneficial ownership in accordance with the rules of the SEC and thus it represents sole or shared voting or investment power with respect to BC&#8217;s securities. Unless otherwise indicated below, to BC&#8217;s knowledge, the persons and entities named in the table have sole voting and sole investment power with respect to all shares that they beneficially owned, subject to community property laws where applicable. The information does not necessarily indicate beneficial ownership for any other purpose, including for purposes of Sections 13(d) and 13(g) of the Exchange Act.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">BC has based its calculation of the percentage of beneficial ownership prior to the completion of the Contributions on 61,317,900 BC Common Shares outstanding as of May&#160;15, 2023. BC has deemed BC Common Shares subject to stock options that are currently exercisable or exercisable within 60 days of May&#160;15, 2023 to be outstanding and to be beneficially owned by the person holding the stock option for the purpose of computing the percentage ownership of that person. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o Beijing Continent Pharmaceuticals Co., Ltd, Room 320507-320509, Building 5, Wangjing SOHO Tower, Yard 1, Futong East Street.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Chaoyang District, Beijing, PRC.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name of Beneficial Owner</div></td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of Shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Owned</div></td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percentage <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of Shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Owned</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Greater than 5% stockholders:<br></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities affiliated with GNI Japan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 0.66pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">34,319,600</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.74pt; text-align: left;">55.97%</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities affiliated with Beijing Lapam Investment Management Consulting Center<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><font style="padding-left: 3.48pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.37pt;">11,779,200</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.74pt; text-align: left;">19.21%</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Beijing Saint Lily Consulting Services Center<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup><font style="padding-left: 1.03pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">7,147,400</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.74pt; text-align: left;"><font style="padding-left: 0.37pt;">11.66%</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Named Executive Officers and Directors:<br></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ying Luo, Ph.D.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup><font style="padding-left: 1.26pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">1,533,000</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.74pt; text-align: left;"><font style="padding-left: 5pt;">2.50%</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Songjiang Ma<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup><font style="padding-left: 1.55pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">3,243,700</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.74pt; text-align: left;"><font style="padding-left: 5pt;">5.29%</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ruoyu Chen<font style="padding-left: 1.39pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 40pt;">&#8211;</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">*%</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Yuwen Wu<font style="padding-left: 2.54pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 40pt;">&#8211;</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">*%</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weiguo Ye<font style="padding-left: 3.02pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 40pt;">&#8211;</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">*%</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Charles Wu, Ph.D.<font style="padding-left: 1.16pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 40pt;">&#8211;</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">*%</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Xiaoxing Jiang<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup><font style="padding-left: 2.11pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">7,147,400</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.74pt; text-align: left;"><font style="padding-left: 0.37pt;">11.66%</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lin Han<font style="padding-left: 3.62pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 40pt;">&#8211;</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">*%</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Li Zhang<font style="padding-left: 4.73pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 40pt;">&#8211;</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">*%</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Qijia Liu<font style="padding-left: 0.29pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">*%</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">All current executive officers and directors as a group (12 persons)<font style="padding-left: 1.72pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.37pt;">11,924,100</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.74pt; text-align: left;">19.45%</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents beneficial ownership of less than one percent (1%) of the outstanding BC Common Shares. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Consists of 34,319,600 BC Common Shares held of record by BJC Limited. BJC Limited, through GNI Japan-affiliated entities, is a wholly-owned subsidiary of GNI Japan. By virtue of such relationship, GNI Japan may be deemed to have voting and investment power with respect to the BC Common Shares held by BJC Limited. Ying Luo, Ph.D., one of BC&#8217;s directors, is a director, representative executive officer, president and chief executive officer and executive committee member of GNI Japan and may be deemed to share voting and dispositive power over the BC Common Shares held of record by BJC Limited. The business address for BJC Limited is c/o GNI Group Ltd., Nihonbashi-Honcho YS Bldg. 3rd Floor 2-2-2 Nihonbashi-Honcho, Chuo-ku, 103-0023 Tokyo, Japan.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Consists of (1) BC Common Shares held by Nepenthe Holdings Limited, a company incorporated under the laws of Hong Kong with limited liability (&#8220;Nepenthe&#8221;) and (2) BC Common Shares held by each of Beijing Lapam Biomedical Venture Investment Center (&#8220;Lapam </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">337<br></div></div></div>
<!--End Page 348-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 349-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_124-principal_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 5.25pt; margin-left: 20pt; text-align: justify;">Biomedical&#8221;) and Beijing Lapam Venture Investment Center (&#8220;Lapam Venture&#8221;). The general partner of each of Lapam Biomedical and Lapam Venture is Beijing Lapam Investment Management Consulting Center, which in turn is managed by its general partner, Mr.&#160;Yu. As such, Beijing Lapam Investment Management Consulting Center and Mr.&#160;Zhihua may be deemed to have voting and investment power with respect to the 5,629,000 BC Common Shares held by Lapam Biomedical and 4,923,800 BC Common Shares held by Lapam Venture. Tibet Hengyuan Venture Investment Center is a limited partner of Lapam Venture with approximately 62.21% partnership interest as of May&#160;15, 2023. As such, it may be deemed to have voting and investment power with respect to the 4,923,800 BC Common Shares held by Lapam Venture. The business address for these entities is Room 705-706, 7<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Floor, No. 3, Suzhou Street, Haidan District, Beijing. Mr.&#160;Yu&#8217;s spouse is an associate director of marketing for investment projects of BC and the sole shareholder of Nepenthe and, accordingly, Mr.&#160;Yu, Lapam Biomedical and Lapam Venture may be deemed to have voting and investment power with respect to the 1,226,400 BC Common Shares held by Nepenthe. Mr.&#160;Yu, Lapam Biomedical and Lapam Venture disclaim beneficial ownership with respect to such BC Common Shares except to the extent of their pecuniary interest therein. The business address for Nepenthe is Level 54, Hopewell Centre, 183 Queen&#8217;s Road East, Hong Kong.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Beijing Saint Lily Consulting Services Center (&#8220;Saint Lily&#8221;) is a limited partnership established in the PRC, which is managed by its general partner, Beijing Saint Lily Management Consulting Limited (&#8220;Beijing Saint Lily&#8221;), which in turn is wholly-owned by Mr.&#160;Jiang Xiaoxing. The limited partners of Saint Lily are Mr.&#160;Xiaoxing with 35.94% partnership interest and Tibet Yundian Digital Technology Partnership (&#8220;Tibet Yundian&#8221;) with 63.69% partnership interest. Therefore, Mr.&#160;Xiaoxing, Tibet Yundian and Beijing Saint Lily may be deemed to have voting and investment power with respect to the 7,147,400 BC Common Shares held by Saint Lily. The business address for these entities is Room 309, First Floor, Building 3, No. 16, Yuanying Road, Zhaofeng Industrial Base Park, Zhaoquanying Town, Shunyi District, Beijing.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Consists of 1,533,000 BC Common Shares owned by Aaring Limited, a company incorporated under the laws of Hong Kong with limited liability. Aaring Limited is wholly owned by the spouse of Ying Luo, Ph.D. The address of Aaring Limited is Room D, 10/F, Tower A, Billion Centre, 1 Wang Kwong Road, Kowloon Bay, Kowloon, Hong Kong.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(5)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Consists of (1) 1,655,600 BC Common Shares owned by Ratel Consulting, a limited partnership established in the PRC and (2) 1,588,100 BC Common Shares owned by Ratel Holdings Limited, a company incorporated in the British Virgin Islands with limited liability, which is wholly-owned by Songjiang Ma&#8217;s spouse. Ratel Consulting is 99% owned by Mr.&#160;Ma as its limited partner and 1% owned by Beijing Ratel Management Consulting Limited as its general partner, which is wholly owned by Mr.&#160;Ma. The address of Ratel Consulting is Room 308, First Floor, Building 3, No. 16, Yuanying Road, Zhaofeng Industrial Base Park, Zhaoquanying Town, Shunyi District, Beijing, the address of Ratel Management Consulting Limited is No. 161, East Building, No. 13, Fuqian Street, Longwantun Town, Shunyi District, Beijing and the address of Ratel Holdings Limited is situated at the offices of Sertus Incorporations (BVI) limited, Sertus Chambers, P.O. Box 905, Quastisky Building, Road Town, Tortola, British Virgin Islands.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(6)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Consists of (1) 1,995,100 BC Common Shares owned by Billionaire Consulting, a limited partnership established in the PRC and (2)&#160;1,299,900 BC Common Shares owned by Rosefinch Holdings Limited, a company incorporated in the British Virgin Islands (&#8220;Rosefinch&#8221;). Billionaire Consulting is 90% owned by Youming Cheng as its general partner and 10% by Mr.&#160;Cheng&#8217;s spouse as its limited partner. Rosefinch is 100% owned by Mr.&#160;Cheng&#8217;s son. Therefore, Mr.&#160;Cheng may be deemed to have voting and investment power with respect to the 1,299,900 BC Common Shares held by Rosefinch. The address of Billionaire Consulting is Room 277, First Floor, Building 3, No. 16, Yuanying Road, Zhaofeng Industrial Base Park, Zhaoquanying Town, Shunyi District, Beijing, and the address of Rosefinch is situated at the offices of Sertus Incorporations (BVI) limited, Sertus Chambers, P.O. Box 905, Quastisky Building, Road Town, Tortola, British Virgin Islands.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">338<br></div></div></div>
<!--End Page 349-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 350-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_124-principal_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPSOT"><!--Anchor--></a>PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Except where specifically noted, the following information and all other information contained in this proxy statement does not give effect to the proposed Reverse Stock Split.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table sets forth certain information regarding beneficial ownership of the combined company&#8217;s common stock immediately after consummation of the Contributions, assuming the consummation of the Contributions occurred on May&#160;15, 2023, for: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each stockholder expected by Catalyst and BC to become the beneficial owner of more than 5% of the combined company&#8217;s outstanding common stock; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each person expected to be a named executive officer of the combined company; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each person expected to be a director of the combined company; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">all of the combined company&#8217;s expected directors and executive officers as a group.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Beneficial ownership has been determined in accordance with the rules of the SEC and thus it represents sole or shared voting or investment power with respect to the combined company&#8217;s securities. Unless otherwise indicated below, to Catalyst&#8217;s and BC&#8217;s knowledge, the persons and entities named in the table have sole voting and sole investment power with respect to all shares that they beneficially owned, subject to community property laws where applicable. The information does not necessarily indicate beneficial ownership for any other purpose, including for purposes of Sections 13(d) and 13(g) of the Exchange Act.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The percentage of beneficial ownership is calculated based on 1,148,532,798 shares of common stock expected to be outstanding upon consummation of the Contributions (which does not include conversion of the Catalyst Convertible Preferred Stock). The number of shares beneficially owned includes shares of common stock that each person has the right to acquire within 60 days of May&#160;15, 2023, including upon the exercise of stock options and the vesting of restricted stock units. These stock options and restricted stock units shall be deemed to be outstanding for the purpose of computing the percentage of outstanding shares of the combined company&#8217;s common stock expected to be owned by such person but shall not be deemed to be outstanding for the purpose of computing the percentage of outstanding shares of the combined organization&#8217;s common stock expected to be owned by any other person. The table gives effect to option awards expected to be granted to Mr.&#160;Eastling, Ms.&#160;Chen and Dr.&#160;Usman upon the consummation of the Contributions, as discussed in the section entitled &#8220;<font style="font-style: italic;">Catalyst Executive and Director </font><font style="font-style: italic;">Compensation&#8212;Post-Closing Arrangements</font>&#8221; beginning on page <a href="#tPCA1">164</a> of this proxy statement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Immediately after the Contributions, Catalyst stockholders as of immediately prior to the Contributions are expected to own approximately 2.5% of the outstanding shares of the combined company, GNI USA is expected to own approximately 85.2% of the outstanding shares of the combined company and the Minority Holders are expected to own approximately 12.3% of the outstanding shares of the combined company, in each case, assuming conversion of the Catalyst Convertible Preferred Stock. The table below assumes that (a) GNI USA will contribute all of the CPI Ordinary Shares it holds immediately prior to the Effective Time to Catalyst in exchange for 688,850,101 shares of Catalyst Common Stock, (b) GNI USA will contribute all of the ordinary shares of Further Challenger it holds immediately prior to the Effective Time to Catalyst in exchange for 264,971,695 shares of Catalyst Common Stock and (c) each Minority Holder will contribute 100% of the interest he or she holds in his or her respective Entity to Catalyst in exchange for an aggregate of 156,954,428 shares of Catalyst Common Stock in the amounts set forth on an annex to the Business Combination Agreement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o Beijing Continent Pharmaceuticals Co., Ltd, Room 320507-320509, Building 5, Wangjing SOHO Tower, Yard 1, Futong East Street.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name of Beneficial Owner</div></td><td class="gutter" style="width: 0.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.68%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of Shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Owned</div></td><td class="gutter" style="width: 0.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percentage <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of Shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Owned</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Greater than 5% stockholders:<br></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entitles affiliated with GNI Japan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 0.66pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">960,088,317</div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.74pt; text-align: left;">83.59%</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Named Executive Officers and Directors<br></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ying Luo, Ph.D.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><font style="padding-left: 1.26pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">126,810,446</div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.74pt; text-align: left;">10.29%</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Charles Wu, Ph.D.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup><font style="padding-left: 2.41pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">2,556,256</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">*%</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">339<br></div></div></div>
<!--End Page 350-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 351-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_124-principal_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name of Beneficial Owner</div></td><td class="gutter" style="width: 0.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.68%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of Shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Owned</div></td><td class="gutter" style="width: 0.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percentage <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of Shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Owned</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thomas Eastling<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup><font style="padding-left: 0.44pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">5,640,480</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: right; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">*%</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Songjiang Ma<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup><font style="padding-left: 1.55pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.74pt;">111,787,717</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.74pt; text-align: left;"><font style="padding-left: 5pt;">9.19</font>%</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ruoyu Chen<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup><font style="padding-left: 2.65pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 40pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.74pt; text-align: left;"><font style="padding-left: 22.5pt;">*</font>%</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gordon G. Carmichael<font style="padding-left: 4.48pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 40pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.74pt; text-align: left;"><font style="padding-left: 22.5pt;">*%</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Han Ying, Ph.D.<font style="padding-left: 4.83pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 40pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.74pt; text-align: left;"><font style="padding-left: 22.5pt;">*%</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Renate Parry, Ph.D.<font style="padding-left: 1.79pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 40pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.74pt; text-align: left;"><font style="padding-left: 22.5pt;">*%</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Nassim Usman, Ph.D.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup><font style="padding-left: 3.51pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">9,506,954</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.74pt; text-align: left;"><font style="padding-left: 22.5pt;">*</font>%</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weiguo Ye<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(7)</sup><font style="padding-left: 4.28pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">24,976,721</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.74pt; text-align: left;"><font style="padding-left: 5pt;">2.13</font>%</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Suzana Corritori, M.D., Ph.D., MSc.<font style="padding-left: 2.55pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 40pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.74pt; text-align: left;"><font style="padding-left: 22.5pt;">*%</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">All current executive officers and directors as a group (11 persons)<font style="padding-left: 2.09pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">281,278,573</div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.74pt; text-align: left;">20.94%</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 16pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents beneficial ownership of less than one percent (1%) of the outstanding shares of the combined company&#8217;s common stock. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Consists of 960,088,317 shares held of record by GNI USA immediately after the Contributions. GNI USA, through GNI Japan-affiliated entities, is a wholly-owned subsidiary of GNI Japan. By virtue of such relationship, GNI Japan may be deemed to have voting and investment power with respect to the shares held by GNI USA. Ying Luo, Ph.D., one of BC&#8217;s directors, is a director, representative executive officer, president and chief executive officer and executive committee member of GNI Japan and may be deemed to share voting and dispositive power over the shares held of record by GNI USA. The address for these entities is c/o GNI Group Ltd., Nihonbashi-Honcho YS Bldg. 3rd Floor 2-2-2 Nihonbashi-Honcho, Chuo-ku, 103-0023 Tokyo, Japan.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Consists of (i) 42,605,648 shares held of record by the spouse of Ying Luo, Ph.D. immediately after the Contributions, (2) 50,263,465 shares underlying options held by Dr.&#160;Luo that are exercisable as of the date of this table or will become exercisable within 60&#160;days after such date, and (3) 33,941,333 shares underlying options held by Dr.&#160;Luo&#8217;s spouse that are exercisable as of the date of this table or will become exercisable within 60 days after such date.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Consists of 2,556,256 shares underlying options that are exercisable as of the date of this table or will become exercisable within 60&#160;days after such date.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Consists of (1) 5,124,779 shares underlying options held by Mr.&#160;Eastling that are exercisable as of the date of this table or will become exercisable within 60&#160;days after such date and (2) 515,701 shares underlying options held by Ms.&#160;Chen, spouse of Mr.&#160;Eastling, that are exercisable as of the date of this table or will become exercisable within 60&#160;days after such date.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(5)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Consists of (i) 44,137,006 shares of record held by Songjiang Ma&#8217;s spouse immediately after the Contributions and (2) 67,650,710 shares underlying options that are exercisable as of the date of this table or will become exercisable within 60 days after such date.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(6)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes (1) 8,456 shares owned by the Usman Family Trust immediately after the Contributions, for which Dr. Usman<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"> </sup>serves as Trustee, (2) 1,168 shares owned by the Nassim Usman IRA immediately after the Contributions, for which Dr. Usman is Trustee and (3)&#160;9,472,789 shares underlying options that are exercisable as of the date of this table or will become exercisable within 60 days after such date.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(7)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Consists of 24,976,721 shares underlying options that are exercisable as of the date of this table or will become exercisable within 60&#160;days after such date.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">340<br></div></div></div>
<!--End Page 351-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 352-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_125-info_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tHI"><!--Anchor--></a>HOUSEHOLDING INFORMATION </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Unless we have received contrary instructions, we may send a single copy of this proxy statement to any household at which two or more stockholders reside if we believe the stockholders are members of the same family. This process, known as &#8220;householding,&#8221; reduces the volume of duplicate information received at any one household and helps to reduce our expenses. However, if stockholders prefer to receive multiple sets of our disclosure documents at the same address this year or in future years, the stockholders should follow the instructions described below. Similarly, if an address is shared with another stockholder and together both of the stockholders would like to receive only a single set of our disclosure documents, the stockholders should follow these instructions:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If the shares of Catalyst Common Stock are registered in the name of the stockholder, the stockholder should contact us at our executive offices at 611 Gateway Boulevard, Suite 120, South San Francisco, California 94080, or by telephone at +1 (650) 871-0761, to inform us of his or her request; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If a bank, broker or other nominee holds the shares of Catalyst Common Stock, the stockholder should contact the bank, broker or other nominee directly.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">341<br></div></div></div>
<!--End Page 352-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 353-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_125-info_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">DELINQUENT SECTION 16(A) REPORTS</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Section 16(a) of the Exchange Act requires our officers and directors, and persons who own more than 10 percent of a registered class of our equity securities, (&#8220;Reporting Persons&#8221;) to file with the SEC reports of ownership and reports of changes in ownership of our Common Stock and our other equity securities. Reporting Persons are required by SEC regulations to furnish us with copies of all Section 16(a) forms they file. Based solely on our review of such reports received or written representations from certain Reporting Persons, to the Company&#8217;s knowledge, all Reporting Persons complied with all applicable requirements during fiscal year ended December&#160;31, 2022, except for the following: (1) each of Messrs. Usman and Grant and Ms.&#160;Miller had one report related to the granting of shares purchased under Catalyst&#8217;s 2018 Employee Stock Purchase Plan on February&#160;9, 2022 that was in each case inadvertently filed late on February&#160;16, 2022; and (2) each of Mr.&#160;Blouse and Ms.&#160;Miller had one report related to stock options granted on February&#160;11, 2022 that was in each case inadvertently filed late on February&#160;23, 2022. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">342<br></div></div></div>
<!--End Page 353-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 354-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_125-info_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tWYC"><!--Anchor--></a>WHERE YOU CAN FIND MORE INFORMATION</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst is subject to the informational requirements of the Exchange Act and in accordance therewith, files annual, quarterly and current reports, proxy statements and other information with the SEC electronically and the SEC maintains a website that contains Catalyst&#8217;s filings as well as reports, proxy and information statements and other information issuers file electronically with the SEC at <font style="font-style: italic;">www.sec.gov</font>.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst also makes available free of charge on or through its website at <font style="font-style: italic;">www.catalystbiosciences.com</font>, its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after Catalyst electronically files such material with or otherwise furnishes it to the SEC. The website addresses for the SEC and Catalyst are inactive textual references and information on those websites is not part of this proxy statement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If you would like to request documents from Catalyst or BC, please send a request in writing or by telephone to either Catalyst or BC at the following addresses: </div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 48.72%; text-align: center; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Catalyst Biosciences, Inc. <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">611 Gateway Blvd, Suite 120 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">South San Francisco, CA 94080 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Attn: Investor Relations <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Tel: (650) 871-0761 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Email: investors@catbio.com</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Beijing Continent Pharmaceuticals Co., Ltd <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Room 320507-320509, Building 5, Wangjing SOHO <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Tower, Yard 1, Futong East Street <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Chaoyang District, Beijing, PRC <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Attn: IR <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Tel: +86-10-88877935 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Email: ir@bjcontinent.com</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If you are a Catalyst stockholder and would like additional copies, without charge, of this proxy statement or if you have questions about the Contributions, including the procedures for voting your shares, you should contact Catalyst&#8217;s proxy solicitor, Broadridge, at the following address and telephone number: </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">Broadridge Financial Solutions, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">51 Mercedes Way<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Edgewood, New York 11717<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">sendmaterial@proxyvote.com<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Telephone: 1 (800) 579-1639</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">343<br></div></div></div>
<!--End Page 354-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 355-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_125-info_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tTN"><!--Anchor--></a>TRADEMARK NOTICE</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This proxy statement contains trademarks, service marks and trade names of Catalyst Biosciences, Inc. and Beijing Continent Pharmaceuticals Co., Ltd, including their respective names and logos. Other trademarks, service marks and trade names referred to in this proxy statement are the property of their respective owners.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="tOM"><!--Anchor--></a>OTHER MATTERS</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Stockholder Proposals </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s stockholders are entitled to present proposals for action at a forthcoming meeting if they comply with the requirements of Catalyst&#8217;s amended and restated bylaws and the rules established by the SEC.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to Rule 14a-8 of the Exchange Act, a stockholder who seeks to include a proposal in the proxy materials for Catalyst&#8217;s 2024 annual meeting of stockholders must submit the proposal so that it is received at Catalyst&#8217;s executive offices not later than the close of business on &#8195;&#8195;&#8195;. If the date of the 2024 annual meeting of stockholders is more than 30 days before or after the anniversary of this special meeting in lieu of a 2023 annual meeting, the deadline for inclusion of proposals in the Catalyst&#8217;s proxy statement is instead a reasonable time before we begin to print and mail our proxy materials. Such proposals will also need to comply with the SEC&#8217;s additional regulations under Rule 14a-8 regarding the inclusion of stockholder proposals in company-sponsored proxy materials.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst&#8217;s amended and restated bylaws also establish an advance notice procedure for stockholders who wish to present a proposal before an annual meeting of stockholders but do not intend for the proposal to be included in Catalyst&#8217;s proxy materials. Stockholders must provide notice of any business that they wish to submit for consideration at the 2024 annual meeting so that it is received at Catalyst&#8217;s executive offices no later than the close of business on and no earlier than the close of business on &#8195;&#8195;&#8195;. However, if the date of the 2024 annual meeting of stockholders is more than thirty days before or more than sixty days after the anniversary of the date of this special meeting in lieu of a 2023 annual meeting, the deadline will instead be not later than the close of business on the 90th day prior to the 2024 annual meeting or, if the first public disclosure of the date of such annual meeting is less than one hundred days prior to such annual meeting, the close of business on the 10th day following such first public disclosure. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, to comply with the universal proxy rules, if a stockholder intends to solicit proxies in support of nominees submitted under Catalyst&#8217;s advance notice bylaws, then the stockholder must provide proper written notice that sets forth all information required under Rule 14a-19 of the Exchange Act to Catalyst no later than &#8195;&#8195;&#8195; (or, if the 2024&#160;annual meeting of stockholders is called for a date that is more than 30 days before or more than 60 days after the anniversary of the date of this special meeting in lieu of a 2023 annual meeting, then notice must be provided by the later of 60 days prior to the 2024 annual meeting of stockholders or the 10th day following the date on which announcement of the 2024 annual meeting of stockholders was first made). The notice requirement under Rule&#160;14a-19 is in addition to the applicable advance notice requirements under Catalyst&#8217;s bylaws as described above. Nominations or proposals should be addressed to the attention of Catalyst&#8217;s Corporate Secretary at our principal executive offices at 611 Gateway Boulevard, Suite 120, South San Francisco, California 94080 and Catalyst suggests that it be sent by certified mail, return receipt requested. Any such nomination or proposal must be made in writing, and must also include the information required by SEC Rule 14A and Catalyst&#8217;s amended and restated bylaws. A copy of the full text of the provisions of Catalyst&#8217;s amended and restated bylaws dealing with stockholder nominations and proposals will be made available to stockholders from Catalyst&#8217;s Corporate Secretary upon written request.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">344<br></div></div></div>
<!--End Page 355-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 356-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_200-fintoc_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tFSS"><!--Anchor--></a>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">INDEX TO FINANCIAL STATEMENTS</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">CATALYST BIOSCIENCES, INC.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;">Page</div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unaudited Condensed Consolidated Financial Statements<br></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCCB">Condensed Consolidated Balance Sheets as of March&#160;31, 2023 (Unaudited) and December&#160;31, 2022<font style="padding-left: 2.11pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;"><a href="#tCCB"><font style="padding-left: 5.55pt;">F-</font>2</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tCCS">Unaudited Condensed Consolidated Statements of Operations for the Three Months Ended March&#160;31, 2023 and 2022<font style="padding-left: 1.4pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;"><a href="#tCCS"><font style="padding-left: 5.55pt;">F-</font>3</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tCCSC">Unaudited Condensed Consolidated Statements of Cash Flows for the Three Months Ended March&#160;31, 2023 and 2022<font style="padding-left: 1.14pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;"><a href="#tCCSC"><font style="padding-left: 5.55pt;">F-</font>5</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tNUI">Notes to the Unaudited Interim Condensed Consolidated Financial Statements<font style="padding-left: 3.16pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;"><a href="#tNUI"><font style="padding-left: 5.55pt;">F-</font>6</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Audited Consolidated Financial Statements<br></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRIRPA">Report of Independent Registered Public Accounting Firm (PCAOB ID #274)<font style="padding-left: 3.16pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;"><a href="#tRIRPA"><font style="padding-left: 0.55pt;">F-</font>17</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCFS">Consolidated Financial Statements<font style="padding-left: 1.98pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;"><a href="#tCFS"><font style="padding-left: 0.55pt;">F-</font>19</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCBS">Consolidated Balance Sheets<font style="padding-left: 4.76pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;"><a href="#tCBS"><font style="padding-left: 0.55pt;">F-</font>19</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCSO">Consolidated Statements of Operations<font style="padding-left: 3.66pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;"><a href="#tCSO"><font style="padding-left: 0.55pt;">F-</font>20</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCSCL">Consolidated Statements of Comprehensive Loss<font style="padding-left: 2.56pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;"><a href="#tCSCL"><font style="padding-left: 0.55pt;">F-</font>21</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tCSR">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)<font style="padding-left: 3.08pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;"><a href="#tCSR"><font style="padding-left: 0.55pt;">F-</font>22</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCSCF1">Consolidated Statements of Cash Flows<font style="padding-left: 4.77pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;"><a href="#tCSCF1"><font style="padding-left: 0.55pt;">F-</font>23</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tNCFS1">Notes to the Consolidated Financial Statements<font style="padding-left: 3.67pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;"><a href="#tNCFS1"><font style="padding-left: 0.55pt;">F-</font>24</a></div></td></tr></table><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; text-align: center;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;">Page</div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unaudited Interim Condensed Consolidated Financial Statements<br></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tICCSP">Unaudited interim condensed consolidated statements of profit or loss and other comprehensive income for the three months ended March 31, 2023 and 2022 <font style="padding-left: 1.21pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;"><a href="#tICCSP"><font style="padding-left: 0.55pt;">F-</font>46</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tICCSF">Unaudited interim condensed consolidated statements of financial position as of March 31, 2023 and audited consolidated statements of financial position as of December 31, 2022<font style="padding-left: 1.24pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;"><a href="#tICCSF"><font style="padding-left: 0.55pt;">F-</font>47</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tICCSC">Unaudited interim condensed consolidated statements of changes in equity for the three months ended March 31, 2023 and 2022<font style="padding-left: 1.14pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;"><a href="#tICCSC"><font style="padding-left: 0.55pt;">F-</font>48</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tICCSCF">Unaudited interim condensed consolidated statements of cash flows for the three months ended March 31, 2023 and 2022<font style="padding-left: 1.14pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;"><a href="#tICCSCF"><font style="padding-left: 0.55pt;">F-</font>49 </a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tNICCFI">Notes to the unaudited interim condensed consolidated financial statements<font style="padding-left: 4.28pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;"><a href="#tNICCFI"><font style="padding-left: 0.55pt;">F-</font>50</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Audited Consolidated Financial Statements<br></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRIRP">Report of Independent Registered Public Accounting Firm<font style="padding-left: 3.68pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;"><a href="#tRIRP"><font style="padding-left: 0.55pt;">F-</font>57</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tCSPL">Consolidated statements of profit or loss and other comprehensive income for the years ended December&#160;31, 2022 and 2021<font style="padding-left: 1.15pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;"><a href="#tCSPL"><font style="padding-left: 0.55pt;">F-</font>58</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCSFP">Consolidated statements of financial position as of December&#160;31, 2022 and 2021<font style="padding-left: 0.68pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;"><a href="#tCSFP"><font style="padding-left: 0.55pt;">F-</font>59</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCSCE">Consolidated statements of changes in equity for the years ended December&#160;31, 2022 and 2021<font style="padding-left: 0.71pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;"><a href="#tCSCE"><font style="padding-left: 0.55pt;">F-</font>60</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCSCF">Consolidated statements of cash flows for the years ended December&#160;31, 2022 and 2021<font style="padding-left: 4.05pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;"><a href="#tCSCF"><font style="padding-left: 0.55pt;">F-</font>61</a></div></td></tr><tr><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tNCFS">Notes to consolidated financial statements<font style="padding-left: 0.34pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.28pt; text-align: left;"><a href="#tNCFS"><font style="padding-left: 0.55pt;">F-</font>62</a></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0.5pt; margin-left: 0pt; text-align: left;"> </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-1<br></div></div></div>
<!--End Page 356-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 357-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_201-fintab_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCCB"><!--Anchor--></a>Catalyst Biosciences, Inc. <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Condensed Consolidated Balance Sheets <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(In thousands, except share and per share amounts) </font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468.1pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.6%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2023</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.06%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2022</div></td></tr><tr class="header"><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.6%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.06%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assets<br></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current assets:<br></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 0.77pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;">$<font style="padding-left: 13.33pt;">8,099</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.5pt; text-align: left;">$<font style="padding-left: 8.33pt;">21,666</font></div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accounts and other receivables<font style="padding-left: 0.78pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 18.33pt;">5,000</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.5pt; text-align: left;"><font style="padding-left: 18.33pt;">5,000</font></div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Prepaid and other current assets<font style="padding-left: 3.01pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">915</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.5pt; text-align: left;"><font style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">1,540</font></div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total current assets<font style="padding-left: 4.8pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 13.33pt;">14,014</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.5pt; text-align: left;"><font style="padding-left: 13.33pt;">28,206</font></div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Long-term receivable from GCBP<font style="padding-left: 4.11pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 18.33pt;">4,550</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.5pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other assets, noncurrent<font style="padding-left: 4.94pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 25.83pt;">168</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.5pt; text-align: left;"><font style="padding-left: 25.83pt;">168</font></div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Right-of-use assets<font style="padding-left: 1.31pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 30.83pt;">17</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.5pt; text-align: left;"><font style="padding-left: 30.83pt;">66</font></div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property and equipment, net<font style="padding-left: 2.7pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 35.83pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">1</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.5pt; text-align: left;"><font style="padding-left: 35.83pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">4</font></div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total assets<font style="font-weight: normal; padding-left: 3.88pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40.83pt;">$</font><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 40.83pt;">18,750</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.5pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40.83pt;">$</font><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 40.83pt;">28,444</font></div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Liabilities, redeemable convertible preferred stock and stockholders&#8217; deficit<br></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current liabilities:<br></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accounts payable<font style="padding-left: 1.31pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;">$<font style="padding-left: 25.83pt;">16</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.5pt; text-align: left;">$<font style="padding-left: 20.83pt;">194</font></div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accrued compensation<font style="padding-left: 0.76pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 18.33pt;">1,085</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.5pt; text-align: left;"><font style="padding-left: 18.33pt;">2,582</font></div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other accrued liabilities<font style="padding-left: 0.77pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 25.83pt;">743</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.5pt; text-align: left;"><font style="padding-left: 18.33pt;">1,452</font></div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Dividends payable<font style="padding-left: 2.97pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.5pt; text-align: left;"><font style="padding-left: 18.33pt;">7,558</font></div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">CVR derivative liability<font style="padding-left: 0.19pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 18.33pt;">5,000</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.5pt; text-align: left;"><font style="padding-left: 18.33pt;">5,000</font></div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Operating lease liability<font style="padding-left: 0.76pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 30.83pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.5pt; text-align: left;"><font style="padding-left: 30.83pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">38</font></div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total current liabilities<font style="padding-left: 0.9pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 18.33pt;">6,844</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.5pt; text-align: left;"><font style="padding-left: 13.33pt;">16,824</font></div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CVR derivative liability, noncurrent<font style="padding-left: 1.69pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">4,550</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.5pt; text-align: left;"><font style="padding-left: 30.83pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities<font style="padding-left: 2.55pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 13.7pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">11,394</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.5pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">16,824</font></div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Commitments and Contingencies (Note 9)<br></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Redeemable convertible preferred stock, $0.001 par value, 123,418 shares authorized; 12,340 shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022<font style="padding-left: 3.25pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 13.33pt;">33,309</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.5pt; text-align: left;"><font style="padding-left: 13.33pt;">33,309</font></div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stockholders&#8217; deficit:<br></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Common stock, $0.001 par value, 100,000,000 shares authorized; 37,759,825 and 37,756,574 shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022, respectively<font style="padding-left: 4.11pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 30.83pt;">37</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.5pt; text-align: left;"><font style="padding-left: 30.83pt;">37</font></div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Additional paid-in capital<font style="padding-left: 4.09pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 8.33pt;">384,686</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.5pt; text-align: left;"><font style="padding-left: 8.33pt;">389,210</font></div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accumulated deficit<font style="padding-left: 1.31pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">(410,676</font><font style="min-width: 40.83pt;">)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.5pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">(410,936</font><font style="min-width: 40.83pt;">)</font></div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total stockholders&#8217; deficit<font style="padding-left: 2.76pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">(25,953</font><font style="min-width: 40.83pt;">)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.5pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">(21,689</font><font style="min-width: 40.83pt;">)</font></div></td></tr><tr><td style="width: 71.78%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; deficit<font style="font-weight: normal; padding-left: 1.85pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.72pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40.83pt;">$</font><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 40.83pt;">18,750</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.5pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40.83pt;">$</font><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 40.83pt;">28,444</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these condensed consolidated financial statements.<font style="font-style: normal;"> </font><br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-2<br></div></div></div>
<!--End Page 357-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 358-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_201-fintab_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCCS"><!--Anchor--></a>Catalyst Biosciences, Inc. <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Condensed Consolidated Statements of Operations<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(In thousands, except share and per share amounts) </font><br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(Unaudited) </font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 25.46%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31,</div></td></tr><tr class="header"><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.36%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023</div></td><td class="gutter" style="width: 1.37%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.37%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.36%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Revenue:<br></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Collaboration<font style="padding-left: 3.51pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;">$<font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;">$<font style="padding-left: 30pt;">794</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses (income):<br></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cost of collaboration<font style="padding-left: 2.41pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 40pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 35pt;">798</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development<font style="padding-left: 4.1pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 35pt;">588</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 27.5pt;">9,703</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">General and administrative<font style="padding-left: 3.55pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 27.5pt;">3,970</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 27.5pt;">4,994</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Gain on disposal of assets, net<font style="padding-left: 3.28pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 24.17pt; border-bottom: 1pt solid #000000; min-width: 50pt;">(4,736</font><font style="min-width: 50pt;">)</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 40pt; border-bottom: 1pt solid #000000; min-width: 50pt;">&#8212;</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total operating expenses (income)<font style="padding-left: 3.14pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 31.67pt; border-bottom: 1pt solid #000000; min-width: 50pt;">(178</font><font style="min-width: 50pt;">)</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 50pt;">15,495</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income (loss) from operations<font style="padding-left: 0.22pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 35pt;">178</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 19.17pt;">(14,701)</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest and other income, net<font style="padding-left: 1.05pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 40pt; border-bottom: 1pt solid #000000; min-width: 50pt;">96</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 35pt; border-bottom: 1pt solid #000000; min-width: 50pt;">165</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income (loss) before income taxes<font style="padding-left: 2.46pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 35pt;">274</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 19.17pt;">(14,536)</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income tax expenses<font style="padding-left: 3.54pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 40pt; border-bottom: 1pt solid #000000; min-width: 50pt;">14</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 40pt; border-bottom: 1pt solid #000000; min-width: 50pt;">&#8212;</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net income (loss)<font style="padding-left: 0.76pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 50pt;">$</font><font style="padding-left: 30pt; border-bottom: 3pt double #000000; min-width: 50pt;">260</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 50pt;">$</font><font style="padding-left: 14.17pt; border-bottom: 3pt double #000000; min-width: 50pt;">(14,536</font><font style="min-width: 50pt;">)</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net income (loss) per share attributable to common stockholders, basic<font style="padding-left: 1.68pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 50pt;">$</font><font style="padding-left: 27.5pt; border-bottom: 3pt double #000000; min-width: 50pt;">0.01</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 50pt;">$</font><font style="padding-left: 24.17pt; border-bottom: 3pt double #000000; min-width: 50pt;">(0.46</font><font style="min-width: 50pt;">)</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net income (loss) per share attributable to common stockholders, diluted<font style="padding-left: 4.45pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 50pt;">$</font><font style="padding-left: 27.5pt; border-bottom: 3pt double #000000; min-width: 50pt;">0.01</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 50pt;">$</font><font style="padding-left: 24.17pt; border-bottom: 3pt double #000000; min-width: 50pt;">(0.46</font><font style="min-width: 50pt;">)</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Shares used to compute net income (loss) per share attributable to common stockholders, basic<font style="padding-left: 1.59pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 50pt;">37,758,416</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 50pt;">31,456,090</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Shares used to compute net income (loss) per share attributable to common stockholders, diluted<font style="padding-left: 4.36pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 50pt;">37,984,324</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 50pt;">31,456,090</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash dividends paid per common share<font style="padding-left: 1.89pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;">$<font style="padding-left: 27.5pt;">0.24</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;">$<font style="padding-left: 35pt;">&#8212;</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CVR cash dividends paid per common share<font style="padding-left: 0.24pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;">$<font style="padding-left: 27.5pt;">0.01</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;">$<font style="padding-left: 35pt;">&#8212;</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these condensed consolidated financial statements.<font style="font-style: normal;"> </font><br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-3<br></div></div></div>
<!--End Page 358-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 359-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_201-fintab_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCCSR"><!--Anchor--></a>Catalyst Biosciences, Inc. <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(In thousands, except share amounts) </font><br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(Unaudited) </font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.1%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.06%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Redeemable Convertible <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Preferred Stock</div></td><td class="gutter" style="width: 0.46%; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.46%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 16.52%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock</div></td><td class="gutter" style="width: 0.46%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 0.46%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 8.01%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Additional <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Paid-In<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Capital</div></td><td class="gutter" rowspan="2" style="width: 0.46%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 0.46%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 9.68%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accumulated<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Deficit</div></td><td class="gutter" rowspan="2" style="width: 0.46%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 0.46%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 10.06%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stockholders'<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Deficit</div></td></tr><tr class="header"><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.1%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.89%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td class="gutter" style="width: 1.1%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.1%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount</div></td><td class="gutter" style="width: 0.46%; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.46%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td class="gutter" style="width: 0.46%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.46%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.98%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount</div></td><td class="gutter" style="width: 0.46%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at December&#160;31, 2022<font style="padding-left: 0.17pt;"></font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.71pt; text-align: left;">12,340</div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.71pt; text-align: left;">$33,309</div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">37,756,574</div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.98%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.49pt; text-align: left;">$37</div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$389,210</div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;">$(410,936)</div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.64pt; text-align: left;">$(21,689)</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Stock-based compensation expense<font style="padding-left: 4.29pt;"></font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.71pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.71pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.98%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.49pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">210</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.64pt; text-align: left;"><font style="padding-left: 20.83pt;">210</font></div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Issuance of common stock from stock grants<font style="padding-left: 2.63pt;"></font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.71pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.71pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">3,251</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.98%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.49pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 32.5pt;">2</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.64pt; text-align: left;"><font style="padding-left: 30.83pt;">2</font></div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">CVR cash dividends paid related to GCBP Agreement ($0.01 per share)<font style="padding-left: 1.82pt;"></font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.71pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.71pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.98%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.49pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 19.17pt;">(206)</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.64pt; text-align: left;"><font style="padding-left: 17.5pt;">(206)</font></div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">CVR derivative liability<font style="padding-left: 3.19pt;"></font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.71pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.71pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.98%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.49pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 11.67pt;">(4,530)</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.64pt; text-align: left;"><font style="padding-left: 10pt;">(4,530)</font></div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net income<font style="padding-left: 4.3pt;"></font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.71pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.71pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 35pt; border-bottom: 1pt solid #000000; min-width: 45pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.98%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.49pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; min-width: 37.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">260</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.64pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">260</font></div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at March&#160;31, 2023<font style="padding-left: 0.16pt;"></font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.71pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">12,340</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.71pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$33,309</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 45pt;">37,759,825</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.98%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.49pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">$37</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 37.5pt;">$384,686</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40.83pt;">$(410,676</font><font style="min-width: 40.83pt;">)</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.64pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">$(25,953</font><font style="min-width: 35.83pt;">)</font></div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.1%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.05%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Redeemable Convertible <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Preferred Stock</div></td><td class="gutter" style="width: 0.46%; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.46%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 16.52%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock</div></td><td class="gutter" style="width: 0.46%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 0.46%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 8.01%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Additional <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Paid-In<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Capital</div></td><td class="gutter" rowspan="2" style="width: 0.46%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 0.46%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 9.68%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accumulated<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Deficit</div></td><td class="gutter" rowspan="2" style="width: 0.46%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 0.46%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 10.06%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stockholders&#8217;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Equity</div></td></tr><tr class="header"><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.1%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.89%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td class="gutter" style="width: 1.1%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.1%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.96%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount</div></td><td class="gutter" style="width: 0.46%; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.46%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td class="gutter" style="width: 0.46%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.46%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.98%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount</div></td><td class="gutter" style="width: 0.46%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at December&#160;31, 2021<font style="padding-left: 0.17pt;"></font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.46pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.47pt; text-align: left;">$&#8212;</div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">31,409,707</div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.98%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.49pt; text-align: left;">$31</div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$443,752</div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;">$(402,694)</div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.64pt; text-align: left;">$<font style="padding-left: 3.33pt;">41,089</font></div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Stock-based compensation expense<font style="padding-left: 4.29pt;"></font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.46pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.47pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">32,684</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.98%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.49pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">515</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.64pt; text-align: left;"><font style="padding-left: 20.83pt;">515</font></div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Issuance of common stock from stock grants<font style="padding-left: 2.63pt;"></font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.46pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.47pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">34,662</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.98%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.49pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 27.5pt;">16</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.64pt; text-align: left;"><font style="padding-left: 25.83pt;">16</font></div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net loss<font style="padding-left: 3.18pt;"></font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.46pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.47pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 35pt; border-bottom: 1pt solid #000000; min-width: 45pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.98%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.49pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; min-width: 37.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">(14,536</font><font style="min-width: 40.83pt;">)</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.64pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(14,536</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at March&#160;31, 2022<font style="padding-left: 0.16pt;"></font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.46pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.47pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">$&#8212;</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 45pt;">31,477,053</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.98%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.49pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">$31</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 37.5pt;">$444,283</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40.83pt;">$(417,230</font><font style="min-width: 40.83pt;">)</font></div></td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.46%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.64pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">$</font><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">27,084</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0.5pt; margin-left: 0pt; text-align: justify;"> </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these condensed consolidated financial statements.<font style="font-style: normal;"> </font><br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-4<br></div></div></div>
<!--End Page 359-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 360-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_201-fintab_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCCSC"><!--Anchor--></a>Catalyst Biosciences, Inc. <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Condensed Consolidated Statements of Cash Flows<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(In thousands) </font><br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(Unaudited) </font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 25.46%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31,</div></td></tr><tr class="header"><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.36%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023</div></td><td class="gutter" style="width: 1.37%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.37%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.36%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating Activities<br></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net income (loss)<font style="padding-left: 0.76pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;">$<font style="padding-left: 15.83pt;">260</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;">$(14,536)</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Adjustments to reconcile net income (loss) to net cash used in operating activities:<br></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Stock-based compensation expense<font style="padding-left: 0.22pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 20.83pt;">210</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 20.83pt;">515</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization<font style="padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 30.83pt;">3</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 21.2pt;">113</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Change in fair value of long-term receivables<font style="padding-left: 1.92pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 22.5pt;">(20)</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Change in fair value of derivative liabilities<font style="padding-left: 4.13pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 25.83pt;">20</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Bad debt expense<font style="padding-left: 1.31pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 20.83pt;">200</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net gain on disposal of assets<font style="padding-left: 0.78pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 10pt;">(4,736)</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Changes in operating assets and liabilities:<br></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Accounts and other receivables<font style="padding-left: 0.78pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 13.33pt;">1,054</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Prepaid and other current assets<font style="padding-left: 3.01pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 20.83pt;">625</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 13.33pt;">1,485</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Accounts payable<font style="padding-left: 1.31pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 17.5pt;">(178)</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 10pt;">(1,713)</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Accrued compensation and other accrued liabilities<font style="padding-left: 4.14pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 10.37pt;">(2,411)</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 13.33pt;">1,036</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Operating lease liability and right-of-use asset<font style="padding-left: 4.7pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 26.2pt;">11</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 25.83pt;">26</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Deferred revenue<font style="padding-left: 2.99pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(230</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash flows used in operating activities<font style="padding-left: 4.13pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(6,216</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(12,050</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Investing Activities<br></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proceeds from maturities of short-term investments<font style="padding-left: 3.59pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 13.33pt;">2,504</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proceeds from the sale of legacy rare bleeding disorder program to GCBP<font style="padding-left: 3.64pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 13.33pt;">1,000</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Payment of transaction costs in connection with the sale of legacy rare bleeding disorder program to GCBP<font style="padding-left: 2.98pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(589</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash flows provided by investing activities<font style="padding-left: 0.8pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 21.2pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">411</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">2,504</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financing Activities<br></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Payment of dividends<font style="padding-left: 4.63pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 10pt;">(7,764)</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Issuance of common stock from stock grants<font style="padding-left: 4.69pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 30.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">2</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">16</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash flows (used in) provided by financing activities<font style="padding-left: 0.27pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(7,762</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">16</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net decrease in cash and cash equivalents<font style="padding-left: 1.37pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 5pt;">(13,567)</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 10pt;">(9,530)</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents at beginning of the period<font style="padding-left: 0.81pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">21,666</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">44,347</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents at end of the period<font style="padding-left: 1.36pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">$</font><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">8,099</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">$</font><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">34,817</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Supplemental Disclosure on Non-Cash Investing and Financing Activities:<br></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CVR derivative liability<font style="padding-left: 0.19pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;">$<font style="padding-left: 8.33pt;">4,530</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;">$<font style="padding-left: 20.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accrued transaction costs related to GCBP asset sale<font style="padding-left: 1.76pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;">$<font style="padding-left: 15.83pt;">205</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.67pt; text-align: left;">$<font style="padding-left: 20.83pt;">&#8212;</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these condensed consolidated financial statements.<font style="font-style: normal;"> </font><br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-5<br></div></div></div>
<!--End Page 360-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 361-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_202-finnotes_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tNUI"><!--Anchor--></a>Catalyst Biosciences, Inc. <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Notes to Condensed Consolidated Financial Statements (Unaudited)</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Nature of Operations and Liquidity</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Catalyst Biosciences, Inc. and its subsidiary (the &#8220;Company&#8221; or &#8220;Catalyst&#8221;) was a biopharmaceutical company with expertise in protease engineering. Prior to ceasing research and development activities in March 2022, the Company had several protease assets that were designed to address unmet medical needs in disorders of the complement or coagulation systems. As discussed further below, the Company recently completed a purchase agreement to acquire a clinical-stage drug candidate for the treatment of NASH (nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease). Concurrent with this purchase agreement, the Company entered into a separate business combination agreement to acquire an indirect controlling interest in a China-based pharmaceutical company. The Company will continue to evaluate the impact of the novel coronavirus disease (&#8220;COVID-19&#8221;) pandemic on its business, operations, and cash requirements. The Company is located in South San Francisco, California and operates in one segment.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">On May&#160;19, 2022, Catalyst entered into and closed on an asset purchase agreement with Vertex Pharmaceuticals&#160;Inc. (&#8220;Vertex&#8221;), pursuant to which Vertex acquired Catalyst&#8217;s complement portfolio, including CB 2782-PEG and CB 4332, as well as its complement-related intellectual property including the ProTUNE<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup> and ImmunoTUNE<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup> platforms. See Note 11, <font style="font-style: italic;">Restructuring.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">On February&#160;27, 2023, Catalyst entered into and closed on an asset purchase agreement with GC Biopharma&#160;Corp. (&#8220;GCBP&#8221;), pursuant to which GCBP acquired Catalyst&#8217;s legacy rare bleeding disorder program, including the coagulation related assets marzeptacog alfa (activated) (&#8220;MarzAA&#8221;), dalcinonacog alfa (&#8220;DalcA&#8221;), and CB-2679d-GT. See Note 11, <font style="font-style: italic;">Restructuring.</font></div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 20pt; text-align: left;">F351 Asset Acquisition</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">On December&#160;26, 2022, the Company executed and closed an Asset Purchase Agreement, which was amended on March&#160;29, 2023 (the &#8220;F351 Agreement&#8221;), with GNI Group Ltd. and GNI Hong Kong Limited (together &#8220;GNI&#8221;) to purchase all of the assets and intellectual property rights primarily related to the proprietary Hydronidone compound (collectively, the &#8220;F351 Assets&#8221;), other than such assets and intellectual property rights located in the People&#8217;s Republic of China. At the closing of the agreement on December&#160;26, 2022, the Company paid $35.0&#160;million in the form of 6,266,521 shares of Catalyst common stock and 12,340 shares of newly designated Series X redeemable convertible preferred stock (&#8220;Catalyst Convertible Preferred Stock&#8221;). Each share of Catalyst Convertible Preferred Stock is convertible into 10,000 shares of common stock, subject to stockholder approval under Nasdaq rules and subject to a beneficial ownership conversion blocker. For additional information, see Note 3, <font style="font-style: italic;">F351 Asset Acquisition</font>.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 20pt; text-align: left;">Business Combination Agreement</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Concurrent with the F351 Asset acquisition, the Company signed a definitive agreement, as amended on March&#160;29, 2023, with GNI Group Ltd., GNI Hong Kong Limited, GNI USA, Inc., Continent Pharmaceuticals&#160;Inc. and Shanghai Genomics, Inc. (collectively, &#8220;GNI&#8221;) and other minority stockholders to acquire an indirect controlling interest in Beijing Continent Pharmaceutical Co Ltd. (&#8220;BC&#8221;), a commercial-stage pharmaceutical company based in China and majority-owned subsidiary of GNI, in exchange for newly issued shares of common stock (the &#8220;Business Combination Agreement&#8221;). The closing of the transactions under the Business Combination Agreement will be subject to stockholder approval at a stockholder meeting expected to be held in the third quarter of 2023 and certain customary closing conditions. For additional information, see Note 9, <font style="font-style: italic;">Commitments and Contingencies</font>.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 20pt; text-align: left;">Contingent Value Rights Agreement</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Pursuant to the Business Combination Agreement, on December&#160;26, 2022, Catalyst and the Rights Agent (as defined therein) executed a contingent value rights agreement, as amended on March&#160;29, 2023 (the &#8220;CVR Agreement&#8221;), pursuant to which each holder of Catalyst common stock as of January&#160;5, 2023 (the &#8220;CVR Holders&#8221;), excluding GNI, received one contractual contingent value right (a &#8220;CVR&#8221;) issued by the Company for each share of Catalyst common stock held by such holder. Each CVR entitles the holder thereof to receive certain cash payments in the future. For additional information, see Note 9, <font style="font-style: italic;">Commitments and Contingencies</font>.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-6<br></div></div></div>
<!--End Page 361-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 362-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_202-finnotes_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 20pt; text-align: left;">Liquidity</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">On January&#160;12, 2023, the Company paid a one-time cash dividend of $0.24 per share to the Company&#8217;s common stockholders of record as of close of business on January&#160;5, 2023, excluding GNI. The aggregate amount of the special dividend payment was approximately $7.6&#160;million.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">On March&#160;8, 2023, the Company distributed the net cash proceeds received from the GCBP asset sale of $0.2&#160;million, or $0.01 per share, to the CVR Holders, excluding GNI. See Note 11, <font style="font-style: italic;">Restructuring</font>, for additional information regarding this distribution.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company had net income of $0.3&#160;million for the three months ended March&#160;31, 2023. As of March&#160;31, 2023, the Company had an accumulated deficit of $410.7&#160;million and cash and cash equivalents of $8.1&#160;million. Its primary uses of cash are to fund operating expenses and general and administrative expenditures. As part of the F351 Agreement, the Company issued 12,340 shares of Catalyst Convertible Preferred Stock, which upon stockholder approval, will be converted to 123,400,000 shares of common stock, subject to applicable beneficial ownership limitations. The terms of the Catalyst Convertible Preferred Stock include a cash settlement feature which provide that, if the Company&#8217;s stockholders fail to approve the conversion of the Catalyst Convertible Preferred Stock by September&#160;30, 2023, the Company could be required to make cash payments to the holders of Catalyst Convertible Preferred Stock significantly in excess of its current liquidity. The Company believes that stockholders who are entitled to vote on the conversion proposal at the Company&#8217;s 2023 Annual Meeting of Stockholders, which is expected to be held in the third quarter of 2023, will vote to approve the proposal. However, as the vote of the Company&#8217;s common stockholders is outside of the control of the Company, there is substantial doubt about its ability to continue as a going concern for at least 12 months following the issuance of these condensed consolidated financial statements. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Summary of Significant Accounting Policies </div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 20pt; text-align: left;">Basis of Presentation </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company&#8217;s condensed consolidated financial statements have been prepared in accordance with U.S.&#160;generally accepted accounting principles (&#8220;GAAP&#8221;) and following the requirements of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair presentation of the Company&#8217;s financial information. These interim results and cash flows for any interim period are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2023, or for any other future annual or interim period.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the consolidated financial statements filed with the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022 (the &#8220;Annual Report&#8221;). </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 20pt; text-align: left;">Use of Estimates</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowance of doubtful accounts, long-term receivable, contingent value rights, operating lease right-of-use assets and liabilities, accrued expenses, income taxes and stock-based compensation. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 20pt; text-align: left;">Accounting Pronouncements Recently Adopted</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In June 2016, the FASB issued ASU 2016-13,<font style="font-style: italic;"> Measurement of Credit Losses on Financial Instruments</font>. The main objective of ASU 2016-13 is to provide financial statement users with more decision-useful information </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-7<br></div></div></div>
<!--End Page 362-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 363-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_202-finnotes_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">about an entity's expected credit losses on financial instruments and other commitments to extend credit at each reporting date. To achieve this objective, the amendments in this update replace the incurred loss impairment methodology currently used today with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. ASU 2016-13 is effective for the Company for fiscal years beginning after December&#160;15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. The Company adopted ASU&#160;2016-13 and related updates as of January&#160;1, 2023 and the adoption did not have a material impact on its condensed consolidated financial statements.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 20pt; text-align: left;">Long-Term Receivable</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company determined that the hold-back from the GCBP asset sale in February 2023 qualified as a long-term receivable. The receivable is considered a loan held for investment since the Company has the intent and ability to hold to maturity. Catalyst has elected to account for the receivable under the fair value option method of accounting and any changes in fair value are recorded in interest and other income, net on the condensed consolidated statement of operations. Refer to Note 4, <font style="font-style: italic;">Fair Value Measurements</font> and Note 11, <font style="font-style: italic;">Restructuring</font>, for additional information regarding the long-term receivable and GCBP asset sale.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 20pt; text-align: left;">Net Income (Loss) per Share Attributable to Common Stockholders</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company calculates basic and diluted net income (loss) per share attributable to common stockholders in conformity with the two-class method required for participating securities. The Catalyst Convertible Preferred Stock contractually entitles the holders of such shares to participate in dividends but such participation is contingent upon the completion of the merger with GNI. As a result, the Catalyst Convertible Preferred Stock is excluded from the basic EPS calculation, as these shares are not participating securities until the merger with GNI closes. As such, net income for the periods presented was not allocated to these securities. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Basic net income (loss) per share attributable to common stockholders is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Participating securities are excluded from the basic weighted average common shares outstanding. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Diluted net income (loss) per share attributable to common stockholders is based on the weighted average number of common shares outstanding during the period, including potential dilutive common shares. For purposes of this calculation, outstanding stock options and warrants are considered potential dilutive common shares. The calculation of diluted EPS does not consider the effect of the Catalyst Convertible Preferred Stock since conversion is contingent upon the occurrence of a specified future event.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">F351 Asset Acquisition</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">On December&#160;26, 2022, the Company acquired the F351 Assets from GNI in accordance with the terms of the F351 Agreement as discussed in Note 1, <font style="font-style: italic;">Nature of Operations and Liquidity</font>. Under the terms of the F351&#160;Agreement, the Company issued 6,266,521 shares of common stock and 12,340 shares of Catalyst Convertible Preferred Stock.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company concluded that the F351 acquisition was not the acquisition of a business, as substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset, the intellectual property rights (outside of China) to a clinical stage drug candidate for the treatment of liver fibrosis, or the F351 Assets.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Subject to stockholder approval, each share of Catalyst Convertible Preferred Stock issued under the F351&#160;Agreement is convertible into 10,000 shares of common stock. The Company is required to hold a stockholders&#8217; meeting to request the approval of the conversion of the Catalyst Convertible Preferred Stock into shares of common stock in accordance with Nasdaq Listing Rule 5635(a) (the &#8220;Conversion Proposal&#8221;). The Company expects to hold its 2023 Annual Meeting of Stockholders in the third quarter of 2023 and will include the following matters as proposals to be voted on at the meeting: (i)&#160;the Conversion Proposal and (ii)&#160;if necessary or appropriate, the approval of an amendment to the Company&#8217;s certificate of incorporation to authorize sufficient shares of common stock for the conversion of the Catalyst Convertible Preferred Stock issued pursuant to the F351 Agreement. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-8<br></div></div></div>
<!--End Page 363-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 364-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_202-finnotes_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">In March 2023, the Company amended the F351 Agreement and the Catalyst Convertible Preferred Stock Certificate of Designation to extend the deadline for the cash settlement of the Catalyst Convertible Preferred Stock from June&#160;26, 2023 to September&#160;30, 2023. Under the amended terms, if the Company&#8217;s stockholders do not approve the conversion of the Catalyst Convertible Preferred Stock by September&#160;30, 2023, then the Catalyst Convertible Preferred Stock would be redeemable at the option of the holders for cash equal to the closing price of the common stock on the last trading day prior to the holder&#8217;s redemption request. Using the closing price on May&#160;8, 2023 of $0.21, if all the currently outstanding Catalyst Convertible Preferred Stock was redeemed for cash, the Company would be required to make a payment of approximately $25.9&#160;million. The Company has insufficient liquidity to make such a payment, if required.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">4.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Fair Value Measurements </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">For a description of the fair value hierarchy and the Company&#8217;s fair value methodology, see &#8220;<font style="font-style: italic;">Part II - Item 8 </font><font style="font-style: italic;">- Financial Statements and Supplementary Data - Note 3</font> &#8211; <font style="font-style: italic;">Summary of Significant Accounting Policies</font>&#8221; in the Company&#8217;s Annual Report. There were no significant changes in these methodologies during the three months ended March&#160;31, 2023.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The following tables present the fair value hierarchy for assets and liabilities measured at fair value on a recurring basis as of March&#160;31, 2023 and December&#160;31, 2022 (<font style="font-style: italic;">in thousands</font>): </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.98%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="10" style="width: 31.07%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2023</div></td></tr><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.98%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.14%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level 1</div></td><td class="gutter" style="width: 0.98%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.98%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level 2</div></td><td class="gutter" style="width: 0.98%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.98%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.14%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level 3</div></td><td class="gutter" style="width: 0.98%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.98%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financial assets:<br></div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Money market funds<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 3.79pt;"></font></div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$8,099</div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.16pt; text-align: left;">$&#8212;</div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 5pt;">8,099</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Long-term receivable from GCBP<font style="padding-left: 3.11pt;"></font></div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.16pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">4,550</font></div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">4,550</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total financial assets<font style="padding-left: 2.13pt;"></font></div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">$8,099</font></div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.16pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">$&#8212;</font></div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">$4,550</font></div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$12,649</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financial liabilities:<br></div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">CVR derivative liability<font style="padding-left: 4.19pt;"></font></div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.16pt; text-align: left;">$&#8212;</div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$5,000</div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 5pt;">5,000</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">CVR derivative liability, noncurrent<font style="padding-left: 0.69pt;"></font></div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.16pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">4,550</font></div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">4,550</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total financial liabilities<font style="padding-left: 3.23pt;"></font></div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">$</font><font style="padding-left: 12.5pt; border-bottom: 3pt double #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.16pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">$&#8212;</font></div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">$9,550</font></div></td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.98%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$</font><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">9,550</font></div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.84%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="10" style="width: 31.35%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2022</div></td></tr><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.84%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level 1</div></td><td class="gutter" style="width: 0.84%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.84%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level 2</div></td><td class="gutter" style="width: 0.84%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.84%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.14%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level 3</div></td><td class="gutter" style="width: 0.84%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.84%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financial assets:<br></div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Money market funds<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 3.79pt;"></font></div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">$21,666</font></div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.16pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 15pt;">$&#8212;</font></div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">$</font><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">$21,666</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total financial assets<font style="padding-left: 2.13pt;"></font></div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$21,666</font></div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.16pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">$&#8212;</font></div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">$</font><font style="padding-left: 12.5pt; border-bottom: 3pt double #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$21,666</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financial liabilities:<br></div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">CVR derivative liability<font style="padding-left: 4.19pt;"></font></div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">$</font><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.16pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 15pt;">$&#8212;</font></div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">$5,000</font></div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">$</font><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">5,000</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total financial liabilities<font style="padding-left: 3.23pt;"></font></div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$</font><font style="padding-left: 17.5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.16pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">$&#8212;</font></div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">$5,000</font></div></td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$</font><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">5,000</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 20pt; margin-top: 12.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The carrying amounts of accounts and other receivables, accounts payable, and accrued liabilities approximate their fair values due to the short-term maturity of these instruments.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 20pt; text-align: left;">Derivative Liabilities and Long-term Receivables</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The CVR derivative liability relates to the CVR Agreement executed in connection with the Business Combination Agreement. The fair value of this derivative liability is based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy. The estimated fair value of the CVR&#160;liability was determined based on the anticipated amount and timing of projected cash flows to be received from Vertex pursuant to the Vertex asset purchase agreement. As of March&#160;31, 2023, the Company expects to </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-9<br></div></div></div>
<!--End Page 364-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 365-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_202-finnotes_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">receive a $5.0&#160;million hold-back payment from Vertex in the second quarter of 2023, which will be distributed, net of expenses, to the holders of Catalyst common stock as of January&#160;5, 2023 under the CVR Agreement. The CVR liability was initially recorded at $5.0&#160;million at issuance on December&#160;26, 2022 and there was no change in the estimated fair value as of March&#160;31, 2023.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The long-term receivable and the corresponding CVR derivative liability, noncurrent relate to the asset purchase agreement with GCBP. The fair value of this long-term receivable and derivative liability is based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy. The estimated fair value of the long-term receivable and CVR derivative liability, noncurrent was determined based on the anticipated amount and timing of projected cash flows to be received from GCBP pursuant to the GCBP asset purchase agreement discounted to their present values using an estimated discount rate of 5.05%. As of March&#160;31, 2023, the Company expects to receive a $5.0&#160;million hold-back payment from GCBP in the first quarter of 2025, which will be distributed, net of expenses, to the holders of Catalyst common stock as of January&#160;5, 2023 under the CVR Agreement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The following table sets forth the changes in the estimated fair value of the Company&#8217;s Level 3 financial assets and liabilities (<font style="font-style: italic;">in thousands</font>):</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.95%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.95%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 16.53%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Long-term receivable<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">from GCBP</div></td><td class="gutter" style="width: 0.95%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.95%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 15.39%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">CVR derivative<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">liability, noncurrent</div></td></tr><tr><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at December&#160;31, 2022<font style="padding-left: 4.17pt;"></font></div></td><td class="gutter" style="width: 0.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 16.53%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.27pt; text-align: left;">$<font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.73pt; text-align: left;">$<font style="padding-left: 12.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additions in the period<font style="padding-left: 0.53pt;"></font></div></td><td class="gutter" style="width: 0.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 16.53%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.27pt; text-align: left;"><font style="padding-left: 5pt;">4,530</font></div></td><td class="gutter" style="width: 0.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.73pt; text-align: left;"><font style="padding-left: 5pt;">4,530</font></div></td></tr><tr><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Changes in fair value<font style="padding-left: 2.76pt;"></font></div></td><td class="gutter" style="width: 0.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 16.53%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.27pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">20</font></div></td><td class="gutter" style="width: 0.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.73pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">20</font></div></td></tr><tr><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at March&#160;31, 2023<font style="padding-left: 4.16pt;"></font></div></td><td class="gutter" style="width: 0.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 16.53%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.27pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">$4,550</font></div></td><td class="gutter" style="width: 0.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.73pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">$4,550</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">5.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Lease</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. In calculating the present value of the lease payments, the Company has elected to utilize its incremental borrowing rate based on the original lease term and not the remaining lease term. The lease includes non-lease components (<font style="font-style: italic;">e.g.</font>, common area maintenance) that are paid separately from rent based on actual costs incurred and, therefore, were not included in the right-of-use asset and lease liability but are reflected as an expense in the period incurred.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company leases office space for its corporate headquarters, located in South San Francisco, CA. The lease term is through April&#160;30, 2023 and there are no stated renewal options. The Company currently has a month-to-month lease that will continue to be utilized following the expiration of the corporate headquarters lease.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In March 2022, the Company entered into a sublease agreement for its leased facility that commenced in April&#160;2022. Under the terms of the sublease agreement, the Company will receive $0.2&#160;million in base lease payments over the term of the sublease, which ends in April 2023. For the three months ended March&#160;31, 2023, the Company recognized sublease income of $38,000. The sublease agreement began in April 2022, so no sublease income was recognized during the three months ended March&#160;31, 2022.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">For the three months ended March&#160;31, 2023 and 2022, the Company&#8217;s operating lease expense was $0.1&#160;million and $0.5&#160;million, respectively.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company has historically prepaid one month&#8217;s worth of rent expense, therefore as of March&#160;31, 2023, the Company does not have any remaining lease payments under its current lease agreement. The present value assumptions used in calculating the present value of the lease payments were as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.12%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2023</div></td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2022</div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average remaining lease term<font style="padding-left: 3.15pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.12%; text-align: right; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">0&#160;years</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.69%; text-align: right; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">0.3&#160;years</div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average discount rate<font style="padding-left: 1.47pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.12%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">0.0%</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.69%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">4.3%</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-10<br></div></div></div>
<!--End Page 365-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 366-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_202-finnotes_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: left;">Supplemental cash flow information related to operating leases was as follows <font style="font-style: italic;">(in thousands)</font>:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.66%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 27.05%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31,</div></td></tr><tr class="header"><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.66%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.42%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023</div></td><td class="gutter" style="width: 1.66%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.66%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.31%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash paid for amounts included in the measurement of lease liabilities<font style="padding-left: 0.17pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.08pt; text-align: left;">$39</div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.58pt; text-align: left;">$502</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">6.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Stock Based Compensation</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 20pt; text-align: left;">2018 Omnibus Incentive Plan </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In June 2018, stockholders of the Company approved the Company&#8217;s 2018 Omnibus Incentive Plan (the &#8220;2018 Plan&#8221;). The 2018 Plan had previously been approved by the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) and the Compensation Committee (the &#8220;Committee&#8221;) of the Board, subject to stockholder approval. The 2018 Plan became effective on June&#160;13, 2018. On June&#160;9, 2021, the stockholders of the Company approved an amendment previously approved by the Board to increase the number of shares of common stock reserved for issuance under the 2018 Plan by 2,500,000 to a total of 5,300,000 shares. The amendment became effective immediately upon stockholder approval. After the option modification (as discussed below), the number of shares of common stock reserved for issuance under the 2018 Plan increased to a total of 31,456,403. As of March&#160;31, 2023, there were 25,521,867 shares of common stock available for future grant.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 20pt; text-align: left;">Performance-Based Stock Option Grants</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In June 2022, the Committee approved the issuance of an option grant to purchase 400,000 shares (2,457,917&#160;shares after the option modification discussed below) of common stock to the Chief Executive Officer pursuant to the 2018 Plan, which will vest upon (a) the achievement of a specified performance goal and (b) the grantee&#8217;s continued employment during the service period. During the three months ended March&#160;31, 2023, this award was cancelled. Prior to cancellation, no expense has been recognized related to this award and no options have vested.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 20pt; text-align: left;">Special Cash Dividend</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">On January&#160;12, 2023, the Company paid a special, one-time cash dividend of $7.6&#160;million (or $0.24 per share) to the Company&#8217;s common stockholders of record as of the close of business on January&#160;5, 2023. The Company determined, in accordance with the adjustment provision of the 2018 Plan, that the special cash dividend was unusual and non-recurring and that appropriate adjustment to the stock options to purchase shares of the Company&#8217;s common stock outstanding under the 2018 Plan was required. The Company treated this adjustment as a modification to the original stock option grants because the terms of the agreements were modified in order to preserve the value of the option awards after a large non-recurring cash dividend. These options were amended to decrease the exercise price and increase the number of shares subject to the stock option on a proportionate basis. No incremental value was provided to the option holders as a result of the modification and no additional compensation cost was recorded by the Company.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: justify;">The following table summarizes stock option activity under the Company&#8217;s 2018 Plan and related information:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.11%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of Shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Underlying <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Outstanding <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Options</div></td><td class="gutter" style="width: 0.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.22%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted- <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average Exercise <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Price</div></td><td class="gutter" style="width: 0.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted- <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Remaining <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Contractual Term <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Years)</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding &#8212; December&#160;31, 2022<font style="padding-left: 1.71pt;"></font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.11%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.63pt; text-align: left;"><font style="padding-left: 7.96pt;">8,678,767</font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.87pt; text-align: left;">$<font style="padding-left: 5pt;">1.42</font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.35pt; text-align: left;">7.47</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Options granted<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 3.78pt;"></font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.11%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.63pt; text-align: left;"><font style="padding-left: 2.96pt;">14,008,093</font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.87pt; text-align: left;">$<font style="padding-left: 5pt;">0.86</font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Options forfeited and cancelled<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 0.48pt;"></font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.11%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.63pt; text-align: left;">(14,210,119)</div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.87pt; text-align: left;">$<font style="padding-left: 5pt;">0.91</font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Options expired<font style="padding-left: 2.52pt;"></font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.11%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.63pt; text-align: left;"><font style="padding-left: 17.13pt; border-bottom: 1pt solid #000000; min-width: 47.96pt;">(12,174</font><font style="min-width: 47.96pt;">)</font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.87pt; text-align: left;">$36.16</div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding &#8212; March&#160;31, 2023<font style="padding-left: 1.7pt;"></font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.11%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.63pt; text-align: left;"><font style="padding-left: 7.96pt; border-bottom: 3pt double #000000; min-width: 47.96pt;">8,464,567</font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.87pt; text-align: left;">$<font style="padding-left: 5pt;">1.30</font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.35pt; text-align: left;">6.01</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exercisable &#8212; March&#160;31, 2023<font style="padding-left: 3.94pt;"></font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.11%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.63pt; text-align: left;"><font style="padding-left: 7.96pt; border-bottom: 3pt double #000000; min-width: 47.96pt;">7,306,692</font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.87pt; text-align: left;">$<font style="padding-left: 5pt;">1.40</font></div></td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.87%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 20pt; margin-top: 12.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes options that were cancelled and re-granted as part of the option modification from the special cash dividend, as further discussed above.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-11<br></div></div></div>
<!--End Page 366-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 367-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_202-finnotes_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 20pt; text-align: left;">Valuation Assumptions </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company estimated the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. Due to its limited relevant historical data, the Company estimated its volatility considering a number of factors including the use of the volatility of comparable public companies. The expected term of options granted under the Plan, all of which qualify as &#8220;plain vanilla&#8221; per SEC Staff Accounting Bulletin 107, is determined based on the simplified method due to the Company&#8217;s limited relevant history. The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with the option. This fair value is being amortized ratably over the requisite service periods of the awards, which is generally the vesting period.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The only options granted during the quarter ended March&#160;31, 2023 were as a result of the option modification. Since no new stock options were granted during the quarter ended March&#160;31, 2023, all weighted-average assumptions for the period were not applicable.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">The fair value of employee stock options was estimated using the following weighted-average assumptions:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.99%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 25.71%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31,</div></td></tr><tr class="header"><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.99%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.58%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023</div></td><td class="gutter" style="width: 0.99%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.99%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.15%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee Stock Options:<br></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Risk-free interest rate<font style="padding-left: 3.22pt;"></font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.21pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.71pt; text-align: left;"><font style="padding-left: 10pt;">1.87%</font></div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Expected term (in years)<font style="padding-left: 0.44pt;"></font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.21pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.71pt; text-align: left;"><font style="padding-left: 15pt;">6.1</font></div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Dividend yield<font style="padding-left: 0.96pt;"></font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.21pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.71pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Volatility<font style="padding-left: 4.46pt;"></font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.21pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.71pt; text-align: left;"><font style="padding-left: 5pt;">91.54%</font></div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Weighted-average fair value of stock options granted<font style="padding-left: 4.62pt;"></font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.21pt; text-align: left;">$&#8212;</div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.71pt; text-align: left;">$<font style="padding-left: 5pt;">0.39</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 20pt; text-align: left;">Total stock-based compensation expense recognized was as follows (<font style="font-style: italic;">in thousands</font>): </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.99%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 25.71%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31,</div></td></tr><tr class="header"><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.99%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023</div></td><td class="gutter" style="width: 0.99%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.99%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development<font style="padding-left: 2.1pt;"></font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.58pt; text-align: left;">$<font style="padding-left: 5pt;">66</font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.58pt; text-align: left;">$128</div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 2.8pt;"></font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.58pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 20pt;">144</font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.58pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 20pt;">387</font></div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Total stock-based compensation expense<font style="padding-left: 1.15pt;"></font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 20pt;">$210</font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 20pt;">$515</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 20pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">No shares of common stock were issued to board members for the three months ended March&#160;31, 2023. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">7.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Collaborations</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7.5pt; margin-left: 20pt; text-align: left;">ISU Abxis</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In December 2018, the Company entered into an amended and restated license agreement with ISU Abxis (the &#8220;A&amp;R ISU Abxis Agreement&#8221;). Under the A&amp;R ISU Abxis Agreement, ISU Abxis will receive commercialization rights in South Korea to the Company&#8217;s engineered Factor IX dalcinonacog alfa - DalcA and the Company will receive clinical development and commercialization rights in the rest of world (excluding South Korea) and manufacturing development and manufacturing rights worldwide (including South Korea). The A&amp;R ISU Abxis Agreement provides for a low single-digit royalty payment to ISU Abxis, on a country-by-country basis, for net product sales of DalcA by the Company or its affiliates in each country other than South Korea. Pursuant to the A&amp;R ISU Abxis Agreement, the Company will also pay up to an aggregate of $19.5&#160;million in milestone payments to ISU Abxis, including $2.5&#160;million in regulatory and development milestone payments and up to $17.0&#160;million in commercial milestone payments, if the applicable milestones are met.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">As a result of the sale of the Company&#8217;s rare bleeding disorders programs, including DalcA and other assets, to GCBP in February 2023, the A&amp;R ISU Abxis Agreement was transferred to GCBP. See Note 11, <font style="font-style: italic;">Restructuring. </font>As of the date of transfer, no milestones have been met.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-12<br></div></div></div>
<!--End Page 367-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 368-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_202-finnotes_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">8.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Net Income (Loss) per Share Attributable to Common Stockholders </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Potentially dilutive securities are excluded from the calculation of diluted net income (loss) per share attributable to common stockholders if their inclusion is anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.99%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 25.71%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31,</div></td></tr><tr class="header"><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.99%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023</div></td><td class="gutter" style="width: 0.99%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.99%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Options to purchase common stock<font style="padding-left: 2.1pt;"></font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.58pt; text-align: left;">8,249,500</div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.58pt; text-align: left;">2,777,710</div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Common stock warrants<font style="padding-left: 2.09pt;"></font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.58pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 40pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.58pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 40pt;">85</font></div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="padding-left: 1.09pt;"></font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">8,249,500</font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">2,777,795</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In addition, the Catalyst Convertible Preferred Stock has also been excluded from the computation of diluted net income (loss) per share attributable to common stockholders because the contingency for conversion of these shares has not been met.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The following is a reconciliation of the numerator (net income or loss) and denominator (number of shares) used in the calculation of basic and diluted net income (loss) per share attributable to common stockholders (in thousands, except share and per share data):</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.99%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 25.71%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31,</div></td></tr><tr class="header"><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.99%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023</div></td><td class="gutter" style="width: 0.99%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.99%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Numerator<br></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net income (loss)<font style="padding-left: 3.76pt;"></font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;">$<font style="padding-left: 30pt;">260</font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;">$<font style="padding-left: 14.17pt;">(14,536)</font></div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Denominator<br></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Weighted-average number of shares used in computing net income (loss) per share available to common stockholders, basic<font style="padding-left: 1.3pt;"></font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 5pt;">37,758,416</font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 5pt;">31,456,090</font></div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Effect of dilutive stock options<font style="padding-left: 4.5pt;"></font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 50pt;">225,908</font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 40pt; border-bottom: 1pt solid #000000; min-width: 50pt;">&#8212;</font></div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Weighted-average number of shares used in computing net income (loss) per share available to common stockholders, diluted<font style="padding-left: 4.07pt;"></font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 50pt;">37,984,324</font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 50pt;">31,456,090</font></div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net income (loss) per share available for common stockholders, basic<font style="padding-left: 0.24pt;"></font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 50pt;">$</font><font style="padding-left: 27.5pt; border-bottom: 3pt double #000000; min-width: 50pt;">0.01</font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 50pt;">$</font><font style="padding-left: 24.17pt; border-bottom: 3pt double #000000; min-width: 50pt;">(0.46</font><font style="min-width: 50pt;">)</font></div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net income (loss) per share available for common stockholders, dilutive<font style="padding-left: 0.24pt;"></font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 50pt;">$</font><font style="padding-left: 27.5pt; border-bottom: 3pt double #000000; min-width: 50pt;">0.01</font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 50pt;">$</font><font style="padding-left: 24.17pt; border-bottom: 3pt double #000000; min-width: 50pt;">(0.46</font><font style="min-width: 50pt;">)</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">9.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Commitments and Contingencies </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">As of March&#160;31, 2023 and December&#160;31, 2022, the Company had cash deposited in certain financial institutions in excess of federally insured levels. The Company regularly monitors the financial stability of these financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents. However, in March and April 2023, certain U.S. government banking regulators took steps to intervene in the operations of certain financial institutions due to liquidity concerns, which caused general heightened uncertainties in financial markets. While these events have not had a material direct impact on the Company&#8217;s operations, if further liquidity and financial stability concerns arise with respect to banks and financial institutions, either nationally or in specific regions, the Company&#8217;s ability to access cash or enter into new financing arrangements may be threatened, which could have a material adverse effect on its business, financial condition and results of operations.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 20pt; text-align: left;">Business Combination Agreement</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Concurrent with the F351 Asset acquisition, as amended on March&#160;29, 2023, the Company entered into the Business Combination Agreement with GNI and other minority stockholders (&#8220;Sellers&#8221; and each a &#8220;Seller&#8221;) to acquire an indirect controlling interest in BC, a commercial-stage pharmaceutical company based in China and majority-owned subsidiary of GNI, in exchange for newly issued shares of Catalyst common stock. The closing of the transactions under the Business Combination Agreement will be subject to stockholder approval at a stockholder meeting expected to be held in the third quarter of 2023 and certain customary closing conditions. If the transaction is approved by stockholders, the Company would issue at closing a total of up to </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-13<br></div></div></div>
<!--End Page 368-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 369-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_202-finnotes_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">1,110,776,224 shares of Catalyst common stock for an indirect controlling interest in BC. Each Seller may elect to be issued Catalyst Convertible Preferred Stock in lieu of the Company&#8217;s common stock.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Business Combination Agreement contains certain termination rights, including the right for Catalyst to terminate the Business Combination Agreement to enter into a definitive agreement for a superior proposal. Upon termination of the Business Combination Agreement under specified circumstances, the Company may be required to pay a termination fee of $2.0&#160;million and either party, as the case may be, may be required to reimburse the other party for reasonable out-of-pocket fees and expenses incurred by such party in connection with the Business Combination Agreement, up to a maximum amount of $2.0&#160;million.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 20pt; text-align: left;">Contingent Value Rights Agreement</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Pursuant to the Business Combination Agreement, on December&#160;26, 2022, Catalyst and the Rights Agent (as defined therein) executed the CVR Agreement, as amended on March&#160;29, 2023, pursuant to which the CVR&#160;Holders received one contractual CVR issued by the Company, subject to and in accordance with the terms and conditions of the CVR Agreement, for each share of Catalyst common stock held by such holder. Each CVR entitles the holder thereof to receive (i)&#160;certain cash payments from the net proceeds related to the disposition of the Company&#8217;s legacy assets (MarzAA, DalcA, and CB 2679d-GT), (ii) 100% of the excess cash (net of all current or contingent liabilities, including transaction-related expenses) retained by the Company in excess of $1.0&#160;million as of the closing date of the transactions under the Business Combination Agreement, (iii) 100%&#160;of the amount actually received by the Company, net of expenses, pursuant to the Vertex asset purchase agreement and (iv) 100% of the excess, by which the preapproved costs to manage, negotiate, settle and finalize certain third party claims exceed the costs actually incurred with respect to such claims. The CVRs are not transferable, except in certain limited circumstances as provided for in the CVR Agreement, will not be certificated or evidenced by any instrument, and will not be registered with the SEC or listed for trading on any exchange.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In February 2023, the Company recorded a $4.5&#160;million long-term CVR derivative liability as a result of the disposition of the Company&#8217;s legacy assets to GCBP. On March&#160;8, 2023, the Company distributed the net cash proceeds received from the GCBP asset sale of $0.2&#160;million to the CVR Holders. Refer to Note 4, <font style="font-style: italic;">Fair Value </font><font style="font-style: italic;">Measurements </font>and Note 11, <font style="font-style: italic;">Restructuring,</font> for additional information regarding the CVR derivative liability and GCBP asset sale.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 20pt; text-align: left;">COVID-19</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The current COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting the Company&#8217;s employees and business operations. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national, and international markets. The COVID-19 pandemic may disrupt the Company&#8217;s ability to conduct the clinical development and commercialization of Hydronidone in NASH fibrosis as planned.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">10.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Income Taxes</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">During the three months ended March&#160;31, 2023 and 2022, the Company recorded an income tax expense of $14,000 and zero, respectively. The Company recorded no income tax benefits for the net operating losses incurred or for the research and development tax credits generated in each period due to its uncertainty of realizing a benefit from those items. All of the Company&#8217;s operating losses since inception have been generated in the United States.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">As of March&#160;31, 2023, after consideration of certain limitations (see below), the Company had approximately $194.1&#160;million federal and $3.6&#160;million state net operating loss carryforwards (&#8220;NOL&#8221;) available to reduce future taxable income which, if unused, the majority will carry forward indefinitely for federal and will begin to expire in 2032 for state tax purposes.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">If the Company experiences a greater than 50 percent aggregate change in ownership over a three-year period (a Section 382 ownership change), utilization of its pre-change NOL carryforwards are subject to annual limitation under Section 382 of the Internal Revenue Code (California has similar provisions). The annual </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-14<br></div></div></div>
<!--End Page 369-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 370-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_202-finnotes_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">limitation is determined by multiplying the value of the Company's stock at the time of such ownership change by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL&#160;carryforwards before utilization. The Company determined that ownership changes occurred on December&#160;31, 2007, August&#160;20, 2015, April&#160;13, 2017, February&#160;15, 2018, February&#160;18, 2020, and December&#160;26, 2022. The ability of the Company to use its remaining NOL and tax credit carry forwards may be further limited if the Company experiences a Section 382 ownership change as a result of future changes in its stock ownership.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">11.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Restructuring</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In November 2021, the Board approved a restructuring of its business based on its decision to stop the clinical development of MarzAA and focus solely on its complement programs and protease medicines platform. The restructuring included a reduction-in-force whereby approximately 35% of employees were terminated.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In March 2022, the Board approved a further reduction of its workforce as part of its restructuring plan whereby 22 full-time employees were terminated. Following this reduction, the Company had five full-time employees remaining. During the quarter ended March&#160;31, 2022, the Company recorded additional charges of $1.0&#160;million for severance and other costs related to the reduction-in-force, recognized as an operating expense within the condensed consolidated statements of operations, which the Company paid during the second quarter of 2022.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 20pt; text-align: left;">Sale of Assets</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In May 2022, the Company entered into an asset purchase agreement with Vertex, pursuant to which Vertex purchased the Company&#8217;s complement portfolio, including CB 2782-PEG and CB 4332, as well as its complement-related intellectual property including the ProTUNE<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup> and ImmunoTUNE<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup> platforms for $60.0&#160;million in cash consideration. Cash of $55.0&#160;million was received upfront in May 2022 and the remaining $5.0&#160;million will be paid one year after the closing upon satisfaction of certain post-closing indemnification obligations. The hold-back amount is recorded within accounts and other receivables on the condensed consolidated balance sheet. Once received, the net proceeds from the hold-back amount will be distributed to the CVR Holders pursuant to the CVR Agreement, see Note 9, <font style="font-style: italic;">Commitments and Contingencies</font>. There were no carrying amounts associated with the intellectual property sold to Vertex, and, therefore, the Company recorded a gain of $57.4&#160;million related to the disposal, net of $2.6&#160;million of transaction costs during the second quarter of 2022.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In February 2023, Catalyst entered into an asset purchase agreement with GCBP, pursuant to which GCBP&#160;acquired the Company&#8217;s legacy rare bleeding disorders programs, including MarzAA, DalcA and CB-2679d-GT, for $6.0&#160;million in cash consideration. Cash of $1.0&#160;million was received upfront in February&#160;2023 and the remaining $5.0&#160;million will be paid two years after the closing upon satisfaction of certain post-closing indemnification obligations. The hold-back amount is recorded as a long-term receivable on the condensed consolidated balance sheet. In March 2023, the Company distributed the net cash proceeds received upfront of $0.2&#160;million to the CVR Holders. Once received, the remaining net proceeds, net of expenses, from the hold-back amount will be distributed to the CVR Holders pursuant to the CVR Agreement, see Note 9, <font style="font-style: italic;">Commitments and Contingencies</font>. There were no carrying amounts associated with the intellectual property sold to GCBP, and, therefore, Catalyst recorded a gain of $4.7&#160;million related to the disposal, net of $0.8&#160;million of transaction costs, which is included in gain on disposal of assets, net in the condensed consolidated statements of operations for the three months ended March&#160;31, 2023. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">12.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Subsequent Events</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 20pt; text-align: left;">Cost Sharing Agreement</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">On April&#160;13, 2023, the Company entered into a Cost Sharing and Agency Agreement with GNI. Under this agreement, GNI will pay for certain costs related to the development of the F351 Assets in the U.S. incurred from December&#160;26, 2022 until the Business Combination Agreement closes. After the Business Combination Agreement closes, the Company will be required to reimburse GNI for such costs. The Company has not incurred any expenses related to the development of the F351 Assets through March&#160;31, 2023.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 20pt; text-align: left;">Manufacturing Agreements</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">On April&#160;18, 2023, the Company entered into two separate agreements to support the F351 Assets acquired from GNI. One agreement will cover analytical method process familiarization and validation to support good manufacturing practices (&#8220;GMP&#8221;) manufacturing, and the other agreement will cover non-GMP manufacturing </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-15<br></div></div></div>
<!--End Page 370-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 371-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_202-finnotes_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">services and clinical supply batch GMP manufacturing of the F351 Assets, with total payments of up to $0.3&#160;million and $0.2&#160;million, respectively. The Company can terminate these agreements at any time upon 90&#160;days written notice. Upon termination, the Company will be responsible to pay for services incurred prior to termination and any non-cancellable obligations in connection with such services.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-16<br></div></div></div>
<!--End Page 371-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 372-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_203-fintab_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tRIRPA"><!--Anchor--></a>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 12pt; margin-left: 0pt; text-align: left;">To the Board of Directors and Stockholders of <br></div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Opinion on the Financial Statements </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We have audited the accompanying consolidated balance sheets of Catalyst Biosciences, Inc. (the &#8220;Company&#8221;) as of December&#160;31, 2022 and 2021 and the related consolidated statements of operations, comprehensive loss, redeemable convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows for each of the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December&#160;31, 2022 and 2021, and the consolidated results of their operations and their cash flows for each of the years then ended in conformity with accounting principles generally accepted in the United States of America. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Going Concern </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the terms of the Convertible Preferred Stock include a cash settlement feature which, provide that, if the Company&#8217;s stockholders fail to approve the conversion of the Convertible Preferred Stock by September&#160;30, 2023, the Company could be required to make cash payments to the holders of the Convertible Preferred Stock significantly in excess of its current liquidity, which raises substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Basis for Opinion </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Critical Audit Matter </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (i)&#160;relates to accounts or disclosures that are material to the financial statements and (ii)&#160;involved especially challenging, subjective, or complex judgments. The communication of critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Asset Acquisition </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As described in Note 1 to the financial statements, during the year ended December&#160;31, 2022, the Company executed and closed an asset purchase agreement, with GNI Group Ltd. and GNI Hong Kong Limited (together &#8220;GNI&#8221;) to purchase all of the assets and intellectual property rights primarily related to GNI&#8217;s proprietary Hydronidone </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-17<br></div></div></div>
<!--End Page 372-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 373-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_203-fintab_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">compound, other than such assets and intellectual property rights located in the People&#8217;s Republic of China. The Company paid GNI $35.0&#160;million in the form of 6,266,521 shares of the Company&#8217;s common stock and 12,340 shares of newly designated Series X redeemable convertible preferred stock (&#8220;Convertible Preferred Stock&#8221;). The Convertible Preferred Stock is classified as temporary equity on the consolidated balance sheet because it would be redeemable at the option of the holders for cash if conversion to common stock is not approved by the shareholders. Concurrently with the asset purchase agreement, the Company executed a contingent value rights agreement, in which certain common stockholders received a contractual contingent value right (&#8220;CVR&#8221;) for each share of common stock held by the stockholder entitling the holder to certain cash payments in the future. Certain contingent payments under the CVR agreement qualified as derivatives and were recorded as a liability on the balance sheet at fair value as of December&#160;31, 2022. Significant management judgment was required in evaluating the various rights of the Convertible Preferred Stock and in classifying the Convertible Preferred Stock. The determination of derivative qualification and the initial and subsequent fair value of the CVR liability also required significant management judgment. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We identified the classification of the Convertible Preferred Stock and the derivative evaluation for contingent payments and the initial and subsequent valuation of the CVR under the CVR agreement as a critical audit matter due to (i)&#160;the significant management judgment required in the applicable accounting guidance; (ii)&#160;the complexity of the accounting guidance in these areas; and (iii)&#160;the significant unusual nature of the transactions. Auditing these elements involved specialized knowledge and experience in dealing with complex debt and equity arrangements. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements. We obtained an understanding and evaluated the design of controls relating to the Company's accounting for significant accounting transactions. We read and analyzed the agreements and contract terms related to the Convertible Preferred Stock and CVR agreement. We evaluated the assumptions and conclusions made by the Company related to the accounting treatment of the Convertible Preferred Stock classification and CVR derivative liability, including the Company&#8217;s consideration of relevant accounting standards and their analysis of the appropriate accounting treatment. We utilized personnel with specialized skill and knowledge in the relevant technical accounting guidance to assist in evaluating the appropriateness of the Company&#8217;s application of the relevant accounting guidance. We tested the valuation of the Convertible Preferred Stock and utilized internal valuation specialists to assist in evaluating the appropriateness of the Company&#8217;s methodology and the assumptions utilized. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">/s/ EisnerAmper LLP </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">We have served as the Company&#8217;s auditor since 2014. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">EISNERAMPER LLP <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Philadelphia, Pennsylvania <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">March&#160;30, 2023</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-18<br></div></div></div>
<!--End Page 373-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 374-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_203-fintab_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCFS"><!--Anchor--></a>Catalyst Biosciences, Inc.<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><a name="tCBS"><!--Anchor--></a>Consolidated Balance Sheets<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(In thousands, except shares and per share amounts)</font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.08%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.37%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.37%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.08%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assets<br></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current assets:<br></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 2.77pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;">$<font style="padding-left: 8.33pt;">21,666</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;">$<font style="padding-left: 8.33pt;">44,347</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Short-term investments<font style="padding-left: 1.08pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 18.33pt;">2,504</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accounts and other receivables<font style="padding-left: 2.78pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 18.33pt;">5,000</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 18.33pt;">1,818</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Prepaid and other current assets<font style="padding-left: 0.01pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 18.33pt;">1,540</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 18.33pt;">2,807</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total current assets<font style="padding-left: 1.8pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 13.33pt;">28,206</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 13.33pt;">51,476</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other assets, noncurrent<font style="padding-left: 1.94pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 25.83pt;">168</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 25.83pt;">472</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Right-of-use assets<font style="padding-left: 3.31pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 30.83pt;">66</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 18.33pt;">2,744</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property and equipment, net<font style="padding-left: 4.7pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 35.83pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">4</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">970</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total assets<font style="font-weight: normal; padding-left: 0.88pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40.83pt;">$</font><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 40.83pt;">28,444</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40.83pt;">$</font><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 40.83pt;">55,662</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Liabilities, redeemable convertible preferred stock and stockholders&#8217; equity (deficit)<br></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current liabilities:<br></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accounts payable<font style="padding-left: 3.31pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;">$<font style="padding-left: 20.83pt;">194</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;">$<font style="padding-left: 13.33pt;">6,419</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accrued compensation<font style="padding-left: 2.76pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 18.33pt;">2,582</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 18.33pt;">1,467</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Deferred revenue<font style="padding-left: 4.99pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 25.83pt;">230</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other accrued liabilities<font style="padding-left: 2.77pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 18.33pt;">1,452</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 18.33pt;">4,072</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Dividends payable<font style="padding-left: 4.97pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 18.33pt;">7,558</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">CVR derivative liability<font style="padding-left: 2.19pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 18.33pt;">5,000</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Operating lease liability<font style="padding-left: 2.76pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 30.83pt;">38</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 18.33pt;">1,977</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total current liabilities<font style="padding-left: 2.9pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 13.33pt;">16,824</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 13.33pt;">14,165</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating lease liability, noncurrent<font style="padding-left: 4.26pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 30.83pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">408</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities<font style="padding-left: 4.55pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">16,824</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">14,573</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Commitments and Contingencies (Note 8)<br></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Redeemable convertible preferred stock, $0.001 par value, 123,418 shares authorized; 12,340 shares issued and outstanding as of December&#160;31, 2022 and no shares issued and outstanding as of December&#160;31, 2021<font style="padding-left: 4.21pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 13.33pt;">33,309</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stockholders&#8217; equity (deficit):<br></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Common stock, $0.001 par value, 100,000,000 shares authorized; 37,756,574 and 31,409,707 shares issued and outstanding at December&#160;31, 2022 and 2021, respectively<font style="padding-left: 2.19pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 30.83pt;">37</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 30.83pt;">31</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Additional paid-in capital<font style="padding-left: 1.09pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 8.33pt;">389,210</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 8.33pt;">443,752</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accumulated deficit<font style="padding-left: 3.31pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">(410,936</font><font style="min-width: 40.83pt;">)</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">(402,694</font><font style="min-width: 40.83pt;">)</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total stockholders&#8217; equity (deficit)<font style="padding-left: 4.77pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">(21,689</font><font style="min-width: 40.83pt;">)</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">41,089</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; equity (deficit)<font style="font-weight: normal; padding-left: 2.2pt;"></font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40.83pt;">$</font><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 40.83pt;">28,444</font></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.17pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40.83pt;">$</font><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 40.83pt;">55,662</font></div></td></tr></table><div class="footer" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; text-align: center;"></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these consolidated financial statements.<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-19<br></div></div></div>
<!--End Page 374-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 375-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_203-fintab_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Catalyst Biosciences, Inc.<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><a name="tCSO"><!--Anchor--></a>Consolidated Statements of Operations<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(In thousands, except share and per share amounts)</font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 23.5%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31,</div></td></tr><tr class="header"><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.68%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.68%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Revenue:<br></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Collaboration<font style="padding-left: 0.51pt;"></font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 30pt;">794</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 22.5pt;">7,338</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses (income):<br></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cost of collaboration<font style="padding-left: 4.41pt;"></font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 35pt;">798</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 27.5pt;">7,380</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development<font style="padding-left: 1.1pt;"></font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">13,037</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">68,889</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">General and administrative<font style="padding-left: 0.55pt;"></font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">17,366</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">18,963</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Acquired in-process research and development<font style="padding-left: 4.48pt;"></font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">35,390</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 40pt;">&#8212;</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Gain on disposal of assets, net<font style="padding-left: 0.28pt;"></font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 19.17pt;">(57,186)</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 40pt;">&#8212;</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total operating expenses<font style="padding-left: 4.57pt;"></font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; min-width: 50pt;">9,405</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 50pt;">95,232</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from operations<font style="padding-left: 3.87pt;"></font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 24.54pt;">(8,611)</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 19.17pt;">(87,894)</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest and other income (expense), net<font style="padding-left: 0.86pt;"></font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 35pt; border-bottom: 1pt solid #000000; min-width: 50pt;">717</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 36.67pt; border-bottom: 1pt solid #000000; min-width: 50pt;">(39</font><font style="min-width: 50pt;">)</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss before income taxes<font style="padding-left: 1.11pt;"></font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 24.17pt;">(7,894)</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 19.17pt;">(87,933)</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income tax expenses<font style="padding-left: 0.54pt;"></font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 35pt; border-bottom: 1pt solid #000000; min-width: 50pt;">348</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 40pt; border-bottom: 1pt solid #000000; min-width: 50pt;">&#8212;</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss<font style="padding-left: 2.18pt;"></font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 19.17pt;">(8,242)</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 14.17pt;">(87,933)</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss per share attributable to common stockholders, basic and diluted<font style="padding-left: 4.23pt;"></font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 50pt;">$</font><font style="padding-left: 24.17pt; border-bottom: 3pt double #000000; min-width: 50pt;">(0.26</font><font style="min-width: 50pt;">)</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 50pt;">$</font><font style="padding-left: 24.17pt; border-bottom: 3pt double #000000; min-width: 50pt;">(2.87</font><font style="min-width: 50pt;">)</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Shares used to compute net loss per share attributable to common stockholders, basic and diluted<font style="padding-left: 1.08pt;"></font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 50pt;">31,545,723</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 50pt;">30,640,977</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash dividends paid per common share<font style="padding-left: 3.89pt;"></font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 27.5pt;">1.43</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 35pt;">&#8212;</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash dividends declared, unpaid, per common share<font style="padding-left: 1.69pt;"></font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 27.5pt;">0.24</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 35pt;">&#8212;</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these consolidated financial statements.<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-20<br></div></div></div>
<!--End Page 375-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 376-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_203-fintab_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Catalyst Biosciences, Inc.<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><a name="tCSCL"><!--Anchor--></a>Consolidated Statements of Comprehensive Loss<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(In thousands)</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 21.85%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31,</div></td></tr><tr class="header"><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.5%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.57%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss<font style="padding-left: 2.18pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.48pt; text-align: left;">$(8,242)</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.48pt; text-align: left;">$(87,933)</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other comprehensive loss:<br></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Unrealized loss on available-for-sale debt securities<font style="padding-left: 4.7pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.48pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.48pt; text-align: left;"><font style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(5</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total comprehensive loss<font style="padding-left: 2.35pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.48pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 30.83pt;">$(8,242</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.48pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">$(87,938</font><font style="min-width: 35.83pt;">)</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these consolidated financial statements.<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-21<br></div></div></div>
<!--End Page 376-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 377-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 528pt;"><a name="ny20006478x8_prer14a_203-fintab_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 30pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Catalyst Biosciences, Inc.<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><a name="tCSR"><!--Anchor--></a>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(In thousands, except share amounts)</font></div></div><div class="block-main" style="width: 528pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 528pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 25.95%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.73%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 16.39%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Redeemable Convertible <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Preferred Stock</div></td><td class="gutter" style="width: 0.73%; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.73%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 14.43%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock</div></td><td class="gutter" style="width: 0.73%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 0.73%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 6.9%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Additional <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Paid-In <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Capital</div></td><td class="gutter" rowspan="2" style="width: 0.73%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 0.73%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 10.07%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accumulated <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Other <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Comprehensive <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Income (Loss)</div></td><td class="gutter" rowspan="2" style="width: 0.73%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 0.73%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 8.58%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accumulated <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Deficit</div></td><td class="gutter" rowspan="2" style="width: 0.73%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 0.73%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 8.92%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stockholders&#8217; <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Equity <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Deficit)</div></td></tr><tr class="header"><td style="width: 25.95%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.73%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.04%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td class="gutter" style="width: 0.73%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.73%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.89%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount</div></td><td class="gutter" style="width: 0.73%; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.73%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.67%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td class="gutter" style="width: 0.73%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.73%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.3%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount</div></td><td class="gutter" style="width: 0.73%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td></tr><tr><td style="width: 25.95%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at December&#160;31, 2020<font style="padding-left: 1.08pt;"></font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.21pt; text-align: left;"><font style="padding-left: 15.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.22pt; text-align: left;">$<font style="padding-left: 15.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">22,097,820</div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.24pt; text-align: left;">$22</div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 1.35pt; text-align: left;">$390,803</div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 19.84pt; text-align: left;">$<font style="padding-left: 4.5pt;">5</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.29pt; text-align: left;">$(314,761)</div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.43pt; text-align: left;">$<font style="padding-left: 2.99pt;">76,069</font></div></td></tr><tr><td style="width: 25.95%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Stock-based compensation expense<font style="padding-left: 0.77pt;"></font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.21pt; text-align: left;"><font style="padding-left: 15.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.22pt; text-align: left;"><font style="padding-left: 20.25pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.75pt;">56,912</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.24pt; text-align: left;"><font style="padding-left: 4.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 1.35pt; text-align: left;"><font style="padding-left: 13.5pt;">3,405</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 19.84pt; text-align: left;"><font style="padding-left: 4.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.29pt; text-align: left;"><font style="padding-left: 27.74pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.43pt; text-align: left;"><font style="padding-left: 11.99pt;">3,405</font></div></td></tr><tr><td style="width: 25.95%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Issuance of common stock from stock grants and option exercises<font style="padding-left: 1.78pt;"></font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.21pt; text-align: left;"><font style="padding-left: 15.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.22pt; text-align: left;"><font style="padding-left: 20.25pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.75pt;">69,975</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.24pt; text-align: left;"><font style="padding-left: 4.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 1.35pt; text-align: left;"><font style="padding-left: 20.25pt;">303</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 19.84pt; text-align: left;"><font style="padding-left: 4.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.29pt; text-align: left;"><font style="padding-left: 27.74pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.43pt; text-align: left;"><font style="padding-left: 18.74pt;">303</font></div></td></tr><tr><td style="width: 25.95%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Issuance of common stock for public offering, net of issuance costs of $3,563<font style="padding-left: 3.52pt;"></font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.21pt; text-align: left;"><font style="padding-left: 15.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.22pt; text-align: left;"><font style="padding-left: 20.25pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.5pt;">9,185,000</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.24pt; text-align: left;"><font style="padding-left: 9pt;">9</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 1.35pt; text-align: left;"><font style="padding-left: 9pt;">49,241</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 19.84pt; text-align: left;"><font style="padding-left: 4.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.29pt; text-align: left;"><font style="padding-left: 27.74pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.43pt; text-align: left;"><font style="padding-left: 7.49pt;">49,250</font></div></td></tr><tr><td style="width: 25.95%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Unrealized loss on available-for-sale debt securities<font style="padding-left: 0.3pt;"></font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.21pt; text-align: left;"><font style="padding-left: 15.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.22pt; text-align: left;"><font style="padding-left: 20.25pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 31.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.24pt; text-align: left;"><font style="padding-left: 4.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 1.35pt; text-align: left;"><font style="padding-left: 24.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 19.84pt; text-align: left;"><font style="padding-left: 6.01pt;">(5)</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.29pt; text-align: left;"><font style="padding-left: 27.74pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.43pt; text-align: left;"><font style="padding-left: 24.75pt;">(5)</font></div></td></tr><tr><td style="width: 25.95%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net loss<font style="padding-left: 4.76pt;"></font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.21pt; text-align: left;"><font style="padding-left: 15.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.22pt; text-align: left;"><font style="padding-left: 20.25pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 31.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.24pt; text-align: left;"><font style="padding-left: 4.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 1.35pt; text-align: left;"><font style="padding-left: 24.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 19.84pt; text-align: left;"><font style="padding-left: 4.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.29pt; text-align: left;"><font style="padding-left: 9pt;">(87,933)</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.43pt; text-align: left;"><font style="padding-left: 4.5pt;">(87,933)</font></div></td></tr><tr><td style="width: 25.95%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at December&#160;31, 2021<font style="padding-left: 1.08pt;"></font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.21pt; text-align: left;"><font style="padding-left: 15.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.22pt; text-align: left;"><font style="padding-left: 20.25pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">31,409,707</div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.24pt; text-align: left;"><font style="padding-left: 4.5pt;">31</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 1.35pt; text-align: left;"><font style="padding-left: 4.5pt;">443,752</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 19.84pt; text-align: left;"><font style="padding-left: 4.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.29pt; text-align: left;"><font style="padding-left: 4.5pt;">(402,694)</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.43pt; text-align: left;"><font style="padding-left: 7.49pt;">41,089</font></div></td></tr><tr><td style="width: 25.95%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Stock-based compensation expense<font style="padding-left: 0.77pt;"></font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.21pt; text-align: left;"><font style="padding-left: 15.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.22pt; text-align: left;"><font style="padding-left: 20.25pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.75pt;">32,684</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.24pt; text-align: left;"><font style="padding-left: 4.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 1.35pt; text-align: left;"><font style="padding-left: 13.5pt;">1,342</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 19.84pt; text-align: left;"><font style="padding-left: 4.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.29pt; text-align: left;"><font style="padding-left: 27.74pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.43pt; text-align: left;"><font style="padding-left: 11.99pt;">1,342</font></div></td></tr><tr><td style="width: 25.95%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Issuance of common stock from stock grants and option exercises<font style="padding-left: 1.78pt;"></font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.21pt; text-align: left;"><font style="padding-left: 15.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.22pt; text-align: left;"><font style="padding-left: 20.25pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.75pt;">47,662</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.24pt; text-align: left;"><font style="padding-left: 4.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 1.35pt; text-align: left;"><font style="padding-left: 24.75pt;">20</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 19.84pt; text-align: left;"><font style="padding-left: 4.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.29pt; text-align: left;"><font style="padding-left: 27.74pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.43pt; text-align: left;"><font style="padding-left: 23.24pt;">20</font></div></td></tr><tr><td style="width: 25.95%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Issuance of common and preferred stock upon acquisition of F351 Assets<font style="padding-left: 2.28pt;"></font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.21pt; text-align: left;">12,340</div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.22pt; text-align: left;"><font style="padding-left: 4.5pt;">33,309</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.5pt;">6,266,521</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.24pt; text-align: left;"><font style="padding-left: 9pt;">6</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 1.35pt; text-align: left;"><font style="padding-left: 13.5pt;">1,685</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 19.84pt; text-align: left;"><font style="padding-left: 4.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.29pt; text-align: left;"><font style="padding-left: 27.74pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.43pt; text-align: left;"><font style="padding-left: 11.99pt;">1,691</font></div></td></tr><tr><td style="width: 25.95%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Cash dividends paid ($1.43 per share)<font style="padding-left: 2.77pt;"></font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.21pt; text-align: left;"><font style="padding-left: 15.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.22pt; text-align: left;"><font style="padding-left: 20.25pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 31.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.24pt; text-align: left;"><font style="padding-left: 4.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 1.35pt; text-align: left;"><font style="padding-left: 6.01pt;">(45,031)</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 19.84pt; text-align: left;"><font style="padding-left: 4.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.29pt; text-align: left;"><font style="padding-left: 27.74pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.43pt; text-align: left;"><font style="padding-left: 4.5pt;">(45,031)</font></div></td></tr><tr><td style="width: 25.95%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Cash dividends declared, unpaid ($0.24 per share)<font style="padding-left: 2.05pt;"></font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.21pt; text-align: left;"><font style="padding-left: 15.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.22pt; text-align: left;"><font style="padding-left: 20.25pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 31.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.24pt; text-align: left;"><font style="padding-left: 4.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 1.35pt; text-align: left;"><font style="padding-left: 10.51pt;">(7,558)</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 19.84pt; text-align: left;"><font style="padding-left: 4.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.29pt; text-align: left;"><font style="padding-left: 27.74pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.43pt; text-align: left;"><font style="padding-left: 9pt;">(7,558)</font></div></td></tr><tr><td style="width: 25.95%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">CVR derivative liability<font style="padding-left: 1.29pt;"></font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.21pt; text-align: left;"><font style="padding-left: 15.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.22pt; text-align: left;"><font style="padding-left: 20.25pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 31.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.24pt; text-align: left;"><font style="padding-left: 4.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 1.35pt; text-align: left;"><font style="padding-left: 10.51pt;">(5,000)</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 19.84pt; text-align: left;"><font style="padding-left: 4.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.29pt; text-align: left;"><font style="padding-left: 27.74pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.43pt; text-align: left;"><font style="padding-left: 9pt;">(5,000)</font></div></td></tr><tr><td style="width: 25.95%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net loss<font style="padding-left: 4.76pt;"></font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.21pt; text-align: left;"><font style="padding-left: 15.75pt; border-bottom: 1pt solid #000000; min-width: 24.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.22pt; text-align: left;"><font style="padding-left: 20.25pt; border-bottom: 1pt solid #000000; min-width: 29.25pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 31.5pt; border-bottom: 1pt solid #000000; min-width: 40.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.24pt; text-align: left;"><font style="padding-left: 4.5pt; border-bottom: 1pt solid #000000; min-width: 13.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 1.35pt; text-align: left;"><font style="padding-left: 24.75pt; border-bottom: 1pt solid #000000; min-width: 33.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 19.84pt; text-align: left;"><font style="padding-left: 4.5pt; border-bottom: 1pt solid #000000; min-width: 13.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.29pt; text-align: left;"><font style="padding-left: 13.5pt; border-bottom: 1pt solid #000000; min-width: 36.74pt;">(8,242</font><font style="min-width: 36.74pt;">)</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.43pt; text-align: left;"><font style="padding-left: 9pt; border-bottom: 1pt solid #000000; min-width: 32.24pt;">(8,242</font><font style="min-width: 32.24pt;">)</font></div></td></tr><tr><td style="width: 25.95%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at December&#160;31, 2022<font style="padding-left: 1.08pt;"></font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.21pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 24.75pt;">12,340</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.89%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 6.22pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 29.25pt;">$33,309</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40.5pt;">37,756,574</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.24pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 13.5pt;">$37</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 1.35pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 33.75pt;">$389,210</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 19.84pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 13.5pt;">$&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.29pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 36.74pt;">$(410,936</font><font style="min-width: 36.74pt;">)</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.43pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.24pt;">$(21,689</font><font style="min-width: 32.24pt;">)</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these consolidated financial statements.<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-22<br></div></div></div>
<!--End Page 377-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 378-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_203-fintab_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Catalyst Biosciences, Inc.<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><a name="tCSCF1"><!--Anchor--></a>Consolidated Statements of Cash Flows<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(In thousands)</font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 21.85%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31,</div></td></tr><tr class="header"><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating Activities<br></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss<font style="padding-left: 2.18pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;">$<font style="padding-left: 5pt;">(8,242)</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;">$(87,933)</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Adjustments to reconcile net loss to net cash used in operating activities:<br></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Acquired in-process research and development<font style="padding-left: 4.48pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 8.33pt;">35,390</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Stock-based compensation expense<font style="padding-left: 2.22pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 13.33pt;">1,342</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 13.33pt;">3,405</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization<font style="padding-left: 2.21pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 20.83pt;">230</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 20.83pt;">290</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Bad debt expense<font style="padding-left: 3.31pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 20.83pt;">200</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Loss on lease termination<font style="padding-left: 0.54pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 21.2pt;">115</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net gain on disposal of assets<font style="padding-left: 2.78pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 5pt;">(57,186)</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Changes in operating assets and liabilities:<br></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Accounts and other receivables<font style="padding-left: 2.78pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 13.33pt;">1,618</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 13.33pt;">1,495</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Prepaid and other current assets<font style="padding-left: 0.01pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 13.33pt;">1,609</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 13.33pt;">3,880</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Accounts payable<font style="padding-left: 3.31pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 10pt;">(6,225)</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 20.83pt;">500</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Accrued compensation and other accrued liabilities<font style="padding-left: 1.14pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 10pt;">(1,895)</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 10pt;">(3,680)</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Operating lease liability and right-of-use asset<font style="padding-left: 1.7pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 20.83pt;">178</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 25.83pt;">41</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Deferred revenue<font style="padding-left: 4.99pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(230</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(1,753</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash flows used in operating activities<font style="padding-left: 1.13pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(33,096</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(83,755</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Investing Activities<br></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proceeds from maturities of short-term investments<font style="padding-left: 0.59pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 13.33pt;">2,504</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 8.33pt;">49,028</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Purchases of property and equipment<font style="padding-left: 3.34pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 17.5pt;">(839)</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proceeds from the sale of property and equipment<font style="padding-left: 0.03pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 20.83pt;">498</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proceeds from the sale of complement portfolio to Vertex<font style="padding-left: 4.11pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 8.33pt;">55,000</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Payment of transaction costs in connection with sale of complement portfolio to Vertex<font style="padding-left: 4.4pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(2,576</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash flows provided by investing activities<font style="padding-left: 2.8pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">55,426</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">48,189</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financing Activities<br></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Issuance of common stock for public offering, net of issuance costs<font style="padding-left: 2.75pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 8.33pt;">49,250</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Payment of dividends<font style="padding-left: 1.63pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 5pt;">(45,031)</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Issuance of common stock from stock grants and option exercises<font style="padding-left: 0.06pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">20</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">303</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash flows (used in) provided by financing activities<font style="padding-left: 2.27pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 5.37pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(45,011</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">49,553</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net (decrease) increase in cash and cash equivalents<font style="padding-left: 0.63pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 5pt;">(22,681)</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 8.33pt;">13,987</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents at beginning of the period<font style="padding-left: 2.81pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">44,347</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">30,360</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents at end of the period<font style="padding-left: 3.36pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">$</font><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">21,666</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">$</font><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">44,347</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Supplemental Disclosure of Non-Cash Investing and Financing Activities:<br></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dividend declared, unpaid<font style="padding-left: 3.04pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;">$<font style="padding-left: 8.33pt;">7,558</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;">$<font style="padding-left: 20.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CVR derivative liability<font style="padding-left: 2.19pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;">$<font style="padding-left: 8.33pt;">5,000</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;">$<font style="padding-left: 20.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Right-of-use assets obtained in exchange for operating lease liabilities<font style="padding-left: 3.4pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;">$<font style="padding-left: 20.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;">$<font style="padding-left: 8.33pt;">1,850</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remeasurement of right-of-use asset due to operating lease modification<font style="padding-left: 3.41pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;">$<font style="padding-left: 20.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;">$<font style="padding-left: 15.83pt;">624</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these consolidated financial statements.<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-23<br></div></div></div>
<!--End Page 378-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 379-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_204-finnotes_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Notes to the Consolidated Financial Statements<br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><a name="tNCFS1"><!--Anchor--></a>1.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Nature of Operations</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Catalyst Biosciences, Inc. and its subsidiary (the &#8220;Company&#8221; or &#8220;Catalyst&#8221;) was a biopharmaceutical company with expertise in protease engineering. Prior to ceasing research and development activities in March 2022, the Company had several protease assets that were designed to address unmet medical needs in disorders of the complement or coagulation systems. As discussed further below, the Company recently completed a purchase agreement to acquire a clinical-stage drug candidate for the treatment of NASH (nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease). Concurrent with this purchase agreement, the Company entered into a separate business combination agreement to acquire an indirect controlling interest in a China-based pharmaceutical company. The Company will continue to evaluate the impact of the novel coronavirus disease (&#8220;COVID-19&#8221;) pandemic on its business, operations, and cash requirements. The Company is located in South San Francisco, California and operates in one segment. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">On May&#160;19, 2022, Catalyst entered into and closed on an asset purchase agreement with Vertex Pharmaceuticals Inc. (&#8220;Vertex&#8221;), pursuant to which Vertex acquired Catalyst&#8217;s complement portfolio, including CB 2782-PEG and CB 4332, as well as its complement-related intellectual property including the ProTUNE<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup> and ImmunoTUNE<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup> platforms. See Note 16, <font style="font-style: italic;">Restructuring</font>. After the transaction of its complement portfolio, Catalyst&#8217;s product candidates consisted of the coagulation related assets marzeptacog alfa (activated) (&#8220;MarzAA&#8221;), dalcinonacog alfa (&#8220;DalcA&#8221;), and CB 2679d-GT. MarzAA is a SQ administered next generation engineered coagulation Factor VIIa (&#8220;FVIIa&#8221;) for the treatment of episodic bleeding and prophylaxis in subjects with rare bleeding disorders. DalcA is a next-generation SQ administered FIX. CB 2679d-GT is an AAV-based gene therapy construct harboring the DalcA sequence. Both MarzAA and DalcA have shown sustained efficacy and safety in mid-stage clinical trials. CB 2679d-GT has obtained preclinical proof-of-concept. Catalyst sold MarzAA, DalcA and CB-2679d-GT in February 2023 to GC Biopharma Corp. (&#8220;GCBP&#8221;). See Note 17, <font style="font-style: italic;">Subsequent Events.</font></div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 20pt; text-align: left;">F351 Asset Acquisition</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">On December&#160;26, 2022, the Company executed and closed an Asset Purchase Agreement (the &#8220;F351&#160;Agreement&#8221;), with GNI Group Ltd. and GNI Hong Kong Limited (together &#8220;GNI&#8221;) to purchase all of the assets and intellectual property rights primarily related to the proprietary Hydronidone compound (collectively, the &#8220;F351 Assets&#8221;), other than such assets and intellectual property rights located in the People&#8217;s Republic of China. At the closing of the agreement on December&#160;26, 2022, the Company paid $35.0&#160;million in the form of 6,266,521 shares of Catalyst common stock and 12,340 shares of newly designated Series X redeemable convertible preferred stock (&#8220;Catalyst Convertible Preferred Stock&#8221;). Each share of Catalyst Convertible Preferred Stock is convertible into 10,000 shares of common stock, subject to stockholder approval under Nasdaq rules and subject to a beneficial ownership conversion blocker. For additional information, see Note 4, <font style="font-style: italic;">F351 Asset Acquisition </font>and Note 14, <font style="font-style: italic;">Stockholders&#8217; Equity.</font></div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 20pt; text-align: left;">Business Combination Agreement</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Concurrent with the F351 Asset acquisition, the Company signed a definitive agreement with GNI Group Ltd., GNI Hong Kong Limited, GNI USA, Inc., Continent Pharmaceuticals Inc. and Shanghai Genomics, Inc. (collectively, &#8220;GNI&#8221;) and other minority stockholders to acquire an indirect controlling interest in Beijing Continent Pharmaceutical Co Ltd. (&#8220;BC&#8221;), a commercial-stage pharmaceutical company based in China and majority-owned subsidiary of GNI, in exchange for newly issued shares of common stock (the &#8220;Business Combination Agreement&#8221;). The closing of the Business Combination Agreement will be subject to stockholder approval at a stockholder meeting expected to be held in the third quarter of 2023 and certain customary closing conditions. For additional information, see Note 8, <font style="font-style: italic;">Commitments and Contingencies</font>.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 20pt; text-align: left;">Contingent Value Rights Agreement</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Pursuant to the Business Combination Agreement, on December&#160;26, 2022, Catalyst and the Rights Agent (as defined therein) executed a contingent value rights agreement (the &#8220;CVR Agreement&#8221;), pursuant to which each holder of Catalyst common stock as of January&#160;5, 2023 (the &#8220;CVR Holders&#8221;), excluding GNI, received one </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-24<br></div></div></div>
<!--End Page 379-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 380-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_204-finnotes_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Notes to the Consolidated Financial Statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: justify;">contractual contingent value right (a &#8220;CVR&#8221;) issued by the Company for each share of Catalyst common stock held by such holder. Each CVR entitles the holder thereof to receive certain cash payments in the future. For additional information, see Note 8, <font style="font-style: italic;">Commitments and Contingencies</font>. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Liquidity </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In October 2021, the Company entered into a sales agreement with Piper Sandler &amp; Co. (&#8220;Piper Sandler&#8221;), pursuant to which the Company could issue and sell shares of common stock, par value of $0.001 per share, through an at-the-market offering program (the &#8220;ATM Program&#8221;). The Company pays Piper Sandler 3% of the gross proceeds from any common stock sold through the sales agreement. There was no activity from the ATM Program during the years ended December&#160;31, 2022 and 2021.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">On September&#160;20, 2022, the Company paid a special, one-time cash dividend of $1.43 per share to the Company&#8217;s common stockholders of record as of close of business on September&#160;6, 2022. The aggregate amount of the special dividend payment was approximately $45.0&#160;million.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">On December&#160;27, 2022, the Company declared a special, one-time cash dividend of $0.24 per share, or approximately $7.6&#160;million, to the Company&#8217;s common stockholders of record as of close of business on January&#160;5, 2022, excluding GNI. This dividend was paid on January&#160;12, 2023.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">For the year ended December&#160;31, 2022, the Company had a net loss of $8.2&#160;million. As of December&#160;31, 2022, the Company had an accumulated deficit of $410.9&#160;million and cash and cash equivalents of $21.7&#160;million. Its primary uses of cash are to fund operating expenses and general and administrative expenditures. As part of the F351 Agreement, the Company issued 12,340 shares of Catalyst Convertible Preferred Stock, which upon stockholder approval, will be converted to 123,400,000 shares of common stock, subject to applicable beneficial ownership limitations. The terms of the Catalyst Convertible Preferred Stock include a cash settlement feature which, as described in Note 14, <font style="font-style: italic;">Stockholders&#8217; Equity,</font> provide that, if the Company&#8217;s stockholders fail to approve the conversion of the Catalyst Convertible Preferred Stock by June&#160;26, 2023 (which has been extended to September&#160;30, 2023, see Note&#160;17, <font style="font-style: italic;">Subsequent Events</font>), the Company could be required to make cash payments to the holders of Catalyst Convertible Preferred Stock significantly in excess of its current liquidity. The Company believes that stockholders who are entitled to vote on the conversion proposal at the Company&#8217;s 2023 Annual Meeting of Stockholders, which is expected to be held in the third quarter of 2023, will vote to approve the proposal. However, as the vote of the Company&#8217;s common stockholders is outside of the control of the Company, there is substantial doubt about its ability to continue as a going concern for at least 12 months following the issuance of these consolidated financial statements. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Summary of Significant Accounting Policies</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 20pt; text-align: left;">Basis of Presentation</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The accompanying consolidated financial statements include the accounts of the Company and its subsidiary. Intercompany accounts and transactions, if applicable, have been eliminated in consolidation. The Company&#8217;s consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;). </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 20pt; text-align: left;">Use of Estimates</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowance of doubtful accounts, contingent value rights, operating lease right-of-use assets </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-25<br></div></div></div>
<!--End Page 380-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 381-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_204-finnotes_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Notes to the Consolidated Financial Statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: justify;">and liabilities, accrued expenses, income taxes and stock-based compensation. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 20pt; text-align: left;">Accounting Pronouncements Recently Adopted</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In May 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;)&#160;2021-04, <font style="font-style: italic;">Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic&#160;470-50), </font><font style="font-style: italic;">Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity </font><font style="font-style: italic;">(Subtopic 815-40)</font>: Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU 2021-04 are effective for all entities for fiscal years beginning after December&#160;15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2021-04 and related updates on January&#160;1, 2022, and the adoption did not have a material impact on its consolidated financial statements.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In August 2020, FASB issued ASU 2020-06, <font style="font-style: italic;">Debt - Debt with Conversion and Other Options (Subtopic 470-20) </font><font style="font-style: italic;">and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</font> to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the previous models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#8217;s own equity. The amendments in this ASU are effective for public business entities for fiscal years beginning after December&#160;15, 2021. The Company adopted ASU 2020-06 on January&#160;1, 2022, and the adoption did not have a material impact on its consolidated financial statements.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 20pt; text-align: left;">New Accounting Pronouncements - Issued But Not Yet Adopted<font style="font-style: normal; font-weight: normal;"> </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In June 2016, the FASB issued ASU 2016-13,<font style="font-style: italic;"> Measurement of Credit Losses on Financial Instruments</font>. The main objective of ASU 2016-13 is to provide financial statement users with more decision-useful information about an entity&#8217;s expected credit losses on financial instruments and other commitments to extend credit at each reporting date. To achieve this objective, the amendments in this update replace the incurred loss impairment methodology currently used today with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. ASU 2016-13 will be effective for the Company for fiscal years beginning after December&#160;15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. The Company adopted ASU&#160;2016-13 and related updates on January&#160;1, 2023 and the adoption did not have a material impact on its consolidated financial statements. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 20pt; text-align: left;">Cash and Cash Equivalents</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company invests its excess cash in bank deposits, consisting primarily of money market mutual funds. The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 20pt; text-align: left;">Fair Value of Financial Instruments</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The fair value hierarchy requires that an entity maximize the use of observable inputs when estimating fair value. The fair value hierarchy includes the following three-level classification which is based on the market observability of the inputs used for estimating the fair value of the assets or liabilities being measured:</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-26<br></div></div></div>
<!--End Page 381-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 382-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_204-finnotes_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Notes to the Consolidated Financial Statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8pt; margin-left: 20pt; text-align: left;">Level 1<font style="font-style: normal;"> &#8211; Quoted prices in active markets for identical assets or liabilities.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Level 2<font style="font-style: normal;"> &#8211; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted </font><font style="font-style: normal;">prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can </font><font style="font-style: normal;">be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Level 3<font style="font-style: normal;"> &#8211; Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that </font><font style="font-style: normal;">market participants would use in pricing the asset or liability.</font></div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 20pt; text-align: left;">Derivative Financial Instruments</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company evaluates its contracts to determine if those contracts qualify as derivatives under ASC 815, <font style="font-style: italic;">Derivatives </font><font style="font-style: italic;">and Hedging</font>. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date. Any changes in fair value are recorded as non-operating, non-cash other income or expense for each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is probable within the next 12 months from the balance sheet date.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company determined that certain contingent payments under the CVR Agreement qualified as derivatives under ASC 815, and as such, were recorded as a liability on the balance sheet as of December&#160;31, 2022. Refer to Note 5, <font style="font-style: italic;">Fair Value Measurement</font> and Note 8, <font style="font-style: italic;">Commitments and Contingencies</font>, for additional information regarding the CVR derivative liability.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 20pt; text-align: left;">Property and Equipment</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, which are three years for computer equipment and software, and three to seven years for furniture and leasehold improvements.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 20pt; text-align: left;">Investments</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company invests its excess cash in investment grade, short to intermediate-term, fixed income securities and recognizes purchased securities on the settlement date. All investments have been classified as &#8220;available-for-sale&#8221; and are carried at estimated fair value based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments at the time of purchase and reevaluates such designation as of each consolidated balance sheet date. Unrealized gains and losses on available-for-sale debt securities are excluded from earnings and are reported as a component of comprehensive loss. Realized gains and losses and declines in fair value determined to be other-than-temporary, if any, on available-for-sale debt securities are included in interest and other income (expense), net. The cost of securities sold is based on the specific-identification method. Interest on short-term investments is included in interest and other income (expense), net.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 20pt; text-align: left;">Revenue Recognition</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;">License and Collaboration Arrangements </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company may enter into collaboration arrangements that fall under the scope Collaborative Arrangements (Topic 808). The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808 to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. The accounting for some of the activities under collaboration arrangements may be analogized to ASC 606 for distinct units of account that are reflective of a vendor-customer relationship.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Under ASC 606, in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-27<br></div></div></div>
<!--End Page 382-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 383-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_204-finnotes_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Notes to the Consolidated Financial Statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: justify;">services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when the Company satisfies each performance obligation.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues attributed to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">At the inception of each arrangement that contain development milestones, the Company evaluates whether the development milestones included are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not generally considered probable of being achieved until those approvals are received.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">At the end of each reporting period, the Company re-evaluates the probability of achievement of any development milestones, and if necessary, adjusts its estimate of the transaction price. Any such adjustments would be recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">For research and development services, the Company elected the practical expedient to recognize revenue as the research and development services are invoiced. As the Company has a right to consideration from the collaboration agreement with Biogen International GmbH (&#8220;Biogen&#8221;), in an amount that corresponds directly with the value of the Company&#8217;s performance completed to date for the research services, the Company recognized revenue related to the research services as invoiced, in line with the practical expedient in ASC&#160;606-10-55-18.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The transaction price is allocated to each performance obligation on a relative stand-alone selling price (&#8220;SSP&#8221;) basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the timing of recognition and the SSP for each performance obligation identified in the contract. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The SSP for licenses are calculated using the residual approach if the Company has not yet established a price for such license and the license has not previously been sold on a standalone basis. Otherwise, selling prices for licenses are determined using an income approach model and include key assumptions such as: development timeline, revenue forecast, commercialization expenses, discount rate and probabilities of technical and regulatory success. To estimate the SSP for research and development services, the Company uses a cost-plus margin approach. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 20pt; text-align: left;">Cost of License and Collaboration</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Cost of license revenue includes sublicense fees paid or payable to Mosaic Biosciences, Inc. (&#8220;Mosaic&#8221;), incurred in the period, under the terms of the Mosaic collaboration agreement, and fees for patent development and protection paid or payable to other third-party vendors corresponding to the recognition of license revenue from the Company&#8217;s collaboration agreement with Biogen. See Note 12, <font style="font-style: italic;">Collaborations</font>. Cost of license revenue does not include any allocated overhead costs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Cost of collaboration revenue includes fees for research and development services paid or payable to Mosaic and other third-party vendors and personnel cost, incurred in the period pertaining to the Company&#8217;s agreement with Biogen. See Note 12, <font style="font-style: italic;">Collaborations</font>. Cost of collaboration revenue does not include any allocated overhead costs.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-28<br></div></div></div>
<!--End Page 383-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 384-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_204-finnotes_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Notes to the Consolidated Financial Statements<br></div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 8pt; margin-left: 20pt; text-align: left;">Research and Development Expenses</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services used in research and development are initially deferred and capitalized in prepaid and other current assets. The capitalized amounts are then expensed as the related goods are delivered or services are performed, or until it is no longer expected that the goods or services will be delivered. Research and development costs consist of payroll and other personnel-related expenses, laboratory supplies and reagents, contract research and development services, materials, and consulting costs, as well as allocations of facilities and other overhead costs. Under the Company&#8217;s collaboration agreement with Biogen, certain specific expenditures are reimbursed by third parties. During the years ended December&#160;31, 2022 and 2021, $0.7&#160;million and $6.5&#160;million, respectively, of research and development expense was recorded as cost of collaboration revenue related to the collaboration agreement with Biogen signed in December 2019 and terminated as of May 2022. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 20pt; text-align: left;">Accrued Research and Development Expenses</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Accrued expenses include estimated costs of research and development activities conducted by external service providers, which include the conduct of preclinical studies and clinical trials and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in other accrued liabilities in the consolidated balance sheet and within research and development expense in the consolidated statement of operations. These costs are a significant component of the research and development expenses. The Company records accrued expenses for these costs based on the estimated amount of work completed and in accordance with agreements established with these external service providers.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 20pt; text-align: left;">Acquired In-Process Research and Development</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquired in-process research and development (&#8220;IPR&amp;D&#8221;) with no alternative future use is charged to expense at the acquisition date. Refer to Note 4, <font style="font-style: italic;">F351</font> <font style="font-style: italic;">Asset Acquisition, </font>for a more detailed description of the accounting policy utilized for the recent asset acquisition.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 20pt; text-align: left;">Concentration of Credit Risk</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, investments and accounts receivable. The Company&#8217;s investment policy restricts cash investments to high credit quality, investment grade investments. The Company believes that it has established guidelines for investment of its excess cash that maintain safety and liquidity through its policies on high quality of investment and investment duration. The Company is exposed to credit risk of $21.4&#160;million in the event of default by the institutions holding the cash and cash equivalents to the extent beyond the amount insured by the federal depository insurance corporation. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 20pt; text-align: left;">Accounts Receivable and Allowance for Doubtful Accounts</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. Customer payments are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under the arrangements. The Company continuously monitors collections and payments from its customers and maintains a provision for estimated credit losses. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time balances are past due, the Company&#8217;s previous loss history, the customer&#8217;s current ability to pay its obligations to the Company and the condition of the general economy and the industry as a whole. The Company writes off accounts receivable when they are determined to be uncollectible. For the year ended December&#160;31, 2022, the Company recognized $0.2&#160;million of bad debt expense and no bad debt expense was recognized during the year ended December&#160;31, 2021.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-29<br></div></div></div>
<!--End Page 384-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 385-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_204-finnotes_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Notes to the Consolidated Financial Statements<br></div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 8pt; margin-left: 20pt; text-align: left;">Income Taxes</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Income taxes are computed using the liability method. Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company follows the authoritative guidance on accounting for uncertainty in income taxes. This guidance prescribes a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken in the Company&#8217;s income tax returns. This interpretation also provides guidance on accounting for interest and penalties and associated with tax positions, accounting for income taxes in interim periods and income tax disclosures.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company&#8217;s policy is to include penalties and interest expense related to income taxes as a component of other expense and interest expense, respectively, as necessary.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 20pt; text-align: left;">Stock-Based Compensation</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company measures the cost of employee, non-employee and director services received in exchange for an award of equity instruments based on the fair value of the award on the date of grant and recognizes the related expense over the period during which the employee, non-employee or director is required to provide service in exchange for the award on a straight-line basis. The estimated fair value of equity awards that contain performance conditions is expensed over the term of the award once the Company has determined that it is probable that performance conditions will be satisfied.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company uses the Black-Scholes option-pricing valuation model to estimate the grant-date fair value of stock-based awards. The determination of fair value for stock-based awards on the date of grant using an option-pricing model requires management to make certain assumptions regarding a number of variables. The Company elected to account for forfeitures when they occur. As such, the Company recognizes stock-based compensation expense, over their requisite service period, based on the vesting provisions of the individual grants.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 20pt; text-align: left;">Restructuring Charges</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Costs and liabilities associated with restructuring are recorded in the period management commits to a restructuring or cost reduction plan, or executes specific actions contemplated by the plan and all criteria for liability recognition have been met. One-time employee termination costs are recognized at the time of communication to employees, unless future service is required, in which case the costs are recognized ratably over the future service period. Restructuring charges are recognized as an operating expense within the consolidated statements of operations and related liabilities are recorded within accrued compensation on the consolidated balance sheets. The Company periodically evaluates and, if necessary, adjusts its estimates based on currently available information.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 20pt; text-align: left;">Leases</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company has elected to combine lease and non-lease components as a single component. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the consolidated balance sheet as right-of-use assets, operating lease liabilities, current and operating lease liabilities, non-current.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-30<br></div></div></div>
<!--End Page 385-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 386-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_204-finnotes_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Notes to the Consolidated Financial Statements<br></div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 8pt; margin-left: 20pt; text-align: left;">Redeemable Convertible Preferred Stock </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company records shares of non-voting redeemable Catalyst Convertible Preferred Stock at its relative fair value on the date of issuance. The Company applied the guidance in ASC 480-10-S99-3A, <font style="font-style: italic;">SEC Staff </font><font style="font-style: italic;">Announcement: Classification and Measurement of Redeemable Securities</font>, and at issuance classified the Catalyst Convertible Preferred Stock as temporary equity on the consolidated balance sheet because if conversion to common stock is not approved by the shareholders, the Catalyst Convertible Preferred Stock would be redeemable at the option of the holders for cash equal to the closing price of the common stock on last trading day prior to the holder&#8217;s redemption request. Refer to Note 14, <font style="font-style: italic;">Stockholders&#8217; Equity</font> for additional information. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">Net Loss per Share Attributable to Common Stockholders</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company calculates basic and diluted net loss per share attributable to common stockholders in conformity with the two-class method required for participating securities. The Company&#8217;s redeemable convertible preferred stock contractually entitled the holders of such shares to participate in dividends but does not contractually require the holders of such shares to participate in the Company&#8217;s losses. As such, net losses for the periods presented were not allocated to these securities.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is the same as basic net loss per share for each period presented since the effects of potentially dilutive securities are antidilutive given the Company&#8217;s net loss.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">4.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">F351 Asset Acquisition</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">On December&#160;26, 2022, the Company acquired the F351 Assets from GNI in accordance with the terms of the F351 Agreement as discussed in Note 1, <font style="font-style: italic;">Nature of Operations</font>. Under the terms of F351 Agreement, the Company issued 6,266,521 shares of common stock and 12,340 shares of Catalyst Convertible Preferred Stock. Each share of Catalyst Convertible Preferred Stock is convertible into 10,000 shares of common stock, subject to certain conditions.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company concluded that the F351 acquisition was not the acquisition of a business, as substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset, the intellectual property rights (outside of China) to a clinical stage drug candidate for the treatment of liver fibrosis, or the F351 Assets.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company determined that the cost to acquire the F351 Assets was $35.4&#160;million, based on the estimated fair value of the F351 Assets acquired and including direct costs of the acquisition of $0.4&#160;million. The cost of the acquisition was allocated entirely to acquired IPR&amp;D as no other assets or liabilities were acquired or assumed.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">As the F351 Assets had not, at the time of the F351 Asset acquisition, received regulatory approval in any territory, the cost attributable to the IPR&amp;D was expensed in the Company&#8217;s consolidated statements of operations for the year ended December&#160;31, 2022 since the acquired IPR&amp;D had no alternative future use, as determined by the Company in accordance with GAAP.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">5.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Fair Value Measurements</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">For a description of the fair value hierarchy and fair value methodology, see Note 3,<font style="font-style: italic;"> Summary of Significant </font><font style="font-style: italic;">Accounting Policies</font>. As of December&#160;31, 2022 and 2021, the Company&#8217;s highly liquid money market funds included within cash equivalents and U.S. government agency securities are valued using Level 1 inputs. There were no transfers in or out of Level 1 and Level 2 during the periods presented. U.S. government agency securities are bonds issued by the U.S. government and are fully backed by the U.S. government. Given the frequency at which U.S. government agency securities trade and the accessibility of observable, quoted prices for such assets in active markets, they are recognized as Level 1 assets.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-31<br></div></div></div>
<!--End Page 386-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 387-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_204-finnotes_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Notes to the Consolidated Financial Statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: justify;">The following tables present the fair value hierarchy for financial assets and liabilities measured at fair value on a recurring basis as of December&#160;31, 2022 and 2021 <font style="font-style: italic;">(in thousands)</font>:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 2.52%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="10" style="width: 41.4%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2022</div></td></tr><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 2.52%; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.5pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level 1</div></td><td class="gutter" style="width: 2.52%; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.52%; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.5pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level 2</div></td><td class="gutter" style="width: 2.52%; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.52%; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.14%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.5pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level 3</div></td><td class="gutter" style="width: 2.52%; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.52%; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.5pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financial assets:<br></div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Money market funds<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 3.79pt;"></font></div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">$21,666</font></div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.16pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 15pt;">$&#8212;</font></div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">$</font><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">$21,666</font></div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total financial assets<font style="padding-left: 2.13pt;"></font></div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$21,666</font></div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.16pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">$&#8212;</font></div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">$</font><font style="padding-left: 12.5pt; border-bottom: 3pt double #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$21,666</font></div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.5pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.5pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.5pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.5pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.5pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financial liabilities:<br></div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">CVR derivative liability<font style="padding-left: 4.19pt;"></font></div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">$</font><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.16pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 15pt;">$&#8212;</font></div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">$5,000</font></div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">$</font><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">5,000</font></div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total financial liabilities<font style="padding-left: 3.23pt;"></font></div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$</font><font style="padding-left: 17.5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.16pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">$&#8212;</font></div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">$5,000</font></div></td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.52%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$</font><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">5,000</font></div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.58%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="10" style="width: 41.27%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2021</div></td></tr><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.58%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level 1</div></td><td class="gutter" style="width: 2.58%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.58%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level 2</div></td><td class="gutter" style="width: 2.58%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.58%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level 3</div></td><td class="gutter" style="width: 2.58%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.58%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financial assets:<br></div></td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Money market funds<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 3.79pt;"></font></div></td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$44,347</div></td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;">$&#8212;</div></td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.16pt; text-align: left;">$&#8212;</div></td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$44,347</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">U.S. government agency securities<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><font style="padding-left: 2.14pt;"></font></div></td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">2,504</font></div></td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.16pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">2,504</font></div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total financial assets<font style="padding-left: 2.13pt;"></font></div></td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$46,851</font></div></td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">$&#8212;</font></div></td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.16pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">$&#8212;</font></div></td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$46,851</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 20pt; margin-top: 12.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Included in cash and cash equivalents on accompanying consolidated balance sheet.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Included in short-term investments on accompanying consolidated balance sheet and are classified as available-for-sale debt securities. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The carrying amounts of accounts and other receivables, accounts payable, and accrued liabilities approximate their fair values due to the short-term maturity of these instruments.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 20pt; text-align: left;">Derivative Liabilities</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The CVR derivative liability relates to the CVR Agreement executed in connection with the Business Combination Agreement. The fair value of this derivative liability is based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy. The estimated fair value of the CVR liability was determined based on the anticipated amount and timing of projected cash flows to be received from Vertex pursuant to the Vertex asset purchase agreement. As of December&#160;31, 2022, the Company expects to receive a $5.0&#160;million hold-back payment from Vertex in the second quarter of 2023, which will be immediately distributed to the holders of Catalyst common stock as of January&#160;5, 2023 under the CVR Agreement. The CVR liability was initially recorded at $5.0&#160;million at issuance on December&#160;26, 2022 and there was no change in the estimated fair value as of December&#160;31, 2022.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">6.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Financial Instruments</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Cash equivalents and investments (debt securities) which are classified as available-for-sale securities, consisted of the following <font style="font-style: italic;">(in thousands)</font>:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31, 2022</div></td><td class="gutter" style="width: 1.75%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.75%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amortized <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cost</div></td><td class="gutter" style="width: 1.75%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.75%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.3%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unrealized <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gains</div></td><td class="gutter" style="width: 1.75%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.75%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.3%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unrealized <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Losses</div></td><td class="gutter" style="width: 1.75%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.75%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.73%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Estimated <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 3.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Money market funds (cash equivalents)<font style="padding-left: 0.9pt;"></font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 3.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.97pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">$21,666</font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 3.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.09pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 15pt;">$&#8212;</font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 3.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.09pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 15pt;">$&#8212;</font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 3.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.07pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">$21,666</font></div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 4.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total financial assets<font style="padding-left: 2.13pt;"></font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 4.5pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 4.5pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 4.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.97pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$21,666</font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 4.5pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 4.5pt;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 4.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.09pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">$&#8212;</font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 4.5pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 4.5pt;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 4.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.09pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">$&#8212;</font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 4.5pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 4.5pt;">&#8203;</td><td style="width: 7.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 4.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.07pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$21,666</font></div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Classified as:<br></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 4.77pt;"></font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td style="width: 7.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.07pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">$21,666</font></div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total financial assets<font style="padding-left: 2.13pt;"></font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.07pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$21,666</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-32<br></div></div></div>
<!--End Page 387-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 388-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_204-finnotes_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Notes to the Consolidated Financial Statements<br></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31, 2021</div></td><td class="gutter" style="width: 1.75%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.75%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amortized <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cost</div></td><td class="gutter" style="width: 1.75%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.75%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.3%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unrealized <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gains</div></td><td class="gutter" style="width: 1.75%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.75%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.3%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unrealized <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Losses</div></td><td class="gutter" style="width: 1.75%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.75%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.73%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Estimated <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Money market funds (cash equivalents)<font style="padding-left: 0.9pt;"></font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.97pt; text-align: left;">$44,347</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.09pt; text-align: left;">$&#8212;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.09pt; text-align: left;">$&#8212;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.07pt; text-align: left;">$44,347</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">U.S. government agency securities<font style="padding-left: 0.89pt;"></font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.97pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">2,504</font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.09pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.09pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.07pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">2,504</font></div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total financial assets<font style="padding-left: 2.13pt;"></font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.97pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$46,851</font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.09pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">$&#8212;</font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.09pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">$&#8212;</font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.07pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$46,851</font></div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Classified as:<br></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 4.77pt;"></font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.07pt; text-align: left;">$44,347</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Short-term investments<font style="padding-left: 3.08pt;"></font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.07pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">2,504</font></div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total financial assets<font style="padding-left: 2.13pt;"></font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.07pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">$46,851</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">There have been no material realized gains or losses on available-for-sale debt securities for the periods presented. As of December&#160;31, 2022, the Company had no available-for-sale debt securities.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">7.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Other Accrued Liabilities </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">Other accrued liabilities consisted of the following <font style="font-style: italic;">(in thousands)</font>:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 4.21%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 27.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December 31,</div></td></tr><tr class="header"><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 4.21%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.44%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 4.21%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 4.21%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.44%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Professional and consulting services<font style="padding-left: 2.78pt;"></font></div></td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.39pt; text-align: left;">$1,417</div></td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.39pt; text-align: left;">$<font style="padding-left: 7.5pt;">509</font></div></td></tr><tr><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Manufacturing<font style="padding-left: 1.08pt;"></font></div></td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.39pt; text-align: left;"><font style="padding-left: 17.5pt;">22</font></div></td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.39pt; text-align: left;"><font style="padding-left: 5pt;">1,381</font></div></td></tr><tr><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Biogen<font style="padding-left: 1.61pt;"></font></div></td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.39pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.39pt; text-align: left;"><font style="padding-left: 12.5pt;">868</font></div></td></tr><tr><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pre-clinical<font style="padding-left: 4.41pt;"></font></div></td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.39pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.39pt; text-align: left;"><font style="padding-left: 12.5pt;">773</font></div></td></tr><tr><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Clinical<font style="padding-left: 3.84pt;"></font></div></td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.39pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.39pt; text-align: left;"><font style="padding-left: 12.5pt;">361</font></div></td></tr><tr><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other<font style="padding-left: 2.73pt;"></font></div></td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.39pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">13</font></div></td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.39pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">180</font></div></td></tr><tr><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total other accrued liabilities<font style="padding-left: 1.25pt;"></font></div></td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.39pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">$1,452</font></div></td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.21%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.39pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">$4,072</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">8.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Commitments and Contingencies </div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 20pt; text-align: left;">Business Combination Agreement</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Concurrent with the F351 Asset acquisition, the Company signed a definitive agreement with GNI and other minority stockholders (&#8220;Sellers&#8221; and each a &#8220;Seller&#8221;) to acquire an indirect controlling interest in BC, a commercial-stage pharmaceutical company based in China and majority-owned subsidiary of GNI, in exchange for newly issued shares of Catalyst common stock. The closing of the Business Combination Agreement will be subject to stockholder approval at a stockholder meeting expected to be held in the third quarter of 2023 and certain customary closing conditions. If the transaction is approved by stockholders, the Company would issue at closing a total of up to 1,110,776,224 shares of Catalyst common stock for an indirect controlling interest in BC. Each Seller may elect to be issued Catalyst Convertible Preferred Stock in lieu of the Company&#8217;s common stock.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Business Combination Agreement contains certain termination rights, including the right for Catalyst to terminate the Business Combination Agreement to enter into a definitive agreement for a superior proposal. Upon termination of the Business Combination Agreement under specified circumstances, the Company may be required to pay a termination fee of $2.0&#160;million and either party, as the case may be, may be required to reimburse the other party for reasonable out-of-pocket fees and expenses incurred by such party in connection with the Business Combination Agreement, up to a maximum amount of $2.0&#160;million.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 20pt; text-align: left;">Contingent Value Rights Agreement</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Pursuant to the Business Combination Agreement, on December&#160;26, 2022, Catalyst and the Rights Agent (as defined therein) executed a CVR Agreement, pursuant to which the CVR Holders received one contractual CVR issued by the Company, subject to and in accordance with the terms and conditions of the CVR Agreement, for </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-33<br></div></div></div>
<!--End Page 388-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 389-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_204-finnotes_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Notes to the Consolidated Financial Statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: justify;">each share of Catalyst common stock held by such holder. Each CVR entitles the holder thereof to receive (i)&#160;certain cash payments from the net proceeds related to the disposition of the Company&#8217;s legacy assets (MarzAA, DalcA, and CB 2679d-GT), (ii) 100% of the excess cash (net of all current or contingent liabilities, including transaction-related expenses) retained by the Company in excess of $1.0&#160;million as of the closing date of the Business Combination Agreement, (iii) 100% of the amount actually received by the Company pursuant to the Vertex asset purchase agreement and (iv) 100% of the excess, by which the preapproved costs to manage, negotiate, settle and finalize certain third party claims exceed the costs actually incurred with respect to such claims. The CVRs are not transferable, except in certain limited circumstances as provided for in the CVR Agreement, will not be certificated or evidenced by any instrument, and will not be registered with the SEC or listed for trading on any exchange.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 20pt; text-align: left;">Manufacturing Agreements</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company previously signed an agreement with AGC Biologics, Inc. (&#8220;AGC&#8221;) to perform certain manufacturing services related to the Company&#8217;s collaboration agreement with Biogen, which included firm work orders totaling $0.7&#160;million. The payment obligations were fully paid off as of March&#160;31, 2022, and Vertex assumed responsibility for further complement-related manufacturing in connection with the sale of the Company&#8217;s complement portfolio to Vertex. See Note 16,<font style="font-style: italic;"> Restructuring</font>. During the year ended December&#160;31, 2022, the Company terminated its manufacturing agreement with AGC for Catalyst&#8217;s remaining programs and has no remaining obligations under the agreement as of December&#160;31, 2022.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In July 2021, the Company entered into an agreement for the Company&#8217;s screening and natural history of disease clinical studies related to CFI deficiency, with total payments of up to $6.5&#160;million. During the year ended December&#160;31, 2022, the Company terminated this agreement and incurred $0.8&#160;million for clinical trial services incurred prior to termination and reasonable wind-down expenses. As of December&#160;31, 2022, the Company has no remaining obligations under this agreement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">On September&#160;16, 2021, the Company signed a Manufacturing and Research and Development Studies Agreement to support the lyophilized drug product, CB 4332. The agreement covers analytical method qualification to support good manufacturing practices (&#8220;GMP&#8221;) manufacturing. The Company had firm work orders related to this agreement totaling $0.3&#160;million. During the year ended December&#160;31, 2022, the Company terminated this agreement and has no remaining obligations under the agreement as of December&#160;31, 2022.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 20pt; text-align: left;">Legal Proceedings </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">On June&#160;15, 2022, certain Company stockholders who beneficially held in the aggregate more than five percent (5%) of the Company&#8217;s common stock filed a lawsuit in Delaware Chancery Court, captioned <font style="font-style: italic;">JDS1, LLC </font><font style="font-style: italic;">v.&#160;Catalyst Biosciences, Inc</font>., alleging that the Company violated Section 271 of the Delaware General Corporation Law and breach of fiduciary duty in connection with the Company&#8217;s asset sale to Vertex, as well as certain claims related to the alleged failure to disclose information related to the Vertex transaction. In August 2022, the lawsuit was dismissed with prejudice and the Company reimbursed JDS1, LLC for its legal and other expenses related to the litigation in the amount of $0.4&#160;million.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 20pt; text-align: left;">COVID-19</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The current COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting the Company&#8217;s employees and business operations. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national, and international markets. The COVID-19 pandemic may disrupt the Company&#8217;s ability to out-license any of its remaining assets.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">9.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Leases</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. In calculating the present value of the lease payments, the Company has elected to utilize its </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-34<br></div></div></div>
<!--End Page 389-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 390-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_204-finnotes_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Notes to the Consolidated Financial Statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: justify;">incremental borrowing rate based on the original lease term and not the remaining lease term. The lease includes non-lease components (<font style="font-style: italic;">e.g.</font>, common area maintenance) that are paid separately from rent based on actual costs incurred and, therefore, were not included in the right-of-use asset and lease liability but are reflected as an expense in the period incurred.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company leases office space for its corporate headquarters, located in South San Francisco, CA. The lease term is through April&#160;30, 2023 and there are no stated renewal options.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In April 2021, the Company entered into a license agreement (the &#8220;License Agreement&#8221;) for the use of laboratory facilities in South San Francisco, CA, for an aggregated undiscounted future payment of $1.9&#160;million. This License Agreement commenced during the second quarter of 2021. In October 2021, the Company amended the License Agreement to extend the lease term for a period of one year. The amendment was not accounted for as a separate lease, and resulted in an adjustment to the right-of-use asset and lease liability of $0.6&#160;million. In August 2022, the Company terminated the License Agreement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In March 2022, the Company entered into a sublease agreement for one of its leased facilities that commenced in April 2022. Under the terms of the sublease agreement, the Company will receive $0.2&#160;million in base lease payments over the term of the sublease, which ends in April 2023. For the year ended December&#160;31, 2022, the Company recognized sublease income of $0.1&#160;million.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">During the year ended December&#160;31, 2022, the Company terminated several of its lease agreements. Pursuant to the termination agreements, the Company paid $0.2&#160;million in termination fees. The termination resulted in the derecognition of the related right-of-use assets of $1.1&#160;million and lease liabilities of $1.0&#160;million, and the recognition of a $0.2&#160;million loss on lease termination for the year ended December&#160;31, 2022, which is included in general and administrative operating expenses in the consolidated statements of operations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">For the years ended December&#160;31, 2022 and 2021, the Company&#8217;s operating lease expense was $1.7&#160;million and $1.7&#160;million, respectively. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">The present value assumptions used in calculating the present value of the lease payments were as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31,</div></td></tr><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.24%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.24%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average remaining lease term<font style="padding-left: 2.15pt;"></font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.24%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.3&#160;years</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.24%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">1.3&#160;years</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average discount rate<font style="padding-left: 0.47pt;"></font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.24%; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">4.3%</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.24%; text-align: right; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">4.8%</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The maturity of the Company&#8217;s operating lease liabilities as of December 31, 2022 were as follows <font style="font-style: italic;">(in&#160;thousands):</font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 88.39%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Year Ending December&#160;31,</div></td><td class="gutter" style="width: 2.68%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.68%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount</div></td></tr><tr><td style="width: 88.39%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2023<font style="padding-left: 3.5pt;"></font></div></td><td class="gutter" style="width: 2.68%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.68%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 15pt;">$38</font></div></td></tr><tr><td style="width: 88.39%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total undiscounted lease payments<font style="padding-left: 1.47pt;"></font></div></td><td class="gutter" style="width: 2.68%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.68%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><font style="padding-left: 5pt;">38</font></div></td></tr><tr><td style="width: 88.39%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Less: imputed interest<font style="padding-left: 3.53pt;"></font></div></td><td class="gutter" style="width: 2.68%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.68%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">&#8212;</font></div></td></tr><tr><td style="width: 88.39%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total operating lease liability<font style="padding-left: 4.24pt;"></font></div></td><td class="gutter" style="width: 2.68%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.68%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">$38</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. The Company did not incur significant variable lease costs for the years ended December&#160;31, 2022 and 2021.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">Supplemental cash flow information related to operating leases was as follows <font style="font-style: italic;">(in thousands)</font>:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 21.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December 31,</div></td></tr><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.44%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.44%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash paid for amounts included in the measurement of lease liabilities<font style="padding-left: 4.17pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.39pt; text-align: left;">$1,512</div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.39pt; text-align: left;">$1,641</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prepaid cash payment for lease<font style="padding-left: 0.79pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.39pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.39pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">208</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash paid for operating leases that were included in operating cash outflows<font style="padding-left: 4.2pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.39pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">$1,512</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.39pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">$1,849</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-35<br></div></div></div>
<!--End Page 390-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 391-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_204-finnotes_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Notes to the Consolidated Financial Statements<br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">10.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Stock Based Compensation</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 20pt; text-align: left;">2018 Omnibus Incentive Plan </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In June 2018, stockholders of the Company approved the Company&#8217;s 2018 Omnibus Incentive Plan (the &#8220;2018 Plan&#8221;). The 2018 Plan had previously been approved by the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) and the Compensation Committee (the &#8220;Committee&#8221;) of the Board, subject to stockholder approval. The 2018 Plan became effective on June&#160;13, 2018. On June&#160;9, 2021, the stockholders of the Company approved an amendment previously approved by the Board to increase the number of shares of common stock reserved for issuance under the 2018 Plan by 2,500,000 to a total of 5,300,000 shares. The amendment became effective immediately upon stockholder approval. After the option modification (as discussed below), the number of shares of common stock reserved for issuance under the 2018 Plan increased by 14,860,784 to a total of 20,160,784. As of December&#160;31, 2022, there were 12,990,839 shares of common stock available for future grant.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 20pt; text-align: left;">Performance-Based Stock Option Grants</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In June 2022, the Committee approved the issuance of an option grant to purchase 400,000 shares (1,521,568&#160;shares after the option modification discussed below) of common stock to the Chief Executive Officer pursuant to the 2018 Plan, which will vest upon (a) the achievement of a specified performance goal and (b) the grantee&#8217;s continued employment during the service period. For the year ended December&#160;31, 2022, no expense has been recognized related to this award and no options have vested as of December&#160;31, 2022.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 20pt; text-align: left;">Special Cash Dividend</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">On September&#160;20, 2022, the Company paid a special, one-time cash dividend of $45.0&#160;million (or $1.43 per share) to the Company&#8217;s common stockholders of record as of the close of business on September&#160;6, 2022. The Company determined, in accordance with the adjustment provision of the 2018 Plan, that the special cash dividend was unusual and non-recurring and that appropriate adjustment to the stock options to purchase shares of the Company&#8217;s common stock outstanding under the 2018 Plan was required. The Company treated this adjustment as a modification to the original stock option grants because the terms of the agreements were modified in order to preserve the value of the option awards after a large non-recurring cash dividend. These options were amended to decrease the exercise price and increase the number of shares subject to the stock option on a proportionate basis. No incremental value was provided to the option holders as a result of the modification and no additional compensation cost was recorded by the Company.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: justify;">The following table summarizes stock option activity under the Company&#8217;s 2018 Plan and related information:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.96%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Underlying <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Outstanding <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Options</div></td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.83%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted- <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercise <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Price</div></td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.22%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted- <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Remaining <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Contractual <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Term <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Years)</div></td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.93%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Aggregate <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Intrinsic <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(thousands)</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding &#8212; December&#160;31, 2021<font style="padding-left: 1.71pt;"></font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.63pt;">2,603,630</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.8pt; text-align: left;">$<font style="padding-left: 5pt;">7.70</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.9pt; text-align: left;">7.46</div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.24pt; text-align: left;">$<font style="padding-left: 12.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Options granted<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 3.78pt;"></font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10,270,911</div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.8pt; text-align: left;"><font style="padding-left: 10pt;">1.34</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Options forfeited and cancelled<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 0.48pt;"></font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.3pt;">(4,148,455)</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.8pt; text-align: left;"><font style="padding-left: 10pt;">4.96</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Options expired<font style="padding-left: 2.52pt;"></font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.8pt; border-bottom: 1pt solid #000000; min-width: 44.63pt;">(47,319</font><font style="min-width: 44.63pt;">)</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.8pt; text-align: left;"><font style="padding-left: 5pt;">13.27</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding &#8212; December&#160;31, 2022<font style="padding-left: 1.71pt;"></font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.63pt; border-bottom: 3pt double #000000; min-width: 44.63pt;">8,678,767</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.8pt; text-align: left;">$<font style="padding-left: 5pt;">1.42</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.9pt; text-align: left;">7.47</div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.24pt; text-align: left;">$1,051</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exercisable &#8212; December&#160;31, 2022<font style="padding-left: 3.95pt;"></font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.63pt; border-bottom: 3pt double #000000; min-width: 44.63pt;">4,317,076</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.8pt; text-align: left;">$<font style="padding-left: 5pt;">2.38</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.9pt; text-align: left;">5.94</div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.24pt; text-align: left;">$<font style="padding-left: 12.5pt;">&#8212;</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 20pt; margin-top: 12.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes options that were cancelled and re-granted as part of the option modification from the special cash dividend, as further discussed above. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The weighted-average grant date fair value of options granted during the years ended December&#160;31, 2022 and 2021 was $0.96 and $4.00, respectively.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-36<br></div></div></div>
<!--End Page 391-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 392-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_204-finnotes_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Notes to the Consolidated Financial Statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: justify;">No options were exercised during the year ended December&#160;31, 2022. The aggregate intrinsic value of options exercised during the year ended December&#160;31, 2021 was $3,000.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The fair value of options vested during the years ended December&#160;31, 2022 and 2021 was $1.9&#160;million and $2.6&#160;million, respectively.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">Valuation Assumptions</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company estimated the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. Due to its limited relevant historical data, the Company estimated its volatility considering a number of factors including the use of the volatility of comparable public companies. The expected term of options granted under the Plan, all of which qualify as &#8220;plain vanilla&#8221; per SEC Staff Accounting Bulletin 107, is determined based on the simplified method due to the Company&#8217;s limited relevant history. The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with the option. This fair value is being amortized ratably over the requisite service periods of the awards, which is generally the vesting period.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">The fair value of employee stock options was estimated using the following weighted-average assumptions: </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 21.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December 31,</div></td></tr><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.44%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.44%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee Stock Options:<br></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Expected term (in years)<font style="padding-left: 2.44pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="padding-left: 5pt;">6.02</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="padding-left: 5pt;">6.00</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Risk-free interest rate<font style="padding-left: 0.22pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="padding-left: 5pt;">3.00%</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="padding-left: 5pt;">0.84%</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Dividend yield<font style="padding-left: 2.96pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Volatility<font style="padding-left: 1.46pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;">92.58%</div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;">93.25%</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 20pt; text-align: left;">Total stock-based compensation recognized was as follows <font style="font-style: italic;">(in thousands):</font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 21.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December 31,</div></td></tr><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.44%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.44%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development<font style="padding-left: 4.1pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.39pt; text-align: left;">$<font style="padding-left: 7.5pt;">330</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.39pt; text-align: left;">$1,202</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 4.8pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.39pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">1,012</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.39pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">2,203</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Total stock-based compensation<font style="padding-left: 3.69pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.39pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">$1,342</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.39pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">$3,405</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 20pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Included in general and administrative stock-based compensation for the years ended December&#160;31, 2022 and 2021 is $30,000 and $0.3&#160;million in expense related to 32,684 shares and 56,912 shares of common stock, respectively, issued to certain board members in lieu of their cash compensation.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">As of December&#160;31, 2022, the Company had unrecognized employee stock-based compensation expense of $1.1&#160;million, related to unvested stock option awards, which is expected to be recognized over an estimated weighted-average period of 1.93&#160;years.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 20pt; text-align: left;">Employee Stock Purchase Plan</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In June 2018, the Company&#8217;s stockholders approved the 2018 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP had previously been approved by the Board and the Compensation Committee of the Board, subject to stockholder approval which became effective as of June&#160;13, 2018. Under the ESPP, employees meeting certain specific employment qualifications are eligible to participate and can purchase shares of common stock semi-annually on February 9<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> and August 9<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> of each year, through payroll deductions. The purchase price is 85% of the lower of the fair market value of the stock at the commencement or end of the offering period. The ESPP permits eligible employees to purchase shares of common stock through payroll deductions for up to 15%&#160;of qualified compensation. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-37<br></div></div></div>
<!--End Page 392-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 393-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_204-finnotes_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Notes to the Consolidated Financial Statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: justify;">The Company&#8217;s ESPP is subject to an Evergreen provision which shares may be added to the pool as needed. As of December&#160;31, 2022, a total of 359,545 shares of common stock may be granted in accordance with the terms of the ESPP.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">For the year ended December&#160;31, 2022, a total of 47,662 shares of common stock for $20,000 have been issued to employees participating in the two ESPP purchases during 2022 and 187,807 shares are available for issuance under the ESPP as of December&#160;31, 2022.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Stock-based compensation expense for the ESPP was not significant and $0.1&#160;million for the years ended December&#160;31, 2022 and 2021, respectively, and is included in total stock-based compensation recognized.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">11.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Income Taxes </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The components of the provision for income taxes for the years ended December&#160;31, 2022 and 2021 consist of the following:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 21.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December 31,</div></td></tr><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.99%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current tax provision:<br></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Federal<font style="padding-left: 3.51pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.14pt; text-align: left;">$341</div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.64pt; text-align: left;">$&#8212;</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">State<font style="padding-left: 3.51pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.14pt; text-align: left;"><font style="padding-left: 15pt; border-bottom: 1pt solid #000000; min-width: 20pt;">7</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.64pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">&#8212;</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total tax provision<font style="font-weight: normal; padding-left: 1.84pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.14pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 20pt;">$348</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.64pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">$&#8212;</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The reconciliation of the federal statutory income tax rate to the Company&#8217;s effective tax rate for the years ended December&#160;31, 2022 and 2021 are as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 21.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December 31,</div></td></tr><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tax at statutory federal rate<font style="padding-left: 0.37pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.81pt; text-align: left;"><font style="padding-left: 1.67pt;">-21.00%</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.8pt; text-align: left;">-21.00%</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">State Tax (benefit)&#8212;net of federal benefit<font style="padding-left: 1.68pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.81pt; text-align: left;"><font style="padding-left: 6.67pt;">-0.01%</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.8pt; text-align: left;"><font style="padding-left: 8.33pt;">0.00%</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Permanent differences<font style="padding-left: 3.17pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.81pt; text-align: left;"><font style="padding-left: 10pt;">1.00%</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.8pt; text-align: left;"><font style="padding-left: 8.33pt;">0.35%</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tax credits<font style="padding-left: 3.66pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.81pt; text-align: left;"><font style="padding-left: 1.67pt;">-42.08%</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.8pt; text-align: left;"><font style="padding-left: 5pt;">-5.86%</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Derecognition due to Sec. 382 and 383 limitations<font style="padding-left: 1.62pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.81pt; text-align: left;">139.00%</div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.8pt; text-align: left;"><font style="padding-left: 8.33pt;">0.00%</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Change in valuation allowance<font style="padding-left: 2.43pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.81pt; text-align: left;"><font style="padding-left: 1.67pt;">-69.24%</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.8pt; text-align: left;"><font style="padding-left: 3.33pt;">26.26%</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fixed assets other adjustment<font style="padding-left: 2.99pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.81pt; text-align: left;"><font style="padding-left: 6.67pt;">-1.19%</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.8pt; text-align: left;"><font style="padding-left: 8.33pt;">0.00%</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other<font style="padding-left: 0.73pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.81pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">-2.07</font><font style="min-width: 27.5pt;">%</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.8pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">0.25</font><font style="min-width: 25.83pt;">%</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Effective tax rate<font style="padding-left: 3.16pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.81pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 3pt double #000000; min-width: 27.5pt;">4.41</font><font style="min-width: 27.5pt;">%</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.8pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">0.00</font><font style="min-width: 25.83pt;">%</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Significant components of the Company&#8217;s deferred tax assets as of December&#160;31, 2022 and 2021 consist of the following (in thousands):</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 21.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December 31,</div></td></tr><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.44%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.44%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred tax assets:<br></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accruals and reserves<font style="padding-left: 4.11pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;">$<font style="padding-left: 8.33pt;">1,273</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;">$<font style="padding-left: 8.33pt;">1,000</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net operating loss carry forwards<font style="padding-left: 1.35pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 8.33pt;">40,770</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 8.33pt;">47,541</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Tax credit carry forwards<font style="padding-left: 4.82pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 13.33pt;">4,463</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 8.33pt;">12,939</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Fixed and intangible assets<font style="padding-left: 2.98pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 13.33pt;">9,510</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 30.83pt;">3</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Valuation allowance<font style="padding-left: 1.31pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(56,016</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(61,483</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net deferred tax assets:<font style="font-weight: normal; padding-left: 0.97pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">$</font><font style="padding-left: 20.83pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">$</font><font style="padding-left: 20.83pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">&#8212;</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Based on the available objective evidence at December&#160;31, 2022, the Company does not believe it is more likely than not that the net deferred tax assets will be realizable. Accordingly, the Company has provided a full </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-38<br></div></div></div>
<!--End Page 393-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 394-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_204-finnotes_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Notes to the Consolidated Financial Statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: justify;">valuation allowance against its net deferred tax assets at December&#160;31, 2022 and 2021. The net valuation allowance decreased by approximately $5.5&#160;million and increased by approximately $23.1&#160;million during the years ended December&#160;31, 2022 and 2021, respectively.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">As of December&#160;31, 2022, after consideration of certain limitations (see below), the Company had approximately $194.1&#160;million federal and $3.6&#160;million state net operating loss carryforwards (&#8220;NOL&#8221;) available to reduce future taxable income which, if unused, will begin to expire in 2037 for federal and 2032 for state tax purposes. The federal net operating loss carryforward includes $192.4&#160;million that have an indefinite life.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">As of December&#160;31, 2022, the Company also had tax credit carry forwards available to offset future tax liabilities of approximately $8,500 for federal and $7.5&#160;million for state. If unused, the federal credit will begin to expire in 2042 and the state tax credit does not expire.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">If the Company experiences a greater than 50 percent aggregate change in ownership over a three-year period (a Section 382 ownership change), utilization of its pre-change NOL carryforwards are subject to annual limitation under Section 382 of the Internal Revenue Code (California has similar provisions). The annual limitation is determined by multiplying the value of the Company&#8217;s stock at the time of such ownership change by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforwards before utilization. The Company determined that ownership changes occurred on December&#160;31, 2007, August&#160;20, 2015, April&#160;13, 2017, February&#160;15, 2018, February&#160;18, 2020, and December&#160;26, 2022. Approximately $156.5&#160;million and $75.2&#160;million of the NOLs will expire unutilized for federal and California purposes, respectively. The Company has derecognized NOL related deferred tax assets in the tax affected amounts of $32.9&#160;million and $0 for federal and California purposes, respectively through the year ended December&#160;31, 2022.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">All of the federal R&amp;D credits could expire unutilized, whereas none of the California R&amp;D credits are subject to expiration. Approximately $26.1&#160;million of gross federal R&amp;D credit-related deferred tax assets were derecognized due to the Section 383 limitation. The ability of the Company to use its remaining NOL and carryforwards may be further limited if the Company experiences a Section 382 ownership change as a result of future changes in its stock ownership.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">On June&#160;29, 2020, the California Governor signed Assembly Bill 85 (&#8220;A.B. 85&#8221;), which now becomes California law. A.B. 85, which includes several tax measures, provides for a three-year suspension of the use of net operating losses for medium and large businesses and a three-year cap on the use of business incentive tax credits to offset no more than $5&#160;million of tax per year. Generally, A.B. 85 suspends the use of net operating losses for taxable years 2020, 2021, and 2022 for taxpayers with taxable income of $1&#160;million or more. Since the Company is not expected to generate California source taxable income of more than $1&#160;million, no material impact is anticipated at this time.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">Accounting for Uncertainty in Income Taxes</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company only recognizes tax benefits if it is more likely than not that they will be sustained upon audit by the relevant tax authority based upon their technical merits. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company had approximately $1.9&#160;million and $4.7&#160;million of unrecognized tax benefits as of December&#160;31, 2022 and 2021, respectively. As the Company has a full valuation allowance on its deferred tax assets, the unrecognized tax benefits have reduced the deferred tax assets and the valuation allowance in the same amount. The Company does not expect the amount of unrecognized tax benefits to materially change in the next twelve&#160;months.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-39<br></div></div></div>
<!--End Page 394-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 395-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_204-finnotes_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Notes to the Consolidated Financial Statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: justify;">A reconciliation of the beginning and ending balance of the unrecognized tax benefits is as follows <font style="font-style: italic;">(in </font><font style="font-style: italic;">thousands)</font>: </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr><td style="width: 85.72%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Beginning Balance at January&#160;1, 2021<font style="font-weight: normal; padding-left: 1.25pt;"></font></div></td><td class="gutter" style="width: 3.7%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.7%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 3.33pt;">2,955</font></div></td></tr><tr><td style="width: 85.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Increase/(Decrease) of unrecognized tax benefits taken in prior years<font style="padding-left: 4.44pt;"></font></div></td><td class="gutter" style="width: 3.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 20.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 85.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Increase/(Decrease) of unrecognized tax benefits related to current year<font style="padding-left: 3.9pt;"></font></div></td><td class="gutter" style="width: 3.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">1,749</font></div></td></tr><tr><td style="width: 85.72%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ending Balance at December 31, 2021<font style="font-weight: normal; padding-left: 0.89pt;"></font></div></td><td class="gutter" style="width: 3.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 3.33pt;">4,704</font></div></td></tr><tr><td style="width: 85.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Increase/(Decrease) of unrecognized tax benefits taken in prior years<font style="padding-left: 4.44pt;"></font></div></td><td class="gutter" style="width: 3.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">(2,841)</font></div></td></tr><tr><td style="width: 85.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Increase/(Decrease) of unrecognized tax benefits related to current year<font style="padding-left: 3.9pt;"></font></div></td><td class="gutter" style="width: 3.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">20</font></div></td></tr><tr><td style="width: 85.72%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ending Balance at December 31, 2022<font style="font-weight: normal; padding-left: 0.89pt;"></font></div></td><td class="gutter" style="width: 3.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 30.83pt;">$</font><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">1,883</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Interest and penalties related to unrecognized tax benefits would be included as income tax expense in the Company&#8217;s consolidated statements of operations. As of December&#160;31, 2022 and 2021, the Company had not recognized any tax-related penalties or interest in its consolidated financial statements.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company files income tax returns in the United States federal and California, with a new filing in Florida for tax year 2022. The Company filed final returns in 2021 in Kansas, Missouri and New Jersey state jurisdictions. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. As of December&#160;31, 2022 and 2021, the Company had no uncertain tax positions which affected its financial position as its results of operations or its cash flow, and will continue to evaluate for uncertain tax positions in the future. The Company is subject to United States federal and state income tax examinations by authorities for all tax years due to accumulated net operating losses that are being carried forward for tax purposes.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">12.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Collaborations</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 20pt; text-align: left;">Mosaic</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In October 2017, the Company entered into a strategic research collaboration with Mosaic to develop intravitreal anti-complement factor 3 (C3) products for the treatment of dry Age-related Macular Degeneration (AMD) and other retinal diseases. The Company subsequently amended this agreement in December 2018, December 2019 and May 2020.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Under the as amended Mosaic collaboration agreement, Mosaic is eligible to receive up to $4.0&#160;million in potential future milestone payments related to regulatory and clinical development events for CB 2782-PEG and an additional anti-complement product candidate in lieu of the Company&#8217;s prior obligations to pay Mosaic a double-digit percentage of funds the Company receives from Biogen or any other amounts the Company receives related to sublicense fees, research and development payments, or any other research, regulatory, clinical or commercial milestones and royalties on any other development candidates.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">As a result of the sale of the Company&#8217;s complement portfolio, including CB 2782-PEG and other assets, to Vertex in May 2022, the Mosaic collaboration agreement was transferred to Vertex. See Note 16<font style="font-style: italic;">, Restructuring</font>.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 20pt; text-align: left;">ISU Abxis</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In December 2018, the Company entered into an amended and restated license agreement with ISU Abxis (the&#160;&#8220;A&amp;R ISU Abxis Agreement&#8221;). Under the A&amp;R ISU Abxis Agreement, ISU Abxis will receive commercialization rights in South Korea to the Company&#8217;s engineered Factor IX dalcinonacog alfa - DalcA and the Company will receive clinical development and commercialization rights in the rest of world (excluding South Korea) and manufacturing development and manufacturing rights worldwide (including South Korea). The A&amp;R ISU Abxis Agreement provides for a low single-digit royalty payment to ISU Abxis, on a country-by-country basis, for net product sales of DalcA by the Company or its affiliates in each country other than South Korea. Pursuant to the A&amp;R ISU Abxis Agreement, the Company will also pay up to an aggregate of $19.5&#160;million in milestone payments to ISU Abxis, including $2.5 million in regulatory and development milestone payments and up to $17.0 million in commercial milestone payments, if the applicable milestones are met. As of December&#160;31, 2022, no milestones have been met.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-40<br></div></div></div>
<!--End Page 395-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 396-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_204-finnotes_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Notes to the Consolidated Financial Statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: justify;">As a result of the sale of the Company&#8217;s rare bleeding disorders programs, including DalcA and other assets, to GCBP in February 2023, the A&amp;R ISU Abxis Agreement was transferred to GCBP. See Note 17, <font style="font-style: italic;">Subsequent </font><font style="font-style: italic;">Events.</font></div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">Biogen</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">On December&#160;18, 2019, the Company and Biogen entered into a License and Collaboration Agreement (the&#160;&#8220;Biogen Agreement&#8221;), under which the Company granted Biogen a worldwide, royalty-bearing, exclusive, with the right to sublicense, license (&#8220;Exclusive License&#8221;) to develop and commercialize CB 2782-PEG and other anti-C3 proteases for potential treatment of dry AMD and other disorders. Pursuant to the Biogen Agreement, the Company performed certain pre-clinical and manufacturing activities (&#8220;Research Services&#8221;), and Biogen was solely responsible for funding the pre-clinical and manufacturing activities and performing IND-enabling activities, worldwide clinical development, and commercialization.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Under the terms of the Biogen Agreement, the Company received an up-front payment for the transfer of the Exclusive License (inclusive of certain know-how) of $15.0&#160;million in January 2020. The Company was eligible to receive development milestones and sales milestones of up to $340.0&#160;million. In addition, the Company was eligible to receive royalties in the range of single-digit to low double-digit percentage rates of annual net sales on a product-by-product and country-by-country basis. The Company also received reimbursements for costs associated with the performance of the Research Services.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company determined that the performance obligations under the Biogen Agreement were the Exclusive License and the Research Services. For the Exclusive License, the Company used the residual approach in determining the standalone selling price, or SSP, which includes the upfront payments, milestones and royalties. For the Research Services, the Company used the historical pricing approach for determining the SSP, which includes the reimbursement of personnel and out-of-pocket costs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In March 2022, the Company received written notice from Biogen declaring intent to terminate the Biogen Agreement which was effective as of May 2022. As a result of the termination, Biogen no longer has the Exclusive License to develop, manufacture and commercialize CB 2782-PEG and other anti-C3 proteases for potential treatment of dry AMD and other disorders. In March 2022, Biogen returned full rights to CB&#160;2782-PEG.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In June 2022, Biogen and the Company reached an agreement to resolve the outstanding obligations and monetary disputes between the parties. The Company agreed to forgive approximately $0.6&#160;million of accounts receivable due from Biogen and to pay Biogen $10,000 in cash. This resulted in the Company recognizing a $0.6&#160;million settlement expense for the year ended December&#160;31, 2022, which is included in general and administrative operating expenses in the consolidated statements of operations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">For the years ended December&#160;31, 2022 and 2021, the Company recognized no license revenue from the Biogen Agreement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">For the years ended December&#160;31, 2022 and 2021, the Company recognized $0.8&#160;million and $7.3&#160;million in collaboration revenue for reimbursable out-of-pocket and personnel costs incurred related to Research Services.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">For the year ended December&#160;31, 2022, the Company recognized $0.2&#160;million in collaboration revenue from the beginning of period deferred revenue balance.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-41<br></div></div></div>
<!--End Page 396-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 397-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_204-finnotes_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Notes to the Consolidated Financial Statements<br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">13.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Interest and Other Income (Expense), Net</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">The following table shows the detail of interest and other income (expense), net as follows <font style="font-style: italic;">(in thousands):</font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 21.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December 31,</div></td></tr><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest income<font style="padding-left: 0.75pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.56pt; text-align: left;">$537</div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.55pt; text-align: left;">$<font style="padding-left: 3.33pt;">39</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gain from extinguishment of liability<font style="padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.56pt; text-align: left;"><font style="padding-left: 5pt;">180</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.55pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other<font style="padding-left: 0.73pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.56pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 20pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.55pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">(78</font><font style="min-width: 18.33pt;">)</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total interest and other income (expense), net<font style="padding-left: 0.67pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.56pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 20pt;">$717</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.55pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 18.33pt;">$(39</font><font style="min-width: 18.33pt;">)</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">14.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Stockholders&#8217; Equity</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 20pt; text-align: left;">Common Stock </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Under the Company&#8217;s amended and restated certificate of incorporation, the Company has 100,000,000 shares of common stock authorized for issuance with a $0.001 par value per share. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of a majority of the Company&#8217;s stock who are entitled to vote. Each share of common stock is entitled to one vote. The holders of common stock are entitled to receive dividends when and as declared or paid by the Board.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company had 0 and 85 issued and outstanding common stock warrants as of December&#160;31, 2022 and 2021, respectively, with a weighted-average exercise price of $392.70. The warrants expired in August 2022.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 20pt; text-align: left;">2021 ATM Program </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">On October&#160;15, 2021, the Company entered into an Equity Distribution Agreement (the &#8220;ATM Agreement&#8221;) with Piper Sandler, as sales agent, pursuant to which the Company may offer and sell, from time to time, through Piper Sandler, shares of the Company&#8217;s common stock, par value of $0.001 per share, with aggregate gross sales proceeds of up to $50.0&#160;million through the ATM Program. The Company will pay Piper Sandler a commission of 3.0% of the gross proceeds of any shares sold. The Company also agreed to reimburse Piper Sandler for certain expenses incurred in connection with its services under the ATM Agreement, including up to $50,000 for legal expenses in connection with the establishment of the ATM Program.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Sales of shares of common stock under the ATM Program will be made pursuant to the registration statement on Form S-3 (File No. 333-253874), which was declared effective by the SEC on May&#160;3, 2021, and a related prospectus supplement file with the SEC on October&#160;15, 2021. For the years ended December&#160;31, 2022 and 2021, no shares of common stock were sold under the ATM Program. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 20pt; text-align: left;">Redeemable Convertible Preferred Stock</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company is authorized to issue 5,000,000 shares of preferred stock with a par value of $0.001 per share under its restated certificate of incorporation. Under the Catalyst Convertible Preferred Stock Certificate of Designation, the Company has designated 123,418 shares to be Catalyst Convertible Preferred Stock and is authorized to issue up to 12,340 shares of Catalyst Convertible Preferred Stock pursuant to the terms of the F351&#160;Agreement and up to 111,078 shares of Catalyst Convertible Preferred stock pursuant to the terms of the Business Combination Agreement. As of December&#160;31, 2022, the Company has 12,340 shares of Catalyst Convertible Preferred Stock issued and outstanding. Refer to Note 1, <font style="font-style: italic;">Nature of Operations</font>, regarding the Company&#8217;s issuance of Catalyst Convertible Preferred Stock in December 2022. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Subject to stockholder approval, each share of Catalyst Convertible Preferred Stock issued under the F351&#160;Agreement is convertible into 10,000 shares of common stock. The Company is required to hold a stockholders&#8217; meeting to request the approval of the conversion of the Catalyst Convertible Preferred Stock into shares of common stock in accordance with Nasdaq Listing Rule 5635(a) (the &#8220;Conversion Proposal&#8221;). The Company expects to hold its 2023 Annual Meeting of Stockholders in the third quarter of 2023 and will include </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-42<br></div></div></div>
<!--End Page 397-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 398-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_204-finnotes_pg20"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Notes to the Consolidated Financial Statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: justify;">the following matters as proposals to be voted on at the meeting: (i)&#160;the Conversion Proposal and (ii)&#160;if necessary or appropriate, the approval of an amendment to the Company&#8217;s certificate of incorporation to authorize sufficient shares of common stock for the conversion of the Catalyst Convertible Preferred Stock issued pursuant to the F351 Agreement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">If the Company&#8217;s stockholders do not approve the conversion of the Catalyst Convertible Preferred Stock by June&#160;26, 2023 (which has been extended to September&#160;30, 2023, see Note&#160;17, <font style="font-style: italic;">Subsequent Events</font>), then the holders of the Catalyst Convertible Preferred Stock are entitled to require the Company to make cash payments at a price per share equal to the fair value of undelivered shares of common stock, defined as the last reported closing price of the Company&#8217;s common stock on the trading day on which notice of conversion is delivered to the Company. Using the closing price on March&#160;24, 2023 of $0.21, if all the currently outstanding Catalyst Convertible Preferred Stock was redeemed for cash, the Company would be required to make a payment of approximately $25.7&#160;million. The Company has insufficient liquidity to make such a payment, if required.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Holders of Catalyst Convertible Preferred Stock are entitled to receive dividends on shares of Catalyst Convertible Preferred Stock equal, on an as-if-converted-to-common-stock basis, and in the same form as dividends actually paid on shares of the Company&#8217;s common stock. Except as otherwise required by law, the Catalyst Convertible Preferred Stock does not have voting rights. However, as long as any shares of Catalyst Convertible Preferred Stock are outstanding, the Company may not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Catalyst Convertible Preferred Stock, (i)&#160;alter or change adversely the powers, preferences or rights given to the Catalyst Convertible Preferred Stock or alter or amend this Certificate of Designation that authorized the Catalyst Convertible Preferred Stock, amend or repeal any provision of or add any provision to, the Certificate of Incorporation or bylaws of the Company, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of preferred stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Catalyst Convertible Preferred Stock, (ii)&#160;issue further shares of Catalyst Convertible Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Catalyst Convertible Preferred Stock, or (iii)&#160;enter into any agreement with respect to any of the foregoing. Additionally, the approval of the holders of a majority of the Catalyst Convertible Preferred Stock is required for certain change of control transactions, provided that this approval right will terminate upon stockholder approval of the Conversion Proposal. The Catalyst Convertible Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of the Company.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Following stockholder approval of the Conversion Proposal, each share of Catalyst Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 10,000 shares of the Company&#8217;s common stock, subject to certain beneficial ownership limitations, including that a holder of Catalyst Convertible Preferred Stock is prohibited from converting shares of Catalyst Convertible Preferred Stock into shares of the Company&#8217;s common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be initially set at 9.99% and thereafter adjustable by the holder to a number between 4.99% and 19.99%) of the total number of shares of the Company&#8217;s common stock issued and outstanding immediately after giving effect to such conversion.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Catalyst Convertible Preferred Stock is classified as temporary equity on the consolidated balance sheet because if conversion to common stock is not approved by the shareholders, the Catalyst Convertible Preferred Stock would be redeemable at the option of the holders for cash equal to the closing price of the common stock on last trading day prior to the holder&#8217;s redemption request. The Catalyst Convertible Preferred Stock is recorded at its relative fair value on the date of issuance (i.e., the closing date of the F351 Asset acquisition) and the Company has not adjusted the carrying value to its redemption value since the Catalyst Convertible Preferred Stock is not currently redeemable, and it is not probable that it will become redeemable in the future at the balance sheet date. Subsequent adjustments to the carrying value will be made only when it becomes probable that such redemption will occur.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-43<br></div></div></div>
<!--End Page 398-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 399-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_204-finnotes_pg21"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Notes to the Consolidated Financial Statements<br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">15.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Net Loss per Share Attributable to Common Stockholders</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 22.54%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December 31,</div></td></tr><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.93%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Options to purchase common stock<font style="padding-left: 4.1pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">8,678,767</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2,603,630</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Redeemable convertible preferred stock<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 2.61pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">123,400,000</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Common stock warrants<font style="padding-left: 4.09pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 40pt; border-bottom: 1pt solid #000000; min-width: 50pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 40pt;">85</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="padding-left: 3.09pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 50pt;">132,078,767</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">2,603,715</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 20pt; margin-top: 11.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Shown as common stock equivalents</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">16.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Restructuring</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In November 2021, the Board approved a restructuring of its business based on its decision to stop the clinical development of MarzAA and focus solely on its complement programs and protease medicines platform. The restructuring included a reduction-in-force whereby approximately 35% of employees were terminated. During the year ended December&#160;31, 2021, the Company recorded charges of $0.4&#160;million related to one-time severance costs and related expenses in connection with the workforce reduction, and charges of $3.8&#160;million related to the write-off of prepaid manufacturing costs that will no longer be used for the clinical development of MarzAA. As of December&#160;31, 2021, the remaining restructuring liability was $0.2&#160;million, which the Company paid during the second quarter of 2022.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In March 2022, the Board approved a further reduction of its workforce as part of its restructuring plan whereby 22 full-time employees were terminated. Following this reduction, the Company had five full-time employees remaining. During the quarter ended March&#160;31, 2022, the Company recorded additional charges of $1.0&#160;million for severance and other costs related to the reduction-in-force, recognized as an operating expense within the consolidated statements of operations, which the Company paid during the second quarter of 2022.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The following table summarizes restructuring charges recorded in each component of operating expenses in the Company&#8217;s consolidated statements of operations (in thousands):</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 21.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31,</div></td></tr><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.4%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.53%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.48%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development<font style="padding-left: 4.1pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.4%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.48pt; text-align: left;">$<font style="padding-left: 7.13pt;">609</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.48pt; text-align: left;">$4,025</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative<font style="padding-left: 3.55pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.4%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.48pt; text-align: left;"><font style="padding-left: 12.13pt; border-bottom: 1pt solid #000000; min-width: 27.13pt;">402</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.48pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">143</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Total restructuring charges<font style="padding-left: 4.98pt;"></font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.4%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.48pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.13pt;">$1,011</font></div></td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.48pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">$4,168</font></div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 20pt; text-align: left;">Sale of Assets</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">During the year ended December&#160;31, 2022, the Company entered into sales agreements, pursuant to which the Company sold various lab equipment, consumables, and furniture and fixtures for total consideration of $0.5&#160;million. The Company recorded a loss on disposal of $0.2&#160;million, which is included in gain on disposal of assets, net in the consolidated statements of operations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In May 2022, the Company entered into an asset purchase agreement with Vertex, pursuant to which Vertex purchased the Company&#8217;s complement portfolio, including CB 2782-PEG and CB 4332, as well as its complement-related intellectual property including the ProTUNE<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup> and ImmunoTUNE<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup> platforms for $60.0&#160;million in cash consideration. Cash of $55.0&#160;million was received upfront in May 2022 and the remaining $5.0&#160;million will be paid one year after the closing upon satisfaction of certain post-closing indemnification </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-44<br></div></div></div>
<!--End Page 399-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 400-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_204-finnotes_pg22"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Notes to the Consolidated Financial Statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: justify;">obligations. The hold-back amount is recorded within accounts and other receivables on the consolidated balance sheet. There were no carrying amounts associated with the intellectual property sold to Vertex, and, therefore, the Company recorded a gain of $57.4&#160;million related to the disposal, net of $2.6&#160;million of transaction costs, which is included in gain on disposal of assets, net in the consolidated statements of operations.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">17.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Subsequent Events</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7.5pt; margin-left: 20pt; text-align: left;">Payment of Dividend</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">On January&#160;12, 2023, the Company paid a one-time cash dividend of $0.24 per share, or approximately $7.6&#160;million, to the Company&#8217;s common stockholders of record as of close of business on January&#160;5, 2023. GNI common stockholders were not entitled to such dividend payment.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">Sale of Assets</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">On February&#160;27, 2023, Catalyst entered into an asset purchase agreement with GC Biopharma Corp. (&#8220;GCBP&#8221;), pursuant to which GCBP acquired the Company&#8217;s legacy rare bleeding disorders programs including MarzAA, DalcA and CB-2679d-GT for $6.0&#160;million in cash consideration. Cash of $1.0&#160;million was received upfront in February 2023 and the remaining $5.0&#160;million will be paid two years after the closing upon satisfaction of certain post-closing indemnification obligations. In March 2023, the Company distributed the net cash proceeds received upfront of $0.2&#160;million to the CVR Holders. Once received, the remaining net proceeds from the transaction will be distributed to the CVR Holders.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">Silicon Valley Bank Closure</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">As of March&#160;10, 2023, the Company maintained two accounts at Silicon Valley Bank (&#8220;SVB&#8221;) holding cash deposits of approximately $9.0&#160;million. On March&#160;10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) was appointed receiver. The FDIC initially announced that all insured depositors will have full access to their insured deposits no later than, March&#160;13, 2023, with uninsured depositors receiving an advance dividend receivership certificate for their uninsured funds. On March&#160;12, 2023, the U.S. Treasury Department, the Federal Reserve and the FDIC jointly announced enabling actions that fully protect all SVB depositors&#8217; insured and uninsured deposits, and that such depositors would have access to all of their funds starting March&#160;13, 2023. On March&#160;13, 2023, the Company was able to access its full deposits with SVB. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">F351 Agreement Amendment</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In March 2023, the Company amended the F351 Agreement and the Catalyst Convertible Preferred Stock Certificate of Designation to extend the deadline for the cash settlement of the Catalyst Convertible Preferred Stock to September&#160;30, 2023. Under the amended terms, if the Company&#8217;s stockholders do not approve the conversion of the Catalyst Convertible Preferred Stock by September&#160;30, 2023, then the Catalyst Convertible Preferred Stock would be redeemable at the option of the holders for cash equal to the closing price of the common stock on last trading day prior to the holder&#8217;s redemption request. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-45<br></div></div></div>
<!--End Page 400-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 401-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_205-fintab_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><a name="tICCSP"><!--Anchor--></a>BEIJING CONTINENT PHARMACEUTICALS CO., LTD. <br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME <br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the three months ended March&#160;31, 2023 and 2022<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB)</font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Notes</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 29.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the three months ended March&#160;31,</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.13%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023</div></td><td class="gutter" style="width: 1.13%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.13%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.81%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.81%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Revenue<font style="font-weight: normal; padding-left: 3.85pt;"></font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.05pt; text-align: left;">4</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;">168,175</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;">159,035</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cost of revenue<font style="padding-left: 0.53pt;"></font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(7,732</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(7,623</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gross profit<font style="font-weight: normal; padding-left: 3.1pt;"></font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;">160,443</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;">151,412</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income and gains<font style="padding-left: 2.76pt;"></font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 10.37pt;">1,711</font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 17.5pt;">701</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Selling expenses<font style="padding-left: 2.74pt;"></font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 1.67pt;">(87,589)</font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 1.67pt;">(72,012)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Administrative expenses<font style="padding-left: 1.09pt;"></font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 1.67pt;">(12,870)</font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 1.67pt;">(15,468)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development expenses<font style="padding-left: 1.68pt;"></font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 1.67pt;">(10,683)</font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 1.67pt;">(13,181)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other expenses<font style="padding-left: 3.31pt;"></font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 6.67pt;">(2,053)</font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 14.17pt;">(939)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Finance costs<font style="padding-left: 0.52pt;"></font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(52</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(87</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Profit before tax<font style="font-weight: normal; padding-left: 3.67pt;"></font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 5pt;">48,907</font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 5pt;">50,426</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income tax expense<font style="padding-left: 4.43pt;"></font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.05pt; text-align: left;">5</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 2.04pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(11,933</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 2.04pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(11,316</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net profit<font style="font-weight: normal; padding-left: 2.93pt;"></font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">36,974</font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 5.37pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">39,110</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other comprehensive income, net of tax<font style="padding-left: 0.85pt;"></font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total comprehensive income<font style="font-weight: normal; padding-left: 2.75pt;"></font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">36,974</font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 5.37pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">39,110</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-46<br></div></div></div>
<!--End Page 401-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 402-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_205-fintab_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><a name="tICCSF"><!--Anchor--></a>BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION AS OF March&#160;31, 2023 AND AUDITED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION AS OF December&#160;31, 2022<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB)</font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">Notes</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.47%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.6%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2023</div></td><td class="gutter" style="width: 1.47%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.47%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.06%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2022</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.6%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.06%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Audited)</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">ASSETS<br></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-current assets<br></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property, plant and equipment<font style="padding-left: 2.57pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.33pt; text-align: left;"><font style="padding-left: 5pt;">6</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;">132,907</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;">123,339</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Right-of-use assets<font style="padding-left: 3.31pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 5pt;">14,585</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 5pt;">15,282</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prepayments and deposits<font style="padding-left: 4.98pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 5pt;">23,459</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 5pt;">21,730</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Intangible assets<font style="padding-left: 3.31pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;">168,983</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;">161,249</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred tax assets<font style="padding-left: 2.78pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 10pt;">2,787</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 10pt;">2,589</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Bank deposits<font style="padding-left: 3.29pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.33pt; text-align: left;"><font style="padding-left: 5pt;">9</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">91,931</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">51,500</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total non-current assets<font style="font-weight: normal; padding-left: 1.09pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">434,652</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">375,689</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current assets<br></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Inventories<font style="padding-left: 0.52pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.33pt; text-align: left;"><font style="padding-left: 5pt;">7</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 5pt;">39,120</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 5pt;">42,639</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade receivables<font style="padding-left: 4.22pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.33pt; text-align: left;"><font style="padding-left: 5pt;">8</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 5pt;">85,926</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;">108,753</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Debt investments at fair value through other comprehensive income<font style="padding-left: 2.28pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 10pt;">4,180</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 5pt;">10,597</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prepayments, deposits and other receivables<font style="padding-left: 0.3pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 5pt;">12,483</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 10pt;">8,493</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and bank balances<font style="padding-left: 2.21pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.33pt; text-align: left;"><font style="padding-left: 5pt;">9</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">181,820</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">163,420</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total current assets<font style="font-weight: normal; padding-left: 0.53pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">323,529</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">333,902</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total assets<font style="font-weight: normal; padding-left: 0.88pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">758,181</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">709,591</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">LIABILITIES AND EQUITY<br></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current liabilities<br></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade payables<font style="padding-left: 4.21pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 10pt;">1,921</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 17.5pt;">850</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other payables and accruals<font style="padding-left: 0.56pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.33pt; text-align: left;">10</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 5pt;">61,212</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 5pt;">61,084</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities<font style="padding-left: 1.64pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 10pt;">3,486</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 10pt;">3,467</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tax payable<font style="padding-left: 1.22pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">21,630</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">12,668</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total current liabilities<font style="font-weight: normal; padding-left: 1.07pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">88,249</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">78,069</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-current liabilities<br></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Customers&#8217; deposits<font style="padding-left: 4.04pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 17.5pt;">382</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 17.5pt;">380</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities<font style="padding-left: 1.64pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 17.5pt;">842</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 10pt;">1,525</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred government grants<font style="padding-left: 1.11pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">6,047</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">5,150</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total non-current liabilities<font style="font-weight: normal; padding-left: 1.63pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">7,271</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">7,055</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities<font style="font-weight: normal; padding-left: 1.43pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">95,520</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">85,124</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Equity<br></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share capital<font style="padding-left: 2.75pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 5pt;">61,318</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 5pt;">61,318</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Capital reserve<font style="padding-left: 4.42pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;">249,880</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;">248,660</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Surplus reserve<font style="padding-left: 2.75pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 5pt;">31,449</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 5pt;">31,449</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Retained profits<font style="padding-left: 0.52pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">320,014</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">283,040</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total equity<font style="font-weight: normal; padding-left: 3.65pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">662,661</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">624,467</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities and equity<font style="font-weight: normal; padding-left: 1.99pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">758,181</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">709,591</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-47<br></div></div></div>
<!--End Page 402-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 403-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_205-fintab_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><a name="tICCSC"><!--Anchor--></a>BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the three months ended March&#160;31, 2023 and 2022<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB)</font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Note</div></td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">capital</div></td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Capital <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">reserve</div></td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Surplus <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">reserve</div></td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Retained <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">profits</div></td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of January&#160;1, 2023 (unaudited)<font style="font-weight: normal; padding-left: 3.37pt;"></font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">61,318</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">248,660</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">31,449</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">283,040</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">624,467</div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Profit for the period<font style="padding-left: 0.31pt;"></font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">36,974</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">36,974</font></div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Equity-settled share option arrangements<font style="padding-left: 0.89pt;"></font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.18pt; text-align: left;">11</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">1,220</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">1,220</font></div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of March&#160;31, 2023 (unaudited)<font style="font-weight: normal; padding-left: 0.23pt;"></font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">61,318</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">249,880</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">31,449</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">320,014</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">662,661</font></div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Note</div></td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">capital</div></td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Capital <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">reserve</div></td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Surplus <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">reserve</div></td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Retained <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">profits</div></td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of January&#160;1, 2022 (unaudited)<font style="font-weight: normal; padding-left: 3.37pt;"></font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">61,318</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">240,055</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">16,346</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">147,109</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">464,828</div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Profit for the period<font style="padding-left: 0.31pt;"></font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5.37pt;">39,110</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5.37pt;">39,110</font></div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Equity-settled share option arrangements<font style="padding-left: 0.89pt;"></font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.18pt; text-align: left;">11</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">4,075</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">4,075</font></div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of March&#160;31, 2022 (unaudited)<font style="font-weight: normal; padding-left: 0.23pt;"></font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">61,318</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">244,130</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">16,346</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">186,219</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">508,013</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-48<br></div></div></div>
<!--End Page 403-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 404-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_205-fintab_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><a name="tICCSCF"><!--Anchor--></a>BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the three months ended March&#160;31, 2023 and 2022<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB)</font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.24%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Note</div></td><td class="gutter" style="width: 1.24%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.24%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 30.1%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the three months ended March&#160;31,</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.24%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023</div></td><td class="gutter" style="width: 1.24%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.24%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.81%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.81%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">CASH FLOWS FROM OPERATING ACTIVITIES<br></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Profit before tax<font style="padding-left: 3.31pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 5pt;">48,907</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 5pt;">50,426</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Finance costs<font style="padding-left: 0.52pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 22.5pt;">52</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 22.5pt;">87</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest income<font style="padding-left: 2.75pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 14.17pt;">(431)</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss on disposal of property, plant and equipment<font style="padding-left: 4.83pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 27.5pt;">6</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 22.5pt;">24</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation of property, plant and equipment<font style="padding-left: 1.49pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 10pt;">1,848</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 10pt;">1,475</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation of right-of-use assets<font style="padding-left: 0.02pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 17.5pt;">957</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 17.5pt;">816</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amortization of intangible assets<font style="padding-left: 0.55pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 17.5pt;">820</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 17.5pt;">819</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recognition of equity-settled share option expenses<font style="padding-left: 4.46pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.18pt; text-align: left;">11</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 10pt;">1,220</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 10pt;">4,075</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Provision for inventories<font style="padding-left: 4.42pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 17.5pt;">180</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 17.5pt;">249</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Reversal for the impairment of trade receivables<font style="padding-left: 2.27pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 14.17pt;">(199)</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 14.17pt;">(174)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amortization of deferred government grants<font style="padding-left: 0.02pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(71</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(38</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 5pt;">53,289</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 5pt;">57,759</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Decrease in inventories<font style="padding-left: 4.99pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 10pt;">3,339</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 10pt;">2,579</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Decrease (increase) in trade receivables<font style="padding-left: 3.39pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 5pt;">29,443</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 6.67pt;">(3,093)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Increase in deposits and other receivables<font style="padding-left: 0.03pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 6.67pt;">(3,990)</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 6.67pt;">(8,218)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Increase (decrease) in trade payables<font style="padding-left: 0.05pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 10pt;">1,071</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 14.17pt;">(340)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Increase in other payables and accruals<font style="padding-left: 0.04pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 17.5pt;">131</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 5pt;">14,401</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Increase in deferred government grants<font style="padding-left: 0.59pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">1,100</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash generated from operations<font style="padding-left: 0.56pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 5pt;">84,383</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 5pt;">63,088</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income tax paid<font style="padding-left: 4.41pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(3,169</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(5,897</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash generated from operating activities<font style="padding-left: 4.47pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">81,214</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">57,191</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">CASH FLOWS FROM INVESTING ACTIVITIES<br></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Purchase of property, plant and equipment<font style="padding-left: 2.05pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 1.67pt;">(12,372)</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 6.67pt;">(3,719)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additions to intangible assets<font style="padding-left: 4.98pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 6.67pt;">(9,466)</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 1.67pt;">(16,132)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Purchase of long-term bank deposits<font style="padding-left: 1.11pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(40,000</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash used in investing activities<font style="padding-left: 2.78pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 1.67pt;">(61,838)</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 1.67pt;">(19,851)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">CASH FLOWS FROM FINANCING ACTIVITIES<br></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Principal portion of lease payments<font style="padding-left: 0.55pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 14.17pt;">(924)</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 14.17pt;">(726)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest paid on lease liabilities<font style="padding-left: 2.78pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(52</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(87</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash used in financing activities<font style="padding-left: 1.68pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(976</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(813</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NET INCREASE IN CASH AND CASH EQUIVALENTS<font style="font-weight: normal; padding-left: 4.26pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="padding-left: 5pt;">18,400</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="padding-left: 5pt;">36,527</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents at beginning of period<font style="padding-left: 3.36pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">163,420</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">166,294</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CASH AND CASH EQUIVALENTS AT END OF PERIOD<font style="padding-left: 3.71pt;"></font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">181,820</font></div></td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.06pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">202,821</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-49<br></div></div></div>
<!--End Page 404-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 405-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_206-finnotes_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB)</font><br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a name="tNICCFI"><!--Anchor--></a>1.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">CORPORATE INFORMATION</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Beijing Continent Pharmaceuticals Co., Ltd. (the &#8220;Company&#8221;) is a limited company registered and established in the People's Republic of China (the &#8220;PRC&#8221;) in 2002. The registered office of the Company is located at 60&#160;Shunkang Road, Shunyi District, Beijing, the PRC.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company and its subsidiary (collectively referred to as the &#8220;Group&#8221;) are principally engaged in the following activities:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">research and development of new drugs</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">manufacture and sale of the Class 1.1 new drug &#8220;ETUARY&#8221; for the treatment of idiopathic pulmonary fibrosis</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">manufacture and sale of other pharmaceutical products</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In the opinion of the directors, the immediate holding company of the Company is BJContinent Pharmaceuticals Limited, which is incorporated in Hong Kong, and the intermediate holding company of the Company is Continent Pharmaceuticals Inc., which is incorporated in the Cayman Islands, and the ultimate holding company of the Company is GNI Group Co., Ltd., which is a listed company on the Tokyo Stock Exchange since September&#160;23, 2011.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">BASIS OF PREPARATION</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The interim condensed consolidated financial information for the three months ended March&#160;31,2023 have been prepared in accordance with International Accounting Standard 34 <font style="font-style: italic;">Interim Financial Reporting</font> (&#8220;IAS 34&#8221;). The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the Group&#8217;s annual consolidated financial statements for the year ended December&#160;31, 2022.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group&#8217;s annual consolidated financial statements for the year ended December&#160;31, 2022, except for the adoption of the following revised International Financial Reporting Standards (&#8220;IFRSs&#8221;) for the first time for the current period&#8217;s financial information. </div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr><td style="width: 32.14%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendments to IAS 8</div></td><td class="gutter" style="width: 4.46%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 4.46%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 58.93%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Definition of Accounting Estimates</div></td></tr><tr><td style="width: 32.14%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Amendments to IAS 1 and IFRS Practice Statement 2</div></td><td class="gutter" style="width: 4.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 4.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 58.93%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Disclosure of Accounting Policies</div></td></tr><tr><td style="width: 32.14%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendments to IAS 12</div></td><td class="gutter" style="width: 4.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 4.46%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 58.93%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred Tax related to Assets and Liabilities arising from a Single Transaction</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 20pt; text-align: left;">The nature and impact of the revised IFRSs are described below:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The amendments to IAS 8 clarify the distinction between changes in accounting estimates, and changes in accounting policies and the correction of errors. They also clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments had no impact on the Group&#8217;s interim condensed consolidated financial statements.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The amendments to IAS 1 and IFRS Practice Statement 2 <font style="font-style: italic;">Making Materiality Judgements</font> provide guidance and examples to help entities apply materiality judgements to accounting policy disclosures. The amendments aim to help entities provide accounting policy disclosures that are more useful by replacing the requirement for entities to disclose their &#8216;significant&#8217; accounting policies with a requirement to disclose their &#8216;material&#8217; accounting policies and adding guidance on how entities apply the concept of materiality in making decisions about accounting policy disclosures. The amendments had no impact on the Group&#8217;s interim condensed consolidated financial statements, but are expected to affect the accounting policy disclosures in the Group&#8217;s annual consolidated financial statements.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-50<br></div></div></div>
<!--End Page 405-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 406-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_206-finnotes_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<font style="padding-left: 4pt;">(continued) </font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;"><font style="font-size: 10pt; font-weight: normal;">3.</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 0pt; margin-left: 20pt; text-align: left;"><font style="font-size: 10pt; font-weight: normal;">CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES</font><font style="font-size: 10pt; font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 0pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The amendments to IAS 12 <font style="font-style: italic;">Income Tax</font> narrow the scope of the initial recognition exception, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences such as leases and decommissioning liabilities. The amendments had an insignificant impact on the Group&#8217;s interim condensed consolidated financial statements. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">REVENUE </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">Revenue is analyzed as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.05%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 30.95%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the three months ended March&#160;31,</div></td></tr><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.05%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.43%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023</div></td><td class="gutter" style="width: 1.05%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.05%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.43%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td></tr><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.43%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.43%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Revenue from contracts with customers<br></div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.43%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.43%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sales of pharmaceutical products<font style="padding-left: 2.56pt;"></font></div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.43%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">168,175</font></div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.43%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">159,035</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 20pt; text-align: left;">Disaggregated revenue information is as follow:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.05%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 30.95%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the three months ended March&#160;31,</div></td></tr><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.05%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.43%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023</div></td><td class="gutter" style="width: 1.05%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.05%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.43%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td></tr><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.43%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.43%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Timing of revenue recognition<br></div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.43%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.43%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Products transferred at a point in time<font style="padding-left: 1.46pt;"></font></div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.43%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">168,175</font></div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.43%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.07pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">159,035</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">INCOME TAX </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company was designated and approved as a High and New Technology Enterprise in December 2019 and December 2022 with a validity period of 3&#160;years, respectively, and was entitled to a preferential tax rate of 15% accordingly. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the interim unaudited condensed consolidated statement of profit or loss are: </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.05%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 30.95%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the three months ended March&#160;31,</div></td></tr><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.05%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.43%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023</div></td><td class="gutter" style="width: 1.05%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.05%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.43%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td></tr><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.43%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.43%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current income tax charge in Mainland China<font style="padding-left: 3.86pt;"></font></div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.43%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.57pt; text-align: left;">12,132</div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.43%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.76pt; text-align: left;">11,353</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred income tax<font style="padding-left: 3.66pt;"></font></div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.43%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.57pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(199</font><font style="min-width: 27.5pt;">)</font></div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.43%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.76pt; text-align: left;"><font style="padding-left: 13.8pt; border-bottom: 1pt solid #000000; min-width: 27.13pt;">(37</font><font style="min-width: 27.13pt;">)</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.43%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.43%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total tax charge for the for the period<font style="padding-left: 1.79pt;"></font></div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.43%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.57pt; text-align: left;"><font style="padding-left: 0.37pt; border-bottom: 3pt double #000000; min-width: 27.5pt;">11,933</font></div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.43%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.76pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.13pt;">11,316</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">PROPERTY, PLANT AND EQUIPMENT</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">During the three months ended March 31, 2023 and 2022, the Company acquired assets with costs of RMB11,422 and RMB2,498, respectively, which were mainly categorized as construction in progress. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The carrying amounts of these projects as of March 31, 2023 and December 31, 2022 were RMB45,011 and RMB33,778, respectively.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-51<br></div></div></div>
<!--End Page 406-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 407-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_206-finnotes_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<font style="padding-left: 4pt;">(continued) </font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB)</font><br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">INVENTORIES</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.12%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 31, 2023</div></td><td class="gutter" style="width: 1.56%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.56%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2022</div></td></tr><tr class="header"><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.12%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Audited)</div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Raw materials<font style="padding-left: 4.19pt;"></font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.12%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.39pt; text-align: left;"><font style="padding-left: 5pt;">6,216</font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.16pt; text-align: left;"><font style="padding-left: 5pt;">7,354</font></div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Work in progress<font style="padding-left: 2.22pt;"></font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.12%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.39pt; text-align: left;"><font style="padding-left: 5pt;">4,596</font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.16pt; text-align: left;"><font style="padding-left: 5pt;">2,749</font></div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Semi-finished goods<font style="padding-left: 4.19pt;"></font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.12%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.39pt; text-align: left;">18,323</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.16pt; text-align: left;">22,790</div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Finished goods<font style="padding-left: 0.84pt;"></font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.12%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.39pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">10,227 </font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.16pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">9,808</font></div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.12%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.39pt; text-align: left;">39,362</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.16pt; text-align: left;">42,701</div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Provision for inventories <font style="padding-left: 3.09pt;"></font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.12%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.39pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(242</font><font style="min-width: 27.5pt;">)</font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.16pt; text-align: left;"><font style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(62</font><font style="min-width: 27.5pt;">)</font></div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.12%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.39pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">39,120</font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.16pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">42,639</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">TRADE RECEIVABLES</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.12%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2023</div></td><td class="gutter" style="width: 1.56%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.56%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2022</div></td></tr><tr class="header"><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.12%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Audited)</div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade receivables<font style="padding-left: 1.22pt;"></font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.12%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.39pt; text-align: left;">86,589</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;">109,615</div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Allowance for impairment<font style="padding-left: 4.76pt;"></font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.12%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.39pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(663</font><font style="min-width: 27.5pt;">)</font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(862</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.12%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.39pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">85,926</font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">108,753</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company&#8217;s trading terms with its customers are mainly on credit, and the credit period is usually within 3&#160;months. The Company seeks to maintain strict control over its outstanding receivables to minimize credit risk. Overdue balances are reviewed regularly by the management. Trade receivables are non-interest-bearing.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">CASH AND BANK BALANCES</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.12%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 31, 2023</div></td><td class="gutter" style="width: 1.56%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.56%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2022</div></td></tr><tr class="header"><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.12%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Audited)</div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and bank balances<font style="padding-left: 4.21pt;"></font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.12%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;">273,751</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;">214,920</div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less: Long-term bank deposits<font style="padding-left: 1.43pt;"></font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.12%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(91,931</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(51,500</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 4.77pt;"></font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.12%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">181,820</font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">163,420</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Cash at banks earns interest at floating rates based on daily bank deposit rates. The bank balances are deposited with creditworthy banks with no recent history of default.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The long-term bank deposits represented certificates of deposits issued by three different banks with due dates in 2025 and 2026. According to management&#8217;s assessment, these deposits have passed &#8220;solely payments of principal and interest test&#8221; and the Company intends to hold them till the due date, so management accounted for them as financial assets measured at amortized cost.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-52<br></div></div></div>
<!--End Page 407-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 408-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_206-finnotes_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<font style="padding-left: 4pt;">(continued) </font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB)</font><br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">OTHER PAYABLES AND ACCRUALS</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.12%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2023</div></td><td class="gutter" style="width: 1.56%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.56%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2022</div></td></tr><tr class="header"><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.12%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Audited)</div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Payroll and welfare payables<font style="padding-left: 4.22pt;"></font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.39pt; text-align: left;">31,825</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.16pt; text-align: left;"><font style="padding-left: 0.37pt;">34,911</font></div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accrued expenses<font style="padding-left: 4.21pt;"></font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 12.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.39pt; text-align: left;">19,154</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 14.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.16pt; text-align: left;"><font style="padding-left: 5pt;">1,970</font></div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other payables<font style="padding-left: 1.42pt;"></font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.39pt; text-align: left;"><font style="padding-left: 5pt;">8,775</font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.16pt; text-align: left;">22,081</div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred government grants*<font style="padding-left: 3.11pt;"></font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 12.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.39pt; text-align: left;"><font style="padding-left: 5pt;">6,329</font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 14.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.16pt; text-align: left;"><font style="padding-left: 5pt;">5,300</font></div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Others<font style="padding-left: 0.85pt;"></font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.39pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">1,558</font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.16pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">2,352</font></div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 12.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.39pt; text-align: left;">67,641</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 14.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.16pt; text-align: left;">66,614</div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less:<br></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Non-current portion of deposits from customers<font style="padding-left: 2.02pt;"></font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 12.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.39pt; text-align: left;"><font style="padding-left: 9.17pt;">(382)</font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 14.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.16pt; text-align: left;"><font style="padding-left: 9.17pt;">(380)</font></div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Non-current portion of deferred government grants<font style="padding-left: 4.26pt;"></font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.39pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(6,047</font><font style="min-width: 27.5pt;">)</font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.16pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(5,150</font><font style="min-width: 27.5pt;">)</font></div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 12.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 14.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current portion<font style="padding-left: 4.74pt;"></font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.39pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">61,212</font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.16pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">61,084</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The balance represents the government grants which were used for research and development projects and the development of the manufacturing plants in two cities in the PRC.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">SHARE OPTION SCHEME </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In February 2021, the board of directors of the Company approved the 2021 Stock Incentive Plan (the &#8220;2021 Plan&#8221;) to certain employees and consultants of the Company to purchase a total of 9,197,685 ordinary shares of the Company. The 2021 Plan has a contractual term of seven years. Share options granted under the 2021 Plan were accounted for as equity awards, and subject to service condition and certain specified performance targets. In addition, share options granted under the 2021 Plan have an exercise price of RMB9.79 per share, and will not be exercisable until the closing of an IPO and the lapse of the applicable lock-up periods after such IPO.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In December 2021, the board of directors of the Company approved to further amend the 2021 Plan, and removed the exercise condition related to the closing of an IPO. In addition, all share options granted under the 2021 Plan will generally vest over twenty months after the grant date, subject to certain specified performance targets.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">A summary of number of share options under the 2021 Plan is as follows:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 2pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 37.5%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 27.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the three months ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 31, 2023 </div></td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 27.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2022</div></td></tr><tr class="header"><td style="width: 37.5%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.28%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">share options</div></td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.78%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">exercise price <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">RMB per share</div></td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.28%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">share options</div></td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.78%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">exercise price <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">RMB per share</div></td></tr><tr class="header"><td style="width: 37.5%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.28%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.78%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.28%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Audited)</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.78%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Audited)</div></td></tr><tr><td style="width: 37.5%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Outstanding at the beginning of the period/year <font style="padding-left: 1.63pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.03pt; text-align: left;">9,195,130</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.78%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.13pt; text-align: left;">9.79</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.03pt; text-align: left;">9,197,685</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.78%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.13pt; text-align: left;">9.79</div></td></tr><tr><td style="width: 37.5%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Forfeited<font style="padding-left: 3.85pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.03pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 1pt solid #000000; min-width: 40pt;">(10,220</font><font style="min-width: 40pt;">)</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.78%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.13pt; text-align: left;">9.79</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.03pt; text-align: left;"><font style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; min-width: 40pt;">(2,555</font><font style="min-width: 40pt;">)</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.78%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.13pt; text-align: left;">9.79</div></td></tr><tr><td style="width: 37.5%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Outstanding at the end of the period/year<font style="padding-left: 4.96pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.03pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">9,184,910</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.78%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.13pt; text-align: left;">9.79</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.03pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">9,195,130</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.78%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.13pt; text-align: left;">9.79</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 20pt; text-align: left;">No share options were granted or exercised during the reporting periods. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">CAPITAL COMMITMENTS </div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.12%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2023</div></td><td class="gutter" style="width: 1.56%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.56%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2022</div></td></tr><tr class="header"><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.12%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Audited)</div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Contracted, but not provided for:<br></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Property, plant and equipment<font style="padding-left: 4.57pt;"></font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 5pt;">45,556</font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 5pt;">39,943</font></div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development<font style="padding-left: 3.1pt;"></font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">225,858</font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">206,023</font></div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt;">&#8203;</td><td style="width: 12.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">271,414</font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt;">&#8203;</td><td style="width: 14.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">245,966</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-53<br></div></div></div>
<!--End Page 408-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 409-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_206-finnotes_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<font style="padding-left: 4pt;">(continued) </font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB)</font><br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">RELATED PARTY TRANSACTIONS </div></td></tr></table><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 48.66%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Related party</div></td><td class="gutter" style="width: 1.34%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.34%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 48.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Relationship with the Company </div></td></tr><tr><td style="width: 48.66%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI Group Ltd.</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.66%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The ultimate holding company of the Company</div></td></tr><tr><td style="width: 48.66%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shanghai Genomics, Inc.</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.66%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company controlled by the ultimate holding company, GNI Group Ltd.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Company had the following transactions with related parties during the periods:</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.05%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 30.95%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the three months ended March&#160;31,</div></td></tr><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.05%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.43%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023</div></td><td class="gutter" style="width: 1.05%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.05%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.43%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td></tr><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.43%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.43%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Capitalized expenditures<br></div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.43%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.43%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Shanghai Genomics, Inc. <font style="padding-left: 1.98pt;"></font></div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.43%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.32pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.43%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.07pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">1,145</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Outstanding balances with related parties</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.12%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2023</div></td><td class="gutter" style="width: 1.56%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.56%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2022</div></td></tr><tr class="header"><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.12%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Audited)</div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Due to related parties, which are trade in nature<br></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">GNI Group Ltd. <font style="padding-left: 2.81pt;"></font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.64pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">774</font></div></td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 25.41pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">785</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">FINANCIAL INSTRUMENTS BY CATEGORY </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The carrying amounts of each of the categories of financial instruments as of March&#160;31, 2023 and December&#160;31, 2022 are as follows: </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;"><u>Financial assets</u></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 22.85%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Financial assets at fair value <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">through other comprehensive <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">income debt investments</div></td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Financial assets at <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">amortized cost</div></td></tr><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023</div></td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.64%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023</div></td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.53%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td></tr><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.74%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.64%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Audited)</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.63%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.53%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Audited)</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade receivables<font style="padding-left: 1.22pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.56pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.32pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.08pt; text-align: left;"><font style="padding-left: 5pt;">85,926</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.53%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;">108,753</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Debt investments at fair value through other comprehensive income<font style="padding-left: 4.2pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.56pt; text-align: left;">4,180</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.32pt; text-align: left;">10,597</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.08pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.53%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Financial assets included in prepayments, deposits and other receivables<font style="padding-left: 3.65pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.56pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.32pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.08pt; text-align: left;"><font style="padding-left: 10pt;">7,381</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.53%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 10pt;">6,799</font></div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and bank balances<font style="padding-left: 4.21pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.56pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.32pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.08pt; text-align: left;">181,820</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.53%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;">163,420</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Bank deposits<font style="padding-left: 0.29pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.56pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.32pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.08pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">91,931</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.53%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">51,500</font></div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.56pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">4,180</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.32pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">10,597</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.08pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">367,058</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.53%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">330,472</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;"><u>Financial liabilities</u></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.43%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.43%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 30.18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Financial liabilities at amortized cost</div></td></tr><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.43%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.43%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.37%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2023</div></td><td class="gutter" style="width: 1.43%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.43%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.95%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2022</div></td></tr><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.43%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.43%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.37%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 1.43%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.43%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.95%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Audited)</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade payables<font style="padding-left: 1.21pt;"></font></div></td><td class="gutter" style="width: 1.43%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.43%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.37%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.97pt; text-align: left;"><font style="padding-left: 5pt;">1,921</font></div></td><td class="gutter" style="width: 1.43%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.43%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.95%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.73pt; text-align: left;"><font style="padding-left: 12.5pt;">850</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Financial liabilities included in customers&#8217; deposits, other payables and accruals<font style="padding-left: 4.74pt;"></font></div></td><td class="gutter" style="width: 1.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.37%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.97pt; text-align: left;"><font style="padding-left: 5pt;">9,931</font></div></td><td class="gutter" style="width: 1.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.95%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.73pt; text-align: left;">23,246</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities<font style="padding-left: 3.64pt;"></font></div></td><td class="gutter" style="width: 1.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.37%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.97pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">4,328</font></div></td><td class="gutter" style="width: 1.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.43%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.95%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.73pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">4,992</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.43%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.43%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.37%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.97pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">16,180</font></div></td><td class="gutter" style="width: 1.43%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.43%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.95%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.73pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">29,088</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-54<br></div></div></div>
<!--End Page 409-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 410-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_206-finnotes_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<font style="padding-left: 4pt;">(continued) </font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB)</font><br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">15.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Management has assessed that the fair values of cash and cash equivalents, trade receivables, financial assets included in prepayments, deposits and other receivables, trade payables, and financial liabilities included in other payables and accruals approximate to their carrying amounts largely due to the short-term maturities of these instruments.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company&#8217;s finance department headed by the finance manager is responsible for determining the policies and procedures for the fair value measurement of financial instruments. The finance department reports directly to the chief financial officer. At each reporting date, the finance department analyses the movements in the values of financial instruments and determines the major inputs applied in the valuation. The valuation is reviewed and approved by the chief financial officer. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The fair values of the financial assets and liabilities are included at the amounts at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The following methods and assumptions were used to estimate the fair values.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The fair value of the debt investments at fair value through other comprehensive income and the long-term bank deposits has been calculated by discounting the expected future cash flows using rates currently available for instruments with similar terms, credit risk and remaining maturities. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">The following tables illustrate the fair value measurement hierarchy of the Company&#8217;s financial instruments:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">Assets measured at fair value:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of March&#160;31, 2023</div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 33.73%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair value measurement using</div></td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 8.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Quoted prices <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in active <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">markets <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level 1) </div></td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Significant <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">observable <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">inputs <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level 2) </div></td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Significant <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">unobservable <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">inputs <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level 3) </div></td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td></tr><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.81%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.63%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.63%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Debt investments at fair value through other comprehensive income<font style="padding-left: 4.2pt;"></font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.81%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.21pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.08pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">4,180</font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.08pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">4,180</font></div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.81%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2022</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 34.38%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair value measurement using</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Quoted prices <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in active <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">markets <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level 1) </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.23%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Significant <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">observable <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">inputs <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level 2) </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Significant <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">unobservable <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">inputs <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level 3) </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td></tr><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.81%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Audited)</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.23%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Audited)</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Audited)</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Audited)</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Debt investments at fair value through other comprehensive income<font style="padding-left: 4.2pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.81%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.22pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.23%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.7pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">10,597</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.8pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">10,597</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company did not have any financial liabilities measured at fair value as of March&#160;31, 2023 and December&#160;31, 2022.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">Assets for which fair values are disclosed:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of March&#160;31, 2023</div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 33.73%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair value measurement using</div></td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 8.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Quoted prices <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in active <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">markets <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level 1) </div></td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Significant <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">observable <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">inputs <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level 2) </div></td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Significant <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">unobservable <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">inputs <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level 3) </div></td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td></tr><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.81%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.63%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.63%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Unaudited)</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Bank deposits, non-current portion<font style="padding-left: 0.6pt;"></font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.81%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.21pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">91,931</font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.63%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">91,931</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-55<br></div></div></div>
<!--End Page 410-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 411-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_206-finnotes_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<font style="padding-left: 4pt;">(continued) </font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;"><font style="font-size: 10pt; font-weight: normal;">15.</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.95pt; font-weight: bold; margin-top: 0pt; margin-left: 20pt; text-align: left;"><font style="font-size: 10pt; font-weight: normal;">FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS</font><font style="font-size: 10pt; font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2022</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 34.38%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair value measurement using</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Quoted prices <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in active <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">markets <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level 1) </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.23%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Significant <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">observable <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">inputs <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level 2) </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Significant <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">unobservable <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">inputs <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level 3) </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td></tr><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.81%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Audited)</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.23%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Audited)</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Audited)</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Audited)</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Bank deposits, non-current portion<font style="padding-left: 0.6pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.81%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.22pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.23%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.7pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">51,500</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.8pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">51,500</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 20pt; text-align: left;">The Company did not have any financial liabilities disclosed at fair value as of March&#160;31, 2023 and 2022.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">During the periods, there were no transfers of fair value measurement between Level 1 and Level 2 and no transfers into or out of Level 3 for both financial assets and liabilities.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">16.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">EVENTS AFTER THE REPORTING PERIOD</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In April 2023, the shareholders of the Company approved to terminate the 2021 Plan. The Company will no longer grant any options under the 2021 Plan, and all unexercised share options previously granted under the 2021 Plan will be terminated and cancelled. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The termination will take effect upon the effective time as defined in the Business Combination Agreement entered among Catalyst Biosciences, Inc. (&#8220;Catalyst&#8221;), GNI Group Ltd. and certain of its subsidiaries, and the Company and certain of its minority shareholders on December 26, 2022, as amended on March 29, 2023. According to the Business Combination Agreement, each outstanding share option under the Company&#8217;s 2021 Plan upon termination will be replaced with options granted under the 2023 Omnibus Incentive Plan of Gyre Therapeutics, Inc., the new name of Catalyst after the business combination closes.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-56<br></div></div></div>
<!--End Page 411-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 412-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_207-fintab_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tRIRP"><!--Anchor--></a>Report of Independent Registered Public Accounting Firm</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">To the Shareholders and Board of Directors of Beijing Continent Pharmaceuticals Co., Ltd.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Opinion</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We have audited the accompanying consolidated statements of financial position of Beijing Continent Pharmaceuticals Co., Ltd. (the &#8220;Company&#8221;) as of December&#160;31, 2022 and 2021, the related consolidated statements of profit or loss and comprehensive income, changes in equity and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Basis for opinion</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (the &#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">/s/ Ernst &amp; Young Hua Ming LLP</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">We have served as the Company&#8217;s auditor since 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Beijing, the People&#8217;s Republic of China<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">March&#160;30, 2023</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-57<br></div></div></div>
<!--End Page 412-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 413-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_207-fintab_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;"><a name="tCSPL"><!--Anchor--></a>CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME For the years ended December&#160;31, 2022 and 2021<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td rowspan="2" style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" rowspan="2" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 3.32%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">Note</div></td><td class="gutter" rowspan="2" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.36%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31,</div></td></tr><tr class="header"><td class="gutter" style="width: 2.02%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 2.02%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.02%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Revenue<font style="font-weight: normal; padding-left: 4.85pt;"></font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.27pt; text-align: left;">4</div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">688,630</font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">571,038</font></div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cost of revenue<font style="padding-left: 1.53pt;"></font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(30,163</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(25,629</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gross profit<font style="font-weight: normal; padding-left: 4.1pt;"></font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">658,467</font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">545,409</font></div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income and gains<font style="padding-left: 3.76pt;"></font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.27pt; text-align: left;">5</div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">10,648</font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">5,062</font></div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Selling expenses<font style="padding-left: 3.74pt;"></font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(353,219)</div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(284,609)</div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Administrative expenses<font style="padding-left: 2.09pt;"></font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">(59,910)</font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">(23,464)</font></div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development expenses<font style="padding-left: 2.68pt;"></font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">(57,214)</font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">(46,188)</font></div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other expenses<font style="padding-left: 4.31pt;"></font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">(7,782)</font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">(6,726)</font></div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Finance costs<font style="padding-left: 1.52pt;"></font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.27pt; text-align: left;">7</div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(299</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(780</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Profit before tax<font style="font-weight: normal; padding-left: 4.67pt;"></font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.27pt; text-align: left;">6</div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">190,691</font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">188,704</font></div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income tax expense<font style="padding-left: 0.43pt;"></font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.27pt; text-align: left;">8</div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(39,657</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(39,317</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net profit<font style="font-weight: normal; padding-left: 3.93pt;"></font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">151,034</font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">149,387</font></div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other comprehensive income, net of tax<font style="padding-left: 1.85pt;"></font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total comprehensive income<font style="font-weight: normal; padding-left: 3.75pt;"></font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">151,034</font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">149,387</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these consolidated financial statements<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-58<br></div></div></div>
<!--End Page 413-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 414-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_207-fintab_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><a name="tCSFP"><!--Anchor--></a>BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">CONSOLIDATED STATEMENTS OF FINANCIAL POSITION<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2022 and 2021<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td rowspan="2" style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" rowspan="2" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 3.32%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">Note</div></td><td class="gutter" rowspan="2" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.83%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 17.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of December&#160;31,</div></td></tr><tr class="header"><td class="gutter" style="width: 1.83%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.83%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.83%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">ASSETS<br></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-current assets<br></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property, plant and equipment<font style="padding-left: 0.57pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.77pt; text-align: left;"><font style="padding-left: 5pt;">9</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">123,339</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">92,250</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Right-of-use assets<font style="padding-left: 1.31pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.77pt; text-align: left;">10</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">15,282</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">18,295</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prepayments and deposits<font style="padding-left: 2.98pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.77pt; text-align: left;">16</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">21,730</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">9,550</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Intangible assets<font style="padding-left: 1.31pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.77pt; text-align: left;"><font style="padding-left: 0.37pt;">11</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">161,249</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">132,354</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred tax assets<font style="padding-left: 0.78pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.77pt; text-align: left;">12</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">2,589</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">2,532</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Bank deposits<font style="padding-left: 1.29pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.77pt; text-align: left;">17</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">51,500</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total non-current assets<font style="font-weight: normal; padding-left: 4.09pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">375,689</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">254,981</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current assets<br></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Inventories<font style="padding-left: 3.52pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.77pt; text-align: left;">13</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">42,639</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">36,457</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade receivables<font style="padding-left: 2.22pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.77pt; text-align: left;">14</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">108,753</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">64,058</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Debt investments at fair value through other comprehensive income<font style="padding-left: 0.28pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.77pt; text-align: left;">15</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">10,597</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">2,480</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prepayments, deposits and other receivables<font style="padding-left: 3.3pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.77pt; text-align: left;">16</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">8,493</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">16,599</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and bank balances<font style="padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.77pt; text-align: left;">17</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">163,420</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">166,294</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total current assets<font style="font-weight: normal; padding-left: 3.53pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">333,902</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">285,888</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total assets<font style="font-weight: normal; padding-left: 3.88pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">709,591</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">540,869</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">LIABILITIES AND EQUITY<br></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current liabilities<br></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade payables<font style="padding-left: 2.21pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.77pt; text-align: left;">18</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">850</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">1,600</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other payables and accruals<font style="padding-left: 3.56pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.77pt; text-align: left;">19</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">61,084</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">45,586</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities<font style="padding-left: 4.64pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.77pt; text-align: left;">10</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">3,467</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">3,103</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tax payable<font style="padding-left: 4.22pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">12,668</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">15,338</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total current liabilities<font style="font-weight: normal; padding-left: 4.07pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">78,069</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">65,627</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-current liabilities<br></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Customers&#8217; deposits<font style="padding-left: 2.04pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.77pt; text-align: left;">19</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">380</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">383</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities<font style="padding-left: 4.64pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.77pt; text-align: left;">10</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">1,525</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">4,731</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred government grants<font style="padding-left: 4.11pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.77pt; text-align: left;">19</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">5,150</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">5,300</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total non-current liabilities<font style="font-weight: normal; padding-left: 4.63pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">7,055</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">10,414</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities<font style="font-weight: normal; padding-left: 4.43pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">85,124</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">76,041</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Equity<br></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share capital<font style="padding-left: 0.75pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.77pt; text-align: left;">20</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">61,318</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">61,318</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Capital reserve<font style="padding-left: 2.42pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.77pt; text-align: left;">21</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">248,660</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">240,055</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Surplus reserve<font style="padding-left: 0.75pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.77pt; text-align: left;">22</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">31,449</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">16,346</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Retained profits<font style="padding-left: 3.52pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">283,040</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">147,109</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total equity<font style="font-weight: normal; padding-left: 1.65pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">624,467</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">464,828</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities and equity<font style="font-weight: normal; padding-left: 4.99pt;"></font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">709,591</font></div></td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.83%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">540,869</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0.5pt; margin-left: 0pt; text-align: justify;"> </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these consolidated financial statements<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-59<br></div></div></div>
<!--End Page 414-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 415-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_207-fintab_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><a name="tCSCE"><!--Anchor--></a>BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195; <br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY <br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021 <br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.32%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">Note</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">capital</div></td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Capital <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">reserve</div></td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.7%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Surplus <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">reserve</div></td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Retained <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">profits</div></td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of January&#160;1, 2022<font style="font-weight: normal; padding-left: 3.53pt;"></font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">61,318</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">240,055</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.7%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.96pt; text-align: left;">16,346</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.7pt; text-align: left;">147,109</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">464,828</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Profit for the year<font style="padding-left: 3.31pt;"></font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.25pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.7%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.96pt; text-align: left;"><font style="padding-left: 15.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.7pt; text-align: left;">151,034</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">151,034</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Allocation to surplus reserve<font style="padding-left: 3.82pt;"></font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.27pt; text-align: left;">22</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.25pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.7%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.96pt; text-align: left;">15,103</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.7pt; text-align: left;"><font style="padding-left: 1.51pt;">(15,103)</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.25pt;">&#8212;</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Equity-settled share option arrangements<font style="padding-left: 4.84pt;"></font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.27pt; text-align: left;">23</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.75pt; border-bottom: 1pt solid #000000; min-width: 24.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9pt; border-bottom: 1pt solid #000000; min-width: 29.25pt;">8,605</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.7%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.96pt; text-align: left;"><font style="padding-left: 15.75pt; border-bottom: 1pt solid #000000; min-width: 24.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.7pt; text-align: left;"><font style="padding-left: 20.25pt; border-bottom: 1pt solid #000000; min-width: 29.25pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9pt; border-bottom: 1pt solid #000000; min-width: 29.25pt;">8,605</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2022<font style="font-weight: normal; padding-left: 2.23pt;"></font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 24.75pt;">61,318</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 29.25pt;">248,660</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.7%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.96pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 24.75pt;">31,449</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.7pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 29.25pt;">283,040</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 29.25pt;">624,467 </font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of January&#160;1, 2021<font style="font-weight: normal; padding-left: 3.53pt;"></font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">61,318</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">241,860</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.7%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.96pt; text-align: left;"><font style="padding-left: 4.5pt;">1,407</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.7pt; text-align: left;"><font style="padding-left: 4.5pt;">12,661</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">317,246</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Profit for the year<font style="padding-left: 3.31pt;"></font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.25pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.7%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.96pt; text-align: left;"><font style="padding-left: 15.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.7pt; text-align: left;">149,387</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">149,387</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Allocation to surplus reserve<font style="padding-left: 3.82pt;"></font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.27pt; text-align: left;">22</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.25pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.7%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.96pt; text-align: left;">14,939</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.7pt; text-align: left;"><font style="padding-left: 1.51pt;">(14,939)</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.25pt;">&#8212;</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Equity-settled share option arrangements<font style="padding-left: 4.84pt;"></font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.27pt; text-align: left;">23</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.75pt; border-bottom: 1pt solid #000000; min-width: 24.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.01pt; border-bottom: 1pt solid #000000; min-width: 29.25pt;">(1,805</font><font style="min-width: 29.25pt;">)</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.7%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.96pt; text-align: left;"><font style="padding-left: 15.75pt; border-bottom: 1pt solid #000000; min-width: 24.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.7pt; text-align: left;"><font style="padding-left: 20.25pt; border-bottom: 1pt solid #000000; min-width: 29.25pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.01pt; border-bottom: 1pt solid #000000; min-width: 29.25pt;">(1,805</font><font style="min-width: 29.25pt;">)</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2021<font style="font-weight: normal; padding-left: 2.23pt;"></font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 24.75pt;">61,318</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 29.25pt;">240,055</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.7%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.96pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 24.75pt;">16,346</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.7pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 29.25pt;">147,109</font></div></td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 29.25pt;">464,828</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these consolidated financial statements<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-60<br></div></div></div>
<!--End Page 415-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 416-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_207-fintab_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><a name="tCSCF"><!--Anchor--></a>BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">CONSOLIDATED STATEMENTS OF CASH FLOWS <br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December&#160;31, 2022 and 2021<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td rowspan="2" style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" rowspan="2" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 3.32%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">Note</div></td><td class="gutter" rowspan="2" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.57%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31,</div></td></tr><tr class="header"><td class="gutter" style="width: 2.57%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 2.57%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.57%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">CASH FLOWS FROM OPERATING ACTIVITIES<br></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Profit before tax<font style="padding-left: 2.31pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt;">190,691</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">188,704</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Finance costs<font style="padding-left: 4.52pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.78pt; text-align: left;"><font style="padding-left: 5pt;">7</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt;">299</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">780</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest income<font style="padding-left: 1.75pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">(1,198)</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Investment income<font style="padding-left: 2.3pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.67pt;">(1,528)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss (gain) on disposal of property, plant and equipment<font style="padding-left: 1.62pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.78pt; text-align: left;"><font style="padding-left: 5pt;">6</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt;">24</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 14.17pt;">(140)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation of property, plant and equipment<font style="padding-left: 0.49pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.78pt; text-align: left;"><font style="padding-left: 5pt;">6</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.33pt;">6,130</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">5,759</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation of right-of-use assets<font style="padding-left: 4.02pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.78pt; text-align: left;"><font style="padding-left: 5pt;">6</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.33pt;">3,388</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">3,245</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amortization of intangible assets<font style="padding-left: 4.55pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.78pt; text-align: left;"><font style="padding-left: 5pt;">6</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.33pt;">3,232</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">3,286</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recognition (reversal) of equity-settled share option expenses<font style="padding-left: 1.83pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.78pt; text-align: left;">23</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.33pt;">8,605</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.67pt;">(1,805)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(Reversal) provision for inventories<font style="padding-left: 4.01pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.78pt; text-align: left;"><font style="padding-left: 5pt;">6</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">(271)</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">292</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Provision for the impairment of trade receivables<font style="padding-left: 2.92pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.78pt; text-align: left;"><font style="padding-left: 5pt;">6</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt;">416</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">263</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amortization of deferred government grants<font style="padding-left: 4.02pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.78pt; text-align: left;"><font style="padding-left: 5pt;">6</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(150</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(150</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.7pt;">211,166</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">198,706</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Increase in inventories<font style="padding-left: 2.32pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10.37pt;">(5,911)</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.67pt;">(15,433)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Increase in trade receivables<font style="padding-left: 3.46pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">(53,228)</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.67pt;">(12,470)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Decrease (increase) in deposits and other receivables<font style="padding-left: 2.96pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.7pt;">8,116</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.67pt;">(6,796)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Decrease in trade payables<font style="padding-left: 0.12pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">(750)</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 14.17pt;">(222)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Increase in other payables and accruals<font style="padding-left: 4.04pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.7pt;">11,812</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">1,818</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Decrease in deferred government grants<font style="padding-left: 1.26pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(1,003</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash generated from operations<font style="padding-left: 4.56pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt;">171,205</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">164,600</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income tax paid<font style="padding-left: 3.41pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(42,384</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(32,300</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash generated from operating activities<font style="padding-left: 3.47pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">128,821</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">132,300</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">CASH FLOWS FROM INVESTING ACTIVITIES<br></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Investment income received<font style="padding-left: 0.1pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">1,528</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Purchase of property, plant and equipment<font style="padding-left: 1.05pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">(34,385)</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.67pt;">(7,160)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proceeds from disposal of property, plant and equipment<font style="padding-left: 2.18pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">140</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additions to intangible assets<font style="padding-left: 3.98pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">(43,492)</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.67pt;">(46,717)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Purchase of long-term bank deposits<font style="padding-left: 0.11pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(50,302</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash used in investing activities<font style="padding-left: 1.78pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(128,179)</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.67pt;">(52,209)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">CASH FLOWS FROM FINANCING ACTIVITIES<br></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Repayment of bank loans<font style="padding-left: 0.09pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.67pt;">(39,900)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Principal portion of lease payments<font style="padding-left: 4.55pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">(3,217)</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.67pt;">(2,825)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest paid on lease liabilities<font style="padding-left: 1.78pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">(299)</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 14.17pt;">(430)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest paid on bank loans<font style="padding-left: 3.43pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(350</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash used in financing activities<font style="padding-left: 0.68pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(3,516</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(43,505</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS<font style="font-weight: normal; padding-left: 3.02pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">(2,874)</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">36,586</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents at beginning of year<font style="padding-left: 0.69pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">166,294</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">129,708</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CASH AND CASH EQUIVALENTS AT END OF YEAR<font style="padding-left: 1.96pt;"></font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">163,420</font></div></td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.57%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">166,294</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these consolidated financial statements<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-61<br></div></div></div>
<!--End Page 416-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 417-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December&#160;31, 2022 and 2021<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a name="tNCFS"><!--Anchor--></a>1.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">CORPORATE INFORMATION</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Beijing Continent Pharmaceuticals Co., Ltd. (the &#8220;Company&#8221;) is a limited company registered and established in the People's Republic of China (the &#8220;PRC&#8221;) in 2002. The registered office of the Company is located at 60&#160;Shunkang Road, Shunyi District, Beijing, the PRC.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">The Company is a pharmaceutical company principally engaged in the following activities:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">research and development of new drugs</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">manufacture and sale of the Class 1.1 new drug &#8220;ETUARY&#8221; for the treatment of idiopathic pulmonary fibrosis</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">manufacture and sale of other pharmaceutical products</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In the opinion of the directors, the immediate holding company of the Company is BJContinent Pharmaceuticals Limited, which is incorporated in Hong Kong, and the intermediate holding company of the Company is Continent Pharmaceuticals Inc., which is incorporated in the Cayman Islands, and the ultimate holding company of the Company is GNI Group Co., Ltd., which is a listed company on the Tokyo Stock Exchange since September&#160;23, 2011.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.1<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">BASIS OF PREPARATION</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">These financial statements have been prepared in accordance with International Financial Reporting Standards (&#8220;IFRSs&#8221;), which comprise all standards and interpretations approved by the International Accounting Standards Board (the &#8220;IASB&#8221;). </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">These financial statements have been prepared under the historical cost convention, except for debt investments at fair value through other comprehensive income which have been measured at fair value.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The preparation of these financial statements in conformity with IFRSs requires the use of certain critical accounting estimates. It also requires the directors of the Company to exercise judgment in the process of applying the Company&#8217;s accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to these financial statements are disclosed in note 3 to the consolidated financial statements.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.2<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company has adopted the following revised IFRSs, for the first time for the reporting periods&#8217; financial statements. The adoption of these revised IFRSs did not have any material impact on the financial position and financial performance of the Company.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The revised IFRSs which were effective for annual periods beginning on or after January&#160;1, 2021 (unless&#160;otherwise stated) are as follows:</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr><td style="width: 32.14%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 65.18%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest Rate Benchmark Reform &#8211; Phase 2</div></td></tr><tr><td style="width: 32.14%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendments to IFRS 16</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 65.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Covid-19-Related Rent Concessions beyond June&#160;30, 2021 (early&#160;adopted)</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The revised IFRSs which were effective for annual periods beginning on or after January&#160;1, 2022 (unless&#160;otherwise stated) are as follows:</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr><td style="width: 32.14%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendments to IFRS 3</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 65.18%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Reference to the Conceptual Framework</div></td></tr><tr><td style="width: 32.14%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendments to IAS 16</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 65.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property, Plant and Equipment: Proceeds before Intended Use</div></td></tr><tr><td style="width: 32.14%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendments to IAS 37</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 65.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Onerous Contracts &#8211; Cost of Fulfilling a Contract</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-62<br></div></div></div>
<!--End Page 417-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 418-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.3<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">ISSUED BUT NOT YET EFFECTIVE INTERNATIONAL FINANCIAL REPORTING STANDARDS</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company has not applied the following new and revised IFRSs, that have been issued but are not yet effective, in the financial statements.</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr><td style="width: 32.14%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Amendments to IFRS 10 and IAS&#160;28</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 65.18%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sale or Contribution of Assets between an Investor and its Associate or Joint Venture<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup></div></td></tr><tr><td style="width: 32.14%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">IFRS 17</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 65.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Insurance Contracts<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup></div></td></tr><tr><td style="width: 32.14%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendments to IFRS 17</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 65.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Insurance Contracts<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1, 3</sup></div></td></tr><tr><td style="width: 32.14%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendments to IAS 1</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 65.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Classification of Liabilities as Current or Non-current (the &#8220;2020 Amendments&#8221;)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4,5</sup></div></td></tr><tr><td style="width: 32.14%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendments to IAS 1</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 65.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-current Liabilities with Covenants (the &#8220;2022 Amendments&#8221;)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4</sup></div></td></tr><tr><td style="width: 32.14%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendments to IAS8</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 65.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Definition of Accounting Estimates<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup> </div></td></tr><tr><td style="width: 32.14%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Amendments to IAS 1 and IFRS Practice Statement 2</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 65.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Disclosure of Accounting Policies<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup></div></td></tr><tr><td style="width: 32.14%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendments to IAS 12</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 65.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred Tax related to Assets and Liabilities arising from a Single Transaction<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup></div></td></tr><tr><td style="width: 32.14%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendments to IFRS 16</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 65.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease Liability in a Sale and Leaseback<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4</sup></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;"><font style="position: relative; top: -3.25pt;">1</font><br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 8pt;">Effective for annual periods beginning on or after January&#160;1, 2023.</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;"><font style="position: relative; top: -3.25pt;">2</font><br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 8pt;">No mandatory effective date yet determined but available for adoption.</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;"><font style="position: relative; top: -3.25pt;">3</font><br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: justify;"><font style="font-size: 8pt;">As a consequence of the amendments to IFRS 17 issued in June 2020, IFRS 4 was amended to extend the temporary exemption that </font><font style="font-size: 8pt;">permits insurers to apply IAS 39 rather than IFRS 9 for annual periods beginning before January&#160;1, 2023.</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;"><font style="position: relative; top: -3.25pt;">4</font><br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 8pt;">Effective for annual periods beginning on or after January&#160;1, 2024.</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;"><font style="position: relative; top: -3.25pt;">5</font><br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: justify;"><font style="font-size: 8pt;">As a consequence of the 2022 Amendments, the effective date of the 2020 Amendments was deferred to annual periods beginning </font><font style="font-size: 8pt;">on or after January&#160;1, 2024.</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company is in the process of assessing the impact of these new and revised IFRSs upon initial application and has concluded that the adoption of them will not have a material impact on the Company&#8217;s financial position and financial performance.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.4<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</div></td></tr></table><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 20pt; text-align: left;"><u>Fair value measurement</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company measures its debt investments at fair value through other comprehensive income at fair value at the end of each reporting period. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either in the principal market for the asset or liability, or in the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible by the Company. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">A fair value measurement of a non-financial asset takes into account a market participant&#8217;s ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-63<br></div></div></div>
<!--End Page 418-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 419-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">2.4</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: justify;">All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 45pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Level 1 &#8211;<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">based on quoted prices (unadjusted) in active markets for identical assets or liabilities</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 45pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Level 2 &#8211;<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">based on valuation techniques for which the lowest level input that is significant to the fair value measurement is observable, either directly or indirectly</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 45pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Level 3 &#8211;<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">based on valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">For assets and liabilities that are recognized in the financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by reassessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 20.5pt; margin-left: 20pt; text-align: left;"><u>Property, plant and equipment and depreciation</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Property, plant and equipment, other than construction in progress, are stated at cost less accumulated depreciation and any impairment losses. The cost of an item of property, plant and equipment comprises its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Expenditure incurred after items of property, plant and equipment that have been put into operation, such as repairs and maintenance, is normally charged to profit or loss in the period in which it is incurred. In situations where the recognition criteria are satisfied, the expenditure for a major inspection is capitalized in the carrying amount of the asset as a replacement. Where significant parts of property, plant and equipment are required to be replaced at intervals, the Company recognizes such parts as individual assets with specific useful lives and depreciates them accordingly.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows: </div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr><td style="width: 40.18%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Buildings</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 57.14%; text-align: right; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">20 to 30&#160;years</div></td></tr><tr><td style="width: 40.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Leasehold improvement</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 57.14%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">4 to 5&#160;years</div></td></tr><tr><td style="width: 40.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Machinery and electronic devices</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 57.14%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">3 to 10&#160;years</div></td></tr><tr><td style="width: 40.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Furniture and fixtures</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 57.14%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">3 to 5&#160;years</div></td></tr><tr><td style="width: 40.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Motor vehicles</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 57.14%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">3 to 5&#160;years</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Where parts of an item of property, plant and equipment have different useful lives, the cost of that item is allocated on a reasonable basis among the parts and each part is depreciated separately. Residual values, useful lives and the depreciation method are reviewed, and adjusted if appropriate, at least annually.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">An item of property, plant and equipment including any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. The difference between the net sales proceeds and the carrying amount of the asset is recorded as gain or loss in profit or loss in the year the relevant asset is derecognized.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Construction in progress represents a building under construction or machinery not yet put into operation, which is stated at cost less any impairment losses, and is not depreciated. Cost comprises the direct costs of construction and machinery and capitalized borrowing costs on related borrowed funds during the period of construction. Construction in progress is reclassified to the appropriate category of property, plant and equipment when completed and ready for use.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-64<br></div></div></div>
<!--End Page 419-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 420-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">2.4</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;"><u>Research and development expenses</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 20pt; text-align: left;">All research expenses are charged to profit or loss as incurred.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Expenditure incurred on projects to develop new products is capitalized under the category of &#8220;Product development in progress&#8221; and deferred only when the Company can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the project and the ability to measure reliably the expenditure during the development. Product development expenditure which does not meet these criteria is expensed when incurred. Expenditure is capitalized before the completion of the product development activities. Product development in progress is included in intangible assets on the consolidated statements of financial position, and stated at cost less any impairment losses. Upon the commencement of the commercial production of a product, the expenditure on development activities is transferred to &#8220;technological know-how&#8221;.</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 20.5pt; margin-left: 20pt; text-align: left;"><u>Intangible assets (other than goodwill)</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 20pt; text-align: left;">Intangible assets acquired separately are measured on initial recognition at cost.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The useful lives of intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives are subsequently amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are reviewed at least annually.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">Patents and technological know-how</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Patents and technological know-how that have finite useful lives are stated at cost less any impairment losses and are amortized on the straight-line basis over their estimated useful life of 10 to 20&#160;years.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">Computer software</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Purchased computer software is stated at cost less any impairment losses and is amortized on the straight-line basis over its estimated useful life of 2 to 3&#160;years.</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 20.5pt; margin-left: 20pt; text-align: left;"><u>Leases</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company assesses at contract inception whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-65<br></div></div></div>
<!--End Page 420-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 421-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">2.4</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;">Company as a lessee</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Company recognizes lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Right-of-use assets</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-align: justify;">Right-of-use assets are recognized at the commencement date of the lease (that is the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and any impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Right-of-use assets are depreciated on a straight-line basis over the shorter of the lease terms and the estimated useful lives of the assets as follows:</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 428pt; margin-left: 40pt;"><tr><td style="width: 56.07%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Leasehold land</div></td><td class="gutter" style="width: 15.09%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 15.09%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.75%; text-align: right; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">35 to 50&#160;years</div></td></tr><tr><td style="width: 56.07%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Buildings</div></td><td class="gutter" style="width: 15.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 15.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.75%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">2 to 5&#160;years</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-align: justify;">If ownership of the leased asset transfers to the Company by the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the asset.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Lease liabilities </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-align: justify;">Lease liabilities are recognized at the commencement date of the lease at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for termination of a lease, if the lease term reflects the Company exercising the option to terminate the lease. The variable lease payments that do not depend on an index or a rate are recognized as an expense in the period in which the event or condition that triggers the payment occurs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-align: justify;">In calculating the present value of lease payments, the Company uses its incremental borrowing rate at the lease commencement date because the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in lease payments (e.g., a change to future lease payments resulting from a change in an index or rate) or a change in assessment of an option to purchase the underlying asset.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Short-term leases </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-align: justify;">The Company applies the short-term lease recognition exemption to its short-term leases of buildings (that&#160;is those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). Lease payments on short-term leases are recognized as an expense on a straight-line basis over the lease term.</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 16.5pt; margin-left: 20pt; text-align: left;"><u>Financial assets</u></div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16pt; margin-left: 20pt; text-align: left;">Initial recognition and measurement</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Financial assets are classified, at initial recognition, as subsequently measured at amortized cost, fair value through other comprehensive income, and fair value through profit or loss.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-66<br></div></div></div>
<!--End Page 421-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 422-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">2.4</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: justify;">The classification of financial assets at initial recognition depends on the financial asset&#8217;s contractual cash flow characteristics and the Company&#8217;s business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient of not adjusting the effect of a significant financing component, the Company initially measures a financial asset at its fair value plus in the case of a financial asset not at fair value through profit or loss, transaction costs. Trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient are measured at the transaction price determined under IFRS 15 in accordance with the policies set out for &#8220;Revenue from contracts with customers&#8221; below.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In order for a financial asset to be classified and measured at amortized cost or fair value through other comprehensive income, it needs to give rise to cash flows that are solely payments of principal and interest (&#8220;SPPI&#8221;) on the principal amount outstanding.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company&#8217;s business model for managing financial assets refers to how it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting contractual cash flows, selling the financial assets, or both. Financial assets classified and measured at amortized cost are held within a business model with the objective to hold financial assets in order to collect contractual cash flows, while financial assets classified and measured at fair value through other comprehensive income are held within a business model with the objective of both holding to collect contractual cash flows and selling the financial assets. Financial assets which are not held within the aforementioned business models are classified and measured at fair value through profit or loss.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">All regular way purchases and sales of financial assets are recognized on the trade date, that is, the date that the Company commits to purchase or sell the asset. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the period generally established by regulation or convention in the marketplace.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">Subsequent measurement</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 20pt; text-align: left;">The subsequent measurement of financial assets depends on their classification as follows:</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">Financial assets at amortized cost (debt instruments)</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Financial assets at amortized cost are subsequently measured using the effective interest method and are subject to impairment. Gains and losses are recognized in profit or loss when the asset is derecognized, modified or impaired.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">Financial assets at fair value through other comprehensive income (debt instruments)</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">For debt investments at fair value through other comprehensive income, interest income, foreign exchange revaluation and impairment losses or reversals are recognized in profit or loss and computed in the same manner as for financial assets measured at amortized cost. The remaining fair value changes are recognized in other comprehensive income. Upon derecognition, the cumulative fair value change recognized in other comprehensive income is recycled to profit or loss.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">Financial assets at fair value through profit or loss</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Financial assets at fair value through profit or loss are carried in the consolidated statements of financial position at fair value with net changes in fair value recognized in profit or loss.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-67<br></div></div></div>
<!--End Page 422-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 423-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">2.4</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;"><u>Derecognition of financial assets</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Company&#8217;s consolidated statements of financial position) when:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The rights to receive cash flows from the asset have expired; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a &#8220;pass-through&#8221; arrangement&#894; and either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, the Company evaluates if, and to what extent, it has retained the risks and rewards of ownership. When the Company has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognize the transferred asset to the extent of its continuing involvement. In that case, the Company also recognizes an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Company could be required to repay.</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 12pt; margin-left: 20pt; text-align: left;"><u>Impairment of financial assets</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company recognizes an allowance for expected credit losses (&#8220;ECLs&#8221;) for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">ECLs are recognized in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12 months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">At the end of each reporting period, the Company assesses whether the credit risk on a financial instrument has increased significantly since initial recognition. When making the assessment, the Company compares the risk of a default occurring on the financial instrument as at the end of each reporting period with the risk of a default occurring on the financial instrument as at the date of initial recognition and considers reasonable and supportable information that is available without undue cost or effort, including historical and forward-looking information. The Company considers that there has been a significant increase in credit risk when contractual payments are more than 90 days past due.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">For debt investments at fair value through other comprehensive income, the Company applies the low credit risk simplification. At each reporting date, the Company evaluates whether the debt investments are considered to have low credit risk using all reasonable and supportable information that is available without undue cost or effort. In making that evaluation, the Company reassesses the external credit ratings of the debt investments. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company considers a financial asset in default when contractual payments are 3 months past due. However, in certain cases, the Company may also consider a financial asset to be in default when internal or external </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-68<br></div></div></div>
<!--End Page 423-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 424-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">2.4</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: justify;">information indicates that the Company is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Company. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Debt investments at fair value through other comprehensive income and financial assets at amortized cost are subject to impairment under the general approach and they are classified within the following stages for measurement of ECLs except for trade receivables which apply the simplified approach as detailed below.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Stage 1 &#8211; Financial instruments for which credit risk has not increased significantly since initial recognition and for which the loss allowance is measured at an amount equal to 12-month ECLs</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Stage 2 &#8211; Financial instruments for which credit risk has increased significantly since initial recognition but that are not credit-impaired financial assets and for which the loss allowance is measured at an amount equal to lifetime ECLs</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Stage 3 &#8211; Financial assets that are credit-impaired at the reporting date (but that are not purchased or originated credit-impaired) and for which the loss allowance is measured at an amount equal to lifetime ECLs.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;">Simplified approach</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">For trade receivables that do not contain a significant financing component or when the Company applies the practical expedient of not adjusting the effect of a significant financing component, the Company applies the simplified approach in calculating ECLs. Under the simplified approach, the Company does not track changes in credit risk, but instead recognizes a loss allowance based on lifetime ECLs at the end of each reporting period. The Company has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment.</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 12pt; margin-left: 20pt; text-align: left;"><u>Financial liabilities</u></div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;">Initial recognition and measurement </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">Financial liabilities are classified, at initial recognition, as loans and borrowings, or payables.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">All financial liabilities are recognized initially at fair value net of directly attributable transaction costs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company&#8217;s financial liabilities include trade payables, financial liabilities included in customers&#8217; deposits, other payables and accruals, and amounts due to related parties.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;">Subsequent measurement </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">The subsequent measurement of the Company&#8217;s financial liabilities is described below:</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;">Loans and borrowings</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortized cost, using the effective interest rate method unless the effect of discounting would be immaterial, in which case they are stated at cost. Gains and losses are recognized in profit or loss when the liabilities are derecognized as well as through the effective interest rate amortization process.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. The effective interest rate amortization is included in finance costs in the consolidated statements of profit or loss and comprehensive income.</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 12pt; margin-left: 20pt; text-align: left;"><u>Derecognition of financial liabilities</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-69<br></div></div></div>
<!--End Page 424-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 425-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">2.4</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: justify;">or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a derecognition of the original liability and a recognition of a new liability. The difference between the respective carrying amounts is recognized in profit or loss.</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 16pt; margin-left: 20pt; text-align: left;"><u>Inventories</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Inventories comprise raw materials, work in progress, semi-finished goods and finished goods and are stated at the lower of cost and net realizable value. Cost is determined on the first-in, first-out basis and, in the case of work in progress, semi-finished goods and finished goods, comprises direct materials, direct labor and an appropriate proportion of overheads. Net realizable value is based on estimated selling prices less any estimated costs to be incurred to completion and disposal.</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 16pt; margin-left: 20pt; text-align: left;"><u>Cash and cash equivalents</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">For the purpose of the consolidated statements of cash flows, cash and cash equivalents comprise cash on hand and demand deposits, and short term highly liquid investments that are readily convertible into known amounts of cash, are subject to an insignificant risk of changes in value, and have a short maturity of generally within three months when acquired, and form an integral part of the Company&#8217;s cash management.</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 16pt; margin-left: 20pt; text-align: left;"><u>Provisions</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">A provision is recognized when a present obligation (legal or constructive) has arisen as a result of a past event and it is probable that a future outflow of resources will be required to settle the obligation, provided that a reliable estimate can be made of the amount of the obligation. Provisions are related to sales and distribution, research and development, and professional service expenses. Amounts of provisions are estimated according to contracts with suppliers.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">When the effect of discounting is material, the amount recognized for a provision is the present value at the end of the reporting period of the future expenditures expected to be required to settle the obligation. The increase in the discounted present value amount arising from the passage of time is included in finance costs in profit or loss.</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 16pt; margin-left: 20pt; text-align: left;"><u>Income tax</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Income tax comprises current and deferred tax. Income tax relating to items recognized outside profit or loss is recognized either in other comprehensive income or directly in equity.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Current tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period, taking into consideration interpretations and practices prevailing in the countries in which the Company operates.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Deferred tax is provided, using the liability method, on all temporary differences at the end of the reporting period between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">Deferred tax liabilities are recognized for all taxable temporary differences, except:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">when the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">in respect of taxable temporary differences associated with investments in subsidiaries, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-70<br></div></div></div>
<!--End Page 425-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 426-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">2.4</font><br></div><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: justify;">Deferred tax assets are recognized for all deductible temporary differences, the carryforward of unused tax credits and any unused tax losses. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carryforward of unused tax credits and unused tax losses can be utilized, except:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">when the deferred tax asset relating to the deductible temporary differences arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">in respect of deductible temporary differences associated with investments in subsidiaries, deferred tax assets are only recognized to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are reassessed at the end of each reporting period and are recognized to the extent that it has become probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be recovered.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Deferred tax assets and deferred tax liabilities are offset if and only if the Company has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred taxes assets and deferred tax liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities which intend either to settle current tax liabilities and assets on a net basis, or to realize the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 20pt; margin-left: 20pt; text-align: left;"><u>Government grants</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Government grants are recognized at their fair value where there is reasonable assurance that the grant will be received and all attaching conditions will be complied with. When the grant relates to an expense item, it is recognized as income on a systematic basis over the periods that the costs, for which it is intended to compensate, are expensed.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Where the grant relates to an asset, the fair value is credited to a deferred income account and is released to profit or loss over the expected useful life of the relevant asset by equal annual instalments or deducted from the carrying amount of the asset and released to profit or loss by way of a reduced depreciation charge.</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 20pt; margin-left: 20pt; text-align: left;"><u>Impairment of non-financial assets</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Where an indication of impairment exists, or when annual impairment testing for an asset is required (other than inventories, deferred tax assets and financial assets), the asset&#8217;s recoverable amount is estimated. An asset&#8217;s recoverable amount is the higher of the asset&#8217;s or cash-generating unit&#8217;s value in use and its fair value less costs of disposal, and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets, in which case the recoverable amount is determined for the cash-generating unit to which the asset belongs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">An impairment loss is recognized only if the carrying amount of an asset exceeds its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-71<br></div></div></div>
<!--End Page 426-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 427-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">2.4</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: justify;">discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. An impairment loss is charged to profit or loss in the period in which it arises in those expense categories consistent with the function of the impaired asset.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">An assessment is made at the end of each reporting period as to whether there is an indication that previously recognized impairment losses may no longer exist or may have decreased. If such an indication exists, the recoverable amount is estimated. A previously recognized impairment loss of an asset other than goodwill is reversed only if there has been a change in the estimates used to determine the recoverable amount of that asset, but not to an amount higher than the carrying amount that would have been determined (net of any depreciation/amortization) had no impairment loss been recognized for the asset in prior years. A reversal of such an impairment loss is credited to profit or loss in the period in which it arises.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company determines whether product development in progress is impaired at least on an annual basis. This requires an estimation of the value in use of the cash-generating units to which the product development in progress is allocated. Estimating the value in use requires the Company to make an estimate of the expected future cash flows from the cash-generating units and also to choose a suitable discount rate in order to calculate the present value of those cash flows.</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 20.5pt; margin-left: 20pt; text-align: left;"><u>Related parties</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 20pt; text-align: left;">A party is considered to be related to the Company if:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">(a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; text-align: left;">the party is a person or a close member of that person&#8217;s family and that person</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">has control or joint control over the Company; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">has significant influence over the Company; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">is a member of the key management personnel of the Company or of a parent of the Company;</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">or </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">(b)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; text-align: left;">the party is an entity where any of the following conditions applies<font style="font-style: normal;">:</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the entity and the Company are members of the same group;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">one entity is an associate or joint venture of the other entity (or of a parent, subsidiary or fellow subsidiary of the other entity);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the entity and the Company are joint ventures of the same third party;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iv)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">one entity is a joint venture of a third entity and the other entity is an associate of the third entity;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(v)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the entity is a post-employment benefit plan for the benefit of employees of either the Company or an entity related to the Company; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(vi)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the entity is controlled or jointly controlled by a person identified in (a);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(vii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">a person identified in (a)(i)&#160;has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity); and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(viii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the entity, or any member of a group of which it is a part, provides key management personnel services to the Company or to the parent of the Company.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-72<br></div></div></div>
<!--End Page 427-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 428-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">2.4</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;"><u>Revenue recognition</u> </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;">Revenue from contracts with customers</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Revenue from contracts with customers is recognized when control of goods or services is transferred to the customers at an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">When the consideration in a contract includes a variable amount, the amount of consideration is estimated to which the Company will be entitled in exchange for transferring the products to the customer. Variable consideration is estimated at contract inception and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with the variable consideration is subsequently resolved.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Sale of pharmaceutical products </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Revenue from the sale of pharmaceutical products is recognized at the point in time when control of the asset is transferred to the customer, generally on completion of delivery of the pharmaceutical products and quality inspection by the customer.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">For contracts which provide a customer with a right to return defective products within a specified period, the expected value method is used to estimate the products that will not be returned because this method best predicts the amount of variable consideration to which the Company will be entitled. The requirements in IFRS 15 on constraining estimates of variable consideration are applied in order to determine the amount of variable consideration that can be included in the transaction price.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">According to the sales contract between the Company and customers, the Company gives the customers certain sales rebates. Payments to the customers are not in exchange for any distinct good or service. The Company accounts for such payments as consideration payable to a customer and deducts the amount from revenue from the customers.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">To estimate the variable consideration for the expected future rebates, the most likely amount method is used for contracts with a single-volume threshold and the expected value method for contracts with more than one volume threshold. The selected method that best predicts the amount of variable consideration is primarily driven by the number of volume thresholds contained in the contract. The requirements on constraining estimates of variable consideration are applied and the expected future rebates are deducted from the trade receivables from the customers.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">License of intellectual property</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Revenue from license is recognized when the control of the right to use of the license is transferred to the customer. Milestone payments, which are included in the transaction price to the extent that it is highly probable that a significant reversal of accumulative revenue recognized will not occur, represent a form of variable consideration when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered highly probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the control of the Company, such as regulatory approvals, are not considered highly probable of being achieved until those approvals are received. </div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 12pt; margin-left: 20pt; text-align: left;"><u>Interest income</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Interest income is recognized on an accrual basis using the effective interest method by applying the rate that exactly discounts the estimated future cash receipts over the expected life of the financial instrument or a shorter period, when appropriate, to the net carrying amount of the financial asset.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-73<br></div></div></div>
<!--End Page 428-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 429-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">2.4</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;"><u>Contract liabilities</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">A contract liability is recognized when a payment is received or a payment is due (whichever is earlier) from a customer before the Company transfers the related goods or services. Contract liabilities are recognized as revenue when the Company performs under the contract (i.e., transfers control of the related goods or services to the customer).</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 20.5pt; margin-left: 20pt; text-align: left;"><u>Share-based payments</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company operates a share option scheme for the purpose of providing incentives and rewards to eligible participants who contribute to the success of the Company's operations. Employees (including directors) of the Company receive remuneration in the form of share-based payments, whereby employees render services in exchange for equity instruments (&#8220;equity-settled transactions&#8221;).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The cost of equity-settled transactions with employees is measured by reference to the fair value at the date at which they are granted. The fair value is determined by an external valuer using a binomial model, further details of which are given in note 23 to the consolidated financial statements.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The cost of equity-settled transactions is recognized in employee benefit expense, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled. The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects the extent to which the vesting period has expired and the Company's best estimate of the number of equity instruments that will ultimately vest. The charge or credit to profit or loss for a period represents the movement in the cumulative expense recognized as at the beginning and end of that period. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Service and non-market performance conditions are not taken into account when determining the grant date fair value of awards, but the likelihood of the conditions being met is assessed as part of the Company&#8217;s best estimate of the number of equity instruments that will ultimately vest. Market performance conditions are reflected within the grant date fair value. Any other conditions attached to an award, but without an associated service requirement, are considered to be non-vesting conditions. Non-vesting conditions are reflected in the fair value of an award and lead to an immediate expensing of an award unless there are also service and/or performance conditions. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">For awards that do not ultimately vest because non-market performance and/or service conditions have not been met, no expense is recognized. Where awards include a market or non-vesting condition, the transactions are treated as vesting irrespective of whether the market or non-vesting condition is satisfied, provided that all other performance and/or service conditions are satisfied.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Where the terms of an equity-settled award are modified, a minimum expense is recognized as if the terms had not been modified, if the original terms of the award are met. In addition, an expense is recognized for any modification that increases the total fair value of the share-based payments, or is otherwise beneficial to the employee as measured at the date of modification. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Where an equity-settled award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognized for the award is recognized immediately. This includes any award where non-vesting conditions within the control of either the Company or the employee are not met. However, if a new award is substituted for the cancelled award, and is designated as a replacement award on the date that it is granted, the cancelled and new awards are treated as if they were a modification of the original award, as described in the previous paragraph.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-74<br></div></div></div>
<!--End Page 429-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 430-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">2.4</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;"><u>Employee benefits</u> </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 20pt; text-align: left;">PRC contribution plan</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The employees of the Company which operates in Mainland China are required to participate in a central pension scheme operated by the local municipal government. The Company is required to contribute 16% of its payroll costs to the central pension scheme. The contributions are charged to profit or loss as they become payable in accordance with the rules of the central pension scheme. </div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.5pt; margin-left: 20pt; text-align: left;"><u>Borrowing costs</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, i.e., assets that necessarily take a substantial period of time to get ready for their intended use or sale, are capitalized as part of the cost of those assets. The capitalization of such borrowing costs ceases when the assets are substantially ready for their intended use or sale. Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs capitalized. All other borrowing costs are expensed in the period in which they are incurred. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.5pt; margin-left: 20pt; text-align: left;"><u>Dividends</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Final dividends are recognized as a liability when they are approved by the shareholders in a general meeting. Proposed final dividends are disclosed in the notes to the consolidated financial statements, if any.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Interim dividends are simultaneously proposed and declared, because the Company's memorandum and articles of association grant the directors the authority to declare interim dividends. Consequently, interim dividends are recognized immediately as a liability when they are proposed and declared.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">SIGNIFICANT ACCOUNTING JUDGMENTS AND ESTIMATES</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The preparation of the Company&#8217;s financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and their accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that could require a material adjustment to the carrying amounts of the assets or liabilities affected in the future.</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 16pt; margin-left: 20pt; text-align: left;"><u>Judgments</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In the process of applying the Company&#8217;s accounting policies, management has made the following judgments, apart from those involving estimations, which have the most significant effect on the amounts recognized in the consolidated financial statements:</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16pt; margin-left: 20pt; text-align: left;">Revenue from contracts with customers</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company applied the following judgment that significantly affects the determination of the amount and timing of revenue from contracts with customers:</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 16pt; margin-left: 20pt; text-align: left;">Determining the method to estimate consideration payable to a customer</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Certain contracts for the sale of pharmaceutical products include certain sales rebates which are incurred after the control and rights of products have been passed to customers that give rise to consideration payable to a customer. As the specific amount of the rebates is not finalized at the point of revenue recognition, the Company makes deductions from revenue based on its historical experience. There may be differences between the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-75<br></div></div></div>
<!--End Page 430-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 431-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">3.</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">SIGNIFICANT ACCOUNTING JUDGMENTS AND ESTIMATES</font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: justify;">deductions and the actual settlements. In estimating consideration payable to a customer, the Company is required to use either the expected value method or the most likely amount method depending on which method better predicts the amount of consideration to which it will be entitled.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company has determined that the most likely amount method is the appropriate method to use in estimating consideration payable to a customer.</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 20.5pt; margin-left: 20pt; text-align: left;"><u>Estimation uncertainty</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The key assumptions concerning the future and other key sources of estimation uncertainty at the end of the reporting period, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">Development costs</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Development costs are capitalized at the end of each reporting period in accordance with the accounting policy for research and development expenses in note 2.4 to the consolidated financial statements. Determining the commencement date of the capitalization period requires management to make assumptions regarding the Company&#8217;s intention to complete and the Company&#8217;s ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the project and the ability to measure reliably the expenditure during the development stage. As of December&#160;31, 2022 and 2021, the best estimates of the carrying amounts of capitalized development costs under the category of &#8220;Product development in progress&#8221; were RMB143,680 and RMB111,644, respectively. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">Impairment of non-financial assets </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company assesses whether there are any indicators of impairment for all non-financial assets at the end of each reporting period. Product development in progress is tested for impairment annually and at other times when such an indicator exists. Other non-financial assets are tested for impairment when there are impairment indicators. An impairment exists when the carrying value of an asset or a cash-generating unit exceeds its recoverable amount, which is the higher of its fair value less costs of disposal and its value in use. The calculation of the fair value less costs of disposal is based on available data from binding sales transactions in an arm&#8217;s length transaction of similar assets or observable market prices less incremental costs for disposing of the asset. When value in use calculations are undertaken, management must estimate the expected future cash flows from the asset or cash-generating unit and choose a suitable discount rate in order to calculate the present value of those cash flows. No impairment losses of product development in progress were recognized for the years ended December&#160;31, 2022 and 2021.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">REVENUE </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">Revenue is analysed as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.77%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 26.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the year ended December&#160;31,</div></td></tr><tr class="header"><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.77%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 0.77%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.77%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>Revenue from contracts with customers</u><br></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sales of pharmaceutical products<font style="padding-left: 1.56pt;"></font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.29pt; text-align: left;">679,130</div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.29pt; text-align: left;">570,438</div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">License of intellectual property<font style="padding-left: 3.78pt;"></font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.29pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">9,500</font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.29pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">600</font></div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.29pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">688,630</font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.29pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">571,038</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-76<br></div></div></div>
<!--End Page 431-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 432-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">4.</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">REVENUE </font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">Disaggregated revenue information is as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.77%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 26.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the year ended December&#160;31,</div></td></tr><tr class="header"><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.77%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 0.77%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.77%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Timing of revenue recognition<br></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Products transferred at a point in time<font style="padding-left: 0.46pt;"></font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.29pt; text-align: left;">679,130</div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.29pt; text-align: left;">570,438</div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">License of intellectual property transferred at a point in time<font style="padding-left: 2.72pt;"></font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.29pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">9,500</font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.29pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">600</font></div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.29pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">688,630</font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.29pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">571,038</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The following table shows the amounts of revenue recognized in the current reporting period that was included in contract liabilities at the beginning of the reporting period:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.77%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 26.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the year ended December&#160;31,</div></td></tr><tr class="header"><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.77%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 0.77%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.77%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sale of pharmaceutical products<font style="padding-left: 0.45pt;"></font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.29pt; text-align: left;"><font style="padding-left: 7.5pt;">304</font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.29pt; text-align: left;">1,101</div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">License of intellectual property<font style="padding-left: 3.78pt;"></font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.29pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">1,900</font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.29pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.29pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">2,204</font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.29pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">1,101</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">OTHER INCOME AND GAINS</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">Other income and gains include the following:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.77%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 26.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the year ended December&#160;31,</div></td></tr><tr class="header"><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.77%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.85%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 0.77%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.77%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Government grants<font style="padding-left: 3.75pt;"></font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="padding-left: 5pt;">5,762</font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="padding-left: 7.5pt;">926</font></div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest income<font style="padding-left: 3.75pt;"></font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="padding-left: 5pt;">4,883</font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;">2,437</div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Investment income<font style="padding-left: 4.3pt;"></font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;">1,528</div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Others<font style="padding-left: 4.85pt;"></font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">3</font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">171</font></div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">10,648</font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">5,062</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">PROFIT BEFORE TAX </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">The Company&#8217;s profit before tax is arrived at after charging (crediting): </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.47%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.88%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 26.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the year ended December&#160;31,</div></td></tr><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.47%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">Note</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.88%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 0.88%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.88%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.14%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cost of inventories sold<font style="padding-left: 4.75pt;"></font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.44pt; text-align: left;">30,434</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.44pt; text-align: left;">25,337</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(Reversal) provision for inventories<font style="padding-left: 2.01pt;"></font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.47%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">13</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.44pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(271</font><font style="min-width: 27.5pt;">)</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.44pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">292</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cost of sales<font style="padding-left: 4.75pt;"></font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.47%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.44pt; text-align: left;">30,163</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.44pt; text-align: left;">25,629</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.47%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation of property, plant and equipment<font style="padding-left: 3.49pt;"></font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.47%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">9</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.44pt; text-align: left;"><font style="padding-left: 5pt;">6,130</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.44pt; text-align: left;"><font style="padding-left: 5pt;">5,759</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation of right-of-use assets<font style="padding-left: 2.02pt;"></font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.47%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">10</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.44pt; text-align: left;"><font style="padding-left: 5pt;">3,388</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.44pt; text-align: left;"><font style="padding-left: 5pt;">3,245</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amortization of intangible assets<font style="padding-left: 2.55pt;"></font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.47%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">11</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.44pt; text-align: left;"><font style="padding-left: 5pt;">3,232</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.44pt; text-align: left;"><font style="padding-left: 5pt;">3,286</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease payments not included in the measurement of lease liabilities<font style="padding-left: 4.84pt;"></font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.47%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.44pt; text-align: left;"><font style="padding-left: 12.5pt;">500</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.44pt; text-align: left;"><font style="padding-left: 12.5pt;">101</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-77<br></div></div></div>
<!--End Page 432-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 433-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">6.</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">PROFIT BEFORE TAX </font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.47%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.88%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 26.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the year ended December&#160;31,</div></td></tr><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.47%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">Note</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.88%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 0.88%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.88%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.14%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee benefit expenses (excluding directors&#8217; remuneration):<br></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.47%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Wages and salaries<font style="padding-left: 0.01pt;"></font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.47%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;">133,378</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;">135,626</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Equity-settled share option expenses<font style="padding-left: 3.66pt;"></font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.47%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 10pt;">4,342</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 14.17pt;">(906)</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Pension scheme contributions<font style="padding-left: 1.42pt;"></font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.47%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 5.37pt;">11,922</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 10pt;">9,433</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Foreign exchange differences, net<font style="padding-left: 4.69pt;"></font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.47%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 19.17pt;">(67)</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Provision for the impairment of trade receivables<font style="padding-left: 0.92pt;"></font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.47%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">14</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 17.5pt;">416</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 17.5pt;">263</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest income<font style="padding-left: 4.75pt;"></font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.47%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 6.67pt;">(4,883)</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 6.67pt;">(2,437)</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Investment income<font style="padding-left: 0.3pt;"></font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.47%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 6.67pt;">(1,528)</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Professional service fees<font style="padding-left: 2pt;"></font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.47%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 5pt;">25,432</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 10pt;">3,930</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss (gain) on disposal of items of property, plant and equipment<font style="padding-left: 2.97pt;"></font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.47%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 22.5pt;">24</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 14.17pt;">(140)</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amortization of deferred government grants<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">*</sup><font style="padding-left: 3.27pt;"></font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.47%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 14.17pt;">(150)</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 14.17pt;">(150)</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">There are no unfulfilled conditions or contingencies relating to the deferred government grants in the consolidated statements of financial position.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">FINANCE COSTS </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 20pt; text-align: left;">An analysis of finance costs is as follows: </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.77%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 26.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the year ended December&#160;31,</div></td></tr><tr class="header"><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.77%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 0.77%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.77%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest on bank borrowings<font style="padding-left: 1.55pt;"></font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.04pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.04pt; text-align: left;">350</div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest on lease liabilities<font style="padding-left: 4.33pt;"></font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.04pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 15pt;">299</font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.04pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 15pt;">430</font></div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.04pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">299</font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.04pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">780</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">INCOME TAX </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company was designated and approved as a High and New Technology Enterprise in December 2019 and December 2022 with a validity period of 3&#160;years, respectively, and was entitled to a preferential tax rate of 15% for the years ended December&#160;31, 2022 and 2021. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">The major components of income tax expense are as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.82%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 26.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the year ended December&#160;31,</div></td></tr><tr class="header"><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.82%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.19%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 0.82%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.82%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.19%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current income tax charge in Mainland China<font style="padding-left: 2.86pt;"></font></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.19%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.56pt; text-align: left;">39,714</div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.19%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.56pt; text-align: left;">38,676</div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred income tax (note 12)<font style="padding-left: 2.12pt;"></font></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.19%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.56pt; text-align: left;"><font style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(57</font><font style="min-width: 27.5pt;">)</font></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.19%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.56pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">641</font></div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total tax charge for the year<font style="padding-left: 4.66pt;"></font></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.19%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.56pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">39,657</font></div></td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.19%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.56pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">39,317</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-78<br></div></div></div>
<!--End Page 433-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 434-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">8.</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">INCOME TAX </font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: justify;">A reconciliation of the tax expense applicable to profit before tax at the statutory rate for the country in which the Company is domiciled to the tax expense at the effective tax rate is as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="10" style="width: 30.73%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the year ended December&#160;31,</div></td></tr><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">%</div></td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">%</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Profit before tax<font style="padding-left: 0.31pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">190,691</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">188,704</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tax at the statutory tax rate<font style="padding-left: 4.36pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">47,673</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt;">25.0</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">47,176</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt;">25.0</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lower tax rates enacted by local authorities<font style="padding-left: 3.14pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.67pt;">(19,069)</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(10.0)</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.67pt;">(18,870)</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(10.0)</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additional deduction of research and development expenses<font style="padding-left: 1.49pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.67pt;">(7,962)</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">(4.2)</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.67pt;">(6,772)</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">(3.6)</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Taxable income from deemed sales<font style="padding-left: 3.26pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">15,812</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">8.3</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">16,183</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">8.6</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expenses not deductible for tax<font style="padding-left: 3.11pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">4,486</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">2.4</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">1,439</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">0.8</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proceeds from technology transfer<font style="padding-left: 2.01pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.67pt;">(1,088)</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">(0.6)</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additional deduction of high-tech enterprise equipment<font style="padding-left: 0.91pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 14.17pt;">(660)</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">(0.3)</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Others<font style="padding-left: 0.85pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">465</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">0.2</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">161</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">0.1</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tax charge at the Company&#8217;s effective tax rate<font style="padding-left: 0.87pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">39,657</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt;">20.8</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">39,317</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt;">20.9</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">PROPERTY, PLANT AND EQUIPMENT </div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the year ended December&#160;31, 2021: <br></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Buildings</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Leasehold <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">improvement</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.45%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Machinery and <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">electronic devices</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Furniture <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">and fixtures</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.95%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Motor <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">vehicles</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Construction <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in progress</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of January&#160;1, 2022:<br></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cost<font style="padding-left: 4.17pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 2.96pt;">74,279</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.9pt; text-align: left;"><font style="padding-left: 3.33pt;">2,264</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;">27,976</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.89pt; text-align: left;"><font style="padding-left: 3.33pt;">3,955</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.08pt; text-align: left;">1,214</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.69pt; text-align: left;"><font style="padding-left: 5pt;">4,787</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 0.37pt;">114,475</font></div></td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accumulated depreciation<font style="padding-left: 1.43pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 4.63pt; border-bottom: 1pt solid #000000; min-width: 30.46pt;">(9,522</font><font style="min-width: 30.46pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.9pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(1,188</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(7,900</font><font style="min-width: 27.5pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.89pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(2,829</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.08pt; text-align: left;"><font style="padding-left: 4.17pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">(786</font><font style="min-width: 22.5pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.69pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(22,225</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net carrying amount<font style="padding-left: 3.09pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 2.96pt; border-bottom: 3pt double #000000; min-width: 30.46pt;">64,757</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.9pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">1,076</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">20,076</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.89pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">1,126</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.08pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 3pt double #000000; min-width: 22.5pt;">428</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.69pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 27.5pt;">4,787</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">92,250</font></div></td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">As of January&#160;1, 2022, net of accumulated depreciation<font style="padding-left: 3.07pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 2.96pt;">64,757</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.9pt; text-align: left;"><font style="padding-left: 3.33pt;">1,076</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;">20,076</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.89pt; text-align: left;"><font style="padding-left: 3.33pt;">1,126</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.08pt; text-align: left;"><font style="padding-left: 7.5pt;">428</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.69pt; text-align: left;"><font style="padding-left: 5pt;">4,787</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">92,250</font></div></td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additions<font style="padding-left: 3.06pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 7.96pt;">1,192</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.9pt; text-align: left;"><font style="padding-left: 15.83pt;">65</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;"><font style="padding-left: 5pt;">6,552</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.89pt; text-align: left;"><font style="padding-left: 10.83pt;">443</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.08pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.69pt; text-align: left;">28,991</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">37,243</font></div></td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Disposals<font style="padding-left: 3.63pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 20.46pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.9pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;"><font style="padding-left: 14.17pt;">(24)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.89pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.08pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.69pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 19.17pt;">(24)</font></div></td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Depreciation provided during the year<font style="padding-left: 4.74pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 4.63pt; border-bottom: 1pt solid #000000; min-width: 30.46pt;">(2,409</font><font style="min-width: 30.46pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.9pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">(494</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(2,594</font><font style="min-width: 27.5pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.89pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">(527</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.08pt; text-align: left;"><font style="padding-left: 4.17pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">(106</font><font style="min-width: 22.5pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.69pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(6,130</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">As of December&#160;31, 2022, net of accumulated depreciation<font style="padding-left: 3.07pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 2.96pt; border-bottom: 3pt double #000000; min-width: 30.46pt;">63,540</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.9pt; text-align: left;"><font style="padding-left: 10.83pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">647</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">24,010</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.89pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">1,042</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.08pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 3pt double #000000; min-width: 22.5pt;">322</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.69pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">33,778</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">123,339</font></div></td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2022:<br></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cost<font style="padding-left: 4.17pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 2.96pt;">75,471</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.9pt; text-align: left;"><font style="padding-left: 3.33pt;">2,329</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;">33,991</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.89pt; text-align: left;"><font style="padding-left: 3.33pt;">4,398</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.08pt; text-align: left;">1,214</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.69pt; text-align: left;">33,778</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">151,181</div></td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accumulated depreciation<font style="padding-left: 1.43pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.46pt;">(11,931</font><font style="min-width: 30.46pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.9pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(1,682</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(9,981</font><font style="min-width: 27.5pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.89pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(3,356</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.08pt; text-align: left;"><font style="padding-left: 4.17pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">(892</font><font style="min-width: 22.5pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.69pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(27,842</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net carrying amount<font style="padding-left: 3.09pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 2.96pt; border-bottom: 3pt double #000000; min-width: 30.46pt;">63,540</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.9pt; text-align: left;"><font style="padding-left: 10.83pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">647</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">24,010</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.89pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">1,042</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.08pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 3pt double #000000; min-width: 22.5pt;">322</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.69pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">33,778</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">123,339</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-79<br></div></div></div>
<!--End Page 434-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 435-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">9.</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">PROPERTY, PLANT AND EQUIPMENT </font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the year ended December&#160;31, 2021: <br></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Buildings</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Leasehold <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">improvement</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.45%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Machinery and <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">electronic devices</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Furniture <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">and fixtures</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.95%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Motor <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">vehicles</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Construction <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in progress</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of January&#160;1, 2021:<br></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cost<font style="padding-left: 4.17pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.49pt; text-align: left;">72,627</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.9pt; text-align: left;"><font style="padding-left: 3.33pt;">2,329</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;">23,650</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.89pt; text-align: left;"><font style="padding-left: 3.33pt;">3,698</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.08pt; text-align: left;">1,206</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.52pt; text-align: left;"><font style="padding-left: 3.33pt;">2,495</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: justify;">106,005</div></td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accumulated depreciation<font style="padding-left: 1.43pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.49pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(7,173</font><font style="min-width: 27.5pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.9pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">(737</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(5,575</font><font style="min-width: 27.5pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.89pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(2,303</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.08pt; text-align: left;"><font style="padding-left: 4.17pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">(678</font><font style="min-width: 22.5pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.52pt; text-align: left;"><font style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: justify;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(16,466</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net carrying amount<font style="padding-left: 3.09pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.49pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">65,454</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.9pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">1,592</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">18,075</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.89pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">1,395</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.08pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 3pt double #000000; min-width: 22.5pt;">528</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.52pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">2,495</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">89,539</font></div></td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">As of January&#160;1, 2021, net of accumulated depreciation<font style="padding-left: 3.07pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.49pt; text-align: left;">65,454</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.9pt; text-align: left;"><font style="padding-left: 3.33pt;">1,592</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;">18,075</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.89pt; text-align: left;"><font style="padding-left: 3.33pt;">1,395</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.08pt; text-align: left;"><font style="padding-left: 7.5pt;">528</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.52pt; text-align: left;"><font style="padding-left: 3.33pt;">2,495</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">89,539</font></div></td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additions<font style="padding-left: 3.06pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.49pt; text-align: left;"><font style="padding-left: 12.5pt;">428</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.9pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;"><font style="padding-left: 5pt;">2,885</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.89pt; text-align: left;"><font style="padding-left: 10.83pt;">257</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.08pt; text-align: left;"><font style="padding-left: 17.5pt;">8</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.52pt; text-align: left;"><font style="padding-left: 3.33pt;">4,957</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">8,535</font></div></td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Disposals<font style="padding-left: 3.63pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.49pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.9pt; text-align: left;"><font style="padding-left: 12.5pt;">(65)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.89pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.08pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.52pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 19.17pt;">(65)</font></div></td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Transfer<font style="padding-left: 3.98pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.49pt; text-align: left;"><font style="padding-left: 5pt;">1,224</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.9pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;"><font style="padding-left: 5pt;">1,441</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.89pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.08pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.52pt; text-align: left;">(2,665)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Depreciation provided during the year<font style="padding-left: 4.74pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.49pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(2,349</font><font style="min-width: 27.5pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.9pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">(451</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(2,325</font><font style="min-width: 27.5pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.89pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">(526</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.08pt; text-align: left;"><font style="padding-left: 4.17pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">(108</font><font style="min-width: 22.5pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.52pt; text-align: left;"><font style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(5,759</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">As of December&#160;31, 2021, net of accumulated depreciation<font style="padding-left: 3.07pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.49pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">64,757</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.9pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">1,076</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">20,076</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.89pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">1,126</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.08pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 3pt double #000000; min-width: 22.5pt;">428</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.52pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">4,787</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">92,250</font></div></td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2021:<br></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cost<font style="padding-left: 4.17pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.49pt; text-align: left;">74,279</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.9pt; text-align: left;"><font style="padding-left: 3.33pt;">2,264</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;">27,976</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.89pt; text-align: left;"><font style="padding-left: 3.33pt;">3,955</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.08pt; text-align: left;">1,214</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.52pt; text-align: left;"><font style="padding-left: 3.33pt;">4,787</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 0.37pt;">114,475</font></div></td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accumulated depreciation<font style="padding-left: 1.43pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.49pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(9,522</font><font style="min-width: 27.5pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.9pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(1,188</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(7,900</font><font style="min-width: 27.5pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.89pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(2,829</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.08pt; text-align: left;"><font style="padding-left: 4.17pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">(786</font><font style="min-width: 22.5pt;">)</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.52pt; text-align: left;"><font style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: justify;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(22,225</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 26.78%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net carrying amount<font style="padding-left: 3.09pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.49pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">64,757</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.9pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">1,076</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">20,076</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.89pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">1,126</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.08pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 3pt double #000000; min-width: 22.5pt;">428</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.52pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">4,787</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">92,250</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">LEASES</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Right-of-use assets</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.88%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.71%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Leasehold land</div></td><td class="gutter" style="width: 0.88%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.88%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.24%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Buildings</div></td><td class="gutter" style="width: 0.88%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.88%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.14%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of January&#160;1, 2021<font style="padding-left: 3.15pt;"></font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.71%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.48pt; text-align: left;"><font style="padding-left: 0.37pt;">11,413</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.32pt; text-align: left;"><font style="padding-left: 3.33pt;">9,381</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">20,794</div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additions<font style="padding-left: 0.06pt;"></font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.71%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.48pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.32pt; text-align: left;"><font style="padding-left: 10.83pt;">746</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">746</font></div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation expense<font style="padding-left: 2.32pt;"></font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.71%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.48pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(279</font><font style="min-width: 27.5pt;">)</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.32pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(2,966</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(3,245</font><font style="min-width: 27.5pt;">)</font></div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.71%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2021 and January&#160;1, 2022<font style="padding-left: 1.8pt;"></font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.71%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.48pt; text-align: left;"><font style="padding-left: 0.37pt;">11,134</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.32pt; text-align: left;"><font style="padding-left: 3.33pt;">7,161</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">18,295</div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additions<font style="padding-left: 0.06pt;"></font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.71%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.48pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.32pt; text-align: left;"><font style="padding-left: 10.83pt;">375</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">375</font></div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation expense<font style="padding-left: 2.32pt;"></font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.71%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.48pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(279</font><font style="min-width: 27.5pt;">)</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.32pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(3,109</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(3,388</font><font style="min-width: 27.5pt;">)</font></div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2022<font style="padding-left: 3.16pt;"></font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.71%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.48pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">10,855</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.32pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">4,427</font></div></td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">15,282</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Lease liabilities</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.79%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.42%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of December&#160;31,</div></td></tr><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.79%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.92%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 2.79%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.79%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.92%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current portion<font style="padding-left: 0.74pt;"></font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.26pt; text-align: left;">3,467</div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.26pt; text-align: left;">3,103</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-current portion<font style="padding-left: 2.42pt;"></font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.92%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.26pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">1,525</font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.92%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.26pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">4,731</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.26pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">4,992</font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.26pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">7,834</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-80<br></div></div></div>
<!--End Page 435-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 436-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg20"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">10.</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">LEASES</font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">The movements in lease liabilities are as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 88.39%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.18%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.18%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Buildings</div></td></tr><tr><td style="width: 88.39%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of January&#160;1, 2021<font style="padding-left: 2.15pt;"></font></div></td><td class="gutter" style="width: 2.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.32pt; text-align: left;"><font style="padding-left: 3.33pt;">9,913</font></div></td></tr><tr><td style="width: 88.39%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additions<font style="padding-left: 4.06pt;"></font></div></td><td class="gutter" style="width: 2.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.32pt; text-align: left;"><font style="padding-left: 10.83pt;">746</font></div></td></tr><tr><td style="width: 88.39%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest expense<font style="padding-left: 2.98pt;"></font></div></td><td class="gutter" style="width: 2.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.32pt; text-align: left;"><font style="padding-left: 10.83pt;">430</font></div></td></tr><tr><td style="width: 88.39%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Payments<font style="padding-left: 4.62pt;"></font></div></td><td class="gutter" style="width: 2.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.32pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(3,255</font><font style="min-width: 25.83pt;">)</font></div></td></tr><tr><td style="width: 88.39%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 88.39%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2021 and January&#160;1, 2022<font style="padding-left: 0.8pt;"></font></div></td><td class="gutter" style="width: 2.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.32pt; text-align: left;"><font style="padding-left: 3.33pt;">7,834</font></div></td></tr><tr><td style="width: 88.39%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additions<font style="padding-left: 4.06pt;"></font></div></td><td class="gutter" style="width: 2.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.32pt; text-align: left;"><font style="padding-left: 10.83pt;">375</font></div></td></tr><tr><td style="width: 88.39%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest expense<font style="padding-left: 2.98pt;"></font></div></td><td class="gutter" style="width: 2.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.32pt; text-align: left;"><font style="padding-left: 10.83pt;">299</font></div></td></tr><tr><td style="width: 88.39%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Payments<font style="padding-left: 4.62pt;"></font></div></td><td class="gutter" style="width: 2.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.32pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(3,516</font><font style="min-width: 25.83pt;">)</font></div></td></tr><tr><td style="width: 88.39%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2022<font style="padding-left: 2.16pt;"></font></div></td><td class="gutter" style="width: 2.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.32pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">4,992</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 20pt; text-align: left;">The maturity analysis of lease liabilities is disclosed in note 28 to the consolidated financial statements.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The amounts recognized in profit or loss in relation to leases are as follows:</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 27.47%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the year ended December&#160;31,</div></td></tr><tr class="header"><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interests on lease liabilities<font style="padding-left: 3.44pt;"></font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.29pt; text-align: left;"><font style="padding-left: 7.5pt;">299</font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.29pt; text-align: left;"><font style="padding-left: 7.5pt;">430</font></div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation charge of right-of-use assets<font style="padding-left: 4.22pt;"></font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.29pt; text-align: left;">3,388</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.29pt; text-align: left;">3,245</div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expense relating to short-term leases<font style="padding-left: 3.46pt;"></font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.29pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">500</font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.29pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">101</font></div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total amount recognized in profit or loss<font style="padding-left: 1.37pt;"></font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.29pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">4,187</font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.29pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">3,776</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">INTANGIBLE ASSETS </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 20pt; text-align: left;">For the year ended December&#160;31, 2022:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.72%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Product <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">development <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in progress</div></td><td class="gutter" style="width: 0.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Patents</div></td><td class="gutter" style="width: 0.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.45%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Technological <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">know-how</div></td><td class="gutter" style="width: 0.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.83%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Computer <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">software</div></td><td class="gutter" style="width: 0.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Cost as of January&#160;1, 2022, net of accumulated amortization and impairment<font style="padding-left: 0.76pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.52pt; text-align: left;"><font style="padding-left: 0.74pt;">111,644</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.7pt;">19,411</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.5pt; text-align: left;"><font style="padding-left: 3.33pt;">1,244</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.38pt; text-align: left;"><font style="padding-left: 8.33pt;">55</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">132,354</div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additions<font style="padding-left: 4.06pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.52pt; text-align: left;"><font style="padding-left: 5pt;">32,036</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.5pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.38pt; text-align: left;"><font style="padding-left: 8.33pt;">91</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">32,127</font></div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amortization provided during the year<font style="padding-left: 0.78pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.52pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">(3,043</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.5pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">(127</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.38pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">(62</font><font style="min-width: 18.33pt;">)</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(3,232</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2022<font style="padding-left: 2.16pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 9.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.52pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">143,680</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 6.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">16,368</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.5pt; text-align: left;"><font style="padding-left: 3.7pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">1,117</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.38pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 18.33pt;">84</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">161,249</font></div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2022:<br></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cost<font style="padding-left: 0.17pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.52pt; text-align: left;">143,680</div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt;">32,612</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.5pt; text-align: left;"><font style="padding-left: 3.33pt;">2,545</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.38pt; text-align: left;"><font style="padding-left: 3.33pt;">724</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">179,561</div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accumulated amortization and impairment<font style="padding-left: 4.11pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.52pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;">(16,244</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.5pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(1,428</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.38pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 18.33pt;">(640</font><font style="min-width: 18.33pt;">)</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(18,312</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net carrying amount<font style="padding-left: 4.09pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.52pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">143,680</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">16,368</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.5pt; text-align: left;"><font style="padding-left: 3.7pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">1,117</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.38pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 18.33pt;">84</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">161,249</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-81<br></div></div></div>
<!--End Page 436-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 437-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg21"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">11.</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">INTANGIBLE ASSETS </font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">For the year ended December&#160;31, 2021:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.72%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Product <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">development <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in progress</div></td><td class="gutter" style="width: 0.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Patents</div></td><td class="gutter" style="width: 0.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.45%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Technological <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">know-how</div></td><td class="gutter" style="width: 0.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.83%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Computer <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">software</div></td><td class="gutter" style="width: 0.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Cost as of January&#160;1, 2021, net of accumulated amortization and impairment<font style="padding-left: 0.76pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.89pt; text-align: left;"><font style="padding-left: 4.26pt;">71,251</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt;">22,454</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.5pt; text-align: left;"><font style="padding-left: 3.33pt;">1,370</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.38pt; text-align: left;"><font style="padding-left: 3.33pt;">172</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">95,247</font></div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additions<font style="padding-left: 4.06pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.89pt; text-align: left;"><font style="padding-left: 4.26pt;">40,393</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.5pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.38pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">40,393</font></div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amortization provided during the year<font style="padding-left: 0.78pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.89pt; text-align: left;"><font style="padding-left: 21.76pt; border-bottom: 1pt solid #000000; min-width: 31.76pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">(3,043</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.5pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">(126</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.38pt; text-align: left;"><font style="padding-left: 0.37pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">(117</font><font style="min-width: 18.33pt;">)</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(3,286</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2021<font style="padding-left: 2.16pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 9.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 31.76pt;">111,644</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 6.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.7pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">19,411</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.5pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">1,244</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.38pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 18.33pt;">55</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">132,354</font></div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2021:<br></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cost<font style="padding-left: 0.17pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.89pt; text-align: left;">111,644</div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt;">32,612</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.5pt; text-align: left;"><font style="padding-left: 3.33pt;">2,545</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.38pt; text-align: left;"><font style="padding-left: 3.33pt;">633</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">147,434</div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accumulated amortization and impairment<font style="padding-left: 4.11pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.89pt; text-align: left;"><font style="padding-left: 21.76pt; border-bottom: 1pt solid #000000; min-width: 31.76pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;">(13,201</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.5pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(1,301</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.38pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 18.33pt;">(578</font><font style="min-width: 18.33pt;">)</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(15,080</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net carrying amount<font style="padding-left: 4.09pt;"></font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 31.76pt;">111,644</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.7pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">19,411</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.5pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">1,244</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.38pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 18.33pt;">55</font></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">132,354</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">DEFERRED TAX </div></td></tr></table><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 20pt; text-align: left;">Deferred tax assets:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.2%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 18.32%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Provisions and accruals</div></td><td class="gutter" style="width: 2.2%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.2%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.89%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share option</div></td><td class="gutter" style="width: 2.2%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.2%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of January&#160;1, 2021<font style="padding-left: 1.15pt;"></font></div></td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.32%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 29.78pt; text-align: left;">1,782</div></td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;">1,734</div></td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">3,516</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred tax charged to profit or loss during the year<font style="padding-left: 3.9pt;"></font></div></td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 18.32%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 29.78pt; text-align: left;"><font style="padding-left: 4.17pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">(713</font><font style="min-width: 22.5pt;">)</font></div></td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="padding-left: 4.17pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">(271</font><font style="min-width: 22.5pt;">)</font></div></td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 4.17pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">(984</font><font style="min-width: 22.5pt;">)</font></div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2021 and January&#160;1, 2022<font style="padding-left: 4.8pt;"></font></div></td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.32%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 29.78pt; text-align: left;">1,069</div></td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;">1,463</div></td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">2,532</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Deferred tax credited (charged) to profit or loss during the year<font style="padding-left: 4.74pt;"></font></div></td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 18.32%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 29.78pt; text-align: left;"><font style="padding-left: 4.17pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">(574</font><font style="min-width: 22.5pt;">)</font></div></td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">1,291</font></div></td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">717</font></div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2022<font style="padding-left: 1.16pt;"></font></div></td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.32%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 29.78pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 3pt double #000000; min-width: 22.5pt;">495</font></div></td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">2,754</font></div></td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">3,249</font></div></td></tr></table><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 18.5pt; margin-left: 20pt; text-align: left;">Deferred tax liabilities:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 448.06pt; margin-left: 20pt;"><tr class="header"><td style="width: 80.35%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.67%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 18.31%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Provisions and accruals</div></td></tr><tr><td style="width: 80.35%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of January&#160;1, 2021<font style="padding-left: 1.15pt;"></font></div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.31%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 31.87pt; text-align: left;"><font style="padding-left: 3.33pt;">343</font></div></td></tr><tr><td style="width: 80.35%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred tax credited to profit or loss during the year<font style="padding-left: 3.17pt;"></font></div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 18.31%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 31.87pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 18.33pt;">(343</font><font style="min-width: 18.33pt;">)</font></div></td></tr><tr><td style="width: 80.35%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2021 and January&#160;1, 2022<font style="padding-left: 4.8pt;"></font></div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.31%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 31.87pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td></tr><tr><td style="width: 80.35%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred tax charged to profit or loss during the year<font style="padding-left: 3.9pt;"></font></div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 18.31%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 31.87pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">660</font></div></td></tr><tr><td style="width: 80.35%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2022<font style="padding-left: 1.16pt;"></font></div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.31%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 31.87pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 18.33pt;">660</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">For presentation purposes, all deferred tax assets and liabilities have been offset in the consolidated statements of financial position.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-82<br></div></div></div>
<!--End Page 437-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 438-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg22"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">INVENTORIES</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.79%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.42%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of December&#160;31,</div></td></tr><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.79%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.92%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 2.79%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.79%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.92%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Raw materials<font style="padding-left: 0.19pt;"></font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="padding-left: 5pt;">7,354</font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="padding-left: 5pt;">4,916</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Work in progress<font style="padding-left: 3.22pt;"></font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="padding-left: 5pt;">2,749</font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="padding-left: 5pt;">6,030</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Semi-finished goods<font style="padding-left: 0.19pt;"></font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;">22,790</div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;">17,222</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Finished goods<font style="padding-left: 1.84pt;"></font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">9,808</font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">8,622</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;">42,701</div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;">36,790</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Provision for inventories<font style="padding-left: 2.42pt;"></font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">62</font><font style="min-width: 27.5pt;">)</font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">333</font><font style="min-width: 27.5pt;">)</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">42,639</font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">36,457</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 20pt; text-align: left;">The movements in provision for impairment of inventories are as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.77%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 26.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the year ended December&#160;31,</div></td></tr><tr class="header"><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.77%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 0.77%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.77%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.04%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">At the beginning of the year<font style="padding-left: 4.88pt;"></font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.55%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.96pt; text-align: left;"><font style="padding-left: 3.33pt;">333</font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.04%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.45pt; text-align: left;"><font style="padding-left: 5pt;">41</font></div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(Reversal) provision for inventories<font style="padding-left: 1.01pt;"></font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.55%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.96pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 18.33pt;">(271</font><font style="min-width: 18.33pt;">)</font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.04%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.45pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 15pt;">292</font></div></td></tr><tr><td style="width: 72.32%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">At the end of the year<font style="padding-left: 0.44pt;"></font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.55%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.96pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 18.33pt;">62</font></div></td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.04%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.45pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">333</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">TRADE RECEIVABLES</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.79%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.42%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of December&#160;31,</div></td></tr><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.79%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.48%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 2.79%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.79%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.36%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade receivables<font style="padding-left: 2.22pt;"></font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.51pt; text-align: left;">109,615</div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.51pt; text-align: left;">64,504</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Allowance for impairment<font style="padding-left: 0.76pt;"></font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.51pt; text-align: left;"><font style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">862</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.51pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">446</font><font style="min-width: 27.5pt;">)</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.51pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">108,753</font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.51pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">64,058</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company&#8217;s trading terms with its customers are mainly on credit, and the credit period is usually within 3 months. The Company seeks to maintain strict control over its outstanding receivables to minimize credit risk. Overdue balances are reviewed regularly by the management. Trade receivables are non-interest-bearing.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">The movements in loss allowance for impairment of trade receivables are as follows: </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.11%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 28.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the year ended December&#160;31,</div></td></tr><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 2.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">At the beginning of the year<font style="padding-left: 0.88pt;"></font></div></td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.38pt; text-align: left;">(446)</div></td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.38pt; text-align: left;">(183)</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Provision for impairment<font style="padding-left: 4.75pt;"></font></div></td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.38pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 18.33pt;">(416</font><font style="min-width: 18.33pt;">)</font></div></td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.38pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 18.33pt;">(263</font><font style="min-width: 18.33pt;">)</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">At the end of the year<font style="padding-left: 1.44pt;"></font></div></td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.38pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 18.33pt;">(862</font><font style="min-width: 18.33pt;">)</font></div></td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.38pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 18.33pt;">(446</font><font style="min-width: 18.33pt;">)</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">An impairment analysis is performed at the end of each reporting period using a provision matrix to measure expected credit losses. The provision rates are based on days past due for groupings of various customer segments with similar loss patterns by product type and customer rating. The calculation reflects the probability-weighted outcome, the time value of money and reasonable and supportable information that is available at the end of each reporting period about past events, current conditions and forecasts of future economic conditions. Generally, trade receivables are written off if past due for more than one year and are not subject to enforcement activity. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-83<br></div></div></div>
<!--End Page 438-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 439-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg23"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">14.</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">TRADE RECEIVABLES</font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: justify;">Set out below is the information about the credit risk exposure on the Company's trade receivables using a provision matrix:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">As of December&#160;31, 2022: </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.21%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 24.95%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Past due</div></td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td></tr><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.21%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Current</div></td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.06%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Within 3 months</div></td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.22%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">3 months to <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">12 months</div></td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected credit loss rate<font style="padding-left: 1.99pt;"></font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.17pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.5pt; text-align: left;"><font style="padding-left: 22.5pt;">3%</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.22%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.16pt; text-align: left;"><font style="padding-left: 5pt;">20%</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gross carrying amount <font style="padding-left: 0.88pt;"></font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.17pt; text-align: left;">84,172</div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.5pt; text-align: left;">24,861</div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.22%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.16pt; text-align: left;">582</div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">109,615</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected credit losses<font style="padding-left: 1.99pt;"></font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.17pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.5pt; text-align: left;"><font style="padding-left: 12.5pt;">746</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.22%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.16pt; text-align: left;"><font style="padding-left: 0.37pt;">116</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">862</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">As of December&#160;31, 2021: </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.21%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.47%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 25.23%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Past due</div></td><td class="gutter" style="width: 1.47%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.47%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 6.14%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.47%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.21%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Current</div></td><td class="gutter" style="width: 1.47%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.47%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.06%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Within 3 months</div></td><td class="gutter" style="width: 1.47%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.47%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.22%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">3 months to <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">12 months</div></td><td class="gutter" style="width: 1.47%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected credit loss rate<font style="padding-left: 1.99pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.17pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.7pt; text-align: left;"><font style="padding-left: 22.13pt;">3%</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.22%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.16pt; text-align: left;"><font style="padding-left: 5pt;">18%</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gross carrying amount <font style="padding-left: 0.88pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.17pt; text-align: left;">52,286</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.7pt; text-align: left;">11,688</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.22%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.16pt; text-align: left;">530</div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">64,504</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected credit losses <font style="padding-left: 3.66pt;"></font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.17pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.7pt; text-align: left;"><font style="padding-left: 12.13pt;">351</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.22%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.16pt; text-align: left;"><font style="padding-left: 5pt;">95</font></div></td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">446</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">15.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">DEBT INVESTMENTS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The balances of RMB10,597 and RMB2,480 as of December&#160;31, 2022 and 2021, respectively, represented bills receivable arising from the sale of pharmaceutical products. As the Company&#8217;s management policy is collect contractual cashflows when the bills expire or endorse the bills to supplier before the bills mature, management accounted for them as debt investments at fair value through other comprehensive income. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">16.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">PREPAYMENTS, DEPOSITS AND OTHER RECEIVABLES</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.79%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.42%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of December&#160;31,</div></td></tr><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.79%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 2.79%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.79%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prepayments<font style="padding-left: 1.85pt;"></font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.93pt; text-align: left;"><font style="padding-left: 3.33pt;">23,424</font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.93pt; text-align: left;">20,584</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deposits and other receivables<font style="padding-left: 3.56pt;"></font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.93pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">6,799</font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.93pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">5,565</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.93pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">30,223</font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.93pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">26,149</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less: Non-current portion of deposits and other receivables<font style="padding-left: 0.28pt;"></font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.93pt; text-align: left;"><font style="padding-left: 12.5pt;">(928)</font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.93pt; text-align: left;"><font style="padding-left: 9.17pt;">(938)</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">&#8195;&#8199;Non-current portion of prepayments<font style="padding-left: 1.34pt;"></font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.93pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;">(20,802</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.93pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(8,612</font><font style="min-width: 27.5pt;">)</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.93pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;">(21,730</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.93pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(9,550</font><font style="min-width: 27.5pt;">)</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.93pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">8,493</font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.93pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">16,599</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">17.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">CASH AND BANK BALANCES</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.62%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.75%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of December&#160;31,</div></td></tr><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.62%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 2.62%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.62%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and bank balances<font style="padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">214,920</div></td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">166,294</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less: Long-term bank deposits<font style="padding-left: 2.43pt;"></font></div></td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(51,500</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 0.77pt;"></font></div></td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">163,420</font></div></td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">166,294</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Cash at banks earns interest at floating rates based on daily bank deposit rates. The bank balances are deposited with creditworthy banks with no recent history of default.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-84<br></div></div></div>
<!--End Page 439-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 440-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg24"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">17.</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">CASH AND BANK BALANCES</font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: justify;">The long-term bank deposits represented certificates of deposits issued by China Merchants Bank which will fall due in February 2025. According to management&#8217;s assessment, the deposits have passed &#8220;solely payments of principal and interest test&#8221; and the Company intends to hold them till the due date, so management accounted for them as financial assets measured at amortized cost.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">TRADE PAYABLES </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 20pt; text-align: left;">Trade payables are non-interest bearing and are normally settled on 90-day terms. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">19.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">OTHER PAYABLES AND ACCRUALS </div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.96%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.93%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 17.7%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of December&#160;31,</div></td></tr><tr class="header"><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.96%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">Note</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.93%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.92%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.93%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.93%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.92%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred government grants*<font style="padding-left: 0.11pt;"></font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="padding-left: 5pt;">5,300</font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="padding-left: 5pt;">5,450</font></div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Contract liabilities<font style="padding-left: 4.52pt;"></font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="padding-left: 5pt;">1,012</font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="padding-left: 5pt;">2,204</font></div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deposits from customers<font style="padding-left: 2.88pt;"></font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="padding-left: 12.5pt;">380</font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="padding-left: 12.5pt;">383</font></div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other tax payables<font style="padding-left: 2.87pt;"></font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="padding-left: 12.5pt;">175</font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="padding-left: 17.5pt;">20</font></div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Payroll and welfare payables<font style="padding-left: 1.22pt;"></font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="padding-left: 0.37pt;">34,911</font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;">27,327</div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accrued expenses<font style="padding-left: 1.21pt;"></font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="padding-left: 5pt;">1,970</font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="padding-left: 5pt;">5,548</font></div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other payables<font style="padding-left: 3.42pt;"></font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;">22,081</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="padding-left: 5pt;">9,654</font></div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amounts due to related parties<font style="padding-left: 3.44pt;"></font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.96%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">25(ii)</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">785</font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">683</font></div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;">66,614</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;">51,269</div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less:<br></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Non-current portion of deposits from customers<font style="padding-left: 4.02pt;"></font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="padding-left: 9.17pt;">(380)</font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="padding-left: 9.17pt;">(383)</font></div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Non-current portion of deferred government grants<font style="padding-left: 1.26pt;"></font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(5,150</font><font style="min-width: 27.5pt;">)</font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(5,300</font><font style="min-width: 27.5pt;">)</font></div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current portion<font style="padding-left: 1.74pt;"></font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">61,084</font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">45,586</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The balance represents the government grants which were used for research and development projects and the development of the manufacturing plant in Cangzhou, Hebei Province, the PRC.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">20.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">SHARE CAPITAL </div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.79%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.42%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of December&#160;31,</div></td></tr><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.79%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.92%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 2.79%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.79%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.92%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Issued and fully paid ordinary share capital<font style="padding-left: 0.8pt;"></font></div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;">61,318</div></td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.79%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.76pt; text-align: left;">61,318</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 20pt; text-align: left;">A summary of movements in the Company&#8217;s share capital is as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.59%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.82%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in issue</div></td><td class="gutter" style="width: 1.59%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.59%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share capital</div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of January&#160;1, 2021, December&#160;31, 2021 and <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">December&#160;31, 2022<font style="padding-left: 4.25pt;"></font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.45pt; text-align: left;">61,318,000</div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.18%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.06pt; text-align: left;">61,318</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-85<br></div></div></div>
<!--End Page 440-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 441-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg25"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">21.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">CAPITAL RESERVE </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The amounts of the capital reserve and the movements therein for the reporting periods are presented in the consolidated statements of changes in equity.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">A summary of the capital reserve is as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr><td style="width: 85.71%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of January&#160;1, 2021<font style="padding-left: 0.15pt;"></font></div></td><td class="gutter" style="width: 3.52%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.52%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">241,860</div></td></tr><tr><td style="width: 85.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share option reserve<font style="padding-left: 2.65pt;"></font></div></td><td class="gutter" style="width: 3.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(1,805</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 85.71%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2021 and January&#160;1, 2022<font style="padding-left: 3.8pt;"></font></div></td><td class="gutter" style="width: 3.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">240,055</div></td></tr><tr><td style="width: 85.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share option reserve<font style="padding-left: 2.65pt;"></font></div></td><td class="gutter" style="width: 3.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">8,605</font></div></td></tr><tr><td style="width: 85.71%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2022<font style="padding-left: 0.16pt;"></font></div></td><td class="gutter" style="width: 3.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">248,660</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">22.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">SURPLUS RESERVE</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The amounts of the surplus reserve and the movements therein for the reporting period are presented in the consolidated statements of changes in equity.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">A summary of the surplus reserve is as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr><td style="width: 85.71%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of January&#160;1, 2021<font style="padding-left: 0.15pt;"></font></div></td><td class="gutter" style="width: 4.07%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.07%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">1,407</font></div></td></tr><tr><td style="width: 85.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Allocation to surplus reserve (Note (a))<font style="padding-left: 4.92pt;"></font></div></td><td class="gutter" style="width: 4.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 4.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">14,939</font></div></td></tr><tr><td style="width: 85.71%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2021 and January&#160;1, 2022<font style="padding-left: 3.8pt;"></font></div></td><td class="gutter" style="width: 4.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">16,346</div></td></tr><tr><td style="width: 85.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Allocation to surplus reserve (Note (a))<font style="padding-left: 4.92pt;"></font></div></td><td class="gutter" style="width: 4.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 4.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">15,103</font></div></td></tr><tr><td style="width: 85.71%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2022<font style="padding-left: 0.16pt;"></font></div></td><td class="gutter" style="width: 4.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">31,449</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Note:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Company allocates 10% of its net profit to surplus reserve each year. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">23.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">SHARE OPTION SCHEME </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In April 2019, Continent Pharmaceuticals Inc. (the intermediate holding company of the Company) issued share options to certain employees and consultants of the Company to purchase a total of 180,000,000 ordinary shares of Continent Pharmaceuticals Inc. (the &#8220;Cayman Share Option Scheme&#8221;). The Cayman Share Option Scheme has a contractual term of four years. Share options granted under the Cayman Share Option Scheme were accounted for as equity awards, and subject to service condition and certain specified performance targets. In addition, share options granted under the Cayman Share Option Scheme have an exercise price of RMB0.5 per share, and will not be exercisable until the closing of an initial public offering (&#8220;IPO&#8221;) and the lapse of the applicable lock-up periods after such IPO. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In February 2021, the board of directors of Continent Pharmaceuticals Inc. approved to terminate the Cayman Share Option Scheme, and the board of directors of the Company approved the 2021&#160;Stock Incentive Plan (the &#8220;2021&#160;Plan&#8221;) to certain employees and consultants of the Company to purchase a total of 9,197,685 ordinary shares of the Company. The 2021&#160;Plan has a contractual term of seven years. Share options granted under the 2021&#160;Plan were accounted for as equity awards, and subject to service condition and certain specified performance targets. In addition, share options granted under the 2021&#160;Plan have an exercise price of RMB9.79 per share, and will not be exercisable until the closing of an IPO and the lapse of the applicable lock-up periods after such IPO. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In December 2021, the board of directors of the Company approved to further amend the 2021&#160;Plan, and removed the exercise condition related to the closing of an IPO. In addition, all share options granted under the 2021&#160;Plan will generally vest over twenty months after the grant date, subject to certain specified performance targets. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-86<br></div></div></div>
<!--End Page 441-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 442-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg26"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">23.</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">SHARE OPTION SCHEME </font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">A summary of share option activity under the Cayman Share Option Scheme is as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 42.86%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.42%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">share options</div></td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.27%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">exercise <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">price <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per share</div></td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">grant-date <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">fair value <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per share</div></td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.73%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">remaining <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">contractual <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">term <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Years)</div></td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.8%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Aggregate <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">intrinsic <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">value</div></td></tr><tr><td style="width: 42.86%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding as of January&#160;1, 2021<font style="padding-left: 3.72pt;"></font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 0.98pt;">180,000,000</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.27%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.95pt; text-align: left;">0.5</div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.03%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.9pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.73%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.2pt; text-align: left;">2.1</div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.8%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.38pt; text-align: left;">&#8212;</div></td></tr><tr><td style="width: 42.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Replaced by the 2021&#160;Plan<font style="padding-left: 3.88pt;"></font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">(180,000,000<font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.27%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.95pt; text-align: left;"><font style="padding-left: 0.59pt;">0.5</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.03%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.9pt; text-align: left;"><font style="padding-left: 0.2pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.73%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.2pt; text-align: left;"><font style="padding-left: 2.7pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.8%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.38pt; text-align: left;"><font style="padding-left: 0.2pt;">&#8212;</font></div></td></tr><tr><td style="width: 42.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding as of December&#160;31, 2021<font style="padding-left: 0.59pt;"></font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 41.17pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.27%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.95pt; text-align: left;"><font style="padding-left: 2.7pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.03%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.9pt; text-align: left;"><font style="padding-left: 0.2pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.73%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.2pt; text-align: left;"><font style="padding-left: 2.7pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.8%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.38pt; text-align: left;"><font style="padding-left: 0.2pt;">&#8212;</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 20pt; text-align: left;">A summary of share option activity under the 2021&#160;Plan is as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 42.86%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.5%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.28%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">share options</div></td><td class="gutter" style="width: 1.5%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.5%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.27%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercise <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">price <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per share</div></td><td class="gutter" style="width: 1.5%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.5%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">grant-date <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">fair value <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per share</div></td><td class="gutter" style="width: 1.5%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.5%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.73%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">remaining <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">contractual <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">term <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Years)</div></td><td class="gutter" style="width: 1.5%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.5%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.8%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Aggregate <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">intrinsic <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">value <br></div></td></tr><tr><td style="width: 42.86%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding as of January&#160;1, 2021<font style="padding-left: 3.72pt;"></font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.54pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.03%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.74pt; text-align: left;"><font style="padding-left: 2.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.73%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.3pt; text-align: left;"><font style="padding-left: 2.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.73pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 42.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Granted in February 2021 as a replacement of Cayman Share Option Scheme<font style="padding-left: 2.33pt;"></font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;">9,197,685</div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.54pt; text-align: left;">9.79</div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.03%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.74pt; text-align: left;">2.4</div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.73%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.3pt; text-align: left;"><font style="padding-left: 2.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.73pt; text-align: left;">63,655</div></td></tr><tr><td style="width: 42.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Granted in December 2021<font style="padding-left: 3.44pt;"></font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 12.5pt;">60,330</font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.54pt; text-align: left;">9.79</div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.03%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.74pt; text-align: left;">3.6</div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.73%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.3pt; text-align: left;"><font style="padding-left: 2.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.73pt; text-align: left;"><font style="padding-left: 12.87pt;">411</font></div></td></tr><tr><td style="width: 42.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Forfeited<font style="padding-left: 2.85pt;"></font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 9.17pt;">(15,330)</font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.54pt; text-align: left;">9.79</div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.03%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.74pt; text-align: left;"><font style="padding-left: 2.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.73%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.3pt; text-align: left;"><font style="padding-left: 2.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.73pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 42.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cancelled<font style="padding-left: 4.51pt;"></font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF; border-bottom: 1px solid #CCEEFF;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 9.17pt;">(45,000)</font></div></td><td class="gutter" style="width: 1.5%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF; border-bottom: 1px solid #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.54pt; text-align: left;">9.79</div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.03%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.74pt; text-align: left;"><font style="padding-left: 2.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.73%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.3pt; text-align: left;"><font style="padding-left: 2.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.73pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 42.86%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding December&#160;31, 2021<font style="padding-left: 2.04pt;"></font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;">9,197,685</div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.54pt; text-align: left;">9.79</div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.03%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.74pt; text-align: left;"><font style="padding-left: 2.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.73%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.3pt; text-align: left;">6.1</div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.73pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 42.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Forfeited<font style="padding-left: 2.85pt;"></font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF; border-bottom: 1px solid #CCEEFF;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 14.17pt;">(2,555)</font></div></td><td class="gutter" style="width: 1.5%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF; border-bottom: 1px solid #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.54pt; text-align: left;">9.79</div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.03%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.74pt; text-align: left;"><font style="padding-left: 2.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.73%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.3pt; text-align: left;"><font style="padding-left: 2.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.73pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 42.86%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding December&#160;31, 2022<font style="padding-left: 2.04pt;"></font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.5%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; border-bottom: 3pt double #000000; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;">9,195,130</div></td><td class="gutter" style="width: 1.5%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.27%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.54pt; text-align: left;">9.79</div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.03%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.74pt; text-align: left;"><font style="padding-left: 2.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.73%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.3pt; text-align: left;">5.1</div></td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.73pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The exercise prices and exercise periods of the share options outstanding as at the end of each reporting period are as follows: </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">As of December&#160;31, 2021: </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>Number of options</u></div></td><td class="gutter" style="width: 0.94%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.94%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercise price <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">RMB per share</div></td><td class="gutter" style="width: 0.94%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.94%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.56%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercise period</div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9,197,685<font style="padding-left: 4.5pt;"></font></div></td><td class="gutter" style="width: 0.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.03%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.2pt; text-align: left;">9.79</div></td><td class="gutter" style="width: 0.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.56%; text-align: right; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">January&#160;4, 2023 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">to <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">January&#160;3, 2025</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 20pt; text-align: left;">As of December&#160;31, 2022: </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>Number of options</u></div></td><td class="gutter" style="width: 0.94%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.94%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercise price <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">RMB per share</div></td><td class="gutter" style="width: 0.94%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.94%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.56%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercise period</div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9,195,130<font style="padding-left: 4.5pt;"></font></div></td><td class="gutter" style="width: 0.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.03%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.2pt; text-align: left;">9.79</div></td><td class="gutter" style="width: 0.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.56%; text-align: right; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">January&#160;4, 2023 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">to <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">January&#160;3, 2025</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">As a result of the termination of Cayman Share Option Scheme and launch of the 2021&#160;Plan as a replacement in February 2021, the fair value of the share options increased by RMB1,897. The Company recognized share option expenses of RMB8,605 for the year ended December 31, 2022 and recognized reversal of share option expenses of RMB1,805 for the year ended December&#160;31, 2021, respectively. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-87<br></div></div></div>
<!--End Page 442-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 443-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg27"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">23.</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">SHARE OPTION SCHEME </font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: justify;">The fair value of equity-settled share options granted during the years ended December&#160;31, 2022 and 2021 was estimated as at the date of grant using a binomial model, taking into account the terms and conditions upon which the options were granted. The following table lists the inputs to the model used:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 27.47%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the year ended December&#160;31,</div></td></tr><tr class="header"><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dividend yield (%)<font style="padding-left: 0.64pt;"></font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: right; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">&#8212;</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: right; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">&#8212;</div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected volatility (%)<font style="padding-left: 4.53pt;"></font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.29%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">43.50 - 45.33</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.29%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">43.50 - 45.33</div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Historical volatility (%)<font style="padding-left: 2.31pt;"></font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">43.50 - 45.33</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">43.50 - 45.33</div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Risk-free interest rate (%)<font style="padding-left: 2.9pt;"></font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.29%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">2.83 - 2.92</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.29%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">2.83 - 2.92</div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected life of share options (year)<font style="padding-left: 4.58pt;"></font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">1.0 - 2.0</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">2.0 - 3.0</div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted average share price of the Company (RMB per share)<font style="padding-left: 2.1pt;"></font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.29%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">16.60</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.29%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">16.60</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The expected life of the options is based on management&#8217;s estimate and is not necessarily indicative of the exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility of comparable public companies is indicative of future trends, which may also not necessarily be the actual outcome.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">No other feature of the options granted was incorporated into the measurement of fair value.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">24.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">CAPITAL COMMITMENTS </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 20pt; text-align: left;">The Company had the following capital commitments as of December&#160;31, 2022 and 2021:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.62%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.75%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of December&#160;31,</div></td></tr><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.62%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 2.62%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.62%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Contracted, but not provided for:<br></div></td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Property, plant and equipment<font style="padding-left: 0.57pt;"></font></div></td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">39,943</font></div></td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">1,008</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development<font style="padding-left: 4.1pt;"></font></div></td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">206,023</font></div></td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">174,674</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">245,966</font></div></td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">175,682</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">25.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">RELATED PARTY TRANSACTIONS </div></td></tr></table><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 48.66%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Related party</div></td><td class="gutter" style="width: 1.34%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.34%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 48.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Relationship with the Company </div></td></tr><tr><td style="width: 48.66%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI Group Ltd.</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.66%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The ultimate holding company of the Company</div></td></tr><tr><td style="width: 48.66%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI Hong Kong Ltd.</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.66%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company controlled by the ultimate holding company, GNI Group Ltd.</div></td></tr><tr><td style="width: 48.66%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shanghai Genomics, Inc.</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.66%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company controlled by the ultimate holding company, GNI Group Ltd.</div></td></tr><tr><td style="width: 48.66%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shanghai Genomics Technology, Ltd.</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.66%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company controlled by the ultimate holding company, GNI Group Ltd.</div></td></tr><tr><td style="width: 48.66%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI Tianjin Limited</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.66%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company controlled by the ultimate holding company, GNI Group Ltd.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-88<br></div></div></div>
<!--End Page 443-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 444-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg28"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">25.</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">RELATED PARTY TRANSACTIONS </font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 0pt; margin-left: 20pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Company had the following transactions with related parties during the years:</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 27.47%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the year ended December&#160;31,</div></td></tr><tr class="header"><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.85%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development expenses and capitalized expenditures<br></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI Group Ltd.<font style="padding-left: 3.14pt;"></font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="padding-left: 12.5pt;">683</font></div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shanghai Genomics, Inc.<font style="padding-left: 2.31pt;"></font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;">1,145</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="padding-left: 12.5pt;">409</font></div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shanghai Genomics Technology, Ltd.<font style="padding-left: 1.62pt;"></font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">3</font></div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">1,145</font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 27.5pt;">1,095</font></div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Acquisition of patents and technological know-how<br></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 69.64%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI Tianjin Limited<font style="padding-left: 0.05pt;"></font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 3pt double #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">16,540</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Outstanding balances with related parties</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 80.36%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 16.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of December&#160;31,</div></td></tr><tr class="header"><td style="width: 80.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.92%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.92%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 80.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Due to related parties, which are trade in nature<br></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 80.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI Group Ltd.<font style="padding-left: 1.14pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">785</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">683</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Commitments with related parties</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">In September 2020, the Company entered into an intellectual property transfer agreement (the &#8220;F351 Transfer Agreement&#8221;) with Shanghai Genomics, Inc., GNI Tianjin Limited, GNI Hong Kong Limited and GNI Group Ltd. (collectively, the &#8220;F351 Transferors&#8221;) for the transfer of patents and technological know-how related to F351, the assets and intellectual property rights primarily related to the proprietary Hydronidone compound located in the PRC. Shanghai Genomics, Inc., GNI Tianjin Limited and GNI Hong Kong Limited are pharmaceutical companies wholly owned by GNI Group Ltd., the Company&#8217;s controlling shareholder. The Company paid Shanghai Genomics, Inc. RMB41,350 and GNI Tianjin Limited RMB16,540 in 2020, respectively. The amount of instalment paid in 2021 is disclosed in note 25(i)&#160;to the financial statements. Under the F351 Transfer Agreement, in exchange for the intellectual property rights, the Company is further obliged to pay RMB33,080 after the application for F351 New Drug Application (&#8220;NDA&#8221;) to the Center for Drug Evaluation of the National Medical Products Administration (the &#8220;NMPA&#8221;) of China is submitted, RMB8,270 after the NDA is passed the on-site inspection for drug registration of the F351 product by the Center for Food and Drug Review and Inspection of the NMPA, and RMB49,620 after the NDA is approved by the NMPA. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iv)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Compensation of key management personnel of the Company</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.11%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 28.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the year ended December&#160;31,</div></td></tr><tr class="header"><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.85%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 2.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.11%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Short term employee benefits<font style="padding-left: 1.99pt;"></font></div></td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="padding-left: 5pt;">7,101</font></div></td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;">5,433</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Performance related bonuses<font style="padding-left: 0.34pt;"></font></div></td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="padding-left: 5pt;">3,676</font></div></td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;">2,314</div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pension scheme contributions<font style="padding-left: 1.42pt;"></font></div></td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="padding-left: 12.5pt;">505</font></div></td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="padding-left: 7.5pt;">396</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recognition (reversal) of equity-settled share option expenses<font style="padding-left: 4.83pt;"></font></div></td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">1,638</font></div></td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="padding-left: 4.17pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">(335</font><font style="min-width: 22.5pt;">)</font></div></td></tr><tr><td style="width: 66.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total compensation paid to key management personnel<font style="padding-left: 2.16pt;"></font></div></td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">12,920</font></div></td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">7,808</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-89<br></div></div></div>
<!--End Page 444-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 445-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg29"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">26.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">FINANCIAL INSTRUMENTS BY CATEGORY </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The carrying amounts of each of the categories of financial instruments as at the end of the reporting period are as follows:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">As of December&#160;31, 2022:</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.5pt; margin-left: 20pt; text-align: left;"><u>Financial assets</u></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 17.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Financial assets at fair <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">value through other <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">comprehensive income <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">debt investments</div></td><td class="gutter" style="width: 0.99%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.99%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Financial assets at <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">amortized cost</div></td></tr><tr><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade receivables<font style="padding-left: 4.22pt;"></font></div></td><td class="gutter" style="width: 1%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 25.56pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.52pt; text-align: left;">108,753</div></td></tr><tr><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Debt investments at fair value through other comprehensive income<font style="padding-left: 2.28pt;"></font></div></td><td class="gutter" style="width: 1%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 17.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 25.56pt; text-align: left;">10,597</div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 14.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.52pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Financial assets included in prepayments, deposits and other receivables<font style="padding-left: 0.53pt;"></font></div></td><td class="gutter" style="width: 1%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 25.56pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.52pt; text-align: left;"><font style="padding-left: 10pt;">6,799</font></div></td></tr><tr><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and bank balances<font style="padding-left: 2.21pt;"></font></div></td><td class="gutter" style="width: 1%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 17.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 25.56pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 14.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.52pt; text-align: left;">163,420</div></td></tr><tr><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Bank deposits <font style="padding-left: 4.96pt;"></font></div></td><td class="gutter" style="width: 1%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 25.56pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.52pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">51,500</font></div></td></tr><tr><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 25.56pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">10,597</font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.52pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">330,472</font></div></td></tr></table><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 12.5pt; margin-left: 20pt; text-align: left;"><u>Financial liabilities</u></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 80.36%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 16.76%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Financial liabilities at <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">amortized cost</div></td></tr><tr><td style="width: 80.36%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade payables<font style="padding-left: 1.21pt;"></font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 16.76%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.81pt; text-align: left;"><font style="padding-left: 12.5pt;">850</font></div></td></tr><tr><td style="width: 80.36%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financial liabilities included in customers&#8217; deposits, other payables and accruals<font style="padding-left: 4.76pt;"></font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 16.76%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.81pt; text-align: left;">22,461</div></td></tr><tr><td style="width: 80.36%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amounts due to related parties<font style="padding-left: 1.44pt;"></font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 16.76%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.81pt; text-align: left;"><font style="padding-left: 12.5pt;">785</font></div></td></tr><tr><td style="width: 80.36%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities<font style="padding-left: 3.64pt;"></font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td style="width: 16.76%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.81pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">4,992</font></div></td></tr><tr><td style="width: 80.36%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 16.76%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.81pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">29,088</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">As of December&#160;31, 2021:</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.5pt; margin-left: 20pt; text-align: left;"><u>Financial assets</u></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 17.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Financial assets at fair <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">value through other <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">comprehensive income <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">debt investments</div></td><td class="gutter" style="width: 0.99%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.99%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Financial assets at <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">amortized cost</div></td></tr><tr><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade receivables<font style="padding-left: 4.22pt;"></font></div></td><td class="gutter" style="width: 1%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.55%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 28.06pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.52pt; text-align: left;"><font style="padding-left: 5pt;">64,058</font></div></td></tr><tr><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Debt investments at fair value through other comprehensive income<font style="padding-left: 2.28pt;"></font></div></td><td class="gutter" style="width: 1%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 17.55%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 28.06pt; text-align: left;">2,480</div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 14.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.52pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Financial assets included in prepayments, deposits and other receivables<font style="padding-left: 0.53pt;"></font></div></td><td class="gutter" style="width: 1%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.55%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 28.06pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.52pt; text-align: left;"><font style="padding-left: 10pt;">5,565</font></div></td></tr><tr><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and bank balances<font style="padding-left: 2.21pt;"></font></div></td><td class="gutter" style="width: 1%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td style="width: 17.55%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 28.06pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td style="width: 14.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.52pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">166,294</font></div></td></tr><tr><td style="width: 64.29%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.55%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 28.06pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">2,480</font></div></td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.99%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.18%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.52pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">235,917</font></div></td></tr></table><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 13pt; margin-left: 20pt; text-align: left;"><u>Financial liabilities</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -1pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 80.36%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 16.76%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Financial liabilities at <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">amortized cost</div></td></tr><tr><td style="width: 80.36%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade payables<font style="padding-left: 1.21pt;"></font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 16.76%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.81pt; text-align: left;"><font style="padding-left: 5pt;">1,600</font></div></td></tr><tr><td style="width: 80.36%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financial liabilities included in customers&#8217; deposits, other payables and accruals<font style="padding-left: 4.76pt;"></font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 16.76%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.81pt; text-align: left;">10,037</div></td></tr><tr><td style="width: 80.36%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amounts due to related parties<font style="padding-left: 1.44pt;"></font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 16.76%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.81pt; text-align: left;"><font style="padding-left: 12.5pt;">683</font></div></td></tr><tr><td style="width: 80.36%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities<font style="padding-left: 3.64pt;"></font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 16.76%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.81pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">7,834</font></div></td></tr><tr><td style="width: 80.36%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 16.76%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.81pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">20,154</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-90<br></div></div></div>
<!--End Page 445-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 446-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg30"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">27.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Management has assessed that the fair values of cash and cash equivalents, trade receivables, financial assets included in prepayments, deposits and other receivables, trade payables, financial liabilities included in other payables and accruals and amounts due from/to related parties approximate to their carrying amounts largely due to the short-term maturities of these instruments.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company&#8217;s finance department headed by the finance manager is responsible for determining the policies and procedures for the fair value measurement of financial instruments. The finance department reports directly to the chief financial officer. At each reporting date, the finance department analyses the movements in the values of financial instruments and determines the major inputs applied in the valuation. The valuation is reviewed and approved by the chief financial officer. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The following methods and assumptions were used to estimate the fair values:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The fair value of the financial assets at fair value through profit or loss, the debt investments at fair value through other comprehensive income, and the long-term bank deposits has been calculated by discounting the expected future cash flows using rates currently available for instruments with similar terms, credit risk and remaining maturities. Management has assessed that the fair values of the Company&#8217;s financial instruments reasonably approximate to their carrying amounts. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">The following tables illustrate the fair value measurement hierarchy of the Company&#8217;s financial instruments:</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">Assets measured at fair value:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>As of December&#160;31, 2022</u></div></td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.38%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 34.78%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair value measurement using</div></td><td class="gutter" style="width: 1.38%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.14%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.38%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Quoted prices <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in active <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">markets <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level 1)</div></td><td class="gutter" style="width: 1.38%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.38%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.23%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Significant <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">observable <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">inputs <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level 2)</div></td><td class="gutter" style="width: 1.38%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.38%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Significant <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">unobservable <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">inputs <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level 3)</div></td><td class="gutter" style="width: 1.38%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.38%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.14%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Debt investments at fair value through other comprehensive income<font style="padding-left: 4.2pt;"></font></div></td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.81%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.21pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.23%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.69pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">10,597</font></div></td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">10,597</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>As of December&#160;31, 2021</u></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.52%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 35.33%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair value measurement using</div></td><td class="gutter" style="width: 1.52%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.02%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.52%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Quoted prices <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in active <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">markets <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level 1)</div></td><td class="gutter" style="width: 1.52%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.52%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.23%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Significant <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">observable <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">inputs <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level 2)</div></td><td class="gutter" style="width: 1.52%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.52%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Significant <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">unobservable <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">inputs <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level 3)</div></td><td class="gutter" style="width: 1.52%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.52%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Debt investments at fair value through other comprehensive income<font style="padding-left: 4.2pt;"></font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.81%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.22pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.23%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.19pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">2,480</font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">2,480</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 20pt; text-align: justify;">The Company did not have any financial liabilities measured at fair value as of December&#160;31, 2022 and 2021.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">During the years, there were no transfers of fair value measurement between Level 1 and Level 2 and no transfers into or out of Level 3 for both financial assets and liabilities.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-91<br></div></div></div>
<!--End Page 446-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 447-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg31"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">27.</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS</font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">Assets for which fair values are disclosed:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>As of December&#160;31, 2022</u></div></td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.38%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 34.78%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair value measurement using</div></td><td class="gutter" style="width: 1.38%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.14%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.38%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Quoted prices <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in active <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">markets <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level 1)</div></td><td class="gutter" style="width: 1.38%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.38%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.23%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Significant <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">observable <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">inputs <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level 2)</div></td><td class="gutter" style="width: 1.38%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.38%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Significant <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">unobservable <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">inputs <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level 3)</div></td><td class="gutter" style="width: 1.38%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.38%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.14%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 53.57%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Bank deposits, non-current portion<font style="padding-left: 0.6pt;"></font></div></td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.81%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.21pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.23%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.69pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">51,500</font></div></td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">51,500</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company did not have any financial liabilities disclosed at fair value as of December&#160;31, 2022 and 2021. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">28.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company&#8217;s principal financial instruments comprise cash and bank balances and bank deposits. The main purpose of these financial instruments is to raise finance for the Company&#8217;s operations. The Company has various other financial assets and liabilities such as trade receivables, amounts due from/to related parties, financial assets included in prepayments, deposits and other receivables, trade payables, lease liabilities, financial liabilities included in customers&#8217; deposits, other payables and accruals, which arise directly from its operations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The main risks arising from the Company&#8217;s financial instruments are foreign currency risk, credit risk and liquidity risk. The board of directors reviews and agrees policies for managing each of these risks and they are summarized below.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;">Foreign currency risk</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company mainly operates in Mainland China with transactions primarily settled in RMB. The foreign exchange risk arising from recognized assets and liabilities is considered to be minimal.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;">Credit risk</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company trades only with recognized and creditworthy third parties. It is the Company&#8217;s policy that all customers who wish to trade on credit terms are subject to credit verification procedures. In addition, balances of receivables are monitored on an ongoing basis and the Company&#8217;s exposure to bad debts is not significant.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The credit risk of the Company&#8217;s other financial assets, which comprise cash and bank balances, bank deposits and other receivables included in the financial statements, arises from default of counterparty with a maximum exposure equal to the carrying amounts of these instruments.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Since the Company trades only with recognized and creditworthy third parties, there is no requirement for collateral. For trade and other receivables, the credit quality of the counterparties is assessed by taking into account their financial position, credit history and other factors. Given the constant repayment history, the Company is of the opinion that the risk of default by these counterparties is not significant.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">At the end of each reporting period, the Company had certain concentrations of credit risk. As of December&#160;31, 2022 and 2021, RMB214,920 and RMB166,294 were deposited with various major reputable financial institutions located in the PRC. In May 2015, a new Deposit Insurance System (&#8220;DIS&#8221;) managed by the People&#8217;s Bank of China (&#8220;PBOC&#8221;) was implemented by the Chinese government. Deposits in the licensed banks in mainland China are protected by DIS, up to a limit of RMB500. In the event of bankruptcy of one of these financial institutions, the Company may be unable to claim its deposits back in full. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">As of December&#160;31, 2022 and 2021, the Company had trade receivables arising from product sales of RMB109,615 and RMB64,504, respectively. The Company monitors economic conditions to identify facts or </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-92<br></div></div></div>
<!--End Page 447-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 448-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg32"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">28.</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES</font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: justify;">circumstances that may indicate receivables are at risk of collection. As of December&#160;31, 2022 and 2021, the Company's three largest customers contributed a total of 69.7% and 77.7% of trade receivables, respectively.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">For the year ended December&#160;31, 2022, revenue contributed by the Company's three largest customers represented 48.3%, 11.4% and 10.9% of pharmaceutical product revenue, respectively. For the year ended December&#160;31, 2021, revenue contributed by the Company's three largest customers represented 48.0%, 12.0% and 10.9% of pharmaceutical product revenue, respectively. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The tables below show the credit quality and the maximum exposure to credit risk based on the Company's credit policy, which is mainly based on past due information unless other information is available without undue cost or effort, and year-end staging classification as of December&#160;31, 2022 and 2021.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">The amounts presented are gross carrying amounts for financial assets.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">As at December&#160;31, 2022</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.81%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.81%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.34%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">12-month <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ECLs</div></td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 26.36%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Lifetime ECLs</div></td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.26%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.81%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.81%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.34%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stage 1</div></td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stage 2</div></td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stage 3</div></td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.84%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Simplified <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">approach</div></td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.26%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade receivables<font style="padding-left: 2.22pt;"></font></div></td><td class="gutter" style="width: 1.81%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.81%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.34%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.31pt; text-align: left;">109,615</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">109,615</div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Debt investments at fair value through other comprehensive income<font style="padding-left: 0.2pt;"></font></div></td><td class="gutter" style="width: 1.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.34%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.31pt; text-align: left;"><font style="padding-left: 5pt;">10,597</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt;">10,597</font></div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Financial assets included in prepayments, deposits and other receivables<font style="padding-left: 1.88pt;"></font></div></td><td class="gutter" style="width: 1.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.34%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 10pt;">6,799</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.31pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 10pt;">6,799</font></div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and bank balances<font style="padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 1.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.34%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.18pt; text-align: left;">163,420</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.31pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">163,420</div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Bank deposits<font style="padding-left: 1.29pt;"></font></div></td><td class="gutter" style="width: 1.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.34%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">51,500</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.31pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">51,500</font></div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.81%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.81%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.34%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">221,719</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.31pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">120,212</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">341,931</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 20pt; text-align: left;">As at December&#160;31, 2021</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 2pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.81%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.81%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.34%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">12-month <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ECLs</div></td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 26.36%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Lifetime ECLs</div></td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.26%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.81%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.81%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.34%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stage 1</div></td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stage 2</div></td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stage 3</div></td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.84%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Simplified <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">approach</div></td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.26%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade receivables<font style="padding-left: 2.22pt;"></font></div></td><td class="gutter" style="width: 1.81%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.81%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.34%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.81pt; text-align: left;">64,504</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt;">64,504</font></div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Debt investments at fair value through other comprehensive income<font style="padding-left: 0.2pt;"></font></div></td><td class="gutter" style="width: 1.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.34%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.81pt; text-align: left;"><font style="padding-left: 5pt;">2,480</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 10pt;">2,480</font></div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Financial assets included in prepayments, deposits and other receivables<font style="padding-left: 1.88pt;"></font></div></td><td class="gutter" style="width: 1.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.34%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 10pt;">5,565</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.81pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 10pt;">5,565</font></div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and bank balances<font style="padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 1.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.34%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">166,294</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.81pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">166,294</font></div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.81%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.81%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.34%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">171,859</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.66pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.81pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">66,984</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">238,843</font></div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18.5pt; margin-left: 20pt; text-align: left;">Liquidity risk</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company&#8217;s policies are to maintain sufficient cash and bank balances and to have available funding through bank and other borrowings to meet its working capital requirements.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-93<br></div></div></div>
<!--End Page 448-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 449-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg33"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">28.</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES</font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: justify;">The maturity profile of the Company&#8217;s financial liabilities as at the end of the reporting period, based on the contractual undiscounted payments, is as follows:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">As at December&#160;31, 2022</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 2pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">On demand</div></td><td class="gutter" style="width: 1.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.44%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Less than <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1&#160;year</div></td><td class="gutter" style="width: 1.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1 to 2 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">years</div></td><td class="gutter" style="width: 1.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.46%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2 to 5 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">years</div></td><td class="gutter" style="width: 1.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.14%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade payables<font style="padding-left: 2.21pt;"></font></div></td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.69pt; text-align: left;"><font style="padding-left: 12.5pt;">850</font></div></td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.41pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.46%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.99pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">850</font></div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Financial liabilities included in customers&#8217; deposits, other payables and accruals<font style="padding-left: 0.78pt;"></font></div></td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.69pt; text-align: left;">22,461</div></td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.41pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.46%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.99pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">22,461</div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amounts due to related parties<font style="padding-left: 2.44pt;"></font></div></td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.69pt; text-align: left;"><font style="padding-left: 12.5pt;">785</font></div></td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.41pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.46%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.99pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">785</font></div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities<font style="padding-left: 4.64pt;"></font></div></td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.69pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.41pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">3,557</font></div></td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">1,620</font></div></td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.46%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.99pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">5,177</font></div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.69pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">24,096</font></div></td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.41pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">3,557</font></div></td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">1,620</font></div></td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.46%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.99pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">29,273</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 20pt; text-align: left;">As at December&#160;31, 2021</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">On demand</div></td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.44%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Less than <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1&#160;year</div></td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1 to 2 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">years</div></td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2 to 5 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">years</div></td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.14%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade payables<font style="padding-left: 2.21pt;"></font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.69pt; text-align: left;"><font style="padding-left: 5pt;">1,600</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.41pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">1,600</font></div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Financial liabilities included in customers&#8217; deposits, other payables and accruals<font style="padding-left: 0.78pt;"></font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.69pt; text-align: left;">10,037</div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.41pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10,037</div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amounts due to related parties<font style="padding-left: 2.44pt;"></font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.69pt; text-align: left;"><font style="padding-left: 12.5pt;">683</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.41pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">683</font></div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities<font style="padding-left: 4.64pt;"></font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.69pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.41pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">3,430</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">3,369</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">1,527</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">8,326</font></div></td></tr><tr><td style="width: 48.21%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.69pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">12,320</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.44%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.41pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">3,430</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">3,369</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">1,527</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">20,646</font></div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18.5pt; margin-left: 20pt; text-align: left;">Capital management</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The primary objectives of the Company&#8217;s capital management are to safeguard the Company&#8217;s ability to continue as a going concern and to maintain healthy capital ratios in order to support its business and maximize shareholders&#8217; value.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Company manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Company may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. No changes were made in the objectives, policies or processes for capital management during the years ended December&#160;31, 2022 and 2021.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-94<br></div></div></div>
<!--End Page 449-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 450-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_208-finnotes_pg34"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BEIJING CONTINENT PHARMACEUTICALS CO., LTD.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">For the years ended December 31, 2022 and 2021<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic; font-weight: normal;">(Amounts expressed in thousands of RMB, except for number of shares and per share data)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">28.</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: -12pt; margin-left: 20pt; text-align: left;"><font style="font-weight: normal;">FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES</font><font style="font-weight: normal; padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: justify;">The Company monitors capital using a gearing ratio, which is net debt divided by the adjusted capital plus net debt. Net debt includes trade payables, other payables and accruals, amounts due to related parties and lease liabilities, less cash and bank balances. Capital includes equity attributable to owners of the parent. The gearing ratios as at each reporting period were as follows:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 448pt; margin-left: 20pt;"><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.5%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of December&#160;31,</div></td></tr><tr class="header"><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2022</div></td><td class="gutter" style="width: 2.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade payables<font style="padding-left: 2.21pt;"></font></div></td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 20.83pt;">850</font></div></td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">1,600</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accrued expenses<font style="padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">1,970</font></div></td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">5,548</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other payables<font style="padding-left: 2.42pt;"></font></div></td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">22,081</font></div></td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">9,654</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amounts due to related parties<font style="padding-left: 2.44pt;"></font></div></td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 20.83pt;">785</font></div></td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 20.83pt;">683</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities<font style="padding-left: 4.64pt;"></font></div></td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">4,992</font></div></td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">7,834</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less: Bank deposits<font style="padding-left: 1.86pt;"></font></div></td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">(51,500)</font></div></td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">&#8195;&#8194;Cash and bank balances<font style="padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 35.83pt;">(163,420</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 35.83pt;">(166,294</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash position<font style="padding-left: 2.41pt;"></font></div></td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(184,242)</div></td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(140,975)</div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Equity attributable to owners of the parent<font style="padding-left: 4.12pt;"></font></div></td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">624,467</font></div></td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">464,828</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Capital and net debt<font style="padding-left: 0.75pt;"></font></div></td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">440,225</font></div></td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">323,853</font></div></td></tr><tr><td style="width: 75%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gearing ratio<font style="padding-left: 4.64pt;"></font></div></td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8%; text-align: right; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(42%)</div></td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.25%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8%; text-align: right; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(44%)</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">29.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">EVENTS AFTER THE REPORTING PERIOD</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">On December&#160;26, 2022, GNI Group Ltd. and certain of its subsidiaries (collectively &#8220;GNI&#8221;) entered into a business combination agreement with Catalyst Biosciences, Inc. (&#8220;Catalyst&#8221;), pursuant to which GNI will transfer 34,319,600 of the Company&#8217;s ordinary shares to Catalyst in exchange for 953,821,796 ordinary shares of Catalyst. As of the issuance date of the consolidated financial statements, the transaction was not completed.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">30.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">APPROVAL OF THE FINANCIAL STATEMENTS</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 20pt; text-align: left;">The financial statements were approved and authorized for issue by the board of directors on March&#160;30, 2023.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-95<br></div></div></div>
<!--End Page 450-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 451-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;">Annex&#160;A</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Certain information identified by bracketed asterisks ([***]) has been omitted from this exhibit because it is both not material and would be competitively harmful if publicly disclosed. </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">BUSINESS COMBINATION AGREEMENT<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">among<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">CATALYST BIOSCIENCES, INC.,<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">GNI USA, INC.,<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">GNI GROUP LTD.<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">GNI HONG KONG LIMITED<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">SHANGHAI GENOMICS, INC.,<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">CONTINENT PHARMACEUTICALS INC.,<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">and<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">THE OTHER PARTIES THAT ARE SIGNATORIES HERETO<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dated as of December&#160;26, 2022</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7.5pt; text-align: center;">This document is not intended to create, nor will it be deemed to create, a legally binding or enforceable offer or <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">agreement, acceptance of an offer or agreement of any type or nature, unless and until agreed to and executed <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">by all parties hereto.</div></div></div></div>
<!--End Page 451-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 452-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">TABLE OF CONTENTS</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 15.38%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 70.51%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Page</div></td></tr><tr><td colspan="7" style="width: 93.59%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAA1">ARTICLE I CONTRIBUTION AND EXCHANGE<font style="padding-left: 1.17pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAA1"><font style="padding-left: 5pt;">A-</font>2</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS11">Section 1.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS11">Contributions<font style="padding-left: 2.5pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS11"><font style="padding-left: 5pt;">A-</font>2</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS12">Section 1.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS12">Closing<font style="padding-left: 1.39pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS12"><font style="padding-left: 5pt;">A-</font>3</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS13">Section 1.3</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS13">Effective Time<font style="padding-left: 2.12pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS13"><font style="padding-left: 5pt;">A-</font>3</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS14">Section 1.4</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS14">Exchange<font style="padding-left: 3.07pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS14"><font style="padding-left: 5pt;">A-</font>3</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS15">Section 1.5</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS15">Treatment of Operating Company Options<font style="padding-left: 4.57pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS15"><font style="padding-left: 5pt;">A-</font>3</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS16">Section 1.6</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS16">Contingent Value Right<font style="padding-left: 1.58pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS16"><font style="padding-left: 5pt;">A-</font>3</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS17">Section 1.7</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS17">Parent Matters.<font style="padding-left: 0.59pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS17"><font style="padding-left: 5pt;">A-</font>4</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS18">Section 1.8</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS18">Company Matters.<font style="padding-left: 2.24pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS18"><font style="padding-left: 5pt;">A-</font>4</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS19">Section 1.9</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS19">Further Challenger Matters.<font style="padding-left: 4.49pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS19"><font style="padding-left: 5pt;">A-</font>4</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS110">Section 1.10</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS110">Entity Matters.<font style="padding-left: 1.68pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS110"><font style="padding-left: 5pt;">A-</font>5</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS111">Section 1.11</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS111">Withholding Rights<font style="padding-left: 2.9pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS111"><font style="padding-left: 5pt;">A-</font>5</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td colspan="7" style="width: 93.59%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAA2">ARTICLE II REPRESENTATIONS AND WARRANTIES OF THE CONTRIBUTORS<font style="padding-left: 4.19pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAA2"><font style="padding-left: 5pt;">A-</font>5</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS21">Section 2.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS21">Organization, Standing and Power<font style="padding-left: 2.45pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS21"><font style="padding-left: 5pt;">A-</font>5</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS22">Section 2.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS22">Capital Stock<font style="padding-left: 2.51pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS22"><font style="padding-left: 5pt;">A-</font>5</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS23">Section 2.3</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS23">Subsidiaries<font style="padding-left: 3.63pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS23"><font style="padding-left: 5pt;">A-</font>6</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS24">Section 2.4</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS24">Authority<font style="padding-left: 3.62pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS24"><font style="padding-left: 5pt;">A-</font>6</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS25">Section 2.5</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS25">No Conflict; Consents and Approvals<font style="padding-left: 4.21pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS25"><font style="padding-left: 5pt;">A-</font>6</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS26">Section 2.6</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS26">Shares<font style="padding-left: 0.85pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS26"><font style="padding-left: 5pt;">A-</font>6</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS27">Section 2.7</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS27">Brokers<font style="padding-left: 0.85pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS27"><font style="padding-left: 5pt;">A-</font>7</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS28">Section 2.8</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS28">Accredited Investor Status<font style="padding-left: 4.77pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS28"><font style="padding-left: 5pt;">A-</font>7</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS29">Section 2.9</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS29">No Other Representations or Warranties<font style="padding-left: 4.11pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS29"><font style="padding-left: 5pt;">A-</font>7</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS210">Section 2.10</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS210">Exclusivity of Representations and Warranties<font style="padding-left: 4.11pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS210"><font style="padding-left: 5pt;">A-</font>7</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td colspan="7" style="width: 93.59%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAA3">ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE COMPANY<font style="padding-left: 3.26pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAA3"><font style="padding-left: 5pt;">A-</font>7</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS31">Section 3.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS31">Organization, Standing and Power<font style="padding-left: 2.45pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS31"><font style="padding-left: 5pt;">A-</font>7</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS32">Section 3.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS32">Authorized Share Capital<font style="padding-left: 4.2pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS32"><font style="padding-left: 5pt;">A-</font>8</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS33">Section 3.3</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS33">Subsidiaries<font style="padding-left: 3.63pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS33"><font style="padding-left: 5pt;">A-</font>8</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS34">Section 3.4</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS34">Authority<font style="padding-left: 3.62pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS34"><font style="padding-left: 5pt;">A-</font>9</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS35">Section 3.5</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS35">No Conflict; Consents and Approvals<font style="padding-left: 4.21pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS35"><font style="padding-left: 5pt;">A-</font>9</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS36">Section 3.6</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS36">Financial Statements<font style="padding-left: 3.08pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS36"><font style="padding-left: 5pt;">A-</font>9</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS37">Section 3.7</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS37">No Undisclosed Liabilities<font style="padding-left: 3.64pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS37">A-10</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS38">Section 3.8</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS38">Absence of Certain Changes or Events<font style="padding-left: 3.68pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS38">A-10</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS39">Section 3.9</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS39">Litigation<font style="padding-left: 3.06pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS39">A-10</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS310">Section 3.10</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS310">Compliance with Laws<font style="padding-left: 3.09pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS310">A-10</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS311">Section 3.11</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS311">Health Care Regulatory Matters.<font style="padding-left: 4.5pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS311"><font style="padding-left: 0.37pt;">A-</font>11</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS312">Section 3.12</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS312">Benefit Plans<font style="padding-left: 3.07pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS312">A-13</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS313">Section 3.13</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS313">Labor and Employment Matters<font style="padding-left: 1.99pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS313">A-14</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS314">Section 3.14</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS314">Environmental Matters<font style="padding-left: 4.2pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS314">A-15</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS315">Section 3.15</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS315">Taxes<font style="padding-left: 4.32pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS315">A-15</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS316">Section 3.16</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS316">Contracts<font style="padding-left: 4.18pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS316">A-17</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS317">Section 3.17</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS317">Insurance<font style="padding-left: 3.63pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS317">A-17</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS318">Section 3.18</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS318">Properties<font style="padding-left: 1.96pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS318">A-17</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS319">Section 3.19</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS319">Intellectual Property<font style="padding-left: 4.75pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS319">A-17</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS320">Section 3.20</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS320">State Takeover Statutes<font style="padding-left: 2.3pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS320">A-19</a></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-i<br></div></div></div>
<!--End Page 452-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 453-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 15.38%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 70.51%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Page</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS321">Section 3.21</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS321">No Rights Plan<font style="padding-left: 4.74pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS321">A-19</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS322">Section 3.22</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS322">Related Party Transactions<font style="padding-left: 3.63pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS322">A-19</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS323">Section 3.23</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS323">Certain Payments<font style="padding-left: 0.86pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS323">A-19</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td colspan="7" style="width: 93.59%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAA4">ARTICLE IV REPRESENTATIONS AND WARRANTIES OF PARENT<font style="padding-left: 1.58pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAA4">A-19</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS41">Section 4.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS41">Organization, Standing and Power<font style="padding-left: 2.45pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS41">A-19</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS42">Section 4.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS42">Capital Stock<font style="padding-left: 2.51pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS42">A-20</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS43">Section 4.3</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS43">Subsidiaries<font style="padding-left: 3.63pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS43">A-21</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS44">Section 4.4</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS44">Authority<font style="padding-left: 3.62pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS44">A-21</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS45">Section 4.5</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS45">No Conflict; Consents and Approvals<font style="padding-left: 4.21pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS45">A-22</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS46">Section 4.6</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS46">SEC Reports; Financial Statements<font style="padding-left: 4.2pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS46">A-22</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS47">Section 4.7</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS47">No Undisclosed Liabilities<font style="padding-left: 3.64pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS47">A-24</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS48">Section 4.8</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS48">Absence of Certain Changes or Events<font style="padding-left: 3.68pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS48">A-24</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS49">Section 4.9</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS49">Litigation<font style="padding-left: 3.06pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS49">A-25</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS410">Section 4.10</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS410">Compliance with Laws<font style="padding-left: 3.09pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS410">A-25</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS411">Section 4.11</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS411">Health Care Regulatory Matters<font style="padding-left: 2pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS411">A-25</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS412">Section 4.12</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS412">Benefit Plans<font style="padding-left: 3.07pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS412">A-27</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS413">Section 4.13</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS413">Labor and Employment Matters<font style="padding-left: 1.99pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS413">A-28</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS414">Section 4.14</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS414">Environmental Matters<font style="padding-left: 4.2pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS414">A-29</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS415">Section 4.15</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS415">Taxes<font style="padding-left: 4.32pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS415">A-29</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS416">Section 4.16</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS416">Contracts<font style="padding-left: 4.18pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS416">A-31</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS417">Section 4.17</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS417">Insurance<font style="padding-left: 3.63pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS417">A-31</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS418">Section 4.18</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS418">Properties<font style="padding-left: 1.96pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS418">A-31</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS419">Section 4.19</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS419">Intellectual Property<font style="padding-left: 4.75pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS419">A-32</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS420">Section 4.20</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS420">Related Party Transactions<font style="padding-left: 3.63pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS420">A-33</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS421">Section 4.21</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS421">Certain Payments<font style="padding-left: 0.86pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS421">A-33</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS422">Section 4.22</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS422">Brokers<font style="padding-left: 0.85pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS422">A-33</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS423">Section 4.23</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS423">State Takeover Statutes<font style="padding-left: 2.3pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS423">A-34</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS424">Section 4.24</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS424">No Other Representations or Warranties<font style="padding-left: 4.11pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS424">A-34</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td colspan="7" style="width: 93.59%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAA5">ARTICLE V REPRESENTATIONS AND WARRANTIES OF THE MINORITY HOLDERS<font style="padding-left: 1.42pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAA5">A-34</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS51">Section 5.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS51">Authority<font style="padding-left: 3.62pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS51">A-34</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS52">Section 5.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS52">No Conflict; Consents and Approvals.<font style="padding-left: 1.71pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS52">A-34</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS53">Section 5.3</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS53">Shares<font style="padding-left: 0.85pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS53">A-35</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS54">Section 5.4</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS54">Accredited Investor Status<font style="padding-left: 4.77pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS54">A-35</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS55">Section 5.5</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS55">Entity Representations and Warranties<font style="padding-left: 1.87pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS55">A-35</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS56">Section 5.6</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS56">No Other Representations or Warranties<font style="padding-left: 4.11pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS56">A-35</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS57">Section 5.7</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS57">Exclusivity of Representations and Warranties<font style="padding-left: 4.11pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS57">A-36</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td colspan="7" style="width: 93.59%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAA6">ARTICLE VI COVENANTS<font style="padding-left: 1.32pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAA6">A-36</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS61">Section 6.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS61">Conduct of Business<font style="padding-left: 3.08pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS61">A-36</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS62">Section 6.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS62">No Solicitation; Recommendation of the Transactions<font style="padding-left: 3.09pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS62">A-38</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS63">Section 6.3</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS63">Preparation of Form S-4 and Proxy Statement; Stockholders&#8217; Meeting<font style="padding-left: 1.67pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS63">A-42</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS64">Section 6.4</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS64">Access to Information; Confidentiality<font style="padding-left: 0.33pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS64">A-43</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS65">Section 6.5</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS65">Regulatory Approvals; Consents<font style="padding-left: 0.86pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS65">A-44</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS66">Section 6.6</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS66">Takeover Laws<font style="padding-left: 0.45pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS66">A-45</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS67">Section 6.7</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS67">Notification of Certain Matters<font style="padding-left: 0.89pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS67">A-45</a></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-ii<br></div></div></div>
<!--End Page 453-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 454-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 15.38%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 70.51%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Page</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS68">Section 6.8</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS68">Indemnification, Exculpation and Insurance<font style="padding-left: 4.51pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS68">A-45</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS69">Section 6.9</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS69">Stock Exchange Listing<font style="padding-left: 0.3pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS69">A-46</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS610">Section 6.10</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS610">Stockholder Litigation<font style="padding-left: 1.4pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS610">A-46</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS611">Section 6.11</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS611">Certain Tax Matters<font style="padding-left: 1.19pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS611">A-46</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS612">Section 6.12</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS612">Dividends<font style="padding-left: 1.4pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS612">A-46</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS613">Section 6.13</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS613">Public Announcements<font style="padding-left: 4.18pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS613">A-47</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS614">Section 6.14</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS614">Section 16 Matters<font style="padding-left: 0.31pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS614">A-47</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS615">Section 6.15</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS615">LTIP<font style="padding-left: 2.31pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS615">A-47</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS616">Section 6.16</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS616">Parent Deliverables<font style="padding-left: 3.09pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS616">A-47</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS617">Section 6.17</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS617">Contributions to GNI USA<font style="padding-left: 1.97pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS617">A-47</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td colspan="7" style="width: 93.59%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAA7">ARTICLE VII CONDITIONS PRECEDENT<font style="padding-left: 1.34pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAA7">A-48</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS71">Section 7.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS71">General Conditions<font style="padding-left: 3.63pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS71">A-48</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS72">Section 7.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS72">Conditions to the Obligations of Parent<font style="padding-left: 1.43pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS72">A-49</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS73">Section 7.3</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS73">Conditions to the Obligations of the Contributors and the Company<font style="padding-left: 0.35pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS73">A-49</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS74">Section 7.4</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS74">Frustration of Closing Conditions<font style="padding-left: 0.3pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS74">A-50</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td colspan="7" style="width: 93.59%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAA8">ARTICLE VIII TERMINATION, AMENDMENT AND WAIVER<font style="padding-left: 0.51pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAA8">A-50</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS81">Section 8.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS81">Termination<font style="padding-left: 3.76pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS81">A-50</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS82">Section 8.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS82">Effect of Termination<font style="padding-left: 4.7pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS82">A-51</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS83">Section 8.3</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS83">Fees and Expenses<font style="padding-left: 0.31pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS83">A-51</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS84">Section 8.4</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS84">Amendment or Supplement<font style="padding-left: 0.3pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS84">A-53</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS85">Section 8.5</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS85">Extension of Time; Waiver<font style="padding-left: 2.38pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS85">A-53</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td colspan="7" style="width: 93.59%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAA9">ARTICLE IX GENERAL PROVISIONS<font style="padding-left: 3.19pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAA9">A-53</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS91">Section 9.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS91">Nonsurvival of Representations and Warranties<font style="padding-left: 0.23pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS91">A-53</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS92">Section 9.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS92">Notices<font style="padding-left: 1.96pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS92">A-54</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS93">Section 9.3</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS93">Certain Definitions<font style="padding-left: 4.75pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS93">A-55</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS94">Section 9.4</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS94">Interpretation<font style="padding-left: 3.08pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS94">A-56</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS95">Section 9.5</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS95">Entire Agreement<font style="padding-left: 0.86pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS95">A-57</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS96">Section 9.6</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS96">No Third Party Beneficiaries<font style="padding-left: 4.4pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS96">A-57</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS97">Section 9.7</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS97">Governing Law<font style="padding-left: 3.63pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS97">A-57</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS98">Section 9.8</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS98">Submission to Jurisdiction<font style="padding-left: 4.74pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS98">A-57</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS99">Section 9.9</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS99">Assignment; Successors<font style="padding-left: 4.76pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS99">A-58</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS910">Section 9.10</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS910">Specific Performance<font style="padding-left: 0.32pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS910">A-58</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS911">Section 9.11</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS911">Currency<font style="padding-left: 0.29pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS911">A-58</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS912">Section 9.12</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS912">Severability<font style="padding-left: 4.18pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS912">A-58</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS913">Section 9.13</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS913">Waiver of Jury Trial<font style="padding-left: 4.43pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS913">A-58</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS914">Section 9.14</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS914">Counterparts<font style="padding-left: 0.85pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS914">A-58</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS915">Section 9.15</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS915">Facsimile or .pdf Signature<font style="padding-left: 1.15pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS915">A-58</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS916">Section 9.16</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS916">No Presumption Against Drafting Party<font style="padding-left: 0.88pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.72pt; text-align: left;"><a href="#tANXAS916">A-58</a></div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 17.95%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit A</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 80.77%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CVR Agreement</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit B</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 80.77%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Tax Certificate</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-iii<br></div></div></div>
<!--End Page 454-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 455-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">INDEX OF DEFINED TERMS</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 48.72%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Definition</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Location</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Acceptable Confidentiality Agreement</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6.2(c)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Acquisition Proposal</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6.2(j)(i)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Action</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.9</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Adverse Recommendation Change</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6.2(d)(i)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Affiliate</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9.3(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Agreement</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preamble</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Business Combination Proposal</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Business Day</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9.3(b)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and Cash Equivalents</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9.3(c)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Charter Amendment Proposal</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Closing</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.2</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Closing Date</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.2</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Closing Form 8-K</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6.13(b)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Closing Press Release</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6.13(b)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Code</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preamble</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Articles</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.1(b)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Balance Sheet</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.6(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Certificate of Incorporation</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.1(b)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Disclosure Letter</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Article III</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Expenses</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8.3(b)(iii)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Material Adverse Effect</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.1(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Ordinary Share</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Owned</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9.3(d)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Plans</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.12(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Products</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.11(c)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Registered IP</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.19(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Safety Notices</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.11(g)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Confidentiality Agreements</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6.4(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Contract</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.5(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Contributor</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preamble</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">control</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9.3(e)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Conversion Proposal</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Covered Person</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.2(d)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">COVID-19</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9.3(f)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CVR</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.6(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CVR Agreement</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.6(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CVR Distribution</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.6(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">D&amp;O Indemnified Parties</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6.8(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">DGCL</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Disqualifying Event</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.2(d)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Effective Time</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.3</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entity</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entity Shares</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.1</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Environmental Law</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.14(b)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ERISA</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.12(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exchange Act</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.5(b)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">F351 Agreement</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">FC Share</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-iv<br></div></div></div>
<!--End Page 455-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 456-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 48.72%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Definition</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Location</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">FDA</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.11(c)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">FDA Ethics Policy</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.11(i)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">FDCA</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.11(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form S-4</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6.3(c)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Further Challenger</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">GAAP</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.1(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI Group</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preamble</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI HK</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preamble</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI USA</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preamble</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI USA Contribution</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.1</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Governmental Entity</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.5(b)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Hazardous Substance</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.14(c)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Health Care Laws</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.11(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">HSR Act</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">7.1(b)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">IFRS</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.1(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Incentive Plan Proposal</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Indebtedness</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9.3(g)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Intellectual Property</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9.3(h)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Intended Tax Treatment</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interim Operating Amount</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6.16(b)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Intervening Event</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6.2(j)(iii)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">IRS</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.12(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">IT Systems</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.19(g)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">knowledge</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9.3(i)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Law</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.5(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Liens</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.5(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">LTIP</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6.15</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Material Contracts</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.16(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Measurement Date</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.2(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Minority Holder</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preamble</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Minority Holder Contribution</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.1</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net Cash</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9.3(j)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net Cash Schedule</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6.16(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating Company</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating Company Common Shares</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.5</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating Company Option</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.5</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ordinary Course Agreement</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.15(g)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outside Date</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8.1(b)(i)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preamble</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Balance Sheet</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9.3(k)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Board</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.6(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Capital Stock</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9.3(l)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Capital Stock Issuance</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.4(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Common Stock</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Convertible Preferred Stock</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Disclosure Letter</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Article IV</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Expenses</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8.3(b)(ii)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent IT Systems</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.19(f)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Legacy Proposal</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6.2(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Material Adverse Effect</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.1(a)</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-v<br></div></div></div>
<!--End Page 456-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 457-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 48.72%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Definition</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Location</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Material Contracts</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.16(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Option</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9.3(m)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Owned IP</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9.3(n)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Plans</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.12(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Products</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.11(c)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Registered IP</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.19(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Safety Notices</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.11(g)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent SEC Documents</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.6(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Stock Awards</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.2(b)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Stockholder Approval</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.4(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Stockholder Matters</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Stockholders Meeting</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6.3(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">PBGC</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.12(c)(iii)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pension Plan</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.12(b)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Permits</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.10</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Permitted Liens</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.18(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Person</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9.3(o)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Personal Information</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9.3(p)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Privacy Laws</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.19(h)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proxy Statement</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6.3(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Record Date</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.6(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Representatives</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6.2(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sarbanes-Oxley Act</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.6(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">SEC</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.8</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Securities Act</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.5(b)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shanghai Genomics</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preamble</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Signing Form 8-K</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6.13(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Subsidiary</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9.3(q)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Superior Proposal</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6.2(j)(ii)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Takeover Laws</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.20</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tax Action</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.15(d)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tax Return</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9.3(r)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Taxes</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9.3(s)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Termination Fee</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8.3(b)(i)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade Secrets</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8.3(h)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Transactions</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">WARN Act</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.13(d)</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-vi<br></div></div></div>
<!--End Page 457-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 458-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tANXA"><!--Anchor--></a>BUSINESS COMBINATION AGREEMENT</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This BUSINESS COMBINATION AGREEMENT (this &#8220;<u>Agreement</u>&#8221;), dated as of December&#160;26, 2022, is by and among CATALYST BIOSCIENCES, INC., a Delaware corporation (&#8220;<u>Parent</u>&#8221;), GNI USA, Inc., a Delaware corporation (&#8220;<u>GNI USA</u>&#8221;), GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (&#8220;<u>GNI Group</u>&#8221;), GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability (&#8220;<u>GNI HK</u>&#8221;), Shanghai Genomics, Inc., a company organized under the laws of the People&#8217;s Republic of China (&#8220;<u>Shanghai Genomics</u>&#8221;, and collectively with GNI USA, GNI Group and GNI HK, &#8220;<u>Contributors</u>,&#8221; and each a &#8220;<u>Contributor</u>&#8221;), the individuals listed on <u>Annex&#160;A</u> hereto (each, a &#8220;<u>Minority Holder</u>&#8221; and collectively, the &#8220;<u>Minority Holders</u>&#8221;) and Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares (the &#8220;<u>Company</u>&#8221;).</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; text-align: center;">RECITALS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, the parties intend to effect the contribution of the interests in each of the Company, Further Challenger International Limited, a company incorporated and existing under the laws of the British Virgin Islands with company number 1982271 (&#8220;<u>Further Challenger</u>&#8221;), and the interest in each of the entities held by the Minority Holders listed on <u>Annex&#160;A</u> hereto (each, an &#8220;<u>Entity</u>&#8221; and collectively, the &#8220;<u>Entities</u>&#8221;), to Parent in exchange for shares of common stock, par value $0.001 per share, of Parent (the &#8220;<u>Parent Common Stock</u>&#8221;), or at the election of GNI USA or the Minority Holders, shares of Parent Convertible Preferred Stock, on the terms and subject to the conditions set forth herein (collectively, the &#8220;<u>Transactions</u>&#8221;);</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, the parties intend that the GNI USA Contribution and Minority Holder Contribution, taken together, will qualify as a transaction governed by Section 351(a) of the Internal Revenue Code of 1986, as amended (the &#8220;<u>Code</u>,&#8221; and such treatment, the &#8220;<u>Intended Tax Treatment</u>&#8221;);</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, the board of directors of Parent has (i)&#160;unanimously approved this Agreement and the Transactions in accordance with the Delaware General Corporation Law (the &#8220;<u>DGCL</u>&#8221;) and determined that the Transactions are advisable and in the best interests of the stockholders of Parent and (ii)&#160;resolved to recommend that Parent stockholders approve (A) the consummation of the transactions contemplated hereby (the &#8220;<u>Business Combination </u><u>Proposal</u>&#8221;), (B) the conversion of the Series X Convertible Preferred Stock, par value $0.001 per share, of Parent (the &#8220;<u>Parent Convertible Preferred Stock</u>&#8221;) issued pursuant to the F351 Agreement into shares of Parent Common Stock in accordance with Nasdaq Listing Rule 5635 (the &#8220;<u>Conversion Proposal</u>&#8221;), (C) if deemed necessary or appropriate by Parent or as otherwise required by applicable Law or Contract, to authorize sufficient Parent Common Stock in Parent&#8217;s certificate of incorporation for the conversion of the Parent Convertible Preferred Stock issued pursuant to the F351 Agreement and/or to effectuate a reverse stock split (collectively, the &#8220;<u>Charter Amendment Proposal</u>&#8221;), and (D) if deemed necessary or appropriate by the parties in order to effectuate Section 1.5 hereto or as otherwise required by applicable Law or Contract, an increase in the share reserve under Parent&#8217;s 2018 Omnibus Incentive Plan (the &#8220;<u>Incentive Plan Proposal</u>&#8221; and, together with the Business Combination Proposal, the Conversion Proposal and the Charter Amendment Proposal, the &#8220;<u>Parent Stockholder Matters</u>&#8221;);</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, prior to the Closing, under <u>Section 6.17</u>, each of GNI Group and GNI HK shall contribute all of its ordinary shares in the capital of the Company, par value $0.0001 per share (each a &#8220;<u>Company Ordinary Share</u>&#8221;) to GNI USA, such that immediately prior to the Closing, GNI USA shall hold 72.22% of the Company Ordinary Shares;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, prior to the Closing, under <u>Section 6.17</u>, Shanghai Genomics shall contribute all of the 50,000 no par value shares of a single class it holds in Further Challenger (each a &#8220;<u>FC Share</u>&#8221;) to GNI USA, such that immediately prior to the Closing, GNI USA shall hold 100% of the FC Shares;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, the executive director of Shanghai Genomics has approved this Agreement and the Transactions, pursuant to which Shanghai Genomics shall contribute all of the FC Shares immediately prior to the Closing to GNI USA upon the terms and subject to the conditions set forth in this Agreement;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, the board of directors of GNI Group has approved this Agreement and the Transactions, pursuant to which GNI Group shall contribute all of the Company Ordinary Shares it holds prior to the Closing to GNI USA upon the terms and subject to the conditions set forth in this Agreement;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, the board of directors of GNI HK has approved this Agreement and the Transactions, pursuant to which GNI HK shall contribute all of the Company Ordinary Shares it holds prior to the Closing to GNI USA upon the terms and subject to the conditions set forth in this Agreement;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-1<br></div></div></div>
<!--End Page 458-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 459-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, the board of directors and the sole stockholder of GNI USA has approved this Agreement and the Transactions, pursuant to which GNI USA shall contribute all of the Company Ordinary Shares and all of the FC Shares it holds immediately prior to the Closing to Parent in exchange for shares of Parent Common Stock upon the terms and subject to the conditions set forth in this Agreement;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, the board of directors of the Company has approved this Agreement and the Transactions, pursuant to which GNI USA shall transfer all of the Company Ordinary Shares and all of the FC Shares it holds immediately prior to the Closing to Parent in exchange for shares of Parent Common Stock upon the terms and subject to the conditions set forth in this Agreement;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, each Minority Holder and the governing body of his or her wholly-owned respective Entity has approved this Agreement and the Transactions, pursuant to which each Minority Holder shall transfer all of his or her interests in such Entity he or she holds immediately prior to the Closing to Parent in exchange for shares of Parent Common Stock upon the terms and subject to the conditions set forth in this Agreement;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, the Company and the Minority Holders hold, in the aggregate, a 65.18% interest in Beijing Continent Pharmaceuticals Co., Ltd., a company organized under the laws of the People&#8217;s Republic of China (the &#8220;<u>Operating Company</u>&#8221;);</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, substantially concurrently with the execution of this Agreement, Parent, GNI Group, and GNI HK are entering into that certain Asset Purchase Agreement dated as of the date hereof (the &#8220;<u>F351 Agreement</u>&#8221;);</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, prior to the Closing, GNI Group and GNI HK shall contribute the shares of Parent Common Stock and Parent Convertible Preferred Stock issued to GNI Group and GNI HK pursuant to the F351 Agreement to GNI USA; and</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, Parent, the Contributors, the Minority Holders, and the Company desire to make certain representations, warranties, covenants and agreements in connection with the Transactions and also to prescribe certain conditions to the Transactions as specified herein.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">AGREEMENT</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">NOW, THEREFORE, in consideration of the premises, and of the representations, warranties, covenants and agreements contained herein, and intending to be legally bound hereby, Parent, the Contributors, and the Company hereby agree as follows:</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="tANXAA1"><!--Anchor--></a>ARTICLE I<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">CONTRIBUTION AND EXCHANGE</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS11"><!--Anchor--></a>Section 1.1&#8195;<u>Contributions</u>. Upon the terms and subject to the conditions set forth in this Agreement, at the Effective Time:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;GNI USA shall contribute all of the Company Ordinary Shares it holds immediately prior to the Closing to Parent in exchange for a number of shares of Parent Common Stock as set forth in <u>Section 1.4(a)(i)</u>;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;GNI USA shall contribute all of the FC Shares it holds immediately prior to the Closing to Parent in exchange for a number of shares of Parent Common Stock as set forth in <u>Section 1.4(a)(ii)</u> (together with the contribution described in <u>Section 1.1(a)</u>, the &#8220;<u>GNI USA Contribution</u>&#8221;); and</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;following the GNI USA Contribution, each Minority Holder shall contribute 100% of the interest he or she holds immediately prior to the Closing in his or her respective Entity (&#8220;<u>Entity Shares</u>&#8221;) to Parent in exchange for a number of shares of Parent Common Stock as set forth in <u>Section 1.4(a)(iii)</u> (such contributions described in this <u>Section 1.1(c)</u> are collectively referred to herein as the &#8220;<u>Minority Holder Contribution</u>&#8221;, and together with the GNI USA Contribution, the &#8220;<u>Contributions</u>&#8221;).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Following the Contributions, (i)&#160;the Company shall continue, directly and indirectly through Parent&#8217;s ownership of Further Challenger, as a wholly-owned subsidiary of Parent; (ii)&#160;Further Challenger shall continue as a wholly-owned subsidiary of Parent; and (iii)&#160;each of the Entities shall continue as a wholly-owned subsidiary of Parent.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-2<br></div></div></div>
<!--End Page 459-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 460-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS12"><!--Anchor--></a>Section 1.2&#8195;<u>Closing</u>. The closing of the Transactions (the &#8220;<u>Closing</u>&#8221;) shall take place at 10:00 a.m., eastern time, on the second Business Day following the satisfaction or, to the extent permitted by applicable Law, waiver of the conditions set forth in <u>Article VII</u> (other than those conditions that by their terms are to be satisfied at the Closing, but subject to the satisfaction or, to the extent permitted by applicable Law, waiver of those conditions), at the offices of Gibson, Dunn &amp; Crutcher LLP, 555 Mission Street, San Francisco, CA 94105, unless another date, time or place is agreed to in writing by Parent, the Contributors and the Company; <u>provided</u>, that the Closing may occur remotely via electronic exchange of required Closing documentation in lieu of an in-person Closing, and the parties shall cooperate in connection therewith. The date on which the Closing occurs is referred to in this Agreement as the &#8220;<u>Closing Date</u>.&#8221;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS13"><!--Anchor--></a>Section 1.3&#8195;<u>Effective Time</u>. The Transactions contemplated herein to occur on and as of the Closing Date shall be deemed to have occurred simultaneously and to be effective as of 12:01 a.m. on the Closing Date or at such other time as Parent, the Contributors and the Company shall agree in writing (the &#8220;<u>Effective Time</u>&#8221;).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS14"><!--Anchor--></a>Section 1.4&#8195;<u>Exchange</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;On the Closing Date, Parent shall issue an aggregate number of book-entry shares (or certificates, if requested) to GNI USA as set forth below:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(i)&#8195;688,850,101 shares of Parent Common Stock to GNI USA in exchange for the contribution of the Company to Parent;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(ii)&#8195;264,971,695 shares of Parent Common Stock to GNI USA in exchange for the contribution of Further Challenger to Parent;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iii)&#8195;an aggregate of 156,954,428 shares of Parent Common Stock to the Minority Holders, in the amounts set forth on <u>Annex&#160;A</u> hereto, in exchange for the contributions of the Entities to Parent.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;At the election of GNI USA or any Minority Holder, in lieu of the issuance of Parent Common Stock that GNI USA or any Minority Holder is entitled to be issued pursuant to <u>Section 1.4(a)</u> at the Closing, GNI USA or such Minority Holder may elect to be issued a number of shares of Parent Convertible Preferred Stock determined by dividing (i)&#160;the number of shares of Parent Common Stock GNI USA or such Minority Holder elects to receive in the form of Parent Convertible Preferred Stock by (ii) 10,000. GNI USA or such Minority Holder shall deliver notice of such election to Parent two (2) Business Days prior to the Closing.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS15"><!--Anchor--></a>Section 1.5&#8195;<u>Treatment of Operating Company Options</u>. At the Effective Time, each option to purchase common shares of the Operating Company (the &#8220;<u>Operating Company Common Shares</u>&#8221;) granted under any employee or director stock option, stock purchase or equity compensation plan, arrangement or agreement of the Operating Company (each, an &#8220;<u>Operating Company Option</u>&#8221;), that is outstanding immediately prior to the Effective Time and held by a United States taxpayer, will be converted into an option to purchase shares of Parent Common Stock with the exercise price, the number of shares of Parent Common Stock subject to such option and the terms and conditions of exercise of such option to be determined in a manner consistent with the requirements of Section&#160;409A of the Code in order to avoid the imposition of any additional taxes thereunder. With respect to any Operating Company Option that is outstanding immediately prior to the Effective Time and held by an individual who is not a United States taxpayer, such Operating Company Option will remain outstanding and, at the time that any such Operating Company Option becomes exercisable, the holder thereof shall have the option to receive, in lieu of Operating Company Common Shares, a number of shares of Parent Common Stock equal to the intrinsic value of such Operating Company Option on the exercise date. Prior to the Effective Time, the Company shall take, or cause to be taken, all actions necessary or appropriate to give effect to the provisions of this <u>Section 1.5</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS16"><!--Anchor--></a>Section 1.6&#8195;<u>Contingent Value Right</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;On the tenth (10<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>) day after the date of this Agreement (or if the tenth (10<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>) calendar day after the date of this Agreement is not a Business Day, then the immediately subsequent Business Day) (the &#8220;<u>Record </u><u>Date</u>&#8221;), the Board of Directors of Parent (the &#8220;<u>Parent Board</u>&#8221;) shall (i)&#160;set a record date for the CVR Distribution (as defined below) to the holders of Parent Common Stock of record on the Record Date and (ii)&#160;declare a distribution (the &#8220;<u>CVR Distribution</u>&#8221;) to the holders of Parent Common Stock of record as of the Record Date of the right to receive one contingent value right (each, a &#8220;<u>CVR</u>&#8221;) for each outstanding share of Parent Common Stock held by such stockholder as of such date (less applicable withholding taxes), each representing the right to receive contingent payments upon the occurrence of certain events set forth in, and subject to and in </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-3<br></div></div></div>
<!--End Page 460-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 461-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">accordance with the terms and conditions of, the Contingent Value Rights Agreement in the form attached hereto as <u>Exhibit A</u> (the &#8220;<u>CVR Agreement</u>&#8221;); <u>provided</u>, that (i)&#160;the holders of shares of Parent Common Stock that are entitled to receive such shares pursuant to this Agreement or the F351 Agreement will not receive CVRs for any such shares of Parent Common Stock held by such stockholder and (ii)&#160;such holders waive any rights to the CVRs for such shares. The CVR Distribution shall occur on the fifth (5<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>) Business Day following the Record Date.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;On the date of this Agreement, the Parent shall (i)&#160;provide Nasdaq, in accordance with Nasdaq Listing Rule 5250(e)(6), written notice of the Record Date, (ii)&#160;provide public disclosure of the CVR Distribution in a manner complaint with Regulation FD and (iii)&#160;make prior notification of the public disclosure to Nasdaq MarketWatch through the Electronic Disclosure submission system.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;Parent shall, as promptly as practicable after the Closing Date (and in any event prior to the CVR Distribution), duly authorize, execute and deliver the CVR Agreement. Parent agrees to pay all costs and fees associated with any action contemplated by this <u>Section 1.6</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS17"><!--Anchor--></a>Section 1.7&#8195;<u>Parent Matters</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;<u>Parent Certification of Incorporation</u>. As of the Effective Time, the certificate of incorporation of Parent shall be identical to the certificate of incorporation of Parent immediately prior to the Effective Time, unless the Contributors elect to amend the certificate of incorporation prior to the Closing, until thereafter amended in accordance with its terms and as provided by applicable Law.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;<u>Parent Bylaws</u>. As of the Effective Time, the bylaws of Parent shall be identical to the bylaws of Parent immediately prior to the Effective Time, unless the Contributors elect to amend the bylaws prior to the Closing, until thereafter amended in accordance with their terms and as provided by applicable Law.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;<u>Parent Directors</u>. Subject to the Parent Stockholder Approval, the parties shall take all action necessary (including, to the extent necessary, procuring the resignation or removal of any directors on the Board of Directors of Parent immediately prior to the Effective Time) so that, as of immediately after the Effective Time, the number of directors that comprise the full Board of Directors of Parent shall be five (5), and such Board of Directors shall immediately after the Effective Time initially consist of the individuals listed in <u>Schedule 1.7(c)</u> unless otherwise designated by the Contributors prior to the Closing, who shall serve in such capacity in accordance with the terms of the governing documents of Parent following the Closing.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;<u>Parent Officers</u>. The parties shall take all action necessary (including, to the extent necessary, procuring the resignation or removal of any officers of Parent immediately prior to the Effective Time) so that, as of the Effective Time, the Parent officers shall initially consist of the Persons listed in <u>Schedule 1.7(d)</u>, unless otherwise designated by the Contributors prior to the Closing.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS18"><!--Anchor--></a>Section 1.8&#8195;<u>Company Matters</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;<u>Company Articles</u>. At the Effective Time, the Company Articles immediately prior to the Effective Time shall be the memorandum and articles of association of the Company until thereafter amended in accordance with its terms and as provided by applicable Law.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;<u>Company Directors and Officers</u>. At the Effective Time, the directors and officers of the Company immediately prior to the Effective Time shall be the directors and officers of the Company until the earlier of their resignation or removal or until their respective successors are duly elected and qualified.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS19"><!--Anchor--></a>Section 1.9&#8195;<u>Further Challenger Matters</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;<u>Further Challenger Articles</u>. At the Effective Time, the memorandum and articles of association of Further Challenger immediately prior to the Effective Time shall be the memorandum and articles of association of Further Challenger until thereafter amended in accordance with its terms and as provided by applicable Law. (b)<u>Further Challenger Directors and Officers</u>. At the Effective Time, the directors and officers of Further Challenger immediately prior to the Effective Time shall be the directors and officers of Further Challenger until the earlier of their resignation or removal or until their respective successors are duly elected and qualified.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-4<br></div></div></div>
<!--End Page 461-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 462-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS110"><!--Anchor--></a>Section 1.10&#8195;<u>Entity Matters</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;<u>Entity Governing Documents</u>. At the Effective Time, the governing documents of each Entity immediately prior to the Effective Time shall be the governing documents of each Entity, unless the Contributors elect to amend the governing documents prior to the Closing, until thereafter amended in accordance with its terms and as provided by applicable Law.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;<u>Entity Directors and Officers</u>. The parties shall take all action necessary (including, to the extent necessary, procuring the resignation or removal of any officers and directors of each Entity immediately prior to the Effective Time) so that, as of the Effective Time, each Entity&#8217;s officers and directors shall consist of the Persons designated by Parent.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS111"><!--Anchor--></a>Section 1.11&#8195;<u>Withholding Rights</u>. Parent shall be entitled to deduct and withhold, or cause to be deducted and withheld, from any amount payable to the Contributors such amounts that are required to be deducted or withheld therefrom in respect of any U.S. federal, state, or local or non-U.S. tax Law; provided, however, that (i)&#160;Parent shall not, absent a change in Law after the date hereof, deduct or withhold from any amount payable to GNI USA in respect of any non-U.S. Tax Law and (ii)&#160;Parent shall give notice to the applicable payee before effecting any such Tax withholding, and cooperate with the applicable payee to minimize any required deduction and withholding. To the extent such amounts are so deducted or withheld and remitted to the applicable Governmental Entity, such amounts shall be treated for all purposes under this Agreement as having been paid to the Person to whom such amounts would otherwise have been paid.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="tANXAA2"><!--Anchor--></a>ARTICLE II<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">REPRESENTATIONS AND WARRANTIES OF THE CONTRIBUTORS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Each Contributor represents and warrants to Parent, each on behalf of itself only and not on behalf of the other, as follows:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS21"><!--Anchor--></a>Section 2.1&#8195;<u>Organization, Standing and Power</u>. The Contributor is an entity duly organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS22"><!--Anchor--></a>Section 2.2&#8195;<u>Capital Stock</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The authorized share capital of the Company and number of outstanding and issued Company Ordinary Shares is set forth in <u>Section 3.2</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The maximum number of shares Further Challenger is authorized to issue consists of 50,000 FC Shares. As of the date hereof, 50,000 FC Shares were issued and outstanding. All outstanding FC Shares are duly authorized, validly issued, fully paid and nonassessable and not subject to any preemptive rights. Further Challenger does not have outstanding any bonds, debentures, notes or other obligations having the right to vote (or convertible into, or exchangeable or exercisable for, interests having the right to vote) with the shareholders of Further Challenger any matter. Except as set forth above in this <u>Section 2.2(b)</u>, there are no outstanding (A)&#160;shares or other voting or equity interests of Further Challenger, (B) securities of Further Challenger convertible into or exchangeable or exercisable for shares of Further Challenger or other voting or equity interests of Further Challenger, (C) profits or revenue-based interests or rights, including beneficial, appreciation, phantom or tracking interests in or rights to the ownership or earnings of Further Challenger or other equity equivalent or equity-based awards or rights, (D) subscriptions, options, warrants, calls, commitments, Contracts or other rights to acquire from Further Challenger, or obligations of Further Challenger to issue, any shares of Further Challenger, voting interests, equity interests or securities convertible into or exchangeable or exercisable for shares or other voting interests or equity interests of Further Challenger or rights or interests described in the preceding clause (C), or (E) obligations of Further Challenger to repurchase, redeem or otherwise acquire any such interests or to issue, grant, deliver or sell, or cause to be issued, granted, delivered or sold, any such interests. There are no shareholder agreements, voting trusts or other agreements or understandings to which Further Challenger is a party or of which Further Challenger has knowledge with respect to the holding, voting, registration, redemption, repurchase or disposition of, or that restrict the transfer of, any shares or other voting interests or equity interests of Further Challenger.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;Further Challenger does not have any option plan or any other plan, program, agreement or arrangement providing for an equity-based compensation for any Person.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-5<br></div></div></div>
<!--End Page 462-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 463-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS23"><!--Anchor--></a>Section 2.3&#8195;<u>Subsidiaries</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(a)&#8195;The Subsidiaries of the Company are set forth in <u>Section 3.3</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Except for the capital stock of, or other equity or voting interests in, the Company, Further Challenger does not own, directly or indirectly, any equity, membership interest, partnership interest, joint venture interest, or other equity or voting interest in, or any interest convertible into, exercisable or exchangeable for any of the foregoing, nor is it under any current or prospective obligation to form or participate in, provide funds to, make any loan, capital contribution, guarantee, credit enhancement or other investment in, or assume any liability or obligation of, any Person.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS24"><!--Anchor--></a>Section 2.4&#8195;<u>Authority</u>. The Contributor has all necessary power and authority to execute, deliver and perform its obligations under this Agreement and to consummate the transactions contemplated hereby. The execution, delivery and performance of this Agreement by the Contributor and the consummation by the Contributor of the transactions contemplated hereby have been duly authorized by all necessary action on the part of the Contributor and no other proceedings on the part of the Contributor are necessary to approve this Agreement or to consummate the transactions contemplated hereby. This Agreement has been duly executed and delivered by the Contributor and, assuming the due authorization, execution and delivery by Parent, constitutes a valid and binding obligation of the Contributor, enforceable against the Contributor in accordance with its terms (except to the extent that enforceability may be limited by applicable bankruptcy, insolvency, moratorium, reorganization or similar Laws affecting the enforcement of creditors&#8217; rights generally or by general principles of equity).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS25"><!--Anchor--></a>Section 2.5&#8195;<u>No Conflict; Consents and Approvals</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The execution, delivery and performance of this Agreement by the Contributor does not, and the consummation of the transactions contemplated hereby and compliance by the Contributor with the provisions hereof will not, conflict with, or result in any violation or breach of, any provision of, or:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(i)&#8195;conflict with or violate the organizational documents of the Contributor;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(ii)&#8195;conflict with or violate any federal, state, local or foreign law (including common law), statute, ordinance, rule, code, regulation, order, judgment, injunction, decree or other legally enforceable requirement (&#8220;<u>Law</u>&#8221;), injunction, decree or order of any Governmental Entity applicable to the Contributor or by which any property or asset of the Contributor is bound or affected; or</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iii)&#8195;conflict with, result in any breach of, constitute a default (or an event that, with notice or lapse of time or both, would become a default) under, create in any party the right to accelerate, terminate, modify or cancel, or require any consent of any Person pursuant to, any material contract or material agreement to which the Contributor is a party;</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">except as, in the case of clauses (ii)&#160;and (iii), as individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;No consent, approval, order or authorization of, or registration, declaration, filing with or notice to, any federal, state, local or foreign government or subdivision thereof or any other governmental, administrative, judicial, arbitral, legislative, executive, regulatory or self-regulatory authority, instrumentality, agency, commission or body (each, a &#8220;<u>Governmental Entity</u>&#8221;) is required by or with respect to the Contributor in connection with the execution, delivery and performance of this Agreement by the Contributor or the consummation by the Company of the Transactions and the other transactions contemplated hereby or compliance with the provisions hereof, except for (i)&#160;the filing with the SEC of such reports under Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;<u>Exchange Act</u>&#8221;), as may be required in connection with this Agreement and the transactions contemplated hereby, (ii)&#160;such other filings and reports as may be required pursuant to the applicable requirements of the Securities Act of 1933, as amended (the &#8220;<u>Securities Act</u>&#8221;), the Exchange Act and any other applicable state or federal securities, takeover and &#8220;blue sky&#8221; laws and (iii)&#160;such other consents, approvals, orders, authorizations, registrations, declarations, filings or notices the failure of which to be obtained or made would not be material to the Contributor.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS26"><!--Anchor--></a>Section 2.6&#8195;<u>Shares</u>. The Contributor is the record and beneficial owner of the Company Ordinary Shares or the FC Shares, as applicable, free and clear of any encumbrance (other than restrictions on transfer that may arise under applicable securities Laws). The Contributor has the right, authority and power to assign and transfer the Company Ordinary Shares or the FC Shares, as applicable, to Parent.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-6<br></div></div></div>
<!--End Page 463-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 464-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS27"><!--Anchor--></a>Section 2.7&#8195;<u>Brokers</u>. No broker, investment banker, financial advisor or other Person is entitled to any broker&#8217;s, finder&#8217;s, financial advisor&#8217;s or other similar fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of the Company or any of its Affiliates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS28"><!--Anchor--></a>Section 2.8&#8195;<u>Accredited Investor Status</u>. Prior to the date of this Agreement, the Contributor is an &#8220;accredited investor&#8221; within the meaning of Regulation D, Rule 501(a), promulgated by the Securities and Exchange Commission (the &#8220;<u>SEC</u>&#8221;) under the Securities Act or is not a &#8220;U.S. person&#8221; within the meaning of Regulation S, Rule 902, promulgated by the SEC under the Securities Act.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS29"><!--Anchor--></a>Section 2.9&#8195;<u>No Other Representations or Warranties</u>. Except for the representations and warranties contained in <u>Article IV</u>, the Contributor acknowledges and agrees that none of Parent or any other Person on behalf of Parent makes any other express or implied representation or warranty whatsoever, and specifically (but without limiting the generality of the foregoing) that none of Parent, its Subsidiaries or any other Person on behalf of Parent makes any representation or warranty with respect to any projections or forecasts delivered or made available to the Contributor or any of its Representatives of future revenues, results of operations (or any component thereof), cash flows or financial condition (or any component thereof) of Parent (including any such projections or forecasts made available to the Contributor and Representatives in certain &#8220;data rooms&#8221; or management presentations in expectation of the transactions contemplated by this Agreement), and the Contributor has not relied on any such information or any representation or warranty not set forth in <u>Article IV</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS210"><!--Anchor--></a>Section 2.10&#8195;<u>Exclusivity of Representations and Warranties</u>. Neither the Contributor nor any of its Affiliates or Representatives is making any representation or warranty on behalf of the Contributor of any kind or nature whatsoever, oral or written, express or implied, except as expressly set forth in this <u>Article II</u>, and the Contributor hereby disclaims any such other representations or warranties.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; text-align: center;"><a name="tANXAA3"><!--Anchor--></a>ARTICLE III<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">REPRESENTATIONS AND WARRANTIES OF THE COMPANY</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Except as set forth in the corresponding section or subsection of the disclosure letter delivered by the Company to Parent immediately prior to the execution of this Agreement (the &#8220;<u>Company Disclosure Letter</u>&#8221;) (it being agreed that the disclosure of any information in a particular section or subsection of the Company Disclosure Letter shall be deemed disclosure of such information with respect to any other section or subsection of this Agreement to which the relevance of such information is reasonably apparent), the Company represents and warrants to Parent as follows (and any references to the Company that are made in Section 3.8 through Section 3.23 (inclusive) shall be deemed to refer to the Company and its Subsidiaries):</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS31"><!--Anchor--></a>Section 3.1&#8195;<u>Organization, Standing and Power</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The Company (i)&#160;is an entity duly organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation, (ii)&#160;has all requisite corporate power and authority to own, lease and operate its properties and to carry on its business as now being conducted and (iii)&#160;is duly qualified or licensed to do business and is in good standing in each jurisdiction in which the nature of its business or the ownership, leasing or operation of its properties makes such qualification or licensing necessary, except in the case of clause (iii), where the failure to be so qualified or licensed or in good standing, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. For purposes of this Agreement, &#8220;<u>Company Material Adverse Effect</u>&#8221; means any event, change, circumstance, occurrence, effect or state of facts that (A) is or would reasonably be expected to be materially adverse to the business, assets, liabilities, financial condition, results of operations of the Company and its Subsidiaries, taken as a whole, or (B) materially impairs the ability of the Company to consummate the Transactions or any of the other transactions contemplated by this Agreement; provided, however, that in the case of clause (A) only, Company Material Adverse Effect shall not include any event, change, circumstance, occurrence, effect or state of facts to the extent resulting from (1) changes or conditions generally affecting the industries in which the Company or any of its Subsidiaries operates, or the economy or the financial, debt, banking, capital, credit or securities markets, in the United States, including effects on such industries, economy or markets resulting from any regulatory and political conditions or developments in general, (2) the outbreak or escalation of war or acts of terrorism or any natural disasters, acts of God or comparable events, epidemic, pandemic or disease outbreak (including the COVID-19 virus) or any worsening of the foregoing or any declaration of martial law, quarantine or similar directive, policy or guidance or Law or other action by any Governmental Entity in response thereto, </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-7<br></div></div></div>
<!--End Page 464-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 465-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">(3) changes in Law or International Financial Reporting Standards (the &#8220;<u>IFRS</u>&#8221;), or the interpretation or enforcement thereof, (4) the public announcement of this Agreement, or (5) any specific action taken (or omitted to be taken) by the Company at or with the express written consent of Parent; provided, that, with respect to clauses (1), (2) and (3), the impact of such event, change, circumstance, occurrence, effect or state of facts is not disproportionately adverse to the Company as compared to other participants in the industries in which the Company operates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The Company has previously made available to Parent true and complete copies of the Company&#8217;s certificate of incorporation (the &#8220;<u>Company Certificate of Incorporation</u>&#8221;) and memorandum and articles of association (the &#8220;<u>Company Articles</u>&#8221;), in each case as amended to the date of this Agreement, and each as so delivered is in full force and effect. The Company is not in violation of any provision of the Company Articles.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;The Operating Company (i)&#160;is an entity duly organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation, (ii)&#160;has all requisite corporate power and authority to own, lease and operate its properties and to carry on its business as now being conducted and (iii)&#160;is duly qualified or licensed to do business and is in good standing in each jurisdiction in which the nature of its business or the ownership, leasing or operation of its properties makes such qualification or licensing necessary, except in the case of clause (iii), where the failure to be so qualified or licensed or in good standing, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;The Company has previously made available to Parent true and complete copies of the Operating Company&#8217;s organizational documents, in each case as amended to the date of this Agreement, and each as so delivered is in full force and effect. The Company is not in violation of any provision of the Operating Company&#8217;s organizational documents.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS32"><!--Anchor--></a>Section 3.2&#8195;<u>Authorized Share Capital</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The authorized share capital of the Company is $50,000.000 divided into 500,000,000 shares of a nominal or par value of $0.0001 each. As of the date hereof, 20,903,448 Company Ordinary Shares are issued and outstanding. All issued and outstanding Company Ordinary Shares are duly authorized, validly issued, fully paid and nonassessable and not subject to any preemptive rights. The Company does not have outstanding any bonds, debentures, notes or other obligations having the right to vote (or convertible into, or exchangeable or exercisable for, interests having the right to vote) with the members of the Company on any matter. Except as set forth above in this <u>Section 3.2(a)</u>, there are no outstanding (A) shares or other voting or equity interests of the Company, (B) securities of the Company convertible into or exchangeable or exercisable for shares of the Company or other voting or equity interests of the Company, (C) profits or revenue-based interests or rights, including beneficial, appreciation, phantom or tracking interests in or rights to the ownership or earnings of the Company or other equity equivalent or equity-based awards or rights, (D) subscriptions, options, warrants, calls, commitments, Contracts or other rights to acquire from the Company, or obligations of the Company to issue, any shares of the Company, voting interests, equity interests or securities convertible into or exchangeable or exercisable for shares or other voting interests or equity interests of the Company or rights or interests described in the preceding clause (C), or (E) obligations of the Company to repurchase, redeem or otherwise acquire any such interests or to issue, grant, deliver or sell, or cause to be issued, granted, delivered or sold, any such interests. There are no shareholder agreements, voting trusts or other agreements or understandings to which the Company is a party or of which the Company has knowledge with respect to the holding, voting, registration, redemption, repurchase or disposition of, or that restrict the transfer of, any shares or other voting interests or equity interests of the Company.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The Company does not have any option plan or any other plan, program, agreement or arrangement providing for an equity-based compensation for any Person.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS33"><!--Anchor--></a>Section 3.3&#8195;<u>Subsidiaries</u>. <u>Section 3.3</u> of the Company Disclosure Letter sets forth a true and complete list of each Subsidiary of the Company, including its jurisdiction of incorporation or formation. Except for the capital stock of, or other equity or voting interests in, its Subsidiaries, the Company does not own, directly or indirectly, any equity, membership interest, partnership interest, joint venture interest, or other equity or voting interest in, or any interest convertible into, exercisable or exchangeable for any of the foregoing, nor is it under any current or prospective obligation to form or participate in, provide funds to, make any loan, capital contribution, guarantee, credit enhancement or other investment in, or assume any liability or obligation of, any Person.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-8<br></div></div></div>
<!--End Page 465-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 466-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS34"><!--Anchor--></a>Section 3.4&#8195;<u>Authority</u>. The Company has all necessary power and authority to execute, deliver and perform its obligations under this Agreement and to consummate the transactions contemplated hereby. The execution, delivery and performance of this Agreement by the Company and the consummation by the Company of the transactions contemplated hereby have been duly authorized by all necessary action on the part of the Company and no other proceedings on the part of the Company are necessary to approve this Agreement or to consummate the Transactions and the other transactions contemplated hereby. This Agreement has been duly executed and delivered by the Company and, assuming the due authorization, execution and delivery by Parent, constitutes a valid and binding obligation of the Company, enforceable against the Company in accordance with its terms (except to the extent that enforceability may be limited by applicable bankruptcy, insolvency, moratorium, reorganization or similar Laws affecting the enforcement of creditors&#8217; rights generally or by general principles of equity).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS35"><!--Anchor--></a>Section 3.5&#8195;<u>No Conflict; Consents and Approvals</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The execution, delivery and performance of this Agreement by the Company does not, and the consummation of the Transactions and the other transactions contemplated hereby and compliance by the Company with the provisions hereof will not, conflict with, or result in any violation or breach of, or default (with or without notice or lapse of time, or both) under, or give rise to a right of, or result in, termination, cancellation, modification or acceleration of any obligation or to the loss of a benefit under, or result in the creation of any pledge, claim, lien, charge, option, right of first refusal, encumbrance or security interest of any kind or nature whatsoever (including any limitation on voting, sale, transfer or other disposition or exercise of any other attribute of ownership) (collectively, &#8220;<u>Liens</u>&#8221;) in or upon any of the properties, assets or rights of the Company under, or give rise to any increased, additional, accelerated or guaranteed rights or entitlements under, or require any consent, waiver or approval of any Person pursuant to, any provision of (i)&#160;the Company Articles, (ii)&#160;any material bond, debenture, note, mortgage, indenture, guarantee, license, lease, purchase or sale order or other contract, commitment, agreement, instrument, obligation, arrangement, understanding, undertaking, permit, concession or franchise, whether oral or written (each, including all amendments thereto, a &#8220;<u>Contract</u>&#8221;) to which the Company is a party or by which the Company or any of its properties or assets may be bound or (iii)&#160;subject to the governmental filings and other matters referred to in <u>Section 3.5(b)</u>, any Law applicable to the Company or by which the Company or any of its properties or assets may be bound, except as, in the case of clauses (ii)&#160;and (iii), as individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;No consent, approval, order or authorization of, or registration, declaration, filing with or notice to, any Governmental Entity is required by or with respect to the Company in connection with the execution, delivery and performance of this Agreement by the Company or the consummation by the Company of the Transactions and the other transactions contemplated hereby or compliance with the provisions hereof, except for (i)&#160;the filing with the SEC of such reports under Section 13(a) or 15(d) of the Exchange Act, as may be required in connection with this Agreement and the transactions contemplated hereby, (ii)&#160;such other filings and reports as may be required pursuant to the applicable requirements of the Securities Act, the Exchange Act and any other applicable state or federal securities, takeover and &#8220;blue sky&#8221; laws, and (iii)&#160;such other consents, approvals, orders, authorizations, registrations, declarations, filings or notices the failure of which to be obtained or made would not be material to the Company.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS36"><!--Anchor--></a>Section 3.6&#8195;<u>Financial Statements</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;A true and complete copy of the balance sheet of the Operating Company for the nine months ended September&#160;30, 2022 (the &#8220;<u>Company Balance Sheet</u>&#8221;) is attached hereto as <u>Section 3.6(a)</u> of the Company Disclosure Letter. The Company Balance Sheet (i)&#160;is correct and complete in all material respects and has been prepared in accordance with the books and records of the Operating Company, (ii)&#160;has been prepared in accordance with IFRS (except that the Company Balance Sheet may not have notes thereto and other presentation items that may be required by IFRS and are subject to normal and recurring year-end adjustments that are not reasonably expected to be material in amount) and (iii)&#160;fairly presents, in all material respects, the financial position, of the Operating Company as at the date thereof.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The Operating Company maintains a system of internal accounting controls consistent with the practices of similarly situated private companies designed to provide reasonable assurance that: (i)&#160;transactions are executed in accordance with management&#8217;s general or specific authorizations, (ii)&#160;transactions are recorded as necessary to permit preparation of the financial statements of the Operating Company in conformity with </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-9<br></div></div></div>
<!--End Page 466-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 467-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">IFRS and to maintain accountability of the Operating Company&#8217;s assets, (iii)&#160;access to the Operating Company&#8217;s assets is permitted only in accordance with management&#8217;s general or specific authorization, and (iv)&#160;the recorded accountability for the Company&#8217;s assets is compared with the existing assets at regular intervals and appropriate action is taken with respect to any differences. The Operating Company maintains internal control over financial reporting that provides reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS37"><!--Anchor--></a>Section 3.7&#8195;<u>No Undisclosed Liabilities</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The Operating Company does not have any liabilities or obligations of any nature, whether accrued, absolute, contingent or otherwise, known or unknown, whether due or to become due and whether or not required to be recorded or reflected on a balance sheet under IFRS, except (a) to the extent accrued or reserved against in the Company Balance Sheet and (b) for liabilities and obligations incurred in the ordinary course of business consistent with past practice since the date of the Company Balance Sheet that are not material to the Operating Company.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The Company does not have any liabilities or obligations of any nature, whether accrued, absolute, contingent or otherwise, known or unknown, whether due or to become due and whether or not required to be recorded or reflected on a balance sheet under IFRS, except (a) to the extent accrued or reserved against in the Company Balance Sheet and (b) for liabilities and obligations incurred in the ordinary course of business consistent with past practice since the date of the Company Balance Sheet that are not material to the Operating Company.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS38"><!--Anchor--></a>Section 3.8&#8195;<u>Absence of Certain Changes or Events</u>. Since the date of the Company Balance Sheet: (x)&#160;except in connection with execution of this Agreement and the consummation of the transactions contemplated hereby, the Company has conducted its business only in the ordinary course of business consistent with past practice; (y) there has not been any change, event or development or prospective change, event or development that, individually or in the aggregate, has had or would reasonably be expected to have a Company Material Adverse Effect; and (z) the Company has not:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;(i)&#160;declared, set aside or paid any dividends on, or made any other distributions (whether in cash, stock or property) in respect of, any of its shares or other equity interests, (ii)&#160;purchased, redeemed or otherwise acquired shares or other equity interests of the Company or any options, warrants, or rights to acquire any such shares or other equity interests, or (iii)&#160;split, combined, reclassified or otherwise amended the terms of any of its shares or other equity interests or issued or authorized the issuance of any other securities in respect of, in lieu of or in substitution for shares of its shares or other equity interests;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;amended or otherwise changed, or authorized or proposed to amend or otherwise change, the Company Certificate of Incorporation or the Company Articles (or similar organizational documents);</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;adopted or entered into a plan of complete or partial liquidation, dissolution, restructuring, recapitalization or reorganization; or</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;changed its financial or Tax accounting methods, principles or practices, except insofar as may have been required by a change in IFRS or applicable Law, or revalued any of its material assets.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS39"><!--Anchor--></a>Section 3.9&#8195;<u>Litigation</u>. There is no action, suit, claim, arbitration, investigation, inquiry, grievance or other proceeding (each, an &#8220;<u>Action</u>&#8221;) (or basis therefor) pending or, to the knowledge of the Company, threatened against or affecting the Company, its material assets, or any present or former officer, director or employee of the Company in such individual&#8217;s capacity as such. Neither the Company nor any of its properties or assets is subject to any outstanding judgment, order, injunction, rule or decree of any Governmental Entity. There is no Action pending or, to the knowledge of the Company, threatened seeking to prevent, hinder, modify, delay or challenge the Transactions or any of the other transactions contemplated by this Agreement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS310"><!--Anchor--></a>Section 3.10&#8195;<u>Compliance with Laws</u>. The Company is and has been in compliance in all material respects with all Laws applicable to its businesses, operations, properties or assets. The Company has not received, since the Company&#8217;s inception, a notice or other written communication alleging or relating to a possible material violation of any Law applicable to its businesses, operations, properties, assets or Company Products (as defined below). The Company has in effect all material permits, licenses, variances, exemptions, applications, approvals, clearances, authorizations, registrations, formulary listings, consents, operating certificates, franchises, orders and approvals </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-10<br></div></div></div>
<!--End Page 467-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 468-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">(collectively, &#8220;<u>Permits</u>&#8221;) of all Governmental Entities necessary or advisable for it to own, lease or operate its properties and assets and to carry on its businesses and operations as now conducted, and there has occurred no violation of, default (with or without notice or lapse of time or both) under or event giving to others any right of revocation, non-renewal, adverse modification or cancellation of, with or without notice or lapse of time or both, any such Permit, nor would any such revocation, nonrenewal, adverse modification or cancellation result from the consummation of the transactions contemplated hereby.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS311"><!--Anchor--></a>Section 3.11&#8195;<u>Health Care Regulatory Matters</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The Company, and to the knowledge of the Company, each of its directors, officers, management employees, agents (while acting in such capacity), contract manufacturers, suppliers, and distributors are, and at all times prior hereto were, in material compliance with all health care laws to the extent applicable to the Company or any of its products or activities, including, but not limited to the following: the Federal Food, Drug &amp; Cosmetic Act (&#8220;<u>FDCA</u>&#8221;); the Public Health Service Act (42 U.S.C. &#167; 201 et seq.), including the Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. &#167; 263a); the Federal Trade Commission Act&#160;(15&#160;U.S.C. &#167; 41 et seq.); the Controlled Substances Act (21 U.S.C. &#167; 801 et seq.); the federal Anti-Kickback Statute (42 U.S.C. &#167; 1320a-7b(b)); the civil monetary penalties law (42 U.S.C. &#167; 1320a-7a); the civil False Claims Act (31 U.S.C. &#167; 3729 et seq.); the administrative False Claims Law (42 U.S.C. &#167; 1320a-7b(a)); the Stark law (42 U.S.C. &#167; 1395nn); the Criminal Health Care Fraud Statute (18 U.S.C. &#167; 1347); the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. &#167; 1320d et seq.), as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. &#167; 17921 et seq.); the exclusion laws (42 U.S.C. &#167; 1320a-7); Medicare (Title XVIII of the Social Security Act); Medicaid (Title XIX of the Social Security Act); and the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (42 U.S.C. &#167; 18001 et seq.); any regulations promulgated pursuant to such laws; and any other state, federal or ex-U.S. laws, accreditation standards, or regulations governing the manufacturing, development, testing, labeling, advertising, marketing or distribution of biological products, kickbacks, patient or program charges, record-keeping, claims process, documentation requirements, medical necessity, referrals, the hiring of employees or acquisition of services or supplies from those who have been excluded from government health care programs, quality, safety, privacy, security, licensure, accreditation or any other aspect of providing health care, clinical laboratory or diagnostic products or services (&#8220;<u>Health Care Laws</u>&#8221;). To the knowledge of the Company, there are no facts or circumstances that reasonably would be expected to give rise to any material liability under any Health Care Laws.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The Company is not party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any Governmental Entity.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;All applications, notifications, submissions, information, claims, reports and statistical analyses, and other data and conclusions derived therefrom, utilized as the basis for or submitted in connection with any and all requests for a Permit from the U.S. Food and Drug Administration (&#8220;<u>FDA</u>&#8221;) or other Governmental Entity relating to products that are regulated as drugs, medical devices, or other healthcare products under Health Care Laws, including biological and drug candidates, compounds or products being researched, tested, stored, developed, labeled, manufactured, packed and/or distributed by the Company or any of its Subsidiaries (&#8220;<u>Company Products</u>&#8221;), including, without limitation, investigational new drug applications, when submitted to the FDA or other Governmental Entity were true, complete and correct in all material respects as of the date of submission and any necessary or required updates, changes, corrections or modification to such applications, submissions, information and data have been submitted to the FDA or other Governmental Entity. The Company does not have knowledge of any facts or circumstances that would be reasonably likely to lead to the revocation, suspension, limitation, or cancellation of a Permit required under Health Care Laws.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;All preclinical studies and clinical trials conducted by or, to the knowledge of the Company, on behalf of the Company have been, and if still pending are being, conducted in material compliance with research protocols and all applicable Health Care Laws, including, but not limited to, the FDCA and its applicable implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58, 312 and 314. No clinical trial conducted by or on behalf of the Company has been conducted using any clinical investigators who have been disqualified, debarred or excluded from healthcare programs. No clinical trial conducted by or on behalf of the Company has been terminated or suspended prior to completion, and no clinical investigator who has participated or is participating in, or institutional review board that has or has had jurisdiction over, a clinical trial conducted by or on behalf of the Company has placed a partial or full clinical hold order on, or otherwise terminated, delayed or suspended, </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-11<br></div></div></div>
<!--End Page 468-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 469-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">such a clinical trial at a clinical research site based on an actual or alleged lack of safety or efficacy of any Company Product or a failure to conduct such clinical trial in compliance with applicable Health Care Laws, their implementing regulations and good clinical practices. The Company has not identified or received notice of instances or allegations of research misconduct (defined as falsification or fabrication of data, or plagiarism, as those terms are defined in 42 C.F.R. Part 93) involving research conducted by, or on behalf of the Company, that could compromise or affect the integrity, reliability, completeness, or accuracy of the data collected in such research, or the rights, safety, or welfare of the research subjects.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;All manufacturing operations conducted by or, to the knowledge of the Company, for the benefit of the Company have been and are being conducted in material compliance with all Permits under applicable Health Care Laws, all applicable provisions of the FDA&#8217;s current good manufacturing practice (cGMP) regulations for biological products at 21 C.F.R. Parts 600 and 610 and all comparable foreign regulatory requirements of any Governmental Entity.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;The Company has not received any written communication that relates to an alleged violation or noncompliance with any Health Care Laws, including any notification of any pending or threatened claim, suit, proceeding, hearing, enforcement, investigation, arbitration, import detention or refusal, FDA Warning Letter or Untitled Letter, or any action by a Governmental Entity relating to any Health Care Laws. All Warning Letters, Form-483 observations, or comparable findings from other Governmental Entities listed in <u>Section 3.11</u> of the Company Disclosure Letter have been resolved and closed out to the satisfaction of the applicable Governmental Entity.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;There have been no seizures, withdrawals, recalls, detentions, or suspensions of manufacturing, testing, or distribution relating to the Company Products required or requested by a Governmental Entity, or other notice of action relating to an alleged lack of safety, efficacy, or regulatory compliance of the Company Products, or any adverse experiences relating to the Company Products that have been reported to FDA or other Governmental Entity (&#8220;<u>Company Safety Notices</u>&#8221;), and, to the knowledge of the Company, there are no facts or circumstances that reasonably would be expected to give rise to a Company Safety Notice.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(h)&#8195;There are no unresolved Company Safety Notices, and to the knowledge the Company, there are no facts that would be reasonably likely to result in a material Company Safety Notice or a termination or suspension of developing and testing of any of the Company Products.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(i)&#8195;Neither the Company, nor, to the knowledge of the Company, any officer, employee, agent, or distributor of the Company has made an untrue statement of a material fact or fraudulent or misleading statement to a Governmental Entity, failed to disclose a material fact required to be disclosed to a Governmental Entity, or committed an act, made a statement, or failed to make a statement that would reasonably be expected to provide a basis for the FDA to invoke its policy respecting the &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy set forth in 56 Fed. Reg. 46191 (September&#160;10, 1991) and any amendments thereto (the &#8220;<u>FDA Ethics Policy</u>&#8221;). To the knowledge of the Company, none of the aforementioned is or has been under investigation resulting from any allegedly untrue, fraudulent, misleading, or false statement or omission, including data fraud, or had any action pending or threatened relating to the FDA Ethics Policy.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(j)&#8195;All reports, documents, claims, Permits and notices required to be filed, maintained or furnished to the FDA or any Governmental Entity by the Company have been so filed, maintained or furnished, except where failure to file, maintain or furnish such reports, documents, claims, Permits or notices has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. All such reports, documents, claims, Permits and notices were true and complete in all material respects on the date filed (or were corrected in or supplemented by a subsequent filing).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(k)&#8195;Neither the Company nor, to the knowledge of the Company, any officer, employee, agent, or distributor of the Company has committed any act, made any statement or failed to make any statement that violates the Federal Anti-Kickback Statute, 28 U.S.C. &#167; 1320a-7b, the Federal False Claims Act, 31 U.S.C. &#167; 3729, other Drug or Health Care Laws, or any other similar federal, state, or ex-U.S. law applicable in the jurisdictions in which the Company Products are sold or intended to be sold.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(l)&#8195;Neither the Company nor, to the knowledge of the Company, any officer, employee, agent, or distributor of the Company has been convicted of any crime or engaged in any conduct that has resulted, or would reasonably be expected to result, in debarment under applicable Law, including, without limitation, </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-12<br></div></div></div>
<!--End Page 469-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 470-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg20"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">21&#160;U.S.C. &#167; 335a, or exclusion under 42 U.S.C. &#167; 1320a-7, or any other statutory provision or similar law applicable in other jurisdictions in which the Company Products are sold or intended to be sold. Neither the Company nor, to the knowledge of the Company, any officer, employee, agent or distributor of the Company, has been excluded from participation in any federal health care program or convicted of any crime or engaged in any conduct for which such Person could be excluded from participating in any federal health care program under Section 1128 of the Social Security Act of 1935, as amended, or any similar Health Care Law or program.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS312"><!--Anchor--></a>Section 3.12&#8195;<u>Benefit Plans</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;<u>Section 3.12(a)</u> of the Company Disclosure Letter contains a true and complete list of each material &#8220;employee benefit plan&#8221; (within the meaning of section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (&#8220;<u>ERISA</u>&#8221;), whether or not subject to ERISA), and all stock purchase, stock option, phantom stock or other equity-based plan, severance, employment, collective bargaining, change-in-control, fringe benefit, bonus, incentive, deferred compensation, supplemental retirement, health, life, or disability insurance, dependent care and all other employee benefit and compensation plans, agreements, programs, policies or other arrangements, in each case, whether written or oral, under which any current or former employee, director or consultant of the Company (or any of their dependents) has any present or future right to compensation or benefits or the Company sponsors or maintains, is making contributions to or has any present or future liability or obligation (contingent or otherwise). All such plans, agreements, programs, policies and arrangements shall be collectively referred to as the &#8220;<u>Company Plans</u>.&#8221; The Company has provided or made available to Parent a current, accurate and complete copy of each material Company Plan, or if such Company Plan is not in written form, a written summary of all of the material terms of such Company Plan. With respect to each Company Plan, the Company has furnished or made available to Parent a current, accurate and complete copy of, to the extent applicable: (i)&#160;any related trust agreement or other funding instrument, (ii)&#160;the most recent determination letter of the Internal Revenue Service (the &#8220;<u>IRS</u>&#8221;), (iii)&#160;any summary plan description, or summary of material modifications, and (iv)&#160;for the most recent year and as applicable (A) the Form 5500 and attached schedules, (B) audited financial statements and (C) actuarial valuation reports.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Neither the Company nor any member of its Controlled Group (defined as any organization which is a member of a controlled, affiliated or otherwise related group of entities within the meaning of Code Section&#160;414(b), (c), (m) or (o)) has, in the past six (6) years, sponsored, maintained, contributed to or been required to contribute to or incurred any liability (contingent or otherwise) with respect to: (i)&#160;a &#8220;multiemployer plan&#8221; (within the meaning of ERISA section 3(37)), (ii)&#160;an &#8220;employee pension benefit plan,&#8221; within the meaning of Section 3(2) of ERISA (&#8220;<u>Pension Plan</u>&#8221;) that is subject to Title IV of ERISA or Section 412 of the Code, (iii)&#160;a Pension Plan which is a &#8220;multiple employer plan&#8221; as defined in Section 413 of the Code, or (iv)&#160;a &#8220;funded welfare plan&#8221; within the meaning of Section 419 of the Code.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(c)&#8195;With respect to the Company Plans:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(i)&#8195;each Company Plan complies in all material respects with its terms and materially complies in form and in operation with the applicable provisions of ERISA and the Code and all other applicable legal requirements;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(ii)&#8195;each Company Plan intended to be qualified under Section 401(a) of the Code has received a favorable determination, advisory and/or opinion letter, as applicable, from the IRS that it is so qualified and nothing has occurred to the knowledge of the Company since the date of such letter that would reasonably be expected to cause the loss of the sponsor&#8217;s ability to rely upon such letter, and nothing has occurred to the knowledge of the Company that would reasonably be expected to result in the loss of the qualified status of such Company Plan;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iii)&#8195;there is no material Action (including any investigation, audit or other administrative proceeding) by the Department of Labor, the Pension Benefit Guaranty Corporation (the &#8220;<u>PBGC</u>&#8221;), the IRS or any other Governmental Entity or by any plan participant or beneficiary pending, or to the knowledge of the Company, threatened, relating to the Company Plans, any fiduciaries thereof with respect to their duties to the Company Plans or the assets of any of the trusts under any of the Company Plans (other than routine claims for benefits);</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-13<br></div></div></div>
<!--End Page 470-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 471-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg21"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iv)&#8195;none of the Company Plans currently provides, or reflects or represents any liability to provide post-termination or retiree welfare benefits to any person for any reason, except as may be required by Section 601 et seq<font style="font-style: italic;">.</font> of ERISA and Section 4980B(b) of the Code or other applicable similar law regarding health care coverage continuation;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(v)&#8195;each Company Plan is subject exclusively to United States Law; and</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(vi)&#8195;the execution and delivery of this Agreement and the consummation of the Transactions will not, either alone or in combination with any other event, (A) entitle any current or former employee, officer, director or consultant of the Company to severance pay, unemployment compensation or any other similar termination payment, or any other compensatory payment, including any bonus, retention, retirement or other benefit (B) accelerate the time of payment or vesting, or increase the amount of or otherwise enhance any benefit due to any such employee, officer, director or consultant, or (C) result in the payment of any &#8220;excess parachute payment&#8221; within the meaning of Section 280G of the Code.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;Each Company Plan that is a &#8220;nonqualified deferred compensation plan&#8221; within the meaning of Section 409A of the Code (or any comparable or similar provision of state, local, or foreign Law) complies in both form and operation in all material respects with the requirements of Section 409A of the and all applicable IRS guidance issued with respect thereto. There is no agreement, plan or other arrangement to which the Company is a party or by which the Company is otherwise bound to reimburse, indemnify or otherwise compensate any person in respect of excise or other Taxes or other liabilities (including interest and penalties) incurred with respect to Section 409A or 4999 of the Code.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS313"><!--Anchor--></a>Section 3.13&#8195;<u>Labor and Employment Matters</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The Company is and, since the Company&#8217;s inception has been, in compliance in all material respects with all applicable Laws relating to labor and employment, including those relating to employment practices, terms and conditions of employment, collective bargaining, disability, immigration, health and safety, wages, hours and benefits, nondiscrimination in employment, workers&#8217; compensation, the collection and payment of withholding and/or payroll Taxes and similar Taxes, unemployment compensation, equal employment opportunity, discrimination, harassment, employee and contractor classification, information privacy and security, and continuation coverage with respect to group health plans. During the preceding three years, there has not been, and as of the date of this Agreement there is not pending or, to the knowledge of the Company, threatened, any labor dispute, work stoppage, labor strike or lockout against the Company by employees.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;No employee of the Company is covered by an effective or pending collective bargaining agreement or similar labor agreement. To the knowledge of the Company, there has not been any activity on behalf of any labor union, labor organization or similar employee group to organize any employees of the Company and there are no representation claims or petitions pending before the National Labor Relations Board or any other labor relations tribunal or authority. There are no (i)&#160;unfair labor practice charges or complaints against the Company pending before the National Labor Relations Board or any other labor relations tribunal or authority and to the knowledge of the Company no such representations, claims or petitions are threatened, or (ii)&#160;grievances or pending arbitration proceedings against the Company that arose out of or under any collective bargaining agreement, except, in each case, as would not, individually or in the aggregate, result in the Company incurring a material liability.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;To the knowledge of the Company, no current employee or officer of the Company intends, or is expected, to terminate his or her employment relationship with such entity in connection with or as a result of the transactions contemplated hereby or otherwise within one year of the Closing Date.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;During the preceding three years, (i)&#160;the Company has not effectuated a &#8220;plant closing&#8221; (as defined in the Worker Adjustment Retraining and Notification Act of 1988, as amended (the &#8220;<u>WARN Act</u>&#8221;)) affecting any site of employment or one or more facilities or operating units within any site of employment or facility, (ii)&#160;there has not occurred a &#8220;mass layoff&#8221; (as defined in the WARN Act) in connection with the Company affecting any site of employment or one or more facilities or operating units within any site of employment or facility and (iii)&#160;the Company has not engaged in layoffs or employment terminations sufficient in number to trigger application of any similar state, local or foreign law. The Company currently properly classifies and for the past three (3) years has properly classified its employees as exempt or nonexempt in accordance with </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-14<br></div></div></div>
<!--End Page 471-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 472-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg22"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">applicable overtime laws, and no person treated as an independent contractor or consultant by the Company within the past three (3) years should have been properly classified as an employee under applicable Law, in each case, except as would not, individually or in the aggregate, result in the Company incurring a material liability.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;With respect to any current or former employee, officer, consultant or other service provider of the Company, there are no Actions against the Company pending, or to the Company&#8217;s knowledge, threatened to be brought or filed, in connection with the employment or engagement of any current or former employee, officer, consultant or other service provider of the Company, including, without limitation, any claim relating to employment discrimination, harassment, retaliation, equal pay, employment classification or any other employment-related matter arising under applicable Laws, except where such action would not, individually or in the aggregate, result in the Company incurring a material liability.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;Since the Company&#8217;s inception, (i)&#160;no allegations of workplace sexual harassment, discrimination or other misconduct have been made, initiated, filed or, to the knowledge of the Company, threatened against the Company or any of its respective current or former directors, officers or senior-level management employees in their capacities as such, (ii)&#160;to the knowledge of the Company, no incidents of any such workplace sexual harassment, discrimination or other misconduct have occurred, and (iii)&#160;the Company has not entered into any settlement agreement related to allegations of sexual harassment, discrimination or other misconduct by any of its directors, officers or employees described in clause (i)&#160;hereof or any independent contractor.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;The Company is and has at all relevant times been in compliance in all material respects with (i)&#160;COVID-19-related Laws, standards, regulations, orders and guidance (including without limitation relating to business reopening), including those issued and enforced by the Occupational Safety and Health Administration, the Centers for Disease Control, the Equal Employment Opportunity Commission, and any other Governmental Entity; and (ii)&#160;the Families First Coronavirus Response Act and any other applicable COVID-19-related leave Law, whether state, local or otherwise.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS314"><!--Anchor--></a>Section 3.14&#8195;<u>Environmental Matters</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Except as would not be material to the Company, (i)&#160;the Company has conducted its businesses in compliance with all, and has not violated any, applicable Environmental Laws; (ii)&#160;the Company has obtained all Permits of all Governmental Entities and any other Person that are required under any Environmental Law; and (iii)&#160;the Company has not received any claims, notices, demand letters or requests for information (except for such claims, notices, demand letters or requests for information the subject matter of which has been resolved prior to the date of this Agreement) from any federal, state, local, foreign or provincial Governmental Entity or any other Person asserting that the Company is in violation of, or liable under, any Environmental Law.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;As used herein, &#8220;<u>Environmental Law</u>&#8221; means any Law relating to (i)&#160;the protection, preservation or restoration of the environment (including air, surface water, groundwater, drinking water supply, surface and subsurface soils and strata, wetlands, plant and animal life or any other natural resource) or (ii)&#160;the exposure to, or the use, storage, recycling, treatment, generation, transportation, processing, handling, labeling, production, release or disposal of Hazardous Substances.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;As used herein, &#8220;<u>Hazardous Substance</u>&#8221; means any substance listed, defined, designated, classified or regulated as a waste, pollutant or contaminant or as hazardous, toxic, radioactive or dangerous or any other term of similar import under any Environmental Law, including but not limited to petroleum.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS315"><!--Anchor--></a>Section 3.15&#8195;<u>Taxes</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The Company has (i)&#160;filed all income Tax Returns and other material Tax Returns required to be filed by or on behalf of it (taking into account any applicable extensions thereof) and all such Tax Returns are true, accurate and complete in all material respects; and (ii)&#160;paid in full (or caused to be timely paid in full) all income and other material Taxes that are required to be paid by it, whether or not such Taxes were shown as due on such Tax Returns.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;All material Taxes not yet due and payable by the Company as of the date of the Company Balance Sheet have been, in all material respects, properly accrued in accordance with IFRS on the Company Balance Sheet, and such Company Balance Sheet reflects an adequate reserve (in accordance with IFRS) for all material </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-15<br></div></div></div>
<!--End Page 472-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 473-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg23"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">Taxes accrued but unpaid by the Company through the date of such Company Balance Sheet. Since the date of the Company Balance Sheet, the Company has not incurred, individually or in the aggregate, any material amount of liability for Taxes outside the ordinary course of business.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;The Company has not executed any waiver of any statute of limitations on, or extended the period for the assessment or collection of, any material amount of Tax, in each case that has not since expired.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;No material audits or other investigations, proceedings, claims, assessments or examinations by any Governmental Entity (each, a &#8220;<u>Tax Action</u>&#8221;) with respect to Taxes or any Tax Return of the Company are presently in progress or have been asserted, threatened or proposed in writing. No deficiencies or claims for a material amount of Taxes have been claimed, proposed, assessed or asserted in writing against the Company by a Governmental Entity, other than any such claim, proposal, assessment or assertion that has been satisfied by payment in full, settled or withdrawn.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;The Company has timely withheld all material amounts of Taxes required to have been withheld from payments made (or deemed made) to its employees, independent contractors, creditors, stockholders and other third parties and, to the extent required, such Taxes have been timely paid to the relevant Governmental Entity.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;The Company has not engaged in a &#8220;reportable transaction&#8221; as set forth in Treasury Regulations &#167; 1.6011-4(b).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;The Company (i)&#160;is not a party to or bound by, or has any liability pursuant to, any Tax sharing, allocation, indemnification or similar agreement or obligation, other than any such agreement or obligation which is a customary commercial agreement or obligation entered into in the ordinary course of business with vendors, lessors, lenders or the like the primary purpose of which is unrelated to Taxes (each, an &#8220;<u>Ordinary&#160;Course Agreement</u>&#8221;); (ii)&#160;is not and has not been a member of a group (other than a group the common parent of which is the Company) filing a consolidated, combined, affiliated, unitary or similar income Tax Return; (iii)&#160;has no liability for the Taxes of any Person (other than its Subsidiaries) pursuant to Treasury Regulations &#167; 1.1502-6 (or any similar provision of state, local or non-United States Law) as a transferee or successor, by Contract (other than Ordinary Course Agreements) or otherwise by operation of Law; and (iv)&#160;is not and has not been treated as a resident for any income Tax purpose, or as subject to Tax by virtue of having a permanent establishment, an office or fixed place of business, in any country other than the country in which it was or is organized.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(h)&#8195;No private-letter rulings, technical advice memoranda, or similar material agreements or rulings have been requested in writing, entered into or issued by any taxing authority with respect to the Company which rulings remain in effect.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(i)&#8195;The Company will not be required to include any item of income in, or exclude any item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of (i)&#160;a change in, or use of improper, method of accounting requested or initiated on or prior to the Closing Date, (ii)&#160;a &#8220;closing agreement&#8221; as described in Section 7121 of the Code (or any similar provision of Law) executed on or prior to the Closing Date, (iii)&#160;an installment sale or open-transaction disposition made on or prior to the Closing Date, or (iv)&#160;any deferred intercompany gain or excess-loss account described in Treasury Regulations under Section 1502 of the Code (or any corresponding or similar provision of state, local or foreign income Tax Law).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(j)&#8195;There are no liens for Taxes upon any of the assets of the Company other than Liens described in clause (i)&#160;of the definition of Permitted Liens.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(k)&#8195;The Company has not distributed stock of another Person or has had its shares distributed by another Person, in a transaction (or series of transactions) that was purported or intended to be governed in whole or in part by Section 355 or 361 of the Code.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(l)&#8195;The Company has not been a United States real property holding corporation, as defined in Section&#160;897(c)(2) of the Code during the applicable period specified in Section 897(c)(1)(A)(ii)&#160;of the Code.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(m)&#8195;No material claim has been made in writing by any Governmental Entity in a jurisdiction where the Company has not paid a specific Tax or filed a specific Tax Return that the Company is or may be required to pay such Tax or file such Tax Return by such jurisdiction.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-16<br></div></div></div>
<!--End Page 473-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 474-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg24"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(n)&#8195;Neither the Company nor any of its Subsidiaries has elected to be treated as other than a corporation for U.S. federal income tax purposes.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(o)&#8195;Neither the Company nor any of its Subsidiaries has taken any action (or agreed to take any action prior to the Closing), nor does it know of any fact or circumstance, in each case, that it knows could reasonably be expected to prevent or impede the Transactions from qualifying for the Intended Tax Treatment.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS316"><!--Anchor--></a>Section 3.16&#8195;<u>Contracts</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;As of the date of this Agreement, there are no Contracts that would constitute a &#8220;material contract&#8221; (as such term is defined in Item 601(b)(10) of Regulation S-K under the Securities Act), with respect to the Company (assuming the Company was subject to the requirements of the Exchange Act), other than those Contracts identified in <u>Section 3.16(a)</u> of the Company Disclosure Letter, which, for the avoidance of doubt, shall exclude any Company Plans (all such contracts, &#8220;<u>Material Contracts</u>&#8221;).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;(i)&#160;Each Material Contract is valid and binding on the Company and to the knowledge of the Company, each other party thereto, and is in full force and effect and enforceable in accordance with its terms; (ii)&#160;the Company, and, to the knowledge of the Company, each other party thereto, has performed all material obligations required to be performed by it under each Material Contract; and (iii)&#160;there is no material default under any Material Contract by the Company or, to the knowledge of the Company, any other party thereto, and no event or condition has occurred that constitutes, or, after notice or lapse of time or both, would constitute, a material default on the part of the Company or, to the knowledge of the Company, any other party thereto under any such Material Contract, nor has the Company received any notice of any such material default, event or condition. The Company has made available to Parent true and complete copies of all Material Contracts, including all amendments thereto.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS317"><!--Anchor--></a>Section 3.17&#8195;<u>Insurance</u>. The Company is covered by valid and currently effective insurance policies issued in favor of the Company that are customary and adequate for companies of similar size in the industries and locations in which the Company operates. With respect to each such insurance policy, (a) such policy is in full force and effect and all premiums due thereon have been paid, (b) the Company is not in breach or default, and has not taken any action or failed to take any action which (with or without notice or lapse of time, or both) would constitute such a breach or default, or would permit termination or modification of, any such policy and (c) to the knowledge of the Company, no insurer issuing any such policy has been declared insolvent or placed in receivership, conservatorship or liquidation. No notice of cancellation or termination has been received with respect to any such policy, nor will any such cancellation or termination result from the consummation of the transactions contemplated hereby.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS318"><!--Anchor--></a>Section 3.18&#8195;<u>Properties</u>. The Company does not own nor has ever owned any real property. The Company does not lease nor has ever leased any real property.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS319"><!--Anchor--></a>Section 3.19&#8195;<u>Intellectual Property</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;<u>Section 3.19(a)</u> of the Company Disclosure Letter sets forth a true and complete list of all (i)&#160;material patents and patent applications; (ii)&#160;material trademark registrations and applications; and (iii)&#160;material copyright registrations and applications (collectively, &#8220;<u>Company Registered IP</u>&#8221;), in each case owned by the Company, and a true and complete list of all domain names owned or exclusively licensed by the Company. Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect (A) all of the Company Registered IP is subsisting and, in the case of any Company Registered IP that is registered or issued and to the knowledge of the Company, valid and enforceable, (B) no Company Registered IP is involved in any interference, reissue, derivation, reexamination, opposition, cancellation or similar proceeding and, to the knowledge of the Company, no such action is threatened with respect to any of the Company Registered IP and (C) the Company owns exclusively, free and clear of any and all Liens (other than Permitted Liens), all Company Owned IP, including all Intellectual Property created on behalf of the Company by employees or independent contractors.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;<u>Section 3.19(b)</u> of the Company Disclosure Letter accurately identifies (i)&#160;all contracts pursuant to which any Company Registered IP are licensed to the Company (other than (A) any non-customized software that (1) is so licensed solely in executable or object code form pursuant to a nonexclusive, internal-use software license and other Intellectual Property associated with such software and (2) is not incorporated into, or material to the development, manufacturing, or distribution of, any of the Company&#8217;s products or services, (B) any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of equipment, reagents or </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-17<br></div></div></div>
<!--End Page 474-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 475-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg25"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">other materials, (C) any confidential information provided under confidentiality agreements and (D) agreements between Company and its employees in Company&#8217;s standard form thereof), (ii)&#160;the corresponding Company contract pursuant to which such Company Registered IP is licensed to the Company and (iii)&#160;whether the license or licenses granted to the Company are exclusive or nonexclusive.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;<u>Section 3.19(c)</u> of the Company Disclosure Letter accurately identifies each Company contract pursuant to which any Person has been granted any license or covenant not to sue under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest in, any Company Registered IP (other than (i)&#160;any confidential information provided under confidentiality agreements and (ii)&#160;any Company Registered IP nonexclusively licensed to academic collaborators, suppliers or service providers for the sole purpose of enabling such academic collaborator, supplier or service providers to provide services for Company&#8217;s benefit).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;To the knowledge of Company, the Company Registered IP constitutes all Intellectual Property necessary for Company to conduct its business as currently conducted; provided, however, that the foregoing representation is not a representation with respect to non-infringement of Intellectual Property.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;The Company has taken commercially reasonable measures to maintain the confidentiality of all information that constitutes or constituted a material Trade Secret of the Company, including requiring all Persons having access thereto to execute written nondisclosure agreements or other binding obligations to maintain confidentiality of such information.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect, (i)&#160;to the knowledge of the Company, the conduct of the businesses of the Company, including the manufacture, marketing, offering for sale, sale, importation, use or intended use or other disposal of any product as currently sold or under development by Company, has not infringed, misappropriated or diluted, and does not infringe, misappropriate or dilute, any Intellectual Property of any Person, (ii)&#160;the Company has not received any written notice or claim asserting or suggesting that any such infringement, misappropriation, or dilution is or may be occurring or has or may have occurred and (iii)&#160;to the knowledge of the Company, no Person is infringing, misappropriating, or diluting in any material respect any Company Registered IP.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect, (i)&#160;the Company has taken commercially reasonable steps to protect the confidentiality and security of the computer and information technology systems used by the Company (the&#160;&#8220;<u>IT&#160;Systems</u>&#8221;) and the information and transactions stored or contained therein or transmitted thereby, (ii)&#160;to the knowledge of the Company, since the Company&#8217;s inception, there has been no unauthorized or improper use, loss, access, transmittal, modification or corruption of any such information or data and (iii)&#160;since the Company&#8217;s inception, there have been no material failures, crashes, viruses, security breaches (including any unauthorized access to any personally identifiable information), affecting the IT Systems.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(h)&#8195;Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect, (i)&#160;to the knowledge of the Company, the Company has at all times complied in all material respects with all applicable Laws relating to privacy, data protection, and the collection, retention, protection, and use of Personal Information (collectively, &#8220;<u>Privacy Laws</u>&#8221;) collected, used, or held for use by the Company, (ii)&#160;since the Company&#8217;s inception, no claims have been asserted or, to the knowledge of the Company, threatened in writing against the Company alleging a violation of any Person&#8217;s privacy or Personal Information, (iii)&#160;neither this Agreement nor the consummation of the transactions contemplated hereby will breach or otherwise violate any applicable Privacy Laws and (iv)&#160;the Company has taken commercially reasonable steps to protect the Personal Information collected, used or held for use by the Company against loss and unauthorized access, use, modification, disclosure or other misuse.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(i)&#8195;To the knowledge of the Company, no government funding, facilities or resources of a university, college, other educational institution or research center or funding from third parties was used in the development of the Company Owned IP, to the knowledge of the Company, exclusively licensed to the Company, and no Governmental Entity, university, college, other educational institution or research center has, to the knowledge of the Company, any claim or right in or to such Intellectual Property.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-18<br></div></div></div>
<!--End Page 475-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 476-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg26"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(j)&#8195;The execution, delivery and performance by the Company of this Agreement, and the consummation of the transactions contemplated hereby, will not result in the loss of, or give rise to any right of any third party to terminate or modify any of the Company&#8217;s rights or obligations under any agreement under which the Company grants to any Person, or any Person grants to the Company, a license or right under or with respect to any Intellectual Property that is material to any of the businesses of the Company.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS320"><!--Anchor--></a>Section 3.20&#8195;<u>State Takeover Statutes</u>. No &#8220;moratorium,&#8221; &#8220;fair price,&#8221; &#8220;business combination,&#8221; &#8220;control share acquisition&#8221; or similar provision of any state anti-takeover Law (collectively, &#8220;<u>Takeover Laws</u>&#8221;) or any similar anti-takeover provision in the Company Articles is, or at the Effective Time will be, applicable to this Agreement, the Transactions or any of the other transactions contemplated hereby.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS321"><!--Anchor--></a>Section 3.21&#8195;<u>No Rights Plan</u>. There is no member rights plan, &#8220;poison pill&#8221; anti-takeover plan or other similar device in effect to which the Company is a party or is otherwise bound.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS322"><!--Anchor--></a>Section 3.22&#8195;<u>Related Party Transactions</u>. Since the Company&#8217;s inception through the date of this Agreement, there have been no transactions, agreements, arrangements or understandings between the Company, on the one hand, and the Affiliates of the Company, on the other hand, that would be required to be disclosed under Item 404 of Regulation S-K under the Securities Act (assuming the Company was subject to the requirements of the Exchange Act).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS323"><!--Anchor--></a>Section 3.23&#8195;<u>Certain Payments</u>. Neither the Company nor, to the knowledge of the Company, any of its respective directors, executives, representatives, agents or employees (a) has used or is using any corporate funds for any illegal contributions, gifts, entertainment or other unlawful expenses relating to political activity, (b) has used or is using any corporate funds for any direct or indirect unlawful payments to any foreign or domestic governmental officials or employees, (c) has violated or is violating any provision of the Foreign Corrupt Practices Act of 1977, (d) has established or maintained, or is maintaining, any unlawful fund of corporate monies or other properties, or (e) has made any bribe, unlawful rebate, payoff, influence payment, kickback or other unlawful payment of any nature.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; text-align: center;"><a name="tANXAA4"><!--Anchor--></a>ARTICLE IV<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">REPRESENTATIONS AND WARRANTIES OF PARENT</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Except (a) as disclosed in the Parent SEC Documents at least two Business Days prior to the date of this Agreement and that is reasonably apparent on the face of such disclosure to be applicable to the representation and warranty set forth herein (other than any disclosures contained or referenced therein under the captions &#8220;Risk&#160;Factors,&#8221; &#8220;Forward-Looking Statements,&#8221; &#8220;Quantitative and Qualitative Disclosures About Market Risk,&#8221; and any other disclosures contained or referenced therein of information, factors, or risks that are predictive, cautionary, or forward-looking in nature); or (b) as set forth in the corresponding section or subsection of the disclosure letter delivered by Parent to the Contributors immediately prior to the execution of this Agreement (the &#8220;<u>Parent Disclosure Letter</u>&#8221;) (it being agreed that the disclosure of any information in a particular section or subsection of the Parent Disclosure Letter shall be deemed disclosure of such information with respect to any other section or subsection of this Agreement to which the relevance of such information is readily apparent on its face), Parent represents and warrants to the Contributors and the Minority Holders as follows:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS41"><!--Anchor--></a>Section 4.1&#8195;<u>Organization, Standing and Power</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Parent is a corporation duly organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation. Parent (i)&#160;has all requisite corporate power and authority to own, lease and operate its properties and to carry on its business as now being conducted and (ii)&#160;is duly qualified or licensed to do business and is in good standing in each jurisdiction in which the nature of its business or the ownership, leasing or operation of its properties makes such qualification or licensing necessary, except in the case of clause (ii), where the failure to be so qualified or licensed or in good standing, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect. For purposes of this Agreement, &#8220;<u>Parent Material Adverse Effect</u>&#8221; means any event, change, circumstance, occurrence, effect or state of facts that (A) is or would reasonably be expected to be materially adverse to the business, assets, liabilities, financial condition, or results of operations of Parent and its Subsidiaries, taken as a whole, or (B)&#160;materially impairs the ability of Parent to consummate the Transactions or any of the other transactions contemplated by this Agreement; provided, however, that in the case of clause (A) only, Parent Material Adverse Effect shall not include any event, change, circumstance, occurrence, effect or state of facts to the extent resulting from (1) changes or conditions generally affecting the industries in which the Parent and its </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-19<br></div></div></div>
<!--End Page 476-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 477-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg27"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">Subsidiaries operate, or the economy or the financial, debt, banking, capital, credit or securities markets, in the United States, including effects on such industries, economy or markets resulting from any regulatory and political conditions or developments in general, (2) the outbreak or escalation of war or acts of terrorism or any natural disasters, acts of God or comparable events, epidemic, pandemic or disease outbreak (including the COVID-19 virus) or any worsening of the foregoing or any declaration of martial law, quarantine or similar directive, policy or guidance or Law or other action by any Governmental Entity in response thereto, (3) changes in Law or generally accepted accounting principles in the United States (&#8220;<u>GAAP</u>&#8221;), or the interpretation or enforcement thereof, (4) the public announcement of this Agreement, or (5) any specific action taken (or omitted to be taken) by the Parent at or with the express written consent of the Contributors; provided, that, with respect to clauses (1), (2) and (3), the impact of such event, change, circumstance, occurrence, effect or state of facts is not disproportionately adverse to Parent and its Subsidiaries, taken as a whole, as compared to other participants in the industries in which Parent and its Subsidiaries operate.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Parent has previously made available to the Contributors true and complete copies of the Certificate of Incorporation and Bylaws (or comparable organizational documents) of Parent, and the Certificate of Incorporation and Bylaws (or comparable organizational documents) of each Subsidiary of Parent, in each case, as amended to the date of this Agreement, and each as so delivered is in full force and effect. Parent is not in violation of any provision of its Certificate of Incorporation or Bylaws (or comparable organizational documents). Except with respect to the extent relating to the transactions contemplated by this Agreement or in draft form and except as may be redacted to preserve a privilege (including attorney-client privilege), Parent has made available to the Contributors true and complete copies of the minutes of all meetings (including any actions taken by written consent) of Parent&#8217;s stockholders, the Parent Board and each committee of the Parent Board held since January&#160;1, 2020.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS42"><!--Anchor--></a>Section 4.2&#8195;<u>Capital Stock</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The authorized capital stock of Parent consists of 100,000,000 shares of Parent Common Stock and 5,000,000 shares of Parent Convertible Preferred Stock. As of the close of business on September&#160;30, 2022, 2022 (the &#8220;<u>Measurement Date</u>&#8221;), (i) 31,490,053 shares of Parent Common Stock (excluding treasury shares) were issued and outstanding, (ii)&#160;no shares of Parent Common Stock were held by Parent in its treasury, (iii)&#160;no shares of Parent Convertible Preferred Stock were issued and outstanding, (iv)&#160;no shares of Parent Convertible Preferred Stock were held by Parent in its treasury, (v) 21,172,695 shares of Parent Common Stock were reserved for issuance pursuant to Parent&#8217;s 2018 Omnibus Incentive Plan, the Catalyst 2004 Plan Residual, the Catalyst 2015 Stock Incentive Plan and the Targacept 2006 Plan (of which 8,906,711 shares were subject to Parent Options), (vi) 359,545 shares of Parent Common Stock were reserved for issuance pursuant to Parent&#8217;s 2018 Employee Stock Purchase Plan and (vii)&#160;no shares of Parent Common Stock were reserved for issuance upon the exercise or conversion of warrants. Neither Parent nor any of its Subsidiaries has outstanding any bonds, debentures, notes or other obligations having the right to vote (or convertible into, or exchangeable or exercisable for, securities having the right to vote) with the stockholders of Parent or such Subsidiary on any matter. Except for changes since the close of business on the Measurement Date resulting from the exercise of any options as described above, as of the Measurement Date, there are no outstanding (A) shares of capital stock or other voting securities or equity interests of Parent, (B) securities of Parent or any of its Subsidiaries convertible into or exchangeable or exercisable for shares of capital stock of Parent or other voting securities or equity interests of Parent or its Subsidiaries, (C) stock appreciation rights, &#8220;phantom&#8221; stock rights, performance units, interests in or rights to the ownership or earnings of Parent or its Subsidiaries or other equity-equivalent or equity-based awards or rights, (D) subscriptions, options, warrants, calls, commitments, Contracts or other rights to acquire from Parent or its Subsidiaries, or obligations of Parent or any of its Subsidiaries to issue, any shares of capital stock of Parent or any of its Subsidiaries, voting securities, equity interests or securities convertible into or exchangeable or exercisable for capital stock or other voting securities or equity interests of Parent or its Subsidiaries or rights or interests described in the preceding clause (C), or (E)&#160;obligations of Parent or any of its Subsidiaries to repurchase, redeem or otherwise acquire any such securities or to issue, grant, deliver or sell, or cause to be issued, granted, delivered or sold, any such securities.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;<u>Section 4.2(b)</u> of the Parent Disclosure Letter sets forth a true and complete list of all holders of rights to purchase or receive shares of Parent Common Stock or similar rights (collectively, &#8220;<u>Parent Stock Awards</u>&#8221;), indicating as applicable, with respect to each Parent Stock Award then outstanding, the type of award, the number of shares of Parent Common Stock subject to such Parent Stock Award, the name of the plan under </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-20<br></div></div></div>
<!--End Page 477-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 478-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg28"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">which such Parent Stock Award was granted, the date of grant, exercise or purchase price, vesting schedule, payment schedule (if different from the vesting schedule) and expiration thereof, and whether (and to what extent) the vesting of such Parent Stock Award will be accelerated or otherwise adjusted in any way or any other terms will be triggered or otherwise adjusted in any way by the consummation of the Transactions and the other transactions contemplated by this Agreement or by the termination of employment or engagement or change in position of any holder thereof following or in connection with the Transactions. Each Parent Option was granted with a per share exercise price that is no less than the fair market value of a share of Parent Common Stock on the date such Parent Option was granted and is exempt from the requirements of Section 409A of the Code. Parent has made available to the Contributors a true and complete copy of the forms of all award agreements evidencing outstanding Parent Stock Awards.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;The shares of Parent Capital Stock to be issued pursuant to the Transactions will be duly authorized, validly issued, fully paid and nonassessable and not subject to any preemptive rights.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;To the knowledge of Parent as of the date of this Agreement and as of the Closing, no &#8220;bad actor&#8221; disqualifying event described in Rule 506(d)(1)(i)-(viii)&#160;of the Securities Act (a &#8220;<u>Disqualifying Event</u>&#8221;) is applicable to Parent or, to Parent&#8217;s knowledge, any Covered Person, except for a Disqualifying Event as to which Rule 506(d)(2)(ii-iv) or (d)(3) of the Securities Act is applicable. &#8220;<u>Covered Person</u>&#8221; means, with respect to Parent as an &#8220;issuer&#8221; for purposes of Rule 506 promulgated under the Securities Act, any person listed in the first paragraph of Rule 506(d)(1).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS43"><!--Anchor--></a>Section 4.3&#8195;<u>Subsidiaries</u>. <u>Section 4.3</u> of the Parent Disclosure Letter sets forth a true and complete list of each Subsidiary of Parent, including its jurisdiction of incorporation or formation. Each of Parent&#8217;s Subsidiaries (i)&#160;is an entity duly organized, validly existing and in good standing under the Laws of the jurisdiction of its organization, (ii)&#160;has all requisite corporate or similar power and authority to own, lease and operate its properties and to carry on its business as now being conducted and (iii)&#160;is duly qualified or licensed to do business and is in good standing in each jurisdiction in which the nature of its business or the ownership, leasing or operation of its properties makes such qualification or licensing necessary, except in the case of clause (iii), where the failure to be so qualified or licensed or in good standing, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect. All outstanding shares of capital stock and other voting securities or equity interests of each such Subsidiary are owned, directly or indirectly, by Parent, free and clear of all Liens other than Permitted Liens of Parent and its Subsidiaries. Except for the capital stock of, or other equity or voting interests in, its Subsidiaries, Parent does not own, directly or indirectly, any equity, membership interest, partnership interest, joint venture interest, or other equity or voting interest in, or any interest convertible into, exercisable or exchangeable for any of the foregoing, nor is it under any current or prospective obligation to form or participate in, provide funds to, make any loan, capital contribution, guarantee, credit enhancement or other investment in, or assume any liability or obligation of, any Person.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS44"><!--Anchor--></a>Section 4.4&#8195;<u>Authority</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Parent has all necessary power and authority to execute, deliver and perform its obligations under this Agreement and to consummate the Transactions and the other transactions contemplated hereby, including the issuance of the shares of Parent Capital Stock to the Contributors (the &#8220;<u>Parent Capital Stock Issuance</u>&#8221;). The execution, delivery and performance of this Agreement by Parent and the consummation by Parent of the Transactions and the other transactions contemplated hereby have been duly authorized by all necessary corporate action on the part of Parent and no other corporate proceedings on the part of Parent are necessary to approve this Agreement or to consummate the Transactions and the other transactions contemplated hereby, subject, in the case of the Parent Stockholder Matters, to the approval by the holders of at least a majority of the outstanding shares of Parent Common Stock in accordance with the requirements of applicable Law and Nasdaq rules and regulations (the &#8220;<u>Parent Stockholder Approval</u>&#8221;). This Agreement has been duly executed and delivered by Parent and, assuming the due authorization, execution and delivery by the Contributors and the Company, constitutes a valid and binding obligation of Parent, enforceable against Parent in accordance with its terms (except to the extent that enforceability may be limited by applicable bankruptcy, insolvency, moratorium, reorganization or similar Laws affecting the enforcement of creditors&#8217; rights generally or by general principles of equity).</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-21<br></div></div></div>
<!--End Page 478-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 479-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg29"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The Parent Board, at a meeting duly called and held at which all directors of Parent were present, unanimously and duly adopted resolutions (i)&#160;determining that the terms of this Agreement, the Transactions, the CVR Agreement and the other transactions contemplated hereby are fair to and in the best interests of Parent and its stockholders, (ii)&#160;approving and declaring advisable this Agreement and the transactions contemplated hereby, including the Transactions, and by the CVR Agreement, and (iii)&#160;resolving to recommend that Parent stockholders approve the Parent Stockholder Matters, which resolutions have not been subsequently rescinded, modified or withdrawn in any way.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;The Parent Stockholder Approval is the only vote of the holders of any class or series of the Parent Capital Stock or other securities required in connection with the consummation of the Transactions and the other transactions contemplated hereby, and by the CVR Agreement, including the Parent Stockholder Matters. Other than the Parent Stockholder Approval, no vote of the holders of any class or series of the Parent&#8217;s Capital Stock or other securities is required in connection with the consummation of any of the transactions contemplated hereby to be consummated by Parent.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS45"><!--Anchor--></a>Section 4.5&#8195;<u>No Conflict; Consents and Approvals</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The execution, delivery and performance of this Agreement by Parent does not, and the consummation of the Transactions and the other transactions contemplated hereby and compliance by Parent with the provisions hereof will not, conflict with, or result in any violation or breach of, or default (with or without notice or lapse of time, or both) under, or give rise to a right of, or result in, termination, cancellation, modification or acceleration of any obligation or to the loss of a benefit under, or result in the creation of any Lien in or upon any of the properties, assets or rights of Parent under, or give rise to any increased, additional, accelerated or guaranteed rights or entitlements under, or require any consent, waiver or approval of any Person pursuant to, any provision of (i)&#160;the Certificate of Incorporation or Bylaws of Parent, (ii)&#160;any material Contract to which Parent is a party by which Parent or any of its properties or assets may be bound, or (iii)&#160;subject to the governmental filings and other matters referred to in <u>Section 3.5</u>, any material Law or any rule or regulation of Nasdaq applicable to Parent or by which Parent or any of its properties or assets may be bound, except as, in the case of clause (iii), as individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;No consent, approval, order or authorization of, or registration, declaration, filing with or notice to, any Governmental Entity is required by or with respect to Parent in connection with the execution, delivery and performance of this Agreement by Parent or the consummation by Parent of the Transactions and the other transactions contemplated hereby or compliance with the provisions hereof, except for (i)&#160;the filing with the SEC of such reports under Section 13(a) or 15(d) of the Exchange Act, as may be required in connection with this Agreement and the transactions contemplated hereby, (ii)&#160;such other filings and reports as may be required pursuant to the applicable requirements of the Securities Act, the Exchange Act and any other applicable state or federal securities, takeover and &#8220;blue sky&#8221; laws, and (iii)&#160;such other consents, approvals, orders, authorizations, registrations, declarations, filings or notices, the failure of which to be obtained or made would not be material to Parent.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;The Parent Board has taken and will take all actions necessary to ensure that the restrictions applicable to business combinations contained in Section 203 of the DGCL are, and will be, inapplicable to the execution, delivery and performance of this Agreement and to the consummation of the transactions contemplated by this Agreement. No other state takeover statute or similar Law applies or purports to apply to the Transactions, this Agreement or any of the other transactions contemplated by this Agreement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS46"><!--Anchor--></a>Section 4.6&#8195;<u>SEC Reports; Financial Statements</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Parent has filed with or furnished to the SEC on a timely basis true and complete copies of all forms, reports, schedules, statements and other documents required to be filed with or furnished to the SEC by Parent since January&#160;1, 2021 (all such documents, together with all exhibits and schedules to the foregoing materials and all information incorporated therein by reference, the &#8220;<u>Parent SEC Documents</u>&#8221;). As of their respective filing dates (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), the Parent SEC Documents complied in all material respects with the applicable requirements of the Securities Act, the Exchange Act and the Sarbanes-Oxley Act of 2002 (the &#8220;<u>Sarbanes-Oxley Act</u>&#8221;), as the case </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-22<br></div></div></div>
<!--End Page 479-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 480-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg30"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">may be, including, in each case, the rules and regulations promulgated thereunder, and none of the Parent SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The financial statements (including the related notes and schedules thereto) included (or incorporated by reference) in the Parent SEC Documents (i)&#160;have been prepared in a manner consistent with the books and records of Parent and its Subsidiary, (ii)&#160;have been prepared in accordance with GAAP (except, in the case of unaudited statements, as permitted by Form 10-Q of the SEC) applied on a consistent basis during the periods involved (except as may be indicated in the notes thereto), (iii)&#160;comply as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto and (iv)&#160;fairly present in all material respects the consolidated financial position of Parent and its Subsidiaries as of the dates thereof and their respective consolidated results of operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal and recurring year-end audit adjustments that were not, or are not expected to be, material in amount), all in accordance with GAAP and the applicable rules and regulations promulgated by the SEC. Since January&#160;1, 2021, Parent has not made any change in the accounting practices or policies applied in the preparation of its financial statements, except as required by GAAP, SEC rule or policy or applicable Law. The books and records of Parent and its Subsidiaries have been, and are being, maintained in all material respects in accordance with GAAP (to the extent applicable) and any other applicable legal and accounting requirements and reflect only actual transactions.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;Parent has established and maintains disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Exchange Act). Such disclosure controls and procedures are designed to ensure that information relating to Parent, including its consolidated Subsidiaries, required to be disclosed in Parent&#8217;s periodic and current reports under the Exchange Act, is made known to Parent&#8217;s chief executive officer and its chief financial officer by others within those entities to allow timely decisions regarding required disclosures as required under the Exchange Act. The chief executive officer and chief financial officer of Parent have evaluated the effectiveness of Parent&#8217;s disclosure controls and procedures and, to the extent required by applicable Law, presented in any applicable Parent SEC Document that is a report on Form 10-K or Form 10-Q, or any amendment thereto, its conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by such report or amendment based on such evaluation.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;Parent and its Subsidiaries have established and maintain a system of internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) which is effective in providing reasonable assurance regarding the reliability of Parent&#8217;s financial reporting and the preparation of Parent&#8217;s financial statements for external purposes in accordance with GAAP. Parent has disclosed, based on its most recent evaluation of Parent&#8217;s internal control over financial reporting prior to the date hereof, to Parent&#8217;s auditors and audit committee (i)&#160;any significant deficiencies and material weaknesses in the design or operation of Parent&#8217;s internal control over financial reporting which are reasonably likely to adversely affect Parent&#8217;s ability to record, process, summarize and report financial information and (ii)&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in Parent&#8217;s internal control over financial reporting. A true, correct and complete summary of any such disclosures made by management to Parent&#8217;s auditors and audit committee is set forth as <u>Section 4.6(d)</u> of Parent Disclosure Letter.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;Since January&#160;1, 2021, (i)&#160;neither Parent nor any of its Subsidiaries nor, to the knowledge of the Parent, any director, officer, employee, auditor, accountant or representative of the Parent or any of its Subsidiaries has received or otherwise had or obtained knowledge of any material complaint, allegation, assertion or claim, whether written or oral, regarding the accounting or auditing practices, procedures, methodologies or methods of Parent or any of its Subsidiaries or their respective internal accounting controls, including any material complaint, allegation, assertion or claim that Parent or any of its Subsidiaries has engaged in questionable accounting or auditing practices and (ii)&#160;no attorney representing Parent or any of its Subsidiaries, whether or not employed by Parent or any of its Subsidiaries, has reported evidence of a material violation of securities Laws, breach of fiduciary duty or similar violation by Parent or any of its Subsidiaries or any of their respective officers, directors, employees or agents to the Parent Board or any committee thereof or to any director or officer of Parent or any of its Subsidiaries.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-23<br></div></div></div>
<!--End Page 480-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 481-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg31"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;As of the date of this Agreement, there are no outstanding or unresolved comments in the comment letters received from the SEC staff with respect to the Parent SEC Documents. To the knowledge of Parent, none of the Parent SEC Documents is subject to ongoing review or outstanding SEC comment or investigation.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;Neither Parent nor any of its Subsidiaries is a party to, or has any commitment to become a party to, any joint venture, off-balance sheet partnership or any similar Contract (including any Contract or arrangement relating to any transaction or relationship between or among Parent and any of its Subsidiaries, on the one hand, and any unconsolidated Affiliate, including any structured finance, special-purpose or limited-purpose entity or Person, on the other hand, or any &#8220;off balance sheet arrangements&#8221; (as defined in Item 303(a) of Regulation S&#160;K under the Exchange Act)), where the result, purpose or intended effect of such Contract is to avoid disclosure of any material transaction involving, or material liabilities of, Parent or any of its Subsidiaries in Parent&#8217;s or such Subsidiary&#8217;s published financial statements or other Parent SEC Documents.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(h)&#8195;Parent is in compliance in all material respects with (i)&#160;the provisions of the Sarbanes-Oxley Act and (ii)&#160;the rules and regulations of Nasdaq, in each case, that are applicable to Parent.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(i)&#8195;No Subsidiary of Parent is required to file any form, report, schedule, statement or other document with the SEC.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(j)&#8195;Parent has not been and is not currently a &#8220;shell company&#8221; as defined under Section 12b-2 of the Exchange Act.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(k)&#8195;Parent is, and since its first date of listing on Nasdaq has been, in compliance in all material respects with the applicable current listing and governance rules and regulations of Nasdaq.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS47"><!--Anchor--></a>Section 4.7&#8195;<u>No Undisclosed Liabilities</u>. Neither Parent nor any of its Subsidiaries has any liabilities or obligations of any nature, whether accrued, absolute, contingent or otherwise, known or unknown, whether due or to become due and whether or not required to be recorded or reflected on a balance sheet under GAAP, except (a)&#160;to the extent accrued or reserved against in the audited consolidated balance sheet of Parent and its Subsidiaries as at December&#160;31, 2021 included in the Annual Report on Form 10-K filed by Parent with the SEC on March&#160;31, 2022 (without giving effect to any amendment thereto filed on or after the date hereof) and (b) for liabilities and obligations incurred in the ordinary course of business consistent with past practice since December&#160;31, 2021 that are not material to Parent and its Subsidiaries, taken as a whole. Parent has not applied for or received any funds or incurred any indebtedness pursuant to the Coronavirus Aid, Relief, and Economic Security Act (P.L. 116-136), enacted March&#160;27, 2020 or any other economic relief or stimulus legislation or program, or otherwise received any funds or incurred any indebtedness from any Governmental Entity.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS48"><!--Anchor--></a>Section 4.8&#8195;<u>Absence of Certain Changes or Events</u>. Since December&#160;31, 2021, except in connection with the execution of this Agreement and the consummation of the transactions contemplated hereby, (x)&#160;Parent and its Subsidiaries have conducted their business only in the ordinary course of business consistent with past practice; (y)&#160;there has not been any change, event or development or prospective change, event or development that, individually or in the aggregate, has had or would reasonably be expected to have a Parent Material Adverse Effect; and (z) neither Parent nor any of its Subsidiaries have:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;(i)&#160;declared, set aside or paid any dividends on, or made any other distributions (whether in cash, stock or property) in respect of, any of its capital stock or other equity interests, except for dividends by a wholly-owned Subsidiary of Parent to its parent, (ii)&#160;purchased, redeemed or otherwise acquired shares of capital stock or other equity interests of Parent or its Subsidiary or any options, warrants, or rights to acquire any such shares or other equity interests, or (iii)&#160;split, combined, reclassified or otherwise amended the terms of any of its capital stock or other equity interests or issued or authorized the issuance of any other securities in respect of, in lieu of or in substitution for shares of its capital stock or other equity interests;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;amended or otherwise changed, or authorized or proposed to amend or otherwise change, its certificate of incorporation or by-laws (or similar organizational documents);</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;adopted or entered into a plan of complete or partial liquidation, dissolution, restructuring, recapitalization or reorganization; or</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;changed its financial or Tax accounting methods, principles or practices, except insofar as may have been required by a change in GAAP or applicable Law, or revalued any of its material assets.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-24<br></div></div></div>
<!--End Page 481-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 482-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg32"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS49"><!--Anchor--></a>Section 4.9&#8195;<u>Litigation</u>. There is no Action (or basis therefor) pending or, to the knowledge of Parent, threatened against or affecting Parent or any of its Subsidiaries, any of their respective properties or assets, or any present or former officer, director or employee of Parent or any of its Subsidiaries in such individual&#8217;s capacity as such, other than any Action that (a) does not involve an amount in controversy in excess of $100,000 and (b) does not seek material injunctive or other nonmonetary relief. Neither Parent nor any of its Subsidiaries nor any of their respective properties or assets is subject to any outstanding judgment, order, injunction, rule or decree of any Governmental Entity. There is no Action pending or, to the knowledge of Parent, threatened seeking to prevent, hinder, modify, delay or challenge the Transactions or any of the other transactions contemplated by this Agreement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS410"><!--Anchor--></a>Section 4.10&#8195;<u>Compliance with Laws</u>. Parent and each of its Subsidiaries are and have been in compliance in all material respects with all Laws applicable to their businesses, operations, properties or assets. None of Parent or any of its Subsidiaries has received, since January&#160;1, 2020, a notice or other written communication alleging or relating to a possible material violation of any Law applicable to their businesses, operations, properties, assets or Parent Products (as defined below). Parent and each of its Subsidiaries have in effect all material Permits of all Governmental Entities necessary or advisable for them to own, lease or operate their properties and assets and to carry on their businesses and operations as now conducted, and there has occurred no violation of, default (with or without notice or lapse of time or both) under or event giving to others any right of revocation, nonrenewal, adverse modification or cancellation of, with or without notice or lapse of time or both, any such Permit, nor would any such revocation, nonrenewal, adverse modification or cancellation result from the consummation of the transactions contemplated hereby.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS411"><!--Anchor--></a>Section 4.11&#8195;<u>Health Care Regulatory Matters.</u></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Parent and, to the knowledge of Parent, each of its directors, officers, management employees, agents (while acting in such capacity), contract manufacturers, suppliers, and distributors are, and at all times prior hereto were, in material compliance with all Health Care Laws to the extent applicable to Parent or any of its products or activities. To the knowledge of Parent, there are no facts or circumstances that reasonably would be expected to give rise to any material liability under any Health Care Laws.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Parent is not party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any Governmental Entity.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;All applications, notifications, submissions, information, claims, reports and statistical analyses, and other data and conclusions derived therefrom, utilized as the basis for or submitted in connection with any and all requests for a Permit from the FDA or other Governmental Entity relating to products that are regulated as drugs, medical devices, or other healthcare products under Health Care Laws, including biological and drug candidates, compounds or products being researched, tested, stored, developed, labeled, manufactured, packed and/or distributed by Parent or any of its Subsidiaries (&#8220;<u>Parent Products</u>&#8221;), including, without limitation, investigational new drug applications, when submitted to the FDA or other Governmental Entity were true, complete and correct in all material respects as of the date of submission and any necessary or required updates, changes, corrections or modification to such applications, submissions, information and data have been submitted to the FDA or other Governmental Entity. Parent does not have knowledge of any facts or circumstances that would be reasonably likely to lead to the revocation, suspension, limitation, or cancellation of a Permit required under Health Care Laws.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;All preclinical studies and clinical trials conducted by or, to the knowledge of Parent, on behalf of Parent have been, and if still pending are being, conducted in material compliance with research protocols and all applicable Health Care Laws, including, but not limited to, the FDCA and its applicable implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58, 312 and 314. No clinical trial conducted by or on behalf of Parent has been conducted using any clinical investigators who have been disqualified, debarred or excluded from healthcare programs. No clinical trial conducted by or on behalf of the Parent has been terminated or suspended prior to completion, and no clinical investigator who has participated or is participating in, or institutional review board that has or has had jurisdiction over, a clinical trial conducted by or on behalf of Parent has placed a partial or full clinical hold order on, or otherwise terminated, delayed or suspended, such a clinical trial at a clinical research site based on an actual or alleged lack of safety or efficacy of any Parent Product or a failure to conduct such clinical trial in compliance with applicable Health Care Laws, their implementing regulations and good clinical practices. The Parent has not identified or received notice of instances or allegations of research </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-25<br></div></div></div>
<!--End Page 482-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 483-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg33"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">misconduct (defined as falsification or fabrication of data, or plagiarism, as those terms are defined in 42 C.F.R. Part 93) involving research conducted by, or on behalf of the Parent, that could compromise or affect the integrity, reliability, completeness or accuracy of the data collected in such research, or the rights, safety or welfare of the research subjects.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;All manufacturing operations conducted by or, to the knowledge of Parent, for the benefit of Parent have been and are being conducted in material compliance with all Permits under applicable Health Care Laws, all applicable provisions of the FDA&#8217;s current good manufacturing practice (cGMP) regulations at 21 C.F.R. Parts 210-211 and Parts 600 and 610 and FDA&#8217;s Quality System (QS) regulations at 21 C.F.R. Part 820, and all comparable foreign regulatory requirements of any Governmental Entity.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;Parent has not received any written communication that relates to an alleged violation or noncompliance with any Health Care Laws, including any notification of any pending or threatened claim, suit, proceeding, hearing, enforcement, investigation, arbitration, import detention or refusal, FDA Warning Letter or Untitled Letter, or any action by a Governmental Entity relating to any Health Care Laws. All Warning Letters, Form-483 observations, or comparable findings from other Governmental Entities listed in <u>Section 4.11(f)</u> of the Parent Disclosure Letter have been resolved and closed out to the satisfaction of the applicable Governmental Entity.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;There have been no seizures, withdrawals, recalls, detentions, or suspensions of manufacturing, testing, or distribution relating to the Parent Products required or requested by a Governmental Entity, or other notice of action relating to an alleged lack of safety, efficacy, or regulatory compliance of the Parent Products, or any adverse experiences relating to the Parent Products that have been reported to FDA or other Governmental Entity (&#8220;<u>Parent Safety Notices</u>&#8221;), and, to the knowledge of Parent, there are no facts or circumstances that reasonably would be expected to give rise to a Parent Safety Notice. All Parent Safety Notices listed in <u>Section 4.11(g)</u> of the Parent Disclosure Letter have been resolved to the satisfaction of the applicable Governmental Entity.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(h)&#8195;There are no unresolved Parent Safety Notices, and to the knowledge Parent, there are no facts that would be reasonably likely to result in a material Parent Safety Notice or a termination or suspension of developing and testing of any of the Parent Products.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(i)&#8195;Neither Parent, nor, to the knowledge of Parent, any officer, employee, agent, or distributor of Parent has made an untrue statement of a material fact or fraudulent or misleading statement to a Governmental Entity, failed to disclose a material fact required to be disclosed to a Governmental Entity, or committed an act, made a statement, or failed to make a statement that would reasonably be expected to provide a basis for the FDA to invoke its FDA Ethics Policy. To the knowledge of Parent, none of the aforementioned is or has been under investigation resulting from any allegedly untrue, fraudulent, misleading, or false statement or omission, including data fraud, or had any action pending or threatened relating to the FDA Ethics Policy.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(j)&#8195;All reports, documents, claims, Permits and notices required to be filed, maintained or furnished to the FDA or any Governmental Entity by Parent have been so filed, maintained or furnished, except where failure to file, maintain or furnish such reports, documents, claims, Permits or notices has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. All such reports, documents, claims, Permits and notices were true and complete in all material respects on the date filed (or were corrected in or supplemented by a subsequent filing).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(k)&#8195;Neither Parent nor, to the knowledge of Parent, any officer, employee, agent, or distributor of Parent has committed any act, made any statement or failed to make any statement that violates the Federal Anti-Kickback Statute, 28 U.S.C. &#167; 1320a-7b, the Federal False Claims Act, 31 U.S.C. &#167; 3729, other Drug or Health Care Laws, or any other similar federal, state, or ex-U.S. law applicable in the jurisdictions in which the Parent Products are sold or intended to be sold.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(l)&#8195;Neither Parent nor, to the knowledge of Parent, any officer, employee, agent, or distributor of Parent has been convicted of any crime or engaged in any conduct that has resulted, or would reasonably be expected to result, in debarment under applicable Law, including, without limitation, 21 U.S.C. &#167; 335a, or exclusion under 42 U.S.C. &#167; 1320a-7, or any other statutory provision or similar law applicable in other jurisdictions in which the Parent Products are sold or intended to be sold. Neither Parent nor, to the knowledge of Parent, any officer, </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-26<br></div></div></div>
<!--End Page 483-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 484-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg34"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">employee, agent or distributor of Parent, has been excluded from participation in any federal health care program or convicted of any crime or engaged in any conduct for which such Person could be excluded from participating in any federal health care program under Section 1128 of the Social Security Act of 1935, as amended, or any similar Health Care Law or program.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS412"><!--Anchor--></a>Section 4.12&#8195;<u>Benefit Plans</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;<u>Section 4.12(a)</u> of the Parent Disclosure Letter contains a true and complete list of each &#8220;employee benefit plan&#8221; (within the meaning of section 3(3) of ERISA, whether or not subject to ERISA), and all stock purchase, stock option, phantom stock or other equity-based plan, severance, employment, collective bargaining, change-in-control, fringe benefit, bonus, incentive, deferred compensation, supplemental retirement, health, life, or disability insurance, dependent care and all other employee benefit and compensation plans, agreements, programs, policies or other arrangements, in each case, whether written or oral, legally binding or not, under which any current or former employee, director or consultant of Parent or its Subsidiaries (or any of their dependents) has any present or future right to compensation or benefits or Parent or any of its Subsidiaries sponsors or maintains, is making contributions to or has any present or future liability or obligation (contingent or otherwise). All such plans, agreements, programs, policies and arrangements shall be collectively referred to as the &#8220;<u>Parent Plans</u>.&#8221; Parent has provided or made available to the Contributors a current, accurate and complete copy of each Parent Plan, or if such Parent Plan is not in written form, a written summary of all of the material terms of such Parent Plan. With respect to each Parent Plan, Parent has furnished or made available to the Contributors a current, accurate and complete copy of, to the extent applicable: (i)&#160;any related trust agreement or other funding instrument, (ii)&#160;the most recent determination letter of the IRS, (iii)&#160;any summary plan description or summary of material modifications, and (iv)&#160;for the most recent year and as applicable (A)&#160;the Form 5500 and attached schedules, (B) audited financial statements and (C) actuarial valuation reports.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Neither Parent, its Subsidiaries or any member of their Controlled Group (defined as any organization which is a member of a controlled, affiliated or otherwise related group of entities within the meaning of Code Section 414(b), (c), (m) or (o)) has, in the past six (6) years, sponsored, maintained, contributed to or been required to contribute to or incurred any liability (contingent or otherwise) with respect to: (i)&#160;a &#8220;multiemployer plan&#8221; (within the meaning of ERISA section 3(37)), (ii)&#160;a Pension Plan that is subject to Title IV of ERISA or Section 412 of the Code, (iii)&#160;a Pension Plan which is a &#8220;multiple employer plan&#8221; as defined in Section 413 of the Code, or (iv)&#160;a &#8220;funded welfare plan&#8221; within the meaning of Section 419 of the Code.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(c)&#8195;With respect to the Parent Plans:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(i)&#8195;each Parent Plan complies in all material respects with its terms and materially complies in form and in operation with the applicable provisions of ERISA and the Code and all other applicable legal requirements;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(ii)&#8195;each Parent Plan intended to be qualified under Section 401(a) of the Code has received a favorable determination, advisory and/or opinion letter, as applicable, from the IRS that it is so qualified and nothing has occurred to the knowledge of the Parent since the date of such letter that would reasonably be expected to cause the loss of the sponsor&#8217;s ability to rely upon such letter, and nothing has occurred to the knowledge of the Parent that would reasonably be expected to result in the loss of the qualified status of such Parent Plan;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iii)&#8195;there is no material Action (including any investigation, audit or other administrative proceeding) by the Department of Labor, the PBGC, the IRS or any other Governmental Entity or by any plan participant or beneficiary pending, or to the knowledge of Parent, threatened, relating to the Parent Plans, any fiduciaries thereof with respect to their duties to Parent Plans or the assets of any of the trusts under any of Parent Plans (other than routine claims for benefits);</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iv)&#8195;none of the Parent Plans currently provides, or reflects or represents any liability to provide post-termination or retiree welfare benefits to any person for any reason, except as may be required by COBRA, and none of Parent, its Subsidiaries or any members of their Controlled Group has any liability to provide post-termination or retiree welfare benefits to any person, except to the extent required by statute or except with respect to a contractual obligation to reimburse any premiums such person may pay in order to obtain health coverage under COBRA;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(v)&#8195;each Parent Plan is subject exclusively to United States Law; and</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-27<br></div></div></div>
<!--End Page 484-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 485-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg35"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(vi)&#8195;the execution and delivery of this Agreement and the consummation of the Transactions will not, either alone or in combination with any other event, (A) entitle any current or former employee, officer, director or consultant of Parent or any Subsidiary to severance pay, unemployment compensation or any other similar termination payment, or any other compensatory payment, including any bonus, retention, retirement or other benefit, (B) accelerate the time of payment or vesting, or increase the amount of or otherwise enhance any benefit due to any such employee, officer, director or consultant, or (C) result in the payment of any &#8220;excess parachute payment&#8221; within the meaning of Section 280G of the Code.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;Each Parent Plan that is a &#8220;nonqualified deferred compensation plan&#8221; within the meaning of Section&#160;409A of the Code (or any comparable or similar provision of state, local, or foreign Law) materially complies in both form and operation in all material respects with the requirements of Section 409A of the Code (or any comparable or similar provision of state, local, or foreign Law) and all applicable IRS guidance issued with respect thereto. There is no agreement, plan or other arrangement to which any of Parent or any Subsidiary is a party or by which any of them is otherwise bound to compensate any person in respect of any excise or other Taxes or other liabilities (including interest and penalties) incurred with respect to Section 409A or 4999 of the Code.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS413"><!--Anchor--></a>Section 4.13&#8195;<u>Labor and Employment Matters</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Parent and its Subsidiaries are and since January&#160;1, 2020 have been in compliance in all material respects with all applicable Laws relating to labor and employment, including those relating to employment practices, terms and conditions of employment, collective bargaining, disability, immigration, health and safety, wages, hours and benefits, non-discrimination in employment, workers&#8217; compensation, the collection and payment of withholding and/or payroll Taxes and similar Taxes, unemployment compensation, equal employment opportunity, discrimination, harassment, employee and contractor classification, information privacy and security, and continuation coverage with respect to group health plans. During the preceding three&#160;years, there has not been, and as of the date of this Agreement there is not pending or, to the knowledge of Parent, threatened, any labor dispute, work stoppage, labor strike or lockout against Parent or any of its Subsidiaries by employees.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;No employee of Parent or any of its Subsidiaries is covered by an effective or pending collective bargaining agreement or similar labor agreement. To the knowledge of Parent, since January&#160;1, 2020, there has not been any activity on behalf of any labor union, labor organization or similar employee group to organize any employees of Parent or any of its Subsidiaries, and there are no representation claims or petitions pending before the National Labor Relations Board or any other labor relations tribunal or authority. There are no (i)&#160;material unfair labor practice charges or complaints against Parent or any of its Subsidiaries pending before the National Labor Relations Board or any other labor relations tribunal or authority and to the knowledge of Parent no such representations, claims or petitions are threatened, or (ii)&#160;grievances or pending arbitration proceedings against Parent or any of its Subsidiaries that arose out of or under any collective bargaining agreement. Neither the consent or consultation of, nor the formal rendering of advice by, any labor union, labor organization or similar employee group is required for Parent to enter into this Agreement or to consummate the transactions contemplated hereby.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;To the knowledge of Parent, no current key employee or officer of Parent or any of its Subsidiaries intends, or is expected, to terminate his or her employment relationship with such entity in connection with or as a result of the transactions contemplated hereby or otherwise within one year of the Closing Date.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;During the preceding three years, (i)&#160;neither Parent nor any Subsidiary has effectuated a &#8220;plant closing&#8221; (as defined in the WARN Act) affecting any site of employment or one or more facilities or operating units within any site of employment or facility, (ii)&#160;there has not occurred a &#8220;mass layoff&#8221; (as defined in the WARN Act) in connection with Parent or any Subsidiary affecting any site of employment or one or more facilities or operating units within any site of employment or facility and (iii)&#160;neither Parent nor any Subsidiary has engaged in layoffs or employment terminations sufficient in number to trigger application of any similar state, local or foreign law. The Parent and its Subsidiaries currently properly classify and for the past three&#160;(3)&#160;years have properly classified its and their employees as exempt or nonexempt in accordance with </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-28<br></div></div></div>
<!--End Page 485-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 486-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg36"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">applicable overtime laws, and no person treated as an independent contractor or consultant by Parent or any Subsidiary within the past three (3) years should have been properly classified as an employee under applicable Law, in each case, except as would not, individually or in the aggregate, result in Parent incurring a material liability.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;With respect to any current or former employee, officer, consultant or other service provider of Parent, there are no Actions against Parent or any of its Subsidiaries pending, or to Parent&#8217;s knowledge, threatened to be brought or filed, in connection with the employment or engagement of any current or former employee, officer, consultant or other service provider of Parent, including, without limitation, any claim relating to employment discrimination, harassment, retaliation, equal pay, employment classification or any other employment related matter arising under applicable Laws, except where such action would not, individually or in the aggregate, result in Parent incurring a material liability.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;Since January&#160;1, 2020, (i)&#160;no allegations of workplace sexual harassment, discrimination or other misconduct have been made, initiated, filed or, to the knowledge of Parent, threatened against Parent, any of its Subsidiaries or any of their respective current or former directors, officers or senior-level management employees in their capacities as such, (ii)&#160;to the knowledge of Parent, no incidents of any such workplace sexual harassment, discrimination or other misconduct have occurred, and (iii)&#160;Parent has not entered into any settlement agreement related to allegations of sexual harassment, discrimination or other misconduct by any of its directors, officers or employees described in clause (i)&#160;hereof or any independent contractor.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;Parent and its Subsidiaries are and have at all relevant times been in compliance in all material respects with (i)&#160;COVID-19 related Laws, standards, regulations, orders and guidance (including without limitation relating to business reopening), including those issued and enforced by the Occupational Safety and Health Administration, the Centers for Disease Control, the Equal Employment Opportunity Commission, and any other Governmental Entity; and (ii)&#160;the Families First Coronavirus Response Act and any other applicable COVID-19-related leave Law, whether state, local or otherwise.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS414"><!--Anchor--></a>Section 4.14&#8195;<u>Environmental Matters</u>. Except as would not be material to the Parent, (i)&#160;Parent and each of its Subsidiaries have conducted their respective businesses in compliance with all, and have not violated any, applicable Environmental Laws; (ii)&#160;Parent and its Subsidiaries have obtained all Permits of all Governmental Entities and any other Person that are required under any Environmental Law; (iii)&#160;there has been no release of any Hazardous Substance by Parent or any of its Subsidiaries or any other Person in any manner that has given or would reasonably be expected to give rise to any remedial or investigative obligation, corrective action requirement or liability of Parent or any of its Subsidiaries under applicable Environmental Laws; (iv)&#160;neither Parent nor any of its Subsidiaries has received any claims, notices, demand letters or requests for information (except for such claims, notices, demand letters or requests for information the subject matter of which has been resolved prior to the date of this Agreement) from any federal, state, local, foreign or provincial Governmental Entity or any other Person asserting that Parent or any of its Subsidiaries is in violation of, or liable under, any Environmental Law; (v)&#160;no Hazardous Substance has been disposed of, arranged to be disposed of, released or transported in violation of any applicable Environmental Law, or in a manner that has given rise to, or that would reasonably be expected to give rise to, any liability under any Environmental Law, in each case, on, at, under or from any current or former properties or facilities owned or operated by Parent or any of its Subsidiaries or as a result of any operations or activities of Parent or any of its Subsidiaries at any location and, to the knowledge of Parent, Hazardous Substances are not otherwise present at or about any such properties or facilities in amount or condition that has resulted in or would reasonably be expected to result in liability to Parent or any of its Subsidiaries under any Environmental Law; and (vi)&#160;neither Parent, its Subsidiaries nor any of their respective properties or facilities are subject to, or are threatened to become subject to, any liabilities relating to any suit, settlement, court order, administrative order, regulatory requirement, judgment or claim asserted or arising under any Environmental Law or any agreement relating to environmental liabilities.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS415"><!--Anchor--></a>Section 4.15&#8195;<u>Taxes</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Parent and each of its Subsidiaries have (i)&#160;filed all income Tax Returns and other material Tax Returns required to be filed by or on behalf of themselves (taking into account any applicable extensions thereof) and all such Tax Returns are true, accurate and complete in all material respects; and (ii)&#160;paid in full (or caused to be timely paid in full) all income and other material Taxes that are required to be paid by it, whether or not such Taxes were shown as due on such Tax Returns.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-29<br></div></div></div>
<!--End Page 486-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 487-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg37"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;All material Taxes not yet due and payable by Parent or any of its Subsidiaries as of the date of the Parent Balance Sheet have been, in all respects, properly accrued in accordance with GAAP on the financial statements (including the related notes and schedules thereto) included (or incorporated by reference) in the Parent SEC Documents, and such financial statements (including the related notes and schedules thereto) included (or incorporated by reference) in the Parent SEC Documents reflect an adequate reserve (in accordance with GAAP) for all material Taxes accrued but unpaid by Parent and each of its Subsidiaries through the date of such financial statements. Since the date of the Parent Balance Sheet, neither Parent nor any of its Subsidiaries has incurred, individually or in the aggregate, any liability for Taxes outside the ordinary course of business.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;Neither Parent nor any of its Subsidiaries has executed any waiver of any statute of limitations on, or extended the period for the assessment or collection of, any material amount of Tax, in each case that has not since expired.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;No material Tax Actions with respect to Taxes or any Tax Return of Parent or any of its Subsidiaries are presently in progress or have been asserted, threatened or proposed in writing. No deficiencies or claims for a material amount of Taxes have been claimed, proposed, assessed or asserted in writing against Parent or any of its Subsidiaries by a Governmental Entity, other than any such claim, proposal, assessment or assertion that has been satisfied by payment in full, settled or withdrawn.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;Parent and each of its Subsidiaries have timely withheld all material amounts of Taxes required to have been withheld from payments made (or deemed made) to their employees, independent contractors, creditors, stockholders and other third parties and, to the extent required, such Taxes have been timely paid to the relevant Governmental Entity.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;Neither Parent nor any of its Subsidiaries has engaged in a &#8220;reportable transaction&#8221; as set forth in Treasury Regulations &#167; 1.6011-4(b).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;Neither Parent nor any of its Subsidiaries (i)&#160;is a party to or bound by, or has any liability pursuant to, any Tax sharing, allocation, indemnification or similar agreement or obligation other than any Ordinary Course Agreement; (ii)&#160;is or has ever been a member of a group (other than a group the common parent of which is Parent) filing a consolidated, combined, affiliated, unitary or similar income Tax Return; (iii)&#160;has any liability for the Taxes of any Person (other than Parent) pursuant to Treasury Regulations &#167; 1.1502-6 (or any similar provision of state, local or non-United States Law) as a transferee or successor, by Contract (other than Ordinary Course Agreements), or otherwise by operation of Law; and (iv)&#160;is or has ever been treated as a resident for any income Tax purpose, or as subject to Tax by virtue of having a permanent establishment, an office or fixed place of business, in any country other than the country in which it was or is organized.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(h)&#8195;No private-letter rulings, technical advice memoranda, or similar material agreements or rulings have been requested in writing, entered into or issued by any taxing authority with respect to Parent or any of its Subsidiaries which rulings remain in effect.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(i)&#8195;Neither Parent nor any of its Subsidiaries will be required to include any item of income in, or exclude any item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of (i)&#160;a change in, or use of improper, method of accounting requested or initiated on or prior to the Closing Date, (ii)&#160;a &#8220;closing agreement&#8221; as described in Section 7121 of the Code (or any similar provision of Law) executed on or prior to the Closing Date, (iii)&#160;an installment sale or open-transaction disposition made on or prior to the Closing Date, or (iv)&#160;any deferred intercompany gain or excess-loss account described in Treasury Regulations under Section 1502 of the Code (or any corresponding or similar provision of state, local or foreign income Tax Law).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(j)&#8195;There are no liens for Taxes upon any of the assets of Parent or any of its Subsidiaries other than Liens described in clause (i)&#160;of the definition of Permitted Liens.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(k)&#8195;Neither Parent nor any of its Subsidiaries has distributed stock of another Person or has had its stock distributed by another Person, in a transaction (or series of transactions) that was purported or intended to be governed in whole or in part by Section 355 or 361 of the Code.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(l)&#8195;Neither Parent nor any of its Subsidiaries has been a United States real property holding corporation, as defined in Section 897(c)(2) of the Code during the applicable period specified in Section 897(c)(1)(A)(ii)&#160;of the Code.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-30<br></div></div></div>
<!--End Page 487-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 488-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg38"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(m)&#8195;No material claim has been made in writing by any Governmental Entity in a jurisdiction where Parent or any of its Subsidiaries does not currently file or has not filed a Tax Return that Parent or any of its Subsidiaries is or may be subject to taxation by such jurisdiction.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(n)&#8195;To Parent&#8217;s knowledge, neither Parent nor any of its Subsidiaries has been, is, and immediately prior to the Effective Time will be, treated as an &#8220;investment company&#8221; within the meanings of Section 351(e) of the Code.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(o)&#8195;Neither Parent nor any of its Subsidiaries has taken any action (or agreed to take any action prior to the Closing), nor does it know of any fact or circumstance, in each case, that it knows could reasonably be expected to prevent or impede the Transactions from qualifying for the Intended Tax Treatment.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(p)&#8195;<u>Section 4.15(p</u>) of the Parent Disclosure Letter sets forth the entity classification of Parent and each of its Subsidiaries for U.S. federal income tax purposes. Neither Parent nor any of its Subsidiaries has made an election to change its federal and state income tax classification from such classification.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS416"><!--Anchor--></a>Section 4.16&#8195;<u>Contracts</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Except as set forth in the Parent SEC Documents publicly available prior to the date of this Agreement, neither Parent nor any of its Subsidiaries is a party to or is bound by any &#8220;material contract&#8221; (as such term is defined in Item 601(b)(10) of Regulation S-K under the Securities Act, excluding, however, any Company Plans) (all such Contracts &#8220;<u>Parent Material Contracts</u>&#8221;).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;(i)&#160;Each Parent Material Contract is valid and binding on Parent and any of its Subsidiaries to the extent such Subsidiary is a party thereto, as applicable, and to the knowledge of Parent, each other party thereto, and is in full force and effect and enforceable in accordance with its terms; (ii)&#160;Parent and each of its Subsidiaries, and, to the knowledge of Parent, each other party thereto, have performed all material obligations required to be performed by themselves under each Parent Material Contract; and (iii)&#160;there is no material default under any Parent Material Contract by Parent or any of its Subsidiaries or, to the knowledge of Parent, any other party thereto, and no event or condition has occurred that constitutes, or, after notice or lapse of time or both, would constitute, a material default on the part of Parent or any of its Subsidiaries or, to the knowledge of Parent, any other party thereto under any such Parent Material Contract, nor has Parent or any of its Subsidiaries received any notice of any such material default, event or condition. Parent has made available to the Contributors true and complete copies of all Parent Material Contracts, including all amendments thereto.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS417"><!--Anchor--></a>Section 4.17&#8195;<u>Insurance</u>. Each of Parent and its Subsidiaries is covered by valid and currently effective insurance policies issued in favor of Parent or one or more of its Subsidiaries that are customary and adequate for companies of similar size in the industries and locations in which Parent operates. <u>Section 4.17</u> of the Parent Disclosure Letter sets forth, as of the date hereof, a true and complete list of all material insurance policies issued in favor of Parent or any of its Subsidiaries, or pursuant to which Parent or any of its Subsidiaries is a named insured or otherwise a beneficiary, as well as any historic incurrence-based policies still in force. With respect to each such insurance policy, (a) such policy is in full force and effect and all premiums due thereon have been paid, (b) neither Parent nor any of its Subsidiaries is in breach or default, and has not taken any action or failed to take any action which (with or without notice or lapse of time, or both) would constitute such a breach or default, or would permit termination or modification of, any such policy and (c) to the knowledge of Parent, no insurer issuing any such policy has been declared insolvent or placed in receivership, conservatorship or liquidation. No notice of cancellation or termination has been received with respect to any such policy, nor will any such cancellation or termination result from the consummation of the transactions contemplated hereby. The transactions contemplated in this Agreement are not deemed to be a change of control under the Parent&#8217;s existing directors&#8217; and officers&#8217; liability insurance policy.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS418"><!--Anchor--></a>Section 4.18&#8195;<u>Properties</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Parent or one of its Subsidiaries has good and valid title to, or in the case of leased property and leased tangible assets, a valid leasehold interest in, all of its real properties and tangible assets that are necessary for Parent and its Subsidiaries to conduct their respective businesses as currently conducted, free and clear of all Liens other than (i)&#160;Liens for current Taxes and assessments not yet past due or the amount or validity of which is being contested in good faith by appropriate proceedings, (ii)&#160;mechanics&#8217;, workmen&#8217;s, repairmen&#8217;s, warehousemen&#8217;s and carriers&#8217; Liens arising in the ordinary course of business consistent with past practice and (iii)&#160;any such matters of record, Liens and other imperfections of title that do not, individually or in the aggregate, materially impair the continued ownership, use and operation of the assets to which they relate in the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-31<br></div></div></div>
<!--End Page 488-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 489-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg39"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">business of the Parent as currently conducted (&#8220;<u>Permitted Liens</u>&#8221;). Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect, the tangible personal property currently used in the operation of the business of Parent and its Subsidiaries is in good working order (reasonable wear and tear excepted).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Each of Parent and its Subsidiaries has complied with the terms of all leases to which it is a party, and all such leases are in full force and effect, except for any such noncompliance or failure to be in full force and effect that, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect. Each of Parent and its Subsidiaries enjoys peaceful and undisturbed possession under all such leases, except for any such failure to do so that, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;<u>Section 4.18(c)</u> of the Parent Disclosure Letter sets forth a true and complete list of (i)&#160;all real property owned by Parent or any of its Subsidiaries and (ii)&#160;all real property leased for the benefit of Parent or any of its Subsidiaries.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(d)&#8195;This <u>Section 4.18</u> does not relate to Intellectual Property, which is the subject of <u>Section 4.19</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS419"><!--Anchor--></a>Section 4.19&#8195;<u>Intellectual Property.</u></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;<u>Section 4.19(a)</u> of the Parent Disclosure Letter sets forth a true and complete list of all (i)&#160;material patents and patent applications; (ii)&#160;material trademark registrations and applications; and (iii)&#160;material copyright registrations and applications (collectively, &#8220;<u>Parent Registered</u> IP&#8221;), in each case owned by the Parent and its Subsidiaries, and a true and complete list of all domain names owned or exclusively licensed by Parent and its Subsidiaries. Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect (A) all of the Parent Registered IP is subsisting and, in the case of any Parent Registered IP that is registered or issued and to the knowledge of Parent, valid and enforceable, (B) no Parent Registered IP is involved in any interference, reissue, derivation, reexamination, opposition, cancellation or similar proceeding and, to the knowledge of Parent, no such action is threatened with respect to any of the Parent Registered IP and (C) Parent or its Subsidiaries own exclusively, free and clear of any and all Liens (other&#160;than Permitted Liens), all Parent Owned IP, including all Intellectual Property created on behalf of Parent or its Subsidiaries by employees or independent contractors.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;<u>Section 4.19(b)</u> of the Parent Disclosure Letter accurately identifies (i)&#160;all contracts pursuant to which any Parent Registered IP is licensed to Parent or its Subsidiaries (other than (A) any non-customized software that (1) is so licensed solely in executable or object code form pursuant to a nonexclusive, internal-use software license and other Intellectual Property associated with such software and (2) is not incorporated into, or material to the development, manufacturing, or distribution of, any of Parent&#8217;s or its Subsidiaries&#8217; products or services, (B) any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of equipment, reagents or other materials, (C) any confidential information provided under confidentiality agreements and (D)&#160;agreements between Parent and any of its Subsidiaries and their employees in Parent&#8217;s standard form thereof), (ii)&#160;the corresponding Parent Contract pursuant to which such Parent Registered IP is licensed to Parent or any of its Subsidiaries and (iii)&#160;whether the license or licenses granted to Parent or its Subsidiaries are exclusive or nonexclusive.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;<u>Section 4.19(c)</u> of the Parent Disclosure Letter accurately identifies each Parent contract pursuant to which any Person has been granted any license or covenant not to sue under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest in, any Parent Registered IP (other than (i)&#160;any confidential information provided under confidentiality agreements and (ii)&#160;any Parent Registered IP nonexclusively licensed to academic collaborators, suppliers or service providers for the sole purpose of enabling such academic collaborator, supplier or service providers to provide services for Parent&#8217;s benefit).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;Parent and its Subsidiaries have taken commercially reasonable measures to maintain the confidentiality of all information that constitutes or constituted a material Trade Secret of Parent or its Subsidiaries, including requiring all Persons having access thereto to execute written nondisclosure agreements or other binding obligations to maintain confidentiality of such information.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect, (i)&#160;to the knowledge of Parent, the conduct of the businesses of Parent and its Subsidiaries, including the manufacture, marketing, offering for sale, sale, importation, use or intended use or </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-32<br></div></div></div>
<!--End Page 489-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 490-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg40"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">other disposal of any product as currently sold or under development by Parent or its Subsidiaries, has not infringed, misappropriated or diluted, and does not infringe, misappropriate or dilute, any Intellectual Property of any Person, (ii)&#160;neither Parent nor any of its Subsidiaries has received any written notice or claim asserting or suggesting that any such infringement, misappropriation, or dilution is or may be occurring or has or may have occurred and (iii)&#160;to the knowledge of Parent, no Person is infringing, misappropriating, or diluting in any material respect any Parent Registered IP.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect, (i)&#160;Parent and its Subsidiaries have taken commercially reasonable steps to protect the confidentiality and security of the computer and information technology systems used by Parent and its Subsidiaries (the &#8220;<u>Parent IT Systems</u>&#8221;) and the information and transactions stored or contained therein or transmitted thereby, (ii)&#160;to the knowledge of Parent, during the past two (2) years, there has been no unauthorized or improper use, loss, access, transmittal, modification or corruption of any such information or data, and (iii)&#160;during the past two (2) years, there have been no material failures, crashes, viruses, or security breaches (including any unauthorized access to any personally identifiable information) affecting the Parent IT Systems.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect, (i)&#160;to the knowledge of Parent, Parent and its Subsidiaries have at all times complied in all material respects with all applicable Privacy Laws, (ii)&#160;during the past two (2) years, no claims have been asserted or, to the knowledge of Parent, threatened in writing against Parent alleging a violation of any Person&#8217;s privacy or Personal Information, (iii)&#160;neither this Agreement nor the consummation of the transactions contemplated hereby will breach or otherwise violate any applicable Privacy Laws and (iv)&#160;Parent and its Subsidiaries have taken commercially reasonable steps to protect the Personal Information collected, used or held for use by Parent or its Subsidiaries against loss and unauthorized access, use, modification, disclosure or other misuse.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(h)&#8195;To the knowledge of Parent, no government funding, facilities or resources of a university, college, other educational institution or research center or funding from third parties was used in the development of the Parent Owned IP, to the knowledge of Parent, exclusively licensed to Parent, and no Governmental Entity, university, college, other educational institution or research center has, to the knowledge of Parent, any claim or right in or to such Intellectual Property.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(i)&#8195;The execution, delivery and performance by Parent of this Agreement, and the consummation of the transactions contemplated hereby, will not result in the loss of, or give rise to any right of any third party to terminate or modify any of Parent&#8217;s or any Subsidiaries&#8217; rights or obligations under any agreement under which Parent or any of its Subsidiaries grants to any Person, or any Person grants to Parent or any of its Subsidiaries, a license or right under or with respect to any Intellectual Property that is material to any of the businesses of Parent or any of its Subsidiaries.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS420"><!--Anchor--></a>Section 4.20&#8195;<u>Related Party Transactions</u>. Since January&#160;1, 2021 through the date of this Agreement, there have been no transactions, agreements, arrangements or understandings between Parent or any of its Subsidiaries, on the one hand, and the Affiliates of Parent, on the other hand (other than Parent&#8217;s Subsidiaries), that would be required to be disclosed under Item 404 of Regulation S-K under the Securities Act and that have not been so disclosed in the Parent SEC Documents.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS421"><!--Anchor--></a>Section 4.21&#8195;<u>Certain Payments</u>. Neither Parent nor any of its Subsidiaries (nor, to the knowledge of the Parent, any of their respective directors, executives, representatives, agents or employees) (a) has used or is using any corporate funds for any illegal contributions, gifts, entertainment or other unlawful expenses relating to political activity, (b) has used or is using any corporate funds for any direct or indirect unlawful payments to any foreign or domestic governmental officials or employees, (c) has violated or is violating any provision of the Foreign Corrupt Practices Act of 1977, (d) has established or maintained, or is maintaining, any unlawful fund of corporate monies or other properties or (e) has made any bribe, unlawful rebate, payoff, influence payment, kickback or other unlawful payment of any nature.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS422"><!--Anchor--></a>Section 4.22&#8195;<u>Brokers</u>. No broker, investment banker, financial advisor or other Person, other than Raymond James &amp; Associates, Inc., the fees and expenses of which will be paid by Parent, is entitled to any broker&#8217;s, finder&#8217;s, financial advisor&#8217;s or other similar fee or commission in connection with the transactions contemplated by this </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-33<br></div></div></div>
<!--End Page 490-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 491-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg41"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Agreement based upon arrangements made by or on behalf of Parent. Parent has furnished to Company a true and complete copy of any Contract between the Parent and Raymond James &amp; Associates, Inc. pursuant to which Raymond James &amp; Associates, Inc. could be entitled to any payment from the Parent relating to the transactions contemplated hereby.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS423"><!--Anchor--></a>Section 4.23&#8195;<u>State Takeover Statutes</u>. No Takeover Laws or any similar anti-takeover provision in the Certificate of Incorporation or Bylaws of Parent applicable to Parent is, or at the Effective Time will be, applicable to this Agreement, the Transactions, the Parent Capital Stock Issuance, or any of the other transactions contemplated hereby.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS424"><!--Anchor--></a>Section 4.24&#8195;<u>No Other Representations or Warranties</u>. Except for the representations and warranties contained in <u>Article II</u> and <u>Article III</u>, Parent acknowledges and agrees that none of the Contributors, the Company or any other Person on behalf of the Contributors or the Company makes any other express or implied representation or warranty whatsoever, and specifically (but without limiting the generality of the foregoing) that none of the Contributors, the Company or any other Person on behalf of the Contributors, the Company or any of its Subsidiaries makes any representation or warranty with respect to any projections or forecasts delivered or made available to Parent or any of its Subsidiaries or Representatives of future revenues, results of operations (or any component thereof), cash flows or financial condition (or any component thereof) of the Company (including any such projections or forecasts made available to Parent or any of its Subsidiaries or Representatives in certain &#8220;data rooms&#8221; or management presentations in expectation of the transactions contemplated by this Agreement), and Parent has not relied on any such information or any representation or warranty not set forth in <u>Article III</u>.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; text-align: center;"><a name="tANXAA5"><!--Anchor--></a>ARTICLE V<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">REPRESENTATIONS AND WARRANTIES OF THE MINORITY HOLDERS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Each Minority Holder represents and warrants to Parent, each on behalf of itself only and not on behalf of another Minority Holder, as follows:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS51"><!--Anchor--></a>Section 5.1&#8195;<u>Authority</u>. Minority Holder has all necessary power and authority to execute, deliver and perform its obligations under this Agreement and to consummate the transactions contemplated hereby. The execution, delivery and performance of this Agreement by Minority Holder and the consummation by Minority Holder of the transactions contemplated hereby have been duly authorized by all necessary action on the part of Minority Holder and no other proceedings on the part of Minority Holder are necessary to approve this Agreement or to consummate the transactions contemplated hereby. This Agreement has been duly executed and delivered by Minority Holder and, assuming the due authorization, execution and delivery by the other parties hereto, constitutes a valid and binding obligation of Minority Holder, enforceable against Minority Holder in accordance with its terms (except to the extent that enforceability may be limited by applicable bankruptcy, insolvency, moratorium, reorganization or similar Laws affecting the enforcement of creditors&#8217; rights generally or by general principles of equity).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS52"><!--Anchor--></a>Section 5.2&#8195;<u>No Conflict; Consents and Approvals.</u></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The execution, delivery and performance of this Agreement by Minority Holder does not, and the consummation of the transactions contemplated hereby and compliance by Minority Holder with the provisions hereof will not, conflict with, or result in any violation or breach of, any provision of, or:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(i)&#8195;conflict with or violate the organizational documents of the Minority Holder (if and as applicable) or his or her Entity;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(ii)&#8195;conflict with or violate any federal, state, local or foreign Law, injunction, decree or order of any Governmental Entity applicable to Minority Holder or his or her respective Entity or by which any property or asset of Minority Holder or his or her respective Entity is bound or affected, or</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iii)&#8195;conflict with, result in any breach of, constitute a default (or an event that, with notice or lapse of time or both, would become a default) under, create in any party the right to accelerate, terminate, modify or cancel, or require any consent of any Person pursuant to, any material contract or material agreement to which his or her respective Entity is a party.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;No consent, approval, order or authorization of, or registration, declaration, filing with or notice to, any Governmental Entity is required by or with respect to Minority Holder in connection with the execution, delivery and performance of this Agreement by Minority Holder or the consummation by the respective Entity of the transactions contemplated hereby or compliance with the provisions hereof, except for (i)&#160;the filing with </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-34<br></div></div></div>
<!--End Page 491-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 492-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg42"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">the SEC of such reports under Section 13(a) or 15(d) of the Exchange Act as may be required in connection with this Agreement and the transactions contemplated hereby, (ii)&#160;such other filings and reports as may be required pursuant to the applicable requirements of the Securities Act, the Exchange Act and any other applicable state or federal securities, takeover and &#8220;blue sky&#8221; laws and (iii)&#160;such other consents, approvals, orders, authorizations, registrations, declarations, filings or notices the failure of which to be obtained or made would not be material to Minority Holder.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS53"><!--Anchor--></a>Section 5.3&#8195;<u>Shares</u>. Minority Holder is the recorded and beneficial owner of the Entity Shares, free and clear of any encumbrance (other than restrictions on transfer that may arise under applicable securities Laws). Minority Holder has the right, authority and power to assign and transfer his or her Entity Shares to Parent.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS54"><!--Anchor--></a>Section 5.4&#8195;<u>Accredited Investor Status</u>. Prior to the date of this Agreement, Minority Holder is an &#8220;accredited investor&#8221; within the meaning of Regulation D, Rule 501(a), promulgated by the SEC under the Securities Act or is not a &#8220;U.S. person&#8221; within the meaning of Regulation S, Rule 902, promulgated by the SEC under the Securities Act.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS55"><!--Anchor--></a>Section 5.5&#8195;<u>Entity Representations and Warranties</u>. Each Minority Holder represents and warrants to Parent on behalf of his or her respective Entity and not on behalf of any other Entity as follows:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;<u>Organization, Standing and Power</u>. Such Entity is an entity duly organized, incorporated, validly existing and in good standing under the Laws of the jurisdiction of its incorporation. Such Entity is not in violation of any provision of its organizational documents. The Minority Holder has previously made available to Parent true and complete copies of such Entity&#8217;s organizational documents, in each case as amended to the date of this Agreement, and each as so delivered is in full force and effect.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;<u>Capital Stock</u>. The maximum number of shares such Entity is authorized to issue and the shares issued and outstanding for such Entity is set forth on <u>Annex&#160;A</u> hereto. All outstanding Entity Shares are duly authorized, validly issued, fully paid and nonassessable and not subject to any preemptive rights. Such Entity does not have outstanding any bonds, debentures, notes or other obligations having the right to vote (or convertible into, or exchangeable or exercisable for, interests having the right to vote) with the shareholders of such Entity on any matter. Except as set forth above on <u>Annex&#160;A</u> hereto, there are no outstanding (A) shares or other voting or equity interests of such Entity, (B) securities of such Entity convertible into or exchangeable or exercisable for shares of such Entity or other voting or equity interests of such Entity, (C) profits or revenue-based interests or rights, including beneficial, appreciation, phantom or tracking interests in or rights to the ownership or earnings of such Entity or other equity equivalent or equity-based awards or rights, (D) subscriptions, options, warrants, calls, commitments, Contracts or other rights to acquire from such Entity, or obligations of such Entity to issue, any shares of such Entity, voting interests, equity interests or securities convertible into or exchangeable or exercisable for shares or other voting interests or equity interests of such Entity or rights or interests described in the preceding clause (C), or (E) obligations of such Entity to repurchase, redeem or otherwise acquire any such interests or to issue, grant, deliver or sell, or cause to be issued, granted, delivered or sold, any such interests. There are no shareholder agreements, voting trusts or other agreements or understandings to which such Entity is a party or of which such Entity has knowledge with respect to the holding, voting, registration, redemption, repurchase or disposition of, or that restrict the transfer of, any shares or other voting interests or equity interests of such Entity. Such Entity does not have any option plan or any other plan, program, agreement or arrangement providing for an equity-based compensation for any Person.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;<u>Subsidiaries</u>. Except for the capital stock of, or other equity or voting interests in, the Operating Company, such Entity does not own, directly or indirectly, any equity, membership interest, partnership interest, joint venture interest, or other equity or voting interest in, or any interest convertible into, exercisable or exchangeable for any of the foregoing, nor is it under any current or prospective obligation to form or participate in, provide funds to, make any loan, capital contribution, guarantee, credit enhancement or other investment in, or assume any liability or obligation of, any Person.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;<u>Taxes</u>. None of the Company, its Subsidiaries or the Entities will recognize any income or other Tax liability for non-U.S. tax purposes with respect to the Transactions.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS56"><!--Anchor--></a>Section 5.6&#8195;<u>No Other Representations or Warranties</u>. Except for the representations and warranties contained in <u>Article IV</u>, Minority Holder acknowledges and agrees that none of Parent or any other Person on behalf of Parent makes any other express or implied representation or warranty whatsoever, and specifically (but without limiting the generality of the foregoing) that none of Parent, its Subsidiaries or any other Person on behalf of Parent makes any </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-35<br></div></div></div>
<!--End Page 492-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 493-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg43"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">representation or warranty with respect to any projections or forecasts delivered or made available to Minority Holder or any of its Representatives of future revenues, results of operations (or any component thereof), cash flows or financial condition (or any component thereof) of Parent (including any such projections or forecasts made available to Minority Holder and Representatives in certain &#8220;data rooms&#8221; or management presentations in expectation of the transactions contemplated by this Agreement), and Minority Holder has not relied on any such information or any representation or warranty not set forth in <u>Article IV</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS57"><!--Anchor--></a>Section 5.7&#8195;<u>Exclusivity of Representations and Warranties</u>. Neither Minority Holder nor any of its Affiliates or Representatives is making any representation or warranty on behalf of Minority Holder or his or her respective Entity of any kind or nature whatsoever, oral or written, express or implied, except as expressly set forth in this <u>Article V</u>, and Minority Holder hereby disclaims any such other representations or warranties.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; text-align: center;"><a name="tANXAA6"><!--Anchor--></a>ARTICLE VI<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">COVENANTS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS61"><!--Anchor--></a>Section 6.1&#8195;<u>Conduct of Business</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;During the period from the date of this Agreement to the Effective Time, except as may be required by applicable Law, Parent shall, and shall cause each of its Subsidiaries to, carry on its business in the ordinary course of business in all material respects consistent with past practice and use reasonable best efforts to preserve intact its business organization, preserve its assets, rights and properties in good repair and condition, keep available the services of its current officers, employees and consultants and preserve its goodwill and its relationships with customers, suppliers, licensors, licensees, distributors and others having business dealings with it and, except (x)&#160;as set forth in <u>Section 6.1(a)</u> of the Parent Disclosure Letter, (y) as consented to in writing in advance by the Contributors, or (z) as otherwise specifically required by this Agreement, Parent shall not, and shall not permit any of its Subsidiaries to, take any action that would reasonably be expected to materially impede or delay the consummation of the Transactions and the other transactions contemplated hereby. In clarification of the foregoing, without the consent in writing in advance by the Contributors (such consent not to unreasonably withheld, delayed, or conditioned), Parent shall not, and shall not permit each of its Subsidiaries to:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(i)&#8195;(A) declare, set aside or pay any dividends on, or make any other distributions (whether in cash, stock or property) in respect of, any of its capital stock or other equity interests, except for dividends by a wholly-owned Subsidiary of Parent to its parent, (B) purchase, redeem or otherwise acquire shares of capital stock or other equity interests of Parent or its Subsidiaries or any options, warrants, or rights to acquire any such shares or other equity interests or (C) split, combine, reclassify or otherwise amend the terms of any of its capital stock or other equity interests or issue or authorize the issuance of any other securities in respect of, in lieu of or in substitution for shares of its capital stock or other equity interests;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(ii)&#8195;issue, deliver, sell, grant, pledge or otherwise encumber or subject to any Lien any shares of its capital stock, or grant any Person any right to acquire any shares of its capital stock;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iii)&#8195;amend or otherwise change, or authorize or propose to amend or otherwise change, its certificate of incorporation or bylaws (or similar organizational documents);</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iv)&#8195;acquire (A) by merging or consolidating with, purchasing an equity interest in or a portion of the assets of, making an investment in or loan or capital contribution to or in any other manner, any corporation, partnership, association or other business organization or division thereof, or (B) any assets;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(v)&#8195;sell, lease, license, sell and leaseback, abandon, mortgage or otherwise encumber or subject to any Lien or otherwise dispose in whole or in part of any of its material properties, assets or rights or any interest therein;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(vi)&#8195;adopt or enter into a plan of complete or partial liquidation, dissolution, restructuring, recapitalization or other reorganization;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(vii)&#8195;(A) incur, create, assume or otherwise become liable for, or repay or prepay, any Indebtedness, or amend, modify or refinance any Indebtedness or (B) make any loans, advances or capital contributions to, or investments in, any other Person;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(viii)&#8195;incur or commit to incur any material new capital expenditure or authorization or commitment with respect thereto;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-36<br></div></div></div>
<!--End Page 493-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 494-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg44"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(ix)&#8195;enter into, materially amend or terminate any Material Contract;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(x)&#8195;commence any Action (other than an Action as a result of an Action commenced against Parent or any of its Subsidiaries), or compromise, settle or agree to settle any Action (including any Action relating to this Agreement or the transactions contemplated hereby);</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(xi)&#8195;implement or adopt any change to its financial or tax accounting methods, principles or practices, except insofar as may have been required by a change in GAAP or applicable Law;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(xii)&#8195;settle or compromise any liability for Taxes; file any amended Tax Return or claim for Tax refund; make (outside of the ordinary course of business and other than on a basis consistent with past practice), revoke or modify any Tax election; file any Tax Return other than on a basis consistent with past practice, unless required by applicable Law; consent to any extension or waiver of the limitation period applicable to any claim or assessment in respect of Taxes (other than an extension for the filing of a Tax Return in the ordinary course of business); grant any power of attorney with respect to Taxes; enter into any Tax allocation agreement, Tax sharing agreement, Tax indemnity agreement, Tax holiday or any closing or other similar agreement; or change any method of accounting for Tax purposes;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(xiii)&#8195;except to the extent required by applicable Law (including Section 409(A) of the Code), any arrangement in effect as of the date hereof, or as consistent with past practice, (A) increase the compensation or benefits of any director or executive officer of Parent, (B) amend or adopt any compensation or benefit plan including any pension, retirement, profit-sharing, bonus or other employee benefit or welfare benefit plan (other than any such adoption or amendment that does not increase the cost to Parent or any of its Subsidiaries of maintaining the applicable compensation or benefit plan) with or for the benefit or its employees or directors or (C) accelerate the vesting of, or the lapsing of restrictions with respect to, any stock options or other stock-based compensation;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(xiv)&#8195;hire employees;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(xv)&#8195;terminate any employees of Parent or its Subsidiaries or otherwise cause any employees of Parent or its Subsidiaries to resign, in each case other than for cause or poor performance (documented in accordance with Parent&#8217;s past practices);</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(xvi)&#8195;pay, discharge or satisfy any claim or liability, other than the payment, discharge or satisfaction, in the ordinary course of business, of liabilities reflected or reserved against on the Parent Balance Sheet or subsequently incurred in the ordinary course of business;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(xvii)&#8195;accelerate the collection of or discount any accounts receivable, delay the payment of accounts payable or defer expenses, reduce inventories or otherwise increase cash on hand;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(xviii)&#8195;fail to keep in force insurance policies or replacement or revised provisions regarding insurance coverage with respect to the assets, operations and activities of Parent and its Subsidiaries as currently in effect;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(xix)&#8195;permit the lapse of any right relating to Intellectual Property or any other intangible asset used in the business of Parent or any of its Subsidiaries;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(xx)&#8195;renew or enter into any non-compete, exclusivity, non-solicitation or similar agreement that would restrict or limit the operations of Parent or any of its Subsidiaries;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(xxi)&#8195;enter into any new line of business outside of its existing business;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(xxii)&#8195;enter into any new lease or amend the terms of any existing lease of real property;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(xxiii)&#8195;take any action (or omit to take any action) if such action (or omission) could reasonably be expected to result in any of the conditions to the Transactions set forth in <u>Article VII</u> not being satisfied; or</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(xxiv)&#8195;authorize any of, or commit, resolve or agree to take any of, the foregoing actions.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;During the period from the date of this Agreement to the Effective Time, except as may be required by applicable Law, each Contributors shall, and shall cause each of its respective Subsidiaries (which, for the avoidance of the doubt, includes the Company and the Operating Company) to, carry on its business in the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-37<br></div></div></div>
<!--End Page 494-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 495-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg45"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">ordinary course of business in all material respects consistent with past practice and use reasonable best efforts to preserve intact its business organization, preserve its assets, rights and properties in good repair and condition, keep available the services of its current officers, employees and consultants and preserve its goodwill and its relationships with customers, suppliers, licensors, licensees, distributors and others having business dealings with it and, except (w) as set forth in <u>Section 6.1(b)</u> of the Company Disclosure Letter, (x)&#160;as consented to in writing in advance by the Parent, (y) as would not reasonably be expected to result in any of the conditions to the Transactions set forth in <u>Article VII</u> not being satisfied, or (z) as otherwise specifically required by this Agreement, the Contributors shall not, and shall not permit any of their Subsidiaries to, take any action that would reasonably be expected to materially impede or delay the consummation of the Transactions and the other transactions contemplated hereby. In clarification of the foregoing, without the consent in writing in advance by the Parent (such consent not to unreasonably withheld, delayed, or conditioned), each Contributor and Minority Holder shall not, and shall not permit each of its Subsidiaries to engage in any of the following actions to the extent such action could reasonably be expected to result in any of the conditions to the Transactions set forth&#160;in <u>Article VII</u> not being satisfied:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(i)&#8195;(A) declare, set aside or pay any dividends on, or make any other distributions (whether in cash, stock or property) in respect of, any of its capital stock or other equity interests, except for dividends by a wholly-owned Subsidiary of the Contributor to its holders, (B) purchase, redeem or otherwise acquire shares of capital stock or other equity interests of its Subsidiaries or any options, warrants, or rights to acquire any such shares or other equity interests, or (C) split, combine, reclassify or otherwise amend the terms of any of its capital stock or other equity interests or issue or authorize the issuance of any other securities in respect of, in lieu of or in substitution for shares of its capital stock or other equity interests, except in each case as contemplated by <u>Section 6.17</u>;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(ii)&#8195;issue, deliver, sell, grant, pledge or otherwise encumber or subject to any Lien any shares of its capital stock, or grant any Person any right to acquire any shares of its capital stock;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iii)&#8195;amend or otherwise change, or authorize or propose to amend or otherwise change, its certificate of incorporation or bylaws (or similar organizational documents);</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iv)&#8195;acquire (A) by merging or consolidating with, purchasing an equity interest in or a portion of the assets of, making an investment in or loan or capital contribution to or in any other manner, any corporation, partnership, association or other business organization or division thereof, or (B) any assets, except in each case as contemplated by <u>Section 6.17</u>;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(v)&#8195;sell, lease, license, sell and leaseback, abandon, mortgage or otherwise encumber or subject to any Lien or otherwise dispose in whole or in part of any of its material properties, assets or rights or any interest therein;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(vi)&#8195;adopt or enter into a plan of complete or partial liquidation, dissolution, restructuring, recapitalization or other reorganization;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(vii)&#8195;enter into any new line of business outside of its existing business; or</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(viii)&#8195;authorize any of, or commit, resolve or agree to take any of, the foregoing actions.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS62"><!--Anchor--></a>Section 6.2&#8195;<u>No Solicitation; Recommendation of the Transactions</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Parent shall not, and shall not permit or authorize any of its Subsidiaries or any director, officer, employee, investment banker, financial advisor, attorney, accountant or other advisor, agent or representative (collectively, &#8220;<u>Representatives</u>&#8221;) of Parent or any of its Subsidiaries, directly or indirectly, to (i)&#160;solicit, initiate, endorse, encourage or facilitate any inquiry, proposal or offer with respect to, or the making or completion of, any Acquisition Proposal, or any inquiry, proposal or offer that is reasonably likely to lead to any Acquisition Proposal, (ii)&#160;enter into, continue or otherwise participate in any discussions or negotiations regarding, or furnish to any Person any information or data with respect to, or otherwise cooperate in any way with, any Acquisition Proposal or (iii)&#160;resolve, agree or propose to do any of the foregoing. Notwithstanding the foregoing, (i)&#160;nothing in this <u>Section 6.2</u> shall preclude the Parent, its Subsidiaries, and their respective Representatives from actively taking any and all actions in the preceding sentence (or otherwise prohibited under this <u>Section 6.2</u>) with respect to the sale or license of the Parent&#8217;s legacy assets, technology, and Intellectual Property (including the Parent&#8217;s bleeding disorder product candidates) in existence as of the date of this Agreement (such permitted transaction, </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-38<br></div></div></div>
<!--End Page 495-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 496-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg46"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">a &#8220;<u>Parent Legacy Proposal</u>&#8221;), and (ii)&#160;each Contributor acknowledges and agrees that (A) a Parent Legacy Proposal shall not be deemed to be an Acquisition Proposal, and (B) any and all actions taken by the Parent, its Subsidiaries, and their respective Representatives with respect to a Parent Legacy Proposal shall not be deemed to be a breach of this <u>Section 6.2</u> or any other provisions of this Agreement, and therefore, the Contributors shall not be entitled to terminate this Agreement or to payment of the Termination Fee as a result of any such actions taken.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Parent shall, and shall cause each of its Subsidiaries and the Representatives of Parent and its Subsidiaries to, (A) immediately cease and cause to be terminated all existing discussions and negotiations with any Person conducted heretofore with respect to any Acquisition Proposal or potential Acquisition Proposal and immediately terminate all physical and electronic data room access previously granted to any such Person, (B)&#160;request the prompt return or destruction of all confidential information previously furnished with respect to any Acquisition Proposal or potential Acquisition Proposal, and (C) not terminate, waive, amend, release or modify any provision of any confidentiality or standstill agreement to which it or any of its Affiliates or Representatives is a party with respect to any Acquisition Proposal or potential Acquisition Proposal, and shall enforce the provisions of any such agreement, which shall include seeking any injunctive relief available to enforce such agreement (<u>provided</u>, that Parent shall be permitted to grant waivers of, and not enforce, any standstill agreement, but solely to the extent that the Parent Board has determined in good faith, after consultation with its outside counsel, that failure to take such action (I) would prohibit the counterparty from making an unsolicited Acquisition Proposal to the Parent Board in compliance with this <u>Section 6.2</u> and (II)&#160;would constitute a breach of its fiduciary duties to the stockholders of Parent under applicable Law).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;Notwithstanding the foregoing, if at any time following the date of this Agreement and prior to obtaining the Parent Stockholder Approval, (1) Parent receives a written Acquisition Proposal that the Parent Board believes in good faith to be bona fide, (2) such Acquisition Proposal was unsolicited and did not otherwise result from a breach of this <u>Section 6.2</u>, (3) the Parent Board determines in good faith (after consultation with outside counsel and its financial advisor) that such Acquisition Proposal constitutes or is reasonably likely to lead to a Superior Proposal, and (4) the Parent Board determines in good faith (after consultation with outside counsel) that the failure to take the actions referred to in clause (x)&#160;or (y) below would constitute a breach of its fiduciary duties to the stockholders of Parent under applicable Law, then Parent may (x)&#160;furnish information with respect to Parent and its Subsidiaries to the Person making such Acquisition Proposal pursuant to a customary confidentiality agreement containing terms substantially similar to, and no less favorable to Parent than, those set forth in the Confidentiality Agreements (including any standstill agreement contained therein) (an &#8220;<u>Acceptable Confidentiality Agreement</u>&#8221;); <u>provided</u>, that (I) Parent shall provide the Contributors a non-redacted copy of each confidentiality agreement Parent has executed in accordance with this <u>Section 6.2</u> and (II)&#160;that any non-public information provided to any such Person shall have been previously provided to the Contributors or shall be provided to the Contributors prior to or concurrently with the time it is provided to such Person, and (y) participate in discussions or negotiations with the Person making such Acquisition Proposal regarding such Acquisition Proposal.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(d)&#8195;Neither the Parent Board nor any committee thereof shall:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(i)&#8195;(A) withdraw (or modify or qualify in any manner adverse to the Contributors) the recommendation or declaration of advisability by the Parent Board or any such committee of this Agreement, the Transactions, the Parent Stockholder Matters or any of the other transactions contemplated hereby, (B) recommend or otherwise declare advisable the approval by the Parent stockholders of any Acquisition Proposal, or (C) resolve, agree or propose to take any such actions (each such action set forth in this <u>Section 6.2(d)(i)</u> being referred to herein as an &#8220;<u>Adverse Recommendation Change</u>&#8221;); or</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(ii)&#8195;cause or permit Parent or any of its Subsidiaries to enter into any letter of intent, memorandum of understanding, agreement in principle, acquisition agreement, merger agreement, option agreement, joint venture agreement, partnership agreement or other Contract, except for an Acceptable Confidentiality Agreement, in each case constituting or related to, or which is intended to or is reasonably likely to lead to, any Acquisition Proposal, or resolve, agree or propose to take any such actions.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;Notwithstanding the foregoing, at any time prior to obtaining the Parent Stockholder Approval, the Parent Board may, if the Parent Board determines in good faith (after consultation with outside counsel) that the failure to do so would result in a breach of its fiduciary duties to the stockholders of Parent under applicable </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-39<br></div></div></div>
<!--End Page 496-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 497-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg47"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">Law, taking into account all adjustments to the terms of this Agreement that may be offered by Contributors pursuant to this <u>Section 6.2</u>, (x)&#160;make an Adverse Recommendation Change in response to either (I) a Superior Proposal or (II) an Intervening Event, or (y) solely in response to a Superior Proposal received after the date hereof that was unsolicited and did not otherwise result from a breach of this <u>Section 6.2</u>, cause Parent to terminate this Agreement in accordance with <u>Section 8.1(c)(ii)</u> and concurrently enter into a binding Alternative Acquisition Agreement with respect to such Superior Proposal; provided, however, that Parent may not make an Adverse Recommendation Change in response to a Superior Proposal or terminate this Agreement pursuant to <u>Section 8.1(d)(ii)</u> unless: (A) Parent notifies the Contributors in writing at least five Business Days before taking that action of its intention to do so, and specifies the reasons therefor, including the terms and conditions of, and the identity of the Person making, such Superior Proposal, and contemporaneously furnishes a copy (if any) of the proposed Alternative Acquisition Agreement and any other relevant transaction documents (it being understood and agreed that any amendment to the financial terms or any other material term of such Superior Proposal shall require a new written notice by agreed that any amendment to the financial terms or any other material term of such Superior Proposal shall require a new written notice by Parent and a new five Business Day period); and (B) if the Contributors make a proposal during such five Business Day period to adjust the terms and conditions of this Agreement, the Parent Board, after taking into consideration the adjusted terms and conditions of this Agreement as proposed by the Contributors, continues to determine in good faith (after consultation with outside counsel and its financial advisor) that such Superior Proposal continues to be a Superior Proposal and that the failure to make an Adverse Recommendation Change or terminate this Agreement, as applicable, would result in a breach of its fiduciary duties to the stockholders of Parent under applicable Law; provided further, that the Parent Board may not make an Adverse Recommendation Change in response to an Intervening Event unless:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 60pt; text-indent: 20pt; text-align: justify;">(1)&#8195;Parent provides the Contributors with written information describing such Intervening Event in reasonable detail as soon as reasonably practicable after becoming aware of it;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 60pt; text-indent: 20pt; text-align: justify;">(2)&#8195;Parent keeps the Contributors reasonably informed of developments with respect to such Intervening Event;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 60pt; text-indent: 20pt; text-align: justify;">(3)&#8195;Parent notifies the Contributors in writing at least five Business Days before making an Adverse Recommendation Change with respect to such Intervening Event of its intention to do so and specifies the reasons therefor; and</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 60pt; text-indent: 20pt; text-align: justify;">(4)&#8195;if the Contributors make a proposal during such five Business Day period to adjust the terms and conditions of this Agreement, the Parent Board, after taking into consideration the adjusted terms and conditions of this Agreement as proposed by the Contributors, continues to determine in good faith (after consultation with outside counsel) that the failure to make such Adverse Recommendation Change would result in a breach of its fiduciary obligations to the stockholders of Parent under applicable Law.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">During the five Business Day period prior to its effecting an Adverse Recommendation Change or terminating this Agreement as referred to above, Parent shall, and shall cause its financial and legal advisors to, negotiate with the Contributors in good faith (to the extent the Company seeks to negotiate) regarding any revisions to the terms of the transactions contemplated by this Agreement proposed by the Contributors. Notwithstanding anything to the contrary contained herein, neither Parent nor any of its Subsidiaries shall enter into any Alternative Acquisition Agreement unless this Agreement has been terminated in accordance with its terms (including the payment of the Termination Fee pursuant to <u>Section&#160;8.3(b)</u>, if applicable).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;In addition to the obligations of Parent set forth in <u>Section 6.2(a)</u>, <u>Section 6.2(b)</u>, <u>Section 6.2(c)</u> and <u>Section 6.2(d)</u>, Parent promptly (and in any event within 24 hours of receipt) shall advise the Contributors in writing in the event Parent or any of its Subsidiaries or Representatives receives (i)&#160;any indication by any Person that it is considering making an Acquisition Proposal, (ii)&#160;any inquiry or request for information, discussion or negotiation that is reasonably likely to lead to or that contemplates an Acquisition Proposal, or (iii)&#160;any proposal or offer that is or is reasonably likely to lead to an Acquisition Proposal, in each case together with a description of the material terms and conditions of and facts surrounding any such indication, inquiry, request, proposal or offer, the identity of the Person making any such indication, inquiry, request, proposal or offer, and a copy of any written proposal, offer or draft agreement provided by such Person. Parent shall keep the Contributors </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-40<br></div></div></div>
<!--End Page 497-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 498-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg48"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">informed (orally and in writing) in all material respects on a timely basis of the status and details (including, within 24 hours after the occurrence of any amendment, modification, development, discussion or negotiation) of any such Acquisition Proposal, request, inquiry, proposal or offer, including furnishing copies of any written inquiries, correspondence and draft documentation, and written summaries of any material oral inquiries or discussions. Without limiting any of the foregoing, Parent shall promptly (and in any event within 24 hours) notify the Contributors orally and in writing if it determines to begin providing information or to engage in discussions or negotiations concerning an Acquisition Proposal pursuant to this <u>Section 6.2</u> and shall in no event begin providing such information or engaging in such discussions or negotiations prior to providing such notice. Parent shall provide the Contributors with at least 24 hours prior notice (or such shorter notice as may be provided to the Parent Board) of a meeting of the Parent Board at which the Parent Board is reasonably expected to consider an Acquisition Proposal.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;Parent shall not, and shall cause its Subsidiaries not to, enter into any confidentiality agreement with any Person subsequent to the date of this Agreement that would restrict Parent&#8217;s ability to comply with any of the terms of this <u>Section 6.2</u>, and represents that neither it nor any of its Subsidiaries is a party to any such agreement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(h)&#8195;Parent shall not take any action to exempt any Person (other than the Contributors and its respective Affiliates) from the restrictions on &#8220;business combinations&#8221; contained in Section 203 of the DGCL (or any similar provision of any other Takeover Law) or otherwise cause such restrictions not to apply, or agree to do any of the foregoing, in each case unless such actions are taken substantially concurrently with a termination of this Agreement pursuant to <u>Section 8.1(d)</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(i)&#8195;Nothing contained in this <u>Section 6.2</u> shall prohibit Parent from taking and disclosing a position contemplated by Rule 14e-2(a), Rule 14d-9 or Item 1012(a) of Regulation M-A promulgated under the Exchange Act; <u>provided</u>, <u>however</u>, that any such disclosure (other than a &#8220;stop, look and listen&#8221; communication or similar communication of the type contemplated by Section 14d-9(f) under the Exchange Act) shall be deemed to be an Adverse Recommendation Change (including for purposes of <u>Section 8.1(d)</u>) unless the Parent Board expressly reaffirms its recommendation to Parent&#8217;s stockholders in favor of the approval of this Agreement and the Transactions in such disclosure and expressly rejects any applicable Acquisition Proposal.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(j)&#8195;For purposes of this Agreement:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(i)&#8195;&#8220;<u>Acquisition Proposal</u>&#8221; means any proposal or offer with respect to any direct or indirect acquisition or purchase or license, in one transaction or a series of transactions, and whether through any merger, reorganization, consolidation, tender offer, self-tender, exchange offer, stock acquisition, asset acquisition, binding share exchange, business combination, recapitalization, liquidation, dissolution, joint venture, licensing or similar transaction, or otherwise, of (A) assets or businesses of Parent and its Subsidiaries that generate 15% or more of the net revenues or net income (for the 12-month period ending on the last day of Parent&#8217;s most recently completed fiscal quarter) or that represent 15% or more of the total assets (based on fair market value) of Parent and its Subsidiaries, taken as a whole, immediately prior to such transaction, or (B) 10% or more of any class of capital stock, other equity securities or voting power of Parent, any of its Subsidiaries or any resulting parent company of Parent, in each case other than the Transactions and other transactions contemplated by this Agreement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(ii)&#8195;&#8220;<u>Superior Proposal</u>&#8221; means any unsolicited bona fide binding written Acquisition Proposal that is fully financed or has fully committed financing that the Parent Board determines in good faith (after consultation with outside counsel and its financial advisor), taking into account all legal, financial, regulatory and other aspects of the proposal and the Person making the proposal, is (A) more favorable to the stockholders of Parent from a financial point of view than the Transactions and the other transactions contemplated by this Agreement (including any adjustment to the terms and conditions proposed by the Contributors in response to such proposal) and (B) reasonably likely of being completed on the terms proposed on a timely basis; <u>provided</u>, that, for purposes of this definition of &#8220;Superior Proposal,&#8221; references in the term &#8220;Acquisition Proposal&#8221; to &#8220;15%&#8221; shall be deemed to be references to &#8220;50%&#8221;.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iii)&#8195;&#8220;<u>Intervening Event</u>&#8221; means a material event or circumstance that was not known or reasonably foreseeable to the Parent Board prior to the execution of this Agreement (or if known, the consequences of which were not known or reasonably foreseeable), which event or circumstance, or any material consequence thereof, becomes known to the Parent Board prior to the receipt of the Parent Stockholder </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-41<br></div></div></div>
<!--End Page 498-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 499-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg49"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">Approval that does not relate to (A) an Acquisition Proposal, (B) the Company or its Subsidiaries (including any Company Material Adverse Effect), (C) any actions taken pursuant to this Agreement or (D)&#160;any changes in the price of Parent Common Stock.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS63"><!--Anchor--></a>Section 6.3&#8195;<u>Preparation of Form S-4 and Proxy Statement; Stockholders&#8217; Meeting</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;As promptly as practicable after the date of this Agreement, Parent shall file with the SEC a proxy statement (as amended or supplemented from time to time, the &#8220;<u>Proxy Statement</u>&#8221;) to be sent to the stockholders of Parent relating to the special meeting of Parent&#8217;s stockholders (the &#8220;<u>Parent Stockholders Meeting</u>&#8221;) to be held to consider the Parent Stockholder Matters; <u>provided</u>, that is it understood and agreed that the Contributors shall prepare the initial draft of the Proxy Statement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Parent covenants and agrees that the Proxy Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith) will (i)&#160;comply as to form in all material respects with the requirements of applicable U.S. federal securities laws and the DGCL, and (ii)&#160;with regard to the information provided in the Proxy Statement by Parent, will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;As promptly as practicable following the date of this Agreement, Parent shall file with the SEC a registration statement on Form S-4 (as amended or supplemented from time to time, the &#8220;<u>Form S-4</u>&#8221;), in which the Proxy Statement will be part of the prospectus, in connection with the registration under the Securities Act of the Parent Common Stock to be issued in the Transactions; <u>provided</u>, that is it understood and agreed that the Contributors shall prepare the initial draft of the Form S-4. The Contributors covenant and agree that all information concerning the Contributors, the Company and Further Challenger furnished by the Contributors, and the Minority Holders covenant and agree, individually and not with respect to each other, that all information concerning the Minority Holders and the Entities, and included in the Proxy Statement and Form&#160;S-4 will (i)&#160;comply as to form in all material respects with the requirements of applicable U.S. federal securities laws and the DGCL, and (ii)&#160;will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. Parent shall use its reasonable best efforts to have the Form S-4 declared effective by the SEC under the Securities Act as promptly as practicable after such filing and to keep the Form S-4 effective as long as is necessary to consummate the Transactions and the other transactions contemplated hereby. Parent shall also take any action (other than qualifying to do business in any jurisdiction in which it is not now so qualified or filing a general consent to service of process) required to be taken under any applicable state securities or &#8220;blue sky&#8221; laws in connection with the issuance of shares of Parent Common Stock in the Transactions and the Contributors shall furnish all information concerning Contributors as may be reasonably requested in connection with any such action. Parent shall use its reasonable best efforts to respond promptly to any comments or requests of the SEC or its staff relating to the Proxy Statement and the Form S-4; provided, that any comments or request of the SEC or its staff which relate to disclosures contained in the Form S-4 or Proxy Statement and which were provided by the Minority Holders or the Contributors will be promptly addressed by the Contributors.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;Parent shall cause the Proxy Statement to be mailed to Parent&#8217;s stockholders as promptly as practicable after the Form S-4 is declared effective by the SEC under the Securities Act. No filing of, or amendment or supplement to, the Form S-4 or the Proxy Statement will be made by Parent, without providing the Contributors a reasonable opportunity to review and comment thereon and without the Contributors&#8217; prior approval (which shall not be unreasonably withheld, conditioned, or delayed). Parent will advise the Contributors promptly after it receives oral or written notice thereof of the time when the Form S-4 has become effective or any amendment or supplement thereto has been filed, the issuance of any stop order, the suspension of the qualification of the Parent Common Stock issuable in connection with the Transactions for offering or sale in any jurisdiction or any oral or written request by the SEC for amendment of the Proxy Statement or the Form&#160;S-4 or comments thereon and responses thereto or requests by the SEC for additional information, and will promptly provide the other with copies of any written communication from the SEC or any state securities commission and a reasonable opportunity to participate in the responses thereto. If at any time prior to the Effective Time any information relating to the Contributors, the Minority Holders or Parent, or any of their respective Affiliates, officers or directors, should be discovered by the Company or Parent that should be set forth in an amendment or supplement to any of the Form S-4 or the Proxy Statement, so that any of such </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-42<br></div></div></div>
<!--End Page 499-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 500-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg50"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">documents would not contain any misstatement of a material fact or omit to state any material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, the party that discovers such information shall promptly notify the other parties hereto and an appropriate amendment or supplement describing such information shall promptly be filed with the SEC and, to the extent required under applicable Law, disseminated to stockholders of Parent; <u>provided</u>, that the delivery of such notice and the filing of any such amendment or supplement shall not affect or be deemed to modify any representation or warranty made by any party hereunder or otherwise affect the remedies available hereunder to any party.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;As promptly as practicable after the Form S-4 is declared effective under the Securities Act, Parent shall duly call, give notice of, convene and hold the Parent Stockholders Meeting to consider and vote to approve the Parent Stockholder Matters pursuant to the terms of this Agreement (and such Parent Stockholders Meeting shall in any event be no later than 45 calendar days after the Form S-4 is declared effective). Parent may postpone or adjourn the Parent Stockholders Meeting solely (i)&#160;with the consent of the Contributors; (ii) (A) due to the absence of a quorum or (B) if Parent has not received proxies representing a sufficient number of shares for the Parent Stockholder Approval, whether or not a quorum is present, to solicit additional proxies; or (iii)&#160;to allow reasonable additional time for the filing and mailing of any supplemental or amended disclosure which the Parent Board has determined in good faith after consultation with outside legal counsel is necessary under applicable Law and for such supplemental or amended disclosure to be disseminated and reviewed by Parent&#8217;s stockholders prior to the Parent Stockholders Meeting; <u>provided</u>, that the Parent may not postpone or adjourn the Parent Stockholders Meeting more than a total of two times pursuant to clause (ii)(A) and/or clause (ii)(B)&#160;of this Section. Notwithstanding the foregoing, Parent shall, at the request of Contributors, to the extent permitted by Law, adjourn the Parent Stockholders Meeting to a date specified by the Contributors for the absence of a quorum or if the Parent has not received proxies representing a sufficient number of shares for the Parent Stockholder Approval; <u>provided</u>, that the Parent shall not be required to adjourn the Parent Stockholders Meeting more than one time pursuant to this sentence, and no such adjournment pursuant to this sentence shall be required to be for a period exceeding 10 Business Days. Parent, through the Parent Board, shall (i)&#160;recommend to its stockholders that they vote to approve the Parent Stockholder Matters, (ii)&#160;include such recommendation in the Proxy Statement and (iii)&#160;publicly reaffirm such recommendation within 24 hours after a request to do so by the Contributors. Without limiting the generality of the foregoing, Parent agrees that (x)&#160;Parent shall use its reasonable best efforts to solicit proxies to obtain the Parent Stockholder Approval and (y) its obligations pursuant to this <u>Section 6.3</u> shall not be affected by the commencement, public proposal, public disclosure or communication to Parent or any other Person of any Acquisition Proposal.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS64"><!--Anchor--></a>Section 6.4&#8195;<u>Access to Information; Confidentiality</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Parent shall, and shall cause each of its Subsidiaries to, afford to the Contributors and their respective Representatives reasonable access during normal business hours, during the period prior to the Effective Time or the termination of this Agreement in accordance with its terms, to all their respective properties, assets, books, contracts, commitments, personnel and records and, during such period, Parent shall, and shall cause each of its Subsidiaries to, furnish promptly to the Contributors: (a) a copy of each report, schedule, registration statement and other document filed or received by it during such period pursuant to the requirements of federal or state securities laws and (b) all other information concerning its business, properties and personnel as the Contributors may reasonably request (including Tax Returns filed and those in preparation and the work papers of its auditors); <u>provided</u>, <u>however</u>, that the foregoing shall not require Parent to disclose any information to the extent such disclosure would contravene applicable Law. All such information shall be held confidential in accordance with the terms of the Confidentiality Agreements between Parent and GNI Group and between Parent and the Operating Company, in each case dated as of October&#160;7, 2022 (the &#8220;<u>Confidentiality Agreements</u>&#8221;). No investigation pursuant to this <u>Section 6.4</u> or information provided, made available or delivered to the Contributors pursuant to this Agreement shall affect any of the representations, warranties, covenants, rights or remedies, or the conditions to the obligations of, the parties hereunder.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Each Contributor shall, and shall cause each of its Subsidiaries to, afford to Parent and its Representatives reasonable access during normal business hours, during the period prior to the Effective Time or the termination of this Agreement in accordance with its terms, to such information, properties and personnel regarding the Contributor and its Subsidiaries as shall be reasonably necessary for Parent to fulfill its obligations pursuant to this Agreement or to confirm that the representations and warranties of the Contributor contained herein are true and correct and that the covenants of the Contributor contained herein have been performed in </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-43<br></div></div></div>
<!--End Page 500-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 501-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg51"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">all material respects; <u>provided</u>, <u>however</u>, that the foregoing shall not require the Contributor to disclose any information to the extent such disclosure would contravene applicable Law. All such information shall be held confidential in accordance with the terms of the Confidentiality Agreements. No investigation pursuant to this <u>Section 6.4(b)</u> or information provided, made available or delivered to Parent pursuant to this Agreement shall affect any of the representations, warranties, covenants, rights or remedies, or the conditions to the obligations of, the parties hereunder.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS65"><!--Anchor--></a>Section 6.5&#8195;<u>Regulatory Approvals; Consents</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Upon the terms and subject to the conditions set forth in this Agreement, each of the parties agrees to use reasonable best efforts to take, or cause to be taken, all actions that are necessary, proper or advisable to consummate and make effective, in the most expeditious manner practicable, the Transactions and the other transactions contemplated by this Agreement, including using reasonable best efforts to accomplish the following: (i)&#160;obtain all required consents, approvals or waivers from, or participation in other discussions or negotiations with, third parties, including as required under any Material Contract, (ii)&#160;obtain all necessary actions or nonactions, waivers, consents, approvals, orders and authorizations from Governmental Entities, make all necessary registrations, declarations and filings and make all commercially reasonable efforts to obtain an approval or waiver from, or to avoid any Action by, any Governmental Entity, including filings under the HSR Act with the United States Federal Trade Commission and the Antitrust Division of the United States Department of Justice, and (iii)&#160;execute and deliver any additional instruments necessary to consummate the transactions contemplated hereby and fully to carry out the purposes of this Agreement; <u>provided</u>, <u>however</u>, that neither party shall commit to the payment of any fee, penalty or other consideration or make any other concession, waiver or amendment under any Contract in connection with obtaining any consent without the prior written consent of the other party. Notwithstanding anything to the contrary in this Agreement, the Contributors have the sole right to control and direct all antitrust strategy in connection with review of the transactions contemplated by this Agreement by any Governmental Entity, or any litigation by, or negotiations with, any antitrust authority or other Person relating to the transaction under the HSR Act or any other antitrust law and will take the lead in all meetings, discussions, and communications with any Governmental Entity relating to obtaining antitrust approval from the transactions contemplated by this Agreement provided that the Contributors will consult with and consider in good faith the comments of Parent in connection with any filing, communication, defense, litigation, negotiation, or strategy. Each of the parties hereto shall furnish to each other party such necessary information and reasonable assistance as such other party may reasonably request in connection with the foregoing. Subject to applicable Law relating to the exchange of information, Parent and the Contributors shall each have the right to review in advance, and to the extent practicable each shall consult with the other in connection with, all of the information relating to Parent or the Contributors, as the case may be, and any of their respective Subsidiaries, that appears in any filing made with, or written materials submitted to, any third party and/or any Governmental Entity in connection with the Transactions and the other transactions contemplated hereby. In exercising the foregoing rights, each of Parent and the Contributors shall act reasonably and as promptly as practicable. Subject to applicable Law and the instructions of any Governmental Entity, the Contributors and Parent shall keep each other reasonably apprised of the status of matters relating to the completion of the transactions contemplated hereby, including promptly furnishing the other with copies of notices or other written communications received by the Contributors or Parent, as the case may be, or any of their respective Subsidiaries, from any Governmental Entity and/or third party with respect to such transactions, and, to the extent practicable under the circumstances, shall provide the other party and its counsel with the opportunity to participate in any meeting with any Governmental Entity in respect of any filing, investigation or other inquiry in connection therewith.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Notwithstanding any other provision of this Agreement to the contrary, in no event shall either Contributor or any of their Affiliates be required to (i)&#160;agree or proffer to divest or hold separate (in a trust or otherwise), or take any other action with respect to, any of the assets or businesses of the Contributor or any of its Affiliates or, assuming the consummation of the Transactions, the Company or Further Challenger or any of their respective Affiliates, (ii)&#160;agree or proffer to limit in any manner whatsoever or not to exercise any rights of ownership of any securities, (iii)&#160;enter into any agreement that in any way limits the ownership or operation of any business of the Contributors or any of their respective Affiliates, or (iv)&#160;agree to obtain prior approval or other approval from a Governmental Entity, or submit a notification or otherwise notify the Governmental Entity, prior to consummating any future transaction (other than the transactions contemplated by this Agreement).</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-44<br></div></div></div>
<!--End Page 501-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 502-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg52"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS66"><!--Anchor--></a>Section 6.6&#8195;<u>Takeover Laws</u>. Each of the Contributors and Parent and their respective boards of directors shall (a) take no action to cause any Takeover Law to become applicable to this Agreement, the Transactions or any of the other transactions contemplated hereby and (b) if any Takeover Law is or becomes applicable to this Agreement, the Transactions or any of the other transactions contemplated hereby, take all action necessary to ensure that the Transactions and the other transactions contemplated hereby may be consummated as promptly as practicable on the terms contemplated by this Agreement and otherwise to eliminate or minimize the effect of such Takeover Law with respect to this Agreement, the Transactions and the other transactions contemplated hereby.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS67"><!--Anchor--></a>Section 6.7&#8195;<u>Notification of Certain Matters</u>. The Contributors and Parent shall promptly notify each other of (a) any notice or other communication received by such party from any Governmental Entity in connection with the Transactions or the other transactions contemplated hereby or from any Person alleging that the consent of such Person is or may be required in connection with the Transactions or the other transactions contemplated hereby, and (b) any Action commenced or, to such party&#8217;s knowledge, threatened against, relating to or involving or otherwise affecting such party or any of its Subsidiaries which relate to the Transactions or the other transactions contemplated hereby; <u>provided</u>, <u>however</u>, that the delivery of any notice pursuant to this <u>Section 6.7</u> shall not (i)&#160;cure any breach of, or non-compliance with, any other provision of this Agreement, or (ii)&#160;limit the remedies available to the party receiving such notice; provided further, that failure to give prompt notice shall not constitute a failure of a condition to the Transactions set forth in <u>Article VII</u> except to the extent that the underlying fact or circumstance not so notified would standing alone constitute such a failure.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS68"><!--Anchor--></a>Section 6.8&#8195;<u>Indemnification, Exculpation and Insurance</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;From the Effective Time through the sixth anniversary of the date on which the Effective Time occurs, each of Parent and the Company shall indemnify and hold harmless each person who is now, or has been at any time prior to the date hereof, or who becomes prior to the Effective Time, a director or officer of Parent, the Company or Further Challenger, respectively (the &#8220;<u>D&amp;O Indemnified Parties</u>&#8221;), against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements, incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the D&amp;O Indemnified Party is or was a director or officer of Parent or the Company, whether asserted or claimed prior to, at or after the Effective Time, in each case, to the fullest extent permitted under the DGCL. Each D&amp;O Indemnified Party will be entitled to advancement of expenses incurred in the defense of any such claim, action, suit, proceeding or investigation from each of Parent or the Company, as the case may be, jointly and severally, upon receipt by Parent or the Company, as the case may be, from the D&amp;O Indemnified Party of a request therefor; provided that any such person to whom expenses are advanced provides an undertaking to Parent or the Company, to the extent then required by the DGCL, to repay such advances if it is ultimately determined that such person is not entitled to indemnification.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The provisions of the certificate of incorporation and bylaws of Parent with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers of Parent that are presently set forth in the certificate of incorporation and bylaws of Parent shall not be amended, modified or repealed for a period of six years from the Effective Time in a manner that would adversely affect the rights thereunder of individuals who, at or prior to the Effective Time, were officers or directors of Parent, unless such modification is required by applicable Law. To the extent permitted by applicable Law, the memorandum and articles of association of the Company shall contain, and Parent shall cause the memorandum and articles of association of the Company to so contain, provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth in the certificate of incorporation and bylaws of Parent.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;From and after the Effective Time through the sixth anniversary of the date on which the Effective Time occurs, (i)&#160;the Company shall fulfill and honor in all respects the obligations of the Company to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under its respective memorandum and articles of association and pursuant to any indemnification agreements between the Company and such D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the Effective Time and (ii)&#160;Parent shall fulfill and honor in all respects the obligations of Parent to its D&amp;O </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-45<br></div></div></div>
<!--End Page 502-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 503-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg53"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under Parent&#8217;s certificate of incorporation and bylaws and pursuant to any indemnification agreements between Parent and such D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the Effective Time.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;From and after the Effective Time through the sixth anniversary of the date on which the Effective Time occurs, Parent shall maintain the directors&#8217; and officers&#8217; liability insurance tail policies, which tail policies shall be purchased by the Parent prior to the Closing in favor of each director or officer of Parent, with an effective date as of the Closing Date, and the cost of such tail policies shall be an expense borne by the Parent prior to the Closing under this Agreement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;In the event Parent or the Company or any of their respective successors or assigns (i)&#160;consolidates with or merges into any other Person and shall not be the continuing or surviving corporation, company, or entity of such consolidation or merger or (ii)&#160;transfers all or substantially all of its properties and assets to any Person, then, and in each such case, proper provision shall be made so that the successors and assigns of Parent or the Company, as the case may be, shall succeed to the obligations set forth in this <u>Section 6.8</u>. Parent shall cause the Company to perform all of its respective obligations under this <u>Section 6.8</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS69"><!--Anchor--></a>Section 6.9&#8195;<u>Stock Exchange Listing</u>. Parent shall use its reasonable best efforts to (a) remain listed as a public company on Nasdaq and (b) cause the shares of Parent Common Stock to be issued in the Transactions, and such other shares of Parent Common Stock to be reserved for issuance in connection with the Transactions, to be approved for listing on Nasdaq, subject to official notice of issuance, prior to the Effective Time. In the event that Parent receives a second notice of delisting from Nasdaq due to failure to comply with Nasdaq&#8217;s $1.00 minimum closing bid price requirement, Parent and the Contributors shall each use their respective best efforts to take actions to regain compliance with such requirement, including effecting a reverse stock split and seeking the requisite stockholder approval.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS610"><!--Anchor--></a>Section 6.10&#8195;<u>Stockholder Litigation</u>. Parent shall give the Contributors the opportunity to participate in the defense and settlement of any stockholder litigation against Parent and/or its officers or directors relating to the Transactions or any of the other transactions contemplated by this Agreement in accordance with the terms of a mutually agreed upon joint defense agreement. Parent shall not enter into any settlement agreement in respect of any stockholder litigation against Parent and/or its directors or officers relating to the Transactions or any of the other transactions contemplated hereby without the prior written consent of each of the Contributors (such consent not to be unreasonably withheld, conditioned or delayed).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS611"><!--Anchor--></a>Section 6.11&#8195;<u>Certain Tax Matters</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Each of Parent and the Contributors will (and will each cause its respective Affiliates to) (i)&#160;use commercially reasonable efforts to cause the Transactions to qualify for the Intended Tax Treatment and (ii)&#160;not take any action or fail to take any action required hereby (or reasonably requested by GNI USA) that could reasonably be expected to prevent or impede the Transactions from qualifying for the Intended Tax Treatment. Parent and Contributors shall not file (or cause their Affiliates, including the Contributors, to file) any U.S. federal, state or local Tax Return after the Closing Date in a manner that is inconsistent with the treatment of the Transactions as qualifying for the Intended Tax Treatment for U.S. federal, state income and other relevant Tax purposes, and shall not take any inconsistent position during the course of any audit, litigation or other proceeding with respect to Taxes, in each case, unless otherwise required by a change in Law after the date hereof or a determination within the meaning of Section 1313(a) of the Code.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;All transfer, documentary, sales, use, stamp, registration, excise, recording, registration value-added and other such similar Taxes and fees (including any penalties and interest) that become payable in connection with or by reason of (i)&#160;the GNI USA Contribution shall be borne and paid by GNI USA and (ii)&#160;the Minority Holder Contribution shall be borne and paid by the Minority Holders. Unless otherwise required by applicable law, Parent shall timely file any Tax Return or other document with respect to such Taxes or fees (and the Contributors shall reasonably cooperate with respect thereto as necessary).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS612"><!--Anchor--></a>Section 6.12&#8195;<u>Dividends</u>. Except as provided in this Agreement with respect to the CVR, the Parent shall not any dividends in respect of Parent Common Stock and the record dates and payment dates relating thereto.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-46<br></div></div></div>
<!--End Page 503-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 504-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg54"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS613"><!--Anchor--></a>Section 6.13&#8195;<u>Public Announcements</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;As promptly as practicable following the date of this Agreement (and in any event within four (4)&#160;Business Days thereafter), Parent shall prepare and file a Current Report on Form 8-K pursuant to the Exchange Act to report the execution of this Agreement (the &#8220;<u>Signing Form 8-K</u>&#8221;) and the parties shall issue a mutually agreeable press release announcing the execution of this Agreement. Parent shall provide the Contributors with a reasonable opportunity to review and comment on the Signing Form 8-K prior to its filing and shall consider such comments in good faith.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;At least five (5) days prior to the Closing, the Contributors shall begin preparing a draft Current Report on Form 8-K in connection with and announcing the Closing, together with, or incorporating by reference, such information that is or may be required to be disclosed with respect to the transactions contemplated by this Agreement pursuant to Form 8-K (the &#8220;<u>Closing Form 8-K</u>&#8221;). The Contributors shall provide Parent with a reasonable opportunity to review and comment on the Closing Form 8-K prior to its filing and shall incorporate any such comments. Prior to the Closing, the Contributors shall prepare a press release announcing the consummation of the transactions contemplated by this Agreement (&#8220;<u>Closing Press Release</u>&#8221;). The Contributors shall provide Parent with a reasonable opportunity to review and comment on the Closing Press Release prior to its filing and shall consider such comments in good faith. Concurrently with or promptly following with the Closing, Parent shall distribute the Closing Press Release, and within four (4) Business Days thereafter, file the Closing Form 8-K with the SEC.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS614"><!--Anchor--></a>Section 6.14&#8195;<u>Section 16 Matters</u>. Prior to the Effective Time, each of Parent and the Contributors shall take all such steps as may be necessary or appropriate to cause the transactions contemplated by this Agreement, including acquisitions of Parent Common Stock (including derivative securities with respect to such Parent Common Stock) resulting from the transactions contemplated by this Agreement by each individual who will become subject to such reporting requirements with respect to Parent to be exempt under Rule 16b-3 promulgated under the Exchange Act.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS615"><!--Anchor--></a>Section 6.15&#8195;<u>LTIP</u>. Prior to the Closing Date, upon request by the Contributors, Parent shall approve and, subject to the Parent Stockholder Approvals, adopt, an increase to the number of shares reserved under the Catalyst Biosciences, Inc. 2018 Omnibus Incentive Plan to be effective upon and following the Closing (the &#8220;<u>LTIP</u>&#8221;).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS616"><!--Anchor--></a>Section 6.16&#8195;<u>Parent Deliverables</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Two Business Days prior to the Closing, Parent will deliver to the Contributors a schedule (the &#8220;<u>Net </u><u>Cash Schedule</u>&#8221;) setting forth, in reasonable detail, Parent&#8217;s good faith, estimated calculation of Net Cash, including each component thereof as of the close of business on the last Business Day prior to the Closing Date prepared and certified by Parent&#8217;s principal financial or accounting officer. Parent shall make available to the Contributors, as requested by the Contributors, the work papers and back-up materials used or useful in preparing the Net Cash Schedule.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Two Business Days prior to the Closing, Parent will deliver to the Contributors a good faith estimate of the costs (the &#8220;<u>Interim Operating Amount</u>&#8221;) to manage, negotiate, settle and finalize the Claims (as defined in the CVR Agreement). Following the Closing, the Contributors acknowledge and agree that (i)&#160;the Special Committee (as defined in the CVR Agreement) will manage, negotiate, settle, and finalize the Claims, and (ii)&#160;Parent will pay any related fees and expenses up to the Interim Operating Amount until such amount has been exhausted, in each case, as such performance and obligations are governed exclusively by the terms and conditions of the CVR Agreement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS617"><!--Anchor--></a>Section 6.17&#8195;<u>Contributions to GNI USA</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;<u>Company Ordinary Shares</u>. Prior to the Closing, each of GNI Group and GNI HK shall contribute all of its Company Ordinary Shares to GNI USA, such that immediately prior to the Closing, GNI USA shall hold 72.22% of the Company Ordinary Shares.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-47<br></div></div></div>
<!--End Page 504-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 505-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg55"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;<u>Further Challenger</u>. Prior to the Closing, Shanghai Genomics shall contribute all of the FC Shares to GNI USA, such that immediately prior to the Closing, GNI USA shall hold 100% of the FC Shares.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(i)&#8195;Prior to or on the Closing Date, but prior to the transfer of the FC Shares from GNI USA to Parent, Shanghai Genomics shall deliver to GNI USA the following:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 60pt; text-indent: 20pt; text-align: justify;">(A)&#8195;a duly executed share transfer form with respect to the FC Shares between Shanghai Genomics as transferor and GNI USA as transferee;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 60pt; text-indent: 20pt; text-align: justify;">(B)&#8195;the share certificate relating to the FC Shares held by Shanghai Genomics (if applicable) which has been marked as &#8220;Cancelled&#8221;; and</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 60pt; text-indent: 20pt; text-align: justify;">(C)&#8195;a certified true copy of the resolution of the directors of Further Challenger (i)&#160;approving the transfer of the FC Shares from Shanghai Genomics to GNI USA; and (ii)&#160;authorizing the name of GNI USA to be entered into Further Challenger&#8217;s register of members as the holder of the FC Shares and directing the issuance of a new share certificate in respect thereof.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(ii)&#8195;Prior to or on the Closing Date (but prior to the transfer of the FC Shares from GNI USA to the Parent) Shanghai Genomics shall procure the entry of GNI USA in Further Challenger&#8217;s register of members as the holder of the FC Shares and shall deliver to GNI USA a copy of Further Challenger&#8217;s register of members reflecting the transfer of the FC Shares to GNI USA.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iii)&#8195;On the Closing Date (and prior to the Effective Time) GNI USA shall deliver to Parent the following:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 60pt; text-indent: 20pt; text-align: justify;">(A)&#8195;a duly executed share transfer form with respect to the FC Shares between GNI USA as transferor and Parent as transferee;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 60pt; text-indent: 20pt; text-align: justify;">(B)&#8195;a registered agent&#8217;s certificate issued by Further Challenger&#8217;s registered agent, attaching certified copies of Further Challenger&#8217;s current register of members, register of directors and register of charges and dated no earlier than 10 Business Days prior to the Closing Date;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 60pt; text-indent: 20pt; text-align: justify;">(C)&#8195;a certificate of good standing issued by the Registrar of Corporate Affairs in the British Virgin Islands with respect to Further Challenger, dated no earlier than 5 Business Days prior to the Closing Date;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 60pt; text-indent: 20pt; text-align: justify;">(D)&#8195;the share certificate relating to the FC Shares held by GNI USA (if applicable) which has been marked as &#8220;Cancelled&#8221;; and</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 60pt; text-indent: 20pt; text-align: justify;">(E)&#8195;a certified true copy of the resolution of the directors of Further Challenger (i)&#160;approving the transfer of the FC Shares from GNI USA to Parent; and (ii)&#160;authorizing the name of Parent to be entered into Further Challenger&#8217;s register of members as the holder of the FC Shares and directing the issuance of a new share certificate in respect thereof.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; text-align: center;"><a name="tANXAA7"><!--Anchor--></a>ARTICLE VII<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">CONDITIONS PRECEDENT</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS71"><!--Anchor--></a>Section 7.1&#8195;<u>General Conditions</u>. The obligation of each party to effect the Transactions is subject to the satisfaction at or prior to the Effective Time of the following conditions:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(a)&#8195;<u>Stockholder Approval</u>. The Parent Stockholder Approval shall have been obtained.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;<u>HSR Act; Antitrust</u>. Any applicable waiting period (and any extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the &#8220;<u>HSR Act</u>&#8221;) as well as any agreement not to close embodied in a &#8220;timing agreement&#8221; between the parties and a Governmental Entity, shall have expired or been terminated. Neither party shall have received a letter from any Governmental Entity stating that although the waiting period under the HSR Act applicable to the transactions contemplated by this Agreement will soon expire, the Governmental Entity has not yet completed any purported investigation of the proposed transaction.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;<u>No Injunctions or Legal Restraints; Illegality</u>. No temporary restraining order, preliminary or permanent injunction or other judgment, order or decree issued by any court of competent jurisdiction or other legal restraint or prohibition shall be in effect, and no Law shall have been enacted, entered, promulgated, enforced or deemed applicable by any Governmental Entity that, in any such case, prohibits or makes illegal the consummation of the Transactions.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-48<br></div></div></div>
<!--End Page 505-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 506-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg56"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;<u>Nasdaq Listing</u>. The shares of Parent Common Stock issuable to the stockholders of the Company as provided for in <u>Article I</u> shall have been approved for listing on Nasdaq, subject only to official notice of issuance, and immediately following the Closing, Parent shall satisfy all applicable initial and continuing listing requirements of Nasdaq and shall not have received any notice of non-compliance therewith.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;<u>Form S-4</u>. The Form S-4 shall have been declared effective by the SEC under the Securities Act and no stop order suspending the effectiveness of the Form S-4 shall have been issued and no proceedings for that purpose shall have been initiated or threatened.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS72"><!--Anchor--></a>Section 7.2&#8195;<u>Conditions to the Obligations of Parent</u>. The obligation of Parent to effect the Transactions is also subject to the satisfaction, or waiver by Parent, at or prior to the Effective Time of the following conditions:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;<u>Representations and Warranties</u>. The representations and warranties of the Contributors and the Company set forth in this Agreement shall be true and correct as of the date of this Agreement and as of the Closing Date as though made as of the Closing Date (except to the extent such representations and warranties expressly relate to an earlier date, in which case as of such earlier date), except for inaccuracies of representations or warranties the circumstances giving rise to which, individually or in the aggregate, have not had and would not reasonably be expected to have a Company Material Adverse Effect (it being understood that, for purposes of determining the accuracy of such representations and warranties, all knowledge, materiality and &#8220;Material Adverse Effect&#8221; qualifications and exceptions contained in such representations and warranties shall be disregarded).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;<u>Performance of Obligations of the Contributors</u>. Each of the Contributors and the Company shall have performed in all material respects all obligations required to be performed by it under this Agreement at or prior to the Effective Time.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;<u>Officers&#8217; Certificate</u>. Parent shall have received a certificate signed by an executive officer of each of the Contributors and the Company certifying as to the matters set forth in <u>Section 7.2(a)</u> and <u>Section 7.2(b)</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;<u>Tax Certificates</u>. (i)&#160;GNI USA shall have delivered to the Parent an accurate, executed, and complete U.S. Internal Revenue Service Form W-9, and (ii)&#160;each of the Minority Holders shall have delivered to Parent an accurate, executed, and complete U.S. Internal Revenue Service Form W-8 or W-9, as the case may be.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS73"><!--Anchor--></a>Section 7.3&#8195;<u>Conditions to the Obligations of the Contributors and the Company</u>. The obligation of each of the Contributors and the Company to effect the Transactions is also subject to the satisfaction, or waiver by the Contributors and the Company, at or prior to the Effective Time of the following conditions:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;<u>Representations and Warranties</u>. The representations and warranties of the Parent set forth in this Agreement shall be true and correct as of the date of this Agreement and as of the Closing Date as though made as of the Closing Date (except to the extent such representations and warranties expressly relate to an earlier date, in which case as of such earlier date), except for inaccuracies of representations or warranties the circumstances giving rise to which, individually or in the aggregate, have not had and would not reasonably be expected to have a Parent Material Adverse Effect (it being understood that, for purposes of determining the accuracy of such representations and warranties, all knowledge, materiality and &#8220;Material Adverse Effect&#8221; qualifications and exceptions contained in such representations and warranties shall be disregarded).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;<u>Performance of Obligations of Parent</u>. Parent shall have performed in all material respects all obligations required to be performed by them under this Agreement at or prior to the Effective Time.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;<u>Officers&#8217; Certificate</u>. The Contributors shall have received a certificate signed by an executive officer of Parent certifying as to the matters set forth in <u>Section 7.3(a)</u> and <u>Section 7.3(b)</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;<u>Directors and Officers</u>. The Persons listed in <u>Schedule 1.7(c)</u> shall have been approved by the Parent Stockholder Approval (with such appointments to take effect immediately following the Closing). The Contributors shall have received the written resignations of all of the directors and officers of Parent (other than such Persons, if any, who will continue as directors following the Closing), effective as of the Closing.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-49<br></div></div></div>
<!--End Page 506-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 507-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg57"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;<u>Tax Certificate</u>. Parent shall have delivered to the Contributors a properly executed Foreign Investment and Real Property Tax Act of 1980 notification letter which states that the shares of Parent Common Stock do not constitute &#8220;United States real property interests&#8221; under Section 897(c) of the Code for purposes of satisfying each Contributor&#8217;s obligations under Treasury Regulation Section 1.1445-2(c)(3), and a form of notice to the IRS prepared in accordance with the requirements of Treasury Regulation Section 1.897-2(h)(2), each in substantially the form of <u>Exhibit B</u> hereto.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS74"><!--Anchor--></a>Section 7.4&#8195;<u>Frustration of Closing Conditions</u>. None of Parent, the Contributors or the Company may rely on the failure of any condition set forth in this <u>Article VII</u> to be satisfied if such failure was caused by such party&#8217;s breach of this Agreement.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="tANXAA8"><!--Anchor--></a>ARTICLE VIII<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">TERMINATION, AMENDMENT AND WAIVER</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS81"><!--Anchor--></a>Section 8.1&#8195;<u>Termination</u>. This Agreement may be terminated and the Transactions may be abandoned at any time prior to the Effective Time, whether before or after the Parent Stockholder Approval has been obtained:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(a)&#8195;by mutual written consent of Parent and the Contributors;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(b)&#8195;by either Parent or the Contributors:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(i)&#8195;if the Transactions shall not have been consummated on or before the date that is the 180th day after the date hereof (the &#8220;<u>Outside Date</u>&#8221;); <u>provided</u>, that the right to terminate this Agreement pursuant to this <u>Section 8.1(b)(i)</u> shall not be available to any party whose failure to fulfill in any material respect any of its obligations under this Agreement has been the primary cause of, or the primary factor that resulted in, the failure of the Transactions to be consummated by the Outside Date;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(ii)&#8195;if any court of competent jurisdiction or other Governmental Entity shall have issued a judgment, order, injunction, rule or decree, or taken any other action restraining, enjoining or otherwise prohibiting any of the transactions contemplated by this Agreement and such judgment, order, injunction, rule, decree or other action shall have become final and nonappealable; <u>provided</u>, that the party seeking to terminate this Agreement pursuant to this <u>Section 8.1(b)(ii)</u> shall have used its reasonable best efforts to contest, appeal and remove such judgment, order, injunction, rule, decree, ruling or other action in accordance with <u>Section&#160;6.5</u>; or</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iii)&#8195;if the Parent Stockholder Approval shall not have been obtained at the Parent Stockholders Meeting duly convened therefor or at any adjournment or postponement thereof at which a vote on the adoption of this Agreement was taken; <u>provided</u>, that Parent shall not be permitted to terminate this Agreement pursuant to this <u>Section 8.1(b)(iii)</u> if the failure to obtain such Parent Stockholder Approval is proximately caused by any action or failure to act of Parent that constitutes a breach of this Agreement;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(c)&#8195;by Parent:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(i)&#8195;if the Contributors or the Company shall have breached or failed to perform any of its representations, warranties, covenants or agreements set forth in this Agreement, or if any representation or warranty of the Contributors or the Company shall have become untrue, which breach or failure to perform or to be true, either individually or in the aggregate, if occurring or continuing at the Effective Time (A) would result in the failure of any of the conditions set forth in <u>Section 7.1</u> or <u>Section 7.2</u> and (B)&#160;cannot be or has not been cured by the earlier of (1) the Outside Date and (2) 30 days after the giving of written notice to the Contributors or Company of such breach or failure; <u>provided</u>, that Parent shall not have the right to terminate this Agreement pursuant to this <u>Section 8.1(c)</u> if Parent is then in material breach of any of its covenants or agreements set forth in this Agreement such that Section 6.2(a) or Section 6.2(b) would not be satisfied; or</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(ii)&#8195;at any time prior to obtaining the Parent Stockholder Approval, in order to accept a Superior Proposal in accordance with <u>Section 6.2(b)</u>; provided, that Parent shall have (A) simultaneously with such termination entered into the associated Alternative Acquisition Agreement, (B) otherwise complied with all provisions of <u>Section 6.2(b)</u>, including the notice provisions thereof, and (C) paid any amounts due pursuant to <u>Section 8.3(b)</u>.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-50<br></div></div></div>
<!--End Page 507-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 508-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg58"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(d)&#8195;by the Contributors:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(i)&#8195;if Parent shall have breached or failed to perform any of its representations, warranties, covenants or agreements set forth in this Agreement (other than with respect to a breach of <u>Section 6.2</u> or <u>Section&#160;6.3(c)</u>, as to which <u>Section 8.1(d)</u> will apply), or if any representation or warranty of Parent shall have become untrue, which breach or failure to perform or to be true, either individually or in the aggregate, if occurring or continuing at the Effective Time (A) would result in the failure of any of the conditions set forth in <u>Section 7.1</u> or <u>Section 7.3</u> and (B) cannot be or has not been cured by the earlier of (1) the Outside Date and (2) 30 days after the giving of written notice to Parent of such breach or failure; <u>provided</u>, that the Contributors shall not have the right to terminate this Agreement pursuant to this <u>Section 8.1(d)</u> if it is then in material breach of any of its covenants or agreements set forth in this Agreement such that <u>Section&#160;7.3(a)</u> or <u>Section 7.3(b)</u> would not be satisfied; or</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(ii)&#8195;if (A) an Adverse Recommendation Change shall have occurred, (B) Parent shall, within 10&#160;Business Days of a tender or exchange offer relating to securities of Parent having been commenced, fail to publicly recommend against such tender or exchange offer, or (C) Parent shall have failed to publicly reaffirm its recommendation of the Transactions within five (5) Business Days after the date any Acquisition Proposal or any material modification thereto is first commenced, publicly announced, distributed or disseminated to Parent&#8217;s stockholders upon a request to do so by the Contributors.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The party desiring to terminate this Agreement pursuant to this <u>Section 8.1</u> (other than pursuant to <u>Section&#160;8.1(a)</u>) shall give notice of such termination to the other party.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS82"><!--Anchor--></a>Section 8.2&#8195;<u>Effect of Termination</u>. In the event of termination of the Agreement, this Agreement shall immediately become void and have no effect, without any liability or obligation on the part of Parent or the Contributors, <u>provided</u>, that:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;the Confidentiality Agreement (as amended hereby) and the provisions of <u>Section 2.7</u> and <u>Section 4.22</u> (Brokers), <u>Section 6.13</u> (Public Announcements), this <u>Section 8.2</u>, <u>Section 8.3</u> (Fees and Expenses), <u>Section 9.2</u> (Notices), <u>Section 9.5</u> (Entire Agreement), <u>Section 9.6</u> (No Third Party Beneficiaries), <u>Section 9.7</u> (Governing Law), <u>Section 9.8</u> (Submission to Jurisdiction), <u>Section 9.9</u> (Assignment; Successors), <u>Section 9.10</u> (Specific Performance), <u>Section 9.12</u> (Severability), <u>Section 9.13</u> (Waiver of Jury Trial) and <u>Section 9.16</u> (No Presumption Against Drafting Party) shall survive the termination hereof;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(b)&#8195;the Contributors may have liability as provided in <u>Section 8.3</u>; and</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;no such termination shall relieve any party from any liability or damages arising out of a willful and material breach of any of its representations, warranties, covenants or agreements set forth in this Agreement or fraud, in which case the non-breaching party shall be entitled to all rights and remedies available at law or in equity.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS83"><!--Anchor--></a>Section 8.3&#8195;<u>Fees and Expenses</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Except as otherwise provided in this <u>Section 8.3</u> or in <u>Section 6.16</u> or under the terms and conditions of the CVR Agreement, all fees and expenses incurred in connection with this Agreement, the Transactions and the other transactions contemplated hereby shall be paid by the party incurring such fees or expenses, whether or not the Transactions are consummated, except for the following:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(i)&#8195;the expenses incurred in connection with the filing, printing and mailing of the Form S-4 and the Proxy Statement, and all filing and other fees paid to the SEC or in respect of the HSR Act, in each case in connection with the Transactions (other than attorneys&#8217; fees, accountants&#8217; fees and related expenses), shall be shared equally by Parent and the Company;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(ii)&#8195;the Contributors shall, on a joint and several basis, reimburse Parent for ongoing operating expenses in excess of $500,000 (but not to exceed $1,000,000) in the aggregate, where such expenses are solely incurred between the date of this Agreement and the Closing; <u>provided</u>, that such expenses shall be set forth on a budget that is approved by the Parent Board after the date of this Agreement and delivered to the Company within 30 days of the date of this Agreement, and the aggregate sum of such reimbursed amounts shall be distributed to the stockholders of Parent pursuant to the CVR Agreement. Operating expenses in excess of $1,000,000 (if any) incurred by Parent, where such expenses are solely incurred between the date of this Agreement and the Closing, shall be borne equally by the Company and Parent; </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-51<br></div></div></div>
<!--End Page 508-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 509-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg59"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">provided, that any such expenses shall be approved by the Parent Board. Expenses that were incurred prior to the date of this Agreement, in whole or in part, shall not be subject to this <u>Section 8.3(a)(ii)</u> or the cost-reimbursement or cost-sharing provisions hereunder.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(b)&#8195;In the event that:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(i)&#8195;One of the follow events occurs:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 60pt; text-indent: 20pt; text-align: justify;">(A)&#8195;(I) an Acquisition Proposal (whether or not conditional) or intention to make an Acquisition Proposal (whether or not conditional) is made directly to the Parent&#8217;s stockholders or is otherwise publicly disclosed or otherwise communicated to senior management of Parent or the Parent Board, (II) this Agreement is terminated by the Contributors or Parent pursuant to <u>Section 8.1(b)(i)</u> or <u>Section&#160;8.1(b)(iii)</u>, and (III) within eighteen (18) months after the date of such termination, Parent enters into an agreement in respect of any Acquisition Proposal, or recommends or submits any Acquisition Proposal to its stockholders for adoption, or a transaction in respect of such Acquisition Proposal is consummated, which, in each case, need not be the same Acquisition Proposal that was made, disclosed or communicated prior to termination hereof (<u>provided</u>, that for purposes of this clause (III), each reference to &#8220;15%&#8221; in the definition of &#8220;Acquisition Proposal&#8221; shall be deemed to be a reference to &#8220;50%&#8221;);</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 60pt; text-indent: 20pt; text-align: left;">(B)&#8195;this Agreement is terminated by the Contributors pursuant to <u>Section 8.1(d)(ii)</u>; or</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 60pt; text-indent: 20pt; text-align: left;">(C)&#8195;this Agreement is terminated by Parent pursuant to <u>Section 8.1(c)(ii)</u>.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">then, in any such event, Parent shall pay to the Contributors a fee of $2,000,000 (the &#8220;<u>Termination Fee</u>&#8221;); <u>provided</u>, that the payment by Parent of the Termination Fee pursuant to this <u>Section 8.3</u> shall not relieve Parent from any liability or damage resulting from a willful and material breach of any of its representations, warranties, covenants or agreements set forth in this Agreement or fraud.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(ii)&#8195;this Agreement is terminated by Parent pursuant to <u>Section 8.1(c)(i)</u>, then, in any such event, the Contributors shall reimburse Parent for all of its reasonable out-of-pocket fees and expenses (including all operating expenses and all fees and expenses of counsel, accountants, investment bankers, experts and consultants to Parent) incurred by Parent or on its behalf in connection with or related to the authorization, preparation, investigation, negotiation, execution, and performance of this Agreement and the Transactions (the &#8220;<u>Parent Expenses</u>&#8221;), up to a maximum amount of $2,000,000; <u>provided</u>, that the payment by the Company of the Parent Expenses pursuant to this <u>Section 8.3</u> shall not relieve the Contributors from any liability or damage resulting from a willful and material breach of any of its representations, warranties, covenants or agreements set forth in this Agreement or fraud.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iii)&#8195;this Agreement is terminated by the Contributors pursuant to <u>Section 8.1(d)(i)</u>, then, in any such event, then Parent shall reimburse the Contributors for all of their reasonable out-of-pocket fees and expenses (including all fees and expenses of counsel, accountants, investment bankers, experts and consultants to the Contributors) incurred by the Contributors or on their behalf in connection with or related to the authorization, preparation, investigation, negotiation, execution, and performance of this Agreement and the Transactions (the &#8220;<u>Company Expenses</u>&#8221;), up to a maximum amount of $2,000,000; <u>provided</u>, that the payment by Parent of the Company Expenses under this Section shall not relieve Parent from any liability or damage resulting from a willful and material breach of any of its representations, warranties, covenants, or agreements set forth in this Agreement or fraud.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;Payment of the Termination Fee shall be made by wire transfer of same-day funds to the accounts designated by the Contributors (i)&#160;on the earliest of the execution of a definitive agreement with respect to, submission to the stockholders of, or consummation of, any transaction contemplated by an Acquisition Proposal, as applicable, in the case of a Termination Fee payable pursuant to <u>Section 8.3(b)(i)(A)</u>, (ii)&#160;as promptly as reasonably practicable after termination (and, in any event, within two Business Days thereof), in the case of termination by Parent pursuant to <u>Section 8.1(c)(ii)</u>, or (iii)&#160;simultaneously with, and as a condition to the effectiveness of, termination, in the case of a termination by the Contributors pursuant to <u>Section&#160;8.1(d)(ii)</u>. Payment of the Parent Expenses or the Company Expenses shall be made by wire transfer of same-day funds to the accounts designated by Parent or the Contributors, as applicable, as promptly as reasonably practicable after termination (and, in any event, within two Business Days thereof), in the case of termination by (x)&#160;Parent pursuant to <u>Section 8.1(c)(i)</u>, or (y) the Contributors pursuant to Section 8.1(d)(i).</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-52<br></div></div></div>
<!--End Page 509-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 510-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg60"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;The parties acknowledges that the agreements contained in this <u>Section 8.3</u> are an integral part of the transactions contemplated by this Agreement, and that, without these agreements, the other party would not enter into this Agreement. Accordingly, if any party fails promptly to pay any amounts due pursuant to this <u>Section&#160;8.3</u>, and, in order to obtain such payment, the other party commences a suit that results in a judgment against such non-paying party for the amounts set forth in this <u>Section 8.3</u>, such non-paying party shall pay to the other party its costs and expenses (including reasonable attorneys&#8217; fees and expenses) in connection with such suit, together with interest on the amounts due pursuant to this <u>Section 8.3</u> from the date such payment was required to be made until the date of payment at the prime lending rate as published in The Wall Street Journal in effect on the date such payment was required to be made.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS84"><!--Anchor--></a>Section 8.4&#8195;<u>Amendment or Supplement</u>. This Agreement may be amended, modified or supplemented by the Parent, the Contributors and the Company by action taken or authorized by their respective boards of directors or equivalent at any time prior to the Effective Time, whether before or after the Parent Stockholder Approval has been obtained; <u>provided</u>, <u>however</u>, that any amendment to <u>Section 1.1</u>, <u>Section 1.4</u>, <u>Article V</u>, <u>Section 6.3(c)</u>, <u>Section&#160;6.3(d)</u>, and this <u>Section 8.4</u> (to the extent such amendment pertains to <u>Section 1.1</u>, <u>Section 1.4</u>, <u>Article V</u>, <u>Section 6.3(c)</u>, <u>Section&#160;6.3(d)</u>) must also be approved by the Minority Holders; <u>provided</u>, <u>further</u>, that after the Parent Stockholder Approval has been obtained, no amendment shall be made that pursuant to applicable Law requires further approval or adoption by the stockholders of Parent without such further approval or adoption. This Agreement may not be amended, modified or supplemented in any manner, whether by course of conduct or otherwise, except by an instrument in writing specifically designated as an amendment hereto, signed on behalf of each of the parties in interest at the time of the amendment.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS85"><!--Anchor--></a>Section 8.5&#8195;<u>Extension of Time; Waiver</u>. At any time prior to the Effective Time, the parties may, by action taken or authorized by their respective boards of directors or equivalent, to the extent permitted by applicable Law, (a) extend the time for the performance of any of the obligations or acts of the other parties, (b) waive any inaccuracies in the representations and warranties of the other parties set forth in this Agreement or any document delivered pursuant hereto or (c) subject to applicable Law, waive compliance with any of the agreements or conditions of the other parties contained herein; <u>provided</u>, <u>however</u>, that after the Parent Stockholder Approval has been obtained, no waiver may be made that pursuant to applicable Law requires further approval or adoption by the stockholders of Parent without such further approval or adoption. Any agreement on the part of a party to any such waiver shall be valid only if set forth in a written instrument executed and delivered by a duly authorized officer on behalf of such party. No failure or delay of any party in exercising any right or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such right or power, or any course of conduct, preclude any other or further exercise thereof or the exercise of any other right or power. The rights and remedies of the parties hereunder are cumulative and are not exclusive of any rights or remedies which they would otherwise have hereunder.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="tANXAA9"><!--Anchor--></a>ARTICLE IX<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">GENERAL PROVISIONS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS91"><!--Anchor--></a>Section 9.1&#8195;<u>Nonsurvival of Representations and Warranties</u>. None of the representations, warranties, covenants or agreements in this Agreement or in any instrument delivered pursuant to this Agreement shall survive the Effective Time, other than those covenants or agreements of the parties which by their terms apply, or are to be performed in whole or in part, after the Effective Time.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-53<br></div></div></div>
<!--End Page 510-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 511-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg61"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS92"><!--Anchor--></a>Section 9.2&#8195;<u>Notices</u>. All notices and other communications hereunder shall be in writing and shall be deemed duly given (a) on the date of delivery if delivered personally, or if by facsimile or e-mail, upon written confirmation of receipt by facsimile, e-mail or otherwise, (b) on the first Business Day following the date of dispatch if delivered utilizing a next-day service by a recognized next-day courier or (c) on the earlier of confirmed receipt or the fifth Business Day following the date of mailing if delivered by registered or certified mail, return receipt requested, postage prepaid. All notices hereunder shall be delivered to the addresses set forth below, or pursuant to such other instructions as may be designated in writing by the party to receive such notice:</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(i) </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.75pt;">&#8203;</td><td colspan="4" style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">if to Parent, to:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td colspan="4" style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">611 Gateway Blvd.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Suite 120</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td colspan="4" style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">South San Francisco, CA 94080</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Nassim Usman, PhD</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">E-mail: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>nusman@catbio.com</u></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td colspan="4" style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">with a copy (which shall not constitute notice) to:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td colspan="4" style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Orrick, Herrington &amp; Sutcliffe LLP<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">51 West 52nd Street<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">New York, NY 10019</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stephen Thau and David Schwartz</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">E-mail: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>sthau@orrick.com</u> and <u>dschwartz@orrick.com</u></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(ii) </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td colspan="4" style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">if to the Contributors, the Company or Further Challenger, to:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td colspan="4" style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">c/o GNI USA, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">12730 High Bluff Drive, Suite 250<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">San Diego, CA 92130</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ying Luo</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thomas Eastling</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">E-mail: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>yluo@gnipharma.com</u></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>t-eastling@gnipharma.com</u></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td colspan="4" style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">with a copy (which shall not constitute notice) to:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td colspan="4" style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gibson, Dunn &amp; Crutcher LLP<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">555 Mission Street, Suite 3000<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">San Francisco, CA 94105</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ryan A. Murr and Branden C. Berns</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">E-mail:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>RMurr@gibsondunn.com</u> and <u>BBerns@gibsondunn.com</u></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(iii)&#8195;if to the Minority Holders, to the addresses listed on <u>Annex&#160;A</u>.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-54<br></div></div></div>
<!--End Page 511-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 512-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg62"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS93"><!--Anchor--></a>Section 9.3&#8195;<u>Certain Definitions</u>. For purposes of this Agreement:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;&#8220;<u>Affiliate</u>&#8221; of any Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such first Person;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;&#8220;<u>Business Day</u>&#8221; means any day other than a Saturday, a Sunday or a day on which banks in New York, New York are authorized or required by applicable Law to be closed;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;&#8220;<u>Cash and Cash Equivalents</u>&#8221; means all (i)&#160;cash and cash equivalents and (ii)&#160;marketable securities, in each case determined in accordance with GAAP;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;&#8220;<u>Company Owned IP</u>&#8221; means all Intellectual Property owned by the Company or any of its Subsidiaries in whole or in part;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;&#8220;<u>control</u>&#8221; (including the terms &#8220;<u>controlled</u>,&#8221; &#8220;<u>controlled by</u>&#8221; and &#8220;<u>under common control with</u>&#8221;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;&#8220;<u>COVID-19</u>&#8221; means SARS-CoV-2 or COVID-19, and any variants or evolutions thereof or related or associate epidemics, pandemic or disease outbreaks;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;&#8220;<u>Indebtedness</u>&#8221; means, with respect to any Person, (i)&#160;all obligations of such Person for borrowed money, or with respect to unearned advances of any kind to such Person, (ii)&#160;all obligations of such Person evidenced by bonds, debentures, notes or similar instruments, (iii)&#160;all capitalized lease obligations of such Person, (iv)&#160;all obligations of such Person under installment sale contracts, (v)&#160;all guarantees and arrangements having the economic effect of a guarantee of such Person of any Indebtedness of any other Person, and (vi)&#160;all obligations or undertakings of such Person to maintain or cause to be maintained the financial position of others or to purchase the obligations of others;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(h)&#8195;&#8220;<u>Intellectual Property</u>&#8221; means all intellectual property rights of any kind or nature in any jurisdiction throughout the world, including all of the following to the extent protected by applicable law: (i)&#160;trademarks or service marks (whether registered or unregistered), trade names, domain names, social media user names, social media addresses, logos, slogans, and trade dress, including applications to register any of the foregoing, together with the goodwill symbolized by any of the foregoing; (ii)&#160;patents, utility models and any similar or equivalent statutory rights with respect to the protection of inventions, and all applications for any of the foregoing, together with all re-issuances, continuations, continuations-in-part, divisionals, revisions, extensions and reexaminations thereof; (iii)&#160;copyrights (registered and unregistered) and applications for registration; (iv)&#160;trade secrets and customer lists, in each case to the extent any of the foregoing derive economic value (actual or potential) from not being generally known to other Persons who can obtain economic value from their disclosure or use, and other confidential information (&#8220;<u>Trade Secrets</u>&#8221;); and (v)&#160;any other proprietary or intellectual property rights of any kind or nature;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(i)&#8195;&#8220;<u>knowledge</u>&#8221; of any party means (i)&#160;the actual knowledge of any executive officer of such party or other officer having primary responsibility for the relevant matter or (ii)&#160;any fact or matter which any such officer of such party could be expected to discover or otherwise become aware of in the course of conducting a reasonably comprehensive investigation, consistent with such officer&#8217;s title and responsibilities, concerning the existence of the relevant matter;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(j)&#8195;&#8220;<u>Net Cash</u>&#8221; means the amount, whether positive or negative, without duplication, as of immediately prior to the Effective Time: (i)&#160;Parent&#8217;s unrestricted Cash and Cash Equivalents, short-term investments, and accounts receivable, determined, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents and the Parent Balance Sheet, minus (ii)&#160;the sum of (x)&#160;Parent&#8217;s consolidated short-term and long-term liabilities accrued at Closing under GAAP (including fees and expenses incurred with respect to the Transactions and related transactions and excluding non-cash liabilities (e.g., deferred revenue)), (y) any accrued and unpaid Tax liabilities of Parent and its Subsidiaries, and (z) the cash cost of change in control payments, including termination or similar payments to current or former employees or other service provider of such party that have to be paid by a party in connection with, or at the time of, the Closing and/or the termination of Parent&#8217;s then employees (if any), minus (iii)&#160;the cash costs of any retention payments or other bonuses due to any current or former employee as of the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-55<br></div></div></div>
<!--End Page 512-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 513-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg63"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">Closing Date, minus (iv) 80% of the sum of estimated cash costs associated with the termination of ongoing contractual obligations relating to Parent&#8217;s legacy business operations (including without limitation CRO fees, consulting fees with termination provisions, manufacturing obligations, etc.), minus (v)&#160;to the extent not included in the balance sheet liabilities, other outstanding contractual obligations of Parent, minus (vi)&#160;the aggregate costs associated with obtaining a D&amp;O tail policy (if applicable), minus (vii)&#160;any amounts paid or payable as bonuses to employees granted prior to the date of this Agreement, plus (viii)&#160;solely with respect to Parent, prepaid expenses;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(k)&#8195;&#8220;<u>Parent Balance Sheet</u>&#8221; means the audited balance sheet of Parent as of December&#160;31, 2021, included in Parent&#8217;s Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(l)&#8195;&#8220;<u>Parent Capital Stock</u>&#8221; means the Parent Common Stock and Parent Convertible Preferred Stock;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(m)&#8195;&#8220;<u>Parent Option</u>&#8221; means any option exercisable for shares of Parent Common Stock granted under the Catalyst Biosciences, Inc. 2018 Omnibus Incentive Plan or under any other employee or director stock option, stock purchase or equity compensation plan, arrangement or agreement of Parent;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(n)&#8195;&#8220;<u>Parent Owned IP</u>&#8221; means all Intellectual Property owned by Parent or any of its Subsidiaries in whole or in part;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(o)&#8195;&#8220;<u>Person</u>&#8221; means an individual, corporation, partnership, limited liability company, association, trust or other entity or organization, including any Governmental Entity;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(p)&#8195;&#8220;<u>Personal Information</u>&#8221; means any information that alone or in combination with other information can be used to identify an individual;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(q)&#8195;&#8220;<u>Subsidiary</u>&#8221; means, with respect to any Person, any other Person of which stock or other equity interests having ordinary voting power to elect more than 50% of the board of directors or other governing body are owned, directly or indirectly, by such first Person; provided, that for purposes of this Agreement, the Operating Company shall be deemed a Subsidiary of the Company;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(r)&#8195;&#8220;<u>Tax Return</u>&#8221; means any return, declaration, report, certificate, bill, election, claim for refund, information return, statement or other written information and any other document filed or supplied or required to be filed or supplied to any Governmental Entity with respect to Taxes, including any schedule, attachment or supplement thereto, and including any amendment thereof; and</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(s)&#8195;&#8220;<u>Taxes</u>&#8221; means all federal, state, local, foreign and other net income, gross income, gross receipts, sales, use, stock, ad valorem, transfer, transaction, franchise, profits, gains, registration, license, wages, lease, service, service use, employee and other withholding, social security, unemployment, welfare, disability, payroll, employment, excise, severance, stamp, environmental, occupation, workers&#8217; compensation, premium, real property, personal property, escheat or unclaimed property, windfall profits, net worth, capital, value-added, alternative or add-on minimum, customs duties, estimated and other taxes, fees, assessments, charges or levies of any kind whatsoever (whether imposed directly or through withholding and including taxes of any third party in respect of which a Person may have a duty to collect or withhold and remit and any amounts resulting from the failure to file any Tax Return), whether disputed or not, together with any interest and any penalties, additions to tax or additional amounts with respect thereto.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS94"><!--Anchor--></a>Section 9.4&#8195;<u>Interpretation</u>. When a reference is made in this Agreement to a Section, Article, Exhibit or Schedule such reference shall be to a Section, Article, Exhibit or Schedule of this Agreement unless otherwise indicated. The table of contents and headings contained in this Agreement or in any Exhibit or Schedule are for convenience of reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. All words used in this Agreement will be construed to be of such gender or number as the circumstances require. Any capitalized terms used in any Exhibit or Schedule but not otherwise defined therein shall have the meaning as defined in this Agreement. All Exhibits and Schedules annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth herein. The word &#8220;including&#8221; and words of similar import when used in this Agreement will mean &#8220;including, without limitation,&#8221; unless otherwise specified. The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of similar import when used in this Agreement shall refer to the Agreement as a whole and not to any particular provision in this Agreement. The term &#8220;or&#8221; is not exclusive. The word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall.&#8221; References to days mean calendar days unless otherwise specified. Each of the terms &#8220;delivered&#8221; and &#8220;made available&#8221; means, with respect </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-56<br></div></div></div>
<!--End Page 513-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 514-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg64"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">to any documentation, that (i)&#160;prior to 11:59 p.m. (Pacific Time) on the date that is two Business Days prior to the date of this Agreement (A) a copy of such material has been posted to and made available by a party to the other party and its Representatives in the electronic data room maintained by such disclosing party or (B) such material is disclosed in the Parent SEC Documents filed with the SEC prior to the date hereof and publicly made available on the SEC&#8217;s Electronic Data Gathering Analysis and Retrieval system or (ii)&#160;such documentation has been delivered by or on behalf of a party or its Representatives via electronic mail or in hard copy form prior to the execution of this Agreement. Whenever the last day for the exercise of any privilege or the discharge of any duty hereunder shall fall upon a Saturday, Sunday, or any date on which banks in New York, New York, are authorized or obligated by Law to be closed, the party having such privilege or duty may exercise such privilege or discharge such duty on the next succeeding day which is a regular Business Day.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS95"><!--Anchor--></a>Section 9.5&#8195;<u>Entire Agreement</u>. This Agreement (including the Exhibits hereto), the Company Disclosure Letter, the Parent Disclosure Letter and the Confidentiality Agreements constitute the entire agreement, and supersede all prior written agreements, arrangements, communications and understandings and all prior and contemporaneous oral agreements, arrangements, communications and understandings among the parties with respect to the subject matter hereof and thereof.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS96"><!--Anchor--></a>Section 9.6&#8195;<u>No Third Party Beneficiaries</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person other than the parties and their respective successors and permitted assigns any legal or equitable right, benefit or remedy of any nature under or by reason of this Agreement, except as provided in <u>Section 6.8</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The representations and warranties in this Agreement are the product of negotiations among the parties hereto and are for the sole benefit of the parties hereto. Any inaccuracies in such representations and warranties are subject to waiver by the parties hereto in accordance with <u>Section 8.5</u> without notice or liability to any other Person. In some instances, the representations and warranties in this Agreement may represent an allocation among the parties hereto of risks associated with particular matters regardless of the knowledge of any of the parties hereto. Consequently, Persons other than the parties hereto may not rely upon the representations and warranties in this Agreement as characterizations of actual facts or circumstances as of the date of this Agreement or as of any other date.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS97"><!--Anchor--></a>Section 9.7&#8195;<u>Governing Law</u>. This Agreement and all disputes or controversies arising out of or relating to this Agreement or the transactions contemplated hereby shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to the laws of any other jurisdiction that might be applied because of the conflicts of laws principles of the State of Delaware.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS98"><!--Anchor--></a>Section 9.8&#8195;<u>Submission to Jurisdiction</u>. Each of the parties irrevocably agrees that any legal action or proceeding arising out of or relating to this Agreement brought by any party or its Affiliates against any other party or its Affiliates shall be brought and determined in the Court of Chancery of the State of Delaware, provided that if jurisdiction is not then available in the Court of Chancery of the State of Delaware, then any such legal action or proceeding may be brought in any federal court located in the State of Delaware. Each of the parties hereby irrevocably submits to the jurisdiction of the aforesaid courts for itself and with respect to its property, generally and unconditionally, with regard to any such action or proceeding arising out of or relating to this Agreement and the transactions contemplated hereby. Each of the parties agrees not to commence any action, suit or proceeding relating thereto except in the courts described above in Delaware, other than actions in any court of competent jurisdiction to enforce any judgment, decree or award rendered by any such court in Delaware as described herein. Each of the parties further agrees that notice as provided herein shall constitute sufficient service of process and the parties further waive any argument that such service is insufficient. Each of the parties hereby irrevocably and unconditionally waives, and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise, in any action or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby, (a) any claim that it is not personally subject to the jurisdiction of the courts in Delaware as described herein for any reason, (b) that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (c) that (i)&#160;the suit, action or proceeding in any such court is brought in an inconvenient forum, (ii)&#160;the venue of such suit, action or proceeding is improper or (iii)&#160;this Agreement, or the subject matter hereof, may not be enforced in or by such courts.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-57<br></div></div></div>
<!--End Page 514-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 515-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg65"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS99"><!--Anchor--></a>Section 9.9&#8195;<u>Assignment; Successors</u>. Neither this Agreement nor any of the rights, interests or obligations under this Agreement may be assigned or delegated, in whole or in part, by operation of law or otherwise, by any party without the prior written consent of the other parties, and any such assignment without such prior written consent shall be null and void; <u>provided</u>, <u>however</u>, that each Contributor may assign, in its sole discretion, any or all of its rights, interests and obligations under this Agreement to (a) any of its Affiliates at any time, in which case all references herein to the Contributor shall be deemed references to such other Affiliate, except that all representations and warranties made herein with respect to the Contributor as of the date of this Agreement shall be deemed to be representations and warranties made with respect to such other Affiliate as of the date of such assignment (provided, however, that in such instance, the Contributor shall remain liable for the performance of all obligations required to be performed by the Contributors and its Subsidiaries at or prior to the Effective Time), or (b) after the Effective Time, any Person. Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit of, and be enforceable by, the parties and their respective successors and assigns.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS910"><!--Anchor--></a>Section 9.10&#8195;<u>Specific Performance</u>. The parties agree that irreparable damage would occur in the event that the parties hereto do not perform the provisions of this Agreement in accordance with its terms or otherwise breach such provisions. Accordingly, prior to any termination of this Agreement pursuant to <u>Section 8.1</u>, the parties acknowledge and agree that each party shall be entitled to an injunction, specific performance and other equitable relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in the Court of Chancery of the State of Delaware, <u>provided</u>, that if jurisdiction is not then available in the Court of Chancery of the State of Delaware, then in any federal court located in the State of Delaware, this being in addition to any other remedy to which such party is entitled at law or in equity. Each of the parties hereby further waives (a) any defense in any action for specific performance that a remedy at law would be adequate and (b) any requirement under any law to post security as a prerequisite to obtaining equitable relief.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS911"><!--Anchor--></a>Section 9.11&#8195;<u>Currency</u>. All references to &#8220;dollars&#8221; or &#8220;$&#8221; or &#8220;US$&#8221; in this Agreement refer to United States dollars, which is the currency used for all purposes in this Agreement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS912"><!--Anchor--></a>Section 9.12&#8195;<u>Severability</u>. Whenever possible, each provision or portion of any provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable Law, but if any provision or portion of any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable Law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or portion of any provision in such jurisdiction, and this Agreement shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision or portion of any provision had never been contained herein.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS913"><!--Anchor--></a>Section 9.13&#8195;<u>Waiver of Jury Trial</u>. EACH OF THE PARTIES TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVES ALL RIGHT TO A TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS914"><!--Anchor--></a>Section 9.14&#8195;<u>Counterparts</u>. This Agreement may be executed in two or more counterparts, all of which shall be considered one and the same instrument and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other party.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS915"><!--Anchor--></a>Section 9.15&#8195;<u>Facsimile or .pdf Signature</u>. This Agreement may be executed by facsimile or .pdf signature and a facsimile or .pdf signature shall constitute an original for all purposes.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS916"><!--Anchor--></a>Section 9.16&#8195;<u>No Presumption Against Drafting Party</u>. Each of Parent, the Contributors and the Company acknowledges that each party to this Agreement has been represented by counsel in connection with this Agreement and the transactions contemplated by this Agreement. Accordingly, any rule of law or any legal decision that would require interpretation of any claimed ambiguities in this Agreement against the drafting party has no application and is expressly waived.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">[<font style="font-style: italic;">The remainder of this page is intentionally left blank</font>.]</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-58<br></div></div></div>
<!--End Page 515-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 516-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg66"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">CATALYST BIOSCIENCES, INC.</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Nassim Usman, Ph.D.</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: Nassim Usman, Ph.D.</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title: Chief Executive Officer</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">[<font style="font-style: italic;">Signature Page to the Business Combination Agreement</font>]<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-59<br></div></div></div>
<!--End Page 516-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 517-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg67"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"></div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI USA, INC.</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Ying Luo</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: Ying Luo</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title: Director</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI GROUP LTD.</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Ying Luo</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: Ying Luo</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title : President and Chief Executive Officer</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI HONG KONG LIMITED</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Ying Luo</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: Ying Luo</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title: Director and President</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">SHANGHAI GENOMICS, INC.</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Yuwen Wu</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: Yuwen Wu</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title: Executive Director, General Manager and Legal Representative</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">CONTINENT PHARMACEUTICALS INC.</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Ying Luo</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: Ying Luo</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title: Chairman</div></td></tr><tr><td colspan="7" style="width: 100%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Zhu Yueying </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Zhu Yueying </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Lan Ping </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lan Ping </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Arthur Cheng </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Arthur Cheng </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Sun Hui </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sun Hui </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">[<font style="font-style: italic;">Signature Page to the Business Combination Agreement</font>]<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-60<br></div></div></div>
<!--End Page 517-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 518-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg68"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Annex A<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Minority Holders </div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-top: 1pt solid #000000;"><tr class="header"><td class="gutter" style="width: 0.64%; font-size: 2pt; border-left: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.98%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Individual </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Entity </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Jurisdiction </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Authorized<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Issued and <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Outstanding <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Notice Address </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.98%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Parent<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stock </div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.75pt;">&#8203;</td></tr><tr><td class="gutter" style="width: 0.64%; font-size: 2pt; border-left: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.98%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Zhu Yueying </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Ratel Holdings Limited </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">BVI </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">50,000 </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">50,000 </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">[***] </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.98%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">44,137,006 </div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td></tr><tr><td class="gutter" style="width: 0.64%; font-size: 2pt; border-left: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.98%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Lan Ping </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Aaring Limited </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Hong Kong </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">10,000 </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">10,000 </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">[***] </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.98%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">42,605,648 </div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td></tr><tr><td class="gutter" style="width: 0.64%; font-size: 2pt; border-left: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.98%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Arthur Cheng </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Rosefinch Holdings Limited </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">BVI </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">50,000 </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">50,000 </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">[***] </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.98%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">36,127,255 </div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td></tr><tr><td class="gutter" style="width: 0.64%; font-size: 2pt; border-left: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.98%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Sun Hui </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Nepenthe Holdings Limited </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Hong Kong </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">10,000 </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">10,000 </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.87%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">[***] </div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.98%; text-align: center; vertical-align: middle; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">34,084,519</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3pt;">&#8203;</td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-61<br></div></div></div>
<!--End Page 518-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 519-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg69"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">AMENDMENT TO BUSINESS COMBINATION AGREEMENT</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This Amendment to Business Combination Agreement (this &#8220;<u>Amendment</u>&#8221;) is dated as of March&#160;29, 2023, with respect to that certain Business Combination Agreement (the &#8220;<u>Business Combination Agreement</u>&#8221;), dated as of December&#160;26, 2022, by and among Catalyst Biosciences, Inc., a Delaware corporation (&#8220;<u>Parent</u>&#8221;), GNI USA, Inc., a Delaware corporation (&#8220;<u>GNI USA</u>&#8221;), GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (&#8220;<u>GNI Group</u>&#8221;), GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability (&#8220;<u>GNI HK</u>&#8221;), Shanghai Genomics, Inc., a company organized under the laws of the People&#8217;s Republic of China (&#8220;<u>Shanghai Genomics</u>&#8221;, and collectively with GNI USA, GNI Group and GNI HK, the &#8220;<u>Contributors</u>,&#8221; and each a &#8220;<u>Contributor</u>&#8221;), the individuals (each, a &#8220;<u>Minority Holder</u>&#8221; and collectively, the &#8220;<u>Minority Holders</u>&#8221;) listed on Annex&#160;A thereto and Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares (the &#8220;<u>Company</u>&#8221;). Capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Business Combination Agreement.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; text-align: center;">RECITALS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, Section&#160;8.4 of the Business Combination Agreement provides that it may be amended, modified or supplemented by Parent, the Contributors and the Company by action taken or authorized by their respective boards of directors or equivalent at any time prior to the Effective Time, whether before or after the Parent Stockholder Approval has been obtained, and by an instrument in writing specifically designated as an amendment thereto, signed on behalf of each of the parties in interest at the time of the amendment; <u>provided</u>, <u>however</u>, that any amendment to &#8206;Section&#160;1.1, &#8206;Section&#160;1.4, &#8206;Article&#160;V, &#8206;Section&#160;6.3(c), &#8206;Section&#160;6.3(d), and &#8206;Section&#160;8.4 (to the extent such amendment pertains to &#8206;Section&#160;1.1, &#8206;Section&#160;1.4, &#8206;Article&#160;V, &#8206;Section&#160;6.3(c), &#8206;Section&#160;6.3(d)) must also be approved by the Minority Holders.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">NOW, THEREFORE, in consideration of the premises, and of the mutual agreements contained herein, and intending to be legally bound hereby, Parent, the Contributors, the Minority Holders and the Company hereby agree as follows: </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; text-align: center;">ARTICLE I<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">AMENDMENT</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 1.1&#8195;<u>Amendments</u>. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The reference to &#8220;Form&#160;S-4&#8221; in the Index of Defined Terms of the Business Combination Agreement shall be deleted.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The following references shall be added into the Index of Defined Terms of the Business Combination Agreement: </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 428pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 89.72%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proxy Clearance Date<font style="padding-left: 2.1pt;"></font></div></td><td class="gutter" style="width: 2.77%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.77%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">6.3(a)</div></td></tr><tr><td style="width: 89.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Resale Shelf Registration Statement<font style="padding-left: 4.88pt;"></font></div></td><td class="gutter" style="width: 2.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">6.3(c)</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">(c)&#8195;Section&#160;1.5 of the Business Combination Agreement is hereby amended and restated as follows: </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 40pt; text-align: left;"><u>Treatment of Operating Company Options</u>. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-align: justify;">At the Effective Time, each option to purchase common shares of the Operating Company (the &#8220;<u>Operating</u><u> </u><u>Company Common Shares</u>&#8221;) granted under any employee or director stock option, stock purchase or equity compensation plan, arrangement or agreement of the Operating Company (each, an &#8220;<u>Operating Company</u><u> </u><u>Option</u>&#8221;), that is outstanding immediately prior to the Effective Time, shall be terminated and replaced with an option granted under Parent&#8217;s 2023 Omnibus Incentive Plan that is substantially similar in all material respects to the terms and conditions applicable to the Operating Company Options (including with respect to vesting and forfeiture). Prior to the Effective Time, the Company shall take, or cause to be taken, all actions necessary or appropriate to give effect to the provisions of this <u>Section&#160;1.5</u>, including causing the Operating Company to terminate its 2021 Stock Incentive Plan effective as of the Effective Time.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">(d)&#8195;Section&#160;6.3 of the Business Combination Agreement is hereby amended and restated as follows:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 40pt; text-align: left;"><u>Preparation of Proxy Statement and Resale Shelf Registration Statement; Stockholders&#8217; Meeting</u> </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(a)&#8195;As promptly as practicable after the date of this Agreement, Parent shall file with the SEC a proxy statement (as amended or supplemented from time to time, the &#8220;<u>Proxy Statement</u>&#8221;) to be sent to the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-62<br></div></div></div>
<!--End Page 519-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 520-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg70"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">stockholders of Parent relating to the special meeting of Parent&#8217;s stockholders (the &#8220;<u>Parent Stockholders </u><u>Meeting</u>&#8221;) to be held to consider the Parent Stockholder Matters; provided, that it is understood and agreed that the Contributors shall prepare the initial draft of the Proxy Statement. Parent shall file the definitive Proxy Statement with the SEC and cause the Proxy Statement to be mailed to its stockholders of record, at such time as reasonably agreed by the Contributors and the Company promptly (and in any event within five (5) Business Days) following (x) in the event the preliminary Proxy Statement is not reviewed by the SEC, the expiration of the waiting period in Rule&#160;14a-6(a) under the Securities Exchange Act or (y) in the event the preliminary Proxy Statement is reviewed by the SEC, receipt of oral or written notification of the completion of the review by the SEC (the date in (x) or (y), the &#8220;<u>Proxy Clearance Date</u>&#8221;). </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Parent covenants and agrees that the Proxy Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith) will (i) comply as to form in all material respects with the requirements of applicable U.S. federal securities laws and the DGCL, and (ii) with regard to the information provided in the Proxy Statement by Parent, will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(c)&#8195;As promptly as practicable following March&#160;29, 2023, Parent shall file with the SEC a registration statement on Form&#160;S-3 or similar short form registration statement that may be available at such time or its successor form, or, if Parent is ineligible to use Form&#160;S-3, a registration statement on Form&#160;S-1, for an offering to be made on a continuous basis pursuant to Rule&#160;415 of the Securities Act registering the resale of the securities from time to time pursuant to any method or combination of methods legally available to, and requested by, the Contributors and the Minority Holders then held by such holders that are not then covered by an effective resale registration statement (the &#8220;<u>Resale Shelf Registration </u><u>Statement</u>&#8221;); <u>provided</u>, that it is understood and agreed that the Contributors shall prepare the initial draft of the Resale Registration Statement. Parent will advise the Contributors promptly after it receives oral or written notice thereof of the time when the Resale Registration Statement has become effective or any amendment or supplement thereto has been filed, the issuance of any stop order, the suspension of the qualification of the Parent Common Stock registered on the Resale Registration Statement for offering or sale in any jurisdiction or any oral or written request by the SEC for amendment of the Resale Registration Statement or comments thereon and responses thereto or requests by the SEC for additional information, and will promptly provide the other with copies of any written communication from the SEC or any state securities commission and a reasonable opportunity to participate in the responses thereto. The Contributors covenant and agree that all information concerning the Contributors, the Company and Further Challenger furnished by the Contributors, and the Minority Holders covenant and agree, individually and not with respect to each other, that all information concerning the Minority Holders and the Entities, and included in the Proxy Statement and the Resale Registration Statement will (i) comply as to form in all material respects with the requirements of applicable U.S. federal securities laws and the DGCL, and (ii) will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. Parent shall use its reasonable best efforts to have the Resale Registration Statement declared effective by the SEC under the Securities Act as promptly as practicable after such filing and to keep the Resale Registration Statement effective until all securities covered by the Resale Registration Statement are sold in accordance with the intended plan of distribution set forth in the Resale Registration Statement or supplement to the prospectus or such securities have been withdrawn. Parent shall also take any action (other than qualifying to do business in any jurisdiction in which it is not now so qualified or filing a general consent to service of process) required to be taken under any applicable state securities or &#8220;blue sky&#8221; laws in connection with the registration of the Parent Common Stock and the Contributors shall furnish all information concerning Contributors as may be reasonably requested in connection with any such action.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(d)&#8195;Parent shall use its reasonable best efforts to respond promptly to any comments or requests of the SEC or its staff relating to the Proxy Statement and the Resale Registration Statement; provided, that any comments or request of the SEC or its staff which relate to disclosures contained in the Proxy Statement or the Resale Registration Statement and which were provided by the Minority Holders or the Contributors will be promptly addressed by the Contributors. No filing of, or amendment or supplement to, the Proxy Statement or the Resale Registration Statement will be made by Parent, without providing the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-63<br></div></div></div>
<!--End Page 520-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 521-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg71"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">Contributors a reasonable opportunity to review and comment thereon and without the Contributors&#8217; prior approval (which shall not be unreasonably withheld, conditioned, or delayed). If at any time prior to the Effective Time any information relating to the Contributors, the Minority Holders or Parent, or any of their respective Affiliates, officers or directors, should be discovered by the Company or Parent that should be set forth in an amendment or supplement to either of the Proxy Statement or the Resale Registration Statement, so that any of such documents would not contain any misstatement of a material fact or omit to state any material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, the party that discovers such information shall promptly notify the other parties hereto and an appropriate amendment or supplement describing such information shall promptly be filed with the SEC and, to the extent required under applicable Law, disseminated to stockholders of Parent; <u>provided</u>, that the delivery of such notice and the filing of any such amendment or supplement shall not affect or be deemed to modify any representation or warranty made by any party hereunder or otherwise affect the remedies available hereunder to any party.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(e)&#8195;As promptly as practicable after the Proxy Clearance Date, Parent shall duly call, give notice of, convene and hold the Parent Stockholders Meeting to consider and vote to approve the Parent Stockholder Matters pursuant to the terms of this Agreement (and such Parent Stockholders Meeting shall in any event be no later than forty-five (45)&#160;calendar days after the Proxy Clearance Date). Parent may postpone or adjourn the Parent Stockholders Meeting solely (i)&#160;with the consent of the Contributors; (ii)&#160;(A) due to the absence of a quorum or (B) if Parent has not received proxies representing a sufficient number of shares for the Parent Stockholder Approval, whether or not a quorum is present, to solicit additional proxies; or (iii)&#160;to allow reasonable additional time for the filing and mailing of any supplemental or amended disclosure which the Parent Board has determined in good faith after consultation with outside legal counsel is necessary under applicable Law and for such supplemental or amended disclosure to be disseminated and reviewed by Parent&#8217;s stockholders prior to the Parent Stockholders Meeting; <u>provided</u>, that Parent may not postpone or adjourn the Parent Stockholders Meeting more than a total of two times pursuant to clause&#160;(ii)(A) and/or clause (ii)(B) of this Section. Notwithstanding the foregoing, Parent shall, at the request of Contributors, to the extent permitted by Law, adjourn the Parent Stockholders Meeting to a date specified by the Contributors for the absence of a quorum or if the Parent has not received proxies representing a sufficient number of shares for the Parent Stockholder Approval; provided, that Parent shall not be required to adjourn the Parent Stockholders Meeting more than one (1) time pursuant to this sentence, and no such adjournment pursuant to this sentence shall be required to be for a period exceeding ten (10) Business Days. Parent, through the Parent Board, shall (i) recommend to its stockholders that they vote to approve the Parent Stockholder Matters, (ii) include such recommendation in the Proxy Statement and (iii) publicly reaffirm such recommendation within 24&#160;hours after a request to do so by the Contributors. Without limiting the generality of the foregoing, Parent agrees that (x) Parent shall use its reasonable best efforts to solicit proxies to obtain the Parent Stockholder Approval and (y) its obligations pursuant to this &#8206;<u>Section&#160;6.3</u> shall not be affected by the commencement, public proposal, public disclosure or communication to Parent or any other Person of any Acquisition Proposal.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">(e)&#8195;Section&#160;7.1(e) of the Business Combination Agreement is hereby amended and restated as follows:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 40pt; text-align: left;">[Intentionally omitted].</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">(f)&#8195;Section&#160;8.1(b)(i) of the Business Combination Agreement is hereby amended and restated as follows:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-align: justify;">if the Transactions shall not have been consummated on or before September&#160;30, 2023 (the &#8220;<u>Outside </u><u>Date</u>&#8221;); provided, that the right to terminate this Agreement pursuant to this &#8206;<u>Section&#160;8.1(b)(i)</u> shall not be available to any party whose failure to fulfill in any material respect any of its obligations under this Agreement has been the primary cause of, or the primary factor that resulted in, the failure of the Transactions to be consummated by the Outside Date;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">(g)&#8195;Section&#160;8.3(a)(i) of the Business Combination Agreement is hereby amended and restated as follows:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-align: justify;">the expenses incurred in connection with the filing, printing and mailing of the Proxy Statement and the Resale Registration Statement, and all filing and other fees paid to the SEC or in respect of the HSR Act, in each case in connection with the Transactions (other than attorneys&#8217; fees, accountants&#8217; fees and related expenses), shall be shared equally by Parent and the Company;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-64<br></div></div></div>
<!--End Page 521-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 522-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg72"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">(h)&#8195;Section&#160;8.3(a)(ii) of the Business Combination Agreement is hereby amended and restated as follows:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-align: justify;">the Contributors shall, on a joint and several basis, reimburse Parent for ongoing operating expenses in excess of $500,000 (but not to exceed $1,000,000) in the aggregate, where such expenses are solely incurred between the date of this Agreement and the Closing; <u>provided</u>, that such expenses shall be set forth on a budget that is approved by the Parent Board after the date of this Agreement and delivered to the Company within 30&#160;days of the date of this Agreement, and the aggregate sum of such reimbursed amounts shall be distributed to the stockholders of Parent pursuant to the terms of the CVR Agreement; <u>provided</u>, <u>further</u>, that, notwithstanding the foregoing, the Contributors shall, on a joint and several basis, reimburse Parent for all ongoing operating expenses incurred between July&#160;20, 2023 and the Closing. Operating expenses in excess of $1,000,000 (if any) incurred by Parent, where such expenses are solely incurred between the date of this Agreement and July&#160;20, 2023, shall be borne equally by the Company and Parent; <u>provided</u>, that any such expenses shall be approved by the Parent Board. Expenses that were incurred prior to the date of this Agreement, in whole or in part, shall not be subject to this Section&#160;8.3(a)(ii) or the cost-reimbursement or cost-sharing provisions hereunder. All expenses required to be paid pursuant to this <u>Section 8.3(a)(ii)</u> shall be made no later than three (3) Business Days prior to the Closing by wire transfer of immediately available funds to an account designated by Parent.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Section 1.2&#8195;<u>Effect of Amendment; Counterparts</u>. Except as specifically modified herein, the Business Combination Agreement remains in full force and effect. This Amendment may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument, with the same effect as if the signatures thereto were in the same instrument. Article IX of the Business Combination Agreement is hereby incorporated by reference.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 20.5pt; text-align: center;">[<font style="font-style: italic;">Remainder of Page Intentionally Left Blank; Signature Pages Follow</font>]</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-65<br></div></div></div>
<!--End Page 522-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 523-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg73"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">IN WITNESS WHEREOF, the parties have each caused this Amendment to be duly executed as of the date first written above. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>PARENT</u>:<font style="font-weight: normal;"> </font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">CATALYST BIOSCIENCES, INC.<font style="font-weight: normal;"> </font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Nassim Usman, Ph.D. </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:&#8194;Nassim Usman, Ph.D. </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:&#8195;Chief Executive Officer</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">[<font style="font-style: italic;">Signature Page to Amendment to Business Combination Agreement</font>]<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-66<br></div></div></div>
<!--End Page 523-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 524-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg74"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">IN WITNESS WHEREOF, the parties have each caused this Amendment to be duly executed as of the date first written above.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>CONTRIBUTORS</u>:<font style="font-weight: normal;"> </font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI USA, INC.<font style="font-weight: normal;"> </font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Ying Luo </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:&#8194;Ying Luo </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:&#8195;Director</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI GROUP LTD.<font style="font-weight: normal;"> </font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Ying Luo </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:&#8194;Ying Luo </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:&#8195;President and Chief Executive Officer</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI HONG KONG LIMITED<font style="font-weight: normal;"> </font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Ying Luo </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:&#8194;Ying Luo </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:&#8195;Director and President</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>COMPANY</u>:<font style="font-weight: normal;"> </font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">CONTINENT PHARMACEUTICALS INC.<font style="font-weight: normal;"> </font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Ying Luo </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:&#8194;Ying Luo </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:&#8195;Chairman</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0.5pt; margin-left: 0pt; text-align: left;"> </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">[<font style="font-style: italic;">Signature Page to Amendment to Business Combination Agreement</font>]<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-67<br></div></div></div>
<!--End Page 524-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 525-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg75"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">IN WITNESS WHEREOF, the parties have each caused this Amendment to be duly executed as of the date first written above.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">SHANGHAI GENOMICS, INC.<font style="font-weight: normal;"> </font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Yuwen Wu </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:&#8194;Yuwen Wu </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 31.32pt; text-indent: -31.32pt; text-align: left;">Title:&#8195;Executive Director, General Manager and Legal Representative</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0.5pt; margin-left: 31.32pt; text-align: left;"> </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">[<font style="font-style: italic;">Signature Page to Amendment to Business Combination Agreement</font>]<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-68<br></div></div></div>
<!--End Page 525-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 526-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_300-annexa_pg76"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">IN WITNESS WHEREOF, the parties have each caused this Amendment to be duly executed as of the date first written above.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>MINORITY HOLDERS:</u>:<font style="font-weight: normal;"> </font></div></td></tr><tr><td colspan="7" style="width: 100%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Zhu Yueying </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Zhu Yueying </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Lan Ping </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lan Ping </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Arthur Cheng </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Arthur Cheng </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Sun Hui </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sun Hui</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">[<font style="font-style: italic;">Signature Page to Amendment to Business Combination Agreement</font>]<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-69<br></div></div></div>
<!--End Page 526-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 527-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;">Annex&#160;B</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Certain information identified by bracketed asterisks ([***]) has been omitted from this exhibit because it is both not material and would be competitively harmful if publicly disclosed.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">ASSET PURCHASE AGREEMENT<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">by and among<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">CATALYST BIOSCIENCES, INC.,<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">as the Buyer,<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">and<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">GNI GROUP LTD.,<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">and<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">GNI HONG KONG LIMITED,<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">as the Sellers<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dated as of December&#160;26, 2022</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7.5pt; text-align: center;">This document is not intended to create, nor will it be deemed to create, a legally binding or enforceable offer or <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">agreement, acceptance of an offer or agreement of any type or nature, unless and until agreed to and executed <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">by all parties hereto.</div></div></div></div>
<!--End Page 527-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 528-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">TABLE OF CONTENTS</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 15.38%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 70.51%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Page</div></td></tr><tr><td colspan="7" style="width: 93.59%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBA1">ARTICLE I PURCHASE AND SALE<font style="padding-left: 3.91pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBA1"><font style="padding-left: 5pt;">B-</font>1</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS11">Section 1.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS11">Purchase and Sale of Assets<font style="padding-left: 2.55pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS11"><font style="padding-left: 5pt;">B-</font>1</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS12">Section 1.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS12">Excluded Assets<font style="padding-left: 0.85pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS12"><font style="padding-left: 5pt;">B-</font>2</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS13">Section 1.3</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS13">Assumed Liabilities<font style="padding-left: 1.41pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS13"><font style="padding-left: 5pt;">B-</font>2</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS14">Section 1.4</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS14">Excluded Liabilities<font style="padding-left: 0.85pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS14"><font style="padding-left: 5pt;">B-</font>2</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS15">Section 1.5</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS15">Consents and Waivers; Further Assurances<font style="padding-left: 3.55pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS15"><font style="padding-left: 5pt;">B-</font>2</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS16">Section 1.6</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS16">Consideration<font style="padding-left: 1.4pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS16"><font style="padding-left: 5pt;">B-</font>3</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS17">Section 1.7</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS17">Closing<font style="padding-left: 1.39pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS17"><font style="padding-left: 5pt;">B-</font>3</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS18">Section 1.8</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS18">Buyer Directors<font style="padding-left: 2.53pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS18"><font style="padding-left: 5pt;">B-</font>4</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS19">Section 1.9</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS19">Withholding Rights<font style="padding-left: 2.9pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS19"><font style="padding-left: 5pt;">B-</font>4</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td colspan="7" style="width: 93.59%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBA2">ARTICLE II REPRESENTATIONS AND WARRANTIES OF THE SELLERS<font style="padding-left: 3.44pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBA2"><font style="padding-left: 5pt;">B-</font>4</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS21">Section 2.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS21">Organization, Standing and Power<font style="padding-left: 2.45pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS21"><font style="padding-left: 5pt;">B-</font>4</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS22">Section 2.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS22">Authority<font style="padding-left: 3.62pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS22"><font style="padding-left: 5pt;">B-</font>5</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS23">Section 2.3</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS23">No Conflict; Consents and Approvals<font style="padding-left: 4.21pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS23"><font style="padding-left: 5pt;">B-</font>5</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS24">Section 2.4</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS24">Purchased Assets<font style="padding-left: 2.53pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS24"><font style="padding-left: 5pt;">B-</font>6</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS25">Section 2.5</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS25">Absence of Certain Changes or Events<font style="padding-left: 3.68pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS25"><font style="padding-left: 5pt;">B-</font>6</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS26">Section 2.6</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS26">Litigation<font style="padding-left: 3.06pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS26"><font style="padding-left: 5pt;">B-</font>6</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS27">Section 2.7</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS27">Compliance with Laws; Permits<font style="padding-left: 1.43pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS27"><font style="padding-left: 5pt;">B-</font>6</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS28">Section 2.8</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS28">Health Care Regulatory Matters.<font style="padding-left: 4.5pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS28"><font style="padding-left: 5pt;">B-</font>6</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS29">Section 2.9</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS29">Taxes<font style="padding-left: 4.32pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS29"><font style="padding-left: 5pt;">B-</font>8</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS210">Section 2.10</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS210">Contracts<font style="padding-left: 4.18pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS210"><font style="padding-left: 5pt;">B-</font>9</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS211">Section 2.11</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS211">Intellectual Property<font style="padding-left: 4.75pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS211"><font style="padding-left: 5pt;">B-</font>9</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS212">Section 2.12</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS212">Brokers<font style="padding-left: 0.85pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS212">B-10</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS213">Section 2.13</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS213">No Other Representations or Warranties<font style="padding-left: 4.11pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS213">B-10</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td colspan="7" style="width: 93.59%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBA3">ARTICLE III REPRESENTATIONS AND WARRANTIES OF BUYER<font style="padding-left: 1.04pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBA3">B-10</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS31">Section 3.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS31">Organization, Standing and Power<font style="padding-left: 2.45pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS31">B-10</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS32">Section 3.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS32">Capital Stock<font style="padding-left: 2.51pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS32"><font style="padding-left: 0.37pt;">B-</font>11</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS33">Section 3.3</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS33">Subsidiaries<font style="padding-left: 3.63pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS33">B-12</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS34">Section 3.4</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS34">Authority<font style="padding-left: 3.62pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS34">B-12</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS35">Section 3.5</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS35">No Conflict; Consents and Approvals<font style="padding-left: 4.21pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS35">B-13</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS36">Section 3.6</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS36">SEC Reports; Financial Statements<font style="padding-left: 4.2pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS36">B-13</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS37">Section 3.7</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS37">No Undisclosed Liabilities<font style="padding-left: 3.64pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS37">B-15</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS38">Section 3.8</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS38">Absence of Certain Changes or Events<font style="padding-left: 3.68pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS38">B-15</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS39">Section 3.9</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS39">Litigation<font style="padding-left: 3.06pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS39">B-16</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS310">Section 3.10</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS310">Compliance with Laws<font style="padding-left: 3.09pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS310">B-16</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS311">Section 3.11</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS311">Health Care Regulatory Matters<font style="padding-left: 2pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS311">B-16</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS312">Section 3.12</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS312">Benefit Plans<font style="padding-left: 3.07pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS312">B-18</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS313">Section 3.13</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS313">Labor and Employment Matters<font style="padding-left: 1.99pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS313">B-19</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS314">Section 3.14</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS314">Environmental Matters<font style="padding-left: 4.2pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS314">B-20</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS315">Section 3.15</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS315">Taxes<font style="padding-left: 4.32pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS315">B-21</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS316">Section 3.16</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS316">Contracts<font style="padding-left: 4.18pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS316">B-22</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS317">Section 3.17</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS317">Insurance<font style="padding-left: 3.63pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS317">B-22</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS318">Section 3.18</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS318">Properties<font style="padding-left: 1.96pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS318">B-22</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS319">Section 3.19</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS319">Intellectual Property<font style="padding-left: 4.75pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS319">B-23</a></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-i<br></div></div></div>
<!--End Page 528-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 529-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 15.38%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 70.51%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Page</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS320">Section 3.20</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS320">Related Party Transactions<font style="padding-left: 3.63pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS320">B-24</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS321">Section 3.21</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS321">Certain Payments<font style="padding-left: 0.86pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS321">B-24</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS322">Section 3.22</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS322">Brokers<font style="padding-left: 0.85pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS322">B-24</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS323">Section 3.23</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS323">No Other Representations or Warranties<font style="padding-left: 4.11pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS323">B-25</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td colspan="7" style="width: 93.59%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBA4">ARTICLE IV COVENANTS<font style="padding-left: 1.32pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBA4">B-25</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS41">Section 4.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS41">Preparation of Form S-4 and Proxy Statement; Stockholders&#8217; Meeting<font style="padding-left: 1.67pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS41">B-25</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS42">Section 4.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS42">Information; Purchased Contracts<font style="padding-left: 0.88pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS42">B-26</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS43">Section 4.3</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS43">Stockholder Litigation<font style="padding-left: 1.4pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS43">B-27</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS44">Section 4.4</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS44">Tax Matters<font style="padding-left: 3.78pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS44">B-27</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS45">Section 4.5</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS45">Stock Exchange Listing<font style="padding-left: 0.3pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS45">B-28</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS46">Section 4.6</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS46">Public Announcements<font style="padding-left: 4.18pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS46">B-28</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS47">Section 4.7</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS47">Section 16 Matters<font style="padding-left: 0.31pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS47">B-28</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS48">Section 4.8</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS48">Private Placement<font style="padding-left: 4.19pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS48">B-28</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS49">Section 4.9</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS49">Refunds and Remittances<font style="padding-left: 3.65pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS49">B-28</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS410">Section 4.10</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS410">Certificate of Designation<font style="padding-left: 1.99pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS410">B-29</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS411">Section 4.11</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS411">Continued Development of Purchased Assets<font style="padding-left: 3.67pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS411">B-29</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS412">Section 4.12</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS412">Bulk Transfer Laws<font style="padding-left: 1.4pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS412">B-29</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS413">Section 4.13</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS413">Further Assurances<font style="padding-left: 4.76pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS413">B-29</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td colspan="7" style="width: 93.59%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBA5">ARTICLE V GENERAL PROVISIONS<font style="padding-left: 1.88pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBA5">B-29</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS51">Section 5.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS51">Non-survival of Representations and Warranties<font style="padding-left: 1.9pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS51">B-29</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS52">Section 5.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS52">Notices<font style="padding-left: 1.96pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS52">B-29</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS53">Section 5.3</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS53">Certain Definitions<font style="padding-left: 4.75pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS53">B-30</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS54">Section 5.4</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS54">Interpretation<font style="padding-left: 3.08pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS54">B-33</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS55">Section 5.5</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS55">Entire Agreement<font style="padding-left: 0.86pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS55">B-34</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS56">Section 5.6</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS56">No Third-Party Beneficiaries<font style="padding-left: 4.4pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS56">B-34</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS57">Section 5.7</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS57">Amendment or Supplement<font style="padding-left: 0.3pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS57">B-34</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS58">Section 5.8</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS58">Waiver<font style="padding-left: 3.87pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS58">B-34</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS59">Section 5.9</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS59">Fees and Expenses<font style="padding-left: 0.31pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS59">B-35</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS510">Section 5.10</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS510">Governing Law<font style="padding-left: 3.63pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS510">B-35</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS511">Section 5.11</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS511">Submission to Jurisdiction<font style="padding-left: 4.74pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS511">B-35</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS512">Section 5.12</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS512">Assignment; Successors<font style="padding-left: 4.76pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS512">B-35</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS513">Section 5.13</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS513">Specific Performance<font style="padding-left: 0.32pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS513">B-35</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS514">Section 5.14</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS514">Currency<font style="padding-left: 0.29pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS514">B-35</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS515">Section 5.15</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS515">Severability<font style="padding-left: 4.18pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS515">B-36</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS516">Section 5.16</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS516">Waiver of Jury Trial<font style="padding-left: 4.43pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS516">B-36</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS517">Section 5.17</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS517">Counterparts<font style="padding-left: 0.85pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS517">B-36</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS518">Section 5.18</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS518">Facsimile or .pdf Signature<font style="padding-left: 1.15pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS518">B-36</a></div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS519">Section 5.19</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 70.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXBS519">No Presumption Against Drafting Party<font style="padding-left: 0.88pt;"></font></a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2pt; text-align: left;"><a href="#tANXBS519">B-36</a></div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 17.95%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit A</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 80.77%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Bill of Sale</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit B</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 80.77%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assignment of Intellectual Property</div></td></tr><tr><td style="width: 17.95%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit C</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 80.77%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Certificate of Designation</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-ii<br></div></div></div>
<!--End Page 529-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 530-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">INDEX OF DEFINED TERMS</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 48.72%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Definition</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Location</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Action</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.6</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Affiliate</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Agreement</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preamble</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Allocation</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.4(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ancillary Agreements</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(b)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assignment of Intellectual Property</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.7(b)(ii)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assumed Liabilities</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.3</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">BC Agreement</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(c)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">BC Transactions Proposal</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Bill of Sale</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.7(b)(i)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Business Day</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(d)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Buyer</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preamble</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Buyer Balance Sheet</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(d)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Buyer Board</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Buyer Capital Stock</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(f)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Buyer Capital Stock Issuance</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.4(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Buyer Common Stock</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.6(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Buyer Convertible Preferred Stock</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.6(b)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Buyer Disclosure Letter</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Article III</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Buyer IT Systems</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.19(f)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Buyer Material Adverse Effect</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.1(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Buyer Material Contracts</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.16(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Buyer Options</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.2(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Buyer Owned IP</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(g)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Buyer Plans</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.12(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Buyer Products</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.11(c)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Buyer Registered IP</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.19(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Buyer Safety Notices</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.11(g)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Buyer SEC Documents</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.6(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Buyer Stock Awards</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.2(b)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Buyer Stockholder Approval</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.4(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Buyer Stockholder Matters</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Buyer Stockholders Meeting</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.1(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Certificate of Designation</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(h)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Charter Amendment Proposal</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Closing</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.7(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Closing Date</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.7</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Code</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(i)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Compound</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(j)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Contract</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.3(a)(iii)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">control</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(k)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Conversion Proposal</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Copyrights</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(t)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Covered Person</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.2(d)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">COVID-19</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(l)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Develop</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(m)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Development</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(l)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Disqualifying Event</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.2(d)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Effective Time</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.7(a)</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-iii<br></div></div></div>
<!--End Page 530-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 531-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 48.72%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Definition</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Location</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Encumbrance</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(n)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Environmental Law</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.14(b)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ERISA Affiliate</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(o)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exchange Act</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.3(b)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Excluded Assets</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.2</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Excluded Liabilities</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.4</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Excluded Taxes</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(p)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">FD&amp;C Act</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(q)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">FDA</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.8(c)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">FDA Ethics Policy</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.8(i)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form 8-K</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.6</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form S-4</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.1(c)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">GAAP</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.1</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Governmental Authority</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(r)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Governmental Entity</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.3(b)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Hazardous Substance</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.14(c)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Health Care Laws</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.8(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Incentive Plan Proposal</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">IND</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(s)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Intellectual Property</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(t)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Inventory</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(u)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">knowledge</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(v)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Law</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.3(a)(ii)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketing Approval</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(w)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marks</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(t)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Measurement Date</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.2(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Multiemployer Plan</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(x)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Nasdaq</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(y)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">NDA</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(z)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Patent Files</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(aa)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Patents</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(bb)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pension Plan</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(cc)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Permits</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.7(b)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Permitted Encumbrance</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(dd)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Person</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(ee)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Personal Information</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(ff)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Product</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(gg)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property Taxes</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.4(b)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proxy Statement</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.1(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Purchase Price</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.6</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Purchased Assets</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.1</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Purchased Contracts</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.1(e)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Purchased Intellectual Property</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(hh)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Purchased Patents</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.1(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Purchased Registered IP</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.11(e)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Purchased Trade Secrets</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.1(b)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Regulatory Materials</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(ii)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Representative</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(jj)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Right</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(kk)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sarbanes-Oxley Act</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.6(a)</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-iv<br></div></div></div>
<!--End Page 531-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 532-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 48.72%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Definition</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Location</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">SEC</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(ll)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Securities Act</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.3(b)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Seller</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preamble</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Seller Material Adverse Effect</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.1</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Seller Products</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.8(c)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Seller Registered IP</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.11(a)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Seller Safety Notices</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.8(g)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sellers Disclosure Letter</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Article II</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Subsidiary</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(mm)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tax Return</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(nn)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Taxes</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(oo)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade Secrets</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(t)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Transfer Taxes</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.4(c)</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-v<br></div></div></div>
<!--End Page 532-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 533-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tANXB"><!--Anchor--></a>ASSET PURCHASE AGREEMENT</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">THIS ASSET PURCHASE AGREEMENT (this &#8220;<u>Agreement</u>&#8221;), dated as of December&#160;26, 2022, is by and among CATALYST BIOSCIENCES, INC., a Delaware corporation (&#8220;<u>Buyer</u>&#8221;), and GNI GROUP LTD., a company incorporated under the laws of Japan with limited liability, and GNI HONG KONG LIMITED, a company incorporated under the laws of Hong Kong with limited liability (each a &#8220;<u>Seller</u>&#8221; and together, the &#8220;<u>Sellers</u>&#8221;).</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; text-align: center;">RECITALS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">WHEREAS, the Sellers own the Purchased Assets (defined below);</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, the Sellers wish to sell to Buyer, and Buyer wishes to purchase from the Seller, the Purchased Assets, and in connection therewith Buyer is willing to assume certain liabilities and obligations of the Sellers relating thereto, all upon the terms and subject to the conditions set forth herein;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, substantially concurrently with the execution of this Agreement, the Buyer is entering into the BC Agreement;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, the board of directors of Buyer (the &#8220;<u>Buyer Board</u>&#8221;) has (i)&#160;unanimously approved this Agreement and determined that the transactions contemplated hereby are advisable and in the best interests of the stockholders of Buyer and (ii)&#160;resolved to recommend that the stockholders of Buyer approve (A) the transactions contemplated by the BC Agreement (the &#8220;<u>BC Transactions Proposal</u>&#8221;), (B) the conversion of the Buyer Convertible Preferred Stock into shares of Buyer Common Stock in accordance with Nasdaq Listing Rule 5635 (the &#8220;<u>Conversion </u><u>Proposal</u>&#8221;), and (C) if deemed necessary or appropriate by Buyer or as otherwise required by applicable Law or Contract, to authorize sufficient Buyer Common Stock in Buyer&#8217;s certificate of incorporation for the conversion of the Buyer Convertible Preferred Stock and/or to effectuate a reverse stock split (collectively, the &#8220;<u>Charter </u><u>Amendment Proposal</u>&#8221;), and (D) if deemed necessary or appropriate by the parties in order to effectuate the treatment of the Operating Company Options (as defined in the BC Agreement) as set forth in Section 1.5 of the BC Agreement or as otherwise required by applicable Law or Contract, an increase in the share reserve under Buyer&#8217;s 2018 Omnibus Incentive Plan (the &#8220;<u>Incentive Plan Proposal</u>&#8221; and, together with the BC Transactions Proposal, the Conversion Proposal and the Charter Amendment Proposal, the &#8220;<u>Buyer Stockholder Matters</u>&#8221;); and</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, Buyer and the Sellers each desire to make certain representations, warranties, covenants and agreements as specified herein.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; text-align: center;">AGREEMENT</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">NOW, THEREFORE, in consideration of the premises, and of the representations, warranties, covenants and agreements contained herein, and intending to be legally bound hereby, Buyer and the Sellers hereby agree as follows:</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; text-align: center;"><a name="tANXBA1"><!--Anchor--></a>ARTICLE I<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">PURCHASE AND SALE</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS11"><!--Anchor--></a>Section 1.1&#8195;<u>Purchase and Sale of Assets</u>. Upon the terms and subject to the conditions of this Agreement, at the Closing, the Sellers shall sell, assign, transfer, convey and deliver, or cause to be sold, assigned, transferred, conveyed and delivered, to Buyer, and Buyer, in reliance on the representations, warranties and covenants of the Sellers contained herein, shall purchase from the Sellers, all of the Sellers&#8217; right, title and interest, direct or indirect, in and to all assets, properties and rights of every nature, kind and description, whether tangible or intangible, real, personal or mixed, accrued or contingent (including goodwill) primarily related to the Compound or the Product, as the same shall exist on the Closing Date, other than the Excluded Assets (collectively, the &#8220;<u>Purchased Assets</u>&#8221;), in each case free and clear of any Encumbrances other than Permitted Encumbrances, including all of the Sellers&#8217; right, title and interest in and to the following:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;(i)&#160;all Patents that are owned by the Sellers as of the Effective Time that disclose or claim the composition of matter, manufacture or use of, or are otherwise related to (A) the Compound, (B) any compound that is structurally similar to, or is a derivative or analog of, the Compound, (C) any compound that is an agonist of the Compound, (D) [***] of any compound described in clause (A), (B) or (C), or (E) a pharmaceutical product containing or comprising any of the foregoing, including the Patents set forth on <u>Schedule 1.1(a)</u> and all Patent Families of such Patents (collectively, &#8220;<u>Purchased Patents</u>&#8221;); (ii)&#160;all legal rights entitled by the Sellers </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-1<br></div></div></div>
<!--End Page 533-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 534-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">to collect royalties under such Purchased Patents, to prosecute all existing Purchased Patents worldwide, to apply for additional Purchased Patents worldwide and to have Purchased Patents assigned and issued in the name of Buyer; and (iii)&#160;all right, title and interest the Sellers have to sue for past, present and future infringement of the Purchased Patents, including without limitation all right, title and interest the Sellers have in and to all causes of action and enforcement rights, whether known, unknown, currently pending, filed, or otherwise, in respect of the Purchased Patents, and all rights to pursue damages, injunctive relief and other remedies for past, current and future infringement of the Purchased Patents;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;all Trade Secrets that are primarily related to the Compound or the Product (&#8220;<u>Purchased Trade </u><u>Secrets</u>&#8221;);</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(c)&#8195;all Regulatory Materials forth on <u>Schedule 1.1(c)</u>;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;a copy of all Patent Files and all other technical books and records (including laboratory notebooks and electronic records) that are primarily related to the Purchased Patents, Purchased Trade Secrets, or Regulatory Materials; and</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(e)&#8195;the Contracts set forth on <u>Schedule 1.1(e)</u> (collectively, the &#8220;<u>Purchased Contracts</u>&#8221;).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS12"><!--Anchor--></a>Section 1.2&#8195;<u>Excluded Assets</u>. The Sellers are not selling, and Buyer is not purchasing, any of the following assets of the Sellers, all of which shall be retained by the Sellers (collectively, the &#8220;<u>Excluded Assets&#8221;):</u></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;all assets of the Sellers or any of their Affiliates that are not Purchased Assets (including, for the avoidance of doubt, all Tax assets), including overpayments of Taxes, claims for refunds, prepaid amounts or credits of the Sellers or any of their Affiliates related to the Purchased Assets for any taxable period (or portion thereof) ending on or prior to the Closing Date, and any other Tax assets of the Sellers and their Affiliates for any taxable period;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(b)&#8195;all rights of the Sellers under this Agreement and the Ancillary Agreements; and</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;all Patents (and any associated rights, titles or interests), Trade Secrets, Regulatory Materials, Inventory, Patent Files and Contracts existing or held for use in the People&#8217;s Republic of China.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS13"><!--Anchor--></a>Section 1.3&#8195;<u>Assumed Liabilities</u>. In connection with the purchase and sale of the Purchased Assets pursuant to this Agreement, subject to <u>Section 4.2</u>, at the Closing, Buyer shall assume and pay, discharge, perform or otherwise satisfy all liabilities accruing, arising out of or relating to ownership or use of the Purchased Assets from and after the Closing Date, whether known or unknown, express or implied, primarily or secondary, direct or indirect, absolute, accrued, contingent or otherwise and whether due or to become due, of Sellers arising out of, relating to or otherwise in respect of the Purchased Assets (the &#8220;<u>Assumed Liabilities&#8221;).</u></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS14"><!--Anchor--></a>Section 1.4&#8195;<u>Excluded Liabilities</u>. Notwithstanding any other provision of this Agreement to the contrary, Buyer is not assuming and Sellers shall pay, perform or otherwise satisfy, all liabilities other than the Assumed Liabilities (the &#8220;<u>Excluded Liabilities</u>&#8221;), including any liability or obligation relating to an Excluded Asset.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS15"><!--Anchor--></a>Section 1.5&#8195;<u>Consents and Waivers; Further Assurances.</u></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Nothing in this Agreement or the Ancillary Agreements shall be construed as an agreement to assign any Seller Contract, Permit, Right or other Purchased Asset that by its terms or pursuant to applicable Law is not capable of being sold, assigned, transferred or delivered without the consent or waiver of a third party or Governmental Authority unless and until such consent or waiver shall be given. The Sellers shall use their reasonable best efforts, and Buyer shall cooperate reasonably with the Sellers, to obtain such consents and waivers and to resolve the impediments to the sale, assignment, transfer or delivery contemplated by this Agreement or the Ancillary Agreements and to obtain any other consents and waivers necessary to convey to Buyer all of the Purchased Assets. If and when any such consents will be obtained after the consummation of the Closing, the Sellers will promptly assign their rights thereunder to Buyer without payment of consideration and Buyer will, without payment of any additional consideration, assume from and after the date of such assignment the obligations thereunder (but only the obligations of the Sellers thereunder arising exclusively from, and accruing exclusively with respect to, the period after the date of such assignment (other than obligations thereunder arising as a result of the breach thereof at or prior to such assignment)). In the event any such consents or waivers are not obtained prior to the Closing Date, the Sellers shall continue to use their reasonable best efforts to obtain the relevant consents or waivers until such consents or waivers are obtained, </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-2<br></div></div></div>
<!--End Page 534-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 535-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">and the Sellers will cooperate with Buyer in any lawful and economically feasible arrangement to provide that Buyer shall receive the interest of the Sellers in the benefits under any such Seller Contract, Permit, Right or other Purchased Asset, including performance by the Sellers, if economically feasible, as agent; <u>provided</u>, that Buyer shall undertake to pay or satisfy the corresponding liabilities for the enjoyment of such benefit to the extent Buyer would have been responsible therefor hereunder if such consents or waivers had been obtained.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;From time to time, whether before, at or following the Closing, the Sellers and Buyer shall execute, acknowledge and deliver all such further conveyances, notices, assumptions and releases and such other instruments, and shall take such further actions, as may be necessary or appropriate to assure fully to Buyer all of the properties, rights, titles, interests, estates, remedies, powers and privileges intended to be conveyed to Buyer under this Agreement and the Ancillary Agreements and to assure fully to the Sellers the assumption of the liabilities and obligations intended to be assumed by Buyer pursuant to this Agreement and the Ancillary Agreements, and to otherwise make effective as promptly as practicable the transactions contemplated hereby and thereby.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS16"><!--Anchor--></a>Section 1.6&#8195;<u>Consideration</u>. In full consideration for the sale, assignment, transfer, conveyance and delivery of the Purchased Assets to Buyer, at the Closing, Buyer shall (a) pay to the Sellers an aggregate payment of $35,000,000 (the &#8220;<u>Purchase Price</u>&#8221;) through the issuance of Buyer Common Stock and Buyer Convertible Preferred Stock to the Sellers as set forth below and (b) assume the Assumed Liabilities. No later than 21 days after the Closing Date, Buyer shall issue (or cause to be issued) an aggregate number of book-entry shares (or certificates, if requested) to the Sellers (as allocated between the Sellers on <u>Schedule 1.6</u>) as follows:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;6,266,521 shares of common stock, par value $0.001 per share, of Buyer (the &#8220;Buyer Common Stock&#8221;); and</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;12,340 shares of Series X Convertible Preferred Stock, par value $0.001 per share, of Buyer (the &#8220;<u>Buyer Convertible Preferred Stock</u>&#8221;).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS17"><!--Anchor--></a>Section 1.7&#8195;<u>Closing</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The sale and purchase of the Purchased Assets and the assumption of the Assumed Liabilities contemplated by this Agreement shall take place at a closing (the &#8220;<u>Closing</u>&#8221;) on the date of this Agreement, or at such other date, time or place as agreed to in writing by Buyer and the Sellers, at the offices of Gibson, Dunn &amp; Crutcher LLP, 555 Mission Street, San Francisco, CA 94105; provided, that the Closing may occur remotely via electronic exchange of required Closing documentation in lieu of an in-person Closing, and the parties shall cooperate in connection therewith. The date on which the Closing occurs is referred to in this Agreement as the &#8220;<u>Closing Date</u>.&#8221; All transactions contemplated herein to occur on and as of the Closing Date shall be deemed to have occurred simultaneously and to be effective as of 12:01 a.m. on the Closing Date (the &#8220;<u>Effective Time</u>&#8221;).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;At the Closing, the Sellers shall deliver or cause to be delivered to Buyer the following documents:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(i)&#8195;a bill of sale for the Purchased Assets, in the form of <u>Exhibit A</u> (the &#8220;<u>Bill of Sale</u>&#8221;), duly executed by the Sellers;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(ii)&#8195;an instrument of assignment of Purchased Intellectual Property, in the form of <u>Exhibit B</u> (the &#8220;<u>Assignment of Intellectual Property</u>&#8221; ), duly executed by the Sellers;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iii)&#8195;certified resolutions of the Board of Directors of the Sellers authorizing the transactions contemplated by this Agreement and the Ancillary Agreements;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(iv)&#8195;the Regulatory Materials;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(v)&#8195;evidence, reasonably satisfactory to Buyer, as to the third party consents and waivers referred to in <u>Schedule 1.7(b)(v)</u>; and</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(vi)&#8195;such other bills of sale, assignments and other instruments of assignment, transfer or conveyance, in form and substance reasonably satisfactory to Buyer, as Buyer may reasonably request or as may be otherwise necessary or desirable to evidence and effect the sale, assignment, transfer, conveyance and delivery of the Purchased Assets to Buyer and to put Buyer in actual possession or control of the Purchased Assets, duly executed by the Sellers.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-3<br></div></div></div>
<!--End Page 535-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 536-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;At the Closing, Buyer shall deliver or cause to be delivered to the Sellers the following documents:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(i)&#8195;evidence that the shares of Buyer Common Stock issuable to the Sellers as provided for in this <u>Article I</u> shall have been approved for listing on the Nasdaq, subject to official notice of issuance and <u>Section 1.6</u>; and</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(ii)&#8195;certified resolutions of the Board of Directors of the Buyer authorizing the transactions contemplated by this Agreement and the Ancillary Agreements.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS18"><!--Anchor--></a>Section 1.8&#8195;<u>Buyer Directors</u>. The parties shall take all action necessary (including, to the extent necessary, procuring the resignation or removal of any directors on the Buyer Board immediately prior to the Effective Time) so that, as of immediately after the Effective Time, the number of directors that comprise the full Buyer Board shall be five (5), and such Board of Directors shall immediately after the Effective Time initially consist of the individuals listed in <u>Schedule 1.8</u>, who shall serve in such capacity in accordance with the terms of the governing documents of Buyer following the Closing.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS19"><!--Anchor--></a>Section 1.9&#8195;<u>Withholding Rights</u>. Buyer shall be entitled to deduct and withhold, or cause to be deducted and withheld, from any amount payable to the Sellers such amounts that are required to be deducted or withheld therefrom in respect of any U.S. federal, state, or local or non-U.S. tax Law; provided, however, that (i)&#160;Buyer shall not, absent a change in Law after the date hereof, deduct or withhold from any amount payable to Sellers in respect of any non-U.S. Tax Law and (ii)&#160;Buyer shall give notice to the applicable payee before effecting any such Tax withholding, and cooperate with the applicable payee to minimize any required deduction and withholding. To the extent such amounts are so deducted or withheld and remitted to the applicable Governmental Entity, such amounts shall be treated for all purposes under this Agreement as having been paid to the Person to whom such amounts would otherwise have been paid.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; text-align: center;"><a name="tANXBA2"><!--Anchor--></a>ARTICLE II<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">REPRESENTATIONS AND WARRANTIES OF THE SELLERS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Except as set forth in the corresponding section or subsection of the disclosure letter delivered by the Sellers to Buyer immediately prior to the execution of this Agreement (the &#8220;<u>Sellers Disclosure Letter</u>&#8221;) (it being agreed that the disclosure of any information in a particular section or subsection of the Sellers Disclosure Letter shall be deemed disclosure of such information with respect to any other section or subsection of this Agreement to which the relevance of such information is reasonably apparent), each Seller represents and warrants to Buyer as follows:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS21"><!--Anchor--></a>Section 2.1&#8195;<u>Organization, Standing and Power</u>. The Seller (i)&#160;is an entity duly organized, validly existing and in good standing under the Laws of the jurisdiction of its organization, (ii)&#160;has all requisite power and authority to own, lease and operate the Purchased Assets as now being conducted and (iii)&#160;is duly qualified or licensed to do business and is in good standing in each jurisdiction in which the nature of its business or the ownership, leasing or operation of the Purchased Assets makes such qualification or licensing necessary, except in the case of clause (iii), where the failure to be so qualified or licensed or in good standing, individually or in the aggregate, has not had and would not reasonably be expected to have a Seller Material Adverse Effect. For purposes of this Agreement, &#8220;<u>Seller </u><u>Material Adverse Effect</u>&#8221; means any event, change, circumstance, occurrence, effect or state of facts that (A) is or would reasonably be expected to be materially adverse to the Purchased Assets, taken as a whole or (B) materially impairs the ability of the Seller to consummate any of the transactions contemplated by this Agreement and each Ancillary Agreements to which it will be a party; provided, however, that in the case of clause (A) only, Seller Material Adverse Effect shall not include any event, change, circumstance, occurrence, effect or state of facts to the extent resulting from (1) changes or conditions generally affecting the biopharmaceutical, or the economy or the financial, debt, banking, capital, credit or securities markets, in the United States, including effects on such industries, economy or markets resulting from any regulatory and political conditions or developments in general, (2) the outbreak or escalation of war or acts of terrorism or any natural disasters, acts of God or comparable events, epidemic, pandemic or disease outbreak (including the COVID-19 virus) or any worsening of the foregoing or any declaration of martial law, quarantine or similar directive, policy or guidance or Law or other action by any Governmental Entity in response thereto, (3) changes in Law (as defined below) or generally accepted accounting principles in the United States (&#8220;<u>GAAP</u>&#8221;), or the interpretation or enforcement thereof, (4) the public announcement of this Agreement, or (5) any specific action taken (or omitted to be taken) by the Seller at or with the express written consent of Buyer; provided, that, with respect to clauses (1), (2) and (3), the impact of such event, change, circumstance, occurrence, effect or state of facts is not disproportionately adverse to the Purchased Assets, taken as a whole, as compared to similarly-situated companies or businesses.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-4<br></div></div></div>
<!--End Page 536-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 537-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS22"><!--Anchor--></a>Section 2.2&#8195;<u>Authority</u>. The Seller has all necessary power and authority to execute, deliver and perform its obligations under this Agreement and each Ancillary Agreements to which it will be a party and to consummate the transactions contemplated hereby and thereby. The execution, delivery and performance by the Seller of this Agreement and each Ancillary Agreements to which it will be a party and the consummation by the Seller of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Seller and no other proceedings on the part of the Seller are necessary to approve this Agreement and each Ancillary Agreements to which it will be a party or to consummate the transactions contemplated hereby and thereby. This Agreement has been, and upon their execution each Ancillary Agreements to which the Seller will be a party have been, duly executed and delivered by the Seller and, assuming the due authorization, execution and delivery by each of the other parties hereto and thereto, this Agreement constitutes, and upon their execution each Ancillary Agreements to which the Seller is a party will constitute, valid and binding obligations of the Seller, enforceable against the Seller in accordance with their respective terms (except to the extent that enforceability may be limited by applicable bankruptcy, insolvency, moratorium, reorganization or similar Laws affecting the enforcement of creditors&#8217; rights generally or by general principles of equity).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS23"><!--Anchor--></a>Section 2.3&#8195;<u>No Conflict; Consents and Approvals</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The execution, delivery and performance by the Seller of this Agreement and each Ancillary Agreements to which it will be a party, and the consummation of the transactions contemplated hereby and thereby, do not and will not:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(i)&#8195;conflict with or violate the certificate of incorporation or bylaws or equivalent organizational documents of the Seller;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(ii)&#8195;conflict with or violate any federal, state, local or foreign law (including common law), statute, ordinance, rule, code, regulation, order, judgment, injunction, decree or other legally enforceable requirement (&#8220;<u>Law</u>&#8221;) applicable to the Seller or any of the Purchased Assets or by which the Seller or any of the Purchased Assets may be bound or affected; or</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iii)&#8195;result in any breach of, constitute a default (or an event that, with notice or lapse of time or both, would become a default) under, require any consent of or notice to any Person pursuant to, give to others any right of termination, amendment, modification, acceleration or cancellation of, allow the imposition of any fees or penalties, require the offering or making of any payment or redemption, give rise to any increased, guaranteed, accelerated or additional rights or entitlements of any Person or otherwise adversely affect any rights of the Seller under, or result in the creation of any Encumbrance on any of the Purchased Assets pursuant to, any material bond, debenture, note, mortgage, indenture, guarantee, license, lease, purchase or sale order or other contract, commitment, agreement, instrument, obligation, arrangement, understanding, undertaking, Permit, concession or franchise, whether oral or written (each, including all amendments thereto, a &#8220;<u>Contract</u>&#8221;) to which the Seller is a party or by which the Seller or the Purchased Assets may be bound or affected.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;No consent, approval, order or authorization of, or registration, declaration, filing with or notice to, any federal, state, local or foreign government or subdivision thereof or any other governmental, administrative, judicial, arbitral, legislative, executive, regulatory or self-regulatory authority, instrumentality, agency, commission or body (each, a &#8220;<u>Governmental Entity</u>&#8221;) is required by or with respect to the Seller in connection with the execution, delivery and performance by the Seller of this Agreement and each Ancillary Agreements to which it will be a party or the consummation by the Seller of the transactions contemplated hereby or thereby or compliance with the provisions hereof or in order to prevent the termination of any right, privilege, license or qualification of or affecting the Purchased Assets, except for (i)&#160;the filing with the SEC of such reports under Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;<u>Exchange Act</u>&#8221;), as may be required in connection with this Agreement and the transactions contemplated hereby, (ii)&#160;such other filings and reports as may be required pursuant to the applicable requirements of the Securities Act of 1933, as amended (the &#8220;<u>Securities Act</u>&#8221;), the Exchange Act and any other applicable state or federal securities, takeover and &#8220;blue sky&#8221; laws, and (iii)&#160;such other consents, approvals, orders, authorizations, registrations, declarations, filings or notices the failure of which to be obtained or made would not be material to the Seller.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-5<br></div></div></div>
<!--End Page 537-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 538-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS24"><!--Anchor--></a>Section 2.4&#8195;<u>Purchased Assets</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The Seller has good, valid, and marketable title to or a valid leasehold interest in the Purchased Assets it holds, free and clear of any Encumbrance, other than Permitted Encumbrances.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The Purchased Assets constitute all of the assets of the Seller and of its Affiliates primarily related to the Compound and the Products, with the exception of those assets existing or held for use in the People&#8217;s Republic of China.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;The delivery to the Buyer of the Bill of Sale and other instruments of assignment, conveyance and transfer pursuant to this Agreement and the Ancillary Agreements will transfer to the Buyer good, valid and marketable title to or a valid leasehold interest in all of the Purchased Assets, free and clear of any Encumbrance other than Permitted Encumbrances.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;The Seller has not marketed, commercialized, distributed, or sold any of the Products at any time prior to the Closing Date.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS25"><!--Anchor--></a>Section 2.5&#8195;<u>Absence of Certain Changes or Events</u>. During the past twelve (12) months and at the Closing Date: (a) there has not been any change, event or development or prospective change, event or development that, individually or in the aggregate, has had or is reasonably likely to have a Seller Material Adverse Effect on the Purchased Assets and (b) the Purchased Assets have not suffered any loss, damage, destruction or other casualty affecting any material properties or assets thereof or included therein, whether or not covered by insurance.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS26"><!--Anchor--></a>Section 2.6&#8195;<u>Litigation</u>. There is no action, suit, claim, arbitration, investigation, inquiry, grievance or other proceeding (each, an &#8220;<u>Action</u>&#8221;) (or basis therefor) pending or, to the knowledge of the Seller, threatened in connection with the Purchased Assets or the Seller&#8217;s ownership or operation thereof. There is no Action pending or, to the knowledge of the Seller, threatened seeking to prevent, hinder, modify, delay or challenge the transactions contemplated by this Agreement or the Ancillary Agreements. There is no outstanding order, writ, judgment, injunction, decree, determination or award of, or pending or, to the knowledge of the Seller, threatened investigation by any Governmental Authority relating to the Purchased Assets, the Seller&#8217;s ownership or operation thereof or the transactions contemplated by this Agreement or the Ancillary Agreements. There is no Action by the Seller pending, or which the Seller has commenced preparations to initiate, against any other Person in connection with the Purchased Assets.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS27"><!--Anchor--></a>Section 2.7&#8195;<u>Compliance with Laws; Permits</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The Seller is and has been in compliance in all material respects with all Laws applicable to the Seller in connection with the ownership or use of the Purchased Assets. The Seller has not received during the past three (3) years a notice or other written communication from any Governmental Authority or any other Person that the Seller is not in compliance in all material respects with any such Laws.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The Seller has in effect all material permits, licenses, variances, exemptions, applications, approvals, clearances, authorizations, registrations, formulary listings, consents, operating certificates, franchises, orders and approvals (collectively, &#8220;<u>Permits</u>&#8221;) of all Governmental Entities necessary or advisable for it to own, lease or operate the Purchased Assets in all material respects as now conducted. The Seller is and has been in compliance in all material respects with all such Permits. No suspension, cancellation, modification, revocation or nonrenewal of any Permit is pending or, to the knowledge of the Seller, threatened. All Permits may be transferred in accordance with applicable Law and assigned to Buyer.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS28"><!--Anchor--></a>Section 2.8&#8195;<u>Health Care Regulatory Matters</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The Seller, and to the knowledge of the Seller, each of its directors, officers, management employees, agents (while acting in such capacity), contract manufacturers, suppliers, and distributors are, and at all times prior hereto were, in material compliance with all Health Care Laws to the extent applicable to the Seller or any of its products or activities, including, but not limited to, the following: the Federal Food, Drug &amp; Cosmetic Act (&#8220;<u>FDCA</u>&#8221;); the Public Health Service Act (42 U.S.C. &#167; 201 et seq.), including the Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. &#167; 263a); the Federal Trade Commission Act (15 U.S.C. &#167; 41 et seq.); the Controlled Substances Act (21 U.S.C. &#167; 801 et seq.); the federal Anti-Kickback Statute (42 U.S.C. &#167; 1320a-7b(b)); the civil monetary penalties law (42 U.S.C. &#167; 1320a-7a); the civil False Claims Act (31 U.S.C. &#167; 3729 et seq.); the administrative False Claims Law (42 U.S.C. &#167; 1320a-7b(a)); the Stark law (42 U.S.C. &#167; 1395nn); the Criminal Health Care Fraud Statute (18 U.S.C. &#167; 1347); the Health Insurance Portability and </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-6<br></div></div></div>
<!--End Page 538-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 539-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">Accountability Act of 1996 (42 U.S.C. &#167; 1320d et seq.), as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. &#167; 17921 et seq.); the exclusion laws (42 U.S.C. &#167; 1320a-7); Medicare (Title XVIII of the Social Security Act); Medicaid (Title XIX of the Social Security Act); and the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (42 U.S.C. &#167; 18001 et seq.); any regulations promulgated pursuant to such Laws; and any other state, federal or ex-U.S. Laws, accreditation standards, or regulations governing the manufacturing, development, testing, labeling, advertising, marketing or distribution of biological or drug products, kickbacks, patient or program charges, record-keeping, claims process, documentation requirements, medical necessity, referrals, the hiring of employees or acquisition of services or supplies from those who have been excluded from government health care programs, quality, safety, privacy, security, licensure, accreditation or any other aspect of providing health care, clinical laboratory or diagnostic products or services (&#8220;<u>Health Care Laws</u>&#8221;). To the knowledge of the Seller, there are no facts or circumstances that reasonably would be expected to give rise to any material liability under any Health Care Laws.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The Seller is not party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any Governmental Entity.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;All applications, notifications, submissions, information, claims, reports and statistical analyses, and other data and conclusions derived therefrom, utilized as the basis for or submitted in connection with any and all requests for a Permit from the U.S. Food and Drug Administration (&#8220;<u>FDA</u>&#8221;) or other Governmental Entity relating to products that are regulated as drugs, medical devices, or other healthcare products under Health Care Laws, including biological and drug candidates, compounds or products being researched, tested, stored, developed, labeled, manufactured, packed and/or distributed by the Seller (&#8220;<u>Seller Products</u>&#8221;), including, without limitation, INDs, when submitted to the FDA or other Governmental Entity were true, complete and correct in all material respects as of the date of submission and any necessary or required updates, changes, corrections or modification to such applications, submissions, information and data have been submitted to the FDA or other Governmental Entity. The Seller does not have knowledge of any facts or circumstances that would be reasonably likely to lead to the revocation, suspension, limitation, or cancellation of a Permit required under Health Care Laws.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;All preclinical studies and clinical trials conducted by or, to the knowledge of the Seller, on behalf of the Seller have been, and if still pending are being, conducted in material compliance with research protocols and all applicable Health Care Laws, including, but not limited to, the FDCA and its applicable implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58, 312 and 314. No clinical trial conducted by or on behalf of the Seller has been conducted using any clinical investigators who have been disqualified, debarred or excluded from healthcare programs. No clinical trial conducted by or on behalf of the Seller has been terminated or suspended prior to completion, and no clinical investigator who has participated or is participating in, or institutional review board that has or has had jurisdiction over, a clinical trial conducted by or on behalf of the Seller has placed a partial or full clinical hold order on, or otherwise terminated, delayed or suspended, such a clinical trial at a clinical research site based on an actual or alleged lack of safety or efficacy of any Seller Product or a failure to conduct such clinical trial in compliance with applicable Health Care Laws, their implementing regulations and good clinical practices. The Seller has not identified or received notice of instances or allegations of research misconduct (defined as falsification or fabrication of data, or plagiarism, as those terms are defined in 42 C.F.R. Part 93) involving research conducted by, or on behalf of the Seller, that could compromise or affect the integrity, reliability, completeness, or accuracy of the data collected in such research, or the rights, safety, or welfare of the research subjects.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;All manufacturing operations conducted by or, to the knowledge of the Seller, for the benefit of the Seller have been and are being conducted in material compliance with all Permits under applicable Health Care Laws, all applicable provisions of the FDA&#8217;s current good manufacturing practice (cGMP) regulations for biological products at 21 C.F.R. Parts 600 and 610 and for drug products at 21 C.F.R. Parts 210-212 and all comparable foreign regulatory requirements of any Governmental Entity.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;The Seller has not received any written communication that relates to an alleged violation or noncompliance with any Health Care Laws, including any notification of any pending or threatened claim, suit, proceeding, hearing, enforcement, investigation, arbitration, import detention or refusal, FDA Warning Letter or </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-7<br></div></div></div>
<!--End Page 539-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 540-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">Untitled Letter, or any action by a Governmental Entity relating to any Health Care Laws. All Warning Letters, Form-483 observations, or comparable findings from other Governmental Entities listed in <u>Section 2.8</u> of the Seller Disclosure Letter have been resolved and closed out to the satisfaction of the applicable Governmental Entity.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;There have been no seizures, withdrawals, recalls, detentions, or suspensions of manufacturing, testing, or distribution relating to the Seller Products required or requested by a Governmental Entity, or other notice of action relating to an alleged lack of safety, efficacy, or regulatory compliance of the Seller Products, or any adverse experiences relating to the Seller Products that have been reported to FDA or other Governmental Entity (&#8220;<u>Seller Safety Notices</u>&#8221;), and, to the knowledge of the Seller, there are no facts or circumstances that reasonably would be expected to give rise to a Seller Safety Notice.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(h)&#8195;There are no unresolved Seller Safety Notices, and to the knowledge of the Seller, there are no facts that would be reasonably likely to result in a material Seller Safety Notice or a termination or suspension of developing and testing of any of the Seller Products.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(i)&#8195;Neither the Seller, nor, to the knowledge of the Seller, any officer, employee, agent, or distributor of the Seller has made an untrue statement of a material fact or fraudulent or misleading statement to a Governmental Entity, failed to disclose a material fact required to be disclosed to a Governmental Entity, or committed an act, made a statement, or failed to make a statement that would reasonably be expected to provide a basis for the FDA to invoke its policy respecting the &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy set forth in 56 Fed. Reg. 46191 (September&#160;10, 1991) and any amendments thereto (the &#8220;<u>FDA Ethics Policy</u>&#8221;). To the knowledge of the Seller, none of the aforementioned is or has been under investigation resulting from any allegedly untrue, fraudulent, misleading, or false statement or omission, including data fraud, or had any action pending or threatened relating to the FDA Ethics Policy.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(j)&#8195;All reports, documents, claims, Permits and notices required to be filed, maintained or furnished to the FDA or any Governmental Entity by the Seller have been so filed, maintained or furnished, except where failure to file, maintain or furnish such reports, documents, claims, Permits or notices has not had and would not reasonably be expected to have, individually or in the aggregate, a Seller Material Adverse Effect. All such reports, documents, claims, Permits and notices were true and complete in all material respects on the date filed (or were corrected in or supplemented by a subsequent filing).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(k)&#8195;Neither the Seller nor, to the knowledge of the Seller, any officer, employee, agent, or distributor of the Seller has committed any act, made any statement or failed to make any statement that violates the Federal Anti-Kickback Statute, 28 U.S.C. &#167; 1320a-7b, the Federal False Claims Act, 31 U.S.C. &#167; 3729, other drug or Health Care Laws, or any other similar federal, state, or ex-U.S. Law applicable in the jurisdictions in which the Seller Products are sold or intended to be sold.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(l)&#8195;Neither the Seller nor, to the knowledge of the Seller, any officer, employee, agent, or distributor of the Seller has been convicted of any crime or engaged in any conduct that has resulted, or would reasonably be expected to result, in debarment under applicable Law, including, without limitation, 21 U.S.C. &#167; 335a, or exclusion under 42 U.S.C. &#167; 1320a-7, or any other statutory provision or similar law applicable in other jurisdictions in which the Seller Products are sold or intended to be sold. Neither the Seller nor, to the knowledge of the Seller, any officer, employee, agent or distributor of the Seller, has been excluded from participation in any federal health care program or convicted of any crime or engaged in any conduct for which such Person could be excluded from participating in any federal health care program under Section 1128 of the Social Security Act of 1935, as amended, or any similar Health Care Law or program.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS29"><!--Anchor--></a>Section 2.9&#8195;<u>Taxes</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The Seller has timely filed all Tax Returns required to be filed with respect to the Purchased Assets it holds (taking into account any extension of time to file), and each such Tax Return has been prepared in compliance with all applicable Laws and regulations and is true, correct and complete in all material respects.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;All material Taxes due and payable with respect to the Purchased Assets (in each case whether or not shown on any Tax Return) have been timely paid in full.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;There are no Encumbrances for Taxes on any of the Purchased Assets, other than Permitted Encumbrances.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-8<br></div></div></div>
<!--End Page 540-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 541-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;No Action, suit, proceeding or audit or any notice of inquiry of any of the foregoing is pending against or with respect to the Purchased Assets regarding Taxes, and, to the knowledge of the Seller, no action, suit, proceeding or audit has been threatened against or with respect to the Purchased Assets regarding Taxes.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;The Seller has not executed any waiver of any statute of limitations on, or extended the period for the assessment or collection of, any Taxes on or with respect to the Purchased Assets.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;No deficiencies for a material amount of Taxes have been claimed, proposed, assessed or asserted in writing with respect to the Purchased Assets by a Governmental Entity, other than any such claim, proposal, assessment, or assertion that has been satisfied by payment in full, settled or withdrawn.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;No private-letter rulings, technical advice memoranda, or similar material written agreements with, or rulings from, a taxing authority have been requested in writing, entered into, or issued by any taxing authority specifically with respect to the taxation of the Purchased Assets which rulings will remain in effect after the Closing.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(h)&#8195;The Seller has not made an election on IRS Form 8832 to be treated as other than a C corporation for U.S. federal income tax purposes.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS210"><!--Anchor--></a>Section 2.10&#8195;<u>Contracts</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;As of the date of this Agreement, no Purchased Contracts would constitute a &#8220;material contract&#8221; (as such term is defined in Item 601(b)(10) of Regulation S-K under the Securities Act) of Buyer.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;(i)&#160;Each Purchased Contract is valid and binding on the Seller and to the knowledge of the Seller, each other party thereto, and is in full force and effect and enforceable in accordance with its terms; (ii)&#160;the Seller, and, to the knowledge of the Seller, each other party thereto, has performed all material obligations required to be performed by it under each Purchased Contract; and (iii)&#160;there is no material default under any Purchased Contract by the Seller or, to the knowledge of the Seller, any other party thereto, and no event or condition has occurred that constitutes, or, after notice or lapse of time or both, would constitute, a material default on the part of the Seller or, to the knowledge of the Seller, any other party thereto under any such Purchased Contract, nor has the Seller received any notice of any such material default, event or condition. The Seller has made available to Buyer true and complete copies of all Purchased Contracts, including all amendments thereto.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS211"><!--Anchor--></a>Section 2.11&#8195;<u>Intellectual Property</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;<u>Section 2.11</u> of the Sellers Disclosure Letter sets forth a true and complete list of all registered Marks, Patents and registered Copyrights included in the Purchased Intellectual Property (the &#8220;<u>Seller Registered IP</u>&#8221;). Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Seller Material Adverse Effect, (i)&#160;all of the Seller Registered IP is subsisting and, in the case of any Seller Registered IP that is registered or issued and to the knowledge of the Seller, valid and enforceable and (i)&#160;no Seller Registered IP is involved in any interference, reissue, derivation, reexamination, opposition, cancellation, or similar proceeding and, to the knowledge of the Seller, no such action is threatened with respect to any of the Seller Registered IP.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Except as would not be material, the Seller owns, licenses or otherwise has the right to use, free and clear of all Encumbrances except for Permitted Encumbrances, all of the Purchased Intellectual Property.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;The Seller has not received any notice or claim challenging its ownership of any of the material Purchased Intellectual Property, nor to the knowledge of the Seller is there a reasonable basis for any claim that it does not so own any of such Purchased Intellectual Property.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;The Seller has taken commercially reasonable steps to protect its rights in the material Purchased Trade Secrets and to protect and maintain the confidentiality thereof. No present or former employee, consultant or contractor of the Seller owns any right, title or interest in or to any material Purchased Intellectual Property.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;Except as would not be material, all registered Marks, issued Patents and registered Copyrights identified on <u>Section 2.11</u> of the Sellers Disclosure Letter (&#8220;<u>Purchased Registered IP</u>&#8221;) are valid and subsisting and, to the knowledge of the Seller, enforceable, and the Seller has not received any written notice or claim challenging the validity or enforceability of any Purchased Registered IP or alleging any misuse of such Purchased Registered IP.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-9<br></div></div></div>
<!--End Page 541-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 542-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Seller Material Adverse Effect, (i)&#160;to the knowledge of the Seller, the manufacture, marketing, offering for sale, sale, importation, use or intended use or other disposal of any Product, has not infringed, misappropriated or diluted, and does not infringe, misappropriate or dilute, any Intellectual Property of any Person, (ii)&#160;the Seller has not in the past three (3) years received any written notice or claim asserting or suggesting that any such infringement, misappropriation, or dilution is or may be occurring or has or may have occurred, and (iii)&#160;to the knowledge of the Seller, no Person is infringing, misappropriating, or diluting in any material respect any Company Registered IP.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;The Seller has not transferred ownership of, or granted any exclusive license with respect to, any material Purchased Intellectual Property. Upon the consummation of the Closing, the Buyer shall succeed to all of the Seller&#8217;s rights and interest in or under all material Purchased Intellectual Property.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(h)&#8195;Except as would not be material, the Seller (i)&#160;takes reasonable measures, directly or indirectly, designed to ensure the confidentiality, privacy and security of customer, employee and other confidential information in connection with the Purchased Assets and (ii)&#160;complies and has complied in all material respects with applicable data protection, privacy and similar Laws, directives and codes of practice in any jurisdiction relating to any data processed by the Seller.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS212"><!--Anchor--></a>Section 2.12&#8195;<u>Brokers</u>. No broker, investment banker, financial advisor or other Person is entitled to any broker&#8217;s, finder&#8217;s, financial advisor&#8217;s or other similar fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of the Sellers or any of their Affiliates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS213"><!--Anchor--></a>Section 2.13&#8195;<u>No Other Representations or Warranties</u>. Except for the representations and warranties contained in <u>Article III</u>, the Seller acknowledges and agrees that none of Buyer or any other Person on behalf of Buyer makes any other express or implied representation or warranty whatsoever, and specifically (but without limiting the generality of the foregoing) that none of Buyer, its Subsidiaries or any other Person on behalf of Buyer makes any representation or warranty with respect to any projections or forecasts delivered or made available to the Seller or any of its Representatives of future revenues, results of operations (or any component thereof), cash flows or financial condition (or any component thereof) of Buyer (including any such projections or forecasts made available to the Seller and Representatives in certain &#8220;data rooms&#8221; or management presentations in expectation of the transactions contemplated by this Agreement and the Ancillary Agreements), and the Seller has not relied on any such information or any representation or warranty not set forth in <u>Article III</u>.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; text-align: center;"><a name="tANXBA3"><!--Anchor--></a>ARTICLE III<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">REPRESENTATIONS AND WARRANTIES OF BUYER</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Except (a) as disclosed in the Buyer SEC Documents at least two (2) Business Days prior to the date of this Agreement and that is reasonably apparent on the face of such disclosure to be applicable to the representation and warranty set forth herein (other than any disclosures contained or referenced therein under the captions &#8220;Risk Factors,&#8221; &#8220;Forward-Looking Statements,&#8221; &#8220;Quantitative and Qualitative Disclosures About Market Risk,&#8221; and any other disclosures contained or referenced therein of information, factors, or risks that are predictive, cautionary, or forward-looking in nature); or (b) as set forth in the corresponding section or subsection of the disclosure letter delivered by Buyer to the Sellers immediately prior to the execution of this Agreement (the &#8220;<u>Buyer Disclosure </u><u>Letter</u>&#8221;) (it being agreed that the disclosure of any information in a particular section or subsection of the Buyer Disclosure Letter shall be deemed disclosure of such information with respect to any other section or subsection of this Agreement to which the relevance of such information is readily apparent on its face), Buyer represents and warrants to the Sellers as follows:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS31"><!--Anchor--></a>Section 3.1&#8195;<u>Organization, Standing and Power</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Buyer is a corporation duly organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation. Buyer (i)&#160;has all requisite corporate power and authority to own, lease and operate its properties and to carry on its business as now being conducted and (ii)&#160;is duly qualified or licensed to do business and is in good standing in each jurisdiction in which the nature of its business or the ownership, leasing or operation of its properties makes such qualification or licensing necessary, except in the case of clause (ii), where the failure to be so qualified or licensed or in good standing, individually or in the aggregate, has not had and would not reasonably be expected to have a Buyer Material Adverse Effect. For purposes of this Agreement, &#8220;<u>Buyer Material Adverse Effect</u>&#8221; means any event, change, circumstance, occurrence, effect or state </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-10<br></div></div></div>
<!--End Page 542-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 543-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">of facts that (A) is or would reasonably be expected to be materially adverse to the business, assets, liabilities, financial condition, or results of operations of Buyer and its Subsidiaries, taken as a whole, or (B) materially impairs the ability of Buyer to consummate the transactions contemplated by this Agreement and each Ancillary Agreements to which it will be a party; provided, however, that in the case of clause (A) only, Buyer Material Adverse Effect shall not include any event, change, circumstance, occurrence, effect or state of facts to the extent resulting from (1) changes or conditions generally affecting the industries in which Buyer and its Subsidiaries operate, or the economy or the financial, debt, banking, capital, credit or securities markets, in the United States, including effects on such industries, economy or markets resulting from any regulatory and political conditions or developments in general, (2) the outbreak or escalation of war or acts of terrorism or any natural disasters, acts of God or comparable events, epidemic, pandemic or disease outbreak (including the COVID-19 virus) or any worsening of the foregoing or any declaration of martial law, quarantine or similar directive, policy or guidance or Law or other action by any Governmental Entity in response thereto, (3) changes in Law or GAAP, or the interpretation or enforcement thereof, (4) the public announcement of this Agreement, or (5) any specific action taken (or omitted to be taken) by Buyer at or with the express written consent of the Sellers; provided, that, with respect to clauses (1), (2) and (3), the impact of such event, change, circumstance, occurrence, effect or state of facts is not disproportionately adverse to Buyer and its Subsidiaries, taken as a whole, as compared to other participants in the industries in which Buyer and its Subsidiaries operate.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Buyer has previously made available to the Sellers true and complete copies of its certificate of incorporation and bylaws, and the certificate of incorporation and bylaws (or comparable organizational documents) of each Subsidiary of Buyer, in each case, as amended to the date of this Agreement, and each as so delivered is in full force and effect. Buyer is not in violation of any provision of its certificate of incorporation or bylaws. Except with respect to the extent relating to the transactions contemplated by this Agreement and the Ancillary Agreements or in draft form and except as may be redacted to preserve a privilege (including attorney-client privilege), Buyer has made available to the Sellers true and complete copies of the minutes of all meetings (including any actions taken by written consent) of Buyer&#8217;s stockholders, the Buyer Board and each committee of the Buyer Board held since January&#160;1, 2020.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS32"><!--Anchor--></a>Section 3.2&#8195;<u>Capital Stock</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The authorized capital stock of Buyer consists of 100,000,000 shares of Buyer Common Stock and 5,000,000 shares of Buyer Convertible Preferred Stock. As of the close of business on September&#160;30, 2022 (the&#160;&#8220;<u>Measurement Date</u>&#8221;), (i) 31,490,053 shares of Buyer Common Stock (excluding treasury shares) were issued and outstanding, (ii)&#160;no shares of Buyer Common Stock were held by Buyer in its treasury, (iii)&#160;no shares of Buyer Convertible Preferred Stock were issued and outstanding, (iv)&#160;no shares of Buyer Convertible Preferred Stock were held by Buyer in its treasury, (v) 21,172,695 shares of Buyer Common Stock were reserved for issuance pursuant to Buyer&#8217;s 2018 Omnibus Incentive Plan, the Catalyst 2004 Plan Residual, the Catalyst 2015 Stock Incentive Plan and the Targacept 2006 Plan (of which 8,906,711 shares were subject to outstanding options to purchase shares of Buyer Common Stock (the &#8220;<u>Buyer Options</u>&#8221;)), (vi) 359,545 shares of Buyer Common Stock were reserved for issuance pursuant to Buyer&#8217;s 2018 Employee Stock Purchase Plan and (vii)&#160;no shares of Buyer Common Stock were reserved for issuance upon the exercise or conversion of warrants. Except as set forth above in this <u>Section 3.2(a)</u>, neither Buyer nor any of its Subsidiaries has outstanding any bonds, debentures, notes or other obligations having the right to vote (or convertible into, or exchangeable or exercisable for, securities having the right to vote) with the stockholders of Buyer or such Subsidiary on any matter. Except as set forth above in this <u>Section 3.2(a)</u> and except for changes since the close of business on the Measurement Date resulting from the exercise of any Buyer Options as described above, as of the Measurement Date, there are no outstanding (A) shares of capital stock or other voting securities or equity interests of Buyer, (B) securities of Buyer or any of its Subsidiaries convertible into or exchangeable or exercisable for shares of capital stock of Buyer or other voting securities or equity interests of Buyer or its Subsidiaries, (C) stock appreciation rights, &#8220;phantom&#8221; stock rights, performance units, interests in or rights to the ownership or earnings of Buyer or its Subsidiaries or other equity-equivalent or equity-based awards or rights, (D)&#160;subscriptions, options, warrants, calls, commitments, Contracts or other rights to acquire from Buyer or its Subsidiaries, or obligations of Buyer or any of its Subsidiaries to issue, any shares of capital stock of Buyer or any of its Subsidiaries, voting securities, equity interests or securities convertible into or exchangeable or </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-11<br></div></div></div>
<!--End Page 543-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 544-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">exercisable for capital stock or other voting securities or equity interests of Buyer or its Subsidiaries or rights or interests described in the preceding clause (C), or (E) obligations of Buyer or any of its Subsidiaries to repurchase, redeem or otherwise acquire any such securities or to issue, grant, deliver or sell, or cause to be issued, granted, delivered or sold, any such securities.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;<u>Section 3.2(b)</u> of the Buyer Disclosure Letter sets forth a true and complete list of all holders of rights to purchase or receive shares of Buyer Common Stock or similar rights (collectively, &#8220;<u>Buyer Stock Awards</u>&#8221;), indicating as applicable, with respect to each Buyer Stock Award then outstanding, the type of award, the number of shares of Buyer Common Stock subject to such Buyer Stock Award, the name of the plan under which such Buyer Stock Award was granted, the date of grant, exercise or purchase price, vesting schedule, payment schedule (if different from the vesting schedule) and expiration thereof, and whether (and to what extent) the vesting of such Buyer Stock Award will be accelerated or otherwise adjusted in any way or any other terms will be triggered or otherwise adjusted in any way by the consummation of the transactions contemplated by this Agreement and the Ancillary Agreements or by the termination of employment or engagement or change in position of any holder thereof following or in connection with the transactions contemplated by this Agreement and the Ancillary Agreements. Each Buyer Option was granted with a per share exercise price that is no less than the fair market value of a share of Buyer Common Stock on the date such Buyer Option was granted and is exempt from the requirements of Section 409A of the Code. Buyer has made available to the Sellers a true and complete copy of the forms of all award agreements evidencing outstanding Buyer Stock Awards.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;The shares of Buyer Capital Stock to be issued pursuant to this Agreement will be duly authorized, validly issued, fully paid and nonassessable and not subject to any preemptive rights.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;To the knowledge of Buyer as of the date of this Agreement and as of the Closing, no &#8220;bad actor&#8221; disqualifying event described in Rule 506(d)(1)(i)-(viii)&#160;of the Securities Act (a &#8220;<u>Disqualifying Event</u>&#8221;) is applicable to Buyer or, to Buyer&#8217;s knowledge, any Covered Person, except for a Disqualifying Event as to which Rule 506(d)(2)(ii-iv) or (d)(3) of the Securities Act is applicable. &#8220;<u>Covered Person</u>&#8221; means, with respect to Buyer as an &#8220;issuer&#8221; for purposes of Rule 506 promulgated under the Securities Act, any person listed in the first paragraph of Rule 506(d)(1).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS33"><!--Anchor--></a>Section 3.3&#8195;<u>Subsidiaries</u>. <u>Section 3.3</u> of the Buyer Disclosure Letter sets forth a true and complete list of each Subsidiary of Buyer, including its jurisdiction of incorporation or formation. Each of Buyer&#8217;s Subsidiaries (i)&#160;is an entity duly organized, validly existing and in good standing under the Laws of the jurisdiction of its organization, (ii)&#160;has all requisite corporate or similar power and authority to own, lease and operate its properties and to carry on its business as now being conducted and (iii)&#160;is duly qualified or licensed to do business and is in good standing in each jurisdiction in which the nature of its business or the ownership, leasing or operation of its properties makes such qualification or licensing necessary, except in the case of clause (iii), where the failure to be so qualified or licensed or in good standing, individually or in the aggregate, has not had and would not reasonably be expected to have a Buyer Material Adverse Effect. All outstanding shares of capital stock and other voting securities or equity interests of each such Subsidiary are owned, directly or indirectly, by Buyer, free and clear of all Encumbrances other than Permitted Encumbrances. Except for the capital stock of, or other equity or voting interests in, its Subsidiaries, Buyer does not own, directly or indirectly, any equity, membership interest, partnership interest, joint venture interest, or other equity or voting interest in, or any interest convertible into, exercisable or exchangeable for any of the foregoing, nor is it under any current or prospective obligation to form or participate in, provide funds to, make any loan, capital contribution, guarantee, credit enhancement or other investment in, or assume any liability or obligation of, any Person.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS34"><!--Anchor--></a>Section 3.4&#8195;<u>Authority</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Buyer has all necessary power and authority to execute, deliver and perform its obligations under this Agreement and each Ancillary Agreements to which it will be a party and to consummate the transactions contemplated hereby and thereby, including the issuance of the shares of Buyer Capital Stock to the Sellers in satisfaction of the Purchase Price (the &#8220;<u>Buyer Capital Stock Issuance</u>&#8221;). The execution, delivery and performance of this Agreement and each Ancillary Agreements to which it will be a party by Buyer and the consummation by Buyer of the transactions contemplated hereby and thereby have been duly authorized by all necessary corporate action on the part of Buyer and no other corporate proceedings on the part of Buyer are necessary to approve this Agreement and the Ancillary Agreements or to consummate the transactions contemplated hereby and thereby, subject, in the case of the Buyer Stockholder Matters, to the approval by the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-12<br></div></div></div>
<!--End Page 544-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 545-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">holders of Buyer Common Stock in accordance with requirements of applicable Law and Nasdaq rules and regulations (the &#8220;<u>Buyer Stockholder Approval</u>&#8221;). This Agreement has been, and the Ancillary Agreements to which Buyer will be a party will have been, duly executed and delivered by Buyer and, assuming the due authorization, execution and delivery by each of the other parties hereto and thereto, constitutes, and upon their execution each Ancillary Agreements to which Buyer will be a party will constitute, a valid and binding obligation of Buyer, enforceable against Buyer in accordance with their respective terms (except to the extent that enforceability may be limited by applicable bankruptcy, insolvency, moratorium, reorganization or similar Laws affecting the enforcement of creditors&#8217; rights generally or by general principles of equity).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The Buyer Board, at a meeting duly called and held at which all directors of Buyer were present, duly adopted resolutions (i)&#160;determining that the terms of this Agreement, the Ancillary Agreements to which Buyer will be a party, and the transactions contemplated hereby and thereby are fair to and in the best interests of Buyer and its stockholders, and (ii)&#160;approving and declaring advisable this Agreement, the Ancillary Agreements to which Buyer will be a party and the transactions contemplated hereby and thereby, which resolutions have not been subsequently rescinded, modified or withdrawn in any way.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;The Buyer Stockholder Approval is the only vote of the holders of any class or series of the Buyer Capital Stock or other securities required in connection with the consummation of the transactions contemplated hereby, including the Buyer Capital Stock Issuance. Other than the Buyer Stockholder Approval, no vote of the holders of any class or series of the Buyer&#8217;s Capital Stock or other securities is required in connection with the consummation of any of the transactions contemplated hereby to be consummated by Buyer.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS35"><!--Anchor--></a>Section 3.5&#8195;<u>No Conflict; Consents and Approvals</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The execution, delivery and performance by Buyer of this Agreement and each Ancillary Agreements to which Buyer will be a party does not, and the consummation of the transactions contemplated hereby and thereby and compliance by Buyer with the provisions hereof and thereof will not, conflict with, or result in any violation or breach of, or default (with or without notice or lapse of time, or both) under, or give rise to a right of, or result in, termination, cancellation, modification or acceleration of any obligation or to the loss of a benefit under, or result in the creation of any Encumbrance in or upon any of the properties, assets or rights of Buyer under, or give rise to any increased, additional, accelerated or guaranteed rights or entitlements under, or require any consent, waiver or approval of any Person pursuant to, any provision of (i)&#160;the certificate of incorporation or bylaws of Buyer, (ii)&#160;any material Contract to which Buyer is a party by which Buyer or any of its properties or assets may be bound, or (iii)&#160;subject to the governmental filings and other matters referred to in <u>Section 2.3</u>, any material Law or any rule or regulation of Nasdaq applicable to Buyer or by which Buyer or any of its properties or assets may be bound, except, in the case of clauses (ii)&#160;and (iii), as individually or in the aggregate, has not had and would not reasonably be expected to have a Buyer Material Adverse Effect.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;No consent, approval, order or authorization of, or registration, declaration, filing with or notice to, any Governmental Entity is required by or with respect to Buyer in connection with the execution, delivery and performance by Buyer of this Agreement and the Ancillary Agreements to which Buyer will be a party or the consummation by Buyer of the transactions contemplated hereby and thereby or compliance with the provisions hereof and thereof, except for (i)&#160;the filing with the SEC of such reports under Section 13(a) or 15(d) of the Exchange Act, as may be required in connection with this Agreement and the Ancillary Agreements and the transactions contemplated hereby and thereby, (ii)&#160;such other filings and reports as may be required pursuant to the applicable requirements of the Securities Act, the Exchange Act and any other applicable state or federal securities, takeover and &#8220;blue sky&#8221; laws, and (iii)&#160;such other consents, approvals, orders, authorizations, registrations, declarations, filings or notices, the failure of which to be obtained or made would not be material to Buyer.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS36"><!--Anchor--></a>Section 3.6&#8195;<u>SEC Reports; Financial Statements</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Buyer has filed with or furnished to the SEC on a timely basis true and complete copies of all forms, reports, schedules, statements and other documents required to be filed with or furnished to the SEC by Buyer since January&#160;1, 2021 (all such documents, together with all exhibits and schedules to the foregoing materials and all information incorporated therein by reference, the &#8220;<u>Buyer SEC Documents</u>&#8221;). As of their respective filing dates (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), the Buyer SEC Documents complied in all material respects with the applicable requirements of the Securities Act, the Exchange Act and the Sarbanes-Oxley Act of 2002 (the &#8220;<u>Sarbanes-Oxley Act</u>&#8221;), as the case </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-13<br></div></div></div>
<!--End Page 545-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 546-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg20"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">may be, including, in each case, the rules and regulations promulgated thereunder, and none of the Buyer SEC&#160;Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The financial statements (including the related notes and schedules thereto) included (or incorporated by reference) in the Buyer SEC Documents (i)&#160;have been prepared in a manner consistent with the books and records of Buyer and its Subsidiaries, (ii)&#160;have been prepared in accordance with GAAP (except, in the case of unaudited statements, as permitted by Form 10-Q of the SEC) applied on a consistent basis during the periods involved (except as may be indicated in the notes thereto), (iii)&#160;comply as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto and (iv)&#160;fairly present in all material respects the consolidated financial position of Buyer and its Subsidiaries as of the dates thereof and their respective consolidated results of operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal and recurring year-end audit adjustments that were not, or are not expected to be, material in amount), all in accordance with GAAP and the applicable rules and regulations promulgated by the SEC. Since January&#160;1, 2021, Buyer has not made any change in the accounting practices or policies applied in the preparation of its financial statements, except as required by GAAP, SEC rule or policy or applicable Law. The books and records of Buyer and its Subsidiaries have been, and are being, maintained in all material respects in accordance with GAAP (to the extent applicable) and any other applicable legal and accounting requirements and reflect only actual transactions.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;Buyer has established and maintains disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Such disclosure controls and procedures are designed to ensure that information relating to Buyer, including its consolidated Subsidiaries, required to be disclosed in Buyer&#8217;s periodic and current reports under the Exchange Act, is made known to Buyer&#8217;s chief executive officer and its chief financial officer by others within those entities to allow timely decisions regarding required disclosures as required under the Exchange Act. The chief executive officer and chief financial officer of Buyer have evaluated the effectiveness of Buyer&#8217;s disclosure controls and procedures and, to the extent required by applicable Law, presented in any applicable Buyer SEC Document that is a report on Form 10-K or Form 10-Q, or any amendment thereto, its conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by such report or amendment based on such evaluation.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;Buyer and its Subsidiaries have established and maintain a system of internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) which is effective in providing reasonable assurance regarding the reliability of Buyer&#8217;s financial reporting and the preparation of Buyer&#8217;s financial statements for external purposes in accordance with GAAP. Buyer has disclosed, based on its most recent evaluation of Buyer&#8217;s internal control over financial reporting prior to the date hereof, to Buyer&#8217;s auditors and audit committee (i)&#160;any significant deficiencies and material weaknesses in the design or operation of Buyer&#8217;s internal control over financial reporting which are reasonably likely to adversely affect Buyer&#8217;s ability to record, process, summarize and report financial information and (ii)&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in Buyer&#8217;s internal control over financial reporting. A true, correct and complete summary of any such disclosures made by management to Buyer&#8217;s auditors and audit committee is set forth as <u>Section 3.6(d)</u> of the Buyer Disclosure Letter.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;Since January&#160;1, 2021, (i)&#160;neither Buyer nor any of its Subsidiaries nor, to the knowledge of Buyer, any director, officer, employee, auditor, accountant or Representative of Buyer or any of its Subsidiaries has received or otherwise had or obtained knowledge of any material complaint, allegation, assertion or claim, whether written or oral, regarding the accounting or auditing practices, procedures, methodologies or methods of Buyer or any of its Subsidiaries or their respective internal accounting controls, including any material complaint, allegation, assertion or claim that Buyer or any of its Subsidiaries has engaged in questionable accounting or auditing practices and (ii)&#160;no attorney representing Buyer or any of its Subsidiaries, whether or not employed by Buyer or any of its Subsidiaries, has reported evidence of a material violation of securities Laws, breach of fiduciary duty or similar violation by Buyer or any of its Subsidiaries or any of their respective officers, directors, employees or agents to the Buyer Board or any committee thereof or to any director or officer of Buyer or any of its Subsidiaries.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-14<br></div></div></div>
<!--End Page 546-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 547-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg21"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;As of the date of this Agreement, there are no outstanding or unresolved comments in the comment letters received from the SEC staff with respect to the Buyer SEC Documents. To the knowledge of Buyer, none of the Buyer SEC Documents is subject to ongoing review or outstanding SEC comment or investigation.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;Neither Buyer nor any of its Subsidiaries is a party to, or has any commitment to become a party to, any joint venture, off-balance sheet partnership or any similar Contract (including any Contract or arrangement relating to any transaction or relationship between or among Buyer and any of its Subsidiaries, on the one hand, and any unconsolidated Affiliate, including any structured finance, special-purpose or limited-purpose entity or Person, on the other hand, or any &#8220;off balance sheet arrangements&#8221; (as defined in Item 303(a) of Regulation S-K under the Securities Act)), where the result, purpose or intended effect of such Contract is to avoid disclosure of any material transaction involving, or material liabilities of, Buyer or any of its Subsidiaries in Buyer&#8217;s or such Subsidiary&#8217;s published financial statements or other Buyer SEC Documents.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(h)&#8195;Buyer is in compliance in all material respects with (i)&#160;the provisions of the Sarbanes-Oxley Act and (ii)&#160;the rules and regulations of Nasdaq, in each case, that are applicable to Buyer.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(i)&#8195;No Subsidiary of Buyer is required to file any form, report, schedule, statement or other document with the SEC.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(j)&#8195;Buyer has not been and is not currently a &#8220;shell company&#8221; as defined under Section 12b-2 of the Exchange Act.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(k)&#8195;Buyer is, and since its first date of listing on Nasdaq has been, in compliance in all material respects with the applicable current listing and governance rules and regulations of Nasdaq.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS37"><!--Anchor--></a>Section 3.7&#8195;<u>No Undisclosed Liabilities</u>. Neither Buyer nor any of its Subsidiaries has any liabilities or obligations of any nature, whether accrued, absolute, contingent or otherwise, known or unknown, whether due or to become due and whether or not required to be recorded or reflected on a balance sheet under GAAP, except (a)&#160;to the extent accrued or reserved against in the audited consolidated balance sheet of Buyer and its Subsidiaries as at December&#160;31, 2021 included in the Annual Report on Form 10-K filed by Buyer with the SEC on March&#160;31, 2022 (without giving effect to any amendment thereto filed on or after the date hereof) and (b) for liabilities and obligations incurred in the ordinary course of business consistent with past practice since December&#160;31, 2021 that are not material to Buyer and its Subsidiaries, taken as a whole. Buyer has not applied for or received any funds or incurred any indebtedness pursuant to the Coronavirus Aid, Relief, and Economic Security Act (P.L. 116-136), enacted March&#160;27,&#160;2020 or any other economic relief or stimulus legislation or program, or otherwise received any funds or incurred any indebtedness from any Governmental Entity.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS38"><!--Anchor--></a>Section 3.8&#8195;<u>Absence of Certain Changes or Events</u>. Since December&#160;31, 2021, except in connection with the execution of this Agreement and the consummation of the transactions contemplated hereby, (x)&#160;Buyer and its Subsidiaries have conducted their business only in the ordinary course of business consistent with past practice; (y)&#160;there has not been any change, event or development or prospective change, event or development that, individually or in the aggregate, has had or would reasonably be expected to have a Buyer Material Adverse Effect; and (z) neither Buyer nor any of its Subsidiaries have:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;(i)&#160;declared, set aside or paid any dividends on, or made any other distributions (whether in cash, stock or property) in respect of, any of its capital stock or other equity interests, except for dividends by a wholly-owned Subsidiary of Buyer to its parent, (ii)&#160;purchased, redeemed or otherwise acquired shares of capital stock or other equity interests of Buyer or its Subsidiaries or any options, warrants, or rights to acquire any such shares or other equity interests, or (iii)&#160;split, combined, reclassified or otherwise amended the terms of any of its capital stock or other equity interests or issued or authorized the issuance of any other securities in respect of, in lieu of or in substitution for shares of its capital stock or other equity interests;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;amended or otherwise changed, or authorized or proposed to amend or otherwise change, its certificate of incorporation or bylaws (or similar organizational documents);</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;adopted or entered into a plan of complete or partial liquidation, dissolution, restructuring, recapitalization or reorganization; or</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;changed its financial or Tax accounting methods, principles or practices, except insofar as may have been required by a change in GAAP or applicable Law, or revalued any of its material assets.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-15<br></div></div></div>
<!--End Page 547-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 548-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg22"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS39"><!--Anchor--></a>Section 3.9&#8195;<u>Litigation</u>. There is no Action (or basis therefor) pending or, to the knowledge of Buyer, threatened against or affecting Buyer or any of its Subsidiaries, any of their respective properties or assets, or any present or former officer, director or employee of Buyer or any of its Subsidiaries in such individual&#8217;s capacity as such, other than any Action that (a) does not involve an amount in controversy in excess of $100,000 and (b) does not seek material injunctive or other nonmonetary relief. Neither Buyer nor any of its Subsidiaries nor any of their respective properties or assets is subject to any outstanding judgment, order, injunction, rule or decree of any Governmental Entity. There is no Action pending or, to the knowledge of Buyer, threatened seeking to prevent, hinder, modify, delay or challenge the transactions contemplated by this Agreement or the Ancillary Agreements.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS310"><!--Anchor--></a>Section 3.10&#8195;<u>Compliance with Laws</u>. Buyer and each of its Subsidiaries are and have been in compliance in all material respects with all Laws applicable to their businesses, operations, properties or assets. None of Buyer or any of its Subsidiaries has received, since January&#160;1, 2020, a notice or other written communication alleging or relating to a possible material violation of any Law applicable to their businesses, operations, properties, assets or Buyer Products. Buyer and each of its Subsidiaries have in effect all material Permits of all Governmental Entities necessary or advisable for them to own, lease or operate their properties and assets and to carry on their businesses and operations as now conducted, and there has occurred no violation of, default (with or without notice or lapse of time or both) under or event giving to others any right of revocation, nonrenewal, adverse modification or cancellation of, with or without notice or lapse of time or both, any such Permit, nor would any such revocation, nonrenewal, adverse modification or cancellation result from the consummation of the transactions contemplated hereby.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS311"><!--Anchor--></a>Section 3.11&#8195;<u>Health Care Regulatory Matters</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Buyer and, to the knowledge of Buyer, each of its directors, officers, management employees, agents (while acting in such capacity), contract manufacturers, suppliers, and distributors are, and at all times prior hereto were, in material compliance with all Health Care Laws to the extent applicable to Buyer or any of its products or activities. To the knowledge of Buyer, there are no facts or circumstances that reasonably would be expected to give rise to any material liability under any Health Care Laws.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Buyer is not party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any Governmental Entity.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;All applications, notifications, submissions, information, claims, reports and statistical analyses, and other data and conclusions derived therefrom, utilized as the basis for or submitted in connection with any and all requests for a Permit from the FDA or other Governmental Entity relating to products that are regulated as drugs, medical devices, or other healthcare products under Health Care Laws, including biological and drug candidates, compounds or products being researched, tested, stored, developed, labeled, manufactured, packed and/or distributed by Buyer or any of its Subsidiaries (&#8220;<u>Buyer Products</u>&#8221;), including, without limitation, investigational new drug applications, when submitted to the FDA or other Governmental Entity were true, complete and correct in all material respects as of the date of submission and any necessary or required updates, changes, corrections or modification to such applications, submissions, information and data have been submitted to the FDA or other Governmental Entity. Buyer does not have knowledge of any facts or circumstances that would be reasonably likely to lead to the revocation, suspension, limitation, or cancellation of a Permit required under Health Care Laws.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;All preclinical studies and clinical trials conducted by or, to the knowledge of Buyer, on behalf of Buyer have been, and if still pending are being, conducted in material compliance with research protocols and all applicable Health Care Laws, including, but not limited to, the FDCA and its applicable implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58, 312 and 313. No clinical trial conducted by or on behalf of Buyer has been conducted using any clinical investigators who have been disqualified, debarred or excluded from healthcare programs. No clinical trial conducted by or on behalf of Buyer has been terminated or suspended prior to completion, and no clinical investigator who has participated or is participating in, or institutional review board that has or has had jurisdiction over, a clinical trial conducted by or on behalf of Buyer has placed a partial or full clinical hold order on, or otherwise terminated, delayed or suspended, such a clinical trial at a clinical research site based on an actual or alleged lack of safety or efficacy of any Buyer Product or a failure to conduct such clinical trial in compliance with applicable Health Care Laws, their implementing regulations and good clinical practices. Buyer has not identified or received notice of instances or allegations of research misconduct </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-16<br></div></div></div>
<!--End Page 548-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 549-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg23"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">(defined as falsification or fabrication of data, or plagiarism, as those terms are defined in 42 C.F.R. Part 93) involving research conducted by, or on behalf of Buyer, that could compromise or affect the integrity, reliability, completeness or accuracy of the data collected in such research, or the rights, safety or welfare of the research subjects.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;All manufacturing operations conducted by or, to the knowledge of Buyer, for the benefit of Buyer have been and are being conducted in material compliance with all Permits under applicable Health Care Laws, all applicable provisions of the FDA&#8217;s current Good Manufacturing Practice (cGMP) regulations at 21 C.F.R. Parts 210-212, 600 and 610, and FDA&#8217;s Quality System (QS) regulations at 21 C.F.R. Part 820, and all comparable foreign regulatory requirements of any Governmental Entity.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;Buyer has not received any written communication that relates to an alleged violation or noncompliance with any Health Care Laws, including any notification of any pending or threatened claim, suit, proceeding, hearing, enforcement, investigation, arbitration, import detention or refusal, FDA Warning Letter or Untitled Letter, or any action by a Governmental Entity relating to any Health Care Laws. All Warning Letters, Form-483 observations, or comparable findings from other Governmental Entities listed in <u>Section 3.11(f)</u> of the Buyer Disclosure Letter have been resolved and closed out to the satisfaction of the applicable Governmental Entity.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;There have been no seizures, withdrawals, recalls, detentions, or suspensions of manufacturing, testing, or distribution relating to the Buyer Products required or requested by a Governmental Entity, or other notice of action relating to an alleged lack of safety, efficacy, or regulatory compliance of the Buyer Products, or any adverse experiences relating to the Buyer Products that have been reported to the FDA or any other Governmental Entity (&#8220;<u>Buyer Safety Notices</u>&#8221;), and, to the knowledge of Buyer, there are no facts or circumstances that reasonably would be expected to give rise to a Buyer Safety Notice. All Buyer Safety Notices listed in <u>Section 3.11(g)</u> of the Buyer Disclosure Letter have been resolved to the satisfaction of the applicable Governmental Entity.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(h)&#8195;There are no unresolved Buyer Safety Notices, and to the knowledge of Buyer, there are no facts that would be reasonably likely to result in a material Buyer Safety Notice or a termination or suspension of developing and testing of any of the Buyer Products.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(i)&#8195;Neither Buyer, nor, to the knowledge of Buyer, any officer, employee, agent, or distributor of Buyer has made an untrue statement of a material fact or fraudulent or misleading statement to a Governmental Entity, failed to disclose a material fact required to be disclosed to a Governmental Entity, or committed an act, made a statement, or failed to make a statement that would reasonably be expected to provide a basis for the FDA to invoke its FDA Ethics Policy. To the knowledge of Buyer, none of the aforementioned is or has been under investigation resulting from any allegedly untrue, fraudulent, misleading, or false statement or omission, including data fraud, or had any action pending or threatened relating to the FDA Ethics Policy.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(j)&#8195;All reports, documents, claims, Permits and notices required to be filed, maintained or furnished to the FDA or any Governmental Entity by Buyer have been so filed, maintained or furnished, except where failure to file, maintain or furnish such reports, documents, claims, Permits or notices has not had and would not reasonably be expected to have, individually or in the aggregate, a Buyer Material Adverse Effect. All such reports, documents, claims, Permits and notices were true and complete in all material respects on the date filed (or were corrected in or supplemented by a subsequent filing).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(k)&#8195;Neither Buyer nor, to the knowledge of Buyer, any officer, employee, agent, or distributor of Buyer has committed any act, made any statement or failed to make any statement that violates the Federal Anti-Kickback Statute, 28 U.S.C. &#167; 1320a-7b, the Federal False Claims Act, 31 U.S.C. &#167; 3729, other drug or Health Care Laws, or any other similar federal, state, or ex-U.S. Law applicable in the jurisdictions in which the Buyer Products are sold or intended to be sold.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(l)&#8195;Neither Buyer nor, to the knowledge of Buyer, any officer, employee, agent, or distributor of Buyer has been convicted of any crime or engaged in any conduct that has resulted, or would reasonably be expected to result, in debarment under applicable Law, including, without limitation, 21 U.S.C. &#167; 335a, or exclusion under 42 U.S.C. &#167; 1320a-7, or any other statutory provision or similar law applicable in other jurisdictions in which the Buyer Products are sold or intended to be sold. Neither Buyer nor, to the knowledge of Buyer, any officer, </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-17<br></div></div></div>
<!--End Page 549-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 550-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg24"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">employee, agent or distributor of Buyer, has been excluded from participation in any federal health care program or convicted of any crime or engaged in any conduct for which such Person could be excluded from participating in any federal health care program under Section 1128 of the Social Security Act of 1935, as amended, or any similar Health Care Law or program.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS312"><!--Anchor--></a>Section 3.12&#8195;<u>Benefit Plans</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;<u>Section 3.12(a)</u> of the Buyer Disclosure Letter contains a true and complete list of each &#8220;employee benefit plan&#8221; (within the meaning of section 3(3) of ERISA, whether or not subject to ERISA), and all stock purchase, stock option, phantom stock or other equity-based plan, severance, employment, collective bargaining, change-in-control, fringe benefit, bonus, incentive, deferred compensation, supplemental retirement, health, life, or disability insurance, dependent care and all other employee benefit and compensation plans, agreements, programs, policies or other arrangements, in each case, whether written or oral, under which any current or former employee, director or consultant of Buyer or its Subsidiaries (or any of their dependents) has any present or future right to compensation or benefits or Buyer or any of its Subsidiaries sponsors or maintains, is making contributions to or has any present or future liability or obligation (contingent or otherwise). All such plans, agreements, programs, policies and arrangements shall be collectively referred to as the &#8220;<u>Buyer Plans</u>.&#8221; Buyer has provided or made available to the Sellers a current, accurate and complete copy of each Buyer Plan, or if such Buyer Plan is not in written form, a written summary of all of the material terms of such Buyer Plan. With respect to each Buyer Plan, Buyer has furnished or made available to the Sellers a current, accurate and complete copy of, to the extent applicable: (i)&#160;any related trust agreement or other funding instrument, (ii)&#160;the most recent determination letter of the IRS, (iii)&#160;any summary plan description or summary of material modifications, and (iv)&#160;for the most recent year and as applicable (A) the Form 5500 and attached schedules, (B) audited financial statements and (C) actuarial valuation reports.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Neither Buyer, its Subsidiaries or any member of their Controlled Group (defined as any organization which is a member of a controlled, affiliated or otherwise related group of entities within the meaning of Code Section 414(b), (c), (m) or (o)) has, in the past six (6) years, sponsored, maintained, contributed to or been required to contribute to or incurred any liability (contingent or otherwise) with respect to: (i)&#160;a &#8220;multiemployer plan&#8221; (within the meaning of ERISA section 3(37)), (ii)&#160;a Pension Plan that is subject to Title IV of ERISA or Section 412 of the Code, (iii)&#160;a Pension Plan which is a &#8220;multiple employer plan&#8221; as defined in Section 413 of the Code, or (iv)&#160;a &#8220;funded welfare plan&#8221; within the meaning of Section 419 of the Code.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(c)&#8195;With respect to the Buyer Plans:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(i)&#8195;each Buyer Plan complies in all material respects with its terms and materially complies in form and in operation with the applicable provisions of ERISA and the Code and all other applicable legal requirements;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(ii)&#8195;each Buyer Plan intended to be qualified under Section 401(a) of the Code has received a favorable determination, advisory and/or opinion letter, as applicable, from the IRS that it is so qualified and nothing has occurred to the knowledge of Buyer since the date of such letter that would reasonably be expected to cause the loss of the sponsor&#8217;s ability to rely upon such letter, and nothing has occurred to the knowledge of Buyer that would reasonably be expected to result in the loss of the qualified status of such Buyer Plan;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iii)&#8195;there is no material Action (including any investigation, audit or other administrative proceeding) by the Department of Labor, the PBGC, the IRS or any other Governmental Entity or by any plan participant or beneficiary pending, or to the knowledge of Buyer, threatened, relating to the Buyer Plans, any fiduciaries thereof with respect to their duties to Buyer Plans or the assets of any of the trusts under any of the Buyer Plans (other than routine claims for benefits);</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iv)&#8195;none of the Buyer Plans currently provides, or reflects or represents any liability to provide post-termination or retiree welfare benefits to any person for any reason, except as may be required by COBRA, and none of Buyer, its Subsidiaries or any members of their Controlled Group has any liability to provide post-termination or retiree welfare benefits to any person, except to the extent required by statute or except with respect to a contractual obligation to reimburse any premiums such Person may pay in order to obtain health coverage under COBRA;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(v)&#8195;each Buyer Plan is subject exclusively to U.S. Law; and</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-18<br></div></div></div>
<!--End Page 550-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 551-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg25"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(vi)&#8195;the execution and delivery of this Agreement and the Ancillary Agreements and the consummation of the transactions contemplated hereby and thereby, either alone or in combination with any other event, (A) entitle any current or former employee, officer, director or consultant of Buyer or any Subsidiary to severance pay, unemployment compensation or any other similar termination payment, or any other compensatory payment, including any bonus, retention, retirement or other benefit, (B) accelerate the time of payment or vesting, or increase the amount of or otherwise enhance any benefit due to any such employee, officer, director or consultant, or (C) result in the payment of any &#8220;excess parachute payment&#8221; within the meaning of Section 280G of the Code.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;Each Buyer Plan that is a &#8220;nonqualified deferred compensation plan&#8221; within the meaning of Section&#160;409A of the Code (or any comparable or similar provision of state, local, or foreign Law) materially complies in both form and operation in all material respects with the requirements of Section 409A of the Code (or any comparable or similar provision of state, local, or foreign Law) and all applicable IRS guidance issued with respect thereto. There is no agreement, plan or other arrangement to which any of Buyer or any Subsidiary is a party or by which any of them is otherwise bound to compensate any person in respect of any excise or other Taxes or other liabilities (including interest and penalties) incurred with respect to Section 409A or 4999 of the Code.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS313"><!--Anchor--></a>Section 3.13&#8195;<u>Labor and Employment Matters</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Buyer and its Subsidiaries are and since January&#160;1, 2020 have been in compliance in all material respects with all applicable Laws relating to labor and employment, including those relating to employment practices, terms and conditions of employment, collective bargaining, disability, immigration, health and safety, wages, hours and benefits, non-discrimination in employment, workers&#8217; compensation, the collection and payment of withholding and/or payroll Taxes and similar Taxes, unemployment compensation, equal employment opportunity, discrimination, harassment, employee and contractor classification, information privacy and security, and continuation coverage with respect to group health plans. During the preceding three (3) years, there has not been, and as of the date of this Agreement there is not pending or, to the knowledge of Buyer, threatened, any labor dispute, work stoppage, labor strike or lockout against Buyer or any of its Subsidiaries by employees.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;No employee of Buyer or any of its Subsidiaries is covered by an effective or pending collective bargaining agreement or similar labor agreement. To the knowledge of Buyer, since January&#160;1, 2020, there has not been any activity on behalf of any labor union, labor organization or similar employee group to organize any employees of Buyer or any of its Subsidiaries, and there are no representation claims or petitions pending before the National Labor Relations Board or any other labor relations tribunal or authority. There are no (i)&#160;material unfair labor practice charges or complaints against Buyer or any of its Subsidiaries pending before the National Labor Relations Board or any other labor relations tribunal or authority and to the knowledge of Buyer no such representations, claims or petitions are threatened, or (ii)&#160;grievances or pending arbitration proceedings against Buyer or any of its Subsidiaries that arose out of or under any collective bargaining agreement. Neither the consent or consultation of, nor the formal rendering of advice by, any labor union, labor organization or similar employee group is required for Buyer to enter into this Agreement or the Ancillary Agreements or to consummate the transactions contemplated hereby and thereby.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;To the knowledge of Buyer, no current key employee or officer of Buyer or any of its Subsidiaries intends, or is expected, to terminate his or her employment relationship with such entity in connection with or as a result of the transactions contemplated hereby or otherwise within one (1) year of the Closing Date.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;During the preceding three (3) years, (i)&#160;neither Buyer nor any Subsidiary has effectuated a &#8220;plant closing&#8221; (as defined in the WARN Act) affecting any site of employment or one or more facilities or operating units within any site of employment or facility, (ii)&#160;there has not occurred a &#8220;mass layoff&#8221; (as defined in the WARN Act) in connection with Buyer or any Subsidiary affecting any site of employment or one or more facilities or operating units within any site of employment or facility and (iii)&#160;neither Buyer nor any Subsidiary has engaged in layoffs or employment terminations sufficient in number to trigger application of any similar state, local or foreign Law. Buyer and its Subsidiaries currently properly classify and for the past three (3) years have properly classified its and their employees as exempt or nonexempt in accordance with applicable overtime </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-19<br></div></div></div>
<!--End Page 551-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 552-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg26"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">Laws, and no Person treated as an independent contractor or consultant by Buyer or any Subsidiary within the past three (3) years should have been properly classified as an employee under applicable Law, in each case, except as would not, individually or in the aggregate, result in Buyer incurring a material liability.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;With respect to any current or former employee, officer, consultant or other service provider of Buyer, there are no Actions against Buyer or any of its Subsidiaries pending, or to Buyer&#8217;s knowledge, threatened to be brought or filed, in connection with the employment or engagement of any current or former employee, officer, consultant or other service provider of Buyer, including, without limitation, any claim relating to employment discrimination, harassment, retaliation, equal pay, employment classification or any other employment-related matter arising under applicable Laws, except where such action would not, individually or in the aggregate, result in Buyer incurring a material liability.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;Since January&#160;1, 2020, (i)&#160;no allegations of workplace sexual harassment, discrimination or other misconduct have been made, initiated, filed or, to the knowledge of Buyer, threatened against Buyer, any of its Subsidiaries or any of their respective current or former directors, officers or senior-level management employees in their capacities as such, (ii)&#160;to the knowledge of Buyer, no incidents of any such workplace sexual harassment, discrimination or other misconduct have occurred, and (iii)&#160;Buyer has not entered into any settlement agreement related to allegations of sexual harassment, discrimination or other misconduct by any of its directors, officers or employees described in clause (i)&#160;hereof or any independent contractor.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;Buyer and its Subsidiaries are and have at all relevant times been in compliance in all material respects with (i)&#160;COVID-19-related Laws, standards, regulations, orders and guidance (including without limitation relating to business reopening), including those issued and enforced by the Occupational Safety and Health Administration, the Centers for Disease Control, the Equal Employment Opportunity Commission, and any other Governmental Entity; and (ii)&#160;the Families First Coronavirus Response Act and any other applicable COVID-19-related leave Law, whether state, local or otherwise.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS314"><!--Anchor--></a>Section 3.14&#8195;<u>Environmental Matters</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Except as would not be material to Buyer, (i)&#160;Buyer and each of its Subsidiaries have conducted their respective businesses in compliance with all, and have not violated any, applicable Environmental Laws; (ii)&#160;Buyer and its Subsidiaries have obtained all Permits of all Governmental Entities and any other Person that are required under any Environmental Law; (iii)&#160;there has been no release of any Hazardous Substance by Buyer or any of its Subsidiaries or any other Person in any manner that has given or would reasonably be expected to give rise to any remedial or investigative obligation, corrective action requirement or liability of Buyer or any of its Subsidiaries under applicable Environmental Laws; (iv)&#160;neither Buyer nor any of its Subsidiaries has received any claims, notices, demand letters or requests for information (except for such claims, notices, demand letters or requests for information the subject matter of which has been resolved prior to the date of this Agreement) from any federal, state, local, foreign or provincial Governmental Entity or any other Person asserting that Buyer or any of its Subsidiaries is in violation of, or liable under, any Environmental Law; (v)&#160;no Hazardous Substance has been disposed of, arranged to be disposed of, released or transported in violation of any applicable Environmental Law, or in a manner that has given rise to, or that would reasonably be expected to give rise to, any liability under any Environmental Law, in each case, on, at, under or from any current or former properties or facilities owned or operated by Buyer or any of its Subsidiaries or as a result of any operations or activities of Buyer or any of its Subsidiaries at any location and, to the knowledge of Buyer, Hazardous Substances are not otherwise present at or about any such properties or facilities in amount or condition that has resulted in or would reasonably be expected to result in liability to Buyer or any of its Subsidiaries under any Environmental Law; and (vi)&#160;neither Buyer, its Subsidiaries nor any of their respective properties or facilities are subject to, or are threatened to become subject to, any liabilities relating to any suit, settlement, court order, administrative order, regulatory requirement, judgment or claim asserted or arising under any Environmental Law or any agreement relating to environmental liabilities.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;As used herein, &#8220;<u>Environmental Law</u>&#8221; means any Law relating to (i)&#160;the protection, preservation or restoration of the environment (including air, surface water, groundwater, drinking water supply, surface and subsurface soils and strata, wetlands, plant and animal life or any other natural resource) or (ii)&#160;the exposure to, or the use, storage, recycling, treatment, generation, transportation, processing, handling, labeling, production, release or disposal of Hazardous Substances.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-20<br></div></div></div>
<!--End Page 552-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 553-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg27"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;As used herein, &#8220;<u>Hazardous Substance</u>&#8221; means any substance listed, defined, designated, classified or regulated as a waste, pollutant or contaminant or as hazardous, toxic, radioactive or dangerous or any other term of similar import under any Environmental Law, including, but not limited to, petroleum.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS315"><!--Anchor--></a>Section 3.15&#8195;<u>Taxes</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Buyer and each of its Subsidiaries have (i)&#160;filed all income Tax Returns and other material Tax Returns required to be filed by or on behalf of themselves (taking into account any applicable extensions thereof) and all such Tax Returns are true, accurate and complete in all material respects; and (ii)&#160;paid in full (or caused to be timely paid in full) all income and other material Taxes that are required to be paid by it, whether or not such Taxes were shown as due on such Tax Returns.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;All material Taxes not yet due and payable by Buyer or any of its Subsidiaries as of the date of the Buyer Balance Sheet have been, in all respects, properly accrued in accordance with GAAP on the financial statements (including the related notes and schedules thereto) included (or incorporated by reference) in the Buyer SEC Documents, and such financial statements (including the related notes and schedules thereto) included (or incorporated by reference) in the Buyer SEC Documents reflect an adequate reserve (in accordance with GAAP) for all material Taxes accrued but unpaid by Buyer and each of its Subsidiaries through the date of such financial statements. Since the date of the Buyer Balance Sheet, neither Buyer nor any of its Subsidiaries has incurred, individually or in the aggregate, any liability for Taxes outside the ordinary course of business.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;Neither Buyer nor any of its Subsidiaries has executed any waiver of any statute of limitations on, or extended the period for the assessment or collection of, any material amount of Tax, in each case that has not since expired.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;No material Tax Actions with respect to Taxes or any Tax Return of Buyer or any of its Subsidiaries are presently in progress or have been asserted, threatened or proposed in writing. No deficiencies for a material amount of Taxes have been claimed, proposed, assessed or asserted in writing against Buyer or any of its Subsidiaries by a Governmental Entity, other than any such claim, proposal, assessment or assertion that has been satisfied by payment in full, settled or withdrawn.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;Buyer and each of its Subsidiaries have timely withheld all material amounts of Taxes required to have been withheld from payments made (or deemed made) to their employees, independent contractors, creditors, shareholders and other third parties and, to the extent required, such Taxes have been timely paid to the relevant Governmental Entity.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;Neither Buyer nor any of its Subsidiaries has engaged in a &#8220;reportable transaction&#8221; as set forth in Treasury Regulations &#167; 1.6011-4(b).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;Neither Buyer nor any of its Subsidiaries (i)&#160;is a party to or bound by, or has any liability pursuant to, any Tax sharing, allocation, indemnification or similar agreement or obligation; (ii)&#160;is or has ever been a member of a group (other than a group the common parent of which is Buyer) filing a consolidated, combined, affiliated, unitary or similar income Tax Return; (iii)&#160;has any liability for the Taxes of any Person (other than Buyer) pursuant to Treasury Regulations &#167; 1.1502-6 (or any similar provision of state, local or non-U.S. Law) as a transferee or successor, by Contract, or otherwise by operation of Law; and (iv)&#160;is or has ever been treated as a resident for any income Tax purpose, or as subject to Tax by virtue of having a permanent establishment, an office or fixed place of business, in any country other than the country in which it was or is organized.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(h)&#8195;No private-letter rulings, technical advice memoranda, or similar material written agreements with, or rulings from, a taxing authority have been requested in writing, entered into or issued by any taxing authority with respect to Buyer or any of its Subsidiaries which rulings will remain in effect after the Closing.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(i)&#8195;Neither Buyer nor any of its Subsidiaries will be required to include any item of income in, or exclude any item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of (i)&#160;a change in, or use of improper, method of accounting requested or initiated on or prior to the Closing Date, (ii)&#160;a &#8220;closing agreement&#8221; as described in Section 7121 of the Code (or any similar provision of Law) executed on or prior to the Closing Date, (iii)&#160;an installment sale or open-transaction disposition made on or prior to the Closing Date, or (iv)&#160;any deferred intercompany gain or excess-loss account described in Treasury Regulations under Section 1502 of the Code (or any corresponding or similar provision of state, local or foreign income Tax Law).</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-21<br></div></div></div>
<!--End Page 553-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 554-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg28"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(j)&#8195;There are no Encumbrances for Taxes upon any of the assets of Buyer or any of its Subsidiaries other than Encumbrances described in clause (i)&#160;of the definition of Permitted Encumbrances.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(k)&#8195;Neither Buyer nor any of its Subsidiaries has distributed stock of another Person or has had its stock distributed by another Person, in a transaction (or series of transactions) that was purported or intended to be governed in whole or in part by Section 355 or 361 of the Code.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(l)&#8195;Neither Buyer nor any of its Subsidiaries has been a United States real property holding corporation, as defined in Section 897(c)(2) of the Code during the applicable period specified in Section 897(c)(1)(A)(ii)&#160;of the Code.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(m)&#8195;No material claim has been made in writing by any Governmental Entity in a jurisdiction where Buyer or any of its Subsidiaries does not currently file or has not filed a Tax Return that Buyer or any of its Subsidiaries is or may be subject to taxation by such jurisdiction.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(n)&#8195;<u>Section 3.15(n)</u> of the Buyer Disclosure Letter sets forth the entity classification of Buyer and each of its Subsidiaries for U.S. federal income tax purposes. Neither Buyer nor any of its Subsidiaries has made an election or taken any other action to change its federal and state income tax classification from such classification.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS316"><!--Anchor--></a>Section 3.16&#8195;<u>Contracts</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Except as set forth in the Buyer SEC Documents publicly available prior to the date of this Agreement, neither Buyer nor any of its Subsidiaries is a party to or is bound by any &#8220;material contract&#8221; (as such term is defined in Item 601(b)(10) of Regulation S-K under the Securities Act, excluding, however, any Buyer Plans) (all such Contracts &#8220;<u>Buyer Material Contracts</u>&#8221;).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;(i)&#160;Each Buyer Material Contract is valid and binding on Buyer and any of its Subsidiaries to the extent such Subsidiary is a party thereto, as applicable, and to the knowledge of Buyer, each other party thereto, and is in full force and effect and enforceable in accordance with its terms; (ii)&#160;Buyer and each of its Subsidiaries, and, to the knowledge of Buyer, each other party thereto, have performed all material obligations required to be performed by themselves under each Buyer Material Contract; and (iii)&#160;there is no material default under any Buyer Material Contract by Buyer or any of its Subsidiaries or, to the knowledge of Buyer, any other party thereto, and no event or condition has occurred that constitutes, or, after notice or lapse of time or both, would constitute, a material default on the part of Buyer or any of its Subsidiaries or, to the knowledge of Buyer, any other party thereto under any such Buyer Material Contract, nor has Buyer or any of its Subsidiaries received any notice of any such material default, event or condition. Buyer has made available to the Sellers true and complete copies of all Buyer Material Contracts, including all amendments thereto.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS317"><!--Anchor--></a>Section 3.17&#8195;<u>Insurance</u>. Each of Buyer and its Subsidiaries is covered by valid and currently-effective insurance policies issued in favor of Buyer or one or more of its Subsidiaries that are customary and adequate for companies of similar size in the industries and locations in which Buyer operates. <u>Section 3.17</u> of the Buyer Disclosure Letter sets forth, as of the date hereof, a true and complete list of all material insurance policies issued in favor of Buyer or any of its Subsidiaries, or pursuant to which Buyer or any of its Subsidiaries is a named insured or otherwise a beneficiary, as well as any historic incurrence-based policies still in force. With respect to each such insurance policy, (a) such policy is in full force and effect and all premiums due thereon have been paid, (b) neither Buyer nor any of its Subsidiaries is in breach or default, and has not taken any action or failed to take any action which (with or without notice or lapse of time, or both) would constitute such a breach or default, or would permit termination or modification of, any such policy and (c) to the knowledge of Buyer, no insurer issuing any such policy has been declared insolvent or placed in receivership, conservatorship or liquidation. No notice of cancellation or termination has been received with respect to any such policy, nor will any such cancellation or termination result from the consummation of the transactions contemplated hereby. The transactions contemplated in this Agreement are not deemed to be a change of control under Buyer&#8217;s existing directors&#8217; and officers&#8217; liability insurance policy.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS318"><!--Anchor--></a>Section 3.18&#8195;<u>Properties</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Buyer or one of its Subsidiaries has good and valid title to, or in the case of leased property and leased tangible assets, a valid leasehold interest in, all of its real properties and tangible assets that are necessary for Buyer and its Subsidiaries to conduct their respective businesses as currently conducted, free and clear of all </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-22<br></div></div></div>
<!--End Page 554-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 555-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg29"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">Encumbrances (other than Permitted Encumbrances). Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Buyer Material Adverse Effect, the tangible personal property currently used in the operation of the business of Buyer and its Subsidiaries is in good working order (reasonable wear and tear excepted).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Each of Buyer and its Subsidiaries has complied with the terms of all leases to which it is a party, and all such leases are in full force and effect, except for any such noncompliance or failure to be in full force and effect that, individually or in the aggregate, has not had and would not reasonably be expected to have a Buyer Material Adverse Effect. Each of Buyer and its Subsidiaries enjoys peaceful and undisturbed possession under all such leases, except for any such failure to do so that, individually or in the aggregate, has not had and would not reasonably be expected to have a Buyer Material Adverse Effect.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)<font style="font-weight: normal;"> &#8195;</font><font style="font-weight: normal;"><u>Section 3.18(c)</u></font><font style="font-weight: normal;"> of the Buyer Disclosure Letter sets forth a true and complete list of (i)&#160;all real property </font><font style="font-weight: normal;">owned by Buyer or any of its Subsidiaries and (ii)&#160;all real property leased for the benefit of Buyer or any of its </font><font style="font-weight: normal;">Subsidiaries.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(d)&#8195;This <u>Section 3.18</u> does not relate to Intellectual Property, which is the subject of <u>Section 3.19</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS319"><!--Anchor--></a>Section 3.19 <u>Intellectual Property</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;<u>Section 3.19(a)</u> of the Buyer Disclosure Letter sets forth a true and complete list of all (i)&#160;Patents; (ii)&#160;material trademark registrations and applications; and (iii)&#160;material copyright registrations and applications (collectively, &#8220;<u>Buyer Registered</u> IP&#8221;), in each case owned by Buyer and its Subsidiaries, and a true and complete list of all domain names owned or exclusively licensed by Buyer and its Subsidiaries. Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Buyer Material Adverse Effect (A) all of the Buyer Registered IP is subsisting and, in the case of any Buyer Registered IP that is registered or issued and to the knowledge of Buyer, valid and enforceable, (B) no Buyer Registered IP is involved in any interference, reissue, derivation, reexamination, opposition, cancellation or similar proceeding and, to the knowledge of Buyer, no such action is threatened with respect to any of the Buyer Registered IP and (C) Buyer or its Subsidiaries own exclusively, free and clear of any and all Encumbrances (other than Permitted Encumbrances), all Buyer Owned IP, including all Intellectual Property created on behalf of Buyer or its Subsidiaries by employees or independent contractors.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;<u>Section 3.19(b)</u> of the Buyer Disclosure Letter accurately identifies (i)&#160;all Contracts pursuant to which any Buyer Registered IP is licensed to Buyer or its Subsidiaries (other than (A) any non-customized software that (1) is so licensed solely in executable or object code form pursuant to a nonexclusive, internal-use software license and other Intellectual Property associated with such software and (2) is not incorporated into, or material to the development, manufacturing, or distribution of, any of Buyer&#8217;s or its Subsidiaries&#8217; products or services, (B) any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of equipment, reagents or other materials, (C) any confidential information provided under confidentiality agreements and (D)&#160;agreements between Buyer and any of its Subsidiaries and their employees in Buyer&#8217;s standard form thereof), (ii)&#160;the corresponding Buyer Contract pursuant to which such Buyer Registered IP is licensed to Buyer or any of its Subsidiaries and (iii)&#160;whether the license or licenses granted to Buyer or its Subsidiaries are exclusive or nonexclusive.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;<u>Section 3.19(c)</u> of the Buyer Disclosure Letter accurately identifies each Buyer Contract pursuant to which any Person has been granted any license or covenant not to sue under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest in, any Buyer Registered IP (other than (i)&#160;any confidential information provided under confidentiality agreements and (ii)&#160;any Buyer Registered IP nonexclusively licensed to academic collaborators, suppliers or service providers for the sole purpose of enabling such academic collaborator, supplier or service providers to provide services for Buyer&#8217;s benefit).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;Buyer and its Subsidiaries have taken commercially reasonable measures to maintain the confidentiality of all information that constitutes or constituted a material Trade Secret of Buyer or its Subsidiaries, including requiring all Persons having access thereto to execute written nondisclosure agreements or other binding obligations to maintain confidentiality of such information.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Buyer Material Adverse Effect, (i)&#160;to the knowledge of Buyer, the conduct of the businesses of Buyer and its Subsidiaries, including the manufacture, marketing, offering for sale, sale, importation, use or intended use or </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-23<br></div></div></div>
<!--End Page 555-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 556-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg30"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">other disposal of any product as currently sold or under development by Buyer or its Subsidiaries, has not infringed, misappropriated or diluted, and does not infringe, misappropriate or dilute, any Intellectual Property of any Person, (ii)&#160;neither Buyer nor any of its Subsidiaries has received any written notice or claim asserting or suggesting that any such infringement, misappropriation, or dilution is or may be occurring or has or may have occurred and (iii)&#160;to the knowledge of Buyer, no Person is infringing, misappropriating, or diluting in any material respect any Buyer Registered IP.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Buyer Material Adverse Effect, (i)&#160;Buyer and its Subsidiaries have taken commercially reasonable steps to protect the confidentiality and security of the computer and information technology systems used by Buyer and its Subsidiaries (the &#8220;<u>Buyer IT Systems</u>&#8221;) and the information and transactions stored or contained therein or transmitted thereby, (ii)&#160;to the knowledge of Buyer, during the past two (2) years, there has been no unauthorized or improper use, loss, access, transmittal, modification or corruption of any such information or data, and (iii)&#160;during the past two (2) years, there have been no material failures, crashes, viruses, or security breaches (including any unauthorized access to any personally identifiable information) affecting the Buyer IT Systems.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Buyer Material Adverse Effect, (i)&#160;to the knowledge of Buyer, Buyer and its Subsidiaries have at all times complied in all material respects with all applicable privacy Laws, (ii)&#160;during the past two (2) years, no claims have been asserted or, to the knowledge of Buyer, threatened in writing against Buyer alleging a violation of any Person&#8217;s privacy or Personal Information, (iii)&#160;neither this Agreement nor the consummation of the transactions contemplated hereby will breach or otherwise violate any applicable privacy Laws and (iv)&#160;Buyer and its Subsidiaries have taken commercially reasonable steps to protect the Personal Information collected, used or held for use by Buyer or its Subsidiaries against loss and unauthorized access, use, modification, disclosure or other misuse.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(h)&#8195;To the knowledge of Buyer, no government funding, facilities or resources of a university, college, other educational institution or research center or funding from third parties was used in the development of the Buyer Owned IP, to the knowledge of Buyer, exclusively licensed to Buyer, and no Governmental Entity, university, college, other educational institution or research center has, to the knowledge of Buyer, any claim or right in or to such Intellectual Property.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(i)&#8195;The execution, delivery and performance by Buyer of this Agreement and the Ancillary Agreements to which Buyer will be a party, and the consummation of the transactions contemplated hereby and thereby, will not result in the loss of, or give rise to any right of any third party to terminate or modify any of Buyer&#8217;s or any Subsidiaries&#8217; rights or obligations under any agreement under which Buyer or any of its Subsidiaries grants to any Person, or any Person grants to Buyer or any of its Subsidiaries, a license or right under or with respect to any Intellectual Property that is material to any of the businesses of Buyer or any of its Subsidiaries.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS320"><!--Anchor--></a>Section 3.20&#8195;<u>Related Party Transactions</u>. Since January&#160;1, 2021 through the date of this Agreement, there have been no transactions, agreements, arrangements or understandings between Buyer or any of its Subsidiaries, on the one hand, and the Affiliates of Buyer, on the other hand (other than Buyer&#8217;s Subsidiaries), that would be required to be disclosed under Item 404 of Regulation S-K under the Securities Act and that have not been so disclosed in the Buyer SEC Documents.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS321"><!--Anchor--></a>Section 3.21&#8195;<u>Certain Payments</u>. Neither Buyer nor any of its Subsidiaries (nor, to the knowledge of Buyer, any of their respective directors, executives, Representatives, agents or employees) (a) has used or is using any corporate funds for any illegal contributions, gifts, entertainment or other unlawful expenses relating to political activity, (b)&#160;has used or is using any corporate funds for any direct or indirect unlawful payments to any foreign or domestic governmental officials or employees, (c) has violated or is violating any provision of the Foreign Corrupt Practices Act of 1977, (d) has established or maintained, or is maintaining, any unlawful fund of corporate monies or other properties or (e) has made any bribe, unlawful rebate, payoff, influence payment, kickback or other unlawful payment of any nature.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS322"><!--Anchor--></a>Section 3.22&#8195;<u>Brokers</u>. No broker, investment banker, financial advisor or other Person, other than Raymond James &amp; Associates, Inc., the fees and expenses of which will be paid by Buyer, is entitled to any broker&#8217;s, finder&#8217;s, financial advisor&#8217;s or other similar fee or commission in connection with the transactions contemplated by this </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-24<br></div></div></div>
<!--End Page 556-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 557-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg31"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Agreement based upon arrangements made by or on behalf of Buyer. Buyer has furnished to the Sellers a true and complete copy of any Contract between Buyer and Raymond James &amp; Associates, Inc. pursuant to which Raymond James &amp; Associates, Inc. could be entitled to any payment from Buyer relating to the transactions contemplated hereby.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS323"><!--Anchor--></a>Section 3.23&#8195;<u>No Other Representations or Warranties</u>. Except for the representations and warranties contained in <u>Article II</u>, Buyer acknowledges and agrees that none of the Sellers or any other Person on behalf of the Sellers makes any other express or implied representation or warranty whatsoever, and Buyer has not relied on any such information or any representation or warranty not set forth in <u>Article II</u>.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; text-align: center;"><a name="tANXBA4"><!--Anchor--></a>ARTICLE IV<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">COVENANTS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS41"><!--Anchor--></a>Section 4.1&#8195;<u>Preparation of Form S-4 and Proxy Statement; Stockholders&#8217; Meeting</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;As promptly as practicable after the date of this Agreement, Buyer shall (i)&#160;file with the SEC a proxy statement (as amended or supplemented from time to time, the &#8220;<u>Proxy Statement</u>&#8221;) to be sent to the stockholders of Buyer relating to the special meeting of Buyer&#8217;s stockholders (the &#8220;<u>Buyer Stockholders Meeting</u>&#8221;) to be held to consider the Buyer Stockholder Matters and (ii)&#160;set a preliminary record date for the Buyer Stockholders Meeting and commence a broker search pursuant to Section 14a-13 of the Exchange Act in Connection therewith; provided, that it is understood and agreed that the Sellers shall prepare the initial draft of the Proxy Statement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Buyer covenants and agrees that the Proxy Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith) will (i)&#160;comply as to form in all material respects with the requirements of applicable U.S. federal securities laws and the DGCL, and (ii)&#160;with regard to the information provided in the Proxy Statement by Buyer, will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;As promptly as practicable following the date of this Agreement, Buyer shall file with the SEC a registration statement on Form S-4 (as amended or supplemented from time to time, the &#8220;<u>Form S-4</u>&#8221;), in which the Proxy Statement will be part of the prospectus, in connection with the registration under the Securities Act of the Buyer Common Stock to be issued pursuant to this Agreement; provided, that it is understood and agreed that the Sellers shall prepare the initial draft of the Form S-4. The Sellers covenant and agree that all information concerning the Sellers and the Purchased Assets furnished by the Sellers and included in the Proxy Statement and Form S-4 will (i)&#160;comply as to form in all material respects with the requirements of applicable U.S. federal securities laws, and (ii)&#160;will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. Buyer shall use its reasonable best efforts to have the Form S-4 declared effective by the SEC under the Securities Act as promptly as practicable after such filing and to keep the Form S-4 effective as long as is necessary to consummate the transactions contemplated hereby. Buyer shall also take any action (other than qualifying to do business in any jurisdiction in which it is not now so qualified or filing a general consent to service of process) required to be taken under any applicable state securities or &#8220;blue sky&#8221; laws in connection with the issuance of shares of Buyer Common Stock pursuant to this Agreement and the Sellers shall furnish all information concerning the Sellers as may be reasonably requested in connection with any such action. Buyer shall use its reasonable best efforts to respond promptly to any comments or requests of the SEC or its staff relating to the Proxy Statement and the Form S-4; <u>provided</u>, that any comments or request of the SEC or its staff which relate to disclosures contained in the Form S-4 or Proxy Statement and which are provided by the Sellers will be promptly addressed by the Sellers.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;Buyer shall cause the Proxy Statement to be mailed to Buyer&#8217;s stockholders as promptly as practicable after the Form S-4 is declared effective by the SEC under the Securities Act. No filing of, or amendment or supplement to, the Form S-4 or the Proxy Statement will be made by Buyer without providing the Sellers a reasonable opportunity to review and comment thereon and without the Sellers&#8217; prior approval (which shall not be unreasonably withheld, conditioned, or delayed). Buyer will advise the Sellers promptly after it receives oral or written notice thereof of the time when the Form S-4 has become effective or any amendment or supplement thereto has been filed, the issuance of any stop order, the suspension of the qualification of the Buyer Common Stock issuable pursuant to this Agreement for offering or sale in any jurisdiction or any oral or written request </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-25<br></div></div></div>
<!--End Page 557-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 558-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg32"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">by the SEC for amendment of the Proxy Statement or the Form S-4 or comments thereon and responses thereto or requests by the SEC for additional information, and will promptly provide the Sellers with copies of any written communication from the SEC or any state securities commission and a reasonable opportunity to participate in the responses thereto. If at any time prior to the Effective Time any information relating to the Sellers or Buyer, or any of their respective Affiliates, officers or directors, should be discovered by the Sellers or Buyer that should be set forth in an amendment or supplement to either of the Form S-4 or the Proxy Statement, so that any of such documents would not contain any misstatement of a material fact or omit to state any material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, the party that discovers such information shall promptly notify the other parties hereto and an appropriate amendment or supplement describing such information shall promptly be filed with the SEC and, to the extent required under applicable Law, disseminated to stockholders of Buyer; provided, that the delivery of such notice and the filing of any such amendment or supplement shall not affect or be deemed to modify any representation or warranty made by any party hereunder or otherwise affect the remedies available hereunder to any party.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;As promptly as practicable after the Form S-4 is declared effective under the Securities Act, Buyer shall duly call, give notice of, convene and hold the Buyer Stockholders Meeting to consider and vote to approve the Buyer Stockholder Matters pursuant to the terms of this Agreement and the BC Agreement (and such Buyer Stockholders Meeting shall in any event be no later than 45 calendar days after the Form S-4 is declared effective). Buyer may postpone or adjourn the Buyer Stockholders Meeting solely (i)&#160;with the consent of the Sellers; (ii) (A) due to the absence of a quorum or (B) if Buyer has not received proxies representing a sufficient number of shares for the Buyer Stockholder Approval, whether or not a quorum is present, to solicit additional proxies; or (iii)&#160;to allow reasonable additional time for the filing and mailing of any supplemental or amended disclosure which the Buyer Board has determined in good faith after consultation with outside legal counsel is necessary under applicable Law and for such supplemental or amended disclosure to be disseminated and reviewed by Buyer&#8217;s stockholders prior to the Buyer Stockholders Meeting; provided, that Buyer may not postpone or adjourn the Buyer Stockholders Meeting more than a total of two times pursuant to clause (ii)(A)&#160;and/or clause (ii)(B) of this <u>Section 4.1(e)</u>. Notwithstanding the foregoing, Buyer shall, at the request of the Sellers, to the extent permitted by Law, adjourn the Buyer Stockholders Meeting to a date specified by the Sellers for the absence of a quorum or if Buyer has not received proxies representing a sufficient number of shares for the Buyer Stockholder Approval; provided, that Buyer shall not be required to adjourn the Buyer Stockholders Meeting more than one (1) time pursuant to this sentence, and no such adjournment pursuant to this sentence shall be required to be for a period exceeding 10 Business Days. Buyer, through the Buyer Board, shall (i)&#160;recommend to its stockholders that they vote to approve the Buyer Stockholder Matters, (ii)&#160;include such recommendation in the Proxy Statement and (iii)&#160;publicly reaffirm such recommendation within 24 hours after a request to do so by the Sellers. Without limiting the generality of the foregoing, Buyer shall use its reasonable best efforts to solicit proxies to obtain the Buyer Stockholder Approval.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;Each Seller agrees that it shall, at the Buyer Stockholders Meeting, however called, or in connection with any written consent of the Buyer Stockholders, vote or consent (or cause to be voted or consented), in person or by proxy, all shares of Buyer Common Stock owned by such Seller (i)&#160;in favor of the approval of the Buyer Stockholder Matters and any other actions contemplated by this Agreement and the BC Agreement and any actions required in furtherance hereof and thereof, including delivering a written consent, (ii)&#160;against approval of any proposal made in opposition to, or in competition with, the Buyer Stockholder Matters, and (iii)&#160;against any other proposal, action, or transaction that would impede, frustrate, prevent or materially delay the consummation of the transactions contemplated by the BC Agreement. Each Seller agrees irreparable damage would occur in the event that such Seller does not perform the provisions of this <u>Section 4.1(f)</u> in accordance with its terms or otherwise breaches such provisions, and accordingly, Buyer would be entitled to the equitable remedies under <u>Section 5.13</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS42"><!--Anchor--></a>Section 4.2&#8195;<u>Information; Purchased Contracts</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;<u>Information</u>. On the Closing Date, the Sellers shall deliver or cause to be delivered to Buyer all original (and any and all copies of) agreements, documents, books and records, files and other information, and all computer disks, records, tapes and any other storage medium on which any such agreements, documents, books and records, files and other information is stored, in any such case, relating to the Purchased Assets, that are in the possession of or under the control of the Sellers. If, notwithstanding the foregoing, the Sellers discover </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-26<br></div></div></div>
<!--End Page 558-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 559-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg33"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">following the Closing Date that it is in possession of or has under its control any such items, the Sellers shall (x)&#160;deliver to Buyer any such items and (y) thereafter permanently delete and erase all such information (including all copies thereof) in its possession or under its control as soon as reasonably practicable.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;<u>Purchased Contracts</u>. During the period beginning on the Closing Date and ending on the closing date of the transactions contemplated by the BC Agreement, the Sellers shall assume and pay, discharge, perform or otherwise satisfy the liabilities and obligations of any kind and nature, whether known or unknown, express or implied, primarily or secondary, direct or indirect, absolute, accrued, contingent or otherwise and whether due or to become due, arising out of, relating to, or otherwise in respect of the Purchased Contracts; and, for the avoidance of doubt, the Sellers agree that any such liabilities and obligations shall be Excluded Liabilities.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS43"><!--Anchor--></a>Section 4.3&#8195;<u>Stockholder Litigation</u>. Buyer shall give the Sellers the opportunity to participate in the defense and settlement of any stockholder litigation against Buyer and/or its officers or directors relating to the transactions contemplated by this Agreement and the Ancillary Agreements in accordance with the terms of a mutually agreed upon joint defense agreement. Buyer shall not enter into any settlement agreement in respect of any stockholder litigation against Buyer and/or its directors or officers relating to the transactions contemplated hereby or thereby without the Sellers&#8217; prior written consent (such consent not to be unreasonably withheld, conditioned or delayed).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS44"><!--Anchor--></a>Section 4.4&#8195;<u>Tax Matters</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;<u>Purchase Price Allocation</u>. Promptly after the Closing Date, the Sellers shall provide the Buyer with an allocation of the Purchase Price (plus other relevant items treated as consideration for tax purposes) among the Purchased Assets (the &#8220;<u>Allocation</u>&#8221; ). The Sellers shall permit the Buyer to review and comment on the draft Allocation and shall consider in good faith such revisions as are reasonably requested by the Buyer within twenty (20) days of receipt of the draft Allocation. The parties shall file all Tax Returns (including amended returns and claims for refund) and information reports in a manner consistent with the Allocation (as finally determined by the parties); <u>provided</u>, that the Sellers may thereafter revise the Allocation as necessary to reflect the fact that the amount treated as consideration for Tax purposes has changed by reason of payments of amounts between the parties subsequent to the Closing Date that were not previously reflected in the Allocation.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;<u>Proration of Taxes</u>. All real property Taxes, personal property Taxes and other similar ad valorem Taxes (&#8220;<u>Property Taxes</u>&#8221;) relating to the any of the Purchased Assets shall be prorated as of the Closing Date for the applicable Tax period that includes the Closing Date between the Seller and the Buyer. The amount of Property Taxes allocable to the Seller shall be equal to the amount of Tax for the period multiplied by a fraction, the numerator of which shall be the number of days from the beginning of the period through the Closing Date and the denominator of which shall be the number of days in the period. The amount of Property Taxes allocable to the Buyer shall be equal to the amount of Tax or other charge for the period multiplied by a fraction, the numerator of which shall be the number of days after the Closing Date and the denominator of which shall be the number of days in the period. All other Taxes shall be allocated as of the Closing Date for the applicable Tax period that includes the Closing Date based on a closing of the books method. In the event that any party pays a Tax for which the other party is obligated in whole or in part under this <u>Section 4.4(b)</u>, the former shall present the latter with a statement setting forth the latter&#8217;s proportionate share, and the latter shall promptly pay such proportionate share to the former. For purposes of this <u>Section 4.4(b)</u>, any exemption, deduction, credit or other item (including, without limitation, the effect of any graduated rates of Tax) that is calculated on an annual basis shall be allocated to the portion of the applicable Tax period ending on the Closing Date on a pro rata basis determined by multiplying the total amount of such item allocated to such Tax period times a fraction, the numerator of which is the number of calendar days in the portion of the Tax period ending on the Closing Date and the denominator of which is the number of calendar days in such Tax period.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;<u>Transfer Taxes</u>. The Sellers shall be responsible for all excise, sales, use, value added, transfer (including real property transfer or gains), stamp, documentary, filing, recordation and other similar Taxes (&#8220;<u>Transfer Taxes</u>&#8221;) arising as a result of the transactions contemplated by this Agreement. The party customarily responsible under applicable Law shall file all necessary Tax Returns with respect to Transfer Taxes and the non-preparing party shall cooperate in duly and properly preparing, executing, and filing any certificates or other documents required to be filed in connection with such Transfer Taxes.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;<u>Cooperation on Tax Matters</u>. The Buyer and the Sellers shall use commercially reasonable efforts to provide to the other such cooperation and information, as and to the extent reasonably requested (and at the requesting party&#8217;s expense), in connection with the filing of any Tax Return or in conducting any audit, litigation </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-27<br></div></div></div>
<!--End Page 559-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 560-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg34"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">or other proceeding with respect to Taxes. Such cooperation shall include the retention and the provision of records and information that are reasonably relevant to any action and making employees available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;<u>Certain Tax Forms</u>. Each of the Sellers shall deliver to Buyer on or prior to the Closing Date an accurate, executed and complete IRS Form W-8BEN-E.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS45"><!--Anchor--></a>Section 4.5&#8195;<u>Stock Exchange Listing</u>. Buyer shall use its reasonable best efforts to (a) remain listed as a public company on the Nasdaq and (b) cause the shares of Buyer Common Stock to be issued in pursuant to this Agreement, and such other shares of Buyer Common Stock to be reserved for issuance in connection with the transactions contemplated hereby (including such shares issuable upon conversion of the Buyer Convertible Preferred Stock), to be approved for listing on the Nasdaq, subject to official notice of issuance, prior to the Effective Time.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS46"><!--Anchor--></a>Section 4.6&#8195;<u>Public Announcements</u>. As promptly as practicable following the date of this Agreement (and in any event within four (4) Business Days thereafter), Buyer shall prepare and file a Current Report on Form 8-K pursuant to the Exchange Act to report the execution of this Agreement (the &#8220;<u>Form 8-K</u>&#8221;) and the parties shall issue a mutually agreeable press release announcing the execution of this Agreement. Buyer shall provide the Sellers with a reasonable opportunity to review and comment on the Form 8-K prior to its filing and shall consider such comments in good faith.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS47"><!--Anchor--></a>Section 4.7&#8195;<u>Section 16 Matters</u>. Prior to the Closing, each of Buyer and the Sellers shall take all such steps as may be necessary or appropriate to cause the transactions contemplated by this Agreement, including acquisitions of Buyer Common Stock (including derivative securities with respect to such Buyer Common Stock) resulting from the transactions contemplated by this Agreement by each individual who will become subject to such reporting requirements with respect to Buyer to be exempt under Rule 16b-3 promulgated under the Exchange Act.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS48"><!--Anchor--></a>Section 4.8&#8195;<u>Private Placement</u>. The Sellers shall provide all documentation, including investor questionnaires, reasonably requested by Buyer to allow Buyer to issue the Buyer Capital Stock to such holders in a manner that satisfies the requirements of Rule 506 of Regulation D under the Securities Act or Rule 902 of Regulation S under the Securities Act, including certifications to Buyer that either (a)(i)(A) such holder is and will be, as of the Effective Time, an &#8220;accredited investor&#8221; (as such term is defined in Rule 501 of Regulation D under the Securities Act) and as to the basis on which such holder is an accredited investor; or (B) such holder is not and will not be, as of the Effective Time, an &#8220;accredited investor,&#8221; in which case such holder either alone or with such holder&#8217;s purchaser representative has such knowledge and experience in financial and business matters that such holder is capable of evaluating the merits and risks of the Buyer Capital Stock; and (ii)&#160;that the Buyer Capital Stock is being acquired for such holder&#8217;s account for investment only and not with a view towards, or with any intention of, a distribution or resale thereof for at least a period of six (6) months following the Closing, or (b) such holder is not a &#8220;U.S. person&#8221; within the meaning of Rule 902 of Regulation S under the Securities Act.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS49"><!--Anchor--></a>Section 4.9&#8195;<u>Refunds and Remittances</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;If, after the Closing, Buyer or any of its Affiliates receive any refund or other amount that is an Excluded Asset or is otherwise properly due and owing to the Sellers or any of their Affiliates in accordance with the terms of this Agreement, Buyer promptly shall remit, or shall cause to be remitted, such refund or amount to the Sellers.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;If, during the period beginning on the Closing Date and ending on the first anniversary of the Closing Date, Buyer or any Affiliates is found subject to an Excluded Liability, (i)&#160;Buyer will return or transfer and convey (without further cost or consideration to Buyer) to the Sellers or the appropriate Subsidiary thereof such Excluded Liability, (ii)&#160;the Sellers will, or will cause its appropriate Subsidiary to, assume (without further cost or consideration to Buyer) such Excluded Liability, and (iii)&#160;the Sellers and Buyer will, and will cause their appropriate Subsidiaries to, execute such documents or instruments of conveyance and assumption and take such further acts as are reasonably necessary or desirable to effect the transfer of such Excluded Liability back to the Sellers or its appropriate Subsidiaries such that each party is put into the same economic position with respect to such Excluded Liability as if such action had been taken on or prior to the Closing Date.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;If, during the period beginning on the Closing Date and ending on the first anniversary of the Closing Date, any asset held by the Sellers or its Subsidiaries is ultimately determined to be a Purchased Asset, (i)&#160;the Sellers or its Subsidiaries will return or transfer and convey (without further cost to or consideration from Buyer) to Buyer such Purchased Assets, and (ii)&#160;the Sellers and Buyer will, and will cause their appropriate Subsidiaries </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-28<br></div></div></div>
<!--End Page 560-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 561-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg35"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">to, execute such documents or instruments of conveyance and assumption and take such further acts as are reasonably necessary or desirable to effect the transfer of such Purchased Assets back to Buyer such that each party is put into the same economic position with respect to such Purchased Asset as if such action had been taken on or prior to the Closing Date.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS410"><!--Anchor--></a>Section 4.10&#8195;<u>Certificate of Designation</u>. The Buyer shall promptly file the Certificate of Designation with the Secretary of State of the State of Delaware, and in any event, within one (1) Business Day after the Closing Date, and shall deliver to the Sellers a copy of the Certificate of Designation, certified by the Secretary of State of the State of Delaware within one (1) Business Day after the Closing Date.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS411"><!--Anchor--></a>Section 4.11&#8195;<u>Continued Development of Purchased Assets</u>. In the event that Buyer Stockholders approve the Conversion Proposal but do not approve the BC Transactions Proposal, Buyer and the Sellers agree to use their commercially reasonable efforts to continue the development of the Purchased Assets in the United States, including obtaining appropriate financing to support such development.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS412"><!--Anchor--></a>Section 4.12&#8195;<u>Bulk Transfer Laws</u>. The parties hereby waive compliance with the provisions of any bulk sales, bulk transfer or similar Laws of any jurisdiction that may otherwise be applicable with respect to the sale of any or all of the Purchased Assets to Buyer.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS413"><!--Anchor--></a>Section 4.13&#8195;<u>Further Assurances</u>. Each of the parties agrees to work diligently, expeditiously and in good faith to consummate the transactions contemplated by this Agreement. From time to time after the Closing Date, the Sellers shall execute and deliver to Buyer such instruments of sale, transfer, conveyance, assignment, consent, assurance, power of attorney, and other such instruments as may be reasonably requested by Buyer in order to vest in the Buyer all right, title, and interest in and to the Purchased Assets.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; text-align: center;"><a name="tANXBA5"><!--Anchor--></a>ARTICLE V<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">GENERAL PROVISIONS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS51"><!--Anchor--></a>Section 5.1&#8195;<u>Non-survival of Representations and Warranties</u>. None of the representations, warranties, covenants or agreements in this Agreement or in any instrument delivered pursuant to this Agreement shall survive the Closing, other than those covenants or agreements of the parties which by their terms apply, or are to be performed in whole or in part, after the Closing, including, for the avoidance of doubt, all of the covenants in Article&#160;IV.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS52"><!--Anchor--></a>Section 5.2&#8195;<u>Notices</u>. All notices and other communications hereunder shall be in writing and shall be deemed duly given (a) on the date of delivery if delivered personally, or if by e-mail, upon written confirmation of receipt by e-mail or otherwise, (b) on the first (1st) Business Day following the date of dispatch if delivered utilizing a next-day service by a recognized next-day courier or (c) on the earlier of confirmed receipt or the fifth (5th) Business Day following the date of mailing if delivered by registered or certified mail, return receipt requested, postage prepaid. All notices hereunder shall be delivered to the addresses set forth below, or pursuant to such other instructions as may be designated in writing by the party to receive such notice:</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(i) </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.75pt;">&#8203;</td><td colspan="4" style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">if to Buyer, to:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td colspan="4" style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">611 Gateway Blvd.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Suite 120</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td colspan="4" style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">South San Francisco, CA 94080</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Nassim Usman, PhD</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">E-mail: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">nusman@catbio.com</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td colspan="4" style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">with a copy (which shall not constitute notice) to:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td colspan="4" style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Orrick, Herrington &amp; Sutcliffe LLP<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">51 West 52nd Street<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">New York, NY 10019</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stephen Thau and David Schwartz</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">E-mail: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>sthau@orrick.com</u> and <u>dschwartz@orrick.com</u></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-29<br></div></div></div>
<!--End Page 561-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 562-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg36"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(ii) </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.75pt;">&#8203;</td><td colspan="4" style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">if to the Sellers, to:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td colspan="4" style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI Group Ltd.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td colspan="4" style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI Hong Kong Limited</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td colspan="4" style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Building 6. No. 230 Chuanhong Road<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chuansha, Pudong New Area<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shanghai, P. R. China</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ying Luo</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thomas Eastling</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">E-mail: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>yluo@gnipharma.com</u></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>t-eastling@gnipharma.com</u></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td colspan="4" style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">with a copy (which shall not constitute notice) to:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td colspan="4" style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gibson, Dunn &amp; Crutcher LLP<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">555 Mission St., Suite 3000<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">San Francisco, CA 94105</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ryan A. Murr</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Branden C. Berns</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">E-mail: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>RMurr@gibsondunn.com</u></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>BBerns@gibsondunn.com</u></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.25pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS53"><!--Anchor--></a>Section 5.3&#8195;<u>Certain Definitions. For purposes of this Agreement:</u></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;&#8220;<u>Affiliate</u>&#8221; of any Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such first Person.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;&#8220;<u>Ancillary Agreements</u>&#8221; means (i)&#160;the Bill of Sale, (ii)&#160;the Assignment of Intellectual Property, and (iii)&#160;each document, certificate, or other instrument required to be delivered under this Agreement or under any other Ancillary Agreement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;&#8220;<u>BC Agreement</u>&#8221; means that certain Business Combination Agreement, dated as of the date hereof, by and among Buyer, GNI Group, GNI Hong Kong, GNI USA, Inc., Shanghai Genomics, Inc., the Minority Holders (as defined therein) and Continent Pharmaceuticals Inc.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;&#8220;<u>Business Day</u>&#8221; means any day other than a Saturday, a Sunday or a day on which banks in New York, New York are authorized or required by applicable Law to be closed.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;&#8220;<u>Buyer Balance Sheet</u>&#8221; means the audited balance sheet of Buyer as of December&#160;31, 2021, included in Buyer&#8217;s Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(f)&#8195;&#8220;<u>Buyer Capital Stock</u>&#8221; means the Buyer Common Stock and Buyer Convertible Preferred Stock.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;&#8220;<u>Buyer Owned IP</u>&#8221; means all Intellectual Property owned by Buyer or any of its Subsidiaries in whole or in part.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(h)&#8195;&#8220;<u>Certificate of Designation</u>&#8221; means a certificate of designation for the Buyer Convertible Preferred Stock in the form attached hereto as <u>Exhibit C</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(i)&#8195;&#8220;<u>Code</u>&#8221; means the Internal Revenue Code of 1986, as amended.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(j)&#8195;&#8220;<u>Compound</u>&#8221; means [***].</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(k)&#8195;&#8220;<u>control</u>&#8221; (including the terms &#8220;<u>controlled</u>,&#8221; &#8220;<u>controlled by</u>&#8221; and &#8220;<u>under common control with</u>&#8221;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(l)&#8195;&#8220;<u>COVID-19</u>&#8221; means SARS-CoV-2 or COVID-19, and any variants or evolutions thereof or related or associate epidemics, pandemic or disease outbreaks.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-30<br></div></div></div>
<!--End Page 562-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 563-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg37"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(m)&#8195;&#8220;<u>Develop</u>&#8221; or &#8220;<u>Development</u>&#8221; means non-clinical, CMC, and clinical drug development activities, including: clinical trials relating to the development of pharmaceutical compounds and pharmaceutical products; regulatory affairs activities, including any written and verbal communications or interactions with, a Governmental Authority for purposes including progressing development of an investigational drug; obtaining Marketing Approval of a pharmaceutical product; and any associated CMC activities to develop analytical or manufacturing capabilities for covered products for investigational or commercial purposes. &#8220;Develop&#8221; and &#8220;Development&#8221; includes product or assay optimization, nonclinical activities, the conduct and documentation of pharmacology and safety studies, toxicology studies, studies to characterize the absorption, distribution, metabolism or excretion of covered compounds or products; CMC development activities, including, formulation, manufacturing process development and scale-up (including bulk compound production); quality assurance and quality control; or technical support.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(n)&#8195;&#8220;<u>Encumbrance</u>&#8221; means any charge, claim, limitation, condition, equitable interest, mortgage, lien, option, pledge, security interest, easement, encroachment, right of first refusal, adverse claim or restriction of any kind, including any restriction on or transfer or other assignment, as security or otherwise, of or relating to use, quiet enjoyment, voting, transfer, receipt of income or exercise of any other attribute of ownership.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(o)&#8195;&#8220;<u>ERISA Affiliate</u>&#8221; means any Person that is (or at any relevant time was) a member of a &#8220;controlled group of corporations&#8221; with or under &#8220;common control&#8221; with the Seller as defined in Section 414(b) or (c) of the Code or that is otherwise (or at any relevant time was) required to be treated, together with the Seller, or as the case may be, as a single employer under Sections 414(m) or (o) of the Code.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(p)&#8195;&#8220;<u>Excluded Taxes</u>&#8221; means any Taxes (i)&#160;irrespective of when asserted, of the Sellers (or any of their Affiliates (excluding the Buyer and its Subsidiaries after the Closing Date)), (ii)&#160;arising out of or imposed on the Purchased Assets for any taxable period (or portion thereof) ending on or before the Closing Date, (iii)&#160;that arise out of the consummation of the transactions contemplated hereby, or (iv)&#160;for which Sellers are responsible pursuant to <u>Section 4.4(c)</u>; but, in each case, excluding any Transfer Taxes for which Buyer is responsible pursuant to <u>Section 4.4(c)</u> and any Taxes resulting from any act taken or transaction entered into by Buyer or any of its Affiliates outside of the ordinary course of business on the Closing Date after the Closing.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(q)&#8195;&#8220;<u>FD&amp;C Act</u>&#8221; means the U.S. Federal Food, Drug, and Cosmetic Act, as amended.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(r)&#8195;&#8220;<u>Governmental Authority</u>&#8221; means any United States or non-United States federal, national, supranational, state, provincial, local or similar government, governmental, regulatory or administrative authority, branch, agency or commission or any court, tribunal, or arbitral or judicial body (including any grand jury).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(s)&#8195;&#8220;<u>IND</u>&#8221; means an Investigational New Drug Application filed with the FDA pursuant to Part 312 of Title 21 of the U.S. Code of Federal Regulations (or its successor regulation), or the equivalent application or filing filed with any equivalent agency or Governmental Authority outside the United States of America (including any supra-national agency such as the EMA).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(t)&#8195;&#8220;<u>Intellectual Property</u>&#8221; means all intellectual property rights arising from or associated with the following, whether protected, created or arising under the laws of the United States or any other jurisdiction: (i)&#160;trade names, trademarks and service marks (registered and unregistered), domain names and other Internet addresses or identifiers, trade dress and similar rights and applications (including intent to use applications and similar reservations of marks and all goodwill associated therewith) to register any of the foregoing (collectively, &#8220;<u>Marks</u>&#8221;); (ii)&#160;Patents; (iii)&#160;copyrights (registered and unregistered) and applications for registration (collectively, &#8220;<u>Copyrights</u>&#8221;); (iv)&#160;trade secrets, know-how, inventions, methods, processes and processing instructions, technical data, specifications, research and development information, technology, product roadmaps, customer lists and any other information, in each case to the extent any of the foregoing derives economic value (actual or potential) from not being generally known to other persons who can obtain economic value from its disclosure or use, excluding any Copyrights or Patents that may cover or protect any of the foregoing (collectively, &#8220;<u>Trade Secrets</u>&#8221;); and (v)&#160;moral rights, publicity rights, data base rights and any other proprietary or intellectual property rights of any kind or nature that do not comprise or are not protected by Marks, Patents, Copyrights or Trade Secrets.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(u)&#8195;&#8220;<u>Inventory</u>&#8221; means all stock of API, drug substance and/or Product that are related to the Compound, including (i)&#160;copies of all papers, records and documents (in paper or electronic format), and (ii)&#160;all technical </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-31<br></div></div></div>
<!--End Page 563-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 564-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg38"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">and descriptive materials, purchasing and sales records, documentation, and related information and materials, in each case, in the possession or control of the Seller or any of its Affiliates, as of immediately prior to the Closing; provided however, that Inventory shall not include any damaged, obsolete, or expired stock (which, for the avoidance of doubt, shall be Excluded Assets).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(v)&#8195;&#8220;<u>knowledge</u>&#8221; of any party means (i)&#160;the actual knowledge of any executive officer of such party or other officer having primary responsibility for the relevant matter or (ii)&#160;any fact or matter which any such officer of such party could be expected to discover or otherwise become aware of in the course of conducting a reasonably comprehensive investigation, consistent with such officer&#8217;s title and responsibilities, concerning the existence of the relevant matter.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(w)&#8195;&#8220;<u>Marketing Approval</u>&#8221; means, with respect to the Product in a particular country or regulatory jurisdiction, receipt of approval necessary for the commercial sale of the Product in such country or regulatory jurisdiction.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(x)&#8195;&#8220;<u>Multiemployer Plan</u>&#8221; means any &#8220;multiemployer plan,&#8221; as defined in Section 4001(a)(3) of ERISA, (i)&#160;that the Seller or any of its ERISA Affiliates maintains, administers, contributes to or is required to contribute to, or, after September&#160;25, 1980, maintained, administered, contributed to or was required to contribute to, or under which the Seller or any of its ERISA Affiliates may incur any liability and (ii)&#160;that covers or has covered any employee or former employee of the Seller or any of its ERISA Affiliates (with respect to their relationship with such entities) or for which the Seller may be responsible.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(y)&#8195;&#8220;<u>Nasdaq</u>&#8221; means the Nasdaq Stock Market, LLC.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(z)&#8195;&#8220;<u>NDA</u>&#8221; means a New Drug Application, as defined in the FD&amp;C Act, and applicable regulations promulgated thereunder by the FDA.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(aa)&#8195;&#8220;<u>Patent Files</u>&#8221; means, with regard to the Purchased Patents, the file histories for such Patents in the possession or control of the Seller or any of its Affiliates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(bb)&#8195;&#8220;<u>Patents</u>&#8221; means all national, regional and international statutory invention registrations, issued patents, and patent applications of any kind, including all applications and filings made pursuant to the Patent Cooperation Treaty (PCTs), provisional applications, nonprovisional applications, converted provisional applications, requests for continued examination, continuation applications, continuation-in-part applications, divisional applications, substitutions, additions, reexaminations, reissue applications, supplemental examinations, oppositions, inter partes review, post-grant review, transitional program for covered business method patent review, interference proceedings, derivation proceedings, all rights in respect of design patents, utility models, certificates of invention, and any similar rights, including so-called pipeline protection, patent term extension, and supplemental protection certificates, all patent rights in inventions disclosed in each such registration, patent or patent application, and all rights and priorities afforded under any Law with respect to any of the foregoing in any jurisdiction, including all earlier-filed applications from which benefit or priority rights are derived, and all extensions, restorations, and renewals of any of the foregoing.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(cc)&#8195;&#8220;<u>Pension Plan</u>&#8221; means any &#8220;employee pension benefit plan&#8221; as defined in Section 3(2) of ERISA (other than a Multiemployer Plan) (i)&#160;that the Seller or any of its ERISA Affiliates maintains, administers, contributes to or is required to contribute to, or, within the five years prior to the Closing Date, maintained, administered, contributed to or was required to contribute to, or under which any such entity may incur any liability and (ii)&#160;that covers or has covered any employee or former employee of the Seller or any of its ERISA Affiliates (with respect to their relationship with such entities) or for which the Seller may be responsible.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(dd)&#8195;&#8220;<u>Permitted Encumbrance</u>&#8221; means any (i)&#160;statutory liens for Taxes not yet due and for which adequate reserves have been established in accordance with GAAP or International Financial Reporting Standards (as applicable), or (ii)&#160;mechanics&#8217;, workmen&#8217;s, repairmen&#8217;s, warehousemen&#8217;s and carriers&#8217; liens arising in the ordinary course of business consistent with past practice.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(ee)&#8195;&#8220;<u>Person</u>&#8221; means an individual, corporation, partnership, limited liability company, association, trust or other entity or organization, including any Governmental Entity.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(ff)&#8195;&#8220;<u>Personal Information</u>&#8221; means any information that alone or in combination with other information can be used to identify an individual.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-32<br></div></div></div>
<!--End Page 564-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 565-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg39"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(gg)&#8195;&#8220;<u>Product</u>&#8221; means any current or future pharmaceutical product containing or comprising the Compound, whether or not as the sole active ingredient, and in any dosage, form or formulation.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(hh)&#8195;&#8220;<u>Purchased Intellectual Property</u>&#8221; means the Purchased Patents and Purchased Trade Secrets.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(ii)&#8195;&#8220;<u>Regulatory Materials</u>&#8221; means the U.S. and foreign regulatory applications, submissions and approvals (including all INDs, NDAs and foreign counterparts thereof, and all Marketing Approvals) for any Compound or Product, and all material correspondence with the FDA and other Governmental Authorities relating to any Compound or Product or any of the foregoing regulatory applications, submissions and approvals and all clinical, regulatory and other data and information contained in the foregoing regulatory applications, submissions and approvals; whether generated, filed or held by or for the Seller or its Affiliates or by any third party on behalf of the Seller or its Affiliates, as applicable, which materials are actually delivered by the Seller to Buyer on or prior to the Closing.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(jj)&#8195;&#8220;<u>Representative</u>&#8221; means, with respect to a party, such party&#8217;s directors, officers, employees, investment bankers, financial advisors, attorneys, accountants or other advisors, agents or representatives.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(kk)&#8195;&#8220;<u>Right</u>&#8221; means all claims, causes of action, rights of recovery and rights of set-off against any Person arising from or related to the Purchased Assets, including: (i)&#160;all rights under any Seller Contract, including all rights to receive payment for products sold and services rendered thereunder, to receive goods and services thereunder, to assert claims and to take other rightful actions in respect of breaches, defaults and other violations thereof; (ii)&#160;all rights under or in respect of any Purchased Intellectual Property, including all rights to sue and recover damages for past, present and future infringement, dilution, misappropriation, violation, unlawful imitation or breach thereof, and all rights of priority and protection of interests therein under the laws of any jurisdiction; and (iii)&#160;all rights under all guarantees, warranties, indemnities and insurance policies arising from or related to the Purchased Assets.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(ll)&#8195;&#8220;<u>SEC</u>&#8221; means the Securities and Exchange Commission.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(mm)&#8195;&#8220;<u>Subsidiary</u>&#8221; means, with respect to any Person, any other Person of which stock or other equity interests having ordinary voting power to elect more than 50% of the board of directors or other governing body are owned, directly or indirectly, by such first Person.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(nn)&#8195;&#8220;<u>Tax Return</u>&#8221; means any return, declaration, report, election, claim for refund, information return, or statement filed or supplied or required to be filed or supplied to any Governmental Entity or any other Person with respect to Taxes, including any schedule, attachment or supplement thereto, and including any amendment thereof.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(oo)&#8195;&#8220;<u>Taxes</u>&#8221; means (i)&#160;all federal, state, local, foreign and other net income, gross income, gross receipts, sales, use, stock, ad valorem, transfer, transaction, franchise, profits, gains, registration, license, wages, lease, service, service use, employee and other withholding, social security, unemployment, welfare, disability, payroll, employment, excise, severance, stamp, environmental, occupation, workers&#8217; compensation, premium, real property, personal property, windfall profits, net worth, capital, value-added, alternative or add-on minimum, customs duties, estimated and other taxes, fees, assessments, charges or levies of any kind whatsoever (whether imposed directly or through withholding and including taxes of any third party in respect of which a Person may have a duty to collect or withhold and remit and any amounts resulting from the failure to file any Tax Return), whether disputed or not, together with any interest and any penalties, additions to tax or additional amounts with respect thereto, (ii)&#160;any liability for payment of amounts described in clause (i)&#160;whether as a result of transferee liability, of being a member of an affiliated, consolidated, combined or unitary group for any period or otherwise through operation of Law, and (iii)&#160;any liability for the payment of amounts described in clauses (i)&#160;or (ii)&#160;as a result of any tax sharing, tax indemnity or tax allocation agreement or any other express or implied agreement to indemnify any other Person (other than any such agreement entered into in the ordinary course of business the primary purpose of which is not related to Taxes).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS54"><!--Anchor--></a>Section 5.4&#8195;<u>Interpretation</u>. When a reference is made in this Agreement to a Section, Article, Exhibit or Schedule such reference shall be to a Section, Article, Exhibit or Schedule of this Agreement unless otherwise indicated. The table of contents and headings contained in this Agreement or in any Exhibit or Schedule are for convenience of reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. All words used in this Agreement will be construed to be of such gender or number as the circumstances require. Any capitalized terms used in any Exhibit or Schedule but not otherwise defined therein shall have the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-33<br></div></div></div>
<!--End Page 565-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 566-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg40"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">meaning as defined in this Agreement. All Exhibits and Schedules annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth herein. The word &#8220;including&#8221; and words of similar import when used in this Agreement will mean &#8220;including, without limitation,&#8221; unless otherwise specified. The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of similar import when used in this Agreement shall refer to the Agreement as a whole and not to any particular provision in this Agreement. The term &#8220;or&#8221; is not exclusive. The word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall.&#8221; References to days mean calendar days unless otherwise specified. Each of the terms &#8220;delivered&#8221; and &#8220;made available&#8221; means, with respect to any documentation, that (i)&#160;prior to 11:59 p.m. (Pacific Time) on the date that is two Business Days prior to the date of this Agreement (A) a copy of such material has been posted to and made available by a party to the other party and its Representatives in the electronic data room maintained by such disclosing party, or (B) such material is disclosed in the Buyer SEC Documents filed with the SEC prior to the date hereof and publicly made available on the SEC&#8217;s Electronic Data Gathering Analysis and Retrieval system or (ii)&#160;such documentation has been delivered by or on behalf of a party or its Representatives via electronic mail or in hard copy form prior to the execution of this Agreement. Whenever the last day for the exercise of any privilege or the discharge of any duty hereunder shall fall upon a Saturday, Sunday, or any date on which banks in New York, New York, are authorized or obligated by Law to be closed, the party having such privilege or duty may exercise such privilege or discharge such duty on the next succeeding day which is a regular Business Day.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS55"><!--Anchor--></a>Section 5.5&#8195;<u>Entire Agreement</u>. This Agreement (including the Exhibits hereto), the Sellers Disclosure Letter, the Buyer Disclosure Letter and the Confidentiality Agreements (as such term is defined in the BC Agreement) constitute the entire agreement, and supersede all prior written agreements, arrangements, communications and understandings and all prior and contemporaneous oral agreements, arrangements, communications and understandings among the parties with respect to the subject matter hereof and thereof.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXBS56"><!--Anchor--></a>Section 5.6&#8195;<u>No Third-Party Beneficiaries</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person other than the parties and their respective successors and permitted assigns any legal or equitable right, benefit or remedy of any nature under or by reason of this Agreement, except as provided in <u>Section 4.2</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The representations and warranties in this Agreement are the product of negotiations among the parties hereto and are for the sole benefit of the parties hereto. Any inaccuracies in such representations and warranties are subject to waiver by the parties hereto in accordance with <u>Section 5.8</u> without notice or liability to any other Person. In some instances, the representations and warranties in this Agreement may represent an allocation among the parties hereto of risks associated with particular matters regardless of the knowledge of any of the parties hereto. Consequently, Persons other than the parties hereto may not rely upon the representations and warranties in this Agreement as characterizations of actual facts or circumstances as of the date of this Agreement or as of any other date.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS57"><!--Anchor--></a>Section 5.7&#8195;<u>Amendment or Supplement</u>. This Agreement may be amended, modified or supplemented by the parties by action taken or authorized by their governing bodies at any time, whether before or after the Buyer Stockholder Approval has been obtained; provided, however, that after the Buyer Stockholder Approval has been obtained, no amendment shall be made that pursuant to applicable Law requires further approval or adoption by the Sellers or the stockholders of the Buyer, as applicable, without such further approval or adoption. This Agreement may not be amended, modified or supplemented in any manner, whether by course of conduct or otherwise, except by an instrument in writing specifically designated as an amendment hereto, signed on behalf of each of the parties in interest at the time of the amendment.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS58"><!--Anchor--></a>Section 5.8&#8195;<u>Waiver</u>. The parties may, by action taken or authorized by their respective Boards of Directors, to the extent permitted by applicable Law, waive compliance with any of the agreements or conditions of the other parties contained herein; provided, however, that after the Buyer Stockholder Approval has been obtained, no waiver may be made that pursuant to applicable Law requires further approval or adoption by the Sellers or the stockholders of the Buyer, as applicable, without such further approval or adoption. Any agreement on the part of a party to any such waiver shall be valid only if set forth in a written instrument executed and delivered by a duly authorized officer on behalf of such party. No failure or delay of any party in exercising any right or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-34<br></div></div></div>
<!--End Page 566-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 567-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg41"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">discontinuance of steps to enforce such right or power, or any course of conduct, preclude any other or further exercise thereof or the exercise of any other right or power. The rights and remedies of the parties hereunder are cumulative and are not exclusive of any rights or remedies which they would otherwise have hereunder.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS59"><!--Anchor--></a>Section 5.9&#8195;<u>Fees and Expenses</u>. Except as otherwise set forth in this Agreement, all fees and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the party incurring such fees or expenses.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS510"><!--Anchor--></a>Section 5.10&#8195;<u>Governing Law</u>. This Agreement and all disputes or controversies arising out of or relating to this Agreement or the transactions contemplated hereby shall be governed by, and construed in accordance with, the internal Laws of the State of Delaware, without regard to the Laws of any other jurisdiction that might be applied because of the conflicts of laws principles of the State of Delaware.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS511"><!--Anchor--></a>Section 5.11&#8195;<u>Submission to Jurisdiction</u>. Each of the parties irrevocably agrees that any legal action or proceeding arising out of or relating to this Agreement brought by any party or its Affiliates against any other party or its Affiliates shall be brought and determined in the Court of Chancery of the State of Delaware; provided, that if jurisdiction is not then available in the Court of Chancery of the State of Delaware, then any such legal action or proceeding may be brought in any federal court located in the State of Delaware or any other Delaware state court. Each of the parties hereby irrevocably submits to the jurisdiction of the aforesaid courts for itself and with respect to its property, generally and unconditionally, with regard to any such action or proceeding arising out of or relating to this Agreement and the transactions contemplated hereby. Each of the parties agrees not to commence any action, suit or proceeding relating thereto except in the courts described above in Delaware, other than actions in any court of competent jurisdiction to enforce any judgment, decree or award rendered by any such court in Delaware as described herein. Each of the parties further agrees that notice as provided herein shall constitute sufficient service of process and the parties further waive any argument that such service is insufficient. Each of the parties hereby irrevocably and unconditionally waives, and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise, in any action or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby, (a) any claim that it is not personally subject to the jurisdiction of the courts in Delaware as described herein for any reason, (b) that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (c) that (i)&#160;the suit, action or proceeding in any such court is brought in an inconvenient forum, (ii)&#160;the venue of such suit, action or proceeding is improper or (iii)&#160;this Agreement, or the subject matter hereof, may not be enforced in or by such courts.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS512"><!--Anchor--></a>Section 5.12&#8195;<u>Assignment; Successors</u>. Neither this Agreement nor any of the rights, interests or obligations under this Agreement may be assigned or delegated, in whole or in part, by operation of law or otherwise, by any party without the prior written consent of the other parties, and any such assignment without such prior written consent shall be null and void; provided, however, that a Seller may assign, in its sole discretion, any or all of its rights, interests and obligations under this Agreement to (a) any of its Affiliates at any time, in which case all references herein to such Seller shall be deemed references to such other Affiliate, except that all representations and warranties made herein with respect to such Seller as of the date of this Agreement shall be deemed to be representations and warranties made with respect to such other Affiliate as of the date of such assignment or (b) after the Closing, any Person. Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit of, and be enforceable by, the parties and their respective successors and assigns.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS513"><!--Anchor--></a>Section 5.13&#8195;<u>Specific Performance</u>. The parties agree that irreparable damage would occur in the event that the parties hereto do not perform the provisions of this Agreement in accordance with its terms or otherwise breach such provisions. Accordingly, the parties acknowledge and agree that each party shall be entitled to an injunction, specific performance and other equitable relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in the Court of Chancery of the State of Delaware, provided, that if jurisdiction is not then available in the Court of Chancery of the State of Delaware, then in any federal court located in the State of Delaware or any other Delaware state court, this being in addition to any other remedy to which such party is entitled at law or in equity. Each of the parties hereby further waives (a) any defense in any action for specific performance that a remedy at law would be adequate and (b) any requirement under any Law to post security as a prerequisite to obtaining equitable relief.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS514"><!--Anchor--></a>Section 5.14&#8195;<u>Currency</u>. All references to &#8220;dollars&#8221; or &#8220;$&#8221; or &#8220;US$&#8221; in this Agreement refer to U.S. dollars, which is the currency used for all purposes in this Agreement.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-35<br></div></div></div>
<!--End Page 567-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 568-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg42"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS515"><!--Anchor--></a>Section 5.15&#8195;<u>Severability</u>. Whenever possible, each provision or portion of any provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable Law, but if any provision or portion of any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable Law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or portion of any provision in such jurisdiction, and this Agreement shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision or portion of any provision had never been contained herein.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS516"><!--Anchor--></a>Section 5.16&#8195;<u>Waiver of Jury Trial</u>. EACH OF THE PARTIES TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVES ALL RIGHT TO A TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS517"><!--Anchor--></a>Section 5.17&#8195;<u>Counterparts</u>. This Agreement may be executed in two or more counterparts, all of which shall be considered one and the same instrument and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other party.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS518"><!--Anchor--></a>Section 5.18&#8195;<u>Facsimile or .pdf Signature</u>. This Agreement may be executed by facsimile or .pdf signature and a facsimile or .pdf signature shall constitute an original for all purposes.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXBS519"><!--Anchor--></a>Section 5.19&#8195;<u>No Presumption Against Drafting Party</u>. Each of Buyer and the Sellers acknowledges that each party to this Agreement has been represented by counsel in connection with this Agreement and the transactions contemplated by this Agreement. Accordingly, any rule of law or any legal decision that would require interpretation of any claimed ambiguities in this Agreement against the drafting party has no application and is expressly waived.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">[<font style="font-style: italic;">The remainder of this page is intentionally left blank</font>.]</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-36<br></div></div></div>
<!--End Page 568-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 569-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg43"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">CATALYST BIOSCIENCES, INC.</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Nassim Usman, Ph.D.</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: Nassim Usman, Ph.D.</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title: Chief Executive Officer</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI GROUP LTD.</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Ying Luo</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: Ying Luo</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title: President and Chief Executive Officer</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI HONG KONG LIMITED</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Ying Luo</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: Ying Luo</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title: Director and President</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 396.5pt; text-align: center;">[<font style="font-style: italic;">Signature Page to Asset Purchase Agreement</font>]</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-37<br></div></div></div>
<!--End Page 569-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 570-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg44"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">AGREEMENT AND AMENDMENT TO ASSET PURCHASE AGREEMENT</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This Agreement and Amendment to Asset Purchase Agreement (this &#8220;<u>Agreement and Amendment</u>&#8221;) is dated as of March&#160;29, 2023, with respect to (i) that certain Asset Purchase Agreement (the &#8220;<u>F351 Agreement</u>&#8221;), dated as of December&#160;26, 2022, by and among Catalyst Biosciences, Inc., a Delaware corporation (&#8220;<u>CBIO</u>&#8221;), GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (&#8220;<u>GNI Group</u>&#8221;) and GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability (&#8220;<u>GNI HK</u>&#8221; and collectively with GNI Group, the &#8220;<u>GNI Parties</u>&#8221;) and (ii) the CBIO Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock, filed with the Secretary of State of the State of Delaware on December&#160;27, 2022 (the &#8220;<u>Certificate of Designation</u>&#8221;). Capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the F351 Agreement and Certificate of Designation. RECITALS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, Section 5.7 of the F351 Agreement provides that it may be amended, modified or supplemented by the parties thereto by action taken or authorized by their governing bodies at any time, whether before or after the Buyer Stockholder Approval has been obtained, and by an instrument in writing specifically designated as an amendment thereto, signed on behalf of each of the parties in interest at the time of the amendment; <u>provided</u>, <u>however</u>, that after the Buyer Stockholder Approval has been obtained, no amendment shall be made that pursuant to applicable Law requires further approval or adoption by the GNI Parties or the stockholders of CBIO, as applicable, without such further approval or adoption. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, as of the date hereof, the GNI Parties hold 12,340 shares of Series X Convertible Preferred Stock and have agreed to extend the deadline for the cash settlement of the Conversion Shares set forth in Section 6(d)(iii) of the Certificate of Designation.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">NOW, THEREFORE, in consideration of the premises, and of the mutual agreements contained herein, and intending to be legally bound hereby, CBIO and the GNI Parties hereby agree as follows:</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">ARTICLE I<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">AMENDMENT TO F351 AGREEMENT</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 1.1&#8195;<u>Amendments</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">(a)&#8195;The reference to &#8220;Form S-4&#8221; in the Index of Defined Terms of the F351 Agreement shall be deleted.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">(b)&#8195;The following references shall be added into the Index of Defined Terms of the F351 Agreement:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 428pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 89.72%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proxy Clearance Date <font style="padding-left: 3.77pt;"></font></div></td><td class="gutter" style="width: 2.77%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.77%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">4.1(a) </div></td></tr><tr><td style="width: 89.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Resale Shelf Registration Statement <font style="padding-left: 1.55pt;"></font></div></td><td class="gutter" style="width: 2.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">4.1(c)</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">(c)&#8195;Section 4.1 of the F351 Agreement is hereby amended and restated as follows:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;"><u>Preparation of Proxy Statement and Resale Shelf Registration Statement; Stockholders&#8217; Meeting</u></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(a)&#8195;As promptly as practicable after the date of this Agreement, Buyer shall (i) file with the SEC a proxy statement (as amended or supplemented from time to time, the &#8220;<u>Proxy Statement</u>&#8221;) to be sent to the stockholders of Buyer relating to the special meeting of Buyer&#8217;s stockholders (the &#8220;<u>Buyer Stockholders </u><u>Meeting</u>&#8221;) to be held to consider the Buyer Stockholder Matters and (ii) set a preliminary record date for the Buyer Stockholders Meeting and commence a broker search pursuant to Section&#160;14a-13 of the Exchange Act in connection therewith; provided, that it is understood and agreed that the Sellers shall prepare the initial draft of the Proxy Statement. Buyer shall file the definitive Proxy Statement with the SEC and cause the Proxy Statement to be mailed to its stockholders of record, at such time as reasonably agreed by the Sellers promptly (and in any event within five (5) Business Days) following (x) in the event the preliminary Proxy Statement is not reviewed by the SEC, the expiration of the waiting period in Rule 14a-6(a) under the Securities Exchange Act or (y) in the event the preliminary Proxy Statement is reviewed by the SEC, receipt of oral or written notification of the completion of the review by the SEC (the date in (x) or (y), the &#8220;<u>Proxy Clearance Date</u>&#8221;).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Buyer covenants and agrees that the Proxy Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith) will (i) comply as to form in all material respects with the requirements of applicable U.S. federal securities laws and the DGCL, and (ii) with regard to the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-38<br></div></div></div>
<!--End Page 570-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 571-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg45"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">information provided in the Proxy Statement by Buyer, will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(c)&#8195;As promptly as practicable following March&#160;29, 2023, Buyer shall file with the SEC a registration statement on Form&#160;S-3 or similar short form registration statement that may be available at such time or its successor form, or, if Buyer is ineligible to use Form&#160;S-3, a registration statement on Form&#160;S-1, for an offering to be made on a continuous basis pursuant to Rule&#160;415 of the Securities Act registering the resale of the Buyer Common Stock to be issued pursuant to this Agreement from time to time pursuant to any method or combination of methods legally available to, and requested by, the Sellers (the &#8220;<u>Resale Shelf </u><u>Registration Statement</u>&#8221;); <u>provided</u>, that it is understood and agreed that the Sellers shall prepare the initial draft of the Resale Registration Statement. Buyer will advise the Sellers promptly after it receives oral or written notice thereof of the time when the Resale Registration Statement has become effective or any amendment or supplement thereto has been filed, the issuance of any stop order, the suspension of the qualification of the Buyer Common Stock registered on the Resale Registration Statement for offering or sale in any jurisdiction or any oral or written request by the SEC for amendment of the Resale Registration Statement or comments thereon and responses thereto or requests by the SEC for additional information, and will promptly provide the other with copies of any written communication from the SEC or any state securities commission and a reasonable opportunity to participate in the responses thereto. The Sellers covenant and agree that all information concerning the Sellers and the Purchased Assets furnished by the Sellers and included in the Proxy Statement and the Resale Registration Statement will (i) comply as to form in all material respects with the requirements of applicable U.S. federal securities laws and the DGCL, and (ii) will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. Buyer shall use its reasonable best efforts to have the Resale Registration Statement declared effective by the SEC under the Securities Act as promptly as practicable after such filing and to keep the Resale Registration Statement effective until all securities covered by the Resale Registration Statement are sold in accordance with the intended plan of distribution set forth in the Resale Registration Statement or supplement to the prospectus or such securities have been withdrawn. Buyer shall also take any action (other than qualifying to do business in any jurisdiction in which it is not now so qualified or filing a general consent to service of process) required to be taken under any applicable state securities or &#8220;blue sky&#8221; laws in connection with the registration of the Buyer Common Stock and the Sellers shall furnish all information concerning the Sellers as may be reasonably requested in connection with any such action.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(d)&#8195;Buyer shall use its reasonable best efforts to respond promptly to any comments or requests of the SEC or its staff relating to the Proxy Statement and the Resale Registration Statement; <u>provided</u>, that any comments or request of the SEC or its staff which relate to disclosures contained in the Proxy Statement or the Resale Registration Statement and which were provided by the Sellers will be promptly addressed by the Sellers. No filing of, or amendment or supplement to, the Proxy Statement or the Resale Registration Statement will be made by Buyer, without providing the Sellers a reasonable opportunity to review and comment thereon and without the Sellers&#8217; prior approval (which shall not be unreasonably withheld, conditioned, or delayed). If at any time prior to the Effective Time any information relating to the Sellers or Buyer, or any of their respective Affiliates, officers or directors, should be discovered by the Sellers or Buyer that should be set forth in an amendment or supplement to either of the Proxy Statement or the Resale Registration Statement, so that any of such documents would not contain any misstatement of a material fact or omit to state any material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, the party that discovers such information shall promptly notify the other parties hereto and an appropriate amendment or supplement describing such information shall promptly be filed with the SEC and, to the extent required under applicable Law, disseminated to stockholders of Buyer; <u>provided</u>, that the delivery of such notice and the filing of any such amendment or supplement shall not affect or be deemed to modify any representation or warranty made by any party hereunder or otherwise affect the remedies available hereunder to any party.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(e)&#8195;As promptly as practicable after the Proxy Clearance Date, Buyer shall duly call, give notice of, convene and hold the Buyer Stockholders Meeting to consider and vote to approve the Buyer Stockholder Matters pursuant to the terms of this Agreement and the BC Agreement (and such Buyer Stockholders </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-39<br></div></div></div>
<!--End Page 571-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 572-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg46"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">Meeting shall in any event be no later than forty-five (45) calendar days after the Proxy Clearance Date). Buyer may postpone or adjourn the Buyer Stockholders Meeting solely (i) with the consent of the Sellers; (ii) (A) due to the absence of a quorum or (B) if Buyer has not received proxies representing a sufficient number of shares for the Buyer Stockholder Approval, whether or not a quorum is present, to solicit additional proxies; or (iii) to allow reasonable additional time for the filing and mailing of any supplemental or amended disclosure which the Buyer Board has determined in good faith after consultation with outside legal counsel is necessary under applicable Law and for such supplemental or amended disclosure to be disseminated and reviewed by Buyer&#8217;s stockholders prior to the Buyer Stockholders Meeting; <u>provided</u>, that Buyer may not postpone or adjourn the Buyer Stockholders Meeting more than a total of two times pursuant to clause (ii)(A) and/or clause (ii)(B) of this <u>Section&#160;4.1(e)</u>. Notwithstanding the foregoing, Buyer shall, at the request of the Sellers, to the extent permitted by Law, adjourn the Buyer Stockholders Meeting to a date specified by the Sellers for the absence of a quorum or if Buyer has not received proxies representing a sufficient number of shares for the Buyer Stockholder Approval; <u>provided</u>, that Buyer shall not be required to adjourn the Buyer Stockholders Meeting more than one (1) time pursuant to this sentence, and no such adjournment pursuant to this sentence shall be required to be for a period exceeding ten (10) Business Days. Buyer, through the Buyer Board, shall (i) recommend to its stockholders that they vote to approve the Buyer Stockholder Matters, (ii) include such recommendation in the Proxy Statement and (iii) publicly reaffirm such recommendation within 24&#160;hours after a request to do so by the Sellers. Without limiting the generality of the foregoing, Buyer shall use its reasonable best efforts to solicit proxies to obtain the Buyer Stockholder Approval.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(f)&#8195;Each Seller agrees that it shall, at the Buyer Stockholders Meeting, however called, or in connection with any written consent of the Buyer Stockholders, vote or consent (or cause to be voted or consented), in person or by proxy, all shares of Buyer Common Stock owned by such Seller (i) in favor of the approval of the Buyer Stockholder Matters and any other actions contemplated by this Agreement and the BC Agreement and any actions required in furtherance hereof and thereof, including delivering a written consent, (ii) against approval of any proposal made in opposition to, or in competition with, the Buyer Stockholder Matters, and (iii) against any other proposal, action, or transaction that would impede, frustrate, prevent or materially delay the consummation of the transactions contemplated by the BC Agreement. Each Seller agrees irreparable damage would occur in the event that such Seller does not perform the provisions of this <u>Section&#160;4.1(f)</u> in accordance with its terms or otherwise breaches such provisions, and accordingly, Buyer would be entitled to the equitable remedies under <u>Section&#160;5.13</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Section 1.2&#8195;<u>Effect of Amendment</u>. Except as specifically modified herein, the F351 Agreement remains in full force and effect.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; text-align: center;">ARTICLE II<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">AGREEMENT ON CASH SETTLEMENT EXTENSION</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Section 2.1&#8195;<u>Cash Settlement Extension</u>. As of the date hereof, the GNI Parties hold 12,340 shares of Series X Convertible Preferred Stock. The GNI Parties and CBIO hereby agree to extend the deadline for the cash settlement of the Conversion Shares as set forth in Section 6(d)(iii) of the Certificate of Designation as follows:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;If, at any time after the earlier of (i) receipt of Stockholder Approval or (ii) September&#160;30, 2023, CBIO fails to deliver to the GNI Parties such certificate or certificates, or electronically deliver (or cause its transfer agent to electronically deliver) such shares in the case of a DWAC Delivery, pursuant to Section&#160;&#8206;6(d)(i) of the Certificate of Designation on or prior to the third (3rd) Trading Day after the Share Delivery Date applicable to such conversion (other than a failure caused by incorrect or incomplete information provided by the GNI Parties to CBIO), then, unless the GNI Parties have rescinded the applicable Notice of Stock Conversion pursuant to Section&#160;6(d)(i) of the Certificate of Designation, CBIO shall, at the request of the GNI Parties, pay an amount equal to the Fair Value (as defined therein) of such undelivered shares, with such payment to be made within two Business Days from the date of request by the GNI Parties, whereupon CBIO&#8217;s obligations to deliver such shares underlying the Notice of Stock Conversion shall be extinguished.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;If any of the GNI Parties assigns any or all of its rights, interests and obligations in the Series&#160;X Convertible Preferred Stock and/or Conversion Shares to any of its Affiliates, then all references herein to such GNI Party shall be deemed references to such other Affiliate. Any preferences, rights and limitations of Series&#160;X Convertible Preferred Stock set forth in the Certificate of Designation will be binding upon, inure to the benefit of, and be enforceable by, the parties and their respective successors and assigns.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-40<br></div></div></div>
<!--End Page 572-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 573-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg47"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Section 2.2&#8195;<u>Effect of Agreement</u>. Except as specifically agreed herein, the preferences, rights and limitations of Series&#160;X Convertible Preferred Stock set forth in the Certificate of Designation remain unchanged and in full force and effect.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">ARTICLE III<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">GENERAL PROVISIONS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Section 3.1&#8195;<u>Counterparts</u>. This Agreement and Amendment may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument, with the same effect as if the signatures thereto were in the same instrument.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 3.2&#8195;<u>General Provisions</u>. Article&#160;V of the F351 Agreement is hereby incorporated by reference.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 20.5pt; text-align: center;">[<font style="font-style: italic;">Remainder of Page Intentionally Left Blank; Signature Pages Follow</font>]</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-41<br></div></div></div>
<!--End Page 573-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 574-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg48"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">IN WITNESS WHEREOF, the parties have each caused this Agreement and Amendment to be duly executed as of the date first written above.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>CBIO</u>:<font style="font-weight: normal;"> </font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">CATALYST BIOSCIENCES, INC.<font style="font-weight: normal;"> </font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Nassim Usman, Ph.D. </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:&#8194;Nassim Usman, Ph.D. </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:&#8195;Chief Executive Officer</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">[<font style="font-style: italic;">Signature Page to Agreement and Amendment to Asset Purchase Agreement</font>]<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-42<br></div></div></div>
<!--End Page 574-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 575-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_301-annexb_pg49"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">IN WITNESS WHEREOF, the parties have each caused this Agreement and Amendment to be duly executed as of the date first written above.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>GNI PARTIES</u>:<font style="font-weight: normal;"> </font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI GROUP LTD.<font style="font-weight: normal;"> </font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Ying Luo </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:&#8194;Ying Luo </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:&#8195;President and Chief Executive Officer</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">GNI HONG KONG LIMITED<font style="font-weight: normal;"> </font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Ying Luo </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:&#8194;Ying Luo </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:&#8195;Director and President</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">[<font style="font-style: italic;">Signature Page to Agreement and Amendment to Asset Purchase Agreement</font>]<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-43<br></div></div></div>
<!--End Page 575-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 576-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_302-annexc_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;"><a name="tANXC"><!--Anchor--></a>Annex C</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; text-align: right;">December&#160;21, 2022</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Board of Directors<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">611 Gateway Blvd., Suite 710<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">South San Francisco, CA 94080</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Members of the Board of Directors:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 12pt; margin-left: 0pt; text-align: justify;">We understand that (a) Catalyst Biosciences, Inc., a Delaware corporation (the &#8220;Company&#8221;), and GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (&#8220;GNI Group&#8221;), and GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability (&#8220;GNI Hong Kong&#8221; and, together with GNI Group, the &#8220;Asset Sellers&#8221; and each, an &#8220;Asset Seller&#8221;), propose to enter into an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement&#8221;) pursuant to which, among other things, the Asset Sellers will sell to the Company, and the Company will purchase from the Asset Sellers, the Purchased Assets (as defined in the Purchase Agreement), and in connection therewith the Company will assume certain liabilities and obligations of the Asset Sellers relating thereto (the &#8220;Asset Purchase&#8221;), and, in connection with the Asset Purchase, the Company will issue to the Asset Sellers (i) 6,298,010 shares of common stock, par value $0.001 per share, of the Company (&#8220;Company Common Stock&#8221;), and (ii) 12,337 shares of Series X Convertible Preferred Stock, par value $0.001 per share, of the Company (&#8220;Company Convertible Preferred Stock&#8221;), and (b) the Company, GNI USA, Inc., a Delaware corporation (&#8220;GNI&#160;USA&#8221;), GNI Group, GNI Hong Kong, Shanghai Genomics, Inc., a company organized under the laws of the People&#8217;s Republic of China (together with GNI USA, &#8220;Contributors&#8221; and each, a &#8220;Contributor&#8221;), Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares (&#8220;Continent&#8221;), and the other parties signatory thereto, propose to enter into a Business Combination Agreement (the &#8220;Business Combination Agreement&#8221; and, together with the Asset Purchase Agreement, the &#8220;Transaction Agreements&#8221;), related, in part, to the interest of Continent and the Minority Holders (as defined below) in Beijing Continent Pharmaceuticals Co., Ltd., a company organized under the laws of the People&#8217;s Republic of China (&#8220;Beijing Continent&#8221;), and pursuant to which, among other things, (i)&#160;GNI USA will transfer all of the ordinary shares in the capital of Continent, par value $0.0001 per share (each, a &#8220;Continent Ordinary Share&#8221;), it holds immediately prior to Closing (as defined in the Business Combination Agreement) to the Company (the &#8220;Continent Contribution&#8221;), (ii)&#160;GNI USA will contribute all of the 50,000, no par value, shares of a single class in Further Challenger International Limited, a company incorporated and existing under the laws of the British Virgin Islands with company number 1982271 (each, a &#8220;FC Share&#8221;), it holds immediately prior to Closing (as defined in the Business Combination Agreement) to the Company (the &#8220;FC Contribution&#8221;), (iii)&#160;each individual listed on Annex&#160;A to the Business Combination Agreement (each, a &#8220;Minority Holder&#8221; and, collectively, the &#8220;Minority Holders&#8221;) will transfer 100% of the interest he or she holds immediately prior to Closing (as defined in the Business Combination Agreement) in his or her respective Entity (as defined in the Business Combination Agreement) to the Company (the &#8220;Minority Holder Contributions&#8221; and, together with the Continent Contribution and the FC Contribution, the &#8220;Contributions&#8221;; the Contributions, together with the Asset Purchase, are collectively referred to herein as the &#8220;Transactions&#8221;), and (iii)&#160;the Company will issue (A)(x)&#160;to GNI USA 689,245,843 shares of Company Common Stock in exchange for the Continent Contribution, (y) to GNI USA 265,123,920 shares of Company Common Stock in exchange for the FC Contribution, and (z) to the Minority Holders an aggregate of 157,043,872 shares of Company Common Stock, in the amounts set forth on Annex&#160;A to the Business Combination Agreement, in exchange for the Minority Holder Contributions, or (B) at the election of GNI USA or any such Minority Holder, in lieu of the issuance of Company Common Stock it is entitled to be issued as set forth in the foregoing clause (A), a number of shares of Company Convertible Preferred Stock determined by dividing (x)&#160;the number of shares of Company Common Stock GNI USA or such Minority Holder elects to receive in the form of Company Convertible Preferred Stock by (y) 10,000. Each share of Company Convertible Preferred Stock is convertible into 10,000 shares of Company Common Stock. The shares of Company Common Stock and Company Convertible Preferred Stock to be issued in the Transactions is referred to herein as the &#8220;Transaction Consideration.&#8221; We have been advised that, prior to consummation of the Contributions, (1) the Company will declare and pay to the holders of Company Common Stock who were holders of Company Common Stock prior to execution of the Transaction Agreements (the &#8220;Existing Stockholders&#8221;) a cash dividend in the aggregate amount of $7,500,000, and (2) the Company will create and issue to the Existing Stockholders one contingent value right (a &#8220;CVR&#8221;) for each share of Company Common Stock held by such stockholder as of the record date set for such issuance. The CVRs </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">C-1<br></div></div></div>
<!--End Page 576-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 577-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_302-annexc_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">will represent the right to receive contingent payments upon the occurrence of certain events set forth in, and subject to and in accordance with the terms and conditions of, the CVR Agreement (as defined in the Business Combination Agreement), including, without limitation, the amount of any cash payment received by the Company pursuant to a Disposition Agreement (as defined in the CVR Agreement), the amount of any excess net cash of the Company over $1,000,000 immediately following the Closing Date (as defined in the Business Combination Agreement), the amount of any cash received by the Company under the Asset Purchase Agreement (net of indemnity claims, if any) and the amount of the excess, if any, by which the Interim Operating Amount (as defined in the Business Combination Agreement) exceeds the Incurred Fees (as defined in the CVR Agreement). The terms and conditions of the Asset Purchase and the Contributions are more completely described in the Asset Purchase Agreement and the Business Combination Agreement, respectively.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Board of Directors of the Company (the &#8220;Board&#8221;) has requested that Raymond James &amp; Associates, Inc. (&#8220;Raymond James&#8221;) provide an opinion (the &#8220;Opinion&#8221;) to the Board as to whether, as of the date hereof, the&#160;Transaction Consideration to be paid by the Company in the Transactions pursuant to the Transaction Agreements is fair, from a financial point of view, to the Company.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with our review of the proposed Transactions and the preparation of this Opinion, we have, among other things:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed the financial terms and conditions of (a) the Asset Purchase as stated in the draft of the Asset Purchase Agreement dated as of December&#160;20, 2022, such draft being the last draft of the Asset Purchase Agreement provided to us, and (b) the Contributions as stated in the draft of the Business Combination Agreement dated as of December&#160;20, 2022, such draft being the last draft of the Business Combination Agreement provided to us;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed the financial terms and conditions of the CVRs as stated in the draft of the CVR Agreement dated as of December&#160;20, 2022, such draft being the last draft of the CVR Agreement provided to us;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed certain information related to the historical, current and future operations, financial condition and prospects of the Company made available to us by the Company;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed certain information related to the historical, current and future operations of Beijing Continent and the Purchased Assets (as defined in the Asset Purchase Agreement) made available to us by the Company, including, but not limited to, financial projections prepared by the management of the Company for the period ending 2023 through 2031, as approved for our use by the Company as of December&#160;19, 2022 (the &#8220;Projections&#8221;);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed the Company&#8217;s recent public filings and certain other publicly available information regarding the Company, GNI Group, the Asset Sellers, the Contributors, Continent and Beijing Continent;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed certain other non-public financial, operating and other information regarding the Company, GNI Group, the Asset Sellers, the Contributors, Continent and Beijing Continent provided to us by the Company;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed the financial and operating performance of selected public companies that we deemed to be relevant;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">considered the publicly available financial terms of certain transactions we deemed to be relevant;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">performed a discounted cash flow analysis with respect to Beijing Continent and the Purchased Assets based upon the Projections;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed the current and historical market prices for the Company Common Stock and the current market prices of the publicly traded securities of certain other companies that we deemed to be relevant;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">considered certain discussions and negotiations between representatives of the Company, Beijing Continent, the Asset Sellers and/or the Contributors in which we participated;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">received a certificate addressed to Raymond James from a member of senior management of the Company regarding, among other things, the accuracy of the information, data and other materials (financial or otherwise) provided to, or discussed with, Raymond James by or on behalf of the Company;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">conducted such other financial studies, analyses and inquiries and considered such other information and factors as we deemed appropriate; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">discussed with members of the senior management of the Company certain information relating to the aforementioned and any other matters which we have deemed relevant to our inquiry.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">C-2<br></div></div></div>
<!--End Page 577-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 578-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_302-annexc_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">With your consent, we have assumed and relied upon the accuracy and completeness of all information supplied by or on behalf of the Company or otherwise reviewed by or discussed with us, and we have undertaken no duty or responsibility to, nor did we, independently verify any of such information. We have not made or obtained an independent appraisal of the assets or liabilities (contingent or otherwise) of the Company or Beijing Continent. With&#160;respect to the Projections and any other forward-looking information and data provided to or otherwise reviewed by or discussed with us, we have, with your consent, assumed that the Projections and such other information and data have been reasonably prepared in good faith on bases reflecting the best currently available estimates and judgments of management of the Company, and we have relied upon the Company to advise us promptly if any information previously provided became inaccurate or was required to be updated during the period of our review. We express no opinion with respect to the Projections or the assumptions on which they are based. We have assumed that the final forms of the Transaction Agreements will be substantially similar to the drafts reviewed by us, and that the Transactions will be consummated in accordance with the terms of the Transaction Agreements without waiver or amendment of any conditions thereto. Furthermore, we have assumed, in all respects material to our analysis, that the representations and warranties of each party contained in the Transaction Agreements are true and correct and that each such party will perform all of the covenants and agreements required to be performed by it under the Transaction Agreements without being waived. We have relied upon and assumed, without independent verification, that (i)&#160;the Transactions will be consummated in a manner that complies in all respects with all applicable international, federal and state statutes, rules and regulations, and (ii)&#160;all governmental, regulatory and other consents and approvals necessary for the consummation of the Transactions will be obtained and that no delay, limitations, restrictions or conditions will be imposed or amendments, modifications or waivers made that would have an effect on the Transactions, the Company or Continent that would be material to our analyses or this Opinion. Furthermore, at the Company&#8217;s direction, we have ascribed no value to the CVRs and therefore are not providing any opinion with regard to any aspect of the CVRs, which are further described in the CVR Agreement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our opinion is based upon market, economic, financial and other circumstances and conditions existing and disclosed to us as of December&#160;20, 2022 and any material change in such circumstances and conditions would require a reevaluation of this Opinion, which we are under no obligation to undertake. We have relied upon and assumed, without independent verification, that there has been no change in the business, assets, liabilities, financial condition, results of operations, cash flows or prospects of the Company, Continent, GNI Group, Beijing Continent, any Asset Seller or any Contributor since the respective dates of the most recent financial statements and other information, financial or otherwise, provided to us that would be material to our analyses or this Opinion, and that there is no information or any facts that would make any of the information reviewed by us incomplete or misleading in any material respect.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We express no opinion as to the underlying business decision to effect the Transactions, the structure or tax consequences of the Transactions or the availability or advisability of any alternatives to the Transactions. While we provided advice to the Company with respect to the proposed Transactions, we did not recommend any specific amount of consideration or that any specific consideration constituted the only appropriate consideration for the Transactions. In addition, we do not express any opinion as to the likely trading range of the Company Common Stock following the Transactions, which may vary depending on numerous factors that generally impact the price of securities or on the financial condition of the Company at that time.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our opinion is limited to the fairness, from a financial point of view, to the Company, of the Transaction Consideration to be paid by the Company in the Transactions. We express no opinion with respect to any other reasons, legal, business or otherwise that may support the decision of the Board to approve or consummate the Transactions. Furthermore, no opinion, counsel or interpretation is intended by Raymond James on matters that require legal, accounting or tax advice. It is assumed that such opinions, counsel or interpretations have been or will be obtained from the appropriate professional sources. Furthermore, we have relied, with the consent of the Board, on the fact that the Company has been assisted by legal, accounting and tax advisors, and we have, with the consent of the Board, relied upon and assumed the accuracy and completeness of the assessments by the Company and its advisors as to all legal, accounting and tax matters with respect to the Company and the Transactions.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In formulating our opinion, we have considered only what we understand to be the Transaction Consideration to be paid by the Company in the Transactions as is described above, and we did not consider, and we express no opinion on, the fairness of the amount or nature of any compensation to be paid or payable to any of the Company&#8217;s, Continent&#8217;s, any Asset Seller&#8217;s or any Contributor&#8217;s officers, directors or employees, or class of such persons, whether relative to the compensation received by any such party or otherwise. We have not been requested to opine as to, and </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">C-3<br></div></div></div>
<!--End Page 578-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 579-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_302-annexc_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">this Opinion does not express an opinion as to or otherwise address, among other things: (i)&#160;the fairness of the Transactions to the holders of any class of securities, creditors or other constituencies of the Company, or to any other party, or (ii)&#160;the fairness of the Transaction to any one class or group of the Company&#8217;s or any other party&#8217;s security holders or other constituencies vis-&#224;-vis any other class or group of the Company&#8217;s or such other party&#8217;s security holders or other constituencies (including, without limitation, the allocation of any consideration to be received in the Transactions amongst or within such classes or groups of security holders or other constituencies or parties). We are not expressing any opinion as to the impact of the Transactions on the solvency or viability of the Company, Continent, any Asset Seller or any Contributor or the ability of the Company, Continent, any Asset Seller or any Contributor to pay their respective obligations when they come due.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">The delivery of this opinion was approved by an opinion committee of Raymond James.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Raymond James has been engaged to render financial advisory services to the Company in connection with the proposed Transactions. Raymond James will receive a fee upon the delivery of this Opinion, which is not contingent upon the successful completion of the Transactions or on the conclusion reached herein. In addition, the Company has agreed to reimburse certain of our expenses and to indemnify us against certain liabilities arising out of our engagement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In the ordinary course of our business, Raymond James may trade in the securities of the Company for our own account or for the accounts of our customers and, accordingly, may at any time hold a long or short position in such securities. In the previous two years, Raymond James provided investment banking services to the Company, for which it was paid fees of approximately $951,000. Other than such services, there are no material relationships that existed during the two years prior to the date of this Opinion or that are mutually understood to be contemplated in which any compensation was received or is intended to be received as a result of the relationship between Raymond James and any party to the Transaction. Raymond James may provide investment banking, financial advisory and other financial services to the Company in the future, for which Raymond James may receive compensation.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">It is understood that this letter is for the information of the Board (solely in each director&#8217;s capacity as such) in&#160;evaluating the proposed Transactions and does not constitute a recommendation to the Board or any stockholder of the Company regarding how the Board or any such stockholder should vote on the proposed Transactions. This Opinion may not be reproduced or used for any other purpose without our prior written consent, except that this Opinion may be disclosed in any proxy statement or prospectus filed with any registration statement that is required to be filed in connection with the Transactions with the Securities and Exchange Commission, provided that this Opinion is quoted in full in such proxy statement or prospectus.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Based upon and subject to the foregoing, it is our opinion that, as of the date hereof, the Transaction Consideration to be paid by the Company in the Transactions pursuant to the Transaction Agreements is fair, from a financial point of view, to the Company.</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Very truly yours,</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">/s/ Raymond James &amp; Associates, Inc.</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">RAYMOND JAMES &amp; ASSOCIATES, INC.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">C-4<br></div></div></div>
<!--End Page 579-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 580-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_303-annexd_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;"><a name="tANXD"><!--Anchor--></a>Annex D</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Certain information identified by bracketed asterisks ([***]) has been omitted from this exhibit because it is both not material and would be competitively harmful if publicly disclosed. </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; text-align: center;">CONTINGENT VALUE RIGHTS AGREEMENT</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">THIS CONTINGENT VALUE RIGHTS AGREEMENT<font style="font-weight: normal;"> (this &#8220;</font><font style="font-weight: normal;"><u>Agreement</u></font><font style="font-weight: normal;">&#8221;), dated as of December&#160;26, 2022 </font><font style="font-weight: normal;">(the &#8220;</font><font style="font-weight: normal;"><u>Effective Date</u></font><font style="font-weight: normal;">&#8221;), is entered into by and between Catalyst Biosciences, Inc., a Delaware corporation (the </font><font style="font-weight: normal;">&#8220;</font><font style="font-weight: normal;"><u>Company</u></font><font style="font-weight: normal;">&#8221;), and American Stock Transfer &amp; Trust Company, LLC, a New York limited liability company, as initial </font><font style="font-weight: normal;">Rights Agent (as defined herein).</font></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; text-align: center;">RECITALS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, on December&#160;22, 2022, the Board of Directors of the Company authorized and declared a dividend distribution of one CVR right for each share of Company common stock outstanding at the close of business on the Record Date (defined below); </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, the Company intends the distribution of the rights underlying the CVRs to be complete and irrevocable and hereby assigns to the Holders the right to receive the Payment Amounts (as defined below); and</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, the parties have done all things necessary to make the CVR, when issued hereunder, the valid obligation of the Company and to make this Agreement a valid and binding agreement of the Company, in accordance with its terms.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">NOW, THEREFORE, in consideration of the premises and the consummation of the transactions referred to above, it is mutually covenanted and agreed, for the proportionate benefit of all Holders (as defined below), as follows: </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; text-align: center;">ARTICLE 1<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">DEFINITIONS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 1.1&#8195;<font style="font-style: italic;">Definitions.</font> </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Capitalized terms used but not otherwise defined herein have the meanings ascribed to thereto in the Business Combination Agreement. The following terms have the meanings ascribed to them as follows:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<u>Affiliate</u>&#8221; shall have the meaning given to such term in Rule 145 under the Securities Act.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<u>Asset Purchase Agreement</u>&#8221; means the Asset Purchase Agreement, dated as of May&#160;19, 2022, by and between the Company and Vertex Pharmaceuticals Incorporated. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<u>Assignee</u>&#8221; has the meaning set forth in <u>Section 6.6</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<u>Business Combination Agreement</u>&#8221; means that certain Business Combination Agreement, dated as of December&#160;26, 2022, by and among the Company, GNI Group Ltd., GNI Hong Kong Limited, GNI USA, Inc., Shanghai Genomics, Inc., Continent Pharmaceuticals Inc., and the Minority Holders (as defined in the Business Combination Agreement). </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<u>Business Day</u>&#8221; means any day other than a day on which banks in the state of New York are authorized or obligated to be closed.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<u>Claim</u>&#8221; means any pending, threatened, or potential claim, suit, proceeding, investigation arbitration, or other legal right that the Company has or may have during the Term against any third party related to the Company&#8217;s business on or before the Effective Time.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<u>Code</u>&#8221; has the meaning set forth in <u>Section 2.3(d)</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<u>CVR</u>&#8221; means a contingent contractual right of Holders to receive the Payment Amounts pursuant to this Agreement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<u>CVR Register</u>&#8221; has the meaning set forth in <u>Section 2.2(b)</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<u>Disposition</u>&#8221; means (i)&#160;the sale, license, transfer or other disposition to a third party of any rights or assets comprising the Legacy Assets, including any sale or disposition of equity securities in any Subsidiary established by </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-1<br></div></div></div>
<!--End Page 580-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 581-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_303-annexd_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">the Company to hold any right, title or interest in any Legacy Assets, or (ii)&#160;the settlement, court order, arbitration ruling, or other disposition of any Claim resulting in payment or the right to receive payment, in each case, during the Disposition Period. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<u>Disposition Agreement</u>&#8221; means a definitive written agreement providing for (i)&#160;a Disposition of any portion of the Legacy Assets during the Disposition Period or (ii)&#160;the settlement of any Claim.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<u>Disposition Period</u>&#8221; means the two-year period following the Record Date; <font style="font-style: italic;"><u>provided</u></font>, <font style="font-style: italic;"><u>however</u></font>, such period will be automatically extended for any Claim for an additional one-year period to the extent any Claim is appealed during the initial two-year term.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<u>Excluded Taxes</u>&#8221; has the meaning set forth in <u>Section 3.2(g)</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<u>Holder</u>&#8221; means, at the relevant time, a Person in whose name CVRs are registered in the CVR Register. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<u>Incurred Fees</u>&#8221; has the meaning set forth in <u>Section 4.4(c)</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<u>Interim Operating Amount</u>&#8221; has the meaning set forth in the Business Combination Agreement. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<u>Law</u>&#8221; means any federal, state, national, foreign, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling, or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any governmental authority (including under the authority of Nasdaq or the Financial Industry Regulatory Authority).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<u>Legacy Assets</u>&#8221; means [***].</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<u>Loss</u>&#8221; has the meaning set forth in <u>Section 3.2(g)</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<u>Majority of Holders</u>&#8221; means, at any time, the registered Holder or Holders of more than 50% of the total number of CVRs registered at such time, as set forth on the CVR Register, except that with respect to the use of the term <font style="font-style: italic;">Majority of Holders</font> in <u>Section 6.7</u>, the term shall mean the registered Holder or Holders of more than 25% of the total number of CVRs registered at such time, as set forth on the CVR Register.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<u>Notice</u>&#8221; has the meaning set forth in <u>Section 6.1</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<u>Officer&#8217;s Certificate</u>&#8221; means a certificate signed by the chief executive officer and the principal financial and accounting officer of the Company, in their respective official capacities. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<u>Payment Amount</u>&#8221; means, with respect to any Payment Triggering Event: (i) 100% of the amount actually received (net of out-of-pocket and documented transaction expenses and potential indemnification obligations) by the Company pursuant to any Disposition Agreement; (ii) 100% of the excess cash (net of all current or contingent liabilities, including transaction-related expenses and unpaid severance or change of control payment obligations) retained by the Company in excess of $1,000,000 as of the Closing of the Closing Date (as defined in the Business Combination Agreement); (iii) 100% of the amount actually received (net of indemnity claims, if any) by the Company pursuant to the Asset Purchase Agreement; and (iv) 100% of the excess, if any, by which the Interim Operating Amount exceeds the Incurred Fees, in each case net of: (a) any Tax incurred by the Company or such Affiliate(s) as a result of the receipt of such payment and (b) the reasonable costs, out-of-pocket fees, expenses or charges incurred, directly or indirectly, by the Rights Agent, the Company or the Company&#8217;s Affiliates (but subject to <u>Section 4.4</u>), or for which the Rights Agent, the Company or the Company&#8217;s Affiliates (subject to <u>Section 4.4</u>) are responsible, in connection with such Payment Triggering Event (in each case to the extent such costs, fees, expenses or charges have not been previously accounted for in the calculation of a prior Payment Amount).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<u>Payment Triggering Event</u>&#8221; means the actual receipt by the Rights Agent or the Company following the Record Date of: (i)&#160;any cash payment pursuant to a Disposition Agreement, (ii)&#160;Net Cash (as defined in the Business Combination Agreement) over $1,000,000 immediately following the Closing Date, (iii) any cash received by the Company under the Asset Purchase Agreement (net of indemnity claims, if any), and (iv)&#160;the excess, if any, by which the Interim Operating Amount exceeds the Incurred Fees under <u>Section 4.4(c)</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<u>Permitted Transfer</u>&#8221; means a transfer of CVRs (i)&#160;upon death of a Holder by will or intestacy, (ii)&#160;pursuant to a court order, (iii)&#160;by operation of law (including by consolidation or merger) or without consideration in connection with the dissolution, liquidation or termination of any corporation, limited liability company, partnership or other entity, (iv)&#160;in the case of CVRs held in book-entry or other similar nominee form, from a nominee to a beneficial owner and, if applicable, through an intermediary, or (v)&#160;as provided in <u>Section 2.5</u>.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-2<br></div></div></div>
<!--End Page 581-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 582-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_303-annexd_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<u>Person</u>&#8221; means any individual, corporation, partnership, joint venture, estate, trust, company, firm, limited liability company, firm, society or other enterprise, association, organization, or any other entity not specifically listed herein, including any governmental authority.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<u>Pro Rata Share</u>&#8221; means, with respect to any Holder, the quotient obtained by dividing (i)&#160;the aggregate number of CVRs held by such Holder by (ii)&#160;the aggregate number of outstanding CVRs held by all Holders, in each case, as reflected in the CVR Register.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<u>Record Date</u>&#8221; means January&#160;5, 2023. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<u>Rights Agent</u>&#8221; means the Rights Agent named in the first paragraph of this Agreement, until a successor Rights Agent shall have been appointed pursuant to <u>&#8206;ARTICLE 3</u> of this Agreement, and thereafter &#8220;Rights Agent&#8221; will mean such successor Rights Agent.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<u>Securities Act</u>&#8221; means the Securities Act of 1933, as amended.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<u>Special Committee</u>&#8221; means an oversight committee initially comprised of the following individuals: Nassim Usman, Ph.D., Augustine Lawlor and Andrea Hunt, and such additional members as may be added by the Special Committee, from time to time.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">An entity shall be deemed to be a &#8220;<u>Subsidiary</u>&#8221; of a Person if such Person directly or indirectly owns or purports to own, beneficially or of record, (a) an amount of voting securities or other interests in such entity that is sufficient to enable such Person to elect at least a majority of the members of such entity&#8217;s board of directors or other governing body, or (b) at least 50% of the outstanding equity, voting, beneficial or financial interests in such entity.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<u>Tax</u>&#8221; means any federal, state, local, foreign or other tax, including any income tax, franchise tax, capital gains tax, gross receipts tax, value-added tax, surtax, estimated tax, unemployment tax, national health insurance tax, excise tax, ad valorem tax, transfer tax, stamp tax, sales tax, use tax, property tax, business tax, withholding tax, payroll tax, customs duty, alternative or add-on minimum or other tax of any kind whatsoever, and including any fine, penalty, addition to tax or interest imposed by a governmental authority with respect thereto.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; text-align: center;">ARTICLE 2<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">CONTINGENT VALUE RIGHTS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 2.1&#8195;<font style="font-style: italic;">Holders of CVRs; Appointment of Rights Agent; Assignment of Rights.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The initial Holders shall be the holders of shares of the Company&#8217;s common stock as of the close of business on the Record Date. Effective five Business Days following the Record Date, each initial Holder shall be issued and distributed in the form of a dividend one CVR for each share of Company common stock held of record by such Holder as of the close of business on the Record Date. Notwithstanding anything to the contrary in this Agreement, in no event shall any CVRs be issued pursuant to this Agreement prior to five&#160;Business Days following the Record Date. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The Company hereby appoints the Rights Agent to act as rights agent for the Company in accordance with the express terms and conditions set forth in this Agreement, and the Rights Agent hereby accepts such appointment. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 2.2&#8195;<font style="font-style: italic;">No Certificate; Registration; Registration of Transfer; Change of Address; CVR Distribution.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Holders&#8217; rights and obligations in respect of CVRs derive solely from this Agreement; CVRs will not be evidenced by a certificate or other instrument.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The Rights Agent will create and maintain a register (the &#8220;<u>CVR Register</u>&#8221;) for the purposes of (i)&#160;identifying the Holders of CVRs, (ii)&#160;determining the Holders&#8217; entitlement to CVRs and (iii)&#160;registering the CVRs and Permitted Transfers thereof. The CVR Register will be created, and CVRs will be distributed, pursuant to written instructions to the Rights Agent from Company. Except for the obligations to the Rights Agent set forth herein, neither the Company nor its Subsidiaries will have any responsibility or liability whatsoever to any Person other than the Holders.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;Subject to the restrictions on transferability set forth in <u>Section 2.6</u>, every request made to transfer CVRs must be in writing and accompanied by a written instrument of transfer reasonably acceptable to the Rights Agent, together with the signature guarantee of a guarantor institution which is a participant in a signature guarantee program approved by the Securities Transfer Association (a &#8220;signature guarantee&#8221;) and other </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-3<br></div></div></div>
<!--End Page 582-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 583-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_303-annexd_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">requested documentation in a form reasonably satisfactory to the Rights Agent, duly executed and properly completed, as applicable, by the Holder or Holders thereof, or by the duly appointed legal representative, personal representative or survivor of such Holder or Holders, setting forth in reasonable detail the circumstances relating to the transfer. Upon receipt of such written notice, the Rights Agent will, subject to its reasonable determination in accordance with its own internal procedures, that the transfer instrument is in proper form and otherwise complies on its face with the other terms and conditions of this Agreement (including the provisions in <u>Section 2.6</u>), register the transfer of the applicable CVRs in the CVR Register. All transfers of CVRs registered in the CVR Register will be the valid obligations of the Company, evidencing the same right, and entitling the transferee to the same benefits and rights under this Agreement, as those held by the transferor. The Company and the Rights Agent may each require evidence of payment of a sum sufficient to cover any stamp or other transfer tax or governmental charge that is imposed in connection with (and would not have been imposed but for) any such registration of transfer (or evidence that such Taxes and charges are not applicable). No transfer of CVRs shall be valid until registered in the CVR Register and unless such transfer would not violate the Securities Act. Any putative transfer not duly registered in the CVR Register or in violation of the Securities Act shall be void.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;A Holder may make a written request to the Rights Agent to change such Holder&#8217;s address of record in the CVR Register. Such written request must be duly executed by such Holder. Upon receipt of such written notice, the Rights Agent shall promptly record the change of address in the CVR Register.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;The Company will provide written instructions to the Rights Agent for the distribution of CVRs to the Holders as of the Record Date. The Company shall inform Rights Agent of the Record Date at least five business days prior thereto. Subject to the terms and conditions of this Agreement and the Company&#8217;s confirmation of the Record Date, the Rights Agent hereunder shall make the CVR distribution, less any applicable withholding taxes imposed pursuant to <u>Section 2.3(d)</u>, to each Holder as of the Record Date, five Business Days following the Record Date, by the mailing of a statement of holding reflecting CVRs. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 2.3&#8195;<font style="font-style: italic;">Payment Procedures.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;If a Payment Triggering Event occurs at any time prior to the termination of this Agreement then, within 10 calendar days after the occurrence of such Payment Triggering Event, the Company will deliver to the Rights Agent (i)&#160;an Officer&#8217;s Certificate certifying the date of the Payment Triggering Event, the amount of the payment and that the Holders are entitled to receive the applicable Payment Amount in respect thereof (the &#8220;<u>Payment Triggering Event Notice</u>&#8221;), and (ii)&#160;an amount in cash equal to the applicable Payment Amount (for further distribution to the Holders in accordance with the terms hereof) by wire transfer of immediately available funds to an account designated by the Rights Agent.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Upon receipt of either the Payment Amount or the wire transfer referred to in <u>Section 2.3(a)</u>, the Rights Agent will promptly (and in any event within 10 Business Days) pay, by check mailed, first-class postage prepaid, to the address of each Holder set forth in the CVR Register at such time or by other method of delivery as specified by the applicable Holder in writing to the Rights Agent, an amount in cash equal to such Holder&#8217;s Pro Rata Share of the applicable Payment Amount. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;With respect to any Payment Amount that is paid to the Company or an Affiliate of the Company, the Company shall have no further liability in respect of such Payment Amount upon delivery of the relevant funds to the Rights Agent in accordance with <u>Section 2.3(a)</u>. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;The Company and the Rights Agent will be entitled to deduct and withhold, or cause to be deducted and withheld, from any amounts required to be paid or distributed under this Agreement (including any Payment Amount payable pursuant to this Agreement), such amounts as it is required to deduct and withhold with respect to the making of such payment or distribution (including in respect of the distribution of CVRs) under any provision of applicable Law relating to Taxes. To the extent that amounts are so deducted and withheld, such deducted and withheld amounts will be treated for all purposes of this Agreement as having been paid or distributed to the Holder in respect of which such deduction and withholding was made. Prior to making any such Tax deductions or withholdings or causing any such Tax deductions or withholdings to be made with respect to any Holder, the Rights Agent will, to the extent reasonably practicable, provide notice to the Holder of such potential Tax deduction or withholding and a reasonable opportunity for the Holder to provide any necessary Tax forms in order to avoid or reduce such withholding amounts; <font style="font-style: italic;"><u>provided</u></font>, that the time period for payment of a Payment Amount by the Rights Agent set forth in <u>Section 2.3(b)</u> will be extended by a period equal </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-4<br></div></div></div>
<!--End Page 583-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 584-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_303-annexd_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">to any delay caused by the Holder providing such forms, <font style="font-style: italic;"><u>provided</u></font>, <font style="font-style: italic;"><u>further</u></font>, that in no event shall such period be extended for more than ten Business Days, unless otherwise requested by the Holder for the purpose of delivering such forms and agreed to by the Rights Agent. The Rights Agent will solicit from each Holder an appropriate Internal Revenue Service Form W-8 or Internal Revenue Service Form W-9, as applicable on or prior to any distribution or other payment to such Holder to permit any payment of any Payment Amount to be made without deduction or withholding of any US. backup withholding taxes or taxes imposed pursuant to Sections 1471 through 1474 of the U.S. Internal Revenue Code, as amended (the &#8220;<u>Code</u>&#8221;).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;Any portion of a Payment Amount that remains undistributed to the Holders on the date that is six months after the Rights Agent&#8217;s receipt of the applicable Payment Triggering Event Notice (including by means of uncashed checks or invalid addresses on the CVR Register) will be delivered by the Rights Agent to the Company or a Person nominated in writing by the Company (with written notice thereof from the Company to the Rights Agent), and any Holder will thereafter look only to the Company for payment of such Payment Amount (which shall be without interest).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;If any Payment Amount (or portion thereof) remains unclaimed by a Holder on the date that is four years after the Rights Agent&#8217;s receipt of the applicable Payment Triggering Event Notice or the Payment Amount (or immediately prior to such earlier date on which such Payment Amount would otherwise escheat to or become the property of any governmental authority), then: (i)&#160;such Payment Amount (or portion thereof) will, to the extent permitted by applicable Law, become the property of the Company and will be transferred to the Company or a Person nominated in writing by the Company (with written notice thereof from the Company to the Rights Agent), free and clear of all claims or interest of any Person previously entitled thereto, and no consideration or compensation shall be payable therefor, and (ii)&#160;the CVRs to which such payment relate shall be deemed abandoned in accordance with <u>Section 2.5</u> and shall no longer be deemed outstanding for any purpose (including for purposes of calculating a Holder&#8217;s Pro Rata Share). Neither the Company nor the Rights Agent will be liable to any Person in respect of a Payment Amount delivered to a public official pursuant to any applicable abandoned property, escheat or similar legal requirement under applicable Law. In addition to and not in limitation of any other indemnity obligation herein, the Company agrees to indemnify and hold harmless the Rights Agent with respect to any liability, penalty, cost or expense the Rights Agent may incur or be subject to in connection with transferring such property to the Company or a public official. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 2.4&#8195;<font style="font-style: italic;">No Voting, Dividends or Interest; No Equity or Ownership Interest.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;CVRs will not have any voting or dividend rights, and interest will not accrue on any amounts payable in respect of CVRs.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;CVRs will not represent any equity or ownership interest in the Company or any of its Affiliates. The sole right of the Holders to receive property hereunder is the right to receive Payment Amounts, if any, in accordance with the terms hereof. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify; line-height: 12pt;">(c)&#8195;The CVRs and the possibility of any payment hereunder with respect thereto are highly speculative and subject to numerous factors outside of the Company&#8217;s control, and there is no assurance that Holders will receive any payments under this Agreement or in connection with the CVRs. It is highly possible that there will not be any CVR Payment Amounts. Neither Company nor its Affiliates owe, by virtue of their obligations under this Agreement, a fiduciary duty or any implied duties to the Holders and the parties hereto intend solely the express provisions of this Agreement to govern their contractual relationship with respect to the CVRs. This <u>Section 2.4(c)</u> is an essential and material term of this Agreement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 2.5&#8195;<font style="font-style: italic;">Ability to Abandon CVR.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">A Holder may at any time, at such Holder&#8217;s option or upon the failure to claim payment under <u>Section 2.3(f)</u>, abandon all of such Holder&#8217;s remaining rights represented by CVRs by transferring such CVR to the Company or a Person nominated in writing by the Company (with written notice thereof from the Company to the Rights Agent) without consideration in compensation therefor, and such rights will be cancelled, with the Rights Agent being promptly notified in writing by the Company of such transfer and cancellation. No such notice to the Rights Agent shall be required in the case of abandonment due to the failure to claim payment under <u>Section 2.3(f)</u>. Nothing in this Agreement is intended to prohibit the Company or its Affiliates from offering to acquire or acquiring CVRs, in private transactions or otherwise, for consideration in its sole discretion.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-5<br></div></div></div>
<!--End Page 584-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 585-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_303-annexd_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 2.6&#8195;<font style="font-style: italic;">Non-transferable.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The CVRs may not be sold, assigned, transferred, pledged, encumbered or in any other manner transferred or disposed of, in whole or in part, other than through a Permitted Transfer. The CVRs will not be listed on any quotation system or traded on any securities exchange.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; text-align: center;">ARTICLE 3<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">THE RIGHTS AGENT</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 3.1&#8195;<font style="font-style: italic;">Certain Duties and Responsibilities.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The Rights Agent will not have any liability for any actions taken or not taken in connection with this Agreement, except to the extent such liability arises as a result of the willful misconduct, bad faith or gross negligence of the Rights Agent (in each case as determined by a final non-appealable judgment of court of competent jurisdiction). Notwithstanding anything in this Agreement to the contrary, any liability of the Rights Agent under this Agreement will be limited to the amount of annual fees paid by the Company to the Rights Agent during the 12 months immediately preceding the event for which recovery from the Rights Agent is being sought. Anything to the contrary notwithstanding, in no event will the Rights Agent be liable for special, punitive, indirect, incidental or consequential loss or damages of any kind whatsoever (including, without limitation, lost profits), even if the Rights Agent has been advised of the likelihood of such loss or damages, and regardless of the form of action. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The Rights Agent will not have any duty or responsibility in the case of the receipt of any written demand from any Holder with respect to any action or default by any Person or entity, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon the Company. All rights of action under this Agreement may be enforced (but shall not be required to be enforced) by the Rights Agent, any claim, action, suit, audit, investigation or proceeding instituted by the Rights Agent will be brought in its name as the Rights Agent and any recovery in connection therewith will be for the proportionate benefit of all the Holders, as their respective rights or interests may appear on the CVR Register.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 3.2&#8195;<font style="font-style: italic;">Certain Rights of Rights Agent.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The Rights Agent undertakes to perform such duties and only such duties as are specifically set forth in this Agreement, and no implied covenants or obligations will be read into this Agreement against the Rights Agent.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The Rights Agent may rely and will be protected by the Company in acting or refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order or other paper or document believed by it in the absence of bad faith to be genuine and to have been signed or presented by or on behalf of the Company.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;Whenever the Rights Agent deems it desirable that a matter be proved or established prior to taking or omitting any action hereunder, the Rights Agent may (i)&#160;rely upon an Officer&#8217;s Certificate and (ii)&#160;incur no liability and be held harmless by the Company for or in respect of any action taken or omitted to be taken by it under the provisions of this Agreement in reliance upon such Officer&#8217;s Certificate.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;The Rights Agent may engage and consult with counsel of its selection, and the advice or opinion of such counsel will, in the absence of bad faith, gross negligence or willful misconduct on the part of the Rights Agent, be full and complete authorization and protection in respect of any action taken or not taken by the Rights Agent in reliance thereon.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(e)&#8195;Any permissive rights of the Rights Agent hereunder will not be construed as a duty. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;The Rights Agent will not be required to give any note or surety in respect of the execution of its powers or otherwise under this Agreement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;The Company agrees to indemnify the Rights Agent for, and to hold the Rights Agent harmless from and against, any loss, liability, damage, judgment, fine, penalty, cost or expense (each, a &#8220;<u>Loss</u>&#8221;) suffered or incurred by the Rights Agent and arising out of or in connection with the Rights Agent&#8217;s performance of its obligations under this Agreement, including the reasonable and documented costs and expenses of defending the Rights Agent against any claims, charges, demands, actions or suits arising out of or in connection in connection </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-6<br></div></div></div>
<!--End Page 585-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 586-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_303-annexd_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">with the execution, acceptance, administration, exercise and performance of its duties under this Agreement, including the costs and expenses of defending against any claim of liability arising therefrom, directly or indirectly, or enforcing its rights hereunder, except to the extent such Loss has been determined by a final non-appealable decision of a court of competent jurisdiction to have resulted from the Rights Agent&#8217;s gross negligence, bad faith or willful misconduct; provided that this <u>Section 3.2(g)</u> shall not apply to (i)&#160;income, receipt, franchise or similar Taxes, (ii)&#160;any Taxes imposed due to the Rights Agent&#8217;s connection with the jurisdiction imposing such Taxes (other than any connection caused solely by this Agreement or the Rights Agent performing, enforcing or receiving payments under this Agreement), or (iii)&#160;any Taxes imposed due to the failure of the Rights Agent to provide any form, document or certificate that would have reduced or eliminated the amount of such withholding taxes (&#8220;<u>Excluded Taxes</u>&#8221;).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(h)&#8195;In addition to the indemnification provided under <u>Section 3.2(g)</u>, the Company agrees (i)&#160;to pay the fees of the Rights Agent in connection with the Rights Agent&#8217;s performance of its obligations hereunder, as agreed upon in writing by the Rights Agent and the Company on or prior to the date of this Agreement, and (ii)&#160;to reimburse the Rights Agent for all reasonable and properly documented out-of-pocket expenses, including all stamp and transfer Taxes (excluding any Excluded Taxes) and governmental charges, incurred by the Rights Agent in the performance of its obligations under this Agreement, except that the Company will have no obligation to pay the fees of the Rights Agent or reimburse the Rights Agent in connection with any lawsuit initiated by the Rights Agent on behalf of itself or the Holders, except in the case of any suit enforcing the provisions of <u>Section 2.3(b)</u> or <u>Section 3.2(g)</u>, if the Company is found by a court of competent jurisdiction to be liable to the Rights Agent or the Holders, as applicable in such suit.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(i)&#8195;No provision of this Agreement shall require the Rights Agent to expend or risk its own funds or otherwise incur any financial liability in the performance of any of its duties hereunder or in the exercise of any of its rights or powers if it believes that repayment of such funds or adequate indemnification against such risk or liability is not reasonably assured to it.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(j)&#8195;The Rights Agent will not be deemed to have knowledge of any event of which it was supposed to receive notice hereunder but has not received written notice of such event, and the Rights Agent will not incur any liability for failing to take action in connection therewith, in each case, unless and until it has received such notice in writing.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(k)&#8195;Subject to applicable Law, (i)&#160;the Rights Agent and any shareholder, affiliate, director, officer or employee of the Rights Agent may buy, sell or deal in any securities of the Company or become peculiarly interested in any transaction in which the Company may be interested, or contract with or lend money to the Company or otherwise act as fully and freely as though it were not the Rights Agent under this Agreement, and (ii)&#160;nothing herein will preclude the Rights Agent from acting in any other capacity for the Company or for any other Person.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(l)&#8195;The Rights Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself or by or through its attorney or agents and the Rights Agent shall not be answerable or accountable for any act, default, neglect or misconduct of any such attorney or agents or for any loss to the Company resulting from any such act, default, neglect or misconduct, absent gross negligence, bad faith or willful misconduct (each as determined by a final non-appealable judgment of a court of competent jurisdiction) in the selection and continued employment thereof.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(m)&#8195;The Company shall perform, acknowledge and deliver or cause to be performed, acknowledged and delivered all such further and other acts, documents, instruments and assurances as may be reasonably required by the Rights Agent for the carrying out or performing by the Rights Agent of the provisions of this Agreement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(n)&#8195;The Rights Agent shall not be liable for or by reason of any of the statements of fact or recitals contained in this Agreement (except its countersignature thereof) or be required to verify the same, and all such statements and recitals are and shall be deemed to have been made by the Company only.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(o)&#8195;The Rights Agent shall act hereunder solely as agent for the Company and shall not assume any obligations or relationship of agency or trust with any of the owners or holders of the CVRs. The Rights Agent </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-7<br></div></div></div>
<!--End Page 586-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 587-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_303-annexd_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">shall not have any duty or responsibility in the case of the receipt of any written demand from any Holders with respect to any action or default by the Company, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon the Company.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(p)&#8195;The Rights Agent may rely on and be fully authorized and protected in acting or failing to act upon (a) any guaranty of signature by an &#8220;eligible guarantor institution&#8221; that is a member or participant in the Securities Transfer Agents Medallion Program or other comparable &#8220;signature guarantee program&#8221; or insurance program in addition to, or in substitution for, the foregoing; or (b) any law, act, regulation or any interpretation of the same even though such law, act, or regulation may thereafter have been altered, changed, amended or repealed.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(q)&#8195;The Rights Agent shall not be liable or responsible for any failure of the Company to comply with any of its obligations relating to any registration statement filed with the Securities and Exchange Commission or this Agreement, including without limitation obligations under applicable regulation or law.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(r)&#8195;The obligations of the Company under this <u>Section 3.2</u> shall survive the expiration of the CVRs and the termination of this Agreement and the resignation, replacement or removal of the Rights Agent.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 3.3&#8195;<font style="font-style: italic;">Resignation and Removal; Appointment of Successor.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The Rights Agent may resign at any time by written notice to the Company. Any such resignation notice shall specify the date on which such resignation will take effect (which shall be at least 30 days following the date that such resignation notice is delivered), and such resignation will be effective on the earlier of (x)&#160;the date so specified and (y) the appointment of a successor Rights Agent.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The Company will have the right to remove the Rights Agent at any time by written notice to the Rights Agent, specifying the date on which such removal will take effect. Such notice will be given at least 30&#160;days prior to the date so specified (or, if earlier, the appointment of the successor Rights Agent).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;If the Rights Agent resigns, is removed or becomes incapable of acting, the Company will promptly appoint a qualified successor Rights Agent. Notwithstanding the foregoing, if the Company fails to make such appointment within a period of 30 days after giving notice of such removal or after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated Rights Agent, then the incumbent Rights Agent may apply to any court of competent jurisdiction for the appointment of a new Rights Agent. The successor Rights Agent so appointed will, upon its acceptance of such appointment in accordance with this <u>&#8206;Section 3.3(c)</u> and <u>&#8206;Section 3.4</u>, become the Rights Agent for all purposes hereunder.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;The Company will give notice to the Holders of each resignation or removal of the Rights Agent and each appointment of a successor Rights Agent in accordance with <u>&#8206;Section 6.2</u>. Each notice will include the name and address of the successor Rights Agent. If the Company fails to send such notice within ten Business Days after acceptance of appointment by a successor Rights Agent, the successor Rights Agent will cause the notice to be mailed at the expense of the Company.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;Notwithstanding anything to the contrary in this <u>Section 3.3</u>, unless consented to in writing by the Majority of Holders, the Company will not appoint as a successor Rights Agent any Person that is not a stock transfer agent of national reputation or the corporate trust department of a commercial bank. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;The Rights Agent will reasonably cooperate with the Company and any successor Rights Agent in connection with the transition of the duties and responsibilities of the Rights Agent to the successor Rights Agent, including the transfer of all relevant data, including the CVR Register, to the successor Rights Agent; but such predecessor Rights Agent shall not be required to make any additional expenditure or assume any additional liability in connection with the foregoing.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 3.4&#8195;<font style="font-style: italic;">Acceptance of Appointment by Successor.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Every successor Rights Agent appointed hereunder will, at or prior to such appointment, execute, acknowledge and deliver to the Company and to the resigning or removed Rights Agent an instrument accepting such appointment and a counterpart of this Agreement, and such successor Rights Agent, without any further act, deed or conveyance, </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-8<br></div></div></div>
<!--End Page 587-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 588-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_303-annexd_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">will become vested with all the rights, powers, trusts and duties of the Rights Agent; <font style="font-style: italic;"><u>provided</u></font>, that upon the request of the Company or the successor Rights Agent, such resigning or removed Rights Agent will execute and deliver an instrument transferring to such successor Rights Agent all the rights, powers and trusts of such resigning or removed Rights Agent. </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; text-align: center;">ARTICLE 4<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">COVENANTS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 4.1&#8195;<font style="font-style: italic;">List of Holders.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Company will furnish or cause to be furnished to the Rights Agent, in such form as the Company receives from its transfer agent (or other agent performing similar services for the Company), the names and addresses of the Holders within 10 Business Days following the Record Date. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 4.2&#8195;<font style="font-style: italic;">Prohibited Actions.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Unless approved by the Special Committee, the Company shall take no action for the principal purpose of (i)&#160;reducing the amount of any Payment Amounts payable under this Agreement or (ii)&#160;restricting the Company&#8217;s ability to pay any of the Payment Amounts hereunder. Unless approved by the Special Committee, the Company shall not grant any lien, security interest, pledge or similar interest in: (x)&#160;any Payment Amounts or proceeds from any Disposition or other Payment Triggering Event during the Term, or (y) any Legacy Assets during the Disposition Period. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 4.3&#8195;<font style="font-style: italic;">Backstop Financing Statement.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">It is the intent of the Company for the distribution to the Holders of the rights to receive the Payment Amount in respect of any Disposition to be complete and irrevocable. Notwithstanding the foregoing, the form of financing statement on Form UCC-1 attached as <u>Exhibit A</u> hereto shall be filed within 10 Business Days from the Record Date for the purpose of establishing a first-priority security interest in the Payment Amounts, to the extent that the assignment of such rights hereunder is not deemed effective, complete, or irrevocable for any reason. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 4.4&#8195;<font style="font-style: italic;">CVR Committee; Efforts.</font> </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Subject to <u>Section 4.4(b)</u>, the Special Committee shall have the sole responsibility, authority, and discretion during the Disposition Period to (i)&#160;negotiate the terms of any Disposition, (ii)&#160;oversee the prosecution and settlement of any Claim(s), and (iii)&#160;oversee the execution of any Payment Triggering Event(s). The Special Committee will recommend to the Board of Directors approval of any Disposition Agreement negotiated by the Special Committee, and provided that such Disposition Agreement does require the Company to expend or risk its own funds or otherwise incur any financial liability in the performance of any duties under such Disposition Agreement following the closing of the transactions thereunder (such as indemnity obligations and any restrictions on the ability to conduct the Company&#8217;s business), the Board of Directors shall promptly cause the Company to execute and deliver such Disposition Agreement. For the avoidance of doubt, payments from the Interim Operating Amount shall not be considered Company financial liabilities for purposes of this <u>Section 4.4</u>. To the extent permitted under Nasdaq listing standards and applicable law, each member of the Special Committee will be entitled to receive reasonable compensation for their services and effort, and reasonable reimbursements for expenses, if any, provided that such compensation will not exceed an equivalent of $400 per hour of service or effort by each such member of the Special Committee.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The responsibility and authority of the Special Committee set forth in <u>Section 4.4(a)</u> will not be revoked or modified at any time during the Disposition Period; <font style="font-style: italic;"><u>provided</u></font>, <font style="font-style: italic;"><u>however</u></font>, no provision of this Agreement will require the Company to expend or risk its own funds or otherwise incur any financial liability in the performance of any duties hereunder or in the exercise of any rights or powers, to the extent in excess of the Interim Operating Amount. The Special Committee and the Company&#8217;s Board of Directors will not owe fiduciary duties to the Holders (in their capacity as such) and will not have any liability to the Holders for any actions taken or not taken in connection with the matters set forth herein. Moreover, neither the Special Committee or any members thereof will be required to expend or risk his or her own funds or otherwise incur any financial liability in the performance of any duties hereunder or in the exercise of any rights or powers.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;In furtherance of the authority granted to the Special Committee under <u>Section 4.4(a)</u>, the Special Committee will be entitled during the Disposition Period to incur, and the Company shall pay any and all, fees, expenses and costs to manage, negotiate, settle and finalize the Claims and any audits under <u>&#8206;Section 4.5</u> (the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-9<br></div></div></div>
<!--End Page 588-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 589-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_303-annexd_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">&#8220;<u>Incurred Fees</u>&#8221;); <font style="font-style: italic;"><u>provided</u></font>, <font style="font-style: italic;"><u>however</u></font>, the Incurred Fees may not exceed the Interim Operating Amount. Upon the expiration of the Disposition Period, to the extent the Interim Operating Amount exceeds the Incurred Fees, any such excess amount will be distributed to the Holders as a Payment Amount. For the avoidance of doubt, the Special Committee may not incur any fees, expenses or costs under this Section in excess of the Interim Operating Amount without the prior written approval of the Company&#8217;s Board of Directors.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;Subject to <u>&#8206;Section 6.7</u>, the Holders will be intended third-party beneficiaries of the provisions of this Agreement and will be entitled to specifically enforce the terms hereof; <font style="font-style: italic;"><u>provided</u></font>, that under no circumstances will the rights of Holders as third-party beneficiaries pursuant to this <u>Section 4</u> be enforceable by such Holders or any other Person acting for or on their behalf other than the Special Committee. The Special Committee has the sole power and authority to act on behalf of the Holders in enforcing any of their rights hereunder.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;Subject to <u>&#8206;Section 4.4&#8206;(b)</u>, during the Disposition Period, the Company will, and will cause its Subsidiaries to, use commercially reasonable efforts to uphold the terms of all Disposition Agreements, including as applicable, effectuate the Disposition of Legacy Assets or Claims pursuant to such Disposition Agreement in accordance with its terms. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;Notwithstanding anything contained herein to the contrary, the Company will not, and will not permit its Affiliates to: (i)&#160;amend any Disposition Agreement or waive any right thereunder, if such amendment or waiver materially and adversely affects the rights of the Holders to receive the CVR Payment Amounts hereunder, unless the Special Committee consents to each such amendment or waiver, which will not be unreasonably withheld, delayed, or conditioned, or (ii)&#160;assign any Disposition Agreement without the consent of the Special Committee, unless such assignee agrees to assume all payment obligations under, and agrees to be bound in writing to the terms of such agreement and this Agreement. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 4.5&#8195;<font style="font-style: italic;">Copies of CVR Records; Audit Rights</font>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Each Holder shall have the right, at any time, to request in writing to receive copies of: (i)&#160;Payment Triggering Event Notices delivered to the Rights Agent, (ii)&#160;any Audit Reports delivered to the Rights Agent pursuant to <u>Section 4.5(b)&#8206;</u>, (iii)&#160;copies of material correspondence between the Company or its Affiliates and the Rights Agent, (iv)&#160;amendments to the Agreement effected pursuant to &#8206;<u>ARTICLE 5</u>, and (v)&#160;the records of the Rights Agent setting forth the dates and amounts of all Payment Amounts delivered to the Rights Agent, whether by Celgene, the Company or an Affiliate of the Company. The requesting Holder(s) shall pay the reasonable out-of-pocket expenses of the Rights Agent (<font style="font-style: italic;">e.g.</font>, photocopying expenses, postage, etc.) incurred in responding to any such document requests. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The Company shall keep, and shall require its Affiliates to keep, complete and accurate books and records that may be necessary for the purpose of calculating the Payment Amounts payable under this Agreement. At the request of the Special Committee, the Special Committee shall have the right to appoint an independent accounting firm to perform, on behalf of all Holders, an inspection of such books and records for the sole purpose of determining the Payment Amounts payable hereunder. Upon at least ten Business Days&#8217; prior written notice from the Special Committee, such audit shall be conducted during regular business hours in such a manner as to not unnecessarily interfere with the Company&#8217;s normal business activities. Such audit shall not be performed more frequently than once per calendar year. If the audit reveals an overpayment, the Company shall be entitled to withhold such amount from future payments of Payment Amounts. If the audit reveals an underpayment, the Company shall promptly (and in any event within 30 days) remit such amount to the Rights Agent for distribution to the Holders. The Company shall pay the audit costs if the underpayment exceeds 5% of the aggregate amount owed with regard to the period of the audit; otherwise, the Special Committee requesting the audit shall bear such audit expenses. A copy of the results of any audit conducted under this &#8206;<u>Section 4.5(b)</u> (an &#8220;<u>Audit Report</u>&#8221;) shall be provided to the Company and the Rights Agent within thirty&#160;(30)&#160;days from issuance by the auditor. </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; text-align: center;">ARTICLE 5<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">AMENDMENTS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 5.1&#8195;<font style="font-style: italic;">Amendments Without Consent of Holders or Rights Agent.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The Company, at any time and from time to time, may enter into one or more amendments to this Agreement for any of the following purposes, without the consent of any of the Holders or the Rights Agent (subject to <u>Section 5.3</u>), <font style="font-style: italic;"><u>provided</u></font>, that if any such amendment(s) (individually or the aggregate) materially </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-10<br></div></div></div>
<!--End Page 589-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 590-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_303-annexd_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">impairs or adversely affects the rights of the Holders hereunder, such amendment shall also require the prior written consent of the Holders in accordance with <u>Section 5.2</u>:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(i)&#8195;to evidence the appointment of another Person as a successor Rights Agent and the assumption by any successor Rights Agent of the covenants and obligations of the Rights Agent herein in accordance with the provisions hereof;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(ii)&#8195;to evidence the succession of another Person to the Company and the assumption of any such successor of the covenants of the Company outlined herein in a transaction contemplated by &#8206;<u>Section 6.6</u>;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iii)&#8195;to add to the covenants of the Company such further covenants, restrictions, conditions or provisions for the protection and benefit of the Holders; <font style="font-style: italic;"><u>provided</u></font>, that in each case, such provisions shall not adversely affect the interests of the Holders;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iv)&#8195;to cure any ambiguity, to correct or supplement any provision in this Agreement that may be defective or inconsistent with any other provision in this Agreement, or to make any other provisions with respect to matters or questions arising under this Agreement;<font style="font-style: italic;"><u> provided</u></font>, that in each case, such provisions shall not adversely affect the interests of the Holders; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(v)&#8195;as may be necessary or appropriate to ensure that CVRs are not subject to registration under the Securities Act or the Securities Exchange Act of 1934, as amended, and the rules and regulations made thereunder, or any applicable state securities or &#8220;blue sky&#8221; laws; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(vi)&#8195;as may be necessary or appropriate to ensure that the Company is not required to produce a prospectus or an admission document in order to comply with applicable Law; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(vii)&#8195;to cancel CVRs (i)&#160;in the event that any Holder has abandoned its rights in accordance with &#8206;<u>Section 2.5</u> or (ii)&#160;following a transfer of such CVRs to the Company or its Affiliates in accordance with <u>Section 2.2</u> and <u>Section 2.6</u>;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(viii)&#8195;as may be necessary or appropriate to ensure that the Company complies with applicable Law; or</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(ix)&#8195;to effect any other amendment to this Agreement that would provide any additional rights or benefits to the Holders or that does not adversely affect the legal rights under this Agreement of any such Holder.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Promptly after the execution by the Company of any amendment pursuant to this &#8206;<u>Section 5.1</u>, the Company will (or will cause the Rights Agent to) notify the Holders in general terms of the substance of such amendment in accordance with <u>&#8206;Section 6.2</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 5.2&#8195;<font style="font-style: italic;">Amendments with Consent of Holders.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;In addition to any amendments to this Agreement that may be made by the Company without the consent of any Holder or the Rights Agent pursuant to &#8206;<u>Section 5.1</u>, with the consent of the Majority of Holders, the Company and the Rights Agent may enter into one or more amendments to this Agreement for the purpose of adding, eliminating or amending any provisions of this Agreement, even if such addition, elimination or amendment is adverse to the interests of the Holders. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Promptly after the execution by the Company and the Rights Agent of any amendment pursuant to the provisions of this <u>&#8206;Section 5.2</u>, the Company will (or will cause the Rights Agent to) notify the Holders in general terms of the substance of such amendment in accordance with &#8206;<u>Section 6.2</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 5.3&#8195;<font style="font-style: italic;">Effect of Amendments.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Upon the execution of any amendment under this <u>&#8206;ARTICLE 5</u>, this Agreement will be modified in accordance therewith, such amendment will form a part of this Agreement for all purposes and every Holder will be bound thereby. Upon the delivery of a certificate from an appropriate officer of the Company which states that the proposed supplement or amendment is in compliance with the terms of this <u>&#8206;ARTICLE 5</u>, the Rights Agent shall execute such supplement or amendment. Notwithstanding anything in this Agreement to the contrary, the Rights Agent shall not be required to execute any supplement or amendment to this Agreement that it has determined would adversely affect its own rights, duties, obligations or immunities under this Agreement. No supplement, amendment or other modification to this Agreement shall be effective unless duly executed by the Rights Agent. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-11<br></div></div></div>
<!--End Page 590-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 591-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_303-annexd_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">ARTICLE 6<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">MISCELLANEOUS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 6.1&#8195;<font style="font-style: italic;">Notices to Rights Agent and to the Company.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">All notices, requests and other communications (each, a &#8220;<u>Notice</u>&#8221;) to any party hereunder shall be in writing and delivered personally, by FedEx or other internationally recognized overnight courier service or, except with respect to any Notice from any Holder, by email. Such Notice shall be deemed given (a) on the date of delivery, if delivered in person or by e-mail (upon confirmation of receipt) prior to 5:00 p.m. in the time zone of the receiving party or on the next Business Day, if delivered after 5:00 p.m. in the time zone of the receiving party or (b) on the first Business Day following the date of dispatch, if delivered by FedEx or by other internationally recognized overnight courier service (upon proof of delivery), addressed as follows:</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td colspan="7" style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">if to the Rights Agent, to:</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">American Stock Transfer &amp; Trust Company, LLC</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6201 15th Ave</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Brooklyn, NY 11219</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Corporate Actions Group</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">E-mail: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">reorg_rm@astfinancial.com</div></td></tr></table><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td colspan="7" style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">if to the Company, to:</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">611 Gateway Blvd.</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Suite 120</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">South San Francisco, CA 94080</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Nassim Usman</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Seline Miller</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">E-mail: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">nusman@catbio.com</div></td></tr><tr><td style="width: 5.13%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">smiller@catbio.com</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">or to such other address as such party may hereafter specify for the purpose by notice to the other parties hereto. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 6.2&#8195;<font style="font-style: italic;">Notice to Holders.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">All Notices required to be given to the Holders will be given (unless otherwise herein expressly provided) in writing and mailed, first-class postage prepaid, to each Holder at such Holder&#8217;s address as set forth in the CVR Register, not later than the latest date, and not earlier than the earliest date, prescribed for the sending of such Notice, if any, and will be deemed given on the date of mailing. In any case where notice to the Holders is given by mail, neither the failure to mail such Notice, nor any defect in any Notice so mailed, to any particular Holder will affect the sufficiency of such Notice with respect to other Holders. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 6.3&#8195;<font style="font-style: italic;">Entire Agreement.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">As between the Company and the Rights Agent, this Agreement constitutes the entire agreement between the parties with respect to the subject matter of this Agreement, notwithstanding the reference to any other agreement herein, and supersedes all prior agreements and understandings, both written and oral, among or between any of the parties with respect to the subject matter of this Agreement. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 6.4&#8195;<font style="font-style: italic;">Successor Substituted.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Upon any consolidation of or merger by the Company with or into any other Person, or any conveyance, transfer or lease of substantially all of the properties and assets of the Company to any Person, the surviving Person or acquiring Person (as applicable) shall succeed to, and be substituted for, and may exercise every right and power of, and shall assume all of the obligations of the Company under this Agreement with the same effect as if such Person had been named as the Company herein.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 6.5&#8195;<font style="font-style: italic;">Merger or Consolidation or Change of Name of Rights Agent.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Any Person into which the Rights Agent or any successor Rights Agent may be merged or with which it may be consolidated, or Person resulting from any merger or consolidation to which the Rights Agent or any successor </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-12<br></div></div></div>
<!--End Page 591-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 592-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_303-annexd_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Rights Agent shall be a party, or any Person succeeding to the stock transfer or other shareholder services business of the Rights Agent or any successor Rights Agent, shall be the successor to the Rights Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of the parties hereto, <font style="font-style: italic;"><u>provided</u></font>, that such Person would be eligible for appointment as a successor Rights Agent under the provisions of <u>&#8206;Section 3.3</u>. The purchase of all or substantially all of the Rights Agent&#8217;s assets employed in the performance of transfer agent activities shall be deemed a merger or consolidation for purposes of this <u>&#8206;Section 6.5</u>. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 6.6&#8195;<font style="font-style: italic;">Successors and Assigns.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This Agreement will be binding upon, and will be enforceable by and inure solely to the benefit of, the Holders, the Company and the Rights Agent and their respective successors and assigns. Except for assignments to its Affiliates and as provided in <u>&#8206;Section 6.5</u>, the Rights Agent may not assign this Agreement without the Company&#8217;s prior written consent. Subject to <u>Section 5.1(a)(ii)</u> and <u>Section 6.4</u> hereof, the Company may assign, in its sole discretion and without the consent of any other party, any or all of its rights, interests and obligations hereunder to one or more of its Affiliates or to any Person with whom the Company is merged or consolidated, or any entity resulting from any merger or consolidation to which the Company shall be a party (each, an &#8220;<u>Assignee</u>&#8221;); <font style="font-style: italic;"><u>provided</u></font>, <font style="font-style: italic;"><u>however</u></font>, that in connection with any assignment to an Assignee, the Company shall agree to remain liable for the performance by the Company of its obligations hereunder (to the extent the Company exists following such assignment). The Company or an Assignee may not otherwise assign this Agreement without the prior consent of the Majority of Holders. Any attempted assignment of this Agreement in violation of this <u>&#8206;Section 6.6</u> will be void <font style="font-style: italic;">ab </font><font style="font-style: italic;">initio</font> and of no effect. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 6.7&#8195;<font style="font-style: italic;">Benefits of Agreement; Action by Majority of Holders.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Nothing in this Agreement, express or implied, will give to any Person (other than the Company, the Rights Agent, the Holders and their respective permitted successors and assigns hereunder) any benefit or any legal or equitable right, remedy or claim under this Agreement or under any covenant or provision herein contained, all such covenants and provisions being for the sole benefit of the Company, the Rights Agent, the Holders and their permitted successors and assigns. The Holders are intended third-party beneficiaries under this Agreement, but will have no rights hereunder except as are expressly set forth herein. Except for the rights of the Rights Agent set forth herein, the Majority of Holders will have the sole right, on behalf of all Holders, by virtue of or under any provision of this Agreement, to institute any action or proceeding at law or in equity with respect to the performance of this Agreement by the Company, and no individual Holder or other group of Holders will be entitled to exercise such rights. Notwithstanding the foregoing, in the event of a bankruptcy of the Company, individual Holders shall be entitled to assert claims in bankruptcy and take related actions in pursuit of such claims with respect to any Payment Amounts that may be claimed by the bankruptcy estate of the Company or by any creditor of the Company. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 6.8&#8195;<font style="font-style: italic;">Governing Law.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This Agreement and the CVRs will be governed by, and construed in accordance with, the Laws of the State of New York, (without giving effect to any rule or principle that would result in application of the law of any other jurisdiction) and for all purposes shall be governed by and construed in accordance with the laws of such State applicable to contracts to be made and performed entirely within such State. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 6.9&#8195;<font style="font-style: italic;">Jurisdiction.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In any action or proceeding between any of the parties hereto arising out of or relating to this Agreement or any of the transactions contemplated hereby, each of the parties hereto: (a) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Supreme Court of the State of New York, County of New York, or, if under applicable Law exclusive jurisdiction is vested in the Federal courts, the United States District Court for the Southern District of New York (and appellate courts thereof); (b) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (a) of this <u>&#8206;Section 6.9</u>; (c) waives any objection to laying venue in any such action or proceeding in such courts; (d) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party; and (e) agrees that service of process upon such party in any such action or proceeding shall be effective if notice is given in accordance with <u>&#8206;&#8206;Section 6.1</u> or <u>&#8206;Section 6.2</u> of this Agreement. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-13<br></div></div></div>
<!--End Page 592-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 593-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_303-annexd_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 6.10&#8195;<font style="font-style: italic;">Waiver of Jury Trial.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Each of the parties hereto hereby irrevocably waives any and all right to trial by jury in any legal proceeding arising out of or related to this Agreement or the transactions contemplated hereby. Each party certifies and acknowledges that (i)&#160;no representative, agent or attorney of any other party has represented, expressly or otherwise, that such other party would not, in the event of litigation, seek to enforce the foregoing waiver, (ii)&#160;each party understands and has considered the implication of this waiver, (iii)&#160;each party makes this waiver voluntarily, and (iv)&#160;each party has been induced to enter into this agreement by, among other things, the mutual waivers and certifications in this <u>&#8206;Section 6.10</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 6.11&#8195;<font style="font-style: italic;">Severability Clause.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In the event that any provision of this Agreement, or the application of any such provision to any Person or set of circumstances, is for any reason determined to be invalid, unlawful, void or unenforceable to any extent, the remainder of this Agreement, and the application of such provision to Persons or circumstances other than those as to which it is determined to be invalid, unlawful, void or unenforceable, will not be impaired or otherwise affected and will continue to be valid and enforceable to the fullest extent permitted by applicable Law. Upon such a determination, the parties hereto will negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible; <font style="font-style: italic;"><u>provided</u></font>, <font style="font-style: italic;"><u>however</u></font>, that if an excluded provision shall affect the rights, immunities, liabilities, duties or obligations of the Rights Agent, the Rights Agent shall be entitled to resign immediately upon written notice to the Company.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 6.12&#8195;<font style="font-style: italic;">Counterparts; Effectiveness.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This Agreement may be signed in any number of counterparts, each of which will be deemed an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement or any counterpart may be executed and delivered by facsimile copies or delivered by electronic communications by portable document format (.pdf), each of which shall be deemed an original. This Agreement will become effective when each party hereto will have received a counterpart hereof signed by the other party hereto. Until and unless each party has received a counterpart hereof signed by the other party hereto, this Agreement will have no effect and no party will have any right or obligation hereunder (whether by virtue of any oral or written agreement or any other communication). </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 6.13&#8195;<font style="font-style: italic;">Termination.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This Agreement will automatically terminate and be of no further force or effect and, except as provided in <u>Section 3.2</u>, the parties hereto will have no further liability hereunder, and the CVRs will expire without any consideration or compensation therefor upon the payment of all amounts potentially due under any Disposition Agreement entered into during the Disposition Period (if any) (the &#8220;<u>Term</u>&#8221;). The termination of this Agreement will not affect or limit the right of Holders to receive the Payment Amounts under <u>Section 2.3(b)</u> to the extent earned prior to the termination of this Agreement, and the provisions applicable thereto will survive the expiration or termination of this Agreement. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 6.14&#8195;<font style="font-style: italic;">Force Majeure</font>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Notwithstanding anything to the contrary contained herein, none of the Rights Agent, the Company or any of its Subsidiaries (except as it relates to the obligations of the Company under <u>&#8206;Section 2.3(a)</u>) will be liable for any delays or failures in performance resulting from acts beyond its reasonable control including acts of God, terrorist acts, shortage of supply, breakdowns or malfunctions, interruptions or malfunctions of computer facilities, or loss of data due to power failures or mechanical difficulties with information storage or retrieval systems, labor difficulties, war or civil unrest. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 6.15&#8195;<font style="font-style: italic;">Construction.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;As used in this Agreement, the words &#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, will not be deemed to be terms of limitation, but rather will be deemed to be followed by the words &#8220;without limitation.&#8221;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The headings contained in this Agreement are for convenience of reference only, will not be deemed to be a part of this Agreement and will not be referred to in connection with the construction or interpretation of this Agreement.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-14<br></div></div></div>
<!--End Page 593-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 594-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_303-annexd_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;Any reference in this Agreement to a date or time shall be deemed to be such date or time in New York City, United States, unless otherwise specified. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and no presumption or burden of proof shall arise favoring or disfavoring any Person by virtue of the authorship of any provision of this Agreement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section 6.16&#8195;<font style="font-style: italic;">Tax Treatment.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Rights Agent agrees to treat (i)&#160;the distribution of the CVRs as a distribution of contractual rights governed by Section 301 of the Code and (ii)&#160;any Payment Amount as a contractual payment pursuant to the rights afforded by this Agreement to the Holder and not as a distribution by the Company in respect of Company common stock for U.S. federal, and, to the extent applicable, state and local income tax purposes.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-15<br></div></div></div>
<!--End Page 594-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 595-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_303-annexd_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed as of the day and year first above written.</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Catalyst Biosciences, Inc.</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Nassim Usman, Ph.D.</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: Nassim Usman, Ph.D.</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title: Chief Executive Officer</div></td></tr></table><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">American Stock Transfer &amp; Trust Company, LLC</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Michael Legregin</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: Michael Legregin</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title: Senior Vice President, <br></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Corporate Actions Relationship <br></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Management &amp; Operations</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.5pt; text-align: center;">[Signature Page to Catalyst Contingent Value Rights Agreement]</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-16<br></div></div></div>
<!--End Page 595-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 596-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_303-annexd_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">AMENDMENT TO CONTINGENT VALUE RIGHTS AGREEMENT</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This Amendment to Contingent Value Rights Agreement (this &#8220;<u>Amendment</u>&#8221;) is dated as of March&#160;29, 2023 (the &#8220;<u>Effective Date</u>&#8221;), with respect to that certain Contingent Value Rights Agreement (the &#8220;<u>CVR Agreement</u>&#8221;), dated December&#160;26, 2022, between Catalyst Biosciences, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), and American Stock Transfer &amp; Trust Company, LLC, a New York limited liability company, as initial Rights Agent (as defined in the CVR Agreement). Capitalized terms used but not defined herein have the meanings ascribed to such terms in the CVR Agreement.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">RECITALS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, the Company desires to amend <u>Section 1.1</u> of the CVR Agreement to modify the definition of &#8220;Disposition Period&#8221;; and</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, pursuant to <u>Section&#160;5.1(a)</u> of the Agreement, the Company, at any time and from time to time, may enter into one or more amendment to the CVR Agreement without the consent of any of the Holders or the Rights Agent for the purposes outlined therein.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">NOW, THEREFORE, pursuant to Section&#160;5.1(a) of the CVR Agreement, the Company hereby amends the CVR Agreement as set forth below:</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">AGREEMENT</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Section 1.1&#8195;<u>Amendment</u>. The definition of &#8220;Disposition Period&#8221; set forth in Section&#160;1.1 of the CVR Agreement is hereby amended and restated in its entirety as follows:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">&#8220;<u>Disposition Period</u>&#8221; the time period beginning on the Record Date and ending on the 90th&#160;calendar day after the remainder of the Holdback Amount (as defined in that certain Asset Purchase Agreement, dated February&#160;27, 2023, by and between the Company and GC Biopharma Corp., a Yongin-si corporation (the &#8220;<u>GCB </u><u>APA</u>&#8221;)) is finally determined and received by the Company pursuant to Section&#160;6.7 of the GCB APA (the &#8220;<u>Initial </u><u>Term</u>&#8221;); <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, such period will be automatically extended for any Claim for an additional one-year period to the extent any Claim is appealed during the Initial Term.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Section 1.2&#8195;<u>Reference to and Effect of the Agreement</u>. On or after the Effective Date, each reference in the CVR Agreement to &#8220;this Agreement&#8221;, &#8220;hereunder&#8221;, &#8220;herein&#8221;, or words of like import shall mean and be a referenced to the CVR Agreement as amended hereby.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Section 1.3&#8195;<u>Effect of Amendment</u>. Except as specifically modified herein, the CVR Agreement remains in full force and effect in accordance with its terms.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Section 1.4&#8195;<u>Miscellaneous</u>. The provisions of <u>ARTICLE&#160;6</u> of the CVR Agreement will apply mutatis mutandis to this Amendment.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 20.5pt; text-align: center;">[<font style="font-style: italic;">Remainder of Page Intentionally Left Blank</font>]</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-17<br></div></div></div>
<!--End Page 596-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 597-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_303-annexd_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">IN WITNESS WHEREOF, the Company has caused this Amendment to be duly executed as of the date first written above.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td colspan="7" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>PARENT</u>:<font style="font-weight: normal;"> </font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.85%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.7%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 36.61%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td colspan="7" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">CATALYST BIOSCIENCES, INC.<font style="font-weight: normal;"> </font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.85%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.7%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 36.61%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.85%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.7%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 36.61%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.85%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By: </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 44.87%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Nassim Usman, Ph.D. </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.85%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.7%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 36.61%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Nassim Usman, Ph.D. </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.85%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.7%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 36.61%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">President &amp; Chief Executive Officer</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">[<font style="font-style: italic;">Signature Page to Amendment to CVR Agreement</font>]<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-18<br></div></div></div>
<!--End Page 597-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 598-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_304-annexe_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;"><a name="tANXE"><!--Anchor--></a>Annex E </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; text-align: center;">THIRD CERTIFICATE OF AMENDMENT TO THE FOURTH AMENDED AND RESTATED <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">CERTIFICATE OF INCORPORATION OF CATALYST BIOSCIENCES, INC. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Catalyst Biosciences, Inc. (the &#8220;Corporation&#8221;), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the &#8220;General Corporation Law&#8221;), does hereby certify as follows: </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">1.&#8195;The current name of the Corporation is Catalyst Biosciences, Inc., and the Corporation was originally incorporated pursuant to the General Corporation Law on March&#160;7, 1997 under the name Targacept, Inc. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">2.&#8195;The Corporation&#8217;s Fourth Amended and Restated Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on April&#160;18, 2006 (as amended from time to time, the &#8220;Certificate of Incorporation&#8221;). </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">3.&#8195;The amendments to the Certificate of Incorporation set forth in this Certificate of Amendment were duly authorized and adopted in accordance with Section&#160;242 of the General Corporation Law. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">4.&#8195;The Certificate of Incorporation is hereby amended by striking out Article First in its entirety and by substituting in lieu of said paragraph the following paragraph: </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">FIRST</font>: The name of the corporation (hereinafter called the &#8220;<font style="font-weight: bold;">corporation</font>&#8221;) is Gyre Therapeutics, Inc.&#8221; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">5.&#8195;The Certificate of Incorporation is hereby further amended by striking out the first and second paragraphs of Article Fourth in its entirety and by substituting in lieu of said paragraphs the following paragraphs: </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">FOURTH</font>:<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup> </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 60pt; text-indent: 20pt; text-align: justify;">1.&#8195;<font style="font-weight: bold;">Authorized Stock.</font> The total number of shares which the corporation shall have authority to issue is &#8195;&#8195;&#160;million (&#8195;&#8195;), of which (1) 20 million (20) shares shall be designated as Voting Common Stock, $0.001 par value per share (&#8220;<font style="font-weight: bold;">Voting Common Stock</font>&#8221;); (2) &#8195;&#8195;&#160;million (&#8195;&#8195;) shares shall be designated as Non-Voting Common Stock, $0.001 par value per share (&#8220;<font style="font-weight: bold;">Non-Voting </font><font style="font-weight: bold;">Common Stock</font>&#8221;); and (3) five million (5,000,000) shares shall be designated as Preferred Stock, $0.001 par value per share (&#8220;<font style="font-weight: bold;">Preferred Stock</font>&#8221;). Any reference to &#8220;Common Stock&#8221; in this Fourth Amended and Restated Certificate of Incorporation shall refer to Voting Common Stock, unless specific reference is made to Non-Voting Common Stock; provided, however, that this sentence shall not alter or affect the rights of the Non-Voting Common Stock hereunder. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 60pt; text-indent: 20pt; text-align: justify;">2.&#8195;<font style="font-weight: bold;">Reverse Stock Split.</font> Upon the effectiveness of the Third Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation (the &#8220;<font style="font-weight: bold;">Effective Time</font>&#8221;), each &#8195;&#8195; shares of Common Stock, issued and outstanding or held by the Corporation in treasury immediately prior to the Effective Time shall be reclassified and combined into one validly issued, fully paid and nonassessable share of outstanding Common Stock or treasury share, as applicable, automatically and without any action by the holder thereof and shall represent one share of Common Stock from and after the Effective Time (such reclassification and combination of shares, the &#8220;<font style="font-weight: bold;">Reverse Stock Split</font>&#8221;). The par value of the Common Stock following the Reverse Stock Split shall remain at $0.001 par value per share. No fractional shares of Common Stock shall be issued as a result of the Reverse Stock Split and, in lieu thereof, upon surrender after the Effective Time of a certificate or book-entry position which formerly represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time, any person who would otherwise be entitled to a fractional share of Common Stock as a result of the Reverse Stock Split, following the Effective Time, shall be entitled to receive a cash payment (without interest and subject to applicable withholding taxes) equal to the fraction of a share of Common Stock to which such holder would otherwise be entitled multiplied by the average (as adjusted in good faith by the corporation to account for the Reverse Stock Split ratio) </div></div><div class="block-footnote" style="width: 468pt; margin-left: 0pt;"><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-top: 3pt; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt;"> </div></div></div><div class="block-footnote" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">These amendments implement Proposals&#160;3, 4 and 5 and reflect the combination of any whole number of shares of the Corporation&#8217;s common stock between and including &#8195;&#8195; and &#8195;&#8195; into one share of the Corporation&#8217;s common stock. If only Proposal&#160;4 is approved by stockholders and implemented by the Board, the Certificate of Amendment filed with the Secretary of State of the State of Delaware will include only the language reflected in Section&#160;4.1(b) &#8220;Reverse Stock Split&#8221; at a ratio determined by the Board to be in the best interests of the Corporation and its stockholders.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">E-1<br></div></div></div>
<!--End Page 598-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 599-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_304-annexe_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 60pt; text-align: justify;">of the high and low trading prices of the Common Stock on The Nasdaq Capital Market during regular trading hours for the five trading days immediately preceding the Effective Time. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 60pt; text-align: justify;">Each stock certificate or book entry position that, immediately prior to the Effective Time, represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall, from and after the Effective Time, automatically and without the necessity of presenting the same for exchange, represent that number of whole shares of Common Stock after the Effective Time into which the shares formerly represented by such certificate or book entry position have been reclassified (as well as the right to receive cash in lieu of fractional shares of Common Stock after the Effective Time); provided, however, that each person of record holding a certificate or book entry position that represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall receive, upon surrender of such certificate or book entry position, a new certificate or book entry position evidencing and representing the number of whole shares of Common Stock after the Effective Time into which the shares of Common Stock formerly represented by such certificate or book entry position shall have been reclassified.&#8221; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">6.&#8195;The Certificate of Incorporation is hereby further amended by striking out the second paragraph of Article Sixth in its entirety and by substituting in lieu of said paragraph the following paragraph: </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">&#8220;2.&#8195;Any action required or permitted to be taken by the stockholders of the corporation must be effected at a duly called annual or special meeting of the stockholders of the corporation and may not be effected by any written consent by such stockholders; provided, however, from and after the effectiveness of the Third Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation until the first date on which GNI USA, Inc., a Delaware corporation, and its affiliates (as defined in Rule&#160;12b-2 under the Securities Exchange Act of 1934, as amended (the &#8220;<font style="font-weight: bold;">Exchange Act</font>&#8221;)), collectively, beneficially own (as defined by Securities and Exchange Commission rules promulgated under Section 13 of the Exchange Act) shares representing less than 50% of the combined voting power of the outstanding shares of Common Stock, any action required or permitted to be taken at any annual or special meeting of the stockholders of the corporation may be taken by written consent in accordance with Section 228 of the General Corporation Law without a meeting, without prior notice and without a vote.&#8221; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">7.&#8195;This Certificate of Amendment to the Certificate of Incorporation shall be effective as of 12:01&#160;a.m. Eastern Time on &#8195;&#8195;&#8195;. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Executed at South San Francisco, California, on &#8195;&#8195;&#8195;, &#8195;&#8195;&#8195;. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 53.85%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.56%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.56%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 53.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.56%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 53.85%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Nassim Usman, Ph.D. </div></td></tr><tr><td style="width: 53.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">President &amp; Chief Executive Officer</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">E-2<br></div></div></div>
<!--End Page 599-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 600-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_305-annexf_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;">Annex F</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; text-align: center;"><a name="tANXF"><!--Anchor--></a>GYRE THERAPEUTICS, INC.<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023 OMNIBUS INCENTIVE PLAN</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">1.&#8195;<u>Purposes of the Plan</u>. The purposes of this Gyre Therapeutics, Inc. 2023 Omnibus Incentive Plan (as&#160;amended from time to time, the &#8220;<font style="font-weight: bold;">Plan</font>&#8221;) is to motivate and reward employees and other individuals to perform at the highest level and contribute significantly to the success of Catalyst Biosciences, Inc., a Delaware corporation (the&#160;&#8220;<font style="font-weight: bold;">Company</font>&#8221;), thereby furthering the best interests of the Company and its shareholders. The Plan (including any Sub-plans established hereunder in accordance with <u>&#8206;Section 4(c)</u>) shall serve as the primary plan under which equity-based incentives are awarded on a worldwide basis to Participants.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">2.&#8195;<u>Definitions</u>. As used in the Plan, the following terms shall have the meanings set forth below:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;&#8220;<font style="font-weight: bold;">Affiliate</font>&#8221; means any entity that, directly or indirectly through one or more intermediaries controls, is controlled by or is under common control with, the Company.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;&#8220;<font style="font-weight: bold;">Award</font>&#8221; means any Option, SAR, Restricted Stock, RSU, Performance Award, Other Cash-Based Award or Other Stock-Based Award granted under the Plan</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;&#8220;<font style="font-weight: bold;">Award Agreement</font>&#8221; means any agreement, contract or other instrument or document (including in electronic form) evidencing any Award granted under the Plan, which may, but need not, be executed or acknowledged by a Participant.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;&#8220;<font style="font-weight: bold;">Beneficial Owner</font>&#8221; has the meaning ascribed to such term in Rule 13d-3 under the Exchange Act.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;&#8220;<font style="font-weight: bold;">Beneficiary</font>&#8221; means a Person entitled to receive payments or other benefits or exercise rights that are available under the Plan in the event of a Participant&#8217;s death. If no such Person can be named or is named by a Participant, or if no Beneficiary designated by a Participant is eligible to receive payments or other benefits or exercise rights that are available under the Plan at a Participant&#8217;s death, such Participant&#8217;s Beneficiary shall be such Participant&#8217;s estate.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(f)&#8195;&#8220;<font style="font-weight: bold;">Board</font>&#8221; means the Board of Directors of the Company.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;&#8220;<font style="font-weight: bold;">Cause</font>&#8221; is as defined in Participant&#8217;s Service Agreement, if any, or Award Agreement or, if not so defined, means: (i)&#160;any theft, fraud, embezzlement, dishonesty, willful misconduct, breach of fiduciary duty for personal profit, falsification of any documents or records of the Company or any of its Affiliates, felony or similar act by Participant (whether or not related to Participant&#8217;s relationship with the Company); (ii)&#160;an act of moral turpitude by Participant, or any act that causes significant injury to, or is otherwise adversely affecting, the reputation, business, assets, operations or business relationship of the Company (or a Subsidiary or Affiliate, when applicable); (iii)&#160;any breach by Participant of any material agreement with or of any material duty of Participant to the Company or any Subsidiary or Affiliate thereof (including breach of confidentiality, non-disclosure, non-use non-competition or non-solicitation covenants towards the Company or any of its Affiliates) or failure to abide by code of conduct or other policies (including, without limitation, policies relating to confidentiality and reasonable workplace conduct); or (iv)&#160;any act which constitutes a breach of a Participant&#8217;s fiduciary duty towards the Company or an Affiliate or Subsidiary, including disclosure of confidential or proprietary information thereof or acceptance or solicitation to receive unauthorized or undisclosed benefits, irrespective of their nature, or funds, or promises to receive either, from individuals, consultants or corporate entities that the Company or a Subsidiary does business with; (v)&#160;Participant&#8217;s unauthorized use, misappropriation, destruction, or diversion of any tangible or intangible asset or corporate opportunity of the Company or any of its Affiliates (including, without limitation, the improper use or disclosure of confidential or proprietary information); or (vi)&#160;any circumstances that constitute grounds for termination for cause under Participant&#8217;s Service Agreement with the Company or Affiliate, to the extent applicable. For the avoidance of doubt, the determination as to whether a termination is for Cause for purposes of this Plan, shall be made in good faith by the Committee and shall be final and binding on Participant.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(h)&#8195;&#8220;<font style="font-weight: bold;">Change in Control</font>&#8221; means the occurrence of any one or more of the following events:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(i)&#8195;any Person, other than (A) any employee plan established by the Company or any Subsidiary, (B)&#160;the Company or any of its Affiliates, (C) an underwriter temporarily holding securities pursuant to an offering of such securities, or (D) an entity owned, directly or indirectly, by shareholders of the Company </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-1<br></div></div></div>
<!--End Page 600-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 601-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_305-annexf_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">in substantially the same proportions as their ownership of the Company, is (or becomes, during any 12-month period) the Beneficial Owner, directly or indirectly, of securities of the Company (not including in the securities beneficially owned by such Person any securities acquired directly from the Company or its Affiliates other than in connection with the acquisition by the Company or its Affiliates of a business) representing 50% or more of the total voting power of the stock of the Company; <font style="font-style: italic;">provided</font> that the provisions of this subsection (i)&#160;are not intended to apply to or include as a Change in Control any transaction that is specifically excepted from the definition of Change in Control under subsection&#160;(iii)&#160;below;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(ii)&#8195;a change in the composition of the Board such that, during any 12-month period, the individuals who, as of the beginning of such period, constitute the Board (the &#8220;<font style="font-weight: bold;">Existing Board</font>&#8221;) cease for any reason to constitute at least 50% of the Board; <font style="font-style: italic;">provided</font>,<font style="font-style: italic;"> however</font>, that any individual becoming a member of the Board subsequent to the beginning of such period whose election, or nomination for election by the Company&#8217;s shareholders, was either (a) a result of the ordinary annual director elections or (b) approved by a vote of at least a majority of the Directors immediately prior to the date of such appointment or election, in each case, shall be considered as though such individual were a member of the Existing Board; <font style="font-style: italic;">provided</font> <font style="font-style: italic;">further</font>,<font style="font-style: italic;"> </font>that, notwithstanding the foregoing, no individual whose initial assumption of office occurs as a result of either an actual or threatened election contest (as such terms are used in Rule 14a-11 or Regulation 14A promulgated under the Exchange Act or successor statutes or rules containing analogous concepts) or other actual or threatened solicitation of proxies or consents by or on behalf of an individual, corporation, partnership, group, associate or other entity or Person other than the Board, shall in any event be considered to be a member of the Existing Board; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iii)&#8195;consummation of a merger, amalgamation or consolidation of the Company with any other corporation or other entity, or the issuance of voting securities in connection with such a transaction pursuant to applicable stock exchange requirements;<font style="font-style: italic;"> provided</font> that immediately following such transaction the voting securities of the Company outstanding immediately prior thereto do not continue to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity of such transaction or parent entity thereof) 50% or more of the total voting power of the Company&#8217;s stock (or, if the Company is not the surviving entity of such merger or consolidation, 50% or more of the total voting power and total fair market value of the stock of such surviving entity or parent entity thereof); and <font style="font-style: italic;">provided</font>,<font style="font-style: italic;"> further</font>, that such a transaction effected to implement a recapitalization of the Company (or similar transaction) in which no Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company (not including in the securities beneficially owned by such Person any securities acquired directly from the Company or its Affiliates other than in connection with the acquisition by the Company or its Affiliates of a business) representing 50% or more of either the then-outstanding Shares or the combined voting power and total fair market value of the Company&#8217;s then-outstanding voting securities shall not be considered a Change in Control; or</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iv)&#8195;the sale or disposition by the Company of all or substantially all of the Company&#8217;s assets in which any Person acquires (or has acquired during the 12-month period ending on the date of the most recent acquisition by such Person) assets from the Company that have a total gross fair market value equal to more than 50% of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Notwithstanding the foregoing, (A) no Change in Control shall be deemed to have occurred if there is consummated any transaction or series of integrated transactions immediately following which the record holders of the Shares immediately prior to such transaction or series of transactions continue to have substantially the same proportionate ownership in an entity which owns substantially all of the assets of the Company immediately prior to such transaction or series of transactions and (B) no Change in Control shall be deemed to have occurred upon the acquisition of additional control of the Company by any Person that is considered to effectively control the Company. In no event will a Change in Control be deemed to have occurred if any Grantee is part of a &#8220;group&#8221; within the meaning of Section 13(d)(3) of the Exchange Act that effects a Change in Control. Notwithstanding the foregoing or any provision of any Award Agreement to the contrary, for any Award that provides for accelerated distribution on a Change in Control of amounts that constitute &#8220;deferred compensation&#8221; (as defined in Section 409A of the Code), if the event that constitutes such Change in Control does not also constitute a change in the ownership or effective control of the Company, or in the ownership of a substantial portion of the Company&#8217;s assets (in either case, as </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-2<br></div></div></div>
<!--End Page 601-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 602-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_305-annexf_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">defined in Section 409A of the Code), such amount shall not be distributed on such Change in Control but instead shall vest as of such Change in Control and shall be distributed on the scheduled payment date specified in the applicable Award Agreement, except to the extent that earlier distribution would not result in the Grantee who holds such Award incurring interest or additional tax under Section 409A of the Code. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(i)&#8195;&#8220;<font style="font-weight: bold;">Code</font>&#8221; means the Internal Revenue Code of 1986, as amended from time to time, and the rules, regulations and guidance thereunder. Any reference to a provision in the Code shall include any successor provision thereto.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(j)&#8195;&#8220;<font style="font-weight: bold;">Committee</font>&#8221; means the compensation committee of the Board unless another committee is designated by the Board If there is no compensation committee of the Board and the Board does not designate another committee, references herein to the &#8220;Committee&#8221; shall refer to the Board.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(k)&#8195;&#8220;<font style="font-weight: bold;">Common Stock</font>&#8221; means the common stock, par value , of the Company.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(l)&#8195;&#8220;<font style="font-weight: bold;">Consultant</font>&#8221; means any individual, including an advisor, who is providing <font style="font-style: italic;">bona fide</font> services to the Company or any Subsidiary or who has accepted an offer of service or consultancy from the Company or any Subsidiary. For purposes of the Plan, in the case of a Consultant, references to employment shall be deemed to refer to such Consultant&#8217;s service in such capacity, but in no event shall the Plan or any action taken hereunder be construed to create an employer-employee relationship between any such Consultant and the Company or of any of its Affiliates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(m)&#8195;&#8220;<font style="font-weight: bold;">Director</font>&#8221; means a member of the Board.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(n)&#8195;&#8220;<font style="font-weight: bold;">Effective Date</font>&#8221; means the date on which the Plan is adopted by the Board.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(o)&#8195;&#8220;<font style="font-weight: bold;">Employee</font>&#8221; means any individual, including any officer, employed by the Company or any Subsidiary or any prospective employee or officer who has accepted an offer of employment from the Company or any Subsidiary, with the status of employment determined based upon such factors as are deemed appropriate by the Committee in its discretion, subject to any requirements of the Code or applicable laws; <font style="font-style: italic;">provided</font> that any such person may not receive any payment or exercise any right relating to an Award until such person has commenced employment or service with the Company or its Subsidiaries. An employee on an approved leave of absence (including maternity leave) shall be considered as still in the employment of the Company or its Subsidiaries for purposes of eligibility for participation in the Plan.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(p)&#8195;&#8220;<font style="font-weight: bold;">Exchange Act</font>&#8221; means the Securities Exchange Act of 1934, as amended from time to time, and the rules, regulations and guidance thereunder. Any reference to a provision in the Exchange Act shall include any successor provision thereto.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(q)&#8195;&#8220;<font style="font-weight: bold;">Fair Market Value</font>&#8221; means (i)&#160;with respect to Shares, the closing price of a Share on the trading day immediately preceding the date of determination (or, if there is no reported sale on such date, on the last preceding date on which any reported sale occurred), on the principal stock market or exchange on which the Shares are quoted or traded, or if Shares are not so quoted or traded, the fair market value of a Share as determined by the Committee, and (ii)&#160;with respect to any property other than Shares, the fair market value of such property determined by such methods or procedures as shall be established from time to time by the Committee.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(r)&#8195;&#8220;<font style="font-weight: bold;">Incentive Stock Option</font>&#8221; means an option representing the right to purchase Shares from the Company, granted pursuant to &#8206;<u>Section 6</u>, that meets the requirements of Section 422 of the Code.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(s)&#8195;&#8220;<font style="font-weight: bold;">Incentive Stock Option</font>&#8221; means an Option intended to qualify as an incentive stock option within the meaning of Section 422 of the Code.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(t)&#8195;&#8220;<font style="font-weight: bold;">Intrinsic Value</font>&#8221; with respect to an Option or SAR Award means (i)&#160;the excess, if any, of the price or implied price per Share in a Change in Control or other event <font style="font-style: italic;">over</font> (ii)&#160;the exercise or hurdle price of such Award <font style="font-style: italic;">multiplied by</font> (iii)&#160;the number of Shares covered by such Award.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(u)&#8195;&#8220;<font style="font-weight: bold;">Non-Employee Director</font>&#8221; means a Director who either (i)&#160;is not a current Employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-3<br></div></div></div>
<!--End Page 602-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 603-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_305-annexf_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">Securities Act (&#8220;<font style="font-weight: bold;">Regulation S-K</font>&#8221;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item 404(b) of Regulation S-K; or (ii)&#160;is otherwise considered a &#8220;non-employee director&#8221; for purposes of Rule 16b-3.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(v)&#8195;&#8220;<font style="font-weight: bold;">Non-Qualified Stock Option</font>&#8221; means an option representing the right to purchase Shares from the Company, granted pursuant to <u>&#8206;Section 6</u>, that is not an Incentive Stock Option.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(w)&#8195;&#8220;<font style="font-weight: bold;">Option</font>&#8221; means an Incentive Stock Option or a Non-Qualified Stock Option.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(x)&#8195;&#8220;<font style="font-weight: bold;">Other Cash-Based Award</font>&#8221; means an Award granted pursuant to &#8206;<u>Section 11</u>, including cash awarded as a bonus or upon the attainment of specified performance criteria or otherwise as permitted under the Plan.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(y)&#8195;&#8220;<font style="font-weight: bold;">Other Stock-Based Award</font>&#8221; means an Award granted pursuant to &#8206;<u>Section 11</u> that may be denominated or payable in, valued in whole or in part by reference to, or otherwise based on, or related to, Shares or factors that may influence the value of Shares, including convertible or exchangeable debt securities, other rights convertible or exchangeable into Shares, purchase rights for Shares, dividend rights or dividend equivalent rights or Awards with value and payment contingent upon performance of the Company or business units thereof or any other factors designated by the Committee.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(z)&#8195;&#8220;<font style="font-weight: bold;">Participant</font>&#8221; means the recipient of an Award granted under the Plan.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(aa)&#8195;&#8220;<font style="font-weight: bold;">Performance Award</font>&#8221; means an Award granted pursuant to <u>Section 10</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(bb)&#8195;&#8220;<font style="font-weight: bold;">Performance Period</font>&#8221; means the period established by the Committee with respect to any Performance Award during which the performance goals specified by the Committee with respect to such Award are to be measured.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(cc)&#8195;&#8220;<font style="font-weight: bold;">Person</font>&#8221; has the meaning ascribed to such term in Section 3(a)(9) of the Exchange Act and used in Sections 13(d) and 14(d) thereof, including a &#8220;group&#8221; as defined in Section 13(d) thereof.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(dd)&#8195;&#8220;<font style="font-weight: bold;">Restricted Stock</font>&#8221; means any Share subject to certain restrictions and forfeiture conditions, granted pursuant to &#8206;<u>Section 8</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(ee)&#8195;&#8220;<font style="font-weight: bold;">RSU</font>&#8221; means a contractual right granted pursuant to &#8206;<u>Section 9</u> that is denominated in Shares. Each RSU represents a right to receive the value of one Share (or a percentage of such value) in cash, Shares or a combination thereof. Awards of RSUs may include the right to receive dividend equivalents.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(ff)&#8195;&#8220;<font style="font-weight: bold;">Rule 16b-3</font>&#8221; means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(gg)&#8195;&#8220;<font style="font-weight: bold;">SAR</font>&#8221; means a right granted pursuant to &#8206;<u>Section 7</u> to receive upon exercise by the Participant or settlement, in cash, Shares or a combination thereof, the excess of (i)&#160;the Fair Market Value of one Share on the date of exercise or settlement over (ii)&#160;the exercise or hurdle price of the right on the date of grant.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(hh)&#8195;&#8220;<font style="font-weight: bold;">Service Agreement</font>&#8221; means any employment, severance, consulting or similar agreement between the Company or any of its Affiliates and a Grantee.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(ii)&#8195;&#8220;<font style="font-weight: bold;">Share</font>&#8221; means a share of the common stock, par value $0.001 per share, of the Company.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(jj)&#8195;&#8220;<font style="font-weight: bold;">Subsidiary</font>&#8221; means an entity of which the Company directly or indirectly holds all or a majority of the value of the outstanding equity interests of such entity or a majority of the voting power with respect to the voting securities of such entity. Whether employment by or service with a Subsidiary is included within the scope of the Plan shall be determined by the Committee.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(kk)&#8195;&#8220;<font style="font-weight: bold;">Substitute Award</font>&#8221; means an Award granted in assumption of, or in substitution for, an outstanding award previously granted by a company or other business acquired by the Company or with which the Company combines.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(ll)&#8195;&#8220;<font style="font-weight: bold;">Termination of Service</font>&#8221; means, in the case of a Grantee who is an Employee, cessation of the employment relationship such that the Grantee is no longer an employee of the Company or any Subsidiary, or, in the case of a Grantee who is a Consultant or Non-Employee Director, the date the performance of services for the Company or any Subsidiary has ended; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that in the case of a Grantee who is an </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-4<br></div></div></div>
<!--End Page 603-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 604-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_305-annexf_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">Employee, the transfer of employment from the Company to a Subsidiary, from a Subsidiary to the Company, from one Subsidiary to another Subsidiary or, unless the Committee determines otherwise, the cessation of employee status but the continuation of the performance of services for the Company or a Subsidiary as a Director or Consultant shall not be deemed a cessation of service that would constitute a Termination of Service; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">further</font>, that a Termination of Service shall be deemed to occur for a Grantee employed by, or performing services for, a Subsidiary when such Subsidiary ceases to be a Subsidiary unless such Grantee&#8217;s employment or service continues with the Company or another Subsidiary. Notwithstanding the foregoing, with respect to any Award subject to Section 409A of the Code (and not exempt therefrom), a Termination of Service occurs when a Grantee experiences a &#8220;separation of service&#8221; (as such term is defined under Section 409A of the Code).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">3.&#8195;<u>Eligibility</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Any Employee, Non-Employee Director or Consultant shall be eligible to be selected to receive an Award under the Plan, to the extent that an offer or receipt of an Award is permitted by applicable law, stock market or exchange rules and regulations or accounting or tax rules and regulations.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Holders of equity compensation awards granted by a company that is acquired by the Company (or&#160;whose business is acquired by the Company) or with which the Company combines are eligible for grants of Substitute Awards under the Plan to the extent permitted under applicable regulations of any stock exchange on which the Company is listed.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">4.&#8195;<u>Administration</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;<font style="font-style: italic;">Administration of the Plan</font>. The Plan shall be administered by the Committee. All decisions of the Committee shall be final, conclusive and binding upon all parties, including the Company, its shareholders, Participants and any Beneficiaries thereof. The Committee may issue rules and regulations for administration of the Plan.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;<font style="font-style: italic;">Delegation of Authority</font>. To the extent permitted by applicable law, including under Section 157(c) of the Delaware General Corporation Law, the Committee may delegate to one or more officers of the Company some or all of its authority under the Plan, including the authority to grant Options and SARs or other Awards in the form of Share rights (except that such delegation shall not apply to any Award for a Person then covered by Section 16 of the Exchange Act), and the Committee may delegate to one or more committees of the Board (which may consist of solely one Director) some or all of its authority under the Plan, including the authority to grant all types of Awards, in accordance with applicable law.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;<font style="font-style: italic;">Establishment of Sub-plans</font>. The Board shall have full discretion and authority to establish one or more sub-plans under the Plan to facilitate local administration of the Plan in any jurisdiction in which the Company or any of its Affiliates operate and to conform the Plan to the legal requirements of any such jurisdiction or to allow for favorable tax treatment under any applicable provision of tax law (each, a &#8220;<font style="font-weight: bold;">Sub-plan</font>&#8221;). The Board shall establish such Sub-plans by adopting supplements to the Plan setting forth (i)&#160;such limitations on the Committee&#8217;s discretion under the Plan as the Board deems necessary or desirable and (ii)&#160;such additional terms and conditions not otherwise inconsistent with the Plan as the Board shall deem necessary or desirable. All Sub-plans adopted by the Board shall be deemed to be part of the Plan, but each Sub-plan shall apply only to Participants within the affected jurisdiction and the Company or an Affiliate, as applicable, shall not be required to provide copies of any Sub-plan to Participants in any jurisdiction that is not affected.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;<font style="font-style: italic;">Authority of Committee</font>. Subject to the terms of the Plan and applicable law, the Committee (or its delegate) shall have full discretion and authority to: (i)&#160;designate Participants; (ii)&#160;determine the type or types of Awards (including Substitute Awards) to be granted to each Participant under the Plan; (iii)&#160;determine the number of Shares to be covered by (or with respect to which payments, rights or other matters are to be calculated in connection with) Awards; (iv)&#160;determine the terms and conditions of any Award and prescribe the form of each Award Agreement, which need not be identical for each Participant; (v)&#160;determine whether, to what extent, under what circumstances and by which methods Awards may be settled or exercised in cash, Shares, other Awards, other property, net settlement (including broker-assisted cashless exercise), or any combination thereof, or canceled, forfeited or suspended; (vi)&#160;determine whether, to what extent and under what circumstances cash, Shares, other Awards, other property and other amounts payable with respect to an Award </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-5<br></div></div></div>
<!--End Page 604-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 605-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_305-annexf_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">under the Plan shall be deferred either automatically or at the election of the holder thereof or of the Committee; (vii)&#160;amend terms or conditions of any outstanding Awards; (viii)&#160;correct any defect, supply any omission and reconcile any inconsistency in the Plan or any Award, in the manner and to the extent it shall deem desirable to carry the Plan into effect; (ix)&#160;interpret and administer the Plan and any instrument or agreement relating to, or Award made under, the Plan; (x)&#160;establish, amend, suspend or waive such rules and regulations and appoint such agents, trustees, brokers, depositories and advisors and determine such terms of their engagement as it shall deem appropriate for the proper administration of the Plan and due compliance with applicable law, stock market or exchange rules and regulations or accounting or tax rules and regulations; and (xi)&#160;make any other determination and take any other action that the Committee deems necessary or desirable for the administration of the Plan and due compliance with applicable law, stock market or exchange rules and regulations or accounting or tax rules and regulations. Notwithstanding anything to the contrary contained herein, the Board may, in its sole discretion, at any time and from time to time, grant Awards or administer the Plan. In any such case, the Board shall have all of the authority and responsibility granted to the Committee herein. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;<font style="font-style: italic;">Rule 16b-3 Compliance</font><font style="font-weight: bold;">.</font> To the extent an Award is intended to qualify for the exemption from Section&#160;16(b) of the Exchange Act that is available under Rule 16b-3 of the Exchange Act, the Award will be granted by the Board or a Committee (or a subcommittee thereof) that consists solely of two or more Non-Employee Directors, as determined under Rule 16b-3(b)(3) of the Exchange Act and thereafter any action establishing or modifying the terms of the Award will be approved by the Board or a Committee (or a subcommittee) meeting such requirements to the extent necessary for such exemption to remain available</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">5.&#8195;<u>Shares Available for Awards</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Subject to adjustment as provided in &#8206;<u>Section 5(c)</u> and except for Substitute Awards, the maximum number of Shares available for issuance under the Plan shall not exceed in the aggregate Shares. The total number of Shares available for issuance under the Plan shall be increased on the first day of each Company fiscal year following the Effective Date in an amount equal to the lesser of (i)&#160;five (5) percent% of outstanding Shares on the last day of the immediately preceding fiscal year and (ii)&#160;such number of Shares as determined by the Committee in its discretion. Shares underlying Substitute Awards and Shares remaining available for grant under a plan of an acquired company or of a company with which the Company combines (whether by way of amalgamation, merger, sale and purchase of shares or other securities or otherwise), appropriately adjusted to reflect the acquisition or combination transaction, shall not reduce the number of Shares remaining available for grant hereunder.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;If any Award is forfeited, cancelled, expires, terminates or otherwise lapses or is settled in cash, in whole or in part, without the delivery of Shares, then the Shares covered by such forfeited, expired, terminated or lapsed Award shall again be available for grant under the Plan. The following shall become available for issuance under the Plan: (i)&#160;any Shares withheld in respect of taxes relating to any Award and (ii)&#160;any Shares tendered or withheld to pay the exercise price of Options.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;In the event that the Committee determines that, as a result of any dividend or other distribution (other than an ordinary dividend or distribution), recapitalization, stock split, reverse stock split, reorganization, merger, amalgamation, consolidation, separation, rights offering, split-up, spin-off, combination, repurchase or exchange of Shares or other securities of the Company, issuance of warrants or other rights to acquire Shares or other securities of the Company, issuance of Shares pursuant to the anti-dilution provisions of securities of the Company, or other similar corporate transaction or event affecting the Shares, or of changes in applicable laws, regulations or accounting principles, an adjustment is necessary in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan, then the Committee shall, subject to <u>Section 19</u> and applicable law, adjust equitably so as to ensure no undue enrichment or harm (including by payment of cash), any or all of:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(i)&#8195;the number and type of Shares (or other securities) which thereafter may be made the subject of Awards, including the aggregate limits specified in &#8206;<u>Section 5(a)</u> and &#8206;<u>Section 5(f)</u>;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(ii)&#8195;the number and type of Shares (or other securities) subject to outstanding Awards;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iii)&#8195;the grant, acquisition, exercise or hurdle price with respect to any Award or, if deemed appropriate, make provision for a cash payment to the holder of an outstanding Award; and</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-6<br></div></div></div>
<!--End Page 605-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 606-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_305-annexf_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iv)&#8195;the terms and conditions of any outstanding Awards, including the performance criteria of any Performance Awards;</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">provided<font style="font-style: normal;">, </font>however<font style="font-style: normal;">, that the number of Shares subject to any Award denominated in Shares shall always be a whole </font><font style="font-style: normal;">number.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;Any Shares delivered pursuant to an Award may consist, in whole or in part, of authorized and unissued Shares or Shares acquired by the Company.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;The aggregate value of all compensation granted or paid, as applicable, to any individual for service as a Non-Employee Director with respect to any calendar year, including Awards granted and cash fees paid by the Company to such Non-Employee Director, will not exceed (i) $500,000 in total value or (ii)&#160;in the event such Non-Employee Director is first appointed or elected to the Board, $750,000 in total value during the initial annual period, in each case calculating the value of any equity awards based on the grant date fair value of such equity awards for financial reporting purposes. The limitations in this &#8206;<u>Section 5(e)</u> shall apply commencing with the first calendar year that begins following the Effective Date.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;Subject to adjustment as provided in <u>Section 5(c)(i)</u>, the maximum number of Shares available for issuance with respect to Incentive Stock Options shall be &#8195;&#8195;. To the extent that the aggregate Fair Market Value (determined at the time of grant) of Shares with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be treated as Nonqualified Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">6.&#8195;<u>Options</u>. The Committee is authorized to grant Options to Participants with the following terms and conditions and with such additional terms and conditions, in either case not inconsistent with the provisions of the Plan, as the Committee shall determine:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The exercise price per Share under an Option shall be determined by the Committee at the time of grant; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that, except in the case of Substitute Awards, such exercise price shall not be less than the Fair Market Value of a Share on the date of grant of such Option.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The term of each Option shall be fixed by the Committee but shall not exceed 10&#160;years from the date of grant of such Option.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;The Committee shall determine the methods by which, and the forms in which payment of the exercise price with respect thereto may be made or deemed to have been made, including cash, Shares, other Awards, other property, net settlement (including broker-assisted cashless exercise) or any combination thereof, having a Fair Market Value on the exercise date equal to the relevant exercise price.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;To the extent an Option is not previously exercised as to all of the Shares subject thereto, and, if the Fair Market Value of one Share is greater than the exercise price then in effect, then the Option shall be deemed automatically exercised immediately before its expiration.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;No grant of Options may be accompanied by a tandem award of dividend equivalents or provide for dividends, dividend equivalents or other distributions to be paid on such Options (except as provided under &#8206;<u>Section 5(c)</u>).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;The terms of any Incentive Stock Option granted under the Plan shall comply in all respects with the provisions of Section 422 of the Code. Incentive Stock Options may be granted only to employees of the Company or of a parent or subsidiary corporation (as defined in Section 424 of the Code).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">7.&#8195;<u>Stock Appreciation Rights</u>. The Committee is authorized to grant SARs to Participants with the following terms and conditions and with such additional terms and conditions, in either case not inconsistent with the provisions of the Plan, as the Committee shall determine:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;SARs may be granted under the Plan to Participants either alone (&#8220;freestanding&#8221;) or in addition to other Awards granted under the Plan (&#8220;tandem&#8221;) and may, but need not, relate to a specific Option granted under &#8206;<u>Section 6</u>.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-7<br></div></div></div>
<!--End Page 606-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 607-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_305-annexf_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The exercise or hurdle price per Share under a SAR shall be determined by the Committee; <font style="font-style: italic;">provided, </font><font style="font-style: italic;">however</font>, that, except in the case of Substitute Awards, such exercise or hurdle price shall not be less than the Fair Market Value of a Share on the date of grant of such SAR.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;The term of each SAR shall be fixed by the Committee but shall not exceed 10&#160;years from the date of grant of such SAR.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;Upon the exercise of a SAR, the Company shall pay to the Participant an amount equal to the number of Shares subject to the SAR multiplied by the excess, if any, of the Fair Market Value of one Share on the exercise date over the exercise or hurdle price of such SAR. The Company shall pay such excess in cash, in Shares valued at Fair Market Value, or any combination thereof, as determined by the Committee.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;To the extent a SAR is not previously exercised as to all of the Shares subject thereto, and, if the Fair Market Value of one Share is greater than the exercise price then in effect, then the SAR shall be deemed automatically exercised immediately before its expiration.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;No grant of SARs may be accompanied by a tandem award of dividend equivalents or provide for dividends, dividend equivalents or other distributions to be paid on such SARs (except as provided under <u>Section 5(c)</u>).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">8.&#8195;<u>Restricted Stock</u>. The Committee is authorized to grant Awards of Restricted Stock to Participants with the following terms and conditions and with such additional terms and conditions, in either case not inconsistent with the provisions of the Plan, as the Committee shall determine: </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(a)&#8195;The Award Agreement shall specify the vesting schedule.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Awards of Restricted Stock shall be subject to such restrictions as the Committee may impose, which restrictions may lapse separately or in combination at such time or times, in such installments or otherwise, as the Committee may deem appropriate.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;Subject to the restrictions set forth in the applicable Award Agreement, a Participant generally shall have the rights and privileges of a shareholder with respect to Awards of Restricted Stock, including the right to vote such Shares of Restricted Stock and the right to receive dividends.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;The Committee may, in its discretion, specify in the applicable Award Agreement that any or all dividends or other distributions paid on Awards of Restricted Stock prior to vesting be paid either in cash or in additional Shares and either on a current or deferred basis and that such dividends or other distributions may be reinvested in additional Shares, which may be subject to the same restrictions as the underlying Awards.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;Any Award of Restricted Stock may be evidenced in such manner as the Committee may deem appropriate, including book-entry registration.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;The Committee may provide in an Award Agreement that an Award of Restricted Stock is conditioned upon the Participant making or refraining from making an election with respect to the Award under Section 83(b) of the Code. If a Participant makes an election pursuant to Section 83(b) of the Code with respect to an Award of Restricted Stock, such Participant shall be required to file promptly a copy of such election with the Company and the applicable Internal Revenue Service office.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">9.&#8195;<u>RSUs</u>. The Committee is authorized to grant Awards of RSUs to Participants with the following terms and conditions and with such additional terms and conditions, in either case not inconsistent with the provisions of the Plan, as the Committee shall determine:.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The Award Agreement shall specify the vesting schedule and the delivery schedule (which may include deferred delivery later than the vesting date).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Awards of RSUs shall be subject to such restrictions as the Committee may impose, which restrictions may lapse separately or in combination at such time or times, in such installments or otherwise, as the Committee may deem appropriate.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;An RSU shall not convey to a Participant the rights and privileges of a shareholder with respect to the Share subject to such RSU, such as the right to vote or the right to receive dividends, unless and until and to the extent a Share is issued to such Participant to settle such RSU.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-8<br></div></div></div>
<!--End Page 607-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 608-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_305-annexf_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;The Committee may, in its discretion, specify in the applicable Award Agreement that any or all dividend equivalents or other distributions paid on Awards of RSUs prior to vesting or settlement, as applicable, be paid either in cash or in additional Shares and either on a current or deferred basis and that such dividend equivalents or other distributions may be reinvested in additional Shares, which may be subject to the same restrictions as such Awards.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;Shares delivered upon the vesting and settlement of an RSU Award may be evidenced in such manner as the Committee may deem appropriate, including book-entry registration.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;The Committee may determine the form or forms (including cash, Shares, other Awards, other property or any combination thereof) in which payment of the amount owing upon settlement of any RSU Award may be made.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">10.&#8195;<u>Performance Awards</u>. The Committee is authorized to grant Performance Awards to Participants with the following terms and conditions and with such additional terms and conditions, in either case not inconsistent with the provisions of the Plan, as the Committee shall determine:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Performance Awards may be denominated as a cash amount, number of Shares or units or a combination thereof and are Awards that may be earned upon achievement or satisfaction of performance conditions specified by the Committee. In addition, the Committee may specify that any other Award shall constitute a Performance Award by conditioning the grant to a Participant or the right of a Participant to exercise the Award or have it settled, and the timing thereof, upon achievement or satisfaction of such performance conditions as may be specified by the Committee. The Committee may use such business criteria and other measures of performance as it may deem appropriate in establishing any performance conditions. Subject to the terms of the Plan, the performance goals to be achieved during any Performance Period, the length of any Performance Period, the amount of any Performance Award granted and the amount of any payment or transfer to be made pursuant to any Performance Award shall be determined by the Committee.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Performance criteria may be measured on an absolute (<font style="font-style: italic;">e.g.</font>, plan or budget) or relative basis, and may be established on a corporate-wide basis, with respect to one or more business units, divisions, Subsidiaries or business segments, or on an individual basis. If the Committee determines that a change in the business, operations, corporate structure or capital structure of the Company, or the manner in which the Company conducts its business, or other events or circumstances render the performance objectives unsuitable, the Committee may modify the performance objectives or the related minimum acceptable level of achievement, in whole or in part, as the Committee deems appropriate and equitable such that it does not provide any undue enrichment or harm. Performance measures may vary from Performance Award to Performance Award and from Participant to Participant, and may be established on a stand-alone basis, in tandem or in the alternative. The Committee shall have the power to impose such other restrictions on Awards subject to this &#8206;<u>Section 10(b)</u> as it may deem necessary or appropriate to ensure that such Awards satisfy all requirements of any applicable law, stock market or exchange rules and regulations or accounting or tax rules and regulations.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;Settlement of Performance Awards shall be in cash, Shares, other Awards, other property, net settlement, or any combination thereof, as determined in the discretion of the Committee.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;A Performance Award shall not convey to a Participant the rights and privileges of a shareholder with respect to the Share subject to such Performance Award, such as the right to vote (except as relates to Restricted Stock) or the right to receive dividends, unless and until and to the extent a Share is issued to such Participant to settle such Performance Award. The Committee, in its sole discretion, may provide that a Performance Award shall convey the right to receive dividend equivalents on the Shares subject to such Performance Award with respect to any dividends declared during the period that such Performance Award is outstanding, in which case, such dividend equivalent rights shall accumulate and shall be paid in cash or Shares on the settlement date of the Performance Award, subject to the Participant&#8217;s earning of the Shares with respect to which such dividend equivalents are paid upon achievement or satisfaction of performance conditions specified by the Committee. Shares delivered upon the vesting and settlement of a Performance Award may be evidenced in such manner as the Committee may deem appropriate, including book-entry registration. For the avoidance of doubt, unless otherwise determined by the Committee, no dividend equivalent rights shall be provided with respect to any Shares subject to Performance Awards that are not earned or otherwise do not vest or settle pursuant to their terms.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-9<br></div></div></div>
<!--End Page 608-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 609-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_305-annexf_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;The Committee may, in its discretion, increase or reduce the amount of a settlement otherwise to be made in connection with a Performance Award.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.&#8195;<u>Other Cash-Based Awards and Other Stock-Based Awards</u>. The Committee is authorized, subject to limitations under applicable law, to grant Other Cash-Based Awards (either independently or as an element of or supplement to any other Award under the Plan) and Other Stock-Based Awards. The Committee shall determine the terms and conditions of such Awards. Shares delivered pursuant to an Award in the nature of a purchase right granted under this <u>&#8206;Section 11</u> shall be purchased for such consideration, and paid for at such times, by such methods and in such forms, including cash, Shares, other Awards, other property, net settlement, broker-assisted cashless exercise or any combination thereof, as the Committee shall determine; <font style="font-style: italic;">provided</font> that the purchase price therefor shall not be less than the Fair Market Value of such Shares on the date of grant of such right.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">12.&#8195;<u>Effect of Termination of Service or a Change in Control on Awards</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The Committee may provide, by rule or regulation or in any applicable Award Agreement, or may determine in any individual case, the circumstances in which, and the extent to which, an Award may be exercised, settled, vested, paid or forfeited in the event of a Grantee&#8217;s Termination of Service prior to the end of a Performance Period or vesting, exercise or settlement of such Award.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Subject to the last sentence of &#8206;&#8206;<u>Section 2(jj)</u>, the Committee may determine, in its discretion, whether, and the extent to which, (i)&#160;an Award will vest during a leave of absence, (ii)&#160;a reduction in service level (for example, from full-time to part-time employment) will cause a reduction, or other change, to an Award and (iii)&#160;a leave of absence or reduction in service will be deemed a Termination of Service. In the event of a Change in Control, the Committee may, in its sole discretion, and on such terms and conditions as it deems appropriate, take any one or more of the following actions with respect to any outstanding Award, which need not be uniform with respect to all Grantees and/or Awards:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(i)&#8195;continuation or assumption of such Award by the Company (if it is the surviving corporation) or by the successor or surviving entity or its parent;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(ii)&#8195;substitution or replacement of such Award by the successor or surviving entity or its parent with cash, securities, rights or other property to be paid or issued, as the case may be, by the successor or surviving entity (or a parent or subsidiary thereof), with substantially the same terms and value as such Award (including any applicable performance targets or criteria with respect thereto);</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iii)&#8195;acceleration of the vesting of such Award and the lapse of any restrictions thereon and, in the case of an Option or SAR Award, acceleration of the right to exercise such Award during a specified period (and the termination of such Option or SAR Award without payment of any consideration therefor to the extent such Award is not timely exercised), in each case, either (A) immediately prior to or as of the date of the Change in Control, (B) upon a Grantee&#8217;s involuntary Termination of Service (including upon a termination of the Grantee&#8217;s employment by the Company (or a successor corporation or its parent) without Cause, by a Grantee for &#8220;good reason&#8221; (as such term may be defined in the applicable Award Agreement and/or a Grantee&#8217;s Service Agreement. as the case may be) and/or due to a Grantee&#8217;s death or Disability) on or within a specified period following the Change in Control or (C) upon the failure of the successor or surviving entity (or its parent) to continue or assume such Award;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iv)&#8195;in the case of a Performance Award, determination of the level of attainment of the applicable performance condition(s); and</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(v)&#8195;cancellation of such Award in consideration of a payment, with the form, amount and timing of such payment determined by the Committee in its sole discretion, subject to the following: (A) such payment shall be made in cash, securities, rights and/or other property; (B) the amount of such payment shall equal the value of such Award, as determined by the Committee in its sole discretion; <font style="font-style: italic;">provided</font> that, in the case of an Option or SAR Award, if such value equals the Intrinsic Value of such Award, such value shall be deemed to be valid; <font style="font-style: italic;">provided further</font> that, if the Intrinsic Value of an Option or SAR Award is equal to or less than zero, the Committee may, in its sole discretion, provide for the cancellation of such Award without payment of any consideration therefor (for the avoidance of doubt, in the event of a Change in Control, the Committee may, in its sole discretion, terminate any Option or SAR Awards for which the exercise or hurdle price is equal to or exceeds the per Share value of the consideration to be paid in the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-10<br></div></div></div>
<!--End Page 609-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 610-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_305-annexf_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">Change in Control transaction without payment of consideration therefor); and (C) such payment shall be made promptly following such Change in Control or on a specified date or dates following such Change in Control; <font style="font-style: italic;">provided</font> that the timing of such payment shall comply with Section 409A of the Code.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;In connection with any of the actions set forth in Sections 12(c)(i) &#8211; (v), the Committee may, in its sole discretion, determine: (i)&#160;that any payments to Grantees made in respect of Awards shall be made or delayed (subject to Section 409A of the Code, where applicable) to the same extent that payment of consideration to the holders of the Shares in connection with the Change of Control is made or delayed as a result of any escrow, indemnification, earn out, holdback or any other contingent or deferred payment arrangement; (ii)&#160;the terms and conditions applying to the payment made or payable to the Grantees, including participation in any escrow, indemnification, earn-outs, holdback or any other contingent or deferred payment arrangement; and (iii)&#160;that any terms and conditions applying under the applicable definitive transaction agreements in connection with the Change in Control shall apply to the Grantees (including, without limitation, appointment and engagement of a stockholders&#8217; or sellers&#8217; representative, payment of fees or other costs and expenses associated with such services, indemnification of such representative, and authorization to such representative within the scope of such representative&#8217;s authority in the applicable definitive transaction agreements).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;Neither the authorities and powers of the Committee under this <u>Section 12</u> nor the exercise or implementation thereof, shall (i)&#160;be restricted or limited in any way by any adverse consequences (tax or otherwise) that may result to any holder of an Award, and (ii)&#160;as, <font style="font-style: italic;">inter alia</font>, being a feature of the Award upon its grant, be deemed to constitute a change or an amendment of the rights of such holder under this Plan, nor shall any such adverse consequences (as well as any adverse tax consequences that may result from any tax ruling or other approval or determination of any relevant tax authority) be deemed to constitute a change or an amendment of the rights of such holder under this Plan, and may be effected without consent of any Grantee and without any liability to the Company or its Affiliates or to its or their respective officers, directors, employees and representatives and the respective successors and assigns of any of the foregoing.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">13.&#8195;<u>General Provisions Applicable to Awards</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Awards shall be granted for such cash or other consideration, if any, as the Committee determines; <font style="font-style: italic;">provided</font> that in no event shall Awards be issued for less than such minimal consideration as may be required by applicable law.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Awards may, in the discretion of the Committee, be granted either alone or in addition to or in tandem with any other Award or any award granted under any other plan of the Company. Awards granted in addition to or in tandem with other Awards, or in addition to or in tandem with awards granted under any other plan of the Company, may be granted either at the same time as or at a different time from the grant of such other Awards or awards.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;Subject to the terms of the Plan, payments or transfers to be made by the Company upon the grant, exercise or settlement of an Award may be made in the form of cash, Shares, other Awards, other property, net settlement, or any combination thereof, as determined by the Committee in its discretion at the time of grant, and may be made in a single payment or transfer, in installments or on a deferred basis, in each case in accordance with rules and procedures established by the Committee. Such rules and procedures may include provisions for the payment or crediting of reasonable interest on installment or deferred payments or the grant or crediting of dividend equivalents in respect of installment or deferred payments.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;Except as may be permitted by the Committee or as specifically provided in an Award Agreement, (i)&#160;no Award and no right under any Award shall be assignable, alienable, saleable or transferable by a Participant other than by will or pursuant to <u>Section 13(e)</u> and (ii)&#160;during a Participant&#8217;s lifetime, each Award, and each right under any Award, shall be exercisable only by such Participant or, if permissible under applicable law, by such Participant&#8217;s guardian or legal representative. The provisions of this &#8206;<u>Section 13(d)</u> shall not apply to any Award that has been fully exercised or settled, as the case may be, and shall not preclude forfeiture of an Award in accordance with the terms thereof.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;A Participant may designate a Beneficiary or change a previous Beneficiary designation only at such times as prescribed by the Committee, in its sole discretion, and only by using forms and following procedures approved or accepted by the Committee for that purpose.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-11<br></div></div></div>
<!--End Page 610-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 611-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_305-annexf_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;All certificates, if any, for Shares and/or other securities delivered under the Plan pursuant to any Award or the exercise or settlement thereof shall be subject to such stop transfer orders and other restrictions as the Committee may deem advisable under the Plan or the rules, regulations and other requirements of the Securities and Exchange Commission, any stock market or exchange upon which such Shares or other securities are then quoted, traded or listed, and any applicable securities laws, and the Committee may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;The Company will not be obligated to deliver any Shares under the Plan or remove restrictions from Shares previously delivered under the Plan until (i)&#160;all Award conditions have been met or removed to the Committee&#8217;s satisfaction, (ii)&#160;as determined by the Committee, all other legal matters regarding the issuance and delivery of such Shares have been satisfied, including any applicable securities laws, stock market or exchange rules and regulations or accounting or tax rules and regulations and (iii)&#160;the Participant has executed and delivered to the Company such representations or agreements as the Committee deems necessary or appropriate to satisfy any applicable laws. The Company&#8217;s inability to obtain authority from any regulatory body having jurisdiction, which the Committee determines is necessary to the lawful issuance and sale of any Shares, will relieve the Company of any liability for failing to issue or sell such Shares as to which such requisite authority has not been obtained.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(h)&#8195;The Committee may impose restrictions on any Award with respect to non-competition, non-solicitation, confidentiality and other restrictive covenants, or requirements to comply with minimum share ownership requirements, as it deems necessary or appropriate in its sole discretion, which such restrictions may be set forth in any applicable Award Agreement or otherwise.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">14.&#8195;<u>Amendments and Terminations</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;<font style="font-style: italic;">Amendment or Termination of the Plan</font>. Except to the extent prohibited by applicable law and unless otherwise expressly provided in an Award Agreement or in the Plan, the Board may amend, alter, suspend, discontinue or terminate the Plan or any portion thereof at any time; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that no such amendment, alteration, suspension, discontinuation or termination shall be made without (i)&#160;shareholder approval if such approval is required by applicable law or the rules of the stock market or exchange, if any, on which the Shares are principally quoted or traded or (ii)&#160;subject to &#8206;<u>Section 5(c)</u> and <u>Section 12</u>, the consent of the affected Participant, if such action would materially adversely affect the rights of such Participant under any outstanding Award, except (x)&#160;to the extent any such amendment, alteration, suspension, discontinuance or termination is made to cause the Plan to comply with applicable law, stock market or exchange rules and regulations or accounting or tax rules and regulations or (y) to impose any &#8220;clawback&#8221; or recoupment provisions on any Awards (including any amounts or benefits arising from such Awards) in accordance with &#8206;<u>Section 18</u>. Notwithstanding anything to the contrary in the Plan, the Committee may amend the Plan, or create Sub-plans, in such manner as may be necessary or desirable to enable the Plan to achieve its stated purposes in any jurisdiction in a tax-efficient manner and in compliance with local rules and regulations.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;<font style="font-style: italic;">Dissolution or Liquidation</font>. In the event of the dissolution or liquidation of the Company, each Award shall terminate immediately prior to the consummation of such action, unless otherwise determined by the Committee.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;<font style="font-style: italic;">Terms of Awards</font>. The Committee may waive any conditions or rights under, amend any terms of, or amend, alter, suspend, discontinue or terminate any Award theretofore granted (including by substituting another Award of the same or a different type), prospectively or retroactively, without the consent of any relevant Participant or holder or Beneficiary of an Award; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that, subject to &#8206;<u>Section 5(c)</u> and &#8206;<u>Section&#160;12</u>, no such action shall materially adversely affect the rights of any affected Participant or holder or Beneficiary under any Award theretofore granted under the Plan, except (x)&#160;to the extent any such action is made to cause the Plan or Award to comply with applicable law, stock market or exchange rules and regulations or accounting or tax rules and regulations, or (y) to impose any &#8220;clawback&#8221; or recoupment provisions on any Awards (including any amounts or benefits arising from such Awards) in accordance with <u>&#8206;Section 18</u>. The Committee shall be authorized to make adjustments in the terms and conditions of, and the criteria included in, Awards in recognition of events (including the events described in <u>&#8206;Section 5(c)</u>) affecting the Company, or the financial statements of the Company, or of changes in applicable laws, regulations or accounting principles, whenever the Committee determines that such adjustments are appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-12<br></div></div></div>
<!--End Page 611-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 612-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_305-annexf_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;<font style="font-style: italic;">Repricing</font>. The Committee shall, without the approval of the Company&#8217;s shareholders, have the authority to (i)&#160;amend any outstanding Option or SAR to reduce the exercise price per Share or (ii)&#160;cancel any Option or SAR in exchange for cash or another Award.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">15.&#8195;<u>Miscellaneous</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;No Employee, Consultant, Non-Employee Director, Participant, or other Person shall have any claim to be granted any Award under the Plan, and there is no obligation for uniformity of treatment of employees, Participants or holders or Beneficiaries of Awards under the Plan. The terms and conditions of Awards need not be the same with respect to each recipient. Any Award granted under the Plan shall be a one-time Award that does not constitute a promise of future grants. The Company, in its sole discretion, maintains the right to make available future grants under the Plan.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The grant of an Award shall not be construed as giving a Participant the right to be retained in the employ of, or to continue to provide services to, the Company or any Affiliate. Further, the Company or any applicable Affiliate may at any time dismiss a Participant, free from any liability, or any claim under the Plan, unless otherwise expressly provided in the Plan or in any Award Agreement or in any other agreement binding on the parties. The receipt of any Award under the Plan is not intended to confer any rights on the receiving Participant except as set forth in the applicable Award Agreement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;In the event a Participant&#8217;s regular level of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an employee of the Company and the Employee has a change in status from a full-time employee to a part-time employee (or serves as a Consultant or Director) or takes an extended leave of absence) after the date of grant of any Award to the Participant, the Board may determine, to the extent permitted by applicable law, to (i)&#160;make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (ii)&#160;in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;As a condition to accepting an Award under the Plan, the Participant agrees to execute any additional documents or instruments necessary or desirable, as determined in the Committee&#8217;s sole discretion, to carry out the purposes or intent of the Award, or facilitate compliance with securities and/or other regulatory requirements, in each case at the Committee&#8217;s request.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;No payment pursuant to the Plan shall be taken into account in determining any benefits under any severance, pension, retirement, savings, profit sharing, group insurance, welfare or other benefit plan of the Company or any Affiliate, except to the extent otherwise expressly provided in writing in such other plan or an agreement thereunder.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;Nothing contained in the Plan shall prevent the Company or any Affiliate from adopting or continuing in effect other or additional compensation arrangements, including the grant of options and other stock-based awards, and such arrangements may be either generally applicable or applicable only in specific cases.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;The Company shall be authorized to withhold from any Award granted or any payment due or transfer made under any Award or under the Plan or from any compensation or other amount owing to a Participant the amount (in cash, Shares, other Awards, other property, net settlement, or any combination thereof) of applicable withholding taxes due in respect of an Award, its exercise or settlement or any payment or transfer under such Award or under the Plan and to take such other action (including providing for elective payment of such amounts in cash or Shares by such Participant) as may be necessary to satisfy all obligations for the payment of such taxes and, unless otherwise determined by the Committee in its discretion, to the extent such withholding would not result in liability classification of such Award (or any portion thereof) pursuant to FASB ASC Subtopic 718-10. As a condition to accepting an Award under the Plan, in the event that the amount of the Company&#8217;s and/or its Affiliate&#8217;s withholding obligation in connection with such Award was greater than the amount actually withheld by the Company and/or its Affiliates, each Participant agrees to indemnify and hold the Company and/or its Affiliates harmless from any failure by the Company and/or its Affiliates to withhold the proper amount.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(h)&#8195;If any provision of the Plan or any Award Agreement is or becomes or is deemed to be invalid, illegal or unenforceable in any jurisdiction, or as to any Person or Award, or would disqualify the Plan or any Award </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-13<br></div></div></div>
<!--End Page 612-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 613-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_305-annexf_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">under any law deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to applicable laws, or if it cannot be so construed or deemed amended without, in the determination of the Committee, materially altering the intent of the Plan or the Award Agreement, such provision shall be stricken as to such jurisdiction, Person or Award, and the remainder of the Plan and any such Award Agreement shall remain in full force and effect.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(i)&#8195;Neither the Plan nor any Award shall create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company and a Participant or any other Person. To the extent that any Person acquires a right to receive payments from the Company pursuant to an Award, such right shall be no greater than the right of any unsecured general creditor of the Company.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(j)&#8195;Any reference herein or in an Award Agreement to a &#8220;written&#8221; agreement or document will include any agreement or document delivered electronically, filed publicly at <font style="font-style: italic;">www.sec.gov</font> (or any successor website thereto) or posted on the Company&#8217;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access). By accepting any Award, the Participant consents to receive documents by electronic delivery and to participate in the Plan through any on-line electronic system established and maintained by the Committee&#8217;s or another third party selected by the Committee. The form of delivery of any Shares (e.g., a stock certificate or electronic entry evidencing such shares) shall be determined by the Company.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(k)&#8195;No fractional Shares shall be issued or delivered pursuant to the Plan or any Award, and the Committee shall determine whether cash or other securities shall be paid or transferred in lieu of any fractional Shares, or whether such fractional Shares or any rights thereto shall be canceled, terminated or otherwise eliminated.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(l)&#8195;Awards may be granted to Participants who are non-United States nationals or employed or providing services outside the United States, or both, on such terms and conditions different from those applicable to Awards to Participants who are employed or providing services in the United States as may, in the judgment of the Committee, be necessary or desirable to recognize differences in local law, tax policy or custom. The Committee also may impose conditions on the exercise or vesting of Awards in order to minimize the Company&#8217;s obligation with respect to tax equalization for Participants on assignments outside their home country.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">16.&#8195;<u>Effective Date of the Plan</u>. The Plan shall be effective as of the Effective Date.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">17.&#8195;<u>Term of the Plan</u>. No Award shall be granted under the Plan after the earliest to occur of (i)&#160;the 10-year anniversary of the Effective Date; (ii)&#160;the maximum number of Shares available for issuance under the Plan have been issued; or (iii)&#160;the Board terminates the Plan in accordance with &#8206;<u>Section 14(a)</u>. However, unless otherwise expressly provided in the Plan or in an applicable Award Agreement, any Award theretofore granted may extend beyond such date, and the authority of the Committee to amend, alter, adjust, suspend, discontinue or terminate any such Award, or to waive any conditions or rights under any such Award, and the authority of the Board to amend the Plan, shall extend beyond such date.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">18.&#8195;<u>Cancellation or &#8220;Clawback&#8221; of Awards</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The Committee may specify in an Award Agreement that a Participant&#8217;s rights, payments and benefits with respect to an Award shall be subject to reduction, cancellation, forfeiture or recoupment upon the occurrence of certain specified events, in addition to any otherwise applicable vesting or performance conditions of an Award. Such events may include a Termination of Service with or without Cause (and, in the case of any Cause that is resulting from an indictment or other non-final determination, the Committee may provide for such Award to be held in escrow or abeyance until a final resolution of the matters related to such event occurs, at which time the Award shall either be reduced, cancelled or forfeited (as provided in such Award Agreement) or remain in effect, depending on the outcome), violation of material policies, breach of non-competition, non-solicitation, confidentiality or other restrictive covenants, or requirements to comply with minimum share ownership requirements, that may apply to the Participant, or other conduct by the Participant that is detrimental to the business or reputation of the Company and/or its Affiliates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The Committee shall have full authority to implement any policies and procedures necessary to comply with Section 10D of the Exchange Act and any rules promulgated thereunder and any other regulatory regimes. Notwithstanding anything to the contrary contained herein, any Awards granted under the Plan (including any amounts or benefits arising from such Awards) shall be subject to any clawback or recoupment arrangements or policies the Company has in place from time to time and the Committee may, to the extent </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-14<br></div></div></div>
<!--End Page 613-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 614-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_305-annexf_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">permitted by applicable law and stock exchange rules or by any applicable Company policy or arrangement, and shall, to the extent required, cancel or require reimbursement of any Awards granted to the Participant or any Shares issued or cash received upon vesting, exercise or settlement of any such Awards or sale of Shares underlying such Awards.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">19.&#8195;<u>Section 409A of the Code</u>. With respect to Awards subject to Section 409A of the Code, the Plan is intended to comply with the requirements of Section 409A of the Code, and the provisions of the Plan and any Award Agreement shall be interpreted in a manner that satisfies the requirements of Section 409A of the Code, and the Plan shall be operated accordingly. If any provision of the Plan or any term or condition of any Award would otherwise frustrate or conflict with this intent, the provision, term or condition shall be interpreted and deemed amended so as to avoid this conflict. Notwithstanding anything in the Plan to the contrary, if the Board considers a Grantee to be a &#8220;specified employee&#8221; under Section 409A of the Code at the time of such Grantee&#8217;s &#8220;separation from service&#8221; (as defined in Section 409A of the Code), and any amount hereunder is &#8220;deferred compensation&#8221; subject to Section&#160;409A of the Code, any distribution of such amount that otherwise would be made to such Grantee with respect to an Award as a result of such &#8220;separation from service&#8221; shall not be made until the date that is six months after such &#8220;separation from service,&#8221; except to the extent that earlier distribution would not result in such Grantee&#8217;s incurring interest or additional tax under Section 409A of the Code. If an Award includes a &#8220;series of installment payments&#8221; (within the meaning of Section 1.409A-2(b)(2)(iii)&#160;of the Treasury Regulations), a Grantee&#8217;s right to such series of installment payments shall be treated as a right to a series of separate payments and not as a right to a single payment, and if an Award includes &#8220;dividend equivalents&#8221; (within the meaning of Section 1.409A-3(e) of the Treasury Regulations), a Grantee&#8217;s right to such dividend equivalents shall be treated separately from the right to other amounts under the Award. Notwithstanding the foregoing, the tax treatment of the benefits provided under the Plan or any Award Agreement is not warranted or guaranteed, and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by a Grantee on account of non-compliance with Section 409A of the Code.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">20.&#8195;<u>Successors and Assigns</u>. The terms of the Plan shall be binding upon and inure to the benefit of the Company and any successor entity, including any successor entity contemplated by &#8206;<u>Section 12(c)</u>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">21.&#8195;<u>Data Protection</u>. In connection with the Plan, the Company may need to process personal data provided by a Grantee to the Company or its Affiliates, third party service providers or others acting on the Company&#8217;s behalf. Examples of such personal data may include, without limitation, the Grantee&#8217;s name, account information, social security number, tax number and contact information. The Company may process such personal data in its legitimate business interests for all purposes relating to the operation and performance of the Plan, including but not limited to:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(a)&#8195;administering and maintaining Grantee records;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(b)&#8195;providing the services described in the Plan;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;providing information to future purchasers or merger partners of the Company or any Affiliate, or the business in which such Grantee works; and</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(d)&#8195;responding to public authorities, court orders and legal investigations, as applicable.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">The Company may share the Grantee&#8217;s personal data with (i)&#160;Affiliates, (ii)&#160;trustees of any employee benefit trust, (iii)&#160;registrars, (iv)&#160;brokers, (v)&#160;third party administrators of the Plan, (vi)&#160;third party service providers acting on the Company&#8217;s behalf to provide the services described above or (vii)&#160;regulators and others, as required by law.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">If necessary, the Company may transfer the Grantee&#8217;s personal data to any of the parties mentioned above in a country or territory that may not provide the same protection for the information as the Grantee&#8217;s home country. Any transfer of the Grantee&#8217;s personal data to recipients in a third country will be made subject to appropriate safeguards or applicable derogations provided for under applicable law. Further information on those safeguards or derogations can be obtained through the contact set forth in the Employee Privacy Notice (the &#8220;<font style="font-weight: bold;">Employee Privacy Notice</font>&#8221;) that previously has been provided by the Company or its applicable Affiliate to the Grantee. The terms set forth in this <u>&#8206;Section 21</u> are supplementary to the terms set forth in the Employee Privacy Notice (which, among other things, further describes the rights of the Grantee with respect to the Grantee&#8217;s personal data); provided that, in the event of any conflict between the terms of this <u>Section 21</u> and the terms of the Employee Privacy Notice, the terms of this &#8206;<u>Section 21</u> shall govern and control in relation to the Plan and any personal data of the Grantee to the extent collected in connection therewith.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-15<br></div></div></div>
<!--End Page 614-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 615-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20006478x8_prer14a_305-annexf_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">The Company will keep personal data collected in connection with the Plan for as long as necessary to operate the Plan or as necessary to comply with any legal or regulatory requirements.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">A Grantee has a right to (i)&#160;request access to and rectification or erasure of the personal data provided, (ii)&#160;request the restriction of the processing of his or her personal data, (iii)&#160;object to the processing of his or her personal data, (iv)&#160;receive the personal data provided to the Company and transmit such data to another party, and (v)&#160;to lodge a complaint with a supervisory authority.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">22.&#8195;<u>Governing Law</u>. The Plan and each Award Agreement shall be governed by the laws of the State of Delaware, without application of the conflicts of law principles thereof.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-16<br></div></div></div>
<!--End Page 615-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 616-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 613.35pt;"><a name="ny20006478x8_prer14a_500-proxycard_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 613.35pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; text-align: center;"><img style="height: 950px; width: 734px;" src="ny20006478x8_pc01.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div></div></div></div>
<!--End Page 616-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 617-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 613.35pt;"><a name="ny20006478x8_prer14a_500-proxycard_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 613.35pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; text-align: center;"><img style="height: 950px; width: 734px;" src="ny20006478x8_pc02.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div></div></div></div>
<!--End Page 617-->
</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>ny20006478x8_bargraph01.jpg
<TEXT>
begin 644 ny20006478x8_bargraph01.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[B_!GAB3Q+X?M-9O\
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M_P#0V^./_!\G_P @T?\ "NK?_H;?''_@^3_Y!KT2B@#SO_A75O\ ]#;XX_\
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MCC_P?)_\@T?\*ZM_^AM\<?\ @^3_ .0:]$HH \[_ .%=6_\ T-OCC_P?)_\
M(-'_  KJW_Z&WQQ_X/D_^0:]$HH \[_X5U;_ /0V^./_  ?)_P#(-'_"NK?_
M *&WQQ_X/D_^0:]$HH \[_X5U;_]#;XX_P#!\G_R#1_PKJW_ .AM\<?^#Y/_
M )!KT2B@#SO_ (5U;_\ 0V^./_!\G_R#1_PKJW_Z&WQQ_P"#Y/\ Y!KT2B@#
MSO\ X5U;_P#0V^./_!\G_P @T?\ "NK?_H;?''_@^3_Y!KT2B@#SO_A75O\
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M\<?^#Y/_ )!KT2B@#SO_ (5U;_\ 0V^./_!\G_R#1_PKJW_Z&WQQ_P"#Y/\
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M^AR4 >B4444 >=_"O_D2=+_Z[:C_ .G"YKT2O._A7_R).E_]=M1_].%S7HE
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?&?_  4!_;1\ _\
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M +/\(S7&C>)_%J7&BZWX4NK'Q)XXT+P[XHNO#:2W7B&#5_C7X(_LP?&O6/\
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M\3?@UKWQ(\%?%/\ :&U^V^.UU\(=0\;^#OVE/!GCW4OAEX#>/PCX$\/&'2?
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MG7=3\;>,_A_X'\9Q3ZAI_C>2'1)[V>1-&D\$Z]8_%3X>^ Y]4U.RU3Q1\/\
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MII[ZKJ5E?@'[PVEY::A;Q7EA=6U[:3!C#=6D\5S;RA7:-C%/"SQ2!75D8HQ
M=64X(('P/_P42_X)Q_LX_P#!2GX5^"?AA^TI?>/-)\*?#3XCZ?\ %;2]4^'O
MB72/"NK->:5HNM:+J.BZOJ>M^'_$EH/"FM:3K-TFN+:VFGZQ$;6SNM*U[2)K
M=I9/Y8_B#\=?V9?V8?\ @O'^Q.O_  2;^(7PY\.?!O\ :4UWX:_ S]JGX??
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M1U&>VTK3K6":_P!0N;F]O)$:XNIYIY))&_K]K^.S_@UO\'^(?A[^TS_P6J\
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M+:66@^/K+PK%)IFB:586,<<WARXM+I+<2ZA;7<[R2O\ MY_P6^_Y1-?MU_\
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M1_\ 3A<UZ)7G?PK_ .1)TO\ Z[:C_P"G"YKT2@ HHHH **** "BBB@ HHHH
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M'QQJ'AK0K'2=0\8^*M6U'PK>WNH>(?$][:SZWK%S/=SM)J%]<%7V;0/YIO\
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M7F@&HR^'KB\=[J\\-W-S/H-[<.\UWIT\C,Q /Y _^"J/[5W['OBK_@K_ /\
M!&[Q9\%OBS\*;K]G[X _$#X:Z!XD^)/@JZTW3_V>O!6EZ'\;/"5]<V.A?$JP
M@M/A5=>'O!&@?8YO$MSX4UZ]\/\ @6QDMX=?NM(\N2&'Z2_X.O/BKX'^*/\
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M&DV22222+:V%G! )))'";G8D _B^_P""8G[97[-?QZ_X*'?MX?'[_@K7\6?
M'@C]H/\ 9_\ B@VB?LJ>!OVI_B%H'A3X>?L\^%-)\8_$32/&7A+X/^&O%>MZ
M?X!B^)'@F_T3P7H^J:E!I4_CUKN!?$6C:CJ&L:UXPU(X_P#P30_:Z^ .D?\
M!P=_P4I^+.H^-I;'PI\;/ NLZ+\&+74/#7BG2_&'Q9U[Q+\4O@(OA;P_\/\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YWX_\
M^/CP/_V/&A_^AR5Z)7G?C_\ X^/ _P#V/&A_^AR4 >B4444 >=_"O_D2=+_Z
M[:C_ .G"YKT2O._A7_R).E_]=M1_].%S7HE !1110 4444 %%%% !44TT-NG
MF3S101[XH_,FD2-/,GE2"&/<Y5=\TTD<,29W22ND: NR@RU_)Y_P5*_:*O\
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M*]2TJS /ZVJ*_"[]O'XM?%G]F]?^"7W_  33^!WQ9^+#>._VN_B58?"7QO\
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M]5_8.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\>./_!V__P ;KT2B@#SO_A +C_H>/''_ (.W_P#C='_" 7'_ $/'CC_P=O\
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M\>./_!V__P ;KT2B@#SO_A +C_H>/''_ (.W_P#C='_" 7'_ $/'CC_P=O\
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M\>./_!V__P ;KT2B@#SO_A +C_H>/''_ (.W_P#C='_" 7'_ $/'CC_P=O\
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MX7->B4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M->UN/3%UO7-,\-:/%#HWA?2M<\1:K>:EKVLZ9IEG8:-I&H7T]S>1+';E0[*
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MFB^+8[&YMK>ZMKK4]"TF;7IM"FE6X,,NC:[+IOB+3KFWN+;5M'L)D57^H?\
M@DO^T'^U]\>_AO\ M+1_MH^ _"WP_P#BG\*_VN_C!\.;7P_X3\4:?XDM/#N@
MP2:/XDMO!5\1KNLZ_$_AN7Q!)>^$]4UJ.PLO%'PK\0_#GQ#X6BG\.W]E-0!^
MKU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC'QOX=\-7&J6-KI6O^([2ST;5 "U^R;\+OV*OVJ/V)/V!]2^&%Q>?'7]F_X
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MI_&7_A%?V!O$OQ*\76*W$7AL>,?'OP5UOQ]KWA?P%;7D-O?V7PQ\!ZEXGN/
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M)O\ #_Q1\/-6\.I!,EHR^&[70'72]+BDCLHP#]6J*** "BBB@ HHHH ****
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ML?A5_P"##4__ )5T?\/4/^">?_1V/PJ_\&&I_P#RKH_U<XA_Z$.=?^&O'?\
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ML-,LK/4M>GT^W^R6$VLWUO!'=:I+96G^BVDE]+.]M;_N862/Y:V** "BBB@
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MCI[:[/\ #/0&\+>*? 6D6/B#1-%C6WFGU?QEJ&NZ[XK?7/#&C^!1)X/FO_$
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M"DW_ (+M0_\ D:@#T2BO._\ A:G@G_H*3?\ @NU#_P"1J/\ A:G@G_H*3?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"&+'Q!KD=M)J/B.\T\ZW9S1^&_#^O:C +F2P6UF_/_ ,#?\%N?!/B[XJ_
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MQ$^+^D^)O$>NWDVJVUGH&F>*;F^L-/\ #NM^)_$(T3PMIUYK%N ?65%?FO\
ML<_\%0/@]^U_\8/B1^SH_P (/VE?V9/VB?AEX97Q_JOP0_:J^%<?PQ\>:W\,
MI=;L_#\/Q'\,0Z9XA\6:/JOA9=6U71M-N;DZO;3F^U2!M+AU;2 -8?\ 0SQ/
MXF\/^"_#7B'QCXLUC3_#WA7PGH>K>)O$VOZM<QV>EZ'X?T&PN-4UG6-2NY2L
M5KI^F:=:W-[>7,C"."V@DE<A5)H W**_GUM_^#A_X/7WPWU#XS:=_P $X/\
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M /0Y*]$KSOQ__P ?'@?_ +'C0_\ T.2@#T2BBB@#SOX5_P#(DZ7_ -=M1_\
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M5XT\3>$-8T7PMXMM]7T$C7-*G\.:Y>V.L0ZEHQ&K6,EFMUIQ%Y%#7X!?&O\
M9Y_X*7?M@^(?VD/V=/BY\ _V?OASK/QU_8F_9;^ 7Q._:5M?B1XQ^(7P!M[+
MPK\8OCSXC^('Q%^$?AG5/@QX<\0^)/BC<Q>*;W4/"OP;U[4?"US\,-2_X1/Q
M-KOQ2N+.]\-ZCK7^=Y_8!^L7_!2.32Y?^"87[>\NB36=QHLG[!O[4LFD7&G3
MQ7.GSZ6_[/GCIK":QN8'DAN+.6T,3VT\,DD4L+))&[(P8Y/_  29_P"48?[
M'_9H?P"_]5MX>K3_ &EOV8?&^I_\$[?B#^Q+^S)8^"KN[\0?LMZY^R;X-O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /R/_ ."Y7_*-3XY?]ASX0?\ JWO!
M-?P/U_?!_P %RO\ E&I\<O\ L.?"#_U;W@FOX'Z_JSP/_P"21QW_ &4&,_\
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M ![X7TSQ-!HVJ/;,]K)J6DKJ7]G7\EI)+:275M-):RRV[1R-^*7[%,L?B?\
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M3_Z#7A;_ ,!;K_Y#H ])HKS;[#\4_P#H->%O_ 6Z_P#D.C[#\4_^@UX6_P#
M6Z_^0Z /2:*\V^P_%/\ Z#7A;_P%NO\ Y#H^P_%/_H->%O\ P%NO_D.@#TFB
MO-OL/Q3_ .@UX6_\!;K_ .0Z/L/Q3_Z#7A;_ ,!;K_Y#H ])HKS;[#\4_P#H
M->%O_ 6Z_P#D.C[#\4_^@UX6_P# 6Z_^0Z /2:*\V^P_%/\ Z#7A;_P%NO\
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M*5)],LF@EUC5XIX)-]K=V&G2Z9*ZF.348#DC]5S+-<MRC#RQ>:8["X##QO\
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M/A]H"VD-N=/TBU\!^$O["M-8L;J#7/[?TGQ!?S:;X0D.F^'-&^U;[XH?&?\
M9EO_ (*? RP_9C^.?[2/PUT7X2^ O"5]^T3X#\2_#/4?$-SXZT*RN?#5]!XS
M\ >+/%OA/4[*.ZL=$TGQ/K'C:373I,EUXDGL;>">YTV<S<?^SG\'/B1\,_%_
M[:_[9'BGX-WMI\8_VG/$/A+5_#O[/_A_Q9X"N/$UGX$^"G@)/!7PT\.Z_P")
MKGQ!;_#/2OB?XWO)==\0^-Y=,\?:SX(TQM3T:VA\2ZE<:7>3S:5+U,7AI1@W
M"E'$4\51GAZEJ<:E%RE4IU5%1J3<XTZ2A%5(U83G*";BVLX/DP]9.5IU'1G0
MJQK0O-PJI1A.GS-PBHN=3FDX.G*$(RT:1XQ_P5+_ &?/AQ\5_P!GWX(?L;?#
MSP!X7TSXC?$WXN?#WPK\#&\->'M)MKOX&>#O"'B#1/$WQ?\ BOHEK9K9S>'_
M  CX.^'&DW>B>(;C3&@BN]1\5>&-"*SZIK.DQ2?L'&@C1(P78(BH&D9G=@H"
M@N[$L[G&69B68Y)))-?AU\.?BG_P4U\)^)/'7Q5\8?\ !*W4O'WQJ\<1W&F+
MXGG_ &SOV:-'\/\ @[P-874]SX1^%G@;2#J.K7V@>#=,E,6K^*+EM2O=9\<^
M-+K5?%>K306H\,>&?"OZ4:M\2/VB/"OQ _9F^'DGP/L?B-H?Q!T'7E_:#^-O
MA?Q7;>%O"?P@\2>&O"-G?12Z;X&UB'6==US2/&WBB2ZL-"@/B%;G2+.)(KJY
MU2X+2K6%JTG4KXA4L13E56&H\DL'B:/)3A*4*$6IT8<\N:M.52<%*%&GRQJ2
MC"FIR5>%10I4?:4:D:;KU%*.)H5+SE&,ZS7+4ER12IQ4(R:E5FI.$7*;BN.^
M+?P^_9I_9Q_9N_:0U[Q5\./#^O>!/%[_ !)^)?Q6T#6-+L]?U?XQ^-_B#K^I
M:XGAV]%]#)<^)O$7BKQ?KFG^#OAYH;&62PN+GPQX8\,PVL5GIEO%\U?LNZ3X
MU_X)Z_\ !-G]G'X3:[HUUX[_ &B]2TD^%OA[\*9+L17_ (A^-GQ;U_Q/\0[+
MX=W%TMQ/'I_AKX90:WJES\1_$UI)-IWACX?^ O%_C%$FM--6&;D?B[X__;^U
M[]I&;Q.?^";?B;XM_!GX2:J9?@/HEW^U/^S3X$T[4_%\'VBUN?C=XQT#4/%'
MB>ZU'Q'!;,UI\*=(NY-.B^'^G7VL:_J%C?>-=7TN;P1[K=_LM:-^WU\//"GB
M;_@HA^S-8>"O&/A+QAXXO?AK\)]"^-?B^XU;X9^%M8MM T&1?$WQ"^"WCOP[
MX>\;>(?%LGAB3Q0;BP5-.T+0M:TCPT+)-8TS7=1U7)MU:U26%HSI5Z5"IAL/
M[;#8C#4E"=6E*M4=>>&E3;;A%X>$8U=8RFXN-2I[.](4X+$5(U*=2K&O5=.M
M1KU.:-.4:<%2C64U92:K2;@K-14E*$>;X8^!'P2/P,_X+3>&-$UGQ#-XX^)/
MC/\ X)K:_P#$KXT?$:ZMTM+GXA_%KQ9^TQK+>*?$45C&HCTCP_906&E^$O G
MAR,R1>$OAWX9\(^$X;BZBT-+F;^QKX*?\DP\*?\ 7#4?_3SJ5?QVZ)_P1O\
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M^'_PD^,7PP^)7Q UOQAJ?[+OC7]G;PIIVK?'SQ/H7Q!^&NN?"_Q%XWC^)?\
M;_AC0/!OA76O^%4:!K=Q_P )?:?&>_U+3(/#7Z2WOQS_ &V?B?\ LR?L[^)O
M@%\"OAAX._:3^-WPZT;QOXWM/V@M9\:CX'?L^S0Z%H5]XLT7Q;+X(L(/'_C3
MQ4VOZ];Z!X)\'Z3#X:&O6]AXFUW5O%6@V?AIH-6_"S]L']DKXI?L8_MN^!/V
M^?\ @CIJ?AOQQXI_:$^#W[4W[3?Q9^ 'BCQ*OC?X'?&CP9HVJ_L^:]\0-9^"
M<VG2O<VWB/XJ2?$70_'5FF@>,=,M=0?PK96?@?6;?1[JQ\!:U_1#^RI^TSHW
M[>G[&7PR_:4^#.H:C\-8_CG\.[W4M"N=1TZP\3:C\.?&-I=ZKX5\1Z?/9:A!
M9Z5XGD\$>-]&UK2DGGM;73?$*:4EZMM!:7JQ* ?+?_!-[]L?]JGXT_%C]L;]
MDK]M;X=?"'PS^T=^Q9KGP8@\4^.OV?+_ ,77/P8^)7AGX\>#=;\;^!]1\-V'
MC@W'B72-6L="T2.XUU-1O8Q>3:S L&B:!+I]Y8+XUX?_ ."BW[4O[2'PX_:S
M_:R_9 \(_ W4/V5OV2O&GQ*\*^&_"WQ+\._$36/BS^V:GP'T;3O$?Q6U3X7>
M//"GC?0_"'P0\.^)+>75_"_P=\0:U\//CG=Z[XBTV#4/%GAOPQ:7%WI%CX_^
MP!/^VW^S!_P4Q_:I_8$_:&^+/@_]I72/C+\ -3_;^\,_M16OPNT;X=?$:Y\3
M:OXW\'? &PT3XA:9X>N!X=^SZ=:>&[C1/#_AZ,:\="\,^"?"FG^%+K1_!D8\
M*^&N _X(*^*?#'@+_@A/XU7Q-X;LK._^!UU^V3IGQI\->(TL-+SX@\,:AXK\
M6ZYHWC&*YBO)-,FA\'ZGH6D:M'XATX75G8VZ"?3YM-2T-P ?O?\ LN?M%?#[
M]K?]GCX/_M)_"VYEG\#?&/P-HWC/1X+J2VDU'19[Z$PZWX6UHV<MQ:)XA\(:
M_;ZIX6\106MQ<6]MKNCZA;PSS1Q+*WQK\5OVS?BSX[_;CN?^"?'[(2_"_2OB
M5\.O@U;_ !U_:+^-WQG\(^+OB-\/OA/H/B#5]%TCP!\-M$^&_@;Q_P#"O6O&
M7Q2\;6NM)XO:/5?B3X)\/^'O!D%OJ4%QXIU"]N=*TCPO_@W.T#Q#X<_X(W?L
M=V?B2&\M+F^L_C1K^F6-]9BSGM?#WB/]H7XKZYX?F0D^9=V>M:5?VWB/3KR0
M RZ?K-LL0-M' S>0_L3[?#O_  <"?\%D-"\4V#KXI\>?"']C7QYX!U:\L[>T
MDU+X=>'/A5X4\*^()-%:8Q7M]I5IXAU'P_X?U&]TZ"XTXZSX<DM]2N8M0@M8
MY@#Z;^%G_!6'P)8?LV_ML_$_]I[1M-^'WQ2_X)Q>./%_PN_:<\'>![R;4M-\
M6:_X=$=MX!\<_"&R\1S6.K6G@_\ :*OI(8/A5H?C*_34=*UJXN_"^L^(]7M]
M'/B_5?,=0_X*)_M5?L_?"[]DK]KG]L'PA\!M _9C_:T\;_"OP/XA\!_#W1/B
M'HWQ3_8]M_CWI,?B#X7>.?BI\5/&'C35/!_Q<T#P_&C>%_C'IND_"CX,77A7
M6-7L-6\,:AXMM]+NM&U7^?+]N#1?%/Q&\&?\'5GC+P'H<]OX,@^,W_!/7PUJ
M%EX?TR+5=.\0:S\$_B?#%\4=034+*SA^RZCX5-FWC;QS$D)?38]6N9];O9FM
M7O+C]</^"^_BCPUXR_X(=^!;#P!X=L-9'QTU[]CSP_\ !72=/.FR7L=]XBO/
M#WC'PO;>#K:P2^M[_5+SPQHE[H=G:Z%=QJ^E:E?2VM[/I\4MO=@'],U%5K**
MY@L[2"\NOMUY#:P175]Y$=K]LN8XD2>Z^S1$Q6_VB4--Y$9,<6_RT)50:LT
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M]HR]@LU\!0_##X2> [277?#W@'QCKMG?_%BWL-;^$_@K1=?UGQ;//HO["T4
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MXT\)Z1XGL[/QYX&M[LVMSX+\>V@UO3;B73=6\5:#XC^Q:* /DWX"_L5? ;X
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MP)(CJ36\8!]&T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&J(=8U?PW-$ ?JY17X5?L%?'S]O3X4_M_?&'_@F?^W'\4/!G[5,ND?LWZ?\
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M\5Z%;0:#J$FJ?##0M4T/P1JANM(FUFP72K*+Q7JFK^(9;[6=2_2__@F[X?\
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M"2?_ (=,V_\ FX7^O_%?_0SC_P"$.7__ #*?UB_\1,'AG_HSW7?_  ]^G_\
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M[+NA?M!_'E/AKK]C\>?$?@GQ-XOT_P ,ZDWQ27Q%\+O!'B+4?#.JS_$7X<>
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MID<^L:9IMIK(LHKG38]033M0U&UN^>^#W_!(3]ASX&ZIK#>!?!/Q('@/4_B
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M>*;:.R^%<'@FVUG3ETS19+6+1[73[;QOX;@TFS@@\J2 3Q6\<4=D5(!_,O\
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MK37KWQB/A_XATW1]6^'\>@QZ9_:5M])6D^D_\%$/^"S'[5'[/WQVT#0?BO\
MLB?L!? /X.V_A;X*^);?3/%'P>\;_';]H/2/"_Q''Q9\>^$KN>;1?'NM^'?"
M/]N>!?"FE>*])\2>'/#<=EJ6M:1::+K^I75YJWS%^W]\4K7_ (*=_P#!./\
M82_8Q^"7BN/7OVC/VM_'W[/6E_&OX>Z3J!?QI\!_#/PGLY+G]ICQC\;/"=M9
MZ?>>&=%^"/Q+\/P^&/$MGXFTG0X[WQI%I]EX;L;_ %6/3[%_JWP?X=B_87_X
M+<_M1?%/XLZ]X:^'7[-O_!1']G7X;:[\-/B%X@U+1O"_@'3/C;^RYX8\->$?
M$7P=U?5]0=+;1_%<_P .X/%7Q:T.35+W0-&UKPVVNV6B#7=3\,ZO%H@!W?\
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MW_"M?!'_ $ HO_ S4?\ Y,H_X5KX(_Z 47_@9J/_ ,F4 =3_ &MI7_03T_\
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M>3:W\6UEF:YO8RXB^+7C2*,;(;F.,;8T5?E09QDY))/XYXX?\DC@O^Q_@_\
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M(_Z 47_@9J/_ ,F4?\*U\$?] *+_ ,#-1_\ DR@#J?[6TK_H)Z?_ .!MM_\
M'*M0W$%RADMYX;B,,5+PR)*@8 $J6C9EW $$C.0"#CD5QG_"M?!'_0"B_P#
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M4?L+?LR^'_&'[/\ _P $9OV%])U']H7]M[XB>,_#?Q2^"ME\4OBUI-O;V2>
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M>ZYJNF_$OQQ+X@LKSPWJNIQ6EO8:+;6>@:PESJNN>'+.YEM%U=)X?S \8_\
M!5[]FW]E']K7]J;]ESX8?\$\/^"AWQ.^-5KX^TGXQ?'A_P!EC]G+PE\6?#OB
M_P 2^,OAI\-='TSXKQ1:'\:$U"VL?$O@?0_ 5C>:E<>&?#?VW6K&YFUNP'BR
M[URYN_WEK\%OCA_P4$_;#U;]L/\ :2^!'_!-_P#X)Q:1\>_&O[/MI\)_"7[2
M'QW^+OQ,\)? [0K_ %K6_#^K>./ ?@?PQ9:_<:+K7CC3M&\/^+[W5-.U^778
MEM9-5UB2V\.)X<U;PMXH\5 '0^!/^"T@^*W[4'[+?[,>F_L)_MX_LYZU\?/B
M-XCT/4O%7[:/[.W_  I/PQ_PA_A;X2?$OQYJ'_"#7UO\0M>N];\9S:YX3T&S
M@LI],;2XM"G\07D\WVRULHI/W(K^>3P?^T1_P6+\<?M5?L4>%?VN_P!@SX+?
M 'X#ZE\?=?D\2?$7P3\1_!/QOURTUJR_9[^.$_AG3$BM/$?B2]\ 6^I7X>.7
MQI8:=97CO'%X477;*U\2WFFZU_0W0 4444 %>=^/_P#CX\#_ /8\:'_Z')7H
ME>=^/_\ CX\#_P#8\:'_ .AR4 >B4444 >=_"O\ Y$G2_P#KMJ/_ *<+FO1*
M\[^%?_(DZ7_UVU'_ -.%S7HE !1110 5XO\ M&_'/PK^S)\!/C%^T/XYTSQ-
MK7@[X*?#GQ;\3/$VD^#-*76_%.HZ+X/T:[UJ_L]$TZ6YL;.2^G@M'1+C5-1T
MO1;!2^H:YJVE:1:WNHVWM%?/_P"U=X:^)7C+]F7X_>%?@Y9^#]4^*GB#X0?$
M'2O &A_$+P[I/BSP%XG\4W?AC4HM(\(^-?#NNYT;5?"GB^Z9/#/B&WU-)K)=
M)U:[FN+:ZCB:WE /Q4\+_M]_\%V_C#X6\,?%7X1_\$CO@[I'PR^(?A[1O&/@
M2T^(O[6O@6W\:MX6\0V$&IZ'>^(+"XUOP=>Z7?:EIMS;:@VDZCX:TC4],2Y2
MQU*SAO8)T7[Q_P"":/QI_;?^,MI^U/)^WA\*M#^!_P 3O!/Q^TKPMX0^%7A;
M4-)\1>%?"_P[G^"'PE\1Z9+H/C32+_6(/&D&O:YKFOZ]J&LOK.H-::SJ&I>'
MT32XM&31[#\>_P!EWXF?\%A?A;^RWX?T"T_;._X(Q^&_!W[-OPZ^'&C?$G3/
MCCK7QHL/B)^S1HWB.V6T^'_PQ_:,E@OM M_AOXJ\(VD</PZBT_Q]:Z7XE>X\
M,-:>(+[7/$D&K:Q??K[_ ,$R[']M\6?[4GB3]NS4_A?K_P 0?&GQS\+>(OA[
MXD^ M_XEU']G[Q#\*&_9[^#&F^'M6^#<_BQO[:'AN[U33]<FUO[9'"USXTD\
M2ZA"CV=[:3S 'Z@T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% '^69XH_Y&;Q%_V'=7_].%Q6%6[XH_Y&
M;Q%_V'=7_P#3A<5A5_H;3_AT_P#!'_TE'\@S^.7^*7YL****LD**** "BBB@
M K^^#_@AK_RC4^!O_8<^+_\ ZM[QM7\#]?W'?\$??C3\,?A/_P $RO@=-XY\
M6Z9I-TVK?%Z>VT6.1K[Q!>QO\7O'2Q/::)9+/J+P2RQO"+V2"*PBD!%Q=PJ&
M8?CGCA_R2."_['^#_P#4#,S]&\,$WQ#B;*__  DXC_U*P)^X5<[XH\7^%O!6
MERZWXN\0Z1X;TJ+*F^UF_MK"&20(SBWMS<2(UU=2*C>3:6RRW4[ )#%(Y"G\
MM?BC_P %#/$>IBYTWX3>'(O#5HV^./Q+XE2VU/72I'R3V>C1M-HNG3(W:]F\
M012*>8HVZ?,/A[X<_M ?M*ZV=<CM/$OB]II7AF\6^);R:W\/V,?GLTUM;:IJ
M+)8QP6DDC-_8VAQS26R-MM].5=JU_*1^^J#W>B_K[OZT/NOXI?\ !0OPOI)N
M--^$WAZ7Q5>KN1/$OB..ZTGP\K#RF2:TT=3;Z]JD3J9HI$O7\-R0RHLB?:8C
MAO@_6?&G[0/[36O+I,EQXH\<3^;#-%X<T.U>W\.:2K2F&WO+C3K!+?1M.BA:
M;R&UO5RLBHP^UZDW+5]]?"S_ ()\>#]$^SZE\5==G\8Z@H5W\/:&]UH_AJ)\
M2*\5QJ ,.NZL@)BEAE@;P\%96BGM;F-N?OCPYX7\-^#]+AT3PKH6D^'=(@)>
M+3M&L+;3K02,%$D[0VL<227$VU6GN9 \\[C?-([DL0+Q6RN]=7_7^7XGY=?"
MS_@GEK-\+;4_B[XE31+=E21_"_A62"^U?#(&\F_UZXBFTJRFADRDT6FVFMPS
M1\PZC$Q##]&/AY\'OAK\*K1K7P'X1TO0WD3R[G4EC>\UN]0L'*7NMW\ESJMS
M#Y@\Q+:2[-K Q/V>")3MKTJB@ER;W84444""BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#\C_ /@N5_RC4^.7_8<^$'_JWO!-?P/U
M_?!_P7*_Y1J?'+_L.?"#_P!6]X)K^!^OZL\#_P#DD<=_V4&,_P#5?E9^"^)_
M_)0X;_L4X?\ ]2L<%%%%?LA^<A1110 4444 %:FA_P#(:T?_ +"FG_\ I7#6
M76IH?_(:T?\ ["FG_P#I7#4S^"7^&7Y,J'QQ_P 4?S1_>I1117\PG[<%%%%
M!1110 4444 %?HK\%/\ DF'A3_KAJ/\ Z>=2K\ZJ_17X*?\ ),/"G_7#4?\
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M7[9D4,,2+'%%%'J7AI(XHHT"I''&BA$1 %50%4  "N5_X*<1W/[=/[/7[?\
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M-?\ E&I\#?\ L.?%_P#]6]XVK\<\</\ DD<%_P!C_!_^H&9GZ-X8?\E#B?\
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MR]\>/VT? 'P5^*G@?]GW0? OQ._: _:.^(7A76/B%H'P$^!MEX&OO'5E\,]
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M ,?'@?\ ['C0_P#T.2O1*\[\?_\ 'QX'_P"QXT/_ -#DH ]$HHHH \[^%?\
MR).E_P#7;4?_ $X7->B5YW\*_P#D2=+_ .NVH_\ IPN:]$H **** "OE#]NW
M4OBSH_[&'[4NI_ ;Q1IO@OXT67P)^)D_PN\3:K=Z?I\.E^.%\*ZD/#K66IZO
MJ.E:1I.NW6I&"R\-:OK%ZND:3XBN=+U'5+>]L+:XL;CZOKROXY?!_P $_M!_
M!GXJ_ OXD6;W_@+XO?#[Q=\.?%MO$T<=VNA>+]#O=#O[K3KB6.5;+5;&&]:^
MTG450S:;J=O:7]N4GMXW4 _F\_8C_P""./\ P3^^+?[+_P (?C#-^V9^V/\
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M9=FEL[+0='TNT\,:;82,5M=.T.U6W6.S:WB3E]%_X)]?M0?LT?"']M']B_\
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M!?$__DH<-_V*</\ ^I6."BBBOV0_.0HHHH **** "M30_P#D-:/_ -A33_\
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MDGSQHO\ P3Z_:@_9H^$/[:/[%_[(-O\ "B/]G/\ :V\7_$GQ;\)/B-XZ\?\
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MS=^Q?^S+_P $_=)^"^J>#?A+XY^%_@/XVZC\=?\ A)+;4[SX$0F^O?B_X_\
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MA'X7T2YEGMH;#7?%,,\WAW1-3N93:Z7JVIV>HW45Q;VLMO+]@U^4?[/FN?\
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M[Y6_[!I?^G:1ZG1117YT?8A1110 4444 %%%% !1110 4444 %%%% !1110
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M#_L:'5=0NV:^TS38S_2?0 4444 %>=^/_P#CX\#_ /8\:'_Z')7HE>=^/_\
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M=\.OBMX7^*_BR[B121#8^"OAE?\ BSQ;=WDC@PI:1:,9A,LD<BQF&;R_,_\
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M[]OCXN_\%$OV7?V;_CW_ ,$QKG]FCX:>*/ /QM^*&L^(?B#\8OA?\9KW2YO
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M+O$ESXXM+7QO=O\ %+XD^+_B)KFEZ5XANM$L;.R\->!_#-E-ILGSM^RWH_\
MP57^,_["GAN]B_;*^&.G_'C0/C]XOU3P#^T!XS_9JTS5/"_[3_[-7AZTU/0?
M#(\5_#ZUO/!<O@SP[\0?%L]YXI\!?$[P7;6_B#Q9\'=!^''BU;-;OQ]K4H_<
M*B@#X$^&'[)WQ5UG]HGP7^UG^UM\5/A_\4/BM\+OA7X@^&7P9\"?"+X8:O\
M#KX/?"*3XC3:%=?%[QWIL7CGQ_\ %3QOXH^)/CA/#>C^%(?%9\0>$=+T;X=V
MT_AB/P?=7VJ:OX@O^[_:B_9KUO\ :0\=?LDF]\1:7IGPG^ W[16D?M'?$3PU
M)_:JZ[X^\2?#+PEXH_X4GH=A+9NFFIHWASXL:UX>^).NQZN)EN;GP+H5K9P>
M;-)<VWV!10 5\%7_ .Q#]N_X*9:+_P %%?\ A9WE?V/^QA+^R'_PI[_A"]_V
MCS?C%JWQ8_X6%_PL'_A+$\G;_:G]@?\ ")_\(1+GR/[5_P"$E'F_V;']ZT4
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M6/ASXAWMFM_X%?2?B9X>\6_$#5O$_C>X^NO'G[4?QC_:5_X*4^._^"=W[/\
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MK0;E%27*\3A&]'YQ6I^Z?_#3/@__ * ?B7_OUI?_ ,LZ/^&F?!__ $ _$O\
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M"6_^/5Z310!YM_P@FL?]#_XI_P# EO\ X]1_P@FL?]#_ .*?_ EO_CU>DT4
M>;?\()K'_0_^*?\ P);_ ./4?\()K'_0_P#BG_P);_X]7I-% 'FW_"":Q_T/
M_BG_ ,"6_P#CU'_"":Q_T/\ XI_\"6_^/5Z310!YM_P@FL?]#_XI_P# EO\
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MI_X<,7_\N,O[,RW_ *%V!_\ "3#_ /RL_.__ (=;?L4_]&_?!O\ \-5X+_\
ME;1_PZV_8I_Z-^^#?_AJO!?_ ,K:_1"BC^W,Z_Z'&:?^'#%__+@_LS+?^A=@
M?_"3#_\ RL_._P#X=;?L4_\ 1OWP;_\ #5>"_P#Y6T?\.MOV*?\ HW[X-_\
MAJO!?_RMK]$**/[<SK_H<9I_X<,7_P#+@_LS+?\ H78'_P ),/\ _*S\[_\
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MFL?]#_XI_P# EO\ X]1_P@FL?]#_ .*?_ EO_CU>DT4 >;?\()K'_0_^*?\
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M[+NA?M!_'E/AKK]C\>?$?@GQ-XOT_P ,ZDWQ27Q%\+O!'B+4?#.JS_$7X<>
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M 'G?PK_Y$G2_^NVH_P#IPN:]$KSOX5_\B3I?_7;4?_3A<UZ)0 4444 %%%%
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M ?#7B#QEXHCT;PH+E'7PV-:UKQQJ]UXKO-+-O=^)H[/P]:ZS/=6GAS1H+/\
MGE^#/A8? GX'?\' ?_!1O]F_25^%/PM^-GAWXC7_ .RAI/@[3+/2?#EY)^RQ
M\!?'WAO4?VF/!-CI4R:1)X4^+?QOUOQ9XQ\.ZM:V]M_:NB>'E\3V0GTC7=+F
MF /VI/\ P42_8X'Q.F^$_P#PN.(Z[:_$1_@]?>+AX&^)9^"&F?&%5NE3X0ZM
M^T</!I_9]TKXJW-[976B67PXU#XFVWC.]\31IX4M-%F\2W%KI,U[]L/_ (*
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M **** "BBB@ KSOQ_P#\?'@?_L>-#_\ 0Y*]$KSOQ_\ \?'@?_L>-#_]#DH
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M=+_Z[:C_ .G"YKT2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/!RW]E/X9NM2T)NNLOA?JMI_P7SU[]D^;]H;]M:__9SUO_@GO+^T/#\*KO\
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M\57WBB'QCX<_X1;X>Z!\0],^'/A6*+Q'H/B/0?'-_!#XGO #^@RBOY_OCO\
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MUI=:5X_^$/BWP;XMMH<3"8VUOKATR_VQ"_L[R!5CH ]*HK^4/_@F%^WO\?\
M]D_X]1_L=?MU^._B1\3_ -GG]HWX^?M*>!?V"/VOOC-XSU/QYXQN_%_P5_:/
M^)GP"U?X!?&7XAZU%"-3\2>)-7^'T&L^#'GFCNM(U'Q+H>AV<%UX=\9Z#IGP
M^_2KQ!\%X+K_ (+!>#-$7XQ?M66?@+4/V0OB-^T=JWPJL/VPOVI;/X5:G\7]
M"_:#^%OA;0]:?X=P?%]/"%EX5T[0-?UK3F^%VEZ/8_"[4(+Q(]1\'W4,"PN
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MP33\>?'OX=>(?BQ\,=;\,^!?B#?^,/"GP[^-/Q2^#/Q7^!WQ[^''@?5[_4_
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSOQ_\
M\?'@?_L>-#_]#DKT2O._'_\ Q\>!_P#L>-#_ /0Y* /1**** /._A7_R).E_
M]=M1_P#3A<UZ)7G?PK_Y$G2_^NVH_P#IPN:]$H **** "BBB@ HHHH ****
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MO?EMNK7OK:Q^3WV6Y_Y]Y_\ OS)_\31]EN?^?>?_ +\R?_$U^L-%?4_ZYO\
MZ%R_\*W_ /,QX7^K:_Z#'_X(7_RX_)[[+<_\^\__ 'YD_P#B:/LMS_S[S_\
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M'Q7\8?#>KZ7>RZ-XZU[6H])T'PO-:0W_ (JL?B[<R+?7^DW;Q_-O_!2/X/\
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M+Q!\1OA+\2_ 6ARKXJ-O%X+/A'7KZSTO3+&ZL/ VE1P:9X>TK]I_V4O^"?\
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MQ)X,\?>%O V@:O8^/+_Q? FF/>/8WZ3-K</B*^N--U2SGO[74U_?M-'\8_\
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MI["/2G_8&_8K?2X93/%IK?LL_ QK"*8F1C-'9GP*;=)29929%C#DR2$G+MD
M_ #]J/XA^&--_P""M?\ P2H_X+(Z?:Z]9?L4?%C0/'7[&VK_ !$UG2DTE-(U
MW6M3_:&\ _"#XO:X+^_6VT+X._&0?$?0_''@3QA?75G-+\,_#=[X@\1:+X>O
M]2T[2]0_>;_@IG\?O"'[-O[!W[4'Q+\5:G9VMQ-\'O''@KP%I4T$^H7?C/XI
M?$'PYJ7A'X:>"M'TBQFAU+6M1\2^+M7TNR-EILBW$6G&_P!4FFM-/T^]O;;Z
MMO\ X3?"O5?AF/@MJ?PT^'^I?!Q?"MCX$7X37_@WPY>?#-?!&F6%OI>F^#1X
M$N--D\+#PKI^F6EIIUCX>&E?V1:6%K;V=O9QV\,<:_/W@'_@GY^Q-\,/%GAG
MQQX%_9?^#6A>*O THG^'NKCP7IFHR_#.42W4Y?X70:O'?V?PR,D]]>S3#P';
M^'EGFN[B68/)-(S '\_?PN_X)TCX0_\ !'C_ ()U_L?_ !S^*VJ?LI?M=>.O
MVN="^+/P$^)NBI9ZMIWPJ_;0U'1OCI\<?@QH'Q#L-?O=(MKFX7X>>&I?A7JF
MA:4;TS?%Z\T72-!B\0F6WO=0_1/_ ()?_'/]JCQ#^T-^U;^S?^WI\*OAA:?M
MB? ;X<_LZVWB[]I/X)7]_<^ /VA?A-JMU\6[[X7W^JZ$=+TS3/!OBG1]3U+Q
MYJJPKI_A:Y\2Q^*=52V\!^%=,\(6]O/^J_QE^ ?P0_:)\-:=X-^/?PC^'/QF
M\):/KT7BG2?#/Q.\':#XWT+3/$T&CZUX?MO$5AI?B*QU"RM-<M-%\1Z[IUEJ
MT$,=_9VVJWJVL\)G9J;\'_@'\%_@!HVIZ%\&?AGX1^'5CKVH+K'B27PYI,%M
MJ_BO68[=+2+6O&'B"43:]XNUJ&RCAT^'5_$FI:IJ4.G6]KI\5TEE:V\$8!Z[
M1110 5Y9\:_AM_PMSX8^*?A^NJ/HTVO6]D;7451I8X+S3-3LM7LQ=0(R&>SF
MN;"*"[C!+B"1Y(<3I$P]3HH#8_'+_AW3\6O^AR^'7_@7XE_^9JC_ (=T_%K_
M *'+X=?^!?B7_P"9JOV-HH*YY=_P7^1^.7_#NGXM?]#E\.O_  +\2_\ S-4?
M\.Z?BU_T.7PZ_P# OQ+_ /,U7[&T4!SR[_@O\C\<O^'=/Q:_Z'+X=?\ @7XE
M_P#F:H_X=T_%K_H<OAU_X%^)?_F:K]C:* YY=_P7^1^6GPI_8(\<>$_B)X0\
M5^*/&?A<Z3X7U[3/$30>')-:FU.\NM&O8-0L[-&OM*TV&VM[BXMXX[JY6=IH
M[<R""(RNLD?LG_!3^>&W_P"":O\ P4)DGFB@1OV(OVJX%>:1(T::Y^!?CNVM
MH0SE09;BXEB@@C!WRS21Q1AG=5/W/7G/Q1^#OPC^./A>7P/\:OA9\./C!X*G
MNH+V;PA\4?!'AGX@>%YKRU):VNY?#_BS2]7TF2ZMV):"X>T,L)),;J2:!-M[
MGYS?\$,]0L=3_P""2G[#%SIUY;7UO'\&H]/DFM9DGB2^TGQ3XDTK5+-GC9E6
MYT_4[*[L+R$G?;W=M/;RJLL3J/%?C+^S1_P3Y_X+8:S^TI\)OCY\-[#3?CK^
MQO\ &7Q+^S\OCOP-XSL-$^//A'P_'I6B>+_"7C;2[VWLY)KCP)XE'BG6(M"T
M#XA>&?%W@2'QAI'CG^R+*ZU>QU"^C_7+X2? ;X&_ '1+KPU\"?@Q\*/@KX<O
MIUNKW0/A)\.O"'PXT2\N4>YE2XNM*\':/HUC<3K)>7<BS2P/(KW5RX8-/*6^
M=OBI_P $U/V!/C;KVJ^+?BE^R-\"_%WC37=<U;Q'KOCR[\":38_$#7-7UR*:
MWU:?6O'FDQ:?XPU:WO;:=[233M0UJXTU;,1VD=HEM##%&"/Q#_X);^,?VF_"
M'P)_X+'_ +(/QP^.MQ^U!\%_V'QXR^%7P2_:5UF36;J?63)\*_B1<_$'X:7?
MB;7+W4#</\*+#2? W]L^&)M7UF3X<:UXFU3P]:>)-<\(-X3DL?S7_9S_ &%?
M%'QJ_P""%W_!/O\ ;'^!?AT_'/XP?L9>./C[\5O$_P"R?\1KW6?BE\$OVA_A
M[HO[2_Q>N?&7P\N_@GXBN]=\)6GCF#PG;C6/"W_")>';#7]?&IZY:V=EK'C?
M7_"FIZ;_ &<:'^Q_^RCX<^#D/[/&C_LU_ JU^!$-S<7I^#TGPJ\$WGPWN-1O
M8Y8K[5+_ ,'7VBW.A:EJ^H)/.-1U;4+*ZU+4#/,UY=3M-(6ZGX/_ +.W[/W[
M/6G:II'P"^!?P<^!VDZY=1WNM:7\'_ACX*^&FG:O>0H8HKO5++P7HFB6VH74
M49,<=Q=Q32HA**X7B@#SS]BW]JOX'_MH_LU_"[]H/]GO4;>;X<^,?#UI';>'
MO(M-/U?X?:SI42:?KGPY\2Z+9.]MHGB#P7J$$NB7EG:/-I-Q#;6VJ^';W5/#
M6HZ/JU]]35X1\,_V6OV8_@MXK\1>//@Y^SG\"/A-XX\7K=KXL\9_#/X0_#[P
M)XK\4+?WXU2^7Q%XB\+>'M*U?6UO=3 U&[&I7ER+F_ NY@]Q^\KW>@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O._'__
M !\>!_\ L>-#_P#0Y*]$KSOQ_P#\?'@?_L>-#_\ 0Y* /1**** /._A7_P B
M3I?_ %VU'_TX7->B5YW\*_\ D2=+_P"NVH_^G"YKT2@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "O._'_ /Q\>!_^QXT/_P!#DKT2O._'_P#Q\>!_^QXT/_T.
M2@#T2BBB@#PGP/XZT/P]X;L])U)-22\MI;TS)'832*OFWDTJC=\OS!'&X8RK
M9!Y%=;_PM7PK_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK
M_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\
MQ5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\
M"U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!
M;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK
M_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\
MQ5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\
M"U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!
M;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK
M_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\
MQ5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\
M"U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!
M;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK
M_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\
MQ5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\
M"U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!
M;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK
M_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\
MQ5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\
M"U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!
M;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK
M_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\
MQ5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\
M"U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!
M;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK
M_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\
MQ5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\
M"U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!
M;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK
M_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\
MQ5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\
M"U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!
M;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK
M_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\
MQ5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\
M"U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!
M;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK
M_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\
MQ5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\
M"U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!
M;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK
M_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\
MQ5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\
M"U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!
M;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK
M_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\
MQ5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\
M"U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!
M;-_\51_PM7PK_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK
M_P!17_P6S?\ Q5>DT4 >;?\ "U?"O_45_P#!;-_\51_PM7PK_P!17_P6S?\
MQ5>DT4 >;?\ "U?"O_45_P#!;-_\57-Z[XPTGQ1J7@ZSTI+]YK;Q?HUY*)[*
M6%5@CF*.^XY'R%PS9P @9B<*:]MHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
3 HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ny20006478x8_bargraph02.jpg
<TEXT>
begin 644 ny20006478x8_bargraph02.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
M+0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0":
M )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0T!
M$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I
M ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F<"
M<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P-:
M V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$
M?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%
M!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'
M3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC[
M"1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*
M\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-
M#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/
M>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('
M$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4
M\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W
M&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;
M8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I
M'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J\B
MW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR;H
M)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K
M:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^
M,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U
M$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_.;PY^3HV
M.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_
MXD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:
M1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+
MXDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q
M4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9
M&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %
M8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUG
MDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>
M;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW
M5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$
M?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(
M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$_
MD:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:
MU9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16
MI,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVN
MH:\6KXNP +!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1
MN4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'# [,%GP>/"7\+;PUC#
MU,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZV
MSS?/N- YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':
M=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-
MYI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_R
MC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<
M_VW__V1E<V,         +DE%0R V,3DV-BTR+3$@1&5F875L="!21T(@0V]L
M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M /D2C_A*/&W_ $3J;_PI=/\ _D2@#T2BO._^$H\;?]$ZF_\ "ET__P"1*/\
MA*/&W_1.IO\ PI=/_P#D2@#T2BO._P#A*/&W_1.IO_"ET_\ ^1*/^$H\;?\
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M /D2C_A*/&W_ $3J;_PI=/\ _D2@#T2BO._^$H\;?]$ZF_\ "ET__P"1*/\
MA*/&W_1.IO\ PI=/_P#D2@#T2BO._P#A*/&W_1.IO_"ET_\ ^1*/^$H\;?\
M1.IO_"ET_P#^1* /1**\[_X2CQM_T3J;_P *73__ )$H_P"$H\;?]$ZF_P#"
MET__ .1* /1**\[_ .$H\;?]$ZF_\*73_P#Y$H_X2CQM_P!$ZF_\*73_ /Y$
MH ]$HKSO_A*/&W_1.IO_  I=/_\ D2C_ (2CQM_T3J;_ ,*73_\ Y$H ]$HK
MSO\ X2CQM_T3J;_PI=/_ /D2C_A*/&W_ $3J;_PI=/\ _D2@#T2BO._^$H\;
M?]$ZF_\ "ET__P"1*/\ A*/&W_1.IO\ PI=/_P#D2@#T2BO._P#A*/&W_1.I
MO_"ET_\ ^1*/^$H\;?\ 1.IO_"ET_P#^1* /1**\[_X2CQM_T3J;_P *73__
M )$H_P"$H\;?]$ZF_P#"ET__ .1* /1**\[_ .$H\;?]$ZF_\*73_P#Y$H_X
M2CQM_P!$ZF_\*73_ /Y$H ]$HKSO_A*/&W_1.IO_  I=/_\ D2C_ (2CQM_T
M3J;_ ,*73_\ Y$H ]$HKSO\ X2CQM_T3J;_PI=/_ /D2C_A*/&W_ $3J;_PI
M=/\ _D2@#T2BO._^$H\;?]$ZF_\ "ET__P"1*/\ A*/&W_1.IO\ PI=/_P#D
M2@#T2BO._P#A*/&W_1.IO_"ET_\ ^1*/^$H\;?\ 1.IO_"ET_P#^1* /1**\
M[_X2CQM_T3J;_P *73__ )$H_P"$H\;?]$ZF_P#"ET__ .1* /1**\[_ .$H
M\;?]$ZF_\*73_P#Y$H_X2CQM_P!$ZF_\*73_ /Y$H ]$HKSO_A*/&W_1.IO_
M  I=/_\ D2C_ (2CQM_T3J;_ ,*73_\ Y$H ]$HKSO\ X2CQM_T3J;_PI=/_
M /D2C_A*/&W_ $3J;_PI=/\ _D2@#T2BO._^$H\;?]$ZF_\ "ET__P"1*/\
MA*/&W_1.IO\ PI=/_P#D2@#T2BO._P#A*/&W_1.IO_"ET_\ ^1*/^$H\;?\
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M /D2C_A*/&W_ $3J;_PI=/\ _D2@#T2BO._^$H\;?]$ZF_\ "ET__P"1*/\
MA*/&W_1.IO\ PI=/_P#D2@#T2BO._P#A*/&W_1.IO_"ET_\ ^1*/^$H\;?\
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M HHHH **** "BBB@ HHHH **** /-OB?_P @?1?^QITC_P!!NZ])KS;XG_\
M('T7_L:=(_\ 0;NO2: /._A7_P B3I?_ %VU'_TX7->B5YW\*_\ D2=+_P"N
MVH_^G"YKT2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBD) !)(  )))P !R22>  .23TH 6BOY^O$__  5_^-7[6G[1
M7C+]E+_@CQ\%?AO^T5JGPP6P'QD_;%^..O>+-$_9(^%%]/J5Y:_V.MIX.M;'
MQC\3I=8_LO5M.\/7WA'Q#83:U?:?J>M^$M&\:^"M#UGQ)9_5&MZM_P %F/@[
MI!\:SZ/^PK^V98:=IDVI>(/@Q\.M$^+G[*/Q/U"]DA<-I7PV^)'CSXB?'7X=
M:Q_9LJ12V=IXX\->#7UZ*>[CE\0Z+<6]G#>@'ZNT5^6'_!(__@H%XT_X*/?
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MJEYX/L[.7Q58WFAQ^V_"?_E5?U7_ +1I?&C_ -1#QW7TO_P;>?\ *%W]C/\
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M>TU]+ZRM=&UO\?O^#O\ _P"3"?V<_P#L[S0O_5,_&*OT?_X*_?\ !.#X;?\
M!3 _ _X;Z1\?]4_9]_;"^"6G_$7XV_LW^*M(AU&\DBT.SUKX7Z-X_O-2LM,O
M=%U.WTVT\5M\)HX/%7A_7K3Q'X+URYTC5["PUJWDO-(O@#<B^.7_  4]^"'[
M;'[&OP#_ &@H?V3?BS^SG^TYXN^*_A6_^.GP:^&7Q:^&'C/PKXH^'G[./Q>^
M,5CX#\1>#_&'Q=^)?AS3KWQ7J?@NUO\ PGXDTK7M5&I^&?!7CFPU/P[H^I3Z
M=J:TOV[/^"E/Q6^%7[;7[+__  32_9+\&?"[5_VIOVF/#.I_$:3XB?'V3QC/
M\&?A7\.M#B\;ZI)=:AX6\ 7.C^+/'GB7Q%I/PL^(\6GZ58^+_"%OH5]IWAV>
M_NM4M/$$B:9^._[(W_!1'_@IA_P3L_;2^!/_  3Z_P""OGA1_C9X.^,OCKPW
M\/\ ]FW]I]3I6NZA8>)_$.I0?#G1_%6B?$^72='E^)?AN:Y\86VB^/G\=QZ/
M\:?!>C^+$UGQ'<OIE];^&-;_ $N_;=_;3G;_ (*7_ []A?\ 8W^!?[/'B'_@
MH)XF^%^J:CJG[77QW\(VFMZ=^S%\&[_2?%/BC6] T:7PY:0_$OQ)XDU3P]IF
MH^(['P5!XH\+^"I=0\0^$X]:;6+3Q-K;^'P#)N?^"GW[4O['_P#P4N^"O_!/
MW]O'2?@E\3/!?[4OA_PRW[/7[0_[./P[^(7PUOE\9>*O%E]X-T[PY\5OA[X[
M^)OQ,T^SSXDTVXTV]G\&>*-2CT73-7\&Z_>O=IJ^MV7AW\L/^#@7Q+_P4(L/
MV_?^"9?AG5_&?P'T_P"#/C/]K71]6_9,^%6AZO\ $F\T6Y^)'PR^)GP<T_1_
MB)^U(\F@:%+J&I7DOQ-T6PL=/\"2:M#X+\+W'C/2_#US-JVJ:AK_ (FYC_@H
MW\!O&?P0_P""VG_!%MOB/^TA\:/VFOB#XW^+/PHUGQ;XT^*]UX5TO1;+5=/^
M.'A/3)K'X8?#/P#X=\+^!OA;X/GD26\3PYHFG7M[-/(MQK_B'Q#J:/J<OUQ_
MP<7_ /)^W_! +_L[SQ;_ .KF_8HH _;I_B?_ ,%'OA!^S'XV\;_%7X ?L\?M
M)_M*:9XMU63PE\-OV8/B9K_PC^&<GPUM?"-GJEOJWBWQI^T)'>ZS9^(H/$.G
M>)--GM/#NBZZEZFJ^#(K>PM+;_A)]<TCYU_X(<_\%'?BY_P5 _9=^+?[0?Q@
M\'_#_P ":KX:_:>\:_"?PKX:^'5KK\.EV'@C0?AC\'?&&DKJ]YXBUS7+W6?$
M?]H^.]974M8M_P"Q]/O(DM!::#IBQ,C_ *[>-?\ D3?%O_8LZ]_Z:KNOY(_^
M#8FP\=ZI_P $8/VVM,^%LK0?$[4?VAOVDK#X<SH\L;P^.[S]E/X!6_A"5)(+
MJQG1H_$$FGNKPWMG*I4-'=6[@2H ?IYX*_X*$_M5_M]_&OXX> ?^"9FB?LZZ
M+\ /V;O&,?PS^(?[7G[2&G?$3Q_X9^)/Q*^QWL^M>%?@%\._AAXD\#)KUCX2
M"Z3>ZAXV\1^/XM)U/3M9TR_TS1)]-U31;_5<3]F'_@K/\6=#_;GU'_@F5_P4
MA^$G@KX,_M0:]OUSX!_%/X.7.M3?L]_M >#IK'Q!?Z7>:/;^--:U;Q7X+U76
MH/#.JP>&H=1UC7X-=\0V.N^"-2'A/QEHNFZ/XJ^%_P#@T(^('AK4OV$_VB?A
M5;W%G%XX\ _M6:OXO\2:/%&\5_!X=^(GPL^&VD^$]9U)7^])J6J_#?QKI$#8
M4K#X:\ID!BW-PW_!POX5FUG_ (*C?\$.I/AC+;Q_&_6/CA;Z?'-;QM/J&F:3
MH'QV^ ^J^ ]8U**"Z29=$TS6=3\>ZBT[QV<$-O8:U,]\T<,YL@#ZM_X*<_\
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M_5"_LT5^XG[%_P#RC8_9._[,=^!/_JA?"M?AW_P:%?\ *-CXW?\ 9\7Q*_\
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MVN99-2_X5Y\08[*\U'P^MZUS<:!JEKKW@RZU/7)_#?\ PD&L<I_P1P_Y"O\
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MXV\5^#]0O_">L:8;^QA_<"OX<K/]L/\ X*Q?\$'?BI\/_A?_ ,%(_MO[:_[
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MM+TGP_>:'H?@2;3]+T5FUX>*]7U.;5K?X_\ ^" GPX_X*+:?_P $M/V?-=^
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MB7Q+\:IOA[X=^%FJ_M ?%GX3:IXVT'PS\/\ PGX N?AUX1\,?"/X.>"_B_\
M"/3/ C>"M#72[G1/$5_XM\3ZQK_B2#6_%GQ%'C/6_$)FTKPS_@E;_P $K?C[
M_P $LOA7XZ^!_@G]K[X4?%KX9>-?&OB_XI_9_%G[)'BKP_XPTCXE>(?A]X<\
M$:9?P>)=&_:WN-+NO!^GS^"O".J:SX6N/"PU76[6RU?2],\7^%[C6(=8TO\
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MQ%JDL^J>(?$.I"W^WZ[KVISSZEK6K7%YJ=_/-=W4TC=I10!\6_MO_L]?'O\
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MA5;&X^+'@+XR:?J=P;3PAXF^&>R4^*I/[2O_  ZUBD/B'0=?USPKJ.DZ[?\
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MM7^)GCWX8?#;X>^ HO$-]:^'=/U_QSX\\/IXCU][C1_"\&N:AI^IV]G^,/\
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M $3J;_PI=/\ _D2@#T2BO._^$H\;?]$ZF_\ "ET__P"1*/\ A*/&W_1.IO\
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M*73_ /Y$H ]$HKSO_A*/&W_1.IO_  I=/_\ D2C_ (2CQM_T3J;_ ,*73_\
MY$H ]$HKSO\ X2CQM_T3J;_PI=/_ /D2C_A*/&W_ $3J;_PI=/\ _D2@#T2B
MO._^$H\;?]$ZF_\ "ET__P"1*/\ A*/&W_1.IO\ PI=/_P#D2@#T2BO._P#A
M*/&W_1.IO_"ET_\ ^1*/^$H\;?\ 1.IO_"ET_P#^1* /1**\[_X2CQM_T3J;
M_P *73__ )$H_P"$H\;?]$ZF_P#"ET__ .1* /1**\[_ .$H\;?]$ZF_\*73
M_P#Y$H_X2CQM_P!$ZF_\*73_ /Y$H ]$HKSO_A*/&W_1.IO_  I=/_\ D2C_
M (2CQM_T3J;_ ,*73_\ Y$H ]$HKSO\ X2CQM_T3J;_PI=/_ /D2C_A*/&W_
M $3J;_PI=/\ _D2@#T2BO._^$H\;?]$ZF_\ "ET__P"1*/\ A*/&W_1.IO\
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M*73_ /Y$H ]$HKSO_A*/&W_1.IO_  I=/_\ D2C_ (2CQM_T3J;_ ,*73_\
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MZIX N/B5;+\./^%T:+\(-2^"EKXKO+%;_P"(=IH4LNN0?J)7\P\W@_X:6/\
MP:GC19;FW;PL_P#P3O@\8"6RM;"YC_X67J-M'X_AMGBL],N;=;A?C%<I9W]T
M]JM_:70N;R^U.TU.&XUB']I?^";GB;Q)XS_X)Y_L*^+?&%S>W_BCQ+^Q_P#L
MW:WKNJ:E?MJFHZUJ6I_![P?=W.O:A?NS2W%[KSRG6+IIW>Y2>^DCN9'N$D=@
M#[3HHHH **** "BBB@ HHHH **** /-OB?\ \@?1?^QITC_T&[KTFO-OB?\
M\@?1?^QITC_T&[KTF@#SOX5_\B3I?_7;4?\ TX7->B5YW\*_^1)TO_KMJ/\
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MV<[/P[K>@R3ZMK-SH/Q.UK2H='3QAXDZ;]H2Q_:/_P""5/[('[%OPO\ V O
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWX9WG[>G@G]J3P+K=IX8\?\ PQL#_P $U=(_9N\(>)/#?B71_B[\5O!'PO\
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M]"TF;7IM"FE6X,,NC:[+IOB+3KFWN+;5M'L)D57^H?\ @DO^T'^U]\>_AO\
MM+1_MH^ _"WP_P#BG\*_VN_C!\.;7P_X3\4:?XDM/#N@P2:/XDMO!5\1KNLZ
M_$_AN7Q!)>^$]4UJ.PLO%'PK\0_#GQ#X6BG\.W]E-0!^KU%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKQ-X>FN(/$&B6L&EZQHWB*'7?#VJV"-9ZEH]W:S3PR^,_L8_\$X/@O\ L?\
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MXM[>;3;F*'\EKS_@W[_X),ZC?ZEJNH?LT^+K[5-9U/4=:UC4KS]JS]L:ZO\
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M0HOA#X]\&7FN1:+I.F6&F6L<-_8PWEE9V=OK,6J)86 M0#Y._P""&?@#X@_
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M>(]5MK'PGX'\(?#CQ7X@O+.*YUW7$\.:#)I>IZGXU^T!X 3]N_\ ;/\ V:_
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MK]Q:V\DT.CZ._B#5] T%-2U&1%M;-]9US1]+6XEC:^U*RMA+<1@&Q17YW?\
M!/7]O:X_;PLOVI+V[^"/B3X#WG[-/[4OC[]F+4O"7C/Q7X=\4>+KK6OAUI'A
MNX\07_B1?"'V_P )Z#JUMKFLZAHESHOAKQ9X\T6(Z2+S3_&.L6UY&\>'XN_;
MT\>^,/VA_CA^S/\ L8_ +PY^TIX[_9=\.>$]8_:(U[QM\;Q\"? /A#Q-X]TS
M6M;\%?"'P=X@M_A=\6K[QW\6-:T?0+V[O[*31/#'P_\ "4MSIVG>+/B+I&KM
MJ>FZ6 ?I;17S7^R)^U;\*/VV/V?O 7[2'P8GUP>"/'D&K1IH_BO3H-&\9>$_
M$'AS6M0\-^*/!_C+1+:^U.#2?$OAO7]*O]-U"WMM1U#3[D10ZEI&HZGHU_I^
MHW?EW[5O[:^F_L^_$CX!_LZ_#[P&?C9^U3^T]JWBNT^#WP>'BZV\ :&GAOX?
M^'[OQ3X_^)'Q-^(=SH7BI/ 7P^\+:/9O&;VT\*^*_%'B369HM'\(^$M>GMM8
MDTD ^Y:*^%_V;/VV]&^+WCC]HWX%_%SPGI?P,_:._9'G\-W'QV\"KXYA\<?#
MN'P9X[T&Z\8^ ?BI\-?BI?\ ASP!<^,_AQX@\(P"[U74?$'@/P%XB\%Z_!J7
MAWQ5X8T\0:5JNN?'J?\ !8)Y?@7<?MVQ?LX7S?\ !-BS^($W@R7]HQOB<R_&
MR^\++\1+OX/Q_'31_P!E\_#?]_\ !B+XF0VMC?2ZG\8]'^+4/@VZE\:VOPCO
MDL7T6< _:JBJUE>V>I6=IJ.G7=M?Z??VT%[8WUE/%=6=[9W423VMW:74#R07
M-M<P2)-!/"[Q31.DD;LC FS0 445\V_M-_ K7/VD?!NF_"&7XB>)OAQ\*_$>
MK+-\:;GX>:WKGA3XF^./!6G(MS#\+O"WC?0+W3=3\ Z)XVU;[+!\1O%.E7<G
MB"\\!6.N> M"@TVY\=2>,O" !^</[7W_  <%_P#!,?\ 8W\5ZY\._%?QAUCX
MO_$SPO>MIWB7P%^S[X;'Q%O=!U"&XN+.^TS5?%]UJ7ASX7VNMZ1>6MS9:[X;
M?QZ?$NAWL+VFK:/9W&V(^=?L\_\ !RG_ ,$M_CQXNM? OB#X@_$+]FCQ)?S0
M6MC%^TYX)L_ &A/=3QV\JPZGXU\.>)/''@;PK$J3LSZAXR\2>'=*5;>5A?E9
M+,W7VI\/OB5_P3>_8W^.OA#]@_X0>#O WP7^.7B;PUX=\1>'_A)\)?V=?'4%
M]K7A/49I_#^G>.=>\7>!?AI>^'[O1EN].O;/Q)\0/%WBI[?3KRTU*?Q=KMK<
MQ7TP\QU/_@J9_P $H/VA/VB=<_8!\7?%7X8?$_XD7OBF[^%.H>!/B)\--7UW
MX5>)O'Z:E/IEW\,8/%WC'PC-\,/$/B.ZUG3(])T_24U:YL_$OB#[%X?\.W.L
M^("FFH ?K-9WEIJ-I:ZAI]U;7UA?6T%Y97MG/%<VEY:7,2SVUU:W,#/#<6UQ
M"Z303PN\4L3K)&S(P)LU\B?LV_LIZ7^R?XA\:^%O@YK]_IG[,OB:RTS6O!GP
M'U;5-?US3/@7X]@O;]?%4'P@O]<U/5I/#_PE\?6-YINJ?\*HM&TWPS\-_%V@
MZOJ?@FU&E_$+4-'\,?7= !1110!YM\3_ /D#Z+_V-.D?^@W=>DUYM\3_ /D#
MZ+_V-.D?^@W=>DT >=_"O_D2=+_Z[:C_ .G"YKT2O._A7_R).E_]=M1_].%S
M7HE !1110 5X]^T%\&]%_:%^!_Q6^"&OZIJ&@:=\4? GB/P=_P )-HT=I+KO
MA'4-8TZ>#1?&?AY;Z*>R7Q'X.UDV'B?P]+=036\&M:3832Q2)&4/L-?GKX7_
M &'O'7@S]F#]JGX V?[9/[47C+Q?^T#XF^,OB_P!\<O'_P 4/%5]\3OV?K_X
MB:)9:?X'T'X:^*=$UG2==T?PE\+M6TJQU_2M&TK4M*L]0U"[\0JUI9V&N7.G
MJ ?G%\5?VA?^#CWX,/>_#SPE^PU^QY^UC?V]SIUAX4_:)\ _$F/P!X3\0V(2
M*%;[QO\ !_X@_&/P+XGT7Q3?Q0R7OB'^Q]:TKP+H>IWKVFC:AJ>EVD-Q=?:7
M_!)[]G;XV_ SX6?&OQ9^UA\1_"_CO]L?]I'XYZK\?OVEM \&ZY:ZMX=^#WB?
MQ7X-\'Z;X+^#^GQ65Y=06L?@_P"&^B^%@C()+7RKZ+3="UCQ1X2TGPYXFU7Y
M/^%'_!$#XI1_#?P6/C;_ ,%A?^"Q=_\ %I_#^G3?$"?X9_MPZYX?\ Q^)YX%
MFU.R\*:9XE\&>+M=71].GD:PM+S5->N;K5$MO[3>VTS[8-+L_JO_ ()4?LQM
M^S/X:_:LL(/VJO&7[8>E^._VH]?UBT^+'Q5\7:KXS^-FGZGX'^'7PZ^$/BKX
M=_&75]9 O_\ A-_A_P"*/AYJWAU()DM&7PW:Z ZZ7I<4D=E& ?JU117\UG_!
M0_\ ;1^-'BG]MWQO^POX:^/7BG]DOP[\-_#_ .PUX_\ !UQX"T[P':_%;]IG
M5OC-^U]\(_ _CR_\.>-O'FF>,K;3O WPK\,ZWY,?@SPQX/L]=\5>)-'\9R^.
MM4\2?"JTU?P=?@']*=%?F/87W_!1;X2_!7]J3PK%?^'_ -J3XU:!\7/"/@S]
MD'XD?$#PGX:^&MIXH\ ?$S2?A5:MX_\ CMI7POM?#WAB^LO@)XE\8?$34?'L
MW@'P[X)F\=^%/AF\?A[0=#U[Q#:6EM^>'C/XE?\ !63_ ()Q?M,?L9ZK^TE^
MUM\.OV\_V<?VR_VC_A[^REXR\$VOP!\$_ 7QC\&?B=\76U ^&?$?PRN/!"7E
MYXA\*>%[/P[>WVI7WB_6+JWU'1].U73=0\,:1XB\067CS2P#^D>BBOYX/@_^
MV!^V#^W?^SS^U]^WY^SM\=%^#GPM^!_C3XQ:9^R)\!+?X=_"GQ=X*_: \-?L
M^Z#8:_+XD_:4\5>,?#>I?$ZSL?CAK$&N>&8?#_PB\;?!?4OAEH4UEJ<7B/Q9
MJ5JNK:@ ?T/T5^ 'C_\ X*_:S\6_V9/^"8VH_LO6>B>%?C[_ ,%3_'ND_#KP
MKJGB>P_X27P]\ ;#P5J^GZ#^U/XWAT74GT>W^(FK?"#6Y;SPYX(T34I](TSQ
M7J=Q8:_?)=V%G)X9UKWOP#^TY\7OV:_^"D/P^_X)Y?'WXP:U^T/X4_:6^ 7B
M+XS_ +/OQG\=>$OAKX2^*VF_$[X=SZD/B?\ !GQ-I_P5\%?#CX<ZMX';P9X:
MU'XE>"/$Q\!:!XCT:ZDU;P;K>L>-5;2-0T@ _82BOYX/@_\ M@?M@_MW_L\_
MM??M^?L[?'1?@Y\+?@?XT^,6F?LB? 2W^'?PI\7>"OV@/#7[/N@V&OR^)/VE
M/%7C'PWJ7Q.L['XX:Q!KGAF'P_\ "+QM\%]2^&6A366IQ>(_%FI6JZMJ'ZV_
ML*_M6^&OVX/V1?@+^U5X5T\Z-8?&'P+;:WJ>@^9-<)X:\9:1?W_A;X@^%H+R
MX@M9=2M?"_CS0?$GA^TU5K:V&K6NFPZDD$*72QJ ?65%?CIX\_:C^,?[2O\
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MOM'VZW^OZ_FR_;C_ ."OW[=MG^U;\1?V4_\ @E9^Q/8_M8ZA^SG::=%^T?\
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MX/U.;Q9ID7V8P7,VF.]W?V44RW$'[&?MD:9XC^+G_!P!_P $NOAYX8-VMM\
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MI-XF^*7B#3/$5M:K:2/)I5IXHL;:\M]+O;KSK6&/[/?QW,K6]I]B_P#!OGX
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M5?\ P70__)E'_"&^*O\ HHFJ_P#@NA_^3*])HH \V_X0WQ5_T435?_!=#_\
M)E'_  AOBK_HHFJ_^"Z'_P"3*])HH \V_P"$-\5?]%$U7_P70_\ R97X<?\
M!P+X?UO2_P!A[PO<ZCXLOM;@;]H7P'$+.YM(X(UD;P9\2V6<.MQ*2R*CH%V@
M$2$Y&,'^A"OP>_X.(_\ DQ'PI_V<;X _]0GXGU]AX?\ _):<-_\ 8TH?^W'S
MO%O_ "36=?\ 8#5_0_B0HHHK^X#^80HHHH *^S?V9OV2]<^,%Q;>+?%Z7F@?
M#6";<DP4P:IXNDA<>99Z*) &@TM2&CO==9&B,@>QTQ;B[2\GTOU+]E_]C&Z\
M0-8?$'XP:=/8Z"K1W>@^"+N-H+W7"I22'4/$438ELM%./W&D2+'>ZJ?WMX+7
M3%2+6/JC]HG]J/PK\"=-7PAX4M],UCQ\MC!#I_A^! FB^%++R52QGUN.S: 0
M(EN(WT_0+62"ZFMA#+*UA8S6MQ<?P/XV?29XCXEXEEX'?1JP[XGX^Q\JN#SS
MB_+W3K95PM0C)4L=]0QTN; K%8/G4<PSVO-Y=D\Y1PV%>*SBI%8#[W).&L-A
ML-_;G$LOJV II3H82I>-7%2:YH<]->_R3_Y=T(KVE;64E&BKU.M^*OQA^&/[
M+O@?3='LM-L8KN*PD@\&^ -%*6DMTJ2-ONKIUCF_L_3C=223ZAK%XDUS?737
M4D2ZCJ+3*?Q.^)WQ2\9?%WQ1=>*_&FI&\O9BT=E8P>9#I.B6.XM%IFC6+RS"
MSLH<Y.Z2:ZNI=]W?W-W>S3W,O-^*/%/B'QKKVI>)_%6K7FMZ]JTYN+_4;Z3?
M-*X54CC15"Q6]M;Q)';VEG;1PVEG;116MK##;Q1QK@5^M_1Z^C/PYX)X*MG>
M8XA<6>)V=PJ5>).,\:JE>K&KBY^VQ> R66*YL3A\%.O*4L7CJS699U7OBL?*
MG2^K9?@O)XAXFQ.=SC0IQ^J990:6&P4+15H+EA4KJ%HRFHZ0A']W1C[M--\U
M297]0G_!MQHVJZO_ ,-F_P!F>(KO0/L__#.WG_9;9+C[7YO_  O3RM^^:'9Y
M'E2;<;MWG-G&T9_E[K^JC_@V7_YO8_[MN_\ >]U^L^*__) 9_P#]TK_U=9<=
M/ /_ "5F4_\ <_\ ^JW&']+_ /PAOBK_ **)JO\ X+H?_DRC_A#?%7_11-5_
M\%T/_P F5A_'O]H7X*?LO?#+Q#\8OC]\2_"/PK^'?AFSN[F^\0^+]:L=(AO;
MJUTZ]U.+0= MKN:.[\2>*]5M]/NHO#_A/08-0\1>(;U%T_1=-OKV2.!IO@U^
MT%\"OVBO#<GB_P" OQC^&/QE\-6\L5M?:S\,?'7AGQQ8Z7?2Q";^S-8F\-ZG
MJ2Z1JT2$BYTK4OLNHVLBR17%M%+&Z+_&9_2!K?\ "&^*O^BB:K_X+H?_ ),H
M_P"$-\5?]%$U7_P70_\ R96A-\3_ (;V_P 1;'X03^/_  9%\5]2\*W_ (YT
M_P"&;^)M&7Q]>>"M+U&STC4?%]OX0-[_ &_+X8LM6U&QTRYUY; Z7%J%W;V3
MW0N94C/<T >;?\(;XJ_Z*)JO_@NA_P#DRC_A#?%7_11-5_\ !=#_ /)E>0_$
MK]NC]B7X,>,]6^''QA_;%_98^%'Q#T!=/?7? ?Q*_:#^$G@7QGHJ:OIEGK6E
M/JWA?Q1XNTK7-.74]'U"PU;3VO+&$7NF7UG?VQEM;F&5_4OA!\=O@A^T'X:O
MO&?P#^,GPJ^-_@_3-<N?#&I>*_A!\0_"/Q*\-:?XELK#3-5O/#U]KO@S5]:T
MNTURTTO6M&U*YTFXNH[^"PU;3+R6W2WO[624 N?\(;XJ_P"BB:K_ ."Z'_Y,
MH_X0WQ5_T435?_!=#_\ )E8WC#]H?X!_#[X@^%/A)XZ^-?PH\(?%?QX-+;P1
M\+_$?Q!\*:/\1?&$6M:RWA[2KGPQX'OM5@\3Z[9WVNI)I,%[IFEW5HU]#/;F
M8203!,+XG_M7_LN?!+Q?X9^'_P 9?VC_ ($_"?QWXS>W3PEX,^)'Q:\!^"?%
M7B,WDSVMF^C:!XDU[3=5U"&\O4_L^TN+>UD@NM3DM]-@DDO[JVMY0#MO^$-\
M5?\ 11-5_P#!=#_\F4?\(;XJ_P"BB:K_ ."Z'_Y,KTFO$/C-^TU^S=^SDGAV
M3]H7]H+X(? >/Q>VJIX2D^,WQ7\!_"]/%#Z"-.;7$\.MXWU_0UUMM&76-);5
M5TPW)TX:IIQO!"+VV\T Z;_A#?%7_11-5_\ !=#_ /)E'_"&^*O^BB:K_P""
MZ'_Y,KSOX0?MB?LC?M!^);[P9\ _VIOV<OC?XPTS0[GQ/J7A3X0?&_X9_$KQ
M+I_AJRO],TJ\\0WVA>#/$^M:I::'::IK6C:;<ZM<6L=A!?ZMIEG+<)<7]K'+
MJG]J?]F0?&6+]G0_M$_ P?M SM*D/P._X6QX#_X6[))#I#^(984^'']O?\)>
M;A/#\<NO&W&C^=_8D,^K",Z?!+<( =?_ ,(;XJ_Z*)JO_@NA_P#DRC_A#?%7
M_11-5_\ !=#_ /)E7OB3\4?AG\&O!^J?$/XO_$3P-\*O .B&U&L^-_B/XMT'
MP1X1TEKVYBLK)=2\2>)K_3-'L6O+R>"TM%N;R)KFZFBMX0\TB(S/AC\5?AA\
M:_!6D?$CX.?$7P-\5_A[KYO5T/QU\./%FA>-O"&KOIM]<Z7J4>F^(_#=_J6D
M7DNFZI9WFF:C#;W<DMCJ-I=6-TD-U;S1( 5/^$-\5?\ 11-5_P#!=#_\F4?\
M(;XJ_P"BB:K_ ."Z'_Y,KTFB@#S;_A#?%7_11-5_\%T/_P F4?\ "&^*O^BB
M:K_X+H?_ ),KTFB@#S;_ (0WQ5_T435?_!=#_P#)E'_"&^*O^BB:K_X+H?\
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MQ9TC,T-_XAD$-Q-:F6VMELK&:\CO/F3]I_\ ;0GUHZA\/O@[J+VVBD2V>O\
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MWP-\#>+]'\.:OHGPR\&Z%/J/A>;5['0+3P5XL\2^,-1E^'NHZIX:T*.WT?\
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M$>L1:AHVO>)O%%]H^C6L=MH.HV]C=>)_"DVI3VVG:M=7^E@'CWQ/_P""??\
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M:OM7M]?-T\^F10. ?T,4444 %%%% 'FWQ/\ ^0/HO_8TZ1_Z#=UZ37FWQ/\
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M%3Q>-K2JUIZ*^D*<$VXTJ4%I3IQN[16[;E)RG*4F4445]P<(4444 %?U4?\
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M:CI4'4<XP=1\T.5<JE"+UN];S6GK\^_HHHKR#T HHHH **** "BBB@ HHHH
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MF9";>]TR\N[.[C*RVL\T3H[?=O\ P1G\9_L _$[X.?M$?$K_ ()W>#Y?A_\
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M_DF\?_BP?_J;ASWN&?\ D<X7_#B/_4>J?O!1117X2?J04444 %%%% !1110
M5^@WP%_Y)AH/_7QK/_IXOJ_/FOT&^ O_ "3#0?\ KXUG_P!/%]7RW%W_ "+*
M/_8;2_\ 3.(/>X=_WVK_ -@L_P#T]0/8J***_.#[(**** "BBB@ HHHH ***
M* "BBB@ KPW]H3Q;\:?"O@#ROV>?A]X>^(7QB\4ZS:>%O!=MX\UC4_#OPK\+
M7EU9:CJEYXV^+'B#0=/UCQ)IO@?0-+TB]+P>&M%U37?$7B2Z\.>$=/CTZ3Q"
M=<TKS[]L#]H?XI_LW> ?#GB_X3?LI_%K]KC7=:\7V_AO4/ GP?O_  YI^O\
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MH<GP]TB]\=6HTV.Z@&GZU?\ C;Q?JQ\-6GQ N=4\2^-M3_@AAMT/XV?\%J?
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MJTL?!EE\/O$-[=W.LW7BN.Z;1C>:#]GO_#GVF/Q/>S/HFC:G:W(!_3/1110
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MU'0?$,>EZUH<>E:+=6,1^(]]\0Y-*T[4=/631-/,6@Z%,W@C3/"4%M\^:?\
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MH:"0 22  "22<  <DDG@ #DD]* %HHHH **** "BBB@ HHHH **** "BBB@
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M[;_XW1_PAOA/_H7-&_\ !?;?_&Z )O\ A*_"W_0RZ!_X.-._^2:/^$K\+?\
M0RZ!_P"#C3O_ ))J'_A#?"?_ $+FC?\ @OMO_C='_"&^$_\ H7-&_P#!?;?_
M !N@";_A*_"W_0RZ!_X.-._^2:/^$K\+?]#+H'_@XT[_ .2:A_X0WPG_ -"Y
MHW_@OMO_ (W1_P (;X3_ .A<T;_P7VW_ ,;H F_X2OPM_P!#+H'_ (.-._\
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M\+?]#+H'_@XT[_Y)J'_A#?"?_0N:-_X+[;_XW1_PAOA/_H7-&_\ !?;?_&Z
M)O\ A*_"W_0RZ!_X.-._^2:/^$K\+?\ 0RZ!_P"#C3O_ ))J'_A#?"?_ $+F
MC?\ @OMO_C='_"&^$_\ H7-&_P#!?;?_ !N@";_A*_"W_0RZ!_X.-._^2:/^
M$K\+?]#+H'_@XT[_ .2:A_X0WPG_ -"YHW_@OMO_ (W1_P (;X3_ .A<T;_P
M7VW_ ,;H F_X2OPM_P!#+H'_ (.-._\ DFC_ (2OPM_T,N@?^#C3O_DFH?\
MA#?"?_0N:-_X+[;_ .-T?\(;X3_Z%S1O_!?;?_&Z )O^$K\+?]#+H'_@XT[_
M .2:/^$K\+?]#+H'_@XT[_Y)J'_A#?"?_0N:-_X+[;_XW1_PAOA/_H7-&_\
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MO_!?;?\ QNC_ (0WPG_T+FC?^"^V_P#C=?G!]D3?\)7X6_Z&70/_  <:=_\
M)-'_  E?A;_H9= _\'&G?_)-0_\ "&^$_P#H7-&_\%]M_P#&Z/\ A#?"?_0N
M:-_X+[;_ .-T 3?\)7X6_P"AET#_ ,'&G?\ R31_PE?A;_H9= _\'&G?_)-0
M_P#"&^$_^A<T;_P7VW_QNC_A#?"?_0N:-_X+[;_XW0!-_P )7X6_Z&70/_!Q
MIW_R31_PE?A;_H9= _\ !QIW_P DU#_PAOA/_H7-&_\ !?;?_&Z/^$-\)_\
M0N:-_P""^V_^-T 3?\)7X6_Z&70/_!QIW_R31_PE?A;_ *&70/\ P<:=_P#)
M-0_\(;X3_P"A<T;_ ,%]M_\ &Z/^$-\)_P#0N:-_X+[;_P"-T =+1110 444
M4 %%%% !1110 4444 %%%% !5'5-4TS1-,U'6M:U&QTC1](L;O5-6U;5+NWL
M-,TO3+"WDN[_ %'4;^[DBM;*QLK6*6YN[NYEBM[:WBDFFD2-&87J^>_VA_V;
M_ G[47A_PY\//B_]H\0_!NR\267BKQW\)9(H/^$8^+]UX>EAU#P?X:^(S.'N
M-6^'NA^)8;3QCJ?@RV%I;>+_ !#X?\+6?B6]O?!=IXF\'^+@#\<OC-_P<"^!
M3K?B3PU^P3^Q/^U__P %(+CPGJ;Z/J_Q"^ 7PP\8K\"I=2M9KFWU.PT;XE:3
MX-\=ZYKLUA+:NR:IIGP^G\)ZS:R0:AX=\3ZQITRW=9/PU_X+X>,-$NYYOVY?
M^"67[?'[%/@6T19=7^,6H_"+XE?%CX2^$[4"Q^TZMXP\0VWPL\ :Y9:):/=M
M%->>&_"_BR[64V<3:<DEU*EI^L^L?MG?LI?"[]H7P3^Q#/XMO-#^/.L^%/#F
MK^"?@YX6^$7Q4U2"#P!>W$WA_0]=M-2\(> -1\#:!X$TN?3+G2KW7;O6].\,
M^%5TVYM]9O-)BL9A%X%X6_X+)?\ !.+QE^U7=_L8^'_VD-#NOCK;>,I_AM%I
MMQX;\9:=X,U/XEVVH7FDR_#S1_B3J/A^U\!ZIXLEU:S?1]+L+37Y(/$6O36_
MAWPW=ZQK\O\ 9B@'Z#_#CXD_#_XP^!?#'Q-^%?C/PU\0_AYXSTN+6?"GC/P?
MK%EKWAS7],F=XA=Z;JNG33VMPL<\4UK<HLGFVEY!<6=U'#=6\T,?;5\X_"C]
MF'X;? OXG_%+Q_\ ""Q@^'WA[XT+I>N?$3X4^&M,TW2?AU??%+2I;J&?XQ:%
MH6FV]G;^'?'GC30KN'0_BA>VD4UMX\'ACP1K5W;V'B'1]=U3Q5]'4 %%%% '
MFWQ/_P"0/HO_ &-.D?\ H-W7I->;?$__ ) ^B_\ 8TZ1_P"@W=>DT >=_"O_
M )$G2_\ KMJ/_IPN:]$KSOX5_P#(DZ7_ -=M1_\ 3A<UZ)0 4444 %?-O[8G
MP C_ &JOV5OV@_V<CK$7AVY^,OPF\:^ M*\07,5Q=66@Z_KFB74'AS6M3L+6
M:WEU;1]+U[^SK[6-$,J0ZYI<%WI%SNMKV56^DJ\.^/O[3'[/O[+'@F7XB_M&
M?&3X=_!GP<GVI+;6/'_B?3- _MB\L[5[V;2?#6GW<ZZKXJUYK6-Y;;P]X;L=
M5UR]P$L]/GD94(!^(OBO_@K_ /M0?L^>$K#X-P?\$._VX?\ A=OA/3+7POI?
M@GX0> 8/$/[+<MUIFD1*B_#KXR?#'0?%VG7G@NUE$;VUOI'@N0Z-HFU-1:SO
M+:>VC^@/^"'_ .R]^TU\"/@3\?OC!^V#I%EX'_:!_;8_:C^)W[5OC;X2Z-+&
MFC_"]_'\EC'!H[:7:ZKKECI>MZQ/9WNOW=E%K.IZEIOA^_\ "OA[Q-<KXGT'
M6+6V^*OB-_P<7W7Q[^(L/[//_!(K]D3XE_MJ?&#7TUR/0_B+XVTW4/A?\$=.
MAT1-"^W>+);36)=&\4ZIX6T.Z\1:-I_B>?QYJGP+L='NM:T(-XAE.LZ9'>?>
M/_!'_P #?MU^%=/_ &VO$7_!0W1+'2_V@/B=^UC%X\-WX96"3X<ZAX+N/@#\
M$]#\*67PROK)YK*\\(>#M/T0>!(]MYJ.I6VJ^&-3M_$.IZMXA34]5O@#]CZ\
ME^,GP(^#_P"T'X7L_!GQH^'WAWXA^&M/\2^%/%]CIFOVKR+9^(O!/B;2?%WA
MS4+6ZMI;:^@%MKFB:>]_9Q7*V&NZ8+SP_KUKJ?A_5-4TN\]:HH B@@AMH8;:
MVABM[>WBC@@@@C2*&"&)!'%##%&%2.*-%5(XT541%"J  !4M%% 'RQ?_ +,>
MG>)_VKM _:A\=:QX>UZ[^&'@S5_"7P.\*Z5X"M-"OO!E[XQTZWTWQQXU\;>-
MKG7-=U7XA>+6TP:YX7^'4VG:?X#T3X>^"?'GQ(T.31/%.J^,KWQ)!]$Z9X5\
M+Z+JFMZYH_AO0-)UOQ+/#=>(]8TS1].L-4U^ZMX4MX+G6]0M;>*[U6>"WCC@
MAFOIIY(H8TB1E154;U% #71)$>.1%DCD5DDC=0Z.C@JR.K JRLI(92"""000
M:R]#T'0_#&E6>@^&M%TGP]H>G(\>GZ-H>G6>DZ58QRS27$D=GIUA#;V=LDD\
MTL[K!"BO-+)(P+NS'6HH Q[KP]H%]K&E>(KW0]'O/$&A17\&B:[=:997&L:-
M!JD:0ZG#I6IS0/>Z=%J,,<<5_':3PI=QQHEPLBJH'SA^U+^S'IW[5FC>!?AW
MXXUCP]'\&].\9Z7XM^*/@Z\\!6GB+Q/\1K+PW?Z=J^B^"M&\::GKB6'@#PEX
MBNK.[\/?%J&'P9XFUOX@?#?6]<\"Z5K?@>'5]1U:[^IZ* ,?7?#V@>*=-ET;
MQ-H>C^(](FEMIYM*UW3++5]-EGLKB*[LYI;'4(+BUDEM+N&&ZMI&B+P7$44T
M3))&K#8HHH Q[#P]H&E:EK.LZ7H>CZ;J_B.6TG\0ZK8:996>I:]/I]O]DL)M
M9OK>".ZU26RM/]%M)+Z6=[:W_<PLD?RT:[X>T#Q3ILNC>)M#T?Q'I$TMM/-I
M6NZ99:OILL]E<17=G-+8ZA!<6LDMI=PPW5M(T1>"XBBFB9)(U8;%% !1110
M4444 %%%% !1110 4444 %%%% '->,_&'AKX>^#_ !7X^\9ZO:^'_!_@?PUK
MOC#Q9KU\SK8Z)X:\,Z7=:UKNKWC(KNMKINEV5U>W#(CN(87*JQP#^#_A/_@K
MM^U%\0+#X@_M#?#[]BOPOXK_ &3O"_[*OP]_:OTKPO+\?[32OVJ+_P"#'B7Q
M[\>-#U'XC6_A&Q^'?B+X4:AXJ?PQ\'[W6F^!*_%:RU72K73XC9_$?Q+XK\2-
MX"\-_O=X@T'1_%.@ZWX8\0Z?;:MH'B/2-2T'7-*O(Q-::GH^KV<VGZGI]U$V
M5EMKRRN)[:>-N'BD93P:_C4T>/XT?\&]_P"U9\2_#<>B>.OVW/\ @F]_PH[X
M)_\ "?:SJ<5E)\6?V/\ X)?$'XZ?M"6W@O3?L$5Q)I7CWPOIWB^X^+6H>(%C
M\.Z#X;U_4?$>CV\U_P##6[U*&T\0@']2/[6O[4=S^RY^S#X__:9T[X+_ !#^
M->E_#[X>Z_\ $K6O"7@/4_ .B:EI7A7PWX2U+QAK/B+Q%J7CKQ9X<L[/PYHF
MF:;++KDOAJ'QCXKCA)?P_P"#/$MRGV)^J_9(^.\G[4/[+W[/O[1TOA=/!,GQ
MS^#_ ( ^*K^#X]9;Q"GAAO''AK3_ !"="77FTO1&UA=,^W_9!J1T?2S>^5]H
M^P6N_P E/ O^"A7BCPSXW_X)5_MP^-/!>K:?KW@[Q=_P3[_:7\4>$]<TEQ)I
M>L^&=?\ V<O&NJZ#JVFR*JK)I^HZ7=VMY9NJJ'MYHV"@' C_ ."3/_*,/]@#
M_LT/X!?^JV\/4 >N?M@_M2VW[*'PRT;Q7I_PO\??'/XE?$'QSI'PJ^"OP0^&
M5M:R>,?BI\3]=TG7_$5IX?M-1U)XM%\,Z)I'A3PGXM\;>,?%VNSQZ9X9\'>%
M=>U9HM0O+>STJ_\ @W]E[_@JO\4_&/[6^C?L/_MS?L1>-_V%?C[\2O"VO>-/
M@#]I^*?ACX\_#'XR:5X6TV\\1^*] TGXD^"M!T/0K+QCX;\,P/J=QI]D=>TZ
M:/2M9@UK4O"6O2^&_#7B#]DY["QNKBQN[JRM+FZTR:6YTVYGMH9KC3[B>UGL
M9[BQFD1I+2::RNKFSEE@:.22UN)[=V,,TB-^4?A7P G[9O\ P45\"_MBI;PW
M7[.W[#'@#XO?"']G#Q08Y8O^%K?M$_&&XT[PM^T#\2?"-Y'.8=:^%'P^\$^&
MK7X0:-K+VQL?%/Q"NO'U]H-U<Z/X4T_4]8 ,#]L?_@I%^U#^SK!\2?B5\'/^
M"<_CG]HC]E[X#3>))/C;\>)OCM\//A-?V>E?#Z/41\6-9^&/PE\0Z1K?CSQ_
MH/PRN=,U2SUGQ%<VWAO3M:U/0-8A\,IJOA>.7QQ9?H+X9_:<^$7B3]EK0/VQ
MWURY\._ K7O@1I?[1S^(?$EDUG?Z%\+M3\!P?$=]2UW3+*349+;4-,\,3&;4
M]-LY;^6*\@FL[9[N01F3Y1_X*M?#7]M?XO\ [(GQ3^&W[&"?!+5M:\9^#/$G
MAKXC^!_BS;>,X-8^)7PZUG3)[+Q=\._AYXH\+^(=#L_"7B7QMX>DU+PK'JVL
MA,V^M3II/B3P)K*V'C'2?'?V8A\$_P#@LM_P2)^$>G^,OAMKWP#^"GQF\(1>
M#-;^#_PF\3-X8M?"^F? ;XF:CX'M/!_A+Q!::!I[6O@(:S\,+"YTS2].TZVC
MB\/);^$]1DN;>#5K6Z -C]FK]N'_ (*1_&CXT^!O!OQ7_P""0WB3]FWX(^*Y
MM6NM:^.WC/\ ;"^%_BF\\&Z!;>'M5UO0[O5?A+X<^'J^*9]>U^\M-*\.CPTF
MI0/HVL:TG]K:G;V.G7UXGZA?$SXB>%/A%\.?'OQ6\=ZBVD>"?AIX-\3>/?%^
MJ);S7<FG^&O".BWNOZY=Q6ELDES>30:;87,D-I;1R7-U*J6\$;S2(A_GA_9S
M\%_ME_\ !*G_ (*)?LT?L6:C\?/B%^UM_P $^OVSK?XR:+\%)_C'>7?BOXQ?
MLV>-/@W\*W^('_",WOC/^RTAO?"T_A_PY;Z=H>AV%YHWA6?29?%/B'2?!7A7
M4O"NK2^+/Z5&57!5U5E/56 8'!R,@Y!P0#]1F@#^<SQ9_P %?O\ @J#X#^!7
MBW]I;QU_P0R\1> /@QX&\(:SX]\4^(OB)_P4!^#/@+Q%H?A70[62]O;W4_AM
MXJ^$NF?$FWU(V\82S\.)X4F\0:I?2P:9I&FZAJ%S;6\WZD_'+]KCXF?!G]EO
MX5?%*U_9KU;QY^U+\9[+X<^'_A_^QOHOQ%TS2]<UWXS^+/",OCOQK\+H/BKJ
M_AB#0[6R^%GA#P_\1_%/B/QSJ_A?2].G\._#S5K[^RK&[O;/3J\5_P""DZ+\
M:_'/[$?[",,:7NG?M,?M%:7\4OC/IUUI4FIZ5=?LS_L=-I7QW^(.EZS)$P&G
MV?C?XGV'P/\ AB99OW5Y!XYO;/E6DQVG_!03_@F9\*O^"A4/PWU3QO\ %CX]
M_!_X@_! >)M4^"7C[X'_ ! ;P7J/P^\:>)?[&>;QD+2+3Y_[9U2)O#VD6B/+
M>V=[9Z4NHVGA_4_#][JMWJC '2?L2?M'_MI_M 77Q%'[6/\ P3^N/V'M/\*V
M_A@^";C4_P!I;P-\>K_XDWFLR:Z-<AL]/\#>"_#\'ANT\*0:7ICWMYK&I-+J
M4WB&Q@TRRG2TU*>TY/PU_P %"M2\0?\ !2R^_P""=FI_LY^// %S8?LV>)?V
MCK3XL^./%G@4VOC+PYI/Q*TWX;:+<>"?!W@G5_&L[^%]?U!O$$L6L>-/$/@O
MQ=97&@26E[\.X+6\M-4F^9O^"1GQ=_;8T+XH?ME?\$_/VY?&-O\ &WX@?L37
M/P*N_A]^TG;:=>V5Y\7OA)\:_"WBG4?!<WBJ:[L;675?$VD6?@EDU/Q#?W6M
M:]JOB&Y\5Z/KWB#Q'J?A.X\4:]R^O?\ *S'X*_[0PW?_ *V'XMH _>JBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY8_:4_:F\(?
ML_Z.;-3;>(_B)J5N7T/PC%<A?LT;%576/$<L):73-)0%FMHBJWFM31M:V CA
MCO\ 4=.\O_:L_;.T?X1PWW@;X=SV6O?$V1)+>\O 8;W1_ ^X21R2Z@H,D-_X
MCB8#[+H<BF"T<B[UH&*.+2M3_-;X)_ 7XG_M4^--1U[4-1U#^Q#JD<OC;XB:
MY)->.UQ((I);#3VF)?5]=-F8S#91LEIIML;1KZ:RMIK&.Y_G;Q)\8<91S)<
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M110 4444 %%%% !7]!'_  0__P"0+^T?_P!A3X6?^DGC^OY]Z_H(_P""'_\
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M- 'G?PK_ .1)TO\ Z[:C_P"G"YKT2O._A7_R).E_]=M1_P#3A<UZ)0 4444
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M7_"7B_X8_%6#Q38P3Z?I,?AB'XD:)X6E@TNUOTEM)I]=M=?^[** /F+]F_\
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M_7RO&O\ R3>/_P 6#_\ 4W#GO<,_\CG"_P"'$?\ J/5/W@HHHK\)/U(****
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MW>M/=V_6_#S]HO\ :(_X*%_M7?MQ_"G]G_\ :$U[]E'X'?L-^+=*^ FG^+_
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MWNHVWM%?/_[5WAKXE>,OV9?C]X5^#EGX/U3XJ>(/A!\0=*\ :'\0O#ND^+/
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M%KFK^'/%?B>VNKJV\3^*_"%@FE)8>$-3AGGAU.>\6\GL8X[&6&6XN+;\P/\
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M2HQC!=$(1IQ48KU?5ON_ZLNF@4445]86%%%% !1110 4444 %?@]_P '$?\
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M_P %-@B"3_@O=^TJ\@51(R?L^^$HT9P!O9(V^*\K(K-DJC22%00I=R-Q\/\
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M_D<X7_#B/_4>J?O!1117X2?J04444 %%%% !1110 5^@WP%_Y)AH/_7QK/\
MZ>+ZOSYK]!O@+_R3#0?^OC6?_3Q?5\MQ=_R+*/\ V&TO_3.(/>X=_P!]J_\
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MV1O G[67[+3Z?J,/C/XT7?PG_:<^%'B#X,:M\,]8T_3?$4EWXUU?Q7I'P\\
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M+\/0Z-JMC=W-E?\ A^'3X3):ZI8ZKI.E_"'[#/\ RG3_ ."YO_8L_P#!./\
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M+KO5OB!X>\?>/=5^%OA_5;3Q)\5=!^ _@#XN^(?A_I"WJ^(=*M-6T^\TJ']
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M?"JV-Q\6/ 7QDT_4[@VGA#Q-\,]DI\52?VE?^'6L4A\0Z#K^N>%=1TG7;_\
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M?#OQ(T3Q'HNH:MIGC3P[XVTGQ8NIW-[K%ZL0!]JT444 %%%% !1110 4444
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MK/Q$"S66JZXH@OM'\%2_OH)XMI:2'4?%-I(HQI\T<NGZ9/@ZJMS-#-I+^/\
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MOT&^ O\ R3#0?^OC6?\ T\7U?+<7?\BRC_V&TO\ TSB#WN'?]]J_]@L__3U
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M)/\ @LW_ ,%'O#OB;PQX=M[?X@7O[,_[1GQE\0_LR:!\2+Z*SUKQO!X \2>
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M70O"-SJFAVWB"SN_ GPNCN;+14O]?TU-2O\ Q!!H-UI?B6]X!_:<^+W[-?\
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MUG_T\7U?+<7?\BRC_P!AM+_TSB#WN'?]]J_]@L__ $]0/8J***_.#[(****
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MW&G>%K/7M&N/#NB>(;^P@\56&O:WX5U!]%OY]4\*S>(M;TB'PCKP!^NU%%%
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M%'C.Z\+:,;7X(:%X;\%>(M!TOXE:)X<O/'6K>$? T.KC7 #Y;_9 M=8^&?\
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MP0__ .0+^T?_ -A3X6?^DGC^OE>-?^2;Q_\ BP?_ *FX<][AG_D<X7_#B/\
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MEW*>+;3PS96UA;:%<:OX2\4^%F\0:;!IFD6MOXKAU_\ L_1M(TQK+3;;RO\
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M#;F^.H7MKI5_%IEWJ7@K0KF;PCX O/"G@USX?K[DHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *_![_@XC_P"3$?"G_9QO@#_U"?B?
M7[PU^#W_  <1_P#)B/A3_LXWP!_ZA/Q/K[#P_P#^2TX;_P"QI0_]N/G>+?\
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M1=-TFPNK66RUB379]#OH]1=VC2RLKRV*[KE2/E#6/V OB[^V1^QS\5?V5_\
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M]9\2>.O''P]\)>&]%_LGP]XBU:\\/PWFM0-K7BJ'0?#\$,\FJ",@'ZH4444
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M^)]?8>'_ /R6G#?_ &-*'_MQ\[Q;_P DUG7_ & U?T/XD****_N _F$****
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MT[481/:_VKX6U[3/%'AV_P#+)&+G1_$.C:7K%C(#F&^L+:9>8Q70T4 %%%%
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MW'PC^%7AR"7Q'H_C?XA6?A+Q)KOB5/"6FZ#HFM>$M#LM6TO^,/%3_DO>(/\
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M HHHH *_![_@XC_Y,1\*?]G&^ /_ %"?B?7[PU^#W_!Q'_R8CX4_[.-\ ?\
MJ$_$^OL/#_\ Y+3AO_L:4/\ VX^=XM_Y)K.O^P&K^A_$A1117]P'\PA1110
M4444 %%%% !7]!'_  0__P"0+^T?_P!A3X6?^DGC^OY]Z_H(_P""'_\ R!?V
MC_\ L*?"S_TD\?U\KQK_ ,DWC_\ %@__ %-PY[W#/_(YPO\ AQ'_ *CU3]X*
M***_"3]2"BBB@ HHHH **** "OT&^ O_ "3#0?\ KXUG_P!/%]7Y\U^@WP%_
MY)AH/_7QK/\ Z>+ZOEN+O^191_[#:7_IG$'O<._[[5_[!9_^GJ![%1117YP?
M9!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZX0SFC@N',LPTZ-2<J<*[<HN*B_:8O$55:[3T4TGYI]#]-**_,O_ (6/X_\
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MXJ23MI=)V=@HHHK$T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*_![_@XC_P"3$?"G_9QO@#_U"?B?7[PU^#W_  <1_P#)B/A3_LXWP!_ZA/Q/
MK[#P_P#^2TX;_P"QI0_]N/G>+?\ DFLZ_P"P&K^A_$A1117]P'\PA1110 44
M44 %%%% !7]!'_!#_P#Y O[1_P#V%/A9_P"DGC^OY]Z_H(_X(?\ _(%_:/\
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MVH_^G"YKT2O._A7_ ,B3I?\ UVU'_P!.%S7HE !1110 4444 %%%% !1110
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MVB?AS)\.OA!^S/!\?/"_BS5=/U*+XB>+?AY\9?B!X+^.OA'Q'=^,K[6O#GQ
MUSQ'K_BW6;9_&L5U/IWW#&;#_@H/_P %GOVKOV=OC]X;T;XG_LF?\$^_@/\
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MPK7P1_T HO\ P,U'_P"3*/\ A6O@C_H!1?\ @9J/_P F4 =3_:VE?]!/3_\
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MS_-?[+<_\^\__?F3_P")H^RW/_/O/_WYD_\ B:_2C_A6O@C_ * 47_@9J/\
M\F4?\*U\$?\ 0"B_\#-1_P#DRN#_ %RJ_P#0!3_\*)?_ "KU_I:]7^K</^@N
M?_@E?_+/7^EK^:_V6Y_Y]Y_^_,G_ ,31]EN?^?>?_OS)_P#$U^E'_"M?!'_0
M"B_\#-1_^3*/^%:^"/\ H!1?^!FH_P#R91_KE5_Z *?_ (42_P#E7K_2U/\
M5N'_ $%S_P#!*_\ EGK_ $M?S7^RW/\ S[S_ /?F3_XFC[+<_P#/O/\ ]^9/
M_B:_2C_A6O@C_H!1?^!FH_\ R91_PK7P1_T HO\ P,U'_P"3*/\ 7*K_ - %
M/_PHE_\ *O7^EJ?ZMP_Z"Y_^"5_\L]?Z6OYK_9;G_GWG_P"_,G_Q-'V6Y_Y]
MY_\ OS)_\37Z4?\ "M?!'_0"B_\  S4?_DRC_A6O@C_H!1?^!FH__)E'^N57
M_H I_P#A1+_Y5Z_TM3_5N'_07/\ \$K_ .6>O]+7E/@G?65K\,?#,%U>6MM/
M'_;.^&>XAAE3=X@U9UWQR.KKN1E=<J,JRL,@@UZI_:VE?]!/3_\ P-MO_CE<
MM_PK7P1_T HO_ S4?_DRC_A6O@C_ * 47_@9J/\ \F5\CB:SQ.)Q&(<5!UZ]
M6LXIW475J2FXIV5TN:U[*]KV/H:%+V-&C13YO94J=+FM;F]G!0O:[M>U[7=N
M[.I_M;2O^@GI_P#X&VW_ ,<H_M;2O^@GI_\ X&VW_P <KEO^%:^"/^@%%_X&
M:C_\F4?\*U\$?] *+_P,U'_Y,K U.I_M;2O^@GI__@;;?_'*/[6TK_H)Z?\
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M1_PK7P1_T HO_ S4?_DR@#J?[6TK_H)Z?_X&VW_QRC^UM*_Z">G_ /@;;?\
MQRN6_P"%:^"/^@%%_P"!FH__ "91_P *U\$?] *+_P #-1_^3* .I_M;2O\
MH)Z?_P"!MM_\<H_M;2O^@GI__@;;?_'*Y;_A6O@C_H!1?^!FH_\ R91_PK7P
M1_T HO\ P,U'_P"3* .I_M;2O^@GI_\ X&VW_P <H_M;2O\ H)Z?_P"!MM_\
M<KEO^%:^"/\ H!1?^!FH_P#R91_PK7P1_P! *+_P,U'_ .3* .I_M;2O^@GI
M_P#X&VW_ ,<H_M;2O^@GI_\ X&VW_P <KEO^%:^"/^@%%_X&:C_\F4?\*U\$
M?] *+_P,U'_Y,H ZG^UM*_Z">G_^!MM_\<K\//\ @X TO4_&'[$'A?2O"6G7
MWBG5(_VA/ EX^F^'+2XUN_2SA\&?$J*6Z>STR.ZN%MHI)X(Y)S&(D>:)&<-(
M@/[-?\*U\$?] *+_ ,#-1_\ DRC_ (5KX(_Z 47_ (&:C_\ )E>OD.:RR/.<
MNS>%".)EE^*IXE4)3=.-5PO[CJ*,W!._Q*$K=F>?FN 6:9=C,OE5=&.+H2HN
MJH*;@I6]Y0<HJ35MG)>I_F7?\*>^+G_1+?B-_P"$1XF_^5E'_"GOBY_T2WXC
M?^$1XF_^5E?Z:/\ PK7P1_T HO\ P,U'_P"3*/\ A6O@C_H!1?\ @9J/_P F
M5^T_\1YQ?_1-8;_PYU?_ )B]?Z6OYK_Q"K#_ /0ZK?\ A%#_ .:3_,N_X4]\
M7/\ HEOQ&_\ "(\3?_*RC_A3WQ<_Z);\1O\ PB/$W_RLK_31_P"%:^"/^@%%
M_P"!FH__ "91_P *U\$?] *+_P #-1_^3*/^(\XO_HFL-_X<ZO\ \Q>O]+4_
MXA5A_P#H=5O_  BA_P#-)_F7?\*>^+G_ $2WXC?^$1XF_P#E91_PI[XN?]$M
M^(W_ (1'B;_Y65_IH_\ "M?!'_0"B_\  S4?_DRC_A6O@C_H!1?^!FH__)E'
M_$><7_T36&_\.=7_ .8O7^EJ?\0JP_\ T.JW_A%#_P":3_,N_P"%/?%S_HEO
MQ&_\(CQ-_P#*RC_A3WQ<_P"B6_$;_P (CQ-_\K*_TT?^%:^"/^@%%_X&:C_\
MF4?\*U\$?] *+_P,U'_Y,H_XCSB_^B:PW_ASJ_\ S%Z_TM3_ (A5A_\ H=5O
M_"*'_P TG^9=_P *>^+G_1+?B-_X1'B;_P"5E?O/_P $7/!?C'PQH_[0R>)?
M"?B7P\UYJ?PQ:S77-"U326NU@M?'8G:V%_:VYG$)EB$IB#B,RQA\;US_ %U?
M\*U\$?\ 0"B_\#-1_P#DRC_A6O@C_H!1?^!FH_\ R97EYSXS8K-\NKY?+(*%
M"-=T6ZL<PJ5''V5:G6T@\)%/F=/E^)63OK:S[LM\-Z&78REBXYM5JNFJBY'A
M(04N>G*F_>6(E:W-?9[6/S7^RW/_ #[S_P#?F3_XFC[+<_\ /O/_ -^9/_B:
M_2C_ (5KX(_Z 47_ (&:C_\ )E'_  K7P1_T HO_  ,U'_Y,KXC_ %RJ_P#0
M!3_\*)?_ "KU_I:_3?ZMP_Z"Y_\ @E?_ "SU_I:_FO\ 9;G_ )]Y_P#OS)_\
M31]EN?\ GWG_ ._,G_Q-?I1_PK7P1_T HO\ P,U'_P"3*/\ A6O@C_H!1?\
M@9J/_P F4?ZY5?\ H I_^%$O_E7K_2U/]6X?]!<__!*_^6>O]+7\U_LMS_S[
MS_\ ?F3_ .)H^RW/_/O/_P!^9/\ XFOTH_X5KX(_Z 47_@9J/_R91_PK7P1_
MT HO_ S4?_DRC_7*K_T 4_\ PHE_\J]?Z6I_JW#_ *"Y_P#@E?\ RSU_I:_F
MO]EN?^?>?_OS)_\ $T?9;G_GWG_[\R?_ !-?I1_PK7P1_P! *+_P,U'_ .3*
M/^%:^"/^@%%_X&:C_P#)E'^N57_H I_^%$O_ )5Z_P!+4_U;A_T%S_\ !*_^
M6>O]+7\U_LMS_P ^\_\ WYD_^)K[U^!M]96GPUT."ZO+6VG2XU<O#<7$4,JA
MM7O64M'(ZNH92&7(&5((R"*[/_A6O@C_ * 47_@9J/\ \F4?\*U\$?\ 0"B_
M\#-1_P#DRO+S;B">:8:&'EA8T5"M&MSQJN;;C"I#ELX1LG[1N]^B5NIW9?E,
M<!6E65>55RI2I<KIJ-N:5.5[J4MG"UK==]->I_M;2O\ H)Z?_P"!MM_\<H_M
M;2O^@GI__@;;?_'*Y;_A6O@C_H!1?^!FH_\ R91_PK7P1_T HO\ P,U'_P"3
M*^>/8.I_M;2O^@GI_P#X&VW_ ,<H_M;2O^@GI_\ X&VW_P <KEO^%:^"/^@%
M%_X&:C_\F4?\*U\$?] *+_P,U'_Y,H ZG^UM*_Z">G_^!MM_\<H_M;2O^@GI
M_P#X&VW_ ,<KEO\ A6O@C_H!1?\ @9J/_P F4?\ "M?!'_0"B_\  S4?_DR@
M#J?[6TK_ *">G_\ @;;?_'*/[6TK_H)Z?_X&VW_QRN6_X5KX(_Z 47_@9J/_
M ,F4?\*U\$?] *+_ ,#-1_\ DR@#J?[6TK_H)Z?_ .!MM_\ '*/[6TK_ *">
MG_\ @;;?_'*Y;_A6O@C_ * 47_@9J/\ \F4?\*U\$?\ 0"B_\#-1_P#DR@#N
M:*** "L?Q#HEKXET+6/#U[=:Q8V>MZ;>Z5=7GA[7=8\,:[;6]];R6TT^C^(_
M#][INO:%J4<<C-9ZOHVH6.J:?<".ZL;NWN8HI4^9/VP/V>/BG^TCX!\.>$/A
M-^U9\6OV1]=T7Q?;^)-0\=_!^P\.:AK_ (ATF'1=9TQ_"6I1>);>YLTT>>\U
M.TUF22!%N1>Z/9J&\II :/[*?P+^('[*?PO\::5\<OVO/B7^U#(_B'4_&\WQ
M1^.D?A7P_>>"O"]KX>TJVN]"%SHL=CI-KX9TMM'U'Q%<7^H.AMY=3U"2>9+:
M)2H!^7O_  05T6/PQ=?\%:_"5OJWB?7+#P;_ ,%<OVI_!>DZIXU\6>)/'?BR
MYT/P=:^"_#.@CQ#XT\8ZIK?BOQ3JL&C:58VUWKOB/6-3UK4I(3=:C?75U)+,
M^/\ \%ZO!-C;:G_P2[^)UOX@\?V^MW7_  5@_8N^&U[X?@^)'CN#X;7_ (:O
MM2^(7B^6;4/A1%XA3X;W_B>+7?"VC36?C2[\+S>+;&TMY=+M-:ATRZN;26C_
M ,$%?BM\+_&7CS_@KQ8>$?B-X%\3ZAXI_P""LG[6GQ0\-:=H/BS0=6U#Q!\-
M?$NK>'E\._$'1K"QOY[O4O!.NM'(FD>*;2&;1-1>.1+2^F>-U5__  <'_%/X
M9>%=)_X)@^&?%'Q$\#^'/$6F?\%8OV0/BGJ>AZ]XKT+2-6TWX9>%K;XKZ?XE
M^(FHV&H7UO=6/@?P_?:A96>L^*[N*'0M-N;J&&[OH9'"T ?07_!=3]HGXO\
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M:_J6ARS:%J'B7Q#JZZ9J.H7$6NI: '[\4444 %%%% !1110 4444 >;?$_\
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M'[2_[+WC?]B[]LOX.^&+7XAZK\'_ !/XKTSXE>%/'/PKN-3T_P .O\1?AO\
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MK_Q4\4:9<RQS6VF?'CXO:DGBGX>6M]:Z=K5K\*=!\*ZSJ%O:7/BZ?3]/]/\
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M^+WBJT72]6^(?CC7M4O_ !'XP\41^'H;_5+'P=H>I>(]7U.3PMX#T>_N= \
M^&!H_@OP\ZZ'H6GQI[+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YM\
M3_\ D#Z+_P!C3I'_ *#=UZ37FWQ/_P"0/HO_ &-.D?\ H-W7I- 'G?PK_P"1
M)TO_ *[:C_Z<+FO1*\[^%?\ R).E_P#7;4?_ $X7->B4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 >;?$_\ Y ^B_P#8TZ1_Z#=UZ37FWQ/_ .0/HO\
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M=VVGZA:0>/M;N].\+ZC M]>6UG::GIFJ7FEZG=3)!IE[=RG: #Z=HKY0U_\
M;G_9&\*_ KP#^TWXG^/?@/P]\!/BCKNA^&OA[\4=:O;O3/#/BS6_$M]J.GZ'
M9:3->64-U,-1ET?5;F&Z>UCLUTO3KW6IKB/1[::^3ZOH **** "BBN-NOB'X
M&L/'>D_#'4/%>AZ?\0O$/A[4O%?ASP?J%_!8Z]XE\.Z)=V]CX@U?PU87;0R^
M(K3PU=7VE1^*&T47S^&1KOAV37DTZ+Q'H3Z@ =E1110 4444 %%%% !1110
M4444 >;?$_\ Y ^B_P#8TZ1_Z#=UZ37FWQ/_ .0/HO\ V-.D?^@W=>DT >=_
M"O\ Y$G2_P#KMJ/_ *<+FO1*\[^%?_(DZ7_UVU'_ -.%S7HE !1110 4444
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M'XJ_^##3/_E77N7_  XT_P""E7_1#M"_\.]\(_\ YM:/^'&G_!2K_HAVA?\
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MC>"_$_C#4?#EEJ.K6W@G[-X7;PUJ\OB&>VN?$_ANRU?J_!_@N?XM_P#!2?\
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MO;?1K7Q9%K-OI*S7-YNTZ.VDCOK^)TO)_P O_P#@I;\6-:_X*-?LW:E^P?\
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MQ-^R;\'_ (&?\%)OV=TM/!?[3?P"^/'P\\&:QXVT^6?2C\2?@/XKB\376O\
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MW3IIX(II;"\D^-_@/3GN[*21&>UN7T^_OK%YX#'*UG>W=J7,%S,C_1_[:?\
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M ?I'_P %$?VL[3]AG]BC]HG]JJXTN/6[[X3> WO/"VCW";[#5?'_ (IUC2O
MWPWT[5]MW8S)H5YX^\3^&[?7Y;2X6^AT62_FL(KB]2"WE^/OA3XUUO\ X)R_
M\$G=-_:/USX7^-_VBOBLWPBU#]K/]IV\TC7/AUX9\6^-?BQ\0/!=S\6_BU\0
M/'OBCQ+K6CV\VAZ!>^7X)T]O#.G^.?%.A^"M%\&>&_"7@K6-"\/6]GIW;?\
M!<'X >)OVE_^"5W[87PP\%:7J6M^,(OA_I/Q&\.:/HUK/J&L:Q??!WQMX7^*
M]QHNDZ9;;KC5-4US2_!NH:+I^FVT-S>7MWJ$,&GVT^H/:H>9^.7Q6U+XY_\
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M,_LL?M$Z[X4\!6W[1?[/WASP3\+8?$&K:;\,[B&SU'4/$%A<6GB#2&!U3P8
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M^(/_ $($/_A3:5_\51_;_P 0?^A A_\ "FTK_P"*H ]$HKSO^W_B#_T($/\
MX4VE?_%4?V_\0?\ H0(?_"FTK_XJ@#T2BO._[?\ B#_T($/_ (4VE?\ Q5']
MO_$'_H0(?_"FTK_XJ@#T2BO._P"W_B#_ -"!#_X4VE?_ !5']O\ Q!_Z$"'_
M ,*;2O\ XJ@#T2BO._[?^(/_ $($/_A3:5_\51_;_P 0?^A A_\ "FTK_P"*
MH ]$HKSO^W_B#_T($/\ X4VE?_%4?V_\0?\ H0(?_"FTK_XJ@#T2BO._[?\
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M^(/_ $($/_A3:5_\51_;_P 0?^A A_\ "FTK_P"*H ]$HKSO^W_B#_T($/\
MX4VE?_%4?V_\0?\ H0(?_"FTK_XJ@#T2BO._[?\ B#_T($/_ (4VE?\ Q5']
MO_$'_H0(?_"FTK_XJ@#T2BO._P"W_B#_ -"!#_X4VE?_ !5']O\ Q!_Z$"'_
M ,*;2O\ XJ@#T2BO._[?^(/_ $($/_A3:5_\51_;_P 0?^A A_\ "FTK_P"*
MH ]$HKSO^W_B#_T($/\ X4VE?_%4?V_\0?\ H0(?_"FTK_XJ@#T2BO._[?\
MB#_T($/_ (4VE?\ Q5']O_$'_H0(?_"FTK_XJ@#T2BO._P"W_B#_ -"!#_X4
MVE?_ !5']O\ Q!_Z$"'_ ,*;2O\ XJ@#T2BO._[?^(/_ $($/_A3:5_\51_;
M_P 0?^A A_\ "FTK_P"*H ]$HKSO^W_B#_T($/\ X4VE?_%4?V_\0?\ H0(?
M_"FTK_XJ@#T2BO._[?\ B#_T($/_ (4VE?\ Q5']O_$'_H0(?_"FTK_XJ@#T
M2BO._P"W_B#_ -"!#_X4VE?_ !5']O\ Q!_Z$"'_ ,*;2O\ XJ@#T2BO._[?
M^(/_ $($/_A3:5_\51_;_P 0?^A A_\ "FTK_P"*H ]$HKSO^W_B#_T($/\
MX4VE?_%4?V_\0?\ H0(?_"FTK_XJ@#T2BO._[?\ B#_T($/_ (4VE?\ Q5']
MO_$'_H0(?_"FTK_XJ@#T2BO._P"W_B#_ -"!#_X4VE?_ !5']O\ Q!_Z$"'_
M ,*;2O\ XJ@#T2BO._[?^(/_ $($/_A3:5_\51_;_P 0?^A A_\ "FTK_P"*
MH ]$HKSO^W_B#_T($/\ X4VE?_%4?V_\0?\ H0(?_"FTK_XJ@#T2BO._[?\
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M^(/_ $($/_A3:5_\51_;_P 0?^A A_\ "FTK_P"*H ]$HKSO^W_B#_T($/\
MX4VE?_%4?V_\0?\ H0(?_"FTK_XJ@#T2BO._[?\ B#_T($/_ (4VE?\ Q5']
MO_$'_H0(?_"FTK_XJ@#T2BO._P"W_B#_ -"!#_X4VE?_ !5']O\ Q!_Z$"'_
M ,*;2O\ XJ@#T2BO._[?^(/_ $($/_A3:5_\51_;_P 0?^A A_\ "FTK_P"*
MH ]$HKSO^W_B#_T($/\ X4VE?_%4?V_\0?\ H0(?_"FTK_XJ@#T2BO._[?\
MB#_T($/_ (4VE?\ Q5']O_$'_H0(?_"FTK_XJ@#T2BO._P"W_B#_ -"!#_X4
MVE?_ !5']O\ Q!_Z$"'_ ,*;2O\ XJ@#T2BO._[?^(/_ $($/_A3:5_\51_;
M_P 0?^A A_\ "FTK_P"*H ]$HKSO^W_B#_T($/\ X4VE?_%4?V_\0?\ H0(?
M_"FTK_XJ@#T2BO._[?\ B#_T($/_ (4VE?\ Q5']O_$'_H0(?_"FTK_XJ@#T
M2BO._P"W_B#_ -"!#_X4VE?_ !5']O\ Q!_Z$"'_ ,*;2O\ XJ@#T2BO._[?
M^(/_ $($/_A3:5_\51_;_P 0?^A A_\ "FTK_P"*H ]$HKSO^W_B#_T($/\
MX4VE?_%4?V_\0?\ H0(?_"FTK_XJ@#T2BO._[?\ B#_T($/_ (4VE?\ Q5']
MO_$'_H0(?_"FTK_XJ@#T2BO._P"W_B#_ -"!#_X4VE?_ !5']O\ Q!_Z$"'_
M ,*;2O\ XJ@#T2BO._[?^(/_ $($/_A3:5_\51_;_P 0?^A A_\ "FTK_P"*
MH ]$HKSO^W_B#_T($/\ X4VE?_%4?V_\0?\ H0(?_"FTK_XJ@#T2BO._[?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
G "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ny20006478x8_graphic01.jpg
<TEXT>
begin 644 ny20006478x8_graphic01.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M4I2P.%<I2>%I-MMTKMMZMO5O5GY_5JU55JI5*EO:3^W+^9^9]6?\-W_MP_\
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MU9_XD/\ %W_YL*/^&[_VX?\ H\K]JS_Q(?XN_P#S85\IT4?V+DW_ $*<L_\
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M]'E?M6?^)#_%W_YL*/\ AN_]N'_H\K]JS_Q(?XN__-A7RG11_8N3?]"G+/\
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MS_Q(?XN__-A7RG11_8N3?]"G+/\ P@PO_P J#VU7_G[4_P# Y?YGU9_PW?\
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M$T?^4A7[$_\ V=!\%/\ U/\ 0Z\^_;:_Y/-_:Y_[.=^/?_JU?%=?-QRC*?\
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ME.BC^Q<F_P"A3EG_ (087_Y4'MJO_/VI_P"!R_S/JS_AN_\ ;A_Z/*_:L_\
M$A_B[_\ -A1_PW?^W#_T>5^U9_XD/\7?_FPKY3HH_L7)O^A3EG_A!A?_ )4'
MMJO_ #]J?^!R_P SZL_X;O\ VX?^CROVK/\ Q(?XN_\ S84?\-W_ +</_1Y7
M[5G_ (D/\7?_ )L*^4Z*/[%R;_H4Y9_X087_ .5![:K_ ,_:G_@<O\SZL_X;
MO_;A_P"CROVK/_$A_B[_ /-A1_PW?^W#_P!'E?M6?^)#_%W_ .;"OE.BC^Q<
MF_Z%.6?^$&%_^5![:K_S]J?^!R_S/JS_ (;O_;A_Z/*_:L_\2'^+O_S84?\
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M $>5^U9_XD/\7?\ YL*^4Z*/[%R;_H4Y9_X087_Y4'MJO_/VI_X'+_,^K/\
MAN_]N'_H\K]JS_Q(?XN__-A1_P -W_MP_P#1Y7[5G_B0_P 7?_FPKY3HH_L7
M)O\ H4Y9_P"$&%_^5![:K_S]J?\ @<O\SZL_X;O_ &X?^CROVK/_ !(?XN__
M #84?\-W_MP_]'E?M6?^)#_%W_YL*^4Z*/[%R;_H4Y9_X087_P"5![:K_P _
M:G_@<O\ ,^K/^&[_ -N'_H\K]JS_ ,2'^+O_ ,V%'_#=_P"W#_T>5^U9_P")
M#_%W_P";"OE.BC^Q<F_Z%.6?^$&%_P#E0>VJ_P#/VI_X'+_,^K/^&[_VX?\
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MA_B[_P#-A1_PW?\ MP_]'E?M6?\ B0_Q=_\ FPKY3HH_L7)O^A3EG_A!A?\
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MY3HH_L7)O^A3EG_A!A?_ )4'MJO_ #]J?^!R_P SZL_X;O\ VX?^CROVK/\
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MN'_H\K]JS_Q(?XN__-A1_P -W_MP_P#1Y7[5G_B0_P 7?_FPKY3HH_L7)O\
MH4Y9_P"$&%_^5![:K_S]J?\ @<O\SZL_X;O_ &X?^CROVK/_ !(?XN__ #84
M?\-W_MP_]'E?M6?^)#_%W_YL*^4Z*/[%R;_H4Y9_X087_P"5![:K_P _:G_@
M<O\ ,^K/^&[_ -N'_H\K]JS_ ,2'^+O_ ,V%?J=_P13_ &K/VHOBK_P4U_9H
M\!?%#]I+X^?$CP+KW_"Y/[<\%^/?C%\0_&'A/6?[+_9_^*NLZ9_:WASQ#XBU
M'1]1_L[6-.T_5K'[99S?9-2L;.^M_+NK6"5/P%K]?O\ @@K_ ,I8?V4_^ZY_
M^LV_&&OF^,LHRFEPAQ54IY7EU.I3X;SR=.I#!8:$X3AEF*E&<)QI*491DE*,
MHM.+2:::-\+5JO%89.I4:>(HIISDTTZD;IJ^J9\6_P##=_[</_1Y7[5G_B0_
MQ=_^;"C_ (;O_;A_Z/*_:L_\2'^+O_S85\IT5])_8N3?]"G+/_"#"_\ RHP]
MM5_Y^U/_  .7^9]6?\-W_MP_]'E?M6?^)#_%W_YL*/\ AN_]N'_H\K]JS_Q(
M?XN__-A7RG11_8N3?]"G+/\ P@PO_P J#VU7_G[4_P# Y?YGU9_PW?\ MP_]
M'E?M6?\ B0_Q=_\ FPH_X;O_ &X?^CROVK/_ !(?XN__ #85\IT4?V+DW_0I
MRS_P@PO_ ,J#VU7_ )^U/_ Y?YGU9_PW?^W#_P!'E?M6?^)#_%W_ .;"C_AN
M_P#;A_Z/*_:L_P#$A_B[_P#-A7RG11_8N3?]"G+/_"#"_P#RH/;5?^?M3_P.
M7^9]6?\ #=_[</\ T>5^U9_XD/\ %W_YL*/^&[_VX?\ H\K]JS_Q(?XN_P#S
M85\IT4?V+DW_ $*<L_\ "#"__*@]M5_Y^U/_  .7^9]6?\-W_MP_]'E?M6?^
M)#_%W_YL*_H>_P"#;;]HG]H'XV?MD?%CP_\ &;XZ?&/XN:#H_P"S]?:_I&B?
M$[XG>-?'ND:5KL'Q1^&5E!K>FZ;XJUO5K*QU>&SOKVTBU*UABO([:\NH$F6*
MXE1_Y-:_IG_X-:/^3W_C5_V;1J?_ *MOX4U\/XE95E=#@7B2K1RW 4:L, G"
MK2P>'IU(/ZQ15XSA34HNS:NFG9G;EU2I+'892J3:=35.<FG[KW3=C^^&BBBO
MX:/MS_)C_;O_ .3X?VRO^SK/VA__ %;OC"OE.OJS]N__ )/A_;*_[.L_:'_]
M6[XPKY3K_1W)?^1-E/\ V+,!_P"HM(_.ZW\6K_U\G_Z4PHHHKTS,**** "BB
MB@ HHHH **** "BOUM_8K_87_9P^,7[&G[3_ .V;^TG\5OC'X"\$?LV_$#X7
M>#=4TCX/>#_!_B_7-2L_B?K_ (:\)V>K)8^+=<\/6\@TG6_%6GW.I11:G'.-
M$M[^>QMM1U*.UTV[=^U=_P $L]3^'G@G]FCXV?L8_$'Q;^VW\#OVL[[QMH/P
MKU'P7\&?&6@_$R'QAX"_M(Z[X0U/X;Q'7=?U*_6+PYXUGMKO2[-&>#P+XJN;
MO3;+3[*QO]3^=_UJR6.95<KJ8BM0KTL94R^5:OA,52P#QU++Z>:U,(LQE26"
MCB(Y?46*5*=>$JE.,_9J;IS4>CZK6=-55%2BX*I:,HN?(ZCI*?LT^?E]HG&Z
MB[.U[)IGY(45Z[XF_9^^//@I? +>,O@E\7/"2_%6_O\ 2_A>?$WPW\9:#_PL
MC4]*OM,TS4].\!?VIHUK_P )??:=J6M:/I]]:^'O[1GM;[5=-M)XX[B]MHY=
M[XN_LJ_M.? #2M'UWXZ?L[_&[X-Z)XAN18Z'K/Q0^%GC?P)I6JZ@;>6[;2['
M4/$VB:9:3ZM':PRW,VE),=1@MT:::VCC&ZO86.P4I481QF%<\0ZD</!8BBY5
MY492A55&*G>JZ4XRC44%)PE&496::,O9SLWR3M&SD^5VBFKIMVTNFFK[IW1X
M)17U+\$?V1_CG\6U\%^/8/@C\;=2_9_U3XA^%_"'BWXR>&/ASXKN_ FAV6I^
M)M.T+7)F\?+X>U'PCI]UI2WC13W%_<3VNF7\EG%J4.ZXAMY_H/\ ;V_8)UO]
MG[]K_P#:P^"G[.'@?XX_%CX/_LP)X/U3Q7XXN?#5WX[O_!'ACQ%\-M \:W/B
M#XH^)O G@[1?"_AK2A=W7B'['JNI:5X?T\:9I$WF23R6%]=MQRSS+(9BLK>+
MI?6GAL1BIVJ4W2I1PN)P6$J4JU3GM2Q#KYAA80HSM.?M-%>R=>PJ^S]IR/EY
MHQ6CN^:,YIQ5M8\M.3<EHK'YKT5W]U\*/BE8_#?3OC)>_#7Q_9_"#6/$TG@O
M2/BK=>#O$5O\-]4\8Q6E_?R^$].\<RZ<GAB^\31V.EZG>R:#;:I+JB6FG7]R
MUJ(;.X>/T36/V2OVJ?#W@;PU\3M>_9J^/FB_#CQE-H,'A+QYJOP@^(&G^#_$
MTOBLV:^%$T'Q'=^'XM)U;_A*6U"R3PRUC=SKX@>YC31S>N2H[98W!P<5/%X:
M#G6EAX*5>E%RKP^.A%.:<JT/M4U><>L40H3=[1D[)2=HO2+VD]-$^CV/GRBO
MO+]IC_@FO^U]^R?\//AI\4/BU\'/'NG>#/'_ ,-?#GQ&US7K?P#X_31/A%+X
MK\2ZEX;T3X??%_7]3\+:=H/@CXESRVFF7=SX.U#4CJ5@/$>B:==I%J\\MA%\
M&U&!S# YE0^LY?BJ&,P_M*E+VV'J1JT_:4I.-2#E%M*47T>\7&2O&46W.G.G
M+EJ1E"5D[25G9JZ?W?C=/5-!111780%%%% !1110 4444 %%%% 'V]_P31_Y
M2%?L3_\ 9T'P4_\ 4_T.O/OVVO\ D\W]KG_LYWX]_P#JU?%=>@_\$T?^4A7[
M$_\ V=!\%/\ U/\ 0Z\^_;:_Y/-_:Y_[.=^/?_JU?%=?,Q_Y+*K_ -DS0_\
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M]U:W$4<]O/&\4L:2(RBC78FFDTTTTFFG=-/5--:--;,@****8!1110 4444
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MO*+Y?=6K5WW7QZ_X(Z_#;2O@I^TMX]_99^.OQ/\ BCX[_8JEO[KX^>&OB_\
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MLC*. SB,,P' )('%9M>A%J45);22:]&KK\#/8_7W_@I!_P FG_\ !)'_ +-
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M<SC["$N?EE6YDX^RBW/F37+='/[.=VN2=TN9KE=U'?F:MM;6^QX+17M_PO\
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MS?\ *-O_ ((Y?]D^_;"_]7YIM?D)7Z]_MS?\HV_^".7_ &3[]L+_ -7YIM?
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M]3^^&BBBOX=/MC_)C_;O_P"3X?VRO^SK/VA__5N^,*^4Z^K/V[_^3X?VRO\
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MW[;7_)YO[7/_ &<[\>__ %:OBNO0?^":/_*0K]B?_LZ#X*?^I_H=>??MM?\
M)YO[7/\ V<[\>_\ U:OBNOF8_P#)95?^R9H?^K7$'0_]TC_V$2_]-P/F*BBB
MOICG"BBB@ HHHH **** "BBB@ K];_\ @A+_ ,I8?V0/^QC^)'_JD_B77Y(5
MTW@[QKXR^'?B72_&?P_\6^)O OC#1)+B71?%?@[7M5\,>)=(EN[2XT^ZDTO7
M=$N['5-/DN;"[NK*X>TNHFFM+FXMI"T,TB-YF=X"6:Y-F^5PJ1HSS++,?@(5
MIQ<HTI8S"U</&I**:<HP=12<4TVDTFFS6A45&O1JM.2I5:=1I:-J$U)I/N[6
M/ZAOAC\:OB5^S[^SY_P<D_%7X2>)]0\&_$#0/VL/AOI7A[Q1I4KV^K>'SX[_
M &K?B7X!UG5=$NXV6;3-<@T'Q)J#:1J]H\5]I.II9:E92Q7=G!(GJWPR^*T'
MQF\&?\&TOQ;_ &KO%6L?$37]8^/G[6.@ZEX\\9WS^(O$^L^*/#7QDT[P9\%Y
M?$/B'7I;O4-3:V\8^'_ARFI:EJ5W/=SBQ.HSS27JB:OY.W^*WQ1DTOQ_H<GQ
M)\?/HOQ7U6RUSXI:._C'Q$VE_$K6]-UB7Q#IVL>/]/;43:>,=5L-?FFURRU#
MQ%#J-W:ZQ-+J<$T=[(\YH:G\0?'NM>%_"7@?6/&_B_5O!?@&769_ OA#4_$N
MLW_A?P5/XCO_ .U?$,WA+P_=7LND^')==U0#4M9DT>TLWU2_'VR^,]Q^\KXB
MMX?1KNM4>*P]'%5\QE7GCZ.&MC88&? LN$GA*=9M3]S&3EF<(N:I6M%Q]I[Y
MVK,.7E7)*4(TTO9RE[CJ+'+%\S6VL%[.]K]=M#^V[_@G7!_P4@@_X*C?\%!H
M/VF;C]H>;X#)X>_:-DT.?XA0^/X_@;=Z\?B7HW_"L7^#B>,#<>'+:TE^'TVL
M7'A.V\%W >+P$LD-P[Z?$J'X"^!$_P ,K7]@W_@@9<_&-[*+X;P?\%#?BA+X
MDFU:33XM"@1/C)XD;2Y_$LNK/'ID?A2#6QILOBI[]Q:+X=34S/F,,I_GMU;]
ML;]KK7]5T#7==_:H_:/UK6_"FE:KH/A?6=6^.'Q-U+5?#>AZ[':1:YHV@:A>
M>)YKO1]*UF*PL8M5T[3IK:SU&.RM$NX9EMX0GD.H?$/Q_J_@WP_\.M5\<^,-
M3^'WA*^U'4_"O@34/$VM7O@WPSJ6L337&K:AX?\ #%S>RZ)HU]JD]Q<3ZC=Z
M=8VUQ>S3S2W,DKRNS<E+P]QDJTJU?&Y=@W5>4*I#*<'5P\:<<LR+B+)95*3E
M4UKUO[:HXF$VH*E]7=#W[0JNWF$%'EC"I.WM;.K-2;=2OA:R3LM(KV$HM:WY
MD]-4OZ3_ -NW1_\ @KTWCW_@JKI'C'Q/XM\/?L/:M\<X+7QEJ'[1,_AR^^$U
MM\(O%'Q1UI_@5>_ V7XF:?K%G#_9>CS^#CJJ? 55\::5K,/@U-:A3Q;INB&S
M_<[X!? _7?A_^UO\?/@%\0?$'[?GQ_T'2/V*+GP/\0_C-\?==\.>'?V*_'MG
MJ_AGP#;:+X$^#'PG\'^!M.\/W^OP>'K_ ,0V=SJLOBN3Q#H3:-\3-/U&3Q#)
MJEWK<_\  ]XW_:6_:-^)G@K1_AM\1_C_ /&SX@?#KPZ]G)X?\ ^-_BKX[\5^
M"M"?3H&MM/?1_"NO:]?Z%ICV-L[6]FUE80&V@9HH"D;%3O2_M@?M:S3>'[B;
M]J/]HJ6?PGH&I>%/"L\OQM^)<DWAGPOK+Z:^L>&_#\C>)B^C:!JSZ-H[ZEH^
MG-;:=?/I6FM=6TIL;4Q<N8^'>:YAEN'P$<9D& ]EA\1AZDLNRJKA75J?5<FP
M^%Q]6M"M]9JXJ/\ 9=15*?M:=!4JV%C*.(EE].5:J>8TJ=5U'"O4O*,OWM53
MLN>K*=-1:Y5']XK.SE>,]8JHU']XU\7?M-?$S_@W1^'B?!CQ3\=/'FN_#K]L
M3Q3X1^+,?PVU[Q[XDUCP;^SKX=^"7Q+&I^%O'4?AJ[N[[1O@QH&@:KX,;4-"
MUM8/!.DZ)=Z!)=6EOIQLF'Z&?LWW/PWMO^"B7_!$P>.FLH_$ES_P1+^#EK\&
M)]34MI</Q:F\ ^*A8F^&Y%/G>"%\=6VGIYT$\VL3Z=!8R?VC+9H_\;'@CXX_
M&OX9>&O&/@SX;_&#XI?#[P?\1+&32_B!X4\$?$#Q9X3\->.M,FL[G3YM.\8Z
M%H.KV&E^)[&6PO+NQDM-;M;ZW>SNKFV:,PSRHV-K'Q/^)?B*\\%ZCX@^(?CG
M7=0^&^BZ%X;^'=]K'BW7]3O/ 7AWPO+Y_AG0?!=U>ZA//X6T7P[/^^T+2]#>
MQL=(E_>:?!;OS7HXSP_K8N.:X:..PV%P^/Q7$F)I5</AIQQ,%Q#@98=TZZ4X
MTZL,)6DTHQE!5L,Y4VZ<IMK.&/C!TI<DYRA##1<923@WAZD97CI=.:CO9VE9
MZI'],/[)ME^W;H7P#_X+#7W_  4D/Q_3X&O^R7\3]-OV_:7C\37/A;5_VIKW
M4K32OA'>?#&;XA6\VDWOBJ+7X;>U\/:GX"D.C6FJ7'PWGG=57P--![!^T[^U
M-\?/V>O@'_P;OZ+\&/B;XL^'6C>,/AI\)]8\?Z7X3UO5-!L_B1;^&A\ +#1O
M#7C]=(O+*7Q3X-MK+Q-XHMI?">HRR:)?1^)-6-_:74CVCVG\O?Q-_:D_::^-
M?A_3O"?QE_:+^.WQ:\+:1=P7^D^&OB;\7?B!X\\/Z7?6UO+:6U[IVC>*O$.J
MZ=97=O:3SVL%S;6T4T5O-+#&ZQR.IXO6_BW\5O$MIX$L/$?Q-^(7B"Q^%MK#
M8_#&RUOQIXDU6T^'-C;G3S;V?@2VO]2N(?"%K =)THPV_A]-/AB.F:>41396
MWEM<!5<5CZ6/S&63\OUVOB:^68/ SCEO*^':F1X?V=*LY)UU5G'%U*LH1Y84
MJ%&G'FH1K2/KZA3E3I^VO[.,8U9U/WEUB(UI7:^SRIP23ZMO232_3_\ X+WZ
M1IFB?\%:OVNK/2;&WT^UFU'X/:O+!:QB**34]?\ V>_A-KVM7S*.#<:GK.I7
M^I7DG66[NYY6^9S7X_5U/C7QUXV^)7B;4_&OQ&\8^*O'_C+6OL7]L>+?&OB'
M5_%7B;5O[.T^TTG3_P"T]>UV\O\ 5;_[!I5A8Z99?:KN7[+I]G:64'EVUO#&
MG+5]SD>7U,IR3)\KJU57JY;E>7Y?4KQ4HQK5,'A*.'G5BI-R2J2IN:4FY)2L
MVWJ<->HJM:M52Y54JU*BC_*IS<DM--$[:!1117J&04444 %%%% !1110 444
M4 >O_L]_\E\^!_\ V5_X:?\ J::+7U__ ,%>?^4EO[8__98-2_\ 35I-?('[
M/?\ R7SX'_\ 97_AI_ZFFBU]?_\ !7G_ )26_MC_ /98-2_]-6DU\S6_Y+++
M_P#LF<X_]6N1G0O]TG_V$4O_ $W6/SAKUVW^ OQBN_@]!^T!;?#[Q!-\&;GX
MBQ?"2#XAI!"?#TOQ)FTE==B\'I-YXG.KOI#+?K']G$1@(/F[OEK]F?#/[*W_
M  3?_99_9V_8G\0?MZ>'_C?XO\<?MW^#_$?Q%U/Q_P#"GQ]!H%A^R[\+)]3T
M:U\ >+])\&0>&->F^(NLZGI6K6^MZY::O::O%9+#K=EI?AO6KS3=/M-7Z/Q!
MH/@NP_X(5:QX9\!>+;[QS\/;3_@LI>Z)X.\<7.AW7@_5/%O@^+X-R66@>)[K
MPW=7-[=^&-1UK1EM=3N-%EO;V;1KJX>R-Y=FW^T2>?B.,83GA%@,%BW0KY]A
M\I^O8O#2C@<52>*QF!Q=; 5Z59\U3#XK!U*:AB8T*E2'+7I4:N&J0K/6.#:4
M_:3CS1H.KR1DN>+Y:<X*I%QT4HU$VX\R33BVI)H_#?XR_!3XJ_L]?$+6OA1\
M:O ^M_#GXC>'8=*N-;\(^(HH8-6TV'7-*L]<TF2XC@FN(@M_I.H65_ 5E;,%
MQ&6VL2H\NK^JSQ9_P3"_9.\4_P#!3S_@HM\ /B5XL^+MI\*?V>OV)8_CCX9\
M?:WXWU;QSXX\*^)+3P!\)M4N?%6MW^M3QW?C;3_#4/BC6KVT\+:A?V5I=VUI
M9:2;RUMXDD3X?_:8_9._82^(/_!,^R_;R_8E\._'/X<7'PR_:3/[.GQ+\+?&
MWQ?H?BN^\7VMSH-KKNG^+]VA6*Z=8^));3Q)X$O)[309-)\/6@U3Q/I(TZ_E
MTC3-9O\ ++>/,MQ:RFC4HXZ=;,*61JIC*6!]EE]+$Y_@EC,OA4Y\77JT5B;3
MIQIQEB70J<L*]7EE"M4=3 U(>UDG32INM:#G>HXT)\E2UH13Y;IM^ZFG[JO=
M+\A/C+\%/BK^SU\0M:^%'QJ\#ZW\.?B-X=ATJXUOPCXBBA@U;38=<TJSUS29
M+B.":XB"W^DZA97\!65LP7$9;:Q*CRZOZ@_C!_P2[^ 9_P""DG[?-GX_UCXV
M:S^R7^PI^S+X;_:'\?(WCM_$OQ8^(&J-\'O#7B[0?A@GQ!\717TU@?%=Q;^*
MWM-0GBDFM-*\/)H-A<:4UW!K>E? &J_##_@FK^T#\;?V36_9:\#?MH2V/Q1O
M/&4O[2O['_PKT)?C7\9OA_\ \(Y#-?:)IGP,\6^(]+\.:3XQTO6]/TO5M4U[
M7/$.N:S<>$?"I@\3:C E[:ZQX9TK;+>-<%C<-A:BP^/Q-\HP>9X[&X7 \N!P
M<\7E3S:E0Q"EBJU;"5*^$BZE)5)5L/3E4H8>KC?;5J2J*I@IPE).5./[V=.$
M)3O.?+55)RC:"4U&;L[6D[2DH6BVOQ[KU'XR_!3XJ_L]?$+6OA1\:O ^M_#G
MXC>'8=*N-;\(^(HH8-6TV'7-*L]<TF2XC@FN(@M_I.H65_ 5E;,%Q&6VL2H_
M<[_@H/\ \$V?@G\._P!A^\_:Y^&'P,^*/[)?CSX;_M Z/\$/B'\!?B;\;O!G
MQONM2\,:_P"#]*\0^'/'&I7?A>34-3^'_P 0-177_#=YK?P\\17FFW6DV^H:
ME*FB1:4?#.JZYXE_P<.?\I8OVB?^Q?\ @?\ ^J/^'U7E/%^&SS,LNPV7T_\
M9<3@^(*F*=9TIUZ&,R;$\/4J=*%7"8G$X*K1JT<ZE5=2C6KPFE1<*L6JD6JN
M$E0IU)5'[T)X=1Y;\LHUHUVVU*,9IQ=&UI1B[WNFK,XCQ%_R@G^'/_:3WQC_
M .LUVE?D)7Z]^(O^4$_PY_[2>^,?_6:[2OR$KLX8^#//^RFSK_U(B9XC>C_V
M#T?_ $A'[)?\&_G_ "ET_9*_[KS_ .LR_&>NA_:6_P""D_AWX>:+^V%^S/\
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M*_0(1Y(0C>_+&,;]^5)7^=CSV[MON[GZ^_\ !2#_ )-/_P""2/\ V:!XA_\
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MM/O+NRG\RVN)HWFT+XA>/O"^G^+=)\,^./&'AW2O'^FC1_'>F:%XEUK2-/\
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MXFMX'\'OJ!T"+2=#DD6_2V&KH;8SS?&/A;]N&R\.?\$TOB1_P3\;X;W5W?\
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M^(@<;_\ 159[_P"''$?_ "?E^?=A_9^"_P"@:C_X!'_+^KORM_/I_P 0T_\
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MJ]+ENY<O)&W-[JO:V[6C_P"&/Y_?^(:?_@FS_P! 'XM_^'6UC_Y H_XAI_\
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M * /Q;_\.MK'_P @4?\ $-/_ ,$V?^@#\6__  ZVL?\ R!7]!=%'_$0.-_\
MHJL]_P##CB/_ )/R_/NP_L_!?] U'_P"/^7]7?E;^?3_ (AI_P#@FS_T ?BW
M_P"'6UC_ .0*/^(:?_@FS_T ?BW_ .'6UC_Y K^@NBC_ (B!QO\ ]%5GO_AQ
MQ'_R?E^?=A_9^"_Z!J/_ (!'_+^KORM_/I_Q#3_\$V?^@#\6_P#PZVL?_(%'
M_$-/_P $V?\ H _%O_PZVL?_ "!7]!=%'_$0.-_^BJSW_P ..(_^3\OS[L/[
M/P7_ $#4?_ (_P"7]7?E;^?3_B&G_P"";/\ T ?BW_X=;6/_ ) H_P"(:?\
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M XW_ .BJSW_PXXC_ .3\OS[L/[/P7_0-1_\  (_Y?U=^5OY]/^(:?_@FS_T
M?BW_ .'6UC_Y H_XAI_^";/_ $ ?BW_X=;6/_D"OZ"Z*/^(@<;_]%5GO_AQQ
M'_R?E^?=A_9^"_Z!J/\ X!'_ "_J[\K?SZ?\0T__  39_P"@#\6__#K:Q_\
M(%'_ !#3_P#!-G_H _%O_P .MK'_ ,@5_0711_Q$#C?_ **K/?\ PXXC_P"3
M\OS[L/[/P7_0-1_\ C_E_5WY6_GT_P"(:?\ X)L_] 'XM_\ AUM8_P#D"C_B
M&G_X)L_] 'XM_P#AUM8_^0*_H+I#G!VD!L':2"P!QP2H*D@'J RDCC(ZT?\
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M?^@#\6__  ZVL?\ R!1_Q#3_ /!-G_H _%O_ ,.MK'_R!7]!=%+_ (B!QO\
M]%5GO_AQQ'_R?E^?=A_9^"_Z!J/_ (!'_+^KORM^"'AG_@W,_P""=?@OQ)X?
M\8Z+H?Q536/">N:3XETEKCXHZM/;KJ6A7]OJEBT\#6(6:$75K$98F($B!D)
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M^@NBC_B('&__ $56>_\ AQQ'_P GY?GW8?V?@O\ H&H_^ 1_R_J[\K?SZ?\
M$-/_ ,$V?^@#\6__  ZVL?\ R!1_Q#3_ /!-G_H _%O_ ,.MK'_R!7]!=%'_
M !$#C?\ Z*K/?_#CB/\ Y/R_/NP_L_!?] U'_P  C_E_5WY6_%27_@B'^Q1J
M/P)B_8[N-'^('_"G/#'Q-M?VA=.MT^(&J+XB/Q#\2^'=:\ 7LL^N?93)+I"Z
M!HL*PZ9Y")'=O)<F60NJ1^/_ /$-/_P39_Z /Q;_ /#K:Q_\@5^\MI_R.6O?
M]BSX2_\ 3KXUKIJX<OX[XRI4JSI<39U3=7'8^M4Y,?7C[2K+&5E*I.TUS3DH
M14I.[=M6SJQ>78%58)86C987!NW(MY82A.73K*4F[=6_*W\^G_$-/_P39_Z
M/Q;_ /#K:Q_\@4?\0T__  39_P"@#\6__#K:Q_\ (%?T%T5W?\1 XW_Z*K/?
M_#CB/_D_+\^[.7^S\%_T#4?_  "/^7]7?E;^?3_B&G_X)L_] 'XM_P#AUM8_
M^0*/^(:?_@FS_P! 'XM_^'6UC_Y K^@NBC_B('&__159[_X<<1_\GY?GW8?V
M?@O^@:C_ . 1_P OZN_*W\^G_$-/_P $V?\ H _%O_PZVL?_ "!1_P 0T_\
MP39_Z /Q;_\ #K:Q_P#(%?T%T4?\1 XW_P"BJSW_ ,..(_\ D_+\^[#^S\%_
MT#4?_ (_Y?U=^5OY]/\ B&G_ .";/_0!^+?_ (=;6/\ Y H_XAI_^";/_0!^
M+?\ X=;6/_D"OZ"Z*/\ B('&_P#T56>_^''$?_)^7Y]V']GX+_H&H_\ @$?\
MOZN_*W\^G_$-/_P39_Z /Q;_ /#K:Q_\@4?\0T__  39_P"@#\6__#K:Q_\
M(%?T%T4?\1 XW_Z*K/?_  XXC_Y/R_/NP_L_!?\ 0-1_\ C_ )?U=^5OQ5^)
M/_!$3]BCX[^%/A7\-?'FC_$"7PU^S#X9D^%'PQ32OB!JFG7L7A;48M+\87"Z
MW=):R'5K_P#M/6IPEXZ0%;=8X?+)0R2>/?\ $-/_ ,$V?^@#\6__  ZVL?\
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ML_!?] U'_P  C_E_5WY6_GT_XAI_^";/_0!^+?\ X=;6/_D"C_B&G_X)L_\
M0!^+?_AUM8_^0*_H+HH_XB!QO_T56>_^''$?_)^7Y]V']GX+_H&H_P#@$?\
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MQ;_\.MK'_P @5_0711_Q$#C?_HJL]_\ #CB/_D_+\^[#^S\%_P! U'_P"/\
ME_5WY6_GT_XAI_\ @FS_ - 'XM_^'6UC_P"0*/\ B&G_ .";/_0!^+?_ (=;
M6/\ Y K^@NBC_B('&_\ T56>_P#AQQ'_ ,GY?GW8?V?@O^@:C_X!'_+^KORM
M_/I_Q#3_ /!-G_H _%O_ ,.MK'_R!1_Q#3_\$V?^@#\6_P#PZVL?_(%?T%T4
M?\1 XW_Z*K/?_#CB/_D_+\^[#^S\%_T#4?\ P"/^7]7?E;^?3_B&G_X)L_\
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M*+34HMIIIN_5@LNP+QF$3PU*SQ.'3]Q+1U8)[*_W=W;I;\&O^(:?_@FS_P!
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M9^"_Z!J/_@$?\OZN_*W\^G_$-/\ \$V?^@#\6_\ PZVL?_(%'_$-/_P39_Z
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M3G[/'_!9+6O^"DWP)^%/BCQYX&N-"^//@KPRNAV=AX!O_'WA/Q%XHT3X>/\
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MRS^+7Q*^'M[XWF^+,'C[P;H7BJ]T*;X9Z?\ #G7XKN]L+?5H-0\2VUH+'Q,
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MWD?M!_&?XJ_M0^)/AK\/_P#A//AG+_PDFB_$7XJ6OB3P;>_\)7#XRD\$Z/\
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MQ_\ "##?_+A?\14QW_0IPG_A16_^0]?Z6O\ H+?\-<_LN_\ 1Q7P+_\ #N>
M/_E_1_PUS^R[_P!'%? O_P .YX _^7]?Y]-%'_$M^4_]%/F/_A!AO_EP?\14
MQW_0IPG_ (45O_D/7^EK_H+?\-<_LN_]'%? O_P[G@#_ .7]'_#7/[+O_1Q7
MP+_\.YX _P#E_7^?311_Q+?E/_13YC_X08;_ .7!_P 14QW_ $*<)_X45O\
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M8_\ A!AO_EP?\14QW_0IPG_A16_^0]?Z6O\ H+?\-<_LN_\ 1Q7P+_\ #N>
M/_E_1_PUS^R[_P!'%? O_P .YX _^7]?Y]-%'_$M^4_]%/F/_A!AO_EP?\14
MQW_0IPG_ (45O_D/7^EK_H+?\-<_LN_]'%? O_P[G@#_ .7]'_#7/[+O_1Q7
MP+_\.YX _P#E_7^?311_Q+?E/_13YC_X08;_ .7!_P 14QW_ $*<)_X45O\
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M3YC_ .$&&_\ EP?\14QW_0IPG_A16_\ D/7^EK_H+?\ #7/[+O\ T<5\"_\
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M:M]0KMTJJ5M-W3J)<E2*YHM.\8^O4445\^=Y_DQ_MW_\GP_ME?\ 9UG[0_\
MZMWQA7RG7U9^W?\ \GP_ME?]G6?M#_\ JW?&%?*=?Z.Y+_R)LI_[%F _]1:1
M^=UOXM7_ *^3_P#2F%%%%>F9A1110 5_7?\ #W_E70_94_[.?\<_^IY^T)7\
MB%?UW_#W_E70_94_[.?\<_\ J>?M"5\5QA_OG O_ &7>4_\ JNS@PQ__ ")L
M^_[%&(_].T#\N****_33\."BBB@ HHHH *_L:_X(B?\ )EFE_P#90/'O_IRM
M*_CEK^QK_@B)_P F6:7_ -E \>_^G*TK\/\ I _\D'2_['V7_P#J/CS]!\-/
M^2BG_P!B[$?^G\*?L-1117\3G[^%%%% !1110 4444 %%%% !1110 4444 %
M%%% %/4/^/&[_P"O>7_T T^R_P"/.T_Z]H/_ $4E,U#_ (\;O_KWE_\ 0#3[
M+_CSM/\ KV@_]%)0+JO1_G$LT444#"BBB@ HHHH **** "N+^)'P\\&_%WX=
M^/?A1\1=$B\2_#[XG^"_%/P\\=>')[J_L8?$'@WQKH=]X;\3Z)-?:5=V&J6<
M6JZ)J5]8276FWUE?VZ3F:SN[>X2.9.THH ^0M?\ VD_V%_V--.\"_ #Q]^TK
M^S3^SJO@CX>>$](\"_#/XJ_'OX>^ _$6F_#?0K$^%/",MGI?Q#\8V7B;4-#B
MM/#LVD6.MW9O/M\^DWB27]U>6]VPOZ%^WE^PWXH\(^.OB!X9_;-_91\1> _A
M?%X<G^)?C;0OVB?A#J_A'X=P^,=8'AWPC-XZ\2:?XPN-&\)1>*O$!&A>')-?
MO=/37-8(TS3#=7I\BOY[/VY_$7P2\-_\%VO$-Y\=?V!?B5_P4,\-3_\ !,KX
M>VVE?"GX7_LU?#O]J#6O!VNM^T7XKEC^(5_X,^).K:/I&A:7:Z?%?^&W\3V5
MQ)J4-WXBM=*2$VNJW+IZ#^UM\5_V;?A-_P $@OVX?VE/@)_P26\'_LHW>A^)
MO@1X/\4_ S]L/]B#X5_![1_C+;Q_'3X-VVC^(/%?PX^&?B$)\0/!_AB7X@:G
M>>"M1U7Q';/HGC[1[R[MK$"RE^W@'])&C?$[X:^(_''C/X8^'OB'X&UWXD_#
MBU\.WOQ#^'NC>+- U3QQX#L_%]E+J7A*[\9^$['4)]>\+VOBC3H)[_P[<:Y8
M6,6MV4,MUICW,$;R#N*_ESA'[?UY_P %I?\ @K1H_P"P;IW[->EZU>?#O]A&
M]^(?Q,_:<E^(.H^$?"UOI7P(UR3P9X.T#PC\-XHM:U7Q#\1-9N+_ .U>(K[4
MHM)\'^%?"GB.Y72==U[4M"M8>]^(G_!7#]LV_P#V6_@S??"KX1_ ;P_^VM)_
MP5BT_P#X)2?'#P=XVN?'&O\ [/[_ !7L?"WCJ?6/&7@G6M)U#1?'NF?#K6M5
MM/ ?BFRO-2M]9UW1/"M]K^CQP^);J'3?$UX ?TGT5^!VH?M4?\%4-6^-_P )
M_P#@G5H=Q^Q/I7[9T/P+U;]J/]I/]H6VT+XLZW^S[X+^"DWQ9UCX4> _#GPN
M^&FI:SI/COQK\8O$#VVF>)O%$OB/5?!O@;1%DN-+TN*^AN;?5+/SSXC?\%>?
MVJ/@#^SW_P % O#?QD^#/P9U/]M'_@G]XK_9XT3QWXA^'MU\0KS]F+7OAO\
MM1W6FWOP^_:"/AN^9_C%:^%O WAV_NE^)_@;P_=>*M9MM<TRWDLO$&GZ7K%\
M/"8!_1-JFJ:9HFF:CK6M:C8Z1H^D6-WJFK:MJEW;V&F:7IEA;R7=_J.HW]W)
M%:V5C96L4MS=W=S+%;VUO%)--(D:,PP_ _COP1\3?"6A>/OAMXR\*_$+P+XI
ML4U3PSXT\#^(=(\6>$O$>F2.\::CH7B/0;R_T?5[%Y(I(TN]/O+BW9XW02%D
M8#\2?V7OVQ_VK/C%X/\ VE;OQ_\ $?\ X)[?MG?L\:%^R]XX^(GAKXZ_LJ>(
M+R!-%^),>DW=S+\!_CM\!O$WQ!\7>)X-.UG1)=6N]/U9)- *Z#X?73?$<$VO
M>)+B/P]\-^'_ /@JG\7/AE^S-_P2D\ > I?V*_V%] _:K_9[\?\ Q U3XV?%
M_P"'/BC2?V3_  5K/@77+*ST[X,_#+POX2^(FA1>"=5NH=1EUS6M1\?:]:>%
MK.PU/1+?1]3OM;U*XM+, _K$KC/&OQ%\ _#B#PY<^/\ QGX8\&0>,/&7AKX=
M^$Y/$VMZ?HH\3^/?&-\--\*>#/#XOYX&UCQ1XCOR;71M"T\7&I:A(DHMK:01
M2E/F/]A#XO?M$?&KX&MXO_:4T#X"6WC"'QKXGT3POX__ &8?B3;_ !*^!?QM
M^'NES6T?ASXO> +L:OK^K>%M+\2S/J=D/!WB+7M9US3/[(2^U"\M9]5?0]'^
M/_'WBW4?CK_P6U^"_P  M2\N^^%7[&'[&GBS]K=;2U-U<V<G[2OQF\=7'P&\
M&MXMMG$NDKJ'@SX-3^.M9\!NZP:K:3>.]?O[;ST6.;3P#]++W]HG]G[3=,^*
MFM:C\=/@Y8:/\"[Y=+^-NK7OQ.\$VNF?!W4WMX;M-.^*E_/K<=K\/;Y[6XM[
ME;3Q;+I%PUO/#,(S'*C-Y=X(_;Z_83^)GB+3_"'PW_;4_9+^(/BS5[B.TTKP
MOX(_:.^#OBOQ%J=U+N,5MI^B:#XRO]2O;B0(_EPVUM+(^QMJG:<?S.?&G_DV
MO_@Z<_[+CIO_ *@7A"LSXZ>//^"9/[0G_!.'Q'\"_P!F3_@G9XG^-O[7GBK]
MG'PKX2\"6_PN_P""=GQ2\$>*M(^+.H^&-$T.U^*<OQDMO@MX;LK'2O OB2Z/
MC?6=<G\6C2?%%CI<^FWT^H:9K=RLP!_5%\8/VO?V3?V>M?TWPI\??VH?V=O@
M=XHUC1X_$.D>&_C!\:_AK\--?U70);V\TV+7--T?QIXFT34;[1Y-1T[4+"/4
M[6VELGO;&\M5G,]K/&G.^#?VZ_V)?B-9^-[_ .''[8'[,'Q%M/AIX)UOXE?$
M27X??'KX6^-SX&^'?AI(G\0^.O%D7A;Q3JTV@>$=#6> ZKXBU2.VTFP,T(NK
MN)I8PW\JG[46E1_![_@IW_P3'\)_MK?LL>.O^"B?C'P/_P $A?!O@WXP?"?X
M<_!OPC^U+XG\7?%C0M:\<Z/XE\?#PA\2M4TS1O$T.E>)K/5-2U'QG>74.H.]
MT=8AM8I;Y[>+]^/^"?.F_LB?$@_%W7/A)_P2?\8?L!:C:Z%IG@+Q5)\;?V*O
M@M^S5K'Q<\&^-?[1O-5\-:-)\/[_ ,02^-_"-E/X;LV\8:-K4]OID5U>^'6D
MLKYI@]J ?JI97MGJ5G::CIUW;7^GW]M!>V-]93Q75G>V=U$D]K=VEU \D%S;
M7,$B303PN\4T3I)&[(P)LU^0'_!''XA>(W^%?[4'[*GBF^FO/^&!?VSOC?\
MLG?#*359KR7Q1<_LY^$KG1_$?[/]WXA:^VRRC3_ OB6/P5H%[$@@OO#7@O2I
MA<:A<?:=2O/U_H *^4_V>_V(/V6?V5O&OQC^(WP%^$NG> _''Q^\0IXF^*_B
M7_A(?&7B?4O$>H0WVJZC:V5E)XR\1^(8_"?AFPO-;U.;3/!G@V/P_P"#]+%P
ML6G:%;0VUK'!]644 %%%% !1110 4444 <?\0/\ D1_%O_8MZY_Z:[NO\X^O
M]'#X@_\ (C^+O^Q;US_TUW=?YQ]?U1]&O^%QC_U\R'_TG.#\=\5_CR+_  YE
M^> "BBBOZ@/R$**** "BBB@ HHHH ]NU[_DV_P"%'_9;OV@?_4#_ &9J\1KV
M[7O^3;_A1_V6[]H'_P!0/]F:O$:\#AK_ )%V)_['_%?_ *U.<'K9U_OE'_L4
MY!_ZHLN"BBBO?/)"BBB@ HHHH **** "BBB@#V[XK_\ (A_LS?\ 9$=>_P#6
MD/V@:\1KV[XK_P#(A_LS?]D1U[_UI#]H&O$:\#AK_D78G_L?\5_^M3G!ZV=?
M[Y1_[%.0?^J++@HHHKWSR0HHHH **** "BBB@ HHHH ]N_:!_P"1\T'_ +(C
M^S-_ZS?\**\1KV[]H'_D?-!_[(C^S-_ZS?\ "BO$:\#A3_DEN&O^Q!D__JNP
MQZV?_P#(]SK_ +&V8_\ J96"BBBO?/)"BBB@ HHHH **** "BBB@#V[]IG_D
MY#]H'_LMWQ7_ /4\UZO$:]N_:9_Y.0_:!_[+=\5__4\UZO$:\#A3_DEN&O\
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M6K]D+XE?MY_\$^OC_P#LH?"#7/ WASXB?%7_ (55_P (]K/Q(U+7]'\%V?\
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M>%;K7+Z7P=/?1^'X?WSHH _*3]JC]D;]IZQ_;(\!_P#!0+]B'7/@C>?&.S^
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M$O\ :)\1ZUX*\)RZEHVDZI;IJ?A71(?#_B_78/M>EW6J:Q+J?@Z"7Q+9\/\
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MKOQ4U2)@3NUS5O"UX>"RX#:=X)TM<Y [8QG\/ZL;U#)97<8&2]K<(!P,EHG
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M*/\ A6_AG_H&6?\ WYC_ /B*/^(H<?\ _169O_X'2_\ E?\ 5WY6/]4>&?\
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MN;6/^IK_ ._VF_\ RFK^QG_A6_AG_H&6?_?F/_XBC_A6_AG_ *!EG_WYC_\
MB*/^(H<?_P#169O_ .!TO_E?]7?E8_U1X9_Z$F!Z?9GY?WO)_P!-G\<W_#N;
M6/\ J:_^_P!IO_RFH_X=S:Q_U-?_ '^TW_Y35_8S_P *W\,_] RS_P"_,?\
M\11_PK?PS_T#+/\ [\Q__$4?\10X_P#^BLS?_P #I?\ RO\ J[\K'^J/#/\
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MS-__  .E_P#*_P"KORMQ?ZH\,_\ 0DP/3[,_+^]Y/^FS^.;_ (=S:Q_U-?\
MW^TW_P"4U'_#N;6/^IK_ ._VF_\ RFK^QG_A6_AG_H&6?_?F/_XBC_A6_AG_
M *!EG_WYC_\ B*/^(H<?_P#169O_ .!TO_E?]7?E8_U1X9_Z$F!Z?9GY?WO)
M_P!-G\<W_#N;6/\ J:_^_P!IO_RFH_X=S:Q_U-?_ '^TW_Y35_8S_P *W\,_
M] RS_P"_,?\ \11_PK?PS_T#+/\ [\Q__$4?\10X_P#^BLS?_P #I?\ RO\
MJ[\K'^J/#/\ T),#T^S/R_O>3_IL_CF_X=S:Q_U-?_?[3?\ Y34?\.YM8_ZF
MO_O]IO\ \IJ_L9_X5OX9_P"@99_]^8__ (BC_A6_AG_H&6?_ 'YC_P#B*/\
MB*''_P#T5F;_ /@=+_Y7_5WY6/\ 5'AG_H28'I]F?E_>\G_39_'-_P .YM8_
MZFO_ +_:;_\ *:C_ (=S:Q_U-?\ W^TW_P"4U?V,_P#"M_#/_0,L_P#OS'_\
M11_PK?PS_P! RS_[\Q__ !%'_$4./_\ HK,W_P# Z7_RO^KORL?ZH\,_]"3
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M-K'_ %-?_?[3?_E-1_P[FUC_ *FO_O\ :;_\IJ_L9_X5OX9_Z!EG_P!^8_\
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MF2/$CV\@AN$2Z=V@E:**X6*95D)BD,$\,P1PK&*:*0#9(C&3^Q=/_P">3_\
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M\G_[_3?_ !=']BZ?_P \G_[_ $W_ ,76K10%EV7W(RO[%T__ )Y/_P!_IO\
MXNC^Q=/_ .>3_P#?Z;_XNM6B@++LON1P]KI%B?%VN1F-]B>'/"KJ/.ER&DU/
MQBK'._)R(DX)P,''4YZ/^Q=/_P">3_\ ?Z;_ .+K.M/^1RU[_L6?"7_IU\:U
MTU<N#_@S_P"PK'?^IN(.K&)>VAHO]UP/1?\ 0%AS*_L73_\ GD__ '^F_P#B
MZ/[%T_\ YY/_ -_IO_BZU:*ZCELNR^Y&5_8NG_\ /)_^_P!-_P#%T?V+I_\
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M8NG_ //)_P#O]-_\71_8NG_\\G_[_3?_ !=:M%=1RV79?<C*_L73_P#GD_\
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MK^.6O[&O^"(G_)EFE_\ 90/'O_IRM*_)/I _\D'2_P"Q]E__ *CX\^U\-/\
MDHI_]B[$?^G\*?L-1117\3G[^%%%% !1110 4444 %%%% !1110 4444 %%%
M% %/4/\ CQN_^O>7_P! -/LO^/.T_P"O:#_T4E,U#_CQN_\ KWE_] -/LO\
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M &T/B!9:RUG/H%EXYU+P3X8\%^(KJT6S>SN(/BV^GZ9$6EMD/K'P;U_]N_\
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M+_X* ?#;P%^W1X^^!/[-G['WB?\ 8-\8K\(--^%_@'QO!X[TOXP? CPYXO\
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MX=V__P#G>5_.E11_Q!KPU_Z)FG_X=,[_ /GEY?GW8?Z]\5_]#:7_ (1Y?_\
M,A_1;_Q$&>*/^C7]&_\ #NW_ /\ .\H_XB#/%'_1K^C?^'=O_P#YWE?SI44?
M\0:\-?\ HF:?_ATSO_YY>7Y]V'^O?%?_ $-I?^$>7_\ S(?T6_\ $09XH_Z-
M?T;_ ,.[?_\ SO*/^(@SQ1_T:_HW_AW;_P#^=Y7\Z5%'_$&O#7_HF:?_ (=,
M[_\ GEY?GW8?Z]\5_P#0VE_X1Y?_ /,A_1;_ ,1!GBC_ *-?T;_P[M__ /.\
MH_XB#/%'_1K^C?\ AW;_ /\ G>5_.E11_P 0:\-?^B9I_P#ATSO_ .>7E^?=
MA_KWQ7_T-I?^$>7_ /S(?TJ^(/\ @N5XC\&:3X'\1Q_LYZ3J#_%OPO=_$&>T
M?XHWMLNARZ;XU\7_  I&EQS+X$G.H)-!\,H=:-X\5FR2:Q)8"W9+%;NZY?\
MXB#/%'_1K^C?^'=O_P#YWE?B!\5_^1#_ &9O^R(Z]_ZTA^T#7B->)D'A!X=5
M\#7G5X<A.<<ZXDHIO,\Y5J6&XBS3#T(6CF*7N4:-.%VN:2C>3E*4F_3S;CCB
MFGBZ489K*,7EF25&OJF ?OU<FP%6H]<*W[U2<I6V5[))))?T6_\ $09XH_Z-
M?T;_ ,.[?_\ SO*/^(@SQ1_T:_HW_AW;_P#^=Y7\Z5%>W_Q!KPU_Z)FG_P"'
M3.__ )Y>7Y]V>9_KWQ7_ -#:7_A'E_\ \R']%O\ Q$&>*/\ HU_1O_#NW_\
M\[RC_B(,\4?]&OZ-_P"'=O\ _P"=Y7\Z5%'_ !!KPU_Z)FG_ .'3._\ YY>7
MY]V'^O?%?_0VE_X1Y?\ _,A_1;_Q$&>*/^C7]&_\.[?_ /SO*/\ B(,\4?\
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MK3W4*DG3J+F@^1N-2'^C)9WD%]"LT#JZL <J0>#T/!/!_3]3;K\?/V /V_\
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MC-=_^H;XMKDQO\&'_87@/_4[#'5@_P"-/_L%QW_J%B#IJ***ZSE/\F/]N_\
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M!^%O#VF>&+2\M;)%F_LJSG'B7PP^#VH?MT?L;_MS?\%*?C-^U1^U3\/?VDO
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M_P#/&7_OV_\ A1Y$_P#SQE_[]O\ X4>UI?\ /RG_ .!Q_P _-?>'LY_R3_\
M 7_EYK[R*BI?(G_YXR_]^W_PH\B?_GC+_P!^W_PH]K2_Y^4__ X_Y^:^\/9S
M_DG_ . O_+S7WD5%2^1/_P \9?\ OV_^%'D3_P#/&7_OV_\ A1[6E_S\I_\
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M*/:TO^?E/_P./^?FOO#V<_Y)_P#@+_R\U]Y%14OD3_\ /&7_ +]O_A1Y$_\
MSQE_[]O_ (4>UI?\_*?_ (''_/S7WA[.?\D__ 7_ )>:^\BHJ7R)_P#GC+_W
M[?\ PH\B?_GC+_W[?_"CVM+_ )^4_P#P./\ GYK[P]G/^2?_ ("_\O-?>145
M+Y$__/&7_OV_^%'D3_\ /&7_ +]O_A1[6E_S\I_^!Q_S\U]X>SG_ "3_ / 7
M_EYK[SVG]H'_ )'S0?\ LB/[,W_K-_PHKQ&O<OV@89CX[T$B*0C_ (4E^S..
M(V/(_9P^%((Z=0001V((/->)>1/_ ,\9?^_;_P"%>!PI5I_ZK\-_O(?\B#)_
MMQ_Z%V&\_-?>>MGT)_V[G7N2_P"1MF/V7_T&5O+S7WHBHJ7R)_\ GC+_ -^W
M_P *]X^$WPCOO$UW::IJUC*UB[H^GZ=)&P.H'.5N;E&&18@\Q1$9O#AG'V3
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M<H4444 %%%% !1110 4444 %<SKW_(5\%?\ 8S7?_J&^+:Z:N9U[_D*^"O\
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M94_[.?\ '/\ ZGG[0E?R(5_7?\/?^5=#]E3_ +.?\<_^IY^T)7-QA_OG O\
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M*Z_\%/"_PX\0VMCXI\'7^I:EKR7P\?\ CGP?%"MO%/%:EK)KF8SMM>-8_GH
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ME\0O'^F>,M6UE[]8M5U/X<2^(-7TSX@6\=C8P^'[34_#6A6FGS1VCRN 9_\
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MR[T>WUVXF\$ZI=7.J>$XO%OC/Q1#IFI7FI7DD=U-K&L-J'Z[_P!M:9_S\_\
MD&X_^-4?VUIG_/S_ .0;C_XU0%UW7WH_*W]H#_@CI^SO\<OBA\5/BKX;^,O[
M7G[,6J?M 0VL7[1WA7]E7X]7OPJ^'O[0;VUC#I$MW\4/!=WX?\4:1<ZCJFB1
M2:+KNI^%H_"U_KMCJ.O/JUS=W_B7Q%>ZKV7QU_X)2?LY?&#PU^ROH7@CQ?\
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MO7);J\@EUHZ;,^GZ5*NG1W-D)Y/T_P#[:TS_ )^?_(-Q_P#&J/[:TS_GY_\
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ME^/K>O:/^>/X?Y^O]+7\*_\ AW)<?\^WZ#_"C_AW)<?\^WZ#_"OW4_M+1O\
MGJO_ 'YN/_C5']I:-_SU7_OS<?\ QJCECV_'T\O+\?6Y[1_SQ_#_ #]?Z6OX
M5_\ #N2X_P"?;]!_A1_P[DN/^?;]!_A7[J?VEHW_ #U7_OS<?_&J/[2T;_GJ
MO_?FX_\ C5'+'M^/IY>7X^MSVC_GC^'^?K_2U_"O_AW)<?\ /M^@_P */^'<
MEQ_S[?H/\*_=3^TM&_YZK_WYN/\ XU1_:6C?\]5_[\W'_P :HY8]OQ]/+R_'
MUN>T?\\?P_S]?Z6OXAS_ + \]UH&F>$?L_.AZQKGB,C X'BJR\/:8#T[GP<1
M_P !K'_X=R7'_/M^@_PK]L;74-)'B[6W,B^6WASPLJGR9^734_&!D&/+R,*\
M?) !SP20<='_ &EHW_/5?^_-Q_\ &JY<'&/L9Z?\Q6.Z_P#4;7[W[?UK?JQE
M1^VA[R_W7 ]%_P! 6'_X/WKMK^%?_#N2X_Y]OT'^%'_#N2X_Y]OT'^%?NI_:
M6C?\]5_[\W'_ ,:H_M+1O^>J_P#?FX_^-5U<L>WX^GEY?CZWY?:/^>/X?Y^O
M]+7\*_\ AW)<?\^WZ#_"C_AW)<?\^WZ#_"OW4_M+1O\ GJO_ 'YN/_C5']I:
M-_SU7_OS<?\ QJCECV_'T\O+\?6Y[1_SQ_#_ #]?Z6OX5_\ #N2X_P"?;]!_
MA1_P[DN/^?;]!_A7[J?VEHW_ #U7_OS<?_&J/[2T;_GJO_?FX_\ C5'+'M^/
MIY>7X^MSVC_GC^'^?K_2U_"O_AW)<?\ /M^@_P */^'<EQ_S[?H/\*_=3^TM
M&_YZK_WYN/\ XU1_:6C?\]5_[\W'_P :HY8]OQ]/+R_'UN>T?\\?P_S]?Z6O
MX5_\.Y+C_GV_0?X4?\.Y+C_GV_0?X5^ZG]I:-_SU7_OS<?\ QJC^TM&_YZK_
M -^;C_XU1RQ[?CZ>7E^/K<]H_P">/X?Y^O\ 2U_$/4_V!Y]<LO#VF"WR?!VC
MS^'",#Y3=:_KGB['3T\5 _C6/_P[DN/^?;]!_A7[8Z)J&DKJ?C M(H5_$=JT
M?[F<Y0>$O"R$\1DC]XD@P<'C.,$$]'_:6C?\]5_[\W'_ ,:KEP<8^QGI_P Q
M6.Z_]1M?O?M_6M^K&5'[:'O+_=<#T7_0%A_^#]Z[:_A7_P .Y+C_ )]OT'^%
M'_#N2X_Y]OT'^%?NI_:6C?\ /5?^_-Q_\:H_M+1O^>J_]^;C_P"-5U<L>WX^
MGEY?CZWY?:/^>/X?Y^O]+7\*_P#AW)<?\^WZ#_"C_AW)<?\ /M^@_P *_=3^
MTM&_YZK_ -^;C_XU1_:6C?\ /5?^_-Q_\:HY8]OQ]/+R_'UN>T?\\?P_S]?Z
M6OX5_P##N2X_Y]OT'^%'_#N2X_Y]OT'^%?NI_:6C?\]5_P"_-Q_\:H_M+1O^
M>J_]^;C_ .-4<L>WX^GEY?CZW/:/^>/X?Y^O]+7\*_\ AW)<?\^WZ#_"C_AW
M)<?\^WZ#_"OW4_M+1O\ GJO_ 'YN/_C5']I:-_SU7_OS<?\ QJCECV_'T\O+
M\?6Y[1_SQ_#_ #]?Z6OX5_\ #N2X_P"?;]!_A1_P[DN/^?;]!_A7[J?VEHW_
M #U7_OS<?_&J/[2T;_GJO_?FX_\ C5'+'M^/IY>7X^MSVC_GC^'^?K_2U_$/
M7/V!Y_%5[!J8M\BUT?P]X<S@=?!V@:9X1(Z?PG0R/PK'_P"'<EQ_S[?H/\*_
M;'PMJ&DIIET))%#'Q'XP8?N9S\C^+M;>,\1D<QLIQU&<$ @@='_:6C?\]5_[
M\W'_ ,:KDP$8_4<$[?\ ,)ANO_3FGY>7X^M^G'5']=QGO*WUK$=O^?LO^#_2
MU_"O_AW)<?\ /O\ ^.C_  KU/X9_\$_[71-9MKN^MD9(I4?#J#\JL,X!&.G7
M(Y/3G%?L#_:6C?\ /5?^_-Q_\:I1J>C@@B501T/DW'_QJNM**V7]:?JOZ=V^
M7VCZS7RLOU_K\^3\!^ =*\&Z5;V-E;1Q>5&JL50*20!G& .#W/?H.Y/HO3I6
M7_;6F?\ /S_Y!N/_ (U1_;6F?\_/_D&X_P#C5,5UW7WHU**R_P"VM,_Y^?\
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M/*:Y6V+^<;=92(S,$,8D^0MNXK^2?X\_M _%;]H+_@GQ^SM_P51/PY\+Z/\
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M:GJ?B6.^M=1N-0:1[/3OC[]G?]D7_@F_-_P2W_9\_P""F7[1_P 9?'GPS_:
M\0:M\//V@OB9_P %%/"/B3QEKO[0>F?M!>(_BO8^'M=\/VZ2:9\3['6-*M?&
M4UQ\&=;\$#X=:SX332+/5]=U#P[IU['JVNVP!^_O[&7[9O\ PUSXC_;&\/\
M_"M_^%??\,F?M>?$W]E7[7_PF'_"6?\ "?\ _"N;#P]>_P#">?9_^$6\-?\
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M-4U_0]4CM!H6H>/+/Q7<>'KZ77-6>^T""YU$ _J8_9*_:M^'G[8_PJN?B_\
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M%%% ',VG_(Y:]_V+/A+_ -.OC6NFKF;3_D<M>_[%GPE_Z=?&M=-7+@_X,_\
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MQ/;:AJ-M\=_"7B3P?J>L:?I-A' DFJ>&4M=%OFM_$<3QVT[K&BP@R#&K?_\
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M>[&CZ2MEWE %/4/^/&[_ .O>7_T T^R_X\[3_KV@_P#124S4/^/&[_Z]Y?\
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MQ'XJU7PEX&U72/$OB35O$&B:A\.M%\(W>B:T]CJFDS65[HVC36$'[*?_  3
M_8F_8K\>:U\3_P!GOX1ZCX<^(6M^#X?AT?%_BSXG?%?XJ:WHWPYM;S3[^S\
M^&+SXI>-_&+^&O"MK=:5ILBV&BBSDN5L+&&_N;N&RLXX/OVB@#\IOB3_ ,$1
MO^"87Q<\<_$/X@>/_P!F&RUC5?BKKVM>+_'>B67Q0^-/AKP'K7CKQ%9:CIVL
M_$&/X=>%OB+HG@?2?'M[:ZKJ!'B_1= T[7;._NI]:T^]M-<GFU*3])S\/O!;
MZUX>\0S^'K"[UKPGI(T7PQ?WXFU"70+#Y XTA;V6XBL+R=(XH;K5+:./5+NW
MBBM[F\F@BCC7LJ*N%2I2;=.I.FY0E3DX2E!RA.+C.#<6FX3BW&47I*+:::8G
M&,M))22::32=FG=/7JGJGNGJCDO%G@SPGXK33+KQ+H6G:K<^&=1MO$&@7US!
M_I^B:MIMQ!?VU]I=_"8[VRD$]I!]I2WG2*^@1K.]CN+266!]W2F#:?:D'($9
M7N.5=E8<^C CT/49%4/%5U)9>&/$-W"_ESV^AZM-!)@'9-%87$D;X8%3L=0V
M&!4XP00<5_$*G_!53]OV.,0Q_M$ZTL:YVH/!GPSP-S%S@_\ "%9Y9B>O?'3B
MOT#@?P\SWQ IYA'*\?EV&IY,\*JD,RKXR$?^%!XF4?JT</A,5%*^$J.K?V=Y
M.#7-=N/S'$/$^7\-3PCQF'Q566.C7Y'A:="37U?V*?M'5K47_P OH\EN;:5[
M:7_N7WI_>7_OH?XT;T_O+_WT/\:_AH_X>J?M^_\ 1Q6M_P#A&_#/_P"8JC_A
MZI^W[_T<5K?_ (1OPS_^8JOO/^)=>,?^AOPS_P"%.:?_ #H]?Z>GSO\ Q%'(
MO^@+-O\ P3@__FT_N7WI_>7_ +Z'^-&]/[R_]]#_ !K^&C_AZI^W[_T<5K?_
M (1OPS_^8JC_ (>J?M^_]'%:W_X1OPS_ /F*H_XEUXQ_Z&_#/_A3FG_SH]?Z
M>A_Q%'(O^@+-O_!.#_\ FT_N7WI_>7_OH?XT;T_O+_WT/\:_AH_X>J?M^_\
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MBM;_ /"-^&?_ ,Q5'_$NO&/_ $-^&?\ PIS3_P"='K_3T/\ B*.1?] 6;?\
M@G!__-I_<OO3^\O_ 'T/\:-Z?WE_[Z'^-?PT?\/5/V_?^CBM;_\ "-^&?_S%
M4?\ #U3]OW_HXK6__"-^&?\ \Q5'_$NO&/\ T-^&?_"G-/\ YT>O]/0_XBCD
M7_0%FW_@G!__ #:?W+[T_O+_ -]#_&C>G]Y?^^A_C7\-'_#U3]OW_HXK6_\
MPC?AG_\ ,51_P]4_;]_Z.*UO_P (WX9__,51_P 2Z\8_]#?AG_PIS3_YT>O]
M/0_XBCD7_0%FW_@G!_\ S:?W+[T_O+_WT/\ &C>G]Y?^^A_C7\-'_#U3]OW_
M *.*UO\ \(WX9_\ S%4?\/5/V_?^CBM;_P#"-^&?_P Q5'_$NO&/_0WX9_\
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M_OH?XU_#1_P]4_;]_P"CBM;_ /"-^&?_ ,Q5'_#U3]OW_HXK6_\ PC?AG_\
M,51_Q+KQC_T-^&?_  IS3_YT>O\ 3T/^(HY%_P! 6;?^"<'_ /-I_<OO3^\O
M_?0_QHWI_>7_ +Z'^-?PT?\ #U3]OW_HXK6__"-^&?\ \Q5'_#U3]OW_ *.*
MUO\ \(WX9_\ S%4?\2Z\8_\ 0WX9_P#"G-/_ )T>O]/0_P"(HY%_T!9M_P""
M<'_\VG]R^]/[R_\ ?0_QHWI_>7_OH?XU_#1_P]4_;]_Z.*UO_P (WX9__,51
M_P /5/V_?^CBM;_\(WX9_P#S%4?\2Z\8_P#0WX9_\*<T_P#G1Z_T]#_B*.1?
M] 6;?^"<'_\ -I_<OO3^\O\ WT/\:-Z?WE_[Z'^-?PT?\/5/V_?^CBM;_P#"
M-^&?_P Q5'_#U3]OW_HXK6__  C?AG_\Q5'_ !+KQC_T-^&?_"G-/_G1Z_T]
M#_B*.1?] 6;?^"<'_P#-I_;CX39?[+N_F7_D9O&G<=_&.O$=_2NG!!Z$'Z'/
M\J_BT^+?_!2G]M[P;XJTK2/#7QYUC2].O/AE\%/%=S;1^$_A[.LOB#QW\&O
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MQ!>Z;+K%B/!.M>&=,\1>&8H+U8]&\0?;-7L!!=WMP[_UQZK\/O 6N^+O"GQ
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M7X1_\&V_[(GQN^''PM\!>$?C+X.TK]@_XZ^&OBOH?A+P_IOQ"TOXL^,?B?\
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M-9&B?!37I]9.E7/C'6M&AU$:1#?64VIFS>86$5Y:R77E)<0E_P!9?V#OV/\
MPI^P?^RI\*OV7O"'B?6?&]I\/K+7;S6_&VOVUM8:EXP\9^-/$^L^-_&_B/\
MLFR>6TT+3M2\5>(=6ET/P_#<WYT+0QIVDW&K:U=VEQK%]VOC_P#9!_9,^+'B
MG4/'/Q3_ &7OV=OB7XVU:.RAU3QCX_\ @G\-?&7BG4HM-LH--TZ+4/$'B+PS
MJ6K7D=AIUK:V%DES=R+:V5M!:P"."&.-0#\0M#^(W@C_ (*"_P#!9$_'[]FO
MQWI7Q'_9R_8,_8;^('@7QI\7/ ]_+?\ @;Q?\=?C]=>)4LOAGH_B.RU#^Q/'
M&EZ1X!6/QA=WVC1:GI6B^(M&^Q:A/_:;Z.]M^2W[,GA;PWJ_[&'_  0M\1^
M?VKO 7[+7[9WA3P%^V:/V:W_ &D?A7<^.OV6_BQ!KWQK\4VOC3P3KOB[7$D\
M)?#;XA+'9:5#I.L:'!>^.-3@US3M)L["?5+GP7-:_P!POA;P+X)\#>'(/!_@
MGP=X5\'^$;6.>*V\+>%O#VD>'_#EO%<Y^TQ0:)I-G::9#'<;F\]([55EW'S
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M!7_8S7?_ *AOBVN3&_P8?]A> _\ 4[#'5@_XT_\ L%QW_J%B#IJ***ZSE/\
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MO_A='\3/'_['VH^ V7X:_%?QR/$MGX._9U:W\22V ^''@;Q>0VF3Z]I,+0W
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M^&<?BO\ ] &/_P "X_\ XFO[6_\ ACCX?_\ 0.@_[]#_ .)H_P"&./A__P!
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M_$T?\,X_%?\ Z ,?_@7'_P#$U_:W_P ,<?#_ /Z!T'_?H?\ Q-'_  QQ\/\
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M_P 0TX9_GS3_ ,*J/_S/_5WY6_BD_P"&<?BO_P! &/\ \"X__B:/^&<?BO\
M] &/_P "X_\ XFO[6_\ ACCX?_\ 0.@_[]#_ .)H_P"&./A__P! Z#_OT/\
MXFC_ (F!X\_Y]9!_X;L3Y?\ 4P\G]_D'_$-.&?Y\T_\ "JC_ /,_]7?E;^*3
M_AG'XK_] &/_ ,"X_P#XFC_AG'XK_P#0!C_\"X__ (FO[6_^&./A_P#] Z#_
M +]#_P")H_X8X^'_ /T#H/\ OT/_ (FC_B8'CS_GUD'_ (;L3Y?]3#R?W^0?
M\0TX9_GS3_PJH_\ S/\ U=^5OXI/^&<?BO\ ] &/_P "X_\ XFC_ (9Q^*__
M $ 8_P#P+C_^)K^UO_ACCX?_ /0.@_[]#_XFC_ACCX?_ /0.@_[]#_XFC_B8
M'CS_ )]9!_X;L3Y?]3#R?W^0?\0TX9_GS3_PJH__ #/_ %=^5OY!/CA\ _B9
MJOC31;JRT2.6&+X/_L]Z:[&Z1<7>C? +X::1?QX*](KZQN8@>C!-PX-7O@_^
MS-XE74[:\US2I)M5:<):6R(9K>Q7=M%PSE0LMT_6-@#';H0REIF!B_KAL?V4
M? ^NPO>W-A"\D%YJ.C*3&"1;^'=0N?#]HOW>B6FEPH!V"@=JZG0OV5/ FB7D
M=W%I=N6C964B$?+@YS@IR?J?P]?E*_B]QEF_"F"X>J8C!8+ 2RS 82K/+\-5
MP^+KX2CA:5)X:>(EB:K5*M&*6(5.-.56-Z3DJ4ZE.?NO@G(,#GV+S2-+$8C$
MK'XNO".*JPJ4*=>>(G/VL*:I0]^$FW2<W)0=I)<\82C\#_L@_L@0V,-GK>N6
M*B0+')B6/Y@2 W1@/3DY'8<XK]CM T&RT&Q@M+2%(DAC5%5%"X &.< <X[?4
MD9/#]$T.RT2TCM;2&.)(U50J* /E& 3@ 9].P]SS6W7YTM%9*R_-]WY_TCZ1
MMMW?_#>2"BBB@04444 %%%% !1110!S/@K_D3?"7_8LZ#_Z:K2NFKF?!7_(F
M^$O^Q9T'_P!-5I735R8#_<<%_P!@F&_],P.K'?[[C/\ L*Q'_IZ84445UG*%
M%%% !1110 4444 %<SXM_P"05:?]C-X*_P#4RT&NFKF?%O\ R"K3_L9O!7_J
M9:#7+CO]RQG_ &"XC_TS,ZL#_ON#_P"PK#_^GH'34445U'*%%%% !1110 44
M44 %%%% !7,Z]_R%?!7_ &,UW_ZAOBVNFKF=>_Y"O@K_ +&:[_\ 4-\6UR8W
M^##_ +"\!_ZG88ZL'_&G_P!@N._]0L0=-11176<I_DQ_MW_\GP_ME?\ 9UG[
M0_\ ZMWQA7RG7U9^W?\ \GP_ME?]G6?M#_\ JW?&%?*=?Z.Y+_R)LI_[%F _
M]1:1^=UOXM7_ *^3_P#2F%?T5?\ !)OXK?\ !1SQ#\'E_9P^&W[ ?@/]NG]C
M74_&6JZYJ7A7XV_#K1=$^'=AX@DFCF\1?\(U\</%[Z5X$L/$L$_E7)CU^'QQ
MJ>ARM&='TBSFF@5_YU:_H!^#_P "?VY_CG_P27^' _8LUO\ :W\3:-X?^,GQ
MGT'X^_!CP;X@TKPG\-]7T#58].U/0?$'@;1=!\'^$/%OQDM]7WW.B>,_#M[\
M1/BA<>&-?TA#!X.T/3O$%B\7@<<+#5,JPN'Q2R>%/%9IAJ$<7G;Q$,%@*KHX
MFI2Q<:N%Q&#KTL3&=-4<-*&-P<I5*ZIQQ$95(QGT8'F564H>U;A2E)PH\KG4
MBI13@U*,XN+3O).$U:-W%I:???[3/_!)+_@F%\5?$7A;X6?"W]H?X0?L5_MY
M?$(/IFF_LMZ+^T!)^T5\&M/^(H>XN$^'GB+Q#J7AK2/&G@[Q9K]U/9:'81-?
MZ?;?VJZZ5X$^'7C&7[##J?\ )S\2_A[XH^$GQ'^('PI\;V4>G>-/AEXV\5_#
MWQ?I\4Z7,5AXH\%Z[?\ AO7[*.YC_=W$=KJVFW<"3I\DJQB1?E85[SXY_9A_
M;2_9$_X0_P",_P 1?@;\?_V>/[$\=>'_ /A!?B5XJ\#>,OAY_9?Q&TW[7XK\
M,?\ ".>)=0L--^R^*K+_ (1J^U_2/L-TFHP?V)<7]MM^Q/)'\V^*/%'B/QOX
MF\1>-/&.NZKXH\7>+]=U?Q1XI\2Z[?7&J:YXA\1Z_J%QJNN:[K.IWDDMWJ.J
MZMJ=W=7^HWUU++<7=Y<37$\CRR,Q?"F6X[+Z4HOBB7$V63HQ5*K7E#$5</C(
M59^UAA\9&KB*U3!NC*G!4<;C,;B:52GS?69*<DS%U(5&G]56&JWU44XQE!I6
M<H-1BIWN[PA"+3^'0PJ_KO\ A[_RKH?LJ?\ 9S_CG_U//VA*_D0K^N_X>_\
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M#1]0@M/#7Q T_P ,?$SP'J_VO4K7PSXETG55/A_48?$VH-%];^;JW_/I:_\
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M-U;_ )]+7_O^W^%:E% 6_O2_#_+R_/NS+\W5O^?2U_[_ +?X4>;JW_/I:_\
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M-U;_ )]+7_O^W^%'FZM_SZ6O_?\ ;_"M2B@+?WI?A_EY?GW9E^;JW_/I:_\
M?]O\*/-U;_GTM?\ O^W^%:E% 6_O2_#_ "\OS[LR_-U;_GTM?^_[?X4>;JW_
M #Z6O_?]O\*U** M_>E^'^7E^?=F7YNK?\^EK_W_ &_PKG/%4NJ'3+7?:VRK
M_P ))X.(*S$G>/%VAF,8QT:0*K'LI)[5V]<SXM_Y!5I_V,W@K_U,M!KEQW^Y
M8S_L%Q'_ *9F=>!7^VX/5_[UA^J_Y_0\O+\^[-+S=6_Y]+7_ +_M_A1YNK?\
M^EK_ -_V_P *U**ZCDM_>E^'^7E^?=F7YNK?\^EK_P!_V_PH\W5O^?2U_P"_
M[?X5J44!;^]+\/\ +R_/NS+\W5O^?2U_[_M_A1YNK?\ /I:_]_V_PK4HH"W]
MZ7X?Y>7Y]V9?FZM_SZ6O_?\ ;_"CS=6_Y]+7_O\ M_A6I10%O[TOP_R\OS[L
MR_-U;_GTM?\ O^W^%'FZM_SZ6O\ W_;_  K4HH"W]Z7X?Y>7Y]V9?FZM_P ^
MEK_W_;_"L'57OFUCP6+F"&*/_A)+LAHY2[%_^$/\5X!! P-I8Y]0!WKLJYG7
MO^0KX*_[&:[_ /4-\6UR8W^##_L+P'_J=ACKP:M6GJ_]UQV]O^@*OY?U\SIJ
M***ZSF/\F/\ ;O\ ^3X?VRO^SK/VA_\ U;OC"OE.OJS]N_\ Y/A_;*_[.L_:
M'_\ 5N^,*^4Z_P!'<E_Y$V4_]BS ?^HM(_.ZW\6K_P!?)_\ I3"OZ1O^"4W[
M*O[7WQ4^!G@?5=._X*E^*OV!/A'\5_BIXG\ _L\?#'0/%?C'5/%OQH\=:3+I
ML?CK5_!'POT?XB?#BQNM'L-7U&STO5M<TW5=5OK>_L-9NO$.F:+I5GINJ:S_
M #<U^UW['/[2_P"U'XN^"G[+/PL^ W[&'Q$_:&^('[!7[64/[0'PY^+/PS\/
M^.?$$OA?X;^-)[CQ)\1O@1XNT_P7X6OK/3]/^*GBO2+;4IO%VNZY)=S:197'
MANPT21;>VN4\+C>CF%?)HT\OG@:,OK477Q6/I976I82DL-BO8UH4\XC/ .4L
M=]3H595(3J0PM;$SH0E6C"+Z,"Z<:UZBG+W?=C3=5.4N>%TW1:J:0YY*S2<X
MQ4FDVUZS_P %1?A/XGT3]D#X1_&!/^"Q/CW_ (*/_#GQW\:]-T7P]X"U;1?&
M,?ACPWKVG?#GQ3KFJ>*-1O\ 6?C+\1[+PY\0/!VDZUHFB:EX"\0:'X>\<Z;I
M?Q,AO;N"QLI)(+[^?BOZ,/\ @JEXR\.^%?V//#?P7^#/_!,G]I?]A_X6>//V
MIK3X_?$_QK\?_#GB2RTG5_C9=_#GQMX?L/ 7P_O]?N]<@AT@>'KO7K_3+2RO
M/#(@TSPW<#3?"=C#>^(9;G^<^HX#G7J9"IUVVGCL;[!SI9)0JO#JHE2]M1X>
MA#+*=5*\7[-RG448UIN/M%2IF.457M'_ )]T[ZUY+FY=>66(;J./57T5^57M
M=E?UW_#W_E70_94_[.?\<_\ J>?M"5_(A7]=_P /?^5=#]E3_LY_QS_ZGG[0
ME3QA_OG O_9=Y3_ZKLX/,Q__ ")L^_[%&(_].T#\N****_33\."BBB@ HHHH
M *_L:_X(B?\ )EFE_P#90/'O_IRM*_CEK^QK_@B)_P F6:7_ -E \>_^G*TK
M\/\ I _\D'2_['V7_P#J/CS]!\-/^2BG_P!B[$?^G\*?L-1117\3G[^%%%%
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MI_X>,[_^>/\ 5WY6/^(@<5_]#*'_ (0X#_YF_J[\K?TQ_P#$0?HO_1K>K_\
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ME&&8Q2>69+4:^I8%^_6R; 5:CN\,_BJ3D[;*]DDDDOZ8_P#B(/T7_HUO5_\
MP[UC_P#.WH_XB#]%_P"C6]7_ /#O6/\ \[>OYG**]K_B"?AK_P!$_4_\/&=_
M_/'^KORMYG_$0.*_^AE#_P (<!_\S?U=^5OZ8_\ B(/T7_HUO5__  [UC_\
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MS3#4(VCF$5[E&C3AS6YI6<I.4FY'IYMQWQ12Q5*,,QBD\LR6HU]2P+]^MDV
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M^>2%%%% !1110 4444 %%%% 'MWQ7_Y$/]F;_LB.O?\ K2'[0->(U[=\5_\
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M5UG*?Y,?[=__ "?#^V5_V=9^T/\ ^K=\85\IU]6?MW_\GP_ME?\ 9UG[0_\
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M1_[_ /\ ]C6K10%EV_K3_)&5_9C_ /02U'_O_P#_ &-']F/_ -!+4?\ O_\
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MEJ/_ '__ /L:U:* LNW]:?Y(RO[,?_H):C_W_P#_ +&C^S'_ .@EJ/\ W_\
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M^S'_ .@EJ/\ W_\ _L:U:*ZCELNW]:?Y(RO[,?\ Z"6H_P#?_P#^QH_LQ_\
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MJ/\ W_\ _L:/[,?_ *"6H_\ ?_\ ^QK5HH"R[?UI_DC*_LQ_^@EJ/_?_ /\
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M:TYN]ER4XPIQQQ5=8BK[1>TLH0@G5FIU)<BMS3DHQ7,^MHI>KNV5_7?\/?\
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M"_X0;_D>?^)'_P ([_PDW_"5_P#,2_L+^R/^)A7N-?RS_$CX7?$3XD_\%O\
MX,?#K]BK]J&/X)^$!_P0W^'MFGQ[T33= _:+\6:M\ M"_:_U&&RC^'?BCXB:
MMXD\/:YXM\9SVO@N _%;Q6/'L[Z!=>(M=AMM1\27^GZW97?B'^VS^WY\-O\
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MW7B/7O%5['\1+26UN]6T"QEB$"\+=_\ !2;]JOP3X$_;@\+^%O%GAW5OC/\
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M#F?!7_(F^$O^Q9T'_P!-5I735S/@K_D3?"7_ &+.@_\ IJM*Z:N3 ?[C@O\
ML$PW_IF!U8[_ 'W&?]A6(_\ 3TPHHHKK.4**** "BBB@ HHHH *YGQ;_ ,@J
MT_[&;P5_ZF6@UTU<SXM_Y!5I_P!C-X*_]3+0:Y<=_N6,_P"P7$?^F9G5@?\
M?<'_ -A6'_\ 3T#IJ***ZCE"BBB@ HHHH **** "BBB@ KF=>_Y"O@K_ +&:
M[_\ 4-\6UTU<SKW_ "%?!7_8S7?_ *AOBVN3&_P8?]A> _\ 4[#'5@_XT_\
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M7[:7QT_X)B_$[X6Z!H/[%O[#_C_]FGXI6GC_ $O5]?\ '?BKXV^/OB3I^K>
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M5'@*/X*^)KW[9H2W-^-=L+[5K30[S2/Z<Z_ES^$OA;X(_$W_ (*7?L*>,?\
M@E=^R_\ $C]G#X9_!GPS\8K+]N?XD67[./Q+_93^#^O>!;GP-:Z+X$^!'Q(\
M*^+?"/PWMOC-\7]-\8W(U+3YI8O$%YX.U"6P\8O/XNBT.YN_"']1E !1110
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M.=$_X9B_:J^+W[(7CW_A-]-T#3?[7^)7P6_X1[_A*=<\(?V#XF\2_;_ U_\
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M.S:2[US2-'UQ_$.GVFFZ]JBZ3=:!H&J:U  <K^T3_P $]OC/K'[3OB/]L?\
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MX5W6@ZW97NMMHUYH4ZS:SH^O:)XAT7Q#8Z-J.F-;R@'ZPT5^6WP6_P""MGP
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MTU<F _W'!?\ 8)AO_3,#JQW^^XS_ +"L1_Z>F%%%%=9RA1110 4444 %%%%
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MT/V5/^SG_'/_ *GG[0E?%<8?[YP+_P!EWE/_ *KLX,,?_P B;/O^Q1B/_3M
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MXNK.\?1;5SX**1?"D2V,(7PQ)'-XA"&0'QB2RLH!^93_ +(/C;2/^"JNK_L
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M/?%?C3XJ75I8^,_AR?%LUI#X#T#P[<07.B:[;W$$S_F5HGQ^_:I^-'_!-O\
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MF^)?A^Z\5-X"O/!^M^&/%%YXKNK'4=$U/P%/;3Z-866ES>9;76NKK/9^&?\
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M=^VQ\#O ^Z=(/B=XW^ EYJ.J7_PFNVLK>?49%^)G@K5/%7A/1X+-K8MXMO\
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M[+OA3]DCX0_L2:;X=F\-_$BT\!_&3X\?'7XO3ZK;V]S\8OB8VIZGK_P<\$_
MBYMK:_T[6YKV#28+;XE:W97-M8V=]J%HZWUQI=IP?Q&_8W7]@/XO_P#!M+^R
MG)XO7Q[JGPU_:$_:EN_$OBZ&R?3+#6O%GCNX\'_$+Q1)H^F.S&PT&RUSQ5?:
M9H4#+%.VD65G<7T8U">[9OZ8OV0OV6?AO^Q1^SE\,_V7_A%>^*]1^'7PIL==
ML/#5[XXU/3M9\4SP>(?%FO>,K\ZMJ>E:/H&GW4B:MXBOX[9K;2+)8[)+:%UE
MEC>>7Q#]MW_@G-\(_P!NWQ%\ O&?C_XE_'WX3>-OV:=>\8^)OA3XT_9\^(&E
M?#OQ5HVM>-[3PY9:M?MK=_X2\3WD=Q;V_ABP33IM+?3)K<3WPEDN%G180#XK
M_P"#@"WTK_AE?]GK4=!TVSO/VB[7]O']DFV_9,G:TCN=4B^.%S\3+*[MK2Q-
ML#X@-K?>$-,\4F_M/#9;4;J2UL&,31VWF0][^W-KK?#S_@J7_P $<?&/AZ\O
M+?Q%\0O$7[8_P&\8Z%H4 BU/QS\+/$GP5T;QH\6OWBW,"WWA/X<_$/P?X+\<
MRZ9>0W0M;U3JFG-;7$5S%J'K7P1_X).?L]?"7XP^$OC_ .._B=^U1^UI\7_A
MS<ZS>_"WQE^V'^T#XK^.!^%E]K]I#8ZKJ'P_\-7T6C>#=!U.XM8(XX-47P[<
M:EIS1PS:9=V<]M:2P9M]\&_&_P"T/_P58\,?'/QKX%\1>$O@S_P3S^#OBKP;
M\"_$>O:->Z0/B_\ '_\ :NT'2%^+GBWP??3730:Y\.?AA\(]!\/> I[I=,MD
MOOB+XL\16]IJ=XGA"Y@0 _5"BBB@#D_'?_(F>*?^Q?UG_P!-MU7^<77^D5KM
MLEYH^IVTJ+)%/8W<4T;Y*O%);R)(C =59&(;IP37\_'[1G_!.7X3M.LOPZ^$
MWAW0H&! 73+6\5<@E>C7,AZCU-?LGA/XCY7P!#/8YE@,PQKS6>6RH_45AG[-
M8)8Y5/:?6*]%WE]:@X<BE\,N;ETO\+QGPKC.)99;]5Q.&P_U-8M5/K'M?>]N
M\-RN'LJ=3X?8RYN;EWC:^MOY?**_;D_\$Y;C)_XI&'J>D-QC\/GI/^'<UQ_T
M*,/_ 'YN/_BZ_7?^)CN%_P#H0\0?=EWE_P!1WG^'K;XG_B%>;_\ 0SRO[\5_
M\H]?Z>GXCT5^W'_#N:X_Z%&'_OS<?_%T?\.YKC_H48?^_-Q_\71_Q,=PO_T(
M>(/NR[R_ZCO/\/6Q_P 0KS?_ *&>5_?BO_E'K_3T_$>GQ12SRQPPQO+-*Z11
M11(SR22.P5(XT4%G=V(554%F8@ $FOVU_P"'<UQ_T*,/_?FX_P#BZU=%_P""
M>FIZ;J$%Y8^&(;:YC)6.<6TK/'Y@V.8R^_8Q0LNY0&VLR@X8@Y5_I'</*C5>
M%X?SN>)]G/V$*\L#2H2K<O[N-:I3Q-:I"FYM*<H4JDXQNXPD]%I2\*LS=2FJ
MV:9?&DYQ]K*DL1.HH77.Z<)TJ<934;\JE.";2O))NWP9\!_@3?WM_:7-S9M=
M:Y=%5BC"B6/2XY?E9(R-RM=LI*SSC(128(#Y1EEN/Z3_ -C/]F*?PM:V6LZC
M"\<FR*3#K@C[I'7!Q^OIUJE^RS^QK'X9EMM1UVR4R1LCGS8\'Y<$Y)7\??W(
M K]:=$T2ST6SAM;6%(DB15554#[HQDX[^@[>YYK^7N(>(<VXHS;$YUG6)>(Q
MF(:48*\:&%H1;=+#86E>2I8>BG:%--N4G.K5E4K5*E2I^O99EN"R?!4LOR^D
MJ6'I*[;UJ5JC2YZU:=DYU9M)RDTDDHP@HTXQBLK2+=;7Q3K,"C 3POX1&.>,
M:GXT'?GM^!KL*YFT_P"1RU[_ +%GPE_Z=?&M=-7S6#_@S_["L=_ZFX@]C&?Q
MH?\ 8+@?_4+#A11174<H4444 %%%% !1110 4444 <SH/_(5\:_]C-:?^H;X
M2KIJYG0?^0KXU_[&:T_]0WPE735RX/\ @S_["L=_ZFX@ZL9_&A_V"X'_ -0L
M.%%%%=1RA1110 4444 %%%% !1110!S/A+_D%7?_ &,WC7_U,M>KIJYGPE_R
M"KO_ +&;QK_ZF6O5TU<F _W'!?\ 8)AO_3,#JQW^^XS_ +"L1_Z>F%%%%=9R
MA1110 4444 %%%% !1110!S/@K_D3?"7_8LZ#_Z:K2NFKF?!7_(F^$O^Q9T'
M_P!-5I735R8#_<<%_P!@F&_],P.K'?[[C/\ L*Q'_IZ84445UG*%%%% !111
M0 4444 %<SXM_P"05:?]C-X*_P#4RT&NFKF?%O\ R"K3_L9O!7_J9:#7+CO]
MRQG_ &"XC_TS,ZL#_ON#_P"PK#_^GH'34445U'*%%%% !1110 4444 %%%%
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M_@)_]LH_M3_J':I_X"?_ &R@+KO_ %I_FC4HK+_M3_J':I_X"?\ VRC^U/\
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M_P!0[5/_  $_^V4!==_ZT_S1J45E_P!J?]0[5/\ P$_^V4?VI_U#M4_\!/\
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M?]J?]0[5/_ 3_P"V4?VI_P!0[5/_  $_^V4!==_ZT_S1J45E_P!J?]0[5/\
MP$_^V4?VI_U#M4_\!/\ [90%UW_K3_-&;X2_Y!5W_P!C-XU_]3+7JZ:N(\*Z
MCLTRZ'V#4GSXD\8OE+7<!O\ %^N/M)WCYTW;)!_"ZLN3C-='_:G_ %#M4_\
M 3_[97)@/]QP7_8)AO\ TS ZL<U]=QG_ &%8C_T]+_-&I167_:G_ %#M4_\
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M^&G_ "44_P#L78C_ -/X4_8:BBBOXG/W\**** "BBB@ HHHH **** "BBB@
MHHHH **** *>H?\ 'C=_]>\O_H!I]E_QYVG_ %[0?^BDIFH?\>-W_P!>\O\
MZ :?9?\ 'G:?]>T'_HI*!=5Z/\XEFBBB@84444 %%%% !117X9_M"?&_]OKX
ME_\ !4_6_P!AS]EO]H3X3_L_^!_"O[$?A/\ ::O];\?? &W^--_JWB#4OC'K
M7PWU'285;QOX)GL+>:SET>\AE-Y<Q0-IUS&+5VOC-  ?N917X@_"K_@H'\?O
MV>_VT?B7^P]_P4(U[X&>*[;PK^R%JW[9O@;]IKX&>$O&_@NWN_A7X$OK[2/B
M'8?%_P"$%_K_ ,2+WPWXIL)= \6:[I>H>$M;N-!U31=#M+>PT^;7==32-*_2
MO5OVO?V<M#_9^\$_M3ZK\3+&T^ ?Q&MOAC=^"_B&VA>+)+/7+?XR:UH'A[X:
M21:+!H,OB>T'BC6?%&@V4"ZAHEH^GMJ"2ZNNGV\-S+  ?2=%?D)X<_X*)VWP
MV_:B_P""MVF?M1^//#G@;]E_]A74?V*4\)^)D\*:M=W_ (:T_P#:!^"VD>(_
M$TGB%_"^GZYX@\2MJ/Q!UO3;72_L^DS/I=M=+"RBTCFN(_8=!_X*[?\ !,[Q
M-JWQ7T;1/VU/@5>77P2T/4_$OQ'NV\5?9-#TG0=(U72M!O=4TCQ+?6MMX<\9
MVIUS7-&T6S;P1JOB)M3U;5=/T[35N[R[@A< _1JBOE;X#_MP?LD_M-?"#Q/\
M>_@C\??AWXS^$'@>;7H/'GCB35V\+:;X ?PQ;RWVNOX^MO&4'A[5/ ]OI^EQ
M-K;W7BNPTBUF\/O;^(+::;1;JVOY>._9Y_X*0_L*_M7^.]:^&/[/'[4/PI^*
M7Q T)+F>X\):#KDEOK6J6-C"L]_JWA2UU>UTT^-]#T]&(U#7O!IU[1K"5)8+
MN^AFAEC0 ^VJ*_-OQC_P5_\ ^":'P\UNW\-^.OVP_A/X1\03^/\ QO\ #*71
MO$-QKVDZCIGB[X=>(=4\)^,(M?M+S0XIO#?A_2_$NBZMHD/C7Q NF>"M7U'3
MKNWT3Q#J+PN!]!_M#_MK?LG_ +*'@+P[\3OVAOCW\.OACX)\9(\G@G5]7UI=
M0F\=(FG0ZLS>!=&T&+5M=\:@:;=6=YGPOIFK9AO].(R=1L1< 'U#17Q!I_\
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M\-1KH^G7Z6J>'[?2["4F7RA=W&K74L>]HYB/T$\!_$+PC\3=!3Q/X)U.;6=
MEN9[6WU1])UK2K:[EMB%N&L3K.G:<]]!#*6MY+NS2>U6ZBN+4S?:;:XBC]'-
M^'\VR6K4IXW!XB%*FZ,?K:H5?JDYUJ,*JA3Q+A[*<H\SA*,9MJ<)Q:3BTL<-
MC</BHQ=*K!RES/V?/'VJ49.-Y0OS).R:NMFGU1VE%%%>*=04444 13_ZB;_K
ME)_Z U5=+_Y!]I_UR'\S5J?_ %$W_7*3_P! :JNE_P#(/M/^N0_F:!=5Z/\
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MUF&RTB;7;V*6TTF.\:_N8WAMW4@'U'\&?^"UG_!-3]H+XI>"?@O\)/V@=?\
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M0 4444 4]0_X\;O_ *]Y?_0#3[+_ (\[3_KV@_\ 124S4/\ CQN_^O>7_P!
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M73-9MSJ5H(KJ:>67]Y=3^&_P[UM?%2:SX"\%ZLOCO^R/^$W74_"VAWZ^,O\
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M7X]@_P"#/_L*QW_J;B#[W&?Q8?\ 8+@?_4+#A11174<H4444 %%%% !1110
M4444 <SH/_(5\:_]C-:?^H;X2KIJYG0?^0KXU_[&:T_]0WPE735RX/\ @S_[
M"L=_ZFX@ZL9_&A_V"X'_ -0L.%%%%=1RA1110 4444 %%%% !1110!S/A+_D
M%7?_ &,WC7_U,M>KIJYGPE_R"KO_ +&;QK_ZF6O5TU<F _W'!?\ 8)AO_3,#
MJQW^^XS_ +"L1_Z>F%%%%=9RA1110 4444 %%%% !1110!S/@K_D3?"7_8LZ
M#_Z:K2NFKF?!7_(F^$O^Q9T'_P!-5I735R8#_<<%_P!@F&_],P.K'?[[C/\
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MN9H;G?$76N?_ ."S7[$O[/?@O]F#X4^(?V>_V1O@UX3^(-C^V1^RHYUSX-?
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MGAO5YO$&C#1K_P *R:[+JVBPV3:CIXTHK+)JSWEM"+$K(UX8B&( /U5^/O\
MP5Q_9Z^ 7Q1^)7PTG^$O[77Q@LO@2(S^T9\6/@'^S=XU^*'P8_9X9O">E>/;
MJ/XJ^/\ 3FM+2UFTCP3K6G>*?$,/A.T\62^&](DN9=>33I]-U2"SZ#1_VE_
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M^.+G]IG3<1ZI<>$M#TKP]/XKN-#L++Y+MWU>72K*UX:SMXMGHO[$^GWOB_\
MX*^?\%C/BUI*^1X#T"U_8H^ 4&HZ5 &T7QI\0O!GP5O?%GCN35-0F2=I?%7P
MW'BS1/"5Q::;=65O:6.J1QZKILUVME?N ?M;1110 4444 %%%% ''_$'_D1_
M%W_8MZY_Z:[NO\X^O]'/Q[&\O@KQ7%$CR22>'=:CCCC4N\COIETJ(B*"S.S$
M*JJ"6)  )-?YYFM?";XJ>&FV>(OAG\0- ?\ N:UX,\1Z4W_?-]IL!_2OZ?\
MHYXS"82EQ>L5BL-AG4J9%R?6*]*CS\L<WYN3VDH\W+S1YK7M=7W1^1>*5"O7
MGD?L:-6MRQS'F]E3G4Y;O VOR1=KV=K[V=MCS^BMS_A&/$O_ $+VN?\ @IO_
M /Y'H_X1CQ+_ -"]KG_@IO\ _P"1Z_IC^V,H_P"AIEW_ (78;_Y;YK[S\G^H
M8[_H"Q?_ (3UO_D/-?>8=%;G_",>)?\ H7M<_P#!3?\ _P CT?\ ",>)?^A>
MUS_P4W__ ,CT?VQE'_0URW_PNPO_ ,M\U]XOJ&._Z \7_P"$];_Y#S7WF'16
MY_PC'B7_ *%[7/\ P4W_ /\ (] \,>)2<#P]KF3P/^)3?_\ R/2_MG*/^AKE
MO_A=A?\ Y;YK[P^H8[_H#Q?_ (3UO_D/-?>8T44DTD<,,;RS2NL<44:L\DDC
ML%2.-%!9W=B%55!9F( !)K]?/^"<^G:[\)O&<VNV\VJ?VSXEAL[+4+&VOKE-
M)MK&&8SP13V,,RV>H:E&[R$7]S',]BDL]IIKPQ7-_+J'RS\"O@/J-YJ-E<7=
MDUQK=T56.,)YD6EQR?*T:$95KMU)6><$J@+00MY9DEN/Z-OV0?V2(=&@L=;U
M:S EQ'*#*F/0XQCKGVR20<YZ_P G>+WBQ'B!U^%>&ZT99)"I&.:9G"TEFM2C
M4C-8?"RZ8"E5A&4JT=<;4BO9M86*>*_:^!^"O[,5+.<VIM9A*+>$PDKKZG"I
M%Q=2LNN)G"32IO2A&34DZSM1_2[X7:K=:M<W=Y=JRS3>%?"FX-C<-NH^+6&>
MY/SMSZ]L8->QUP_A_38=*\2:O90*%2+POX2    '_$S\9K@8]E'3CC&3@&NX
MK^<,)_"G_P!A6._]3<1Z_F?JN,_BP_[!<#_ZA8<****ZCE"BBB@ HHHH ***
M* "BBB@#F=!_Y"OC7_L9K3_U#?"5=-7,Z#_R%?&O_8S6G_J&^$JZ:N7!_P &
M?_85CO\ U-Q!U8S^-#_L%P/_ *A8<****ZCE"BBB@ HHHH **** "BBB@#F?
M"7_(*N_^QF\:_P#J9:]735S/A+_D%7?_ &,WC7_U,M>KIJY,!_N."_[!,-_Z
M9@=6._WW&?\ 85B/_3TPHHHKK.4**** "BBB@ HHHH **** .9\%?\B;X2_[
M%G0?_35:5TU<SX*_Y$WPE_V+.@_^FJTKIJY,!_N."_[!,-_Z9@=6._WW&?\
M85B/_3TPHHHKK.4**** "BBB@ HHHH *YGQ;_P @JT_[&;P5_P"IEH-=-7,^
M+?\ D%6G_8S>"O\ U,M!KEQW^Y8S_L%Q'_IF9U8'_?<'_P!A6'_]/0.FHHHK
MJ.4**** "BBB@ HHHH **** "N9U[_D*^"O^QFN__4-\6UTU<SKW_(5\%?\
M8S7?_J&^+:Y,;_!A_P!A> _]3L,=6#_C3_[!<=_ZA8@Z:BBBNLY3_)C_ &[_
M /D^']LK_LZS]H?_ -6[XPKY3K^B#]J7_@BI\?\ XJ_M-_M&?%#1OV@?A=HN
MC_$CX[_%WQ[I6CZAX0\1W-_I.F^,/B!XA\0V.FWUS!*(+B\L;748K6YGA BE
MFB>2,!&%>$?\.%_VDO\ HY/X1?\ A%>*/_CM=:_:J?0@R!+(<U\7)8?,\D2R
MC,</_JOQ+45#'Y;;!XRC[2GELH3]EB*52'/"4H2Y7*+:LW[,/ GQ1Q<(8K#\
M,U*E#$QCB*,_KN7KGHUDJE.=I8I27-":=FDULU<_%:BOVI_X<+_M)?\ 1R?P
MB_\ "*\4?_':/^'"_P"TE_T<G\(O_"*\4?\ QVG_ ,5:_H(_]'BE_P"(IQ/Y
M?]2OS_!]B_\ B /BO_T2U7_PNR[_ .:OZL_*_P"*U%?M3_PX7_:2_P"CD_A%
M_P"$5XH_^.T?\.%_VDO^CD_A%_X17BC_ ..T?\5:_H(_]'BE_P"(IQ/Y?]2O
MS_!]@_X@#XK_ /1+5?\ PNR[_P":OZL_*_XK5_7?\/?^5=#]E3_LY_QS_P"I
MY^T)7Y<_\.%_VDO^CD_A%_X17BC_ ..U_7!^P3^PE\-_"O\ P2X^!/[+W[4N
MFZ9\:=.\%>._B'XGN;GPQJ?C+P9IU]XAU3XC_$K6-&U*!M%\0>']:B_LW0O$
M\VD3VDFH-8W$Z/=O:R2>5)'ZV0_M#/HJ>,>=95E7AOX@UN)<SX2QE/CG.L%2
MR'-L#5H<-Y4GE>-QL*F:8;!8:I*EC<\RVBJ/MXU)>W<DN2G-KP^(O!SQ R7)
M\9_:^2?V?3S6F\HPE>MBL-4IRQV)7MZ5*:PM3$58J5+"UY<RIM+DMNXW_D>H
MK^R__AVE_P $U?\ HVO4_P#PZWQG_P#GJT?\.TO^":O_ $;7J?\ X=;XS_\
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M5E^5JW_/W:_]^&_QH\K5O^?NU_[\-_C0%_[LOP_S\_S[,U**R_*U;_G[M?\
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M2BLORM6_Y^[7_OPW^-'E:M_S]VO_ 'X;_&@+_P!V7X?Y^?Y]F9OA+_D%7?\
MV,WC7_U,M>KIJXCPK%JATRZV75LJ_P#"2>,00T))WCQ=K@D.<]&D#,H[*0.U
M='Y6K?\ /W:_]^&_QKDP'^XX+_L$PW_IF!UXY_[;C/=?^]8CM_S^EY^?]69J
M45E^5JW_ #]VO_?AO\:/*U;_ )^[7_OPW^-=9R7_ +LOP_S\_P ^S-2BLORM
M6_Y^[7_OPW^-'E:M_P _=K_WX;_&@+_W9?A_GY_GV9J45E^5JW_/W:_]^&_Q
MH\K5O^?NU_[\-_C0%_[LOP_S\_S[,U**R_*U;_G[M?\ OPW^-'E:M_S]VO\
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M_P"_#?XT!?\ NR_#_/S_ #[,U**R_*U;_G[M?^_#?XT>5JW_ #]VO_?AO\:
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M5&$Y0BE:,I12;]>E9TJ;3YDZ<+2NW=<JUO)*3OO=I-[M)Z!7M7PU_P"/&?\
MWG_]&"O%:]J^&O\ QXS_ .\__HP5^M>!O_):5?\ L28[_P!2,"?-\7?\BJ'_
M &&4/_2:IZ=1117]>GYN%%%% !117,^-?^1-\6_]BSKW_IJNZ .FHK_.H_X)
MZ:;_ ,&V,_[''P4E_;B^&GCO7?VJ'TSQ4?BWJNDV'[>DVG7FH#Q]XK7PXUM)
M\(=;M?ARRQ^"QX;A<^&;>. 2QR"_#:L+]F_J#_;%_8!_9?L? ?PP\<_'GQC\
M:-=_X)J?LG_LY^$_AM\.OV OA)IWQVU(ZI\0;[Q3H/A/P!\4-8\0_#+XA/\
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M9+^#G[87_!13QE\:?VDOVC_VC/!]O\9['Q.?CE\4_ 'A3X(6'CV,ZKX.\.?
M_P"'WPY\7^'?!'@JU\-^%Y-%2X2XT35OM6NG5IKN!;6Z?38P#^E:BOY;?VYO
MAW^TU^Q-^QO_ ,$^?!_QI^,OC?\ ;3\6?"W_ (+0?LKZO\,_$%AY\/QN^)?P
MBM/%/C;Q!X#^%_C77O&7B>WTWQG\5;XP77AT:_J^MZ'X<NA>^']*U"YBMM'N
M=>O?T9^ 7_!2+X\:[^U?X@_8\_;!_8OMOV4/BA>_LZZO^TI\'[_1?VB_"OQW
M\)_%#POX:UFST/Q;X1&LZ!X'\('0?&GAN[O&EN+%;;6!=6&CZ_JQALM&B\-:
MEXK /UYHK^>/X%_\%S?B5X]_97\7?M^_&?\ 8'\0?!+]AK1OAC=^(/!WQ>TS
M]HOP#\4O'OQ.^+5E\2M!^#,7P?\ !WP8TWPIX8\5)-XA^*>IZ]X;\/>,?%-Q
MX8T4Z9X0NO$NL0Z9;ZWI]A;_ $CX6_X*7?M#?#OXV?LZ?"S]O#]A6^_90\,?
MM<>)+3X>?!#XG>$/V@/"O[0VA:/\9=4L;J^T'X,?&BP\/^"_!EUX'\6>)(;"
M2/0=9\.2^./#5_JFI6NF)>+IVA^+_$F@@'[%T5_.W=_\%J/VL?$FB?M8_$[X
M*?\ !+S4OBG\ OV)?C%\>?A1\=_BB_[7?P\\*:C+)^S_ *M?3>,;[P!\/-4^
M',WBSQ)>67PXG\-_$J^LGMK:V1[_ %'P-HNH>(-5L8]8G^I/#'[5O[/GQ0_;
M6_9-^*UM\--<TV\^,'_!+?QY^U%X2^-WB7XAZQHJ>!?@5KWBWX->+=0\">*/
M@]86VH^$K_6;V'Q%HOB'4/&C^()M2\-G0+W0M.BO['4Y[M #]@**_$CX;_\
M!5+]IOXB>"OA[^TOI_\ P34^*%_^Q-\5/'%EH?@WXG^"OBG!X_\ VCC\-_$7
MC!?"'@GXWZQ^R1HGPQC\2_\ "$>)9+O3M=N-+\,^/O%/B31_"LLWBJ.QUC0F
ML;R\^M?^"K]Q/:?\$ROV^KFUGFMKF#]D?X]RP7%O(\,\,L?PX\0,DL4L;+)'
M(C ,CHRLK $$$4 ?H%17X=_LH_\ !1W]F_0?V"?V;/"FLVO[5,_B31?V0_@[
MX>U6ZTW]@O\ ;S\2:/-KFG?!GPYIM]<6'C/0OV;M5\+:_IDE_#+):^)]&UW4
M?#^JVK1ZKIVK7FG3PWDGQ/\ \$W_ -OK5?V5?^"1/_!+7X<> ?@OXQ_:K_:P
M_:MG^._A7X!_ [1O&.C^!%\7CX=_&+XB>(_B7XJ\9_%+Q9;ZII'@CPAX!\)7
MMG?ZEJT^E:[=O<7FF6PTVWT8:SK^@@']3E%?C9I7_!5+Q[X*TK]M3P%^U#^R
MG)\#OVJ?V/\ ]DOQY^VCI/PATKXSZ3\1OAU^T+\"?!GA_P 1R)XP^'/Q?TOP
M3IE[H,$OCOPS/X%\3Z?XD^'+:AX2N=7T2^M8O%<S:UI>B>7?"[_@K]^T9JWA
MO]F7X^?'O_@G1KWP%_8K_:@UGX7^'O#_ .T0G[2G@CXB:W\/KCXSG3=,^%/B
MWXD?"BP\#>'=6T3X;_$#Q1X@T#3-)\6'70NCZ%>VOB/Q%96%[K.C^&9P#]Y*
M*_)#XY_MZ_MI:-\3/CCX3_99_P"";'BKXW^ ?V=WT?3?%_Q1^-'QRTG]DO2_
MB;XKO;"+4]4\/?L_Z;\0?ASX@3XAZ#HUEJ&G>9\2K[5O#WA75-4MM6TO0(=8
MMI?#>M>(?S)_:F_X*:_M)_M#W?\ P1@^.7['7PD\11_"/]IKXQ:IX@?P'XC_
M &A+?X1WGQ6^(G@[_A//#6K_  #^)5MHG@[Q;86_@;PWJ7A?_A,M)\=WUQXB
MT77[YM,6?P%I^HZ9;7D !_5+17\>O_!0W]JSQ/\ #S]CS_@MWXC_ &1_A/XM
M^ 'Q:\"?M@? 'X??M ?''P[^T_XQN/$SQ^+KWP';:G\4OA_I-QX7LG\)7&I7
M%YH/P:N_A_X)UG1XO[$\=ZS\0T\1I+X;D\/:O^G&H?M::'\-/VY=>^(7[2O[
M)E[\,/VC_AC_ ,$<_C?^TK\2-<^'_P"T5K/QCTS0/@S\+_VE5?4/@CX9\&1>
M"/ ?@OQIXE\1MI&F?$&Q^)KVVA:]875PWP[_ +-GTT3:S* ?NE17XJ_LE?\
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M-=1RCJ*;O3^\O_?0_P :-Z?WE_[Z'^- #J*;O3^\O_?0_P :-Z?WE_[Z'^-
M#J*;O3^\O_?0_P :-Z?WE_[Z'^- #J*;O3^\O_?0_P :-Z?WE_[Z'^- '-Z#
M_P A7QK_ -C-:?\ J&^$JZ:N7T%E_M3QI\R\^)K7'(_Z$[PF/7UKIMZ?WE_[
MZ'^-<N#_ (,_^PK'?^IN(.K&?QH?]@N!_P#4+#CJ*;O3^\O_ 'T/\:-Z?WE_
M[Z'^-=1RCJ*;O3^\O_?0_P :-Z?WE_[Z'^- #J*;O3^\O_?0_P :-Z?WE_[Z
M'^- #J*;O3^\O_?0_P :-Z?WE_[Z'^- #J*;O3^\O_?0_P :-Z?WE_[Z'^-
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MKG_ITNJYNND\9?\ (W^*O^QDUS_TZ75<W7_&YXE?\G%X^_[+7BK_ -7N//\
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M'G[3'QZ\;?M\?L$_%WQ'^T3X _:1^(ND)\1?@I\&?VC1\%OCEX3\(^++RQ\
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M^AKA_P#!#H'_ ,K:^?Z*/^)G_I(_]'[\8O\ Q9'%W_SW#_B'W G_ $1O"_\
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MI-;6]CJK7EK_ &9=2Q7PN(3;B1?Y"/A;^TE^Q)\(/%FO^%[K]FSXE3:/XO\
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MB?\ ^4U'_"Y/AS_T';G_ ,)WQ/\ _*:C_B6SZ1?_ $8+QJ_\59QS_P#.(/\
M7K@C_HL>%?\ Q(<H_P#FP]/HKS#_ (7)\.?^@[<_^$[XG_\ E-1_PN3X<_\
M0=N?_"=\3_\ RFH_XEL^D7_T8+QJ_P#%6<<__.(/]>N"/^BQX5_\2'*/_FP]
M/HKS#_A<GPY_Z#MS_P"$[XG_ /E-1_PN3X<_]!VY_P#"=\3_ /RFH_XEL^D7
M_P!&"\:O_%6<<_\ SB#_ %ZX(_Z+'A7_ ,2'*/\ YL/:KC_D7-*_[#?B#_T@
M\,UB5RMU\6/ 2>#]"U!M9N!:77B7Q7902_V%XB+/<V&E^#)[J,PC23,@CBU&
MS8221I%*966%Y'AG6/FO^%R?#G_H.W/_ (3OB?\ ^4U?2<5_1U^D%B\TPM7"
M^!7C'B:4.&^#,-*IA_#'C:M3CB<%P?D6#QF'E.GDDHJOA,70KX7$TFU4H8FC
M5H58PJTYQ7/A>-^"Z=*4:G%W#%.3Q&,J*,\_RJ,G"KBZ]6E-*6+3<*E*<*E.
M6TX2C.+<9)OT^BO,/^%R?#G_ *#MS_X3OB?_ .4U'_"Y/AS_ -!VY_\ "=\3
M_P#RFKYO_B6SZ1?_ $8+QJ_\59QS_P#.(Z/]>N"/^BQX5_\ $ARC_P";#T^B
MO,/^%R?#G_H.W/\ X3OB?_Y34?\ "Y/AS_T';G_PG?$__P IJ/\ B6SZ1?\
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M=N?_  G?$_\ \IJ/^);/I%_]&"\:O_%6<<__ #B#_7K@C_HL>%?_ !(<H_\
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MLK;IJ_BC7CIMK;'5_$6JI9VB:EK>H?:-3OEM;=;JZE$$06[_ &+I_P#SR?\
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M/_YY/_W^F_\ BZ/[%T__ )Y/_P!_IO\ XN@->R^]_P"1JT5E?V+I_P#SR?\
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MT5G=@H) &O9?>_\ (VZ*^3?V3OVL/V6OVX_AKJ/Q>_98^)-O\5OAYI'B_5/
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MB-X\U*P@\#:?K'B/2]/U/Q%9W$DR0_??]BZ?_P \G_[_ $W_ ,70&O9?>_\
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M==7]?A8Y;RZN_J_3R]?ZVU  H  P!P *6LK^Q=/_ .>3_P#?Z;_XNC^Q=/\
M^>3_ /?Z;_XN@6O9??\ \#U_IZ:M%97]BZ?_ ,\G_P"_TW_Q=']BZ?\ \\G_
M ._TW_Q= :]E][_R-6BLK^Q=/_YY/_W^F_\ BZ/[%T__ )Y/_P!_IO\ XN@-
M>R^]_P"1JT5E?V+I_P#SR?\ [_3?_%T?V+I__/)_^_TW_P 70&O9?>_\C.\%
M?\B;X2_[%G0?_35:5TU</X.TBQE\(^%9'C<O)X<T-V(FE +/IEJS' < 9)/
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M70&O9?>_\C5HK*_L73_^>3_]_IO_ (NC^Q=/_P">3_\ ?Z;_ .+H#7LOO?\
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MWQ%/(\EX1SB%3*\OS?@SA7"9#D5.'$$,-A*>65*^'J5<-7PT<'@Z."HNKXW
MM&AE.99EP]ALRR/,:.'RS+<RC/(<BP648:#Q>*S'#..(KX;-,QJ8S%R>#=2H
M\0H3C&I"HZM6567+S'[2'PUU;XR_L]_'+X2:!J%OI6N_$WX1_$3P%HNHWDT]
MO86FK>+/">K:'ITNIRVT%U<KI0O+V%=5%O;3SOIS7,<43R,JG^:;P1XE_:Y^
M$_Q1M++2?^"5WQ"EUF#]A_2OV)M3\*6GA*YN/@EK_C.T\<ZKK6J_%37O%6F>
M#[[P/KGA7Q(]VESX@TF]\221:J)KTWWQ"FM)EUV7^E?]I/6?'WAW]G;X\>(/
MA4MR_P 3=#^#GQ,U?X?"RM(M0OAXTTWP9K-YX9;3].GM+^#4M036(;-[#3;B
MSN+;4+Q8;.X3R9Y"/YY-!\>-^WMX>\/>%M8_:*_:6\/?LE?L@_LI2?%#]I_X
MRZ4FL>'_ !SXK_:1G67Q/JFAZTDEAJUUXC@^'MMI]]K>GVUOI&LP69\-ZQ::
M3<E-0\/^)[G]#^B)7S.CP%QS/-\FX8SOPTAG]&/$=;-5Q[6S'AS&XK*(T<'7
MH9?P3FN3/.JW%>9QX?X9X>R#$XRCFF;YU.HLDQV64,)G=7$>)XF1H2SC*%A<
M3F&%SYX*;P,<,\FA0QU*GBN>K"=;-L-BUA89=A_KN/QN-A2EA\-A4OK='$3J
MX2-/]X_V*/@EXB_9R_94^"'P5\7:JNL^*? G@NWL?$5W%<&\M8-:U*^OM=U+
M2=/NRD1N=*T&[U270])N#%'YVF:=:2>6F[:/W<^#7_)MO@W_ +#^N?\ I[\0
M5_/]_P $^/&GQ/\ B)^Q=^SOXT^,DFJW/Q$U_P"']M=ZWJ.N#_B<:U9QZEJ-
MKX:\0ZDY1'N+SQ'X6M]$UV>[F4W%X^H&[N6>XFD=OZ ?@U_R;;X-_P"P_KG_
M *>_$%???0WCG4/I4?25AQ)C<NS+B*' GBY'/\QR=1648_.H^)_"*S3&Y6HJ
M,5EV*QRKU\"HQC%8:I2LDM#QO%)X27AUP)+ 4J]# RSCAEX.ABK_ %FCA'D.
M8O#TL0VV_;TZ/)"M=M^T4KMFO1117][GXR%0P7%O<H9+:>&XC626%G@E25%F
M@D:&>(M&S*)(94>*5"=T<B,C@,I FK^433/'WQL_98^//[6GP0^!G_!5K]A_
MX<>%=,^)OQ=_:0\1_!SQ7\'O&WC7P[^SOHGC/XJV.D>(]'U#QW%'=>$O!%\G
MC3QIX?MO$OPZ?Q9;IHWBW6=2OM#\(^'K"]U*(>_D>0RSU8V%'%PP^(PL*-6%
M.KA<?B*=:E.HZ55NIE^%QE2C*G*5'E]I05*ISRC[6$U"-3CQ>,6$=)SIN<*C
ME%RC4HPE&22<4HUJE*,U)<U^6?-&R?*TVX_U=T5Q'PSGUZY^&_P_N?%7B;P[
MXT\3W'@CPI/XD\8^$(HX/"?BW7I=!L)-8\3>%X(IKB*'P[KVH-<:KHD4=Q/'
M'IMW;(DTJ@.W;UX4X\DYPYE+DE*/-&_++E;7-'F496=KKFC%VW2>AUQ?,E*S
M5TG9VNKJ]G9M776S:[-A7M7PU_X\9_\ >?\ ]&"O%:]J^&O_ !XS_P"\_P#Z
M,%?L/@;_ ,EI5_[$F._]2,"?,<7?\BJ'_890_P#2:IZ=1117]>GYN%%%% !1
M110 4444 %%%% !1110 4444 %%%% %/4/\ CQN_^O>7_P! -/LO^/.T_P"O
M:#_T4E,U#_CQN_\ KWE_] -/LO\ CSM/^O:#_P!%)0+JO1_G$LT444#"OQ8_
MX+X?M-WO[/W_  3W\<>!/">JII?Q1_:\\2:#^R/\/;G^SM4UE].C^+Z7MA\1
M_$$FD^'K34O$\UOHWPJL_&BVM[X<TG5-7L/$E_X;-A8W5]<6EM-^T]?"/Q=_
M8ALOC5^W-^RW^V)XU^)%U=>'?V1_ _Q1T_X7?!&/PK;_ -F'XI_%NR/A[Q)\
M4]:\7R:Z[WQL_!\&E:5H/A<^%E.DZUI</B:V\0B=S8( ?B-_P3W^-_[+O[,'
M_!4G1OV9OV7O&GB_6OV:/VR/V3OA9X:\.VWCCX:?%7X<7.@?M0?L6_#FV\ 0
M+86OQ)\!_#[3Y4^)G[//ANVU_P 8:WI-KJNH^)?B/I=DFHRV\MQIT5Q]"?!?
M6O\ @HC_ ,%'+']M;X\_"/\ ;CUO]E>U^$_[2OQN_9]_8]^"?ACX3_"/4OAP
M9O@7=P^'H/&7[2^H?$/X<>.OBEKS?$[5I/*U[PC;)X<N?ATD$_B#1-+UI+[3
M_#]M^G/[>G[$UK^VKX+^#=GI/Q)NO@S\5/V>/VA?AG^TG\&?BK8^%+;QJ_AG
MQU\-[R[9+'5/#%QKGAD>(/#7B'2]2OM/UC17UZPM;B9=,OKI;P:9':3?'WQ)
M_P""4/QCN-=_:N\,_LX?MW^)OV;OV;/VV_'?BWXE?M!_!2U^ G@GXD>*(O&G
MQ6TNPT+XYZW\&OC)KOBS1]6^&$_Q;T>Q*ZDNH>%?',?A;5KR\UOP<NC7C6XM
MP#6_94_:%_:K\1?\%//C_P#LT?'WQKX7OM+^&G[#W[+7Q UCP)\/K*"7X;:+
M\<?%SS67Q3U_P)K^L>&M%^(&H>&=8U>WNO[#M?%4_FVVDBT$FG6MX)B?PO\
MVV_BC^T-^U3^R3^U?JOQ)_:&\>Q67[/7_!P_XY_9A^'>@:'X>^%EII=I\*]
M^(OP=L?A7IU]+/\ #^ZU2\OO@_<WVN:KX/OY-0\_5KW7KY/'C>+[&#3;2Q_;
MSQU_P2+\3>#/C-\'?C?^P+^UQK?[$_BCX:_LKZ#^QSXEM+WX)>"_VC]*\?\
MP<\(Z]#XE\*W=U:_$/Q!HJ:;\1['5T%WJGCS45\3WFN26M@MQ8P0R>(8?$?
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MG'?>-[6V&CZ[%K_]L:II$Z::)X]0BN_M2?L ^/OBC^TY\/\ ]M']EW]IV_\
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M$U(>)FG>\FTS06M39K&MM<"<O%7_ ."@W[#>K?MK>%_@5/X$^-VH?LZ_&?\
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M.4**** "BBB@ HHHH **** .9\%?\B;X2_[%G0?_ $U6E=-7,^"O^1-\)?\
M8LZ#_P"FJTKIJY,!_N."_P"P3#?^F8'5CO\ ?<9_V%8C_P!/3"BBBNLY0HHH
MH **** "BBB@ KF?%O\ R"K3_L9O!7_J9:#735S/BW_D%6G_ &,W@K_U,M!K
MEQW^Y8S_ +!<1_Z9F=6!_P!]P?\ V%8?_P!/0.FHHHKJ.4**** "BBB@ HHH
MH **** "N9U[_D*^"O\ L9KO_P!0WQ;735S.O?\ (5\%?]C-=_\ J&^+:Y,;
M_!A_V%X#_P!3L,=6#_C3_P"P7'?^H6(.FHHHKK.4_!OQE_R-_BK_ +&37/\
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MQ%3X:Z%J/BS6/"-OH6K0:7XE\6Z5X0N/!T.MJFG]!\6+?Q_^RW\#_P#@XO\
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MD6RCO;<M<+W/Q*^.-Y\.OB]^S_\ "B#X-?&CQ];?';5?'^F7OQ.\ >"Y=?\
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M83%NG4R%4WBL-1Q#IJ<<X<E!U83Y.9QBY<MKN,;WLK=S_P +/^)?_10_'/\
MX5NO_P#RPH_X6?\ $O\ Z*'XY_\ "MU__P"6%<-17^.O_$2O$;_HO^-O_$JS
MW_YO\E]Q_3W]@Y'_ -";*?\ PW8/_P"4^2^X[G_A9_Q+_P"BA^.?_"MU_P#^
M6%'_  L_XE_]%#\<_P#A6Z__ /+"N&HH_P"(E>(W_1?\;?\ B59[_P#-_DON
M#^P<C_Z$V4_^&[!__*?)?<=S_P +/^)?_10_'/\ X5NO_P#RPH_X6?\ $O\
MZ*'XY_\ "MU__P"6%<-11_Q$KQ&_Z+_C;_Q*L]_^;_)?<']@Y'_T)LI_\-V#
M_P#E/DON.Y_X6?\ $O\ Z*'XY_\ "MU__P"6%'_"S_B7_P!%#\<_^%;K_P#\
ML*X:BC_B)7B-_P!%_P ;?^)5GO\ \W^2^X/[!R/_ *$V4_\ ANP?_P I\E]Q
MZ;-\1?B"FBZ?>IX[\9+>7&J:O:SW:^)];6YGMK.TT.6TMYIQ?"62"UEOKV6W
MA=VC@DO+IXE5KB4OE_\ "S_B7_T4/QS_ .%;K_\ \L*P;C_D7-*_[#?B#_T@
M\,UB5]1Q?XC>(5'-L)"EQWQE2B^%^"*KC3XGSN$74K<%\/UJU1J..2<ZM:<Z
MM6;7-4J3E4FW*3;Y<'D>22I3<LGRN36*QL4WE^$;488VO&$;NCM&,8QBMHQB
MDK))'<_\+/\ B7_T4/QS_P"%;K__ ,L*/^%G_$O_ **'XY_\*W7_ /Y85PU%
M?+_\1*\1O^B_XV_\2K/?_F_R7W'5_8.1_P#0FRG_ ,-V#_\ E/DON.Y_X6?\
M2_\ HH?CG_PK=?\ _EA1_P +/^)?_10_'/\ X5NO_P#RPKAJ*/\ B)7B-_T7
M_&W_ (E6>_\ S?Y+[@_L'(_^A-E/_ANP?_RGR7W'<_\ "S_B7_T4/QS_ .%;
MK_\ \L*/^%G_ !+_ .BA^.?_  K=?_\ EA7#44?\1*\1O^B_XV_\2K/?_F_R
M7W!_8.1_]";*?_#=@_\ Y3Y+[CN?^%G_ !+_ .BA^.?_  K=?_\ EA1_PL_X
ME_\ 10_'/_A6Z_\ _+"N&HH_XB5XC?\ 1?\ &W_B59[_ /-_DON#^P<C_P"A
M-E/_ (;L'_\ *?)?<=S_ ,+/^)?_ $4/QS_X5NO_ /RPH_X6?\2_^BA^.?\
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MMX-L;F9;F[@\->"M"L?#NC"^NUBA^VZ@]AI\$FH7S1))?7KSW<J^;,]>DT4
M?D+<_P#!%#]D./X,/\%/"WB?]H'X<Z9X<_:1\;_M1? KQW\-?BC;^#/BA^RQ
MX]^(*Q0^(_#G[.OB_2?#$3^#_AI<6JW$"^!_$%AXOT^6>]EUF^EO?$-KI>L:
M?TW@S_@CO^R/H?P5_:A^#?Q$O_C1^T7>?MEMX<;]HSXT?M!_$R?QS\<_B&W@
M0V\OPR%SXWT[2/#=EI4'PLNK.QO/A_9Z+X?T^RT2>PL8Y+:\M+*VMHOU4HH
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MHVH2Z9;^'K/46\9RZI;1QW^KKK":7/9EHH="MI2)Q\T_%W_@C]^S]\4?B?\
M%'XBZ!\;/VQO@%HOQ[UN\\2_M#?!C]G3]HO7_A;\$?COXAUG3K#1_%.N_$'P
M/::5J4UOK/C;1M,LM*\:ZKX(UGP=J'BBR2Z35[FYDU/59;[B?V6O^"O/AO\
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M F"X;RBOE/">58_B7.N*N%*N6915RCA?)\KS2>)PN39UFF=8GZKC\%B<+"&
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MXNA#X:FG/6HTX7U5H\W,];)V=O2J*R_[4_ZAVJ?^ G_VRC^U/^H=JG_@)_\
M;*_K$_.KKO\ UI_FC4HK+_M3_J':I_X"?_;*/[4_ZAVJ?^ G_P!LH"Z[_P!:
M?YHU**R_[4_ZAVJ?^ G_ -LH_M3_ *AVJ?\ @)_]LH"Z[_UI_FC4HK+_ +4_
MZAVJ?^ G_P!LH_M3_J':I_X"?_;* NN_]:?YHU**R_[4_P"H=JG_ ("?_;*/
M[4_ZAVJ?^ G_ -LH"Z[_ -:?YHU**R_[4_ZAVJ?^ G_VRC^U/^H=JG_@)_\
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M!/\ [90%UW_K3_-&I167_:G_ %#M4_\  3_[91_:G_4.U3_P$_\ ME 77?\
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M_P 5+GQ7XN\$#Q?9^*/"NN^#?B[IOAZ^?4M1\(:C;P 77?\ K3_-'XN?%_\
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M;<M_P5T_;FE6WO\ 4[*SG,3Z_P""U6417$\<AC9D=5<+M+(P!)4X^X?V0_\
M@G+^PO\ L'WOB#5_V4OV9=%^%?B+Q38R:5KOC W/B_QSXZOM%FO+/4+C0!X[
M^)'B?QAXPM?#EUJ.G:=J%WX=LM;MM$NM0TW3KVXL);JPLY8?G3QY_P $-/\
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M^H=JG_@)_P#;*/[4_P"H=JG_ ("?_;* NN_]:?YHU**R_P"U/^H=JG_@)_\
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MA1_PS_X'_P"@3:_]^8O\*]F_M3_J':I_X"?_ &RC^U/^H=JG_@)_]LIW??\
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M^U/^H=JG_@)_]LH"Z[_UI_FC4HK+_M3_ *AVJ?\ @)_]LH_M3_J':I_X"?\
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MVI_U#M4_\!/_ +91_:G_ %#M4_\  3_[90%UW_K3_-&I167_ &I_U#M4_P#
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M87,'&C)8G#*EB,-A,0GAYX^<IT)5_>QW"+P^3X?-\/FN"FZF"H8RME&-JX?
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M=Z'X,:)OV;?&VN:E9Z-=2_M(^'M?U/0O$OPTT'PUJNI:/9>(]4&DZTUNVO\
MAFXTZUU2R\4>'+G5/J/]KK]L+X)?L3?L_>)_VD_C9K=_'\/_  \V@V=A9>$[
M.W\0>+/&^O\ BK4;72O#'A;P%H?VZR7Q)X@UVZNTDL[6*]@M8-,@U#7-2O;'
M0]+U+4;0 ^HJ*^ OC5_P4=^!?P)B^'7AKQ3X3^-_BK]H+XG_  ^L_B7X?_9
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M<> [_P 5W_@.XLK>Y\=>!;:XO;X^)/ACXD-\LO@_QA$UO#KT-O=R1VD'D$,
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M]C-X*_\ 4RT&N7'?[EC/^P7$?^F9G5@?]]P?_85A_P#T] Z:BBBNHY0HHHH
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M1_#7BN&RDL?"WA_XM3V;>!=$T.&>SFTR#QCKN()DU-4_.?\ X);?''_@JO\
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MIEEKT'BO\^O WQ5_:S_;G7]JS]IV_P#%'_!9?3?B#'\</C3X,_8[TG]CO5/
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MZ-:_TD_ W_@EI\/_ (2?M(:K^UWXS_:/_:F_:(_:&U[X+^*?@!K'C7XU^,_
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M:P:G-/>:?-;+X=U'4M#O #\<_P!EK]LO2OV=_%O[27B#3_C1_P %)/AU\1?
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M"/ 'PP^'OA>YUSX@Z9;1:/X_\5^(=.UK6?%.D++8WDJ)J6MOJOSYX3_X(;_
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M#_Q)CXL\%ZYHVI"P:Y6S-E<ZKKESJOD^C_\ !##]D7PE\ _#OP"\ ^/?VC/
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MS\%?]#KBK_PJRC_YS?U=^5OV._X:G^"G_0Z6_P#X)_$7_P J:/\ AJ?X*?\
M0Z6__@G\1?\ RIK\<:*/^*LWC_\ ]$)X/?\ AGXU_P#HZ#_B6?@K_H=<5?\
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M!QW[#@5V%?WQ@_X,_P#L*QW_ *FX@_&\9_%A_P!@N!_]0L.%%%%=1RA1110
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MN#_["L/_ .GH'34445U'*%%%% !1110 4444 %%%% !7,Z]_R%?!7_8S7?\
MZAOBVNFKF=>_Y"O@K_L9KO\ ]0WQ;7)C?X,/^PO ?^IV&.K!_P :?_8+CO\
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M51&,B!OX=_#7P$^,/PE^ W[$'[5OP3_93^!_[*_QJ\:>.OV>/&ND_M\^)?\
M@J#XCUSX@?M>:U\8E\,>,/&O@WXK^#_%/PJTB3XCM^U!#87FNZG\,]7U[4K3
MPQJ<^I-HNE+IUOKMAJ/W9^S7_P $Z_V6_P!O;]M#_@L[:?M6^#]<^*>@>%/V
MNH-!^'7AFY\>>/-"\/?#;6?&7PHTN+QI\0/">@>'O$NF>'8_B%XCLM-\':?+
MXLU31M3U:PL?!.B66GW,%C+J5I> ']$OQ0^*GQ7\&?&7]G7X?>"O@;_PL7X>
M?%C5OB'8_%OXL?\ "S/#?A'_ (418>%/"L&M^$]3_P"$$U;3KK7/BA_PG6N2
M2^&_L7AF]TV;PQY/]L:D]S:2+$(OVM/C]#^RW^S/\??VASX:B\<7'P/^#GQ"
M^+B>!CX@3PQ-XLA\ ^';S7I=&773I'B!]&BU![:&PDU@:#K":>]U',VGW1VP
M2?R>?L+_ !-\=_%_0_\ @U?\<?$GQ-JWC#Q;-XK_ ."G/A>Y\0:[?76IZM>Z
M/\/-'\=?#WPI#>ZA>S7%W>2Z;X3\+:)I:SW$TDLD=DA9L\#GO#?[%O[+O[0/
M_!$C]JO_ (*-_M&2:S<?\%!-<\%_ME>+_BI^T!??$KQSH/CGPM\9O!_CKXR^
M!]!^" \.KXEL_#/A+PMXG\/7.B?![6/AA%X7TW2?%_A/QA:VKZ)Y=YX8&F '
M]A7P$^+L'QL_9]^"WQYNM(A\&VWQ=^#OPX^+<^@7&L)JT'A6+Q_X*T;QA)HT
MNOR6&BQZG'HBZN;%]7?2]*6^6V-XVGV(E^S1>MW-W:V47GWES;VD&^*+SKF:
M."+S)I%AAC\R5D3?-*Z11)G=)(ZH@+, ?Y.?V;/A3X'_ &V?VOOV-/V7/VO-
M/NO'W[/7P0_X(I_LA_'_ ."'[.?B'6=4'PN\??$/Q+;>%O!/C#XY>)/#>C:C
MIMCXHUCP?:RR?#K3="\90:]I]I#<2ZWIMC93-+/<_%'[6=A=?!C]DC_@N'^Q
MS\'_ !SXVN/V3?V5_P!K3_@G1;_LQ03>-==\33?!?Q'\3/&_P^\5_&;X7?#S
MQGJ]YJFNZ/I'PO\ '-CI5II'AY==NG\*:U]MU*:WM_$6M:YJ6L ']T$<\,KS
MQQ312/;2B"Y2.1'>WF:&&Y6&=5),4K6]Q!.(Y KF&>&4#9(C,-<0)/%;//"M
MS/'--#;M(BSS16[0K<2Q1%A))' UQ;K,Z*5B:>$.5,J!OYF?%'[&O[.__!/#
M_@L+_P $A-!_8P\ 7OP3T3]HOP9^W_X*^.7AWP]X[\>ZEIOQ?T7X.?L^Z?X]
M^'4'CT>+?$^OGQ%J>C>,?$-YKG]OZO)=:M>ZC;Z/<ZE>W1T/2_LOXT?!_P"#
M?Q9_:>_82^-'[>/Q2_9-^&OBG]HGQKXI^,/Q)\0?\%,O'O\ P4H\0_!/XM?L
MW_%#X:^.O%FC^!9= ^&D7PMU(_"+1_@;<V&@Z3H/PNTGQ=IL7C#P_IOAQ-*D
MTK2]2\#6?AT _MB^('[2]C\+OVF?@C\!/''A@Z/X7_:)\->-;?X5?%C^V+J?
M3-2^-/@*)/$6J_!37M&7PZEEX=UCQ%\-O[4\=?#S7+GQ7.GC#_A"_'_AT:/I
M>IZ)HC^*?J"OYP_^"E?B;QYJ7_!+K_@FM\6_&^N>%_'O[4?AK]IS_@FK\2O
ME_X1UJSUGPS\6_VC9;[1;/4;GP9XDT"73[&[T3QQI.N^._$&EZKH=C?V=SH-
MPW]GV1M9H]0M/Z/* *>H?\>-W_U[R_\ H!I]E_QYVG_7M!_Z*2F:A_QXW?\
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MP_L-)U+4M4%Q>SF;0+:RENY%ACL=)_9Z@ HHHH **** "BBB@ HHHH ****
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M8 C\1FOB']ECX/#P7H&GP31[9]!MTTL[A]TSLVO-GCUUK/ISZD9^W@   .@
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MW!_]A6'_ /3T#IJ***ZCE"BBB@ HHHH **** "BBB@ KF=>_Y"O@K_L9KO\
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MAZI?6/\ :.C:GIVK67G_ &G3KZTO(H;B/N** /E;X=_L3?LQ?"?XA_"CXJ^
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M^V_C!^S%_P +2_X4=XO_ .$B\5Z;_P (1_PNGPI9^"/B9_Q(-(UVP\+^)?\
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M_E-7]$?_  C.D_\ /K#_ -^U_P :/^$9TG_GUA_[]K_C1_Q+7]'/_HP?@O\
M^*MX&\O^I%Z_AYA_Q$'CS_HL^*__ !(\Y_\ FSU_IZ?SN?\ "EOVDO\ H/W/
M_A/Z!_\ *:C_ (4M^TE_T'[G_P )_0/_ )35_1'_ ,(SI/\ SZP_]^U_QH_X
M1G2?^?6'_OVO^-'_ !+7]'/_ *,'X+_^*MX&\O\ J1>OX>8?\1!X\_Z+/BO_
M ,2/.?\ YL]?Z>G\[G_"EOVDO^@_<_\ A/Z!_P#*:C_A2W[27_0?N?\ PG]
M_P#E-7]$?_",Z3_SZP_]^U_QH_X1G2?^?6'_ +]K_C1_Q+7]'/\ Z,'X+_\
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M2,:?&'%%.+H86HXPXAS>,74JX:C5JS:CBTG.I5G.I4D_>G4E*<FY2;/YW/\
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M^A-E/_ANP?\ \I\E]Q\C_P## W[$O_1J/P!_\-;X1_\ E71_PP-^Q+_T:C\
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M_P"B!X*_\17(O_F ^@_M_/?^AUFW_AQQG_RX\?\ ^% ?!C_HG'AG_P  V_\
MCE'_  H#X,?]$X\,_P#@&W_QRO8**/\ B&OAU_T0/!7_ (BN1?\ S ']OY[_
M -#K-O\ PXXS_P"7'C__  H#X,?]$X\,_P#@&W_QRC_A0'P8_P"B<>&?_ -O
M_CE>P44?\0U\.O\ H@>"O_$5R+_Y@#^W\]_Z'6;?^''&?_+CQ_\ X4!\&/\
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M:U** LNR^Y&7_8NF?\^W_D:X_P#CM']BZ9_S[?\ D:X_^.UJ44!9=E]R,O\
ML73/^?;_ ,C7'_QVC^Q=,_Y]O_(UQ_\ ':U** LNR^Y&7_8NF?\ /M_Y&N/_
M ([1_8NF?\^W_D:X_P#CM:E% 679?<C+_L73/^?;_P C7'_QVC^Q=,_Y]O\
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M73/^?;_R-<?_ !VC^Q=,_P"?;_R-<?\ QVM2B@++LON1E_V+IG_/M_Y&N/\
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M>L^+]'TK2-2T"QU33X8=1\->']7U>TUC4KJQT26VM %U+S;FTCG]CH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(],\!_#6]\0?VOKUX[0:;I.L7FEVA=(0UUJ-\\-S!;6]O:VEOYMW>SD".W@
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M*X_;R^T:TN]!O/#T*K8V-UI%QHT26L:(EG:36;V2+;P@"-%MX6 AC "*$50
MHQ7X9?"K_@CA^T-\&?@#X2_96^&__!6C]JCP!^S[X.M-5TG1_"'P\^$_[.W@
MOQ9IVB>(?$&J>)/$-GH_Q:T_P--\3-/OK_4]<UBYM=6G\2:A<:7->*+6,V=M
M!9* ?GS^P3\=_B?\//V;_P#@GG\'O"'BU?$?PJ\+?\%G_C?^Q]X \8>+O#_A
M7QOJOCS]F'P;X9^-OB#P5-H]_P"-M"U[7_ <FGW\"^'=$U#P[J&D>*]#\/\
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MLI(HHJJ/^]TO^PB'_IQ"E_#?^!_^DCK)52RM$151%M8%55 5558D"JJC "@
M     8'%6:**QG\<O\4OS94=EZ+\@HHHJ1A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ny20006478x8_graphic01x1.jpg
<TEXT>
begin 644 ny20006478x8_graphic01x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
M+0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0":
M )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0T!
M$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I
M ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F<"
M<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P-:
M V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$
M?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%
M!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'
M3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC[
M"1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*
M\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-
M#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/
M>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('
M$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4
M\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W
M&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;
M8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I
M'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J\B
MW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR;H
M)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K
M:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^
M,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U
M$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_.;PY^3HV
M.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_
MXD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:
M1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+
MXDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q
M4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9
M&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %
M8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUG
MDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>
M;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW
M5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$
M?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(
M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$_
MD:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:
MU9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16
MI,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVN
MH:\6KXNP +!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1
MN4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'# [,%GP>/"7\+;PUC#
MU,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZV
MSS?/N- YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':
M=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-
MYI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_R
MC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<
M_VW__V1E<V,         +DE%0R V,3DV-BTR+3$@1&5F875L="!21T(@0V]L
M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M4I2P.%<I2>%I-MMTKMMZMO5O5GY_5JU55JI5*EO:3^W+^9^9]6?\-W_MP_\
M1Y7[5G_B0_Q=_P#FPH_X;O\ VX?^CROVK/\ Q(?XN_\ S85\IT5Z7]BY-_T*
M<L_\(,+_ /*C/VU7_G[4_P# Y?YGU9_PW?\ MP_]'E?M6?\ B0_Q=_\ FPH_
MX;O_ &X?^CROVK/_ !(?XN__ #85\IT4?V+DW_0IRS_P@PO_ ,J#VU7_ )^U
M/_ Y?YGU9_PW?^W#_P!'E?M6?^)#_%W_ .;"C_AN_P#;A_Z/*_:L_P#$A_B[
M_P#-A7RG11_8N3?]"G+/_"#"_P#RH/;5?^?M3_P.7^9]6?\ #=_[</\ T>5^
MU9_XD/\ %W_YL*/^&[_VX?\ H\K]JS_Q(?XN_P#S85\IT4?V+DW_ $*<L_\
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M]'E?M6?^)#_%W_YL*/\ AN_]N'_H\K]JS_Q(?XN__-A7RG11_8N3?]"G+/\
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MS_Q(?XN__-A7RG11_8N3?]"G+/\ P@PO_P J#VU7_G[4_P# Y?YGU9_PW?\
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MY3HH_L7)O^A3EG_A!A?_ )4'MJO_ #]J?^!R_P SZL_X;O\ VX?^CROVK/\
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M_P 2'^+O_P V%'_#=_[</_1Y7[5G_B0_Q=_^;"OE.BC^Q<F_Z%.6?^$&%_\
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M $*<L_\ "#"__*@]M5_Y^U/_  .7^9]6?\-W_MP_]'E?M6?^)#_%W_YL*/\
MAN_]N'_H\K]JS_Q(?XN__-A7RG11_8N3?]"G+/\ P@PO_P J#VU7_G[4_P#
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MV:/)(ZVUE:P0*[NP0%F)^!?^&[_VX?\ H\K]JS_Q(?XN_P#S85[E_P %>?\
ME);^V/\ ]E@U+_TU:37YPUYG#.3Y34X;X?G/*\NG.>295.<YX'#2G.<L!AW*
M4I.DW*4FVY2;;;;;=S3$5:JKUTJE1)5JJ24Y62YY:;GU9_PW?^W#_P!'E?M6
M?^)#_%W_ .;"C_AN_P#;A_Z/*_:L_P#$A_B[_P#-A7RG17M_V+DW_0IRS_P@
MPO\ \J,?;5?^?M3_ ,#E_F?5G_#=_P"W#_T>5^U9_P")#_%W_P";"C_AN_\
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M'B/1O%O_  A?B.^\13ZQX6_X2G1X(-)\1_V'>6/]MZ;#%8ZG]JM8TB'Y8_\
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M$S_ABW_ANK^W/ O_  J3_A?_ /PSC_PCO]I^(/\ A8W_  F__"&_\)Q_:O\
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MMA?\H=?^"/'_ &'_ -O'_P!:">OQBKY;A#_D68__ +*GC3_UKLZ.G%?Q*?\
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M< K?\*?\C3X:_P"P_H__ *<;:NX^!'P=\3?M"_&GX5? KP7?:%IGB[XO^/\
MPI\./#6H^*+K4++PY8ZYXPUFTT/3+K7;O2M,UK4[;2H+N]BDOI[#2-3NXK=9
M'M[&ZE"POO\ Q,^#OB;]GK]I+QC\"O&E]H6I^+OA!\7M2^''B74?"]UJ%[X<
MOM<\'^*GT/4[K0[O5=,T74[G2I[NREDL9[_2-,NY;=HWN+&UE+0IRU,7AO;S
MP/MH?7/JDL7]7N_:?5N=T?;6M;D]K[E[WYNA:A+E52SY.=0YNG-;FMZVU/\
M6^T7_D&6W_;;_P!*):U*R]%_Y!EM_P!MO_2B6M2O\VC]$CLO1?D?Y,?[=_\
MR?#^V5_V=9^T/_ZMWQA7RG7U9^W?_P GP_ME?]G6?M#_ /JW?&%?*=?Z.Y+_
M ,B;*?\ L68#_P!1:1^>5OXM7_KY/_TIA1117IF84444 %%%% !1110 4444
M %?U+_L#?#'P_P#&+_@WF_;&^'_BCXN_#KX%Z'K/[=.BRWWQ-^*L^NVW@G0$
MTS2OV1]36/4I/#>C:]JS76J/:+I6DPP:<\4^JWEG#=7%G;/+=P_RT5^B'@#]
MO[4/ O\ P39^-W_!.R/X76>IZ=\9_CCI/QJF^*[^+I[2]\/3Z5_PJ''AZ+P:
MOAVX@U.*?_A5$6=3?Q+8O'_;DF+%_P"SU^V?)\895F&;8/*:&77C6PW$F18^
MK6C+#J6&PV#QT*V(Q4(XI^RJRP\$ZD:+C4=5QY%2J7Y7UX2K3I3K.I9J6&KT
MU%\UI2G"T8MP]Y*3TO=6O=M;G[+^)OC7^Q3XYU;_ ((S?\$OO@K\15_;*\$?
M!W]J/P9J/QH^*/C3X>ZMI7A#Q.OC?XA36EU\.=&TGQW:_P!HW?A.YB\7:_#=
M^'K6+4/"=EX5T_P/I8U_Q)JMKJBZ1%XK^!_[$G[3O_!6'3O^"77PL_9E^'_P
MK^$GA+]J#XF^/?B9\:_"=S=P?%OQT_@WX;?$'QW\0_@O87/D65IX'^$]GXOB
M3X<>%/"GA 6EKX6T'PK8^(;'[1K4]Q=+_.9^S1\:)_V<?VAO@E\?;;P]%XMN
M/@S\4?!/Q,@\+SZF^BP^()?!GB"PUY-'EU>.QU-]-CU!K$6K7R:=?-;"0S"U
MG*>6WN9_;P^*/AO]OSQ%_P %!OA5INF^ OB5J?QR\:_&G2?#%[<W'B;0;%/'
MFIZU+XB\"ZQ=QQ>'[[7/#FM>'?$.L>$-<GM%T#4K[1=2O7L+C1[Z2"YMOFJO
M!>882OBX95CLP=N'L[J8/'XC,%04^+<TQ^)Q<<PQ6&P7U:C*=*>(G*DU@GA*
M%.22I2JTX6Z5C:<XP]K"G_O-'GIQI\UL)2IPA[.$I\[2:@K^_P [:WLV?M[^
MS7K_ .PG^WI^V;XQ_P"":NJ_\$YO@7\%?AE=3?%OP?\ !CXS?"C5_$NE_M$>
M ]8^$_A[Q1J;^*_'?Q#O;B[E^*TVN-X4EN;'1O$%M#I^C37<5EK+>-+>.YN+
MKQ7PC\%O@G_P3J_X)B>#/VS_ !O^S?\ !']K/]H+X]_M._$3X&:39_'_ $K5
M/%OPJ^&/@[X;ZY\5_!VJOIG@K2]<T^VU[7=7UOX1ZO?PZ])?:9J%K!XAT[[%
M=10:&\>O^?:7_P %G?@?\*/'/Q6_:$_9<_X)N_#CX$_M>?%K0_%^FZO\=;[X
M]_$#XG>&] U?Q]K']L^+?%7A#X-:YX8TCPOX:UC4+LF:VCTG5;33;1XXK.2Q
MN] N=:T+6?FW]GO_ (*6^"/"7[)3?L5?M;?LI:3^V)\$?#_Q7N?C/\+K:[^-
M7CGX)>*OA_XRU.TU2#6;=O$_@S2=;O\ 7?#E_<Z[XBU,:8@T6_6^\5^*'O-9
MU".ZT2/P]YBR+B:UZ&69SALG^M\.RS#(:V?X?$YEF:PM'-5G-?#8R6>5</0I
M8K$5\HG4I5,TPLL>L!7G7I0G5E#$:>VPWVJM&5;DQ"A76'E&G3<I4?8J4/8*
M4G&,:R4E2E[-S2BVDG']@?VA=+^"'Q5^%O\ P;<:;X0^%:^&_@C\5OVH_$;:
ME\&/&#2^*=#TK2_B/^T;\&KGXA_#I9-=L+>X\2?#J+6-<\2Z!X5?7+:ZNM9\
M '1FU6[U:>YN-0O/%OV?_P!F/X#^)/\ @XY^(_[/^I? _P"'6M_ 70_&GQNC
M_P"%2W/@?1K[X;:3I6C_  6UN^T56\*/82:'9V.G^(WTVXL"]I'!!J\EDT)6
MZDAW?GI^T/\ \%:/&OQH\/?L'Z=X,^"?@+X*ZM^P#X[U?QI\)9/"^JZAK?A.
M2"U\6^#/$/PU\.-X6UC3UOX;#P!IG@'PWH-YJ.L^*O$^N>.'@O->\0ZB-7U&
M]EF^RK#_ (+X> O!_P"U9%^V)\*_^">'PV\ ?&?QOIMYHG[17B@?&WQ;X@U/
MXPZ$_A5M*L='\/0WW@FV\+?":$^*].\'>,O$>KZ%X2UOQ5XLD\&:?HVJ>(EM
MM4U^ZU/DCP]QC@LKQF%P>78N=7,,EXUP%*G'.L'SX''9KQ#BLQRS%XK$5L;!
MUJM; UK4\50=?$1Q+4,7]6A.I6IV\1@ZE6$IU8)4ZV#J2?L9VJ0IT(4ZD(Q4
M'91G%WC)*/+K#F:47RGP-^'/P%_8M_X)O7?_  46\?\ [,GP=_:I^*WQ<_;&
MU;]G?X8>#OC3-<>)?A1\.?AUI&C^+M8UC5M3^'%C+%8:CXQU34?AOXKTJR.M
MLEUI&FZEX3U[26AL$U73?%7Z)?\ !'']HO\ 8^^)/_!1#X_VW[)O[)'AKX4^
M ?%W[.'BKXRR2_$?2]*U[XA?#GX@Z/-X4\.>.? /PEU_2=3NHO#/P)\6IXB&
MI3^$YVN;W^U4NUTJ3PSX5?2O!NC?A/\ LT_\%%/ OPU^ 'Q(_9/_ &F/V5M!
M_:O_ &<_&_QEM_C]H7@Z;XL>*_@UXL\!?$]--AT2\U30?B!X7T3Q!J TW4="
MM8=+NM-@TW3Y?)NM<V7ZIKM[%7MGA#_@M5X[\(_\%"S^W)IW[//PMTSPL?A3
M=_ 9OV>O"EPGA706^$$I^VVVBR>,[;P[>3W/BJ/7X;/6KWQ=>>%;E+X6_P#8
MT>A66BBSL;'KSOA?/\SP_%6%JY?C\5B\=0S1X',99_&CEM?#R>7U<HRREEGU
MZ5L10=*O2G5Q.'P.&I5%6K>WQ"Q]7EBABL/2GA9J<(0A*E[2FL/S5%)<ZJU7
M5Y%[LKQ:493DU9<L7!7_ "V_:&^,6G_'KXL>(OBAI?PA^$GP*L=?M]#@B^&7
MP.\-7'A'X:Z"=&T/3]&DGT/0;K4=5FLY]8DL'UG5W:]E%UJ]]>W*K&LPC7Q2
MO:/V@O''P@^(WQ7\2>+_ ($? V/]G#X7ZG'I">'?A!%\2O%GQ<7PPUCH]C8Z
MI*WC[QM%;^(];DUO5;>\UR47D$,5A)J#:?911V5M H\7K]:P,(T\%A(1PU;!
MQAAJ,8X3$5*=;$8:,:<4J%:K2Q&+I5*M%+V=2=/%8B$I1<HUZL6IR\JHVYS;
MDIMR?OQ349:_$DXP:3W2<8M+>*V"BBBNH@**** "BBB@ HHHH **** "OV[^
M*G_* 7]F#_L_WXA?^J_^(-?B)7[=_%3_ )0"_LP?]G^_$+_U7_Q!KY/BG^/P
MI_V5F _]5^:'3A_AQ/\ V#3_ /3E(_$2BBBOK#F"BBB@ HHHH **** "BBB@
M HHHH *_I3_:"AAN?^#=;_@E;;W$2307'[8/Q+AGAE4/'+#+\3_VM(Y8I$8%
M721&974@AE)!&#7\UE?H_P"._P#@H9J/C?\ X)\_LM_L%R?"JRTVP_9E^+_B
M+XLVOQ.3QC/=7GC&;Q!XG^*WB1M#N/"9\-P0Z'':M\4);-=0C\0ZHTRZ+'.;
M.,W[16GRO$^6XW,:W"\\'2]JLMXFH9CC'[2E3='"0RG.,+*JO:3@ZC5?%X>'
MLZ7/4?/S*#C&<H]6%JPIK$\[M[3#2IPT;O-UJ,K:)V]V,G=V6EKW:3_I$^*V
M@?\ !,OX=?\ !7V#_@GK9?\ !._X+^)=$_:$T7PUX7^*OCR]2]TR?X;>(O&/
MPKM+SPGH_P #O!VF6EAX=^'5A;:3I>@>(/$7C+P=<:3XYU#Q3XY\1:K:^(K"
MYT&WM+_\^OA)^Q]^SG^QQ\ ?^"I7[:/C/X.^#OVH]5_9#_;0\8?L=_ +X7_&
MT7>J_#FR;PK\3?"?A.[\?>/]$TNXTZ+QQ>7&D>/]#>+2KVSL;%9=!U%+62TN
M=;2_T+X ^(O_  5)U7X@?\%0?#G_  4LD^"^GZ7J?A_Q#X U]?A GCNYO+"Z
M;P)\/]+\!QVK>-F\)VUQ"NIQZ8-3>8>%Y#:/,;18[A4%P_4_##_@K#9:+KO[
M=_A?XY_LTZ3\?/V8?V\OC)XC^.GC7]GZZ^+?BCX>WG@3Q]JOQ'N_B'I>I^#O
MB;X>\/WU[#+932:-IVMW/_"*6M[XB/A#PG<QW.BVMAJ&EZM\!0X6XJP6 R^E
M2>:UXU,EX3_UAPDL]]KB,=C<#F:GGF!P>(Q&90AA:M7+9/#QJ4,3A,'7P]*&
M&^LJ_,=[Q6%G4FW[*+5;%?5Y^PM&G"=-*A.<8TVY)5%S-2C.<6W+EZ'V]^U%
MX_\ A=\5_P#@@/X=^)_PP^#VC_ <^.?^"C=EJ_Q!^&?@U=3A^%NB_$:S^#OB
MG0-9OOA%8ZR;C4M&\ Z_I&C:!KT?AV?5]?A\->*-1\3^']/U=],TRRLK+Z]^
M,G_!/[]CO5O^"RG[0>@:[\#O#6F?L\?LN_L'?\-4W'P)^&FDKX*\->/O%?A&
M+1+>WT+4M+\&6EOJ$ECJKZW=:MJ,6D6TMUK-_I.FZ5?6VHZ=?WFGW7X=_M(?
M\%-]$^-?[%NG?L-?#W]EOP7\ _A#X0^/L'QB^&MOX4\?^)O%<_A7P_#X<\0:
M9+X+UN[\7:9=^)/'6NZIXB\5^(?%FK_$+7O%"WD\VH1:%I_A_2]!TS2K.R]H
M\1?\%N_B'J7_  43U+]O;1/@;X6TRP\7_!N#X!_$WX%:SXON_$?A_P >?#*:
MVM4UK1KCQ</#&CWNEW%_J.F:)K=E=0Z#=1V.HZ-:Q7MKK.ES7VG727#/%M*A
MB_[.P^,R_P!LN-:M"E/.*,L3".9U^')Y11J8JGC*S6,J83!9AAJ>*]M6>!JW
ME/%I3AB*I]9PKE#VDH5+?4E)JB^7]U'$*JU!PC[BE.G)QY5SK:#:<5R7C+]H
M#]DW]N@?LV>"? O_  3?T'P/^UZ?CYX2\.:MX"_96OX/A)\(/CS\%Y+I@?A[
M.)]3U:X\#?$'7;R_-K?_ !.NO#VLS:!I>E2ZUJ?B&YT^\73_  K^UWQ8_8R^
M WQ1_90_;V\#_%7]DS]@O]F7XJ?LP_L\^)/CU\$O!W[+/Q-MO'_[5'PD'PS\
M%^)->?P[^U7XMT57M/%MSXC&F:9IAN]7O+RR\06NL:MJ::7_ ,)!H^C>*K;\
M<H/^"PWAGX2-^S)X?_8T_8T\#?LQ_#?]GKX]ZC\?-6T&\^)FL?&'QW\4-5UR
MPN/#WB'PEK?Q7\2>#]"\0Z;X7UOPAJ6H^&;N)['6KX6UCX,N$NQ+X,L$NO0O
M$7_!:_X666B?MRZ9\%OV!O#WPBU+_@H%\/?BGH'QZ\3W'[1'C'Q_K>I?$'XE
MZ'XLT@>/-/76_ =AI6EZ/H%WX]\;:_%X#T33=&MM2UCQ->M<:_#8VFC66EO,
M\DXKK3R^.49-FF687"XCZUA%6XDAB\7A:G]MT*M6GBW//7@Z.&JY;2J5*6'P
MM'.9?OIY?/%8?#RFF4J^%2J.M6I592BH2MAG&,U[%I.%J'.Y*HTG*4J*T511
ME(^[/VB_VF_".@?\&^G['_C^T_9)_93D/QQ^(_Q3^%]SX4F^&EP/"GP_\16$
M/[07PW3XW?#_ $^'6XI]*^,\MCX#L=;F\77]WJ:G7-4U:9+%+22UL[7@O$7_
M  3N_9Z_:$^/?_!"?X'6G@OP[\+O#/[07["7@SXJ_'O6?AUH.D^'/$GQ'U/P
MO\&;#XD>(;W6M2L8;6>_\3>-;G1Y]$O?$]TUWJFGKKMYK48NKBU$,OY:>!_^
M"EW@UO\ @GC:?\$^_P!H']E30_CUX<^'OB+QYXS_ &>/B+%\7?%WPLU3X/\
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MJU4C)+AQ<Z=2O.=*W)*-)Z1Y%S^RA[7W;*W[WGO96;NU=-,****^D.8****
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M2A%M<UMK;M)_TL_##_E:Q_:+_P"R-Z'_ .LG? FOX=Z_;#PS_P %E-:\.?\
M!4GXA?\ !31?V?\ 2[O5/'W@^R\)2?!UOB3=PV&EI9_"KP/\,!?)XX'@F6XN
MVDB\%)K)MV\+6X6347L?.9;47<_XGUR\%9'F>45%+,,,J"_U.X&RFZK4*O\
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M<PQ6%IK".+A>G/#.=J<O:0E"2^L5$W1C=5%S;U9R=X^Y!P1^LG[+GP=^!_\
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M'0]&N_.@E_X2!O$6]/A_BO\ M?"5L-3S/+,'2P^5++W+,,-6HY13H8*I3S+
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M%N"6SOO"FK2W'A#P6OQ N[-I6C\&SC^T-;\)>(K'6K>.;0+.[U#@5_Y0D?\
M!7?_ +26VW_JR?@17\T%[XD\1:GK=UXEU+7M:U#Q'>SRW5[K][JE]=ZW=W,Z
M&*:XNM5GGDOKB>:-FCEFEG>21&*.Q4D51_M'4/LT]G]OO/L=U-]HNK7[5/\
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M2?,[I-U5=7V=C\\_^&&?VV?^C//VIO\ Q'WXM?\ S(T?\,,_ML_]&>?M3?\
MB/OQ:_\ F1K]#/\ B(<_X*Q?]'$^'_\ PQ_P/_\ G?4?\1#G_!6+_HXGP_\
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M%&G&JO95JE&7-&G5J05Y4VU:<M+-V;LO\BG_ (9[^/G_ $0_XO\ _AM/&?\
M\I:/^&>_CY_T0_XO_P#AM/&?_P I:_UUO[&TW_GV'_?V;_XY1_8VF_\ /L/^
M_LW_ ,<KQ?\ B8?&?]$MA?\ PZU?_F'U_I:^A_J^O^@E_P#@M?\ R1_D4_\
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MO]+4_P!7U_T$O_P6O_DC_(I_X9[^/G_1#_B__P"&T\9__*6C_AGOX^?]$/\
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M*/*[MK2&21I*HOK#?M:;I? E;FE&7-\3O;EM;SW/\CO_ (9[^/G_ $0_XO\
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M"_\ AUJ__,/K_2U/]7U_T$O_ ,%K_P"2/\BG_AGOX^?]$/\ B_\ ^&T\9_\
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M'_$P^,_Z);"_^'6K_P#,/K_2U/\ 5]?]!+_\%K_Y(_R*?^&>_CY_T0_XO_\
MAM/&?_REH_X9[^/G_1#_ (O_ /AM/&?_ ,I:_P!=;^QM-_Y]A_W]F_\ CE']
MC:;_ ,^P_P"_LW_QRC_B8?&?]$MA?_#K5_\ F'U_I:G^KZ_Z"7_X+7_R1_D4
M_P##/?Q\_P"B'_%__P -IXS_ /E+1_PSW\?/^B'_ !?_ /#:>,__ )2U_KK?
MV-IO_/L/^_LW_P <H_L;3?\ GV'_ ']F_P#CE'_$P^,_Z);"_P#AUJ__ ##Z
M_P!+4_U?7_02_P#P6O\ Y(_R*?\ AGOX^?\ 1#_B_P#^&T\9_P#REH_X9[^/
MG_1#_B__ .&T\9__ "EK_76_L;3?^?8?]_9O_CE']C:;_P ^P_[^S?\ QRC_
M (F'QG_1+87_ ,.M7_YA]?Z6I_J^O^@E_P#@M?\ R1_D4_\ #/?Q\_Z(?\7_
M /PVGC/_ .4M'_#/?Q\_Z(?\7_\ PVGC/_Y2U_KK?V-IO_/L/^_LW_QRC^QM
M-_Y]A_W]F_\ CE'_ !,/C/\ HEL+_P"'6K_\P^O]+4_U?7_02_\ P6O_ )(_
MR*?^&>_CY_T0_P"+_P#X;3QG_P#*6C_AGOX^?]$/^+__ (;3QG_\I:_UUO[&
MTW_GV'_?V;_XY1_8VF_\^P_[^S?_ !RC_B8?&?\ 1+87_P .M7_YA]?Z6I_J
M^O\ H)?_ (+7_P D?Y%/_#/?Q\_Z(?\ %_\ \-IXS_\ E+1_PSW\?/\ HA_Q
M?_\ #:>,_P#Y2U_KK?V-IO\ S[#_ +^S?_'*\9^/7Q)\-_ WX=7OCS4=,346
M@U70]+L=)^URP3:I/J6I01W=O:R-)M%S;:-'JFIQJWRL+!@_RYK?"^/V9XW$
MT,)AN$L/5Q&)JTZ%&FLVJ)SJ5)*$5=X%1BFWK*348KWI-139%3(Z=*$ZE3%\
ML(1<I2=/:*5W]J[\DM6]%J?Y1_\ PSW\?/\ HA_Q?_\ #:>,_P#Y2T?\,]_'
MS_HA_P 7_P#PVGC/_P"4M?ZY.FV_A_5].L-6TSR;W3=4LK74=/O8)YG@N[&]
M@CN;2ZA?S!NBN()8Y8VQ\R.I[U=_L;3?^?8?]_9O_CE8/Z0V.BW&7"N&4HMJ
M2>:UDTT[--/ 733333U3WVUM9!%JZQ3:>J:IJS7?XC_(I_X9[^/G_1#_ (O_
M /AM/&?_ ,I:/^&>_CY_T0_XO_\ AM/&?_REK_76_L;3?^?8?]_9O_CE']C:
M;_S[#_O[-_\ '*/^)A\9_P!$MA?_  ZU?_F'U_I:G^KZ_P"@E_\ @M?_ "1_
MD4_\,]_'S_HA_P 7_P#PVGC/_P"4M'_#/?Q\_P"B'_%__P -IXS_ /E+7^NM
M_8VF_P#/L/\ O[-_\<H_L;3?^?8?]_9O_CE'_$P^,_Z);"_^'6K_ /,/K_2U
M/]7U_P!!+_\ !:_^2/\ .,_X*A?!SXNZ]X'_ ."8\6A_"OXCZS+H7_!-;X#Z
M'K<>D^!_$^HR:/K5IK7C=KO2-52STN9M/U2U66)KC3[L0W<"R1F6%0ZD_DY_
MPSW\?/\ HA_Q?_\ #:>,_P#Y2U_KC6&FV4SWPD@#"&]FBC^>4;8UV[5^5QG&
M>IR?4UH?V-IO_/L/^_LW_P <KS<H\=L7E6 HX"/#>'KQHSQ,U4EF=6#E]8Q5
M;$M.*P4DN1UG!.[NHJ5E>Q=3(U5FZGUAQYE%6]FG;EA&._,M[7/\BG_AGOX^
M?]$/^+__ (;3QG_\I:/^&>_CY_T0_P"+_P#X;3QG_P#*6O\ 76_L;3?^?8?]
M_9O_ (Y1_8VF_P#/L/\ O[-_\<KTO^)A\9_T2V%_\.M7_P"8?7^EK'^KZ_Z"
M7_X+7_R1_D4_\,]_'S_HA_Q?_P##:>,__E+1_P ,]_'S_HA_Q?\ _#:>,_\
MY2U_KK?V-IO_ #[#_O[-_P#'*/[&TW_GV'_?V;_XY1_Q,/C/^B6PO_AUJ_\
MS#Z_TM3_ %?7_02__!:_^2/\BG_AGOX^?]$/^+__ (;3QG_\I:/^&>_CY_T0
M_P"+_P#X;3QG_P#*6O\ 76_L;3?^?8?]_9O_ (Y1_8VF_P#/L/\ O[-_\<H_
MXF'QG_1+87_PZU?_ )A]?Z6I_J^O^@E_^"U_\D?Y%/\ PSW\?/\ HA_Q?_\
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M&?\ \I:/^&>_CY_T0_XO_P#AM/&?_P I:_UUO[&TW_GV'_?V;_XY1_8VF_\
M/L/^_LW_ ,<H_P")A\9_T2V%_P##K5_^8?7^EJ?ZOK_H)?\ X+7_ ,D?Y%/_
M  SW\?/^B'_%_P#\-IXS_P#E+1_PSW\?/^B'_%__ ,-IXS_^4M?ZZW]C:;_S
M[#_O[-_\<H_L;3?^?8?]_9O_ (Y1_P 3#XS_ *);"_\ AUJ__,/K_2U/]7U_
MT$O_ ,%K_P"2/\BG_AGOX^?]$/\ B_\ ^&T\9_\ REH_X9[^/G_1#_B__P"&
MT\9__*6O]=;^QM-_Y]A_W]F_^.4?V-IO_/L/^_LW_P <H_XF'QG_ $2V%_\
M#K5_^8?7^EJ?ZOK_ *"7_P""U_\ )'^13_PSW\?/^B'_ !?_ /#:>,__ )2T
M?\,]_'S_ *(?\7__  VGC/\ ^4M?ZZW]C:;_ ,^P_P"_LW_QRC^QM-_Y]A_W
M]F_^.4?\3#XS_HEL+_X=:O\ \P^O]+4_U?7_ $$O_P %K_Y(_P BG_AGOX^?
M]$/^+_\ X;3QG_\ *6OV#_X+Q?!_XM^+/^"G?QYUWPK\+?B+XFT2[T+X-I::
MSX?\$>)M9TJZ>V^#G@:VN5M]1T[3+FTF:WN8I;>=8YF,4\4D4@61&4?Z*?\
M8VF_\^P_[^S?_'*Y_P ):=:7?A7PS=7,;SW-SX?T:XN)Y9[AY9IYM.MI)99'
M:4L\DDC,[L22S$D]:\>OX]8JIGV5YB^&L.IX3*L[PD:2S.HX5(8_%9#5G.4_
MJ:<94G@(1A%1DIJK)N47!*?3#A__ &2N_K/N_6,*G^[UNZ>+:M[UK6C*^M[V
MMU/\DG_AGOX^?]$/^+__ (;3QG_\I:/^&>_CY_T0_P"+_P#X;3QG_P#*6O\
M76_L;3?^?8?]_9O_ (Y1_8VF_P#/L/\ O[-_\<KV/^)A\9_T2V%_\.M7_P"8
M?7^EKS?ZOK_H)?\ X+7_ ,D?Y%/_  SW\?/^B'_%_P#\-IXS_P#E+1_PSW\?
M/^B'_%__ ,-IXS_^4M?ZZW]C:;_S[#_O[-_\<H_L;3?^?8?]_9O_ (Y1_P 3
M#XS_ *);"_\ AUJ__,/K_2U/]7U_T$O_ ,%K_P"2/\BG_AGOX^?]$/\ B_\
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M $$O_P %K_Y(_P BG_AGOX^?]$/^+_\ X;3QG_\ *6C_ (9[^/G_ $0_XO\
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M]!+_ /!:_P#DC_(I_P"&>_CY_P!$/^+_ /X;3QG_ /*6C_AGOX^?]$/^+_\
MX;3QG_\ *6O]=;^QM-_Y]A_W]F_^.4?V-IO_ #[#_O[-_P#'*/\ B8?&?]$M
MA?\ PZU?_F'U_I:G^KZ_Z"7_ ."U_P#)'^13_P ,]_'S_HA_Q?\ _#:>,_\
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ML/Z1X#_Y)3*O3&?^I^*"BBBOS ^O"BBB@ HHHH **** "BBB@ HHHH ****
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MW/AWPE;OH>E:G%IMQJ4.EWSIJ.MOIFBP"W*W>I0,\2N?#']H;X.?&7QA\8_
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M;P%X/UO1_@-)IKW'AO3- \"Z"TUUXB\<_$RYD\3?$IF\>>']-\/6[6>F3F,
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M'_B7\//#4,JPRSEM7\:>/_ _AGP=X?MBD+JMYKVNZ;:-,8K99S<3PQ2>:?\
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MQ?+*,HNK=2BTTT]4U9I,_4FBORV_X?*?L!?]%9UO_P -E\3/_F3H_P"'RG[
M7_16=;_\-E\3/_F3K3_4+CC_ *)#B;_PR9E_\S>?Y]F+_63A[_H>93_X<,+_
M /+3]2:*_+;_ (?*?L!?]%9UO_PV7Q,_^9.C_A\I^P%_T5G6_P#PV7Q,_P#F
M3H_U"XX_Z)#B;_PR9E_\S>?Y]F'^LG#W_0\RG_PX87_Y:?J317Y;?\/E/V O
M^BLZW_X;+XF?_,G1_P /E/V O^BLZW_X;+XF?_,G1_J%QQ_T2'$W_ADS+_YF
M\_S[,/\ 63A[_H>93_X<,+_\M/U)HK\MO^'RG[ 7_16=;_\ #9?$S_YDZ/\
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MV0XAR%X#$S6=94X1QF!C*7U_"\JE.CF#C%OVMDY*$W%/5J,FMF?J-17Y;?\
M#Y3]@+_HK.M_^&R^)G_S)T?\/E/V O\ HK.M_P#ALOB9_P#,G7=_J%QQ_P!$
MAQ-_X9,R_P#F;S_/LSC_ -9.'O\ H>93_P"'#"__ "T_4FBORV_X?*?L!?\
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MF?\ S)UV_P"H7''_ $2'$W_ADS+_ .9O/\^S./\ UDX>_P"AYE/_ (<,+_\
M+3]2:*_+;_A\I^P%_P!%9UO_ ,-E\3/_ )DZ/^'RG[ 7_16=;_\ #9?$S_YD
MZ/\ 4+CC_HD.)O\ PR9E_P#,WG^?9A_K)P]_T/,I_P##AA?_ ):?J317Y;?\
M/E/V O\ HK.M_P#ALOB9_P#,G1_P^4_8"_Z*SK?_ (;+XF?_ #)T?ZA<<?\
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M:*_+;_A\I^P%_P!%9UO_ ,-E\3/_ )DZ/^'RG[ 7_16=;_\ #9?$S_YDZ/\
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M!XQ\3V-U/:WT;37%CIYL_E']D*__ ."@^D?MZ?\ !:.Y_8_T3]F+Q]X3U?\
M:JTW1;[PW^T9\0?B5\/(_A]\3S\,[1] ^)&D/\._AI\0)?&OA2^L;FUL_'_@
MVXNO"NMWL7A?PZGA?Q!ITEWJURG]2E?-?C#5_P!DW]C?2?B-\</'.H?!7]G#
M1?B9XQTK5_BI\4/$5QX6^'-AXW\=WML-(T;4/&7B>];38=;\1W-I;C3["XU.
MZGOI88O(A8JA4 'X1_%K_@AY\7M*_90_8F\"_"KQ=\(_CI\:/V?OVN-1_;#_
M &E/!O[1,^L:-\ ?VKOB=\1W.H?$[4/$]AX<\%^(IWFT.[AL_"?P[75_##6:
M^ +K78O$%M>:A>/IU_[?X%_8$_;MU_\ X*3_ +'/[;'Q9M?V1?A;\%_V??"O
MQ^^'MK^S#^SWKGC:\TOX8>'/B-\.M;TW1_%^D>)M;^&7@?3OB-X_\;>+_$4>
MF?$&TMO"'PU\/>&_#'@?PO?:%<^*=1O]2MH/O^W_ ."K_P#P3*NYX+6V_;Z_
M9'GN;F:.WMX(OCU\.))9IYG6.**)%\0%GDDD941%!+,P !)KZ$\3?M5_LT>"
MX/C)=>+OCU\)?#5M^SO-X1M_CQ/K?CSPYIL7P>G\?);2>"(OB.]WJ$2^$)/%
MD=Y:/X>37#9MJRW,)LA,)%R ?S@>)O\ @CY_P4)/[%?_  4]_8'\/7_[),WP
M;_:?_:'N_P!H;]G+QA-X^^*]O\0[#5]7_:5^#'Q#E\,_%&*X^'%SH%AH]E\*
M/AK=0O/H5OJ>H6WCX0Z=#=Z]H&J-KNC?L#_P4E_8Z^*W[6_B#_@GSJGPPU#P
M98VW[+G_  4,_9Y_:F^(Z^+]7U32I;WX;_"R]U>X\267A5=-T+6UU/Q7/'?0
MC2M,U!]'TZZ82"XUBS"@M^F]O<074$%U;2QW%M<PQW%O/"ZR1303(LD4L4BD
MJ\<D;*Z.I*LK!@2#4M '\^7Q(_X) ?$_XU^ ?^"MO@+Q9XZ\%>#+S]M']I+X
M??M"?LU>-]"NM4US4? 'B+X6V/AG4_"M]XUL;G0+ Z/-=^(_#AT764\/W&O7
M$7A?6-3GL;EKXQ6S>^:%\%?^"L7QW^._[*WB#]IOXF_ O]G/X&_LZ:K<>._B
MMX7_ &//C'\8]9\3?M9_$O3+%K/PSIGBY/$_PQ^'-AX7^ QO&_M77OAMJFH^
M+WUR)K_3-6BO9[W0-8\#_LC10!^;?_!7;]DGXG_MT_\ !/']H3]E?X-7WA#3
M?B3\4O\ A4__  C=[X\U74M$\*0?\(1\</AK\1M8_M74](T3Q%J-KYF@^$=4
MAL?L^C7GG:E)9V\WV>"66Z@_0SP[83Z5X?T+2[DQM<Z;HVF6%PT+,T33V=E!
M;RF)F5&:,R1L49D1BN"54G YOXG?%+X;_!7P+K_Q/^+OCOPI\,_AUX5AL[CQ
M+XX\<:[IWAKPMH,&H:E9Z/82ZMKFK7%KI]A'>:MJ-AIUL]S/&)KV\MK:,M+-
M&K=O;W$%U!!=6TL=Q;7,,=Q;SPNLD4T$R+)%+%(I*O')&RNCJ2K*P8$@T ?D
MG^WI^Q_^U-XU_:N_8Y_;E_8NU3X+3_&#]FG2_B]\/?'?PV^//B'QUX4\$?%?
MX4?%K1K&Q;3+?Q'X%\.>*]0TK7?">JPW^M:4EUH_]GW.HWNGZI>W-PGAR/0-
M>^)/"O\ P2^_;U\3_$C_ (*T?&[X_>,OV<-0^)/_  44_85\0_ 3PIHWPSUO
MQ_;^!_AW\1KKX9ZW\,?"?A>6?Q-X4.LS^!- \/VWA+^UO'"VHUC7-9E\1:LO
M@JSWPQ7/])E<#\2OBCX ^#_A?_A,_B5XHT_PEX;;7O"GA6#4=0%S*;WQ-XY\
M3:5X-\'>'M-LK*"ZU#4]:\2^*=<TC0M'TS3[6YO;[4+^W@AA8L2H!^*_PH_X
M)H?M!^"?VH?^"./QDUC6/AA)X4_8(_8+E_9G^-EO8^(]?FUK5/B$_P "#\-1
M>?#^SE\)V]KKOAC_ (2 ^<=2UF_\-W_]F9N?[)^T?Z)7V%^S)^R3\3_@]_P4
M._X*>_M4>*K[PA<?#;]L7_ABO_A5-EHVJZE=^*]/_P"&>_@?K_PY\<_\)GIE
MUHECIVD?:M>U.WF\._V7K.N_;]-66XO?[,G5;5_M+3/CA\'-9^)'CKX.Z3\4
M/ FI?%;X8Z'I'B7XB_#FR\3Z1<^-/ _A[7[.WU#1-;\4^'8KIM4T32]6L;JV
MO-/O=0MH+>[MKB&:&1TD1C\IV7_!5O\ X)DW]U#9V_\ P4!_8[6:=BL9NOVB
M/A780;@K/B2[OO$]M:Q9"D)YLR!W*QIND=%8 _*'X5_\$=_VJ?A3^R!^P@/
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MGA73M<BTNU_X372/^$@N8O"T]Q8^7??8[34O)B^T>#>)_P#@EC^U5X3\8?\
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M7B(6\N4PF"X26VEFAD /P _X-L/V??%VD?L\_$7]KGXD>/-2^*-_\9;WPU\
M/V>_%^LV2Z?<1?L>?LA+J_PB^$9TW19E%[X0M_$>L67BJ\NO#\K2->:;HGA7
M7KN[U"[OVNC_ $K5B^&_#?A[P=X>T+PCX1T+1_"WA3PMH^F>'?#/AGP[IEEH
MN@>'M T6RAT[1]#T/1].AMM/TK2-*T^VM['3=-L;>"SLK."&VMH8H8D1=J@
MHHHH **** "FN2J.1U"L1]0"13J9)_JY/]QO_030!_ 1^W$V_P#;(_:C8\%O
MCS\4CZ]?&&K5\LU]2?MO_P#)XW[4/_9>/BC_ .IAJU?+=?Z8</?\B#(_^Q/E
MG_J%0/Y-S3_D99C_ -AV+_\ 4BH%%%%>P<(4444 %%%% !1110![=KW_ ";?
M\*/^RW?M _\ J!_LS5XC7MVO?\FW_"C_ ++=^T#_ .H'^S-7B->!PU_R+L3_
M -C_ (K_ /6IS@];.O\ ?*/_ &*<@_\ 5%EP4445[YY(4444 %%%% !1110
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MW_L->"O_ %6'@BOSQKHX*_Y(WA+_ +)G(?\ U580_%\__P"1[G7_ &-LQ_\
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M"VI>#_&<UUH^F:E=ZQX>;3/$%Q%9Q1>(+'39=01C=:>ES:JTP /@OP)^W_\
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MMM5_:@^''P^T;X1^ ?B[XAU7Q9X63XQ?";6_#X^(/BG7/AIXF\4Z[XE\1?\
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MO$4NH:]>_P!J^*M5T?2M]I:NLB6GVS[5<D[+:&5P5K]@* /Q9_:L\:-^RO\
M\%9O^"?OQ*\.>5HWA7]N_0/BM^R)^T4C1S)I/B+6_AOH=O\ $7]ESQ');V3)
M'-X_TCQ=K_C/P+I^N:C;WLK^"?%6IZ-)/;6NGZ>]I^TU?@?^W1X9N/VI?^"Q
M?_!+/X#^%X[W6]"_9!L?C#^VO^T4;(N=+\$65S::#X:_9PN=7N)@FEMKVO\
MQ/\ ".JV.GZ%'+<>)DT*]OO$4%C;:+!<7\W[X4 %%%% !1110 4444 %%%%
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M_P#EA1_PQ;XK_P"@E?\ _@B/_P L*/\ B-WAI_T4%3_PS9YY?]2[S_JZN?\
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MLN65:FK-IOF=DU&5OS3HK[9_X8M\5_\ 02O_ /P1'_Y84?\ #%OBO_H)7_\
MX(C_ /+"O9_XC=X:?]%!4_\ #-GGE_U+O/\ JZOYG_$/>+?^A7#_ ,+\N_\
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MXK_Z"5__ ."(_P#RPH_XC=X:?]%!4_\ #-GGE_U+O/\ JZN?\0]XM_Z%</\
MPOR[_P":_/\ /LSXFKV[]F;_ ).0_9^_[+=\*/\ U/-!KVO_ (8M\5_]!*__
M /!$?_EA7J?P,_9'\2^&_C9\'O$4^H7KP:!\4_A]K4R/HQB5XM*\6Z1?2*TO
MVY_+5D@8-)L;8"6VMC!\7B3QG\.<3P[GV&H9]4G6Q&2YI0HP_LC.H\U6M@:U
M.G'FGE\81YISBN:4E%7NVEJ>GDO /%='.<IJU,LC&G2S/ 5)R^O9>[0ABJ,I
M.T<4Y.T4W9)M[)-GYIT5]L_\,6^*_P#H)7__ ((C_P#+"C_ABWQ7_P!!*_\
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M5_\ ^"(__+"C_ABWQ7_T$K__ ,$1_P#EA1_Q&[PT_P"B@J?^&;//+_J7>?\
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MYJX[ANI3SZI*&&SJO7K/^R,Z7)2EP[GN&4K/+TY7K8FC#E@I2][FMR1<EZ>
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MQ7_T$K__ ,$1_P#EA1_Q&[PT_P"B@J?^&;//+_J7>?\ 5U<_XA[Q;_T*X?\
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MO)S_ /Y$6=?]BG,?_4.L;8?_ 'BA_P!?J7_I<3]S?^"KO_*03]HW_L->"O\
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M *"W_DA;_P#Q5 7?9_A_F:E%9?V34_\ H+?^2%O_ /%4?9-3_P"@M_Y(6_\
M\50%WV?X?YGG.K^!-*\62ZM!J-O%.J738WHK</+<!N&Z9VCH3D#WK@F_9M\%
MLQ)TFU))SDP1?U!KW.QM[YWOO+U#RBM[,LA^R0R>;(-NZ7#,-F[CY%RHQP:T
M/LFI_P#06_\ )"W_ /BJ=W_7W_GKZBC>RT>W2UM=>_\ EZ=OGK_AFSP5_P!
MBT_[\1?_ !-'_#-G@K_H$6G_ 'XB_P#B:^A?LFI_]!;_ ,D+?_XJC[)J?_06
M_P#)"W_^*HN^[_K_ (9?<.[[/\/\SYZ_X9L\%?\ 0(M/^_$7_P 31_PS9X*_
MZ!%I_P!^(O\ XFOH7[)J?_06_P#)"W_^*H^R:G_T%O\ R0M__BJ+ON_Z_P"&
M7W!=]G^'^9\]?\,V>"O^@1:?]^(O_B:/^&;/!7_0(M/^_$7_ ,37T+]DU/\
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M+ON_Z_X9?<%WV?X?YGSU_P ,V>"O^@1:?]^(O_B:/^&;/!7_ $"+3_OQ%_\
M$U]"_9-3_P"@M_Y(6_\ \51]DU/_ *"W_DA;_P#Q5%WW?]?\,ON"[[/\/\SY
MZ_X9L\%?] BT_P"_$7_Q-'_#-G@K_H$6G_?B+_XFOH7[)J?_ $%O_)"W_P#B
MJ/LFI_\ 06_\D+?_ .*HN^[_ *_X9?<%WV?X?YGSU_PS9X*_Z!%I_P!^(O\
MXFC_ (9L\%?] BT_[\1?_$U]"_9-3_Z"W_DA;_\ Q5'V34_^@M_Y(6__ ,51
M=]W_ %_PR^X+OL_P_P SYZ_X9L\%?] BT_[\1?\ Q-9FB_L_>$=:T;2=8N=+
MM9+G5M,L-2N)&AB+//?6L5U*[$KDEI)68D\DG)KZ8^R:G_T%O_)"W_\ BJYS
MP=;:@WA'PJR:GY:-X;T,I']B@?8ITRU*IN+9;:,#<>3C)Y-<DV_KV&U?^Z8W
MK_T^R\ZH-_4L1H_]ZP?;_GSCO,\=_P"&;/!7_0(M/^_$7_Q-'_#-G@K_ *!%
MI_WXB_\ B:^A?LFI_P#06_\ )"W_ /BJ/LFI_P#06_\ )"W_ /BJZ[ON_P"O
M^&7W'+=]G^'^9\]?\,V>"O\ H$6G_?B+_P")H_X9L\%?] BT_P"_$7_Q-?0O
MV34_^@M_Y(6__P 51]DU/_H+?^2%O_\ %47?=_U_PR^X+OL_P_S/GK_AFSP5
M_P! BT_[\1?_ !-'_#-G@K_H$6G_ 'XB_P#B:^A?LFI_]!;_ ,D+?_XJC[)J
M?_06_P#)"W_^*HN^[_K_ (9?<%WV?X?YGSU_PS9X*_Z!%I_WXB_^)H_X9L\%
M?] BT_[\1?\ Q-?0OV34_P#H+?\ DA;_ /Q5'V34_P#H+?\ DA;_ /Q5%WW?
M]?\ #+[@N^S_  _S/GK_ (9L\%?] BT_[\1?_$T?\,V>"O\ H$6G_?B+_P")
MKZ%^R:G_ -!;_P D+?\ ^*H^R:G_ -!;_P D+?\ ^*HN^[_K_AE]P7?9_A_F
M?/7_  S9X*_Z!%I_WXB_^)K,UK]G[PCHNC:MK%MI=K'<Z3IE_J5O(L,09)[&
MUENHG4A<@K)$K CD$9%?3'V34_\ H+?^2%O_ /%5SGC&VU!?"/BIGU/S$7PW
MKA>/[% F]1IET63<&RNX9&X<C.1R*Y,<W]2QFO\ S"XC_P!,R_R7W'5@6_KN
M#T?^]8?M_P _H>9X[_PS9X*_Z!%I_P!^(O\ XFC_ (9L\%?] BT_[\1?_$U]
M"_9-3_Z"W_DA;_\ Q5'V34_^@M_Y(6__ ,577=]W_7_#+[CEN^S_  _S/GK_
M (9L\%?] BT_[\1?_$T?\,V>"O\ H$6G_?B+_P")KZ%^R:G_ -!;_P D+?\
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M_P#$T?\ #-G@K_H$6G_?B+_XFOH7[)J?_06_\D+?_P"*H^R:G_T%O_)"W_\
MBJ+ON_Z_X9?<%WV?X?YGS/?_ +/WA&QNM%M8M+M5CUK4Y=-N5$,0$D$6C:MK
M"HP"\@7.DV\F#QN13U K3_X9L\%?] BT_P"_$7_Q->Q:Y;:@-3\'!M3W%O$E
MT$/V* >6W_"(^*F+X#8?**\>T\#?NZJ*Z/[)J?\ T%O_ "0M_P#XJN3#-^VQ
M^K_WN'7_ *@<$=6(;]C@='_NL^W_ $&XSS/GK_AFSP5_T"+3_OQ%_P#$T?\
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M^DW\\1T*#6P#]\**_![6/^"]'PQ\":]X+\-_&+]AW]O_ .$^L_'/PIJGBO\
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M2>>\T3QEXC\4VMSX/\%P^'H/$^F>)M;@EFT_47T4+JS 'ZQ45\$?%'_@HM\
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M*DU*,DTTTVFFFM&CF_M# Q]V6-PD91]V498FBI)K1IISNFFM4]4?35%?,O\
MPVI^QY_T=5^SC_X>_P"&/_S44?\ #:G['G_1U7[./_A[_AC_ /-15?V'G?\
MT)\U_P##?B__ )3YK[P_M'+_ /H.P?\ X4T/_DSZ:HKYE_X;4_8\_P"CJOV<
M?_#W_#'_ .:BC_AM3]CS_HZK]G'_ ,/?\,?_ )J*/[#SO_H3YK_X;\7_ /*?
M-?>']HY?_P!!V#_\*:'_ ,F?35%?,O\ PVI^QY_T=5^SC_X>_P"&/_S44?\
M#:G['G_1U7[./_A[_AC_ /-11_8>=_\ 0GS7_P -^+_^4^:^\/[1R_\ Z#L'
M_P"%-#_Y,^FJ*^9?^&U/V//^CJOV<?\ P]_PQ_\ FHH_X;4_8\_Z.J_9Q_\
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M_9Q_\/?\,?\ YJ*/^&U/V//^CJOV<?\ P]_PQ_\ FHH_L/._^A/FO_AOQ?\
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MQ?#W'BTIX0^(WBW0[>;QW-I]SXQO;2SUFZ2SU+Q'=Z5)-I=[JNJ6AAU&YO\
M3II;&^:Z^UVDLD$T;M^L_P"S[\3O#OP_MO 7CJU_X*I>&-(\30? OP?\+I_
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MM-M_ZSJ* /XT_&/QW^/?P*^!_P#P1V^$?QG^+?[3?[$?[ &L?\$]? *_&?\
M:'_9Q^$<GB/XL0?'R+PQHNDVWPD\6>+XO /Q!\?? :PTS1+/P_?:9K7ACPHV
MK^(]3\2:SI4^EZE'H4VO^ ?)_@YX7:[^)7_!;VX^&7AC]MCQE\,_C'_P1U^*
MUS\"/BW^UUIGQ?\ $/Q;_:%M?#?@;Q7X-UGQ;'JOQ-TVT\4SKXC\;ZE=Z?\
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MOHK]'TUYI;2.WGM9I_5?V^/VV_V:?%'Q\_X(E?\ !2'PM\0SXA_8H\'?'O\
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MK/ -%T3X-_$37+9K?5=1UU+F"30K?Q/I_A1]:>>UL]-^U:C?Z?977;_M/?\
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M.XM#MO&P\-6]YX>.L7$UWH(FTQ9KK3@"AJGP9^+W[;?_  5M_P""DWP:U/\
M;R_;Q_9T^''[.W@/]CO5OAKX._9@^/4?PZ\+VVI?%CX075_XJFU70-;\*>,=
M.FBFU7P_!JBIHL>@S37NH:M/>W-U+=Q/;>@_"+XH?MM?\$__ /@HK^SE^Q%^
MTS^T7?\ [97[,O[;/A;XMC]GKXN^//#GA[P[\;_A9\4?@SX5M/'?B_PQX]U'
MPQIMK;>+_"^LV=[#8Z'>Z@U[J37?B31X[.?1-)\):M9ZIX_X6_;;_92_8P_X
M+7_\%;M4_:C^-_@WX,67CGX:_L&Q^#Y?%DFI;_$<OA;X):K<:_#I-OI>GZC<
MW<^FPZUI3301PF9S?V\<"2R/M$]C\;O!'_!8K_@J;^P]\4?V3;76O'G['/\
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MUI/CK]I2[T3PGX)OWENQ%I-Q8ZWI+^,+.:UM/[0O84F@E\^P+26 !^XM%%%
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M7XE?W=&_[_ZI_P#*>C_AF7XE?W=&_P"_^J?_ "GH_P"(I>'O_1693_X-J?\
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M*_NZ-_W_ -4_^4]?57P'_9EUB.\M;8V$MSJUZ8UO[[R7"J"ZM]DM"ZAX[5"
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M^!DMM7@T*+QW9V.@VMS? 'AW_!5']LSXV?M]V]U_P2$\.?\ !//Q?\%/C?\
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MW^*?P<O/$ATWPM\;?&>D:9XNU7X>?$3X1^-?#_@'7K>^N/AG=^&--U[5M'E
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M"""-(H8(8D$<4,,485(XHT54CC151$4*H  %4/M]S_T#+K_OJ/\ QH^WW/\
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M;[G_ *!EU_WU'_C0',O/[G_EYK[S4HZ]:R_M]S_T#+K_ +ZC_P :/M]S_P!
MRZ_[ZC_QH#F7G]S_ ,O-?>>*^,_A;I?C\ZI:ZA DB1W4F,J& ,DL^3R.,[0#
MD9SZUX1)^Q=X,D=G-C!ECDYA!Y_[YK[0L+J6.2^9-/FD:6\E9RFP,ASD1.3@
MDH68^@+$CJ<Z/V^Y_P"@9=?]]1_XT[^C]5VM\^EK=A1DK+5K6_NIVO>_ZK[]
M#X:_X8K\%_\ /C!_WY'_ ,31_P ,5^"_^?&#_OR/_B:^Y?M]S_T#+K_OJ/\
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M7W>G^7XON',OYI=._P#=\O)??YH^&O\ ABOP7_SXP?\ ?D?_ !-'_#%?@O\
MY\8/^_(_^)K[E^WW/_0,NO\ OJ/_ !H^WW/_ $#+K_OJ/_&B_DON]/\ +\7W
M#F7\TNG?^[Y>2^_S1\-?\,5^"_\ GQ@_[\C_ .)J"U_9%\)>);:W\1W-G"UQ
MK\$6MW#&($M-JL:WTK$[>29)V)/<FONS[?<_] RZ_P"^H_\ &N<\'7MPGA'P
MJBZ=<NJ^&]#4.K)M<+IEJ RY.<,!D9YP:Y)O_;L-HO\ =,9T[5LO_.VOJSJA
M+_8<1K+_ 'K!:Z_\^<;;IULO4^/?^&*_!?\ SXP?]^1_\31_PQ7X+_Y\8/\
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MN?\ H&77_?4?^-'V^Y_Z!EU_WU'_ (T@4ETO]S\O+S7WFI167]ON?^@9=?\
M?4?^-'V^Y_Z!EU_WU'_C0',O/[G_ )>:^\U**R_M]S_T#+K_ +ZC_P :/M]S
M_P! RZ_[ZC_QH#F7G]S_ ,O-?>:E%9?V^Y_Z!EU_WU'_ (T?;[G_ *!EU_WU
M'_C0',O/[G_EYK[S-U[_ )"O@K_L9KO_ -0WQ;735Q&N7MPVI^#B=.N5*>)+
MIE!9,N3X1\5)M7GJ%8OSQM1N^*Z/[?<_] RZ_P"^H_\ &N3#?QL?_P!A</\
MU!P1UXB2]C@=_P#=9]'_ -!N,\C4HK+^WW/_ $#+K_OJ/_&C[?<_] RZ_P"^
MH_\ &NLY.9>?W/\ R\U]YJ45E_;[G_H&77_?4?\ C1]ON?\ H&77_?4?^- <
MR\_N?^7FOO-2BLO[?<_] RZ_[ZC_ ,:/M]S_ - RZ_[ZC_QH#F7G]S_R\U]Y
MJ45E_;[G_H&77_?4?^-'V^Y_Z!EU_P!]1_XT!S+S^Y_Y>:^\U**R_M]S_P!
MRZ_[ZC_QH^WW/_0,NO\ OJ/_ !H#F7G]S_R\U]YJ5S.@_P#(5\:_]C-:?^H;
MX2K2^WW/_0,NO^^H_P#&N<T.]N%U/QB1IURQ?Q):LP#)E"/"/A5-K<]2JA^.
M-KKWS7+B/XV!_P"PJ?\ ZA8PZ\/)>QQW_8+#H_\ H-P?EYK[SMZ*R_M]S_T#
M+K_OJ/\ QH^WW/\ T#+K_OJ/_&NHY.9>?W/_ "\U]YJ45E_;[G_H&77_ 'U'
M_C1]ON?^@9=?]]1_XT!S+S^Y_P"7FOO-2BLO[?<_] RZ_P"^H_\ &C[?<_\
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M.PD:#HQPU*5&:=)Z2KXA/#T\)**IU)5Y52BBBOT$^9/Z4_\ @WV_X]/VE_\
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MD);6-HLMU</\L,,C9%?4'_"VOAA_PM;_ (45_P + \(?\+G_ .%>_P#"VO\
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MTGQ%XT\(_"[P)XCT;2/!7A3PAX&\ ^$M5TB?Q#\6M3OS#XJM;7Q;JNG>&O\
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MC\/^*!X^BDL]&^)OQ)T>X\3ZXVD1>#=-?2K"#2H=< /U._X)H?\ !2KX7_\
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M7TGA>SMYK6[MI[O6ELK:&[LKZTEE6YLKJ*%OP5_:S_9:_:1O?$&F?L]?M(?
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M&?PU_:Q_96G\=_LQ_MT:=+>_$FQL?"WQ,\57'B"X\):_K?C9?$-IIOA_Q?\
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MVJ:AI>F:CI5A>6MYJNGW]S;7NF6]Q#+?06ZR*3QGPF_;%_9)^/7B_6/A_P#
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M2>&O$$UOK.L^ X[>_OM4UGPM%!?0I=!99!^*?_!1;X;?\$Y_@AIO_!2/P?\
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M6M@,*ZBE4G[*,95:OLZ>$I4X\]6GB:];RJBBBOU ^0/Z4_\ @WV_X]/VE_\
ML*_"G_TV_$FOZ3:_FR_X-]O^/3]I?_L*_"G_ --OQ)K^DVOX&\9O^3E<3?X\
MJ_\ 5'EA_2/ ?_)*95Z8S_U/Q1\A?M^_LY2?M<?L4_M0?LWV=OI]SKWQ:^#'
MC?PUX,&K3"WTNV^(B:1/JGPWU'4+@H_D6>E>/=.\.:G<3!2T45HTBX901^(?
MQ(^#_P 8/^"J'_!!S]E#X6_ V"SU#XW>#+G]G?P=\6-#^).M2>$=7\/?$?\
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MSB*>*&ZMI6C$UI>06]Y:R0W5O#,G<44%'Y0?"O\ X(;?\$H_@O\ $W2?B_\
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M6F7UBVJ66H^+8)+U9?#EC>:8CZC:W>L)9V]Q8JUW%(]NID !^=WQ/_X(O_\
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MPTFQNM3U6^L]-TVQ@DNK[4-0N8;.QL[:%2\UQ=7=R\<%O!$@+R332)&B@LS
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M:"-;>#S;N[DGN;J79 1)/<SS7,SJ99Y'D<NW0U_(C^U'_P %2_VU_A;^TO\
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M4X2P^:MO Y757+A\*URU\LPE>"UQJU4*D5);*2:3:LW_ &S45_$S_P /A_\
M@H!_T6/2?_#8_#'_ .9*C_A\/_P4 _Z+'I/_ (;'X8__ #)5Z7_$O'''_0?P
MS_X79E_\Z/ZL_*_#_P 1/X>_Z!LV_P#"?"__ #<?VS45_$S_ ,/A_P#@H!_T
M6/2?_#8_#'_YDJ/^'P__  4 _P"BQZ3_ .&Q^&/_ ,R5'_$O'''_ $'\,_\
MA=F7_P Z/ZL_*Y_Q$_A[_H&S;_PGPO\ \W']LU%?Q,_\/A_^"@'_ $6/2?\
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M0WQ;735R8;^-C_\ L+A_Z@X(ZL1_!P/_ &"S_P#4W&!11176<H4444 %%%%
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M2_&-[XE\0W7B2RDLVM]8GUO5);Z.9[VX+_AQ\*OA7\.?"W_!M/\ M(?$/0/
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M^J/+#^D> _\ DE,J],9_ZGXH****_,#Z\**** "BBB@ HHHH **** "BBB@
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M]IF&65N?^SG[OL,-FT.7E^O:\_UB][KEY+6?-=?RU45_3M_P[OO/^@9'_P"
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M3_XFC_B9./\ T1=7_P /\?\ YS?U9^5S_B%*_P"B@A_X;'_\WG\Q-%?T[?\
M#N^\_P"@9'_X#)_\31_P[OO/^@9'_P" R?\ Q-'_ !,G'_HBZO\ X?X__.;^
MK/RN?\0I7_100_\ #8__ )O/YB:]N_9F_P"3D/V?O^RW?"C_ -3S0:_H(_X=
MWWG_ $#(_P#P&3_XFM_PI^PC=>$/%/AKQ8VG1HOA?7]&\1,XMU4HNB:C;:D6
M#;<@J+;.>V,UY6>_2*CC<DSG!_ZG5*7UO*LPPWM'GL9^S]OA*M+GY?[(CS<G
M/S<O-&_*US*Z9Z&4>%RH9KEE?^WH3]CF&"J\G]FM<WL\33GRW^O.W-:U[.U[
MV>Q_+57TA\'O@_?Z[>V.L:K9R%'>*;2].=&#2G(:*]NDQD19P]O"P_>8$TH\
MK8DW[SC_ ()W7A(']F1#W-L@'_H!_E7N?PF_8.31]8MKK4+3Y(G4X:/).T@]
MP/3)SD@X'>O)XP\>,VXAR>KE.493+A[ZW>EC<<LQ>-Q,\+.-IX?#2C@L)]6=
M6[C5K)U*GLVX4O9N3J+IR+PYP&5XZ&.QN.6:^PM/#X?ZI]7I1K)IQJU4Z]?V
MJAHX0:C%2M*?,DHGAW[)7[)USJ]U8:QJED=@,<F)(S@<@G.Y<>G3)Z<^O[S>
M ?!5AX1TBVL;6!(UBB5,*@7)4 =!C/3DGZ>M5_ '@#2_!VE6]G:6\:")%7Y4
M"Y( '8#OGGMT!)Y'I/3I7X%HE9?-]7HE]VBT^?I^DMN6K^[L%%%% @HHHH *
M*** "BBB@#F=>_Y"O@K_ +&:[_\ 4-\6UTU<SKW_ "%?!7_8S7?_ *AOBVNF
MKDPW\;'_ /87#_U!P1U8C^#@?^P6?_J;C HHHKK.4**** "BBB@ HHHH ***
M* "N9T'_ )"OC7_L9K3_ -0WPE735S.@_P#(5\:_]C-:?^H;X2KEQ'\; _\
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MEW,MEJ>D:SI&HP6VH:7JFG7D,UI?6%[;P7=I<Q2P7$4<L;(/WNU[_@MMX/\
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M_P"J/+#^D> _^24RKTQG_J?B@HHHK\P/KPHHHH **** "BBB@ HHHH ****
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M/\J7]B_MMG_S]VW_ '_B_P#BZ9_9]C_SZ6__ 'Z3_"C^S['_ )]+?_OTG^%
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M:P;5\->%&"^4F S:IXS#$#& 6"(">X4>@KI/[/L?^?2W_P"_2?X5RX/^#/\
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M^+KF-=L;-=4\& 6L #^);I7 B0!E'@_Q6X!XY&Y5;![J#U%=)_9]C_SZ6_\
MWZ3_  KDPW\;'_\ 87#_ -0<$=6(O[' [?[K._\ X6XO;\?P'_;;/_G[MO\
MO_%_\71]ML_^?NV_[_Q?_%TS^S['_GTM_P#OTG^%']GV/_/I;_\ ?I/\*ZSE
MU\OQ\O\ @_AYC_MMG_S]VW_?^+_XNC[;9_\ /W;?]_XO_BZ9_9]C_P ^EO\
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M9]C_ ,^EO_WZ3_"@-?+\?+_@_AYC_MMG_P _=M_W_B_^+H^VV?\ S]VW_?\
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M3]HW_L->"O\ U6'@BOSQKHX*_P"2-X2_[)G(?_55A#\7S_\ Y'N=?]C;,?\
MU,K!1117TQY(4444 %%%% ']*?\ P;[?\>G[2_\ V%?A3_Z;?B37])M?S9?\
M&^W_ !Z?M+_]A7X4_P#IM^)-?TFU_ WC-_R<KB;_ !Y5_P"J/+#^D> _^24R
MKTQG_J?B@HHHK\P/KPHHHH **** "BBB@ HHHH **** "BBB@ HHHH *QX_^
M0Y<?]>*?^C(JV*QX_P#D.7'_ %XI_P"C(J"9?9_Q+]38HHHH*"BBB@ HHHH
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M "LR_P"(IY;_ -"O'?\ @S#_ /R1_?MO3^\O_?0_QHWI_>7_ +Z'^-?P$_\
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MT?QX_P##H>+_ /Y:T?\ $N.?_P#10Y/_ .",;_\ *P_XBGEO_0KQW_@S#_\
MR1_?MO3^\O\ WT/\:-Z?WE_[Z'^-?P$_\-R?MD_]'1_'C_PZ'B__ .6M'_#<
MG[9/_1T?QX_\.AXO_P#EK1_Q+CG_ /T4.3_^",;_ /*P_P"(IY;_ -"O'?\
M@S#_ /R1_?MO3^\O_?0_QHWI_>7_ +Z'^-?P$_\ #<G[9/\ T='\>/\ PZ'B
M_P#^6M'_  W)^V3_ -'1_'C_ ,.AXO\ _EK1_P 2XY__ -%#D_\ X(QO_P K
M#_B*>6_]"O'?^#,/_P#)']^V]/[R_P#?0_QHWI_>7_OH?XU_ 3_PW)^V3_T=
M'\>/_#H>+_\ Y:T?\-R?MD_]'1_'C_PZ'B__ .6M'_$N.?\ _10Y/_X(QO\
M\K#_ (BGEO\ T*\=_P"#,/\ _)']^V]/[R_]]#_&N9\%LH\'>$P67/\ PC.@
M]Q_T"[7WK^"__AN3]LG_ *.C^/'_ (=#Q?\ _+6O6?CW^V1^UAX7^.GQI\->
M'/VCOC3H?A[P[\6?B-H6@Z)I7Q&\4V.EZ/HVD^,-9L-+TO3;*WU*.WL[#3[&
MW@M+.U@1(;>WACBB1410/,J_1ZSV.<X#"//\H<Z^5YOB8S]CC.6,<+B\DI2B
MU[._-)XR#C;2T)7U:.^GXG9<\KQE?^S<;RT\?EM)Q]I0NW6P^:S37O6M%4))
M];R5NI_<[O3^\O\ WT/\:-Z?WE_[Z'^-?P$_\-R?MD_]'1_'C_PZ'B__ .6M
M'_#<G[9/_1T?QX_\.AXO_P#EK7I_\2XY_P#]%#D__@C&_P#RLX/^(IY;_P!"
MO'?^#,/_ /)']^V]/[R_]]#_ !HWI_>7_OH?XU_ 3_PW)^V3_P!'1_'C_P .
MAXO_ /EK1_PW)^V3_P!'1_'C_P .AXO_ /EK1_Q+CG__ $4.3_\ @C&__*P_
MXBGEO_0KQW_@S#__ "1_?MO3^\O_ 'T/\:-Z?WE_[Z'^-?P$_P##<G[9/_1T
M?QX_\.AXO_\ EK1_PW)^V3_T='\>/_#H>+__ ):T?\2XY_\ ]%#D_P#X(QO_
M ,K#_B*>6_\ 0KQW_@S#_P#R1_?MO3^\O_?0_P :-Z?WE_[Z'^-?P$_\-R?M
MD_\ 1T?QX_\ #H>+_P#Y:T?\-R?MD_\ 1T?QX_\ #H>+_P#Y:T?\2XY__P!%
M#D__ ((QO_RL/^(IY;_T*\=_X,P__P D?W[;T_O+_P!]#_&C>G]Y?^^A_C7\
M!/\ PW)^V3_T='\>/_#H>+__ ):T?\-R?MD_]'1_'C_PZ'B__P"6M'_$N.?_
M /10Y/\ ^",;_P#*P_XBGEO_ $*\=_X,P_\ \D?W[;T_O+_WT/\ &N9\:,I\
M'>+0&7/_  C.O=Q_T"[OWK^"_P#X;D_;)_Z.C^/'_AT/%_\ \M:]9^ G[9'[
M6'BCXZ?!;PUXC_:.^-.N>'O$7Q9^'.A:]HFJ_$;Q3?:7K&C:MXPT:PU32]2L
MKC4I+>\L-0L;B>TO+6='AN+>:2*5&1V!\S.OH]9[@LFS;&3S_*)PPF68_$RA
M&CC%*<:&%JU91BW3LI24&DWI=ZZ'?E7B=EU?-,MH1RW&QE6Q^#I*3J4+1=3$
M4X)NTKV3=W;6Q_<[O3^\O_?0_P :4$'D$$>H.:_@(_X;D_;)_P"CH_CQ_P"'
M0\7_ /RUK^@S]@S_ (*N#XV6&E?#OXQSV6E_%S3;1()-2B2&RTSX@VMK$ ^M
MZ=:QB.WL->6)#/X@T*U5+4LLVL:'!%I;7>EZ!XW&'@OQ+PEE4LX^L83.,'0;
M>.^H0KQK8*C9<N)J4JL$YX=.ZK5(-N@N6I4C[+GJ4^O(N/,JSO&+ ^RK8&O4
M2^K_ %F5-PQ$];TH3A)J-5JSA&5O::QB^?EC+][**YGPWXEL/$-E%=6DZ2K(
MBD%2">1WP3UXQUYR"<XSTU?CY]P%%%% !1110 4444 %%%% ',Z]_P A7P5_
MV,UW_P"H;XMKIJYG7O\ D*^"O^QFN_\ U#?%M=-7)AOXV/\ ^PN'_J#@CJQ'
M\' _]@L__4W&!11176<H4444 %%%% !1110 4444 %<SH/\ R%?&O_8S6G_J
M&^$JZ:N9T'_D*^-?^QFM/_4-\)5RXC^-@?\ L*G_ .H6,.K#_P ''?\ 8+#_
M -3<&=-11174<H4444 %%%% !1110 4444 %%%% ',^"O^1-\)?]BSH/_IJM
M*Z:N9\%?\B;X2_[%G0?_ $U6E=-7)@/]QP7_ &"8;_TS ZL=_ON,_P"PK$?^
MGIG^3'^W?_R?#^V5_P!G6?M#_P#JW?&%?*=?5G[=_P#R?#^V5_V=9^T/_P"K
M=\85\IU_I1DO_(FRG_L68#_U%I'YC6_BU?\ KY/_ -*85^GO_!+;]E3]L#]J
MKXG_ !A\,?LE?%#PY\&!9? SQIH/QM^('C;Q'K'AOP1+\(?B'%'X4\2^"/$$
MVB^&O%D^H/XGLIKO4-.L[C2(K>QG\,R>);?6=#U;P_I>I0?F%7[@?\$6/%GP
M7T^]_;2^&_[1_P"U+X2_9N^!7QP_9IU3X5^.K?7Y);/Q%XUD\4W5YI&BW_P[
MU2#Q/I)L?%G@6XU&XU*YM[WPM\0=&USPGJWB7P]K/AVVLM5?6=/\[B_$XK"<
M.9GB,'"%3$0IT(PC4P%3-$XU,70I57'+Z49SQ=6-*<Y4:+2IRK*G[64*2G..
MN$C&6(I1FVHMRNU45+50DU>H[<BNES2W4;V3=D?J[\/?@S^U7\"_V9M0_9F^
M&O\ P7T_8.T+X-VGACQ7HUCX5T_Q+\'=3\1Z9H?B6+5+G7M \*>.M4FO/'6B
M)?3ZG?G2Y])UVSU#0[FY67P[<:1(D6S^.*OZ"M0_X)B?\$H+6POKFT_X+7?#
MR]NK>SN9[:S7X'31M=W$4+R0VJO_ ,++;8;B15B#[6VE\[3C%?SZUXG T<+S
M9U6P^+K8RKB:^&Q&+JU^#WPI4G7J+$N5:<I9?@99G5K2YI5*LG6E0:3E*+Q%
MY[8WFM14HQBHQE&"CC%BDHKDT24Y^R2Z+12O97Y="ONG_@F%_P I&/V&_P#L
MZGX&_P#JP]!KX6K[I_X)A?\ *1C]AO\ [.I^!O\ ZL/0:^IS_P#Y$6=?]BG,
M?_4.L<V'_P!XH?\ 7ZE_Z7$_<W_@J[_RD$_:-_[#7@K_ -5AX(K\\:_0[_@J
M[_RD$_:-_P"PUX*_]5AX(K\\:Z."O^2-X2_[)G(?_55A#\7S_P#Y'N=?]C;,
M?_4RL%%%%?3'DA1110 4444 ?TI_\&^W_'I^TO\ ]A7X4_\ IM^)-?TFU_-E
M_P &^W_'I^TO_P!A7X4_^FWXDU_2;7\#>,W_ "<KB;_'E7_JCRP_I'@/_DE,
MJ],9_P"I^*"BBBOS ^O"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'C
M_P"0Y<?]>*?^C(JV*QX_^0Y<?]>*?^C(J"9?9_Q+]38HHHH*"BBB@ HHHH *
M*** "OQX_P""RGQT_:6^#/P[_8B\,_LL_&V7]GWQY^TU_P %'_V:_P!E'Q#\
M2X/AU\._BG-HO@7XSZ'\4=/U:>'PC\3-"UWP_>RZ=K.E^'M?C6W&D:G<OHHT
MR+7-/LM0O_._8>OP'_X. _!K_$7X=_\ !,3X?1^+O&G@!_'?_!9#]BWP:GCS
MX;ZS#X=^(G@E_$^A_&?1%\7> O$%S8:K;Z%XT\-F^&L^%M9GTS48=+URRL;V
M6PO$@:WD /%?VT/B/_P5I_X),?"J7]L_X@?MY_"S]OGX#^ _%7@+1?BM\"/B
MG^S-\,/V:_&>I^'?&WC'1?"<UQ\+/'7P9\^6Y\:6]QJ=NU@NN6%[H^BZ;/K'
MB34_#OBRVT#^Q;O]2/CO_P %:_\ @GE^S%XF\;^!_CY^TEH'PT\=_#C_ (5V
MOC+P+JOA/XBZMXQTR?XJ>&+KQCX*MK#P[X7\'Z]J7BB:_P##UG->ZB/"$&OQ
M^'G>SL_$,FEWNI:=;W?SDO\ P0]^"7BSQ)X"U/\ :-_:]_X*'_ME^#OAUXXT
M3XCZ'\&_VJOVE--^(7P>N_&7AR*^CT/6->\':!\./!CZRVGF_N"+6[U-K.\M
MI+K2=2M[W0M4UG2]2^>OV7/"WAK5_P#@XZ_X*@>(M5\/Z+J>O^%OV:/V6/\
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MVTR:\N-2TB.__*[_ ()O?M5_LZ_LP?%#_@MSIO[0/Q@\!_"'7?!7_!2#X_\
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ME;7E[?OX'L/B7X7\'R>/?[/L-/O]1U!?!7]O-8:;8WFHW@AL;6>XCN_M+_\
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M .%-S?:)X,\*^%II/&>E?&K1K#5?$<7Q,N=/L;#Q-#?ZIXF@\4.+G7KRVO\
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M1XJT]](\4Z9KO@33=&MO"^LV/B;2I)=-\16NI:7=0ZY8RR6NJ)=02.C>QT4
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M-_E/17ZL?\-V_L;_ /2+WX-_^'2U_P#^8JC_ (;M_8W_ .D7OP;_ /#I:_\
M_,57T/\ K!Q#_P!$'GG_ (=N$_\ Y_?U9^5_,_LS*_\ HH\O_P#"+.O_ )VG
MY3T5^K'_  W;^QO_ -(O?@W_ .'2U_\ ^8JC_ANW]C?_ *1>_!O_ ,.EK_\
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MHUERMR@^>G&[BW&\6I&Q16/_ &??_P#06F_[\K_\=H_L^_\ ^@M-_P!^5_\
MCM?GA]/=_P K^]?Y^O\ 3TV**Q_[/O\ _H+3?]^5_P#CM']GW_\ T%IO^_*_
M_': N_Y7]Z_S]?Z>FQ16/_9]_P#]!:;_ +\K_P#':/[/O_\ H+3?]^5_^.T!
M=_RO[U_GZ_T]-BBL?^S[_P#Z"TW_ 'Y7_P".T?V??_\ 06F_[\K_ /': N_Y
M7]Z_S]?Z>FQ16/\ V??_ /06F_[\K_\ ':/[/O\ _H+3?]^5_P#CM 7?\K^]
M?Y^O]/38HK'_ +/O_P#H+3?]^5_^.T?V??\ _06F_P"_*_\ QV@+O^5_>O\
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MW_?E?_CM']GW_P#T%IO^_*__ !V@+O\ E?WK_/U_IZ:?D0_\\T_[Y%'D0_\
M/-/^^169_9]__P!!:;_ORO\ \=H_L^__ .@M-_WY7_X[0%W_ "O[U_GZ_P!/
M33\B'_GFG_?(KFO!<,1\'>$R8T)/AK0B25&23I=KDFM+^S[_ /Z"TW_?E?\
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MO_\ H+3?]^5_^.T?V??_ /06F_[\K_\ ': N_P"5_>O\_7^GIL45C_V??_\
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M_P#9]_\ ]!:;_ORO_P =H_L^_P#^@M-_WY7_ ..T!=_RO[U_GZ_T]-BBL?\
ML^__ .@M-_WY7_X[1_9]_P#]!:;_ +\K_P#': N_Y7]Z_P _7^GIL45C_P!G
MW_\ T%IO^_*__':/[/O_ /H+3?\ ?E?_ ([0%W_*_O7^?K_3TV*YG0?^0KXU
M_P"QFM/_ %#?"57O[/O_ /H+3?\ ?E?_ ([7.:)8WK:GXQ U252GB.U5V$*G
MS&/A'PLX<_O!@A66/'/" YYP.7$?QL#_ -A4_P#U"QAUX=OV..]W_F%AU7_0
M;@_^#]WGIW=%8_\ 9]__ -!:;_ORO_QVC^S[_P#Z"TW_ 'Y7_P".UU')=_RO
M[U_GZ_T]-BBL?^S[_P#Z"TW_ 'Y7_P".T?V??_\ 06F_[\K_ /': N_Y7]Z_
MS]?Z>FQ16/\ V??_ /06F_[\K_\ ':/[/O\ _H+3?]^5_P#CM 7?\K^]?Y^O
M]/38HK'_ +/O_P#H+3?]^5_^.T?V??\ _06F_P"_*_\ QV@+O^5_>O\ /U_I
MZ;%%8_\ 9]__ -!:;_ORO_QVC^S[_P#Z"TW_ 'Y7_P".T!=_RO[U_GZ_T]-B
MBL?^S[__ *"TW_?E?_CM']GW_P#T%IO^_*__ !V@+O\ E?WK_/U_IZ4?!7_(
MF^$O^Q9T'_TU6E=-7,^"O^1-\)?]BSH/_IJM*Z:N3 ?[C@O^P3#?^F8'9CO]
M]QG_ &%8C_T],_R8_P!N_P#Y/A_;*_[.L_:'_P#5N^,*^4Z^K/V[_P#D^']L
MK_LZS]H?_P!6[XPKY3K_ $HR7_D393_V+,!_ZBTC\QK?Q:O_ %\G_P"E,MZ>
MEG)?V2:C++#I[W=LE]- ,S16;3(+J6$>7+F6. NT8\J7+@#RW^Z?Z+?^&??^
M#9C_ */F_;L_\)$?_0>5_./7W3^PM^V9X8_8T\6>._$_B?\ 9;^!/[4D'C/P
M[IV@VN@?';PYI_B/2?"TMAJ3:@^KZ#!J&D:NEMJ-XA%E<RQQPL]L A=A\M>7
MQ/EF.QV%C7R['Y[A\3A(S]G@LES#+\N>/=:=%-5Z^8X+%THNA"$YTG>FK2J1
M?/*<.77"U:=.?+4IT)1FU>=:G4J>S2N_=C3G!OF=DUK\M3]0]1_9_P#^#:6/
M3[^33/VX?VYY]12SNGT^&?PD!!->K [6D4Q_X9 AQ%).(TD/FQ80L?,3[P_G
M3K^OW]AC_@H+X!_;W\;>-/V>_A7_ ,$K_P!A[X;?'V3X8^.O'_PQ^)EO\'O"
MOBCX>:)JG@G3[;48M+\?Z)IWASP;XK\+V'B61_\ A&=$^(^@^--0E\,^,]:\
M*F?P1KMG/="/^0*O'X*J9C#%9W@,UGGBQF$CEE5T,\SC*LWJ0H8I8[V5;#2R
MK!86G1I5Y4*D)*K.K4J2H:0HJG>KMC53<*%2DJ')/VBYJ%&K27-!4[QE[6<W
M*4>9/W4DE*]WS6B5]T_\$PO^4C'[#?\ V=3\#?\ U8>@U\+5]T_\$PO^4C'[
M#?\ V=3\#?\ U8>@U]3G_P#R(LZ_[%.8_P#J'6.;#_[Q0_Z_4O\ TN)^YO\
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M5W735S/C7_D3?%O_ &+.O?\ IJNZY<=_N6,_[!<1_P"F9G5@?]]P?_85A_\
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M;>%+R>RW^'H[/7#JVGVNMZ_)/H>EQZ$-?^0OV+/^"YGQ:_:L^%^I_M3>,/\
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MKX>>'PE8^"=0U#P79Z/9>'?^%@^(/'TOB>Y:ST70+70+N[N/SI^./QE_:_\
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M3,GW5XWU3XR?\$V_^"HW[9?[3\W[)G[57[5G[.?[?WPO_9[UF#Q#^R7\+/\
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MX8^&SI']D:2=2T+6-:\)6L5I\0- \7:MX2GU;3_#7BI/"=AXMM;/^TM+OK0
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MVB'_ )Z+^O\ A1]HA_YZ+^O^%?YOO_"0Z_\ ]!S6/_!G>_\ Q^C_ (2'7_\
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M/_ZMWQA7RG7^E&2_\B;*?^Q9@/\ U%I'YC6_BU?^OD__ $IA1117IF84444
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MQ%XE\$6%J-#T?3+2[BL/"UI/=K;.YNXYKJZEES!^UW\2-#_X)Y_\%;/V3?\
M@HKXW^,'QB\5_P#!.+XE?"/P'XC^.'P.\1:3\'/CQ\7_ (-_%;XC>'=3^"?B
MN/6-2M?$5CX?\87$>D/-K6L75GJ!UWP3<VNEWVH:]XGCUOQAK8!_6[17Y,?&
MK_@ICJ/PY^-,?[*G[,G[(WQR_;/^-'@7X4_#GXJ?%G2OA]XI^&'A#P[\*_ O
MCA;S^PK3Q5XR\?>)]+^W_$G4="TM_$.D^#K31$3Q!9ZCHWV77(9]0GCL-W5_
M^"NW[+V@_L=^#_VPM4T#XV167CWXE0_ ;PC\ (/A=J]Q^TCX@_:/EU'5=&/[
M/VD?#99DCO\ XCC5=$U:UACAUH^'[Q;/SK+7+C[39QW !^I5%?F)^SQ_P4JM
M_B5\:?!G[.7[1G[,?QQ_8F^-?Q?\*:YX_P#V?_"_QQ/@_4]&^./A'PW9KJWB
M6Q\(>+? VO:YI.G_ !2\$Z#-9Z]\0_A#XC72?&7@[2]0L[JYM[R)IG@^;/'O
M_!;C3;#1/B=\8_@?^PW^U;^TG^R#\#O$/BW0?BO^U9\.K;X?Z9X-C@\ 1W@\
M=^)OA?X/\4>*M,\9?$[P;X,NM/U"W\3>,(;'PYX9TJ'2]5U2;5CI5K#>W8!^
MYU%?DU\:/^"L/@KPSI?[)6E_LT? 'XO_ +7WQ=_;=^$>H_''X#_"WP#<^#/
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M#?QL?_V%P_\ 4'!'5B/X.!_[!9_^IN,"BBBNLY0HHHH **** "BBB@ HHHH
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MGA5%%%?K)\6?TI_\&^W_ !Z?M+_]A7X4_P#IM^)-?TFU_-E_P;[?\>G[2_\
MV%?A3_Z;?B37])M?P-XS?\G*XF_QY5_ZH\L/Z1X#_P"24RKTQG_J?B@HHHK\
MP/KPHHHH **** "BBB@ HHHH **** "BBB@ HHHH *QX_P#D.7'_ %XI_P"C
M(JV*QX_^0Y<?]>*?^C(J"9?9_P 2_4V****"CG/&,;R^$/%442/)))X;UR..
M.-2[R.^F72HB(H+,[,0JJH)8D  DU_,)_P $0O\ @DE^P[\4/^":'[+OQ/\
MVG/V+/A_XD^/6K7'Q@N?&FJ_%/P=K$'BJ^DT+]H;XJ:1X67Q'H.M36L4MO#X
M1TKP]:6EIJ&E&UOM%ALS+#<VTY:7^IZB@#\&/^"T?P%U;X;?L)_L]ZO^RA\
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MT7B:YL++Z[H _F5_:#_9^_X*:?M$_P#!-[]EW]J/XF^%] \>?\%!OV9OVO/
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M_0KX4_\ "/-?+_J>>OX>8?\ $,.'/^@O._\ P=@O_G<?R"?\*9^)G_0K3_\
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M!<1_Z9F=6!_WW!_]A6'_ /3T#IJ***ZCE"BBB@ HHHH **** "BBB@ HHHH
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M;_N:;^=Q_P#%4!?R?W>G^?X/L:U%9.[6_P"YIOYW'_Q5&[6_[FF_G<?_ !5
M7\G]WI_G^#[&M163NUO^YIOYW'_Q5&[6_P"YIOYW'_Q5 7\G]WI_G^#[&M16
M3NUO^YIOYW'_ ,51NUO^YIOYW'_Q5 7\G]WI_G^#[&M163NUO^YIOYW'_P 5
M1NUO^YIOYW'_ ,50%_)_=Z?Y_@^QK45D[M;_ +FF_G<?_%4;M;_N:;^=Q_\
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MJ@+^3^[T_P _P?8UJ*R=VM_W--_.X_\ BJ-VM_W--_.X_P#BJ OY/[O3_/\
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M']I^#MZZ?N_X2.Z\K:9\%_\ A$?%6=^6SM\KS"-O._9VS71[M;_N:;^=Q_\
M%5R8;^-C_P#L+A_Z@X(ZL0_W.!T>N%G\O]MQ>_W_ (,UJ*R=VM_W--_.X_\
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M;_V+.O?^FJ[KIJYGQK_R)OBW_L6=>_\ 35=URX[_ '+&?]@N(_\ 3,SJP/\
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M ,$PO^4C'[#?_9U/P-_]6'H-?"U?=/\ P3"_Y2,?L-_]G4_ W_U8>@UY.?\
M_(BSK_L4YC_ZAUC;#_[Q0_Z_4O\ TN)^YO\ P5=_Y2"?M&_]AKP5_P"JP\$5
M^>-?H=_P5=_Y2"?M&_\ 8:\%?^JP\$5^>-='!7_)&\)?]DSD/_JJPA^+Y_\
M\CW.O^QMF/\ ZF5@HHHKZ8\D**** "BBB@#^E/\ X-]O^/3]I?\ ["OPI_\
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M2_\ !<'X+? ;]M_P-XF\)7WPQT?P;\0O$_Q%^(_Q8^)O[..O?#&YUC4-.M_
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M10!_-O\ \%7O@SH?[0?_  5\_P""+GPA\2>+/B7X'T7Q=X9_;_\ MOBCX/\
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M!TNW\4:KIEN+1;?3M2\016J:M?6,"V%BL-I=7<MO$+.T"1J+>'8 ?S1_M;>
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M%W$E''XVE3S;$PIT\7B:=."5*T80K3C&*_=[)))'[E?\/[OVI?\ HEWP+_\
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M#!X-UC2K);O0O%=QH^N0W-N^FK)7XN_L@?L/?\%K/V)?A/X3^!WP*UG_ ()
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M+J_B/37L?%WA*TUW0;?1KC0]!U?4SXFU&_L_#<-K92/<:M$6B63^:?\ 8?\
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M*ZC#$UMX>U_PI-JV@>$=+!-WIW@[PCX<DU.."YOU$@!_7]\,_&?B'Q'^S?\
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M-^U#_P!EX^*/_J8:M7RW7^F'#W_(@R/_ +$^6?\ J%0/Y-S3_D99C_V'8O\
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M4**** "BBB@ HHHH **** "N9\:_\B;XM_[%G7O_ $U7==-7,^-?^1-\6_\
M8LZ]_P"FJ[KEQW^Y8S_L%Q'_ *9F=6!_WW!_]A6'_P#3T#IJ***ZCE"BBB@
MHHHH **** "BBB@ HHHH YG7O^0KX*_[&:[_ /4-\6UTU<SKW_(5\%?]C-=_
M^H;XMKIJY,-_&Q__ &%P_P#4'!'5B/X.!_[!9_\ J;C HHHKK.4**** "BBB
M@ HHHH **** "N9T'_D*^-?^QFM/_4-\)5TU<SH/_(5\:_\ 8S6G_J&^$JY<
M1_&P/_85/_U"QAU8?^#CO^P6'_J;@SIJ***ZCE"BBB@ HHHH **** "BBB@
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M8].TV>ZNK'0K[77M4U36/#%O<WMY<+X5UBZO_#;SW=S-)I;R3RLWJ=]^SO\
M 74M"^$WA:]^#/PPF\,? 7Q!X:\5_!'PX/ _AR+0?A'XE\&64VG>$=;^'&CP
MZ='IW@W4O#.GW$]EH-UH%M82:5:RR061AB8K7IO]K)_SXZE_X"C_ ..T?VLG
M_/CJ7_@*/_CM 77?^M/\T>2?'#]F7]G3]IG2M$T3]HCX%_";XX:5X9OKC4_#
M=C\5/ 'ACQU#X=U&\BB@O+W0?^$CTS4'T>ZO8(((+V;3FMI+N&&&*Y:6.)%7
MSKX__L%?L7?M4>)=!\9_M%?LP?!3XP^,/#2V,.D^*_''@+0M6\2QZ=IL]U=6
M.A7VNO:IJFL>&+>YO;RX7PKK%U?^&WGN[F:32WDGE9OJ#^UD_P"?'4O_  %'
M_P =H_M9/^?'4O\ P%'_ ,=H"Z[_ -:?YH\ROOV=_@+J6A?";PM>_!GX83>&
M/@+X@\->*_@CX<'@?PY%H/PC\2^#+*;3O".M_#C1X=.CT[P;J7AG3[B>RT&Z
MT"VL)-*M99(+(PQ,5KH==^$WPP\4?$'P'\6/$?P_\(:Y\3OA=:>*+#X<>/\
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M@MK:&*&&-(T51JUD_P!K)_SXZE_X"C_X[1_:R?\ /CJ7_@*/_CM 77?^M/\
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MK45D_P!K)_SXZE_X"C_X[1_:R?\ /CJ7_@*/_CM 77?^M/\ -&M163_:R?\
M/CJ7_@*/_CM']K)_SXZE_P" H_\ CM 77?\ K3_-&M7,^"O^1-\)?]BSH/\
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MHK)_M9/^?'4O_ 4?_':/[63_ )\=2_\  4?_ !V@+KO_ %I_FC6HK)_M9/\
MGQU+_P !1_\ ':/[63_GQU+_ ,!1_P#': NN_P#6G^:-:BLG^UD_Y\=2_P#
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M_P!EKQ5_ZO<>?Z<9!_R(LE_[%.7?^H=$****^*/6"BBB@ KTOX,_\E:^&O\
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M\0W'A[1IKW5X=#LI8KO5I+-;"WD2:X1AF>/_ /@J;\?_ !'\4_VG/"/[%7[
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M:N7!_P &?_85CO\ U-Q!U8S^-#_L%P/_ *A8<****ZCE"BBB@ HHHH ****
M"BBB@ KF?!7_ ")OA+_L6=!_]-5I735S/@K_ )$WPE_V+.@_^FJTKDG_ +]A
MO^P3&_\ I[ '5#_<L1_V%8/_ -,XXZ:BBBNLY0HHHH **** "BBB@ HHHH *
MYGQK_P B;XM_[%G7O_35=UTU<SXU_P"1-\6_]BSKW_IJNZY<=_N6,_[!<1_Z
M9F=6!_WW!_\ 85A__3T#IJ***ZCE"BBB@ HHHH **** "BBB@ HHHH YG7O^
M0KX*_P"QFN__ %#?%M=-7,Z]_P A7P5_V,UW_P"H;XMKIJY,-_&Q_P#V%P_]
M0<$=6(_@X'_L%G_ZFXP****ZSE"BBB@ HHHH **** "BBB@ KF=!_P"0KXU_
M[&:T_P#4-\)5TU<SH/\ R%?&O_8S6G_J&^$JY<1_&P/_ &%3_P#4+&'5A_X.
M._[!8?\ J;@SIJ***ZCE"BBB@ HHHH **** "BBB@ HHHH YGP5_R)OA+_L6
M=!_]-5I735S/@K_D3?"7_8LZ#_Z:K2NFKDP'^XX+_L$PW_IF!U8[_?<9_P!A
M6(_]/3/P;\9?\C?XJ_[&37/_ $Z75<W72>,O^1O\5?\ 8R:Y_P"G2ZKFZ_XY
M_$K_ ).+Q]_V6O%7_J]QY_IQD'_(BR7_ +%.7?\ J'1"BBBOBCU@HHK\B_BU
M_P %'/%?PR\6?MYZI>^%/ VG_"G]CSP?X6\,>&I-6UC4_P#A//B-\?OB)I^C
MWW@K3[SPZ(K2>Q\ W=Y>W>F&]L0)I;#3KWQ%9:GJUC-<Q^&/OO#_ ,-.+O$[
M'X_+.#\!2S#&Y=A\KKUZ-7%X?"2J2SOB7(^$,HPF%5><)8O'9AQ!Q'E.!PV$
MH*=:7MZE>48X?#UZM/QLZS[+,@HT<1F=:5"E7GB(0E&E4J)+"8#%YEB:E1PB
MU3I4,%@<36G4FXQ7(H)NI.$9?KI7I?P9_P"2M?#7_L=_#7_IVM:_!_\ 8N_:
M9_;:?XZ_"_X1?MCW7P>UBR_:*_9[U'X^_#-O %A>:3XU\$R6=SX>NSX.\=:/
M);:7'IS1:)K-]'.9--U.%M8TPV>G>+=6EL=9AB_>#X,_\E:^&O\ V._AK_T[
M6M?H>%\-<Y\+?'+PQX?SG,N'L[^M\6\%9MEV=<*YE/-LBS/ SXNAEE2M@<;5
MPN"K3^K9GE>99=B8U<+1E#%8*O&*G3]G5GXE3/L+Q%PCQ!C<+0QN$]EEN;8:
MOA,QH+#8S#UEECQ$85J4:E6"]IA\10KP<:DTZ=:#;4N:*_2_QM_R-&K?]=+?
M_P!(K:N5KJO&W_(T:M_UTM__ $BMJY6O]V.+O^2KXG_[*'.O_5EB3^/LM_Y%
MV _[ L+_ .F*85Q_Q#\(1_$'P!XY\!2ZOJGA^+QOX/\ $WA"37M#F6WUK1(_
M$NBWNC/J^CW#!E@U335O3>:?,RE8KN&%R"%Q785YS\8O#GB#QA\(_BGX2\)^
M)O\ A"_%/BGX<^-_#GAKQCY[VO\ PB?B#6_#.IZ9HWB;[3'#</;_ -@ZC=6V
MJ>>D$[P_9?,6&4J$;PZ#:KT6JBI-5:;562YHTGSJU1Q2;DH?$TD[I6L]CKG\
M,M'+W7[J=G+1Z)W5F]KW7J?QI^$OV:_AAX[MOB9^R+XY_:6_X)Q>*OVT_#_P
M1^#G["W[(7P[\&:CXOO/AK\*?#GAKXD1^)?C!\8H_'.M>%(K6/\ :P\6>)-3
M\7^-EL/"<\GC*P\:V][X;D%T/$2Z%8_VW0QM%#%$TLD[1QI&T\WE^=,R*%,L
MOE1Q1>9(1O?RXHX]Q.R-%PH_BQMO .K^*?V*/!?_  3A\-_\$8_B)X,_;:-I
MX1^' _:EN?@CHEI\%/#GB32=?T:'4_VJH/VLO#\5YXDFN;Z#3)?$%SJFCWD^
M@374TGAFQUO7/#XM?"^H_P!I5G%/!:6L%S<M>7,-M!%<7C1I"UU/'$J2W+0Q
MDQQ-/(K2F-"40N54[0*_2?$6K.H\NY\3*I;%YJX4:E7+JW/!4LJHK,L*\MK5
M:='+\T=!UJ-"MS5OK-/&8B6*QDL1.=/P\DC&*K<L$OW6'3E&->-G?$2="I[>
M,7.M0YU&4XVC[.5."ITU!)V****_,3WCTKX;?\A&X_[9_P#HB\KVZO$?AM_R
M$;C_ +9_^B+RO;J_MOPF_P"3?</?X,R_]7&8'Y3Q%_R.L=_BH?\ J)APHHHK
M]%/%"BBB@ K^>;_@XQT;Q7XC^"'_  3K\/> _&?_  KCQSKO_!6_]D?1O!GQ
M#_X1W3?%_P#P@?BO5/"/QPL?#OC/_A$M9E@T?Q1_PB^L3V>N?\([JL\.FZW]
MA_LR^ECM;F5Q_0S7S-^TW^R5\'OVM[#X+Z;\8K+7[VU^ O[07PZ_:9^'RZ!K
MD^A/;_%+X6PZ_;^$[O57@BE.IZ+#'XEU07VCR;(;TO"7D7R5R ?'G[//[(W_
M  5"^''QC\$^-?CY_P %>_\ AI'X1Z'=:K+XQ^"?_# 7[/7P>_X3JVN] U73
M],M?^%D>#/$M]XF\,?V1KMWI?B+S]*M)I+_^R/[)N MGJ%PZY/[7?A'5O^"H
M?PH^+GP8_8N_X*(77[.LOP?\=?$[X"?M*3> OAU!XNU.Z\=V6EZ#;ZS\,?%V
MH:WK/@KQ#X6TO0;&\UJPUR^\$Z@CZCJ6IW%A_;Q?PGKWA^^_7*OR4^/W_!&O
M]FKXX_%CXK_&'PW\5OVK_P!F/Q%^T+9V-C^TGHO[*WQUOOA3X)_:'M]/L_[-
MB/Q4\)7&@^)M*O+FXTQ[RPU.]\,1^%[W68M8\23:M<7M[XJ\376K 'XQ?L\6
M'[/O[?'_  35_P""3WP:UGXUZ?\ \$ZH_A5^VXFE?#30_A9IVM^+#\;OC+^S
MU>>+K*W?]GWXO>+?$-Q!X3UKQM=>.]4\:^'O&WBJ'Q]<P?$^]DL=*T[Q1J6A
MP'4ON?P_8_%K_@G5_P %6_V,/V9?"'[5?[3?[3OP)_;]\#?M&GQ]\-/VI_BE
M>_''Q1\'/&'P%\#0>/O#WQ.^'/C77;*QU[P]HOBF22_\/:SX8-]+HMW&?$NJ
MWEKJFIV7@N#PY^F'CO\ X)J?L>>._P!E?X;_ +&[_#&;P?\ !7X+ZGX:\2?!
M:#X?^*/$OA'QO\(_''A"\O\ 4O#_ ,1O ?Q"T[4_^$NTSXA6FJZMK&K7OBVZ
MU2_U77]2UK6KSQ%-J\NKZB;FC^R__P $Y/@S^S'\3]:^.I^(G[1/[1/QZUCP
M+#\+H?C7^U3\9M>^,_Q!\._#&'58=>?P!X2NK^WTG0_#7AN\UVWBUK4H]+T*
M#4-3U3SKS4-0N9KR]:X /SW_ ."KOPB^%7PL^)__  2HO?AG\-? ?P^O?B1_
MP6I^ 'Q#^(=]X+\):%X9O?'GCWQ)I_Q)U'7O&GC*\T>PL[GQ/XIU>]NKBXU#
M7M:EO=3N7E827+* H_H'KYR_: _98^$W[2^K? 36OBC9ZY=WW[-OQV\'_M%_
M#%M%UJ?1X[7XE>!K;5;30;K68X8Y!J^CQPZQ>BZTF8QQ7+-&S2+Y8S]&T %%
M%% !1110 5CQ_P#(<N/^O%/_ $9%6Q6/'_R'+C_KQ3_T9%03+[/^)?J;%%%%
M!04444 %%%% !5:\BN)[2ZAM+HV5U-;3Q6UZ(8[@VEQ)$R0W0MYOW4YMY"LH
MAE_=RE-C_*QJS10!^ O_  ;7W_AW2O\ @F=H/P@>.TT[XQ? KXY_M"_#K]H?
M0)66+Q+I7Q2C^+7BG65;Q39306VJPW[^#]2\,:;#<:K$]Q-'H[VHF!T^2SL_
M8?\ @H!^U3^SCXQ^"_\ P5V_9-\%S-=?M&?"C_@F[\>OB#\7Y=.\'7(TVST#
MQ+\ /%\?A72]=\?V=H^FR>)(M-U;2;ZS\+:Q?P:N=$OUO](M+NPL=5DT_J?C
MY_P1H_9Q^,7QN\:_M%_#?XR_M?\ [&'Q@^*307'Q>\5_L4_'_4?@B/BQJ=I:
M_8;/6_&^BSZ!XLT"XUF"UDO?-O\ 1=,T274K_5=7US61J/B#4[S59?4O@Y_P
M2O\ V4O@9^S+^T7^S'X)L?'USI_[6OA3X@^&/VC/C3XM\8OXP_:&^+,_Q)\(
MZYX*UOQ-XJ^)GB#3KW[7KNGZ1XBU>?P[:QZ)%X4T76=1U;6[?PRVI^(/$ESK
M !_-3\</V#/V?/V8?^"+'[&?_!2#X1:9XT\/?MP^#O 7[ 7Q9T[]HK_A9OQ'
MN/&\\_Q2/P>\+ZAX(NTG\52:,OP\\/>!?%,/P_\ "?A2QTNRT_0/!GA[2-!T
M](+"75H=2^I;C]AG]GG]NO\ X."/^"DO@G]J+PIJ/Q+^%O@3X!?LM>,].^&P
M\:_$3P9H5U\1Y?AC\.]"\-^/;^?X>>,O"-U?ZQX.\-:EXYT+0HM3.HV]I#X\
MUF[M!9WD<<LG[O\ Q6_X)W? CXQ?L-^!O^"?OBO5?B-;_ _X?^"O@3X#T/5-
M&\0:):?$.71?V>;CP9<^!9=1UZZ\+WVBSZA=R>!=&'B.>'PS;0Z@LM^+&VTL
MSPFV[;P!^Q7\(_AO^V#\?/VV] U'QO-\7_VC?!/P^\!>/=.U/6=*N/ UIHOP
MUTG2-&\/R^&]&@T"UU;3]0FM-%M&U.>^\0:I#<S-.\%M:*Z1Q@'XA?L0_L9?
ML]_\%2;O_@HY\9/V^/AM??&3XI:3^W1^TM^R9X.L/&_B;5XY?V</@O\ "?\
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M7Q%J.KZYX?OM$FMKWX?1WOA=M,\+0PRW=LMG;WVIZH=3^:/^#B'2=<U[X/\
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MRT_3K?4KZ"< _ 3P]H'QL^"7AW_@MU\#XO@)#^R3^RMXS_X)8_'_ .,7@_\
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MA;3_ !5XA6WM]$T8""SAN(=%TNPN+^VT_3K34+FZMK"TBB /T1HHHH ****
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M<_\ @C __*S]J_\ A>_PD_Z'[PM_X.K+_P".T?\ "]_A)_T/WA;_ ,'5E_\
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M:C@#_P .7$7_ ,U>O]+4_P"):N'O^BCSG_P1@?\ Y6?M7_PO?X2?]#]X6_\
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M** "BBB@ HHHH *YG0?^0KXU_P"QFM/_ %#?"5=-7,Z#_P A7QK_ -C-:?\
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M/E^(E/AH:6+*^MI=9U/4O$GBGU']N/X:_&SQ)X\_9.^)_P"T'\ /VU/VUO\
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M9XQNO&_AR6'P3XON8?[<CN+JXT#7-?U&YN7OHV#WD-Q&/W__ &+/A]H_PZ^
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MQM*LJD5*IR62KU>1P@XJ6JYI-M.5KF116O\ \(_KW_0$U?\ \%M[_P#&:/\
MA']>_P"@)J__ (+;W_XS7R/]C9Q_T*LR_P#"'%?_ "H]+ZUAO^@BA_X.I_\
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M!==U_7_#K[S\*=5_X(6>#+;PU\1_@3\,/VU?VN?@O^Q-\7/$_B#Q/XY_8_\
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M\5_#K1O&QU.WU-(9$%T[1EV0JPDDFW,N[KT4Y[^_%>.2_LF> W<L;*S8GO\
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M_%3_ (7K-_T(.O\ _@7:_P#QJC_A>LW_ $(.O_\ @7:__&J_:O\ X9)\!?\
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M^T*?LP>"IKVXT%K*T-KIMK9ZO"I,6U;C6YKZSN6'S8W-'X?M V.<(N>U6O\
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MKCB_R_ZFWK^/97/^(\^)'_0VPG3_ )E66>7_ %#>?XNW0_%3_A>LW_0@Z_\
M^!=K_P#&JZOQY\9Y=+\<>,],'@C6[L:=XK\16 NHKFV6*Y%GJ]Y;BXB5HRRQ
MS>7YB!B2%8 DFOV _P"&2? 7_/A9_G%_\556Q_9@\%>(+*SUZ[LK1[K6[6WU
M>Y9C%N:XU*%+R9FRV=S23,3GG).:UC^SI^BI2HSR>'!.<K 8^K1S/$TGQKQ8
MYSQ>4PJX7!5%5>:NI"-.CG68QE",E"HZL93C)TJ3CHO''Q#E2GBGFF%=:C4I
M8>G+^R\MLJ6)C4J58N*P_*W*6%HN[3DN5J+2D[_B]_PO6;_H0=?_ / NU_\
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M1_PO6;_H0=?_ / NU_\ C5?M7_PR3X"_Y\+/\XO_ (JC_ADGP%_SX6?YQ?\
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M]3U/4/#'Q(U>UC7Q%>S7A\5Z;;;H_"7B/PZQWUXS\4/VW?BG^P[^QM_P2?\
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M7Z*ZCELNR^Y%#^R]/_Y]8OR/^-']EZ?_ ,^L7Y'_ !J_10%EV7W(H?V7I_\
MSZQ?D?\ &C^R]/\ ^?6+\C_C5^B@++LON10_LO3_ /GUB_(_XT?V7I__ #ZQ
M?D?\:OT4!9=E]R*']EZ?_P ^L7Y'_&C^R]/_ .?6+\C_ (U?HH"R[+[D4/[+
MT_\ Y]8OR/\ C7-^#=.L9/"'A1WMHV=_#>ANS$'+,VEVI8GGJ22379US/@K_
M )$WPE_V+.@_^FJTKDG_ +]AO^P3&_\ I[ '5!+ZEB-%_O6#Z+_GSCC7_LO3
M_P#GUB_(_P"-']EZ?_SZQ?D?\:OT5UG+9=E]R*']EZ?_ ,^L7Y'_ !H_LO3_
M /GUB_(_XU?HH"R[+[D4/[+T_P#Y]8OR/^-']EZ?_P ^L7Y'_&K]% 679?<B
MA_9>G_\ /K%^1_QH_LO3_P#GUB_(_P"-7Z* LNR^Y%#^R]/_ .?6+\C_ (T?
MV7I__/K%^1_QJ_10%EV7W(H?V7I__/K%^1_QKF_&6G6,?A#Q6Z6T:NGAO7'5
M@#E672[HJ1SU! (KLZYGQK_R)OBW_L6=>_\ 35=URX[_ '+&?]@N(_\ 3,SJ
MP*7UW!Z+_>L/T7_/Z!K_ -EZ?_SZQ?D?\:/[+T__ )]8OR/^-7Z*ZCELNR^Y
M%#^R]/\ ^?6+\C_C1_9>G_\ /K%^1_QJ_10%EV7W(H?V7I__ #ZQ?D?\:/[+
MT_\ Y]8OR/\ C5^B@++LON10_LO3_P#GUB_(_P"-']EZ?_SZQ?D?\:OT4!9=
ME]R*']EZ?_SZQ?D?\:/[+T__ )]8OR/^-7Z* LNR^Y%#^R]/_P"?6+\C_C1_
M9>G_ //K%^1_QJ_10%EV7W(XS7-.L5U3P:%MHP)/$ETC@ _,H\(>*W //3>B
MM]5%=)_9>G_\^L7Y'_&LC7O^0KX*_P"QFN__ %#?%M=-7)AOXV/_ .PN'_J#
M@CJQ"7L<#HO]UGT7_0;C"A_9>G_\^L7Y'_&C^R]/_P"?6+\C_C5^BNLY;+LO
MN10_LO3_ /GUB_(_XT?V7I__ #ZQ?D?\:OT4!9=E]R*']EZ?_P ^L7Y'_&C^
MR]/_ .?6+\C_ (U?HH"R[+[D4/[+T_\ Y]8OR/\ C1_9>G_\^L7Y'_&K]% 6
M79?<BA_9>G_\^L7Y'_&C^R]/_P"?6+\C_C5^B@++LON10_LO3_\ GUB_(_XU
MS>AZ=8MJGC(-;1D1^)+5$!!^53X0\*.0.>F]V;ZL:[.N9T'_ )"OC7_L9K3_
M -0WPE7+B/XV!_["I_\ J%C#JPZ7L<=HO]UAT7_0;@S7_LO3_P#GUB_(_P"-
M']EZ?_SZQ?D?\:OT5U'+9=E]R*']EZ?_ ,^L7Y'_ !H_LO3_ /GUB_(_XU?H
MH"R[+[D4/[+T_P#Y]8OR/^-']EZ?_P ^L7Y'_&K]% 679?<BA_9>G_\ /K%^
M1_QH_LO3_P#GUB_(_P"-7Z* LNR^Y%#^R]/_ .?6+\C_ (T?V7I__/K%^1_Q
MJ_10%EV7W(H?V7I__/K%^1_QH_LO3_\ GUB_(_XU?HH"R[+[D<SX*_Y$WPE_
MV+.@_P#IJM*Z:N9\%?\ (F^$O^Q9T'_TU6E=-7)@/]QP7_8)AO\ TS Z\=_O
MN,_["L1_Z>F?@WXR_P"1O\5?]C)KG_ITNJX]M.T]Y;B=[&S>>\@-M=S-:P-+
M=6S*$:WN)"A>> HJH8I2T950I7  KL/&7_(W^*O^QDUS_P!.EU7Y1_MA?\$H
M_P!G?]MGXJ6'Q>^*OC/XT>'_ !+IW@W2? \%C\/O$7@?2M#?2=&U/7-6M;B6
MV\1_#KQ7?MJ,ESX@O$N)DU-+9H(K98[2*1)9)O\ D=Q>5<%YQXR<>X+CWC7,
M^ >'Y<4\95)Y_E/"=7C3%K%T\^Q4L-@_[$HYYP].5+$2YG/%?VBEAW2B_857
M)<O^D5+$9KA>%LEJY/E.'SG&K+LJBL'B<RCE5+V4L'352K];EA,:E*FK6I^P
M;GS.THVU_1W_ (1GPY_T+^B?^"JP_P#D>OSL_P""37Q\^)W[2?[(.C?$[XN:
MQIVN>,;KQ[XXT::_TOPYX?\ "UHVGZ1>VL5C$-)\,Z;I6EH\:2.'G2T6:8D-
M-([ $?)7_$/)^Q;_ -%._:A_\+3X4?\ SE*_4S]DS]E;X>_L<?""S^"OPQUG
MQEKOA6QU[7/$46H>/-0T34_$#7NOSQ3WD4EUX?\ #OA?3C:Q/"HMD72DF12P
MEGF)##[3C"GX \->%'%.0<$^(V=>*7&_$/%O V89;F.?>%53@FMPOD?#V"XR
MI9]AL!FN)XJXHJU:?$&(SS))8S"4)8"%1Y'A)UEBW3HO#>5E;XRQ_$>78W-<
MBPG#V4X'+<WHUZ&#XBCFL,PQ>-JY5+!SK8>GEV7QC+!0PF+5*I-5G'ZW54'2
M4I>T^EZ_GI_:9_X*3_$;X"_&']O[3O$WQ2TOPYK_ ,+/"WA+X8_LL_L\KX4L
M9M7UCQ3\2=%\*ZM:_':3Q+);W%KXAA\.P37/B&Y\,:U;ZC9Q:7<6VD1+I-S=
M3P^(_P!F?VB/&OQQ\#>%_"6H_ 3X4Z?\7?$FI_$CPMH/BG0]1UZR\/Q:!\/M
M134CXE\8PW5]J.FQW=SH;P:>L6G12S3W/VQC':S"-MOYH?M63?M97'[2FM^(
MO G_  2T^ /[0^E^"I_#\/PW^._C:_\ AH/&VH6MMH^F:J)8I]?UBWUS3CX=
M\27>JVND+)' ;":U:_TX0R7)N)?4^B[D?"ZXBQF-XYR/@'BC(L\X<Q;P> XC
M\2/#+@W&X+%<,<8\%YEBJ%:KQ_BWALKI\3815^&ZTJ-#!\1XWAW-,_QO#6+]
MGEN9J7/XA8S,/J5*CE&,SG+\9A,=256M@<BS_-*5:GC\LS2A3G&.34_:8B6
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M?]L__1%Y7MU>(_#;_D(W'_;/_P!$7E>W5_;?A-_R;[A[_!F7_JXS _*>(O\
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MXFT?XA^#/VUOVD_VL_BSK$?ARUU'2)-(^'G[3FGV.CS>$YYKUFF'B/1=-AO
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MQC45+$4H5J:G&.4RBIJ$XJ:C*24KI2:U/V&HK\>?^&H_C9_T-D/_ ((/#_\
M\K*/^&H_C9_T-D/_ ((/#_\ \K*\C_BJ_P#1N_Z)?QB_\1KA'_Z/3J_XERXZ
M_P"@_AC_ ,+\R_\ G.?L-17X\_\ #4?QL_Z&R'_P0>'_ /Y64?\ #4?QL_Z&
MR'_P0>'_ /Y64?\ %5_Z-W_1+^,7_B-<(_\ T>A_Q+EQU_T'\,?^%^9?_.<_
M8:BOQY_X:C^-G_0V0_\ @@\/_P#RLH_X:C^-G_0V0_\ @@\/_P#RLH_XJO\
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M#2C&,,,U/'9BG[3!PCA*K26427*ZM";@[W<'%RC%MQ7[#45^//\ PU'\;/\
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M_P#!!X?_ /E91_PU'\;/^ALA_P#!!X?_ /E91_Q5?^C=_P!$OXQ?^(UPC_\
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M6UTU<SKW_(5\%?\ 8S7?_J&^+:Z:N3#?QL?_ -A</_4'!'5B/X.!_P"P6?\
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M="^(7AG7-5?^U?%6K:'HEO\ 9=+T^\NMMUJ4#S^3Y%LLUQ)%"_SE_P -*_\
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MS7=,^&<NLVNFZZ;^.'Q[K=S?:)'JG[Y?M<_ _P 2_M)?LU?&/X(>"_BYX^^
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M+[/^)?J;%%%%!04444 %-=TC1Y)'6..-6>21V"(B("S.[,0JJJ@EF)  !)(
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M29VU*QU3Q-+\>H89O%UI!>G2D\./;64<TGS!HW_!8C]K;XZ_"+XG_MT^!?\
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M^ 7PZ\<ZWK/B..Q^*O@V;X+^*E^)'COPK>>(;^W\!^)=!UG6M*LI;/3Y-:T
MZ##8^&=* /U6^$G_  5V_85\7_ /]G?XQ_%G]I/X#_ #7OC[\%O"GQ?L_AS\
M3/BUX2\-Z_I%OK%UJ_AOQ#96T>OWNCWFKZ;X<^(/A7QKX)&O0V$%GJ.I^%=3
M\E(VAEAC^7_%?[6?[7'[=G[:/QO_ &1OV /CS\)_V=/@W^S)\*_@)\1?B?\
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MUNQJO@^YT!=7UG0_%FDZ+XBU".]-I;:_XE43O9:?^??PX_X)!?M4_#']A?\
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M.3!?P9_]A>/_ /4[$A1117RAUA1110 4444 %%%% !1110 5M^)O^1C\0?\
M8;U7_P!+[BL2MOQ-_P C'X@_[#>J_P#I?<5]7@_^2'XB_P"RKX,_]5''AQS_
M .1AA?\ L#QW_I_+C$KJ/"_C'Q!X/ODOM#OY;9@P:2W+N;6?&/\ 6PA@"W
M==L@ QNVDJ>7JAJ>J:=HMC<:GJU]:Z=I]HF^XO+R9(((E)"KNDD(&YW98XXQ
MEY9&2.-6=E4G!'$O&7"/%62Y[X?YMGF2\7X7&T89)C.':N)IYM+&5ZD:-/"8
M>GA.:IC%C936%JY?*G7HX^G5EA*^'KTJLJ4LLVP&5YEEV*P>=8;"8K+*E*;Q
M=+'1IRPRI0BY2JSE4M&DZ23J1KJ4)T7%5(3A**DOT[^$/[3&F:[]GTK79!I^
MI[0FR=AY<QP-S02G D'4[3B0 ,S1JN&/V3INJVFIP)-;2I(KCAE((/3'0\$Y
MZ?\ UA7\O:?'.^\1^([;3/ >CW$FG17*B36KV*2.XO&24;&L+/&ZUMSM#B:[
MQ=R(^#:6;QYD_<']F'7/%6IZ#:?VTLP/E)GS"Q/W1G.X<\@8QVR<XK_J?^B]
MQ+X^\4^&6!S+Z0W"64<*\7-TE@_J5=X?-\VRUTDX9AQ)PW2H2P7#.:U'R2JX
M+#9C.52=2K[?)>'IT(8*K_GCXA8#@[+L_JT."<RQ.8Y9JZOM8<^&PU=2M*C@
M<?*:JX_#QN^6K4H)148J&*QJFZL?M:BD4DJI/4J"?J12U_1Q\,%%%% !1110
M 5S/C7_D3?%O_8LZ]_Z:KNNFKF?&O_(F^+?^Q9U[_P!-5W7+CO\ <L9_V"XC
M_P!,S.K _P"^X/\ ["L/_P"GH'34445U'*%%%% !1110 4444 %%%% !1110
M!S.O?\A7P5_V,UW_ .H;XMKIJYG7O^0KX*_[&:[_ /4-\6UTU<F&_C8__L+A
M_P"H.".K$?P<#_V"S_\ 4W&!11176<H4444 %%%% !1110 4444 %<SH/_(5
M\:_]C-:?^H;X2KIJYG0?^0KXU_[&:T_]0WPE7+B/XV!_["I_^H6,.K#_ ,''
M?]@L/_4W!G34445U'*%%%% !1110 4444 %%%% !1110!S/@K_D3?"7_ &+.
M@_\ IJM*Z:N9\%?\B;X2_P"Q9T'_ --5I735R8#_ ''!?]@F&_\ 3,#JQW^^
MXS_L*Q'_ *>F?@WXR_Y&_P 5?]C)KG_ITNJYNND\9?\ (W^*O^QDUS_TZ75<
MW7_'/XE?\G%X^_[+7BK_ -7N//\ 3C(/^1%DO_8IR[_U#HA1117Q1ZP4444
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M_P!3T?5/V?KYC_:V_9"^!W[;/PAOO@M\>O#MYK/AE]6L/$N@:QH>IS:#XO\
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MA=:;J>C6MS]JBM9K;QIHKVW]B^(_$\-^ ?M-\&_VN/V5?VBM5UO0O@!^TM\
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M^(--U#YW_89_Y3I_\%S?^Q9_X)Q_^LS14 ?M;\3/BK\+_@KX-U/XB_&3XD>
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M*G04VE1LG-0YFE=)O3L_GW_A-O!G_0W>&/\ P?Z5_P#)='_";>#/^AN\,?\
M@_TK_P"2Z][_ .'>%G_S[_\ D-?_ (JC_AWA9_\ /O\ ^0U_^*KPO^*0W!'_
M $>/BSI_S3>3>7_4?Y_\/I?M_P")E\U_Z)C+>G_,?B?+_ISY_P##Z7\$_P"$
MV\&?]#=X8_\ !_I7_P ET?\ ";>#/^AN\,?^#_2O_DNO>_\ AWA9_P#/O_Y#
M7_XJC_AWA9_\^_\ Y#7_ .*H_P"*0W!'_1X^+.G_ #3>3>7_ %'^?_#Z7/\
MB9?-?^B8RWI_S'XGR_Z<^?\ P^E_!/\ A-O!G_0W>&/_  ?Z5_\ )='_  FW
M@S_H;O#'_@_TK_Y+KWO_ (=X6?\ S[_^0U_^*H_X=X6?_/O_ .0U_P#BJ/\
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M!/\ A-O!G_0W>&/_  ?Z5_\ )='_  FW@S_H;O#'_@_TK_Y+KWO_ (=X6?\
MS[_^0U_^*H_X=X6?_/O_ .0U_P#BJ/\ BD-P1_T>/BSI_P TWDWE_P!1_G_P
M^ES_ (F7S7_HF,MZ?\Q^)\O^G/G_ ,/I?P3_ (3;P9_T-WAC_P '^E?_ "71
M_P )MX,_Z&[PQ_X/]*_^2Z][_P"'>%G_ ,^__D-?_BJ/^'>%G_S[_P#D-?\
MXJC_ (I#<$?]'CXLZ?\ --Y-Y?\ 4?Y_\/I<_P")E\U_Z)C+>G_,?B?+_ISY
M_P##Z7\$_P"$V\&?]#=X8_\ !_I7_P ET?\ ";>#/^AN\,?^#_2O_DNO>_\
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MNO\ OF/_  H"[_E?WK_/U_IZ:E%9?V"Y_P"@G=?]\Q_X4?8+G_H)W7_?,?\
MA0%W_*_O7^?K_3TU**R_L%S_ -!.Z_[YC_PH^P7/_03NO^^8_P#"@+O^5_>O
M\_7^GIJ5CQ_\ARX_Z\4_]&15)]@N?^@G=?\ ?,?^%9J6DYU6:(7TX<6BN9P$
M\QE+QC81]W:"<\#.0/>@4F_=NK>\NJ^[\_Z>G345E_8+G_H)W7_?,?\ A1]@
MN?\ H)W7_?,?^% [O^5_>O\ /U_IZ:E%9?V"Y_Z"=U_WS'_A1]@N?^@G=?\
M?,?^% 7?\K^]?Y^O]/34HK+^P7/_ $$[K_OF/_"C[!<_]!.Z_P"^8_\ "@+O
M^5_>O\_7^GIJ45E_8+G_ *"=U_WS'_A1]@N?^@G=?]\Q_P"% 7?\K^]?Y^O]
M/34HK+^P7/\ T$[K_OF/_"C[!<_]!.Z_[YC_ ,* N_Y7]Z_S]?Z>FI7Y(?\
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MUL_8M_P[/BV/3_\ CYU1K*T_TBO2OVZ?^"?WC6[_ ."AGA_]NSPG^PY\"_\
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M *"=U_WS'_A0%W_*_O7^?K_3T_GZ_;<\+_\ !1__ (*-_P#!-;]H'X1^-O\
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M (4?8+G_ *"=U_WS'_A0%W_*_O7^?K_3TU**R_L%S_T$[K_OF/\ PH^P7/\
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M"=U_WS'_ (4?8+G_ *"=U_WS'_A0%W_*_O7^?K_3TO\ D0_\\T_[Y%'D0_\
M/-/^^15#[!<_]!.Z_P"^8_\ "C[!<_\ 03NO^^8_\* N_P"5_>O\_7^GI?\
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M%W_*_O7^?K_3TU**R_L%S_T$[K_OF/\ PH^P7/\ T$[K_OF/_"@+O^5_>O\
M/U_IZ:E%9?V"Y_Z"=U_WS'_A1]@N?^@G=?\ ?,?^% 7?\K^]?Y^O]/34KF?&
MO_(F^+?^Q9U[_P!-5W6E]@N?^@G=?]\Q_P"%<YXQLKA/"/BIVU&Y=5\-ZXQ1
ME3:X73+HE6P,X8#!QS@URX[_ '+&?]@N(_\ 3,SKP+?UW!^[_P Q6'ZK_G]#
M_@_T].WHK+^P7/\ T$[K_OF/_"C[!<_]!.Z_[YC_ ,*ZCDN_Y7]Z_P _7^GI
MJ45E_8+G_H)W7_?,?^%'V"Y_Z"=U_P!\Q_X4!=_RO[U_GZ_T]-2BLO[!<_\
M03NO^^8_\*/L%S_T$[K_ +YC_P * N_Y7]Z_S]?Z>FI167]@N?\ H)W7_?,?
M^%'V"Y_Z"=U_WS'_ (4!=_RO[U_GZ_T]-2BLO[!<_P#03NO^^8_\*/L%S_T$
M[K_OF/\ PH"[_E?WK_/U_IZ:E%9?V"Y_Z"=U_P!\Q_X4?8+G_H)W7_?,?^%
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MU%[YKEQ'\; _]A4__4+&'7AV_8X[W?\ F%AU7_0;@_\ @_=YZ=O167]@N?\
MH)W7_?,?^%'V"Y_Z"=U_WS'_ (5U')=_RO[U_GZ_T]-2BLO[!<_]!.Z_[YC_
M ,*/L%S_ -!.Z_[YC_PH"[_E?WK_ #]?Z>FI167]@N?^@G=?]\Q_X4?8+G_H
M)W7_ 'S'_A0%W_*_O7^?K_3TU**R_L%S_P!!.Z_[YC_PH^P7/_03NO\ OF/_
M  H"[_E?WK_/U_IZ:E%9?V"Y_P"@G=?]\Q_X4?8+G_H)W7_?,?\ A0%W_*_O
M7^?K_3TU**R_L%S_ -!.Z_[YC_PH^P7/_03NO^^8_P#"@+O^5_>O\_7^GIF^
M"O\ D3?"7_8LZ#_Z:K2NFKF?!7_(F^$O^Q9T'_TU6E=-7)@/]QP7_8)AO_3,
M#LQW^^XS_L*Q'_IZ9_G2_M7_ /)TO[2G_9?OC'_ZL3Q'7@->_?M7_P#)TO[2
MG_9?OC'_ .K$\1UX#7^LG#__ "(<D_[%&6_^H5$_RYSS_D=9Q_V-,P_]2ZQ]
M>? 7]B/XY?M.?#[Q1XX^!T'@SQWJ_@_79M)USX66WC70])^*T>EPZ39:J/&%
MCX6UZXTN'5/"T[WC:3:W%AJD^JWNM6=Y866DW+PEC\W>-/ GC?X;^(+OPG\0
M_!_BCP+XHL AO?#GC#0-5\-:Y:+(-T3W&E:S:V=]$DJC=%(\ 25/GC9E(-?I
M5_P3E^ _PQ^*,>M^+V^$/[2G[0OQP\$^*XI/"GPQ^#_B+3_A-\-=*TP:/;WF
MAZ_\5?CQJ-QHDW@637-837;7PY%X;\36GB R^&+NX33;VUD8I[I\>_\ @HIX
MR^*_@_Q'\._VQ?V7[31/@]\0OV?]9U_]E8+X=UOQ%\0= \8:EHWE_"7XIV7Q
M<^(?BBWU7Q%I$T[-#XQ\4Z7#/>:M8HL4F@W_ -HU?3]5^)J\69_1XJS#*,'@
M,-GF782I0>+I.K@\HSC+XXB,90C@L-4S+%8G/:<J4,1B:52>5Y-AY4:-94LP
MQDZ4DOLJ7"^15N&<#FN,QV)R7'XJG66%J^SQ6:Y3CY4).,Y8O$4LOPV'R24:
MDZ&'JPAF>;XB-:K2=7 86-2+?XP>!?"=[X^\;^#O NFW>GZ?J/C3Q5X>\)V%
M_JT_V72[*]\1ZO9Z/:W>I76U_LVGVT]Y'->3['\FV223:VW!_:G4?^"?7['O
MB#XB_!SX)^ ?&/[1UKXC\4?%W]IW]F_Q7X[UKPKX8U8W?QL^"7AOP!>V>NV7
M@O2[RWGT7X-VM[X@UG5=2N;FYN/%2Z7:&WU2XTG3DG\5:=^*O@;PUJGC/QMX
M.\'Z'=6MCK?BOQ3X?\-:/?7UX-.LK/5-=U:TTO3[J\U!BJV-K;W=U#-<7C,!
M:Q(\Y("9K^H:P\;?M@>./"7CGX,_%#]NW3_ &O\ C?XT>/OV3/@;K]E^S39P
M_$#XV^*_!>FV&@_$?49]3TB&TOO!'@:#6)AX/'Q"TZ&'6M+U:SCUV]UW2YM/
MM;'4^#Q,S7.,LQ643RO/*>6P6&S-XC#J>8*JI5L.\-0S-X;+\BSN>94LL=2I
MF$\%46&A&G@:U=^TI1K8G =WAUEF4YCA\TAF633S"?UG+?85G# .E*-'$1Q%
M;+EB,=G>30RZIF*IPP$<7!XF4JF-HT%[.K.CA\=_*K/$8)IH&:-VAEDB9X9%
MEB<QN4+12H2DD;%<I(A*NI#*2"*^K_V"O^3V/V4/^S@OA1_ZF>D5\G2(T4CQ
MOMW1NR-L=)$W(Q4[9(V:.1<@[71F1AAE8J03]8_L%?\ )['[*'_9P7PH_P#4
MSTBOT#B7_DF\_P!;_P#"'FNJV?\ L%?7YGP?#W_)09'I;_A9RW3M_MM'0_J&
M_:>_Y+K\0/\ K\T?_P!1O1J\%KWK]I[_ )+K\0/^OS1__4;T:O!:_P#.\^D/
M_P G_P#'+_L\/B9_ZVN=G_3OP-_R1/!__9+</_\ JIP@445WNB^'CJ?@_P 2
MRP>&=?U/7X;K0M7TO4-/TS5[NSL?"EE'XFMO%=[=R6BM8QV@U$:#$;R[B=8)
M+2XCAN+?;=I+^;9'DF-X@QM3 8#D]O3R[-<Q_>1Q$U.&4Y;BLREAX+"T,35>
M*QWU58#+X.FJ=;,<5A*%6K0IU95H>_C,92P-&->M?DE7PN']UTTU+%8BEAU4
MDZDZ<53H^T]M7?,Y0H4ZLXQG**A*IX'\%W/CO6/[$L]=\-:'>/%&UJWB;4WT
MR#4+F:ZM[2#3M/:*UNY+K4KB6Y4P6D<6^5$D*$LH5NG\<?"'5O NC'6[GQ5X
M#\16T6N0^'KN#PAXC_MV[T[4Y[34+Q(M2CCLH8[+]WIEVFR>9)VE0JD+B.9H
MN'\)+J#^*_#":3J$.DZJ_B'15TS5+F00V^FZ@VI6PLM0GF(810V=R8KF60JP
M1(V8@@8KZ>^.VD:AIW@N6:UM- T72;KQCH]QJ]OI7P_U'P+<^(M8O-&U^:SO
MYAJ?B+7I)FT1H=:M[K1+8:?#IG]K6-\UFDFHM#9_O' ' O"G$_@SXA\38GA+
M-,3Q!P='$RCQ!A<^A2HM8G 5\7@'3R*KB:*Q,<MJ8><\YJ<GLJ.65*=6A+%9
MC4H8&K\7G><YEEW%F19?3S/#0P.;.FG@:N"E*:]G7ITJU\9"G/D=>,[82+?-
M+$*49JG0C.M'Y HHHK^;S[X_0+]AC_7>.O\ KX\/_P#I)XAK]%J_.G]AC_7>
M.O\ KX\/_P#I)XAK]%J_ZA?V?7_*('@[_P!@W&?_ *\;B\_SL\;O^3I<5_\
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M3H5M<:M%IUD@UN'5;A/#5MIZ6D$P!_1M17Y(?L>?\%$/BO\ '*']IO\ 9_\
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M17 >*/BQ\+/ _BSP#X"\:_$OX?\ @_QU\5KS6=/^%W@OQ1XR\.^'_%GQ)O\
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MU[_TU7=<N._W+&?]@N(_],S.K _[[@_^PK#_ /IZ!TU%%%=1RA1110 4444
M%%%% !1110 4444 <SKW_(5\%?\ 8S7?_J&^+:Z:N9U[_D*^"O\ L9KO_P!0
MWQ;735R8;^-C_P#L+A_Z@X(ZL1_!P/\ V"S_ /4W&!11176<H4444 %%%% !
M1110 4444 %<SH/_ "%?&O\ V,UI_P"H;X2KIJYG0?\ D*^-?^QFM/\ U#?"
M5<N(_C8'_L*G_P"H6,.K#_P<=_V"P_\ 4W!G34445U'*%%%% !1110 4444
M%%%% !1110!S/@K_ )$WPE_V+.@_^FJTKIJYGP5_R)OA+_L6=!_]-5I735R8
M#_<<%_V"8;_TS ZL=_ON,_["L1_Z>F?YTO[5_P#R=+^TI_V7[XQ_^K$\1UX#
M7OW[5_\ R=+^TI_V7[XQ_P#JQ/$=> U_K)P__P B')/^Q1EO_J%1/\N<\_Y'
M6<?]C3,/_4NL?MM_P2J_:I^$GP_T>T^"_P 5?%?Q)^&__"-?'S2?VCO#'B+X
M=^&/%_C:Q^(<EGX.3P3XA^%?Q$\+^ ]+UCQ->:"+2VTSQ-X>GBTK4M-M=9M[
MR\OFL'LK:UUWYZ_X* >(OAGHW@?]E[]GCX/R_%KQ9X#^!'A_XEM#\7/BWX/\
M4^!K_P >^(?B)K_A_6=<TKPOX:\6:5I.H:5X2\&1:1I<&F6"6ENEH^M3QRP7
M%QYNNZ[]1_\ !.WQ+X\C_8L^,/@WX(_M-?L\?LI?&/4_V@-,U5O&_P 5_&W@
M_P ,^(/&7P^C^'=KINJ^#R=;T'7]>T+2=-UFZTW7_#/BC0--N[AM5'B?2DGT
M@27$][\C_P#!0'3OVBK#_A4O_"_?VP_@O^UAYO\ PGG_  B?_"H?BHOQ,_X0
M'R_^$,_MW_A(=OA3PQ_8G_"4[]&_LG/V[^TO^$<U/_CV^P?Z1^3Y9AL%/Q4Q
M^)A-82<,QK)Y;5S+$SEB<9ALCQT(YMA\)#AR%'WJ&:YA35&MQ)6H0C7Q%7ZO
M#%4L/AJ/ZCF.)QD/#/ X><7BH3R^DUF%++\-%8;"8C.L#-Y77Q4^(9U?=K97
M@:CK4N'J-><J.'I>WGAJF(Q%;X-\"^&]5\9>-_!WA#0KNVL-<\5>*O#WAO1K
MZ]O1IMG9:KKFKV>EZ==W>HDJ+"VMKNZAFGO2RBUB1YR0(\U_47)\.?A!XI^*
M/PGN?B!_P4#_ &OO'_[0/A?7/CI^RGX'\6:!X5\'^$]'B^*7@GPUH^A?%7X?
M^'+;Q+X'U"T\/>+O%>E?$-+7P_XS\2Z_/?\ B*[TR*[M_B"=6\/^&;M/Y;O!
MWA[Q!XN\7^%?"GA*"6Z\5>)_$FA^'O#-K#.EK-<^(-:U.UTW1H(KF22*.VEF
MU&YMHXYY)8TA=A(\B*I8?TGZ/9?'OP%XGTSX=_#O_@H)X(\;?&+]H7XL_&OP
MAXN\<>./@C<R:+X2_:L^#/PV\ >!IO!?PY\0ZEH=_<Z?KGB30/$EEX(U+XH0
MZ1;:'<>']&MET>QGU]ET/4]_%>%2I7RF-'-:&"K1R[/O9T7@I59NG/!IXNOB
M\;3X=S^>$RN&"I8BIBZ/-@EF,,-4P,88NI657+\?"^=.G1S25;+*V,HRS#(U
M.LL7&G!3CC+86CA,'4X@R*&*S.6,J8>GAJ_+C?[/GB*>-G+"TZ4J>/\ YCY(
MY(9)(9HWBEB=XY8I$9)(Y$8J\<B, R.C JZ, RL"" 017UC^P5_R>Q^RA_V<
M%\*/_4STBOD^6.6&66&='CFBD>.:.12LD<J,5D216 971P5=6 (8$$9%?6'[
M!7_)['[*'_9P7PH_]3/2*_3>)?\ DF\_U3_X0\UU6S_V"OJM]/FS\XX>_P"2
M@R/I_P +&6:/=?[;1W/ZAOVGO^2Z_$#_ *_-'_\ 4;T:O!:]Z_:>_P"2Z_$#
M_K\T?_U&]&KP6O\ SN_I#_\ )_\ QR_[/#XF?^MKG9_T[\#?\D3P?_V2W#__
M *J<(36R027%O'<S-;6SS1)<7"0FX>"!I%669( \1G:*,LZPB6,R%0F]-VX?
M:?@K62G@JQMM%UO6[U/"^G:UJ<1L_@QXEO!J^A:7=^.-,\.W&N:M8^.(-/FT
M:PN]>UC4ECCTU+6WU7[1:ZV^MKI-SO\ B:OM/P;=W_\ P@OP_P! C\21Q>)[
M[0O$'BKPXO\ PA[WVA-8>'8O'=GHFF>)_%L'B"SEBE\/WMUKVL:=.MA/IWAF
M]EMWUJWN%LD _2_HFXF5'B[B=4L-!U5PQ34,32S'&9;CY8C&<3\-99EN"P56
MGQOP=A*^(KYIC,&J> DLSQ.9TY8G+XX2K1Q%2F_GO$RFI97ESE4?+_:+<J<J
M%+$45"E@,?B,16JQEE&:U80AAJ55RKQ>'AAY*G7=6,H1DOESX?C0V\:>&4\1
MZ1JNO:1+K-A%<Z/HLMO'J.HM+<1QV]I ES;W$5TLUPT4<UB/LTM]"TEI#?6$
MLR7</O?QN\.:QH/@^S.L:+X[+2^(]-M;'5?'WQ#\+>*[K0[:+2-6NU\/Z+HV
MA7\][I<&I0W=O?:@]Y"((DTW2XQLEN(6?P3P,D/_  D.G7*ZUJ.BZO8ZGH=U
MX=ETO0GU^\N-877M,CA2"T2\M")[2"2XU*U3$_VZZLH=,$<;7HN(?>_C%,\7
MP^;3K;5'U6+3_B*^BZY=-\+9?!ES'K&BV&OSVN@ZAK:^*=9M'A\,6NM7-CX?
MT*/3;41Z5<.MM>36NCK#'7A?A\'+P%\6%C<)45>GA<7F.79CE^8>'$=:V&I8
M"679SEN<+%<89G)U,#/%8+#X%9;/A["O%9[E]2OB\TPBF<15*JXTX:]C47+*
MI2H8BA7H9\](U766(PF(PKI97AURUHTJTZSQ$<=5]E@J\84\-4M\J4445_*)
M^E'Z!?L,?Z[QU_U\>'__ $D\0U^BU?G3^PQ_KO'7_7QX?_\ 23Q#7Z+5_P!0
MO[/K_E$#P=_[!N,__7C<7G^=GC=_R=+BO_K[E/\ ZH,J"BBBO[+/RH_D$_X)
M3_L(Z7^T!\!_C%\1+O\ X*-?\% _V9YKG]L;]J?23\+OV=/VG?!_PK^&MJNE
M_%#4HEUJU\):U\-?%%]#J^L;S-JU\VJO%>RQQO'!"%*G^EC]DCX$V/[.WPSU
M'X?67[2O[07[4PG\7:EXFE^(G[2WQ3T3XN_$73SJFFZ/8KX6MO$NA>&O"EK;
M>%M/&D'4-+TB32WGM[_5=8N6O)DO$C@^'O$G_! K_@D7XN\1:_XL\1?L;>&]
M3\0>)]:U3Q#KNI/\3OCI ^H:SK5]/J6J7KP6GQ0@M86N[VYGG:*V@AMXS(4A
MBCC547[/_9+_ &%?V4?V%O#OB[PG^RE\(=.^$7A_QWK5CXA\6:;IWB3QMXD3
M6-9TVQ;3;*]DG\;>)?$MU;-!9,8!%8SVUNX.^2)Y/GH _,K_ ()Q?\IC?^"^
MW_8S?\$Z_P#U0GQ.IVI>*M(^&7_!QO!)X_O;#PAI'QR_X)3V?@OX5:[XCU"U
MTC2_'7CWP;^TRWB'6_ GA:ZO7BMM:\6V/AH7OB*]T"SG?5[/1K2/49;$V5_:
M7#_KQ\/OV;O@G\*_BW\<_CKX!\"VOAWXK_M*7/@"[^-WB^'5O$-[<>.[CX6Z
M'J7AKP%+=Z;J>KWNB:0?#VB:OJ-A"OAW3-'2]2Y:;4UO;F.*:/SC]K[]A']D
MS]O3P9X<\ _M9_!K1OB[X;\(:])XE\+)=:YXO\(ZYX>U>>T:QO9='\7> /$/
MA3Q;86>IVIBCUC2;;7(](UEK+3)=5L;R;2M-DM0#\H_^"D][I'Q._P""Q'_!
M$/X,^%-7L]3\>_#[QM^T]\<O'6BV+"]N_!_P^TKX?>%[S1];\200/OTBQ\6Z
MAX)\2:'X?N[ORX;O5-+N+929VM8;GP#X1^./VJOVN?\ @K+^VE^VQ^S3\#O@
MM\<OAA^RG8/_ ,$Z/@[J7QP^.&O_  =T#1M:\+W=KXO^/NO^#K?PG\%/C:OB
MG7-5\9:A<6$?BHS>%V3X<>(M'TL'7K;59;?0OV:_9"_X)??L(_L&ZUXT\3?L
MH_L_Z1\+/%'Q"TB#0/%?BI_&7Q*\>>*[W08;M-0.B6'B;XE^,_&6N^'](N]1
MAM-2U/3?#NH:59ZMJ6FZ1J&J0WEYHVE3V?OG[-O[+WP%_9"^&5O\'/V<?ASI
MGPP^'-MKFN>)AX?T[4=>UF2Z\0^([H7FM:SJ>M^*-5USQ#J^HWTJ0QM=:KJU
MY+#9VMGI]LT-A96EM" ?S-_L?Z]\0_V9?V2/^"S7_!*7XZ>'M \ ^,/V>/V>
M?VF/VB_V>?!WASQAJOCGPK#^S!^T/\+/''B@^%?A_P"+]=\)^#-:\;Z!\'_B
M!J\NC>)/&6J:!I5S?^*_'<^F?8+9])FABXSX$_L7?\%#/B;_ ,$2_P!F/QS^
MQ3_P4$_:2\)^)(O@?8^+S^S7IUQ\*/ UAXKT?2-9U.]N_AS\%OC5X%^%_AGX
ML?##Q-J5E:7<7AC4/%_BCX@Z?JWB"YL])\0W^DZ+>7.J:?\ TY_%+]C']F?X
MT?$ZX^,OQ)^%]IX@^)M]\$/&W[-NI>+(?$GC/0+W6/@7\1(M9C\6_#37+;PU
MXCT?3=<\.:A)X@U>_M(]7LKV[T/5[S^V] NM+UB"VOH?4O@S\&_AI^SW\+?!
M/P6^#OA>#P5\,?AUHL7A[P7X5MM0U?5;?0]&AFFN(K*+4-?U#5=8NU2:XF?S
M=0U&[N"7(,I4*  ?F3_P0OU;]D76/^"?/P_O?V0]*\5^']+N/$WB>X^/&@?$
MWQ)#XO\ C3I7[2\O]G#XK0_&?Q+%I7A\Z_XWEFCT>6SUP^&O"T.L>"&\(:A8
M^%_#FGSVNB6'YY?L&?L*? [P=_P6[_;ST#2K;7)/A?\ L52?#CXU_LO_  :N
M]167X8?!WXJ?MS_#;2]<^-7B_P '>&(X(;/2YH8_ L&A^#-*MT31/#.C7T8M
M=.?5M"\/ZMIW] ?P@_9'_9V^ 7Q-^.'QA^#GPST_X?\ Q _:1\16GB[XVZKH
M6L^)TTSQ]XKL[C5KR/Q+J'A.ZURY\(:?K\][KNMWNHZOH>@Z7?ZK?:OJ5YJE
MQ>75[<2R=/X1_9Y^#G@3XS?%[]H3PGX)M='^,7QYT[P!I'Q:\:QZKK]S=>,-
M.^%VCW.@^ [:YTN^U6YT'3%\/Z1>7-G#)H>E:9+>K*9=3DO9U250#^:W_@J?
MH6M> /C3_P %2O@]>:#XE\3^._\ @J/^Q3\"(OV.K72-*U77[KQW\1?V6G\8
M>&_BK^S_ .$8+*SDD7QC%HWB[PW\4-/\-6T<G]LV^NW\\%_>:M<6FC6GKGBS
M6=9_X)P?M._MH?&[]N[4_B7^UG??%/\ 9C\._#S]CS]I?Q+X.\/!/'VB7NN:
MG&O_  3KO/A]\'?AQX(\&Z3\;_B#\6=1B\8Z*OA#PU?Z?\2? $%SXMUR;P5%
MX$UNP3]\OC_^SA\"/VJ?ASJ7PD_:*^%'@KXP?#O4YOM<GAKQMHUOJD%AJBV5
M[I]OKV@7I$>J>&/$]C9:EJ%OI?BCPY?:5XBTI+VZ.FZG:M-(S?+GP0_X)1?\
M$_/V>/B%H7Q8^&G[.ND-\2/"=G:V'@KQG\2/'/Q3^.&N^ ;2P1(K"+X=W?QM
M\<_$,_#XZ?!&+6PD\%KH4MC:/-9VLD-K<3Q2 '>_\$Y?@MXW_9T_8-_9%^!_
MQ+^U1_$+X9_ #X:>&/&MC=ZC;:M)H?B>T\-6,FM>&8M1L\V=U9>%;^:?PYIS
MVDD]J-/TNU2WNKN%$N9?M&BB@ K'C_Y#EQ_UXI_Z,BK8K'C_ .0Y<?\ 7BG_
M *,BH)E]G_$OU-BBBB@H**** "OP'_X(1:IIFB_#[_@JKJNL:C8Z3IEC_P %
MF?VWIKW4=3N[>PL+2$:9\&U,UU>74D5O;Q!F4&261$!(&<D5^_%?D=XZ_P""
M$7_!)SXE^._&/Q+\<?L?^&_$'C?Q_P"+?$/CKQAKMQ\2/C9;/K?BKQ5K%YK_
M (@U:>QL/B7::7;MJ6KW]W>26EE96UA$9FAMK6&W5(5 /SRG\<:-^U3_ ,%9
MO^"E7Q_^"FJ:9XK^!W[,?_!)/7?V/_&OQ)\):IH^K^#O%_QH\9>)M6^-5OHV
MDZU876H6GB27POHD'B'0?$5QI,B3>'==\,0:1JCVT=U:IJ_QI\,-8^&_CS]D
MG_@@A^SE;_LD^'OVQOVE]?\ @G\9OB5\$?AW\:OBNOPT_9;T"S\-Z'J$?BOQ
M=\6_#VI^&_%VC_&'6=*L+)]0\(>#[;PY?:SH7]F:KJZ7^D6M^;?6_P"M'X9?
MLO\ [/7P7^#M_P#L_P#PB^#_ (&^&?P;U73M=TS5/ /@;18/#&CZG#XGTXZ5
MXANM2?1_LE_?ZQK6G[;;4O$%W>3:[=)'"TNHM)!"\?SK\0/^"6?[!OQ/^%7P
M%^"_C#X"6MQX"_9>>Y?]GV+0OB'\6?!GBWX4&]FLKB]7PE\2_!?CSP_\2[..
M^N=-TNYOHI?%T\=Y<Z5I5Q<I+-IEC);@'\V_[,^@?$#X:?\ !7#_ (*4_#7Q
MUX-_8Z^$GB2Z_P""/_Q5\3?$+X2?L,6WBK3_ (/>'O%$'C'X;S^%/^$UMO%&
MA>%S>?&*V\&>+EO?$FJZ-X<T71;W3/$NFWD-E_:5]JUQ<+X%_92_X)T0?\&Q
MMU\?K?X6_"N+XA0_LZ>)O'T'QZU/PYHNF_&*S_:STGQ5JWAS1;/3?B391-XT
MM9[+XSPVGP^\*:);ZS!I]]X;>PTBXTY-/U2\@D_I%^#O_!*[]@']G[7[KQ5\
M&?V</#?P]\3:G\*?%_P2\0:_H/B?XA)K'C'X:>/-5?6_%F@^/=0NO%]S=>/[
MS5]3-O<OXG\:RZ]XLM!INB6^GZ[:6V@Z+#8>2>"O^"&__!*?X>^/?"7Q(\)_
ML=^"[#Q+X'OM!U;PW;7GC'XK:[X,MM:\,VJ6FB>(-0^&VO\ C[5/ASK_ (CL
MXT69O$7B#PKJFMW=]NU.]O[G47>Z8 _#?6_"_P"VE^T1_P %7_@-X3^,_P %
M/V0/B_\ &OX>?\$G_P!GWXB^"OA9^W!XA\<:9\+K/QKK]WX4?]H7XG>&/"7A
M'X3_ !+TZY^-^D?&@>)_"A9]+MAIO@SP[!JL%U+>:-I_]@Q:%\%=6^&W[,__
M  <3>!->UW]B >#K#X*7'CC4?V4?V1_%'Q1\>?#W]E+]H"U^!?CBU\2:KI%C
M\2O@S\./#GA/4/B''I>G:Q=6W@W4-8?PSXJ\'ZAX4M[3PPWA*31['^G/]J#]
MA']E#]LNX\$ZA^T7\);7QMK_ ,.)=5D\!^,='\6^/OAIX_\ "D6O6ILM;L-%
M^(7PK\5>"?&]GI&L6Q\O5-$C\0?V1?E4DNK&66-'5?@9^P=^R%^S9\"/%_[,
MOP6^ _@SP;\#?B%;^);3X@> G_M?Q+:>/8/&.AKX9\3KXWUCQ=JFO^)/%SZS
MX<CCT&[E\0ZSJ,QT>*'3HY([2&*) #\'[/P]H'ASXO\ _!JK:^'M#T?0;:_^
M$7QCUJ^M]%TRRTN"]UG5OV$?AI=ZKJUW%8P01W.IZG=.]SJ%_,KW5Y<,TUS+
M)(Q8P_\ !-7]G[]BOXZ_L)_M\_'G]OSX7_#?QO\ %/4?VF?VV1^V[\2?BSX,
MT?Q'X^^$MWX$O+U=5T#POXPO]'OO'/@:P^&GPUCT/Q!X0M?"ZZ'JGA'7;NXO
MO"^G6&H1V4A_:+X)?\$O/V%/V=(_@G%\'?@3#X43]G/QM\3OB+\%3<?$7XM^
M*I/ 7C'XR>&M,\(?$K5M.E\9>/?$$M]'XG\/:/I]A+I6LOJ6CZ:\4M]HVGZ=
MJ-W>7<_!_&G_ ((U?\$S?VA?B]KOQV^+?[*/A'Q)\3?%6HVFL>+]7T_Q;\3O
M!VB^--7LYHKB/5/&W@;P1XX\.> _&6HW%S"EUJ-]XG\,ZK<ZM=[[K5);RXEE
MD< ^H?V-=:^"^O\ [*7[/FH_LYZ]XM\4_ 8?"CP=IWP@\1^.;3QO9^*M;^'N
MB:1;Z+X6U/5D^(VE:)XTN6N]*T^VFM-3UO3+=]8L&M=6LFN=-O;.ZG_D,^$_
M_!,+X_\ [=^O?\%8OBI\-OVGM>\$:G^S5_P6(_;2^(O[)GP!.@^&KSX7:M^V
M'X*\>^ _&#_$;XP?\)':WNG>)]*\0>#;;PM\+_"UAJUG=6'@:ZN_$'BATO=$
MU/Q7X0\:?V\:-HVD>'='TKP_X?TO3M#T'0M-L=&T31=(LK?3M)T?2-+M8K'3
M=+TS3[..&TL-.T^S@AM+*RM88K>UMH8H((TB15'E7P9_9Y^#G[/G_"UO^%/>
M";7P5_PN_P"-'CK]H;XI_9M5U_5/^$M^,?Q*_LO_ (3?QM<?V]JNJ_V==:]_
M8NF>;I6B_P!FZ!9_9%_L[2K/S)O, /P _:/_ &^_#W[?O_!!S]NWQ?J&A/\
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M -)/$-?HM7YT_L,?Z[QU_P!?'A__ -)/$-?HM7_4+^SZ_P"40/!W_L&XS_\
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MVEQ>%AI<FWR]2/B![I=)&GR;TV7AN_L[[EVR'<,_S+> /A%\-OVR_P#@J/\
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MJ'Q3_:__ ."=/PZ^(O[-WAF&#5/B5\5?V+/CM?\ C_Q+\,O#,<%[-J_B2_\
MA;\1?"7A3Q-XDTO0T@AO->U*)_#GAWP_I*W6J:KXABLX99;?X<_X*R:-X?\
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M>L-4N+#Q!,L]M=VOA*RCDUMK5K>RM[+4?%&O>%?#.N?S4>,/@M^T_:?LI_\
M!L#\(O WQ%3X3?M#^,M<_:0NO 7Q,\0V+ZW)\-= ^+.J>#O&7@GQ FD7=I(;
MO4_!_P )?%NDOX?T6XABACU/3M,TV6ZM(8S>P_K-_P $T8K7_@D;^W%\7O\
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M 4444 <SX*_Y$WPE_P!BSH/_ *:K2NFKF?!7_(F^$O\ L6=!_P#35:5TU<F
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MT586AM_$;>)+R:6'Q"LAN(K0K:"$HNZOK&B@#XW^'7["7P!^%O[$^H?\$_\
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MK;[MHH _*+]DCX*>/?B5^W1^UK_P40^,G@SQ'\/[[4M&@_8G_96\&^+-(O\
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MHHKK.4**** "BBB@ HHHH **** "N9T'_D*^-?\ L9K3_P!0WPE735S.@_\
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ME?\ X[6Q17LG)RKS^]_Y^2^XQ_[/O_\ H+3?]^5_^.T?V??_ /06F_[\K_\
M':V** Y5Y_>_\_)?<8_]GW__ $%IO^_*_P#QVC^S[_\ Z"TW_?E?_CM;%% <
MJ\_O?^?DON,?^S[_ /Z"TW_?E?\ X[1_9]__ -!:;_ORO_QVMBB@.5>?WO\
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M]EM6FJLXSY>6U*A2MS-_P*%*CS7T^+V:E:VE[7=KO'_L^_\ ^@M-_P!^5_\
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MV%K6=^:]URV>T9I4*E'E?[RK1J\W,]/8PKPY>7KS>VO>ZY>2UG>ZQ_[/O_\
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M_9]__P!!:;_ORO\ \=H_L^__ .@M-_WY7_X[6Q16ICRKS^]_Y^2^XQ_[/O\
M_H+3?]^5_P#CM']GW_\ T%IO^_*__':V** Y5Y_>_P#/R7W&/_9]_P#]!:;_
M +\K_P#':/[/O_\ H+3?]^5_^.UL44!RKS^]_P"?DON,?^S[_P#Z"TW_ 'Y7
M_P".T?V??_\ 06F_[\K_ /':V** Y5Y_>_\ /R7W&/\ V??_ /06F_[\K_\
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M6K4J\M^;E]I-SY;V5[7M>ROO9;!1116QD%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMV?'[]EGXU?L+?L__LZ?#3X/>/O'W[:?Q ^)?P_T[4/C5XJ\:>$O!_A2_P#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7DD_Z5          8  X  '  '  Z444 +1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
G%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ny20006478x8_graphic02.jpg
<TEXT>
begin 644 ny20006478x8_graphic02.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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MU-(1+&;0RW'XX?\ $(GXN_Z/O\.?^([:G_\ /FK^V>B@#\)_^"G7_!&K6?\
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MPUNO&,?C1M8\+_#OPZ+J"P@\<>&FT$6[>!'NS#)=ZL95U-(1+&;0RW'XX?\
M$(GXN_Z/O\.?^([:G_\ /FK^V>B@#\)_^"G7_!&K6?\ @H;\(/V0_A;IW[0.
MF?"F7]EWPWKF@76M7OPUNO&,?C1M8\+_  [\.BZ@L(/''AIM!%NW@1[LPR7>
MK&5=32$2QFT,MQ^.'_$(GXN_Z/O\.?\ B.VI_P#SYJ_MGHH _"?_ (*=?\$:
MM9_X*&_"#]D/X6Z=^T#IGPIE_9=\-ZYH%UK5[\-;KQC'XT;6/"_P[\.BZ@L(
M/''AIM!%NW@1[LPR7>K&5=32$2QFT,MQ^.'_ !")^+O^C[_#G_B.VI__ #YJ
M_MGHH _"?_@IU_P1JUG_ (*&_"#]D/X6Z=^T#IGPIE_9=\-ZYH%UK5[\-;KQ
MC'XT;6/"_P ._#HNH+"#QQX:;01;MX$>[,,EWJQE74TA$L9M#+<?CA_Q")^+
MO^C[_#G_ (CMJ?\ \^:O[9Z* /PG_P""G7_!&K6?^"AOP@_9#^%NG?M Z9\*
M9?V7?#>N:!=:U>_#6Z\8Q^-&UCPO\._#HNH+"#QQX:;01;MX$>[,,EWJQE74
MTA$L9M#+<?CA_P 0B?B[_H^_PY_XCMJ?_P ^:O[9Z* /PG_X*=?\$:M9_P""
MAOP@_9#^%NG?M Z9\*9?V7?#>N:!=:U>_#6Z\8Q^-&UCPO\ #OPZ+J"P@\<>
M&FT$6[>!'NS#)=ZL95U-(1+&;0RW'XX?\0B?B[_H^_PY_P"([:G_ //FK^V>
MB@#\)_\ @IU_P1JUG_@H;\(/V0_A;IW[0.F?"F7]EWPWKF@76M7OPUNO&,?C
M1M8\+_#OPZ+J"P@\<>&FT$6[>!'NS#)=ZL95U-(1+&;0RW'XX?\ $(GXN_Z/
MO\.?^([:G_\ /FK^V>B@#\)_^"G7_!&K6?\ @H;\(/V0_A;IW[0.F?"F7]EW
MPWKF@76M7OPUNO&,?C1M8\+_  [\.BZ@L(/''AIM!%NW@1[LPR7>K&5=32$2
MQFT,MQ^.'_$(GXN_Z/O\.?\ B.VI_P#SYJ_MGHH _"?_ (*=?\$:M9_X*&_"
M#]D/X6Z=^T#IGPIE_9=\-ZYH%UK5[\-;KQC'XT;6/"_P[\.BZ@L(/''AIM!%
MNW@1[LPR7>K&5=32$2QFT,MQ^.'_ !")^+O^C[_#G_B.VI__ #YJ_MGHH _"
M?_@IU_P1JUG_ (*&_"#]D/X6Z=^T#IGPIE_9=\-ZYH%UK5[\-;KQC'XT;6/"
M_P ._#HNH+"#QQX:;01;MX$>[,,EWJQE74TA$L9M#+<?CA_Q")^+O^C[_#G_
M (CMJ?\ \^:O[9Z* /PG_P""G7_!&K6?^"AOP@_9#^%NG?M Z9\*9?V7?#>N
M:!=:U>_#6Z\8Q^-&UCPO\._#HNH+"#QQX:;01;MX$>[,,EWJQE74TA$L9M#+
M<?CA_P 0B?B[_H^_PY_XCMJ?_P ^:O[9Z* /PG_X*=?\$:M9_P""AOP@_9#^
M%NG?M Z9\*9?V7?#>N:!=:U>_#6Z\8Q^-&UCPO\ #OPZ+J"P@\<>&FT$6[>!
M'NS#)=ZL95U-(1+&;0RW'XX?\0B?B[_H^_PY_P"([:G_ //FK^V>B@#\)_\
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MH+"#QQX:;01;MX$>[,,EWJQE74TA$L9M#+<?CA_Q")^+O^C[_#G_ (CMJ?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !110<]CCD?EGD?B./;K0 45&YD&-BJ?7)QC_/X_ACEXS@9&#@9
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MII)W ;<@@DMV'^.?K[]J=0,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M\9,GED HHXP26!R,'D57X?U_2]0\_P M?/\ ([*BBB@ HHHH **** "BBB@
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M\2ZQXGG?QAI#ZEK-YX5\#:%HN@Z78Z)IMDE[XZU6^\1P3:]J40T76!HOAO\
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M>%;3]H/]LSQA\$_A]\5O#OQNG_9U\>_%/P'K?P2\;_$OPQ>K-8:]XR\#:?\
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M\/:3::5_PDWC;7+.PTNWUKQ5K0M!J&OZNFGVK:GJD]S>RQ":>0GMZ "BBB@
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M/%VLV^D:!X?L+G4-3U.ZE1(;>"WC9CN#L-SG;LC !+$JJ@DBOY*M.\?^-_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6V?A35]5BLO$=KK0\%76K73^';/2;G0]-36[S4=+ .DO/^"L_@[X[_LN?\%
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MB%\0+"?_ $;QQXB@6'!=X]5N!OD!&1M7>&_W6" @')SA:^:S#P2R;'4FJO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M (*3?M?_ +/W_!9S]B7]D'X5_$G3?#_P#^,NL_LGV?Q"\(7'@/P)K=YK-O\
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MZ1?VC;]S0%E1E /OZBO\K/\ XB0_^"T7_1Y?_FN_[*7_ ,XRC_B)#_X+1?\
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M+Z%0!7NK2UOK>2TO;:WO+68 36UU#'<6\H5E=1)#,KQN%=5<!E(#*K#D U.
M        !@ #@  <  =!2T4 %5;>QLK1[F6TL[6UDO)C<7<EO;Q0O=7#9W3W
M+QHK3S')S+*6<Y.6YJU10 4444 %07-K;7L$MK>6\%W:SH8Y[:YACG@F0X)2
M6&57CD0D E74@X'%3T4 <S_PA7@W_H4O#/\ X(=*_P#D2C_A"O!O_0I>&?\
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M?PEX4T*T>62XDM])\/Z#9V&E:?%+<2RW$J6MK$);B66>3=+([MVE% !1110
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M^[1D7?;@F1A&93*^%.%4L>F:Q/$WB[6?%5[+-J=U+-!?;6LX4\P(H0A520#
M5AD#G V\>];<DWCGXS^+)]5O!-J>JW\ZEK]I,1+!#')PQY"' ;<S*%(RHW,0
M#^A7[)?[!/CWXU>*+;1/"O@N_P#&.K3.@O+N1$B\-:'&67,EU=S.L9ER2VP
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M !1110 4444 %%%-9U4@$]2!^.>,_P"?Z5,_A?R_,!U9DMP5!5"<LY!..,=
M%.>H)YQT^M:61G'?_P#5_C7P#^W%^W;\%?V'_AMJOC3XF>(K5]:FBN8O#'@Z
MTGC?6M<U=HO]%2TMXRTL5NC[1<S.IC7(!P6 .V&PN-QU:CA,OP\Z^)KM1@HK
MW86:3E/JHZ_%LMWH<N,QF$P&'JXO'5H4,+1BY59R=M+727>3Z+=NR6Y\/?\
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MCI@#'%2445!H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_);64JVEC:W%W<&.WADD7_/4_P"';O\ P41_Z,)_;1_\1;^./_S"T ?UY_\
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M91@\@*G$5QKFBVFG1ZQ=:QI=MI$R020ZI<:A:0Z=+'<A3;21WTDRVTB7 93
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MH1-K7P4U"ZL-(TZSBA1H8-.^&6O_  TLHY'^UW,%]*)$F_H_HH _RQ/VO?\
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M37II]VB_K<[@HHHJP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<6DW&C30W<=E+HCLGC))&:RN?AZ?%UIJ$<EE<3H?WQ          P !P  .
M .@I: /X]OA7K?\ P2_N/@?_ ,%,+#_@F=X5_:(L-$F_X)$?%^[^,.IV=_XE
MF_9:M/$'_"L?'<VC:9XTA^)>JGQQ-^TQ!;W4EK#?Z78WOAB?PW#XP339+/4(
MO%L^H^ _LK_ +X8_ OQC_P &YWQZ^%.E:UX0^+'[26I_%?1_CCXOM?&7C*_N
M_B)HVFZ!X2TK2=$U6UU?7M0T^PT#2='O+W1['P_H-II.AKIERUK<:?<+!9FV
M_N MK6VLXO(M+>"UA#R2"&VAC@B$DTC2S/Y<2JF^65WDD;&YY'9V)9B3/0!_
MG)_MZ_%[P/J/QU_:M_:#\*Z3\,_@1\>_A/\ M_W,-E!K7BW]HWXA?MP1R> ?
M%ECI6J_$!]63Q!;_  *^%_P'AFEMK3PYX;L/#VO2V>LSQ^ M)U"73]+\)ZCJ
M7NGQE^ 'PG^(O[//_!P-^T/XATO5-3^*O[//_!1_QYJ_P+\7VGC/Q=:VGP\O
MO&7[4&C6/BS6O#/ARPUZ+P>NK^+=&L]/TC6/$,^A76M7.EZ=I$5MJ5N^D:3-
M9_WXI:VT=Q-=QV\"75PD4=Q<I#&MQ/'!O\A)IE422I#YDGE*[,L>]]@&YLST
M ?R:?%+X)?#C]KO_ (+*?L0?"_\ :)TG5OB1X#^('_!'3X>:WX^\/7?C#QEH
M,7CB_P!.\?\ Q6\5VG_"77WA37]"U7Q#9IXJL=.\32Z;JE_<Z?=:_I>EZM=6
ML][IUI+%^)VD_P#"6:_^R)_P3 \&_%_Q3\/]5_9(TC]H7]N'P7<VO[3'B3X\
M:;^SUHOCW0X]&_X5U!\7=>^!FJ:=XQTFT@M-6U?_ (59'H<FFVVDZU<^.9M7
M>+P%J/C-8_\ 1\JO=6EK?6\EI>VUO>6LP FMKJ&.XMY0K*ZB2&97C<*ZJX#*
M0&56'(!H _@QUW0_&FB_\$@?V*FUKXCP_$KX<:K_ ,%JOAC?_ 2[L;7XM6VA
M>$_A+:_#[XF:!:^!O!S_ !CT#0_$M]X'T/Q=HGBVX\.7]K+K.G.FIWEK)JG]
MKV>J:?8?WK4@         &  .  !P !T%+0 5_#O_P '>W[1_P '?$ND_LZ_
MLOZ3XFU&3XX_#/QQJ?Q*\7^#;[P5X[T>VM? GC3P7]A\-^)M'\8:QX9L/ WB
MW3K_ %&UOM*E;PCXEUR;3=7TW5=)U2*RU+2]1M;;^XBOY:?^#I+_ ()WI^TC
M^R5I_P"V'\/=%:Y^+_[(EE?WOBV/3K)9=0\6?L]ZQ>0S^,H;IK>SDO+EOA7J
M93XBV$EU?6^EZ%X3E^*=T89[W4[<H >;_P#!HS\=_A?JG[&_Q=_9MT_7M1NO
MC%X0^./C#XO^)O#<7A#QH=(T7P!XP\,?#'PKX6U6^\=GP\/A]'J.OZWX8\1V
M^E^%1XJ;Q;=VV@ZQJD6AMI.FWE]#_6]7X>?\&_O_  3[_P"&"_V _!(\8Z#_
M &3\>?VBO[/^-GQE^VV?V;6]$.N:;'_PKSX;W_VBQLM3M/\ A ?!LUK_ &MH
M6H>?_8WQ \0>/_LDQM[Y:_<.@ HHHH **** "BBB@ HHHH *^6OVI?V)?V3_
M -M;PDG@O]J3X$> ?C#I%K!<6^D7_B+3)+3Q?X8CNY(9;QO!OC_0KC2?'7@N
M:\>W@^VS^%/$>CS7D<:PW3S0YC/U+10!_#A^W#_P:)W$9U7QG_P3\^.2W"9G
MO%^!_P"T-<K',J[;R[EL_"'Q>\,Z.(9F,GV32M T'QIX-M@D>;G7_B7(ZR3O
M_.[IGBC_ (*V_P#!$SXHG35E^/O[).KZAJUS(VA:O;+K?P0^)U[IT%K#>W=K
M97B^)_@?\6A9VDEO:MKNCMXCGTE)1'::G87."O\ K8UQ?Q"^&_P\^+?A'6/A
M_P#%7P'X-^)G@3Q!"MMKW@KQ_P"&-$\8^$]:MTD6:.'5O#OB*QU'2-1BCE1)
M8TN[.94E1)% =58 '\:W[#G_  =T^%M8?1O!/_!0+X)R^$;R5[:QE^.?P"M[
MS6/#*M+/9VJZAXP^$FN:C=>)-(LK2U^V:GK>L>"?%'C&]O)]EKH?PZMHRJ)_
M6K^S=^UK^S1^U_X(B^(?[,WQL^'_ ,9?"IBLWOKCP;KL%WJ_AZ:_MUN[73O&
M/A:Z%IXJ\$ZV]NZS/H'B_1=$UN!"//L(CQ7\[7[</_!J1^QU\<#JOC#]D/QA
MKW[)7CZY,]X/"$Z:C\2O@AJUVRWER\,>@ZUJT7C7P/+J6H36\;7N@>+=4\,>
M'].B,&C?#EU6*%?Y+/VC_P#@E]_P5:_X)*>-#\89/"WQ)\&Z3X0ENVTK]J3]
MF'Q9XAU;P98Z?&]I'/?:EXP\'?V3XM^'VD:C+/!9BT^*&@^"?[;99;:&QOX%
M?(!_K 45_G@?L.?\'8O[5/P@?1O!O[:?@'1/VH? D+VUG<?$3PO'I7PX^.&D
MV1GLXI;VYCTZRA^'/Q _LW3(;D6>D7>A>!=:UG49Q<ZW\0F.]F_L1_8E_P""
MO'[ G[?UKIEG\!/CKH4/Q&O[:*6X^"/Q',/P_P#C'87+6J7EW8VWA'6;GRO&
M)TN)U34]7^'&J^-?#5K-F+^W'84 ?I=1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% #7QM8D[0 23D@  9.<8.,=:_)C2?V"-1^,O[87C[]I
MC]I6\3Q;HG@[Q1K&A? ?P->L;K1]"\.V]T#9:^]H^83?R11IY99-RL[,&8#Y
M?UH8$@XQGWZ'V/L>G?'7!Z4T)C()W9<OR.G.5 Y_A('/?'3FCJFKIQ=TTVK/
MIM^MR914DXM)IJUFO\T_OW7G<S[72K6Q@@MK*..U@ME6."&&)$BBC5=JHD:X
M50HZ8Z5?,:L-K?,-P;T&1Z@<$=\=/TJ2BG*4I.\FV_-A&$8II+1VNO2WW;=!
M@4C'S=,]L9Y/],#\*"NX,IY5OZ]1UZ8^E/II)&,#/;\3T^@SU.#[ GBI>VG=
M?FFRC^=VU\+Q?&W_ (+FZS>75DM_I?P&^&$UR)95W16^IE(K1#ELA)$:_P!B
MJF22H-?T/QH$5 @VKMY7T) .?PQ@#'2OPE\2_M$?LF_\$^_VO/VA?C;^UK\8
M/"OPAD^+5_\ 8/!VG7EKK_BSQOK^CB>XD_M6P\"^ ]%\4^,W\.(^EW%M+XA_
ML0:%#J"0:9+J":C=6MK-^JG[-/[6W[-_[8G@:;XC?LT_%WPI\6O"=G?RZ7JE
MUH$M[::MH.HQS7,267B;PMKMEI/BKPQ=7:VDUUIL/B#1=-?5=.\K5=,%WIEQ
M;WDNM6I*<81E*ZC%)+M>VFEO*W8CV<(M<L4M%=K=OW7=O>^GX:GT7117@_P:
M_:;^!G[06O\ QC\+?!_Q]:>-->^ 'Q(UGX1?%[3[;1_$FEOX,^(OA^]O].UC
MPU<S:]HVE6VJ3V5[IE] U_H4^J:3*;<O;W\L;QN^:5M"SWBBBB@ HHHH ***
MX+QW\4_AQ\,/^$27XA>-_#7@Z;Q[XT\.?#KP/:Z]JUI87WB_QUXMU*#2O#WA
M3PS82R"\US6]1N[A6%CIL%S+;6,-YJMZ+?2["^O+< [VD(!&#R#2T4 ,$: D
MA<$XSUP2I!!QZ@@5R/B;X?\ @OQE=:/?>*?#6CZ[>>'KZ'4]#N=3LH;N;2M1
MMW$D%Y9/(I:"XB<;DD0A@>0178T4!MMH,2-8_N@#( .!UP,#\ ,@#MFGT44
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YM
M_P#!6S]K;XG_ +#G["7Q:_:4^#MAX0U+X@>!]7^&ECHUGX[TK4M:\,R0^+_B
M5X5\(ZH;[3M(UOP]?SR1Z7K5Y)9M%JUNL5XL$LJSQH\$G\=?_$5!_P %)/\
MH2OV4?\ PV/Q#_\ GQ5_59_P7M^&'Q*^,7_!+[X]?#_X1_#SQS\4_'FL:_\
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M/AYXP&F>(9KB.XTYIO#=A;Q6#11/]ANP]W'N=BM?TKT %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !5+4M-T[6M.U#1]8T^RU;2-
M6LKK3=4TO4K6"_T[4M.OH)+6^T_4+&ZCEMKRRO+:66WNK6YBD@N())(9HWC=
ME-VB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0@$$$ @@@@C((/!!
M!X((X(/6EHH _#3]N'_@WG_X)P_MIG5?$T'PR;]FWXMZ@9[H_$S]GF#2?!<.
MIZE(MY*+CQ?\.&T^Y^'/B5;W4[O^T=?U2W\/:'XXUN2,1R>-K7>TE?QW_MM?
M\&S'_!1']DZ35/&7P8TJR_;!^&.DRRWMIKOP4LK^S^+VFV5M-:1V=SK'P2O+
MB[\3W6JW-S.7M]/^%FK_ !2EM8+6:_U"XT^%"5_TVZ* /\NS]C/_ (.'O^"F
M'[#6KP?#[XB>*[S]H[X=>&KU=&UGX4?M*IK5_P"./#<=C>6T.IZ;X?\ B=,T
M'Q,\-:S:6EDVC:=IWB^[\:>$_#<9D%OX&,RD5_8-^P__ ,'*/_!.G]KA-)\,
M_$3Q=<_LB?%B\@M8[GPI\=M0TVP^'][J3P+)>Q>%OC5;&#P7<Z=;3LMI:3^/
M8_AKKFKS,HL/#3_,%_1C]LK_ ()C?L._M[:7<P?M+? +P?XM\4O8)I^G?%/1
MK=_"'Q>T.*VBE33DT[XD>&VT[Q+<V&ER3-<VGAW7+S6/"DLX O\ 0+V!I(7_
M (^OVX_^#2'XW^ _[8\9?L%?%K3_ (Y^&X5DN;7X-_&"\T3P)\7(8Q]CA@T[
M0?'\4>E?"WQM>S2/?7UQ<^(H?@[:V%E#%:6XUF](>8 _OQLKVSU*SM-1TZ[M
MK_3[^V@O;&^LIXKJSO;.ZB2>UN[2Z@>2"YMKF"1)H)X7>*:)TDC=D8$V:_R8
M_@Q^VU_P5@_X(V_$C_A6-KXA^,GP,.EW U#4_P!G3XZ^&]6U3X6:_ITFI1S7
M>H:9X!\9Q-I5II_B.:P%O+\0/A==Z!K6KV",FE^,?LSAS_5;^P__ ,':?[-O
MQ.32?!_[<?PRUC]G#Q>\%K;W7Q2^'L&M?$CX,ZG>K OVV_O_  [:VU[\4/ 4
M-U>,(]-TBUL?BE!!!NFU7Q7;*FY@#^N^BO,?A#\:_A!^T!X(T[XD_ [XG^ _
MBYX!U5FCL?%WP[\4Z-XNT&2YCBAEN-/EU#1+R\@M-4LEGB74-)NV@U+3IG\B
M_M;><-&/3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1E##!
M&1]3_2EHH _E9\":M^SQX/\ ^"[?_!3[XJ?MR6GAI=>^#?[/7P^^*WP OO'F
MA-XJ\-^'/@OX(^''A'5?B%XN^'.DZCINHW%UXXTK2;?2YH+?P-I=[XD:_N_B
MQ8Z/'<W,NOI<?*_@CXB?#;1OV\O^"V'Q(_X)S^)K31?V?H_^"3'Q+^)S>*/@
M5,F@?#/0_P!H2R^%?@OQ)X&\1> I/!R6NG:+XUTN^NO&VH6D9CTW7-$\9GXJ
M01P6>HV%];K_ $O?M=?\$S?V)/VZ-<\,^+?VF/@CIWCCQMX-TH:#X:\<Z5XH
M\;> _&.GZ$FI3ZM#HD^O^ O$?AJ]UK1[+4;S4KW2M+\0/JMCHMYK&LWVC0:?
M?:M?W,_EO[-G_!(7]CO]D+XI^-?'O[/.F_$OP'X&^)GPPN/AE\2OV=;GXG>*
MO&GP#\?I)-<):^,/%_A7QY>>)M>\0^*-/T;5?$?ARRCUGQ5?^&++2/$NLG3_
M  W9:A?7E]=']?<!^->L_M:_M"6W[-/_  ;G:D/V@_B9!XT_:,_:H^#^B_&:
M[_X6%KD?B+XR^#)_B7X.T?Q/IWCMCJ0U#QIX>>#7;+3=:AU7[=8A=7M+6\ ^
MWP)+Y)>?MZ?M!?LK_L]?\%Y?B[\/?%&HWOQ&\'_\%-/%GPE^$^N:Y8VGB?3/
MAAIWB?XN^*]%FU2VTC5DGTLPZ/X>@OK;P]!J%I?Z7#XDFT%]1TW4K!+BPN/W
M:^&?_!$K_@F3\(O$_@[QGX&_9KCL/%/PY^)_@WXO_#W6[_XK?&O6[[P1XT^'
M^L77B'PK)X=DU?XC7HM- L]=NY-8U7PG,MQX9\6:A;Z7<>,-*U]]"T+^S?H6
M'_@GA^QK%X/_ &H? $GP1TK4/!W[9OC;7OB1^TEH.L^*/'NNV?Q%\=>(]6N=
M?U'Q/$=:\57\_@K5(-?N6UW0Y?A[-X33PQK5OI^K>&DTG4-+TVXM #^>C]G_
M /:._P""F_P;UW]IWX4#XQ_%7XAZ)J_[#_BGXX?!_P"(O[=&C?L__##Q=\.?
MVB9YY%T/5+2>[^,WC#1X?@MXT-CXE3P!J7Q"UUOAQIWB*+0=!GM-/T'PQXIO
M/%',_P#!.#]N7]HGP;^TA\)K/]J7XO?M\6'BKX\?!GQUK]M\+/VAO W@?XI?
MLV_M1^+O!?@"Y\;:5XA_8Z^-GAB_^'FG_#BQU:%[*]\-Z1X/\$?$[PAXOM]<
MTGP[J?Q U'5-4\(ZC<?T#_ O_@EA^PE^SKI7Q1TGX;_ RUDC^,WPXC^#OQ'O
MO'GC3X@_%'5]>^$T.G'28OAK;ZM\1O%7B>^\/>"AIJVEE-H'AF;1K&\BTG0#
M?1W,GAS07T[)_9U_X),?L&?LL?$KPI\7_@_\&M3L/B)X T36?#7P[\0>+_BK
M\7?B0OP\\/\ B!-0CUC2O ^C?$#QSXDT#PU%>QZOK$3W>F:7#J21:SK,45ZD
M>L:FMV ?B5^Q-\7_ -KG]H'X0_LZ?\%'?BA_P5U\,?"#4/C/^U4WPY\4_LW_
M !"T/P1HO[.47ASPQXK\5P1_L^:%I,MW!)HWQ*\:>#_#":WHNNM>:7XGO?"_
MB/2[B\UK4/$\=GXCU/Y.\;_\% O^"F?Q>\>_M4_M4?!#XL?'O0S^SO\ M:ZG
M\$?A;\!K#X;_  BMOV0X_AS8>,]%\/P^$?CSXJ\6?$WP[K?_  M'Q?;ZO80V
M>H2^$M:U=M>6XT7P7XIT6;Q7IT'@3^D3PU_P1G_X)N^#OC]H_P"TMX7_ &;]
M.T3XI:!\0/\ A:VB2V?CKXF_\(7I/Q'74FU>V\6Z9\-IO&4O@'3KW3]3\F^T
MFPL?#MOH>D7=G8W&F:5:365J\6GXY_X(_P#_  3N^)'QL\1?'[QC^SQ8:MX\
M\9>.M#^)_C;3T\=?$S3OAOXW^(GAV>:ZTSQAXR^$>F>,;/X8^)M5:ZN]1N]6
MBU?PI=Z;XCO=9\0WWB.PU:]\2:_<:D ?BY\2/&/[:/[3/_!1?_@J-\,OA_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "LS6-:T?P]IUSJ^OZMIFAZ391M+>:GK%_:Z9IUI$H):6YO;V6"V@C4
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MUX9DA\7_ !*\*^$=4-]IVD:WX>OYY(]+UJ\DLVBU:W6*\6"659XT>"3^.O\
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M./#WA?5O GA_4=(U'S+/6[76?$MC+HEQ;WD>K+9-97?D>L_M'_\ !17]BO\
M9)T/X4>)_P!H#X^>&?!'AKXY:3K&O?"3Q!9:1XO\<Z)X]T/0K/PMJ&HZSH.J
M_#SP[XKL9M*6P\:^%KVSU":>&TU6TUFVN=*EO84G>'^<7X9:+\*?"_\ P0?^
M"WC/]FS]BO\ 9I_:L\#:O\./'&N_MQ7'Q;\5^%_AKXK\/>(/"=AK]QX^\2WO
MC*'6/#WC^X\9Z9XDM]6TCX<2:)K4?C;2O"D?A!O!+VD$NB$_*?[2'Q"\3_%O
MX7?\&U/C7]F;X5?#'X9^+]4^)O[0VD_!/X2^//%/Q)\=_"+PYKOA?XZ_ 7PE
MX+T#Q9XEU_6]6^)>K>")+S0[*35E;6Y]4L]*N)M-TB6"VM+&*( _KT_94_X*
M!?L@?MNW7C>R_9;^,^F_%FZ^'%OX?NO&L.G^%_'?APZ';^*9-8AT&25O&?A;
MPXEV-0DT#5U0:<UVT!LV-TL E@,OKOQZ_:-^!/[+O@*Y^)_[0OQ7\$_"+P+;
MW+6$6N^-=;MM+75M7%A?ZK'H'AO3V9]6\4^)KK3=+U*]L?#/ANPU7Q!J%MI]
M[+8Z;<+;3%/@/PU\:O\ @H+^S#^S1\8_C)^UI^S!\&OC3\3?#WB?P39_#SX.
M_P#!-_PO\5==\3^+_#&MZKIVA:Q=ZKI/C./Q'KEYJ/ARZU2;7)CI-HUE:^';
M'4+BY6-E>9?QF_X*#_M*>+OVGOVA_P#@A_\ $OQA\!O%_P"RKXIU3]HO]J#2
M?"?PJ_:^\,>*M"M++XFZ!<_LXV'P8\3_ ! \-6]IX;\07'@R]^(FIZ#*););
M.>;2Y-06WOX4EEG0 _J%_9U_:B_9]_:U\ CXG_LX?%?PG\6_!"W[:3>:OX7N
MYC/HVL):6E^^B>(]%U&WL=>\,ZVEA?V-\^C>(=+TS4TL[RTNFM!!<0R/E?L_
M_M=?LY_M37_Q8T[]G_XGZ7\39O@AX[NOAK\2KK1-)\2VND:)XQLS<B;3M-U[
M6-%TS1/%UF1:7#V^O^#=0\0>';N-%EM-6GCDB9_P"_X)J?!&3XE>)/\ @L'^
MPE\?M8U?X2_M.>)/CC\/?B'^T#\5OV/O&Z>$O NJ^#_B.G_"7^'/#'P.N+?P
MI:S_  [TVSTFSUCPOXTTKQ59ZMXOUW2_'.KV>OWUWJUKK=IHWI'_  ;\_#CP
MC\'?'W_!6OX1> -.ETCP'\+/^"@'Q ^''@G29[Z^U2?2_"/@?6O&'AGPWITV
MIZG<76I:C+9:-I=E;27VH75S?7;Q&XN[B:>221@#^D2BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH \<^./[/7P,_:8\#7OPU_:!^$O@#XQ>!;[S'
M?PY\0/#&E^)+*TNGA>!=4TA]0MY;K0M;MDD8V&NZ+<:?K.G3;;BPOK:=$D7^
M4K]N/_@T@^"?CS^V/&7[!/Q<OO@;XDE62XM/@U\8KK7/'7PEN+@_8X8+#0_B
M%!'JOQ0\#V,427U[=7'B"S^,5U?7TT5K;#1K$ P_V,44 ?Y*_P 0_P!FO_@K
M/_P1;^)Y\?SZ+\<OV:+^*ZT^Q@^,GPOUFZU?X.^-[5-1^UZ3H>L^,O"L^J_#
MKQ5I^HW5I'?-\./B"LEY*GDC7?"$+/Y-?NO^P_\ \'<_Q(\+II/@W]OSX+6W
MQ-TF""ULY?C5\";72_"_Q 800+'+J/BGX7ZQ?Z?X#\3:CJ-R3<7=UX1UWX8Z
M;IT*M'8^%;UV5%_N_P!9T;1_$6DZEH/B#2M-UW0M9L;G3-7T76;&UU/2=5TV
M]A>WO-/U+3KV*>SOK&[@D>"YM+J&6">%WCEC=&*G^=O]N/\ X-C_ /@GQ^U5
M_;'BOX,Z7J'[&OQ7OUDFBU?X/Z79W_PCO;]_L<22Z]\#;Z[TW0+2RMK2VFCM
M]/\ A?KOPLCDO;N74M4?59M\<H!^L'[(?_!17]BW]NS0QJW[+_[0'@;XC:G#
M9&_U?P']NE\.?%'PW;1F".XN/$/PS\30Z3XVTW3H+J=;)=>;19/#E_=)(NDZ
MQJ$:>:?M:O\ +/\ VN?^""?_  5#_P""?/B!?BAX.\':Y\8/!_@S48M?\/\
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MW+ZY/9:")=9T/1;<:CJ%C*91I=PNHCY"_8U_X+^> /CA\9_VX[GX_>&?$/P
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M[6/[!W[>_P"R7\+-/_:,\3_LH:G\4?#WCC]G_5_'?AGP%)KW@SXG^&9="O\
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MZM/<>'M(N_$,D^C'0Y=&\4W,+G6M!LHXYM;76-.TJ=5AMM<\RW75%)F73[/
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M1110!6O+2WU"TNK"[C\ZTO;:>TNHM[Q^;;W,3PS1^9$R2)OC=EWQNCKG*,K
M$>+_ +.7[-WP6_9*^$?ASX$_L^^#/^$ ^%7A*YUV[\/^%O\ A(O%?BK^S[CQ
M+KNH>)=;D_MSQMKOB3Q'=_;=:U6_O=E[J]REMY_V:T6"TBA@C]QHH _([XA?
M\$)_^"5/Q/\ '^K_ !)\4_LGZ)'XA\0:O>:]KUGX7^(GQ>\#>%=5U>]FDN9;
MQO!G@KQ_H'A;3@+F:><6NB:3I=E*T\R7-M/$YCKZG\2?\$^?V-_%6H_LO:GJ
M'P*\-Z<_[%^N7WB3]F33_"&J^+/ 7A[X5ZUJFK^%]?U*]L/"W@;Q!X=\->(#
MJ&M^#?#VJWD'C#2?$-M<W]I=74T+RZOK+:A]E5^%/Q6_:B_;2_:8_:R^+?P3
M_8;^(OA[X;_#S]GI3X/\4^+;GX>>"_'MQX\^)=@UN_Q @^U^/KS3].T32/AY
M>W>F^$O(L6@N+K6Y+Z]:XUFQU'31HH>AEF5XW-\4L'@*=*=9TJ]>4L1BL+@<
M-1H8:E.M7K8G&XZOAL'A:-.G!MU<17I0<G&G&3J3A"7[K5^,W_!3W_@FCJ__
M  4%_:'_ ."?WB#7M*\ ^)OV?/@'XD^.C?M#^#O%OB;Q5X<U[Q1X1^*&G?"R
MTTVQ\&/X5TXWDNHQ2^"M3EN+M/$OA2]TJ;^S;O3-2-R3):_+&N?$W_@IOX>&
M;_\ ;\^%]QR1C0_@7^S]XF.0)3T\-Z[JO'[IL'H28@#F:'S/O#_@FG^V)\0O
MCO#\7O@A^T%K6C:O\?O@AK]G>-X@TO0[#PK;_$OX3^+(1<^$?'5MH%A.;"#4
M;*]2^T/Q5:Z';+I6B2/X<MYYI=2U&X=W9[_UM?\ )GT&?< \6<-9=0S;.<J6
M&RW$XF.$HXRCF&5YA0EB94ZE6%)RR[&XOD<Z=*I*+J*,9<DE&3DK'T3^R)^P
M+^RI^PM9>/[3]F?X:S^!KCXIZGH^L?$76=4\:>.O'6O^+K_P^-870Y=4UGQW
MXD\1WR1Z4/$&M&UMK&6SM3-JE]=S0S7EW<7$GHGP1_97^ W[.7B+XV>+/@UX
M$_X0[Q!^T5\3M;^,GQCU#_A)_&7B'_A,/B1XCOM0U+6?$?V7Q5XAURR\/_;+
MW5;^;^Q_"UMHF@V_G^7:Z7!%%#'']!T4CX\**** "BBB@ HHHH **** "BBB
M@ HHHH *_CE'[>OQI\3?%/\ X*BQ_%G_ (+%#]CN;]F?]I_]HCP'^S]\*+[X
M;?L[^*+GQ)X.\$^+/'%MX7L-,\,ZYX+?XB^-(=*;1]*\-);:)-J>MZG@(]U<
M:E*7?^QJOY_O!/\ P13L_''A/_@J#\//VIKKX9ZYH'[:?[7'Q%_:/^!'B[P$
M^LZ]XY^"\^O:_P",-9\#^*[B7Q'X5\*?V%X]\.GQ'##K&D^&=9U?1-;TBY\1
M^%+WQ!>:#K=^EX =%^S?_P %5_&OP_\ ^"5_[,?[77[;/@+QQXN^./QP\96W
MPA^'OPX^#7P]+?$W]H'QEK/C/Q1X>^'5[X7^'?FZ5INFZUXY\+>&9O%URMI+
MI/AW6T"7O@;2XAXK\'>$+CL+G_@NU^RCI_P6\;_$/6/AI^TGH'QA^'_QB\ _
ML_:_^R!KOPL-A^TN?B_\3D\0W/@;PM8>$1K4^AW47B33/!_B_5]*O6\1PSW-
MKX=N-,.G1^*=3T'PYJWS=\;_ /@EA^W'^TO_ ,$^?V:O@5^T+X\_9Q^*_P"U
M'^R1\?O#_C7PIXO\0^./C/?> OCQ\%?#NFWFEMX(^+7C*P\$^$/B7X<\7^(-
M)U*VT/7M=\.6FK:KJD'@S1]7D\<67B7Q1J^O:'X/;_\ !";X^Z)\-A\4_AEH
M7['?P7_:[\!_ME?![]ISX-^%_#'BO]HOQK\(8?!7P8CUB\\-?#;XH^/_ !]/
MJ?BKQ3JPUCQ!/>C4-%\":""='.GS>)7L/$JR^$ #T;]G3_@K1\9O&7_!0+_@
MH;J?Q7\.?'/X<?LW_LO?L):M^T._[)WQ-^'G@_PA\6/ 'BCX;>&_A9KWC-%$
M]M8ZKJ.H^*;*Z\2ZMX.GU;QG+X9UO1?%FAZO"^GV5Q:FQ_4RX_X*>_!6UMO^
M">5Y<^#/B1!;?\%'M-DU7X3S36WA.*+P':Q>$?"OC*5_B;))XI6.P$>F^++*
M%W\-MXDC2YM;TLX@2&:;\[OA/_P2Q_;?\?\ [2?_  4'_:+_ &O_ (A?LSZ!
MJ7[>?[$GCS]EV;3/@#>_$_Q%!\+]9\4^&/!7P]T"]M]#\?\ A?0(]7T?0O!O
M@ZWU+6+I?&*W6K>++B\AM-/M-,N$OH?// /_  2H_P""BGC36?\ @FMX._:8
M\2_L>/\  [_@GQ!XO\"W,/PW\7?%V;X@?%/P!XG\.V/A#^TB-4^%NF:)9ZCI
MW@[0O#7AS3M)%WH,D]W!XB\2:MK,TVIZ7IFD@'W#\%O^"VGP!^./Q1\"^&O#
M/P(_:MTWX'?%WXK/\$/@S^UQKGPAGL_V?OB/\3(YM=MXM(L=9_M5_$FE:;K%
MUHKV6@ZG?^'?.6\36%\7:;X.M?#.NW=IG^.O^"Z/[+/P[^,/Q \#^(_A;^TS
M_P *4^%?QGG_ &=_B'^V/IGPH?4OV8O"'QETXVT.N>$=:\91:RNLQ+H&H7']
ME:E=VGAV\N)+C[+J>F:=J/A;5-*\1WO@_P"Q!^P5_P %:/V2='^!G[*^D_M'
M?LP^$_V-O@?\</$WCR]\<>"]&\3>)OVA?BA\)/$'B3Q'XLN_A#JOAKQ_\.[[
MX=>'8O$NLZ_J<^O:WI&I6VN>%I]7M[WPSXCUI_#Z6^J_)_B3_@W^^*E]\>?C
M!;0>!OV,O&?P)^+'[6>I?'*S^)GQ$\;?M.Q?%?P-\%_%NO#5_%/P4M_@[X%U
M+PM\-?$>IZ2SC_A%/$5QXOTN_F\B^FU'Q38C5]+T[P> ?UHU^5G[</\ P1>_
MX)[?M^#5=;^,GP1T[PM\5-4$DC?'3X.O:?#CXLM>R_88VU'7-6T_3[OP[\0+
MQ+/3X-.M&^)_ACQO%IEB\T>D1:?,ZSI^IMO!%:P06T"E8;>&."%6=Y&6*%%C
MC5I)6>60A% +R.[N?F=F8DF:@#_.5_;>_P"#4O\ ;+^!O]K>+_V2O%GA_P#:
MU\ 6WFW2>%=EA\-_C;IEFOFSR1_\(YK>JR^#?&":?;*L7VGP]XOM/$6N77&F
M> X9)8[4?G_^R[_P5_\ ^"JG_!+3Q6/@[<>+O'*>'_ D]OI^M?LN?M6^%?$N
MK:1X;MUL<V6BV6B>*I-!^)GPOLX;:[34K/2/!/B/PCI=S/);WU_IFIP.8YO]
M6JOEW]J+]BG]E+]M3PBG@G]J/X$_#_XQ:/;07%OI%]XETDV_B[PNEW/:W%X_
M@OQ]HLVE^.?!,]])96HO[GPEXBT:>_@B%K>23VK20L ?A#^PY_P=/?L/?M$O
MHW@W]IS1M<_8[^)=_+!8_P!K>)+Q_'/P-U2]GG@L[4V_Q)TC3+#6/"37;O-?
M7Q\>^#M!\*>'+)1'=>/=39'N#_2SX,\;>#/B/X7T7QQ\//%WACQYX+\262:E
MX=\7^#-?TKQ1X7U_3I2RQW^B^(-#N[[2=4LI&5@EU8W<\#E6"R$@X_B>_;>_
MX-$O^0MXR_X)_P#QS_YZW<?P1_:%G_ZZSS6?A7XN^&=(_P!RRT31O%_@W_GF
M^M_$'_6W=?SIVFN?\%;?^")GQ36P\[X_?LBZWJ.J33C2;](]<^"'Q/O;&P@C
MNKF"TG_X2OX$_& :98ZA#;OJ5A_PE$N@33K'#>:;J40\H _UM**_B:_8@_X.
M[/#NIC2?!G_!0#X&2^&[UFCM9/C=^SY#<ZGX?<O-!!#=>*OA%XDU2?7=)@MK
M99KW6=:\(>,O%,]]=/Y6C?#[3H D(_K5_9I_; _9A_;%\&_\)[^S'\<?A[\9
MO#D4%C-J9\'ZY#/KWAHZDL[6%IXT\'WJV7B_P/J=VEM<20:1XPT+0]4>.&20
M6>Q2U 'TA1110 4444 %%%% !1110 4444 %%%% !1110 5\<_\ !0#]KFT_
M80_9!^,_[65_X$N?B9:?!_3?"^HS>!K3Q%%X3N-?'B7QWX6\$+#%X@FT;Q#%
MIILY/$RZDSMH][YZ6;6H6(SB>+[&K\8?^#A?_E#E^VM_V+/PL_\ 5]_"J@#S
M;_@D-_P7'T/_ (*P_$?XO_#W2?V;M5^!\GPF\$Z%XSFU74?BG9_$!-<36]=?
M1%T^.SMO /@]M/:V9/M)N6N;P2@^4((R/,K]YZ_@&_X,Z_\ DY3]L?\ [(=X
M#_\ 4]FK^_F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /PM\
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MXRV>MVGAZ\^'T_Q3'@H^!5U6QU6\ABU/4TUN3PQH]L)-1UC7;#38VNZ_3^@
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MQP]&7?\ [*'[.3_#WPMXO^#W[=</@?3/@1+XY^#_ (F^'>D^)O%^HZ#>:?\
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M],TS3K:.SL-/L;2!(X+6SLK6&*VM;:%$B@@C2*-%15 T*Q/\VPHHHH ****
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MT31_[+273K:&YL=)U*^GU_7-1T?PS806FV^UJWN+JP@N_P"4?XK?#L_L^?\
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MP/X=T>77Y?#?AG0KCQ)<7'B>[3PYHVE7E[K]WJ&H7EY.VK:LE]_HGT %%%%
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M#A?_ )0Y?MK?]BS\+/\ U??PJK]GJ_&'_@X7_P"4.7[:W_8L_"S_ -7W\*J
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MN;?Q#X-U7PGXAM-4U)]2NI(OS[L;Z)?%44DC-LM;5RX&"0]RLH?"\$[=UF6
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M2?\ !G7_ ,G*?MC_ /9#O ?_ *GLU?W\U_ -_P &=?\ R<I^V/\ ]D.\!_\
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MV5G#<F,DE/,*%B5!K_1)K^";_@I#(EQ^W+^TD(%5,?%#Q#;LJXVK-%>R+*Y
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M\,DB_P">I_P[=_X*(_\ 1A/[:/\ XBW\<?\ YA: /ZS_ /@J/^RE^TQ\3/\
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MU\*Z=X;L)GA@M[G5;J!&GUGQ%J4=LJ6_]L^)];N-2\1:W+"B1SZOJE[.JJ)
MH]>K^=7XG_L]?%/X0ZE;^'_&/_!2/]L&3Q0VEV6IWF@^'OBYXOU>:P6]R(X+
MB^EMM/T]9CMDECBDN(9WM%BNV@CBN[3S_(_!O[1OQ7_9!^,GPK^*'B']I/\
M: ^,?[/5_P"*++P)\>M&^.'BQO%-OX;\+>-)8]&TCXC:/%-)JSZ*/ ?B672]
M3U>72Y)=4US2IIM(CCMX);AY,^5VOY7V?EY>?X,_FVOX4<5T^'\5Q/0IX7'9
M1A,)+'RQ&%^OKVV"@X^TQ6%>*P&%IXBA3I.6(E5I5)0EAZ=2K3<U'7^H:BFJ
MRNJNC*Z.H9'4AE96 *LK D,K @@@D$$$'%.I'YH%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4
M-5TK3-<TS4-%UO3;#6-&U>RNM,U72=5L[?4-,U/3;Z![:]T_4+"[CFM;VRO+
M:62WNK2YBE@N()'BFC>-V4_SP?MP?\&RO_!//]JLZOXJ^$&BZA^QQ\5+Y+F:
M+6/@QIMA-\*+W49EMXX)=?\ @A?367ANUT^SBAD\G3OACJWPM\^XN9;K4;F_
MDPI_HNHH _RT_P!L#_@@1_P4^_X)_P"MGXF>#?!^K_&SP1X2O/[=T7XV?LL7
MGB36O$?A,6$MW=6NKZWX-T^UTWXJ>"K_ $JPLQJNL:_IFC:OX.\/!P/^$YN&
MC:6O;/V'_P#@Z _;^_9?_LKPC\>GTO\ ;+^%^GK':O:_$_49_#WQETZT@BO
ML6E?&C3-/U._U:XFO+F*YU*]^)_A?XDZM=0V<6GV&IZ-$QF7_3 K\LOVW_\
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M@W#"8=;)4:";C%VT=27/6FOCJ284444SP@HHHH **** "BBB@ HHHH ****
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M'XD\52Z_XGT_3Y](TJ/P[H%Q!K6LM>74(T[3)H[VZ,=NZN?ZZ*_FH_X*#_\
M!4+]JS]G+_@L+^QC^Q=\,]7\$VOP/^-VL?LLV7CNPUCP99:MXCN(/BS\?-<^
M'GC :9XAFN([C3FF\-V%O%8-%$_V&[#W<>YV*U_2O0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R65(8I)I6VQQ1
MO+(V"VU(U+.V%!8X4$X4$GH 3Q7X!_L1ZS;?M5?M _M$?\%,?'\5S<_#W0%U
M?P_\%=,GB^T7&@?"SX:S:M:>%].M[*X,_P#9^M:I>V&N?$#Q5H\5Z8K3QEJ.
MAWMJ\<5PZ+^_]?S\Z)H;_L0?MW?'']F1D.E?L\?M^>#O&GC[X*[8A!H_AOXI
MZAIE]8^-_ MAY=K;6T)LM9U!KS3=(LYK/2?#_A'Q%H'VB=[IV8!];P95H1S>
MI0J)QKX[!5L!A*T9\DZ#Q56A3S#V+2DWB\5DO]J9?@>6$YK'8S#.FE44)P\R
M\>>,M7^(7C'Q'XUUV3?JGB/5+C49T#O)%:QR$)9Z?;-(6D^QZ991V^GV2NQ9
M+2UA0DE<UYKXG\.:1XP\.:YX5U^V%YHOB+2K[1M4MB=C2V6HVTEK.(Y "T,Z
MI(7MYTQ);SK'-$RR1JPW:\K^-/Q)A^%'PX\1>,!;G4-6@@CTWPMHR1O<7&N^
M+=7D6P\/:1;VD+K=79N-1FBDNX;,/=+IT%[<0QN8"*WT2\DOP/\ 2W&O*<FR
M/$O%PP^&R/+,KJQKTI03PU'+,)A7&=%TW=2I0PT'35*SYHI02;=G^P?_  22
M^/NK_$_]GG5O@QXWU(ZO\3/V3O$W_"D_$.M#][%XG\(:;;&3X7^*!<0K);+=
M7/A.!/#VJ64]]>:Y'JOAB]U'71;W.JQ(_P"J-?#_ /P3Q_9=F_9-_9?\%^ ?
M$)%U\4O%4][\3_C;K+RI<76K_%CQPMO?^)%N;N*>>WO1X=MXM-\'VM_:M'!J
M5GX=M]4,*7%]<%ON"L#_ "NQD\-4QF*J8*C4P^#GB:\\)0JU/:U:&&E5E*A1
MJ5;+VE2G2<(3J67/*+E97L%%%%!S!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^:W_!
M1#_@E9^S+_P4XM?A+I_[1]]\2++3_@]J^OZQH=M\-=9\*>&;C79/$4>D07=A
MXDUO5O!/B7Q(^DV\&E21VNG>']9\/0-)JE]=WHO+^#1KK2?TIHH _!GX-?\
M!M]_P3&^!/Q*\)?%OP%X5^-]EXZ\!ZQI_B/P;K8^/?C_ $J[\.>(]*O;>^TW
M7-/N_"M[X=U#[9:2VYC^SW-[<:9=6UQ<V]_87<4@5?WFHHH *_&'_@X7_P"4
M.7[:W_8L_"S_ -7W\*J_9ZOQA_X.%_\ E#E^VM_V+/PL_P#5]_"J@#^:3_@S
MK_Y.4_;'_P"R'> __4]FK^_FOX!O^#.O_DY3]L?_ +(=X#_]3V:O[^: "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "OB']N/]A;X8_MP_#RR\->+;JX\*^./"K7]W\//B+IEI
M%>ZAX;O-0BA2]L-0T^66W36_#.JM:V;:MHYN[&>22SMKFPU'3[N$3-]O44'1
MA,7B<#B:.,P=:IA\3AYJI1K4I<LZ<ULT]FFFU*+3C*+<9)Q;3_AW^.?_  2F
M_;?^!5]<+!\*=2^,/AI;K[/I_B;X.6][X\-Y&^6B:;PGIUNOCG3V" "Y:[\-
M_8(9LQQ:E=+ME;!^"/\ P2\_;>^.VN1:6OP7\4?"S0H[F&/5?$_QFTC5OAMI
M>G12C>T\6D^(+"W\5ZX57(":!H&J()ML=S+:J6F7^Z:OYZ;[_@KC\=U^!/\
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M?[#=A[N/<[%:_I7H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+J_:'^Q]?@MY;R73=3,?QX^'VJ?LQ?\ !3O_ (*!?&C]I3_@FS\9OV]OA?\
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MUF:2#3-;NY[ VVOV:Q7T=O+<)=6Z26LW\@O_ !%>?\%$?^B,_L7?^&[^./\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEK*WKU\N]]NH44458@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYCU33?%VO^)!*8[2#4KK68[ZZO;.-20B2:K>7C6=I;IEI)[J&WA5Y'13G?\
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ME2"]U&,?:U?%'[3>IWVHZ[\$?%VI3O=ZBW[3_P .M7UB]D&Z2X.L7^L#5)W
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MAVZL97@NX(_A=XUT1O \D:7%AJ5CJN@W5OS:/>13>EX#_2F\0,X\"_%+C+Q
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MY_34?\$IO@9X'TE-2^(_Q8FM+A%#RO<:K;Z>A9 #+$&62,R1-M();.[)!^Z
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M_P##NRD@\W7Y=.\6W-K?:=#H=Y802#6;#Q#IVJ:%Y"M?/:0WMM;WUOPWP?\
MAIX-^#G[7'B3P?\ #;2I?"_A75O@YJU_J&@6^IZI>Z?=:CX?UGX5+I6HS+JE
M[?3RW]JGBO7XDNI9GE\O4KA-P#MGU3]M33[O5?V9OBK8V<K1,?#UQJ$^V66$
MR6F@@^(KF(O#B3:\6DD-%D17 !M[G=;2S(W1E/"O"^09-+AW(N&\@R7A^<,1
M3GD64Y/EV79-*&+3CBH2RS!X>C@I0Q,92CB(N@U63:J*2;,L;G&;YECEFF8Y
MIF./S)2I268XW'8G%8Y2H-.C)8NO5J8A2HM)TFJEZ;2<+61^37['/_!/?]F7
MX_ZA<_$+XH^-/'OQ;B^%WC>;1=(^#GB+QU;7_P -->TGP_;VC^%/'?C_ ,&B
MP&L>);_5[B6YF<W^J6WA;6VT^>QU+0M3M9-5M;G]1_VO/V,/V??VL/"FEM\8
M8]7\(ZK\.X[W5?"?Q?\  WB&W\#^/?AQ9B)9M:ETKQ7<6E[IMMHEQ96S'5+#
M7].U/0TBC&H?9(+ZUMKZWX+P_P##_P $?"S]J[X'Z/\ #KPSHWA"QU[X(^/&
MUVWT2TCMGUC[-+X;>VDU6?YKJ^=)K"&=9;J65VNEGN69KBXNI)?=OVNM..J_
MLS_&NV$T\'E> ]8U'?;3&"1AHZQZN86<!MT%P+$P74.,7-K+-;DJ)2PZ,#D&
M0Y9EU;*,MR3*,ORG$>W]OE>!RW!X3+JWUJ/+BO;8+#T:>&J?68MQK\]*7MHN
MU3F6AGB,RS'%XF&-Q>/QN)QE/V?L\7B,57K8FG[%WH\E>I4E5C[)ZT^6:Y'K
M&S/Q[_8S_8"_9J_:!U+5?'/Q1\9>/OBK!\*O')\/Z5\&]?\ 'L-]\-?%6A:!
M::=>>$?B!\1/!?V$:QXFO-6U&:\S]NU2V\(Z[-H4]GJ6A:I%_:]K<?IE^V1^
MQ-^SM^U)H.E>(_BW>:Y\-O$GPUL;R?P]\;?A_P");'P'XW\%^'PDL^JZ=)XD
MOK'4-(F\*S1-<27FFZ_IU]86:S7EQIYTZYN[JYEXFT\ >"/A3^U;^S;I/PY\
M-Z1X-L_$7P]\=1:];Z%;K9OKT$/A6[NE76)E)N=52*]T72KY3?2W'EZA"U\I
M6\O+N:X]&_;XL]4U/]F[Q9I6ERLGVR=+S48U9D%QI?AG3-6\97<3LBE]L9\.
M1W04%5D>V2.9O(>53."X=X?R[+<1DV7Y%DV RC%_6/K658++,%A<MQ/UN"IX
MKZQ@:%"GA:WUFFE3Q'M*4O;02C4YHZ#KYGF6*Q5/'8G,,=B,;1]G['&5\7B*
MN*I>QES4?9XBI4E5I^RE[U/EFN26L;/4_,_]BK_@GQ^S3\=TTWXR?%;Q/XU^
M+>I>!_%+V]K\%?$WC6WU;X464N@I'#X:\3>*O KV<FJZ[J.HHDU\R>(-7F\.
M:TIN;>_T/4;=[Z.?]%?VSOV'OV</VI=-TWQS\7+WQ%\-?&'PUTF^;2?CI\.O
M$EIX'\>^&?"T0NK_ %+1K[Q#>:?JFF:EX45Y[V\.FZ]IFH0Z9+>ZK-HLFES:
MSJ\E]K>'OAK\/?A5^U;X)TGX<>%=$\'6FL_ ?X@/K5EH=NMJNH_V;XO^'4&F
MW%^@9FGFB"3;;J;=-/,UU-+++/+<.]G]O+3I=7_9XUW2T+M#=:YH<U[ MQ+;
M)<V6E27&MSQ3-"\9D1/[,2YCA8E7N((2!O5"*PG#^08#+*N2X#(\HP63XB->
M-?*<)EN"PV65HXI..*C5P%&A#"U(XE-JNITI*LFU44DV*MF68XG%PQ^(Q^-K
MXZFZ3IXRMBJ]7%TW1:=%PQ$ZDJT'2:3I.,TZ;2Y+61^:W["W[!'[.'QM&D?'
MWXI:UXQ^*/BGP9XH/V'X.^)O&L6L?"CPQJ>C1VZ>'/$^H^ 6M6U"_P!9NHX[
MFYC/B/5K[0-1+3R/HEQ*DLQ_?.OC+PU\/O GPR_:C\)Z5\/?#6C>#[+5_A%\
M2(M8T[0+=+"UOX=%UCX0/HTM[9PL(I9K6?4M7DAO)(S<RSWNH2232RSSLWV;
M6^693E6282&7Y-EF7Y1@*<ISA@LLP6&P&$A.I+FJ3AAL)2I48RJ2]Z<E!.4M
M9-LSQ>-QF/K2Q..Q>)QN(DHQEB,77JXFM*,%:,95:TYS:BM(IR:2T5D%%%,=
MRHX5G/'"XR1G!QD@$@<D9Z5W-NZ27SZ;]_OO]YS"LP&,$9SR.,XY[?YYJJ\\
MBDX5L=L*2?I@ G\?0$CI6'XE\6^'?"6E7FM^)=8TS0]*LHI)[C4=1NXK:TA@
MCX9WED91E>^T.HZ9.:_#O]KS_@NE\"?@I->>%?@UI=S\:_&T9FM5?1KE+/PW
M9785@CW.JR))O5"KMMC@8,0JA@3QZN79/F.:U84<#A*N(E)I7BK0CJM93;48
MK6UV]+ZV/,S'.,ORFC*OCL1"C3BKZIR;UVC"*E*3\E%G[MRWVSY0&#*N9&=&
M6%,<Y:5@JCCKDC'7IS7F/B_X\_!_X?6T]UXW^)O@/P[';*6G&I^*]"LY8\#)
M4P3WZ2D@=<)G)Q7\/OQ6_P""E/[?_P"TSJ$J6_BS5/!6@W4\J_\ ",?#BSN[
M[58+>4D01S7&+-"^Q@N\3D D$CK7A6D_LB?M@_&/5S)/\+/C)XPGOP'36O&5
M_P"1:7TC ?/*YN',()P"-LAQSCFOTS!>%?)35?/^(\ER6G*SC1J8NC5KR5KS
MO&$Y.#@^56;][FVT;?Y]B_$B-2:ADF3YMFLI.2=2G@\1"A"SCR7<H)OG3D[[
M)1WN[/\ M-U;_@J=^PAHUU)97O[1/@1+E&9"L%^UXNY6P</;12HPX.&5F4Y!
M!((K.L_^"KG[!UW-Y,7[1?@?.X*?/DOK= 3QGS9+18L9QR6P.^#7\G'@W_@C
M]^V_K4[)>_ KPWH(9F$5[>>*HIF\MB0CE1:LX8J 2&7*DD$9KN]:_P""*G[9
M^E1AXOA]X.UJ5UW"&W\2+ V2,[7=K$9 )P!M&!W-=4N!. TU&/'.#E)M1NFG
M%RTTORM*[OT:\R(<8\5-<]3AC%P32M'V-;F4F[I-=K*S=DT]]S^Q/P;^UU^S
MA\0+>&Y\)?&KX;ZM%/M\O9XNT*&5RXRH6">^CER<$X* ],]>/=-/\2Z/JT23
M:9J6GZC"_P!V:PO[2]C=<9#*UK-+D$8.1\OOD@'_ #Z/'/\ P3D_;(^%<<FH
M>(O@3XFL8(7+1WG@;Q ^I21[.#(T42P[-O!7;U&[!XQ7F>@?&W]IOX*WSZ;H
MGQE^*GP_U.R81)I7BIKV"WB *L8@&E=)!E$4 G. 3@BJH>%.3YM5G1R'C'+<
M9BDO]WJ55!7T:M-M13?1WMOL95O$K'9:N;.>'L?A:2M*52.'J248W2;?NMM*
M^OY'^CSYXVAQN()(!VD >@RV <<G/3MV-/$HV;F(4YXW$<]^BD\XX[<BOX8O
MAG_P6;_;W^%\-O#J5_X2^*>C+LC\N^\VWOY=F TJW$<4^'< ??PI/5L\C[W^
M'?\ P<9R1QQV?Q:_9Y\0:=<6RJMWJ>@:O:7\!< !G6T98)!GD@$Y&<8KPLZ\
M(.-\E7M:N73QF$?\.O@''$J:=K/]USS:?WV[N]O4RKQ6X+S6?L*.9PHXM6<Z
M.*52CRNZNG[11BEKT;^YG]5*N&[$<9YI]?SY:=_P<0?LE.8%O_#'Q%LI)"HE
M0:$LPBR<$[A=+N ]0 !_+T=?^"_O["SQ*TM[\0X9"H,B'P?=-L<CYEW+.5;;
MR,J6!ZU\K_J;Q5&R>0YJV_\ J"KM_A#;KJ?2QXNX:E?_ (7,LBUT>,H+JEUF
MNK/W%R/4?F*,\^V#GCCMCGIW/>OPT/\ P7^_87V3O%=_$.0PIO"#P?.I8_PJ
M"]R@Y/J?7L*\&\8?\'&OP(L6F_X0WX1?$3Q/&#(MO)+%;:9YQ4J$8I)/+A6/
M/&2.,CG-:4N".+:M2%-</YK&4TN1SPE:$97M9MN/77?;J17XQX8H0=2>>Y;R
M0NY..)I2T5KVM)[*^U[KY']'LD@'4@G/"@C'U)!R!UR2,#V[?+'[5?[6_P *
M/V4OAAXC^(/Q)\1Z=I:Z=IM[-I6CO=P'6-9OX86,%GI]BKF>=YY"JJZKL&22
MP"DU_+?\7/\ @OY^U5\0?[1T_P"$7PJT+X::7-F.#6/$FI"_U"%&##_CW@M@
M/,8$,,X V9+<BOR<^)?Q1^+GQT\0/XQ^./Q!U7Q]K,\RR6VG2NZ:-IXSE8H+
M,RO&(D)/1$R.@/-?J'!_@1Q/F>-ISSW#3R_!0=*K.+M[2K%23<5;576C=MM%
M;<_-^*_&KAS+L%)9'B:6:8N:J4XRI2;HTIV2O)M*[3L^W?30;\2_B]XO^/'Q
MI\:_M":Y=ZII/BCQ;XBN/$7AV6-Y4U3PW8I=$Z:+=8G\Z.=+=(?+\L!P0"!N
MZ?J=\%/^"UO[7_P'\,6?A?QSX(N?BSIUM8*NEZ[J,4EIK"Q1JJH=0EU'[.LH
M"@$L69NI'J?RO^'^HZ;HWCOP5J^L0QW,46O:-)J<$J*+9K7S[?=%(F&41QI@
M8&0P!S@'C^G;4/$O[#?CS1M(\)>)]1\%0O<:;"(8XXX(98Y6C0%?/4*P^8XR
M00&!R,8K]VXXX:X7P\<MH8KAO&YE1AAXT'4PM!NI2CAU':RO)/G5HJ4-I7;:
MU_(.#N+.*\?]:JOB#"X&I[>=6$*U=-6KN\(-\R45+D=TN;6S]/R9_:%_X+.?
MM<_M">'+SP]X;&F?!7PEJ,,UG?RZ3>0MX@OO.7RYH;=[>9KAG=6*@P?=)X.!
MFO;_ /@D]^Q]K&I^)F^-_B[3M2^URW<DVAW&JQS&^\0:I>;'N-7N9)@TKM"C
M*$>3^&1@#C-?7'B_]F__ ()[^&]/L==U;5_#D5OI$L>HVR07MM<33^60RQ[
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MCL;"VN;Z\>WM)%M;.WGN9RD,4CK_ )W?_#!W[<?_ $9E^U=_XCM\7O\ YCZ
M/Z\O^"H_[*7[3'Q,_P""\?\ P3_^.'P\^ GQ;\;?!SP)KW[&,_C3XH>%_ ?B
M/6_ GA6'P?\ M->(_$GBJ77_ !/I^GSZ1I4?AW0+B#6M9:\NH1IVF31WMT8[
M=U<_UT5_-1_P4'_X*A?M6?LY?\%A?V,?V+OAGJ_@FU^!_P ;M8_99LO'=AK'
M@RRU;Q'<0?%GX^:Y\//& TSQ#-<1W&G--X;L+>*P:*)_L-V'NX]SL5K^E>@
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M7II%ZWA>U^#'B_3+C71"W]FPZIJ'B;P2;/2WNB!'_:$\.F7MREJI:7[+ TY
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MC.>:^@[72;*QCCALK#3K2&%=L:6]I'$%'8 (HX'J23Z@YK5^S1\<#CIG)_\
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M?\1]3TLZI\2].L_!GA[0M @>TTRPT/PA?26-]<SVLYNIXI9=4TX)8QG4;B0
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M/@=^S=H7AOX>ZCXG\0>!=0G\/?%SQ_\ $#Q/X4TWQIXA\$MXXTZ^6Z\)^'?
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M?VC1M0U;3M1]%^.O[>OQ/_;X\3:S;_!WXD_$#X*?LI>$-3TW3]+@\"W=_P"
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M7X&MOB-I\-[ K6S'0OB1X6\=V6G1,X;_ (1K^Q-0"PQ:M:0M_6/T+L3XA5^
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MPS^T?':>&[C]IWPAI?QR\&WT\MW::;IWBK599$\:?"_7[K5TM%MOB-X>CO\
MP[/JVEP?:8@MU!$M_<7$UK"_E\$YSX_93]$_Q(XJX6\5L\\1JN;<-\)9SAL7
M2Q&=X_BGPYQU;B'%X+C?(,MS7'UL7CJV-P?#U+#XW,98>IAY9+!U,QRVA1]O
MALTQ_9G^!\-\9XR<+Y1F_!^ X7C@LUSG U:,Z6 P^4<48>&64*^09CBL'AH4
M</3H5\RG4H895(5(X^2CA<54J>SK83#=Q=^ ]:\$ZMH/Q.^ 7B?7?A/\:?AS
MHIT_X>>*_#VIRFU6QLK>;[+X-\0Z-JZZKH6M^#M2D9;?4M)U/2[NVFCV_:(K
MJU6>RN>H^)G[9?Q$_P""G<-E;^+9]9\!_L\>$?#?@+3?$_P?\-:JVF:+\3/C
M1;:7!X@\:ZWXGOK39XDO/!F@:U>6-OX/\+7NLW%F/[*T3Q)(8=<CO0WVQK7[
M7_[.'PB_89\8> /$GA:SUSXRZJFM6'@KP[;:-:W.L>//&6NWMX?!6M:5J%ND
M]]/>Z&=3M-.C6".;4(8+9(X+6;3+F[EC_,_PK\"/B'^P5XFTGX&_M"-IN@W_
M ,6O"'ACXQ>"M;:^5M$N?$&KZ1IVC_$'X<W6LRE-)D\:>"]=L;6QNK'3;R_3
M4+*:RU:"Y>UU32Q<=7#.<>/N3?1&\0>).%O%7//$>KFF3\ 9Y@<XP=;.,=Q5
MP%5S/'YG2\2.%\)FN-Q.-S"MC<@P-+(YXROA:M*>44\9F6.P6'PEJ>/ECFN!
M\.,=XT\-Y5G'!^7\+0PF.XDR_$8&M#!8?*.(X83#X.?"N;5\'0I8?#4\/F5>
M>81H4ZT)QQLZ&$P]>I6][#KL)O FN> M:TGXI?L^^*O$'PC^-7@3P\-'\"^*
M?#NJS&QETO3XGDLO!/B70M875O#^N>#+ZX6%;_2-3TFZM9'6*>XBNHXI+:?^
MIK]CK]H2T_:J_9D^#?Q^M;&+2Y_B)X22\US2[<2"STOQ=HFH7_A?QKINGF>6
M:>33-/\ %^AZW::9-<2-<SZ?#;37 29Y$7\:-;_;!_9L^$W[#OB?X<:[X4MM
M>^-VL1ZQI?@OPM9:);7FN>/_ !SK^I7P\$:UHUY:)<ZE<WNBC5M.TU%BAEU"
M%(%@MK272KFXD3]9/^"?7[/FM?LN?L=_ [X*^*6A;QAX:\-7NK>,Q \<Z6_B
M_P ;>(-8\<>(],^UQ2S1WXT35?$5SH<>H12M#>PZ;%<0!()(HT_IKZ#T>.I\
M!XK,.)?%#%>*.09[DW"6?9/B\?5S3&X_A/B',*>>+B[@K$9GFN(Q>(QM3)HT
M,AE6A&M2HX;%8JO['"4Z5>-;$?E'C^^'H\14<-E7"5'A',<OQV=9=CJ.&AA*
M&'SG+,-++WDN?4L)@Z5"EAXXYU,R4).$YUJ5&G[2M*=-PI_9-%%%?V^?@(44
M44 %%%% !1110 4444 %%%% !1110 4444 %&.,=/IQ110*WDAI4]F;/N::5
M;CDD\]^GYGO4E%'_  ?QM^5OQ!*U]6_5WMZ$:Q@#! (R&QCHWK_GBN(\>^"?
M#?Q&\-:WX-\5:7::SHFNV%S8WME>0)/;O#<HT;DI(-A<J<HV<@CJ!FN[JE<Q
MC!S]PX)]=PSC!!7@<=3Z]>E53J5:,E4I2<*L9*5.49.+C*+334EK=6O?OY"E
M"$E::3CM)-)J2>Z?D^O97/X4O^"GO_!-?7_V3O%]]KNB6-WX@_9]\3W-[>Z5
M>V\9GE\$ZE=NCW5C>#&8;9BT36I5BI"R?=(./P.\=?#O4/!EXLB*VHZ'=Q17
M-KJ-LWF6HCEPR9 Y249VD-@AAC%?ZJGQ*^&'@KXN^#]8\#>/-#L-?\-:W;36
M]Y97422L&EC,8GA\PMMG0'<C #!4<=#7\8'_  4*_P""5_Q%_9>U_6O$'@#2
MKWXE_L^:W>7.HBXM[9Y?$W@@7<C2-976GA?*OK"Q=BJ3Q3P-Y 7,!<$'^H_#
M/Q.P_$& APKQ+.%'$T8^SPV-J)*=:]N6,IR=G)7T6[L^78_FWQ!\.Z^28C%\
M1<-TW7CC:OM\7A.9^SH2:5YQC"/-&-^RLGJ]&K?S-36D=T8+V&:6*]M9"]E?
MVS>7=PMDC:)%PV#DAMP..?6NKLO'7Q+TF,1*=/U^WPNPO/;_ &L $$>=+<F
M@C&#N)'U'->R>*_@U+(SWOA6YA$,1=I;"59K:Y#-_J5DBE19$FE;:HA( #L%
M:<9W#R/4O#'B733Y4NB7:(#ABBA1*0<YW$D'MP"2>M??YKP-AL9*$Z5&&+A5
MLXRPTE-M.UG*R<;Z:W3OTV1OP?XY\7^'> 639-FV.IX>?OU,%C)4I49U79RC
M&4J4:D(7^'632\M22?XK?$:<&.'PUINDNPQY[W=C*1C@MF":8Y/I@G/'TY2:
M#Q/XXU73],U_6S+-J5XD-MI\<LRZ2D\OR1+</)#%;QNS#F9G**,;F!S706GA
MCQ)>;4CT"]+NQ5&!+Q D\%W;RB!SSA3^/6O4_"WP7UV]FBGUBYBTQ(&\Q[>!
MI!N+#A9;AT&UP"'C\@389LD]0>?+O#O#4JBQ#PT\+R-7GC)IT4DTFY<T8+IL
M[][-ZGN<3_27\3,\RV.$SG/)TL#6A*$\-D\*;Q>+E)))33IU'22;Z)WUO9'"
M^(/A=XL\+>)9? UYIT,.LVT5E]ICL+BVO[.&"ZL[>>*:*[LI)8&:2.5&<;\J
MQPP4U],_#7X,6UK-IT$EG/JFNW"P6]II]M;-?2232/B+RK>)3(9GD(!8#*-D
MD@$@_6/[._[)OQ5^.'B*P\+_  J\+ZGKVH9MX+W7M:6YCTRU552/=>ZP;6:;
MR88!&T;I:2$@[ JXR?ZY/V&_^"6/PX_9OT[1_%GQ 6Q\=?$YK6&XEDGLE;1M
M&NI/WKIIPN&DGO/+9C&MQ-#;,V XA3)49<5^(G#G .&^KT)8?-<Z<7"%/"<L
MJ.&K.*Y:C<97@HIQ;@DUI;2Y^<</\#\0\>^UQ&/@\+D^)J1G7Q6.G5698BDI
M)J#4%3I57)JSJ*--:6<96L?GM_P3V_X)$7>KKH?Q9_:'T_[#8HEM=Z%X%NE6
M6YFBVJ\,VJ+]P(?E=H&;<.%8#&*_IM\,^'-)\+Z)8:)H=A::9ING1);VMI:1
M)%!# B"-0B1@ '9P /I[UJ6=FD$:1JB(D:>6BH  B #"J!A54#@ #H,# J\J
M*H(48![#_P"O7\E<1\3YMQ3C:F.S;%5,14D[TTWRPIPYG*-.--6BE"[LW>3O
MJS^FN'N'LNX:RZAEV64(4,/1BH\J3<Y-0A#GG4E>4I24([NR2TZ69&B*,+C
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MWB;48M.^,_@34-0DL=!\/V6H:K=QV-A;7-]>/;VDBVMG;SW,Y2&*1U_SN_\
MA@[]N/\ Z,R_:N_\1V^+W_S'T ?UY?\ !4?]E+]ICXF?\%X_^"?_ ,</AY\!
M/BWXV^#G@37OV,9_&GQ0\+^ _$>M^!/"L/@_]IKQ'XD\52Z_XGT_3Y](TJ/P
M[H%Q!K6LM>74(T[3)H[VZ,=NZN?ZZ*_FE_X*;?\ !4?]J?\ 9!_X*L?L9_LO
M^!-;\"V?[/?QJLOV=-7^(<'B'P?87&K_ &+QW^T)XQ^''CZ"R\8WETO]E?\
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M_@-XYTGXF>$/A+/KGCWPY>_;?"OB7XA^,/%_Q F\*/"Z-IG_  CVE^)M9OM
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MN7*[ERH9201V=[\!/^"J<@4:?^PKI=I\F':[_:&^!%^Y;: 70Q?$;3T7Y]S
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MJ.M6O@?PGX9T#7=9F\3V_@31=+N8M-T?5%U2>&'^D&@ HHHH **** "BBB@
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M;<7FJQZ;XG\1:HD)O_#VG:)//J^JV1DCETBQU:PU;2M._E=_:I\7?%SX,_\
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MX\0_%3P7K*V>AZ;:^$Y_&.KZ?XH@\,V<G@F35TT;X5Z)XC /VG\=_P#!8_\
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M_9/_ &>/!_PI_P"&6OV"-#^(WBG]K+6-,^#^A1W,G[1/[4GB'P+J?B[P=/\
M!_78-,TCQ#X/T%])UU-(T2+P/HS1:OH.@ZYXF /WE^+_ /P6G_9J^&O_  4"
M^ 7["VFZII6O?\++70)/'_Q>MKO5=2\*>%-2^*'@9?$?P'\&>%(M T;4T\8Z
MO\4KWQ+\.=23Q;8W[^"="\,^*K!IM0O+R[U6;PE]I^+O^"@_[$O@+X\:9^S'
MXQ_:<^$7AWXZZM/!8V_P^U/Q5:P7]KJ]XUHNF^'=:U3#>'_#OBK6#J%C_8?A
M/Q!J^F>)-<6\M6TC2KU9XBW\ROP[^$?Q$^#7[9O_  1 ^/?CW]C_ /:"\0^
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M][IT'P6^'_A>'P=<:;\1?".D:A>:7K%CKLU[X;UNTTWP]K<^M:);@^&](U0
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M &]H7F^/K'S_  K'_;6D[]6']HV?G ']R=%%% !1110 4444 %%%% !1110
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MK]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P ,QH<7AOP[\-H=4LO#NN_";3;ZUT3QAX9U2SU?48=,_L&[\%WVG@'Y:?\
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M5X<UJ\FGLO"WAO6+S1C%IWBS0IA%K,%C+(UV\4:-+;7*1?%__$1G_P $D/\
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MOZ?INE>'-:O)I[+PMX;UB\T8Q:=XLT*81:S!8RR-=O%&C2VURD7Q?_Q$9_\
M!)#_ *.,\1_^&+^.7_SOJ /W%HKX*_:C_P""F/[''[&G@WX.^/OVA/B9J?@W
MPO\ 'K3+_5_A??V7@#Q]XJDU_3]-TKPYK5Y-/9>%O#>L7FC&+3O%FA3"+68+
M&61KMXHT:6VN4B^+_P#B(S_X)(?]'&>(_P#PQ?QR_P#G?4 ?N+17P5^U'_P4
MQ_8X_8T\&_!WQ]^T)\3-3\&^%_CUIE_J_P +[^R\ >/O%4FOZ?INE>'-:O)I
M[+PMX;UB\T8Q:=XLT*81:S!8RR-=O%&C2VURD7Q?_P 1&?\ P20_Z.,\1_\
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M>:,8M.\6:%,(M9@L99&NWBC1I;:Y2+XO_P"(C/\ X)(?]'&>(_\ PQ?QR_\
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M7]/TW2O#FM7DT]EX6\-ZQ>:,8M.\6:%,(M9@L99&NWBC1I;:Y2+XO_XB,_\
M@DA_T<9XC_\ #%_'+_YWU '[BT5\%?M1_P#!3']CC]C3P;\'?'W[0GQ,U/P;
MX7^/6F7^K_"^_LO 'C[Q5)K^GZ;I7AS6KR:>R\+>&]8O-&,6G>+-"F$6LP6,
MLC7;Q1HTMM<I%\7_ /$1G_P20_Z.,\1_^&+^.7_SOJ /W%HKX*_:C_X*8_L<
M?L:>#?@[X^_:$^)FI^#?"_QZTR_U?X7W]EX \?>*I-?T_3=*\.:U>33V7A;P
MWK%YHQBT[Q9H4PBUF"QED:[>*-&EMKE(OB__ (B,_P#@DA_T<9XC_P##%_'+
M_P"=]0!^XM%?!7[4?_!3']CC]C3P;\'?'W[0GQ,U/P;X7^/6F7^K_"^_LO '
MC[Q5)K^GZ;I7AS6KR:>R\+>&]8O-&,6G>+-"F$6LP6,LC7;Q1HTMM<I%\7_\
M1&?_  20_P"CC/$?_AB_CE_\[Z@#]Q:*^"OVH_\ @IC^QQ^QIX-^#OC[]H3X
MF:GX-\+_ !ZTR_U?X7W]EX \?>*I-?T_3=*\.:U>33V7A;PWK%YHQBT[Q9H4
MPBUF"QED:[>*-&EMKE(OB_\ XB,_^"2'_1QGB/\ \,7\<O\ YWU '[BT5\%?
MM1_\%,?V./V-/!OP=\??M"?$S4_!OA?X]:9?ZO\ "^_LO 'C[Q5)K^GZ;I7A
MS6KR:>R\+>&]8O-&,6G>+-"F$6LP6,LC7;Q1HTMM<I%\7_\ $1G_ ,$D/^CC
M/$?_ (8OXY?_ #OJ /W%HKX*_:C_ ."F/[''[&G@WX.^/OVA/B9J?@WPO\>M
M,O\ 5_A??V7@#Q]XJDU_3]-TKPYK5Y-/9>%O#>L7FC&+3O%FA3"+68+&61KM
MXHT:6VN4B^+_ /B(S_X)(?\ 1QGB/_PQ?QR_^=]0!^XM%?!7[4?_  4Q_8X_
M8T\&_!WQ]^T)\3-3\&^%_CUIE_J_POO[+P!X^\52:_I^FZ5X<UJ\FGLO"WAO
M6+S1C%IWBS0IA%K,%C+(UV\4:-+;7*1?%_\ Q$9_\$D/^CC/$?\ X8OXY?\
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M]EX6\-ZQ>:,8M.\6:%,(M9@L99&NWBC1I;:Y2+XO_P"(C/\ X)(?]'&>(_\
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MV6?!^AO8SPWL%IKGA:PLYOVB?&OA*]>T2.?3_$&B^/-)U.TN)+:Y6;3[UTD
M/ZDOVS/^"E'[&W[!>A3:A^T1\8M#T7Q2]@;[0_A1X:9/%7Q<\3J\%S-9#2O
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MIUKX#T#0+GPYH^J0_L+110 4444 %%%% !1110 4444 %%%% !1110 5X?\
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M>:O/']@\Z*6.>ZO9;CX__P"(>?\ X(^_]&A_^9^_:@_^?77[144 ?#O[2_\
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M>!?'7AG4M;\[3?"N@VWF^([S5YX_L'G12QSW5[+<?'__ !#S_P#!'W_HT/\
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M_/KK]HJ* /AW]I?_ ()N_L7?M@^$?A)X$_:+^#/_  L3PK\"]-OM)^%>E?\
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M*B@#X=_:7_X)N_L7?M@^$?A)X$_:+^#/_"Q/"OP+TV^TGX5Z5_PL3XK^$O\
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M3X(?P[\3+R[M=<N(]0UR#0/A[JFMZQ9Z-?>.+G2-,GET6ZTPZ;9WEPNF"R,
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MR2: ;_/\I)?C<^M/AA\;O^%E>&?AOXCM_ GBFUM_B)>>.+1[K3A::SH7@_\
MX0O5=8TP3>*M9>32IK./Q ^D.FC&VTJZ$M]+]@F,96.>?W6ORI^#EC;ZQI'[
M#V@WXDETK7+[]KW2]4M%EDB2[LKR#QQ;SPR>6RDYBED"M]Z-FW(58 UT_P /
M-:UWQCK'P@_9KUNZU"?5?@)\0_%6L_$6_B:2UNK[PG\'VMD^%=S]C6-FO=$\
M47'B3PU:^0WFW%Y'H<UUAFD5Z 4N_E][4?+SO\F?I?17Y3Z9KFC?V[^SI\3O
MAMX1T;P'IWCOXU6GAQ=;G^*&L^)?BQX[\,Z]?:Q9>)(_B#HDEC<6U_IK7VGP
MD2ZKXR\2WGAG4(-/L;6&T34)%ALWGPS\-^(_!?[8OQ1U6?Q))XQ^'/Q@^,=Y
MX O[7Q5XATVW\':GX?TG1-?MM8T*PTW4;2TM]6NKV2VCO[Z6*>:6TTW3K>$V
MZP.90.9O9?CY)]O/L?J?7CWA_P"./@GQ+\6/%GP<TT:M_P )/X0L/MU[?S6M
MJOAW4&ABT674]/T?4HK^::ZU31/^$@TN/6+*:RM9+26=E4RB&5EU9?'%MX4^
M$"?$3Q),]Q#HGP]M_%6K2%XHI[Z6U\/QZC/%$6"Q_;-0N 8+:,+^\NIXXHT+
M.JG\^+"'QO\ #/P-\'?C7XF^'?B+2=;\-_$C5OB-\5?&EU?>%!I^I^&_CA?)
MIOB]F\/Z?XFN_$@O;6QOO"<=I;7FB0-I\FA-+=P61C?RP&]FMGJ[]M/T=_D?
MJG17Y_7/PG\%_%_]H7]J"#QRFL:QI7AS0O@]>:+I-KXCUK2]'BU/5/ VLF/7
MI+32+ZSCO-4TV.Q9-'N+EIH+-=0U%UMY)+A)(LG2?$VF>,OA=^RGX?\ &OA:
M/XK^./&OAOQ+J.CQ^/\ QMJ'A_P-*?#.G6W]L:OXVE-KKL?BK5+33Y;>728+
MOPUXBU"*1-0U!9M.GD>\N +^7?KV:7;S/LCXG_$J+X:Q^ 9)='DUC_A.OB?X
M-^&L8CO5L?[-E\7W5Q;)K#EK6Z^UQV'V<NUDHMVN=^T74.,GT^ORD\.:GJ%W
M\,_AGI%W>P7=AX._X*#>%O"'AR.RU^_\5:9IOAO2=;,FEZ3HOB35(X=0UO0]
M/6[E@T;4;NWMIKK3!:R-;6V1"G5:NNL:=J_B;]C.*2]BA\9_&'1]>\-7D5Q<
M6<EG\!O$\FH_$7QA#H]T"\F[PYJ'AS7/"TC74BB\EUH0Q!@,D#F_';U:32^=
MWJ?IC7,^&_$DGB)_$22>&_$OAT>'_$FH^'8W\26%M8IK\>GQVLB^(?#QMKZ]
M^V^&]0%SMTZ_G%I/,\%RDMG \++7Q5\5-,T[P+\5]4^*GC?P[I7Q2\ 7GC+X
M9:/H^I:;XLO+;QS\#?$6D1Z;:VNEZ+X:@E3^TK#5M7N;#7;W1_#=S9:Q?V]]
M<MKVE:MI\8EN.9TKPGXA\>Z%\9M(T+4]&NK[3OVV/'&MR>!?$^N7>C:-\3M%
MT+P_HEUJ'@*ZN;037#P7$3C58[66SU#1VETM#J^GO8B2XM0+[Z:ZNWI:WWW\
M_OT/TAHKP7]F[Q!X4U_X90+X0\(7/@*PT/Q'XH\/ZAX2DU-]<L=$\06.M74V
MNVFAZZL]Q8ZOH0U&ZG?3;O1Y%TA(F:SL+>TCM3:0>]4%+5)]PHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#S>'X.?"6W\1-XNA^&7@*+Q0VH-JY\0)X2T(:NNK/.+I]62^^P_:(]4>
MZ!N7U&-UO'N&DG:8RR2,UG6?A3\,/$>O1>*?$'P[\$:WXDA:!X]>U;PMHNH:
MMOM%1;1WO[JREN9'LQ'']C>21VM"B&W,152"B@++L:'BSX?>!/'J6$?C?P;X
M7\7)I4LTVFKXET+3-:%A)<B$7)M!J-M<>0MT+>W%TD>U+D00B=9!%&%2+X?>
M!(+*STZ'P=X8AT_3O$J>,M/LHM#TZ.UL?%D=U)>Q^)+2!+<16VMQW4LD\>IP
MJEW'([,DJYHHH ;XN^'7@'Q^EDGCCP7X7\7#36G;3CXBT/3=7>P-T(A<_8I+
MZWFDM5N?(@^T+ R+.8(#*',,>VKKGPL^&?B;2](T3Q#\/O!>M:/X>MUM- TS
M4O#&C7=CH5HL<,0M=%MIK-HM*MO)MK>$P6"V\1A@BB*&.-%!10%EV_K^DON+
M=M\// 5GI_AW2;3P7X6M=+\(ZDNL^%M-MM!TR"P\/:NK7#C5='M(K98-/U$2
M7=U-]MM8X[GS[B:<R^=([G>UG1=(\1Z7>Z'K^F6&LZ-J4)MM0TO4[6&]L+VW
M+*Q@NK2X22&>(LJDQR(RDJ"1Q110!#K?AW0/$NC77AWQ#HNEZWH-]'##>:+J
MMC;7^EW45O-%<01SV-S');2I!/!#-"KQD1RPQ2(%9%(EUK1-%\1Z9=Z)XATC
M3-=T:_C6*^TG6;"UU/3;R-7658[JQO8I[6X194215EB<+(B. &52"B@#CK3X
M0?"FP\/:EX3LOAMX%M?#.L30W&KZ#!X5T2/2M4N;9Q):W.HV2V0@O;FTD5'M
M+FY22>T:.,V\D1C3;?M/AI\.[#PO>>"+'P+X0L_!VHNTFH>%K;PYI,&@7\SF
M!FGO=)CM%LKJY9[6U=KF>&2<R6UO(9-\,;*44!9=O+Y=C?T'P_H?A;2++0/#
M6CZ;H.B:<DD=AI&D6=OI^G6:3327,JVUG:QQ00B6XFFGDV(/,FEDE?+NS'B3
M\%OA ?$)\6'X7^ 3XE.HG6#KA\)Z&=3.K&7[0=4-V;+S3J)N?]*-]N^T_:_]
M*\W[1^]HHH"R['6>'/"7A?P?;7UGX4\.Z+X;L]2U.YUK4+30]-L]+MKS5KR.
M"&ZU*X@LH88I+RXBM;:.:X9#(Z01*S$1J!S$/P<^$MOXB;Q=#\,O 47BAM0;
M5SX@3PEH0U==6><73ZLE]]A^T1ZH]T#<OJ,;K>/<-).TQEDD9BB@++L:?B'X
M;?#WQ;J^G:_XI\#>$O$>N:0D46EZOKGA[2=5U&PB@GDNH(K:\O;2>>**WNI9
M;JWC5PD%U+)<0JDSLYMZ-X%\%^';K3[W0?"GA[1KS2M!/A;3+O3-(L;*YL/#
M9O5U(Z#:3V\$<D&DG446^-A&RVQO!]I,9F)<E% 67;^OZ2^XCT_P!X&TG_A'
M?[+\(>&M._X1"769_"OV+1=/M?\ A')O$7VC^WY-#\FW3^RWUK[7<_VH;/R?
MMWGR_:/,WMF_9^%/#&G:_J_BJP\/:+9^)O$$5I!KGB"VTVSAUG5X+"&*WLH=
M1U*.%;R[BM8(((8(YYG2..&)54") I10%EV_K;\M#D;'X+?"#3-637M.^%_@
M&QUN/5(M:BU>U\)Z'!J4.K03O<PZA#>1V2W$-U%<R-<1RQ2(R3[95(D1&7IU
M\%^$5T[Q)I">&-!32_&%YJ6H>*].32K);+Q'?ZS;Q6FK7NM6RPB+4KO4K:"&
M"^N+M99;J.*-9G<(N"B@+);*Q9U7POX;UW09/"VM:#H^K>&IH+6UET#4-.M+
MO1I;6QD@FL[:339XGLWM[66VMW@A:$QQM!$44;%Q<U;1]*U[2[[1-;TVQU;1
M]3M9;+4=+U&UAO+"]M)E*2VUU:SH\,T,BG#1R(RGCC(%%% &?I?A+PMHEUJ-
M[HWAS1-*N]7L](T[5;C3M+LK.;4;#0+.33]#LKU[>&-KFUTBPEELM-MYB\5E
M:.UO;K'$=E8&J?"?X8ZWH6B^&-8^'W@[5/#OAS/]@:)?^'=*NM+T;<AC<:99
M36KP60D0D2K B"7@R!B 044"LNR+-E\-/AWIUA9Z5I_@7PE8:9I_B.V\86&G
M67A[2K6QL?%=GL^Q^([.U@M8X+;6K411K;:E"B74"1I'%*B(JCDK;X8WLGQV
MU/XPZMJ&FSVUM\/;+X?^$M)MK)UO+&VFU=M=UW4M4O9F837D]\%M=/%KLBAT
MYYXW19IIWN"B@=OP.IN/A;\-;OQ2GCBZ^'_@RY\91SVUTGBF?PSHTVOK>6:Q
MI:7JZK)9M>B^M4AACMKWSOM4$4,444R1QHJLU7X5?#+7+&_TS6?A]X-U73]5
M\07'BS4;/4/#>DW=O>>*+R&.VN_$4\<]HZOK=U;1);7.J$?;9[<>3+,\3,A*
M* .JT70]%\-Z7::)X=TC3-!T;3T>.PTC1K"UTS3+*.25YY$M+&RB@M;='FEE
MF=8HD#RR22,"[LQU*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ny20006478x8_graphic03.jpg
<TEXT>
begin 644 ny20006478x8_graphic03.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /V4_;'_ &6_^"S?['?[
M3/QD_;M_X)T_M"7G[7_PT^+/B4^.OC#^P1\=S:2K8VVEZ/I6B6=C\$8K2?P_
MHUQ%H?A;28-+TH>$]1^'?Q/N-,\+^$=$U@_'C5FFBE^J?^">'_!=_P#9)_;G
M\2#X&^.;37OV0/VS-*U._P##GB;]E?X^-+X?\22^*-*FM[;4-%\ >*M8TOPW
M8>-=3@NKB2T_X1#4-*\)?%-9M,URYG^',.BZ6=8G_;NOS$_X*&?\$AOV(?\
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M;/Q;#Z9\5_'.A>??:;JA^&5QI374NFZDJ1W<,5A\&;C6=5T/Q-I%M;ZW\>_
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M6K)X;\!_M\?!?18]8\.>);.&XNXEU?Q'9>']/L/"_C](;)K75-2M_#=C\/\
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MR\TZ#Q=\-O&'A[QSX8FU#3W6._L8M?\ #&HZII4EY8R.J7EJEV9[9V59D1F
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MWP3_ .4,7PC_ .T8?@+_ -94TFOF'_@Y@_Y0D_MJ_P#=N'_K6WP&KZ>^"?\
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M$_\ E#%\(_\ M&'X"_\ 65-)KYA_X.8/^4)/[:O_ ';A_P"M;? :OI[X)_\
M*&+X1_\ :,/P%_ZRII-3]O\ [=_4G[?_ &[^I^=7_!J%_P HB?!__9=_C=_Z
M>M,K^E&OYKO^#4+_ )1$^#_^R[_&[_T]:97]*-..R]%^0X[+T7Y!1113&%%%
M% !1110 4444 %%%% !1110 4444 ?R<_P#!";_E+]_P<-_]G/:-_P"KA_:7
MK^L:OY.?^"$W_*7[_@X;_P"SGM&_]7#^TO7]8U3#X5\_S9,/A7S_ #844451
M04444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X2_\','_ "A)_;5_
M[MP_]:V^ U?3WP3_ .4,7PC_ .T8?@+_ -94TFOF'_@Y@_Y0D_MJ_P#=N'_K
M6WP&KZ>^"?\ RAB^$?\ VC#\!?\ K*FDU/V_^W?U)^W_ -N_J?G5_P &H7_*
M(GP?_P!EW^-W_IZTROZ4:_FN_P"#4+_E$3X/_P"R[_&[_P!/6F5_2C3CLO1?
MD..R]%^04444QA1110 4444 %%%% !1110 4444 %%%% '\G/_!";_E+]_P<
M-_\ 9SVC?^KA_:7K^L:OY.?^"$W_ "E^_P"#AO\ [.>T;_U</[2]?UC5,/A7
MS_-DP^%?/\V%%%%44%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M^$O_  <P?\H2?VU?^[</_6MO@-7T]\$_^4,7PC_[1A^ O_65-)KYA_X.8/\
ME"3^VK_W;A_ZUM\!J^GO@G_RAB^$?_:,/P%_ZRII-3]O_MW]2?M_]N_J?G5_
MP:A?\HB?!_\ V7?XW?\ IZTROZ4:_FN_X-0O^41/@_\ [+O\;O\ T]:97]*-
M..R]%^0X[+T7Y!1113&%%%% !1110 4444 %%%% !1110 4444 ?R<_\$)O^
M4OW_  <-_P#9SVC?^KA_:7K^L:OY.?\ @A-_RE^_X.&_^SGM&_\ 5P_M+U_6
M-4P^%?/\V3#X5\_S84445104444 %%%% !1110 4444 %%%% !1110 4444
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M9^)O"'BGXC?#KQ+XFM-0TVSU_P *ZE+IWA5OCS1?^"B7_!5K_@BOJ>F_#O\
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MTGQ'=S:[=P66LC1]*34;G3M+_IAHBFD[Z-MO\@BFD[Z-MO\ (****HH****
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M$6WTN#[ IVON[^2VZ??\_N':^[OY+;I]_P _N.&^&OPQ^''P:\$>'OAI\)/
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MW_!PW_V<]HW_ *N']I>OZQJ4/A7S_-BA\*^?YL****HH**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#\)?\ @Y@_Y0D_MJ_]VX?^M;? :OT5_P""
M=W_*/W]A?_LSK]F3_P!4IX)K\ZO^#F#_ )0D_MJ_]VX?^M;? :OT5_X)W?\
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MX8ZY^W5^Q-;7]IH/A7]M?X43/KGQ"\,:6\FG6.DP^-O$.KQZ6=;UF1)([?\
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M265QK^JWL>D6DYTO1(=-TB*VL(?JZBBJ*"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /QK_P""
MD?\ P0W_ &*_^"CHN_'?B/P]=? S]IRU6*\\-?M._!VVM="\=KK6GP1KHEQ\
M0=*A-GH_Q0L-/N+/2MLNNFT\:Z?IVF0Z5X1\=^$8)9I&_ #QU^V)_P '!?\
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MX]7ET2/75TV34TTS3DOWMC=K8VBRBWC+J]NMK_(+J]NMK_(]QHHHIC"BBB@
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MFZ3=]+ZIOJK);^7;S/FK]J?PS9?LS_\ !TW^P)\1?@Y;IH5W^V7\ ?&GA?\
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MY(UBN53>F\PNX7<N2-PS.[36B;>MO)?G9[^HNSV3E=?^ O\ .Q\5_P#!<?\
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M[^[Z=1_:_P"W?U/NBBBBK*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4\;^$_AQ\/\ PI9#4?$WC;QSX@TKPMX5T"R::*V2YU;7M;NK+3+"*6ZGM[2
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M#<Z)H_Q8L]-L@OCKX>6_AGXB>&K<:]H-]X#MP#^F#]J[_@J!\$_V-?B'X?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
64444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ny20006478x8_graphic04.jpg
<TEXT>
begin 644 ny20006478x8_graphic04.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M'_Z+"ON/]O'_ ()3?MX?M3>._@[XI^!?_!6W]H3]D_0OAW^SO\/OA#XO\*>
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MT[K.ER:7XKTNPNM!U!-2T?5;![2_F6\TV^MS):R_U$T466GEMJ_ZZ(#^=_\
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MAU_P30_X)B_MM?L6_'?Q9\4OVDO^"IGQW_;>\#:_\)->\ :5\*/BAJ?Q:O=
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M;TZOIMU _!SX,_\ !+#]NCX<?L2_M3?LT>,?^"L7[0'Q+^-/QSU[P-JOPO\
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M%[7OVO[;5/C&OQ%\7?#ZY\,>-=$A^#>H7<'QYM_&C^&[;4_$NBZZD-[X_O\
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M^/QQ\<?B)I::YH.E^&-;T&TDL]'L-56T\4WZV^M6MNUW:WW[J4465[Z_>_\
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M?[6\]+*XT_\ ._\ X<$_\%7?^EA/]K__ ,'W[2/_ -%A7]:M%%EIY;:O_/R
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M234;2P7RK\,MO<E]=G]S_K^O2X?NY17\U7[+/_!0/_@O)8?M&_!_X'?MQ_\
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M]>?83DEHW_7GV/[9**_$W_B(P_X(O_\ 1\'A?_PU'[0/_P Z:C_B(P_X(O\
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M_P Z:C_B(P_X(O\ _1\'A?\ \-1^T#_\Z:BZ[K[T%UW7WH_;*BOQ-_XB,/\
M@B__ -'P>%__  U'[0/_ ,Z:C_B(P_X(O_\ 1\'A?_PU'[0/_P Z:BZ[K[T%
MUW7WH_;*BOQ-_P"(C#_@B_\ ]'P>%_\ PU'[0/\ \Z:C_B(P_P""+_\ T?!X
M7_\ #4?M _\ SIJ+KNOO077=?>C]LJ*_S'?#7_!??]I3]G;_ (+$>.OVE_&7
M[3<G[8?[,FM^);GX7:_IGP]TKQ+X%^%WB3]F2\UP:GX6OOA=\'?&7V&7X?\
MC[X<V]U'KNG6>MO/XBO/%=OXM\-:W\1_$NC>-M>\::]_?M^TWX+G_P""A7[
MWCO0/V5?VD-<^&$W[1/PBL=?^"?[0GPOU[4=&DB75X+#Q)X8N9=6TR#^WK/P
MGXJBBB\-^.;;3HK/Q-;^&-7UZRLO[/UV*(P)23OW73^M!*2=[;KII^&MOQ/M
M#P]XG\-^+M/EU;PIXAT/Q/I4&K^(/#\^I^'M6L-:T^'7O"6O:EX5\5:)+>Z;
M<7-M'J_AGQ/HVK^'/$&FO(+W1M>TK4M'U&&VU"QNK>+<K_+Y_P""6/\ P5S_
M &@/^""GQA_:._9#_:G^"_C+QK\/X/%FH1^+_@W'XAL]$\5_"SXUZ&+;3YO&
M7@O4[Y-1\-ZSX9\?>'(+"'6C;.VF>+=*M? GC?PIXB_L^SN+;Q;^Y'_$9W^S
M+_T9=\=O_"_^'_\ \8HYUUT?;73\ 4EUT?5/I_7];,_L^HK^,'_B,[_9E_Z,
MN^.W_A?_  __ /C%'_$9W^S+_P!&7?';_P +_P"'_P#\8HYX]_P?^0<T>Z_K
M_A_S[,_L^HK^,'_B,[_9E_Z,N^.W_A?_  __ /C%'_$9W^S+_P!&7?';_P +
M_P"'_P#\8HYX]_P?^0<T>Z_K_A_S[,_L^HK^<3_@F9_P<<?!7_@IC^U)I/[+
MG@;]F_XH_#+7]6\%^,/&D?BGQ9XK\)ZOI$5KX/L[>\N;)[/1XDO6GO%N D$B
MGRXV4F08(K^CNFFGL--/8*Q?$7B3P[X0T:^\1^+-?T7POX>TQ(I-2U[Q%JMC
MHFC:>D]Q%:0/?:IJ4]M8VB375Q!;1-//&)+B:*%"9)$5MJOQ<_X.'?\ E#;^
MVS_V+'PK_P#5^?"FANR;[*XS]2_#OQ[^!?B_6+/P]X3^-'PG\4:_J#.EAH?A
MWXC>#];UB^>.-I9$L],TW6+F]N62)'D=88'*QHSL JDCK;_QYX'TOQ3I'@;4
M_&7A33O&NOVLE[H7@^_\1:19^*=;LHEO&EN](\/W%Y'JVI6L2Z??M)<6=I-$
MBV-X6<"VF*?YA?Q!A_X(J>'_ /@D]\(/&7P7\7>+_"W_  5ZT"S^&FO-<?#K
M7?VCHM4D^(EGX_M5\3MXBE\2I>_!_P /6&D^#9;OQ!I5_P##JZ\-:_#XNTGP
MU_8>I2PG6--O_P"A?X7?%74/^'EW_!!?PI^UE^S]!XU_;,\;?\$^_#>O:O\
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MTOPW->)K.H6,4>CZM))=VEE-;HFEZB[2!;*Y,75U_#]X#^+W[6_QB_X.:/\
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M:_G#_P"#AS]H[QWJ'PY^ G_!+_\ 9Y\0G3?V@?\ @H[X]C^'GBF[TZ.:_O\
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M7_!(G_HPGX$_^"K6_P#Y>5^LE%.R[+[D.R[+^O\ AE]Q^3?_  XJ_P""1/\
MT83\"?\ P5:W_P#+RC_AQ5_P2)_Z,)^!/_@JUO\ ^7E?K)119=E]R"R[+^O^
M&7W'P5^SW_P2]_X)_?LI?$:V^+G[.O[*WPN^$GQ*L])U70K7QCX3L-3M]7@T
MC6XHX-6L$DNM3NXA!?111QS@PEBJ@*RU]ZT44[);*PPK\Q?^"RW[//QA_:M_
MX)H_M1_L_? +PA_PGOQ=^(VA> ++P;X2_P"$@\+^%O[8N=$^+OP^\4:G'_;W
MC36_#GAC3_LVA:'JE]OU76K&.;[+]FMWEO)[>WF_3JBAZIKN!^27_!*'_@GY
MX#_9@_8W_9:T[XM_LM?!3P!^UAX&^&MAI?Q)\5VO@7X2:U\1[3Q5#K%W?3&^
M^*?@ZWUJ37;Q1'IMP=2L/%>IQM);VQ6[:6V41_-7[6/[$?[3WQ,_X+T?\$\O
MVT?!/PR_MO\ 9I^!GP-\5>#OBG\2?^$T^'NF_P#"+^(]2T[]HN"RT[_A#M7\
M66'C[6_.E\=^%$^U^'?"NKV$?]J[I;J-;'4FL_Z J*5M$NUOP _G]_X-X?V(
M_P!I[]A?]FK]HWX?_M3_  R_X5=XN\>?M6^+?B5X4TG_ (33X>^-O[5\%:GX
M!^'FBV.M?;_AUXL\7:98^?J>A:K;?V=J5[9ZM%]E\Z:PCMY[:6;YB_8R_P""
M3/[2LV@?\%]OA1^T3X$@^$WA;_@H-\4/&][^SSXSN_&7@7Q;9ZQIVL^)/VA-
M7\*>.;W2OA_XL\1ZYHEEH6I>,O ?B"\T+Q39:!K-Y:S2Z>+ W$&H0VO]3]%%
MEIY;?=8#_/L^!O\ P1!_;#T_PY\'?V<_'7_!';]FV;X@>%/C%<6GQ?\ V]/B
MK^U)X@\8?#;QM\%K[6]>CBU"#X!?"C]H/X7>+9=4T;3=7TG4--O/#6JZ'XBU
M;2O"FFZ1K_A#0]?UW7=2M?WW^ 7[ ?[1/PM_X+^?M ?M?)\)UT+]CS7OV.?!
MGP6^&GQ#7QSX&U%;O7_#/@S]G+P];^&E\('QGJ/Q1MELO^%>^([,:OK_ (:B
MLK@:1Y[ZM<?;[">]_H<HI<JT\FGTZ>B _C"U;_@D[_P4 N?AE_P<C^'H/@%O
MUC]OG]H_X:^/?V2[/_A:?P57_A;'A/P_^UU\:_BAJ^J_:'^(ZVO@7[)X&\7>
M'M<^P_$J?P;J4_\ :']F6UG-K%I?:?;>T_M=?\$P?V[KC]CW_@B=\8?V=OAM
MX:\3?MD_\$N_#'PK?QA^SOXH\7>#X;#Q3>:7HGPDU/7-+C\7#QIIW@G5&\(>
M*_A1#IFH66A^,+1_$N@^)M8O/#7B2;5=(T2SU'^M2BCE7=[6_&_;N!_*)X"_
M9B_X*B_M/_\ !<']C+_@H]^T[^Q/X6_9Q^!GP[^"/Q-^$^M>%M,_:!^%'Q:U
MOX=>&[GX7?M,:'X?MOB')I^M:'JWBSQ+XR\=_%K[7$O@'P3J&C:'X3\0>'+'
MQ!+::MH_BJ6T^5_@5^R1_P %T/\ @F'\!_VO_P#@GS^S/^R%\,?VI_@W\:O%
MWCV_^#'[3*_&#X8>#Y?"]O\ $;P?HG@;7]?U3X?^-?B'X?U-M0'@_1M'DM?#
M?B2WTC1?#/Q$M]8NX=?^)WA1X;:__MCHHY?-WUUOKK\O+Y= /XO=9_X(8?M8
M_!;X1?\ !#[X9_"OX?Z-\5/$7[,G[7/B/]HW]M#Q7X=\<>!/#FA^$K_QO\3_
M ("^)[R[TN'Q[XH\+:OXRM/"O@KP"WA2-O".F:OJFL_\(0=2CT:TEUO3=/D_
M3_\ :'_8C_:?\=?\'#W["/[<_A7X9?VI^RQ\&?V4_&'PV^)/Q1_X33X>V/\
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MJ_5KTT/\]3_AG/\ X/*_^AA^._\ XE+^QA_\]ZC_ (9S_P"#RO\ Z&'X[_\
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M_P#GO5_H5T4<B[R^_P#X'DON#E_O2^\_SU/^&<_^#RO_ *&'X[_^)2_L8?\
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M%H=B."A(0AE\PN7^OZ_*9Q<HQJRBE'$*52,5=QC'F=-05U\,%%0BND4D?I.
MC&E1C&+O./)*<NKG.$*BD_/EE'U:;UU/YX/@+<6OPZ_X.8M(M$AE2Z^-G_!*
MS6]/OC;,+@?;]&^/%Y?;]26\96T^,6'P?MH$32U9GF6P>5 M[J3K_5O7\D_C
M6*]T'_@Z!_8 NU^TZ79^+?V4?VA_#!ND,EI!XC71M!_:2\6/X>EE0HFJQZ09
MM-U\Z9*TZ6<K6FI^3%+Y4H_K8K]$X=O_ &+EZ>\,/&G_ ."KTU^$=NFQ\AGE
MO[8S%I64\3*I;_K[&%1_C+?KN%%%%>T>4%%%% !1110 4444 %%%% !1110
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MK\!_#;Q+XF\,VU_ Y"W%M=:[IEA;2VV<W*RF!06D /TU7R%_P4 \+?#WQO\
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M:_:W\71^%]0\1Z'KFB:=JNBZ]X3\+Z9?KX336[2RDNO#_P#PDG@[6M>AN+:
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M/%WA^>_TFYN[6+6O"_B?1]6\.^(-,>5;W1];TR_TO4(;>]M)X8^HJB@HHHH
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M1O*456E^[2E*;<547-9))99E5;$XZ&/Q\U+ZM=X?#QDZD(3>TIRY:<)3AO\
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MZ@E?]FJ_)[_@AW^T1\9?VKO^"7/[,'Q]_:!\;77Q%^+OCW_A=7_"6^,KS2M
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M=_U_P?,:BEKN^["BBBJ*"BBB@ HHHH **** /(?CM\?/@S^S'\+?%7QK^/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4T[3;7S/.O+RW@1Y58'AG_!&O5OV6M=_X)N?LXZK^Q7X7^*W@S]F>Z_X6_\
M\*U\-?&ZXT:Z^*&F^1\>?BA;>,O^$GG\/^(O%>D2?;/'\/BJ_P!%^R:_?[?#
MUUI*7'V6Z6:RMOT[K\J/^"(_[-GQJ_9#_P""87[,G[._[1'@O_A7OQB^'O\
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M5_PW/_PQO^S-XK_9P_X1C]IW5-%^-/\ PE'Q+\5_$7_A9?Q'3^V_M/C/2O\
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MX6O;+[<NC:;<6>B6UW%J?B"\TG1TGU"'^(/]J+_@N]_P4S_X+"?%+4OV/_\
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M>[L+&ZU1];U?0M'U7_.A_:[_ ."FG_!0/_@OI^T_\,OV7_#][IGPU^'?Q/\
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MX4V.JZWXFO[BYT.]'Q&N(M#UBX\+>&_$/A[Q%Y^@6EO=7E[_ $#5\:?M<?L
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MY;#3/B[X5T.%OB5X#LI%LW E\5_#[2+76XH[O4H;736^&UE%;6TFK>.AY_\
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M-7G,Y6V60'\;AB*^99U7Q=>_,JDJDD].51;4(I-NR4G&RV4=M%<_T HY#E/
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M6E!M6VJUM8^5"3VDC]_Z***^]/C@HHHH **** "BBB@ HHHH **** "BBB@
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MU^&/_!1W3="^!'QS^!/QW_9^N]/^&?[3GAC6M8^)^D>*]$B43Z;K^E7^C?\
M".:[JVDG?8W&B^+;R#Q)H'CC26M?[/\ B#H#:[I7B2"_CDE9^C^R\%F3E1P6
M&>!Q2IU)TE"O5K86K[.#FZ=;ZS.I5HRFHN,*RK2@IN,)TDI.I#]$S;Z-WAWX
MK1Q&4>&7"M?P[XYI9=F>/R3"8+/\YSW@_.Y99@:^85<KSA<5X[-<[R7%8RGA
MIX?+L\H9[B,OIXZMA\'CLIC0Q/\ :. _T)J*^6_V)?VFM$_;)_9,^ /[3FAV
MMIIJ?&#X;Z'XEUS0K&YEO;7PKXW@231OB)X,BO9HXI;S_A"_'NE^)/"CWC1I
M]JDT9YP-L@KZDKY+;1II]4U9KR:>J?DS_."I3J4JDZ56$Z=6E.5.I3J1<)TZ
MD).,X3A)*49QDG&49).+332:"BBB@@**Y+2O'_@373X?&B>-?"6L'Q9!K5UX
M5&E>)-&U ^)K;PW/%:^(KCP^+2]F_MF#0+JX@MM:FT[[3'I4\T4-\T$DB*W6
MT %%4(-5TNZO[[2[74K"YU/2X[2;4].@O+>:_P!.BU#[1]@EOK..1KBTCOOL
MEW]D>XCC6Y^RW'DE_)DVWZ "BBB@ HHHH *_$/\ X(Q?M>_"']K#_AMG_A4_
M[&_P;_9%_P"%1_M*:GX!\7?\*BM/#%K_ ,+AU^W_ +9\SXA>,?\ A&_A[X!\
M[Q%<?9)?-DU/_A(+T_:YMVK-EO,_;ROPU_X(J?L;>&OV1/\ AN#_ (1W]I_X
M&?M*?\+B_:8U/XA:E_PI3Q%8:_\ \*QO+C^VMW@KQQ]AU;5/[/\ $T'VMO-M
M+C[)*/LTV8!M.%U7H_T_X('[E4444P"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHK,UK6M&\-Z/JOB'Q%JVF:!X?T+3KW6-<US6K^UTK1]&TC3;:2\
MU'5-5U.^E@LM.T[3[.&:ZO;Z[GAMK6VBDGGECBC9P :=?,G[5W[9/[,O[#_P
MNO?C#^U)\7_"?PD\$V[R6VG2Z[=27'B#Q7JL:+)_8'@;PAI<5]XI\;^(#$PN
M7T;POI&JWUM8)<:I>Q6VEV=Y>V_\RG_!4/\ X.M_@A\#I/$'P8_X)XZ3HO[2
M7Q<C-UH]Y\<M76[?X!>#M3%RUF[>#K:SEM-9^-6K0-#<?9;W2KG0?AT7N-'U
MC2O%/CVQ-_H=?EW^R5_P0;_X*5?\%?\ XIV7[8/_  5;^,'Q0^%GP\\3);:C
M;IXW%H?V@?&?AJ?46OX_#?PU^&-U8Q>$?V>O CQW.K3Z4=;\,:;:Z-<7-E?>
M'?A!K^BZQ)JMO+ETCJ_P7S)<ND=7^"]6=#^V)_P<)_\ !07_ (*E_%!_V.O^
M"1'PB^*GPT\->+9&LH_$GA.WMY/VF?&NB+(MI?:SJWBO3-1F\*?LZ>!+>?4+
M%]7U[2_$<>IZ(MI;:AJOQ;T;1]4U3P\/T _X)@?\&I'PV^&UWH_QV_X*8Z]I
M_P ??BM=SP^(X?V?]!U34KOX2^'-9N+EM3>?XG^+6:SUKXP>(5G:V;5=&MQI
M/P]74%UC3M4;XHZ)>VVH#^G3]CO]A?\ 95_8)^&<?PI_96^#_AKX7^'9Q:3>
M(]4LHI=2\:>.]3LQ<^3K7C_QOJTEYXG\7ZG"U[>_86UG4KBST2VNY=,\/V>D
MZ.D&GP_6M'+UD[O\/N_J_8%'K)W?X+Y?UZ&+X;\-^'?!OA[1/"7A#0-%\*^%
M?#.DZ?H/AOPSX;TJQT/P]X?T/2;6*QTO1M$T73(+73=)TG3;*"&ST_3K"VM[
M.SM88K>WACBC1!M445104444 ?+'[<7P/\6?M,?L;_M1?L\^!-0\/:3XT^-G
MP(^*'PO\*ZIXMN]2L/"^GZ_XU\(ZKH&E7GB"]T;2=>U:TT>WO+Z*74+C3=$U
M:]BMED>VT^[E"PO^6'[*7_!*W]H'X&_M-?LM?&;QCXO^#.J>$_@E_P $:/!7
M_!.WQ=IOA[7_ !K>Z[J?QH\.?$"^\5:AXFT"SU3X>:1IMY\+)]-ND@M=9U/5
M-)\5RW@>*?P1!;@7#?OM12LG_7FG^B _FK_9$_X(X?M.? *R_P""(-MXQ\=?
M C4G_P"":FL?\%!=0^.I\->)_B#>)XLA_:OU_6-5^':_"8ZI\,-&.NRZ-;ZA
M"GC1?&"^ TTZ995T-_$:*DCX_P#PY@_:B_X0'_A%?^$\^ ?]H?\ $0;_ ,/8
M/._X2CXA_8_^&=O[%_L[_A#/,_X59Y__  NGS_G_ .$=^S_\(-Y7S?\ "QM_
MR5_3910HI?UVM_D@/Y'/&W_!&S_@J'K/PJ_;]_8_T/QQ^PY;?LP?\% _VW_$
M7[3'B/Q[J/B+XS:G\9?A3X0U/XL>&?B%-;:;X>/PKTSPKX@\4ZMIO@;P39Q:
M++K#Z3H>I:7KL%KXHQXEM?$OACWG]J;_ ((D_';XP6__  6(T3X=>//A!X>\
M)_MT_#7_ ()Y^$/V<+77_$'CK4-<\-2_L3Z-\-XM9TSXMM_PA3P:1;>*KKX?
M+I6@:YX<UCQW=_9=036M;T^UN89=*E_IJHHY5_3Z:K]7]_H!X_\  &/XP0_!
MSP#;_'S0_A[X;^+EIHOV/QAHGPJ\2^(/%_@+3YK.]N[728M"\2>*/#?A#7-4
M+Z!#I4VJRWGAW3HX=:EU&ULA=6$%K>W/L%%%, HHHH **** "BBB@ K\Q;K_
M ()8? &Z_P""I>G?\%3VA0?%:R^!ES\,7\+#3$739OB*8D\)67QO?54O%N)/
M%EO\&IK[X0/I\]I+IK>'3I]]$(M4LEN'_3JBBU_S"U_S"BBB@ HHHH ****
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M]SX.\3ZUI_A2_P#$_B%OV<M:C\*M>:_IEMX9DT2'^P2OA'X,?\$UOV/?V?\
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M-GQJ\%\I)&Z:A\.OB=\0_$_P_P!>BD$F3%XB\,:M'&Z(\"PMN+=Y_P %.?\
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MD)^QU_P7,_8W_;?^'/[5GQ0^#WAOX[Z=X<_8\^%W_"W/BK!XZ\%>$=%U6_\
M"_\ 87CKQ#Y'@VVTGXA^(+?5]8^P_#W74^R:I>:';?:9=.C^V[+B>6U^#/\
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MXY+NQCTNQ2SNGA9'B>XM5@$$[Q.B/&TJ,49$92"H(-;[^BM_7],#^>+X'_\
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MLO#GA[36F?3M!T:P>XA:VG>RTNQM6GMW(+P3-!!&987*J6B<LC%02I(%4O\
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M>^ WA'7H-2\'_#%+E;36X].\2>-=>T^U\36\&H:6EQ8:[%\&;DPZCX?\6ZC
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M.^LGN]+O+"^NG==_Z_IH#WZBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#O\ X=?M^?L _L ?LE?LPZY\??AOH7_!+JQ_:.T?QKXV\+_LQWOPG\=:=?\
MA;Q)H%[H"_$#3M8T#P)\*=/FTO7;$^)O"EWJ4WB#PMX:N]076;5K>VN1;7+P
M_$7[8G_!9CX\?'+]I#]CS]B[_@CM>_!CQGXR_:]^&'B#XQZ5^TA\8])\6V_@
M+0O!OAW6_B]H>IVUEX<U/1K/6=(N]%D^"'CC4M<U3Q#X/\0R7=M_8FD^&?#&
MIZEK$%S'^^WQY_9*_9?_ &I/^$4_X:1_9^^#_P =?^$%_MS_ (0S_A:_P_\
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M3YKIX6U&^U&[ND[-VWTN_D]/74#]GO#WA[0/".@:)X4\*:'H_ACPOX9TG3M
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M#_\ X+S?M5_M1S>#O'/B#X*^-O!'[.WB)/"?[07[4.EQ> O'EU^VI^SJ-/\
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M_!$S]JO_ (+&?L2?$W6=,T7]G+X8WGB7]O#]E^PM[^STV34[7Q'IWA;1-?\
MV>/!]SKFK7,FN^+VU#4OAS\,/ ^FM<B>XUKP%XUU?5VA%Q>267VU\5_%.B>)
M_P!M719/%I9_AE^PKX6\2_&KXDVZW5K;KJ'C/0)-(OM$\-V;W+&PU+5=5\:K
M\.?!6G:?<30.]SK'B>Q ?=+&_P"%G_!53]FK5/'/P)\(?MH>+/A]I/Q%^-_P
M!^+MQ^T/\6_ ^NZ7=QZ7\3_AOXQ\9Z7XB^*/@+Q;I^DVL&L1Z-HL=CHFLZA
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MZ^_AB]\2>-;[QUHOAJV\*VT6KHD:6NO2V&HW%C=:?K-M9S:-J6GZA<\SJ_\
MP5,_94^(?[*/[8'[0W[(?QK^%'[16O\ [*GP*^-/Q7U7P7HWB*XM[PZE\+_
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MX(T?MT?LK?"K_@DUX\^#'BS]EKQE^U9_P3M?]KOPSX^\)>._&?Q:M?@;\2_
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M>?\ NZ:MNG^-][+]+ ?<5%?!W[0G_!3O]@C]E/QG;_#[]H7]IOX??"[Q;?\
MPDTSXZ:/I>O+X@GC\1?"_6O$U_X/T?Q#X5U32-$U+2/%=YJFNZ7JD6G^%_#=
M_JGBZ\T_3=0UVWT&30;*YU.+VZ?]IGX4ZM^S1K_[5?PM\3:+\9OA58?#+Q9\
M3O#6M?#O6],UBQ\<Z?X5TK5;Z71O#VIQSM9'7+O4](N?#)T^Z>*[TWQ(DVC:
MG;VNHVEU:Q,#Z#HK\IOCQI'B/PI\6OV1]$^->L?'CQ_XC_:D^,-[\'KSQA\&
MOVH?BI^S1\(?@)XCTCX!?$_XQVEAX-^$OPJ\4:%J/Q4TK6)_@SX@=)OC))XU
MU7[3JM]-JGC*V\.IH7PV3[(^#FL?$/POXW\9? SXF>*KKXBW'A3PQX-\:_#K
MXIZMI&AZ#XE\<>!_$$FM^&]5TGQO:>'(]*\.ZQ\2/ _BCPI<7WBSQ%X/\(>"
M?"5[X:^(/PXCM?#5GK::]-<J^_E_P/\ /S ^D:***8!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5^*7_!=_]JO]G3]D#]D3X<_$
MO]IO]CSP-^VUX"US]H_PAX&TCX5?$"X\-VVC>'_%VI_#+XOZ_8?$&VD\4>"?
M'FGG4]*T;PSK_AR%(='MKPVOBN],>I0P+<6MY^UM?A/_ ,'!_P"PWXX_;^_8
MQ^&7P<\ _%W]G[X,:QX:_:>\&?$RY\4?M(>/M7^'7@>_TS1OA5\:?"TV@:5K
M>B^$O&=U=>*[JZ\9V>HV.E2:7!;SZ1I6NW;W\4EC%;W2=[.V_3^F!A_\%E/V
MY_VE_P!D3]I'_@D[\//@+XYL/"/A/]J3]J@?#'XUZ=>>#_"'B:3Q1X,_X3SX
M$:'_ &9:WWB;1-5OO#LO]F^-_$D']H>'KC3-0W7R3?:?.M+1X?WTK\1/^"LW
MPX_8#\=?M ?\$QM5_;,_:"^)'P6^)/@S]I4:Q^R;X9\"^%];\0Z5\7/BI_PF
MOP5N?^$3\9WFD_"[XA6^A:/_ &]IW@/3_MVIZQX&MOLVOZC+_;>RUFNM+_;N
MA=?7]$ 5\*_\%/?%WBSP!_P3G_;B\<>!/$_B'P5XT\)?LL?&_P 0^%?%_A+6
MM2\-^*/#.OZ3\/M=O=*USP_K^C7-EJVC:QIEY#%=Z?J>FW=M>V5S%'/;3QRH
MKC[JKY8_;B\1_"#PA^QO^U%XI_:!\%ZM\1_@;X>^!'Q0UGXN> -!N'M-;\9_
M#O3_  AJMUXM\-:3<QZWX:DM]0UG18[RPM)D\0:*T<TZ,NIV1 N$8'PK_P &
M_OQ/^)?QF_X)&_LE?$GXP?$/QS\5OB+XD_X7S_PD7C[XD^+=?\=>-=>_L?\
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ML-3TCQ+97-D][9_:[>3[R^(G[:_Q$\<072V=F^DZA>VPM)]?U37K_P 3Z]%
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MN>5;>VABMX0XCACCC55'Y1_\%Z_ W[#'Q!_8I\,Z'_P4&^-'Q1^!'P-B^/\
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MR:K'I.F)J#V@B:[73[,3%Q;Q;?XZ/^#<K]BS]D3]H/XJ?\%4=,^.G[-'P/\
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MX5\,>);W1]4U/P9#IL-EI,]K'K$LL]M',*5][+[_ "Z[=?Q0'ZW_ !]_:2^
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M+O7=0MK'PWI6L:E<QW]OX1TW5I-=UKQ)_>;33;O=6L[?@O\ , HHHI@%%%%
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MMSJWA'3O$?CC5FMM3O\ Q#>Z[=^(9O&?C8^(_F#]F#]O+XK0?M%_L;Z;X_\
M$?[1_P 8I-:_X-Y_@C^V;XW^&7@./2/&<7Q8^*]_K=I%KFOZ#\-;'PW;^)O$
M?QU\:7B2Z1IMY%XPTOPU<QWUK9W>F:>BW.L1GC/_ (+_ 'B_6/ ?[:'@SX??
ML6?$7X?_ +5'P&_8\\0?M<?#?P#\3_B%\)-<M3\-]+UCP_H?B/Q#\9=%\&^+
M[O6?A9X\^$VA>*!\6/%W[/7B<V/Q!U;PSX0\0>$[B_\ "?BG5?#"ZL7C^73T
M:7KMIUMY ?G'^VS_ ,$@?VQ/VA/B[^U1\)/ _P"R[^T3X)\#?M&_ML6?QHMO
MB%X7_;=^$,_["B:5XG\:6LGCS]J/Q#^S'XB$'QCL?C9>>!_M=GKG@^37_$\/
M]M:EJUYX,L(=%\/>"_#UY_0%\8_^".?P>^*W[1GQ8_:'\/\ [2?[8_P'D_:$
MUOX3^(OVA?A;\ ?C!I/PY^'?Q;UKX*_V.? ^J:C-:>"KOQYX6U,_V+:QZ]JW
M@OQKH.K7T4^H3:3?:#J>IZCJ5U\C_!3_ (+/_%;P[^QQ^P%<?%S]EGXJ?&S]
MO#]M;PAJ=Q\'?@A\,=<^'$=]\:]%\$^"](\4Z[^T!KFO6::-X-^#OP_\5Z;J
M!\2)H5SI=[JGA33O[1^TZ6VE>&]>U#2]KQO_ ,'!GPQT;]GGX:_&/P/^RO\
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M%% 'Y2_MY_\ !9G]B7_@F_\ $[PE\(_VF=<^(NE^,?&O@2V^(VAP^#OA_?\
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M;MI'A_Q/<Z3:3^(-&TQ[2\U"UDL=-U>2\M+66WU"^AEAA22.]NE83R$6WO\
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M3M?!WPKU)X)-2TW5H8-0MM3\/ZKIE_9V-Y::)H_Q_P##LEW:ZC-I,H_L*
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M_P#ZK7Q#7\[7["O[*/[7_P"TWJG_  1+^(\W['&F?LP_!7]B3]DOQMXCU/\
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M[+"8;$8JK:_L\/1J5YV[\E*,I6\['ZNUY5\</@A\*/VD_A)X^^!/QR\$:/\
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MOK694FMKRRNX9K:YMY466&>)XY%5U('XI?\ !RM^U!^T!^R3_P $^_"'Q/\
MV;OBIXI^#_C^^_::^'7A"[\5>$;BVMM4N/#.J^!/BOJ6HZ-))=6UW&;.[OM%
MTJZE41!S+8P$. &#?ME^S[KFK^)_@+\$?$NOW\^JZ]XA^$/PVUS6]4NBK76I
M:OJW@S1;_4K^Y9556GO+RXFN)BJJIDD8A0.!*M>6]]+_ ':6 ]=K\(O^",7_
M  3 ^/O_  3J\>_M[^*?C9XN^$'BC3_VI?C!X:^('P^A^%FO^--;O-'T;1M9
M^+.HW5MXQC\6_#_P1!I^IR0>/-(2"'1+CQ#:M+;:DLE[$D-J]Y^[M%.RNGVV
M^8'\V?[7/_!)_P#;G^'G_!0+Q+_P4=_X).?';X.?"_XB_&KP[:^'/VB_@W\=
MM/U=?A[XQGM8](2\UVPNM&\,>,4O[?Q3+X>\/:GK.DMIGA3Q!H?B;3-7\2:)
MXYO%\7ZAH6F<)\'/^"1G_!2WXX_\%(O@?_P43_X*5_M,?LUWFJ_L[PV/_"M/
MA?\ LT^%O$M[8KI-C=>)-4L/ UUJ/B?PA\/Y-$TBQUOQ?K6KW.OZEJ/Q2\1Z
MAD:.-1@LFL[O3/ZAZ*++\;[O?37\/0#\(O\ @G?_ ,$P/C[^R3_P4F_X*/\
M[8OQ'\7?"#6_AE^V!XO\4Z_\--"\$Z_XTU+QWH=GKGQ5UCQS:1>.M,UWX?\
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M:9<1^(->2>PT?5[.UF36]762)EU*]$WJU+E5WZW26BZ=/5 ?BE_P5 _X)O\
MQP_;7_:[_P""4'Q]^%?BKX4Z!X._84_:/N?C!\7--^(&N>+]*\2^(O#4WQ._
M9P\:+8_#FS\.>!O%>EZOKHTOX/\ B6W:V\3:SX0T\:A?:%$-3-O<ZA=:9^UM
M%%5W\_\ )+] "BBB@ HHHH **** /@?]N;]A[_AM#6?V,M7_ .%G_P#"MO\
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M@?@EX@_X(?G7IO#,R_M4:MHTGAK_ ((PZ)_P2,AN=$^%EUIFH3W&A2RW%O\
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M8V8*<1)TZ:<IRC",=W.22C\Y.R8;[:G\W&F?\$ /VB_V;?BA\6M5_P"";/\
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MQD^*'Q,\4?M*C3/V1==^%VJ'3]"^'/Q8_P"$U^"L'_"0_$>$?%3X=_;O#O\
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MYLUR?E5J=/#XBI+VV"C;2/U#$JI0A"[FL-]6J3UJHZ:BBBD?E@4444 %%%%
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M\U*[O$=-2O)/$FO3WEUI\NJ^9(^J0Z(-*LKZ1VDN+1V8FOO_ /X(E?"VU_:
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M[5_P'_9Q_: _X)C>#/C#^QC\-_VI_$?Q\_:5'@3X5>//'6LZ'I>J_LV^*/\
MA-?@KI7_  L7P9!J_P -?'EQJ6L?;O%6A:S]FTO5O!5S]I\':<G]L[YH+G3?
MV[H6[]?T0!7Y]?\ !6.WN+O_ ()C?M^VMK!-<W-Q^R)\?88+>WB>:>>63X;>
M(52*&*-6DDD=B%1$5F9B  2:_06ODC]OGXQ^-?V>?V(_VLOCM\.)].MO'_P?
M_9[^+'Q&\&7&KZ?'JNEP>)O"'@S5];T:74-,E>.*_LX[^S@:XM)'5)XPT;,
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M*T_PYI6I6]L-/L-'\.6/EZ<FK:C*UII]A!/.QN+IVN;Z[@TWS8IOR)_X.?\
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M=6D8L;76/$V@Z?*ZR,XN-4M5"%69E_HNK^:;_@Z?^._QP_9Z_P""?/P=\:?
M+XR_%;X'>,=3_;(^'WA?4O%GP?\ B)XO^&GB74/#5[\$OVAM6O/#M]KO@O6-
M$U2[T*[U31-&U*YTBXNI-/GU#2=,O);=[BPM9(IE:SO>WEON2?5G_!5K]@__
M (;"^/G_  3/^(O_  O[X4_!G_AE;]I ?%#_ (1KXBW?V;6?BS_Q6GP9UW_A
M%? 4?VZS^T:[_P 4-]@$?EW7^EZ]I2^5\^U_VMK^5'_@XJ_Y/'_X(-?]GS#_
M -6E^RW7]5U-=?7]$ 5\D?M\Z!\*_%7[$?[67AKXX^.]1^%WP;U[]GOXL:3\
M4?B/I&A:CXGU3P+X#O\ P9J]MXH\5Z?X<TG3]6U37+S0M(DNM1M]*T_3-0O+
MZ6W6WM[2>618V^MZ^%?^"GOA'Q9X_P#^"<_[<7@?P)X8\0^-?&GBW]ECXW^'
MO"OA#PEHNI>)/%'B;7]6^'VNV6E:'X?T#1K:]U;6=8U.\FBM-/TS3;2YO;VY
MEC@MH))75"P/+O\ @C7X*_9P^'?_  3<_9Q\'?LD?&;7?V@_V>]'_P"%O_\
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MC_P4!^,O[&'[0G_!+SX:_"WPQ\*=?T+]K7]IH?"GXD7?Q%\*:IXCUG1/#O\
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M6HZ-XW^%GQK&EZ?J^L>(;+X)_&KPHL6B>)?$7AC1-'GU[6_ GC;0?AM\1O\
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MU4Z$-3T\ZVNGKJS:-]MMO[5&E-<M9KJ9T_S/M8T]KM'M5O3#]F-RC0"0RJ5
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M&_B3\/KGQEHGP[?XJ_ GQG!>ZE:V4?C'Q&'T:PU?X;^."NM:1:77V5-3\/\
MB_Q]IS7<DUU9V-S^<7_"D/\ @J'_ -(\['_Q+SX$?_%U<9**L[[]F]++LG^.
MO7S/[$\)/%?@W)\@Q2XESN.6YMB\71J8VC/ YEB/K6(PN PN71S.-3!X3$TK
MXW!8/ QQ*G.->IF%#&XJI&V)@WL5]&_\$D_A;_PN;XH?%;]NK7K9KCP;HO\
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MIQ]I*4G'DDOB7O-IZ-)ZZFZA%/G2M.:7.ELK)))>2UL]/0DHHHK]1*"BBB@
MK\&?^#>']C[_ (8H_8K^)_PK_P"&B?V</VF?[?\ VHO&OQ _X3S]F#XA_P#"
MR_ .D_VK\)_@GX<_X1'5]=_L[3/LGC"P_P"$4_MG4-)^SOY&BZ]X?O/.;[?L
MC_>:OY4/^#0#_E&I\</^SY?B7_ZH/]F:EU7H_P X@?U7T444P"BBB@ HHHH
M**** "O#?VGOA.WQZ_9J_:&^!J-&C_&?X&_%KX3J\SQ1Q(WQ%\ ^(/""M*\\
M%S D:G6 7>:VN(E4$R02H&C;W*B@#^:3_@W0^)$7C_\ X)+?L[:5/?377B+X
M4ZS\6_A3XKMKF2Z>[T;4M!^*GBS6M#T:Z2\>2XMI++P+XD\(E+1F6.UMY88+
M>&VMDBMH?Z'/!#K>Z%?:?*VX)-/"4XRMO=P+QCT:3[003U.1VK^8W_@E-J4G
M[./_  4N_P""R_\ P3XU<Z?H]E8_M'M^VA\'/#.GVDD-NG@7X^PV&K>)?L4B
MHEM%IGAGP]XA^!&A6UK$"8KJXOH=\C6TI']*W@"[\K4;NT) 6[MA(N>K2VSY
M51_VRFF8^RU\1AU]4XCJ4IZ0Q%2K!I[..)@ZD8^:]HXQ\K/JCZR<OK.04JD?
MCP].DUM>,\--4IM[Z\BE*^[371G\U7_!:WXMVMYIUY\-;().? /AF2/6E+O_
M ,C)\0[W0[6&Q:W:$J]QI.AQZ;J=O/$TA#ZQ-%^XDMI'KS7_ (-O]'\3_LG?
MM?\ _!1[]@WXE:@L7B#7M _9]_;&^'>CK;2VT5UX>^(?A@R_$>_MQ<102L?#
M]Y\0OA3X,U)!"([76M(U&V#N8PS=_P#M&_L^3_%O_@JG:_ #4(KK5O#=Q\4C
M^T)\0YKB6:2*/X>66F6OC2TT:Y8(X_LW7-9UN#PC8+N5+9[);5"OV=O+?^WZ
MTW[%O_!93_@E_P#\%#$O7TGX5_&F]U#_ ()^_M!3K=VNB:'91^/O^$@F^%FL
M^)KZ6YBCN=-AU?Q7?>+M4ENXDM-,T_X+:;)-/S;?9^3A^;PF<XG#U';GE6PN
MJWJ49MIOM[L))=&Y=[')F%.>,PE3'VMR5*,DEM[.<5&7:ZBITKNWV6WHG;^K
MBOYU?^#B']KSQOX(^ _PY_X)[?LZWP;]J3_@HQX@N?A%I<MK=2))X ^!$<EG
M#\8_'.N?8;/5;W3M'UG1[W_A"IKJ73H_^*0U'XD^)-'O5U/P*T1_H)\7>+?#
M'@#PGXG\=^-M?TGPIX,\%>'M:\6^+O%&O7T&F:%X;\,>&]-N=8U_7]:U*Z>.
MUT_2='TJRN]1U&^N9(X+2SMIIYG6.-F'\4/[&?B/Q-_P48_;)_:&_P""O'Q2
MTK4+3PIXEOM1^ ?[#?A+7P[S^ O@'X'OM1T;4_$=K93OJ%MIFK>*+]]2BU23
M2-5,,'C76_C3!'#_ &3K>G,?N\35]C2E+JU:/J]%_F_),KA3(:O$>>8++(<R
MI3G[;&58K6A@J+C+$5+V?+)Q:HTF]/K%:BGHVU^I'[%O[*/@WX*_#?X2_LS?
M#7_B6>"_ &@+::IXBO@D4LEO:_:-<\=^/]?E+&UAU'7-2GUCQ%?J9+?3EU34
METZR6TLS:6\7._\ !3?QA-XR^&-YXC\"VLEOX>^#D":-X&T:.-OM5WX2US3K
MGP!XA@C^T36RPZEXHL_$ NIIKDPX6RTNWU-Y!923M]8R:A_PA?@E]%LV:+Q-
MX^M+:\\0W"$)/I?@OS$N]&\/JVWSHI/$\J0>(]4"LD<^B)X;C5I8KZ^A7XP_
M:C>$? ?X@PRP-=27EAIUI9VL98S3WTVMZ8+0PQI^\E>VE47KQH&S#;2LX\I)
M"/*PU24*]!1;YYUJ;J/JU*:2A]TFY=Y-)J\$?U!5RW#XFEB,1*E"GE^5Y=B,
MOR7#)<M&E"%'V>(QJC_?]E#!X5ZJ.$HU:E.4J>/DE\?_ /!.?XHZ'KO@[XB1
MV6L6MSX;MGTKQ;97"EHS$T\%[IFN_:(I52:WN+<:5I$$UK/''/#,&BDC5R ?
MR:T[X0^//^"MW[0WQV_:TT[QC<>%_@Y\)M=7X-_LEW%Y;ZA!8:T^A7"W?C#X
MBZ8D0TR[B>]<6CVFIW6DK>7UKXALM O[VSU3X>K]G^3KCXQ_$70)/C[^RG\
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M7/B9\+_&_A2-)IIX;OPC\0?#'A:\O6@:0ZGI-YJ'AR_MI])US4;*_;XH\/\
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M:/[L4$$:[Y)&DN+B4R7-U--<RRROVE%%, HHHH **** "BBB@ HHHH ****
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M&I]>@\6>'?$N@Z/Z[0 4444 %%%% 'Y!:#_P2E_L3_@K]XT_X*M?\+Y^T_\
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M_%#>#=-U+5M-\/3:F^)KC3]-O?[.2X\U["TTZTDATZU]8HHI@%%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2:Z_MW6=4UF;_A,OBMXBTZYELO$_CB:UL4U'Q+I'@KPUXCO_ -YJ**$K*RZ
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M=/@G9?'+X2:]\/OV\/"'[77@CX:?&/P'^Q=\6? OP%^%?Q$^%7PX\6ZG\/\
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M]G[:M>25.$*KA)?C+^R3\<?VD?V?OV@OVD/VTOA!X \1>+_@#\.?#.@?#_\
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M (0OX>^*O^$W\%?\)]\!-%_L7[?XU\)^(]3\-?\ $L\:^)K;^T?"-[H&K?\
M$R\[[?\ :+/3Y;7^@*A;OU_1 %%%%, HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BO@S]N7]NSPO\ L<:+X&T#3?!>L_%[X^?&:[U_2?@K\'-
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M)^UEX \.1> 9/"'BKQ!JMCI>B6W[07PY;5K_ ,/:)X7UB_U!K&/XJ>!K[3]
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MW:YABC-Y++:QSO+>")?Z/->_;3\)ZS^R;;?!?_A&-6'CP>#]%\"3SRV&F?\
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MAEN+JU(4,)FF#P,:%2=58G,*.)S3V2AAJE.MBJ\7?&/@NIC_  ^PG##PG$&
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M74-:U:[950W.HZG=2WMY/Y<86.,27$TC+'&JQQJ0D:JBJ!]5?M@?\$Y_C_\
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MO#4<&FW^- U/P0-"74;B;1))ION']E[_ ()M?M#?'CXF^!?BA^V1X/T#X._
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M=TV>'2='^).FV'BFZ?PWH^C^$=2\/7>C6MO)9_E?\#OV8/VNOVM[_P 7^&_
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M%%%%?//[7/C'XL?#W]E;]I+QY\!O#5QXR^-W@SX$_%CQ1\(O"MIISZS=Z_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ",RJK,S!54%F9B
MJJ!DLQ.   "22< <FOYSO&?[;OP[\3?\%"O"/[2VA^%O'&M_!?X,^![WX8Z_
MXLT/1+C4'N+'4&^(%E!XZ:QDCL_[)T&75?'-O%:VFJ7-OJMUIMB;M+9=3NXM
M"C_?;XJ2/%\,/B/+$[QRQ^ _&$D<D;%)(W3P]J+(Z.I#*ZL RLI!4@$$$5^6
M/A#PU:>"O^"?_P"V%X9$5E;1:'\7/VBM#OVAMK:QMIDT?QVNA2M/#"\ENL/V
M"PCM#&9IH8[*&.U$KV\24 ?KEX>U_1O%>@:'XI\.ZA!JWA_Q+H^F:_H6JVK%
MK74]&UFR@U'3-0MF8*S07EE<P7,+,JDQR*2 >*^!/^"E/[1?@SX.? #Q-\/=
M1@NM;\=?'+PWXF\">$?#FFNJW$-MJ>F/INK>*=1D:.40Z7HQU&UBAMHXY+[6
M=4N[33[*);9=5U/2?H']CG_DU#]G+_LB_P .O_47TVOEGX_^%VU/_@H1^REX
MGGBAN+#P_:V6BM%/#!,L>H>(O"O[1>MV%Q%YLOF12Q2>!3.C0VT@\^VM9GN+
M>:UM%F -#_@FE\=?"WC#X)>$_@=<Z;XA\)?%#X1>#M._M[POXJTR32KG5_#E
M_?W3Z3XQ\->>4FU/P_=Q75E%=3O;6TVGW]U!!)%+9WFEZCJ7Z%^*?$VA>"O#
M/B'QCXHU"/2?#7A31-5\1^(-4FCGFBT[1=%L9]2U.]>&UBGNIEM;*VFF,-K!
M/<S;/+@AEE9(V^!])$"_\%5/$@A$08?L01&X$00-Y[_&?07)F"<^:T31.2_S
MM&T;<J5-?5_[0.A-XI^%'B'PNI4?\)/J?@SPVXDB2>)XM?\ ''AO29HIX)98
M8KBWFBO'BN+::6.&XA=X9G6.1B #\+/V??VSOA]8?MT_&;]I;Q1X:\9^&O@]
M\8+*Q^&VF>,+G23=Z5X6U.-O!,&CWGB^^@*V6G6^IV7@^ZOKNWLKC4;S2OM4
M:F&]L[:\U&'^CFOPD^+8@A_X(Z_"U"(8H9-&\(%D(2.*2>37-9N(RRG"--)?
M^5.A(+O>;)%S-M:OW;H _#O_ (+"_&SPIK'ACPA^S'X<AU/Q'\3I?%>C?$/5
M]/TBSFNX]!T:QT/Q#9Z?:78BC>6XU?6EU=]0M;"S2:6TTNPEO]1^RQ7NE_;O
MU(_9T_:(\&?M*>!KSQGX1T[Q%H%SH7B'4/!WC#PGXMTQM*\1^$_%VD06=QJ>
MB:E;;Y8I&@BO[62*YMY65UE,%S'9ZE;7^GV?RGX2T26#_@JA\2?$#0H+74_V
M7)]-AD"P[GOM$\3?!>:[8[9#-O6TUZPC\R2)%,9$<4LNV6.#MOV1TL8_C/\
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M[Q8#Y<_5W[4LD8\&_P#!-&(NHE?]J+]F"1(RPWM'%I2+(ZKU*HTL2NP&%,B
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M5TDUK=117$,L:_D_\!K+3= _9'_;,T^;[';Z1HO[5?QCLI=\<4%A!ING>)/
M\#[XF)AALXK6$[HV)BCA4J256OLO]@?_ ),Y_9]_[$&T_P#2^_H XC_@H/\
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M8O#MWX4TNS,JV$MKIVC:6V@S:[=WDVJZ9I-V-?:#4-6T_4[K]UOVA=(M=?\
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M[=3OHS7MJ?.M8(K:^%K+<O>6WZ$5\UVO[3_@V\^ '@S]H6T\/^*[SP[XYNO
MVG:+X:L[;27\4RZGX\\9Z3X%TVR$5SJUII&ZWUC54EGEEU:"-K&"22,FY:.U
M;Z#T?5;'7=)TO7-,E-QINLZ=9:KI\[1R0M-8ZC;17=I*T,R1S1&2WFC<QRHD
MD9;;(BL"  ?-^F? #4;#]JS6?V@FURRDT34O 6K^'H]$"3C5$US6HOACILLC
MDP?9!I5IIGPUBGCE6Z>\NK_6Y(6MK6WTQ9=0G^"7P*UCX9_%7]I7XG:WK>F:
MC/\ '/QUX?UK2M,TJ.Z6+1?#GA30Y=)TF/4)+N*-WUJ[>^O7U%+8S6*+#:O;
M39EEBBZR;X]^#H?V@[/]F_[)K;^.+KX:R?% WRV</]@1:(-:GT2.S-W]I-T=
M1,UI//.K6:6D4,U@D-U<W%Q<PV&KX"^+^A?$+QA\3O!^D:3KMK+\+_$D?A;4
M-9U"&QCT?7-533K&^U6#16AOIM1WZ&^H6=OJ']I:?803"^L9]+N-11[U;  Y
M[]I7X3:M\:OA%XK\!^']0T[3-=U?1_$6FZ5=ZP]S'I$,OB;PEXB\$WD^H-96
ME]>&.RTOQ1?ZA;16UN6N-0L[.VEE@MYIIDXKX[_L[ZS\6O&7[,&NZ7XATS2M
M*^!'Q1T_Q[K=O?VUU)J&MVFDV=K]BM-*DMP]M%<27EA%%=)=K'&;:ZDN(;E)
M;1;6\]2^/'QF\,_L^?"CQ;\7_&%GJ^H>'O"$>CF^L]"@MKC4YY=>\0:3X9TY
M((KNZLX/+&IZU9M>2M/O@LEN)X8;J:..VFRO&WQ]\)>!-"^%7B'5]*\336/Q
M9U:TT[28K*PLY+[0[6;P+XA^(=]K'B&UEU&'R;'1/#WAK4)-5ATN35-3\_9%
MIUAJ!#8 /<J^2/AK^S=JGA3QC^U;X@\0>(K"[L/VB=7@_LV'1H+A+O0M"BTO
MQ): WPO8S"=667Q3=Q%;>2ZLY4T^WO-\+7LEA9_6]>.?#SXW^$?B5XY^+/@'
M0;76H=7^#_B6U\+>(;K4;."#3=1O[C2;#5)I-%GBNIYI[>R:_2QN3>V]C*UQ
M&9;:*>TDBN& .5_91^">J?L]_!#PW\+-:U:PUO4]&UCQKJ5QJ&E_:/L,D?B7
MQIK_ (BLH83=V]I<.]MI^IVEO=.]M$K7D=P85,'E,?HVO#_@#\>_"7[17@FX
M\=>#=.U_3-+MM6BTI[;Q%:V=K?%KSPWX=\7Z?.JV-]J%LT=QH'BO1I9PER_V
M74&OK#=-]C%S/[A0 4444 %%%% !7\SO_!:?X&_\%(OAAX8_:D_;R^ /_!3O
MQ_\ !?X-_#/X=^'_ !7H?[+WAOX>P36UO-X<T+PUX:UV&T\=3^*@EM)XFUU;
M_P 32SOX6N!:2ZA):>5<;!.W],5?E/\ \%Q?^42O[=W_ &0W5?\ T]:)1:__
M  [7Y ?DY_P1O\(_\%'OB#\%_@#_ ,%0?VA/^"E/Q>^-?P'F\"?';QYXU_8[
M7X81:YK7BZS\*:7\6_AWI>D:9XHM/%5I_;&N6?B71-*\<:%8P^%[=M1U2PL?
M#X,;3'4A^QOPZ_X*W?L3?%#]A[XC?\%"O#'C[7?^&<OA1J&N:)X[U'4O"FI6
M/B[0_$FBWV@Z?'X8E\*$R74FNZY/XL\)'0+6*=HK^+Q1HLKW%NMQ-Y'A7_!O
M%_RAM_8F_P"Q8^*G_J_/BM7\A_[4W[.WQZ^"_P"V_P#M)?\ !!_X/)KGA_X%
M?M]_MM_LX_'7X=2V,%U+X9\'?!'5%\:>)_$[:3X=GD,FJZ#X)GN_"2^*=:2]
MCN91^RA'"3-O)BB[276Z]=7:V[VW _KW\4_\%[/^"=?P]C^ MW\4O'/Q!^%F
ME?M'? W7?VBOAQK/COX;:WI=A+\+](G^(5OINI:LMG)J-_::MXV?X<:FO@#P
M_9V6HZOXNEUWPA:Z5:R7OB.SMA[1^P[_ ,%=_P!AO_@H'X=^*>O? WXGRZ+<
M_!>'5-7^(WACXL65I\._%'A[P/I2EYOB;<6&I:G<6A^'917^U>)!J 30)52U
M\56V@7=S9V]Q_,]_P69\2_!;]C+_ (+:?\$FO$.N?"X>(OV?OV:_V9/AA'=>
M!-*T+4_%*^#_ (5_#7Q_\:--A\4:=H-BMUJ.JK\%O#.EQ?$2U@*SJ5\$))>E
M[9+@GRGQ3H^I?\%:?^"D/_!4W]H3_@FX?$Q^"]M_P3C^*'PCU3QUH?@2Y\'Z
M7^T7\3O&'PVL=$L?AG-I7B#1-)UR?5OB;JMM>'3[GQ!8:1K[GP!::U?2VMFV
ME07[N[VTW2M9WU6_7;\NH']&'PW_ .#B'_@E/\3OCA)\"M(_:!O-"U2Z\3OX
M.\+_ !$\8>"?$?AWX.^-O$,=VUD]IX>^(MU:OI-G9M*;9K;6_%B>&-!OXM1T
MR33M3NQ?6^_]!_V^_'_C#X3_ +"?[:GQ2^'FN7/ACQ_\-?V2OVCO'_@;Q+9Q
M6D]YX>\8>#?@[XR\1>&=<M8+^WN[&:YTG6M.LK^"*\M;FTDEMU2XMYH2\;?Y
MR'PVU;PG\?/V(/V6/^">'CO]L7]HC7/'%I^TIK/A2W_X)R_"_P#X)]?"/6_B
M5\'/B-?^+OB5;KX^MOCMX[\2_!J\U]-6U;Q6^G:_I'B/XJZ/KGAZX\9:IH>O
M:5%X7\%/?1?Z#W_!1'2M1T'_ ()5?MSZ'K&LR>(M7T;_ ()]?M-Z5JGB":SA
MTZ77=1T[]G+QM9WVLRZ?;37%O82:G<PRWKV<$\\-JTY@BFD1%=B+OVZ?UN_Q
MMZ ?SR^'_CK^U;K_ ,#[+X'VW[?O[:9_X*]ZI\6O#G[.6F_LS_\ "?\ [*#_
M  MNO$_C#PS%\2]!_:U^Q6'[(6J?%6+]C6+X"3-\<=:UF>VB\1:3+8WOPAU#
M5[+Q&UIXIG_HU_X)B_%3X@?'#_@GM^QU\7OBKXENO&/Q'^(OP ^'GBKQIXIO
MK>PM+S7_ !#JNB03ZCJEU;Z7:6&GQ3W<Q,DJVEG;P[R2L:DG/\P7@S]L#X>>
M&;WP[_P6GG_;4_9MD_:"\*^'?"/PJL/^"?4/[1?[+TOC;4?^"6V@I:6^K_"V
M[\(CQSI_BNT_;+U36&O?VM;/PY)X^U>_T_QK9:7\ 6\-W.H37/A&#^CS_@C?
M_P HKOV!?^S8/A9_ZCUO23UW>WX:6?J]>W>RN!^E=%%%6 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %?@S_ ,'#_P#PP?\ \,5_##_AX9_PT?\
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M3PCJ6B2Z<-,\2_#XVD&J:5="]DM9)-1?QA"^@P:>##&EC;W.K:KJ&D21C32
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MME;PVMO&9':20I! D<2%Y&9W*J-SLS'))-?YYMW_ ,%2?^"@Z?\ !%GXU?M
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MM9=N;50W[L4+=^OZ( HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%%
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M7H/L^K:7JME#<VUZBKB*1]R^8EU:D++97L+QWEA<1Q7-G/!<11R)K?\ !/\
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M9PV'Q=?B;+<,\?.57,G"K"AD$\MEA\<LXC@:]6,<51PKRYXWVF'I_P!W9?\
M1]XIQO&U'A*ICL'A\+4R3"\1U,\]E5J4(93BJJP\8PPJE"53,HXE5:'U)XBG
M!NC.K]:5!QJR_3G_ ((Z?%#]E31+GQUX&F\=_#_2?VFO''B>^F\)^&=;UE=.
M\<>*/@U;Z1HU]H4?A"RUF2 :K:MKMEXLO]7T[P^)M;D32;>_\0VGV#2](G@_
MH!) !)(  )))P !R22>  .IK^/'QK\.?!WQ!TB+1_$VCQ7$5EJ5MKFC:C8S7
M&D:_X:\16-PEYIWB7PMXATN6TUGPWXCTZ[CCN;+6]&O;/4()5($YC>1'Y'6?
MV]_VA?VKO!_A?_@GK\1?$_BO3;GX,?\ "P[#]K+XF:7?ZGX>\2_M)?#737T/
M1/@=H%YK6C7]O?:)8_$OPIXJN-8^--I%.]UXWG\--'!J.FZ-K^KZ5><?A%].
M[P^\1^%O$7B'/^'\SX*Q?AQD=3B?,,HCC\/Q!+-LA5>G@J57)\7'#91[3,9Y
MG7P66U<#B\+A,/2Q.9Y:XYA6I5L34PG1QI]'CB3A?-^&,LRW,L+GU'BC,(Y3
MAL:\/4RU8+,?9RKSAC:+JXWEPL<)3Q&*A7HU:U6=+"8J^&A.%*-;[9_;'^-'
M_!-[Q+^V5\*O%NE_$7X2^(_"OASQ3//^U[XB\)ZMJ7B#P/9R-=:3#X8/BG5?
M#?V[PK=7TES::S!XJ3P]/<7T?ES#QPL1>-W_ */O!GBSP=X[\*Z!XP^'OB7P
MUXQ\$>(=,MM2\+^*/!VL:7X@\+:WH\R8M+[0M:T6XN])U'39(UQ;W-A<S6S*
MN(W(7 _DRT7PSX<\.:3IN@^']!T?1-$T:V^R:3I.E:;:6&G:;:[2A@L;.VAC
M@M8F4L'2&- ^YM^XLQ+O@'^TU:?\$U_C3X3\71:CJ.C?LC_&'5?%/AGXV?"[
M3S?ZCX<\+_$6X\)ZSXG^'WQ5^&GA6-C8^$_$>NZUX9/@/QM;:(=/T;Q79>(-
M'O-0TB]\1:1I6H0^%X(_3_X4\7/$7+?#W,N!<QX-K<05:^$X=S:>>X?.\-B\
MPI_6Z^'P694(Y9E<\MGC<)0I0PU2A4S.$LRK+!34*/)C9^AQ]]&_.."^&,5Q
M+A>(<+GD,MA3K9G@HY=5P%6CAI>PIU:^$J/%XN.*5"O4G*K&I'"M82G[>+E4
MYJ$?Z(_VQ/VPOV2?V9_#5AX7_:9\4:=>3?%"WOM'\._!W3?"6M?%#QY\1[46
MMW)>0Z;\,_"ND:_K=YH8^QRVEUXBU33K'PI9:E)9:??:W::A?:?!<?EE_P $
MH?VK_P!E[X4?VC\ O'OB2T^&OQN^-7Q4O+KX<MXO\+ZSH.G^/=&_L;0=(\,>
M +#XE7FF#PI=>,+#Q!#XBATKX>7_ (EB\03ZEK\<>AZ9?7VO+'/^:'P:O/$G
MQ1M[_P#:D^++P:Y\<OVC0/B3XM\02B>XET'PYXH*:OX*^&7AF34)+B^T7P1X
M#\*RZ'H6E>'HKC[/%/837DXEO)GEKTSQEX)\+?$/PSJOA+QKH&G^)?#.L0BV
MU'2]3MEN+63),EO+&QQ):7UK-&+K3[^UD@OK"[@BO+&X@N8(YD^!XW_:3Y5P
MQXD9QPQE7AS4SWA'(<^JY+B^(%GZPF:X^GEV*Q.#S;,<KRQY;5PKHRJ0C5RJ
MCBL?1EB:%!RQ57!RQR67_1Y!]%C%YMPM@<VQG%$<NSK,<NACZ.6O+76P>&GB
MJ5*O@\+B\6L5"LIJ$G#&3HX>:I5*B5&%=8=_6?Z[-:UK1_#>CZMXB\1:MIF@
M^']!TR_UK7-<UJ_M=+T?1='TNUEOM3U;5M3OI8++3M,TZR@GO+^_O)X;6TM8
M9;BXECBC=Q_,[^UK^VA^Q'\>?VD?V??BI\+;;4?B7X+^%?CB>7X\?$'1O@OX
MXO/#GQ#\.:%XA\-26^F>&I;_ ,*V\OQLM_#.F^'/%K7+>$]/\2Z9<:/J6F1:
M9>ZO8:I91#X8U']JGXC_ +2O@7X3?\$ZOBCX@UGQ=I/[,/B3X@:Q\>M>U^>:
M^O?CMX%\'R^#3^R;HWC2_LY;6VU2V.A^.[G4_'NE:W!J8\7>)OA3IFIZQYTT
MEW)=^_0006L$-K:PQ6UM;11P6]O!&D,$$$*".*&&*-5CBBBC54CC151$4*JA
M0!7W7T@?IZY'X3YQPWD?!G"M+CJMG?"N5<78C,<5FU3)\OP>7<29=/&\.T:,
M:> QN)Q.+KX:I@\VQD9QP]*G@*U#"TJLL5BZM;+OGO#;Z.F8<98'-,PSW.)\
M/0P&<8S):6%HX.&.Q-;%97B8T,SJ5)2Q%"E2HTZL:^#H.+J3EB:=2M."I480
MQ7]/'P%_:%^"W[3_ ,-]*^+?P%^(>@_$KP!J\TUG#K>B/=0S:?JEK'!+>Z#X
MBT35+:PU_P +>)-/BNK634O#7B72])U[3X[JV>]TZ!+B%I/B'_@HK^V'^R)\
M._!'C#]FSXJ^(+3QI\9OB)X!\0S^#/@]X6\':Y\2_%VEZI+IPMO"WC/Q)9^&
M]*U2T^&FFZ=K&I:?JVE>*O&=_P"&8YK>RU+4= N+\:/J7V;^?#Q/^T=XK_X)
MT>-=5_:U^$=A%N\8^%_&7PS^+/@".!QX=^(?B75_!/B2Y^!OC;Q!I,-W9P7/
MB'P+\6K#PS87^M6]N_B.]\ ^(O%6B1WT<#Q*G3_";X>R^!O#[WOB*_F\4_%+
MQC*/%'Q>^(VJRF_\3?$+XA:IOOO$6OZYK,^Z]OHVU2[O8](MIYG@TK2_L]A9
MI%#%AJXN^G]PIDO@KP9XF9+PIB,PXFXTS/.<DH<'XW,XX>CDV8\-?4GQ#4Q^
M;4<)4EBL'A89IE-; /#X.C7S"CFN$=:&7SABJ=!9+]'#.,?QYGO"F/SBEALJ
MR'"8''U,[H81U9X["YK[=9;##X.=>"HUZTL)C(8GVE>=/#3P=90EB8RHRJ?L
M)_P2@_:M_9D7X=^"OV2[;Q7IOA/]I6.'QIXPU7P3K_AO5_"%_P#$JWNO$&MZ
MU;>(/!7B+5M*L-!^*5UI/@9=)M]5A\,ZQK>N:%I7AR\CU"QM=*\/7$]M^L_Q
M4^*WPW^"'P^\4_%;XN^-/#WP\^'7@K3CJOB?Q?XHU"'3='TJT:>&TMDDFE.^
MXOM1U"YM-*T?2K..YU36]8O;#1](L[W5+ZTM)OY)OB9\--!^*'AE]$UI;FPO
MK2YCU;PAXNTIWLO%'@/QAIP\[0_&G@W6X&BO=$\3>'KTP7UA?V-Q#)E3:W/F
MV5S<6\WG4'[3_P 3O^"B7B[P/K7Q\M5NM'_8]\)Z'\*+GPM</IUUX7\:?M8Z
M/)=P?%CX^2Z/90VUB=0&G6?ANT\#V]Y:7%GX7&LZ_=^'HM,O;FXFDU\/_I]\
M'\4>%7B-Q_Q#PMB>'\[\//[-G5X5PN:PS!9]#B/&U,!P['*\RK8+!S4YXR/U
M?-Y5,!)9?1@\QC"M1J+#TYXD^CCG>4\8<+\-Y9F]+,<OXF6*4<WK826&>72R
MRA#$9F\7A85ZZ<51E[7!*.(7UF;6%<H5(NI/[<;]N7]A>V_;LT_]K2/0O%?A
M7]GZR\&W4^K^.=6^ /Q(LH[[X@7<>I2Q_&"S\"V_A*[\:_V!>QW^FVO_  G1
M\)6COKL-WJ%Q&ESYNJ37/VIO%O@'Q'_P4;\4>+?AKXE\.>,_"'QV_8G_ &?/
MBIH_C#PIX@M/$'A[Q1%X4^*/QW\!?VCHVI6=S>Z?J%O#I\FD03RZ/<)96I-N
M+N$W]Z\K^.XSD$9!!!&,Y!Z@CN,=:^.?A[\,= ^$?[<VEZCX86'1?"WQ7^ ?
MQ'BL_"=LWV72-+\7^'/'?PXUC7[GP_IZQI96-MK%AJ%OJ5SI&FK'&NJG7=;E
MC5]1D+S]&KZ=6&\<?$&AX=9_P/#A+-LUP..Q7#^.P&<U,WP>/Q.5X2OF./P&
M*I5\NP-7!U/[-PV)Q>&KPJ8BG4^K5:-2-*<Z4I_IN7^ M;PSXGX5XLRWB&6<
M83#9Q#+\SH8G PP-;#T<YH5LHH5Z,X8G$0KQEB<;3P]6G*-*<?;0G!R2FE^C
MU%%%?Z&']('PK_P4&UH:5\ _%D1D2+[1X/\ 'LT;N\48%PGAJ;3;;!D!W.9]
M818XQQ+(RQ8+O'CZP_8D_:D_8\_9G_:%E^(GC234OA)\$KOX1> /A+\//%WB
M[X1^/-$L- \76FB_#KPG<:WXBAF\.:AK/PWTSQK=^'_%&I1^,O&ZZ)9W^FZN
MVH^(]6M1JMRS?"/_  4=\[6?AY:^$;4LUWKL_A708((UF>29O&GQ%\*>'6AC
MBB4R3&:%)E:&V)N)$5U78QC:OM$Z>=3BN;,V1U"&6UN!=VIMC=Q267E,+L7,
M&R1'M?)+BX$J&+RBPD^0FOXP^E9]*K%?1PS3@+!8'@_"\82XNI9[B,=AZN;5
MLIQ. H9/B^'X498:=++\QC7ECZ./S.BE4I15#$8?#5[UJ<*N'K?F'B?X44?%
M#,LEPF(SJMD?^KW">'QU*I#!4\92Q-7B'/>*J+56,\3AG3^KK(L!4;C-NI1J
MSIVIRE"K#^L/3-<T36]$T_Q+HVL:5JWAS5M*M-<TKQ!IFH6E_HFIZ)?VD=_8
MZQI^JVLTMA>Z5>V$L5[::A;3RVES:2QW,,SPNKG^<G_@H5^VO^Q5^T5JO@'2
M?@QJ5M\<O%/PK^)VF2_$7XA> ?AIX@\2^$)/ ^B17<FJ_#[1?BY_8$/A'X@S
M:I?:Y:7VF^%_!OB3Q)IM]*E_,'BN8IE?\KI_B_\ %;P=9^)?^"6V@>+M?TK]
MGSXU>*/#7QGL%T_5[Y-2\&_ >+2O'?\ PNS]G;1-1.I0:EH'@7X@?$?PYX&E
ML='\.&QLM-\(^)?B)H<RWUCXAU"U;ZUTS3--T73K+2-'T^RTK2M,M8+'3M,T
MZU@LK"PLK:-8;:TL[.V2.WMK:")%CA@AC2*-%5$4* *_-O&?]H!PWX?Y9X=X
MK@KA2?%^,XZX5P'&M>AF>92R:ED63YA6KX7#X#$2P^#S%XC.98S YEAL32IR
MCA\%]3A74\93Q=&W\\<"_1NS3B3%\34<^SE9+0X>SC$Y#3J83"QQT\PQV&IT
MJU3$TE5KX;V>!5#$86K2E*+JU_;NG:A.C4/Z0/V5/VL_V8?VJ?!VH77[,_CO
M0O$&E?#R33_"WB/P/!H6J^!O%?PSEBBN;+2-"\2_#3Q+I/A[Q/X.M6CTB_L]
M -YH-GH^IPZ1?+H%S?6NGS/%S/[77[97[(7[,VCZ?X3_ &FO&V@->?$>TN++
M0O@]!X4U?XI^.?B#82)>+*ME\*_"NB>)]?U+0)I;"ZLIM;U+1H/"T5]&MC>Z
MK!<R1Q-_,QX\\;:O^RC\1?AM^V=X6?6/#/BCX->*?!B?$V/2K:>*?XF?L[>)
M_$NEZ+\3/ 7B;36DM[37]+B\.:S=>,?"LVK0WH\-^)=$L-?T,V>H(MVM#X1:
MOXD^+G]N?M5_$^]&N_%[]IJ6U^*&O:E*[7,/A7PAX@MH]1^'?PK\*2W&^ZT_
MP3\/?"5SIFC:7IKSS/)>IJ.I74TUS>,4[,;]/CAC#> >%\6*?"6)?%N*XHQ'
M SX&K9E*G1P_$>#P%#-<9BZN<?4'4EDE'*\7A,;"I_9]/%5\3B(94HTYPQ&.
MH8T/HY9K5\1JW!TLZI+):.44N(/]8(852J5<KKXB>$HT88+ZQR+'U,92K4)1
M^LRI4Z5)XQN494L/4_0__@E]^V'^R=\"EU7X/?%O7(/A)\7_ (Q?%.\D\!>(
M?&W@;7/#GA_Q3H=WH^B67AWX>O\ %2?1AX5TKQ!INNZ;X@>U\#^(_$.E7*ZA
MK=I'I5M=ZEKD=O+_ $1ZMJVE:#I>I:YKNIZ?HNB:-87>J:OK&K7MMIVEZ5IE
MA!)=7^HZEJ%Y)#:6-A96L4MS=WEU-%;VT$<DTTB1HS#^1[Q+X0T3QQX;UKPY
MXHT"T\1^%]5LS8:YINHV?VO3I[6Y.U$N@RE87,BJ]K.'BGAN8XY[62.XBCD7
MR;5_VH_B7\0_V9/A9_P36^(/BO6?$XTC]J'XF>$?'OB/6;]M2\5^./V2O@=X
M%^&GQN^%OA7QIK%V/-OIO$6N_%;X?^"=7NM,-C?ZAX1\ W%C=B2'4-8FN_0\
M"/IRY#XIY%XCX_BSA:?"&9>'?">9<=XC"X',7FV'SGA;*TXXVM@)XC"Y?5IY
MAA,7/"8&6&FJE+$UL=A94*\9SJT*/-XA_1]S'A',>%\-DV;K.\+Q-G.%X>IU
ML1A5@JN S?%M2P\,1&G6Q,)8:M15;$*K%QG2AAZJJ0<5"I/[:_;[_;[^ _[8
MNG>&?!?[/'@_XE?$S2OAGX\MO$4WQS@^'[:5\,/%-NFGZOI6J^#_ (=:[X@N
M=.\5^*Y)-1\B74-3L/#$/@6Y.E6LT'B34!-I4D_[4?LB?MW?L]_MK:'KMW\(
MM:U_2/&?@V2"#XA?![XE:!/X(^+_ ,.Y[OFR_P"$J\'7LUR?L%_&4>QU_0=0
MUWPU=R,]G!K+ZC:WMG;?SUV]O%;Q06MK!'!!!'';VUM;QK%%#%$JQPP00QJJ
M1QQHJQQQQJ%10JJH  KS?XO:]K_['/Q(^%W[8$NA:[X)^('P$\7^"9?%EK>:
M=<>'-8\>_ CQOXJTSPI\2?AOKL6K1VD5YHFL>'O$%_KOABYUBVO+3P]XOTK3
M-?THV=RES<O^7>#W[0[->/O$K)N%^)O#C"Y-PKQ/Q#EW#.79SD^.S#,,7D>:
M<08KZGP[2SJK7P]/!8RGC,4OJU>I1IY9.$'6QM&C5IX.KAZGUW&WT9L'P[PK
MCLVRGBBMCLXRG+,3FN)P..P^&P]#'X3+:/MLTG@84ZDL10E0HOVM.,Y8N,I<
MF'G.$J\*D?Z0/VP/^"@G[.'[&XT?PU\3+_Q)XU^*7C/2KG4_!GP&^%?AF;Q[
M\5_&.D1SRV4^IQ^'89K32] \-M-!?0?\)+XWUGPUX;NGTW5[:SU*[N]-O;6+
M\??V!_V\/V?_ -EGQO\ $+PE\>= \:_!?2_CW\1+/4_"_P 4=?\ !D$'PF\*
M$W&I6NB>!/B)XZTB\N[/P;=Q76L-'IE[>P/X%M$N-0NYO$NGV<=Q<-\3_!_Q
MCXF^-T7BG]JKXC@3_$[]IK7[SXEZQ-)-%>#P_P""+JYN(/A-\.M%N0IFM_"W
M@3X>IH6F:9ITLLTB:A+K&HW<LVIZE?3R^W77@6\\8^%O$OVOPC>>)O!D=DVF
M^+GET*XU;PW!I^K(]HUEX@E-K/IL%MJ,;R6XAU!TCN@S1JKY(KF\0OVB^9<-
M^*N?<)<*^'&#XDX3X6SG'Y1F&/EF6-CGF;PR*O7I9YF>6K"X>K@L#@J:PV)G
M@WB:..C/"X>..Q-;#PKRH873AKZ,.$S3@_+LYSCBBOE6<YO@<-C<-AXX7#O
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M(HD9V53]!X[_ $]<PX+R[PHEX:\*Y=F>9^(/!^4\>9C2XCCCL1#+,MS;$8G
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M+<_#WX^_$?P7\2O"^E_&;X/?#WX-WXO;/XN? CP9XD\2^"]"^'GQ.^)5C>^
MM<O_  W#HVB76HKX+G6X\)7[:7X1@\/SZ3J^K?WE7EA8Z@D<5_96E]%#-'<Q
M1WEM#<I%<1;O*N(TF1U2:/<WERJ!(FYMK#)JW5<NKUWO^/S_ $_) ?P5?\%?
M/#7AWP]_P;,_\$B)]!T'1]%G@\9_LM:E!/I>FV=A/#J'C/\ 99^//BWQ?>PS
M6L,4D5UXH\4LWB/Q#.C+)K&N8U74&N+X"<?WJT44)6OKNDON5@"BBBJ ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8Y%61"\4BL4=5=<X900135KM>E_FNGW 6J***8!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?S7_P#!3W0=7\#?\%$?AWXUU:W1?!_Q_P#V6K/P
M#X2UF=S(Z_$3X"_$+QKXL\0^$K;8"+1=2\%?%FS\2VT5SL-^V@:U):/*;"YC
MA[G]A_P?\+_''QNAT3XHVNGZE9_\(YJ-[X7T;5I&33-8\56=]I4EO9W4(D2+
M40FD?VS=II5VLEE?&V*W"3>6EK<?KE^V!^R1\-/VS_@_/\)OB/=^(?#\NGZ_
MI7C;P#X_\&WT>F>-OAI\0O#Z7<>A>,_"E_/!=6T>H6MM?ZCI=[:7EK<6>IZ)
MJNJ:;/&GVI+B#\6;O_@E/_P43T;6;?P_H'[17[)'C3P=#]FMV^)'C7X:?%;P
MM\0[BW*JMU?7OPY\*>(]4\&7&IPX9HX['QKH^GWKLI:WTY$,<G^<_P!(#Z*_
M&G$/T@^%_';@7(N$^.L%"OD%;B[@7B[,HY;AL?B<@HT\OHU85\3@L=@:F!Q6
M58?!4G&IA\14P688..*E@,SH8BI0I?T_X;^,&0Y9X:YMX>\0YCG/#V(=/,:>
M2\09+A98JKAZ.8SEB9Q=.C7P^(CB*.,J5Y7C5IQKX:NZ2Q&$G3C4E\Z_\%DO
MV9]*^./QB\)_L??LHZ);WOQ)\;>'?&/Q3UKP1X>C:XT_1KCX6_#GXF^*KZWD
ME8R6OA2#Q%K;?#/P?IMN9M,TP:]XRL-*MI"MS=Z2O ?"[QWI7Q.^'?@SQ_HI
MB&G^*_#VFZNEO$ZO_9]U/;JNHZ1-M)$=YHNHI=Z3?0'#VU[97%O(%DC8#^@W
M]A;_ ()^^$OV-[/Q7XNU_P <:G\<?VAOB/#:6/Q ^-WB/1K;P],?#6F7$EWH
MWP[^'OA"TO\ 5=/^'GPZTJ^FN-7?0=.U"^OM?U^ZEUGQ+J^JRVFAV^B_(7[4
M/_!)_P"(NL_%'QU\:/V-_C'X'^&MY\1]1G\3^-?@/\7?!VM:[\']5\?ZK>I<
M>(_'/A3Q)X/UBP\5?#;4_$TC7NL^)]-L=#\4:-X@\4W][KTUE97=Y.YP\>OH
M89SXA>&&2X;@W#\*</\ '.4\9\7<:5N&\OK5,%PC"'',LO\ [6R#)L7'+L):
M>74<DR&&&S'%9;E]#,:^#Q^(^IY/2Q]'!X/3PZ\=<#PUQ;CJF>5,XS+A_&9%
MDN0PS7$TX5\ZE+A^.)^IYCCJ+Q5;W<5/'YC*KAJ.*Q-3"TZV&I^WQL\/.O6]
MI\;_  J_93T3]AR7XB2VWAK3&TWX=P>);7XAR726_B"3Q\NBJ9;35]3-W-*+
M=]=:>SUSP]<SS:+H5J+VZ2ULETJ*^M/YE?V1]/\ %OA+Q7\29/''AFZ\*VW[
M3TM_^V/\%3JMJUIJGBOX.>/_ !UXP\'Z9JK1A1&D5M!X7\.Z[#!(4NVTCQUH
M6JR1&#5[>63]M/AC_P $=?C9\0]<T"Y_;9^.7PTU/X8Z3J1O/$7P#_9U\,>-
M-*T/XH6]L\<MCI/C_P"*OC/7+7Q2WA.XE1UU_P (>'/"FBIKEE,VGW>O-$AD
MD_1W]MK]@3X>_MC>"/ FFVOBC6/@E\4?@U<7][\#_BUX$TS3;NZ\ '4]/M-,
MU;PW?^$KPVNB^*OAWK]GIND0>(?!,\VEPW\6C:6MGJ>EM;%W^@S'Z*69>(GA
M1Q-E.>\)\!>%/&V:\!\(<)9/@>#L0\=E4<?P7FT\ZIYUQ%C,'E.70F\]Q,,/
MEWU.AALYQ&293&I5EF^<XRM2H9?YN%\8L+PQQCE6,R_.>(^,<APG$.=9SCL1
MG=/ZOC'A\]P<<#/ 990KXS$R2R^DZF)]M5JX&EC\8XP6"P-"$ZF)^*O^">WP
M]^#_ (_\6>.H/B-I&B^)/$>EZ;HUSX0\/^(%6ZT^XL;AM7M_$E^FE3NUCJMQ
M9,VB1A;RWF-@+I;JUC:8M/:?CC_P4V^%?A[7_P!K36=6_9[L)O$G@#]@?2=+
M_:9^+=AH<>H^((O#O@^?XC? _P /^(-(M;Y6NMVHZ79P?%/QXD%]=+)9>%/A
MGKMZJ75K%93W7Z&)_P $JO\ @HO=:W/X?N_VA?V0-)\&LT]G%\2],^&GQ;U/
MX@BSV,EOK"?#'4/$UIX-@UDDK))82^/]0TF*5"0;B&06\7Z\_LB_L-?"3]DS
MX0^(OAK8M=?%+Q%\3IKG4_CS\3OB):66J>)?C5KE]IC:+<?\)192)/I=GX0T
MW07/AGPKX L(O^$:\-^&U>RBM[S4=1UW5]8Y?H]_1BXER'ACA/A?Q0X!X#X>
MJ<!X[C;&4>-.&<SH9AQCQJ^-,DXCX<K8',ZU+)Z+P.5X+*N)*TI5JV;XK$8R
MMDG#%&.5X.CEU>=?;Q*\6<JS#-LYS?A+B/B+,X\18?(*,\AS7"5,-D>0K(L?
ME6:PQ&%A/'36(QF(QF507)3P5&G0AF&;3>+K5,334/P(\+2^'M5U/P[/JFHN
MOA34K_2)=1U;2ME[(OAZ\N+=[O4=-$?F1W;C39)+FSV;TN&\O;N5QG]'?^"G
M/AW]EG]GW]D&^^*FDZ7X:\,7_A[3XH_!<_ANYC:\\<VMW920C2KR\%S<2>(I
M-6D>P@T[7]1_M+4#KUUI&GQWZ_VY-%=^ ^.O^"-W[0OPIO[ZP_8O_: ^&^H?
M">XU$MX6^#_[4FB^.-4N/A/H;+/)'X<\'?%OP/J&H>(_$7AC26:VTOPWH7C#
MPQ=:CH^A6UM:S>+-3N+9[B\]N_9@_P""3'BS0_B?X(^-O[97Q:\'?%W6_AQ>
M6/B?X=_!#X8>#]8\-?!?P;\1M-N//TSX@ZSJOB?7-3\4_%'Q#X>*QS^$?[<T
MOPWHOAO55?6[70IM3^R3V/YMX/?0PXYX&Q?B-X?<7\(>&W%O!'&U7*\/A_$S
M%9@WQ-D&399BZ^(J2R'):F4XK&4LZQU&M1E1A''Y3@\JSG"T<QK9AGN&P>&P
M=?ZGC;QUX?X@H\+\2Y)G?%.39_D$,95J\*4<-_PE9ECL71I4XQS''0QM&A/
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M#J4KWLW@SX@^#]91] ^)7P__ +6;^VHO#6KO8WVEZJ;F]\->(- N-2U:2_\
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M1/'^L6T3Q6^H>,O'7BB^U3Q%K7V0373Z;ILE]%HFCR7VHR:/I=@VHWQN/CO
M/Z*G&/@]1SC@S->..&>)/"[%\:9/QWA\!3X8Q>&XKQ>>\.8S*LPR-XC,YYG+
M Y=@J./R'),;C\+##9M+$U,N]A@\1EU+&XYU_;\1O&'(^-ZF!SW!\/YME?%U
M'(L=P]4Q,LVHU<GHY?FE#&8;,/9X2.$5?%5YX?,<?0P]5U<$J4<3[2O3Q4Z&
M'5/^73P/\-]:_9D\6>.OV-_';7%KXO\ @/KVLVG@R;4S%#<?$3X"ZQKNHZA\
M(?B?H2(SPWND7OAJYM?"^N?8KF^/A_QGX=UWP_J\UOJ5L86_:'X"_MP_L_\
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MK7BC7?&OP&U.XAFN+6U\2W/@?7/"-SX=-Q=6]KXEU3PEXVT[PZ=4GT>9Y/V
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M1P1PMC.&<#F-;.<VI9_Q1Q'F4,\XJSS#Y;#)\'F.;T\IRK(J,L!E$,3C5EN
MPF3Y)E> PN%GC<;7<,*\3BL7B<9B,17J?D&?YQ1S;$86G@<'/+LHRO"RR_)\
MOJXIXZOA<%+&XO,*BQ.-E2P_UK$U\;C\7B:U:.'H4^:LJ5&A1H4Z=.)1117V
MAX(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\)O&O@C3M6UB\DN)9=1U?4+.XU+4YBD^H75S-#"Z>3?\.)O^"6?_ $;9K?\
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MHHHH&%%%% !1110 4444 %%%% !1110 445^5UU_P6[_ ."3MC=7-E=_MT_
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M\/\ P#/:ZFT\Z/'#IUOJMJ8@S->HX",).^NFK>R?;UMY ?GA^V]_P4)_:/\
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M[+J>DZS:7'Q+B\9RSZAK5M?6NJW;:]%=BZM;N%95_:O]@/1OV]-$^"&HVO\
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M>%IOA%K_ (TUZSL-&LM&N].EMM?D\9?#_P  SVNIM/.CQPZ=;ZK:F(,S7J.
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:@?LS12 @@$$$$ @@Y!!Y!!'!!'((ZTM, HHHH **** "BBB@ HHHH ****
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MU/4)+6QB>]U"[N;RY,ES/+(_?44 %%%% !1110 4444 %%%% !1110 4444
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MI0EWU?Y>2\M/U ****8!1110 4444 %?#W[<_P#P3I_9,_X*+?#>+X<?M/\
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MU?L8?M)>+[GP!^S]^U/\!/C1XXL]#O/$UUX2^&7Q2\'^,_$-OX>TZ[T^PO\
M6YM)T'5KV]CTNSO=5TRTN;UH1;PW%_:122*\\8;R#_A[5_P2_P#^D@?[('_A
M_P#X:_\ S0T77<#]"Z*^2/B-^WS^Q'\(-)^'6O?%3]K+]GOX=Z+\7?!NG?$3
MX6ZKXR^+'@SP]8?$+P'K%M:WFE>,?!UUJFKVT/B'PWJ-I?6=S9:QICW-C<PW
M4$D4S+*A-OX;?MU?L8?&/PW\3?&/PG_:G^ GQ'\)_!;PQ)XU^+OB/P7\4O!_
MB/1?AIX0AL-:U67Q-XWU'2]6N;7PUH<>F^'-?OWU/5I;6T6TT;4IS*([.=D
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MFPU"RN8H[BUN[>:":-)(V4%UW ^[Z*^0O%/_  4 _8=\$?#WX<_%KQC^UO\
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M\,_&WX?ZSXA\2^(=9NXK'2=$T32;#79[W4M4U*]FAM;*RM(9;BYN)4BBC9V
M)XU_X*:_\$[OAOXO\3> /B!^V[^RYX,\<>#-<U+PSXM\)>)OC;\/]&\0^&O$
M.C7<MCJVB:WI-_KL%[INJ:;>PS6M[97<,5Q;7$4D4L:NI +KN!]R45\FZO\
MMX_L5>'_ (0>%/V@=<_:M^ &D? WQUXAOO"7@OXN:C\5?!MI\._%7BC3'UF+
M4?#^@>+9]631=5UBQD\.Z\EUI]G>2W,#:/J2R1J;.?9%\'/V^?V(_P!H;QK!
M\./@3^UE^SW\8/']SIVH:O;^#/AS\6/!GB_Q-/I>E1I+J>H1:-HFKWE_)9V$
M4B27=PL!BMT96D900: /K>BOST_X>U?\$O\ _I('^R!_X?\ ^&O_ ,T->O\
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MW7B#5+'0M5O;BRT>WOM1L+.;4+B-+:.YO;:%Y \T:MXW_P /:O\ @E__ -)
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M_L\>&/AA\7_^$B_X59\0-=^+7@K3/"'Q$_X1&_CTOQ3_ ,(;K]WK$6F^(?\
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M\;?A_HWB'PUXAT:[EL=6T36])O\ 78+W3=4TV]AFM;VRNX8KBVN(I(I8U=2
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M1LM(T?2M/^/'PYN[_4]4U*YBL]/T^QM8=?>:YO+V[FAMK:WB1I9II4CC5F8
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M%?'^A:) +#1-*T^P1K73('F2W6:Y::Y>69_TQHHLNR^Y ?GCX3_X)1?\$^_
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M&N=:N-&T+2_#6F2RZ;X:^(6BZ):FUT/1=,L%6PTRU21+59IEDN9)II.LL?\
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MSO::UJ</V&?Q!+I0%TS+8AXX6CY/X!_\$7O^"9/[+_Q<\&_'?X$?LL:#\/\
MXL?#^YU2[\'^,+/X@?&#6;G1;C6="U3PUJ<L6F^)?B%K6B71NM#UK4[!EO\
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MX=&T33)I[:'4=7U00FQTVQEN;>.[O9X;>2>)9#(OUWX=M_C GQ5^(=SXFO\
MP=+\'IM-\+1_#33M-@O1XPM-3BT]?^$KG\0SR0QV;6]SJ;W'V-(I[K-G'I_E
MI9RQWYO?./VD/@YXJ^+FH?L_77ABZT2VC^%W[0GP^^*?B,:S=WEJT_ASPK+>
MS:C;Z2+33[\7.K2B:-+.VN396TCM^^O8$!< 'DOQ _:4U]O@3\=/&7@?X/?&
M+X(^*/ G@@:MHWB#XJ_#CPYX<M+J_NKL6L(T>V?6/$-OK-U8 27,]O?:?)8P
M!K=KA91,D,G,:3\5_P!H'X5_L_>(?VKOC1\0M!\8Z/JGPNT7Q#X8^#>@>#-'
MT?2_#VN^,;WPQ:^!Y[OQG"8=>U1YO[7AB\5VL@:SMIM1O&T031V-D)?K#]H[
MX=Z[\6O@;\2_AQX9FTVWU_Q?X:N-)TJ;6+BXM=,2Z>>WF4WEQ:VE]<0Q%867
M?':3D,5RH7++R'BW]G^3Q]^RA!^SMXBU2UL=3;X6>#_!\VM:<);W3K7Q/X0T
MW0Y=.U*%+FWM+F]TF'Q'H5I<R1O!8WEUIRNB&QNI%>$ ^:_B'XN_;"_9R\ 6
MW[0_Q(^*W@WXC^&]-U#PW<?$KX)VGPZTGPI:>&]'\5ZM8Z))9^!_'%G/<>(-
M6U30=5UG3[2U;Q&H@N8%FO+R2Y:V:"_N_%7XW_$:]_:1UKX/0_'[PO\ LRZ'
M8^&/".O?##4O$'P]T/Q3:_&6;Q!9&?6/MWB#Q=?V>E:)#HFKP'0+'1M.ETS6
MM:FGN'M+F:XMXXA;\3?!#]KGXU^!/#'P1^-.L_!+2OAI'>^&$^)OBOP1J'C+
M4_''CW1?"=[8:K9V>E:=JWA_2M(T&_UC4=(LIM9U(W4:V]VXOM-LOL=O-H5_
MZ!^T%\,_C[\6M+^(WPSA\$?LZ>)/AWXDL8K'X?\ B/QCJGBNR\2^ 3=:'#9:
MAJUWH=OX0\065]X@TS5&O+WPM?Z'JVB"S4:>;TS;;B) #YR_:7\%_'&\_:K_
M &.88_C=I6C:]X@MOB7;>$[ZQ^%NCW^G_#W7]$^''A1?'VJ6]GJ.M^;XNLO'
M-X)IK'3];N+5O"L#)%:7%^RF0_J!I/VSPUX1TT^-/$]IJ^H:!X=M#XK\975E
M9>&K'4[O2]-C.N>);C3HKB33] M+N6"ZU.:SCNGL]+AD:%;AH8!(?CCXA?LU
M?$BQM?V1=;^%>O>&?$7B_P#9:LY= E@\>W>JZ!IWC?0-5\(:'X5UZ<7VF:=X
MJN-)U2ZBT&%K*"6WNX+*+4)Y?MLTNGP07WU5?^%]1\>_"J]\%_$9;"TU;QI\
M/[GPQX[7PG<7?]EVNH>(_#KZ5XG7PU=Z@@OOL,%Q>7PT>YO8Q=&W2WEN8Q,7
M0 'X@>#O%7B'Q7J7Q _9=\&>)=/\(_ 7]J7XR>,_$G@/X^>.?#?B/3[GQ1HU
M[-8Q^+?!'@Z'4[>PT[Q!XAU.^M-*T#3KS5;S26GF74K-%&K^(] M=._8/X&_
M$'P/KC>-/A+X!T77M.T;]G:_T'X2F^U,Z?-IM]+H6AP6L=EH]Y::G?7=TVC6
MEG;VFHMJ5O87*SR0[HC(TR0_&=[^S+^T_K7P'C_9?\4Z3^SAXL\%Z(EGH_@O
MXFZAJ?CVQ\2^&]+TQIQI?B6+PQ9:(R?\)KI=I.8-/DLO$5AIN3+IFM?V_I%[
MJ;7_ +Q^R=\$OC-^S[)XN\!>+M9\ ^./A_J>K:YXULOB/9OXELOBGXH\:>(+
MS3&U&Z\=Z7JC:IIES)/:PW0?5(/$%]? 66FQS2WIN9VL0"O^U]\)OB+XKUKX
M&_&+X9>']*\?>(/@%XPU7Q+<?"_5[RWTR/QII>MQ:/'=OI.IWR3:?:^(]"?1
M8;K1C>0_(US<7UE)-J5A9:3JUKX6_M'_  W^*WAWXU^(O!GA._\ AI\:O!_A
MNZ_X6)X7\8>%].T3Q]:7GA_1M6E\.W&L2+'*_B'1]*OYM2M=-^WR--ISRW,=
M[I6E+JL$=[Z]\7A^T1!J'A/4?@6?A9J-A;G5(/&OAKXER^(=-.HPSOIKZ3>^
M'M<\.VE]+8WMD(-3@N(KVTFLY([V*;R+B6!$3R#X0_ 'XBS?%'XK_&[X_P!U
MX#E\9?$7P;8_#/2O#/PU?5YO#GA_P#$L4VHVU_J&O:;I^H:OKFIW=O9--<S0
MS16HM)EM;AK*[MM.TH \[T'X]_%34/\ @G3/\>;GQ)&WQ5C\!^)-57Q.NB:"
MB_VIIGC+5-#M;XZ(-,_X1XR+8VD(>#^ROL3RAI&M?F*UB^(-3O-:_;9_8BUG
M491/J&K? OQWJ=_,L<<2S7E_X*U6ZNI1%$J11"2>5W$<2)&@.U%50 .//[+7
M[85I^SEJ/[*^E^)O@;;> [&V\2V>G^,_M'BV7Q=XGT2_UZZ\1Z5X?O=,FT#^
MR/#CW-[=S6^LZM!)J\UM8F&UT\7%Q#+JEY]*W'[/OC:3X_\ [-'Q/6_\-'P[
M\'?A7X@\%>*(#?:B-5O-7U+PU<:+;2Z';?V1]GNK$W-R)9)KV\TZ9+:.1OLY
ME\N&0 ^/_@GXLUKP-^P]^U]XL\.RV<&MZ+\8_C)<Z=-?Z9INLV<5Q(/"=L))
M]*UBUOM*OT1)W86VH6=U9R,%$]O-'NC;W_X3_&OXH6'QR^"/@WQ]KL&H?#SX
M^?LS>%/%W@*VM_#>AZ1!IOQ0\/\ AO2-5\:Z7;7FE6-G/);W6CK?:]+:7#M8
M6!U/1].TFULXHV26OX9_90^).B_LL?M#_!:ZU+P?)XM^*OCOX@>)_#=S;ZGJ
MKZ';V'B6;06TV+5[R30HKNUN]NDSM<1VNGWT,0EMP)W9IA#TWQE_9G^(GBOX
M%_ 31OA[KWAS0/CI^S^G@&Z\+^*+FYO8M&:[T3PW9^&_%FEQZDFDW&H+HNL+
M!#?[)-)0ZD=(T^UOK>VBFF\H P_"'Q9^-'Q4TS]IGQYX9^*/@3X>_#G0_BE#
M\.OAKXE\=:+I5UX<\(>%O!%N--^('Q$L;U4T@>))_$-_>6FH>'(_%&N3:!:W
MUM=:?/Y%JK0UG_ K]H_5M2_:,C^"B?';PQ^TAX.U_P !ZUXEL/&FF>&O#^@>
M(O"OBG0+^VBNO#^HS>$%T[PMJ^A7FEFYO[._M-*-\]S/;0><+:TFN+_6\5_L
M?ZZ/V4?@W\%/!]WX2O/%/PC\4>!?B!>:5XI?49_AY\0?$>CZAJ&J^,] \2,F
MG3ZC/X5U_4_$&MWUM!/I,C3FWTNRNX+.%Y;FTZ'PE\'_ (]ZM^T=X%^-'Q&M
M/A%X8\*^"_ ?BOP-HW@GX?ZMXCU6[T?3]2BTPZ<\VI:IX<T*RU.:XNUOD>WL
MM.T6PT?2[+3HH%O[FXN3" ?/O@'XF?MD?&7X6?&/Q_X9^+?@[P=!\)O&GQ2T
M[1K9OAYH.OZ_X\G\*F77+?PWJ<]ZNG:#X5T"QTF?2]#TG4[2PU77[Z[?4+_6
M[W9#;-/^@WP#^)%Y\7_@S\-_B9J.GVVE:EXQ\*Z=J^I6%DTK6-MJ3HT&H+8^
M?)-.EB]Y#/)9Q7$\]Q#;/%%///*CROXE^SY^S[XV^%GP;^,OP_\ $=]X;N-;
M^(7CSXJ>)=$GTB^U&YTVWT_QII=GIVD)J<]UI-E<074<MJ\M[';6EY'# \9B
MEGE+PQ^O?LX_#O7?A+\#?AI\./$TVFW&O^$/#5OI.JS:/<7%UICW23W$S&SN
M+JTL;B:(+,J[Y+2 E@V%*X9@#XX^/WAK1/VHOVJ;+X%:YJ,-IX ^"_P?\7>(
M_&%PX!C'Q%^*^BGPWX2LI4N)X;;^U?#>AWUCXZ\/7*JQ2:&^@<A9&VU/AU\=
M?&^C?\$^_'6KV-_%H_Q=_9WTCQ%\)=8N39V>I)I/B3X>W=GHNEW*P:E'?V.J
M2IX9N=%FGN;NWN;.[U47C/!*B/&?7?@O^R/H<-S\4_'/[1O@7X4_$GXE?$_X
MFZ_XO,^HZ%9>.M.\,>%YA#!X<\+:/>^+M!CN((M,@2X5S;6L EMGL+6=YSI\
M3)YYXO\ V./&-A??M4^'?A'%\//#7PL_: ^&GAN'1?"ZF[\/P>%?B9X<FM['
MR['2-(T2XTK3O#.KZ5+K&IZC=V8:Y;5[BPM4TY+2V,Z '/:Y\7/VK_ /@WX%
M_M#^*?'G@C7/!'Q#\1?#72?$WP9T?P396D&E^&/B)9(NGZY'X_N;I-?O_%42
M3V=U?6MG8:=H-MKMXT=M8WF@V,D5U]1?M%>(O%/AN7P]>G]HCP'^SI\/EM[^
M36/$&KZ/X=UKQQXAUV%3]CT/P[;^-?M/AE-,2VD^W:@UOH^K:_+-;Q6MI%;P
M7$ES'S'Q1_9]\;>,OV</@_\ "+2;[PVGB;P!??!*;6KN]OM1AT6XC^'::3%K
MK:;=1Z3/>S^=]CFDTT7.GVAN$V>>+5VV!/C'\%OB7??M"> OC_\ #G1_AKXX
MN/#OP[U;P#=^$/BAJ>J:-::#>OKW_"0Z-XW\&ZEIOAOQ3]B\0^?<7.FZI=&R
MMKE=(MXK.SFD;4);C30#Y8U;X\:]\:/V,_VP=,\1>)O#WCV[^&=QJ7A72OB-
MX7T@Z#I?CSPQ/'I%[HGB&XT@75S!I^LW!^VC4[73TM],@'V6"TCE:*>YG]7^
M"GQ2\>^!_B?^S7\-/%&L_:_A-\9OV6/!-U\.+232M(MO[$^)7@GPAH=WXETI
M-7M[6'5;VWOO#J+J<BZI>7:K?ZIIUEIL5NJ2++'8_LM_'#4/A/\ M<>'_&>L
M_#:Z^('[0^I66MZ9/X;N?$-EX3L;\Z-I\5]9RC4M+N=5L]/L[R*:PTZX9=0N
MKZUMXK^\CLI;E[:'#_;,\%WGPY_8_P#A#K*:S::7\7/V?;_X-+X$U31U:ZEU
M3QEI\&C^$-4T719+FU@O;S3]0MVN]<-FUG$VHQ>'[3[=9I''*D0!SGBW]JCX
MWKX4^/GQ;\-ZYIVG?"2S_:!\+?!7P9XCF\(6OBB#X9^!]%2]T;XC?&BUT_3H
M++4?'%M?ZS=:'<:-IVI:AJ-G'>R7%A%;)##);OZEXC\<_$;P[^R9\<?B/:_M
M">"OV@[6'PF;[P'XVTSP#X-T_P#LRY8>3K&F^(M%TV75O".K36OVRR,.GZAH
MMM<V4BW%KKFGW#D(/6?"'PM^*?P1^ 7P@^&WP:TWX;ZSK'A*#38/B!I/C_4=
M>TW2?$4&IV>I:CXV?0M9T73M9ET_5;_Q?J+WUE+J.E:AIR::]S!+;R,L$3^%
M6W['WQ!F^'W[6Z?9OA=X)\4_M&V/ARS\/?#SP+=:S'\.?!R>&;.:)+R[U:;P
M_I<]SK7B&YOKNZUJ6P\)VUI'>QM<V[S)J4D-@ 8/CS]H/XD6,W[,G@Z_^,'A
M_P#9T\*_$WX#^&/&MW\9]0^'^@>)+/6OB-+I^F)>>!!;ZR]IX+\&:3'8WT7B
M"?4[NSMK2'S;32[6XL(I5%?HE\.X?%$'@KP]'XR\4Z+XW\1?8FDO?%WA[2DT
M31_$,,UQ--IFJ6>EPWVI6]H+K2I+)YUM;V>SDN?.FLV6VDBC3YEU3X>_M :;
MX$\&?"O3_!'[/'Q/\ :=\'/!7@S6M)^(NL>*K'[/X[T#2UTK4]4DCB\'>(;'
MQ#X.>*"RFL+0Z?HFO&:*XD-Q9,85/JO[,GP?U#X#? [P)\*]6UR'Q%JGAJTU
M-]1U.TCN8M/^VZWKFI^(+FQTN.[=[G^R]+EU1M-L)IUMYKRWM$O9;*QDN7LX
M #WFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N#\=^&O#GB4>$(O$
M>@:+X@BTGQMHFN:5'K>E6.JIIFMZ?%??8-8T]+^"=;+5++S9?LFH6PBN[;S9
M/)F3>V2B@#O**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ny20006478x8_graphic05.jpg
<TEXT>
begin 644 ny20006478x8_graphic05.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
M+0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0":
M )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0T!
M$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I
M ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F<"
M<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P-:
M V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$
M?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%
M!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'
M3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC[
M"1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*
M\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-
M#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/
M>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('
M$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4
M\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W
M&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;
M8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I
M'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J\B
MW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR;H
M)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K
M:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^
M,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U
M$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_.;PY^3HV
M.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_
MXD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:
M1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+
MXDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q
M4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9
M&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %
M8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUG
MDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>
M;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW
M5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$
M?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(
M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$_
MD:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:
MU9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16
MI,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVN
MH:\6KXNP +!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1
MN4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'# [,%GP>/"7\+;PUC#
MU,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZV
MSS?/N- YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':
M=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-
MYI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_R
MC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<
M_VW__V1E<V,         +DE%0R V,3DV-BTR+3$@1&5F875L="!21T(@0V]L
M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***_ ?\ X**?
M\%AM%^%YU;X,?LH:OI/BKXBA+FP\6?%NW^R:QX4\!S?ZIM,\(*Z7.F>+?%L1
M,C7FIRBZ\,>'72&T$?B#5I=0M/#OEYOG.7Y)A)8S,*RIP5U3IQM*OB*G2E0I
MW3J3=U?50@O?J2A!.2^#\1/$GA'PNX?K<1\79E'!X6/-3P6#I*-;,\VQ:BG'
M Y7@W.$\5B)7CSR<J>'PU-NOC*^'PT9UH_K-^T9^US^S]^RIH,6N?&KXA:7X
M;N;Z)I=#\*VHDUCQMXC ,R!]$\*::)]6N+(3PM;3ZU/!:Z!87+11:EJMFTT>
M[\&?C[_P7W\3ZB]YI'[-'PAL?#MB2T<'C?XN3C6-=EAE@4>9:^!_#6H1:-HU
M]:W&]H9[[Q;XML[F,(9],B.Z.OY\_%_C'Q;\0/$>J^+_ !SXEUWQAXJURX-W
MK'B+Q+JM[K6M:E<;5C66\U+4)KBZG,<2)#$))2L,,<<,2I%&B+S=?BN<>(V<
MXZ4Z>7<N5X5Z1]FHU,7./>>(G%JFWHTJ$*<H_#[2:NW_ )C^)'TSO$KBJOB<
M)P<Z/ F12<J=)X.-'&\0XBEJN?$YMB*4H82<[1G&.58;"5L.[TOKN)C><_N/
MXB?\%*/VYOB>CP^(_P!I'X@Z;;.6'V7P'<Z=\,HC$P*FWE;X=:?X7N+J HQ1
MX[V:Y\Y<B<RDDGY,U?XA>/O$$L=QKWCCQAK<\*ND4VK^)=:U*6))&WNL<EY>
MS.BN_P [JK ,WS$$\UQ]%?$8C'X[%RYL5C<7B9/[6(Q%:M+OO4G)]#^7,XXM
MXKXAJNOG_$W$&=UI;U<WSG,<RJ/5/X\9B:TK)QC97LN56V1:M[Z]M)FN;6\N
MK:X<,'N+>XFAF<.P9PTL;K(P=@&8%B&8 G) ->C>%_C?\:? \EM+X+^+WQ0\
M(2V?F_9)/"_C_P 5^'Y+7SY#+-]F?2=6M&@\Z4F27RBOF2$N^6)->7T5A"K5
MI-2I5*E.2V<)R@UK?1Q:>Z3]4>3A<?CL#457!8W%X.K%WC4PN)K8>I%W4KJ=
M&<))\T8NZ>\4]TC]*?AI_P %</V\OAL^E0_\+E;Q]HVENA;0OB7X9\.^*DU2
M-6+&#5?$O]GV/CVX1\E7EA\7VUUMP%N%*J1^OW[/G_!>KX4>)QIVB?M'?#?6
M_AEJ\GV6VNO&O@5IO&7@AYBA^V:E?Z#+Y/C'P[8K( (+#3$\?7FUOWER<%J_
ME8HKZ/+N,N(LME%TLRK8FFK7H8Z4L92<59*"=63JTXV2THU:3\]6?M/!?TDO
M&7@>O3E@>,\RSG!0Y%/*N*:U;B' 3I024:$'F%6ICL%22BDEEF-P4DKKFLY)
M_P"CG\/?B/X"^+'A33/'7PT\8>'O'/A#649].\0^&=4M=6TV=XSLN+9Y[623
M[-?V<N;?4-.NA#?Z?=)):7UM;W,4D2]K7^>A^S_^TS\;?V8/&$'C/X,>.]8\
M*7C7-C-K6BQW,MQX4\6VU@TWE:;XN\-R2?V9KUD(KJ\AA:ZA^W:;]KGNM'O=
M-OS'>1_V0?L'?\%$?A5^VGX3AL8Y['P3\;=$L8V\8_#"]O(UFN_)@A-WXH\"
MO/,T^O>$IIW<2*"^L>'9@+/78%@FTG5]:_8>&>-\#GTHX2O!8',N72C*:E1Q
M+7Q/#5)6;G]IT)KVBC\$JJC.4?\ 1[P-^E)PKXM5:7#^;8>GPIQJZ:=/+:V)
MC5RW.Y07[V61XRHJ=26(5G5GE6)A]:ITI7PU;,(4<16I?H?1117W!_4P4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[.*9I[69$_++_@I7\7?VGOA[\1/@;I?P;U7]H)_A!-X3^)'B?XWZ'^Q/X0^
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MEZ_T]/UWHK\B/^&)?^"F'_28#7?_ !"SX0?_ #=U\_?M5?!S_@IA^S'^SO\
M%GX^C_@JMKGC<_"WPK/XH_X1,_LC_"#PX-=^SW5K;?83KA\1^(!IH?[3O-P=
M&U$#9L-NP?<N.)XDS#"8>OB\1PAG]/#X:C5Q%>I];X6G[.C1A*I5GR0XBE.7
M+",I<L(RE*UHIMI'IY)X)\'<19SE'#^3?2-\(,9F^>YG@,FRK"?ZO>/>'^M9
MEF>*HX+ X;ZQBO!:AA:'M\57ITO;8FM1H4N;GK5:=-2G']^**\7_ &;O&.O_
M !$_9V^ GQ \67<>H>*?'7P6^%OC'Q+?Q6MM8Q7NO^)_ VA:WK-W'9644%G9
MQW.HWUS,EK:00VUNKB*"*.)$0>T5]-0K1Q%"CB(*2A7I4ZT%))24:L%.*DDV
ME)*2NDVD[V;W/PO-<NKY/FF993BI4IXG*\?C,NQ$Z$I3HRKX'$5,-6E1E.%.
M<J4JE*3IRG3A*4&G*$6W%%%%%:G %%%% !1110 4444 %%%% !1110 4444
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M$8_X65X&UWP9_P )#_87]IZ+_;7]B_VU_:7]D_VSI/\ :7V;['_:=AYWVJ(
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M/CS^U=O_ .$6_P"$6_X0_P#X7=J^EZK_ ,(%M_X2/Q'_ ,)!_P (Q_9OD?\
M"4[M$_MKS_-_X1S2?+\N0 ^OZ*** "BBB@ HHHH **** "BBB@#\U-?_ ."0
M_P"P+XC\9?$'Q]>?"GXAZ=XG^*?C_P 7?%+Q[<^%?VH_VL/!&F^(/'_CO6+C
M7O%GB1_#G@WXX:#X;T^[UC5;J6XE@TG2;"QMHQ#9V5K;65M;6\7O7@7]A_\
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M;CX7?$&RL[;[1;6-X  ?VZ.Z1H\DCK''&K.[NP5$1069W9B%554$LQ(  ))
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MF6ZU*U\"7D;1/K=_;A[SX-^-_P -O^"D'B'X5_L=_LCVO[(OQ6\5?LF_#_\
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M63Q9)HOB36H];UKP=X8L%UO5+6^U?Q%<W>GZ/HVNZM9_//\ P5G_ &>OB?\
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M*>&?$L,VN^+=<_M_7X-0TF+4-.T:X_2F@ HHHH **** "BBB@ HHHH ****
M"BBB@ K^ ;_@\4_Y.4_8X_[(=X\_]3V&O[^:_P Z_P#X.WOC5X!^(/[:OP9^
M%OAN^U63QK\"/A1?Z#\1],U'P]KFD6^G7OCC4-*\<>%Y=(U74K"VTKQ/I^I>
M'-2M;HZEX<O-3LK.[%UI%_-:ZO8WMC;@']67_!O1_P H<OV*?^Q9^*?_ *OO
MXJU^SU?@1_P;4?&WP!\4/^"4OP.\!>#;W6+_ %[X!WWCOX>?$M[KPUK^E:-I
MGC+6_B)XQ^(UKH6DZ_J>G6FC^)KNV\'>,?"VL:J?#UYJ46DIKVFV^H26]W<"
M ?OO0 4444 %%%% !1110 4444 %%%% 'Q#^WK^Q?X4_;4^"M[X*O#IVC_$?
MPR+W7/A/XVO(7_XI[Q*\"+-I>I7-M!/?#PGXI2VM=.\2VUO#=&-8=.UR'3[[
M4]!TR&OX9_B#\/?&WPI\9:_\/OB-X9U;P?XS\,7SZ?KGA_6[5[2_LK@*DL3[
M6S'<V=Y;20WNG:A:23V&IZ?<6VH:?<W-E<P3R?Z.U?$O[9O[!GP3_;4\+167
MCJR?PW\0=%L9;7P9\5= M;<^)_#ZF26XBTW48Y##%XF\+&\EEGN/#FI31K&U
MS?3Z)?Z'J5[-J5?G_&7!BSY+'X!TZ6:4J?)*,[1IXVG'X(5)[0KTU>-*K+W9
M1M2JM0C"=+^0_I*_1II^*\(\6\)2PN X[P.%5"O0K\M#!\4X2A&*PV&Q>);4
M<+F>%IQE1P&/JITJM)T\#CIT\-3PV)P/\&-%?H)^UK_P34_:9_9)N-1UCQ#X
M8?Q]\+;>61K7XK> [:[U3P_!9[T$,GBW35C?6/!%SB:VAG;7+=="DU"8V.C>
M(=;,;3'\^Z_"<;@<9EU>>&QV&K86O#>G6@X-J[2E%OW9PE;W:D'*$EK&36I_
ME%Q+PKQ'P=FM?).*<ES'(LUP[_>8/,<-/#U)0NU&M0E)>RQ.&J6;HXK#3JX:
MO&TZ-6<&I,HHHKE/ "BBB@ HHJU96-[J=Y::=IMG=:AJ%_<P6=C865O+=WE[
M=W,BPVUK:6L"23W-S<3.D4$$*/++(ZI&K,P!$FW9*[>B2W;[#C&4I*,4Y2DU
M&,8IN4I-V226K;>B2U;T15K[3_88_8Q\<_MH?&33/!6CVVIZ5\/-#GM-4^*G
MC^&U<V'A3PUYK,;&VOIH)K!O%WB-8+BP\*:3*L\UQ<)=ZM/:/HFAZW<VGV]^
MR'_P14^.7QF_LSQA\?[F]^ OP\F>"Y'A^]L%G^+7B"T$L#200^';L+:^!X[F
MW-W"NH>+!+K6GW<4,C>"=0LIUN!_5'\&/@I\,_V??A[HGPP^$OA:P\)^$-"B
M_<V=HIDN]1OI$1;S6=;U&7=>:SK>HM&CWVJ7\LUS.4CB#I;P00Q?H_"W 6-S
M"M1QF;T9X/+H.-14*BY,3C$G=0]F[3H496]^I449R@[48OF]K#^T/ ;Z)?$W
M&.8Y?Q)XB9=B^'.#</.AC899C82PV<\2QC.-2&$CA)2ABLKRRM%)XG&XJ%'$
MU\/.,,NI2]O]>PO0_#SX?>#OA1X'\+_#CX?Z%9^&O!G@W1[30_#VBV"D06=A
M:)@%Y'+SW=Y=2M+>:CJ-W)-?:GJ%Q=:A?W%Q>7,\\G9T45^[PA"G"-.G&,(0
MC&$(12C&$(I1C&,591C%)))))))+0_UAPV'P^#P]#"82A2PV%PM&EA\-AJ%.
M%&AA\/0A&E1H4:5-1A2I4J<8TZ=.$8PA",8Q2BD@K\PO^"S/_*,_]J3_ + 7
MP_\ _5O_  ]K]/:_,+_@LS_RC/\ VI/^P%\/_P#U;_P]KPN*_P#DEN)?^Q!G
M'_JNQ)^R?1\_Y/WX(?\ 9WO#7_UL\E/N;X#?\D-^#/\ V2CX=_\ J(:/7J]>
M4? ;_DAOP9_[)1\._P#U$-'KU>O6P7^YX3_L&H?^FH'YUQ'_ ,E#GW_8YS3_
M -3JX445\<?\%#M>^(GA?]@[]L;Q%\)Q?+\1=&_9I^,^H>%;K2;Z\T[6],U"
MW\ ZZ[ZWX?NM/@N;[_A(]!M!<ZUX=M[2,7%[K=A8644UL]P+B+I/&.CD_;@_
M8WC^+MO\ F_:E^ 1^--SJTGAZ/X8Q_%?P5+XR7Q)%-]G;PO<:+%K+W=KXI,X
M\J/PS=)#KLTGRPZ?(2*^FVL[1[J*]>UMGO8(WAANV@B:ZAAE(,D45P5,L<<A
M +QHX5R 6!Q7\KWP+_94_P"",%I_P1B_93^-'[5/@3X0^%O FO>&/A3?^.?C
MUHVD:G:_%_5?C7J/B>#3/&WAA/B+X'TJ]^+NH1_\)U8>)O#'B7PUH]U<:?X<
M\*:)K%Q%#HNC>%$UG1_6_P#@K#^V?^T#\//C-X=^"_[(_P"TM\9?"FI>#OV5
M-9^.WBKX9_ W]F;P-\:O%^BVFC7=[=:%\5/VB?C%\?O$>B^'?AA\&X=+L+"W
MUQFN+SQ<ETS/XMT_4XO'/AHVP!_29+%%/%)#-''-#-&\4L4J+)%+%(I22.2-
MP4>-T)5T8%64E6!!(IEM;6UG!%:VEO!:VT*A(;>VBC@@B09(2**)5CC4$DA4
M4#D\5_$]XI_X*G_\%*OB?\.OV6?BEI?Q!^,?AGP7XT_9!UCQQXKUG]BOX&?
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MXI_#/P[KOBCPY/X^N]<\$?#SQ(^CZ<VH^&[?PMI*7T*ZO_!-?]M?_@H_XO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &LB,49D
M5FC8O&64$QN4>,NA()5C'(Z%EP2CNN=K$%U%% !1110 4U$2-$CC18XXU5$1
M%"HB* JHBJ JJJ@!5       IU% !1110 4444 %%%% !1110 4444 %%%%
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M1CU.WA\':/K>H3:[;?Z _P"P'_P5)_8Z_P""D7@UM?\ V=?B/$_C/2M.@O\
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M /+&C_A4?_!8/_H[S]E+_P ,%K?_ ,L:/[>Q/_1,\1?^"LI\O^IOY_@^P?\
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M?%_X=_\ "(?"_P"-WB+]G_Q1_P )%H.K_P#"P/"^AVOB'5/[+TJZ:?4O#_\
M9]YJ>DP_9=<A(M;FX^U[X$4.D,I^6O=J\7%X7,\5CXO#YGC\LPF'IX>3A1H9
M/7PV/G*K5E6@WBL-BL=1E3A"G3JM.A3E&K"5!RJ1JRC^G\/Y]P/D'"-6GF_
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M?G3^TK^U_P#M0_!CXH7?@CX4?\$_/BA^T7X1@T;2-1A^)7A3XA:/X;TBZO\
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M']5M+;4=/O;G3M8L([/6=.FET_4+61@#Z5HHHH **** "BBB@ HHHH ****
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M491E%?[!_0/S:GF_BGBLRPE11P^;< 9AB\11I*4*=/%O-<J>,PW([/DPF/\
MK5&CSJ\J=.%6#E3J0J2X+_@KEKY\.>-OA+?1 _;+OX-_&70;.09S%_PD/CGX
M):1?LI'*LVFW-V 5Y8@)RK,#\!?\$@_@2/C?^W)\-;G4[!-0\*_!\R_%O78Y
M8!=6CZIH#+'X(LIV?;!&TOB22/6K97\R65O#DR* A::+ZR_X+<W<MMX\_9GB
MB/S7GA?XJPA<'YFA\3?"BYB^Z=QVRQ)\HY.<#DBOH?\ X(5^$[;X8? /]HW]
MIGQ#H#VS:S.NG^%-=ED@ECU;0O"UE<0KI\ A)>VW^)EG^S[Y7\V/5[1G,8NK
M,7'I?1ZQTJ7T7^#L!0][$YA6XAPM.FOBFZW%N:TU!=.6K6GA:%1:WA6DFDFK
M^-](K!4Z7TG>.,SQ#C"C27#6*G5EI"%' \%9+B*[FT[Q=/ X7,\13=X)5:<6
MY:Z_3W[77C0>,OC=XN:*4RV?AR6#PI9D-OC!T7?'J!0K\N'U66^.> VW(SCC
MYB )/'7KUQTYZU>U*\N]1N[O4[N1I[B_NKF[N79?WDUS<S/-<2L<_*YED,CQ
M[-R LJ AU-8M]?PZ987FJ7 D%MI]I+?SO''Y^V&WBEG9=B.I>5TA<0PAU><_
MZHL%8C^W<GP='*<JR[+*3BXX/!X;"PMRI594X*DYIWM>K4C*;;M)N3;2O8_R
MMXFS/$<1\19SGM6,N?-,PQ6.G%\TYT8U:CJ1I227,U1IN-.*BI+E@HQ;4=/F
MC]J+QY;>'_"XT7SEW21MK.JQ*^&%E8L396K;=S*UYJ"+)&/+8DVFX*24W?NK
M_P &]7[+VJ>!?A=\0/VC?%UD8-<^(%Y>>#?#S7%NXE:*#4[?6/B'J-G.XVI9
MSZ[9^%_ =Y:P,_EZW\*]3:>8EX;6R_F)\>^./#&J>+9O&WQ%U6ZTKPEHMY#K
MU]!:V=OJFJ7DEO<0P>%-!TC3[NXL=-UK58S'?:]:>'[W4=*LM=/AFXL+S6-,
MM;JXU.T_HG\ ?\%!/^"BW[+=C\,-#\7_ +"WPH^&?[+>@Z1IC:=\([G5/',/
M[5.B_"JQ,INO$FJZWJVKZ=\//%7Q U"TCN-<U;3K7P]8:C?^)[J\L-:MM+U>
MXO/LO\J?3!\:.$/#[)^'N"N(N(\KX=CG./P4L=B\TQD,'AI8G$U'_9V7U*]1
MQP]-XG&4HM5:]2G2A.AA*3J^UQM*G+^[_H2>#F=Y]BLZX^P>58K,WE]#&X7+
MZ6#I/$5G*,(+'XNG2@O:2CA,%5E3M",Y5XXNK44(K!U+?U&45^-WQ,_X*6_$
M'XPW>D_#_P#X)O?#71/C?XY;X8>#_C%\1/'7CW[4GP[^#_A'QMI+ZQH?A?Q!
MHWA_7-/U_6?BI>V)C>7PMIVH :-<,MNZ:Y=6VMV6B>+?"+_@LKK/PWBU[P_^
MWAX,\*>&]2A\+>)_%'P]^(_P0CUFY\*_$.Z\+:5!>R_#>X\*>*=1N=6\._$/
M5FP-#U&[UN#PEX@O]0331_PCR:>;N_\ XKQ?'G!^7\697P-CL_P&#XLSO"XS
M%Y-DN)G.AB,TI9?1CB<?#+ZE2G'#8O%X+"3AC,5@:%>>-H8*I3QM7#QPLX57
M_?\ 0X>SO$Y-C.(,/EN)KY-E]:A0QV/I1C4I8.>)FZ6&EB8QDZM&C7K*5"CB
M*E..'J8B,J$*KK1E!?OU17\^'C?_ (*%_P#!3;P1KOAWXB>(/V8_@=X2^$_B
M^/\ X23PE\'/%>J>+[?XO:[X$6YMIC;S_$.RUF?P9HGC^>PE@S'?^%ET_0UU
M2V_M?PY+<K&DOHFI_P#!4WXR_M-^'[BW_P""<_P.LO%NI^#O!VA>+_CGX\^-
MT.I6GAKX0W&NVVM!?AW:>$O#^J:7KOC3QY!)H^HWCZCI.HW&@6<.E%!IVMQZ
MB\VE>?@O%#@',9<5T\!Q-@,7B.!YT8<5X+#PQ57,<G6)P\\9@ZM;+88=X^MA
M\PPM.IB,LQ6$PV(PV94:<ZF JXB$)-=-?A+B/"K)I8C*<30I<01F\GKU72AA
ML=[*K&A7A3Q4JBP\*N&K2C2Q=&M5IU<)4E&&)A2E))_N717X#_"W_@M%=?#_
M $;Q=X;_ &UOAWIVB?$C2_#EYXC^&6L_ ZTU?4O!_P ;YXM0T;1[7P'X>T/Q
M!J6H>(/#OQ!-_K5H\\>IWDN@SZ?%J.JR7&BV]MIUMK&7XM_X*'_\%*/@WX\L
M/$/QL_9G^"ND_#O4H(_$DOP1T/5?%#_&;3_ 5W<WYM9--^($NN7G@;7O&^FP
M#R]8LSH-EI^JW6DMIMEI/A[4+]VM^/$^,/A?A.&\@XPQ'&^04^%>)Z^%PV2\
M1?6^;)\36QM>KA</&OF$(RPV71EBZ%?!U*F95,'2P^-HUL'B)TL52G2CT4N"
M.+:V:YCD=+(,QEG&54ZU7'99[&V.I0H4X5:CIX:357$M4:M.O&&%C6G4P]2%
M>G&=&49O[$_X*_\ QD^*'P+_ &0#XZ^$7C76? 7B[_A;WPKT+^W]!EAAO_[(
MUG7);;5+#?/#.GD7L"B*=?+W%1PRGFOU(KXXUV^_9,_;C_9C\!^-OB)_PC_B
MKX!?$1O"WCG0U\7>)+KP;;P>(-/O)?[.T_5+_2O$&D26GB/P]KT%_HVIZ,FK
M3Q1ZUI]]8.MV(,G['K[/#87$T\YS3%U,3&>%Q.#RFCAL*JM24L/5PL\R>)JR
MHR2ITEB5B*"C.G)RJ^PDJB7LX7]C.<^R/%^&G ?#N$R6MA>(,DXF\0<QSG/I
M8#!T:&;Y?GN%X'I9)@*.8TZDL;CJF35,FSBI6PV+I4Z& 6;4I82526-Q2@44
M45ZQ^>A1110 4444 %%%% !1110 4444 %?D=_P5._X) _!K_@J[)\ (OC#\
M3?B+\.=/^ MW\3;BP'PWMO#)U?Q!#\3+7P1%J%K+J7B?2]<M-,2RN? >CW*/
M'H]\;I'G@986\J>/]<:* /XA/VUO^#1/P_I/POM?$7[ GQM\;>)/B?X:TS4)
M]<^&_P"T7J_A)K+XFRQYN[:'P;XX\(^$/!VF>!M?V)/INGZ7XKTC4O#>LSW&
MF?VKXO\ !L%EJ6KZC_/S^R_^WW_P4O\ ^"(_QNUSX436OC'P-;:'J\LGQ&_9
M3^.VEZU<_#C7A=N8Y/$&D:))>6K:+<ZU';0WVA_$WX9ZM90>*+2UTRY?5O%7
MA5OL%[_K U\=?MG_ + _[*G[?WPVD^&7[3_PJT;QU8VL%]_PB?BV '1OB+\/
M-1OHXP^L> O&]@J:UH%UY]O975YIHFNO#?B!K"TL_%6A:]I2/I\@!\.?\$T/
M^"ZO[&7_  4AL])\'Z3KB_ O]I">"%-0_9^^)>M:?'JFM7_V47%TWPG\7&/3
M=(^*FFQ%+SR[?3[/1O'$-I876IZSX%T;3/L]W<?M17^:9_P4M_X-M_VN?V(;
MS7?C-^R]<>(?VGOV?O#]U)X@@U/PC8RP_'WX7:?97,-U;W?B[P3H<:S^);;0
M@\<DWCKX;1W:Q0:;J/BCQ#X3\ Z1:YC]:_X)A?\ !T+^T#^S<?#_ ,(_VY+7
MQ'^T[\$[8+I]E\4(+J"Y_:)\"6F(Q"][JVL7EII_QBTBV,<BO:>+]1TKQJAO
MI;S_ (3_ %*STO3_  O, ?Z+-%?/7[,O[5W[.W[8_P ,=/\ C%^S/\6/"OQ;
M\ 7\HM)=4\.74R:AH6J_9X+N30/%WAO4X+#Q+X-\206MU:W5QX=\4Z1I&M0V
MMU:W;V(M;JVFE^A: "BBB@ K@_B1\4OAM\'O"MYXX^*WCSPE\.?"%@\<5UXC
M\9Z_IGAW2$N9@YM[*.\U2YMHKC4+LQNEEI]NTM]>RCR;2WFE(0_)7[;_ .W!
MHO[)VB^%O"OA+PL_Q<_:,^*MV=,^$GP:TW4([*XU!49UU'QKXQO5$LOAWP#X
M>2*=[S5)(0VIWL)TZUEL[*WU[7_#OYFC]F>X\8^(H/VA?^"BOB6U^/WQJOTN
M!X0^#D5O>6?PB^$>G72QR-X:\-^#[F2"&WB@"VW]I76H0R>)+JZM-,O_ !!J
M5CXIM=1@UC\3\8_'K@/P5RK$8WB;,*$\QIX*.80RF.*HX>5'!U:U3#4,PS7%
M55.&6Y?6Q-*O2PS5+%YIFDL)CZ7#^49UB\!BL+3^KX7X.SCBK$TZ6 HS5"59
MT'B/9RJ<]:,(U)T,-2BU+$5X4Y0E4]ZEAL,JM&>.Q6$I5J=5_55Y_P %GOV<
M-5O)X/A'\(?VJ?CQI8N7M+/QA\-O@W]G\$7TT<TL+,NN^._$G@RXM8%,:LTM
MWI<+*LT9:(;9_(HV7_!:?]G^QN+4?$OX _MC_!S1'"_VCXU\>?!""7P7I!;O
M>:CX3\7>)M9D3')^R^'YY1R#".,^.ZQK\FINT=GI^EZ#I:I%;VVCZ'86NG6<
M-K;K&EO#-]EAA>]>-8D9IKHR%IM\J+$7*C K_*/-/VN7%.'XBQ']E>$W#.8<
M+T\2XT*=?/<XP6;U\/"M--QS%X2KAU[:BJ;I5:N149PDW*K@DW[&/](8;Z,^
M73P-/ZSQ)F%#,94TYN&$PM7#0FX1=G052,_=GS*48XR<6DE&L_B?Z[? ;]L'
M]F+]IVT%S\"?C9X%^(5R(9;F?P_8:F^E^,[*UA?8]WJ7@3Q!!I'C/2[3=PEU
MJ.@VMO+@F*1P":^DJ_F%^(/[-GP/^)L[:AXJ^'>@'7_M$5[%XMT*!_"_C&"^
MM\&TO$\4^'9-,UN66T=4EMTNKVXMED16:!P"#QF@_MV?'7]BC7KS1M#_ &I/
M O[4O@?0[B*#Q!\"_P!I7XH:%8?&;0U5HI;F#PC\999DO3JC+-\FF^/=/O\
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M^<OP>\(88!C;1D%CXN+X@RO"3G2E7E7K4WRU*6#HU<5*E+3W:\J,)TL.]?\
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M@Z'I]II.BZ)HVEVL5EIFDZ1I=A#;V.FZ9IUE!#:6-A9P0VMI:PQ6]O%'%&B
M X7X,_!?X5_L\?##P;\&/@EX%T#X;?"_X?Z/#H?A+P=X:M#:Z9I=C$SS2R.\
MKS7NI:IJ5Y+<:GKFNZM=7VN>(-9O+[6]<U'4-6O[R]G^1_CC^R-\:]5_:4L/
MVK_V6/VB/#_P0^(VH_"JU^#_ ,4_!/Q'^$VH?&+X2?%GPWH7B6X\2>"M:U3P
M]HOQ/^%6K^'?''@Z?5_$-A9^+-/UG4+V_P!"U"'P^\5E80SM=?H-10!^).M?
M\$EOB1J/A6^\;/\ M5Z;KO[8'B+]M7X-_ML>,?C?XG^"1;X;:[XF^!'AW5_"
M'PU^&6G?!70/B?HTOAWP%X?\-:HM@;N+X@:CXGU22"XEOM4*7.GPZ'[OXH_X
M)PS>*?VD]5_:)N/C1';7&K?MF?LZ_M>3^%(OANSQ1S? 3]DS7OV7I? ,>M-X
M^#"/Q<^N-XZ3Q.VE,WAY;8>%SX?UPR_\)''^G]% 'YK_ !C_ .">7_"VOA!_
MP40^%/\ PM[_ (1__AO;QKI_C#^WO^$ _M7_ (51]A^$?P>^%?\ 9W]E_P#"
M;:;_ ,)UYO\ PJ?^W?M?]H^#MG]O_P!E_97_ +*_M'4O,/VCO^";GQE^)_B7
M]M.'X)?M3^&?@E\-?V__  ?X3\/_ !]T'7_@')\4?&6AZKX:^'Z_"K6M4^%G
MBR'XN> =*TC3?B7\.[73?"_C/1?%7A3Q3/IXAU36O".LZ+J^LI/I7Z[T4 ?A
M_P#%'_@C8WQ$\*3:#%^T1:V-S%^Q_P#L9_LM6<6K_!Q?$'A35;O]D#XHVOQ,
M@\4>.?"<OQ.L[7QCX*^)[6O_  C_ (A^%5Y=VUMIEI+]L;Q9KLD,=K72^&/^
M"5_Q NOBC^T1\6OB;^T%\+S?_'C]A_Q[^P_HWPZ^!W[,?_"GOA;\'/!?BV^M
M]6TO6_!FBW?QH\<ZGJS:5K=WXNU_6=+UK4DE\1:OXJ?[#J_AC2M)M-*E_9NB
M@#\/?"__  2E^,W@BX^%7C3P]\?_ -G35_BEX6_9C\&?LI?$6X^)O[&X^)'P
MS\;^$OA)?:S;?!;XHZ+X*O/CGHVM^&/C%X(\(ZK_ ,([K>HW/C/7?"7C2-$6
M7PSH5C;065?JE^S7\%U_9W^!'PO^"Q\6:CX\N_ 'A:TTC6/'&K:?9:1?^,?$
M4\L^I^)O%$^CZ:TECHPU[Q#?:GJD&CVT]W%I5O=1:>+V^-L;R?W"B@ HHHH
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MPK^-FAZE8^&/CCJ]G9Z-?:_XR\0Q64.HQZY=>,=-DO)-5TO59I[K4(])6_\
MLFCZJ^I1Q6@#I?7W\S<2?1R?%'COPOXQYEXA<03R?A/%5LXROP]>%A++L+Q#
M7R/ 9%B,QP.<+&PKX/!XS#Y1E6(QV6_V?7=?%86I*GC*%'%5J+_5LK\3UE/A
MYF_ ^%X:RV.-SFC#!8OB55I+%5LLIYAB<QI8;$8)X>5.O7H5<;C*6'Q7UFFJ
M=&M%2H5)T83/Q9\8?MF+\?O@Y\*+O6=9\%:=X%^&_A2WM['4[.==/F17TC2+
M)_\ A+Y[K5[RRM=9TZTTF"UNK6VBTR."^;4-UMB2"&V^5OV!_CY\1/V5?B5\
M7O$4?A:R\#V_[7NA3?$OX2S^/=,GME\9?#T>-O'>EZ=K>@0+JEBL6J:1?K>W
MFCZ=<K)_:&D:C<:W_95_X?N=&U!_V:^*?P7_ &5K_P#:JUO7];_9(\!ZW\(/
M#7B;0/#GQ6U.'1/#=EX?U;XU^,;JVN]&\<:KX!B-JGB]M*M=1U33]=GGTJ]C
MU1KW6M3ODO[RVL(=2^V/VXOAU\+?$OP-M]*\0_!SPQ\1O$UOJNA^#/@=9W&B
MZ,EYX(^(?BNYM- \(ZOX7U>ZAB_X10:5?)IUR!9W%C9W_P#9UCH]ZR6<^^'X
MCASZ(V9<._\ $5<RI^-G&N(XO\0<%PWEF1<8K!4<-F_"&6<)5\-4R/#UE3S*
M5/B.I3PN!P.68RO4>4K$Y?1K0I4L+B\3+&0^@S3QIPN9_P"I^%EP%D-/)>&J
M^:8O,,C=>=7!9WB\YIU8YA5AS86,LLC*KB,1BZ%.*QKI8J=.4YUJ-)4)?R9_
MM1Z;J/Q*N= \(> ?"'_"RO$/PKMO$/Q[^(^EZ4]O=2>$_A/\.-+6Y\67OB/%
MQ')I^F:E'J-FGELRW%W+;6T,,;3W%FLWZ(?&[]M!OCYX-\'_ !!\;>(_!,'@
M_P %^&[K^SM<T,/9VEVM^EBVHWFH?:M1OI'UV]?3;*VDTJU2T:*]A^PVVEPW
M<DD+?MS^P_\ ";X7_#;X?^(;#P[\$/#7PF^*-AJNG^#OCE>V6G:!/K?CGQII
MWAG0_$<WB#5?$VER75SKFG:U:^+X_$%I87MT(M%OM<U:QBLH91<S7/QO'^S5
M^S6/VJ=9U2[_ &,OA_'\!M)\::/\+DMQX=\&_P#"'Q?'[6KK2IH?B#+\-7>/
M33:7NG:QI/AD/#I%Q9QV4ECK(MQ=S7UK9?/9A]!^AB?"#@[P?R[Q=XIRC)<G
MQN-Q'&D\-E=*K@>/,/C,]H<0PH5<EJYM]6R2ME688>$\EQ-/$9E##.=6IC\-
MFE:4*E/TL-X_U*7&V><;8G@O*,;CL;0H4\AC5Q<X8CAVK0R^>62J0Q\,%[7'
MT\9AJDHX^E*EA95;0CAJN$@I1G_.C_P3=\>_&+_@FC\1[WQ1\1=!T#X,6?[?
MWP9\+_&+X$77B)H+OP/?>"Y_$GBN32_"_P#:MW?V^GV?Q TRP\1^&/$WA_PU
M<W-_>66@:]I*>(H8KWQ)9Z)??J#^P#\=O %W\6_C]^RUIOCOPWXHM=3L(?C9
MX?T#2=8BUBY\.ZKK]]?>&OC+X946;7MI;3-JFF:/X\N='::+48]6\3ZW<3V<
M45['-)^SG_!1W1OASKG[.-UHGC/X1>#_ (O^*_$OBWPYX'^"6C^*]*T.Z/AO
MXQ>-I+CP]X2\9^'];UNRNHO"6O>&([K4-6L-<M9]*FD:U.CR:OIUKJD]U%^=
MZ?!3P)\$_P!DN'XH>$O@=X,^$WQO_8O^,_A;Q3^T1J_@BPT*XUGXIZ-;^&[7
M3_C9K_B'Q?I-A:ZIXK27X9_%#Q+XEFL]3FO6T?Q)X6EL= DU'2;;2;W5?ZBX
M/\*L7D?CI1\3\+X@\5QR?&Y!5X:J\ 8JK'&\.T*^-P?#^7RS/!UL35GB,'4J
MSX7X>Q>+5.,L16Q6#KU98SV>-Q-"?XMQ;Q90S7PQQ?"5?AC)YX_"8Z.=4^(Z
M--T<TJPP=;,L6\%5I4H1HU_W.;9KA<.YMTJ5/%4XK#N>'I3C^:7Q&\'ZG\//
M&>O^#M<MI+2^T34+FVC>5&$FHV?G2&QU*+<SB2'4;18[F!H"(S&X4*) ZCAQ
M-;VT4\MV;86RQ^;<279400PJ7=YIGW+'Y,,<S[1*S0L@E+QNH!K]#?V^_"+)
MXF\'_$*S2&;1];T$Z!+>6YB:*2]TZYO=3MI3\WSKJ%IJ;-"T8VE+.23+"0*/
MQU_:>\5W?A+X0>(M1L)/)N;_ ,K1U;8&4)=17+7"L"K@1RP6TRR_(69#(@^9
MAG_9#@[,I<29#E&85)4_;8JDHXAP4[4\30DZ&)NN9RBU4A.2@K.,)QLU&S/\
M+N/N&8\)<<9YP_1C5E1IXZ$<#*JZ:]ME^.]GB,')3LJ<H0IUZ=*4[OFG3FDI
MR4HGYK_'G4H6^%E_I(E<P6/COPEK&FIEAY^I7$.N:"]DQ$3!Y'\.ZEK6M&)?
M*E5?#PG9C!&\4W[1?\$0_P#DUKXF_P#9QOBKCH!_Q:_X/X Z\8P>.Y-?@#^T
M&ZV?Q<\9^$K>[DN-+^'FG>'?"VF0LC1K#?3Z!X+U3Q3J+*V?-U/6M=N9EO=2
M=Y9;JPT_1K0R"STRQMK7]_\ _@B+_P FM_$W_LXWQ5_ZJ_X/G^=?Q1].[%/,
M/"J>9<GL88SQ$RJ,**E=)8#*<TRYUY[KVF(^K*2C%\D*,*.GM95I2_TX_9^9
M;')^/L-ERJO$2AX=9CC?;2CR<L,VS+)LSIX:$=&X48XE.<Y>]+$U<0DW05!1
M^;?^"XH9?'W[+,L942KX>^, CW %<C6_A0Q+@\;. "2" "3TS7Z9_L7>,_AA
M\5?^"7UIX#^#-_9ZEXB\"^!=)A\7>&T2[CU_2=0T#5]&U'64O;*>$W<TRZ9H
MUT77S3//<PV,2M,+ZU>3\T?^"X8W>._V4UP26T?XO >F?[:^$K<^Q (_'H:X
M_P#X('>(==TS]MK7/!6E"\N=#\:?!KQ;J?B.VMEQISW'@T:9-I&HW"&)6C=H
M-2DBDE)@DN0+)+@%[1$2/H[4)4_HY\"9YSIO(,QSS,H4)I\E7ZKQ7F>)A"4K
M\KC.I0]E4IOEDU.G6C4OAU3J[?28I0QGT@^.LDES+_6+*LFR256*YITJ.;\*
MY3@*U2FEK&OAX55B*$[N%H5Z$Z;>*A6P_P!C2SI(-S!59F)D5=S2,[[G9GW/
M)N<@DXC 3&"J\Y/SU\>_%5[H'AJRT2S-L3XCGG-V['S)ELK-X[M1 J2*P0W$
MT<1\Q7AE2-XY8&5H]OUG\0]-L](\<^-M*T\(MAIWBKQ%96T85=JVEOK%W! !
MM14"A54$@ D$C!7)K\]?B=-/XT^*\VCV]O=:G#I44&FPZ7:*LL^I36T+75SI
MMI&6"F_U2\N3I-A'GS;F_FM+6%EGFB*_WYEU3#.A_:N)G&A@<'@IYC4G5C+D
MIX=48UG*K+FNHTJ;YVX\O+&#6D4K_P"34\!B(YO+)L/3J8O'5<=]1A1PW)*6
M)Q,*WL*=+#QL^:=?$3A1C&7,Y5*B4DY7B?)EWX8^(?C3QQ:W/PL\"W?Q,3]F
M'0H?VLOCMINC&-9-$^'O@[7/"<XFU.>XN$MY8-%\,ZG::A=65@)=7L(_$7B2
M\N[(6MA<?9OZ%?C9_P %#O"'QX\+>&/BCXS^+/PZU71='\-W5IX9MM U;2-.
MN=8OQ9Q:OJ=G;:%<:F;V3QSJ:+8QZGH4<%G=6LT-I:-I&G>4T=?O-_P3D^%N
M@?"#]G?3_A]/\*O"_P ,?C%X3N],\/?M('P\-&U)O&WQG7P?X9\1:[XROO%^
MF6=K<^+X-:TOQ/I%UHLVK>9<^&=&FM/!5OY=AX<M4'P#X&^"/P#T7]LS6/B?
M<_L+_![0_@;-\8+'X,_#V\M/#O@*&WT+XW0:[;:='\;=)^&<FGI8Z?>^)KZ?
MP_:/K>GV&D:II^EW&F^(+-M1U--:#?X:_2M\&X_2FX@KYEG/'O%O#&58_-I5
M<^R7**M.IEW$V18/,*.-X?RK,L'6J1H4JW#ZH..5XZ$*DZ,\1B*N(HXNK["I
M1_WX^CSQ!#P"X1RGA[+N'<DSC&Y9E<*>%S+%PG#$Y?G6*PTX9YF.%KPA*M.G
MFV(K5)XK#U)QYJ=.A2IU*4%4C4_)S]E2?]H#_@G/K-I#XWGC^$$'[8GPK\(?
M$+P!K'V6VDTB]TS46U!SX U2^UVPE@T+X@>'[?5]+O+;1VDCUG1(=52(W<%Y
MK2V4_'?%GX=^//VM-9'P]_9S\-V?Q4U[X)Z3XG^-'Q%;2]^H6&BZ=X.L)8[+
MP=]OLXKFUO\ Q;XQO_MFDZ3X-M)9-:U+4K&.)[>""WNKBW_K9_;3M-.UCX(W
M7A*X\$>&?'.M^/\ Q7X6^'O@FV\66.G7FE^'/&WC/4#H?A[QG#+J-O='2]7\
M,7-TVI:'K%A%_:&FZO'974$D,:33)+^QYH.E^#/A?J/P\@\ >#O 7B3X;>)E
M\%^/AX(M-.M]*\8^,[;PCX2UW4/'E[<6.E:1+J>O^)[/7]/N_$6I:E!<:A<Z
MXNH-+?W\0ANY?D<U^C/P[G7C=D_C-F/%G%V+60TL34RO@;$9C+$<,8#-,;D5
M+A[&YA@(UI3Q& ACL'A\)B\PPN#E1>.S7"TL9BL35I\^%E]K@_%;-,#P#CN!
M<+D^2T?[1G1CB^(*6%C3S;$82AF,LSH8;$N"5+$O#UJE:AAJM>,UA\'6G0HT
MH3M67\W7C7]MW2OBW\/_  GXT^(7Q6LK_P /^"M'/A_1K'5_[*L-?T6Y%G;S
M7GAV]T>PABU/4?%S0Z?;)>12IJ.JZBME%=)<7MMLNY/+?V6OB'\?_P!B>Z\;
M>"_B':7'P E_:\TS2OB_X.MM;T[3+:/Q;X8\6_VK86^@6>IZK9SKX?\ %GAP
M:@D*^&X[O3/%NF-XBB,MI'/+9LO[R3>%O#5W^U[XB^.$WP)^%%WX \-?%'PQ
M\";JYN]&\.KXH_X73KNO>$?LOQOMK$Z%>0S^-K23Q9IVA#Q4]Y9^(!X,$EHN
MII<6_P#9\OTQ^W!I]CXC^$>F^!#X#\(^.?$?Q$\;>'_!/@M_&=G87.G>#/%&
MOM<6.F^.;":]L;^73]<T&691I&I::L&HZ?>727T,YCMIH)_A\B^AIDF0Y9XF
M4L/XJ>*%;B3Q$ED5.EQQ5SV4>*N',#PXZU/+<'A<SI.&(S&-;+:\\CS.>-JJ
M.*R11P&%I9?'FJ2]_,?'/,,QQ?"DZO"'"4,KX9CF$IY!#+D\GS3$9G[.>*KU
ML)-2I85T\52CF&$C0A>CCW+$UIXE\L8_R8_$+PGXY_:2\76OB#]GSPJWQ7TC
M]DG36^.7Q5U/PZ\-[:)IFG^(?#;CPEX=U6,M8ZSXMGTK2]8UYO#-G=&\U+3=
M%OO[/%WJFER:<?I_XL?MMZ3\6M$T;XH^.?B?8>.)TT6/P_X5L-.ATN#Q#JL]
MNWVN+PUI_A?1K.RO)O$ES?ZM"+U+K3Q?12W]HVI306"6S0_TK_LC0>'=*^%#
M>$M#^&OA#X6W_@3Q)J'@_P 7:!X%T_2=/\,ZGXLT[3M(N]0\5V']DV&F"Z?Q
M/9ZCIVK7MQJ%HNJI?SW5I>W%^]JNH77Q/\+[#P8/VK&^-3_ SX3V/@[XA_$C
MQ#\-_A_?V&BZ)'XP\->.-!6:74OBE#;+X;6WLM<\:$BW\1:A9ZG8ZZ\-\%N+
MS4UTZ3^TN+.?H/<#YMX>^'_AK#CGCW+.'>#O;PSK#Y?F%"CA^.*6*SO%<13>
M>8!TI8&&)P.:9AF4\CQ4*%:64T,?B*2AB:CA7AT8'Q_S_!<3<2<52X?X=Q>9
MYY[.6 J8G#5)U>'YTL!1RR/]GXGG6(=+$83"X6.8474@L;4PU.;E2CS4WI?L
MI?L=_#SPQ_P37^ O[/7[:VA^&WL--N)_'OB'PSXE\4ZEX3TOPYXN\6?$/Q3\
M2/#7A^;4;/6M!GMM:\-KXHM]+U'2X=1ELIM>M=32(7\!263]9Z_&O_@NQ_R8
MH?\ LNGP8_\ 4CFK]E*_K_!XJE//,VP$,)1I3P> R6K/%Q4?;8F&*GFL:5"J
M^12<,)]5FZ/-4FD\35LH7ES_ ".?</8[!^%'AUQ16X@S'&X'B#BWQ,RS"<-5
MY57E>18CA[!^'U;&YGE\)8FI1CBN((Y[A*68NEA,-.4,DP'M:N)4:4<.4445
M[9^9!1110 4444 %%%% !1110 4444 %%%% !1110 5^ 7_!3C_@WF_8]_X*
M /K_ ,3/ UK;?LQ_M-:D][J5Q\3_  !H-G)X/^(&M7=P;RXN?BY\.H)=,T_Q
M#J.H7$M[)=^-/#][X<\:SWU\-1\0:KXLMM/MM$?]_:* /\GGXG? +_@JE_P0
M7_:#L?&T-UXU^">K2WLNC^%_C5\-[F3Q7\!?C'ID,MU.FB7-[J.ER>$_%EE=
M1V4NKO\ #?XG>&['Q1IL45GKM]X/TN9--OA_4!_P11_X.)_B1^VG^UKXD_9Q
M_;)C^&W@J]^+7A_PPW[.EWX,TJZ\-^'+3XC>$_#\-IXT^'US+J=YK5_=W7Q4
M\B\\:^$7US7L:5X@T[4/ NF7.K7'B;PIIMI_39^V'^RA\-/VW?V>/B#^S)\8
M;_QAIOPX^)<.BP>)+CP'K%EX?\4"/0-?TSQ/IHT[6+_2-;AM FL:-I\UTC:?
M-%?VL4NFWT=QIEY?6ES_ #_)_P &E_["OAG7](\:?"?]I/\ ;7^&WCKPOK5A
MXG\'>)+3Q[\([^;PIXGT.YAU/PWKFCRV/P6\/ZY;7NAZU:V>J6MQ#X@BOEFM
MD-K?6<XCN8@#^INOG_\ :A_:*\&?LJ?!#QK\;/&\-UJ-CX8M+:WT7PSIA)US
MQIXOUJ[ATKPIX-T*)(;F634_$.M75K9B:.UN4TRR-YK-Y#_9^FWDB>T>';/5
M].\/Z'I_B#6E\1Z]8Z/IEGK?B%-,@T5->U>ULH(-2UI-'M9KBVTE=4O4FOET
MRWGG@L!.+6&:2.)7;\6_VD9KC]L+_@I)X _9NN;J9?@E^Q=H&A?&SXL6:M>)
M::I\6_&.DRZOX0.K1JX@,7A#P Z:EX6U>WQ<Z?XA\4:E:SI/;3NL7RW&O$L>
M$.&,US_ZNL;B<+3P^&RS 2J_5X9EGF:XS#Y3D&63Q3A.&#IYEG6.P&!J8ZM'
MZO@H8B6+Q,HT*-24?1RG ?VGF&&P;J.E3J2G4Q%91YW0P>&I3Q.-Q$:=TZLJ
M&$HUJT:,7SU905."<Y13QOV:_A?XF\%6GBS]M;]IT66N?M4_'F/_ (20P?9U
MFL?A3X*\U+?PCX,\("Z><6=GI-O:V6G>'H[6>XAEN;-O%%]J^N7"Z#J5GC>(
M->U#Q+JUUJ^IS-+<7+DJI9F2WAW,8[>'<21''N)R?FDD:2:4O-+([>T?M ^-
M)/$/B4Z="$M[2V,=T]E"JQPV@,(@TG3UC1$C2/3=)6!(1$ A6Y)8%EX^?:_Y
MA_I=>,F:>(WB)FV2PS:IF&3Y'F=>>.QL8U*$.(N)I0IT,QSNMA:E:O4P].E"
MC1RW*LKK5\3_ &!EF$P^1X;$5<%E^$<?] /"_A;#Y)D>&Q\L-&ABL;AX1P]%
MN,Y8#+5)SP^$C4481G.I*4L3BL1"%/Z[B*DL74A&M6J7****_D@_3PKF?V$O
MAO\ !CQ#^W=^U=\,OBQ\*/AK\2+CXB?"7X3_ !U\#_\ ">> ?"?BXZ#9>%+R
M\^&7CA=+G\0Z9J,]I_;FLZEH%Y>I;[(YYK)7D"M&N_P+X6?LZ>%_C=^W#XO^
M"WQL^.'[2?A#P]\4_A['\2?@%'\-OC%=^#M!/B#P9ML?B;\/ETK4=)UNSU#5
MXM+GA\<:7#HL%@-*\.VFJM?M>27,3P?M9^SK_P $V/V=/V9/BM_PNKP%??%G
M7/B*WA/4O!DNN?$'XFZ[XP-QHVKW-A=WZ7%O>"&&>66YTZ"=%D5K2"=GN(+2
M.=8)8?\ >?\ 9W_15SKP^QO#GTA<N\2L@XAX8\0?#?$Y?7X?R[*<?3Q=%YKC
M,JQ]; XC'8C$JA#'9!G>22R_'>SP\T\1A<51I35.;D_XW\</$;"9W1Q_!%?(
M,;@LQR3/:=>&-KXFC*E+ZO2Q%&%:%*$.=TL;A,6JU'FFO<J4YR7,DE]1>"/V
M?O@-\,]:/B3X<?!+X1?#_P 1-9SZ<VO>"/AMX-\*:TVGW3PR7-B=4T'1;"^-
MG</;P//:F?R)GAA:1&,:%?7:**_UQ/YG.<\8>,/"GP]\*>(_'7CKQ'HG@_P9
MX0T74?$?BGQ5XDU*TT;0/#V@Z1:RWNJ:QK&JW\L%EI^G6%I#+<75W<S1PPQ1
ML[L */!_C#PI\0O"GASQUX%\1Z)XP\&>+]%T[Q'X6\5>&]2M-9T#Q#H.KVL5
M[I>L:/JMA+/9:AIU_:317%K=VTTD,T4BNC$&OQW_ ."Q7Q%@\5VG[*_["=CX
M>\7>.7_:V^-FD:]\9?!OP^T"_P#$OC'4/V6/V>K_ $GXI_&"PTNTTNYMY],U
M#QAJ.G^#_!VG7NH21:;?:=J/B>UD:5+>Y1/ASX2_MB_$[]E[X(?M:?L=> M$
M\4?!?XC> OVP_A1X=_9>O_B]\-Q$_P (_P!E;]OKX]:?8^$/&]YX'UOQ!:_\
M)1:? ;7_ !)\0_#%D\^HS^$8?$#_  RT'4EN-'FO-*H _IWU_P 0:#X4T75/
M$GBC6](\-^'=#LI]2UK7]?U*RT?1=(TZU0RW-_JFJZC-;6.GV5M&#)/=7<\,
M$* O)(J@FLC0_'W@CQ-XE\;>#?#OBSP]K?BSX:W^BZ5\0?#FEZM97NM>"M2\
M2>'[#Q7X?L/$^G6\TEUHMWK7AG5--U_3(+^*"2]TB^M;^!7MIXY&_G)_X*C_
M  Z^-'PY_85_:Y^#OQ/_ ."@6I_'R:P\(_LQ?%SP]X/U[2?@3X3_ &@=,L[O
M]H73?!/CB;Q?X>\(_#^T.M_ +Q3XLU31-=\":W!I.A^(/"GC+P-'X)/C#Q!X
M<@U'2[_U?XA_%3]JKX62?\%/M<^%WQ2\3>/=;_8.^+O[%/Q,EM=;\+_""P\8
M?'?X,>#/V7/@_P#$']HKP'\0?$'AGX8Z';7^M?$3PA>^.->M=9T70M-U;2?$
MEIHFA>"CX9\/B#2K< _H-KR'X\?&7X3?L_?"CQ5\7?CGKT'ACX6>$O[#_P"$
MHURY\/Z[XI@L?[>\2:/X8T3?H7AK1]?UN^^T^(M:TBS7[%I-W]E>X6\N?(M+
M>XN8?QT\2_MR_$'XF:%_P4 _:-^&?[3>C_"K]FCX>>)?@-^RG^RQXXT_X6O\
M98]=^+U[J'A35/C?\0/"WPUTOPS?^+/B;\0-9U?XFZ'\'/A'H,%WJG@E_$/A
MJ;5O$&AOI]MX@D3\FOVS?VA?VD=;\!_MM_LN_%#XB_M<ZI\-[']G+]G?]JWP
M=I_[67@3]F3P+\7&O)_VQ-!^#WB+PWJVF_ _0;AT^%/BN\\4:)XY\/:3XA@^
M'7Q$\->)/AKH-A:Z)I?@&\U.V^('FYSB,5A,HS7%X&@L5CL+EN.Q&#PKI5*Z
MQ.*HX6K5P]!T:,HUJRK5HPINE2E&I4YN2$E)IK[;PTR;(.(_$;@#A[BO-99#
MPOGW&W"N3<29Y#'8+*YY-D&:9[@,#G&:PS/,J5?+LNEEV75\3C(X['T*V"PC
MHK$8JE4H4ZD'_:-:7%O>6MM=VCB2UNK>&XMG"-&'MYXUEA<1NJ.@:-E(1T5E
MSM95((%BOYWOVC_VAOVO=(_:>L_V+_A;XQ_;#L/#7P'_ &3/A/XYUWXB?L]_
M W]FOXM?'+XE_%KQIJ?B72-&\5_$,?%9O"_P\/PET1/!T<&NZ1\-? _AJ;Q/
MXR;Q'H-[K6AZ*VFVJ?JM_P $^_C9\7_VB/V0_@_\7/CSX4T;P=\5_$EEXHL_
M%FF^'9].FT#49O"_C;Q)X4TSQ1I,>EZ_XGM;"V\7Z-HFG>)I=(76[\:->ZK=
M:5%<W-M9P74_H1;<8MJS<4VMK-K56>JL^Y\;6C"%6K"G+FA&I.,)74N:$9-1
MES1LG=).Z23O=:'V7112'@$^@-49BUR'@OQUX<\?Z-/KWA>[FO=.MM<\1>')
MGFM+BRFCU?PMK=]X>UJV:VO(X9U%OJFG7<4<C(([B)$N8&>":*1_&OCG\>-3
M^%UUX1TGP7X.E^*WBW5=::;7_AUX9O(F\<V_@+3]+U'4_$/BC1].=Q!+=:;;
MV:'3-/U6:P@\2ZE+:>&=-O4UG5M/S_*__P %=?VI/CAH_P =/A+H'[*G[7WB
MOX'?#'XJ_$?4O''CC6_"5]K&B:M\-?$NG:%X7\+ZMH'CSP/!'HWQ"\+:TEQ?
M7.K^*/!?BS2UTZX@ETOQ##H_]LIK E^=S'B;+,NI8VK/$4+9?B(X;%NM6CAJ
M5*HX4*L_W]1.G-4:=>G[>--3E2E.$:GLY:/OX;RO&\4<4Y3PQE6&Q^.QF95,
MQH_5\JR^MFN9RJ8')L7G%L#EE"<,1F-5T\&Z,\-A/:8A2Q%.:IRY>2?]F6]?
M7_/_ -;O]".M>9W/QI^$MIJL^B7/Q%\'PZG:WZZ5=6SZ]IX%KJKND::5=7'G
M_9K?4WDD1$T^:9+MG=56$E@#^$G["7QA\9?$/PKX4^'W[8'B7]HWQEX'N/&1
M\$?#7XY>(_B'JW@SP1\8O$>J07FH3V&LWW@L^"-=\;:<MPDN@.-:N]3\!P7+
M6'AJ*TN]1759C^N$7Q#T#Q)>:M\$_@CX=\!1Z)X/T2^3QC<^*/#M[:?#WPQ8
MV>KZCX<E\/1>%K.'2?[;O'U/1]=M-0M!=:786"Z;=3W-S.7@@N>S(\RCQ-AJ
M>,RFMAH8:6&ABYU<3S^Y0G0HXF-246Z'LZ=2AB*%2E4O4G4]M2A'#NI-0/BX
M<18;&T*N+RV=1X:&,^HTX8S+L;0S+$8B;G]7@\LK?5:N%ABJ-.6,HUZU65-X
M-2Q,U"A3J5(?6J2I)M*$,&4,&4@J5(R""#@Y&",9X.?7$E?FW\,OB!\;-&\)
M?&+QSX0_X0G5/@9\./"E_K?PTFUC0M>\'Z9\1M5T&PU36/%,7@Z\U;QGXFOO
M#7PD2VL[+3O"/C#4EGL;F^EU/4=%T"?P58Z1<ZG]V_#3QQ9?$WX>>!?B+IMC
M?Z7IWCSP=X:\96.F:K$(-4T^S\3:/9ZS;66H0@E8[VUAO$AN44E5F5@#C%>M
M3Y:F'I8BG6H5J=1N*G0E5<'):WA[>C0J3I37O4JRI^SJP]Z+L>I@,>\;"+J8
M6O@ZKI^T5.M*A4C4ASRA[6A6P]6M2J4FXJ4).4)RISIU'3C&<3MZ***#T0HH
MHH **** "BBB@ HHHH X+XH_$_P)\%_A[XO^*GQ-\1V/A/P'X%T2[\0>)M?U
M R-#9:?:*/DAM[>.:[U#4+V=X;#2M)T^"YU/5]4NK/2],M+J_N[:WE_ OQ/+
M\;_^"F5^WC3XT7'B3X'_ +%46H^9\//@3:R1P>*?BK;6%VQMO$?Q0A4O;:]J
M-P\27!T/4'O_ (;^!;F.&P@TWQSXMTZ\UBW]K_:SUYOVR/VQ+?\ 9KDN;B7]
MF[]D*/P]\1_CK!92O%;?$#XXZQ8VNK>"/ -Q=P/BXL_!?A_6M$U$00RJ8?$7
MBO4]7DA76OAG8/#W6N^+/$%TNL:QH,/AVT\,^$+:_L+32);*\^U>)5\&6DL_
MB#P[X&M[&[L[#1+#POI&FW>D:?<W5OJ-M=>(+"\T::RTJWL$U+4?A^(<SQ%>
MK4R[!.?LZ2E]9]E.5.=>4%&=2#JP<9PPM%-1J^RG"=>MST74A3PU>G7\J>%S
M//\ %5\LRBC5KQPM&M7QBH2]G*K"A352M&5;F@Z>&HIJ-7V<X5*]>]#VE.G0
MQ$*V;I-AX3^%=E/X*^$FCZ)\+= TO1;:^\7>(["P_M'7DTNZFEL='T^;5;R1
M=0U_7-<GL[]K&VNYKC0-&BTV:9_#XAN]/L;KE]*N- \6:\NAZ6_BZR\07\%V
MVB^.]5\3ZA-J]OKEK:S7EG-<^'K5H?#,>CW,T*Q:CX=LM/AT>\B<RRV&]01K
M:EHU[XFLO&%KI;Q/'=?%'2I9+IC_ */'I]O\*O!\L#F2,9=!-?7$L"KN+/.2
MOR\KD>'_  S-X.^)G@JT:Z^VI=W]LRS!/)&ZY::RF387<_*&(!)Y##CUY<NP
M%"674IU*4)*I3DX6C&-.BG=<E&G!1ITHW3;4(I-M6:][F_I[POX X+GP%]=Q
MV#PV+SK'Y/F.,H49TTXX:G##3JPC2A&"I4N1K^$^6G4A",W2E+FD=+>:K;^*
M]$\"/J-FQT?Q#I$_C/Q'H[-YD-_HFB^$KGQ&^A7;@$3V=YK4FBV]_!('MM3T
MQ+[3KR.:SOIH9. 'Q7\;Q3I(FI6\5HH$<>FC2]/%@+91L&GK$;3?]D6/]RJF
M8S"/&)]WS#N/A[8QWW_"N])NG\RWM/@EXZLIEY!DNM+;X=:(S[OX2T#W\+<@
M[;A_FXP='XA:9;2Z)INFV=G#'<7&LZ=9V BB13%YJRJQ544818U9G4  A=[
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MT\L:D&O;:\2_: _:(^$W[,'P_P#^%G_&CQ%<>%_!?]OZ'X8_M2UT/7/$,O\
M;7B.Z:STBU_L_P /Z?J>H;;FX4HUQ]F^SP ;IY8U(->VUR4ZW-C,50^M8:I[
M*CA9_4Z<+8O#>V>)7ML3/ZQ/FI8KV5L,OJU#D>'Q'[ROS6H_08S+O8<-9%FG
M]@9W@_[0S/B#"_ZQXO$<^09Y_9U+))_V;DV&_LG#>PS#(?K_ +7.ZO\ ;6:?
M6*>=90OJ64^PY\S****ZSY\**** "BBB@ HHHH **** "BBB@ HHHH ****
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M8?\ @IS\'O@E=ZW_ ,$X/V=OAM\:O$IT^]?Q3KNM^)[O5_B5X*M4M-2:?4?
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MA#WNAWM];*9ECD:+=*/,".4R%;'85_I:?@85Y9J'P.^#FJ?%C0/CQ?\ PO\
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MX7X-Q.;\*<,3KX>HZE&.<9GA\=0SOB/"TJEJM+"^RR+#.?-3QE#&X>=2C/\
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MJ6,HT,'6JU<+5<Z=:*IXB$)49N5*K%1F^:G-7B_T+PDR/,>)O%;PRX;R?/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS3J3E+D:E#FE)N7*U*2<;M\K4I)JS4GN%%%%49A1110 4444 %%%% !1110
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M<_"[QAX \2_L_/X.\9V7Q$\9_#CX]:/KG@G6?!GB'X<6>B_\)9K$W@;XI?\
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MX]/V/?V6?BQ/I_\ P3A^!/B>R_:Y\,_$7]G']HW0?&OCOX?3_L6>$?A5X%^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML\7:D]@^H_VG%HVNONL GFK:_8<7!.PSP@;C]I5Y]'$T)YEC\+#%UJE?#X;
M5:V"E3A&AA:>)EC51K4JBP\)SGBW0JQK1GB:\::PU-PIX?GDZ_U^99+F>%X)
MX4SZOP]EV"RG.,[XOP&6\2T,7B*F:9]B\EH<+U,SRS,,%/-\3AL+A>'X9MEU
M7+JU#)<JJXN>>8^.(QN;+#4(984445Z!\@%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!GZMIZ:OI>I:5)=:A8QZGI]YI[WV
MDWLVFZK9I>V\ELUUINHVS+<6&H6XE,UG>V[+-:W*1SQ,'C4C_)+_ &EOV0_V
MOO#/_!6OQM^RMJ6NZ]X__:S\1_M1Z?;>$_B3J:PVFH_$#7O'_B:Q\5^ /C/J
M<]DE]9Z/9^(=%UK1OB'X@NB)K;PI;R:JNK>4VC7Z1?ZXE?''BC]ACX#>+OVW
MOA=^WWJ_AY9OCM\*/@SXV^#'A[4&56LFTSQ7JEK=:;XDDC)!A\2>%-%U+XD^
M%-,O(AB[\/\ Q0\06NHB<Z;H36 !]$_"KP=K'P]^&7P^\"^(O&_B'XF>(?"'
M@WPWX<\0?$;Q9(C^)O'NNZ1I%I8ZQXRUX0G[-#JOB;4H;G6;VTLECL+*:]>S
MT^&"R@@A3OJ** "BBB@ HHHH **** "O&OV@O#OQH\6?"+Q=X?\ V>?B'H7P
MI^,-_P#V#_PB'C[Q+X<L_%NB:#]E\3Z+>Z_]M\/7]EJ%IJ']J>%[;6]%MO-L
MYOLEWJ,%]'Y<MLDJ>RU\!_\ !4/XZ_$S]FK]A;XY?&SX/:[!X:^(W@K_ (5G
M_P ([K=SH^CZ_!9?\)'\8?A_X2U??I.O6.HZ3=_:="U[4[1?M=E-Y#SK<P>7
M<PPRQ^=G&)H8/*,TQ>*>)6%PN78[$XEX.I*EC%0H8:K5K/"U85*,Z>)5.,G0
MJ1K4I0J\LHU(-*2^U\-LES;B3Q%X!X=R"&25,]S[C7A;)<EI\2X2CC^'*F;9
MIGF P.70X@P.(P694,;DDL97HQS7"5\NQ]'$X%UZ-3!8J$Y4*GWI9I<QVEK'
M>3+<7:6\"74Z((TGN5B59YDC  C624,ZH  H8*  ,58K*T*ZFOM#T:]N6#W%
MYI6G75PX54#S7%G#+*P1 J*&D=B%4!5SA0  *U:[XM.,6KV<4U?5V:TN]=>^
MKU/CJT90K582Y>:-2<9<B2AS1DT^1)12C=/E2BDE966P44451F%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 45!<W5O9PO<74T<$*8W22,%
M&2<*H[L[G"HB@N[$*BLQ .6^K7; M:Z%JEPG.R1VT^S63T(CN[V*ZC!YR)K:
M-P!G8<BKC3G-7225[<TI1A&^FG--QC?5-J]TG?8B52,79MMVORQC*<K=W&"D
MTO-JS>AMT5XQKOQ4GLH-<CL=/T^&YT"TGOM8U&]OY+G1-$L;.-KB_O-5O;6W
MBLX(K*WCF:ZEDOXK:U:.3SIR8)8A_(1_P4%_X.(O&^JP>-O _P"P1XDMX] \
M-ZIJ/A'QO^VUX_AFT?X,:#K%O%.G]E_ KPO;6EWJ'Q8\32QS0W^D7MYX=U&Y
MN+2RN]5L_AKXM\'NOC2Q]&GE5=_Q90I2<7.%-7K59P45-U+4N:G3I*#YI5J]
M2E3C'WI24+R7GU,TH0NZ:E4C&2A.H[4J<)RGR*DG4Y:E6M*=HPHT*=6K.;4(
MQ<VHG]D7Q(^*GPP^#?A>Z\<?%[XC^ OA5X*LI[:UO?&'Q(\8>'O WA>TN;R0
M0V=O=>(/$^HZ7I-O/=3$16T,MVDD\A"1*['%?#/B[_@L+_P2U\$SPV^L_M\?
MLNWLD[.J-X1^+/AGQ_ ICB@E8S7/@.\\26ULI2XC"-<2Q+)*L\,9::VN8XOX
M:?@S_P $WO\ @IO_ ,%1]3T#XPW_ ,)/BG\9]'\4:<XT;]JS_@I!\6?&7@[X
M>1^']6BB\2:)K?PE^$7AC7)?B!:^$]2@N%M-.N?"Y^-GPVU"*:*YT^P\/,,6
MGZ@^$/\ @V0_;F;PG?67BO\ :1_X)\>%]755?3='\-?L+_!OXC64\\EY%).E
MW\0/&?P6\,^,;&$1&>:)H].U0!UCTZ*WMK&4O;\<Z5*FVI8B,VM+48.I9JUU
M*4G3IM7;7-2J58MIN,G%QD^JG6JU5=8:=.+2:E6E&GS)[.,(^TJQ=O><:U.C
M.*:C**DI17ZK_%3_ (.:O^"=WA3QE/X#^"7AW]I?]L#6K6(M=ZC^SC\'CJOA
MFRN8[S[++9RZA\0O$/P^UC4<JLDUIJGAKP[X@T"^ C%MK#K+YB>&6/\ P=+?
M!.Q?4[[Q[^P%^WGX2\+6UR6L-?L_ 'A/5C-I,%U?1:AJ&JVVL>*/"=AI5Q90
MV@=K.WUK5K=KE;^UFU*V6Q%Q<^4^$O\ @U[\%0:+INH?M8_M-_%G]H&RL+B'
M5KGX5_!+2_"_[.?P=\.32M%+JECX;^'NC:/XHL(;*1H8XGU/PG:^!I[B,2W;
MZ!:SLDUI]12?\&R__!(OX@^&-.?P%X9^.?PUUG3[.&VD\7^"?C?XD;QE;ZJB
MVCC5;N#QU;^-_#5KK"-!*ZMIWAZWT9FO+I[6R:-+(VG5+#X>&&A75/$5Z<O=
ME6IUJ--4:CM^[JX=4L1*#6O(YUH*LK./(TTN58C%SQ$Z'M,+AYQ]Z-"I0KU9
M5J:O[]/$.MAHROISJ.'G[%W3=16D_O;]C_\ X+3_ /!-S]MV^TCPS\'?VCO#
M>C?$O5XM/6W^$?Q9MKSX5?$*?5-2,BP>'M"LO%T=CH'C[7HC$YNK'X9^(O&H
MMXP)9)A$0Y_5&OX:_P!NC_@VA_:9\):'KWC+]FWXLZ9^W+X8L;>ZOI?A%^TM
M!!H7[1L%K##';P0?#KX^Z/=:;)XEU2Q@#7MAX9US5?A_X+,]N1+X6\6W<L.C
M7GRQ_P $Y?\ @MU^T_\ \$]?$R_!;]HC_A:WQE_96^&^I6G@KXE_"+XQ:1<:
M=^UQ^Q;:PZM9:)%/%+JUGIVK^.OA[X;EO[7PTNE:U!86%K<6>B:%;Z5\$+G6
M?#7A[Q;C+#0G&4\)6==0BY3I5*:HXF,8IN=14E4K0J4XQ3E)TJTYPA&=2K3I
MTX.9M'%U*<HPQE%8=U)1A3JTZKKX64YM1A3E6E2H3I59S:A!5J-.G4G*G3I5
M:E6:IG^AW17E?P1^-WPG_:0^%7@GXW_ [QUH7Q)^%?Q$T@:WX0\9>'+AYM.U
M2S6YN+"\@DBGBM[[3-7T?5+.^T7Q!H.K6ECKGAW7M.U+0M=T[3]7TZ]LH/5*
MXSM"BBB@ HHHH **** "BBB@ HHHH 0D $D@  DDG  ')))X  Y)/2OY6O\
M@K=_P5-'[2'B#3?^"6G_  3:^(>G^/\ XL?&R=O#W[27Q[^&=]:^*O"OP3^#
MLUPNF^-_#?AWQ-H^H+I.I^.]<MKC^Q/$-QI^IR0>'["\E\%65U%\0_%-E/X/
MU/\ @Y8\8_%#Q'>_\$Z?V.O#_C[Q5\/?@U^U[\<O'/AKXXWG@W5+C2=7\4V'
MA3_A5^G>%? UW-9I-)?Z1K[?$#Q'<MI6HVNH>'9/$&E>'-5UK3;P:/9A/K+]
MC7_@GK^S=^QEH$&@_ _X<Z3I&OW5LB:YXMF$VH>(=5F\L"XEO=<U*2ZU6YMT
MDDN3:"^N[F2QAO+FQT\VMA.+!?I\@R2CCE]?QM:$<!A\1[.>'A)_6<7.G&G5
MG135HX>@XU(1JXF<N>*G^XI5IPFH?+<09WB,'+^S<OHS>88C#*K'&5(Q^J8&
MG5G4HTZTE)N6*Q*E3JSHX2$/9R=/_::^'A.FZNA^PY^PE\(?V/\ X6^'/AU\
M,_"VF6&H:=86TOB'Q)+;VLVK:KK#6D%K>ZOJVI6]K;_VGK^H) B:AJPA@DO?
M*%M9PZ;H5KIVD:=]WWGA.[6W>ZTZ.YNXX%S<#RBVP  LXDC4( ,KF-L, 1AF
M) /IF@^'=.\.Z''K.NAI8IF=[*P#_9Y-3E09DN+B0@M;Z?"@ #* SKM<D"1!
M<\'XG\?S7)F=9;>VL;1)) QVVVEZ?!&C-(UK;ED@@AB1=TEQ+PP5GEW#]X?J
M9YCBLPQ5L-"+HT;48J,5##TX0M&.'P]..D:=->Y"G3Y(4[<JYYJ:7S-'+<)E
MN$2JRDJM5.M-SDYXFM.?O3Q6*K2UJ5JK_>5*M1SG5;YI.,'!O\=_VU?^"6'P
MH_:6\06?QQ^$>OZQ^RG^V9X.O3KG@3]I?X0-=>%O%']OPVLEI''X]@\/W6CW
M'BBUN;5SI\VKK>67BVRLBMI;ZU-HQOM!U+RCX2_\%Q_VF?V%=;\/_ O_ (+2
M? '7M&LFOX/#OA;]NSX$Z"_B?X3^/HHUAMX-7\:>%-$LK5;75);:SU7Q!K#^
M!;6S\5FVFLK6+X":&D<M]<_H[XX_:C\':1<O::<U[XRO825>33Y(K71XV4L&
M1-2E1EN&R%*RV%G=VKHV5NMR[*\OU'X]_"?XHZ%JW@?XP?#.QU;P=X@MC8ZO
MH>OV&E>//#&IVDA8RPZUH^IZ=;QSVPVQLBKIU^QD.1%&8UD/K8W@'-,UPZQC
MRS$4*O+S>WIJDJU1.UG4PM2=.O727PM0A4:LO:.$8Q/"PGB1D&4XKZA'.L'5
MCS<KH5)5GAJ;7Q*GC:5.KA<*[_$G5E24N:3I>TE*1]X?#S_@J3_P3>^*>A6/
MB'P7^W3^RK=V>H63ZA'8:U\</A_X.\3VEI&)&DEUCP9XRUS0/%^@-&D4DDD.
MN:'ITZ1HTCQA!NK>O_\ @I/_ ,$Z=*G%MJG[?7[%6FW+1K*+>_\ VI_@99SF
M)V95E$5QX[CD,;,CJKA=I9& )*G'X#>+/^"4W_!&+XC:A<^(+WX&^%= NKZY
M%Q/;^$_&OQ?^'6GI((D1HK;PUH/BC1-&TZV90I,&G:5:VWFAY(P)&D9J,W_!
M)G_@C'INFS647P;T.)+JR^PS7</CGXO:]J6Q$7%Q#<7OB+6;BQO05W_;+);6
M:9V9)'E0^77RB\/<^=3D]C4BKR2YL#F7M%;;GIQPDU%O2ZA.HXWZ]?K'XD<.
M*E[3ZUA9-1C)N.:95[%W<;^SJSQD'*R=TZE.DI:*ZOI_5+\/OB;\-OBUX>B\
M7?"KX@^!_B9X3GG>UA\3_#[Q9H/C/P]-<Q1Q2RV\6M>'+_4M-DGCBG@E>%+D
MR)'-$[*%D0GMZ_B:_P"'4O@[X)>*Y/B[_P $C?VN/B/^R[^T)I"+<Z7X9UKQ
M+X@U3X>>/K:S2:[MO!_BG2_&&E7A\6:9>7\,!?3/$5KXPT*W1I[R_P#"^J,M
MLD/Z_P#_  2F_P""P.I?M1^,O$G[&'[:_ACP_P# #_@H5\-+G5X;KP3;Q7.A
M>"_CQX:TJ.\U$^+/A)!K.I:E</XATG0;674?%O@R+5-2DO-'LKOXA>$'F\,Q
M^*M"^'/A9SPWFV1./U_#RC3DU%5HPK0@IR4G&$X8BE0KTI3492I^UHTU549N
MDYJ$^7W\CXHR?B&,O[.Q,)U(*4G2]KAZLI0@X1G.G5PE?$X:M&$IPC55&O4E
M1E."K1INI3YOWFHHHKP3Z$**** "BBB@ HHHH **** /C7]NS]DC_AM;X%'X
M*_\ "P/^%:9\=>#/&O\ PDO_  BG_"9?\BAJ+ZA_9G]C?\))X4_Y"&_R?MG]
MJ_Z)CS/LESG8/LJO$OV@/A_\6?B5\/\ _A&O@O\ '"X_9\\:?V_H>I?\+!M?
M .A_$B7^Q=/NFFU?P_\ \(WX@U'2]/VZ[;D6K:E]J^T:>%\V"*1B5KVVN"CA
MJ,,QQV*C@ZM*OB,/@*5;&RJPE2Q<,-+&.C1IT5B)SI3PCKU75G+#4%56*IJ%
M7$>SDJ'UV99UF6*X*X5R&OQ'@<;E>3YWQ;C\OX7I8"O1S#A_%9U0X8IYEFF-
MS&>48;#8W#\1PRG 4L%AJ&=YK4P,LAQDJ^!RA8RC4S0HHHKO/D0HHHH **\<
M^.7[0?P7_9K\$3_$7XY_$3P]\./",5Q]B@U'7)YFNM5U$V\]VND^']%T^"]U
MSQ)K,EI:W5U%H^@Z;J.IR6UM<3I:M%!*Z?E=??\ !67XO^/+J[U#]F_]A/X@
M>-OAJ)S:Z;\4OB_\1]$^"EIJ!B-JTNJVG@VZ\-^*=9O/#\\5RDUCJ*:E!<36
M\UM)<V%I=-+I\?S'%7&O!W V7K-N-.*N'N$\M;E&&.XCSG+\FPM6<(J4J5&M
MF&(P\*U9)IJC2<ZLKQ48-R2?H9=E.:9O7^K95EV.S+$*S=' X6OBJD5)V4IQ
MH0FX1;TYI6CO=Z'[:45^'T/_  4W_:]\/B"/Q-^PSX/\:QIQJ&J?#;]I;2]-
M*I$09;FQT#QM\/K*YN?.5Q]FL6U>.?=;SB2;=+;HWJO@#_@LI^R]J>KV?AKX
MX^&/C-^RIX@O#;6UI<?'#P!=V7@K5M3F?RYK71/''A:X\1Z8UC;,LCOKGB*W
M\,:28(VD-PC?NZ^9X+\:?"'Q%JQP_ GB;P)Q9C)1YO[.R/BC)L?FD(VD[U<J
MHXN68T;QA.2]MA87C&4E=)M>AFO"G$^11<\XX?SC+:2=O;XS+L51P[=TO=Q,
MZ2H3U:7N5):M+=GZV45S/@_QIX.^(7A[3O%W@'Q9X:\;^%-7C:;2O$WA'7=+
M\2>']3B1VB>33]9T:ZO-.O$21'C=K>YD"2*R,0RD#IJ_33Y\**** "BBB@ H
MHHH **** "BBB@ HHHH ***^3_VG_P!M?]GO]D;2]/E^+/BZ27Q?X@$*^"_A
M/X-L_P#A*OBQX[N;JXDL[.W\+>"K.:.\FBO+V*2P@UC5IM)\/#4%%A-K$5Y+
M#!(FTDVVDDFVV[)):MMO1)+=CC&4I1C&+E*348QBFY2DW91BE=MMM))*[>B/
MK"BOY_?'/_!4K]L?Q]<E/@#^S#X ^#OAS_3I+;Q-^U#XFU36_%6JVL4CVJ6\
MOPP^&U[INI>!/$,,ZN[6/B;6M7M&$8+R")E+_-?BO]NO_@I);W\5_<_M*?LO
M^#[VSN;EKKP;:_#O2X= NX+B+RX4?4?%-]J?BK99R1B6V2*;3;AY9IENIKV*
M.&"OD,PX^X/RNI*EC,^PD:D6HR5".(QBC)VT<L'1Q$4U?5.5X];69^I9%X)^
M*?$E*%7*>#LPJPJ1E."QF(R[*JLH1=G)4<VQN!K6;^%^S]]-.',FF_ZEJ*_E
ML\'_ /!8+]NWP!>VLGQ%^'7[,_[0/AR-?(FLOAQXMN/ 7Q!O[@XV317!UKQ7
MI44:ECYR1>!)4;82DT"#>_ZL_LI?\%7_ -F']IC4=-\":WJ-[\!OC;>SQ6"_
M"?XL2V^DS:SJ<T]O9PVW@7QBP@\,^,VOKZX6STK38+C3?%>I2QSO%X62WC$S
M^EE'%'#V>MPRC.,!CJJBYO#TJ\5BHP5KSEA:G)B8PU2YW24;Z7O<\3BKPUX^
MX)@JW%7"6=Y-A93C2CC\3@JD\LG6E?EH0S3#^VR^==V;]A'$NJE9N"33?Z=4
M445[Q\.%%%% !1110 5XG^T7^S_\._VI/@WXQ^!/Q7MM6N_ 'CK_ (1[^W[?
M0]4ET75)/^$8\5:'XQTK[+J<,<LEMLUKP]ISS[4;SK=9K<X64D>V5XU^T%\"
M? G[2_PB\7?!+XE_V[_PA/C7^P?[:_X1K6KGP]K?_%.>)]%\6Z;]BUBT5KBS
M_P")OH-A]I\L'[1:>?:OA)V-<N.I*O@L90>&HXU5L+B*3P>)G[/#XM5*,X?5
MJ]3V5;DHU^;V56?L:O+"<I>RJ6Y'[_"F82RGBGAK-8YYF7#$LLS_ ";,(\2Y
M-AGC<XX>E@LQPV)6>95@UCLL>+S+*73^OX'#+,LO=?%8>E26.PG/[>GZY96D
M-A9VEC;AA;V5M!:0!V+,(;>)(8@S'EF"(H+'DG)[U9JO9VL5C:6ME!N\BSMX
M+6'>Q=_*MXEBCWN>7;8@W,>6.2>35BNE*R2LE9)66J6FR>FB]#PZCYISES2G
M><GSR5I3NV^:2O*TI;M<SLV]7N%%%%,@**** "BJM[>V6FV=SJ&HW=K86%E!
M+=7E]>W$5K9VEM"ADFN+FYG>.&""*-6>665TCC0%G8 $U\?>+_\ @H7^Q;X(
MFDM];_:&\"W4L3M&X\*-K/CU Z$A@)? VE>(XFP01E7()X!)(! /LNBOD_P1
M^W3^R%\0[JTL?"_[0/PZDOK^58+*QUW5I/!][=W#RM#';6]IXPMM"N);F:5=
MD%LD9GN"T9ACD$L1?ZO5E=5=&#*P#*RD,K*PR&4C(((((()!!R* %HHHH **
M** "BOYE?V%OVO\ X[?!7]K+]K2?]H;X@ZWXU_8X^.O_  5#_:W_ &7?AQXH
M\6:SJ&M3?LS?'OP9XZ^U_#+P5<ZAK.IS3:'\&_C1X3U,^#?"VGZ;#-X<\%>/
MO!FCVHL_#-EXOU#4=5ZWX"_\%--5^ _[+?[+?PVU+4/!OQ)_:#^/WQ-_;TU'
M3_%_[3?[1>F_!WX7>!? 'PB_:\^,GAVWUWXG?%?Q;9^,_$Q@^SW'A_P7\-O"
M/AWPOK=WJ\.B7NE6USH&F^'XF< _H]HK\1M$_P""S.A_$CX5?#B'X*? S_A9
M?[6WQ/\ VBO&?[*^B?L\:3\8/!=[X(M?B7\,_!^G_$#XF>.(?CYH=IK'ASQ3
M\!_"?@?6-'\46?Q'\->&[J\\26NKZ=91>&])N%UF70[OA+_@IY^TOK.N?M1?
M#;Q'^Q'X;\)?&+]F'XC_   ^'OB_3-:_:>\/:;\(-%TCXT>"O&?CJ^^-'COX
MS7OPZCA\*_!_P]X?\+Z5J.GWMCX-\1>,M9F\9:#H%UX2T;7%U"&T /VLHK^9
MO]H+_@JO\</C%_P3]_;NU3X.-\&O _[0'[*WQ%^"'P^\=_$;X"?M%/\ %GX8
M:A\/?C'JGA#^S/B/\#?BGH/PV$>I>(-7O]1UCP#JWA6]M]&U7P%#:>(-</C2
MV\:Z/9>%Q]4:I^W'XU_9Y\4?MP_$?QY\*'O?^%%_'[]AOPO^U*--^/GCSX@_
M#[X<_#_XN_ CX/-\1/B=\$?#FL?"_1KRQ\/?"B7QE8ZIKGAFS\-^&?\ A8%E
MIOB7XCZ]-X6U.XO-/B /V\HK\8?VH/\ @KYH?[/OQU^)?P4T?X7^'O%<G@WQ
MG\#O@EX?\8>-/B]H?PA\#:M\>OB]X/\ $_Q6\0Z7XI\:^)M#OM \)?"WX-_"
M/2O"_B+XC^.+*7Q1X@L_$WC_ ,*>$+/P1-<7LFH0_1O["7[?F@?MAZO\;/AG
MJ>D^ M#^,O[.VH^#[7XAQ_"+XM^'OCO\%_%.A?$&TUR]\$>./A3\5] LM%/B
M+1=:MO#NJQZWH6M^&] \3^!M:MVT#Q!8O,;6]O #]$:*** "BBLK7-=T3PQH
M^I^(O$NLZ5X>\/Z+97&I:SKNN:C::3H^DZ=:1M-=7^IZG?S6]E865M$K2W%U
M=3Q00QJSR2*H)H U:*_&/XY_\%Z/^">?P7N;W3-,\=^*OC'K-A>7VGW%K\+/
M"YFTN.\LI'A+P^)_&U_X+\.ZWI<TJ9@U?PEJ/B6SNK=ENK)KN)HR_P"9OB3_
M (.EO"L,]Q#X4_9)N;NW69Q:W^M?&:>">: &4(UQI-I\)7BMYF B=UBURZCC
M)>)9)1B<?0Y5PEQ3GL%5R;AS.\THMJ/M\#E>-Q.'3=TE+$4J,J,=4_BJ+9]F
M>+F/$G#^43]GFF=Y3E]6S?L<7F&%H5FE:[C1J58U96NK\L'NNZ/ZSJ*_D5\*
M?\'2\'DP1>,OV2[&XN#Q<7NA?%[4=&A7]Y,=\6EW?PR\3,?W7D)Y;ZR!O$DI
ME"R"&#[\^#G_  <5?L(?$:YM].\<6GQ1^$%W*LKSZEK?ARQ\8^&H K$0HLW@
M35-<\8RS2K@LK>!H88V.P7$@!:M<UX,XNR.$JN;\,Y[E]&%^;$8K*\93PJMJ
M[8IT?J\K+5N-5V6KT(R_BCAO-I1IY;GV4XVK*UJ&'S##5,1KHKX=5/;*[T2=
M-7>FY^]U%<3\./B/X'^+O@7PO\3/AMXDT_Q?X%\::3;ZYX9\1Z6TWV/4].N=
MRK((KF*WN[2XAE26UOM/OK:UU#3;Z"YL-0M;:]MIX(^VKYD]T**** "BBB@
MHHHH **** "BBB@ HHKGK[6_WD]CI-I<ZK?1I*DAM#$MI9S ;5CN[R:6*"*;
M<2?(1GF4(V]8_E)N%.51VBMM7)M1C%?S3D[1C'SDTNFY$YQIJ\G:^B23<I/M
M&*3E)^23?78K)-%))>^(M48IIU@9$TJ.3)C2"$-'+J2QAF$EQ?2L\5HVQ9!:
M^4L>3<-GD/''B<ZAI]MHOA[46MKO5GMS>7JPW:366FRRQHXCVI&XN[CS$*P(
M3,]J)2%19X9QV4^E33>$X]*GBCDN$TNSCEAEF*(T]K'!(\?VB-P$;S82(YBS
MPJX625)80\;_ (M?\%:/VV(_V%_V(/B#\:_!-]=I\6/&5W:?"7X!67V%[NXN
M?C#XV@U"/1M2TXQ:=?Z??S^!M%L=>\?/8:E96EMJ<GA=/#Y N-6M5D]C!PP[
M<\54;:P=3EIP24J+48_N+QM)RE.49S_EJ35WS7:/(QDZ\53P]-*/UN"E5FVX
MU4Y22K<LG*-E",HPWO3@TERI*2_"/_@X+_X*JKXR\8>*?^">7P \8>(-.^ /
MPF73=%_;+\>?#S4-+3Q3\9/B-J$2V^B_LT>&/$$:7%I L;Z9-9?$>Z*:E>2Z
MC8>+['4?"6LZ3\*];\+>-/KC_@DU_P $/_!GAJW^&?[2W_!2'PKX/\0_$?3=
M-4?!#]D76;S[1\+/V4?!T<\NMZ';>+_!U]J%[8^(/'VIZIJ-[JVO:/XQ;6H]
M/\3:K=>)/&\WBGXL:GK&L:)^1G_!"?\ 80B^,W[1NO\ QU^)T3^(?AQ^QEXM
M%AX;-X\6J:=\0/VP=6@L=8\;^,+G53=:O9Z^GPIGMM+N-&U2QGT]M0:'X1^*
MX";N/Q"FI?U_?M7?M<?L[_L(_!K7/C;\==1+^$=%2TTZ]M(EEG\1^./$>L!Y
M=)\'?#S2%N[";4/$FI"&6;3%GEBMK*RL]1\5>);K1]"TG4;K1N^EEKEAYSQ,
MYQ@Y5Y5FHT^>I4I*4*M2I5G*-.G1PTVZ="/,XU:T77?[N4%3\Z>8KZQ3^KQA
M*?+1C03E4Y*5*JX3IPITH1E4J5L5!*I7GRJ5&E*.'UG"<JOZNVEU:7EO%<V-
MQ;7=I(I\FXM)HI[>148H?*EA9XF565D.QB%92O!!%6*_@7_:N_;[_P""B/C?
MX=7'QW^(_P"TX/\ @D5^RCX_BUJ]^!/P7\.6FJ>,/VT?C=:Z /MVCZU::-I$
M'A7Q99#59Y=-TW4-?F\6_!SP7IVF:MH-SK&GZIH.JZ=XDUSX-_9<_P""@W[9
MVL>-[&#]F+_@L)^T<WQ7O"MCHGPO_;LM+CQ5X0\;W$YMEO+#1M7\8>-OV@O
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MRRY9M'$8/$UZ.#=&IETH5(8JE4J8BG&K3J0=)4W*=6U.$I+]XO\ @CY^W/\
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M?%GQ+_9[^(]OX!CNWU?X3^)/B9J/PB\(W?PP^)%H?[-FAL]6T/5[77]+FO\
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M2;;:23;)E*,(RG.480A%RG.348QC%-RE*3:48Q2;;;223;=CSC_@H#_P5!^
MG[ NC6^D^*?MOCWXT^(M*&H^"_A!X<<Q:C>V]U+=V6G:QXHU@V]U;>&?#]YJ
M=I+I]JR6VJ^(]7N4F7P_X;U:*RU.XT_^.;]LK]L;X]_M,W,OCC]L[XN^)_"?
MA:[U-+GP-^RQ\*6CTMK&"V6XMS=7VG:I?:IH?@+4+$WLGD:QXITWX@_$.4VN
MJ:+XD?PFD_AU;WR_XT^//&W@KQ#J?[1G[06OZCXT_:H^)%S>:[)IGB-H)]1\
M WNKVT(TVQNHEC:#1/&&D:#]@FU/3M,BM!\)K"30OAOIL'AGQ5H^LZ;I7Y=Z
M_P"(-9\4:K=:UKVH7&IZE=N7EN+ERQ52S,L$$8Q';6L.XK;VL"1V]O'B.&-$
M 6O[-\*? [+L/A<-GG$U&EC\=4C&K'"U8TZ^#PDN9OV-&G.,Z&*JQBHJMCI*
MM1524HY:E[&GF-;^7O$/Q9QU?$8C*<AJU,)A*<I0>)IRJ4<5B4HI.I5G&4:N
M'IRDY>SPD?957"*>.=ZD\%1] U?XL7:R-%X%\->'OAU9QW$-W;7NBVG]I^-X
M[N%%4WW_  LC7O[1\:V=U<D2/=PZ!J^AZ3,)I85TN.W81#R:BBOZCH8>AAH*
M%"G&G%1C'17DU!<L5*;O.?*M$YRDTM+G\_U:]6O)SJSE-MREK913D[RY8I*,
M>9ZM123>M@IRJY^958X/!4$X(]P.HIM?U.?\$!_V</V9_C;)XX\$?'[X9>%?
MBMK/B7X2:%\6_ L/B;3+T_\ ",:9X:^,'Q2^&7C2WLKF*>S%RNIW3>"KN:1&
MN(%9%@C:*YM[Q&_/_$_CV?AUP_AL\AE"SE8C-L/ED\,\:\ J4<1A<=B?K#K+
M!XWF2E@XT?9NG!-UE+VGN\D_LN >#X<;9U7RF69/*W1RZMCXUUA5BW4E1Q&$
MH>Q5-XG"\K<<2ZO.IR:5)KD?-S1_9K_@W[^+,OQ(_P"">WA_P[<[%G^$GQ)\
M<>"(5W.UQ)INNOIGQ2M9YPY. EU\0M1TVW"D(D.F+"H'E$5^W5>+_!/]G7X'
M_LX:'J_AKX&_#/PO\,]$U_5AKFM6'AFS>W74]56SM[".[O)IY;BYF:&TMHH8
M(FF,$ \UX8DDN+AY?:*_S3Q$Z52O7J4:7L*-2M4G2H<_M/8TI3E*G2]IRP]I
M[.#4.?DAS<O-RQO9?W;1A4IT:4*M3VU6%.G"I5Y>3VM2,4IU.3FER<\DY<O-
M+EO;F=KLHHHK$T"BBB@ HHHH **** "BBB@#/U9YX]+U*2UW?:4L+Q[?9G>)
MEMY&C* 9)<.!L ZM@5%I$-JFD:?%9.?LQM8'26,J'DWJLLDKD9'FSR,[SM]X
MR/(<ACD:M>$6\FI>,-<U*Q\%SMHGA2P?[/?:FL]^UM>W3N7E&F6<%U!;!7Y(
MBB:.$VQ$]PZB[@MG[L+0>(I54YJC3HN-:K7DKTXI^Y&,K>\YMMJC""E*3<UR
MI7DN+$UO85:4E!UJE92HTZ,7:HVK3E*%URJ"23JRDXJ*4'?H^^\:>*-$TS0M
M<MI-7L8M1DTS4;6VM5N$>Z^VRV4JP(T,+--&=[QDLP3:"#D9&?X??^#E'X\3
M0_&/]BKX-Z=>:MI<7[-GP-^+7[8.MZEIDL5Q:1^-O'?C!O OP#GU*S*RPF;1
MOB5\/M+LI1<1B:+1OB!(&PERK5_9C\5M?_9]^ O@<^,OC-\3?AQ\'O"=E=6]
MM_PG/Q:\8^%O!_A?^TY/.EMK2>Z\6ZAI/AN:[N@LOE6$*Q75V(R(59U+5_G(
M?\%H/C'X2_:X_P""@7[5/CWX,?$7PG\3?A9#%^R5^R[X'\2_#9I]9\-^*K'Q
M)I&F>/M5M_!5QIT\MCJLVF_$/P/XFM%BMUOK/4KFUU&XTD7$4<%\>VC6PU.E
M"EA77J3IXB6-DYQY7*>#PU>=)J%/F:H\RYJC=1SC!2=X?$<&)HXFK.I4Q*HT
MX5L/# *,)72IXW%8>E53G4Y4ZZ@W&DO9\DJCBDJE^0_L@_X)@?LD:?\ LL?\
M$V_V+_#%IHHT?7?&_P +M ^*/Q1N);1;359/B-\9+>'XC:A'XD7RH9I]8\/Z
M?K]GX%2:X$DD&D^"]+TUIVALK9G_ #"_:3\/Z9^W'_P72^$/[//CT6FN?!/]
MAW]GR\_:)USX>ZE;6M[H_B'XK^(O$&@:?I46OPPSR)<PVMIX@^$>M0:)K\,D
M,UIX:U^V6QET7Q3>M=?UNZCJ/AS4=)DT"QMH-3$UI':66CVMI(D,7EJJV8(6
M.&+3H;)HXY5<O UHD(>$*\:"OY-/VPGG_P"">O\ P7<\*_&G6=.CO/ ?[?O[
M**?#'0/$&J7<NGZ-'\:O GB'P5:ZEH1NF%Q]HO(M,\&^ =/T^SM4TV&>;XE:
M'!*L^H17%Y>>IE=>>*65935A[.K5S"AAZ<:S5*%:G.JI4U-U'&,8_6'1@W4:
MIN,5JVJB7FYK"G@EFN<4YNI1H9?B,36G1C*M4HRITK594XTE.<Y?5U6J*-).
MHF[<J4H-_F/\4/\ @F+^U_\ MC_\%0_B_P#&']OSPSX@\,_LL^$=9\2^(='U
M^R\7:1?^'_%'P=\)^(9=+^#OP5^&]WX>UB>]\/3^,K2ZL+SQ$/L/A?7;87OC
M3Q)J::)X]U^VDN['Q?\ ^"-G[(?B3Q!X2\5^&;O6O@OX9\/76GMXX\.:=K5[
MJWA_Q=H5E(&FMSJOBW6;K5/"FL7L*QV5QKMIJ=W:& -.=$;5I9=3?]G_ (_?
MM,ZU+H U+Q?<1IIR7$<&B^$M AD@35M:=)!;1JLTMU=7,Y4,TD]U/-!91"62
MUMTEE\FX^;-/^#FN?$32M+^(7QCU:>2"_P!9U6VT7X56<LEEIOA^UL;+3;JV
MN]7N+6>&XOM0ECUKRG4107$+VIBN[Z>&5]+L_P"C^%?"O(\)EF(Q/%=/#5XY
MCCU.-:M1^MXRI5H*5983+Y15"=TN=XNJZM#!\KA1K5*KY:=3^1^.O&WB'&YW
MALOX#EBZ>(RO+7[2C3Q'U#+Z%#%3A0>89SS?6:<82:C'+\-##XK,I.-7$8>A
M1@IUJ/YY?\%&_'7@+3/AIX%^/WP8\4II7[0W[(?Q&^'_ ,3_ (0>*=*T2_O)
M[630O%>B07NC7&IWMDUG?>'X2+#Q/=033W5G?3>&[>VE=[6^OTG_ *7-+_X*
MR:C^U;\-_ FI_LO_ +('[0?Q1MO%N@^%?$?B61=.M].\/Z1<:WI%AJ\.B)XL
MT.R\:6)MK*^O8K>YU?5[308V-K]K2W^RY67^>O\ X*>ZYH'@7]DS6OA)X&T*
MS7XD?M ^(_"/PC^&'@WPQI-H=;\3ZQK'BG1[C5;33],M+<W-UYNDQW6F&X2)
MB-8US2+0S)>:I:^;_:E^QC\%HOV>?V4?V<?@PTMA>ZC\,?@9\)_A_JNKV$,\
M4.KWO@SP+H?AV2\B^UO)??97.GDV<=Y*\\5NR+(1)OS\1XCYEP;DW&3QZX9J
M9W5CD^7Q6'QN<5L)AZ>9+$8WEQ6-654<)B*L_J$,+&GAH8FBZ2A0J.M4C-*/
MWWA1D_B-GW ,,OEQKA^&X//\TF\7E/#E#'8BIE+PN7_[%@)9_B\QPM&,<RGC
M9U<;4P->-=SKT8X6A*FYS^-]+_X*@OX#\B']J#]D+]HG]F[0OMUEI,?C.Z\,
MZCXU^'VG*[K:R3ZGXB70_"EV;>WG!2"/P]HOB2\O8/)FMK5C/'$?T@^%_P 6
M?AM\:O"%CX\^%7C/0_'/A/4'>&'6-"NO/CANXDCDGT_4;618K[2=4MDFA:ZT
MK5;6SU*U6:(W%K%YB;NZO;*SU*SNM/U&TMK^POK>:SO;&]@BNK.\M+F-H;BU
MNK:=)(;BWGB=XIH)D>*6-F1U96(/XK_M@? /1_V ]+\<_M\_LL^-?!?P%T_P
M%HEQK'QM^%?C"^M=,^"WQ$\+KJ,%P]GI.GW5[80Z!XCGNI18Z'X5\/7%K)K=
M_-IFC?#Z#0O$EP;+Q1\!1AP)Q7)X3#X6? 6=57; 5JN9XG,^$\75:M#"X^KF
M"J9KDDJT[1AF4\;F6"A*26+HX2@IXJG^BXBKXH<"PCF&+QT/%/ARBN;-*%#)
M<'DG'F7X=23J8[*Z&4NCD7$T,/2YIU<GI9;DV9580?U#$8_$NG@:OYH?\'7'
MBSP3I/A;_@G)X?US2DNO$]Q^TQXH\>V>I?:IHY+/X=_#O0O#'_"R]/6T@@FE
MGBU&7Q1X-NY;B%7GMCH\<$%O<27H5?N;_@V1M_$T/_!'O]GZ37KL7.EW?C;X
M\W'@N$121_8/#*_&?QI:W5H7>")9R_C&V\6W_FPR7,8%Z(3.LL,MM;_QZ?M[
M?MG?&7_@LW^VEX2\0?"GP#K.G7WQ#T;1?V6?V-/@C=ZLFI:E8Z;XO:\L_C1\
M6M>6. Z5!I^J7%YXGT#5O%NI:-H=A;>&KRQN(-9N;WX%>(KK3_\ 1M_8U_9I
M\,_L<_LK_ ;]F+PE-#>Z3\&/AOX>\'W.L06K6*>)?$D%L;WQGXO>R>:X-G<>
M,O&%[KOBF[M!-(EM=:Q-#&QC1:^#Q-.="E1P]3E513K5W&+C-*%:-&-)\\9.
M,U4C1]M3E%RISH5*-:G.<*R:_5,)6IXJK6Q5'F=&5.A0C*<9P;G1E7G57LIQ
MC*G*E.O]7K1FHU:>)HU\/5ITYT&G],4445QG>%%%% !1110 4444 %%%% '\
MC6I6%WI__!SE^U)/X_CO[:ZUS]DKX::G\#6N0KZ;J'@&W\!_"[2/%KVK7#,T
M,J?$72_%4=HEEY<+S6.MO+&TY:4_O*SE=+@B&-LE_<R-Z[H;>U5!],3N?QK\
M<_\ @X ^'WB#]FGXW?L7?\%>? NF:AJMO^S[XDL/V??VD;"TMKR^3_A1_CW6
M=8NO"7B.XAMIK6."S\,>+O$_BO25CN)]FK^+O'7@2S)@BMY_/_4O0OB%X>\5
M?#?3/B+X>O[75?"VL>&8O&FCZE9W,%W:7&E7FDKJ2S0W%M*]O<)+ D/[V&=H
MB8CY<A5MU?H_#LXXO*L-2IV=7!XF>&J4U\7[^I4Q&'JO;^+*K6IQW?\ LLKZ
M.*/SG/X?4\VQE2K=4L;AZ>-IU7\*6&I4<)BJ2_Z\1H4*LWHK8R"2;4F?G%\:
M/$\GBOXD>)KTN6M;"^DT/3E#B2-;+1W>R$D+8&([RYCN=1VG.U[QUR0!7EM.
M=VD=G=BSNS.['DLS$EF)[DDDGWIM?U3A,/#"87#X6FDJ>'HTJ,;*UU3@H7>^
MLK7;;;;;;;;;/XGQV+J8_&XO&UFW5Q>(K8B;;O:5:I*;2V5H\W+%))))))))
M!11170<H4444 %%%% %34(;>XL+VWNT,EK/:7,-S&IPSV\L+I,BG(P6C9E!R
M.3U%?//_  0;\;ZYX(_X*V_M8?#J..SM/"/[4G[(O@S]H._@M8X6EO?'OPH\
M;>'/AY<:M=& *EK/K&N>+_B]K=^K+NGNM4MY7"M*%'M/CB[.G^"_%]^,9LO"
M_B"[&X,5S;:3=S#<$(8C*<A2&(Z$'!KX[_X)57DFB_\ !;C]FFUM[XV*^)_^
M"?GQ4LK^&.X,"ZVB?%GXKZW'831EU^V^0VAV&H?9L.$;28KO8/LHD7X#Q=P%
M&MX;U\?.*=;"<49/##R^U"-; YM#$13WY:BG0<TK*4J5-N_(D?H?@CFN(H>,
M&#RFE-QP^-X&XCKXRG?W:D\/FW#LL%.2NDYT;8Q4Y/F<8UZRCRJI)O\ N<HH
MHK^1C^Y3Y._;H^*OQ1^"O[(WQ[^(OP/^'WCGXH_&;2? &I:;\*/!?PZ\'ZUX
M\\4WWQ$\4R6_A3PAJD/A;P_8ZAJ>IZ1X6US6K+Q5XG$5N([;PSHNKW5Q/;00
MR3Q_B5X[_P""?7[47[$G[+_[#GQA^%OC'6_CW\1?^"=7BOPGXQM?@#\+?@K8
M7WC7QOX:^,FJV/AO]L#P9X(\0:3J&K^*/$MYXWL?&/BKQ1<SW^F7]S=C23J5
MK:V^H06:1_TS5CW_ (B\/Z5.+;5-=T;3;EHUF6WO]3LK.=HF9E6417$\<AC9
MD=5<+M+(P!)4@ '\_P#XOET#X0?%W_@J%9?'/]B#XP?M8^*OVIM6\)^-O@ V
MC_LU^-?%6@?M"?##5?@1\-?!GA_]GC5OBSX=^'WBBU^#"_##QKX/U"W\4#XH
M-X7?P;82I\2;#3=3U7Y9_"+?X??&;4OV.O\ @IU\"KGX!_&?3?B[??\ !4_X
M9_'#3?".G_#;XK^*-$\2_#?Q7^UG^S#KT/B;X9?$'4O!.DV_Q;\-Z/HWP[\:
M:WJ_B+1[?^T;#PKH@\8>*M*T'3=1MY7_ *:?^$U\&_\ 0V^&?_!]I7_R71_P
MFO@W_H;?#/\ X/M*_P#DN@#\$[?]DOXUP_\ !0[P]^R[_P *_P#$K?L%^&/V
MF/$7_!5K2OB \/B?_A"[/X@:CX>MM%T+]FW3=:BLHO"5A>:'^U7JGC#]HN+X
M;+=,!X4O-,U.*P$5L)8?SO\ VV]$_:8^)'PH_:>\">%/@S^T%X+^*-W^VSXC
M\:>&?V9OV=/^"?GC"X\':O;>%/C]IGC.+]K#QU^U[XB^&_C/5?'^N^-_"/A9
M];TW5O@S\0?A[K6M>)]9T7PS9>$;SP);ZWI5S_7Y_P )KX-_Z&WPS_X/M*_^
M2Z/^$U\&_P#0V^&?_!]I7_R70!_+9_P4)^ 7QC^*/QL_X*M>#/#'PD^/&LW'
MCK6O^"=7QT\$2>"O@]XJ\0:7\7_AC\"_"MKX)^/7A_X<>,;S1_\ A7>L_$3P
MYI?C:[O=&\#W.L3>(?$NI:'>:5H&C:A?VMR;'[3_ .">OPI\2ZY^W9\4/VCV
M\4?M(^,_#UA^RSX1^$VI?$?XM?LE:+^Q9X2\?ZWK/CF+7M'\*Z?\-7^%/PQ\
M0_$/7_A!HW@Z?3Y_B%/IMQ;^&[3Q2G@FPU-]*,,%QV/_  74\7>%9OV$KEK?
MQ)H5U]E^-7P@O;A;35;&[DBM+37KB:YN&BMIY9?*@B5GD8(0JC)K]BO _CSP
M/\3O">A^/?AMXR\*_$'P-XGLDU+PWXR\$^(-)\5>%?$&G2,Z)?Z+XAT*[OM)
MU2S9T=%N;&[GA+HZ;]RL!XV%Q="IGF;X*&#I4J^%P.3UJV.CR>VQ=/%SS14:
M%6U*,^3!O#594N>M5C?%5.2%+WG4_2L]X>S/!>%7AWQ-7XDQ^.RG/N*_$K+,
MMX5K+$?V=P]B^'L)P!5S/-<"YX^MAGB>)(9YEU''JAEV!JJ.08+ZQB<>G0C@
MNKHHHKV3\U/Q5_X*9/J'[0_[1G[('[".DWK_ /".>*-9O/V@OCAIL2F1;GP7
MX/U6W\-?#BRUBV611J?A;5_&EQK[Z_IDRJC?V'8:A WVO3X9;;T/]H;Q3:&7
M2O!^@HUKH&F6-G8Z9;!V;R_#VB;K'1XG=OGF:\N(;G4KIIBTOVL*[2.237F?
MP_>Y\6_\%8OVX_&%V7ND^#WPM^$O@SP=?2*A.F6__"GG\1:_IMHSHDL=NWB?
MQ^EY/"@E5[X1WA+QB-X,WXIW+W'C75$9RR6D5A;1 ]$06-O.Z*,# $\\S'KE
MF8@X(Q_BK^TG\1LTI8+B;)</6J4*-?B7*/#^E[.?-">3Y?PMD_&>.Q&'DY\U
M!YKFW$V;9+GU&$52QL>&,@E752KE^'E0_JOP(R+#U,3EN)J1C.5++\7GTU)6
M:Q=;,<1E-"$U:T_JV&P.&QF#FWS47C\:H-1KS4O/****_P 43^M0KXU^,7@G
MX*>'OVF_V=?CA\>O 'A;Q_\ !?6]8A^ _P :+/Q=#))I/AG0_&-U<R>!OB.;
ME)84T:'P5XIN9I_$&JR,S7.A71T>,(]W'(G3?M2_'OQ7\!?#.AZQX:^'LOBJ
M#6[ZXT[5/%^HS:G'X)^&Z;[&"TU[QLF@:7K&O3:3)+>O(8M/M;9IHK&Z@COD
MOY;"TN_KW]G_ /X)B:)^TGX=\/\ Q8_:K_:DT_\ :5\%ZTZ:IH_PJ_9Q\0/X
M<_9LD^QW]SNL=0\3Z+/%XL^),=A>0P-!>74OA/6]%U&VNM-O)[](G!_U(_9S
M?1Y\9<P\0N#_ !_X<S'AG)> ,HS'-,KS>IC\YHXW,^(<LK4L1E.>Y+0R+*7C
M,5@L5%36)PLN(GD\(5J. S7"PQM#ZM*M_/'CIQOPK0R3-."\?0S#%YUBJ&'Q
M&&C1PLJ6'P.(C*GB<'BYXS$^RIU:;M[.HL#]:;A*MAJKI3]HH_IYX&_8._8P
M^&NK^'?$/@?]F#X)^'O$?A+4K76?#7B2U^'^@3>)-&U>QNOMMCJMEX@O;.YU
MF/4;&["SV-Z;UKFSDCA-M)$((0GUG4<,,5O%%!!&D,,,:0PQ1J$CBBC4)''&
MB@*J(BA550 J@   5)7_ $('\3!7XK_$_P"$/[1_[4O_  51'C'P_?>*_@+\
M)_V"_@6FB?"3XH>+/@Y-XBT3XD?'/]INU,GQ+U[X77?BPZ1X6\7:-X7^%.BZ
M;\/_ !-J.F3:R_A;Q%=ZAISM!<:PRV_[452O]3TW2H!<ZIJ%EIMLTBQ"XO[N
M"S@,KAF6(2W$D<9D94=E0-N(1B 0IP ?RC:5\!OCO^S+XD\&_LX?%7X%?%W]
MHG]D3]AC_@H+8?'WP]=^$OV<=5\8>"O'G[/W[37P9^*UQ9ZKX*\#Z5I'B2/Q
MC=_LC?'OQMK%]XQ\)>%I?$?BC2[/QI;Z]H?AV33_  G;36?T?^T[KC^--!^'
M_P >?A7^Q5\9_AO\(_ __!7K]E?XT^)M<T'X._&,_%7XV^#_  +\.9[+XE?M
M,:K^S''\+=)\=>"/#5K<RZ+X*TG6CI>K>)OB1%X=B\0:QINDW-UI-G>_T(_\
M)KX-_P"AM\,_^#[2O_DNC_A-?!O_ $-OAG_P?:5_\ET ?@5#^SO\8S^RM^T5
M\7_"WPM^(EG\??V:O^"L/[5?[<7P \)7GAKQ7X6\8?%/PAH_Q_\ %.LZ_P"$
MO#.EOI,/B+Q-H'[0WP$U[QUX-\,6.EVMQIGC34/$?AV2V:\6*VD3B;WX9?'?
MX3_L5?LT_$GQA\%IY/C9^U!^W)J7[8W[4/C:_P#V=?B5^T_XQ_9#\5?%_P .
M?$+7O"WCC0?V>-$A'B8^*O@]X.C^'GP4237-)UG2/AC?0WLTOA#4-0?3X;+^
MBO\ X37P;_T-OAG_ ,'VE?\ R71_PFO@W_H;?#/_ (/M*_\ DN@#^.K1O!'Q
M^T'XM?%SXX:]\*?VSO'GPETG_@JA_P $UOC_ &OCGQE^R!XK^'OC?Q_\/_AK
M\.?C/X,^+_QJT;X$?##X0^"A8:4=9TC1)KFPTCX=67CB/P]J?@&Z^(=G=^,_
M$+:AK'N/[5GP.^+6D?M#?\%1$\;6O[4.JV'[4UCX(UWX8:'\)OV"]!_:.T/]
MICX?Q?!OP[X8\-_"*#XHZA\*/'\GP4\5_";Q+I>H:)?'Q9KO@J+0433?B=IL
M/]IHM[-_5)_PFO@W_H;?#/\ X/M*_P#DNO)O@A^U3^SI^TC<^.M/^!OQD\!_
M$G6?AAXJU[P3\1_#?AW7+:7Q5X%\3^&]>U7PSJFF^*_"UR;?Q#H:-K.B:I!I
M.HZAIL&E>(;:U.J>'K[5-*FM[V4 UOV;OA]K'PE_9Y^!7PL\0ZKKFN:[\-_@
M]\-O NLZMXFU.SUOQ%J&I^$_!VCZ%?7.MZUI\,%GK&J/<V,GVW5H8R-2G#WK
MRSR3O-)[3110 5^#?[4_C%/BE_P48U*=A/?>$/\ @GK^SO\ \)391RV5K/I^
MF_M/_M%7>FZ7X%N)8KV.2"[N]%\#7NB>/_#UR$DGTK6_!EQ=VGE36LK-^\E?
MS*:!]HU3Q?\ \%(/']U)"]SXI_X*&W'PY%Q#<Y^TZ;\#O!_C/2K.S$#RR3,-
M+B\86<=ZY<VZ7CQ10Q6WEB)?F.,LQJY7PWFN+H\RK1PM6%*I&3BZ56=.?LZC
M:U:4U%<NBDY*+T;/O_"_)</GW'&08#%>SEAWCL-5KT*D5+ZS1AB*,:U&*=TI
M^RG.JIV;@J;G&THIK\X/VE/%L^O?$";15FWZ=X5MX[*!5;<CZA>PP7FJ7#$C
M=YV]K>PE4DA3IX*@,SEOGFM37-2EUG6M7U>9BTVJZI?ZC(Q))+WMU+<L<E4/
M60X^1>/X5Z#+K_/S$576K5:K=^><I*_2-_=7I&-HKR1_T%Y#EM/)\FRS+*<8
MQ6$P=&E4Y5RJ5?D4L14:Z2JUY5*LO[TV%%%;/AW0=2\4Z[I'AO1ULGU77=1M
M-*TU-1U32]$LI+V^F2WMH[G5M;O-/TG3XI)G1#<ZA?6MK&6!DF0<UG&,IRC"
M$93G.2C"$4Y2E*32C&,4FY2DVDDDVVTDKGI5:M*A2J5Z]2G1HT:<ZM:M5G&G
M2I4J<7.I4J5)M0A3A!.4YR:C&*<I-)-FKX;7PZNC?$?4-8T#7/%&M:!\./$/
MBCP7H6D^)M+\*65[K?AB73]=UV7Q%J>IZ)K33:-I/P]L/&VNQZ1I8T[6=?UK
M2M'T'3=1@N=359/T5\&?\$SOVNOCG\#-,\1?".Q_8G\->&?BSX1^&_C#PI\3
M+SXH_M$ZUXYL(+37M"^(.CZWX<1/!4WACP_KTTFDV.E:['J?@^74M,MKK6=)
ML7TZ:ZODA^6_V9/AGX]^*GQ4?2/V:OASJWQ_^(_PQUC1]2UW6=2G;X:?L_\
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MG@+X5ZCKNB_M.6WQ%\3^$_!GVZR^'?A;X=?%JR\2^+M3TG2T?_A&?#]_XF\
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MJ%-*,*4(TXI*VD4DOF[7?F?PM5J2K5)U9N\JDI3D[WU;O^&R\@HHKO\ X;^
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M_5J=2M4<JO\ )SXB4(4:,:DH1;IU:K=2.'G1J? WP"_X)P_\%,_^"N'B2?\
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M_@M%_P!&:?\ FQ'[*7_S\Z/^(;S_ (+1?]&:?^;$?LI?_/SK_5,HH _RL_\
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MEI3+?2M?6N@365N8CB.XN(I)/W:O7Z)T5_K$?KQ_ -_Q!U_M*?\ 1X_P._\
M"$\>_P#QZC_B#K_:4_Z/'^!W_A">/?\ X]7]_-% '\ W_$'7^TI_T>/\#O\
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M[EE\$ZTVJ^'(=6U_3$DAU?1;N"6Z\-^)/%'AXSI);V6OWLD$_E\;_P %'O\
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MX1?5XX3V$XPJX>KA94Y4,1AZ\(8FAB*=6EB81KPJ111117F'LA1110 4444
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MUKPKX"AURZ&HC<&5];OXKA/-N#90VT)DMT_5[X9_\&Z_[0GQ<A%S_P %!O\
M@H9XXUC1-2CN3K_P1_8_T/3?A3X*OKB>2*5TUKX@:OH-M+XXTZX*O!=QZ_\
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MGRQ15[4],U#1M0O=)U:RN=.U/3KF:SO["\A>WNK2ZMW,<T$\,@5XY(W4JRL
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M9S/ X:5U.-2I!IIT:E?$5,.XNRY7AJE66'<%9<L'3Y86]U(_CR_8+_X([_\
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M?]N^WT?RQ]F62;P[XS\3? C0?&$_F74<@D@M-!.J$K&@D#2W MI(;R2&1?\
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M1['0/#F@Z;"SNMKIVEZ=#!:VZR322W-Q(L?G7=W-/=W4DUU/-*_;U^4.D?\
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M9OV@-;T#P^T%A#J5\;KQAX<^'>L>$+FVTZWF_P!/U'3==O=+@DBG7[:ZPNP
M/TVHKB_AO\0/#'Q8^'G@+XI^"+RYU#P9\2_!?A;X@>$;^]TW4=%O+[PQXRT.
MQ\1:!>7>CZQ:V6K:3<W.E:E:33Z;JEE::C82N]K>VMO<Q2Q)VE !7C7[07P)
M\"?M+_"+Q=\$OB7_ &[_ ,(3XU_L'^VO^$:UJY\/:W_Q3GB?1?%NF_8M8M%:
MXL_^)OH-A]I\L'[1:>?:OA)V->RU^5G_  6RNKJR_P""8W[3-S9W,]I<Q?\
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M%C\$+6/QCKFJ^(KEKF>YT3PY:ZE9ZYH\6IZSK]K-IFFW>I6?XS_&3]I_XW_
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M\OB/3_B/<ZK:VOQ$MO'U]87G@EH+"Y\-0ZY-)>V_UUK7[:G[7GC3]J+]LO\
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M)#IB+I^O-JEC=OK-D!;:DUU#\E=9\^?R;>,_B=\>?V?/CA\,/#'AGXM?%_\
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MID]M?1?"B?2/'NL^'OA_I=OX)TW1-%\6Z5'HO@:TL4U:QU"XU+X?L_CG\4_
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MW5+RRM;"PL[6^O9I[V"QL+*RBG6TM+>&, _([XB#PW\;/C/_ ,%//B+^TO\
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MVC:]X=\*_LB_LS:!H?BO0+_PIXKTO2_@7\,;6S\5>&-4U/1M;U/P[XGBC\,
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MI_'=KXYU66=M(O;:"Y;L?V(/V#+;]DKQY^T'\6-0U;X/#QG^T0WPTAU[P?\
MLY_ I/V<?@?X5L/AC9>*X=-ET+X<Q^/_ (CW.H^*_$%_XSUO4_%GC+6/$4EY
MJDIL;>TT[3(H+HWX!X?^WC_P4H^+O['6K?%#4K3X'? ?_A6OPCT#3/$L.N?'
MW]KOPU\!O'?[1BR>$;CQ/XD\,_LQ?#J3P#XTOO&&K>%Y&M="DO=<U+2[OQ#X
MKM]1\*>$_"^N7BP7QW?&/_!0WXX>+?CMX.^"?[('[+OAWXZ_\)Q^Q/\ "_\
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M>ZI\4_BC#XL\6S^#?.L[#2_"&F> M"T?69;C6[19%OKO3' /T]HHHH ****
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M /P;\(?%W6OV2?\ @HS_ ,%8OB-X\_9P_;%\=>&/C+J7[%^I?"+4_@?^R?\
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MZ,L64445[)^9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*DKV\#2* [0Q$E% )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *]U9VE]%Y%[:V]Y!N5
M_)NH(KB+>ARC^7*KIN0\JV,J>00:_*;XC?#S_@LI>_$+QW>_"_X_?L;:-\-+
MOQGXHNOAWI'BCP9XSNO$VE>!;C6[Z7PEIOB*ZM?!-W:W.NV.@/I]KJ\]M=7,
M$VH17$D-Q-&RR-^L-%>;F.6PS*%.$\7F.#]G)RY\NQU; U)W5N6K.@XNI!;Q
MC*Z3NUN?;<%\<8K@K$XS$8?AW@SB3ZY0A0>'XUX6RSBK"87EJ*HZV!PV:4ZM
M+"8BI90JUZ*C.I22A)M)6\2M=*^/J_L[-HMWXG\ O^TY_P *BO--3QC#I^H#
MX8CXU-X3GM[+Q"=+;3AJG_"%1^,C;ZA/9?V5]M;1EDA6Q:8B EKI7Q]7]G9M
M%N_$_@%_VG/^%17FFIXQAT_4!\,1\:F\)SV]EXA.EMIPU3_A"H_&1M]0GLO[
M*^VMHRR0K8M,1 ?;:*W^J1T_?XO3"?5/]YJ:QT_?O77%Z?[S_$WUU/*?$55\
M_P#PD\/+GXA7$6F2X-<M5<W_  DQ]SW>'O>UR5?['[L?<]U'Y*^!?AW_ ,%G
M;3QOX-N_B'^T!^QCJO@"V\5>'KCQSI?A[P7XTM]?U+P?#J]G)XFL-#N+CP/;
M6\&L7FBK>V^F33W-O#%>R0/+/$BM(OW[\9=*^/NIW?PD;X%^)_ /ANRT[XN^
M$=2^,\?CK3]0OYO$'P5MI;@^-?#W@MK#3M06R\:ZC$ULNBWMZUC90.DIGOH
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M_B[Q5\/+[]G2_P##OA:#X3>%-(T[48?B+H?B>WL;%/%]YXLU*;38=.N],O\
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MR7-L71GBLJHX6--8C 4L+*$<'BYU,312JS;"BBBO6/ST**** "BBB@ HHHH
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MNUN?[3OIEF@<@)W\MOQ2_P ['UC17SW?_'/5YO$OB[PQX'^$OC/XAS^%-?\
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M:?<6MPZ6\LCV\70T#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P VK7];?+R/ _BMX$\=ZEX\^%OQ-^':^&+[6?A^OB_3-5\/>*M1U#1K+7]
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M^VUL9ET[5[HKI^C6VGVVJZ@OV2&&UEN)!]+>(/#VO>//AAXE\*^(#8^&-?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ny20006478x8_graphic06.jpg
<TEXT>
begin 644 ny20006478x8_graphic06.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M=7_Z"?Z#_P",UO44>TEVAT^Q'I;R_NK\0Y%WE]__  /)?<8/V'5_^@G^@_\
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M!<R1#=PN9$Y^@+*&_ ],XI^TEVAT^Q'I;R_NK\1<B[R^_P#X'DON,?[#J_\
MT$_T'_QFC[#J_P#T$_T'_P 9K:9PJEB5"J!N+,% ]R3D ?CUXH21),['1P.#
MM<,0>X8#."/KGVH]I+M#I]B/2WE_=7XAR+O+[_\ @>2^XQ?L.K_]!/\ 0?\
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MM7>WN77]R/3E\O)?B'L_.7W^GEZ6^1^COV'5_P#H)_H/_C-'V'5_^@G^@_\
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M0:8ELW]IBU9(F?3KO[3LMIS#'N>&48^6OLZA5):64.GV(^7EY+\0Y%WE]_\
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M/_C-;U%'M)=H=/L1Z6\O[J_$.1=Y??\ \#R7W&#]AU?_ *"?Z#_XS1]AU?\
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MQ@_8=7_Z"?Z#_P",T?8=7_Z"?Z#_ .,UO44>TEVAT^Q'I;R_NK\0Y%WE]_\
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M91@G+HEKHN_I^73=(+[:ZW_^1W>G;5K73SN?FC^W-_P4!_:Q^,G[$G_!)/\
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MDG92?D/V%X2_X(G?\%%OVE/B=\!(?^"GG[9_@KXP?L]_LU:AINM^!?A]\/-
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MW1-=L9M-U*U6ZMY(;BV>XM+F6-9H9%D3.Y2"!760JR0Q([F1TC17D8 -(RJ
MSL%PH+$%B!P"<#BO,OC9H_Q%\0_"3XD:#\(]:TOPY\3-:\%^(M*\"Z_K44LV
MEZ+XHU#3+BUT?5KZ.&*:5K?3[N1+EUCBD=C&,(>C40?Q]_\ !3N__9V\"?!B
MV_X((?\ !+OX0P>,_B7\7O&6D7?Q,LM&DU#Q%9_">SFURPU6_P!<\1>(I_/<
MZR9M/M8[RYO+KR-(TQ9()-DI5$S_ -J+X'_\*1_X*K_\$%_V8?$MQ#XBT+X2
M_!6#2;NWNF%QHUYXMTBY*7VL002JL9E?4[.*>VDD7S/+2!6S@*8OV8?^"(G_
M  7*_9!\=_$[XG? []L;]EW0_B%\8-2N-5\>^,]?\+7OB[Q%K%U=W9OKI1JO
MB7P#JEU9VMQ=E9Y[.T>*"61$9DRH-?JA^V]_P2=_:?\ VOO@;^RI\2+GX_\
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MX<_Z#ND?^#*R_P#C]?C!_P 0_P#^P1_S\_M*?^),?%?_ .7]'_$/_P#L$?\
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MKBZ\B-(1+*KLJ(J@XR*_+;_B'_\ V"/^?G]I3_Q)CXK_ /R_H_XA_P#]@?\
MY^?VE/\ Q)CXK_\ R_HOY?CZ7Z>OX!9?S?\ DOI_>]?ZW_9__A)_#G_0=TC_
M ,&5E_\ 'Z/^$G\.?]!W2/\ P967_P ?K\8/^(?_ /8'_P"?G]I3_P 29^*_
MU_Z#_IS2?\. /V!_^?G]I/\ \29^*_\ \OZ/E^/IY>OX>867\W_DOI_>]?ZW
M_:#_ (2?PY_T'=(_\&5E_P#'Z/\ A)_#G_0=TC_P967_ ,?K\7_^' '[ _\
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M_P )/X<_Z#ND?^#*R_\ C]?C!_Q#_P#[!'_/S^TI_P"),?%?_P"7]'_$/_\
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MO[9T7S54KYG]H6!< X^4.92V#@9PR]!G/;\9?^(?_P#8'_Y^?VE/_$F/BO\
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M '[ XZW7[28QUS^TS\5QC/3_ )C_ 'H_X< ?L#?\_7[2?_B3/Q7],_\ 0?\
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M]?ZW_9__ (2?PY_T'=(_\&5E_P#'Z/\ A)_#G_0=TC_P967_ ,?K\8/^(?\
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M/^'],BBD'0<8]O2EH$%%-W*.K*/Q'^-&]/[R_P#?0_QH =13=Z?WE_[Z'^-
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MP3_9"^"EU<_"#XJ^!?AO^S[XX^$OQ-^&_C;Q7XBT_P"&OA;QYX@U?7-0\/\
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MCX2U/3]+O[F>P\-^)]7DM)K9[Z"X.GZXNG7+Q3*RQXVAO=?VL_VL?C7\+/\
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M7CCXX_LFZK\)_%UAX9^!7@/P1X'^$W[17A.]FGAO_&?@'X.W^F^+?AC-H]I
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_1L7P8Z9_P"1%T;I_P" OZ=?:EKY?=_P?7^EJ_=_O?>O\O7^GIY5_P /:O\
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M_I:GN_WOO7^7K_3T\J_X>U?\$Y?^CM/A/_X.9/\ Y&H_X>U?\$Y?^CM/A/\
M^#F3_P"1J]6_X8!_8M_Z-B^"_P#X0VB__(M'_# /[%O_ $;%\%__  AM%_\
MD6C7R^[_ (/K_2U/=_O?>O\ +U_IZ>4_\/:O^"<O_1VGPG_\',G_ ,C4?\/:
MO^"<O_1VGPG_ /!S)_\ (U>K?\, _L6_]&Q?!?\ \(;1?_D6C_A@']BW_HV+
MX+_^$-HO_P BT:^7W?\ !]?Z6I[O][[U_EZ_T]/*?^'M7_!.7_H[3X3_ /@Y
MD_\ D:D/_!6O_@G*/^;M/A.?^XS+_2U->K_\, _L6_\ 1L7P7_\ "&T7_P"1
M:0_L ?L6'K^S!\%C]? NBG^=K1KY?=_P?7^EJ>[_ 'OO7^7K_3T\J_X>U_\
M!.7_ *.T^$__ (.9/_D:C_A[5_P3E_Z.T^$__@YD_P#D:O5O^& ?V+1T_9A^
M"_\ X0VB_P#R+1_PP#^Q;_T;%\%__"&T7_Y%HU\ON_X/K_2U/=_O?>O\O7^G
MIY3_ ,/:O^"<O_1VGPG_ /!S)_\ (U'_  ]J_P""<O\ T=I\)_\ P<R?_(U>
MK?\ # /[%O\ T;%\%_\ PAM%_P#D6C_A@']BW_HV+X+_ /A#:+_\BT:^7W?\
M'U_I:GN_WOO7^7K_ $]/*?\ A[5_P3E_Z.T^$_\ X.9/_D:C_A[5_P $Y?\
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M:?"?_P ',G_R-7JW_# /[%O_ $;%\%__  AM%_\ D6C_ (8!_8M_Z-B^"_\
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M?UXZT@_8#_8L(!_X9B^#&#_U(FC]^/\ GTZ^W6C7R^[_ (/K_2U/=_O?>O\
M+U_IZ>5_\/:O^"<O_1VGPG_\',G_ ,C4?\/:O^"<O_1VGPG_ /!S)_\ (U>J
M#]@3]BL]/V8_@OTS_P B-HW0$C/_ !Z\C(QQWXZD4[_A@']BW_HV+X+_ /A#
M:+_\BT:^7W?\'U_I:GN_WOO7^7K_ $]/*?\ A[5_P3E_Z.T^$_\ X.9/_D:C
M_A[5_P $Y?\ H[3X3_\ @YD_^1J]6_X8!_8M_P"C8O@O_P"$-HO_ ,BT?\,
M_L6_]&Q?!?\ \(;1?_D6C7R^[_@^O]+4]W^]]Z_R]?Z>GE/_  ]J_P""<O\
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M(W_!6G_@G(RE6_:S^$Q# @@ZS(001@@C[/R".".XKU?_ (8!_8M_Z-B^"_\
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MO?>O\O7^GIY3_P /:O\ @G+_ -':?"?_ ,',G_R-1_P]J_X)R_\ 1VGPG_\
M!S)_\C5ZM_PP#^Q;_P!&Q?!?_P (;1?_ )%H_P"& ?V+?^C8O@O_ .$-HO\
M\BT:^7W?\'U_I:GN_P![[U_EZ_T]/*?^'M7_  3E_P"CM/A/_P"#F3_Y&H_X
M>U?\$Y?^CM/A/_X.9/\ Y&KU;_A@']BW_HV+X+_^$-HO_P BT?\ # /[%O\
MT;%\%_\ PAM%_P#D6C7R^[_@^O\ 2U/=_O?>O\O7^GIY3_P]J_X)R_\ 1VGP
MG_\ !S)_\C4G_#VO_@G-G'_#6GPG_P#!S+_\BX_6O5_^& ?V+?\ HV+X+_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M44*R)%&LKK)*J*))$3RU>3'SNJ9;8&;+!-Q"YP#@5+00%%%% !1110 4444
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MXMUV\GO-1\)VAFM+%GT#PS>23:!I5S;0RVLD-BH$Q<$5Z5^T'^R&O[2OQ \
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MQDNUELX-JW)@F"%"^-AW;<BOIC[%;?\ /M:_]^(O_C=&O=?<_P#,6G9_?_\
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M^C+O^"B7_B,.J?\ R_H_X?J_"3_HR[_@HE_XC#JG_P OZ_;DV=L,?Z+:\_\
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M2K&?4M2U;4&M+6PL=/MH7N)[RZNI0L,5O%"C2-(SA0HSFC7NON?^8:=G]_\
M]J?BW_P_5^$G_1EW_!1+_P 1AU3_ .7]'_#]7X2?]&7?\%$O_$8=4_\ E_7Z
M(?#W]M3]C_XK>"/'?Q(^'?QV^%WBSP-\,89+CX@>)M+U6W;3?"5O%')*T^M/
M/!#+:P^7%(ZR&(HZK\A8D ]+X5_:D_9D\;_#"P^-'A3XO?#C7/A9J>JQZ%8>
M-[/4[3^Q+G6Y;I+&+2(YY8HI/[3ENY$@BL6B6YD=ALC8'-&O=?<_\PT6Z?W_
M /VI^97_  _5^$G_ $9=_P %$O\ Q&'5/_E_1_P_5^$G_1EW_!1+_P 1AU3_
M .7]?MM#;V5Q#%/%!:/%-&DL;B"+#HZAD8?NQD,I!![@YJ3[%;?\^UK_ -^(
MO_C=&O=?<_\ ,-.S^]?Y'XB_\/U?A)_T9=_P42_\1AU3_P"7]'_#]7X2?]&7
M?\%$O_$8=4_^7]?MU]BMO^?:U_[\1?\ QNC[%;?\^UK_ -^(O_C=&O=?<_\
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MFMGO3J5X+QS]D1TC$7RJ5&UVW<#.>^*\,_X:$\;_ //KHG_@))_\=KVKX/\
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MTNVUSPKXNT/5/#?B/1;Q2]IJVA:W92:?JNFW2JRL8+VSFFMY@K*QCE8 @\T
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M3;!K:P24F1+96-/^OR_R_!!>ZL^B27_!_'[V?35%%%!(4444 %%%% !1110
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MVD<LLDCO)'$R'?\ S_X'KI\^Y5UIOH[[6[>?D]?0_GB^$'PK\<?&3QY^T/\
ML*_$K3_V:;7XI>)?V;OAQXX\)_M$?LX>!9- \*Z9I-O>6<OA_P $?%#PDFI7
M%MKGV*ZACECDE>"36-+D=<+&5V?.FH0>.OV>_B=H?@.^\/>#?VKO^%<_':+Q
MGXB\-^#QIGP6^!?C+]IGQ%IA;PG:>'+VY^T:!X?D^$FF:+=S^(M'NB]O<ZMJ
M,0EA+E1#_3-^SC^Q7^S-^R7#XKB_9_\ A7H?P^;QO/!-XHN[*?5=1U'5EME=
M;:VGU+6=0U"_6SM5DD%K917"6=MN)A@2L_QM^PI^RE\1/AAX@^#GB[X.>&]5
M^'GBGQG<_$37-"WZE9/?>-KR[%]<^)&U33[ZTU:+4YK@ O/#?1EHMT!_<LT9
M6OS];_FM?FF'-ZVTZ6Z)/9Z:>J.N_96^/EA^TS\"/A_\9=.T"X\+_P#"7:8\
MU]X;N+F&];0]2LKA['4=-CU"!([?4+>UN8I$AO;=!#<HH>(F,@GZ)KB?AW\.
MO!GPG\%^&_AW\/- L?"W@OPCID&C^'O#^FHR66FZ?;C$,$7F-),Y7JTDLLDD
MC9:1V9B3VU,G^OZW"BBB@ HHHH **** "BBB@#PG]I'X/:5\>/A#XI^&6O\
MB;Q9X7\/Z_;Q'7[GP9JIT;5M5T2SD%SJOAJXU!(99H='\164<NDZQ]G:"Y>Q
MNI4@N(9"'K\O?^"!MMH7AO\ X)W:/I>G1V>D:)HGQU_:!T72[?[0%M[6RM?B
MEKEM9V275TWF3;$$4,;SN\\A5=Q+FOVSG@CN(I(95#Q2QO%*C %7CD&UU(/9
MDW*?9C7SCHW[(G[/7AWX4GX(^'OAOI&@?"X^,C\0#X2T6XU32[$^+V\4IXSD
MUGS;._ANQ++XD1=3FA6X%O-)F&6)[9FA)U3];_.UOR8T]&N]OEW/Q,_X*T^
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M]%%% @HHHH **** "HY2ZJS(GF,J,53<5W,,87=G:,^X-244 ?E;^U)\</\
M@J)X)^+=]H7[,/['_P ,OBY\*(](TBYL/&7BCXLV'A75)]6N+0/J]A-I$^)8
MHK&Z/E03*)5G4%\J,!?GC_AI[_@N1_TCR^!W_A_=,_\ B:_=FBG]^]^G=::I
MZ:->CZ]6G;HGZW\O/RZ:;Z:L_";_ (:>_P""Y'_2/+X'?^']TS_XFC_AI[_@
MN1_TCR^!W_A_=,_^)KZI^)?_  5H_8Z^$_Q>N_A#XN\3^,X;C2?$^F>"_$GQ
M$T[X>^*M4^$/A?Q7JICC@T'Q#\2K*PD\-Z9J%O<S16=]%+<LME=R"WN6CD#
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M#$ FBZ[[67V=_=T^'R_'[VK_ ,J^Y^7GZ?TV?.G_  T]_P %R/\ I'E\#O\
MP_NF?_$T?\-/?\%R/^D>7P._\/[IG_Q-?1_Q+_X*]_LH?#3XEZA\(9M,^.GC
M;X@:+X6\)>,O$.@?#7X&?$'QQ<>'=!\<Z=_:OA>XUM]&TF6+3I=4L0TT-O<.
MDPVNK)NC<#[H^#'QK\,_''X:Z3\4_#6D^+_#OA[5[>6YAL_B%X5UCP-XAM8H
M,F=M1T+7K:VO[!(URQDFCV,JLRY"YH37>]O\/2W]WR?W_>KVM[J\M'Y>?I^/
M=GY$?\-/?\%R/^D>7P._\/[IG_Q-'_#3W_!<C_I'E\#O_#^Z9_\ $U]4^&?^
M"M/[&_BCXT:1\$[3Q1XST_5/$OBO4? WA'Q[K?P\\6:/\)/&/BS32R2Z'X6^
M)-[IT?AG5[V:>.2VLTM[PK>W*&&V:1]JMUVF_P#!37]DS5?VC[W]E^U\9:W_
M ,)]8^*;SP#-K\OA'7X?AFWQ$L+=+BX^'T/Q%DM%\,R^,!$Y=-%6\^TL(W0*
M9-JDNN_9?9WTT^'K9_?]YJOLK:^SVT\_+7YWW9\4?\-/?\%R/^D>7P._\/[I
MG_Q-'_#3W_!<C_I'E\#O_#^Z9_\ $U]F6/\ P4]_94O?VAU_9L?7?&6G^,)_
M%=SX$T_Q7JG@#Q3IWPMU?QI:VJ73^%](^(MUIZ>';_6)"S6]O;07)$]TAMXW
M:0J&]Q\9?M@_L_\ @7]H;X9?LK:]X_TY/CO\6]/UW5O!_@"RBNM1U1M*\.V#
MZC?ZEK+64,\6AV;0Q3+92ZFUM]NDC=+59/+<@NN^UE]G?W=/A\OQ^\N_Y5M?
M9[::[_UK?=GYA?\ #3W_  7(_P"D>7P._P##^Z9_\31_PT]_P7(_Z1Y? [_P
M_NF?_$U[WXL_X+'?LH>&_B1\1_A=I?AW]H?XA>(OA/XLO/ _CJZ^&7P ^(WC
M?0-%\4V"1R7>D2ZYHVDS6+7-NLJF0H[1GG#X!(_3#P'XSTWXA>$?#_C/2+36
M+#3?$>EVNJV=EX@TJ\T/6K:"[C$B0ZGI&H1PWNGW: XEMKB-9(V!5@"*$UWO
M;_#TM_=\G]_WEVE?E5O1^7G_ ,/KYGXJ?\-/?\%R/^D>7P._\/[IG_Q-'_#3
MW_!<C_I'E\#O_#^Z9_\ $U^[-%/[^G\OE_=\G]["_P#=C^/^?E^?=GX3?\-/
M?\%R/^D>7P._\/[IG_Q-'_#3W_!<C_I'E\#O_#^Z9_\ $U^[-%'W]/Y?+^[Y
M/[V%_P"['\?\_+\^[/PF_P"&GO\ @N1_TCR^!W_A_=,_^)H_X:>_X+D?](\O
M@=_X?W3/_B:_=FBC[^G\OE_=\G]["_\ =C^/^?E^?=GX3?\ #3W_  7(_P"D
M>7P._P##^Z9_\31_PT]_P7(_Z1Y? [_P_NF?_$U^[->7?&7XS_#3]G[X;>+O
MB[\7_%VD^"/A[X(TBZUKQ#XBUB<16UI96D#S,L:+OGN[RX*>196-K%+=WER\
M5O;12RRHM'W]/Y?+^[Y/[V%_[L?Q_P _+\^[/QW_ .&GO^"Y'_2/+X'?^']T
MS_XFC_AI[_@N1_TCR^!W_A_=,_\ B:_8SX/_ !<\%?'7X6^ _C)\.-0FUCP)
M\2?#&D^+_">I3V=QIT]]H>MVBWVGW$MG>)'<6SS6TB.8ID1T+8<*>!\D>&/^
M"G/[(WB[]HB]_9GT?QUJC^.[7Q+J/@BUURZ\*Z]9?#K6O'FD1B75/ NA^/[F
MS3PYJ?BVP3>UQHUO>-< PS(I=XRI5UIKV_EUV_N];?C]Y=Z^ZM-]'_GY?GYG
MQ5_PT]_P7(_Z1Y? [_P_NF?_ !-'_#3W_!<C_I'E\#O_  _NF?\ Q-?=?PR_
MX*.?LO\ Q9^+GQ'^"_A7Q-X@C\4_#&P\4:GK>IZYX/\ $6A^$-5L?!$\MMXN
MN/"OBO4;"#1O$:^'YH774ET^ZD:%1O42"OI/X)_&SP%^T%\/M%^*7PQU"[UC
MP/XC-S)H.LW6EWVEIJ]G;S-"NHV,&H107$FGW+*6M;EHE2>/YT!4@T_OZ?R^
M7]WR?WL+V^RNG1_+KY?GYGY _P##3W_!<C_I'E\#O_#^Z9_\31_PT]_P7(_Z
M1Y? [_P_NF?_ !-?NS11]_3^7R_N^3^]A?\ NQ_'_/R_/NS\)O\ AI[_ (+D
M?](\O@=_X?W3/_B:/^&GO^"Y'_2/+X'?^']TS_XFOW9HH^_I_+Y?W?)_>PO_
M '8_C_GY?GW9^$W_  T]_P %R/\ I'E\#O\ P_NF?_$T?\-/?\%R/^D>7P._
M\/[IG_Q-?NS11]_3^7R_N^3^]A?^['\?\_+\^[/PF_X:>_X+D?\ 2/+X'?\
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M:>?]:]V?D5_PT]_P7(_Z1Y? [_P_NF?_ !-'_#3W_!<C_I'E\#O_  _NF?\
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M?_$U^[-%'W]/Y?+^[Y/[V%_[L?Q_S\OS[L_";_AI[_@N1_TCR^!W_A_=,_\
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MY?;W5KMH]=O/7I_39^-W_#3W_!<C_I'E\#O_  _NF?\ Q-'_  T]_P %R/\
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M 9AC,%' 4*D<+7G1C4=6HG-1:M*2LE%M/5)R2MOK8_T0S^V'^RH!D_M%?!H
M?]5#\,?_ "QKT7P!\9/A/\5EU-OAG\1O!GCY=&>!-7/A'Q!INOC37N59[9+[
M^S;BX^S/.B%HEFVLZC<H(P:_S=_L%DQ"_8[;YLCF)6QP3T/?BOZ8O^#=FWMX
M+;]J 11)'G5/ 6[8JHIVV&I#.%5220!G<[8QQBN'BSPNR[AW(,=F]#-L;B:V
M$^K\M&KAZ$*<_;8FA0ES2A/F7*JK:LG=I75KG3D7&N(S?-,/E\\#2HQK*HW4
MC4G)QY(2DDD]'=JS\KN^U_Z;]PYYZ'!]C0&4]"/3\2< ?7/;_&OYY/\ @N+^
MT]^UA^SCXK_9*N?V8/'6J>'XSXB\2>*_B%X,TZWT^1/B/X8\*R:*UUX;NY;Z
M"=HH9;6\N3)Y+Q.8S(X<.B,O/_\ !;']OCXT?#+]C[X3ZA^R)\1[GP+\6OBA
MH%M\81XET:"UU.2V^''@^/0KOQC907-Q%>6-L\DVN0VK2,NV=;::&,GYJ_%;
MVOOI^/H?H=MOTU?W']'8(/3T!_ ]./\ /<=0:6OC#X(?M<?#+Q=XATKX&ZKX
MIO9_C;X>^ OP]^,OBZSU'1;VP@O_  UXHT>WGDU[3]3:"+2]1D-R+AK^UT^1
MI+*5P)(DCY'+:O\ \%*_V3]'_9^L?VEW\:ZMJ'PSUSQ1>>#/"#:5X5UV_P#$
MWCKQ+9:K/HTVD^"_"T-HVM>(;@ZA;S0QFQM7C81/*76$;PQ6?;^GM]Y]\45\
M6_!3]O\ _9B^.WPH^(?QB\+>/#H/A;X02:I!\6;#Q]I.H^"?%/PVGT>U-]>1
M>,?#6NPVVJZ.QLE-Q;>= 5ND9!;M([;:X;]G7_@IU^RS^TSXWU'X?^!]6\=>
M'?$-OX=N_%^BQ_$SX=>*_AW9^,_"MA),+S7_  3?>)K"RM_$NFVUM$NH2S6#
M,RZ?/#<[#&Q(/Z_&WYZ>H[/71Z;GZ%T5^8WPU_X*Y?L;_%7XQ^%?@MX9\0?$
M"WUOQ[K6N>'? 'BWQ%\+_&GAWX:^.]9\/&5=1L?"?CW5M+MO#^KR%H)H[4V]
MV5N94*0L[8!] \(?\%)?V9?'W[0_BS]F7P=JOC;Q!\1? /B'6?"WCR\L?A]X
MK?P3X*US0K%]1O;3Q+XV;3AX?TQ3;1OY$\MYY4L@"*Q9E! L^W2_R/OC(_+K
M_A]?;W'J*/E;T./TS_7]:_FI_;Y_X+)^!O$'A?X2>&?V._B+\1-#\6ZW^UO\
M'/AY)X_;X;ZUIWP[\?\ A6X\;C1/'>A>$O&WB'2UT'7XFC$EM>OI$\DZ1Q3/
M$X4%J^U/V?/VQ/!_PSTO]OKXI?'+]K"3XK> O@[^T;>^&FTZ;P#JVAW?P8^T
MZ5I$>E_"#2(8;)I_&^I7&J7T,>G7>EI.E]=7:01-YA<(!RM?/IUZ?YG[!' P
M3V/'U/'ZY_6@,#T_D??VZ\'CK^8K\EKG_@IQ\&OV@_@-^UM#\ M;\?\ @CXU
M_!CX!^./B"OAGXD_#SQ#\//&>BQ)X5U*[\/>*[30O%EA;O?:8FHI;JEU$LT(
MG")( '3/OG_!-+XG^/\ XS_L-?LY_$[XG>(KCQ7X]\7?#G1=5\2>(+N"W@N-
M5U.:U4SW4T5JD4*/*V68(H )..M&ZNM5KKZ67Z]/F%FM]-;>?W?UN?=NX<#/
M7D?I_C_/T-&Y<XR,^F><>N.H'OTK^/?]DGX\2_M'V7Q>U_\ :0_X+0?%7]GG
MXD:=^T3\5O FC_"/1/&GPS\)6VD^&_#_ (NN],\,16>E:UHEY?R+=6QCCBD$
MBF0!%!+Y:OUJ^*WQ/\7?"K]H+X2?#+0?VS=<UN:U_8M^)7B^Q^&6M^$DUC6O
MC%JV@V6HRZ9\8-2\=V5A#HEC>6CVD &GIL6[>-GBA*S$JD[_ #:M\[?Y[;]K
MW0W%K[K[/RZ[==]EU:/V?!S_ )Q^AY_SFBOY[_\ @F;_ ,%B/A)\0_A/\"/A
ME^T)\1_'&J_&_P =:OK/A63XI:_\/-9TOX5^)O%_]I7\^G^&+#XCVFFP^#I-
M;AL1:Z;]B^U13-?J+4J9VVG]%K3_ (*3?LR:I^TGJW[*FB:IXWU_XJ^&=6DT
M7QH=%^'WBK4/"'@6^CLY[_;XR\90Z>?#_A^%[2!YX[F]O4AD7"JVYA3$TUT_
MKN??5%?FSX$_X*P?L;?$+XTV'P/T/QGXFMM<UWQ)JG@[PCXQUSP)XJT3X7^-
MO%>CS>1>^'O!_P 0]0TZ+PWKVI^:#';QV=XR7+C; \A(S%\7?^"L'[(7P5^+
M6M_"'QGKOCR2_P#"FI:)HOC;QMX=^&_BOQ)\-/ FKZ_<QVEAI?B_QSI%C<Z-
MHM\)Y[>.Z@N9E>T>>/S@H)(+KOY?/L%GM9WW/TJW+G&1G&<?Q8YYV]>QQQS2
M]>E?E--^TOX>^'_[;O[0D_CO]K&U'PJ^'7P \+_$+4?@5=^#[^VT[P+87%G;
M7(\<0^-Q&UIK,NOQ,CVNC6CO=//=0P1Q>:Z@^Q?LO?\ !2#]FW]K/QOJ'PU^
M'%S\0- \=67AM/&5EX:^)OPZ\4_#S4O$?A!IDMO^$G\,1^(K&U37-&6:6!7O
M+)W11-&6 W4!9_+OZGWO1110(**** "BBB@ HHHH **** /QZ_X+166IZ?\
ML\?"[XG0Z1J^L>'/@[^T'\,/'_CA=#L;C4;[3?"6GZPD.JZT]O;13,MCI4,Q
MN[^Y=1';6R/-(RQHSK\R?M0_&GX+_MK_ +:O_!+;P]^S+\2O"OQOF^%/QDUK
MXQ?$Z?X:ZW8^*;#P'X%M?!ESIUKJ_BF^TB2Z@T:2YUJ[M;"VM+^2WEDEE\M4
MWE:_H1U/2]-UJPN]*U>PL]4TR_MYK._T[4+:"]L;VTN8VBN+6[M;F.6"XMYX
MF:.6*6-DD1BK @D5YUX!^!?P4^%5W?7_ ,,?A%\,OAU?:G&L6I7O@;P'X6\)
MWFHQ*YD$5]<Z#I5A/=QB1C)LN'D7>2V-QS0]?P_!W*3M;35-M=M;+;Y=S^+R
MW^&'PZLO^":'[9GQJLO!>BP_%G1_^"H>HSZ+\1ET>!O&&B&#XV^'K.-=&U=X
M6O\ 3X9+*>5)XK.2*VF$TIE7>V\^H?M>:+X-N]3_ ."GWB;Q?H7A^]L?#O[2
M_P"QGJVJZ[K^DV5W:Z'82:;:Q7>I7-Y=VY6TM#%))#<W ;9Y<C12OM<AO[#5
M^&'PW71KWPXO@+P:/#^I:L^O:CH8\,:)_9%_KCW2WS:S>Z;]A^QW6J->(MT;
M^:%[HW"K.93*JN$U7X6_#77+/Q%I^M?#_P %:O8>+OLO_"5V.I^%M#O[/Q+]
M@5%L3K]M=V,T.L?8U15MO[02X\@ "/: ,&UEV27W#Y];Z[]^EUIT[?B<+\)/
M$GP+UZ\U1/A1J_PWU/7X- \'7/BE?!$^@S:G%I&HZ0MQX0FUE=*_TE;"XTTM
M)H9N3Y7V/=]DVQ@U_/'_ ,%$_ NM^,?V[OCYXF\&"<?$?X'?LH^%OC1\-[B*
M![G[%XC\&^*8;C4)TA"2>;./"_\ :Z1PQJ9'FEC0KC)'],OA[P'X)\)7-W>>
M%?"7AOPU=W]KIEC?W.@Z)INDSWMEHL+VVD6=W-86T$ES:Z9;2/;V%O,SQ6<)
M,=NL:DBK4OA'PM/JEUKD_AS0YM:OM..D7NKRZ58/J=YI3$E]-NK]K<W5S8.6
M.^TFEDMVR08\&@E.SOOMU[6_X;R/X^?ACXK'[27[0/[(7_!0/4-#NM(U#]JK
M]IS6]&\,Q7D,T>HGX8_"C0-1\-^$9=0211'#-),NIB3R@D;>6N,A U<I\'4M
MX?B7^SC%!#Y:KX\_X*;L52(JBL;%59L*H502[#?@"0ERI;FO['K+X;?#W3;+
MP_ING>!O"%AI_A.1Y?"]C9>&]&M;/PY)()%=]"MH+*.#26=995<V$=N7$C[L
MEB2V'X9_#JVFMKBW\!^#H9[)]4DLIHO#.BQR6DFN?\AE[9TLE:%M6P/[2:,J
M;[ ^U&7 H?KV_2_7O?Y-=G=J5NG]?CMHEV7K<_BL_90T_P >ZI\,O@G;_":*
M\/Q/O/\ @E?\?K;P<;2&X_M%]2;Q;KR3P6(BC^T"\GL%GAMXH=MPTLB^44:5
M7KZ/^!>K_LRZWXV_X)=Z5^Q]I^B#XP>&/@_\1X/VB4\#::;?Q'X;\-'P5+:^
M,-/^.:6[-=VNJ7OB5;N&S'BQ9]3:^#/#+\Z[OZR='^'7@'P]+I\^@>"O">B3
MZ3I\VD:7-I/AW1].ET[2KB1I9]-L)+2SB:SL)I7:26SMC%;R.Q9XV/-9'A?X
M-_"3P1K&O>(?!GPP^'WA+7_%+2OXEUOPSX,\.:%JWB!IY'EG;6M0TO3;6ZU,
MS2N\LIO99C)(S,^XLQ9)626FR6VNC3T[;!S;Z;WTOIKIKMT^=_73^+;X$_"W
MX:>#?^";7_!+GXN>$/!>BZ!\3M2_X*7^%H;OX@6>F0P^+;FQU3XN^.[:]L;C
M6(K=M3.D3VD$$,FG22BR"HH$0&T5^T?_  <5KX5_X8"T=_&UO+<>$+?]HWX'
MR>(X[?[4+C^R$\0SK=&%K-X[D.8G(+PON"EBH^]7[:P?##X;VVC:1X=M_ /@
MR#0/#^J1:WH>B0^%]#BTG1]9AGDNHM5TO3DL%L]/U*.YEDN([VTAAN4G=Y4E
M61F8_/W[9O['OP__ &U_A9I/PD^(^M>(-$\/:5\0/!WQ"6?PZ]HMU=ZAX-OW
MO[/3KM;ZVN;:73KTL\-Y#Y9D>-CY;(^' UI;T\MK=O3;Y707U71*5_1-K3Y6
M/YN?C+;Z!\0/B3^V?JG_  3*M+#4O"K_ /!.RR\/^/=7^"=ON\%:KXW5;@:/
MH6CW7A8/IUU\3+;3C<'4[>W\O74B,BW4AF\P5YO^R/X3\6^,/BO^S?KGP:^/
MG['5C\5?"7[-'Q%TK3_AW^R-\-_%T/C#Q#]L^'MO:G1_VE=<>6YTW0->T3Q*
MT\L<OB%!>77BIKT0*9"GE_V!_#SX2?#/X4:))X=^&_@+P=X$TBX9);_3_!_A
MC0_#5EJ-TL20M>7]KHUC90W=W+&H\ZXGC>23+9;G%1>#?@Q\(?ASJ>L:W\/O
MA=\/? NL^(3NU_5_!_@WP[X:U/6W,SW)?5K[1M.L[G46:XDDG=KN68O*[R/E
MV)HMM\]E;=I]_+^MA\VC5KW[OR2[>5_ZN?R!_!S4O@+<?#+_ ()A^#O@3I^G
MP_MZ>'OVD?$4GQKT_0=+F3XRZ%X=3Q=KY^,-S\75R-=L]#O]'>RFAD\7!K=[
M"6!]/$4!./$? -_^R)??LC_M9>#-%LO#5_\ MHZC_P %$-;;X8Z'IEO%<?&B
M;7+?XAZ/-X>UCP=! 9?$R^ K,M=S7MSI"KHD,0U!9E:09;^V>Q^#'PET7Q1K
M'CO0OAGX T3QWKT$]OK/C?2?!WAW3O%VIQW,20S?;_$5GIL6KWQ=(XE;[5=R
MAEBC5LJB@?+7[*?_  3T_9Y_94'B*^\,^&-)\:>,->^(GBSX@P_$/QOX;\+Z
MKX\T*[\677VJ[T;0_$ZZ0FJV.C6;[UM;6.Z1D$DI9G,AHM\]&NOEYZ[/?R#F
M6NCUMU\[VOT7161_,)^TMIOQ<O=$_P""I_\ PC[Z?(NE_MT?L<ZA\:)M9TW6
M-5\+0Z)8_#WPPVNZIXVLM#$>HS_#_3M0CGN/&*QM':II)G:=BBDU^E__  28
M\-FZ_;3^/GQ"\/\ QW_9?\;:#J7P7\(:7XF^'O[%7@#Q/HGP$MO$JZZTNF>*
M=2\2WKS>&I?B&=%C2PO](TZ<ZBND&QGNHU"N6_H0/P_\#%/%,;>$/#+)XX)/
MC56T+2B/%Y:S73V;Q./LG_$]+6"+9,=4^U;K51"?DXJEX ^%OPU^%6F7.B_#
M+X?^"OAYH]Y=MJ%WI?@CPMH7A33[J^>..%[RYLM L-/MKBZ:.)$-Q+$\Q153
M?M50"VM_7\6_\[?UHG+2WDORC_E_5CO****9(4444 %%%% !1110 4444 ?S
MS?ME_M/_ +*_[3GC_P 2_L#:;\:?V=/A=\([#Q_I$W[6?B#Q=XR\,^%_$&L:
MSI_B/3M>B^''@/1+B>SGO/&FIZ_IMFVN>(96E2S"26KYN[D+7Y[_ +4.N>%_
M"'PQ_P""DO[(][J-M<?M%?&K]HOX12? #X;VT-P/&?C[POJ.O^&[KP9>>#E5
M!?>(=.TO1=(OVENK$S06.QXY)8S,H;^J;5OV5OV8]?URY\3Z[^SO\#]:\2WE
M^=5N_$.J_"GP+?ZY=:FTJSMJ-QJUSH4E_/?-.JS-=RW#SM(JN9,JI';ZE\(?
MA5K'BW1?'VK?#7P%JGCKPW%##X>\9ZAX0\/WGBK0HK99%MX]'\07&G2:MIJ0
M++*L*V=W"(A(X3:&.5]W9WUNNOYNV_\ E2=O/[EU3\^J^ZVQ^"_[8O[3W[.W
MQPU'4?\ @G#I_P 9_P!G_P"#^@RQ>"T_;$\?>-_&?A3P[JNG^6VB7I^'OA#1
M]1FM[CQ%\1?$-QI_D7NL2>?%X>:!X;W_ $J>*OJ[XZZ+:?&/]JS]D#]D'1A;
MZA^S]\/_  0?CKXWM;:=Y;;6IOA\VFZ5\+-!NY8)#;ZCH5Z;N34[BUE4VUV+
M2WD.\(HK]!M>_9;_ &:?%.O7GBGQ/^S[\%/$7B;4+L:A?^(==^%O@?5M;O;]
M7#B^NM5O]#GOKB[#*I6XFG>52JE6!&:]<MO#/AVROXM4L]"TBUU*"PATJ#4+
M?3;*&]@TR#B'3H;J.!9X[&(8$=HCBW0 ;8Q@4Q7V\K_BE^/GY(_E4^(4W@^U
M_P""N_[?\?BG_@HCK_[ $*_#S]F1=-.B>(OASX<@^*")X4UR+S''Q"T^]M;M
M/"\:PP1?V/LD@^WL+LXEC _8WPU^T'\5O"_@[X*Z#\#/">I_M_?"[4]/&E^/
M?VJH/BW\+M+BMUM+F2#5-5UNRM(H[+7+BWMV\VXAT6&&(KB,A7)!^U/&_P"S
ME^S[\2]8_P"$A^(WP.^$/C[7S#';MK?C/X;>#?$VK-!$"L4+:CK.C7MX8HP2
M$C\[RU!P% KN?"G@+P1X#T&'PKX'\(>&?!WABW$H@\.^%M!TK0-"A6<YG6/2
M-*M+33T6;I*%MP'!PV>#1W\]=^M[O?OK]]]QMK33RU\DK:JS^3;/Y^_%7[0O
M[*'_  4$_:!^%'P<T#XS_L[>#_V<OV>OBK9>)?#WA>/QSX5TOXC_ !=^/_AQ
M;L>%]'\#^&(KB*[TGPUX6U^YO?[9G%GO\32W0CL3*(I&7X'OO%&B:UX$^''[
M)%K*=6_:NT/_ (+'>&_B%XD^&MG936_C>T\(>&]8N=5\3_$JYTDQK>R^$!H<
M\2OXC\HV5TORH[^42O\ 5?IG[*W[,>BZY:>)]'_9W^!VE>)+"^74['Q!IOPI
M\"6.MV6I+,9UO[35;708K^WO1,S2?:HKA)R[,Q<DDUW47PG^&$'C>3XF0_#O
MP/%\1IK5K&7Q]'X3T"/QG)9,,&TD\3IIZZU);$!08)+UHB$4%3CD_KY:>FOF
M[^@7MWT2LO/2]_*_Z;=/YSOV\OCI\(/%GQJ_9IU?]GWXNP_$7XE?#']IOP-X
M)F_8%U#2-.M[,>)I=>N4\1_%S5?".GV-OXWL-=\*6$LNL6/B&[E;1%C6.YN%
M(D;?[/\ M(_![X<_#+_@L;_P3F\8>$?"EGHGB_XO7O[1WBWXC:ZK7-YJFN:R
MOP]T^QBBN+Z[DN#:Z59PP"*QTFTFM]/BG>>:.U\Z9G;]OH?@M\'[?QS-\3[?
MX6?#N#XDW&XS_$"'P5X;C\;2^9 EM(9/%2Z8-=8R6Z)#(3?DO$HC8E/EKKK[
MPOX;U/6-)\0ZEH&C:AKV@BZ&AZS>Z98W6JZ.+U%BO/[+U">![O3_ +5&JI<"
MTFA$R@+(&'%)Z_>OPM_D%]DNS3VUNK=%T\[MG\AG[.5YX"M_VC/^"BX\5?\
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M.>'[B57T_1YKV2P,EY)9QYB-R[L[!02S%VV\9_PQG_P6*_Z2:^'/_#/Z'_\
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M (8S_P""Q7_237PY_P"&?T/_ .0*_=&BBWK][_KI^?=A=^7W+_(_"[_AC/\
MX+%?])-?#G_AG]#_ /D"C_AC/_@L5_TDU\.?^&?T/_Y K]T:*+>OWO\ KI^?
M=A=^7W+_ "/PN_X8S_X+%?\ 237PY_X9_0__ ) H_P"&,_\ @L5_TDU\.?\
MAG]#_P#D"OW1HHMZ_>_ZZ?GW87?E]R_R/PN_X8S_ ."Q7_237PY_X9_0_P#Y
M H_X8S_X+%?])-?#G_AG]#_^0*_=&BBWK][_ *Z?GW87?E]R_P C\+O^&,_^
M"Q7_ $DU\.?^&?T/_P"0*/\ AC/_ (+%?])-?#G_ (9_0_\ Y K]T:*+>OWO
M^NGY]V%WY?<O\C\+O^&,_P#@L5_TDU\.?^&?T/\ ^0*/^&,_^"Q7_237PY_X
M9_0__D"OW1HHMZ_>_P"NGY]V%WY?<O\ (_"[_AC/_@L5_P!)-?#G_AG]#_\
MD"C_ (8S_P""Q7_237PY_P"&?T/_ .0*_=&BBWK][_KI^?=A=^7W+_(_"[_A
MC/\ X+%?])-?#G_AG]#_ /D"C_AC/_@L5_TDU\.?^&?T/_Y K]T:*+>OWO\
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M*+>OWO\ KI^?=A=^7W+_ "/PN_X8S_X+%?\ 237PY_X9_0__ ) H_P"&,_\
M@L5_TDU\.?\ AG]#_P#D"OW1HHMZ_>_ZZ?GW87?E]R_R/PN_X8S_ ."Q7_23
M7PY_X9_0_P#Y H_X8S_X+%?])-?#G_AG]#_^0*_=&BBWK][_ *Z?GW87?E]R
M_P C\+O^&,_^"Q7_ $DU\.?^&?T/_P"0*/\ AC/_ (+%?])-?#G_ (9_0_\
MY K]T:*+>OWO^NGY]V%WY?<O\C\+O^&,_P#@L5_TDU\.?^&?T/\ ^0*/^&,_
M^"Q7_237PY_X9_0__D"OW1HHMZ_>_P"NGY]V%WY?<O\ (_"[_AC/_@L5_P!)
M-?#G_AG]#_\ D"C_ (8S_P""Q7_237PY_P"&?T/_ .0*_=&BBWK][_KI^?=A
M=^7W+_(_"[_AC/\ X+%?])-?#G_AG]#_ /D"C_AC/_@L5_TDU\.?^&?T/_Y
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPG4=&A-4Z<ZCC"6M\8OVW?A'\,?$K_#;0AK?Q7^,,T9%I\,/AI82>)->CN)
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M-WWZ=KGJT/H+_2JKV;\(\UH)V][%9SPQADK_ ,WM<[C:W7L]S^GZBOY7[O\
MX.+_ !7<-G0?V4]6GCZ@7.K7TKG 4$9M[3:27#   ^F,YK"?_@X3_:(NR_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !112$@=>/<@@?F>/UH 6BF[U_O _3G^5()$/0]/
M8_X4 /HI@D0]&SCV/^%+O7.,]/8_SQBE==U_7_#K[P'44W<OK^8('X$C!]\=
M.]-:6-<!F STSD9QU[=N_I3"ZWOIW)**8)4()# @'!(!//Y>]127=K"NZ:XB
MA7^],ZQ#OSERHQP>>G!]*!I-M))MO9)7;OM9=;DS$J,@ _4A1^)/0?0$^U>:
M?$GXQ?#;X0Z++XA^)'C#0?".E1K(8IM8U*VM;B]EC3>;73;%W%]J5XX*B*TL
M;>>XD8@)&20#Y+^TY^TCIGP-^'%WKNAVMOXQ\=ZSJ-MX6^'_ (+L;VW^W>)?
M%NJ2-;:;8I'YH8P0R![N^=1F&U@D)(8H#XG\+?V-]%ANW^-O[4VK'XY_%Z6*
M+7;J;Q39IJG@;X=-9Q&]^P_#OP?<)/9Z,=.P(GU."*34[R6!I2ZL^T^1BLPK
MRQ'U#+:5*OBE!5,16K2DL)@:<TU2E6=/WZU:I)-TL+3<'.$)SJ5:,>1S_0\A
MX1RBCDL.+N.<QQV4\/U\7B,#DV697AJ=?B'BC&8)8>6.IY='%2A@\LRW K$T
M*>-SK'^TIPK5HX?+\!F>(I8NGA4D_;IUKXBR)%^SC^SM\5/B[ILI9(?&]]I\
M?@7P;#."5!ED\5-IVL7$!X826FFR!E=2IP21EZCX@_X*%7VG:CK7B.3]FKX)
M>$[6&2]NM7OM=UO7;_1-/B0FXN=6NM3M;'P_:BU1?/:1[DVR#Y)I$526_.CX
MI_\ !PW^S'\.?VS/A%^S[X9AMM4^"/B+0_$4GQ+^)T_@KXE:;KO@GQ%H\UY:
M6.E:1X27PO'=ZY:W$MK$CWUE97-LBS!A.!$V[EO^"[_PZ^-'[4W["/Q"^/7P
MK_:9U?X=_LE^$/@3JOQ4N_ WAC1-5T/Q1\7_ !!"T!T+3/%%S>IINI67@]X)
M9GO='O((WEN%@DN;)I(HGBSCEN,J^]B\YQE62U=/!0H8##WM&Z@H1JXE1OJN
M?%U91O92L=DN.N',NO2X:\-.%L+27NPQO%-7,^+\WJ6=XRQ$L5B<#D#JM?$L
M/P[A*$DE^Y5VW^H6E?!;]LKQKI=IXCTO]O;38-*UFVCO]-O/!7PA^&_B'0[J
MSN '@N-,U.Z6>._M9$PT,Z2NCK@JQX-<!XK\&?'OX:ZG8Z+X]_X*M^'/"VN:
ML(Y-*T+QO\-_@3X8O]01Y!"GV*QO;^POKR-YF6)&MT;>S*H)8@'O?^"/Y+?\
M$Q/V('D)=_\ AGCX>,S,#(Q']D1@Y.&8G@^I[U\#_P#!9;]B+X$0?!/]IS]J
M&P_9W\0?&_\ :$^(_P .%\#0>/-7U>77=+^ VCZ9;(R?$[1M/U&[BE\(Z=X0
MAM4UC4+KPI%)JMPT3*L4D<DZL/(<%+WW6S9R=I-_V]G<4WI]FGCXP6VG+!)=
M%T%'Q:XHBO9T\K\.J--M+DCX2^%U2R5K)5<1PA5Q"M_-*M.3WDVW<^W?%8_;
M ^"EA8:OXE_:\^ 6IZ??SPVFEW7QDTGP_P##;3=8NYE+06EI?6$\$<UQ<*K.
ML5O--)(H5XE(/.O<?M$_MD?"H6$GQ9^ WP]\?P:G(5TF3X+?$*V35-:!0.@T
MG1_&ITF34KIH9%F%I9S3NT9S&1N2OP,_:0_9<^.G[2?[)O\ P3Q\??"^TU'_
M (*'_#/PS^RCXN^%^MR^&-4@O$N_BUXDT6TTSPO\8+BW\8W>E22KX7O(I+>3
M4[J,ZWIW]G'_ $>-Y6->A?!O]I/X5^!_CG\)_$7[</QML[7X<?\ !/#P1I_P
M-\)>*)WU[Q#;_$S]I[7=*MG^)5X^F6-AJ=SKEO\ #+3CI>FV^MI;&'2[M/M'
MVQ$.0_[(E#_=<TS;#-:04\6L;!-V=Y+,:6+<^75*\D[+XEHTO^(C4\9=9YP%
MX>9S&37M94>'9<,8IQ37,J=;@[&</PHR>J?[B<>O*TE$_H*^'/[>/P(\;ZY'
MX+\0:CJWPG^(&P"X\&?%32[SP9>I=EQ%]AL]3U>&WT+5K@RDQQQZ5J5VTA5F
MC5D 8_95O=1W*JT95E90ZLCAU93@J588W @Y!7(]Z\)\4_#?X%_M0_#[1;_Q
M!X:\&?$_P1XCTVR\0>&=8FL+'4TDM=1M5N+#6="U,QF>QNC#+#+!>6SQW%O(
M" RNF1^3G[1OQV^.7_!)71=-O=-T_7_VCOV;O$^IMI/A:+Q;K5Q<>.?A;KLL
MF^'P_=>()#)=>(]#U5IF72FO$>ZM'MUM598A&'Y<9FN+R&A4Q><J&)RRC&]7
M,L%1J0J86+:2EC,"I5I3IWTEB<+-J+:E/#4J?-./T/#O '#_ (N9G@\@\,(X
MW)>.\PJ<F!X'XES7 XC+\]J*,ZE:CPWQ75IY52H8V$(NI1R?/\-2GB*,)TL+
MG6.QZI8;$?O%17\I-U_P<(_'F]>5?#?[&UQ<G@Q_:KWQ;+A<#!>.QTO&6S_"
MW<$$Y&,Z?_@N9^WMX@!B\+_L4V]M*XVQR?\ "/\ Q'U#!8?(3YD%NA/0@EAG
M!'?(^>?BGP?>U/%XZNUH_995F+LVTDO>P\=7K;TL?KU/Z WTD='C>'N%,JA]
MJ>9>(/!E!06C<I*&<U9I*ZO:#?D?UCT5_).?^"H'_!87Q1G_ (1O]EO[#OSM
M*_#OQ"X7=G;L-]J* XSP&)Z<@]IQ^U%_P<"^*/WFB?!2?3(92"FWP!X=A:,,
M?E ?5=<7L,G>A(SSSQ4KQ,RBH_\ 9\FXJQ2[X?(L1)-6NFN><'9ZVNETO:YN
M_H,^(N%2>=>)?@%P]W6<>*V3TG':]UAZ&(U5^E^Q_6@S;5+'H/\ /8&H#/CJ
MHSUP7 X_X$!_D5_)M+XE_P"#BGQ.GE3Z!JNAPW&#YD>F?#K3!&KDN SV][(R
M;1A0#DC(7.:IC]G_ /X+\>*PW]H_$[5M#$F6=G\::;IS(6P2H&G12,,<XV97
M^[\Q)#7B%4J?[MP7QE65])3RGV,7MI>=5VZ^OW!'Z'.!PJ3SKZ3OT:,NZRCA
M?$&>;32TN^7#9=3NT]+)ZZ]M/ZUC.H_A/7'4?YQ[]/>H)=0@@4M,\4*CO+-&
MGKUR>!P>I'OBOY0(O^";?_!:[Q-N;5?VO+S2$E 9U;XR>-K8*3ABJQZ79$ C
M)!VX&>_2I&_X(V_\%2== C\3?MNR-"XRZGXI?%34<9Z@I+]G0GMD#\3P /C3
MB*?\#P^S^5[6=;$83#[V>JFFUIOO;\7*^C'X-8626:?3&\'Z5K<ZRS*.),W:
M2MS<KH0HQF^B2:OO=']4=QXR\+6?-YXBT"U&[;FXUG3X1NP3M)DG7!P"?H">
ME<[=_&'X56&_[=\2? -F$!+_ &GQCX?@**.K.);]-@'<M@8YR17\Q5K_ ,$!
M_P!J35R/^$O_ &Q+N=6&YS!J/B[46\WA0W^G7\8/R-+EB223@J=QKKM/_P"#
M<$WPW^*_VK/%4\K#]X+#P\MSGYN06U#5!N4C!YZ'(P>,RN)N.ZUE0\/IP[RQ
M7$&7TNWV726OES*ZO:SVI^!WT3\ KYI],"EB6K761>$G%.-OM\,I8NS6KLVE
MY]C^AC5/VH/V==%0R:G\<?A/:(-W,GQ \,,?E ) 6+4I&X!] />O+-8_X*#_
M +&.@EAJ?[1GPLB*D B'Q387>,]<_97E)QU^4-D=*_&C3_\ @VQ^#T+1OJG[
M17Q+U#'^L2WT/P]9*PYX#,;EL=OO9'4$G->DZ/\ \&Z7[*-HP.J_$'XKZJ,
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MG3U?W>9Y_P#Q'WZ+]#3"_0SR*HH_"\;XM<:U6[6MSQCAN5[:K5=K+0_D^?\
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M<LRW#Q4*& R^E7JU(8/"4HI*&'P\:=*-M(WU"BBBMSR0HHHH **** "BBB@
MHHHH **** "BDR 0,\GH/7')IN\>A'X?X=,]03P1WZT /HII<#J"."3QP,=<
MGIGM@9.: P/3GC/T^HZ]O2@!U%&>O7C]?I_*B@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !0>AQU[444 ?'7[57AO]L;QO'X0\*_LK?$CP!\%
M[:]OYY_''Q5\4^%K/Q]K>AV%O#));6/AWP/J_E:/JSWTZQ0SW5W=1?9XF=T4
MLM?D59?\%%_VH_A)\"/^"CW@3XN>,/ 7C7X[?L1>*O!/ACPS\?-,\-:5X?\
M"GCO_A:[V/\ PC$^L>!K=VT71=6\/R70@O[".]G2;&PE#$S/]B_\%6/^"C%G
M^Q;X4^'_ ,./"VH:?H'QB^/VI7?AOPCXY\5Z-KU_\//A5HZQB'6?B1XSN="L
M-1N/*T!9UFTS2EMY6U&]C$<T8MPQ;X \/^&?^"7WB#_@G?\ &GP&?&'Q1_;
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MLHVB$KH27SOV0]$^ 'BK_@ICHNO?\$R-)N-(_90MOV??$GA[]J34?".G>(M
M^$FI^/;V[9? ]LMEKL%DUUX\@TP23R:A;P.@MHW_ 'B.TRM\/7421_LA_%3_
M ()'3Z5XELOVL_%__!07Q7K?ACP+-X=UIEN_A=J7Q6L/B5IOQ".O"R;0X_#]
MWX9TRZD%P+UY5E="8-QWTM':U]WU=M.6VOG=W7=?-TDM;^6Z2:5[/3IW\EK<
M_M0M9A<V\-PH^2>-)D/JLBAQQVQG'7GKWJQ6=I%J+'2]/L1N_P!"LK6TRYW.
MPMH(X [$X)+B/=G SG/>M&F9A1110 4444 %%'^?\_3_ /57SW\9/VK_ -G#
M]GJ\L-/^-OQF\ ?#*^U6TDOM-M/%_B"QT>XO;.(D27%O#=2)))&K J2J_>!
M!- 'T)17YBZW_P %G/\ @EUX=4OJ_P"VM\$K8 E<+XBDN26!P0HM;2;)SP,=
M>U>1:W_P<"?\$D]%5V/[7O@?5"C!-ND6>MW98DG)1CIT2,%QRP;'(P3FBZ[K
M[_Z[CL]K>1^R]%?SZ>)_^#FK_@E#X=$GD?%_Q#XB,6[ T+PG=W#2;>NQKN6T
M0@YX!([=*\'UG_@[0_X)@:7))';:9\?=:*!R)--\":/Y,FW&-C3^*H.6SA25
M!R#GT*NNZ^]"ZV_K^M3^H.BOY(];_P"#OO\ 83B+#PQ\&_CYK(!8 WND>'M.
M=\#Y?E37IV!+<,-[8'.#C%>+:[_P>!?#ERR^"/V./B9KQ.X0MJ&IK;*[8)4-
M]F@N>IP&&>,GDT<T>Z^\=MMM=M4?VBT5_#/J7_!WK\6;E1'X7_X)[:S=W,B@
M*;[Q'XEE3))'_'O8Z&9"?^!KZC.?EYZ?_@Z*_P""B/C9_L_PX_X)V)"\J%X/
M^)7\0=7+(7"JYW6]JI!!"YWH,D,H)(!7-'O^#_R"S_+\;=K]U_PY_=S17\'C
M_P#!<W_@O;X[S'\/_P!@?[(UR4:V,?PM\7:@$CC.QP%NM2@W_.K#.\ D<$<B
MJ,W_  46_P"#J3QC(K>&OV0K[0;>?,<;CX".%4-_&)]5ULNA ((;)&1T8T^9
M=F^]D_+T[_UH%O->FM_RM^)_>C17\%DWQ4_X.SO'ZJDG@+5?"JOMB+)X2\-^
M'RI=MX<_\3!V10!@D9(X&.>&+^R[_P '5GQ)V->?&?6/!XDD>3+_ !#M] ,9
MD)#*RV,,Q54#G;M5L 9QD 4N;LI/Y>GGY_Y!;^ON]._6R\S^];IUK.N-5TVU
M/^D:A96^,[OM%U#"!QW:1A]>/Y5_"'%_P24_X.;?%:[M<_;PN]$BE+%X9OVB
MO&T3*"Q5E:'2]#>(*PRVU6&Y2"3N)JS!_P &^_\ P6]\7*Q^(/\ P4-'[]8Q
M=*OQ8^(NK!RJ[3N>73X5E"DMAN.""1SP7?\ *_FTNWK_ ,/^!;^M/+S3Z]M.
MI_<I=?$#P/99^V^,O"=G@X)NO$>C0!>W/FWL9]3\VVN:OOCG\%M,5VU'XO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_"V@V6H^+3J&H7UG#;>./$]Z@N=7CU,EU@T!(?*=&F>]BB6*+?)6_P""E_\
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MU[Y_D^9%&DCJ^K7EKOO[MK/O:[WZOR*TMJK>E[O:^^FU_G;:ZOZS_P $R/\
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M=>*?&/C#3?VE=?TS3M+\37/GMX%T^?3TNI?".F1>7$UEIND7,KVT-DR!8!&
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M^,IY[;PG\-_"&O>-?$D]K;O=7,.B>'M,N=4U"2"VCS)-*MM:R%$0$NV$4%J
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MCJ&I:MYP-_J"KI2JL$#(GTG\7_B#H/[)GQL_X+P_#'XV22^%/%?[5_@(:_\
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M7PD\):7\1?CQ91:=\7O$R:>T]YX]L85*)9Z_'=2SVEU:LIQ+$+:/SR%:7S&
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M^:R-QIFAZH9EE_LNXO+N.&WG>17%FDK/("8R:_(X?M0?MO\ P*^/W[-7A/\
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M3ZWIJ6]S?6O_  D>GW,QN!"#);/N9XH@:3:NK>E]>WYG] M%?DI^Q]^UE^U
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M@JE];>BOIN[V6]];/I^8K75_PZZ6O^9^^M%%%,05')*D:NTC*B*K%GD(6-5
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M7UOZ'QK_ ,$A;'1O!/\ P44_X*5^'O&UO:?!'XW^.-8\%>,G_9'T&UCD\%^
M/ -M;S6'A_Q;H'B/1%MO!>NZGXCMO*NM630K.VDT_P X176Z5V5;O_!;?1M.
MU']JW_@FYJ'AFTB^-WQGT7XJ:M=>#?V,]1MD3P]\:=+:!1J^MZQX@U:*X\(^
M%8O#,:EQ?>*;6[MKE798+<B&X:OHSX&_\$R_VBO"?C+]L#]JOXJ?M >#KO\
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M<_!CX92:Y*GB[5;O3YX;/5GTOPG=Z?XEU+5M+F?=IT%G=QV_R#[1E"V?"?\
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MK7=^;1N.BVM=[M=-'W_,;QM_P4D\7?#/7[+Q/\0/V2/'?@[]EVY^*:?"<_M
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MIWZ>?]6]+Q_:N&TUK>7[F>NUNFO2WR/E;]H[_@DMX7^/'Q1\:_$[P_\ M/\
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MO]7U2_\ @9X"NM0U35;NYOM2U"\DT> W%Y?7EU++<W-U<2>9)-+-*SNSY)&
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MCSQ)XCTS0[S7_'6H06_A#X=:'<><+[QEKVF^=#J&O6VG,D0&E:2YO)S("J.
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MC]@_5?AE\-_VU/VK?"_[,7BJUU3]A;0?!OASQ)XC\>SZU)XB\$:;\7+H2?\
M"1_V9\4-2>[E\0*D[J;B"74;BVTV-T>-&612_M/[='@3]@[XV_&;]E_6_P!J
MCXT:[X5\-:9HGC6Y^'EQ8Z]-X4^#7C"TU,0?VC_;?Q5TVZLUT[4AY+'1+:VU
M"*34#&T<1R,.1K5/J3_>?O(S<.>56,/<551NJSA-/W7:-3D]Y[*-U9\D(XA>
MZVG34^10YVG[/9TU?5R3;2T5[]#]"/@CIG[1^E>%[VW_ &F?$/PF\1^.AJUQ
M_9]]\&]&UK1_"XT8(HMTN;76VEGFU$.KL\D+F(JPPS/PWU?\%?C[:67Q9L_V
M;5\$^+I+[5?#VK>-3X^MK)CX2L8M]O&-+GU$1MMU1S)YBPB1!\@ '0M^%_\
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MX]LM F:WUJ[\+6GAV^?6;;2IEPT=]-9&5+>0_(LKKN^56QS7Q>_8[\"_&/\
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M[1W%IJ*REIR$E9R22?L[]D?P+<_#GX%>#O"%WXP\4>/;C2_[5$WBGQC>M?\
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M _";5O&?[/\ KW_!1?\ 9"^(O[ ?B^W^(7C#XV:OJU_^T[/X<U/4?&>F:?\
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MQO;C7-5O_#FE^(;YR]WK>C>"[V^F\+Z1J<I=]MY9:8DT+'S(F5^1]%?$K/\
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M'YDD7:RGY.1CI^-?H;^P*3_PAWCD'J/%,1)]<V(/3M7Y>U^H7[ O_(G^.O\
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MG9I]K?@K/[_P/P,_X)3>$W\0_M7_ +;?[1WP4^&?B/X)_L6_$Z#X<>'?A1X
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MZE5D5D) #=<-S@C(&.*_43]CY=OP#\&C.>-2/YZC<FOQ<R?4_F:_:3]D @_
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MC7/%%OJ/A_0/#FDZX;E-*O=:UQVMK!;P631W4D9FC(:*$[I%!!X6N4\ >/\
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MV!\1L=/[=T7'_@M_Q_SC%?H97Y7Q7_R4.9_]?:7_ *CT3[3)W?+<*]O=J?\
MIZH@HHHKYX],**** "BBB@ HHHH **** "BBB@ HHHH ***"<?T]3WP/4\4
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M65X?%/PVFB.V2+3=5DC;KM>.[9U;'0\@9S[>E?I\V<''7&!]3P,^V>M?DO\
MMQ^*K'5_B+H?AN"&>*\\*Z-))>R2!3#/%K$A>);<C+*4569R3D8"J02PKZO@
MN$Y9]0E&+<:=#$SJ/I&+I.FFUU3G.,?5H\;/G%9=44I).52DHK^9QG&37E[J
MD[OLSYH_X6CXUPH&JH-HP,VT9XZ=S^M'_"T?&W_05C_\!(O\:X!@1R<'+$9'
M3.>N.P)Z9Q2A6.<*QP<'"D\XSQ@<\'MFOUWZIA?^@>A\Z4'V?\ODCXOVE3^>
M6]]WO=/]$=]_PM'QM_T%8_\ P$B_QH_X6CXV_P"@K'_X"1?XUP!! !/?IZ\>
MHZC\:-K'&%8YS@A6(XZY(! _'%'U3"_] U#_ ,%0\O[OD@]I4_GE][\O\D?0
M7P7\4:WXE^./PJ.L78NC;>(V$)$2Q[!+:3Y "]AM'UZ\5^WBG*J?50?TK\ ?
MA5XCM/!WQ(\&>)M0AN)[32=<M9)HK0I]H87!-HGE[R%^62X1G^925! (R2/W
MYMI!+;P2KD++%'*H/4"10X!Z\@-S@XSTXK\RX]H^SQN7RC!0I/!SA#EBHQYH
MUYRG%))*Z4X-OKS=6F?5<.2O1Q2<FY^WC-WWLZ4(I^C<7VU370FHHHKX0^C"
MOPG_ &C3_P 7U^)8]=<4_E:Q#^M?LM\5M9U3PY\._&.O:-.+74](\/ZA?6,[
M1).L5S! [1NT,C*D@#8RK'!K\'-=\0ZUXTUJ^\1Z[-]OUW6IX[O4+F*".%+B
MX\E8E\J&( 1KL X;JPZDG-?H? 6%J.MCL;S0]DJ<<)RW?M/:.I1Q',UR\O(X
M4Y1YE)M2:32NF_E^)*L.3#4->?G=:]O=Y8IP:;Z/WK^:,2BK$EK/$H:6-HP>
MAD!0$YP -P&22" !G.#BF_9Y_+67RV$;9VN1A3@X'/3YB1M_O9&W.17Z:?+7
M5D[Z.S7FGL_Q(:</NM_P'^="J6("X.<8P>.0&'/3D']&'\)Q,]K<1*KR1F-&
M.T,Y4#<&==IYX.4/![;3W%*Z[K_A@NOZ^7^:/U6_80.?AAK_ /V-]Z/RM;<5
M]Q5^1O[&?CWQ38?$?2OA[;7T<7A754UO5K_3VM(S++?P60>.5+G/F( 0I*X
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MND[.Y_2C\&+FVNOA;X$>UN(;A(_"^CP,\,BR*LD-E$DB,RD@.C JZ$[D8$,
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MRP<$ESJRE.+E:7*FEK]*A<@G:Q _B R!QGG_ #]<4@&3@''7!P3^@YYK\GO
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M^!_Q!O?A9\0?&'B.+Q[IMG9:CJ6@>&_ 7BSQ9+I]EJ2F2QGO9]#TVZA@^U1
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MXI^&?V?_  M\&O&VE7NKK9>&YO%0^(MG:J\PT@21:C(^F@NL9NI@'V"%GD#
MG \RL_VI?VO?B[K_ ,1/%G[+_P &/ 'CGX)_"SQU;^!-0C\1ZE?6?Q%^(4]F
MQ_X2'5?!4D<\.D0P6J*RQB^89E0+ND(*+\A>#O#?PY^ W[0O[(WAO]BGXX>)
MOB[:_$+0=5T;XN^'?^$TG\>:+<^$_P"QDCMO$.MZ:;R\MO EYLE>0Z:?L[6\
MBF"-2R2*WRY9>!?!WPE_9U^,GBJ\^-/C+PU^U[\(/CI=:;\+/ 5IXLN-%O)+
MR7Q&VHZ)HEM\-4D4^,]/U-IVGN-?ELYT8L8)0T9-?2O&8BG1HPG*:=%5?K=6
M.)H352=.C1JJ-&NZ,8SE)3J25&%)7]G*#G'W7+RXX:$JDW:/O\L</!4JMHQE
M4E&4ZE/G<TDJ:_>RDHQA-3:::M_4 ^LVUIH'_"2:[&=!M+70SK>MVUZ\4LFB
M>3:)=W]C=2PN\$LMBS-;2R1.T<DR,5)5@3^<GPT_:=_;0^,<.@_&SX<? /P-
MXC_9A\5^/+WPWH6F'5)[3XTCPEIFK3Z#J/C2Z\Z[@T5+&TO[.YO!&09FL@BQ
MQL,R5]3:MJ&K?$G]GNZ\$ZYJ>DV7QJ\;_ BROM7\')>VMGX@CUO5?#5K+=W*
M:*9?MEK!+JC2\K L,4H,2X*[!^ /@Z'PU\*/V=OV=/B%\)/C-XPN_P!M%/CA
MIW@/4/A)'XFN)I9M"?QKJFF>(M-U?X3;BFF6<>DK%/\ VK-8!9H9C=J S>8/
M0Q^+J4IX6493C0C2E6J.$Z:G4DG24*<5.,Y3G[TKTHQ3D]%.,DHOGPM'VBJ1
M:@ZO/"G!S4Y02?,Y2;C**A'W8WJR;C"+=TU<_LD_9 P?CUX:(S@Z3K)&<YP;
M8D9) R0#@D<,>02""?VDK\5_V.A-_P +R\(M=QB"];0=3-Y;(Q:.WN6L4,\"
M,20R12[XU;NJ@X&<#]J*_/\ CIWS>@^^7X=]MYUNG0^EX<_W*IM_O-3;5?#
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MAH&^/6N@\?\ %.Z$>/I(/?U/XU^SQZ?BO\Q7XP_MBLT7QWUZ98S,8O#FBR)
MH DGDCAN2D$;E@%:;+1@,57+#+"OM.!/^1Q6_P"Q?7?W5\-K\E<\'B+_ '*F
MO^HB'G]BIT_#R/QE_;C_ &YK+]D67X5>&]#\/V'C3QY\4?%^G:1'H5Y+=PVV
MC>&9[N"ROM>O)[8((Y(YYPMO"\@5R0S_ "GF/]H3]J;XS^'/CMX7_9L_9O\
M '@+Q;\3M1^&&J?%SQ!J/Q3O[[2?#%EX9TF+S)['2Y],E2[N=1F)C\D,6ME,
MP1VW"0K^.W[:'B[XS6]AXE\;_&+]EWXM:1XU\9?M#^%!HOC>X323X+B\&^%+
MF.S\+>'/"$K/+=6]_K=J3/J179!<W"0.X+"1E^T/CA?>%OCS^V+X4\!?M-:A
M>?L]_"[3_P!GF'QSX*N]0U/3_ _C&?Q%/I\;ZGH>H_$BW>"4VNE.UR+KP;;Z
MA)9ZI)'N\DS.Q;[2KF->K4QL8UY8>/M<$J2J16'5*FY351.O5C*,)5O9/FG[
M.7+S>S4)-<[\".&A"&'J.$9OEQ+FXS593DO92A:E#X^12:A#F3FDW=)V7Z1?
MLC_M$+^U%\%='^)KZ OAS7HM9UCPAXLT**Y$]C:>*_#5U]CU@:+=-O:\TF60
M?Z%,SNQ8['=]F6^;OB%^UW^T'XB^+GQB^'?[*OPK^''C31/V=="BU;XM>)/B
M1JFHZ=<7]XT%Q?S:+X)BTN1/.U".PL[PQI?D(T\#D,(U7=7_ ."97Q%GN?V=
MM8'BNX\+Z!X-T'XN^+O"/PN\6/9Z7X*LO'GANQU%DTK4X()#9V^IW]^J[8[Z
M)IY]39A(9)6#;?"_VEO#GP7\%?$W]IGXA_#7]L2X_9Y^(%S\-W_X7K\*7T73
M+_\ X6,U[IM[#H;>&SXBN+9[F^U22Y73VF\,P7<]NK^<Q4M(5Z:N+KO+<%75
M:TFHRQ+C*C0K5.6-3^&L1+D495()S7,G.DI.+O)(RA1@L77I2C=)R5'>K"/O
M4XVJ1BFV^63L]%";U4E'7]5_V>?C'X:^/_P]^&WQ<\*Q7%KI?BY]*N)=*O3$
M;W1M1MM5MK34]+O#$2CR6][%/Y3QMAK<PLX5VP?Z?M/&+"R'_3I;=?\ KBE?
MQN?\$J_ OB'X?_L=? S2O%.G7VD:OJE__P )$^FZC&\%[;VVK>(TEM9+F"0*
MZ274"Q78+ 96<8R"#7]DEA_QXV7_ %Z6W_HE*^.XVJ5*V%R"K5CRU*F&Q%2<
M;-6E-8:3T>JW/<R!1A7S"$'>$)PC%]XQ=1)W^;MZENBBBOS\^F/+/C?_ ,DB
M^(O_ &*FK?\ I.U?RA?\%"/B'=?#']BWXWZ_I>M7/AS7+WP:= T'7;.ZELKW
M3-8U*2$PW-I>V[QSVUPD!D\N6)A("<)\Q K^KWXW_P#)(OB+_P!BIJW_ *3M
M7\S7[1=AXEU#X-ZV?"?PI\(_&[5],DL=37X9^-R9-*\26MEYT\]MIT10QR:Z
MK%$TX3F.*9@5=AM"O^E<&1G/*,XA3DX3G-PA-1E-PE+#N,9*$6I2Y6T^5--V
MLFMSY+/I*..PDFE)1A=Q;44TJD6TY2T2:T;>B6K/S]_8,UO]CJRL+OQ'\*_C
M9\8_'OQG\)_!^U\2>/M ^)_C/QS<6LTTV@BXU34-&\+>-;>SM]1MX-3651/I
MJ744<.V590K+*?D7PGXY\?\ AKX<_ 7_ (*&R_$OQW?>/_C#^T^/!'C7PA>^
M*M2N/AN/ /BG7=0\.'3-+\&7$ITRUDTZRTI+FVECC98)9"(41D53]G>%OAS\
M5_VH_P!K?X;?'GQ=\ O$7[,G@;X/?"7Q3X'O-.\;K96WB+Q]=^,/#5SH,6E6
M":44MF\.^')2K6\EPJS"T8)&=_R)\Z^#/V:OVD-5\-_!G]B/Q1\']<T;X=_!
M?]HMOBK??']FMI/A_P")/".@ZQ>>(M+TW3$$8OVOM7EU":QC>5Y6$B*50+'(
MR^O..)E"C"%-J%..)I8>K2IU:<)U_:8&6&JRI2<JE+DA.M2]I.3@_95)R<'-
M0.-2I1J59N45.?LIU*=2K"I*G3DZZJ0C*,5&IHJ32BKVM:UKO]OOB/X<U?QM
MX(\3>&?"OC34?A]JOB'3#9:1XSTNU2_U/0$NO+DCO+*VN)4A6X6%98U1G6:/
MS'E4ME<?DKX@^'3_ +*'[7O[*'@/X&_%;XJ^,?$_Q3BUF#XW>#OB%XTU?QI8
MZIX7MK2"1_&#:;?R21>%X[_4$GF@2+,:A5@C8@$M^C'Q9^+/Q/\ "^A?%NT^
M&7P&\:>+_%/@SPI;7WPZG=K8>'O'>N7\C6EMI>F,KB\B;1D"WM^)%!=(7C0@
MLHK\]_V+;KXK>#_'5UXL^,7[(/[1^J?'KXKZ@H^(GQU\6PZ OAKPQ922+)%H
M6@6UM)_Q)_">G,L>^VLQ ]T%::6,-B,>KCG3J8C#4U3G[;VL:CQ*HUG"C3IU
M:<ITXSIPDG+$?PK6M&G*4Y-16O'AE*,*E2\'2M).ES)3E*4;1;B[RM35Y)I2
M]Y12?5?T6?LAA1^T!X;" A/[,\1;00%(']G9 8#@-_>   ;. !P/V@K\7/V/
MQCX^^&AN# :;XD 88 *BP(7 &!@+@<>G/-?M'7Y[QU_R.*7_ & 8?_TNJ?3\
M.?[A/_L*J[;?!2V"BBBOBSWCX,_;Y)'@#P:<9 \7$GZ"Q)P/=B H)X!89XK^
M67X__#O]LG4_V[/#OQC^ WPC\$>)/#O@7X$7_AC1=<^*6IW5GX0U/Q-<>(7U
M&2QTU=,F6[/B*2UD,-JLT<<!5)':95VX_J9_;U<'P'X+P#N/BUBHSM/-@P(S
MS@XR,8.[.T=21_/M\9?V:?B=XY^($_Q&^#G[4/C;X"ZYK'A.3PCXEL+'0-,\
M:^'M5L7D21+_ $[2-=GCM=!U6)HUC2]LD^U(H)$JEV4_J_#=*=7AG"1A&M.4
M,96JJ%"=&%1^SK-\O-6]QQ;M?WHO325KI_%YG)0S6HVX1<L/2BW4C*4;3IP3
M^%-IN*DN9:):/1HSOV:OC7I/[9OP:;XBZG\,/"D/Q/\ ACXB\5:!/X9\36,6
MHZ%X2^*?AS[1IMS>:7=RQ3RVFD7=XD06^MP]Y%9QL7\R50[?,7[&4GBOPM^W
M'^UCX6^-VG:7I?[0/Q%T/P[\0KNU^'TDC?"@^#]#MK;2XFT'[2T>I7>IB2ZA
MCO7NXQ^]4C<PP&^@%_82T#PI\#/!/PD^$'Q5\;_"7QEX)\6W/Q#@^+>C.-2U
M3Q!X^UIX)O$^N>*/#]U.NEZS9:W(+E8M'NF:STU9(VA5V0[MKX,_L=ZI\+O$
M'Q5^*OB+XSZW\2_VC/BEHDWAZ;XS:KX?TS2E\.::MO'#IMMHG@VUDET>.VL9
M88+F2U9D@NW@6-T5&=F]Z-#%REESK47*MAW[6O64J2I3YJ,X5$H0E!NO&,U"
MFW&%+XTGJD_.YZ$88J,)R]G5]VE&4)^UC:I"2YG[UJ3<6Y1A>3Y8*VKD>5?M
MS_#+]I#XF?%S]DJ^^!'PX\/>,K#X7^.]4\=:GJ_CC4;C3_ &@ZN;"33K)?%3
M64BZC]FEC"RQ)9QS3-,R#:02M>L?LE_M/^,OC?K'QB^&'QA\$Z'X ^./P*\3
M0:'XXTKPK<S7?@_4]-U:)[K0-7\.7%P\EV8YK=2MS#=L"C%'0+N\N/;^*'[.
M?Q2\=Z9\+]7\._M.>,?AS\8_AQ:_9+WXE:7X=TC4='\;K/&1?RZ_\/)Y8O#C
M33SEIXY LDD#%0K,0'&M^S1^R_HW[.]KXXUB\\6ZM\3?BG\4]?\ ^$A^)7Q0
MURUBT^_\57ZNRV$4&CVLDMGI%G91R&**WMI&C96'$:HH%+#XB.83KP56-.LH
MO$^TE0G1E&.'A"$::@_;0K1E&+;<^1OGTG%Q1/M:<L)[.;BY4^94N6,U-3E5
M4G*3DHKDE"^F_P *=FI-_P!&7[&)+? ?02?^@MKO_I::^JZ^5/V,6#_ ?0",
MC.J:[D'&0?MS @X)&01S@D>YKZKK\=SUIYSFC3NGCL0TUU_>2/N\N_W#!Z6_
MV:CIV]Q!37^Z?P_F*=3'.%/!/L,9..>Y Z#UKRMCLZK_ !1?W--GX"?M'+))
M\1?C9#%<VEG-/=^*(;:[OY/*LK2YGTP00W-Y*<B*T@=UEN),$I$LC=J_G+L-
M"_:O_P"">_P/^&7Q6C_:,\$?%#P9XF^,MCIGB3X3^'=)TN\\&^);;QE?SFZU
M+PSXTM@-5U76UBMXH?)C4*9T93DQ5_2-^T#IRS_%GXJ:?JECYEGJ>MZDMQ87
M]O(L%]8W<<4&7210)K6X3?&=@='1B"<$X_,SPE_P3L_9;\%^.=+\=:3X=\7W
MDGA_7Y/$_AKP;KOC76=:^'7AG6VN?MD5]H/@^]D?3[%[2Z+3V:YD%L['9VQ^
MX2PE;$8++JF&;C6IX*E3A6CB9TO8NI2HMS=**Y,1'W5S4Y3BY1O%-*3DOSU5
MH4JV)A57-"5:<I4Y4(55/EG)<O-*TJ;5])1O):MIV*_[;?@_6OCW^S5\1K#P
M)\<+7X?Z+HW@N?6_B=X=L(M$U:+6M/\ LVGZW'X5\5ZD;AK[PI*[VYM1(%\Z
M25G5DW+BN_\ V%_'5I\5/V1?@9XUTSPC#X)L+SP7;V</ANS:YGL-*32+R[TV
M)[2>Y"22VEREC]N2YG"$&?:#(%+'E/BQ_P $_?V:?C/XUUWQYXMT;QCI6J>*
MH+&W\7Z5X,\;:QX7\+>,4T^7SH&\2^'M.=+'4IG=(!<2.%\]8OG&YBY^@I_@
MYX%:\^'UQIEMJWABQ^&.F7VB^%/#OA75[O0_#46F:C;BVN+34M&M6%KJL440
MQ:?:P\D#DRK)O)([H4,0L96Q+ITHQ=!4>15IS=>4:D94Y^_"*H1IP]HG"$9Q
MG*>Z45S8.=+ZO&C&4W:HIMSIPBXKD<7%-6=2[:;DU%I16CO<^$OVJM<\0_MI
M^(]8_8@^!=JUUX7MM0TR3]IGXP&UDF\,^ O#UM>"];P=I=VJK#J7C'49K:.-
M;>%IA;RJT,XCB)=?U[_9XT>S\-_$;X+^&M.1TT[P]JWAK0+)9%"2"TTJWAL(
M6=5^597CLXWE"ED\QGVD@Y'Y6Z?_ ,$M?V6M%O-8N_#NK?'KPQ_;^N7GB76+
M;P_\:?%&G65_KNH3/->:E<6T;%7GF9@A+.P$0\OH2U?JQ^SOHJ:5\2_A-HNE
MIJ5Y9Z-KNE0))<R3ZC>):6S1J+F^NV#SW#E8RUS=3%F,C%G*JPQSNEB51S*O
MBX4XU:N#Q%-2A6YXQI4J%;V-%*5&DU%)RE)MSYJE1NZ2432,J7M<%3I<SA#$
M4IM3A&,I5)RI*<_=E):J/)RVCRPA%N][O]_!R ?4"EHHK\)/T4*^5?VR?^2%
M>*/^OS1/_2Y*^JJ\4^/WP[U;XH?#;6/"&BW5E9W]]<6-Q'/J F>U5+2832+(
MMOAPSJN$;D9QG &:]#*:L*&:9?6JR4*=+%T)U)R=E&,:BDY/R5M?OU.7&PE4
MPF)IP3E.=&I&*6K;<6DEYL_D^_;QL_V?T\-?"WQ+^TG\)_&?Q+^''A7QND]Q
MJ7AB"?4]&\$W]R8;:PU'QIX>LH+O4/$&C:E*L</V"TM90?\ EHOS+O\ A/X'
M_#_QE\2/B7^VOXH_8>TRV^%WP"^)/@#3?"WP_&OZ;J_@/P%J/Q$G^RPZUXB\
M-^%'MK+4/#^S2XKVSAOHK"-TDD:3S%\PQ#]Z]3LYM%U34M(F>*6ZTJ^NM-N6
M ,L3R64\D#2(ERD@,;/&YC5\_+C(4DU2:7?C<%&.<(D<:Y/7"1JB*/154*.P
M%?ME7+X8G$PQ3JQ4&HR7LZ485VO93IV6)C)3=.4:G-R3A+5*S2T/@8UW"C*C
MRMNSA:<N>E'WXS;]BXVYTX)*4912LWR\VI_/U\-_AS^UY\.O^"A'[.'AKQ+\
M//@GIB^$/@:VB/J'@G4/%ESX3F\/"[U :OK.H:W=6V!XZO[C[3=W-K(?)>XD
MC#(N\$_IC^T=^VSX%^#'P9^(_P 1_!^E^(/'GB+P=KZ>"+3PY!X7U^,?\)C>
MQRM;RW@%M%+<:#I68[S5+RR=@T,4D$+M*R@_:GF#:5QPW4\9_#K2)*RG@+@?
MWHH''3'(\I&)QW,F?4MWJA@*F%HXFEA\744J\YU(5:L55E1E.G"%XWE%2<7#
MG5[7>CZME6NJLZ,JE*+C3C",H0O!5(PE>S>KBFFU]II7L]+'Y!_\$_\ X@?L
M_>)/B#K_ (OU/XE:[\4_VO\ XP6TVI^-O$.I_#[QIH&C>'],")<)X)\)7^O:
M-9VVF:)H_P#J \4T#W9ABF:./'S_ -+W[!'_ "43QO\ ['A2P4?1M1E)S[Y'
MM7Q T[,,8BQ_LVMO&V<_\] C2X]M^,Y( ))/Z4?L/_#'7-)BO/B?<7MA)HGB
MS1#I]C8Q^:;^VELM3E+O</Y:0N)0I)*DL" .!D5XN?QA@>',70KUH2G4C&E2
ME&FZ:JU'4A4LTZE1NK-0G.4G-\S3>B22[<NYJ^:8>=.G.T9RJ33DI*E!0E'1
MJ$%&$7.,(I+1-*[U9^B%%%%?C9]V%?F!^WJQ3Q#\-9!_RSTK66Z*>LL*'((.
M1M8\>H!X(!'Z?$9!!Z$$?GQ7P5^W=X9TF;P3H'BF6WW:W8:NNE6EUYC[8K*^
M62:Z1H#^ZE+/&FTR*VT @$!F!^BX3JQHY_@')-^TE5H1MK[]>E*G!OR4FN9]
M%=ZVL_+SJ#GEN)M:\%"I9NR:IU(2:OT=D[:.[LNI_-S\5_V)_'OCW7_B(/"7
M[6GQ2^'WPQ^++VZ>/?A>NFV?B:SO8=Q75;+P]KNI7J7_ (;L]7@:6W:SL(5@
MB64H/,C CKJ/&?['DD6E?"BT_9W^-7CK]FN[^$7AR;P=H!T"$>)M O\ PW*5
M>[BUKPOJ]S;:;>ZJ]TPE_MB027,99E0$*K5]J'DD^OK@'\0H"C\ !Z "BOV'
MZAAG*I-1ES5(J/-[2JI0C=2M2DIJ5%.24FJ/(KJ]N9MOX?VU71<RY8_#'V=.
MR;23;CR<DI65N:47*VE]#X]^%O[(]S\&?AOXU\._#CXN^(M)^+OQ)\3KXP\>
M_'2^T:RUCQ!XA\0/J$=SJ-P-!NI18VME<J)[.VM8))$MEN6=#GJ[XW?LG:E\
M1_'EG\6?A?\ &?Q-\!_BBWA6Z\#>*?%V@:+8:_#XQ\-WMC_9]Q;WVEWDD5K%
MJ,:;S97Q99[*3"P@"&,U]@453P5!TE0Y6J:Y>6,93@X\KO%PG&2J1E>[<E-2
M;>KWN*K44N?G?/:W,[-/;1QDFFM+6]%>RL_"OV=OV?\ P;^S-\)K'X7^"Y[[
M48(KK4=>\2>(=3)_M3Q;XMU=-^L^)M37.U+S4GC0LJ>8JQ1QIYI*9?\ I;^
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M_P#3G<5]6U\I?L8_\D*T+_L)ZY_Z<[BOJVOP?/\ _D=YK_V'XK_T[(_1,O\
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M^ /Q?_X)Z_M:^#M1_9<\,_#SX_:S\3?"?@KXS6_B6;53\,]#M-0^'<UYJ?\
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MUEN?T!DE65?*,MK345*K@Z$Y*-U%.5--I)N32[)M^H4445X1Z@4444 %%%%
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M'_#\E@#_ ,6$MCD@9'BN^)&<\_\ 'B>?;OZBA9/F+_YAO_*M#R_Z>>:^\/\
M63)_^@F3]*-?R_Z=?U=?/^U;]A _\6QU[_L;KP_^2EO7W%7XI_\ !#K]K,_M
M??LV^/O'K>#D\%/HGQ6U3PXVFQZF^IK<"'2-,O%O#+)#"Z,ZW(C:-DX*$AF!
MK]K*_GOBFE.CQ%FU*HN6<,59J\96O2I-:Q;B]&GHS]7R.K3KY3@:M)N5.=&\
M6U*+:YY+5249)W36J04445X!ZI\U_M=#/P \> ?\^MB/SU&V _,G%?BF67@[
M@054@@@@@J"#U[BOT'_X+%?&'QA\!?\ @GE\>_BEX#DLHO%/ANU\(G39-1M(
MKZT5M0\::#ITQEM9@T<H\FZD(4CKCD=:_A.'_!8O]L  ;;[P.HPO \)Z< #@
M X CPH]!S@<9-?M?ASE>*QN2XBI0='ECF.(B_:5)P:_<8![1I3^6O1Z+<_-^
M,<YPF6YA0IXCVRE4PD7%PIQG'E]M.]VZD&GH]U;S9_53D>H_,49'J/S%?RK_
M /#XS]L+_H(>"/\ PE-/_P#C='_#XS]L+_H(>"/_  E-/_\ C=??_P"K^8]\
M)_X/J^7_ %#^;^[S/D?]:LL[XCI_S#Q_N_\ 3_S?W>3/ZJ,CU'YBHIV40R\C
M[C=_:OY7/^'QG[87_00\$?\ A*:?_P#&ZAN/^"QG[87D3?\ $P\$#]T^"/"F
MGY!VG!&$4Y!Y'(Y%#R#,4KMX2R5W:M5;MI>R^KJ[WZJ]M]07%.6S:BOK#E)J
M*7L(J[ERI*[KV6K>^BMKLS_2F^#W_)+O /\ V*6A?^D$->DU\S_L9>,-7^(/
M[)W[.?CK7S =:\7_  :^'OB+5#;1"&W^W:MX9TZ]N?*B!PB>;,^T#  QA1TK
MZ8K^7\=%PQN,A+XH8K$1=M5>-6:>OJC]OPLE/#8><;\LZ%&4;JSM*G%JZUL[
M/57"D/3\1_,4M-8X [\_S!%<IN?CY^VG#*_QQ<I&[@^&=' *JQ&0+KC(&,\B
MODS[)=?\^\W_ '[?_"OQC_X.%OVD_CQ\+?\ @HEJ?AKX??%+Q5X3\.Q_!_X=
M7J:-I%]]GLA=WB:O]IN#'M;,DI96+<'*#VQ^''_#;/[5O_1<_'O_ (-C_P#&
MZ_I3AG(Z^)X?R:M&O2BIY=AG:49-KFCSI73U:C--Z6Z(_%<]XFP^"SC,L//#
M59RIXNI%RC."3<>5-V:]6O+S/[8_LEU_S[S?]^W_ ,*/LEU_S[S?]^W_ ,*_
MB<_X;9_:M_Z+GX]_\&Q_^-T?\-L_M6_]%S\>_P#@V/\ \;KW?]7,3_T$4/\
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M>Q<GU/YFO[B/^#4W_DW?]IS_ ++#H?\ ZC(_S^=?P[5_<3_P:F?\F[_M.?\
M98=#_P#49%?G?BDDN$<99)?O\%M_V&4#[KP[;?$N'NV_]GQ+U?7V4E?[FUZ-
MKJ?U;T445_+A_0H5_-=_P=#_ /)AO@+W^._AG_TRZY7]*-?S7?\ !T/_ ,F&
M^ O^R[^&?_3)KE?4<%?\E5DG_88O_3=0\#BG_DG\U_[!G_Z<@?P(4445_7Z2
MLM.B_3_)?<?R\%%%%.R[+^O^&7W =1X&_P"1Y\$_]CAX8_\ 3W95_KW^!O\
MD2O"'_8L:#_Z:[6O\A#P-_R//@G_ +'#PQ_Z>[*O]>_P-_R)7A#_ +%C0?\
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M#5Z_R-G_ -9+_P!=IO\ T:]?O7@U_NV<_P#81AO_ $U4/QSQ4_BY5_UZQ/\
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MBOY /Z>"OD#]OL;OV)OVKP>0?@'\4,@\@@>$]4ZY]J^OZ^0?V^?^3)_VKO\
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M#/%#_D;X+_L C_Z?KA1117ZT?F05%/\ ZB;_ *Y2?^@&I:BG_P!1-_URD_\
M0&J9_!+_  R_)FE'^+2_Z^0_]*1_K"?\$^O^3'/V2O\ LWSX4_\ J&Z37V#7
MQ]_P3Z_Y,<_9*_[-\^%/_J&Z37V#7\3YI_R,LQ_[#L7_ .I%0_K' ?[C@O\
ML$PW_IF 4Q^@^O\ 0T^F/T'U_H:X3K/\\#_@Y3_Y27:K_P!D7^&'_H.J5^ -
M?O\ ?\'*?_*2[5?^R+_##_T'5*_ &OZ^X*_Y)?)/^Q;@_P#TQ _F/B[_ )*/
M-_\ L.K_ )Q"BBBOJK+LOZ_X9?<?-A7[P?\ !N#_ ,I._"/_ &27XE_^DVFU
M^#]?O!_P;@_\I._"/_9)?B7_ .DVF5\UQBE_JQGFG_,LQO\ ZC5/\D?0<*_\
ME%D__8PPG_J13/\ 1@HHHK^/#^GX[+T7Y!52_P#^/&]_Z]+G_P!$O5NJE_\
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M_,4_CE_BE^;"BBB@DZ#PC_R-_A'_ +&KP[_Z>+.O]?WP?_R*7A?_ +%[1O\
MTW6U?Y 7A'_D;_"/_8U>'?\ T\6=?Z_O@_\ Y%+PO_V+VC?^FZVK\(\9OCR/
MTQO_ +KG['X5?P\X_P >%_\ 2:IT=%%%?AQ^NA7^7U_P68_Y2<_M?_\ 91=-
M_P#41T&O]06O\OK_ (+,?\I.?VO_ /LHNF_^HCH-?K7@_P#\C[,?^Q7_ .[V
M#/S;Q/\ ^1)@_P#L8Q_]1<2?F)1117]''X0%%%% ']6?_!J=_P G#?M/?]DH
M\,?^I/7]QM?PY?\ !J=_R<-^T]_V2CPQ_P"I/7]QM?RMXF_\E?C_ /KQ@O\
MU%IG]'< _P#),8#_ !5__3L@HHHKX ^R/R!_X+N_\HMOVF_^P'X;_P#4KT6O
M\ST?=3_='\S7^F%_P7=_Y1;?M-_]@/PW_P"I7HM?YGH^ZG^Z/YFOZ,\'O^1%
MCO\ L95__4? 'X7XH?\ (YP7_8O?_I\****_7#\S"HI_]3+_ +C?RJ6HI_\
M4R_[C?RJ*G\.I_@E_P"DLTH_Q:7_ %\A_P"E(_U<?^"<?_)AW[)'_9 _AK_Z
MC&GU]J5\5_\ !./_ ),._9(_[('\-?\ U&-/K[4K^*\X_P"1MFG_ &,<;_ZD
MU3^K\M_Y%V _[ L+_P"F*84445YQVG\:W_!V#_Q\?L>?[_Q'_P#<#7\=%?V+
M_P#!V#_Q\?L>?[_Q'_\ <#7\=%?U9X:_\D?E?_<S_P"I=<_G'C[_ )*C,?\
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M>_P-_P B5X0_[%C0?_37:U_D(>!O^1Y\$_\ 8X>&/_3W95_KW^!O^1*\(?\
M8L:#_P"FNUK\)\9_BX?_ .ZG^6 /V3PK_A9Q_BP?_NR=31117X:?K@5_ /\
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MO6,_]1Y'Q_'G_)+YC_W+_P#J12/Y,J***_JT_FZ.R]%^04444#/T6_X)&_\
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MY)QG^]XG_K_5_P#2Y!11176<P5_I+_\ !OK_ ,HL_P!GS_KOX_\ _4[UZO\
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M_P#J35/ZORW_ )%V _[ L+_Z8IA1117G':?QK?\ !V#_ ,?'['G^_P#$?_W
MU_'17]B__!V#_P ?'['G^_\ $?\ ]P-?QT5_5GAK_P D?E?_ ',_^I=<_G'C
M[_DJ,Q_[E?\ U"PP4445]X?&A7VE_P $Y/\ D_7]D3_LNW@C_P!."U\6U]I?
M\$Y/^3]?V1/^R[>"/_3@M>=F_P#R*\P_[!*__IN1ZF2_\C7 _P#813_]*1_J
MVKT'T'\J6D7H/H/Y4M?Q0?U8%077_'M<?]<)O_1;5/4%U_Q[7'_7";_T6U..
MZ]5^8'^1E^TI_P G$?'7_LKWQ&_]2[5J\3KVS]I3_DXCXZ_]E>^(W_J7:M7B
M=?VWE_\ N.#_ .P7#?\ IBF?R3CO]\Q7_816_P#3D@HHHKL.4*_N)_X-3/\
MDW?]IS_LL.A_^HR*_AVK^XG_ (-3/^3=_P!IS_LL.A_^HR*_.O%+_DD<9_U_
MP7_J90/NO#K_ )*6A_V#XG_TTS^K>BBBOY</Z&"OYKO^#H?_ ),-\!?]EW\,
M_P#IDUROZ4:_FN_X.A_^3#? 7_9=_#/_ *9-<KZC@K_DJLD_[#%_Z;J'@<4_
M\D_FO_8,_P#TY _@0HHHK^OX[+T7Y'\O!1113 ZCP-_R//@G_L</#'_I[LJ_
MU[_ W_(E>$/^Q8T'_P!-=K7^0AX&_P"1Y\$_]CAX8_\ 3W95_KW^!O\ D2O"
M'_8L:#_Z:[6OPGQG^+A__NI_E@#]D\*_X6<?XL'_ .[)U-%%%?AI^N!7\ __
M  =!?\GZ?#__ +(+H'_J1Z_7]_%?P#_\'07_ "?I\/\ _L@N@?\ J1Z_7Z3X
M4_\ )6T_^P#&?^XCX;Q$_P"2;K?]A-#\JA_-O1117]/G\\!1110!^TW_  ;[
M?\I2O@;_ -B_\1__ %&)Z_TFJ_S9?^#?;_E*5\#?^Q?^(_\ ZC$]?Z35?S5X
MN?\ )2X?_L64?_4C$G[_ .&O_)/2_P"PVM_Z12"BBBORP_03PK]J'_DVWX^_
M]D<^)/\ ZB&KU_D;/_K)?^NTW_HUZ_UR?VH?^3;?C[_V1SXD_P#J(:O7^1L_
M^LE_Z[3?^C7K]Z\&O]VSG_L(PW_IJH?CGBI_%RK_ *]8G_TY2&T445^W'Y$%
M%%%*6S]'^0I;/T?Y'^B]_P &X/\ RB]^&G_8^?%'_P!3'4:_>*OP=_X-P?\
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M(/[?/_)D_P"U=_V0/XI?^HEJE?7U?(/[?/\ R9/^U=_V0/XI?^HEJE=N6_\
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M<C\V****_HX_"@HHHI/;YQ_- ?WE?\&LG_)E7Q>_[+]K'_J,:#7].U?S$_\
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MU]@U\??\$^O^3'/V2O\ LWSX4_\ J&Z37V#7\3YI_P C+,?^P[%_^I%0_K'
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MX1_Y&_PC_P!C5X=_]/%G7^O[X/\ ^12\+_\ 8O:-_P"FZVK\(\9OCR/TQO\
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MZ'_Y,-\!?]EW\,_^F37*^HX*_P"2JR3_ +#%_P"FZAX'%/\ R3^:_P#8,_\
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M_P"HAJ]?Y&S_ .LE_P"NTW_HUZ_UR?VH?^3;?C[_ -D<^)/_ *B&KU_D;/\
MZR7_ *[3?^C7K]Z\&O\ =LY_[",-_P"FJA^.>*G\7*O^O6)_].4AM%%%?MQ^
M1!1112EL_1_D*6S]'^1_HO?\&X/_ "B]^&G_ &/GQ1_]3'4:_>*OP=_X-P?^
M47OPT_['SXH_^ICJ-?O%7\<<5_\ )2YY_P!C+%?^G9']4<._\B+*?^P##?\
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M'GC[6K+Q'9>'DOT4P7&HV&DB:2^@1O,L+RWD@F"NG'Y07-_HP_8$^+O_  3
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M]6'X8K_--'W4_P!T?S-?T=X0?\D_C/\ L:8C_P!1L$?AGBA_R-\%_P!@$/\
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M>?[_ ,1__<#7\=%?V+_\'8/_ !\?L>?[_P 1_P#W U_'17]6>&O_ "1^5_\
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M\4O^21QG_7_!?^IE ^Z\.O\ DI:'_8/B?_33/ZMZ***_EP_H8*_FN_X.A_\
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M0GC!Z$9\/K^V\!_N>&_Z\4?_ $U _DG&_P"]XG_K_5_]+D%%%%=9S!7^DO\
M\&^O_*+/]GS_ *[^/_\ U.]>K_-HK_23_P"#?J6*'_@EI^SV)9$0M-\0" S+
MR!X\UY3W[$'WQST(-?DOB_\ \D]A?/-,/;S_ '-=Z?)-_)GZ;X7_ /(VQW_8
M$O\ T[$_:VBD5@P#*00>A'0^X]O?O2U_.)^YA7\UO_!T1_R8;X!_[+YX3_\
M3-X@K^BWQ;XR\*> O#^J>*_&OB+1_"GAG18!=:OK_B"_M]*TC3;<NL8GO;^\
MDBMK>(NRH'ED52S!<Y(%?RX_\')'[0OP'^*_[$?@CP]\,_C%\-_'NOV_QP\+
MZE+HWA+QAH>O:E'I\.D:['->/:Z;>W$R6L4DL:23LHC1G0,V2!7UW!%"O+B;
M)ZT:-:5&&,2G5C3G*G!NE4LI347&+=U9-INZMNCYOBVK37#^;4W4@JE3!5.2
MFYQ4YW:2Y(M\TKO163U/X<J*!R ?6BOZZWV/YEG\4O\ $_S84444$G0>$?\
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MI62;;=DC^=7_ (.P?^/C]CS_ '_B/_[@:_CHK]OO^"Q?_!5GX>_\%,3\$O\
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M$)Y36PBP[RK"4Z;;E+VDI4W2IM3A+X9>^G*-HN,DTU<^VZ***_+S] "BBB@
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MG@KPWX&T'PKKGAMV:XAOK*[^'EM!X9UF0R.H:[C,ET5**S8"U_>K_P $*?\
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M/'UQXKC@T70]6;59M'FTN+3F;^V+&\\E+=+F<8@\O<S*7W%5(_J(K^+7_@[
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MPR^MS0M%INI:A;6Y*W_]F7$J7*V-TDEC<2(AN8VC5J_;+]NKP]KGB'_@F?\
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MXK_,5_F*?\%M"I_X*E?M9;BVU?%_A0R #DI_PA'ATN@.5.&"D'!')ZCJ/?\
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M:_S%?^"W!S_P5'_:Q7!PWBCPNN>1]_P?H"ELCD*H.21R,'%?Z=3]!]?Z&O\
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M:P_L+Q]I*ZK>-JL$LFGRZ;:F"6;^T8YFM7@7SXY&C()^E/\ @KMXB\/>+?\
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M,,Z$(X&HZM.-&,5*O!5JJB\/2G>Z:<4Y19]7? JS\/?LX:-_P2=_9NT#P#X
M\1>#/VUM)\1:_P#'RX\6>#M#U[Q'XE'C'9I]K:66NZA:37^E0:&EXRV4=C-
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M$LGA7PY'X%M/B;)\3E\7QM>#Q1+J;6DEB+'&_P"PM8!2LA?899&4J7"[0O\
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M\=O$WQF'A;QE\=/&TD&C_!I/#5MXC'CVXUS^SI?%&J2>(R;.32?#-M.;.**
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MU^6K"DH3?LU-N\FFH\K_ ,%)_P!G3Q3^RQ^U/\0/A'XJ^)>L?%MK/1_#VO\
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MO#U_-X9L_#VN:+'\+/AS;?:K_4[;7+W4(8H=0\33W=])9E;!YK/"J^5V_/\
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M:6COIQ\79)BL]R^CA<).C3J4L7#$2E7E.,>6-.4&ER4ZC;NXZ-)6NW)62?\
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MP3X>\0ZI%I\3R216,=]JNG75REK&\LCI )/+5I'(&6)/^:-_P5S\+^&O!?\
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M[&9E7ISEB\'A''#U(S<53_>)_#;76<KZIM6LTTFOX$F)R<D$],A57Y2@4K@
M9! R=P+;N<@T!L8P ,$D<9QD8/4GC'&.F.U-HK^HELM]E?5W>BW=[OIOV1_.
MW-+;F>UOZ[;O;N*&(&!@#/&%4 <8Q@+@CZ@^O6C<>/0$';_#P=V-O0 G[P
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MH?\ X);?LZ;\MMC\:8RQX_XK#5C@#/W022%^Z#R *_S8&Z'Z'^5?Z4/_  0
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M7K_4I7H/H/Y5_.7B_P#\CK+?^Q<__4BI_FS]X\,_^1+B/^PR?_IND+2$ C!
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M (-]?^46?[/G_7?Q_P#^IWKU?DOB_P#\D]AO^QIA_P#TS6/TWPO_ .1OCO\
ML"7_ *=1^U-%%%?SB?N85_-;_P '1'_)AO@'_LOGA/\ ],WB"OZ4J_FM_P"#
MHC_DPWP#_P!E\\)_^F;Q!7U/!/\ R562?]A?_N&J?/<6?\DWG'_8%4_.)_ C
M1117]?G\Q3^.7^*7YL****"3H/"/_(W^$?\ L:O#O_IXLZ_U_?!__(I>%_\
ML7M&_P#3=;5_D!>$?^1O\(_]C5X=_P#3Q9U_K^^#_P#D4O"__8O:-_Z;K:OP
MCQF^/(_3&_\ NN?L?A5_#SC_ !X7_P!)JG1T445^''ZZ%?Y?7_!9C_E)S^U_
M_P!E%TW_ -1'0:_U!:_R^O\ @LQ_RDY_:_\ ^RBZ;_ZB.@U^M>#_ /R/LQ_[
M%?\ [O8,_-O$_P#Y$F#_ .QC'_U%Q)^8E%%%?T<?A 4444 ?U9_\&IW_ "<-
M^T]_V2CPQ_ZD]?W&U_#E_P &IW_)PW[3W_9*/#'_ *D]?W&U_*WB;_R5^/\
M^O&"_P#46F?T=P#_ ,DQ@/\ %7_].R"BBBO@#[(_('_@N[_RBV_:;_[ ?AO_
M -2O1:_S/1]U/]T?S-?Z87_!=W_E%M^TW_V _#?_ *E>BU_F>C[J?[H_F:_H
MSP>_Y$6._P"QE7_]1\ ?A?BA_P CG!?]B]_^GPHHHK]</S,*BG_U,O\ N-_*
MI:BG_P!3+_N-_*HJ?PZG^"7_ *2S2C_%I?\ 7R'_ *4C_5Q_X)Q_\F'?LD?]
MD#^&O_J,:?7VI7Q7_P $X_\ DP[]DC_L@?PU_P#48T^OM2OXKSC_ )&V:?\
M8QQO_J35/ZORW_D78#_L"PO_ *8IA1117G':?QK?\'8/_'Q^QY_O_$?_ -P-
M?QT5_8O_ ,'8/_'Q^QY_O_$?_P!P-?QT5_5GAK_R1^5_]S/_ *EUS^<>/O\
MDJ,Q_P"Y7_U"PP4445]X?&A7VE_P3D_Y/U_9$_[+MX(_]."U\6U]I?\ !.3_
M )/U_9$_[+MX(_\ 3@M>=F__ "*\P_[!*_\ Z;D>IDO_ "-<#_V$4_\ TI'^
MK:O0?0?RI:1>@^@_E2U_%!_5@5!=?\>UQ_UPF_\ 1;5/4%U_Q[7'_7";_P!%
MM3CNO5?F!_D9?M*?\G$?'7_LKWQ&_P#4NU:O$Z]L_:4_Y.(^.O\ V5[XC?\
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M\U>+G_)2X?\ [%E'_P!2,2?O_AK_ ,D]+_L-K?\ I%(****_+#]!/"OVH?\
MDVWX^_\ 9'/B3_ZB&KU_D;/_ *R7_KM-_P"C7K_7)_:A_P"3;?C[_P!D<^)/
M_J(:O7^1L_\ K)?^NTW_ *->OWKP:_W;.?\ L(PW_IJH?CGBI_%RK_KUB?\
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MZ'^5?Z4/_! #_E%M^SK_ -<_&G_J8:K7Y-XP?\D]@?\ L:TO_4;$GZ7X8?\
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M^O%'_P!-0/Y)QG^]XG_K_5_]+D%%%%=9S!7^DO\ \&^O_*+/]GS_ *[^/_\
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M?K7@_P#\C[,?^Q7_ .[V#/S;Q/\ ^1)@_P#L8Q_]1<2?F)1117]''X0%%%%
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MORP_03PK]J'_ )-M^/O_ &1SXD_^HAJ]?Y&S_P"LE_Z[3?\ HUZ_UR?VH?\
MDVWX^_\ 9'/B3_ZB&KU_D;/_ *R7_KM-_P"C7K]Z\&O]VSG_ +",-_Z:J'XY
MXJ?Q<J_Z]8G_ -.4AM%%%?MQ^1!1112EL_1_D*6S]'^1_HO?\&X/_*+WX:?]
MCY\4?_4QU&OWBK\'?^#<'_E%[\-/^Q\^*/\ ZF.HU^\5?QQQ7_R4N>?]C+%?
M^G9']4<._P#(BRG_ + ,-_Z;B%%%%?/GLA1110 4444 %%%% !1110 4444
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MX<?KH5_E]?\ !9C_ )2<_M?_ /91=-_]1'0:_P!06O\ +Z_X+,?\I.?VO_\
MLHNF_P#J(Z#7ZUX/_P#(^S'_ +%?_N]@S\V\3_\ D28/_L8Q_P#47$GYB444
M5_1Q^$!1110!_5G_ ,&IW_)PW[3W_9*/#'_J3U_<;7\.7_!J=_R<-^T]_P!D
MH\,?^I/7]QM?RMXF_P#)7X__ *\8+_U%IG]'< _\DQ@/\5?_ -.R"BBBO@#[
M(_('_@N[_P HMOVF_P#L!^&__4KT6O\ ,]'W4_W1_,U_IA?\%W?^46W[3?\
MV _#?_J5Z+7^9Z/NI_NC^9K^C/![_D18[_L95_\ U'P!^%^*'_(YP7_8O?\
MZ?"BBBOUP_,PJ*?_ %,O^XW\JEJ*?_4R_P"XW\JBI_#J?X)?^DLTH_Q:7_7R
M'_I2/]7'_@G'_P F'?LD?]D#^&O_ *C&GU]J5\5_\$X_^3#OV2/^R!_#7_U&
M-/K[4K^*\X_Y&V:?]C'&_P#J35/ZORW_ )%V _[ L+_Z8IA1117G':?QK?\
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MF>,O^27SS_L6XS_TQ4/H>%/^2ARG_L-P_P#Z=@?Z*E%%%?QZ?T^%?(/[?/\
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MJQ_]-&KU_J4KT'T'\J_G+Q?_ .1UEO\ V+G_ .I%0_>/#/\ Y$N(_P"PR?\
MZ:I"T445^2'Z0%?Y<W_!83_E)M^V5_V5F]_]-VFU_J,U_ES?\%A/^4FW[97_
M &5F]_\ 3=IM?K7A!_R/<?\ ]B__ -V*9^:>)_\ R)L'_P!AJ_\ 3<C\V***
M*_HX_"@HHHI/;YQ_- ?WE?\ !K)_R95\7O\ LOVL?^HQH-?T[5_,3_P:R?\
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M1'_)AO@'_LOGA/\ ],WB"OZ4J_FM_P"#HC_DPWP#_P!E\\)_^F;Q!7U/!/\
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M7^0AX&_Y'GP3_P!CAX8_]/=E7^O?X&_Y$KPA_P!BQH/_ *:[6OPGQG^+A_\
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MV_,?XU_5I_-Z3LM'LNGI_FOO$HI<'V_,?XT8/M^8_P : L^S_K_AU]Y^BO\
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M_P"Q>T;_ --UM7^0%X2X\7^$.G/BOPX!R#R=9L@.GJ37^OYX/(_X1+POR/\
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MB_X-,OCE&BQK^W3\/]B !<? S4BV,8^=CXW^9L #. ,#@"I/^(33XY_]'T^
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M\-]'U31/#D?@[]G/4=(@-IK-XEY?O> ^-@\TK/'$D1+,L85F !8@_P!2U(2
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M .."< ^M'^N'%'_0^S3_ ,*ZG^?DON#_ %7X<_Z$65?^$5#R_N>7XON?QO\
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M6/P>&Q=*,N>-/$4858*2LN91DFD[:-]FULS^(C_B$T^.?_1]/@'_ ,,9J/\
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MSUQ@_A2_+Z#TZ#KW'X=_3O5?ZX<4?]#[-/\ PKJ?Y^2^X7^J_#G_ $(LJ_\
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M )MZ/^(33XY_]'T^ ?\ PQFH_P#S;U_;OE/;@XZ=_3IU]1U'<4!HR< KGGC
MR,8SD=1U!Y'0@].:/]<.*/\ H?9I_P"%=3_/R7W!_JOPY_T(LJ_\(J'E_<\O
MQ?<_D-_97_X-U?VQ/V-_C;X;^/\ \'?VZ?A&WCWPM::O8Z9'XD_9]O\ 4=(>
MVUNQ;3[X7-J_C9][>0Y\ID"2(XW*XSBOU_\ ^%*?\%E_^CW/V4?_ !%G5O\
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M/ZNJ_DF^#?A[Q9\9M;_X)R?"7X#?LL_'#]G;XY?LT>)-,O?VJOBYXQ\!:SX
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MXTE19ZI=QRV)\3^(M/6"X\7^,I?W,-N\%O D<4+N?+_B5\-_C-X"\'?MG_\
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MWH$5]#H/AOQ#JR2V&AVT%[=LE_)+IEY(_DJJ *I5_P BOCSI7Q/_ &<?B?\
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M-/TC0]2C\=WVA+JOB76_'7B;7[>]AU;PJ5-O-I6C6]G8BTMY)R]PY^:O:_\
M@DS^T1\5_P!IG]C7P5\1?C)J&G>(?%MOKGBKPI_PF^EVRV=AX]TOPMKUYHNG
M>+HK:.*"*&35;>T5[D11)$]TDTD8*.I/YE?\% _VQ?$?Q>\7?#C]E[3_ (._
MMC?"[]C;Q)X$T?Q9\9?B!\,?V=?&^K>+_'GAZ[A/]G?!'PY#I:*?!EM,+=;3
MQN][;+>_89X[&P*M'(DW[<?L7^,/A!XM^ /@Z+X%?#/QK\(_ACX8MW\+>&?
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M  O\<_#=!'HB+?Z!IEL(O#7BA&-U<Z3<0":2*!I+?>ZEY/)OAC^TY\?/@?\
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MR/$4/C7P.VDZ?;7&AZ/<ZD]U9RVM]))&MC&L:RW+PY3]@/VL/C9K'[.W[/\
M\2_C!X<^&OC'XO\ B;P9X:O]1\-_#CP%I5QK/B?Q9KPA9-,TFQLK4&=HY[DI
M]KD0@QVJRL S;5/X6_\ !/'XL^!?B#\8M8^*_P"T-\,?VI_$O[;/[0>CZEX>
MO_%7CG]F[QYX5^%/P/\ "5Y;W<EM\)_ FM:M%-;^'O#>DQW+1:CK-S,;C5[G
MS2[F)HU<TND^Z>[6S5[VZ6T^=^A23LWTL^B;;_.RT9XYX6_:W_:BT[P)\&?^
M"H^I?M$>.-9^%_QQ_;%T?X&77[+M\NC0_"KPQ\+?&'C#4_AOI>HZ88].;57\
M1Z->:'+J_P!L,I6ZDN\2@;6\S]5/^"B/A#Q]<6%Y\8?%O[??B#]C/]G/P+X,
MCDL#\/K32]'\0Z[\2M5DFBLIO%?B;64O5U30[B/[%:Z/X;T^PAN9;V29GG=W
M0+^+O@OX-_&77?@7\ ?^"2E]\"OBWHWCKX+?ML:!\4?&'Q3U3P7K"?!.]^$'
M@KQOJOQ%;6M(^),<8TV\O]5LM92PL]-2*.:6ZMGB9ED(6OW/_:\_:V\._ CQ
M7#\+/C1^Q]\8/C+\&==\(6NI^&/&7P[^&(^-6@ZOXPT^243>%-?\(6=M=7.A
M7%A$EI<66MZHBV=S)*1;,CP,P6O6W2V^^G1VZ].O4;6J]=+6^'2UK[]=?+7;
M3\S]-_;+_:U_: _9<_X)F_!;7_'FO? [XZ_MO>*_&.E^+_B_X1M=-L?%]A\/
M_A;J%W,OB+1]+O;2:QTW6O'WAT:9<ME ;>>626.-8YMB^V?!C]J#XYZ#^R[_
M ,%0_@QXE^*>O>-OB_\ L)WGQ)\)>"/C5KD6G3>,?$FCCP-)XF\)>)M<BM[1
M-,DUO3I)GAF;R&28VZ--&P+$_!OPZ_9D_:*_9F^&7[%'[87COX-_$C5='^"7
M[3OQ=^(=]\"_"MKJOCSXG_#7X*_&Z)+#2+"Q\/PJ=0O9O#\D;:Q=:';RQ_V6
MEXEI(J+$VWZ[^#'P7^)OC?\ 9B_X*Z?M*M\,_'GA_4_VV+[XE^(_A%\-O$OA
MJ^T?XFS>$M+\!2>'/#T.K^$;E7N[+6M;N8I)+;3G\R9XS'M)W<BOU_K3R\_7
M\AV2UT:3_'FVWN_=Z;==3Y<_9"\>?"+XS_!?X+>,/B9_P79^.>B_&+QYH6BW
MWB?P%:_%/X<Z1]A\4ZC<[6T&#1KOPQ)>0[I-EM%;%P\N]6B(61*_J_\ #%J+
M/P]H=JNK76O+;:-IELNMWTD<U[K*PV4,8U6ZGB5(I9]1"_:YGBC2)I9G9$52
M%'\RG[#W[5/[''P9_9D^ O@#XH?\$_\ ]HB'XM>!O!NBZ7XIU(_L):CJ-[%X
MFL)&,ET->BT1Y[F:.78Z7OF++P"2K#(_ID\'Z[8^)O"_A[Q%IECJ.F:=KNB:
M9J]AIVKZ;+H^IV%GJ%I'<VUGJ.E3A9M-O;>&1([FQF1);616A<;DPJC_ )>N
MRW_X'YW%.^ETUVO;:RVM_P '\SI****H@^%_VK/V</CY^T-XE\(:=X*_:N\;
M_LV_"G0+2]U+Q-#\(M+T^T^)'BCQ(8Y(+"&;Q;K*WUC:>%[>TE>:?3X=-6:6
M^BBE>YV@*GX@Z1^W7^U5H_[)WQ@^#5C\:(/&'Q-TK]M6#]C[X-_M/3PZ9-K?
MB#PP^JP-K_B'4X8K1=*OO&7AS15O]):YMH75]2$4JO*\8D;[=_X*U?M:_&+X
M>:W\//V9?AKX!_:'TCPE\7+"XO?C!^T7\&?A)XD^)EUX \"?:9K#4?#GA)=
M(%GX[UV%98+>[O(W@TZVG6YVDL&7Y1^*?@7X=?$;]A+X7W7[$7[.'QOL=/\
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MUOKFH:G,+MU: ,P$@;Z0_8AM_&?QP_;&_:]_;QMO@[\0_A_X)\1>!?!GPO\
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M'BCXB^"?%.CV-E-/!&/$$]CX>T'3KZ*6TE"Q13F<Q@S,KHV1C]E <@'U /\
MG-?E?^R=^UG^R5\1?B>G@SX)_LG_ !E^"_BC5M,N&F\3^)OV3=3^#FARV5L5
M=[*\\4MI=E#\S,&CM9I&61AE5R,G]4%X51Z =\]O4DD_4DY]3UH6R_X/:_77
MK]UA2O?7R[=O+<6BBBF2%%%% !1110 4444 (Q(&0,G('/ &>Y/H*Y.Y\<^$
M;.XEMKKQ+HMO/ YCF@FU"VCDC=>"KJSAE;O@CN.HKK#D@@8R0<9Y&>V1W'KS
M6'+X:T">1YIM#T>:61B\DLMA;/([G[S,[1EB2>Y).,"C3K_7]*X&1_PL3P/_
M -#5H/\ X,[;_P"+H_X6)X'_ .AJT'_P9VW_ ,76G_PBOAO_ *%_1/\ P6VO
M_P :H_X17PW_ -"_HG_@MM?_ (U3T\_N_P"#Z_T] S/^%B>!_P#H:M!_\&=M
M_P#%T?\ "Q/ _P#T-6@_^#.V_P#BZT_^$5\-_P#0OZ)_X+;7_P"-4?\ "*^&
M_P#H7]$_\%MK_P#&J-//[O\ @^O]/0,S_A8G@?\ Z&K0?_!G;?\ Q='_  L3
MP/\ ]#5H/_@SMO\ XNM/_A%?#?\ T+^B?^"VU_\ C5'_  BOAO\ Z%_1/_!;
M:_\ QJC3S^[_ (/K_3T#);X@^!FQGQ5H7'IJ=KW_ .!]/;IR>](/B!X%'3Q5
MH0.,9_M.UZ>XW8/KR.M:_P#PBOAO_H7]$_\ !;:__&J/^$5\-_\ 0OZ)_P""
MVU_^-4:>?W?\'U_IZ!DCX@^!5Z>*M"'.?^0K;^_'^LZ<]._?-*?B%X&8@_\
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MU_\ C5&GG]W_  ?7^GH&9_PL3P/_ -#5H/\ X,[;_P"+H/Q$\#G_ )FK0?\
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MO_BZT_\ A%?#?_0OZ)_X+;7_ .-4?\(KX;_Z%_1/_!;:_P#QJC3S^[_@^O\
M3T#+/Q$\#G_F:M!_\&=K_5S3/^$_\"8Q_P )5H77.?[4MB3QCDER??ZUK_\
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M? HZ>*M!&?34[8=,'^_ZC.>H/0BM;_A%?#?_ $+^B?\ @MM?_C5'_"*^&_\
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MHG_@MM?_ (U1IY_=_P 'U_IZ!ECXA^!P /\ A*]"./75+8G\27R?J<GWI?\
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M_P"$5\-_]"_HG_@MM?\ XU1IY_=_P?7^GH&2OQ \"J<CQ5H.0,?\A.U_#@,
M,#@8P/;/-+_PL+P-N+?\)5H.3U_XF=KC([_?R#VR#^O-:O\ PBOAO_H7]$_\
M%MK_ /&J/^$5\-_]"_HG_@MM?_C5&GG]W_!]?Z>@9!^('@;)/_"5Z$"0 2-3
MM><9QGYL9YZ]>/KE1\0O Z]/%FA]<G_B:6N#QCIN_P#KUK?\(KX;_P"A?T3_
M ,%MK_\ &J/^$5\-_P#0OZ)_X+;7_P"-4:>?W?\ !]?Z>@9G_"Q/ _\ T-6@
M_P#@SMO_ (NC_A8G@?\ Z&K0?_!G;?\ Q=:?_"*^&_\ H7]$_P#!;:__ !JC
M_A%?#?\ T+^B?^"VU_\ C5&GG]W_  ?7^GH&4WQ"\#,,'Q7H0^FIVO\ 5CC(
MR"1@X[TU?B!X%7 'BK0<#I_Q,[3UXY# \=AG'MFM?_A%?#?_ $+^B?\ @MM?
M_C5'_"*^&_\ H7]$_P#!;:__ !JC3S^[_@^O]/0,@?$#P*.?^$KT+/<_VI:Y
M/_CWH,8& >X))-'_  L#P+P!XJT$ = -3M<=QC&_I@XQT QCH*U_^$5\-_\
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ML,YQG.UQG.!^5+_PL#P*"3_PE.@Y.<_\3*UZG'. V,@  'V]<FM;_A%?#?\
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M /%>A8 QSJEL?_9_Y<>U._X6)X'_ .AJT'_P9VW_ ,76G_PBOAO_ *%_1/\
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M_H7]$_\ !;:__&J/^$5\-_\ 0OZ)_P""VU_^-4:>?W?\'U_IZ!F?\+$\#_\
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-;I %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ny20006478x8_graphic07.jpg
<TEXT>
begin 644 ny20006478x8_graphic07.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOK4:N(II3A2A2K<M:HH<S_JO,T(SF6,;?O9=1M^O/'XUXGH_Q]\%:U\:M?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /Y_OA'_P %!?\ @JO^TU%\3/%W[-W[%?[,
M7BCX7^!_C1\3O@_I^N>,_P!H#7/">OZA?_#;Q#+HMY<WFC2Z/*(?/C-M.)(7
M:!VE=8\!"!ZY_P +W_X+H_\ 1A?[''_B4NK_ /RCJQ_P0W_Y-C^/W_9^/[6W
M_J=V]?L[4I-I.[U2?3R\OZ^;-YRC"3BJ=-I6U:DWLGK[R_KU=_Q:_P"%[_\
M!='_ *,+_8X_\2EU?_Y1T?\ "]_^"Z/_ $87^QQ_XE+J_P#\HZ_:6BBW]Z7X
M?Y>7Y]V3[1?\^J7W2_\ DO+\^[/Q:_X7O_P71_Z,+_8X_P#$I=7_ /E'1_PO
M?_@NC_T87^QQ_P")2ZO_ /*.OVEHHM_>E^'^7E^?=A[1?\^J7W2_^2\OS[L_
M%K_A>_\ P71_Z,+_ &./_$I=7_\ E'1_PO?_ (+H_P#1A?[''_B4NK__ "CK
M]I:*+?WI?A_EY?GW8>T7_/JE]TO_ )+R_/NS\6O^%[_\%T?^C"_V./\ Q*75
M_P#Y1T?\+W_X+H_]&%_L<?\ B4NK_P#RCK]I:*+?WI?A_EY?GW8>T7_/JE]T
MO_DO+\^[/Q:_X7O_ ,%T?^C"_P!CC_Q*75__ )1T?\+W_P""Z/\ T87^QQ_X
ME+J__P HZ_:6BBW]Z7X?Y>7Y]V'M%_SZI?=+_P"2\OS[L_%K_A>__!='_HPO
M]CC_ ,2EU?\ ^4='_"]_^"Z/_1A?[''_ (E+J_\ \HZ_:6BBW]Z7X?Y>7Y]V
M'M%_SZI?=+_Y+R_/NS\6O^%[_P#!='_HPO\ 8X_\2EU?_P"4='_"]_\ @NC_
M -&%_L<?^)2ZO_\ *.OVEHHM_>E^'^7E^?=A[1?\^J7W2_\ DO+\^[/Q:_X7
MO_P71_Z,+_8X_P#$I=7_ /E'1_PO?_@NC_T87^QQ_P")2ZO_ /*.OVEHHM_>
ME^'^7E^?=A[1?\^J7W2_^2\OS[L_%K_A>_\ P71_Z,+_ &./_$I=7_\ E'1_
MPO?_ (+H_P#1A?[''_B4NK__ "CK]I:*+?WI?A_EY?GW8>T7_/JE]TO_ )+R
M_/NS\6O^%[_\%T?^C"_V./\ Q*75_P#Y1T?\+W_X+H_]&%_L<?\ B4NK_P#R
MCK]I:*+?WI?A_EY?GW8>T7_/JE]TO_DO+\^[/Q:_X7O_ ,%T?^C"_P!CC_Q*
M75__ )1T?\+W_P""Z/\ T87^QQ_XE+J__P HZ_:6BBW]Z7X?Y>7Y]V'M%_SZ
MI?=+_P"2\OS[L_%K_A>__!='_HPO]CC_ ,2EU?\ ^4='_"]_^"Z/_1A?[''_
M (E+J_\ \HZ_:6BBW]Z7X?Y>7Y]V'M%_SZI?=+_Y+R_/NS\6O^%[_P#!='_H
MPO\ 8X_\2EU?_P"4='_"]_\ @NC_ -&%_L<?^)2ZO_\ *.OVEHHM_>E^'^7E
M^?=A[1?\^J7W2_\ DO+\^[/Q:_X7O_P71_Z,+_8X_P#$I=7_ /E'1_PO?_@N
MC_T87^QQ_P")2ZO_ /*.OVEHHM_>E^'^7E^?=A[1?\^J7W2_^2\OS[L_%K_A
M>_\ P71_Z,+_ &./_$I=7_\ E'1_PO?_ (+H_P#1A?[''_B4NK__ "CK]I:*
M+?WI?A_EY?GW8>T7_/JE]TO_ )+R_/NS\6O^%[_\%T?^C"_V./\ Q*75_P#Y
M1T?\+W_X+H_]&%_L<?\ B4NK_P#RCK]I:*+?WI?A_EY?GW8>T7_/JE]TO_DO
M+\^[/YQ/B!X _P""L_Q.\<0?$+Q?_P $\OV4[WQ';H8@UO\ MF>,K'39HR8B
M4NM)M=/CL+E3Y$8(FA<%01T)KZ*T_P"-'_!<?2[&TTZQ_8&_8V@L[&VAM;:%
M/VI-6 2&WC6*->-#&2$103U)Y-?MC11"/LZ,</3;A0C.I5C1C:-.-2K.52K-
M0245*I4G.<W:\I2DW=R=R=7VE1UJE.G.JXP@ZDE*4W"G"-.$7)R;M&$(0BKV
M48QCLDC\6O\ A>__  71_P"C"_V./_$I=7_^4=,D^.?_  7/ECDB?]@O]CDI
M(CQN!^U-JX)5U*M@C0\@X)P1R*_:BBDX*2<9-N,DTT[---6:::U36C3WUONP
M56S35.FFM4[2NFK6?Q^7]79_/S\(S_P6)^!T'BJV^'7_  3V_9"TF'QGXMU[
MQOKZ7/[7'B34OM7B+Q)=B]U>\C-[I,IMTN+A0ZP0[8HA\J*!7L/_  O?_@NC
M_P!&%_L<?^)2ZO\ _*.OVEHK2<IU&I5*DYM1A!.3NU"G&,(13:^&$(QC%;**
M26F@YUW4J5*LX0G4JU)U:M27/*=2K4ES3J3DYMRG.3<I2;;DVVWJS\6O^%[_
M /!='_HPO]CC_P 2EU?_ .4='_"]_P#@NC_T87^QQ_XE+J__ ,HZ_:6BHM_>
ME^'^7E^?=B]HO^?5+[I?_)>7Y]V?BU_PO?\ X+H_]&%_L<?^)2ZO_P#*.C_A
M>_\ P71_Z,+_ &./_$I=7_\ E'7[2T46_O2_#_+R_/NP]HO^?5+[I?\ R7E^
M?=GXM?\ "]_^"Z/_ $87^QQ_XE+J_P#\HZ/^%[_\%T?^C"_V./\ Q*75_P#Y
M1U^TM%%O[TOP_P O+\^[#VB_Y]4ONE_\EY?GW9^+7_"]_P#@NC_T87^QQ_XE
M+J__ ,HZ/^%[_P#!='_HPO\ 8X_\2EU?_P"4=?M+11;^]+\/\O+\^[#VB_Y]
M4ONE_P#)>7Y]V?BU_P +W_X+H_\ 1A?[''_B4NK_ /RCH_X7O_P71_Z,+_8X
M_P#$I=7_ /E'7[2T46_O2_#_ "\OS[L/:+_GU2^Z7_R7E^?=GXM?\+W_ ."Z
M/_1A?[''_B4NK_\ RCH_X7O_ ,%T?^C"_P!CC_Q*75__ )1U^TM%%O[TOP_R
M\OS[L/:+_GU2^Z7_ ,EY?GW9^+7_  O?_@NC_P!&%_L<?^)2ZO\ _*.C_A>_
M_!='_HPO]CC_ ,2EU?\ ^4=?M+11;^]+\/\ +R_/NP]HO^?5+[I?_)>7Y]V?
MBU_PO?\ X+H_]&%_L<?^)2ZO_P#*.C_A>_\ P71_Z,+_ &./_$I=7_\ E'7[
M2T46_O2_#_+R_/NP]HO^?5+[I?\ R7E^?=GXM?\ "]_^"Z/_ $87^QQ_XE+J
M_P#\HZ/^%[_\%T?^C"_V./\ Q*75_P#Y1U^TM%%O[TOP_P O+\^[#VB_Y]4O
MNE_\EY?GW9^+7_"]_P#@NC_T87^QQ_XE+J__ ,HZ/^%[_P#!='_HPO\ 8X_\
M2EU?_P"4=?M+11;^]+\/\O+\^[#VB_Y]4ONE_P#)>7Y]V?BU_P +W_X+H_\
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M[_L_']K;_P!3NWK]G:_&+_@AO_R;'\?O^S\?VMO_ %.[>OV=I1V7HOR-*O\
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M)_\ YGJ/^&[O^"BW_2(+XB_^)0_"?_YGJ.9=I?\ @$__ )$/9R[P_P#!E/\
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M[O\ @HM_TB"^(O\ XE#\)_\ YGJ/^&[O^"BW_2(+XB_^)0_"?_YGJ.9=I?\
M@$__ )$/9R[P_P#!E/\ ^2/V!HK\?O\ AN[_ (*+?](@OB+_ .)0_"?_ .9Z
MC_AN[_@HM_TB"^(O_B4/PG_^9ZCF7:7_ (!/_P"1#V<N\/\ P93_ /DC]@:*
M_'[_ (;N_P""BW_2(+XB_P#B4/PG_P#F>H_X;N_X*+?](@OB+_XE#\)__F>H
MYEVE_P" 3_\ D0]G+O#_ ,&4_P#Y(_8&BOQ^_P"&[O\ @HM_TB"^(O\ XE#\
M)_\ YGJ/^&[O^"BW_2(+XB_^)0_"?_YGJ.9=I?\ @$__ )$/9R[P_P#!E/\
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M[O\ @HM_TB"^(O\ XE#\)_\ YGJ/^&[O^"BW_2(+XB_^)0_"?_YGJ.9=I?\
M@$__ )$/9R[P_P#!E/\ ^2/V!HK\?O\ AN[_ (*+?](@OB+_ .)0_"?_ .9Z
MC_AN[_@HM_TB"^(O_B4/PG_^9ZCF7:7_ (!/_P"1#V<N\/\ P93_ /DC]@:*
M_'[_ (;N_P""BW_2(+XB_P#B4/PG_P#F>H_X;N_X*+?](@OB+_XE#\)__F>H
MYEVE_P" 3_\ D0]G+O#_ ,&4_P#Y(_8&BOQ^_P"&[O\ @HM_TB"^(O\ XE#\
M)_\ YGJ/^&[O^"BW_2(+XB_^)0_"?_YGJ.9=I?\ @$__ )$/9R[P_P#!E/\
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M[O\ @HM_TB"^(O\ XE#\)_\ YGJ/^&[O^"BW_2(+XB_^)0_"?_YGJ.9=I?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO;0R,4CEN$B9H8W9065'D"JS $A22 2,5^-?_#07_!;S_I'O^RS_ .)71_\
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MC_[=I_\ IN(44451F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5^._[2W_ "F1_P"":'_9&?VP/_4'MJ_8BOQW_:6_
MY3(_\$T/^R,_M@?^H/;5,ME_BA_Z7$TI[R_Z]U/_ $AG[$44451F%%%% !17
MPO\ \%!OVS)_V%/V?_$'QZ/PTN?B;I_AS8U]HMKXBM?#DBQR30P+)]KN+'4"
M1YD\8*QVLC8)., D?''QL_X*\:O\&? '[*WCJ\_9KU+5XOVH-6T;1])T^/XB
MZ3:R>'KK6I=02W6:;^QITOSLL1)G;9H!+AG5E(J<-..+J2IX=NI.&<9?D,H\
MLH_\*V:T?K& PB<U%.6(H^_&JFZ$=%4JPDTBZT)8>$:E:T(3RW,,WC)RBU_9
MV52C',,2[-M1PTI14X-*I*ZY(2/VOHKSC3/BEX-DL-$;Q!XF\*>&-<UBPT^[
M_P"$=U/Q5HD>I03ZA;0W,=H(9;N&:>4"954)#F0X*J016S-\0/ =M?G2KCQM
MX1M]362VB;3IO$FC17XEO%#V<9LWO5N!)=(0ULACW3J0T0<'-:2BX2E!V<HS
MG3?+)33G3ER3491;C+EEH^5M7,XOG@II2Y90A43E&46H5$G"4E))Q4E)6YDK
MW7<ZZBO++?XY_!.[NY;"T^,/PMNK^"^&ES6-M\0?"4]W%J;3M:KITMM%J[S1
MWS72M;+:.@N#<*T(C,@*U\BVW_!0+PEI=Y^T%?>/] T;PEX%^!.G+?2^+[3Q
M_P"'O$I\0RF768FL?[&TH&]T>ZW:2$BANVDDGFN/(C0R1,K9>TI^_><8QIX.
MMCY5)M0I+"X>M@J%6HJTK4I2C4S#"*-*,W5G&LITX2A"<H],,)B*K4:=&<YR
MQ6'P4:45>M+$XKV_L*4:/\63G]7K7DH.$'!J<HMJ_P"AM%?/7P?_ &G?A#\8
MOA1X#^+ND^-/"^D>'/B%H5MK^AKK7B+2=.N'M;BRBOWC>*^N;61;BTMYE:\A
M:-9+8 F94%?,_P =_P#@H;X=^#'[1_[-7P)L_!4/C?1?VCM5U+3M)^)&C>,-
M+.B:/'IV@7>NO>B""VO(]3MWCMA%YL-]!$%D\T2,$*'IEAZT,?0RR=*<,=B,
M57P5*A.+BWBL-A<9C*]&<W:G2G3P^ QDW[6<$W0G!-U+1>,(2G0Q.)A:5#!X
M:IC,144HN,,-2G3IU*L=;U%&=6"M24Y/F3C%J[/T=HKF-)\;>#->NWT_0_%W
MAC6;^.)9I+'2M?TK4;R.)FV+*]M:7<TRQE_E#L@4M\H.>*KZW\0? 7AJXDM/
M$?C?PAX?NHH!=2VVM^)=&TJXBMC((1<20W][!(D!F(B$K*(S(0F[<0*Q6O);
M7VEO9VUY^:UN3^:]U;EO>ZL*SO)6=X_$K.\?\2WC\['7T5YEX@^-?P:\)7D6
MG>*OBU\,O#.H3V)U."Q\0>//"NC7DVFAQ&=0BM=1U6VGDL1(1&;M$: .0IDW
M'%+XH^+?@#PWX5'BR3QGX*DT^\B/]A7-SXP\/Z?IVO71W"&TTS5;F^6RNIIV
M1UC6WDF8E6PIVG&5:M3H4:N(JRY:-",I59I2GRJ"FY*T%*3E^[FE"*<Y2A*,
M8N2:+A2J5*E.E"#<ZKBJ:?N\W-RV=Y62C:<&Y-J*C)2;2:9Z917PA^P-^VY8
M?MR_#CQ5\0;#P)-X"C\,>,M:\(OI\GB&U\1I>MI&K:KI@OX;ZTL[*(1W(TSS
MUC$;[5F4"20 .WW?734ISI."FN5U*&'Q$-4^:CBJ%/$X>>C=E4H5J=1)VE%2
MY9)232B2<*M>C)6J8;$XK!UX:-T\3@\14PN)I-JZ;I5Z-2FY1;C)QYH2E%IL
MHHHK,05^.O@'_E.G\?/^T>/PU_\ 5QPU^Q5?CKX!_P"4Z?Q\_P"T>/PU_P#5
MQPU,OL_XE^II3^W_ ->Y?H?L51115&84444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'XQ?\$-_P#DV/X_?]GX_M;?^IW;
MU^SM?C%_P0W_ .38_C]_V?C^UM_ZG=O7[.TH[+T7Y&E7^)+Y?^DH****9F?C
M-_P2U_Y.2_X*]?\ 9^^M?^H5H]?LS7XS?\$M?^3DO^"O7_9^^M?^H5H]?LS4
MP^%?/\V:5?C_ .W:?_IN(44451F%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !114;RQ1D"22.,L&*AW520HRQ 8C(4<L1T')P* )**H6FJ:9J#S1
MV&HV-[);L5G2TNX+EH6!VE91#(YC8-P5?!!X(S5^CL^C2:?=/5-=TUJGU#OY
M-I^36Z?FNJ"BBB@ HKX!_:N_X*8?LE_L4^)-&\,?M%_$2'P%?^(+-]0TAKG3
M-=U*.[LX[A[5Y@VBZ1J:Q8GCDC\N9HY6*,RH5P3Z-^RS^W3^R]^VCI^OZI^S
M=\2XOB)8^%[BRM==N(/#WBG1(;.YOX)KFVB27Q%HNDI>;XK><E[,SHAC*NRL
M0"75[75[7M=-V]-RN65N;EER_P UG;MO:V^A]<5^._[2W_*9'_@FA_V1G]L#
M_P!0>VK]B*_'?]I;_E,C_P $T/\ LC/[8'_J#VU3+9?XH?\ I<2J>\O^O=3_
M -(9^Q%%%%49A1110!^(?_!?^2:[_P"">GQ.T"PT[5]5U?6XK>UT^QT;2=0U
M6XED6]L9FREA;7#1*L4,C>9(%4%0,[B ?P\_:M\$0:'\'/\ @EQK&D:I\;?%
MEUI_C7P7JOB'1-?LO$^M:?X<L[2\UT7<EMI8T2.2P:"1=D41+2&%@8U9&#'^
MW^BLLMIO+L34Q*DJLJG%O#W%-N5PM_8.#6#67WYIIPQ45&<L3RJ5)IQ5*HG=
M:XV<<;AH8:494XQX<XAX><E-2YHY_4A4GBTN1<L\*X6A2O*-5-\TXG\=_P 9
M/!GQHO\ 4?VVX=?T;Q3JWQ3\<WOPUE_90UI=&U>YFTP)\.8[>Z/A_45CD3PV
M5UA[$3"ZN;$F[C\XXV,1G>&_ W[07A#]H+X5_$NT?4?BM;^+];^"'A[XQ_#O
MQ9X5\07OBOPIXET/2M*T"3Q+H_C#4XX="M]*LW@U/4+^.R^U32F2W#2 Q[Z_
MLAJ"Y@%S;S6Y=XQ-&T9>,X= PQN0G.&'4''6NJEB:N&C@W2A3G]2A"'LM8+%
MTJ.%P6#6'K2DZD(QQE#!1K9C6=*=7$9G-9C2EAI4W0GKB<2L7]952$8?6XQC
M-QYN6E/V=&U2FH.%51PV(PU"M@:4:T8X:BJV$E[>G7G)?P.^"=,\*:]X/_:"
M\->#/"=S=?'H_MK>#[S0M2TSPMJ=[?:?I"?&;QC)?$ZY:V<EK;V\2M:-<1M<
MQ%EB^\OEL5^@OAM\,?%.O_"[_@I;X:UOP/KFIZX/#?A[4+N*[\,ZM'%JFL:1
MK'CF\U2]TYKBT":A<).IN1]D>>1B\;+N,B[OZC/V2?V%?AM^QYJOQ.U7X?>*
M_'6NM\5/%&I^*]=M/%>HV-Y9V>H:IK&K:U.FFQVEA:&*%;K6;H)YK2R&-(@S
MDJ2WVW7D4<LA3RJ.$E7JSKXS@K+^'<8G>5#!XNG@.$J5:KA*<KI^RQ/#+=:2
MFECWB*=;FP\L-%5?H\;Q,IYUBL9AL+!X:AQMC^)L!5E+V>(Q.'K9KFF-HT<7
MRPTBZ.8*%"DE_L+56*>(C5;7\1FO>*_#%E^SG^QCX$\*^ /''ACQ=:? 3Q/:
MKKNI^#_$.J> F\4S_"V2#6;6_P#"%GHL6H+KEQ*B06NL37:VXU"XM+O:\5M(
M*\M\):KXHN](_P""8D?BW2_B-)/X'O?B#HWBJ^M_"OB>*\\/6LWPNN+-6MY3
MIDK1"V:X=H#$'RZL(LMP/[JY?$GAV#4?[(FU[18=6\HS_P!ERZI8QZCY 5G,
MWV)YQ<^4$1V,GE;-J,V<*2+6G:OI6KQR3:3J>GZI%#*T$LNG7MM>QQ3)C?#(
M]M+*J2ID;HV(=<C(&17L>WG/,<1F3_>/$8_.<QG1;DZ,9YKB.)VXTTG:E#"K
MB;$8:]*,%5EAU4DH5\1B)2\!8MT\"\#['E7U.C@U5349J,<'1P\Y27):HZOL
M*6(BJG,Z?P1E*DJ<8?S.?\$H?#/Q.\ _M-:EX>DG;XE_"+6?A[8>(O!7Q#N_
M!VO>&O&.E:;<:XUM9Z7XSUCQ-';W>MWL,-O(]S!!9VX,UQ#=1A8T<5\Y?\%>
M_$MYKGQT_:(\+>#?#OCC3O&]O\'([>+4-<\/:YXOT+Q'91>/=&N&M_ C:1IB
M0>&=6+!YEN[R\N4^R6]]!L#7*,/[ *R;C7M"M-0MM(N]:TFUU6\ -GIEQJ-G
M#J%T"6 -M923+<S@E6 ,43C*L.H..7'0>+>40I5*E!95A\3A<.W)5,354E4>
M$E.M2CAW.6#BZ49.4)SQ<*-Z\W4DZD=L%F4\/CLQS&M0AB:^8XG 8S$J[IT?
M:X6O@ZV,DJ5JD81Q\L/5<HPY*>%GB7+#P4:<*;_BD^*GA/2_BS^T7\%M6\<>
M ->\8V'_  P7X@M]0N=;\%:_=J?%UIX\N8;<7 GTTL+Z.V0+%YF'\GR\94J:
MO? R+QK)X*_8.U3X\>&?%^O?L\:):_$FP\1:1K7A?7M7@L_&R_%_6F\)O>:
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M@  DD"ORY_9B_P""ENB?&WQE?>%M>\)G1])O?'WQ \%>#O%]MKFDWEOXANO
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M%/B/P!ID"Z%KMU?";3];AO=*U+[7?Q?8I[..:69TNHIHR(QT%[^T[^P[^RY
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M:YK.F:1:Q*6>;4;VWM$51WS-(A/H H))X )K\QYOC)^W]\;X?#@^"?P#\-?
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MDG:H7)ZG QD^YZFG5F>:M$O1!1110,**** "OQU\ _\ *=/X^?\ :/'X:_\
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M_K_3TMP2;3J0NG9Z5-U_VX?L!17X_P#_  PK_P %&_\ I+UX^_\ $6_A-_\
M+^C_ (85_P""C?\ TEZ\??\ B+?PF_\ E_1?^[/_ ,D_^3]?Z>BY8_\ /R'W
M5/\ Y6?L!17X_P#_  PK_P %&_\ I+UX^_\ $6_A-_\ +^C_ (85_P""C?\
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M$@X-#BV[\TEY+EM^,7V_/NQJ:22]G3=E:[4KOS=I)7^1^.'_  T9_P %IO\
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M@@1I'D9549-?$,__  4 \>?&&XUKP_\ LC?L^>./&_B#2+B.UN-0^+NDZO\
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M?L]R:=??L;?'?7-.\-:?J%YJNO\ PM^*;GXBR^-8VLS%;:+;>./&E_>77A.
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M/\BH?''_ !1_-'B/_!*[_E'+^QC_ -F_^ /_ $TQU]^5\!_\$KO^4<O[&/\
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MQ?8#P_X?U#16TF*ZU+7;\VEV]_>71NI/^)O&N^)8T4P/C<'&-?\ ;=_X)_\
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MK?=.25KTH*ZNKNIJK7NO?U5DW?LK['Y2_P##=7_!1O\ Z1"^/O\ Q*3X3?\
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M9/&=_K#6-HOAO1$N)Y3/J,\%NUD-2%E)ITUS!'<">XMXY?-C@4NZHK*U=O\
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M3D_\(OXY?_*^OV!HHY?[TOO#G_N4_P#P%_Y^7Y]V?C]_PAW_  70_P"BP?\
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MYI+1[+3EEK;Y/;Y6/SB\&_\ !2;X3VFIZ'X0_:-T+Q-^R]XZU_5X?#N@Z/\
M%_3QX<A\7:Y,',<'A0?:;ZYO+>7RY%BEN%A!>*0$C"Y_1'3]0LM5L[;4-.N8
MKRRNXDGMKF%MT4T,BADD1L#*LI!!QR#7"_$#X1_#7XI6#:=X\\&>'_$<8#>1
M=:AI=E-J5C(RLOGZ=J3PF^T^X"LP6XM)X9E#,%<;CGX&U#]@CQG\(+FPUC]D
M#XW>+OA=8Z=J!U+4/AKJ[)XLT#Q=F>6YFTZ_\1>*[W5=3T>UN6<PM)I\!:&,
MYB3(HU]?P[?\'_(=HO9N+\]8_>M5]S3[JVOZ?U^;?_!4#XD^+?"O[.M[X$\
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M.PK]@:_'[]K;_E+#_P $L/\ L7/VNO\ U6=A7[ TE]K_ !O_ -(IG)+X:?\
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MID\.W^B17XU/0O&=E>^$KY+W2S+'>V5DWB&UTP:F\<\,D$4EC',D[!&B#"1
M?>_@[\;OAM\>/"S>+_AEXGTOQ+H\.I:AH]W)I]W#</9ZGI5PUI?VEQ'&Q>-X
M+E'BW.BK(5+(2*?Z_P!?J*S5[IJV^FWJ>LT444""BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K-U76='T.U:
M^UO5=-T>R3[]YJM]:Z?:ID@#=<7<L,2\D#EQR0.]:5?DQ_P5>T/Q!H/PR\'?
M&C1)?$FO6WP_\6:?9ZY\.X-66#PKXHL/%U_I/AI9=>TJ9?LM_#HYNY-4C$[
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M/W1X.\!>"OA[I,&@^!?"N@^$=%MD$=OI?A_3+72[&%%"A4CMK2.*)% 50 %
M&!6QJ^NZ)X?M);_7M8TK1+&%'EFO=6U"TTZUBCC7=)))<7DT,2(B_,[,X"CD
MD"OB/XJ_\%%OV<OAKKOAWPC8:UJOQ"\7>,)I[7PGIO@71M6\1:1K-U%:R72Q
M#Q7HVGZGH%G%-'$PCNKB[6 G'SG(IZ+R_P V_P!7^(_?G9:R\DM-%Y:;;OMN
M?>-<WXF\9>$/!=A+JOC#Q3X<\*:9"ADEU#Q)K>F:'91H.-SW6IW5K HSP"9
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M]0UG5KV17=+/3=+M)KZ^NG6-7D9+>U@EE98T9R$(568@'4KR;X^?\D+^-/\
MV2;XC?\ J'ZS0-:M+NT?G?;_ /!<;_@F5=PI<V?[0\]Y;2@F*ZM/A=\6KFVF
M56*EX;B#P0\4J;E(#QNRD@X-3?\ #[W_ ()I_P#1?K__ ,-/\7__ )AJE_X(
MN>'M N_^"6_[&5S=:'H]S<2_"J1I9[C3+*::5O\ A+/$HW22R0,[M@ 99B<
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M1?\ A%?#'_0N:#_X)]/_ /D>C_A%?#'_ $+F@_\ @GT__P"1Z=I_S1_\!?\
M\F3>G_+/_P &1_\ E9^77_#[W_@FG_T7Z_\ _#3_ !?_ /F&H_X?>_\ !-/_
M *+]?_\ AI_B_P#_ ##5^HO_  BOAC_H7-!_\$^G_P#R/1_PBOAC_H7-!_\
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MK[S]3:*_++_A]A_P2Y_Z.X\(?^$=\5/_ )@Z/^'V'_!+G_H[CPA_X1WQ4_\
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M+2>9-=W<=@9+R\N;V[+2WM].E_>7TB37<K23R; D:LQ\M44*!](*JHH5%5%
MP%4!5 ]    /H*6NCOH]=-GK9ZZW5U:ZMU0[Q3=HMM6UETZ_"M.O5OH]#\TK
M3]@+Q)\2+U-<_:A^/7C_ .*1U#2(K#Q%\+M/UJ9?@K=3M%)'?26'AC5K%K^&
M*\$S)()+OS&CBMP3E*^RO@S^SW\%_P!GKPQ8>#?@Q\.O#?P\\-Z9:QV=GI7A
MVS-K;16\6W9& TDC$#:O+,3QR:]EHI_+^OZ0G)O2^G9:+3RV^>X4444$A111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M];!S2>BT\HZ?EOY;Z[;GI-M:6ME$L%G;6]I @ 2&VAC@B4 8 6.)410
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M>#=)\!ZGX4^'/A2_TJTGU>PM+J2?3$EU)A>W^H2$K' LAA/S+7]#?Q:_8_\
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MY)(_8:BOQY_X<Q?"#_H[[_@HM_XE?JW_ ,RU'_#F+X0?]'??\%%O_$K]6_\
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M(ZPD<<<:!GDDD<A41069B%4$D"O5:" 000"",$'D$'J".X- T[-/L[G\S/\
MP3"_X*P?L5?L[?L#_LR?!3XM^.?&WAGXC_#OP!)H7BW0?^%0_%#4?[,U/_A(
M]<O?LWVW3O"MS97!^S7<#E[>>1 7VEMRL!]Y?\/R/^"<O_15O&W_ (93XN__
M #'5^M']G:?_ ,^-G_X#0_\ Q%']G:?_ ,^-G_X#0?\ Q%2E))*\=/[LO+^_
MY?B_*URE"4G)PG>3;=IJUV[_ //L_)?_ (?D?\$Y?^BK>-O_  RGQ=_^8ZC_
M (?D?\$Y?^BK>-O_  RGQ=_^8ZOUH_L[3_\ GQL__ :#_P"(H_L[3_\ GQL_
M_ :#_P"(H][O#_P&7_R?]7?E97I_RS_\&1_^5GY+_P##\C_@G+_T5;QM_P"&
M4^+O_P QU'_#\C_@G+_T5;QM_P"&4^+O_P QU?K1_9VG_P#/C9_^ T'_ ,11
M_9VG_P#/C9_^ T'_ ,11[W>'_@,O_D_ZN_*Q>G_+/_P9'_Y6?DO_ ,/R/^"<
MO_15O&W_ (93XN__ #'4?\/R/^"<O_15O&W_ (93XN__ #'5^M']G:?_ ,^-
MG_X#0?\ Q%']G:?_ ,^-G_X#0?\ Q%'O=X?^ R_^3_J[\K%Z?\L__!D?_E9^
M2_\ P_(_X)R_]%6\;?\ AE/B[_\ ,=1_P_(_X)R_]%6\;?\ AE/B[_\ ,=7Z
MT?V=I_\ SXV?_@-!_P#$4?V=I_\ SXV?_@-!_P#$4>]WA_X#+_Y/^KORL7I_
MRS_\&1_^5GY+_P##\C_@G+_T5;QM_P"&4^+O_P QU'_#\C_@G+_T5;QM_P"&
M4^+O_P QU?K1_9VG_P#/C9_^ T'_ ,11_9VG_P#/C9_^ T'_ ,11[W>'_@,O
M_D_ZN_*Q>G_+/_P9'_Y6?DO_ ,/R/^"<O_15O&W_ (93XN__ #'4?\/R/^"<
MO_15O&W_ (93XN__ #'5^M']G:?_ ,^-G_X#0?\ Q%']G:?_ ,^-G_X#0?\
MQ%'O=X?^ R_^3_J[\K%Z?\L__!D?_E9^2_\ P_(_X)R_]%6\;?\ AE/B[_\
M,=1_P_(_X)R_]%6\;?\ AE/B[_\ ,=7ZT?V=I_\ SXV?_@-!_P#$4?V=I_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ny20006478x8_graphic08a.jpg
<TEXT>
begin 644 ny20006478x8_graphic08a.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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MRTUWQCY&H^4T=IJ=WI%IHQ<CSM1AC#.OXP_%C]L_]L']JVYN8/#FI:[^QE\
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M2GS4:<7?D<)S7O3M$HHHK] /G0IRJSLJ(K.[L%1%!9F9B JJH!+,Q(  !))
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MK?'G7_CO\3;W4?A/JFM_$:;_ (*-? ;]I#X#?MA6NI_#O2;+P#^S/IWA_P"
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M7D?ZN9+_ -#K-/\ PPX3_P"B(][_ %DQW_0KPG_ATK?_ #J]?Z>G1T5SG_#
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M #J]?Z>G1T5SG_# _P"PK_T99^R9_P"(Y?![_P"8ZC_A@?\ 85_Z,L_9,_\
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M4Z_]>3_M95]Q5\._\$]?^2"^/O\ L^+_ (*=?^O)_P!K*ON*@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /FOQ3_R>#\"_
M^S:_VKO_ %:'[&5?2E?-?BG_ )/!^!?_ &;7^U=_ZM#]C*I=,_:V_9_U?X@6
M'PSL/'-U)XDU?X@>,/A/HNH3>"?B!9^ =>^*?P_L?$.H^-OAIH'Q6O?"MO\
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M:;X \$VMO:6FH_$;QK/'>6VA:%;0"WT?Q/XHO/"OA'Q!A_M9?\EZ_P""8O\
MV?%X_P#_ %VQ_P %"J^XJ /RG_8M^)'[/_PC_93\/?!S]F7XU_!K]I/XNWB?
MM'^*/ D/AWQ=H7@GX=_M*_M&237'[0OQML/@OXET[3K_ ,,7_P *M(^(OQDM
M-!EUCX>GXA:)\']#N4\#^(=6U3Q9X \4V5M^3&A_L\_$3XS?\%2_'W[.7Q_^
M!VH>$I_VGO\ @E%\0]#_ &F?B?I_QB\%ZOX\-SXL^/=_<Q?'SPN;?0/%>GSZ
MMI'C;1/ _P ,?A;\.KVYNH/A-X$T+P7;Z=>ZCX1^'>F:!>?U<O;6\DT-S)!"
M]Q;+*MO.\2-- LX03K#*REXEF$<8E",HD"('!"KB:@#^?SQOIOB3]GWPUJOQ
M5^&\MO\ $'2%_P""@?AO2M)^('Q)T&ZN?AGXE_:W_:X_:(\-_!;XM?M-^./!
MGACQ3X8UJ]^ W[).@^-+GX$_ ?P<_CVPN[SQEH&O7OB;4-5D\(?"CXR']5?V
M'OC_ .+/VH_V5_A'\=O''@RS\">*?'6F>(#JNC:3<7EUX<U,^&?&/B+P?9^.
MO!L^HJ-0;P%\3M/\/VGQ)\ +?37UW%X+\6:%%<ZIJ\R/J=W](W/A?PS>^'9/
M!]YX=T*[\)2Z6-$E\+W.D:?/X=DT58!:KI$FB2V[Z8^EK;*MN-/:U-H(%$(A
M\L!:V+>W@M8(;6UABMK:VBCM[>WMXTA@@@A18X8888U6.***-52.-%5$1555
M"@"@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^'?^">O_ "07
MQ]_V?%_P4Z_]>3_M95\U^'?&/A&3_@NC\5] 3Q5X<?76_P""8/P%T)=%37-,
M;5FUNP_:=_:2\37VC+IPNC>'5;+PY?V/B"[TX0F[MM$O;359H4L+F&X?Z4_X
M)Z_\D%\??]GQ?\%.O_7D_P"UE7W%0!_+WXZ'[4>F?\%8_P#@E9\1?B[^S#H^
MB?&?XE^.OVP8?%&KGX\^%O$>F0_#)O@[H&B/X4\&WMAH-W=Z;X._9S^'^KZW
MXLT3PK-9:-#\6/B!K?COQ5!9>#?%/Q.\1S6OZ3_MA?M]_LBZ%\+= TCPA^T;
M^R7IWQ$_:X^'OB?PE\(_B9\3_BE\+=%^&.F_#=[G4?#?BOXK^+/$GB?5[72_
M%?@/X?7]]K,VE?#:VO9+WXJ^.[.7X?Z;_8UE+XV\:>"?U=J&WMK>TACMK2"&
MUMX5VQ06\20PQ+DG;'%&JHBY).%4#))QDT ?@Y9?LE?LP:/X,_99^+_[)WCC
MQ+\3=*LH_P!E_P"$_P"SQX'NUMSX%^//Q$_8D\,_M ?#'X!?%OQCXGCT#P_J
M.J?"WP1H_P 0?'?QR^*?C[PC:WFG?%;P?\'/A;XX^"U[?6$&BZ#\6.D_9>_:
MB^*7P\_;0OOV*D\$:-XF^'9^.7QV^&GBKQCJUCJ]E^T/J/C[P7^SC\#_ -J;
MQK^V!\4M1M]?O_!.H_"WXT^.?CA+\-O#'A3PYX)\%Z?X"N=:^&&E^'-73PT]
MCX \/?MT]A8RWUMJ<ME:2:E96MY96>H/;0O?6EGJ,ME-J%I;7;(;B"UOIM,T
MZ6\MXI$BNI=/LI)T=[2 QTX?#^@6^N7GB:#0](A\2:CI]II.H>((=-LH]<OM
M+T^:XN+#3;S5D@6_NM/LI[NZGM+.>X>VMIKFXDAC1YI&8 UZ*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ^:_%/_)X/P+_[-K_:N_\ 5H?L
M95]*5\U^*?\ D\'X%_\ 9M?[5W_JT/V,J^E*]3,/]TR/_L5UO_5UG!QX7^/F
M/_89#_U7X$****\L[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?Q]?\/Y_V[?^A1_9*_\ #4?&+_Z)"C_A_/\ MV_]"C^R5_X:CXQ?_1(5\?\
M\0(\0O\ H#RW_P .F'/<_P"(B\,?]!&*_P#".K_D?V"T5_'U_P /Y_V[?^A1
M_9*_\-1\8O\ Z)"C_A_/^W;_ -"C^R5_X:CXQ?\ T2%'_$"/$+_H#RW_ ,.F
M'#_B(O#'_01BO_".K_D?V"T5_'U_P_G_ &[?^A1_9*_\-1\8O_HD*/\ A_/^
MW;_T*/[)7_AJ/C%_]$A1_P 0(\0O^@/+?_#IAP_XB+PQ_P!!&*_\(ZO^1_8+
M17\?7_#^?]NW_H4?V2O_  U'QB_^B0H_X?S_ +=O_0H_LE?^&H^,7_T2%'_$
M"/$+_H#RW_PZ8</^(B\,?]!&*_\ ".K_ )']@M%?Q]?\/Y_V[?\ H4?V2O\
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M?V"T5_'U_P /Y_V[?^A1_9*_\-1\8O\ Z)"C_A_/^W;_ -"C^R5_X:CXQ?\
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MW_PZ8</^(B\,?]!&*_\ ".K_ )']@M%?Q]?\/Y_V[?\ H4?V2O\ PU'QB_\
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M?\.G_@C_ .DH\N?QR_Q2_-A1115DA1110 4444 %%%% !1110 4444 %%%%
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M'_1I'[6O_B+OQ[_^=Y111_Q$W/O^@3*/_"?&_P#S>'^J&6_\_P#'?^#</_\
M,P?\,L?M8?\ 1I'[6O\ XB[\>_\ YWE'_#+'[6'_ $:1^UK_ .(N_'O_ .=Y
M111_Q$W/O^@3*/\ PGQO_P WA_JAEO\ S_QW_@W#_P#S,'_#+'[6'_1I'[6O
M_B+OQ[_^=Y1_PRQ^UA_T:1^UK_XB[\>__G>444?\1-S[_H$RC_PGQO\ \WA_
MJAEO_/\ QW_@W#__ #,'_#+'[6'_ $:1^UK_ .(N_'O_ .=Y1_PRQ^UA_P!&
MD?M:_P#B+OQ[_P#G>444?\1-S[_H$RC_ ,)\;_\ -X?ZH9;_ ,_\=_X-P_\
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M=Y1_PRQ^UA_T:1^UK_XB[\>__G>444?\1-S[_H$RC_PGQO\ \WA_JAEO_/\
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M6O\ XB[\>_\ YWE'_#+'[6'_ $:1^UK_ .(N_'O_ .=Y111_Q$W/O^@3*/\
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M?ZH9;_S_ ,=_X-P__P S!_PRQ^UA_P!&D?M:_P#B+OQ[_P#G>4?\,L?M8?\
M1I'[6O\ XB[\>_\ YWE%%'_$3<^_Z!,H_P#"?&__ #>'^J&6_P#/_'?^#</_
M /,P?\,L?M8?]&D?M:_^(N_'O_YWE'_#+'[6'_1I'[6O_B+OQ[_^=Y111_Q$
MW/O^@3*/_"?&_P#S>'^J&6_\_P#'?^#</_\ ,P?\,L?M8?\ 1I'[6O\ XB[\
M>_\ YWE'_#+'[6'_ $:1^UK_ .(N_'O_ .=Y111_Q$W/O^@3*/\ PGQO_P W
MA_JAEO\ S_QW_@W#_P#S,'_#+'[6'_1I'[6O_B+OQ[_^=Y1_PRQ^UA_T:1^U
MK_XB[\>__G>444?\1-S[_H$RC_PGQO\ \WA_JAEO_/\ QW_@W#__ #,'_#+'
M[6'_ $:1^UK_ .(N_'O_ .=Y1_PRQ^UA_P!&D?M:_P#B+OQ[_P#G>444?\1-
MS[_H$RC_ ,)\;_\ -X?ZH9;_ ,_\=_X-P_\ \S!_PRQ^UA_T:1^UK_XB[\>_
M_G>4?\,L?M8?]&D?M:_^(N_'O_YWE%%'_$3<^_Z!,H_\)\;_ /-X?ZH9;_S_
M ,=_X-P__P S!_PRQ^UA_P!&D?M:_P#B+OQ[_P#G>4?\,L?M8?\ 1I'[6O\
MXB[\>_\ YWE%%'_$3<^_Z!,H_P#"?&__ #>'^J&6_P#/_'?^#</_ /,P?\,L
M?M8?]&D?M:_^(N_'O_YWE'_#+'[6'_1I'[6O_B+OQ[_^=Y111_Q$W/O^@3*/
M_"?&_P#S>'^J&6_\_P#'?^#</_\ ,P?\,L?M8?\ 1I'[6O\ XB[\>_\ YWE'
M_#+'[6'_ $:1^UK_ .(N_'O_ .=Y111_Q$W/O^@3*/\ PGQO_P WA_JAEO\
MS_QW_@W#_P#S,>:_%/\ 8Y_;&\1^'[.QT7]CW]K6\NHM9M[N2+_AF3XY6^VW
MCLM1A>3?=^ H(SB2>)=BN7._(4JK$%%%<M;Q!SJM-U)87*TVDK1HXM+16ZXU
9O\3HI\,X"E'DC6Q;5V_>J46]?3#K\C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ny20006478x8_graphic08b.jpg
<TEXT>
begin 644 ny20006478x8_graphic08b.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
M                                                          !8
M65H@        ]M8  0    #3+71E>'0     0V]P>7)I9VAT($AE=VQE='0@
M4&%C:V%R9"P@,C P- !S9C,R       !#$0   7?___S)@  !Y0  /V/___[
MH?___:(   /;  # =?_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_  !$( =H$N ,!(@ "$0$#$0'_Q  ?   !!0$!
M 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T!
M @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F
M)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M#^S==T/P]8ZI8_;M+OKW3;S[+=1?:K"\NK.??;W$T;_H17SA^U)_R3_X>_\
M9V?["/\ ZVY^SW7L\.9[G=;B'(:57.<UJTJN<Y73JTJF8XN=.I3GCJ$9TZD)
M5G&<)Q;C*,DXRBVFFFT>=G&6Y=3RG-)PP&"A.&78Z<)PPM",X3CAJKC*,E33
MC*+2<9)III-.Y^C]%%%=Y\N%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/V3/_$<O@]_\QU'_  P/^PK_ -&6?LF?^(Y?![_YCJ^LZ*/[<SK_ *'&:?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HKY^\0_M.?"OPWXL\5>"9[;XNZ]X@\$:GI^B^*U\
M_LZ?M#_$W1]%UC5/#.@>,K+2;GQ1\.?A;XI\,/J;^&/%/AW69K"WUB:ZM+75
M[,7D4$LAB&9_PU=\+_\ H5OVE/\ Q#+]L'_YQ=>G'),YG"%2&49G.%6G3JTI
MQP&*E"I2JPC4I5(25)J=.K3G"I3G%N,X3C*+<9)OD>88",I1EC<(I0E*$XO$
MT5*,X2<)PDG.\90DG&479QDFFDTT?2E%?-?_  U=\+_^A6_:4_\ $,OVP?\
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M_P"A6_:4_P#$,OVP?_G%T?V'G?\ T)\U_P##?B__ )3YK[P_M'+_ /H.P?\
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M\9*2NFF=-.I3JP52E4A5IRORSIRC.$K-Q=I1;B[233L]&FGJ@HHHK(L****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBOSS_X*U1>9_P3
M%_;X<37=O):_LG_'"_MY[&]O-/N(KK3O .M7UJZW%C/;S[%N+>(S0&0V]U$'
MMKJ*:VEEA< _0RBOYMO^"A>I>,+SXO?\%6/&7BV*_P!,\=_LN?L+_LC>-/\
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M!OC[_@GGX+_:RM/&OQDU;QEI_B;X->)/C-^TS\0/A:=>G^+5K^S_ /#+XO\
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M5K?\B/+O^QKG/_J)D1QP_P"1ABO^P/ _^G\Q"BBBO*.P**** "BBB@ HHHH
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M)_VAM)U#]IS]M6/X=>%=2\<ZAX#\+7/P5_X)\_!SP%K_ ,-?AW!>2W.F:_\
MM0Z!X>T>S\/_  GUW]FRUBTG]X_ ?C30?B1X'\&?$3PM+>3^&/'OA3P[XT\.
M3ZAIU[I%_-H/BG2+/7-(EOM)U*"VU'3+R33[ZW>YTZ_MK>]LIB]M=013Q21J
M =71110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?_"(_8?_ /H.*/\ A5_QX_Z/P_:A_P#"(_8?_P#H.*/K&3_]#W+_ /PFSO\
M^= ?V;FG_0OK?^#\!_\ -A\K?\%5?B]\2_V/?V=_#GPN^"WPN^%5E^S3\2_A
MQXN_9WU&U@\/ZOIEW\,9]7\)ZGH^D:=X:BT/Q#I6@VECJ'A";5)/#EJ_A^[B
ML-0\*ZC)J,MS#?V=HOWY^P]\7_C1\??V=_"/QD^-_A?PAX,UWX@RWFO>%O#_
M (/L=?L((? 4IA@\-ZGJD?B'5]:N);[Q"(+SQ#8SVETMC-X;U3095B6Y>Y)^
M8/B_^R7XM^/?@'6/A?\ %W]L/]I3QMX%UZ739]3T"]\+?L=Z4D]QH^I6NKZ;
M/%JOAC]D_0?$.GRVVH65O*9M)UG3KB: 364TSV=U=03=]IGP<^,^BZ;I^C:/
M^W#^TMI>DZ38VFF:7IEAX _8:M+'3M.L+>.ULK&RM8/V-DAMK2TMHHK>VMX4
M2*&&-(XU5% 'U^+XFX0K\&Y7D5*>4T<[PF9XS$8O.5A<\O7P56G2]C"*_LUI
M8FK*,*6)?L(15# 864*E2IB,0H>'1X;XBIY[C,QFL54R^O@Z%*C@'B,!:EB(
M2ESR;^LJ]*"<ITE[23=3$UDXQC2I\WZ-T5^>7_"K_CQ_T?A^U#_X1'[#_P#]
M!Q1_PJ_X\?\ 1^'[4/\ X1'[#_\ ]!Q7R'UC)_\ H>Y?_P"$V=__ #H/<_LW
M-/\ H7UO_!^ _P#FP_0VBOSR_P"%7_'C_H_#]J'_ ,(C]A__ .@XH_X5?\>/
M^C\/VH?_  B/V'__ *#BCZQD_P#T/<O_ /";._\ YT!_9N:?]"^M_P"#\!_\
MV'Z&T5^>7PJU'XS>"_VK_ 'PT\5_M&?%'XS^"?'7[//[0/CF]T7XD^%OV?M*
M_LGQ3\,_B3^R[H'AO5-%U+X/?!#X4:LN[2?BOXOM-1L=6O\ 5].NO.L)X[2W
MN;&.9OT-KHK484Z>%K4L30Q5#&X>6(H5J$<1&,H0Q6)P<U*&*H8:M&<:^%JI
MIT[.*C*,FI:<3YXU:]"K2G1K8>I&E5IS=.34IT*.(BU*E4JP:=.O!W4KIW32
M:"BBBN<84444 %%%?*_[9OB_QQX)^!3ZE\.?&6J?#[Q5KGQE_9?^'D/C+0]+
M\):SK6@Z+\5_VG?@_P#"_P 776CZ?X[\-^,/",FJ2>$?&&N6NGSZYX8UJTLK
MNXAOELI)[:%EZ,+AY8O%8;"PG3IRQ.(HX>-2KS^RIRK5(TU.I[.%2I[.+DI3
M]G3J3Y4^6$I6BXJ35.G4J.,I*G"<W&/+S24(N7+'FE&/,[67-*,;[R2U/JBB
MOSR_X5?\>/\ H_#]J'_PB/V'_P#Z#BC_ (5?\>/^C\/VH?\ PB/V'_\ Z#BN
M?ZQD_P#T/<O_ /";._\ YT'?_9N:?]"^M_X/P'_S8?H;17YY?\*O^/'_ $?A
M^U#_ .$1^P__ /0<4?\ "K_CQ_T?A^U#_P"$1^P__P#0<4?6,G_Z'N7_ /A-
MG?\ \Z _LW-/^A?6_P#!^ _^;#]#:_FA\4_M#_\ !0P_\%,/#7[.,6N^"G\6
MZ'?^,_A]X0\7O\.],:R_X45\2M3\ _$/7O'EY8_;+:PO[ZS\)?##P]JMQ#!=
M*MIK>E:YX7MI9+Z=D'ZH_P#"K_CQ_P!'X?M0_P#A$?L/_P#T'%>?R?LM^-I?
MBC;?&J3]L;]I!_BG:>!Y_AM;>,SX)_8I_M.+P/<ZW'XCF\/B(?L@BP>V.M1"
M^BN)+-[^W:2Z@MKN&UO;V"X^OX1XJX9X>J9O4Q]3(LX>-R?&83 _6\MS3$?4
MLQJTY4L/B?WV3O\ V9TZM:EC*$+/$4YQ3^!(\3.^&,]S2.!CAECL#]7QU"OB
M/88S"4_K&%A.,ZM+]WC/XJE"G.A4E?V4XMKXF?H;XZ^%'PR^*$.CP_$GP!X.
M\?+X?EU6?0SXO\-Z/K[Z1+K^@:EX3\1-ICZC9SM8+XC\*:UK7A7Q%#:&&#7O
M"^M:QX<U:*[T75+^QN+LGPX^'DOC/1OB/+X#\&2?$/PYX:U+P9X>\>2>%]#?
MQGH/@_6;K3;[5_"FC>*&L3KFE^&M5OM'TB\U+0K&^@TN^NM*TVXNK66:QM7B
M^)?^%7_'C_H_#]J'_P (C]A__P"@XH_X5?\ 'C_H_#]J'_PB/V'_ /Z#BOD/
MK&3_ /0]R_\ \)L[_P#G0>W_ &;FG_0OK?\ @_ ?_-A]+:Q^R[^S;XBT!_"N
MO_ 7X0ZWX9E\8^./B#-H&K?#WPMJ.CS^-OB;<:S<_$GQ/<:==Z7-:SZQ\09/
M$?B!/&]W-$[^*[;6]6L]=^WVFH7<$OK%[X6\/ZCXBT'Q9?Z7;W?B'PQ8Z[IW
MA_4IS*\FDVWB4Z5_;9M(#)]E2ZOH]%L+<WY@:^@LQ=V5K<P6FIZG!>?"/_"K
M_CQ_T?A^U#_X1'[#_P#]!Q1_PJ_X\?\ 1^'[4/\ X1'[#_\ ]!Q1]8R?_H>Y
M?_X39W_\Z _LW-/^A?6_\'X#_P";#Z_\'_!?X4> /&'C;X@>"_ 'AGPWXT^(
MTT,_C7Q)I6G16^IZZ8=1U?6_(FG&?LME/XB\0^)/%5[I]@MI8ZAXO\3^*/%M
M];W'B3Q+KFJ7_IU?GE_PJ_X\?]'X?M0_^$1^P_\ _0<5[+^QEXO\<>-O@4FI
M?$;QEJGQ!\5:'\9?VH/AY-XRUS2_"6C:UKVB_"C]IWXP?"_PC=:QI_@3PWX/
M\(QZI'X1\'Z':ZA/H?AC1;2]N[>:^:RCGN9F;HC3PM;"UL5A,RP>-CA\1AL/
M5IT:>8TZL98JGBJE*?\ M> PM.5-+!U8RY:CFI2A:#BY2CS5J.*PU2E3Q.%J
MT'6A5G3E*IAIQ:HRHQG']SB*LE+]]%J\5%I2]Y-)/ZHHHHKG("BBB@ HHHH
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MJK[V=GW29U4Y<\(3M;GC&5DU*UU>W,M';:ZNGT;1XII__)]7P)_[-,_;#_\
M5P_L*5]]U\":?_R?5\"?^S3/VP__ %</["E??=?H5+_D2\.?]BO%?^M!GA\#
MC_\ D;YO_P!A>&_]566A11169@%%%% !7QU^W9_R0;0_^SH?V%?_ %N#]G>O
MJ?Q/XI\-^"M"U'Q1XOU[2/#'AK2(XY]6\0:]J%KI6C:5;RW$5LMUJ6IWLL-G
M86BS3Q++=W<T-M K>9/+'&K.ORE^W'<V]Y^S]X<N[2>&ZM+K]IO]A"YMKFVE
M2>WN;>?]MW]G:6&>":)FCFAFC99(I8V9)$971BI!/IY33FLRRNJX35.69X6G
M&HXODE.%>A*<%.W*YQC.$I13O%3BVDI*^&(E'V.(AS+F5"I)QNN91<)I2:W2
M;C))VLVFELSNZ***_+#]/"BBN"^)7Q.\"_"#PG=>-_B)KT?A[PY;:AHFC)<"
MQU/5]1U/7O$^LV/ASPQX;\/>']"LM3\0^)_%'B?Q#JFFZ#X:\,>'=+U37]?U
MK4++2](TZ\OKF&!Q)MI)-MNR2U;;V275L3:2;;225VV[)+NV]$CO:*^&/&'_
M  4?_9*^'OAKX@^+/'_BWXG>!]+^%6G^ ]7^(=KXN_9H_:;\.^)O"FB_$[7-
M6\,^ M?U'P3JWP?M?&C>&_$_B30M7\/Z;XFM/#]SX>;7+&;2)=4BU QVSIKG
M_!2+]D'PYI]K>ZSX[\?VE[/\3/"7P;OO"*_LZ_M)W7Q)\,?$_P"(-KI=[\._
M!GCSX5V?PCN/B3\.M8^(]MK6F2?#E/'GA3PY!X^^T[/"$^M20W"1:>QK/:E5
M=W9?NY:NR=MM[2B[=I)[-&?MZ"WK4EI?^)#:[5]]KQDK]TUNF?=%%?-7CO\
M:B\%>"75XO#OC+Q7IL'QW^#G[.VLZYX?M-"@TO0/B%\9?$'AWP[IRWW_  DF
MOZ!J6HZ1X2O/&?@N/QC?>&M.UY["^\3PZ+86^I:SX;\>V/A'T[X7?%#P]\6/
M#U_KN@P:CIMQH7BKQ5X%\5>'-<CLH=?\*>,O!>M7>@^(O#VM0Z;?:GI_VFVO
M+07=C>Z=J.H:3K>B7NE>(-$U#4-%U;3KZYEPDH\S7NWM?SLG^33^:[HI3A*3
MBI)R5W;R3LWYZIK3L^QZ/1114EA7%?L)_P#)!M<_[.A_;J_];@_:(KM:X?\
M88EB@^ 7B"::2.&&']I[]NV6665UCBBBC_;>_:)>2221R$2-$!9W8A54%F(
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M-/5->31SG[ __)BO[%G_ &:9^SE_ZI[P;7UG7R9^P/\ \F*_L6?]FF?LY?\
MJGO!M?6=?JF>?\CK./\ L:9A_P"I=8_+<!_N."_[!,-_Z9@%%%%>6=84444
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M^(GPVUR[_L_X$2>'OAK?]L8O_GSE7_ACR3_YW^7Y]V<GU&A_/C/_  XYA_\
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M^+?[!W@6P\:V\UMI=Q=7%WX,N-?M=/MI]+N-1FM(=;T:2_\ M;]H.Q^'6J_
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M:67PQ>?L\W?[-'@W6/%'[.ND^)=:^&_P(^.'[/OA^W\0?%=3XQO?$?BW24^
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MJ^J?V4NJBP&HWHMQ<R^LT45DVVVWJVVV_-ZLV244HI644DEV25DM==NYSG[
M_P#R8K^Q9_V:9^SE_P"J>\&U]9U\F?L#_P#)BO[%G_9IG[.7_JGO!M?6=?J>
M>?\ (ZSC_L:9A_ZEUC\MP'^XX+_L$PW_ *9@%%%%>6=84444 %%%% !1110
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M5J5E<*\%Y8:C8W$]I>6LR/%<6\TD4BLCL#QW_#(GQ _Z/H_:S_\ "8_8C_\
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M)\0/^CZ/VL__  F/V(__ *#:C_53_JH,C_\  ,__ /G$'^LU'_H69I_YC/\
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M)\0/^CZ/VL__  F/V(__ *#:C_53_JH,C_\  ,__ /G$'^LU'_H69I_YC/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"J/+CCP/\  G_V&9C_ .K#%!1117E'8%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5\U_L9?\F??LH_\ 9M?P+_\ 57^%
MJ^E*^:_V,O\ DS[]E'_LVOX%_P#JK_"U>I1_Y$N8?]C3)_\ U$SPXY_\C#"_
M]@>._P#3^7'TI1117EG8%%%% !1110 4444 %?-?BG_D\'X%_P#9M?[5W_JT
M/V,J^E*^:_%/_)X/P+_[-K_:N_\ 5H?L95ZF3_[W6_[%>>?^J7,#CQW\"'_8
M9EW_ *L,*?2E%%%>6=@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU[4/&VA^&(=>^)GPQL?$5YK7A:TTO6]!U'Q)8VBZM!;7-M<>6=A]6+_P4/\
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M6D\5:!8_#SQM=VOCKPAJNJ>$)O#-@ ?I7IOQA\/Z[\8-4^#WAW3M7U^_\,^
M[#QSXV\7::EE)X+\'/XDU&"U\"^#M4U5[U)KWQKXVTJ'Q#XLL-$T2SU,Z#X3
M\/P:WXRG\.6WC?X;?\)EZU7X]I\)/VV?@[^U)\,-'^''BC5_%'PP\9:_\(?'
M_P :?&<'ACPC;^#/B)XQUJ__ &AG_;2\6_%<:Q=:GXZT*[?PRO[*?A']ESPO
MHWC34?\ A =%\->%O ?A>WUGX<> /B);R?L)0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 45^ WP9_X)]_\ !4[Q-\/=&UGXV_\ !4GXL_"WXCW4
MVJKK?@GPOX0\-?$31=*@M]5O+?2);7Q:OBCPX-1?4=)BLM1N(_[(MOL-Q=2V
M.Z?[/Y\G[#VOPP^(4'[.#?!V;XU^(;KXIM\'KSX>#]H5]$M5\4KXYN/",_A^
M#XMCPZ-2:S.N6FMRQ^*X](_M?[.]["MH=06-C<#W\TRC+LOJPI8?B3*\UE]9
M>'KO X?-/98>$7RRQ/ML1@*-'$T$T^66#J5Y5$N:G&47%OSL)C<3B8RG4RS%
MX2/LE4IK$5,)SU&U=4O9T\1.=*I9ZJM&FHNZDTTT>Y45^0G@+_@GU^VYX5\=
M>"_%'B3_ (*Q?&WQSX=\-^+/#FO:]X)U'X2>'[#3_&.BZ/K%GJ.J>%K^^B\>
MW4ME9>(;&WGTFZNX[6YDMX+N29()F01M]N?M8_!+XN?'KX=:+X/^#'[2GBW]
MEKQ1IOC73O$E_P#$'P9X9L?%6J:QH%GH7B/2[KP=/IU_K6A0PV&H:CK&E:W+
M>K=R2QW'AZU@6V=;EY8<\1EN64L7A,/1XBR_%8>NW]8QU+!9S3H8*ST=:E7R
MZEBJO-NOJM"O:VMBJ>*Q4Z-:I/+<11J4[>SP\Z^"E4KWWY)T\3.C"W_3VI3O
MT/I^BOSN_95_9#_:?^!7Q*OO&?QC_;_^)W[3_A2Y\)ZIH-O\.O&/P^TCPMI5
MEK5]J.C7EIXICU*Q\6:Y-)>Z;:Z=?Z?#:&S2.6+5YY&G0PJDEG]K']DG]IKX
M]?$71?&'P8_;W^)G[+7A?3?!6G>&[_X?>#/ &D^*M+UC7[/7?$>J77C&?4;_
M ,5Z%-#?ZAIVL:5HDMDMI)%';^'K6=;EVN7BA/[-RS^T5A/]8LO^I^Q]I_:O
MU+.?JJJ6O[!X?^SOK_/TYUA'2O\ \O+:A]:Q7U9UO[-Q'MN?E^J>WP7M7'_G
MY[3ZS]7Y?+VW/I\)^A%%?+'[)GP,^,/P$\"^(?"_QH_:<\8?M4>(M6\63Z]I
MGC;QGX7L?"FH:#HLNCZ1IT?A:VL;#6]=BN+*"^T^^U9;M[J*1I]6GA, 6%9)
M/C3XD_L ?MK^,OB+X^\8>%/^"K/QJ^'7A?Q7XU\5>)/#?P^TKX3:!J6E^!=
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MVL;#6]=BN+*"^T^^U9;M[J*1I]6GA, 6%9)/C3XD_L ?MK^,OB+X^\8>%/\
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M_P#HR:]'HKR_]:_^J?R/_P #S_\ ^?IZ7^K-'_H9YI_YC/\ YV_U=^5O./\
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MCKP7X7\2?\$G?C;X&\.^)/%GAS0=>\;:C\6_#]_I_@[1=8UBST[5/%-_8Q>
MK66]LO#UC<3ZM=6D=U;27$%I)"D\+.)%^W/VL?C;\7/@+\.M%\8?!C]FOQ;^
MU+XHU+QKIWAN_P#A]X,\36/A75-'T"\T+Q'JEUXQGU&_T7789K#3]1T?2M$E
MLEM(Y9+CQ#:SK<HML\4WT_15XC,LLJXO"8BCP[E^%P]!OZQ@:6-SFI0QMWHJ
MU6OF-7%4N79?5:]"]];DT\+BH4:U.>98BM4J6]GB)T,%&I0MOR0IX:%&=_\
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MQQC<L7'"T(XJ3<9-XA4HJL^:/NN]3F=X^Z^F@4445Y9UA1110 4444 %%%%
M!1534-0L-)L+W5-4O;33=,TVTN=0U'4=0N8;.PT^PLX7N;R]O;RY>.WM;2UM
MXY)[FYGDCA@AC>65T168>=>#/C?\%OB/J$ND_#SXO?"_QYJL,8EFTSP9X_\
M"GBC4(HBDL@DELM#U:^N8XRD$[AWC"E(96SB-R #U"BO(=!_:"^ OBK7%\,>
M&/C=\(?$?B5YS;)X>T'XE>#-8UQ[D7,=D;==)T_6KB_:<7DT-H8A;F3[3+'!
MM\UU0^I:CJ.GZ18W>J:M?V>EZ980275]J.HW4%E8V5M"I>6XN[NY>*WMH(E!
M:2::1(T4%F8 9H N45P/A#XK_"WXA?9?^$!^)7@#QQ]NMM5O++_A$/&/AWQ+
M]LM-"N-)M-;NK7^Q=1O?M%MH]WKVAVNJSP[XM/N-:TF&[:&34;-9KWB_XA^
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M4\337::,VBW]G=6MU9ZI]M^Q7-O<030SO'*C-LZ%KNB^*-$T;Q-X;U;3=?\
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MDFVG!*3Y6^2\ES2DW\/_ +0/[0?[2OBCPS^U'9^(K33_  #>_LW?MW_\$X/
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M]/BA_P!&9?M*?^%3^Q]_]%=7F_V/B_\ G]E7_A\R3_YX>?Y]F=7UZA_)C/\
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MS7_PO3XH?]&9?M*?^%3^Q]_]%=1_PO3XH?\ 1F7[2G_A4_L??_174?V/B_\
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M -FU_ O_ -5?X6H_X7I\4/\ HS+]I3_PJ?V/O_HKJ\K\/_$K5?V1OV8?V./
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M%OHK!;D:KKTUM-XE\2>)=9UCV>@ HHHH **** "BBB@ HHHH **** "BBB@
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MSNJWFJP:*-.AUS51_;&M)?ZL3>GG_%OP'\"^,/&UY\1;F\\?>'_&>I>#]+\
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M?B7\6/V8;OX=Z%>?L ZU_P %"/AYIW@;XLV?Q8\2>*_AMX0$$/BOP=KNER^
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MO_"K]H#QA\/CX>\43>!_VO?"7B7X1?%/PA\>E\9ZKI$_[)GP%^$_Q2TGQ/\
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M_P#Q,SXK_P#T"=>J44?ZSR_Z$N3_ /@6<_\ SX"^*_Z#\3_X+P/_ ,QGE?\
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M4XT_JF+BY)M2EG>;*#4:6&K-JHLU<)+V>*HRO!R4DYM749,^CO\ A*?VZO\
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MFHJ4I-*UY-ZOSZ-*-&E2HP;<:-.%*+DTY.-.*@G)I)-M)7:25]DM@HHHKG-
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MC.]\->*?&NG_  (NK-](E\0_V-K]G\:/BQ=ZQH6J-I'A)["#Q9+=VLNSK/\
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MY^./_)Z/[-/_ &:_^V9_ZM?]A.OT3(O^28E_U\XW_P#66RTY:VV*_P 63?\
MJRF>J4445^=G4%?GGI?[;MS/_P %![S]D?5?"L&E?#77OAYXBT[X7_$^[E2*
M7QQ^T9\)=/\ "'Q#^-/PRT6.+4+H:EINA?!_XN_#S7;'4'T[3!#XC\&?%O0S
M=:C=>';BWTW]!KE;E[:X6SE@@NV@E6UGN;>2[MH;DQL();BUBN;*6Y@CE*O+
M;QWEI)-&&C2Y@9A*GYN^+_V M=UGX)_L[>%O"GQ@\,>$?VB?@%\<=$_:*?\
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M*I_$=!48>Q<]%[[I\KEHM;Z+8****\8[@HHHH ^3/V^/^3%?VT_^S3/VC?\
MU3WC*LJM7]OC_DQ7]M/_ +-,_:-_]4]XRK*K^;_I-?\ (E\._P#L:<=_^HG
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MAZKC^C2Q5.-25/WFJ<HPJU-%3I3G!3A&I*4E9RC*#T4DO:4U)ISC>O\ %KX
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M&/1_PM#X\?\ 1A_[4/\ X6_[#_\ ]&/4_P"K&<?R9?\ ^'O)/_GB5_;V5_\
M/^M_X0X__P"9CWVBO O^%H?'C_HP_P#:A_\ "W_8?_\ HQZ/^%H?'C_HP_\
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M)?V@[[0/#.C>(-5^(4?B;2YM6\*>,+[P[IVBMX;O)?$MUJ8\3:?[S\3OVO\
M]GWX/>-XOASX]\::K8^,'N?AQ83Z7H?P]^)7C6+3=2^,.H^,M&^%&E:UJG@G
MPAXATC1-8^(^N^ ?$_A_P5I&K7]GJ7B/Q#;Z9H.F6MQJ_B3PU9ZOYCK/[/?C
MGQS^UAX$_;7^'WQ3T3PA;6O[*FO? 6Q^&?Q&^!'C"^U;[+X_^)?@WXJZEXJU
MBYN?BG\,]?T#5K8>"O#^@IX,U;PC;WVDR_VS/J=[)<W$-AIOS;\4_P#@G?\
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MM5BMH-2\(^._'6I6<FMZ_H>A>"/%_C9[ROB'/>;_ *&V;<M]N?ZWB.6_E?\
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MT6\T>3QVVLO?>)(];AU&PUVXUV\A\,R:#HEK9:%=LWB&]\0^R?\ #/7[9/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *^:_%/\ R>#\"_\ LVO]J[_U:'[&5?2E?-?BG_D\'X%_
M]FU_M7?^K0_8RKU,G_WNM_V*\\_]4N8''COX$/\ L,R[_P!6&%/I2BBBO+.P
M**** "BBB@ HHHH **** "BBB@ HHHH _+G]J/\ :D^'_P 7_@9_P5I_9Z\-
M:/XQL?&G[*_[*_CJR^(6IZ[I^B6WA?6)?B[^SS\2?%7AMO!M[8>(=3U;4(['
M3]%NH=<.MZ)X>:VO9+>.P34H'DN(OJZOE?P3^PMXGO/CM_P52U[XH:QIEO\
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M]'S_ +6?_A,_L2?_ $&U'_#(7C[_ */G_:S_ /"9_8D_^@VH_P!5/^J@R/\
M\ S_ /\ G$'+BO\ H"Q'_@S!_P#S5_5GY7]!HKS[_AD+Q]_T?/\ M9_^$S^Q
M)_\ 0;4?\,A>/O\ H^?]K/\ \)G]B3_Z#:C_ %4_ZJ#(_P#P#/\ _P"<0<N*
M_P"@+$?^#,'_ /-7]6?E?T&BO/O^&0O'W_1\_P"UG_X3/[$G_P!!M1_PR%X^
M_P"CY_VL_P#PF?V)/_H-J/\ 53_JH,C_ / ,_P#_ )Q!RXK_ * L1_X,P?\
M\U?U9^5_0:*\^_X9"\??]'S_ +6?_A,_L2?_ $&U'_#(7C[_ */G_:S_ /"9
M_8D_^@VH_P!5/^J@R/\ \ S_ /\ G$'+BO\ H"Q'_@S!_P#S5_5GY7/V0O\
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M7_\ H[*/]6)?]#K)_P#P'.?_ )SA;%?] &)_\&8'_P";#U2BO*_^%'?MH_\
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MX@Y<5_T!8C_P9@__ )J_JS\K^@T5Y]_PR%X^_P"CY_VL_P#PF?V)/_H-J/\
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MQ1_]&-1_PV;XS_Z,=_:S_P#"B_8H_P#HQJW:*/\ B9GBO_HC^ O_  GXP_\
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M2PKH?B36/#?A;Q7>:%J&I1-"TSW&F75E:SVS1S1JKP(65@"#^K%>">*OA/\
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M0LH=E9E0D;F5"H=@N<E5+H&(&%+J"06&?Q5_;:BT3XE_MQ> ? 'QQM],U/\
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MCS>&OA[\0_#6J"XTV>262!4U32KM(69SYT(CF& X ]FK\]O@I^SW\5OV6_\
M@A;\>O@I\:_#UOX6^(WA;]F+]M:ZUO1+76]$\106L'B+1_BWXATEEU;P]?ZG
MI-R;G2=3LKEEMKV5H&E,$XCGCDC3]":_B?Z6V'P.$7".%RRLL3EV&XE\1Z&
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MS/'?_(JPG_8SI?\ J'CCLOV]?^3?=+_[.:_8:_\ 6W/V>:DJ/]O7_DWW2_\
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M_;*G*GY57*Z>(A2<*]2I[!T:4(UH473Y,+5Y9PDEAXRE?EE=.\742:]QM/\
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M***\0[PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"'_89EW_ *L,*?2E%%%>6=@4444 %%%% !1110 4444 %%%% !1110 4444
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MDS_Q+WXP_P#T#-'_  BW[=7_ $1+]DS_ ,2]^,/_ - S1_Q+]XK_ /0@RO\
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M ZG:%7)ZG:H&>@ XI:^+/?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC^[I4XVC:/NWM=MLHHHKE-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQO4?+.+UC)6:>S1^@_\ P]A_X*1_]'9^(?\ PSO[,?\ \XVC_A[#_P %(_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>;^TI_X2W['W_P!"C1_PHOXH?]'F_M*?^$M^Q]_]"C1_9^$_Z'F5?^"<[_\
MG/\ U9^5SZS7_P"A=C/_  /+_P#YN/I2BOFO_A1?Q0_Z/-_:4_\ "6_8^_\
MH4:/^%%_%#_H\W]I3_PEOV/O_H4:/[/PG_0\RK_P3G?_ ,Y_ZL_*Y]9K_P#0
MNQG_ ('E_P#\W'TI17S7_P *+^*'_1YO[2G_ (2W['W_ -"C1_PHOXH?]'F_
MM*?^$M^Q]_\ 0HT?V?A/^AYE7_@G._\ YS_U9^5SZS7_ .A=C/\ P/+_ /YN
M/I2BOFO_ (47\4/^CS?VE/\ PEOV/O\ Z%&C_A1?Q0_Z/-_:4_\ "6_8^_\
MH4:/[/PG_0\RK_P3G?\ \Y_ZL_*Y]9K_ /0NQG_@>7__ #<?2E%?-?\ PHOX
MH?\ 1YO[2G_A+?L??_0HT?\ "B_BA_T>;^TI_P"$M^Q]_P#0HT?V?A/^AYE7
M_@G._P#YS_U9^5SZS7_Z%V,_\#R__P";CZ4HKYK_ .%%_%#_ */-_:4_\);]
MC[_Z%&C_ (47\4/^CS?VE/\ PEOV/O\ Z%&C^S\)_P!#S*O_  3G?_SG_JS\
MKGUFO_T+L9_X'E__ ,W'TI17S7_PHOXH?]'F_M*?^$M^Q]_]"C1_PHOXH?\
M1YO[2G_A+?L??_0HT?V?A/\ H>95_P""<[_^<_\ 5GY7/K-?_H78S_P/+_\
MYN/I2BOFO_A1?Q0_Z/-_:4_\);]C[_Z%&C_A1?Q0_P"CS?VE/_"6_8^_^A1H
M_L_"?]#S*O\ P3G?_P Y_P"K/RN?6:__ $+L9_X'E_\ \W'TI17S7_PHOXH?
M]'F_M*?^$M^Q]_\ 0HT?\*+^*'_1YO[2G_A+?L??_0HT?V?A/^AYE7_@G.__
M )S_ -6?E<^LU_\ H78S_P #R_\ ^;CZ4HKYK_X47\4/^CS?VE/_  EOV/O_
M *%&C_A1?Q0_Z/-_:4_\);]C[_Z%&C^S\)_T/,J_\$YW_P#.?^K/RN?6:_\
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MC_UIWX-5]/P3_P EGPC_ -E/D'_JUPAY.?\ _(BSK_L4YC_ZAUC^*BBBBO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2/:44SEQG"O#D*4)0R?!1;Q6!@VJ6O+4QN'ISCOM*$I1?DV?EM_Q#Z_LG_\
M1=OVM?\ PI_@)_\ 0[4?\0^O[)__ $7;]K7_ ,*?X"?_ $.U?N[17G_\1.X_
M_P"BKS?_ ,'K_P"0.K_5+AK_ *$N!_\ !7_!/PB_XA]?V3_^B[?M:_\ A3_
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MW2G4HPY92IN4)N#=W>+E"$O6*"BBBOFCU0HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]8\8^$=-U_\ X2RZUG2H;SQ1X9T/X8RM]J!U/Q#H_@[Q)JME)#!I\L'ZM_\
M#+?P_P#^BA?M9_\ B=W[;G_T0E4F_9)^%[:C%J[>,_VIFU:&RGTV'5&_;C_;
M5.HQ:=<SV]U<V$5Z?V@#<QV5Q<VEK<3VJ2B"6>VMY9(VDAC9?K>$_$+(^%)Y
MO.A+,\6\TRG%9?#ZSD&65/JF)JP<<-F%'VF?3_>X;GJQ]GI"K"K.-125K>)G
M/!6:9S'!1JRP-'ZGC:.)E[+,L;'V]*$DZN&J<N61]RKRQ?-\494XN+5V?I8!
M@ <\#'))/'J3DD^Y))[T5^<'_#+?P_\ ^BA?M9_^)W?MN?\ T0E'_#+?P_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "OCK]NS_ )(-H?\ V=#^PK_ZW!^S
MO7V+7QU^W9_R0;0_^SH?V%?_ %N#]G>O0RG_ )&N6?\ 8PP7_J32,<1_N]?_
M *\U?_2)':T445^7GZ<%%%% 'QO^T'^V1IGP"^,WP*^ Z? CXY?&'Q]^T78_
M$2[^&L/PJE^!EKI-U<?"K1(?$WC?3-7U+XN_&_X3KI-]I7AVYM=7ADFB?3=1
MAN8[/3M0NM4CN+""O:_MY_ 6_P#A3;_$W3KCQ3?:K=?&QOV8X/@^ND6-G\8)
M/VFK;6F\/ZK\!$\/:IK%AH$GCG0M0@O[S6]5C\4O\/+#PEI.K?$=O'#_  UL
M)_%Z^&?MK_ +XG_%']L#_@G[\3?#/PV^('CGX6?!N#]KFR^,&K?#+XH:!\+?
M&'A2'XL_"/P]X.\%3:/K-Q\5/A5XS\_4]:M[N-[SP-K$E_I5O:2W%Y+:)+;"
MX^'_ (:?L7?M:_"3P[\'?C!IGPJ\1^)]1_9L_P""C?QU^./PU_9X\1_$7X1:
MG\9/$/[)_P ??AYKGPZ\:7WCSQY:>)--^%WQ3_::L]?\5Z]\3?#OB/XF?%'6
MO$\>EW%_X:UCXRZYJ]U;X[(TJ$J=-N<8SY;R3J)<T^>M%0=Y/ENH4KMJ*BIN
M;DTTEPSJXB-6JE"4H*:4'[.348<F'E*:M%<_*YUK)2DYR@H**:;/V@^%7QYU
M3XC>-_%7P]\2_ ?XV?!/Q)X5\,>&O%K#XIV?PUNM"\1:1XGU#7=+MO\ A%/%
MOPH^)?Q1\):SJ&EWGAZ]3Q%HO]N6VN>'XKO0[O5=,MK+Q#HES??0=>:?#SQK
MXM\<1W6IZY\+?%7PNTA;'26T^Q\>ZCX0F\87^J7<,MSJ\-QHW@CQ)XQT;2M,
MT,-9Z;'>S^)I[[6M8_MK[-I5IH&F:+X@\6^EURRM=V2CHM%+F6RO9W>[UM=V
MVZ'9"_*KR<KMV<H\KM?2ZM'9=;*^]M0HHHJ2@KBOV$_^2#:Y_P!G0_MU?^MP
M?M$5VM<5^PG_ ,D&US_LZ']NK_UN#]HBOL.'?^15F_\ V,,E_P#4;/#Y7B+_
M 'C+_P#KSC__ $O 'V+1117H'@A1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %?'7[=G_)!M#_[.A_85_P#6X/V=Z^Q:
M^.OV[/\ D@VA_P#9T/["O_K<'[.]>AE/_(URS_L88+_U)I&.(_W>O_UYJ_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*/\ J?\ _F+_ /PB'^NW_4L_\O?_ +T/]&>BO\YC_AM_]M+_ *.]_:A_\/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
&*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ny20006478x8_graphic08c.jpg
<TEXT>
begin 644 ny20006478x8_graphic08c.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
M+0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0":
M )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0T!
M$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I
M ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F<"
M<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P-:
M V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$
M?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%
M!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'
M3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC[
M"1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*
M\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-
M#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/
M>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('
M$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4
M\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W
M&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;
M8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I
M'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J\B
MW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR;H
M)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K
M:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^
M,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U
M$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_.;PY^3HV
M.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_
MXD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:
M1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+
MXDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q
M4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9
M&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %
M8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUG
MDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>
M;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW
M5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$
M?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(
M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$_
MD:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:
MU9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16
MI,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVN
MH:\6KXNP +!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1
MN4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'# [,%GP>/"7\+;PUC#
MU,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZV
MSS?/N- YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':
M=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-
MYI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_R
MC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<
M_VW__V1E<V,         +DE%0R V,3DV-BTR+3$@1&5F875L="!21T(@0V]L
M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M#O#GQ:^-?PNT?4_&G[5OQ!\*>)=9_P"%+_%_QQ\(-0UW4O#6A_L?>.=+T/\
MMS5/ U[J]GIEKXNU_P"R6%[:Q3ZA+<+,J[__  N[]M+_ *-J_9>_\3-^*_\
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M (?<F_\ F\/98G_H#Q__ (08W_Y0?=-%?"W_  N[]M+_ *-J_9>_\3-^*_\
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M0 4444 %>!?%#_DO/[!__9T/C?\ ]8?_ &QZ]]KP+XH?\EY_8/\ ^SH?&_\
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M%% 'R]^V_P#\F6_M>_\ 9KWQ_P#_ %5'BVOTQK\SOVW_ /DRW]KW_LU[X_\
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M^2\_L'_]G0^-_P#UA_\ ;'KWVO OBA_R7G]@_P#[.A\;_P#K#_[8]?0<,?\
M(XA_V+\[_P#5)F)X^??\BNO_ -?L#_ZGX8_0VBBBOH#X\**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2E=77*I)R36M[JZM;79GU5:,I4:L8?'*G.,'>UI.+47?I9V=^FZ.T\1ZM:?
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M %CIF@:OXNM9/%GC:U\76UY;^+-*T*XFT#0-,L+BZ'BF^U.^\.:)K_2?"_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUQ;7>BZ)J6I0:='?ZGIUC<V5G.+>_N+A;J2RL6OOM1L++[/P%%-9=E\9JI'
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M/_Q!']MS_P"A[H_X:D^'_P#T3W]K/_Q!']MS_P"A[H_U8XE_Z)[//_#3C_\
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M $/=+_5CB7_HGL\_\-./_P#F<?\ ;>2_]#?*_P#POPG_ ,M\U]Y]'T5\X?\
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M,H3A*,X3BW&46I1;33/DS]OC_DQ7]M/_ +-,_:-_]4]XRKHZI?MLZ!KOBO\
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MY_\ 43(CCA_R,,5_V!X'_P!/YB%%%%>4=@4444 %%%% !1110 4444 %%%%
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M6B2^&[SQ#XX_X0?4(]&%YK-[HF@>)[73K"/5_A>V_P""D7QT^&WPW_X*(O\
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M3X=KX-_92^.NL_"'X[?M,7ME;WECXCT[X>:)I^B6SV?@R?5Y;JT^-/COX>?
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MB[1/#NA66K>#M:T?XSZ7IGB[7K*S\/>/]-C\)-J%E?>IGG_(ZSC_ +&F8?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_M_(O^AUE/\ X<<'_P#+CO?^"CO[3/P3^#'[/7Q<^&?Q+\7W/AGQG\:_@/\
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M&%/I2BBBO+.P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,<9_X!E__P PGS7_ ,+T^*'_ $9E^TI_X5/['W_T5U'_  O3XH?]&9?M*?\
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M#4JQ49YAC;*I2J*T,O7O4:L*T/\ F!V4Z<;KJKKJ?-?_  O3XH?]&9?M*?\
MA4_L??\ T5U'_"]/BA_T9E^TI_X5/['W_P!%=7TI16/]H83_ *$>5?\ @[._
M_GQ_5WY6T^K5_P#H8XS_ , R_P#^83YK_P"%Z?%#_HS+]I3_ ,*G]C[_ .BN
MH_X7I\4/^C,OVE/_  J?V/O_ **ZOI2BC^T,)_T(\J_\'9W_ //C^KORL?5J
M_P#T,<9_X!E__P PGS7_ ,+T^*'_ $9E^TI_X5/['W_T5U'_  O3XH?]&9?M
M*?\ A4_L??\ T5U?2E%']H83_H1Y5_X.SO\ ^?']7?E8^K5_^ACC/_ ,O_\
MF$^:_P#A>GQ0_P"C,OVE/_"I_8^_^BNH_P"%Z?%#_HS+]I3_ ,*G]C[_ .BN
MKZ4HH_M#"?\ 0CRK_P '9W_\^/ZN_*Q]6K_]#'&?^ 9?_P#,)\U_\+T^*'_1
MF7[2G_A4_L??_174?\+T^*'_ $9E^TI_X5/['W_T5U?2E%']H83_ *$>5?\
M@[.__GQ_5WY6/JU?_H8XS_P#+_\ YA/FO_A>GQ0_Z,R_:4_\*G]C[_Z*ZC_A
M>GQ0_P"C,OVE/_"I_8^_^BNKZ4HH_M#"?]"/*O\ P=G?_P ^/ZN_*Q]6K_\
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MZ,R_:4_\*G]C[_Z*ZC_A>GQ0_P"C,OVE/_"I_8^_^BNKZ4HH_M#"?]"/*O\
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MI3_PJ?V/O_HKJ^E**/[0PG_0CRK_ ,'9W_\ /C^KORL?5J__ $,<9_X!E_\
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MZR&06R!.+_9+^%'_  4(\!>.O$.I_M=?M4_#;X[^ [OPG/8>'?#/@SX3:#X
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MM*?^(9?M@_\ SBZ/^&KOA?\ ]"M^TI_XAE^V#_\ .+KZ4HH]MDG_ $+\U_\
M#QA/_G'Z_P!+4Y,P_P"@G!_^$-?_ .>)\U_\-7?"_P#Z%;]I3_Q#+]L'_P"<
M71_PU=\+_P#H5OVE/_$,OVP?_G%U]*44>VR3_H7YK_X>,)_\X_7^EJ<F8?\
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M3_YXGS7_ ,/>_P#@G;_T<+_YB;XX_P#SLZ/^'O?_  3M_P"CA?\ S$WQQ_\
MG9U]*?\ #&7['W_1J/[-?_AB_A?_ /,M7Y7?MY?#?X06WQP_9F_8N_9A^$G[
M.GP2_:&^/EUXS\:Z9\0M?_8^_9]^(OPV;P%\._ WCC7?$/AS7U\0Z/<:QHVL
M7UUH5K=Z5>:+X2U<226L5G=7MC;7ES)'Z&5X+PUS;%K"4<'QQ1M1Q.)K8C$9
MQD?U?#87!X>IBL5B:_U?AW$5O94:%*I.;I4:L[1T@];<V+K\68.BZU2OP].]
M2E2A3IX',/:5:M>K"C2I4_:9I3@YSJ3C&*E.*UW/KW_A[W_P3M_Z.%_\Q-\<
M?_G9T?\ #WO_ ()V_P#1PO\ YB;XX_\ SLZ\"_95_P"":OQ9\"_$J^UG]K"?
M]AWXX_#.7PGJEA8^#O!W[%?P/\":K;>+I]1T:;2]=DUK2_AII5S+966FVVM6
M<U@URT4\NHP3-"S6R,G1_M<?\$X?&OC_ ,1^$;S]D#3_ -B?X"^&]/T2^MO&
M&D>-?V./@G\0+K7]<EOQ+8ZE97FK?#C5Y-/M[:PS:R6T,D*2R'S61F&ZNEY=
MX3K,88#Z[Q)*E*G[1YHLZP/]G0?)*7LIM\'K&^TO'D]W!2ASRC[_ "N4HY+$
M\9O#2Q'L,I4U+E6$> Q/UF2NESQ2SMT.77FUKJ5HOW;V3]:_X>]_\$[?^CA?
M_,3?''_YV='_  ][_P""=O\ T<+_ .8F^./_ ,[.O-_V0O\ @G/XB^']WX]D
M_;$T/]BSX^V>JVWAQ/ $'@G]C[X*_#V3PO<V<NM-XDFU&32/AWHYU5-7BN=$
M2U2<W LSIT[1B(W+E_)_VC_^"9/Q]\8?%WQ'X@_9LU[]A/X0?!^\MM"3PUX!
M\4_L/_ KQEK>D7-KH6G6NO377B#4?AAJ5W>+J>O0ZCJ=NDEY(+6VNXK5!&D*
MQJZ>6^$T\QK8!X_B.G2I4HU8YG/.L%_9U>35%NC1<.#IXUU8^UDG[7!4J=Z%
M6U1KV;J$L3QI'#0Q"H93*<YN+PL<!B?K--)S7/-//%0Y'RIKEKRE:<+Q7O<O
MU!_P][_X)V_]'"_^8F^./_SLZ/\ A[W_ ,$[?^CA?_,3?''_ .=G53]D[_@G
MYH/@/X=:UI'[6_PZ_8^^.OQ'N?&NHZEHGB[P9^RG\'/ .EZ=X(FT+PY:Z;X<
MGT?2O 6DV]S?VFO6?B34Y=3>V>::WU>UM6G9+.../XU^*G_!+?\ :TUWXE>/
M-9^%'Q!_8#\#_#/5/%FNW_@'P=K'[!OP$UW5?"_A&ZU&XFT'0M1UJZ^%-W<Z
MK>Z9IKV]I<W\]S/+=2Q-,\LC.6)A\N\)J^,Q6$GCN(\-3PR3ACL1G6!^IXN[
MBK85T>#ZV);2;;]OAL/I%]6D%3$\9TZ%*LJ&4U95?BP]/ 8EUZ.C?[U3SN%)
M;6_=U:FK7G;[5_X>]_\ !.W_ *.%_P#,3?''_P"=G7KO@'_@H?\ L0?$G1[G
M7/#O[3_PBTZRM-3FTF6#Q]XGM_A3K#W4%K9WCRVWAWXHIX.\07NF-%?P)#K5
MGID^CW%TEY8V]_+>Z=J%O:\K\ OV$?A%X5^$7@WP_P#M _!']D_XI_&#3K;5
M$\:>/O#?[-/PD\)Z)XAN9]=U2ZTN:Q\/V'@K3[335LM!GTK3)DALX1/<V4UT
MP9YVD;\;/ ?_  3._;5\1>*OC5H^C_%W]A2UU'P%\3=*\)^*I];_ &&/@;K6
MFZEK]Y\&_A+XYM[WPAIM[\+;FV\(^'8_"_C/PWIUSX>TB'3]/N?%FG^*/%<M
MF^J^)]3O[XPN3>&.9+-H8?,L_P KEE?LYK%YGF6#Q.$QM&6,AA)5L+3P?#4,
M1[+FJ4Y*==4*B5:@GAY<U7V!5QW%N%>#E5PV68M8OFBZ.$PN(I5J$U0E64*L
MJ^:RI\]HS3C3]I%^SJ?O%:'M/WT_X;-_8^_Z.N_9K_\ #Z?"_P#^:FC_ (;-
M_8^_Z.N_9K_\/I\+_P#YJ:\6U?\ 8.^%=Q^SY<>$](^"_P"R98?M$/\ ">+0
M;?XKS?LS?".X\,P_%M?"T=C+XZ;PB_@E[!]&?Q6)=;70#IYM%LW%C]D\I?*K
M\V_#?_!*O]MFS\1:!>>)OBS_ ,$^=8\.6FM:5<^(-(M?V /@!976JZ)!?02Z
MKIUM>1_"6*2TN+ZP2XMH;F.2-X))5E1T9 P\G Y3P%C(8B53/<PP#H5)4XPQ
MLH*>*44G[7#?5<LQ473EJH^WE0G>W-"*U.ROC.(Z$J2C@,)B%4BI2E04W&DV
M[<M7VN*I/F6[]FJBLM&WH??/_#WO_@G;_P!'"_\ F)OCC_\ .SH_X>]_\$[?
M^CA?_,3?''_YV==%^T=^P7\-/&'PB\2>'_V;/@[^R5\(?C!>7.A/X:\?>*?V
M8_A#XRT31[:UUW3KK7H;KP]J/@C4K2\?5-!AU'2[=Y;.4VMQ=Q749CDA61?A
MGX+_ /!+W]J+PY\4_!&N?&SQM^P3\1?A3IFMQ7/CGP1H/["?P&\-ZQXDT-89
MEETW3]=L_A7976F7#S-#(MS!=0.JQLH<!B#Z>#P/A/BL%7Q=3%<3X&I1=51P
M&,SK+UC<1[.G"HG06&X1Q.&:K.3I4O:XJDW4A+VBIP<9OEK5^,Z->G1C2R>O
M&?)?$4<!BG0I\TW%^T=7.J55<B7//DI3]UKEYI7BOL3_ (>]_P#!.W_HX7_S
M$WQQ_P#G9T?\/>_^"=O_ $<+_P"8F^./_P [.N:_:Y_X)YKX_P##OA"S_9 \
M&?L;? 7Q'I^M7USXPU?QK^R5\&?B!:Z_HDMBL5AIUE9ZM\/]7CT^XMK\-<R7
M,,<+RQD1,[*-M>3_ +*O_!-7XL^!?B5?:S^UA/\ L._''X9R^$]4L+'P=X._
M8K^!_@35;;Q=/J.C3:7KLFM:7\--*N9;*RTVVUJSFL&N6BGEU&"9H6:V1D*6
M!\)ZF73Q\L5Q/2JQC4DLKJYUE_\ :,W"?*HP5/A&>"YJBO.GS8V*<+<[A)N*
M4\1QG'$K#JEE$X-Q7UN& Q7U:/,DVVY9U&O:%^65J#=T^525F_??^'O?_!.W
M_HX7_P Q-\<?_G9T?\/>_P#@G;_T<+_YB;XX_P#SLZ\4_:T_X)M_$?Q[XZ\/
M:G^R+%^Q%\"/ =IX3@L/$7AGQG^QE\$?'^HZMXN76-7N)]=MM4U7X;:M/9V4
MFC7&CZ>MA'/'$L]A/<"(/<.[]9^Q_P#\$ZM9^'W_  L/_AL;P[^Q=\?_ .U_
M^$2_X5S_ ,(1^R#\%OAY_P (E]@_X2;_ (2_^T_[(^'FC_VQ_;WVWPQ]B^T?
M:/[/_L:[\KR?MLOFD\!X3QRU9@L7Q-.LXPE_94,ZR_\ M).=6%)P:EPC' \U
M.,G6G_MW+[*$N64JEJ;%B.,WBOJWLLHC"\E]<> Q7U72#FG=9TZ]I-<D?]GO
MSM72C>2[_P#X>]_\$[?^CA?_ #$WQQ_^=G1_P][_ ."=O_1PO_F)OCC_ /.S
MKY?_ &C_ /@F3\??&'Q=\1^(/V;->_83^$'P?O+;0D\-> ?%/[#_ ,"O&6MZ
M1<VNA:=:Z]-=>(-1^&&I7=XNIZ]#J.IVZ27D@M;:[BM4$:0K&OTK^R=_P3\T
M'P'\.M:TC]K?X=?L??'7XCW/C74=2T3Q=X,_93^#G@'2].\$3:%X<M=-\.3Z
M/I7@+2;>YO[37K/Q)J<NIO;/--;ZO:VK3LEG''&8C >$]#+Z6.CB^)L35J1H
MREEN'SK+WF%%U8Q<H556X1HX/FH-N-;V>,J1YHOV<JD6I!3Q'&=3$SH.ED]*
M$'-+%5,!BOJT^1V3@X9U.M:IO#FHQ=OC47H6_P#A[W_P3M_Z.%_\Q-\<?_G9
MT?\ #WO_ ()V_P#1PO\ YB;XX_\ SLZ^(?B3_P $M/VO=9^(OC[5_AG\1_V
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M?VB/@G_P5(\7?&+QAXA_9S_;2^$GPE^#6H?\(_\ \(=\/O$_P0\,^+]<\/\
MV3PMHECXA^W>(M0\+ZC>:C_:OBJVUS6[;SKR;[)9ZE;V,?EQ6R1(Z>#X!J9C
M7P#CCJ5*C2C5CF=3C*/]G8B4E1;HT'#PRGC75C[:2E[7!4:=\/7Y:DE[)U25
M;B2.&IXA2PLYU)N#PL<AE]9I).:YZBEQ9&AR/D37)7G*U2%XI\ZAJ_\ #WO_
M ()V_P#1PO\ YB;XX_\ SLZ/^'O?_!.W_HX7_P Q-\<?_G9U])?LJ^#/VF_
MOPUOM&_:P^,?A3XX_$R7Q9JE_8^,?!W@O3? FE6WA&?3M&ATO0I-%TO3-*MI
M;VRU*WUJ[FOS;-+/%J$$+2NMLBI\->/?V?\ _@L/JOCKQIJG@#]OOX)>%O >
MI>+/$=_X)\,ZC^SWX2U74/#GA&\UB\N/#>A7^J7'A"XGU*]TC1I++3[J_FGG
MEO)[>2XDFD>1G8PV#X!Q&+Q>%G''X6&&:4,;B>,HK"8R[M?".AX95\0TE[S^
ML8?#NVR;T"K6XDIT:-6,L+6E53<J%+(9>VH:7M653BRG33>W[NI45T];:GJ?
M_#WO_@G;_P!'"_\ F)OCC_\ .SH_X>]_\$[?^CA?_,3?''_YV=?:'PBT'XM^
M'_A!X2\/_&#QUHWC[XQ6'AQK/Q=X_P!%T"U\/Z)KWB0M<E=7LO#UI:6=II]J
M%>V!LX;.&,^2Y\OYSG\L/^&;_P#@MK_TD8^ W_B-?@W_ .8JE@<)P#C*N+IU
M(8_+XX6JJ<*N.XR@J6-3E4C[7"?5?#/%U'22IJ;^L4\//EJT[0<N>,"O6XDH
MPHSC/"XAU8N4H4,BFYT&E!\E;VO%E&*D^9I>RE5C>$_>MRN7O_\ P][_ ."=
MO_1PO_F)OCC_ /.SH_X>]_\ !.W_ *.%_P#,3?''_P"=G7U]\1/#?QNU?X$Z
MQX7^'/Q&T'PE\>KCP5I^FZ/\3M3\-66L>'=/\;PV]BFH^(Y_"UQ97-C<6%W<
MQ7TT6F/8/#"MS&BP*(E"_G=X"_9__P""P^E>.O!>J>/_ -OOX)>*? >F^+/#
ME_XV\,Z=^SWX2TK4/$?A&SUBSN/$FA6&J6_A"WGTV]U?1H[W3[6_AG@ELY[B
M.XCFC>-76<%A> L91Q%:I3S' 2H3G"-#&\94U7Q*A!253#K"^&F*I.$V^2'M
MJM&7.GS1C&TFZ]7B.C4IPC4PF(52,6ZE#(IN%)N5G&I[7BNE+FC\4O9PJ*VS
M;T/4_P#A[W_P3M_Z.%_\Q-\<?_G9U]*?\-7?"_\ Z%;]I3_Q#+]L'_YQ=>/?
M\%+O#WQD\0_L<_&)?@W\0-#^'\NB^#/&_B'XG/KGAVT\1#QE\&]*^'?C.3Q_
M\/\ 25N[.\&BZYXILWM+?3O$5L+:[TIX'D@O+=I"Q\W_ &=_@G_P5(\(_&+P
M?XA_:,_;2^$GQ:^#6G_\)!_PF/P^\,?!#PSX0USQ!]K\+:W8^'OL/B+3_"^G
M7FG?V5XJN=#UNY\F\A^UV>FW%C)YD5R\3Q/+.$,1DU/-L-/%9=4]KF5*66YG
MQ(L5C,3+!4,'6IPPDL'P/2PT:M;ZS*"AB*T*=Y46ZT$ZBA4<5G=+'2P594,5
M'DPLUBL)E3HT:2Q%2O3DZRK\03JN$/9*3E3@Y64TH2:CS?5/_#5WPO\ ^A6_
M:4_\0R_;!_\ G%T?\-7?"_\ Z%;]I3_Q#+]L'_YQ=<1^U[\.OVT?B!9^ X_V
M._VAO OP"O-+N?$;^/KCQM\.-'^(2>*+:\BT5?#<.G1ZMHVL+I3:1+;:V]T\
M"P&\&HVZR&06R!."_9.^$O\ P41\!_$76M7_ &M_VK_AG\=?AQ<^"M1TW1/"
M/@SX1Z!X!U33O&\VN^'+K3?$<^L:5X>TFXN;"TT&S\2:9+ICW+PS7&KVMTT#
M/9QR1^;3P'#L\M>8/%PIUE&I+^RIYU7_ +2DX5'34$H<(3P/-52]K3OCE'V<
MH\\H33@NJ6(S2.*6'5)R@W%?6XX"'U5<T5)MMYU&O:+?+*U!OF3LG'WG[I_P
MU=\+_P#H5OVE/_$,OVP?_G%T?\-7?"__ *%;]I3_ ,0R_;!_^<77A?[6/PE_
MX*(^//B+HNK_ +)'[5_PS^!7PXMO!6G:;K?A'QG\(] \?:IJ/C>'7?$=UJ7B
M.#6-5\/:M<6UA=Z#>>&],BTQ+E(8;C2+JZ6!7O))).]_9"^'7[:/P_L_'D?[
M8G[0W@7X^WFJ7/AQ_ -QX)^'&C_#U/"]M9Q:TOB2'48])T;1UU5M7EN=$>U>
M=9S9C3KA8S&+EPY4P'#L,MCF"Q<*E9QIR>54\ZK_ -I1<ZD8.#4^$8X'FIJ3
MJSMCG%4XRY93FE"1'$9I+%/#NDXP3DOK<L!#ZJ^6+DFG'.I5[2:Y8WH)\S7,
MHQO)=O\ \-7?"_\ Z%;]I3_Q#+]L'_YQ='_#5WPO_P"A6_:4_P#$,OVP?_G%
MU\K?M$?!/_@J1XN^,7C#Q#^SG^VE\)/A+\&M0_X1_P#X0[X?>)_@AX9\7ZYX
M?^R>%M$L?$/V[Q%J'A?4;S4?[5\56VN:W;>=>3?9+/4K>QC\N*V2)/KG]F+P
ME^T3X*^%EIH?[47Q8\,_&CXK1ZWK-S=^-_"7A'3_  1H\^AW$T;:-IJ:%IFG
M:7:QW&GPK+'/<BU#W+.&=W*@A8G \.X? 4,;#%1Q=6LJ+EEV%SJL\?A_:T_:
M2C75?A&AA$Z#O2K>RQ=9*HU[)U8>^W2KYG5Q%2A*E[&,'-+$U<!!8>KR2Y4Z
M;IYU4K6J+WX<]&#Y?C4)>Z9__#5WPO\ ^A6_:4_\0R_;!_\ G%T?\-7?"_\
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MWWP0@LM.TS3K*">\O[^\GAM;2UAEN+B6.*-W'S1^SO\ !/\ X*D>$?C%X/\
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M-6G3C@,;B%-1;K4%A72IN4G%QJ.KBJ4[Q2YI<E.:Y6N5R=XK[&_8J_:K\/\
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M?A%\,]8T>UFT[76^%7B9O$.KZY\4K'XDZE-]CT %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'S7^V;_R9]^U=_V;7\=/_57^*:^E*^:_VS?^3/OVKO\
MLVOXZ?\ JK_%-?2E>K6_Y$>7?]C7.?\ U$R(XX?\C#%?]@>!_P#3^8A1117E
M'8%%%% !1110 4444 %%%% !7Y:_'K]F;XR>./\ @J7^PI^TSX:\,VU]\&_@
MG\/?CEH'Q'\32>(- L[G1-4\:_#[X@:#X=MX/#]YJ4&OZLM[JFO:9;O-I.FW
ML-HL[37<D,,,TD?ZE5\)_%?]LN\^&G[=G[*_[&D7P^MM8L_VD/"'Q1\4W/Q!
MD\2RV-SX1?X<^$/%WBB.R@\-+H=U%K2ZLWAA;)[B37-+-DMZTZPW1@$,ON9!
M4S*GB<<\KHT:]:61Y]3Q,:S2C#+:F4XN&9UH7K4;UJ&!E7JT4I3;J0BE1K-J
ME+S\QCA94L.L74G3@LPR^5)P3;EBHXRC+"TW:$_<J8A4X3;44H-MSA\2^[**
M**\,] **** "BBB@ KYK^!?_ "5#]LW_ +.4\+?^L>_LHU]*5\U_ O\ Y*A^
MV;_V<IX6_P#6/?V4:]7+O]TSW_L54?\ U>9,<>*_CY=_V&3_ /5?CAOA7]KG
MX%>+-._:0UR/Q1J'ACPY^R;XEU/PK\=/$7Q"\,^(OAWIG@V_T/X<^'/BMK=]
M<+XTTW1-1ET#2_!'BK1]9D\0C3TT:^M)S=Z1>:C8>5>2Y'P]_;2^ /Q \(?$
M?QK)XFU'X>:5\)/ VD?%?XAVGQ9T+4/AUK/A?X/^)]"UGQ5X,^+FJ:7XACM[
MFV^'WC'PMX?US6=(UB4)/87&A^(_"OBBQ\/>.O"?BSPKH?Y<>-/@'\3_ (_?
M";_@OE\$O#/@[XJ^%O%W[0_CWQ/=_ _4-?\  _C7X;Z#\3YK3]BK]GWP%H]O
MX9\;^-M T+PGKGA7Q-\3/ ^L_#_6[_3M8N;*?2!K%UYQTF2.^D\[^.O[,OQ1
M_;YUC]O'XU?##PA\6/AE8?$S_@D!X _9!^&GA'Q?X9\0?!B[\<?'K4O$'Q9^
M/.K^$)O#_C^RT"]BTKP>/$?PY^$7B3Q'>V[>'K*\\7?$;P3;ZW+J?A?Q;::5
MY1V'ZJV7_!0[]FV[\+7&NW&J^+M#\0R>(/@UX9\-_"SQ1X0U'PM\5_'&I?M(
M:G+I?[.K^$?!NOMI\][IGQHE@O9O#>L:A=:7I?A>+1/&<7Q1N_A_??#CXDV?
MA'U/0_VK?@[XQ\/?LZ>)_A]JVK?$#3?VJ%M-0^#T/AS1+RVU;4_"1\,3>,=>
M\>^(]$\3CP[JW@OP?X*T&.#_ (3.^\4V>E:AHGB75_#/P^;2Y_B+XN\*^$M9
M_++1_@7X2_:O_; \=_MQ?$KP?\4?A%\$OA=^Q/\ LA^'/"USXO\  GB7X8^(
M/#_QW^#GQI\=_M=:QXPT#P=XV\-_VO<7WP%L[OP+X+U*_F\-ZYX;U*\U_P")
M?PGF.OC3O'?AZW\N^(<7[2_[(WP=^$GQ;^ GPMUGPGK/B'X1_$CP)\&OASK/
M@W6_BSXM^#WPO^!_P+UWQE^QG^Q1K&B75QJFMV/C[]JKXB:';ZY^TS\1_M=[
MXZU?XHR:/\$+7XA:]=^&_@GXKTH _HNHJ*%IFAB:XC2&=HHVFBCE,\<4Q0&2
M..9HH6F1'+*LIAB,B@.8HR=HEH **** "BBB@ HHHH **** /D>X\0S>$OVF
M/VE/$\'A[6_%<F@?LJ_LO:L/#GAR70(==UA;'XE?MH7$EEI4GBG7?#/AU;R2
M-',1U?7])LB5Q)>19&?.=/\ V_?"&N_LV_LB?'7PW\/?%.K>*OVXF^'6E_ #
MX0M?6%MJ]_XG^(_@'6?B?;V7C+Q1''=Z-X6\/>#? 7AOQ+XL\>^)XX-7&F:1
MX?U&+P]I/BG7;C1=#U?T#4AJ#?M&?M1II.CWWB#5)/V1?V;8M.T/3)])MM0U
M>^E\>_MKQVNG65QKVIZ-HL%S>3LD$,VJZOINGQNX>[OK:$/*OYY_"O\ 97^/
MG@/]E/\ X(\>(]5^#&NP?'3_ ()[:M\/-#^*?PL_X2WX<ZCXAO\ P'XI_9M\
M:_LT?&*?P7J.B>-M9^'?B"[\.7?CK0_B)91W?BO3]4U+PQX&\0:=H,?_  D^
MJZ/I&I^KG/\ O='_ +%61?\ JCRXX\#_  )_]AF8_P#JPQ1]4VW_  4H^'7B
M^T^&NB_"#X:^/OBA\7_'UU^T)!K'P7L[GPOH/BCX;-^R5XDLO!_[1NF>.M<U
M#69O"%AXD\(^,M3T3P)X.TNTUN\TSXB>+_%G@^?3=?TWX>:IJ?Q$T'-^&W_!
M53]G3XR_%/X5> _A-9^+_'7A/XIV7P1BL_B=IVGP66AZ+XF_:+^%/QK^-/PL
MT"_T34Y[37[F%/ _P \<V_Q$U2QM9CX!\8Z[X \+3:?K#S_$W4/A1\4?L_\
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M1Z_?:'JOQ%^$^F^/?QC_ &7?@/\ $C]DS]HS0OVW/B#\./CMKOP[_:-\6_\
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M^'Q+I^E0Z-;:Q/X$;Q[)>RL+2%99;!?',<;WA\T3I;_Z(?C/2?\ @GUK6A_
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M[,S+_H78[_PDQ'_RL[?[0P'_ $'8/_PIH_\ R?FOO/LBBOC?_AN_X"?] /\
M:B_\03_;B_\ H=J/^&[_ ("?] /]J+_Q!/\ ;B_^AVH_LS,O^A=CO_"3$?\
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MJ*EF"YFKK17>J/<?^&]?V??^@7^TU_X@U^VY_P#0\T?\-Z_L^_\ 0+_::_\
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MZ(M^'^-2;>?X1)*[;R6JDDMVW_;>BW]/EKTO_#?'["O_ $>G^R9_XD;\'O\
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MW717PI_PN[]M7_HVC]ES_P 3/^+'_P! A1_PN[]M7_HVC]ES_P 3/^+'_P!
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M$'_8MPO_ *OLF%F'_,)_V%/_ -1,4>TT445^>G.%%%% !1110 4444 %%%%
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M %AW]C>O?*\#^&'_ "7O]O+_ +.B\#_^L._L;U[Y7SO$O_(VG_V Y/\ ^J;
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MP\1?\B?)_P#L99Y_ZBY >UPW_ON9_P#8+E?_ *>S0****^-/K@HHHH ****
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M%L\&CWWBV_\ #?A[Q3KHT33;J1-0O;+2]$N;O5([7^RX[C3?MAU.S_,[Q?\
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MEJ-*UW2M:T?5M(N[W3-5L+NX_ WQW^Q-\>OV5_V)?#DWQ:TCX'>*?!O[,O\
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M"7^NP/8ZMIVO:$T>DZI+K]I<:WI4=MI?B'4=,\RP3Q7;:5J4-O:?HC;?L]_
M6S!6V^"GPHB!U?3-?X^'OA-L:[HEG_9^C:RI?26*:II5CNM=.OT*W5E"\J6T
ML8EEWSV_P$^!MH+(6_P<^%L?]F7.M7FFG_A ?"SOIUUXDC2'Q!/8/)I3/92:
MU!'%;:H;9HOMMM##;7'F011QKTOBO(EE<,L66591ITJT:=66#P"<:];)<SP$
MJT(>TDZ<7F./HYC.C3J1A4>%]G.ZJNV?]FXQXAXAUXIRE%RBJM;6,,7AJRBY
M<JYG["A.@I2C>/M.9?"CX!^&G[6G[0=WX \,^/O%4OPQ\4/\0?V2?C?\?/#G
MAS3O#.I>"X?#_BSX37OA.+3]'U?Q)J/CC5K75- UR/Q+.+^>2T\.OIL=K:C[
M=B.\OKKZG_9[\9?'GQQXK\;ZC\0+>WLOA9:>'OA[+X"DU;X9^(OAYXUUOQ+X
MF\*Z9XE\:+J5AK^LM)9:1X-U"\/AZR@CT6Y-W-<R6-SXANM5\+ZO-J?0?$+]
MEOX3^*_AYXE\%>#_  9X ^&&JZOX&\0^ -$\7^%OAMX-34O"WA[Q1!-;:YH^
MFP)IMDT?A_7+:YN['7M'T^]TIM0L+Z]6VO\ 3M0D@U*VQO@!^S59?!K7_$?B
MR:R^$>DZSKVE6VA_V=\#_A;J?P<\(O90WTE_-?ZYX9E^(/CBPUW7YIA:QV&I
MJFF#0;!+S3--@,.I:A-<Y9EFG"V-RO-*V#PN%R_,*]2M3PV$>51E55&6/I8C
M#RH5:$HX/".C@O\ 8774G6JQIXJK7I3KU\-5A5##YC2Q&&A5J5*]"$82J55B
M6H\ZH2A44XR_>U5*M^^4&N6+E3C"<80J1?U37$_L]?\ )Y/[3/\ V;+^QK_Z
MM/\ ;HKMJXG]GK_D\G]IG_LV7]C7_P!6G^W17W7T=O\ DMLT_P"R6QO_ *ML
MD/&X[_Y%6$_[&=+_ -0\<??U%%%?V:?E@4444 %%%% 'COQ;^ /PD^.EU\+K
MWXJ>$_\ A*;GX+_%/PM\:OAI)_;WB;1/^$:^)O@J2>7PSXEV>'-9TB/6/[,D
MN9V_L;7TU7P_>[\:AI5VJH%]BK\?_P#@K)>7=IXF_P""8(M;JXMA=?\ !47]
MERVN1;SRPBXMI=0UT26\XC91+!(  \4FZ-\?,IK]@*]C&X2O1RG),54QE6M1
MQD<Q>'PD^?V>"6'Q?LJJI<U24/\ :)_O9\E.E[WQ<[]XX</6ISQF/I1H0IU*
M#PRJ5ER\U?VE'G@YVBG^ZC[D>:4]-N5:'YF?L._\F5?L?_\ 9KG[/_\ ZJ?P
ME7U'7RY^P[_R95^Q_P#]FN?L_P#_ *J?PE7U'7Y[G_\ R/<Z_P"QMF/_ *F5
MC]'RK_D5Y;_V 8/_ -1Z85\Q?%K]ES0/B_\ '7]G3X]ZM\2OBAX;U[]F/6?&
M7B#P%X2\*R?#F/P3JVK^/_!FN_#SQ3>>+X/$GPX\2>*M1:_\&^(M3T2*'2/%
MFA6]@DD>H6$-MJR&_;Q#P9\=/C!^TK^T;^U=\*OA?XDTCX2_"_\ 9/\ $/@#
MX:#Q['X5T_Q[KWQ1^-FO^";7XA^+]+N1K%_;Z'H/P]^'FE^(?"'AWQ!X<TVQ
M7QUXDUJ^U.YL?'G@6WLK6'4?E&P_;E^-/[,W[4?Q&\$?MP>,;F[^'7@+]CW2
M?C9XD_X5)\%=8\4>'?#][>_M1_M#> S\6;L> -!\:^,_"/P]N_@Y\-?!_BF[
MT[QAXGU2U\$)J4N@:SK&O>+HFU'5.&%&JG+D<>=03Y%>4W"K!:)*+3YH32:O
M>-[.ST-JE>DU'GC)TW4:51V5-3I3W;YDTHSC=-K7E<HWC9O]#OCW^RII_P <
MOB3\'_BQ:?%[XL?"+QG\'O#GQ=\$Z?>?#.7X?O:>*? _QOMO T?COPUXIT_X
M@> ?'5I/#)=_#?PAJ6C:AI<>EZCH]]I\MS!.]Q):SV7F?[,O_!/SP-^R_P"-
M_!7C[P]\9/C?X]U;P)^R[\-/V0]$TSX@W/PFFT&/X/\ PDU?7=<\#63P^$/A
M+X0UR36='O\ Q)JBKJLWB":6ZLFM;._6\2UC8^MW/[8/P)M?B_H/P2;Q!KTO
MC'Q'\2M:^#.F7MOX(\8S^#G^+6@_";2/CI>_#Z7QFFBGP['KDGPFUJV\865U
M]N;0+V*TUC0H-9?Q3HFK:%9_D1=_MY_M,:+I\^K:Y\5]#LM+TG_@N^_[#^NZ
MC>>"_ ^G6-K^S'I<&EW-]H4MW<:88-,G^SZ5JD^J^+[M[CQ%##K6I26NN:<E
MEI1TZJ<,1.'(GRPY593CR\T)2DTXOE;<>9RUO:[T\HJSPU.?M&N>?,[N$N;E
MG&--/F3FHQER\G2[25S[4^&/_!++X;_"A?@4GA?]H']H^*W_ &:_!'QN^&_P
M9L+B^^"5]I_A+P5\=K#PGI7B;2!%JGP0U&YU)])LO _AJ30KG4;RXV:G;7^I
MZG#J4^LZFMQ:^&G_  2[^&_P:O/ <GPM^/W[2G@[3?#_ ,%_AA^SW\2M$L->
M^%$NG_M ?"7X.RZZGP_T/XHF;X0&YTG7=%T/Q%JG@T>.?A)/\,?&9\(WU_:V
M^MVNO7C^(T[ZT_X*7?LE3^'?B'XGN?%WC'3;'X:_!!/VF-8L;SX5_$>;Q#JW
M[.\^LWVAVWQF\,^&=+\-:CK^L>"C>6$MSJ\BZ=!K7@[1I[+Q#X[T?PMH5]::
MC+=\*?\ !1[]ECQ7X;^('B<>(/B'X6MOAOI_P:U;7-)\>?!;XM^"?$^K:7^T
M)XBNO!WP4U+P1X8\1>#;#7/B!IOQ)\965YX5\+:CX,LM;L=1U>!?+N!I]W87
MUT.6+UNJK3:4KT[IN4N9)^[9MSJ*26_/)27O68*."3C:5)-)N/[S5*,4FU[U
MTE"DHO9<D'%^[='K?[-7[,_AO]F'0_B3H7ACQS\0_',7Q2^,_P 3?COXCO?B
M)+X&FOK?QW\7/$U[XO\ &QTG_A!O O@2RMM&O==O[BZL].NK*];3XREM:W*6
MZB.OI"O@K0/^"D7[,WBB;Q3I6A7/Q+O?%WA#XRZG^SYJ_@>3X4^-K#Q'+\8_
M#>CZAXD\;^"M'GU/2[/PUKLWP]\-:9<>(?'&NZ1XAO/"VA:5=^'99-<FF\9^
M"X/$.3X"_P""H'[)WQ:\=?#WX>_!_4?C!\6->^)7AGP/XWT*Z\!?L\_'#5_#
MFF^"/'OC.]\ :?XT\6>)YO =GH7A3PIH/BW2/$.@^.->UN_M-.\#ZYX6\5>'
M?$T^F^)?#FK:-:YRI5Y.4I4ZC>CD^1Z)[-V5DGT;LG9]F:PK8>,8PA5II;1C
MSIMV=K)-W;5U=:M75[71^A=%%%8FY\L_L/?M,?#G0?V*_P!D#0K[PW^T%/>Z
M+^RY^S_I-Y/HO[)?[5/B31YKK3OA/X2L[B72?$7AWX,ZIX?U[3))87>PUK0]
M3U'1]4M3%?:9?W=E/!<2?47_  U=\+_^A6_:4_\ $,OVP?\ YQ=<]^P)_P F
M)?L5?]FE?LX_^J=\&U]:U^RYO5R99MFBE@,S<EF.-YG'-\+&+E]9J<SC%Y)-
MQ3=VHN4FDTG*5FW^18*&/^IX2V)PB7U:A9/!5FTO90LFUF"3:6[25][+8_.G
MX_7_ .RG^TS:^"+3XL>$?VWG7X<>)V\:>#+GX;?"G_@IO\"M3T;Q7_9]QI4.
MO#5_@7X3^'&JZAJ-CIUY?6NESZK>WQTB/4=2_LL6C:C?-<0Z3/\ LD:/\-?#
M_P )4\ ?MAZWX,\.?$[PE\8X!XY^ W_!17XE^+=9^(W@7XD:/\6_"7B3QC\1
M_B1\/?%GQ&\<W&A?$#P[X=UNP@\8>*];M((/#V@Z%' OAW2-/TFW_1RBO/\
M;9)_T+\U_P##QA/_ )Q^O]+7IY,P_P"@G!_^$-?_ .>)^?7C_P 1_LM_%+4O
MB1>?$#P-^UUXHTSXN?!34_V>_B#X+U#]G/\ X* )\.=?^&&MRZ^^LZ>?AU:?
M#"V\&:9XCU6W\3:QIE]X]T?1=/\ '4VC7$.D'Q$-/L[2WA=X6\6_LY>"-$\4
MZ;X2T#]LG2=:\6> /#OPSO?B#>_LV?MU>+/B59>$/!6F>(=,\!V&G>-O''P=
M\3ZRLO@C_A*_$>K:#=7TU]-+XGUW7?%FN-K/B7Q#K^JZI^@=%'MLD_Z%^:_^
M'C"?_./U_I:G)F'_ $$X/_PAK_\ SQ/RL^*'@']AGXM?"[X:?!KQ'\'_ -IS
M3OAW\)_"FO?#OPCHGA?]D[]M?P_/'\+O&'PZU+X3>/?A?J.M6?P3_MN_\$^/
MOA]JD^A>+;*345U+4+FVTCQ+;ZK9>+="T37M/]B^/G[:_AGP)\$?BMXR\!^&
M?C=#XR\)^ /%'B#PJWC+]D;]JG0?" US1](N;W3$\3:SX@^$?AW0])T![J"*
M/5=0U37M$L;.Q:::?5=/1#=1?>-<!\5OAQH7QA^&?CWX5>*+G5+3PY\1?"6N
M^#=<NM$N+6UUBWTKQ#IUQIE]+IES>V6HVD%\EO<R-;2W-A>0QRA6DMI5!0]6
M Q/#M+'8*IBLMS.6&IXO#3Q,9YIA:T94(5H2K1E262P=6+IJ:=-3@YI\JE&]
MS'$TLTGAZ\*.*PBK2HU8TFL'6@U4E"2@U-X^2@U)IJ3C+E>O*[6/Y\O$7_!8
M;X;_ +2_[&W[5GPD^)/@?7/AQ\8_$G[*?[0NDZ.WARQU3QAX"\4ZK)\&_%<9
M-I<V%M<^(/"'G2M=7<T7B*SN_#VAZ7:R76J>.&5'9?V\KY<^/_[+GP%_9C_X
M)Y?MK^'O@G\-M \&1W/[(G[14.K:W##)J/BSQ#Y7P@\:3*WB'Q9JDEYX@UA$
MGDEFMK.[U!].TYI7BTNSLK;; OU'7/XFXSAG'++:_"F58W*,KEF6><F&QN+6
M)G*?U?(6ZE.G:<L)"2:7U>6,QO*TY1K1BU2AZW 5#-L/_:%/.<9A\;C%A<KO
M5P]%TDH^TS1<DY7BJ\D[OVJH8>Z=G3;3G(HHHK\H/T0*^*OVR/VD_&/P/N?V
M<?AK\*M%T#6_C!^U-\?_  W\$_!L_BB&]U/0/ ^@+HNO>-_B9\4]:\,Z3JFA
M:OXML/ ?@3PMJUQ#X>L/$'AU;_7-2T1+_7M-TT7<C_:M?''[9W[)UQ^U5X7^
M$K^&/B5=_![XL_ #XY^ _P!H+X._$6+PVOC/2=*\:>"O[2TZZT;QCX-&O>$[
MGQ;X)\6>%M>U_P /Z_H5EXM\,W,QO+*]_M.2"QFTW4-*7)[2/M+*-W=M-I.S
MY7)*[<5*SDDFVDTDVS.MS^SE[._/I9)I-KF7,HN7NJ3C=1;LE)IMHX_XIV7[
M7OPYTOXKZM9?&G2?$'P\T7]F_P"+'C+POXVG^'/@C3?'G@WXT^#[GPKK_AC3
M_%6G*9O#7C[P7XGT=?%MI:6^A>$_!-[X;T;1]2T[7-<UWQ+KWAGQ9H7XN^)O
M^"J?[6%K^S!<>-? /Q:^&?Q9\8:=_P $XO G[:OCSQYX)^'.A'3/@/\ %_6=
M:\%V=Y\!?BH(]2U_P1K,7BRU\;ZO!H/A33)/!GQ?\(-\/AX@\0VFJ^'M7N)F
M_>;Q'\(?VB?B!\/OBEX:\:_'#X<6>O>//A9J/PW\-IX2^"_B.W\ ^$;WQ+IY
MT_Q=XSUWPYJ_QGOO$GCO6+Q<_P#"*6<7C3P9IWA&QEFTZZB\57,U[K&H>%^.
M?V"?%WC;_@F=H_\ P3NE^-_AW3YM/^ W@;]GR]^,B_!_4KF.\\(^ O#^D>&M
M,U6U^'1^+UNUAXBNK#P_I$E[<3>/-0TUKH:C)#ID,5Y;0:?TT:E"/*JL:4_W
MM.[Y&K0WE*7[J\E'1.$;<S6JDF^;DK4L1/F=&5:G^YJ.*=1-NIIR05ZEHMZO
MFES<J;2<7RJ/WI\.8]>C\ ^#1XH\0R^+/$<GAK1I]<\23:9INC-K.JW-A!<7
MM\FDZ1#!IVFP2W$K_9K*V1UMK<1123W4JR7,O9USGA#2M7T/POX?T77M3T[6
MM7TG2;+3K[5=(T>Y\/Z;?S6<"6XN;31;S6_$EUIT<D<:$VTVNZFRON/VEE8*
MO1UQ/=_IHONT.Z/PJ][V5[N[VZN[N^[N[]V%%%% PKFOV!/^3$OV*O\ LTK]
MG'_U3O@VNEKFOV!/^3$OV*O^S2OV<?\ U3O@VOLN'?\ D3YQ_P!C+(__ %%S
M\^1XD_WW+/\ L%S3_P!/96?6M%%%=QXH4444 %>'>*O^&:_^%X_"_P#X3?\
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MUMK.+R+2W@M80\D@AMH8X(A)-(TLS^7$JIOEE=Y)&QN>1V=B68DST4 %%%%
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MO17YT?\ "4_MU?\ 1;?V3/\ Q$+XP_\ T<U'_"4_MU?]%M_9,_\ $0OC#_\
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M$IO&UA\3?V@/ASK5YX&T#6/"WA;4_P#A3?Q_^)WP@TW6=+\.:_XL\=:MHO\
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M9^5U_J-F?_0APW_@>5?_ #1Y+[CWW_A@?]A7_HRS]DS_ ,1R^#W_ ,QU'_#
M_P"PK_T99^R9_P"(Y?![_P"8ZODCQ[?_ +1?PI3X<>+(/VQ?CIXTM[G]H;]E
MSP-K7A/QCX&_9)3PWX@\+?%3]I+X4_"_QAI>HS>#/V8O!WBJU^U>%?&.L1V=
M]H/B?1M1L;\VMY!=@P&-_P!:J^[X>X[?%64+/,@XFS+'Y=_:6,RF53V^<86<
M,;@<+EV,KPE2QM/#3</89KA)0J04X2DZD;IP=_'QF2PR[%/!XW*\-AZZP]'$
MJ+I8.HI4:U3$4J<E*A*K&_/A:B<6TTE%V::/DS_A@?\ 85_Z,L_9,_\ $<O@
M]_\ ,=1_PP/^PK_T99^R9_XCE\'O_F.KQ37?C+^U?XJ^-7[17A#X:>.?V>?!
M/@GX-?$WPK\.=%L_'/P!^)/Q*\4ZM_:WP ^"?Q?U+6=4\1Z!^T_\*M)&=6^*
MM_I-EI]IX1@^RZ=I-H\]]?7,\TBS_P#"4_MU?]%M_9,_\1"^,/\ ]'-7EYOX
MN\+Y!F%;*<Z\3)Y=F>%AAY8K!5,/QSB9X=XK#4<72ISKX#(,7@ZD_85Z4I.A
MB:T$VX\[:=M\+PQCL;1CB<'PVL1AIRJ1IUHRR2G&I[*K*C*485\=2JQ7/3DE
MSTX2:C?ELU?V3_A@?]A7_HRS]DS_ ,1R^#W_ ,QU'_# _P"PK_T99^R9_P"(
MY?![_P"8ZO&_^$I_;J_Z+;^R9_XB%\8?_HYJ/^$I_;J_Z+;^R9_XB%\8?_HY
MJ\W_ (CKP%_T=C_RP\1/_H8.C_4W-_\ HE?_ "KP_P"7_4R_JWH>R?\ # _[
M"O\ T99^R9_XCE\'O_F.KUKX7? /X%? [^W?^%*_!;X2_"#_ (2C^S/^$E_X
M5=\.?!_P_P#^$B_L7^T/[&_MW_A$]&TG^UO[)_M;5?[,^W_:/L']IZA]E\K[
M;<^;\@_\)3^W5_T6W]DS_P 1"^,/_P!'-1_PE/[=7_1;?V3/_$0OC#_]'-65
M;QN\/,32E1Q'BE2Q%&?+ST:V6^(56E/EDIQYJ=3A>4)<LXQE&Z=I14EJDRZ?
M".=TI*=+AB=.<;\LX5\@A*-URNTHYFFKQ;3L]5=;;_HO17YT?\)3^W5_T6W]
MDS_Q$+XP_P#T<U'_  E/[=7_ $6W]DS_ ,1"^,/_ -'-7!_Q%GPH_P"C@Y7_
M .&'CK_Z$SH_U<XE_P"A#B__  MR3_YZ_P!6?E?]%Z*_.C_A*?VZO^BV_LF?
M^(A?&'_Z.:C_ (2G]NK_ *+;^R9_XB%\8?\ Z.:C_B+/A1_T<'*__##QU_\
M0F'^KG$O_0AQ?_A;DG_SU_JS\K_HO17YT?\ "4_MU?\ 1;?V3/\ Q$+XP_\
MT<U=_P#LU_%KXZ^)OC+\:?A)\:M>^$OBO_A OAE\!_B-X:\0?"[X8^,/A=N_
MX6MXJ_:$\,ZSHVNZ5XL^,OQE_M'^SO\ A36E7NF:A8:EHN/[8U"VNK&X\FVN
M%]K(^-N!^)\37P/#G%F SC'X?"RQL\'1ROB?!U7A88C#X:I5C5S;(,OPC]G4
MQ5'F@\2JCBVX0GRM')B\KS?+X4ZN/RO$82C5JJC&M4Q&6U8^U=.I5C%QPN/Q
M%5<T:4[25-Q35I-73?NWQ;_X9_\ M7PN_P"%[_\ "G?MO_"T_"W_  I7_A;?
M_"%?:O\ A=OF3_\ "$_\*N_X3'][_P +3\W[5_PBW_")_P#%6^9Y_P#9/S>9
M7L5?C_\ \%9+.[N_$W_!,$VMK<7(M?\ @J+^RY<W)MX)9A;VT6H:Z9+B<QJP
MB@C!!>63;&F?F85^P%?>8W!*AE.2XSZQ4J?7XYBW0D_W>'^K8OV-J2N[>U_B
M3T5Y=]SQ,/7]IC,?0]G"/U=X9>T2]ZK[6CS^^[:\GPQU>A^9G[#O_)E7['__
M &:Y^S__ .JG\)5]1U\N?L._\F5?L?\ _9KG[/\ _P"JG\)5]1U^>Y__ ,CW
M.O\ L;9C_P"IE8_1\J_Y%>6_]@&#_P#4>F?G[I_[(7Q5^%_[5/[0'[1_[/WQ
MK\'^&]$_:CTSX?7/Q:^$_P 5/A5KWQ"T33OB3\-O"5[X(T'XE_#_ %OPM\6/
MAI<Z(NH^'D\/P>,?!NIZ=JG_  E-SH\UU#XOT![JP_L;QCXW?\$W/BG\:M=_
M:"\0ZI^U'X?BU+]H7]B"R_8O\17VL_ 2^UN]TFQF\:?$3QUXB^(-@^F?'#PO
M8R37.J_%'Q-IOA;PDNFVMAX6\/V/A?3KK5O$EQI.H7^M_K317GJO5BU)27,H
MPBGR0;Y8<O(FW%M\JC%:W=DD[I'0\-1DG%QERN4Y\OM*B2E-R<VDI)+F<I-I
M:7;:5S\AX?\ @G'\;9?VCOAA\=_$/[3O@GQFWPM_:&B^-&@2>*_@1K.H^/\
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M_1W4?\*-_;4_Z.8_9=_\0P^+'_T=U?=U%'M8?] 64_\ AERC_P"8@_LW"_\
M43_X78W_ .:/+\^[/A'_ (4;^VI_T<Q^R[_XAA\6/_H[J/\ A1O[:G_1S'[+
MO_B&'Q8_^CNK[NHH]K#_ * LI_\ #+E'_P Q!_9N%_ZB?_"[&_\ S1Y?GW9\
M(_\ "C?VU/\ HYC]EW_Q##XL?_1W4?\ "C?VU/\ HYC]EW_Q##XL?_1W5]W4
M4>UA_P! 64_^&7*/_F(/[-PO_43_ .%V-_\ FCR_/NSY+^ 7P"^)_P .?B?\
M5OBS\6?BMX"^(_B/XC^ O@]\.[*R^'?P>\0_"/1/#^B?"/Q#\:O$MM=75MXE
M^-7QHOM<U37+[XT:E%//%J6B6EC::)8QQV-U-=3SI]:4445Z]3$5%4J*FI*G
M1I1C2HT</3C3P]&GAZ,(4</3I4H*%*E"'N07-;FES3<I/JH4*>'IJE24E",I
MR2E4J59<U2<JDVYU93G)RG.3]Z3M>RM%)(KY5\8?L7_ CQOXY\9_$?4T^,NA
M^*_B%JFE:YXSG^'?[4/[3_PGT37M;T7PCX:\!Z=K%UX1^%WQA\'^$8M4B\(^
M#_#&A3ZA:Z%;W=[::+8M?37,\;3-]544Z&)Q.%E.6&Q%?#RJ0]G4E0JU*,IT
M^>%3V<W3E%RA[2G3GR2O'GA"5N:,6BK0HUXQC7HTJT8RYXQJTX5(QFE**G%3
M4DI*,I1YEK:4E>S9\;_\,(? 3_H.?M1?^)V?MQ?_ $1-'_#"'P$_Z#G[47_B
M=G[<7_T1-?9%%;_VGF7_ $,<=_X5XC_Y88?V?@/^@'!_^$U'_P"0\E]Q\;_\
M,(? 3_H.?M1?^)V?MQ?_ $1-'_#"'P$_Z#G[47_B=G[<7_T1-?9%%']IYE_T
M,<=_X5XC_P"6!_9^ _Z <'_X34?_ )#R7W'QO_PPA\!/^@Y^U%_XG9^W%_\
M1$T?\,(? 3_H.?M1?^)V?MQ?_1$U]D44?VGF7_0QQW_A7B/_ )8']GX#_H!P
M?_A-1_\ D/)?<?&__#"'P$_Z#G[47_B=G[<7_P!$31_PPA\!/^@Y^U%_XG9^
MW%_]$37V111_:>9?]#''?^%>(_\ E@?V?@/^@'!_^$U'_P"0\E]Q\;_\,(?
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M ,3L_;B_^B)H_P"&$/@)_P!!S]J+_P 3L_;B_P#HB:^R**/[3S+_ *&.._\
M"O$?_+!?V?@/^@'!_P#A-1_^0\E]Q\;_ /#"'P$_Z#G[47_B=G[<7_T1-'_#
M"'P$_P"@Y^U%_P")V?MQ?_1$U]D44?VGF7_0QQW_ (5XC_Y8']GX#_H!P?\
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M&$;1BDNBG2I48*G1ITZ5.+DXTZ<(TX)RDYR:C%**<I2E*5EK)MN[;85\1?\
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M *&N9?\ A=BO_EI7U'!?] >%_P#">E_\@?)7_# G["7_ $95^R5_XCC\'?\
MYC:/^&!/V$O^C*OV2O\ Q''X._\ S&U]:T4?VSG'_0US+_PNQ7_RT/J."_Z
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M&T?\,"?L)?\ 1E7[)7_B./P=_P#F-KZUHH_MG./^AKF7_A=BO_EH?4<%_P!
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M[\K]2P=.,:48SJ1]CB*V)@TX-JK75=5+\T&G%_6*MHM:.2M\*M^77CG]DO\
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M?7I_$-WX;2XN+N&]U!Y([GO/B[^S%\:/C)9^)O%NK?\ "N-%^(_B;P-^SUX
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M7.O:;#J;Z_J&E_VYIN@&T>Y$L>NZIH@?6=*T:54U+4])AN-2L+6XL[:>:/\
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M>M+^%[0^&=<^)OB;XK>&_P!HC4/V8?#G@[38- \0W_@U-8\<_%2ULM+TR?\
MX3"?PSIEMJD.I:KXFATJVO-0AS+O_@HKX)M(Y/ #^ -=F_:C@_:*T3]D^X_9
MVM=;TRYN;;XS^(?AE)\:M)U"Y\?16[:5!\&;KX-6][\6$^)TNC+?GP=IVI::
M/!!^)5A=?#J+XST;]D;]HC5OV#?%7@W4_@IK/ASX\?"3_@HKXO\ VZ_@_P"!
MO$/C;X7S#Q]9^'?^"@.O_M4^&?#NF:WX/\>^+O"5EX@\<_":[O\ P=I]IXXU
M/1-$T?QOXCTYM>N[+2M-N]8M<RZ_8=^+MO\ M?:W_P %,['X2ZR/B;JW[>'P
M\\>_\*?D\3^$G\?#]DWPY^QAK?[#NI:C]F3Q)<?#T>.KG5/%VI_'V/PW)XM_
MMBW^&^G1>&TGL_B==R^";?RCL/K+Q]_P5;^!?@SX2>#/B7I_A#Q_XIUSQ)KO
M[3GA_P 0?"^QB\/67C#X?:Q^Q7X*^(?CW]J+PYXLU"ZUIO!\'B_P/I?PQU_P
M]X.T:V\23:=\2/&&M^"9-+U_3?AMK&N?$WPM]BZ;\>M-\4?&/P[\)/ V@W7B
M8-\,H/BS\2O%4MW)H^G_  P\.>)Y%L_A5HVIV%QIT][JGC?XHWMMXGO=&\,J
M=.&A>%? GBS7_%&I:3<W/@71?&_YZ?"']C*U^&?[(WQUU3XP?LW:?\9?B]\<
MOVI?VJ?VPQ^SW?:SI>IPV/Q#_:N\4^-/">@?"GQ'XLTJZU?PM::-_P *<\=V
M'PG^/>L65UXI^&[^$M4^*,=X?''@*>Z.M\WXT^ _[:WPB^,?P,@^$_BSQ;XQ
MA\8:Y\.?B)\;OB!X4BTS1/#'CKXY:W^T_P# V+]JGQ-\<-(UK499Y_AQ9?L2
MZ=XP^'/[+/@JZUK6(_AUX7\!:?X T'49?'6@?!Z](!^UM%%% !1110 4444
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M7L,3B<?1PV+CS0E>>$JUH)6DY*,HME;,L+0I4:U1XCV>(CS4N3!8VK.UHO\
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MI5EK5]J.LV=WX6DTV^\)ZY-)>Z;:Z=8:A-=B\2.6+5X(U@0PL\GK'[(_Q_\
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MO@SIT4,TNHZW:WUKK=ZCV5K-:P3OZ#^T#X@_: \._ CQ=K_[.O@7PEX^^/\
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MAN-8O)M3O;*P2VL$GF-U>6L.P/<0A_HWX9?&WX/_ !HM]7N_A'\3/!'Q*M-
MFM+;6[GP3XDTOQ);Z5<7Z3RV4%_-I5S<QVTUS';7$D,4K*[I$[A=HS7XS?\
M!5GXD?L-_M2?LQZM-X2_:Z_91UCXM?"&>Y\>_#RUT[]H+X0WNLZY;QVZ1>,O
M!.G06WBF[U"\G\3:' EWIFD:=";O6/%GA_PM9*0C.#[%^P!\7/V"OV2_V8O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'_L,A_ZK\"%%%%>6=@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>FZ7IMCK4%W<0R7,.HWNF)IA2[/R'^S;8^-OV<_V>O\ @H;HVL?"7]ICQO\
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M5H5WIVD>)6L;&^2S_=+X=^--%\2^&O%'Q$T_P!XM\%:5JNM:GJKCQ%\/]?\
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M7+RVMS^SNHMR;C!.GS*&J3E*SLTD4445SG4%%%% !1110!Q'["/_ "077?\
MLZ/]NW_UN/\ :)K['KXX_81_Y(+KO_9T?[=O_K<?[1-?8]?IV:?\C+,?^P[%
M_P#J14/S'#_[O0_Z\TO_ $B(4445PFP4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S7\=/^2H?L9?\
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M?VH__"X_8<_^C)H_X6E\>O\ HPW]J/\ \+C]AS_Z,FOT/HH^JY3_ -"3 _\
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M *,-_:C_ /"X_8<_^C)H_P"%I?'K_HPW]J/_ ,+C]AS_ .C)K]#Z*/JN4_\
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M^Z9'_P!BNM_ZNLX./"_Q\Q_[#(?^J_ A1117EG8%%%% !1110 4444 %%%%
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M?#>IZKX?NM,U*[ /9:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^:_CI_R
M5#]C+_LY3Q3_ .L>_M75]*5\U_'3_DJ'[&7_ &<IXI_]8]_:NKZ4KU,P_P!T
MR/\ [%=;_P!76<''A?X^8_\ 89#_ -5^!"BBBO+.P**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YK^.G_)4/V,O^SE/
M%/\ ZQ[^U=7TI7S7\=/^2H?L9?\ 9RGBG_UCW]JZOI2O4S#_ '3(_P#L5UO_
M %=9P<>%_CYC_P!AD/\ U7X$****\L[ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
MR-?U_0?">@ZWXI\4ZWI'AKPQX:TC4M?\1^(]?U*ST;0= T'1K.;4=7UO6]7U
M&:VT_2M(TK3[:XOM2U*^N(+.QLX)KJZFB@B=U<8RE)1BG*4FHQC%-RE)NR22
MU;;T26K>B$VDFVTDDVVW9)+5MMZ));LUZ*^2O^&^_P!A+_H]7]DK_P 2.^#O
M_P V5'_#??["7_1ZO[)7_B1WP=_^;*O1_L;./^A5F7_A#BO_ )4<WU[!?]!F
M%_\ "BE_\F?6M%?)7_#??["7_1ZO[)7_ (D=\'?_ )LJ/^&^_P!A+_H]7]DK
M_P 2.^#O_P V5']C9Q_T*LR_\(<5_P#*@^O8+_H,PO\ X44O_DSZUHKY*_X;
M[_82_P"CU?V2O_$CO@[_ /-E1_PWW^PE_P!'J_LE?^)'?!W_ .;*C^QLX_Z%
M69?^$.*_^5!]>P7_ $&87_PHI?\ R9]:T5\E?\-]_L)?]'J_LE?^)'?!W_YL
MJ/\ AOO]A+_H]7]DK_Q([X.__-E1_8V<?]"K,O\ PAQ7_P J#Z]@O^@S"_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M^:_CI_R5#]C+_LY3Q3_ZQ[^U=7TI7S7\=/\ DJ'[&7_9RGBG_P!8]_:NKZ4K
MU,P_W3(_^Q76_P#5UG!QX7^/F/\ V&0_]5^!"BBBO+.P**** "BBB@ HHHH
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M^"=91/B0/$.E7/CSX8:C/<'Q=XN@^%D7W?7YG?M ?LF>+OVFOVBO@UX^\:?
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M4_\ K'O[5U?2E>IF'^Z9'_V*ZW_JZS@X\+_'S'_L,A_ZK\"%%%%>6=@4444
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M/^C,OVE/_"I_8^_^BNKZ4HH_M#"?]"/*O_!V=_\ SX_J[\K'U:O_ -#'&?\
M@&7_ /S"?-?_  O3XH?]&9?M*?\ A4_L??\ T5U'_"]/BA_T9E^TI_X5/['W
M_P!%=7TI11_:&$_Z$>5?^#L[_P#GQ_5WY6/JU?\ Z&.,_P# ,O\ _F$^:_\
MA>GQ0_Z,R_:4_P#"I_8^_P#HKJ/^%Z?%#_HS+]I3_P *G]C[_P"BNKZ4HH_M
M#"?]"/*O_!V=_P#SX_J[\K'U:O\ ]#'&?^ 9?_\ ,)\U_P#"]/BA_P!&9?M*
M?^%3^Q]_]%=1_P +T^*'_1F7[2G_ (5/['W_ -%=7TI11_:&$_Z$>5?^#L[_
M /GQ_5WY6/JU?_H8XS_P#+__ )A/FO\ X7I\4/\ HS+]I3_PJ?V/O_HKJ/\
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M_P"CS?VE/_"6_8^_^A1H_P"%%_%#_H\W]I3_ ,);]C[_ .A1KZ4HH_MC%_\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "ODK]OO\
MY,2_;5_[-*_:._\ 5.^,J^M:^2OV^_\ DQ+]M7_LTK]H[_U3OC*O2R;_ )'&
M5?\ 8RP/_J52.7'?[EC/^P7$?^F9G2T445^6GZD%%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\0?_ #C#ZAFW_0HQ?_A1E7_SQ_JS\K_?=%? G]H?MU?]%V_9,_\ $//C#_\
M1UUZ9^RO\3_BQ\0'^/\ X:^,6I_#S7?$WP9^.%G\-+'Q#\-/ _B3X=Z%KFA:
MI\!?@7\8+6[N_"WBGXE?%?4+/5K/4/BOJFBSSP^+IK.]L]+L+F.PL9Y+A'UA
M3P>(IXF>!S7 X^6$HQQ%>E0I9I2J0H2Q%#"^U3QV6X2E)*OB:$'"-5U/WG,H
M.$9RCC6HXS#.E];P-?"PK5'1IU*E7!5(RJ^RJ5N2V&Q=>:;ITJDE)P4/<:<D
MY14OJ^BBBN8D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_.#]EO_ ))_
M\0O^SL_V[O\ UMS]H2OT?K\X/V6_^2?_ !"_[.S_ &[O_6W/VA*SS7_DFL9_
MV/,E_P#4#B$]#)/^1U3_ .Q7F'_J7E1]'T445\&?<!1110!YSX8^,/PC\;:G
M_8O@SXI_#GQ=K/V>2[_LGPQXW\,Z_J?V6%HTFN?L&E:G=W7V>)YHDDF\KRXV
MEC5F!=0>J\1^)_#7@[1[OQ#XN\0Z'X5T"P$9OM<\1ZM8:'H]D)I$AB-WJ>IW
M%K96PEFD2*,S3H'D=(URS '^3G]IWX5ZMKG[+/\ P6/\6^!_ _P4TVU\ _\
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M_!RW_L9_^\W,C[7HHHKU#YP**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *_.#]EO_ ))_\0O^SL_V[O\ UMS]H2OT?K\K
M_AN_[0GPBM/B'X-NOV-_CSXUAG_:&_:F\<Z-XL\%^-_V1E\->(?"WQ6_:6^+
M'Q3\'ZIIL/C3]J#P;XKM?M7A3QEHSWECKWA?1=1L+\W5G/: P"23;$X2MF&1
MXS"8:6&^L?VME.(5.OC,'@W*C1P>=TJLX2QE>A":ISQ%",E"4I+VD6U9W.C+
ML31P>:TL1B'4C1_L_&T>>%&M62J3Q&73A&2HTZDHN4:51IR23Y'K<^P*^1M;
M_8:_9RU_QC\:_']]HGQ.M_%O[1.G>&=&^,NKZ'^T;^T?X9/C30_!O]JKX8T"
M6Q\-_%G2=-T3P_HUMKNNZ=::#X;L]&TC^Q];UC19;*32=4O[*X[S_A:'QX_Z
M,/\ VH?_  M_V'__ *,>C_A:'QX_Z,/_ &H?_"W_ &'_ /Z,>OFX\-9U"_(L
M#&]D^7/<EC=)J23MF*O9I->:3W2/II9WE$[<]2I*S;7-@,=*S:<6U?"NS<6X
MNVZ;6S9Y;<?\$]/V/+BYEG_X4Y;VEM-^S9J'[(,FA:7XV^)&C^$C^SAJB7@O
MOA>O@O2O&-GX2CTR:>_NM175X]%7Q-#K3QZ[!K<6LV]O?1;ME^Q#^SC:_"_X
M@?!^Y\*>*=:\&?%/X6>'_@=X]DU_XL?%G6/%^O\ P<\*:;KFC^&_AD?B%>^-
MY/'FE^#-(TKQ/XGLXM$T3Q'IMK=MXG\4W^IK?:IXH\17VJ=K_P +0^/'_1A_
M[4/_ (6_[#__ -&/1_PM#X\?]&'_ +4/_A;_ +#_ /\ 1CT_]7,\[X+1IK_A
M>R;1III_\C+=-)KLTFB?[8R5;2DM&O\ D78W:2Y6O]UV:T?=76S/*=6_X)[?
MLHZ[I7Q"T35_!'C>^TOXJ_!KPC^SW\0+27X]_M!A?$GP:\"-JS>%? =S)'\4
MTFM=+TM=?U^ W.G26>J7]GKVN66IW]Y9ZQJ4%SF>'_\ @F]^Q]X;LOB;HMC\
M-_$EYX2^+^B^.M&\<?#_ ,1?&3XV>*_AQ=R_%"PN-+^)'BC1/ 'B?XB:OX3\
M)?$+QQIUU=VGB'XE>%=)T;Q]<QW^L/#XCMYO$/B&75?:?^%H?'C_ *,/_:A_
M\+?]A_\ ^C'H_P"%H?'C_HP_]J'_ ,+?]A__ .C'I_ZNY[:W-@[-W:_M[)K-
MI))_\C+=))>B2Z(7]KY+=.[NKV?]G8RZO>__ #"=6V_5M[GC?A/_ ()V?LM^
M#[3XE6-GH?Q6UJV^+OP8TK]GGQ^OC']I#]HOQI+K/P:T.#7K/1O L%SXG^*>
MJ76BZ;I-AXFUZPTRYT*;3=3T^VUC6?L5]!-KNN3:E;^&/_!/3]E/X-^,]#\<
M?#;P5XT\-7V@6G@Z"'P\OQO^.>K?#[6+WX=^$[7P+\/_ !#XP^&NN_$?4_ ?
MCOQ9X'\)6&EZ-X2\4^-/#VO:]H"Z)X=U'3;^WUCPSX>U'2_6?^%H?'C_ *,/
M_:A_\+?]A_\ ^C'H_P"%H?'C_HP_]J'_ ,+?]A__ .C'H_U=SS7WL'[RM+_A
M>R;WE9*S_P"%+5626O1)=$"SC)5RV<DXN\7_ &=C+Q;=VT_JETVVVVM6VWN?
M.5E_P2T_8LT^XF:S^'WCFTTI_"GQQ\!6OA*P^/7Q[TKP-HW@/]HW6)/$/Q>\
M$^&_!.D?$JP\+^&?"OBG79YM8_L3P_I>FV6FZH+'4=,BM;W1/#\^E?:7PS^'
M'A#X/_#[P9\+/A_I][I'@;X?>'-*\)>$-(U#7_$7BBYTCPYH=K'8:/I/]N^+
M-5USQ#?VVF6$,%C9'4]5O9;>RM[>TCD6W@AC3SK_ (6A\>/^C#_VH?\ PM_V
M'_\ Z,>C_A:'QX_Z,/\ VH?_  M_V'__ *,>E+AO.YJTW@I).Z4L]R623UUL
M\Q>NK^]]QPSG)J;;A*<&U9N.7XV+MHK76%6EDM-M%V/?:\X_9$_Y*!^W1_V=
MGX8_]8C_ &-JXG_A:'QX_P"C#_VH?_"W_8?_ /HQZ]$_8_\ #7Q'TR[_ &G/
M&7Q'^%_BCX13?%G]H;3O'/A/PGXTUOX;:YXE/A;2?V:?V<OA8VJ:E-\*O'OQ
M)\*67VWQ7\-O%*6=BOBB?4186]K>7EI9B\AC/M9)E6+RRGG57&/!4XU\IIX>
MBJ69Y;BJE2L\YRBOR0HX7%UJK:HT*U1ODY8QIR<FM+^1G>8X3'0P%/"SJU)4
M\?[:IS87%4HQIK 8ZGS.=:C3@E[2K3BES7;DK)GV31115GE!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
C 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ny20006478x8_graphic09.jpg
<TEXT>
begin 644 ny20006478x8_graphic09.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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KLR1QI*\+.J(&"@K9Z=**!A1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ny20006478x8_pc01.jpg
<TEXT>
begin 644 ny20006478x8_pc01.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?S'?\
M!V+_ ,HQ-"_[.5^&7_I@\=5_3C7\QW_!V+_RC$T+_LY7X9?^F#QU0!^@_P#P
M0G_Y1)?L/_\ 9)9?_4M\2U^M5?DK_P $)_\ E$E^P_\ ]DEE_P#4M\2U^M5
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M1YO$$7@C0=#369=)34]2339-16Y>P34+Y;4Q"[N!( ?7'_$93X-_Z1^^)O\
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MB;Q1!8YDENCKOPBL)]-L_'=\+:STJQD\?_ 6X\)?%C59'^QMX-T_PY97=Q<
M']L]%?SZ_P#!-_\ X.*/V-/VWY]%^%_Q6NH_V3/VF+F>#1I/AQ\3]8@B\#>,
M/$#3S6C6?PX^)UY!I>E76H7%REI;0>#_ !I:^$/%]QJ^HQZ%X;T_Q@UI/JDG
M]!5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %?S'?\'8O_*,30O\ LY7X9?\ I@\=5_3C7\QW_!V+_P HQ-"_[.5^
M&7_I@\=4 ?H/_P $)_\ E$E^P_\ ]DEE_P#4M\2U^M5?DK_P0G_Y1)?L/_\
M9)9?_4M\2U^M5 !1110 5\P_MM?\F:?M9_\ 9M?QQ_\ 59^)J^GJ^8?VVO\
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MW1/B#JVE+X4\675S=RQV6FP>#OB'I_A/6M8UB<%[/PA'XIM8GB349GK^IO\
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M6KZSI[Z_X@UKQ1KMG8ZAX@U^]L=$\)Z-X:_8R@ HHHH **** "ORL_X+??\
M*)K]NO\ [(=JO_IYT2OU3K\K/^"WW_*)K]NO_LAVJ_\ IYT2@#YH_P"#9[_E
M#E^S1_V,WQ^_]7W\1Z_>JOP5_P"#9[_E#E^S1_V,WQ^_]7W\1Z_>J@#\<O\
M@I#_ ,$/?V)O^"D-EK'BCQCX27X0?M#7-L_]F_M$?"[3M/TWQ;?7T-BEGIZ_
M$O0MMOH7Q6TF!;73+:4>(U@\7VNCZ=%HWA?QMX6M99F;^?FQ^-'_  6O_P"#
M>B]M/#_QV\/S_M]?\$\-'G.EZ'XSMM7UG5(_ V@I%:Z?HMMIWCZXT[7?'OP)
MGL8SH6GV_@SXE:1XJ^$)=;_PU\-;^6_GN?$UM_<G5:]LK/4K.[T[4;2VO]/O
M[:>ROK&]@BNK.]L[J)X+JTN[6=)(+FVN8)'AG@F1XIHG>.1&1B" ?G3^P)_P
M5=_8K_X*0>'!>_L\?$Z&'X@6.G2:EXH^!?C]+'PI\9_"=M;R6\5U>WGA(ZC?
MV_B+0K5[RP2X\6^!=6\5^$K:XU"STZ\URVU=Y=-A_1^OY@_V_P#_ (-IO@3\
M7_$DG[0G_!/WQG)^PW^TYH.IIXNT"V\(76M:#\&-3\6Z<TU[IFI:7:^%'C\2
M_ S7(]133Y+;Q/\ "U)]!T2&SDN+;X:7FL7DNJI^:/[%/_!R+^T;^R7\7[O]
MC+_@ICH&F?M'GP3XIL_ARGQ]_9]\1^!OB9\0[#4@\=C90:T?AYJ]]X#^-T,;
MW.EV-[=^'M1\/_$_1[NVUJR\76'C7XB)?Z%:@']U5%8'A3Q+IWC+PSX?\6Z1
M;Z]::7XFT;3==TZU\4^%_$O@CQ);66JVD5[;0:]X.\9Z3H/B[PMJ\4,R)J/A
M_P 3:)I&NZ3="6QU73K.]@FMX]^@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ K^8[_@[%_Y1B:%_V<K\,O\ TP>.J_IQK^8[_@[%
M_P"48FA?]G*_#+_TP>.J /T'_P""$_\ RB2_8?\ ^R2R_P#J6^):_6JOR5_X
M(3_\HDOV'_\ LDLO_J6^):_6J@ HHHH *^8?VVO^3-/VL_\ LVOXX_\ JL_$
MU?3U?,/[;7_)FG[6?_9M?QQ_]5GXFH _FH_X,]O^30?VJO\ LXW2?_5:^'J_
MKUK^0K_@SV_Y-!_:J_[.-TG_ -5KX>K^O6@#@_B=\4OAO\%? NO_ !/^+OCG
MPK\-?AUX5AL[CQ-XX\;:W8>'/"^@0:AJ5EH]C/J^MZI/;6%A#=:KJ-AI\$ES
M/&CW=W;PAM\J@P_"WXL_##XX> M#^*7P<^(/@[XH?#;Q,NI-X=\=^ _$.E^*
M/">MKH^K7^A:L=,U[1[F[TZ\_LS6M+U+2;\07#FUU&PN[.<)/;RHLGQ5^&/@
MKXU?#+X@_!_XDZ+#XC^'_P 4?!GB7P!XUT*>26%-5\,>+='N]#UNR%Q T=Q:
MRSZ??3K!>6LD5U9S^7=6LL5Q#'(O^=%X:_;J^.7_  1J^ 7_  50_P""0?C>
M;Q+>?$Z?Q1)H7[,?C:PLWBLM*T[XJ?V7X<^(7BZUE35+C4O#=G\0/@;J7ASX
MI_"ZVTQF;P]XSO-3FU PZWJDS4 ?WF:;_P %&?V!]9\#>+_B=I/[9'[-FI?#
MGP!K'AOP_P"-_'5C\8O UUX3\*:[XP;4U\*Z1KVOPZR^F:9J/B)M%U8:/9W5
MS'/J TZ[-LD@@<B_\0O^"@O[#/PE@\"77Q/_ &NOV=OA_;?%'P'H/Q2^'$_B
M_P"+?@K0(O'/PW\4I+)X;\=^%7U+6+==<\*:['!,^DZ[IYGTZ^6*0V]Q($;'
M\DG[=G[![?\ !/G_ (-F?"7PF\2:/#I?QC\<?&SX.?&/X\G8RWL7Q,\>:A)<
M-X9O\W=["+GX=>$[/PQ\.;EM/N/[+OM0\*W^N6<2/K%P\OYR_P#!2FV^V_&+
M_@WDL_\ A4'_  T']K_X)I?\$V+;_A0?]I_V+_PN_P _Q3)%_P *@_MG[#J?
M]D_\+*W_ /"&?VG_ &;J'V#^VOM7V&[\K[/( ?WT^ _^"BO[!?Q1?Q=%\-_V
MQ?V;_'<G@'P+XC^)_C>/PG\7_!&O/X3^'/@^*WG\5^.?$*:;K-PVD^%?#D-W
M;3:WKEZ(=.TV*>*2[N(D<$^X_!?X^?!']H[PA+\0/@#\6OAW\9O \&LWOAV?
MQ;\,_%VA^-/#]OK^FP65U?Z+/JN@7M]9PZK9VNHZ?=7-A+*ES%;7]G.\0BN8
M7?\ !C_@E!\)_#5[\</B9%XF_P""#6F_\$W+"^^!_B?P_<_%G5?BC%\3;+XB
MZ3XB\2>$=/USX/7?A^?X=^$[=;+Q#IIDUV^GN+N]BFMO#3V,EBZ7;2Q?SI:-
M^UY\6?\ @WO^,W_!6;]@K2!KLV@_$#PY<^(_V/-:87&H-X7\9>,;C1=/^&/Q
M)AOKP0Z9+-;?!#QG=:CXWOFLM6M[SXF_!?PYX0*K$FJM0!_?]\(?VFOV=OV@
M-6\>Z#\#?CA\*OB]K7PLU.TT7XDZ7\./'7ASQC?>!=5O[G6;*QL/%-MH.H7T
MNBW-[=^'=?M[2._6$W,VC:G'#O:RN!'7\-?M2_LV^,_C)XG_ &=_"'QV^%'B
MCX[^";2^OO&/P@\/^.O#NK_$7PM9Z8VFQZE=>(/"=A?SZSI$&GRZSI,%[+?V
MD"6MQJ5C;SE)[F&-_P#.^_9"U[]I'_@W5_:$_9L_:1^/WA+5/$'PF_;;_8_\
M7>*_$7@/2;>\L+\:E<V=YXG\&_#?4I-8>UCT?XG>!_%4/P:U3QQJ%SI=R_A'
MPM\4?$6@VUI?ZB+XR?T&?\&OG[,GBR]^%7[0W_!37XY*VM?'#]M_XG>+I-#\
M3ZE;P'4I_AYH_C#4]3\;>(;696%S8)\2?C'+X@.JZ5+"L$EE\-O!^J63O:WD
M04 _HR\?_M4?LT_"CXH>!?@G\3OCW\(OA]\7_B<VC+\.OAIXR\?^&?#GC?QP
M_B+7+CPSX?C\*^'-6U*TU37)=<\1VEQH&D1:=;7$FI:S"^F6:S7H$)[OXI?%
MGX8? _P+KGQ/^,OQ"\&?"OX<^&A8'Q!XY^('B32?"7A31CJFI6>C:6NI:[KE
MW9:;:2:EJ^H6&E:?%-<+)>ZC>VEE;++<W$43_P -7_!S7\%/$_[2'_!7?]@S
MX ^"M:TKPYXQ^,OP-^&?PV\)Z[KDM_!HND^)/%_[0'Q7T70[_5[G2[:]U.UT
MRVU.[MI+Z[TZQOKZUM1+<6EC>3Q1VTOP)^W=XX_X*_?MN_LY_$CP5^U]H6M?
M#[X8?\$E_"WAOP[^T%>>(#?Z5_PMSXZ^(?&ND^!/ OB?6PTLL7Q&^).L> /&
M/AW5K#Q!IT^I>#K7P:-?^)NFZM8/\8]#TSQ( ?Z2GPR^*?PV^-'@30?BA\(_
M'?A/XE?#CQ3#>W/AOQSX(UW3O$GA77;?3M2O='OYM*US2KBYTZ^BLM5TZ_TZ
MY>WGD6&]L[FWD*RPR*OE?P._;%_90_::U;Q!H/[._P"T?\%/C=K?A.RMM2\2
MZ1\+?B3X3\;ZEH6G7ES)9VNH:G9>']4O[BTLI[N)[:.[FC6!IPL7F;W16_E7
M\+_MJ-^Q+_P:E_!'Q-H&JRZ7\4?C5X2^*/[/'PEGM9+J"^LO$OQ+^-/QKA\1
M^(K*\L9X+S2K_P (?#?3?&WB?0]71C%:^*M,\.VTOS7T2M^/'[%WB7P'_P $
M:OVK?^"7?[46A_M#_"_XE>!_VJ?@?+X7_;5\.>!OB5X1\7:A\(Q\1O%L6HZ[
MH/CG0_#3:QJ_@ZT^%WA?Q/\ !#Q@^G:B5U7Q)\0_A)\1M-LKF'2]]G  ?WDZ
MO_P50_X)KZ!JVJ:#KG[=_P"R?I.M:)J-[I&KZ5J'QU^'=I?Z9JFFW,MGJ&GW
MUK-KZ36UY97<,UM<V\J+)#-&\;JK*0.F\!_\%&_V!?BCJ&M:3\./VROV:O'6
MI^'/"?B7QYK^G^%?C'X%UR\T;P5X-TV76?%GBO4K?3]:GDL] \-Z3!-J6M:K
M.J6>FV44ES=2Q1(SC^8G_@YK_P""??[%W[.?[#.D?'3X&_L[_#SX;?%KQA^U
M;X+TWQ)X]\-6=_#KFM:?XK\'_%SQ%XAMKN:XU"Y@>+5]:TVPU*ZV0H7N+6)D
M*J"I_0GX9_\ !/K]B_X-?\$A?$/[2OPO_9V^'O@KX[^*_P#@DKXOU/Q%\3M%
ML[^+Q-J]_P"/OV0I]3\975W/-J$ULTOB&_N9[K4"ML@>61C&(Q@  _3;_A[-
M_P $P_\ H_\ _9#_ /#^_#;_ .:&O0O'G_!0W]A+X76O@6^^)'[8'[.7@6S^
M)W@C2?B7\.KKQ7\7O!&AP>./A[K\ES#HGC7PM+J&LP)K?AC5I;*[CT_6M/,]
MA=O;3K#.YB<#_/J_X)"^$?[?_9K\;WG_  XF_P"'GOE?''Q+;?\ "_/^%O?\
M(!_PB.SP%\-)?^%0?V-_PKKQ=]I_L#SO^$S_ +3_ +2@\[_A/_LOV&+[%]HN
M?L7_ (+-:1X=\+_\%)O^"-6DS?L@3:CX;TC]E']E5+S]A72HK#QA<M8Q?&'Q
MS-??LSV,6KZ?#IOB>YM<S_#R(7^DPVNLS0@S:=$EP;90#^ZGX(?M*_L\?M+Z
M+JOB/]G?XY_"7XXZ'H-[#IFOZE\*/B#X5\>VV@:E<1R36VGZ\WAG5-2;1;V[
MMXI+JTM-36UGN[11=V\<MLRRF'X/?M._LZ_M!ZMX^T'X%_'#X6_%[6OA7J-A
MI'Q*TKX=>-_#_BZ_\":IJESKEGING^++71+Z\FT*\O[OPQXBMK2WU%+>2>;1
M-4CC5FLK@1_Q/_\ !OQX>L/BQ_P6E_:O^+_P7\#)^PS\)?AOX"\6V/B']B23
MQIXAE\8R"YGT/X>2^&_$?A3Q/9VVM76E^$/'UI<^/?&\=W;:7:_#?XBZEX3\
M'Z-96^E75O9V_N?_  ;F?%?P;\"/'/\ P7R^-GQ$OY-,\!_"3QGX%^)'C&^@
MB^T7-OX;\%^(/VT/$.L-9VN]&O+]K'3YH["QC837MX\%I"#+,@(!_6=J7[8W
M[)^C?'&']F;5OVD/@GIG[0US?:9ID'P3O_B5X3M/B?+J6M:';>)M'TZ/P7/J
MB:\U]JOA^]L]9TVT%E]HO=-N[6[MHY(;B%G[7XU?'_X'_LW^$;?Q_P#'_P"+
M7P\^#'@B[UNS\-6OBWXF>+-%\&^'KCQ#J-I?WUAHD.K:[>65E)JEY9:5J5U;
M623&XFM["[E2-DMY"O\ EW^(5\2_'3X4?M)?\%G]1_:1^&W@O]LC0/V\_ /Q
M$^&WP6G^)GA9/B38^$;/59=<U'Q7X,^'FNWM]XM\2:1X&\<>*O@WH/P_ABLS
MINC>!OAA\16U&"]L+&S:U_I(_P""_O[4OA+]M;_@@G^R?^U)X+2"UTCXP_'[
MX,>(K_2+>XDNX_#'B^T^'7QRT+Q_X-:\EAMWO)O!?CK2?$?A2>]\B..\FT=[
MJ%?)FC) /["O#/B7P]XT\-^'_&/A'6]+\2^%/%FB:3XE\,>(]$O;?4M%U_P]
MKMA;ZIHNMZ1J-I)+:W^EZKIMU;7UA>VTLEO=6D\4\,CQR*Q^>OCQ^VU^R!^R
M]J>DZ'^T3^TU\#_@QK^O):3:/X<^(GQ*\*^&O$FH65[=_8(=6M_#NHZG%K3:
M$ET&BN]?-B-%L-DDE]?VT44CKA_\$^O^3"?V(O\ LT/]FO\ ]4SX+K^)3]N7
M]F#XW_\ !.K_ (*3_M9_MI_M=_\ !/VQ_P""D/[&OQX\7_$?Q/9^./$MWK.M
M:/\ #WPKX\\26>JZ*]_XBT?3O$UI\)?$_P .-/U#3_AQHK^/_!ECH%]IVFP6
M/PVU?28TM=1T\ _O[\#>/O OQ/\ "FB^//AKXS\*?$+P/XDLTU#P]XQ\$>(=
M(\5^%M=L),B.]T?Q!H5Y?Z3J=JY!"W%E=S1$@@/D$5YY\>?VE?V??V7?!Z>/
MOVBOC-\./@MX1GN9;&PUKXB^+-'\,0ZQJ4-K+>OI'A^WU*ZAO/$.M&T@FN(]
M%T.VU#59HHG>&SD"FO@O_@B_XV_81\?_ +%.F>(_^">'ASQ)X#^!5W\1_&4^
MM?#'Q==^(;[Q!\+OBEJ=OH6N^,_ ]]=^(M6\0S3I90ZMHNJ6,FF>)?$.B/I^
MKVC:9J8A)L;+^<W_ (.9/C?\/]2_;A_9$;X8VL/[5'Q)_8KT'QK\1_VD_P!D
MWQ%X"U[XA?!SP;\.)I_AK\0(?$/Q,M;;19-%L-/\=^%I19?$*6;4KP:9X6L/
M FH:HF@%]-?6@#^UKX:?%#X;?&?P1H7Q*^$7CWP?\3OA[XG@FN?#OC?P'XBT
MGQ7X6UN&VNI[&Z?3==T2ZO=.NS:7UK<V-XD-PTEI>VUQ:7"Q7$$L:>>R?M5?
MLTP_':+]E^;X\_":']HVX@^TV_P-E\=^'8OBI<6__"+R>-O.M_!#WZ^()XO^
M$/AF\3%XK%U&APS:D3]EBDE7^4S_ (-X_P!LC]F3]G#X?_ []DSPOXB\=_M"
M?M)?\% /B5\1/V@=;\ _ 3PUIX^%'[(&@:<@\*77A?XG?\+ \<^#Y?"7]B:;
M\/O$OBK59?"N@^(=9U;0X=(33-+U[1KWX7ZWX]]A_P"#F#]G7X@?"G4?V6?^
M"O?[.MLFG?%S]CSQ]X/T#XF:C;1W+?;? L_C"VU;X7:WK\<=_:P7/AKP_P#$
M#4-5\!>)--CMY[OQ+I7Q@M[#49/["T:5(@#^E+XW_M5?LT_LT3>$+?\ :$^/
M/PF^"MSX_GU6V\#6WQ-\=^'?!EQXON-#?28]9A\-P:[?V4NLRZ7)KVB1WZ6"
M3M:OJ^G),$:\MQ)RGQU_;E_8U_9BU^P\)_M#?M1_ ?X->+M4LM,U6P\(?$+X
MH>$/#7BVYT;6-2GT?3M>3POJ&JQ:\OAVXU&TOK;_ (2%]/7183IVIR3W\4.F
M7\EO_$WXI_:+\7_\%?\ ]O+]HK_@I+\//"VKQ?LW?\$I_P!B#Q%\<_@_X1\;
M:=;W,-M\=O"/PE\5?$?X::/XDT>/55TO4-:C_:!L_$OCW4KB&+4-.\6> /@;
MI?AG4;:Y34]*LY?IK_@W\_X)E_L?_P#!1#]F_P",?[:?[<.CZQ^US\??B!\<
M_'/@'Q%J7Q)\>^/KEO"=KH_A+PG=2->-IFOZ1?:OXX\06_BQ=;D\3ZKJ.K/H
MNCMX1MO"2>'-1TO5+K40#^PN+]H[]GZX^#%Q^T;9_&_X3ZC^S_:Z5?:Y/\;=
M*^(/A75?A2FCZ7J<^BZEJ?\ PGVFZI=>%WL=.UFVN=)OKE-3:*TU.VN+"X:.
MZ@EB3Y>_X>S?\$P_^C__ -D/_P /[\-O_FAK^67]D/X(>"_V4_\ @O-^T7_P
M2+^'-SJ?Q<_X)[_M!> _$%U\5/@%XOUS6O%?A3P0\_P,TKXTZ8-;>ZGM6;7O
M#?B+3]+^']GXACNM1UC4O!GBC0=(\7:IJ_B*REN].\M_X*F_L&_L??!K_@N1
M_P $OOV=/A=\ / 7@KX(?&+_ (4%_P +.^&VBVE]%X<\9_\ "3?M'>-?"FO?
MVS!-?37$O]J>'=/LM(NO)N(=UI;1JNUP7(!_9';?\%&_V!;SX=ZK\7+3]LK]
MFJY^%VA^+-*\!ZS\08?C'X%D\'Z7XUUS2]0UO1O"E_X@76CIMKK^J:1I.IZG
M8:5-<)>75CI]Y<PQ/%;RLN)X9_X*@_\ !.3QIXD\/^#O"/[<O[*WB7Q7XLUS
M2?#7ACPYHGQP^'VI:UK_ (AUV_M]+T71-(TZUUV6ZO\ 5-5U*ZMK&PLK:.2X
MNKN>*"%'DD53_.O_ ,'(?['G[,?['G_!*C2_#?[,GP8\'?!G0O&/[:/P@USQ
M/IG@ZVN[:VUK5K#X5_&NPL[^\6[O+QFGM[-C;QE&11&<%2>:\0_X)@_#>PU9
M/V ;C4_^#<V*&QN=,_9CU&?]O>;XVF6*Y\O3/!E_%^U:W@L?#",_\3.:./XJ
MCPY_PDW[IKH:>=9D"?:V /[@Z_*S_@M]_P HFOVZ_P#LAVJ_^GG1*_5.ORL_
MX+??\HFOVZ_^R':K_P"GG1* /FC_ (-GO^4.7[-'_8S?'[_U??Q'K]ZJ_!7_
M (-GO^4.7[-'_8S?'[_U??Q'K]8OVFOVL_V<?V-_AO>?%G]IGXN^$/A%X'MF
MEAM;_P 2WSG5/$&H0PFX;1?!_AC3XKWQ-XSU]H%:=-!\*Z1J^K-;)+=?8Q;0
MS31@'T17YA?\%"O^"O'[%?\ P39T&9?CE\0UU_XKW>G+?^&/@!\.6L/$OQ;U
MZ.XV_8KW4-&-]:V'@?P[=!I)X?$WCK4O#VEZC;V6HQ>'7U[5K0:3+_/=\6/^
M"SG_  4C_P""M?C?Q'^S7_P1B^ GC'X8?#$3-H'CK]JSQG%9:5XKT?2]3BCB
MEU*;Q;-+=^ _@3#-9/JT^GVNG:AXX^,NLV=M::WX D\->);.72$^\O\ @GU_
MP;8?LX?L_:_'\>/VVO$3?MP?M/ZSJ<_BO7KWQ^E_K'P>T?Q;JDC7VJZHOAKQ
M/)>:M\6?$$FI7-_+=^,/BK)>VNKS26VM6_@/PYKD O" ?E_+XO\ ^"VO_!Q!
M<R6/@O3Y?V O^"<OB*9[>[UJ2XUW3M/\?^%)KJ:SO(IM=6#P_P"/?VDKV2U.
MI6DVE>&;7P/\"KR^TM-+\33:'KMO#?S_ -%'_!./_@BI^Q-_P3:T[3M>^''@
MS_A9GQY%I$FL?M$?%*STS6O'\=W+IUQ8:I!\/[9;4:1\+/#]ZFH:K:MI_A*"
M+7=2T>\BTGQCXJ\8"PM+M/UPBBBMXHH((HX8(8TBAAB18XHHHU"1Q11H%2..
M-%"(B *J@*H  %24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[^P_^1,\2?V?]E_M/_3O/_L^']GJ* /R_P#^"MG_  3=_P"'I/[,.A?LX?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;;43::5J4-OJ4=G:Q7=S;PI>0*?Z4***!A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?ESX/^(]E^SY^V%^
MVGJ_QY^&GQHCO?BSXJ^%6O? CXS^%/@C\6?C3X0\4? 3PE\ O >C-\(=)\0?
M"#P9\0C\/=5^'_QMTOXW>)W^&7C6;PWK/C'7OBA=^-/ ND^((O$MY'IGQOKW
MP]_;#\7:UX-_;_\ 'G[.L4'CG5OVL?V6O''@7PC:^,_B#K/[0_P#_8Y'CA?@
MQ=_"NZ^ &@_!O5=)M_%Z?!WXY_&GXT?'ZSMOBP;VR\5^*];T[6KB^T7X4^$O
M#NF?T'44 ?BG\;K[]KN[_:"_;2N_@#\-?&&F_%#XU']FO]AW]GKXGZWX3\5:
M%\._AGX$^''PQ^(/[0OQA_:FUSQU>^%]:\.V?AWPQJW[2WBKX?\ @#4K?2_$
ML7CGXZ?#[PYX%@\/^);70_$D.D_+?C[X6?$[]FZT^-?[-</[,'Q!T3X$?&'Q
M-_P2_P!4CC_9OT7]H+]K#PE;>#/"GQ:F^''[6\GBOQ7H7P-\,^+K_P 4WW[-
M/[._@6W\;67_  C'B#7]=O\ QWI7B+6M8UJ_\53VZ_TH44 ?EM\0OA/HG[5?
M[6/P6\56_AOXNZ?^S]XT_9H^(Y_:0T?Q=\,O''PP\-?&P_"WXS?#Z;]F;X*_
M&/PK\5? OAWQ<FBZ/K?C;]I'Q[<>!YHO#$_B[PU-/H?C73/&'PC^(NJ:)K//
M_LMZZEA^UQ\4M0_9PTGXXM^S/\=[?X@_'7]H#PI\9_V8/C!\"--^#'[2%M%\
M-?"MCJ/PDUWXL_#7X8^+O%6I?'33]/\ $.N_$CX5Q:-\0;;0O$/A>?XBV_B?
MX<OXOM/"_P 4/UIHH ^(O^"=/AGQYH'[(GPVUSXI^'-5\'?$WXP:Y\6/VD/'
MW@_7])U+0?$7@WQ/^TY\8/'O[0%[X(\1:)K$-OJVBZYX%B^)%OX+U+1=2@@N
M]%N- ;2)((/L*PI^$OC+P3^U!\3?!/B'5/!'@+]J^[\;?%+XS?\ !0'XRZ_\
M)_'W[-WC?X=>"_@WXT^-1^,7[/\ ^Q)\:5^(6K?#?P?XM^(7Q ^'GA3QO\$K
M?5/A[;>*_B%X+\#_  \L_''Q9U_3/ NJ_!?P)J]O_5O10!^1'@/QGX8_8O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_$O]L+_@D_\ #V[\'_#WXBZ3KWA/_@ICJ6H>!/BY\<?&/[.?POUR;P=^S_\
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M#-6M_'FI>%;GQ5#J?A&PT#0K'PQ?QZJMUH%GHNDVVE2VD.G6:0@'\^/[,/\
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M^V\+6GB77;6UBU37;;PU;:KJ=OH$&J75U%HT&HW\6G);1WEPL@!_-+K?Q_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO0+:>+2;JXLY #\<[[]L+]N37/%O@1_#/CCPLWA;]JO]HG]L+X2_L_:+X/\
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M-;ZYJOBC0=?L_%5S\0_A+K>AG5+FR^$%[<GQ(ND>'I;S1M"BU&'7+Z^_IO\
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M  I?X._\+4_X7K_PJ;X:?\+N_P"$9_X0O_A<?_"">%O^%J?\(=YWVC_A$_\
MA87]E?\ "7?\(S]H_?\ ]@_VO_9?G?O?LN_YJ /Y!/A;^V/_ ,%5/BK^T]\5
M/B[X#^(WQ);4_AY_P4TD_98^(7[.?C3XD_L.^!?V4="^#VD^/++PI:_!G2/#
MWQ1^+_AKX_77QQU[3YH?^$=^(7@CP-<77C_6EO\ 1?#4NO:[;:AY/]HU?,VL
M_L6_L?>(OC#:_M">(/V6?V>=<^.UCJ^C^(;/XPZO\&_A[J7Q*M?$GAV>SN?#
M_B:#QG>>'YM?C\3Z#-IVGOHGB-;X:WI(L;-+"_MTMH53Z9H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /S;\9_'/XX2_MY6
M?[.>K?$;P?\ L]?#J;PS\,_'OP,DU;X3ZMXUG_:Z-O<>+;_]H7X=6GQ3UKQ!
MH/@CPAXS\ ^&?#\5Q8_"WPS877Q-T_1+RQ^-YU3QAX#LO%?@70.<^'O[6?QB
M\?\ [%7[*/QSMX=-LOB7^UO\??@JW@72#HEI<Q6GP$^,?[1D7CB33VLX;EK7
M^W?"W[#MOXBU&76[B9ICK_A]]=NK674&?3I/HN]_9.N/%?Q6T3XA?%?]H+XS
M?&#PCX)^(VN?%/X:?!+QAI7P,TCX9>!O%>K:+XG\-Z63<?#WX,^"OB%XWTGP
M)H'C'7]+\":3\1/'7BJVLWNK/Q#XJ_X2_P 9Z#X9\3Z)XUX&_P"";7A+P1IG
M@CP@O[1O[2FO_#+X*_##QG\+?V:?AQK.L?"9=(_9TM/&'@?5OAA9^-/ ^OZ7
M\(M.\9^*?B-\.?AAKVL_#7X5^*?BOXC^(#>%/!6KZS87MCKVJZYK>M:B ?-J
M_'G]K?XM^&O^"??C'P!^T=X>^&;?MT^.O'%QHGA9?@MX+\8C1/@=<>#/VC/V
MF_ GQ!6XUG4K;4+C4K'X*>'?@G\*M3MDD;3?^$L\06GBBXGO)-2N;:X[+]D?
M]H;XR_'+]HKXI^$-?_:+\97OA[X0?&;XA_"BT\%67['WB+1_"/Q#TOX!Z5H?
MPL^(WBK5OVB9/",WPQT;6?$GQ[T+XCZHGA+PSXON[[2=#BTWPM:QV^J6M\UG
M]X:-^RO\+?#_ (\_9V\=:.FM6(_9;^"OCKX%_"'PC#/I \':-X7\>Q?"33[[
M6KBQ.BG5I/%>B^'_ (.Z)X6\.:A9ZU8:;I_A[Q%XSLKC1[Z76;:YTWF/V6_V
M33^RKI$_A3P_^T+\>/B=X$>]\?ZW9^!_BO!\!;K3-.\5_$WXC:Q\4_&7C!/$
M/P]^!7PZ^(.J^(-6\7>)/$]Y,WB3QGKFENGB+43-I<MW%IEWIP!C_&7XJ?&_
MP_\ M>?L@?"'P/<?#VU^%?Q+?XO^)?BQ!>V>L:O\3M6\*?#GX:^(GGNM"8M9
M>'?!_ACPY\3/%'P,T_4M4=/%&L>+)_',NF1?\(+!X>27Q[\]_MA?M:?'']D;
MXJ6/B9O$_P -_B_\*CX.^,/Q-\4_L[^%/@QXKTCXP^"_@]\*O@-X]\4VGCJ_
M^-9^,WB'PP=3\:?M#Z+\./@QX4BU?X1:%IGB>^^*NG>'=%TX:CX5\2>,D^_[
M[X0>&M2^-_A?X^7M]KDWC#P;\*O'?P@\-Z:US8#PUIOAKXE^+OASXS\:WT5F
M-,&J-KFN:I\)O $$]S)K#6"6'A^VBATR.XDGNI/B?PQ_P3+\'Z-I/[2VE^)?
MVF?VG/B=<?M8Z)XBT[XO^)_'J?LS'Q[>ZQJ5E-8^#?%>A_$#P=^S3X/\::-?
M_!:*=F^!WA6/7)_A?\,V54T3P +<R0. :O[-WQ3_ &P[+]I/5/@%^U)K'P1\
M<W>I?LR^#OV@KO4_@=\/O$O@'2?@WXOUSQWJ_@B^^$NJ7/BOXK_$75/B#H.M
M-I>KWGP_\?RZ3X+N];;P%XYN-1T+3UFT[2-+_1BOGGX%_L^6_P &[_QWXN\0
M?$OX@?&[XL?$Z?PVOCGXM_%"'P):>*=2T'P5I]YI_@CP/I.C_#3P5\/O _A?
MP)X/.L>)]6T3PWX?\*V,1\3>-/&_BO5;C4_$GBW7-4O/H:@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO@/
M3_V[+"_^ O\ P3T^.0^&EW%!^WUXD_9X\.V'AL^*X7E^&#?'[X+>(OC';W=Y
MJO\ PCZIXM7PO#H#:!-##I_ATZO+=+J22Z<D)LI #[\HKYGO/VR?V7=.\-?%
MOQGJ7QM\#Z9X.^!=]_9?Q2\6:GJ$VG>&?#>IG7[KPC'IL&OWMM!I7B/4)_&M
ME>> [6R\+7>MW-W\0+2Y\!VT4OB^&315],^#_P 9/A?\?OA[H/Q5^#GC31_'
M_P /_$IU%-(\2:(\_P!FENM&U2\T36M-N[6\@M=1TK6-$UK3M0T?6]%U6SLM
M6T?5;&[T[4K*UO+::% #TRBOQZ3_ (++?LT>(M>^%UWX1UE-(^&FJ_M=_%/]
ME?XK>,OB98:CX3D\/7/@3X&?'KXB^%O$_@RTB:]_X2(?$WQU\(=*\&^"= F6
M/Q?JR^);>PG\*:;XKO\ 2M%F^PO&/_!03]BGP!\-/A9\8O%W[2_PHTCX:?&R
M*\NOA9XL;Q)#>V/C'3](:W3Q+J^G0:='>:A!H7@B:[M;;XB:]J%G9Z-\.;RY
M@LO'5]X>NYHX6 /L.BOGW]J;X]V?[,W[,?QV_:4?P\WCFP^"?PA\<_%H^&++
M68M&;Q5:^"_#5_XD&DVNO&PU>'3O[6BLA;PZG_9NHQVXF6X^R7*KY;9DO[8_
M[+,'Q@O_ ( W/QW^&]G\9-+\2Z1X,U/X?WOB&VLM=T[QAXCT?3=?\*^$[Y;O
MR;6T\2^,M'U2&_\ !.A7%S'JGC2&TUL>%K75Y/#NOII@!]*T5^</P_\ ^"KW
M[$GCKX<?%7XL7GQ3;X>^!_A+\:]8^ ^JZC\1-'OM#O\ Q1XUTZ^UNTTI? .@
MV2:MK?C%?%MMX8\2:]X=T'1["?QLGAK0]4UGQ'X4\/1:??Q6OKNN?\% /V+?
M#EUH]GJW[27PNAN=?^$<7Q\T>.VUX:F+[X(R^%O%7C-?BS%)ID-Y&OP]'ASP
M5XBO9?%DKQZ+#<6UCI4UY'J^N:%8:D ?8-%?+.F_MO?LB:Q\,_'WQCT[]HOX
M3W/PS^%L6D3^/_%X\7:;'IWABV\331V_@NZOXYI([U[3XBRW%DOPON[6UN+?
MXH+J6DR?#Z7Q+'J^F-=^06O_  4]_8_UGXL?LR_"/P?\0+SQUJG[5^E>.-6^
M&7B;PIH=_?>$;/\ X077D\(W^D>+[VX6SU?P]XCOO&*:KX5CT&71)[[0-9\.
MZ[;^.4\)"#3VU( _06BOD;]JC]MGX'_L=W_P,TWXR7GB2VN?V@?BE;_"KP6?
M#WA^XUR'3]1;2[K5=1\1>)'BEB>R\-Z1%#9VEV=-CU;Q!<7VL::NF:!?6,6L
M7^D=SX:_:K_9O\8_&'7_ -G_ ,*_&OX=^(/C+X8.K1:W\/M*\26-YKMI?>'O
MLY\4:+&L4C6M[XC\(1WNG3^,_#-A<W7B#P=;:KH]UXGTS2;;6-,ENP#Z HKY
M&_:H_;9^!_['=_\  S3?C)>>)+:Y_:!^*5O\*O!9\/>'[C7(=/U%M+NM5U'Q
M%XD>*6)[+PWI$4-G:79TV/5O$%Q?:QIJZ9H%]8Q:Q?Z1J:?^VU^RAJVD?%_7
M]*^.G@;4]%^ 6NV'A3XQ:GIU[=7MGX"\8:KXPUGP!IO@K6IK:SE4^-[_ ,9:
M%=^'[3P79?:_%$]]=Z (]):+Q3X9EU< ^I:*^/-5_P""@?[%6B>'_AWXJU/]
MI?X46_A_XLZ7XMUGX=:D/$D-Q'XIT_X>ZO9Z%\1I+&*V2:XBG^&FIW;0?$RR
MO8;6^^'4>F>(KSQK;:%9>%_$EQI7J'_#3'P$?QOX:^'-I\4_"FJ^+_%_@RR^
M(GA[3="O)-?M;_P1JVG:KJ^@^)FUO1(;_0;+2_$^DZ#K^J>$9M0U.U/B[3M
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MO#GP[LXO#/A[3?#^J:AK !].?LE_M&V_[5'P5TOXM_\ "O?%?PDUB3Q=\2_
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M=?!'Q2_X)>:W^U!\2=1\0^/]-7]D31[#XC>-/BFVM_LP?M:?&KXE7?Q*\?\
MC?PMXI^&WB#Q4GP@^(?PP\ ? OX%:SXK^'OB[7+CQO\ $3X>>#]4^-VK^--;
MN)]#^(_AFX\/R>-/'P!],I_P4Z^!<NK_ +6LEIX=^(.K> ?V4/#/P>U%_'^@
MZ+#J]I\>_%_QG\;_ !+^&'A7P!^SWH\%TEWX\UB_^*OPXE^$^@ZC/<:/I'BS
MXAZU9:?H-S<>&VL_%>I6+#_@HKH%OHGQ1LO'?[/WQH^''QH^%OQ2^ 7PFO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS]GSPWXZ_9]\'_$_19M+N_!?@[PCX+\<^%O!'Q<MHOB'X9\&> I+?6+7Q?\
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M[I.D?#GX>^.OV?/B=\6?V^/A<-)TW6KGP5,/%7[$7P;75=*\67)DO_#WA_\
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M (*(?%KQK\$_V7-5\=^ /%_BKP#X@E^-G[(_@"Y\8> _AY!\6O'>A^$?B_\
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M*?!4OPO_ &3O@7^S9^TO\7_"?[0GQ,\2Z;^T5X7^$7[-VL>";7PSJ_[.6O\
MP/T'PG#K?ACXX:HNJ?#KXT6_C?2?B+IWPVBO5U:[N-+UW5?@P_N/CK_@I/I'
M@WX2>$/$J?!;7Y/CAXM^-OCK]G9_@3XG^*/P@\ V?A?XF_"W1_$WB/X@W_BG
MXS>)O%D'P[L_AK8>'O# U3PYXPTZ?5=9\22^,/AYH,G@S1_%'B+4]#\.]GX^
M_;5U/5?^"<7Q%_;C_9]\"VWBGQ#H/P(\??$_0/A[XUU?3+:WT/Q1\/K36K;Q
MMX>\:7^@ZV^FZFWPQUWP[XFM_%6F^%_$JGQ++X5U#1O"_B&*XU/3=40 \4^&
MG[ /Q,\%_";]F/P-J&J?"R37?@O_ ,$F_B%^P=XJO=.O=?>PU#XL>-=!_9IL
M3K^@7,_@RUO+OX:W&J_!KQ/?:OJNHVFE>)9C?:#<_P#"'W=S=:@FE^3VG_!/
M/]I7P-X,TW4O#=W\&_&WQ \%_P#!0;]G[]L7PYX8U+Q_XR\)^'?%/A7X7?L+
M_!K]E'Q-X6UKQJ?A5XEU#PUXDN_%G@SQ9XHTB:V\'>)=.NO#::";R[L=7U2_
MTS1N/\-?\%'OVB? ?Q!^-7Q7^*G[/OQ \8?#+P5^P%^Q3^T]\6_"7@#QY\,#
MX9_9^\-ZYXE_:_O?C+\1-$A\4>)]&U/QCX@\6> ?"'AOQMI?@;0CJ%Q=>'?A
MMJVAW_B'3?%%AH-AXP^RM9_X*5^!-(_:Q'[.#_#[4&\&V?Q>\._L[:Y\;)_B
M3\*K2WLOCKXO\'Z+XM\.>&],^$C>*I?BMK7@BXOO$OA[X::A\2$\/V6FV/Q;
MU,^$(=+OM/T_4_$EF =;_P %.;[2=+_8Z^)&KQZSI^F?%;PO=^&OB+^S)ITS
MPOK7C7]J?X/ZU;?&+X!_#CPEI?G0ZAXEU_X@^/? &F^$YO"NBE]5\2>'-5\0
M:0D;V=U>"OBS2?\ @G_^U9\)/!_QW^&WPR'P-^)FG?MB_LI?#GX1_&[XD?%7
MXA>*O#VM_#_X]W5K\:;3]H+XN:-\.K+X.>/M+^)_@3XBZ_\ &WQ'\9;/X:WG
MCWP%;R?%"\\:Z7/<:3I'Q&O_ !-H'Z@_M"_M W7P7N?A-X1\)_#K5_BW\5_C
MEXYU+P+\-O >E^(-!\)64LOASP+XK^)/B[Q1XN\5^()C;>&_!_ASPGX.U&*?
M4K/2_$&I7OBK6/"/ANTT=VU]M0T_\MOAY_P4W\3?!#]D+5_VB_V@_ NOWUG>
M?M8?M]Z/XAT?XE_&[]G#X5^-_AAX0^$W[4_Q4T?PO\%-(MO'WQ/T'P_\3?BQ
MX7\!:8WA;PCX%\ >(=8T75C\/=6LY_'MDUUX8N/$@!ZSXM_8Q_:9M/&7Q>\%
M^ %^$&N?!?XQ_M[?L+?MEZE\1/B#\5?'5I\5= T+]FF^_8VD^)G@>3P9IOP>
M\0:/XJ\5ZZ_[(=AJG@SQ#=?$#1=/U9O'>HV/B9M G\/P:GX@^U_V-/@5XE_9
MT^"VI?#KQ?=^&;_Q!J/QZ_:P^*LU]X3GO[K3)]&^.O[4WQC^-7@^&YN=4TC0
M[V37-,\%>/O#FC^(HVL7M;+7-.O]/TO4=7TFTL=5O."\ _MW> ?B1KO@WPEX
M;\*Z]/XN\7_M)>+_ ( '0GO+ /HFC^'?@SJG[2&B?&'4ID#R#P)XS^!$_P -
M_&&BM':FX@UWXN>"/!NH26^H7%Q>1\9^T1\=_CE\.OVU?@9\.?A%\-_$7QHM
M?&?[*_[2?C/4OAG8^-/"?P_\,+J_@;XN?LL:98^-_$?B?Q4S);7>CZ)XR\1>
M&_#5EIMAJMUJ6M>+[>TOH-(T%]9\5>'P"QXE_8GUWQ7^TG\3_&][XPMM(^"'
MCGPEX^\8Z/I.AZGK%O\ $GPI^U)\5?@_X-_9F\1_$SPO(NGP:'X3TSP=\ _
M-Q;^$+W3M3O]9U3QS\:/BQJNJ6&E+!87FN_-?A_]BC]K+XB?!/PS\%_C18_L
M_P#PR3X1_P#!.GXX_L2^$/$?PE^(7B[QM:?$SQC\9/ /PO\ ATOCO6=$U+X*
M?"]_A?\ #3P_IGPFT[Q"_P .M-NO'<FH^(O$NGQ?:+>+X5Z%JWC#JOA7_P %
MA_@S\9OB?\*]!\$?#KQ-'\'/BEKGPN^'UI\8_$_COX3:#K&C?%KXQ?#'PO\
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MQ^\4?L\>,/ VK>)/"'B"+X?>)?#_ .R_X]_:LTOQ=:>(_#&HZCI?C?X?>-?
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M-3\+:3XR\-W.N7GBJ?Q];ZO\'M6T77-"T*QU+1]!BB\2:EK7B73V\-V=AXD
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO"7@O]GG]DGXU:!KOQ9?P3>^+;#QG\:?B#^V+X)^(T=OJG@SP5X*@7P[K)^
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M:#X6TR"7X*7\3^(/C%\-O^%=:BUA?_$)?!6M>+-9_M_Q=\-O%VOWP!]N:O\
ML,_ SX7?L_?M1V'QN_:!^)=]X,^+_P"Q5HO[*/QQ^,/C_6/A%X,D\)? +X5Z
M-^T/9Z-XJL+OP]\,_#'@GPQXC\+>#_VA/%FF7_B;6]#U;0[BP\(^$-4U;1)M
M4M_%&H^*/;M(_9$M_"_Q^\;?&GP7\</B9X6TCXD_$/1?BMX_^"]MX6^ &M>
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MBG\+OB%H>JZ?XSTO]KGXDV/C:VU6VNS+)H/P[UCPG)X2\1>%I=8U7\,OVB?
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M? /A^\G_ &J-:\"RP7:^*["]OK#P=XKOO"GC+XBS>);[QN ?KM\$_P!D2W^
M7C?7-?\ "?QP^)E[\-;_ ,7?%CQWIWP5U_PM\ &\'^%M7^+WC+7?'_B&QT?Q
MMI/P7T;XR?\ "+Z%XD\3>(+OPEHVI_$N_?1["_CT&[U'5/#FEZ3H]CI?'']E
M)?BS\4/!?QM\$?&WXK?L\?%SP=\.O'OPC;QO\)M+^#>LW7BCX<?$+6?!_B74
M/#OB?2OC+\*/BKHMT_AOQ/X(TCQ'X(U73K#3-0\/:I=:]%)+J6C>(M:TB^_)
M7]K[Q/HO[1G_  1?UCQOI?CWXL:5IG@;XR?#D>)?$\GQET;XC17[_"O]KSPY
MX"^(=['\==(TV#1/C!\&/"TMGK_BSP7\298-,N[S3O"'A;Q-XRM="\3Z#XC\
M.Z?T/[2W[4Q\,>/?C3I*?MP>(OA#:_ K]D#X%?&?]A?0O#?CKX,^)C^W#XB\
M<:)\2X[+QK>67B'0-5\2?M.W7CCQOX2\+_!^+X6> -5T^VOQXGT[Q1H<]OX\
M^*'PW\3^$ #]6?@)^R%\)OV;O$^I^)?AE+XJMEU'X"?LY?LYQZ%K.KV>JZ1I
MW@/]F&3XM2> +^UF?2H?$%YXMUAOC)XH?QOKNN:[J_\ ;\]GHU[!::9?)K%U
MK/ _$']FGX!?&WXB_ME^$M3\=^+U\>_M#_LR?!#X+_&_PSX?U?0;>[\%?"K3
M-2_:6B^&GBCPK%?^$]1_LKQ#XIOOB)\6K>XO];N/%&E71\(Z0+;0=,-CJ#ZY
M\Y?MB?'*31/V@_@A\)?CK^U%J?[!7P5\4_LX?%/XQ'XE^'?B7\'O <WC3XX?
M#_Q3\,K"]^&L_P 1OBUX5\0:1'8?"OPOXKG\?P>%M+TV&/XL0W%]<>)+74O
MG@/Q5X7U_P#,KQ?^T3XL;Q'\=OC+X_\ VF_$G[./[55Q_P $GOV*?CC\%?A9
MIVI^#_A]JGQ[_:+M+?\ ;(U#PSIU]\(/$.G7GB7XE7VH>,-3\%:#??LSZ5-?
M6T>J_%:#P;JNEZ[XK7P=K&C@'[M?%[]BCX<_%Z3XQ7MSXU^(?@_Q7\7/%W[/
MOQ#/BOPO+X O=5^'GC3]FS6M*USX9^(? ^F>-O /B_PVZSWVAQVWBO2O'&A>
M,]"\3:3=:QHD^G0Z9J%U;'Q_QS^R'H5KXL^!NIZ]^V;\3?!WQYF7XO\ PI\
M^,SX)_8[L]8^*^C^/M/T3XJ^(?ANOP\U?]G"[\"ZY<^!-'^"#^.?"FH^'O"]
MGXXT72]'\:W6N>(-<\-ZEK>FM^6^N?$?0_V;?VH_^"I=]XR^,_Q8\(_%?XP^
M/OV,[;P[X+M/C_X#\"6_AVR^*G@+X2V^I^-M5\=>.?"/B73?AK\#_!/CF<_
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M$7[-WQLGMIK&/2OB!XN^$?[$W@NX^.GC_P $F6+3/%?C[XPZ!HUQ"UU'%/:
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M?$_]HGXX>'_^";6N>,[OXSZIH?B#0/VV/B3^RYX\_:-UW6_AM\/?$WA7X(>
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MT:1HTK)&ID9(XT+DE4084?SR^%?V@?$GCR\^".@?M4?ML^*/V:/@AXA^(/\
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MM\=?$_Q$\%>)+GXZW[_#KQOH^D_#_P"#OQ*^+&O:;I]I:Z%XK\(^)=4TG1O
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M?LVHV5I?V^])/L][;0W4/F1G=')Y4Z21[XVY1]NY3RI!JW110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117R9X1_;G_
M &5?&WQ9N?@?HGQ8M;?XDQ^*?'7@;2]'\3^%/'?@;2/&7C3X8^*=9\%?$'PG
M\-?&?C;POX>\$?%3Q'X.\4^&_$>C:_HOPW\1^*M1T^Y\.Z^\]NL&BZG-:@'U
MG117,Z[XKL/#^K>#M&N].\37MUXWU^\\.Z9<Z%X3\2>(-)TJ[L?#'B#Q9-?^
M,=;T73+[2/ V@2:?X;O-.L_$/B^]T;1=0\3W_A_PC8WMSXE\2:%I6H '3444
M4 %%?G3K'_!57]C'1X_B@LGBCXR7&I_!OPAJGC?XC:)_PRG^U1I>H>%=!T[P
MQKGBZWGUV?Q#\&M%T?0&\0:)X<U:;PI)X@U72;3Q+-;"#2+JZ>1,_HHC%T1F
M1HV958QN4+QD@$HYC>2,LA.UC'(Z$@[79<$@#J**^??AO^U7^SS\6_V>A^U?
M\/\ XJ>'-=_9U_X1WQQXME^+$HU'1?#%KX:^&NI^(M'\=ZW?-X@L-*O[#3_#
M&H^$_$=OJ=Q>V5NL:Z3<SQ^9;>5-( ?05%>??"CXI^!?C=\-_!7Q<^&.LS>(
M_A[\1/#]AXJ\&Z_-HNO>'FUKP]JL7GZ;JL>C^)]+T;7;.VO[<I<VG]HZ9:23
MVLL-S'&T$T4C]3XB\1>'_"'A_7?%GBS7='\+^%?"^CZGXB\3>)O$6IV6B>'_
M  [X?T2RGU+6==UW6=2GMM.TC1](TZVN=0U/4]0N;>RL+*WGNKJ>*"*210#8
MHKD5\;:/+XG\.^%K6U\17UQXH\*:[XSTS7M/\+>([WP1'H^@WWA:PE@U3QY;
M:9)X/T?7]5?Q=IUWX9\+ZGK5KXC\4Z58>)=8T#2]0TOPIXCN],ZZ@ HHKFO&
M/C/P?\._"VO^.?'_ (J\.>!_!7A72[K6_$_B_P 7ZWIGAOPOX<T:QC,M[JVN
MZ]K-S9:5I.FVD0,ES?7]U;VT" M)*HYH Z6BOFSX&?M:_!']HZ^N]/\ A3J/
MQ#O9K70+/Q7%-XU^!7QW^$>G:QX9U"X2UL/$'A?5_B[\-O VE>+M'O9I$^R:
MCX6O=8M;F(FXAE>!6E'TG0 45S&D>-O!OB#Q#XM\(Z#XL\-ZUXJ\ W&C6GCK
MPWI.MZ;J.N^#+OQ%I,.OZ!9^*M)L[F:^\/7>MZ#<VVMZ5:ZM!:3ZAH]U:ZG:
MQRV-S!/)T] !1110 4444 %%%>0^*OCCX!\&_%WX5? _7)?$R^/OC-I_CG4_
M T>G>"?%VL>&I+7X=:5;:UXF/B+QKI>BW?A'P?.EC=0G2+;Q5K.D7'B"YWV>
MAQW]W%)"H!Z]17%>(OB5\.O"'B;P/X*\6>/O!?ACQE\3K[5]+^&WA+Q!XHT3
M1O$_Q"U+P_IC:WK^G^!] U&^MM5\67NA:*CZQK-KH-I?S:7I2/J-\EO9HTP[
M6@ HJGJ%];Z987VI799;73[.YOKED4NXM[2%[B8H@Y=A'&Q51RQP!UKPK]EC
M]IGX6_MC? /X>?M)_!:[UJ^^&/Q/L]:OO"MUXAT>;0-9FM] \3ZWX1U WND7
M$DLUFRZQX?U%(E>1C+;K%.,+*  #Z!HKYR_9M_:G^$W[5FD_%?6OA'>:Y>6/
MP8^.WQ)_9T\;MKNBSZ))!\2OA3<Z=:>+K738YY)#J&CPS:I:"PU:,I%>JSLD
M:[#GZ-H ***^<K+]J?X37_[5^M?L86]YKA^-^@_ G3OVB]0L'T6=?#B_#75/
M&[_#ZTNHO$)D^SRZPWB)&C?21$)4M,71D*_+0!]&T45\Y?"G]J?X3?&7XV_M
M)_L_^";S7)_B)^RCK'PWT/XNVVHZ+/I^DV=_\5?"5QXU\)+H6J22/%K<4VAV
MTLE_)!'$+*Y"V[AV8-0!]&T5\Y?#3]J?X3?%G]H/]IK]F7PA>:Y-\4OV2O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?^$G^%?PU\1V/AV+4+/PKXU\+7E[H'PO^'_A0"REN/&/A6^C\$Z?]ON7C/\
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MOP%_^8&C_AV+_P $V/\ I'K^P[_XB;\!?_F!H _F&\ _LG_M>_L]^.#^U_\
M!#X-?MB0?M$>(?\ @X,^*/@CQ1X%TP_%[PYX%\=_L _$[6-0\0^+M;\1> [_
M $Z3X?:9\%O&FNZ/HDUU\?\ 6_#LOAC3KR32=9NO%$A\/>&GT?S/]GOP#^V^
MOA?]KC4O GP8_;0\$6GQM_X)1_M1)\0O VH?"K]O&PO(_P!M71]:\+6O@O0[
MCQ?^T?\ %?XH:Y\8/VC$\.7UY;Z%X]^&'A7X7:)K6FZEJWA;P5X:U6_\.^*6
MTK^L7_AV+_P38_Z1Z_L._P#B)OP%_P#F!H_X=B_\$V/^D>O[#O\ XB;\!?\
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M63<^!_'NN?"O1_A#HLEYXGNM,USQ1\4]>MX[K4]>U36&G_>/_AV+_P $V/\
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M^&OCM\/O#WA;QE\-M;\,R:9XN^'7AWXRZ-\*/B!X2\:Z-<:AILOAF?XV^!/
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M&M1U*-]*?5M U+_A*?!\>I:IJWAN>^G /LJBOYOOA1\?_P!MWXP_ +_@C/\
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M:\7?&+1K/P#KOQE\:>)/#7Q/N_%WBWX?WMY%\1-"\+>&;VUU/6?"/AKPB]@
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MP+HWCOX.>.+37;;6? GCC0_ OC#PWI?BG2[67Q-KFJ^'+G5[6XU3PIX@OO\
MA(?#=_I>M6ME?6W2?%7]E/X&?&>Z\?ZEX]\*ZQ<ZW\2_#GP1\+>*/$GAOX@?
M$7P)XF33OV;OB7XS^,?P-O/#'B+P-XK\.ZQX&\1_#CXF_$#Q7XPT3Q;X*O-
M\43ZCJ-O#JVKZCI^D:-9Z?\ G'\/-'^/-M_P48A\5ZWX ^-,7[(NK>*O&FBV
MMO#I'C"T\,6/[>VG?![1-(\:?M P>$-0T:W\4^'/V0O%OPTTKQ]\,OA[X@UW
M5[CX8:M^T9-XC^(D7A[4;[XI_"[XF7'!_MS?LZ?$KXI_&'_@H+\3-'T7]HV7
MQ'\*?V&?V:O$?['6J?#3Q)\8M#TBV_:1TCQ5^V!K^MZU\,M \&ZC:^%?'GQ=
M\-2Z/\)[2^M&TCQ-K&F^'?%5MX;U33CX=^(=[INN '[/?##X9Z)\)O"R^$]
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M;#PUX2L+KPSKGC3XT?#_ %=/A+9GP5XNT76OB!X4B\>3^#M>T&Q3XF:YI&O
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MM[K._P""D^J?'?5_VD](G^$7PO\ BKH'CWX0R_LXZS\*?'GA#X<_MB?%*_\
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M=$\.^#])ZSXQ-\=KO]OCPQKGPL^$OQ9^'%QX*^/>G_"CQ#I>@_#?]LGQDOQ
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MQ-;V7TQ8Z%?^'T^*'Q2_8Q\"_M8_\*2_9WU#]E'X\:+X)^(OAW]JP>-_B/\
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M/!?Q%U'PY_P4_P#CKXZUV;Q+??#GPI\:/&'P]\3^#_B1^Q)H?B<SS:=I>G>
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M/@SXJ>.;#Q78:-X:CL/$NIZK8:Y>Z;<>(O#_ (9U'2?YYI_V4_C9\"?V6/\
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MZ-X\\/7WAJ^TGPIX\T75-2^E_P!H/QGX[^/_ ([_ &FOB#X(\+_MDZ5^S?\
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M0WN@?LU? G3-:\,ZGX-T#7_".I> [FRDT[1-;UOQPFM_DU\4_@)^SPG[1O\
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M8S3>'?&K^+_B$O@;1@#[RU7]GKX/ZWH'[0WA?4_"'VG0OVJ[K5;SX^6/]O\
MBB'_ (3RYUOX.>"?@!JDGVFWUJ*\\+_:OA'\.O!WA+9X,N/#L</]C_V];K%X
MFU#5=9OO'8OV!OV7X/B;I_Q6A\'>+8M=T?XEVGQIT;PY#\8/C%!\+M)^,EII
M%KH!^*VG_""#QY'\,+?Q]?:-:FQU;Q$/"9O-6&I>([O4#<:AXN\5W>M?9-%
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M0XO$>O\ AKPSI6B^$=;U;0+WU3X;_LL?!CX1?$S7OBQ\.=$\1^&/$_BCX?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV=G=ZA+?7WB"PNS?WUUJ$WQ-_P %;?@/X>_9<_;"^*GP_P#V7?@#XRU'X?\
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MY\/RW,4<[Z>TJ*XX[Q/^R?\ LL^-OA;X4^!WC/\ 9I^ 'B[X*> [ZSU3P/\
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MZ@+> ZAJDT$E_?O%')>7$TBAJ].H **YG7/%=AH&L^#=#N].\3WEUXXUS4-
MTR[T3PGXD\0:-I-WIOA?7_%LUYXRUW1=+OM'\"Z'/I_AR\TW3_$'B^]T;1=2
M\47V@>$;"^N/$OB30M+U#IJ "BBB@ HKP'Q%^TG\.O"OCWP5\-]<L_'FG^)?
MB'\7/$GP4\("]^'OBW3=-\0>,O"GP"\1?M(ZM=>']3U32[&U\5>$E^'7A77;
M6V\8^$FU[P]=>.-+U3P%%?GQ1HNN:=IGKOA'Q+9>,_"GACQAIMCXATO3O%GA
M[1?$MAIGB[PSK_@KQ7IUEKNFVVJ6MCXG\&^*].TCQ1X2\0VD%U';ZUX9\2:3
MI>OZ#J4=SI6L:=9:C:W-M$ =#1110 4444 %%%% !117,>)?&W@WP9)X:A\7
M^+/#?A:;QGXGL/!/@^'Q#K>FZ--XK\9:K:W]_IOA/PW%J-S;R:YXDO[#2M5O
M[31-,6ZU*>QTO4KV.V:VL+N6$ Z>BBN9N/%=A;>,M)\#OIWB=]4UCPQX@\5V
M^K6_A/Q)<^#;6P\-ZKX9TB\T[5O'4&ER>$-&\3WUQXKL+GP_X3U36;3Q)XET
MK3O$VL:#I>H:9X3\1W>F '345Y;X[^,7@OX<^-O@IX \2SZA%XB^/_COQ#\.
M?AW%9V$EW:7/B7PQ\*?B'\9M5BU6Z1E32[-/!/PP\53P7<JNDVHQ6.GJHDO$
M=?4J "BBB@ HHHH **** "BBB@ HHHH **YCQEXV\&_#OP]>>+O'_BSPWX(\
M*Z?<:7:7WB3Q;K>F^'="M+O7-6L= T2SN-6U>YM+&*[UK7M4TS1-(M7G$^IZ
MQJ-AIEE'/?7EM!)T] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#W[2GQ$^*#:S\0OV^/AA\8OV==5^+/A&X\)^(?B</%/Q/^#GA+QMJ'A+Q_\
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M&=8\:^*;NPTF&>TC_LWPKX/T#6/$.LW$UW%,]O:1:;I%OJOB#4M(T?4/E_\
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MQITH^%KB;5?@-#HWQNTKX#S7WQFL[:YG/@?3=3\1WFN>,?"VI7CSV7C3X2>
M_'WQ4\'SZ[X,\-SZI, ?)_PRT3XUQ?\ !0*^_9;\3ZCK=_\ "OX4:S>?\%'9
M_%6F:O?S^'9I_C]X.\2_!OP]\ =1MKV_;43X?O/VET_:S_:,\.Z?>K-8Z#;>
M"OAII-E"%TU6M?/OVWK;Q7=?'[]I<>//"O[5WB3Q3I?[.GPPU/\ X)KWO[/.
MF?M/2>"])^.=^GQ9TWQ#'>ZY\)=+N_@WX6^,T7Q2MOA^WB?Q-\=[N/PC%\#M
M;T&PUF%/A@OQDBU;]1O@O:?!./XI?M,M\,]-UR?X@Z-\1O#GA;XY^+?$&L>+
M?$UQ=>,+KP'H7Q;T#P1HNN^,M=URZLO"?@_PE\8=+US1O _A3^ROAWX*N_'F
MKVGAK1M/U*_\20+R'@#]M;X;?%/6?BI'\/? 7QX\7> OA/8>.9+WXSZ%\'O%
M.H_"OQ]KWPTU*_T3QUX,^#>I6L4OBCXN^)]#U_2M4\/6R^ _">M:%XH\0:;J
M&A^#-<\1ZG8W=K" ?G'XVUSXW>%?%_[1_P &]>\(?'[7OB1\3?\ @JE_P3:^
M+W@36_AY\)?CCXC^%C_ "SU?_@G1-\8?$6E?$O2O#6I^"/"7PU\,7GP7^/\
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MU_:B\+?'K1_ /C7]GCP[\*OV@M'TGX:>*_VMK[]D[XMS>$_VZ_C/K>F[-?\
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M?032VEOXGOO$G[07Q-\8^&=,G*R7/@CPOXBBMY!;^#G,_P"C7A[XN_"KQ?\
M!;3OVQ_"_A35_$.@:O\  ^?XD^%]8TOP0MW\4_$WPGNM$_X6'I.E>'=*6/\
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MH/PYX?>77KO1O'7Q-\.^(/@YX[^"O[0'Q)\!^%_AIXBU+XC6'@KX!V_CB?\
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M]#>:G/Y;7#JOG=E_P4N_9DNO ?Q(^)UV?BWX=\!_#_X+^+?VC=*\3>,O@O\
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M6I/>ZAX?U;P5XAUSQ!;:7X*MH/%-S^D% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#XG?#WP[I7QN\*:6U[X<T;Q5XYT7XB:1I<&JZ8VG:9I5J/%.C^/.]\(?&?\
M:8^(7[&/QB\6?#31_A_\2/VIOAUK/[2'PD\%7%I82^"_AA\6/B7\"?B9XY^%
M>G^(]%TCQ'XNNE\/VOB74O"!:^\,:YX]30M$\;1:QX4E\?R>&;"/QM/^<GQ#
M_;3^*-I\3OV2M,^'NL>%]7^)7Q.^&7Q;^"?BWXS_ !I^ 'A3P]\7_@-XTU7_
M (*$_L#_ +-?C+0/%>A>']=M[2RU+PF_Q.U;1;OPEX.\277PA^*OQBT+X/\
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MSX&U3Q'XJN=-TWQ''\'[;QAJ_AVY\3ZO;::=1OK)=2DLK='4 W/AY^PA\3/
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M_8 T>;]NC7]8\2^./V^?!'A+QMXL\(?!KPG\/-&\2>'_ !;\-OB'KFFZ!?\
MA3P]XCNK;5/A_P"&]1\*:D;+PEXGUCQ+%KW]NZ'=^*-7UO6O!VE:O=Y/PW_:
MC_;0^),GPWT"7XO_  Z\)7?[6'[8/[9GP#^%_BV/X#G6-+^!?P[_ &-?B%^U
M-I-Y9,DWCZVM/B+\>OC#H_PGT^3PW?>(UT?X?>%O"7@CQ%KDO@CQ3K^EZE:>
M,0#[Y_;?_9C\<_M5?#W1OA_X0\3?!7P@EE?ZGK4'B_XF_!SQC\2?'OPW\;II
MIL? GQ?^ 7B[P9\;/@]JOPG^*WPXGN]9O]&\3V<FJ:G=3:C;0V6J^';6TU.#
MQ!\V7/\ P3O^(Q^&W[0_P6TW]HOPM?\ A#XH_M2)^U-I>C>)/AAKM[+K\/C;
MQE?^,?BU\'OVD;7PU\7/"L7Q3^%?Q(O8QI]M8>#;?X1Q1PV-U;^*++QWX<N-
M3\(7?#>#OVE?VP?C?\:_@I\ O!GQ=^$WP_U1?A]^W[>_%'XGV_P,O_%WASXD
M^*OV,?VI_@Y^SIX=UKP'X3U;XHZ?=^#-$\5ZIXWO[CXAZ'=>*?%4FER6'C3P
M/X3\1K?P^&/BGIGS;X"_;3_:/_:$^/?P,\+_  R/P7_9X\2_MI_L;?\ !.3X
MD>*OC_#\)-+\:^,?!.I_%+X*_M[?M!ZM\-_#MMJ^JV;>-]0N8_A-JEG\([;X
MFZUXC\(?"_2F^*>OQ^'/%&O>)S87X!]-_"S_ ()0:C\);GX(W_AWXG_"&W3X
M>_$_]I_Q%XV\#^'/V>+WP#\*-5^%O[7VG>!-+^*OPR^&'@OPU\81=?#BX\.V
M'@A++X<>)M6U_P =BQAU'[3XOT7Q;J=O=W^K4?A)_P $Q+NS\!_#+PAJGQ0_
M9?UU_@=X[_9A;0_C!\)OV9M9\*_%OQ7%^R1^TA\*?BUXG\)?$KQ/>_M&>.-%
M&I^/M0^!NB^&/'=MX>T?1;31_'\5QXRDT)X]%L_ 47V#^T'XP^//@Z?]D'X&
M>"/B3IFB>,?CO\3M8^''CO\ : UCX>Z+K-U96W@+X _%?XQ:@?"7@0ZG9^%+
M+QY\0-2^&<<-G%JMIK7AG0_!MMX]NH-,DUJT\.R1?C+\!/C;^V_I/@+3O@+^
MS_XD\+S?%?7/CC_P5O\ CKXY^(7A+X(:-XX\-_%+QU\-O^"A'B7PC:>&O"GA
M;QU\<?"D/@'X.Z]XH^(EWJWQ U"#Q%X[^(/A[0]>^'.D^%M7%U=ZUK\@!^Q$
MO[*&A:WXS\;ZO9?&+29[W5/V]O 7[6.HZ-:Z!9W=UH6M^!/@1\*_ C?!^],7
MB_S1JFI:'X+LO'!\03VMI=V.E>)+6,^$;NSMX=8U#Y)\1_\ !)"]\1?#O]H+
MX+MXT_9NLO OQ7T']J[1_AW\1O\ AEOQ+J'[1/PH3]IE_B%%8P'Q_<_M$Q^%
M_$D/PXT7XEZ]X-^W6'@CPCJ7C3P):Z?X>O9="OI=7\0:E\[_  U\??%?5/C_
M .*=+TKPKX)^&'QA^.G_  5)^)>BBX^(G@WPM\3]:_9_^)%W_P &_?P_\>6=
M[X:OUN;RTL]?\)>--!M?#'B?5/"FL+'XM\$R^+O!XU2?P]XKOFG]%\:_M[_M
M8?&;6OA)H'P"ME^%5G\4KOX5_!_QA/:?#'PO\6_B)\*OVBK7]F[XG_M4?M$?
M#72/#WC+XA_#WPCJOC/P7X='P3\%62>(M9GT?1H;+]H*XOM#UKQ+X<\-068!
M]R_M3_L)3_M&W/[2^J67Q0M_!^J?'GX,_L@?#30X[WP3-XAT_P &>(OV0/V@
M_CA^T+X=\4:J+?Q?H%UXJTCQGKGQ=T_P]J_AJTD\,7>D:9X6NKVT\27]QXAB
M@T'SK4/V9/VNO /CWXS?M3>#O$W[-'B3]H77?@#XV\%Z!X3^$7P.\8_ KPU\
M<?B_?V/A"V^$7BW]IS4?%G[2/Q%L/'VB?!2?P]J&F>';^.'2/B#:^#/$>O:1
MX>\8Z+ID]SX0USSCX&?%_P#X*'_'+XQ?$+X2^+_%?P^_9^\3_!W]C?X1>,O%
M?A2]^%.D>)=4\2_M ?&?5/VR/A9X7\:1ZO:_$+Q)I?A/X6KJOP4\'_&?_A H
M_P#A*?$TMO=:)X-O?%.DPQ>+K+6OH#]AW]L'Q1^V#J/BWQQ)9Z7X0^'_ ()\
M!_!;X:>*_!\L42:[X;_;.OM UKQU^TO\+M0O[N9[J[A^#VC^(?A)X.M8K15C
MD\53?$&TO)+VZT5%L0#T/_@H3X#\8?$C]@']KCX;>&=-UGQ?XY\:?LU?%3PE
MH^E^$M)GN-=\0^(M9\#ZIIEO;^'M$MO[1N9-1O[V<?V=IT)O91-)% IN",OX
M+J?[#_C?XW>,=<^)'QF_:'^&7BSXP:#\1OV%[>ZU+X2?!_5?"/A7P]X5_8F_
M:,@_:U@\%ZKX/UWXW?$76M.\>?&+5_%=S#XAUNZ\7IIWA+PQ=^ +K1_!.K-I
M.J7WCCCOVLOVF?VE_ WQ._;E'PN^)WPX\&>#OV*/V*?A3^UW8^#_ !/\/(_$
MU_\ %'Q#J2?M9ZEKO@CQ/XFD\0Z;<>&?AMKNG_ S1M+UK4O#NF3^,M-U&^T[
M5-!UW1H++5-&\7?#5E\>_P!KY?VL?VW_ (,?LHVUSX&\6>+OVC/B7^T'J4VK
M?"/PQ\4M;UW6O 7[%7_!+KPSX:^%E_I_B?XM?#71_"_@V'5OB0R?&;Q'I$GB
M#QIIJZCX&L_!?]F/J&K:D@!^FNI_L)_$I_''Q9T'0?C?X+TG]ESXX?M1>!/V
MJ_'OPNN?A+XFO_BS:>)_#%Y\+O%/C#P!X5^+O_"YK;PM8> /BK\1?A1IOB?Q
M/'?_  @O]9TK1?&/Q%\+:-?))K?AWQ#X/X]?V'=%^#DW[3OQG^,'Q*\>_'2Q
M_:W^%7B_P-^VYX$\(_!?Q?XLN?C=J.LZD_@_X/ZC\)?AYX,UWQUXK^&6F?"#
MX0^*_$GP//A?0[7QQ_PEOP_3PCXL^('B1/$?@'6?&7B#R?\ :K_;Y^//PKU_
MP/XF\"Z7K<#?#31?V6;_ /:V^!LOPL^'/B+PK\)-2_:"\::/I&K^%?B5\?-?
M_:#^']U!XRNO#OB-+3X7Z+\#/"7Q2NM'\7Z#8ZUXXTWQ?X5^('AK18J_CC]L
M3]KSX>>$/COX/\8LOA7]J"\^/WP:^'GP]\#W?PF\+>*O O@#X,?'W]I/4_@U
M\,OCC\+->TGXG:!8_&O3O%7@RWM]-TCPU\1_%?@?Q;X?_:)2WTGXD>&?"G@'
MQ/X<T>Y /MS]@#X2>,_V;_V,/A9I7[0'B.2[^--]X6OOB]^TMXT\5W^C+>O\
M6?'SW'CGXC/XE\0V4BZ1=V7@.:__ .$%TW5Q=-I]IX.\&:);6TZ:786JQ^4:
M+^R1\;[[X%_%_P"!/PZ_:I^'V@_L[_%6R^+_ (E^!'BOX=?"WQ9:?%;X=67Q
MI^(EY\6?#.C+\3=#^/R>&_&WPQ\-P^*/$7A"RD\&>&OASXKU[X9WWAZPT'QM
MX3\0Z._C35?G']IO_AK[X@_\$P/C=X=^..OW/P\^(.@^/_\ A!->\6:S\+OA
MTH_:%^!.N>*?#^BZ=<Z_\--)\;>./#'@E_%&C>-K;P_X\TJUUJ>VU36/!/B:
MWL=&M/!?B^TME[#2/VB_VB/"ESX]\3Z5XT^&FC?!W]E+]JGX$?L*:C^SVWP-
M;0_&7Q1_X2VZ_9W\!WOCW3_%&C^.;+2O /B?Q-??&W1/&/P!\!>$_!DO@!/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV\,:[\+O$UK;K%-#<:G\6_B5\6_V;/"7BA;LQ-J7P\^ #Z1"DT!NI+8 ^_\
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M+<:7-\9M%\+>'M#\ Z+J%W>GQSIOA_1-*\*V,\&FZ;:6$/J.D^"_V8O"]_\
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M?%/XA?%;P9\<_ D-O9:1X]^ NJ^$M.O=&\(:AX?UO3?%OAK78-2\2>(?$^A
M'ZF>)? W[#WBWX8:7HOBSPK^RUKWP<\%:&?V?- L-8TCX4WGP\\%^'QX@\"
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MM?TZ_OY/!/BFPU35-!U[2YHY-"U2WU+4-/O()EO;F*7A]:@_9H^,?A+Q9/\
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MYT75O!/B[_@GGXFT#4_@_P"/M/L'AGM;_6/B1\5/C!^S/X?\207XC75OA_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6%J&N^.=#\46G_"/VEG'XDUK^P_#&M^7H5]:2VGVN\:6SBQ=4_9P_P""?GQ
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MUKXHM[;X>V^@+H^K&4_V/I/Y&_\ !,WQ)X_\:?#[XVV^D^%_"FD_M[?MM_\
M!+/]I_X[^%?^"@%S^UM\4?&WC<:=8_%F7X=:[I?QZ\.:[<Z/\//@#?#Q[X?7
M4/ OQ$\'3V6G?"^V\/>'M+U*YUGQ,OC**Q_L+^ 7QR^#.I>)/BE^SMX(T'PE
M\)$_9O\ BTG[-W@OX>6-QX5\,V'B&S\*? #X)_&MI/A?X'T@:>+/PKX6\)?&
M#1M$;1M)TTQ:+'X?NK@Q6NF26H7(\(?LB_L!^#?$/Q@\+>!?V</V3O#/BKXE
M^#+S3OCIX;\,?"WX4:5KWC'X=^-+BX:_T[XD:+INC0W^I>!_%=Y974UU8:]:
MOX?UN^M+BXEAN;J"21 #^*7PE?\ QH_9S^%O[<7[,]OX)\1?LL?LXV'Q$_X)
M(?"W]KSPOI'[3U]\4;_X::]\5M:DTO\ :8^)OA7QUX%\>>-/#/A[5?CH/#<6
MF_$;3M,\<>&+I? .K^#M-\5Z?IFHS1^'=._=3]A+X\7W[&]Y^VM\#?V<_P!F
M_P#:C_:X_9I^'?\ P4$^)'PG^#UM\&M=T;XF)\!+;0/@_P# ;6?B+\.-0U#X
ML_$?1K[3? WAGXB>+/$%MX7M],\0^);N34+?Q=-J]AI>H[KK6_VB^&G[/'[$
ML/P@\7_ /X1_!?\ 9CE^!6NWD%U\0/A!X$\!_#"]^&.O:EK^DZ#J]M>^-_!6
MBZ9/X;UG4M:T.U\,:G!>^(=/NKS4M)MM O8Y9K.#3I4]$_9_\/?L]>$OA=HG
MA7]ES2?A!H/P:\/76L:;X?T/X&6W@^S^'>E:BNJW5QXBMM/M/ RKX?@U1]=N
M+^Z\0>4HOIM:N+VZU0OJ$]Q(X!_(7^PC\3/%^K?\%/(?BS^T-\(/"7Q&_::^
M.O[:/_!1#]F'X-?'FX_:*^*OB/XB_LS>)_@)\/?$,E[X.E_9:L[M?AH/V?/#
MW@G7],\(V%LVI77BS2H[K6/&^N^(+6Q/@B#4/B7P)+^VA^Q,O[5_ASP9X;U#
MP9\=;S_@DG\?_C!^U5\3]#_:VE^-MM\?O%.O_M!6&F>$/VQ]!O/ WC?Q[#X4
M\;^'OAKXWN]0^&&IZ[9> ?&1C'CO55BL]&8ZWK']DOP9MO\ @F#\1?'?QG_:
MR^#GA#]D^Y^(_@#QEX]\"_&K]H73OA_X!\-^+])\2V#W_A[Q]<>)/B+JFA:3
MJ]QIFN(NJZ;>>-_[3G\/^.M,CO9+'7M>T<M._NGPR_9@_8Y_9X\"_$"+X1_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\]IXEU&/5] T*Q\/ZE8ZCHEU?^(=&O-.^:OV._V\OB!%9^&/"G[0?PX^(O\
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M:A?^&-(\&'0-;U"V\+:%X>\.-/JAUC2KFZ7\SI/V)/B!XQ\3> -6\<?LD?M
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MX6U+Q+X%>/P_X U[2M-U[PIX7UG7_ 'A6]NM2\!^!]1U#P#X>\/2/\Z^/O\
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MM4T7Q+HOB70M=L]+L;&Q\0:F >,:)^QCXN^)7QB^!WC/5_V3]#^&O[..F?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?Z;X*O=?L=7AU;QMI?PT\(>(_%EQ-)HVLO%9Z#J^O7]C<6ME>,/P7T#]I?\
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M /P=TWX"> OAE;6/Q6^(^C? /]@'XO\ ["O@?P?:>+?!6B>*_B#\+OB'X7^
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M=[XF^SV+^'?$FK>'KG]":* /SSL/^":'P TK7OA3XJTKQ!\5]/\ %7[/VE_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVAOC!^T[\2/V>[[QQ\)I_P!GWQ/\4/C7]K_X2FXOO#=G\$[#QPVE:=YFD_\
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M!#<VT\9RDT$\:RPRH2 2DD;JZD@9!'% $]%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,=UX8T.WT&PUOXZ^/I= M_B3>7%K\0M=M-'\&_"Z_P#%6NZKX_N[N_\ >?\
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MD?#O]L+]HC]G7]K[XJPS_LO_ /!&[]B_XY>#_$O@/QI\-O'6@?$OXC?"6?\
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MFZU8;_QDU_P#^QG^Q]\1/B#X9^'.GZIX%_8Z_9O\9>-_!/PXM+M-.1/"_P
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M\"^&XM2\6:II_P!GO(=%DM=0L);K&\:?MK?LE?#SX>_#_P"*_C#]HCX3Z/\
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MID?B.U!U:]_?ZB@#\>M3_8\^)WB?X8?%:3Q;^S)X+U3XI?$GQY\$M<U(R_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%?E?_P5
M!_:'_;:_9%^"GQ4_:?\ V?Q^RQK/PB^"_P *$\7^*_!WQB\)_%K5OB1KOBBU
M\07UKJ47A[6O!7Q \*^&++0)=&O?#@L8-2TV?48]3M];EGO9+6XL(+8 _5"B
MOR?^(G[5'[:7P);X._L_^,/!7[._QR_;7_:H\:_$*R^ >C_"Z#XH?"KX >$/
MAC\*O"GA?7OB9\3_ (Z>)_&6I_$GQ58:7X$D\0V>[3O"EM<:OXTOO$/A7PIX
M<TV'4[F]U.'OOAG^T9^U;\,/C_\ ##]G;]MKP;\%]0E_:&3QC;? 3XX_LSVO
MQ"L/ &H>./A]X-U7XB^*OA)\3/!7Q&O_ !#KO@GQ5-X!\/\ BCQ=X'\1V/B[
MQ#X>\9Z7X/\ $]O<6_AC6+.UTN\ /TBHKXS_ &G?VC/&7[/'Q8_8Z@FT7PU>
M? KX\_'&Z_9W^*?B2[M=?G\7^"/'_P 1/"6J77[.^JZ)+I]RNAV_AGQ1\2/#
M[?#+Q2^O6<TAUOQYX&.E7=HZ7D%_C?M-_M@P?L__ !3\"^$6M=&?P7X;^"G[
M17[67[3_ (HO[;5=5U'X<_LU?L_>#8(KB^\-Z3H]S;//XY\9_$OQ;X2M_#,&
MI"[L]0\(^#OBJ;+3;O5=-M9[  ^Y:*_'/1?VHO\ @I_XG^$UA^V#HW[,_P"S
MS#\ M3\,0?%/2?V5[SQ1\1;C]L[6O@S<Z4OB*RU6+QC;1Q_!W2_C3JOA=HM:
ML/@?<>&KRPBU"Y@\):E\5['7EN$AY7]J3]M']M[PMX7_ &=OVA/V7M4_8Y\3
M?LQ_M>?%7]COX<? M/BI\/?CJ?BG8:;^UL? ^C:#XR\<7'A_XE^'?#\ECI^L
M^)[G73I.FZ+8ZE#X=>QTRX\[6(+NZF /VVHK\>?CS^TI_P %"/A5\3?V"/V8
MM$?]C74/C]^U;>_M2GQQXUU7P3\;7^#_ (?T_P"!?A'1_B!X:3PIX>M/B;:>
M-(;W5?#NHRZ9KDFKZWJT$FM)'=6$5A8AH6_37X-0_&J#X>Z-%^T)J'PNU3XK
MK-JI\0WOP:T?Q9H/P]EMSJMX=$&C:9XWUSQ'XD@FCT0Z?'JK7VKW*3:JMY-:
M+!:/!!& >HT5^8W_  54_;4^,O[#7P6^#7Q$^!7PJT#XU>.?B1^U!\,/@D?A
MOK0UP:CXGT;QCH7CK6[_ $CP5+H5]:36WC_6)?"5IHGA*XO[?6-)BU/4T-]H
MNH(51?HCXN?M:>"/ _['>K?M?> T'Q*\,:S\*O#'C[X+Z1IKS6DWQ=\0_%:T
MT2S^ _@G19'MY)K74_BWXS\7^"/!VAM-;[H-2\3V?VB- DFT ^L:*_,KX0?M
M^7T__!+GPU_P4"^.GASP_8>(V^"VH_$+Q!X%^'O]JV^E>(/'*ZKJ'ASPK\.O
M <>M76NZN^K>/_%ZZ#X,\)VU[<ZA=7GB#Q#I]OAS.L0R_A9^V]\8-;_8/_:Q
M^,WQ2\">!?"G[6/[&.G_ +4'A3XR_#;1%\33_#&'XK_ GPKK/CSP?=Z ^KW]
MMXLU'X<?$WX=WOPV^(>C7<NH6VH7/A[QHL-K?B2%+P@'ZDT5^-G[,?[9/[;^
MN>/_ -B>#]HKP;^R[XF^$W[>?PJB\=_#O7O@,_Q3\(?$OX2ZM9_ %OCSK*_$
MKP#X[U;X@Z3XA\#A7L_A[;^,_#GC'28M/\5:KX6_MBQ@N?&6C:+'8B_X*A:_
M8W/[5?@"#X76/Q9_:/\ !7[:GQ/_ &4OV2/V<_AC>2:3XQ^-EMX"^#7P1^)-
MQXO\=:SXBU34=(\">"O!UY\4[Z\^+GQ>U%-'\#^"_"UOHEO%IM_XPU?0M!\4
M '[%T5YY\)8_BQ%\-?!:_'2\^'M]\8&T&SF^(<OPHTSQ'I/PWA\3SJ9]0L/!
MMMXOUC7/$T^AZ6TBZ9::MK=[!?ZZ+1M;FT?P[_: \/Z9^)O[,?\ P4X_:R\7
M?"']BK]I+XY^ /V=-9^"_P"VG^T#;?LW:5H7PC?XB>#?C%\,O'7B'XE?$GX;
M^%-570/&FO\ CSPO\5?"4$OP\?Q-XZO=.\1^ ->\+^%KO6-7T_PYXCB\,7":
MB ?OK17PY^Q!^U!XS_:=_P"&O?\ A,M"\,:%_P ,]?MQ_'[]E_PK_P (S#JL
M/]L>#/A-_P (G_8>N^(?[5U35/-\3ZA_;]U_:TVF_P!G:4_DV_V/2[3$GF>!
MQ?M5?MH_M/\ Q)^.FA?L+> OV>/#/PF_9N^*OC'X#^*OB[^U;)\4+J3XN_&[
MX<7$5C\1O!OPN\#?#*71]0T#P-X)UJ0^%=6^+WB36=9BU#Q+#J=KX9^'WB"T
MT6]NW /U?HK\M;7_ (*6PZ5\ -3\5^-/@9XOM?VI-!_:9L?V'[C]EO0-7L;B
M[\5?M;:II6C^)M"\*^"_B/K5MH_AR3X4^)/AUKVF?&NS^*^OVVDV.E?!R2]\
M0:KHX\0:9+X8G]Q^"EO_ ,%&S\0=!U']HG5_V*C\)]1\.ZE<>)?"'P;\,?'*
M#XC^$/%;H[:/I>C_ ! \:>,KWPM\0M!A<QQ:KK-W\./AM?3!9);+1(@R1@ ^
MV:*_$3X7?\%0_B]\</@)\,= ^"WPL\!?$W]O+XS^,?V@=+T3X7:=>Z[H_P &
M_@K\*OA)^U'\5O@%9_M&?M%:[)JFL>(/"/PRLM*\ VEU'HFGWTWCCXQ^/EU7
MP?\ "G2%C@UJ_P#!_K'B7]H7]O;XI?'OX[_L\?LMC]CSPSXD_91\/_"*W^)G
MB#]HOP[\;;N3XQ^+OBY\.M+\=:)XC^'/@GX>^+=.F^%_P=>Y3Q5X8M/%>M>,
M?C#K5WXM\)^*O#::&/\ A%9]:U< _6.BO#OVGOBAK7P0_9K_ &AOC1X<L-+U
M3Q#\(?@;\6?BAH.F:VEW)HNHZUX \!:_XKTNPU>.PNK&^DTN\OM)@M[]+.]L
M[MK225;>ZMYBDR?G;^S3^W1^TSJOCS]A?PA^TIX/^!&LZ)_P4%^"6K?%?X2^
M*?@/-XY\->(OA]J_AKX->&?C7XD\/_$[X:>/]5\7QS>#[71O$!\+Z?\ $GPK
M\0]0DG\7MX;L-6\$:'!XKMY], /V#HK\>?V;OVE/^"A'[47Q>_:.F\&/^QKX
M3^ G[._[<?Q7_9?U+3?$_@GXVZC\7O$/@SX2:[X<;5M=L=;TKXFP>#+;Q/K'
MAGQ L.G37'A\:5;Z[ ;BYTMM/86I^H_V(/VH/&?[3O\ PU[_ ,)EH7AC0O\
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M/!.M6'BSQ+I/B)[>V /W3HKX<_;?_:@\9_LQ?\,A?\(;H7AC7?\ AH7]N/X
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M;O-%\:6_COXE>.M/UWPJ#9-;VVL:'?\ AC5[X%7ET;3"Y6( ^]**_'7X2?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7YK?\%A_ GC?XF_\$Q_VS?
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M0N[7QEXZ^*GPA\(> ]&O9'MFTRPMD\37;:EK$]IIU@;F>\MA)]F44 ?S>_\
M!/KX(?';]@K]FB3]IKP#^SWX^\2ZG\3_ (U?M(:Q^VI^S7<^$M4T?X]^(?#>
MC?M5_&ZP^&/Q^^!^@ZYH]OXH\1^-?#OP<N/#TK_ ^>>V\/\ QE^'1T'Q)\)A
MHOQ*EO$^,?N/_!175_@W\4)=>\5_";X)_MIZ=_P43^%GPLNS^Q[\:?@[^RW^
MU-X.U.Z\6>-?!5IXQ\!^%O$OQA7X8VOP5UKX.6_BGQ!I6C_&/X=?M!ZS+X/\
M%7E[XTT3Q/X8T3Q,VI*?W1HH ^+?VI?#7Q4\4?\ !.W]HSP?K^F0>,_C=XA_
M8M^+WAK6]'^&NB:O?6WBOXJ:M\#?$.EZEIG@#PXBZAKUY!KOBZXFM?"NB(M[
MJ]Q'=6%BJW-ZX#_BA_P3Y^#'AWP1^T#^P)X@_9E_9*_:P^"_Q3A_9Y\*>%/^
M"DOQ9^,/P/\ C7\&_@QKO@GP7^S'<^%]-^'%A:_M)^'O#;:S\3K/]H^'X>ZG
MH=W^SGIMA93Z1I/BW5O%EWXF\+7#3V7]0-% '\O_ .RI\'?V8?AY^U5^V!XY
M_:C_ &(OVHM9_:"O_P#@J+\<OBM\"OB]I?[%W[8/CGPI_P ()<>-/".J_"?Q
MOHWQ+\ ?#C5?AC_PCEOXIL-8UVSUB]U5]/@M%_M;4)O[(EAF;Z?_ &#/BHOP
M"^(_[>?P4^,7P%_:]TS5?CC_ ,%0?VG/&W@;7M*_8W_:A\4?"SQ%\.?BGJO@
MGPYX6\9O\8/"OPLU/X;:;X/U273=1N;GQ/?>*[/2-+T6%M>O[^TT@I?']X:*
M /PM_8[_ &H[_P#8._98T7]D/]HWX#?MB:_\7_V2K;Q9\&_ H^#O[''QW^+7
MAO\ :6^&WP]U&_A^"GC;X0^/OA1X'\5_"1[KQO\ #"3P7!K&D^-O'_@_5_"W
MC<Z[IGC=-%>QNKZM:;]F'X]Q_P#!)7Q"-=\&QV?[95KXX\??\%'M!^'OA^P'
MB'4?#G[3]S^T[XC_ &[_  I\&='A@:>*^UJQ\0WMC\!M5N='+V.M&;69+&.Y
MT_5#%/\ MY10!^!7C7X5_&R/]@KPS^V1I?P;^*6H?M8:#^VIIW_!3-?@AI^@
MZW!\9]4\/^(?B5=^#KKX#ZKX572KCQ-%\0=&_P""?/B-/@3J7A)=+GU%/%'A
MJ'1_L1$"VB?HM_P3A^&/C7X5_L8?!2P^*=E?:=\8_B#IOB7X^_&ZQU73Y-+U
MC3OC5^TCXT\1_'OXK:+JUE<117D%YX:\<?$;6_#*V]\IN[.TT:UL9F/V50/M
M^B@#^?#1?@O\8HO^%;>;\)OB7']A_P"#@_XV_&B^\SP)XI3['\'=6_X:!_LO
MXLW6[2A]G^&FI?VUH_\ 9_CN;9X6O/[6TW[-JLGV^U\VMK'[,OQI^ W_  51
M_80\ ?#[X7>+_$/[$]A\<_VN?VFO 7C3PMX6U/4?!/[,^O\ Q@_98^-^@?&3
MX*^-=4TM+C2/ ?@CQ%\9?$^A?$?X(OJ\>CZ?J6K?%WQW\./#Q^Q^ M#L&_H8
MHH _'K_@LKX"U'QU\-OV*9?^%6_$OXM^"? O_!1W]F;XA_%_P_\ "OX7?$CX
MP>(=+^$/AK3?B1_PG'B2\\%_"?PYXJ\<7>BZ;97L,%Y/HVC7-R+F^LK2V#7U
MY:12_DK\4?V>O$\?[ W_  5.^&/[&/[(_P"UC\.OV2-;N/V3+_\ 9[^"/Q*^
M$?Q/3XP^._CGIWQ]M?%7[4'CSX6?"_QQI>H?M/S_  YU/PC%\*;J.'XD66H1
MOK7AWQA?>!H=(T&SUC2K#^N^B@#\0/VVOB/<?M=_"+X6_$GX&?!7]J[4M=_8
M<_;'_94_:]\2_#GX@_LF?M"_!7QC\3O 7P^\9:Q8^/\ 0/A'I?QF^'G@&3XD
M>--)\":MXH\3VGAGP:^LZU<W^C:/HJ:?/J7B30[#4^BO_B'/^W#_ ,% ?V#/
M&_P7\ ?&K2?A!^R%9?M*_%_XP_$+XS_L]?'7X!:>_BGXH_!=_@9\,?AEX+7X
MU> ? =UXP\27R?$/QIXK\4#0K"_TWP]I?@VV%UJ\=SJ]E:7G[.T4 ?R__LJ?
M!W]F'X>?M5?M@>.?VH_V(OVHM9_:"O\ _@J+\<OBM\"OB]I?[%W[8/CGPI_P
M@EQXT\(ZK\)_&^C?$OP!\.-5^&/_  CEOXIL-8UVSUB]U5]/@M%_M;4)O[(E
MAF;]E?\ @I1\%?B7\>/V-OBGX4^"=G::G\;/".I_#+XX?!O1KXZ>MKXE^)_[
M/'Q5\%?'/P=X-EDUB[L=$MU\=ZM\/H?!/VS6[J#1]//B'[?J,L5K:R2)]UT4
M ?AY^UA^V!?_ +9G[+'BO]D_]GS]G;]L'2OCM^U[X2C_ &?O$^E_&']CS]H7
MX5^#_P!FGPC\9]+/ACXL_$?XT?$GXB^ /"WPO32_AE\/=7\5:AI]OX&\:^,+
M_P :>+K;P_H?A&+48M7_ +5L_F[XN?\ !+VT_:^_:I_X*YV_BOX::UX4UR32
M/V&O$/[%7QI\:>&]?7X>+\5_AE^SIKVGVE_:'7-,O_ WQ?\ !7A_QA::+X:^
M*OA;5-)\::7'I]Y>:??:?9>('TZZMOZ5** / /V5OBEXP^-7[.GP=^)WQ$^&
M7B?X,_$7Q5X'TB?XB_"KQ?X9U[PCK'@+XA:;&VC>.?#<6C^);2RU:30-/\5:
M;J\?A'79(#8^*O"?]B>*='N+S1]9L+N?^5G]A;]GA/ W@K_@G=<?#3]B_P#;
M'\!_\%)? OQIB\.?%7XQ^+_V??CQ\+O@G\/OV:-0_:B\8>,OCCIGQ0\3_'3P
MQX>^!7B.S\8_L[ZIJ]AX9E^%JW_Q8NO%>J>&+'PSXELM2L[K2+O^R6B@#\)_
MV /B_-^SG\4OVZ?A'\5_@3^U]HWB#XR?\%2?VE?B#\//$FD_L;?M/^*OA;KG
M@'XE:SX'T+PAXX;XO>&/A5JWPST_PAJ%UI-_=W'B74?%-KHVFZ-;G7=1O;71
MV2];9^"?[.O[57[2%Y^V3^T=XLUSX8?"KPU^W)J6N?"%/@;^TM^RQ\:O%GQ!
MT#]DOX1CQ[\'_A9X:UW3U_:8_9]O? J?%#0]=\??&G6/"%[X);7--U#XR7B:
MCKDLD5MIFC?M_10!_/CX"\+?M2? ;0/V)/C?XZ^'?QC^+OB?_@G=J?[2/[ _
M[1.D>"/A7KNK^//C?^S+XS'P]M?A/^U7\'O"UWJ>I:Y\3FBL/A'^SQXS\>:5
M\.6\4^)M1NO$OQA\/6(U3Q-\.+_P[<?H+J_[5WPZ_:D^%'[17PY^#_@G]I*[
M\0Q?L]?$V_63Q_\ LF?M-?!?1[S4-1\,7VB:;X3T;5OC-\*/ -IXC\::C?:E
M%]@\+^'7U;5;N"WOKB"!X[.<K^A-% 'X'?\ !/OX<_%G_@FW^RC^QA9:%\!_
MB%XF_9^^,7P?_9_U;]I'X9^'/ GB35/VB?V5?VFO'OPP\$V?Q(^(ES\-M/\
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M /CM\1?!FOZ3#%K&J_LZ&?PU\0FT#XUZ-JD6AGP=8'7V\1Z?=6EW)9_UR44
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M'J'A6TO=1C6XBTN\F'NE% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOXC\9>._&^F>'M2U^[^$MMXV\*V3Z NGZ+%XBUM/''@O09Y=*U._N[NTW_\
MAXGX_P#@!H'[:5G^UUX4^'/BSQ1^QKX2^ _B"\\2_LM7/B>]\.?$_P 5?M':
MEK_ASX8_!6#P3XYEU#7?AU\9M3\36/@V!_#6I>+_ !;I$?AKXL?#GQ=?:_I>
MEZTJ'X \7_LU?%VX_81TFY^)_P $/VA)?A/^V]_P4J^+?[5/[?7[/OPG\*1:
M]^T/H7[+/Q[UGXFZSX!\)ZEX0TS2O%'CRVNO"L^C_LT2_'#PE\&=%'QNT_3+
M;QCH_AV\TS7+3Q#K5>(^/_V*_$WBWX#_ +>'PH_8*^$'[1]O^PO/X:_9K_:
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M??BW]G/Q]\(_A;\$?!_A;XA^+;WXM?LTVG[1-_XH;66\/?!WX+_M"_'OPI\
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MT_XO_"*QTKQ!]OFT[4+'Q!K5[XNT:*WL[BRN?".H"^2ZL_UI_9A^ 6B_LQ?
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MC%\;OA%I/P_^&'CW0=,U_P /Z%9PZ%*?&^J^._#_ (@\20>(8?$GAGPK\2?
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M=_\ $GXU']H;]GJ\\,_&+1;72O#?@VQM?AO\3/@/+\']9^%5AIWA31M*\-^
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MXD:GXFU73O&7C/X&^,['Q+X,\2^($\?Z[9:K\.=8U^^U*  _:NBBB@ HHHH
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M&Q;1_ ^O/+>LY2.XCMH"I:Y4K]J44 ?SE?\ $4Y_P2;_ .AO^./_ (9;6?\
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M>.[;X<Z'-X/\*W7BS4)/$MWX?U_Q-#%<V-I/;O;V9TOPWJ;M=LY19UAAVDS
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M/BKP]<>&-6.K>&+B&VU5'TJYFGE2!)9XQ!.9-LRY90 *\6_X* ?\%3OV3?\
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MM:B_X3+QMX;^'^B?8M'MY(9KSS/$7BO2(KG9(OV>T>>Z;*P,I^C:* /YRO\
MB*<_X)-_]#?\<?\ PRVL_P#RRH_XBG/^"3?_ $-_QQ_\,MK/_P LJ_HUHH _
M$S]EC_@X#_X)V?MC?'SX>?LV?!;Q)\5[[XG?$^\UJQ\*VOB+X7:IH&C37&@>
M&-;\7:@+W5Y[Z6&S5='\/ZB\3/&PEN%B@&&E!'[3ZA?6^F6%]J5V66UT^SN;
MZY9%+N+>TA>XF*(.781QL54<L< =:N44 ?SE?\13G_!)O_H;_CC_ .&6UG_Y
M94?\13G_  2;_P"AO^./_AEM9_\ EE7]&M% '\Y7_$4Y_P $F_\ H;_CC_X9
M;6?_ )95_13I]];ZG86.I6A9K74+.VOK9G4HYM[N%+B$NAY1C'(I93RIR#TJ
MY10!^)G[4_\ P<!_\$[/V.?CY\0_V;/C3XD^*]C\3OAA>:+8^*K7P[\+M4U_
M1H;C7_#&B>+M/%EJ\%]%#>*VC^(-.>5DC417#30'+1$GY]_XBG/^"3?_ $-_
MQQ_\,MK/_P LJ_HUHH _G*_XBG/^"3?_ $-_QQ_\,MK/_P LJ_9S]D']K7X/
M?MP_ /PA^TG\![W7]0^&/CB\\3V.@W7B;0Y_#FLR7'A'Q/JWA'61=:1<RS36
MRIK&BWR6[-(PGMUBG7"R #Z9HH _-G]OW_@JY^R+_P $U+_X7:;^T_K/CO2K
MKXOV?BZ^\&+X,\$7OB])[?P1-X<M]=.H/:7-N+!HY/%.DBV63>;D/.5V^2<_
MGA_Q%.?\$F_^AO\ CC_X9;6?_EE7]&M% '\Y7_$4Y_P2;_Z&_P"./_AEM9_^
M65?H?^P%_P %7/V1?^"E=_\ %'3?V8-9\=ZK=?""S\(WWC-?&?@B]\()!;^-
MYO$=OH1T][NYN!?M))X6U87*Q[#;!("V[SAC])J* /F;]K[]K7X/?L/? /Q?
M^TG\>+W7]/\ ACX'O/#%CKUUX9T.?Q'K,=QXN\3Z3X1T86ND6TL,URKZQK5B
MEPRR*(+=I9VRL9!_&/\ XBG/^"3?_0W_ !Q_\,MK/_RRK^C6B@#^<K_B*<_X
M)-_]#?\ ''_PRVL__+*OHW]DK_@OK_P3T_;6_:#^'_[,OP-\1_%6_P#BE\2_
M^$K_ .$7M/$GPPU/P[HLO_"&^"?$GQ UO[;K%Q>S0V?E^'?"FKRVV^-OM%VD
M%JN&G5A^U%% '.>,?%6D^!?"/BKQOK[SQZ%X.\.:YXJUJ2U@:YN4TGP]IEUJ
M^I/;VRE6N)UL[.9H8%8-+(%C!!;-?SV_\13G_!)O_H;_ (X_^&6UG_Y95_1K
M10!_.5_Q%.?\$F_^AO\ CC_X9;6?_EE1_P 13G_!)O\ Z&_XX_\ AEM9_P#E
ME7]&M% !7X:?M%_\'#__  3=_9:^-_Q)_9[^+'B;XN6?Q&^%'B.?PKXNMM#^
M%6JZUI,.K6]O;W,B6&JPWT<5]!Y5U$1.D:J6++C*FOW+HH _G*_XBG/^"3?_
M $-_QQ_\,MK/_P LJ/\ B*<_X)-_]#?\<?\ PRVL_P#RRK^C6B@#YR_9*_:G
M^$W[:W[/GP__ &FO@;>:Y?\ PM^)?_"5_P#"+W?B319O#NM2_P#"&^-O$GP_
MUO[;H]Q)--9^7XB\*:O%;;Y&^T6B072X6=5'R=^WM_P5X_8V_P"";GB[P#X(
M_:;UKX@:7KOQ)\.:GXJ\,1^#O E]XNMI=)TG4UTB\>\N;2ZMULYUO&"QP.K-
M)'^\! XK]/J* /YRO^(IS_@DW_T-_P <?_#+:S_\LJ/^(IS_ ()-_P#0W_''
M_P ,MK/_ ,LJ_HUHH _.7_@G_P#\%3OV3?\ @I?_ ,+:_P"&7=7\<ZK_ ,*5
M_P"$#_X3G_A,_!=[X/\ (_X6/_PF?_",_P!F_;+FX_M'S?\ A _$'VSR]GV3
MR[7?N^U+M]I_;1_;1^"'[!'P0O\ ]H3]H2_\1Z=\.=.\1^'O"MS<^%?#UQXG
MU8:MXGN)K;2D32K::"5X'E@D$\XDVPKAF!!KZQHH _G*_P"(IS_@DW_T-_QQ
M_P##+:S_ /+*C_B*<_X)-_\ 0W_''_PRVL__ "RK^C6B@#\8_P!D'_@O/_P3
M[_;A^/GA#]FSX#^(OBEJ'Q.\<6?B>^T&U\3?#/4_#FC26_A'PQJWB[63<ZO<
MWLT-LR:/HM\]NK1L9[A8X%PT@(_6'XI?$;PU\'_AE\1?BWXSEO(/!WPM\">+
MOB-XLFT^T>_OX?#7@CP_J'B;79;&QC9)+V\CTO3+I[:T1E>YF"0JP9P1W=%
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M?1O#6D67A_PYI+:SK_A_4-1;3/#^@Z;IVB:)8&Y-KI6D6%EIMA%!96L$,?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO%NIPQ2QW%Y:^']'U!M-LF;4=3:RTZ*:[C\:_P""8'[!_A'_ ()S?L;?"_\
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MB;0C/9+':7]CI7BCPQK-EI&K6\%G%K&D0V.JK8:>+S[#;]7_ ,$M[6X\9_\
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M^"GQQ^$7[1_PS\,?&3X%?$/PQ\4OAAXRM9KKPYXS\(ZC'J6D7XM;J:QO[1V
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M]F2^(O!/C+2/#_BO3-/U.2QU"'2M9FTC^Q-7GT[48M*U&]:QNA%^-O@4!O\
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MS%G=.WEW<>/X//C!\;?V5_VY?!/_  5(_;0^-WQ2USPE^VI\5/CG\/\ Q?\
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M[1=*LI;EI'MM/M8BL*>QT4 ?G#\ _P#@ES^S;^S[\7_VYOC#HVH_$?Q[??\
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M]+M] \0VL&OZ]8GQ++:?V'%HGU1XG_X)F? ?7_\ @H7X+_X*7:3XM^+G@/\
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M6\?:C<IK\/@"#P8-3AUC6;JVLICX :UCTR."&>RN;I9+R7YP_9A_X(C?#/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5\0_\%"/V]?@Q_P3B_9J\4?M'_&B
M6\OK*RO+?POX#\#Z/)#%XB^)GQ'U>SU&\\/>"-"EN%>WLY+NWTK4]5UC5[E)
M;?0O#FD:SK+6U])91:=>?;U?Y^?_  >%?&?Q7JO[5G[*W[/$K10^!_ 7[/>H
M?&>Q6&2Y2;4/%?Q;^(_B[P/JK:E%YYL[F+1](^"FC#0Y#;+<V3ZYX@43M%?F
M- #YTU[_ (*6_P#!>W_@L=\5?$FF?L9VWQF^'_@+1+VZ-CX&_97U*?X5>$?
M%E<074FFVGQ$_:+OM1\)WEYXIU/2H P'BSXA:#I>LZI:7=]X)\%>'Q*^FP];
M_P .]?\ @[)_Z'[]N+_Q9UX,_P#HLJ_O!_8G_92^&W[%/[,/PA_9R^&'A_3M
M#TCX?^#M%L=>O+*U@M[WQ=XXDT^VD\:>./$$\+RF_P!?\5>(/MVJZA<O/-'"
M)XM/L#!I5C86MO\ 5- '^<K_ ,.]?^#LG_H?OVXO_%G7@S_Z+*C_ (=Z_P#!
MV3_T/W[<7_BSKP9_]%E7]\W@#]K?]E/XK^-)_AO\+?VF_P!GOXE?$2V6]:X\
M!> /C/\ #CQCXTMUTV$W.HM/X6\.^)-1UR);"W5I[TR6*BUA4RSF- 6KN_\
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M_P 5_ </PQO]6COKO3'TNR\>R:^OA6ZU%-2L+[3WL8-5DN5OK*[M#$)[::-
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MTZ]^+-M\5? D_P ,[/4+>9+>>PNO'D6O-X6M[V"XD2":UEU5)XYG2)XU=@I
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M&&VF= #_ #T/^'>O_!V3_P!#]^W%_P"+.O!G_P!%E1_P[U_X.R?^A^_;B_\
M%G7@S_Z+*O[]?BM^U'^S+\!]7TGP_P#'']HKX$_!K7]?M$O]"T/XK?%SX?\
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M['0+2]T_3;K7+S1_"GB#5M1MM'MM1U;2K"XU.:V2RAO=2T^UDG6>\MHY #^
MK_AWK_P=D_\ 0_?MQ?\ BSKP9_\ 194?\.]?^#LG_H?OVXO_ !9UX,_^BRK_
M $:J* /\Y7_AWK_P=D_]#]^W%_XLZ\&?_194?\.]?^#LG_H?OVXO_%G7@S_Z
M+*O]"CQA\6_A3\/?$'@?PGX^^)OP]\#^*OB=JDVA_#;PSXP\:>&_#/B#XA:W
M;3Z9:W&C^!]&UK4K+4?%FJ07.MZ-;S:?H-M?W<4^KZ9"\*R7]JLM/5/C;\&=
M#^)6A_!C6OBY\,='^,/B?3_[6\-?"C5/'WA73_B5XATKRM4G_M/0_ MWJT/B
MC5M/\C0]:F^V6&E7%MY6CZI)YFS3[MH0#_/C_P"'>O\ P=D_]#]^W%_XLZ\&
M?_194?\ #O7_ (.R?^A^_;B_\6=>#/\ Z+*O[P_C!^W!^R!\ O$MCX*^,'[2
M/P?\"^.-0\5>%?!4'@;5?&VC3^.(O$WCBPGU/PAINH>#M-N;[Q+I(\1Z?;R7
MFDWNJ:79Z==P/;O'=D7=KYWN?Q(^(G@SX1?#SQY\5OB+KD/AKX?_  Q\%>*O
MB)XZ\13VM_?1:!X,\$Z'>^)/%&N2V.E6E_JM[#I.BZ=>7TMKIEC>W]PL/DV=
MI<7,D4+@'^>3_P .]?\ @[)_Z'[]N+_Q9UX,_P#HLJ/^'>O_  =D_P#0_?MQ
M?^+.O!G_ -%E7^@Y\&?C)\-/VA/A;X)^-/P=\40>-?AC\1=%B\0^"_%5MI^K
MZ5;ZYHTTTUO%>Q:?K^GZ5K%HKS6\R>5J&G6EP"A)B"E2>,^"7[4_P#_:,\1?
M&KPG\%_B'9^./$'[.WQ.UOX-_&;3;71?$^DOX(^)?AR^U#3=:\+W4_B#1-)M
M=5GL;W2[^!]0\/SZMI$IMV>WU":-XG< _@6_X=Z_\'9/_0_?MQ?^+.O!G_T6
M5'_#O7_@[)_Z'[]N+_Q9UX,_^BRK_1JKY^^*O[4_P#^"/Q2^ _P6^*7Q#L_"
M?Q._::UKQ/X>^!GA6XT7Q/J-QX^UGP9#H%QXFLK34-&T34M'T=M+A\4:"\DO
MB34=&M[@:@@LY;AH;D0 '\"W_#O7_@[)_P"A^_;B_P#%G7@S_P"BRH_X=Z_\
M'9/_ $/W[<7_ (LZ\&?_ $65?W]?M%_M(_!/]DOX2>(_CK^T-XZM?AO\*/"5
MSH5IXA\7WND^(=<M]-N/$NN:?X:T.)]-\*Z1KNMSF_UO5=/L$:UTR=(7N!-<
MM#;)+,GL]G=V^H6EK?V<HFM+VV@N[68*ZB6WN8EF@E"R*KJ)(G5@KJK@'#*"
M"  ?YSW_  [U_P"#LG_H?OVXO_%G7@S_ .BRH_X=Z_\ !V3_ -#]^W%_XLZ\
M&?\ T65?Z'_CCQYX'^&7A;5O'/Q)\9^%/A]X)T".VFUWQCXX\1:1X3\+:+%>
M7MMIMI+JWB#7KRPTG38[K4;RSL+9[R[A6>]NK:UB+3SQ1OYK\,/VH_V9?C;K
M]YX4^#'[17P)^+OBC3]'N/$-_P"&_AA\7/A_X^U^QT"TO=/TVZUR\T?PIX@U
M;4;;1[;4=6TJPN-3FMDLH;W4M/M9)UGO+:.0 _@*_P"'>O\ P=D_]#]^W%_X
MLZ\&?_194?\ #O7_ (.R?^A^_;B_\6=>#/\ Z+*O]&JB@#_.5_X=Z_\ !V3_
M -#]^W%_XLZ\&?\ T65'_#O7_@[)_P"A^_;B_P#%G7@S_P"BRK_0N^(_Q4^&
M'P=\-OXR^+GQ'\!_"SPA'>VFFR>*_B/XO\/>!_#::C?F06.GOKOB;4=+TM;V
M\,4HM+5KH3W!CD$,;[&QPWQR_:8^!7[-OP.U_P#:4^,_Q%TCPA\#?#%EX5U+
M6/B-#:ZQXIT6'3O&_B'0?"WA/4+2'P;IOB#4]6LM<UWQ/H-G976DV%] T>I0
MWTDD>GK-=1@'\!7_  [U_P"#LG_H?OVXO_%G7@S_ .BRH_X=Z_\ !V3_ -#]
M^W%_XLZ\&?\ T65?WG_"O]LG]FKXV?&#Q]\!/A?\4+'Q7\7/A?X+^'WQ#\=^
M#K?0/%VG7/A_P;\5/"_A_P 9^ =;FU/6?#^G:%>1>(O#/BK0-5AM=-U2]O[*
M/44M]3M+*\ANK>#Z;H _SE?^'>O_  =D_P#0_?MQ?^+.O!G_ -%E1_P[U_X.
MR?\ H?OVXO\ Q9UX,_\ HLJ_T:J* /\ .5_X=Z_\'9/_ $/W[<7_ (LZ\&?_
M $65'_#O7_@[)_Z'[]N+_P 6=>#/_HLJ_P!$3QIXCE\'>#O%GBZ#PUXF\9S^
M%O#.O>(X?!_@NRL]2\8^*Y=#TNZU./PUX3T[4=1TC3[_ ,3:Z]J-+T&ROM6T
MRSNM4NK6"ZU&R@D>YB_-CX;_ /!4_0/B=\;-:^ .C_L2_M\:1\0?!]U\+U^(
M\/B+X2_"RQTSX8:+\8+S6;7P1XM\=75G\<M1N-.\,7\'AOQ+JDU[IUEJMY%I
MGA_5)H["::**WF /XXO^'>O_  =D_P#0_?MQ?^+.O!G_ -%E1_P[U_X.R?\
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M7_BSKP9_]%E1_P .]?\ @[)_Z'[]N+_Q9UX,_P#HLJ_T-/AIXS3XC?#CX?\
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M_P#!V3_T/W[<7_BSKP9_]%E7^C510!_G*_\ #O7_ (.R?^A^_;B_\6=>#/\
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MKP9_]%E7^C510!_G*_\ #O7_ (.R?^A^_;B_\6=>#/\ Z+*C_AWK_P '9/\
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M!^T%\1/"W[(7_!0:70-+^+GB[5]-\(_"+X]Z-H,/A>P^(7C/5+ZVTK3/A_\
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MGQ&&E6_@G0M5D^+7C&#X4:;XB\?^+[K7;FW\0^*_%/C?5HM'T]-;M[33@#]
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M;Z7:Z:SP6'AG^^7P5_R)OA+_ +%G0?\ TU6E?SSZ]_P;)_L?>(/ .N_!.?\
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M-#H]GJ6KZ1J&@ 'YY?\ !)'_ )31?\%#?^S'?^"<?_K*7[.=?U35\ _L[?\
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MSXXO+"?]2OVY/@'>_M/_ +(?[0GP*T:[GTWQ9X\^&>OP_#O6;;4+C2KCP_\
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M !"^-WPF^ WA33)/V'OB]\9O"WPW\;^._!W@#Q;!X1\.>(M1^)'BGQ-X3M_
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MIHOB[2-/\2:.+A=*\0:?9:W9WD.GZWIT=W>06>K6:P7]O;WM[;1W"P7=S'*
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M\$]-?^,'CNZ\9Z\/%7[0_P ;-?\ VCO!'B/XO_!CXHZ2^NC3=4\&_"+7-/\
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M"3_\$\/^"</[6&L?$'Q8G[6O[2/[9/\ P3TU_P",'CNZ\9Z\/%7[0_QLU_\
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MUIVN>!O$'CZ3Q/X>M]5TO66UOQG;RSZWJ=KXQN9;S6='M X!^7'QI_Y2'?\
M!TY_VBLTW_UA7PA7[B?\$0?^437["G_9#M*_]/.MUY O_!(?Q1J_Q4_X*0?&
M/QQ^U)9>)/&G_!1K]B[PO^RIXOFTWX%#P[IW@'Q1I/[.OAWX%^(/BY86*_%W
M55\067B#5M%N_'5K\.A)X=&AP:E'X4'C74Q8_P#"0W7Z$_L0?LR_\,:_LF_
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M>TK4/$%AX;U)+_4=<NWTZRTS6-&MK!K7Q3JDB^#^/_\ @W__ .$Y_P"%W_\
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M)^R_^T9#\7_C_P#LY>*-=%@WP[\*?M5>!X+R^DT_4O&%UJVEZ)+=6.B>#/\
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M^)K/PG:/JOC/PU=>%=1>T!T&XU2V6^O6@M]&U+3;_1K_ $FY;6?V&H ****
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M-\:>'-:\(^*O#FJ0"XTK7O#/B+3+G1M<T34;8X6?3]4TJ\NK"[@) DMIY(^
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M\57_ &@/V%_ OPP^'&H6'Q&^+OQ,^(OPG^#?B3XX_!+PKXS\46W[-W@CQ/\
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M#R/PQX6\/7L]KX[T?4KBQM=2_%K1OB7^UPV@Z%^SQI_QO_:I^$%WX4_X+7?
M/X!:=J'QH^)GPN^)G[2/A3]GCXD_LBZ1\>?'?PE\=?%#P!K7Q;\ ?$MUU#Q7
MXENO U[XK\0?$R]T..X\':=XMO[F_P#"*:7H_P"W'Q"\+?L]_MN7OP?\*^./
M!/QD%WX3\+^ /VPOA#\2?#>J?%'X0OX(U?Q1IWBGP9HBZ'\8_A=XG\./#X^B
M\/:[K]MXI^'*>(M1L;CPYK5K?:UI>HV$^FW"7? /_!/#]DGX:W$5]X9^'GB:
M?5%^._AG]IVYUKQ7\9_CAX\UK5?C_P"$O MY\-M+^*NN:KXW^(_B"^UOQ1=>
M#]0N]/\ $<FJS7=AXOO'CUSQ78ZSKUM:ZG  ?E/\3?B+^T-^R-XJ_;F_9@\%
M_M0_&'Q;H&HR?\$WM<^#WQ=^.>L:9\4_B!^S3!^WG^UQXO\ V9?C'>6'B_7-
M*74_$N@>!]*TFW\8_"ZS\6IXAM?!NLI:6,UGJVD_;(YO</"?P<U7X&?\%=_V
M7_ T7[1'Q7^,/@L_L#?M<ZUH7@OXW>-[GXH?$+P+XDOOC1^RM:>,?&4OQ"UZ
MT_X2_4?#GQ1BT[PW:Z5X;U?6-1T3POJGP]\0IX1L/#^DZF^EI^E_Q&_9%_9U
M^+>J?&+6?B+\-K/Q3J/Q\^&'@GX-_%>:]U[Q9!'XF^'OPXUSQCXG\"Z1;VMC
MKUI:>&=2\+>(O'OBC7-(\6>$H-"\7VVJWME?C7C<Z'H,FF?*7P9^"W[&7PE_
M;UU#P-X4\+?&/Q'^U[X)_9+T?QM)\:?BU\7OBY\8[\_L]?%#XE7?@.Q^'2>,
MOBA\4O%VL7Z6'C'X&/KEIX=O]";3?#D^H:UXDT+58M?^(?C]]9 .S_X*=>*?
MB+\*OV6KO]HWX:>(_&^D7_[*7Q-^%?[27C?P]X*U>XTM?B3\$?AIXPL)OV@O
MA]XJ@AW0ZUX9U/X'ZE\0-972KV&:U7Q+H/AS5L0W.EVUU;_#MK^VIXP^&/[3
MGQB_;$^(OQ.\4ZM^P7XW;]K+X$?#+PQ#J6F7W@31_$W["OPJT#XDW'CKPC96
M\/F)KWQ)\2_"3_@H;HFKZRM]<0^)M(^&OPAM8%98-/S^YOBOPMX=\<^%O$O@
MGQ?I%EX@\)^,= UGPMXHT'48_.T_6_#OB'3KG2=;TB_A!4RV6I:;=W-E=1AE
MWP32+D9S7YY_$']G_P#8/\-:-^R7_P $U_%/P.N-1^&^O_\ ">?$'X%^"8-3
M\47?AKPY?_L\_P!B>)O$=_XI\8S^-K?QWJ.H:Z?B?<PZJFL7WBF'XD6>O^,M
M&^(+:EH^N:M:ZL ?"?P,^''[6OCO]KOX#? OXX_M5_M&^&-,T?\ X)J_"S]I
M7]H'PIX,^)%UX>U?Q%^TWXZ_:C\>>)]5\//J\^EZA?Z)\._#$UUXC\ 2Z/X2
ME\*:I?>!/!_P]\!7&H_\(+IVJ>&-0\#TCX6^(OVK/V=_^"''Q6^*/[17[5,'
MCGXB_'V[\ >)=;\&_'[QSX5N)GM_V:OV]/&2>/[1[&\:6U^*;_V!:^$9?'RR
MMK<G@"[U/P>TO]E7\T9_I(B^#_PY@^,5_P#'Z+P[M^+>I_#32?@_?>+/[7UU
MO/\ ASH?BG6O&FE^'?[!;4SX9C^R^)O$.L:E_:\.C1Z[/]L^QW.IS:?;VMK!
MX3K?["'[-&L?!#X1?L]6OA/Q9X3^&GP$\6Z+X[^#4/@7XM?%GP9XO^'?B[0(
MO$EKINMZ%\1O#_C:Q\?O<I8^,/%&G3QZIXDU"VN[#6[NWN8)52U-N ?A+X0^
M-/\ P4+^.7A[XM?M$_!'2_VX_&OQ^\ _M<_%_P"'_P (_!&F^(_V7]$_8KTG
MX0?![X_ZC\--3^ _QB^&VN_&;3/%_BOQ)JOP[\.Z[?>+/BWK/@VS^+ND>.M:
MTR^\!^*;7PKI6FW.M?T^>*_#\?BWPMXE\*S:MK^@P^)M UGP_+KGA36+KP]X
MIT6/6=.N=.?5O#6OV++>Z'K^G+<F\T;6+-ENM,U&&VO;=A- AKY3TW]@C]G/
M0/'^N?$7PI;?&3P/JGBOQ_IOQ6\:^'? /[3?[27@7X=>._B7IT.E02^./'/P
MR\)_%?2/ 7BW7_$<>B:7_P +!GUWP_>V_P 4I;1+GXF6WBZY:29OLN@#^3OQ
M/\ M1^&?_!)'_@H!?>!OB_\ &7Q'XN\1_P#!0/XH> O#DWQF^)OB3XG>%_#6
MM?#C_@KQJOA/PWXTM= UU[FUM_$_B>]%KXC^*FNP0O?_ !!U])]8UD37DK;O
MJO\ :V^*GQL_X)G^)?CI%\+/C=\>?CEI_C+_ ()P?M<?M):#HWQ_\76_QAN/
MA_\ 'K]G+Q%\$M!T'X@>&;S7;73I=&\%:II?QCU;7?'OPVTPVW@:$^$;"X\*
M^&]'ADN].N/U/_X8%_9CDT_XV:!>>%?&NI>$/V@_B5:?&#XE> ]1^,_QFNO
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ME/&_[//_  R7_P *'_X0WX'>)?C-_P )?_POC_A:/]I?\(]X]^&G@C_A&_[
M_P"%,_#O[']L_P"%B?VI_;']MW7V?^Q_L7]ES_VA]KL?Z-: "BBB@ K^'?\
MX/,_^<;_ /W>!_[ZY7]Q%?P[_P#!YG_SC?\ ^[P/_?7* /ZIO^"8O_*-C_@G
MK_V8[^R;_P"J%\ U]Q5\._\ !,7_ )1L?\$]?^S'?V3?_5"^ :^XJ "BBB@
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MS:(OB'<?%I_B]:>%=(N?"/CWX\6,EMX>C^$VIPZGX2TOQ#;WFHG6-0T&[T(
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MJ.*6*XBBG@ECF@FC26&:)UDBEBD4/'+%(A9)(Y$8.CH2K*0RD@@U)0 4444
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M\--3\:QZ1;R/9M?ZIX5F@\->(IOL<TFM>%HY-"ODNM/D:U;VK]KSXH?M!_\
M!-CXD?M":M\-?V@_CS\>-$^(?_!-[]K;]I/0O"'QYU[P_P#$VW^&/[0'[..N
M? OPWH'Q!\$B70- C\.^ [[2?BQJOB#QS\,-'6R\%&ZT674-%T2R@%KHT/Z[
M^,OV&OV6OB &'B[X7?VN&^%7PH^"3?\ %;?$2PS\,?@?\2+3XN?"[PS_ ,2S
MQ=98_P"$8^(5C:^(/[:&/$.M>5_9/B'5M6T1Y--?TWQS^SU\&?B9XYTSXC>/
M_ >F>+?%>D_"SXG_  2MKC6KK5KO1KCX5_&>Y\(77Q/\&:MX3;4!X2U[3/%T
MG@3PLE_+KFAZC?6]KITMCIUW9V6J:O;WX!^27['A_;6T/]H;]GG5+6S_ &W?
M&WP*^*?PZ\92_M;^,_VO/%O[,_B/P%<>.8? UEXF^%OQ>_9XT7X2_&'QWKGP
MN@\5>+8-6\,:M\-?!EG:_"?_ (13Q1H5]!X;M]9T#_A(WR?B[\+[WXU?\%T?
M%7PUF^-/Q.^$_A>^_P""1?PR\1:]IWP8\97_ ,-?B/XLN]"_;)^,%EH5Q:?$
M+0].?Q+H'AOPS/KUW<:W9>&_$'AR^UW4M3\.66HOK'AI->TBY_4+X%?L<?!C
M]G&]T>?X7W_QNATSPQX1'@+P?X/\;?M-?M&_%+X=^"_!T;V!L]#\*?#CXF_%
M/Q;X&T9-)M]-LM+T#4H- .M^'/#T/_"+Z!J>F^&I)-)?%^,7["?[.7QO^+]M
M^T)XJT;XB^'/CO9?#C3/A#8_%[X3?'3XW_!;QU9_#'2M>\5^*(? \.J_"CXA
M>$(CX?NO$'C37M7U:SFM9?[9U$:#?:H]W=^#_!\V@@'X):3^V7^U;\9/BQ\*
M_P!C/7=8_:N\4^"?A_\ %'_@H]\-O''C_P#9EO\ X/\ P^^/?[6/AS]D/XR_
M#WX6_"?4M/\ B=XU\>?"%O!EQX;TWQE/>_&W6OA7JVC>)/%OBWPU*NE6K>%-
M3\0W&F^W?"KQ/^UAX=_:>_8DG_:A\'?%'4O%/POC_P""K%E\$X_B=)\+;CX\
M?%#X :!X _9P\0?".[^)LWPC\0:Y\.[[XISVUY?^ ]6U;3+G3Y/$5YX;M?$6
MLVAU35[[4K_]<]2_X)^_LI7?@#X'_#G1_AWJ_@32?V:[O7=0^!7B+X9?$OXI
M?#7XE?#G4/%UK?VGCF^TSXK^"?&>B?$G5;CXD+JFI7/Q1/B;Q3KB?%'4[^ZU
MCXA1^)=6F:]/H7A/]E/X+>$-;^$7BFUTOQOXC\7_  ,M/BA9?#7QG\1OC%\8
MOBIXRTJ#XS2:/)\2%UCQ3\2?'GBK7/&)UT:!HUO9GQG?:_\ \(MI^G6NE^$!
MH&F1+9@ _$CP_P#$WXZ>&_\ @G9\"?\ @K*W[57QA^(_QV\=1_L^?$/QW\(+
M#Q+Y_P"S1X_T3X\?&+X=> ]6_9A\*? @Z1J/AWP9KGA+3/&<OPZ\ ^._"C:+
M\29OBKH]EKOQ#\?>)M&O_$5E=\YJ_P 6/VQO%GPMUK_@GM\&_C)\6/\ ALO]
MF_\ :4_;*U34?B+JOBVVO_B3\0_@+^SEX(C_ &@OV6Y?&FNZQ;WM[?\ A_XO
M>(OVE/V&_A!X[>^1YO%WA&[^)MB;^Y07\M?KIX7_ .":G[(7@WQ+X3U[0/ _
MCBVT7P!\5K_XY^ ?A3<_'3XZ:E\!?!'Q?U'7=1\4R>/_  I\!-2^(UW\(=$U
M>P\3ZOJWB;P_:67@V/0_"OB74KSQ%X7TG1];F-^/?]!_9J^!WACX^^//VHM!
M^'NEZ=\>OB;X+\/?#WQQ\18KS69-1U[PCX7DMY-'TN33)]2E\/V,J"PTB#4=
M5TS2++6-<L_#_ABQUS4-1LO"_AZWTT ^1OV4?V@)_P!L+]I+Q_\ '#X>^,/%
M;_LW^!/V:OV=O"7@_P *B]EM?"VM_%_]H7POIW[3_CK7=>TF+;:ZAXH\&_!/
MQ5^S-I>A7=R9[KPY_P )O\0-+MULO[7U!;S]*Z^2_"'[#/[+?P^^'-E\)O ?
MPTN/!?P_T_XT6'[05OH/A7Q_\3- =OBKI6N6&OZ;K5WK&E>,K77=0T.PN=*T
MC3+3P#?ZG<_#V#PIH^D>"(_"R^#-*T_0;;ZTH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HKBW@NH)[6YB
MCN+:YADM[B"9%DBF@F1HY8I8V!5XY(V9'1@596*D$&I:* /SW_X=,_\ !,/_
M *, _9#_ /#!?#;_ .9ZC_ATS_P3#_Z, _9#_P##!?#;_P"9ZOT(HH _/?\
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MD^)/A7]CSX>?M+_"'XG^*_@9\,9OVB_C%XSUKP7HOQRM?A_\/V\9^'M7\ _
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M^WYX@^%WP_\ &TWPK\;K^R[X@^,/[;7PX^+7[+/@GPU8:#XA\8:-IOB_X7_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** /\Y7_@T*_P"4D_QN_P"S'?B5_P"KZ_9HK_1JK_.5_P"#0K_E)/\
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M\.ZY:07T$\5MJ^@:W86.L:+J4*I>Z7JEE::A8SP7=M#,FO110 4444 %%%%
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M&RT?PMI&D:=HND^&["RK]5*** "BBB@ HHHH ^%_^"BG[!/PM_X*/?LS:_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\T<C;E?R7>!_CE^TGX!_9?\ V0KWPK^U#XS^!?P#^%/[!O\ P1&TGQN="@^
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MXC>)=+^&?V^R^*-]%X=\6/KNCZMXON]0\4:C<^!7\.^%]# /W"HHHH ****
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M4B_75?'_ .TW^S9=_M _$G]DC6;ZU\%ZQ\.?@U\6_BQXK^+WA/QDMW=)XS\
M?$G]D7]HW]GBX\-:5I":-JFE:[+?:Y\8]%?7-+\076C:7-X2A\02+>7=_%9Z
M-J8!7O/VYO@%X1\3?M$:-\8_'/@[X&:%^SY\;_ _P'NO&OQ4\;^&?"?AOQMX
MP\=?L[_#3]H[3XO#EWK%[8()[3PA\0KJ.[TV626]CM?!GB?Q%(L6A6%S=6OJ
M;_M$_LVZKXT\&?#EOC1\'-5\=^,O"UG\3_ 7A)?'?A'4==\1>$'TC4_$>D^.
M?#6GIJ4\]_HU]X?T77_$>A:[8*]OJ>@^'O$NN:3<7.F>'M;N['\F?!?[!G[>
M_P &I/BI9^%?C/X7^)/@_P"(7[4,?BK5=&7XW_$CX'_%+XD_LZ^"/V3/A5^S
ME\#=/^)G[1&B?"'XB^/_  Y\3_"M[\(_#NK?%C4_AK9V>L?%*Y>?QG:?$+P[
M+)JGPXUV[\&/V&OVQ/@TO[.OAC1='^"']@>!?V9/!7P*_:C67]HCXAZ[\*_V
MO=#\"?LYZ]X&T3P7XJ^"_BK]F?6)/ &MZ=\4I/#'A[1/CWX=\8ZEXSA^!>FW
M-GXR\,_$&"'1/A'I(!^ANJ_MK?LZ7WASPAX[\*_&3]G_ ,9_!36_%OCWPE\0
MOB@_QN\&67ACP;8^!O@[XO\ BWK=W9D)JFF>,[J'0-!TK6-6T0:MH:6'PSUV
M?XJ#4+[PQIL,6KUO!'[=G[ OQ UKP=X5^'W[6/[+/BKQ!K_BBX\&?#_P]X;^
M,'PTU#5M9\5K%9H=$\'Z79ZX]UJ%_?P:QIJZ:FBPS+K,&L:;_9CWL>IV?VC\
MR?'G_!.#]LKXS?LU7'P3\9>-?AS9:/X=\;?'N#X+^!/B+\8_&OQKU#X9?!GX
MH?L/?$W]GS0/A]KWQVF^"/A+Q?\ $^'2_C'\2M6UFPF\:^$M8\5>&_A)]FT[
M4?B%X_UO3['1+?[9^+'[&/COQKXV_:=\8^'+_P"'NFWOQN^*W_!/;QKH-_>7
MFMV>JV_A[]D'XN^!?B'XJT_Q'/8^&+MH+Z:PT'Q$OP_MK&XU6TFU;4X4U2\\
M-V]U=WEN ?6GQ2^.>D_"WXE_LT_#2_T+4=5OOVEOBEXO^%NAZG9W-M#:>&;_
M ,(? ?XN_'BYU75H9@9KNSO-)^$6HZ#!#9XF34=8LKF0_9H)P?*KC]N'X ^'
MO&'[0OA'XO\ C7P;\%]-^!'QH\'? N?Q+\4?&GAGPUH7CWQ+XU_9[^%G[0T3
M>'3J]Y9[H=,\)_$_R-8M9S+)8V?A;Q#XCO6MO#]I<7=M:_:Q^#7Q)^(-_P#L
M[?%CX,V_@S6OBM^R]\:[WXN^%O!/Q$\3ZSX&\%_$33O%/P9^+7P%\9>$=7\<
MZ!X-^(FJ^#;Q?"/QBU?Q1X=URW\!>*H9?$GAG2= U"QT_2]<OO$&C? /Q._8
MN_;%UW2OBE\8? &D?"CP7^V#\9_CWXA^.OAOQ]X2_:5\:^%M*_99UG1O@#\'
M?V<_ACX>L[R__9=\6Z7^U!\.O%?A+X/:9XB^/_@'X@?#_P #>'-1U2_M]$\.
MZ1XCO_#OACXBZ& ?=FH?\%$?V ?#.L^*/"&J_ME?LNZ!K?P]?4=.\6^'[_XU
M_#G2[SPE=Z!KZ>$=6T75[&XU^!M+U;1/$#6VC:CH4R1:GIMS=:?'<V4,=_8M
M/Z7JW[4/[+&F^.OAEX$UKX^_ VT^(GQ2T/0/$WP@\-7_ ,2/!$?B;QYX>\>3
M7>G>$=:\ V<VK_;-?TSQY<:;J5EX2O-#%S!XQETG5;?07U-M*OTMODSX*?L1
M^/?A[KO[*&N>+-1^&6L7OP"^,O[?GQ2\17VC+K4,MU/^UI\2?BIXM\+ZAX/M
M+[P^#;:S%HGQ#>S\;6]]J-G'IUQ=:O8:3J_BFT$=_>_(R?L ?MY0^"?V:?@I
M??$?X<>(/A?\$M!_8 ?2ETWXZ_%+X:^&/AUXA_9>^*7@OQS\:YH_ASX1^"\U
M]^T3J/CZP\#:5;_#&_\ BIX\\+>$?"%Q)IUU#X \-:WX2_M[QF ?KGX!_:L_
M9D^*GQ&\2_!_X:?M!?!KQ[\5O!HUC_A+/AOX1^)'A+Q!XX\.-X=UF7P_XBAU
MGPOIFK7.LZ?<>'=9CCT_Q!;7-G'<:'/?:1_:L5HFM:0][M_M$_&/3/V=OV?O
MCI^T#K6C7WB/1_@7\'/B=\8]6\/:7/;VNIZ[IGPR\$ZWXUO]&TZZNP;6VOM4
MM=$EL;2>Y!MX;B>.28&-6%?&7P[_ &1O'OPDT[]F_5I+OP<R_ W]JS]N']HO
MXCV_@\^)+W5?%W@C]HJ7]K'6O#&A>&["U\*V][XG\8QWWQD^&]SXET/4H["Q
M;4O#.H'1=4U^YT?PZ=5]4^+'@SXP?M?_ /!.;XK?#O7/"&A?!CXZ_M0_L:?$
M3P5=> _%&O:IJ&@?"OXE?&KX,:UH,'A;Q;XDL/#3:O/9^"]?\2PZ7XHU73/"
M=S=C^SM1N--T6]=;>UF /(_%W_!3CX=?"3QSH'@']HCPA;_LY:E;?&*3X5_$
MW7OBS\3? >F>"/"NC:M\"?BC\9?AQ\4O!GB_2+S5]*\<^$?BGJGPPO\ X;^$
M-!\0O\-/B./%$UU!JW@G3]1@T71/$GTS\8OVK_AG\,_V1?B;^V9X4U'2_C)\
M*OA_\&/%WQMTJ_\ ASXCT75]-\?>&/"GAV_\1%?"WB6UGN]#N1JD%A);6E\L
M\UK'.Q\T_NW4>77_ .P[\.O"OQ#_ &6M>^"G@7X?>"/"?P?_ &COB)^T!\3+
M:Y&IS^)?&?B3QE^S-\7/@A:^*QJMW9:[J/BWQ['JGC3PC'<ZSXNUVUNK;PEH
M3Q6>KRRZ3I&C7'B?BG]C7X_:_P#L$?M:?L56LOP8L)/C%\.OVN-.^&'C-?&7
MC065IXP_:3^.'[1WC71]$\8Z)'\+U;P]X-\(>!?'GPN2;7?#UUXJU2X\1W'C
MG1+7PI'H_A;P[X@\9@'UA\)_VEM;\6_%.^^!7Q>^"?C7X"_%IO#/C#Q[X+T_
M7-?\%>._!/Q9^''@+Q+X/\)^+?''PX\;>!=<U-S9>'-:^(GP_M=<\._$/P]\
M._&]D/&F@W4?A>ZL)KF\M?JRO@/3OAE^UAXL^.FK?M'?$GPI^S[X;\1?"'X"
M_%GX5_LQ_"?P;\9OB/XR\,^+?%OQ<USP+XJ\3^,/C?\ $[6/V?O 6K>#+"XN
M_@W\,?"F@Z1X)^&7Q!E\)Z/JOQ&\1W5WXTU&_P##N@Z1][VYG:"!KI(8[DPQ
MFYCMY7G@CG**9D@FDAMY)H4DW+'+)! \B!7:&-B44 EHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** /G;Q_\ M??LF?"?Q3J'@;XI_M0_L[?#3QMI,=E-JG@[Q_\
M&SX:^#?%.FQ:E90:EITNH>'_ !%XFTW5K.._TZZM;^R>YM(UNK*Y@NH#)!-'
M(WN7A[Q#H'BW0-#\5^%-<T?Q-X7\3:/IGB'PWXD\/:G9:UH'B'0-:LH-2T?7
M-#UC39[G3M6T?5M.N;:_TS4["YN+*_LKB"ZM9Y8)8Y&_B@_:2\(>*/&7_!Q%
M^W7I_A3_ ()K_#7_ (*>WUM^S/\ !.\N/@S\4/BC\'OA3HO@6T7P#^S[ WQ.
ML-<^-'A_Q%X=U#5+.::'PJFE:9:0ZT]IXHNKN.X%C:7L4GW'X?\ V@_^"G/[
M9'[2?QK_ &,?V"O&/P!_X)D^"/\ @GE\$_@%H'B7X=Z]\//"/QIUC5?BA\0/
MA=IFI:;\&+6XOO"NJ>#M&^$'PEU?PQK_ ,,K3QM\,_#END>BZ=I_B[2K'QAI
M_BWP[H?A, _J3HK^+;_A^3_P4*_:2\"_\$E[K]FF#X/?#_XW?M6_&S]K']FG
MXW>%_$7@F\\0_!'7/'WP\D^ NE^!/B!8:ACQ-\0-(\$>$M%^+Q\?ZP/!GB:[
M2;4K+5M(U&ZU_2-*6U;^N']G?PU\:?!WP3^''AC]HKXD:/\ %_XW:-X>BM/B
M1\2] \-Z;X0T;QAXB%S<R2ZMIWAG2--TC3=&MFMI+:!+.TTVTC7R"YC+N[L
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MQ1#\.;34-8T\74-M\2_&/C;Q#J.K>,/$UIXW'@W3-$$.BZ(PE@L)P#^I&D)
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M[BMH([J\$"6PN[A(E6>Y%M&SI;B>4-*($=DB#^6K,%!/YN_\%>OVR(OV%/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#\_/V4O^"6/[ _[#_Q$UGXK_LL_L\Z/\)?
MB#XA\%ZC\/-8\1Z?XT^)OB.:]\&ZMKGASQ)J&B-8^-/&OB32XHKG6_"7AZ_:
MZM[&*_1]-2&*[CMY[J&?] Z** "BBB@ K^'?_@\S_P"<;_\ W>!_[ZY7]Q%?
MP[_\'F?_ #C?_P"[P/\ WUR@#^J;_@F+_P HV/\ @GK_ -F._LF_^J%\ U]Q
M5\._\$Q?^4;'_!/7_LQW]DW_ -4+X!K[BH **** "BBB@ HHHH **** "O\
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M\]S<-'%(XCC8JC' /\=W[1/P\_X*+_";XF?M!?LR>'(OVZ_'7_!.WP5^V?\
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MX/BI;^ S\0(3X"UN#6/$OB+5?$/AK7O$GWM::U^V)HW[)O\ P41T?X'?#O\
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M\,:!XCU75]*5[A-2M;2>QOH;;\H/^"(6A?&O0M7_ &FX_&?B/]J1_A7J.C_
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M=\.]!T#QEJ-^?VOO&6I>#-*^"MWH_B:RTB_MM>M[7Q%]$_MBWO\ P4(\0_\
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MR3QU;7O@_P 0W-_KUAHUMI>B66JVU_;00:;HVF;M.EOK5+X?KI10!^37A/\
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MGGNK:\M&CL8OO"BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN%\8/V\]?^$GC+XA:3X'_P""GD7[1?[-_P */!7P;^-'BWQOX>^*O[ GA_\
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M<:I8QS[E?RN?%3]LKXHW]Q^S)^T%H?QB@\/:7X[TO]M_X3>-?VE4E^'.@/\
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M@M=/MI[R9TMXGD7^?S]HOPK^S!\?OVEOC+X#\(?&#]A?1/ 7Q,_9!_;S\/\
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MFNWT%MHVE:E?VOY4#_@Y@_X(XD@']ICQ*H) +'X _'W !/4[?AN6P.IP"<=
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M, ?U445^6G[7_P"WA\:?V=_VX/V#?V6/A_\ LSZW\6?"7[5]U\86\2>,]/\
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MQ-X!LM/\,0Z'J>A^//L<M[>ZGX<LK*]\7?=7_!3#_@K9^T/^Q?XGO)/ M_\
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M:^*;0/I-U<QV7@;X>>(=>U#63I5C:76E>$/&.L6%M'I/AC6SI?G/@7_@HO\
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MN-K L;[Q:=)MWU"T\-6LLNM:A:R6LVGV-RM[9F?RCX:_\%"OV<?VA[G0]3^
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MYJ'AGQ!\/K$ZYJWB_P">9OV1OVLO"/Q*\#>/_!WA;X)>,H?@%^VG^U'^T+X
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M\0? ?PX^'US^T_\ MA:A^UMX/D^!GC1/V=?&=[J.G^%[O7=7^'?Q&GU7X<^
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M">![2+0X]&^%?@>X\$6FH>*P#[$^,W[77[*OP9G_ &P/BEX#\0_#;XG?M(_
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MUNPT_6M%O[#5;"SO(/R+/_!M[_P1>))/[&8R22<?M#_M6*,DYX5?CF% ]
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M_P!L?V/_ &Q_:']E_P!K:7_:'V?[)_:-EYWVF+UZB@#\W?V9/^"<'@;X)_\
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MYX=TOQ+X:TC6-#AU<7%MIVM>'M,OM-,%YI%I);M\.? ']E'0_##> O#'P=^
MEGX2M/#_ (F^'\WA73O W@)]'3PO\6]3TWQ;XS\&7FF+ILD$FB?$[6++1_$W
MBC0+J)[+QKJ5IIFLZM:ZG<V]I<H ?F]J7[2G[>WPI^)?Q;TCXC?$S]E_X@>!
MO@-\:_V+?!_B4^&/V</B/X$\3?$GP]^V#\2O OP^UG2=!FOOVG_&>F_#2Z^$
ML7BR;7/#NMZC;?$U_'+/::/K=AH']E76KZ[]#_ /]JGXO7>I?M:>&?V@=)5?
MC3\"M&U'XD:9^SEX.^#VO^%==E^&!OOB1!X$\1_#3XI:A\3?'/A/]HGPE\5;
M3P3;Z3X9\1Z1I7PZ\3>'_'FE>*],^(?@7P3>:UHO@?PE]O:KX"^$NL:KKMMK
MG@OX=:IK?BNX\(>*?$MOJOASPU?:KXENOAOJUAJ7@+Q'KL5Y9RW>LW'@+7=-
MTN_\(:O?K<R>%M6T^PNM&N+&\M;>2/C_ (+? ']FWX&GQ;/^S]\(?@]\*CXI
MN-(_X327X4^#/"7A(:Q)I=M=ZOX>M-<;PQ860FM=)L_%FH:GH&FW.+/2[7Q-
M>WFEVUO#K5Q)= 'XM?%7]K#]L[Q9^R=XQNM:^*7[/@N?VI/^"57[1W[<'PQU
M_P"$_P 'O'NE:C\!K+X;>%_@-J>H> KZ_P!<^/&NCXDVGC'P9\=I](\'?%>.
MT^'.H>'/B%H%SXO?P'XB\/W4/@7PY[]XV^&GQ^_9_P#A7_P2N^"_[/\ \7_A
M!\&=(3X\/\//&-CX&_9WUS0?AQXGTO5?V?\ X]_$'P[9_P#"N]&^/.E&Q\/6
M4GAN^;Q/H.J^*_$<WCGXDZGX?^)5QK.DWOAZX\.^(_I[X7?#3]@/P9\5?CS\
M'/A=^S7\ O =ZOP#^&'BWXO>)/#7PE^$?A_X>>/_ (1?M%>.OV@O!>G> -0U
M72($;Q!H\OB;X%_$6Z\:>#=;TFW\'LWB32;JV?6M4UOQ#!I?J7[8UW^S=X;_
M &:_BIXK_:4^&GA/XL?"3X.?#7QK\==4^&6J^%O!_B^^U;2/@=X1U7Q[>R^!
M_"GBZZT[1+OQ/IFDZ-<IH#OJ&D6UK=3PPW.KZ78SSW* 'XC:?^U[^U?^PY^S
MQ<_%F*;X,_$GX.>.OVCO^"G7A+P#\*(/AGXUTOQIX"\0^"?C/^U]\6-$^)WQ
M#^+$'Q4O['Q/X+M=7^'WB6]^)FB:'\+_  M/H'PWFM+C1-3O=>\-ZIJ'B7Z^
M_:G\8_M/Q_\ !-;_ (*9Z/\ M):=X<U;5O ?[/'Q3U'X=_%[P]\/+GX1>%/B
M;X8U;X.7NKWEO=?"^_\ BI\7?$WA76O GB^VU_P]J\MQXIN=/U_PZ_A;6]*<
M:C=ZW8Z=^IVN_!OX%7OANU\,>)OA5\)KOPA%JWC*:R\/:[X&\'W'AN/7/C%'
MXHT#X@S6NDZAI;Z8FK?%.+XC>--%\9216XO/'$?COQ1INMG5%\3ZM#?<EX/_
M &:OV6?AEX!\2_!#P5\#_@?X.^&?Q&%S8>,?A3I'@'P7IW@[QXFJ>&VT:ZT_
MQ+X-33%TGQ1!>^#_  X^D/8:II]]#+X9T%M.\DZ3I9A@ /AW6_VK/VD/@WXM
M\5_"_P")'BSX-?%76=#^(G_!-^_3XJ>"?AIXB^&W@N#X?_MP_M1^)/V?O$_@
M>X\,ZG\6/B0\?B7PI#X$U+7_  5XL;QO<)>6/Q"\&6>N>';N[TG^U/&?+:_^
MW1\==)_:7\8:/KE[X$\%_LD_#W]KRQ_9MUKXR:7\(?$WQ>$'BK6?!'[,E_X;
M^&OQ1U+P[\6_"]U\&E\8^+OC#XM\&>'/C*O@SQ[X,T;X@-X7T?XDV'@>P\.M
M:?%;Z7\9)^PC\#_&7PD_82U[X,?##P]:?MN0_%6]\+?"NP^#_AZ?X4^/9/@7
MX5\"7OBFS\;V%OH[>%[273?#%WX,TWPA!K]D+2:+1-)\.Z&]O/IVB:>_ ^&?
MA=_P3'TK]LBR_9T\'_LK_L_:3^TK\,/A;X?_ &DK77/#W[/?@+3(?#&D>'?%
M?A;PKX8U"3Q[I_AZW4_$?PMJ*^"=<T;3KBXG\1^&=(F\*>)[2;3X[S1[F8 ^
M$_ '[97[4'AC0?VIO%?PWMOV;O /P&_8YTCXJ?'3QQ\.%^$/CS7_ !C\6WU7
M]MC]O3PMXWT3P]XMA^-WAO1_AYJFN>&/@4?%LWB.]\,>-4O/BGXDDU%M'L?"
M<=]X;OO?_B!^UC_P4-\1^/\ ]I#4?V8?A/X&\?>%O@A\<_$?[-]M\$M;^&E]
M'\0FFTGX/^&O&T7QUU'XHZ[^T!\-_!>K?:_%7C'PUJ'ACX*#1_!UOXM^$^LZ
M)K-S\8O"^MZU))H?Z=Q_";]G6S\.>,8XOAI\%;3PC\3M$U*Q^("1^#? T'AS
MXA>&[C4_&OC36+/QBJZ:FF>+-$GUGQS\1?%FI6^M"_L)-3\8^-==ND:Z\0:[
M=7?R]^TI\'O^"?%UX@N?BU\:/V8_@)\9OB!XQ^+'P,^!'BWQ%+\*?A5XZ\>Q
M^,OBIXK\*_!OX;3^.M0UY(-1B7PO!XTTA1J6H7EQXF\/>"DD'AFSNUBL=,N
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MG^VO\1_@]\>_#_AOX3ZYH'C#P9X$\?\ [)7@']HWP'<? G5M0?P/#^U'\=-
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M#U32_"D]YX?TO2=5E\-V=[>>'M3A6]PM5^"/[#/[/=SKO[3,WP6_9Y^&&J_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW[1/[8VO?&SX;7.@7'@G5OAC^TI+_P %%/B7X\T[QI\1?$FD^*/!&C_LZ_M
M?#_]G_P)H'@?PU8?#3Q9;>#=2^&'P6TSP/>OX,L/%_A.#Q[\;O&?QEUOXCP>
M!_$&G6MQK8!ZG_P44_90^(/Q\^-O@/5M'^&OQ_\ &7PM;]C3]J3X$>);[]FO
MXS?"KX-^-]+\7_%GXM_LF:YX6T+69OB?\0?!^BZ[\.]>\)_#3X@Q^--(U+PW
M\1_"USI%@;#5_ ^OW]YHFE7GD/AWX'?MI^'M.B^$7C7]GB;QGXD\;?ML_P#!
M/;]J/QY\;?AGXK^#GAKX%:3H/PF\(_L2Z1\?%T;PSXA\?^'_ (C6.H>$O'/P
M+^(5QX?\%Z=\/Y;75_AZ=&U3PWJM]KS_ /"%(W]GW_@H]\</@G^R+\*O%'[5
MWP@T347;_@G+X(_:<^&/B?PQ\=O$?Q,^(?Q=F\+67P1^'-WI7QJO/%WPM\+6
MO@;Q_P#$?QA\9/AUXAOO$=KXC^)&@: OB;Q.WB7Q%J"^$[CQ#KWZ>_LL_';X
MG_%Z+XD^'/C+\+]#^''Q!^&?B+1+">\^'_B#QQXZ^$/CCPYXJ\-6/B+1/$/P
M_P#B#XY^%_PDU/6KC3+R37/"'C'1)O"5I>^'_$'AN2ZD,NCZ_H%U= 'Y*>$O
MV3_VB)-(^-G@3P-^R[J7@;X;:I^T]^QQ\:_"OB+XLZ1^S/X-_:4U^X\-?M;Z
MG\6/C;X6\??$#X-?%[QYHGQW\"?"3PXD_C'P#\1?B)J>E?%G5KCQYXB\.SW?
MQ<\22:CXG>C;?\$UOC!\+?V3?#GPN_9N^#7A7X->.O%W_!*#Q+\)?V@(? M]
M\-/"^J?%;]JS2+CX :KHW@;X@>+=*U^QN?$GBCQ[8#]I'P.?C*VM:AI7AJ/Q
MSK^MR>-+*2\T*>X^N[S2OVH_@1;_ +)O[*_C;]J7QMX^\8_M._%^'P9XJ_:3
MTSP3X7T[Q1X0\*?!?]AY/$7C/0_"5MXP'COPQI?C7XT_%GX*>)/'D&J:MH'B
M+^Q/#WQ ^(EOI%G#XCT/0_%5O['\0_'_ (X_9,F^#?[/GPEOO$_[27QH_:9^
M)'Q @^%<7[3WQ<NM!\+^!/#O@7X9S^-_&\FO?%3PQ\)?&?C+4O#GA^WT!+KP
MUX8U#P]XS\=>(?$?C*[L5\4:-X(TB6\\' 'YA?$_]CSQ##\)KS7_ -GW]@_X
MSZ'XJB^)U]\2/AE^RU\1_A#_ ,$\-3_9'TKQ]I_P7T7X?:MIWQ ^!&F_M)0>
M'?#7@3XWZ5<VOA77_B)\./$,'Q!\$>+/!7BKQIHL^E:'XRURU^-'V)^P?\!/
MBQX3OOVM? GB7X#ZS\ OA3\4M!L+_P -_$+QAHGP(T3]IRY^('C[6OB_??$C
MP=KGQ,^ ?Q$^($?QS\%_"J\\2VOB3X5?&/XGKX:^*$UW\0-:L]?OOB-K":YX
MNAAU[_@H_P#M!:QH_AVW^%'[,OPKO_'6F_#/]N+Q[\9]$^(O[0_BCP]X6\#Z
MK^P9\?\ PW^S]\2?"G@'Q9X7^ /BZ^^)K^-_$^IZG>> ]:U;PO\ #6TCT*VA
MU3Q-;:/J\5QX2?%L_P#@I5^TYJ_Q)^!/P1M/V5?@SHWQ7_:8TGX4^/?AC9ZW
M^TWXNN/"GAWX7_%OX-?M5_%FSO?B9K&G?LW_ -HV'Q(\&P_LKZYINO>"/!FD
M>,/#.L77BG2H-'^)$5I9:AK,0![G^SI)^T3X'^ /PT_8HUKX ?&7X:^,_AS\
M XO@'IW[6&@:K^S[XD^!&GZC\-_A5-X-\&_&;0;-OC;_ ,+>?2_$^I:%HU_H
MG@[5?@\OBO1M?U6WTSQ-HUMX5L+_ ,9C\N]"_8.^,NO_  #\2_#_ ,!_L(ZA
M^S1XZO?^"5?Q_P#V:?V@;]_$O[.6E+^UC^U/\0_^%&P^%-1D\4?#WXO^)]5\
M?RZ7J?@WXU>+8/C7\9F\-:^%^+92?5+36?$/C[2].^\/C'_P5$\0?"WX!Z+\
M7K7X;?"'5_&WAF#]J8?&GX&WGQA^)\_Q'2]_9!^)>O?"#XKW7P,TCX<?LV_%
M#4_'_P /D\:^#O%IC^+7Q%TGX/>#/#%@? L?CN3PU)XQUNY\ ]+XQ_;Z_:!T
M[QM\:O\ A"?V<?A?XB^#WPQ^/G@']EKPSXSU[X]^)?#GCWQW\9OC1\-?@UXF
M^$MQ'\/+3X&Z_HVA?#Z7Q_\ &WP/X!\7ZW?_ !".N:=I^L:GXOL/#US#X1DT
M;Q, >(>+O^"8G@_PE\4/CS\0?@1^R;\&_!>IQ?''_@G?XS_9VU7P5X7^$?@X
M^"M$^$WQ;^&FL_M%Z]\-K2VDTI/AEJ%YX(T76[7QX^F6WAK6/BKHNDZ?X>DB
M\7I;Z/IIP?V</V-OB3X1\=>$KE?V3+7X(_%#PI^UG_P4)^+GQ;_:.BN?@G)<
M?M!_ GXY:M^T[_PJ3P _BOP+XVU_XA^(6\5:E\6_@1XIE\(?$C2=)TGP;#\
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M?BWXW\6_LH?%OX=ZMX=\ _'/X'> /VJ_V8_ /[<_C_\ :'\)_#K2K?X$>#O
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M(UKP9\6_#AN]&U[PCI6L>'==MM7TF5]8TZWTSQ%K0!]1T444 %%%% !1110
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MFI7OA?4?&FD>/_ NHS>,.D_87_:7_:>^(U_^SWIW[2VN_!CQ1=_M2_L8Z?\
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M=<ZOJUGHXDN8P#\K?!O[='[2&E?#7]M7Q#\&=&_9T^$7@7]@+2_VBOCGXT\
M>,/A3X_UR[_:2^V?M+?MI7,]MX(\3:5\:/#,'PPL/$UK\%M5TZY\:R>&?B7>
MZ[\>]2\4W,7A73?"WAL>$O%/V+<?M6?M3:=\;_BMXEU'5O@U#^S=\./VX/@-
M^QS:?"W_ (59XN?XS:S#\>O!O[-;1^/;_P"*_P#PN"#PGHM_X-\>_'JQ\OPY
M#\*=6MM1\*Z3XCMKK5'U;4-!O=#^F_C+^S=^QA<Z1?\ Q/\ %7[(7P0^-'BC
MX8>&-=\9^']"T?X-_!_Q1\0[^TOO%>M_%.YM/"$7B>'2-.EN_%'Q*U#7/'-E
M_:FN:7H^H_$?4[_Q?<:A#X@N;O6*^CIO 7PEO;S5-/G\%_#J[O\ 7O&ND_%/
M6[&;PYX:GO-9^(W@?_A"_P"POB-JEL]F\VH^-?"']@?#S^R?%]VDVN^'_P"Q
M?!?V/4;3^SM#\D ]%HHHH **** /Y^_^"S/Q/_:=\;?M#?\ !.C_ ()S_LT?
M'SQ-^RZW[;?C?XPWWQ8^-_@22[T_XB:%X#^!WA[PMXP?0?!/B#2;NRU[1+W6
MK:[U^XNI-$U/P[>ZEJ&E^'="OO$$/A/5O%EA>V[O_@@9HC:7<QZ=_P %6?\
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M-Z3XBU+6M%MM4T_5-*GUVRTR+5M+OM+>\@?X4^$/_!"?QCXB^&G@KQ#\?_\
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MJ_[.OPU_X*<ZO%\!+CXC^-_VS/!'C_PI^SA?_P#!/NY7QCXAUG5?&WB7PO\
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MM_"<OP!\4?L.^ _"_B#QSXGM?[8^"GC;PWX<E\2?![1VOO%46I>(]8U/PO\
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MX2N?B%+X?\5_&WQO!\8['X86^N</)\/_ -I#1/!TOQP/A?\ :[T[]MKXK?\
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M+3+JYUS6;F_P/$W["/[.OB(>"Y;'3?B?\/\ 4_ %Y\;+GPWXA^$/Q_\ CO\
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M\0OBE;?LE>!_"G[.^N^"=2^%OQ"_8W\$^$/#WQ6T/X0_$OQYX%^%]QIOP_\
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MKSPZVH:-?ZYI^H> _P!MSXT^,+O3M;OX-8UW]K2PUYBUFVA75QVO[=O[&OQ
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MQ<>&Y_"GAOQ#K$O@'X<6&I?T.T4 ?AI\,/V!]=^#T'PR^(VC_LZVT/Q7U_\
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MQ3N7UWP#\,/%_C37O$^D)+X%M=;\11:MJNA>)+R[272M5T;]^** /PX\ ?\
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M .%2ZOI4]_XALY/#EEJ?B*PNK3Q'K%E+X?\ K!/^".GB;_AHK]ASXTQ_M >
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MQN_X(@?!7XM?'K]@WXK:5\1-6\)^ OV,OA5\+O@?XK^#^H^%AXQTS]H7X4_
M37=#\7? WPGXNUNZ\4Z/9Z-!X,\7:5=:OKD][X5\9'Q=;WZ::\6C)9BXN?*_
MV4?^"#&E?LR#X0:K=?M0:C\3?''PM_;#^&7[1UUXYUOX1C2M8\5?"CX&_L\Z
M]^SO\$_V=9HT^*.K1Z7I_P -_#?B35+K2O'BR:AYMO<-HX\%6T8BOHOZ#J*
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M[DBM;*QLK6*6YN[NYEBM[:WBDFFD2-&8>-3_ +4'[-%M8:OJES^T1\#+?3-
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MM$ENKB&)_P",[X>_\%,_^"@.O_LP_P#!1O2_#7[5EIK7CCX1_$G_ ()LZ?\
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M1?A;^TU^U[H>G>%]4\2? [PO=^$]5U7P9IND2^--*UWPKX*3XF>([&;PY?\
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M]GK]C:Z^&MGJ6@_LK?$K_@MC\=D_8<TCXJ>#M%\5^)M!_8FU#X.?%_7/AO\
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MN^)GP3_:E_8>^"^G_MU:I^P1\#OCG\-_VM+_ .+?Q=TWP+\//%Y@U?X<>&?
MNL?#V(WOCK1K^7P[<WNM7UQX?L+S1=0TZ^O[O7HM&LV75]1TJ]L?D?X=_M?_
M /!4']I?X7?\$B[/PU\:=5^&OQ5_:!_9+_;>^-'QCT'0_!'PRAU+]H*^_9]U
M'P]'\$-.AO?%'A#4+'X?7WQBL)_#+ZSXD\*_\(W!HVE^.]?UG0XK.[M-#6S
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M6NLZ'<6.HV\5R@![W1110 4444 ?@'^V;X7^$O[+_P"TE\=?VEM"^%-WXO\
M$?PJ_8_UC]JG3/#]UXX^(\?A4_&VW_:!B\CXG>*--LO%(M+/PQX:GN1XB\<?
M8;!K6P\$:3K;66E2>1%:M]^_!?X[?&/P9\5_VD?@]^U7\0/@WXTM?@3\#?@U
M^T9<_&/X5_#3Q5\(/#VD>$OBMK?[0^F^(?"GB_P;XE^*_P :)X+GP/%\!KO7
M]&UZP\5^=J_A#Q!90:OHL.JZ.^N^*/6/&_Q8_8KN_C1+\!?B/\0/V:;SX_\
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M,NL?L_6#>!_B/^P+\"?@MXT^/7P3B\4>)-)TWX'^%O!OQEF_9W^(?@?XOO\
M![7S=W'ABQ\9^%[OPC<6D3+>3:YX<\+_  V\;1>,+6PG\&7L3WGI?Q/^&O\
MP2_L?VAO@%X;^)GCO]CK0S:?"/XC>#_A7^S'XR;X20V_C*[_ &H/'_@;Q1;?
M%+PGHNL:M%+=7?B^]^'OBGP@FJ:;H5]'\0KOXDZOHMSKEQ>:\-'\1 'A.O\
M_!1_]J"Z^'GCW]I7P[X9^&?A_P"$?PH_X)V?LJ?MA^(/A#K/@?Q9XA\>Z_\
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M^&7Q,^-&E?!?Q=\4[G7_ (E>*_@O^QSIW@KP]\7[[1OBWX7O/A _Q M_'B^
M?!_QO@\$^.O ECXHL? FG?$*P\%Z9H)B^+?JFA_M'?\ !-+]M&378_VC]-_8
MJUSXN_ :_P#VG;+7OAW\;=5^"OQ-\9_"'X=?!3XL^*_!/CGQOJ4GCO1K?4?
MGAO7O#GPW\,_%3QC:SV.F6OAWPYJGAJ_UZ\U#1[;1_$FH=5XE\6?\$A=0'A_
M]L7Q3K'[!5S+#\0['2- _:(U-_@DVH2?%WP1I6GZ_H>@1^/9%^WW?Q2\(Z;X
M<T;4O#'A^YOIO&>@OI>C2:#8VEW%IX(!^9GCC]H_]K+X ? >_P#C+X_\<?![
M]HCXE^!_VO\ _@IK8_"+4O&'PI\:^'&^'&N? CX2?MY7EI+IUPWQM\6W(\->
M(3X+T7PSH'AN);6/P+\)]1U/P9:WOB*^GT_Q78_=?C?]J']KKX50?%/X)>+?
M%WP(\3_'+2/B)^PEH'ASXUZ!\%O&7A/X2^#?#/[<'QVUSX.-/XF^%6J_'OQ1
MXC\3:I\/M5\&^)].\(/9_$O0+?Q7J7B;X::=X@AM&@\5:S>^[O>?\$N=9^(7
M[2%E=R?L1:K\2/",6K>./VK8-43X+WVO>'(].\,^(/ /B;Q9\:/[125],;3_
M  EXV\4>"_&&M>*3"]EHOC#6O#GB2XBM?$5Y9WG3?&^?]F?XS?LQ_%'XO:=\
M1/V4]+^''Q&\*>&['QC^T#\7?!?PU^*OP1U?PC\,_'=\UMX?^+]MXH\0>$]!
M\7^$_#/B&Z\9>%SX>\1>--$F\$^)M?\ $0TVYT+Q2MU0!\0_$7X\_'GQM_P3
MQ_X+6Z)\6/'OPX\3?$+]E;PI^UE\%?"_Q+^!OAGQ'\,].U.UT#]@7X8?%ZTU
M^71=3^('Q"U/P[X\TCQA\4=?L=9CTWQ;-;Z)JNDQZ?IY5],-Y<9GPG^+/CG]
MFW7_ -J'PQ;64'PZO/"W[<G["?P9A^ ?B?XJ_%3XY^"/ 7P9_:0^(OPL\#+\
M9_ACXS^).LZ5?:+X5^,T/Q"\4Z!X2\)>%O#?@GX:_#CXA_"G5_"-AX.U77M*
M\5ZAXBYSX+_&[]B7X%V_P/\ V*_@KXS_ &,?VE8_V_/'?Q-\<?'6[L?%/PR^
M&'P4U/PMKP\,?"OQCHOACX&^"_#WQ+\.:U>^(=+MM"^!'PU_9ZU2YLYM<LO!
MGB"'XB^/-0U?P_XOU+6/TZ^.FO\ [$%MX]TCX7?M$M^SK<_$O]H[P]H/PMT_
MP3\3=*\#:MXQ^+7@RR\77,OA7P=?Z5K=E>:MK_@BS^(?B>>/PU8ZM')X9M_B
M!XGCM-)V>*O$$$-Z ?E!\;_VW?&_@']J_P#:Q^,.F^'O"_C.\_8__9W_ &UO
MAW\.=/T^+4&T>2VTB?\ X);>,YM5^)=U8:I<W<FD>"O''Q-\4ZC\2+W0_P"S
M;W2? WAF_M[?3UUK2IIKOWSXE_M*?\% O@7\/=<UWXK:;X0M_A_\.?B%!JGQ
M(_:T\.?LN^*?$>E:7\#;OX=?\)+<^,+[]D_1/VGKKXF6.A?#GXA:=KGAWXO>
M*O#OQ \9ZOIOPW/AOQ1X:\"W;:OXR\5?"WZ'^&?B7_@E%#X;^->G?"#5/V##
MX5^&W@KQOIO[0EI\/V^!$VD>&OAQKNB^&?#OQ*C^*R:"LD \#Z]H_P -O"GA
MCQY<^)O.\/ZP/AQI?AOQ%-=7/@>.PTGQ;P9;?\$*OB-;^!OA1X&C_P"":'C.
M'5O'NK:/\._ .B']GG67UOQ[J6C^%-"U33/"V@Q&>;6KWQ%X?TSP'H_V/3[>
M[L_%&B:?X+T^VCU+3[7P_"@!U_[>?P+\3?%[QC\"?V@M(\+_  B^,'P-^"WP
M7_:.O?B#X"^)?[2OQ#_9ST74V^(&H?L]>+/"7Q.T7Q/X(^&OQ!\/^(#X,\%_
M"[XFV:0>-]1\#Z#9/XXT^^?Q78Z9)K-S:_GG\?/C3XB^.?BOXE_%*W^#R?$7
M]C+]G[_@FW^S#^U[X:^"7CC]JGXR?LS^*]0^'GQ6T+X\>-O$?B'1?!/PJ\/^
M((/B-\4+GPW\-;'P9I]C\</$6E>&OA_XM^&V@V?A'4]+U/XF>-/&GAK](OCM
M^T#_ ,$??C/XCD\/_M*_%K]@3XG^*/@=<^*;672?C1XI^!_B[4OAG?/XDT;P
MSXWT-[7QE=7SZ!?R>*="\+V'BOPRR0W<FJ:7X3GUC36EMM G7T'XW^(O^"8V
MI>/O@1XA_:)UG]B/4OB5XDT?P[J'[.6O?%N]^"=_XMUGPQ=:M9ZYX/U'X6ZM
MXIDFU&\\(W/BA-&U/PG?Z#</X>G\:MX:N-#F?Q3-H+. >#:?X>U3X:_\%*?A
MI;6NA>-_A=X#^,V@_&SQAH7B/2OVG?B;\6]+_:5\2+X;TKQ'XB\-?$_]G/Q]
M>#2?@9I_PODU>37O"'COP?I'B+2].6P\$?"FU\=?#31_$>D?"SQQ\.>&+'QS
M_P $_P#]E;XV?L^>(_"_@KP/^V7H'_!-GQ7\23^TG\)/VC/B;\<D\0:5\,+3
MP?\ #/XB?'KQQIWQ*^&WPXUGX5^)-&\<^-U^*7@W1M-\->-[;Q;IGAWQ79Z%
MKNNZSX,UG0Y/UB_9ZO/^":-C\=OB+H/[+;?L96'[2=O;>)[/XH:5\$X?@]8_
M&*WL[/Q@Y\;Z3XJMO!T</BV"UL?'<2:GXRT6\5(K+Q1J>GZ[K]G#J7B+3[[4
M?+_%/BK_ ()2_L7_  ]_:PT72/#/[)'PYT_P)\)=3UW]ISX0_"[P[\'M \7:
M]X BTVUT6Q\$^+O!FEG0SK U8?$'P[X.\->#_$<MMIMM<_$[P?HRQ:59>.M$
M.H@'E]E^T==^"_VE?A#^RI\,;'P1XS_8IOOBI?\ [!^I^#Q^S]J?A[1?A9KW
MP^_9/\>>/3\-K'XR>,/V@I$^,FL64_PXDTCQ'I?A3]G34? >D^"]1OO">M^,
MM/\ 'O@C59?&7H/@_P"/7B#X7?L#^!IH_&L_A+Q[;?%7Q)^RC\#/$/B3X:>,
M?VC/$/Q)_P"%>_M#>-?@C\)KV#P1I/C;X;^(?''BKXN?"7X>6GBNU\6>(/'/
MA[1-#O-<?XE>/[R[\,Z)K^GWV+X:N_\ @D]X3L/@KXUB^+_[+6B?&KXK^ +#
MP]\%/VFO&OBKX!W'[4GC"?3?"7_"C;7XC:!\3O%>GWVI^(_B';6^BVWP^U#Q
MO):ZG;Z]XGT[3O!NLG6[B>ST*Z[']H3XY_L->#?V<OV@/@-8Z/\  S]H6W_8
M[^!4_C+7_P!DJ\\0>']=32M!^ ]AX?OO#?A[68M0TSQDGA_5/!^HV_@8->WF
MDZMX@\%:EJ?A'6-0L8+O5-$EO0#X4^'_ /P49_;E\9^'?VE/B9JLOP \)>$_
MV'?A]J?C#XV> M5^"GB.Z\>?%K6?!/[27[8WP<\9^%O#VI^&?VJ?%G@[X-WT
MO@;]FRRU4*OB'XYV>C?$_56L4UO6_"&E7L&N^A_M9?&KX[_$C7_%EC>>-/A#
MX9^"/PL_X*V_\$U/V:[#X2:I\/?$*?%_7;W2_P!H[]ACXX?\)O#\3/\ A9PT
M,ZQK>L>+7U;1_!\7PPEL6^#EE#KDNKKXAN+AK+])=)\&?L(_"OX>?'7P]H7@
M?]EGX>_"CX>Z!)X-_:1T/1O!WPN\+_#_ ,+^&++1=3^)L_A3XP:;8:79>';/
M1++0?BCK/CNYT'Q9"+*UT_XB:KXBGM(X_%EY=W_$^&+C_@FK^TE\0-%^+GA.
M/]C_ .-_Q*O_ (H:%9>'OB!I=E\*_'WBF_\ C+\+_!W_  GGA#4M&UU(-3OK
MOXC>"/AWX;3Q;X*\3V,\GB+1O ND0:QX9U6'PY;P3@ _/?\ X*$:EXKUG]H7
MXA:E::YX6\/>+O@_XX_X(\>#O@3?^/=,U/Q+X3\"Q?'_ /X*"2ZE\1?B1J?A
MW1]?\)3ZIH'CSQ7\*?AIH7B71(?&GAK5]5C_ &>].MTU+PI97=MX@U7Z$U/X
MH_%.]ETZ]\?S^'/'GQN_9$_X*-_ _P#9STOQ_P##SPUJOP\T/XM>!?VC?!WP
M+MOB'/+X,N/$OC>:RM/ GPK_ &H=7U3QKX;D\7:QX:O?'7P TSX@6XTG5M(T
MKPWX;]O^-]__ ,$[/'?Q!\!:W\?/B%^SOXAU'XLZ5XD^ 7AWX=?$SQ#\,]<\
M(?'N]\%?&CPY!#X;NO 7BZ'4;?XD^,/@3\:-+U"S\(FS@NM2^%7B#Q;\1V2/
M3VU[79XM[X=O^Q+\1=,^$$WP!^*?PH3PEX<\<_%O0/@]I/P1\4?#QO"S_'/Q
M7\._$6O^+O%/AZ#1[/44U?XJZ-\*_$/Q%\7Z=*EQ=V&I>#_B+XF\>ZUHOB:U
MU+P]K^G &3_P4?\ $'QBTO\ 9CTOQ#^S]\6=,^%GB;_AH3]E+2K_ ,7/X:U3
MQ@E]X3\8_M)?##P+JVCVHT#QYX"N+*QN[GQ+87/BB0ZO>6WB'P38>*? LUMI
MQ\6+XG\/?#OP^\?_ +5_P0^.7[2OC5/'_P $?$'PEU#_ (*9?LT_ GXH>"I/
M@[XOL/'7CKQ-\<?@-^Q!\)O$WQ)\+^.4^,UUHWPYTO0-;\6^'M>\,> +KP3X
M\E-AIWB73]:\;:G+J^BW7A_[D\-^*?\ @G;X-^%WPF_8(O?BE^SEX@\&W?@'
M1/@AX!^!GQ#\=?#SQ#J/Q!\/^ M<U7X-VF@7/A76[O/B_7)_'7PX\4>%)4.E
MRWVM^/\ P?XMM+."?7?#^L16.EX,^,/_  3:@_X3WX1^ OB#^QX'^"C0_%+X
ME?#GPSKGPFEN/AS>?L\Q:!H,7C_Q=X7T^9[C1-<^"%M\-/!=@WB/5+.+6?AQ
M9>%/ GF7>CVMKX4<@'C_ .QW^TS^UM\>_'>E>/\ Q;X)\.2?LY?$O7_VC/"]
MEH&C_#K4?!OC;]G#6?@I\4];\ ^#-.^)'CKQ#\6-=M_BKJ_C6W\(^+=(^(>G
M^%?AMX2?X=?$JWTS0M/37?#4>I^(E\2TW]M']KWQ!\%O#W[2^G:M\)?#6C?M
M _M.:;^R-\,?@SXH^#'BC64_9B\4:I^U/<?L[V7C[X_^.](^,_A_5?'VMZ5-
MX;\1Z5XI^'.@:1\/-,U'XG>+/A]X%T7QAX=L-&UOQCXP[KP7^U=_P2E^'WP=
ML?\ @ICX&\/? SP':_'+QWX6\">(OBAX>\+?"CPY\4KWXD_'/7O"-WXB\.>/
MM:TS4[:-/&$,4VF_$/XQVT_B6]U9?#WA+4_%.K_VS/H4(;U6YT3_ ()&>)/B
MSK7@*^T?]@36?C5^U1X:MM>\1^"K_3O@5>>/OCQX>^(5YX9^)5AJ>O>&KJ%]
M7\=M\0+[PSX4^(6GS:E8W^H>,[CP?I?C"T.J/X034M+ /#+C]J#]MG4_&FA_
MLR:#X[_9S@^+^G_MP>(/V5?%?[0%Q\$/'6H?#_6/ NG?L#6_[9<?B[1?@S%\
M>+74-+^)NF76M:=X!U?2Y?BUJ?A%-8TZ?Q$+2&RO9O!.F9^N_P#!1'XZ>'O
MGA274=$^&UQ\0/CCX.^*_P #?@9=V?AGQ'IW@R[_ &YOA#^V!;_L>M;ZSI=W
MXUU?5W^%WQ)UKX@^#?BUHO@N#Q%+XL\(_#'X3_&2^U;QEJZVO]IZ/VWQ1_:I
M_P""?7[%5[\:O@C\,OAI\"-+^,O[)'P?\2_M=:)\&/#&G_#;X<F?Q/XD\!?$
M:\\1'PQ?Z9IFIZYH'Q5UKX:Z+K&I_$/Q+#X0N=7'PX\=Z3J6JWVM:;XDN[.O
MIGPS\=/^"=/C+X8ZI\6_"7Q._9!\2?!_]F_XA:UX\U'XAZ)X@^$NH^ ?@M\4
M?%$FO7.K^/(?$=K-)HG@CQIXS?XB^);L>,+*ZL-7\9+X_P!9NK34]63Q;=R:
MB ?GI>_M[?MU1? #X^?M6Z5\/O &K_#"Q^&7[:&K> O"=_\ #+6O"NJ?L_\
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MAAB18XHHHU"1Q11H%2..-%"(B *J@*H  %2444 %?GM\9?\ @FW\'/C_ /M
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M9OVUH?AC!^T'\0;R;3_V=)]%^'C>#O"ND:Y:_LV2-XF_:2^(_B7Q-XIL-/\
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MVM2>#O&'A[6O#'A[6/#&L:UH6J^$=*T#4=+US6K*Z@U6\\6_;&NOBGHGQ0^
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MC#X9_$/X>V/Q=MM?\"V6EZ3JOP]^*?A35 #YD^)_['7[;?Q T+]J^PM/A_\
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M#XRQ?$"P\5>#?$>L^%?!6A>%-*L+K2?&T]EX@D2Q2'X,_M7^+/A/_P $O?\
M@G9\3]7L-2^-OQP^/GP5_85^&/A6#Q[X\UC1C\0_C9\=?ASX M/^$@^*'Q8O
M- \?ZUHUA-=W>N>+_&?C.[\.>+_$.I26EU;Z;H_B/Q5K&F:9J !K_MF?LE?'
M/XW^+?VD[3X<6'PIU'P5^U/^PS+^ROXAU?Q[XZ\2^&=3^'OBGPIJ'Q\\1>$]
M93PQHWPS\:6WC7PMXOU#XS6^A>(2-?\ #NI^%K+2+K5[33?%#S1:2^3^U/\
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M8TSX^+>_"#X9Z;H_Q5U/3_CIX%\5WNL>#-8\=^#M2U.[\4Z(NMK-HFD:UXR
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M$_AWXQE\?^(="^'WA76/%%WJ.NZQX8T#4O$ TGX=:7--J%YXE\0^!_G'4?\
M@IO\:/!?PDU;XL_$O]F+P%H]EXW_ &'?C'^W5^SEH?@G]H+4O'&I^*O!OP?T
MWX/7^H?#7XNS7WP7\'Z;\/O&^K6OQP\!ZC;:SX-O_B?X-A>Z\1:$-7N9?#ND
MZSXU /V4HK\C5_;Q_:Q\'?$3Q[X1^,'[+OP(T3PY\'OBQ^R]X#^*?BWP#^U!
MX[\7/'H_[77CGPGX ^']Y\-M#UW]E_P=/XSUSP!JWBJ.^^)-IXJO/AKIUSHT
M%E<^#KW5]0U.[TG0M+P3_P %%OB#G1/B/\8O@QX%\#_LY^-?C5^V!\!_!7BW
MP5\4_$_Q%^*P\3_LCR?M*ZUJWB3Q?\-7^$OAC1],\.^,_!G[*WQ3N[+3_#'C
MKQEK^AZW%X4L[FUU"V\3:G+X. /U@HK\7-(_X*<_M!7?PQTOQC=_LE>#[CQ5
M\4O^&3]:^ FC:)\;/&=W\.=<T7]JCXR^%OA%:>#_ (L?&*[_ &?[31?A_P#%
M+X:OXS\+^*?%VD>$=!^*&A:OH.M27G@;5O%,.@:M)7?:)_P43^)%O\9/A_\
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M\(],^/'[5_P \(?''Q_\:/B-X#UOX6^,O&UGXMU'QKXET?X2^&K[X<:+\(/
M_P +M%\9^+=<\0Q^)O$-HOP4UOQI\3M2M=4NM:U/XD^-_$^O>,GB\3:Q?V=I
M\T_M/_!'XT^?X3UKX*? GXU77[;M[^SW\$?AKIW[47P6^/,/P4_8[\(^)? 7
MB'QY/IMO\6O@I>?M'Z'<?$+X<?"37_B!\0?'D?@/7/V<_BG/XG\'>/K;P/X9
MUZZUL:E<>!_N30/AOXTLOVWOBQ\7[K1O*^'?B;]E7]GOX;Z)XA_M'27^V^-/
M WQ<_:<\3^*=&_LF.^?7+;^R]#^(?@^^_M&[TRWTF]_M?[-IU]=WFGZI;V0!
MXS\3_P!CG]B3X36OB/\ :6^)?@OQ->>'_@L_[2WQR&B:K\1OC#XO\ ^%]1^/
M7A;X@1_M(ZCX8^"<GC&_\#ZK??%K2?'WCR&]\)1^$=4MKG6O%=\G@_1M,U?5
M 9>)^ G[*G[ _P 1?V;X/BA\/A\1M8^%7[1OP8^!^D0^-/B/^T/^T!J_C71_
MAM\+M;O?&WP0\):-XE\>?%'4_$OP@U?X/>-=>U*]TC3?".I>&-<\,^/!J$FI
M2S>(HKJ9O=_VO/A=\:/C?=? OX9?#2?PUX9\$V7Q8\/?&GXM^/O&FB?\)AX9
MAM/@-K6A>/OA9\.&\$Z+\1/AUXVUK5_&OQEM_ OBXW>E:Q:>%K;P;\+/'&B^
M,-3CE\2^'?#OBK\Q/%O[*'Q;^'>K>'? /QS^!W@#]JO]F/P#^W/X_P#VA_"?
MPZTJW^!'@[P)X^\-_M-_L^_'_4_'OAWPY\'/VDOCE)HK:_\ L_\ [27BCQCX
M_@\->-/B&GAZ?X9?%7_A(_AVFJ^(/ABOAWP^ ?J9X0_9-^ 7P[^),GQ9\-^)
MOBUIOB76KKPZ_B:QN_VGOCK?^!/B-XK\->!O#_P&TWQ5\1/AQJ?Q-N? 'Q!\
M>7GA?1O"GA/Q!XB\3^'=5UGQ9XBT?PWK/B>76/&NFZ7JT.3\$_V-?V3OV?/$
MOAKXQ?#*QUFSU/P!\&;S]G/P)XC\3?'#XI>//#/P_P#@5)XG\+ZZWPM\*:7X
MW\?^(/!^A^'-/\1^"?#"6,T.F_V]IT.C6GA^#6(](B73!^ _@G_@GWXW_:A_
M8N^&?B+P1^S_ .%=/M-!_9\_X*L:Y^SQX:U;5?AOKFE^#/'?QR_X*$Z'\:/V
M>/#/P_US4=>:TT>_^(GP)T?Q-X5\"?'KPG?0:;X+\-^*)/$^E^-=&GU31KJ\
M^F/$?[%&J36/PO\ %7@_]BKXJQ?LZ6O[2<_C+XO?L >)_AA^PG:>!(+N\_9E
MUKX;^'OCI\/O@KHWQPNO@MJMCX8\7?\ ",:7XO\ !VO^-C=7WB>?6?C#X1\%
MZCX@\/:9XB\0 'ZI>(/V&?V3-1^*-S\2]6LO&FD>,M=^('B'XD:7I6A?M%_'
M+P)X5TGXO_$+X9>(_A3XD^)O@CX>>$/BAX=\(>&?BIXG^'VJ^*K(>./#.@V/
MBVWU"_\ $7B_1-2L/%NH:SKUUZQ\&?@-\%OV>/#_ (^N_!USK5Y%\2?$L/BW
MXF>/OBC\3_&7Q7\5>,M<T_PSX>^'6GS>*/B%\4?$WBC7;RRT;PMX3T#PKI>C
MRZNFCZ9;V#I:V$5_?ZI/>_BWXU_X)93?$'P%\7EU?]GS4/'_ (A3]D?]AKX3
M?LV^)?CQ=_ V_P#CQ\-Y_AG\8OCIXM^(?@71O&?ACQ5JUA\./$GP\\#^+?A]
MH.H>*O"7BZ"W\66NA:!%8>-?&^L:%<W\72_&;]@OQ7X4^(VHP>#?V3?#OCS]
MC'2/VUX?B='^R9\.?!'[-MYX#UWPCXE_8+\ _"J'XO:5\&/B'XV^'GPRO(_A
MY^T'H/B)-3\#:\;#5;W4?%FL?&'0O#.N:_X>\/:K=@'Z+>"?^">O['?PYTK6
MO!6E^'O&6I:)XJ^!OB?]EO3_  IX\_:'^._Q!L?#'[/_ (ZL8Y_$7P>^%NF>
M._BCKY^&_A;5],\)VC"'X?+H&KPZ/X-T2RLM2@T;P3H%KHNS^T/\4/V1?$?[
M/O[6GPP^+5^/&_PI^%'@;4_A=^T7\-_#LOBT>)WTCQ9\/?#^I1?#O1I/#]WH
MWB;5O$OB[PMXZ\+Z3H?_  AVN_VG)K_B33M%CU:Q\0B>&U_,?5O^":NOZAX+
M^._BW3?@5JGC'XM>%_V!_P!FOX;?L0^+_CS<_ K6?CC\*OBW\,O$/[2?C*S\
M)Z)XCT;Q1KOA7X>>,OAK>>(O@EHK^.-,\2QZ/KD7A_0"WCWQ<VB:UJ2?>_[/
M'[.^B?"/]M7]M?Q@O[,.@^&[7X\>*?"?Q7\*?M$>'_"WPAM-(UO39/AI\&O#
MOCGX<:QJ.F:Y%\6+?QAK'QB\(>*_BQJUIJ/@T>$-=O[N7QE=>)[CQ=?&&X .
M.\&_#[]B37[#Q%9Q> OBSX[\-?MP:[\<?V-?'GQ ^+GQ9^-OQ;U+5V^#>H?&
MKPWX@^%,?C/XJ?%;QKXY^''PX\0WO@WXV77P_O/A[J?AKP3J&NVVFZEI4]IX
MD\8>!;G5?=/$O[$7P&E^'.DZ#XIUC]HOQ/!\-/')^-/@SQMK7[5_[3&M_%_P
M7XST?P'J_@-K_P &_%?4OBVWC[1;"^\#:QX@\/:SX4M?$MOX1\4P^(-=N/%.
MCZM?:WJM[=6OVO8+76K#X%?#33+]?#^HW?Q^^%7QEU+6;1EMXO!GPO\ V8/'
MOAOX]?$[Q3JR03126WA?6[3PEH_P9U2^2UO8$UKXS>'+&\AMX=4;4;+V+X=_
M$&3X]?L\^$/BAI7A#Q1X+_X7#\)=*\;:+X)\;PZ;IWC'0;;QUX5BUG1M%\4V
MEEJ.H:;I?B"WM=3M(=7L%U.XCTR^\^TGN-]O*0 ?+O[-_P #OV7/'6C^!OVI
M?A;J_P =M%C^,WP[^#WQ"UOPKXE_:@^.MW8^)9O%OP'\&^!?!.L_'#X;-\9/
M$?@3Q9\6M1^%*^#-"\3^(_$D7B76?&&O:)H7BK6=<\4>*M+TCQ0ON2?LB?LW
M2^$9OAY'X!BD\+6_[-B_L=7&BIXQ\;N\'[/#Z-'I:?#B:\7Q0=4B=M&EBC7Q
M6]XOCMHI([H>)C*ZSG\8/V=OV"_$FA?LX?#WP9K_ , ?#O[ NK_#;_@FYJGP
M8^._Q%U6X^!\6G^,_P!KW2-9^!OB[X(?M"S:Y\*O&7C'3?&]U^SK\0_A!\0?
MC+IWQ!^(5Q:ZUINM_%^QAT>>\U.^^(UEIOZ;?\$SQXX\6_LR67[1_P 5O#Z^
M%_BS^V7XR\0_M4>-M!6=YSH6B?$"VTC0?@9X5E:2ULI5N_ W[,O@[X)^!=2$
M]K!<S:IX:OKN\C6]N;D4 >@Z=^QE^R[I/Q0\5_%O3M$UJ#Q-J?Q!\%_%3Q[H
MTOQ@^)]_\.=3^)WP[\%:!X1^'OCGQ/\ "C4O'%Y\-8O$_@[PMX<\*W&@7[^%
M;1X-5\.>$_&4J7'BCPSX;UW3,NW_ &(/V7[?2/C5;-_PL6Y^&OQHA^,MI\3_
M (<7O[2/QVNO@G')\7?%&H>(?C3<:%\-YOB<? /P]U'7/&$OB#5-2O/!^D^'
MKKPMK6K>*V\//X>EUS7TO?Q@\;?L6_M?_%7Q)^U7KK_LGZ-\,_&/QF_9&_X*
M&_!WXA3_  VT']DGX3?"OXF?$/XN?%#X<ZU\#&\*>*?"OCF\^/\ \5=?\;:1
MH'BSQIXO^+O[0>H^$[+2_$>O7EYIWACX=ZQXP\:^'[7ZZ^-?[!VI>%!\<? O
MP&_9E\#C]EC5/&?_  3;^)+?LX> -(^$/A;P1\:'^#GQ_P#%.K?M0Z*W@C5-
M6\->'I-=/PIT+X0:UJ$/C3^QM&^*DW@K0/!<VHZS'=>(+>, _0#Q9I?P$_;I
MT'X^_L_^.M"\:ZWX/^"_QF\!> _'=OIOCKQ?\-K/Q/XNM/A/\#?VHO".K>&O
M%7PC\>Z!XHU?PE9:/\8/ 4DL.J7^D07GBS0]6@N-"U#2=.T?6-4\N^'7P?\
MV6/VHO@WH&DV,OQWN=,^'_QW^)GB_P &7_C;]ISX^ZA\>/ ?Q0^#OC?XF_LU
M:UXV\*_%&?XW>*/BEH'AK5)/#WCW1]%TBU\<1>%=<\(>)=6LM>\+P3>(O$NB
M-G?\$Z/@MXD^#J_MH7>H_L]K^S)X(^+7[9FM?$[X,_#!+_X=SQI\+(_V;OV:
M/AE8^)H]&^&7B7Q/X?\ !<?B?Q?\-?&6IIX(N+K3]4\-I(+.;2+.S^P-/\/?
M ;]BGXPZ'XET6W\.?LZQ_LL?&_1/VH_^"BOQ.\?_ +8EG'\$=7O_ (I?"'X^
M7O[44'P1TJ/6O!/C/Q'\0/&-Q<Z_\7O@#\0/^$#^)6BZ;H_AA/V=5_M2+1]6
MTSX>6NH 'Z-3> _@?^S!JWPU^(Z_%S4OA]\$?@[HGB[X)V7PYF\4>-/%FEZ_
M\9/VG_C1\,9V\?\ Q0\1:EXF\4>*OB+\4]2\:Q?8+?Q!X\AUSQ%;:I\5?B5X
MW\3^)I)_$6KZI;]GXV_9*_9Z^*'Q7'Q^U>]^*=I\3=9\,:3\.8O%OPY_:F_:
M1^%MKJ'A7PUJ6K:Y8^$[30OA5\8?!_A26P@U>XU?5M1L+;1LZIJ"W-[K*WMQ
M;>9%^(G@S_@G7?:Q^RC<Z+JW["/BSPC\4?!?A#]BB[^)/P4\3^&OV-KOX;?'
MGXF?L_?&[0/&/Q/\>^#-9T/XL>,KCQY\:M;^'Z_&7P6_Q>^+.L> ;[XI^!OB
MY:^'O'FK:C>W6KZ=X6]^\<?L0_'R_P#$7BOQ!\(_AA_P@OPK^"-UHW[<O[%W
MP2&L_#SP?)I/[5'B(?!/Q%KG[.+Z;X=\6W'AGP!'97_P=_:!\*>/=<.JM\+M
M1TK]O?Q#:>&/$FJ6?@O7+JP /TXTG]D?]F3P_P#%>X^*FG:1JEIX[US4?BO>
M>'K)OB]\2F\,^%/%_P 6)9KGXU^+_A)\.Y?'#>#/AE\1O'5S)J5[XV\:_#3P
M]X<\82ZAK/B_4SJMIJ/C?QQ=>(>2\'_L(_LG> /AEXZ^!'AD_%FS^%NO?#G4
MOAKXN^'.H_M@?M5>(-#T?P%XH?[9JEGI>G>(OCGJLG@"ZUU([L77BCPN?#OB
M2^L+[6[-M:DL-9UF"]_*S1_^"?GQ0T#XRZ-??&#X*?$#XD^(_&_@G]FKXA>&
M/VDO@KIG[-6L:O\ LL?M,R_&_P")'QR_:M7P?K?QF^)?AGQIX \-^(/CIX\O
M?C)J>N> ?!OBM/B7X(\4:[\-M=@\0IX-\+>$]1Y,_P#!/SXQZS\*/VL/!-W^
MS]\5-,_:=\4?"_\ ;_\  >N_'O2(_P!ECPMX$_;3M?CMXXUS4/AO<?$+X@V'
MQ;O_ (OZQJ6N:9<^!_%G@33_ !OX:\&6OP1U/P[XB\"0ZIX7\&1:;IOB@ _9
M;PG^Q]X&\&:Q\'+GX3?$_P",V@> ?A1X^N?%.K> ]8^/WQX^+VB>,9/#'PV^
M(WPD\,> 9;KXH_%OQC#X4\#>"]1\<7GB;4O!&@6$.DZUXR\$>!GUNS63P9IZ
M1>$?MW>'?V$/%R?&S7/VB8/'7B;Q=\%OV3_$^N?&'P!\(OBA\4_AAXP\>?LP
M>-[KQ5=WO@'Q6G@#X@_##0OB1X<\1:I\.?%ITWP7XM\3S0Z<!KAN(](\/^--
M6;7_ &+]FK]FC2OV;OCY^T-IWPG^$W@KX.?LU>*_AU^SC=^ /#/PZTCP?X4\
M(7GQ6T";XU:)\7-8C\'^&#;7EAKLWA&+X(V&L:]JNDVD?B*#3]*6SOM4N])U
M<VGPU^WC^Q9K7Q*^,G[7'BKX??LFZ3\1?%W[4'_!/N^^"'@SXU>'[#X):'K'
M@WXS>'-+^/\ I.JP^,O&/C#Q=X2\?Z%>_$KX?>-_AO\ #30O%OARTUVVN-.\
M/V/ASQ9JF@>%] L[BU /T<\(?LU_L_>!OBK?_M#V6K>,-<\9:%IWCGP=I6K_
M !"^/7Q3^)?A#X6:?XWUOPK>?$'P]\/O"_Q"\?>)/!GPOCUG5_!7A6RO].\+
MZ7HATBQT>V\+Z/%I&@//HTV1)^PC^S-<?%L_&N3PGXN?Q8/B-KOQCL=&A^,'
MQ@M/A=IGQ8\6?#W5?A;XJ^)>F?!NQ\=VWPHM?&OB?P+KVN:1K/B!?!S7UU/K
MNOZXLD?B#Q!KFJZC^3?[0/\ P3DO/ O[3FD^(/@Y^QQX3\8_L-6>I_ O5?&_
M[+_PP\#?LX3>"_&OC[3OA5^UGX!U/XPW/P8^)WCCX=^!/%6N_"RYUWX':9J\
M/B9!>Z]IWB>Q\;>'+?Q3XL^$UDNE?L-\"?@X_AG]D?P-\#9M0^*_AVWM_A$_
M@.R?X@ZEX.?XO> ]$U/1[O3M%\/:MK'PZU?7_!S^(_AUHUY8^&]/U+P_XC\1
MV[#P_8W3^(]?NS/K%Z ?,?PWM_V+OBXF@?"/X=? [XS^*/@]XK_9KUC]CCPM
M\7++P?\ &V+X%>(OV?-$\,WR7'@#2/BC=ZM;W5UX:U'P]I\T'A7XZ[4T3QS=
M3:=9>"?C!XAUW5=,M[OZ-TS]D[X":+\5?&?QC\/W_P 1_#VOZ]J-C>_$CPUX
M?_:$^-&C?";7O$FF?"[1?AE:ZWXV^#FF_$2W^%M[XB7X7Z=X4TN\O=5\)_:=
M2@T3PEXDU5;W7=%T36K7Y\_9TD_:)\#_  !^&G[%&M? #XR_#7QG\.?@'%\
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M %_X5O[S6H)F\07FM7D4Y/Q!XN_X)B>#_"7Q0^//Q!^!'[)OP;\%ZG%\<?\
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M^#G[$O[2W[-G@OXA_#WX1?%K]G?X<>(?B7IW[9WP]U\_$_Q=\%?B,OCSX[_
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M=!_\%) ""5_8>^#P8 @D'^R/V5FP?0[2#@\X(/0BOZ6Z_*O_ ()V?\$Q+?\
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MB?5-2?\ 8R@ HHHH *_AW_X/,_\ G&__ -W@?^^N5_<17\.__!YG_P XW_\
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M+/PA_;YT/XK^/?#'ANX^!7QD^'G@3XA?&'X[_ #X7?&/QI<_"F3P9\1/B_\
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M34?$GBBPO7M]/UGP[]DTIM. /(Y?^"BGQ335/CVOQR^"WQ&_9-\!_ O]I?\
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M5X9M=#U34]:N=?O_ !J ??G@_P#:%\ >+K/X^Z\L]QH7@G]G?X@>*/A]XO\
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M7_#GAQ/C;\0'^&&F7/C.WN?!D&JKI4NHZWHT$6G* <=\6OV_M;^!'[3'Q_\
M /Q/^"OB?3_V=/@7^S5\-_CGJ7QLTG4_A[?WE[?>-=6^+6DPV-EX7;XFQ^,M
M:B\7>)O FF?";X>>&M,\!)XJN_B;#K5QK(M?!&L^$O$-]]%? /\ :=?XS>,O
MB%\,/%_P2^+/[/7Q8^&_ASP%X[UCX=_%NZ^%.K:EJ/P[^*6J>/\ 2/ 7C+0M
M?^#GQ-^*O@[4+6_U/X9>--$U[23XB@UOPSX@T*ZM+ZPETF]\/:[KO%?M%?L,
M^ ?VE/%'CK6_%GC[XC>'-"^+/P OOV<OBSX*\*K\/CHOC?P9;3^/=8^'^OIJ
M?B?P'XF\5>$O'7PG\8_$;Q!XX\#>(?!VOZ'$/$<6D/XCT[7]-TU-/D[CX%?L
MRR?!_P =_$CXK>+/C9\5_C]\4OB?X4^&/@+6_&WQ5L?A)H]QIG@;X0W7Q U+
MP9X9\/:'\'?A=\*_#=A:C7/BEX\\2:Y=W.DW^H:MKWB*ZD2ZLM(M-(T;3 #\
M]OC=_P %!?VD_#?B']I70-&_9V^(FA:5^S[^V[^QY\%/"VN^$KCX&^)M?^,7
M@_XJ^//V84\1?#RPT7Q#\5KZ.U\9_&#PI\7-=U#P5KVK6'P\\/\ A+P9K?A^
M+Q=XO\!?$32]:72_1M6_X*R^#-$;Q!X9O_V9_P!H%OC'\,5^).K_ !^^"MEJ
MWP N/%GP/\"_"O3O >N:_P".]=UJ3XV6W@SQMIWB30/B3X6U?X:>&_ACXB\8
M^.O'\7]OVFE>%HK_ ,+:_:V'TEXK_8E\)>+OBSXW^)5Y\4/BEI^A?$+XG?L_
M_&[Q+\+-+_X5PG@RX^,7[-_B#X3ZIX$\<VVK7_P\U#X@VIU'0_@UX/\ !?BG
MPY'XS_X1S4= ;5+S3M.T?Q-<6FOV/G_C/_@G-X*U?XW>*OVB_AW\:OB]\&OB
M[XZUOQQ?^,?$7A;0?@#XSL]=T/QWX-^!?A"Z\)2Z'\8?@C\1]-ATGPS+^S[X
M-\5>"KY(FU[0O$FN>/H[C5M4\,^+;KPW;@'UAX]^,>G^&/@M=_&WP3X?O/B]
MH3>'- \6^']/\(^*OAOX87Q+X:\12Z7);^)+7Q=\5_&WP\^'NF^'=.T/5/\
MA+=5U/6O%M@[>&]/OFT.TUW7I-*T#5/BOP=_P4Z\#?&+3/AI9?LZ?!;XE_'7
MXH_$'1?BAXOU/X3>%/&?P M=1^'G@7X-_%O5?@CXW\6^+?B+<_&*;X-ZCIVI
M_$;1=0\/?#,^!?B%XP@^)$BKK6DW=IX.L]>\4:)]1_M)_LQ^$_VF/ACX=^&W
MB7Q'XB\+_P#"&^/OAO\ $WPGXE\.V'@O4;G2_&/PMUZSU_PU>:AX2\9^%/%/
MPW\3Z6US:&.[T#Q+X+U32())8-8T.UT;Q)HWAW6]'^:?#O\ P36T'P!?^"O%
M_P +?VGOVCOA]\7?"Y_:+@\0?&2RL?V</$'B[XFZ3^T_\7+7XY_$/1?'>A>*
MOV>]8^&XT[0OB=:+XC^&D'@_P-X2B\#BXU#1K:*^\/ZKJND7H!NZ+_P43\":
MK\.OB[^T1<?"WXC:5^R-\,_#OCG5O#G[2=QJ/PYN]"^,FK?#_P 8CP'?Z#\,
MOAUIWC>Z^*=Z?%_BM+W1/A;JNO>$]#L/'E_I-VUL=.T[6/ VH^,>(UG_ (*8
MW6A>./#_ ,%-4_8L_:ET_P#:3\7:_P"&].\+_ *]UC]F!/$.K>&O&_@']H#X
MB>$OB"?'MG^T7?\ P?LO";Z3^S5\4](\4P7/Q!7Q5X:\3Z"=)@\-:Y'JWA2]
M\3=O8_\ !.KP/;_"WX[_ +/-_P#&?XR:S^S-\;]*^-EE9_ :\LO@G:>&_@[J
M/QS\<7OQ%U?7/A)XMTCX.Z=\2]+N_ /BW5M=U3X36/BKQGXNT?P:^L-'-I^M
M1:#X/3PUK^!?V!_#^@_'3PU^TK\1OCU\=/CI\:O"M]X5;2_%GQ!C^"N@V@\/
M^"?AK^T!\,_#?A"3PY\)_@W\.=%30[>V_:9^+'C*_FM+6UUO4O'6L6E[)JT7
MAC3;/PG$ >*:1_P5J^'-Q\*_%'QB\5?LX_M)?#KP;I/[._QV_:,\*7'BZU^"
MTU_\2]!_9EU?PSX:^-_A+PGHWA/XS>*-:T_Q7X4\3^+=(TG1W\:Z;X4\-^.+
M<7GB#P?K^K^'([;5;SVGPA^U=9^'_"7QJT2+]D_XC_"?XB?!?2O"7Q5U3]G_
M %/Q%^S'X3U?6_ ?QX\9^,VT_P"+%MXRLOC7'\"=)L=0\6^&/BUK'Q+&O?$N
MP\46&M>"_&5\NF^*-1UWP=+XU\?_ &GO^"=6@>(/V1O&?PN^$D_C7Q3XZ\*_
MLH?M>_ +X4:'KWB7PIIUIXF/[4]SX6\1>(H?%&J-HF@6L.HVVO>!]"L?#6J6
MNH^'--TK3KS5/[9BU2>2UO[#T?QS_P $Z?!GQ-T+7V^(OQI^+_CCXGZMXE_9
M[\06'QE\26'P>O?$^DVO[+WB#Q#XK^$'AJY\%)\*X/@YXJT#3/%'CCXC^*M:
MM_&'PVURYU/Q5\0=:\065SI%_H/P^?P6 <-I7_!4WP7XWT7X2:C\&_V</C[\
M<-5^*GA+]H;QO<>&_AKKG[-NI3> _#W[+7Q:\/?!WXOW?B+QAJ'[0&F_"_7Q
M%XG\06R^ Y/AQX]\<6GQ AN-*NM$NUTC4I-7L.MUK]LO]F:36G^)NF>!I-3^
M*NHZ5^S)X)^%7B[3/#'@2[^)_P 0?@U^V+]G\4_#_P 9^ -6O]1&L2_"?2+C
MPW\7/%_C70-6O-/FM8?V=_BGXD@\,:O;:1HMUK/H/P4_83^'/P3U32_$5G\0
M_BWX]\4V7AO]I_P_J?B/QYJ/@!KWQ'-^UO\ &GPS\>OBKK^JV'@OX=^#-!LM
M4M_''A>TA\'67AK2- \,^'?#MW>Z,?#U\J:;<:?\_P"@_L'VB?M2_LO7\/A+
MQ1H7P7_86_93O/@EX"^(FO>-/"]]XC^.WBS5?A_9?"3X<:OJ7AWPP8UBD^ O
MPM\2?M#:3<:QXK\+^%H[_P 6?'W5+GP5HLFB0ZE*0"OX4_X*8Z%H?A#X;QZC
M\)?VB_BUX?T3]DG]E_\ ::^.O[1(TKX!>%/#WP_^''Q]T#Q0NE>/?B/X?E^*
M/@^>3Q*+OP'XC\5>.?"'P;\'^*=.\.Z%;:Y>Z#;SPV&AZ+K7J'@;_@HAHOCG
MXP_"GX=V_P"SO\<](^'OQW^-'QK^!OP:_:&U&Y^#]U\*_'/BKX!^&OCAXB\;
MZ@NG:'\5-7^)GA[0=6C^ ?C(?#Z_\1> M-;QKILNGZ]90VVEM<2P=)8_\$\_
M@MI_PC^(_P &(?$_Q0;PO\4/V2/@I^QGK]_+K7A1M?L_A?\  CPS\1O"GA'7
MM'ND\%)IUOX]U'3OB=KTWB35+W2M0\/7E[::1)IGA;1X+>]MM0^8?AQ^QY\6
M1^V7\,/%3VWQU\!?L[_LT?'3]J_X^^#_  Y\0_B)^SGXF^%WB;QQ^T5I?Q?\
M*>1\&O#GPN\)6_QIL_#EVOQS^(OCZ[/Q_P#%BWGPS>XT[X<> -'U;P[J-U>>
M'@#Z5^.?[>VC?!#XG_%3P!/\!_C-X[\.? 'X0_#[X^?'[XL^$9_A5!X&^%/P
MC\?:G\4['_A);[3O%7Q*\.?$#Q=J'AK3O@_XV\5:YX=\!>"_$VI_\(QHUW+I
MZWNOS:'X>US \8?\%'/"/A'QQ\9_"7_"AOCCXCTWX0?%GP-^SSIWBWP]/\&1
MIWQE_:-^)VA_![Q3X"^"/P?TCQ!\7?#_ (DU3Q)J7A7XOV7BC7?%GC32? OP
MM\):#X=US4-:\>Q):7:V6)\1_P!B;Q%\;/VJ?VGO%?C+QIX[\'? 3XW_ +,_
M[.7P+\7>%O".H?#Z71?CAX;\*^+_ -H[4OB?X#\7VVN^&O$7C3PQ:)X:^(>G
M^%O^$A\(ZEX+U&^\,?$OQG9Z9JMQKEGI&L^$/9/B+^P[\-?B#X8^+6B)XQ^(
MWA#7OBC^TC\./VL=.\?^&I_ EQXL^%7QK^%&D_![1O!FN_#6/Q7X#\3>%X-+
MMK/X*^'8-6T7QGX;\9VVNV.O^-=&U-Y]"UZ/3-/ /+]9_P""EWPO\ _#WQ-X
M_P#C/\)_C7\'U^&GQ4OO@A\:/#&N:+X/\9^(?A7\4I_A)X?^,7P_T341\*_&
MGCO2/%>D_&C0?%O@[P[\(M>\$ZIK\?B;XA>.?!'P]U&ST+QCKTNBZ=Z7\./V
MV?"/CW7_ (;_  _U+X<_$#P)\8O&OQ:^(/PC\6?![Q'/X(U#QG\'M0^'7PC_
M .%UZOXH^(LGA/Q=XAT >#[OP3X@^$+V.L>%=8\2@:M\>?A/I]W#:_VY?3Z9
MQMO_ ,$X_A#K^E>*M*^-OCKXJ?M#VWQ%^)OBWXR_%.U^)=WX!T?2?B/\2=?^
M$W@KX'>%O$&O:3\*_A_\.K>SB^#GPR\#:7HGP<TK0FTJQ\*:X\'Q(U./Q%\5
MO#/@7QWX3YK]G7]D[Q)X:_;/^+7[3WCC3/%]F^A_ GP!^R]\/-?\=>+_  =X
MA\8_&B\T6\TR]^,?[4/C+3/AW#9>#=$\1_&?1_AW^SEX.\B/1/"OB!K3X(M-
MJ7A'PUI=WH6EP@'Z5T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7G'C[X.?"+XKW/A:]^*7PK^''Q)O/ VKC7_!-WX^\#^&/&-SX.UX26LH
MUOPM/XBTO49?#VKB6QLI1J6DO:7@DL[5Q-NMX2GH]% !1110 4444 %<OX:\
M#^"O!DWB6X\'^#_"WA.X\9^)+[QEXPG\->'])T*;Q7XOU2&UM]2\5>)9=+M+
M5]=\2:C;V-E!?:YJC76J7<-G:Q7%U(EO$J=110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %?P[_P#!YG_SC?\ ^[P/_?7*_N(K^'?_ (/,
M_P#G&_\ ]W@?^^N4 ?U3?\$Q?^4;'_!/7_LQW]DW_P!4+X!K[BKX=_X)B_\
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M7[4OPUTW0/C7X?\ &.D?M2?'75]>A^*FI_M#^(O#^I^!?%WQM^*_BGX+Z_X
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M_&^\\>>);%-8'Q2_9<\2W'S'^W]\*_C9XG_:?_:SF\#:#\;M7TOQ[^S_ /\
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M[0'A35S\'-2\!SK\.?"-_P"+?B/X>T:.+XF>)!X=U7P\OAU8[OP-INK2^/\
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M5M1U'P\/[*KL?V;_ -E_X*?LF^!M8^'OP-\+7_AS1/$_CGQ3\4/&>HZ]XO\
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MA'6O!FC6T5A:K\8'\3>%/!.D^/-8LY/B#>2>'HOL[6O^"Z&I1_LZ_#?6]-^
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M+J6O+JJR:]+H_B+PC\M_LE?\$6/^"@G@;]O?]E[XS?$3]DR+P)\&?A__ ,%
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M4OA7\!OAOXI_8_\ VI_#_P"TA^R]X.\:W/P:_:,^)7_!2WP3\0OV:_@A\3_
M'@35;KX">(_@K^SK=>-/&']G1^)M?\,^!/"-UHND-I7A7P!<G3M7U32]1\)Z
M;-X8TX _H\^ '_!8/]F'X^_'[P9^SB?A_P#M3? _QW\6K#Q#JGP"U+]H[]G?
MQK\(?"'[0NF^$M%N?$?B6^^$FNZTMP^HVVCZ%:3:E<2>*+'PIYZM;6-B+O5+
MZQL;GXU\-_\ !SE_P3?\90> XO!WA[]JKQ;XE^(ES?:%H7@CPS\"7UWQ4OQ
MDUW^P?!7PKDATSQ9<Z/J'Q%^*,W^F^ =$\.ZSKEI/8-"WB;4_#%Y<VMG-^8W
M[-W_  31_P""B.H?MA?\$P?CS\4OV9?VBK#5/V=/&^J:C^UU\<_VFOVZ_ O[
M1'C#QGXKU;PYX=BU?Q'X&\%S?$O6+/PI\*M(UG2]2_X16V\&+KGCGQ%_PD4]
MKXR35;;PCH&OZAU/P*_X)9?&SX7?\$@OAG^R=^TW_P $T/B'^T+\2=1_:U^)
M/Q>\3^&OA'^U;\&/A?\ $CX(7=WX+?PIX)^.'A+QO;^/M<\%>+M=.E16?AVT
M\ RWNH^'_+_XJ#Q;I0N]%TV#4 #^J;]EK]HVR_:F^%%K\5K'X._'WX$I/KVN
M>';CX=?M+?#6;X3_ !4TN]T"XCMKN?4_!\VJZR;?3[B9V73[V/4)H;P0S-$=
MJ M]%U^3?_!%[X-_MX_ S]BC2O!'_!0[QEK'BSXV#XB>+=2\,Z?XI^(%E\5?
M&O@/X4/8^'M-\*>"/&?Q$TN_UK2O%6MVNKZ7XGU^VO--\1>(;6R\/>(M"T<Z
MC!<:;/I.F?K)0!_,E_P6._:M_;7_ &-_%/QC^+G@#_@J/^R=\"M \+>&/AUX
MS^ W["'B/X5_#GQY\=_C5I%[:V7A7Q"=4_MRVNOB9;:?XF^)&E^,H?#^M>#M
M&U#PY!IVFRQ:QXI\)IHNN7=G^AWQS\;?\%"_C5_P2R\+?'']FN/_ (9R_;KU
M'X*?#[XW3?"N]\&^'/%T.J>(CX5MO$'CKX)GPY\0O#_BV?2=3\06=[J$?@ZQ
MO8++Q1I'C*S\,>'/%&KZ=;/XG+?FY_P6<^!?[4_[95Y\9_@CX _X(J^ /C;X
MN?0?"O@SX ?\%!-6_:&_9^\+^+O#_AF")/&5WJNGV6L'PK\3O#,/@WQCJOBS
M2-)^'FL>/;?P[K6HWFH^*;NQO-/UK_A'_$7[Y_L>?"WXB_!#]E3]G7X0?%[Q
MQ=?$GXI?#7X-?#SP9\0O'%WJ-UK$GB+QAH'AC3M/U^\BUF_MK34]9LH]2AN+
M33M8UBW36]5T^WM=0UHR:K<WDK@'\ZGA3_@M3\>?^"D-U_P3Z_9E_P"">VJV
MWPL_:6^,NG2?$[]NSQ[/X(T/QOHW[+/PU^&^H7OA#XEZ?9Z#XNTKQ5H$E_XR
M\16MUK?P_D\1&VN5T_4_A-H.I3V.I?$]KC0OTC^*G_!=O]@SX0?&/QM\)-<O
MOCCXET+X0>.;;X7_ !X_:#\%?!/Q7XD_9V^!'Q%FUV;PS_PB/Q5^)-M%:_V9
MJRZU;364LOAW0/$.DF[CN+2"_>[L[VVM?'/^"3?[!WQS_9>_;V_X+#_'+XO?
M!O2/ /@+]I?X_:#XH_9L\76^O_#?7;CQ5X G^(?[0/BCQ5)I^F^#_$>N>(O!
M5A?+XF^'>JZCHOBS3?#%UJ-RVG$Z?<7>AW2:=^0GB[_@E%^VW\)OB/\ MZ_!
M_4OV3_VJ?VQ?V>?VB_CWXO\ C+\)E^"G_!23P[^S#\&O&MEX]UJ#7]7TW]H?
MX:>+_%\]MK/B;0[6V\.6]QXIUOP-<ZCKFN^%FL;6^U71SH&KZ. ?O]\<?^"U
MG[(W[/?Q#UOPM\0O!?[4W_"L?!WB:P\'_$/]JOP[^SCX\\0_LJ?#WQ%JLEC#
MIEAX@^+5C"R:F-1N=3L+6QNO!>A^++.[N;J&&"XD=B!Q7[3_ /P7R_8*_9'^
M.?QG_9V^+#_&F;XF?!)_A7-KMAX*^&T/B_2_$NA_%+P3H/Q%_P"$K\):KIOB
M06\OAGP#X.\2:7K'C[4?$H\,R6RS"T\+6WBR]>"VF_G@_:+_ ."3?_!4WXC_
M  D_:=_9XUWX ?M"_'O7['QSH&A?LA>.=7_;R\#^&?V5/AE^RO\ #76/ =M\
M.O"?@G]GC4OB186M_P#%%_"_A>[\,WT/Q,BL='M[#4;GQI-=/\0M%M/$/B_]
M,?A;_P $[?VD_A_^UA_P4X^.WQ1_8R'QX^'/QQ_X)W_LX_L[?#?X<#XW?##P
M;+\==9T+]F[X#?#OXQ_"-/$5CX\FU?X9I+XF^']_I4GQ!UG3-+^PG04\0>!M
M0U2272GU( _97]B__@HIX!_;BU;Q!!\.OV?_ -KKX:^$M/\ ".@^/_!WQ3^/
M?P,O/AA\+_C#X(\4S(OAOQ1\(O%-SKVJ?\);I>MV4B:O8F6QTNZ;2'6\EMH@
MRH?T%K^;#_@BG^QY^W)^S)^T9^T3?>+_  %\6_V9?^">&J^ M+L_V?/V2/CE
M^T1X/_:$\4>"_B;JNK>&-5U_5O!=]X(UGQ!I_A3P3X?GT_XB:9Y.L3:'K_B/
M3O%7@N^U&'Q5J>G:MKEI_2?0!^?O_!4G]L>+]@S]A#]H;]I2TN+&/QIX4\&R
M:#\*;6^CMKJ*^^+?C>Z@\(_#SS-+N71=9L-&\1:O:>)_$&EQGS)_"^@ZY(6B
MBAEFC^'/^"*'[</[6'QWNOVI_P!E3_@H/>:2?VSOV7O&7@77M<2PT3PEX6&I
M_"3XQ>!='\3^"]FB^$+#2=(O+_P[>QZ@=;U2PTVWCAT_Q7X/M+U3?.US>8__
M  6)_88_:B_X*3?'O]A[]FCP_HWB#P1^P]X.\8>)/C;^TS\=]'\2?"66ZLO&
MFD:)K&F?#7PQX=\!^*=:N?&VI>(M-L[?Q)I2ZH/ 7B3P/%+\6]'U/58=2B\*
M:U96WD/AW_@F/^U]^QM_P5G_ &<OVS_@C\1?C9^V?\.?C1X/\6?!+]N3Q=\8
M?&/P%T3XA^$_!;6?AK3/ 7B>ZN#%\+7\:>'="U+3_!OB3^R_"7A?Q+XXL],^
M$FH:)%->1>)="TJ, ^.?^"/'_!=_X=?"_P#8M\!6/[<OC7]K/XH^);OXS>+_
M  ]\1?VIO$'@#Q[\4OA%\(4\2:K:#X?^&/BO\9-1O+B?3;V^T\K?:7H7A^R\
M475AI=];W-W;644LGE_N5\1/^"OW[./A/]H37/V:_AM\+_VJ/VH_''@76?A_
MH?Q@\0?LM? O5/BQ\./@A=_%&VMKWP-/\3_'*:OHFDZ?INN6-P]TFJ>'3XFL
M;/[!J]G?SVNI:1J5E:_S#?"[]@#_ (+*> _^"3OQ7_X)17O_  3JT9[C]HOX
MXZ)\0Q\?)?VE/V;%T3X;>'++QA\)O$FJ6'C/PIHGB;7+[6=9MK[X3P75GXFM
M-?U*_?POXGATW1M-?6_!UCI5Y]6?M0?\$U_VY[?]J#X=ZY_P3S_9B^-/[,_Q
MY^'NL? ?X5>+?^"@Z?MA^ ;?X-?M$_ OX<_"KP=\/-1\<?&#X"-XLU#QK!J-
MEJ'A3PV+GP5H>DZY>>,M!T?7M>\6^&=?\4ZY!'I@!^@G[)7_  7)\3?M _MQ
M_M.?L^>.OV0OVE_A;\'_ (4Z!X.U;POKVN_LX^/=(^(?PE@7X:>+/B+XZU?]
ML6"?Q3JUE\*;'Q)!X>@LO@MIVG>''O?%C3(IN-0N=5LXK'[)^ '_  6#_9A^
M/OQ^\&?LXGX?_M3? _QW\6K#Q#JGP"U+]H[]G?QK\(?"'[0NF^$M%N?$?B6^
M^$FNZTMP^HVVCZ%:3:E<2>*+'PIYZM;6-B+O5+ZQL;G\[/BC^SC_ ,%-O@-_
MP4$_X*A?$G]D_P"!-OXU\,?\%#O@E\/[/X2?M)6'Q0^&'AQ?V>?BK\)_@9KG
MA71G\3>!?&.OV.NZK<W/C.=;?3M4M;&?2M+BU'0O$R0>*#I>O^$5^#_V;O\
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M )1L?\$]?^S'?V3?_5"^ :^XJ^'?^"8O_*-C_@GK_P!F._LF_P#JA? -?<5
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M#\#;O6_AU\<OB/+'=>+=0^,WAOX,Z]<6'CCPSX4URUATZ?5=1F\-@'Z]1_\
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MX=/PLU+0/B!X4TWQ1J,/_"":(_Q0\,6GA/P8^K,\M]J%]_9% 'W-X5_X*?\
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MD^";CPW\1;V+X3ZY<>$?COX5?28]7^'OB72/#?CCP]X+U2>\O;?5;Z6]\RS
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M5A%X8\1:9I7B.+4],N=+AU"V_E$U[_@D9^U/\-/A!#X3F_X)\:+^TAXC\?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=A\7]:_:'TC4?V@O&6C?#72M+^%EM\!M1T2U^$7C:X_9_EU?QGK7Q.T+X_\
MAO6K6+Q-X2\':/\ #N72-5T7Q1K.HR7.C:EJ0!^LM%?D;\(_VJ_'WPR_X)D_
M\$[/B1+K?P^^)'QG^+O[-?[,$EW;_'KXI?%>P\:_%;7]5_9ST?QMXRU'PK'\
M-?@S^T9\7_C)\5=4O[)M4U;1M*\#:AJ<NE7WBCQ]J^L7,GAUM$\1<FG_  5'
M^*/B?P=XC^,/P^_9X\!W?P:^$W[#/[.O[>7QPO/&'QJ\0^'OB-H_@'XSZ-\:
M/$WBKX?_  Y\'VOP:U/2/%GC'P)X<^"7BR\LM4\7>*OAWHOB36(=,T%HM'@U
MJZU[PV ?L]17YBW_ .W3\6K#XM?%R&7X)_#T?LY?!7]KWX'?L?>*O'X^+OB)
MOC#JOB_]H/0_V<4\&^*]"^$O_"IU\,1^'=!\<?M,^ -"\0V6I?%2#7KW0?\
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M.5\(_M.?MQ:G^USJGPK^+?@OX,_:]"_:1USX8_"O1_AO^T3\3M'\#:9X\/\
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M^+'A2ZBTFX^'FA6OPRMWUB;Q/J6OW5CX;TOQOO>./^"AGQ!\/^*?BGXI\,?
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MJ.L2:?X)T?Q#<7-YKOB+P> ?L?17Y(6G_!0;XWZE\*M:^++?"K]FWPAINO\
M[0GQ1^"/P$\(^.?V@?C-+\1_C'I_P1^(WQS\ _$#7M-^'OPQ_9+^)OC2Y\8Z
MG<?"S0M3\)?#'P%X?^(E]'X,U+Q?X^\2>(M+/A>Q\&:]\W^*_P!OG]HOXF>&
M?CK\4+?P3X9T3]ENZ_X)8_!O]KK3?#GACXV^-?A]\??"6J_%7PS\=+[4X] \
M7Z+\$[34-)\:+XQ\#MX$EOX?%=EI_ACPSX4T/XC^'H+CQ1XGUKP9HP!^_P#1
M7Y7^./\ @H9\0?#_ (I^*?BGPQ\"_!OB/]F7X(_M0?#[]CWXB?$'4OC%K?A[
MXQ2_%OXA^+?A%\/U\0>$_@[_ ,*@U3P[J7P\\(>/?C'X7\/:K<:O\6-$\4^)
M=-77O%GAC0)M.T?P]9^/.T_8S_;/^+O[0-S\)K3XV_ _P%\&[G]H7]F73/VK
MO@S:>!/C%KOQ:O7^'8E^&NG^(M#^(Z:M\(OAG8>%O%^EW/Q7\":I:V_A_4_&
M6E7MKK^HZ0-1%SX2GU7Q  ?HY1110 4444 %%?-O[4_[7W[-G[$_POF^,G[4
M?Q:\.?"/X?)JMEH5IJFM1:MJNJ:[KNHEVM=#\*^$_#.G:WXN\7:R;:&ZU*XT
MOPQH6K7UEHNGZIKM]!;:-I6I7]K^5 _X.8/^".)(!_:8\2J"0"Q^ /Q]P 3U
M.WX;EL#J< G'0$\4 ?O317A/[./[3GP"_:Z^%FC_ !J_9M^*7A?XN?#36Y9+
M2W\1^&;BX#Z?JD%M9WMUX?\ $FAZG;:?XB\(>*+"TU#3[G4O"OBO2-&\1Z;!
M?V4M_I=LEW;F3W:@ HHHH **** "BO)_CC\=?A!^S5\+?%WQK^/'Q!\.?"_X
M6^!=..I^)_&/BB\-KI]E$\B6]G9VL$,=QJ.LZYJ]]+;Z7X?\.:)9ZCX@\1:S
M=V6BZ%IFHZK>VEG-^.,W_!R]_P $<(Y98T_:<\17"1R.B3P_ #]H%8IU1BJS
M1+/\-()Q'( '030PRA6 DBC?*  _>:BODS]D3]N?]E#]N_P)J/Q$_92^,_AO
MXL^']#O8-.\36EA;ZSX?\6>$;^Z:]2QMO%_@;Q9IF@^,O#*ZH=,U)]"O-9T*
MST_Q%;Z?>7OA^\U.QMWN1]9T %%%% !1110 45Y/\<?CK\(/V:OA;XN^-?QX
M^(/ASX7_  M\"Z<=3\3^,?%%X;73[*)Y$M[.SM8(8[C4=9US5[Z6WTOP_P"'
M-$L]1\0>(M9N[+1="TS4=5O;2SF_'&;_ (.7O^".$<LL:?M.>(KA(Y'1)X?@
M!^T"L4ZHQ59HEG^&D$XCD #H)H890K 211OE  ?O-17R9^R)^W/^RA^W?X$U
M'XB?LI?&?PW\6?#^AWL&G>)K2PM]9\/^+/"-_=->I8VWB_P-XLTS0?&7AE=4
M.F:D^A7FLZ%9Z?XBM]/O+WP_>:G8V[W(^LZ "BBB@ HHHH **0D $D@  DDG
M  ')))X  Y)/2OFK5?VROV4]$^%"?'35?V@_A19?!^?QCK_P]TWXBR^,=(/A
M?7O'7AC5_$&@ZUX0\+ZDEP\?BKQ';:MX4\26D&D>&QJE[J)T34IM-AO+>UDE
M !]+45SOA'Q?X5\?^%O#WC?P-XCT3Q?X.\6:/8>(/#'BCPWJ=IK.@>(-#U6V
MCO--U;2-5L)9[+4-/OK66.>VNK::2&6-U9&(-=%0 4444 %%>:^*_C'\+/ W
MC[X7?"SQAX\\->'?B-\;+KQ=9?"7P9JNHQ6VO_$"Z\!>'SXJ\9Q>&;!SYNH'
MPUX>VZKJ[1@):6TL&]O,N($D]*H ***X?XG?$CP7\&_AK\0_B_\ $C6?^$<^
M'?PJ\#>+/B1X]\0_V=JVL?V#X+\#:!J'B?Q3K/\ 9.@V.J:YJG]EZ'I=]??V
M=HVF:CJU[Y'V;3K&[O)8;>0 [BBN5\7^-?#O@2PTS4_$MS?6MGK'BKPAX*L'
MT_0]=U^63Q%X[\2Z7X1\-6T]KX>TW5+NRL;K7M8T^WU#7+Z"VT+0+.2;6/$&
MI:7HUE>ZA;]50 4444 %%%8^O>(O#_A;3O[7\3Z[H_AS2?M^D:5_:FO:G9:1
MIW]I^(-7L?#^@:=]MU">WMOM^MZ]J>FZ)I%GYOVC4M7U&QTVRCFO+NWAD -B
MBBB@ HHK'U7Q%X?T*XT.TUO7='T:Z\3ZP/#OAJVU74[+3[CQ#X@;3-3UM="T
M.&[GADU;6#HVB:SJXTRP6XO3IFD:G?B#[+874L0!L45P_P ._B1X+^+'AEO&
M/@#6?[?\.+XF\=>#VU'^SM6TK'B/X:^./$7PW\:Z=]DUJQTV_/\ 8OC3PGX@
MT;[6+4V.H_V?_:.DW5_I-U97USW% !17C^B_';X;^(_C1XS^ .@ZAKVJ_$?X
M<^%M$\6^/(;3P5XT;PAX3LO$YMI/#6D:O\2'T!/AY'XRUZPN?[<T[P);^)[C
MQD?#D,GB*ZT.VT62UOKCV"@ HHHH **** "BBL3Q-XDT+P;X;\0>,/%.J6NA
M^&?"FAZMXD\1ZU?.8[+2-"T*PN-4U?5+R158I:Z?I]K<7=PX5BL,+L%)&* -
MNBO'_!GQV^&_CCX+6O[0FG:AKV@_"B\\)ZQX]37_ (@>"O&GPSU.U\$Z)'J%
MW<^*=6\'_$#0/#?C/0M)N=(TV;Q!ISZWX?TZYOO#\]CJ\%LUI>VTDFY\)OBC
MX4^-?PZ\*?%3P-'XH7P=XVTY]8\-2^,O _C/X;^(+[1FN[FVL=5NO!?Q"T+P
MSXRT:SUB"W75=&_MW0=,N-1T6\T_58(#9WUM)( >B45CZ)XB\/\ B6WO+OPY
MKNCZ_:Z=K&M>'=0N=$U.RU6WL?$'AO4[K1/$6A7DUC//';:QH.LV-[I&M:9.
MR7NEZG9W5A?0075O+$FQ0 4444 %%</J'Q(\%Z7\2O"?P@OM9\CXB>.? WQ#
M^)'A;P]_9VK2_P!J>"_A5K_PQ\,>/=9_M:&QDT.R_L'7/C)\-['^SM1U.TU;
M5/\ A(_M.C6.HV>CZ]<:7>N/&OAVU\;Z3\.IKF^7Q9KGA7Q#XUTVT30]=ETR
M7P[X6U?PQH6MW,_B6+37\,V%]!J7C'0(K30[_6+77=6M[B]O](TV^T_1=;NM
M. .JHHHH **** "BL>/Q%X?F\07GA.+7='E\4Z?H^G>(K_PU'J=D_B"Q\/ZQ
M>ZKIND:[>:,LYU&VT?5-1T/6[#3M3FMDLKZ]T?5;6VGEGT^[CAV* "BBB@ H
MHHH **** "BBB@ HKYM_:G_:^_9L_8G^%\WQD_:C^+7ASX1_#Y-5LM"M-4UJ
M+5M5U37==U$NUKH?A7PGX9T[6_%WB[63;0W6I7&E^&-"U:^LM%T_5-=OH+;1
MM*U*_M?RH'_!S!_P1Q) /[3'B502 6/P!^/N ">IV_#<M@=3@$XZ GB@#]Z:
M*\)_9Q_:<^ 7[77PLT?XU?LV_%+PO\7/AIK<LEI;^(_#-Q<!]/U2"VL[VZ\/
M^)-#U.VT_P 1>$/%%A::AI]SJ7A7Q7I&C>(]-@O[*6_TNV2[MS)[M0 4444
M%%%% !17S;^U/^U]^S9^Q/\ "^;XR?M1_%KPY\(_A\FJV6A6FJ:U%JVJZIKN
MNZB7:UT/PKX3\,Z=K?B[Q=K)MH;K4KC2_#&A:M?66BZ?JFNWT%MHVE:E?VOY
M4#_@Y@_X(XD@']ICQ*H) +'X _'W !/4[?AN6P.IP"<= 3Q0!^]-%>$_LX_M
M.? +]KKX6:/\:OV;?BEX7^+GPTUN62TM_$?AFXN ^GZI!;6=[=>'_$FAZG;:
M?XB\(>*+"TU#3[G4O"OBO2-&\1Z;!?V4M_I=LEW;F3W:@ HHHH **** "BO)
M_CC\=?A!^S5\+?%WQK^/'Q!\.?"_X6^!=..I^)_&/BB\-KI]E$\B6]G9VL$,
M=QJ.LZYJ]]+;Z7X?\.:)9ZCX@\1:S=V6BZ%IFHZK>VEG-^.,W_!R]_P1PCEE
MC3]ISQ%<)'(Z)/#\ /V@5BG5&*K-$L_PT@G$<@ =!-##*%8"2*-\H #]YJ*^
M3/V1/VY_V4/V[_ FH_$3]E+XS^&_BSX?T.]@T[Q-:6%OK/A_Q9X1O[IKU+&V
M\7^!O%FF:#XR\,KJATS4GT*\UG0K/3_$5OI]Y>^'[S4[&W>Y'UG0 4444 %%
M%% !17-^,?&/A+X>>%/$7COQ[XGT#P5X)\(:-J/B+Q7XN\5:O8:!X:\-:!I%
MK)>ZIK6NZWJMQ:Z;I6E:=9PRW-[?WUS!:VT$;RS2HBDC\1M1_P"#E;_@C?87
MUS9)^U)K.HK;2F+[;IWP%_:"DLKAE WM;2W'PQMI)8E?<@E\E8Y2IDA:6%HY
M7 /W=HKX/_8R_P""FG[#W_!0$>)+?]E/X\^'_B/K_@^$WGB;P5>Z/XH\#>/=
M*TL2V5N=>_X0KQ[H?AKQ'J7AA;K4]-L9?%6C:?J7ANWU._MM(N-5AU9S8K]X
M4 %%%% !7\.__!YG_P XW_\ N\#_ -]<K^XBOX=_^#S/_G&__P!W@?\ OKE
M']4W_!,7_E&Q_P $]?\ LQW]DW_U0O@&ON*OAW_@F+_RC8_X)Z_]F._LF_\
MJA? -?<5 !1110 4444 %%%% !1110 5_G*_\'>O_*2?X(_]F._#7_U?7[2]
M?Z-5?YRO_!WK_P I)_@C_P!F._#7_P!7U^TO0!_HU4444 %%%% '*^./!ND?
M$'PGKO@O7KKQ/8Z/XBL7T^_O/!?C;QE\./%=K"[I()]!\=?#W7O"_C;POJ,4
MD:/!JWAKQ!I.J6Y!\F[0,P;Q3P'^R3\%?AQX?\8:#X;L_B))<_$/Q]X-^)WC
M_P ::_\ &[XU>)_BEXT\8^ +SPG=^$KCQ%\5_$'Q U'XC7WA[28O!/A[1(_
M0\3Q?#Z?PA#J/@:Y\+3>"]?U_0-3^E:* "BBB@ HHHH \1^)7[.'P6^,$WCJ
M?XD^![;Q2_Q+^#'B+]GOQNEWK'B.UM]=^$'BNYN[O7_"$EIINL65K9"^N;ZY
MF77M-AL_$]F\B_8-:M1%"(_E_P" 7A+]BOP_/^UYIW@W4?'_ (OM/#MIIGPI
M_:L^)G[1GC;]H'XF>%K_ $;X?>'?&*3?#F7XS?M*ZWX@\,^)_"OPO\/^(_%W
M_"=Z9X%\3ZEX9\):EXLUR?QW-#XOUS7I9OA7Q]+\:3^T]\39M5?]LIOVG]/_
M &_OV<-'^ $W@6R_:Y'[(Y_84U?Q'^SGJ7Q(?6+3P]:G]DBZ\,1_"M_CE8?&
M74_'37'CQ?C#I$'V+4M+OX_A EGU'AK]B*/3O^";W_!2'X0Z)X*^.D?B_P"+
M?BS]O^'PAX5\1?%?]H*^\3>*ET?XP?'#4_@%=>&&\5^/+O6O[/\ '5O-X7U#
M4-0T2:&R^.NDZLES\0I_'NF>(;UM0 /J;P+^Q7^PH=<^*/P1\-P?$GQ/XUT[
MX<?LIZCXPNO$OQ[_ &E_&/BOPG\./AS\1/'OC_\ 9&?P'\2/%WQ"U1_"=CX$
M^(O@7QQXF\(6OPS\0Z?>Z?JVGW&I>*H)AK\$VL=0G_!,/]D2VO=6US2= ^,?
MAKQAXD\6?$_QIXM^(?A']J3]I[PC\1_&&M_&G0OA?X;^*T?B;QUX:^+VE^)M
M3T#QII?P7^%WVGPF^HIX6T+4O!>C:[X1T;P]KL#:D_Y9>)/V;[OQ;H'[4'QY
M^ &F?MP:+J/PS_8._9MU#]D]$\7_ +:/@'Q/K_QT^'_C?]L37]>TW6O!?C76
M-#\<?&OQ?H'B.?0=&7P9\5])\<0:7X(\9V^D:#H=MX.^(5I_;/TEX/TKXO:E
M_P %"/B'>>.O'OQ_\&?%#P_^U+'_ ,*]A3P/^V)XJ_9C^(7[&=Y\"M N-.\
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M<%F_Q-^.'_!1.+]HZ.U_:1_;!\#^&[WX>:+\;/BG??LUZ!/IVC?$S1+#X1^
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M(] _9&^&WA;P%X!?Q9;_ !A\7?'R'QAXS\5^&OL&EOX1T>TTOX-^*IP#]/\
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M-0N9/$6N:WX,F^(VKWG@^3QA#J7POITGQ%_X6K=2Z$/V]$^.&G_MC?LB:/\
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MY;&+XG?'7_@HO'^T-$G[2?[7W@G0KOX:Z+\;_BK??LS>'[W3]"^)>A:9\)/
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M4#XF65EIMD^E_M!^+?$5W!XN\(ZY\6Q>>$_$GP+U7P1=_LW:O%J.I_'K3;@
M_:2BBB@ HHHH _G&_P""K7@GPC\7_P#@K[_P0Q^$_P 3_#ND^.OAI?\ B/\
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M[\4/^"JW[+_A'X@>%KAYHM/\5>&=6T[Q]I.I:)JCVLD%T^GWEAJE[%-!%<1
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M+:6.XM;NVEE@N()$EAD>-U8@'\RO[$7A3PQ\*?\ @Y0_X*<?#GX9^'M$\ >
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M0Q?@'&_\%(]>UZ'PC\'/!5IX%^*6I^&?&WQ'U9?$GQ4^&FH_M?W ^$%YX>\
M^*-2\,WWB+X??L-ZYX8^.OQ0A\6ZE))H?AWPM/XH\(_#VT\5QZ-K^L>*=/\
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MU36?&&OZ=#X>\)>);K3@#\\[+PO^VFWCC2?!NK6O[1-MX2_8_P#CU^S7\#?
M_B6SN_B#<VO[0'PP^)G[>_@;XB>)?B)XDU.&>6?XHZ/\(OV,/A]\!O!OQ ^)
MNK-J5C9>)/&G[3WA_P 2:E%'%XN6X\H3Q1^T#;^#OVB_"WA6P_;!\;_#>W_:
M,_9@\8?&']I+0]$_X*!> _CIX]_9P\?_ !\\7:?\7?AKX"^"?Q#T73?'_P /
M/C?\&O!T-A+\3_%'[&6C6FE>(/@3<Z7%X5\.?"?Q%H/P[\':-^M'P[_;9\!>
M+_B%8:)KFJWWA#2_'&B? 2T\#^"/%_P?^+_@#XD>&O&OQ??]HM[*+XEW?CC2
M-)TO2]!\<#X&7FD?#5;K0/#5TVN645KJ-YJ<OQ-^&]I/))_P47_917QOI/@*
MW\9>+M3U34/%T_@G5=;T7X2?%;6O G@36G^-OC7]G/PZ_P 3OB)I?@V[\#_#
M72?'WQH^'GB_P1\-];\:Z_HNE^/9]).M>&+K4?#5Y8ZS<@'Y>? S]GKQ?^T#
M^T[XF\%ZOKG[?OA_]A+PYI7[2A_9\;QE\4OVTO@]K!>+PS_P3VLO"LVO>+/&
MWB3PC\5/$NA:)\4[G]J?5_@1X=^+>HZ]976CZ=JFM^%+#4/!/AKPTFE?</\
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MM/=?!7PKXV\.>!=*\*M^R_XI^%^N:UXQ\>:#XKN&\7/XR\=V7BOQ'HW]0U%
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M@^ /@=!)\.%30/ 7B7POIWAWPW=:1+XF\F\>>+?VD==_X**:'?\ PO\ A_\
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MMI_C+2M?\:?#WQ[_ $RT4 ?S.?&7Q7\?/&/A3Q]XK\7_  Z_X*#?"3XHW?[
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M<:G;:CI%]!#>:;>1S65S%'-"Z#W.BB@ HHHH **** /YQO\ @JUX)\(_%_\
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MUKX O_&^JB2+PYI7BSX@?#[P5X1\(:5K&IHCV^CG6M=\1:;;07>IO:6,=O\
MVAJ,]S%IVCZM=67]%\US;VUO-=W$\-O:6\,ES/<S2I%;PV\2&66>::1ECCAC
MC5I))7941%+LP4$T ?S,?\$#]%TCP%^V1_P74^$O@K3+'PK\,? /[<5J/!'@
M+0;6'3/"GA&+4/$_QUTRYM?#FB6B16&C6)TSPWX?TR"PL(8+*STW1=+T^SMX
M+.QMX8_Z;:_F7_X(':G8>/?VO/\ @N;\:/!MW;^)/A3\1_VZ1!X"\?:1-'>>
M&?%QT3Q)\:]7U&70-2A9H=1M8M(\8^%=5CN[<O;7.G>(-+O+:66&Z1Z_IHH
M**** "BBB@#^=G_@XGT/2O'7P^_X)I_"KQ99IK7P]^*'_!5;]E_PC\0/"UP\
MT6G^*O#.K:=X^TG4M$U1[62"Z?3[RPU2]BF@BN(@7DBN1BZM;2:#^@_0/#^@
M^%-$TKPUX7T32/#?AS0K"UTK0_#^@:;9Z/HFC:791+!9Z;I6E:=#;6&G6%I
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M\8KIT-NFOZV]QX3\+-<:SJ*SZI=KX;T**ZNYH=)L(X/Z>:_F1^-.M:3\1_\
M@Z0_8ST_P'J-EXMN_@9^PY\31\7XM"NH-0/PZFUFQ^/5MIUIXJ,$CC2[^XE^
M('@8_8)R+R*+Q;X?GE@2'4K>1OZ;J "BBB@ K^'?_@\S_P"<;_\ W>!_[ZY7
M]Q%?P[_\'F?_ #C?_P"[P/\ WUR@#^J;_@F+_P HV/\ @GK_ -F._LF_^J%\
M U]Q5\._\$Q?^4;'_!/7_LQW]DW_ -4+X!K[BH **** "BBB@ HHHH ****
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M@FC?\%>].U+PK:>-[W]A[]K[1_"VH_LS:;^V=8:G<WG[+4Y_X99DTN'5-?\
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M^'OB#P]K;:3; 'G&C?\ !4WP3XNT+P_%\/O@%\7/B3\5?$'[1_B#]E>'X0>
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M^*TU7XM^([;Q+\0/A1XF^ ^G:GK=IIB^&O#'Q DU*TB33_"5OI=Y#KO[&T4
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M8:?K6BW]AJMA9WD'Y%G_ (-O?^"+Q))_8S&223C]H?\ :L49)SPJ_',*!Z
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M-G:RP_<=%% !1110 5_#O_P>9_\ .-__ +O _P#?7*_N(K^'?_@\S_YQO_\
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MOXF0:U;-J'B_7]6M/#OVVT\/ ']-M%?S]?M__P#!3[]J/]CS]J3XG?LQ>&?
MWPS\8^*_C]\'/@3K'_!-T:MH7B2PM/%/QS\9?&_PO\!?B=\+_B3JD'B46_BJ
M[\//XLM_C':IHD/@^/2/ FF2Z=J=]=W-[#?)XA^T#_P5Q_:Z^#GC+]JSQY8_
M\,^3_#W]A?\ :)^ _P"R[XO_ &5?$GA/Q7I7[3O[5NI?%B3P99ZC\6OA;J=O
MXXGL/ -MXE&OWWBOX&^%HO"_Q M=?\$:'XOU+Q'?W$VC6'VD _ITHK^<)_\
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M]H7X0_'?7(/%OAV#Q'K/@32-3O?$MA?:'9^#$\-6+V,_B"WOH?,63Y_^%?\
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MO?V?](M[^#3=5T?PCJ4L^H_%634;"^>Q\/SV4MH]M(QD/[YT %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%?FC^T9_P6
M&_X)O?LE_%OQ'\"OVAOVG-#^&_Q7\)6VA7?B'PA>^ OBUKEQIMOXET/3_$FA
MROJ7A7P#KNB3B_T35=/OT6UU.=X4N%AN5AN$EA3[Z^&_Q#\&_%WX=^ OBO\
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MW_U0O@&ON*@ HHHH **** "BBB@ HHHH *_SE?\ @[U_Y23_  1_[,=^&O\
MZOK]I>O]&JO\Y7_@[U_Y23_!'_LQWX:_^KZ_:7H _P!&JBBB@ HHHH *\7LO
MV;_V>--^&EI\%].^ OP7L/@[8:Y!XGL?A/9?"[P/:_#2R\2VOBE/'-KXAM/
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MC_PDO_"2_;_[*_X1[^PO[7_M3^W/[4_XEO\ 9/V7[?\ ;_\ 0_L_VC]W7JM
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M;3--U'Q1H>IW=MI,E[(]Y-I*3#39[MOM,UJ\X#C?\1_LW?L]>,/'TWQ4\6?
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M2XO+^^N8+6V@1Y9I4C5F !N4444 %%%% !1110 4444 %%%% !1110 4444
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MW?C?XA^+--^+FJ+\1YM$^&NDV7PLU#PWHEE\/[;Q1X1@CNK?5O"?B*74-6U
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MC?V;%-HMY"T]TDWQ=\!/^",ES\(OBC^RG\<?$O[2K>._BO\ !?\ :D_;/_;
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M[J^G:9X3URXU[4= TNZ\,:#)93V>JZ_:WMM>6UMV'@[_ (*T_L/?$SQE\ O
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M(U*;X&R?!&'PN_Q!M_B-#8M'=RZ9<:-%IZVMQ:77]J&VO;.:=^J_\%<OV%M
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MBL]NCZM+9<[XC_X+D_\ !./PMX/\,^+]3^*GQ!;_ (2O5?C5X>T_PC9?L_\
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M*Z#I/]J:#H^EZSJ?V#[?K&HZAJ=U>7EP ?R9ZE^UO_P5"_:#_P""77_!//\
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M^'WBGP_KO[%_L_\ B[]FZ3QO=ZI\,/$&N:UXP_;!_P"$Z_:RM[/7]"U2WO\
M2K'P%X=_9^^ 'CRVGAO/#NE7OPYGT6ZL_AOH.I^!/&4MMXOD\7IXT@6UF'AC
M7K'P[XU\/?\ @IU\!OB#\/O$/C7QC\.OCOX-N-)^/WQ!^!G@?P#J/[.7Q[\3
M?$+XH^,/A[XI^).GV(^&W@2R^$\?BKQ+XCC\/_"_7O%_CW0]#T34'^!Z07>G
M_$W5] ETRZO* /C#P]^V+^V]JNB_LT^!?L5[JGQM_;#^ W[*'[6/@.UC\/:-
MH.FZ#%\._@WJWQ'_ &S?@]LFT:\M_#7A/Q?XC^&'P=^'<FH>(9=2\4>"O$_[
M=&S0]8CC\&Z//H_OO_!++X\?$?XY:;;^+-9_:X\%?M2^&O''P!^$?Q-\::1/
MXW^!M[\3_@A\<?%$NKOXM\*VWPY^"G@GPS<^ /A7K,7VK1=*\(?%/4-:\?>
M?%OPVU[P_?:]XDO[_79](_3CX6?&3X;_ !H^&^E_%OX=>(_[6\ ZM_PD4<6L
M:KH^O>#[S3;SP?KVL>%?&&D>)O#GC/2_#_B?PAK_ (0\3^']=\.>+/#OBO1M
M&UWPSKNC:II.N:=87]A=6\7YH?&W_@J?\']$_9W^(7Q._9AT7QIXG^(MQKGP
M/TGP-%XI_9:_:,&A^(K+]H[QTW@;X8?'H^%;#PAX-\9?$WX%ZU=6/B*;0?&O
M@S5+?2?'^O:7I/@'PUXJA\5^-_",&J 'P!X\_P""C'Q@O?$7[65[\$/VA/%[
MZ7=?LA?\%"_BCX1\"?$_Q)^S=XJ^*/[/OQ7_ &=/B7\.?!O@35-4^#?PT^!^
M@^(O@UX8TZ37?&&A>$/!7QU^*7C_ ,<^/-&T:'4/'?AKP]X\\)^,KO7OUR^!
MWC?XC?![XG?M7?![XI?%SXJ_M):-\#OA#\%?CWI?C+Q;X2^&[_%.\_X6DOQY
MA\8>"-%\.?!/X;_#70]:LK?4/@I_:_@G1X?#EWKL=UXMN/"MK?SZ3IN@6=I\
MT_LK_P#!2H:UX+^)OQ$_: L_&]M#=?'?4/@)\'/AU\/_ -A3]J#PA\8/B-XL
M^'-MX^TSQYK@\$SCXB^)/'_B_7&^&'C+QQXN\&^#M MH?V;/".@VWA'XG:WJ
M/B:.]U)ON#3?VY_V?/$_BOX6^#OAYJGCOXLZK\5O"WP]\>V%Q\*/A5\1_B!H
MO@;P!\5KF:R^'GC;XOZWX>\-7FF?"30O%%[;7L5DOCVYT35H+32?$>N7^EVG
MASPEXLUC0P#\*/@5^U]^T)^TO^TM\(/V>O /[<'Q4@^$OQ@D^#WCZ\\<>'O&
MO[%7Q>^/OA/0/'W[.G[?/Q#UOX<^+?$'PT_9;M?@C\,_&6L:O\$_A'K^N^ M
M.L/BCK?P_P!/6XG\+^/=&L?&>B6?ASOF_:G_ &W/@Q^SCHWQ=E_:)\9_';QI
M\1OV*_VY/B==:=XW\"? W3O#/PRU?]EWXL?!3P;X7^+'A#1O OPL\&ZUK>M^
M&/A;XW\9^-OB%X5\5>)?$6@?$GQ;I,<.AZ5X.TZ>PT6S_93]C?\ :S\)_M8^
M%_B-K/A3X8?$SX86_P .OBS\2_AQ<:?\0?AIX_\  $&L'P;\1O&?@N+6M+G\
M:^"?!MO=ZOJ3>$Y]3\8^%-/CU'6/AOK6HKX5\8RP:[$XF]#^"O[37PO^/>K^
M,/#G@NU^*&@>*? FG>%-=\2>$OB[\$?C'\"_%=MX:\=W/BJS\%^*+3PY\9/
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M ?ES\,?BQ^U9^R%^Q;\*]2\&_'GQQ\9I/$O_  1FE_:6T+P]\0?"7P@7P_\
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M\?VO?&'Q%7XH_!;X"?M=_%S7?#7BOPM\9O@%XC\):C\1/V1KWQE\2=,\&_\
M!/;XC_'#2OB7\(/A1X,_9MUKXI2?"[XL>(?#7@W5=;^/.O\ Q'\(:9XRA^)N
MM:/\)/#-OX,\9_!OQ'X,^C=*_:B^(US\8?"7PZ^&7_!0+P5<:+X%^%_[*7B[
M]FZ#XE_&7]DW2O!'[;EC\2_BIX]\,_&0^-?$NF?"K_A(O%]Y8:OX6U#]G#PC
MH/P#C\*:E\,?%VA^&_$/BFU\6^(_&EE8M]2?M ?\%9O@;X/^#.N>)?V;M+\=
M>)/BQXHA^'&G_!0^*?V1_P!J(>"?'OA7QS\0_ WPQTGXS>&X;/P#X*U'XN_
M[PCK/Q#T&WDU7X=>)X[7Q!K'B+X?>$_#NMVU]\8/AA>^*/OG7OB_\-_@K\ O
M _Q<^->I1VEM9Z#X#A2ZL_A#XL\/^+?$/Q \=IH^EZ;X?\#_  )M[7Q5\3=+
M\>>.O%FJP:=HOPBTVW\0^.;76+^/PU.-2U*SN9V /QB\"_&K7/B9^U]_P3WE
M^(G[5.M^,OBSKG_!1+_@H18>*/V3K^/X1?V-\$].^!'[/_\ P4&^%/AJ+PY;
M>$_ N@_$G1K3PCX0O_">B3:GXY\4:^GQ23QA9_$"&.))K 0?5'@']H?QGXL_
M:E_:WT?Q=^T9%HG[0?P'^)GQ&^'O[.G_  3RLOB!\&_">@?&;P!:_L[:5\4?
MA?XQUG1-=\)WOQC\<:M\44U;4O'=SXP\.>)[#1/ C^"[[PMI]C#IG@WXFCQ9
M](Z[_P %%OV6? @M-1\<6_QD\ ZM?>$K/QW\2+77/V9/CR-4^"O@7^W/%WA/
M2/&7[2-]H7PWU?3O@MX2O=8\&>)XO#_B/XE:IHNBZMX<TW4/'FBWMW\.;#4_
M%EG#\1O^"C_[)/PQ^*?B+X=^+I_BW/XO\#?$'3/@MK?B#PQ^S!^T+X]\)Z?\
M6O%7@OPS\0?"GPATSXB^"_A=X@\+:W\1O''AOQ;X=N/#/@/PSK>J^(M6O]6T
MG2CID6IZUH=KJ8!^4?PJ_:B_:7^)7P \$>)?AQ_P4!T+XD7OQQUK_@G;:^-O
M%>C:[^R[XM^-O[-OQ)_: _:7\$?#_P",?A[PW\(_"?PDN_"W@CP'KW@SQ'XC
M\/>%_"7QSTGQKXK^'7CSX=ZMHVL7OBZYN_$!TO=\"Z3XK^&?_!2'Q;^SZ_[:
M7QE\2>+OBA^TK?:+=:)XZN_V:]4^*8^'5U_P2BU'5]$^/WA;3H/@9IFH:7K?
MA7XE>&H_!NB^,M.T4> +N3PDWAGQ7X=\1ZCJ'BP^(/TW\1_\%)/V0_ F@>%?
M$XD^+>H/\1O#_P 8O'*:#X'_ &7OVA/$_CO2=&_9]\<:3\./CMK'Q/\ !'AK
MX77OB[X:M\*?&>M6V@^-)?B7I/AJ2RU/.GP->7]SI]K>[^@_\%#_ -D#Q%X4
M\8_$^S\6^,+31_!ND?"N]-[K?P$^.F@^*O'/A?XZ>(M2\-_!/5_@[X5UCX9V
M7C?XW>'/BYXLT?5=$^'%U\(]$\9VOC#6K":#1%NY)+=IP#\7?A1\5?C[^R;^
MP_\ L_\ B+X0>,-6^)?B"U_X)*_'S]I:SC^(OAGX=:K<>#-5TOQU^QL^NZOH
M3>$/ OA'6]>T'X;^%O%GQ'^(-IX-U74M2U7XC>(V:V\8:_KVHRZ-?:3V'[7'
M[</A_P"!WP6OK;]FC_@I1X^^-'C?PO\ "+X[_M"Z)\9_$WQP_8:D^$7C/Q!X
M5\,_#6XL?A!J&LV7[-WC34?BEX]34-<T7Q/X._9P^#?ACP_KDND?&5H?$OC+
MP5HWB'X W/AK];]2_P""CW[+VE^"O#OC*XU#XOS7OB?XL:C\!=/^&-C^SE\?
MK_XYVWQLTKX<7'Q:O/AAK'P/M/AQ+\4=$\1K\/((_&$-SJGA:U\.W'A6^TSQ
M=!KDGA'4;/7I?:/^%^? *R^!,7[2RZQ!;?!^STJ?Q5;^(%\"^*X-?MY;O4&T
M"XTV'X>GPS'\1X/']UX@D;PE-X#7PFGQ F\6R'PC)X>;Q$QTL@'X4?$_XR^,
MOV?_ (J_MZ^(-)_:\\7>!M;^)'[4W[(,_C+3_%_C#]G#3Y?@#^S)\<O W[*?
MAKQ/^T5X1TCQE\+8GM-#\"^)-='[-GAKXE^-U\0?#/P%I5\GC#X@:1XN\9>%
MM;UK6/K;QO\ M'_&OX;_ +"6@^.6_::\ ^(_#EW^UIX%^#6N_MP^$_&GP1^(
M5U\.OV8?&OQ[TKP'>?%_QKJ=OX'M_P!GM?BM\/;;6(?A9XXU.7P=J'P[\,:K
M:W/Q5\3Z UKINN^%+;ZDUS]N_P"&=E\>/V??@]=_!OXZQ2?M#?#+XG>+/^$Q
M\3_L^_&;PS'X$T[X?^.O"/@:ZT+QY9:[\,X1HFC2:IXCU35_%FO^(-7T7POX
M)\,VOA+QEK%S<^$?BCX%U_5*FD?\%-?V*+G0+RZMO%_C;1=%'AC3_%'@*RUS
M]GKX\>$V^.'@_7/$GA/P1H>L?LVZ-K_PQTJZ_:%T[Q!XT\>^#O"FB6_P<L_&
M-WJ^H>+?"EW8V4^A^,/"FK:V ?FE>ZAXQ_:6\7? #POIW[:7Q0^*GPP^#?\
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MBBB@ HHHH **** "BBB@#\OM>_8#^(UUX\^)6D^&_C?X#T+]F;XO?MC?!_\
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M^+_@B/A=+XY^,_A#Q5H_P#_9J^,?[+'P^_L'X7ZIX*F?X3^.=>^!>O>%M?\
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MN?'O@?Q-\6_$=UJ5QX;E^#7A#1/@[K&A:A\/?%W_  C?B_5+;Q-<^/M!T>,
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MP7XX_9"G\.:/I&CZGJMYH7AC3[.[\1ZY?W5MX8TS1X]7U/4KC4]9&H:@4N5
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MVH\1:+X,US0_$/@I^V9\6O%7Q9^#DVI?M:)XC^-_Q0_:,_;(^$'[0?[!J-\
M+[2_V9_A[\!?!_[4FI^'-?T?3?#/@*P^.7A^_P#!/BCX:?!K3[WX@?$+QMXA
MT'XL6WQ7LKM-(MM+\4?#B/PL ?ISX#^"/@C]GC]D+XF> /VC/B7X7\2>$M>;
M]ICXG?M&?%&^TP_";P1>)^T'\0_B5\7?B]JD>EW_ (N\5R> O!FE-\0]<TO2
M(+WQMK=SHGAO3;$WFO7EU#->/^?OP7^ GPGU[X.> /A?XG_;2_8F^)&O:3IO
M[(WACX2?&#X8^";?P_\ %KQ?X+^ _P </AA\9;'1/%LNO_M/?$.+7KGXM?\
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M-:IX+TWP[X4T'3-'M=+L #]+/"'P"T#P-^TY\,-6^./[4OPFU7]J7XB?M/\
MQ$_:WM/AWX;\$GX>?\+"TVS_ &)[W]D"S\#_  V\%>(OBSXX\4VVD?#SX>Z'
M8>-/$'B]]4\3SZ[JVE>)99=#\-V.KH="^D=)_9=UGPG^RO\ $+]G;0O$7PP\
M97OCCQ7\?/$%Q=?&CX1:AX\^%NK:)\?OCI\0/BYXD\$^-?A9I?Q)\*WOB71X
MO#OQ"U3P ]S'X[TZ*\N(8/%=UH\UH9_!L_YQ?"_Q5I7@?P!_P38^(OC;5I_
M_P %]&_:^_;]^)OPXUSXD7][HL?@[]D&3X'_ /!0#QM\!=5U^Y\5RV]WX5\&
M>'_V=9O!5[X<T[7_ +!=>#?AO:^'M'UZ"QU'1]1BB_4[]J_QOK/A?]F#XJ^-
M? 7QB^&GP4\0KX,CF\%_%WXJ>)/#'A+X>>'M:UR[T_3_  Y/JOB[QGI'B3PG
MX;D\0WVHV>@>'O$/B#PGXVTG2/$&LZ1J-YX"\=PV[>$-: /CSPA_P3J^('AS
MP9^S_P"%]<^/&C>/X_AMHW[3_P *?B-I?C?P9\1?$>@Z]^S9^U1XR\*ZYXA^
M#/PNU'6_CAJ?Q'\#'X7>#_ OA/X<_"GQ3X]\??%V73="L)WU+2;FR&DZ)H_C
M.N?\$LOCEXGT3]F:^^(O[6GPHU#QA^P7\.O!WA;]DSQK8_LS^*-%LM&UOP7\
M1O@#XRU/XB?'71[S]IK4(_B!=^+O O[/>C?#+Q)HOA'5OA?IUC8>,/'OBO1[
M^PN]3T71_#>?\(O^"ANA6EE^SMXP\=_''Q1X0^#WC3]G7]N;0I_$7[0'B#X(
M:E<^-OVEO@#\>_@[X,TG0?"WQ4^$FA:1\,OB]=Z5I-U\4-*^#]Y\-&FG^,?@
M?2KGQ%=:/XC\:Z+XHFTOS7_@G5^U?XP_:=TO^W?VE_VQSX;^/^C_  \\%Z-X
M-_9 TKQ9\#O#^C_%_P"'OC;]BGX?_&?2OC9J?@N7P:/BE\0=;^)D7BSQ/\6Y
M==\$:_HGA?P5+X)O/!FA:79:+X/^)$7BH ^U_'7[&_B[]J#Q/^S)^UI-^TM\
M/[/X[?!/X3_%V3X$_&'X(?#*?4/A-)KGQRUWP-JWA?X@V'A7Q+\7_'-CXZ^'
M%]\&]!U#X:^,O"]WXKO/^%C:/\0-9\>_#WQQ\(/$]AX+U+PY]D^ ;?XX>(W^
M.^E?&"#PGHWA^X\7IX7^"\OAO3S'?ZC\/(_A5X&L]=\9^*(/^$L\1I#J'B#X
MMW7Q+NO#_A_[99W>B^!+3PE9:M)=:U)J-_+^7'_!,*3XR?#.T_89^&7BK]H+
MX@?&'P%\:_\ @F!X8^-0\(>./#OPJTK1?A7XF^&D?[,'A?P_HGPON/ /P]\'
M>(K?PD?"7QBN="O['QSKWCG6-0E\*Z+K]YKLVOW_ (AU#5O1/VE/C5\1?AW\
M?/VSO'WB/X[_ !W\(_ 7]E3]COX)_$73_A5\#/#7P%O-3U3QO\:+C]K#P5K_
M ,1-5UKXO_#CQ+&DW@"V\'^#?%WAP>(_%N@?!_P[J?AV;Q=\7M,U_P %:-J-
MDH!!H?[#]W\%OV<]#\-_M/>--5_:C\"?L_?L&^-_V%_!_A3X"? /Q;H/Q#\=
M?"CXJ67PN\+?$&\U;P;8?$'XLZEXG\?:[X<^#WPL\.Z(WAQM%TOPXEAXW\4:
MJ\UGXG\CPA[U^P+\'O$_A?\ 8,\'^ _%7Q6.M?&KQ]I7Q;\2_'/XN^ ]<\*Z
M[JVE?M*?%GQQXW\1_'&71_$&C1ZKX8NO$/PF^+/B#Q/X&TY&@N[31)_ MEH-
MUI\46D/IL/X]0_&WQA\8!\,-<^*O[<FO^&OAM^S5_P %1+/X;K\>/"/QA_9=
M\9^%;#P/X_\ V ;GQMHW_">_&JU_9J\"_"7Q!XA\'?%'Q-J_PRL]3L_"Z:1I
M>I?$G7OA[KVJ^/\ QMX=\+>-M,]O3]JSQFVK_"WP%\9/VR8?V%_@[KT'_!2/
MQ_8_';1E_9J\'W/Q%^(_P#_;O\4> = ^%L]Q\:OAGXP\#VECX ^%MY9>.-7T
M+1/#MOXT^+ROJ>HZQKEUIOA;QS'XA /O3]AS]@OQ5^REX_\ 'OQ+\:?$[X>_
M$#Q-X\^#7P3^$.KW'@;X3>+/ NK^)K[X.:O\3=7N_BW\4_''C_XU_&KQO\4_
MBG\1;CXD2+XCUW7=8M/L%EH&CZ=:_;C%<7]UM_%7]A_Q9XO\(_M!:1X'^-C>
M$-7^.G[6'@3]IN_@N?#/B1/".IZ-X2^'7P4^&VM_!#XEV7@OXD>"?%WCCP#X
MVTGX0O=:]+HOC/P.;W^V=/T+7=)\1>%-*UW0?&3;']J#Q3HO_!+3PE^UG\;D
M\=>&?'.I_L<> OBI\2+OX1:!X,B\=^%O&/C/X8Z%J.N^)?"6A_$ZUU3X;>&K
MWPUKVN2^(S_PM"UU'X<^![2PN+SXAF[\):)K<DGYN?!?]HK]I/\ : \0>$?@
M)H?[8_B6PT6?_@H)XL^">H?''X2^*OV;/CAXTU3X-V/_  3FO_VD'^'UC\4]
M/_9L\,?!S5?$6D?%*"ZTS6O%NA_"O4];\)RQ:CX,C\7:_P"(?"Q\770!]?>"
M?V#]6_9:\$?"OQE%^T%\"_ ^C? :^_;4\4_%[7=6^",GPV^"FE_ W]JWXGZ1
M\</BII7@OP_#\<;:R^"MC\);/P7I>F>#O%GBKQCX[\/:/X8TV_U'Q;I.H-YD
MT?,?!K_@E=\1O@GX \-?L]>&_P!HWP'>_LS0?&C]E7X_^-?#%]\ _$:_%37?
M'O[-ME^S_JFN:1X;^("_'Z7PUX7\&?%WXG_L]^'_ (BZI97_ ,._$^L>$K?Q
M1XS\&V&JZW9:AHVL>'?S!_:Q_:P^)OQ$_9+_ ."A6@_'?]L3Q#\*9/A3^Q5\
M5_AY\.? \>F_ ;3K']K35+SXW_MN_LI>+_&GC/2+SX7IKFI>)OB!+\(?!'A#
M4/#OP?O/ VB?"O6-57Q=IVGV=OXKTN"T_H/_ ."C'AG7O%_[ _[9.@>%_$7B
MWPOX@N?V:?C+=Z5J7@==(;Q+=76D>!-;UA?#MFNMZ'XBLVL_%Z6#^$M:6WTU
M=:;0];U(>'-4T'Q"=+UW30"#]H[X-WGQI^*GP1\9?!CXO?#7P-^TA^R7XGU/
MQ[;Z=XT\,7WQ2TN?X<_&_P"'WQ ^%^L^&/'7P_\ "_Q-^&7BC0])\<O82:_X
M+\9C7(A#XH^%CQVNG^(--MO$FE2<W^R+^Q1JO[-'C;QK\2/$GQ7L?B5XR^)G
MA'4++QY/I7P\F\ Z/?>//$W[3_[47[4'C'Q7H6FW/CSQQ<Z-X>OM?_:;OO"G
MAWP==:EK%WX>T+P;ITUYXM\076J3+8_DAKNL^/-$?]K?]IK]G/\ ;L^(OBS2
M?V??^">W[)7Q5T+Q5X97]FSQ_P"&OVA-?\(^./VW-7;1/BOXBT[X07NE:GX3
MT"/0M<^&K:-\*6^&]];)=ZE<:_J>H^,- TC4]*^MOV#OVC?C=\9?CY>77C+]
MI?P+XFU^_P#%/[5WA+X^_L<ZY\1?@6/%'[.5]\)/C%>>#?APOPG^'W@3P/I_
MQC:U\(V&F6/A?XB:W\6/%>M:?\0;'Q_X;^*6C7.AVMYX=\/Z@ ?ME1110 44
M44 ?F#_P4S_X*8Z#_P $\?#OP9T70O@KXX_:6_:*_:6\;W?@']GOX > KT:)
MJ7CS6-%F\/\ _"47NI>)3HWB6;1-)T.'Q/H-LK:;X7\3:KJ&MZ[HEDNE6NCR
M:WXCT#Y$N_V^?^"Y-CI=SK-Q_P $+=*DLK.PFU.>"R_X*#?L]W^K26MO;M=R
MQ6FAV%M=ZW>ZBT2,D&DV6FW.JW-R4L[>QFNW2W;(_P""B7_*;_\ X(3_ /=\
M_P#ZIC1J_H0H _-__@FG_P %(? W_!1SX6>._$VG?#3QM\"OB]\%/'UW\*/C
M]\!_B*T4WBCX8_$33K99;W31?+9Z3=ZKHIO8M6T:TU#6?#GA#7_[9\.>(=/U
M;PGHT^GJMQ^D%?S2_P#!#S_E(5_P< _]GQ:1_P"II^T?7]+5 !1110 4444
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MX6N_#^K>+M&U:#6V_6BOYI?V8?\ E:#_ ."D?_9COP>_]-/[*]?TM4 %%%%
M!1110!\&_P#!1S]OWX;?\$WOV;-0_:"^(7A?Q-\0-0U+Q7HGPS^%WPR\'B*/
MQ!\2_BOXLLM8OO"_@^UU"XBN(-&L[BST#6=6UK639:K=Z=H>D:E-H^@^)=<&
MF>'=5_/31O\ @H#_ ,%PO$VDZ?XAT?\ X(46EEI6M6D.IZ;9^)/^"@/P"\-^
M(+6RO$$]M!K6@>)=,\/^(-'U.*%T2]T_6=#TC4;:=7BN].LYE:!,S_@OW_SB
M6_[2\?LG?^[=7]"% 'Y+_P#!-W_@J9!^W%XS^-_[/_Q;_9W\?_LA_M>?LW_V
M+=?%GX"^/M5M_$2)X?\ $<LHT3Q1X1\3KI/AF_UK3)K1]%U#4?MWA32;2WM/
M%GA:[\/ZMXNT;5H-;;]:*_FE_9A_Y6@_^"D?_9COP>_]-/[*]?TM4 %%%% !
M1110 5\-_LQ?%K]HSQUXP_;:\(_%^Q^%$OBSX*_'73_"'PN\/>!-0\26GA"T
M\(>(_P!G[X1?%7PAHGB3QKK'A]_$&KZO+=^/9/\ A+/%</@FUBMKRYO8]"\*
MS:=IUA;W/W)7E7@3X0>&OA[XY^-OC_1;[7+K6?CUXX\-^/\ QA;:I<V$VF:;
MK/A?X5^ /A#I]MX;AM-,LKJSTR;PU\.=#OKR'5+W6+J37+K5;F"]M[">TTRQ
M /#OV&/BG\9?BY\$]=U[X_7'@:X^*GAGX]_M+_"WQ&WPUT_5-.\#1)\)/CU\
M0?AQI5KX;BUR:;6[G3;/2?#5E:PZGK!BU35A#_:5_:V=U=2VL/V-7@G@_P"
M&D_#WP/XE\$>!/'OQ#\*Q^*OCAXT^.VI>)+"X\&7GB--:^(WQROOCIXY\'VK
M:UX*U70H_ _B34=7UKP%=6\NA3^*;/X?:Q>0:3XKT_QG%I_C2R][H **** /
MSS_;<UC]I7PCXE^ ^J?!7]H&Q^&'AWXE_&/X7_ W7/"]]\(/"/C[R;CQE?\
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MK/C'7(/&MUX^\%V?B7P?HO@V#P7)H'A[QZ^E>.X=>T"+%T#]K[XP^'?VDO\
M@H!X^^,7@_XSZ!^S/^R1>^"/AYIVC6UW^S7-\-=&\/7&@_"#Q_\ $#X]:_<:
M7XCN_C7J&L6_@'X@W?Q;DM]0U6W\(^%/@;X9U'3'\+)\:=1O?"EO]2?$#]B7
MPE\1=3_:MCU3XH?%+2_ G[8W@!O"'Q9^&^B?\*XBT.T\2GP%X6^%:?%#P?KN
MI_#S5?&FD>,(_AWX.T3PTNF:EXDUOP&_DR:M-X/EU9UNX^E\>?!K1_!'A/\
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M%K"9[[1/&NC6NE^")8KB&WTWPM)<66O6OB35GCUN+$\ ?L2^$OA;XB^%&K^
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MA\4>+8?AWX+\8-X \ :AI7C3Q:=-TG4[$SGB;]BK]GCP5\%-:\-^,OB-XO\
M"7PS\-?L%7G[#OB+QGXF\7^!]!MM ^ FG>&GT;4/'>M>(M5\*VF@:5XYL=)C
MDO;SQ/?00>#+:1'N)O"26RM$.IUW]BS1I_CPOQY\#_&'XC_#+5-;\'_";P1\
M3_!WA_PK\!?$WA/XJZ1\&-8\17_A"_\ $,OQ+^#7CCQ7H/B2ZT7Q7K7@?Q'K
MO@?Q-X8N=5\''1K2"/3]:\,>&]=TL YT_M[^'XOCOXS^$-S\"OC7:^"/A_\
M'7P3^S5XK_:*N'^$MO\ "'3_ (S?$SPA\-_%OP^\+6^G7/Q2@^+6JVVOM\4?
M"7A:YUW2OAE>:1I/BWQ!X>TR>YEM;[5]0\/;W[$/[3'Q5_:;\)?%/Q!\4O@/
MKOP2N/ OQR^,OPPT-=4U[X>:S:>(-/\ AO\ %KQ]\/Q9!?!'Q)^(5Q%XH\)P
M>$K+3/'=]>G2?#6L^)KJYO?A_)K'AGRKR+L-6_9"^&NL_P#"?_:M<\<Q_P#"
MQOVJOA#^U[K?D:EH"_9?B5\%O^%(_P#"+:'I7F>&9?(\#7__  H3P?\ V_IM
MW]NU^Z_M+Q+_ &=XFTK[9I?]C8_@_0/A%^QQKWBZ/Q?^T7'H/AO]I3XYZWK_
M ,,?AI\6/$/PL\.:;I?Q<^*?B7Q+XY\=>%OA!=V_AWPOXX\97OCOQ7XBU7Q3
M=>'O$>O^.[_0K:S<Z"=&T*UU!7 +?QV_:QM_A%\1?"OP;\$?!7XL_M&_&#Q)
MX(U_XJ7GPZ^#MW\)M.U?PK\*O"VO:%X;U7QOXCU3XP_%#X5>&X8]3UO78="\
M%>']/UG4?$7B_7;34K>STZVT?1?$.O:-\H?"7]K7XG?M,_MS_#>Q^&NE_%S2
MOV0O^&//A-^T=H>L6(^ %EX0^)C?M&Z=\0[CP?XK^)MEX@U75/CWHNE^&(_!
MUSX+\.^"O!=CX;U>'XGV7B#6?B)I\_@;3_"FJ:S],?%/]G#PU^T5XO\ AE^T
MI\(OVB?B'\'_ !A!\(?%G@#0?BW^S_)\$O%5A\2?@K\7KSP3XUA@FO/B?\+_
M (N^&=8T^QU3PEH'C+X9>+?#D-G-I%UJ.K7%O>:OH/B75M,U#L/@9^R9\+OV
M>=3\-:A\/+GQ3'!X2_9G^!/[*6AZ3J^HZ9>Z9;?#3]GJ[\>W?@:^?[/HMEJ$
M_BV];XAZS%XEU6;4&T[48[32WL]&TRYCOKC4 #B/^"@OQG\:? +]F'6/B-X!
M\22^#_$7_"X_V5/A_)XJMO %]\5-1\/>&OC+^U;\%/@YXXUC1?AOI=GJ.J^-
MO$-AX)\>>(;GP[X;TK3M1U75==CT^UTW3[Z^>"TF\_TS]HBZ\*>#OV2-=\2?
M%KXO?$2'XE_$+XW6.I:K'^S5)\+/$7Q'TWX>_!/]H'XB2^'?%GP?\;>'-$^)
M_@J'1D^&S7GA5_!?AVW\5^./$/A_PI$D-]X-\8:C/=?5'[0GP.T?]HGX92?#
M36O%WC3P$D?CWX.?$S1O&7P]?PBOB[PYXR^!7QB\!_'+P%J>EQ^/?"'CWP?=
M10>-_AUX>_M73_$'A'6[#4M';4-/>VC>YCNH/!?B;\-OAQX9;]G2W^./[8?C
MFP^*&@_%KQA;_L__ !"\>ZS^S7X/^(?B_P"*_P 5_A%\1?@QIOACPUX7TWX,
M>&/AYXYUWPYX=^)&N^(_"/AS3_AMJ%W)K>D:=J?C"V\4^&+#6='OP#S^#_@H
MW::O\)?V?_B=X._9D^-7Q U']J7XC:K\/O@3X$\">./V7_%6H^,H;'X4^+OB
M]%XVN/'&B_M 7OPGT#P?:>'O!'B;2?%$FK>/H?$'A[Q-X>UW2[?P_K<$>@7W
MB/K_ !9_P4 \":3\,?@EXT\'?"_XF?$3X@?M >*_&W@?P#\!]*U3X0^&?B-9
M^*/A2GBQ?C+8>,]>\;_%'P[\)?#5K\)-2\%:[X:\8ZROQ(U+1IO%K:'X=\+W
MWB.^\2:&+V#X*_\ !/+X:_!WQ=IWQ%E^(?Q&\;?$&W_:+\5_M/:OKVH:=\*/
M!6C>(_B3XP_9ZU']FK5SJ'@/X5_#/P)X'T_3[OP5JM[XEU6]\/:#HWBSQ/\
M$:>7Q3XL\3Z[!)_8ZY]S^Q3\&_B-\.?A3!\(_C7XOT+4?@E^T+^T)\7_ (?_
M !C\#3?!3XC:Q8^-/BQX]^-5M\>/AKJ\7C/X;>.?A]K'@Z/Q+\2O&_@[6/#$
MWAF'Q)X9UKP9X8-SKUOXU\%R:I* ;'A_]OSP;\0/$W[*WACX0_"3XL?%2?\
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M[\ ^)/AY\5/!MG\.?AKXDB?P[H>I>!)/ OBOX@>(-#NKSQ-X7^)G@?Q!XA\
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M-1^&5GX ^ <'QP\2W/A?X<GQM:>*OB#X=\>>()9Y;>/Q+XO@^'7@SQBWP_\
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MW>JZ*;V+5M&M-0UGPYX0U_\ MGPYXAT_5O">C3Z>JW'Z05_-+_P0\_Y2%?\
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M#_X*1_\ 9COP>_\ 33^RO7]+5 !1110 4444 ?./[77[4GPO_8J_9O\ BO\
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M2R6MTD7RMKW[ OC?7_[1L8O$_A;PG:>*/V^OCI^U#XG\0>#M9U[1_&$/P_\
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M%<EQI'A749O"$&K7NK6DT?B_2&L'=_"_V/\ ]E[]IKP#X[_98U?XZ>%OV?\
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M1*** "BBB@ HHHH _ [_ (.%/ /Q4NOV9/V;/VCOA;\/=8^*R_L0?ML? _\
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MX<?$+X&_%3XE6WQLOO%&AR:GXJ\5?"OQ#\(]*N?">A>#M(EO=7M-$T+3_BM
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M$@4 ?@5;?MA^)O MW\9T^'?[=:_M6_L]?"+QM_P3&\8>+_VF=:O?V<_$-OX
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M3WCU-M^I1M96S)J#[0N^^0Q%;MMJJNZX$AV@#. !5\         #  '   X
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MP_JGQAUG_BC_  3X<T;Q+KEUX+MXM;C\2>*-2\-76A:UI_@3PQXQ\0?VL/\
M@H!\6?V5?VH_C+X,_P"$<^'OPY\0_!;]N63P7JFB?"3Q#HOQ#_95\0_LV>(/
M&6@>&[+Q;XSO/CW93_$7QY\0=!^'_CSPOK6J>#/!WA"7X&_&V3PS>6&D>/?"
M^A:J^H_L+\-/V1OV5O@QJ[:_\(OV;O@7\,=;.L1^((]5\!?"GP/X3O[76XM-
M\8:-'JNGW.AZ)92Z;?)I/Q#^(&FK<6#6T@L?'7C*UW>3XGUM+Z?0OV4/V8/"
M_CGQU\3?#G[//P5T+XA?$^#Q3;?$;QGI/PR\'6'B/QS!XZFL[GQS'XKU6VT>
M.ZUT>-KG3K"Y\8G4I+AO%-S96MQKQU":")U /RW\0?M'?'3X&>./&7A](_@W
MXU^//CKPS_P2^^#W_#0L_P *O&.D>#K34_VF_C=^T]X)T3Q9\5?!-G\9-1UK
M6?!WP_L[:TTKP=X;TGXBZ!J/BKXE^,FL]0\8:+IWC"&3PM#I'[5?_!0'Q;^T
MCX^_9)\-_$?]E2R\4_ +3/CIJGCSXU:E^SY\2]8\.?%&+X8?#_\ 89^)?@S2
M]#^&MA^TEI$_@#6]07]K'4?!OQ.NC\0O&5A;'PG<:MX5TW1=1UNVTKPI^HUC
M^R)^RKIOPXUKX/V7[-OP+@^%?B30=&\+>(OAW_PJKP1)X-\0>&O#GB;7?&GA
MOP_K?AV71'TO5M&\.>,/%'B3Q5X>TW4+:XL]"\1:_K&M:5#::CJ-W<R]#\.?
MV<?V?/@_;6]I\*?@;\(OAO!:V7BK3H1X(^'7A'PQ(MCX[U#0]6\<VSSZ/I%I
M/+%XUU;PQX;U7Q>)I9#XGU/P_HFH:X;Z[TJQF@ /E#XI?MB^.HOV.OV7/CQ\
M+/#?A_1O&W[6VO\ [(GA#PQJ'CS1]7\5_#[X0WW[5>I>#;*T\5?$'1?#OB7P
MAK7B/1_#<GBF/0]+T/2_%WAF7Q3XVU+PKX>D\2:#::Q<:S9?G]^T+>?M'?M-
MZ_\ "#]FCXJ>//V=?$</PB_X*<Z)\!OB/JUU^S=XB\2?"CX\#3OV&(/VPOAK
MKWB'X5:U\?IHM)G\!:MJ]QH?C/P)-XN\4Z#KWCW2/"7CBPU'PU8^'[[X>:C^
MY?B/X+?![QA\+3\#O%GPI^''B7X+'0=$\*CX1Z[X(\-:K\,T\,^&CI[>&_#T
M?@6]TR;PQ%HOAUM(TE]!TR/3$L]&?2].?38;9[&U:+(\"_L[_ +X8:#X>\+_
M  Y^"?PG\#>'?"?C'4/B)X8T;PI\/?"FA:?H'Q"U?2=5T'5_'^DVVFZ5;QV/
MCG5]$UW6](U7Q?;A/$6I:;K.K6-]J4]MJ5Y', ?%?[4=_P#M"K^VY^S5X<\!
M_&?0O!_P<\0?LU_M6Z_XZ^&FI?#[7?$0\87W@#Q-\ !JLL^M67Q1\+Z3%KFH
M^'?&T.F> =5OO".LO\.9;/QMJ367C"'QK_9_AG\]_@5^U[^U?^R#^Q1\';OX
M@3?!GXO:)_PZ;\-_M)?!KP]X,^&?C7P-/\+I_A5I?[.OP[T_1/BGXCO/BIXU
ME^(W@NRT+XS^'/&OQ(\9:#H'P^U'3[7P3X[U'0] MM/U/1=&T3]]?B!\&?A)
M\5[[P3JGQ.^&?@3X@:G\-O$L'C'X>ZCXQ\*Z+XBOO!/BJV\OR?$'A:[U6SNK
MC0]57RH=UYITEO-)Y,'F,_DQ;&S?!7X-W.BV/ANX^$OPSN/#NF?#/5_@KIN@
MS> _"TNBZ?\ !OQ!::+8:]\);'2Y-*:QM/AGK=CX;\.V6K^ X((_"VI6F@Z+
M;WFE30Z78I  ?.WP*\3_ +3UUX+^.?AK]I.QT;4]5\'@S_#WXP^$?A]/\']
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MJWAK3CH_AK68_&=UHLNOC6O#>CL^C^'M8^WG4]#TF6;3-+NK2QFEMW /A_\
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MXFM/&]Y^U/\ "74M9\2?M!7_ .U-\8?!WBO]F#QEXB^%?CSXRZ!X0^&?PW^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"TCKFK>"=.\._!+7?B!HMSH=QH_BS1[OQ[HVB:EXHT[P??:3?>)=,U>&(
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M#X&\/W?[/6@W'[8?[5?[.O[4?P]\'_M4_$?X>ZAXI_: _9!\,67B'XA>#O\
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MUBZT-]$O+'6/"_B7Q!HNJ:-XIUG4=?\ #=KX1M8[34=^J/=+9K^?7@3_ (+
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M/Q/^/,_PX^'?Q+^!_P"S%XCT_P"'_P 0/BCI'B*R^'7B2UO)_'WQ8;7OAO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC]F+1]7UKQ0+#X26?B6/XRZ\_B""RTBWT*/0O"&I0M=^(K*&2[8V>H_9I/\
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MA0G@]? 4?A8^(GU<^+@\7A5(].A\0#7QXGAFCCU6+6DUA%OQ[510!^<WC/\
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MZ[NK*;VGX=?LW?!?X3_%?X[?&_P!X,_L#XH?M+ZGX%UCXV^)_P#A(O%>J_\
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MH7]E<:G<:EMTR.[6QU)[, ]0HKRWX+?%_P (_'?X6?#KXM>"VO+?0_B3\//
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M3]!: "BBB@ HK\C?^"J/PJ^%UWI/P-^,GB7X?>)_'/BC3/C?\,_!FIZ/X/\
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M^-2_\*M\':A=_ *5/A'I&LZ9\3M9N_'>JZKX<\4:G?6>D6L^H@']-]%?F_\
MMF_M:?%#]F[QO:^"?#FF^$M0OOCU\)%\)_LN7&MZ5JDUG!^UW=?&3X>_"+P[
MX9\>RVNM6+:[X/\ $W_"_O 'CHZ+HG]C:UH_@7X*_&[7[C69+(0SZ#X)\3/V
MO_VN;C7?CMXN^&WB#X'>!?AU\'OVT_@_^P=9_"_X@?!;QOXQ^+&O^)?C3XC_
M &>O MI\<F\7:7\=?!&@I#H^J?M :+\3?!/PNM_ IM/&GPJT2:/6O'^@:GXV
ML]<^'0!^S=%?SM_ +]IW_@H5<? W]D'X7>#?''@+XG?&/QM^Q-K?[6T_CGX@
M_ _QOXENOBA#X:E^%OA+P[\!)=17]H33);7Q7)XF\6W5U\8_C[JNHWO]A0>+
M?AX-*^$TDFI:G<6WZY?$/XZ>-/"OCC]AW0V\-VOA&U_:4^)_B'P1\0?#WBT6
MU[XB\*2V7[+/QN^-UEX7L-4T769-!7Q78^*?AI9:;J,UK-K^GW^EV&OKI8D1
MH=4M0#ZRHK\6/"G[8?[4_P ?/'7P4^'GPI^)_P"SE\*A\1O!'_!1CXA:EXY\
M9?"CQ-\4=,U/2OV1_P!LGPC\ OAA8^%]/TOXW?#BSMK37/!?BF'Q!X\UZXUC
M7%O;;3]2NO#NG:(+VWO]$\]^"'_!2/\ :B^.WPW\,?M7V>B?"'X<_!R+]H?]
MCC]G#Q/^S'XG^'?CC4_CCJU]^U+%^RM#J_CG2_B\/BEH.AZ'=Z'/^TI8>+_A
MSX3N?@MJUMXD^&>A_P!H>)M:TW5/&%O<?#\ _>FBOR7_ &>/VIOVI?$GQ(^$
MVK_%[7/@IJWPF_:)_:4_;%_9T^'W@7P'\+O&'AOQW\/O^&;/$W[1D_A'QGXH
M^)6M?%[Q)HGC*7Q;X6^ .N6/B?1-.^&?AB&QU+6/"T^CWD:Z;XADUZIXY_;F
M^)NA?M>^&_ _@;6O#GQ!_9_\0_''QK^S-XDD/P'UCPI_PK?XO>"OV7_B3\:[
MOPY9?'#Q!^T);/\ %KQ5#XI^'DZ>([/P-^SO/X'T+PIJ5[X7U'QII'C_ ,"Z
MC-XP /USHK\L/V%_VE_VGOB-?_L]Z=^TMKOP8\47?[4O[&.G_M>^$8/@]\,/
M%WPYA^%QTZ?X*Z=XC^'VN:CXK^+?Q*;Q_%>P_&SPQJ&F^([32O!<L&K:1XM$
MNF'2=2\/Z;HGS!X]_P""GWQG\$ZG\<_%GA*?P7\7/@Q>_LR?MI?'3]G/QS?_
M  $\1_"'P[%K_P"S#\0/AAX*MK74-5U;]H[Q;XZ^+GPK\+6_Q':]^*OQ(M/A
M+\(=)\0IX;?Q9\*-4U'P[XJMM%\* '[W45_/IK_B;XH^#_VQ_P!H32_C5XD^
M!_Q]\8Z+<_\ !"3P(=;\._#7Q#X!T73K+QG^W=^UK<:=JVI>!Y_BGX[GT+XE
M>$+GQC-XH\)W\/BZ[T@0P^"=:OM"NM^H6E]'\4_^"DO[7O@+X"1?M:P?\*'_
M .%>?%+Q9^VI\./ GP'U3X5^.M.^*7P3U+]E7X:_M;>/-.\6?$SXAM\9[K1?
M&UW!>_LO:CHWQI\*6GPY\ Z;X4E\2V=MX?\ %#2^$[Z^\=@']!]%?E/^TS^V
M%\<_!_Q,^-7PJ^!]Y\(%U[PEXB_X)G^#?!^L^./#>O>,M)\/ZU^VC^T=X_\
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MB_XH_:4_X*!^#/$?PR_9R\167@33_B)\8?C)KWAWP'^U?-^S?X@;X<ZU\/\
MPU\!-?\ B_KOA^Q_9PMOVF+GQ3;_ !=M?%/A;Q!X9L(M:^+UCX7OOAQI&J?$
M&T.I:WI-[X7/SI\8OBU^V?=I^V-XL^.]Q\.-+\)^%_\ @EIX'^)/CK]C[QA\
M.=?\0>#)O&US>?M2>"_%$-EXCT;X[/8KI/BKQGX _P"$QO-:703XDUKX3:UX
M"^&NLP>'O$?A&\\5ZL ?T5T5^0'C#]KK]JSP9\6/CQXVEG^$7B#]G?X-?MG_
M  =_9&TKX-:'\+O%4WQP\<_\+G\"?LZ75IXNM_BU=_&+3O!ND:OH7Q!^.>GV
M^E^'I/A9?66I^&K'7;?4=535-0T.^T&+]CK]J[]J'QY\9_V9O#/QQ^)O[-_C
MKP-^T_\ \$^O&?[;EI8_"CX8^+?A[XA^&6I6?BK]E33=%\,W.L^(_C#\0[3Q
M9\/!IGQN\6Q:+XNN=#\+:QXAO=!N)[VRTY-*DMKD _82HH9X;A#)!-%.BRSP
M,\,B2(LUM-);7,)9"P$MO<12P3QD[XIHY(I KHRC\?/^"R7C7QKX5^!'@Z?X
M8WG@O0O&NI:3^UA?^'OB)XC\+ZKXMU;P%%X1_8)_:F\?ZQJWP^CTGQCX.72/
M&/B3PYX7U;P-IWBB]N]8LO#UKXJN]:/A[6Y;*+3[CT/Q$GQ4_8L_8(_9]\ ?
M $?L_:1\01\1_P!E_P"!WAB[A^#&N^$O@;H5A\=_C]X(\ :CKA^#WAGXI+K[
MR:/H?CN\U?4K>W^*<&H^+O%=M?:Y>:UIUSKDXM #]1:*_&/Q!^V#^UC#JWA#
M]F72-9^&8^/5U^U?\2_V</$W[1-M\ O%NO\ PTN-*^&_[,'A_P#:DL;_ $#X
M$P?'C3M63XC^-/"WC'1M"71[[XQKX>M+?P;\5?&]C$]KI>A>$IM3P!^U=^VG
M\3?'?C[0?$O@SPY\ M6_9&^!WP6^+_QW^#DGPVD^*?Q"_:4USQY8_$F_\2:-
M\%=5LOBUHNE?#[X>ZJGPJ\2^&?AKK5_#XW\6W/CK4(?^$HM+&T\%ZIX7\9@'
M[$45^(/@G]J?_@I1XC_9^L_BY9_#WP/\3])^*'PG^!/QY\+>.OA#\#=7GD^&
M_A3XA7BWWQ3^'O@[X3>)_P!HZW\0_M)^)_!W@;6?"_BSX:^)K'Q%\-7\:V,?
MC6[?P'JGB;2O!_PK\=:/C[_@HMXJ\ W'PY^)7B[XS?#GPA^RU\7OV=M*\0?
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M4H[S3)?#WC#4-:UZ"\G@\+>/M3M]7U&;P;JMC#X6ATS5/A[&FKZ=XCO?WQH
M**** "OX=_\ @\S_ .<;_P#W>!_[ZY7]Q%?P[_\ !YG_ ,XW_P#N\#_WUR@#
M^J;_ ()B_P#*-C_@GK_V8[^R;_ZH7P#7W%7P[_P3%_Y1L?\ !/7_ +,=_9-_
M]4+X!K[BH **** "BBB@ HHHH **** "O\Y7_@[U_P"4D_P1_P"S'?AK_P"K
MZ_:7K_1JK_.5_P"#O7_E)/\ !'_LQWX:_P#J^OVEZ /]&JBBB@ HHHH \I^/
M'@[PW\1/@=\9?A_XR^'VN?%OP?XZ^%/Q$\'>*_A5X8UFQ\.^)?B;X;\3^$-8
MT37?A]X>\0:GXN^'^FZ%KGC/2[ZZ\.:3K.H>//!-CIE_J5O>W?B[PW;P2:S9
M?%7[*5E^T'\/[_XZ:]=?!7]H[1O@AJOB#X&Z/\#?@M\>OV@_#'QP_:!LM4U+
M6M4TO]H#XM:IX\\<?'OXIV_A[X6VNF^)?".NZ)\,M5^-GB+Q7:6'PM\?ZAX1
M\)VVM>./"_@"Z_2NB@ HHHH **** /RD_;M_9M_:)^,&L?M(:G\$+:XL-2\8
M_P#!/[Q5\(/!6M6OB;0= F\1_$AOB>?%\GPK%[=:WIVK>&$^(GA6"[\(S>.R
MMAIOAB'Q')JL.N6FI:='Y;/V1?@OXK^&7Q(_:N^(?P/_ &-;+]B_X<>+?@5\
M _"_PF^ OBE?@CX*\->,?CW\.G_:"U#Q=X_UOPQ^S;XZ^*'A?PCIM_IGC7X.
M_#36/%$<L7B?Q18^!);W[%K.A^'_  C?W/L>O_\ !0/P1HOQ/U_PC9_"#XQ^
M)/A5X)^.G@3]F/XA_M+Z%_PJJ3X0>"?CU\2-<^'_ (6\->!K_3-0^*.G_%[5
MK&Q\6_$SP?X-\:>,?#GPPU?PKX/\6ZW;:5?ZE-!I'C74/"'-?\$\_C%\??CU
M+^T]\1_C=H'Q3\&Z?'^T-\2/AS\-/ ?C2Z_9\N?!O@/PQ\(/B#X\^&=YX6\&
MS?!O5?$'B_5?$UGJ?AF2Z^*7B3XF^(=:L=7\27MI:_"Z_N?!6DQW=R ?E#\.
M_P!B#]H^;PW\5;W6/V-8/"/P_P#&4/\ P3+\4?%3]FC2_A_^Q'\(OAS\7_$'
MP _:5\:>./VC_ 'PZ^%/P>^(WB#P]+X%\*_#W6_#E[X9N_CS\0]7\4_%J3PI
M:?#W5?$>K^"[?0[4,\$?L-^.?#7[2GQX^*GQ0_X)?W?Q9_9#^(GQ&_:"O_@K
M^R#;G]CO7[+X9>(-9^#?[$/@CP;\;H_ WC;XV:%\._"C?&FV^$_Q;\(!;+49
M?&/P333;;3_[%\.^$_'>N:H_UM8_\%&OVJO$=[\"M6/[)WQ5TF[U[]NO]IS]
MG"[^$OA#5_V<=3UGXP>&OA9\/_VM8='T1/$.O?&C4]!\%:E\,?$_PB\(^(/B
MUXOO?&/@C1]5O-&U=?AM+XW\/7\&@:Q]#>(O^"J'PUTGP3X"\3:#\#_CAXS\
M2^(/ /Q=^*?Q(^&.BS?!S3_''P+\ ? /X@7GPJ^+FJ^/U\2_%K0_#NO:SHGQ
M$TGQ%X5\*^$OA=KWC_Q'\2+WPMXFN?!%AJ^FZ-=WJ 'Y:6W[)WQ+U[Q#\2?@
M7XX_9ZMOC5^U?H__  20_P""=WP2\'_M#W]W\,_$&H?LN?M(VH_:@T!OB=+X
M[\8>*K'QYH\7ASQY#I7Q0/Q#^$T7B;Q?JLOP8^U2-=^+[KP):ZW^K'[$7P!U
M3]F'P;^UOX"^'O[+W@_X2^-F^-/QT\<_#OQC#HOPK\'?#+XYZ!X[^(WQ2\>?
M O2H]2^%FJ:KXUL?#_PV\.^(=#\%:UIGC'P7X:F\$6]Y-IO@73=6TN&4P_0O
M[0GQ\^&WP _9G^,G[:OAWP_X>\;)I/P2MO'>EZQH<=O:77Q3TK2=*U/5_A/H
M%YXOT_2]1U%O#&H:OXO=-)U.YMM3L/#%GXKUG7+>Q\JXU!;CD]6\8?%K]EGP
M+\1_VBOVL?VA_"7C?X9>#?AQJ6O^*_ WP_\ @3_PAZZ/XO@O]*&B67PJU&?X
MC>)?$^JPZR'N?"&G>#/&,_BO7O%_C'7?#UYI?BGPK;PS>&]1 /QG^%__  3\
M^./CK3/'_AWQW^Q[I'PW^%WQ8U+_ ():7_Q7^#Y\#_L;_!SX3:YKWP)_:G\5
M^.OVF]-\'?";X!>/O%T=W\+/"WPIU?2])M[SXM>+O&'Q(^)NBVMQX3MKSQ/H
MFC^%=-;V?Q%^PUXH\#?'_P"(>IZC^PUX;^/G[+FC6O[5VA?LP? WPS:?L]Z=
MX3^$WB#XI>"_V+/%'A[Q-X,\,>*_&'A32OAM8_$[XF>"OC_H]_XMT^VLO$OP
MVUG3GUF"STCPU\09=5OOLS6?^"F-UH7CCP_\%-4_8L_:ET_]I/Q=K_AO3O"_
MP"O=8_9@3Q#JWAKQOX!_: ^(GA+X@GQ[9_M%W_P?LO";Z3^S5\4](\4P7/Q!
M7Q5X:\3Z"=)@\-:Y'JWA2]\386D?\%:OAS<?"OQ1\8O%7[./[27PZ\&Z3^SO
M\=OVC/"EQXNM?@M-?_$O0?V9=7\,^&OC?X2\)Z-X3^,WBC6M/\5^%/$_BW2-
M)T=_&NF^%/#?CBW%YX@\'Z_J_AR.VU6\ /&_%O[./QZL?^"?7_!-7]FWQ1^S
M%X<^+MM\,_@O\%_ W[2GA'_A!?V8/CG\4?A3XR\ ?LOIX&M+WX2Z/^TCXQL?
MV;GU=?&CZWX!\1_$B_O_ !_;:5X;UR[M]$\+:YX<\3ZWXK\+_"_A']E#XI>(
M9O'?P,\?_LL6WCW]J[1O^"1__!/7X'>!?C!J%]\&?$FH?L??'^QN?VI_#FF>
M.IO'EYXHT[7-$3PCXIM_#_Q*?Q[\"[;Q#K-[/\%B]I'+XFE\ 6&L?N9IG[9^
MI7&A?&J+Q!^S5\7O!'Q8^"WAOX=>/]3^"7B_QI^SAI/B;6OA?\5]<\2Z!X0^
M(UKX^;XY2?!'2-!L[[P)\1T\9V6N_%"PU_PZWP[\1Q6&D>(9-2\#+XQ^?]"_
MX*6_"WQ6WPX\;_!#]E7XS?&;QS\<? 7QN\0^(T^%MU^S!>>(O#G@K]CCXP6O
MPE^($'C?XBWGQZTOX?>+]/\ #WB[Q_JDOPKM_ ?Q%\>Z7XM_X2,WWA>:WTOQ
M)J&L6P!\K^'/@->?$?\ :Y_;&U/P?^SE9S_%W2O^"GG[+GC?2OVT_L7PO@O_
M (??#'X5?!']C/QC\7OAW+XEN-?M_C%I<WB;X<Z%\0?AS;^%O#/A>^\%^*!^
MT-]DOYGT*;XG3:'YYH__  3F_P"%7?$_3?BI\5/^">&A?M;^&/B)'^W]-\2/
MAKH^A_LJ^(/$MM\7/B)^V-XD^(W[/OQ:\97_ ,7_ (E^!]#\6'QA^SSXAN_A
MUX9\2/KGB#Q/\!M&AA\-1V'A+3/&?CPVWZK:'^VO^SY9WEZ_@[PK?_VY\4/'
MG[)FH^&;/P]I7A2QUSXY:/\ MB:+H6F?#;XYZ7#;ZM;W6M^'-$\*^"OB0/&>
MJ^(3!XMTSP?^S/\ $:XT_2=5T7PWX;_M7=_:]_:8^*O[/?BW]E/P_P##3X#Z
M[\:K?X\_'+4_AAXJ;1->^'FBW>@:?8_"7XB_$"SLM';QY\2?A];CQ1K<_@Z7
M4["^N!JGAJU\,^%/&5EJLEEXFU;P/9ZR ?F_X<_8,_;!MM&_9C^$]SK2:1X2
M\9?L_?LK>*/VL_B,WB70M=U/P1^UY^Q7\'=?T?X=>*X;*_U.YUGXC>)/&7QA
M'[+7B%_%%K%JVDS>&OV-+BR\7:FEUXWT5]1]T_X):?LSZG\#M/M=3UO]G/XE
M_LN>-X/V??A!\,?C)X8O;#]F^U^%?Q=^*7@V;6IM7^*-IK/P=^)GQ&\:_$CX
MAVFJ7OB<W_Q<^(:>'==\>^%/&NAS>*#K/B;3);#PE]%?#3_@H'X(^)_Q%\!>
M&]+^$'QCTGX4?&3XC_$7X0_ S]I35O\ A54OPA^+OQ&^%>E_$S7/%6D>'[#0
M_BCK/Q6T31M2T?X1?$"]\!>+?&?PV\.>'_'"^%]1.F7D,&I^"KGQCZ)\;OVK
M!\,_BEX3^ WPV^$'CS]H7XX^)O!.J_%6]^'7@#7/AQX6?PA\)-#U_3_#%]X\
M\5>)_BGXS\#^&K*+5_$>H)X:\%Z#::C?:UXIU^WU ?9M+\.:'XD\3:( ?B!X
MV_8M_:_^*OB3]JO77_9/T;X9^,?C-^R-_P %#?@[\0I_AMH/[)/PF^%?Q,^(
M?Q<^*'PYUKX&-X4\4^%?'-Y\?_BKK_C;2- \6>-/%_Q=_:#U'PG9:7XCUZ\O
M-.\,?#O6/&'C7P_:_KG\%_V;M3_9F^*7[5EK^SC\&?AE\+O@YXD^#7P*U#X)
M>"/#=IX9\!_#'6_C[X;L_CGH_CV[UCP_X*MWUG0I=0T:'X#Z3XK\57/AT3:S
MI=G8RZ7-K6HZ-JB6_GWQ$_X*>:-X/^.OB_\ 9^\*?LO_ ![^)_B_PW\2]5^#
MNCZOX?\ $7[.GA3PMXV^)&@_"#X>?'KQ'HWA^^^)OQS\$:G8:-X3^%OQ"T[6
MO%/C/Q7H_AWPC9ZW<>'?!.CZQKWC+Q=I&AUTVK_\%,OA#I5E^S+XL;P/XTE^
M%G[4-Q\+="\)_$FZ\:_L]Z GASQ[\5OB'!\+K/X=ZY\-/$_QLT7XS:UXG\ >
M,;JTL/BS_P (!\.O&6E^"X;S[7#J&MV^A^-'\* 'Y*_L^?\ !-WXG^.?VG/@
MSXL^.7[#W@KPC^SQ;O\ !3Q7\9?A9XF^%G[$G@7X)0?%GP5^SW^WIX/\07/@
MO]G_ ."7C/XA+KO@;PAXP^,7P6T+P?XB^)^J^/\ XEZG?IINK'59O"?P\T#5
M='[FZ_X)@?&+X?\ [-^B^%OV>O@GX6^%'Q9U_P#8Q_;L^%WQ=U3PAJ7PR\/>
M)/B'XD\:?%OX)>+_ (%_!WQ=XWT_Q%97^K:5XL^'WA#QO\,_ WB/^W+S1?@9
MX5U5].L-5\$VL.F6,OVI\.?^"G7CR_\ "%U)\2/V2/B;9?%CQ3^TQ\??@3\&
M/A/X6\:_L[6^J^/K#X(>,_BE8>+]5OM?\0_M KX,\+I\)_#/P^LM-^*/BCQ1
MXI\/^&]>\?\ B+0M(^%D/BBU\2:,K?I/\#_C'X-_:"^$G@#XS_#^:]D\)_$/
MP[9^(--M]4AAM=:TB:4O;:MX<\0V5O<WD&G^)O"^LV^H>'/$NF1W=TNFZ]I>
MHV'VB;[.9& /QJ\&?\$^?!OQ%\3_  ':^_8YU[P!^SOIW[65[\7_ (F?LO\
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M!^:?[5W["'[0/[5GC?Q#'IO[!G@;X<VMT_Q*T'PE?6/PQ_8C\+>#8/@GJW[
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M&/[/WB/7/BQ\8?BEX^\4_LW?\%&)=$_9[\61_!KX;>*?V=+#P[X(\(07&O\
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MA36_$7P_T'3L:CK6L^'M-TS7+#[#IT.L7MOJWB+PUK\^B7'AC0/%<\/5S?\
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M;>,6\=64[W/@"_NKN[T[3+:R^)WBF[:\T>\UK1[./PKH?VC7GO\ Q,VE:?\
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MM6T$Z/XO\/VFKVVNZM+8?)_CZ7XTG]I[XFS:J_[93?M/Z?\ M_?LX:/\ )O
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M([C4]1^$.H_%K3M&UGQ1\(/A[XY\9>&='^)EAIOB#QIH#:PIL+?7?%6G:_\
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M:QXNN-?UO]G;X2>&/%GB3QCJ6M>)-3\&>%8[:RU32_$^IZYXKU7]/J* /&?
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M'?%F[6?"FH^!M1\7Z=:Z=9ZQG5? U]X4N]:AS?>%+G1Y)=(?UZB@#\Q/ ?\
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MCX._:%^&?AW27TJ;0?AY^T#I7P_T3PUX&N/B78V%]'XDM]8\):%;Z%K/P_\
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M9_\ .-__ +O _P#?7*_N(K^'?_@\S_YQO_\ =X'_ +ZY0!_5-_P3%_Y1L?\
M!/7_ +,=_9-_]4+X!K[BKX=_X)B_\HV/^">O_9CO[)O_ *H7P#7W%0 4444
M%%%% !1110 4444 %?YRO_!WK_RDG^"/_9COPU_]7U^TO7^C57^<K_P=Z_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7/\ @I1\:K7X4?L"?#'2O^"<WQ._9-N_VC/%EAJ_[;NF6VJ:+\1_&'[1^J>
M)-8EUKXE^,/B T7BSR/BGJ-[X$M_@9J/B+PSH5BVO2:38V^9:?L]?MM_ ?XM
M_P#!4+QSH?@+]HN;]NO]H3]@S]F/XA_!?XE^"]4_:*\4?"#Q)\;[#X'>+[']
MM>WT?7=)UV]^#UM\1- ^(U[J4/[-GPS\5*]U\-;[5_"&B_ 3PKX2\&ZB-,F_
ML.HH _ /_@B%H7QKT+5_VFX_&?B/]J1_A7J.C_ 36_"'@#]IGP#^U-H5QX&^
M)FIZ5\0(OC#%X3\=?M7:?8>,/&.MZOJ^GZ1J7Q6TWPJU_P"!?#WBVXL[OPW?
M/I_B*&-/C3X"?L(?MW>,/V4O^"S?AG0OB;\7_A/9_'+]H[_@I!I?PO\ V5O&
MWP4\!^$O#WQ=F^(]M9+X3^)VB?$SQQX/TWXG'0/BCIDK>#-$U?2/%B?#F:U5
M]8M"\D5_<'^L>B@#^1K1?"'B3]IA/^"+WPB^ 7[&'QZ_9U^*W[%MGH7C3]IS
MXJ^.?V:?BK\%/#_P9\(?#WX*MX8^*'[/.E>-?&_A+0[3XG2?M)^*[JXTFQ7P
MMK'BF[U:WAA\2:YL74/$MSI_G_\ P15_95_:8_9_^.W_  3E\4?M0? _]H+5
M/#&H_L9?M)>!?@[?ZO\ !;6/!5M^QA\5A\>/'WB/QUX)^.MK9^"]-UO2-+^+
MGPV?3M:^&7CCXP:U:7-[K?BB]\'>%])U*QDL]1T;^R6B@#^3;_@L5^R5XGU'
M]MCX\?&/0O@U^U/\2[#X_P#_  2(_:*^#/PZU#X+G]ICXC:#<?M8:9K6EQ>&
M_ /B+PS\,]6U7PSX0\(:]\)[:XU'3_A[XETK3/A+X]\=VE[XO_X177_BTDNN
MM'IWPC_X*1_LNV?[6GP>_98U#]L#QGHGC;_@D!\+_B[X)U[XR7WQ0\=V_AG]
MM+3M9MO!WCWPA\$_%&O6D>C^ OBW+\,+C7-5T7X.^$I+&ZM/%FG>#3;>'K/1
MM T33;'^LVB@#\ _^"(6A?&O0M7_ &FX_&?B/]J1_A7J.C_ 36_"'@#]IGP#
M^U-H5QX&^)FIZ5\0(OC#%X3\=?M7:?8>,/&.MZOJ^GZ1J7Q6TWPJU_X%\/>+
M;BSN_#=\^G^(H8T_([P_^R%\?_@#XQ_:+U.3X:?M\:%^R!XM_P""P7QH\,_M
M(Z-\)O$/[7VN?&WXF_L@-X%T:\^$7Q(\+):ZYKGCSXB_":;QY#J*_&CXT>!D
MUOXN^/\ P\NE:-_PGVK66G2167]MM% '\F_PY\ ?MK?$WX%?L':I\2?A]^T_
MXN\+^"O^"N_QA\5_!"W^,_@OQUK7[07PZ_8:LOA!\;?#/P;UC]I.XU329O%>
MF:I#JM_=6"^+/'T@>]TS6_!L":K/:ZAHJ2?!GAKP)^V]\)OV9/AWX1^+WPT_
MX*6>']6\#?\ !.3P._\ P3K\*?LI>#/VB?#EG\-OVRE\1^--/\3:5^T?X7^'
MNCVD\'Q(EUZ?1=42Q^+=M_PB$GP(GU_2K&PN?%6H6,2_W=T4 ?R?_M@_!O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=DR326S7$P!^/?@7]JG]M#P?X$_8A^*/B;Q3XI_:FU7]I?X\_$7P!?\ P/\
MA5\+O@A\.-7OM*\$_!;]JS58+&W\5>./%7AKP_IND_\ "3^ ? WCSQ'X@U+Q
MAX:O=(TOP9J6FZ5_PD3:Y)X5UOZ%T?\ X*Y?!G7+C29+3X2?&.V\/:#/X1TO
M]HWQ5JMY\&M-TO\ 93\3^,_BOXI^"MEX4^*MG/\ %K^W/$VL:!XY\&ZW<^.)
M?@[I7Q*T?P=X$_LOX@ZQJD7AK6]*N;KZU\'?LA?#7P1I/[-FCZ3KGCFXMOV6
M_''C[Q_\/Y-1U+0)9]8UGXB^"_BKX%UNV\8M;>&;2/4-,M=(^+_B6XTJ'1(O
M#UU!J-CH<UW>WUM;7]GJ?AO@G_@F[X(^%7Q1U+XG?"/XV?%_X?R>,=7N=7^*
M_A2/P[^SQXO\/_%*XF^.GQ9^.T;ZW<^//@7XF\2>'[R&^^-/C/X<-JW@K7?#
MFJW?PPM_">E7=Y-XJ\):+XQMP#W[]I#]I4_L_7WP6\.Z5\(OB-\:_'7Q]^(^
MK_"[X>^#/AQ>?#W2KQM?T7X7?$'XMZCJ7B#6OB9XW\!>&M%\-:?X5^&_B"XU
M#4#J]UJ*NL$&F:/JU_/;V$_R/\3?^"LGPH^&'AGP!XEU#X)_'/6U\2>$?C?X
MQ^(NEZ/'\*(=0^!5K^S3\:_!7[/OQST7XA?VU\4M)M/$'BCPG\6/&EKX&\.^
M'_A'=?$K4?B1XFCL[7P'%K>D:O9ZZ/=OVN/@%\0_C;\2_P!BS7/ 7B7Q%X%B
M^"G[07B_XE^*?'_A.Z\%C7O"6D7?[-?QT^'U@\&C>.M)\0Z-XDT[Q-XB\;:/
MX)\0Z0GA_4[_ /X1WQ+JM_8RZ)=64/B/2/(/C;^Q#^R=X*_9]^(>J_&_QC\1
M;7X:^%_V9_VJ/ OQ9\<22Z=J&N7FE?M'?$?PW^T'\=?CO=V'AOP%J5XOQA/Q
M6\'?\+*\,W?@SP_;^'?#VOZEJ,>B?#^6U@T"PT< [1?^"A?AGPWI7Q0N_C9\
M!?CC^S[JWP4LOA#XT^*WAWXBO\(-?O/!WP.^-GBSQGX.\+?'RZUGX1_%?XE^
M$[SX=>%-3\ ^+9/BX+3Q#)XC^&FG>%_$NNZIHEYX9L=+UW6_,K'_ (*0^$+/
M_A.?B-J7A?X[36GB#P/^R5<?!?\ 9[UOPQ\)?"OB[Q7K7[2OQ)^/_A#X5W7A
M2^UOQ;H%UI6O_%C0? .G^/O&>C_&+Q9X:TGX0_#K1--UC78_"FNVWQ+TC3/6
M]/\ ^"?_ (6U?4_&VM_&SXY_&W]HC5OB:/@EHOQ(/Q*M?@CHNC>.OAI^S[J?
MQ$\2_#_X-^(O#?PK^#/P[T6X^&5]XZ^)OB3Q]\0M#MK2UO/B/K,K>%?%6IWO
MPDU'6_AIJG.:M_P3(^#=[X1\1>&=,^(_QET;4;J+]GB'X=^+VO\ X:>)O$/P
M6B_92^+?Q*^*_P !+3X?)XR^&'B'1-1L/!-O\3=3^%%U;_$G2/'TOBSX0Z/I
M/AOQ9<ZQKM[XK\5>)0"Q\._^"CW@3XG^/_A/\)O#/PD^)/\ PM'Q[J_Q&T7Q
MOX'U3Q3\"-'U/X0W_P (_&>G^"?B3;:I=:G\8;33?BE>>$WU?2O'FI6'P&N_
MBC>1_"/4=*\?&%5\5_#_ $;QEZG^V3^V1X:_8J\#67Q0\??#SQ7XJ^'%O9^)
M=4\:>+/#OCCX!^$H/!6G>&[.QO3#_9/QF^,?PMU[QUXEU^VNKZX\,^$/AGIG
MC'7M63P[K5D+6#7KKPCHGBOSKQ[^P%%\6+7X/Z1\4_VDOC!XW\.?"?XC>"/B
MU_8$WP]_92\,CQ%\0/AS\38OB9X3\1VWB7P5^SIX;\<_#W48%M--^'NK7_PP
M\5>#]4UCX;Z?_8\VH1:]K/BGQ-X@T_VM/^"?W@#]K?Q/)XLUWXH_%?X7:OJO
MP(^)W[-7BN\^&L/PIO;[7?A!\6I].N/%^BZ5>_%;X7_$Z3X>Z[>_8'LIO&/P
MW7PIXFO]+OFM=6U&_GT3P=>>& #D?&__  4G\(>#O%7QJ\/V_P !_C1XHTCX
M0?%'P-\ =+\9Z-J7P4L?#_QB_:&^)^@_!WQ9X#^#OPKM_$WQ<T'Q!<ZG<^#_
M (P6?C+Q5XW\::+X+^%_@OPKX8\1:MJWC:0V5Q;6WU7^SE\?_#O[1_P\N/&V
MBZ%K?@W6- \8>+_AS\0/A]XHO/#&H>*/A[\0O NLSZ+XD\+:Y?>"_$'BKPGJ
M#*8[36]$UGPYXCUC1/$/A;6M \1:5?36&K6[5X9\1_V%OA+XC^&?Q<\,R^-O
MB+X2N/''QT^'7[4]O\1-+3X?ZWXK^%_Q7^#7AGX/Z!X5U[P)8>*_AWXH\)SZ
M2FC?!#0;;Q!X?\7>$_&,'B/3_$7CG1+LMH^OV^FZ;ZM\$_#'A+X@?LQ^'[*'
MXH^+/C5X!^-GP[N/$=C\3M3T+PS\*_%/BWP%\7M$?5]&O;;2_A?X%^$<'A*6
M'PCX@L+'0YX?"NA^,=,M;6PFUR\N/$T%WJ$@!\Y>"O\ @I?\-/$WB#QMX(\0
M_##Q_P" OB)\/OB1^S#\.O$_@6^\;_LZ?$35=+G_ &L?BYJ/P:^'>HZEJ7P-
M^.'Q5\/:-<^'O$^D:E)\1/"^MZOIOBGP]816=_I>E>(=-UOP_J&J\GXU_P""
M@GC]_P!L=?V7?AE^SUXU\2>%-!L/C;H/Q%^+#ZO\++&VT;QE\./"7[,GC=-;
M\-Z?KOQ3TK7+SP?X(\+_ +1FAW_CR&[\$:AK^NWNJZ#9?#_3-=;2?%D5KY'X
MT_8<_9J_9)^$4DGQ)_:(_:7NFU^Q_8_^ 7P6U+P9\._A?J_CGP1XA_9B^+.N
M_%_]FK1_@E\)?@!^S1%9>(?&:?$#4-6U[QG=>*_ /CO3/%&B6VJ)XTAL? 5A
M?VUE]*^%_P#@G5H/A/QK9_$^S_:0_:$U/XG7GQ-^(7Q$\=^-M>'P0U"\^(.G
M?%WP)\"O /Q.^&NIZ3%\%[/0/#W@/Q+IW[.WPYO]/'@_3-!\6^$KV#4[7PMX
MKTO0Y]/TC3 #P+]F7_@J3;/^S-\/?'G[6/PM^-/POUR#]B#P1^U)+\1O&.E_
M""6T_:(T?3='^''AOQYXD^'/A+X4^/M>OO#VO^)_B1\0_"">#OA_XL\,?#W5
MM9M?B+X0CL- T>[FU/P_H'MFO?\ !2+2_!.A>.HOB+^RQ^TIX%^+?@CQ!^S5
MI,'P!U"7X :Y\1O&VE_M;_%W5_@K\$->\%:]X2^.VO\ PBNH-8\=>']?T#Q-
M9^(/B9X<G\&ZMH>H+K;1:#<:%XCUOL/%/_!.?X#>,_A3X/\ @YXBU7XB7_A+
MP1^Q?XH_8<T:5M8\-)K'_"L_$\/PBV^.)KU/" AB^+GAK4/@IX+UWPKXFTZT
ML-!TG7%O]0;PE=.=,32^>'[&OPVTKQ;JVN_&W]IOXM_%[XO>,]2_9S^(5MK_
M (_O/@7X:\77'@_]@WXIS_&7P3H/A7P;\+?@_P" =)NO!6F^/?B#J.K?%2[L
M?"]_K=_=?$ VUMKWAB&[\*6>E 'F>I_\%!_&_P -8/BGK&M_LV_M&_%*33/C
M[X(^$5SX,TC6_P!DO2]6^%_Q.\>_!O\ 9\\2Z+^S]X1@?XS>&=6^+5Z=<^)D
MVH/XFTE/%[C5KKQG*^OI\._#.C:E!Z[JG_!1OX0Z+\<]8^%.J^$_&FG?#SP[
M\4KOX"Z]^TI?:M\,;7X/:9\=K'P"WQ%N_AO+ITOQ"'Q7=;335/A2\\;K\-QX
M"@^)Q'PY_P"$B?Q&D\$'%Z+^Q=\-OC7X^\/_ +:OP9_:N_:6\'V/Q:GD_:%\
M!6?A/3OV?[[X?V^J?&+X,?"KX?+\2?#_ (+^.G[,OCSQ!H?BK6/A#X \-^']
M.U37I1XK\*:'XG^(7A_2VT"Q\?\ C32=3]-NOV4_AU\(/B9\:_VBM0^.NO\
MP_\ @UXVUW6_C=\=/A3XLT;]G:W^!<6J67PKTWP5XZ\9:QXZ\7_"2;XG>"/"
MVHZ%X2TKQYXX6U^+.DZ0GBO2=4\3M=Z7INO>+-.U@ \C^!7[;?Q&_:%_:K_9
MP\.6_P (/B[\#?@U\6OV*?VC?VC-*T;XJV?P?NI/B;:67Q,_8FTWX,>-+'4/
M /C/Q_XA\)ZQX>\(_%3XBQ^)?A]K>H^&+S3QXZT:3Q+HVK:E9:1)X?C;_@HO
MXJ\'?%']K#PC\4_V;?B+9^&_@]^T%\-?V>_@9-X-UGX.:IXJ^.?C_P"*/@WX
M1:QX&\!Z-I.H_&NU6/Q9XZ?XB7_Q$T?5_$<7@'P-X/\ A):)-\2]?\+>+-!\
M4:;:3_L._L[_  !C\0_#CX[?!K]JOXN_M&:#^SW^S]KW[$/PSTWQ3J/P]?P9
MX/\ AM=ZM\&_'A%Y!X;^%7@GQ)XC\>7NB?#GX536'Q#U+6[C3_&GP]N- \0P
MV>MPZQI?BBY]/^+?[ 7A+XL>,_BGXP/QF^,'@1_B=XV^"WQDATOP=:?!VYA^
M'O[0GP"NOAK'\.OCGX"U+QM\)O&.LVWB>#PO\*_#W@7Q!X5\27_B;X:^)/"5
M_P")++4_!<EUK4M[$ >C_#3]JI?B1\,OCIXL7X*?%GPK\3_V=-2\0>%_B7^S
MUKS?#W4/B9'XZT?X7>%?B]H_A;POJO@_QWXH^''BB/Q[X-\<^#[_ ,#:]8>-
METF^;Q!;V.NR^'=8T_7=*TCQ3Q)_P4N^$G_"6^$OA_\ !WP!\2OVBO'7Q-\&
M_"GQ?\)/#_PNG^&^GP_$&+XJ_#[Q_P#%Q;6W\1?$KX@> O#?AR'X??"?P=X=
M^(WQ'U'Q-JNF0Z7X>^+OPCM/#L7BGQ-XTL?#Z^W?#7X8^$/V/? 7QV^)'C3X
MF_$OXGZAXV\8:Q\??C7\3_&GA[0]<\9:OJ>D_#OP1\/XH](\%_!'X<>&;4Z-
MX7^'?PP\(^&_#/A?PIX(OM:EM-'5[B37M>O[V_O/GK3_ /@F5\$?A;X3\/R_
M"?XF?&#X/>*OAC\>/&O[1_@WXK:%+\-/%7BWPE+XE^$DWP+O/A5:Z9X\^%_C
M#PG>_!'P[\!K'PK\*/"_@J;PK-K6D>%_AQ\/;NW\3S>+O#<'B.X .:'_  4H
MU;6?C!^S_H_AK]G_ ,=6'P4^('P^_:J\0_&SQIXZUGX1>&?$?P'\4_LJ?&'P
MI\'_ (NZ/XOL'^,TENEC\%=6G\37_P 3+OPQ:>.[+Q7IFJ>"]2^#VL>,K*#Q
M.]G[U^RK^W)X0_:DUR_\-P?#'XD_![7;KX;>#_C=X T?XHW?PTEU7XD?!/QU
M>ZAIN@_$'1[#X=_$'Q[-X<FM;ZQM[?Q9X&\<#PSX]\%OXA\*IXD\.V$VO6T2
M?,^F?!G]D3PE\,?V&O'1_:D\;Z=X;^)GC7QWHOPT\>?$2T^&GV_]LN\_X*&^
M(I/VA_B1\,?B5H'BGX.Z9I5K>?M$:KH[ZY%IO@WPC\*/%&A16TGAKPU)X=FD
M33*]V_9Y^'OPP_8E\0?"/]F+7?VJ?&'Q"\1?$+P3=^"OV;?AI\6=%^!NF^+Y
M/!/P&T".^\1QZ'KGPH^#?PX\3^-;SP]X0O?#<'BG7_'VLZ[-=VFC:-J##_A(
M[[7M5UL \QUK_@H+/X#^/?QB^!?A_P"#?[2G[3GC31/'?Q+UA=#\!:1^SUX9
MTKX8_#KX1?"O]DKQ#XV@L=<\;?%'X7IXCT03_M"Z+J_ALZW>:O\ $#Q#XVU_
M7/"T=O:>$M)T;4]/^C_VA_VGKOP#^PW\3_VP/@=X6_X6[_8G[/&I_'?X<:*M
MSI6GV'B'1)O!B^,=&\0:L^M>(_"D+>&=)T*X3Q;XEL+'7K7Q'J'AS3-3T[PI
M!J?BBYT?2[V?PU^QE\+_  M\>_B5^T3I^O>/9O&OQ3L?B=I_B#2[S5/#TGA:
MSA^*_AS]FWPOXB;1K*#PM;ZM;RV5A^RY\/YM%:]UO44M[S6/&,E\FHPZAHMO
MX?UY/@K\&/#/[-&B?L1:SXGOIO ]S^S/JOP(T[3-5U[1Q\3O%'PE\'_#G2/A
M;XGURSM]/TVS;5]8TSP]K.C'7]6T'PNNFZ?K.NZ8YTJS34M/L) #X N_^"C_
M ,7_ (;?&#XN:C\5?V9?CS<_"/P3^S'^R_\ &KX@:-X<G_9OO+?]F;3?&GC;
M]I;0OB'XX\8ZS%\7K?5O'8\2Z)X%\(>*=.\(_#G6/BE?Z/X1\):Y=/I_AWQ'
M(VB>*>F^(7_!4OX;:MX!^-T^@:-\8OA=X>L_A7^TEXG^!7[0NGVGP(\5V7Q<
MN?V;[BYT;XCZK\(O!.J?$#Q'J!U32IX;KQ3\/;/XT^"O!^@_$_PAHNK^+-%6
M_P##-C+<R^U^"_V./AG\5/@=\2#K_P 9_C=\5;#]KO\ 9<^&GP<\4_$KQ5I/
M@3P!XXU#X5:-!\6==\!ZW8>$M,^$'@?3O!WC>+P_\=-5TK5(/$/@1)(X]"\.
MIK7A:S\16OB2?6J>F_\ !-WP1IW@7XW_  :7XV?%\_ 3XT:1\<](@^$%MX=_
M9XT[3_A?;_'_ ,3ZOXM\5)\//'-A\"X/B:EGX8U/Q'XFM?A[I/BWQCXJTKP_
MH>NOH6IV?B#3='\-0Z* >]?"O]IG_A;GQW^//P:\/?![XEZ?X>_9Y\2+X#\9
M_&W7+KX=VOPWUCXCW/@?X4?$BR\">$-+M/'5]\3M5U,>"_BMIVLZGK6H?#_1
M_".G'3Y--C\17VK7:6$'QAXE_;]\:>._C'^RIH'PU^&?Q;^'_P %_B1^U9^T
ME\*;[XS:U9_!;6_!/QM\(? #]F#]M2^U^U\*V=IXS\6>/?"4,_QK^#?A'QIX
M U77?"_@J[\=>%?!]S=K?Q^&-6U+1-:_1OX;_"#PU\+M?^,WB+P_?:Y>7OQR
M^*O_  M_Q9%K%S87%KIWB7_A6OPW^%OV'PZEEIFGS6FA_P#"/_"_0+S[-J4^
MKW_]LWFL7']I_8KBRT_3_D?1/^"=/@71OB'\+_%R_&OXYW'@WX)_%W]I/XU_
M"SX,_;/A?:?#GP]XP_:GT+XOZ%\0[>_DL_A?#XUUW0/#4/QR^(4OPMTZ\\7Q
MS^"X]4CTN>^UW1+>/30 >3>%?^"HWPH\)_#GP?J/CO3_ (K>)])\+?L>_!']
MI+XK?%S7H/@EX9\1/H_Q;\"6NI>!-4D^#ND?$#1_&OBG7/B1XN6U\!RW/P7^
M'7B#X9Z5\8?&&@_#[1M::*R\82^!?:/%O[;/Q \ >&?A&_C+]BSX_6'Q8^.W
MQ?U_X1?"[X':5XS_ &;M;\7:K<:/\(_%GQF3Q9KWBJ'XVVWPQ\+^'+;POX*\
M367B1-1\;/K6CZWH&JVVCZ5XHL)O#6H^)?'/BG_P2(^"GQJ\*_"'X:?$SXO?
M&GQ/\)?@/\(HOA'\)O!,FF? +2]:\%6D?[/^I_L\MXDTKXL:'\#=,^+O]IW.
MCZDGQ)O=&NO&MSX/O/BWI'A[7[CPY)X6\/:+X*L?K;PS^S#?0ZA\&?$'Q3^/
MOQ@^.?B_X$_$WQ-\3/ _BKQQIGP6\,WTT_B?X*^*?@==>&O$.G?";X1_#O0]
M4T&#0_&GB?Q9%<0Z98>(G\;:HT\NNMX3L].\(68!\0_%7_@K9H>D_#+X[^+/
MA-\#?'WB.\\,?"G]I#QQ^SAXO\2Z[\'+?X=?M$ZC^S-=SZ3\3+[P]86?QDM/
M'6E>%O"R0:E\1K.'QGI'@3Q!\5/A-X1\7>(OA1;>(KR#2;34NJB_X*&:IX>^
M+$'PXU_X/?'GQ%\??B9\,O@?J_P[_8\T8_LV1ZIIVI^(H/VF-?\ %7B^P^)4
MGQ9L?"<>AOX6^$<&L^/KWQ;\3+W1O"FGCX<:+X-LM2\?^,M<\-7'KO@W_@GM
MX*\'^&_C-\+X_BY\3]6^ 7QAT7X_Z#_PHV\\.? 73_#WP_TW]H[6M?UWQM8^
M"/''A_X+Z/\ %R/3?#]SXM\66/P_TOQ%\0-?L?#NAZ\^B7\.NZ?HOAJ+1/'O
MBE^Q!\+?AWJ/PT_:*^(?[6'[0'AWXY^#/%?[.7PB\%_M&0>&?@=J7BJ77?$G
MC#XK?LZ_"[P5J'@K2_V>=7\!3Z+\3M2_;%3X=>-'D\$6FEQ'1/AWX[N=6\':
MKX0USQI=@'9WO_!2[0+X?#2P^''[+O[3'Q4\8^/?#?[1?B?Q'\/?#</P,T/Q
M9\(8/V3OBYX?^"OQXT;XD7'CCXW^%_!A\1>%_'FMOH.A:?X'\7^-;3QMJ-O:
MS>&M2O/#>HQ>)8?JKQ+^TO\ #S0?A+\(?C7IZZKXI\"?&WQ;^SSX6\#7V@PV
M;2W</[2WC;P5X*\ >(;B._O;*./18)_'>CZQK#12S7T.DQW36-G?7BPVLWAW
M[-G[*GP4\.:;X3\=>!O'OQ=\<W_A?P]^U]\)=4\6_$.TTG0=?\<^)?CU^TM#
M\3?VA_''B_1T^&G@)&\67OQK\ :K/X;U3PSX?\-^ )= U&[N/#>@:OX:O_#&
MIVWI.N_LA>!-6_99^&O[*>G^+_B'X;\-_![1/@%I_P -?B+HU_X6?XG>&==_
M9IUOP+XF^%/C1+S5O".I^"M2\0:?X@^'?AW4-=LM3\$77A/Q'"=5T?4O#3Z%
MJESIA /-OB)^WKH/A#Q<WPZ\'_!'XO?%SXBW7[4.L?LG:%X2\&7/PPT>35_'
MVB?LP6G[5VH^)'USX@_$/P;X>TKP'I_PZN9K?4-4U'4XM=75].O;73/#6K22
M:9'J7D=W_P %8/ADVB>.?$GAOX _M#>-M$^ ?A36O%G[8-[X8M_@RS?LDIX4
M\3?$SP;XX\-?$:QUOXQZ+J7CKQGX(USX1>/=0\0:#\#;/XI"3P5H(\7:'>ZU
M;^(_ =CXPRO%O_!/CQIHWCS]G[6_A_\ '#XV:]K\7[:WCC]J_P",WQP\2:A\
M%G\;^'=;UG]BSQE^SU&N@^&H_AIHO@B[\%>)KO3?!OA/4O!=MX(UF]TG1_&'
MB5]!O_#NFZ=H=YX3V-8_X)0_"^YTKXF>'_"_QY_:"^'GA[]H?X<7/PY_:MTC
MPBWP.D'[3$>M^./BS\0?''C3QYJ/BGX)^)=7\+^/?B/K7QR^*.F>--:^%=_X
M"T^?PIXFAT#0-&\/CPQX-O/#@!ZK'^WYX:?XY>+_ (4-\#OC1'X"\"_''P-^
MSAXE_:0>;X1Q_!RU^,/Q0\'?#;QA\.O#5E93?%2+XL:Q9>(A\4_"/AF;Q!I'
MPSO=&TOQ7XA\.Z=-=S6E]JVH^'_7?B1^T_HWP_\ V@?@_P#LX6?@'Q=XR\<_
M%S1M7\66USI>N_"_PQI6A^"_#NM:3H7B7Q!;Q_$CX@^"M:^(5SX4?6[7Q%XM
M\,?"G2/''B?PUX,MKG7-6TNWO=5\#Z+XRHZG^Q_\,M43QY'-K/C:"/XA?M3_
M  @_:ZUB.UU'P_$EE\1_@H/@@OA30='5O#,BVW@2]7X!^#AKVEW0O==N1J/B
M0:;XETH7FE_V-E?M*?L?Z/\ M0^*OA;J?CGXK?$'2? WPO\ '?PT^)ME\+?#
M_A[X,-HU_P"/OA1X^LOB!X:\5V'C[Q!\*M=^-?@76M1NK"V\+>*+SX=?$[PH
M^I>"!=Z'I@T.YUC7]4U8 SE_;I^$%OX6^&GC;7[/Q'X6\)_$CXL?M-?"DZ]K
MR:-;Z?X.G_93T[]H+5OB/XN\630:Q<&U\)SZ;^SEXSO='N=.74=1:#4=#;4M
M-T[S-1&G_(_C?_@H+\=M8U']CSQQ\,_V3_V@(/A[\>/C'>Z9X)\&OJ/[-@\9
M?M*?#'Q'^RO^T'\2_">KV]MXB^*<*_!2P\/Z[X(\%_$OQ&OC[Q%X!\3VO@V7
M3-.$&L>)[GQ5\,+'VSPO^P=\';CXKIJJ_'KXH^//"'PA^,?QW^)-M^S-J&M?
M!W5OA;X"\:_M8^#?B?<_%?POXKT[3?AE#\3+S0O$VE?M"^(_&GA+PUXR\=7%
MYX7L->TJV\.7<7@'4'\/W_5_!3]A#3OA!%^S_IFJ_M%?'SXN^&?V5KZPD^ /
MAOXD1?!"&'P7H^G?!WXG_ NW\/ZMKGP_^#'@;Q3XVM/^$!^)K6;ZCXJUS4-=
M>^\$^#=1;5&NW\:R>,P#MM-_;3^%1_9'UK]L;Q;I?C'P!X!\*Z-XXN?&'A'Q
M)I^CW7Q"\.^*_AUXRUWX;>*OAN=,\-Z[KN@ZWXVB^)/AS4? FB6GAWQ'JNE>
M)-??3X]%U:[M=1M;E_E7XS_\%)/B3X&\!>,5\/\ ['/QF\.?'KP)\0/V2[/Q
M!\&?BCKW[/QO1\(OVI_CAJ'PG\)_$O2_$?@C]H36/ NK+JVI>$_%WP^@T:T\
M<MKG@[XJ3Z'=>+]"/PQCNO&=U];ZI^QM\)-<_9=^*7[)&LW7BW4_AC\6I/CI
M<^(-1N=1T8>,=*U#X]_$?QQ\5=?U;PUJL.@0Z7IFJ^#O&7CN]U#X=W\VAWUQ
MH#Z+X=N+]]:U&PN+Z^\IN?\ @G[I7B+1?C._Q(_:-^/?Q/\ B9\9='_9_P!$
MF^,7B:S^!&C^+O 5E^R[\0M=^+7P4'@;P_X$^"?A#X;Q'P_\3_$NO>.M;3Q/
MX*\30>)M:U>]M;Z&/PZFFZ%IH!XI\+_V_P#XE:9\<OC9X$^,/P%^-S?#NU_;
M!^%'P#T+XHQK\!!X%^!NN?&GX#?LU:MX(^#WBB+0?B3!X_\ &VJ0_%OXD:M8
M^)_&WACPKX^\-Z-?^._#5K:>-M8T"&ZC\):^K?\ !7#X(:'HWQ2\::K\,OBS
M:_#'P=\/OVA_B)\+_B.EU\)]0T?]HW3?V7+VXLOBS8?"K0=(^)VH^-=-OV2S
MO]<^'_\ PLSPUX#MOB/X/TK5_&'A>:ZT&P:\D^E[']B_P,/#OB#1_$/CWXE^
M*]6\8?M(? W]JOQ?XLU*X\#:=K&N_%OX$6/P*M=#F^P^'O ND>'-,\,>*;G]
MG_PIJ7BW0M+T2UD:ZUOQ5#X9U'PU8W.B6F@^'^#?^"?_ ,*-=^%/Q:\ ^$OV
MB?B/XG_9?_:&\-?&M/#G@'PM8?LUW/A/P3HG[1GB/5?&>OWWPG^)_A[X(MX^
MOM$T*^\3>)(OAI:^(?'/C#0M&\/:\VBW]OXCTO2/#,6B@'1_M0_M-?&+X>_L
MN_#/XV:'\(OBC\-_B!XC_:8_9=\#ZA\#M1;X(^)OBSJ?A+XC?M5> ?AAJG@1
MKJ#Q[XD^#.G^)?B7X'UM[>UO$^)]M9>#W\30O>^-?#>JZ/=ZGIO>^ ?VUO#'
MBWQ/X&^'?B7X9_$+X;_%7Q-\>?%O[.GBOX>^)+CP1JU_\-OB#X7_ &>M6_:A
MM9_$&N^#_%OB+PQK/AKQ9\'K;P_XB\,ZQX1U;7I'D\8:-I>MV6B:O8^);#0O
M4_VE_P!GG0/VG?AE!\-/$'C3Q]\.UT[XA_"CXI^'_&OPRO/"UEXS\.>-O@O\
M2?"_Q7\#:II<OC3PGXX\,RQVOBWPAH\M_9ZKX9U*WOK!;FT*1&831^*ZO^PK
MH&I:98:M9?&SXP>&_C?8_M!ZC^TW)^T-H5O\*6\>ZC\3M3^#E]^SK-%J7A?7
MOAEKOPFNO!T'P#N-/^%-IX8?X?"*'1O#GASQ"UY+X]T]_%MR <Y\*?\ @H5X
M(^.WQ/\ &7PD^'WPU^)D%]X%TSXI77CCQ;JFJ_!O2$\(V_P]^(OQ9^%4'B6R
M\#ZW\38/B5XT\(:YXP^$6M:38>,_!_@+Q)X2L?$&O>&/#6LW\&JVGQ$M? 'E
M'A3_ (*8Z%H?A#X;QZC\)?VB_BUX?T3]DG]E_P#::^.O[1(TKX!>%/#WP_\
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M_P#@HG\=O"EI\>-<L;?3_P!JOPU\:_"GA[5M?^&=IXEU?Q+X<T;P9\3?AO\
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M\)_$O7;>>SAG\!^)OA=\==3^'J:!?>)5TN/3/BG_ ,(EH,[)K6H6-C<<G8>
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M^%M5^'M_X=@\*2>$-'\*>&_$VFZSH_BW69]5MY[/4T_1:B@#^7KX5:-^TO\
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MK.C^#T\<Z9>?T$44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\)-_PAOV;[1_PC']F_8?^$F_XE']N?;O["^T?/\ VE]G_?5]<5^1'[=OA_\
M:5M/'O[2'C_]F[P[XW;QW9?\$X?%6B^!?$WA7P_K%[J-SXOL_B\=>U;PE\/-
M3M;&YLIOC1>^"HM7G^&NCJ;J]7Q9-X>OY=.N+%9%?L/V#D@M_C;^T39_"-_V
ML'_95B^&/[.EWX,?]K!?VL)=:F^/NIZ]\?[SXX3^ K[]L:,?%672Y?"#?!";
MQS;VMQ/X3@\?3:I]CM[#Q:WCD78!^H]%?RI?&WXF_M-_8OVX_B1X3\+?M1?
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M//@!J'BGX+ZKKDOPP^'GP]O/B5HGP8\1^&/%NA>$/#=YXGNO&<]_9Z]JU_\
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M#+WP5=>#](\.^)=:L/TV_;"\,>)?$_\ PRU_PC?A[7/$/_"/?MC?!'Q/K_\
M8>DW^K?V'X:TG_A)_P"U?$.L?8+>X_LS0],^T0?VAJU[Y%A9^?#]IN(_,3<
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M'B+0+Z&.XOM&UUKG2M*TN'7=)M6UW1-)U'6=6\,WVC^*K+0M5M/.M&_X('6
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MJF_X)B_\HV/^">O_ &8[^R;_ .J%\ U]Q5\._P#!,7_E&Q_P3U_[,=_9-_\
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MP=>^*].T/Q#J-I>Q:'X0L'CU+0K2:PL/!&C2W.I:_J^I:OJDO[0444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^'?\
MX/,_^<;_ /W>!_[ZY7]Q%?P[_P#!YG_SC?\ ^[P/_?7* /ZIO^"8O_*-C_@G
MK_V8[^R;_P"J%\ U]Q5\._\ !,7_ )1L?\$]?^S'?V3?_5"^ :^XJ "BBB@
MHHHH **** "BBB@ K_.5_P"#O7_E)/\ !'_LQWX:_P#J^OVEZ_T:J_SE?^#O
M7_E)/\$?^S'?AK_ZOK]I>@#_ $:J*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"OX=_P#@\S_YQO\ _=X'_OKE?W$5_#O_ ,'F?_.-_P#[O _]]<H _JF_X)B_
M\HV/^">O_9CO[)O_ *H7P#7W%7P[_P $Q?\ E&Q_P3U_[,=_9-_]4+X!K[BH
M **** "BBB@ HHHH **** "O\Y7_ (.]?^4D_P $?^S'?AK_ .KZ_:7K_1JK
M_.5_X.]?^4D_P1_[,=^&O_J^OVEZ /\ 1JHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ K^'?\ X/,_^<;_ /W>!_[ZY7]Q%?P[_P#!YG_SC?\ ^[P/
M_?7* /ZIO^"8O_*-C_@GK_V8[^R;_P"J%\ U]Q5\._\ !,7_ )1L?\$]?^S'
M?V3?_5"^ :^XJ "BBB@ HHHH **** "BBB@ K_.5_P"#O7_E)/\ !'_LQWX:
M_P#J^OVEZ_T:J_SE?^#O7_E)/\$?^S'?AK_ZOK]I>@#_ $:J*** "BBB@#Y'
M_;_\<>+?AE^P?^VQ\2? .NWWA;QU\/?V1_VD/''@OQ-I;I'J?ASQ;X3^#GC/
M7O#FNZ<\B2QI?:1K%A9ZA:/)'(BW%O&71U!4_G/:?&/X\?"OXL?"+Q7\2_$O
M[2?A_P#9A@_:9^,6K>#-)^.L6A6'QEUGX6>!OV _VEOB!XW\.Z_X=^'(35/'
M7PAT'QIX3T+Q%\(%^-*:M\<=0\5:1K5]XL%Y;:3\/=<OOV8^)WPW\%_&3X:_
M$/X0?$C1O^$C^'?Q5\#>+/AOX]\/?VCJVC_V]X+\<Z!J'ACQ3HW]K:#?:7KF
ME_VIH>J7UC_:.C:GIVK67G_:=.OK2\BAN(X_%OPQ\#>.O$/P[\5>+-!CUC7/
MA1XBUOQ7X"NY;[5+>+1->\1^!?%?PTUJ\EL+.]MM.UF._P#!'C?Q1H;V.O6F
MJ:=$NJ&_M[2+5+/3[ZU /R^\!_\ !2/XIZ]\+->\=?$'X0?!+X1WWB?X9_!S
MXN? C5O%7QR^)-Y\(?$FC_&'Q79^'(?A3\0/B7I/[-]S<Z;^T9X=L]3T/4-)
M^%?PS\*?$^U^*FL^)-&\-^ ?%,]I%KGBG1\*Q_X*QW47AKX)^-?'GPJ\&?"+
MP5XRU_X\>&?B5XQ^)/C?XP^'?#=AXO\ V?\ XO>)OA=XC^%OPFN-7_9LTC6]
M?^,7BS1?"VI_$?X:?#;XU^'?@!XJ^()?2?AEX8TC4?&,_C*Z^'7UCHG_  3G
M_9F\/_#BS^$VG1_'!_ GA_4/AWJGPZTC5OVHOVDO$$_P:N_A/?WE[\/)/@CJ
MVO\ Q4U/5_A&?#4%]<:! _@.^T274?!AA\":S)J7@RUM=!A6W_X)Q_LKVNE^
M$_#<>B?%NY\%^%/&C?$:7X?:Q^TM^TAXE^'OC?Q^_P 8KS]H&7QI\5?!7B?X
MK:SX>^*_B>[^,E]<>.M6UOXA6'B+4/$%^+33/$-QJOA_3-+TBR ,+]B[]L+X
MH?M)7BP_$WX(:/\ #&Q\7_"+P'\>?A;KO@3QKXL^*7A:\\$^.IKJ*7P'X_\
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MI>AZ-%XITK0]/UN.^\->%?%*W@\7>%] U[3N8\4?\$_/V4_$FL>&O$-C\/\
M7/AQK_@[1_"?AWPOK?P2^*'Q5^!6I:!X>\&>#-:^'&D:-HUS\(?&O@MM)M+C
MX?:S'X*UZ;3!::AXE\->%?AII>O7NH0?"3X6CP> ?-?P=_;^^-O[7=SHUO\
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M?&7B71-6L=:T[5GTB\:CJG_!-C]E[6?"WCCP?J'_  T!-I'Q6UK7M<^,;_\
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MQM'\!]+F^&6N?#2+X6^)O$GQ"@\&^&_BQIFI6GV+0/ .J^*?$5Y86M_@:_\
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M\@TS3-%UG5FAU;PAI-_X^T>SU:_\/^-H]$\.\/\ %+]E']D[XI?M"6&J>/=
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M+OB'\!OVM?B5?:;H'PA\=_L*^*;3XLS?"/PM\2O%FH?'JU\/?"/7/$>O^(/
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M+7'P3\2:?\2_$'A/P]\.=>U^V\7>*]>^&'@7QDC^']'\/:J5UW5M?\'>P?\
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MU_QUXYU[6;#0_P#A(-9UGQUXQU2[\2>/->U1O#?A#2KK4-4NM/T6+4-.\&>
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M3?PQ_8NNW7]M_P"FZG<_V;I'V#RBW_8,_9RM[7XP:(VG?%2Z\"_'6W^*]O\
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MKXM?'?XX_%SQ5IW_  S]\1]1^+OP?T71?$_Q(^(?B;7]*\,>#?B/J^H^*O\
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MN^,_&'BO7KC3XIK]8D^6OV<_^";_ ,%/A;^S+X.^!OQ)T74?B#JDG[+7A?\
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MKK7?@!\:/@A\-)?"7@'3?!_Q72_5_BG\6_B!XI^'OA/4O$UIJNG:?;?!_P
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MUII_[1GQ%\+?LW^%%^ GP*^(?@#X6O\ $3QOX^^*FD>,['4_'WPS^ ?Q;O\
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MX>ZGK?Q*\ >,/ .L:SXD\5>&OBQX0M;OX@OX]GTKQ+XFU'Q'<:="8L']C/\
M8$\&?L\0^-/B'XUTVTU7X\?%CQ/\8/$OCG6-,^)/Q@^(.C:)IOQGA^#VE^(O
M ^E>+OBIXAO?&?CU%T#]G_X11:K\1O'%K;^+]>\1:#K6O:79^#-+\277A6V
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M^TS\%)_"U[I+:K!J&H?$WXI^*)_"UM'X.U>_UO\ 8'Q]X[\*_"WP#XS^)OQ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/_!/G_@K?X7T/Q?XB\0_$ZS\0Z=KO@?]JOP9H/[*VM:UX_\ $5T-2O/B9/\
M [07U7X9>._$>JW/C'Q'X3&M>+=+U?4K"]U?4I_N?]EWQ_X,^%'QQ\1^&O#E
M[^T=IGP"^.S? KX?? [0_P!H6/\ :2\4>/=:_:QB\#_M*?%K]HA+)_VAVUCX
MHZ#X;T_X'^!/A3JOC/6M5N[7X:P_$31_%VG6-W!\19_&=OJGZ7?$;X>>#?BU
MX"\8?##XAZ)%XD\"^/O#NK>$_%WA^>ZO[&'6?#VN6<NGZKILMYI5W8ZE:I=V
M<\L+3V-[:W40??!/%(%<;M[X>T#4M5T77=1T/1]0UOPT^H2>'-8O=,LKK5=
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MO7;**\OM.DO-&URPN-,U.UCU#3+FSU*Q>XLKJ>%+S3[RTOK5G$]I<P7"1RH
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M'PY?3OB[:^+[\W/ _P )?'WQC\1?#WX:Z1>_MP:=^QA_P\(\?6_A%?%GC?\
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M .+D?P]U7X4:-\;=0NM!TWXP_#FQU#4?B'HFM?!'Q#J-CXJ\.9_PZ^ _B?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ*^'?^'G7_!-C_I(5^P[_P")9? 7_P";ZC_AYU_P38_Z2%?L._\ B67P%_\
MF^H ^XJ*^'?^'G7_  38_P"DA7[#O_B67P%_^;ZC_AYU_P $V/\ I(5^P[_X
MEE\!?_F^H ^XJ*^'?^'G7_!-C_I(5^P[_P")9? 7_P";ZC_AYU_P38_Z2%?L
M._\ B67P%_\ F^H ^XJ*^'?^'G7_  38_P"DA7[#O_B67P%_^;ZC_AYU_P $
MV/\ I(5^P[_XEE\!?_F^H ^XJ*^'?^'G7_!-C_I(5^P[_P")9? 7_P";ZC_A
MYU_P38_Z2%?L._\ B67P%_\ F^H ^XJ*^'?^'G7_  38_P"DA7[#O_B67P%_
M^;ZC_AYU_P $V/\ I(5^P[_XEE\!?_F^H ^XJ*^'?^'G7_!-C_I(5^P[_P")
M9? 7_P";ZC_AYU_P38_Z2%?L._\ B67P%_\ F^H ^XJ*^'?^'G7_  38_P"D
MA7[#O_B67P%_^;ZC_AYU_P $V/\ I(5^P[_XEE\!?_F^H ^XJ*^'?^'G7_!-
MC_I(5^P[_P")9? 7_P";ZC_AYU_P38_Z2%?L._\ B67P%_\ F^H ^XJ*^'?^
M'G7_  38_P"DA7[#O_B67P%_^;ZC_AYU_P $V/\ I(5^P[_XEE\!?_F^H ^X
MJ*^'?^'G7_!-C_I(5^P[_P")9? 7_P";ZC_AYU_P38_Z2%?L._\ B67P%_\
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MJ*^'?^'G7_!-C_I(5^P[_P")9? 7_P";ZC_AYU_P38_Z2%?L._\ B67P%_\
MF^H ^XJ*^'?^'G7_  38_P"DA7[#O_B67P%_^;ZMSPQ_P42_X)^^-O$OA[P9
MX,_;I_8Y\7>,/%VN:3X8\*>%/#'[3?P4U_Q+XG\2Z_?V^E:%X>\/:%I7C>[U
M36M<UK5+NUTW2=)TVUN;_4;^YM[.SMYKB:.-@#[&HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_AW_X/,_\
MG&__ -W@?^^N5_<17\.__!YG_P XW_\ N\#_ -]<H _JF_X)B_\ *-C_ ()Z
M_P#9CO[)O_JA? -?<5?#O_!,7_E&Q_P3U_[,=_9-_P#5"^ :^XJ "BBB@ HH
MHH **** "BBB@ K_ #E?^#O7_E)/\$?^S'?AK_ZOK]I>O]&JO\Y7_@[U_P"4
MD_P1_P"S'?AK_P"KZ_:7H _T:J*** "BBB@#X=_X*%?\D%\ _P#9\7_!,7_U
MY/\ LFU]Q5\._P#!0K_D@O@'_L^+_@F+_P"O)_V3:^XJ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"O)_V3: /N*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K^'?\ X/,_^<;_ /W>!_[ZY7]Q%?P[_P#!YG_S
MC?\ ^[P/_?7* /ZIO^"8O_*-C_@GK_V8[^R;_P"J%\ U]Q5\._\ !,7_ )1L
M?\$]?^S'?V3?_5"^ :^XJ "BBB@ HHHH **** "BBB@ K_.5_P"#O7_E)/\
M!'_LQWX:_P#J^OVEZ_T:J_SE?^#O7_E)/\$?^S'?AK_ZOK]I>@#_ $:J***
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M-_\ 5"^ : /N*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "OAW_@F+_P HV/\ @GK_ -F._LF_^J%\ U]Q5\._\$Q?^4;'_!/7_LQW
M]DW_ -4+X!H ^XJ*** "BBB@ HHHH **** "OAW_ (*%?\D%\ _]GQ?\$Q?_
M %Y/^R;7W%7P[_P4*_Y(+X!_[/B_X)B_^O)_V3: /N*BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^'?_@\S
M_P"<;_\ W>!_[ZY7]Q%?P[_\'F?_ #C?_P"[P/\ WUR@#^J;_@F+_P HV/\
M@GK_ -F._LF_^J%\ U]Q5\._\$Q?^4;'_!/7_LQW]DW_ -4+X!K[BH ****
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M_JA? -?<5?#O_!,7_E&Q_P $]?\ LQW]DW_U0O@&@#[BHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX=_X)B_\HV/^">O_9CO[)O_
M *H7P#7W%7P[_P $Q?\ E&Q_P3U_[,=_9-_]4+X!H ^XJ*** "BBB@ HHHH
M**** "OAW_@H5_R07P#_ -GQ?\$Q?_7D_P"R;7W%7P[_ ,%"O^2"^ ?^SXO^
M"8O_ *\G_9-H ^XJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "OX=_P#@\S_YQO\ _=X'_OKE?W$5_#O_ ,'F
M?_.-_P#[O _]]<H _JF_X)B_\HV/^">O_9CO[)O_ *H7P#7W%7P[_P $Q?\
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M\-/VGOV./B1XH^$WQ(U75/B7XN\)?LI:G>:5\-OAY\7M$^+,_C76_#FL^,?
M7PTU'P#\2=+U/4].UNTUK6-$N]&U.VU#5K>WN$O;/\UOB1_P48_:S^,?[+7_
M  4T\&?";XW?L)>-?B)^S+^RO>?'BU_:9_9(\:_$;Q9X!?X6^-/A=^T1;^(_
M"G@^32/'6J:IX"_:>^&7BGX/KK/@[Q@_CKQ)X2O=/\0>'->U#PCH-S MG=@'
MG7_#@7_@I/\ ]+%/[<7_ ( ?'K_Z.&C_ (<"_P#!2?\ Z6*?VXO_   ^/7_T
M<-?L)X)_:!_:1\#?%3]@[X _&Y/@SXE\5?M$?#W]ICQ/\2/%?PXTCQYI>EV7
M_"F])^&VL^ $\)V_B[Q9K>I0W6IZ3XY,7CB;7IM8^W:M:-<:*=*MG,3_ #G\
M<?\ @I#^T/X#\<?$'P'\,?A+\+_'/B+1O^"H/P(_8*\%Z7X@O_%_AZSO_"?Q
ME_98\'?&FX\:^+?$.DR^([G2+SPQXQ\4S/K&MZ3X3UBSL/A[I5ZT/@[5]=B2
MYG /@?\ X<"_\%)_^EBG]N+_ , /CU_]'#61XA_X(3?\%"?"6@:YXK\5_P#!
MR+^V7X9\+^&='U/Q#XD\2>(9/C=HN@>'M T6RGU+6-<US6-2_;HMM.TG1])T
MZVN;_4]3O[FWLK"RMY[JZGB@BDD7ZB^(G_!6WXZ?#O7_ -H?PGJOB+_@G?IG
MBK]B.'2=.^,OASQ_\>]3^&/B7]J[Q]!\.-(^*/COP%^RQX4UK6M3\2?#-?"^
MDZYIW@W0O%WQ&T[XHV7C/XF2W7A>/1M"MM)U;5K/[U_;;^)F@_&G_@C_ /M=
M?&/PK!J-MX7^+/\ P39^/GQ,\-VVKPPVVK6^@^//V8/%GBG1X-4M[>>Z@@U&
M+3]5MX[V&&YN(8KE94CGF15D8 _%#P'_ ,$1OVZOBIX4TKQY\,/^#F']K/XC
M^!M=^W?V'XS\!ZM\8?%_A36?[+U*\T;4_P"RO$7A[]N[4='U'^SM8T[4-*OO
ML=Y-]DU*QO+&X\NZMIXDZ_\ X<"_\%)_^EBG]N+_ , /CU_]'#7O/_!3?2O@
ME-^U!_P1X\*?'3X7>*/BE\$=8\*?MN6GBWX6?#SX1_$GXQZSX@DE_9Z\!2:-
M/I7PR^#7AOQ/XYU&^TCQ!<6^NV^MZ#HIN/"=S;R>*Y-1TA--FU6V\2_9W\'_
M !%^&_[;'_!*WPUJFD?'#P!\%-3^/7_!4F]_95^$_P"T%K&OWOQ:^&?[,%G^
MRS\)]-\!^ O&-KXGU'5/%FEZ3I'C32_B#J_PT\*>-M3U/Q5X-^%^L>"/#NL7
M$=]IDEO  4_^' O_  4G_P"EBG]N+_P ^/7_ -'#1_PX%_X*3_\ 2Q3^W%_X
M ?'K_P"CAKZ3_P""QVE^ ?$'[:'_  2A\.?%3X#?$7]IWX=ZK>_MPOXB^!GP
MOTNUUWQ5XSFT_P"#?@&\T6ZM=$O_ !AX%T^_B\+ZLEMXENFN?$=F;2RTVZN8
M([J5%M)_HKXF>/=(^ __  3R\"?#/]DGX,>.?V2?B-^T[\0H_P!EW]FGX2_$
M+1&T7Q[\*_B;\;O'OB;1?$'Q.UG1O#OB;QZMG;_#7P=:?$/]I@R6_B/4;>7P
MMX3@FO9--:[EL[0 _.+_ (<"_P#!2?\ Z6*?VXO_   ^/7_T<-'_  X%_P""
MD_\ TL4_MQ?^ 'QZ_P#HX:_0/]E'P#\0_A?\+OV_/^"7?PV^(FM^ _'WP'T_
MQCJO[&OQ.\0OJNJZEX6^ O[6?A;QEXI^ ?B5-9U:\U'7/%9^!/QIA^+'PMFU
M.2:ZN(]/^%WA]&:-[NUMDQ?^"8W@_P#8U\$_$B?18OV:O%G[*/\ P4<T/X17
M_AOX\^%_BW?^.K[Q[\7--N]=\&:I\4_BGX*^)?B+Q?XL\-_M3_#?5?BEHNE3
MV/QITS7O%'BC2X)=*L?$8\$GQ*-!O@#X6_X<"_\ !2?_ *6*?VXO_ #X]?\
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MQP$UOP];>&M4T#2+&"&Z /B__AP+_P %)_\ I8I_;B_\ /CU_P#1PUB>)?\
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M_P#TL4_MQ?\ @!\>O_HX:_2W_@@X O\ P2C_ &554 *!\<     !^TA\8
M.  . !P!7Z\T ?RL_P##@7_@I/\ ]+%/[<7_ ( ?'K_Z.&C_ (<"_P#!2?\
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MMM7-O#KGA'QAH&A>*_#&K1QK?Z!XET72==TJXM-4TZSNH=S_ (<"_P#!2?\
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M?_1PT?\ #@7_ (*3_P#2Q3^W%_X ?'K_ .CAK]=?A]^TM^UUX9_:SU_]E_\
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MD1:S8:=>ZH] 'Y<?\.!?^"D__2Q3^W%_X ?'K_Z.&C_AP+_P4G_Z6*?VXO\
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ML_\ #@7_ (*3_P#2Q3^W%_X ?'K_ .CAH_X<"_\ !2?_ *6*?VXO_ #X]?\
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MOC#X]^&WQ,^*OP7^'O[<?A[6?$.G^)O"?BOP<?&7[*OCW1?@]:?$GP3X6O;
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M5RLJ1SS(JR, ?S._\.!?^"D__2Q3^W%_X ?'K_Z.&C_AP+_P4G_Z6*?VXO\
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M#I&HW^K?VA_+1_Q&4^,O^D?OAG_Q)35?_G(T?\1E/C+_ *1^^&?_ !)35?\
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MGBN$6>H:Y\?TU'Q_<^%+;QM&EO;ZM=^'XO$+VV;M_P"77_B,I\9?](_?#/\
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M"/\ @G=_PI/7?V/M:_X7!_PDW_#*'_#:G^C?\*__ +&_X3W_ (; ^(L/C_\
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M$%_IFEP>&(OR:_XC*?&7_2/WPS_XDIJO_P Y&C_B,I\9?](_?#/_ (DIJO\
M\Y&@#^I?]M?_ ()^V_[9.NZSJUU\6]0^',&L?L8_M9?LC-;:9X3;6[J%OVGK
MKX1WD?CTZ@OBS0?.M/!<GPJ2WU'P0UHL?C?3_$%U8R^)O#D5J[7V)\%?V*?C
MQX._:$^ OQP^)_QY^">J^'?V?/@!\3_V>?!WP6^"'[+VH?!3P)%H'Q,OO@_K
M.J>+=-:Y^.WCV+PUXAEUKX/Z-]KT;2]$?PC%X;_LSP_HNC:/?Z7?>)=?_F#_
M .(RGQE_TC]\,_\ B2FJ_P#SD:/^(RGQE_TC]\,_^)*:K_\ .1H _HU\0?\
M!.3XVWWA?Q?X3\/_ +2/PYT*W\-_MXZG^W]^S+K%U\!_%.IZO\//B)XJ^-_B
M[XU>-_A_\5#9?'K0HOB9X \2+\0?'W@"X;PV_P -M>'AWQ;=W0OU6QM=&?J;
M;_@GI\3_ !1XA_;R\??&#]I/0_%7CG]NG]EGP]^S1?6WA#X-:EX4\!_!6Q\,
M:!\:/#.DZMX'T'6_B_XSU_7=(.G_ !9@U?6/#^M>*K.ZU;QKIWBOQ%::]H6C
M^,],\(^!OYH?^(RGQE_TC]\,_P#B2FJ__.1H_P"(RGQE_P!(_?#/_B2FJ_\
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M16]SX=2TO?Y'O^(RGQE_TC]\,_\ B2FJ_P#SD:/^(RGQE_TC]\,_^)*:K_\
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M_G(T ?W745_"C_Q&4^,O^D?OAG_Q)35?_G(T?\1E/C+_ *1^^&?_ !)35?\
MYR- ']UU%?PH_P#$93XR_P"D?OAG_P 24U7_ .<C1_Q&4^,O^D?OAG_Q)35?
M_G(T ?W745_"C_Q&4^,O^D?OAG_Q)35?_G(T?\1E/C+_ *1^^&?_ !)35?\
MYR- ']UU%?PH_P#$93XR_P"D?OAG_P 24U7_ .<C1_Q&4^,O^D?OAG_Q)35?
M_G(T ?W745_"C_Q&4^,O^D?OAG_Q)35?_G(T?\1E/C+_ *1^^&?_ !)35?\
MYR- ']UU%?PH_P#$93XR_P"D?OAG_P 24U7_ .<C1_Q&4^,O^D?OAG_Q)35?
M_G(T ?W745_"C_Q&4^,O^D?OAG_Q)35?_G(T?\1E/C+_ *1^^&?_ !)35?\
MYR- ']UU%?PH_P#$93XR_P"D?OAG_P 24U7_ .<C1_Q&4^,O^D?OAG_Q)35?
M_G(T ?W745_"C_Q&4^,O^D?OAG_Q)35?_G(T?\1E/C+_ *1^^&?_ !)35?\
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MC]\,_P#B2FJ__.1H _NNHK^%'_B,I\9?](_?#/\ XDIJO_SD:/\ B,I\9?\
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MC*?&7_2/WPS_ .)*:K_\Y&@#^ZZOX-/^#R#XF^&-7^*W["WP=L[Z*7QCX!\
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M_AWU^P3_ -&1?LA_^(U_!G_YBZ^O** /D/\ X=]?L$_]&1?LA_\ B-?P9_\
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M** /D/\ X=]?L$_]&1?LA_\ B-?P9_\ F+H_X=]?L$_]&1?LA_\ B-?P9_\
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M?P9_^8NC_AWU^P3_ -&1?LA_^(U_!G_YBZ^O** /D/\ X=]?L$_]&1?LA_\
MB-?P9_\ F+H_X=]?L$_]&1?LA_\ B-?P9_\ F+KZ\HH ^0_^'?7[!/\ T9%^
MR'_XC7\&?_F+H_X=]?L$_P#1D7[(?_B-?P9_^8NOKRB@#Y#_ .'?7[!/_1D7
M[(?_ (C7\&?_ )BZ/^'?7[!/_1D7[(?_ (C7\&?_ )BZ^O** /D/_AWU^P3_
M -&1?LA_^(U_!G_YBZ/^'?7[!/\ T9%^R'_XC7\&?_F+KZ\HH ^0_P#AWU^P
M3_T9%^R'_P"(U_!G_P"8NC_AWU^P3_T9%^R'_P"(U_!G_P"8NOKRB@#Y#_X=
M]?L$_P#1D7[(?_B-?P9_^8NC_AWU^P3_ -&1?LA_^(U_!G_YBZ^O** /D/\
MX=]?L$_]&1?LA_\ B-?P9_\ F+H_X=]?L$_]&1?LA_\ B-?P9_\ F+KZ\HH
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M!G_YBZ^O** /D/\ X=]?L$_]&1?LA_\ B-?P9_\ F+H_X=]?L$_]&1?LA_\
MB-?P9_\ F+KZ\HH ^0_^'?7[!/\ T9%^R'_XC7\&?_F+H_X=]?L$_P#1D7[(
M?_B-?P9_^8NOKRB@#Y#_ .'?7[!/_1D7[(?_ (C7\&?_ )BZ/^'?7[!/_1D7
M[(?_ (C7\&?_ )BZ^O** /D/_AWU^P3_ -&1?LA_^(U_!G_YBZ/^'?7[!/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ny20006478x8_pc02.jpg
<TEXT>
begin 644 ny20006478x8_pc02.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,Z7#\0-4\&Q:CIVD:A%X5O\ Q8FKW?AZ.^TG2[Q-(ELUNM.LIP]M$ ?+-_\
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M_!S-KOP\\+_\%-_^"4OB7XNC1S\)_#MYX8UWXGCQ#H[>(M /P\TG]H'PM?\
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M,= @URQLKW4K.SUB'2M9M(]3M+34=0MK>]6>&"]NHD2>3^1G]HG]O[_@L/X
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M62&*2>9UC^+_ .R>Y6&"%7EFE8 B.*)'DD<A$5F(! /['**_BQ_9)_X*T_\
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M_P *PA\6:9OM/!5_;_\ "4W>D2?:_L:SZA; ']D'B'_@J7^S]X:_X*1>!/\
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M7+XJ\'176E:;-]B?\$8O^"GOQE_;NC_:;^!7[4GPN\,?#7]J;]B[QOI/P_\
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ML4_!/_@G'^SA\-_^";-YX0\>7J^)_C1XITOX(_L\>)==GNM=^'TGAA[#X?\
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M (KT#PR--_X1C1O 'A3PY?0Z0NEZ)XM\)>++S6OA]XENH-;U1M0@T>OOY_\
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MBU_#-OHWAZPM_%$%AH-[<V=AX*U\VT%O$ ?LW7YK? O_ (*E_L_?M!?MZ?M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *_DJ_8*_9O_ &A_!W_!R9_P4 ^.OB[X"_&CPM\$?&?P]^+EEX/^,?B/
MX7>.-#^%?BN\U+Q3\"[C3K3PU\0M3T*U\(Z[<W]OI&K3V4&EZO=2W4.EZC+
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M?\)?&/Q7\'II%UJ&C1^*[>36]+A\-^#[C7?$/Y__ +9G[+\?[2'[(/P<N_\
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M?&;XJ^'+?XE?%?X1_L[_ !]L?@CX-\-:UXG+W7AW1]=\"ZG\)]2\06'CW0O
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MX4^(&JZ):>$_$5]?:?H&NWUG::1J]Y<7-GHNK74,;P:=>/#\^?\ !'#]E?\
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MA>!M"T/QAKW@B'QAX5\00>,--U];C3]2T&/K_P#@G'\!?VE?VM/^"N7[1/\
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M#_7110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7#?$_X@Z!\)?AI\0_BKXKDFB\+?#+P-XM^(/B66W5&GCT#P9H&H>(]9D@6
M1XXVF33M-N6C622-"X4,ZJ2P[FL[6-.TG6-)U32->L=/U/0M4TZ^T[6M-U:W
MM[S2]0TF^MI;;4;'4K2[22UNM/N[.6:WO+>YC>WGMI)(ID:-F4@'\57[)7[7
MW_!PW_P6"A^*G[2_['7Q_P#V5OV6/@G\/?'UU\.-'^%/B?PUX:U&TO\ 7=/T
M?2/%$NF?VAXA^"?QO\<:SJB>%_$_AU=;\3:SK'@[POJ6L7!/A#1-#2+6+?2/
MUY_;Y_X*\ZC_ ,$N?V-/@_)\>F^%_P 5O^"A>N_"7X2:MXO^!]KXFN/!>F:I
MXE\164^A_$3Q[HCZ)X?UZVU'P5X8\<Z+XBLX+#3Y=';6;:RS:WVD1O&5_&#]
MO7_@DI^T3_P1I\._$S_@H+_P2S_;2\6?"3X)^#;G0O%WQ'^!'C;Q9="/[-J'
MB;3O#WA_3--:[MM2^'GQTT*#4O%<-CH?A#XL^'H-?T[3DVV'BCQUXGU""*1G
M_!4/XTZ%_P %"/\ @WF^"_\ P40^+GP-^$.A_M0>)/'_ (:^'=Y\1]"\!Z6/
M$6F:)X-^-WQ-\#ZII?@;QGK<>K^-]$\$>)KO0;O7[SPK%XEFTRTUG5M7LV^V
M>4UW< ']/O\ P3O_ ."BGP-_;P_9W\(?$7PQ\4OAGK?Q4\,?!?X,>-?VH?"/
M@N[U*TT7X+?$#XB^!I]=\0>'-1_X2":XGTK2]+\1^'O'.F67V[6=5EMK3PU=
M?;]3N'A:[FU_ 7_!4_\ X)S_ !1^+\7P'^'O[9OP \7?%.\N+6QTGPYHWC_2
MKFT\1ZG>SRVUKHOA+Q3YB^$/&&OSSPO&GA_POKVKZUDQDV $T)?^5C_@J+X)
M\*?L]?\ !M]^P_K7[./PJ^'7PHN_VJ?"O[ >F?M9>,OA9\/_  EX0\0_%[3+
M']FGQ5\2+.;XM:_X8T.QU;Q?<S_%>RL-9GU[Q+J-W>KKU]J%I-/+-XJU)+KU
M?_@IU_P3G_X)N_"[_@W[\)?'CX*_!WX?:)X]\/?"S]ECX@?"KX\6>BQ:-\6/
MB;K/Q=\4?"RU\1:CXQUL:F=:\8CQCX2\7^*-=E\(ZYJFO:%X*0O=^%=)TVT\
M-6,-L ?V.>/OB!X$^%7@[Q#\0_B;XR\,?#[P'X2TZ;5_$_C/QGKNF^&O#'A_
M2[? EO\ 6-<UBYM-.T^U1F1/-N;B-6D>.)"TCHK?G]:?\%(_V-OVI_A/^TKH
M'[)O[4O@#XD_$OX?_ 7XM>-9M*\!^(;_ $_QGH&G^'_#]YI@\9Z5;W-OI.L-
MIFD>(M1T."+Q1HJS6-GJ&IZ*\6H))J.G//\ QH?\%$/CK\7?C?\ \$R_^#?7
MP#^U?XX\5>&OAC\9?$'Q-U3XY>-=3876LZEX6^$_Q%\$?"7X;_$G5)M25;W4
MM:T7X!>-]8\60ZQJLTJ^*IO%4NL7-U?7"S7K?V87_P"P3^Q=^R9^SU\=-?\
MV9_V;_A/\'M=M?V3_BK\-F\5^!O#EM8^*?$/@D^$+C5Q8>+_ !:SW'B#QY=W
M&HZ%I&H3^(_&6J:_XBO+FT6>XU>9IIVE /R4_P"#<?\ ;7UV;_@EM^T3^TC^
MW)^T_P",/$>A?#?]KKQSHVK_ !A_:-^*OBCQK/X6\)#X1_LX?V)X=C\4>.M8
MUK5+;2Y_%7BFZ30_#EC<,EWXC\231:783:KK+I<^"_\ !QY_P4'\0ZC^QO\
ML>?'C]@?]J[XH>%?!7Q ^-_Q)\.R?$SX ?$;XD_"ZS\<6GAGPP;2]L#K7AR]
M\*W7B?2-&\06U[9LP>^TNUURRU&T21=1L+V*#^2O]GKQ?XJN?@C^S/\ "?\
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MY?Q? +XT26-H\BPI=7D?Q;_91:VMGF=D2)9Y@D32.Z*@8LS* 2 #^DWXF_\
M!1[]@[X,?&.U_9]^*O[6?P-\!?&6XNK"QF\!>)/'>D:?J^CW^K65KJ.DV/BB
M5YCIWA&]U:PO["\TJS\47ND7.IVVH6$MC%<)>VIE_$'_ ((/_M"?'KXP?\%
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MI9%AU*/[0!)'$@*-C@ _:'_@O'_P4+_:N_8@^-G_  3,\&_LV_$+3O!'A_\
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M /8S? '_ -7W\.* /Q&U;_@H7_P<'?L[?L9?!+_@J/X]^-O[+OQZ_97\<?\
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MPM8I=WD]JNK3)I7P[\,W5J;GXC^,U_LW3++4]%T'QC-I6%_P0O\ ^"67C/\
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M^(_%92VLK325G<S6K1NFG116X!^BE%%% !1110 4444 %%%% !1110 4444
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M]9UB'2[NY2UNF@M;][>XD%M<;8R8)0@!['1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%>,?&3]H7X/_L_R_"2#XN>+_P#A$I?CK\:/!O[/7PK7
M^P/%&O?\)3\8/B!9Z]J'A'PAN\,Z+K*Z'_:UGX9UN;^W_$9TCPO8?8O+U/6K
M*6YM$N/9Z "BN/\ 'OQ"\ _"OPIJGCSXH>./!_PW\#Z&;$:UXS\>^)M%\'^%
M-'.IZC::/IHU3Q%XAO=.TC3SJ&K7]AI=B+N\A^UZC>VEE;^9<W,,3]7;W$%U
M!#=6LT5S;7,4=Q;W%O(DT$\$R+)#-#-&S1RQ2QLKQR(S(Z,K*Q4@T 2T444
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MU#2]/L9K#3='O-3^&OPX^&OC>'2].C>&2QM=*\8::+<V=M;HPL#<V=Q]H_\
M!52U^+_PC_X)U^+OV:/V*/V,M8^/UO\ %SX3^./V1=+^'WPS\16/@JV^!?PV
M\;_!/QOX)TOXA6NES>'==A\1:-X*D71-+A\(I<>'7U1KZW1O$FGE6E?]>J*
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M?#/BOPMXUTB#7_!OB70/%N@W+RQVVM^&=9T[7M(N)(&V31P:EI5S=V<KPO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *_G&_X.*/V7/V9?#/\ P2H_
M;2^,_AO]G7X$^'OC#<ZQ\&/$-S\5]#^$?P_TGXE7&O\ BW]JCX/0>*]<G\=6
M'A^W\42ZQXF@UK6(?$.IR:JU[K46K:G'J4]RE_=++_1S7X=_\'(?_*%W]LS_
M +MW_P#6K?@90!Z/_P %&/V7/V9?@E_P3B_X*%^*_@Q^SK\"?A%XHU#]BO\
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MV*_COH'_  7B_:$^'>D^"/"7[9_C35_ _P"UQ\&8/"6FV6O_ +&/[-GQFO\
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MA>&+?Q=J,=[X8NX+KQ9X)U'5[32M'\1ZA)I%_%J=Q=V%G<7RRR>=?LB*J?\
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MOVA !_P:YZ   !_PZM_9C. ,<GX/_"<D\=R223W))/)KR?\ ;^\)_#WX,?\
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MPAX03]G3X[W'[&?CR3Q]XA^-OBCX<?&;0];^('[07PY-K\*M1\!>#OA[XO\
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M (>_%:[\?ZG\0M2^&/[.'[->I['_ &@O$$OQG^-/B2P_9F^ FH2>+M3TZ/\
MX3/_ (1W5=.N+E=4&CS>"_ 6GM87'AU+_P *2Z/<>9_\$\?V5?@S^V7\#O\
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M;4?$7P^M?B7\2?\ A!/#?C#3A=P:_H7@GQ'I4,&=-$*[G['/_!8G]A_]GO\
MX)W_  B\,?M&?%#1O@A\?_V4?@3X-^"?Q=_95\612:%\?K'XD_!3PI:?#R?P
MQX7^%=]%::[K+^,[OPQ;:IX6;3(;G2-.TOQ%I*>(M7TG[+J<MF >R?%[_@M1
M\/-%_93_ &*/VM/V?/@SXS^.OA?]M/X^V/[/?@[X=7NJZ9\/_B;I/C_4]/\
MB1I6G^$;NPG3Q%X?7Q;+\4O =M\/+F"YUZ#PY NL-XHMO$=_HMO:R:C\K_\
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MX:\*VFI>/+"YGU;2_$DOAS36\,73Z?:ZEHTX@OVM;7\,O&_[/6N?L\_L\_\
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MP5^-EGXT\%> +\:[X]T_2/$EMX7\<>!+'5?#UWXBL+'0[S1M/M+RYUZP_/\
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MU -;_:M?SQ_\%O/ ^F^%?CQ_P31_;'^)7C+XT_#S]FWX#?$WXY_"+]H+XF?
M3Q-XW\)?$+X.Z)^TWX T'P]X*^*K^)_ UM/J?A/X?Z1XP\$V?AWXEZYN4W^E
M>)=(\+VUMJ.HZYI]E* ?9WP"_;5_:,T/]I[PO^QI^WS\&OA7\)?B_P#&'P'X
MO^)?[./Q!^ ?Q"U[XA?!KXO:=\.YX;GXF?#MSXU\/>$?'7A;XG?#SP_JWA_Q
M%=076A7_ (;\3Z%)K.JV.K:/+86.DZK\X?#G_@HW_P %!/VM[S]H"#]B[]C3
MX&W6D?LO?M%?&OX#>/\ Q?\ 'WX_Z[X:TCXC>(OA%XNNM.@\$_";3/"G@&_U
M6#QEKW@\^'/$>I^(?')T3X?>&=1\8:9H<&K^))-*UZYL<K]E_P #?\$N/C)^
MV/\  _Q?\'?V_?C+^V/^TG\ _"/Q(^*?PJT?Q)^UKXY_:'T;P+X3\:Z!9?#+
MXC:C=M.NK>'?#<FLZ;XJT;2M7\/ZGK&DZW?2C3'GTNYBTYA#[I_P1D@AB^"?
M[6LD4,4;W/\ P4R_;[GN7CC1'N)E^/.NVRS3LH!EE6WMX(!)(6<0P0Q [(T5
M0"]K'_!6[X>:#_P3YM_VUM5^$'CRV^(U_P#$#4?V=M+_ &3(]2T2^^*>J_M>
MZ=\1M8^$4G[/NG:IIK7FG7US)XZT+4]13Q%8V%UJ,GPXM)O%]OX/N-75?![_
M )/_ /!:O]HW]OW0_P#@GK\3OAK^V/\ LF?"/PGX,^/'COX$:-X$^*O[-OQO
MU;XGZ9\,/%?AW]H3X5?$W3?A_P#'#PSXW\#> M:CDU_PIX&\7PZ=\2_ ;Z]X
M1/BFPT?PWJ.EZ3-XFTF\;A?$'@CQE>_L!>*?V@_"'A3Q-\0+?]A7_@X;^*O[
M;7CGX?>";*[U3QIXR^&GP9_:H\;V'CK3_#&F6MG=+>W^CZ%XQN/%UW]LDL;&
MQT7PWJFJW-X%T];>Y]/_ ."Y_P#P4T_9&_:+_P""=NN_"C]EOXN^#/VC?$GQ
M'\:?L_\ BSQ;#\+_ +9XO?X._"W0?C;\/-8D^('Q.NK"U:V^%BW?CL> /AG9
MZ9XVET3Q)J&O_$&QTBST:<MJ$MB ?L-\?OVS/COJO[07B_\ 8Z_80^$'PZ^+
MOQ]^&'@#P?\ $GXW^//CCX\UCP%\ ?@AI'Q%GU5/ASX2\1WG@C0/&7C_ ,3_
M !0\<Z?HFI>)=)\(:;H.BZ;:>#H%\0W7BF21QI5<G\-_^"J/@G2_V?\ ]L/X
MB_M:>!;G]G_XP?\ !/J_FT?]JOX1:/XATKQW!%=:QHL'B3X2ZY\(O%$DN@6W
MC'P[\>M%U'1X/AB/$4'@_5I/%-[=>&M;L[""RM]>U/\ +/XY>%_@E^SK_P %
MA_VQ-5_;(_:E_:(_9!^&7[;7PX_9P^*O[/7QB^&GQ[^(/[/WPG\4Z]\'/ C?
M!CXF_"SXE>/M(-EX6NO'7ARXT[1O%GA;3-7U!+;PQX*\0"2[OK*7Q3HMG?7/
MCA^Q=^RC^U1_P3G_ ."KFJ_\$XOC[\4?VN/C#\:-&^%&@_%3QYXG^+7COXY:
MG\0_'/[(.K^%_C%X-^'OAGQ/JND71\9^(;[P0W_"&>&)?#MUKNFZ@VOZ)X=A
MU:QA29K8 [O]N?\ ;,_X*-'_ ()M_M/_ !6_:!_82^&_A#]G+X__ +)7Q/\
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M9/%6FP?M&?$#QB="(:+3;7X.Z#"Z">S:&$ _>#]I+QU_P47MO&GA+P'^R'\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKVST3Q'=Z1I]SKNCVFHA%U"UTK5YK=]0T^VOQ&@O8+2XABN@B"=9 HQNT44
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]OXL\.WFGZQI6GS^,M)T6SU\6EW$M_H%QJFF70DL[RXB?X^\$? C]M'X!?\
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M&NWEY_97A_3_ (B)X>T3X-:;H?@CPY;V?AVS>'4O#6C*UG;Z4)"GSI_P6/\
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MX.\/?#F]TA==NKBPU2;5/&$-W)H<+)$K:D( #!_X*K?M8^+_ -B/]@3]H?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *\9^*_P ^%GQLU[X->)?B/X?N-;UCX _%*R
M^,OPMN8-:UK25T#XA:=X<\1>%+36;BWTF_LK?6H8]#\5:W:G2M:CO]*D>Z2Y
MDLVN+:WEB]FHH **** "BBB@ KY3^$'[%/[.WP/^-'Q0_:(\#^$_$%U\:_B]
M9S:+XL^(GCOXC?$?XG^(+'PC-XFO_&3?#_P/-\1?%7B>#X<?#H>*-1GUH>!?
M 4'AWPP]W;Z0)M-E@\/Z!%IGU910 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7Y9?\%%/^"M?P*_X)I:Y\+=!^,?P>_::^)MQ
M\6M)\4ZOH%Y\ _A]X/\ &FG:5#X2O-%L]1MO$=QXI^)'@-[&]N'UVSEL(;*'
M4EE@2X>>6V*Q)-^IM% '\R/_ !%3_L0_]&G_ /!1K_PQ/PC_ /HAZ/\ B*G_
M &(?^C3_ /@HU_X8GX1__1#U_3=10!^9'_!.7_@JI\$/^"FG_"X_^%-?"?\
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M>:-IL]U9RPSO9P[PH\:_XBI_V(?^C3_^"C7_ (8GX1__ $0]?TW44 ?S(_\
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M[R_AU:XO(M3O]'MX].FANKBYM/NFB@#^9'_B*G_8A_Z-/_X*-?\ AB?A'_\
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M]I.EWEYIDUK<7.G64TCVT7F/_$5/^Q#_ -&G_P#!1K_PQ/PC_P#HAZ_INHH
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MF>SDAEGL[65G@3^C:B@#^9'_ (BI_P!B'_HT_P#X*-?^&)^$?_T0]'_$5/\
ML0_]&G_\%&O_  Q/PC_^B'K^FZB@#S'X)_%70_CM\&?A)\;_  QI/B/0/#?Q
MD^&/@+XJ^'M"\8V%GI?B[1=#^(?A72O%VDZ3XJTS3]1U>PT[Q'IUAJ]O9ZY8
M6.K:I9V>IPW5O;:C>PQI<R_EG^WG_P %P/V;O^">OQQM_@)\6?@1^U[\0O$]
MSX'T#Q]#XB^"?PO\!^+/!3:3XBOM:T^TLAJ_B7XL^"M0.K6MQH-Y]OMET9K:
M!9+?R[R=WE2']FJ* /YD?^(J?]B'_HT__@HU_P"&)^$?_P!$/1_Q%3_L0_\
M1I__  4:_P##$_"/_P"B'K^FZB@#X6_X)]_M_P#PL_X*.?!GQ-\;_A%\/?C5
M\-?#?A;XG:S\*K[0OCMX3\.>#O%UWKFA^%?!?BZYU;3M,\,>,_'-A/X<GL/'
M.F6=G?S:M;WDNIV&L6\FG0PVMO<W?$?\%%/^"G7P;_X)I:#\+O$7QB^%'[1'
MQ/L/BQJ_B?1=%7X ^!?"WC6?1+OPK9Z-?71\4CQ1X^\!PZ;%J,.LQC1S:3ZE
M+>/8ZD)(K=+97E_2"B@#^9'_ (BI_P!B'_HT_P#X*-?^&)^$?_T0]'_$5/\
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M92FTR11OE!D?\14_[$/_ $:?_P %&O\ PQ/PC_\ HAZ_INHH _F1_P"(J?\
M8A_Z-/\ ^"C7_AB?A'_]$/7]$GP9^*&C_&_X/_"CXT>'='\2>'O#_P 7OAKX
M%^*&A:!XST^UTGQAH>C^/_"^E^*],T?Q7I5CJ&K66F>)-,LM6@LM=T^SU74[
M6RU2"ZMK?4+V&-+F3TJB@#\0_P!MG_@O)^S)^PC^T'XG_9P^*'[/G[9WCGQ;
MX6TCPMK5SXH^$'PH^'_B;P#J5IXLT&RU^Q&CZWXA^,'A#4[R6RAO18:H)-#M
MXK;5+6\M89;E(?.?Y-_XBI_V(?\ HT__ (*-?^&)^$?_ -$/7]-U% '\R/\
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M/1M2GM;.*:=+.;85/]!-%% '\R/_ !%3_L0_]&G_ /!1K_PQ/PC_ /HAZ/\
MB*G_ &(?^C3_ /@HU_X8GX1__1#U_3=10!_,C_Q%3_L0_P#1I_\ P4:_\,3\
M(_\ Z(>OZ6-!U>'Q!H>BZ];VU[96^MZ3IVKP6>I0K;:C:0ZE9PWD5M?VZ2S)
M!>P),L5U"DTJQ3I(BRR!0YUJ* /PM_;'_P""_O[+'[$O[2'Q&_9B^(_[/?[:
MGCCQG\,_^$0_MGQ3\)?A/\.O$WP^U3_A,_ ?A?X@Z=_PC^MZ]\9?"FJWOV+2
MO%=CIVJ_:M L/LVMVFI6D'VJVMX;VY^8_P#B*G_8A_Z-/_X*-?\ AB?A'_\
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M !%3_L0_]&G_ /!1K_PQ/PC_ /HAZ^AOV4?^#A3]E/\ :_\ VA/AG^S?\/\
M]G+]N#PCXP^*>K:CI&B>)/B7\(?AQH/@729M,T#5_$=S<^(]8T3XU>)M4L+(
MV.C74236FA:BWVJ2W22*.%Y)XOWHHH R=>U>'P_H>M:]<6U[>V^B:3J.KSV>
MFPK<ZC=PZ;9S7DMM86[RPI/>SI"T5K"\T2RSO&C2QABX_FG_ .(J?]B'_HT_
M_@HU_P"&)^$?_P!$/7]-U% '\R/_ !%3_L0_]&G_ /!1K_PQ/PC_ /HAZ/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445\S?MES?
M'RR_99^.6L_LMZO%I'[07ACP#JWC+X5)/X>T?Q3#XD\4>"C#XLA^'\VC:]')
MIDD7Q,M=&NOAW)?OY5WHJ>*#K6F7%KJ>GV=S$ ?3-%?G%\9/VP=0\<_L6_ W
MXM_LNZS;:;\2?VW[CX%> OV:M2U+3+#Q++X5\0?M 06.LZMXSU+P_.MSI>KW
MWP#^%$'Q'^,'BCPYJ44UC-'\*M;TC5K22(75JW _'7X]?MA> ?\ @I/^PK\'
M8+GX7^&?V1_C=XN^,_@F_@LS-XJ^,'Q<UCP/^R;\2_B]/K?BF;4/#&E:)\*?
M#?A7QMX=T33M T;P;J.NZ[XOFL-5U?7M9T30KJS\*S 'ZMT5^9/QS\;?M/\
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M/A?0]-\'ZSX?^&?P+L/"'P(^)$VE^+6^W>)/"OP-UK2/%=_X?\17LWAZ_@\
M^/?%=IXILM.\+:Q;VOC&Z?73>Z, ?IW17XZ?#7XG?ME? ?\ ;^^!/[(_Q@_:
M8\&?ME:'\>?@?\</C'X_%A\!_#'P0\;?LX6?PQU+P9I?A#QI9P^"?%&N6.H_
M!_XD>)O$M]\.M(TCQK!J_C"U\5Z?]KMO'VO6MOJEA9?9?[?/QM^)G[.7[(WQ
ME^-GPCT"RU_QG\/])\/ZJS:CX=U7QCI_A3PA<>,O#NE_$CXF7W@[0]6T'6?&
M-I\)OAU?^*OB;<>$],UO2;WQ)%X2?1H=0M&O?.0 ^P**_'?6OC[\3_V,?V-?
MC3^V#XJ_;-LO^"D/AC7=#^$6F?L\I9>"_@#\-O"5U\3_ !QXZ?X5:9!I/Q"^
M!]EIN@Z[\/?''Q!\?>!DU6YU&+7=5^'?AGP?KE[;ZUXEO+J^"<3^S?\ M >-
M/%_A+X\_%'1_^"N_P(_;6\4>!?V=?BSXFU;X'_ WX>_L\Z)X2^''CS2[6VU/
MPSX\\/)X=U'Q5\8G\%^')['4O#EK_P +"U[Q'HGCAM9TG6A=Z>;3^S-2 /V^
MHK\./^"67QU\?_M,>&_@#\4/%'_!5[P+^T?XS\1? CP/\3/C+^R5X5\%?LG:
M=K'@_P 3^.OASI=[KFAZS-\--(L_BAH%O\-O'.N2:5<O<+9.NN^'KCPUXB$=
M]#JNG1=I_P % /VV/C1X&^(G@?X<_LN:OIFD6'PB_:*_8WT#]KKX@:EX>TCQ
M+I]OIO[2_P >?AC\,_"_[-WAR'68+BTM?B!XM\ _$#5/B_XR\0V22ZM\-?!6
ME?#F$6T-S\:O#VMZ* ?LG17Y4?\ !1;X^?M@_ [XA?L<R?!>7X6>$_@+X\_;
M _9&^$'QD\6ZVUUXH^*WC*'XU_'K1/A_KOPT\(>$+[PX?"G@_P ,Q^#+B[U;
M7?B5<^(]2\5SW^IZ9HGA30-!DL+_ ,3OT/QS\;?M/_&W]L'4_P!DW]G#XU)^
MS/X:^#O[._A/XZ?%_P"+]M\+?!/Q:\2>(O%7QF\<^//!GP;^&N@Z%\0XY?#F
MAZ)I]I\'?B/XL\<:S]@U+5-;M;G0?#VA7?AJ[2_UJ  _3:BOAG_@GO\ M&>.
M/VC/@7XBF^+;>&7^.'P*^.?QP_9>^-UQX.M9M.\-:M\1O@+\0M7\%7/BO1](
MN;J\NM#LO'OANV\->/H=%FN)DTQ/%"VMC/=:9'8W=Q]S4 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 ?C!^QU^Q7\;OA/^U;XKT7XA^%]"TS]D+]DCQ7\?_%7[!-Y
M8ZIH=TWB2Z_;3\0:=\0_&+3^'-.\0:AKGA.[_9:M;SXK_ ;P;=>)=(TA?$'@
M3XOZ@N@P3Z?I;7DOU#^T[\$OB=\0_P!LO_@FC\5_!_AG^V/ /[/WQ5_:3\2?
M%W7O[:\/:?\ \(EHOC_]D_XI?#3PE>_V7JFK66M:]_:WC;Q'HVB_9O#&G:U=
MV'VS^TM3@LM)M[J_@^_J* /S&^+?A_\ :#^ /[</B#]J?X6_ GQY^TM\*/C?
M^S'X$^"GQ)\ ?"?Q+\(] ^(G@CXF? SXB_$;Q;\+?&/V3XU?%'X4>%]=\%>+
M=!^-_CCPUK+Z1K]SKOA/4]"T[5)=*O=)UF^GT[\[+?\ 8%^._A2R_9H^*_QO
M_9.T[]K3PWXM^,_[;_[4'[9?['7AWXE^ =0M/"?QU_:J\=^$_B%\'O&FE>$/
MB=XR^'7P'_:2U?\ 9N\'>'M3^"5S;>/O%UW8:6VMW'B[X2:9JMU#I=S8?TF4
M4 ?S/S?\$Y/CHWA:7XH^#?V9H/"_PX^%W_!1[X#_ +7/[/O_  35\;^-?A=X
MD@\%_"7P5\+M3^'/QNT7P1?VWQ/UKX"_#OQS\1_&'Q#\8?&CP%\,=)^)MC\%
M_!.N^!/!%DFH:4-8US3X_LWX4^"OVEI_VK/VR/\ @H+IG[)'B_X3R:M^R=X#
M^"WPD_9:\5^//@1X=^)7[5'Q.^&FM_$+Q]9_$+XG^(O ?C_XA?#/X<7L4WB#
M1O@U\/\ 6O$?C/5=6@\+W6NZQXGM;+1]+\,Z=)^R=% 'XR_L+Z'^TNGB;QKJ
MW[5O[$W[0'A/X]_M5P7$W[2/[3-U\4?V1X?AUX TW0O!VM0^!?@Y\)M-^$O[
M4WCOXU>&O@_\/4DF\(?#1]&\/:IXMOO&?BC6?BWXXO=-UWQ5XIUG2_K_ ,&_
M #0?V)? /Q-\6? #P9^TW^T=XH\0MX(-Q\,/&'[4WC+XK^*M;AT?7+G3I3X"
MUG]K?XU)X#\%W.F:/XKUWQ%K<$?BWPA%XMM]"L=-N[K4-3L?#MO%]MT4 ?S1
M?%W_ ()S?&3]HOP5^W)+\'/V8-._9!^$WQ7^&W[.VO\ PV_8Q^+&I?!\^!_C
M;^U!\%/V@3\=O%GQ8\;>"_@9\1?B)\-OA-!\4?!GAGPC\"M:71O%.F:QXVMM
M9U?Q'\2+:QNO#NA7Z?7-EX$_:"^,_P"VU\(OVK[3]BOQ[^S+X2_9,_9;_:"\
M OX5\:^+?V:(?B)^U/XQ^)UOX)3PA\ -+_X5+\6_B3X3TGX1?#^[\&7?B71?
M%_CKQ-X?TN+QKJ^D+H6EVN@3^+-1'[244 ?D=]@_: _:A_:X_8\\;ZG^PYX[
M_94^'O[*7B?XE?$'Q3\7_C%XY_9RO/'7B.7Q%\#?B/\ !VV^ 7PV\+_ GXJ?
M&2[O/ VNZY\3-*\?^)O$VOZKX=\-W$7PQTRVTJPGUJ>PN;+YM^/G_!,3]K?1
M/V;X/A/\#_VJ=<^(M_KO[8?P5_:"\7RZO\'_ (*:/XWU'Q--^U;X"^+GQ$^-
M?B+QQXFUFTL_%&N_#RQTZY\6:;X;O;:YM]9T+P5H/PUT/0)M'AT?P\O] =%
M'YM_MK?L^?&[XI_"#]B[P=X8FN?C+XW^#W[;/[!WQ6^*_C*];P/X$O-;\(?!
M/XM^$_$?Q:^*5WHK7WAWPW:7+Z=I6I^*)_!W@^"6Y>6=]'\):#>,EI8G*^+?
MA_\ :#^ /[</B#]J?X6_ GQY^TM\*/C?^S'X$^"GQ)\ ?"?Q+\(] ^(G@CXF
M? SXB_$;Q;\+?&/V3XU?%'X4>%]=\%>+=!^-_CCPUK+Z1K]SKOA/4]"T[5)=
M*O=)UF^GT[].:* /A'_@G;\ ?'GP&^ FOW?Q@T72/#7QP_:"^.7QR_:I^-/A
MG0]7M?$.G>$?'OQ_^(FL^-T\!1^)+)!9^(YOAMX1NO"GPYNM=L9;G2=1N?"D
ML^@W,N@G3"/NZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^(?\
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MB">%Y3?Z_P"*O$'V[5=0N7GFCA$\6GV!@TJQL+6W^J: /\Y7_AWK_P '9/\
MT/W[<7_BSKP9_P#194?\.]?^#LG_ *'[]N+_ ,6=>#/_ *+*O]&JB@#_ #E?
M^'>O_!V3_P!#]^W%_P"+.O!G_P!%E1_P[U_X.R?^A^_;B_\ %G7@S_Z+*O\
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MO]&JB@#_ #E?^'>O_!V3_P!#]^W%_P"+.O!G_P!%E1_P[U_X.R?^A^_;B_\
M%G7@S_Z+*O\ 1JHH _SE?^'>O_!V3_T/W[<7_BSKP9_]%E1_P[U_X.R?^A^_
M;B_\6=>#/_HLJ_T:J* /\Y7_ (=Z_P#!V3_T/W[<7_BSKP9_]%E1_P .]?\
M@[)_Z'[]N+_Q9UX,_P#HLJ_T:J* /\Y7_AWK_P '9/\ T/W[<7_BSKP9_P#1
M94?\.]?^#LG_ *'[]N+_ ,6=>#/_ *+*O]&JB@#_ #E?^'>O_!V3_P!#]^W%
M_P"+.O!G_P!%E1_P[U_X.R?^A^_;B_\ %G7@S_Z+*O\ 1JHH _SE?^'>O_!V
M3_T/W[<7_BSKP9_]%E1_P[U_X.R?^A^_;B_\6=>#/_HLJ_T:J* /\Y7_ (=Z
M_P#!V3_T/W[<7_BSKP9_]%E1_P .]?\ @[)_Z'[]N+_Q9UX,_P#HLJ_T:J*
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MKP9_]%E1_P .]?\ @[)_Z'[]N+_Q9UX,_P#HLJ_T:J* /\Y7_AWK_P '9/\
MT/W[<7_BSKP9_P#194?\.]?^#LG_ *'[]N+_ ,6=>#/_ *+*O]&JB@#_ #E?
M^'>O_!V3_P!#]^W%_P"+.O!G_P!%E1_P[U_X.R?^A^_;B_\ %G7@S_Z+*O\
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M[JMS]D\.>)/#6F^'?">JW4EIX<O_  [HFKK;ZIXA_L9K_/3_ .#L[]EKX>_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB'3]7T61Q-J!>68(HC^V/^"1/[6WQ/\ VZ?^">/[/?[5'QEL?"&F_$GXI?\
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MWBDMI$2.Z],^,'_!9G]K'P'^V9_P1Q^ &B^'O@K+X(_;X^ W['GQ,^-EU?\
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MM_X?U;2_%/A^XMM<MK/3?$^I_F_^SE\!OVQ?VB_^"Z'_  5J^'?[&G[5MO\
MLA>+KKQS^T=<?$/XC#PC:^*]8U3X:-^TGX9LM3\.^&V>V.I:#KC:U=Z'K-KK
M&AZOX;U,II$NG#7;.UO[D2>__P#!8'_@F5\-?^"6G_!#+P7\$?!GBF[^)'C#
MQ7^W+\-_'/Q5^*FH:(GANX\:^)Y_A;\8=*TZ/3O#B:MKY\.>&_#V@V-CIND:
M(==U8K=MJ^M37;7NN7B* ?1\W_!<K_@JU^QSKG[(OQ0_X*(_LU?LS:E^QY^U
MM9^$=<\+_$KX$3^(M/\ &47AKQCX2\+>*3J-C#J'Q/\ %[Z=K/@[2?&>EZQJ
MOA+QAX!TK_A+7TO6=$\,>*K>.-_$%G^D7_!4'_@K]\8/@!^T?\-?^">7_!/K
MX(:#^TE^WE\4]/TW7#I'BJZ:7X??#70[^WU#6H[?Q)8:;XG\(W5UXDN?!^C:
MKXOO#K7BWP=X=\$^$9-(\:Z_?ZQI=ZNDR?S*^-/@UXQ_8X_:,_X(H?'+_@H?
M\8/%W[:'["OQ@^&WP9\2_#K2OB9XC\:^%_"'[*>IWGACX774^C:?X;TGQO?^
M&$T/X2V^H_"KQ5JES<6%EHWQG\%^&/$'A[7_  7+<:$;RW_4WQS\0- _8T_X
M.M/$?Q3_ &B;C2/ _P *?VL?@%X;\-_"SXG>.+O3-,\':)(WP4^'O@RWU"#Q
M)J&K0:?H3W_Q#^#/B#P!++=>3<0W?C"W6ZT^'2M=M]=D /5?$'_!7/\ X*P_
M\$U_BC\*7_X*_P#[-'P7N/V5?B]X@D\)Q_'O]FU-2O+_ , >*M4D&MQV>JBU
M\9>)].U2/PIH"ZJ#X*O_  KX:\3>+-$T35->\'>+?&-[X3UVRU?[)_X*[?\
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M  7+^+O[)WQ(_;W\)_L\_L2?%#]FCX'>-/%W@_XRV5M:>,O!/CCPU#X(\*>
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M?2_A]KW]C>(9OC!);ZOY?B+6+**U\F&/[3:-)=+M2,J?[,= \?>!?%FK>(=
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M\0:S\%/&WA?2=8L)-0LO-A\0Z9\(/&NDVSSB'3WFF.FW6K:;<:G8QW_["_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEPI%>^)==.I>*->N3+J/B'6=5U*>:[D_5JB@#\TOA)_P1]_X)T_ OX,_'O\
M9]^%?[.__"+?"']I[3/#^C_'+PC_ ,+;^.>M_P#";Z=X6.JMH5M_;_B/XFZO
MXG\-?83K>IGSO"&M:!/=?:?],EN!#;^5\Y67_!N1_P $9M.O;34+/]CCR;RQ
MNH+RUF_X:%_:ID\JYM94G@D\N7XXO$^R5%;9(CQMC:ZLI(/[=44 ?"G@#_@F
MC^Q-\+OC1^T)^T+X%^"O]A_&#]JG0_'OAOX]>+_^%C_%K4_^$[T7XG:Y;>)/
M'%E_8&L>/-0\+^%_[;UJTM[W[3X,T7P[=Z;Y?V;2)]/M'>!L/P=_P2M_8)\
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MRWO]B>%/B]H?AW3=T-M"GV;2-(L+1=FY8 S.S?K?10!^3-__ ,$-/^"6FJ?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5_#O_P 'F?\ SC?_ .[P/_?7*_N(
MK^'?_@\S_P"<;_\ W>!_[ZY0!_5-_P $Q?\ E&Q_P3U_[,=_9-_]4+X!K[BK
MX=_X)B_\HV/^">O_ &8[^R;_ .J%\ U]Q4 %%%% !1110 4444 %%%% !7^<
MK_P=Z_\ *2?X(_\ 9COPU_\ 5]?M+U_HU5_G*_\ !WK_ ,I)_@C_ -F._#7_
M -7U^TO0!_HU4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?P[_\ !YG_ ,XW
M_P#N\#_WURO[B*_AW_X/,_\ G&__ -W@?^^N4 ?U3?\ !,7_ )1L?\$]?^S'
M?V3?_5"^ :^XJ^'?^"8O_*-C_@GK_P!F._LF_P#JA? -?<5 !1110 4444 %
M%%% !1110 5_G*_\'>O_ "DG^"/_ &8[\-?_ %?7[2]?Z-5?YRO_  =Z_P#*
M2?X(_P#9COPU_P#5]?M+T ?Z-5%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^V_=75M96T]Y>W$%I:6L,EQ<W5U-';VUO!$I>6>>>5DBAAB16>221E1%!9F
M!- $]%? W[=7QK_:O\*_LO77Q(_X)Q>"/@G^T1\:I?%7A*UT/0?B'XQ\-VOP
MXU'PCJ<K2^(M5'B&Z^+OPAT:2]M-.DLKK3$3QY$]PMPKPZ?J*NJCZ_\ "?B'
M6(OAMX4\3_%$:#X3\2/X-\/:MX^BBU"SA\-^'_$5QH]E<>([2VU-]5U.Q&DZ
M?J\MW;6EU_;>I0/;1Q.NIWJLMS* =U17DGQ.^(T>@? WXE?%7P+J.@^(6\-?
M"_QMXW\,:C!<Q:UX=U.[T#PMJFMZ7(UQIEXD>H:9/<V</G?8[Z(SV[.L-S&S
M+(OYV_\ !%#]N/XQ_P#!0W]AG0?VC_CKIO@32O'VI_$GXB>$;BT^'.BZOH'A
MH:7X5U&TM=-DBT[6_$/B>^6\>*=S=RMJKQ2N%,<$(!! /UMHK^>[_@LU_P %
MQM=_X)0?$WX,?#S2/V;=+^.2?%GP'X@\:3:KJ'Q3O/A^^A-H>OIHOV".RM?
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M&_ O@SP_9;_L>A>%/".C67A_P[HUIYC/)]FTS2-/L[*#>[OY4";F9LD_A_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*_AW_P"#S/\ YQO_ /=X'_OKE?W$5_#O_P 'F?\ SC?_ .[P/_?7* /ZIO\
M@F+_ ,HV/^">O_9CO[)O_JA? -?<5?#O_!,7_E&Q_P $]?\ LQW]DW_U0O@&
MON*@ HHHH **** "BBB@ HHHH *_SE?^#O7_ )23_!'_ +,=^&O_ *OK]I>O
M]&JO\Y7_ (.]?^4D_P $?^S'?AK_ .KZ_:7H _T:J*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:WACPGI?C^/P9?>'=2\475_:?3'_  2__8+^*&L?M%_MO?LH_&7]AO\ :1^
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M=XD_9^\,?M3>,I]>\9Z0GQ+T^P^'/@+PO>26'@VS\4GP;X,T;7(;"35-"N_
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MUS?7VI*NEQVEQ:6U@ ?EW\-OVPK'_@M/_P $T/\ @H_\&OV_?@'X>M_V@O\
M@G9X-\:?$6^N? OB3Q;X?\#7WQ6\+_"GX[:?\/?'5HO@_P 9O$/$WA;Q%X*\
M:6OB/PO/XB\1_#;Q(TUCK.DZ;<Z5<-HVA?FI^Q)X-\*?LD?\&]O[4O\ P4J_
M9ZT35O 7[;_B.;7_ -F#4/V@/#WC3QY#KOASX2?$+]H?X(^'-:MM%T%/$S>#
MO"WB&WL?L1\.>.M \/:/XW\/:\=)UC2_$4%S%MN/[&_V!_\ @EI^RE_P3O\
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M!MC8R:'J>B'PEH-UX?\ #^I>&+.QL=*UGP=?Z0A\&Z]X>M=5\16NM 'XU_\
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M:UXB\5ZKXQL);;QCH>H>'/$5_K<UW<>%[S1+2YT_09[*3P_I<_[??_!)F/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *_AW_ .#S/_G&_P#]W@?^^N5_<17\._\
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M' 8=.TZ]G98VL_\ $3#_ ,$<O^CE_$W_ (8+X]__ #N*^-?^#9O2],UO3/\
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M?_5"^ :^XJ "BBB@ HHHH **** "BBB@ K_.5_X.]?\ E)/\$?\ LQWX:_\
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MU;Q)=;+'P_)?6UK%K>H3VNGZ9)=7MW:P3?39 (((!!!!!&00>""#P01P0>M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ:;J6JZ2-9T>].D:OJVF&TU&Z_2'_A:W[.O_ !$2_P#"I/\ AE*Q_P"&D?\
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M0])\.Z3?>$=>NY/$FAZ+JBZC=6OBGP]XGU[PA:^)/A]H>C>*VUK0?YZ_!_\
MP1$_;9\0_P#!"?Q3>+\+];T_]I'5_P!K[0?VQ='_ &?KRVNM(^(>M_!OPO\
M"?7/AHN@6W@\-I9T/XGWLOB[7?B!8^!]EIXEN?#.C6/A?3;!O'>KZ;X5A^F_
MV0?A9^Q=\=?VJ_V3]'L/^">G_!:70OCW\,_BY\/_ !WX@\0?M'^-?'US\&/V
M9O$GAS4K+QO%XEUCQIX@>_U>YTR/4O">GFQBUKP1\.)/&'E:=9M)IUW+';P
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M_9VNFZBWFPPVLR_%/P4^ '_!2+X6?!;_ (./=:_9Y^#_ .T'\*_CC\5_VG-
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MDZ5I%WJ[^%VO?$FF:KX;GU+3KJUT+Q%I^IVFAZCI*Q7OY]?M>_#?XY?M4_\
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M1=474;JU\4^'O$^O>$+7Q)\/M#T;Q6VM:#C_ !X_X+>_&G7_ -KWXJ?L7?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5_#O_P 'F?\ SC?_ .[P/_?7*_N(K^'?_@\S_P"<;_\ W>!_[ZY0!_5-
M_P $Q?\ E&Q_P3U_[,=_9-_]4+X!K[BKX=_X)B_\HV/^">O_ &8[^R;_ .J%
M\ U]Q4 %%%% !1110 4444 %%%% !7^<K_P=Z_\ *2?X(_\ 9COPU_\ 5]?M
M+U_HU5_G*_\ !WK_ ,I)_@C_ -F._#7_ -7U^TO0!_HU4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_#O_P 'F?\ SC?_
M .[P/_?7*_N(K^'?_@\S_P"<;_\ W>!_[ZY0!_5-_P $Q?\ E&Q_P3U_[,=_
M9-_]4+X!K[BKX=_X)B_\HV/^">O_ &8[^R;_ .J%\ U]Q4 %%%% !1110 44
M44 %%%% !7^<K_P=Z_\ *2?X(_\ 9COPU_\ 5]?M+U_HU5_G*_\ !WK_ ,I)
M_@C_ -F._#7_ -7U^TO0!_HU4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?P
M[_\ !YG_ ,XW_P#N\#_WURO[B*_AW_X/,_\ G&__ -W@?^^N4 ?U3?\ !,7_
M )1L?\$]?^S'?V3?_5"^ :^XJ^'?^"8O_*-C_@GK_P!F._LF_P#JA? -?<5
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MV@:M;1WNEZYX?U_1[F\TK6='U*SFBN]/U/3KNYLKRVECGMIY(G5R =#1110
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MOIH%O_$?BC6KFWTK0M'MC)?:I?S16MI#+,ZH0#L:*** "BBB@ HHHH ****
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MOQ!;V&I:GIT.LZ5?1Z?J>HV2P7L_FG[+'[5-U^TAXZ_;#\&W/@FW\(I^RO\
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M;^S5\6=#\=W7PPU3Q'^V)?7/Q8M;GPU#XTLO"NL?$+PKX4_9_P#$7@W1M/\
M%7C'0=%\(>)O"FA^.]<\8?#&6^UJ_P!5@U^^T2?PXWG_ /P2W^,W[=WQ)^-'
M[=FD?'SP7\-)/AUX4_;:^*/A;5]8M?VD/B#\1]=^$?B32O@?^SYJ.F?!WX3>
M$O$?P;\.:7JGP@LTU6/Q';Z]_P )#X&E@\1^*_%13P"9DDU76OE'X>:WX)TK
M]N3]G*]_X)3_  4_:Q^"8^*GQDN]6_X*.?!SQQ^SU\</@9^RKX7^%DOA'4+O
M7/$/C?P7\:/!&@>!?AU^T7_:$?AVZ^'D_P "+K29/%9M]1LO$QUJPUE$U+[1
M_8Q\:Z7\)/VOO^"A_P"R;\3/!_QAT;QQ^T#^V=XU_:&^%OB*'X+?%JX^$_C7
MX1^./V7O@A;7.NZ?\:+'P?<?#32&\-:Q\.?$G@_6GU_Q/I$9\:R:3X6T275]
M>OUL(@"MX7_X*/?MB?M&>&O%7Q[_ &(/V#/#_P <_P!DWP[X@UW2/ WCOQW^
MTKH?PE^*G[3FG>$?$>L>#?&/B7X"_#C_ (0'Q=H>F>']-\0Z%JLGAF]^+7CG
MP5>^.=+LHFL-)TJ_U 6MEZQJG_!5'X8^+?V>_P!ECXN?LQ_#7QE^T/\ $S]M
MVZ\4Z+^S1\ 5UKPI\,O%.L^(OAYHWB35/BS'\3O$WB?4;S0?ASX8^"]UX4U?
M0/BKXHT^/QP=&U[^S]/\-Z1XN;5=.:X^"_V(OVO;K_@FC^R)9?L,_M"_L[?M
M8^)_VB_V7-1^+/PX^$FA?"3]EGXP>-_#/[8?AC2?&7B7Q/\ #3QE\#O''@/P
M5X@^'JVOBKPIKFC0Z['XO\3:/K/AS5[+7)O%$2ZC#=PUY#\,?V5/VF/V"?@_
M_P $B?VJO%_PG\?_ !AUW]FW4/VNI/VQO@K\$O!<7CCXF^!M&_X*#:G=?$*Y
M\0^"/ 6D7$TFL-^S_P",U\->%/B3IGPX@U/5M6TO^TM5T*"3PGINJSP 'T%_
MP4(\6?M@:_\ !3X#V7[67P9^!OPODTS_ (*6?\$X]0\!Z]\#?C?XK^+FB^*+
M36_VB))-:T+7M/\ &GP@^$^L^%];\!V5CX7MKS5(4US1?&5WKM[>:2NB0:2]
ME-^CW[/'[:VL?M8_'/QUI?P%^%L?B/\ 8[^&T&I^&;W]L/5O%$VF^&_B[\8-
M)U2[TK7?"/[.GA2#P]>)\3OA]X*O;.XTGQ5\:&\3:1X1O?$]IJ>@^"K?Q3::
M<=>N?S?_ ."B?Q!^&_\ P5/_ &5O!/PM^"'PK_:4^*/@*/\ ;/\ V)8OBL;_
M /9M_:0^%,%]\,/$_P 5[_3_ (E7F@:KXQ\ >"];O].\ ^'M&U[_ (67XI\*
MF2Q^&RW&FWFL:WI;WMC.?L_]BR/X\_LA^+?#G_!/KXO^#/%WQ+^#/A+P=)!^
MQQ^UQX*^'EQ+X6U#X2^";*WM+'X%?M1Q^!]"B\*_"7XV_#;0TLM,\*_$*^L_
M#?P\_:#\-6EM=Z<^C_%>TUSPSK8!^47_  3*_;$_:M\ ?L4_&:3]G?\ 8Y\.
M?&GX9_LM?'W]LK5?B]XR\=?'^'X2^(?&6NI\=?B;\6?$'P\^ _@C3_AE\1I?
M%>NZ%\._%_@[6G\3^.=;^'_A?4=>U#4/!>DMJ&I:;=W]O^L/Q/\ ^"H'A6U^
M#'[''C+]F_X/^+OVAOC7_P % _#D?B;]E7X R>(_"WPUU+5M(TWP'IWQ)^(.
MN_%/QWJUYKGA?X>>'_A-X7U.UB\=WNGGQC>+XDN].T+0-.UF*\FU6QY;_@DW
M\+/'7PQ_X)^^(O"/CKX<^+/A[XVU/XU_MIZ]=>&/%GA#6/"?BK4+;Q/^T-\6
M;_PIK4^BZQI]AJ]W!XA\+SZ#>>'M1DMI(]6T";2+C39KC3I+)S^8?P1^$7Q[
M_9;_ &</^"%G[7NM_ 'XW^)(_P!D;X=?&?X'_M2? WPQ\(_%.N_'SP-X#_:1
M\/1:99_$RV^%DNEKXW%O\+/%G@W0[OQUHVAZ%<>,;CPOXD:XM;%M)LM7=0#]
M=?@]^W'\;-(_:;\%?L@?MN_LZ>&O@%\4?C5X>\;^)_V;?B!\)_BXOQI^"OQN
M3X9Z/9>*/B5X*M=3U7P;\./'O@CXA^!/#.J6NKSZ7XF\$C1/$^EZ9X@U;1]=
MMUM=.T_4OA']@3]K'PS^QW_P2H\/_$35O"FO_$CQCXW_ &V_VE_@E\%?A+X5
MO-'TSQ+\7?CA\6/VUOC!X9^'/P\TG6/$5Y8:!H2ZMJ<LM]K7B#5[H6NA>&]+
MUK5H[35KRSM='U#TFV^)-Q_P4?\ ^"CO[$GQ-^!_PZ^,VC_LO?L.Z!\?OBYX
MV^._Q7^"'Q&^#?AKXF_%/XM> 3\%O!GP>^%J?%7PMX,\::MK'@]-2\2^+OB#
M?6FBOX8AM]+M-'O[C^TY=%>X^.-*_9A_:#T[_@E]^R]XQC^"7Q8O/B+^Q;_P
M5LU[]N+7?@3%X UJV^,?Q"^%7@O]L3XX7&OV?P_\"^(+?2+[7=?U?X7_ !'N
M?'_@NTVQOXJTS3[9_"SWVJ:EH2W0![)^UA^T%^UEK_[37_!*CX,_M8?LL>%/
M@QJGB+_@H-X#^+?P]\??"#XU'XW?#6_TWPI\%?C_ .&O%7PV\9ZAJ_@'X8^)
M/"OQ.\/'XB^$+^R-OX<UGP=XVTMO$>H>'_$%O-X<U#2U^X/$'[??[2'Q0\=_
MM%:+^PI^R-X7_:-\"?LE>-?$_P */BQXX^)'[0-O\#I?B+\<_ NF6>I>//@;
M\ -"M/AK\3;C7O$W@_\ MC1](U?QE\2[CX:^!G\5O?\ AS3+_48+*37E^0/V
MC_VGM=_;B_:D_P""9FG_ +,7P!_:/\7_  3^"7[:F@?$O]H3XQ^+_P!F[XP_
M"W2/AGXDC^%_Q7\)^%/"LD/Q-\&^%/$MW96,&I>.)/B?XET[19_ 7@C5X_AU
MHNO^*8M>\9>'M.G^?O WP7_9X_9*^.O[9WPY_;C\$_M[:&_Q*_;!^*_QT_9M
M^*O[-7C+_@IS/\&OC'\.?V@]2;XA:-X$TW2/V-?&LO@O2OC7\/\ Q!/XE\)>
M--,\0^%O#&LZXMKHFLV=SK>FW<&I. ?H3\6O^"PGA72OA1_P3^^,7[.GP5\2
M?M#:%_P4(USQ3X.^%WA5?$VE^ O&&F?$"U\!:YJ'A#P3K[W=GXA\,:1=3?%C
M3[+X9_$GQ%>:Z?#/PXL(_$OC<:CXETGP\MOJ/,0?$CXR_M7?M[?LB_LP_M*_
M"70?A/J7[-WP1\5_\%"_C7\/O!OCB+XM_#R_^+47Q?\ $_P"_9*\,-X[7P]X
M4GO3X6TJW\8?M$?8+_0=/,7CFR\ 2VD-U-X%EU"?D=;_ &6? _@CQW_P0YT'
M]E?]G'XM^"OV;/A3\</V@_B;?>$O%_A+XK:WK7P3TWXH? GXL>-;?4OC'<_$
MFY\5>,? &LZC\4O&,K10_$C6[;4-(\7ZC:^'+3[%>VECI=M]#?$[P[=_ S_@
MK[\!OVBM:OS;?"_]KO\ 96\1?L1S2D0VVFZ+^T'\,/'.L_M$_"5-:OIYD4S_
M !(^'<WQD\.>&HDC(DUSP?9Z0L@U#7],M;X E^#7[=/[5W[3'Q6^*P^ '[*O
MP<UC]G3X%_M3^/OV5OB#XT\??M377A3XSZIK?PQ\8Z;X4^(/CGP_\)M"^"7C
M'2/#MAX6BDU+7],\#_$#QUX>\6^.-%ET*]M3X:@U:VDF/@?XF'[/G_!4S]I'
M]D+3-.NHOAG^T_\ !"Q_X*&^ F$,-GH7A'XM0>.['X(?M+^%=)>0^;?2?$+4
MA\-?C3=6-DQ6P\6>(OB1KU[$)/%4<A_.C]JKQ9X%3]H:Q^)7_!,SX%_M@_";
M_@IAXN^/G@+PS\4M"M/V:_CU\)?@1\7_ (6VWQ'.F>/_ !]^UE!X_P# =C^S
M[XC^%VN>%%\4:CX7^-.CWT7Q2DUJ_P!&UC3/$T#VUPUC^B7PQ\.W?QS_ ."O
MOQY_:*T6_-S\+_V1/V5O#O[$<,H$-SINM?M!_$_QSHW[1/Q:31;Z"9U$_P -
M_AW#\&_#GB6)XP(]<\87FD-(=0T#4[6Q /,_^"]/Q!T?X2?LA_!;XJ^(;+6-
M2T#X9?MY?L8_$'7-.\/6<>HZ_?Z/X,^+^F^(]3LM#T^6XM(K[6+JRTV>#3+.
M6[M8[F]D@@>XA5S(OKO@[]O']I'P=^T5^SE\$?VR/V1?#'P!TK]L!O&^C_!'
MQ3\._P!H2Q^.,WA#XA^ O!UQXYO?AC\=K63X<_#C2] U[Q%X;TO5[KPYK?PW
MUKXD^'YM;BM?#1N+B(WGB.UF_P""M_PS\:?%7X*?LW^'O!7P_P#%'Q(ETW_@
MH!^Q1XJ\4:'X7\*:KXPDL/ GAOXUZ'J'C'Q'K^F:38:BUKX2T'14N+[Q-K&H
MP1Z-I>EI-<ZI<06BR.)_^"C/P^\?>./C#_P2WU/P7X(\7^+]-^'W_!0?PGXT
M\>ZAX7\-:UX@L?!'@ZV^"'QMTFX\6>+[O2;*[M_#7AF#5=6TO3)M>UF2RTN+
M4-2T^R>Z6YO+>.0 Q_$'[??[2'Q0\=_M%:+^PI^R-X7_ &C? G[)7C7Q/\*/
MBQXX^)'[0-O\#I?B+\<_ NF6>I>//@;\ -"M/AK\3;C7O$W@_P#MC1](U?QE
M\2[CX:^!G\5O?^'-,O\ 48+*37E\:UK_ (+*7'Q$\8_LE^"_V,_V<K_]HS5?
MVVOV8_%?QU^"<7B+XB:;\*(M#\2^#/'6B>'?&'@_XN:G/H7B[1?!FE> /#D'
MQ'U/Q9KVF:EXEFO?&G@>P^'7A'3M>O?&.D:U%\2>!O@O^SQ^R5\=?VSOAS^W
M'X)_;VT-_B5^V#\5_CI^S;\5?V:O&7_!3F?X-?&/X<_M!ZDWQ"T;P)IND?L:
M^-9?!>E?&OX?^()_$OA+QIIGB'PMX8UG7%M=$UFSN=;TV[@U)_K3]F_]EGP/
M\(_V_OV'M2_9S_9Q^+?PJ_94\&?\$X_VD%\+1_$3PE\5II_ACXX^,7[1OP_^
M*%QX.\<>)?BK<^(O$_A3XH^('\2^.-9N/!GC'Q*OBZRLI]=TR+3[73--GL;,
M ^E]1_;I_:5\;?%>]_9B_9S_ &6_A[\0/VD/@U\)_A#X_P#VRF^(7[04WP]^
M!?[/GC?XN^$!XN\,_!/P_P"/="^%OQ!\<?%CQUKUCI^NW>EZKI?PST#P=IGA
MP^'/$6OZ[:7&N-X?LO@[]NO]O/PQ\:OV"/V=_P!II_AAXX\-^,/V??\ @JC^
MREX4_: _9WLKO0/%OQ&\ ?'#]G3]HO2%^*OP9T;5M,OK3POXTU<:GI'E>!M>
MM+[2M/\ %FD:WX:U:]MO#=SJ-[I&E97QN^"OP?\ V>/^"CO[9GQ>_;(\'_MA
MQ?L[?M6Z1\!?B;\(/CI^RWXQ_;YL?!G@_P <^!?A_I?P9^(OPB^-6B_L4^,+
M&^L_%>L7^A>&_&/PXUSQ9X.NM*O-!UG4]$T_Q,M]I]WI5NW]JWX$>'/!'_!/
M'P)XR_X)K?LE?M)Z]KVN?\%+/@'^UE=?"CXI>'/VC=<^,/Q)^(O@OXI^&;7Q
M#\2O'^E_M*ZOXA^*OASPOXMM/AQX:N]0\2>/I_#WAR/PV\/C+6$TVUU:_P!4
MN@#] ]'_ &\OVDOA/\:/@1\.?VYOV3?"7P$\#?M5^.(OA;\%/BI\+/CY;?&[
M1_#'QEU70M2\0>$O@K\;M.O/A]\.KC0/%?C2P\/>((?#7B?P#/X]\)7VOV\.
MA/-#8I=>)8M[X5?\%)M"U_\ 8I_:F_:F^+?@:S^'/C3]BWQ9^TY\.?VA?A)I
M/BN3Q%;:#\2/V<;_ %B1/"OASQGJ>@>&8O$)^(OA=O VO>%M0BT2&VGG\=Z=
MIEN;^2W,]Q\:_M%_&G3_ /@IQ\:?^">7P>_9X^%?[26GZ=\!?VX/A5^V)^T7
M\0/B]^S9\8/@IX-^"VA?LY>&O%NNVGPN\4ZU\5_"7A!;[XJ^/O%OB?P[H&@>
M'_ ;>*HUMX=7U/5;^V\-1S7L_AO[;'[._P 1]0_X*@Z3^R-X9\-6NL?LK_\
M!6'6_@)^T1^T@+V:ZFT_PW)_P3XU:'Q!\<]&M-'TPVXT73_CSX:TK]F;P1K_
M (CGD635]=U6:T>0R33?: #^B+X#>-?''Q)^"7PC^(GQ+\"+\+?B!X]^&_@S
MQGXQ^&@U677)/A]XA\3^'[#6]4\%76L3:=I#ZE?^%[J^DT74;P:;9QS7]E<O
M#"L)C)_-7]IG]M[]O_\ 9C\.?&;]H;Q=^PA\+]0_9/\ @5XF\8+XD71?VIVU
M?]I3Q7\&O#7BO^S8OV@_#'@.P^$,GPSTS1&\%6UUX_NOACXA^*,'C.WTN[AL
M=3U#0]1TK4[=OU\N6N%MYVM(XIKI896MH9Y6@AEN C&&.:=(IWAB>0*LDJPS
M-&A+K%(0$/\ #[XU^#B_M'?L._'"S_:3_99_;N_:;_X+3WG@;]HI/$ND?$?P
M;^U@?AQ\'YX[CX@3:-KOPJ&G6VG?LJVGP_?P!H NO@1X2^'MGXEUSXJ?$M?#
MOA3PY8ZGJ5_8WNE ']&W[0__  45\=?#O]JG]G[]E3X _L[0_M%>*?VFOV?/
M%WQI^&7B4?%&S^'7@[3Y/#6O>'U6Y\?Z]>>%/$S>'?APW@J^UKQ#<>+=%TWQ
M5XCN-=M_#7A'1/ ^K77B=;_3K_PJ_P""@OCN?Q-^TO\  ;]I3X!V'P2_:M_9
MO^!5Q^T?;^"/#?Q+A^)/PI^-_P %9(?$.GZ9\2/A7\1&\*^%/$<.E1^-/#.H
M>#?%FB^+OA_HNK^%M4N=,%JWB,3WPTW\\O&OQ5\8_LS_ /!1[_@G/XKU'X2?
M$GQAX6\-_P#!)KQEX:_:!T[P-\._$?C[XE_"OP,_CWX&Z?/XSMOA=X<T_4/B
M)KTGASXJ6_P_\.^,=)\'>&]=\5:%X8USQ'KMSH;Z/H6N36O665SJO[6_[7G[
M;O[?W@OP'\5?!G[.'@+_ ()4^)/V.OAGXM^+WPM\8_"*^^.GBSQ1XM\8?'CQ
MIXX^'7A?X@:1X=\<7/P]\'Z?9>%_"CZ]XE\-Z+;ZGXCO[]/#"7]I:ZM=  [_
M ,&_\%:/VJO%G[(_@[_@H,G_  3WV_L?)\.;+XC?%2:T_:'T>7]HG2/!^CV"
MS_%;XF_#OX0WGP\L?"?BKX;_  _N=,\57FB#Q/\ %CP1XS^('@_3+7QC'X;\
M*V=W#9S_ %=\;_\ @H;J</Q%^!_P!_8L^#]G^UA\>OCU\&M-_:8T:VU3XB6?
MP@^$7PZ_9CUC5=/\/Z/\</B1X_U+P_XGU\:5XBU[5+?3O"/A'P?X&\2^*/$#
MV.NO+!I!T^S35/Q^^$7[:'B?5_\ @B#\//V-C^S/^TSK?[8'Q6_8!T_X#?!?
MX;>!OV=/B+XD\#?$'PG\4?A#:_#_ .#_ ,:M/^-=EX>G^ <7P]3X?>,?!/CK
MXJ:GXB^(NE:EX*U$>)_#WBO1K/Q%82Z=-]'VOPT\9?\ !+3]J+]D#XW^-/!'
MQ-^+W[.L'_!,'X6_\$_OC5X[^!OPH\:_%_4_@O\ $C]FC4=-\4>$OBCXL\.>
M#=$\0?$2/X4_$72+[Q+X>2[T'P]>QZ5X@TFPN_%*Q27NCJX!]E_#_P#;V\6>
M(M2_:9_9C_:Z_9LTKX0?M-?!S]G/Q=^T#)\,]-^(6F_%?X*_M$_L^6_]M>$[
MKQ[\.?'J^'=$UB'0+SQ782>$O%_@_P >^ ]%\1^&DU[0VDMM>2^OX]-^4_"G
M_!5/Q;X8T?\ X)Q?L_\ [+_[">@>(?%'[9?[$WA[XT_!7X4^&/BOH?PU^&GP
M>?2XO",]UX+\1Z_>^!UL="^%'P^^&<WB[Q _B/0?#U[XBU._\+^'_ _AKX?7
M.H^*[>ZTREI)\<_MS_M??M5_MH> OA+\8O"7[//PM_X)M?$3]D;X$:I\3/A#
MXR^&GB[]IGXD?%S7+OXH>)O''PR\'^+]#T+XAZA\//#>F>'?#7@W2?[>\.VJ
MZ_XHU^6X\,1236^M018/_!/_ .!/QC\(?M"?\$G==\:_!OXF>&-*^&/_  18
MU+X8^.-9\4_#SQ3HNG_#WXK2^,/@,P^'GBO4=6TBVMO"?Q"DTW3=?8>$]7FT
M_P 2/8V&L$:>8+6],8!]R?!O]N+]I#XE>)/VH_V8M>_9T^%GA#]N_P#9ET3X
M4^+(/ -U\=]8G_9W^,O@+XK2RMI7Q \#_%J'X3S?$/1M+TR#2?$-EX@T;7/@
MU->Z+XA3P[I#7]\FMWE[HGRE_P $X_VQ/VJ?!O\ P38^,O[4?[6'A/PQXM^'
MOP1T']M[XJ:3XYM?C[XM^(OQ@^(NH_"3]H+]H&]USX<ZQI/C7X;^'=-\-:+X
M9C\+R_#?X7ZG#XX\0B^\-:+X57_A'/#$$RZ!I7UIX*^'WCZT_P""RWQ\^*%U
MX(\7VWPSUG_@GQ\ O!>D?$2X\-:U#X%U7QCHWQU^,6KZOX3TWQ=)9+H%]XFT
MK2=3TW5-2T&UU"75+'3M1L;VZM8K:[MY9/C[]BWPKI_Q;_80_:Q_X).>,]"^
M+'PV^.]I;?\ !17P%XGU;QM\#/BWX>^'-OX;^.'[0WQJO_AQ\3_"7Q,USP?I
M_P ._%VC>(-'^+_AOQ1X0TS2_$\OB/Q%I^C>(-6T_1)M"T>XU0@'5_#7]H'Q
MA^PE^P9^QSXZF^%ME\:?VMO^"DOQX\!ZWXJTKQ5XZT_X%>&]7_:>_;"\,Z_\
M8]:?QUX]UOP_XHC\+^'?AUX>T&T^$?@?P[9>'-;\3WVA>"_ 7@/PUH=W<PK]
MF]F_:NT+]JWXI_L%_&[QU\:OA/\ "[X0?M1_LI7K?M0?LW:I\%?B;K_QQ\-:
MU\2/V>/#L/Q.\+ZWI3>(OAE\+?$FAVWQ EMO&'P1\7>"-0T75KG4_ GBCQ+:
M?VO>6GB46T'C'AWXK?LM?%/_ ()9_LX^ _V]O@7\1/BYX9T'0;']G+]H_P .
M>&_@=\4OCC>? [X__LSZ+J'PN^*WB/QS-\#]"\4>./A-)HOC/PAKH\-_$;1&
MT[5H[+Q)HVIZ'JRZ9K0U%OF[X=?&G]H7P=^P)_P4ATEK;]HO6/@AXN\2P_LP
M_P#!*!/VH](UCPY^TW\0M<^/G@VQ^$?A#PV]OX_TSPW\2/$?P\M?C-XSTF^^
M%OB;XF6T_CA?AO#KEQXEUAM.\)R'2@#^@O\ 9P^-&C_M'_L]_ S]H/P_IMQH
MVB?''X0_#CXMZ9HEY=6U[?:%9_$3PAH_BR'0M0NK,FVFU'15U;^R]0>#$?VV
MTG 5<;1_+!_P1Z\9^,?V'_'_ (2\:>+M>O[_ /9$_P""FO[3_P"T]\+;NZU*
MZ#:7\$/VYOAU^T+\7/"7PSC5 EK!I_AO]I+X5^%=,\%6S)'K&J7WQ&\"Z4NI
MW^CZ'%ID$W]17[*OP37]FS]F+]G?]GI=3AUQ_@=\$?A;\)KC7;>![6'7KWX?
M^"=$\+7VNQVS_/;C6KS2Y]4\EL-&;LH0",5^4/[%O[$+?'C_ (),_$/]D;]H
M_P %^.OA==_$7XQ_M>WMF/$OAK7/"/CSP)JVH_M6?%'QY\(_BQX=TO6HM%U6
M#4-#U+_A%/B-X+OR8-/URV@TV=)KO1-2<W !WG[#/_*7#_@N;_V,W_!./_UC
MV*I_%/[?/[=7P ?X/?$[]L#]A[X3_"3]G?XL_%KX6_!KQ-=_#_\ :I/Q7^+G
M[.FL_%;Q3%X-\->,_BYIJ_"'PK\,O$/@R7Q-K/AO1M8?X>?$#5KCPX]S<7J7
M7B);BSLZ^ O^"?>C_P#!2[3'_P""XWQ4^)/P3\8>!_VR_$'PN^!'@?X/>*-;
M\(ZGI7@/X[_'7]F_]E[X@_!'3OBI\*=<\6^&M&\(>.O#_CKQQX-\.^/[:+3(
M)_#-J?&>E:-J$MIIUS',?AOXC?L_?#+XX?LR?!'Q)\)_V4/V^OCS_P %%])\
M7?LE^)?VP?C'^T5X)_;)N_%_PFU73/C)\(]1^+FB6L'Q5LK7X;ZWXE@UW68H
M](\#_!KPU>V7A?X(-XS^(MY=Z-X=\/:I>:J ?T.>*/VY?VIO'?[4W[2W[-_[
M(?[+?P>^*4?[']S\*[3XP>(_C1^U!=_!?6?%6L_%?X;6OQ)T+PS\./!7A[X+
M?%;6+"V_LC5+*.V^(?CIM%\)ZSJ.F^(=*T6WOUTZ;5((->_;I_:N\?\ [3G[
M1O[.?[)O[*OP<^)$W[(3?":W^-.M?&7]J:Z^$&K>(O$/Q:^&=G\2](\)?#7P
MEX=^"7Q1U>WM(M,U6T@M/B3XZ30/">O:AI?B#3M$L[Q;";4K?XB_X*@^)O@,
M?'?Q0\>_L^?!?]MCP%_P5B\ Z*WA+]G#XJ_L^_LS?'S2;OXV:S#8Z')H]GXC
M\;Q?#_4?V=?CQ^SWH][)I.D?$-_BQ=Z[9:#X>TO5-/\ #_V*5=/^U\+^WAXL
M\"W6FW?Q%\*? O\ ;!^&/_!;7P3\*O"?ACX=?$7]EW]FOX]6.F?%[XL#PEX2
MGUG1[CQ]#X#U;]G/X_\ [,GAWQ?-%H/C&X^*VH>(;'1?"6CWMEX>DM9?[/>\
M /T]TG]I3PEH'[7/_!0C0+#]GWP7HGQ)_9[_ &6/V?\ XM^,OBKINJ6J>+?C
M%9ZUX8^,FO\ AWX>^)K^'PM!>V^C_#^7PEJECX?U*?4M<0IXGU"YMM(T[8\%
MW\9^'_\ @LQ\?5_9.^''_!1?XA_L/V7@C]@[6+/X?)\2O%D/QVM]?_:!\+V_
MC#5O#G@;6OBGX4^#-G\/8M'\4_"'PY\5=7N_"NEI>_$+0?B9XL\)P0?$H>!M
M T:2/3;CHOAY\,/VC[S]I;_@IUXU^*OPK\36/BCXI_\ !-W]D+PN^K>'?"GB
M"Y\ ^,OC5I'PF^/=O\3/!GPM\0I93:9XQNO#OBW7;;3VTK0+[5-1LX]4T6.Z
MB234;3S_ #;XV?!#XTZM_P &W?PT^!FE_"'XH:E\;+#]EK]B_P /7WP=T_P!
MXKO/BG9:_P"%O'WP/O/$^AW?P^M])D\6VVL>'+/2=5N]>TR;2$O=(MM,U"?4
M(+>*RN7C /MGP3^WI^TGX<^*W[./A+]K[]C&T_9R\!_M>^*=7^'OP:\4>'?C
MQI?Q>\3^ ?BA9>$-?\=>&OAO^T5X8@\!>"M+\'Z_\1O"WA+Q->^&;KX;^*?B
MIINE:WI__"+^)9K%EN-<@^YOVG?^3:_VA?\ LAWQ9_\ 4"U^OD?_ (*(>!/&
M_C;QM_P32N_!G@WQ5XNM? ?_  4I^%GCOQQ<^&/#VKZ_;^#/!&G_ +/W[3>B
MW_C+Q7-I5G=Q^'?"MCK&OZ%I-YXAU=K/2+;4]:TFPFO$NM1LXIOT(\7>%]'\
M;^%/$_@OQ##+<Z!XO\/:UX7URW@GEM9I]'U_3;G2=3AAN866:VEELKN=(YXF
M66%V$D;!U! !\,?\$F?^48?[ '_9H?P"_P#5;>'J_(3]DW]L/6?V0O '[:A\
M&?"W3_B_\3_VCO\ @XG_ &R_V:/A3X1\0_$G3/@[X,/CCQWJY\066H>,?B5J
M_A_Q3;:%I=OI_@[4H++3=.\.Z]XF\3ZY=:7H'AS1KV]O6:W]U_9-_;L3_@GU
M^S?\._V(_P!J_P#9[_:XO/C_ /LQ^';CX*^#D^"7[+'Q9^*_@G]I[P?\.+JZ
MT?P!X[^ /C+PEHM_X7UJUUWX<V_A;4O$.G^,-9\&ZGX:\23ZOHNK017%@\C\
M]\)_@S\'/A5_P3\\4?\ #T']F#QWXEL/V[_VKOC_ /MC_&;X8^#/@G\9?CTG
M[-WB+XY:[JWC;09?&NI_"+PMJWCSX6ZUX%\%P:!X>OO'?A_3?#>J^&?&.H:C
MHUE=0RQ:EJLX!]>_M&_\% ?VD_V)OV7;/XZ?M4_LM> Y?%T?[1GPA^#+>#/V
M>OCAJ_Q-LO&7@WXDZGHVFZAX]\%W/C#X4?#/4[3Q587=WK&F:)\-/$5E!#K&
MHZ79-<>.M.LM8%Q8^>^-/^"E7[9_P4^)WPO^!OQK_P""?&AS?&O]JK0?$&J?
ML@>!/A%^T_HWC'2O$_BCP'_PC.J_%/X8_'7QYKWPQ\+Z/\)];^&G@#7KKXE:
MUXU\.V'Q%\#ZWHF@Z_HWA"[U_5],@;5/SDT_P[^UM\7O@))X:T+P'^UG\1?V
M5/AU_P %9_V"]9_8MOOV@/A[XYN?VD5_9T\&_$#PGK7Q7\4>,;'6_#-A\4;K
MX'>"M:2;4OA[\0_BUI[^)K7P++<Q>*]>-MH<,5A^PW[5_P /O'OB/_@IA_P2
M:\>>'O!'B_7? WPX_P"&[_\ A8?C/1O#6LZIX4\!_P#"7_ 'PYHWA+_A,_$5
MC93Z/X7_ .$HUB"?2O#O]N7EC_;>I0RV.F?:;J-X@ >J_LP?M<_$?XD_&OXQ
M?LK?M'_!72?@=^T;\'/!OP^^*?V7P/\ $5_BO\(_BG\(OB7>^)=#T'Q_\-?&
M>I>$/AUXM']C>+?!WB3P?XQ\/>+OA_X>NM)UBSLYM(O_ !%87TT^G_+GBG]O
MG]NKX /\'OB=^V!^P]\)_A)^SO\ %GXM?"WX->)KOX?_ +5)^*_Q<_9TUGXK
M>*8O!OAKQG\7--7X0^%?AEXA\&2^)M9\-Z-K#_#SX@:M<>''N;B]2Z\1+<6=
MG53]HSPA^T[I/[=7[:?Q<_9Y\!>*+OQL_P#P1I\.>#?@)XUG\-SMX(U7]H[0
MOC5^U)XC\*^"K#Q)K&G2^"]3\8Z7=ZUX1UVX\(W]XS_V?JVCSZU!::-JL=XW
MX4_$;]G[X9?'#]F3X(^)/A/^RA^WU\>?^"B^D^+OV2_$O[8/QC_:*\$_MDW?
MB_X3:KIGQD^$>H_%S1+6#XJV5K\-];\2P:[K,4>D>!_@UX:O;+PO\$&\9_$6
M\N]&\.^'M4O-5 /WU^+7_!1?]HA?VZ_B?_P3Y_9C_9.\.?%GXJ^#/AA\,/BY
M;_$OXA?&D?#+X0^%O GC"WU^W\6>(?B3<6?@;Q=XN6YT'Q*W@#P]X2\)> M
M\7:YXS'BCQ!K-Y+X5TKP9=S:A]0?L._MDW'[6NA?&C1/&OPQG^"?QV_9I^-'
MB'X#_'7X6-XMT[QWI6D>+=%TW2==TOQ1X)\866GZ'<>)_AWXTT#6K/4O"^MZ
MMX8\+:I-/;:QI]QHJKID=_?^*? 7X;^.-(_X*T_\%!_B?K/@+Q7IG@7QA^SM
M^Q1X>\$?$/4_"VKV7A+Q3J?AM?C4_C#0_"OBVZL8M'UN^T"2]T)O$NF:1J%U
M<:4]WI+:I! UQ9E_)?A#XKNOV0/C1_P7'_:M^-W@?XA>'/@[X>\>_#/XSZ+K
MLGA2[T\?$SP=\,_V0/ Z^(S\*[[Q+)X?\.^-;YM;T2]\(V9L=>CTO_A+@FA:
MAJFGW*SF  _:BOY3=:T;_@D]K/[;'_!96S_X*27/[)FEW][\:?@5:>#-:^-&
MK^"/#?QIT_PW'^R=\,+S5)O@UXC>YL?C!I4\&I0I.LWPQO8+XZLL,48DO)DA
ME_IM^$'Q(L/C)\)_AC\7=*\/^*?">E?%+X?>#OB+I?A?QQ8Z?I?C3P[IOC7P
M]IWB2PT7Q;IFE:KKFFZ;XDTRTU*&SUO3['6=4M;+4H;FVAO[I(A,_P"8W[(?
M[.L$G[>/_!5+XE_%;X%1/:>*/VA?@#K?P>\?_$+X8HUMXBT?1/V9/AQI&K:O
M\-/%7B30S%J^FZ1XGT^[TS4;_P +W]Q:V&O65Q97,L6H6TL2 'XPVO[0_P <
MO _[/W_!O[\<_B?X=^+_ .T!\3]1_:6_:CT;X.^'_'VLZ;IGQF^,7AOXD^#_
M (R_#7]D4?$+QGXE^QZ/I]YXU\'^*?A3=:_\2]8:\MX/!]^?'^L'6;P7R7G[
MZ? ?]M?XT:I^U=+^QG^UI^SQX5^!OQ;\3_!/4?VB/A)XA^%GQEE^-GPO\;>!
M-"\6:9X2\8>#=1U_7?AW\)/$NB?%#P/J&OZ)+?:?;>#]6\-Z_I+:GK=AKFG0
MVMA9ZKRW[<_PS\:>./VUO^"2GB;0?A_XH\8>$?AI^T9\<O$OQ!\0:1X4U7Q!
MX<\ 6%U^S/X_TWPUK_C+5;.PN],\*VESXKETJPT/5=;N+"&;Q#+I]K83MJ3V
MT9G^/?P^\?:Q_P %8_\ @GK\1M(\$>+]5^'O@K]GO]MW1?&7CS3?#6M7W@SP
MEK/BR/X'CPMI/B;Q1:V4NAZ#J?B4Z3JH\/V&JWUI=:R=,U :=%<_8KGRP"M_
MP6^_Y1-?MU_]D.U7_P!/.B5Q?C7_ ((T_L5^-?#GA'XE_L_?#W2_V)OVF_#7
MA+3K[X6?M%?LJ:?%\)==\$^*Y-$B%MJFN^ _!LV@?#SXDZ#J$SFR\9>&?&&@
M77_"6>'+S6-#.KZ4^JR:E#F?\%&/&GC?]KK_ ()C_P#!2OP#\-OV;_VF]$\=
M>"[[XH_L^^&?!?C?X/ZOIOBWXXZGX%U;PE(GQ-^ GAS0;KQ+K'Q+^#GC>/49
M)/A]XTT^SM;CQ*FDZRXT6S6P8NOB?_@I#\:->\&O\*?V0?\ @GM^W/X]^.UY
MX.@T#P#XP^._[-_BO]FC]F_P_P"*TT5X$\0_$;QY\=[[X;:Y'X7\-/;G5[S2
M=%\.S:SXL,-OX9T&:#5=42ZL@#ZE_P""8G[1?Q#_ &K/V$_V??C7\7;2WM/B
MUJ^A^*_!/Q4:TAM[6VU+XE?!OXB>,/@QX\\00V%EIFCV.EIXF\5_#_5O$7]C
MZ?IMMIVCG5#I>GB2RM()I/O2OS<^$_@K3_\ @D[_ ,$W_A]X(T_P%\=_VII?
MV=_!WAW3M>\)_LZ?#N3XC_&?XI>-/B!\0K63Q[XB\!_#B;6]*EO-/'C;Q[X@
M\;W^F2:XK^&? 5CJ=P]Q?-HQ2Y^@/B7^UK\//AA^T]^S5^R9J7A[QYX@^)O[
M3^C?&/Q)X5OO"NEZ#?\ A/P+X:^"?A[2M?\ $?B#XH:AJ'B;2M8\/Z3KDNM6
M/AWPC<Z+H/B8ZMXE=M.NX],B47; 'M_Q(USQ?X8^'?CWQ+\/O S_ !/\>^'O
M!?BG7/!'PTC\2:1X-D^(?B_2=#OK_P ->!H_%^OJV@^%'\6ZS;V6@+XDUM6T
MC0FU :IJ2FSM9A7YH>'/VW?VN_AA^T-^SG\'_P!M;]E?X2?"GP;^UQXC\3>"
M?A3\2O@I^T+K'Q<L_A[\3-!\!:CXZTKX4?&+3_%7PB^&"RZ_XRL/#?B:/PUX
MG\"7FM:'<:E;VNC&P=4NM9'JO_!5O5_VI-"_8"_:'U/]C2Q\;W_[0$&B>%E\
M-1_#"SBU+XH0^&)O'WA6'XGW7PUTR2SOI-0\>P?#"3Q@_A:"P@;6XM7^S7GA
MU9_$%MIEK/\ A58?LY_LY^)?VM/^"=WQ9_8/_92_; \3VG@O]KWP7J_[5/[6
M7Q^\)_M?3^+FFD^&7Q8TR#3=<N/VD86U358;#7M+U@_&CQSX:T31_A]X"\5V
M_P -O"%SK+W7BO0]'TX _371/^"DW[7'QQ_:/_:Q_9G_ &4/V+/ WCC7/V0?
MBU>>#OB'\3OB[^T0WPP^&5_X<N/#OA_6_ FEZ NC_#'QQXRU'XH?$.[C^(>G
MOI47AW_A"/A]8^&?#FM^)?&=XWC"VT>Q]'T;_@K7\,=;_84\"?M@V7PH\=2^
M/_B3\6[']E_P?^RRFM>$Q\2-5_:YU/XD:C\)+'X%GQ/<ZC:^$;!)O%^EWNLG
MQGJD]C%%\-X?^$NE\/KJLD7A*39_X)R_#?QQX&^,_P#P5+USQGX"\5^#K7XC
M?\% _$WB[P/J_B?PMJ_AZW\=^"#\$O@SIEAXG\*:AJMC:1^*/"IUBRUW3[/6
MM(FOM(.I6FK6D-S]J@O(T_*?4OV8?V@[;]C>X^)-G\$OBQJ?B[]D[_@O?\0/
MV_%^#MIX UJ/XI?%[X(^$?VDO&JZS=?"?PGKMOI,GB^]USX<>/-4\;>!GLG>
M#Q=9Z*$\)W.H:O=Z/'. >R?M8?M!?M9:_P#M-?\ !*CX,_M8?LL>%/@QJGB+
M_@H-X#^+?P]\??"#XU'XW?#6_P!-\*?!7X_^&O%7PV\9ZAJ_@'X8^)/"OQ.\
M/'XB^$+^R-OX<UGP=XVTMO$>H>'_ !!;S>'-0TM?UL_X*.>"OC_\1OV%?VI?
M _[+FK7FC?'GQ)\(/$^G_#^?2]0DT?7K^Z:&.76_#OA;6XI(6T'QEXL\,1:W
MX7\&^(&N+6+0?%.L:1J\]W:0V4ES%^6G[1_[3VN_MQ?M2?\ !,S3_P!F+X _
MM'^+_@G\$OVU- ^)?[0GQC\7_LW?&'X6Z1\,_$D?PO\ BOX3\*>%9(?B;X-\
M*>);NRL8-2\<2?$_Q+IVBS^ O!&KQ_#K1=?\4Q:]XR\/:=/^XOQV^+UC\!?A
M1XN^+>I^!/BE\2].\&PZ5=7_ (-^"W@>_P#B1\2]3LM2U[2]$NKOP[X)TJ6'
M4]>CT&'4W\0Z[!IYEO;7PYI6KW]M:WDUHEI. ?DU_P $R_@C_P $>_'O_"#_
M !:_8V^ O@7X>?M"?LVS>(-'\8Z!XOTG7_#'[7GP.\=>+] U[P1X\\,?M!:;
MXJU%OB'J?B*6*_\ %WAF34_&TWB;PQ>WL.M3^!]6N(K47</K_B#]OO\ :0^*
M'CO]HK1?V%/V1O"_[1O@3]DKQKXG^%'Q8\<?$C]H&W^!TOQ%^.?@73+/4O'G
MP-^ &A6GPU^)MQKWB;P?_;&CZ1J_C+XEW'PU\#/XK>_\.:9?ZC!92:\OPSXF
M^(?PR_X*)?\ !0G]A3XO?L9?LZ?'OP7\0?V?_B;?^.OVAOVW?&W[/'CCX%^%
MU_9]MOAMXMT#Q1^R_KGB'Q_I?A?4_B?XI\?:_KOA;1-*\/SZ!KS^"=-?Q!KW
M@_5[#2;SQA>'R7P-\%_V>/V2OCK^V=\.?VX_!/[>VAO\2OVP?BO\=/V;?BK^
MS5XR_P""G,_P:^,?PY_:#U)OB%HW@33=(_8U\:R^"]*^-?P_\03^)?"7C33/
M$/A;PQK.N+:Z)K-G<ZWIMW!J3@'UA\7?VC_AI^UY\>/^"!?[2GP?O-1N_AU\
M8/C5^T'XK\/+K-K!8ZYIAD_9,^*UAJ_AWQ!9VEWJ%E:^(O"^NV6J>&_$%O8:
MEJ>G0ZSI5]'I^IZC9+!>SQ_$K_@J)\/?V1/!'[;_ ,9M!_9+T:WM_A1_P4O\
M#_LU?%2W^&VKZ?9^,OC/J'C7P?\ "FXU_P"-UQ;+X6TV#6/B5!X=UVTT/2/"
MVKZE(FO/X<T:PN_&^E6MQYMAH:E^S)X1^'GC_P#X(=Z-^R9^SU\8_A_^SE\+
M/C1^T;\0M1\+^)O#'Q;U37O@KH?Q?_9_^+WB>:Y^,MY\1+OQ/XS\!:CKOQ$\
M=7MK-9_$G7+:\L/$NL1^%(5M+B&UTB#Y-^*7[.WQUUB']K6WA^!?Q:U2W\5?
M\'!7[*/QBT6"/X8^,;Z'Q)\%]!3]G:/Q-\4]+B71)4UCX7Z*FBZXFN^.+1;C
MPIIR:3JJZAJD(L+L1 'Z6^!_V^OVF_ _[0'[-OP8_;?_ &2?!G[/.F_MCW7C
M#1/@CXE^'7[0EC\:9? GQ#\(>$G\9'X0_'B*7P#X#T;3O%?B'1[+4D\.>(_A
MEKGC_P ,ZEKXM/#D.^,W.O0V?$'[??[2'Q0\=_M%:+^PI^R-X7_:-\"?LE>-
M?$_PH^+'CCXD?M V_P #I?B+\<_ NF6>I>//@;\ -"M/AK\3;C7O$W@_^V-'
MTC5_&7Q+N/AKX&?Q6]_X<TR_U&"RDUY=C_@HS\/O'WCCXP_\$M]3\%^"/%_B
M_3?A]_P4'\)^-/'NH>%_#6M>(+'P1X.MO@A\;=)N/%GB^[TFRN[?PUX9@U75
MM+TR;7M9DLM+BU#4M/LGNEN;RWCD_*?P-\%_V>/V2OCK^V=\.?VX_!/[>VAO
M\2OVP?BO\=/V;?BK^S5XR_X*<S_!KXQ_#G]H/4F^(6C>!--TC]C7QK+X+TKX
MU_#_ ,03^)?"7C33/$/A;PQK.N+:Z)K-G<ZWIMW!J3@']%/[+_[1_P -/VO/
MV?OA1^TI\'[S4;OX=?&#PE9^*_#RZS:P6.N:89)9[#5_#OB"SM+O4+*U\1>%
M]=L=4\-^(+>PU+4].AUG2KZ/3]3U&R6"]G_F_P#^"@MQXK^$7_!9;Q!^W)X,
M?6KB7]AK]C;]E[XJ_%GPYHEG/JMUXP_99\:?''X_?##]IK38-(6_L+*YU#PA
M\._$[_&'2KK4'EALK[X7Q^2D4]PES!_0Y^QG\)?@G\$/V9/A)\._V=?ACXS^
M#7P;L]#U'Q1X,^&7Q&7X@Q>/?"2?$;Q%K/Q'UVQ\8V?Q6UC7_B)I7B2X\3>+
M-:U'6-$\6ZI-JVA7U[-H\D%A%8Q:?:_&UC\&->\5?\%<?VG=?\;?##Q!K'P)
M^(O_  3;^#'PEO\ Q+KOA'5IOACXQU&7XS?&I_&/P[/B*YL1X;UC5E\,:]:S
MZ]X9BOYM1@T;5[6YO;..TO8)) #T'_@IY\=/%O@3]DH^#O@1K-N/CQ^V-XQ\
M#_LF?LU:Y93W,ME8>//C^USI3_$5=4TF.[ELM+^&GPU@\;?%C^W(8;FTMT\(
M6\DH:"?=7XW_ +#NJ_"?]C3_ ()XZ;\.]0^"WAWX[^!?"O\ P6U\0_LU^ -#
M^(MY9RR>$+V7]K&#X<> ?BQ#=W?A[7(KKQG\.39V/B72G@LM-N+G5[8-;ZKI
M+L+A/HO_ ()]?LQ?M.3?M>>!_ O[3?@?Q38?!7_@D!\+?'OP$_9"^(OBG1]0
MTZU_:'U;XU>(-9T+P+\9O#NLVC1^&?$D/PP_8R\+_#OX3>)K"W74)?#OQ'\8
M>,%GOH-9CU#3-*\5_P"&?/CW_P ,>_\ ",_\*0^+W_"2?\1!_P#PNC_A'O\
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M]CX:33?$_B#X=_"[4/-_L^%8IM,_X12&#3A#'%#?7BL73^>K6/V=/VCO%O\
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M]GG]H_PE^V)\>-=_9Q^'_P ?/#NL_LZ?$WP_\)?V:;+PQ\4_ OC3XO\ Q/\
M$_QFU3PY9?!K7?A+IUI\/O%-G\//$WPQ\=>,)O'#WGAY_!=K>7-P!; 'VC\8
M?^"B_P"T-8?MH?&3]AG]F3]D#2_CO\6/AE\-?A#\7K;Q!XI^-MG\)?A_'X \
M;V_BE/&>I>+->OO _B233-;T3Q!:^ ?#'@OPMHEKKVI^,G\8:]XCNG\/Z'X
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MH^L^'-7LM<F\41+J,-W#0!][+_P5#^'NL?"K]B_]JOPCX/O]3_8Q_:H\4?\
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M:+^PI^R-X7_:-\"?LE>-?$_PH^+'CCXD?M V_P #I?B+\<_ NF6>I>//@;\
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M/^"_&FDZSHT6K_0#?M"_ K7OVE_AA\3(_C!^U!HOB>__ &*OC'\5-#_99N/
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M/M&U#Q;IWQ/TGQG;^']=^&FJ>&-,5=7UW3?'6F>'[W3=$FM=<N84T>]L[Z<
M^E:*^"/@I_P4H_9=_:&^)'AOX=_".X^-/BJP\<W7B#3?AW\8/^&;/V@-)_9Y
M^(NL>$M*\4:YXHTOP5\>M:^'&G_"_6CH^C^$=6OX=87Q)#X9\2(^GV_@W7/$
M=[?V]JW >-/^"O/[$/P]\8^*?#?C#Q7\6M"\*^ OB7KWP8^(/QSO_P!F_P#:
M MOV</ ?Q:\-^,1X U/P'XI^/$_PWC^&^GZC#XM2^T9]937;CPC;7&F7QO\
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M\>_::_;2^"G[*%_X!\._$>#XK>)_'OQ7L_&U]\,?AC\%?@E\6/CE\0O'%O\
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MB_B+X$\(WKZ;(/%WQ&\._!OPAXQF^'FA)IFJVFO6S>,I-$U+7M#9[_PMINO
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MM_%[P7XD^&OQ)\$>-?A?X8TO7_$WAS4M/\>>$O&/A70_$'ACQG9WWA/4[M_
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M!^F-%?.OQ:_:W_9I^!OP4T[]HOXG_&GP)X>^"NNVFB7?A/Q_::NOB?2_'_\
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MA74I8H],\8P_#GXL^&?"/B;5_"%\+K37'B30[#4]*L&UC1K75[G3K_5;&TF
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MT72[2UTW2=)TVUMK#3K"VM[.SMX;>&.-?F7XW_L$_L4_M*>,--^(7Q\_95^
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M>13Q-;WUW;7,4\31K*O[>?&7]ES]G+]H;X;Z3\(/C=\$?AG\3?AEX>N])O\
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M'@H79\4G5!KG_"9-8#2/['?QNNLC^U4\;-IQ\5QZBTEXFL+<222-]6W'P^\
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MA_P@7]F_V-_PA'_" _V;_P (I_PB']C_ /$J_P"$:_LG^QO[-_T'[%]E_=4
M?SI-%^T#J/\ P57_ &4/$7A3XZ?#3X+>+OC3_P $=OAQX=^$?CWXZ? _7/C9
MX8\?^*?#7Q17QI\=?AQX%TO2/C]\!$M/B@UAKOP[\?\ B&Y@N_$6H7O@Z""
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M\=Z7K>A^/[74K>XT.6PD_P"%A:'XDUW1/B%/':1W/CS1M5O-*\73:SI\IMP
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MZZU'Q'X8;2M=O+N]O+NXU"2YNIY9/6_@S\"O@O\ LZ>![3X:? 7X5^ /@[X
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MM0ETNQU'4;Z]M;6*YN[B60 ^2/V[_P!EWP_^U1X,^$?A^#X\:W^S;\:OA?\
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M:AJM[IVC6=I!J&KZC%:VR:EJU^MSJ6HB"(WMU.8U( /YP/BYKWAFV_X)0?\
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M_!O3_ >A/\0=/M@TXT+X@_%35_">G>#A>SE;;7;'^T[:P;SXM1@]@_X)D?\
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MN(H;A$FD#=K\,?V=O@!\%#IC?![X'_"/X5RZ-X.M_AWI5Q\//ASX0\'7>G^
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MK?\ :)^,+)X>O?$/QD_X1JXTWPQ!XB\/:/;7WCWQ+X;TN/2].U%/L=E$O<_
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MP#X=N/&>L:-JWA:X\"ZE;:SJLMBTFL2WO@6[NO ]Q?:FMUJ$G@NZN?"1NO\
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MAJ34_%6JWVN>*-1?0M$L;'2WOO$FMZIJ6L:_=M:FXUC5=1OM0U&2XN[NXFD
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M%>LZGJ6K^)#?:9.=<U34+W4-3-U=W4\TGBWP@_X)_P#[$'P#D^T?!W]D_P"
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M6]I;6]D #^S)]<T6*SU'4)-8TN.PTB6YAU:^?4+1+/2YK+!O(=1N6F$-E+:
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MGBO()'MY(0%;,J2,@VMEN#7X/?\ !7/Q+XM\9_M8?\$X/V3+[X3_ !$_:!^
MOQHD_:D^)GQ>_9L^''CKX>?#W4/VB]1^!'@OP%?^ O!7B76?B7\5O@UX8UKX
M?^"M6\:7GQ+\8> =4\87>F>-1H&CQ:CX:UFUTATB\Y^$?P2^.GP:^*W[=VJ?
M#[]B#QA^PS^P3\6?V"/'GB+6?A+K_C_]FO4O!]E^V5X1&H:!_P )7\,OA?\
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MQ1\)?'CXT_![P5\5-&\#>&_"</@GPKX9UNW\=V/AK6_%NJZZFD:;<ZI'=R>
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M']IW^RI_^&HS^R6/VR_^&^_^$S^(?_#1W_#0 ^!!^)H^-X^,G]L_\++&D_\
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M\%>'I?B);_"J[U:7X;7/C[^Q8+KQ9'\-W\2W5UXBO/"46H+>S:(VJ7%UJ?\
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M,2W<]G8R2K<W4-J9X1<RP1.D!FB$K*9$S\:_\$W_ -HCQW^UI^PS^S/^T?\
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M7>B7@T_6;6PO[2\N-(OS#'<"QU2"WEDEL+PV\L4XMKM8IC#)'*$V.K'Y_P#
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M& 'H9KN\EAMX@>Q>10:LS7MG;6K7UQ=VT%BD0G>\FGBBM4A8 K,UP[K"L1#
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M7_89_8Y_9?\ VJ?@GH<'A[]L#X-_M(_L@>,?'?[345[XCO/B_P#M >)/B_\
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M^T!^U)_P2+^#OBW4]?TWP=XZ_:9^.&F^-8?#>N:WX<U'Q'X)M?V;/&VJ^,?
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M[>/2-+0_&W@W_@G3\ O"G_!OI;?M8IH;2?MEZ/\ L:^&OVK?"7[6@U/Q#/\
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M2CM[2V76K[2K;4TTA=2U..&Z2*UBCMXHAJ5];BYD$ZZ5;W$A474QV11O$)Y
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M4/@1\'OC7%J4<OQ&_9X?X<:V/#G@WPOXU\(:=:? >\^T>'M(U%M#%CJ6KZD
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M_P#=X'_OKE?W$5_#O_P>9_\ .-__ +O _P#?7* /ZIO^"8O_ "C8_P"">O\
MV8[^R;_ZH7P#7W%7P[_P3%_Y1L?\$]?^S'?V3?\ U0O@&ON*@ HHHH ****
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M&C^(=?O;77[#]9:* /A']HW]A+P_\;/&/PD^,WP[^,GQ6_9H_:1^!?@_Q+X
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M)TG3+6"QTW3-,T^WCM+#3]/LK9(K:SLK*UABMK2UMXXX+>"*.&)$C15'Q?\
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MO/B2S\(PQZ/;>.XXXXGC_4:B@#YR\%?LP^ ? G[3'QR_:JTC5_%]S\0OV@/
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MX/>*_%/BWP5I_B=?&WP\\2>)?#NL;_&?B/PMK/BKPKKVG>(9/!&HS:'X=O\
MPQ>R3:S+]S44 ?,?[-/[*/P[_98^!]U\ OA]K/C36/!UWXJ^+GB^34O&6HZ'
MJ'B5=3^,WC[Q5\1?%$"7FB>'/#VEBQL-;\7ZE:Z!$VC-<6NE06,&HW.J7<5Q
M?7/S/<_\$KO@9;?LT?LL_LZ^#_B)\;? &K_L5ZK8>(/V:_VB/"_B#P1!\?/
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MJJZ3=>*?#7B_PUK/A3QAH&H7?A_QWX(\4>&]:\,>+M&DB@U+3S=V.EWUA?\
MV</@)\6_A!+XDUGXR?M>_&G]JKQ1XEL=%TX3?$3PO\$_A_X,\*P:)<:M,L_@
MOP+\%_AEX!L].U+6DU.*/Q)J>O:GXGNM0&E:8+%M*ABG@N/J:B@#X@_9U_8
M^!W[,G[0?[2_[27P^U#Q_J7CG]I_5X-5\2:1XQU[2=;\)?#F.?QAXX^(_BK1
M?A!86_AW3=7\(^'_ (@_$KXA^)OB'XWTG4-=\0V^J>+;J'4;+^S(H?LS^%Z5
M_P $R=?^&6K^,M%_9B_;F_:D_9<^ OQ&\<^./B-XH_9_^&VB_LY^(_#/A;Q/
M\0-0.M^)5^!?BKXI? [QUXQ^"OA[5/$5QJGB&X\+:'J>JZ%8ZMK.HS>&+/PW
M%+'#'^J=% 'S5>?LM> ;_P#:D\ _M<76N^-Y?B9\._@-XP_9YTC2WU319/!^
MH>#O&WB[PGXTU?6=;LI/#SZ_=^+8]6\':;%9ZC:^);'2TLKG4$NM$N[F:WNK
M7Y=_::_X)T>+OVHKKXE^$_%_[>/[6_A_]G3XURL/BI^SIX9'P&M?#VH:)]DT
MVQE\#>"OB'/\%IOBIX$^'NN6=A-;^,?#=OXLU>?Q-'J6I1R:O8Q7U['=?IO1
M0!^?OQQ_X)Z^ OB'J_P,^('P3^)GQ'_9&^-?[-/P[U;X1_!KXK?!*'P-J,]C
M\)M4TO2M.'PE^('@SXH>$/'G@_XG?#'3Y]!T/6M)\->)-,^VZ)K^F1ZOX?US
M2+V\U26_^A_V?/@_XY^#OA?6=-^(_P"T7\6_VE_%WB+7!K^J>-_BO8?#'07T
MV7^R=,TLZ!X,\)_"3X?_  [\)^%O"4<FG2:I!I9TS5M4_M/4]2GO=?OTEMX[
M;WNB@#X3_:5_8^^+'QX\2:WJ?@G]O']J7]G;PIXT\+6O@;QS\.?A?9? ?4O#
M-QX:CM]3AO[_ ,!ZIX\^#OBCQO\ #7Q_K']ILM_XYT/Q9=7*6]O:Q6.F6<]K
M9W5K1\'?\$WOV=/AYI/["WA[P)_PG'A7P[_P3YU#Q7JWP3T/3=;TB:RU_4O&
MWP^\2?#WQ/>_$N;5/#FH:CK]SJT'BW7?%%U-H%]X4DD\6WKWS,VF;M';[ZHH
M _,OXD_\$XM1U3XO?%[XM?L\_MB_M*?LAG]H_4=(U;]H7P/\&X_A!K'@[QSX
M@TOPK:>#)OB!X/M?B9\,O&NH_"+XKZ[X=TO0]/\ $7Q \!ZA8W6L/H>GZM=Z
M:_B1'UQ\WPS_ ,$AOV3/!W['OB7]B7PW<?%C2OA1J'QEU?X]^!/$UOXYMC\6
M_@A\3Y_&EMX[\)^)?A!\17\/OJ>BZG\-]9LK6#P;J_B2#Q9K]SI"76F>-]7\
M90:MK7]I?J-10!\:? ']F?XW?"WQI<^,?B[^W3^T+^TS;VNCZSX=\,^"/'7A
M']G?X?\ @;2M,U*^TNZL]9US3_@Y\&_ FN>,/'>E6^F'3K;Q-J_B%-,:UU/5
M9%\+PWES%<V]W]LO]C3P!^VEX&^'_ACQ=XN^('PT\5_![XO>"OCU\&_BM\+-
M1T+3O'7PV^+'P_;4!X<\1Z4/%'A_Q5X9U:R-OJNHZ?K&@>(?#VJ:3JNGWDB/
M##>0V5]:?7U% 'YO_"C_ ()O^%_!O[17PW_;!^*G[07QY_:%_:@^'_A'XB^!
MI?B-\0+CX8Z!H&M^$?B-IWA2TD\'P?#OX>_#?PKX;\*>#_!-_P"'=7\0^ ]'
M\*?V7?6^O_$'QWJ/C+6?&TVI:6=%^A/V:?V4?AW^RQ\#[KX!?#[6?&FL>#KO
MQ5\7/%\FI>,M1T/4/$JZG\9O'WBKXB^*($O-$\.>'M+%C8:WXOU*UT")M&:X
MM=*@L8-1N=4NXKB^N?IRB@#\SKS_ ():_!:V_9<_9A_9H\$_$SXX?#O4/V--
M8TOQ+^S?^T)X6\1>#(/COX#\1:=8>(-'N[JZU>;P&_@;Q)HOBOP_XHUKPUXZ
M\'ZKX"?PGXLT&ZCM[_2%O;'3=0LH/@S_ ,$R_#W@3]IOP3^VM\7_ -I+]H#]
MI']JGP=X*\;_  W/Q!\>W'PV\+^$-0^'WC&ST2WL_!=E\*_A]X \.>$_">A>
M#+[3]>\1>'/^$2&CZOJ/B3Q]XSU/QQJWC%)O#MKX;_3BB@#P#]J?]G'P1^UW
M^SS\6/V:OB3JOBK1/ OQB\*W'A#Q-JW@>^TC3?%MCIES=6MV\^A7^O:'XET>
MUOA):1JDNH:#JEN$9P;9F*LN$_[*/P[D_:;^'/[5IUGQH/B)\,?@!XK_ &<=
M!T8:CH?_  A=WX(\8>*_"/B_4]5U?3CX<.N7'BJ#4_!FEP6-]9>(]/TB*QN+
M^*XT.ZN);>YM?IRB@#YRTC]F'P#HO[5WC7]L*UU?Q?)\3/'?P.\$_ '5]#N+
M_17\"VW@[P'XR\5>.-(U+3=,CT"+7X?$USJWB_4K?4KRZ\3WFES:=!8Q6NC6
M=S%<7=R?M,_LP^ ?VJ_"OP^\(_$/5_%^C:;\-OCC\(/C]H4_@R_T73KZ[\8_
M!7QA9>-?"VFZM+KF@>(K>?PS?ZK8PV_B"SL[:PU2ZT]I(M.UG2KDK=I]&T4
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M/_?7* /ZIO\ @F+_ ,HV/^">O_9CO[)O_JA? -?<5?#O_!,7_E&Q_P $]?\
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MMQ?#S]G!_%D7P(USX5GXC_"#XT_L\Z!XE^%MAIMY\/OB9X]^'$7B'P/X_P#
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M'P@\4^'9O ?P/^,FB?#7PG?:7XEO;WXL>(X_&7Q1T30=0MSI_C_3;/PCHO\
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M1_%&/X/KX%T[^P+[6+;Q/J_]N'PMKP^UZ%HNIV&F?8?^)Q=:>+JS^T '8?\
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M_%E]XQLO!GA:Z^)G@K3- M?!MWJ_B36=4M)H;.?\SO$?@;_@I=J'_!)W4/\
M@D]X8_8H^)<7[0/A_P" /B+X"7_[0NI^.?@#HW[,WB'X5>"5UFT\-S>"?$\7
MQ2O_ !5K'BWXS?#?P[I/PQT?PQXB\&>#Y_"7BOQO#XD^(>L^'/#FD:EJS?8_
MC+X'_M4_LG_M"_LQ?MM_![X"^(OVC]/3]A7P5^QC^UM^S[X'\=> _#WQ*\+0
M_#S4K'XB^!OBY\,[;Q;KNB>"OB=K>A:_=^-? 7B3PTOC2POIM,U+0KOPBNJQ
M76LWNF@'S9_P4$U7]N'X*_&/_@DX_C;Q'\"OVEOVCO\ AM'XO>!_@OXC\-?#
MGQM\#/A_J5C\1_V9I_AOX<\5_&KPC#XX^+NJV2>"?%WB?Q1XZ^(S?#W68+/4
M?A[HMO8>'M/T76OM-[7Z'_!C]I+]KCX:_MP^'OV+/VQ+SX%?$6#XT_ #QA\>
M?@G\:?@AX%\<?".RM_$7PW\5^'-$^)?P4U[P#XT\??%@ZY_8^E>,-)\3>&O&
MUAXUTR]&B6)MM?\ #EU?ZPEWI7#>.]$_:*_:]_:(_P"";?[05O\ LH_%OX%^
M"?V>?VE?CGKWC[2/C7XF^".G>.=.^&_BO]EO7O"WA+XAW?A?P1\5_&[P6OB#
MQSXM/@]/"5I>ZEXXT>\T>]U3Q#X?TG1);>_?W7XU? ;XK^+?^"F/[#?[07A[
MPK_:'PA^#OP._:]\'_$;Q=_;GANT_P"$=\1_%&/X/KX%T[^P+[6+;Q/J_P#;
MA\+:\/M>A:+J=AIGV'_B<76GBZL_M ![/^W-^UCX?_8?_97^+/[37B'PMJGC
MQ?AYIV@VWA_P%HMY%IVJ>.?''C;Q7H7@'P#X1MM1EM;\:7#KOC/Q1H=CJ>LK
MINJOH>D2ZAK0TK4AIYLI_P X?C/^TU_P5&_87^%EA^V%^UU_PQS\5/V?O#FI
M>'#^TM\%_@'X.^+?A3XE?!'P9XK\8:-X0L?%WPE^)/BOQCXLTOXUWWA!_$UG
MK'CO0O$_@?X=PZM8Z-=6_A;4M-6X?4X?NG_@I5^RSXE_;,_8G^.'P"\":_'X
M5^)FO:5X<\8?"?Q#/<&SM-/^+'PH\9^'?BI\-XM1U!8;F72]'U?Q?X-TC0M=
MU6VMKF\TO1-4U&_L;>>\MX(V_-C]J?Q#^WK_ ,%(/V>M._86U3]@3XS?LK:E
M\9->^%OAK]L/XY^._B3\"KSX4?"CX56/B70/%OQ.NO@/KO@KXH>,/$7QNU[Q
M)!X>OO"'AW2%\):7:VUKK:2>+9=-MIIKNU )_&_AC]MO4/\ @MKX#;PM^T#^
MSM9Z???L+_'/Q/X-&H?L\>.-:@TS]GQOVJ_V>5U+P!JKV?[0NF0Z]\3]1EF\
M-S67Q7L5T;P];6NF:C#)\-;W^U+6;2_)OV/]<_;A\7?MF?\ !7GX4_LH:M\
M/A1X:\)_MN:G\0O&GQ;^/'P_^(/Q9E\3^*/&?PE^'6C^$?AMX!\&>"_'GPMT
M[2[;2H?AKJE]\3/%^N^*]:OM/TKQMX2C\,>$;B^2\OD^]OVF]!^,_P #?V__
M -G?]K/X8?LR_%;]I3X;#]DKXV_LH>,_#GP5U+X56GBOX=Z[XG^*OP0^)OPX
MU^?2_BC\1_AY::IX:UQ_ >N^'M7U&WU.&Q\)001ZOK%ZJRV=C?>H_L'? ;XK
M_!CXI_\ !1GQ)\2O"O\ PC>B_'C]N+Q+\8/A1>_VYX;UC_A*OASJ'P@^$7A:
MS\1?9] UC5;O0_.UWPOKMC_9'B2#1]=C^P_:I=,2SN;.XN #Y0TW_@K3\0;[
M]A3X+_%R3X,>#K/]LGXT_M4W_P"P)IOP=OO%NN6GPD\*?M1Z)X]\<^!?$GBG
MQIXH71;GQ?HOP;\-Z)\/];^+&N6D.D:CXCT_0Y+'P,VM2ZE<+XPKUKX6_M8?
MM+_"#]LCX(_LC?M>>-OV<?C-:?M:_#WXH>)_@1\5?V=/!7C#X97'A7XH? _2
M;'QE\5/A'\0?!'BGXE?%NVU7PW>>!-=@U[X9?$/3_%F@ZS>-X0\3:7XA\&7,
MM[!JND?!/C?_ ()C_M"^,OV-_%6CZU\#? /C[XK_  A_X*Z_&W]O3X>_L[?%
M#5/A;XB\!_M,?![Q!\6?'9D^&7B+5M5O?%7@3PS'\5?A-X_UF_T8>,X89=#\
M4Z?X?LO%5IX;1[R^T[[Q_8X^&O[/MY\:=.\4^ ?^"*FG_L0ZSX%T?Q4\?Q^\
M:? []B/X8^(M#\6RV\/A:\\*_#JX^!WCSQW\1]8M/%/AS7_$MM/XTTVWT7PC
M>^'H=1TR?4[H:U'I\X!P'_!-?]K7]O[]N+4(OBWXLL_V:OA_^S3\-OC+^T-\
M%/'^CV?ACQ_>?&+XN:SX"\5_$+2_"OBSP'J!\87'A#X?^%/#]O=?"K0-4L]=
MM/$VN^*]?\._%C4D3PWI6H^#(8OI+_@J1^UQ\8?V+_V>O WQ6^!O@7P]\3?'
MGB']I3X _":'X?\ B(ZA"GC#2?B9XYMO#NJ>&]%U+39UET+Q-KD,JZ5H'B":
MQUVST74;R+4+KP[K<4!T^:?_ ()6? ;XK_LW?LB67PO^-/A7_A#/'4/QQ_:A
M\82:'_;GAOQ%M\.?$7]HKXF>._!NH_VGX4UC7='/]L>%/$.CZK]D74#?Z?\
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M&^)]/U'Q#I4GPJU#7]!TGP/I+6MQ??$_Q+X+OM4\5:?X1TKQ MQD>'?VKO\
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M^B7UGX/USX\P_$_7/%FE^/;Z7Q!I-E+\2-5^'\_PM'Q*CN;^XT5- N+ORYY
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M_B#X;?%_4]0T[QOI$-M#=I9^ O%SR6UJFGW+6_I7QJ^ WQ7\6_\ !3']AO\
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M.3XC_LN?LW^%/@3_ ,$V?VKOV</AM^R'^UG\*H?!%EX.L?&W@SPFGPH_:O\
MB/X&&@:'HW[0W[-?QKN=+B\/?$SXC>,]6N="\1W.CW=_8?&WPSXTUN_\.'2;
MZ_\ #FH7\4GCSPE^W!<?\%NO!$7AWX^_L]:;:W'[#7QW\1>$X-6_9U\=:LNC
M? %?VK?V>HM6^'FLBV_:$TM-:^*=[<2>'9+7XJ6<>BZ!:6^EZE;S?#2\;4[6
M72\3]J#5_P!L+_@J!X?^%W[*MW_P3;^,'[+_ (=MOCI\'/B3\6OVF_CMX_\
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MJ4O@Z#Q;;ZAX^\8:JVEWWB'2]*MTNXM*TW)T#_@K'XRN/V9;[4M:^"7AN/\
M;=T?]N.U_P""9UQ\#[7QOK%I\)=<_:SFU&Q(\3Z1\1I/"FI>);#X%7'P\N+S
MXR)J]_X1N-;M= TK4O!B2ZCK-M%KUW@?"A?VJ_\ @FW\6/VP?AYH?[&?QO\
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M[3]*\;>$H_#'A&XODO+Y/I?3?^"LWQ)U+]A3X+?%BW^!WA1OVU/C=^U5>_\
M!/\ T+X(2^+-:MOA;H/[5VD^/_''@'6]=\6>)CHT_BW1_A'HNE^ =8^*.JV,
M6E7_ (BL=(N-.\"-K<NI7*^,*^L/V#?@/\6/@S\4O^"C'B3XE^$SX9T;X\_M
MP^)?C#\*;LZ[X:U@^*?AUJ'P?^$7A>T\0FW\/ZSJUSH9EU[POKM@=)\1PZ1K
MD?V'[5)IJ65S9W-Q^:UY_P $^_VN],_92UWQ!X-\ 6,/[4/[//\ P5\^,?\
MP4._9_\ AAJOQ!\&:5H_QQ\"ZA\9?&5U;^ ]7\=:7K6L:-X+M?BO\'_'?B,V
M2:[>:7>Z9K\6B:5XOB\/V5QJDUJ ?4NM_M+_ +?_ .Q;\3_V;/\ AM_5?V7O
MC;\!OVHOC%\._P!G*[\7_L\^!?B1\)O&?[/_ ,>OBRNHVO@6&XT7QOXU^(VD
M_$SX(ZAKND1^'+[Q;>ZGX$\8:/>Z]#KM[I4EA8QZ)>_.WPC_ &K_  Q^PY\/
M/^"\O[57B[0+[Q9I?PA_X*!>+-5L_">G7BZ;=>+/%.O?!O\ 9M\(>!_"JZJU
MGJ0T>'Q)XU\0^']$NM9&F:J^D6M]-J2:5JCVJV%QZC\6D_:N_P""D?Q?_8_^
M'>M?L9_&W]DG]G/]G[]I?P1^T_\ M$?$/X[^+/@U!K?BSQ?\ TO_ !!\,_@Q
M\,/!WPV^)7Q$NO'WA'Q?X\O='U#Q1X_ODT+0K+1=#EETN7^VX+6QO./^(G_!
M-KXZ_'3]F3_@M3\"-=TVU^'NM_M>_M7:M\;/V:]?O_$7AR_T[Q,G@_P5\ ?$
MGPTUC5)?#VIZYJ'A#2=8^*'PE/A[5?[<T^R\3:)IR7.N1:!<1C3A>@'A?_!4
M35_^"GGA#]D30S^TW-^RC\1?AE\9/C_^R'HGC_0/@5X1^)G@CQ'^S)XAL?VH
M_@IXZ\+W5CXL\8^,_&FG_&[P+J>I^#I/A_XAU*^T'X9:_9>*_%OAW7-'LKS0
M/MNCV'Z'?$3]K+]I7XU_M=?'7]E#]D?Q1^S[\$M%_9-T3X9S?'3XY_M$>$?%
M?Q/?Q3\2OBYX4?X@^#?A5\)OAMX7^(/PEL)-+T/PA'IE[\3_ !_K?Q!NK[2;
MGQ7IVAZ'X*:^T^;5;GX__;8\3?\ !1S]OOX">"/V?? ?_!/GXK_ ?Q!H7QA_
M9S^(W[3&I?%[XH_L^0^"M=T7X:_%SX>>,-3\!? 3Q%X8^*.OK\2Y[?7K6R^)
M%QXIUVV^'VCP>$/AMK>AVJ:GX^U_P_X3N=7X^_L9:#\(_P!OC]IS]I[XH_\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_#O_P>9_\ .-__ +O
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M?Q#8>"K"_P#$%\GAKP;X1@UZYGUI_#/P^\+^$M#NM49+Z]L+FXM[62#[,HH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K^'?_ (/,_P#G&_\ ]W@?^^N5_<17\.__  >9_P#.-_\
M[O _]]<H _JF_P""8O\ RC8_X)Z_]F._LF_^J%\ U]Q5\._\$Q?^4;'_  3U
M_P"S'?V3?_5"^ :^XJ "BBB@ HHHH **** "BBB@ K_.5_X.]?\ E)/\$?\
MLQWX:_\ J^OVEZ_T:J_SE?\ @[U_Y23_  1_[,=^&O\ ZOK]I>@#_1JHHHH
M**** /QR_;$_;?\ V_OV3;K3M?N/V1/V8/%_PP\=?M(> _V?/A7KJ?M<_$/2
MO&&L3_%[XA+X&^%_B/QGX4_X98OM+\*I>)=Z9J7C&PTKQ5XJ_P"$<::\M=,N
MO$@M8I[JS^T!^U_^WC\ /A?\.?%_Q<^"?[-?PRU[QW^V3^R'\!-)MO GQ>\>
M?'O3=7\!_&SXGQ^#?B5?7QUGX7? :?PMXDT?3;G3V\)7,)\4V,]W=W5SJ5DD
M>GQ6M_;_ ."R_P#R1#]E'_M);^P%_P"K_P##M>>?\%]/"GB+QY^QS\'_  -X
M0\5ZAX#\6>,_VZOV-_"GA?QSI-Q<6FJ^#/$7B+XMZ?I&B^*],N[0K=VNH>'=
M2O+;5[*XMF%Q#<V<<D)$BJ: /VPM]1T^[N;ZSM+^SNKS3)88=2M;>Z@FN=.F
MN($NH(;Z"-VEM)9[:2.XACN$C>6"1)D#1NK%MWJ>FZ?+8P7^H6-E/J=R++38
M;N[M[:74+PQO*+2QCFD1[NY,4<DH@@$DICC=]FU6(_ ;X\?LE_L_?\$_OVN/
M^"5/Q'_9!^&VB? JY\>_M*>)/V5/BYIG@.75=)3XV_#;XF_!;XD^)(3\:-2.
MI3ZA\5M9\(>+?!.F>+=!UOX@R>)=>'B(0:FVL1W-C:R+\=?"OP78_MN_$7_@
MHEX^_:<_X)K_ !@_X*#^(4_;'_:9_9:\&_$"R^)_[)VG:'^SK\'?@]X@MO!7
M@_X1?!K1/C/^U)\-?%GP>\;:%%!-X[\1?$3P+X)\&^)/$OB;QA_PD+>(M5/D
M7( /ZS*_,W]HC]J3_@H1\-O$WQ0G^"'_  38T_XV?"OX7VD5_9>*]>_:[\!_
M#;QU\8K>'3[*[UI?A1\,]/\ AY\19%_LH7\TEFOC[Q/X/U;Q%+X>UO2M,T%;
MZ\\.OJ_I?_!-/2OVK_#_ .PU^SSX;_;?L=4L?VG_  MX6UGPG\2O[>\4^&?&
M_B'48?"OC/Q+X>\">(/$OB[P?XD\8:#XA\3>)_AOIO@_Q'XCU2#Q/K=_=:WJ
MM^^MW\NN?VECSG]O?]I?X@:9+HW[$_[(\MAKO[</[1WAG5$\,2R17-[H/[,_
MP=NVNM!\8?M9?%V:TAN(/#WA3P9(T^E_#;3]5Q=_$OXKR:+X5\.Z3XBBLO$E
MK9@"6O\ P5"^"FL_\$X_"?\ P4:\+>'?%GB?PA\0/"V@#P!\)]*@\_XA>+OC
M)XH\9I\)]"^!>D0P6]PEYXKN?C([_#V?5;&TO=+@^R7_ (GC6XT*T>8\_P#"
MW]O']H_3/C[\&?@;^VM^Q7:?LI1_M)6OBW3O@?X^\+?M%>'_ -H7PKJ?Q,\'
M>'F\97_P<\?76@?#OP/;>!?&NI>#--\2^(/#-W]MUOP]XJE\/:AH7A[4=1U*
M"79\7_M^_L^^#OV.?V7_ /@C!^S[\,+#41\(O@1_P56_X)\>&/$FH+##;-=:
M+I^H>/A=^/?&;V<<=I#<^(_BQ?Z)XO\ $MQ$D%I>^*-8:-(ECO5MV]\_X+(7
M%\=8_P""3&FZ#!>W?B>\_P""R'['%Y8P:9N:]@\.Z5I'Q8G^(&IRPH"9=(LO
M \VMQ:RQ!CMK*\-VY3R!(@![A^T1^U)_P4(^&WB;XH3_  0_X)L:?\;/A7\+
M[2*_LO%>O?M=^ _AMXZ^,5O#I]E=ZTOPH^&>G_#SXBR+_90OYI+-?'WB?P?J
MWB*7P]K>E:9H*WUYX=?5^K\!?MP^)?VC_P!@CX?_ +:G[%OP!U#]HOQ%\4/#
MFAZQX0^!6K_$_P )_!G4'U3_ (2X^"_B)H&M_$?QA97_ (9TJ?X9:SIWBN'5
MKN&PU&/7F\,7$?AR&^?4=.\[F?V]_P!I?X@:9+HW[$_[(\MAKO[</[1WAG5$
M\,2R17-[H/[,_P ';MKK0?&'[67Q=FM(;B#P]X4\&2-/I?PVT_5<7?Q+^*\F
MB^%?#ND^(HK+Q):V?T/\%?V8=-_9B_8_\'_LI?LY>(K3X?R?#'X-3_#GX:_$
M#6_"EIXMCTGQJ="O(H/BIXI\%P:GX;L?%NHZAXXO;CX@^+/#\6L^'[7Q+JE[
MJEDFI:3%?BYMP#Y%^'7[?7[2WAK]JGX,?LO?MI_L9:5^S[+^TU9^-U^ /Q7^
M%G[0.E?'WX>:SXP^'O@F?XB>*_AGX[:;X??#'7O!?B6P\*V5])I>K2Z3>Z-X
MNU:UGT_PVEW;6E[J5O\ ;?[6'[2?@3]C_P#9R^+W[2WQ)AU.]\'_  A\(7?B
M:_TG1(X9=<\1:@]Q;:5X<\*Z&ES+!:G6_%GB74=(\-:0;N>"S74M5MFNYX+<
M2RI^'.D_#W]JK]GW_@K1^P]JW[?_ ,>?"_[;T'Q<TW]I;X>_L<>,/!W@WP[^
MSS/^S-X\3X:3>*OBEJFI? _P];:O!XVTSQW\-M(A\%P^--1^)7B[5_#+7<EE
M>6MI'<Z?=:O^_7QM^#7P[_:'^$7Q'^!OQ:\/P>*?AM\5O!^N>"/&6ASLT37>
MBZ]92V5Q+97<>+C3-7L&DCU'1-9LGBU'1=8M+'5M-GM[^RMIXP#XR_9Y^.?_
M  4G\>>/_ DGQ^_86^$'P4^#/CL>(YM8U'1?VL;?Q_\ %[X+VNF^'M6U3PS_
M ,)[X*M_A1I7A+QC>>+M;MM&\./9^ ?'<[^&#J]QJVK-+#I,MG<_H7<:WHUI
M%+-=:OIEM##?P:5-+<7]K#%%J=R\$=MITLDDJI'?W$ES;)!9N1<2O<0+'&S2
MQAOQ8\(_%/\ :\_X)O?&?]FO]FS]I'QQ8?M>_LC?M'?%S3_V=/@!^TUK-PGA
M_P#:E^$/CK4?"_BS7OAU\-_V@_#.G:;<:)\<]/U[3?"\.A67QN\-KX5U>"XT
MCQ-XI^*5G!<:CH%EJ'SU^QO^PY^RS^U7^U;_ ,%>/$7[2?@GPM\?%T7]NWQ)
MX1\-?";XC_:O$OA+X9V^I_!;X676M_$GPWX/O+IM"T/QG\2DN;/PW-X]L]/B
M\6P6'PMT^PTK6;""UGCF /Z/ZHV&IZ;JL4L^EZA8ZE!!<W%E--87=O>10WEI
M(8KJTEDMY)$CN;:4&*X@<B6&0%)$5@17\<&L_&OXUZ-^QQ_PQMH>L_&'XC_"
M/0O^"_7Q$_X)G:?I?A[XHVNA_&;XE_L<>"+;Q!\0=&_9JT[XS_$/X@_#FXT_
M4?%DEB?@I'XFU;XE>''/@;2KGP=8ZBVCWECIS_1'Q(\)_M#_ +$GC[7?VN/V
M)/\ @F7XO_85^#'PZ_8J_;!'[5F@ZQX\_9&?X6>/]3^%'P+\1?$K]DSQM>?"
M3X$?M)?$.;Q%XX\%?%?P_JGAWQ'XYC\(?\)MJ'@[XB:Q;:KXAN](74P@!_4;
M/XB\/VNMV/AJYUW1[;Q'JEE=ZGIGA^?4[*'6]1TW3Y;>"_U"QTJ2=;^[LK*>
M[M(;N[MX)(+:6YMXYI$>:,-Y3\(M1^.M]X@^-L7QD7X0CP[IWQ8OK'X%GX7W
M'B6?7&^$*^&?#4VGGXO)K]W=6EO\2_\ A)YO$XO8/#:6FA#P^- >*V%X]Y))
M^=?["W_!.K]BS4_V?_V8/VBO%WPA\$?'C]HGQMX._9__ &FO$/[6'Q4M+[XC
M_'+QA\96\*^#/'FG_$FQ^*GCB74O'NA62:];6&I:!X5TG5-(\,Z3IEK8:3'H
M$=G ]NWRU\)/BC^S]\'OAG_P7V\:?M41:Q>_L^R_MT_$GP1\4-$\.1>()?$G
MBOP_\4O@%^SY\,$\$>&U\*7^D^(X_$7CG4O&%CX0T.YT?6-$O+/5-:M;Q-<T
M58'U6S /Z"](\3^&O$%SJUGH/B'0];N]!O5TW7;72-6L-2N=%U%K:"\6PU:"
MSN)I=.O6M+FVNEM;Q89S;7$$XC,4L;-\4?L8?M,?$+]H'XD?MY>$O'%GX8M=
M,_9H_;"\0? ;X?2>'=-O["\O/!6E_"WX7^,[:Z\3RWNK:G'J.OMJWC+5HY;Z
MP@TFS:RCLH5TU)899Y_P2MO"5U\"/VYO^"8/Q*^%'_!++2?^"9_A?Q9^T->?
M 6U\3VGQ7^#T?C7X]_"CXF_!CXA7VJ>$/C3\#O@Q/JTIUO0+KP_HWBRTU[XC
M^./$VM^$_$=GI4%RMUK%W)'HOZS_ /!+[_DM_P#P5W_[26^,O_5 ? .@#2_X
M*!?\%1;']@?]HK]CKX4>*OA7%XF^&'[1FJ>(X_BE\79/&0T!/@/X6TCQS\)?
MAS;>.=1T&30-1B\1>'K?Q)\7M!D\1.-8T>?2=*M[B[A2].Y8OU7U?5M+T#2M
M3UW6]0L])T71=/O=6U?5=1N(K33],TO3;:6\U#4+Z[G9(;:SLK2&:YN;B9TB
MAAC>21E121^(7[?_ ,'?!7[0O_!3#]B+X$_$>RDU#P)\8/V*/^"E'PX\66T#
MI%>#0_%^@? O0[ZYTZX>.46>JV45X;W2;]$,NGZE;VM[!MF@C8?,WC;]I#XK
M?'S]@?X(_P#!-G7?%%TO[;OQP_:'UO\ X)A_M%ZKINNO+XKTOP1^S[$-2_:R
M_:*MQXBL[6[\2:3X\_93TK1O'BW 6W$MQ^T'X7-G>WDK6ZW@!^AG_!+K_@I?
M>?\ !2*R_:+UUO@G?_!KP_\ "+XA^%='\ -K'B.?6=<^(?PS^(W@VU^(_P -
M/B%JVDS^'=#'A2X\6> =8\-^)(M$ANM=BAMM:B":K.J+))^IEKJ>FWUQ?6EE
MJ%C>7>ES1VVIVMK=V]Q<:=<2Q+/%!?0Q2/):320.DT<5PL;O$RR*I1@3_))^
MT1\0?&7[)WPH_P"#@*\_9LO;KX2:EX:_:"_X)_?!?P5K7@2?2?#5[\+?!'CO
MX1_LQ_!F\N/!5[J.IZ!I/A?4M$\%>)+O1O!^L2:[X?@\*:K-I.MQZSI0TE;R
M'Z)T;]D[XG?"[XY_L.^/?V&/^"47Q:_8S\1_#+X]>#O"7[27Q8\0?&C]CF6T
M^*7['7CPWFC_ !XTCXU2?#[]K3X@^/?COXML+Z3PK\4O#>L^-M!\<^+[/Q-X
M*%WX<OK?6[FU64 _I2N]3TW3Y;&"_P!0L;*?4[D66FPW=W;VTNH7AC>46EC'
M-(CW=R8HY)1! ))3'&[[-JL1X#^T9^U#\,OV8=-^&6I?$9M7N!\5_CE\&O@'
MX<LO#ZZ)/?6GBKXW^.M.\ >&=>UF#6-<T1;3P;H^JZBM[XGU>VDO;RPTNVNI
M;#2]4O$CLI?YO_A7X+L?VW?B+_P42\??M.?\$U_C!_P4'\0I^V/^TS^RUX-^
M(%E\3_V3M.T/]G7X._![Q!;>"O!_PB^#6B?&?]J3X:^+/@]XVT**";QWXB^(
MG@7P3X-\2>)?$WC#_A(6\1:J?(N1TOQS_95\5^,OV"O^"56L?\%)_@/X%\6?
MMJZ+^V[^Q'^S5\6/%?Q)M/AU\5/B#KOP=N?VP+WPK8>%?%OQ#T#5O&^G>)].
M^)?PONM(UWQ[I\?BW7(-;U;Q3KP\2S76M7>L!@#^C"\U[XTS?'WPG#HES\%[
MC]F&Z^$7BO5/%-]<ZAX@D^-3?%>V\3>'XO"DGAE;:^_X0R7X7CPI)XD;Q+=7
MEI+K<?B%=$6RNHK)KN.3U]?$7A]]0T_2%UW1VU75M.EU?2M,74[)M0U/283$
M)M3T^R$YN;S3HC/ );VVBDMHS-$'E!D3=_/Y^TS\// GPG_X*$>%/AQ\,?!_
MASP!X!\(?\$4/VY=(\+>#?"&CV.@>&O#VEQ_$SX92QZ?H^C:;#;V.GV:22RR
M+;VT$<8>1V"Y8D_!O@W_ ()T_ +PI_P;Z6W[6*:&TG[9>C_L:^&OVK?"7[6@
MU/Q#/\=O ?B3X:^";'QO\(_"_P /?B#<ZTWB+X>^$? 7P]\/^%OA-IGA3P5?
MZ%X370='%]+H5UJ4T]S< ']@.H:A8:38W6IZK?6>FZ;8P275]J&H7,-G8V=M
M"I>:XNKNY>."W@B0%Y)II$C1069@ 33+/5M+U'RO[/U+3[[S[2*_A^QWEO<^
M=8SO)%#>Q>1(_F6DTD4L<5RF89'CD1'+(P'\^GC$:'^W9_P4N_9'_9S_ &K]
M%TCXA_ &Q_X)76'[;&G?!;69-0C^%WC_ /:6\8?%_P *^!-1\0>,/!"7W]@^
M/[?X>^"/M[^$/#GC2UUW3] D\6:MJ^EVOVG^TKBNE_8\_9]^"7[,_P#P6F_:
MU^&OP L[;PQX ?\ 8.^!'BO_ (5;HU_=/X,^#^O^*/CG\5-2UKP7X"\-RS26
M'@+POK4[1_% ^#M BLM M?$'Q$U[6-.L+-=;DA4 _?6LO3-<T76FOET?6-+U
M9M,NVL-273-0M+]M/OUCCF:ROA:S2FTNUBEBE:VN!',(Y(W*!74G\D/^"Q7B
M/Q'<^!OV*_@!:^,_$/P_^&_[8/\ P4 ^ W[,_P =]>\*ZYK7AC7]>^#_ (NT
M7X@>)?$?PMTSQ1X9FM/$GAN7XLWWA#2O!5]JVC7]E-)H>H:OHUY<)IFL7K+\
MO?ME?LF_LZ_\$X?''_!/GX__ +#WPZ\/_LT_$CQ%^W#^RW^R'XQT+X82ZWH&
M@?M!? [XR:WKOASQC\-?B1X8M+R7PYX]\1I9+_PFNB?$#QQ8ZIXNTG6_"UOJ
MZ^(+C4;73T !]V:A^T+\<_BY_P %#-<_9T^"/Q:^"G@/X*_LW?#/X!?$WXZ_
M\))\/;_XB_$'XN^(_C=XI^,5G%\)O!>KP?$[P3I/@6QTWP'\,HO$+^-+71/&
MNH:;XFUG2X;W1+_2X+W2+_WO]MG]K73OV./@[IGQ!3X?Z[\7O'_CWXG?#GX'
M?!7X.^&=7TCP[KGQ6^,GQ7U^+P_X+\&6GB37R-#\.6TS"_UC6=?U426ND:#H
M^J7WV>[FAALY_P ROV1/V)_V0/!__!6S_@H%=>%?V9?@;X=N?@O\-/V _&GP
MCGT;X9^$].E^&OB[Q[I/[4$GC;Q+X(>UTN-O#>N>*Y-#T9_$&IZ4;:[U5M+L
M#>2RFUAV?K-^U7^S!\.OVOO@QKOP5^)5UXHT/3[_ %7PSXK\+>.O &LCPS\2
MOAA\0_ VO6'BGP)\2OAKXK%K>2^&/&WA#Q#IEGJ.DZK%;3Q21B[TO4;6^TC4
MM1L+H \A_9H^*W[?'B?QA>Z=^UQ^RI\$O@EX!N?A_>>,=+\>?"_]IF?XK7F@
M>*(M7T.UMOA7XS\)ZO\ "WP.W]J_V'>Z_KU]X[\,^(-7\'VQ\/1Z9$+F;6(;
MFT];^ W[4WPN_:*U[X\>'/ ,NJ0ZC^SW\<_$'P!\6KK9T.!==\5^&O _P^\>
M:CKG@]-+UW5[C5/!YTWXCZ1I]MJVH0:1>RZMI^LPOI45I;VE[??GI\(?C1^T
M[\+_ -HOP;_P3/\ ^"B5E\+?VEO#O[27PA^-&H? W]J;PCH=OX:'QP\,?#32
M?#=K\4/A9^T;^ST;35-"\'^+QX3\5W>JZGXK\.ZW_P *P\5Z3J.B^'-+TN;Q
M%<>(HM,^%O@#\(/@O^R-\#O^"[?[47[/'P!^#W@CXZ_LM?'K]M#2O@+XT\/_
M  W\)VFL?#?PQX/_ &-/@3XXT7PKX>FBTM7L_ ^D^)]0U3Q+=^$;9HM(OI;O
M55DM]^HW#L ?TWG7-%&KIX?.L:6->>TDOTT0ZA:#5WL(GCCEO4TTS?;&M(WF
MA22Y$)A1Y8U9P74&_//#;0S7-S-%;V]O%)////(D4,$,2&26::60JD<4:*SR
M2.RHB*68@ FOYMO^'97[%O\ PZJ/[3O]E3_\-1G]DL?ME_\ #??_  F?Q#_X
M:._X: 'P(/Q-'QO'QD_MG_A98TG_ (2,GQ&? XOQX5.G8M#X8-TJR#-^#/B>
M3_@IU^T5^Q#\%/VT;7_A-_AC:?\ !'[]GW]O+Q)\$;Z\UO1?A_\ '#]H/XM_
M$'P[X?U3XC?$3P7X?O[+PIX^\%_#^/PM:W/A'P'XRLK[0=&U[X@ZE=+HVH+#
M'/  ?JS^W;^UGXH_9_\ A'\ /B3\%KOP)XLM_BU^UU^RO\$KS5=167Q/X?N_
MA_\ &SXH:1X/\3:IX>N] US3H'U==%OY9] U47E]IUO=^7<7%AJ$(,#??TE[
M9PW-M92W=M%>7BS-:6DD\27-TMNH>X:V@9Q+.L"$/,8D81*0SE00:_GV_P""
MMOP0^%W[('[%_P +K?\ 9#_9N\!>&I[K_@I5^QK\6M-^"'PJL/#GPH\.?$;X
MKP?$GP7I>FZ39+:64'A/P=?>,HO!WA3PJ^K1Z7!I&G>5!J=Y9R>7=/-[S_P2
MJ\"^ _CMIFJ?\%%/BA\0(OCA^VS\3;?4_AG\6KC5="U7PG;_ +&5UX9U*5_$
MG[$WPW^%'B=1XD^#%C\*=5NAIOC;_A(X_P#A.?BOKQD^*/B+5-2TSQAHYH ^
MF?\ @G-^U3XR_:G_ &8='^,'Q=;P7HGC#6/C;^T1\,[*S\-V]SH.D7UG\+/C
MG\1_AWX6M[&QUC6M8O+G6[GPSX/M+O5%AOI?ME\FH7EK9V=J1;0??SND:/)(
MZQQQJSR2.P1$1 69W9B%554$LQ(  )) %?RD?\$T_P#@F3^S9^TC^PC^TG\3
MOV@O ^@_%'XA?$?XS?ML^&OA'XZ\4Q:CKGB+]G3P5X=^,OQ$TW1=/^#S7U^M
MM\.M:T_XKV7C;XK/XA\#KH.O:OK/BUH=8UB\M;6VM;6/P/X[\4?MX_#7_@@!
M^S%^TQXR\6>(O@K^U3^SW\??B#^T?X>N?&?C"PU3]J/Q?^S!\*O!L'@7PQ\0
M_%VA:E8>)]?TZ;5+_4?BMX^TC6=9;3?&VL:=:7.M->WVG6;3 ']5>DZSI&O6
M:ZCH>JZ;K.GM+<6ZWVDWUKJ-FT]K,]O=0K=6<LT!EMKB.2"XC#EX9HWBD575
ME'PW_P $WOVF_'_[67[+=M\:?BG:^%=-\42?%_\ :,\"SQ>$]/OM(T*/0OA-
M\=OB'\-_#DYMM4U?6KE+V7P[X5TZ?6+EM0\BYU)KNZM[>RMY([6'X!\8? OX
M2?L _P#!4C_@G=I/['/A;1_@3X2_;:D_:?\ AQ^T;\!OAW_:.@_"[XCZ-\&_
M@1'\0_ ?Q,LOAO:R_P#"O_"OC'X9Z]IEM;7WBK0-'TC7]<T?Q;J6F7<UZFJZ
MM<-^:'[-T$7QD\*?\$F/V(OB(]]J/[,W[37[:/\ P6(\8?'CP%;:QK>AZ;\6
M)_V</B#\7?'GPP^'OC&?0+W3[G6_ T_BS6YO%NO^#=5N)/#7B>;PAIL.LV5X
MUI91@ _HY^)_[3OBCP[^VQ^P_P# 3P7/X-USX7?M)_#+]K_QGXOUQ(YM6U<7
M_P "=/\ @5=>"CX3US3M8CTFVT^[E^)'B :\MSIVK-?I#IHLKC3C;3M=?;DN
MIZ;#?VNE3:A8Q:I>PW%S9:;+=V\=_=V]IL%U/:V;R"XN(;8R1_:)8HW2'S$\
MQEW+G^>/4_V3_@-^R3_P6H_8J;]F[PYI?P]\.^/OV7/VTO$^J_LZ^![F?1OA
MWX:\6Z#IOPCTIOB'X1\!1RMX9\#:G\6M-BTCPSXBD\+Z7I.G^(+GX5:?J>H6
M5QJ\5_?WGYP?LY_"/X@?ML?\$[]4_:'N_P#@G5\>OVA?V\?VC='^(/Q;\"?\
M%&=*^-?[(?A_Q/X)^/6B^,O%T_P/U?X/>)O%G[7_ (9^,GP3^&OP)\2:-X3\
M)V_PW\)^'_!&G#2O!FH6%]X.N&OKB"< _L]N-1T^T:1+N_L[5X;.?49DN+J"
M%HM/M2HN;^19'4I9VY=!/=,!!"642.I89J7&OZ#:?V/]KUO2+7_A(;F*ST#[
M1J5G#_;EW/;2WL-KH_F3+_:=S-9PS7<4%EY\LEM#+.BF*-W'\V/Q4_9X\0_M
M>?\ !2#_ ()N_#?]M;PW%+J>H_\ !*_Q?XS_ &O/@S%X@BB\*^./'FB>.?@M
MJ?B+X<^([GP#J,FC>)_"?AOX^R^'/&?]E:/KC>$-=O/ 6E"2YUKPXTNEZMC?
MM"_L<_ _]D?]ICX]_'/]K[]A#P'^U'_P3I\3_#'X%^"_A[\6-(T;_A;/BW_@
MGK\*O@?\(_#/PRO_  3JGP.UM+K7[#X,K-HEUXX'Q$^ 6FZEXN\)68UG4?',
M>O7&H0W&E ']/U9=WKFBV%_IVE7^L:79:IJ[R1Z3IMWJ%I;7^J20Q23RQZ=9
MS3)<7KQ0Q2S2);1RLD4<DC (C$9.AZ_H6K>"-'\4>!9K+Q)X:U/PKI^O^#I]
M$NHYM.U_0KW2(=1\/3:1>+YD4MEJFGR6;V%TOF1O!/%*-RGG^=G_ ()H_L"?
MLE?\%#/V#/!G[7G[87P_TO\ :/\ VF/VO5\8>.?BI\>O$^L>+3\0O"FN:+\5
M/&ND^'/"OP:\1MJUOK'P/T7X36VBV'@_0M%^%L_AG2H4\.K;R+J6E^3$P!^L
M_P#P4'_:9\6_LT_ K3M2^%%_\/H?CE\4?C+^S_\  3X16_Q+AOM0\'6?BSX[
M_&;P=\,AXF\4:1H^M^'M5O-"\)Z%KGB#Q3-%#K6D07EQH45A-J5LEP[#Z:^#
M&F?$?1OA?X/TOXN?$OPK\8OB)9Z=-%XF^)O@KP%_PK'PSXON#?WCV6I:=X%'
MC3XA1Z R:6UC9W\=OXNU.TOM2MKS4[.'2;6]AT;3_P"4&'P?X$_;)_X)F?\
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MQJ5TEI:75T]O91S2K;VUQ,4$<,C+\1_M5?M/>//@A^TW_P $^OA'X;@\)_\
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M^&]S)!X1\41^%] 73KO6/#-Y8_VC]&_\%2OV1OV7_P!F#_@E3_P4;U+]G'X
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MMK_@BR\1^'?$GQ#N?%'B"#Q+);ZU/JDL^G0(_1_L;_L__ '_ (*)_$W]N?\
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MON-'B;]M#PW^QQH?[5'@?]K6QO==7XZ?#_6?AMX:3XA?!?PO\/OB"^JQ>(_
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M:AJMC9P)K-X\,=GI+37$\<:ZG=O<6Z6U@6%U.\\*Q1.94#?E!^W]_P G\_\
M!&+_ +.7_:/_ /61OB?7Q)^QG^P%^SA^U-^VG_P5N^*'[3OPY\.?'K1/#'[;
M/BGX<_#3X<?$R*_\3_#_ .'NH:U\'OA;J?Q-\<Z%X'U"]E\'0^./'VFW'P[T
M6;QLVB2>+]%L/ASI$&@ZWI<4MRLX!_2I6;JVLZ1H%C-JFNZKINBZ9; &XU'5
MKZUTZQ@!Z&:[O)8;>('L7D4&OR<_X(HZGXHMOV._%7PI\1^*M<\:V/[-O[5O
M[5_[-O@3Q#XGU+5-9\23_#;X1_&KQ/H?@?3M6U76-1U2_O!X?T-[?P]HT4EV
M\6E^&]+T71+8?9],B9_ /!_P+^$G[?W_  5(_P""B&D_MC>%M'^.WA+]B.;]
ME[X=?LX_ ;XB?VCKWPM^'.C_ !B^!4GQ%\=_$N^^&UW+_P *_P#%GB_XFZ_J
M5S:V?BCQ#HVL:[HVB^$].TFVEM(M+TJ=0#]ZYKVSMK5KZXN[:"Q2(3O>33Q1
M6J0L 5F:X=UA6(A@1(7"$$$'!%)#?65Q<W=E!>6L]YIY@%_:0W$,ES9&ZC\Z
MV%W CM+;&XA_>P"9$\Z/]Y'N7FOY _VE-$L_V?/V=O\ @X6_84^%FKZQ)^R[
M^SU\"?V7?B-\%_AQJGB'Q)XHM?@%K'[0'A+6->^(?PT\.:MXNOM5U>U\'ZWJ
M7A?3?'WAWPM::E+H/A=]>U9=.BAN-6OXT^J/VN/V8_ '[(O[+_[(7PT^&=KJ
M?A;Q5_P4?_;K_8,_9P_X*"?&W0?&'C.R^*G[0?ACQ[?^//%7Q5U'Q/\ $:UU
M2U\566I?$_Q/>^)O#]_?:#-H$%MH'Q%UKPU:V6E^%)4TBT /UR_:V_:@\2_!
MOQ'^Q1IOPQN?!6OZ=^T#^W-X+_9G^(L]\LNNMIGA+6OA+\=?&FN+H4VD:S91
M:3XOL?$/PUT.T$^I+J5O:6KZK:7.D/<SPSVGV]=ZGINGRV,%_J%C93ZG<BRT
MV&[N[>VEU"\,;RBTL8YI$>[N3%')*((!)*8XW?9M5B/YQOVR?V$OV5/V5/VO
M?^"1_C7]FOP3X8^ 4_B3]N3PIX'\6?"3X;&Y\,>"_B=9:'\'/B[J7ASXD^(?
M ]E<IX=U7QM\,#+JWAJ'Q]+IO_"676F_%>_TW6M8U*U?3X[/YZ^%?@NQ_;=^
M(O\ P42\??M.?\$U_C!_P4'\0I^V/^TS^RUX-^(%E\3_ -D[3M#_ &=?@[\'
MO$%MX*\'_"+X-:)\9_VI/AKXL^#WC;0HH)O'?B+XB>!?!/@WQ)XE\3>,/^$A
M;Q%JI\BY !_6+)=6T,UO;S7$$4]X\D=I!)-&DUT\,3SRI;QLP>=XH$>:18E8
MI$CR, BDB"WU/3;NP&J6NHV-SIABEF&HV]W;S6!AMRZSRB\CD:W\J%HI!+)Y
MFV,QN'*E&Q_*3\4O@;^U#\6_AQ_P0(_9X_;Y?Q1H/QUUCXX_M#_#/]HBWN/B
M)IVJ^+/&WPM\.?"+XLZ+JFA^*OB/\,_%'BF/4]3^-W[.NC6NB>/=7T/QG=:_
M?-XYUZ+4/$FG^(Y;[4K3^E;X=_LV? ;X3? ^/]FKX>?"GP;X8^ <>B^,/#G_
M  J6TTJ.X\$R>'_B!J>O:QXUT2XT;4&NX+K2O$VH^)_$%QJ^GW/FVMT-6O(6
MB^SR>4 #GO@-^U-\+OVBM>^/'ASP#+JD.H_L]_'/Q!\ ?%JZV=#@77?%?AKP
M/\/O'FHZYX/32]=U>XU3P>=-^(^D:?;:MJ$&D7LNK:?K,+Z5%:6]I>WWO=WK
MFBV%_IVE7^L:79:IJ[R1Z3IMWJ%I;7^J20Q23RQZ=9S3)<7KQ0Q2S2);1RLD
M4<DC (C$?AC_ ,$H_P!E3]FCX7?%K_@I9\1/AQ^SK\)/#?CSX4_\%!OC1\+?
MAGKGA7P'X9T+Q'X4^&T?[._[-&N)\-?"6L66FQW6@>$[K6==UJ\&AV#Q:8+[
M6=0NFM6DNYS)XC_P31_8$_9*_P""AG[!G@S]KS]L+X?Z7^T?^TQ^UZOC#QS\
M5/CUXGUCQ:?B%X4US1?BIXUTGPYX5^#7B-M6M]8^!^B_":VT6P\'Z%HOPMG\
M,Z5"GAU;>1=2TOR8F /Z4*P]3\3^&M%O](TK6?$.AZ3JGB"Z>RT'3=3U:PL+
M_6[V.WN+M[32+.ZN(KC4KI+2TNKI[>RCFE6WMKB8H(X9&7\S_P#@BW\9?B1\
M>/\ @FY^S]X\^*WCC4?BEXOM+SXO_#W_ (6GJ\US<ZK\2_#GPE^-WQ&^%_@[
MQKJMY?*NI:CJ^K^%/".C_P!M:QJQDU?7=7@OM;U65[_4;@U^:_[5WAW]EG]K
M[XI?MJWGP%_X)*6W[:_C&R\5ZS\#?VH_VQ_B1\2?AI\$O#GPW^)/PJ\!Z1X"
MU73O@KX\^+-]XK^(-EX@^#NE:#HD/B*X^"W@'POH%MK&FW&K/J7B#6M6EN=<
M /WH_:,_:A^&7[,.F_#+4OB,VKW ^*_QR^#7P#\.67A]=$GOK3Q5\;_'6G>
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MJF_X)B_\HV/^">O_ &8[^R;_ .J%\ U]Q5\._P#!,7_E&Q_P3U_[,=_9-_\
M5"^ :^XJ "BBB@ HHHH **** "BBB@ K_.5_X.]?^4D_P1_[,=^&O_J^OVEZ
M_P!&JO\ .5_X.]?^4D_P1_[,=^&O_J^OVEZ /]&JBBB@ HHHH ^<OVF?V8?
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M (9B_P"$G_M;PW_PL_\ X0+_ (0C_A O[7_MK_A$_P#A%/\ A+_['_TG[?\
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MP9\0/ASXL^QZ@_AKQEX6U_2[._TO4_L5Y;2QBZTO5+'4=&U'4=.N_E'X=_\
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MU:[^TY\9?VE_CW^V#^T9J_@F[^'&B^/OC=?^$[#PQ\,? ^IZM8:UXAT/X/\
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M*MI\GQA\'_ C]N3]KG]FC]GK]H/QC\0?&_Q6_9]^%MU\&+OPYINL?%":6_\
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M"?3-/\.:+<>$?!5WXZ^+WC_Q5=:)=W^N22ZOKDDPO5CABB7[AHH ^%OV._\
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M!=(\">#?"]G9^%5\1+X@\3>(/T.HH \#_:?_ &=/ _[6/P,\<_ /XAZIXO\
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MU;]H7P/\&X_A!K'@[QSX@TOPK:>#)OB!X/M?B9\,O&NH_"+XKZ[X=TO0]/\
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M_#KQ)\7K+X6^&?"OPG^'GB#7[/7=>MOA_P##CX1?#[P!X0TKQIXM_LG0=/\
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M/BWP3XE\36&F:-):3W.GR^ =?\&ZG)-J%V-0O[V)+2.V\0_X+"^#?C7\"?\
M@G[\%]/T3XI>-_VJOC9X>_;]_9)\2_#WQ#\:M,\!:;K'BKQE%\8--U#P/X-U
MFR^#_@WX8>'_ .P6UZWL-+#:?HMCK$EG=S^=JDEQY4\?ZN_M^?LY:U^UU^Q;
M^TS^S7X9U32M%\5?&+X0^+?!_A+5=?N[RQ\/V/BZYL6NO"D_B&\T[2M<U&V\
M/KXAM--&N3:=H^IW\>E&\:RLKBZ$4;?*?QM^ _[9W[:O[.?P/T+XQ^ /@/\
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M^-/VB_&?QR\"7_[#G[1OQ7\6:]XW\'_"WP[XC\;^--#_ &B_ &E^ -=\0?\
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M3PIX=N?%<MU9KJ-AHT<.K2^I_MD_LP^/OVAOB+^PKXN\%ZOX0TO3?V8OVO-
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MM?\ BJX\)^#O"'A3X9^'Y?&NL>)GTQ+74/$]SJ&FV6BW8N[+47U?2.^^&?\
MP39UBX_8H_;3_9%^-WB+PG+_ ,-/_M"?M9_%SPIXI\"W.NZQ_P (%!\9OB?J
M/Q*^#GBS&KZ3X0NXOB%\+_$*^&?%S6=BTVF67BGP]:KIVOZC;(MZP!^>/_!9
MBYB_:W\3?MC?#&.4:E\(?^"8_P#P3\^.7QT^(-HA$FGZC^V#^TA\&?'?A3X(
M:!K6FZC8O;WLWPM^ P\??$O2M3T>X\[1]>^(_A>6:>.YA6&/^@_]F+_DVO\
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MCX8_$73)-1\!6VEV5II]K81WUPLWD7[2_P 6?VF?CE^WCX:_X)]?LY?&*?\
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MQO\ M"?![]OWPG^T)\/_ (3?&/XA_#CX5Z/\=OV3_CW\-_A%>_$/1-?C\1>
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M;\+H'UJ_\=_"_P"*G[7VJ_"/QA^U%XHU@7WAK3=#T"TU7Q?\.?$$'A*W\/\
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M*?!*Z9KG@+2_&WCVSU/3;[6;_38+S5;35-5T[WOX)W'_  4!_;6_:P_X*)^
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M#7P%?:(]SJNE>._B!JWBWQMX>O=!T'P]K@!^Y-%%% !1110 5_#O_P 'F?\
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MZ@OK&\@?.R>UN[626WN(6P=LD4CHV#AC7X'_ /!5GPA\)+7]KG]E/XN_M_\
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M>\)7OCZ+]NVW\37W@N__ &>$^($E_9^ &TNTUO3+_P 1GXHW-Y9:,?A=;_\
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MQIMUH:_0/QC_ &UOC5J/[2GC3]DC]BO]G_P?\>?BI\&/!7@+X@?M#^,/BO\
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M_#3P]JOPITV%M!EOF\,^*=4US3_$VI21^);2V74?#]BLFCW<C)=VX!]]T5^
M/PH_X*T_MD_M%?"SXR_'3X!?\$_?"FO_  I_9D\5?&3PO\8-4\<_M,P^#]?^
M(>N?"#Q'XG76?"7[.V@:;\*?%%UXBUJS^'5MX*\8W^O?$7_A O#%UXH\0ZO\
M-_#]SJUYX=N?$4O[+_LY_'?P/^T_\!OA#^T1\-7OCX%^,_P]\+_$3PW;ZLEG
M%K6F6/B?2K;4FT/7H-.O=2L+7Q#H%Q-/HGB"SLM1O[6SUFPOK6"]NHX5G< ]
MGKB/A[\2_A[\6?#:>,?AAXU\,?$#PF^K:_H*>(_"&M6'B#17UKPIK=_X:\3:
M4NHZ9/<6IU#0?$&EZEHNK6HE\ZPU.QN[*Y2.>"1%_%K]E3XW_P#!13Q/_P %
M/_VROA[\2_AM\'8?AUX9\#?L82^,O"5C^U1\2_%?ASX*^&_$VG_M$SV/BWX,
M>&M4^ NBZ1XH\8?$QM),WQ)TJZC^'$5E)X5\+(WB7Q:@A.C?&'_!,K]L3]JW
MP!^Q3\9I/V=_V.?#GQI^&?[+7Q]_;*U7XO>,O'7Q_A^$OB'QEKJ?'7XF_%GQ
M!\//@/X(T_X9?$:7Q7KNA?#OQ?X.UI_$_CG6_A_X7U'7M0U#P7I+:AJ6FW=_
M;@']5=%?F%X^_P""FGA&7X2_L7^)_P!G3X6^(OCG\9?^"A6@1>(_V6_@EJOB
M3P]\,Y+G0M,\!:?\2_B/XF^+GCJZ?Q1HG@#PU\(/">HVX\>3:!9^/M;F\2W.
MF^&_">A^(Y=0-]:]]^S)^V)X_P#'WQZ^*G[('[3?PB\,_ []J#X8^ O"7QFT
MK2_A]\2YOBW\*OC#\"/&.IWOA2S^*7PY\6ZIX,^'/B[3_P"P/B'HNO>!O&7A
M#QKX"T+4='OX=#U/2=2\1Z;KTCZ2 ?>&H:KI>DQ)/JNI6&F022"&.;4+RWLH
MGE*LXB22YDB1I"B.X16+%49L84D6K>X@NH(KFUGAN;:XC2:"XMY$F@FBD4-'
M+%+&S1R1NI#(Z,RLI!4D'-?AW_P6K@^"USK7_!,&']HJ'X7S_!!_^"B/A3_A
M947QJC\*2_"I_#2_ 3X[O<_\)S'XY#>$6T-9E@:?^WP; 2B(R?,$-?GM8_M8
M_LX?L5?M,?ML?&K_ ()@1^&?BO\ L:?!_P#8.U#XZ?M%_!_X,^/$B_9 T_\
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M?$<YA\,Z]X&\8:)>:W>Z+XJLKK0XM+U3XK\#_P#!7?\ :L^*_P !_C)^U/\
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MSU'P5X?T*_@O5%\EP+PF<_:VF_$'P#K'C/Q-\.=(\;^$-5^(7@K3/#^M>,O
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M!?P[^&WA66VU+Q!J.G:!XL\3ZAJ&J:%H7ASPGJ]WJDDMB ?TK5SWB[Q;X7\
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M7A3X<> _"FJZ]XIU&_M?^$<BAT#P]X/\/V%WJUY=V\-L\<6E:;ITDT,5NZ)
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MPG_PE_B#X=^++#Q#I6GR^'&OIS3MOB3<?\%'_P#@H[^Q)\3?@?\ #KXS:/\
MLO?L.Z!\?OBYXV^._P 5_@A\1O@WX:^)OQ3^+7@$_!;P9\'OA:GQ5\+>#/&F
MK:QX/34O$OB[X@WUIHK^&(;?2[31[^X_M.717N/W?HH _(__ ()/?#'Q]\-?
M^"?FO>#_ ![\//%_@#QI??&C]M36I/"WB[PGK7A7Q1>6?BG]HKXNZIX5U9]$
MUG3[#5KBU\1>'+S1M1\/W[6KQ:OHEUI=WITMQ8SVDC? &B_"WXM?##_@B#_P
M30O_ !7\'?C!%XL_9.^/7[#/QW^+_P (M/\ A?XVU'XT:3X)^$?[3.A^(?B
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MX/$6J2^-;'6]&O/"4=CIT[^)+75],N-&%[#?VKR_O=10!^&7[1WPD^*VN?\
M!#S]GOX3:+\,?B%K'Q4T7X>_\$N;+6?AGI?@OQ)J'Q!TF\^'WQT_91U?Q[::
MGX,M--F\1V%SX(TGP[X@U3Q?!=:;%+X:T[0M9O=92RMM+O98/F_XW?!7X/\
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M BUOPQJVIV^C7&ERZTRZ<_CVI?L[^-_VMOVB_P#@KI9Z9X7^('@#X<_MI_\
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M2^/="\<>$/#GB3P!H'B7Q+'!8^$]6\:Z1H-GXHCU/1+S0I;^TUO2IKO]DZ*
M/QP_8B^(-C\$_P!LS_@H%^R]\0_!_P 7M&^('QR_;9\6?M)?"7Q&/@G\6;SX
M1^-?A5XN_9D^!JR:[9?&6S\'W'PSTQ?#6N?#;Q%X/UW_ (2#Q/I$3^-)-*\*
M:++J^O:@MA%^/?AC]CWXE>$/A/\ \$]_V@OC+\ _VIM1^&WP'_:>_P""F/@G
M]HSX;?!M?VD_AK^TKX4^&'[4'QZ\6ZW\,OCCX6T#X&Z]X!^-.M> O#FK^$]
MU?QE8^%'U>Z\1?#WQE9^(-/\/:]HUE-=6O\ 8G10!^"/PI_9@_8-_:K\%?M?
M:C^R'X1_:I@^)WQ9_8M^*G[)-O\ M)_M17O_  4(O/#-SX%^.VGZW%+X,\$W
M_P"VCX@N[C7+3PWXTT#2_$OBE? OA^2Y\-R-#&-2MY/$=W:7WR5\0_VLOB)J
MG_!'#4_^">_@C]DO]K/7/V]=&_8>M_V7O''P*U#]F#XI6NF:%!X*^$;_  U^
M)_Q+L/B2/#!^#OB/PKJ7A;PQXKUSX,_\('XV\2>(?B3XIOO!'A3P1X>U#Q#K
M=O90?U1T4 >.?L[:7J>B?L_? O1=:TZ^TC6-(^#GPQTO5M)U2TN+#4]+U.P\
M$Z):7^G:C87<<5U97UE=12VUW:7,45Q;7$4D,T:2(RCV.BB@#\LO^"EOP:^+
MUUJW[)G[:?[.O@34_BK\;/V%/C)K/CF7X3:*^G/K_P 5/V?OBWX1N_AC^TEX
M'\%6>L:IHNEW/Q)F\"7EKXF\ K=Z@7GUOPNNE:;IVJZQJNFV4GQ1^UI_P6/\
M/_$_X91_LI?LN_!C]I'PM^VK^UDNI_L_?##PM^TK\%/%O[-6A_![QMX[T:[L
M;OQ%\1_%WQ8L=*\,3:OX1\*W5_XS\/>%? ]SX_U3Q3JUIHFA16#-JV%_HDKP
MS]H?]FKX(_M6?#P?"WX^>!;;QWX.@\2^&_&FE0+K/B3PIXA\,^,_"&HIJGAG
MQAX+\;^"=9\-^./ _BO1;I9$LO$G@_Q%HFM)8WFI:4U\VEZKJ5G= 'Y"?M+_
M +-'BG]C3X4_\$=?%/P]\,>-/C-X-_X)Q?%#P-X%^,4'PZ^'7BGQIXRO/A5X
MM^ 7B/X%_$#XW:=\/? MMXA\6:H?#FIZA!XQUGP_X=TW7;^&WU>ZO%ANK32;
MD2\UI/Q6\8_MK?\ !7']E#XS_##X*_'8?L9?#;]FC]JSX9VOQZ\;?!+XG?"O
M1-?^)_C:T^']_P"*8;6#Q_X;\.^)-*\)7&@CP)I?@;Q/XGT/P[9>-/%EA\1M
M)\('6V\%:W/;?T$V-G#IUE9Z?;O=206-K;V<$E]?7NJ7KPVL*01O>:GJ=Q=Z
MEJ-TR(K7%]J%W=7MW,7N+NXFGDDD:U0!_(7^RQ\"OV1_V</V=X?V+/V^O@W_
M ,%'Y_V@?AS=_%+X27/A'X+^(/\ @K'XL^"G[57P]M/$&MGP_P"-O@;H/[/?
MCW4?@7=>"?''P]US1H?$GA&1/"0T;6Y/$.F^*/#ND_Z2A^^?VY_"7_!/3X=^
M&?A-\)_$G[/G[9?@7XL_LR? WP;X8_8F^,/[,/P(_:BUWXL^%QHGA&^T/P#\
M&OA)^T3X \.>+-.\4>+="TO2HH==^'WQB\6:UX2G;4'U3QC#J-U<ZM?P_OW1
M0!_.EXF\9?M0^!/AA_P1$_;%_;K\#?$&_P#'_P $_'OQ./[7DGPS^$OBGQ[X
MK\"?\+K_ &6OC5\,_"'Q!\;_  ]^$GA?5[K0(+>_U7P<GQ1AT30+>S\-^+/$
M$VC:3HJS&ST@=OJ7[._C?]K;]HO_ (*Z6>F>%_B!X ^'/[:?_!.3]ESX<?"'
MXH?$3X:^/_ ^@7.O^+_AE^T#820W-IXIT+0M477O 5SXR\-W'Q#\"SP6OBWP
MI)=)HOB72=)U*<6U?OM10!_-;)_P4$\;+_P397]CI/V/_P!KU_\ @HBW[+\?
M[,'_  SJ?V7/B2F@_P#"P#X)/P1F^+0^*+>#?^&>W^ -OJ^SQW)XI3QTV@?\
M(A/;VNP12-+'[U^SW^R3\0_V>/V[/^"=7@R\\,^(?%O@K]F[_@D1XJ_9\\2_
M&73?">O2?#D?$_P]XY^!&E'3X_%-Q8R:5HFM^*;/0O$>LZ!X<O=1AUR;P['?
M&&VFM+2[=?W8HH _&CQEH.L^!_\ @I[^V!\<?'GP-^*WQ&^ ]Q_P3*^#G@R^
M'A3X,^+/BCIGQ-U73_C1\9[OQ7\*O"VAZ9H6I6'Q%\73>'=<LI-5^'VGC4-2
MDT?5[>;4M.33;U97^:?V&;G2?#/[?'A?P-_P3>\"_M,^"O\ @GEJ/PP^+/B3
M]JGP-\9_A9\:/AI^SW\,OC=+J>G/X TK]F[2OVA?"?AWQGX0^),GB.XUZV^*
MOPY^'UQ%\+[70+NWO;?P_!J>B++IW]%M% 'Y,?\ !8?5/V@].^ 'P:A^#"?'
MN'X<ZM^U1\'M)_; U;]EVR\1ZC\?=%_9)O!XC7XG:A\/[?P3IFJ?$"V>/4QX
M5/B'5?A[ WC#3_#JZD+*,Z=<ZK<6OX\^%?V8_A.W[97@OXH_L#_L;?M%^$_V
M;=6_8R_;Z\*:W\<_'W@C]IZ76/B_\7?%7PS\"3Z*DEO^T*NI?$JV\/:M;:KI
MMC\-/$FOQ:);_%GQI>_$RR\(6&M7'A'5M3N_Z[:* /PLB^#OQ0M_^#=0_ Z#
MX6>/8?C(W_!+N;P(WP?B\#^(8_B:WQ$N?@-)IUQX-/P_32U\4GQI<>()9;&;
MP\=(_MR76))+62S:]=D/ :[9>(_V+_VS/V.?VYOBA\./C#J_P*\1_P#!+/1?
MV*?B[JGPV^#_ (\^*'B+]G_XA>"?'7@[XU>&_$7Q3\%>!]#U[X@:+X-\0VEW
MXQ\)7.JZ/X7U2/1/%&BVMGXLATY;K2)F_H2HH _#']C?QW\4OVA_^"L'[3/[
M3D_P"^,GPT_9OU_]BSX,?"_X ?$KXG_"GQ;\-!\5-'\'?&/XCZGKNLW>E^*=
M+TW6/#VMW7BW6?%L^A^%/&5IH?CNY^&</@CQO=^&M/\ #GBOP]<77M__  4)
M^#OQ'_;"^-'[)7[(6C1_%+P1\#K/Q=J?[6/[1GQJ\(:%'%HUC;? 6XTS_A0W
MPBL=?\:^"?%_PE\3^)_&GQNU_P /_$/4? ?B"PU^[MO"WPAN=9U'PS/I=Y;3
MO^K]% 'X8?\ !1/_ ()X_'?QE^SQ/\4/A;^UA^U'\;_VA_V3_&?A7]K+]FKP
M%\2+#]GW5?#VO?&'X)W<OB&P\/#2OA;^SW\-_&.KZEXT\+-XI\#:/I%MXLM=
M,OM9\2:=_;%EJ=E"]G)Z-H^G>._BW_P5-_8[_:9_X4M\6?"'P\UO_@F-\5I-
M5O\ QY\.?$V@/\,/'OQ ^*GP5\4:?\+O'UYJ6E0V7@_XJ6NB_P!N6M_X.U.Y
ML_$ 72=>6.RDM;2\=?V)HH _&CQEH.L^!_\ @I[^V!\<?'GP-^*WQ&^ ]Q_P
M3*^#G@R^'A3X,^+/BCIGQ-U73_C1\9[OQ7\*O"VAZ9H6I6'Q%\73>'=<LI-5
M^'VGC4-2DT?5[>;4M.33;U97^5?V--.\)C]M_3OA)_P3^^&G[1VA?\$U?&'P
M=^-%U^V'\+_CQ\)?C)\/OV;/ _Q7UFYM+3PEX9_9\T']HKPCX?\ %_ACQ[J6
MKZAXDTWXO?#+P%,GPKC\-:A'<P^'H=1T82Z=_2#10!_-7_P32_9-^,/BGXE^
M+_@5^UW\*OB#-\$/^">O[/?QR_8'^!&O_%OP#<Z'X>_:%\%_'SXY^/K;7?B7
M\/=8O+2"#7_#-G^R?\)_V=_ABVH:1)) D?B;Q3823&6ZNDKJ_P#@DM\"?VE-
M3^,OC"\_:R^&OQ%\#Z?^P5^S#HO_  3)_9]UWQ7HFL^'?#7QI\/:!\3O&=S\
M1OVA/A]#KNFV,VHV'CCX<?#O]FG1]/\ '&B->Z9K<.GZO#;ZG=R1WI;^BFB@
M#^0O]ECX%?LC_LX?L[P_L6?M]?!O_@H_/^T#\.;OXI?"2Y\(_!?Q!_P5C\6?
M!3]JKX>VGB#6SX?\;? W0?V>_'NH_ NZ\$^./A[KFC0^)/",B>$AHVMR>(=-
M\4>'=)_TE#^L6@_LY#X<?\%1OV+3\-/@_P"+]#_9T^!G_!+_ .)OP5\%Z_<Z
M#XKUSPG\.)](^)'P4T7P#\/-0^(.NG6A!XU7P!HVH6UK::[XFN_%VM:18:S>
M7%QJ2?VE=O\ LE10!_-__P %0?$WP&/COXH>/?V?/@O^VQX"_P""L7@'16\)
M?LX?%7]GW]F;X^:3=_&S68;'0Y-'L_$?C>+X?ZC^SK\>/V>]'O9-)TCXAO\
M%B[UVRT'P]I>J:?X?^Q2KI_VO]EOB+\6/C+\'/V,M=^+_B'X7ZK\2_VBO!?P
M#M_$NI?!_P"$^@^(?&EUXR^.L?@VU+>!/".E^$[#7M<O-&U7XBS+HZ:I96=Y
M!I.@23:]?S1Z987=W%]544 ?C]^R%_P3.^)_P+_9U\"^ ]>_;E_:O\/>/-<L
M=1^('QPL?!DG[+NH^&-:^.7Q2OKKQO\ &G6;;4O&O[,?C/Q9KMGJ_C_7M?:T
MOO$WBC7K^325L;3[6MC;6EI;?F_K_P"S7^T)\$O^"5?_  5A_P""8VC?"SXY
M?$[1_@-)KTG[&'BVQ^&GB'7W^-7P$^/>HV?Q3\+^"/!NI>&M!2U^(WQ,^%'B
M^X\?>%_B/IOA/2;8:.9/#OV/0-*T:\TRV3^J&B@#^:+]M;]H3Q1_P49_8CT?
M_@G9X3_9[_:4\)_M@?'K7OV<?A[\?_#'B']FSXJ>$_AC^S!;^&/BCX#\;?&+
MXC^-/BSK_AC3/A-J'POTJR\ >)[3P!KGP[\:>*[WQHU]X<D\'65W<72BV^@I
M_B/+_P $X?\ @HU^V_\ $_XY?#[XRZK^S!^V_H7[/GQ=\$_';X5? WXD?&3P
MO\,?B9\)O ?_  I;QW\)_BL?A1X6\:>,]#U+Q';Z;X:\<>!]0O\ 1(_"TFFZ
MAJ6EV%U_:MMK(C_=NB@#^8[5_P!FOX[_ +>/PC_X+?\ [1=A\)_B/\(!^VE\
M+/A]\$OV3OA5\7O M]\.OBIXP\,_LL_#G7Y=,\=^)/"6LQZ=K.AV/QT^(7B*
M\TSP)!XNL['Q'I&@6,%Y?VS:/<Z0TO/?MR_M;_$/]M?]CKX"_L]?L^?LQ?M3
M^(?C+8_$_P#8Y\=?M<>$=7_99^//@FU^ V@> _B;\,]7\6>'9=3\>^"/#\?B
M?QA8?$67PK-;Z/X$;QBP^&&D^._B)J-Y9>$_#-_J]?U)44 ?CA^U1\0;']F'
M_@J!^SI^TS\1_!_Q>UCX->,/V)OV@_V;6\6?"?X)_%GXU)X8^*NH_'#]G_XF
M^$M"\5Z9\)_!_C#6-);QYH_AG7M,\'_\2^:75M;TVZM_*AL[:\OK7]0_C3X6
MU+QS\'/BSX)T<Q+J_C'X9^//"VE&X+B :EXA\+:KI%B9C$DDHB%U>1&0QQR.
M$W;$=L*?3** /Y:K;7]4_:4_X);_ /!.;]GOP5\#?VB[SXI_LF_'/_@E%X _
M:1^&OC7]F?XU>%;[P5<_"GQ+X8\,?$J:]'BSP'I^B^)O#/AFS\"ZOX@\8ZOX
M>OM;TCPCX3U7P_J/C>;0!KMG;2?J7_P49^'WC[QQ\8?^"6^I^"_!'B_Q?IOP
M^_X*#^$_&GCW4/"_AK6O$%CX(\'6WP0^-NDW'BSQ?=Z397=OX:\,P:KJVEZ9
M-KVLR66EQ:AJ6GV3W2W-Y;QR?J510!_*[X&^"_[/'[)7QU_;.^'/[<?@G]O;
M0W^)7[8/Q7^.G[-OQ5_9J\9?\%.9_@U\8_AS^T'J3?$+1O FFZ1^QKXUE\%Z
M5\:_A_X@G\2^$O&FF>(?"WAC6=<6UT36;.YUO3;N#4G_ *!?V,_A+\$_@A^S
M)\)/AW^SK\,?&?P:^#=GH>H^*/!GPR^(R_$&+Q[X23XC>(M9^(^NV/C&S^*V
ML:_\1-*\27'B;Q9K6HZQHGBW5)M6T*^O9M'D@L(K&+3[7Z=HH _#R^U_XK?\
M$QOVL?VIO%UM^S)\<OCQ^Q#^V-XTT;]H]/$G[+_P[3XK?$#X#_M0ZGX7TGP3
M\:-/\>?"W0M5;X@:]\//B;I'@+PU\14^(6@Z1=6'A+Q+->^'KS3;R/69-4TG
M]!/V>_VQO@I^V)'XET[X1:/\=+GPS:>&+>\O?&WC_P#9T^/'P3\&:D^KWFIZ
M+?\ ASPQXG^+_P /O UKXD\3Z')9M)K=GX<&I0Z=#=VDJWDS"Z2U^OZ* /YP
M/V(OVO;K_@FC^R)9?L,_M"_L[?M8^)_VB_V7-1^+/PX^$FA?"3]EGXP>-_#/
M[8?AC2?&7B7Q/\-/&7P.\<> _!7B#X>K:^*O"FN:-#KL?B_Q-H^L^'-7LM<F
M\41+J,-W#7*?L]?L7?M ?!#PS_P0;\*_$+X=>(=;\8^ OV@?VL?CI^T;+X8\
M(7VJ^%?@MK_Q_P#A9\</B3:Z)XQOM"M+_P ->$(O"GBCQ_I/P\AU.2]M/#^H
M>,M+V>'+F7[;81M_3510!^6OQ[^'WC[6/^"L?_!/7XC:1X(\7ZK\/?!7[/?[
M;NB^,O'FF^&M:OO!GA+6?%D?P/'A;2?$WBBULI=#T'4_$ITG51X?L-5OK2ZU
MDZ9J TZ*Y^Q7/E_*_P *_%TOPN^)?_!7;]D3Q3\/OC8OQ8_:)^.WQZ^/_P $
M+W2O@1\8-;^&OQ)^'GC[]B_X4V5K>:%\5M(\%WOP]AO='\3?#O7? VI6FK^(
MM,>\\=W&C>#O#[:UXBU./3D_?*B@#^>CXB? SXLO_P &U^G_  %T7X._$1OC
M0/\ @G_\+_"LWP7TOX?>)6^* \=IH'A&;7_#DOPZM-(/BO\ X2U-574I=8T=
M]'_ME=06]>]MQ<B<UTG[3GCKXH_LU_\ !3K]C?\ :.N/@!\;O'_[/&A_L'_%
M/X1?M ?$;X:?!GQY\4!\([3Q-\1?AQKNBZC+I?@W0M8UN_UJ'Q?X9\+PZUX<
M\-V.K>,;/P)>>+?%::!<^'O#NO75G^^=% 'X(_"?POJ_[?G_  4#_:=_:^\#
M^$?BE\.OV<T_X)OP?L$?##Q_\8?A/XS^%-Y\9/%_Q/\ B5XA^+OC'XC?#WPA
MX_TKPUXYU#X=^!+ ^%_#DNL>)/#^A0:OXBN]0A\,"]M;;5KQ?A'Q'^T1\74_
MX(G:A_P37\+?LO\ [3FL_M^>'?V4O$7[-GBKX-6/[,_QN_X1[1O"/P[TK6?"
M7BCXB1_$_5/!ME\-O$FD>,OA'X4U?4_A8W@GQ9XFU;XB_$+7?"W@SPAH=_J^
MKPV</];E% 'X7_M-S:O\!U_X(N?M(>.? WQ2O/AU^S1XEUC0/CK%X&^%7Q#^
M(WB_X9V?Q6_8@^(OPGTWQ3XJ\$^!_#FO>*M/\-^'/'%_I>C>++IM)>\TN[U.
MRLXK&[U&XAL9.9U+]G?QO^UM^T7_ ,%=+/3/"_Q \ ?#G]M/_@G)^RY\./A#
M\4/B)\-?'_@?0+G7_%_PR_:!L)(;FT\4Z%H6J+KW@*Y\9>&[CXA^!9X+7Q;X
M4DNDT7Q+I.DZE.+:OWVHH _FMD_X*">-E_X)LK^QTG['_P"UZ_\ P41;]E^/
M]F#_ (9U/[+GQ)30?^%@'P2?@C-\6A\46\&_\,]O\ ;?5]GCN3Q2GCIM _X1
M">WM=@BD:6/WK]GO]DGXA_L\?MV?\$ZO!EYX9\0^+?!7[-W_  2(\5?L^>)?
MC+IOA/7I/AR/B?X>\<_ C2CI\?BFXL9-*T36_%-GH7B/6= \.7NHPZY-X=CO
MC#;36EI=NO[L44 ?C1XRT'6? _\ P4]_; ^./CSX&_%;XC? >X_X)E?!SP9?
M#PI\&?%GQ1TSXFZKI_QH^,]WXK^%7A;0],T+4K#XB^+IO#NN64FJ_#[3QJ&I
M2:/J]O-J6G)IMZLK_-/[#-SI/AG]OCPOX&_X)O>!?VF?!7_!/+4?AA\6?$G[
M5/@;XS_"SXT?#3]GOX9?&Z74].?P!I7[-VE?M"^$_#OC/PA\29/$=QKUM\5?
MAS\/KB+X7VN@7=O>V_A^#4]$673OZ+:* /#OV;OC?_PT=\%_!GQF_P"%0_''
MX#_\)E_PD7_%J/VD? '_  J[XT>%?^$>\5Z[X5_XK/P+_:VN?V'_ &Y_8?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP>_[/5E\(;NWT^#0ETJYCUQ/%1^*,L<US)JVE'1_[%C9(-2^WLMH ?6%%%%
M!117C/AGQW\4]6^-WQ2^'^O_  6N/#'PF\'^%OAWK'P\^.+^.M%U:W^*GB'Q
M0/$9\;^%8? -KI\.N>$'^')TO0Q+J^JZC>VOB;_A)$.G06@TRY\X ]FHHHH
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MK"UBMM=@'UA1110 4444 %?P[_\ !YG_ ,XW_P#N\#_WURO[B*_AW_X/,_\
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M_M.?'C]FK]E[1?V%/A3^W5%\+/@5X+^"VKGP+HWQ/&N?LO\ PUOO _Q"^/\
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MGC*/Q!H7B:3Q]X@\6>*O$TOB"Y\;6_BCPUX?LM/\':?X"@F\0?4_[&_[(?\
MPR5^S3>_L[_\+"_X6!]L\<_'KQG_ ,)A_P (G_PBGE_\+O\ BEXX^)7]F_\
M"/\ _"2^)-__  C'_"9_V+]L_MM?[:_LW^TOLND_;/L%J ?CAHO[7?Q]_;(^
M#_\ P0Q^ WB#XI^._A1=_P#!1/P+\8?&7[3_ ,7/@YKMC\/_ (I^)=-_97^"
M4'BO6/#7@[Q7H^DVDOP[?XT^.;G3-:\5WGP\MO#WB/1?#UIK&B^%-7TK27U
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MXH\37?B)O&UMK?A/P_I6E>!]/\!1R^(P#\3OAY\?OB'^U%^QCXD_;2OO'/\
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M%'Q&UKQ)J]QXVMO$PN+N#Q5HWQ$O?#DVA6_AO39M-CM&U"+Q!=27:VMIX?\
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MXJ^//BK\<_B!^Q[X*O?%TNO:'=:_X5T?X1^#]=^(.G>%;;3-%U+Q*_@N_O\
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M_P"'OPI\6? S7T^*7PWU?XI?"+XX?!CQ!K<'C32/AQ\1=#\.^._AYXL\/?\
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M9]/TO1O"]A:6EK"D9!\X_P""F7C?]FS0?AQ\*?"?[0_QH_:6^'C>+?BM!>>
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M+>CVWC3QCXTT9_B=X[\-VNE^*]'\%:%]@TWQCH4.M7;3_0'Q;\'_  (_9/\
M@M^U3X(^%G_!7;X)_!W]B_Q7\0?COXD\<?LS6?A'X->,_C?X.U+6=7\5S_M
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MEO)LM,TRSM;*TBR?+@@C3)QF@#\//VV/!_Q<^/'_  5D_9C_ &8M ^/?QO\
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M (1?_A'?^$#_ +7\,_";P+_PA_VS_A(M=_X2C[/_ ,(/_:G_  D'V7P[YO\
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M_P (_P".?CAXS_X2O_A&_P#A$OM?_"YOCK\2?C5_9O\ 87]O^)OL_P#PC?\
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M_P#\%1O''[9_QI_:%_:)_:<\(>%?A1^UO\?_ -DS]GKX,_L\?M >-/@+X/\
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M_"L/VE_@#^T1_:7_  B__"5_VY_PHWX@:=XZ_P"$/^Q_\)%X:_LS_A*/[/\
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MC'\0/B'\7/B=\>OB_P#$R]\.V7@RR\7?%7XMZ\==\6:EX>\#:=J&K:?X*\/
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M\:_$/XA>./%7Q'\>^$-)L?"5Y+?7NE:+X?T"[UC2[*QU/[397M@ ?E3^P?\
MLB_%[]L/]C[X[?M _&;]L?\ :_/Q-TOXL_M?>%/V1+KPG^TQ\3_ _A?X%6/P
M_P#BW\3+/P_XMNM!\'ZIIO\ PGWB^;X@R^+-,U:Y^*4OC_3%^%.G^#_ 6@Z+
MH^B:)!;O^W'_  3,^/7CC]I[]@#]DGX\_$RYBO\ XB?$;X)^#]6\<ZM#!96B
M:_XLLK-M%U_Q*;'3++3=,TZ7Q-J>EW.OSZ7IEA::;IDVI2:?I\*6=M"*V/V-
M_P!D/_ADK]FF]_9W_P"%A?\ "P/MGCGX]>,_^$P_X1/_ (13R_\ A=_Q2\<?
M$K^S?^$?_P"$E\2;_P#A&/\ A,_[%^V?VVO]M?V;_:7V72?MGV"UZ;]B#]F7
M_AC7]DWX%?LN_P#";?\ "Q_^%*^!K7P9_P )S_PC?_"'_P#"2_9KV]O/[2_X
M1G^W_%']C;_MGE_8_P#A(-5V^7O^U-OVJ ?G%_P5BG^,MM^U?_P2*G_9\TOX
M8ZU\88_VD/C^?!6E_&37_%7A?X:W=TW[+OC]=47Q1KO@GPWXO\4:?!'H+:K-
M8/I/AS4Y)M7CT^VN$@LYKF[M[O[9/[47_!2/]EW]@3]IKXQ?%S0?V0_A_P#&
M:WU+X+?#OX >)/@7XU^)/Q(\+>&-9^,OQ5\.?"?7?'?Q&C^-/PQ^'VEV#^!4
M\8:;XD\+6[67B+P[JFI6,EMXKMDTL&WO/OWX_P#[*G_"\_C[^QC\<?\ A//^
M$7_X9$^)GQ'^(G_"+_\ "+_VW_PL+_A8/PC\4?"O^Q_[;_X2+2/^$3_LC_A)
M/[=_M#^R/$OV_P"Q?V7]ALOM']HP=O\ M8?LU?#W]L/]G'XO_LS_ !2CNO\
MA"OB_P"#KWPQ?ZAIX@.K>'-52:WU7PKXST+[5'-:+XC\#^+--T/QAX<>\@N+
M./7-#T][NVN;998) #\5?VX/V8?&/_!-#]D_Q5^W?\ _VO\ ]K[QC\?OV;5\
M+^-/B$_[0O[1_BSXF_#']J3PYJ7Q!\,Z-XQ\"_%CX9>,I[[X>Z%#=>'M?U^Q
M^'4_PG\/> ]=\*:Q>:>NAW=SJPL[J/2U_P"%'Q+_ &S?^"LG[8?P5\2_M&?M
M-_#+]E_P3^S5^R'\3;OP%\%OC+XI^$FL3_$OQ%9_$RP\)0C6] U(:UX>\-2Z
M9=>,]>\9^'/"JZ7;^,?&/A_X=ZGXKU*[@\&Z=I>I>U>+O^">'[<_[27ACX;?
ML^?MK_MK?"'XM?LI^ /&7PS\5?$31/AW^S5K?@'XN?M=Z9\,]4TSQ)IG@GX]
MZ_KGQE\9^#O"_AG5/%6@:'K?BU?AUX96\\5_9[FU$N@/);W=M][_  Y_94_X
M5_\ ME_M,?M<?\)Y_:W_  T5\,_@#\._^%??\(O]@_X0_P#X4:OQ 7^V/^$K
M_P"$BO?^$@_X2C_A.L_V?_PC6A_V)_9>/MVK_;O]# /R,_9R_9G\7_MM?M,_
M\%3(OCC^U%^U;8_"3X3?MF^)/A[\#/AQ\(_VB/B5\(HOAOXLN_A5\*?$&N>.
M[?5/!.IZ5K&J-H$4GA#_ (5EX-UG6-5^&7A+5QXYUQ_A_=ZOXJN=1;YK^#GA
M']HKXP?\$?/'O_!4#XA?ML?M4-^V-\/_ ("_&OXM_#'7O"?Q7\0^&/@[X*_X
M9$D\>:#I.B3?L]Z?<1?!SQY'\;M,^#UKJ?QQNOB=X/\ &L^O:]XKUF31I-*M
M+#34'] _[+W[*G_#-OC?]KOQE_PGG_"9_P##57[2^L_M$?V;_P (O_PCO_"!
M_P!K_#_P#X%_X0_[9_PD6N_\)1]G_P"$'_M3_A(/LOAWS?[4^P_V)%]B^V7?
MAWPK_P""=W_"L_\ @E]XP_X)N?\ "X/[;_X2SX'?M(_!G_A<W_"O_P"S?L'_
M  T)=_$^Z_X23_A7?_";7_VK_A$?^%D;/['_ .$ZMO[?_L;=_:FB_P!H[;$
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M%<R@'R1XF^"WQ'_:\_X+%?M??!;QW^T+^T+X7_9(^&'[.7[*WCGQ1\$_A/\
M&KQM\*K#QQ\0_$\'Q(TCPQI^I:YX,U#3/&.B>!)](_X3S5_&VA> ?$G@R3QG
MXHT_X>WWBF^U>V\+6%B/#/%/[8_[2G["W[%O_!9[P=HOQ/\ $WQ5\6?L*?'C
MP%\/_P!F#XG?%[7!\0_&?@[P)^U+IWP:7X?Z9XN\1^+-.N+SQY/\#KSXIWNM
MV.O_ !$G\4SZI':Q:/XAEU+PUI%K:2_N9\.?V5/^%?\ [9?[3'[7'_">?VM_
MPT5\,_@#\._^%??\(O\ 8/\ A#_^%&K\0%_MC_A*_P#A(KW_ (2#_A*/^$ZS
M_9__  C6A_V)_9>/MVK_ &[_ $/Y[\8?\$P?A_\ $[3?^"F7A;XH>.KOQ/X)
M_P""C^J^#-5U31M.\+PZ)JOP?O/ OPB\)_#CP]J>BZU<Z_KEIXMUS1O$G@_2
M/B-HE]?:#H=A9:M:6>E7^CZO9P3W%X ?F!_P5'_8#OOV<?V1O#OQ(^'W[57[
M5/C+4!^T)^R)H_[2.F_'GX]^+_B[X>_:'T?5OVG?@U'IFN3^#/&][J?ASP%X
M_P##'Q'T_P #>(?#^H?!_3O ME8^#=/\3^%+W2=1T*\A73NV^-/Q\T[]H#_@
MH=^V)\%_VBM8_P""@47[/G[(T'P1\!_"/X7?L+_#G]LJ?3?$_P 0/B1\*].^
M*OCSXJ_'/X@?L>^"KWQ=+KVAW6O^%='^$?@_7?B#IWA6VTS1=2\2OX+O[_4[
MN^E]U^-?_!-+]NW]KWP+\/?A#^U=^WA\+=1^'OP4^('PJ^)G@O6/@[^S#JW@
MWQE\7_&WPQ\4>&]4M=?_ &@K?7?C;K^ARV<WANW\9:7;>$OAB?"&D1^-?$'A
M_P"(E_=:C;>#;;P-J?TQ\5_V,?VA?!_[4GQ-_;#_ &&_C3\(_AE\0?CWX&^'
M7@O]H;X4_'_X3>+/B?\ "7XIZM\*1<Z+\._BE::IX"^*'PT\;^"/B!X2\"ZC
M?>"WBLKO7/#/B?1;;1(K_2--O].DU>Z /RLB_:W_ &T]%_86^%'P0\4Z[^TK
M\+_&7Q=_X*W>!O\ @F5\,OVH/CC\-O$/PG_:@\2_L=^/-;_X27P=^T4VE_%O
MP!X9N7^+VL?"."Z^%Z?$+5? R:A>>/\ 3]3\1-)-\1K:XUT>B_M9_L8M^RU^
MU-_P2AU?X:?'K]H'Q1\(O%G[?O@W3?'WPG^.WQO\;?'=-0^+-C\&OCGJ/A3X
MP>$M;^*>J^)?&7A76+K1+WXD:1\1M-\/Z[:>"_$5UK?A#4&\-Z;JFD175[^G
M/QV_8L^)O[47[*N@?";XX?'WP^_[2'@7XJ^#OC[\*_VD/AK\&+;PIH7PK^-'
MPO\ '_\ PG'PK\1^&_@[XE\?>.H=5T?PM9(/!6N:5XC\>:A>>,/#]]KUP^J:
M%J>J6L^D_.VL?\$\_P!K[]H']H']E3]H?]KS]KGX6ZEJ7['7Q>A\??#3X8_
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M.UU\8OAQ\6F^!F@_\)/\6/@WKFLZU\+OAAXJ\%?%#P!H&J^%-:N;NW\(>)O
M_BC0]0US4M$\1V]UH,6CZL ?K'17\^WA_P#X+,?'U?V3OAQ_P47^(?[#]EX(
M_8.UBS^'R?$KQ9#\=K?7_P!H'PO;^,-6\.>!M:^*?A3X,V?P]BT?Q3\(?#GQ
M5U>[\*Z6E[\0M!^)GBSPG!!\2AX&T#1I(]-N/K+P3^WI^TGX<^*W[./A+]K[
M]C&T_9R\!_M>^*=7^'OP:\4>'?CQI?Q>\3^ ?BA9>$-?\=>&OAO^T5X8@\!>
M"M+\'Z_\1O"WA+Q->^&;KX;^*?BIINE:WI__  B_B6:Q9;C7( #])O"7Q#\"
M>/;GQE9^"?&'ASQ9=_#OQC??#SQY;>']8L=6F\'>.],TG1=>U#P?XDCLIIFT
M?Q'9:+XCT#5;K1[X0WT%AK.FW4D*PWD#OV-?SA_LH?'W]K'P_P#M'_\ !5SX
M2?LG?LN^#OC1J_AG_@H7XY^*OC_QC\7OC8WP1\ P:;XN^"'P&\/>&/AWX'OM
M)\ ?$W7?$_Q)UMOAMXKNM0?4=$\/^#_!=A<>%K_6=>OG\01:=!]JP?\ !6WX
M7W'[)&D?M!1_"3XC#XSZY^T:W[$-C^R++J'A2W^)Z_MQ1^)K[P=/^SU>>+)]
M5C\!V$%MJNFWGB6[^(5YJD&DVGPU@D\67.E1:RK>#@ ?K/17YK?"']M/XVZ=
M^TSX%_9/_;0_9^\#? 3XC?'/X<^+_B9^SGXH^%'QMN/C?\._B./AHVG7?Q;^
M%>LWNN?#7X3>*/"OQ2^&GA_Q'X5\1SF'PSKW@;QAHEYK=[HOBJRNM#BTO5/*
M_P!A;_@HO^T-^W/XKLM4\(?L@:7X/_9Y\(_$KXW?"'XU?&KQ#\;;,:EHOC_X
M::]X^T_P]IOPN^&Y\#V^L?$/1-1TO2_A==>*O%-]JGA?3-&UOXCZWX=T5/$-
MQ\-=>NK\ _7VJ<5]87-Q=V,-Y9W%W9",7UG%<0RW%H+A"\(N[=':6 3Q@M&)
MD3S$RR[AS7(?%'X9^"OC/\./'7PD^)&D2^(/A_\ $GPKKG@GQGH<.KZWH$VK
M^&?$FGSZ5K.G1ZWX:U+1_$&DO=V%S/ NH:+JNG:G:E_.L[RWG1)5_DKM[;_@
MDUXQ_:P_8,^'_P#P11MO#VG_ +5OP]_:7^%VL?%#QC\!IOBKX6\-6'[&_AV?
M4M?_ &@[7XP>*_%T5AX1^-.F>)?#HM= 70GU_7/B%J&HW%G;1ZW9:787^F:@
M ?U5^%/@#^SY\,?$NL_$7P/\%/@W\/?&.IV7E^(?'?A3X<>"?"?B74-/M+<1
M>7K/B?2-&T_5+NRMK2,1[;Z^D@AMXPF%B3 ]B1TD1)(W62.15>.1&#HZ. RN
MC*2K*RD%6!(((()!K\9O^"YOP%\4_&/]@W]HCQ&WQS^(7@'X6_"']FK]H?X@
M^+?@]X"CTS1;;XV>.]%\%6VJ_"MO'_CE4?Q/%\// =YI?B34M:^&NCFUTKXC
M:QJ_ANY\3:@NE^#VT3Q#^E7[,7_)M?[/7_9#OA-_Z@6@4 >XU%-<06RJ]Q/#
M CS0VZ/-(D2O/<RI!;P*SLH::XGDCAAC!+RRND<:L[*IEKX'_:?_ ."=O[!G
M[2?BG7/C9^UI\'/"GQ,O]&^'.H>%[SQ!\4O&7B\^#O ?@6QL=9N-;U70M'N_
M%EEX+^'=[%9ZA>ZEJ_CS0-.T/Q'#)IVEZQ/X@BNO#VDW=@ ??%,$D;.\2R(9
M(U1I(PRET63=Y;.@.Y5?8^PL &V-MSM./Y4/@=\=?C+^QI_P;_\ [7/QW^'_
M (G\77W@NW^*'QRTS_@G)K'B^35+CX@>$?V:/B_\;= ^"G[,^O:M-XIM!JMQ
MJ&G^(/%NI_$;PA)XABN+27PO?^%-P3PZ;6U@]0_;9_8*_9>_X)0_LE>$OV[/
MV7_!>K^$?V@OV-/B#\ _%_C'XK6_BCQ%J'C7]H;P1XG^*/@;X5_'SPU\:KS5
M]3U*U\6:;\2?!?CCQ1KNH(FGPW6@Z[;V3^"/[!MXQI\H!_2[-<06RJ]Q/# C
MS0VZ/-(D2O/<RI!;P*SLH::XGDCAAC!+RRND<:L[*IEKX'_:?_X)V_L&?M)^
M*=<^-G[6GP<\*?$R_P!&^'.H>%[SQ!\4O&7B\^#O ?@6QL=9N-;U70M'N_%E
MEX+^'=[%9ZA>ZEJ_CS0-.T/Q'#)IVEZQ/X@BNO#VDW=A\2?\$;_@_<_$7_@F
MO\0/AGX_UGX@>)/V5_BK\;?VE=/_ &28M8\5^//"?Q.M_P!A;7/&=UI'PDLM
M2\8V%_X<^(VD76M6]IXF\2>&]6M]7LM43P7XB\-MI=W;:4VGV\ !^YT5Q!,T
MZ0SPS/;3?9[E(I$D:WG\J*?R)U1B8IO(G@F\N0*_E312;=DB,9:_FE_: _88
M_9E_95_;_P#^"6?A_P#X)T_#[0_@%^TSK/QGU;6/C!HGP\U#Q&N@^(_V#O!7
MAOQ1?_'K5?C)HTFH:MIEW/JFJ:SH7@GX;>,?&$*ZOK'C#6H-%TG5[Z[\,Z6G
MA[^EJ@ HKB_B1KGB_P ,?#OQ[XE^'W@9_B?X]\/>"_%.N>"/AI'XDTCP;)\0
M_%^DZ'?7_AKP-'XOU]6T'PH_BW6;>RT!?$FMJVD:$VH#5-24V=K,*_-#PY^V
M[^UW\,/VAOV<_@_^VM^RO\)/A3X-_:X\1^)O!/PI^)7P4_:%UCXN6?P]^)F@
M^ M1\=:5\*/C%I_BKX1?#!9=?\96'AOQ-'X:\3^!+S6M#N-2M[71C8.J76L@
M _6.N%\/_"[X9^$O%OC+Q]X5^'?@7PSXZ^(KZ7+\0?&OA_PCH&C>+?'<FB02
MVVBR>,O$>FZ?;:QXG?2+:>>WTM];O+YM/@FEBM#%'(ZG\UO@U^W3^U=^TQ\5
MOBL/@!^RK\'-8_9T^!?[4_C[]E;X@^-/'W[4UUX4^,^J:W\,?&.F^%/B#XY\
M/_";0O@EXQTCP[8>%HI-2U_3/ _Q \=>'O%OCC19="O;4^&H-6MI)OT>^+.I
M_%31_A[XDU+X)^$?!?COXH6L%BWA3PG\0_&NJ_#KP;K%Q)JEC#J,>M^,]#\&
M_$#5=$BMM&DU&^M9;3P?K37=_;6FGR1VL-W+?VH!X\_[<7['$/CCXM_#>Z_:
M@^!-CXU^ GAZ7Q7\;-$U+XG>$M-?X4^'K76+?P]?ZGX_OK_5+;3/"T.D:Y>Z
M=I.N)J][:SZ%?:KH]OK$5E)K&F"[]J;XH_#=/'NB_"QO'?A,?$GQ)X.U'XA>
M'_ O]O::?%6M^!-(U'3=(U3QAI>B"X.H7WAO3]4UC2M/N]9MH)+""[U&R@DG
M$EQ$K?S-?LK_ !W^*OPV_P"".O[7GQ^_:8_9-_9W^+'P??Q9^V9\7O$F@2_%
M35/$6H_M"?$?6/VTOBWI_P 1M ^*'@_6_@A:>'?#^@:1JUO-HGASQ#!JGC&X
M\0:#X9T"_O/#/AV:]DTO2_T/UJZAO?\ @M?^RI>V]I%807?_  2Y^/EU!8P$
M&&RAN/CQ\")8[2$JD:F*V1UAC(CC&Q!A$'R@ _9*BOQ)O/\ @JQ\:_$_P>^(
M7[;7P1_8[L/B9_P3S^%6H>+KS5_BW?\ QXTOPG\>OBC\*/A?XBU'0/C#\=_@
ME\#Y/ FK>%=2\"> 8_#'C76]$T+XE?&'X;^,_B3HN@1W6EZ3X>DU"TAE^C?C
M;^WYJP\>? KX#_L7_##0?VG/CS^T/\%KK]I;PNGB3XB1_"?X0^ /V;H[GP_I
M&G?&OXC^,7\.>+?%LND^)?$?BS0=#\'>%/!W@/7M>\077]KMJ$_AFWTZ&YO@
M#[XB^(?@2;X@WOPGA\8>')/B;IO@[2_B'J'@!-8L6\767@36];U?PWI'C"YT
M 3'4H?#FI^(- US1;'6'MUL;G4])U"RBF:XM)D3L:_!+]CSXT_%#XQ_\%D?V
ME(/C9\$;GX"_%KX4?\$^/@9\+?'/A&V\8V'Q$\%:S>VW[1?QJ\>:)XW^&'CZ
MRTW0)O%?@'Q3X2\?>';RQNM:\,>%?$6CZY'K_A77_#]CJF@7+3?I#^TY^U==
M_LT_%[]C+PEKO@[2K[X6_M3?'34_V=?$/Q)N_%$VF:A\.OB9XA^'_B7Q5\$]
M-L?"\>A7\7BFV^)GB;PEJO@JZGFUO0!X?OKK1[E/[6:]^QH ?9E<KXX\=^"/
MAEX2UWQ]\2?&7A7X>^!?"UB^J>)O&GCCQ#I'A/PEX<TR-TC?4==\1Z]>6&CZ
M18I)+'&]WJ%Y;VZO(B&0,Z@_F]\4/^"E,'PY_P""DGP@_83C^%MOK'@3QUI'
MA/1_B!^T*WCB"PT[X7?&OXI>#/C_ /$#X._!K4/"#Z%.^I^(?B#X6_9^UK4=
M/E&OV,D<7B7P^RVDOGQ+=^:?MU?MX^$/#'A7_@I+\/=>_9X\#_M#?";]BS]F
MCX0>-_C-X;\>:^;?0_'_ ,1_C5J/B'7=*^">H^'[[P5XCTAM'TGX9Z+X7\?:
MSXBFFU259_&OA[2U\.*JR:B0#]D8)X;F&&YMIHKBWN(HYX)X)$EAGAE02130
MRQEDDBD1E>.1&9'1@RD@@UQNE?$OX>ZYX[\6?"_1O&OAC5/B/X#TGPUKWC7P
M-8:U877BKPIHOC(:F?">J^(-#AG?4=*T_P 2#1=7.BW5Y!##J(TV]-J\OV:7
M;^*G[:WQS_;X\*_MN_\ !.#PG\!/AQ\)O^%8^.O&?Q>'@OPSJ?[37Q$^'6E_
M&JXL/V-O'WB?6_"?QN\->'?@?XFTGPWX8^&]W'J?BCX?3P2_$I-;\4>&?#%S
M-HOA*YNAJ>A^/Z?\=OV@_ G_  6?_;-^&?P/_9^\+?%WX^?%G]DK]B_Q)JMA
MXJ^+TGPS^"GPK\,_#ZP^)ECXX\5>*OB+'X!\8^,/$%M8^,?B/X(\/^%_#'A7
MX97?B/Q=;:CJ>KS)X:L-"U&:, _I"HKXC_8?_;!O?VLO#/QAT[QK\+;SX)_&
M[]G#XV>*/V?_ (Y_#*7Q3I_CG1-+\;>'-,T/Q!9>(? GC2QL=$G\6?#[Q=X:
M\2:/JWAS6M6\,>%-6:?^U=.NM"6/3H-3U/XX_P""O/Q@_;0^%L?[*$7[./AS
MP/%X*\3?MG?L9>&=5\5W?Q]\<_"SQ?XH\9^)?C[IFEP_!3Q%X>\+?"WQ1:3?
M!?XB62Z1HOQ!\3S>*+ZYAT;5M9M9?AOXGM;-;/50#];+GXE_#VS^(FE?".[\
M:^&+;XHZYX3U7QYHWP]FUJPC\8:IX*T+5-.T36?%=AX?><:G=:!I>KZOI>F7
M^JPVSV=K?:A:6TTR2SQJW;U_-[^T=\>OV@?A9_P5I_88OO\ AG?PY\1?VH_B
MW^P'\>?AQH_P5\&?&)=,^%VG>,)_C+\/O'7B/4=;^.?BSP#I=_IG@+PI\//
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MT_P_';^(M6\%Z"+CPG9IJK:CI'AG_!+SX\?M8>-O^"?7Q+^(O[4_@3P%\0/
M6@VG[:6K:3XKU;XZ^,OBA\0/B=>>$?VB?C]I_B3X;>.= \7?"W2[+P_X&\,V
MFBW/PY\%ZE;^+/%8O? NB: 6\*^'+>0>'=+ /W!\)>+O"GC[POX?\;^!/$_A
M[QKX+\6:/I_B'PKXN\):UIOB/POXFT#5K:.]TO7/#^OZ/<WFE:SH^I6<T5WI
M^IZ==W-E>6TL<]M/)$ZN6^+O!WA'X@>&M8\&>/?"OASQOX/\16;:?X@\)^+M
M#TSQ+X:UVP=TD>QUC0M9M;W2]3LW>.-VMKVUGA9T1BA*J1^./PD_X*'7VO\
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M(;/6OA#X6\"^#?A1\3?%DOB.'PWHVCZM;^.?$;Z#X(AN?&6G6RMJ<NA:Y:H
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M_P")6B^'?%JZ!XF^%?BCXI>%],\4:58^%=8GBM]3'B>W /U:) !)(  )))P
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MX9NM1O?!,^J7UCHX!^T]%?B7XT_X*5?MG_!3XG?"_P"!OQK_ ."?&AS?&O\
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M7^S>W6=(($N98Y[E88UN)H86MXIIU11++%;M-<-!')(&=(6N)VB4A#-*5WL
M2T444 %%%% !7\.__!YG_P XW_\ N\#_ -]<K^XBOX=_^#S/_G&__P!W@?\
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M'CXO0_ ;X4>*_BQ<_#CXN_%N#PF-$:;X?? ?P#J'Q0^*^O1ZUXCTCPZS^%/
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MX-V_VD/@E'\&_BK)\9M<_P"&U_[$^$:?#SQ<WQ.UC_A*_P!N/XT^+?"_]E>
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MCI>HS_O?10!^&/[&_COXI?M#_P#!6#]IG]IR?X!?&3X:?LWZ_P#L6?!CX7_
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ME^RC\4?VB?VX?^"B_@S3?#/B+P[X2_:%_P""/GAS]GCP1\7-;\.>(K?X8_\
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M^P-/^*'BRY^*$'A:TU>3P=K&JW7Z-?\ !)[X8^/OAK_P3\U[P?X]^'GB_P
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MA[X$\/2?$-/#WAQ-0OOB#=6GPVT]](?7K7Q'I_NO_!-7XL?"OX:WMK\)+/\
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MC^$7AKX]>%?"$=C-XIU_X#^,/BEX$\(>%_B]9:#;7\6HWT'@;5M9U$Z%!?\
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MEX>_;V^.VAZIK'B&&YF1+[0=&\;^)O >J7]GY%XC&TAGNX;>P@N]1L0#]\_
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M!XX7X[?'!O'O@SQO9W4QNH_&WCK3=6LH-$T'4XY=6U9?$6@:9IT>HFYL!/\
M:G_!$'_E$U^PI_V0[2O_ $\ZW0!XQ^UE^UYX3_9:_P""K_P&O/C)\7?$W@GX
M):G^P;\9))?!.GMXZ\4V/C/XI:E^T-\%_#7@N+P[\(O UCXAUSX@_$B:WU+4
M=/T*U\->$=>\50Z/+K,MO'%I$&JS1?HW^S;^V+\ ?VKK'QX_PA\5ZJ_B/X4:
MU9>'?BU\-O'_ (+\9?"CXM?"O6M4T]]5T>T^(?PM^)6A>%O'/A:#7=-BN;SP
M_JVI:)'HGB"&PU3^Q-2OWTG5$L_SU^,?@3PWXN_X+T_L8:_KEF;K4OA?^P%^
MTWX[\'S!]JZ?XDO_ (D^!OAK<7CKM;S0WA/XA^*+%4RFV2]28-F(*WS1^UMX
M0\<:Q^VK_P %BO WP4LM6/Q!^+W_  1,\+ZE9:/X82>37?&?Q/M;W]I7P#X-
M.FQPN+@^*9]&^R^$_#TUF\$L$]Q:R0E;E1, #],?!O\ P53_ &'/'WQ*\*?#
M;PM\7-4OX_B!\0KWX1?#;XL3?"_XK:=^SE\3?BUIZZJUQ\,_AS^TIJ/@JU^!
M?C7QE.VCWMKHNF>'_'U\GBG5/L^A^%+G6]<N[;39-"__ ."GO[&5C\:XOV=(
M_B5K^L?&EOCG+^SS>^ _#7PN^*/B?4]"\?VX^'2W%]XIN= \'ZCIGA3X?Q77
MQ7\#V ^)?B.^TOP+<7^I:C:V>O7$GAKQ/_8_Y%?#S]EGXY_MW_\ !)O]G?X8
MZ)_P4/\ V5/A_P#LR^,_A)^S/:>!=1\(?L6^(K'Q[\,=?^%FI?#[7O!7A*T\
M>7_[>5UI,/Q-\&>.O!FF^$/$32^'8[[4=<L]:TY]*MKB_>!/LC_@F%X+TVW_
M &E?^"T?CK1XX;+QKXJ_;ZO/!=UK$EO;RC^S?!/P0^'NL>%(YAY'VB>'3-6^
M(GB:Z%O//-;C[=)Y$$+S73W(!].>.?\ @JK^PU\.OB'XE^'OB;XNZF(O 7CK
M1?A=\4/BEHGPP^*OB?\ 9[^$'Q*\0ZIINB:1X$^+O[17ASP7JGP3^&WB1]7U
M6TTS5[/Q=XYTJ+PE?>?:^,[CP[-;RHOS?^TW^U_X._9=_P""J/PGE^,'Q0\5
M^'?A+K__  3P^,1T;X<Z%#XW\9M\0?C%=?M0?L_:7X3M?!7P@\$6>OZSX_\
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MI?#[7O!7A*T\>7_[>5UI,/Q-\&>.O!FF^$/$32^'8[[4=<L]:TY]*MKB_>!
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MQI;^(?%7BGQ7JOB'1].TB^C2+P])=:7>1W0!Q/[?/[;/PY^/G_!(#]N+X_\
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MZ/8ZAH6D^#? WAV\^/=M)\./'OA>Q\1V6DQ:Y8KKT$7N'_!6OQ1X0\>^./\
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MHOXC>%?A9\./'OBZW\5?$CP]XB\7?!N7XB?!OXQ_"+PU\>O"OA".QF\4Z_\
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M=.TV_NK;\^?^"*.GVNA?LW_M$>$])C>S\-^"_P#@H=^W=X5\)Z,L\\MCX?\
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M.:!HUG-J&KZYKNM:I/:Z;I.D:786\][J.I7]S;V=E:0RW%S-'#&[CXD^"/\
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M+7AFZ^$O@RY\6Z?\1/$_B>2[\ 2?"K6/ $1N/'>@_%O1/'EKX;U[X6Z_X-M
MFH>)-'\>:9H%_I6D7%EK=Q"NC:A87]S^<_[/G@GPOJ__  70_P""@_Q1EMEN
M?%/A7]C;]CCP7X=U2.97AA\,_$?4O'WB#Q- BJ&67^T;_P"&7@^>*=9 %CL7
M4!UGROY4?MM>%O$4W[/O_!QYX-\!6.H?\(OH/[7'[(/Q<\8^'-$TF^UQ3X1O
M/"'[,'Q&_:'\1SZ/8ZSH-_?Z?/X4T+7?%OCFSM_$.BKJ7AO1=7L#J.G6MQ)*
M@!_0?\"O^"E_['W[1?Q&\*_"SX<>/?%UOXJ^)'A[Q%XN^#<OQ$^#?QC^$7AK
MX]>%?"$=C-XIU_X#^,/BEX$\(>%_B]9:#;7\6HWT'@;5M9U$Z%!?^)[:QN/#
M&G7VL6_WI7XG^,_V4_VB?VI]5_8>^)'Q%_X*'_LM>(OAM\)/VE/@U^U3\('^
M"G[(&M_#K5OBQ'X*TO6I)O WA7QUJ?[;GQ%TYO"_Q$^&WB+Q+H^IC2_"6O&+
M3KFWU<:==Q:1]EE_;"@#P_X)_M&?"3]H?X73_&7X3^([GQ%\/;;7_B%X9FUF
MXT+7=#F76?A;XMU_P1XVMAI6N:=I^JLFE^)/#.LV,5PMF;?48[9;O3I+JTN+
M>:3YF\5_\%3_ -A7P'\%/@/^T5XZ^.%IX-^#/[2>D^+M:^$?CCQ'X3\;Z=8Z
M_9>"/".N>-M;CN[%_#K:OHNIS:-X?O[?P_HFJZ?:ZUXK\02Z9X6\,Z?JWB/6
M=*TN\^"/^"<?QQ\"?L[?\$O_ -K*]^*&I0>'-0_91_:(_P""@WACXK:'J=]I
MUAJ-KXPM/C3\3/B#I7A32UN+L+J.M>*])\7^&[+PG9P@W'B/5]6M+'1H;Y[B
MU-Q\%?LW>#/#OCS]GW_@UNT/Q18)J6F67Q-^(?C&WMI"0J>(/AW\$_B5\0/"
M5]QG+:7XJ\,:-J:*>'>T5&^5C0!_13^S;^WQ^S9^U3XO\3?#;X;>(?&F@_%7
MPEX;L?'.K?"7XQ?"KXE_ [XH2?#G5]0&F:)\2]&\#_%CPMX1UWQ%\/=8NY+.
M&W\6:#::EI5E<:GI5AK,VF:GJ5G93><>._\ @JQ^PW\.?B;XH^&'B3XLZL\W
MP]\76OP^^*WQ)T#X8_%'Q1\!?@YX_OK[3],M?!/Q<^/_ (=\'ZE\'OAYXD74
M]2@TW5M/\2^,K'_A%=22;3O%\GA^^06[>&_'_3[73?\ @M;_ ,$[=>T^-[+5
M_%/[)/[<'A7Q'>VT\\+ZWX<\-:G\$O$&@Z+J2)*L-WI^EZYK&HZM:V\L;(FH
M3K=$-+;VS0_+O_!+CX@_!KX5?\$/O&FC_M3:IX?S\$!^W!X&_;1\(^)-;T=_
M$\'CA?CM\<&\>^#/&]G=3&ZC\;>.M-U:R@T30=3CEU;5E\1:!IFG1ZB;FP$X
M!]!?\$]?VR/A[\%?^"07[%7Q^_:V^,^J1W/BWX;^%M#?Q3XQO?%GQ%^)?Q.^
M(/B+7-:M=$\,>&=%T^#Q1\1_BCX^UM;:0V'A[PWI?B+Q)=6-A>7HL_[.TR]N
M;;ZNT?\ X*9?L?:M\&OC[\;[CQ[XI\+>'OV6$L'_ &BO!GC[X3_%3X??&;X/
M#5]-L=8T.3QG\$O&?@_1/BE9V7B+3-0BO/#.KVWA:[T3Q*EMJT>@ZEJ,^A:W
M%I_\V_P,LOB5IWPJ_P"#9GQIX7^)G@;X-:(GPN_:K^&_AGXJ_%KX8:I\5OA-
MX1^.WQ&\!Z3%\.]$\2>&--^+OP36?Q?\2?">@_$CPG\-+FX\9M+::TFI1:?I
M=W<7[%?J3_@J%^R!\:/"GP3_ ."C7[7?QQ_:Z^$GQ<\>ZC_P3=/[.>L_"+X1
M_L\:I\"[--!MOCEHGQ*\#_$KQ3#K7[2WQRU+4-6TB>3QYX6TJ9]*TJ&_TSQ!
M)'#J*?V$UK>@'[/Z7_P4_P#V(]5\#_M&?%*+XQ36GPH_97O-"L/BW\5-3^'O
MQ,T[X>"Z\1^)]=\$:3'\.O%-WX/CT[XQ+=^-?#NI^$K:7X3R>,HKW7VTRPT]
M[MM=T-M1\=^,?[</[+_Q_P#V1OVJ]1O?BI^U[^RQX,^'7PYL]<^('Q=LO@1^
MT;^SK\8? G@GQ'JUU:^&_B1\(=4\=_"S1]1UU]:;1;M]/N/!UIKVKZ?I\RG7
M=*TA[ZVCD]>^.?[)/P3^,_[ _AO]DGQCXTUCX-_#5/ OP&\*^!/''A3Q!H?@
M[Q5\/_$GPNU3P)K/P=U/PAK%_:+I5GKVE>+/"/A>+3[&VLX3J:B31K&.V:]C
M,7XD?MV?M4_'9?V2/^"JO_!.S]I?Q=\._CW\4_@#^Q;X9^,%K^T]\)M$/@JR
M\8^&/&7C:P\-P>$OC;\*;:;5M!^$_P ;[.2UM?$?]D^%?$VI>&_%?A/5H-;T
MS1?#"63VM\ ?T"?'S]LC]GG]DWPI\-KKXN>.=<EUGXFYT7X3>!/"OA'QE\4O
MC1\7M3TO1[;4M0C\$_"_X?Z#XB\>>*9["QGLKOQ+J]IH(T7P])JFG/XBU+21
MJEB9^ ^#/_!2S]C[X]ZM\2_#GPX^(FNW7BSX,?#"_P#BW\7O!?B3X:_$GP1X
MU^%_AC2]?\3>'-2T_P >>$O&/A70_$'ACQG9WWA/4[M_ VJZ?;>*YM NO#_B
M>TTJX\.>)_#VJ:G\)^)O$FF_"/\ X+;?LE>-OBWK6F>&?AQ\</\ @ESXN^ 7
MP'UKQ/K6E:;H5W^T%X=^/?@?X@^./"FC#4;R,0^+O$GP\U'PA%9;4M;S6DLX
M-%TDZM-+>6UCXF_Q7^#OQ<_X*??\%6]6^#E_X?U^S\,_\$J/"/@KQWXR\*W>
MFZKH'C'XA:-J_P 6[K4K^Q\0:0TVGZ]/X;T#4_#7P\UBYAO+R32=>\%ZIX6O
M);>^\/W.GV8!]X:#_P %K_\ @G+XF_L#5-%^-7B"\^'FLMX%L=4^.(^#OQBB
M_9]\ >*/B5H_A[7?!G@7XI?'*;P*GPQ^&_C74-/\3Z4NJ:#XO\2Z5+X0U,W6
MA>-9?#NN6=QIT?V!^T?^U_\  /\ 93@\%Q?%_P 6:I#XK^)NKWN@?"WX7^ _
M!GC/XJ_&'XH:SIEH+[5+'X??"?X::#XJ\?\ BF/2+5[>77=4TW0)=$\/K>Z<
M==U/31J-B;C\2])^&'@?1?\ @UFF\*V6@VHT*?\ X)BZS\3Y+"0NT9\<:[\/
M;WXRWVO95D;[5_PL>_G\2P@DHEV(U97B4HW,0V?Q]N/^"I_[).L^#_CI\./@
MOXI^,/\ P1Q^&?A;X/\ CWX]?!7Q%\=?#OC_ ,2^%?B<GC#XY?#GP39V'[07
MP)EC^*C:=K?PZ\?^)+_^T/$VK:EX0AACFM[>VLS*X!^\?P<_:]_9Q^/'P<\3
M?'OX>?%+1&^%_@*_\;Z/\3=<\96^J_#2^^$>N?#,W!^(>@?&#PU\1K#PMXF^
M%6M^"[>V?4O$.F>/M(\/W5AH4MCXC9&\/:GIFJ7?XT_\% /^"L?[-OQ5_91U
MWPQ^SQ\9/BGX)^)'C/XI?LIWOP8\6:E\.?CE\![/XU^$K;]L/]G>Q^(MW\!O
MB)XS\)>"=,^)^CIX.UG5[;Q19^"]9U&;4/!EQK6H36-[X/EN]0D\)_X*'?L6
M_'+X7?L&_P#!:_XS:I^TCX3_ &BOB9^TIH?[+GC'XG>!O@C\'[_X(>'_ (:Z
M5^S;JGA"S^+]X=!N_CK\<]2AO_'G[/\ I\-[XVEO=0TEH--\+3ZQ-::G!JYC
MM/IS_@N1\8/V:=;_ &%_V=XH/$'@CQ;J'Q8_:N_8\U7]EVX\-:OHFIP7%WIG
MQ8\)Z[J_C/PK'ITTXN/#5I\(QXP\.W.L:6ITVR?Q=H^G3W,3ZM9V]R ?NSXZ
M\9:)\.O!/C'X@^)3J*^'/ OA7Q#XR\0-I&D:GX@U9=$\,:3>:WJITO0=%M;[
M6=;U$6%C.;+2-)LKS4]2N?*L["UN+J:*%_GCQQ^V[^S1\.?V1;+]NGQ;\0SI
MW[,>H^ ?A[\2['X@P^&_%&HW%SX4^*EUX:T_P)/'X3T[1[KQ=_:6N:EXO\/:
M8NAOHBZQ8ZCJ L]1LK2>WNDA^KG1)$>.1%DCD5DDC=0Z.C@JR.K JRLI(92"
M""000:_E)_9H\/2:U\6_@Q_P11UNUN;WPQ^PU^WC\?/C_P"-=+N]>@UB[U?]
MBKX-Z?X6^/G['5IXWL+VWE34])\5_%;]JWX(Z3%I<R/:_9/@KK%M&0EFL40!
M_17XD_:P^!?A;X >!?VG-0\77-U\'?B=;?!BY^'NO:-X;\2:WJOC'_AH/7?"
M'AOX0VN@^$M,TJY\57VH>,-7\=^&(+;3X]'^V6,5_+>:I#96EA?SVWQ)J'[6
MOP:_9K\#?M]_%7PW\5_VE/VA=;\%_M(^,_#?B;P7K/P^^,_QGTGX'_&.W^"?
MAKQ/IWPE\#^'O!'@N[U7PI\ K#3M.TGQ%J6O6+MX(T36_%>LO>>++*_U%8D_
M+K]D1=0^(7Q\_8P_X),:_?:IKD7_  2G_: _:>^-WQEE\4-?VNMZW\./V>M:
ML] _X)R:C:W-LJ6,]AK?AW]I3X>>-(M(FDFAD'P@\V)<6FRU^SOV2["]U72?
M^"]VEZ;:7%_J.I?MC_M!6&GV-I$\]U>7MY^R3\'[>UM+:",-)-<7$\D<,,2*
MSR2.J*"Q H \.^.O_!1S4/C]_P $XOV(?VDK3Q#\0?@5XJO_ -J;_@FC>?M#
M:]+X.^,'[._P^4?$+Q+X*\2?%RP\&^)_B)#HD'CKX$7$-WK=O+X@TKQ3XS\$
M:KX22W;4O$FLV<XO+G]7_@7_ ,%+/V/?VBOB7X=^$OPY^(/BFT\:^/?#>K>,
MOA+9_$KX/_&+X,Z?\<?"7A^VBN_$7B+X':S\7/ G@K2_BUIV@6SRWNJ_\(1=
M:Q=0Z19W_B*.VF\-V<^L)^*G[1OA[P+\:?\ @A/_ ,$A?ASK-S8^)/!OCOQ/
M_P $A_AKXQM-+U"WG\[2]6_X5YX#\8Z/)/;-.+:\M;B'7M!O8W7S;'5+"^LY
MXUNK.XA3]'/^"FEK;Z=^TE_P1[\7V,2VOB73?^"A$?@ZPUB'*W=KX7\>?L\?
M&JT\8:+$<^6++7[;1],@OT,9=H[.)8WC&_< ?L!7YQ^"/^"LO[!OQ$\::3X$
M\*_&I[S5;[2_BGK>O:O>^ _B'H_@7X;:1\'+[XH6'C;4/C!\1]8\+V/@'X20
MP-\&OB)>Z0OQ"\2>'I]=T?1+77-+BN=(\0^&KW5_T<K^-NY^%]VG_!M_^V5J
M7@'2K^:Y\6_M=_&WXN?&"#2-%EUJZU7P1\/_ -OG2M+^)NJWNEZ3J/AG4=5T
M70O@Q\+EU'Q3:-XBTVXOO"?AS5]+?6K#3YD%J ?T8? K_@I?^Q]^T7\1O"OP
ML^''CWQ=;^*OB1X>\1>+O@W+\1/@W\8_A%X:^/7A7PA'8S>*=?\ @/XP^*7@
M3PAX7^+UEH-M?Q:C?0>!M6UG43H4%_XGMK&X\,:=?:Q;TW_X*<?LCS?&?6O@
M9H'B#XL>./%'A/XH#X)>//%'PZ_9Q_:$^(/PF^'?Q?DUK3/#T/PZ\=?%[P=\
M,M9^'/A[Q%_;6J1:=J1N?$;:5X9N;:^3Q=J?A\VKU\G^,_V4_P!HG]J?5?V'
MOB1\1?\ @H?^RUXB^&WPD_:4^#7[5/P@?X*?L@:W\.M6^+$?@K2]:DF\#>%?
M'6I_MN?$73F\+_$3X;>(O$NCZF-+\):\8M.N;?5QIUW%I'V67QGXQ>)/$_\
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MFA:'IU_K&K7K06&F65U>W$$$GYB>,KJUT7_@MA\#;[6+JVTJS\1_\$P_VF=
M\/W6HW$-E!K>N:)^TY^S+XEUC2-*DN'C6_U+2_#L<NNW]E:F6XM-(AFU&>-+
M2&25?U:H _)7]@?_ (*?Z)^V'\5OVF/ACJO@CXD>&;KX;?M!^._!?PKU*]_9
MN_:$^'WA]_A%X2^&?PI\3V\_Q<\9_$'PS%X5\'?%V?Q)XJ\6_:? ^O7_ (+\
M1'PW'X6NX?!20W]MJ^M="?\ @L[_ ,$Z_P#A)ETD?''4F\$GQ\_PK;]H0?"K
MXM?\,JQ_$A;E+5/"+_M/'P2/@?\ :9F:2:+7$\;OX2^RV\US)XACA\IY?C7P
MEX;\<^,/V;O^#B?X0?#(W3_'#Q7^TS^UQ;^!O".F7,<'C+4-0^)'["/P%C^'
MG]D61G@OK6?QP]E?6WA#5@8([BYMKB\L+K.FSRP=-)^T5^QY%_P;VKXW?Q+X
M 7X%-_P3OB^%R^&?^$BT4D^/YO@<W@2+X/"86Q_XN:WQ$23PD(/[*_M,>+8Y
M-4-H#&\Z@'[UHZ2(DD;K)'(JO'(C!T=' 971E)5E92"K D$$$$@U^/7C'_@K
M!X7\(_\ !172/V0;GX??&*X^'L?P9^(VI^(M>T[]D_\ :=USQA+\:?#?QI^&
MGP\\//X9U#2/!=SH6M_ EO#_ (B\576O?%;2M"U?P)!K?_"+J_Q"TR*_M=/U
MK[._8!\(_$/P!^PM^QKX&^+5MJ=C\3O!W[+GP%\,>/M.ULEM;TKQ9H?PO\+Z
M;KFCZW*TDSSZSI%_;3:;JUS)--)=:A:W-Q)-,\K2-\O>,KJUT7_@MA\#;[6+
MJVTJS\1_\$P_VF= \/W6HW$-E!K>N:)^TY^S+XEUC2-*DN'C6_U+2_#L<NNW
M]E:F6XM-(AFU&>-+2&250#Y/_9M_X*,_"KX$?M _\%+?A]\?/B9\7O'7BZS_
M &[?B)-\-/A;X'\ ?&[]HWQGX1^#WA7X,? :;6M6L/!7PP\+>/\ 4?AU\*M
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M7-CIO]HZ@\.GVMYJM]<)&8H7N[B7YV .]T[]EK]F72/!7BWX;:7^SM\#-/\
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M".JKIO\ :GAC3M+L+#0KS3[2TAA3R']M+X0?'?\ :]^)GPU_92U7X%^%;?\
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M HHHH **** "BBB@ K_.5_X.]?\ E)/\$?\ LQWX:_\ J^OVEZ_T:J_SE?\
M@[U_Y23_  1_[,=^&O\ ZOK]I>@#_1JHHHH **** /YK/VP/V<?AY\%?VT/V
MK?VO/V_/V+O"/[9G[$?QH\-_"Q['X_)I*?%WQ_\ L,>%OAU\.M%\(>,M&\2?
M!'5X9=;L_A/JVOV>K?$BZ^(W[/\ I-]XJ\*13Z[J?C>#6YM1@FTGT*]_8^_8
M=^(7_!97X0>(],_9T_9]\7>%?B+_ ,$ZOB]^TM'J\?PZ\(:KIGC#XFC]I_\
M9P?PE\:GNGTR5-7\9#0_$NI-I'C.9IM7%CK=YY-Z$O9O,^VOVFO^"='B[]J*
MZ^)?A/Q?^WC^UOX?_9T^-<K#XJ?LZ>&1\!K7P]J&B?9--L9? W@KXAS_  6F
M^*G@3X>ZY9V$UOXQ\-V_BS5Y_$T>I:E')J]C%?7L=UU_QI_X)_:3XW\;?L\?
M$CX#_'?XJ_LA>-OV<?A=XE^ GA35/@UHWPK\0V&L? ?Q:? C:C\-=?T/XO>
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M]K>K\:+;Q^R^)8/$JZ6-+*11^%YM F\#F3PO( 4_$'[!'[%_[+'P-^.WB_\
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MCZ[^)'C'_@G/\0_V:=*^)WC>"R_9B_X."O#7[%_[-7Q+U7Q3K&L_$#P5\+O
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M&U*_T6;P9IFC?!5?&"^%KGPSIUKH%GKEGJ=^/&VJ_P#"03:KXBUFUNC;Z?\
MV=9:5Y5S]K /PR^"?[.WP@N/AO\ \%I/V*?&W@'PE\3?V<OV5OCEKGQ,_9O^
M&_Q#T5/&7AWX*7GQ+_94TWXH0Z!\.M,\47&M6?A7P]X%U_Q)K<O@C3]$AL(=
M"N-<\0WEDD#ZU<11_/WCOPAX?^ 7_!(S_@D)X _9Y^$+^%++_@H!XY_X)Z>
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M\$O'E_\ #WPSX)\.WWB;X9:[HNGZAI/A?2-3B\/P>*IKOQ5= 'QMX/U'Q_\
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M/$G@/XB>$_'_ (1\9^#?B5\/KN_TG2M=@\->(-($FE:[8KJ6AZGI4UYJGV\
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MX=;PI9^(VN-:T_PUX9TRST+PMJFM:YI=G)J#+-J-S]U?M0_L-_"S]@K]F_X
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MYJ'AOQ#HWB_P!K@\+?$?X>>-O!>OZ?XI\&?$#X<^+/L>H/X:\9>%M?TNSO\
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M^$T?C.RUJ\^'DOQ,\,+=:'X<\.^(==TSP_XTL9?$GC30=*U+6M4N]!MF\,R
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MW\._"?BKQ=XMMF7P_+X<&KS:QJUYXUUC3M=;4?$6H:)?:.MK:1Z';3+<W-T
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M2?67U3XJZ_X6U_P19>(_#OB3XAW/BCQ!!XEDM]:GU26?3H$?H_V-_P!G_P"
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MZCJIL?ACJ6F_$]/&GQ8FU[P%#X:U[6_$?C"[&N:M?V\%M#;_ -2W@_PEX<\
M^$O"_@3P=I-KH'A'P5X=T3PEX5T*R\S['HOASPYIEMH^AZ3:>=)+-]ETW3+.
MUL[?S99)/*A3?([98^"_LT_LH_#O]ECX'W7P"^'VL^--8\'7?BKXN>+Y-2\9
M:CH>H>)5U/XS>/O%7Q%\40)>:)X<\/:6+&PUOQ?J5KH$3:,UQ:Z5!8P:C<ZI
M=Q7%]<@'\Z_P^\;^+/V[/AA_P0 _9>_:=\:^)_$OP6_:G_9__:$^(/[1?A]O
M%GC'2-0_:@\3?LP_#'PC#\._"7Q"\4Z%J]MXFU^P2ZU"\^)_Q"TW6-;_ +*\
M>ZYI5OJ&L1RWEE90GZU^*W[,WP$_8U_X*2?L'?#C]F?X>>%/A=\)_P#@H-I'
M[6GP3_:T_9D\+65S:?!3XS>!OAQ^SR_B_P .^,;KX39E^&NBZ[X(O;;^Q]=U
MW2="TS6/$WASQIK&BZB]_!K.L3O]JZM_P2H^!,_[*W[,/[+WACXC_'3P%/\
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MAC_P3E_X)Q_M;_%#]@SX3^ /V4OB+\28/V=?A;XG\;_ +POX/^%>J6.A:_\
M&OPW\+8O$MK+8W'A'PYIWC'0O#?Q:\;6GAKQK>:GH.H:-K_B&U\17_B:U?2H
M;ZU^>M&_9.^)WPN^.?[#OCW]AC_@E%\6OV,_$?PR^/7@[PE^TE\6/$'QH_8Y
MEM/BE^QUX\-YH_QXTCXU2?#[]K3X@^/?COXML+Z3PK\4O#>L^-M!\<^+[/Q-
MX*%WX<OK?6[FU67]:/#O[#VJ^*?@M\</@=^V'^TM\5_VV/!_QZ\&6/@'Q+IG
MQ1\)_!GX?Z+X7T"PB\0V_P!J\!:5\&?ASX%N=&\4ZB-8TO4]2\6:OJ_B'68/
M$WA'PUXB\-S^&[NSDCEI_ G]B[XT_![Q9X+G\3?\%$/VM/C5\*_AC%;V?@;X
M2?$'1_V<+*'4].MO#-UX;MK+XO\ Q*\&_ SPW\3_ (L?8/M,>LV%U>^)] NY
MM9L+"\\03>(#'<+= 'K'[=OQ3\;? W]B;]KOXS_#9DB^(/PH_9H^.'Q%\$W4
MMM!>P:=XI\'?#;Q)K^AZM<6-TDEO?VVCZC86^J7-A.C17L%I):OA9B1^+O\
MP[*_8M_X=5']IW^RI_\ AJ,_LEC]LO\ X;[_ .$S^(?_  T=_P - #X$'XFC
MXWCXR?VS_P ++&D_\)&3XC/@<7X\*G3L6A\,&Z59!_1_JNE:9KFF:EHFM:?9
M:OHVL6%YI6K:3J=K!?:;J>F:A;R6E_I^H65RDMM>65[:S2VUW:W$<D%Q!+)#
M*CQNRG\7I/\ @BWHDOPL7]E1_P!N?]L]OV$%:.'_ (9./B+X4B#_ (1J'Q$=
M>A^% ^.R_"Y?CI_PI-;9G\-2> G\:2:E)X96WTO_ (2Y%MUD8 ^(=>^"/P)_
M;!^)'_! /]H#]H_]G;X+>/?BO^V+X#\2^)_VEM<\2_#+PA?3_%^^L?\ @FYX
MO\:Z&?&,4VE.FKZ-I/B72](\2>%=&U 7%IX<DL=(33TB?3;=T_IXL-%T_1M"
MLO#OA^VM_#^E:3I-MHNB6>DVMI;VNB:?8V:6.FVVF630/8P6^FVT4$5G:FV>
MTBCACA,#0KY9\'\=?LN_#7QW\4OV5_BM<2:[X;U/]C_7/'VM_"?PSX2DT'2/
M!DO_  L+X/\ B7X):CI'B/1Y?#][=2Z'HW@[Q1>R^'+#PYJ7AHZ?JUIITEQ-
M?:7!-I5Q[]JUC)J>EZEIL.HZAH\VH:?>6,6KZ2UJFJ:7)=V\ENFHZ:]]:7]D
MFH6+2"YLVO+&]M5N8HS<6ES"'A< _FB_X)^? SX*_L&?%'X!? G]N[]C;X>^
M"/VQ+WXD^-=(_9^_X*/^'[+_ (67X;_:[^)'BC3_ !=?7;:M\8;_ .V?%/X7
M_&3Q/X,U37[&7X:?&!M/\.^*+O2]:O/A]=#[9HWANV^M?^"0WB'0M!_X)A>/
MM8UC5K#3M,\(?&C_ (*!7GBF]NKF*.'P];:9^TC\;=:U"36#N)T_[)I$L6IS
MI<B.1+&:&Z*^3+&[>W>'_P#@F3-JOQC^"7Q2_:-_;)_:>_:RT;]F'Q:?'G[/
MGPV^+L?P4T/PUX7\=)HT^D:=X^\?WWPF^$GP\UGXL^._#7VN[N?"7B+Q)=VP
MT1IY%?3[Y[C4)K[!\1?\$G]!OM>^-&@>#_VK/VC?AM^S%^TQ\5O&'QC_ &B?
MV4O"*?"2#P-\1?$WQ%DTU_B;X?TGXBS_  TD^,_@#X=_%:*QN[3XD>$?"WCV
MW;6+36]9M]"U;PQ'?2*0#\@?V63:_&W]F'_@W[_8+^(FJ:U9_LY_M,_ []I_
MQ]\:_".B^)/%?@]_CA'\ ? ,=]X2^#6M:YX,U;2=5O/ =W>^/=2\<>/?"=_=
M6^B^*K7P?HFGWSW4(FL)_P!"O^"I7[(W[+_[,'_!*G_@HWJ7[./P!^$WP*N/
MB!\ -&T[QM'\)_ ^@^ K#Q/;^!-8G'A236-*\-66G:9>7VDCQ7XBVZI)9_VG
M=G5;AK^[NF6$Q_4FK_\ !*?X!7G[)_[-G[*N@^/_ (Z>"'_9!U31O$7[.7[0
MG@WQIH&@?M#_  W\3Z,FKV<FL6WBK3_!UOX0U:V\1Z)KVK^&O&/AC5? MQX2
M\2Z%>*EYH2ZKI^CZMINOJ7_!/SQ/\5?V<?V@?V</VJ_VSOVB?VD=!_:'\':'
MX$UOQ!J/A[]G_P"&FH?#_0]#O-6N&N?AII?P]^#FF:-8Z]XCBOM.3Q;JWC6U
M\=?VI<:!IMSIUKHJM=V\X!^6'[67[$'P@_8;_8\_9/\ VL/A7H5IHO[8OP7_
M &B?V,?%7Q,_:5T>]UV#XM?M"Z]\5OBC\//AM\>]*^*GQ"N-3?Q7XJ\#?%Q?
M&^O7NN>#-?O-3\*VMA*N@Z5X?TW2'-I'_3A7S'^TM^RC\._VI_@?:_ +X@ZS
MXTT?P=:>*OA'XOCU+P;J.AZ?XE;4_@SX^\*_$7PO ]YK?ASQ#I9L;_6_"&FV
MNOQ+HRW%UI4]]!IUSI=W+;WUM].4 ?P^>'_@YIGP5_X)!_M$?\%!?"L>H#]K
MC3/VH_C=\(/@1\>H?$<\'C7]F;X/?%?]MOQ#^SYXYT/X1W&MZ[X;\)?#^^U6
M/XL?&_78/$4=]I-Y;>+?BD/$^J>+K1="T1?#OZ1Z-^R=\3OA=\<_V'?'O[#'
M_!*+XM?L9^(_AE\>O!WA+]I+XL>(/C1^QS+:?%+]CKQX;S1_CQI'QJD^'W[6
MGQ!\>_'?Q;87TGA7XI>&]9\;:#XY\7V?B;P4+OPY?6^MW-JLOZ^>"/\ @GK^
MSQX1_9!^('[$&KV?B?XD? KXG7OQFO?%UC\0-2TF\\17;_'#Q]XH^)'B066K
M^&] \+P:7-X?\3>*KFZ\#:I8:=;ZYX;?3-#U"/5+K7-.75I>?^!/[%WQI^#W
MBSP7/XF_X*(?M:?&KX5_#&*WL_ WPD^(.C_LX64.IZ=;>&;KPW;67Q?^)7@W
MX&>&_B?\6/L'VF/6;"ZO?$^@7<VLV%A>>()O$!CN%N@#\?\ 6O''B[]CW]DK
M_@J)_P $YOARVG67Q0TK]I'3/A%^PWX=MY+KPE90_#;_ (*Q^*5F^"]IX0U)
MXVEN[GX0?$#QQ^T"+R]M1)'9+\);]W"VMJLDOK.H_LK?"+XF_P#!1;X ?\$T
M?C#:3>//V//V*O\ @F'\*OBU\*?V>_$=_J]OX+^)_P 3],^,-Q\%8OBW\3_#
MVC7%CH'Q)7P9X5\':=HUKX=\<1:QI%MK_B_7M8ATZZ.N:MG]3/BO^P!\#OC'
M^V%\"/VU_%NH>/X_B?\  +2!I6A^$]+U[28?A7XVDTNR^)%MX"UKXC>$[_P[
MJ-]K?B#X4WGQ<^(FN?#75M(U[P_<:!K7B:_NKG^TX2ELL/[5W[#7A_\ :4\>
M?"7XW^$_C)\7/V:?VCO@9I_C31/AQ\;O@K<>#&U>7POX^M]/3Q)X#^(GA/Q_
MX1\9^#?B5\/KN_TG2M=@\->(-($FE:[8KJ6AZGI4UYJGV\ _'?XFZO:?\$K_
M -L']LWX?_L8:3;^$?A!>_\ !(7]H?\ ;[E_9ML)]9U'X7_#S]HWX/\ Q N=
M \-?%'PCX0U2^ET+P'X6\=:=>S:#XP\&^ QHNDZM_P (E97DFE0G2=(A;[J_
M87_X)U_L5ZE^S]^S#^T7XO\ A%X'^._[1'C7P=\ /VF_$7[6/Q5M;[XC?''Q
M?\9&\*^#/'MA\2K+XJ^.9=1\>Z#91Z];6&I:#X5TG5-(\,:3IEK8:3'H$=G
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M "BBB@ HHHH **** "BBB@ K_.5_X.]?^4D_P1_[,=^&O_J^OVEZ_P!&JO\
M.5_X.]?^4D_P1_[,=^&O_J^OVEZ /]&JBBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K^'?_@\S_YQO_\ =X'_ +ZY7]Q%?P[_ /!YG_SC?_[O _\ ?7* /ZIO
M^"8O_*-C_@GK_P!F._LF_P#JA? -?<5?#O\ P3%_Y1L?\$]?^S'?V3?_ %0O
M@&ON*@ HHHH **** "BBB@ HHHH *_SE?^#O7_E)/\$?^S'?AK_ZOK]I>O\
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MI4<<VJ:C8Z;%-*((I;^[M[..69E9EAC>XDC5Y65'81J2Y56(&%)%Z@ HHHH
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M;X%^,G[*6D^"?&>N^!_&_C:S^)'BJV\;:Q9:IJ?AY?!'C#P/J'Q!MI-1\/\
MPZ\4WOQ:37=3\1VUOI'A?0M,!L]"_O\ ?V?]7^*'B#X#?!+7OC?HEIX:^-.M
M_"+X;:O\7_#E@J)8Z!\4-2\&Z+>^/]$LDCDFC2TTKQ9-JUA;*DLJ+# @61U
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M ,4OC9\#_B%_P5&TSQGHOC;XJ?#RP^&FH:CKUC\$O%_@#Q!<>&O#]NL6H?\
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M2O"GBOQ%/?Z/I_CB*RTM_#FC:OHMCXNN?B7X4\2ZAH?B+P]%9ZF ?U4_$?\
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M_!0+XR?L ?L?Z_XQ^ WPR^+&N?$SQCI][9>&_C7X3^&-C\0OA)^S_=Z5XH\
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M0=9^_41(T2.-%CCC54CC10B(B *J(J@*JJH 50      *_DN_P"#G;PUXE\
M_$;_ ()7?MLZGX*U+Q]\!?V5/VD;Z]^-6EVUL^HV5A:ZYXX^!OC30[34;) $
M@TWQO8_"SQ1X6NM3O9K33AJQ\-:)+<B^UW3HI0#XX_;;_;^\#_MS?\%5O^"'
MRZ7\%_VB_P!G;XC?"K]IW2%\??"#]IOX6W_PP\>:9I7CSXG? :^\&>+-*MI;
MO4=.UWPAXH;P[XGM-'U*WO8-2-QX=U!M3T73+:XTF?4OV0\S]C3_ (B)?+^R
M?M.?\-J_\,H9^V?VC\*_^&7/^%>?\(Q_J_[-_LS_ (6Q_P )I_9_'G?VK_8?
MVSGR/(XK\*/VT/V^?V<O^"@O_!<K_@D=\1OV7;74?%/PU\ _%_X'?#V[^-^I
M^!O&7@EO'GBUOC3H7C+5_ NG0^,;+2+V]TOX6V'BK1IV$FB:9?6NO>/=?:07
M^B7?AW4[O]._^=LG_NQW_P!TR@#Z'\-_\')/['7C;XJ>$_@7X-^%'Q_UCXO^
M*?VID_9G?PA)H?A"./PY;0^,?!W@N^^,7B75=,\6ZS#I_P .WU7Q9);Z(L<%
MSK^J7OA[6;>]TO1;6.#49M;XQ_\ !QC^R9\./'?Q=T;X=? /]K_]IKX4_L]:
MK_8/QV_:/_9_^$FG>)_@A\/-9_M&/2'MKGQCKGBKPY9S646J+?:<FOZD^A^'
MM;N;2.X\'ZKXHTB]@U6OCG_@V0\(Z5)K7_!6WQ+:B2Q\2>(_VN9_"-UK5OL%
MW!I6@W?Q,U#1Q;/M$D<EE?\ B[6+M?WA1I9(B%5HRS?@M^R+!\//V0?AU^UK
M_P $_P#_ (* _P#!0[]K#_@G-XGTWX@?$+P_\0_@'X)^!UW\2?A'\;O!WC?P
M/X=\%:GX@L-6T+P5XIUO5Y?'F@:?-I\6H:C::=X.\2?#@^"_$7ACQ+J5EJE_
M'I(!_<%^TY_P5Y_88_98_9/^'7[9'C#XHS^-OA/\:+6VG^!^G_#+27U_QQ\7
MKB:U-[=V'A3P[J]QX=BTNYT"UCG_ .$LF\<ZCX0T_P ):C"OASQ'>Z;XIO=,
MT.^_'']KG_@X8^+K_L6_&OXA? ']@S]N_P" 7Q*TW2O"$W@OXU_%W]GW1]3^
M#W@+1O&GBBRC\/?$#QCJ&IZA>Z99:/XG\+QW5EX6O]7T#4?#6H>,]8TK2]-N
M?$EK;75PWY@_MV_L_P"F_LR?L$?\$,_VO_V=HOB?^T/^Q]^QU\:_B#\2-4O/
MB7X+M?#WBIO"_P 8/C]X)^.?A"^\9>$M!>^L= \(>,]1\&>)/"AUW6-2M8%?
M6OAYHE[/;ZKXET_38OV4_;Z_X* ?LP_\%8?^"5?_  4<^'G[#7C#7_BSXD^$
MWP,^&OQ3\?07G@'QMX)CT71;#XB6/Q$U/285\8Z%HMWK6OZ9X7^%7C"\NX-!
MM-3TIIK6UMK75[F6Z4( ?0?_  2G_P""JM[\7O\ @GWJ_P ??VT?"_QW^$EI
M^SW\*O"GC7XN?M3?'7X70^!?A1\>/^$IU#QW-J/BGX#7?A6R%GX_L=#E\.6.
MC7FC>#?#-K<KJOB7P?X?T#1+N^UJQL6P_A+_ ,'&'[)GQ#^(?PET+QO\!/VO
M?V?/@Y^T#XMO_!GP._:E^.7PFTSPG\ /'VL606WB:'QC;>*]3\C3[_67@T5=
M2TRVUZPT&?4=-O\ QK<>%-)&M7^B?D]\*_B5X7_X*.?\&V/Q _8?_9)N_$7Q
M&_:E_9M^!?P;U?XI_"#3O#'B>SU4#P?^T&_CJ+P_HMY<Z1'I/CO7/%/A#X8>
M)/$/A#P[X*OO$&J:GJD7A[09[>S\0ZG;Z;7YQ^$O%'[!W[7_ .R9^R_^S7^T
M5_P5C_;@N_%>B7'P?\&>'?V(!^S;;:W%\./BWX?T"+X5:-HO@#Q!!X9L_ I\
M-^'5\0:OX<\':MJGCW2M7F\)7@&LZ/IFKO?Z1: ']@?[;7_!:/\ 9M_8Q_:
M\(?LH6GPS_:%_:D_:7\3Z:FOZA\%OV6OAY:_$?QGX0T"33TUVUN/$%A>:]H+
MSZUJWAI-0\3:5X:\/IK>JP^']-;7/$Z>&-#U3P_J>L?C1_P2#_:#\!_M4?\
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MQ?\ @GQ?:%XUO?VR]4U#]H3PAIGP:A^'WCV^O5^&GC/P]IMY\3_BEXAUJQT
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MAXRMKNSN]5T&TUR'3O&'BWP%X7TS4/$MQ\6=-O+&UUF_ /\ 2FHHHH ****
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MVVCZ98ZWKFLZGJDT:+;QW6H2%W /5OB5_P $H?VZOVS/^"B'P=^/O[>OQ_\
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MJ]K>6C212QQRQN82R21HZD,JD?G+_P %G/CW\6_V8?\ @F;^U+\=?@5XQN?
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M@\"Q>-F\::AJ!TFR\$KH<FMK=MXUNM4V:;#X/"'Q(]_<6EH-+^T7MI'-];4
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M%%_9^ ].\/\ A3QYK?C.QE\7:CKZ:9XLM+>?PCX>N"MQ^PW_  6P_;C^,?\
MP3R_89U[]H_X%:;X$U7Q]IGQ)^'?A&WM/B-HNKZ_X:.E^*M1N[74I)=.T3Q#
MX8OFO$B@0VDJZJD43EC)!,"  #]1/$?@7P3XQETJ?Q=X.\*^*IM"OX-5T.;Q
M'X>TC7)=&U2U8O:ZEI4FIV=T^G7]L[,T%Y:&&XA9BT<BDDUU          &
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MJMA;>(=&T[6K>RU2RD6:SU*TAU*VN8[:_M)566VO(52X@D57BD1@#6^
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M]CMUBM+G^P?B#X'Q<0RJWFN&E< _3?1_ G@CP]K6L^)= \&^%=#\1^(_L_\
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M?4M;T1KJ-(;IM(U6\LYK_36N88HXIS9W$)FCC1)-RHH'\\^I?\%&/B9\0O\
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M,_LI:W^V+<?&OX4^+/@T/#WBF_\ A[XI\/?$OP=/X:^+GB[P[HWBG4;/X;>
M/%L>J7'A_6O&OB#4_!^N>&M.T>SNKF]CUW3[^PGM1=:?>01?E;\"_P#@L=IG
M_!1#_@GS^T-\0_@?\:OV<_V'OVM_#_A;X@:[X6\._%SXQ>$_%\'P5\&^$_$W
MA+PYI_QB^*9USX=Z@MKX.U"^\1V5E-J>H?"K4M$M+[7='TU([^>:&\E /Z(
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M )1L?\$]?^S'?V3?_5"^ :^XJ^'?^"8O_*-C_@GK_P!F._LF_P#JA? -?<5
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M .)7C/X;W/A7P\^FZ/X>L+CPOINH>$;R/PM>6F@Z)!?>'3IEXFDZ<)_LD/\
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M4W$,.N7W]J>(-+M;[4-/T;5M-TR]GLG^NOA5^Q-^S%\$?C]\;/VHOAA\,_\
MA&/CI^T7]E_X7)XY_P"$S^(.M?\ "8_8[F*\MO\ BF?$/BO5O!_A[R[B"*3_
M (I7P_H>_;LDWHS*0#^3[_@EY\!?V9OVK?\ @L3_ ,%E(/V]/AYX'^,'Q4^'
MGQ1\1Z+\'?!7QUL;3Q3H>C_";P[\0OB3X%U2ZT;PUXNDNM+U&Q\!_#KPY\%=
M \%>()K._N/#?@Y[._T+4K6&[^WS1_\ !$J]_9\\,^(?^"^G[./C&]TW7/\
M@E-\/O&WC;4TOO$'B?4==^'?ASX='Q-\9_!DMWH6J6EUJ>JZY=>.?A%X0\/7
M%OXQT759_%6I1_#CP9J.G.^O7>FR1_T0?ME_\$8/^"=W[>'Q$;XP_'_X'/=?
M%NYT[1M&U;XD>!/&?B_X>^(_$FDZ$D=II]IXKB\+ZQ8Z%XIN8M&BA\-)KVO:
M-J'B:V\,6VGZ#8ZU::;H^C0:?V%K_P $DO\ @GS8_LFS_L/:?\ (](_9CU+Q
MA:_$#Q-\._#OQ,^,'A2Y\=^,[.>WNK;7_B-XW\*^/]%^('Q"GAN;'2)K>R\9
M>*-:TFU_X1OPC%::?!;^#?"D.C '\%'_  3CUCPK>_MM?\$X? W[8=]\:)O^
M"9VG_'/X^^(?^">D?QBT73[7P5K'B?5OB3+I7AEO%MQI,C:-)IA^,>A^$/\
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M/B98_P#"O]%T^%+>SLO[$TWQE9^'?%?DPQHGVGQMI'B2[DQNEG=B6(!\3_\
M!PO_ ,H<OVUO^Q9^%G_J^_A57\L/B3]E[_@G]IG_  :Y:%^TA!X3^&,W[5&M
M^+M*AT[XN7UCX?MOC/J'Q=7]IH^%]=^&-K?MJT^MS:+HWP7L-;>V\'1W<=G/
MX%T=/B@_AB'4)'E']ZO[0W[/7P?_ &J_@YXV^ 'Q\\(?\)Y\(_B+:Z59^,?"
M7]O^*/"_]L6VB:_I7BC3(_[>\&:UX=\3:?\ 9M=T32[[?I6LV,DWV7[-<-+9
MS7%O+^4$_P#P;C_\$@V\;^!_&MC^RY)I:>!VTZ1/!T'Q2^*VI^!O%<NC_9/[
M-D\;:#XC\8ZXWB'RS91?VG%+>P6_BD/<IXPA\0)=7*R@'\YG_!3WQ?\ ''QC
M^Q5_P;;>&/BS:Z+XK\#?$+PYX1UGXB>%OBKXVUGP5\)_B7XETC2OV?-(^%W_
M  OGXA7$JMX8T[6_AOXGUT:YXROK^RO=-TGQ9\1]>CU&VBL[C4;']$OV/?V$
M_P!LCX6?\%>_V=_VL+G]GC]BW]B#X2>)_A)XS^'/Q0^!?[+7QQ\/V^@_&#P[
M!\/_ !W/I'C'1OA?::;IB:U/9>(Y_AIK&N0>%],329/^$#TWQ5>^5J]SK6KW
MW]*W[2_[(7[-O[8/P:N/V?\ ]HSX2^&OB1\)9+K1]1L?"UW]OT-O#FJ^'XI;
M;0]9\':YX8O=%\0^#-8TNQN;W2;;5/"NJZ1>_P!A:EJWA^6:70]8U33KSXY_
M8P_X(M_\$^_V"?BKJ'QN_9Y^%?B/2_BE<Z;K>@:=XL\6?$OQWXPF\.>%_$"V
M4>H>&]#TK5M<?04L3%86\$.I:GI>I^)HK;SK;^WFMYYHG /*O^#@G]D<_M=?
M\$OOCSI>D:>VH>/O@3;VO[2WP\1)'5_[3^%%EJESXTM(H(HWFU&[U;X2:K\1
M=(T?2XL-=^(+[1V4220QQ/\ @A^QK^TCX@_X+D_\%&/^"5Z>*4U+5?!'_!.K
M]ENW^/G[0,^JP#3KG6OVI/#^NZ7X;O/$-O>0*]GJ%IXG^(?ACX#^---T>6,/
M_8=OXXM80J"]DB_N6N+>"Z@FM;J&*YMKF*2WN+>XC2:">"9&CFAFAD5HY8I8
MV9)(W5D=&964J2*^(?V./^";?[%7_!/^?XBW7[(WP2M?A'<_%<>&E\>W">.?
MB;XYGUN+P@^OR>';>*;XE>-/&4FBVNGR>)];=K30&TNVO7NHFU"*Z:QT\VH!
M_,#_ ,$R/@A^S?\ M>?\%E/^"SUQ_P % / /@CXS?%_P3\6O%5A\)_"'QVL+
M'Q/HFF?"[1OB-\2_!>M7VC^&/%37&D7]EX'^'WA_X+Z'X+UY[&]F\->#Y+.^
MT#4;."Z^W3=Q_P &]/@SX8^+/C__ ,%G?V-=%\'^&/C9_P $[_#_ .T':WWP
MW\(>/8]*^*OPB\FR^*?Q0T#P?]ET?Q5'XET3QLGC/P3X"\%:K_PD^H37]S?V
M_P +_!VLW&Z]EMIX?W;_ &R_^",'_!.[]O#XB-\8?C_\#GNOBW<Z=HVC:M\2
M/ GC/Q?\/?$?B32="2.TT^T\5Q>%]8L="\4W,6C10^&DU[7M&U#Q-;>&+;3]
M!L=:M--T?1H-/^N?V4OV/_V</V(?A/:_!+]E[X7:-\*OAW#K&H>([S2].N]8
MUG5->\2ZLEM%J/B3Q3XH\2:CK/B?Q1KEQ:V6GZ<FHZ]J]_/9:-IFD:#IS6>A
MZ/I>G68!_$=_P1'\#^$?#/[!'_!9CXO>$?AYX!M?VP_V?/#GQL;X$_$!_!/A
MV3X\?![4]3_9\^+6E6\'PN\0S:5)XY\':I?MIOB33[#2?#ES9#5KZRU#2IK.
M[C^VVK?-O[)W["GQP_;&_P""3-MHGP/_ &0/V [M[CQ7K/BO7/VX_$_Q[TOP
MS^U/X#\6^%?B?J5[>6OCN>_M#<>!='/A6Q?PK9>"=:O['PSJ7@C4=(^(]MIT
M_B'5-/\ %4G]J/@3_@C;^P'\,_VS[O\ ;T\#?"G7/#W[0%YXI\8^/&N[/XA^
M-SX+A\??$"U\0V7C'QE;^"Y=:DTB/4M<M?%?B&.32]K>%K!M3FGTGP]I]S%;
M30_/WQ _X-R/^"1GQ%^)-W\2=1_9JO?#LVKZWJGB'Q%X)\"?%'XF>"OAQKNI
M:K)-.ZIX1\/^*+.U\)Z993W$TNEZ%\/)O!VAZ<DAL[;3DT]4LU /P=_:J\$W
MGQ,_X*__ /!"KX"?\%$-;TKXA?#./]ASX$P>-TU;Q/%X[^%/Q+^/;Z3\7;;6
M]6N-;N&C\,>,!\7/BWX-^%VG^*Y8OM%KXI\+W7AFUU&+4;"]MA>;_P &/A?^
MS'\'?^#LSPWX _93TCPMX7\!Z-X#\=KXJ\#^ =+T+1_A]X#^)TG[*/C+_A,/
M"W@VQ\.SRZ;:V5N5T[4O$.G);Z:^A>.=3\6>'6TRS32(T/\ 4/\ MD?\$N_V
M*OV[_AQ\./AE^T1\)5US1_@[:/I_PGUGPWXBU_PEXL^'VG3:;IND76EZ%X@T
M:_@N;C1KW3]'TB*^T/74UC1KR?2=+U"XL)-2TVQO+?@_V:_^",__  3<_9%^
M*GP^^./P _9QM_ WQ>^&6@Z_X=\+>/%^)GQAUK4?L7BJQ\1:9XBN==TK7OB!
MJ7ACQ/JVJ:=XJUJP;6/$.A:EJ5CI\NGZ=I5S86&A:#;:8 9G_!;[_E$U^W7_
M -D.U7_T\Z)7\</_  4+\+MXX_X)A?\ !N%X*75;K0F\80?$GPNNMV(9KW1V
M\0>*O@QI(U6S5)K9S=:>;O[7;A;BW8S0H%FB.)%_T'/CA\$OAC^T?\)O'?P-
M^,_AG_A,OA;\2]#E\-^-O"_]M>(?#O\ ;6BSS07$ME_;?A35M#\1:;NFMH7^
MTZ1J]A=KLVK.%9U;Y#\9_P#!*']@/XA?#[]F/X6>,/@)_:_@/]C>ZNKS]F_0
MO^%I?&G3_P#A7-S>:CH6JW,G]IZ7\1K+6?%_F7_AK1)]GCS4?%$:?8O*C58;
MF[CG /Y[/^"D'[+?P _8F_X+&?\ !#/7_P!DSX4^"?V?9OB)\7G^'WC+3OA;
MX:T7PGI&OZ#IWCWX:>$IIM5LM+L(!J>NZWX4^*'BSPYXA\0ZE)>:QK&EW%I'
M<W9GM%G;^L+]H;XR>&?V=O@)\:OC[XTTW5=9\(_!7X5>/_BKXFT;0K:VN];U
M?0_ /A75?%&IZ5I%O>SVEC+J6I6FF2V5D-0N[/3Q<SQM?WEI9K/<1><?'']B
M;]F+]I#XM_L__'7XT?#/_A,_BI^RWXFF\8? CQ3_ ,)G\0?#O_""^(Y]7\-Z
M]+J/]A^%/%>A>'/$^_5O"/AZ[^R>,=(\0V*_V?Y"VJVUW?0W/T;XG\,^'?&O
MAKQ#X-\7Z'I7B;PGXMT/5O#/BCPWKMC;ZGHGB'P[KUA<:5K>AZQIMW'+::AI
M6K:;=W-AJ%C=126]W:7$UO-&\<C*0#_-G_;-\.Z?\3/^"3'A?]JKX=?L,_\
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MB+3/$5SKNE:]\0-2\,>)]6U33O%6M6#:QXAT+4M2L=/ET_3M*N;"PT+0;;3
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MAGK_ .R9\*?!/[/LWQ$^+S_#[QEIWPM\-:+X3TC7]!T[Q[\-/"4TVJV6EV$
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M_P#$;0M;U!?M'A>R\3S^+]%\+>?X!=EMO$'B'1/A]X"U'1I[77H-"U3]*/\
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M(?$&D:9J5WJNFZ;)'K6JR^']+MK.[O)&+:#H6DW-^([9M6GU":WBE4 ^&_\
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M$(+;X(_$WQ'XR_9\\,>(OAGX$CM?A _A7]H1AX6\4?!W1]2T00?#Z7P]'?\
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MN:UJ>J70!_-K_P $2/A?X<U7_@KC_P %0OV4_BW\._V/?%/PQUCX)::?B_\
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MT^XU-YB]W+&?SG_X(_? ;]AGX\?\$UO^"M7QS_;JTGPKXK_:'T#6OBC?>/\
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M-"M#'#$0X;^@'X*?L'?LH_LZ_'3XY?M*_!SX5?\ "'_&O]I+4]0UCXT^-/\
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MY_X1SQ3XPUOPGX=\_7[RYO\ R?">@Z%!%YGV6&*.R2.V33_9V_8F_9B_9/\
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MGT76M6L+P _D@_X*Q?!K]FW]A[_@J+_P1@\5?\$\_AU\/OA5\<O$_P 5]/\
M#WC;X=_ J32?"5MXR^'%WXY^$GA'P?%XIT3P[)]EL1\4_#7CCXL^"M6\:W.D
M3:CX^\-SZS_;VK:G'X<MBGR?_P %^]93P7_P4@^/NO?\$W[SXD0?'"Y_8O\
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MWT<EU)\.?\$D/^"QW[9GQ3_;[T*S_;7^)4\/[*W[:7P7_:3^,G[+F@ZIX=\
M:+X>^'-K\+/BE\0)C%=>+-%\-:+K,EAX+\(_!+XN^$KNUUG6M<N[I1X5UF]E
MEFOH;F4 _IU_;[_;M^$?_!.?]GG4OVE?C;X=^(_BGP+I?BKPQX0N-)^%>D>&
M=;\6OJ?BRZGM-.GAL/%OB_P/H[6,,D#M>ROKT=Q&A4P6URQ*KZIK?[4OP"\&
M?#KX8_$_XG?%/P-\(/#GQ@TSPO?> (OBKXO\+^"]6\17_B[3--U31_#&D66H
MZSMUWQ9)%JUE;OH/AR?6;N2[E6*S^U*\4DG\<E__ ,%1?^"E^K_\$>OVK_\
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MO/$O]F?"SQKX2T?0+^=E\*>"_&&GZ;XGCMO!OA32?&@TB\USX8>-K76+F6
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M%F\7AK1]5U6/Q!I.N?$2UUVTM-#^&'@NXM;R4 _T J*_C8_;;_X+<_M;7?\
MP3D_X)6?MQ?L\W&F?#?Q_P#'_P"-OBKPU\9OA5H>G:%KOACQ_J'PL\2:IX0U
M[P)'+XHT[Q#KWAOPMXYU_P *7M[I::=JUMXLTCP]XEL;=O$5W>VR:G+_ $-?
M\$Y?A+^WS\*/AG\2$_X*'_'WP#\?OC%XV^*5UXR\/:G\,[>ZLO!W@7P3>>$?
M"FFP> -&L9_ _@"*UL])\0Z9K]Y;FVT5Q=PZ@E]=WD^HW5X0 86D?\%0/@QK
M/_!2KQ3_ ,$O[?P+\3XOC/X3\!V_Q OO'4UGX4'PPN-+N? GASQ^EG:7B>*7
M\5MJ"Z5XFL[1EF\+0V_]H07*"X-L(KB7]*J_A@_:*T_]J3Q%_P '3GQ8\#?L
M@^-_#'PI^+GQ!^#?A/PF_P 9/%W@9?B/I7P?\&O^ROX#USQ5X^MO!UU<6^C:
MWXAL[+1(]%\)V/B43^'+SQ1KFD66KPBWN?/@^H_@U_P4<_X*%?LY?M%_\%._
M^";?[67QW\._';XD_L^?L:?';]H7]G;]IW3OAKX:\#^+1XE\-? [PS\3O"&G
M3^&M$TI?"&H:.F@>)Y?%+0^(]-UW4M%\6^']9\.7?B7Q3H%UI5EI0!_7Y17\
MP'["'[>O[6WQ<_X-^?VH?VQ_B)\8M1\2_M*> ? O[6.K>$?BA/X9\#6-]HVH
M?#OPW>7W@VYCT#2O#%AX1NFT2ZC2:)+_ ,/W45T5"Z@EVF5/S5\=?^"J?_!0
M3X9?\&\W[(G[9'P_\7WOB7]H_P",?Q'U7PA\6?CW<_#CPIX@E\#>#[;Q_P#&
M^RM_$LGARW\*O\.-$NM0F\%^"? -IK&O>&)='B35I(8+5O%6IZ3J=L ?U*_M
M3_M'>"/V1/V>?BQ^TK\2=*\5:WX%^#OA6X\7^)M)\#V.D:EXMOM,MKJUM'@T
M*PU[7/#6CW5\9+N-DBU#7M+MRBN3<JP56/V6/VCO!'[7?[//PG_:5^&VE>*M
M$\"_&+PK;^+_  SI/CBQTC3?%MCIES=75HD&NV&@ZYXET>UOA):2,\6GZ]JE
MN$9"+EF+*O\ ,Q\*/VT/C%9?\$S?V^_VG?A#_P %F9?VY_&'@'X':/XE\"^'
MM5_9L^%_P/\ BE^S=\0+K7([CQ-K/BSP;K$/B?Q9K^FZM)?)H7A.?5X)?AK:
MII>MV/A:3Q$MK!J-A\]?MF_\%9/^"A7P5_8,_P""(GQW^%OQ:O=>^+?[2<?C
M?5?C5I5UX+\"W=O\>-2\->(?A@NA>$]9L;7PHDNB6FM_VSJ6A7'_  @'_"+Z
MH\&LRO:W<5]%97%N ?VUT5_)]XP_:0_X*E?\$\_^"JW["GPC_:H_:\\-?M:?
M []O?Q!>>!M1\(Z!\$O!7PG\/_#;Q-J'B32O"Z:;X&L]+O;[Q,EGX UKQGX)
MO+/Q1K>N3W?B_P +W&KV6O:/?^(;:/4X/EOX\_\ !7/]H?\ :5_;:_;*^%7A
MC_@IS\&/^"57P7_9$\9^)_A5\(K#Q=\*M$^)/B+]H[XB>$==\8^$+_7?$VIZ
M[I6KW>D^&)M;\+W5YJEW8P)8^%O#GB'P7;6_PZ\;>)[77-;B /[9:*_B-\;_
M /!>C]N[QO\ \$-=#_:F^%UAI/A_]IOP?^U=I_[*/QQ^-'A[P/H7BK2]+\/:
M-\-+;X@)\9HO"%UH^L^ O!VH_$&ZUGP=X,U"[U;1IO!$7B>]\2KX,T?1)-6\
M*:?X>_0O]@C]K;XLZC^QU^VC^T=\*O\ @J(?^"K'C/X=_L\>)O'GPT^ .M?L
MT>&O@O\ $SX8?%W2/"WBCQ.]GXT\!>';O4/B[XMT7Q+XCBTK0?#5K87MIX.G
MMM)U_0_!%_K<JVNJZ< ?TST5_&A_P1,_;Y_: _;5^,/PR\1?'/\ X+.K'\7K
MKQ%XJ'Q0_P"">_BS]EWX2> X?'7AK1F\00>$M*^%/Q=ELM+T;5-1O%DTWQ5X
MBT_X>>&[?XC1Z/9ZQHNHP6ECH,'BZ]_LDU"18K"^E>^CTQ(K.YD;4I3 (M/5
M(79KZ0W/^C".T ,[FX_<;8SYO[O=0!;HK_/W_:>_X*B?MG_LP^'+3XG^&?\
M@OE\$_VK_P!ICP?>Z0OCC]EGX2_LIV>L? ;4=#N]?TG3M6L_"_QN\,_"RR^&
M?B>+2#=Q2WVK:Y;?##Q'>:0FH6OA_P 1+XG:RTS6/MK_ (*J_P#!7/\ :?\
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M%7B)/!6L:!)X1N]2TK5?#_B*UO=?TOP7X:\-ZEX=\>>##9>#=!UFQN[_ %(
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M].M-/@N;J6'3[*"W6&!/Y%/V,?CM_P %C_\ @MOJ?QL_:A^!/[;'@_\ 8/\
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MQ1%=^'[#5)?$;SG2=02UM8UF(!]T_MO_ /!5/]FS]B/]D_P5^V7JJ^(/CO\
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MXBBOX<_B1_P6I_;D\6_\$"/A?^UUX2^*C_#_ /:@\,?MKV/[,OQ"^*.A^#/
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M)H]6U'PM=P^(M&EUR[MO[.M+0 _I:HK_ #_;[_@M?^V)^U1X._:>_:S\-_\
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M=-U5/^"5-I\$/#ATFX^%%K\2'\-77AM_&EW977BB"\O-+DD\23V">(G\;/\
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M^$G\:VOC_3?"_@NQU+3O$/ACQ=?ZCINJP@']==?CG^WI_P %H/@E^PS^T)X
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M_ O[0WP*\1W/BWX4?$BUU>]\(>(;O0M<\-7&I6^A^(=7\*ZD\NA^)=/TK6[
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MU'PY)X0TS['XH71-2T[S;#X?K;?:H+O]\J* /\W;_@IW_P $OO%O[ /[(_\
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MZ\1:QXV4:3JQLK+6_$_CGP$_X)<_\%AO^"7/Q._:0\$_\$T?'/[&_CC]EO\
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MO%?ABZF\3:%/I&C>)]3\#3>#?$::/I^N:Q\0?M&_\$M/B-^PC_P1W_X*V?M
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M"/@'_A,?$LOE>5X>\*_\)7J^D_\ "0ZY)Y\/EZ3I'VR_?SHMMN?,3(!^/O\
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M+?X8SV^H^*/"BZ=XAL(O%>F6$UK'-8<#X"_X(;?M9>%OV!_^"JO[+.H?$/\
M9VF^(/[<GQV\._$_X3:Q9^+/B5)X-\/:!I'Q-T'QI<V?Q$U"?X26^MZ3K#Z7
MI=Q;P6_AKP]XMLFOWABDU"*W9[J/^JJB@#^?GXS?\$I/VA_B)_P0H\%_\$Q-
M$\9_!>U^/?ASPA\)- OO%VJ>(O'$'PAEO/ 7Q=T/Q]K$MIK]I\.K[QF]M<Z/
MIL]MIKS> ()9M3>&&ZAL[5GO(_BS]O;_ ()O_$;X>_$K_@DG\;O@M^VU^R#^
MS!^WG^S7^S?\/OV<=$TS]HWXC7GA+X<_&V/X(>'-'TC6%^%TMWX2U'7O%?V6
M_P#B7XNT+Q%HD_@J/5/$WA#QQX?63_A&[K3##/\ ULU\6_M@_P#!._\ 8S_;
MXLO!UE^UM\#M&^+R_#YM;/@R]N?$GCGP?K/AY/$BZ<-=@L-?^'WBCPGKBVFI
MG2-+DNK.749;1Y["UN!"L\*2  _D0_X)ZVOQD^-G_!S->?$[QY\?_A#^U3XV
M\!_"+QWXY^,WQ-_9WMIF^ 'A6UU#X)I\,M'^'OPCU6&[U?\ MOPG\/K[QYX&
M\$MKNLR:7JVH^(H?$0\0/J7BJ'4-5UW^W/XU_"3P?\?O@[\5O@9\08;VX\"?
M&3X<^-?A=XQCTRY2RU4^&?'GAS4?"^MOI5])!<K8:K%IVJ7$NF7YMYS8WR6]
MVL3M"%/A_P"R;^P-^QY^PQHFM:#^RE\!/!?P?@\2M;'Q)JVE'6=?\7^(HK(N
MUA9Z_P"._&.J^(O&VLZ=I\DL\VG:7J7B"ZT[3[BZO+BSM8)[RZDF^OJ /X\?
M"O\ P2O_ ."Z'[/'[*'Q6_X)A_ ;XP?L0^+_ -D'XHS?%'P[IGQH\</\2- ^
M*_A?X6_$R:\M_&7A>?0K?0O$&E^&Y/'MAK6LW.IZ9I>B?$V70;W5_$,>C>.K
M9YM+OX_HWX\_\$"_'J?LA_\ !-7]E7]F;XC_  UN4_8V^/O_  NSXP>./B]>
M^)_"-W\2]7U[5[7Q)XVU;PKI?@SP7X]6"ZNM9:^LO"_A[7+V"/1?"UGX?T;4
M/%NLWEC=:O=?U T4 %?S,_M'?\$UO^"D7PO_ ."KGQ;_ ."D7[!&H_L??$:7
M]HSX=>%_AKK_ (;_ &K8/'/VGX-W6D>$_AUX<N?%/A\>%H$N[VWM7^$OAZ_T
MG5M%U\ZI GB/5_"]WX#U#3+.WUYOZ9J* /Y'?A?_ ,$$OVU_ W[(G_!73]GK
MQ?\ 'GX!?$_XA_M[^-?@GXM^&GQ9U36?B/H+:OJ?@/XO^)?B'X[\2?&G1XOA
MIK4G@S6O$]KJUO?6-AX+O?B=:MKMYJ-E=ZG:6-K;ZG>_;GQF_P""4G[0_P 1
M/^"%'@O_ ()B:)XS^"]K\>_#GA#X2:!?>+M4\1>.(/A#+>> OB[H?C[6);37
M[3X=7WC-[:YT?39[;37F\ 02S:F\,-U#9VK/>1_T#44 ?R+_ /!P!\ ?A9X'
M_P""*_[/WPQ^*7Q7^%FA_M/_ +%/A3]E2/P5I.E^);)_$OCG54\/Z=\"_&>B
M^ ['4X](\;W7A3Q%!IOBCQYI^HQ^'+.2_3X0?;=2M--A\/ZQ+I/Z3?\ !O?^
MR1JO[+G_  3B^''B3QW:W7_"Y?VJ=5U']J'XJ:CJLGVO7+B;XEV]E-X!LM2O
M9T&HI-!\-K/PMJVJ:1?MYVD>,-?\6K+%%>W5\TGV-^TA_P $N/V!_P!KSXU>
M#_VA?VE/V<O#/Q=^*_@30M&\,>'M<\3^(_'W]AGP[X?UK5?$.E:'X@\ Z9XL
MT_X>^,=+M]6US5KB6R\8>%==M[V&_GL;Z.YL&%JOWQ%%%;Q10011PP0QI%##
M$BQQ111J$CBBC0*D<<:*$1$ 55 50  * /@/_@J/^QMX@_;^_82^/7[*'A+Q
MIIW@#Q7\3-,\(W7AGQ)KD6H3^'(?$'@+X@>%/B+I&F^)8]*2?4$T#7;_ ,)P
M:+J=]96>IW>C0W_]MVNCZQ<Z;#I=W_-S\8O^"+__  65_:T_93_9Q_9K^*?C
MW]@;X1>#OV+M:\$:1\)_A]X#G^*NBZ-\9K;PGX8NO!MS\7?BQXNT?PGXQBL_
M&UAH>C:+:>%+;0_A]IB:_'X[\?ZKXDL?"%_8Z;I>K?VC51U35-,T33-1UK6M
M1L=(T?2+&[U35M6U2[M[#3-+TRPMY+N_U'4;^[DBM;*QLK6*6YN[NYEBM[:W
MBDFFD2-&8 '\WG[9'_!,_P#;[^'W_!48?\%1O^"9OB3X ZEXU^*'P]TSX;_'
M+X6?M%:EXLT[PS?2VGA[PYX%&LP+X5BM+C4O"<_AKP?X(UJ_T[3_ !#H/B+2
M?%W@]=7LHO%4&OW.DV'S+^SE_P $SOVJ?^">'Q#_ ."G'_!0O]O/]H?]FSQ;
MI'Q^_8]^.EOXO\2>"->\9:5JD7Q9^(]YX9\=:O8Q^'O%'P]\*>';3PXOB'3-
M8\'>!;+1/$%UK&N;_"EEIWA+3+G53HFE?TI7W[:7[(&G_!X_M"W'[4?[/LGP
M&&OKX5/QGL?B_P" M3^%O_"3//\ 91X>'CS3=>N_#+:T+G]PVF+J9O$F_=O"
MK\4_]HK]FO\ 9Q_;L^!Q^$WQY\*6OQ>^!_C6;PKXR32=.\9>,/#.FZ^-+GMO
M$/A76+7Q'\.O$OAG6[BP\TVNI6RVVL_V??QF%IXKF$JM '\E7_!.G_@F5'_P
M4R_X-TO"?P+N?$:_#CQW:?M(?%;XU? ;QMJUK<77AM/&WA;5]?\ !$=OXIMK
M -J=QX,\1V.H^-/!^JW.G+/>Z!J,EGXLM](\13^&H/#VK?1GQ<_X)9_\%EO^
M"CFE?LX?LP?\%%OBQ^R3X,_9(_9\\:>%?$WC/Q7\ KGQMJWQC^-=SX5\*ZEX
M8M?$-N?%.@OI</B^[\.Z]K_A9=7OK7X?Z%HMYXAUCQC<^!O&DNG:3H5Y_3QX
M"\ ? W]DGX&:7X(\!Z%X-^"?P#^"'@O49[73[9X-#\(>"/!WA^VOM>\0:YJV
MI7\Y(5%&J^)?%?B?7+ZYU+5=1N-6\1^(=3O=3O;^_GU?@]\</@Y^T)X+@^(_
MP*^*'@3XO> ;K4+_ $FW\9?#GQ/I'B[PU/JFE2+%J6GQ:SHEU>6+WEA*Z1W=
MNLQE@=U615+#(!_/A^VG_P $K?VV?!O_  4S^%W_  4R_P""96I?L[Q>)M%^
M%_A[X6^._A!\>]:\;:3X7O\ ^S?"5_\ "2&]@M/"=A +[P39_#-O"K2:1;^*
M="UW2/$7@JVUG2H?$4E\-*@QOV'?^"-W[<'P+_:X_;X_:B_:,^-W[/\ \4=<
M_;1_9D^)7@234?!=[\1-*U#2_C'\6[OP3XGUNVN_#>L>!/[.T7X5^#]>TS7_
M  KX4O\ 3/$^N:Y<^$-+\,7TOA/2+J]O-!T7^A?XN?M#? GX!?\ "'?\+N^,
M'PX^$W_"PO$,7A+P+_PL+Q?H?A/_ (2_Q1-Y7E>'_#O]M7EG_:^KR>?!LL++
MSKEO-CQ'\ZY]CH _)[_@B[^PE\7/^"<_[$&A?LU?&WQ%\./%/CK2_B/\0O%]
MQJWPKU?Q-K?A)],\6:A:7>G00W_BWPAX'UAKZ&.!UO8GT&.WC<J(+FY4EE^<
MO^"*G_!+3]H'_@G#\(_VM/ /QP\8?!SQ5K'QY^(__"7^$+GX5>(/&VN:9INF
M?\(SJ.B^1XDF\7?#WP-=6=]]JNXI/*TNSUBW^SJ[_:?,"Q-^]U4M2U+3M%T[
M4-8UC4++2=(TFRNM2U35-2NH+#3M-TZQ@DNK[4-0OKJ2*VL[*SMHI;BZNKF6
M."W@CDFFD2-&8 '\=G_$//\ MH_\.=/^'>W_  L[]E__ (7/_P -U_\ #3O_
M  D__":?%?\ X5A_P@7_  J3_A O[(_MK_A2G_"5_P#"7_VQ_I/V#_A"O[&_
MLW]]_;_VK_0Z_1K]OO\ X)2?M#_M4>/?^"-WBGX>^,_@OHVG_P#!/+Q?H>O_
M !IA\9>(O'&GWGB>STS6?V9=1GB^%\>B?#KQ%!K5R\'P8\4)"GBNX\%1-+?Z
M KS1I=:B^E?KO\!OVP?V6/VI+_QKIG[./[07PD^.%]\.I],@\;0?##QOH7C'
M_A'3K27+Z/<7TNBWEW";#538ZA%IVI023:?>7.FZG:6]U)=:;?0V_P!'T ?A
M[\8/^":'QR^(7_!<C]E__@I?I?BGX1Q? /X*_ ?Q%\+?%W@_5M;\7Q_%G4]<
MUCX?_M%^$X;G0?#]OX#O?!E[HHO_ (N^');B;4_'FE7@L;+7'33Y9K:PMM3_
M #8^'O\ P2+_ ."E_P#P3N\6?%_X<?L'^%?^"=/[3O[+/Q.^*%[XR^'-K^VA
MX(UO5_BS\%H?$=EIEA<QZGJ^F66DW.K:;X<TS2-+T64V7BWQ;8^(9M*'C/3?
MASX7UGQ)XDT6;^NFB@#^9_\ ;E_X)!_MD_M?_#3_ ()<6(\:?LH:!\3?V1?'
MWB?XB?M$-H]OXH^&GPXUW5O%GBKX:>)KVU^"_ASP/\(;ZVFM;0>$-6LHSXCT
MGP;/?.=.O]0GGOM0U.XM_KC_ (*-?\$X_C?^U[^W+_P2^_:9^&OBGX5:)X#_
M &*/B]?>/_BII/CC7/%VF^+M?T:Z\=?";Q/';?#^PT#P-XFT;5=3%AX#U>%X
M?$>O>%+47ESIL:WK0S75Q9_M17EOQB^.'P<_9[\%S_$?XZ_%#P)\(? -KJ%A
MI-QXR^(WB?2/"/AJ#5-5D>+3=/EUG6[JSL4O+^5'CM+=IA+.Z,L:L5. #^?'
M]MG_ ()K?\%"_#G_  5BT#_@IS_P3HO?V<M;\0>+OA18_#3XC^%/VB=>\76>
MC:9KR^$K_P"'5SXBN=*\-V-K>7WA&W\(Z?X%U.R3PYXE3Q%'XLT.]-SH&HZ/
M=2PWW]*%I!<RZ7;6VM"TN[N33X8-66*/?87-R]NL=^(XIHUWVDTIE"1RQ+NA
M8*\8R5!I&K:7K^E:9KNB:A9ZMHNM:?9:MI&JZ=<17>GZGI>I6T5YI^H6-W S
MPW-G>VDT-S;7$+O%-#(DD;,C G0H _DR^$O_  2X_P""PG_!,C5_VD/A!_P3
M!^)_[)GBW]ES]H+QS=^)_ ][^T'<^.K;XL? :[U+1_[-BUU+;3M,G\,ZGKOA
M_2+;2O"LFO2?\)]:^+SX?T#Q/=?#WP])-J.B6EC4O^#=OXF>#?\ @C?K?[ W
MPE^*'PIUC]I7XH_'/P/\>_C!\2/'5]XM\-_"Q]<T&&VTZ7P?X/O- \"^*_&+
M^&?"^A:?8Z?H%WK7AM+WQ'K=QXC\47EKX3M]>MO"VA_UBT4 ><?!WPAJ?P]^
M$?PL\ ZU/8W6L>!_AQX'\(:M<Z7+<3:9<:GX:\,Z7HM_/ITUW;65U+8RW5E+
M):2W-G:7$ENT;S6T$A:)/Y'O^#MCPI>>.];_ ."7/@?3]4_L._\ &7Q@^,WA
M2QUORI)_['O/$-W\ =(MM4\B*6WEF_L^:\2[\J.>&23R=B2QL0Z_UI^%/CM\
M$/'?C_QM\*/ _P 9/A5XR^*7PT\K_A8_PU\*?$/PCXB\?_#_ ,^5(8?^$V\&
MZ1J]YXB\*>=-(D47]NZ=8>9*Z1IEF /E'[2O[$'[+7[8.K?";7?VC_A-I_Q-
MU;X&>([WQ;\*;R^\1^,]!;PCXAU&Y\/WE[J5O'X2\2:!!J3SW/A70)3!K<6I
M6J'3D6.!$FNEG /P0O\ _@E[_P %3_VY_P!N7]DSXS?\%//B)^RI8? []AC7
MK3Q5X%T7]FN+Q:UY\8?%MGK?A#Q9=:O?Z5XMTI;K1XO'>M>"?"-K\0[F]U#0
MK"PTGPN-&\"> ]/?6KSQ,O0^+?\ @F-_P4I_8A_;G_:G_:\_X)4^,/V8_&'@
M/]LN\F\3_%+X+_M.3>-]/NO"GQ#\0^)M6\2:SK7AV7PF-.TW6=&T+Q1XC\3>
M*_#%U-XFT*?2-&\3ZGX&F\&^(TT?3]<UC^GJB@#^:_\ 8P_X)4_MY_L/_ C]
ML?X\^!?BY^SW\0?^"K'[8WQ3\._$?Q3XL\:VOB-?V<O#>E0?%BX\=>-?#%O)
MIW@NS\5ZKJ7CVP\3>/+WQ%J5IX;\-:9!J^I>%=#\/V>D0^#O^$S\0\)_P3__
M ."2?[9L7_!3F3_@J%^V]I7[*GP-\1Z#X.U[1_"/P*_8_L-5TOPWJWBOQ!X(
MU;X8:EXA\:6MS;W=A]GN/#>M:SXDO;R7QAXPU[Q!XNO]+N;E] T_0;;2V_J+
MHH _F3\'_P#!-7_@HQ^R7_P5[^/_ .UM^R%J'[->O?LR?ME^-- U?XSI\7=>
M\82>-_ WAK6/&'A7QQ\6Y=!T/2-.L,^.9-9B\>6_PQGM]1\4>%%T[Q#81>*]
M,L)K6.:P_!S_ ((5^!?^"J)^'7[>'C7_ ()J>*OV:X)O&7Q%T7X5_$GP]\>X
M/$L.O^&M4M+7Q3>^"OBQ\)M4TQ)O#?\ PD/A:W\9>*6U+3?&,-[HDZV^E32^
M&?&4T5OIMG_HGU\I_LK_ +$'[+7[$VD^.-"_9>^$VG_"C2?B1XC@\6^-K/3_
M !'XS\1+KOB&VMI+.#4I9/&7B3Q'/:/';2R1"#3I;.U(;<T!<!@ ?SY>%O\
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MM^#_ !%H5CXDN+ZPU>+7O#IEG:*[1P#]#_V!?^"TUO\ M$>)?VTOA1^U_P#
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M>\9CQCHB:Q_PE\7@W5/B-K5QIUQX*T7QGX1\6:?%X=6/Q38Z??S7-J >_?\
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M-5\-SZEIUU:Z%XBT_4[30]1TE8KWYYOO^"_'QW^/'BCXTZQ_P39_X)J_$O\
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MH71=8L-3N=9TKPYJ6H:DUIX>UZW6V,MA=I%^,7P3_9\^$GP5^"B_LE_M[?\
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MT7=A:^"OAC<>%==\*7&D?$:+5+]/#<'+_P#!2OX$_&_QW_P6Y_X)"?%?P/\
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M'PT_X)^_$'0OA3XCUWQWH'[3O[0,6J^*?%OPG^"GB+1-!\:Z]X2\%:-XKM_
M.@Z+K>O:UI-C\.=8UR[U?4-*.A_\+ T_0TT.[DGL-:N?BS]CSX%_M3_MG_\
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M^"8?_!3+PS_P46\$?%JUU3X6>(OV?_VC/V;OB#>?"W]I']G_ ,3ZG_PD%_\
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M  9\->-_@UIGPQ\3:S?^+_B9\0_$GV/4W\'W7A#1_A_XBN="\,>'/!EMXO\
M&>O^+[2ZUR2UTSPI*DNCVUO=S:EIW[6_LV>/?B)\4_V?O@M\2?B[\/;GX3?%
M+QW\,O!GBOXA_#"]@U&UN_A_XQUS0;+4/$/A"YM]7BAU6";0-3GN=-DBU&*.
M\1K<K<(LH85_/1X8_95^+_A[_@Y(\ _%FZ^$OQA\1?!'X>_L1Z/X(TG]H?6_
M 7C&Z^']SXSTGX6S^"WCOOB>VEMX1G\9:E9WFHVM_82:U)J,UUJ-TK0&9P1_
M4'0!_/G\:?\ @M#\>/$?[3_[0/[,_P#P3C_8"\5_MQ7W['QN[7]ISQU)\5?#
M_P */#_AOQ1ITNNV.H^ _!%GJND:Q>^+?$EOK'A[7-!M+2%U\4>(O$GA3Q;H
M_A'P)XBT[3(_$D_YR_\ !7W_ (* ?"G_ (*5?\&_$_[2OPKTS5/#'VG]H7X1
M^"_B+X!UJXCO]3^''Q0T&YAU#Q-X.EUFWMK.T\0V%O::[H^L^'O$=O9:<VN^
M&=:T;4K_ $7P]JMSJ'A[2OC'XV_L;0?L,_\ !0G]NSQ3^V9^S+_P47^+'[-?
M[1?Q6USX[? _XZ_\$^/$GB^TTG3+7Q[XT\;^*I?!7Q,L=(UKPYH=[XBL;OQ?
M:^$7C\5^*_#>OZ)JGAB^UK1="\1^$_B!H^MVWT#^TG^QD-0_X('?$OP/^Q-^
MPW^VY\.)?BE^V;X8^)UC^SS\6O#?CKXE?M#ZC:Z0NB^$;WXE:AX T;PY<Z[X
M:TG7=(\+:7.UI!;ZO9I965KJS:]>6VH6[1 '[!?'K_@JI>?L@>#?V"?V0?V>
M_P!GGQ)^UQ^V[^T;^S[\,_$/PX^"6C>*-,\!:%I/@NS\"&"3QIXR\9:M:W\-
MC8R3^%/%5S9VD=G!IBZ/X,\8ZQXH\5>#=.TFSNM5]#_8Q_X+&:/\8O%7[77P
M1_;*^!VJ?L0_M-?L1^"]=^+OQN^&FM^,;3XH>'(_@=X=\/Z+XAUCXI:!XT\.
MZ+IT%_9:18Z[I5]J&GV-CJNGWOA[Q#X-\2>$_$WBJT\17EMX?_%+_@JY^P=\
M9=/_ &@?^"<W[<VH?L\_M,_'KX!^$OV1?AC^SO\ M&_#/]E34O%WA;]ISX:Z
M[X:\,>-[RU\16<'A^VD\3Z9ILC>/8EO8$TZ+1A>^ ]>\'>.-<\&R>./#NJOZ
MA^P7^QU^RG^UG'^W=-^RU^S!_P %%_@!K7QJ_8B^*_[-T/[3/[>NL>)%T3QE
M?_%F"U\/VGA_1=%DU#Q4GBVV\'ZOX/T#6]7O+?QK/>:3I^CV^D2:':R7]M)
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M#)J$GA>YO/ 4&N>*? MM\0HO#?V;6_Z>*_SP?@U\"OV6?B+\/O@C^R]^T/\
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M/->Z-IWAWQ!IUY\6?$/@'Q?I.M:GI/B!]>T+3/$>A^&]:\+ZYHNHW(!^_/\
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M;I_BAX/U2#2K2WU 6$?S+^U!^QK\1K;_ (*1?\$!$^&O[.'QOOO@)^S9\*?
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M/AA=^'?$Z64GAG7;/Q[?:K!X6N](\2)J6G-X?U&WU26TUK^T+$:9+=&[MQ(
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M3%\;(B>OYKO^"V7_  5TC\%?LO?!#XC?\$UOVT/A7KOB2[_:V\$?#/XHZO\
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M1:\+0WWB&]\/6FDQ7]CHRRZH=-M])C$Z]]\=_P!N+]CG]E_6]+\,?M$?M/\
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M'@6+QLWC34-0.DV7@E=#DUM;MO&MUJFS38?!X0^)'O[BTM!I?VB]M(YOK:@
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M%+?3M:GL;R5=;TF9(6AU&SDF[RR_:-^ 6I?!5_VD=/\ C/\ #&]_9_CT*_\
M$\GQIMO&WAZ;X8IX>TJ]N=-U+6&\:QW[>'UT^PU*SNM.N[DW_EV]_;364A6Y
MC>( 'L]%<'\,?BE\-_C5X%T#XG_"+QSX5^)7PZ\50WEQX9\<>"=;L/$?A?7X
M-/U*]T>^GTC6]+GN;"_AM=5TZ_T^>2VGD1+NTN(2V^)@/PV;_@X8_9#?_@H;
M?_L=?\)5\'=*^!?A[P5<^(M;_;.UOX]^$K?X8:CXG7PKINNP>!/#EI'IW]C3
M7]OJFIMX>U'4+WQREU#K.CZMIL?A]GC6Z0 _H%HK^6_]@_\ X*C?$E_^"E__
M  5O^'_[9W[4_A'PI^RS^S)\0/%'A_X5I\4;GX8?#CPAX CB^->O^$=!T>W\
M7-I/AS4M8U"ZTBSMM'TRQUO7-9U/5)HT6WCNM0D+O_2!\'_C;\(/V@O 6E_%
M+X'?$OP3\6/AUK,EW#IOC/P%XCTSQ-X>N;G3YFM]0L_[1TNXN((;_3[A6@O[
M"X:*\LI@8KJ")_EH ]0HKY*^&_[>W[$?QB^)\GP5^%/[6O[.WQ%^+2W.J6<'
MP[\&?%_P+XA\6ZG=:'IUQJVN6^AZ-IFMW-WK\VB:99WU]K$>B1Z@VE6VFZG+
M?BW73+\V_P!:T %%?Q;?!'_@L=_P7*_:H\9_MF3_ +*WP-_8H^*/A/\ 8R^(
M1T;QQX2\3:5XN\'^+M0\'ZQJ_P 6K?0=4TN^UCXY^&=$U:XL=,^$^LMK7DZQ
MIM^-1NM(;3=$U6WN;V"R_H-_X)'?\%&[+_@J!^R)I_[1)^'MS\,?%>A>._$'
MPH^(OA5;Q]4\/Q^-_"^D>&M?NM3\&ZM.D-[J'A?5M#\7Z#?6XU&VAOM)U.75
M?#\\VJ#1TUO4P#]/**^1?#W[?O[#GBSXNR_ /PQ^UY^S?K_QGCU)M#7X:Z3\
M9/ -_P"++OQ%'=7UE=>%M-TNWUV275?%NGW6FWT6K>%--^U^(M(-NS:GIEHC
M1L_>?';]JS]F3]E^QTO4?VC?V@?@W\#K?7H=1G\.Q_%/XC>$_!-]XF32/LO]
MJKX7TO7]5L=3\2S:=]NLOMMOH5IJ$]M]KMO.C3SXMP![]17S]\'OVK_V9OV@
MO .M_%'X(?'OX3?%7X?^%[66\\5^*O _CKP]X@TSPC#!I\NJW"^+FL+Z6;PK
M<V^F03W]Q9^((=-O(+6&6>:!(XW8<GX3_;J_8T\?:[\(O"_@3]I[X(>-_$?Q
M[D\2K\&M#\'?$3PWXHU7XC1>#AXB'BF^\,6.AW]_<7VE:#/X1\2V.IZQY::5
M;:IHM_I+W@U.$VA /JVBOR:_;N_X*0?L]^"?V;_VV/"WP"_; ^ \?[7?P;_9
M^^._B#PQX&\-?$[X9^)?B9X9^(?PZ\"^*M8GAA\!WE_J\FI>(/!=[X?O+SQ'
MX<NM%U&?0QIET/$6EV\$4JUTW_!&/X]_%O\ :>_X)F_LM?'7XZ^,;GQ_\5_'
M^A?$"[\7^+[O3-#T:XUFXT;XO_$+PUILLNF^&M+T;1+4VNB:-IE@JV&F6J2)
M:K-,LES)--( ?I_17B7QV_:5_9\_9@\*0^./VBOC3\,O@GX4O+J:PTS6?B7X
MST+PC!K>IP6DM_)H_AZ'6+VUNO$6MBR@GNDT70X-0U66"&26*S=$8C$L_P!K
MO]E?4O@GJO[26E_M&_!'5?V?=">.+7/C5I/Q.\':I\,-%N)-3L-%%GJ_C6PU
MBX\/Z;?1ZSJFG:3/87M]!>6VIWMM87$$5U*D1 /HBBOY#/\ @E7_ ,%$?VE/
M^"@O_!2SXM>)_&O_  43^&G@+X%^"OC3\5/!_P $/V#]-T+X9MXG_: ^&$/A
M/XBZEH.J^&-7$-KXHO[/P'IWA_PIX\UOQG8R^+M1U]-,\66EO/X1\/7!6X_H
M8_X*0?M$>._V2_V&?VF/VC_AC:>'+[Q]\(?AM?>+?"UIXOT^^U7PU/JEOJ&G
M6L::QIVFZIHM]=V?EW<I:*VU6QD+A")P 58 ^VZ*_CI^#/\ P5V_X+PZS^R+
MX)_X*&W7['/[(O[1G[(FM:/X^\8^,;/X37WCGP-\8_"/A+X7>/\ Q+\/O&-S
M?Z;K?Q)\1W%I'#>^#]=UD:EX:^'WQ1@TOPW&OB'7(M.M+34;6W^^O'7_  4^
M\0_MU?\ !*BU_:Q_87_:E^!7[!'Q57XG^%O ?C_Q7^U?X@\*P^!_A)XNL)(;
MKQ?\,-8\0^*/A5\1_#NMWWB32-4T35O ^NV_@2%]=T35+"Z=?#.L#5=%TT _
MH<HKY9TW]I[X*_#?2?@GX$^.7[2'P3TWXO\ Q ^$]IXSL1J/CWPIX>7XE6?A
MCP;_ ,)!X_\ B)X,LKYO#ZZAX+MK73-;\3W&L6.DZ?I6G:#!-?3V^FV=O)'!
M$_[<W[',7P+MOVG+K]IGX+:=^SW?ZYK'AG2OC'JOC_P_I/P_USQ#H.KZQH6H
MZ+X>\1ZG>6EAXAU/^UO#^M6EA9Z))?SZN=.N)M(2^MU65@#ZKHKR+X*_'_X&
M_M(^#Y?B!^S]\7_AM\:O!-OJ]UX?N_%/PO\ &?A_QOHEAX@LK6QOKS0=1O\
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M;X<_$_P[X>U:!+;5-"T+Q]X/T;Q7I&C:E;1 16^H:7I^K6]C>01@)%<P21H
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MS?9O$7B";P[XF^-6A?#CXI75E-=(+SX9>!]?_:1L_ /ACQ ]C:SQ)X2TC4_
M?P^AMFN[:5%UGPWX1B_TB\DCANO[+_AE_P $]?V/_@Y^ROXT_8H^&_PB_P"$
M<_9D^(>F>.='\8?#/_A/OB?J_P#;&G?$JSDL/&MM_P )GKWC75/B!I_]M6DK
MQ>=I?BNRGT[=YFDRV$H#C:\/_L*?LF>&OV2Q^PM8?!?0+W]E >'=8\+#X/\
MB75?%/C+2AH^N>)K_P :78'B#Q=KVN>,O[4M/%^HS>)] \0?\)'_ &_X7UZ#
M3=5\-:GI-[H^DS60!_*=X5_8#_:ZN?VL?^"97[4_P@_99_X)Y?L2> /@_P#%
M#P#IMSXN_98_:<T Q_M+_!_Q!XE\)C7/#]Q?-;^3\5O$FJ^ (?&VCVFN6MWX
M@\6>/+'QKJ-IKVI:ZEMHOV#^JK_@H+_R83^V[_V:'^TI_P"J9\:5\5?LY?\
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M;1OL'V!X&TRZO;*YL_&;_@F+^P[^T'^SG\'/V2_B_P#!'_A+OV??@!_PC/\
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M'Q1>>-K:?QFWA[XC:SJ=CXY\1Z?#K'CO0_$&H:+IDNCZ5X>GTG3/"WA6ST4
MU_\ @KA^RMK?[:O[ 'QU_9K\.?%;P?\ !G7/B*?AW'H_C7X@WEUIW@=M8T'X
MH>#?$FA^%_$^H63F\L=/\::WI.G>%8KJSL]8NX-0U:RDM- UVY$6DW?\_/\
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MX)K_ /#,/_#&O_#-_P#QC;_PM[_A?/\ PKC_ (7!\>_^2K_\(W_PB'_"5?\
M"8?\+2_X3W_D7?\ B7_V'_PE'_"-_P#+W_8_V[_2: /Y%?\ @K1^SC^PK\!?
M^"-?_!+/XT_LQZ%X!\*?M*^-=5^!OB+2OBIX+BT?1/C7\4+:_P#@AX@\6?%C
MQ9XOOM&UFY\07^I^&OBPO@N349GU+7)/ACXNO],\&Z5-I,%]Y2_37_!2_P#9
M"_:D_9H_:M^-O_!82[\!_L,?MG_#N3X2_"32?VGOV<?VE]&T+QG/\&-3OOAC
M\'_!VM:7'X'\8W45E;:O=7.EZ5??#O7_  _K<7C'^S/%]WH<G@'5]"U.X7Q/
M^_7PZ_X("?\ !*SX4?'_ ,,?M%^!OV;(M-\6^"]2L_$'A3PKJ'COQWXE^&>B
M>*].G>ZT_P 56O@?Q/X@UC3YM4T^Z9+S3;*]DNO#FEZC;6>JZ;H5IJMG;7L>
MC^T__P $(_\ @FS^V#\?]?\ VE?CG\(_%_B#XF^,[G3;OQ]/I?Q?^)WA_1/'
M$VB>&-&\'Z%_:^DZ5XF@724T;0- TRSLX_!L_A9)3"\M^+V25V(!_/3_ ,%I
M/&'[/?[7O_!!?]C3]M[X3?LL>!O@EJFH_$[X=?#3PS9:?X+\+W'BOX/?"WP6
MOQ^\#W_PG\/^/M,\+:#JEM\((/'7AQ;KPWIEI:^'O#6JK=Z%JH\/6.H7L-O'
MU?\ P5[^&_P+^&G[)W_!$:T^ ?@#X4_#SPUXS_:2^"/Q(\0V?PC\)^$O"&C>
M*?%GBWX8_"=KSQWKEIX/T_3K/6?$GB32K#1C=^)=0CN-5U>PLM-$][<6]K:B
M/^L?XJ?L3?LO_&7]EF;]BSQS\)=#G_9I/ACPMX0L/AEH5UJWA73]"T;P1?Z5
MJOA!/#^I^&]0TO6]'N_#^J:)I=_:7MGJ4=S<SVSIJ4E];WE_!=?%_P .O^"%
M?_!-#X<_"OP/\'[;X'>(/$_A3X=_&A_VA/"TWB?XQ?%]M8M/BY_8_AWP]#XJ
MGO?#GC;PY#>1VNA^$_#NF0>'[BT?PR(=,2>71Y;VYOKJZ /P?_X*K_L^?L\Z
M=_P<2_\ !,_1=;^!WP:L_AU\>=(\.:I\7-(U+X9>"H?!?QF^(7B?XK_%VPU;
M4_B/I]QH8T3XB>,=>O+OPO:ZI?\ B>'6-9U*:XT*.\FF:2P![3X<VW@3X2?\
M'95[X1T?2O#W@#P/KW[+GA?P)\&/#^@:58>'O!IT;P[^RGX(LM#\->!]-TJW
MM-#L- T?3/A_KVAZ+IVD0P:79'P[)H6GPQR6T5HO]$G[=W_!,7]C[_@H]IO@
M"S_:B\ ZQXBU/X676M7'@'Q3X6\8>(_!?B7P[#XEET27Q'IT=YH=]!9ZEIVM
M-X=T?S[?6M/U(V+V?VC1I-,NY[FXF\6^/W_!#W_@FS^TIX6^!GA7XF_ O49H
MOV<OAIX.^#/PHUSP_P#$SXDZ!XGT7X3^!KE[G0O >J:W9^*/M'B?28'N-0VW
MWB,:GXALGU75;G2-:TV]O[BZ8 _&O_@G3XO^%O[1W_!QQ_P5^O=*BT'XB?"_
MQ1^SUKGPPURRU>PTW7_"GBZU\':Y^SI\)/'VD7EA=#4-&\1>%M4U;PWXATMD
MG2[TO7M%D#R12VEZ8CX?_P $@_@!^SO:?\%N_P#@K=X0USX&? D3_ _XA>+/
M&G[-OA/Q7\-/ T.F?"74/"GQ^E/@SQ)\)-)U#14B^'BZ"]_X-70M;\$PZ--I
M5O=Z VE75NLFGM7]//[,'_!,+]A3]C'XG^(/C)^S%\ -'^$GQ$\4_#K1OA3K
M^LZ%XN^(U]I^H^!]#B\*1V>G-X5U_P 8:OX0MM2N9O!7A[4=;\3V6@VWBGQ)
MK5OJ&N^(=:U/6=>UZ^U/RWXN_P#!&W]@/XV_M?>'OVY/'/PIUQ_V@M#\4^"/
M'%UKFA_$/QOH'A_Q/XO^&H\/+X#\0^)/"^F:U!I5Q>^'?^$4\/%8M-CTJQUM
MM,B?Q/9ZVTMT9P#^*#_@F[^S=^T-^W#^RW^W#I&C_L@?L;_M-?&[XI?$GXD6
M7Q=_:%_:9^+T?A7]K7X*^,=:\.:-J5GXL\,Z'JFG3:UX+T[1O&=]JOB^+Q5"
MNFV'CGQ:GBOP?XNN-:T?PW=>']/_ +=?^"/'PV^-'P<_X)Q_LU?"?X_>+?#'
MCOXD?#O1?&GA.X\6>#?B#IWQ/\-:EX5TKXE>,HOA]8Z3XQTHO87]KX6\"'P[
MX/CM;>>X&ECP\-->19+5X(?(/VF/^""'_!+_ /:M^+?B#XX_$OX!7ND_$CQK
MXB3Q1\0]8^''Q!\<?#_3OB#JKNLVJ7/B;PUH&MP>&DOO$EVO]I>*->\/Z3H7
MB?Q#K4MUK^IZY<:Y?7NHW'Z@_!;X,_#3]GCX4^ _@C\'?#$/@SX7_#/P[9>%
M?!/A>#4-7U=-&T.P#?9[4ZKK^H:KKFI2[I));B_U;4K[4+N>22>ZNIII'<@'
M\=7Q!_9X^%_[3'_!V9\0_ /QG\*^'_B!\-=*^#WA?QIXC^'/C#1;7Q%X/\=R
M:#^RIX$AT#2/%&AZ@S:=J>EZ3XFU'1O&$5GJ-IJ%C/JOAC38[FQEC8O%P_PL
M\/ZO^Q[_ ,%*O^#B[X2?L=V=[\,M#\)?\$\OBC\5/AIX*^'EK#I,/A7XAV/P
M[^&GC/POJ?@72]$M;7^S+[P/JWQ/\:-\/])T>!5TX7]MIMI:W;QVZ-_7!8?L
M'?LHZ9^UYK7[>-C\*O(_:N\0^&8O!^L?%7_A.?B1)]L\.0>&M)\'Q:=_P@TW
MC"3X;V^WP[H>EZ=]KM?!\%^WV7[6UT;Z>YNIM/P+^Q-^S%\-/VH?BS^V=X)^
M&?\ 8O[2OQQ\,V/@_P"*7Q(_X3/X@ZE_PE'AS3HO",%EIW_"'ZMXKO\ P#HG
MDQ>!/"J_:_#OA;2+Z3^RMTMU(U]J1O #^,_]AW]D+_@FGX[_ .#<#]H_X^?$
MSP#\)]0_:&TCP-^TKJ_BGXN>()M,'Q3\%_''P1?^,+O]GWPIX0\37U_!K7AM
M/$%A9_#!+7P+HM]I.D?$6ZUZ]T[6M/UA=8N]_P !?M(ZKX\^/O\ P2Y_X(!>
M&/C-+K\]I??&[]I[X,^'_$-[J<LVM:Q\)-)^+OPD\#>%9+">6)9--M/">@*_
M@#PS!^^2VT;P;I4T#F!XD3^Q;QS_ ,&Y_P#P2)\??$J_^)>I_LP2Z-/K.L:E
MK^O>"O!GQ0^*7@OX;ZKJNIW7VQY8/!WAOQ=IUCX7L+.5[E--\/\ @:3PMX;L
M+6[FL[?1TM4MH;?[A^.G_!-_]B?]I'3/V>-#^+OP'T36M!_9/N(+C]GCP_X:
M\3>/?AKX>^%PM(_"L%E9:'H/PQ\5^#M(NM)L+?P1X6MM/T76K+5-'L+72(K6
MSL8+>>\CN #^5']LO]@?]D7PW_P<A_L!?LT^#/@5\/\ P+\ OB_^S[X7^(7Q
M/^#_ (/T"QT'X<^.=;\&:O\ M+:S:VOB+P=811:!J&AZU/\ !;P GBC0YK Z
M9XC.E376KVUW?7][<S_0W_!+;X9^"/V=?^#E;_@IY\ O@KH%E\._@S9?LSS^
M*].^&WAN,:?X1TO5]0\0_LF>)XSI>BP!++3K'1]1^)/C2'P]IMG%#8:!I>N7
M&DZ7;VVGK%;I_2IXX_8:_9:^(_[5OPN_;>\9_"[^V?VH/@OX0?P'\-/B=_PF
MWQ%T[_A&O"C_ /"=[M*_X0O2O%UC\/=8S_PLSQO_ *=K_A/5=2']M\7@_LW2
M/L!X'_8:_9:^''[5OQ1_;>\&?"[^QOVH/C1X07P'\2_B=_PFWQ%U'_A)?"B?
M\()MTK_A"]5\77WP]T?'_"L_!'^G:!X3TK4C_8G-X?[2U?[> ?PW?![_ )0Y
M?\'$7_9WG@G_ -7WX/KT'X[_ +!_[,OA;_@UX^$_[3$?PK\%7'[2"K\+_B+=
M?'6/PQI-K\3M7_X3WX]-X-3PCK?B]X;O7]0\'^'/ 'B>S\)Z3X>&IP:1&GAC
M0=2BL+:XMWB?^O+1_P#@E#^P'H'P<_:(^ &D_ 3[)\(_VK_%]EX\^/WA+_A:
M7QIG_P"$]\5Z=K]GXHL]5_MZY^(TWB;PMY.NV%I??8?!>L^'--D\K[-+9O9R
M2V[^A>*?^">O['_C3]D/2OV#O$WPB_M+]E'1-,\-:/IGPJ_X3[XGV?V;3O"'
MB6T\8>';;_A.=/\ &MK\2)O[.\16-KJ/G7'C"6>[\K[)?2W-B\EJX!_&K^W5
MXF^,'QI_;\_X(C>'_'G@KX4?M%Z+XA_X)K? ?XB^"OA1^U1XW_X03]GCXF_&
MSQOX(^(E[XVOO&VO7D']@7/BS7=7\.^!ISX8F!M?&FLZ)\.?!^H:;?VOB2'2
M-7^L?@Q^R/\ M\_L8_$G_@KK\?\ 2_AW^S_^RAH7Q;_X)R?'KQEX4_9@_97^
M-=GXCC^'OQJ\'^#_  ]/X$^)G@/X7Z;9V^O:5]GN;'XCZAX7EL=-MM%T#Q-X
MYD\/^'HK?2I-+T2+^E+]HK_@F+^PY^U;\#OA-^SO\=/@5I/C+X9? ;1-'\._
M!BW_ .$D\::1XM^&^BZ'X<TSPG9:9X=^(>C^(K+QX=/N="T30[77=/U3Q%J5
MAXJGT+0]1\4VVLZGHVF7EKSO["?_  2I_8L_X)RW'C+5_P!F'X>:[H/BWXAZ
M?9:1XV\:^+/'GB[QIXA\0:1IFI7>JZ;ILD>M:K+X?TNVL[N\D8MH.A:3<WXC
MMFU:?4)K>*50#^'_ /9._84^.'[8W_!)FVT3X'_L@?L!W;W'BO6?%>N?MQ^)
M_CWI?AG]J?P'XM\*_$_4KV\M?'<]_:&X\"Z.?"MB_A6R\$ZU?V/AG4O!&HZ1
M\1[;3I_$.J:?XJD_T#?V/['XDZ5^R=^S+I7QDUZQ\5_%K2O@%\(=+^)?BS3/
M$MOXST[Q;XZTWP!H%EXI\5V7BRT5;7Q';>)M:@O-=AUFV,D&H)J N8IIXY%F
MD_,+X@?\&Y'_  2,^(OQ)N_B3J/[-5[X=FU?6]4\0^(O!/@3XH_$SP5\.-=U
M+59)IW5/"/A_Q19VOA/3+*>XFETO0OAY-X.T/3DD-G;:<FGJEFO[8^']!TCP
MMH.B>&/#]C#I>@^'-(TW0=$TRW,A@T[2-(LX=/TVQ@,KR2F&TLK>&WC,DCR%
M(U+NS98@'\$?[9G[.GQ5_P""3/[2G[5W[>GQ-^!/[ W_  4J_8W_ &IOVF/$
M-KXQT_XRZ;X5\5?%'P!XC\2_$+QUXNNOAWX:D\7V6NWWP[^(VD7MQKOAWQ!J
M7A6Q^)NDW-MX8TO6O%7A32+_ $"SL_#>9XP\=?$+]LS_ (+H^+?&VA_LP?L[
M_M+0^+?V,/V=_'?[+?[-_P"W/XNM/!_PT\._#?XC_ CX!_$>TM_!7AW7M/O_
M  _XX\>Z'?>/_'-Q<>"8[#5K6TU?5OB9XFL]-^W^#?MNA?TL>,?^#>S_ ()6
M_$'X^>)OVB?&OP%\0>)O&'C3QKKOQ)\7:!J_Q<^*%[X%\1^/_$WBFZ\8^(/$
M^K>'IO%+2W)U?6;RX-]X;_M%?!=Q8R-I[^&3:,\3?3/[:7_!*3]A+]OU?"%W
M^TC\$;#7/%'P]\.R^$_ ?CSP=KOB'X=^-/"WAII7N;/P_;:MX-U+2(M8\/Z+
M>RW.H>'?#OBFRU_0/#M_J&KW>BZ98S:WK#7X!_,9X1_8]_:<_8S_ ."9_P#P
M7F\&_&G3_A#X#^&_Q!\/^'?B7\+_ (!?"'XV6GQ4T/X!ZOKWB/QA-XI\*?V0
M?,USPY9WGAN?X=Z-HU]XC>/5=<TCP-8M<OJ-S9W-X/CG]M75/&=[_P $[O\
M@VS^'=W8>'/$7P3\7WWB'4/&?@?XC^,+[P!\%?&_C71O''PLTKPGH_QC\<0/
M#:^#?"[^'O%/C;2IO%$MYI]QH?A?Q#X]U>&^M(M/N+^P_LF^"7_!(W]@CX ?
MLR_%G]D3X?\ P9O4^"7QYCMQ\:=%UCXC_$K4-<^(T]O966GI=ZIXKC\66NOZ
M%)]GL+?;;>"K[POIUO(;B6TL;=[JY,OI?C/_ ()P_L5?$+]DSPM^PYXT^!.A
M^)/V8O UMI-OX(^'>K^(/&M_?>#9M!FOIM'U;PQ\0+KQ+-\2=%\0V*ZIJUBG
MB.Q\7Q:Y/H^L:SH%W?W&AZQJ>G78!_/7^R9^PK^VK\*?^"MOP$_:RMOV=/V)
M_P!B7X:^)/@SX[^'?Q!^ W[,?QST"U\,_&32K?X<^/KCP]XNTWX96.GZ4-8-
MKXJG^&.K>(8O"NG1:6\?@73_ !7=M#K%QK6L7WRO_P &XW[-_P"Q+^U=X$_;
MA^)?[=/PX\$?&']L#P_\=-7U3XIZS^T,L>H:WX4\"Z]I6EZY)XM%AXGOH8?"
MWBB7XH:9\3&\6^-+;3M+\1:7+:V.FSZW;6LILJ_I"_8P_P""+?\ P3[_ &"?
MBKJ'QN_9Y^%?B/2_BE<Z;K>@:=XL\6?$OQWXPF\.>%_$"V4>H>&]#TK5M<?0
M4L3%86\$.I:GI>I^)HK;SK;^WFMYYHGX#]H7_@@-_P $M/VFOC+XD^/'Q)_9
MZN[7X@>.=?O_ !3\1)? OQ(^(G@/0?'WB+54=M3UKQ!X<\,^)+#2+/5M6U%S
MKVN:IX7MO#NH^(?$;W6O>(+K5-4U/5;F_ /PX_X*H_ +]G2V_P"#B#_@F5IF
MJ?!/X+P_#/X_Z)X9UGXK:=>_#7P0/ WQK\>^*_BK\7+/4M7^(=G+HG]@_$?Q
M;XBN;WPM;ZCJ7B2+6=7U22YT%+N>8RV&?#?C[X+\9>,_^#AOXX_"+P;^R_\
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M0[G7)=!U74M,N@#]&/\ @GU_R83^Q%_V:'^S7_ZIGP77\B/[0?PC_9_^.?\
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M1:NG@_0[S7/B%;:1;_$36]734]<U7Q5=ZQK^OWVI_0O[+O[(O[._[&'PA@^
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M_/I&AW6MZ5J%SH6CRV(!_,%\$_V0OV_OV.?B=_P5P^/&B_#CX _LJZ1\8?\
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MW_\ N\#_ -]<K^XBOX=_^#S/_G&__P!W@?\ OKE ']4W_!,7_E&Q_P $]?\
MLQW]DW_U0O@&ON*OAW_@F+_RC8_X)Z_]F._LF_\ JA? -?<5 !1110 4444
M%%%% !1110 5_G*_\'>O_*2?X(_]F._#7_U?7[2]?Z-5?YRO_!WK_P I)_@C
M_P!F._#7_P!7U^TO0!_HU4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?P[_\
M'F?_ #C?_P"[P/\ WURO[B*_AW_X/,_^<;__ '>!_P"^N4 ?U3?\$Q?^4;'_
M  3U_P"S'?V3?_5"^ :^XJ^'?^"8O_*-C_@GK_V8[^R;_P"J%\ U]Q4 %%%%
M !1110 4444 %%%% !7^<K_P=Z_\I)_@C_V8[\-?_5]?M+U_HU5_G*_\'>O_
M "DG^"/_ &8[\-?_ %?7[2] '^C51110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5_#O_P>9_\ .-__ +O _P#?7*_N(K^'?_@\S_YQO_\ =X'_ +ZY0!_5-_P3
M%_Y1L?\ !/7_ +,=_9-_]4+X!K[BKX=_X)B_\HV/^">O_9CO[)O_ *H7P#7W
M%0 4444 %%%% !1110 4444 %?YRO_!WK_RDG^"/_9COPU_]7U^TO7^C57^<
MK_P=Z_\ *2?X(_\ 9COPU_\ 5]?M+T ?Z-5%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7\.__!YG_P XW_\ N\#_ -]<K^XBOX=_^#S/_G&__P!W@?\ OKE
M']4W_!,7_E&Q_P $]?\ LQW]DW_U0O@&ON*OAW_@F+_RC8_X)Z_]F._LF_\
MJA? -?<5 !1110 4444 %%%% !1110 5_G*_\'>O_*2?X(_]F._#7_U?7[2]
M?Z-5?YRO_!WK_P I)_@C_P!F._#7_P!7U^TO0!_HU4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %?P[_\'F?_ #C?_P"[P/\ WURO[B*_AW_X/,_^<;__ '>!
M_P"^N4 ?U3?\$Q?^4;'_  3U_P"S'?V3?_5"^ :^XJ^'?^"8O_*-C_@GK_V8
M[^R;_P"J%\ U]Q4 %%%% !1110 4444 %%%% !7^<K_P=Z_\I)_@C_V8[\-?
M_5]?M+U_HU5_G*_\'>O_ "DG^"/_ &8[\-?_ %?7[2] '^C51110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5_#O_P>9_\ .-__ +O _P#?7*_N(K^'?_@\S_YQ
MO_\ =X'_ +ZY0!_5-_P3%_Y1L?\ !/7_ +,=_9-_]4+X!K[BKX=_X)B_\HV/
M^">O_9CO[)O_ *H7P#7W%0 4444 %%%% !1110 4444 %?YRO_!WK_RDG^"/
M_9COPU_]7U^TO7^C57^<K_P=Z_\ *2?X(_\ 9COPU_\ 5]?M+T ?Z-5%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7\.__!YG_P XW_\ N\#_ -]<K^XBOX=_
M^#S/_G&__P!W@?\ OKE ']4W_!,7_E&Q_P $]?\ LQW]DW_U0O@&ON*OAW_@
MF+_RC8_X)Z_]F._LF_\ JA? -?<5 !1110 4444 %%%% !1110 5_G*_\'>O
M_*2?X(_]F._#7_U?7[2]?Z-5?YRO_!WK_P I)_@C_P!F._#7_P!7U^TO0!_H
MU4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %?P[_\'F?_ #C?_P"[P/\ WURO
M[B*_AW_X/,_^<;__ '>!_P"^N4 ?U3?\$Q?^4;'_  3U_P"S'?V3?_5"^ :^
MXJ^'?^"8O_*-C_@GK_V8[^R;_P"J%\ U]Q4 %%%% !1110 4444 %%%% !7^
M<K_P=Z_\I)_@C_V8[\-?_5]?M+U_HU5_G*_\'>O_ "DG^"/_ &8[\-?_ %?7
M[2] '^C51110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_#O_P>9_\ .-__ +O
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M5^&^G-9W<^I>-H?![:M;:/%I/V;Q-IZW=SKO@ZX/B_2="M[@ \H_9F_X+2_
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MPQK&CZY??/?_  ;;?!WXN? O_@F/X6\ _&WX6?$?X.^.K?XQ_%S5+CP7\5/
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MQ3K_ ,.]"\+^'M,TVT\/ZUK6FW/AG0M1U70=66TN8:?_  6 _8D_;O\ A_\
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M'6W^'_A2+4M'MHCX&E\#^$?B/9Z)X5TFXT7X=6WCF3X/ZE'I'A;5M7\7W5D
M?TC_ ++7_!=S]D/]I_XU?#CX&S_#G]J']G3Q%\<M(FUK]G;Q+^TU\(K+X;^
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M_P"^N5_<17\._P#P>9_\XW_^[P/_ 'UR@#^J;_@F+_RC8_X)Z_\ 9CO[)O\
MZH7P#7W%7P[_ ,$Q?^4;'_!/7_LQW]DW_P!4+X!K[BH **** "BBB@ HHHH
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M_$E-5_\ G(T?\1E/C+_I'[X9_P#$E-5_^<C0!_==17\*/_$93XR_Z1^^&?\
MQ)35?_G(T?\ $93XR_Z1^^&?_$E-5_\ G(T ?W745_"C_P 1E/C+_I'[X9_\
M24U7_P"<C1_Q&4^,O^D?OAG_ ,24U7_YR- ']UU%?PH_\1E/C+_I'[X9_P#$
ME-5_^<C1_P 1E/C+_I'[X9_\24U7_P"<C0!_==17\*/_ !&4^,O^D?OAG_Q)
M35?_ )R-'_$93XR_Z1^^&?\ Q)35?_G(T ?W745_"C_Q&4^,O^D?OAG_ ,24
MU7_YR-'_ !&4^,O^D?OAG_Q)35?_ )R- ']UU%?PH_\ $93XR_Z1^^&?_$E-
M5_\ G(T?\1E/C+_I'[X9_P#$E-5_^<C0!_==17\*/_$93XR_Z1^^&?\ Q)35
M?_G(T?\ $93XR_Z1^^&?_$E-5_\ G(T ?W745_"C_P 1E/C+_I'[X9_\24U7
M_P"<C1_Q&4^,O^D?OAG_ ,24U7_YR- ']UU%?PH_\1E/C+_I'[X9_P#$E-5_
M^<C1_P 1E/C+_I'[X9_\24U7_P"<C0!_==17\*/_ !&4^,O^D?OAG_Q)35?_
M )R-'_$93XR_Z1^^&?\ Q)35?_G(T ?W745_"C_Q&4^,O^D?OAG_ ,24U7_Y
MR-'_ !&4^,O^D?OAG_Q)35?_ )R- ']UU%?PH_\ $93XR_Z1^^&?_$E-5_\
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M\1E/C+_I'[X9_P#$E-5_^<C0!_==17\*/_$93XR_Z1^^&?\ Q)35?_G(T?\
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MI-W-:G\9/^(RGQE_TC]\,_\ B2FJ_P#SD:/^(RGQE_TC]\,_^)*:K_\ .1H
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M^)*:K_\ .1H _NNHK^%'_B,I\9?](_?#/_B2FJ__ #D:/^(RGQE_TC]\,_\
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M #D: /[KJ*_A1_XC*?&7_2/WPS_XDIJO_P Y&C_B,I\9?](_?#/_ (DIJO\
M\Y&@#^ZZBOX4?^(RGQE_TC]\,_\ B2FJ_P#SD:/^(RGQE_TC]\,_^)*:K_\
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M#^ZZBOX4?^(RGQE_TC]\,_\ B2FJ_P#SD:/^(RGQE_TC]\,_^)*:K_\ .1H
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M/$7AKX,^"]&UO2[RVN(XI[>ZT_4K*YM+B">*.:*:)XY(T=64?7M%% !1110
M4444 %%%% !1110 4444 <!\2/A/\+/C)X>_X1'XO?#3P!\5?"GVRWU'_A&/
MB1X-\.^.?#W]H6A8VM]_8OB?3=4TW[9;%F-O<_9O.A+,8W7)KP+_ (=]?L$_
M]&1?LA_^(U_!G_YBZ^O** /D/_AWU^P3_P!&1?LA_P#B-?P9_P#F+H_X=]?L
M$_\ 1D7[(?\ XC7\&?\ YBZ^O** /D/_ (=]?L$_]&1?LA_^(U_!G_YBZ/\
MAWU^P3_T9%^R'_XC7\&?_F+KZ\HH ^0_^'?7[!/_ $9%^R'_ .(U_!G_ .8N
MC_AWU^P3_P!&1?LA_P#B-?P9_P#F+KZ\HH ^0_\ AWU^P3_T9%^R'_XC7\&?
M_F+H_P"'?7[!/_1D7[(?_B-?P9_^8NOKRB@#Y#_X=]?L$_\ 1D7[(?\ XC7\
M&?\ YBZ/^'?7[!/_ $9%^R'_ .(U_!G_ .8NOKRB@#Y#_P"'?7[!/_1D7[(?
M_B-?P9_^8NC_ (=]?L$_]&1?LA_^(U_!G_YBZ^O** /D/_AWU^P3_P!&1?LA
M_P#B-?P9_P#F+H_X=]?L$_\ 1D7[(?\ XC7\&?\ YBZ^O** /D/_ (=]?L$_
M]&1?LA_^(U_!G_YBZ/\ AWU^P3_T9%^R'_XC7\&?_F+KZ\HH ^0_^'?7[!/_
M $9%^R'_ .(U_!G_ .8NC_AWU^P3_P!&1?LA_P#B-?P9_P#F+KZ\HH ^0_\
MAWU^P3_T9%^R'_XC7\&?_F+H_P"'?7[!/_1D7[(?_B-?P9_^8NOKRB@#Y#_X
M=]?L$_\ 1D7[(?\ XC7\&?\ YBZ/^'?7[!/_ $9%^R'_ .(U_!G_ .8NOKRB
M@#Y#_P"'?7[!/_1D7[(?_B-?P9_^8NC_ (=]?L$_]&1?LA_^(U_!G_YBZ^O*
M* /D/_AWU^P3_P!&1?LA_P#B-?P9_P#F+H_X=]?L$_\ 1D7[(?\ XC7\&?\
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M$_\ 1D7[(?\ XC7\&?\ YBZ^O** /D/_ (=]?L$_]&1?LA_^(U_!G_YBZ/\
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M $9%^R'_ .(U_!G_ .8NC_AWU^P3_P!&1?LA_P#B-?P9_P#F+KZ\HH ^0_\
MAWU^P3_T9%^R'_XC7\&?_F+H_P"'?7[!/_1D7[(?_B-?P9_^8NOKRB@#Y#_X
M=]?L$_\ 1D7[(?\ XC7\&?\ YBZ/^'?7[!/_ $9%^R'_ .(U_!G_ .8NOKRB
M@#Y#_P"'?7[!/_1D7[(?_B-?P9_^8NC_ (=]?L$_]&1?LA_^(U_!G_YBZ^O*
M* /D/_AWU^P3_P!&1?LA_P#B-?P9_P#F+H_X=]?L$_\ 1D7[(?\ XC7\&?\
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M$_\ 1D7[(?\ XC7\&?\ YBZ^O** /D/_ (=]?L$_]&1?LA_^(U_!G_YBZ/\
MAWU^P3_T9%^R'_XC7\&?_F+KZ\HH ^0_^'?7[!/_ $9%^R'_ .(U_!G_ .8N
MC_AWU^P3_P!&1?LA_P#B-?P9_P#F+KZ\HH ^0_\ AWU^P3_T9%^R'_XC7\&?
M_F+H_P"'?7[!/_1D7[(?_B-?P9_^8NOKRB@#Y#_X=]?L$_\ 1D7[(?\ XC7\
M&?\ YBZ/^'?7[!/_ $9%^R'_ .(U_!G_ .8NOKRB@#Y#_P"'?7[!/_1D7[(?
M_B-?P9_^8NC_ (=]?L$_]&1?LA_^(U_!G_YBZ^O** /D/_AWU^P3_P!&1?LA
M_P#B-?P9_P#F+H_X=]?L$_\ 1D7[(?\ XC7\&?\ YBZ^O** /D/_ (=]?L$_
M]&1?LA_^(U_!G_YBZ/\ AWU^P3_T9%^R'_XC7\&?_F+KZ\HH ^0_^'?7[!/_
M $9%^R'_ .(U_!G_ .8NC_AWU^P3_P!&1?LA_P#B-?P9_P#F+KZ\HH ^0_\
MAWU^P3_T9%^R'_XC7\&?_F+H_P"'?7[!/_1D7[(?_B-?P9_^8NOKRB@#Y#_X
M=]?L$_\ 1D7[(?\ XC7\&?\ YBZ/^'?7[!/_ $9%^R'_ .(U_!G_ .8NOKRB
M@#Y#_P"'?7[!/_1D7[(?_B-?P9_^8NC_ (=]?L$_]&1?LA_^(U_!G_YBZ^O*
M* /D/_AWU^P3_P!&1?LA_P#B-?P9_P#F+H_X=]?L$_\ 1D7[(?\ XC7\&?\
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M$_\ 1D7[(?\ XC7\&?\ YBZ^O** /D/_ (=]?L$_]&1?LA_^(U_!G_YBZ/\
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M $9%^R'_ .(U_!G_ .8NC_AWU^P3_P!&1?LA_P#B-?P9_P#F+KZ\HH ^0_\
MAWU^P3_T9%^R'_XC7\&?_F+H_P"'?7[!/_1D7[(?_B-?P9_^8NOKRB@#Y#_X
M=]?L$_\ 1D7[(?\ XC7\&?\ YBZ/^'?7[!/_ $9%^R'_ .(U_!G_ .8NOKRB
M@#Y#_P"'?7[!/_1D7[(?_B-?P9_^8NC_ (=]?L$_]&1?LA_^(U_!G_YBZ^O*
M* /D/_AWU^P3_P!&1?LA_P#B-?P9_P#F+H_X=]?L$_\ 1D7[(?\ XC7\&?\
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M$_\ 1D7[(?\ XC7\&?\ YBZ^O** /D/_ (=]?L$_]&1?LA_^(U_!G_YBZ/\
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M $9%^R'_ .(U_!G_ .8NC_AWU^P3_P!&1?LA_P#B-?P9_P#F+KZ\HH ^0_\
MAWU^P3_T9%^R'_XC7\&?_F+H_P"'?7[!/_1D7[(?_B-?P9_^8NOKRB@#Y#_X
M=]?L$_\ 1D7[(?\ XC7\&?\ YBZ/^'?7[!/_ $9%^R'_ .(U_!G_ .8NOKRB
M@#Y#_P"'?7[!/_1D7[(?_B-?P9_^8NC_ (=]?L$_]&1?LA_^(U_!G_YBZ^O*
M* /F+PM^Q+^QCX'\0Z3XN\%?LC?LQ>#_ !7H%Y'J.A>)_"WP#^%7A_Q#HNH1
M!A%?:3K6D^%+34M-O(PS".YL[F&9 S!7&37T[110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
04 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
